{"title": "PDF", "author": "PDF", "url": "https://www.socium.uni-bremen.de/lib/download.php?file=d3b0645833.pdf&filename=180327%20Aktualisierung%20Langfassung.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\n\u00a0\u00a0\n\u00a0\nInnovationsreport\u00a02017\u00a0\nLangfassung\u00a0\nAuswertungsergebnisse\u00a0von\u00a0Routinedaten\u00a0der\u00a0\nTechniker\u00a0Krankenkasse\u00a0aus\u00a0den\u00a0Jahren\u00a02014\u00a0bis\u00a02016\u00a0\n\u00a0\n\u00a0\n\u00a0\nHerausgeber:\u00a0Gerd\u00a0Glaeske\u00a0und\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nErstellt\u00a0mit\u00a0freundliche r\u00a0Unterst\u00fctzung\u00a0der\u00a0\u00a0\nTechniker\u00a0Krankenkasse\u00a0(TK)\u00a0\n\u00a0\n\u00a0\n\u00a02\u00a0\u00a0\n\u00a03\u00a0\u00a0\nHerausgeber\u00a0\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0\u00a0\nProf.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\nExperten\u00a0f\u00fcr\u00a0ausgew\u00e4hlte\u00a0Kapitel\u00a0\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Manfred\u00a0Anlauf,\u00a0Bremerhaven\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Peter\u00a0Berlit,\u00a0Essen\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Winfried\u00a0V.\u00a0Kern,\u00a0Freiburg\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Ulrich\u00a0A.\u00a0M\u00fcller,\u00a0MSc,\u00a0Jena\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Die ter\u00a0Ukena,\u00a0Bremen\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\nAutoren\u00a0der\u00a0Kapitel\u00a0\n\u00a0\nD\u00f6rte\u00a0Fuchs,\u00a0Dr.\u00a0Judith\u00a0G\u00fcnther,\u00a0Dr.\u00a0Iris\u00a0Hinneburg,\u00a0Andr\u00e9\u00a0Mora wetz,\u00a0\u00a0\nLutz\u00a0Muth,\u00a0Saskia\u00a0Ritter,\u00a0Dr.\u00a0Kristin\u00a0Sauer\u00a0\n\u00a0\nunter\u00a0Mitarbeit\u00a0von\u00a0\n\u00a0\nAnnika\u00a0Becker,\u00a0Angela\u00a0Fritsch,\u00a0Friederike\u00a0H\u00f6fel,\u00a0Linda\u00a0Jesperse n,\u00a0\u00a0\nPia\u00a0K\u00e4mpfert,\u00a0Linda\u00a0Richter,\u00a0Cornelia\u00a0Trittin,\u00a0Sarah\u00a0Volz \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nAnschrift:\u00a0Universit\u00e4t\u00a0Bremen,\u00a0S OCIUM,\u00a0Mary\u2010Somerville\u2010Str.\u00a05,\u00a0 28359\u00a0Bremen\u00a0\n\u00a0\n\u00a0\u00a0\nAus\u00a0Gr\u00fcnden\u00a0der\u00a0besseren\u00a0Lesbarke it\u00a0wurde\u00a0an\u00a0manchen\u00a0Stellen\u00a0au f\u00a0die\u00a0Nen\u2010\nnung\u00a0beider\u00a0geschlechtsspezifisch er\u00a0Formen\u00a0verzichtet.\u00a0Im\u00a0Allge meinen\u00a0ist\u00a0\naber\u00a0das\u00a0jeweils\u00a0andere\u00a0Geschlecht\u00a0ebenfalls\u00a0gemeint.\u00a0\n\u00a04\u00a0Inhaltsverzeichnis\u00a0\nVorwort\u00a0zum\u00a0Innova tionsreport\u00a02017\u00a0............................ .................\u00a07 \u00a0\nZweites\u00a0Vorwort\u00a0zum\u00a0In novationsreport\u00a02017\u00a0.................... ............\u00a09\u00a0\n1\u00a0Einleitung\u00a0.................................................... ............................\u00a013 \u00a0\n2\u00a0Ziele\u00a0und\u00a0Methodik\u00a0............................................ .....................\u00a030 \u00a0\n2.1\u00a0Zielsetzung\u00a0................................................... ......................\u00a030 \u00a0\n2.2\u00a0Methodik\u00a0zur\u00a0Bewertung\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0.............\u00a030 \u00a0\n2.3\u00a0Methodik\u00a0der\u00a0Routinedaten\u2010Analyse\u00a0............................. ....\u00a036\u00a0\n3\u00a0Neue\u00a0Arzneimittel\u00a0des\u00a0Ja hres\u00a02014\u00a0\u2013\u00a0\u00dcbersicht\u00a0................. .......\u00a041\u00a0\n4\u00a0Bewertungen\u00a0der\u00a0ne uen\u00a0Wirkstoffe\u00a0.............................. ...........\u00a055\u00a0\n4.1\u00a0Albiglutid\u00a0.................................................... ........................\u00a055 \u00a0\n4.2\u00a0Alipogentiparvovec\u00a0............................................ ................\u00a067 \u00a0\n4.3\u00a0Bedaquilin\u00a0.................................................... ......................\u00a079 \u00a0\n4.4\u00a0Cabozantinib\u00a0.................................................. ....................\u00a095 \u00a0\n4.5\u00a0Chols\u00e4ure\u00a0..................................................... ....................\u00a0107 \u00a0\n4.6\u00a0Cobicistat\u00a0.................................................... .....................\u00a0113 \u00a0\n4.7\u00a0Daclatasvir\u00a0................................................... .....................\u00a0121 \u00a0\n4.8\u00a0Delamanid\u00a0..................................................... ...................\u00a0134 \u00a0\n4.9\u00a0Dexlansoprazol\u00a0................................................ .................\u00a0148 \u00a0\n4.10\u00a0Dimethylfumarat\u00a0............................................... ...............\u00a0157 \u00a0\n4.11\u00a0Dolutegravir\u00a0.................................................. ...................\u00a0179 \u00a0\n4.12\u00a0Elosulfase\u00a0alfa\u00a0............................................... ...................\u00a0191 \u00a0\n4.13\u00a0Empagliflozin\u00a0................................................. ...................\u00a0199 \u00a0\n4.14\u00a0Ibrutinib\u00a0..................................................... ......................\u00a0215 \u00a0\n4.15\u00a0Idelalisib\u00a0.................................................... .......................\u00a0229 \u00a0\n4.16\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0....................................... .............\u00a0247 \u00a0\n4.17\u00a0Macitentan\u00a0.................................................... ...................\u00a0260 \u00a0\n4.18\u00a0Nalmefen\u00a0...................................................... ...................\u00a0278 \u00a0\n4.19\u00a0Obinutuzumab\u00a0.................................................. ...............\u00a0291 \u00a0\n4.20\u00a0Olodaterol\u00a0.................................................... ....................\u00a0308 \u00a0\n4.21\u00a0Riociguat\u00a0..................................................... .....................\u00a0320 \u00a0\n4.22\u00a0Siltuximab\u00a0.................................................... ....................\u00a0339 \u00a05\u00a04.23\u00a0Simeprevir\u00a0.................................................... ....................\u00a0346 \u00a0\n4.24\u00a0Simoctocog\u00a0alfa\u00a0............................................... .................\u00a0359 \u00a0\n4.25\u00a0Sofosbuvir\u00a0.................................................... ....................\u00a0367 \u00a0\n4.26\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0....................................... ...........\u00a0380 \u00a0\n4.27\u00a0Teduglutid\u00a0.................................................... ....................\u00a0392 \u00a0\n4.28\u00a0Trastuzumab\u00a0Emtansin\u00a0.......................................... ..........\u00a0405 \u00a0\n4.29\u00a0Turoctocog\u00a0alfa\u00a0............................................... .................\u00a0417 \u00a0\n4.1\u00a0Umeclidinium\u00a0+\u00a0Vilanterol\u00a0..................................... ..........\u00a0426 \u00a0\n4.2\u00a0Vedolizumab\u00a0................................................... .................\u00a0437 \u00a0\n4.3\u00a0Vilanterol\u00a0+\u00a0Fluticasonfuroat\u00a0................................. ..........\u00a0449 \u00a0\n5\u00a0Diskussion\u00a0.................................................... .........................\u00a0466 \u00a0\n6\u00a0Biosimilars\u00a0in\u00a0de r\u00a0Onkologie\u00a0.................................. ................\u00a0476 \u00a0\n7\u00a0Keypoints\u00a0un d\u00a0Fazit\u00a0........................................... ....................\u00a0497 \u00a0\n7.1\u00a0Keypoints\u00a0..................................................... ....................\u00a0497 \u00a0\n7.2\u00a0Fazit\u00a0......................................................... .........................\u00a0499 \u00a0\n8\u00a0Abk\u00fcrzungsve rzeichnis\u00a0......................................... .................\u00a0501 \u00a0\n9\u00a0Anhang:\u00a0Nutzenbewertungs\u2010News\u00a0z u\u00a0neuen\u00a0Arzneimitteln\u00a0....\u00a0504 \u00a0\n10\u00a0Lebensl\u00e4ufe\u00a0................................................... ........................\u00a0504 \u00a0\n\u00a0\n\u00a0\u00a0\u00a06\u00a0\u00a0\u00a07\u00a0Vorwort\u00a0zum\u00a0Innovationsreport\u00a02017\u00a0\nDr.\u00a0Jens\u00a0Baas,\u00a0Vorsitzender\u00a0des\u00a0 Vorstands\u00a0der\u00a0Techniker\u00a0Kranken kasse\u00a0\nDer\u00a0Innovationsreport,\u00a0den\u00a0die\u00a0T echniker\u00a0Krankenkasse\u00a0herausgib t,\u00a0erscheint\u00a0in\u00a0\ndiesem\u00a0Jahr\u00a0zum\u00a0f\u00fcnften\u00a0Mal.\u00a0Ziel\u00a0ist\u00a0es,\u00a0den\u00a0Marktzugang\u00a0von\u00a0n euen\u00a0Arzneimit\u2010\nteln\u00a0kritisch\u00a0zu\u00a0begleiten.\u00a0F\u00fcr\u00a0uns\u00a0stehen\u00a0dabei\u00a0die\u00a0Fragestell ungen\u00a0im\u00a0Mittelpunkt,\u00a0\nwelcher\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Versicherten\u00a0durch\u00a0den\u00a0Einsatz\u00a0neuer\u00a0Arz neimittel\u00a0entste\u2010\nhen\u00a0kann\u00a0und\u00a0was\u00a0dies\u00a0f\u00fcr\u00a0das\u00a0Gesundheitssystem,\u00a0auch\u00a0unter\u00a0Kos tenaspekten,\u00a0\nbedeutet.\u00a0\nDie\u00a0\"Bilanz\"\u00a0f\u00fcr\u00a0echte\u00a0Innovationen\u00a0war\u00a0schon\u00a0in\u00a0den\u00a0letzten\u00a0Ja hren\u00a0eher\u00a0ern\u00fcch\u2010\nternd.\u00a0Auch\u00a0wenn\u00a0deutliche\u00a0therapeutische\u00a0Fortschritte\u00a0durch\u00a0ne ue\u00a0Arzneimittel,\u00a0\nzum\u00a0Beispiel\u00a0im\u00a0Bereich\u00a0der\u00a0chro nischen\u00a0Hepatitis\u00a0C\u00a0zu\u00a0verzeich nen\u00a0sind,\u00a0wurde\u00a0f\u00fcr\u00a0\nrund\u00a050\u00a0%\u00a0der\u00a0bewerteten\u00a0Arzneimittel\u00a0eine\u00a0\"rote\u00a0Gesamtampel\"\u00a0v ergeben.\u00a0Be\u2010\nwertet\u00a0 wurde\u00a0 nach\u00a0 drei\u00a0 Kriterien:\u00a0 verf\u00fcgbare\u00a0 Therapien,\u00a0 (Zusatz \u2010)Nutzen\u00a0 und\u00a0\nKosten.\u00a0Im\u00a0Ergebnis\u00a0stellen\u00a0wir\u00a0fest,\u00a0dass\u00a0die\u00a0neuen\u00a0Arzneimitt el\u00a0h\u00e4ufig\u00a0keine\u00a0wirk\u2010\nlichen\u00a0Innovationen\u00a0sind,\u00a0sondern\u00a0meist\u00a0zu\u00a0hohen\u00a0Preisen\u00a0nur\u00a0kl eine\u00a0Therapiefort\u2010\nschritte\u00a0bieten.\u00a0Insbesondere\u00a0a ufgrund\u00a0der\u00a0massiven\u00a0Preis\u2010\u00a0und\u00a0 Kostensteigerun\u2010\ngen\u00a0muss\u00a0die\u00a0Frage\u00a0gestellt\u00a0werden,\u00a0wie\u00a0unser\u00a0Gesundheitssystem \u00a0mit\u00a0diesen\u00a0\nKosten\u00a0umgehen\u00a0wird\u00a0und\u00a0ob\u00a0wir\u00a0bereit\u00a0sind,\u00a0so\u00a0hohe\u00a0Preise\u00a0f\u00fcr\u00a0 kleine\u00a0Fortschritte\u00a0\nzu\u00a0 zahlen.\u00a0 Die\u00a0 Antwort\u00a0 darauf\u00a0 kann\u00a0 nur\u00a0 durch\u00a0 einen\u00a0 gesamtgesell schaftlichen\u00a0\nDiskurs\u00a0gegeben\u00a0werden.\u00a0Dabei\u00a0sind\u00a0sorgsam\u00a0die\u00a0Faktoren\u00a0Patient ennutzen\u00a0und\u00a0\nEvidenzlage\u00a0abzuw\u00e4gen,\u00a0Kostenauswirkungen\u00a0zu\u00a0analysieren\u00a0und\u00a0gl eichzeitig\u00a0An\u2010\nreize\u00a0f\u00fcr\u00a0echte\u00a0Innovationen\u00a0zu\u00a0schaffen.\u00a0\nIm\u00a0Innovationsreport\u00a02017\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0V orjahren\u00a0deutlich\u00a0\nmehr\u00a0Arzneimittel\u00a0auf\u00a0den\u00a0Markt\u00a0gebracht\u00a0und\u00a0bewertet\u00a0wurden.\u00a0D er\u00a0durchschnitt\u2010\nliche\u00a0 Packungspreis\u00a0 ist\u00a0 erneut\u00a0 gestiegen\u00a0 (Innovationsreport\u00a0 201 6:\u00a0 1.418\u00a0Euro;\u00a0\nInnovationsreport\u00a02017:\u00a02.458\u00a0Euro).\u00a0Die\u00a0Ums\u00e4tze\u00a0der\u00a0neuen\u00a0Arzn eimittel\u00a0im\u00a0Jahr\u00a0\nnach\u00a0der\u00a0Markteinf\u00fchrung\u00a0haben\u00a0sich\u00a0fast\u00a0verf\u00fcnffacht.\u00a0Dieser\u00a0E ffekt\u00a0ist\u00a0teilweise\u00a0\ndurch\u00a0sehr\u00a0teure\u00a0Arzneimittel\u00a0bedingt.\u00a0So\u00a0finden\u00a0wir\u00a0Wirkstoffe ,\u00a0deren\u00a0Therapie\u2010\nkosten\u00a0400.000\u00a0bis\u00a0500.000\u00a0Euro\u00a0und\u00a0sogar\u00a0bis\u00a0zu\u00a01,2\u00a0Mio.\u00a0Euro\u00a0 betragen\u00a0und\u00a0die\u00a0\ndamit\u00a0in\u00a0extrem\u00a0hohe\u00a0Kostendimensionen\u00a0vorsto\u00dfen.\u00a0Wir\u00a0m\u00fcssen\u00a0ab er\u00a0auch\u00a0generell\u00a0\nfeststellen,\u00a0dass\u00a0das\u00a0Kostenvolumen\u00a0durch\u00a0den\u00a0Einsatz\u00a0neuer\u00a0Arz neimittel\u00a0zuk\u00fcnftig\u00a0\nweiter\u00a0steigen\u00a0wird,\u00a0da\u00a0sich\u00a0das\u00a0Preisniveau\u00a0konstant\u00a0nach\u00a0oben \u00a0entwickelt.\u00a0\nWir\u00a0werden\u00a0damit\u00a0absehbar\u00a0nicht\u00a0umhin\u00a0kommen,\u00a0weitere\u00a0Ma\u00dfnahmen \u00a0zur\u00a0Kos\u2010\ntenbegrenzung\u00a0 einzuf\u00fchren.\u00a0 Eine\u00a0 A nhebung\u00a0 des\u00a0 Herstellerabschlag s\u00a0 w\u00e4re\u00a0 ein\u00a0\ngeeignetes\u00a0Instrument,\u00a0um\u00a0dies\u00a0kurzfristig\u00a0und\u00a0schnell\u00a0umzusetz en.\u00a0Aber\u00a0auch\u00a0die\u00a0\nRealisierung\u00a0von\u00a0Wirtschaftlichkeitsreserven\u00a0beim\u00a0Einsatz\u00a0von\u00a0B iosimilars\u00a0muss\u00a0\nvorangetrieben\u00a0werden.\u00a0Denn\u00a0mit\u00a0 den\u00a0Biosimilars\u00a0steht\u00a0eine\u00a0Ther apieoption\u00a0zur\u00a08\u00a0Verf\u00fcgung,\u00a0die\u00a0keine\u00a0klinischen\u00a0N achteile\u00a0in\u00a0der\u00a0Behandlung\u00a0der \u00a0Patienten\u00a0nach\u00a0\nsich\u00a0zieht,\u00a0aber\u00a0mit\u00a0deutlichen\u00a0Kostenvorteilen\u00a0verbunden\u00a0ist.\u00a0 Gemeinsam\u00a0mit\u00a0dem\u00a0\nBerufsverband\u00a0der\u00a0niedergelassene n\u00a0Gastroenterologen\u00a0Deutschlan ds,\u00a0dem\u00a0Be\u2010\nrufsverband\u00a0 Deutscher\u00a0 Rheumatologen\u00a0 und\u00a0 einigen\u00a0 Krankenkassen\u00a0 h at\u00a0 die\u00a0 TK\u00a0\nerste\u00a0Vertr\u00e4ge\u00a0geschlossen,\u00a0um\u00a0die\u00a0Biosimilars\u00a0im\u00a0Markt\u00a0st\u00e4rker \u00a0zu\u00a0etablieren.\u00a0\nAber\u00a0auch\u00a0Vorgaben\u00a0zum\u00a0Einsatz\u00a0von\u00a0Biosimilars\u00a0in\u00a0der\u00a0Onkologie \u00a0sollten\u00a0zeitnah\u00a0\neingef\u00fchrt\u00a0werden.\u00a0\nDer\u00a0Innovationsreport\u00a02017\u00a0soll\u00a0aber\u00a0nicht\u00a0nur\u00a0die\u00a0derzeitige\u00a0S ituation\u00a0beschreiben\u00a0\nund\u00a0bewerten,\u00a0sondern\u00a0eine\u00a0Diskussionsgrundlage\u00a0f\u00fcr\u00a0die\u00a0Entwick lung\u00a0von\u00a0Ma\u00df\u2010\nnahmen\u00a0sein,\u00a0die\u00a0unser\u00a0Gesundheitssystem\u00a0zuk\u00fcnftig\u00a0besser\u00a0mache n.\u00a0Echte\u00a0Inno\u2010\nvationen\u00a0haben\u00a0daf\u00fcr\u00a0das\u00a0Potenzial\u00a0und\u00a0wir\u00a0als\u00a0Techniker\u00a0Kranke nkasse\u00a0sehen\u00a0uns\u00a0\nin\u00a0der\u00a0Pflicht,\u00a0diese\u00a0voranzutre iben.\u00a0Wir\u00a0betrachten\u00a0dabei\u00a0das\u00a0 Arzneimittel\u00a0nicht\u00a0\nnur\u00a0als\u00a0potentiell\u00a0innovatives\u00a0Produkt,\u00a0sondern\u00a0sehen\u00a0es\u00a0eingeb ettet\u00a0in\u00a0das\u00a0Ver\u2010\nsorgungsgeschehen.\u00a0Dieses\u00a0Versorgungsgeschehen\u00a0k\u00f6nnen\u00a0wir\u00a0durch \u00a0innovative\u00a0\nVersorgungsmodelle\u00a0mitgestalten.\u00a0\nDabei\u00a0werden\u00a0zunehmend\u00a0digitale \u00a0Anwendungen\u00a0zum\u00a0Einsatz\u00a0kommen. \u00a0F\u00fcr\u00a0die\u00a0TK\u00a0\nist\u00a0die\u00a0Digitalisierung\u00a0der\u00a0Ges undheitsversorgung\u00a0schon\u00a0seit\u00a0l\u00e4 ngerem\u00a0ein\u00a0zentrales\u00a0\nThema.\u00a0Die\u00a0Digitalisierung\u00a0von\u00a0Arbeitsprozessen,\u00a0zum\u00a0Beispiel\u00a0d urch\u00a0telemedizini\u2010\nsche\u00a0Anwendungen\u00a0oder\u00a0auch\u00a0die\u00a0elektronische\u00a0Gesundheitsakte,\u00a0d ie\u00a0den\u00a0Versi\u2010\ncherten\u00a0Mehrwerte\u00a0bietet,\u00a0werden \u00a0dabei\u00a0eine\u00a0entscheidende\u00a0Rolle \u00a0spielen.\u00a0Ver\u2010\nsorgungsmodelle,\u00a0die\u00a0digitale\u00a0T echnologien\u00a0einbinden,\u00a0k\u00f6nnen\u00a0au ch\u00a0genutzt\u00a0wer\u2010\nden,\u00a0um\u00a0beispielsweise\u00a0die\u00a0notwe ndige\u00a0Begleitforschung\u00a0f\u00fcr\u00a0den\u00a0 Langzeitnutzen\u00a0\nvon\u00a0Arzneimitteln\u00a0zu\u00a0unterst\u00fctzen.\u00a0Bei\u00a0diesen\u00a0Modellen\u00a0sehen\u00a0wi r\u00a0die\u00a0pharmazeu\u2010\ntische\u00a0Industrie\u00a0in\u00a0der\u00a0Pflicht,\u00a0 diese,\u00a0auch\u00a0finanziell,\u00a0mitzut ragen.\u00a0\nNicht\u00a0vergessen\u00a0sollten\u00a0wir\u00a0aber\u00a0auch,\u00a0dass\u00a0die\u00a0Erforschung\u00a0neu er\u00a0Wirkstoffe\u00a0we i\u2010\nterhin\u00a0unabdingbar\u00a0sein\u00a0wird,\u00a0um\u00a0echte\u00a0Arzneimittelinnovationen \u00a0auf\u00a0den\u00a0Markt\u00a0\nzu\u00a0bringen.\u00a0Innovationen\u00a0finden\u00a0jedoch\u00a0meistens\u00a0nur\u00a0dort\u00a0statt, \u00a0wo\u00a0hohe\u00a0Renditen\u00a0\nerwartet\u00a0werden\u00a0und\u00a0nicht\u00a0in\u00a0Indikationen,\u00a0in\u00a0denen\u00a0es\u00a0einen\u00a0ho hen\u00a0medizin i\u2010\nschen\u00a0Bedarf\u00a0gibt.\u00a0Die\u00a0Antibiotikaforschung\u00a0ist\u00a0daf\u00fcr\u00a0ein\u00a0gutes \u00a0Beispiel.\u00a0Hier\u00a0muss\u2010\nten\u00a0durch\u00a0den\u00a0Gesetzgeber\u00a0im\u00a0AMVSG\u00a0Anreize\u00a0geschaffen\u00a0werden,\u00a0u m\u00a0eine\u00a0sinnvolle\u00a0\nAntibiotikaforschung\u00a0zu\u00a0f\u00f6rdern.\u00a0Wir\u00a0w\u00fcnschen\u00a0uns\u00a0f\u00fcr\u00a0alle\u00a0Indi kationsbereiche\u00a0eine\u00a0\npatienten\u2010\u00a0und\u00a0nutzenorientierte\u00a0Forschung,\u00a0die\u00a0nicht\u00a0nur\u00a0die\u00a0G ewinnmaximierung\u00a0\nim\u00a0Auge\u00a0hat.\u00a0 \u00a09\u00a0Zweites\u00a0Vorwort\u00a0zum\u00a0Innovationsreport\u00a02017\u00a0\nProf.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\nIm\u00a0Jahr\u00a02014\u00a0wurden\u00a0in\u00a0Deutschland\u00a046\u00a0Arzneimittel\u00a0mit\u00a0neuen\u00a0Wi rkstoffen\u00a0in\u00a0den\u00a0\nMarkt\u00a0eingef\u00fchrt\u00a0(im\u00a0Vorjahr\u00a0dagegen\u00a0nur\u00a027),\u00a0von\u00a0denen\u00a032\u00a0Arzn eimittel\u00a0im\u00a0vor\u2010\nliegenden\u00a0Innovationsreport\u00a02017\u00a0 in\u00a0Wirkstoffportr\u00e4ts\u00a0kritisch\u00a0 bewertet\u00a0werden.\u00a0\nBewertungskriterien\u00a0waren,\u00a0wie\u00a0in\u00a0den\u00a0vorherigen\u00a0Innovationsrep orten,\u00a0der\u00a0Ver\u2010\ngleich\u00a0mit\u00a0den\u00a0f\u00fcr\u00a0das\u00a0zugelassene\u00a0Anwendungsgebiet\u00a0des\u00a0neuen\u00a0W irkstoffs\u00a0be\u2010\nreits\u00a0verf\u00fcgbaren\u00a0medikament\u00f6sen \u00a0Therapien,\u00a0der\u00a0(Zusatz\u2010)Nutzen \u00a0und\u00a0die\u00a0Kosten.\u00a0\nDer\u00a0in\u00a0der\u00a0Entwicklung\u00a0neuer\u00a0Wir kstoffe\u00a0bereits\u00a0seit\u00a0einigen\u00a0Ja hren\u00a0zu\u00a0beobach\u2010\ntende\u00a0Trend\u00a0\u2013\u00a0 Orphan\u2010Arzneimittel\u00a0(insgesamt\u00a0zw\u00f6lf,\u00a0sie\u00a0machen\u00a0mehr\u00a0als\u00a0ein\u00a0\nDrittel\u00a0der\u00a0im\u00a0Innovationsreport\u00a02016\u00a0bewerteten\u00a0Wirkstoffe\u00a0aus )\u00a0und\u00a0Arzneimit\u2010\ntel\u00a0zur\u00a0Behandlung\u00a0von\u00a0onkologis chen\u00a0Erkrankungen\u00a0(insgesamt\u00a0f\u00fc nf)\u00a0\u2013\u00a0h\u00e4lt\u00a0an\u00a0und\u00a0\ndie\u00a0Zahl\u00a0der\u00a0in\u00a0beschleunigten\u00a0Verfahren\u00a0zugelassenen\u00a0Arzneimit tel\u00a0steigt\u00a0weiter.\u00a0\nDie\u00a0Entwicklung\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0wurde\u00a0von\u00a0pharmazeutischen\u00a0Unter\u2010\nnehmern\u00a0(pU)\u00a0lange\u00a0Zeit\u00a0vernachl\u00e4ssigt,\u00a0insbesondere\u00a0wegen\u00a0hohe r\u00a0Kosten\u00a0f\u00fcr\u00a0\nForschung\u00a0und\u00a0Entwicklung\u00a0sowie\u00a0geringer\u00a0Umsatzerwartungen.\u00a0Heu te\u00a0jedoch\u00a0sind\u00a0\nOrphan\u2010Arzneimittel\u00a0zu\u00a0einem\u00a0\u00e4u\u00dferst\u00a0lukrativen\u00a0Gesch\u00e4ftsmodell\u00a0f\u00fcr\u00a0p U\u00a0gewor\u2010\nden,\u00a0wof\u00fcr\u00a0in\u00a0erster\u00a0Linie\u00a0finan zielle\u00a0Anreize\u00a0verantwortlich\u00a0s ind.\u00a0Hierzu\u00a0z\u00e4hlen\u00a0das\u00a0\nzehnj\u00e4hrige\u00a0Marktexklusivit\u00e4tsrecht\u00a0und\u00a0die\u00a0in\u00a0der\u00a0Verordnung\u00a0( EG)\u00a0Nr.\u00a0141/2000\u00a0\nvorgesehenen\u00a0Erleichterungen\u00a0bei \u00a0der\u00a0Zulassung\u00a0(wie\u00a0die\u00a0Befreiu ng\u00a0bzw.\u00a0Erm\u00e4\u00dfi\u2010\ngung\u00a0von\u00a0Geb\u00fchren\u00a0beim\u00a0Zulassungsverfahren\u00a0und\u00a0die\u00a0beschleunigt e\u00a0Bearbeitung\u00a0\ndes\u00a0Zulassungsantrags).\u00a0Eine\u00a0wichtige\u00a0Rolle\u00a0spielt\u00a0aber\u00a0auch\u00a0di e\u00a0\u201eOrphanisierung\u201c\u00a0\nvon\u00a0Krankheiten\u00a0im\u00a0Rahmen\u00a0der\u00a0Pr\u00e4 zisionsmedizin,\u00a0die\u00a0bei\u00a0neuen\u00a0 Wirkstoffen\u00a0im\u00a0\nJahr\u00a02014\u00a0erm\u00f6glicht\u00a0hat,\u00a0dass\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0(im\u00a0Innov ationsreport:\u00a0\nObinutuzumab)\u00a0bzw.\u00a0Inhibitoren\u00a0von\u00a0Signalwegen\u00a0(im\u00a0Report:\u00a0Ibru tinib)\u00a0als\u00a0 Or\u2010\nphan\u2010Arzneimittel\u00a0zur\u00a0Behandlung\u00a0der \u00a0chronischen\u00a0lymphatischen\u00a0Leuk \u00e4mie,\u00a0der\u00a0\nbei\u00a0\u00e4lteren\u00a0Patienten\u00a0h\u00e4ufigsten \u00a0Leuk\u00e4mieform,\u00a0zugelassen\u00a0wurde n.\u00a0Untersuchun\u2010\ngen\u00a0in\u00a0den\u00a0letzten\u00a0zehn\u00a0Jahren\u00a0haben\u00a0verdeutlicht,\u00a0dass\u00a0Wirksam keit\u00a0und\u00a0Sicher\u2010\nheit\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0h\u00e4ufig\u00a0unzureichend\u00a0\nbelegt\u00a0sind.\u00a0Randomisierte\u00a0kontrollierte\u00a0Studien\u00a0werden\u00a0bei\u00a0 Orphan\u2010Arzneimitteln\u00a0\nseltener\u00a0als\u00a0im\u00a0Rahmen\u00a0der\u00a0regul\u00e4ren\u00a0Zulassung\u00a0durchgef\u00fchrt\u00a0und \u00a0in\u00a0den\u00a0f\u00fcr\u00a0die\u00a0\nZulassung\u00a0relevanten\u00a0Studien\u00a0meist\u00a0nur\u00a0wenige\u00a0(unter\u00a0200)\u00a0Patie nten\u00a0untersucht.\u00a0\nDies\u00a0hat\u00a0zur\u00a0Folge,\u00a0dass\u00a0bei\u00a0der\u00a0Zulassung\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0h\u00e4ufig\u00a0nur\u00a0\neine\u00a0schwache\u00a0Evidenz\u00a0f\u00fcr\u00a0den\u00a0klinischen\u00a0Nutzen\u00a0vorliegt\u00a0und\u00a0\u00c4r zte\u00a0sowie\u00a0Patien\u2010\nten\u00a0deshalb\u00a0mit\u00a0erheblicher\u00a0Unsicherheit\u00a0bei\u00a0der\u00a0Verordnung\u00a0bzw .\u00a0Behandlung\u00a0mit\u00a0\nOrphan\u2010Arzneimitteln\u00a0umgehen\u00a0m\u00fcssen.\u00a0Angesichts\u00a0dieser\u00a0Fakten\u00a0\u00fcberras cht\u00a0auch\u00a0\nnicht,\u00a0dass\u00a0vom\u00a0Gemeinsamen\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0in\u00a0den\u00a0erste n\u00a0f\u00fcnf\u00a0Jahren\u00a0\nder\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0bei\u00a0mehr\u00a0als\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0 Orphan\u2010Arzneimittel\u00a0der\u00a0\nZusatznutzen\u00a0als\u00a0nicht\u00a0quantifizierbar\u00a0beurteilt\u00a0wurde.\u00a0Auch\u00a0di e\u00a0Bewertungen\u00a0des\u00a0\n(Zusatz\u2010)Nutzens\u00a0anhand\u00a0des\u00a0Ampels chemas\u00a0im\u00a0Innovationsreport\u00a02 017\u00a0ergeben\u00a010\u00a0f\u00fcr\u00a0keines\u00a0der\u00a0zw\u00f6lf\u00a0bewerteten\u00a0 Orphan\u2010Arzneimittel\u00a0eine\u00a0\u00fcberzeugende\u00a0Verbes\u2010\nserung\u00a0klinisch\u00a0relevanter\u00a0Endpunkte.\u00a0Wie\u00a0bereits\u00a0seit\u00a0l\u00e4ngerer \u00a0Zeit\u00a0gefordert,\u00a0gilt\u00a0\nes\u00a0jetzt,\u00a0einen\u00a0weiteren\u00a0Missbrauch\u00a0der\u00a0bestehenden\u00a0Verordnung\u00a0 Nr.\u00a0141/2000\u00a0\nf\u00fcr\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0zu\u00a0verhindern\u00a0und\u00a0Ma\u00dfnahmen \u00a0zu\u00a0ergreifen,\u00a0\ndie\u00a0dem\u00a0urspr\u00fcnglichen,\u00a0sehr\u00a0sinnvollen\u00a0Geist\u00a0dieser\u00a0Verordnung \u00a0entsprechen.\u00a0Er\u00a0\nbetrifft\u00a0die\u00a0F\u00f6rderung\u00a0der\u00a0Entwicklung\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0mit\u00a0gro\u00dfem\u00a0For\u2010\nschungsaufwand\u00a0und\u00a0geringer\u00a0Nachfrage,\u00a0beispielsweise\u00a0f\u00fcr\u00a0die\u00a0h eute\u00a0nicht\u00a0im\u00a0Mit\u2010\ntelpunkt\u00a0der\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0von\u00a0pU\u00a0stehenden\u00a0seltene n\u00a0genetisch\u00a0be\u2010\ndingten\u00a0Krankheiten,\u00a0f\u00fcr\u00a0die\u00a0meist\u00a0noch\u00a0wirksame\u00a0medikament\u00f6se\u00a0 Therapien\u00a0fehlen.\u00a0\nAktuelle\u00a0 Prognosen\u00a0 sprechen\u00a0 daf\u00fcr,\u00a0 dass\u00a0 das\u00a0 dynamische\u00a0 Umsatzwa chstum\u00a0 der\u00a0\nOrphan\u2010Arzneimittel\u00a0anh\u00e4lt\u00a0und\u00a0auch\u00a0k\u00fcnftig\u00a0etwa\u00a0ein\u00a0Drittel\u00a0der\u00a0deut schen\u00a0Markt\u2010\nneueinf\u00fchrungen\u00a0 Orphan\u2010Arzneimittel\u00a0 sein\u00a0 werden.\u00a0 Deshalb\u00a0 erscheint\u00a0 es\u00a0 zuneh\u2010\nmend\u00a0wichtig,\u00a0Patienten\u00a0vor\u00a0schlecht\u00a0gepr\u00fcften\u00a0Wirkstoffen\u00a0bess er\u00a0zu\u00a0sch\u00fctzen,\u00a0mit\u00a0\nder\u00a0 Zulassung\u00a0 eindeutige\u00a0 Auflage n\u00a0 durch\u00a0 die\u00a0 Europ\u00e4ische\u00a0 Arzneim ittel\u2010Agentur\u00a0\n(EMA)\u00a0zu\u00a0verbinden\u00a0\u2013\u00a0die\u00a0auch\u00a0rasch\u00a0erf\u00fcllt\u00a0werden\u00a0m\u00fcssen\u00a0\u2013\u00a0und \u00a0unangemessene\u00a0\nfinanzielle\u00a0 Belastungen\u00a0 f\u00fcr\u00a0 unser\u00a0 solidarisch\u00a0 finanziertes\u00a0 Gesu ndheitssystem\u00a0 zu\u00a0\nverhindern.\u00a0Erst\u00a0dann\u00a0kann\u00a0davon\u00a0ausgegangen\u00a0werden,\u00a0dass\u00a0das\u00a0i n\u00a0der\u00a0genannten\u00a0\nVerordnung\u00a0Nr.\u00a0141/2000,\u00a0S.\u00a03\u00a0ausdr\u00fccklich\u00a0erw\u00e4hnte\u00a0Ziel\u00a0erreic ht\u00a0wird:\u00a0\u201ePatienten\u00a0\nmit\u00a0solchen\u00a0Leiden\u00a0haben\u00a0denselb en\u00a0Anspruch\u00a0auf\u00a0Qualit\u00e4t,\u00a0Unbed enklichkeit\u00a0und\u00a0\nWirksamkeit\u00a0von\u00a0Arzneimitteln\u00a0wie\u00a0andere\u00a0Patienten\u00a0und\u00a0deshalb\u00a0 sollten\u00a0Orphan\u2010\nArzneimittel\u00a0dem\u00a0normalen\u00a0Bewertungsverfahren\u00a0unterliegen.\u201c\u00a0\u00a0\nNeben\u00a0der\u00a0Verordnung\u00a0\u00fcber\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0exist ieren\u00a0heute\u00a0so\u2010\nwohl\u00a0in\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0(EU)\u00a0als\u00a0auch\u00a0in\u00a0den\u00a0USA\u00a0weitere ,\u00a0verst\u00e4rkt\u00a0von\u00a0pU\u00a0\ngenutzte\u00a0Verfahren\u00a0f\u00fcr\u00a0eine\u00a0beschleunigte\u00a0Zulassung\u00a0neuer\u00a0Arzne imittel.\u00a0Diese,\u00a0\nvon\u00a0europ\u00e4ischen\u00a0und\u00a0US\u2010amerikani schen\u00a0Dachverb\u00e4nden\u00a0der\u00a0pharma zeutischen\u00a0\nIndustrie\u00a0bereits\u00a0seit\u00a0Jahren\u00a0geforderten\u00a0Verfahren,\u00a0sollen\u00a0ang eblich\u00a0die\u00a0Zulas\u2010\nsungsverfahren\u00a0an\u00a0neue\u00a0wissenschaftliche\u00a0Entwicklungen\u00a0besser\u00a0a npassen\u00a0damit\u00a0\nneue\u00a0Arzneimittel\u00a0f\u00fcr\u00a0Patienten,\u00a0vor\u00a0allem\u00a0mit\u00a0schweren\u00a0Erkrank ungen\u00a0und\u00a0nur\u00a0\nwenigen\u00a0medikament\u00f6sen\u00a0Therapieoptionen,\u00a0rascher\u00a0zu\u00a0Verf\u00fcgung\u00a0s tehen.\u00a0Aktu\u2010\nelle\u00a0Untersuchungen,\u00a0insbesondere\u00a0zu\u00a0den\u00a0in\u00a0den\u00a0USA\u00a0zwischen\u00a020 00\u00a0und\u00a02013\u00a0\nbeschleunigt\u00a0zugelassenen\u00a0Arzneimitteln,\u00a0haben\u00a0jedoch\u00a0deutlich\u00a0 gezeigt,\u00a0dass\u00a0zum\u00a0\nZeitpunkt\u00a0der\u00a0beschleunigten\u00a0Zulassung\u00a0h\u00e4ufig\u00a0betr\u00e4chtliche\u00a0Uns icherheiten\u00a0hin\u2010\nsichtlich\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0neuer\u00a0Arzneimittel\u00a0bestehe n,\u00a0die\u00a0nur\u00a0selten\u00a0\ndanach\u00a0durch\u00a0weitere\u00a0randomisierte\u00a0klinische\u00a0Studien\u00a0\u00fcberzeugen d\u00a0beseitigt\u00a0wer\u2010\nden\u00a0(Naci\u00a0et\u00a0al.,\u00a02017;\u00a0Pease\u00a0et\u00a0al.,\u00a02017).\u00a0Offensichtliche\u00a0M\u00e4 ngel\u00a0der\u00a0Zulassungs\u2010\nstudien\u00a0im\u00a0Rahmen\u00a0beschleunigter\u00a0Verfahren\u00a0betreffen\u00a0u.a.\u00a0ihr\u00a0D esign,\u00a0das\u00a0h\u00e4ufig\u00a0\nnicht\u00a0darauf\u00a0ausgerichtet\u00a0ist,\u00a0eine\u00a0\u00dcberlegenheit\u00a0des\u00a0neuen\u00a0Arz neimittels\u00a0im\u00a0Ver\u2010\ngleich\u00a0zur\u00a0Standardtherapie\u00a0in\u00a0randomisierten\u00a0kontrollierten\u00a0St udien\u00a0zu\u00a0belegen,\u00a0\ndie\u00a0meist\u00a0kleinen\u00a0Patientenzahle n\u00a0dieser\u00a0Studien,\u00a0die\u00a0in\u00a0der\u00a0Re gel\u00a0kurze\u00a0Nachbe\u2010\nobachtung\u00a0und\u00a0die\u00a0mitunter\u00a0erst\u00a0relativ\u00a0sp\u00e4t\u00a0erf\u00fcllten\u00a0Auflagen \u00a0der\u00a0Zulassungsbe\u201011\u00a0h\u00f6rden.\u00a0Sowohl\u00a0in\u00a0den\u00a0USA\u00a0als\u00a0auch\u00a0in\u00a0Europa\u00a0ist\u00a0die\u00a0Tendenz\u00a0er kennbar,\u00a0dass\u00a0\nbeschleunigt\u00a0 zugelassene\u00a0 Arzneim ittel\u00a0 trotz\u00a0 der\u00a0 geschilderten\u00a0 M \u00e4ngel\u00a0 rasch\u00a0 in\u00a0\nLeitlinien\u00a0empfohlen\u00a0werden\u00a0(sie he\u00a0Tabelle\u00a05.1,\u00a0ausf\u00fchrlicher\u00a0i n\u00a0den\u00a0Wirkstoff\u2010\nportr\u00e4ts\u00a0der\u00a0Internetversion\u00a0auf\u00a0der\u00a0Homepage\u00a0des\u00a0SOCIUM)\u00a0und\u00a0s omit\u00a0als\u00a0wichti\u2010\nger\u00a0Bestandteil\u00a0der\u00a0medikament \u00f6sen\u00a0Standardtherapie\u00a0gelten.\u00a0\u00a0\nVor\u00a0diesem\u00a0Hintergrund\u00a0sind\u00a0neue\u00a0Zulassungsverfahren,\u00a0die\u00a0derze it\u00a0noch\u00a0im\u00a0Rah\u2010\nmen\u00a0von\u00a0Pilotprojekten\u00a0der\u00a0EMA\u00a0untersucht\u00a0werden,\u00a0wie\u00a0vor\u00a0allem \u00a0die\u00a0sog.\u00a0Adap\u2010\ntive\u00a0Pathways ,\u00a0sehr\u00a0kritisch\u00a0zu\u00a0sehen.\u00a0Dieses \u00a0auf\u00a0adaptiven\u00a0Studiendesigns\u00a0b asie\u2010\nrende\u00a0Verfahren\u00a0soll\u00a0besonders\u00a0bei\u00a0Arzneimitteln\u00a0zur\u00a0Behandlung \u00a0von\u00a0Patienten\u00a0\nmit\u00a0schweren\u00a0Krankheiten\u00a0zur\u00a0Anwendung\u00a0kommen,\u00a0bei\u00a0denen\u00a0ein\u00a0ho her\u00a0und\u00a0\ndurch\u00a0zugelassene\u00a0Arzneimittel\u00a0nicht\u00a0gedeckter\u00a0medizinischer\u00a0Be darf\u00a0(high\u00a0unmet\u00a0\nmedical\u00a0need ;\u00a0beispielsweise\u00a0in\u00a0der\u00a0Onkologie)\u00a0besteht.\u00a0 Adaptive\u00a0Pathways \u00a0bedeu\u2010\nten\u00a0jedoch\u00a0eine\u00a0noch\u00a0st\u00e4rkere\u00a0Abkehr\u00a0von\u00a0lange\u00a0bew\u00e4hrten\u00a0und\u00a0ev idenzbasierten\u00a0\nAnforderungen\u00a0an\u00a0die\u00a0Zulassung\u00a0neuer\u00a0Arzneimittel\u00a0als\u00a0die\u00a0heute \u00a0praktizierten,\u00a0\nbeschleunigten\u00a0 Verfahren\u00a0 (Ludwig,\u00a0 2017).\u00a0 Bevor\u00a0 Adaptive\u00a0 Pathways \u00a0 als\u00a0 neues\u00a0\nZulassungsverfahren\u00a0durch\u00a0die\u00a0EMA \u00a0weiterverfolgt\u00a0oder\u00a0sogar\u00a0eta bliert\u00a0wird,\u00a0m\u00fcs\u2010\nsen\u00a0deshalb\u00a0gewichtige\u00a0Bedenken\u00a0noch\u00a0ausger\u00e4umt\u00a0und\u00a0Fragen\u00a0bean twortet\u00a0wer\u2010\nden.\u00a0Hierzu\u00a0z\u00e4hlen\u00a0die\u00a0Definition\u00a0des\u00a0Begriffes\u00a0 high\u00a0unmet\u00a0medical\u00a0need \u00a0und\u00a0der\u00a0\nUmgang\u00a0von\u00a0\u00c4rzten\u00a0und\u00a0Patienten\u00a0mit\u00a0erheblicher\u00a0Unsicherheit\u00a0be i\u00a0neuen\u00a0Arz\u2010\nneimitteln,\u00a0die\u00a0nicht\u00a0dem\u00a0heutig en\u00a0Standard\u00a0entsprechend\u00a0gepr\u00fcf t\u00a0wurden.\u00a0Vor\u00a0\nallem\u00a0stellt\u00a0sich\u00a0die\u00a0Frage,\u00a0wie\u00a0garantiert\u00a0werden\u00a0kann,\u00a0dass\u00a0a ngesichts\u00a0der\u00a0Verla\u2010\ngerung\u00a0der\u00a0Beweislast\u00a0f\u00fcr\u00a0ein\u00a0po sitives\u00a0Nutzen\u2010Risiko\u2010Verh\u00e4ltni s\u00a0von\u00a0der\u00a0Pr\u00e4\u2010\u00a0in\u00a0die\u00a0\nPost\u2010Marketing\u2010Phase,\u00a0die\u00a0mit\u00a0der\u00a0Zulassung\u00a0verbundenen\u00a0Auflage n\u00a0rechtzeitig\u00a0\nvon\u00a0pU\u00a0erf\u00fcllt\u00a0werden.\u00a0Problemat isch\u00a0ist\u00a0sicher\u00a0auch\u00a0die\u00a0Tatsac he,\u00a0dass\u00a0im\u00a0Rahmen\u00a0\nvon\u00a0Adaptive\u00a0Pathways \u00a0 die\u00a0 Verantwortung\u00a0 f\u00fcr\u00a0 die\u00a0 Finanzierung\u00a0 neuer,\u00a0 unzu\u2010\nreichend\u00a0gepr\u00fcfter\u00a0und\u00a0zumeist\u00a0se hr\u00a0teurer\u00a0Wirkstoffe\u00a0von\u00a0pU\u00a0au f\u00a0unser\u00a0Gesund\u2010\nheitssystem\u00a0bzw.\u00a0die\u00a0Kostentr\u00e4ger\u00a0verlagert\u00a0wird.\u00a0\u00a0\nBez\u00fcglich\u00a0des\u00a0im\u00a0letzten\u00a0Jahrzehnt\u00a0stetig\u00a0wachsenden\u00a0Umsatzes\u00a0v on\u00a0Biologika\u00a0und\u00a0\nbereits\u00a0erfolgter\u00a0oder\u00a0in\u00a0K\u00fcrze\u00a0bevorstehender\u00a0Patentabl\u00e4ufe\u00a0vo n\u00a0Blockbustern\u00a0\nunter\u00a0den\u00a0Biologika\u00a0\u2013\u00a0vor\u00a0allem\u00a0zur\u00a0Behandlung\u00a0onkologischer\u00a0Er krankungen\u00a0(z.B.\u00a0\nRituximab,\u00a0Trastuzumab)\u00a0\u2013\u00a0gewinnen\u00a0heute\u00a0Biosimilars\u00a0immer\u00a0mehr \u00a0an\u00a0Bedeu\u2010\ntung.\u00a0Insgesamt\u00a0sind\u00a0in\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0bis\u00a0zum\u00a030.\u00a0Juni \u00a02017\u00a029\u00a0Biosimi\u2010\nlars\u00a0zugelassen\u00a0worden,\u00a0drei\u00a0davon\u00a0im\u00a0Jahr\u00a02014.\u00a0In\u00a0Deutschland \u00a0auf\u00a0dem\u00a0Markt\u00a0\nverf\u00fcgbar\u00a0sind\u00a0derzeit\u00a023\u00a0Biosimilars.\u00a0Im\u00a0Kapitel\u00a06\u00a0werden\u00a0die\u00a0 onkologischen\u00a0Bio\u2010\nsimilars\u00a0ausf\u00fchrlich\u00a0besprochen.\u00a0Einsparpotenziale\u00a0der\u00a0Biosimil ars\u00a0finden\u00a0sich\u00a0in\u00a0\nTabelle\u00a01.4\u00a0in\u00a0der\u00a0Einf\u00fchrung.\u00a0Eine\u00a0Vielzahl\u00a0von\u00a0Studien\u00a0hat\u00a0si ch\u00a0in\u00a0den\u00a0letzten\u00a0\nJahren\u00a0mit\u00a0der\u00a0Umstellung\u00a0von\u00a0bio logischen\u00a0Referenzarzneimittel n\u00a0auf\u00a0Biosimilars\u00a0\n(sog.\u00a0Switching )\u00a0besch\u00e4ftigt\u00a0und\u00a0\u00fcbereinstimmend\u00a0gezeigt,\u00a0 dass\u00a0eine\u00a0derartige\u00a0\nUmstellung\u00a0der\u00a0Therapie\u00a0auf\u00a0das\u00a0 preisg\u00fcnstigere\u00a0Biosimilar\u00a0ohne \u00a0Nachteile\u00a0hin\u201012\u00a0sichtlich\u00a0Wirksamkeit\u00a0und\u00a0Nebenwirkungen\u00a0m\u00f6glich\u00a0ist\u00a0\u2013\u00a0im\u00a0Rahme n\u00a0der\u00a0zugelas\u2010\nsenen\u00a0Indikationen\u00a0und\u00a0bei\u00a0Verf\u00fcgbarkeit\u00a0einer\u00a0geeigneten\u00a0Darre ichungsform.\u00a0Die\u00a0\nin\u00a0den\u00a0letzten\u00a0Jahren\u00a0immer\u00a0wieder,\u00a0mitunter\u00a0auch\u00a0von\u00a0medizinis chen\u00a0Fachgesell\u2010\nschaften,\u00a0ge\u00e4u\u00dferten\u00a0Bedenken\u00a0gegen\u00a0die\u00a0Verordnung\u00a0von\u00a0Biosimil ars\u00a0sind\u00a0somit\u00a0\nwiderlegt.\u00a0Die\u00a0in\u00a0Europa\u00a0nach\u00a0wissenschaftlich\u00a0fundierten\u00a0und\u00a0s treng\u00a0kontrollier\u2010\nten\u00a0Verfahren\u00a0zugelassenen\u00a0Biosimilars\u00a0sind\u00a0therapeutisch\u00a0gleic hwertig\u00a0mit\u00a0ihren\u00a0\nReferenzarzneimitteln,\u00a0k\u00f6nnen\u00a0desh alb\u00a0wie\u00a0diese\u00a0eingesetzt\u00a0werd en\u00a0und\u00a0leisten\u00a0\ndaher\u00a0einen\u00a0wichtigen\u00a0Beitrag\u00a0zur\u00a0Versorgung\u00a0von\u00a0Patienten\u00a0mit\u00a0 den\u00a0heute\u00a0bei\u00a0\nzahlreichen\u00a0Erkrankungen\u00a0unverzi chtbaren\u00a0Biologika.\u00a0Die\u00a0Arzneim ittelkommission\u00a0\nder\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0hat\u00a0Ende\u00a0Juli\u00a02017\u00a0einen\u00a0aktualisiert en\u00a0Leitfaden\u00a0zu\u00a0\nBiosimilars\u00a0ver\u00f6ffentlicht\u00a0(Akd\u00c4,\u00a02017),\u00a0in\u00a0dem\u00a0sie\u00a0eindeutige\u00a0 Empfehlungen\u00a0zu\u00a0\nihrem\u00a0rationalen\u00a0Einsatz\u00a0gibt\u00a0und\u00a0die\u00a0Bedeutung\u00a0\u00a0ausf\u00fchrlicher, \u00a0\u00a0unabh\u00e4ngiger\u00a0\u00a0\nInformationen\u00a0f\u00fcr\u00a0Patienten,\u00a0a ber\u00a0auch\u00a0f\u00fcr\u00a0\u00c4rzte,\u00a0betont.\u00a0\u00a0\nQuellen\u00a0\nAkd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2017). \u00a0Leitfaden\u00a0der\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\n\u00c4rzteschaft\u00a0(Akd\u00c4):\u00a0Biosimilars.\u00a0https://www.akdae.de/Arzneimit teltherapie/LF/Biosimilars/,\u00a0letzter\u00a0Zugriff:\u00a0\n03.08.2017.\u00a0\nLudwig\u00a0W\u2010D\u00a0(2017).\u00a0Nutzen\u00a0und\u00a0Risiken\u00a0von\u00a0Orphan\u00a0Drugs\u00a0und\u00a0Adap tive\u00a0Pathways\u00a0f\u00fcr\u00a0Patient,\u00a0Arzt\u00a0und\u00a0Hersteller.\u00a0In:\u00a0Grandt\u00a0D,\u00a0\nSchubert\u00a0I\u00a0(Hrsg.)\u00a0Arzneimittelreport\u00a02017.\u00a0Asgard:\u00a0Siegburg:\u00a02 32\u2010247.\u00a0\nNaci\u00a0H,\u00a0Wouters\u00a0OJ,\u00a0Gupta\u00a0R,\u00a0Ioannidis\u00a0JPA\u00a0(2017).\u00a0Timing\u00a0and\u00a0c haracteristics\u00a0of\u00a0cumulative\u00a0evidence\u00a0available\u00a0on\u00a0novel\u00a0\ntherapeutic\u00a0agents\u00a0receiving\u00a0Foo d\u00a0and\u00a0Drug\u00a0Administration\u00a0accel erated\u00a0approval.\u00a0The\u00a0Milbank\u00a0Quartely\u00a095:\u00a0\u00a0\n261\u2010290.\u00a0\nPease\u00a0AM,\u00a0Krumholz\u00a0HM,\u00a0Hines\u00a0HH,\u00a0Downing\u00a0NS,\u00a0Aminawung\u00a0JA,\u00a0Shah \u00a0ND\u00a0et\u00a0al.\u00a0(2017).\u00a0Postapproval\u00a0studies\u00a0of\u00a0drugs\u00a0initially\u00a0\napproved\u00a0by\u00a0the\u00a0FDA\u00a0on\u00a0the\u00a0basis \u00a0of\u00a0limited\u00a0evidence:\u00a0systemati c\u00a0review.\u00a0BMJ\u00a0357:\u00a0j1680\u00a0doi:\u00a010.1136bmj.j\u00a01680.\u00a0\nVerordnung\u00a0(EG)\u00a0Nr.\u00a0141/2000\u00a0des\u00a0Europ\u00e4ischen\u00a0Parlaments\u00a0und\u00a0de s\u00a0Rates\u00a0vom\u00a016.\u00a0Dezember\u00a01999\u00a0\u00fcber\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0\nLeiden.\u00a0https://ec.europa.eu/health//sites/health/files/files/e udralex/vol\u20101/reg_2000_141_cons\u20102009\u2010\n07/reg_2000_141_cons\u20102009\u201007_de.pdf,\u00a0letzter\u00a0Zugriff:\u00a007.08.201 7.\u00a0\n\u00a0\u00a013\u00a01 Einleitung\u00a0\nGerd\u00a0Glaeske\u00a0\nSeit\u00a02013\u00a0bietet\u00a0der\u00a0j\u00e4hrlich\u00a0ersc heinende\u00a0Innovationsreport\u00a0Da ten\u00a0und\u00a0Fakten\u00a0zur\u00a0\nMarktentwicklung\u00a0 neuer\u00a0 Arzneimittel\u00a0 in\u00a0 der\u00a0 vertrags\u00e4rztlichen\u00a0 V ersorgung\u00a0 an.\u00a0\nBereits\u00a0 zum\u00a0 f\u00fcnften\u00a0 Mal\u00a0 analysiert\u00a0 der\u00a0 Innovationsreport\u00a0 auf\u00a0 Ba sis\u00a0 der\u00a0 Ver\u2010\nordnungsdaten\u00a0der\u00a0Techniker\u00a0Krank enkasse\u00a0(TK)\u00a0solche\u00a0neu\u00a0eingef \u00fchrten\u00a0Arznei\u2010\nmittel,\u00a0in\u00a0der\u00a0vorliegenden\u00a0Ausgabe\u00a0die\u00a0des\u00a0Jahres\u00a02014.\u00a032\u00a0Arz neimittel\u00a0wurden\u00a0\nim\u00a0Hinblick\u00a0auf\u00a0ihren\u00a0therapeutischen\u00a0Nutzen\u00a0nach\u00a0den\u00a0Kriterien \u00a0der\u00a0evidenzba\u2010\nsierten\u00a0Medizin\u00a0bewertet,\u00a0erg\u00e4nzt\u00a0um\u00a0Daten\u00a0aus\u00a0Marktentwicklung \u00a0und\u00a0Verord\u2010\nnungsrealit\u00e4t.\u00a0Durch\u00a0die\u00a0gro\u00dfe\u00a0A nzahl\u00a0von\u00a0gepr\u00fcften\u00a0Arzneimitte ln\u00a0ist\u00a0der\u00a0Innova\u2010\ntionsreport\u00a02017\u00a0deutlich\u00a0umfangreicher\u00a0als\u00a0die\u00a0bisherigen\u00a0Ausg aben.\u00a0Daher\u00a0ha\u2010\nben\u00a0wir\u00a0auch\u00a0eine\u00a0Ver\u00e4nderung\u00a0bei\u00a0der\u00a0Art\u00a0der\u00a0Ver\u00f6ffentlichung\u00a0 vorgenommen.\u00a0\nW\u00e4hrend\u00a0bislang\u00a0eine\u00a0Kurz\u2010\u00a0und\u00a0eine\u00a0Langfassung\u00a0als\u00a0Buch\u00a0publiz iert\u00a0wurden,\u00a0wird\u00a0\neine\u00a0detailliertere\u00a0Langfassung\u00a0Informationen\u00a0zu\u00a0Wirkstoff\u00a0und\u00a0 Pharmakologie,\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat,\u00a0zum\u00a0Indikationsgebiet,\u00a0Evidenz\u00a0zum\u00a0Nutz en\u00a0und\u00a0Schaden,\u00a0\nLeitlinienempfehlungen,\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V,\u00a0Kost en\u00a0etc.\u00a0k\u00fcnftig\u00a0\nim\u00a0Internet\u00a0auf\u00a0den\u00a0Seiten\u00a0des\u00a0SOCIUM\u00a0der\u00a0Universit\u00e4t\u00a0Bremen\u00a0ab rufbar\u00a0sein\u00a0\n(www.socium.uni\u2010bremen.de/abteilungen/gesundheit\u2010pflege\u2010und\u2010alt erssicherung/\u00a0\narbeitsgruppen/ag\u2010glaeske/).\u00a0Die s\u00a0ist\u00a0verbunden\u00a0mit\u00a0einem\u00a0Aktua lit\u00e4tsanspruch\u00a0\nund\u00a0Updates\u00a0der\u00a0Internetversion\u00a0sowie\u00a0einer\u00a0einfacheren\u00a0Zug\u00e4ngl ichkeit\u00a0und\u00a0gr\u00f6\u2010\n\u00dferen\u00a0Verbreitung\u00a0des\u00a0Innovationsreports.\u00a0\u00a0\nDie\u00a0vorliegende\u00a0gedruckte\u00a0Fassung\u00a0enth\u00e4lt\u00a0auf\u00a0Basis\u00a0eines\u00a0erwei terten\u00a0einheitli\u2010\nchen\u00a0Schemas\u00a0die\u00a0zusammenfassenden\u00a0Bewertungen\u00a0der\u00a0Wirkstoffe,\u00a0 dazu\u00a0Daten\u2010\nanalysen,\u00a0Patientennutzenaspekte,\u00a0Kostenanalysen\u00a0sowie\u00a0Verordnu ngspr\u00e4valen\u2010\nzen.\u00a0Der\u00a0neue\u00a0Innovationsreport\u00a02017\u00a0entspricht\u00a0im\u00a0Wesentlichen \u00a0einer\u00a0Kombina\u2010\ntion\u00a0der\u00a0bisherigen\u00a0Kurz\u2010\u00a0und\u00a0Langfassungen.\u00a0Zur\u00a0schnellen\u00a0\u00dcber sicht\u00a0dient\u00a0wie\u00a0\ngewohnt\u00a0ein\u00a0Einleger\u00a0mit\u00a0den\u00a0Ampelbewertungen\u00a0der\u00a0Wirkstoffe,\u00a0d en\u00a0Gesamt\u2010\nScores\u00a0der\u00a0Innovationsbewertungen\u00a0und\u00a0den\u00a0regionalen\u00a0Verordnung spr\u00e4valenzen.\u00a0\nDer\u00a0Arzneimittelmarkt\u00a0ver\u00e4ndert\u00a0sich:\u00a0steigende\u00a0Ausgaben\u00a0durch\u00a0 Biopharma\u2010\nzeutika\u00a0\nDer\u00a0Arzneimittelmarkt\u00a0hat\u00a0sich\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0deutlich\u00a0v er\u00e4ndert:\u00a0F\u00fcr\u00a0viele\u00a0\n\u00f6konomisch\u00a0erfolgreiche\u00a0chemisch\u2010synthetisierte\u00a0Arzneimittel\u00a0is t\u00a0der\u00a0Patentschutz\u00a0\nin\u00a0der\u00a0Zwischenzeit\u00a0ausgelaufen, \u00a0der\u00a0Generikamarkt\u00a0wird\u00a0durch\u00a0i mmer\u00a0neue\u00a0kos\u2010\nteng\u00fcnstige\u00a0Nachahmerprodukte\u00a0erweitert\u00a0und\u00a0deckt\u00a0in\u00a0der\u00a0Zwisch enzeit\u00a075\u00a0%\u00a0des\u00a0\nVerordnungsvolumens\u00a0in\u00a0der\u00a0Gese tzlichen\u00a0Krankenversicherung\u00a0(GK V).\u00a0Unterst\u00fctzt\u00a0\nwird\u00a0dies\u00a0auch\u00a0durch\u00a0Rabattvertr\u00e4ge\u00a0der\u00a0pharmazeutischen\u00a0Untern ehmer\u00a0(pU)\u00a0mit\u00a0\neinzelnen\u00a0Krankenkassen,\u00a0die\u00a0seit\u00a0dem\u00a0Jahre\u00a02003\u00a0nach\u00a0\u00a7130a\u00a0Abs .\u00a08\u00a0SGB\u00a0V\u00a0abge\u201014\u00a0schlossen\u00a0werden\u00a0k\u00f6nnen\u00a0und\u00a0die\u00a0zum\u00a01.\u00a0April\u00a02007\u00a0durch\u00a0die\u00a0ver pflichtenden\u00a0\nRegelungen\u00a0des\u00a0GKV\u2010Wettbewerbsst \u00e4rkungsgesetzes\u00a0(GKV\u2010WSG)\u00a0zur\u00a0A bgabe\u00a0der\u00a0\nMittel\u00a0in\u00a0Apotheken\u00a0aus\u00a0dem\u00a0Rabattvertrag\u00a0\u00f6konomisch\u00a0im\u00a0Sinne\u00a0e iner\u00a0sp\u00fcrbaren\u00a0\nAusgabend\u00e4mpfung\u00a0wirksam\u00a0wurden.\u00a0Damit\u00a0konnte\u00a0ein\u00a0wesentliches\u00a0 Ziel\u00a0dieses\u00a0\nRabattvertragssystems\u00a0erreicht\u00a0wer den,\u00a0n\u00e4mlich\u00a0der\u00a0Kostensteige rung\u00a0im\u00a0Arznei\u2010\nmittelsektor\u00a0entgegenzuwirken.\u00a0An fang\u00a02017\u00a0gab\u00a0es\u00a0bereits\u00a0mehr\u00a0 als\u00a025.203\u00a0kas\u2010\nsenspezifische\u00a0Rabattvertr\u00e4ge,\u00a0die\u00a0regeln,\u00a0welches\u00a0Pr\u00e4parat\u00a0ver schiedener\u00a0pU\u00a0f\u00fcr\u00a0\ndie\u00a0jeweiligen\u00a0Versicherten\u00a0abgegeben\u00a0werden\u00a0kann.\u00a0Die\u00a0Einsparu ngen\u00a0aus\u00a0diesen\u00a0\nVertr\u00e4gen\u00a0bis\u00a0Anfang\u00a02017\u00a0betrugen\u00a03,9\u00a0Mrd.\u00a0Euro,\u00a0beteiligt\u00a0war en\u00a0daran\u00a0113\u00a0\nKrankenkassen,\u00a0die\u00a015.266\u00a0rabatti erten\u00a0Arzneimittel\u00a0stammten\u00a0vo n\u00a0165\u00a0pU\u00a0(Pro\u00a0\nGenerika,\u00a02017).\u00a0\u00a0\nGleichzeitig,\u00a0und\u00a0aus\u00a0Sicht\u00a0der\u00a0 pU\u00a0geradezu\u00a0kompensatorisch,\u00a0w\u00e4 chst\u00a0aber\u00a0der\u00a0\nAnteil\u00a0meist\u00a0hochpreisiger\u00a0gent echnisch\u00a0hergestellter\u00a0Biopharma zeutika\u00a0st\u00e4ndig\u00a0an\u00a0\n(z.B.\u00a0Analoginsuline\u00a0bei\u00a0Diabetes ,\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0bei\u00a0r heumatoider\u00a0Arth\u2010\nritis\u00a0(RA),\u00a0multipler\u00a0Sklerose\u00a0(MS)\u00a0oder\u00a0onkologischen\u00a0Erkranku ngen).\u00a0Dies\u00a0zeigt\u00a0\nauch\u00a0die\u00a0Auflistung\u00a0der\u00a0umsatzst\u00e4rksten\u00a0Arzneimittel\u00a0im\u00a0Jahre\u00a02 016\u00a0(siehe\u00a0Tabelle\u00a0\n1.1),\u00a0in\u00a0der\u00a0viele\u00a0Biopharmazeutika\u00a0genannt\u00a0sind\u00a0(z.B.\u00a0Produkte \u00a0wie\u00a0Humira\u00ae,\u00a0En\u2010\nbrel\u00ae,\u00a0Lantus\u00ae,\u00a0Rebif\u00ae,\u00a0Lucentis\u00ae,\u00a0Eylea\u00ae\u00a0oder\u00a0Simponi\u00ae).\u00a0 \u00a015\u00a0Tabelle\u00a01.1:\u00a0Die\u00a020\u00a0f\u00fchrenden\u00a0Pr\u00e4parate\u00a0nach\u00a0Industrieumsatz\u00a0im \u00a0Jahr\u00a02016\u00a0\nRang\u00a0 Pr\u00e4parat\u00a0(Hersteller)\u00a0(Wirkstoff)\u00a0 Anwendungsgebiet\u00a0Umsatz\u00a0\n2016\u00a0in\u00a0\nMio.\u00a0\u20ac\u00a0Gegen\u00fcber\u00a0\n2015\u00a0in\u00a0%\u00a0\n1\u00a0 Humira\u00ae\u00a0(Abbott)\u00a0\u00a0\n(Adalimumab)\u00a0z.B.\u00a0RA\u00a0 750,8\u00a0 +10,5\u00a0\n2\u00a0 Xarelto\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Rivaroxaban)\u00a0Thromboseprophylaxe\u00a0 434,0\u00a0 +7,5\u00a0\n3\u00a0 Enbrel\u00ae\u00a0(Pfizer)\u00a0\u00a0\n(Etanercept)\u00a0z.B.\u00a0RA\u00a0 384,7\u00a0 +14,9\u00a0\n4\u00a0 Harvoni\u00ae\u00a0(Gilead)\u00a0\n(Ledipasvir+Sofosbuvir)\u00a0Hepatitis\u00a0C\u00a0 320,4\u00a0 \u201053,0\u00a0\n5\u00a0 Eliquis\u00ae\u00a0(Pfizer)\u00a0\u00a0\n(Apixaban)\u00a0Thromboseprophylaxe\u00a0 289,5\u00a0 +68,2\u00a0\n6\u00a0 Revlimid\u00ae\u00a0(Celgene)\u00a0\n(Lenalidomid)\u00a0Myelom\u00a0 270,0\u00a0 +41,6\u00a0\n7\u00a0 Gilenya\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Fingolimod)\u00a0MS\u00a0 244,9\u00a0 +16,1\u00a0\n8\u00a0 Lucentis\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Ranibizumab)\u00a0Makuladegeneration\u00a0 236,4\u00a0 +17,1\u00a0\n9\u00a0 Glivec\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Imatinib)\u00a0Krebs\u00a0 233,7\u00a0 \u20100,5\u00a0\n10\u00a0 Copaxone\u00ae\u00a0(Sanofi\u2010Aventis)\u00a0\u00a0\n(Glatiramer)\u00a0MS\u00a0 229,4\u00a0 +9,9\u00a0\n11\u00a0 Xtandi\u00ae\u00a0(Astellas)\u00a0\u00a0\n(Enzalutamid)\u00a0Prostatakrebs\u00a0 217,8\u00a0 +35,7\u00a0\n12\u00a0 Tecfidera\u00ae\u00a0(Biogen)\u00a0\n(Dimethylfumarat)\u00a0MS\u00a0 209,3\u00a0 \u201019,9\u00a0\n13\u00a0 Lantus\u00ae\u00a0(Sanofi\u2010Aventis)\u00a0\u00a0\n(Insulin\u00a0glargin)\u00a0Diabetes\u00a0 202,2\u00a0 \u20102,5\u00a0\n14\u00a0 Rebif\u00ae\u00a0(Merck\u2010Serono)\u00a0\u00a0\n(Interferon\u00a0\u00df\u20101a)\u00a0MS\u00a0 196,8\u00a0 \u20104,7\u00a0\n15\u00a0 Spiriva\u00ae\u00a0(Boehr.\u00a0Ingelheim)\u00a0\n(Tiotropium)\u00a0COPD\u00a0 193,2\u00a0 \u20107,0\u00a0\n16\u00a0 Zytiga\u00ae\u00a0(Janssen)\u00a0\u00a0\n(Abitareron)\u00a0Prostatakrebs\u00a0 182,0\u00a0 \u201014,0\u00a0\n17\u00a0 Eylea\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Aflibercept)\u00a0Makuladegeneration\u00a0 174,8\u00a0 +17,1\u00a0\n18\u00a0 Simponi\u00ae\u00a0(MSD)\u00a0\u00a0\n(Golimumab)\u00a0z.B.\u00a0RA\u00a0 172,1\u00a0 +18,4\u00a0\n19\u00a0 Symbicort\u00ae\u00a0(AstraZ)\u00a0\n(Budesonid\u00a0+\u00a0Formoterol)\u00a0Asthma/COPD\u00a0 167,0\u00a0 \u20100,9\u00a0\n20\u00a0 Clexane\u00ae\u00a0(Sanofi\u2010Aventis)\u00a0\n(Enoxaparin)\u00a0Thromboseprophylaxe\u00a0 160,6\u00a0 \u20104,1\u00a0\n\u00a0 Gesamtmarkt\u00a0 \u00a0 31.481,2\u00a0 +3,1\u00a0\nQuelle:\u00a0nach\u00a0IMS\u00a0Health,\u00a02016\u00a0\nIn\u00a0Deutschland\u00a0sind\u00a0derzeit\u00a0221\u00a0Arzneimittel\u00a0mit\u00a0173\u00a0Wirkstoffe n\u00a0zugelassen,\u00a0die\u00a0\ngentechnisch\u00a0hergestellt\u00a0werden,\u00a02015\u00a0waren\u00a0es\u00a0noch\u00a0155\u00a0(vfa,\u00a02 017;\u00a02015).\u00a0Wichti\u2010\nge\u00a0Anwendungsbereiche\u00a0sind\u00a0u.a.\u00a0Diabetes\u00a0(Insuline),\u00a0MS\u00a0und\u00a0Aut oimmunkrankhei\u2010\nten\u00a0wie\u00a0RA,\u00a0CED\u00a0(chronisch\u2010entz\u00fcndliche\u00a0Darmerkrankungen),\u00a0(vgl .\u00a0auch\u00a0Rheuma\u201016\u00a0Daten\u00a0in\u00a0Tab.\u00a01.5)\u00a0und\u00a0Psoriasis\u00a0(Immunmodulatoren),\u00a0Krebserkra nkungen\u00a0(mono\u2010\nklonale\u00a0Antik\u00f6rper),\u00a0angeborene\u00a0Stoffwechsel\u2010\u00a0und\u00a0Gerinnungsst\u00f6 rungen\u00a0(Enzyme,\u00a0\nGerinnungsfaktoren)\u00a0 sowie\u00a0 Schutzimpfungen\u00a0 (Geb\u00e4rmutterhalskrebs ,\u00a0 Hepatitis\u00a0 B)\u00a0\nund\u00a0Osteoporose.\u00a0\nDiese\u00a0173\u00a0Wirkstoffe\u00a0aus\u00a0gentechnologischer\u00a0Herstellung\u00a0entspre chen\u00a09\u00a0%\u00a0aller\u00a0\nzugelassenen\u00a0Wirkstoffe\u00a0und\u00a030\u00a0%\u00a0 aller\u00a0j\u00e4hrlichen\u00a0Neuerungen.\u00a0E inige\u00a0stammen\u00a0\naus\u00a0derselben\u00a0Produktionsst\u00e4tte,\u00a0sind\u00a0aber\u00a0unter\u00a0verschiedenen\u00a0 Markennamen\u00a0\nzugelassen\u00a0(sogenannte\u00a0Zweitmarken\u00a0oder\u00a0 Bioidenticals )\u00a0(vfa,\u00a02017).\u00a0\nAuff\u00e4llig\u00a0sind\u00a0die\u00a0Marktanteile\u00a0d er\u00a0Biopharmazeutika\u00a0in\u00a0drei\u00a0In dikationsbereichen:\u00a0\nIm\u00a0Bereich\u00a0Stoffwechsel\u00a0(z.B.\u00a0Diabetes)\u00a0lag\u00a0der\u00a0Anteil\u00a0im\u00a0Jahre \u00a02014\u00a0bei\u00a038\u00a0%\u00a0\n(2005:\u00a023\u00a0%),\u00a0im\u00a0Bereich\u00a0Onkologie\u00a0bei\u00a038\u00a0%\u00a0(2005:\u00a021\u00a0%)\u00a0und\u00a0im \u00a0Bereich\u00a0Immuno\u2010\nlogie\u00a0bei\u00a073\u00a0%\u00a0(2005:\u00a019\u00a0%).\u00a0Der\u00a0Umsatz\u00a0der\u00a0Branche\u00a0wuchs\u00a0inner halb\u00a0eines\u00a0Jahres\u00a0\ngar\u00a0um\u00a07\u00a0%\u00a0(vfa\u00a0bio\u00a0&\u00a0Boston\u00a0Consulting,\u00a02015).\u00a0Vor\u00a0allem\u00a0die\u00a0e rweiterten\u00a0Behand\u2010\nlungsm\u00f6glichkeiten,\u00a0 insbesondere\u00a0 f\u00fcr\u00a0 Patienten\u00a0 mit\u00a0 Autoimmun\u2010\u00a0 u nd\u00a0 Krebser\u2010\nkrankungen,\u00a0f\u00fchren\u00a0offenbar\u00a0zu\u00a0diesem\u00a0Umsatzwachstum.\u00a0All\u00a0diese \u00a0Mittel\u00a0haben\u00a0\neines\u00a0gemeinsam\u00a0\u2013\u00a0sie\u00a0sind\u00a0extrem \u00a0teuer:\u00a0Immer\u00a0h\u00e4ufiger\u00a0kritisi eren\u00a0insbesondere\u00a0\nOnkologen\u00a0\u201edie\u00a0Preisentwicklung\u00a0u nd\u00a0damit\u00a0die\u00a0Erschwinglichkeit \u00a0onkologischer\u00a0\nWirkstoffe\u00a0\u2013\u00a0teilweise\u00a0mit\u00a0Jahrestherapiekosten\u00a0von\u00a050.000\u00a0bis\u00a0 mehr\u00a0als\u00a0100.000\u00a0\nEuro\u00a0pro\u00a0Patienten.\u201c\u00a0(Ludwig\u00a0&\u00a0Schildmann,\u00a02015).\u00a0Insgesamt\u00a0ver ursachen\u00a0die\u00a0\netwa\u00a04\u00a0%\u00a0aller\u00a0Verordnungen\u00a0mit\u00a0solchen\u00a0biopharmazeutischen\u00a0Pro dukten\u00a0rund\u00a0\n40\u00a0%\u00a0aller\u00a0Arzneimittelausgaben\u00a0in\u00a0der\u00a0GKV\u00a0(Glaeske,\u00a02016a).\u00a0Au ch\u00a0in\u00a0diesem\u00a0\nBereich\u00a0wird\u00a0\u2013\u00a0wie\u00a0schon\u00a0bei\u00a0den\u00a0chemisch\u00a0synthetisierten\u00a0Arzne imittelwirkstoffen\u00a0\n\u2013\u00a0die\u00a0Me\u2010too\u2010Strategie\u00a0einbezogen.\u00a0Es\u00a0werden \u00a0lukrative,\u00a0aber\u00a0(sehr)\u00a0\u00e4hnlich e\u00a0Wirk\u2010\nstoffe\u00a0 zu\u00a0 hohen\u00a0 Preisen\u00a0 angeboten,\u00a0 notwendige\u00a0 und\u00a0 wirkliche\u00a0 the rapeutische\u00a0\nInnovationen\u00a0geraten\u00a0\u00fcber\u00a0solche\u00a0vor\u00a0allem\u00a0\u00f6konomisch\u00a0orientier ten\u00a0Forschungs\u2010\u00a0\nund\u00a0Angebotsstrategien\u00a0oftmals\u00a0in\u00a0den\u00a0Hintergrund.\u00a0\nIn\u00a0diesem\u00a0Zusammenhang\u00a0spielen\u00a0a uch\u00a0Biosimilars\u00a0eine\u00a0bedeutende \u00a0Rolle.\u00a0Es\u00a0sind\u00a0\nbiotechnologisch\u00a0hergestellte\u00a0Ar zneimittel\u00a0als\u00a0Folgepr\u00e4parate\u00a0v on\u00a0Biopharmazeu\u2010\ntika\u00a0nach\u00a0deren\u00a0Patentablauf.\u00a0Da \u00a0ihr\u00a0Wirkstoff\u00a0vergleichbar\u00a0ist \u00a0mit\u00a0dem\u00a0Wirkstoff\u00a0\ndes\u00a0 bereits\u00a0 zugelassenen\u00a0 biotec hnologisch\u00a0 hergestellten\u00a0 Arzneim ittels\u00a0 sind\u00a0 die\u00a0\nurspr\u00fcnglichen\u00a0 Biopharmazeutika\u00a0 deren\u00a0 \u201eReferenzprodukte\u201c.\u00a0 Derze it\u00a0 sind\u00a0 die\u00a0\nfolgenden\u00a0Biosimilars,\u00a0von\u00a0denen\u00a0 einige\u00a0auch\u00a0in\u00a0der\u00a0Krebstherap ie\u00a0eine\u00a0wichtige\u00a0\nRolle\u00a0spielen,\u00a0in\u00a0Deutschland\u00a0zugelassen:\u00a0 \u00a017\u00a0Tabelle\u00a01.2:\u00a0Zugelassene\u00a0Biosimilars\u00a0\nHandelsname/\u00a0\nHersteller\u00a0INN\u00a0 Referenzprodukt\u00a0 Datum\u00a0der\u00a0\nZulassung\nOmnitrope\u00ae/Sandoz\u00a0 Somatropin\u00a0 Genotropin\u00ae\u00a0 12.04.2006\u00a0\nBinocrit\u00ae/Sandoz\u00a0\nEpoetin\u00a0alfa\u00a0Hexal\u00ae/Hexal\u00a0\nAbseamed\u00ae/Medice\u00a0Epoetin\u00a0alfa\u00a0 Erypo\u00ae\u00a0 28.08.2007\u00a0\nRetacrit\u00ae/Hospira\u00a0\nSilapo\u00ae/STADA\u00a0Epoetin\u00a0zeta\u00a0 Eprex\u00ae\u00a0 18.12.2007\u00a0\nBiograstim\u00ae/AbZ\u00a0 Filgrastim\u00a0 Neupogen\u00ae\u00a0 15.09.2008\u00a0\nFilgrastim\u00a0Hexal\u00ae/Hexal\u00a0\u00a0 Filgrastim\u00a0 Neupogen\u00ae\u00a0 06.02.2009\u00a0\nNivestim\u00ae/Hospira\u00a0 Filgrastim\u00a0 Neupogen\u00ae\u00a0 08.06.2010\u00a0\nGrastofil\u00ae/STADA/\u00a0\ncell\u00a0pharm\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 18.10.2013\u00a0\nAccofil\u00ae/Accord\u00a0Healthcare\u00a0 Filgrastim\u00a0 Neupogen\u00ae\u00a0 18.09.2014\u00a0\nInflectra\u00ae/Hospira\u00a0\nRemsima\u00ae/MundipharmaInfliximab\u00a0 Remicade\u00ae\u00a0 10.09.2013\u00a0\nFlixabi\u00ae/Biogen\u00a0 Inflix imab\u00a0 Remicade\u00ae\u00a0 30.05.2016\u00a0\nOvaleap\u00ae/Teva\u00a0 Follitropin\u00a0alfa\u00a0 GONAL\u2010f\u00ae\u00a0 27.09.2013\u00a0\nBemfola\u00ae/Finox\u00a0 Follitropin\u00a0alfa\u00a0 GONAL\u2010f\u00ae\u00a0 27.03.2014\u00a0\nAbasaglar\u00ae/Lilly/\u00a0\nBoehringer\u00a0Ingelheim\u00a0Insulin\u00a0Glargin\u00a0 Lantus\u00ae\u00a0 09.09.2014\u00a0\nBenepali\u00ae/Biogen\u00a0 Etanercept\u00a0 Enbrel\u00ae\u00a0 14.01.2016\u00a0\nTruxima\u00ae/Mundipharma\u00a0 Rituximab\u00a0 MabThera\u00ae\u00a0 22.02.2017\u00a0\nQuelle:\u00a0nach\u00a0Pro\u00a0Biosimilars,\u00a02017a,\u00a0erg\u00e4nzt\u00a0\nUnter\u00a0diesen\u00a0Aspekten\u00a0kann\u00a0die\u00a0ver\u00e4nderte\u00a0Ausgabenentwicklung\u00a0i n\u00a0der\u00a0GKV\u00a0nicht\u00a0\nerstaunen.\u00a0Die\u00a0kostend\u00e4mpfende\u00a0Wirkung\u00a0von\u00a0Generika,\u00a0Rabattvert r\u00e4gen,\u00a0gesetz\u2010\nlich\u00a0verf\u00fcgten\u00a0Herstellerrabatten\u00a0auf\u00a0patentgesch\u00fctzte\u00a0Arzneimi ttel\u00a0(ab\u00a0Sommer\u00a0\n2010:\u00a016\u00a0%,\u00a0Januar\u00a0bis\u00a0M\u00e4rz\u00a02014\u00a06\u00a0%,\u00a0ab\u00a0April\u00a02014:\u00a07\u00a0%)\u00a0oder\u00a0 auch\u00a0das\u00a0Arznei\u2010\nmittelmarktneuordnungsgesetz\u00a0(AM NOG)\u00a0mit\u00a0der\u00a0Verhandlung\u00a0von\u00a0Er stattungsbe\u2010\ntr\u00e4gen\u00a0ab\u00a02011\u00a0haben\u00a0bisher\u00a0nicht\u00a0dazu\u00a0gef\u00fchrt,\u00a0den\u00a0Ausgabenans tieg\u00a0\u2013\u00a0insbeson\u2010\ndere\u00a0wegen\u00a0der\u00a0hohen\u00a0Preise\u00a0von\u00a0 Biopharmazeutika\u00a0\u2013\u00a0zu\u00a0kontrolli eren.\u00a0Die\u00a0Ausga\u2010\nben\u00a0f\u00fcr\u00a0Arzneimittel\u00a0in\u00a0der\u00a0GKV\u00a0aus\u00a0Versandhandel,\u00a0Apotheken\u00a0un d\u00a0aus\u00a0sonstigen\u00a0\nQuellen\u00a0sind\u00a02016\u00a0auf\u00a036,27\u00a0Mrd.\u00a0Euro\u00a0angestiegen.\u00a0Im\u00a0Jahre\u00a0201 5\u00a0betrugen\u00a0sie\u00a0\nnoch\u00a034,84\u00a0Mrd.\u00a0Euro\u00a0(GKV\u2010Spitzenverband,\u00a02016).\u00a0Die\u00a0folgende\u00a0A bbildung\u00a01.1\u00a0\nzeigt\u00a0den\u00a0Ausgabenanstieg\u00a0\u00fcber\u00a0die\u00a0vergangenen\u00a0Jahre\u00a0bis\u00a0zum\u00a0Ja hr\u00a02016\u00a0(GKV\u2010\nSpitzenverband,\u00a02016).\u00a0 \u00a018\u00a0Abbildung\u00a01.1:\u00a0Arzneimittelausgaben\u00a0in\u00a0der\u00a0GKV\u00a0bis\u00a0zum\u00a0Jahr\u00a0201 6\u00a0\n\u00a0\nQuelle:\u00a0Amtliche\u00a0Statistik\u00a0KJ\u00a01\u00a0nach\u00a0GKV\u2010Spitzenverband,\u00a02016\u00a0\nEine\u00a0differenzierte\u00a0Betrachtung\u00a0der\u00a0Arzneimittelverordnungen\u00a0in \u00a0der\u00a0GKV\u00a0zeigt,\u00a0\ndass\u00a0insbesondere\u00a0die\u00a0patentgesch\u00fctzten\u00a0Mittel,\u00a0zu\u00a0denen\u00a0auch\u00a0n och\u00a0die\u00a0meisten\u00a0\nBiologika\u00a0geh\u00f6ren,\u00a0zu\u00a0den\u00a0erke nnbaren\u00a0Ausgabensteigerungen\u00a0f\u00fchr en.\u00a0\u00a0\nAbbildung\u00a01.2:\u00a0Neue\u00a0Arzneimittel\u00a0als\u00a0Kostentreiber\u00a0\n\u00a0\nQuelle:\u00a0GKV\u2010Arzneimittelindex\u00a0im\u00a0WidO\u00a02010\u00a0nach\u00a0GKV\u2010Spitzenverb and,\u00a02016\u00a0\n19\u00a0Diese\u00a0Abbildung\u00a0best\u00e4tigt\u00a0zwar\u00a0d ie\u00a0immer\u00a0wieder\u00a0getroffene\u00a0Auss age,\u00a0dass\u00a0die\u00a0\nPreisentwicklung\u00a0 im\u00a0 deutschen\u00a0 Arzneimittelmarkt\u00a0 moderat\u00a0 bis\u00a0 sta bil\u00a0 verlaufe,\u00a0\nwenn\u00a0man\u00a0den\u00a0Gesamtmarkt\u00a0betracht et.\u00a0Sie\u00a0zeigt\u00a0bei\u00a0differenzier ter\u00a0Betrachtung\u00a0\ndie\u00a0v\u00f6llig\u00a0unterschiedlichen\u00a0Entwicklungen\u00a0bei\u00a0den\u00a0festbetrags\u2010 \u00a0und\u00a0nicht\u2010festbe\u2010\ntragsgeregelten\u00a0Arzneimitteln,\u00a0zu\u00a0denen\u00a0auch\u00a0der\u00a0Gro\u00dfteil\u00a0der\u00a0g entechnologisch\u00a0\nhergestellten\u00a0Mittel\u00a0geh\u00f6ren.\u00a0Let ztlich\u00a0tr\u00e4gt\u00a0die\u00a0sinkende\u00a0Ausg abenentwicklung\u00a0im\u00a0\nimmer\u00a0gr\u00f6\u00dfer\u00a0werdenden\u00a0Festbetragsmarkt,\u00a0auch\u00a0bedingt\u00a0durch\u00a0die \u00a0steigende\u00a0\nAnzahl\u00a0von\u00a0Rabattvertr\u00e4gen,\u00a0zur\u00a0 Kompensation\u00a0der\u00a0steigenden\u00a0Aus gaben\u00a0im\u00a0deut\u2010\nlich\u00a0kleineren\u00a0Markt\u00a0der\u00a0teuren\u00a0patentgesch\u00fctzten\u00a0Arzneimittel\u00a0 bei.\u00a0Die\u00a0Preise\u00a0der\u00a0\nneuen\u00a0patentgesch\u00fctzten\u00a0Arzneimittel\u00a0stehen\u00a0h\u00e4ufig\u00a0in\u00a0keiner\u00a0er kennbaren\u00a0Bezie\u2010\nhung\u00a0zum\u00a0nachgewiesenen\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0bisher\u00a0angeboten en\u00a0Thera\u2010\npieoptionen.\u00a0Die\u00a0Preise\u00a0spiegeln\u00a0eher\u00a0die\u00a0Vorstellung\u00a0der\u00a0pU\u00a0wi der,\u00a0dass\u00a0der\u00a0Preis,\u00a0\nden\u00a0der\u00a0Markt\u00a0bereit\u00a0ist\u00a0zu\u00a0zahlen,\u00a0der\u00a0angemessene\u00a0ist.\u00a0In\u00a0die sem\u00a0Zusammenhang\u00a0\nbilden\u00a0die\u00a0Preisverhandlungen\u00a0im\u00a0AMNOG\u00a0noch\u00a0keine\u00a0erkennbar\u00a0wir ksame\u00a0Strate\u2010\ngie\u00a0gegen\u00fcber\u00a0den\u00a0Vorstellungen\u00a0 und\u00a0Erwartungen\u00a0der\u00a0pU.\u00a0Schlie\u00df lich\u00a0soll\u00a0es\u00a0nicht\u00a0\nprim\u00e4r\u00a0um\u00a0die\u00a0Profitinteressen\u00a0der\u00a0Industrie\u00a0gehen,\u00a0sondern\u00a0um\u00a0 den\u00a0Nutzen\u00a0f\u00fcr\u00a0\ndie\u00a0Patienten,\u00a0der\u00a0im\u00a05.\u00a0Sozialg esetzbuch\u00a0(SGB\u00a0V),\u00a0\u00a7\u00a035\u00a0b,\u00a0wie\u00a0 folgt\u00a0konkretisiert\u00a0\nwird:\u00a0\u201eBeim\u00a0Patienten\u2010Nutzen\u00a0so llen\u00a0insbesondere\u00a0die\u00a0Verbesseru ng\u00a0des\u00a0Gesund\u2010\nheitszustandes,\u00a0eine\u00a0Verk\u00fcrzung\u00a0der\u00a0Krankheitsdauer,\u00a0eine\u00a0Verl\u00e4 ngerung\u00a0der\u00a0Le\u2010\nbensdauer,\u00a0eine\u00a0Verringerung\u00a0der\u00a0Nebenwirkungen\u00a0sowie\u00a0eine\u00a0Verb esserung\u00a0der\u00a0\nLebensqualit\u00e4t\u00a0[\u2026]\u00a0ber\u00fccksichtigt\u00a0werden.\u201c\u00a0\nMit\u00a0 einer\u00a0 ausschlie\u00dflich\u00a0 vergle ichenden\u00a0 Nutzenbewertung\u00a0 l\u00e4sst\u00a0 s ich\u00a0 daher\u00a0 die\u00a0\nFrage\u00a0 nach\u00a0 der\u00a0 Wirtschaftlichkei t\u00a0 eines\u00a0 Arzneimittels\u00a0 keinesweg s\u00a0 ausreichend\u00a0\nbeantworten.\u00a0Dies\u00a0ist\u00a0erst\u00a0mit\u00a0einer\u00a0gesundheits\u00f6konomischen\u00a0Ev aluation\u00a0m\u00f6glich,\u00a0\ndie\u00a0nicht\u00a0nur\u00a0die\u00a0absoluten\u00a0Arzne imittelpreise\u00a0vergleichend\u00a0bet rachtet\u00a0(zweckm\u00e4\u2010\n\u00dfige\u00a0Vergleichstherapie\u00a0gegen\u00fcber\u00a0den\u00a0Kosten\u00a0des\u00a0neuen\u00a0Arzneimi ttels),\u00a0sondern\u00a0\nauch\u00a0die\u00a0gesamten\u00a0Ressourcenverbr \u00e4uche\u00a0der\u00a0Therapiealternativen \u00a0und\u00a0die\u00a0Sum\u2010\nme\u00a0der\u00a0lebenslangen\u00a0Krankheitskosten\u00a0ber\u00fccksichtigt\u00a0(Wasem\u00a0et\u00a0a l.,\u00a02005).\u00a0Die\u00a0\nForderung,\u00a0dass\u00a0jedes\u00a0in\u00a0der\u00a0GKV\u00a0 verordnete\u00a0Arzneimittel\u00a0eine\u00a0K osten\u2010Nutzen\u2010\nBewertung\u00a0durchl\u00e4uft,\u00a0ist\u00a0deshalb\u00a0eine\u00a0Voraussetzung,\u00a0um\u00a0im\u00a0Rah men\u00a0einer\u00a0ver\u2010\ngleichenden\u00a0Wirtschaftlichkeitsanalyse\u00a0eine\u00a0m\u00f6glichst\u00a0effizient e\u00a0Arzneimittelthe\u2010\nrapie\u00a0zu\u00a0identifizieren.\u00a0Der\u00a0Nut zen\u00a0bekommt\u00a0in\u00a0diesem\u00a0Zusammenh ang\u00a0den\u00a0Rang\u00a0\neines\u00a0medizinisch\u00a0positiven\u00a0Kausaleffekts\u00a0zuerkannt.\u00a0Die\u00a0Bewert ung\u00a0des\u00a0Kosten\u2010\nNutzen\u2010Verh\u00e4ltnisses\u00a0soll\u00a0daher\u00a0insbesondere\u00a0dabei\u00a0helfen,\u00a0eine n\u00a0\u201eH\u00f6chstbetrag\u201c\u00a0\nzu\u00a0finden,\u00a0der\u00a0den\u00a0Nutzen\u00a0eines\u00a0Arzneimittels\u00a0angemessen\u00a0verg\u00fct et.\u00a0Die\u00a0Art\u00a0und\u00a0\nWeise\u00a0der\u00a0Kosten\u2010Nutzen\u2010Bewertung\u00a0im\u00a0AMNOG\u00a0war\u00a0allerdings\u00a0von\u00a0B eginn\u00a0an\u00a0\nGegenstand\u00a0erheblicher\u00a0Kontrovers en:\u00a0Das\u00a0IQWiG\u00a0verfolgt\u00a0n\u00e4mlich \u00a0nicht\u00a0den\u00a0von\u00a0\neinigen\u00a0Gesundheits\u00f6konomen\u00a0bef\u00fcrworteten\u00a0objektiv\u00a0utilitaristi schen\u00a0Ansatz,\u00a0in\u00a0\ndem\u00a0z.B.\u00a0 Quality\u00a0Adjusted\u00a0Life\u00a0Years \u00a0(QALYs)\u00a0\u2013\u00a0wie\u00a0in\u00a0Gro\u00dfbritannien\u00a0\u00fcblich\u00a0\u2013\u00a0\u00a0als\u00a0\nEntscheidungsgr\u00f6\u00dfe\u00a0eingef\u00fchrt\u00a0werden.\u00a0Es\u00a0favorisiert\u00a0als\u00a0Method e\u00a0die\u00a0\u201eAnalyse\u00a020\u00a0der\u00a0Effizienzgrenze\u201c,\u00a0wobei\u00a0jede \u00a0Arzneimitteltherapie\u00a0f\u00fcr\u00a0sich, \u00a0unter\u00a0Ber\u00fccksichti\u2010\ngung\u00a0sonstiger\u00a0f\u00fcr\u00a0diese\u00a0Krankheit\u00a0in\u00a0Frage\u00a0kommender\u00a0Medikamen te,\u00a0bewertet\u00a0\nwerden\u00a0soll\u00a0(Dintsios\u00a0et\u00a0al.,\u00a02009).\u00a0Die\u00a0einschr\u00e4nkende\u00a0und\u00a0in\u00a0 diesem\u00a0Zusammen\u2010\nhang\u00a0 eher\u00a0 wenig\u00a0 sinnvolle\u00a0 Hypothe k\u00a0 der\u00a0 rein\u00a0 arzneimittelwirksto ffbezogenen\u00a0\nPreisvergleiche\u00a0aus\u00a0der\u00a0Festbetr agsregelung\u00a0ist\u00a0in\u00a0diesem\u00a0Konst rukt\u00a0unschwer\u00a0zu\u00a0\nerkennen.\u00a0Der\u00a0AMNOG\u2010Prozess\u00a0wurde\u00a0von\u00a0Beginn\u00a0an\u00a0als\u00a0lernendes\u00a0S ystem\u00a0ver\u2010\nstanden;\u00a0in\u00a0seiner\u00a0Weiterentwick lung\u00a0sollte\u00a0dies\u00a0auch\u00a0erkennbar \u00a0sein.\u00a0\nBiologika\u00a0und\u00a0Biosimilars\u00a0in\u00a0der\u00a0Onkologie\u00a0\u2013\u00a0Zahlen,\u00a0Daten,\u00a0Fak ten\u00a0\nIm\u00a0Kapitel\u00a06,\u00a0mit\u00a0dem\u00a0Thema\u00a0Bios imilars\u00a0in\u00a0der\u00a0Onkologie,\u00a0werde n\u00a0M\u00f6glichkeiten\u00a0\nangesprochen,\u00a0die\u00a0derzeitig\u00a0h\u00e4uf ig\u00a0verordneten\u00a0Biologika\u00a0in\u00a0der \u00a0onkologischen\u00a0\nVersorgung\u00a0 durch\u00a0 kosteng\u00fcnstigere \u00a0 Biosimilars\u00a0 zu\u00a0 substituieren. \u00a0 Dies\u00a0 ist\u00a0 auch\u00a0\ndeshalb\u00a0ein\u00a0wichtiger\u00a0Schritt\u00a0zur\u00a0Ausgabensenkung,\u00a0weil\u00a0im\u00a0Jahr e\u00a02015\u00a0alleine\u00a0die\u00a0\nGruppen\u00a0der\u00a0gentechnologisch\u00a0herg estellten\u00a0Arzneimittel\u00a0aus\u00a0den \u00a0Bereichen\u00a0Im\u2010\nmunsuppressiva,\u00a0Antidiabetika\u00a0und\u00a0Immunstimulanzien\u00a0in\u00a0der\u00a0GKV\u00a0 Ausgaben\u00a0von\u00a0\n7,2\u00a0Mrd.\u00a0Euro\u00a0verursacht\u00a0haben\u00a0(20\u00a0%\u00a0der\u00a0Gesamtausgaben\u00a0bei\u00a0ein em\u00a0Verord\u2010\nnungsanteil\u00a0von\u00a02,5\u00a0%).\u00a02015\u00a0kam en\u00a037\u00a0neue\u00a0Wirkstoffe\u00a0auf\u00a0den\u00a0M arkt,\u00a0davon\u00a0\nwaren\u00a012\u00a0in\u00a0der\u00a0Onkologie\u00a0zugelassene\u00a0Biosimilars\u00a0(vgl.\u00a0Tab.\u00a06. 1).\u00a0Seit\u00a0dem\u00a0Jahre\u00a0\n2005\u00a0sind\u00a0die\u00a0Ausgaben\u00a0f\u00fcr\u00a0solche\u00a0Arzneimittel\u00a0um\u00a0153\u00a0%\u00a0angesti egen\u00a0(Schwabe\u00a0&\u00a0\nPaffrath,\u00a02016).\u00a0\nTabelle\u00a01.3:\u00a0Verordnungen\u00a0von\u00a0Biologika\u00a0mit\u00a0Ersatzpotenzial\u00a0dur ch\u00a0Biosimilars\u00a0f\u00fcr\u00a0\nVersicherte\u00a0mit\u00a0ICD\u2010Diagnosegruppe\u00a0C\u00a0(auf\u00a0der\u00a0Basis\u00a0von\u00a0TK\u2010Ausw ertungen)\u00a001.10.2015\u00a0\u2010\u00a030.09.2016 \u00a0Kennzahlen\u00a0\nHochrechnung\u00a0\nGKV\u00a0Anzahl\u00a0GKV\u2010\nVersicherte*\u00a0Brutto\u00a0\nAusgaben/Euro\u00a0Summe\u00a0DDDs\u00a0 Pro\u00a0DDD\u00a0Brutto\u00a0\nAusgaben/Euro\u00a0\u00a0\nB03XA02\u00a032.307\u00a0 34.313.911,72\u00a0 3.254.275,09\u00a0 10,54\u00a0Darbepoetin\u00a0alfa\u00a0\nL01XC02\u00a063.531\u00a0 312.541.540,60\u00a0 2.367.633,21\u00a0 132,01\u00a0Rituximab\u00a0\nL01XC03\u00a065.022\u00a0 537.577.038,92\u00a0 4.579.863,59\u00a0 117,38\u00a0Trastuzumab\u00a0\nL01XC06\u00a011.138\u00a0 81.190.874,25\u00a0 412.153,38\u00a0 196,99\u00a0Cetuximab\u00a0\nL01XC07\u00a061.596\u00a0 569.959.533,19\u00a0 2.970.776,85\u00a0 191,86\u00a0Bevacizumab\u00a0\nL01XC08\u00a09.357\u00a0 67.580.115,69\u00a0 357.949,31\u00a0 188,80\u00a0Panitumumab\u00a0\nL01XC11\u00a01.084\u00a0 29.245.321,93\u00a0 36.973,77\u00a0 790,97\u00a0Ipilimumab\u00a0\nL03AA13\u00a041.035\u00a0 122.365.624,81\u00a0 1.430.733,38\u00a0 85,53\u00a0Pegfilgrastim\u00a0\n*Versicherte\u00a0 mit\u00a0 mindestens\u00a0 einer\u00a0 einmal\u00a0 abgerechneten\u00a0 ambulant en\u00a0 oder\u00a0 station\u00e4ren\u00a0 C\u2010Diagnose\u00a0 (Auswertungszeitraum\u00a0\n01.10.2015\u00a0bis\u00a030.09.2016,\u00a0Datenbasis\u00a0\u00a7300er\u00a0Apothekendaten\u00a0und \u00a0Rezepturen;\u00a0Stand:\u00a020.04.2017)\u00a021\u00a0Neben\u00a0den\u00a0Originator\u2010Biologika\u00a0mehr\u00a0und\u00a0mehr\u00a0Biosimilars\u00a0\nBisher\u00a0sind\u00a0die\u00a0meisten\u00a0Biologik a\u00a0im\u00a0Bereich\u00a0der\u00a0(begleitenden) \u00a0Krebsbehandlung\u00a0\nnoch\u00a0immer\u00a0als\u00a0Originatorprodukte\u00a0auf\u00a0dem\u00a0Markt\u00a0\u2013\u00a0nur\u00a0einige\u00a0we nige\u00a0Mittel\u00a0sind\u00a0\nals\u00a0kosteng\u00fcnstige\u00a0Biosimilars\u00a0verf\u00fcgbar\u00a0(z.B.\u00a0Erythropoetin\u00a0od er\u00a0Filgrastim).\u00a0Im\u00a0\nKapitel\u00a06,\u00a0Tabelle\u00a06.2,\u00a0wird\u00a0dar auf\u00a0hingewiesen,\u00a0dass\u00a0eine\u00a0Reih e\u00a0von\u00a0h\u00e4ufig\u00a0in\u00a0der\u00a0\nOnkologie\u00a0eingesetzten\u00a0Biologika \u00a0schon\u00a0ihren\u00a0europ\u00e4ischen\u00a0Paten tschutz\u00a0verloren\u00a0\nhaben\u00a0oder\u00a0in\u00a0absehbarer\u00a0Zeit\u00a0verlieren\u00a0werden,\u00a0so\u00a0z.B.\u00a0Rituxim ab\u00a0(November\u00a0\n2013),\u00a0Cetuximab\u00a0(Juni\u00a02014),\u00a0Trastuzumab\u00a0(August\u00a02015),\u00a0Darbep oetin\u00a0alfa\u00a0(Juli\u00a0\n2016),\u00a0Pegfilgrastim\u00a0(August\u00a02017).\u00a0Als\u00a0erstes\u00a0Biosimilar\u00a0diese r\u00a0Gruppe\u00a0von\u00a0Biolo\u2010\ngika\u00a0wurde\u00a0am\u00a022.\u00a0Februar\u00a02017\u00a0Truxima\u00ae\u00a0des\u00a0s\u00fcdkoreanischen\u00a0Unt ernehmens\u00a0\nCelltrion\u00a0mit\u00a0dem\u00a0Wirkstoff\u00a0Rituximab\u00a0f\u00fcr\u00a0den\u00a0europ\u00e4ischen\u00a0Mark t\u00a0zugelassen.\u00a0Es\u00a0\nwird\u00a0in\u00a0Deutschland\u00a0durch\u00a0die\u00a0Firma\u00a0Mundipharma\u00a0vertrieben.\u00a0Tru xima\u00ae\u00a0ist\u00a0das\u00a0\nNachfolgepr\u00e4parat\u00a0von\u00a0MabThera\u00ae\u00a0\u00a0und\u00a0wird\u00a0in\u00a0den\u00a0gleichen\u00a0Indikationsgebieten\u00a0\neingesetzt\u00a0wie\u00a0das\u00a0Originalpr\u00e4parat,\u00a0z.B.\u00a0also\u00a0bei\u00a0Non\u2010Hodgkin\u2010 Lymphomen\u00a0oder\u00a0\nbei\u00a0chronisch\u00a0lymphatischer\u00a0Leuk\u00e4mie.\u00a0Die\u00a0breitere\u00a0Verordnung\u00a0v on\u00a0Biosimilars\u00a0\nkann\u00a0zu\u00a0einem\u00a0Einsparpotenzial\u00a0von\u00a020\u00a0bis\u00a040\u00a0%\u00a0f\u00fchren\u00a0und\u00a0somit \u00a0auch\u00a0die\u00a0im\u2010\nmens\u00a0gestiegenen\u00a0Kosten\u00a0in\u00a0der\u00a0onkologischen\u00a0Therapie\u00a0d\u00e4mpfen.\u00a0 Auf\u00a0diesem\u00a0\nWeg\u00a0sollten\u00a0dann\u00a0auch\u00a0die\u00a0Behandlungen\u00a0von\u00a0Patienten\u00a0mit\u00a0onkolo gischen\u00a0Er\u2010\nkrankungen\u00a0bezahlbar\u00a0bleiben.\u00a0Dies\u00a0ist\u00a0auch\u00a0dringend\u00a0erforderli ch,\u00a0denn\u00a0die\u00a0Aus\u2010\ngaben\u00a0f\u00fcr\u00a0Onkologika\u00a0in\u00a0der\u00a0ambul anten\u00a0Versorgung\u00a0steigen\u00a0seit\u00a0 einigen\u00a0Jahren\u00a0\ndeutlich\u00a0an\u00a0\u2013\u00a0seit\u00a02011\u00a0um\u00a041\u00a0%\u00a0(Grandt\u00a0&\u00a0Schubert,\u00a02017).\u00a0Das\u00a0 IMS\u00a0Health\u00a0Institu\u2010\nte\u00a0meldete\u00a0im\u00a0M\u00e4rz\u00a02016,\u00a0dass\u00a0bis\u00a02020\u00a0Einsparungen\u00a0in\u00a0H\u00f6he\u00a0von \u00a0110\u00a0Mrd.\u00a0US\u00a0\nDollar\u00a0durch\u00a0Biosimilars\u00a0in\u00a0US A\u00a0und\u00a0Europa\u00a0m\u00f6glich\u00a0seien.\u00a0Dies\u00a0 entspr\u00e4che\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0Therapie\u00a0mit\u00a0Originalprodukten\u00a0einer\u00a030\u00a0%igen\u00a0Verringe rung\u00a0der\u00a0Kosten\u00a0\npro\u00a0Behandlungstag\u00a0(IMS\u00a0Health,\u00a02016).\u00a0\u00a0\nNoch\u00a0 immer\u00a0 bestehen\u00a0 allerdings\u00a0 V orbehalte\u00a0 gegen\u00fcber\u00a0 einer\u00a0 Veror dnung\u00a0 von\u00a0\nBiosimilars,\u00a0die\u00a0oftmals\u00a0von\u00a0Herstellern\u00a0von\u00a0Originalprodukten\u00a0 sowohl\u00a0\u00c4rzten\u00a0als\u00a0\nauch\u00a0Patienten\u00a0gegen\u00fcber\u00a0kommuniziert\u00a0werden\u00a0(Deutsche\u00a0Rheuma\u2010L iga,\u00a02014).\u00a0\nDies\u00a0erinnert\u00a0sehr\u00a0an\u00a0die\u00a0Einf\u00fchrung\u00a0der\u00a0ersten\u00a0Generika.\u00a0Wisse nschaftliche\u00a0Stu\u2010\ndien\u00a0weisen\u00a0aber\u00a0darauf\u00a0hin,\u00a0da ss\u00a0eine\u00a0Ersteinstellung\u00a0auf\u00a0Bios imilars\u00a0in\u00a0den\u00a0aller\u2010\nmeisten\u00a0F\u00e4llen\u00a0unproblematisch\u00a0is t.\u00a0In\u00a0Bezug\u00a0auf\u00a0eine\u00a0Umstellun g\u00a0oder\u00a0Austausch\u2010\nbarkeit\u00a0(Interchangeability )\u00a0der\u00a0Originalarzneimittel\u00a0gegen\u00a0Biosimilars\u00a0bestehen\u00a0\ndagegen\u00a0Unsicherheiten\u00a0bei\u00a0\u00c4rzten\u00a0und\u00a0Patienten.\u00a0Dies\u00a0steht\u00a0sic herlich\u00a0im\u00a0Zu\u2010\nsammenhang\u00a0damit,\u00a0dass\u00a0die\u00a0Zulassung\u00a0eines\u00a0Biosimilars\u00a0nur\u00a0auf\u00a0 dem\u00a0Beleg\u00a0der\u00a0\nausreichenden\u00a0\u00c4hnlichkeit\u00a0zum\u00a0Re ferenzprodukt\u00a0in\u00a0Bezug\u00a0auf\u00a0Qual it\u00e4t,\u00a0Wirksam\u2010\nkeit\u00a0und\u00a0Sicherheit\u00a0beruht.\u00a0Aus\u00a0rechtlicher\u00a0Sicht\u00a0muss\u00a0festgeha lten\u00a0werden,\u00a0dass\u00a0\ndie\u00a0Entscheidung\u00a0\u00fcber\u00a0die\u00a0Austauschbarkeit\u00a0von\u00a0Originalarzneimi tteln\u00a0gegen\u00a0Bio\u2010\nsimilars\u00a0( Switching )\u00a0vom\u00a0behandelnden\u00a0Arzt\u00a0getroffen\u00a0bzw.\u00a0eine\u00a0automatische\u00a0\nSubstitution\u00a0im\u00a0Rahmen\u00a0vorliege nder\u00a0Rabattvertr\u00e4ge\u00a0durch\u00a0den\u00a0Ap otheker\u00a0nach\u00a0\nden\u00a0Vorgaben\u00a0des\u00a0jeweiligen\u00a0Gesundheitssystems\u00a0veranlasst\u00a0wird. \u00a0Diese\u00a0Entschei\u201022\u00a0dung\u00a0ist\u00a0aber\u00a0weder\u00a0durch\u00a0die\u00a0nationalen\u00a0Beh\u00f6rden\u00a0noch\u00a0durch\u00a0di e\u00a0europ\u00e4ische\u00a0\nArzneimittelagentur\u00a0( European\u00a0Medicines\u00a0Agency ,\u00a0EMA)\u00a0gedeckt.\u00a0Bei\u00a0den\u00a0Ausga\u2010\nben\u00a0der\u00a0GKV\u00a0f\u00fcr\u00a0Arzneimittel\u00a0entfielen\u00a02015\u00a0etwa\u00a019\u00a0%\u00a0(6,4\u00a0Mrd. \u00a0Euro)\u00a0auf\u00a0Biologi\u2010\nka,\u00a0davon\u00a030\u00a0%\u00a0auf\u00a0Biosimilars\u00a0(Schwabe\u00a0&\u00a0Paffrath,\u00a02016).\u00a0Verg leichsweise\u00a0preis\u2010\ng\u00fcnstigere\u00a0Mittel\u00a0aus\u00a0dieser\u00a0Produktgruppe\u00a0sollten\u00a0weiter\u00a0und\u00a0h \u00e4ufiger\u00a0genutzt\u00a0\nwerden,\u00a0 um\u00a0 Einsparungen\u00a0 in\u00a0 einem\u00a0 ansonsten\u00a0 besonders\u00a0 ausgabenin tensiven\u00a0\nMarktsegment\u00a0zu\u00a0realisieren.\u00a0D ie\u00a0vorliegenden\u00a0Studiendaten\u00a0und\u00a0 Expertenemp\u2010\nfehlungen\u00a0lassen\u00a0keinen\u00a0Zweifel\u00a0daran,\u00a0dass\u00a0mit\u00a0Biosimilars,\u00a0in sbesondere\u00a0bei\u00a0der\u00a0\nErsteinstellung,\u00a0aber\u00a0auch\u00a0im\u00a0Rahmen\u00a0des\u00a0 Switching ,\u00a0wirksame\u00a0und\u00a0vertr\u00e4gliche\u00a0\nAlternativen\u00a0nun\u00a0auch\u00a0in\u00a0der\u00a0Onkologie\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen.\u00a0Di e\u00a0immer\u00a0wieder\u00a0\nzitierten\u00a0Unterschiede\u00a0in\u00a0der\u00a0Wirksamkeit,\u00a0Vertr\u00e4glichkeit\u00a0und\u00a0 Qualit\u00e4t\u00a0sind\u00a0eher\u00a0\nArgumente\u00a0aus\u00a0dem\u00a0Bereich\u00a0des\u00a0Marketings,\u00a0nicht\u00a0aber\u00a0aus\u00a0dem\u00a0Be reich\u00a0wissen\u2010\nschaftlicher\u00a0Studien.\u00a0\nKeine\u00a0Sicherheitsbedenken\u00a0bei\u00a0der\u00a0Biosimilar\u2010Verordnung\u00a0\u00a0\nIm\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Umstellung\u00a0von\u00a0Biologika\u00a0auf\u00a0Biosimilar s\u00a0werden\u00a0auch\u00a0\nimmer\u00a0wieder\u00a0Sicherheits\u2010\u00a0oder\u00a0Wirksamkeitsunterschiede\u00a0im\u00a0Verg leich\u00a0zum\u00a0Ori\u2010\nginatorprodukt\u00a0diskutiert\u00a0(McKeage,\u00a02014).\u00a0Nach\u00a0den\u00a0bisherigen\u00a0 Erfahrungen\u00a0wird\u00a0\naber\u00a0 z.B.\u00a0 eine\u00a0 durch\u00a0 den\u00a0 Switch\u00a0 erh\u00f6hte\u00a0 Immunogenit\u00e4t\u00a0 als\u00a0 unwahrscheinlich\u00a0\neingesch\u00e4tzt\u00a0und\u00a0best\u00e4tigt\u00a0sich\u00a0in\u00a0den\u00a0Studien\u00a0nicht.\u00a0Die\u00a0Gefah r\u00a0der\u00a0Bildung\u00a0von\u00a0\nAntik\u00f6rpern\u00a0besteht\u00a0\u00fcbrigens\u00a0grunds\u00e4tzlich\u00a0bei\u00a0allen\u00a0Biopharmaz eutika.\u00a0Der\u00a0bei\u00a0\nder\u00a0Zulassung\u00a0vereinbarte\u00a0Risikomanagementplan\u00a0sieht\u00a0au\u00dferdem\u00a0v or,\u00a0dass\u00a0der\u00a0\npU\u00a0 f\u00fcr\u00a0 alle\u00a0 biologischen\u00a0 Arzneimi ttel,\u00a0 einschlie\u00dflich\u00a0 der\u00a0 Biosi milars,\u00a0 nach\u00a0 dem\u00a0\nMarkteintritt\u00a0entsprechende\u00a0Siche rheitsdaten\u00a0erheben\u00a0muss.\u00a0Auch \u00a0hier\u00a0zeigten\u00a0\nsich\u00a0bisher\u00a0keine\u00a0Unterschiede\u00a0i n\u00a0der\u00a0Immunogenit\u00e4t.\u00a0Ein\u00a0besond eres\u00a0Problem\u00a0\nergibt\u00a0sich\u00a0in\u00a0dieser\u00a0Hinsicht\u00a0bei\u00a0der\u00a0gleichzeitigen\u00a0Vermarktu ng\u00a0und\u00a0Anwendung\u00a0\nvon\u00a0Biologika\u00a0und\u00a0Biosimilars\u00a0mit \u00a0gleichen\u00a0Wirkstoffen\u00a0in\u00a0Bezug \u00a0auf\u00a0die\u00a0Meldung\u00a0\nvon\u00a0unerw\u00fcnschten\u00a0Wirkungen\u00a0(UAW) \u00a0oder\u00a0sonstigen\u00a0Ereignissen.\u00a0D aher\u00a0sollte\u00a0im\u00a0\nSinne\u00a0einer\u00a0eindeutigen\u00a0Informati on\u00a0neben\u00a0dem\u00a0internationalen\u00a0F reinamen\u00a0( Inter\u2010\nnational\u00a0Nonproprietary\u00a0Name ,\u00a0INN)\u00a0auch\u00a0die\u00a0Handelsbezeichnung\u00a0und\u00a0die\u00a0Char\u2010\ngennummer\u00a0angegeben\u00a0werden.\u00a0Eine\u00a0N achverfolgung\u00a0w\u00e4re\u00a0mittels\u00a0\u201eS ecurpharm\u201c\u00a0\nm\u00f6glich,\u00a0es\u00a0wurde\u00a0aufgrund\u00a0einer\u00a0EU\u2010Vorgabe\u00a0entwickelt.\u00a0\u00a0Die\u00a0Er weiterung\u00a0dieses\u00a0\nSystems\u00a0bis\u00a0zum\u00a0Patienten\u00a0w\u00e4re\u00a0zu\u00a0pr\u00fcfen,\u00a0insbesondere\u00a0im\u00a0Konte xt\u00a0der\u00a0Pharma\u2010\nkovigilanz.\u00a0\nIn\u00a0Deutschland\u00a0ist\u00a0die\u00a0automatische\u00a0Substitution\u00a0nach\u00a0dem\u00a0Rahme nvertrag\u00a0\u00fcber\u00a0\ndie\u00a0Arzneimittelversorgung\u00a0nach\u00a0\u00a7\u00a0129\u00a0Absatz\u00a02\u00a0SGB\u00a0V\u00a0(Fassung\u00a0v om\u00a015.\u00a0Juni\u00a02012)\u00a0\nzwischen\u00a0dem\u00a0GKV\u2010Spitzenverband\u00a0 und\u00a0dem\u00a0Deutschen\u00a0Apothekerverb and\u00a0nur\u00a0f\u00fcr\u00a0\nals\u00a0 wirkstoffgleich\u00a0 geltende\u00a0 bio technologisch\u00a0 hergestellte\u00a0 Arzn eimittel\u00a0 erlaubt,\u00a0\n\u201esofern\u00a0diese\u00a0auf\u00a0das\u00a0jeweilige\u00a0 Referenzarzneimittel\u00a0Bezug\u00a0nehm end\u00a0zugelassen\u00a0\nsind\u00a0und\u00a0sich\u00a0in\u00a0Ausgangsstoffen\u00a0und\u00a0Herstellungsprozess\u00a0nicht\u00a0 unterscheiden.\u201c\u00a023\u00a0(GKV\u2010Spitzenverband,\u00a02012).\u00a0Daraus\u00a0ergibt\u00a0sich\u00a0implizit\u00a0eine\u00a0Au stauschm\u00f6glichkeit\u00a0\nnur\u00a0f\u00fcr\u00a0die\u00a0 Bioidenticals ,\u00a0die\u00a0aus\u00a0der\u00a0gleichen\u00a0Produktionsst\u00e4tte\u00a0kommen,\u00a0also\u00a0im\u00a0\ngleichen\u00a0Herstellungsprozess\u00a0und\u00a0vom\u00a0gleichen\u00a0Hersteller\u00a0produz iert,\u00a0aber\u00a0von\u00a0\nunterschiedlichen\u00a0 pU\u00a0 vertrieben\u00a0 werden.\u00a0 Eine\u00a0 automatische\u00a0 Subst itution\u00a0 von\u00a0\nbiologischen\u00a0Originalarzneimitteln\u00a0durch\u00a0Biosimilars\u00a0ist\u00a0demnac h\u00a0nicht\u00a0vorgese\u2010\nhen.\u00a0In\u00a0einem\u00a0Positionspapier\u00a0des\u00a0Paul\u2010Ehrlich\u2010Institutes\u00a0(PEI) \u00a0wird\u00a0aber\u00a0darauf\u00a0\nhingewiesen,\u00a0dass\u00a0Biosimilars\u00a0grunds\u00e4tzlich\u00a0nach\u00a0erwiesener\u00a0\u00c4qu ivalenz\u00a0und\u00a0er\u2010\nfolgter\u00a0 Zulassung\u00a0 wie\u00a0 Originalpro dukte\u00a0 eingesetzt\u00a0 werden\u00a0 k\u00f6nnen .\u00a0 Damit\u00a0 sind\u00a0\nnach\u00a0Auffassung\u00a0des\u00a0PEI\u00a0sowohl\u00a0Patienten\u00a0gemeint,\u00a0die\u00a0vorher\u00a0no ch\u00a0keine\u00a0Thera\u2010\npie\u00a0mit\u00a0Biologika\u00a0erhalten\u00a0hatte n\u00a0als\u00a0auch\u00a0solche\u00a0Patienten,\u00a0di e\u00a0vorher\u00a0mit\u00a0einem\u00a0\nOriginalarzneimittel\u00a0behandelt\u00a0wurden\u00a0(PEI,\u00a02015).\u00a0Diese\u00a0Stellu ngnahme\u00a0ist\u00a0unter\u00a0\ndem\u00a0Eindruck\u00a0eines\u00a0Vergleichs\u00a0de s\u00a0Wirkstoffes\u00a0Infliximab\u00a0(Refer enzarzneimittel\u00a0\nRemicade\u00ae)\u00a0mit\u00a0den\u00a0ersten\u00a0Biosilimars\u00a0Inflectra\u00ae\u00a0und\u00a0Remsima\u00ae\u00a0p ubliziert\u00a0worden\u00a0\n(vgl.\u00a0Kapitel\u00a06).\u00a0Auch\u00a0ein\u00a0Jahr\u00a0nach\u00a0Markteintritt\u00a0liegen\u00a0keine \u00a0Meldungen\u00a0oder\u00a0\nHinweise\u00a0zu\u00a0umstellungsbedingten\u00a0Problemen\u00a0vor.\u00a0Studien\u00a0und\u00a0The rapieregister\u00a0\nhaben\u00a0keine\u00a0Sicherheitsbedenken\u00a0oder\u00a0\u2010probleme\u00a0durch\u00a0die\u00a0Umstel lung\u00a0gezeigt.\u00a0\nVergleichbare\u00a0Ergebnisse\u00a0sind\u00a0auch\u00a0bei\u00a0der\u00a0Verordnung\u00a0von\u00a0Ritux imab\u2010haltigen\u00a0\nBiologika\u00a0und\u00a0Biosimilars\u00a0zu\u00a0erwarten.\u00a0Die\u00a0Arzneimittelkommissi on\u00a0der\u00a0deutschen\u00a0\n\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0hat\u00a0zum\u00a0gleichen\u00a0Thema\u00a0bereits\u00a02008\u00a0darauf\u00a0h ingewiesen,\u00a0dass\u00a0\naufgrund\u00a0der\u00a0 beh\u00f6rdlichen\u00a0 Anford erungen\u00a0 bei\u00a0der\u00a0Zulassung\u00a0die\u00a0n otwendigen\u00a0\nNachweise\u00a0f\u00fcr\u00a0die\u00a0Wirksamkeit\u00a0 und\u00a0Unbedenklichkeit\u00a0vorliegen.\u00a0E s\u00a0wurde\u00a0den\u2010\nnoch\u00a0empfohlen,\u00a0nach\u00a0der\u00a0Umstellung\u00a0von\u00a0Originalprodukten\u00a0auf\u00a0e in\u00a0Biosimilar\u00a0\neine\u00a0so\u00a0engmaschige\u00a0\u00dcberwachung\u00a0wie\u00a0nach\u00a0einer\u00a0Neueinstellung\u00a0v orzunehmen\u00a0\n(Akd\u00c4,\u00a02008).\u00a0\nBiosimilars\u00a0werden\u00a0ebenso\u00a0biotec hnologisch\u00a0hergestellt\u00a0wie\u00a0die\u00a0 erstangebotenen\u00a0\nBiologika.\u00a0Ein\u00a0Biosimilar\u00a0muss\u00a0dieselbe\u00a0Aminos\u00e4uresequenz\u00a0aufwe isen\u00a0wie\u00a0das\u00a0\njeweilige\u00a0Referenz\u2010Biologikum\u00a0und\u00a0darf\u00a0nur\u00a0soweit\u00a0von\u00a0dessen\u00a0Gl ykolisierungsmus\u2010\nter\u00a0abweichen,\u00a0dass\u00a0weder\u00a0die\u00a0klinische\u00a0Wirksamkeit\u00a0noch\u00a0die\u00a0Si cherheit\u00a0geschm\u00e4\u2010\nlert\u00a0werden.\u00a0Im\u00a0Zulassungsverfahren\u00a0steht\u00a0daher\u00a0nicht\u00a0der\u00a0thera peutische\u00a0Effekt,\u00a0\nsondern\u00a0die\u00a0klinische\u00a0\u00c4quivalenz \u00a0im\u00a0Mittelpunkt\u00a0der\u00a0nachzuweise nden\u00a0Effekte.\u00a0\nDaneben\u00a0werden\u00a0eine\u00a0Reihe\u00a0weiterer\u00a0Parameter\u00a0verglichen,\u00a0die\u00a0nu r\u00a0innerhalb\u00a0\neines\u00a0bestimmten\u00a0Zielbereiches\u00a0abweichen\u00a0d\u00fcrfen.\u00a0F\u00fcr\u00a0jedes\u00a0Erge bnis\u00a0au\u00dferhalb\u00a0\ndieses\u00a0festgelegten\u00a0Bereiches\u00a0ist\u00a0der\u00a0Nachweis\u00a0erforderlich,\u00a0da ss\u00a0dadurch\u00a0weder\u00a0\ndie\u00a0Sicherheit\u00a0noch\u00a0die\u00a0Wirksamkeit\u00a0beeinflusst\u00a0werden.\u00a0Hierzu\u00a0 geh\u00f6rt\u00a0auch\u00a0die\u00a0\nFrage\u00a0der\u00a0Bildung\u00a0von\u00a0 Anti\u00a0Drug\u00a0Antibodies ,\u00a0ADA,\u00a0die\u00a0m\u00f6glicherweise\u00a0die\u00a0Wirkun\u2010\ngen\u00a0von\u00a0Biologika\u00a0verringern\u00a0k\u00f6nnen.\u00a0\nBei\u00a0den\u00a0Biologika\u00a0hat\u00a0sich\u00a0wisse nschaftlich\u00a0und\u00a0regulatorisch\u00a0d as\u00a0Konzept\u00a0der\u00a0\nExtrapolation\u00a0durchgesetzt,\u00a0das\u00a0sich\u00a0auch\u00a0bei\u00a0patentgesch\u00fctzten \u00a0Biologika\u00a0nach\u00a0\neiner\u00a0Ver\u00e4nderung\u00a0des\u00a0Herstellung sprozesses\u00a0oder\u00a0im\u00a0Rahmen\u00a0der\u00a0 Zulassung\u00a0einer\u00a024\u00a0neuen\u00a0Darreichungsform\u00a0etabliert\u00a0hat.\u00a0Die\u00a0Ver\u00e4nderung\u00a0in\u00a0den\u00a0He rstellungspro\u2010\nzessen\u00a0des\u00a0gleichen\u00a0Biologikums\u00a0ist\u00a0\u00fcbrigens\u00a0betr\u00e4chtlich:\u00a0So\u00a0w urden\u00a0seit\u00a0ihrer\u00a0\nZulassungen\u00a0f\u00fcr\u00a0die\u00a0Mittel\u00a0\n\uf0b7 Remicade\u00ae\u00a036\u00a0\u00c4nderungen,\u00a0\n\uf0b7 Humira\u00ae\u00a021\u00a0\u00c4nderungen,\u00a0\n\uf0b7 MabThera\u00ae\u00a06\u00a0\u00c4nderungen\u00a0und\u00a0f\u00fcr\u00a0\n\uf0b7 Benlysta\u00ae\u00a02\u00a0\u00c4nderungen\u00a0\nim\u00a0Herstellungsprozess\u00a0dokumentiert,\u00a0ohne\u00a0dass\u00a0ein\u00a0Einfluss\u00a0auf \u00a0Wirksamkeit\u00a0und\u00a0\nSicherheit\u00a0festgestellt\u00a0wurde\u00a0(Schneider,\u00a02013).\u00a0Bei\u00a0den\u00a0genann ten\u00a0Referenzpro\u2010\ndukten\u00a0haben\u00a0\u00c4rzte\u00a0die\u00a0Extrapolation\u00a0m\u00f6glicherweise\u00a0\u201eunerkannt\u201c \u00a0akzeptiert.\u00a0Nur\u00a0\nweil\u00a0bei\u00a0den\u00a0Nachfolgeprodukten\u00a0v on\u00a0Biologika\u00a0offener\u00a0auf\u00a0die\u00a0E xtrapolation\u00a0hin\u2010\ngewiesen\u00a0wird,\u00a0sollte\u00a0diese\u00a0Meth ode\u00a0nicht\u00a0in\u00a0Zweifel\u00a0gezogen\u00a0un d\u00a0als\u00a0Argument\u00a0\ngegen\u00a0die\u00a0Anwendung\u00a0von\u00a0Biosi milars\u00a0genutzt\u00a0werden.\u00a0\u00a0\nDie\u00a0Konsequenz\u00a0ist\u00a0vielmehr:\u00a0Wenn\u00a0bei\u00a0einem\u00a0Biosimilar\u00a0im\u00a0Rahme n\u00a0der\u00a0Zulassung\u00a0\neine\u00a0 mit\u00a0 dem\u00a0 Referenzprodukt\u00a0 (\u201eO riginal\u201c)\u00a0 vergleichbare\u00a0 Wirksam keit\u00a0 in\u00a0 einer\u00a0\nzugelassenen\u00a0Indikation\u00a0nachgewiesen\u00a0wurde\u00a0und\u00a0keine\u00a0relevanten \u00a0Unterschiede\u00a0\nin\u00a0 einzelnen\u00a0 Parametern\u00a0 festgestellt\u00a0 werden\u00a0 konnten,\u00a0 verzichtet \u00a0d i e \u00a0E M A \u00a0a u f \u00a0\nweitere\u00a0 Studien\u00a0 f\u00fcr\u00a0 andere\u00a0 Indika tionen.\u00a0 Eine\u00a0 Extrapolation\u00a0 der \u00a0 vorhandenen\u00a0\nDaten\u00a0 erm\u00f6glicht\u00a0 demnach\u00a0 eine\u00a0 Indikationserweiterung\u00a0 bei\u00a0 allen\u00a0 Biologika,\u00a0 so\u00a0\nauch\u00a0bei\u00a0den\u00a0Biosimilars.\u00a0Bisher\u00a0existieren\u00a0keinerlei\u00a0Hinweise\u00a0 daf\u00fcr,\u00a0dass\u00a0diese\u00a0\nExtrapolation\u00a0 zu\u00a0 Nachteilen\u00a0 in\u00a0 der\u00a0 Sicherheit\u00a0 oder\u00a0 Wirksamkeit\u00a0 gef\u00fchrt\u00a0 h\u00e4tte.\u00a0\nAllerdings\u00a0gab\u00a0und\u00a0gibt\u00a0es\u00a0immer\u00a0wieder\u00a0auch\u00a0kritische\u00a0Stimmen\u00a0 zum\u00a0Extrapolati\u2010\nonsverfahren.\u00a0Bei\u00a0vielen\u00a0\u00c4rzten\u00a0kommt\u00a0es\u00a0in\u00a0diesem\u00a0Zusammenhang \u00a0zu\u00a0Vorbehal\u2010\nten\u00a0gegen\u00a0die\u00a0Anwendung\u00a0von\u00a0Biosi milars\u00a0bei\u00a0Indikationserweiter ungen.\u00a0Es\u00a0wurde\u00a0\ndaher\u00a0beschlossen,\u00a0dass\u00a0k\u00fcnftig\u00a0 in\u00a0den\u00a0\u00f6ffentlich\u00a0zug\u00e4nglichen\u00a0 Assessment\u00a0Reports \u00a0\nder\u00a0EMA\u00a0( European\u00a0Public\u00a0Assessment\u00a0Reports,\u00a0 EPAR)\u00a0die\u00a0Begr\u00fcndung\u00a0f\u00fcr\u00a0die\u00a0\njeweilige\u00a0Extrapolation\u00a0ausf\u00fchrlich\u00a0dargestellt\u00a0werden\u00a0soll,\u00a0um \u00a0die\u00a0Akzeptanz\u00a0der\u00a0\nVerordner\u00a0in\u00a0den\u00a0jeweiligen\u00a0(erweiterten)\u00a0Indikationen\u00a0zu\u00a0verbe ssern\u00a0(Ludwig\u00a0&\u00a0\nDicheva,\u00a02016).\u00a0\nBetr\u00e4chtliche\u00a0Einsparungen\u00a0durch\u00a0onkologische\u00a0Biosimilars\u00a0in\u00a0de r\u00a0Zukunft\u00a0\nDer\u00a0Empfehlung\u00a0der\u00a0breiteren\u00a0Nutzung\u00a0von\u00a0Biosimilars\u00a0liegt\u00a0letz tlich\u00a0die\u00a0\u00dcberzeu\u2010\ngung\u00a0zugrunde,\u00a0dass\u00a0mit\u00a0diesen\u00a0Mitteln\u00a0eine\u00a0vergleichbar\u00a0gute\u00a0B ehandlungsquali\u2010\nt\u00e4t\u00a0zu\u00a0deutlich\u00a0g\u00fcnstigeren\u00a0Kost en\u00a0erreicht\u00a0werden\u00a0kann.\u00a0Dies\u00a0b edeutet\u00a0gleicher\u2010\nma\u00dfen,\u00a0dass\u00a0mehr\u00a0Patienten\u00a0zu\u00a0den\u00a0gleichen\u00a0Kosten,\u00a0die\u00a0vorher\u00a0f \u00fcr\u00a0die\u00a0patentge\u2010\nsch\u00fctzten\u00a0Biologika\u00a0angefallen\u00a0sind,\u00a0behandelt\u00a0werden\u00a0k\u00f6nnen.\u00a0G erade\u00a0bei\u00a0einer\u00a0\nDauertherapie\u00a0sind\u00a0daher\u00a0mit\u00a0Bi osimilars\u00a0erhebliche\u00a0Einsparunge n\u00a0m\u00f6glich.\u00a025\u00a0Um\u00a0eine\u00a0F\u00f6rderung\u00a0der\u00a0Biosimilar\u2010Verordnungen\u00a0zu\u00a0erreichen,\u00a0sol lten\u00a0\u00c4rzte\u00a0vor\u00a0\nallem\u00a0folgende\u00a0Strategien\u00a0nutzen:\u00a0\n\uf0b7 Bei\u00a0Neueinstellungen\u00a0von\u00a0Patienten\u00a0m\u00f6glichst\u00a0auf\u00a0Biosimilars\u00a0zu r\u00fcckgreifen.\u00a0\n\uf0b7 Bei\u00a0den\u00a0bereits\u00a0mit\u00a0dem\u00a0Referenz produkt\u00a0behandelten\u00a0Patienten\u00a0s orgf\u00e4ltig\u00a0\npr\u00fcfen,\u00a0ob\u00a0der\u00a0Therapieerfolg\u00a0bei\u00a0einem\u00a0 Switch\u00a0auf\u00a0ein\u00a0Biosimilar\u00a0z.B.\u00a0durch\u00a0\neine\u00a0verschlechterte\u00a0Adh\u00e4renz\u00a0gef \u00e4hrdet\u00a0sein\u00a0kann\u00a0oder\u00a0ob\u00a0die\u00a0j eweiligen\u00a0\nPatienten\u00a0nach\u00a0einer\u00a0entsprechenden\u00a0Aufkl\u00e4rung\u00a0einem\u00a0 Switch\u00a0auf\u00a0ein\u00a0Bio\u2010\nsimilar\u00a0zustimmen.\u00a0\nIn\u00a0diesem\u00a0Fall\u00a0ist\u00a0in\u00a0der\u00a0ersten\u00a0Zeit\u00a0eine\u00a0w\u00f6chentliche\u00a0Konsult ation\u00a0sinnvoll,\u00a0um\u00a0\nVertr\u00e4glichkeit\u00a0und\u00a0Wirksamkeit\u00a0 zu\u00a0evaluieren\u00a0(Ludwig\u00a0&\u00a0Dicheva ,\u00a02016).\u00a0Entspre\u2010\nchende\u00a0Hinweise\u00a0sollten\u00a0auch\u00a0von\u00a0 Apothekern\u00a0in\u00a0der\u00a0Kommunikatio n\u00a0mit\u00a0\u00c4rzten\u00a0\nund\u00a0Patienten\u00a0weitergegeben\u00a0werden.\u00a0\u00a0\nBiosimilars\u00a0sollten,\u00a0wann\u00a0immer\u00a0 es\u00a0m\u00f6glich\u00a0erscheint,\u00a0auch\u00a0Eing ang\u00a0in\u00a0die\u00a0Verord\u2010\nnung\u00a0finden.\u00a0Dass\u00a0eine\u00a0Quotierung \u00a0der\u00a0Verordnung\u00a0von\u00a0Biologika\u00a0 und\u00a0deren\u00a0Bio\u2010\nsimilars\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0durchaus\u00a0hilfreich\u00a0sein\u00a0kann,\u00a0z eigen\u00a0Ergebnisse\u00a0\naus\u00a0den\u00a0unterschiedlichen\u00a0Kassen\u00e4rztlichen\u00a0Vereinigungen\u00a0(z.B.\u00a0 schwanken\u00a0die\u00a0\nErgebnisse\u00a0bei\u00a0Etanercept\u00a0zwischen\u00a0knapp\u00a012\u00a0und\u00a050\u00a0%)\u00a0(Pro\u00a0Bios imilars,\u00a02017b).\u00a0\nDabei\u00a0signalisieren\u00a0\u00c4rzte\u00a0in\u00a0einer\u00a0Befragung\u00a0deutliche\u00a0Unterst\u00fc tzung:\u00a049\u00a0%\u00a0der\u00a0\nBefragten\u00a0stimmen\u00a0der\u00a0Aussage\u00a0zu,\u00a0dass\u00a0Biosimilars\u00a0dazu\u00a0beitrag en\u00a0k\u00f6nnen,\u00a0die\u00a0\nVersorgung\u00a0zu\u00a0verbessern\u00a0und\u00a0dass\u00a0durch\u00a0deren\u00a0g\u00fcnstigeren\u00a0Preis \u00a0bestehende\u00a0\nVersorgungsl\u00fccken\u00a0geschlossen\u00a0we rden\u00a0k\u00f6nnten\u00a0(Pro\u00a0Biosimilars,\u00a0 2017c).\u00a0\nWie\u00a0sich\u00a0Einsparpotenziale\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0auswirken\u00a0k\u00f6nnten,\u00a0wird\u00a0 in\u00a0der\u00a0folgenden\u00a0\nTabelle\u00a01.4\u00a0der\u00a0derzeit\u00a0verordneten\u00a0Biologika\u00a0deutlich.\u00a0Nun\u00a0wir d\u00a0eine\u00a0100%ige\u00a0\nSubstitution\u00a0durch\u00a0Biosimilars\u00a0nicht\u00a0erreichbar\u00a0sein,\u00a0aber\u00a0auch \u00a0bei\u00a0einer\u00a0angestreb\u2010\nten\u00a0Quotierung\u00a0von\u00a050\u00a0%\u00a0w\u00fcrde\u00a0si ch\u00a0eine\u00a0erhebliche\u00a0Effizienzopt imierung\u00a0ergeben\u00a0\n\u2013\u00a0gleiche\u00a0Qualit\u00e4t\u00a0zu\u00a0niedrigeren\u00a0Preisen.\u00a0Danach\u00a0k\u00f6nnen\u00a0von\u00a0de n\u00a0derzeitigen\u00a0\nGKV\u2010Ausgaben\u00a0in\u00a0H\u00f6he\u00a0von\u00a01,75\u00a0Mrd.\u00a0Euro\u00a0rund\u00a0200\u00a0bis\u00a0300\u00a0Mio.\u00a0E uro\u00a0eingespart\u00a0\nwerden\u00a0(Berechnungsgrundlage\u00a0Einsp arpotenzial:\u00a0Differenz\u00a0zwisch en\u00a0Originator\u2010\nprodukt\u2010\u00a0und\u00a0Biosimilaraus gaben,\u00a0Anteil\u00a050\u00a0%).\u00a0\u00a0\n\u00a0 \u00a026\u00a0Tabelle\u00a0 1.4:\u00a0 Approximative\u00a0 Einsparpotenziale\u00a0 durch\u00a0 Nutzung\u00a0 von\u00a0 Biosimilars\u00a0\ngegen\u00fcber\u00a0bisher\u00a0patentgesch\u00fctzter\u00a0Biologika\u00a0\n01.10.2015\u00a0\u2010\u00a030.09.2016 \u00a0Kennzahlen\u00a0\nHochrechnung\u00a0\nGKV\u00a0Anzahl\u00a0GKV\u2010\nVersicherte\u00a0Brutto\u00a0\nAusgaben/Euro\u00a0Einsparpotenzial\u00a0\nbei\u00a020\u00a0%iger\u00a0\nKostenreduktion\u00a0Einsparpotenzial\u00a0\nbei\u00a030\u00a0%iger\u00a0\nKostenreduktion\u00a0\nB03XA02\u00a032.307\u00a0 34.313.911,72\u00a0 6.862.782,34\u00a0 10.294.173,48\u00a0Darbepoetin\u00a0alfa\u00a0\nL01XC02\u00a063.531\u00a0 312.541.540,60\u00a0 62.508.308,12\u00a0 93.762.462,18\u00a0Rituximab\u00a0\nL01XC03\u00a065.022\u00a0 537.577.038,92\u00a0 107.515.407,80\u00a0 161.273.111,70\u00a0Trastuzumab\u00a0\nL01XC06\u00a011.138\u00a0 81.190.874,25\u00a0 16.238.174,85\u00a0 24.357.262,28\u00a0Cetuximab\u00a0\nL01XC07\u00a061.596\u00a0 569.959.533,19\u00a0 113.991.906,60\u00a0 170.987.859,90\u00a0Bevacizumab\u00a0\nL01XC08\u00a09.357\u00a0 67.580.115,69\u00a0 13.516.023,14\u00a0 20.274.034,71\u00a0Panitumumab\u00a0\nL01XC11\u00a01.084\u00a0 29.245.321,93\u00a0 5.849.064,39\u00a0 8.773.596,59\u00a0Ipilimumab\u00a0\nL03AA13\u00a041.035\u00a0 122.365.624,81\u00a0 24.473.124,96\u00a0 36.709.687,44\u00a0Pegfilgrastim\u00a0\n\u00a0Summe\u00a0\u00a0 1.754.773.960,91\u00a0 350.954.791,84\u00a0 526.432.188,28\u00a0\n\u00a0Ausgaben\u00a0bei\u00a0100%\u00a0Biosimilars\u00a0 1.403.819.169,07\u00a0 1.228.341.772,63\u00a0\nTK\u2010Basisdaten\u00a0aus\u00a0Tabelle\u00a01.3\u00a0\nBiosimilars\u00a0sind\u00a0die\u00a0\u201eneuen\u00a0Gener ika\u201c\u00a0der\u00a0biologischen\u00a0Arzneimi ttelmittelversor\u2010\ngung,\u00a0zum\u00a0Nutzen\u00a0vieler\u00a0Patienten\u00a0und\u00a0F\u00f6rderer\u00a0des\u00a0Preiswettbew erbs,\u00a0da\u00a0unter\u00a0\ndem\u00a0 Druck\u00a0 der\u00a0 g\u00fcnstigeren\u00a0 Preise \u00a0v o n \u00a0B i o s i m i l a r s \u00a0a u c h \u00a0O r g i n a t o r produkte\u00a0 zu\u00a0\nniedrigeren\u00a0Preisen\u00a0angeboten\u00a0werden.\u00a0\nInsofern\u00a0stimmt\u00a0es\u00a0hoffnungsfroh,\u00a0dass\u00a0bis\u00a02020\u00a0viele\u00a0weitere\u00a0B iologika\u00a0den\u00a0Pa\u2010\ntentschutz\u00a0verlieren\u00a0und\u00a0Biosimilars\u00a0auf\u00a0den\u00a0Markt\u00a0dr\u00e4ngen\u00a0werd en\u00a0(vgl.\u00a0dazu\u00a0\nauch\u00a0Tab.\u00a06.2\u00a0im\u00a0Kapitel\u00a06).\u00a0Die\u00a0Krankenkassen\u00a0bekommen\u00a0somit\u00a0e ine\u00a0M\u00f6glichkeit\u00a0\ngeboten,\u00a0\u00fcber\u00a0steuernde\u00a0Versorgun gsvertr\u00e4ge,\u00a0gekoppelt\u00a0mit\u00a0Quot ierungen\u00a0nach\u00a0\n\u00a7\u00a084\u00a0SGB\u00a0V,\u00a0den\u00a0Anteil\u00a0der\u00a0Biosimilars\u00a0erh\u00f6hen\u00a0zu\u00a0k\u00f6nnen.\u00a0Und\u00a0s ie\u00a0sollten\u00a0sich\u00a0\nrechtzeitig\u00a0auf\u00a0die\u00a0Nutzung\u00a0dies er\u00a0Angebote\u00a0f\u00fcr\u00a0eine\u00a0m\u00f6gliche\u00a0E ffizienzoptimie\u2010\nrung\u00a0vorbereiten.\u00a0\nBiosimilarvertr\u00e4ge\u00a0in\u00a0der\u00a0Versorgung\u00a0\nDer\u00a0umfassende\u00a0Einsatz\u00a0von\u00a0Biosimilars\u00a0impliziert\u00a0ein\u00a0deutliche s\u00a0Wirtschaftlich\u2010\nkeitspotenzial\u00a0 ohne\u00a0 klinische\u00a0 Nachteile\u00a0 f\u00fcr\u00a0 den\u00a0 Patienten.\u00a0 Aus\u00a0 diesem\u00a0 Grund\u00a0\u00a0\nhaben\u00a0viele\u00a0Krankenkassen\u00a0besonde re\u00a0Versorgungsvertr\u00e4ge\u00a0zum\u00a0zie lgerichteten\u00a0\ntherapeutischen\u00a0Einsatz\u00a0der\u00a0Bios imilars\u00a0mit\u00a0\u00c4rzteverb\u00e4nden\u00a0gesc hlossen.\u00a0Nach\u00a0der\u00a0\nTK,\u00a0die\u00a0z.B.\u00a0bereits\u00a0Mitte\u00a02016\u00a0einen\u00a0Vertrag\u00a0zur\u00a0wirtschaftlic hen\u00a0Pharmakothera\u2010\npie\u00a0bei\u00a0chronisch\u00a0entz\u00fcndlichen\u00a0Darmerkrankungen\u00a0(CED)\u00a0mit\u00a0dem\u00a0 Berufsverband\u00a027\u00a0der\u00a0niedergelassenen\u00a0Gastroenterologen\u00a0Deutschlands\u00a0e.V.\u00a0(bng)\u00a0 geschlossen\u00a0hat,\u00a0\nhaben\u00a0sich\u00a0sieben\u00a0weitere\u00a0Krankenkassen\u00a0diesem\u00a0Vertrag\u00a0angeschl ossen.\u00a0Sowohl\u00a0\nder\u00a0Einsatz\u00a0wirtschaftlicher\u00a0Biol ogika\u00a0bei\u00a0Ein\u2010\u00a0bzw.\u00a0Umstellung \u00a0der\u00a0Therapie\u00a0wer\u2010\nden\u00a0im\u00a0Vertragskonzept\u00a0ber\u00fccksichtigt,\u00a0als\u00a0auch\u00a0eine\u00a0Quote\u00a0f\u00fcr\u00a0 Biosimilars\u00a0verein\u2010\nbart.\u00a0Die\u00a0Biosimilarquote\u00a0umfa sst\u00a0alle\u00a0am\u00a0Vertrag\u00a0teilnehmenden \u00a0Gastroenterolo\u2010\ngen\u00a0und\u00a0bietet\u00a0ausreichenden\u00a0i ndividuellen\u00a0Therapieentscheidung raum.\u00a0\u00a0\nUnterst\u00fctzende\u00a0Versorgungsma\u00dfnah men,\u00a0wie\u00a0Beratungsangebote\u00a0f\u00fcr\u00a0 \u00c4rzte\u00a0und\u00a0\nPatienten\u00a0zur\u00a0evidenzbasierten\u00a0Pharmakotherapie\u00a0und\u00a0\u2010sicherheit \u00a0(z.B.\u00a0Ergebnisse\u00a0\nder\u00a0fr\u00fchen\u00a0Nutzenbewertung),\u00a0sind\u00a0durch\u00a0die\u00a0Vertr\u00e4ge\u00a0mit\u00a0Inform ationen\u00a0zu\u00a0wirt\u2010\nschaftlichen\u00a0Aspekten\u00a0gekoppelt.\u00a0Die\u00a0TK\u00a0bietet\u00a0CED\u2010Patienten\u00a0zu s\u00e4tzlich\u00a0ein\u00a0tele\u2010\nfonisches\u00a0Patientencoaching\u00a0an,\u00a0um\u00a0relevante\u00a0Informationen\u00a0zur\u00a0 sicheren\u00a0und\u00a0\nsachgerechten\u00a0Arzneimittelanwendung\u00a0zu\u00a0vermitteln\u00a0und\u00a0die\u00a0Thera pietreue\u00a0und\u00a0\ndas\u00a0Selbstmanagement\u00a0der\u00a0Patienten\u00a0zu\u00a0f\u00f6rdern.\u00a0\u00a0\nAuch\u00a0an\u00a0einem\u00a0Versorgungsvertrag\u00a0zur\u00a0Therapie\u00a0von\u00a0Rheumapatient en\u00a0mit\u00a0dem\u00a0\nBerufsverband\u00a0Deutscher\u00a0Rheumatologen\u00a0e.V.\u00a0(BDRh)\u00a0nehmen\u00a0zwisch enzeitlich\u00a0\nbereits\u00a0rund\u00a050\u00a0Krankenkassen\u00a0teil.\u00a0In\u00a0weiteren\u00a0Vertr\u00e4gen\u00a0mit\u00a0K rankenhausapo\u2010\ntheken\u00a0(nach\u00a0\u00a7\u00a0129\u00a0a)\u00a0wurde\u00a0z.B.\u00a0 das\u00a0Preisniveau\u00a0auf\u00a0H\u00f6he\u00a0der\u00a0B iosimilars\u00a0fixiert.\u00a0\u00a0\nInsgesamt\u00a0zeigt\u00a0sich\u00a0(s.\u00a0Tabelle \u00a01.5),\u00a0dass\u00a0die\u00a0Verordnungspr\u00e4v alenz\u00a0der\u00a0Biosimilars\u00a0\ndeutlich\u00a0zugenommen\u00a0hat.\u00a0Die\u00a0Vertr\u00e4ge\u00a0zwischen\u00a0Krankenkassen\u00a0un d\u00a0Verb\u00e4nden\u00a0\nhaben\u00a0dies\u00a0ma\u00dfgeblich\u00a0mitgestaltet\u00a0und\u00a0sind\u00a0auch\u00a0in\u00a0der\u00a0Zukunft \u00a0daf\u00fcr\u00a0gut\u00a0geeignet.\u00a0\nTabelle\u00a01.5:\u00a0Biosimilarquote\u00a0anhand\u00a0der\u00a0Bruttoausgaben\u00a0von\u00a0Infl iximab\u00a0und\u00a0\nEtanercept\u00a0\nAnteil\u00a0der\u00a0Bruttoausgaben\u00a0f\u00fcr\u00a0Biosimilars\u00a0von\u00a0Infliximab\u00a0und\u00a0Et anercept\u00a0\u00a0\n\u00a0Q1/2016\u00a0 Q2/2016\u00a0 Q3/2016\u00a0 Q4/2016\u00a0\nTK\u00a0 8,49%\u00a0 11,46%\u00a0 15,66%\u00a0 20,35%\u00a0\nGKV\u00a0 7,22%\u00a0 11,02%\u00a0 15,28%\u00a0 19,99%\u00a0\nQuelle:\u00a0TK\u00a0\nAusblick\u00a0\nDie\u00a0steigenden\u00a0Arzneimittelausga ben\u00a0sind\u00a0vor\u00a0allem\u00a0gepr\u00e4gt\u00a0von\u00a0 der\u00a0h\u00e4ufigeren\u00a0\nVerordnung\u00a0 von\u00a0 gentechnologisch\u00a0 he rgestellten\u00a0 Arzneimitteln,\u00a0 vo r\u00a0 allem\u00a0 von\u00a0\nBiologika.\u00a0Diese\u00a0Mittel\u00a0er\u00f6ffnen \u00a0f\u00fcr\u00a0viele\u00a0Erkrankungen\u00a0wie\u00a0RA, \u00a0CED,\u00a0Psoriasis\u00a0oder\u00a0\nKrebs\u00a0neue\u00a0M\u00f6glichkeiten\u00a0der\u00a0Behandlung,\u00a0die\u00a0oft\u00a0den\u00a0bisherigen \u00a0\u00fcberlegen\u00a0sind.\u00a0\nBei\u00a0allem\u00a0therapeutischen\u00a0Optimi smus\u00a0sollten\u00a0aber\u00a0der\u00a0Patienten nutzen\u00a0und\u00a0die\u00a0\nBezahlbarkeit\u00a0im\u00a0Blick\u00a0bleiben.\u00a0Das\u00a0AMNOG\u00a0hilft\u00a0zwar\u00a0durch\u00a0die\u00a0 \u201eFr\u00fchbewertung\u201c\u00a028\u00a0eine\u00a0erste\u00a0Einstufung\u00a0der\u00a0Mittel\u00a0in\u00a0das\u00a0therapeutische\u00a0Repertoi re\u00a0vornehmen\u00a0zu\u00a0\nk\u00f6nnen,\u00a0ein\u00a0abschlie\u00dfender\u00a0Patientennutzen\u00a0im\u00a0Sinne\u00a0von\u00a0verring erter\u00a0Mortalit\u00e4t,\u00a0\nMorbidit\u00e4tslast\u00a0und\u00a0Nebenwirkungsh\u00e4ufigkeit\u00a0sowie\u00a0einer\u00a0verbess erten\u00a0Lebens\u2010\nqualit\u00e4t\u00a0ist\u00a0aber\u00a0erst\u00a0im\u00a0Rahmen\u00a0der\u00a0\u00fcblichen\u00a0Versorgung\u00a0mit\u00a0au sreichender\u00a0Si\u2010\ncherheit\u00a0festzustellen.\u00a0Daher\u00a0sollte\u00a0das\u00a0AMNOG\u00a0dahingehend\u00a0erwe itert\u00a0werden,\u00a0\ndass\u00a0im\u00a0Rahmen\u00a0einer\u00a0\u201eSp\u00e4tbewertung\u201c\u00a0nach\u00a0etwa\u00a03\u00a0bis\u00a05\u00a0Jahren\u00a0e ine\u00a0erneute\u00a0und\u00a0\nabschlie\u00dfende\u00a0Bewertung\u00a0des\u00a0Mittels\u00a0vorgenommen\u00a0wird.\u00a0Dies\u00a0gilt \u00a0insbesondere\u00a0\nim\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Strategie\u00a0beschleunigter\u00a0Zulassungen\u00a0( Breakthrough\u00a0\noder\u00a0Adaptive\u00a0Licensing ),\u00a0die\u00a0mehr\u00a0und\u00a0mehr\u00a0den\u00a0Vermarktungsinteressen\u00a0der\u00a0pU\u00a0\nentgegenkommen,\u00a0dabei\u00a0aber\u00a0vielfach\u00a0Sicherheits\u2010\u00a0und\u00a0Nutzenaspe kte\u00a0wegen\u00a0der\u00a0\nbeschr\u00e4nkten\u00a0Behandlungszeitr\u00e4ume\u00a0und\u00a0der\u00a0geringen\u00a0Patientenzah l\u00a0noch\u00a0nicht\u00a0\nausreichend\u00a0ber\u00fccksichtigen\u00a0k\u00f6nnen\u00a0(Glaeske,\u00a02016b).\u00a0Eine\u00a0solch e\u00a0sp\u00e4te\u00a0Nutzen\u2010\nbewertung\u00a0muss\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Preisfestlegung\u00a0Relevanz\u00a0haben,\u00a0wei l\u00a0erst\u00a0nach\u00a0eini\u2010\nger\u00a0Zeit\u00a0der\u00a0Behandlungserfahrung\u00a0in\u00a0der\u00a0\u201erealen\u00a0Patientenwelt\u201c \u00a0\u00fcber\u00a0den\u00a0Nutzen\u00a0\n(Effectiveness )\u00a0Aussagen\u00a0getroffen\u00a0werden\u00a0k\u00f6nne n.\u00a0Auf\u00a0diese\u00a0Weise\u00a0k\u00f6nnte\u00a0sich \u00a0\ndas\u00a0AMNOG\u00a0der\u00a0Anforderung\u00a0einer\u00a0gesundheits\u00f6konomischen\u00a0Evaluat ion\u00a0n\u00e4hern,\u00a0\ndie\u00a0im\u00a0Rahmen\u00a0einer\u00a0\u201eFr\u00fchbewertung\u201c\u00a0nur\u00a0bedingt\u00a0durchgef\u00fchrt\u00a0we rden.\u00a0Die\u00a0\nGleichung\u00a0 Money\u00a0for\u00a0Value\u00a0and\u00a0Value\u00a0for\u00a0Money \u00a0wird\u00a0derzeit\u00a0im\u00a0AMNOG\u00a0nur\u00a0\nungen\u00fcgend\u00a0operationalisiert\u00a0\u2013\u00a0es\u00a0wird\u00a0h\u00f6chste\u00a0Zeit,\u00a0diese\u00a0Stra tegie\u00a0umzusetzen,\u00a0\num\u00a0den\u00a0oft\u00a0schwer\u00a0nachvollziehba ren\u00a0Preisvorstellungen\u00a0der\u00a0pU\u00a0e ine\u00a0rationale\u00a0\nBasis\u00a0entgegense tzen\u00a0zu\u00a0k\u00f6nnen.\u00a0\nQuellen\u00a0\nAkd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2008). \u00a0Stellungnahme\u00a0der\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\n\u00c4rzteschaft\u00a0zu\u00a0Biosimilars.\u00a0www.akdae.de/Stellungnahmen/Weitere /20081209.pdf,\u00a0letzter\u00a0Zugriff:\u00a025.10.2016.\u00a0\nDeutsche\u00a0Rheuma\u2010Liga\u00a0Bundesverband\u00a0e.V.\u00a0(2014).\u00a0Positionierung\u00a0 der\u00a0Deutschen\u00a0Rheuma\u2010Liga\u00a0Bundesverband\u00a0e.V.\u00a0zur\u00a0Einf\u00fchrung\u00a0\nvon\u00a0Biosimilars\u00a0in\u00a0Deutschland.\u00a0https://www.rheuma\u2010liga.de/bios imilars/,\u00a0letzter\u00a0Zugriff:\u00a006.07.2017.\u00a0\nDintsios\u00a0CM,\u00a0Koch\u00a0K,\u00a0Sawicki\u00a0PT\u00a0(2009).\u00a0Bewertung\u00a0von\u00a0Kosten\u2010Nu tzen\u2010Verh\u00e4ltnissen:\u00a0Ein\u00a0Vorschlag,\u00a0die\u00a0Kontroverse\u00a0und\u00a0ihre\u00a0\nHintergr\u00fcnde.\u00a0Monitor\u00a0Versorgungsforschung\u00a02(1):\u00a032\u201037.\u00a0\nGKV\u2010Spitzenverband\u00a0(2012).\u00a0Rahmenvertrag\u00a0\u00fcber\u00a0die\u00a0Arzneimittelv ersorgung\u00a0nach\u00a0\u00a7\u00a0129\u00a0Absatz\u00a02\u00a0SGB\u00a0V\u00a0in\u00a0der\u00a0Fassung\u00a0vom\u00a015.\u00a0\nJuni\u00a02012\u00a0zwischen\u00a0dem\u00a0Spitzenverband\u00a0Bund\u00a0der\u00a0Krankenkassen,\u00a0B erlin\u00a0und\u00a0dem\u00a0Deutschen\u00a0Apothekerverband\u00a0e.\u00a0\nV.\u00a0https://www.gkv\u2010spitzenverband.de/media/dokumente/krankenver sicherung_1\u00a0\n/arzneimittel/rahmenvertraege/apotheken/AM_20120615_S_RVtg_129_ Abs2.pdf,\u00a0letzter\u00a0Zugriff:\u00a025.10.2016.\u00a0\nGKV\u2010Spitzenverband\u00a0(2016).\u00a0Kennzahlen\u00a0der\u00a0gesetzlichen\u00a0Krankenv ersicherung.\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02016.\u00a0\nhttps://www.gkvspitzenverband.de/media/grafiken/gkv_kennzahlen/ kennzahlen_gkv_2016_q4/GKV_Kennzahlen_B\nooklet_Q4\u20102015_300dpi_2016\u201003\u201010.pdf,\u00a0letzter\u00a0Zugriff:\u00a027.06.20 17.\u00a0\nGlaeske\u00a0G\u00a0(2016a).\u00a0Preisbewertung\u00a0von\u00a0Arzneimitteln\u00a0bei\u00a0Marktei ntritt\u00a0\u2013\u00a0Anforderungen\u00a0und\u00a0Ma\u00dfst\u00e4be.\u00a0G\u00a0+\u00a0S\u00a02:\u00a020\u201028.\u00a0\nGlaeske\u00a0G\u00a0(2016b).\u00a0F\u00fcnf\u00a0Jahre\u00a0AMNOG.\u00a0In:\u00a0Glaeske\u00a0G,\u00a0Ludwig\u00a0WD,\u00a0 Th\u00fcrmann\u00a0P\u00a0(Hrsg).\u00a0Innovationsreport\u00a02016.\u00a0Bremen.\u00a0145\u2010160.\u00a0\nGrandt\u00a0D,\u00a0Schubert\u00a0I\u00a0(Hrsg.)\u00a0(2017).\u00a0Arzneimittelreport\u00a02017.\u00a0S iegburg:\u00a0Asgard.\u00a0\u00a029\u00a0IMS\u00a0Health\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0medizinische\u00a0Statistik\u00a0(Hrsg)\u00a0(2016). \u00a0\u00a0Der\u00a0Pharmazeutische\u00a0Markt\u00a0in\u00a0Deutschland.\u00a0Stand\u00a0der\u00a0Informati on:\u00a0\nDezember\u00a02016,\u00a0Frankfurt\u00a0a.M.:\u00a0Im\u00a0Eigenverlag.\u00a0\nIMS\u00a0Health\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0medizinische\u00a0Statistik\u00a0(2016).\u00a0Surge\u00a0 in\u00a0Biosimilars\u00a0to\u00a0Drive\u00a0Significa nt\u00a0Change\u00a0in\u00a0Health\u00a0System\u00a0Cos ts,\u00a0\nPatient\u00a0Access\u00a0and\u00a0Competition\u00a0 by\u00a02020.\u00a0www.imshealth.com/en/ab out\u2010us/news/ims\u2010health\u2010surge\u2010in\u2010biosimilars\u2010\nto\u2010drive\u2010change\u2010in\u2010health\u2010system\u2010costs,\u00a0letzter\u00a0Zugriff:\u00a018.10. 2016.\u00a0\nLudwig\u00a0WD,\u00a0Dicheva\u00a0A\u00a0(2016).\u00a0Bi osimilars\u00a0in\u00a0der\u00a0Onkologie:\u00a0Eine \u00a0therapeutische\u00a0Alternative\u00a0zu\u00a0Referenzarzneimitteln?\u00a0Z\u00a0\nGastroenterol\u00a054(11):\u00a01223\u20101229.\u00a0\nLudwig\u00a0WD,\u00a0Schildmann\u00a0J\u00a0(2015).\u00a0Kostenexplosion\u00a0in\u00a0der\u00a0medikame nt\u00f6sen\u00a0Therapie\u00a0onkologischer\u00a0Erkrankungen.\u00a0Onkologe\u00a021:\u00a0\n708\u2010716.\u00a0\nMcKeage\u00a0K\u00a0(2014).\u00a0A\u00a0Review\u00a0of\u00a0CT \u2010P13:\u00a0An\u00a0Infliximab\u00a0Biosimilar. \u00a0BioDrugs\u00a028\u00a0(3):\u00a0313\u2010321.\u00a0\nPEI\u00a0\u2013\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0(2015).\u00a0Position\u00a0des\u00a0Paul\u2010Ehrlich\u2010I nstituts\u00a0zum\u00a0Einsatz\u00a0von\u00a0Biosimilars.\u00a0\nwww.pei.de/DE/arzneimittel/immunglobuline\u2010monoklonale\u2010antikoerp er/monoklonale\u2010antikoerper/\u00a0zusatz/position\u2010\npei\u2010interchangebility\u2010biosimila rs\u2010inhalt.html?nn=3257580,\u00a0letzt er\u00a0Zugriff:\u00a018.10.2016.\u00a0\nPro\u00a0Generika\u00a0(2017).\u00a0Generika\u00a0i n\u00a0Zahlen.\u00a0www.progenerika.de/pub likationen/,\u00a0letzter\u00a0Zugriff\u00a005.07.2017.\u00a0\nWasem\u00a0J,\u00a0Niebuhr\u00a0D,\u00a0Gre\u00df\u00a0S\u00a0(2005).\u00a0Marktzugang\u00a0und\u00a0Preisbildung \u00a0auf\u00a0Arzneimittelm\u00e4rkten\u00a0im\u00a0internationalen\u00a0Vergleich\u00a0(No.\u00a0142) .\u00a0\nDiskussionsbeitr\u00e4ge\u00a0aus\u00a0dem\u00a0Fac hbereich\u00a0Wirtschaftswissenschaft en\u00a0der\u00a0Universit\u00e4t\u00a0Duisburg\u2010Essen,\u00a0Campus\u00a0Essen.\u00a0\nPro\u00a0Biosimilars\u00a0(2017a).\u00a0Von\u00a0der\u00a0E MA\u00a0zugelassene\u00a0Biosimilars\u00a020 17.\u00a0http://probiosimilars.de/publikationen/infografik\u2010biosimila rs\u2010\n2/,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\u00a0\nPro\u00a0Biosimilars\u00a0\u2013\u00a0Gesundheit\u00a0adhoc\u00a0(2017b).\u00a0Vergleich\u00a0der\u00a0Krank enkassenversorgungsanteile\u00a0von\u00a0Etanercept\u2010Biosimilars.\u00a0Stand\u00a0\nApril\u00a02017.\u00a0 www.gesundheit\u2010adhoc.de/vergleic h\u2010der\u2010krankenkassen verordnungsanteile\u2010von\u2010etanercept\u2010\nbiosimilars.html,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nPro\u00a0Biosimilars\u00a0\u2013\u00a0Gesundheit\u00a0adhoc\u00a0(2017c).\u00a0Ergebnis\u00a0\u00c4rztebefra gung:\u00a0Biosimilars\u00a0k\u00f6nnen\u00a0dazu\u00a0beitragen,\u00a0die\u00a0Versorgung\u00a0der\u00a0\nPatientinnen\u00a0und\u00a0Patienten\u00a0zu\u00a0verbessern.\u00a0Stand\u00a0der\u00a0Information en:\u00a0Juni\u00a02017.\u00a0www.gesundheit\u2010\nadhoc.de/ergebnis\u2010aerztebefragung\u2010biosimilars\u2010koennen\u2010dazu\u2010beit ragen\u2010die\u2010versorgung\u2010der\u2010patientinnen\u2010\nund.html,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nSchneider\u00a0CK\u00a0(2013).\u00a0Biosimilars\u00a0in\u00a0rheumatology:\u00a0the\u00a0wind\u00a0of\u00a0c hange.\u00a0Ann\u00a0Rheum\u00a0Dis\u00a072\u00a0(3):\u00a0315\u2010318.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0(2016).\u00a0Arzneiverordnungs\u2010Report\u00a0 2016.\u00a0Springer.\u00a0Berlin,\u00a0Heidelberg.\u00a0\nvfa\u00a0\u2013\u00a0Verband\u00a0forschender\u00a0Arzneimittelhersteller\u00a0bio,\u00a0Boston\u00a0Co nsulting\u00a0Group\u00a0(Hrsg.)\u00a0(2015).\u00a0Medizinische\u00a0Biotechnologie\u00a0in\u00a0\nDeutschland\u00a02005\u00a0\u2013\u00a02015\u00a0\u2013\u00a02025:\u00a0Bedeutung\u00a0f\u00fcr\u00a0Patienten,\u00a0Gesell schaft\u00a0und\u00a0Standort.\u00a0Berlin.\u00a0\nvfa\u00a0\u2013\u00a0Verband\u00a0forschender\u00a0Arzneimittelhersteller\u00a0(2017).\u00a0Origin alpr\u00e4parate\u00a0und\u00a0Biosimilars\u00a0(zugelassen\u00a0in\u00a0der\u00a0EU).\u00a0\nwww.vfa.de/download/biosimilars\u2010uebersicht\u2010originalpraeparate.p df,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a030\u00a02 Ziele\u00a0und\u00a0Methodik\u00a0\u00a0\nKristin\u00a0Sauer\u00a0\n2.1 Zielsetzung\u00a0\nDie\u00a0Ziele\u00a0des\u00a0vorliegenden\u00a0Innovationsreports\u00a0sind\u00a0zum\u00a0einen,\u00a0n eue\u00a0Arzneimittel\u00a0\nnach\u00a0der\u00a0Markteinf\u00fchrung\u00a0anhand\u00a0der\u00a0aktuellen\u00a0Studienlage\u00a0nach\u00a0 den\u00a0Kriterien\u00a0\nder\u00a0evidenzbasierten\u00a0Medizin\u00a0zu\u00a0bewerten\u00a0und\u00a0zum\u00a0anderen,\u00a0Veror dnungscharak\u2010\nteristika\u00a0dieser\u00a0Arzneimittel\u00a0nach\u00a0ihrer\u00a0Markteinf\u00fchrung\u00a0auf\u00a0de r\u00a0Basis\u00a0von\u00a0Daten\u00a0\nder\u00a0Techniker\u00a0Krankenkasse\u00a0(TK)\u00a0darzustellen.\u00a0\u00a0\nIm\u00a0diesj\u00e4hrigen\u00a0Innovationsreport\u00a0stehen\u00a0schwerpunktm\u00e4\u00dfig\u00a0die\u00a0n euen\u00a0Wirkstoffe\u00a0\ndes\u00a0Jahres\u00a02014\u00a0im\u00a0Fokus.\u00a0Zur\u00a0Bewertung\u00a0werden\u00a0auch\u00a0Studien\u00a0ber \u00fccksichtigt,\u00a0\nderen\u00a0Ergebnisse\u00a0erst\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung\u00a0der\u00a0jeweiligen\u00a0W irkstoffe\u00a0publi\u2010\nziert\u00a0worden\u00a0sind.\u00a0Ebenso\u00a0finden\u00a0neue\u00a0Erkenntnisse\u00a0zu\u00a0Sicherhei tsrisiken\u00a0Beach\u2010\ntung,\u00a0 die\u00a0 zum\u00a0 Zeitpunkt\u00a0 der\u00a0 Zulassung\u00a0 und\u00a0 zum\u00a0 Zeitpunkt\u00a0 der\u00a0 AMN OG\u2010\nNutzenbewertung\u00a0noch\u00a0nicht\u00a0bekannt\u00a0waren.\u00a0Unsere\u00a0Bewertungen\u00a0we rden\u00a0durch\u00a0\nAnalysen\u00a0der\u00a0Routinedaten\u00a0der\u00a0TK\u00a0aus\u00a0den\u00a0Jahren\u00a02014\u00a0und\u00a02015 \u00a0erg\u00e4nzt,\u00a0um\u00a0\nEinsichten\u00a0in\u00a0das\u00a0Versorgungsgeschehen\u00a0zu\u00a0gewinnen.\u00a0Im\u00a0R\u00fcckblic k\u00a0auf\u00a0die\u00a0im\u00a0\nInnovationsreport\u00a0 2016\u00a0 behandelten\u00a0 Arzneimittel\u00a0 (neue\u00a0 Wirkstoff e\u00a0 des\u00a0 Jahres\u00a0\n2013)\u00a0wird\u00a0auch\u00a0gezeigt,\u00a0wie\u00a0diese\u00a0sich\u00a0im\u00a0Markt\u00a0weiterentwicke lt\u00a0haben\u00a0und\u00a0ob\u00a0\nneue\u00a0Risiken\u00a0aufgetreten\u00a0sind,\u00a0d ie\u00a0die\u00a0Therapiesicherheit\u00a0gef\u00e4h rden.\u00a0\u00a0\nEin\u00a0Sonderkapitel\u00a0(Kapitel\u00a06)\u00a0der\u00a0Autoren\u00a0Stanislava\u00a0Dicheva\u00a0un d\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\nbehandelt\u00a0Biosimilars\u00a0in\u00a0der\u00a0Onkologie.\u00a0Dabei\u00a0geht\u00a0es\u00a0vor\u00a0allem \u00a0um\u00a0das\u00a0derzeitige\u00a0\nAngebot\u00a0und\u00a0Marktvolumen\u00a0von\u00a0Biologika\u00a0in\u00a0diesem\u00a0Indikationsber eich\u00a0und\u00a0um\u00a0die\u00a0\nm\u00f6glichen\u00a0Einsparpotenziale\u00a0durc h\u00a0die\u00a0Verordnungen\u00a0von\u00a0Biosimil ars,\u00a0deren\u00a0Zulas\u2010\nsungen\u00a0bevorstehen.\u00a0Hier\u00a0werden\u00a0 auch\u00a0die\u00a0Diskussionen\u00a0zur\u00a0Austa uschbarkeit,\u00a0Qua\u2010\nlit\u00e4t\u00a0und\u00a0Sicherheit\u00a0der\u00a0Therapie\u00a0mit\u00a0Biosimilars\u00a0gef\u00fchrt.\u00a0\n2.2 Methodik\u00a0zur\u00a0Bewertung\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0\nF\u00fcr\u00a0den\u00a0vorliegenden\u00a0Report\u00a0wurde n\u00a0Medikamente\u00a0mit\u00a0neuen\u00a0Wirkst offen\u00a0be\u2010\nr\u00fccksichtigt,\u00a0die\u00a0im\u00a0Jahr\u00a02014\u00a0erstmals\u00a0in\u00a0den\u00a0deutschen\u00a0Arznei mittelmarkt\u00a0einge\u2010\nf\u00fchrt\u00a0wurden\u00a0(Tabelle\u00a02.1),\u00a0darunter\u00a0auch\u00a0bekannte\u00a0Wirkstoffe\u00a0i n\u00a0neuen\u00a0Indikatio\u2010\nnen\u00a0 (z.B.\u00a0 Dimethylfumarat).\u00a0 Generell\u00a0 wurden\u00a0 neue\u00a0 Arzneimittel\u00a0 m it\u00a0 bereits\u00a0 in\u00a0\nanderen\u00a0zugelassenen\u00a0Pr\u00e4paraten\u00a0verf\u00fcgbaren\u00a0Wirkstoffen\u00a0(z.B.\u00a0G enerika)\u00a0oder\u00a0\nn e u e \u00a0K o m b i n a t i o n e n \u00a0a u s \u00a0b e r e i t s \u00a0b e k a n n t e n \u00a0W i r k s t o f f e n \u00a0n i c h t \u00a0b e r \u00fc cksichtigt.\u00a0\nEbenfalls\u00a0keine\u00a0Ber\u00fccksichtigung\u00a0fanden\u00a0die\u00a0nicht\u00a0vom\u00a0G\u2010BA\u00a0im\u00a0R ahmen\u00a0der\u00a0fr\u00fc\u2010\nhen\u00a0Nutzenbewertung\u00a0bewerteten\u00a0Arzneimittel\u00a0Ceftobiprol\u00a0medocar il\u00a0(Zevtera\u00ae),\u00a031\u00a0Levosimendan\u00a0(Simdax\u00ae)\u00a0und\u00a0Telavancin\u00a0(Vibativ\u00ae)\u00a0(kein\u00a0Unterlag enschutz),\u00a0Pegin\u2010\nterferon\u00a0beta\u20101a\u00a0(Plegridy\u00ae)\u00a0(ke in\u00a0neuer\u00a0Wirkstoff),\u00a0Avanafil\u00a0( Spedra\u00ae)\u00a0(nicht\u00a0er\u2010\nstattungsf\u00e4higes\u00a0Lifestyle\u2010Arzneimittel),\u00a0Chloroprocain\u00a0(Ampres s\u00ae)\u00a0und\u00a0Defibrotid\u00a0\n(Defitelio\u00ae)\u00a0(wegen\u00a0Geringf\u00fcgigk eit\u00a0der\u00a0erwarteten\u00a0Kosten\u00a0f\u00fcr\u00a0d ie\u00a0GKV)\u00a0sowie\u00a0der\u00a0\npr\u00e4pandemische\u00a0Influenza\u2010Impfstoff\u00a0H5N1\u00a0(Aflunov\u00ae)\u00a0(zur\u00a0Krankhe itspr\u00e4vention\u00a0\nnicht\u00a0generell\u00a0erstattungsf\u00e4hig).\u00a0Die\u00a02014\u00a0neu\u00a0eingef\u00fchrten\u00a0Arz neimittel\u00a0Canag\u2010\nliflozin\u00a0(Invokana\u00ae),\u00a0Insulin\u00a0deg ludec\u00a0(Tresiba\u00ae),\u00a0Lurasidon\u00a0(L atuda\u00ae)\u00a0und\u00a0Mirabe\u2010\ngron\u00a0(Betmiga\u00ae)\u00a0wurden\u00a0nicht\u00a0in\u00a0unsere\u00a0Bewertung\u00a0miteinbezogen, \u00a0da\u00a0deren\u00a0Ver\u2010\ntrieb\u00a0in\u00a0Deutschland\u00a0zwischenzeitlich\u00a0aufgrund\u00a0gescheiterter\u00a0bz w.\u00a0nicht\u00a0eingeleite\u2010\nter\u00a0Preisverhandlungen\u00a0mit\u00a0dem\u00a0G KV\u2010Spitzenverband\u00a0eingestellt\u00a0w urde.\u00a0Gleiches\u00a0\ngilt\u00a0 f\u00fcr\u00a0 das\u00a0 Arzneimittel\u00a0 Sipuleucel\u2010T\u00a0 (Provenge\u00ae),\u00a0 dessen\u00a0 Zula ssung\u00a0 aus\u00a0 Wirt\u2010\nschaftlichkeitsgr\u00fcnden\u00a0auf\u00a0Antrag\u00a0des\u00a0Herstellers\u00a0durch\u00a0die\u00a0EMA \u00a0europaweit\u00a0zu\u2010\nr\u00fcckgezogen\u00a0wurde.\u00a0Diagnosti ka\u00a0werden\u00a0nicht\u00a0bewertet.\u00a0\nDie\u00a0Bewertung\u00a0der\u00a0Studienlage\u00a0basierte\u00a0zum\u00a0einen\u00a0auf\u00a0den\u00a0Ergebn issen\u00a0der\u00a0Zulas\u2010\nsungsstudien\u00a0sowie\u00a0dem\u00a0Beurteilungsbericht\u00a0der\u00a0verantwortlichen \u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0und\u00a0zum\u00a0anderen\u00a0auf\u00a0Litera turrecherchen,\u00a0welche\u00a0die\u00a0jewei ligen\u00a0Autoren\u00a0\nunabh\u00e4ngig\u00a0voneinander\u00a0durchf\u00fchrten.\u00a0Haupts\u00e4chlich\u00a0wurde\u00a0in\u00a0der \u00a0Literaturda\u2010\ntenbank\u00a0MEDLINE\u00a0\u00fcber\u00a0PubMed\u00a0recherchiert.\u00a0Zus\u00e4tzlich\u00a0zur\u00a0Suche\u00a0 \u00fcber\u00a0Literatur\u2010\ndatenbanken\u00a0wurden\u00a0Standardwerke\u00a0 der\u00a0wissenschaftlichen\u00a0Literat ur\u00a0genutzt.\u00a0\nGem\u00e4\u00df\u00a0den\u00a0Grunds\u00e4tzen\u00a0der\u00a0Evidenzbasierten\u00a0Medizin\u00a0(EbM),\u00a0dem\u00a0M ethodenpa\u2010\npier\u00a0IQWiG,\u00a0analog\u00a0zum\u00a0Vorgehen\u00a0nach\u00a0\u00a7\u00a035\u00a0Absatz\u00a01b\u00a0Satz\u00a01\u00a0bis\u00a0 5\u00a0(SGB\u00a0V)\u00a0und\u00a0\nnach\u00a0\u00a7\u00a013\u00a0Absatz\u00a02\u00a0der\u00a0Verfahrensordnung\u00a0des\u00a0G\u2010BA\u00a0wurden\u00a0im\u00a0Wes entlichen\u00a0\nklinische\u00a0kontrollierte\u00a0und\u00a0bzw.\u00a0oder\u00a0versorgungsrelevante\u00a0Stud ien\u00a0mit\u00a0patienten\u2010\nrelevanten\u00a0Endpunkten\u00a0eingeschlo ssen,\u00a0insbesondere\u00a0zur\u00a0Mortalit \u00e4t,\u00a0Morbidit\u00e4t\u00a0\nund\u00a0Lebensqualit\u00e4t.\u00a0Bei\u00a0der\u00a0Extraktion\u00a0der\u00a0Ergebnisse\u00a0zu\u00a0prim\u00e4r en\u00a0und\u00a0sekund\u00e4ren\u00a0\nEndpunkten\u00a0der\u00a0Studien\u00a0wurde\u00a0auf\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0von\u00a0Ergebnis sen\u00a0zur\u00a0Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life\u00a0(HRQoL) \u00a0geachtet;\u00a0wenn\u00a0vorhanden,\u00a0wurden\u00a0sie\u00a0in\u00a0den\u00a0\nBericht\u00a0aufgenommen.\u00a0\u00a0\nDie\u00a0Bewertung\u00a0neuer\u00a0Arzneimittel\u00a0wird\u00a0durch\u00a0Sekund\u00e4rliteratur\u00a0u nter\u00a0dem\u00a0Aspekt\u00a0\n\"Wie\u00a0bewerten\u00a0andere\"\u00a0erg\u00e4nzt.\u00a0D azu\u00a0geh\u00f6ren\u00a0die\u00a0Bewertungen\u00a0nac h\u00a0der\u00a0Metho\u2010\nde\u00a0von\u00a0Fricke\u00a0und\u00a0Klaus,\u00a0die\u00a0Bewertung\u00a0des\u00a0arznei\u2010telegramms\u00a0(a \u2010t)\u00a0und\u00a0des\u00a0Arz\u2010\nneimittelbriefes\u00a0(AMB)\u00a0sowie\u00a0die \u00a0sieben\u00a0Bewertungsstufen\u00a0von\u00a0Pr escrire\u00a0(zwischen\u00a0\n\u201eBRAVO\u201c\u00a0und\u00a0\u201enot\u00a0acceptable \u201c).\u00a0Die\u00a0Methode\u00a0von\u00a0Fricke\u00a0und\u00a0Klaus\u00a0basiert\u00a0auf\u00a0\npharmakologischen\u00a0Kriterien\u00a0und\u00a0bewertet\u00a0prim\u00e4r\u00a0die\u00a0Neuartigkei t\u00a0des\u00a0Wirkungs\u2010\nmechanismus\u00a0der\u00a0Arzneistoffe\u00a0sowie\u00a0den\u00a0angestrebten\u00a0therapeutis chen\u00a0Effekt:\u00a0\n\u201eF\u00fchrt\u00a0ein\u00a0neuer\u00a0Wirkungsmechanismus\u00a0(A)\u00a0oder\u00a0ein\u00a0verbessertes\u00a0 Wirkprinzip\u00a0(B)\u00a0\nnicht\u00a0zu\u00a0der\u00a0entsprechenden\u00a0Verbesserung\u00a0des\u00a0therapeutischen\u00a0Nu tzens,\u00a0wird\u00a0die\u00a0\nunterschiedliche\u00a0Bewertung\u00a0der\u00a0klinischen\u00a0Eigenschaften\u00a0durch\u00a0e ine\u00a0zus\u00e4tzliche\u00a032\u00a0Kennzeichnung\u00a0 hervorgehoben.\u00a0 Solc he\u00a0 Doppelbewertungen\u00a0 ergeben\u00a0 s ich\u00a0 aus\u00a0\neiner\u00a0unterschiedlichen\u00a0Beurteilung\u00a0der\u00a0pharmakologischen\u00a0Aspek te\u00a0(z.B.\u00a0neuarti\u2010\nges\u00a0 Wirkprinzip)\u00a0 und\u00a0 der\u00a0 klinischen\u00a0 Studiendaten,\u00a0 wenn\u00a0 ein\u00a0 phar makologisch\u00a0\ninnovatives\u00a0Arzneimittel\u00a0keine\u00a0th erapeutische\u00a0\u00dcberlegenheit\u00a0geg en\u00fcber\u00a0bereits\u00a0\nverf\u00fcgbaren\u00a0 Arzneimitteln\u00a0 mit\u00a0 gle icher\u00a0 Indikation\u00a0 gezeigt\u00a0 hat\u00a0 ( A/C)\u201c\u00a0 (Fricke\u00a0 &\u00a0\nSchwabe,\u00a02015).\u00a0\nDie\u00a0anschlie\u00dfende\u00a0Beurteilung\u00a0der\u00a0Evidenz\u00a0nahmen\u00a0die\u00a0Autoren\u00a0im \u00a0Konsensver\u2010\nfahren\u00a0vor.\u00a0F\u00fcr\u00a0die\u00a0Leitlinienempfehlungen\u00a0zu\u00a0den\u00a0einzelnen\u00a0Arz neimitteln\u00a0und\u00a0\nihren\u00a0jeweiligen\u00a0Indikationsgebieten\u00a0wurden\u00a0Leitlinien\u00a0genutzt, \u00a0die\u00a0im\u00a0Register\u00a0der\u00a0\nArbeitsgemeinschaft\u00a0 der\u00a0 Wissensc haftlichen\u00a0 Medizinischen\u00a0 Fachge sellschaften\u00a0\ne.V.\u00a0 (AWMF)\u00a0 eingetragen\u00a0 sind.\u00a0 Sollte\u00a0 zu\u00a0 den\u00a0 bestimmten\u00a0 Indikati onsgebieten\u00a0\nkeine\u00a0AWMF\u2010Leitlinie\u00a0zu\u00a0finden\u00a0gewesen\u00a0sein,\u00a0wurde\u00a0nach\u00a0anderen \u00a0nationalen\u00a0\noder\u00a0internationalen\u00a0Handlun gsempfehlungen\u00a0gesucht.\u00a0\u00a0\nBei\u00a0den\u00a0einzelnen\u00a0Wirkstoffen\u00a0wurden\u00a0verschiedene\u00a0Punkte\u00a0separa t\u00a0bewertet:\u00a0\nErstens\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0bestehender\u00a0medikament\u00f6ser\u00a0Therapien, \u00a0zweitens\u00a0der\u00a0\npatientenorientierte\u00a0(Zusatz\u2010)Nutzen\u00a0und\u00a0drittens\u00a0die\u00a0Kosten\u00a0de s\u00a0neuen\u00a0Arzneimit\u2010\ntels\u00a0im\u00a0Vergleich\u00a0zu\u00a0bisher\u00a0verf \u00fcgbaren\u00a0Arzneimitteln.\u00a0Waren\u00a0bi s\u00a0dato\u00a0keine\u00a0medi\u2010\nkament\u00f6sen\u00a0Therapien\u00a0f\u00fcr\u00a0die\u00a0jeweilige\u00a0Erkrankung\u00a0verf\u00fcgbar,\u00a0wu rde\u00a0der\u00a0Nutzen\u00a0\n(therapeutische\u00a0Wirksamkeit)\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0bewertet.\u00a0 F\u00fcr\u00a0jeden\u00a0der\u00a0\ndrei\u00a0genannten\u00a0Punkte\u00a0wurde\u00a0ein\u00a0Ampelschema\u00a0genutzt,\u00a0wobei\u00a0die\u00a0 Farben\u00a0das\u00a0\nFolgende\u00a0bedeuten:\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt\u00a0l ediglich\u00a0eine\u00a0weitere\u00a0Therapieo pti\u2010\non\u00a0f\u00fcr\u00a0das\u00a0zugelassene\u00a0Anwendungsgebiet\u00a0dar,\u00a0es\u00a0gibt\u00a0f\u00fcr\u00a0die\u00a0Be \u2010\nhandlung\u00a0der\u00a0jeweiligen\u00a0Erkrankung(en)\u00a0bereits\u00a0zugelassene\u00a0Arzn ei\u2010\nmittel\u00a0auf\u00a0dem\u00a0deutschen\u00a0Markt.\u00a0\n\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt\u00a0eine\u00a0Subgruppen\u2010Novit\u00e4t\u00a0dar,\u00a0da\u00a0\nf\u00fcr\u00a0eine\u00a0bestimmte\u00a0Untergruppe\u00a0der\u00a0Erkrankten\u00a0keine\u00a0Therapiem\u00f6g \u2010\nlichkeit\u00a0vorhanden\u00a0ist,\u00a0z.B.\u00a0weil\u00a0bei\u00a0bisher\u00a0zugelassenen\u00a0Arzne imit\u2010\nteln\u00a0Resistenzen\u00a0vorliegen.\u00a0\n\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0e rstmals\u00a0die\u00a0M\u00f6glichkeit,\u00a0die\u00a0Er \u2010\nkrankung,\u00a0f\u00fcr\u00a0die\u00a0es\u00a0zugelassen\u00a0 ist,\u00a0medikament\u00f6s\u00a0zu\u00a0behandeln. \u00a0\n\u00a0 \u00a033\u00a0(Zusatz\u2010)Nutzen\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0f \u00fcr\u00a0die\u00a0Behandlung\u00a0gegen\u00fcber\u00a0den \u00a0\nbisher\u00a0verf\u00fcgbaren\u00a0Arz neimitteln\u00a0keine\u00a0patientenrelevante\u00a0Verbe s\u2010\nserung\u00a0oder\u00a0weist\u00a0sogar\u00a0eine\u00a0sch lechtere\u00a0Nutzen\u2010Schaden\u2010Relatio n\u00a0\nauf\u00a0als\u00a0bisher\u00a0verf\u00fcgbare\u00a0Arznei mittel\u00a0(z.B.\u00a0mehr\u00a0Nebenwirkunge n).\u00a0\n\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0Verbesserungen\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0\ntherapeutische\u00a0Wirksamkeit\u00a0oder\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0bzw.\u00a0Therap ie\u2010\nsicherheit,\u00a0wobei\u00a0die\u00a0Evidenz\u00a0ni cht\u00a0eindeutig\u00a0ist\u00a0(z.B.\u00a0heterog ene\u00a0\nStudienergebnisse)\u00a0oder\u00a0die\u00a0beoba chteten\u00a0Verbesserungen\u00a0eher\u00a0ge \u2010\nring\u00a0ausfallen.\u00a0\n\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0f\u00fcr\u00a0die\u00a0zugelassene\u00a0Behandlung\u00a0\nder\u00a0spezifischen\u00a0Erkrankung\u00a0eine \u00a0Verbesserung\u00a0gegen\u00fcber\u00a0den\u00a0bis \u2010\nher\u00a0 verf\u00fcgbaren\u00a0 Arzneimitteln\u00a0 bez \u00fcglich\u00a0 klinisch\u00a0 relevanter\u00a0 End \u2010\npunkte.\u00a0Der\u00a0erforderliche\u00a0Zusatzeffekt\u00a0wird\u00a0hier\u00a0in\u00a0Abh\u00e4ngigkei t\u00a0von\u00a0\nder\u00a0jeweiligen\u00a0Indikation\u00a0festgelegt,\u00a0so\u00a0dass\u00a0z.B.\u00a0auch\u00a0kleiner e\u00a0(aber\u00a0\npatientenrelevante)\u00a0Verbesserung en\u00a0bei\u00a0seltenen\u00a0Erkrankungen,\u00a0f \u00fcr\u00a0\ndie\u00a0es\u00a0noch\u00a0keine\u00a0Therapie\u00a0gibt,\u00a0an\u00a0Gewicht\u00a0gewinnen.\u00a0Auch\u00a0wenn \u00a0es\u00a0\neindeutige\u00a0Belege\u00a0daf\u00fcr\u00a0gibt,\u00a0da ss\u00a0die\u00a0Nutzen\u2010Schaden\u2010Bilanz\u00a0ge gen\u2010\n\u00fcber\u00a0bisherigen\u00a0Therapien\u00a0z.B.\u00a0aufgrund\u00a0einer\u00a0Verminderung\u00a0schw e\u2010\nrer\u00a0unerw\u00fcnschter\u00a0Wirkungen\u00a0reduziert\u00a0ist,\u00a0wurde\u00a0mit\u00a0\u201egr\u00fcn\u201c\u00a0be\u2010\nwertet.\u00a0\nKosten\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren\u00a0A n\u2010\nwendungszeitraum\u00a0teurer\u00a0als\u00a0andere \u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0An\u2010\nwendungsgebiet\u00a0zugelassene\u00a0Arzneim ittel\u00a0(zweckm\u00e4\u00dfige\u00a0Vergleichs \u2010\ntherapie).\u00a0Bei\u00a0mehreren\u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation\u00a0 f\u00fcr\u00a0die\u00a0\nBewertung\u00a0relevant,\u00a0bei\u00a0welcher \u00a0aufgrund\u00a0epidemiologischer\u00a0Date n\u00a0\ndie\u00a0meisten\u00a0Anwender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\n\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0kostet\u00a0i n\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichba\u2010\nren\u00a0Anwendungszeitraum\u00a0ungef\u00e4hr\u00a0gleich\u00a0viel\u00a0wie\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0 je\u2010\nweilige\u00a0Anwendungsgebiet\u00a0zugelasse ne\u00a0Arzneimittel\u00a0(zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie).\u00a0Oder\u00a0einige\u00a0wichtige\u00a0Arzneimittelgruppen\u00a0s ind\u00a0\ng\u00fcnstiger,\u00a0w\u00e4hrend\u00a0andere\u00a0relevante\u00a0Alternativen\u00a0teurer\u00a0sind\u00a0al s\u00a0das\u00a0\nneue\u00a0Arzneimittel.\u00a0Bei\u00a0mehreren\u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Ind ikati\u2010\non\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0relevant,\u00a0b ei\u00a0welcher\u00a0aufgrund\u00a0epidemiolog i\u2010\nscher\u00a0Daten\u00a0die\u00a0meisten\u00a0An wender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\u00a034\u00a0\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren\u00a0\nAnwendungszeitraum\u00a0g\u00fcnstiger\u00a0als\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwen \u2010\ndungsgebiet\u00a0zugelassene\u00a0Arzneimi ttel\u00a0(zweckm\u00e4\u00dfige\u00a0Vergleichsthe \u2010\nrapie).\u00a0Bei\u00a0mehreren\u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation\u00a0f\u00fcr \u00a0die\u00a0\nBewertung\u00a0relevant,\u00a0bei\u00a0welcher \u00a0aufgrund\u00a0epidemiologischer\u00a0Date n\u00a0\ndie\u00a0meisten\u00a0Anwender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\n\u2022 Wei\u00df:\u00a0Ein\u00a0aktueller\u00a0Kostenvergleich\u00a0 mit\u00a0Arzneimitteln,\u00a0die\u00a0sich\u00a0ber eits\u00a0\nl\u00e4nger\u00a0auf\u00a0dem\u00a0Markt\u00a0befinden,\u00a0ist\u00a0entweder\u00a0aufgrund\u00a0einer\u00a0fehl en\u2010\nden\u00a0Markteinf\u00fchrung\u00a0bzw.\u00a0einer\u00a0Marktr\u00fccknahme\u00a0des\u00a0neuen\u00a0Arznei\u2010mittels\u00a0oder\u00a0aufgrund\u00a0des\u00a0Fehlens\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0medikament \u00f6\u2010\nsen\u00a0Vergleichstherapie\u00a0nicht\u00a0m\u00f6glich.\u00a0\nWenn\u00a0die\u00a0Ampel\u00a0bei\u00a0den\u00a0\u201everf\u00fcgbaren\u00a0Therapien\u201c\u00a0rot\u00a0gekennzeichn et\u00a0ist,\u00a0ist\u00a0dies\u00a0\nnicht\u00a0automatisch\u00a0negativ\u00a0zu\u00a0sehen.\u00a0Sofern\u00a0diese\u00a0neue\u00a0Substanz\u00a0 einen\u00a0deutlichen\u00a0\ntherapeutischen\u00a0Fortschritt\u00a0mit\u00a0 sich\u00a0bringt,\u00a0also\u00a0eine\u00a0gr\u00fcne\u00a0Am pel\u00a0beim\u00a0\u201e(Zusatz\u2010)\u00a0\nNutzen\u201c\u00a0zu\u00a0sehen\u00a0ist,\u00a0kann\u00a0immer\u00a0noch\u00a0eine\u00a0relevante\u00a0therapeuti sche\u00a0Innovation\u00a0\nvorliegen.\u00a0In\u00a0der\u00a0Regel\u00a0ist\u00a0jedo ch\u00a0bei\u00a0einem\u00a0nachgewiesenen\u00a0(Zu satz\u2010)\u00a0Nutzen\u00a0die\u00a0\nVerf\u00fcgbarkeitsampel\u00a0mindestens\u00a0au f\u00a0\u201egelb\u201c\u00a0gestellt,\u00a0weil\u00a0mit\u00a0de r\u00a0Anwendung\u00a0des\u00a0\nMittels\u00a0Vorteile\u00a0verbunden\u00a0sein\u00a0k\u00f6nnen,\u00a0z.B.\u00a0f\u00fcr\u00a0definierte\u00a0kle ine\u00a0Patientengrup\u2010\npen.\u00a0Die\u00a0Verf\u00fcgbarkeit\u00a0bestehender\u00a0Therapien\u00a0orientiert\u00a0sich\u00a0hi er\u00a0an\u00a0der\u00a0Situation\u00a0\nzum\u00a0Zeitpunkt\u00a0des\u00a0Redaktionsschlusses,\u00a0der\u00a0(Zusatz\u2010)\u00a0Nutzen\u00a0wir d\u00a0auf\u00a0Basis\u00a0der\u00a0\naktuellen\u00a0Literatur\u00a0(Redaktionsschluss:\u00a001.05.2017)\u00a0bestimmt,\u00a0e benso\u00a0werden\u00a0die\u00a0\nKosten\u00a0auf\u00a0Basis\u00a0aktueller\u00a0Preisst\u00e4nde\u00a0(Lauer\u2010Taxe,\u00a0Stand:\u00a001.0 5.2017)\u00a0beurteilt.\u00a0\nSollte\u00a0das\u00a0neue\u00a0Arzneimittel\u00a0f\u00fc r\u00a0mehrere\u00a0Anwendungsgebiete\u00a0zuge lassen\u00a0sein,\u00a0\nwurde\u00a0unsere\u00a0Bewertung\u00a0durch\u00a0die\u00a0Haupt\u2010\u00a0bzw.\u00a0Erstindikation\u00a0gel eitet,\u00a0sofern\u00a0\ndiese\u00a0identifizierbar\u00a0war.\u00a0\u00a0\nIm\u00a0Rahmen\u00a0von\u00a0Arzneimittelstudien \u00a0m\u00f6glicherweise\u00a0auftretende\u00a0un erw\u00fcnschte\u00a0\nEreignisse\u00a0bzw.\u00a0Nebenwirkungen\u00a0wurden\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a03\u00a0Abs.\u00a06,\u00a07\u00a0und\u00a08 \u00a0der\u00a0\u201eVerord\u2010\nnung\u00a0\u00fcber\u00a0die\u00a0Anwendung\u00a0der\u00a0Guten\u00a0Klinischen\u00a0Praxis\u00a0bei\u00a0der\u00a0Dur chf\u00fchrung\u00a0von\u00a0\nklinischen\u00a0 Pr\u00fcfungen\u00a0 mit\u00a0 Arzneimitteln\u00a0 zur\u00a0 Anwendung\u00a0 am\u00a0 Mensche n\u201c\u00a0 (GCP\u2010\nVerordnung)\u00a0wie\u00a0folgt\u00a0definiert\u00a0und\u00a0so\u00a0auch\u00a0in\u00a0den\u00a0Bewertungen\u00a0 dieses\u00a0Reports\u00a0\nbehandelt:\u00a0\u00a0\n\u2022 Unerw\u00fcnschtes\u00a0Ereignis \u00a0(Unerw\u00fcnschtes\u00a0Arzneimittelereignis,\u00a0UAE)\u00a0\nist\u00a0jedes\u00a0nachteilige\u00a0Vorkommnis,\u00a0 das\u00a0einer\u00a0betroffenen\u00a0Person\u00a0 wi\u2010\nderf\u00e4hrt,\u00a0 der\u00a0 ein\u00a0 Pr\u00fcfpr\u00e4parat\u00a0 verabreicht\u00a0 wurde,\u00a0 das\u00a0 aber\u00a0 nich t\u00a0\nnotwendigerweise\u00a0in\u00a0urs\u00e4chliche m\u00a0Zusammenhang\u00a0mit\u00a0dieser\u00a0Be\u2010\nhandlung\u00a0steht.\u00a035\u00a0\u2022 Nebenwirkung \u00a0ist\u00a0jede\u00a0nachteilige\u00a0und\u00a0unbeabsichtigte\u00a0Reaktion\u00a0auf\u00a0\nein\u00a0Pr\u00fcfpr\u00e4parat,\u00a0unabh\u00e4ngig\u00a0von\u00a0dessen\u00a0Dosierung.\u00a0\n\u2022 Schwerwiegendes\u00a0 unerw\u00fcnschtes\u00a0 Ereignis \u00a0 oder\u00a0 schwerwiegende\u00a0\nNebenwirkung\u00a0ist\u00a0jedes\u00a0unerw\u00fcnschte\u00a0Ereignis\u00a0oder\u00a0jede\u00a0Nebenwir \u2010\nkung,\u00a0das\u00a0oder\u00a0die\u00a0t\u00f6dlich\u00a0oder\u00a0lebensbedrohend\u00a0ist,\u00a0eine\u00a0stati on\u00e4re\u00a0\nBehandlung\u00a0oder\u00a0deren\u00a0Verl\u00e4nger ung\u00a0erforderlich\u00a0macht\u00a0oder\u00a0zu\u00a0\nbleibender\u00a0oder\u00a0schwerwiegender\u00a0B ehinderung\u00a0oder\u00a0Invalidit\u00e4t\u00a0f\u00fc hrt\u00a0\noder\u00a0eine\u00a0kongenitale\u00a0Anomalie\u00a0o der\u00a0einen\u00a0Geburtsfehler\u00a0zur\u00a0Fol ge\u00a0\nhat\u00a0(Bundesministerium\u00a0der\u00a0Justi z\u00a0und\u00a0f\u00fcr\u00a0Verbraucherschutz,\u00a020 12).\u00a0\nDie\u00a0 im\u00a0 Rahmen\u00a0 der\u00a0 Wirkstoffportr\u00e4ts\u00a0 angegebenen\u00a0 Therapiekosten\u00a0 wurden\u00a0 \u2013\u00a0\nwenn\u00a0der\u00a0neue\u00a0Arzneistoff\u00a0einer\u00a0 Wirkstoffklasse\u00a0zugeordnet\u00a0werd en\u00a0konnte\u00a0\u2013\u00a0\ninnerhalb\u00a0einer\u00a0solchen\u00a0durchgef\u00fchrt\u00a0und\u00a0f\u00fcr\u00a0die\u00a0Packungsgr\u00f6\u00dfe\u00a0 berechnet,\u00a0deren\u00a0\nVerordnung\u00a0f\u00fcr\u00a0die\u00a0angegebene\u00a0Behandlungsdauer\u00a0am\u00a0preisg\u00fcnstigs ten\u00a0war.\u00a0Die\u00a0\nBerechnung\u00a0erfolgte\u00a0auf\u00a0Basis\u00a0der\u00a0Brutto\u2010Apothekenverkaufspreis e\u00a0zum\u00a0Preisstand\u00a0\n02.05.2017\u00a0(Lauer\u2010Taxe).\u00a0Reimporte\u00a0sowie\u00a0m\u00f6gliche\u00a0Rabatte\u00a0(durc h\u00a0pU\u00a0und\u00a0Apo\u2010\ntheke)\u00a0wurden\u00a0nicht\u00a0ber\u00fccksichtigt,\u00a0so\u00a0dass\u00a0die\u00a0Preise\u00a0nur\u00a0als\u00a0 Richtwert\u00a0betrachtet\u00a0\nwerden\u00a0k\u00f6nnen.\u00a0Sofern\u00a0das\u00a0jeweilige\u00a0Arzneimittel\u00a0f\u00fcr\u00a0mehrere\u00a0In dikationsgebiete\u00a0\nzugelassen\u00a0ist,\u00a0wurden\u00a0die\u00a0Therapiekosten\u00a0ggf.\u00a0separat\u00a0f\u00fcr\u00a0jede s\u00a0Indikationsgebiet\u00a0\nberechnet.\u00a0Die\u00a0Dosierungen\u00a0wurde n\u00a0den\u00a0Fachinformationen\u00a0der\u00a0pU\u00a0 entnommen.\u00a0\nGab\u00a0es\u00a0unterschiedliche\u00a0Dosierungsempfehlungen\u00a0(z.B.\u00a0Initialdos is,\u00a0Erhaltungsdo\u2010\nsis,\u00a0Co\u2010Medikation)\u00a0wurden\u00a0die\u00a0definierten\u00a0Tagesdosen\u00a0zur\u00a0Dosis berechnung\u00a0hin\u2010\nzugezogen.\u00a0Abweichungen\u00a0in\u00a0den\u00a0 Berechnungen\u00a0finden\u00a0explizit\u00a0Erw \u00e4hnung\u00a0bei\u00a0\nden\u00a0jeweiligen\u00a0Wirkstoffportr\u00e4ts.\u00a0Bezog\u00a0sich\u00a0die\u00a0Wirkstoffmenge \u00a0auf\u00a0das\u00a0K\u00f6rper\u2010\ngewicht\u00a0(KG)\u00a0oder\u00a0die\u00a0K\u00f6rperoberfl\u00e4che,\u00a0wurden\u00a0als\u00a0Standard\u00a072\u00a0 kg\u00a0K\u00f6rpergewicht\u00a0\nbzw.\u00a01,73\u00a0m2\u00a0als\u00a0durchschnittliche\u00a0K\u00f6rperoberfl\u00e4che\u00a0(KOF)\u00a0angenommen.\u00a0F\u00fcr\u00a0d as\u00a0\nOrphan\u00a0Arzneimittel\u00a0Elosulfase\u00a0alfa\u00a0wurde\u00a0\u2013\u00a0analog\u00a0zum\u00a0Vorgehen\u00a0des\u00a0G \u2010BA\u00a0\u2013\u00a0eine\u00a0\nKostenberechnung\u00a0erstellt,\u00a0der\u00a0das\u00a0K\u00f6rpergewicht\u00a0von\u00a024,8\u00a0kg\u00a0f\u00fc r\u00a0Kinder\u00a0zugrunde\u00a0\nliegt.\u00a0Sind\u00a0die\u00a0neuen\u00a0Wirkstoffe \u00a0als\u00a0Tabletten,\u00a0Filmtabletten\u00a0o der\u00a0(Hart\u2010)Kapseln\u00a0\nzugelassen,\u00a0so\u00a0wurde\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Therapiedauer\u00a0ben\u00f6tigte\u00a0St\u00fcckz ahl\u00a0in\u00a0die\u00a0Berech\u2010\nnungen\u00a0einbezogen,\u00a0gleiches\u00a0gilt\u00a0f\u00fcr\u00a0Ampullen\u00a0bzw.\u00a0Fertigspritz en\u00a0mit\u00a0Injektionsl\u00f6\u2010\nsungen.\u00a0\u00a0\nIm\u00a0Hinblick\u00a0auf\u00a0die\u00a0Vergleichstherapie\u00a0orientierten\u00a0wir\u00a0uns\u00a0an\u00a0 den\u00a0Arzneimitteln,\u00a0\ndie\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0als\u00a0zweckm\u00e4\u00dfig e\u00a0Vergleichstherapeutika\u00a0festg elegt\u00a0worden\u00a0\nwaren,\u00a0sofern\u00a0diese\u00a0zum\u00a0Zeitpunkt\u00a0unserer\u00a0Bewertung\u00a0noch\u00a0als\u00a0so lche\u00a0einzustufen\u00a0\nwaren;\u00a0gegebenenfalls\u00a0fanden\u00a0Anpassungen\u00a0statt.\u00a0Hilfsmittel\u00a0f\u00fcr \u00a0Injektionen\u00a0oder\u00a0\nsonstige\u00a0Kosten\u00a0im\u00a0Zusammenhang \u00a0mit\u00a0der\u00a0Arzneimittelanwendung\u00a0f anden\u00a0keine\u00a0\nBer\u00fccksichtigung.\u00a036\u00a02.3 Methodik\u00a0der\u00a0Routinedaten\u2010Analyse\u00a0\nF\u00fcr\u00a0die\u00a0Analyse\u00a0zur\u00a0Versorgung\u00a0mit\u00a0innovativen\u00a0Arzneimitteln\u00a0wu rden\u00a0Arzneimit\u2010\nteldaten\u00a0aus\u00a0der\u00a0ambulanten\u00a0Versorgung\u00a0von\u00a08,9\u00a0Mio.\u00a0Versicherte n\u00a0(im\u00a0Jahr\u00a02014)\u00a0\nund\u00a09,3\u00a0Mio.\u00a0Versicherten\u00a0(im\u00a0Jahr\u00a02015)\u00a0der\u00a0TK\u00a0aus\u00a0den\u00a0o.g.\u00a0Ja hren\u00a0genutzt.\u00a0Die\u00a0\nzur\u00a0Erstellung\u00a0des\u00a0Reports\u00a0ben\u00f6t igten\u00a0Daten\u00a0wurden\u00a0bereits\u00a0im\u00a0H aus\u00a0der\u00a0TK\u00a0selek\u2010\ntiert\u00a0und\u00a0anonymisiert\u00a0an\u00a0die\u00a0Universit\u00e4t\u00a0Bremen\u00a0weitergeleitet .\u00a0Die\u00a0Anonymisie\u2010\nrung\u00a0s\u00e4mtlicher\u00a0Daten\u00a0erfolgte\u00a0unter\u00a0Verwendung\u00a0einer\u00a0Fallnumme r,\u00a0die\u00a0es\u00a0er\u2010\nm\u00f6glichte,\u00a0anonymisierte\u00a0Datens\u00e4 tze\u00a0miteinander\u00a0zu\u00a0verkn\u00fcpfen,\u00a0 ohne\u00a0dass\u00a0die\u00a0\nIdentit\u00e4t\u00a0der\u00a0Versicherten\u00a0festgestellt\u00a0werden\u00a0kann.\u00a0Es\u00a0wurden\u00a0 f\u00fcr\u00a0die\u00a0allgemeinen\u00a0\nAuswertungen\u00a0nur\u00a0Daten\u00a0ber\u00fccksichtigt,\u00a0bei\u00a0denen\u00a0auch\u00a0Angaben\u00a0z u\u00a0Alter\u00a0und\u00a0\nGeschlecht\u00a0 der\u00a0 Versicherten\u00a0 vorl agen.\u00a0 Nach\u00a0 unserer\u00a0 Methodik\u00a0 ent sprach\u00a0 eine\u00a0\n\u00e4rztliche\u00a0 Verordnung\u00a0 analog\u00a0 zum\u00a0 Arzneiverordnungs\u2010Report\u00a0 2011\u00a0 g enau\u00a0 einer\u00a0\nArzneimittelpackung,\u00a0d.h.\u00a0zwei\u00a0au f\u00a0einem\u00a0Rezeptblatt\u00a0verordnete \u00a0Packungen\u00a0z\u00e4hl\u2010\nten\u00a0 als\u00a0 zwei\u00a0 Verordnungen.\u00a0 Bei\u00a0 den\u00a0 Verordnungsanalysen\u00a0 wurden\u00a0 n eben\u00a0 Fer\u2010\ntigarzneimitteln\u00a0auch\u00a0Rezepturen \u00a0mit\u00a0den\u00a0neuen\u00a0Wirkstoffen\u00a0ber\u00fc cksichtigt.\u00a0Hier\u00a0\nflossen\u00a0die\u00a0Abrechnungsdaten\u00a0ein,\u00a0die\u00a0auf\u00a0dem\u00a0Rezept\u00a0vermerkt\u00a0w aren\u00a0(Brutto\u2010\nApothekenabgabepreis).\u00a0\nBei\u00a0der\u00a0Untersuchung\u00a0der\u00a0Arzneimittelverordnungsdaten\u00a0wurde\u00a0die \u00a0von\u00a0der\u00a0WHO\u00a0\nseit\u00a0dem\u00a0Jahr\u00a01981\u00a0empfohlene\u00a0ATC\u2010Codierung\u00a0genutzt\u00a0(Tabelle\u00a02. 1).\u00a0Es\u00a0handelt\u00a0\nsich\u00a0hierbei\u00a0um\u00a0ein\u00a0Klassifikationssystem\u00a0( Anatomical\u00a0Therapeutic\u00a0Chemical ),\u00a0bei\u00a0\ndem\u00a0die\u00a0jeweiligen\u00a0Wirkstoffe\u00a0entsprechend\u00a0dem\u00a0Organ\u00a0oder\u00a0Organ system,\u00a0auf\u00a0\ndas\u00a0sie\u00a0einwirken,\u00a0sowie\u00a0nach\u00a0ihren\u00a0chemischen,\u00a0pharmakologisch en\u00a0und\u00a0thera\u2010\npeutischen\u00a0 Eigenschaften\u00a0 in\u00a0 verschiedene\u00a0 Gruppen\u00a0 aufgeteilt\u00a0 wer den\u00a0 (WHO,\u00a0\n2004).\u00a0Das\u00a0wissenschaftliche\u00a0Institut\u00a0der\u00a0Ortskrankenkassen\u00a0(WI dO)\u00a0f\u00fchrt\u00a0eine\u00a0\nATC\u2010Datenbank,\u00a0die\u00a0den\u00a0deutschen\u00a0 Verh\u00e4ltnissen\u00a0nach\u00a0WHO\u2010Richtli nien\u00a0angepasst\u00a0\nwurde.\u00a0Die\u00a0Arzneimittel\u00a0werden\u00a0n ach\u00a0dem\u00a0ATC\u2010System\u00a0in\u00a014\u00a0Hauptg ruppen\u00a0(Ebene\u00a0\n1)\u00a0gegliedert,\u00a0mit\u00a0zwei\u00a0therapeutisch\u2010pharmakologischen\u00a0Untergr uppen\u00a0(Ebene\u00a02\u00a0\nund\u00a03).\u00a0Eine\u00a0anatomisch\u2010therapeutisch\u2010chemische\u00a0Untergruppe\u00a0bil det\u00a0die\u00a04.\u00a0Ebene,\u00a0\nw\u00e4hrend\u00a0die\u00a05.\u00a0Ebene\u00a0den\u00a0che mischen\u00a0Wirkstoff\u00a0benennt.\u00a0\nSeit\u00a0dem\u00a0Inkrafttreten\u00a0des\u00a0GKV\u2010Modernisierungsgesetzes\u00a0(GMG)\u00a0am \u00a01.1.2004\u00a0sind\u00a0\ndie\u00a0Kassen\u00e4rztlichen\u00a0Vereinigun gen\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a0295\u00a0SGB\u00a0V\u00a0zur\u00a0Weiter gabe\u00a0ambulan\u2010\nter\u00a0Daten\u00a0an\u00a0die\u00a0GKV\u00a0verpflichte t.\u00a0So\u00a0muss\u00a0f\u00fcr\u00a0jeden\u00a0Patienten\u00a0 der\u00a0Behandlungsan\u2010\nlass,\u00a0 das\u00a0 Datum\u00a0 der\u00a0 Leistungserbringung\u00a0 und\u00a0 die\u00a0 Art\u00a0 der\u00a0 Leistun gserbringung\u00a0\ngenannt\u00a0werden,\u00a0wenn\u00a0die\u00a0Leistungen\u00a0abgerechnet\u00a0werden\u00a0sollen.\u00a0 Die\u00a0von\u00a0der\u00a0\nWHO\u00a0entwickelte\u00a0internationale\u00a0Klassifikation\u00a0der\u00a0Krankheiten\u00a0 International\u00a0Clas\u2010\nsification\u00a0of\u00a0Diseases \u00a0and\u00a0Related\u00a0Health\u00a0Problems \u00a0(ICD)\u00a0stellt\u00a0die\u00a0Grundlage\u00a0der\u00a0\ngesetzlich\u00a0vorgeschriebenen\u00a0Diagnoseverschl\u00fcsselung\u00a0im\u00a0ambulant en\u00a0und\u00a0statio\u2010\nn\u00e4ren\u00a0Sektor\u00a0dar.\u00a0In\u00a0Deutschland\u00a0wird\u00a0die\u00a0Diagnose\u00a0als\u00a0Behandlu ngsanlass\u00a0nach\u00a037\u00a0der\u00a0internationalen\u00a0Klassifikati on\u00a0von\u00a0Krankheiten\u00a0in\u00a0der\u00a0deuts chen\u00a0Fassung\u00a0(ICD\u2010\nGM;\u00a0German\u00a0Modification )\u00a0verschl\u00fcsselt\u00a0und\u00a0\u00fcbermittelt.\u00a0Eine\u00a0Hierarchisierung\u00a0\nnach\u00a0Haupt\u2010\u00a0und\u00a0Nebendiagnosen\u00a0je \u00a0Behandlungsfall\u00a0ist\u00a0derzeit\u00a0n icht\u00a0m\u00f6glich,\u00a0\nweswegen\u00a0ein\u00a0einzelner\u00a0Arztbesuch,\u00a0eine\u00a0Arzneimittelverordnung\u00a0 bzw.\u00a0eine\u00a0the\u2010\nrapeutische\u00a0Ma\u00dfnahme\u00a0nicht\u00a0eindeutig\u00a0einer\u00a0Diagnose\u00a0zugeordnet\u00a0 werden\u00a0kann.\u00a0\nWerden\u00a0Diagnosen\u00a0in\u00a0mehreren\u00a0Quartalen\u00a0bzw.\u00a0von\u00a0unterschiedlich en\u00a0\u00c4rzten\u00a0wie\u2010\nderholt,\u00a0kann\u00a0dies\u00a0als\u00a0Ma\u00dfnahme\u00a0betrachtet\u00a0werden,\u00a0m\u00f6glichst\u00a0nu r\u00a0tats\u00e4chlich\u00a0Er\u2010\nkrankte\u00a0auszuw\u00e4hlen\u00a0(Windt,\u00a02010).\u00a0\u00a0\nZur\u00a0 Messung\u00a0 der\u00a0 Verordnungsvolumina\u00a0 wurden\u00a0 definierte\u00a0 Tagesdose n\u00a0 (DDD)\u00a0\nverwendet.\u00a0Es\u00a0handelt\u00a0sich\u00a0dabei\u00a0 um\u00a0eine\u00a0rein\u00a0rechnerische,\u00a0int ernational\u00a0ge\u2010\nbr\u00e4uchliche\u00a0Messgr\u00f6\u00dfe,\u00a0die\u00a0nicht\u00a0 notwendigerweise\u00a0die\u00a0empfohlen e\u00a0Dosierung\u00a0\noder\u00a0 die\u00a0 tats\u00e4chlich\u00a0 angewendeten\u00a0 Dosierungen\u00a0 (PDD,\u00a0 Prescribed\u00a0 Daily\u00a0 Dose )\u00a0\neines\u00a0Arzneimittels\u00a0wiedergibt\u00a0( Pfannkuche\u00a0et\u00a0al.,\u00a02009).\u00a0F\u00fcr\u00a0j eden\u00a0Wirkstoff\u00a0legt\u00a0\ndie\u00a0WHO\u00a0eine\u00a0Dosierung\u00a0fest,\u00a0die\u00a0f\u00fcr\u00a0dessen\u00a0Hauptindikation\u00a0der \u00a0mittleren\u00a0t\u00e4gli\u2010\nchen\u00a0Erhaltungsdosis\u00a0f\u00fcr\u00a0Erwachsene\u00a0entspricht\u00a0(Fricke\u00a0&\u00a0G\u00fcnthe r,\u00a02001).\u00a0Eine\u00a0\n\u00dcbersetzung\u00a0und\u00a0Anpassung\u00a0an\u00a0den\u00a0deutschen\u00a0Markt\u00a0wird\u00a0j\u00e4hrlich\u00a0 vom\u00a0WIdO\u00a0\nerstellt\u00a0und\u00a0wurde\u00a02004\u00a0vom\u00a0dama ligen\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Ges undheit\u00a0und\u00a0\nSoziale\u00a0Sicherung\u00a0als\u00a0amtlich\u00a0erkl\u00e4rt\u00a0(Fricke\u00a0&\u00a0Zawinell,\u00a02009) .\u00a0Diese\u00a0j\u00e4hrlich\u00a0aktua\u2010\nlisierte\u00a0Liste\u00a0ist\u00a0im\u00a0Internet\u00a0verf\u00fcgbar\u00a0unter:\u00a0http://www.dimd i.de/static/de/klassi/\u00a0\natcddd/.\u00a0In\u00a0diesem\u00a0Report\u00a0wurden\u00a0je\u00a0nach\u00a0Untersuchungsjahr\u00a0jewe ils\u00a0die\u00a0zuletzt\u00a0\nge\u00e4nderten\u00a0Fassungen\u00a0der\u00a0ent sprechenden\u00a0Jahre\u00a0genutzt.\u00a0\nZus\u00e4tzliche\u00a0\u00dcberwachung\u00a0 \u25bc\u00a0\nSeit\u00a0dem\u00a0Jahr\u00a02013\u00a0wird\u00a0in\u00a0der\u00a0EU\u00a0ein\u00a0Arzneimittel,\u00a0das\u00a0unter\u00a0z us\u00e4tzlicher\u00a0\u00dcberwa\u2010\nchung\u00a0steht,\u00a0durch\u00a0ein\u00a0auf\u00a0dem\u00a0Kopf\u00a0stehendes\u00a0schwarzes\u00a0Dreieck \u00a0markiert.\u00a0Die\u00a0\nMarkierung\u00a0befindet\u00a0sich\u00a0nicht\u00a0auf\u00a0der\u00a0Arzneimittelverpackung,\u00a0 sondern\u00a0in\u00a0der\u00a0\nPackungsbeilage\u00a0und\u00a0in\u00a0der\u00a0Fachinformation.\u00a0Dies\u00a0soll\u00a0f\u00fcr\u00a0erh\u00f6h te\u00a0Aufmerksamkeit\u00a0\nbei\u00a0Patienten\u00a0und\u00a0Angeh\u00f6rigen\u00a0von\u00a0Gesundheitsberufen\u00a0sorgen,\u00a0je der\u00a0Verdachts\u2010\nfall\u00a0einer\u00a0Nebenwirkung\u00a0soll\u00a0geme ldet\u00a0werden,\u00a0vor\u00a0allen\u00a0Dingen\u00a0 durch\u00a0die\u00a0Berufs\u2010\ngruppen,\u00a0die\u00a0dazu\u00a0laut\u00a0Ihrer\u00a0Berufsordnung\u00a0verpflichtet\u00a0sind.\u00a0D as\u00a0schwarze\u00a0Dreieck\u00a0\nwird\u00a0z.B.\u00a0vergeben,\u00a0weil\u00a0das\u00a0Arzneimittel\u00a0neu\u00a0auf\u00a0dem\u00a0Markt\u00a0ode r\u00a0in\u00a0der\u00a0Langzeit\u2010\nanwendung\u00a0ungepr\u00fcft\u00a0ist\u00a0und\u00a0erm\u00f6glicht\u00a0eine\u00a0schnelle\u00a0Identifizi erung\u00a0neuer\u00a0Er\u2010\nkenntnisse\u00a0\u00fcber\u00a0seine\u00a0Sicherheit.\u00a0\nBis\u00a0auf\u00a0Alipogentiparvovec ,\u00a0Dexlansoprazol,\u00a0Dimethylf umarat\u00a0und\u00a0Sucroferric\u00a0Oxy\u2010\nhydroxid\u00a0finden\u00a0sich\u00a0alle\u00a0der\u00a0von\u00a0uns\u00a0bewerteten\u00a0neuen\u00a0Wirkstof fe\u00a0des\u00a0Jahres\u00a0\n2014\u00a0unter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung\u00a0(Tabelle\u00a02.1).\u00a0\n\u00a0\u00a038\u00a0Blaue\u00a0Hand\u00a0\u00a0\u00a0\u00a0\nDieses\u00a0beh\u00f6rdlich\u00a0angeordnete\u00a0und\u00a0(nach\u00a0der\u00a0Erstellung\u00a0durch\u00a0de n\u00a0pU)\u00a0freigege\u2010\nbene\u00a0Schulungsmaterial\u00a0( educational \u00a0material)\u00a0wird\u00a0seit\u00a0Dezember\u00a02016\u00a0analog\u00a0\nder\u00a0Roten\u2010Hand\u2010Briefe\u00a0nunmehr\u00a0mit\u00a0dem\u00a0Symbol\u00a0der\u00a0Blauen\u00a0Hand\u00a0ge kennzeich\u2010\nnet,\u00a0um\u00a0eine\u00a0Wiedererkennung\u00a0und\u00a0 den\u00a0Verbreitungsgrad\u00a0der\u00a0Infor mationen\u00a0zu\u00a0\nerh\u00f6hen.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Wirkstoffe\u00a0Chols\u00e4ure,\u00a0De lamanid,\u00a0Elosulfase\u00a0alfa\u00a0und\u00a0Ma citentan\u00a0wurde\u00a0\ndieses\u00a0Schulungsmaterial\u00a0herausgegeben.\u00a0\nTabelle\u00a0 2.1:\u00a0 Im\u00a0 Report\u00a0 bewertete\u00a0 neue\u00a0 Wirkstoffe\u00a0 des\u00a0 Jahres\u00a0 201 4\u00a0 und\u00a0 die\u00a0\u00a0\nentsprechenden\u00a0ATC\u2010Codes\u00a0\nWirkstoff\u00a0 Besonderheiten \u00a0 ATC\u2010Code\u00a0\nAlbiglutid\u00a0 \u25bc\u00a0\u00a0AA10BJ04\nalt:\u00a0A10BX13\u00a0\nAlipogentiparvovec\u00a0 \u00a0O,\u00a0E\u00a0 Verkehrsf\u00e4higke it\u00a0endet\u00a0Okt.\u00a02017 \u00a0C10AX10\u00a0\nBedaquilin\u00a0 \u25bcO,\u00a0C\u00a0G\u2010BA\u00a0Verfahren\u00a0eingestellt,\u00a0\nWarnhinweis\u00a0der\u00a0EMAJ04AK05\u00a0\nCabozantinib\u00a0 \u25bcO,\u00a0C\u00a0 neues\u00a0Anwendungsgebiet\u00a0 L01XE26\u00a0\nChols\u00e4ure\u00a0 \u25bcO,\u00a0E\u00a0Blaue\u00a0Hand \u00a0 A05AA03\u00a0\nCobicistat\u00a0 \u25bc\u00a0\u00a0 V03AX03\u00a0\nDaclatasvir\u00a0 \u25bc\u00a0Rote\u2010Hand\u2010Brief\u00a0(RHB) \u00a0 J05AX14\u00a0\nDelamanid\u00a0 \u25bcO,\u00a0C\u00a0 Blaue\u00a0Hand \u00a0 J04AK06\u00a0\nDexlansoprazol\u00a0 \u00a0\u00a0\u00a0 A02BC06\u00a0\nDimethylfumarat\u00a0 \u00a0\u00a0 2\u00a0RHB,\u00a04\u00a0G\u2010BA\u2010Beschl\u00fcsse \u00a0 N07XX09\u00a0\nDolutegravir\u00a0 \u25bc\u00a0Zulassungserweiterung\u00a0Kinder,\u00a0\n5\u00a0G\u2010BA\u2010Beschl\u00fcsseJ05AX12\u00a0und\u00a0\nJ05AR13\u00a0\nElosulfase\u00a0alfa\u00a0 \u25bcO\u00a0 Blaue\u00a0Hand \u00a0 A16AB12\u00a0\nEmpagliflozin\u00a0 \u25bc\u00a02\u00a0Risikobewertungsverfahren\u00a0+\u00a0\nInfobriefe\u00a0(EMA,\u00a0BfArM)\u00a0\u00a0\nf\u00fcr\u00a0SGLT2\u2010GruppeA10BK03\u00a0\nalt:\u00a0A10BX12\u00a0\nIbrutinib\u00a0 \u25bcO\u00a0neue\u00a0Anwendungsgebiete,\u00a0\n5\u00a0G\u2010BA\u2010Beschl\u00fcsseL01XE27\u00a0\nIdelalisib\u00a0 \u25bc\u00a02\u00a0RHB,\u00a02\u00a0G\u2010BA\u2010Beschl\u00fcsse \u00a0 L01XX47\u00a0\n39\u00a0Wirkstoff\u00a0 Besonderheiten \u00a0 ATC\u2010Code\u00a0\nLedipasvir\u00a0+\u00a0\nSofosbuvir\u00a0\u25bc\u00a0R H B \u00a0 J05AX65\u00a0\nMacitentan\u00a0 \u25bcO\u00a0Blaue\u00a0Hand \u00a0 C02KX04\u00a0\nNalmefen\u00a0 \u25bc\u00a0\u00a0 N07BB05\u00a0\nObinutuzumab\u00a0 \u25bcO\u00a0neues\u00a0Anwendungsgebiet\u00a0 L01XC15\u00a0\nOlodaterol\u00a0 \u25bc\u00a0\u00a0 R03AC19\u00a0\nRiociguat\u00a0 \u25bcO\u00a0RHB\u00a0 C02KX05\u00a0\nSiltuximab\u00a0 \u25bcO\u00a0\u00a0 L04AC11\u00a0\nSimeprevir\u00a0 \u25bc\u00a0\u00a0 J05AE14\u00a0\nSimoctocog\u00a0alfa\u00a0 \u25bc\u00a0\u00a0 B02BD17\u00a0\nSofosbuvir\u00a0 \u25bc\u00a0R H B \u00a0 J05AX15\u00a0\u00a0\nSucroferric\u00a0Oxyhy\u2010\ndroxid\u00a0(Eisen\u00a0III)\u00a0\u00a0\u00a0\u00a0 V03AE05\u00a0\nTeduglutid\u00a0 \u25bcO\u00a0Register\u00a0EUPAS7973,\u00a0\nZulassungserweiterung\u00a0Kinder,\u00a0\u00a02\u00a0G\u2010BA\u2010Beschl\u00fcsseA16AX08\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0\u25bc\u00a0\u00a0 L01XC14\u00a0\nTuroctocog\u00a0alfa\u00a0 \u25bc\u00a0\u00a0 B02BD16\u00a0\nUmeclidinium\u00a0+\u00a0\nVilanterol\u00a0\u25bc\u00a0\u00a0 R03AL03\u00a0\nVedolizumab\u00a0 \u25bc\u00a0\u00a0 L04AA33\u00a0\nVilanterol\u00a0+\u00a0\nFluticasonfuroat\u00a0\u25bc\u00a0\u00a0 R03AK10\u00a0\nO:\u00a0Orphan\u2010Arzneimittel,\u00a0C:\u00a0 Conditional\u00a0approval :\u00a0Bedingte\u00a0Zulassung,\u00a0E :\u00a0Exceptional\u00a0approval :\u00a0Zulassung\u00a0unter\u00a0au\u00dfergew\u00f6hnlichen\u00a0\nUmst\u00e4nden\u00a0\n\u00a0 \u00a040\u00a0Quellen\u00a0\nBundesministerium\u00a0der\u00a0Justiz\u00a0und\u00a0f\u00fcr\u00a0Verbraucherschutz\u00a0(2012).\u00a0 Verordnung\u00a0\u00fcber\u00a0die\u00a0Anwendung\u00a0der\u00a0Guten\u00a0Klinischen\u00a0Praxis\u00a0bei\u00a0\nder\u00a0Durchf\u00fchrung\u00a0von\u00a0klinischen\u00a0Pr\u00fcfungen\u00a0mit\u00a0Arzneimitteln\u00a0zur \u00a0Anwendung\u00a0am\u00a0Menschen\u00a0(GCP266\u00a0Verordnung\u00a0\u2013\u00a0\nGCP\u2010V).\u00a0GCP\u2010Verordnung\u00a0vom\u00a09.\u00a0August\u00a02004\u00a0(BGBl.\u00a0I\u00a0S.\u00a02081),\u00a0di e\u00a0zuletzt\u00a0durch\u00a0Artikel\u00a08\u00a0des\u00a0Gesetzes\u00a0vom\u00a019.\u00a0\nOktober\u00a02012\u00a0(BGBl.\u00a0I \u00a0S.\u00a02192)\u00a0ge\u00e4ndert\u00a0wo rden\u00a0ist.\u00a0www.gesetze \u2010im\u2010internet.de/gcpv/BJNR208100004.html,\u00a0\nletzter\u00a0Zugriff:\u00a018.01.2016.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Find\u00a0Medicine:\u00a0nach\u00a0den \u00a0jeweiligen\u00a0Wirkstoffen.\u00a0www.ema.eu\u00a0\nFricke\u00a0U,\u00a0G\u00fcnther\u00a0J\u00a0(2001).\u00a0Meth odik\u00a0der\u00a0ATC\u2010Klassifikation\u00a0und \u00a0DDD\u2010Festlegung\u00a0f\u00fcr\u00a0den\u00a0deutschen\u00a0Arzneimittelmarkt.\u00a0Bonn:\u00a0\nWIdO.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nFricke\u00a0U,\u00a0Zawinell\u00a0A\u00a0(2009).\u00a0Anato misch\u2010therapeutisch\u2010chemische \u00a0Klassifikation\u00a0mit\u00a0Tagesdosen\u00a0f\u00fcr\u00a0den\u00a0deutschen\u00a0\nArzneimittelmarkt\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a073\u00a0Abs.\u00a08\u00a0Satz\u00a05\u00a0SGB\u00a0V.\u00a0Beschlussfass ung\u00a0der\u00a0Arbeitsgruppe\u00a0ATC/\u00a0DDD\u00a0des\u00a0Kuratoriums\u00a0\nf\u00fcr\u00a0Fragen\u00a0der\u00a0Klassifikation\u00a0im\u00a0Gesundheitswesen.\u00a0Stand\u00a0der\u00a0In formation:\u00a0November\u00a02009.\u00a0\nPfannkuche\u00a0M,\u00a0Glaeske\u00a0G,\u00a0Neye\u00a0H,\u00a0Sch\u00f6ffski\u00a0O,\u00a0Hoffmann\u00a0F\u00a0(2009) .\u00a0Kostenvergleiche\u00a0f\u00fcr\u00a0Arzneimittel\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0DDD\u00a0im\u00a0\nRahmen\u00a0der\u00a0Vertrags\u00e4rztlichen\u00a0Versorgung.\u00a0Gesundh\u00a0\u00f6kon\u00a0Qual\u00a0man ag\u00a014\u00a0(1):\u00a017\u201023.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2004).\u00a0Guidelines\u00a0for\u00a0ATC\u00a0clas sification\u00a0and\u00a0DDD\u00a0assignment\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0\nCollaborating\u00a0Centre\u00a0for\u00a0Drug\u00a0Statistics\u00a0Methodology.\u00a0New\u00a0York: \u00a0WHO.\u00a0\nWindt\u00a0R\u00a0(2010).\u00a0Analyse\u00a0der\u00a0medikament\u00f6sen\u00a0Versorgung\u00a0von\u00a0Asthm apatienten\u00a0im\u00a0Erwachsenenalter\u00a0mit\u00a0Routinedaten.\u00a0\nDissertation.\u00a0Saarbr\u00fccken:\u00a0S\u00fcdwestdeutscher\u00a0Verlag\u00a0f\u00fcr\u00a0Hochschu lschriften.\u00a0\n\u00a0\u00a041\u00a03 Neue\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0\u2013\u00a0\u00dcbersicht\u00a0\nIm\u00a0Jahr\u00a02014\u00a0wurden\u00a0in\u00a0Deutschland\u00a046\u00a0Arzneimittel\u00a0mit\u00a0neuen\u00a0Wi rkstoffen\u00a0in\u00a0den\u00a0\nMarkt\u00a0eingef\u00fchrt.\u00a0Im\u00a0Vergleich\u00a0zum\u00a0Vorjahr,\u00a0in\u00a0dem\u00a027\u00a0neue\u00a0Wirk stoffe\u00a0auf\u00a0den\u00a0\nMarkt\u00a0kamen,\u00a0entspricht\u00a0dies\u00a0einer\u00a0Steigerung\u00a0um\u00a070\u00a0%\u00a0(Abb.\u00a03.1 ).\u00a014\u00a0der\u00a0neuen\u00a0\nArzneimittel\u00a0wurden\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0zugelassen.\u00a0\nAbbildung\u00a03.1:\u00a0Markteinf\u00fchrung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirk stoffen\u00a0\neingeteilt\u00a0in\u00a0innovative\u00a0und\u00a0verbesserte\u00a0Wirkstoffe\u00a0im\u00a0Zeitraum \u00a01995\u20102014\u00a0\n\u00a0\nEigene\u00a0Darstellung\u00a0nach\u00a0Schwabe\u00a0&\u00a0Paffrath,\u00a02015\u00a0\nBasierend\u00a0auf\u00a0der\u00a0Klassifikation\u00a0nach\u00a0Fricke\u00a0&\u00a0Klaus\u00a0zur\u00a0Bewert ung\u00a0des\u00a0Innovati\u2010\nonsgrades\u00a0vergaben\u00a0die\u00a0Autoren\u00a0des\u00a0Arzneiverordnungs\u2010Reports\u00a0(F ricke\u00a0&\u00a0Schwa\u2010\nbe,\u00a02015)\u00a0insgesamt\u00a0zwanzigmal\u00a0ei n\u00a0\u201eA\u201c\u00a0f\u00fcr\u00a0innovative\u00a0Substanze n\u00a0(Abb.\u00a03.1).\u00a0\nDarunter\u00a0wurden\u00a014\u00a0Wirkstoffe\u00a0und\u00a0damit\u00a0fast\u00a0dreimal\u00a0so\u00a0viele\u00a0w ie\u00a0im\u00a0Vorjahr\u00a0\n(f\u00fcnfmal\u00a0 \u201eA\u201c,\u00a0 ohne\u00a0 Doppelbewertung)\u00a0 als\u00a0 innovative\u00a0 Struktur\u00a0 bzw .\u00a0 neuartiges\u00a0\nWirkprinzip\u00a0mit\u00a0therapeutischer\u00a0Relevanz\u00a0bewertet\u00a0(A):\u00a0Ataluren \u00a0zur\u00a0Behandlung\u00a0\nder\u00a0 Duchenne\u2010Muskeldystrophie,\u00a0 B edaquilin\u00a0 zur\u00a0 Therapie\u00a0 der\u00a0 mult iresistenten\u00a0\npulmonalen\u00a0Tuberkulose,\u00a0Daclatasvir\u00a0bei\u00a0chronischen\u00a0Infektionen \u00a0mit\u00a0dem\u00a0Hepati\u2010\ntis\u2010C\u2010Virus,\u00a0 Defibrotid\u00a0 zur\u00a0 Therapie\u00a0 der\u00a0 schweren\u00a0 hepatischen\u00a0 v enooklusiven\u00a0\nKrankheit\u00a0 bei\u00a0 h\u00e4matopoetischer\u00a0 Stammzelltransplantation,\u00a0 Elosul fase\u00a0 alfa\u00a0 zur\u00a0\nBehandlung\u00a0der\u00a0Mucopolysacharidos e\u00a0Typ\u00a0IVA\u00a0(auch\u00a0Morquio\u00a0A\u2010Synd rom),\u00a0Ibruti\u2010\nnib\u00a0beim\u00a0rezidivierten\u00a0oder\u00a0refr akt\u00e4ren\u00a0Mantelzell\u2010Lymphom\u00a0und\u00a0 bei\u00a0der\u00a0chro\u2010\nnisch\u00a0lymphatischen\u00a0Leuk\u00e4mie,\u00a0Id elalisib\u00a0zur\u00a0Therapie\u00a0der\u00a0chron ischen\u00a0lymphati\u2010\n42\u00a0schen\u00a0Leuk\u00e4mie\u00a0in\u00a0Kombination\u00a0mit\u00a0Rituximab\u00a0und\u00a0als\u00a0Monotherapi e\u00a0beim\u00a0folliku\u2010\nl\u00e4ren\u00a0Lymphom,\u00a0Ledipasvir\u00a0und\u00a0So fosbuvir\u00a0zur\u00a0Behandlung\u00a0der\u00a0chr onischen\u00a0Hepa\u2010\ntitis\u00a0C,\u00a0der\u00a0pr\u00e4pandemische\u00a0Influenzaimpfstoff\u00a0zur\u00a0aktiven\u00a0Immu nisierung\u00a0gegen\u00a0\nden\u00a0 H5N1\u2010Subtyp\u00a0 des\u00a0 Influenza\u2010A\u2010Virus,\u00a0 Riociguat\u00a0 zur\u00a0 Therapie\u00a0 d er\u00a0 chronisch\u00a0\nthromboembolischen\u00a0pulmonalen\u00a0Hypertonie\u00a0und\u00a0pulmonal\u00a0arteriell en\u00a0Hyperto\u2010\nn i e , \u00a0S i l t u x i m a b \u00a0b e i \u00a0d e r \u00a0C a s t l e m a n \u2010Krankheit,\u00a0 Sipuleucel\u2010T\u00a0 zur\u00a0 B ehandlung\u00a0 des\u00a0\nasymptomatischen\u00a0 oder\u00a0 minimal\u00a0 sy mptomatischen,\u00a0 metastasierenden \u00a0 kastrati\u2010\nonsresistenten\u00a0 Prostatakarzinoms , \u00a0S o f o s b u v i r \u00a0b e i \u00a0c h r o n i s c h e r \u00a0H e patitis\u00a0 C\u00a0 und\u00a0\nTeduglutid\u00a0zur\u00a0Behandlung\u00a0des\u00a0Ku rzdarmsyndroms\u00a0bei\u00a0Erwachsenen. \u00a0Drei\u00a0neue\u00a0\nWirkstoffe\u00a0zeigten\u00a0dabei\u00a0jedoch\u00a0keine\u00a0\u00dcberlegenheit\u00a0gegen\u00fcber\u00a0b ekannten\u00a0thera\u2010\npeutischen\u00a0Alternativen\u00a0(A/C):\u00a0Levosimendan\u00a0bei\u00a0akut\u00a0dekompensi erter\u00a0schwerer\u00a0\nchronischer\u00a0 Herzinsuffizienz,\u00a0 Mirabegron\u00a0 zur\u00a0 Behandlung\u00a0 von\u00a0 Har ndrang\u00a0 und\u00a0\nDranginkontinenz\u00a0bei\u00a0einer\u00a0\u00fcbera ktiven\u00a0Blase\u00a0und\u00a0Vedolizumab\u00a0zu r\u00a0Therapie\u00a0der\u00a0\nmittelschweren\u00a0bis\u00a0schweren\u00a0Col itis\u00a0ulcerosa\u00a0und\u00a0mittelschwerem \u00a0bis\u00a0schwerem\u00a0\nMorbus\u00a0Crohn.\u00a0Einen\u00a0unklaren\u00a0therapeutischen\u00a0Stellenwert\u00a0(A/D)\u00a0 wiesen\u00a0demnach\u00a0\nChols\u00e4ure\u00a0zur\u00a0Behandlung\u00a0angeborener\u00a0St\u00f6rungen\u00a0der\u00a0prim\u00e4ren\u00a0Gal lens\u00e4uresyn\u2010\nthese\u00a0und\u00a0Alipogentiparvovec\u00a0zur\u00a0Behandlung\u00a0der\u00a0famili\u00e4ren\u00a0Lipo proteinlipasede\u2010\nfizienz\u00a0bei\u00a0Erwachsenen\u00a0auf\u00a0(F ricke\u00a0&\u00a0Schwabe,\u00a02014,\u00a02015).\u00a0\nDie\u00a0weiteren\u00a0Bewertungen\u00a0nach\u00a0de m\u00a0Schema\u00a0von\u00a0Fricke/Klaus\u00a0finde n\u00a0sich\u00a0im\u00a0\nEinzelnen\u00a0f\u00fcr\u00a0die\u00a0im\u00a0Innovationsr eport\u00a02017\u00a0beha ndelten\u00a0Wirksto ffe\u00a0in\u00a0Tabelle\u00a03.1,\u00a0\nebenso\u00a0wie\u00a0die\u00a0Bewertungen\u00a0anderer\u00a0Standardwerke.\u00a0\n\u00a0\u00a043\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Erkl\u00e4rung\u00a0zu\u00a0Tabelle\u00a03.1\u00a0auf\u00a0den\u00a0folgenden\u00a0Seiten\u00a0NBW=Nutzenbewertung,\u00a0a\u2010t=arznei\u2010telegramm,\u00a0atd=Arzneimitteldate nbank,\u00a0AMB=Der\u00a0Arzneimittelbrief,\u00a0PZ=Pharmazeutische\u00a0\nZeitung,\u00a0O\u00a0=\u00a0Orphan\u2010Arzneimittel,\u00a0Abk\u00fcrzungen\u00a0bei\u00a0AMNOG\u2010NBW:\u00a0B= Beleg\u00a0f\u00fcr\u00a0Zusatznutzen\u00a0mit\u00a0dem\u00a0Ausma\u00df\u00a0\u2026,\u00a0H=Hinweis\u00a0auf\u00a0\nZusatznutzen\u00a0mit\u00a0dem\u00a0Ausma\u00df\u00a0\u2026,\u00a0A=Anhaltspunkt\u00a0f\u00fcr\u00a0Zusatznutzen\u00a0 mit\u00a0dem\u00a0Ausma\u00df\u00a0\u2026\u00a0,\u00a0(beispielsweise\u00a01/11)\u00a0=\u00a0(Anzahl\u00a0Subgrup\u2010\npen\u00a0mit\u00a0entsprechender\u00a0Bewertung\u00a0im\u00a0Verh\u00e4ltnis\u00a0zur\u00a0gesamten\u00a0Anz ahl\u00a0der\u00a0bewerteten\u00a0Subgruppen)\u00a0\u00a0\nCA=Carcinom,\u00a0cHCV=chronische\u00a0Hepatitis\u00a0C\u00a0Virus\u2010Infektion,\u00a0CLL=c hronisch\u2010lymphatische\u00a0Leuk\u00e4mie,\u00a0COPD=chronisch\u2010obstruktive\u00a0\nLungenerkrankung,\u00a0CTEPH=chronisch\u00a0thrombo\u2010embolische\u00a0pulmonale\u00a0 Hypertonie,\u00a0CU=Colitis\u00a0ulc erosa,\u00a0ERD=Erosive\u00a0Reflux\u00a0\nDisease,\u00a0FB=Festbetragsgruppe, \u00a0FL=follikul\u00e4res\u00a0Lymphom,\u00a0GERD=Ga stroesophageal\u00a0Reflux\u00a0Disease,\u00a0HER2+=human\u00a0epidermal\u00a0\ngrowth\u00a0factor\u00a0receptor\u00a02\u00a0positiv,\u00a0MC=Morbus\u00a0Crohn,\u00a0MCL=Mantelze ll\u2010Lymphom,\u00a0met=metastasiert,\u00a0MS=Multiple\u00a0Sklerose,\u00a0\nMW=Morbus\u00a0Waldenstr\u00f6m,\u00a0PAH=pulmonal\u2010arterielle\u00a0Hypertonie,\u00a0WHO\u2010 FC=WHO\u2010Funktionsklasse,\u00a0ZN=\u00a0Zusatznutzen\u00a0\u00a0\n1)\u00a0F\u00fcr\u00a0die\u00a0Kombination\u00a0mit\u00a0Metformin\u00a0bei\u00a0einer\u00a0Subgruppe\u00a02)\u00a0Medull\u00e4res\u00a0Schilddr\u00fcsenkarzinom\u00a03)\u00a0GT\u00a0=\u00a0Genotyp\u00a04)\u00a0Therapienaiv\u00a05)\u00a0Therapierfahren\u00a06)\u00a0Chronische\u00a0Lymphatische\u00a0Leuk\u00e4mie\u00a07)\u00a0Mantelzell\u2010Lymphom\u00a08)\u00a0Morbus\u00a0Waldenstr\u00f6m\u00a09)\u00a0Mit\u00a0rezidivierender\u00a0oder\u00a0refrakt\u00e4rer\u00a0CLL\u00a0\n10)\u00a0Chemotherapie\u00a0indiziert\u00a0\n11)\u00a0Chemotherapie\u00a0nicht\u00a0indiziert\u00a0(mit\u00a0Beschluss\u00a0vom\u00a016.03.2017 \u00a0aufgehoben)\u00a0\n12)\u00a0Therapiefortsetzung\u00a013)\u00a0F\u00fcr\u00a0Chemoimmuntherapie\u00a0ungeeignet\u00a014)\u00a0Bisherige\u00a0 Non\u2010Responder\u00a0\n15)\u00a0Mit\u00a0HIV\u00a016)\u00a0Kinder\u00a0ab\u00a01\u00a0Jahr\u00a017)\u00a0Morquio\u00a0A\u2010Syndrom\u00a044\u00a0Tabelle\u00a03.1:\u00a0\u00dcbersicht\u00a0der\u00a0neuen\u00a0Wirkstoffe/Wirkstoffkombinatio nen\u00a0des\u00a0Jahres\u00a0\n2014\u00a0und\u00a0deren\u00a0Bewertungen\u00a0in\u00a0Standardwerken\u00a0\nWirkstoff\u00a0 Indikation\u00a0G\u2010BA\u00a0\nNutzenbewertung\u00a0Fricke\nKlaus\u00a0a\u2010t\u00a0\natd\u00a0AMB\u2010\nBewertung\u00a0PZ\u2010\nBewertung\u00a0\nAlbiglutid\u00a0Diabetes\u00a0mellitus\u00a0\nTyp\u00a02\u00a0geringer\u00a0ZNH1\u00a0in\u00a01/5\u00a0\nder\u00a0Subgruppen;\u00a0ZN\u00a0\nnicht\u00a0belegt\u00a0(4/5)\u00a0C\u00a0Umstrittenes\u00a0\nTherapieprinzipkeine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nAlipogenti\u2010\nparvovec\u00a0(O,\u00a0E)\u00a0Fam.\u00a0Lipoprotein\u2010\nlipasedefizienz\u00a0bei\u00a0\nErw.\u00a0ZN\u00a0nicht\u00a0\nquantifizierbar\u00a0(1/1)\u00a0A/D\u00a0keine\u00a0 keine\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nBedaquilin\u00a0\u00a0\n(O,\u00a0C)\u00a0MDR\u2010TB\u00a0 Verfahren\u00a0eingestellt\u00a0 A\u00a0 keine\u00a0weitere\u00a0Studien\u00a0\nnotwendig\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nCabozantinib\u00a0\n(O,\u00a0C)\u00a0Medull\u00e4res\u00a0\nSchilddr\u00fcsen\u2010CA\u00a0geringer\u00a0ZN2\u00a0(1/1)\u00a0 C\u00a0keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nChols\u00e4ure\u00a0\n(O,\u00a0E)\u00a0Angeb.\u00a0St\u00f6rung\u00a0d.\u00a0\nprim\u00e4ren\u00a0Gallen\u2010\ns\u00e4uresynthese\u00a0ZN\u00a0nicht\u00a0\nquantifizierbar\u00a0(1/1)\u00a0A/D\u00a0 keine\u00a0 keine\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nCobicistat\u00a0Booster\u00a0von\u00a0\nAtazanavir\u00a0od.\u00a0\nDarunavir\u00a0bei\u00a0HIV\u2010\nKombith.\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(1/1)\u00a0 C\u00a0keine\u00a0 keine\u00a0 keine\u00a0\nDaclatasvir\u00a0 HCV\u00a0betr\u00e4chtlicher\u00a0ZNA\u00a0\n(1/7);\u00a0\ngeringer\u00a0ZNA\u00a0(1/7);\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(5/7).\u00a0A\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0Kombi\u00a0mit\u00a0\nAsunaprevir\u00a0\nund\u00a0Standard\u2010\ntherapie\u00a0erh\u00f6ht\u00a0Wirkst\u00e4rke\u00a0und\u00a0\nverh.\u00a0Resist.\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nDelamanid\u00a0\u00a0\n(O,\u00a0E)\u00a0MDR\u2010TB\u00a0Kombith.\u00a0Verfahren\u00a0wegen\u00a0\nGeringf\u00fcgigkeit\u00a0\neingestellt\u00a0B\u00a0keine\u00a0erweitert\u00a0die\u00a0\nBehandlungs\u2010\nm\u00f6glichkeiten\u00a0\nder\u00a0MDR\u2010TB\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nDexlansoprazol\u00a0 ERD,\u00a0GERD\u00a0keiner\u00a0Bewertung\u00a0\nunterzogen;\u00a0FB\u00a0C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellenwertkeine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nDimethyl\u2010\nfumarat\u00a0Schubf\u00f6rmige\u00a0\nremittierende\u00a0MS\u00a0kein\u00a0ZN\u00a0belegt\u00a0(0/1)\u00a0 keine\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0bei\u00a0\nUnvertr\u00e4glich\u2010\nkeit\u00a0von\u00a0IFN\u2010\u03b2\u00a0\noder\u00a0Glatira\u2010\nmeracetat\u00a0keine\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nDolutegravir\u00a0 HIV\u2010Infektion\u00a0Erw.4:\u00a0betr\u00e4chtlicher\u00a0\nZNB4\u00a0(1/5);\u00a0\nErw.5\u00a0Integrase\u2010Inhib.\u00a0\nMdW.:\u00a0geringer\u00a0ZNH5\u00a0\n(1/5)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(2/5)\u00a0B\u00a0 keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nElosulfase\u00a0alfa\u00a0\n(O)\u00a0Mucopolysacha\u2010\nridase\u00a0Typ\u00a0IVA17\u00a0\u00a0geringer\u00a0ZN\u00a0(1/1)\u00a0 A\u00a0keine\u00a0 keine\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nEmpagliflozin\u00a0Diabetes\u00a0mellitus\u00a0\nTyp\u00a02\u00a0betr\u00e4chtlicher\u00a0ZNA\u00a0in\u00a0\nKombith.\u00a0nach\u00a02.\u00a0\nBewertung\u00a0(4/10);\u00a0\nGeringer\u00a0ZNA\u00a0(1/10);\u00a0\nsonstige\u00a0Subgruppen:\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(5/10)\u00a0C\u00a0Umstrittenes\u00a0\nTherapieprinzipKeine\u00a0Daten\u00a0z.\u00a0\nLangzeitsicherh.EMPA\u2010REG\u2010\nOutcome\u00a0\nDaten\u00a0\nzweifelhaft\u00a0\n\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a045\u00a0Wirkstoff\u00a0 Indikation\u00a0G\u2010BA\u00a0\nNutzenbewertung\u00a0Fricke\nKlaus\u00a0a\u2010t\u00a0\natd\u00a0AMB\u2010\nBewertung\u00a0PZ\u2010\nBewertung\u00a0\nIbrutinib\u00a0(O)\u00a0 MCL,\u00a0CLL;\u00a0MW\u00a0betr\u00e4chtlicher\u00a0ZNHA\u00a0\n(2/11);\u00a0nicht\u00a0quantifizb.\u00a0\nZNA\u00a0(2/11);\u00a0ZN\u00a0nicht\u00a0\nbelegt\u00a0(7/11)\u00a0A\u00a0keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nIdelalisib\u00a0CLL\u00a0in\u00a0Kombination\u00a0\nmit\u00a0Rituximab,\u00a0FL\u00a0\nMonotherapie\u00a0ZN\u00a0nicht\u00a0quantifizb.A,\u00a09,\u00a011\u00a0\n(1/6);\u00a0\u00a0\nZN\u00a0nicht\u00a0belegt9,\u00a010,\u00a012,\u00a013,\u00a014\n(5/6)\u00a0A\u00a0 keine\u00a0weitere\u00a0Daten\u00a0\nerforderlich\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nLedipasvir\u00a0+\u00a0\nSofosbuvir\u00a0cHCV\u00a0betr\u00e4chtlicher\u00a0ZNA\u00a0\n(3/7);\u00a0ZN\u00a0nicht\u00a0\nquantifizierbarA\u00a0(2/7);\u00a0\ngeringer\u00a0ZNA\u00a0(1/7);\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(1/7)\u00a0A\u00a0Mittel\u00a0der\u00a0\nWahl\u00a0einfache,\u00a0wirk\u2010\nsame\u00a0u.\u00a0offens.\u00a0\ngut\u00a0vertr\u00e4gliche\u00a0\nTherapie,\u00a0\nextrem\u00a0teuer\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nMacitentan\u00a0(O)\u00a0 PAH,\u00a0WHO\u2010FC\u00a0II\u2010III ZN\u00a0nicht\u00a0belegt\u00a0(0/1)\u00a0 C\u00a0 keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nNalmefen\u00a0Red.\u00a0des\u00a0Alkohol\u2010\nkonsums\u00a0bei\u00a0Erw.\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(0/1)\u00a0 C\u00a0Umstrittenes\u00a0\nTherapieprinzipkeine\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nObinutuzumab\u00a0\n(O)\u00a0CLL\u00a0in\u00a0Kombi.\u00a0mit\u00a0\nChlorambucil;\u00a0FL\u00a0ZN\u00a0nicht\u00a0\nquantifizierbar\u00a0(2/2)\u00a0C\u00a0 keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nOlodaterol\u00a0 COPD\u00a0ZN\u00a0nicht\u00a0belegt,\u00a0daher\u00a0\nFB\u00a0C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellenw.\u00a0keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nRiociguat\u00a0(O)\u00a0CTEPH,\u00a0PAH\u00a0\n(WHO\u2010FC:\u00a0II\u2010III)\u00a0geringer\u00a0ZN\u00a0(2/2)\u00a0 A\u00a0 keine\u00a0schwach\u00a0stat.\u00a0\nsignifikant\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nSiltuximab\u00a0(O)\u00a0Castleman\u2010\nKrankheit\u00a0ZN\u00a0nicht\u00a0\nquantifizierbar\u00a0(1/1)\u00a0A\u00a0keine\u00a0 keine\u00a0 keine\u00a0\nSimeprevir\u00a0cHCV\u00a0\u00a0\n(GT\u00a01\u00a0bzw.\u00a04)\u00a0betr\u00e4chtlicher\u00a0ZNH\u00a0\n(3/7);\u00a0geringer\u00a0ZNA\u00a0\n(2/7);\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(2/7)\u00a0B\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nSimoctocog\u00a0\nalfa\u00a0H\u00e4mophilie\u00a0A\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(0/1)\u00a0C\u00a0keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nSofosbuvir\u00a0 cHCV\u00a0(GT1\u20106)\u00a0betr\u00e4chtlicher\u00a0ZNH\u00a0\n(1/9);\u00a0geringer\u00a0ZNA\u00a0\n(5/9);\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(3/9)\u00a0A\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0K\u00fcrzere\u00a0\nTherapiedauer\u00a0\nm\u00f6glich\u00a0Schritt\u2010\u00a0\ninnovation\u00a0\nSucroferric\u00a0\nOxyhydroxid\u00a0Phosphatbinder\u00a0in\u00a0\nder\u00a0Dialyse\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(0/2)\u00a0 C\u00a0keine\u00a0 Keine\u00a0 keine\u00a0\nTeduglutid\u00a0(O)\u00a0 Kurzdarmsyndrom\u00a0Erw.:\u00a0geringer\u00a0ZN\u00a0\n(1/2),\u00a0Kdr.:\u00a0ZN\u00a0nicht\u00a0quantifizierbar\n16(1/2)\u00a0A\u00a0Umstrittenes\u00a0\nTherapieprinzipkeine\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0HER2\u2010(+),\u00a0\ninoperabler\u00a0lokal\u00a0\nfortgeschr.\u00a0o.\u00a0met.\u00a0\nMamma\u2010CA\u00a0betr\u00e4chtlicher\u00a0ZNH\u00a0\n(1/3);\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(2/3)\u00a0B\u00a0keine\u00a0Daten\u00a0vielver\u2010\nsprechend,\u00a0\nweitere\u00a0\nStudien\u00a0notw.\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nTuroctocog\u00a0alfa\u00a0 H\u00e4mophilie\u00a0A\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0(0/1)\u00a0 C\u00a0 keine\u00a0 keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nUmeclidinium\u00a0\u00a0\n+\u00a0Vilanterol\u00a0COPD\u00a0 kein\u00a0ZN\u00a0 C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0\nStellenwert\u00a0keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a0\nVedolizumab\u00a0Mittel\u2010\u00a0bis\u00a0schwer\u00a0\naktive\u00a0CU\u00a0bzw.\u00a0MCZN\u00a0nicht\u00a0belegt\u00a0(0/4)\u00a0 A/C\u00a0 keine\u00a0 keine\u00a0Sprung\u2010\u00a0\ninnovation\u00a0\nVilanterol\u00a0+\u00a0\nFluticason\u2010\nfuroat\u00a0Asthma\u00a0\nbronchiale,\u00a0COPD\u00a0keine\u00a0Bewertung\u00a0 C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0\nStellenwert\u00a0keine\u00a0Analog\u2010\u00a0\npr\u00e4parat\u00a046\u00a0Basierend\u00a0auf\u00a0der\u00a0Klassifikation\u00a0nach\u00a0Fricke\u00a0&\u00a0Klaus\u00a0zur\u00a0Bewert ung\u00a0des\u00a0Innovati\u2010\nonsgrades\u00a0vergaben\u00a0die\u00a0Autoren\u00a0des\u00a0Arzneiverordnungs\u2010Reports\u00a0(F ricke\u00a0&\u00a0Schwa\u2010\nbe,\u00a02015)\u00a0f\u00fcr\u00a0die\u00a0Arzneimittel\u00a0in\u00a0diesem\u00a0Report\u00a0des\u00a0Zulassungsj ahrs\u00a02014\u00a0zehnmal\u00a0\nein\u00a0einfaches\u00a0\u201eA\u201c\u00a0f\u00fcr\u00a0innovative\u00a0Substanzen:\u00a0Bedaquilin\u00a0zur\u00a0Anw endung\u00a0bei\u00a0multi\u2010\nresistenter\u00a0pulmonaler\u00a0Tuberkulose\u00a0(MDR\u2010TB),\u00a0Daclatasvir\u00a0zur\u00a0Th erapie\u00a0von\u00a0chro\u2010\nnischer\u00a0Infektion\u00a0mit\u00a0dem\u00a0Hepati tis\u2010\u00a0C\u2010Virus\u00a0(HCV),\u00a0Elosulfase\u00a0 alfa\u00a0bei\u00a0Mucopoly\u2010\nsacharidose\u00a0Typ\u00a0IVA\u00a0(Morquio\u00a0A\u2010Syndrom),\u00a0Ibrutinib\u00a0zur\u00a0Therapie \u00a0des\u00a0rezidivierten\u00a0\noder\u00a0refrakt\u00e4ren\u00a0Mantelzell\u2010Lymphom\u00a0und\u00a0der\u00a0chronischen\u00a0lymphat ischen\u00a0Leu\u2010\nk\u00e4mie\u00a0(CLL),\u00a0Idelalisib\u00a0zur\u00a0Anwendung\u00a0bei\u00a0CLL\u00a0in\u00a0Kombination\u00a0mi t\u00a0Rituximab\u00a0und\u00a0\nbei\u00a0follikul\u00e4rem\u00a0Lymphom\u00a0als\u00a0Monotherapie,\u00a0Ledipasvir\u00a0+\u00a0Sofosbu vir\u00a0bei\u00a0chroni\u2010\nscher\u00a0Hepatitis\u00a0C,\u00a0Riociguat\u00a0zur\u00a0Therapie\u00a0einer\u00a0chronischen\u00a0thr omboembolischen\u00a0\npulmonalen\u00a0Hypertonie\u00a0sowie\u00a0pulmo naler\u00a0arterieller\u00a0Hypertonie,\u00a0 Siltuximab\u00a0bei\u00a0\nder\u00a0Castleman\u2010Krankheit,\u00a0Sofos buvir\u00a0zur\u00a0Anwendung\u00a0bei\u00a0chronisch er\u00a0Hepatitis\u00a0C\u00a0\nund\u00a0Teduglutid\u00a0bei\u00a0Kurzdarmsyndrom\u00a0Erwachsener.\u00a0Nach\u00a0dieser\u00a0Kla ssifizierung\u00a0\nwurde\u00a0im\u00a0Vergleich\u00a0zum\u00a0Jahr\u00a02013\u00a0(zehnmal\u00a0\u201eA\u201c)\u00a0ein\u00a0gleich\u00a0hoher \u00a0Innovationsgrad\u00a0\nerreicht.\u00a0W\u00e4hrend\u00a0es\u00a0sich\u00a0bei\u00a0de r\u00a0Einstufung\u00a0\u201eA\u201c\u00a0des\u00a0Innovation sgrades\u00a0im\u00a0Vorjahr\u00a0\nviermal\u00a0um\u00a0eine\u00a0Doppelbewertung\u00a0wie\u00a0A/C\u00a0(\u201eInnovative\u00a0Struktur\u00a0b zw.\u00a0neuartiges\u00a0\nWirkprinzip\u00a0mit\u00a0therapeutischer\u00a0Relevanz/Analogpr\u00e4parat\u00a0mit\u00a0kei nen\u00a0oder\u00a0nur\u00a0mar\u2010\nginalen\u00a0Unterschieden\u00a0zu\u00a0bereits\u00a0eingef\u00fchrten\u00a0Pr\u00e4paraten\u201c)\u00a0oder \u00a0A/D\u00a0(Innovative\u00a0\nStruktur\u00a0 bzw.\u00a0 neuartiges\u00a0 Wirkprinzip\u00a0 mit\u00a0 therapeutischer\u00a0 Releva nz/Nicht\u00a0 ausrei\u2010\nchend\u00a0gesichertes\u00a0Wirkprinzip\u00a0oder\u00a0unklarer\u00a0therapeutischer\u00a0Ste llenwert\u201c)\u00a0handelte,\u00a0\nwurden\u00a0f\u00fcr\u00a0Wirkstoffe\u00a0des\u00a0Innovationsreportes\u00a02017\u00a0drei\u00a0Wirksto ffe\u00a0doppelt\u00a0bewer\u2010\ntet\u00a0(Vedolizumab\u00a0bei\u00a0Colitis\u00a0ulcerosa\u00a0bzw.\u00a0Morbus\u00a0Crohn\u00a0mit\u00a0A/C \u00a0und\u00a0Alipogentipar\u2010\nv o v e c \u00a0z ur \u00a0B e h an dl ung \u00a0v o n \u00a0f am i l i \u00e4r e r \u00a0L i po p ro t ei nl i pa s e d ef i z i e nz \u00a0 bei\u00a0Erwachsenen\u00a0\nund\u00a0Chols\u00e4ure\u00a0bei\u00a0angeborenen\u00a0St\u00f6rungen\u00a0der\u00a0prim\u00e4ren\u00a0Gallens\u00e4ur esynthese\u00a0je\u2010\nweils\u00a0mit\u00a0A/D).\u00a0Vier\u00a0Wirkstoffe\u00a0wiesen\u00a0nach\u00a0Auffassung\u00a0der\u00a0Auto ren\u00a0gegen\u00fcber\u00a0\nbereits\u00a0 verf\u00fcgbaren\u00a0 Arzneistoffe n\u00a0 mit\u00a0 gleicher\u00a0 Indikation\u00a0 pharm akodynamische\u00a0\nund/oder\u00a0pharmakokinetische\u00a0Verbesserungen\u00a0auf\u00a0(Kategorie\u00a0\u201eB\u201c). \u00a0Als\u00a0Analogpr\u00e4pa\u2010\nrate\u00a0(Kategorie\u00a0\u201eC\u201c)\u00a0wurden\u00a0vierzehn\u00a0Wirkstoffe\u00a0eingestuft\u00a0(Tab elle\u00a03.1).\u00a0\nDie\u00a0Pharmazeutische\u00a0Zeitung\u00a0(PZ)\u00a0kam\u00a0in\u00a0ihrer\u00a0Bewertung\u00a0der\u00a0in\u00a0 diesem\u00a0Report\u00a0zu\u00a0\nuntersuchenden\u00a032\u00a0Wirkstoffe\u00a0bzw.\u00a0Wirkstoffkombinationen\u00a0zu\u00a0and eren\u00a0Ergebnis\u2010\nsen.\u00a0Sieben\u00a0der\u00a0Substanzen\u00a0wurde n\u00a0von\u00a0den\u00a0PZ\u2010Autoren\u00a0vorl\u00e4ufig\u00a0 als\u00a0Sprunginno\u2010\nvation\u00a0 (Alipogentiparvovec,\u00a0 Bedaquilin,\u00a0 Chols\u00e4ure,\u00a0 Elosulfase\u00a0 a lfa,\u00a0 Teduglutid,\u00a0\nTrastuzumab\u00a0Emtansin,\u00a0Vedolizumab)\u00a0und\u00a0knapp\u00a0die\u00a0H\u00e4lfte\u00a0(14)\u00a0de r\u00a0Wirkstoffe\u00a0\nbzw.\u00a0Wirkstoffkombinationen\u00a0als\u00a0A nalogpr\u00e4parate\u00a0(Albiglutid,\u00a0Ca bozantinib,\u00a0Dex\u2010\nlansoprazol,\u00a0 Dolutegravir,\u00a0 Empag liflozin,\u00a0 Ibrutinib,\u00a0 Macitentan ,\u00a0 Obinutuzumab,\u00a0\nOlodaterol\u00a0Simeprevir,\u00a0Simoctocog\u00a0alfa,\u00a0Turoctocog\u00a0alfa,\u00a0Umecli dinium\u00a0+\u00a0Vilan\u2010\nterol,\u00a0Vilanterol\u00a0+\u00a0Fluticasonfuroat)\u00a0bewertet.\u00a0Acht\u00a0Substanzen \u00a0erhielten\u00a0den\u00a0Sta\u2010\ntus\u00a0 als\u00a0 Schrittinnovation\u00a0 (Daclat asvir,\u00a0 Delamanid,\u00a0 Dimethylfuma rat,\u00a0 Idelalisib,\u00a0\nLedipasvir\u00a0+\u00a0Sofosbuvir,\u00a0Nalmefen,\u00a0Riociguat,\u00a0Sofosbuvir).\u00a047\u00a0Anders\u00a0f\u00e4llt\u00a0das\u00a0Ergebnis\u00a0einer\u00a0 ausschlie\u00dflich\u00a0auf\u00a0der\u00a0Nutzen\u2010S chaden\u2010Relation\u00a0und\u00a0\ndem\u00a0daraus\u00a0folgenden\u00a0therapeutisc hen\u00a0Stellenwert\u00a0basierenden\u00a0Be wertung\u00a0des\u00a0\narznei\u2010telegramms\u00a0(a\u2010t)\u00a0bzw.\u00a0der\u00a0Arzneimitteldatenbank\u00a0(aus\u00a0der \u00a0gleichen\u00a0Quelle)\u00a0\naus:\u00a0Hier\u00a0wurde\u00a0bei\u00a0den\u00a0dreizehn\u00a0bewerteten\u00a0Arzneimitteln\u00a0des\u00a0J ahres\u00a02014\u00a0nur\u00a0\nLedipasvir\u00a0+\u00a0Sofosbuvir\u00a0als\u00a0\u201eMi ttel\u00a0der\u00a0Wahl\u201c\u00a0bezeichnet.\u00a0Dacla tasvir,\u00a0Dimethyl\u2010\nfumarat\u00a0(bei\u00a0Unvertr\u00e4glichkeit\u00a0vo n\u00a0IFN\u03b2\u00a0oder\u00a0Glatirameracetat), \u00a0Simeprevir,\u00a0So\u2010\nfosbuvir\u00a0werden\u00a0nach\u00a0Auffassung\u00a0der\u00a0Autoren\u00a0als\u00a0\u201eMittel\u00a0der\u00a0Res erve\u201c\u00a0bezeichnet.\u00a0\nDexlansoprazol,\u00a0Olodaterol,\u00a0Umeclidinium\u00a0+\u00a0Vilanterol\u00a0sowie\u00a0Vil anterol\u00a0+\u00a0Fluti\u2010\ncasonfuroat\u00a0werden\u00a0hingegen\u00a0als\u00a0\u201eVariante\u00a0ohne\u00a0besonderen\u00a0Stell enwert\u201c\u00a0bewer\u2010\ntet.\u00a0 Albiglutid,\u00a0 Empagliflozin,\u00a0 Idelalisib,\u00a0 Nalmefen\u00a0 und\u00a0 Tedugl utid\u00a0 fielen\u00a0 in\u00a0 die\u00a0\nKategorie\u00a0 \u201eumstrittenes\u00a0 Therapieprinzip\u201c.\u00a0 Als\u00a0 \u201ezweifelhaftes\u00a0 Th erapieprinzip\u201c\u00a0\nwurde\u00a0kein\u00a0Wirkstoff\u00a0betrachtet.\u00a0\nDer\u00a0 Arzneimittelbrief\u00a0 (AMB)\u00a0 bewertete\u00a0 sieben\u00a0 Wirkstoffe,\u00a0 jedoch \u00a0 werden\u00a0 hier\u00a0\nkeine\u00a0Kategorien\u00a0gebildet,\u00a0sta ttdessen\u00a0wurden\u00a0individuelle\u00a0Bewe rtungen\u00a0abgege\u2010\nben\u00a0(vgl.\u00a0Tabelle\u00a03.1\u00a0und\u00a0einz elne\u00a0Wirkstoffbewertungen).\u00a0\u00a0\nDie\u00a0Bewertung\u00a0des\u00a0Zusatznutzens\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0nach\u00a0der\u00a0Arzneim ittel\u2010Nutzen\u2010\nbewertungsverordnung\u00a0 (AM\u2010NutzenV)\u00a0 des\u00a0 Bundesministeriums\u00a0 f\u00fcr\u00a0 Ge sundheit\u00a0\nergab,\u00a0dass\u00a0Empagliflozin\u00a0nach\u00a0einer\u00a0erneuten\u00a0Bewertung\u00a0ein\u00a0erh eblicher\u00a0Zusatz\u2010\nnutzen\u00a0zukommt.\u00a0Je\u00a0nach\u00a0Genotyp,\u00a0Morbidit\u00e4t\u00a0sowie\u00a0Therapiestatu s\u00a0wurden\u00a0die\u00a0\nHepatitis\u00a0C\u2010Mittel\u00a0Daclatasvir,\u00a0Simeprevir\u00a0und\u00a0Sofosbuvir\u00a0sowie \u00a0die\u00a0Kombination\u00a0\nvon\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0f\u00fcr\u00a0 Subgruppen\u00a0teilweise\u00a0mit\u00a0einem\u00a0 geringen\u00a0bis\u00a0zu\u00a0\neinem\u00a0betr\u00e4chtlichem\u00a0Zusatznutzen \u00a0bewertet,\u00a0desgleichen\u00a0das\u00a0HIV \u2010Mittel\u00a0Dolut\u2010\negravir\u00a0(vgl.\u00a0ebenfalls\u00a0Tabelle\u00a03 .1).\u00a0Bei\u00a0Trastuzumab\u00a0Emtansin\u00a0 in\u00a0einer\u00a0Subgruppe\u00a0\nwurde\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen\u00a0festges tellt.\u00a0Vier\u00a0Wirk\u2010\nstoffe\u00a0(Cabozantinib\u00a0und\u00a0Elosul fase\u00a0alfa,\u00a0f\u00fcr\u00a0Subgruppen\u00a0Caboza ntinib\u00a0und\u00a0Rioci\u2010\nguat),\u00a0hatten\u00a0 einen\u00a0geringen\u00a0Zusatznutzen.\u00a0Zehn\u00a0Wirkstoffe\u00a0(Cob icistat\u00a0(\u201enicht\u00a0\nbelegt\u201c),\u00a0 Dimethylfumarat,\u00a0 Macitentan,\u00a0 Nalmefen,\u00a0 Olodaterol,\u00a0 Si moctococ\u00a0 alfa,\u00a0\nSucroferric\u00a0Oxyhydroxi d\u00a0(Eisen\u00a0III),\u00a0Turoctococ\u00a0alfa,\u00a0Umeclidin ium\u00a0\u00a0+\u00a0Vilanterol,\u00a0Ve\u2010\ndolizumab)\u00a0hatten\u00a0keinen\u00a0Zusatznutzen.\u00a0Dazu\u00a0geh\u00f6rte\u00a0je\u00a0nach\u00a0Mor bidit\u00e4t\u00a0und\u00a0The\u2010\nrapiestatus\u00a0auch\u00a0Daclatasvir.\u00a0Bei\u00a0sechs\u00a0Wirkstoffen\u00a0(Alipogenti parvovec,\u00a0Chols\u00e4ure,\u00a0\nIbrutinib,\u00a0 Obinutuzumab,\u00a0 Siltuximab,\u00a0 Teduglutid)\u00a0 konnte\u00a0 der\u00a0 Zus atznutzen\u00a0 nicht\u00a0\nquantifiziert\u00a0werden.\u00a0Je\u00a0nach\u00a0Morbidit\u00e4t\u00a0und\u00a0Therapiestatus\u00a0bet rifft\u00a0dies\u00a0Idelalisib\u00a0\nund\u00a0je\u00a0nach\u00a0Genotyp\u00a0auch\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir.\u00a0Wegen\u00a0Geringf \u00fcgigkeit\u00a0wurde\u00a0\nDelamanid\u00a0auf\u00a0Antrag\u00a0des\u00a0pU\u00a0von\u00a0der\u00a0Nutzenbewertung\u00a0freigestell t.\u00a0Bei\u00a0Bedaquilin\u00a0\nwurde\u00a0das\u00a0Verfahren\u00a0eingestellt,\u00a0da\u00a0nur\u00a0eine\u00a0Klinikpackung\u00a0mit\u00a0 188\u00a0Tabletten,\u00a0die\u00a0\nnicht\u00a0ambulant\u00a0zu\u00a0Lasten\u00a0der\u00a0GKV\u00a0abgerechnet\u00a0werden\u00a0kann,\u00a0in\u00a0de n\u00a0Handel\u00a0ge\u2010\nbracht\u00a0wurde.\u00a0Dexlansoprazol\u00a0wurde\u00a0keiner\u00a0Bewertung\u00a0unterzogen\u00a0 und\u00a0gleich\u00a0in\u00a0die\u00a0\nFestbetragsgruppe\u00a0der\u00a0Protonenpumpeninhibitioren\u00a0eingruppiert,\u00a0 was\u00a0zu\u00a0erhebli\u2010\nchen\u00a0Mehrkosten\u00a0f\u00fcr\u00a0gesetzlich\u00a0Krankenversicherte\u00a0f\u00fchrte.\u00a048\u00a0Tabelle\u00a03.2:\u00a0Top\u2010Liste\u00a0der\u00a0neuen \u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0\u2013 \u00a0nach\u00a0Brutto\u2010\nUmsatz\u00a0im\u00a0Jahr\u00a02015\u00a0(TK\u00a0und\u00a0GKV)\u00a0\nRang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt\u00a0\nUmsatz\u00a0\n2015\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Umsatz\u2010\n\u00e4nd.\u00a0\nzum\nVorjahr\u00a0Verordnete\nPackg.\u00a02015\n[in\u00a0Tsd.]Umsatz\u00a02015\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a02015\u00a0\n[in\u00a0Tsd.]\u00a0\n\u00a0\u00a0\u00a01\u00a0Ledipasvir\u00a0+\u00a0Sofos\u2010\nbuvir\u00a0\n(Harvoni\u00ae)\u00a089.281,4\u00a0 +>999%\u00a0 4,1\u00a0 785.659,0\u00a0 36,0\u00a0\n\u00a0\u00a0\u00a02\u00a0Dimethylfumarat\u00a0\n(Tecfidera\u00ae)\u00a055.518,1\u00a0 +8%\u00a0 23,6\u00a0 293.746,2\u00a0 130,4\u00a0\n\u00a0\u00a0\u00a03\u00a0Sofosbuvir\u00a0\n(Sovaldi\u00ae)\u00a024.921,7\u00a0 +47%\u00a0 1,4\u00a0 277.280,9\u00a0 15,1\u00a0\n\u00a0\u00a0\u00a04\u00a0Ibrutinib\u00a0\n(Imbruvica\u00ae)\u00a013.364,7\u00a0 +>999%\u00a0 1,4\u00a0 95.926,4\u00a0 10,4\u00a0\n\u00a0\u00a0\u00a05\u00a0Vedolizumab\u00a0\n(Entyvio\u00ae)\u00a012.520,0\u00a0 +233%\u00a0 3,5\u00a0 51.090,8\u00a0 14,5\u00a0\n\u00a0\u00a0\u00a06\u00a0Daclatasvir\u00a0\n(Daklinza\u00ae)\u00a08.930,2\u00a0 +13%\u00a0 0,7\u00a0 93.559,8\u00a0 7,3\u00a0\n\u00a0\u00a0\u00a07\u00a0Trastuzumab\u00a0Em\u2010\ntansin\u00a0\n(Kadcyla\u00ae)\u00a07.650,5\u00a0 +1%\u00a0 3,1\u00a0 1.111,3\u00a0 0,5\u00a0\n\u00a0\u00a0\u00a08\u00a0Dolutegravir1\u00a0\n(Tivicay\u00ae)\u00a06.831,3\u00a0 +17%\u00a0 4,4\u00a0 38.022,6\u00a0 25,0\u00a0\n\u00a0\u00a0\u00a09\u00a0Elosulfase\u00a0alfa\u00a0\n(Vimizim\u00ae)\u00a04.305,8\u00a0 +212%\u00a0 4,2\u00a0 8.793,7\u00a0 8,4\u00a0\n\u00a0\u00a010\u00a0Riociguat\u00a0\n(Adempas\u00ae)\u00a03.477,2\u00a0 +113%\u00a0 0,8\u00a0 36.989,8\u00a0 8,6\u00a0\n\u00a0\u00a011\u00a0Macitentan\u00a0\n(Opsumit\u00ae)\u00a03.323,7\u00a0 +65%\u00a0 1,2\u00a0 43.238,4\u00a0 15,0\u00a0\n\u00a0\u00a012\u00a0Vilanterol\u00a0(+\u00a0\nFluticasonfuroat)\u00a0\n(Relvar\u00ae\u00a0Ellipta\u00ae)\u00a02.791,4\u00a0 +113%\u00a0 29,2\u00a0 23.020,2\u00a0 244,8\u00a0\n\u00a0\u00a013\u00a0Idelalisib\u00a0\n(Zydelig\u00ae)\u00a01.943,0\u00a0 +>999%\u00a0 0,3\u00a0 21.383,5\u00a0 3,8\u00a0\n\u00a0\u00a014\u00a0Empagliflozin\u00a0\n(Jardiance\u00ae)\u00a01.274,8\u00a0 +>999%\u00a0 7,6\u00a0 14.466,7\u00a0 86,5\u00a0\n\u00a0\u00a015\u00a0Simoctocog\u00a0alfa\u00a0\n(Nuwiq\u00ae)\u00a01.029,0\u00a0 \u2010\u00a0 1,2\u00a0 *\u00a0 *\u00a0\n\u00a0\u00a016\u00a0Simeprevir\u00a0\n(Olysio\u00ae)\u00a0867,0\u00a0 +84%\u00a0 0,1\u00a0 8.691,1\u00a0 0,9\u00a0\n\u00a0\u00a017\u00a0Umeclidinium\u00a0\n(+\u00a0Vilanterol)\u00a0\n(Anoro\u00ae)\u00a0673,6\u00a0 +607%\u00a0 5,4\u00a0 9.306,1\u00a0 76,0\u00a0\n\u00a0\u00a018\u00a0Teduglutid\u00a0\n(Revestive\u00ae)\u00a0620,6\u00a0 +633%\u00a0 0,0\u00a0 9.254,6\u00a0 0,4\u00a0\n\u00a0\u00a019\u00a0Obinutuzumab\u00a0\n(Gazyvaro\u00ae)\u00a0594,2\u00a0 +209%\u00a0 0,1\u00a0 362,7\u00a0 0,1\u00a0\n\u00a0\u00a020\u00a0Turoctocog\u00a0alfa\u00a0\n(NovoEight\u00ae)\u00a0510,0\u00a0 +79%\u00a0 0,4\u00a0 *\u00a0 *\u00a0\n\u00a0\u00a021\u00a0Olodaterol\u00a0\n(Striverdi\u00ae)\u00a0344,2\u00a0 +235%\u00a0 3,9\u00a0 5.020,8\u00a0 59,7\u00a049\u00a0Rang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt\u00a0\nUmsatz\u00a0\n2015\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Umsatz\u2010\n\u00e4nd.\u00a0\nzum\nVorjahr\u00a0Verordnete\nPackg.\u00a02015\n[in\u00a0Tsd.]Umsatz\u00a02015\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a02015\u00a0\n[in\u00a0Tsd.]\u00a0\n\u00a0\u00a022\u00a0Cabozantinib\u00a0\n(Cometriq\u00ae)\u00a0306,9\u00a0 +473%\u00a0 0,0\u00a0 1.466,0\u00a0 0,2\u00a0\n\u00a0\u00a023\u00a0Siltuximab\u00a0\n(Sylvant\u00ae)\u00a0224,8\u00a0 +367%\u00a0 0,1 122,4\u00a0 0,1\u00a0\n\u00a0\u00a024\u00a0Nalmefen\u00a0\n(Selincro\u00ae)\u00a0161,9\u00a0 +174%\u00a0 1,0\u00a0 1.207,1\u00a0 7,7\u00a0\n\u00a0\u00a025\u00a0Sucroferric\u00a0\u00a0\nOxyhydroxid\u00a0\n(Velphoro\u00ae)\u00a0125,1\u00a0+>999%\u00a0 0,4 1.821,5\u00a0 6,2\u00a0\n\u00a0\u00a026\u00a0Bedaquilin\u00a0\n(Sirturo\u00ae)\u00a030,2\u00a0 \u2010\u00a0 0,0\u00a0 396,0\u00a0 0,0\u00a0\n\u00a0\u00a027\u00a0Cobicistat\u00a0\n(Tybost\u00ae)\u00a08,9\u00a0+342%\u00a0 0,1 65,9\u00a0 0,7\u00a0\n\u00a0\u00a028\u00a0Delamanid\u00a0\n(Deltyba\u00ae)\u00a08,2\u00a0 \u2010\u00a0 0,0 243,6\u00a0 0,1\u00a0\n\u00a0\u00a029\u00a0Chols\u00e4ure\u00a0\n(Orphacol\u00ae)\u00a02,7\u00a0 \u2010\u00a0 0,0 251,0\u00a0 0,0\u00a0\n\u00a0\u00a030\u00a0Albiglutid\u00a0\n(Eperzan\u00ae)\u00a02,5\u00a0 \u2010\u00a0 0,0 13,4\u00a0 0,1\u00a0\n1\u201030\u00a0Gesamt\u00a0 241.643,6\u00a0 +77%\u00a0 98,3 1.822.511,6\u00a0 758,9\u00a0\n1\u00a0nur\u00a0das\u00a0Monopr\u00e4parat\u00a0\n*GKV\u2010Zahlen\u00a0sind\u00a0nicht\u00a0abbildbar,\u00a0da\u00a0Verordnungen\u00a0nur\u00a0\u00fcber\u00a0Spez ialambulanzen\u00a0abgegeben\u00a0wurden\u00a0\n\u00a0\u00a050\u00a0Tabelle\u00a03.3:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0\u2013 \u00a0nach\u00a0Anzahl\u00a0\nverordneter\u00a0Packungen\u00a0im\u00a0Jahr\u00a02015\u00a0(TK\u00a0und\u00a0GKV)\u00a0\n\u00a0\u00a0\u00a0Rang\u00a0 Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt\u00a0\nVerordnete\u00a0\nPackg.\n2015\n[in\u00a0Tsd.]\u00a0Packg.\u00a0\u00a0\n\u00c4nderung\u00a0\nzum\u00a0Vorjahr\u00a0Umsatz\u00a02015\n[in\u00a0Tsd.\u00a0\u20ac]Absatz\u00a0\n2015\n[in\u00a0Tsd.]\u00a0Umsatz\u00a02015\u00a0\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0\n\u00a0\u00a0\u00a01\u00a0Vilanterol\u00a0\u00a0\n+\u00a0Fluticasonfuroat\u00a0\n(Relvar\u00ae\u00a0Ellipta\u00ae)\u00a029,2\u00a0 +109%\u00a0\u00a0 2.791,4\u00a0 244,8\u00a0 23.020,2\u00a0\n\u00a0\u00a0\u00a02\u00a0Dimethylfumarat\u00a0\n(Tecfidera\u00ae)\u00a023,6\u00a0 (+17%)\u00a0 55.518,1\u00a0 130,4\u00a0 293.746,2\u00a0\n\u00a0\u00a0\u00a03\u00a0Empagliflozin\u00a0\n(Jardiance\u00ae)\u00a07,6\u00a0 +953%\u00a0\u00a0 1.274,8\u00a0 86,5\u00a0 14.466,7\u00a0\n\u00a0\u00a0\u00a04\u00a0Umeclidinium\u00a0\u00a0+\u00a0\nVilanterol\u00a0\n(Anoro\u00ae)\u00a05,4\u00a0 +636%\u00a0\u00a0 673,6\u00a0 76,0\u00a0 9.306,1\u00a0\n\u00a0\u00a0\u00a05\u00a0Dolutegravir1\u00a0\n(Tivicay\u00ae)\u00a04,4\u00a0 +11%\u00a0\u00a0 6.831,3\u00a0 25,0\u00a0 38.022,6\u00a0\n\u00a0\u00a0\u00a06\u00a0Elosulfase\u00a0alfa\u00a0\n(Vimizim\u00ae)\u00a04,2\u00a0 +238%\u00a0\u00a0 4.305,8\u00a0 8,4\u00a0 8.793,7\u00a0\n\u00a0\u00a0\u00a07\u00a0Ledipasvir\u00a0+\u00a0\nSofosbuvir\u00a0\n(Harvoni\u00ae)\u00a04,1\u00a0 +>999%\u00a0\u00a0 89.281,4\u00a0 36,0\u00a0 785.659,0\u00a0\n\u00a0\u00a0\u00a08\u00a0Olodaterol\u00a0\n(Striverdi\u00ae)\u00a03,9\u00a0 +203%\u00a0\u00a0 344,2\u00a0 59,7\u00a0 5.020,8\u00a0\n\u00a0\u00a0\u00a09\u00a0Vedolizumab\u00a0\n(Entyvio\u00ae)\u00a03,5\u00a0 +301%\u00a0\u00a0 12.520,0\u00a0 14,5\u00a0 51.090,8\u00a0\n\u00a0\u00a010\u00a0Trastuzumab\u00a0\nEmtansin\u00a0\n(Kadcyla\u00ae)\u00a03,1\u00a0 +28%\u00a0\u00a0 7.650,5\u00a0 0,5\u00a0 1.111,3\u00a0\n\u00a0\u00a011\u00a0Ibrutinib\u00a0\n(Imbruvica\u00ae)\u00a01,4\u00a0 +>999%\u00a0\u00a0 13.364,7\u00a0 10,4\u00a0 95.926,4\u00a0\n\u00a0\u00a012\u00a0Sofosbuvir\u00a0\n(Sovaldi\u00ae)\u00a01,4\u00a0 (+42%)\u00a0 24.921,7\u00a0 15,1\u00a0 277.280,9\u00a0\n\u00a0\u00a013\u00a0Simoctocog\u00a0alfa\u00a0\n(Nuwiq\u00ae)\u00a01,2\u00a0 \u2010\u00a01.029,0\u00a0 *\u00a0 *\u00a0\n\u00a0\u00a014\u00a0Macitentan\u00a0\n(Opsumit\u00ae)\u00a01,2\u00a0 +117%\u00a0\u00a0 3.323,7\u00a0 15,0\u00a0 43.238,4\u00a0\n\u00a0\u00a015\u00a0Nalmefen\u00a0\n(Selincro\u00ae)\u00a01,0\u00a0 +159%\u00a0\u00a0 161,9\u00a0 7,7\u00a0 1.207,1\u00a0\n\u00a0\u00a016\u00a0Riociguat\u00a0\n(Adempas\u00ae)\u00a00,8\u00a0 +48%\u00a0\u00a0 3.477,2\u00a0 8,6\u00a0 36.989,8\u00a0\n\u00a0\u00a017\u00a0Daclatasvir\u00a0\n(Daklinza\u00ae)\u00a00,7\u00a0 +14%\u00a0\u00a0 8.930,2\u00a0 7,3\u00a0 93.559,8\u00a0\n\u00a0\u00a018\u00a0Sucroferric\u00a0\u00a0\nOxyhydroxid\u00a0\n(Velphoro\u00ae)\u00a00,4\u00a0 +>999%\u00a0\u00a0 125,1\u00a0 6,2\u00a0 1.821,5\u00a0\n\u00a0\u00a019\u00a0Turoctocog\u00a0alfa\u00a0\n(NovoEight\u00ae)\u00a00,4\u00a0 +80%\u00a0\u00a0 510,0\u00a0 *\u00a0 *\u00a0\n\u00a0\u00a020\u00a0Idelalisib\u00a0\n(Zydelig\u00ae)\u00a00,3\u00a0 +>999%\u00a0\u00a0 1.943,0\u00a0 3,8\u00a0 21.383,5\u00a051\u00a0\u00a0\u00a0\u00a0Rang\u00a0 Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt\u00a0\nVerordnete\u00a0\nPackg.\n2015\n[in\u00a0Tsd.]\u00a0Packg.\u00a0\u00a0\n\u00c4nderung\u00a0\nzum\u00a0Vorjahr\u00a0Umsatz\u00a02015\n[in\u00a0Tsd.\u00a0\u20ac]Absatz\u00a0\n2015\n[in\u00a0Tsd.]\u00a0Umsatz\u00a02015\u00a0\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0\n\u00a0\u00a021\u00a0Obinutuzumab\u00a0\n(Gazyvaro\u00ae)\u00a00,1\u00a0 +234%\u00a0\u00a0 594,2\u00a0 0,1\u00a0 362,7\u00a0\n\u00a0\u00a022\u00a0Siltuximab\u00a0\n(Sylvant\u00ae)\u00a00,1\u00a0 +327%\u00a0\u00a0 224,8\u00a0 0,1\u00a0 122,4\u00a0\n\u00a0\u00a023\u00a0Cobicistat\u00a0\n(Tybost\u00ae)\u00a00,1\u00a0 +194%\u00a0\u00a0 8,9 0,7\u00a0 65,9\u00a0\n\u00a0\u00a024\u00a0Simeprevir\u00a0\n(Olysio\u00ae)\u00a00,1\u00a0 (+74%)\u00a0 867,0\u00a0 0,9\u00a0 8.691,1\u00a0\n\u00a0\u00a025\u00a0Cabozantinib\u00a0\n(Cometriq\u00ae)\u00a00,0\u00a0 +571%\u00a0\u00a0 306,9 0,2\u00a0 1.466,0\u00a0\n\u00a0\u00a026\u00a0Teduglutid\u00a0\n(Revestive\u00ae)\u00a00,0\u00a0 +667%\u00a0\u00a0 620,6\u00a0 0,4\u00a0 9.254,6\u00a0\n\u00a0\u00a027\u00a0Albiglutid\u00a0\n(Eperzan\u00ae)\u00a00,0\u00a0 \u2010\u00a0 2,5 0,1\u00a0 13,4\u00a0\n\u00a0\u00a028\u00a0Delamanid\u00a0\n(Deltyba\u00ae)\u00a00,0\u00a0 \u2010\u00a0 8,2 0,1\u00a0 243,6\u00a0\n\u00a0\u00a029\u00a0Chols\u00e4ure\u00a0\n(Orphacol\u00ae)\u00a00,0\u00a0 \u2010\u00a0 2,7 0,0\u00a0 251,0\u00a0\n\u00a0\u00a030\u00a0Bedaquilin\u00a0\n(Sirturo\u00ae)\u00a00,0\u00a0 \u2010\u00a0 30,2 0,0\u00a0 396,0\u00a0\n1\u201030\u00a0 Gesamt\u00a0 98,3\u00a0 +68%\u00a0\u00a0 241.643,6 758,9\u00a0 1.822.511,6\u00a0\n1\u00a0nur\u00a0das\u00a0Monopr\u00e4parat\u00a0\n*GKV\u2010Zahlen\u00a0sind\u00a0nicht\u00a0abbildbar,\u00a0da\u00a0Verordnungen\u00a0nur\u00a0\u00fcber\u00a0Spez ialambulanzen\u00a0abgegeben\u00a0wurden\u00a0\nDer\u00a0Umsatz\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0lag\u00a0in\u00a0der\u00a0un tersuchten\u00a0Popu\u2010\nlation\u00a0der\u00a0TK\u2010Versicherten\u00a0im\u00a0Jahr\u00a02015\u00a0bei\u00a0241,6\u00a0Mio.\u00a0Euro.\u00a0Ve rglichen\u00a0mit\u00a0den\u00a0\nneuen\u00a0Arzneimitteln\u00a0des\u00a0Jahres\u00a02013\u00a0(54,6\u00a0Mio.\u00a0Euro\u00a0Ausgaben\u00a0im \u00a0Jahr\u00a02014)\u00a0\nhaben\u00a0sich\u00a0die\u00a0Kosten\u00a0der\u00a0neue n\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0im \u00a0Jahr\u00a0nach\u00a0der\u00a0\nMarkteinf\u00fchrung\u00a0vervierfacht.\u00a0Di e\u00a0Menge\u00a0der\u00a0verordneten\u00a0Packung en\u00a0lag\u00a0mit\u00a098,3\u00a0\nTausend\u00a0rund\u00a0zweieinhalb\u00a0mal\u00a0so\u00a0hoch\u00a0wie\u00a0im\u00a0Vorjahr\u00a0(n=38,5\u00a0Tsd .\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a0\n2014).\u00a0Lag\u00a0der\u00a0durchschnittliche\u00a0Preis\u00a0pro\u00a0Packung\u00a0damals\u00a0bei\u00a01 .418\u00a0Euro,\u00a0so\u00a0wa\u2010\nren\u00a0es\u00a0nun\u00a02.458\u00a0Euro.\u00a0Die\u00a030\u00a0im\u00a0Einzelnen\u00a0aufgef\u00fchrten\u00a0Arzneim ittel\u00a0(statt\u00a032\u00a0im\u00a0\nReport\u00a0behandelten;\u00a0Dexlansopraz ol\u00a0und\u00a0Alipogentiparvovec\u00a0fehle n)\u00a0der\u00a0folgen\u2010\nden\u00a0Tabellen\u00a0sind\u00a0nur\u00a0diejenigen, \u00a0f\u00fcr\u00a0welche\u00a0Verordnungen\u00a0der\u00a0T K\u00a0abgerechnet\u00a0\nwurden.\u00a0Das\u00a0umsatzst\u00e4rkste\u00a0 Arzne imittel\u00a0unter\u00a0den\u00a0 Arzneimitteln euheiten\u00a0des\u00a0\nJahres\u00a02014\u00a0war\u00a0im\u00a0Jahr\u00a02015\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0(Tabelle\u00a03 .2),\u00a0das\u00a0der\u00a0Be\u2010\nhandlung\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C\u00a0dient\u00a0und\u00a01.538\u00a0TK\u2010Versich erten\u00a0verordnet\u00a0\nwurde\u00a0(Tabelle\u00a03.4).\u00a0Dimethylfumarat\u00a0zur\u00a0Therapie\u00a0der\u00a0schubf\u00f6rm ig\u00a0remittieren\u2010\nden\u00a0multiplen\u00a0Sklerose\u00a0und\u00a0Sofosbuvir\u00a0bei\u00a0chronischer\u00a0Hepatitis \u00a0C\u00a0folgten\u00a0auf\u00a0Rang\u00a0\n2\u00a0und\u00a03\u00a0der\u00a0umsatzst\u00e4rksten\u00a0neue n\u00a0Arzneimittel\u00a0(Tabelle\u00a03.2).\u00a0\u00a052\u00a0Das\u00a0im\u00a0Jahr\u00a02015\u00a0am\u00a0h\u00e4ufigsten\u00a0verschriebene\u00a0Arzneimittel\u00a0war\u00a0m it\u00a029,2\u00a0Tsd.\u00a0\nverschriebenen\u00a0Packungen\u00a0Vilante rol\u00a0+\u00a0Fluticasonfuroat\u00a0zur\u00a0Ther apie\u00a0von\u00a0Asthma\u00a0\nbronchiale\u00a0und\u00a0der\u00a0chronisch\u00a0obstruktiven\u00a0Lungenerkrankung\u00a0(COP D).\u00a0Auf\u00a0Platz\u00a02\u00a0\nund\u00a03\u00a0der\u00a0h\u00e4ufigsten\u00a0Verordnungen\u00a0rangierten\u00a0wieder\u00a0Dimethylfum arat\u00a0zur\u00a0The\u2010\nrapie\u00a0der\u00a0schubf\u00f6rmig\u00a0remittiere nden\u00a0multiplen\u00a0Sklerose\u00a0und\u00a0Emp agliflozin\u00a0zur\u00a0\nBehandlung\u00a0des\u00a0Diabetes\u00a0melli tus\u00a0Typ\u00a02\u00a0(Tabelle\u00a03.3).\u00a0\nInsgesamt\u00a0erhielten\u00a029.641\u00a0TK\u2010Versicherte\u00a0im\u00a0Jahr\u00a02015\u00a0ein\u00a0Arzn eimittel,\u00a0das\u00a0im\u00a0\nLaufe\u00a0des\u00a0Vorjahres\u00a0eingef\u00fchrt\u00a0worden\u00a0war\u00a0(Tabelle\u00a03.4).\u00a0Diese\u00a0 Anzahl\u00a0stieg\u00a0zum\u00a0\nVorjahr\u00a0um\u00a0rund\u00a0116\u00a0%:\u00a02014\u00a0bekamen\u00a0noch\u00a013.467\u00a0Versicherte\u00a0ein \u00a0im\u00a0Vorjahr\u00a0\nneu\u00a0zugelassenes\u00a0Arzn eimittel\u00a0verordnet.\u00a0\u00a0\nAuf\u00a0Bundeslandebene\u00a0zeigten\u00a0sich\u00a0hinsichtlich\u00a0der\u00a0Verordnungspr \u00e4valenz\u00a0bei\u00a0den\u00a0\nNeueinf\u00fchrungen\u00a0wie\u00a0auch\u00a0schon\u00a0in\u00a0den\u00a0Jahren\u00a0zuvor\u00a0regionale\u00a0Di fferenzen.\u00a0Die\u00a0\ndargestellten\u00a0Zahlen\u00a0in\u00a0Abb.\u00a03.2\u00a0 geben\u00a0die\u00a0Verordnungsanteile\u00a0d er\u00a0TK\u2010Versicherten\u00a0\n(je\u00a0Tausend\u00a0Versicherte)\u00a0im\u00a0Vergleich\u00a0zu\u00a0allen\u00a0TK\u2010Versicherten\u00a0 des\u00a0jeweiligen\u00a0Bun\u2010\ndeslandes\u00a0wieder.\u00a0Die\u00a0h\u00f6chsten\u00a0Anteile\u00a0fanden\u00a0sich\u00a0in\u00a0Nordrhein \u2010Westfalen,\u00a0Ham\u2010\nburg\u00a0und\u00a0im\u00a0Saarland\u00a0(zwischen\u00a05,67\u00a0und\u00a04,39\u00a0Promille),\u00a0w\u00e4hrend \u00a0der\u00a0S\u00fcdosten\u00a0\ndie\u00a0niedrigsten\u00a0Verordnungspr\u00e4valenzen\u00a0aufwies.\u00a0Im\u00a0Jahr\u00a0zuvor\u00a0z eigte\u00a0sich\u00a0ein\u00a0fast\u00a0\nspiegelverkehrtes\u00a0Bild:\u00a0In\u00a0Nordrhein\u2010Westfalen\u00a0und\u00a0im\u00a0Saarland\u00a0 waren\u00a0die\u00a0Verord\u2010\nnungspr\u00e4valenzen\u00a0besonders\u00a0niedr ig\u00a0(1,33\u00a0und\u00a01,09\u00a0Promille),\u00a0w\u00e4 hrend\u00a0die\u00a0h\u00f6chs\u2010\nten\u00a0Werte\u00a0vor\u00a0allem\u00a0im\u00a0Osten\u00a0zu\u00a0verzeichnen\u00a0waren.\u00a0Die\u00a0Gr\u00fcnde\u00a0f \u00fcr\u00a0solche\u00a0Diffe\u2010\nrenzen\u00a0sind\u00a0im\u00a0Einzelnen\u00a0nicht\u00a0klar,\u00a0aus\u00a0fr\u00fcheren\u00a0Untersuchunge n\u00a0sind\u00a0insbeson\u2010\nd e r e \u00a0O s t \u2010 W e s t \u2010 U n t e r s c h i e d e \u00a0m i t \u00a0k ostenintensiver\u00a0 Verordnung\u00a0 in\u00a0 d en\u00a0 ehemals\u00a0\nneuen\u00a0Bundesl\u00e4ndern\u00a0bekannt \u00a0(H\u00e4ussler\u00a0et\u00a0al.,\u00a02013).\u00a0\u00a0\nBei\u00a0drei\u00a0Wirkstoffen\u00a0lag\u00a0die\u00a0Verordnungspr\u00e4valenz\u00a0bei\u00a0\u00fcber\u00a030\u00a0j e\u00a0100.000\u00a0Versi\u2010\ncherten,\u00a0und\u00a0zwar\u00a0bei\u00a0Dimethylfumarat\u00a0zur\u00a0Therapie\u00a0der\u00a0schubf\u00f6r mig\u00a0remittieren\u2010\nden\u00a0multiplen\u00a0Sklerose\u00a0und\u00a0Empagliflozin\u00a0zur\u00a0Behandlung\u00a0des\u00a0Dia betes\u00a0mellitus\u00a0\u00a0\nTyp\u00a02.\u00a0Bei\u00a0Vilanterol\u00a0+\u00a0Fluticasonfuroat\u00a0zur\u00a0Therapie\u00a0von\u00a0Asthm a\u00a0bronchiale\u00a0und\u00a0der\u00a0\nchronisch\u00a0 obstruktiven \u00a0 Lungenerkrankung\u00a0 (COPD)\u00a0 lag\u00a0 die\u00a0 Verordnu ngspr\u00e4valenz\u00a0\nsogar\u00a0bei\u00a0141\u00a0je\u00a0100.000\u00a0Versicherten.\u00a0Im\u00a0Mittel\u00a0waren\u00a0TK\u2010Versi cherte\u00a0mit\u00a0der\u00a0\nVerordnung\u00a0eines\u00a0neuen\u00a0Arzneimittels\u00a052\u00a0Jahre\u00a0alt\u00a0(Vorjahresinn ovationen:\u00a054,3\u00a0\nJahre),\u00a0gleiche\u00a0Anteile\u00a0entfielen\u00a0auf\u00a0M\u00e4nner\u00a0und\u00a0Frauen\u00a0(Tabell e\u00a03.4).\u00a0\u00a0\n\u00a0 \u00a053\u00a0Abbildung\u00a03.2:\u00a0Verordnungspr\u00e4valenz\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Ja hres\u00a02014\u00a0\nin\u00a0Promille\u00a0nach\u00a0Bundesl\u00e4ndern\u00a0( nur\u00a0Verordnungen\u00a0im\u00a0Jahr\u00a02015)\u00a0 bezogen\u00a0\nauf\u00a0Versicherte\u00a0der\u00a0TK\u00a0\n\u00a0\n54\u00a0Tabelle\u00a03.4:\u00a0Anzahl,\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0der\u00a0Versicherten\u00a0mit\u00a0 mindestens\u00a0einer\u00a0\nVerordnung\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a02014\u00a0(Daten\u00a0aus\u00a02015 )\u00a0\nWirkstoff\u00a0 Anz.\u00a0\nVersicherte\u00a0Pr\u00e4valenz\u00a0\u00a0\nje\u00a0100.000\u00a0Vers.\u00a0Alter\u00a0\nMittelwert\u00a0Anteil\u00a0weiblich\nin\u00a0%\u00a0\nCobicistat\u00a0 28\u00a0 0,3\u00a0 47,8\u00a0 14,2\u00a0\u00a0\nDaclatasvir\u00a0 251\u00a0 2,7\u00a0 52,8\u00a0 38,2\u00a0\u00a0\nDimethylfumarat\u00a0 3.634\u00a0 39,0\u00a0 41,1\u00a0 70,6\u00a0\u00a0\nDolutegravir\u00a0\n(Monopr\u00e4parat)\u00a01.072\u00a0 11,5\u00a0 45,1\u00a0 11,5\u00a0\u00a0\nSucroferric\u00a0\u00a0\nOxyhydroxid\u00a0152\u00a0 1,6\u00a0 56,9\u00a0 24,3\u00a0\u00a0\nEmpagliflozin\u00a0 3.263\u00a0 35,0\u00a0 60,1\u00a0 33,9\u00a0\u00a0\nIbrutinib\u00a0 253\u00a0 2,7\u00a0 69,1\u00a0 25,6\u00a0\u00a0\nIdelalisib\u00a0 72\u00a0 0,8\u00a0 67,5\u00a0 25,0\u00a0\u00a0\nLedipasvir\u00a0+\u00a0\u00a0\nSofosbuvir\u00a01.538\u00a0 16,5\u00a0 53,9\u00a0 44,1\u00a0\u00a0\nMacitentan\u00a0 157\u00a0 1,7\u00a0 57,5\u00a0 65,6\u00a0\u00a0\nNalmefen\u00a0 674\u00a0 7,2\u00a0 51,7\u00a0 38,4\u00a0\u00a0\nObinutuzumab\u00a0 29\u00a0 0,3\u00a0 73,8\u00a0 20,6\u00a0\u00a0\nOlodaterol\u00a0 1.538\u00a0 16,5\u00a0 66,6\u00a0 42,3\u00a0\u00a0\nRiociguat\u00a0 111\u00a0 1,2\u00a0 67,4\u00a0 54,0\u00a0\u00a0\nSimeprevir\u00a0 34\u00a0 0,4\u00a0 57,9\u00a0 38,2\u00a0\u00a0\nSofosbuvir\u00a0 450\u00a0 4,8\u00a0 53,3\u00a0 38,0\u00a0\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0208\u00a0 2,2\u00a0 59,2\u00a0 100,0\u00a0\u00a0\nUmeclidinium\u00a0\u00a0+\u00a0\nVilanterol\u00a02.290\u00a0 24,5\u00a0 65,2\u00a0 43,5\u00a0\nVedolizumab\u00a0 681\u00a0 7,3\u00a0 38,9\u00a0 52,7\u00a0\u00a0\nVilanterol\u00a0+\u00a0\nFluticasonfuroat\u00a013.162\u00a0 141,1\u00a0 49,4\u00a0 54,9\u00a0\u00a0\nGesamt*\u00a0 29.641\u00a0 311,4\u00a0 52,0\u00a0 50,0\u00a0\nMehrfachz\u00e4hlung\u00a0von\u00a0Versicherten\u00a0mit\u00a0Verordnung\u00a0in\u00a02015\u00a0(Einfac hz\u00e4hlung:\u00a0n=\u00a029.055\u00a0in\u00a02015)\u00a0\u00a0\n*Kleine\u00a0Fallzahlen\u00a0wurden\u00a0nicht\u00a0dargestellt\u00a0\n\u00a0 \u00a055\u00a04 Bewertungen\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0\n4.1 Albiglutid\u00a0\nHandelsname:\u00a0Eperzan\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Typ\u20102\u2010Diabetes\u00a0mellitus\u00a0\u00a0 GlaxoSmithKline\u00a0\nATC\u2010Code:\u00a0A10BX13\u00a0\u00a0(neu:\u00a0A10BJ 04)\u00a0 Markteinf\u00fchrung:\u00a0Oktober\u00a02014 \u00a0\nDarreichungsform:\u00a0Pulver\u00a0u.\u00a0L\u00f6sungsmittel\u00a0\u00a0\nzur\u00a0Herstellung\u00a0einer\u00a0Injektionsl\u00f6sung\u00a0 DDD:\u00a05,7\u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nAlbiglutid\u00a0(Eperzan\u00ae)\u00a0war\u00a02014\u00a0der\u00a0vierte\u00a0GLP\u00a0( Glucagon\u00a0Like \u00a0Peptide)\u20101\u2010Agonist\u00a0mit\u00a0\neiner\u00a0europ\u00e4ischen\u00a0Zulassung\u00a0zur\u00a0Behandlung\u00a0des\u00a0 Diabetes\u00a0mellitus\u00a0Typ\u00a02 .\u00a0Zulas\u2010\nsungsgem\u00e4\u00df\u00a0wird\u00a0das\u00a0Pr\u00e4parat\u00a0bei\u00a0bestehenden\u00a0Kontraindikationen \u00a0oder\u00a0Unvertr\u00e4g\u2010\nlichkeiten\u00a0gegen\u00fcber\u00a0Metformin\u00a0e ingesetzt.\u00a0Dabei\u00a0wird\u00a0vorausges etzt,\u00a0dass\u00a0zuvor\u00a0\nerfolgte\u00a0Allgemeinma\u00dfnahmen\u00a0wie\u00a0\u00c4nderungen\u00a0der\u00a0Ern\u00e4hrungs\u2010\u00a0und\u00a0 Bewegungs\u2010\ngewohnheiten\u00a0den\u00a0Blutzucker\u00a0nicht\u00a0ausreichend\u00a0senken\u00a0konnten.\u00a0S owohl\u00a0die\u00a0Mono\u2010\ntherapie\u00a0als\u00a0auch\u00a0die\u00a0Kombination\u00a0mit\u00a0anderen\u00a0blutzuckersenkend en\u00a0Arzneimitteln\u00a0\n(einschlie\u00dflich\u00a0Basalinsulin)\u00a0sind\u00a0vorgesehen.\u00a0Albiglutid\u00a0leite t\u00a0sich\u00a0strukturell\u00a0vom\u00a0\nGLP\u20101\u00a0ab,\u00a0einem\u00a0Inkretin\u2010Hormon,\u00a0das\u00a0die\u00a0Synthese\u00a0und\u00a0Freisetzu ng\u00a0von\u00a0Insulin\u00a0aus\u00a0\nden\u00a0Betazellen\u00a0des\u00a0Pankreas\u00a0verst\u00e4rkt\u00a0und\u00a0seine\u00a0Glucoseempfindl ichkeit\u00a0steigert.\u00a0\nWeitere\u00a0Effekte\u00a0sind\u00a0eine\u00a0vermin derte\u00a0Glucagonaussch\u00fcttung\u00a0der\u00a0 Alphazellen,\u00a0eine\u00a0\nVerz\u00f6gerung\u00a0der\u00a0Magenentleerung\u00a0sowie\u00a0die\u00a0Beeinflussung\u00a0der\u00a0App etitregulation.\u00a0\nF\u00fcr\u00a0Albiglutid\u00a0wurden\u00a0erstmals\u00a0zwei\u00a0identische,\u00a030\u00a0Aminos\u00e4uren\u00a0 umfassende\u00a0GLP\u20101\u2010\nMolek\u00fcl\u00a0(7\u201037)\u00a0in\u00a0Reihe\u00a0mit\u00a0humanem\u00a0Albumin\u00a0verkn\u00fcpft,\u00a0wodurch\u00a0 Abbauprozesse\u00a0\nverlangsamt\u00a0und\u00a0somit\u00a0die\u00a0Verweildauer\u00a0der\u00a0Substanz\u00a0im\u00a0Organism us\u00a0verl\u00e4ngert\u00a0\nwerden\u00a0(EMA,\u00a02014).\u00a0Mit\u00a0einer\u00a0Hal bwertzeit\u00a0von\u00a0f\u00fcnf\u00a0Tagen\u00a0ergib t\u00a0sich\u00a0f\u00fcr\u00a0Albuglutid\u00a0\ninnerhalb\u00a0der\u00a0Wirkstoffklasse\u00a0die\u00a0l\u00e4ngste\u00a0Verweildauer,\u00a0sodass\u00a0 die\u00a0Anwendung\u00a0nur\u00a0\neinmal\u00a0w\u00f6chentlich\u00a0erfolgt.\u00a0Die\u00a0empfohlene\u00a0Dosis\u00a0betr\u00e4gt\u00a0dabei\u00a0 30\u00a0mg\u00a0und\u00a0wird\u00a0\nunabh\u00e4ngig\u00a0von\u00a0den\u00a0Mahlzeiten\u00a0zu\u00a0einer\u00a0beliebigen\u00a0Tageszeit\u00a0sub kutan\u00a0appliziert.\u00a0In\u00a0\nAbh\u00e4ngigkeit\u00a0vom\u00a0individuellen\u00a0Ansprechen\u00a0kann\u00a0sukzessive\u00a0auf\u00a05 0\u00a0mg\u00a0erh\u00f6ht\u00a0wer\u2010\nden\u00a0(Fachinformation\u00a0Eperzan \u00ae,\u00a02016).\u00a0\u00a0\nGegen\u00fcber\u00a0Placebo\u00a0ist\u00a0eine\u00a0blutzuckersenkende\u00a0Wirkung\u00a0durch\u00a0Alb iglutid\u00a0sowohl\u00a0in\u00a0\nder\u00a0Monotherapie\u00a0als\u00a0auch\u00a0in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0Antidiabet ika\u00a0belegt\u00a0(Nauck\u00a0\net\u00a0al.,\u00a02016).\u00a0In\u00a0der\u00a0vom\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0fin anzierten\u00a0zulas\u2010\nsungsbegr\u00fcndenden\u00a0Studie\u00a0HARMONY\u00a07\u00a0(Pratley\u00a0et\u00a0al.,\u00a02014)\u00a0zeigt e\u00a0sich\u00a0der\u00a0Wirkstoff\u00a0\ngegen\u00fcber\u00a0Liraglutid\u00a0bez\u00fcglich\u00a0des\u00a0Ausma\u00dfes\u00a0der\u00a0Senkung\u00a0des\u00a0HbA 1c\u2010Wertes\u00a0sowie\u00a0\nder\u00a0Reduktion\u00a0des\u00a0K\u00f6rpergewichtes\u00a0nach\u00a032\u00a0Wochen\u00a0nicht\u00a0\u00fcberlege n\u00a0(0,78\u00a0%\u00a0vs.\u00a0\n0,99\u00a0%\u00a0NI\u00a0p=0,0846;\u00a00,64\u00a0kg\u00a0vs.\u00a02,19\u00a0kg\u00a0NI\u00a0p\u00a0<\u00a00,0001).\u00a0Weitere \u00a0vergleichende\u00a0Unter\u201056\u00a0suchungen\u00a0 im\u00a0 Rahmen\u00a0 des\u00a0 Phase\u2010III\u2010Studienprogramms\u00a0 HARMONY\u00a0 zu\u00a0 a nderen\u00a0\nInkretinanaloga\u00a0wurden\u00a0nicht\u00a0durchgef\u00fchrt.\u00a0In\u00a0einer\u00a0Gegen\u00fcberst ellung\u00a0der\u00a0Zulas\u2010\nsungsstudien\u00a0mit\u00a0Vertr etern\u00a0weiterer\u00a0antidiabetisch\u00a0wirksamer\u00a0S ubstanzklassen\u00a0zeigt\u00a0\nder\u00a0indirekte\u00a0Vergleich\u00a0weder\u00a0f\u00fcr\u00a0die\u00a0blutzuckersenkende\u00a0Wirkun g\u00a0noch\u00a0f\u00fcr\u00a0den\u00a0\nEinfluss\u00a0auf\u00a0 das\u00a0K\u00f6rpergewicht\u00a0ei ne\u00a0\u00dcberlegenheit\u00a0 von\u00a0 Albigluti d\u00a0(Trujillo\u00a0 et\u00a0al.,\u00a0\n2015).\u00a0Valide\u00a0Daten\u00a0zur\u00a0Erfassung\u00a0der\u00a0gesundheitsbezogenen\u00a0Lebe nsqualit\u00e4t\u00a0oder\u00a0\ndes\u00a0Risikos\u00a0f\u00fcr\u00a0Folgeerkrankungen\u00a0fehlen,\u00a0sodass\u00a0dieser\u00a0Aspekt\u00a0 nicht\u00a0abschlie\u00dfend\u00a0\nbewertet\u00a0werden\u00a0kann.\u00a0Daher\u00a0hat\u00a0die\u00a0amerikanische\u00a0Zulassungsbeh \u00f6rde,\u00a0die\u00a0 Food\u00a0\nand\u00a0Drug\u00a0Administration \u00a0(FDA),\u00a0die\u00a0Durchf\u00fchrung\u00a0einer\u00a0entsprechenden\u00a0Studie\u00a0zur\u00a0\nAuflage\u00a0gemacht,\u00a0in\u00a0der\u00a0diverse\u00a0Aspekte\u00a0wie\u00a0das\u00a0Auftreten\u00a0kardi ovaskul\u00e4rer\u00a0Ereignis\u2010\nse,\u00a0Schilddr\u00fcsen\u2010\u00a0und\u00a0Pankreaskarzinome,\u00a0bzw.\u00a0Pankreatitiden\u00a0un tersucht\u00a0werden\u00a0\nsollen.\u00a0Mit\u00a0Ergebnissen\u00a0kann\u00a0voraussichtlich\u00a02020\u00a0gerechnet\u00a0wer den\u00a0(FDA,\u00a02013).\u00a0\nBez\u00fcglich\u00a0des\u00a0therapeutischen\u00a0Stellenwertes\u00a0ergibt\u00a0sich\u00a0aus\u00a0den \u00a0Leitlinien\u00a0f\u00fcr\u00a0die\u00a0\nKlasse\u00a0der\u00a0Inkretin\u2010Analoga\u00a0und\u00a0anderen\u00a0Antidiabetika\u00a0eine\u00a0hete rogene\u00a0Einsch\u00e4t\u2010\nzung.\u00a0So\u00a0enth\u00e4lt\u00a0die\u00a0aktuelle\u00a0nationale\u00a0Versorgungungsleitlinie \u00a0(NVL,\u00a02013)\u00a0erst\u2010\nmals\u00a0einen\u00a0Therapiealgorithmus,\u00a0der\u00a0zwei\u00a0unterschiedliche\u00a0Stufe nschemata\u00a0be\u2010\nschreibt\u00a0und\u00a0gleicherma\u00dfen\u00a0empfiehlt.\u00a0So\u00a0sieht\u00a0das\u00a0Schema\u00a0der\u00a0A rzneimittelkom\u2010\nmission\u00a0der\u00a0Deutschen\u00a0\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0und\u00a0der\u00a0Deutschen\u00a0Gese llschaft\u00a0f\u00fcr\u00a0\nAllgemeinmedizin\u00a0(DEGAM)\u00a0keinen\u00a0 Einsatz\u00a0von\u00a0GLP\u20101\u2010Agonisten\u00a0als \u00a0Bestandteil\u00a0\nder\u00a0antidiabetischen\u00a0Therapie\u00a0vor.\u00a0Die\u00a0Deutsche\u00a0Diabetes\u00a0Gesell schaft\u00a0(DDG)\u00a0und\u00a0\ndie\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Innere\u00a0Medizin\u00a0(DGIM)\u00a0empfehlen\u00a0d en\u00a0Einsatz\u00a0der\u00a0\nInkretinmimetika\u00a0in\u00a0der\u00a0Kombination\u00a0mit\u00a0Verz\u00f6gerungsinsulinen\u00a0u nd\u00a0evtl.\u00a0oralen\u00a0\nAntidiabetika\u00a0bei\u00a0Patienten,\u00a0die\u00a0auf\u00a0bisherige\u00a0therapeutische\u00a0M a\u00dfnahmen\u00a0unge\u2010\nn\u00fcgend\u00a0ansprachen\u00a0(NVL,\u00a02013).\u00a0\u00a0\nDer\u00a0Gemeinsame\u00a0Bunde ssausschuss\u00a0(G\u2010BA)\u00a0stellte\u00a02015\u00a0lediglich\u00a0f \u00fcr\u00a0die\u00a0Kombination\u00a0\nvon\u00a0Albiglutid\u00a0und\u00a0Metformin\u00a0einen\u00a0 Hinweis\u00a0auf\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0fest.\u00a0\nDiese\u00a0Entscheidung\u00a0beruhte\u00a0auf\u00a0d en\u00a0Ergebnissen\u00a0der\u00a0Studie\u00a0HARMO NY\u00a03\u00a0(Ahren\u00a0et\u00a0\nal.,\u00a02014),\u00a0die\u00a0f\u00fcr\u00a0die\u00a0mit\u00a0Glimepirid\u00a0und\u00a0Metformin\u00a0behandelte \u00a0Teilpopulation,\u00a0die\u00a0\ngleichzeitig\u00a0 Albiglutid\u00a0 erhielt,\u00a0 eine\u00a0 signifikant\u00a0 geringere\u00a0 Anz ahl\u00a0 an\u00a0 nicht\u2010schweren\u00a0\nHypoglyk\u00e4mien\u00a0zeigten.\u00a0Dabei\u00a0reduzierten\u00a0methodische\u00a0M\u00e4ngel\u00a0die \u00a0Aussagesicher\u2010\nheit\u00a0dieses\u00a0Effektes.\u00a0Weder\u00a0f\u00fcr\u00a0die\u00a0Beurteilung\u00a0der\u00a0gesundheits bezogenen\u00a0Lebens\u2010\nqualit\u00e4t\u00a0noch\u00a0f\u00fcr\u00a0einen\u00a0Vergleich\u00a0mit\u00a0anderen\u00a0vom\u00a0G\u2010BA\u00a0gesetzte n\u00a0zweckm\u00e4\u00dfigen\u00a0\nVergleichstherapien\u00a0(zVT)\u00a0wurden\u00a0Daten\u00a0vorgelegt.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a057\u00a0Verf\u00fcgbare\u00a0Therapien\u00a0 \u00a0\u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen\u00a0 \u00a0Kosten\u00a0\n\u00a0\nweitere\u00a0\nblutzuckersenkende\u00a0\nTherapieoption\u00a0bei\u00a0Typ\u2010\n2\u2010Diabetes \u00a0lediglich\u00a0f\u00fcr\u00a0die\u00a0Kombi\u2010\nnation\u00a0von\u00a0Albiglutid\u00a0und\u00a0\nMetformin\u00a0ist\u00a0ein\u00a0\ntherapeutischer\u00a0Vorteil\u00a0\nbelegt\u00a0teurer\u00a0als\u00a0zVT \u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Umstrittenes\u00a0\nTherapieprinzip\u00a0\u2013\u00a0 \u2013\u00a0 Analogpr\u00e4parat\u00a0\nKosten\u00a0Monotherapien\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nZu\u00a0bewertendes\u00a0\nArzneimittel \u00a0\u00a0 \u00a0 \u00a0\nAlbiglutid \u00a0 1\u00a0x\u00a0w\u00f6chentlich \u00a0 52\u00a0 1.452,79\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0(GLIB)\u00a0 1\u00a0\u2013\u00a02\u00a0x\u00a0tgl.\u00a0 365\u00a0 13,03\u00a0\u2013\u00a078,17\u00a0\u20ac\u00a0\nGlimepirid\u00a0(GLIM)\u00a0 1\u00a0x\u00a0tgl.\u00a0 365\u00a0 29,67\u00a0\u2013\u00a0152,29\u00a0\u20ac\u00a0\nKosten\u00a0Kombinationstherapien\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nZu\u00a0bewertendes\u00a0\nArzneimittel\u00a0(AM) \u00a0\u00a0 \u00a0 \u00a0\nAlbiglutid\u00a0\u00b1\u00a0\u00a0\nMetformin\u00a0(MET)\u00a01\u00a0x\u00a0w\u00f6chentlich\u00a0\n2\u00a0\u2013\u00a03x\u00a0tgl. \u00a052\u00a0\n365\u00a0\u00a0\n1.396,17\u00a0\u2013\u00a01.462,31\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 47,79\u00a0\u2013\u00a0187,55\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0 1x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 66,04\u2010233,32\u00a0\u20ac\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nAlbiglutid\u00a0+ \u00a0 1x\u00a0w\u00f6chentlich\u00a0 52\u00a0 \u00a0\nGlibenclamid\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 1.377,82\u00a0\u2013\u00a01.451,52\u00a0\u20ac\u00a0\nGlimepirid\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 1.396,07\u00a0\u2013\u00a01.497,19\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 47,79\u00a0\u2013\u00a0187,55\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0 1x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 66,04\u00a0\u2013\u00a0233,32\u00a0\u20ac\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nAlbiglutid\u00a0+ \u00a0 1x\u00a0w\u00f6chentlich \u00a0 52\u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 1.410,89\u00a0\u2013\u00a01.550,64\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0\nFortsetzung\u00a0auf\u00a0n\u00e4chster\u00a0\nSeite\u00a01x\u00a0tgl.\u00a0 365\u00a0 1.429,14\u00a0\u2013\u00a01.596,41\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n58\u00a0Wirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)*\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n+\u00a0Metformin\u00a0oder\u00a0 2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0 365\u00a0 425,70\u00a0\u2013\u00a0884,47\u00a0\u20ac*\u00a0\nKonventionelle\u00a0\nInsulintherapie\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 392,62\u00a0\u2013\u00a0785,25\u00a0\u20ac*\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nAlbiglutid\u00a0+\u00a0\u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)\u00a0\n\u00b1\u00a0Metformin\u00a0\nVergleichstherapie \u00a01x\u00a0w\u00f6chentlich \u00a0\n1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0\n2\u00a0\u2013\u00a03x\u00a0tgl. \u00a052\u00a0\n365\u00a0\n365\u00a0\u00a0\n1.755,72\u00a0\u2013\u00a02.148,34\u00a0\u20ac\u00a0\n1.788,99\u00a0\u2013\u00a02.247,56\u00a0\u20ac \u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)*\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n+\u00a0Metformin\u00a0 2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0 365\u00a0 425,70\u00a0\u2013\u00a0884,47\u00a0\u20ac\u00a0\nKonventionelle\u00a0\nInsulintherapie\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 392,62\u00a0\u2013\u00a0785,25\u00a0\u20ac\u00a0\n*Angaben\u00a0exkl.\u00a0zus\u00e4tzliche\u00a0GKV\u2010Leistungen\u00a0f\u00fcr\u00a0Blutzuckerteststr eifen,\u00a0Lanzetten,\u00a0Einmalnadeln\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen \u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0 Albiglutid\u00a0erstellt\u00a0werden.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nAlbiglutid\u00a0(Eperzan\u00ae)\u00a0ist\u00a0wie\u00a0Exenatid,\u00a0Liraglutid\u00a0und\u00a0Dulaglut id\u00a0ein\u00a0weiterer\u00a0GLP\u20101\u00a0\nRezeptorantagonist\u00a0mit\u00a0inkretinanaloger\u00a0Wirkung.\u00a0Physiologisch\u00a0 vermitteln\u00a0Inkre\u2010\ntinhormone\u00a0wie\u00a0das\u00a0 Glucagon\u00a0Like\u00a0Peptide\u00a01 \u00a0(GLP\u20101)\u00a0nach\u00a0Bindung\u00a0an\u00a0den\u00a0GLP\u20101\u00a0\nRezeptor,\u00a0der\u00a0in\u00a0verschiedenen\u00a0gastroentestinalen\u00a0Geweben\u00a0sowie \u00a0in\u00a0Hypophyse,\u00a0\nLunge,\u00a0Nieren,\u00a0Myokard\u00a0exprimiert\u00a0wird,\u00a0eine\u00a0gesteigerte\u00a0Synthe se\u00a0und\u00a0Freiset\u2010\nzung\u00a0von\u00a0Insulin\u00a0aus\u00a0den\u00a0Betazellen\u00a0des\u00a0Pankreas\u00a0und\u00a0verst\u00e4rken \u00a0ihre\u00a0Glucosesen\u2010\nsitivit\u00e4t.\u00a0Weiterhin\u00a0senkt\u00a0es\u00a0die\u00a0durch\u00a0Alphazellen\u00a0vermittelte \u00a0Glucagonsekretion,\u00a0\nverz\u00f6gert\u00a0die\u00a0Magenentleerung\u00a0und\u00a0greift\u00a0u.\u00a0a.\u00a0auf\u00a0zentraler\u00a0Eb ene\u00a0in\u00a0die\u00a0Appetit\u2010\nregulation\u00a0und\u00a0den\u00a0Energiehaushalt\u00a0ein.\u00a0Mit\u00a0Fortschreiten\u00a0des\u00a0D iabetes\u00a0geht\u00a0eine\u00a0\nVerminderung\u00a0der\u00a0endogenen\u00a0GLP\u20101\u2010Synthese\u00a0einher\u00a0(Nauck\u00a0et\u00a0al., \u00a02011).\u00a0Ein\u00a0\ntherapeutischer\u00a0 Einsatz\u00a0 von\u00a0 GLP\u20101\u00a0 ist\u00a0 nicht\u00a0 m\u00f6glich,\u00a0 da\u00a0 die\u00a0 Hal bwertszeit\u00a0 des\u00a0\nHormons\u00a0nach\u00a0Sekretion\u00a0aus\u00a0den\u00a0L\u2010Zellen\u00a0des\u00a0D\u00fcnndarms\u00a0nur\u00a0zwei\u00a0 Minuten\u00a0be\u2010\ntr\u00e4gt.\u00a0Zur\u00a0Wirkstoffgruppe\u00a0der\u00a0Inkretinananloga\u00a0(auch\u00a0Inkretinm imetika)\u00a0geh\u00f6ren\u00a0\nvon\u00a0GLP\u20101\u2010abgeleitete\u00a0Substanzen.\u00a0So\u00a0ist\u00a0Albiglutid\u00a0ein\u00a0rekombi nantes\u00a0Fusionspro\u2010\ntein,\u00a0das\u00a0aus\u00a0zwei\u00a0Kopien\u00a0einer\u00a030\u2010Aminos\u00e4uren\u2010Sequenz\u00a0von\u00a0modi fizierten\u00a0huma\u2010\nnen\u00a0GLP\u20101\u00a0besteht,\u00a0die\u00a0genetisch\u00a0in\u00a0Reihe\u00a0mit\u00a0Humanalbumin\u00a0fusi oniert\u00a0wurden\u00a0\n(GSK,\u00a02016).\u00a0Diese\u00a0Strukturver\u00e4nderung\u00a0f\u00fchrt\u00a0zu\u00a0einem\u00a0verminder ten\u00a0Abbau\u00a0des\u00a0\nWirkstoffes\u00a0u.\u00a0a.\u00a0durch\u00a0endogene\u00a0Dipeptidylpeptidasen\u00a0(DDP).\u00a0Di e\u00a0Halbwertzeit\u00a0\nvon\u00a0Albiglutid\u00a0betr\u00e4gt\u00a0etwa\u00a0f\u00fcnf\u00a0Tage\u00a0und\u00a0ist\u00a0damit\u00a0die\u00a0l\u00e4ngste \u00a0innerhalb\u00a0der\u00a0Wirk\u2010\nstoffklasse,\u00a0im\u00a0Vergleich\u00a0zu\u00a0zwei\u00a0bis\u00a0drei\u00a0Stunden\u00a0bei\u00a0Exsenati d\u00a0(Fachinformation\u00a059\u00a0Astra\u00a0Zeneca,\u00a02016),\u00a013\u00a0Stunden\u00a0bei\u00a0Liraglutid\u00a0(Fachinformation \u00a0Eperzan\u00ae,\u00a02016)\u00a0\noder\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0Tag en\u00a0bei\u00a0Dulaglutid\u00a0(F achinformation\u00a0Eli\u00a0Li lly\u00a0Nederland,\u00a02016).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nAlbiglutid\u00a0(Eperzan\u00ae)\u00a0ist\u00a0zuge lassen\u00a0zur\u00a0Behandlung\u00a0erwachsener \u00a0Patienten\u00a0mit\u00a0\nTyp\u20102\u2010Diabetes,\u00a0wenn\u00a0Di\u00e4t\u00a0und\u00a0Bew egung\u00a0allein\u00a0zur\u00a0Blutzuckerein stellung\u00a0nicht\u00a0\nausreichen.\u00a0Die\u00a0Anwendung\u00a0kann\u00a0bei\u00a0Kontraindikationen\u00a0oder\u00a0Unve rtr\u00e4glichkeit\u00a0\ngegen\u00fcber\u00a0Metformin\u00a0im\u00a0Rahmen\u00a0eine r\u00a0Monotherapie\u00a0oder\u00a0in\u00a0Kombin ation\u00a0mit\u00a0\nanderen\u00a0blutzuckersenkenden\u00a0Arzn eimitteln,\u00a0einschlie\u00dflich\u00a0Basal insulin,\u00a0erfolgen,\u00a0\nwenn\u00a0diese\u00a0zusammen\u00a0mit\u00a0den\u00a0bereits\u00a0durchgef\u00fchrten\u00a0Allgemeinma\u00df nahmen\u00a0den\u00a0\nBlutzucker\u00a0nicht\u00a0ausreichend\u00a0senken\u00a0konnten.\u00a0\nAlbiglutid\u00a0wird\u00a0einmal\u00a0w\u00f6chentlic h\u00a0zu\u00a0einer\u00a0beliebigen\u00a0Tageszei t\u00a0unabh\u00e4ngig\u00a0von\u00a0\nden\u00a0Mahlzeiten\u00a0subkutan\u00a0verabreicht.\u00a0Die\u00a0empfohlene\u00a0Dosis\u00a0betr\u00e4 gt\u00a030\u00a0mg,\u00a0die\u00a0\nsukzessive\u00a0 abh\u00e4ngig\u00a0 vom\u00a0 individuellen\u00a0 Ansprechen\u00a0 auf\u00a0 50\u00a0mg\u00a0 erh\u00f6 ht\u00a0 werden\u00a0\nkann.\u00a0F\u00fcr\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0stehen\u00a0keine\u00a0Studiendaten\u00a0zur\u00a0 Verf\u00fcgung,\u00a0so\u2010\ndass\u00a0eine\u00a0Anwendung\u00a0innerhalb\u00a0dieser\u00a0Patientenpopulation\u00a0nicht\u00a0 empfohlen\u00a0wird.\u00a0\nDiese\u00a0Einschr\u00e4nkung\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0Typ\u20101\u2010Diabetes\u00a0 oder\u00a0bei\u00a0Komorbi\u2010\ndit\u00e4ten\u00a0wie\u00a0schweren\u00a0Nierenfunktionsst\u00f6rungen.\u00a0Aufgrund\u00a0der\u00a0beg renzten\u00a0Erfah\u2010\nrung\u00a0ist\u00a0Albiglutid\u00a0f\u00fcr\u00a0Schwangere\u00a0und\u00a0Stillende\u00a0nicht\u00a0geeignet .\u00a0So\u00a0zeigten\u00a0tierex\u2010\nperimentelle\u00a0Studien\u00a0eine\u00a0Reproduktionstoxizit\u00e4t\u00a0(GSK,\u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nUngef\u00e4hr\u00a0422\u00a0Mio.\u00a0Menschen\u00a0weltweit\u00a0haben\u00a0Diabetes\u00a0(WHO,\u00a02016). \u00a0In\u00a0Deutsch\u2010\nland\u00a0haben\u00a0\u00a07,4\u00a0%\u00a0bei\u00a0einer\u00a0\u00a0Gesamtbev\u00f6lkerung\u00a0von\u00a0ca.\u00a080,7\u00a0Mio .\u00a0MenschenDia\u2010\nbetes\u00a0(WHO,\u00a02017),\u00a0von\u00a0diesen\u00a0wie derum\u00a0\u2013\u00a0unter\u00a0Ber\u00fccksichtigung \u00a0einer\u00a0Dunkel\u2010\nziffer\u00a0von\u00a0zwei\u00a0Mio.\u00a0Menschen\u00a0\u2013\u00a0betr\u00e4gt\u00a0der\u00a0Anteil\u00a0an\u00a0Typ\u20102\u2010Dia betes\u2010Erkrankten\u00a0\nsch\u00e4tzungsweise\u00a095\u00a0%\u00a0(Tamayo\u00a0&\u00a0Rathmann,\u00a02016).\u00a0Nicht\u00a0zuletzt\u00a0a ufgrund\u00a0der\u00a0\nInstallation\u00a0 eines\u00a0 Disease\u2010Management\u2010Programmes \u00a0( D M P ) \u00a0f \u00fc r \u00a0T y p \u2010 1 \u2010 \u00a0u n d \u00a0\u2010 2 \u2010\nDiabetes\u00a0ist\u00a0die\u00a0Generierung\u00a0epidemiologischer\u00a0Daten\u00a0f\u00fcr\u00a0das\u00a0Bu ndesgebiet\u00a0aber\u00a0\nbeg\u00fcnstigt.\u00a0Eine\u00a0Tendenz\u00a0zur\u00a0\u00dcbe rdiagnostik\u00a0ist\u00a0zu\u00a0vermuten,\u00a0di e\u00a0im\u00a0Hinblick\u00a0auf\u00a0\ndie\u00a0 hohe\u00a0 Erkrankungspr\u00e4valenz\u00a0 ber\u00fccksichtigt\u00a0 werden\u00a0 sollte.\u00a0 Ber eits\u00a0 seit\u00a0 2012\u00a0\nsehen\u00a0die\u00a0amerikanischen\u00a0und\u00a0europ\u00e4ischen\u00a0Leitlinien\u00a0f\u00fcr\u00a0Typ\u20102\u2010 Diabetes\u00a0keine\u00a0\nTitration\u00a0auf\u00a0einen\u00a0HbA1c\u00a0von\u00a0unter\u00a06,5\u00a0%\u00a0vor,\u00a0sondern\u00a0definier en\u00a0einen\u00a0patien\u2010\ntenindividuellen\u00a0Zielkorridor\u00a0von\u00a07,5\u00a0bis\u00a08,0\u00a0%\u00a0oder\u00a0h\u00f6her\u00a0(Inz ucchi\u00a0et\u00a0al.,\u00a02012).\u00a0\nAuch\u00a0 die\u00a0 Nationale\u00a0 Versorgungsleitlinie\u00a0 (NVL)\u00a0 Typ\u20102\u2010Diabetes\u00a0 be schreibt\u00a0 eine\u00a0\nSpanne\u00a0von\u00a06,5\u00a0bis\u00a07,5\u00a0%\u00a0HbA1c\u00a0(NVL,\u00a02013).\u00a0Die\u00a0im\u00a0DMP\u2010Qualit\u00e4t sbericht\u00a02015\u00a0\nder\u00a0Kassen\u00e4rztlichen\u00a0Vereinigung\u00a0N ordrhein\u00a0(KVNo)\u00a0vorgenommene\u00a0 Analyse\u00a0der\u00a0\nDaten\u00a0zeigt,\u00a0dass\u00a0ein\u00a0erheblic her\u00a0Anteil,\u00a0im\u00a0Mittel\u00a041,5\u00a0%,\u00a0der \u00a0Patienten,\u00a0die\u00a0min\u2010\ndestens\u00a0ein\u00a0halbes\u00a0Jahr\u00a0am\u00a0DMP\u00a0teilnahmen,\u00a0einen\u00a0HbA1c\u00a0von\u00a0unte r\u00a06,5\u00a0%\u00a0aufwie\u201060\u00a0sen\u00a0(KVNo,\u00a02016).\u00a0So\u00a0k\u00f6nnten\u00a0Menschen\u00a0mit\u00a0Vorstadien\u00a0des\u00a0Diabet es,\u00a0mit\u00a0HbA1c\u2010\nWerten\u00a0im\u00a0Graubereich\u00a0oder\u00a0\u201enicht\u00a0wirklich\u00a0n\u00fcchternen\u201c\u00a0N\u00fcchtern blutglukose\u2010\nwerten\u00a0f\u00e4lschlicherweise\u00a0die\u00a0Diagnose\u00a0Diabetes\u00a0erhalten\u00a0haben.\u00a0 Im\u00a0Rahmen\u00a0des\u00a0\nGesundheitsmonitorings\u00a0 des\u00a0 Robert\u00a0 Koch\u2010Institutes\u00a0 (RKI)\u00a0 durchge f\u00fchrte\u00a0 Befra\u2010\ngung,\u00a0Untersuchungen\u00a0und\u00a0Tests\u00a0von\u00a0ca.\u00a08.000\u00a0Teilnehmern\u00a0im\u00a0Alt er\u00a0zwischen\u00a018\u00a0\nund\u00a079\u00a0Jahren\u00a0ergab,\u00a0dass\u00a0f\u00fcr\u00a07,2\u00a0 %\u00a0der\u00a0deutschen\u00a0Bev\u00f6lkerung\u00a0D iabetes\u00a0vorliegt,\u00a0\n1998\u00a0zeigte\u00a0der\u00a0Bundessurvey\u00a0des\u00a0RKI\u00a0noch\u00a0eine\u00a0Pr\u00e4valenz\u00a0von\u00a05, 2\u00a0%.\u00a0Bezogen\u00a0auf\u00a0\ndie\u00a0Anzahl\u00a0der\u00a0Betroffenen\u00a0entspricht\u00a0das\u00a0einer\u00a0Erh\u00f6hung\u00a0des\u00a0An teils\u00a0um\u00a0etwa\u00a0\n38\u00a0%.\u00a0Etwa\u00a0ein\u00a0Drittel\u00a0des\u00a0beobachteten\u00a0Anstiegs\u00a0ist\u00a0auf\u00a0die\u00a0de mografische\u00a0Alte\u2010\nrung\u00a0 innerhalb\u00a0 des\u00a0 Beobachtungszei traums\u00a0 zur\u00fcckzuf\u00fchren\u00a0 (Heidem ann\u00a0 et\u00a0 al.,\u00a0\n2013).\u00a0Dem\u00a0gr\u00f6\u00dferen\u00a0Teil\u00a0der\u00a0relativen\u00a0Zunahme\u00a0liegen\u00a0daher\u00a0ver mutlich\u00a0Faktoren\u00a0\nwie\u00a0Ver\u00e4nderung\u00a0des\u00a0Lebensstils,\u00a0des\u00a0Wohn\u2010\u00a0und\u00a0Arbeitsumfelds\u00a0o der\u00a0von\u00a0ande\u2010\nren\u00a0Lebensbedingungen\u00a0wie\u00a0z.B.\u00a0U mweltschadstoffen\u00a0zugrunde\u00a0(Tam ayo\u00a0&\u00a0Rath\u2010\nmann,\u00a02016).\u00a0Die\u00a0Erkrankungsh\u00e4ufigkeit\u00a0nimmt\u00a0mit\u00a0dem\u00a0Alter\u00a0zu.\u00a0 W\u00e4hrend\u00a0die\u00a0\nTyp\u20102\u2010Diabetes\u2010Pr\u00e4valenz\u00a0bei\u00a0Bef ragten\u00a0zwischen\u00a040\u00a0und\u00a059\u00a0Jahre n\u00a0zwischen\u00a04\u00a0und\u00a0\n10\u00a0%\u00a0lag,\u00a0stieg\u00a0der\u00a0Wert\u00a0in\u00a0der\u00a0Altersgruppe\u00a0zwischen\u00a070\u00a0und\u00a079 \u00a0Jahren\u00a0auf\u00a0\u00fcber\u00a0\n20\u00a0%\u00a0an\u00a0(Heidemann\u00a0et\u00a0al.,\u00a02013).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDas\u00a0 HARMONY\u2010Studienprogramm\u00a0 umfasst\u00a0 acht\u00a0 zulassungsrelevante\u00a0 Ph ase\u2010III\u2010\nS t u d i e n \u00a0mi t \u00a0i ns g e s a m t \u00a05 . 0 66\u00a0P a t i e n t e n , \u00a0di e \u00a0i n n e r h a l b \u00a0e i ne s \u00a0B e o b achtungszeit\u2010\nraums\u00a0von\u00a0sechs\u00a0Monaten\u00a0bis\u00a0zu\u00a0zwei\u00a0Jahren\u00a0die\u00a0blutzuckersenken de\u00a0Wirksamkeit\u00a0\nvon\u00a0Albiglutid\u00a0untersuchen.\u00a0Gegen\u00fcber\u00a0Placebo\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0d ie\u00a0Monotherapie\u00a0\nmit\u00a030\u00a0mg\u00a0Albiglutid\u00a0eine\u00a0signifikant\u00a0st\u00e4rkere\u00a0Senkung\u00a0des\u00a0HbA1 c\u2010Wertes\u00a0(\u20100.84\u00a0%\u00a0\nvs.\u00a0\u20101.04\u00a0%)\u00a0(Nauck\u00a0et\u00a0al.\u00a02016),\u00a0deren\u00a0Ausma\u00df\u00a0sich\u00a0jedoch\u00a0im\u00a0V ergleich\u00a0zu\u00a0anderen\u00a0\nAntidiabetika\u00a0relativiert.\u00a0Studi en\u00a0zeigten\u00a0f\u00fcr\u00a0Albiglutid\u00a0eine\u00a0 Nicht\u2010Unterlegenheit\u00a0\nbez\u00fcglich\u00a0der\u00a0Reduktion\u00a0des\u00a0HbA1c \u2010Wertes\u00a0zu\u00a0Insulin\u00a0glargin\u00a0(\u20100 ,67\u00a0%\u00a0vs.\u00a0\u20100,79\u00a0%,\u00a0\np=0,0086)\u00a0und\u00a0Insulin\u00a0lispro\u00a0in\u00a0der\u00a0Kombination\u00a0mit\u00a0Insulin\u00a0gla rgin\u00a0(\u20100,82\u00a0vs.\u00a0\u20100,66,\u00a0\np\u00a0<\u00a00,0001).\u00a0Ein\u00a0Vorteil\u00a0zeigt\u00a0sich\u00a0gegen\u00fcber\u00a0Sitagliptin\u00a0(\u20100,6 3\u00a0vs.\u00a0\u20100,28\u00a0p\u00a0<\u00a00,0001)\u00a0\nund\u00a0 Glimepririd\u00a0 (\u20100,63\u00a0 vs.\u00a0 \u20100,36\u00a0 p=0,0033),\u00a0 wohingegen\u00a0 Untersuc hungen\u00a0 eine\u00a0\nUnterlegenheit\u00a0zu\u00a0Pioglitazon\u00a0(\u20100,55\u00a0vs.\u00a0\u20100,80\u00a0NI\u2010p=0,2685)\u00a0und \u00a0Liraglutid\u00a0(\u20100,78\u00a0vs.\u00a0\n\u20100,99,\u00a0NI\u2010p=0,0846\u00a0zeigen\u00a0(EMA,\u00a02014).\u00a0Weiterhin\u00a0best\u00e4tigen\u00a0Stu dien\u00a0zur\u00a0Entwick\u2010\nlung\u00a0des\u00a0K\u00f6rpergewichtes\u00a0unter\u00a0Albiglutid\u00a0eine\u00a0\u00e4hnliche\u00a0Tendenz \u00a0wie\u00a0Placebo\u00a0bzw.\u00a0\neine\u00a0g\u00fcnstigere\u00a0Wirkung\u00a0als\u00a0Sitagliptin,\u00a0Glimepirid,\u00a0Insulin\u00a0gl argin\u00a0und\u00a0lispro.\u00a0Ge\u2010\ngen\u00fcber\u00a0Liraglutid\u00a0zeigt\u00a0es\u00a0sich\u00a0in\u00a0HARMONY\u00a07\u00a0(Pratley\u00a0et\u00a0al.,\u00a0 2014)\u00a0bez\u00fcglich\u00a0des\u00a0\nAusma\u00dfes\u00a0der\u00a0Senkung\u00a0des\u00a0HbA1c\u2010Wertes\u00a0sowie\u00a0der\u00a0Reduktion\u00a0des\u00a0K \u00f6rpergewich\u2010\ntes\u00a0nach\u00a032\u00a0Wochen\u00a0nicht\u00a0\u00fcberlegen\u00a0(0,78\u00a0%\u00a0vs.\u00a0\u20100,99\u00a0%\u00a0NI\u2010p\u00a0=\u00a00 ,0846;\u00a0\u20100,64\u00a0kg\u00a0vs.\u00a0\u2010\n2,19\u00a0kg\u00a0NI\u2010p\u00a0<\u00a00,0001).\u00a0\u00a0\nDer\u00a0 Einfluss\u00a0 auf\u00a0 Folgeerkrankungen\u00a0 wurde\u00a0 bisher\u00a0 nicht\u00a0 abschlie\u00df end\u00a0 gepr\u00fcft\u00a0\n(CDER,\u00a02013)\u00a0In\u00a0diesem\u00a0Zusammenhang\u00a0wird\u00a0aktuell\u00a0eine\u00a0Studie\u00a0na ch\u00a0Auflagen\u00a0der\u00a061\u00a0FDA\u00a0durchgef\u00fchrt,\u00a0die\u00a0verschiedene\u00a0Aspekte\u00a0wie\u00a0das\u00a0Auftreten\u00a0ka rdiovaskul\u00e4rer\u00a0\nEreignisse,\u00a0von\u00a0Schilddr\u00fcsen\u2010\u00a0und\u00a0Pankreaskarzinomen,\u00a0Pankreati den\u00a0etc.\u00a0unter\u2010\nsucht.\u00a0Mit\u00a0Ergebnissen\u00a0kann\u00a0vora ussichtlich\u00a02020\u00a0gerechnet\u00a0werd en\u00a0(FDA,\u00a02013).\u00a0\u00a0\nIn\u00a0 der\u00a0 Gesamtschau\u00a0 der\u00a0 zulassungsbegr\u00fcndenden\u00a0 Studien\u00a0 zeigten\u00a0 s ich\u00a0 sowohl\u00a0\nunter\u00a0Therapie\u00a0mit\u00a0Albiglutid\u00a0als\u00a0auch\u00a0mit\u00a0den\u00a0Komparatoren\u00a0seh r\u00a0h\u00e4ufig\u00a0gastroin\u2010\ntestinale\u00a0 AE\u00a0 wie\u00a0 Durchfall\u00a0 (12,9\u00a0%\u00a0 n=2116\u00a0 vs.\u00a0 9,2\u00a0%;\u00a0 n=2284\u00a0%)\u00a0 und\u00a0 \u00dcbelkeit\u00a0\n(11,5\u00a0%;\u00a0n=2116\u00a0vs.\u00a010,6\u00a0%;\u00a0n=2284)\u00a0und\u00a0Reaktionen\u00a0an\u00a0der\u00a0Einst ichstelle\u00a0(8,8\u00a0%;\u00a0\nn=2116;\u00a02,0\u00a0%;\u00a0n=2284)\u00a0(EMA,\u00a02014).\u00a0Bez\u00fcglich\u00a0des\u00a0Auftretens\u00a0vo n\u00a0Hypoglyk\u00e4mien\u00a0\nergab\u00a0sich\u00a0ein\u00a0Vorteil\u00a0f\u00fcr\u00a0Albi glutid\u00a0gegen\u00fcber\u00a0s\u00e4mtlichen\u00a0Verg leichsmedikationen:\u00a0\n15,8\u00a0%\u00a0(absolut:\u00a045\u00a0Hypoglyk\u00e4mien)\u00a0n=285\u00a0vs.\u00a0Insulin\u00a0lispro\u00a029, 9\u00a0%\u00a0(84)\u00a0n=281;\u00a0\n3,0\u00a0%\u00a0(9)\u00a0n=302\u00a0vs.\u00a0Sitagliptin\u00a01,7\u00a0%\u00a0(5)\u00a0n=302\u00a0vs.\u00a0Glimepirid\u00a0 17,9\u00a0%\u00a0(55)\u00a0n=307,\u00a0\n13,3\u00a0%\u00a0(36)\u00a0n=271\u00a0vs.\u00a0Pioglitazon\u00a024,5\u00a0%\u00a0(68)\u00a0n=277.\u00a0In\u00a0Kombina tion\u00a0mit\u00a0einem\u00a0\nSulfonylharnstoff\u00a0 %)\u00a0 erh\u00f6hte\u00a0 sich\u00a0 die\u00a0 Rate,\u00a0 wie\u00a0 die\u00a0 Ergebnisse\u00a0 der\u00a0 Studie\u00a0\nHARMONY\u00a04\u00a0(Weissmann\u00a0et\u00a0al.,\u00a02014)\u00a020,6\u00a0%\u00a0(85)\u00a0n=413\u00a0vs.\u00a01,1\u00a0%\u00a0 (1)\u00a0n=91\u00a0zeigen.\u00a0\nSchwere\u00a0Unterzuckerungen\u00a0traten\u00a0in\u00a0der\u00a0Gesamt\u00fcbersicht\u00a0selten\u00a0a uf.\u00a0So\u00a0wurden\u00a0\ninnerhalb\u00a0des\u00a0Studienprogramms\u00a0f\u00fcnf\u00a0F\u00e4lle\u00a0dokumentiert.\u00a0Neben\u00a0g astrointestina\u2010\nlen\u00a0Nebenwirkungen\u00a0und\u00a0Hypoglyk\u00e4mien\u00a0hatte\u00a0das\u00a0 Pharmacovigilance\u00a0Risk\u00a0Asses\u2010\nsment\u00a0Committee ,\u00a0PRAC\u00a0der\u00a0EMA\u00a0( European\u00a0Medicines\u00a0Agency ,\u00a0Europ\u00e4ische\u00a0Medi\u2010\nzinagentur)\u00a0anhand\u00a0der\u00a0vorliegenden\u00a0Daten\u00a0die\u00a0akute\u00a0Pankreatiti s\u00a0als\u00a0wichtiges\u00a0\nRisiko\u00a0(Important\u00a0identified\u00a0risk )\u00a0identifiziert.\u00a0Die\u00a0Analyse\u00a0der\u00a0Studienergebnisse\u00a0\ndetektierte\u00a07\u00a0F\u00e4lle\u00a0von\u00a0Pankreatiden\u00a0(2,1\u00a0F\u00e4lle\u00a0je\u00a01.000\u00a0Patien tenjahre).\u00a0Dieser\u00a0\nAspekt\u00a0wurde\u00a0im\u00a0 Risk\u00a0Management\u00a0Plan \u00a0(RMP)\u00a0ber\u00fccksichtigt\u00a0und\u00a0soll\u00a0auch\u00a0Ge\u2010\ngenstand\u00a0der\u00a0Postmarketing\u2010\u00dcberwachung\u00a0sein.\u00a0Auch\u00a0die\u00a0amerikani sche\u00a0Arznei\u2010\nmittelbeh\u00f6rde\u00a0 Food\u00a0and\u00a0Drug\u00a0Administration\u00a0 (FDA)\u00a0teilte\u00a0diese\u00a0Einsch\u00e4tzung\u00a0und\u00a0\ninformierte\u00a0mittels\u00a0eines\u00a0im\u00a0Rahmen\u00a0der\u00a0 Risk\u00a0Evaluation\u00a0and\u00a0Mitigation\u00a0Strategy \u00a0\n(REMS)\u00a0erstellten\u00a0 Factsheets \u00a0Akteure\u00a0des\u00a0Gesundheitssystems\u00a0zu\u00a0dieser\u00a0Problema\u2010\ntik\u00a0(FDA,\u00a02015).\u00a0Weiterhin\u00a0postu lierte\u00a0das\u00a0PRAC\u00a0medull\u00e4re\u00a0Schil ddr\u00fcsenkarzinome\u00a0\nals\u00a0potenzielles\u00a0wichtiges\u00a0Risiko.\u00a0Diese\u00a0Problematik\u00a0wird\u00a0als\u00a0K lasseneffekt\u00a0der\u00a0GLP\u2010\n1\u2010Analoga\u00a0diskutiert.\u00a0Grundlage\u00a0f\u00fcr\u00a0diese\u00a0These\u00a0bilden\u00a0Untersuc hungen\u00a0an\u00a0Nage\u2010\ntierspezies,\u00a0die\u00a0neben\u00a0einem\u00a0Ans tieg\u00a0der\u00a0Cacitonin\u2010Serumkonzent rationen\u00a0C\u2010Zell\u2010\nHyperblasien\u00a0und\u00a0\u2010Tumore\u00a0konstatieren.\u00a0Auch\u00a0f\u00fcr\u00a0Albiglutid\u00a0zeig t\u00a0sich\u00a0ein\u00a0erh\u00f6hter\u00a0\nCalcitonin\u2010Wert,\u00a0sodass\u00a0zwar\u00a0theoretisch\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fc r\u00a0Schilddr\u00fcsentu\u2010\nmore\u00a0besteht,\u00a0aber\u00a0mit\u00a0grunds\u00e4tzlich\u00a0fraglicher\u00a0klinischer\u00a0Rele vanz.\u00a0Daher\u00a0fordern\u00a0\nFDA\u00a0sowie\u00a0der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0Medicinal\u00a0Pro\u2010\nducts\u00a0for\u00a0Human\u00a0Use ,\u00a0CHMP)\u00a0der\u00a0EMA\u00a0die\u00a0Durchf\u00fchrung\u00a0von\u00a0Studien,\u00a0die\u00a0das\u00a0\nkanzerogene\u00a0Potential\u00a0von\u00a0 Albiglutid\u00a0untersuchen.\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0aktuelle\u00a0NVL\u00a0wurde\u00a0unter\u00a0Beteiligung\u00a0verschiedener\u00a0Institut ionen\u00a0erarbeitet.\u00a0\nErstmalig\u00a0 enth\u00e4lt\u00a0 diese\u00a0 einen\u00a0 Th erapiealgorithmus,\u00a0 der\u00a0 zwei\u00a0 unt erschiedliche\u00a062\u00a0Stufenschemata\u00a0 beschreibt\u00a0 und\u00a0 gleicherma\u00dfen\u00a0 empfiehlt\u00a0 (B\u00c4K,\u00a0 KBV ,\u00a0 AWMF,\u00a0\n2013).\u00a0Diese\u00a0Entscheidung\u00a0beruht\u00a0auf\u00a0dem\u00a0Dissens\u00a0zwischen\u00a0der\u00a0A rzneimittel\u2010\nkommission\u00a0der\u00a0Deutschen\u00a0\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0und\u00a0der\u00a0Deutschen\u00a0G esellschaft\u00a0f\u00fcr\u00a0\nAllgemeinmedizin\u00a0und\u00a0F amilienmedizin\u00a0(DEGAM)\u00a0auf\u00a0der\u00a0einen\u00a0und\u00a0 Deutschen\u00a0\nDiabetischen\u00a0Gesellschaft\u00a0(DDG)\u00a0und\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0 f\u00fcr\u00a0Innere\u00a0Medi\u2010\nzin\u00a0(DGIM)\u00a0auf\u00a0der\u00a0anderen\u00a0Seite.\u00a0In\u00a0einem\u00a0Informationsschreibe n\u00a0gehen\u00a0die\u00a0Her\u2010\nausgeber\u00a0auf\u00a0die\u00a0bestehende\u00a0Problematik\u00a0ein\u00a0und\u00a0benennen\u00a0die\u00a0je weiligen\u00a0Be\u2010\nweggr\u00fcnde\u00a0(B\u00c4K,\u00a0KBV,\u00a0AWMF,\u00a02015).\u00a0So\u00a0empfehlen\u00a0Akd\u00c4\u00a0und\u00a0DEGAM\u00a0v orrangig\u00a0\nWirkstoffe,\u00a0die\u00a0in\u00a0Studien\u00a0gezeigt\u00a0haben,\u00a0dass\u00a0sie\u00a0klinische\u00a0En dpunkte\u00a0wirksam\u00a0\nbeeinflussen\u00a0k\u00f6nnen,\u00a0sodass\u00a0ein\u00a0signifikanter\u00a0Einfluss\u00a0auf\u00a0mikr o\u2010\u00a0und/oder\u00a0makro\u2010\nvaskul\u00e4re\u00a0Ereignisse\u00a0belegt\u00a0ist.\u00a0Liegt\u00a0allein\u00a0der\u00a0Nachweis\u00a0f\u00fcr\u00a0 eine\u00a0Senkung\u00a0des\u00a0\nHbA1c\u2010Wertes\u00a0eines\u00a0Wirkstoffes\u00a0vor,\u00a0wird\u00a0dieser\u00a0nachrangig\u00a0empf ohlen,\u00a0da\u00a0f\u00fcr\u00a0die\u00a0\nOrganisationen\u00a0nicht\u00a0ersichtlich\u00a0ist,\u00a0ob\u00a0Folgesch\u00e4den\u00a0des\u00a0Diabe tes\u00a0positiv\u00a0beein\u2010\nflusst\u00a0werden.\u00a0F\u00fcr\u00a0DGIM\u00a0und\u00a0DDG\u00a0hingegen\u00a0ist\u00a0ma\u00dfgeblich,\u00a0dass\u00a0e inige\u00a0neue\u00a0orale\u00a0\nAntidiabetika\u00a0ein\u00a0geringeres\u00a0Ris iko\u00a0f\u00fcr\u00a0Hypoglyk\u00e4mien\u00a0aufweisen \u00a0und\u00a0damit\u00a0ein\u00a0\ng\u00fcnstigeres\u00a0Nebenwirkungsprofil\u00a0 haben\u00a0als\u00a0 Sulfonylharnstoffe,\u00a0d eren\u00a0Wirksam\u2010\nkeitsnachweise\u00a0sie\u00a0dar\u00fcber\u00a0hinaus\u00a0kritisch\u00a0bewerten.\u00a0Einigkeit\u00a0 besteht\u00a0unter\u00a0den\u00a0\nExperten,\u00a0 dass\u00a0 f\u00fcr\u00a0 Patienten,\u00a0 di e\u00a0 das\u00a0 individuell\u00a0 vereinbarte\u00a0 H bA1c\u2010Ziel\u00a0 durch\u00a0\nLebensstil\u00e4nderungen\u00a0nicht\u00a0erreichen\u00a0konnten,\u00a0Metformin\u00a0das\u00a0Mit tel\u00a0der\u00a0ersten\u00a0\nWahl\u00a0ist.\u00a0Bei\u00a0ungen\u00fcgendem\u00a0Ansprechen\u00a0auf\u00a0die\u00a0Monotherapie\u00a0nenn en\u00a0Akd\u00c4\u00a0und\u00a0\nDEGAM\u00a0drei\u00a0m\u00f6gliche\u00a0Therapieopti onen,\u00a0die\u00a0eine\u00a0Kombination\u00a0von\u00a0 Metformin\u00a0mit\u00a0\nInsulin,\u00a0Glibenclamid\u00a0oder\u00a0einem\u00a0Dipeptidypeptidase\u2010Inhibitor\u00a0v orsehen.\u00a0Die\u00a0je\u2010\nweilige\u00a0Kombination\u00a0kann\u00a0bei\u00a0einer\u00a0nicht\u00a0ausreichenden\u00a0Blutzuck ersenkung\u00a0auf\u00a0\neine\u00a0Monotherapie\u00a0mit\u00a0Insulin\u00a0umgestellt\u00a0werden.\u00a0Die\u00a0Entscheidu ng\u00a0f\u00fcr\u00a0einen\u00a0\nBehandlungsalgoriythmus\u00a0wird\u00a0im\u00a0Konsens\u00a0mit\u00a0dem\u00a0Patienten\u00a0nach\u00a0 ausf\u00fchrlicher\u00a0\nDiskussion\u00a0\u00fcber\u00a0m\u00f6gliche\u00a0Vor\u2010\u00a0und\u00a0Nachteile\u00a0getroffen.\u00a0Demgegen \u00fcber\u00a0forcieren\u00a0\ndie\u00a0diabetischen\u00a0Fachgesellschaften\u00a0bei\u00a0erfolgloser\u00a0Metformin\u2010B ehandlung\u00a0eine\u00a0\nnach\u00a0Patientenpr\u00e4ferenzen\u00a0und\u00a0Therapiezielen\u00a0ausgew\u00e4hlte\u00a0Kombin ation\u00a0zweier\u00a0\noraler\u00a0Antidiabetika.\u00a0Prinzipiell\u00a0k\u00f6nnen\u00a0nach\u00a0Ansicht\u00a0der\u00a0diabe tischen\u00a0Fachgesell\u2010\nschaften\u00a0alle\u00a0verf\u00fcgbaren\u00a0Substanzen\u00a0kombiniert\u00a0werden,\u00a0wobei\u00a0d er\u00a0Einsatz\u00a0von\u00a0\nSulfonylharnstoffen\u00a0 aufgrund\u00a0 bes tehender\u00a0 Hinweise\u00a0 auf\u00a0 eine\u00a0 m\u00f6gl icherweise\u00a0\nerh\u00f6hte\u00a0kardiovaskul\u00e4re\u00a0Mortalit\u00e4t\u00a0kritisch\u00a0bewertet\u00a0wird.\u00a0Bei\u00a0 unzureichendem\u00a0\nErfolg\u00a0sieht\u00a0die\u00a0Empfehlung\u00a0der\u00a0b eiden\u00a0Fachgesellschaften\u00a0eine\u00a0 Dreierkombination\u00a0\nverschiedener\u00a0Antidiabetika\u00a0einschlie\u00dflich\u00a0der\u00a0GLP\u20101\u00a0Agonisten\u00a0 oder\u00a0die\u00a0Umstel\u2010\nlung\u00a0auf\u00a0eine\u00a0Monotherapie\u00a0mit\u00a0Insulin\u00a0vor.\u00a0Albiglutid\u00a0erhielt\u00a0 erst\u00a02014\u00a0die\u00a0Zulas\u2010\nsung,\u00a0sodass\u00a0der\u00a0Wirkstoff\u00a0nicht\u00a0in\u00a0der\u00a0Leitlinie\u00a0ber\u00fccksichtig t\u00a0wurde.\u00a0\nGLP\u20101\u00a0Agonisten\u00a0listet\u00a0die\u00a0NVL\u00a0als\u00a0Arzneimittel\u00a0ohne\u00a0gesicherte \u00a0g\u00fcnstige\u00a0Beeinflus\u2010\nsung\u00a0klinischer\u00a0Endpunkte.\u00a0Zwar\u00a0zeigten\u00a0klinische\u00a0Studien\u00a0neben \u00a0einer\u00a0Gewichts\u2010\nabnahme\u00a0f\u00fcr\u00a0alle\u00a0Verbindungen\u00a0eine\u00a0Senkung\u00a0des\u00a0Hb1Ac\u2010Werts;\u00a0Dat en\u00a0zu\u00a0diabe\u2010\ntesbedingten\u00a0 Komplikationen,\u00a0 zur \u00a0 kardiovaskul\u00e4ren\u00a0 Morbidit\u00e4t\u00a0 un d\u00a0 Mortalit\u00e4t\u00a063\u00a0oder\u00a0zur\u00a0Gesamtsterblichkeit\u00a0liegen\u00a0jedoch\u00a0nicht\u00a0vor.\u00a0Die\u00a0NVL\u00a0w urde\u00a0im\u00a0August\u00a0\n2013\u00a0ver\u00f6ffentlicht\u00a0und\u00a0zuletzt\u00a0im\u00a0November\u00a02014\u00a0aktualisiert.\u00a0 Folglich\u00a0reflektie\u2010\nren\u00a0die\u00a0formulierten\u00a0Empfehlungen\u00a0nicht\u00a0in\u00a0allen\u00a0Punkten\u00a0die\u00a0de rzeitige\u00a0Evidenz.\u00a0\nIn\u00a0der\u00a02016\u00a0ver\u00f6ffentlichten\u00a0LEADER\u2010Studie\u00a0(Marso\u00a0et\u00a0al.,\u00a02016) \u00a0verbesserte\u00a0die\u00a0\nTherapie\u00a0 mit\u00a0 Liraglutid\u00a0 kardiovaskul\u00e4re\u00a0 Endpunkte\u00a0 und\u00a0 f\u00fchrte\u00a0 im \u00a0 Vergleich\u00a0 zu\u00a0\nPlacebo\u00a0 zu\u00a0 einer\u00a0 Reduktion\u00a0 der\u00a0 G esamttodesf\u00e4lle\u00a0 (Absolute\u00a0 Risik o\u00a0 Reduktion,\u00a0\nARR=1,4\u00a0%,\u00a0 NNT=\u00a0 72,\u00a0 p=0,007)\u00a0 sowie\u00a0 des\u00a0 kardiovaskul\u00e4r\u00a0 bedingten \u00a0T o d e s \u00a0\n(ARR=1,3%,\u00a0NNT=80,\u00a0p=0,02).\u00a0\u00a0Auch\u00a0die\u00a0Einsch\u00e4tzung\u00a0des\u00a0Einsatze s\u00a0von\u00a0Sulfonyl\u2010\nharnstoffen\u00a0 bedarf\u00a0 einer\u00a0 Aktua lisierung.\u00a0 Bereits\u00a0 2013\u00a0 ver\u00f6ffent lichten\u00a0 Hem\u2010\nmingsen\u00a0et\u00a0al.\u00a0einen\u00a0Cochrane\u2010\u00a0R eview,\u00a0in\u00a0dem\u00a0die\u00a0Autoren\u00a0Sulfo nylharnstoffen\u00a0\ngegen\u00fcber\u00a0Metformin\u00a0weniger\u00a0nicht\u00a0 t\u00f6dliche\u00a0makrovaskul\u00e4re\u00a0Kompl ikationen\u00a0(RR\u00a0\n0.67,\u00a095%\u00a0CI\u00a00.48\u00a0to\u00a00.93;\u00a0P=0.02;\u00a0n=3018;\u00a03\u00a0Studien)\u00a0sowie\u00a0kei ne\u00a0signifikanten\u00a0\nUnterschiede\u00a0bez\u00fcglich\u00a0der\u00a0kardiovaskul\u00e4ren\u00a0Tode\u00a0(RR\u00a01.47;\u00a095%\u00a0 CI\u00a00.54\u00a0to\u00a04.01;\u00a0\nP=0.45;\u00a0n=3528;\u00a06\u00a0Studien)\u00a0postulierten.\u00a0Auch\u00a0eine\u00a0weitere\u00a0\u00dcber sichtsarbeit\u00a0(Pal\u2010\nmer\u00a0et\u00a0al.,\u00a02016)\u00a0formulierte\u00a0keinen\u00a0Nachteil\u00a0im\u00a0Vergleich\u00a0zu\u00a0a nderen\u00a0Antidiabeti\u2010\nka.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nAlbiglutid\u00a0wurde\u00a0im\u00a0Jahr\u00a02015\u00a0de m\u00a0Verfahren\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbe wertung\u00a0unter\u2010\nzogen\u00a0(GBA,\u00a02015).\u00a0Diese\u00a0erfolgte\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0von\u00a0den\u00a0Thera pieregimen.\u00a0F\u00fcr\u00a0\ndie\u00a0Monotherapie\u00a0wurde\u00a0eine\u00a0Behandlung\u00a0mit\u00a0einem\u00a0Sulfonylharnst off\u00a0als\u00a0zVT\u00a0\nfestgelegt.\u00a0Der\u00a0Vergleich\u00a0der\u00a0Ko mbination\u00a0mit\u00a0Metformin\u00a0oder\u00a0an deren\u00a0Antidiabe\u2010\ntika\u00a0au\u00dfer\u00a0Insulin\u00a0erfolgte\u00a0gege n\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Metformin \u00a0und\u00a0einem\u00a0Sul\u2010\nfonylharnstoff.\u00a0Weiterhin\u00a0wurde\u00a0die\u00a0 Add\u2010on\u2010Therapie\u00a0von\u00a0Albiglutid\u00a0mit\u00a0mindes\u2010\ntens\u00a0zwei\u00a0weiteren\u00a0blutzuckersenkenden\u00a0Arzneimitteln\u00a0bzw.\u00a0mit\u00a0I nsulin\u00a0mit\u00a0oder\u00a0\nohne\u00a0andere\u00a0Antidiabetika\u00a0einer \u00a0Therapie\u00a0mit\u00a0Metformin\u00a0und\u00a0Huma ninsulin\u00a0ge\u2010\ngen\u00fcbergestellt.\u00a0\nLediglich\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0vo n\u00a0Albiglutid\u00a0und\u00a0Metformin\u00a0legt e\u00a0der\u00a0pU\u00a0eine\u00a0\nStudie\u00a0vor,\u00a0die\u00a0vom\u00a0G\u2010BA\u00a0als\u00a0Basis\u00a0f\u00fcr\u00a0die\u00a0Quantifizierung\u00a0des\u00a0 Zusatznutzens\u00a0her\u2010\nangezogen\u00a0werden\u00a0konnte.\u00a0Im\u00a0Rahmen\u00a0der\u00a0zulassungsrelevanten,\u00a0do ppelblinden,\u00a0\nrandomisierten\u00a0Phase\u00a0III\u00a0Studie\u00a0HA RMONY\u00a03\u00a0(Ahren\u00a0et\u00a0al.,\u00a02014)\u00a0 wurden\u00a0die\u00a0Kom\u2010\nbinationen\u00a0Albiglutid\u00a0plus\u00a0Metformin\u00a0mit\u00a0Glimepirid\u00a0plus\u00a0Metfor min\u00a0verglichen.\u00a0\nHinsichtlich\u00a0der\u00a0Kriterien\u00a0Mortalit\u00e4t\u00a0und\u00a0Morbidit\u00e4t\u00a0ergaben\u00a0si ch\u00a0keine\u00a0signifikan\u2010\nten\u00a0Unterschiede.\u00a0Die\u00a0Reduktion\u00a0des\u00a0HbA1c\u00a0betrug\u00a0in\u00a0beiden\u00a0Inte rventionsgrup\u2010\npen\u00a00,8\u00a0%\u00a0nach\u00a016\u00a0Wochen.\u00a0Erst\u00a0im\u00a0weiteren\u00a0Beobachtungsverlauf\u00a0 differierten\u00a0die\u00a0\nEffekte,\u00a0so\u00a0ist\u00a0ab\u00a0Woche\u00a024\u00a0eine\u00a0ausgepr\u00e4gtere\u00a0Senkung\u00a0des\u00a0Blut zuckers\u00a0innerhalb\u00a0\nder\u00a0Albiglutid\u2010Gruppe\u00a0dokumentiert.\u00a0F\u00fcr\u00a0den\u00a0Endpunkt\u00a0Nebenwirku ngen\u00a0ergaben\u00a0\nsich\u00a0sowohl\u00a0positive\u00a0als\u00a0auch\u00a0negative\u00a0Effekte\u00a0durch\u00a0Albiglutid .\u00a0So\u00a0zeigte\u00a0sich\u00a0im\u00a0\nAlbiglutid/Metformin\u2010Studienarm\u00a0 eine\u00a0 geringere\u00a0 Anzahl\u00a0 an\u00a0 nicht\u2010 schweren\u00a0 Hy\u2010\npoglyk\u00e4mien\u00a0 (Blutzucker\u00a0 \u2264\u00a0 54\u00a0mg/d l)\u00a0 gegen\u00fcber\u00a0 der\u00a0 Kombination\u00a0 G limepi\u201064\u00a0rid/Metformin\u00a0(3\u00a0(1,0\u00a0%)\u00a0n=302\u00a0vs.\u00a024\u00a0(7,8\u00a0%)\u00a0n=307;\u00a0RR=0,13,\u00a09 5\u00a0%\u2010KI\u00a0[0,04;\u00a00,42],\u00a0\np\u00a0<\u00a00,00113)(IQWiG,\u00a02014),\u00a0der\u00a0ei n\u00a0vergleichsweise\u00a0h\u00f6heres\u00a0Auft reten\u00a0von\u00a0Reakti\u2010\nonen\u00a0an\u00a0der\u00a0Einstichstelle\u00a0gegen\u00fcbersteht\u00a0(55\u00a0(18,2\u00a0%)\u00a0vs.\u00a026\u00a0( 8,5\u00a0%);\u00a0RR=2,15,\u00a0\n95\u00a0%\u2010KI\u00a0[1,39;\u00a03,33]12,\u00a0p\u00a0<\u00a00,00113)\u00a0(IQWiG,\u00a02014).\u00a0Aus\u00a0Sicht\u00a0d es\u00a0G\u2010BA\u00a0mindert\u00a0\ndieser\u00a0Schaden\u00a0nach\u00a0Abw\u00e4gung\u00a0der\u00a0jeweiligen\u00a0klinischen\u00a0Relevanz \u00a0nicht\u00a0den\u00a0fest\u2010\ngestellten\u00a0Vorteil,\u00a0sodass\u00a0der\u00a0Ausschuss\u00a0einen\u00a0Hinweis\u00a0auf\u00a0eine n\u00a0geringen\u00a0Zusatz\u2010\nnutzen\u00a0feststellte.\u00a0Langzeitdaten\u00a0\u00fcber\u00a0die\u00a0Studiendauer\u00a0von\u00a0164 \u00a0Wochen\u00a0hinaus\u00a0\nfehlen.\u00a0F\u00fcr\u00a0alle\u00a0anderen\u00a0Kombinationstherapien\u00a0sowie\u00a0die\u00a0Monoth erapie\u00a0legte\u00a0der\u00a0\npU\u00a0keine\u00a0Studien\u00a0vor.\u00a0Folglich\u00a0gilt\u00a0f\u00fcr\u00a0die\u00a0betreffenden\u00a0Therap ieregime\u00a0einen\u00a0Zu\u2010\nsatznutzen\u00a0als\u00a0nicht\u00a0belegt.\u00a0\nEine\u00a0Versorgungsanalyse\u00a0entf\u00e4llt\u00a0aufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0v on\u00a0mit\u00a0Albiglutid\u00a0\nbehandelten\u00a0Versicherten\u00a0aus\u00a0datenschutzrechtlichen\u00a0Gr\u00fcnden.\u00a0\nQuellen\u00a0\nAhr\u00e9n\u00a0B,\u00a0Johnson\u00a0SL,\u00a0Stewart\u00a0M,\u00a0Cirkel\u00a0DT,\u00a0Yang\u00a0F,\u00a0Perry\u00a0C\u00a0et\u00a0a l.\u00a0(2014).\u00a0HARMONY\u00a03:\u00a0104\u2010week\u00a0randomized,\u00a0double\u2010blind,\u00a0\nplacebo\u2010\u00a0and\u00a0active\u2010controlled\u00a0trial\u00a0assessing\u00a0the\u00a0efficacy\u00a0and \u00a0safety\u00a0of\u00a0albiglutide\u00a0compared\u00a0with\u00a0placebo,\u00a0\nsitagliptin,\u00a0and\u00a0glimepiride\u00a0in\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes\u00a0t aking\u00a0metformin.\u00a0Diabetes\u00a0care\u00a037\u00a0(8):\u00a02141\u20102148.\u00a0\u00a0\nAstra\u00a0Zeneca\u00a0(2016):\u00a0Fachinformation\u00a0Byetta\u00ae.\u00a0Stand\u00a0der\u00a0Informa tion:\u00a0Juli\u00a02016.\u00a0www.fachinfo.de/ pdf/010031,\u00a0letzter\u00a0Zugriff:\u00a0\n10.02.2017\u00a0\na\u2010t\u2013\u00a0arzneimittel\u2010telegramm\u00a0(2015).\u00a0Arzneimitteldatenbank\u00a0Albig lutid.\u00a0Stand\u00a0der\u00a0Information:\u00a0M \u00e4rz\u00a02015.\u00a0https://www.arznei\u2010\ntelegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Albiglutid& ord=uaw,\u00a0letzter\u00a0Zugriff:\u00a016.06.2017.\u00a0\nB\u00c4K\u00a0\u2013\u00a0Bundes\u00e4rztekammer,\u00a0Kassen\u00e4rz tliche\u00a0Bundesvereinigung\u00a0(KBV ),\u00a0Arbeitsgemeinschaft\u00a0der\u00a0Wissenschaftlichen\u00a0Medizinischen\u00a0\nFachgesellschaften\u00a0(AWMF)\u00a0(2015):\u00a0NVL\u2010INFO\u00a02015/1.\u00a0Therapie\u00a0des \u00a0Typ\u20102\u2010Diabetes\u00a0\u2013\u00a0Uneinigkeit\u00a0bei\u00a0den\u00a0\nMedikamenten?\u00a0\nDMP\u2010(2016\u00a0)Qualit\u00e4tssicherungsbericht\u00a02015\u00a0\u2013\u00a0KVNo,\u00a0https://www. kvno.de/downloads/quali/qualbe_dmp15.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n18.09.17.\u00a0\nEli\u00a0Lilly\u00a0Nederland\u00a0(2016):\u00a0Fachin formation\u00a0Trulicity\u00ae.\u00a0Stand\u00a0d er\u00a0Information:\u00a0Dezember\u00a02016. \u00a0www.fachinfo.de/pdf/020484,\u00a0\nletzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2014).\u00a0Committee\u00a0for\u00a0Medical\u00a0P roducts\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP):\u00a0International\u00a0Nonproprietary\u00a0\nUse\u00a0(INN)\u2010Albiglutide.\u00a0 www.ema.europa.eu/.../de_DE/ document_library/EPAR_\u2010\n_Product_Information/human/002735/WC500165117.pdf ,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nFachinformation\u00a0Byetta\u00ae(2016).\u00a0Fachinformation\u00a0Byetta\u00ae.\u00a0Stand\u00a0d er\u00a0Information:\u00a0Juli\u00a02016.\u00a0 www.fachinfo.de/pdf/010031 ,\u00a0letzter\u00a0\nZugriff:\u00a010.02.2017.\u00a0\nFachinformation\u00a0Eperzan\u00ae\u00a0(2016).\u00a0 Fachinformation.\u00a0Stand\u00a0der\u00a0Inf ormation:\u00a0Juli\u00a02016.\u00a0 https://us.gsk.com/media/390947/Harmony\u2010\nClinical\u2010Trial\u2010Medical \u2010Media\u2010Factsheet.pdf ,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nFDA\u00a0\u2013\u00a0U.S.\u00a0Food\u00a0and\u00a0Drug\u00a0Adminis tration\u00a0(2013).\u00a0Postmarket\u00a0Requ irements\u00a0and\u00a0Commitments.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a0\n2013.\u00a0www.accessdata.fda.gov/scripts/cder/pmc/index.cfm ,\u00a0letzter\u00a0Zugriff:\u00a008.02.2017.\u00a065\u00a0FDA\u00a0\u2013\u00a0U.S.\u00a0Food\u00a0and\u00a0Drug\u00a0Administration,\u00a0CDER\u00a0\u2013\u00a0Center\u00a0for\u00a0Drug \u00a0Evaluation\u00a0and\u00a0Research\u00a0(2013).\u00a0Application\u00a0Number:\u00a0\n125431Orig1s000.\u00a0Summary\u00a0Review.\u00a0Albiglutide\u00a0(TANZEUM).\u00a0https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431o rig1s000sumr.pdf ,\u00a0letzter\u00a0Zugriff:\u00a026.04.2017\u00a0\nFDA\u00a0\u2013\u00a0U.S.\u00a0Food\u00a0and\u00a0Drug\u00a0Adminis tration,\u00a0GSK\u00a0\u2013\u00a0GlaxoSmithKline\u00a0 LLC\u00a0(2014).\u00a0Tanzeum\u00ae\u00a0Risk\u00a0Evaluation\u00a0and\u00a0Mitigation\u00a0Strategy\u00a0\n(REMS).\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02014.\u00a0https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?even t=IndvRemsDetails.page&REMS=316 ,\u00a0letzter\u00a0\nZugriff:\u00a010.02.2017\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Albiglutid.\u00a0Stand\u00a0der\u00a0Information:\u00a0\nJanuar\u00a02015.\u00a0 https://www.g\u2010ba.de/informationen/nutzenbewertung/140/#tab/besc hluesse,\u00a0letzter\u00a0Zugriff:\u00a0\n08.09.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Albiglutid\u00a0Stand\u00a0der\u00a0I nformation:\u00a0M\u00e4rz\u00a02015.\u00a0 https://www.g\u2010\nba.de/downloads/40\u2010268\u20103159/2015\u201003\u201019_AM\u2010RL\u2010XII_Albiglutid_201 4\u201010\u201001\u2010D\u2010132_TrG.pdf ,\u00a0letzter\u00a0Zugriff:\u00a0\n21.06.2017.\u00a0\nHeidemann\u00a0C,\u00a0Du\u00a0Y,\u00a0Schubert\u00a0I,\u00a0Rathmann\u00a0W,\u00a0Scheidt\u2010Nave\u00a0C\u00a0(2013 ).\u00a0Pr\u00e4valenz\u00a0und\u00a0zeitliche\u00a0Entwicklung\u00a0des\u00a0bekannten\u00a0Diabetes\u00a0\nmellitus:\u00a0Ergebnisse\u00a0der\u00a0Studie\u00a0zur\u00a0Gesundheit\u00a0Erwachsener\u00a0in\u00a0D eutschland\u00a0(DEGS1).\u00a0Bundesgesundheitsblatt,\u00a0\nGesundheitsforschung,\u00a0Gesundheitsschutz\u00a056\u00a0(5\u20106):\u00a0668\u2010677.\u00a0\u00a0\nHemmingsen\u00a0B,\u00a0Schroll\u00a0JB,\u00a0Lund\u00a0SS,\u00a0Wetterslev\u00a0J,\u00a0Gluud\u00a0C,\u00a0Vaag\u00a0 A,\u00a0Sonne\u00a0DP,\u00a0Lundstr\u00f8m\u00a0LH,\u00a0Almdal\u00a0T\u00a0(2013).\u00a0Sulphonylu\u2010rea\u00a0\nmonotherapy\u00a0for\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes\u00a0mellitus.\u00a0Cochran e\u00a0Database\u00a0Syst\u00a0Rev.\u00a02013\u00a0Apr\u00a030;4:CD009008.\u00a0\nIDF\u00a0\u2013\u00a0International\u00a0Diabetes\u00a0Federation\u00a0(2015):\u00a0IDF\u00a0Diabetes\u00a0At las.\u00a0http://www.diabetesatlas.org/resources/2015\u2010atlas.html ,\u00a0\nletzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nInzucchi\u00a0SE,\u00a0Bergenstal\u00a0RM,\u00a0Buse\u00a0JB,\u00a0Diamant\u00a0M,\u00a0Ferrannini\u00a0E,\u00a0N auck\u00a0M\u00a0et\u00a0al.\u00a0(2012).\u00a0Management\u00a0of\u00a0hyperglycaemia\u00a0in\u00a0type\u00a02\u00a0\ndiabetes:\u00a0a\u00a0patient\u2010centered\u00a0approach.\u00a0Position\u00a0statement\u00a0of\u00a0th e\u00a0American\u00a0Diabetes\u00a0Association\u00a0(ADA)\u00a0and\u00a0the\u00a0\nEuropean\u00a0Association\u00a0for\u00a0the\u00a0Study\u00a0of\u00a0Diabetes\u00a0(EASD).\u00a0Diabetol ogia,\u00a055(6):\u00a01577\u20101596.\u00a0\nIQWiG,\u00a0Nutzenbewertung\u00a0A\u00a014\u201036\u00a0vom\u00a023.\u00a0Dezember\u00a02014.\u00a0Marso\u00a0SP,\u00a0Daniels\u00a0GH,\u00a0Brown\u2010Frandsen\u00a0K,\u00a0Kristensen\u00a0P,\u00a0Mann\u00a0JF,\u00a0 Nauck\u00a0MA,\u00a0Nissen\u00a0SE,\u00a0Pocock\u00a0S,\u00a0Poulter\u00a0NR,\u00a0Ravn\u00a0LS,\u00a0Stein\u2010berg\u00a0\nWM,\u00a0Stockner\u00a0M,\u00a0Zinman\u00a0B,\u00a0Bergenstal\u00a0RM,\u00a0Buse\u00a0JB;\u00a0LEADER\u00a0Steeri ng\u00a0Committee;\u00a0LEADER\u00a0Trial\u00a0Investigators.\u00a0N\u00a0Engl\u00a0\nJ\u00a0Med.\u00a02016\u00a0Jul\u00a028;375(4):311\u201022.\u00a0\u00a0\nNauck\u00a0MA,\u00a0Stewart\u00a0MW,\u00a0Perkins\u00a0C, \u00a0Jones\u2010Leone\u00a0A,\u00a0Yang\u00a0F,\u00a0Perry\u00a0C \u00a0et\u00a0al.\u00a0(2016):\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0once\u2010weekly\u00a0GLP\u20101\u00a0recept or\u00a0\nagonist\u00a0albiglutide\u00a0(HARMONY\u00a02):\u00a052\u00a0week\u00a0primary\u00a0endpoint\u00a0resul ts\u00a0from\u00a0a\u00a0randomised,\u00a0placebo\u2010controlled\u00a0trial\u00a0in\u00a0\npatients\u00a0with\u00a0type\u00a02\u00a0diabetes\u00a0 mellitus\u00a0inadequately\u00a0controlled\u00a0 with\u00a0diet\u00a0and\u00a0exercise.\u00a0Diabetologia\u00a059\u00a0(2):\u00a0266\u2010274.\u00a0\nNauck,\u00a0M.\u00a0A.;\u00a0Vardarli,\u00a0I.;\u00a0Deacon,\u00a0C.\u00a0F.;\u00a0Holst,\u00a0J.\u00a0J.;\u00a0Meier, \u00a0J.\u00a0J.\u00a0(2011):\u00a0Secretion\u00a0of\u00a0gluca gon\u2010like\u00a0peptide\u20101\u00a0(GLP\u20101)\u00a0in\u00a0 type\u00a02\u00a0\ndiabetes:\u00a0what\u00a0is\u00a0up,\u00a0what\u00a0is\u00a0do wn?\u00a0In:\u00a0Diabetologia\u00a054\u00a0(1),\u00a0S. \u00a010\u201318.\u00a0DOI:\u00a010.1007/s00125\u2010010\u20101896\u20104.\u00a0\nNovo\u00a0Nordisk\u00a0(2016):\u00a0Fachinformation\u00a0Victoza\u00ae.\u00a0Stand\u00a0der\u00a0Inform ation:\u00a0September\u00a02016.\u00a0\nhttps://www.google.de/search?q=Fachinformation+Victoza&ie=utf\u20108 &oe=utf\u20108&client=firefox\u2010b&gfe_rd=cr&ei=S\u2010\nOdWIC0Kaer8weBko_wCg#, \u00a0Letzter\u00a0Zugriff:\u00a010.02.2017\u00a0\nNVL\u00a0\u2013\u00a0Nationale\u00a0Versorgungsleitlinie\u00a0(2013).\u00a0Therapie\u00a0des\u00a0Typ\u20102 \u2010Diabetes.\u00a0Langfassung.\u00a0Stand\u00a0der\u00a0Information:\u00a0November\u00a02014.\u00a0\nAWMF\u2010Register\u00a0Nr.:\u00a0nvl\u2010001gIn.\u00a0 www.leitlinien.de/mdb/downloads/nvl/diabetes\u2010mellitus/dm\u2010therap ie\u20101aufl\u2010vers4\u2010\nlang.pdf,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a066\u00a0Palmer\u00a0SC1\u00a0et\u00a0al\u00a0Comparison\u00a0of\u00a0Clinical\u00a0Outcomes\u00a0and\u00a0Adverse\u00a0Ev ents\u00a0Associated\u00a0With\u00a0Glucose\u2010Low ering\u00a0Drugs\u00a0in\u00a0Patients\u00a0With\u00a0\nType\u00a02\u00a0Diabetes:\u00a0A\u00a0Meta\u2010analysis.\u00a0JAMA.\u00a02016\u00a0Jul\u00a019;316(3):313\u2010 24.\u00a0\u00a0\nPratley\u00a0RE,\u00a0Nauck\u00a0MA,\u00a0Barnett\u00a0AH ,\u00a0Feinglos\u00a0MN,\u00a0Ovalle\u00a0F,\u00a0Harman \u2010Boehm\u00a0I\u00a0et\u00a0al.\u00a0(2014).\u00a0Once\u2010weekly\u00a0albiglutide\u00a0versus\u00a0once\u2010dai ly\u00a0\nliraglutide\u00a0in\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes\u00a0inadequately\u00a0contr olled\u00a0on\u00a0oral\u00a0drugs\u00a0(HARMONY\u00a07):\u00a0a\u00a0randomised,\u00a0\nopen\u2010label,\u00a0multicentre,\u00a0non\u2010inf eriority\u00a0phase\u00a03\u00a0study.\u00a0HARMONY \u00a07.\u00a0Lancet\u00a0Diabetes\u00a0Endocrinol\u00a02(4):\u00a0289\u2010297.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Albiglutid.\u00a0Eperzan\u00ae.12\u00a0I\u00a02014.\u00a0www.pharmazeutische\u2010\nzeitung.de/?id=54980,\u00a0letzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nTamayo,\u00a0Teresa;\u00a0Rathmann,\u00a0Wolfgan g:\u00a0Epidemiologie\u00a0des\u00a0Diabetes\u00a0 in\u00a0Deutschland.\u00a0In:\u00a0Deutscher\u00a0Gesundheitsbericht\u00a02016.\u00a0\nhttps://www.diabetesde.org/system/files/documents/fileadmin/use rs/Patientenseite/PDFs_und_TEXTE/Infomateri\nal/Gesundheitsbericht_2016.pdf ,\u00a0letzter\u00a0Zugriff:\u00a018.09.2017.\u00a0\nTrujillo\u00a0JM,\u00a0Nuffer\u00a0W,\u00a0Ellis\u00a0SL\u00a0( 2015).\u00a0GLP\u20101\u00a0receptor\u00a0agonists :\u00a0a\u00a0review\u00a0of\u00a0head\u2010to\u2010head\u00a0clinical\u00a0studies.\u00a0Therapeutic\u00a0Advanc es\u00a0in\u00a0\nEndocrinology\u00a0and\u00a0Metabolism\u00a06(1):\u00a019\u201028.\u00a0\nWeissman\u00a0PN,\u00a0Carr\u00a0MC,\u00a0Ye\u00a0J,\u00a0Cirkel\u00a0DT,\u00a0Stewart\u00a0M,\u00a0Perry\u00a0C,\u00a0Prat ley\u00a0R.\u00a0HARMONY\u00a04:\u00a0randomised\u00a0clinical\u00a0trial\u00a0comparing\u00a0once\u2010\nweekly\u00a0albiglutide\u00a0and\u00a0insulin\u00a0glargine\u00a0in\u00a0patients\u00a0with\u00a0type\u00a02 \u00a0diabetes\u00a0inadequately\u00a0controlled\u00a0with\u00a0metformin\u00a0with\u00a0\nor\u00a0without\u00a0sulfonylurea.\u00a0Diabetologia.\u00a02014\u00a0Dec;57(12):2475\u201084. \u00a0\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2016).\u00a010\u00a0facts\u00a0on\u00a0diabetes.\u00a0w ww.who.int/features/factfiles/diabetes/en/,\u00a0letzter\u00a0Zugriff:\u00a0\n15.06.2017.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2017).\u00a0Diabetes\u00a0country\u00a0profil es\u00a02016.\u00a0www.who.int/entity/diabetes/country\u2010profiles/\u00a0\ndeu_en.pdf?ua=1,\u00a0letzter\u00a0Zugriff:\u00a015.06.2017.\u00a0\n\u00a0\u00a067\u00a04.2 Alipogentiparvovec\u00a0\nHandelsname:\u00a0Glybera\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0fam.\u00a0Lipoproteinlipas edefizienz\u00a0 uniQure\u00a0biopharma\u00a0B .V.,\u00a0Vertrieb\u00a0\nbei\u00a0Erwachsenen\u00a0\u00a0 \u00a0 \u00a0 \u00fcber\u00a0Chiesi\u00a0GmbH\u00a0\nATC\u2010Code:\u00a0C10AX10\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0November\u00a02014\u00a0\nDarreichungsform:\u00a0Injektion sl\u00f6sung\u00a0\u00a0 DDD:\u00a024\u00a0DE\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0E\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0Zulassungserteilung\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Commissi\u2010\non,\u00a0EC)\u00a0stand\u00a0mit\u00a0Alipogentiparvov ec\u00a0das\u00a0erste\u00a0Gentherapeutikum\u00a0i n\u00a0der\u00a0westli\u2010\nchen\u00a0Welt\u00a0zur\u00a0Verf\u00fcgung.\u00a0Dazu\u00a0wa ren\u00a0zwei\u00a0Bewertungsverfahren\u00a0no twendig,\u00a0da\u00a0\nsich\u00a0der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0 for\u00a0Medical\u00a0Products\u00a0of\u00a0\nHuman\u00a0Use ,\u00a0CHMP)\u00a0zun\u00e4chst\u00a0gegen\u00a0eine\u00a0Empf ehlung\u00a0zur\u00a0Zulassung\u00a0ausgesproc hen\u00a0\nhatte.\u00a0Im\u00a0zweiten\u00a0Anlauf\u00a0revidierten\u00a0die\u00a0Experten\u00a0ihre\u00a0Entschei dung,\u00a0forderten\u00a0\njedoch\u00a0eine\u00a0\u201eZulassung\u00a0unter\u00a0besonderen\u00a0Umst\u00e4nden\u201c\u00a0( Approval\u00a0Under\u00a0Exceptio\u2010\nnal\u00a0Circumstances )\u00a0(CHMP,\u00a02012).\u00a0Die\u00a0von\u00a0der\u00a0EC\u00a0best\u00e4tigte\u00a0Indikation\u00a0ist\u00a0die\u00a0fa mi\u2010\nli\u00e4re\u00a0Lipoproteinlipasedefizienz\u00a0(LPLD)\u00a0bei\u00a0erwachsenen\u00a0Patient en,\u00a0bei\u00a0denen\u00a0trotz\u00a0\nfettarmer\u00a0Ern\u00e4hrung\u00a0schwere\u00a0oder\u00a0multiple\u00a0Pankreatitissch\u00fcbe\u00a0au ftreten.\u00a0Dabei\u00a0\nm\u00fcssen\u00a0sowohl\u00a0die\u00a0Diagnose\u00a0durch\u00a0einen\u00a0Gentest\u00a0abgesichert\u00a0als\u00a0 auch\u00a0nachweis\u2010\nbare\u00a0Mengen\u00a0von\u00a0Lipoprotein\u2010Lipa se\u00a0(LPL)\u00a0beim\u00a0Patienten\u00a0vorhand en\u00a0sein\u00a0(Fachin\u2010\nformation\u00a0Glybera\u00ae,\u00a02012).\u00a0Der\u00a0Wirkstoff\u00a0mit\u00a0 Orphan\u00a0Designation\u00a0 (Ausweisung\u00a0als\u00a0\nArzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden)\u00a0(EU/3/04/194)\u00a0bietet\u00a0den\u00a0erste n\u00a0kurativen\u00a0Be\u2010\nhandlungsansatz\u00a0f\u00fcr\u00a0die\u00a0mit\u00a0einer\u00a0Pr\u00e4valenz\u00a0von\u00a01:1.000.000\u00a0seh r\u00a0seltene\u00a0Erkran\u2010\nkung.\u00a0Dieser\u00a0liegt\u00a0eine\u00a0autosomal\u00a0rezessiv\u00a0vererbte\u00a0Mutation\u00a0de s\u00a0LPL\u2010Gens\u00a0zu\u2010\ngrunde,\u00a0die\u00a0einen\u00a0partiellen\u00a0oder\u00a0vollst\u00e4ndigen\u00a0Funktionsverlus t\u00a0des\u00a0Enzyms\u00a0LPL\u00a0\nbewirkt.\u00a0LPL\u00a0wird\u00a0im\u00a0Muskel\u00a0und\u00a0Fettgewebe\u00a0exprimiert\u00a0und\u00a0ist\u00a0m a\u00dfgeblich\u00a0am\u00a0\nMetabolismus\u00a0einiger\u00a0Lipoproteine ,\u00a0insbesondere\u00a0von\u00a0Chylomikron en,\u00a0beteiligt.\u00a0\nPhysiologisch\u00a0hydrolysiert\u00a0LPL\u00a0Triglyceride\u00a0aus\u00a0den\u00a0Lipoprotein partikeln\u00a0zu\u00a0freien\u00a0\nFetts\u00e4uren,\u00a0die\u00a0im\u00a0Muskel\u00a0der\u00a0Energiegewinnung\u00a0dienen\u00a0oder\u00a0nach \u00a0Re\u2010Synthese\u00a0zu\u00a0\nTriglyceriden\u00a0(TG)\u00a0im\u00a0Fettgewebe\u00a0 gespeichert\u00a0werden.\u00a0Die\u00a0Funkti onsst\u00f6rung\u00a0von\u00a0\nLPL\u00a0bewirkt\u00a0einen\u00a0Anstieg\u00a0der\u00a0Chylomikronen\u00a0im\u00a0Serum,\u00a0auch\u00a0als\u00a0 Chylomikron\u00e4\u2010\nmie\u2010Syndrom\u00a0bezeichnet,\u00a0das\u00a0labor chemisch\u00a0durch\u00a0bereits\u00a0n\u00fcchter n\u00a0stark\u00a0erh\u00f6hte\u00a0\nTG\u2010Werte\u00a0(>\u00a011,2\u00a0mmol/l;\u00a01.000\u00a0mg/dl)\u00a0sowie\u00a0milchig\u2010eingetr\u00fcbte s\u00a0Serum\u00a0nach\u2010\nweisbar\u00a0ist\u00a0(Burnett\u00a0et\u00a0al.\u00a02011).\u00a0\u00a0\nDer\u00a0Wirkstoff\u00a0Alipogentiparvovec \u00a0ist\u00a0ein\u00a0rekombinanter\u00a0viraler\u00a0 Vektor,\u00a0bestehend\u00a0\naus\u00a0dem\u00a0Capsid\u00a0vom\u00a0f\u00fcr\u00a0Muskelzellen\u00a0besonders\u00a0affinen\u00a0Adeno\u2010ass oziierten\u00a0Virus\u00a0\n(AAV)\u00a0Typ\u00a01\u00a0(Wang\u00a0et\u00a0al.,\u00a02005 )\u00a0und\u00a0einer\u00a0Expressionskassette\u00a0d es\u00a0Serotyps\u00a02,\u00a0die\u00a0\ndie\u00a0Information\u00a0der\u00a0Variante\u00a0S447X\u00a0der\u00a0humanen\u00a0LPL\u00a0enth\u00e4lt,\u00a0die \u00a0mit\u00a0einem\u00a0pro\u201068\u00a0tektiven\u00a0Effekt\u00a0( Gain\u00a0of\u00a0Function )\u00a0f\u00fcr\u00a0kardiovaskul\u00e4re\u00a0Erkr ankungen\u00a0assoziiert\u00a0ist\u00a0\n(Rip\u00a0et\u00a0al.,\u00a02006;\u00a0Fachinformation\u00a0Glybera\u00ae,2012).\u00a0Die\u00a0Dosierun g\u00a0erfolgt\u00a0in\u00a0Abh\u00e4n\u2010\ngigkeit\u00a0vom\u00a0K\u00f6rpergewicht\u00a0und\u00a0betr\u00e4gt\u00a0maximal\u00a01\u00a0x\u00a01012\u00a0Genomkopien\u00a0( genome\u00a0\ncopies,\u00a0gc)\u00a0pro\u00a0kg.\u00a0W\u00e4hrend\u00a0der\u00a0einmaligen\u00a0Behandlung\u00a0werden\u00a0pro\u00a0Inje ktionsstel\u2010\nle\u00a00,5\u00a0ml\u00a0Zubereitung\u00a0unter\u00a0aseptischen\u00a0Bedingungen\u00a0in\u00a0Ober\u2010\u00a0un d\u00a0Unterschen\u2010\nkelmuskeln\u00a0appliziert.\u00a0Aufgrund\u00a0der\u00a0hohen\u00a0Anzahl\u00a0an\u00a0Injektionen \u00a0(z.B.\u00a0bei\u00a072\u00a0kg\u00a048\u00a0\nSpritzen)\u00a0wird\u00a0eine\u00a0Spinal\u2010\u00a0oder \u00a0Regionalan\u00e4sthesie\u00a0empfohlen.\u00a0 Ferner\u00a0ist\u00a0eine\u00a0\nimmunsuppressive\u00a0Therapie\u00a0drei\u00a0Tage\u00a0vor\u00a0bis\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach\u00a0d er\u00a0Anwendung\u00a0\nerforderlich\u00a0(Fachinformation\u00a0Glybera\u00ae,\u00a02012).\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0regulatorischen\u00a0Anforderungen\u00a0legte\u00a0der\u00a0pharmazeu tische\u00a0Unter\u2010\nnehmer\u00a0(pU)\u00a0drei\u00a0Interventionsstudien\u00a0mit\u00a0insgesamt\u00a027\u00a0Teilnehm ern\u00a0vor,\u00a0in\u00a0de\u2010\nnen\u00a0 die\u00a0 Wirksamkeit\u00a0 von\u00a0 Alipogentiparvovec\u00a0 anhand\u00a0 der\u00a0 Reduktion \u00a0d e r \u00a0T G \u2010\nKonzentrationen\u00a0gemessen\u00a0wurde.\u00a0D ie\u00a0Studien\u00a0CT\u2010AMT\u2010010\u201001\u00a0(mit\u00a0 der\u00a0Vorl\u00e4ufer\u2010\nsubstanz\u00a0AMT\u2010010)\u00a0(Stroes\u00a0et\u00a0al .,\u00a02008),\u00a0CT\u2010AMT\u2010011\u201001\u00a0(Gaudet\u00a0 et\u00a0al.,\u00a02013)\u00a0und\u00a0\nCT\u2010AMT\u2010011\u201002\u00a0(Carpentier\u00a0et\u00a0al.,\u00a02012)\u00a0waren\u00a0weder\u00a0randomisier t\u00a0noch\u00a0kontrol\u2010\nliert.\u00a0 Zur\u00a0 Erstellung\u00a0 eines\u00a0 Vorhe r\u2010Nachher\u2010Vergleichs\u00a0 wurden\u00a0 di e\u00a0 Vorstudien\u00a0\nPREPARATION\u20101\u00a0und\u00a02\u00a0genutzt\u00a0( Within\u2010subject\u00a0Design ),\u00a0da\u00a0nicht\u00a0genug\u00a0Patienten\u00a0\nf\u00fcr\u00a0eine\u00a0Kontrollgruppe\u00a0zur\u00a0Verf\u00fcgung\u00a0standen.\u00a0In\u00a0der\u00a0Gesamtsch au\u00a0zeigten\u00a0sich\u00a0\nsignifikante,\u00a0aber\u00a0transiente\u00a0E ffekte,\u00a0sodass\u00a0die\u00a0TG\u2010Werte\u00a0s\u00e4mt licher\u00a0Teilnehmer\u00a0\nbinnen\u00a0eines\u00a0Jahres\u00a0auf\u00a0das\u00a0zum\u00a0Beobachtungsbeginn\u00a0vorliegende\u00a0 Niveau\u00a0anstie\u2010\ngen.\u00a0Der\u00a0pU\u00a0legte\u00a0zudem\u00a0die\u00a0retr ospektiven\u00a0Datenreview\u2010Studien\u00a0 CT\u2010AMT\u2010011\u201003\u00a0\nund\u00a0sp\u00e4ter\u00a0CT\u2010AMT\u2010011\u201005\u00a0(Gaudet\u00a0et\u00a0al.,\u00a02016)\u00a0vor,\u00a0die\u00a0eine\u00a0Ef fektivit\u00e4t\u00a0der\u00a0Be\u2010\nhandlung\u00a0 anhand\u00a0 einer\u00a0 Hospitalis ierung\u00a0 assoziierter\u00a0 abdominaler \u00a0S c h m e r z \u2010\nereignisse\u00a0ableitete.\u00a0Bez\u00fcglic h\u00a0des\u00a0Endpunktes\u00a0ergaben\u00a0sich\u00a0sig nifikante\u00a0Effekte\u00a0\n(HR\u00a00,38\u00a0(0,18;\u00a00,80);\u00a0p=0,0103;\u00a0HR\u00a00,44\u00a0(0,28;\u00a00,70);\u00a0p=0,0005 ),\u00a0die\u00a0nach\u00a0Einsch\u00e4t\u2010\nzung\u00a0des\u00a0CHMP\u00a0nicht\u00a0gen\u00fcgten,\u00a0um\u00a0die\u00a0Wirksamkeit\u00a0abschlie\u00dfend\u00a0z u\u00a0belegen.\u00a0Die\u00a0\nExperten\u00a0kritisierten,\u00a0dass\u00a0das\u00a0 Auftreten\u00a0von\u00a0Pankreatitiden\u00a0ei ner\u00a0hohen\u00a0Variabili\u2010\nt\u00e4t\u00a0unterl\u00e4ge\u00a0und\u00a0hatten\u00a0daher\u00a0eine\u00a0Nachbeobachtungszeit\u00a0von\u00a015 \u00a0Jahren\u00a0als\u00a0\nangemessen\u00a0empfohlen\u00a0(CHMP,\u00a02012).\u00a0Die\u00a0Beobachtungszeit\u00a0erstrec kte\u00a0sich\u00a0aber\u00a0\nnur\u00a0auf\u00a0maximal\u00a0f\u00fcnf\u00a0Jahre.\u00a0Weiterhin\u00a0wurde\u00a0die\u00a0Eignung\u00a0der\u00a0aus gew\u00e4hlten\u00a0Pati\u2010\nenten\u00a0bezweifelt,\u00a0die\u00a0entgegen\u00a0d er\u00a0Zulassungsbedingungen\u00a0teilwe ise\u00a0keine\u00a0Pan\u2010\nkreatitiden\u00a0in\u00a0der\u00a0Vorgeschichte\u00a0entwickelt\u00a0hatten.\u00a0Die\u00a0Zahl\u00a0de r\u00a0Patienten,\u00a0die\u00a0\nAlipogentiparvovec\u00a0(exklusive\u00a0Vorl\u00e4uferpr\u00e4parat\u00a0AMT\u2010010)\u00a0erhalt en\u00a0hatten,\u00a0war\u00a0\nau\u00dferdem\u00a0gering.\u00a0Zus\u00e4tzlich\u00a0bedingt\u00a0das\u00a0Fehlen\u00a0einer\u00a0Kontrollgr uppe\u00a0sowie\u00a0einer\u00a0\nRandomisierung\u00a0ein\u00a0hohes\u00a0Verzerrungspotential,\u00a0sodass\u00a0die\u00a0Valid it\u00e4t\u00a0der\u00a0Ergebnis\u2010\nse\u00a0kritisch\u00a0zu\u00a0bewerten\u00a0ist.\u00a0Der\u00a0CHMP\u00a0entschied\u00a0sich\u00a0dennoch\u00a0an gesichts\u00a0der\u00a0Sel\u2010\ntenheit\u00a0der\u00a0Erkrankung\u00a0f\u00fcr\u00a0eine\u00a0Empfehlung\u00a0von\u00a0Alipogentiparvov ec,\u00a0forderte\u00a0aber\u00a0\nein\u00a0internationales\u00a0Register\u00a0zur \u00a0Erfassung\u00a0von\u00a0Langzeitdaten.\u00a0W eiterhin\u00a0wurde\u00a0der\u00a0\npU\u00a0 verpflichtet,\u00a0 halbj\u00e4hrlich\u00a0 aktualisierte\u00a0 Unbedenklichkeitsbe richte\u00a0 (Periodic\u00a0\nSafety\u00a0Update\u00a0Reports ,\u00a0PSUR)\u00a0vorzulegen.\u00a0Dar\u00fcber\u00a0hinaus\u00a0pr\u00fcft\u00a0der\u00a0CHMP\u00a0j\u00e4hrlich\u00a069\u00a0auf\u00a0Grundlage\u00a0der\u00a0erhobenen\u00a0Daten\u00a0die\u00a0Verl\u00e4ngerung\u00a0der\u00a0Zulassun g.\u00a0In\u00a0diesem\u00a0\nZusammenhang\u00a0teilte\u00a0der\u00a0pU\u00a02017\u00a0mit,\u00a0keinen\u00a0weiteren\u00a0Antrag\u00a0auf \u00a0Verl\u00e4ngerung\u00a0\nzu\u00a0stellen,\u00a0dessen\u00a0n\u00e4chste\u00a0Re\u2010Evaluierung\u00a0zum\u00a025.\u00a0Oktober\u00a02017\u00a0 bevorsteht\u00a0(uni\u2010\nQure,\u00a02017).\u00a0Zulassung\u00a0und\u00a0Verkehrsf\u00e4higkeit\u00a0erl\u00f6schen\u00a0also\u00a0vor aussichtlich\u00a0am\u00a0\n26.10.2017.\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0hatte\u00a0die\u00a0Bewertung\u00a0nach\u00a0 \u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nzun\u00e4chst\u00a0vertagt.\u00a0Das\u00a0Gremium\u00a0reagierte\u00a0damit\u00a0auf\u00a0den\u00a0Umstand,\u00a0 dass\u00a0neue\u00a0In\u2010\nformationen\u00a0aus\u00a0der\u00a0Datenauswertung\u00a0der\u00a0Nachbeobachtung\u00a0zum\u00a0Ris iko\u2010Nutzen\u2010\nVerh\u00e4ltnis\u00a0sowohl\u00a0an\u00a0die\u00a0Europ\u00e4ische\u00a0Arzneimittelagentur\u00a0( European\u00a0Medicines\u00a0\nAgency,\u00a0EMA)\u00a0als\u00a0auch\u00a0an\u00a0die\u00a0US\u2010B\u00f6rsenaufsichtsbeh\u00f6rde\u00a0( United\u00a0States\u00a0Securities\u00a0\nand\u00a0Exchange\u00a0Commission ,\u00a0SEC),\u00a0jedoch\u00a0nicht\u00a0an\u00a0den\u00a0G\u2010BA\u00a0weitergeleitet\u00a0wurden\u00a0\n(G\u2010BA,\u00a02015a).\u00a0In\u00a0seinem\u00a0Beschluss\u00a0vom\u00a0Mai\u00a02015\u00a0stufte\u00a0der\u00a0G\u2010BA \u00a0das\u00a0Ausma\u00df\u00a0des\u00a0\ngem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V\u00a0bestehenden\u00a0 Zusatznutzens\u00a0 als\u00a0nicht\u00a0quanti\u2010\nfizierbar\u00a0ein.\u00a0Grundlage\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0waren\u00a0die\u00a0beiden\u00a0Datenreview\u2010 Studien\u00a0\nCT\u2010AMT\u2010011\u201003\u00a0und\u00a0CT\u2010AMT\u2010011\u201005\u00a0(Gaudet\u00a0et\u00a0al.,\u00a02016).\u00a0Wie\u00a0bere its\u00a0der\u00a0CHMP,\u00a0\nbezweifelten\u00a0die\u00a0Experten\u00a0die\u00a0\u00dcbereinstimmung\u00a0von\u00a0Studienpopula tion\u00a0und\u00a0zulas\u2010\nsungsgem\u00e4\u00dfer\u00a0Zielpopulation,\u00a0da\u00a0einige\u00a0Teilnehmer\u00a0keine\u00a0multipl en\u00a0Pankreatiti\u2010\nden\u00a0in\u00a0der\u00a0Vorgeschichte\u00a0aufwiesen\u00a0bzw.\u00a0eine\u00a0nicht\u00a0zulassungsko nforme\u00a0Dosie\u2010\nrung\u00a0erhalten\u00a0hatten.\u00a0Auch\u00a0die\u00a0geringe\u00a0Anzahl\u00a0der\u00a0Patienten\u00a0im\u00a0 Label\u00a0(acht\u00a0Pro\u2010\nbanden)\u00a0minderte\u00a0die\u00a0Validit\u00e4t\u00a0der\u00a0Ergebnisse.\u00a0Der\u00a0G\u2010BA\u00a0kritisi erte\u00a0ferner\u00a0die\u00a0ge\u2010\nringe\u00a0Nachbeobachtungszeit\u00a0und\u00a0die\u00a0fehlende\u00a0Ber\u00fccksichtigung\u00a0am bulanter\u00a0Ereig\u2010\nnisse\u00a0sowie\u00a0im\u00a0Rahmen\u00a0der\u00a0Pharmakovigilanz\u00a0gemeldeter\u00a0Daten\u00a0nac h\u00a0Beendigung\u00a0\nder\u00a0Follow\u2010Up \u2010Studie\u00a0CT\u2010AMT\u2010011\u201005.\u00a0Abschlie\u00df end\u00a0befristete\u00a0der\u00a0G\u2010BA\u00a0die\u00a0G\u00fcl tig\u2010\nkeit\u00a0seines\u00a0Beschlusses\u00a0bis\u00a0zum\u00a01.\u00a0Juni\u00a02016,\u00a0um\u00a0weiterf\u00fchrende \u00a0Daten\u00a0aus\u00a0den\u00a0\nPSUR,\u00a0dem\u00a0LPLD\u2010Register\u00a0sowie\u00a0der\u00a0j\u00e4hrlichen\u00a0Neubewertung\u00a0durch \u00a0den\u00a0CHMP\u00a0zu\u00a0\nber\u00fccksichtigen\u00a0(G\u2010BA,\u00a02015a).\u00a0Diese\u00a0Befristung\u00a0wurde\u00a0im\u00a0Mai\u00a020 16\u00a0um\u00a0ein\u00a0weiteres\u00a0\nJahr\u00a0verl\u00e4ngert\u00a0(G\u2010BA,\u00a02016).\u00a0Die\u00a0Beschlussfassung\u00a0der\u00a0erneuten \u00a0Pr\u00fcfung\u00a0ist\u00a0f\u00fcr\u00a0\nMitte\u00a0Mai\u00a02017\u00a0angek\u00fcndigt.\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0Erster\u00a0kausaler\u00a0\nBehandlungsansatz\u00a0f\u00fcr\u00a0\ndie\u00a0famili\u00e4re\u00a0LPLD\u00a0\n\u00a0Kurative\u00a0Wirkung\u00a0\nnicht\u00a0belegt,\u00a0keine\u00a0\nBeeinflussung\u00a0\nrelevanter\u00a0\nEndpunkte\u00a0\u00a0kein\u00a0Kostenvergleich,\u00a0\nda\u00a0Orphan\u2010Arznei\u2010\nmittel,\u00a0gilt\u00a0zurzeit\u00a0als\u00a0\nweltweit\u00a0teuerstes\u00a0\nArzneimittel\u00a0\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\n70\u00a0Wie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung \u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA/D\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nAlipogentiparvovec\u00a0 24\u00a0Ampullen\u00a0je\u00a0\u00a0\n3\u00a0x\u00a01012\u00a0gc\u00a01\u00a0 1.170.960,00\u00a0\u20ac*\u00a0\n*Klinik\u2010Einkaufspreis\u00a0+\u00a019%\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0wurde\u00a0keine\u00a0Versorgun gsanalyse\u00a0erstellt.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nBei\u00a0dem\u00a0Gentherapeutikum\u00a0Ali pogentiparvovec\u00a0(AAV1\u2010LPLS447X)\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0\neinen\u00a0viralen\u00a0Vektor,\u00a0der\u00a0sich\u00a0aus\u00a0einer\u00a0rekombinant\u00a0exprimiert en\u00a0Virush\u00fclle\u00a0des\u00a0\nf\u00fcr\u00a0Muskelzellen\u00a0besonders\u00a0affinen \u00a0Adeno\u2010assoziierten\u00a0Virus\u00a0(AA V)\u00a0Typ\u00a01\u00a0(Wang\u00a0et\u00a0\nal.,\u00a02005)\u00a0und\u00a0der\u00a0darin\u00a0verpackten\u00a0Expressionskassette\u00a0des\u00a0AAV \u2010Serotyps\u00a02,\u00a0die\u00a0\ndas\u00a0Gen\u00a0f\u00fcr\u00a0die\u00a0Variante\u00a0S447X\u00a0der\u00a0humanen\u00a0Lipoprotein\u2010Lipase\u00a0( LPL)\u00a0enth\u00e4lt,\u00a0\nzusammensetzt.\u00a0Die\u00a0LPL\u2010Genvariante\u00a0S447X\u00a0ist\u00a0mit\u00a0einem\u00a0 Gain\u00a0of\u00a0Function \u00a0hin\u2010\nsichtlich\u00a0kardiovaskul\u00e4rer\u00a0Erkra nkungen\u00a0assoziiert\u00a0(Nierman\u00a0et\u00a0 al.,\u00a02006;\u00a0Fachin\u2010\nformation\u00a0Glybera\u00ae,\u00a02012).\u00a0Nach\u00a0intramuskul\u00e4rer\u00a0Injektion\u00a0wird\u00a0 der\u00a0Vektor\u00a0\u00fcber\u00a0\nEndozytose\u00a0in\u00a0die\u00a0Muskelzellen \u00a0aufgenommen\u00a0und\u00a0zum\u00a0Zellkern\u00a0tra nsportiert,\u00a0wo\u00a0\ndie\u00a0Freisetzung\u00a0des\u00a0Gens\u00a0aus\u00a0der\u00a0 Expressionskassette\u00a0erfolgt.\u00a0W eil\u00a0den\u00a0rekombina\u2010\nten\u00a0 Alipogentiparvovec\u2010Vektoren\u00a0 infolge\u00a0 gentechnologischer\u00a0 Modi fikation\u00a0 die\u00a0\nF\u00e4higkeit\u00a0fehlt,\u00a0ihre\u00a0Erbinformation\u00a0in\u00a0die\u00a0chromosomale\u00a0DNA\u00a0de r\u00a0Wirtszelle\u00a0zu\u00a0\nintegrieren,\u00a0persistiert\u00a0das\u00a0Gen\u00a0f\u00fcr\u00a0LPLS447X\u00a0als\u00a0episomales\u00a0Transgen,\u00a0wodurch\u00a0das\u00a0\nRisiko\u00a0f\u00fcr\u00a0eine\u00a0durch\u00a0Einbau\u00a0ins\u00a0Genom\u00a0verursachte\u00a0Mutagenese\u00a0m inimiert\u00a0wird.\u00a0\nNach\u00a0der\u00a0Transkription\u00a0und\u00a0Translation\u00a0durch\u00a0die\u00a0Wirtszelle\u00a0wir d\u00a0die\u00a0funktionsf\u00e4\u2010\nhige\u00a0 LPLS447X\u00a0 in\u00a0 die\u00a0 Muskelkapillaren\u00a0 sezerniert\u00a0 und\u00a0 dort\u00a0 \u00fcber\u00a0 Heparan\u2010Sulfa t\u2010\nProteoglykane\u00a0an\u00a0die\u00a0Oberfl\u00e4ch e\u00a0der\u00a0Endothelzellen\u00a0gebunden\u00a0(St ray\u00a0et\u00a0al.,\u00a01985).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nBereits\u00a02004\u00a0best\u00e4tigte\u00a0die\u00a0EC\u00a0dem\u00a0Wirkstoff\u00a0Alipogentiparvovec \u00a0die\u00a0Ausweisung\u00a0\nals\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0( Orphan\u00a0Designation )\u00a0(EU/3/04/194).\u00a0Als\u00a0Gen\u2010\ntherapeutikum\u00a0unterliegt\u00a0der\u00a0Zulassungsprozess\u00a0den\u00a0regulatorisc hen\u00a0Anforderun\u201071\u00a0gen\u00a0der\u00a0Arzneimittel\u00a0f\u00fcr\u00a0neuartige\u00a0Therapien\u00a0( Advanced\u00a0Therapy\u00a0Medicinal\u00a0Pro\u2010\nducts,\u00a0ATMP),\u00a0die\u00a0eine\u00a0Ersteinsch\u00e4tzung\u00a0durch\u00a0das\u00a0Komitee\u00a0f\u00fcr\u00a0neuart ige\u00a0Thera\u2010\npien\u00a0 (Committee\u00a0 for\u00a0 Advanced\u00a0 Therapies ,\u00a0 CAT)\u00a0 vorsehen.\u00a0 Aufgrund\u00a0 fehlender\u00a0\nBelege\u00a0f\u00fcr\u00a0den\u00a0langfristigen\u00a0Nutzen\u00a0der\u00a0Therapie\u00a0mit\u00a0Alipogenti parvovec\u00a0entschie\u2010\nden\u00a0sich\u00a0die\u00a0Experten\u00a0des\u00a0CAT\u00a0und\u00a0des\u00a0CHMP\u00a0zun\u00e4chst\u00a0gegen\u00a0eine\u00a0 Empfehlung\u00a0zur\u00a0\nMarktzulassung.\u00a0Aus\u00a0der\u00a0wiederholten\u00a0Pr\u00fcfung\u00a0resultierte\u00a0ein\u00a0Di ssens\u00a0zwischen\u00a0\nbeiden\u00a0Gremien,\u00a0in\u00a0dem\u00a0sich\u00a0der\u00a0CAT\u00a0neu\u00a0positionierte\u00a0und\u00a0mit\u00a0d em\u00a0Hinweis\u00a0einer\u00a0\nm\u00f6glichen\u00a0Evaluation\u00a0der\u00a0Effekte\u00a0in\u00a0weiteren\u00a0Studien\u00a0( Post\u2010marketing\u00a0Studies )\u00a0\neine\u00a0Empfehlung\u00a0aussprach.\u00a0Auf\u00a0Ersuchen\u00a0der\u00a0EC\u00a0wurde\u00a0ein\u00a0zweite s\u00a0Verfahren\u00a0\neingeleitet,\u00a0das\u00a0die\u00a0Zielpopulat ion\u00a0auf\u00a0Patienten\u00a0mit\u00a0schweren\u00a0 oder\u00a0h\u00e4ufigen\u00a0Pan\u2010\nkreatiden\u00a0spezifizierte.\u00a0Insbesondere\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Selte nheit\u00a0der\u00a0Erkrankung\u00a0\nund\u00a0die\u00a0Ergebnisse\u00a0der\u00a0zulassungsbegr\u00fcndenden\u00a0Studien\u00a0bef\u00fcrwort ete\u00a0der\u00a0CHMP\u00a0\nschlie\u00dflich\u00a0den\u00a0Einsatz\u00a0des\u00a0Wirk stoffes\u00a0f\u00fcr\u00a0die\u00a0definierte\u00a0Popu lation\u00a0und\u00a0empfahl\u00a0\ndie\u00a0\u201eZulassung\u00a0unter\u00a0besonderen\u00a0Umst\u00e4nden\u201c\u00a0(CHMP,\u00a02012).\u00a0\nDie\u00a0EC\u00a0folgte\u00a0der\u00a0Einsch\u00e4tzung\u00a0des\u00a0Ausschusses\u00a0und\u00a0erteilte\u00a0201 2\u00a0die\u00a0Zulassung\u00a0f\u00fcr\u00a0\nAlipogentiparvovec\u00a0f\u00fcr\u00a0Patienten \u00a0mit\u00a0LPLD,\u00a0bei\u00a0denen\u00a0trotz\u00a0eine r\u00a0fettreduzierten\u00a0\nDi\u00e4t\u00a0schwere\u00a0multiple\u00a0Pankreatitis\u2010Sch\u00fcbe\u00a0auftreten.\u00a0Auch\u00a0bei\u00a0d er\u00a0amerikanischen\u00a0\nArzneimittelbeh\u00f6rde\u00a0( Food\u00a0and\u00a0Drug\u00a0Administration ,\u00a0FDA)\u00a0legte\u00a0der\u00a0pU\u00a0Daten\u00a0zum\u00a0\nZweck\u00a0der\u00a0Zulassung\u00a0vor,\u00a0stellte\u00a0seine\u00a0Bem\u00fchungen\u00a0jedoch\u00a0ein,\u00a0s odass\u00a0das\u00a0Pr\u00e4pa\u2010\nrat\u00a0aktuell\u00a0nur\u00a0im\u00a0europ\u00e4ischen\u00a0R aum\u00a0verf\u00fcgbar\u00a0ist.\u00a0Im\u00a0April\u00a020 17\u00a0teilte\u00a0der\u00a0pU\u00a0\nmit,\u00a0keinen\u00a0weiteren\u00a0Antrag\u00a0auf\u00a0Verl\u00e4ngerung\u00a0der\u00a0Zulassung\u00a0zu\u00a0s tellen,\u00a0dessen\u00a0\nn\u00e4chste\u00a0Re\u2010Evaluierung\u00a0zum\u00a025.\u00a0Oktober\u00a02017\u00a0bevorsteht.\u00a0Damit\u00a0g eht\u00a0das\u00a0Erl\u00f6\u2010\nschen\u00a0der\u00a0Zulassung\u00a0sowie\u00a0der\u00a0Ver kehrsf\u00e4higkeit\u00a0einher\u00a0(uniQure ,\u00a02017).\u00a0\nEine\u00a0Ampulle\u00a0zu\u00a0je\u00a01\u00a0ml\u00a0der\u00a0sterilen\u00a0L\u00f6sung\u00a0enth\u00e4lt\u00a03\u00a0x\u00a01012\u00a0gc\u00a0des\u00a0Vektors.\u00a0Die\u00a0\nerforderliche\u00a0Dosierung\u00a0wird\u00a0unter\u00a0Einbeziehung\u00a0des\u00a0K\u00f6rpergewic hts\u00a0errechnet\u00a0\nund\u00a0soll\u00a0eine\u00a0Gesamtdosis\u00a0von\u00a01\u00a0x\u00a01012\u00a0gc/kg\u00a0nicht\u00a0\u00fcberschreiten.\u00a0In\u00a0einer\u00a0einmali\u2010\ngen\u00a0 Sitzung\u00a0 werden\u00a0 pro\u00a0 Injektionsstelle\u00a0 0,5\u00a0 ml\u00a0 Zubereitung\u00a0 unte r\u00a0 aseptischen\u00a0\nBedingungen\u00a0in\u00a0Ober\u2010\u00a0und\u00a0Unterschenkelmuskeln\u00a0gespritzt.\u00a0Aufgru nd\u00a0der\u00a0hohen\u00a0\nAnzahl\u00a0der\u00a0ben\u00f6tigten\u00a0Injektionen\u00a0(bei\u00a072\u00a0kg\u00a0z.B.\u00a048\u00a0Spritzen)\u00a0 wird\u00a0eine\u00a0Spinal\u2010\u00a0\noder\u00a0Regionalan\u00e4sthesie\u00a0empfohlen.\u00a0Um\u00a0eine\u00a0versehentliche\u00a0intra vaskul\u00e4re\u00a0Injek\u2010\ntion\u00a0zu\u00a0vermeiden\u00a0und\u00a0eine\u00a0sichere\u00a0intramuskul\u00e4re\u00a0Injektion\u00a0zu\u00a0 gew\u00e4hrleisten,\u00a0\nkann\u00a0eine\u00a0Ultraschall\u2010\u00a0oder\u00a0elektr ophysiologisch\u00a0gesteuerte\u00a0App likation\u00a0sinnvoll\u00a0\nsein.\u00a0Ferner\u00a0ist\u00a0eine\u00a0immunsuppr essive\u00a0Therapie\u00a0vorgesehen.\u00a0Die se\u00a0umfasst\u00a0die\u00a0\nEinnahme\u00a0von\u00a0Ciclosporin\u00a0(30mg/kg/Tag)\u00a0und\u00a0Mycophenolatmofetil\u00a0 (2\u00a0x\u00a01\u00a0g/Tag)\u00a0\ninnerhalb\u00a0des\u00a0Zeitraums\u00a0von\u00a0drei\u00a0Tagen\u00a0vor\u00a0bis\u00a0zw\u00f6lf\u00a0Wochen\u00a0nac h\u00a0der\u00a0Sitzung\u00a0\nsowie\u00a0eine\u00a0intraven\u00f6se\u00a0Gabe\u00a0von\u00a0 Methylprednisolon\u00a0(1mg/kg)\u00a0als\u00a0 Bolus\u00a0eine\u00a0halbe\u00a0\nStunde\u00a0vor\u00a0der\u00a0Behandlung\u00a0(Fachi nformation\u00a0Glybera\u00ae,\u00a02012).\u00a072\u00a0Die\u00a0Durchstechflaschen\u00a0m\u00fcssen\u00a0ti efgek\u00fchlt\u00a0bei\u00a0\u201025\u00b0C\u00a0bis\u00a0\u201015\u00b0C\u00a0g elagert\u00a0und\u00a0trans\u2010\nportiert\u00a0werden.\u00a0Einmal\u00a0angetaut\u00a0muss\u00a0das\u00a0Arzneimittel\u00a0sofort\u00a0v erwendet\u00a0werden.\u00a0\nWenn\u00a0die\u00a0Durchstechflaschen\u00a0nach\u00a0dem\u00a0Auftauen\u00a0nicht\u00a0sofort\u00a0verw endet\u00a0werden,\u00a0\nk\u00f6nnen\u00a0diese\u00a0im\u00a0K\u00fchlschrank\u00a0bei\u00a02\u00b0C\u00a0bis\u00a08\u00b0C\u00a0und\u00a0vor\u00a0Licht\u00a0gesch \u00fctzt\u00a0\u00fcber\u00a0maximal\u00a0\nacht\u00a0Stunden\u00a0aufbewahrt\u00a0werden.\u00a0Nach\u00a0dem\u00a0Antauen\u00a0darf\u00a0das\u00a0Arzne imittel\u00a0nicht\u00a0\nerneut\u00a0eingefroren\u00a0werden.\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0famili\u00e4re\u00a0LPL\u2010Defizienz\u00a0mein t\u00a0den\u00a0vollst\u00e4ndigen\u00a0oder\u00a0teilwe isen\u00a0Funktionsver\u2010\nlust\u00a0des\u00a0Enzyms\u00a0LPL\u00a0aufgrund\u00a0eine r\u00a0autosomal\u00a0rezessiv\u00a0vererbten \u00a0Mutation.\u00a0Physi\u2010\nologisch\u00a0hydrolysiert\u00a0die\u00a0im\u00a0Muskel\u00a0\u2013\u00a0und\u00a0Fettgewebe\u00a0vorkommend e\u00a0LPL\u00a0Triglyce\u2010\nride\u00a0(TG).\u00a0Die\u00a0freien\u00a0Fetts\u00e4uren\u00a0dienen\u00a0im\u00a0Rahmen\u00a0des\u00a0oxidative n\u00a0Abbaus\u00a0im\u00a0Mus\u2010\nkel\u00a0 der\u00a0 Energiegewinnung\u00a0 oder\u00a0 wer den\u00a0 nach\u00a0 Re\u2010Synthese\u00a0 zu\u00a0 Trigly ceriden\u00a0 im\u00a0\nFettgewebe\u00a0gespeichert.\u00a0Das\u00a0von\u00a0Myozyten\u00a0gebildete\u00a0Enzym\u00a0bindet \u00a0nach\u00a0Sezer\u2010\nnierung\u00a0in\u00a0das\u00a0Kapillarlumen\u00a0\u00fcber\u00a0Heparan\u2010Sulfat\u2010Proteoglykane\u00a0 an\u00a0die\u00a0dort\u00a0be\u2010\nfindlichen\u00a0Endothelzellen\u00a0und\u00a0inte ragiert\u00a0u.a.\u00a0mit\u00a0postprandial \u00a0gebildeten\u00a0Chylo\u2010\nmikronen\u00a0(Stray\u00a0et.\u00a0al,\u00a01985).\u00a0Diese\u00a0z\u00e4hlen\u00a0zu\u00a0den\u00a0gr\u00f6\u00dften\u00a0Lipo proteinen\u00a0mit\u00a0hohem\u00a0\nTG\u2010Anteil.\u00a0LPL\u00a0vermittelt\u00a0den\u00a0Abbau\u00a0der\u00a0Partikel\u00a0sowie\u00a0von\u00a0Chyl omikronen\u2010 Rem\u2010\nnants\u00a0in\u00a0der\u00a0Leber\u00a0(Hussain\u00a0et.\u00a0al,\u00a02000).\u00a0Aus\u00a0der\u00a0verminderten\u00a0Enzy maktivit\u00e4t\u00a0resul\u2010\ntiert\u00a0ein\u00a0Chylomikron\u00e4mie\u2010Syndrom ,\u00a0das\u00a0laborchemisch\u00a0durch\u00a0bere its\u00a0n\u00fcchtern\u00a0stark\u00a0\nerh\u00f6hte\u00a0TG\u2010Werte\u00a0(>\u00a011,2\u00a0mmol/l;\u00a01.000mg/dl)\u00a0sowie\u00a0milchig\u2010eing etr\u00fcbtes\u00a0Serum\u00a0\ncharakterisiert\u00a0ist\u00a0(Burnett,\u00a02011).\u00a0\u00a0\nDie\u00a0Erkrankung\u00a0weist\u00a0eine\u00a0gering e\u00a0Pr\u00e4valenz\u00a0von\u00a01:1.000.000\u00a0auf .\u00a0Unter\u00a0den\u00a0bereits\u00a0\nim\u00a0 Kindesalter\u00a0 auftretenden\u00a0 Symptomen\u00a0 wie\u00a0 Hypertriglycerid\u00e4mie, \u00a0k o l i k a r t i g e n \u00a0\nBauchschmerzen,\u00a0Ausbildung\u00a0eruptiver\u00a0Xanthome\u00a0und\u00a0Hepatosplenom egalie\u00a0stellen\u00a0\nwiederkehrende\u00a0Pankreatiden\u00a0eine\u00a0schwere,\u00a0oftmals\u00a0lebensbedrohl iche\u00a0Komplikati\u2010\non\u00a0dar.\u00a0Trotz\u00a0der\u00a0hohen\u00a0TG\u2010Serumkonzentrationen\u00a0besteht\u00a0gem\u00e4\u00df\u00a0d es\u00a0aktuellen\u00a0\nKenntnisstands\u00a0 kein\u00a0 erh\u00f6htes\u00a0 art eriosklerotisches\u00a0 Risiko\u00a0 (Burne t t \u00a0e t \u00a0a l . , \u00a02 0 1 1 ; \u00a0\nAWMF,\u00a02015).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0im\u00a0Rahmen\u00a0des\u00a0Antrages\u00a0auf\u00a0Zulassung\u00a0vorgelegte\u00a0Evidenz\u00a0umf asste\u00a0sechs\u00a0\nvom\u00a0pU\u00a0gesponserte\u00a0Studien.\u00a0Zun\u00e4chst\u00a0wurde\u00a0mittels\u00a0der\u00a0Vorstudi e\u00a0PREPARA\u2010\nTION\u20101\u00a0ein\u00a0geeignetes\u00a0Patientenkollektiv\u00a0f\u00fcr\u00a0die\u00a0weitere\u00a0klinis che\u00a0Pr\u00fcfung\u00a0ermit\u2010\ntelt.\u00a0Von\u00a018\u00a0ausgew\u00e4hlten\u00a0Individuen\u00a0entsprachen\u00a0acht\u00a0Patienten \u00a0den\u00a0Inklusions\u2010\nkriterien\u00a0wie\u00a0dem\u00a0Vorliegen\u00a0der\u00a0obligatorischen\u00a0LPL\u2010Mutation.\u00a0D ie\u00a0im\u00a0Beobach\u2010\ntungszeittraum\u00a0von\u00a018\u00a0Monaten\u00a0erf assten\u00a0Daten\u00a0zu\u00a0TG\u2010Werten\u00a0sowi e\u00a0zur\u00a0Pr\u00e4\u2010\nvalenz\u00a0von\u00a0Pankreatiden\u00a0unter\u00a0einer\u00a0speziellen\u00a0kalorien\u2010\u00a0und\u00a0fe ttreduzierten\u00a0Di\u00e4t\u00a0\nbildeten\u00a0die\u00a0Vergleichs\u00a0\u2013\u00a0bzw.\u00a0Kontrollwerte\u00a0f\u00fcr\u00a0die\u00a0anschlie\u00dfe nde\u00a0Interventions\u201073\u00a0studie\u00a0CMT\u2010AMT\u2010010\u201001\u00a0(Stroes\u00a0et\u00a0al.,\u00a02008).\u00a0Diese\u00a0wurde\u00a0mit\u00a0de m\u00a0Ziel\u00a0der\u00a0Dosis\u2010\nfindung\u00a0und\u00a0Evaluation\u00a0der\u00a0Langzeit\u2010Sicherheit\u00a0initiiert.\u00a0Daf\u00fcr \u00a0wurden\u00a0zwei\u00a0Kohor\u2010\nten\u00a0zu\u00a0je\u00a0vier\u00a0Patienten\u00a0kategorisiert,\u00a0die\u00a0einmalig\u00a0mit\u00a01\u00a0x\u00a01011\u00a0gc/kg\u00a0bzw.\u00a03x1011\u00a0\ngc/kg\u00a0K\u00f6rpergewicht\u00a0behandelt\u00a0w urden.\u00a0Die\u00a0verwendete\u00a0Formulieru ng\u00a0war\u00a0ein\u00a0\nVorl\u00e4uferpr\u00e4parat\u00a0(AMT\u201001)\u00a0von\u00a0Alipogentiparvovec\u00a0(AMT\u2010011),\u00a0de ssen\u00a0Synthese\u00a0\nzun\u00e4chst\u00a0durch\u00a0infizierte\u00a0Nierenzellen\u00a0von\u00a0Embryonen\u00a0( Human\u00a0Embryonic\u00a0 Kidney,\u00a0\nHEK293)\u00a0erfolgte,\u00a0jedoch\u00a0kapazitiv\u00a0nicht\u00a0den\u00a0Anforderungen\u00a0eine r\u00a0umf\u00e4nglichen\u00a0\nProduktion\u00a0entsprach.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0bestand\u00a0im\u00a0Erreichen \u00a0eines\u00a0media\u2010\nnen\u00a0N\u00fcchtern\u2010TG\u2010Wertes\u00a0kleiner\u00a010\u00a0mmol/l\u00a0oder\u00a0einer\u00a040%igen\u00a0Red uktion\u00a0der\u00a0\nmedianen\u00a0TG.\u00a0Zwei\u00a0Teilnehmer\u00a0erz ielten\u00a0entsprechende\u00a0Ergebnisse \u00a0innerhalb\u00a0von\u00a0\nzw\u00f6lf\u00a0Wochen\u00a0nach\u00a0der\u00a0Behandlung,\u00a0die\u00a0sich\u00a0im\u00a0weiteren\u00a0Verlauf\u00a0 aber\u00a0wieder\u00a0\nverschlechterten.\u00a0Nach\u00a0drei\u00a0Jahr en\u00a0lagen\u00a0die\u00a0TG\u2010Werte\u00a0aller\u00a0Tei lnehmer\u00a0auf\u00a0oder\u00a0\n\u00fcber\u00a0den\u00a0Ausgangswerten.\u00a0Die\u00a0Auto ren\u00a0Mingozzi\u00a0et\u00a0al.,\u00a02009\u00a0verm uteten\u00a0in\u00a0die\u2010\nsem\u00a0Zusammenhang,\u00a0dass\u00a0die\u00a0Bildung\u00a0von\u00a0Antik\u00f6rpern\u00a0gegen\u00a0das\u00a0AA V1\u2010Capsid\u00a0zur\u00a0\nReduktion\u00a0bzw.\u00a0zum\u00a0Verlust\u00a0der\u00a0Wi rksamkeit\u00a0gef\u00fchrt\u00a0habe.\u00a0Daher\u00a0 wurde\u00a0in\u00a0weite\u2010\nren\u00a0klinischen\u00a0Studien\u00a0die\u00a0zus\u00e4tzliche\u00a0Gabe\u00a0von\u00a0Immunsupressiva \u00a0implementiert.\u00a0\nNeben\u00a0CMT\u2010AMT\u2010010\u201001\u00a0bildete\u00a0die\u00a0konzeptionell\u00a0\u00e4hnlich\u00a0struktur ierte\u00a0monozent\u2010\nrische,\u00a0offene\u00a0Phase\u00a0I/II\u00a0\u2013\u00a0St udie\u00a0CT\u2010AMT\u2010011\u201001\u00a0(Gaudet\u00a0et\u00a0al. ,\u00a02013)\u00a0die\u00a0Kernevi\u2010\ndenz.\u00a0Mittels\u00a0der\u00a0Vorstudie\u00a0PREPARATION\u20102\u00a0wurden\u00a0aus\u00a022\u00a0Persone n\u00a0geeignete\u00a0\nPatienten\u00a0selektiert\u00a0sowie\u00a0Kontroll\u2010\u00a0und\u00a0Vergleichswerte\u00a0( Within\u2010Subjec ts\u2010Design )\u00a0\nerfasst.\u00a0Das\u00a0finale\u00a0Patientenkollektiv\u00a0umfasste\u00a014\u00a0Teilnehmer,\u00a0 die\u00a0in\u00a0drei\u00a0Kohorten\u00a0\neingeteilt\u00a0wurden.\u00a0Die\u00a0Zielstellung\u00a0umfasste\u00a0die\u00a0Evaluation\u00a0der \u00a0Sicherheit\u00a0sowie\u00a0\nklinischer\u00a0Effekte.\u00a0Die\u00a0Gruppen\u00a0(G)\u00a01\u00a0(n\u00a0=\u00a02)\u00a0und\u00a02\u00a0(n\u00a0=\u00a04)\u00a0erh ielten\u00a03\u00a0x\u00a01011\u00a0gc/kg,\u00a0\ndie\u00a0Dritte\u00a0(n\u00a0=\u00a08)\u00a01\u00a0x\u00a01012\u00a0gc/kg\u00a0Alipogentiparvovec.\u00a0Di e\u00a0Dosisregime\u00a0der\u00a0Kohorten\u00a0\n2\u00a0und\u00a03\u00a0sahen\u00a0\u00fcberdies\u00a0die\u00a0Einnahme\u00a0von\u00a0Immunsuppressiva\u00a0(Cyclo sporin\u00a0A\u00a03\u00a0\nmg/kg/Tag\u00a0und\u00a0Mycophenolatmofetil\u00a02g/Tag)\u00a0f\u00fcr\u00a0einen\u00a0Zeitraum\u00a0vo n\u00a0zw\u00f6lf\u00a0Wo\u2010\nchen\u00a0nach\u00a0Applikation\u00a0vor.\u00a0Innerhalb\u00a0von\u00a0drei\u00a0bis\u00a0zw\u00f6lf\u00a0Wochen\u00a0 erreichte\u00a0die\u00a0\nH\u00e4lfte\u00a0der\u00a0Patienten\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0der\u00a040\u00a0%igen\u00a0Redukti on\u00a0des\u00a0media\u2010\nnen\u00a0TG\u2010Wertes\u00a0(G1\u00a050\u00a0%;\u00a0G2\u00a025\u00a0%; \u00a0G3\u00a063%).\u00a0Die\u00a0Effekte\u00a0zeigten\u00a0s ich\u00a0auch\u00a0hier\u00a0nur\u00a0\ntempor\u00e4r,\u00a0sodass\u00a0nach\u00a0einem\u00a0Jahr\u00a0alle\u00a0Teilnehmer\u00a0\u00e4hnliche\u00a0Werte \u00a0wie\u00a0zu\u00a0Studien\u2010\nbeginn\u00a0aufwiesen.\u00a0Dar\u00fcber\u00a0hinaus \u00a0untersuchte\u00a0die\u00a0offene,\u00a0monoze ntrische\u00a0Phase\u00a0\nII/III\u2010Studie\u00a0 CT\u2010AMT\u2010011\u201002\u00a0 (Carpentier\u00a0 et\u00a0 al.,\u00a0 2012)\u00a0 mit\u00a0 f\u00fcnf\u00a0 Teilnehmern\u00a0 die\u00a0\nWirksamkeit\u00a0von\u00a0Alipogentiparvov ec\u00a0anhand\u00a0der\u00a0postprandialen\u00a0Ei nfl\u00fcsse\u00a0auf\u00a0den\u00a0\nLipoprotein\u2010Stoffwechsel.\u00a0Zus\u00e4tzlich\u00a0zur\u00a0Reduktion\u00a0des\u00a0N\u00fcchtern \u2010TG\u2010Wertes\u00a0auf\u00a0\nkleiner\u00a010\u00a0mmol/l\u00a0wurden\u00a0die\u00a0Chylomikronen\u00a0(CM)\u00a0bestimmt.\u00a0W\u00e4hre nd\u00a0nur\u00a0ein\u00a0\nTeilnehmer\u00a0die\u00a0vorgegeben\u00a0TG\u2010Reduktion\u00a0nach\u00a0zw\u00f6lf\u00a0Wochen\u00a0erreic hte,\u00a0zeigten\u00a0\ndrei\u00a0Patienten\u00a0bis\u00a0Woche\u00a052\u00a0eine\u00a0Verringerung\u00a0der\u00a0CM\u2010Werte.\u00a0Die \u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0bezweifelte\u00a0die\u00a0Validit\u00e4t\u00a0d er\u00a0Ergebnisse.\u00a0So\u00a0lagen\u00a0nicht\u00a0 gen\u00fcgend\u00a0Daten\u00a0zu\u00a0\nPankreatiden\u00a0und\u00a0TG\u2010Werten\u00a0vor.\u00a0W eiterhin\u00a0stellen\u00a0CM\u2010Werte\u00a0eine n\u00a0bisher\u00a0nicht\u00a0\nf\u00fcr\u00a0Pankreatitis\u00a0validierten\u00a0Su rrogatparameter\u00a0dar.\u00a0In\u00a0der\u00a0Unte rsuchung\u00a0wurde\u00a0\nauch\u00a0die\u00a0Lebensqualit\u00e4t\u00a0mittels\u00a0des\u00a0Fragebogens\u00a0SF\u201036\u00a0erfasst.\u00a0 Die\u00a0Auswertung\u00a074\u00a0ergab\u00a0sowohl\u00a0f\u00fcr\u00a0die\u00a0psychische\u00a0als\u00a0auch\u00a0physische\u00a0Komponente\u00a0d urchschnittlich\u00a0\neine\u00a0Verschlechterung\u00a0der\u00a0Lebens qualit\u00e4t\u00a0bis\u00a052\u00a0Wochen\u00a0nach\u00a0der \u00a0Behandlung. \u00a0\u00a0\nIn\u00a0der\u00a0Gesamtschau\u00a0zeigt\u00a0sich\u00a0der\u00a0Einfluss\u00a0der\u00a0geringen\u00a0Patient enzahlen\u00a0auf\u00a0das\u00a0\nDesign\u00a0der\u00a0klinischen\u00a0Studien.\u00a0So\u00a0wurden\u00a0in\u00a0drei\u00a0Interventionss tudien\u00a027\u00a0Patienten\u00a0\nbehandelt,\u00a0davon\u00a0acht\u00a0mit\u00a0dem\u00a0Vorl\u00e4uferpr\u00e4parat,\u00a0so\u00a0dass\u00a0final\u00a0 nur\u00a019\u00a0Teilnehmer\u00a0\nAlipogentiparvovec\u00a0erhielten,\u00a0davon\u00a0lediglich\u00a013\u00a0Patienten\u00a0in\u00a0d er\u00a0zugelassenen\u00a0Do\u2010\nsierung.\u00a0 Das\u00a0 Fehlen\u00a0 von\u00a0 Kontrollgruppen\u00a0 wurde\u00a0 mittels\u00a0 Within\u2010Subjects\u2010Design\u00a0\ndurch\u00a0Implementierung\u00a0von\u00a0Vorstudien\u00a0kompensiert.\u00a0Auf\u00a0die\u00a0post\u00a0 hoc\u00a0Analyse\u00a0von\u00a0\nSubgruppen\u00a0wurde\u00a0aufgrund\u00a0der\u00a0wen igen\u00a0Teilnehmer\u00a0verzichtet.\u00a0We iterhin\u00a0wurde\u00a0\nkeine\u00a0Randomisierung\u00a0durchgef\u00fchrt,\u00a0was\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0 eine\u00a0Verzerrung\u00a0der\u00a0\nErgebnisse\u00a0bedingt.\u00a0\u00a0\nDer\u00a0pU\u00a0legte\u00a0zus\u00e4tzlich\u00a0die\u00a0retrospektive\u00a0Datenreview\u2010Studie\u00a0CT \u2010AMT\u2010011\u201003\u00a0(Gau\u2010\ndet\u00a0et\u00a0al.,\u00a02016)\u00a0vor,\u00a0die\u00a0eine\u00a0Auswertung\u00a0der\u00a0kombinierten\u00a0Dat en\u00a0der\u00a0Studien\u00a0\nPREPARATION\u201002,\u00a0CT\u2010AMT\u2010011\u201001 \u00a0(Gaudet\u00a0et\u00a0al.,\u00a02013)\u00a0und\u00a0CT\u2010AMT\u2010011\u201002\u00a0(Car\u2010\npentier\u00a0et\u00a0al.,\u00a02012)\u00a0vornahm.\u00a0Das\u00a0betrachtete\u00a0Patientenkollekt iv\u00a0setzte\u00a0sich\u00a0aus\u00a017\u00a0\nTeilnehmern,\u00a0 die\u00a0 Alipogentiparvovec\u00a0erhalten\u00a0hatten,\u00a0 und\u00a0 f\u00fcnf\u00a0P robanden\u00a0 ohne\u00a0\nIntervention\u00a0zusammen,\u00a0die\u00a0der\u00a0V erblindung\u00a0im\u00a0sp\u00e4teren\u00a0Bewertun gsprozess\u00a0dien\u2010\nten.\u00a0Ziel\u00a0war\u00a0die\u00a0Erfassung\u00a0von\u00a0Daten\u00a0zu\u00a0allen\u00a0akuten\u00a0abdominal en\u00a0Schmerzereignis\u2010\nsen,\u00a0die\u00a0zu\u00a0einer\u00a0Hospitalisierung\u00a0f\u00fchrten.\u00a0Daf\u00fcr\u00a0wurden\u00a0die\u00a0Pa tienten\u00a0mittels\u00a0klini\u2010\nschem\u00a0 Fragebogen\u00a0 zur\u00a0 Krankheitsgeschichte\u00a0 und\u00a0 demographischem\u00a0 H intergrund\u00a0\ninterviewt\u00a0und\u00a0verf\u00fcgbare\u00a0Informationen\u00a0zu\u00a0Pankreatitis\u2010Sch\u00fcben \u00a0sowie\u00a0anderen\u00a0\nabdominalen\u00a0 Ereignissen\u00a0 den\u00a0 Krankenhausakten\u00a0 entnommen.\u00a0 S\u00e4mtlic he\u00a0 Daten\u00a0\nwurden\u00a0zur\u00a0Evaluation\u00a0an\u00a0ein\u00a0unabh\u00e4ngiges\u00a0medizinisches\u00a0Experte npanel\u00a0weiterge\u2010\nleitet.\u00a0Die\u00a0Nachbeobachtungszeit\u00a0betrug\u00a0im\u00a0Durch\u2010schnitt\u00a0drei\u00a0J ahre.\u00a0Die\u00a0Auswer\u2010\ntung\u00a0ergab\u00a0eine\u00a0signifikante\u00a0Reduktion\u00a0der\u00a0Endpunkte\u00a0\u201ebest\u00e4tigt e\u00a0und\u00a0wahrschein\u2010\nliche\u00a0Pankreatitis\u2010Ereignisse\u201c\u00a0so wie\u00a0der\u00a0kombinierten\u00a0Daten\u00a0zu\u00a0 best\u00e4tigten\u00a0und\u00a0\nwahrscheinlichen\u00a0Pankreatiden\u00a0und\u00a0abdominalen\u00a0Schmerzen\u00a0(HR\u00a00,3 8\u00a0(0,18;\u00a00,80);\u00a0\np=0,0103;\u00a0HR\u00a00,44\u00a0(0,28;\u00a00,70);\u00a0p=0,0005).\u00a0Weiterhin\u00a0liegen\u00a0die \u00a0Ergebnisse\u00a0einer\u00a0\nweiteren,\u00a0 zum\u00a0 Zeitpunkt\u00a0 der\u00a0 Zulassung\u00a0 nicht\u00a0 abgeschlossenen\u00a0 Dat en\u00a0 Review\u2010\nStudie\u00a0CT\u2010AMT\u2010011\u201005\u00a0(Gaudet\u00a0et\u00a0al.,\u00a02016)\u00a0vor.\u00a0Diese\u00a0bezieht\u00a0s ich\u00a0auf\u00a0die\u00a0Daten\u00a0\neines\u00a0aus\u00a0den\u00a0Studien\u00a0PREPARATION \u201002,\u00a0CT\u2010AMT\u2010010\u201001\u00a0(Stroes\u00a0et\u00a0 al.,\u00a02008),\u00a0CT\u2010\nAMT\u2010011\u201001\u00a0(Gaudet\u00a0et\u00a0al.,\u00a02013)\u00a0und\u00a0CT\u2010AMT\u2010011\u201002\u00a0(Carpentier\u00a0 et\u00a0al.,\u00a02012)\u00a0\nrekrutierten\u00a0Patientenkollektivs\u00a0von\u00a029\u00a0Teilnehmern,\u00a0wovon\u00a0f\u00fcnf \u00a0Probanden\u00a0keine\u00a0\nIntervention\u00a0erhielten.\u00a0Die\u00a0Vorg ehensweise\u00a0entspricht\u00a0CT\u2010AMT\u201001 1\u201003\u00a0(Gaudet\u00a0et\u00a0\nal.,\u00a02016),\u00a0erg\u00e4nzt\u00a0um\u00a0die\u00a0Erfassung\u00a0von\u00a0Informationen\u00a0zu\u00a0schwe ren\u00a0unerw\u00fcnsch\u2010\nten\u00a0Ereignissen\u00a0(SUE)\u00a0sowie\u00a0Schwangerschaften\u00a0seit\u00a0der\u00a0Studient eilnahme.\u00a0Die\u00a0\nNachbeobachtungszeit\u00a0betrug\u00a0im\u00a0Schnitt\u00a05,3\u00a0Jahre,\u00a0die\u00a0Bewertung \u00a0erfolgte\u00a0durch\u00a0\ndie\u00a0gleiche\u00a0Expertengruppe.\u00a0Die\u00a0Analyse\u00a0der\u00a0Daten\u00a0ergab\u00a0f\u00fcr\u00a0den \u00a0kombinierten\u00a0\nEndpunkt\u00a0\u201ebest\u00e4tigte\u00a0und\u00a0wahrscheinliche\u00a0akute\u00a0Pankreatitis\u00a0ode r\u00a0Hospitalisierung\u00a075\u00a0f\u00fcr\u00a0mindestens\u00a0drei\u00a0Tage\u00a0aufgrund\u00a0von\u00a0Abdominalschmerzen\u201c\u00a0eine\u00a0 signifikante\u00a0\nVerbesserung\u00a0nach\u00a0Gabe\u00a0von\u00a0Alipogentiparvovec.\u00a0Ein\u00a0valider\u00a0R\u00fcck schluss\u00a0auf\u00a0die\u00a0\nWirksamkeit,\u00a0basierend\u00a0auf\u00a0den\u00a0Ergebnissen,\u00a0ist\u00a0jedoch\u00a0nicht\u00a0m\u00f6 glich.\u00a0Das\u00a0Auftre\u2010\nten\u00a0von\u00a0Pankreatiden\u00a0unterliegt\u00a0einer\u00a0gro\u00dfen\u00a0Variabilit\u00e4t.\u00a0Eini ge\u00a0Studienteilneh\u2010\nmer\u00a0zeigten\u00a0vor\u00a0der\u00a0Therapie\u00a0kom plikationsfreie\u00a0Intervalle\u00a0von\u00a0 einigen\u00a0Jahren.\u00a0Der\u00a0\nCHMP\u00a0hatte\u00a0daher\u00a0eine\u00a0Nachbeobachtungszeit\u00a0von\u00a015\u00a0Jahren\u00a0empfoh len\u00a0(CHMP,\u00a0\n2012),\u00a0dem\u00a0der\u00a0pU\u00a0nicht\u00a0entsprach.\u00a0Weiterhin\u00a0ergibt\u00a0sich\u00a0in\u00a0die sem\u00a0Zusammenhang\u00a0\ndie\u00a0Frage\u00a0nach\u00a0der\u00a0Eignung\u00a0der\u00a0S tudienpopulation\u00a0reflektierten\u00a0 doch\u00a0die\u00a0Ergebnisse\u00a0\nder\u00a0zugeh\u00f6rigen\u00a0Surrogatparameter\u00a0(TG\u2010Werte)\u00a0nicht\u00a0den\u00a0positive n\u00a0Effekt.\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nGem\u00e4\u00df\u00a0der\u00a0aktuellen\u00a0S2k\u2010Leitlinie \u00a0zur\u00a0\u201eDiagnostik\u00a0und\u00a0Therapie\u00a0 von\u00a0Hyperlipid\u00e4mien\u00a0\nbei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u201c\u00a0wird\u00a0eine\u00a0di\u00e4tetische\u00a0Therapie\u00a0mi t\u00a0strenger\u00a0Begren\u2010\nzung\u00a0der\u00a0Zufuhr\u00a0nat\u00fcrlicher\u00a0langkettiger\u00a0Fette\u00a0auf\u00a0etwa\u00a012\u00a0bis2 5\u00a0g/Tag\u00a0empfohlen.\u00a0\nAuch\u00a0die\u00a0Substitution\u00a0durch\u00a0mittelkettige\u00a0TG,\u00a0die\u00a0\u00fcberwiegend\u00a0o hne\u00a0Bildung\u00a0von\u00a0\nChylomikronen\u00a0\u00fcber\u00a0den\u00a0Portalkreislauf\u00a0zur\u00a0Leber\u00a0transportiert\u00a0 werden\u00a0und\u00a0somit\u00a0\nbesser\u00a0vertr\u00e4glich\u00a0sind,\u00a0ist\u00a0m\u00f6glich.\u00a0Ferner\u00a0sollte\u00a0bei\u00a0Kindern \u00a0die\u00a0Konzentration\u00a0es\u2010\nsentieller\u00a0Fetts\u00e4uren\u00a0sowie\u00a0lipidl\u00f6slicher\u00a0Vitamine\u00a0im\u00a0Blut\u00a0\u00fcbe rwacht\u00a0und\u00a0gegebe\u2010\nnenfalls\u00a0eine\u00a0Supplementierung\u00a0erwogen\u00a0werden.\u00a0Die\u00a0Gentherapie\u00a0 wird\u00a0nur\u00a0bei\u00a0\nErwachsenen\u00a0mit\u00a0schweren\u00a0Pankreatitissch\u00fcben\u00a0in\u00a0Betracht\u00a0gezoge n\u00a0(AWMF,\u00a02014).\u00a0\u00a0\nAuch\u00a0die\u00a0von\u00a0der\u00a0 European\u00a0Society\u00a0of\u00a0Cardiology \u00a0(ESC)\u00a0und\u00a0 European\u00a0Atherosclero\u2010\nsis\u00a0Society \u00a0(EAS)\u2009\u00a02016\u00a0herausgegebenen\u00a0 Guidelines\u00a0for\u00a0the\u00a0Management\u00a0of\u00a0Dysli\u2010\npidaemias \u00a0erw\u00e4hnen\u00a0die\u00a0Zulassung\u00a0von\u00a0Alipogentiparvovec\u00a0durch\u00a0die\u00a0EC,\u00a0sp rechen\u00a0\njedoch\u00a0keine\u00a0Empfehlung\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0aus.\u00a0Die\u00a0Experten\u00a0sehe n\u00a0insbesondere\u00a0\ndie\u00a0Pr\u00e4vention\u00a0von\u00a0Pankratiden\u00a0im\u00a0Vordergrund,\u00a0die\u00a0in\u00a0erster\u00a0Li nie\u00a0durch\u00a0hohe\u00a0\nSerum\u2010TG\u00a0getriggert\u00a0werden\u00a0(>\u00a010\u00a0mmol/l;\u00a0880\u00a0mg/dl).\u00a0Die\u00a0abgele iteten\u00a0di\u00e4tischen\u00a0\nMa\u00dfnahmen\u00a0sehen\u00a0neben\u00a0Kalorienre duktion\u00a0eine\u00a0t\u00e4gliche\u00a0Fettzufuh r\u00a0von\u00a010\u00a0bis\u00a0\n15\u00a0%\u00a0vor.\u00a0Weiterhin\u00a0ist\u00a0eine\u00a0Alkoholabstinenz\u00a0obligatorisch.\u00a0Di e\u00a0Behandlung\u00a0der\u00a0\nakuten\u00a0Pankreatitis\u00a0erfordert\u00a0di e\u00a0rapide\u00a0Senkung\u00a0der\u00a0TG\u2010Werte\u00a0i nnerhalb\u00a0von\u00a0zwei\u00a0\nbis\u00a0f\u00fcnf\u00a0Tagen.\u00a0Pharma kotherapeutisch\u00a0werden\u00a0Fibrate\u00a0in\u00a0Kombina tion\u00a0mit\u00a0Ome\u2010\nga\u20103\u2010Fetts\u00e4uren\u00a0oder\u00a0Nicotins\u00e4ure,\u00a0in\u00a0besonders\u00a0schweren\u00a0F\u00e4llen \u00a0Lomitapid\u00a0emp\u2010\nfohlen.\u00a0Auch\u00a0die\u00a0Durchf\u00fchrung\u00a0einer\u00a0Plasmapherese\u00a0kann\u00a0erwogen\u00a0 werden,\u00a0um\u00a0\nzeitnah\u00a0die\u00a0TG\u2010Konzentration\u00a0zu\u00a0 senken\u00a0(Catapano\u00a0et\u00a0al.,\u00a02016). \u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0Gemeinsame\u00a0Bundessausschuss\u00a0(G\u2010BA)\u00a0setzte\u00a0das\u00a02014\u00a0eingelei tete\u00a0Bewer\u2010\ntungsverfahren\u00a0aus,\u00a0nachdem\u00a0Info rmationen\u00a0eines\u00a0zust\u00e4ndigen\u00a0Rap porteurs\u00a0der\u00a0\nEMA\u00a0vorlagen,\u00a0die,\u00a0basierend \u00a0auf\u00a0Auswertungsdaten\u00a0der\u00a0 Follow\u2010up \u2010Beobachtung,\u00a0\nein\u00a0negatives\u00a0Kosten\u2010Risiko\u2010Verh\u00e4ltnis\u00a0f\u00fcr\u00a0den\u00a0Wirkstoff\u00a0formul ierten.\u00a0Damit\u00a0wur\u201076\u00a0de\u00a0erstmals\u00a0die\u00a0gesetzliche\u00a0Verfahrensfrist\u00a0\u00fcberschritten.\u00a0In\u00a0d iesem\u00a0Zusammen\u2010\nhang\u00a0kritisierte\u00a0das\u00a0Gremium\u00a0den\u00a0Umstand,\u00a0dass\u00a0der\u00a0pU\u00a0die\u00a0US\u2010B\u00f6 rsenaufsichts\u2010\nbeh\u00f6rde\u00a0( United\u00a0States\u00a0Securities\u00a0and\u00a0Exchange\u00a0Commission ,\u00a0SEC)\u00a0bereits\u00a0infor\u2010\nmiert\u00a0hatte,\u00a0eine\u00a0Unterrichtung\u00a0des\u00a0G\u2010BA\u00a0jedoch\u00a0nicht\u00a0stattfand \u00a0(G\u2010BA,\u00a02015b).\u00a0\u00a0\nGem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V\u00a0gilt\u00a0der\u00a0Zusatznutzen\u00a0eines\u00a0 Arzneimittels\u00a0zur\u00a0\nBehandlung\u00a0seltener\u00a0Leiden\u00a0nach\u00a0Verordnung\u00a0EG\u00a0Nr.\u00a0141/2000\u00a0per\u00a0 Zulassung\u00a0als\u00a0\nbelegt,\u00a0sodass\u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0anhand\u00a0der\u00a0Zulassungsstudien \u00a0beurteilt.\u00a0In\u00a0\nder\u00a0Gesamtschau\u00a0stufte\u00a0das\u00a0Gremium\u00a0die\u00a0Datenlage\u00a0als\u00a0unzureiche nd\u00a0ein.\u00a0F\u00fcr\u00a0die\u00a0\ndrei\u00a0vorliegenden\u00a0Interventionsst udien\u00a0CT\u2010AMT\u2010010\u201001\u00a0(mit\u00a0AMT\u20100 10),\u00a0CT\u2010AMT\u2010\n011\u201001\u00a0und\u00a0CT\u2010AMT\u2010011\u201002\u00a0wird\u00a0aufgrund\u00a0fehlender\u00a0Randomisierung \u00a0und\u00a0Kontrol\u2010\nle\u00a0ein\u00a0hohes\u00a0Verzerrungspotential\u00a0angenommen.\u00a0Auch\u00a0die\u00a0Entsprec hung\u00a0von\u00a0Stu\u2010\ndienpopulation\u00a0 und\u00a0 zulassungsgem\u00e4\u00dfer\u00a0 Zielpopulation\u00a0 wurde\u00a0 angez weifelt,\u00a0 da\u00a0\neinige\u00a0Teilnehmer\u00a0keine\u00a0multiple n\u00a0Pankreatiden\u00a0in\u00a0der\u00a0Vorgeschi chte\u00a0aufwiesen\u00a0\nbzw.\u00a0eine\u00a0nicht\u00a0zulassungskonform e\u00a0Dosierung\u00a0erhielten.\u00a0Diese\u00a0m ethodische\u00a0Prob\u2010\nlematik\u00a0besteht\u00a0ferner\u00a0f\u00fcr\u00a0die\u00a0v orgelegten\u00a0Datenreview\u2010Studien\u00a0 CT\u2010AMT\u2010011\u201003\u00a0\nund\u00a0CT\u2010AMT\u2010011\u201005,\u00a0die\u00a0grundlegend\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0herangezog en\u00a0wurden.\u00a0\nWeiterhin\u00a0limitiert\u00a0die\u00a0geringe\u00a0Anzahl\u00a0der\u00a0Patienten\u00a0im\u00a0Label\u00a0( 8\u00a0Probanden)\u00a0die\u00a0\nValidit\u00e4t\u00a0der\u00a0Ergebnisse.\u00a0Die\u00a0Daten\u00a0zur\u00a0Morbidit\u00e4t,\u00a0die\u00a0in\u00a0beid en\u00a0Reviews\u00a0anhand\u00a0\ndes\u00a0Outcomes\u00a0\u201ePankreatitis\u00a0und\u00a0abdominale\u00a0Schmerzen\u201c\u00a0erfasste\u00a0w urden,\u00a0waren\u00a0\nnicht\u00a0geeignet,\u00a0um\u00a0einen\u00a0Zusatz nutzen\u00a0abzuleiten.\u00a0Der\u00a0G\u2010BA\u00a0krit isierte\u00a0eine\u00a0zu\u00a0\ngeringe\u00a0 Nachbeobachtungszeit\u00a0 und\u00a0 die\u00a0 fehlende\u00a0 Ber\u00fccksichtigung\u00a0 ambulanter\u00a0\nEreignisse\u00a0sowie\u00a0der\u00a0im\u00a0Rahmen\u00a0der\u00a0Pharmakovigilanz\u00a0gemeldeten\u00a0 Daten\u00a0nach\u00a0\nBeendigung\u00a0der\u00a0Follow\u2010Up\u2010Studie\u00a0CT\u2010AMT\u2010011\u201005.\u00a0Die\u00a0mittels\u00a0Frag ebogen\u00a0Short\u00a0\nForm\u201036\u00a0untersuchte\u00a0Lebensqualit\u00e4t\u00a0wurde\u00a0unvollst\u00e4ndig\u00a0erfasst\u00a0und\u00a0kon nte\u00a0da\u2010\nher\u00a0 nicht\u00a0 abschlie\u00dfend\u00a0 beurteilt\u00a0 werden.\u00a0 Auch\u00a0 fehlt\u00a0 der\u00a0 qualita tive\u00a0 Vorher\u2010\nNachher\u2010Vergleich\u00a0der\u00a0Nebenwirku ngen.\u00a0Daten\u00a0zur\u00a0Mortalit\u00e4t\u00a0wurd en\u00a0nicht\u00a0erho\u2010\nben.\u00a0Abschlie\u00dfend\u00a0stufte\u00a0der\u00a0G\u2010BA\u00a0den\u00a0Zusatznutzen\u00a0als\u00a0nicht\u00a0qu antifizierbar\u00a0ein,\u00a0\nbefristete\u00a0dabei\u00a0aber\u00a0die\u00a0G\u00fcltigkeit\u00a0seines\u00a0Beschlusses\u00a0bis\u00a0zum \u00a01.\u00a0Juni\u00a02016,\u00a0um\u00a0\nweiterf\u00fchrende\u00a0Daten\u00a0aus\u00a0den\u00a0halbj\u00e4hrlich\u00a0aktualisierten\u00a0Unbede nklichkeitsbe\u2010\nrichten\u00a0(Periodic\u00a0safety\u00a0update\u00a0report ,\u00a0PSUR),\u00a0aus\u00a0dem\u00a0LPLD\u2010Register\u00a0sowie\u00a0aus\u00a0der\u00a0\nj\u00e4hrlichen\u00a0Neubewertung\u00a0durch\u00a0den\u00a0CHMP\u00a0zu\u00a0ber\u00fccksichtigen\u00a0(G\u2010BA ,\u00a02015a).\u00a0Im\u00a0\nMai\u00a02016\u00a0beschloss\u00a0das\u00a0Gremium\u00a0die\u00a0Verl\u00e4ngerung\u00a0der\u00a0Frist\u00a0um\u00a0ei n\u00a0weiteres\u00a0Jahr\u00a0\n(G\u2010BA,\u00a02016).\u00a0Zurzeit\u00a0pr\u00fcft\u00a0der\u00a0G\u2010BA\u00a0erneut\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusa tznutzens\u00a0f\u00fcr\u00a0Ali\u2010\npogentiparvovec.\u00a0Die\u00a0Beschlussfassung\u00a0ist\u00a0f\u00fcr\u00a0Mitte\u00a0Mai\u00a02017\u00a0vo rgesehen\u00a0und\u00a0er\u2010\nfolgt\u00a0vor\u00a0dem\u00a0Hintergrund\u00a0des\u00a0vom\u00a0pU\u00a0angek\u00fcndigten\u00a0Verzichts\u00a0au f\u00a0erneute\u00a0\u00dcber\u2010\npr\u00fcfung\u00a0und\u00a0somit\u00a0Erl\u00f6schung\u00a0der\u00a0Zulassung\u00a0zum\u00a025.\u00a0Oktober\u00a02017 \u00a0(uniQure,\u00a02017).\u00a0\n\u00a0\u00a077\u00a0Quellen\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften\u00a0e.V.\u00a0(2014).\u00a0 S2k\u2010Leitlinie\u00a0zur\u00a0\u201eDiagnostik\u00a0\nund\u00a0Therapie\u00a0von\u00a0Hyperlipid\u00e4mien\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u201c\u00a0http://www.awmf.org/uploads/tx_szleitlinien/027\u2010068l_s2k_Hyperl ipid%C3%A4mien_Kinder_Jugendliche_2016\u2010\n02.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.09.2017.\u00a0\nBurnett\u00a0JR,\u00a0Hooper\u00a0AJ,\u00a0Hegele\u00a0RA\u00a0(2011).\u00a0Familial\u00a0Lipoprotein\u00a0L ipase\u00a0Deficiency.\u00a0GeneReviews\u00ae.\u00a0University\u00a0of\u00a0Washington,\u00a0Seatt le.\u00a0\u00a0\nBurnett\u00a0JR,\u00a0Hooper\u00a0AJ,\u00a0Hegele\u00a0RA\u00a0(1993).\u00a0Familial\u00a0Lipoprotein\u00a0L ipase\u00a0Deficiency.\u00a0GeneReviews\u00ae.\u00a0University\u00a0of\u00a0Washington,\u00a0Seatt le.\u00a0\u00a0\nCarpentier\u00a0AC,\u00a0Frisch\u00a0F,\u00a0Labb\u00e9\u00a0S M,\u00a0Gagnon\u00a0R,\u00a0de\u00a0Wal\u00a0J,\u00a0Greentre e\u00a0S\u00a0et\u00a0al.\u00a0(2012).\u00a0Effect\u00a0of\u00a0alipogene\u00a0tiparvovec\u00a0(AAV1\u2010LPL(S44 7X))\u00a0\non\u00a0postprandial\u00a0chylomicron\u00a0metabolism\u00a0in\u00a0lipoprotein\u00a0lipase\u2010de ficient\u00a0patients.\u00a0J\u00a0Clin\u00a0Endocrinol\u00a0Metab\u00a0(97):\u00a01635\u2010\n1644.\u00a0\u00a0\nCatapano\u00a0AL,\u00a0Graham,I,\u00a0De\u00a0Backer\u00a0G,\u00a0Wiklund\u00a0O,\u00a0Chapman\u00a0M\u00a0J,\u00a0Dre xel\u00a0H\u00a0et\u00a0al.\u00a0(2016).\u00a02016\u00a0ESC/EAS\u00a0Guidelines\u00a0for\u00a0the\u00a0\nManagement\u00a0of\u00a0Dyslipidaemias.\u00a0Eur\u00a0Heart\u00a0J\u00a037(39):\u00a02999\u20103058.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2012).\u00a0S ummary\u00a0of\u00a0positive\u00a0opinion\u00a0for\u00a0Glybera.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Summary_of _opinion_\u2010\n_Initial_authorisation/human/002145/WC500130151.pdf,\u00a0\u00a0\nEPAR\u00a0(n.d.).\u00a0www.ema.europa.eu/docs/en_GB/document_library/EPAR _\u2010\n_All_Authorised_presentations/human/002145/WC500135475.pdf,\u00a0let zter\u00a0Zugriff:\u00a006.07.2017.\u00a0\nFachinformation\u00a0Glybera\u00ae\u00a0(2012) .\u00a0Fachinformation\u00a0Glybera\u00ae.\u00a0\nwww.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/me dicines/002145/human_med_001480.jsp\n%26mid=WC0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a006.07.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nGaudet\u00a0D,\u00a0M\u00e9thot\u00a0J,\u00a0D\u00e9ry\u00a0S,\u00a0Brisson\u00a0D,\u00a0Essiembre\u00a0C,\u00a0Tremblay\u00a0G\u00a0 et\u00a0al.\u00a0(2013).\u00a0Efficacy\u00a0and\u00a0long\u2010term\u00a0safety\u00a0of\u00a0alipogene\u00a0tipar vovec\u00a0\n(AAV1\u2010LPLS447X)\u00a0gene\u00a0therapy\u00a0for\u00a0lipoprotein\u00a0lipase\u00a0deficiency: \u00a0an\u00a0open\u2010label\u00a0trial.\u00a0Gene\u00a0Therapy,\u00a020(4):\u00a0361\u2010369.\u00a0\u00a0\nGaudet\u00a0D,\u00a0Stroes\u00a0ES,\u00a0M\u00e9thot\u00a0J,\u00a0Brisson\u00a0D,\u00a0Trembla,\u00a0K,\u00a0Bernelot\u00a0 Moens\u00a0SJ\u00a0et\u00a0al.\u00a0(2016).\u00a0Long\u2010Term\u00a0Retrospective\u00a0Analysis\u00a0of\u00a0Gen e\u00a0\nTherapy\u00a0with\u00a0Alipogene\u00a0Tiparvovec \u00a0and\u00a0Its\u00a0Effect\u00a0on\u00a0Lipoprotein \u00a0Lipase\u00a0Deficiency\u2010Induced\u00a0Pancreatitis\u00a0|\u00a0Read\u00a0by\u00a0\nQxMD.\u00a0Human\u00a0Gene\u00a0Therapy\u00a027(11):\u00a0916\u2010925.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015a).\u00a0Nutzenbewertungsver fahren\u00a0zum\u00a0Wirkstoff\u00a0Alipogen\u00a0tiparvovec.\u00a0https://www.g\u2010\nba.de/downloads/39\u2010261\u20102250/2015\u201005\u201021_AM\u2010RL\u2010XII_Alipogentiparv ovec_2014\u201011\u201001\u2010D\u2010138_BAnz.pdf,\u00a0letzter\u00a0\nZugriff:\u00a017.01.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015b).\u00a0Pressemitteilung\u00a0Nr .\u00a008/2015\u00a0vom\u00a016.\u00a0April\u00a0 2015.\u00a0https://www.g\u2010\nba.de/downloads/34\u2010215\u2010572/08\u20102015\u201004\u201016\u2010AM_Glybera.pdf,\u00a0letzte r\u00a0Zugriff:\u00a024.04.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Verl\u00e4ngerung\u00a0der\u00a0Bef ristung\u00a0der\u00a0Geltungsdauer\u00a0Alipogen\u00a0tiparvovec,\u00a0\nhttps://www.g\u2010ba.de/downloads/ 40\u2010268\u20103764/2016\u201005\u201019_AM\u2010RL\u2010XII_ Alipogentiparvovec_D\u2010\n138_Fristverl_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a024.04.2017.\u00a0\nHussain\u00a0MM\u00a0(2000).\u00a0A\u00a0proposed\u00a0model\u00a0for\u00a0the\u00a0assembly\u00a0of\u00a0chylomi crons.\u00a0Atherosclerosis\u00a0148(1):\u00a01\u201015.\u00a0\nMingozzi\u00a0F,\u00a0Meulenberg\u00a0JJ,\u00a0Hui\u00a0DJ,\u00a0Basner\u2010Tschakarjan\u00a0E,\u00a0Hasbro uck\u00a0NC,\u00a0Edmonson\u00a0SA\u00a0et\u00a0al.\u00a0(2009).\u00a0AAV\u20101\u2013mediated\u00a0gene\u00a0transfer \u00a0\nto\u00a0skeletal\u00a0muscle\u00a0in\u00a0humans\u00a0results\u00a0in\u00a0dose\u2010dependent\u00a0activati on\u00a0of\u00a0capsid\u2010specific\u00a0T\u00a0cells.\u00a0Blood\u00a0114(10):\u00a02077\u2010\n2086.\u00a078\u00a0PZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2014).\u00a0Arzneistoffe:\u00a0Alipogentipa rvovec|Glybera\u00ae|58|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=55373.\u00a0Stand\u00a0der\u00a0Information\u00a013.06.2016 .\u00a0\nRip\u00a0J,\u00a0Nierman\u00a0MC,\u00a0Ross\u00a0CJ,\u00a0Juke ma\u00a0JW,\u00a0Hayden\u00a0MR,\u00a0Kastelein\u00a0JJP \u00a0et\u00a0al.\u00a0(2006).\u00a0Lipoprotein\u00a0Lipase\u00a0S447X.\u00a0Arterioscler\u00a0Thromb\u00a0V asc\u00a0\nBiol\u00a026(6):\u00a01236\u20101245.\u00a0\u00a0\nStray\u00a0N,\u00a0Letnes\u00a0H,\u00a0Blomhoff\u00a0JP\u00a0(1985).\u00a0Synthesis\u00a0and\u00a0secretion\u00a0 of\u00a0lipoprotein\u00a0lipase\u00a0by\u00a0human\u00a0monocyte\u2010derived\u00a0macrophages.\u00a0\nScand\u00a0J\u00a0Gastroenterol\u00a020(sup107):\u00a067\u201072.\u00a0\nStroes\u00a0ES,\u00a0Nierman\u00a0MC,\u00a0Meulenberg\u00a0JJ,\u00a0Franssen\u00a0R,\u00a0Twisk\u00a0J,\u00a0Henn y\u00a0CP\u00a0et\u00a0al.\u00a0(2008).\u00a0Intramuscular\u00a0Administration\u00a0of\u00a0AAV1\u2010\nLipoprotein\u00a0LipaseS447X\u00a0Lowers\u00a0Triglycerides\u00a0in\u00a0Lipoprotein\u00a0Lip ase\u2013Deficient\u00a0Patients.\u00a0Arterioscler\u00a0Thromb\u00a0Vasc\u00a0Biol\u00a0\n28(12):\u00a02303\u20102304.\u00a0\nuniQure\u00a0(2017).\u00a0Glybera\u00a0\u2013\u00a0Gene\u00a0Therapy\u00a0\u2013\u00a0Pressemitteilung\u00a020.04 .2017.\u00a0http://www.uniqure.com/gene\u2010therapy/glybera.php,\u00a0\nletzter\u00a0Zugriff:\u00a006.07.2017.\u00a0\nWang\u00a0Z,\u00a0Zhu\u00a0T,\u00a0Qiao\u00a0C,\u00a0Zhou\u00a0L,\u00a0Wang\u00a0B,\u00a0Zhang\u00a0J\u00a0et\u00a0al.\u00a0(2005).\u00a0A deno\u2010associated\u00a0virus\u00a0serotype\u00a08\u00a0efficiently\u00a0delivers\u00a0genes\u00a0to\u00a0 muscle\u00a0\nand\u00a0heart.\u00a0Nature\u00a0Biotechnology\u00a023(3):\u00a0321\u2010328.\u00a0\u00a0\n\u00a0 \u00a079\u00a04.3 Bedaquilin\u00a0\nHandelsname: \u00a0Sirturo\u00ae\u00a0 \u00a0 Pharmazeutische r\u00a0Unternehmer:\u00a0Janssen\u00a0\nIndikation:\u00a0Multiresistente\u00a0\u00a0\nLungentuberkulose\u00a0 \u00a0\nATC\u2010Code:\u00a0J04AK05\u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Mai\u00a02014\u00a0\nDarreichungsform:\u00a0Tabletten\u00a0 DDD:\u00a086\u00a0mg\u00a0O\u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0C,\u00a0O, \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nBedaquilin\u00a0(Handelsname\u00a0Sirturo\u00ae) \u00a0hemmt\u00a0das\u00a0Enzym\u00a0ATP\u2010Synthase\u00a0 und\u00a0blockiert\u00a0\nsomit\u00a0die\u00a0Energiegewinnung\u00a0von\u00a0My cobacterium\u00a0tuberculosis,\u00a0der\u00a0 Erreger\u00a0der\u00a0\nTuberkulose\u00a0(TB).\u00a0Es\u00a0wirkt\u00a0bakterizid\u00a0sowohl\u00a0auf\u00a0sich\u00a0teilende\u00a0 als\u00a0auch\u00a0auf\u00a0sich\u00a0\nnicht\u2010teilende\u00a0 Tuberkelbakterien.\u00a0 Der\u00a0 Wirkstoff\u00a0 wurde\u00a0 aufgrund\u00a0 einer\u00a0 Versor\u2010\ngungsl\u00fccke\u00a0( Unmet\u00a0medical\u00a0need )\u00a0zur\u00a0Behandlung\u00a0multiresistenter\u00a0Lungentuber\u2010\nkulose\u00a0(pulmonaler\u00a0MDR,\u00a0 Multidrug \u2010Resistenz\u2010TB),\u00a0einer\u00a0in\u00a0Europa\u00a0seltenen\u00a0Er\u2010\nkrankung\u00a0( Orphan\u2010Arzneimittel),\u00a0von\u00a0der\u00a0europ\u00e4ischen\u00a0Zulassungsbeh\u00f6rde\u00a0EMA\u00a0\n(European\u00a0 Medicines\u00a0 Agency ,\u00a0 Europ\u00e4ische\u00a0 Arzneimittel agentur)\u00a0 basierend\u00a0 auf\u00a0\nPhase\u2010IIb\u2010Studiendaten\u00a0 mit\u00a0 Surrogatparametern\u00a0 als\u00a0 prim\u00e4ren\u00a0 Endp unkten\u00a0 zur\u00a0\nZulassung\u00a0empfohlen\u00a0und\u00a0im\u00a0M\u00e4rz\u00a02014\u00a0seitens\u00a0des\u00a0EU\u2010Kommission\u00a0 (EC)\u00a0unter\u00a0\nVorbehalt\u00a0zugelassen\u00a0( Conditional\u00a0Marketing\u00a0Authorization ).\u00a0Die\u00a0EMA\u00a0verpflichtet\u00a0\nden\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulassung,\u00a0 eine\u00a0Vielzahl\u00a0\nweiterer\u00a0 Studienergebnisse\u00a0 einsc hlie\u00dflich\u00a0 einer\u00a0 Phase\u2010III\u2010Studi e\u00a0 (STREAM\u00a0 NCT\u00a0\n02409290)\u00a0 bis\u00a0 2021\u00a0 vorzulegen\u00a0 (CHMP,\u00a0 2013;\u00a0 ClinicalTrials.gov,\u00a0 2015).\u00a0 Zudem\u00a0\nerfolgt\u00a0im\u00a0Rahmen\u00a0des\u00a0Risikomanagementplans\u00a0eine\u00a0engmaschige\u00a0Pr \u00fcfung\u00a0durch\u00a0\nden\u00a0Ausschuss\u00a0 Pharmacovigilance\u00a0Risk\u00a0Assessment\u00a0Committee \u00a0(PRAC)\u00a0der\u00a0EMA.\u00a0\u00a0\nBereits\u00a0im\u00a0Dezember\u00a02012\u00a0erfolgte\u00a0die\u00a0Zulassung\u00a0seitens\u00a0der\u00a0ame rikanischen\u00a0Zulas\u2010\nsungsbeh\u00f6rde\u00a0 Food\u00a0and\u00a0Drug\u00a0Administration ,\u00a0FDA,\u00a0ebenfalls\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0\nim\u00a0beschleunigten\u00a0Verfahren\u00a0(Avorn,\u00a02013)\u00a0basierend\u00a0auf\u00a0Phase\u2010I Ib\u2010Studienergebnis\u2010\nsen,\u00a0wobei\u00a0die\u00a0urspr\u00fcnglich\u00a0vom\u00a0pU\u00a0Janssen\u00a0avisierte\u00a0Indikation :\u00a0\u201eBehandlung\u00a0Er\u2010\nwachsener\u00a0mit\u00a0multiresistenter\u00a0Lungentuberkulose\u00a0(MDR\u2010TB)\u00a0als\u00a0T eil\u00a0einer\u00a0Kombina\u2010\ntionsbehandlung\u201c\u00a0 (eigene\u00a0 \u00dcbersetzung)\u00a0 eingeschr\u00e4nkt\u00a0 wurde\u00a0 auf\u00a0 P atienten,\u00a0 bei\u00a0\ndenen\u00a0anderweitige\u00a0Therapien\u00a0nicht\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen\u00a0(CDER,\u00a0 2012a).\u00a0Bedaquilin\u00a0\nist\u00a0in\u00a0der\u00a0EU\u00a0\u201ebei\u00a0erwachsenen\u00a0Patienten\u00a0als\u00a0Teil\u00a0einer\u00a0geeigne ten\u00a0Kombinationsthe\u2010\nrapie\u00a0der\u00a0multiresistenten\u00a0pulmonalen\u00a0Tuberkulose,\u00a0[...]\u00a0wenn\u00a0e in\u00a0wirksames\u00a0Be\u2010\nhandlungsregime\u00a0 aufgrund\u00a0 von\u00a0 Resistenzen\u00a0 oder\u00a0 Unvertr\u00e4glichkeit \u00a0 nicht\u00a0 anders\u00a0\nzusammengestellt\u00a0werden\u00a0kann\u201c\u00a0zugelassen\u00a0(CHMP,\u00a02014a).\u00a0Bedaqui lin\u00a0wird\u00a0zus\u00e4tz\u2010\nlich\u00a0zu\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0weiteren\u00a0Antituberkulotika\u00a0initial\u00a0\u00fcber\u00a0z wei\u00a0Wochen\u00a0mit\u00a0400\u00a0mg\u00a0\nt\u00e4glich\u00a0 nach\u00a0 dem\u00a0 Fr\u00fchst\u00fcck,\u00a0 danach\u00a0 \u00fcber\u00a0 22\u00a0 Wochen\u00a0 mit\u00a0 dreimal\u00a0 w \u00f6chentlich\u00a0\n200\u00a0mg\u00a0nach\u00a0einer\u00a0Mahlzeit\u00a0gegeben\u00a0(Zeitabstand\u00a048\u00a0Stunden).\u00a0Es \u00a0ist\u00a0vorwiegend\u00a0als\u00a080\u00a0direkt\u00a0\u00fcberwachte\u00a0Therapie\u00a0( Directly\u00a0Observed\u00a0Therapy ,\u00a0DOT)\u00a0gedacht,\u00a0um\u00a0die\u00a0Adh\u00e4\u2010\nrenz\u00a0zu\u00a0gew\u00e4hrleisten.\u00a0\nDie\u00a0Therapie\u00a0der\u00a0Tuberkulose,\u00a0an\u00a0der\u00a0weltweit\u00a09\u00a0Mio.\u00a0Menschen\u00a0e rkranken\u00a0und\u00a01,8\u00a0\nMio.\u00a0Menschen\u00a0versterben\u00a0(Haas\u00a0et\u00a0al.,\u00a02016),\u00a0stellt\u00a0eine\u00a0globa le\u00a0Herausforderung\u00a0\ndar,\u00a0insbesondere,\u00a0wenn\u00a0es\u00a0sich\u00a0um\u00a0multiresistente\u00a0oder\u00a0gar\u00a0ext remresistente\u00a0Erre\u2010\nger\u00a0(XDR\u2010TB)\u00a0handelt.\u00a0In\u00a0diesem\u00a0Kontext\u00a0ist\u00a0es\u00a0zu\u00a0verstehen,\u00a0da ss\u00a0sowohl\u00a0FDA\u00a0als\u00a0\nauch\u00a0 EMA\u00a0 eine\u00a0 bedingte\u00a0 Zulassung\u00a0 basierend\u00a0 auf\u00a0 Phase\u2010IIb\u2010Studie nergebnissen\u00a0\nerm\u00f6glichten.\u00a0Vom\u00a0pU\u00a0wurden\u00a0zulassungsbegr\u00fcndend\u00a0die\u00a0zweistufig e\u00a0Studie\u00a0C208,\u00a0\n(die\u00a0eher\u00a0als\u00a0zwei\u00a0singul\u00e4re\u00a0Studien\u00a0mit\u00a0denselben\u00a0Methoden,\u00a0En dpunkten\u00a0und\u00a0Ba\u2010\nsistherapieregimen\u00a0zu\u00a0betrachten\u00a0ist)\u00a0und\u00a0Daten\u00a0der\u00a0Studie\u00a0C209 \u00a0vorgelegt\u00a0(CDER,\u00a0\n2012a;\u00a0CHMP,\u00a02013).\u00a0\nDie\u00a0Zulassungsstudie\u00a0C208\u00a0Stufe\u00a01\u00a0(Sponsor:\u00a0Janssen,\u00a0NCT0044964 4)\u00a0ist\u00a0multizent\u2010\nrisch,\u00a0 doppelblind,\u00a0 1:1\u00a0 randomisiert\u00a0 und\u00a0 placebokontrolliert\u00a0 al s\u00a0 Phase\u2010IIb\u2010Studie\u00a0\ndurchgef\u00fchrt\u00a0 worden.\u00a0 47\u00a0 Patienten\u00a0 mit\u00a0 neu\u00a0 diagnostizierter\u00a0 pulm onaler\u00a0 MDR\u2010TB\u00a0\nerhielten\u00a0zus\u00e4tzlich\u00a0zum\u00a0Basistherapieregime\u00a0(BR)\u00a0aus\u00a0Kanamycin ,\u00a0Ofloxacin,\u00a0Ethio\u2010\nnamid,\u00a0Pyrazinamid\u00a0sowie\u00a0Cyclose rin\u00a0oder\u00a0Terizidon\u00a0entweder\u00a0Bed aquilin\u00a0(n=23)\u00a0oder\u00a0\nPlacebo\u00a0(n=24)\u00a0f\u00fcr\u00a0eine\u00a0Therapiedauer\u00a0von\u00a0acht\u00a0Wochen\u00a0sowie\u00a0nac hfolgend\u00a0die\u00a0Fort\u2010\nf\u00fchrung\u00a0der\u00a0Therapie\u00a0m it\u00a0BR.\u00a0Bedaqu ilin\u00a0wurde\u00a0initial\u00a014\u00a0Tage\u00a0l ang\u00a0mit\u00a0400\u00a0mg\u00a0t\u00e4glich,\u00a0\ndanach\u00a0\u00fcber\u00a06\u00a0Wochen\u00a0mit\u00a0200\u00a0mg\u00a0dreimal\u00a0w\u00f6chentlich\u00a0gegeben.\u00a0Pr im\u00e4rer\u00a0Endpunkt\u00a0\nwar\u00a0die\u00a0mediane\u00a0Zeit\u00a0bis\u00a0zum\u00a0Vorliegen\u00a0einer\u00a0TB\u2010negativen\u00a0Sputu mkultur,\u00a0die\u00a0soge\u2010\nnannte\u00a0Sputum\u00a0Culture\u00a0Conversion\u00a0(SCC)\u00a0bis\u00a0zur\u00a0Woche\u00a0acht.\u00a0Die\u00a0 Autoren\u00a0nutzten\u00a0\neine\u00a0 modifizierte\u00a0 Intention\u2010to\u2010treat\u00a0 Population.\u00a0 Sekund\u00e4re\u00a0 Endp unkte\u00a0 waren\u00a0 der\u00a0\nAnteil\u00a0Patienten\u00a0mit\u00a0SCC\u00a0sowie\u00a0d ie\u00a0Evaluation\u00a0der\u00a0Pharmakokinet ik,\u00a0Sicherheit\u00a0und\u00a0\nWirksamkeit.\u00a0Die\u00a0Nachbeobachtungsphase\u00a0dauerte\u00a096\u00a0Wochen.\u00a0In\u00a0de r\u00a0BR\u00a0plus\u00a0Be\u2010\ndaquilin\u2010Gruppe\u00a0konnte\u00a0eine\u00a0Verk\u00fcrzung\u00a0der\u00a0Zeit\u00a0bis\u00a0SCC\u00a0erzielt \u00a0werden.\u00a0Die\u00a0SCC\u2010Rate\u00a0\nwar\u00a0mit\u00a048\u00a0%\u00a0besser\u00a0als\u00a0in\u00a0der\u00a0BR\u00a0plus\u00a0Placebo\u2010Gruppe\u00a0(9\u00a0%)\u00a0(Di acon\u00a0et\u00a0al.,\u00a02009).\u00a0\nDie\u00a0 zweite\u00a0 Stufe\u00a0 der\u00a0 Zulassungsstudie\u00a0 C208\u00a0 Stage\u00a0 2\u00a0 (Sponsor:\u00a0 Ja nssen,\u00a0 NCT\u00a0\n00449644)\u00a0wurde\u00a0mit\u00a0dem\u00a0Ziel\u00a0eines\u00a0Nachweises\u00a0der\u00a0Erfolgswirksa mkeit\u00a0als\u00a0multi\u2010\nzentrische,\u00a0 doppelblinde,\u00a0 1:1\u00a0 randomisierte\u00a0 und\u00a0 placebokontroll ierte\u00a0 Phase\u2010IIb\u2010\nStudie\u00a0durchgef\u00fchrt.\u00a0160\u00a0neu\u00a0diagnostizierte\u00a0MDR\u2010TB\u00a0Patienten\u00a0e rhielten\u00a0zus\u00e4tzlich\u00a0\nzu\u00a0BR,\u00a0das\u00a0auch\u00a0die\u00a0regionalen\u00a0BR\u00a0ber\u00fccksichtigte,\u00a0\u00fcber\u00a018\u00a0bis\u00a0 24\u00a0Monate\u00a0entweder\u00a0\nBedaquilin\u00a0oder\u00a0Placebo\u00a0f\u00fcr\u00a024\u00a0Wochen.\u00a0Die\u00a0Dosierung\u00a0erfolgte\u00a0a nalog\u00a0C208\u00a0Stufe\u00a01.\u00a0\nNunmehr\u00a0wurden\u00a0als\u00a0Ausschlusskriterien\u00a0Patienten\u00a0unter\u00a0Gyrasehe mmern\u00a0(Moxi\u2010\u00a0\noder\u00a0 Gatifloxacin),\u00a0 CYP\u20103A4\u2010Induktoren\u00a0 bzw.\u00a0 \u2010Inhibitoren\u00a0 sowie\u00a0 HIV\u2010seropositive\u00a0\nPatienten\u00a0(CD4+\u00a0Zellstatus\u00a0<300/ml\u00a0bzw.\u00a0antiretroviraler\u00a0Therap ie,\u00a0ARV)\u00a0definiert.\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0wiederum\u00a0der\u00a0Surrogatparameter\u00a0\"Zeit\"\u00a0bis \u00a0zur\u00a0SCC.\u00a0Patien\u2010\nten\u00a0unter\u00a0BR\u00a0plus\u00a0Bedaquilin\u00a0zeigten\u00a0median\u00a0bereits\u00a0nach\u00a083\u00a0Tag en\u00a0SCC,\u00a0unter\u00a0BR\u00a0\nplus\u00a0Placebo\u00a0war\u00a0dies\u00a0median\u00a0nach\u00a0125\u00a0Tagen\u00a0der\u00a0Fall.\u00a0Weiterhin \u00a0wurde\u00a0nach\u00a024\u00a081\u00a0Wochen\u00a0die\u00a0Rate\u00a0der\u00a0TB\u2010freien\u00a0Kulturen\u00a0als\u00a0sekund\u00e4rer\u00a0Endpunkt\u00a0 verglichen.\u00a0Unter\u00a0\nBR\u00a0plus\u00a0Bedaquilin\u00a0waren\u00a079\u00a0%\u00a0TB\u2010frei,\u00a0unter\u00a0BR\u00a0plus\u00a0Placebo\u00a0nu r\u00a058\u00a0%.\u00a0Basierend\u00a0\nauf\u00a0der\u00a0Definition\u00a0der\u00a0WHO\u00a0zur\u00a0Heilung\u00a0der\u00a0MDR\u2010TB\u00a0konnten\u00a0nach\u00a0 120\u00a0Wochen\u00a058\u00a0%\u00a0\nder\u00a0Patienten\u00a0mit\u00a0BR\u00a0plus\u00a0Bedaquilin\u00a0und\u00a032\u00a0%\u00a0der\u00a0Patienten\u00a0mit \u00a0BR\u00a0plus\u00a0Placebo\u00a0als\u00a0\ngeheilt\u00a0definiert\u00a0und\u00a0die\u00a0klinische\u00a0Wirksamkeit\u00a0von\u00a0Bedaquilin\u00a0 bei\u00a0MDR\u2010TB\u00a0gegen\u2010\n\u00fcber\u00a0Placebo\u00a0gezeigt\u00a0werden\u00a0(Diacon\u00a0et\u00a0al.,\u00a02014).\u00a0\nIn\u00a0 der\u00a0 Zulassungsstudie\u00a0 C209\u00a0 (Sponsor:\u00a0 Janssen,\u00a0 NCT00910871),\u00a0 d ie\u00a0 multizen\u2010\ntrisch,\u00a0offen\u00a0und\u00a0einarmig\u00a0durchgef\u00fchrt\u00a0wurde,\u00a0erhielten\u00a0233\u00a0Pa tienten\u00a0mit\u00a0neu\u00a0di\u2010\nagnostizierter\u00a0oder\u00a0k\u00fcrzlich\u00a0behandelter\u00a0MDR\u2010TB\u00a0(63,5\u00a0%),\u00a0pre\u2010X DR\u2010TB\u00a0(18,9\u00a0%)\u00a0\noder\u00a0XDR\u2010TB\u00a0(16,3\u00a0%)\u00a0zus\u00e4tzlich\u00a0zu\u00a0einem\u00a0BR\u00a0gem\u00e4\u00df\u00a0regionalem\u00a0Ve rsorgungspro\u2010\ngramm\u00a0Bedaquilin\u00a0in\u00a0einer\u00a0Dosierung\u00a0analog\u00a0der\u00a0Studie\u00a0C208.\u00a0Pri m\u00e4rer\u00a0Endpunkt\u00a0\nwar\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0SCC\u00a0binnen\u00a024\u00a0Wochen.\u00a0Von\u00a0Pym\u00a0et\u00a0al.\u00a0wurde \u00a0berichtet,\u00a0dass\u00a0\nnach\u00a0120\u00a0Wochen\u00a072,2\u00a0%\u00a0eine\u00a0SCC\u00a0vorweisen\u00a0konnten,\u00a0wobei\u00a0untert eilt\u00a0werden\u00a0\nkann\u00a0nach\u00a0MDR\u2010TB\u00a0(73,1\u00a0%),\u00a0pr\u00e4\u2010XDR\u2010TB\u00a0(70,5\u00a0%)\u00a0sowie\u00a0XDR\u2010TB\u00a0(62 ,2\u00a0%)\u00a0(Pym\u00a0et\u00a0\nal.,\u00a02016).\u00a0\nIn\u00a0keiner\u00a0der\u00a0drei\u00a0Studien\u00a0wurde n\u00a0Daten\u00a0zur\u00a0gesundheitsbezogene n\u00a0Lebensqualit\u00e4t\u00a0\nder\u00a0Patienten\u00a0erhoben\u00a0(EMA,\u00a02013).\u00a0\nDas\u00a0Profil\u00a0der\u00a0unerw\u00fcnschten\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0ist\u00a0i m\u00a0Kontext\u00a0einer\u00a0the\u2010\nrapeutischen\u00a0Situation\u00a0zu\u00a0beurteilen,\u00a0in\u00a0der\u00a0Resistenzen\u00a0gegen\u00a0 viele\u00a0andere\u00a0Antitu\u2010\nberkulotika\u00a0gegeben\u00a0sind.\u00a0Komorbidit\u00e4ten,\u00a0wie\u00a0HIV\u2010Infektionen,\u00a0 mindern\u00a0die\u00a0Aus\u2010\nsichten\u00a0eines\u00a0Therapieerfolges\u00a0z us\u00e4tzlich.\u00a0Die\u00a0Therapie\u00a0mit\u00a0Bed aquilin\u00a0erfolgt\u00a0stets\u00a0in\u00a0\nKombination\u00a0mit\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0we iteren\u00a0Arzneimitteln.\u00a0In\u00a0den\u00a0Ph ase\u2010IIb\u2010Studien\u00a0wur\u2010\nde\u00a0ein\u00a0Anstieg\u00a0der\u00a0Leberenzyme\u00a0berichtet,\u00a0Verl\u00e4ngerungen\u00a0der\u00a0QT \u2010Zeit\u00a0kamen\u00a0vor,\u00a0\nteils\u00a0\u00fcber\u00a0500\u00a0msek,\u00a0des\u00a0Weiteren\u00a0Arthralgie,\u00a0Nausea\u00a0sowie\u00a0Inte raktionen,\u00a0basierend\u00a0\nauf\u00a0CYP3A4\u2010Metabolismus\u00a0von\u00a0Bedaquilin\u00a0und\u00a0Hauptmetabolit.\u00a0In\u00a0d er\u00a0Studie\u00a0C208\u00a0\nStufe\u00a0 zwei\u00a0 wurde\u00a0 unter\u00a0 Bedaquilin \u00a0 eine\u00a0 statistisch\u00a0 signifikante \u00a0\u00dc b e r s t e r b l i c h k e i t \u00a0\n(10:2)\u00a0beobachtet,\u00a0welche\u00a0nicht\u00a0erkl\u00e4rt\u00a0werden\u00a0konnte\u00a0(Cox\u00a0&\u00a0La essig,\u00a02014).\u00a0Dies\u00a0\nf\u00fchrte\u00a0einerseits\u00a0zur\u00a0Einschr\u00e4nkung\u00a0des\u00a0Anwendungsgebietes\u00a0(CDE R,\u00a02012a),\u00a0ande\u2010\nrerseits\u00a0zu\u00a0einem\u00a0umfangreichen\u00a0 Risikomanagementplan\u00a0(CHMP,\u00a0201 4b)\u00a0und\u00a0Hand\u2010\nlungsempfehlungen\u00a0zum\u00a0therapeutischen\u00a0Einsatz\u00a0von\u00a0Bedaquilin,\u00a0w elche\u00a0von\u00a0der\u00a0\nGesundheitsbeh\u00f6rde\u00a0der\u00a0USA\u00a0( Centers\u00a0for\u00a0Disease\u00a0Co ntrol\u00a0and\u00a0Prevention ,\u00a0CDC)\u00a0und\u00a0\nder\u00a0WHO\u00a0ver\u00f6ffentlicht\u00a0wurden\u00a0(CDC,\u00a02013;\u00a0WHO,\u00a02013).\u00a0\nAktuelle\u00a0Daten\u00a0zur\u00a0Evidenz\u00a0des\u00a0therapeutischen\u00a0Einsatzes\u00a0von\u00a0Be daquilin,\u00a0insbeson\u2010\ndere\u00a0auch\u00a0bei\u00a0HIV\u2010positiven\u00a0Pati enten,\u00a0bietet\u00a0ein\u00a0Review\u00a0der\u00a0WH O,\u00a0welches\u00a0den\u00a0\ntherapeutischen\u00a0Einsatz\u00a0gem\u00e4\u00df\u00a0der\u00a0WHO\u2010Leitlinien\u00a0empfiehlt,\u00a0exp lizit\u00a0auf\u00a0eine\u00a0m\u00f6g\u2010\nliche\u00a0Verl\u00e4ngerung\u00a0der\u00a0QT\u2010Zeit\u00a0hinweist\u00a0und\u00a0die\u00a0Anzahl\u00a0der\u00a0Tode sf\u00e4lle\u00a0unter\u00a0Thera\u2010\npie\u00a0mit\u00a0Bedaquilin\u00a0in\u00a0praxi\u00a0relat iviert\u00a0(Gonzalez\u2010Angulo,\u00a02016) .\u00a082\u00a0Die\u00a0Zulassung\u00a0von\u00a0Bedaquilin\u00a0wird\u00a0in\u00a0der\u00a0Fach\u00f6ffentlichkeit\u00a0mit unter\u00a0kritisch\u00a0hinter\u2010\nfragt.\u00a0Avorn\u00a0kritisiert\u00a0die\u00a0FDA\u2010Zulassung,\u00a0da\u00a0die\u00a0Datenlage\u00a0auf \u00a0einer\u00a0geringen\u00a0Anzahl\u00a0\nvon\u00a0Patienten\u00a0basiert\u00a0und\u00a0als\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Surrogatpar ameter\u00a0SCC\u00a0nach\u00a08\u00a0\nbzw.\u00a024\u00a0Wochen\u00a0 gew\u00e4hlt\u00a0wurde,\u00a0 welcher\u00a0bei\u00a0sp\u00e4teren\u00a0 Auswertungsz eitpunkten\u00a0\nnicht\u00a0 mehr\u00a0 signifikant\u00a0 erscheint.\u00a0 Die\u00a0 \u00dcbersterblichkeit\u00a0 in\u00a0 Stud ie\u00a0 C208\u00a0 unter\u00a0 Be\u2010\ndaquilin\u00a0beunruhigt\u00a0dahingehend,\u00a0dass\u00a0bei\u00a0f\u00fcnf\u00a0der\u00a010\u00a0Todesf\u00e4ll e\u00a0das\u00a0Fortschreiten\u00a0\nder\u00a0Tuberkulose\u00a0die\u00a0Ursache\u00a0war\u00a0(Avorn,\u00a02013).\u00a0\nF\u00fcr\u00a0eine\u00a0Bewertung\u00a0eines\u00a0neuen\u00a0Arzneimittels\u00a0durch\u00a0den\u00a0Gemeinsa men\u00a0Bundesaus\u2010\nschuss\u00a0(G\u2010BA)\u00a0wird\u00a0vorausgesetzt,\u00a0dass\u00a0eine\u00a0Erstattung\u00a0durch\u00a0di e\u00a0gesetzliche\u00a0Kran\u2010\nkenversicherung\u00a0(GKV)\u00a0erfolgen\u00a0kann.\u00a0Zum\u00a0Markteintritt\u00a0hat\u00a0der\u00a0 pU\u00a0Bedaquilin\u00a0in\u00a0\neiner\u00a0Packung\u00a0mit\u00a0188\u00a0Tabletten\u00a0in\u00a0den\u00a0Handel\u00a0gebracht,\u00a0welche\u00a0 durch\u00a0\u00dcberschrei\u2010\nten\u00a0der\u00a0Messzahl\u00a0nicht\u00a0zu\u00a0Lasten\u00a0der\u00a0GKV\u00a0abrechnungsf\u00e4hig\u00a0war.\u00a0 Hiermit\u00a0hat\u00a0der\u00a0\u00a0\nG\u2010BA\u00a0auch\u00a0die\u00a0 Einstellung\u00a0des\u00a0Verfahrens \u00a0begr\u00fcndet\u00a0(G\u2010BA,\u00a02014a,\u00a02014b).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0\nNeues\u00a0Therapieprinzip\u00a0f\u00fcr\u00a0\nmultiresistente\u00a0Lungen\u2010\ntuberkulose\u00a0(MDR\u2010TB)\u00a0\nATP\u2010Synthase\u2010Hemmer\u00a0In\u00a0Zulassungsstudie\u00a0unter\u00a0\nBedaquilin\u00a0mehr\u00a0\nTodesf\u00e4lle.\u00a0\nOrphan\u2010Arzneimittel;\u00a0\u00a0\nG\u2010BA\u00a0Verfahren\u00a0\neingestellt.\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung \u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0Judgement\u00a0\nreserved\u00a0\u00a0Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff \u00a0 Behandlungsmodus \u00a0Behandlungstage \u00a0Jahrestherapiekosten \u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nBedaquilin\u00a0 2\u00a0Wochen\u00a04\u00a0Tbl.\u00a0tgl.,\u00a0\ndanach\u00a03x\u00a02\u00a0\nw\u00f6chentlich\u00a0\n(insgesamt\u00a0188)\u00a0168\u00a0Tage\u00a0 33.389,82\u00a0\u20ac\u00a0\nMit\u00a0Einf\u00fchrung\u00a0einer\u00a0kleineren\u00a0Packungsgr\u00f6\u00dfe\u00a0(24\u00a0Tabletten)\u00a0zum \u00a01.\u00a0M\u00e4rz\u00a02016\u00a0und\u00a0\nR\u00fccknahme\u00a0der\u00a0Packungsgr\u00f6\u00dfe\u00a0mit\u00a0188\u00a0Tabletten\u00a0zum\u00a015.\u00a0Mai\u00a02016\u00a0 ergab\u00a0sich\u00a0\neinerseits\u00a0eine\u00a0GKV\u2010konforme\u00a0Abrechnungsm\u00f6glichkeit,\u00a0d.h.\u00a0Wegfa ll\u00a0der\u00a0Begr\u00fcn\u2010\n83\u00a0dung\u00a0der\u00a0Einstellung\u00a0des\u00a0Nutzenbewertungsverfahrens\u00a0des\u00a0G\u2010BA\u00a0un d\u00a0andererseits\u00a0\neine\u00a0Erh\u00f6hung\u00a0der\u00a0Therapiekosten\u00a0um\u00a01.102,05\u00a0Euro,\u00a0da\u00a0nun\u00a0acht\u00a0 mal\u00a0eine\u00a0Packung\u00a0\nmit\u00a0je\u00a024\u00a0Tabletten\u00a0zur\u00a0Therapie\u00a0ben\u00f6tigt\u00a0werden\u00a0(Lauer\u2010Fischer ,\u00a02017).\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0wurde\u00a0keine\u00a0Versorgun gsanalyse\u00a0erstellt.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nDas\u00a0Diarylchinolin\u00a0Bedaquilin\u00a0blockiert\u00a0spezifisch\u00a0das\u00a0zur\u00a0Ener giegewinnung\u00a0von\u00a0\nMycobacterium\u00a0 tuberculosis\u00a0 notwe ndige\u00a0 Enzym\u00a0 ATP(Adenosin\u20105\u2018\u2010tri phosphat)\u2010\nSynthase.\u00a0Somit\u00a0wirkt\u00a0es\u00a0bakterizid\u00a0auf\u00a0sowohl\u00a0sich\u00a0teilende\u00a0al s\u00a0auch\u00a0sich\u00a0nicht\u2010\nteilende\u00a0Tuberkelbakterien.\u00a0Die\u00a0Wirkung\u00a0von\u00a0Bedaquilin\u00a0konnte\u00a0g egen\u00a0empfindli\u2010\nche\u00a0und\u00a0resistente\u00a0(multiresistente\u00a0(MDR H&R\u2010TB)\u00a0einschlie\u00dflich\u00a0pr\u00e4\u2010extensiv\u00a0resis\u2010\ntenter\u00a0(pr\u00e4\u2010XDR\u2010TB)\u00a0und\u00a0extensiv\u00a0resistenter\u00a0St\u00e4mme\u00a0(XDR\u2010TB)\u00a0vo n\u00a0Mycobacteri\u2010\num\u00a0tuberculosis\u00a0gezeigt\u00a0werden.\u00a0Hierbei\u00a0liegt\u00a0die\u00a0minimale\u00a0Hemm konzentration\u00a0\nim\u00a0Bereich\u00a0von\u00a0\u2264\u00a00,008\u00a0bis\u00a00,12\u00a0mg/l.\u00a0\nResistenzen\u00a0gegen\u00a0Bedaquilin\u00a0beruhen\u00a0auf\u00a0Mutationen\u00a0im\u00a0atpE\u2010Gen \u00a0(Zielstruktur\u00a0\ndes\u00a0Wirkstoffes)\u00a0und\u00a0im\u00a0Rv0678\u2010Gen,\u00a0das\u00a0eine\u00a0Effluxpumpe\u00a0kodier t.\u00a0Erstere\u00a0bedin\u2010\ngen\u00a0eine\u00a08\u2010\u00a0bis\u00a0133\u2010fache\u00a0MHK\u2010Erh\u00f6hung,\u00a0letztere\u00a0eine\u00a0zwei\u2010\u00a0bis \u00a0achtfache.\u00a0Als\u00a0\nepidemiologischer\u00a0 Cut\u2010Off\u00a0(ECOFF)\u00a0wird\u00a0ein\u00a0Wert\u00a0von\u00a00,25\u00a0Milligramm\u00a0je\u00a0Liter\u00a0\nangegeben,\u00a0d.h.\u00a0bei\u00a0Werten\u00a0\u00fcber\u00a00,25\u00a0mg/l\u00a0ist\u00a0von\u00a0einer\u00a0Resiste nz\u00a0der\u00a0Mycobakte\u2010\nrien\u00a0auszugehen.\u00a0\nPraxisrelevant\u00a0ist\u00a0eine\u00a0kontinui erliche\u00a0Einnahme\u00a0des\u00a0Arzneimitt els\u00a0\u00fcber\u00a0einen\u00a0Zeit\u2010\nraum\u00a0von\u00a024\u00a0Wochen,\u00a0was\u00a0eine\u00a0hohe\u00a0Therapietreue\u00a0der\u00a0Patienten\u00a0w \u00e4hrend\u00a0der\u00a0\ngesamten\u00a0Therapiedauer\u00a0voraussetzt.\u00a0Unerw\u00fcnschte\u00a0Arzneimittelwi rkungen\u00a0bzw.\u00a0\nInteraktionen\u00a0sind\u00a0hierbei\u00a0zu\u00a0beachten.\u00a0Bedaquilin\u00a0wird\u00a0einmal\u00a0 t\u00e4glich\u00a0mit\u00a0einer\u00a0\nMahlzeit\u00a0eingenommen,\u00a0da\u00a0sich\u00a0hierdurch\u00a0die\u00a0orale\u00a0Bioverf\u00fcgbark eit\u00a0(Area\u00a0Under\u00a0\nthe\u00a0Curve ,\u00a0AUC)\u00a0im\u00a0Vergleich\u00a0zur\u00a0N\u00fcchtern gabe\u00a0verbessert,\u00a0d.h.\u00a0ca.\u00a0zweif ach\u00a0er\u2010\nh\u00f6ht.\u00a0Auf\u00a0Wechselwirkungen\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0ist\u00a0zu\u00a0ach ten,\u00a0da\u00a0der\u00a0Ab\u2010\nbau\u00a0von\u00a0Bedaquilin\u00a0\u00fcber\u00a0das\u00a0Cytochrom\u2010P 450\u2010Isoenzym\u00a03A4\u00a0(CYP3A4)\u00a0erfolgt.\u00a0Eine\u00a0\nInteraktionsstudie\u00a0mit\u00a0einer\u00a0Einzeldosis\u00a0Bedaquilin\u00a0in\u00a0Kombinat ion\u00a0mit\u00a0Rifampicin\u00a0\n(starker\u00a0CYP3A4\u2010Induktor)\u00a0an\u00a0ge sunden\u00a0Probanden\u00a0zeigte,\u00a0dass\u00a0di e\u00a0Bioverf\u00fcgbar\u2010\nkeit\u00a0von\u00a0Bedaquilin\u00a0um\u00a052\u00a0%\u00a0vermindert\u00a0war\u00a0(CHMP,\u00a02014b).\u00a0Wie\u00a0s ich\u00a0dies\u00a0im\u00a0\nklinischen\u00a0Alltag\u00a0bei\u00a0multimorbiden\u00a0Patienten\u00a0mit\u00a0einer\u00a0Pharmak otherapie\u00a0von\u00a0\nBedaquiln\u00a0in\u00a0 Steady\u2010State \u2010Konzentration\u00a0(c ss)\u00a0darstellt,\u00a0ist\u00a0noch\u00a0zu\u00a0pr\u00fcfen.\u00a0Bei\u00a0einer\u00a0\nzeitgleichen\u00a0Erkrankung\u00a0an\u00a0HIV\u00a0sind\u00a0Interaktionen\u00a0mit\u00a0antiretro viralen\u00a0Arzneimit\u2010\nteln\u00a0zu\u00a0beachten.\u00a0Wurde\u00a0eine\u00a0Einzeldosis\u00a0Bedaquilin\u00a0zu\u00a0Mehrfach dosen\u00a0der\u00a0Kom\u2010\nbination\u00a0Lopinavir/Ritonavir\u00a0gegeben,\u00a0war\u00a0die\u00a0AUC\u00a0von\u00a0Bedaquili n\u00a0um\u00a022\u00a0%\u00a0er\u201084\u00a0h\u00f6ht.\u00a0Der\u00a0pU\u00a0f\u00fchrt\u00a0dies\u00a0auf\u00a0den\u00a0 Booster\u00a0Ritonavir\u00a0zur\u00fcck.\u00a0Bei\u00a0der\u00a0Gabe\u00a0von\u00a0Mehr\u2010\nfachdosen\u00a0des\u00a0Wirkstoffes\u00a0Nevira pin\u00a0konnte\u00a0keine\u00a0klinisch\u00a0signi fikante\u00a0\u00c4nderung\u00a0\nder\u00a0AUC\u00a0von\u00a0einer\u00a0Einzeldosis\u00a0Bedaquilin\u00a0gezeigt\u00a0werden.\u00a0Eine\u00a0g emeinsame\u00a0The\u2010\nrapie\u00a0mit\u00a0dem\u00a0CYP\u20103A4\u2010Induktor\u00a0Efavirenz\u00a0und\u00a0Bedaquilin\u00a0wird\u00a0se itens\u00a0des\u00a0pU\u00a0\nnicht\u00a0empfohlen,\u00a0da\u00a0man\u00a0eine\u00a0verminderte\u00a0AUC\u00a0von\u00a0Bedaquilin\u00a0und \u00a0somit\u00a0einen\u00a0\nWirkungsverlust\u00a0f\u00fcrchtet.\u00a0\nSowohl\u00a0die\u00a0sehr\u00a0hohe\u00a0Bindung\u00a0an\u00a0Plasmaeiwei\u00dfe\u00a0von\u00a0Bedaquilin\u00a0un d\u00a0des\u00a0Haupt\u2010\nmetaboliten\u00a0M2\u00a0als\u00a0auch\u00a0die\u00a0sehr \u00a0lange\u00a0terminale\u00a0Eliminationsha lbwertzeit,\u00a0wel\u2010\nche\u00a0zwischen\u00a0zwei\u00a0und\u00a0acht\u00a0Monaten\u00a0betr\u00e4gt,\u00a0im\u00a0Mittel\u00a0f\u00fcnf\u00a0Mona te,\u00a0sind\u00a0im\u00a0\nKontext\u00a0von\u00a0Interaktionen\u00a0zu\u00a0beachten.\u00a0Somit\u00a0muss\u00a0man\u00a0beachten, \u00a0dass\u00a0Wech\u2010\nselwirkungen\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0auch\u00a0nach\u00a0Absetzen\u00a0einer \u00a0Pharmakothe\u2010\nrapie\u00a0mit\u00a0Bedaquilin\u00a0noch\u00a0theoretisch\u00a0bis\u00a0zu\u00a040\u00a0Monate\u00a0(l\u00e4nger\u00a0 als\u00a0drei\u00a0Jahre)\u00a0\nauftreten\u00a0k\u00f6nnten.\u00a0Bedaquilin\u00a0ve rl\u00e4ngert\u00a0das\u00a0QTc\u2010Intervall.\u00a0Die s\u00a0ist\u00a0bei\u00a0Patienten\u00a0\nmit\u00a0einer\u00a0angeborenen\u00a0QT\u2010Zeitver l\u00e4ngerung\u00a0sowie\u00a0kumulativen\u00a0Eff ekten\u00a0in\u00a0Folge\u00a0\nvon\u00a0Kombinationstherapien\u00a0verschiedener\u00a0Arzneimittel\u00a0zu\u00a0beachte n.\u00a0Zur\u00a0Risikomi\u2010\nnimierung\u00a0 sollten\u00a0 vor\u00a0 und\u00a0 w\u00e4hre nd\u00a0 der\u00a0 Behandlung\u00a0 mit\u00a0 Bedaquilin \u00a0E K G \u2010\nKontrolluntersuchungen\u00a0 durchgef\u00fchrt\u00a0 werden.\u00a0 Auswirkungen\u00a0 der\u00a0 Th erapie\u00a0 mit\u00a0\nBedaquilin\u00a0auf\u00a0die\u00a0Leberfunktion,\u00a0speziell\u00a0ein\u00a0Anstieg\u00a0der\u00a0Tran saminasen,\u00a0sollte\u00a0\nbeachtet\u00a0werden.\u00a0\nDie\u00a0Tabletten\u00a0sollen\u00a0im\u00a0Originalb eh\u00e4ltnis\u00a0aufbewahrt\u00a0werden,\u00a0um \u00a0einen\u00a0Licht\u2010\nschutz\u00a0des\u00a0Produktes\u00a0zu\u00a0gew\u00e4hrlei sten\u00a0(CHMP,\u00a02014b).\u00a0In\u00a0diesem\u00a0 Kontext\u00a0ist\u00a0die\u00a0\nzeitweilige\u00a0Empfehlung\u00a0des\u00a0pU\u00a0zur\u00a0Auseinzelung\u00a0aus\u00a0dem\u00a0Original beh\u00e4ltnis\u00a0zwecks\u00a0\nHerbeif\u00fchrung\u00a0einer\u00a0Erstattungsf\u00e4higkeit\u00a0im\u00a0ambulanten\u00a0Bereich\u00a0 kritisch\u00a0zu\u00a0w\u00fcrdi\u2010\ngen\u00a0(Janssen,\u00a02014a,\u00a02014b;\u00a0KVWL,\u00a02014).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nBedaquilin\u00a0wurde\u00a0von\u00a0der\u00a0EU\u00a0Kommission\u00a0(European\u00a0Commission,\u00a0EC )\u00a0am\u00a05.\u00a0M\u00e4rz\u00a0\n2014\u00a0bedingt\u00a0( Conditional\u00a0approval )\u00a0als\u00a0Arzneimittel\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Leiden\u00a0\n(Orphan\u2010designation )\u00a0 unter\u00a0 zus\u00e4tzlicher\u00a0 \u00dcberwachung\u00a0 ( Additional\u00a0 monitoring )\u00a0\ndurch\u00a0die\u00a0EMA\u00a0zugelassen\u00a0(CHMP,\u00a02014a).\u00a0\nF\u00fcr\u00a0Patienten\u00a0mit\u00a0lebensbedrohlic hen\u00a0Krankheiten\u00a0k\u00f6nnen\u00a0Arzneim ittel\u00a0bereits\u00a0vor\u00a0\nAbschluss\u00a0 der\u00a0 vollst\u00e4ndigen\u00a0 klinischen\u00a0 Pr\u00fcfung\u00a0 im\u00a0 Rahmen\u00a0 einer\u00a0 sogenannten\u00a0\n\u201ebedingten\u00a0Zulassung\u201c\u00a0auf\u00a0den\u00a0Markt\u00a0gebracht\u00a0werden.\u00a0Eine\u00a0engma schige\u00a0\u00dcber\u2010\nwachung\u00a0durch\u00a0den\u00a0Ausschuss\u00a0PRAC\u00a0der\u00a0EMA\u00a0und\u00a0zeitliche\u00a0Befristu ng\u00a0der\u00a0Zulas\u2010\nsung\u00a0sollen\u00a0ein\u00a0positives\u00a0Nutzen\u2010Risiko\u2010Verh\u00e4ltnis\u00a0gew\u00e4hrleiste n.\u00a0Die\u00a0Arzneimittel\u00a0\nunter\u00a0besonderer\u00a0\u00dcberwachung\u00a0werde n\u00a0mit\u00a0Hilfe\u00a0eines\u00a0\u201eschwarzen\u00a0 Dreiecks\u201c\u00a0u.a.\u00a0\nin\u00a0der\u00a0Gebrauchsinformation\u00a0geke nnzeichnet\u00a0(BfArM,\u00a02013).\u00a0Von\u00a0s eltenen\u00a0Krank\u2010\nheiten\u00a0spricht\u00a0man\u00a0in\u00a0der\u00a0EU,\u00a0wenn\u00a0nur\u00a0f\u00fcnf\u00a0oder\u00a0weniger\u00a0je\u00a010. 000\u00a0Personen\u00a0in\u00a085\u00a0einem\u00a0Land\u00a0der\u00a0EU\u00a0betroffen\u00a0si nd.\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0d ieser\u00a0Krankheiten\u00a0\nerhalten\u00a0einen\u00a0besonderen\u00a0Zulassungsstatus\u00a0( Orphan\u2010Arzneimittel)\u00a0(BfArM,\u00a02013).\u00a0\nBedaquilin\u00a0ist\u00a0zugelassen\u00a0zur\u00a0Therapie\u00a0von\u00a0Erwachsenen\u00a0mit\u00a0mult iresistenter\u00a0Lun\u2010\ngentuberkulose,\u00a0wenn\u00a0andere\u00a0wirks ame\u00a0Behandlungsregime\u00a0in\u00a0Folge \u00a0von\u00a0Resitenz\u00a0\noder\u00a0Unvertr\u00e4glichkeit\u00a0nicht\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen.\u00a0Es\u00a0wird\u00a0stet s\u00a0kombiniert\u00a0mit\u00a0\ndrei\u00a0bis\u00a0vier\u00a0anderen\u00a0Antituberkulotika.\u00a0Eine\u00a0Therapie\u00a0unter\u00a0di rekter\u00a0\u00dcberwachung\u00a0\nwird\u00a0angeraten,\u00a0um\u00a0eine\u00a0100%ige\u00a0Adh\u00e4renz\u00a0zu\u00a0gew\u00e4hrleisten.\u00a0Die\u00a0 offiziellen\u00a0Leitli\u2010\nnien\u00a0zur\u00a0Therapie\u00a0zum\u00a0angemessenen\u00a0Gebrauch\u00a0von\u00a0antibakterielle n\u00a0Wirkstoffen\u00a0\nsind\u00a0zu\u00a0ber\u00fccksichtigen\u00a0(CHMP,\u00a02014b).\u00a0\nDie\u00a0 amerikanische\u00a0 Zulassungsbeh\u00f6rde\u00a0 FDA\u00a0 hat\u00a0 das\u00a0 seitens\u00a0 des\u00a0 pU\u00a0 beantragte\u00a0\nbreite\u00a0Anwendungsgebiet\u00a0\u201eBehandlung\u00a0Erwachsener\u00a0mit\u00a0multiresist enter\u00a0Lungen\u2010\ntuberkulose\u00a0(MDR\u2010TB)\u00a0als\u00a0Teil\u00a0einer\u00a0Kombinationsbehandlung\u201c\u00a0aus \u00a0Gr\u00fcnden\u00a0der\u00a0\nSicherheit,\u00a0speziell\u00a0der\u00a0erh\u00f6hten\u00a0Mortalit\u00e4t,\u00a0der\u00a0Verl\u00e4ngerung\u00a0 der\u00a0QT\u2010Zeit\u00a0sowie\u00a0\nm\u00f6glicher\u00a0hepatischer\u00a0Ereignisse \u00a0auf\u00a0das\u00a0aktuell\u00a0zugelassene\u00a0An wendungsgebiet\u00a0\neingegrenzt:\u00a0\u201eDer\u00a0Einsatz\u00a0von \u00a0Bedaquilin\u00a0ist\u00a0beschr\u00e4nkt\u00a0auf\u00a0den\u00a0Gebrauch\u00a0f\u00fcr\u00a0den\u00a0\nFall,\u00a0dass\u00a0ein\u00a0effektives\u00a0antimykobakterielles\u00a0Regime\u00a0anders\u00a0ni cht\u00a0bereitgestellt\u00a0\nwerden\u00a0kann\u201c\u00a0(CDER,\u00a02012a,\u00a0eigene\u00a0\u00dcbersetzung).\u00a0\nAb\u00a01.\u00a0M\u00e4rz\u00a02016\u00a0befindet\u00a0sich\u00a0eine\u00a0Packung\u00a0mit\u00a024\u00a0Tabletten\u00a0im\u00a0 Handel\u00a0neben\u00a0der\u00a0\nPackung\u00a0mit\u00a0188\u00a0Tabletten,\u00a0welche\u00a0f\u00fcr\u00a0die\u00a024\u2010w\u00f6chige\u00a0Therapie\u00a0a usreicht\u00a0und\u00a0in\u00a0\nder\u00a0Lauer\u2010Taxe\u00a0zum\u00a015.\u00a0Mai\u00a02016\u00a0au\u00dfer\u00a0Vertrieb\u00a0gemeldet\u00a0wurde\u00a0( DIMDI,\u00a02017;\u00a0\nWebApo\u00a0 Lauer\u2010Fischer,\u00a0 2017).\u00a0 Der\u00a0 Wechsel\u00a0 der\u00a0 Packungsgr\u00f6\u00dfen\u00a0 von \u00a0n i c h t \u2010\nnormiert\u00a0auf\u00a0N1\u00a0bedingt\u00a0einerseits\u00a0eine\u00a0Erstattungsf\u00e4higkeit\u00a0du rch\u00a0die\u00a0GKV,\u00a0ande\u2010\nrerseits\u00a0kommt\u00a0dies\u00a0einer\u00a0Preiserh\u00f6hung\u00a0gleich.\u00a0Eine\u00a0Packung\u00a0mi t\u00a0188\u00a0Tabletten\u00a0\nkostete\u00a032.998,19\u00a0Euro\u00a0und\u00a0bei\u00a0therapeutischer\u00a0Verwendung\u00a0der\u00a0j etzt\u00a0nur\u00a0noch\u00a0\nverf\u00fcgbaren\u00a0Packungen\u00a0mit\u00a024\u00a0Tabletten\u00a0(N1)\u00a0werdenf\u00fcr\u00a0eine\u00a024\u2010w \u00f6chige\u00a0Thera\u2010\npie\u00a0acht\u00a0Packungen\u00a0zu\u00a04.262,53\u00a0Euro\u00a0ben\u00f6tigt,\u00a0insgesamt\u00a0fallen\u00a0 nun\u00a0also\u00a034.100,24\u00a0\nEuro\u00a0an\u00a0(Preise\u00a0WebApo\u00a0Lauer\u2010Fischer,\u00a02017;\u00a0Stand\u00a015.04.2017).\u00a0 Um\u00a0eine\u00a0Erstat\u2010\ntung\u00a0seitens\u00a0der\u00a0GKV\u00a0herbeizuf\u00fchren,\u00a0d.h.\u00a0in\u00a0der\u00a0Zeit\u00a0von\u00a0Markt einf\u00fchrung\u00a0bis\u00a0zur\u00a0\nEtablierung\u00a0 der\u00a0 N1\u2010Packungsgr\u00f6sse,\u00a0 unterst\u00fctzte\u00a0 der\u00a0 pU\u00a0 \u00c4rzte\u00a0 un d\u00a0 Apotheker\u00a0\nmittels\u00a0exakter\u00a0Handlungsanweisungen\u00a0zur\u00a0sogenannten\u00a0\u201eAuseinzel ung\u201c\u00a0(Janssen,\u00a0\n2014a,\u00a02014b).\u00a0So\u00a0umging\u00a0der\u00a0pU\u00a0Janssen\u00a0die\u00a0Nutzenbewertung\u00a0dur ch\u00a0den\u00a0G\u2010BA.\u00a0\nZudem\u00a0wurde\u00a0durch\u00a0die\u00a0Handlungsanweisungen\u00a0ein\u00a0Mehraufwand\u00a0bei\u00a0 gesetzli\u2010\nchen\u00a0Kostentr\u00e4gen\u00a0infolge\u00a0von\u00a0Antr\u00e4gen\u00a0auf\u00a0Kosten\u00fcbernahme\u00a0f\u00fcr\u00a0 den\u00a0ambulan\u2010\nten\u00a0Bereich\u00a0und\u00a0nachfolgend\u00a0manue ller\u00a0Einzelfallabrechnungen\u00a0ve rursacht\u00a0(KVWL,\u00a0\n2014).\u00a0\nBedaquilin\u00a0wird\u00a0gem\u00e4\u00df\u00a0Fachinformat ion\u00a0w\u00e4hrend\u00a0der\u00a0Initialphase\u00a0 von\u00a0zwei\u00a0Wo\u2010\nchen\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a0400\u00a0mg\u00a0(vier\u00a0Tabletten)\u00a0t\u00e4glich\u00a0w\u00e4h rend\u00a0des\u00a0Fr\u00fch\u2010\nst\u00fccks\u00a0und\u00a0danach\u00a0\u00fcber\u00a022\u00a0Wochen\u00a0mit\u00a0dreimal\u00a0200\u00a0mg\u00a0w\u00f6chentlich \u00a0(48\u00a0Stunden\u00a086\u00a0Abstand\u00a0zwischen\u00a0den\u00a0Einzelgaben)\u00a0w\u00e4hrend\u00a0des\u00a0Fr\u00fchst\u00fccks\u00a0eingen ommen.\u00a0Eine\u00a0\nEinnahme\u00a0unter\u00a0direkter\u00a0\u00dcberwachung\u00a0wird\u00a0seitens\u00a0des\u00a0pU\u00a0empfohl en\u00a0(CHMP,\u00a0\n2014b).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nBei\u00a0TB\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0bakterielle\u00a0Infektionskrankheit, \u00a0die\u00a0durch\u00a0den\u00a0My\u2010\ncobacterium\u00a0tuberculosis\u00a0Komplex\u00a0verursacht\u00a0wird.\u00a0Neben\u00a0Malaria \u00a0und\u00a0HIV/AIDS\u00a0\nz\u00e4hlt\u00a0TB\u00a0weltweit\u00a0zu\u00a0den\u00a0h\u00e4ufigsten\u00a0Infektionskrankheiten.\u00a0Laut \u00a0Weltgesundheits\u2010\norganisation\u00a0WHO\u00a0soll\u00a0ein\u00a0Drittel\u00a0der\u00a0Weltbev\u00f6lkerung\u00a0infiziert \u00a0sein,\u00a0hiervon\u00a0er\u2010\nkranken\u00a0ca.\u00a05\u00a0bis\u00a010\u00a0%\u00a0der\u00a0Erwachsenen\u00a0in\u00a0Form\u00a0einer\u00a0behandlung sbed\u00fcrftigen\u00a0TB,\u00a0\nglobal\u00a0sind\u00a0dies\u00a0j\u00e4hrlich\u00a0ca.\u00a09\u00a0Mio.\u00a0Menschen\u00a0sowie\u00a0ca.\u00a01,8\u00a0Mio .\u00a0Todesf\u00e4lle\u00a0durch\u00a0\ndie\u00a0Folgen\u00a0der\u00a0TB\u00a0(Bruhn,\u00a02016). \u00a0Somit\u00a0ist\u00a0TB\u00a0die\u00a0weltweit\u00a0h\u00e4uf igste\u00a0Todesursache,\u00a0\nbei\u00a0HIV\u2010Infizierten\u00a0ist\u00a0sie\u00a0die\u00a0f\u00fchrende\u00a0Todesursache.\u00a0Im\u00a0Subsa hara\u2010Afrika\u00a0sowie\u00a0in\u00a0\nS\u00fcdostasien\u00a0und\u00a0der\u00a0westlichen\u00a0Pazifikregion\u00a0leben\u00a085\u00a0%\u00a0der\u00a0an\u00a0 TB\u00a0neu\u00a0erkrankten\u00a0\nPersonen.\u00a0Prinzipiell\u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0TB\u00a0um\u00a0eine\u00a0behandelba re\u00a0Erkrankung,\u00a0\nwobei\u00a0zunehmend\u00a0Resistenzen\u00a0gege n\u00a0etablierte\u00a0Pharmakotherapien\u00a0 und\u00a0Komor\u2010\nbidit\u00e4ten,\u00a0 speziell\u00a0 die\u00a0 Koinfekt ion\u00a0 mit\u00a0 HIV,\u00a0 zu\u00a0 ber\u00fccksichtigen \u00a0 sind.\u00a0 In\u00a0 Europa\u00a0\nnimmt\u00a0die\u00a0Inzidenz\u00a0(Anzahl\u00a0Erkrankter\u00a0je\u00a0100.000\u00a0Einwohner)\u00a0von \u00a0West\u00a0nach\u00a0Ost\u00a0\nzu,\u00a0d.h.\u00a0in\u00a0Westeuropa\u00a0ist\u00a0sie\u00a0kleiner\u00a0als\u00a015,\u00a0auf\u00a0dem\u00a0Balkan\u00a02 0\u00a0und\u00a0liegt\u00a0bei\u00a0\u00fcber\u00a0\n100\u00a0in\u00a0den\u00a0Neuen\u00a0Unabh\u00e4ngigen\u00a0Staaten\u00a0(GUS,\u00a0NUS;\u00a0Nachfolgestaat en\u00a0der\u00a0Sow\u2010\njetunion).\u00a0Bei\u00a0letzteren\u00a0erscheint\u00a0die\u00a0Situation\u00a0resistenter\u00a0Er reger\u00a0in\u00a0Folge\u00a0des\u00a0\nZusammenbruchs\u00a0der\u00a0\u00f6ffentlichen\u00a0Gesundheitswesen\u00a0eine\u00a0ernste\u00a0Ge fahr\u00a0darzu\u2010\nstellen\u00a0(RKI,\u00a02013).\u00a0\nDie\u00a0Inzidenz\u00a0der\u00a0TB\u00a0in\u00a0Deutschland\u00a0betrug\u00a0im\u00a0Jahr\u00a02002\u00a09,3\u00a0F\u00e4ll e,\u00a0in\u00a02012\u00a0lag\u00a0ein\u00a0\nNadir\u00a0mit\u00a05,2\u00a0F\u00e4llen\u00a0vor,\u00a0seither\u00a0steigt\u00a0die\u00a0Anzahl\u00a0der\u00a0an\u00a0TB\u00a0E rkrankten\u00a0wieder\u00a0an.\u00a0\nIm\u00a0Jahr\u00a02015\u00a0wurden\u00a0seitens\u00a0des\u00a0Robert\u00a0Koch\u2010Institutes\u00a05.865\u00a0Er krankte\u00a0im\u00a0Rah\u2010\nmen\u00a0der\u00a0Statistik\u00a0des\u00a0Infektionsschutzgesetzes\u00a0erfa\u00dft,\u00a0davon\u00a050 2\u00a0F\u00e4lle\u00a0mit\u00a0\u201ejegli\u2010\ncher\u201c\u00a0Resistenz.\u00a0Hierzu\u00a0z\u00e4hlen\u00a0125\u00a0F\u00e4lle\u00a0mit\u00a0Resistenz\u00a0gegen\u00a0Is oniazid\u00a0und\u00a0Rifampi\u2010\nzin\u00a0(MDR)\u00a0sowie\u00a013\u00a0F\u00e4lle\u00a0mit\u00a0extremer\u00a0Resistenz\u00a0(XDR,\u00a0 Extensive\u2010Drug\u2010Resistance ),\u00a0\nd.h.\u00a0sowohl\u00a0die\u00a0Basismedikamente\u00a0Isoniazid\u00a0und\u00a0Rifampicin\u00a0als\u00a0a uch\u00a0die\u00a0Antibioti\u2010\nka\u00a0zur\u00a0Injektion\u00a0wie\u00a0Amikacin,\u00a0C apreomycin\u00a0oder\u00a0Kanamycin\u00a0und\u00a0d ie\u00a0Wirkstoff\u2010\ngruppe\u00a0der\u00a0Fluorchinolone\u00a0zeigte n\u00a0keine\u00a0Wirkung\u00a0(Haas\u00a0et\u00a0al.,\u00a02 016;\u00a0Haas,\u00a02017).\u00a0\u00a0\nTB\u00a0wird\u00a0vorwiegend\u00a0\u00fcber\u00a0Tr\u00f6pfcheni nfektion\u00a0\u00fcbertragen,\u00a0haupts\u00e4c hlich\u00a0ist\u00a0die\u00a0\nLunge\u00a0betroffen.\u00a0Im\u00a0weiteren\u00a0Krankheitsverlauf\u00a0k\u00f6nnen\u00a0durch\u00a0Aus breitung\u00a0der\u00a0\nErreger\u00a0\u00fcber\u00a0Blutgef\u00e4\u00df\u2010\u00a0und\u00a0Lym phsystem\u00a0auch\u00a0andere\u00a0Organe\u00a0befa llen\u00a0sein.\u00a0Die\u00a0\nInkubationszeit\u00a0betr\u00e4gt\u00a0sechs\u00a0bis\u00a0acht\u00a0Wochen,\u00a0danach\u00a0kann\u00a0eine \u00a0Immunantwort\u00a0\ngemessen\u00a0werden.\u00a0Von\u00a0Infizierten\u00a0 erkrankt\u00a0nur\u00a0ein\u00a0Anteil\u00a0von\u00a0et wa\u00a010\u00a0%,\u00a0zumeist\u00a0\nkapselt\u00a0der\u00a0Organismus\u00a0die\u00a0Mykobakterien\u00a0erfolgreich\u00a0ein,\u00a0dann\u00a0 liegt\u00a0eine\u00a0latent\u00a0\ntuberkul\u00f6se\u00a0Infektion\u00a0(LTBI)\u00a0vor.\u00a0Bei\u00a0Schw\u00e4chung\u00a0der\u00a0k\u00f6rpereige nen\u00a0Abwehrkr\u00e4fte\u00a087\u00a0kann\u00a0es\u00a0zu\u00a0einer\u00a0Reaktivierung\u00a0ko mmen.\u00a0Die\u00a0manifeste\u00a0Lungentube rkulose\u00a0ist\u00a0\ngekennzeichnet\u00a0durch\u00a0mehrw\u00f6chigen\u00a0Husten\u00a0mit\u00a0und\u00a0ohne\u00a0ggf.\u00a0blut igen\u00a0Auswurf,\u00a0\nBrustschmerz,\u00a0Atemnot,\u00a0Gewichtsabnahme,\u00a0Nachtschwei\u00df\u00a0sowie\u00a0vers chlechtertes\u00a0\nAllgemeinbefinden.\u00a0\u00dcber\u00a0das\u00a0Blut\u00a0k\u00f6nnen\u00a0auch\u00a0andere\u00a0Organe\u00a0(Kno chen,\u00a0Gelenke,\u00a0\nGehirn\u00a0oder\u00a0der\u00a0Urogenitalbereic h)\u00a0befallen\u00a0werden.\u00a0Beg\u00fcnstigt\u00a0 werden\u00a0die\u00a0mani\u2010\nfeste\u00a0Erkrankung,\u00a0eine\u00a0fortgeschrittene\u00a0Lungentuberkulose\u00a0und\u00a0d ie\u00a0Streuung\u00a0der\u00a0\nMykobakterien\u00a0durch\u00a0ein\u00a0geschw\u00e4chtes\u00a0Immunsystem,\u00a0beispielsweis e\u00a0durch\u00a0Arz\u2010\nneimittel\u00a0(Immunsuppressiva,\u00a0TNF alpha\u2010Blocker),\u00a0HIV\u2010Infektion,\u00a0Diabetes\u00a0mellitus,\u00a0\nLeberzirrhose,\u00a0Alkohol\u2010\u00a0und\u00a0Dr ogenabusus\u00a0oder\u00a0Silikose.\u00a0\nZur\u00a0Therapie\u00a0der\u00a0Tuberkulose\u00a0werden\u00a0ausschlie\u00dflich\u00a0Kombinatione n\u00a0von\u00a0Arznei\u2010\nmitteln\u00a0eingesetzt,\u00a0einerseits\u00a0um\u00a0die\u00a0Bildung\u00a0von\u00a0Resistenzen\u00a0z u\u00a0vermeiden,\u00a0ande\u2010\nrerseits\u00a0um\u00a0die\u00a0Erreger\u00a0in\u00a0den\u00a0v erschiedenen\u00a0Stufen\u00a0der\u00a0Vermehr ung\u00a0zu\u00a0stoppen\u00a0\nbzw.\u00a0abzut\u00f6ten.\u00a0Die\u00a0WHO\u00a0unterscheidet\u00a0f\u00fcnf\u00a0Gruppen\u00a0von\u00a0Wirkstof fen\u00a0zur\u00a0Thera\u2010\npie\u00a0der\u00a0Tuberkulose.\u00a0Bei\u00a0Vorliegen\u00a0empfindlicher\u00a0Erreger\u00a0( Drug\u2010Sensitive ,\u00a0DS\u2010TB)\u00a0\nerhalten\u00a0 erwachsene\u00a0 Patienten\u00a0 mit\u00a0 Lungentuberkulose\u00a0 eine\u00a0 \u201eStand ard\u2010Kurz\u2010\nzeittherapie\u201c\u00a0mit\u00a0\u201eErstrang\u00a0Antituberkulotika\u201c\u00a0der\u00a0sogenannten\u00a0 WHO\u2010Gruppe\u00a01\u00a0\n\u00fcber\u00a0sechs\u00a0Monate.\u00a0Initial\u00a0werden\u00a0Isoniazid,\u00a0Rifampicin,\u00a0Pyrazi namid\u00a0und\u00a0Etham\u2010\nbutol\u00a0\u00fcber\u00a0zwei\u00a0Monate\u00a0gegeben,\u00a0hiernach\u00a0in\u00a0der\u00a0sogenannten\u00a0\u201eSt abilisierungs\u2010\u00a0\noder\u00a0Kontinuit\u00e4tsphase\u201c\u00a0\u00fcber\u00a0vier\u00a0Monate\u00a0Isoniazid\u00a0und\u00a0Rifampic in.\u00a0Erscheint\u00a0der\u00a0\nPatient\u00a0unzuverl\u00e4ssig,\u00a0so\u00a0erfolgt\u00a0 eine\u00a0DOT\u00a0(RKI,\u00a02013).\u00a0Liegen\u00a0 Resistenzen\u00a0vor,\u00a0\nverl\u00e4ngert\u00a0sich\u00a0die\u00a0Therapiedauer\u00a0auf\u00a0\u00fcber\u00a0mindestens\u00a020\u00a0Monate ;\u00a0hierbei\u00a0werden\u00a0\nInjektabilia\u00a0\u00fcber\u00a0acht\u00a0Monate\u00a0gegeben.\u00a0Erschwert\u00a0wird\u00a0die\u00a0Thera pie\u00a0der\u00a0Tuberku\u2010\nlose\u00a0durch\u00a0die\u00a0sehr\u00a0langsame\u00a0Te ilung\u00a0der\u00a0Mycobakterien\u00a0und\u00a0den\u00a0 hohen\u00a0Anteil\u00a0von\u00a0\nLipiden\u00a0in\u00a0der\u00a0Zellwand,\u00a0der\u00a0das\u00a0Gelangen\u00a0der\u00a0Wirkstoffe\u00a0zum\u00a0Wi rkort\u00a0reduziert\u00a0\n(Bruhn,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0TB,\u00a0insbesondere\u00a0MDR\u2010TB\u00a0oder\u00a0XDR\u2010TB,\u00a0stellt\u00a0weltweit\u00a0eine\u00a0e rnste\u00a0Bedroh\u2010\nnung\u00a0der\u00a0\u00f6ffentlichen\u00a0Gesundheit\u00a0dar.\u00a0Um\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0 nach\u00a0\u00fcber\u00a0vier\u2010\nzig\u00a0Jahren\u00a0Versorgungsl\u00fccken\u00a0in\u00a0der\u00a0Therapie\u00a0zu\u00a0schlie\u00dfen,\u00a0habe n\u00a0sowohl\u00a0die\u00a0ame\u2010\nrikanische\u00a0Zulassungsbeh\u00f6rde\u00a0FDA\u00a0als\u00a0auch\u00a0die\u00a0EC\u00a0auf\u00a0Empfehlung \u00a0der\u00a0europ\u00e4i\u2010\nschen\u00a0EMA\u00a0den\u00a0Wirkstoff\u00a0Bedaquilin\u00a0im\u00a0beschleunigten\u00a0Verfahren\u00a0 (FDA\u00a0\u201eaccelera\u2010\nted\u00a0approval \u201c)\u00a0(CDER,\u00a02012b)\u00a0mit\u00a0besonderen\u00a0Auflagen\u00a0auf\u00a0Basis\u00a0von\u00a0zwei\u00a0Pha se\u2010\nIIb\u2010Studien\u00a0C208\u00a0und\u00a0C209,\u00a0hierunter\u00a0eine\u00a0zweistufige\u00a0(C208\u00a0Stu fe\u00a01\u00a0und\u00a02),\u00a0zuge\u2010\nlassen\u00a0(AMB,\u00a02014;\u00a0CDER,\u00a02012b;\u00a0CHMP,\u00a02014a).\u00a0\nIn\u00a0der\u00a0ersten\u00a0exploratorischen\u00a0Stufe\u00a0der\u00a0Zulassungsstudie\u00a0C208\u00a0 (Sponsor:\u00a0Janssen)\u00a0\nerhielten\u00a047\u00a0Patienten\u00a0mit\u00a0neu\u00a0diagnostizierter\u00a0MDR\u2010TB,\u00a0in\u00a0S\u00fcda frika\u00a0hospitalisiert\u00a0\nbehandelt,\u00a0multizentrisch,\u00a0doppelverblindet,\u00a01:1\u00a0randomisiert\u00a0s owie\u00a0plazebokon\u2010\ntrolliert\u00a0in\u00a0einer\u00a0Phase\u2010II\u2010Studi e\u00a0zus\u00e4tzlich\u00a0zu\u00a0einem\u00a0bevorzug ten\u00a0BR,\u00a0bestehend\u00a088\u00a0aus\u00a0Kanamycin,\u00a0Ofloxacin,\u00a0Ethion amid,\u00a0Pyrazinamid\u00a0sowie\u00a0Cyclose rin\u00a0oder\u00a0Teri\u2010\nzidon,\u00a0entweder\u00a0Bedaquilin\u00a0oder\u00a0P lazebo\u00a0\u00fcber\u00a0acht\u00a0Wochen.\u00a0Bedaq uilin\u00a0wurde\u00a0in\u00a0\nder\u00a0zulassungsrelevanten\u00a0Dosierung\u00a0von\u00a0400\u00a0mg\u00a0t\u00e4glich\u00a0binnen\u00a0de r\u00a0ersten\u00a014\u00a0Tage\u00a0\nund\u00a0\u00fcber\u00a0sechs\u00a0Wochen\u00a0mit\u00a0dreimal\u00a0200\u00a0mg\u00a0t\u00e4glich\u00a0mit\u00a048\u00a0Stunden \u00a0Abstand\u00a0zwi\u2010\nschen\u00a0den\u00a0Gaben\u00a0getestet.\u00a0Die\u00a0Einnahme\u00a0erfolgte\u00a0stets\u00a0nach\u00a0dem\u00a0 Fr\u00fchst\u00fcck.\u00a0Die\u00a0\nTherapie\u00a0mit\u00a0BR\u00a0wurde\u00a0fortgesetzt\u00a0und\u00a0es\u00a0schloss\u00a0sich\u00a0eine\u00a0Nach beobachtungs\u2010\nphase\u00a0von\u00a096\u00a0Wochen\u00a0an.\u00a0Ausgeschlossen\u00a0wurden\u00a0Patienten\u00a0mit\u00a0XDR \u2010TB,\u00a0vorheri\u2010\nger\u00a0 MDR\u2010TB\u2010Therapie,\u00a0 extrapulmonaler\u00a0 Manifestation\u00a0 der\u00a0 TB,\u00a0 HIV\u2010 Positive\u00a0 mit\u00a0\nweniger\u00a0als\u00a0300\u00a0CD4+Zellen\u00a0je\u00a0ml,\u00a0Patienten\u00a0unter\u00a0antiretrovira ler\u00a0Therapie,\u00a0anti\u2010\nfungaler\u00a0 Therapie,\u00a0 Herzrhythmusst\u00f6rungen,\u00a0 Arzneimittel\u00fcberempfi ndlichkeit,\u00a0\nAlkohol\u2010\u00a0oder\u00a0Drogenmissbrauch,\u00a0 Begleiterkrankungen,\u00a0abnormen\u00a0L aborwerten,\u00a0\nSchwangerschaft,\u00a0Stillzeit\u00a0oder\u00a0 Teilnahme\u00a0in\u00a0anderen\u00a0klinischen \u00a0Studien.\u00a0Prim\u00e4rer\u00a0\nEndpunkt\u00a0war\u00a0die\u00a0Zeit\u00a0bis\u00a0zum\u00a0fehlenden\u00a0Nachweis\u00a0von\u00a0Tuberkelba kterien\u00a0im\u00a0\nSputum,\u00a0d.h.\u00a0die\u00a0SCC\u00a0von\u00a0TB\u00a0positiv\u00a0zu\u00a0TB\u00a0negativ.\u00a0Per\u00a0Definiti on\u00a0lag\u00a0eine\u00a0SCC\u00a0vor,\u00a0\nwenn\u00a0bei\u00a0Patienten\u00a0in\u00a0den\u00a0Wochen\u00a0sieben\u00a0und\u00a0acht\u00a0keine\u00a0Tuberkel bakterien\u00a0im\u00a0\nSputum\u00a0nachgewiesen\u00a0werden\u00a0konnten.\u00a0Somit\u00a0wurde\u00a0ein\u00a0Surrogatpar ameter\u00a0als\u00a0\nprim\u00e4rer\u00a0Endpunkt\u00a0zu\u00a0Pr\u00fcfung\u00a0der\u00a0klinischen\u00a0Wirksamkeit\u00a0definie rt.\u00a0Bei\u00a010\u00a0von\u00a021\u00a0\nPatienten\u00a0unter\u00a0Bedaquilin,\u00a0d.h.\u00a0bei\u00a048\u00a0%\u00a0konnte\u00a0der\u00a0prim\u00e4re\u00a0En dpunkt\u00a0erreicht\u00a0\nwerden,\u00a0wohingegen\u00a0unter\u00a0BR\u00a0plus\u00a0Plazebo\u00a0nur\u00a0zwei\u00a0von\u00a023\u00a0MDR\u2010TB \u00a0Patienten,\u00a0\nd.h.\u00a09\u00a0%,\u00a0diesen\u00a0unter\u00a0BR\u00a0in\u00a0Woche\u00a0acht\u00a0erreichen\u00a0konnten.\u00a0\nSekund\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0Ver\u00e4nderung\u00a0der\u00a0log10\u2010Z\u00e4hlung\u00a0der\u00a0K oloniebilden\u2010\nden\u00a0Einheiten\u00a0im\u00a0Vergleich\u00a0zum\u00a0Ausgangswert.\u00a0Unter\u00a0Bedaquilin\u00a0k onnte\u00a0eine\u00a0QT\u2010\nZ e i t v e r l \u00e4 n g e r u n g \u00a0v o n \u00a01 \u00a0b i s \u00a01 0 , 8 \u00a0 m s e k \u00a0b e o b a c h t e t \u00a0w e r d e n , \u00a0j e d o c h \u00a0 keine\u00a0 \u00fcber\u00a0\n500\u00a0msek.\u00a0Eine\u00a0Untersuchung\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqual it\u00e4t\u00a0(Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0war\u00a0in\u00a0der\u00a0Studie\u00a0nicht \u00a0vorgesehen.\u00a0Die\u00a0Publikation\u00a0\nvon\u00a0Diacon\u00a0erstattet\u00a0\u00fcber\u00a0den\u00a0Zeitraum\u00a0von\u00a024\u00a0Wochen\u00a0Bericht,\u00a0d ie\u00a0Nachbeobach\u2010\ntung\u00a0l\u00e4uft\u00a0\u00fcber\u00a0insgesamt\u00a096\u00a0 Wochen\u00a0(Diacon\u00a0et\u00a0al.,\u00a02009).\u00a0\nDie\u00a0zweite\u00a0Stufe\u00a0der\u00a0Zulassungsstudie\u00a0C208\u00a0(Sponsor:\u00a0Janssen)\u00a0w urde\u00a0mit\u00a0dem\u00a0Ziel\u00a0\neines\u00a0Nachweises\u00a0der\u00a0Erfolgswirksamkeit\u00a0( Proof\u00a0of\u00a0effectiveness )\u00a0als\u00a0multizentri\u2010\nsche,\u00a0 doppelblinde,\u00a0 1:1\u00a0 randomisierte,\u00a0 plazebokontrollierte\u00a0 Pha se\u2010IIb\u2010Studie\u00a0\ndurchgef\u00fchrt.\u00a0160\u00a0neu\u00a0diagnostizierte\u00a0MDR\u2010TB\u00a0Patienten\u00a0erhielte n\u00a0zus\u00e4tzlich\u00a0zum\u00a0\nBR,\u00a0das\u00a0auch\u00a0die\u00a0regionalen\u00a0BR\u00a0ber\u00fccksichtigte,\u00a0\u00fcber\u00a018\u00a0bis\u00a024\u00a0 Monate\u00a0entweder\u00a0\nBedaquilin\u00a0oder\u00a0Plazebo\u00a0f\u00fcr\u00a024\u00a0Wochen.\u00a0Die\u00a0Dosierung\u00a0erfolgte\u00a0a nalog\u00a0C208\u00a0Stufe\u00a0\n1.\u00a0Hervorzuheben\u00a0ist,\u00a0dass\u00a0bei\u00a0den\u00a0Ausschlusskriterien\u00a0von\u00a0C208 \u00a0Stufe\u00a02\u00a0nunmehr\u00a0\nPatienten\u00a0unter\u00a0Therapie\u00a0mit\u00a0Moxi\u2010\u00a0oder\u00a0Gatifloxacin\u00a0oder\u00a0die\u00a0G abe\u00a0von\u00a0CYP\u00a03A4\u00a0\nInduktoren\u00a0oder\u00a0Inhibitoren\u00a0in\u00a0der\u00a0Publikation\u00a0von\u00a0Diacon\u00a0expli zit\u00a0genannt\u00a0wer\u2010\nden.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0wiederum\u00a0der\u00a0Surrogatparameter\u00a0Zeit\u00a0 bis\u00a0zur\u00a0SCC.\u00a0\nPatienten\u00a0unter\u00a0BR\u00a0plus\u00a0Bedaquilin\u00a0zeigten\u00a0median\u00a0bereits\u00a0nach\u00a0 83\u00a0Tagen\u00a0SCC,\u00a0\nunter\u00a0BR\u00a0plus\u00a0Plazebo\u00a0war\u00a0dies\u00a0median\u00a0nach\u00a0125\u00a0Tagen\u00a0der\u00a0Fall.\u00a0 Weiterhin\u00a0wurde\u00a089\u00a0nach\u00a024\u00a0Wochen\u00a0die\u00a0Rate\u00a0der\u00a0TB\u2010freien\u00a0Kulturen\u00a0als\u00a0sekund\u00e4rer\u00a0E ndpunkt\u00a0vergli\u2010\nchen.\u00a0Unter\u00a0BR\u00a0plus\u00a0Bedaquilin\u00a0waren\u00a079\u00a0%\u00a0TB\u2010frei,\u00a0unter\u00a0BR\u00a0plu s\u00a0Plazebo\u00a0nur\u00a0\n58\u00a0%.\u00a0Basierend\u00a0auf\u00a0der\u00a0Definition\u00a0der\u00a0WHO\u00a0zur\u00a0Heilung\u00a0der\u00a0MDR\u2010 TB\u00a0konnten\u00a0nach\u00a0\n120\u00a0Wochen\u00a058%\u00a0der\u00a0Patienten\u00a0mit\u00a0BR\u00a0plus\u00a0Bedaquilin\u00a0und\u00a032\u00a0%\u00a0de r\u00a0Patienten\u00a0mit\u00a0\nBR\u00a0plus\u00a0Plazebo\u00a0als\u00a0geheilt\u00a0definiert\u00a0werden.\u00a0Somit\u00a0konnte\u00a0anha nd\u00a0des\u00a0Surrogatpa\u2010\nrameters\u00a0SCC\u00a0die\u00a0klinische\u00a0Wirksamkeit\u00a0von\u00a0Bedaquilin\u00a0bei\u00a0MDR\u2010T B\u00a0gegen\u00fcber\u00a0\nPlazebo\u00a0gezeigt\u00a0werden\u00a0(Diacon\u00a0et\u00a0al.,\u00a02014).\u00a0\nDiacon\u00a0und\u00a0Kollegen\u00a0berichteten\u00a0im\u00a0Jahr\u00a02014\u00a0eine\u00a0\u00dcbersterblich keit\u00a0unter\u00a0Be\u2010\ndaquilin\u00a0gegen\u00fcber\u00a0Plazebo\u00a0(10:2).\u00a0Die\u00a0Todesf\u00e4lle\u00a0unter\u00a0Bedaqui llin\u00a0wurden\u00a0wie\u00a0\nfolgt\u00a0erkl\u00e4rt:\u00a0Ein\u00a0Verkehrsunfall\u00a0in\u00a0Woche\u00a0130\u00a0der\u00a0Nachbeobacht ungsphase,\u00a0f\u00fcnf\u00a0\nTodesf\u00e4lle\u00a0aufgrund\u00a0Fortschreitens \u00a0der\u00a0MDR/XDR\u2010TB,\u00a0dies\u00a0trifft\u00a0 auch\u00a0f\u00fcr\u00a0die\u00a0beiden\u00a0\nTodesf\u00e4lle\u00a0in\u00a0der\u00a0Plazebogruppe\u00a0zu.\u00a0Im\u00a0Median\u00a0traten\u00a0die\u00a0Todesf \u00e4lle\u00a0der\u00a0Bedaquil\u2010\nlingruppe\u00a0329\u00a0Tage\u00a0nach\u00a0der\u00a0letzten\u00a0Gabe\u00a0auf.\u00a0Obschon\u00a0Bedaquili n\u00a0eine\u00a0sehr\u00a0lange\u00a0\nterminale\u00a0Eliminationshalbwertzeit\u00a0von\u00a0zwei\u00a0bis\u00a0zu\u00a0acht\u00a0Monaten \u00a0aufweist,\u00a0f\u00e4llt\u00a0\neine\u00a0Erkl\u00e4rung\u00a0eines\u00a0m\u00f6glichen\u00a0Zusammenhanges\u00a0von\u00a0Ursache\u00a0und\u00a0A rzneimittel\u00a0\nschwer.\u00a0Dies\u00a0f\u00fchrte\u00a0zu\u00a0einer\u00a0Einschr\u00e4nkung\u00a0der\u00a0Indikation\u00a0von\u00a0B edaquilin\u00a0auf\u00a0an\u00a0\n\u201epulmonal\u00a0MDR\u2010TB\u00a0Erkrankte,\u00a0f\u00fcr\u00a0die\u00a0keine\u00a0andere\u00a0Therapie\u00a0in\u00a0Fr age\u00a0kommt\u201c.\u00a0Die\u00a0\nbeiden\u00a0Zulassungsbeh\u00f6rden,\u00a0d.h.\u00a0FDA\u00a0und\u00a0f\u00fcr\u00a0die\u00a0EC\u00a0die\u00a0EMA,\u00a0ord neten\u00a0die\u00a0Durch\u2010\nf\u00fchrung\u00a0einer\u00a0regul\u00e4re\u00a0Phase\u00a0III\u00a0Studie\u00a0(\u201eSTREAM\u201c\u00a0(ClinicalTria ls.gov,\u00a02015))\u00a0mit\u00a0\nharten\u00a0Endpunkten\u00a0wie\u00a0Mortalit\u00e4t,\u00a0Heilung\u00a0der\u00a0Tuberkulose,\u00a0R\u00fcck fallraten,\u00a0einer\u00a0\nbis\u00a0 zu\u00a0 zweij\u00e4hrigen\u00a0 Nachbeobachtungsphase\u00a0 nach\u00a0 Arzneimittelther apie\u00a0 sowie\u00a0\neinem\u00a0Patientenregister\u00a0 f\u00fcr\u00a0Bedaquilin\u00a0an\u00a0(CDER,\u00a02012b;\u00a0 CHMP,\u00a02 013,\u00a0 2014c;\u00a0\nEMA,\u00a02013).\u00a0Im\u00a0Kontext\u00a0des\u00a0Zulassungsverfahrens\u00a0wurden\u00a0einersei ts\u00a0das\u00a0individu\u2010\nelle\u00a0Risiko\u00a0der\u00a0betroffenen\u00a0Pati enten\u00a0sowie\u00a0andererseits\u00a0das\u00a0de r\u00a0\u00f6ffentlichen\u00a0Ge\u2010\nsundheit,\u00a0d.h.\u00a0m\u00f6glicher\u00a0Kontaktpersonen\u00a0von\u00a0MDR\u2010/XDR\u2010TB\u2010Patien ten\u00a0abgewo\u2010\ngen\u00a0(Cox\u00a0&\u00a0Laessig,\u00a02014).\u00a0\nMit\u00a0der\u00a0Zulassungsstudie\u00a0C209\u00a0(Sponsor:\u00a0Janssen)\u00a0wurde\u00a0multizen trisch,\u00a0offen,\u00a0\nohne\u00a0Kontrolle\u00a0in\u00a0einer\u00a0einarmigen\u00a0Phase\u2010IIbStudie\u00a0das\u00a0Ziel\u00a0der \u00a0Best\u00e4tigung\u00a0der\u00a0\nSicherheit\u00a0und\u00a0Erfolgswirksamkeit\u00a0verfolgt.\u00a0233\u00a0Patienten\u00a0mit\u00a0n eu\u00a0festgestellter\u00a0\noder\u00a0 k\u00fcrzlich\u00a0 behandelter\u00a0 MDR\u2010TB\u00a0 (63,5\u00a0%),\u00a0 pre\u2010XDR\u2010TB\u00a0 (18,9\u00a0%)\u00a0 oder\u00a0 XDR\u2010TB\u00a0\n(16,3\u00a0%)\u00a0 erhielten\u00a0 BR\u00a0 nach\u00a0 natio nalem\u00a0 Versorgungsprogramm\u00a0 plus\u00a0 Bedaquilin\u00a0\n(initial\u00a0400\u00a0mg\u00a0t\u00e4glich\u00a0f\u00fcr\u00a0zwei\u00a0Wochen,\u00a0danach\u00a0200\u00a0mg\u00a0dreimal\u00a0 w\u00f6chentlich\u00a0\u00fcber\u00a0\n22\u00a0Wochen).\u00a0Die\u00a0Nachbeobachtungszeit\u00a0dauerte\u00a0bis\u00a0120\u00a0Wochen\u00a0nac h\u00a0Behand\u2010\nlungsbeginn\u00a0mit\u00a0Bedaquilin.\u00a0Von\u00a0233\u00a0in\u00a0die\u00a0Studie\u00a0aufgenommenen \u00a0Pati enten\u00a0\nverstarben\u00a016\u00a0(6,9\u00a0%)\u00a0und\u00a020\u00a0brachen\u00a0die\u00a0Teilnahme\u00a0an\u00a0der\u00a0Studi e\u00a0vor\u00a0Woche\u00a024\u00a0\nab\u00a0(8,6\u00a0%).\u00a0Hierbei\u00a0zeigte\u00a0sich\u00a0beim\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0SCC\u00a0nach \u00a0120\u00a0Wochen\u00a0bei\u00a0\n72,2\u00a0%\u00a0der\u00a0Patienten\u00a0eine\u00a0SCC\u00a0(MDR\u2010TB\u00a073,1\u00a0%,\u00a0pre\u2010XDR\u2010TB\u00a070,5\u00a0% \u00a0sowie\u00a0XDR\u2010TB\u00a0\n62,2\u00a0%)\u00a0(Pym\u00a0et\u00a0al.,\u00a02016).\u00a090\u00a0Die\u00a0WHO\u00a0hat\u00a0die\u00a0beschleunigte\u00a0Zulassung\u00a0von\u00a0Bedaquilin\u00a0nur\u00a0auf\u00a0 Grundlage\u00a0von\u00a0\nPhase\u2010IIb\u2010Studien\u00a0sowohl\u00a0seitens\u00a0FDA\u00a0als\u00a0auch\u00a0EC\u00a0zum\u00a0Anlass\u00a0gen ommen,\u00a0Hand\u2010\nlungsempfehlungen\u00a0 zum\u00a0 zielf\u00fchre nden\u00a0 Einsatz\u00a0 von\u00a0 Bedaquilin\u00a0 hera uszugeben\u00a0\n(WHO,\u00a02013).\u00a0In\u00a0diesem\u00a0Kontext\u00a0hat\u00a0die\u00a0Gruppe\u00a0zur\u00a0Entwickung\u00a0vo n\u00a0Leitlinen\u00a0der\u00a0\nWHO\u00a0 einen\u00a0 Report\u00a0 zur\u00a0 Evidenz\u00a0 der\u00a0 Pharmakotherapie\u00a0 mit\u00a0 Bedaquili n\u00a0 erstellt\u00a0\n(Gonzalez\u2010Angulo,\u00a02017;\u00a0G onzalez\u2010Angulo,\u00a02016).\u00a0\nDatenbasis\u00a0des\u00a0WHO\u00a0 Reviews\u00a0sind\u00a0f\u00fcnf\u00a0Kohorten:\u00a0Die\u00a0Studie\u00a0C209\u00a0des\u00a0pU\u00a0(n=205),\u00a0\nErgebnisse\u00a0eines\u00a0franz\u00f6sischen\u00a0C ompassionate\u00a0Use \u00a0Programms\u00a0(n=45),\u00a0Daten\u00a0des\u00a0\nSouth\u00a0African\u00a0Bedaquiline\u00a0Clinical\u00a0Access\u00a0Programme \u00a0(n=195)\u00a0sowie\u00a0des\u00a0 Compas\u2010\nsionate\u00a0Use \u2010Programme\u00a0von\u00a0\u00c4rzte\u00a0ohne\u00a0Grenzen\u00a0in\u00a0Armenien\u00a0(n=30)\u00a0und\u00a0Georgi en\u00a0\n(n=62).\u00a0F\u00fcr\u00a0eine\u00a0gepoolte\u00a0Datenanalyse\u00a0konnten\u00a0somit\u00a0537\u00a0Patien ten\u00a0ber\u00fccksich\u2010\ntigt\u00a0werden.\u00a0Um\u00a0das\u00a0\u00dcberleben\u00a0unter\u00a0der\u00a0Therapie\u00a0mit\u00a0Bedaquilin \u00a0einsch\u00e4tzen\u00a0zu\u00a0\nk\u00f6nnen,\u00a0wurden\u00a0zum\u00a0Vergleich\u00a0Daten\u00a0des\u00a0 South\u00a0African\u00a0Electronic\u00a0Drug\u2010Resistant\u00a0\nTuberculosis\u00a0Register \u00a0ber\u00fccksichtigt\u00a0(25.095\u00a0Patienten\u00a0mit\u00a0MDR\u2010TB,\u00a0von\u00a0denen\u00a0\n1.556\u00a0Bedaquilin\u00a0erhielten).\u00a0Das\u00a0Durchschnittsalter\u00a0der\u00a0aus\u00a0f\u00fcn f\u00a0Kohorten\u00a0gepool\u2010\nten\u00a0Daten\u00a0betrug\u00a036,4\u00a0Lebensjahr e,\u00a064\u00a0%\u00a0waren\u00a0m\u00e4nnlich,\u00a0138\u00a0MDR \u2010TB\u2010Patienten\u00a0\nwaren\u00a0HIV\u00a0positiv\u00a0(25,7\u00a0%),\u00a0hiervon\u00a0erhielten\u00a0120\u00a0eine\u00a0ARV\u00a0Ther apie\u00a0(87\u00a0%).\u00a0Die\u00a0\nTherapie\u00a0mit\u00a0Bedaquilin\u00a0betrug\u00a06,37\u00a0Monate.\u00a0Bedaquilin\u00a0bewirkte \u00a0bei\u00a079,7\u00a0%\u00a0der\u00a0\nMDR\u2010TB\u2010Patienten\u00a0eine\u00a0SCC\u00a0nach\u00a0sechs\u00a0Monaten.\u00a0Am\u00a0Ende\u00a0der\u00a0Nachb eobach\u2010\ntungszeit\u00a0von\u00a018\u00a0bis\u00a024\u00a0Monaten\u00a0konnte\u00a0ein\u00a0Therapieerfolg\u00a0(\u201e cured\u00a0+\u00a0completed \u201c)\u00a0\nbei\u00a069,1\u00a0%\u00a0gezeigt\u00a0werden.\u00a0F\u00fcr\u00a0alle\u00a0Patienten\u00a0der\u00a0f\u00fcnf\u00a0Kohorten \u00a0wurden\u00a0Daten\u00a0zur\u00a0\nArzneimittelsicherheit\u00a0gesammelt\u00a0und\u00a0um\u00a028\u00a0Einzelfallberichte\u00a0d es\u00a0pU\u00a0erg\u00e4nzt.\u00a0\nInsgesamt\u00a0wurden\u00a02.622\u00a0UE\u00a0( Adverse\u00a0Events )\u00a0berichtet,\u00a0hiervon\u00a014\u00a0%\u00a0gastrointes\u2010\ntinale,\u00a0 8,5\u00a0%\u00a0 metabolische\u00a0 und\u00a0 we itere\u00a0 8,5\u00a0%\u00a0 das\u00a0 Nervensystem\u00a0 b etreffende.\u00a0\nSevere\u00a0Adverse\u00a0Events \u00a0traten\u00a0bei\u00a020\u00a0%\u00a0der\u00a0Patienten\u00a0auf,\u00a0 Serious\u00a0Adverse\u00a0Events \u00a0\nbei\u00a07\u00a0%.\u00a0Die\u00a0Kardiotoxizit\u00e4t\u00a0zeigte\u00a0sich\u00a0in\u00a0Form\u00a0von\u00a0QT\u2010Zeitver l\u00e4ngerungen,\u00a0bei\u00a0\n4,7\u00a0%\u00a0sogar\u00a0\u00fcber\u00a0500\u00a0msek.\u00a0F\u00fcr\u00a0das\u00a0Gesamt\u00fcberleben\u00a0wurden\u00a0die\u00a0k ompletten\u00a0\nDatens\u00e4tze\u00a0der\u00a0Nachbeobachtungsz eit\u00a018\u00a0bis\u00a024\u00a0Monate\u00a0ber\u00fccksich tigt\u00a0(n=351),\u00a0\nwelche\u00a0eine\u00a0Mortalit\u00e4tsrate\u00a0von\u00a010,6\u00a0%\u00a0ergab.\u00a0Weitere\u00a019\u00a0Todesf \u00e4lle\u00a0wurden\u00a0f\u00fcr\u00a0\nPatienten\u00a0berichtet,\u00a0welche\u00a0unvollst\u00e4ndige\u00a0Datens\u00e4tze\u00a0in\u00a0der\u00a0Na chbeobachtungs\u2010\nzeit\u00a0aufwiesen.\u00a0Tendenziell\u00a0ist\u00a0bei\u00a0HIV\u2010Infizierten\u00a0die\u00a0Mortali t\u00e4t\u00a0an\u00a0MDR\u2010TB\u00a0h\u00f6her,\u00a0\nweiterhin\u00a0 wirkt\u00a0 sich\u00a0 eine\u00a0 zus\u00e4tzliche\u00a0 Resistenz\u00a0 gegen\u00fcber\u00a0 Fluor chinolinen\u00a0 und\u00a0\nInjektabilia\u00a0f\u00fcr\u00a0MDR\u2010TB\u2010Erkrankte\u00a0ung\u00fcnstig\u00a0aus\u00a0(Gonzalez\u2010Angul o,\u00a02016).\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0WHO\u00a0f\u00fchrt\u00a0Bedaquilin\u00a0auf\u00a0der\u00a0aktuellen\u00a0Liste\u00a0unentbehrliche r\u00a0Arzneimittel\u00a0in\u00a0\nder\u00a0zweiten\u00a0Kategorie\u00a0erg\u00e4nzend,\u00a0 complementary \u00a0(WHO,\u00a02015).\u00a0Neben\u00a0den\u00a0Leitli\u2010\nnien\u00a0zur\u00a0Therapie\u00a0der\u00a0MDR\u2010TB\u00a0(WHO,\u00a02016)\u00a0hat\u00a0die\u00a0WHO\u00a0einerseits \u00a0kontinuierlich\u00a0\nmittels\u00a0Reviews\u00a0die\u00a0verf\u00fcgbaren\u00a0Daten\u00a0zum\u00a0Einsatz\u00a0von\u00a0Bedaquilin\u00a0zusammenge\u2010\nf\u00fchrt\u00a0und\u00a0bewertet\u00a0(Gonzalez\u2010Ang ulo,\u00a02016)\u00a0als\u00a0auch\u00a0eine\u00a0eigene \u00a0Handlungsemp\u201091\u00a0fehlung\u00a0zum\u00a0Gebrauch\u00a0des\u00a0Arzneimittels\u00a0( Interim\u00a0Policy\u00a0Guidance )\u00a0herausgegeben\u00a0\n(WHO,\u00a02013).\u00a0\nKonkret\u00a0schl\u00e4gt\u00a0die\u00a0WHO\u00a0f\u00fcnf\u00a0Kriterien\u00a0f\u00fcr\u00a0den\u00a0therapeutischen\u00a0 Einsatz\u00a0von\u00a0Be\u2010\ndaquilin\u00a0vor:\u00a0\n1. Angemessene\u00a0Auswahl\u00a0der\u00a0Patienten,\u00a0insbesondere\u00a0bei\u00a0\u00c4lteren\u00a0(> \u00a065\u00a0Le\u2010\nbensjahre),\u00a0HIV\u2010Positiven;\u00a0keine \u00a0Therapie\u00a0mit\u00a0Bedaquilin\u00a0bei\u00a0Sc hwange\u2010\nren\u00a0und\u00a0Kindern.\u00a0\n2. Aufkl\u00e4rung\u00a0der\u00a0Patienten\u00a0\u00fcber\u00a0di e\u00a0Besonderheiten\u00a0des\u00a0Arzneimitt els,\u00a0\nspeziell\u00a0die\u00a0Nutzen\u2010Risiko\u2010Einsch\u00e4tzung.\u00a0\n3. \u00dcbereinstimmung\u00a0mit\u00a0den\u00a0WHO\u2010Empfehlungen\u00a0zu\u00a0Therapieregimen\u00a0der \u00a0\nMDR\u2010TB;\u00a0Einsatz\u00a0von\u00a0Bedaquilin,\u00a0so fern\u00a0die\u00a0Umsetzung\u00a0eines\u00a0Stan dard\u2010\nRegimes\u00a0nicht\u00a0m\u00f6glich\u00a0erscheint,\u00a0da\u00a0(i)\u00a0in\u00a0vitro\u00a0Resistenz\u00a0gege n\u00fcber\u00a0Flu\u2010\norchinolonen\u00a0und/\u00a0oder\u00a0Zweitlinien\u00a0Injektabilia\u00a0besteht;\u00a0(ii)\u00a0f alls\u00a0gegen\u2010\n\u00fcber\u00a0einer\u00a0Komponente\u00a0der\u00a0Kombina tionstherapie\u00a0Unvertr\u00e4glichkei ten\u00a0\nbestehen,\u00a0Gegenanzeigen\u00a0vorliege n\u00a0oder\u00a0schwache\u00a0Akzeptanz\u00a0gegeb en\u00a0\nist;\u00a0(iii)\u00a0Nichtverf\u00fcgbarkeit\u00a0oder\u00a0eine\u00a0mangelhafte\u00a0Versorgung\u00a0 mit\u00a0den\u00a0\nArzneimitteln\u00a0gegeben\u00a0ist.\u00a0\n4. Die\u00a0Durchf\u00fchrung\u00a0der\u00a0Behandlung\u00a0e rfolgt\u00a0unter\u00a0engmaschiger\u00a0\u00dcber wa\u2010\nchung,\u00a0sodass\u00a0optimale\u00a0Erfolgswirk samkeit\u00a0und\u00a0Sicherheit\u00a0gew\u00e4hr leistet\u00a0\nsind.\u00a0\n5. Anwendung\u00a0von\u00a0Bedaquilin\u00a0unter\u00a0akt iver\u00a0Pharmakovigilanz\u00a0und\u00a0gee igne\u2010\ntem\u00a0Management\u00a0von\u00a0UE\u00a0sowie\u00a0Pr\u00e4v ention\u00a0von\u00a0Komplikationen\u00a0in\u00a0Fo lge\u00a0\nvon\u00a0Arzneimittelinteraktionen.\u00a0\nAuch\u00a0die\u00a0CDC\u00a0haben\u00a0im\u00a0Jahr\u00a02013\u00a0einen\u00a0vorl\u00e4ufigen\u00a0Leitfaden\u00a0zur \u00a0Anwendung\u00a0von\u00a0\nBedaquilin\u00a0herausgegeben,\u00a0welcher\u00a0einerseits\u00a0die\u00a0Evidenz\u00a0der\u00a0bi sherigen\u00a0Studien\u00a0\nzusammenfasst,\u00a0 andererseits\u00a0 aber\u00a0 bei\u00a0 fehlender\u00a0 Evidenz\u00a0 auch\u00a0 den \u00a0E i n s a tz \u00a0b e i \u00a0\nPatientengruppen\u00a0au\u00dferhalb\u00a0der\u00a0Z ulassung,\u00a0wie\u00a0HIV\u2010Positiven,\u00a0Ki ndern\u00a0oder\u00a0Pati\u2010\nenten\u00a0in\u00a0h\u00f6herem\u00a0Lebensalter\u00a0\u2013\u00a0b asierend\u00a0auf\u00a0einer\u00a0individuelle n\u00a0Nutzen\u2010Risiko\u2010\nAbw\u00e4gung\u00a0\u2013\u00a0vorsieht.\u00a0In\u00a0der\u00a0vom\u00a0Deutschen\u00a0Zentralkommittee\u00a0zur\u00a0 Bek\u00e4mpfung\u00a0\nder\u00a0Tuberkulose\u00a0im\u00a0Jahr\u00a02012\u00a0publizierten\u00a0Empfehlung\u00a0wird\u00a0Bedaq uilin\u00a0historisch\u00a0\nbedingt\u00a0nicht\u00a0ber\u00fccksichtigt\u00a0(Schaberg\u00a0et\u00a0al.,\u00a02012).\u00a0Bei\u00a0AWMF\u00a0 online\u00a0sind\u00a0Vorha\u2010\nben\u00a0zur\u00a0Erstellung\u00a0zweier\u00a0neuer\u00a0S2k\u00a0Leitlinien\u00a0sowohl\u00a0f\u00fcr\u00a0Kinde r\u00a0und\u00a0Jugendliche\u00a0\nals\u00a0auch\u00a0f\u00fcr\u00a0Erwachsene\u00a0angek\u00fcndigt:\u00a0\u201eTuberkulose\u00a0im\u00a0Kindes\u2010\u00a0un d\u00a0Jugendalter:\u00a0\nDiagnostik,\u00a0Pr\u00e4vention\u00a0und\u00a0Therapie\u201c\u00a0mit\u00a0Registernummer\u00a0048\u2010016 \u00a0und\u00a0geplanter\u00a0\nFertigstellung\u00a0zum\u00a031.\u00a0Mai\u00a02017\u00a0(Feiterna\u2010Sperling,\u00a02014)\u00a0und\u00a0\u201e Tuberkulose\u00a0im\u00a0\nErwachsenenalter,\u00a0Empfehlungen\u00a0zur\u00a0Diagnostik\u00a0und\u00a0Therapie,\u00a0Che mopr\u00e4vention\u00a0\nund\u00a0Chemoprophylaxe\u201c\u00a0unter\u00a0der\u00a0Registernummer\u00a0020\u2010019\u00a0und\u00a0gepla nter\u00a0Fertig\u201092\u00a0stellung\u00a0zum\u00a030.06.2017\u00a0(Bauer\u00a0et\u00a0al.,\u00a02014).\u00a0Eine\u00a0systematisch e\u00a0Evidenzbewertung\u00a0\nist\u00a0im\u00a0Kontext\u00a0der\u00a0S2k\u2010Leitlinie nvorhaben\u00a0nicht\u00a0vorgesehen\u00a0(Bau er\u00a0et\u00a0al.,\u00a02014).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nBedaquilin\u00a0wurde\u00a0von\u00a0der\u00a0EC\u00a0zur\u00a0Behandlung\u00a0seltener\u00a0Erkrankunge n\u00a0zugelassen.\u00a0\nDer\u00a0G\u2010BA\u00a0erkennt\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0einer\u00a0Zulassung\u00a0zur\u00a0Thera pie\u00a0seltener\u00a0Lei\u2010\nden\u00a0(Orphan\u2010Arzneimittel)\u00a0einen\u00a0Zusatznutzen\u00a0 automatisch\u00a0an,\u00a0lediglich\u00a0das\u00a0 Aus\u2010\nma\u00df\u00a0des\u00a0Zusatznutzens\u00a0ist\u00a0nachzuweisen.\u00a0\u00dcberschreiten\u00a0die\u00a0Ums\u00e4t ze\u00a0eines\u00a0Arz\u2010\nneimittels\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Leiden\u00a0eine\u00a0Grenze\u00a0von\u00a050\u00a0Mio. \u00a0Euro\u00a0zu\u00a0Lasten\u00a0\nder\u00a0GKV\u00a0binnen\u00a012\u00a0Monaten,\u00a0so\u00a0erfolgt\u00a0eine\u00a0uneingeschr\u00e4nkte\u00a0Nut zenbewertung.\u00a0\nBei\u00a0 Therapiekosten\u00a0 von\u00a0 34.100,24\u00a0 Euro\u00a0 (WebApo\u00a0 Lauer\u2010Fischer,\u00a0 20 17,\u00a0 Stand:\u00a0\n01.05.2017)\u00a0je\u00a0Patient\u00a0m\u00fcssten\u00a01.466\u00a0Patienten\u00a0binnen\u00a0zw\u00f6lf\u00a0Mon aten\u00a0in\u00a0Deutsch\u2010\nland\u00a0mit\u00a0Bedaquillin\u00a0behandelt\u00a0wer den,\u00a0um\u00a0eine\u00a0regul\u00e4re\u00a0Nutzenb ewertung\u00a0her\u2010\nbeizuf\u00fchren.\u00a0MDR\u2010Tuberkulose\u00a0kommt\u00a0in\u00a0Deutschland\u00a0allerdings\u00a0be i\u00a03,3\u00a0%\u00a0von\u00a0\n5.852\u00a0F\u00e4llen\u00a0des\u00a0Jahres\u00a02016,\u00a0d.h.\u00a0bei\u00a0125\u00a0Patienten\u00a0im\u00a0Jahr\u00a020 16\u00a0vor\u00a0(Haas,\u00a02017),\u00a0\nsodass\u00a0eine\u00a0regul\u00e4re\u00a0Bewertung\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0Bedaquilin \u00a0aufgrund\u00a0des\u00a0\n\u00dcberschreitens\u00a0der\u00a0Umsatzschwelle\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0zeitnah\u00a0nich t\u00a0stattfinden\u00a0\nwird\u00a0(G\u2010BA,\u00a02014b).\u00a0\u00a0\nMit\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0vom\u00a021.\u00a0August\u00a02014\u00a0wurde\u00a0das\u00a0Verfahren\u00a0 zur\u00a0Nutzenbe\u2010\nwertung\u00a0von\u00a0Bedaquilin\u00a0eingestellt\u00a0(G\u2010BA,\u00a02014a).\u00a0Der\u00a0pU\u00a0hatte\u00a0 keine\u00a0in\u00a0der\u00a0GKV\u00a0\nabrechnungsf\u00e4hige\u00a0Packungsgr\u00f6\u00dfe\u00a0(188\u00a0Tabletten\u00a0in\u00a0einer\u00a0Dose\u00a0>\u00a0 N3)\u00a0auf\u00a0den\u00a0\nMarkt\u00a0gebracht.\u00a0Somit\u00a0war\u00a0eine\u00a0Erstattung\u00a0zu\u00a0Lasten\u00a0der\u00a0GKV\u00a0aus geschlossen.\u00a0Eine\u00a0\ngrunds\u00e4tzliche\u00a0 Voraussetzung\u00a0 f\u00fcr\u00a0 die\u00a0 Nutzenbewertung\u00a0 von\u00a0 Arznei mitteln\u00a0 mit\u00a0\nneuen\u00a0Wirkstoffen\u00a0stellt\u00a0die\u00a0Erstattungsf\u00e4higkeit\u00a0zu\u00a0Lasten\u00a0der \u00a0GKV\u00a0dar.\u00a0\nQuellen\u00a0\nAMB\u00a0\u2010\u00a0Der\u00a0Arzneimittelbrief\u00a0(2014).\u00a0Tuberkulose\u00a0\u2010\u00a0eine\u00a0vernachl \u00e4ssigte\u00a0Infektionskrankheit.\u00a0Gibt\u00a0es\u00a0neue\u00a0Therapien?\u00a0AMB\u00a048,\u00a057 f.\u00a0\nAvorn\u00a0J\u00a0(2013).\u00a0Approval\u00a0of\u00a0a\u00a0tuberculosis\u00a0drug\u00a0based\u00a0on\u00a0a\u00a0para doxical\u00a0surrogate\u00a0measure.\u00a0JAMA\u00a0309(13):\u00a01349\u20101350.\u00a0\u00a0\nBauer\u00a0T,\u00a0Otto\u2010Knapp\u00a0R,\u00a0Schenkel\u00a0K\u00a0(2014).\u00a0Tuberkulose\u00a0im\u00a0Erwach senenalter,\u00a0Empfehlungen\u00a0zur\u00a0Diagnostik\u00a0und\u00a0Therapie,\u00a0\nChemopr\u00e4vention\u00a0und\u00a0Chemoprophylaxe:\u00a0Angemeldetes\u00a0Leitlinienvor haben\u00a0S2k.\u00a0Registernummer\u00a0020\u201019.\u00a0\nwww.awmf.org/leitlinien/detail/anmeldung/1/ll/020\u2010019.html,\u00a0let zter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nBfArM\u00a0(2013).\u00a0BfArM\u00a0\u2010\u00a0Glossar\u00a0\u2010\u00a0B edingte\u00a0Zulassung.\u00a0www.bfarm.d e/SharedDocs/Glossareintraege/DE/B/Bedingte%20Zulass\u00a0\nung.html,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nBruhn\u00a0C\u00a0(2016).\u00a0Die\u00a0Sc hwindsucht\u00a0will\u00a0nicht\u00a0schwinden:\u00a0Warum\u00a0ei ne\u00a0Tuberkulose\u2010Eradikation\u00a0so\u00a0schwierig\u00a0ist.DAZ\u00a0(45),\u00a042.\u00a0\nCDC\u00a0\u2013\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention\u00a0(2013).\u00a0Provis ional\u00a0CDC\u00a0Guidelines\u00a0for\u00a0the\u00a0U se\u00a0and\u00a0Safety\u00a0Monitoring\u00a0of\u00a0\nBedaquiline\u00a0Fumarate\u00a0(Sirturo)\u00a0for\u00a0the\u00a0Treatment\u00a0of\u00a0Multidrug\u2010R esistant\u00a0Tuberculosis.\u00a0MMWR\u00a0Morbidity\u00a0and\u00a0\nMortality\u00a0Weekly\u00a0Report,\u00a062(9).\u00a0https://www.cdc.gov/mmwr/PDF/rr /rr6209.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a093\u00a0CDER\u00a0(2012a).\u00a0SIRTURO\u00a0(bedaquiline )\u00a0100\u00a0mg\u00a0tablets.:\u00a0FDA\u00a0accele rated\u00a0approval\u00a0letter\u00a0to\u00a0Janssen.\u00a0\nwww.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384Ori g1s000ltr.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nCDER\u00a0(2012b).\u00a0FDA\u00a0CDER\u00a0summary\u00a0review.\u00a0application\u00a0number\u00a020438 4Trig1s000.\u00a0\nwww.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000 SumR.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2013).\u00a0S irturo,\u00a0INN\u2010bedaquiline\u00a0CHMP\u00a0assessment\u00a0report\u00a0EPAR:\u00a0\nEMA/CHMP/329898/2013\u00a0Public\u00a0assessment\u00a0report.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 Sirturo\u00a0(INN:\u00a0bedaquiline).\u00a0Authorisation\u00a0details.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/002614/human_med_001730.jsp&\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 Sirturo,\u00a0INN\u2010bedaquiline\u00a0EPAR\u00a0Anhang\u00a01:\u00a0Zusammenfassung\u00a0\nder\u00a0Merkmale\u00a0des\u00a0Arzneimittels.\u00a0www.ema.europa.eu/docs/de_DE/do cument_library/EPAR_\u2010\n_Product_Information/human/002614/WC500163209.pdf,\u00a0letzter\u00a0Zugr iff:\u00a013.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014c).\u00a0 Sirturo,\u00a0INN\u2010bedaquiline\u00a0RMP\u00a0summary:\u00a0Summary\u00a0of\u00a0the\u00a0risk\u00a0\nmanagement\u00a0plan\u00a0(RMP)\u00a0for\u00a0Sirturo\u00a0(bedaquiline).\u00a0www.ema.europa .eu/docs/en_GB/document_library/EPAR_\u2010\n_Risk\u2010management\u2010plan_summary/human/002614/WC500162201.pdf,\u00a0let zter\u00a0Zugriff:\u00a013.06.2017.\u00a0\nClinicalTrials.gov\u00a0( 2015).\u00a0Bedaquiline\u00a0STREAM\u00a0NCT02409290.\u00a0clin icaltrials.gov/ct2/show/results/NCT02409290,\u00a0letzter\u00a0Zugriff:\u00a0\n01.06.2017.\u00a0\u00a0\nCox\u00a0E,\u00a0Laessig\u00a0K\u00a0(2014).\u00a0FDA\u00a0approval\u00a0of\u00a0bedaquiline\u00a0\u2013\u00a0the\u00a0bene fit\u2010risk\u00a0balance\u00a0for\u00a0drug\u2010resist ant\u00a0tuberculosis.\u00a0NEJM\u00a0371(8):\u00a0 689\u2010\n691.\u00a0\u00a0\nDiacon\u00a0AH,\u00a0Pym\u00a0A,\u00a0Grobusch\u00a0M,\u00a0Patientia\u00a0R,\u00a0Rustomjee\u00a0R,\u00a0Page\u2010Sh ipp\u00a0L\u00a0et\u00a0al.\u00a0(2009).\u00a0The\u00a0diarylquinoline\u00a0TMC207\u00a0for\u00a0multidrug\u2010\nresistant\u00a0tuberculosis:\u00a0Studie\u00a0C208\u00a0Stage\u00a01.\u00a0NEJM\u00a0360(23):\u00a02397 \u20102405.\u00a0\u00a0\nDiacon\u00a0AH,\u00a0Pym\u00a0A,\u00a0Grobusch\u00a0MP,\u00a0los\u00a0Rios\u00a0JM\u00a0de,\u00a0Gotuzzo\u00a0E,\u00a0Vasil yeva\u00a0I\u00a0et\u00a0al.\u00a0(2014).\u00a0Multidrug\u2010resistant\u00a0tuberculosis\u00a0and\u00a0cult ure\u00a0\nconversion\u00a0with\u00a0bedaquiline.\u00a0NEJM\u00a0371(8):\u00a0723\u2010732.\u00a0\u00a0\nDIMDI\u00a0\u2013\u00a0Deutsches\u00a0Institut\u00a0f\u00fcr\u00a0Medizinische\u00a0Dokumentation\u00a0und\u00a0I nformation\u00a0(2017).\u00a0DIMDI\u00a0\u2010\u00a0Packungsgr\u00f6\u00dfen\u00a0\u2010\u00a0Anlage\u00a01\u00a0\u2010\u00a0\n\u00dcbersicht\u00a0Messzahlen:\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a02017.\u00a0 www.dimdi.de/dynamic/de/amg/packungsgro \u00a0\nessen/historie/anlage1/packungsgroessen\u2010anlage\u20101\u201020170120.pdf,\u00a0 letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2013).\u00a0European\u00a0Medicines\u00a0Agen cy\u00a0recommends\u00a0approval\u00a0of\u00a0a\u00a0new\u00a0medicine\u00a0for\u00a0multidrug\u2010\nresistant\u00a0tuberculosis:\u00a0press\u00a0release.\u00a0 www.ema.europa.eu/docs/en_GB/document_library/Press_release/ \u00a0\n2013/12/WC500158699.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nFeiterna\u2010Sperling\u00a0C\u00a0(2014).\u00a0Tuberkulose\u00a0im\u00a0Kindes\u2010\u00a0und\u00a0Jugendal ter:\u00a0Diagnostik,\u00a0Pr\u00e4vention\u00a0und\u00a0Therapie:\u00a0AWMF\u00a0angemeldetes\u00a0\nLeitlinienvorhaben\u00a0S2k.\u00a0Registernummer\u00a0048\u2010016.\u00a0www.awmf.org/le itlinien/detail/anmeldung/1/ll/048\u2010016.html,\u00a0\nletzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014a).\u00a0Beschluss\u00a0Bedaquili n:\u00a0Einstellung\u00a0des\u00a0Verfahrens.\u00a0www.g\u2010ba.de/downloads/39\u2010\n261\u20102050/2014\u201008\u201021_35a_Einstellung\u2010Verfahren\u2010Bedaquilin_D\u2010112_ BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a013.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0Bes chluss\u00a0Bedaquilin.\u00a0www.g\u2010ba.de/downloads/40\u2010268\u2010\n2920/2014\u201008\u201021_35a_Einstellung\u2010Verfahren\u2010Bedaquilin_D\u2010112_TrG. pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a094\u00a0Gonzalez\u2010Angulo\u00a0L\u00a0(2016).\u00a0The\u00a0use\u00a0of\u00a0bedaquiline\u00a0in\u00a0the\u00a0treatme nt\u00a0of\u00a0multidrug\u2010resistant\u00a0tuberculosis:\u00a0WHO\u00a0Report\u00a0of\u00a0the\u00a0\nGuideline\u00a0Development\u00a0Group\u00a0Meeting\u00a0on.\u00a0apps.who.int/iris/bitst ream/10665/254712/1/WHO\u2010HTM\u2010TB\u20102017.01\u2010\neng.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nGonzalez\u2010Angulo\u00a0L\u00a0(2017).\u00a0WHO\u00a0FAQ\u00a0Bedaquiline\u00a0implementation:\u00a0F requently\u00a0asked\u00a0questions\u00a0about\u00a0the\u00a0use\u00a0of\u00a0bedaquiline\u00a0\naccording\u00a0to\u00a0the\u00a0WHO\u00a0guidelines\u00a0 and\u00a0evidence\u00a0from\u00a0its\u00a0early\u00a0use \u00a0in\u00a0selected\u00a0countries.\u00a0\nwww.who.int/tb/publications/2017/FAQs_Bedaquiline.pdf,\u00a0letzter\u00a0 Zugriff:\u00a001.06.2017.\u00a0\u00a0\nHaas\u00a0W\u00a0(2017).\u00a0Epidemiologische\u00a0Situation\u00a0in\u00a0Deutschland:\u00a0Vortr ag\u00a0anl\u00e4\u00dflich\u00a0des\u00a0Welttuberkulosetages\u00a02017.\u00a0 www.rki.de/DE/ \u00a0\nContent/InfAZ/T/Tuberkulose/WTBTag2017/Vortrag_1.pdf?__blob=pub licationFile,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\u00a0\nHaas\u00a0W,\u00a0Brodhun,\u00a0B,\u00a0Altmann\u00a0D,\u00a0Hauer\u00a0et\u00a0al.\u00a0(2016).\u00a0Bericht\u00a0zur \u00a0Epidemiologie\u00a0der\u00a0Tuberkulose\u00a0in\u00a0Deutschland\u00a0f\u00fcr\u00a02015.\u00a0\nwww.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2015.pdf?_ _blob=publicationFile,\u00a0letzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nJanssen\u00a0(2014a).\u00a0Handlungsempfehlung\u00a0f\u00fcr\u00a0Sirturo:\u00a0Verordnung\u00a0un d\u00a0Abgabe\u00a0von\u00a0ausgeeinzelten\u00a0Teilmengen.\u00a0Briefpapier\u00a0\nPatientenkommunikation.\u00a0www.janssen\u2010med.de/sites/janssen_med_de/files/Sitruro%20Handlungsanweisung_ Apotheke.pdf,\u00a0letzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nJanssen\u00a0(2014b).\u00a0Handlungsempfehlungen\u00a0f\u00fcr\u00a0Sirturo\u00a0\u2010\u00a0\u00c4rzte:\u00a0Ver ordnung\u00a0und\u00a0Abgabe\u00a0von\u00a0ausgeeinzelten\u00a0Teilnemengen\u00a0in\u00a0der\u00a0\nambulanten\u00a0Versorgung.\u00a0Briefpapier\u00a0Patientenkommunikation.\u00a0www. janssen\u2010\nmed.de/sites/janssen_med_de/files/Sitruro%20Handlungsanweisung_ Arzt.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\nKVWL\u00a0(2014).\u00a0Bedaquilin\u00a0Sirturo\u00ae\u00a0\u2010\u00a0Fr\u00fche\u00a0Nutzenbewertung:\u00a0Veror dnungsinformationen.\u00a0\nhttps://www.kvwl.de/arzt/verordnung/arzneimittel/info/fn_pdf/be daquilin_sirturo.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0Bedaquilin\u00a0Sirturo\u00a0Preise\u00a0und\u00a0Packungsgr\u00f6 \u00dfen.\u00a0https://webapo\u2010info.lauer\u2010fischer.de/Infosystem \u00a0\n140901/?ApplikationHash=VFlDRPX2HXuWisP%2flIV97X%2fMb2iw2uDJ%2f 6iB4WW6c3lMH6%2fJP47k%2bKQnbzOx\ntFK%2brXfzVSaH9qHVy8VfmMt9%2fQ%3d%3d&LoginNameHash=mo5GDWXQbRP3 jVYOFIwgFTdlDKq3XXrfu7U4FYp\nbYgFtPvk4G4Uzu5yVLj4ZamRAMi4PwvlI79JTX5Jggk24lg%3d%3d&StartValu e=KakvOutigZJAnshWYPo4WIg8UsndznR\ndIs6pXO1KWmk%3d&Server=www.lauer\u2010fischer.de,\u00a0letzter\u00a0Zugriff:\u00a00 2.06.2017.\u00a0\nPrescrire\u00a0International\u00a0(2014).\u00a0Tuberculosis.\u00a0Multidrug\u2010resista nt\u00a0tuberculosis:\u00a0treatment\u00a0is\u00a0empirical,\u00a0for\u00a0want\u00a0of\u00a0robust\u00a0tri als.\u00a0\nPrescrire\u00a0Int\u00a034(367):\u00a0368\u2010370.\u00a0\u00a0\nPym\u00a0AS,\u00a0Diacon\u00a0AH,\u00a0Tang\u00a0S\u2010J,\u00a0Con radie\u00a0F,\u00a0Danilovits\u00a0M,\u00a0Chuchott aworn\u00a0C\u00a0et\u00a0al.\u00a0(2016).\u00a0Bedaquiline\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0multidru g\u2010\u00a0\nand\u00a0extensively\u00a0drug\u2010resistant\u00a0tuberculosis.\u00a0Eur\u00a0resp\u00a0J\u00a047(2):\u00a0 564\u2010574.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Bedaq uilin|Sirturo\u00ae.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=52572#,\u00a0letzter\u00a0Zugriff:\u00a025.04.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2013).\u00a0Tuberkulose:\u00a0RKI\u2010Ratgeber\u00a0f\u00fc r\u00a0\u00c4rzte.\u00a0http://www.rki.de/DE/Content/Infekt/EpidBull/\u00a0\u00a0\nMerkblaetter/Ratgeber_Tuberkulose.html,\u00a0letzter\u00a0Zugriff:\u00a018.09. 2017.\u00a0\nSchaberg\u00a0T,\u00a0Bauer\u00a0T,\u00a0Castell,S,\u00a0Da lhoff\u00a0K,\u00a0Detjen\u00a0A,\u00a0Diel\u00a0R,\u00a0et \u00a0al.\u00a0(2012).\u00a0Empfehlungen\u00a0zur\u00a0The rapie,\u00a0Chemopravention\u00a0und\u00a0Che mo\u2010\nprophylaxe\u00a0der\u00a0Tuberkulose\u00a0im\u00a0Erwachsenen\u2010\u00a0und\u00a0Kindesalter.\u00a0Deu tsches\u00a0Zentralkomitee\u00a0zur\u00a0Bekampfung\u00a0der\u00a0Tu\u2010\nberkulose\u00a0(DZK),\u00a0Deutsche\u00a0Gesellschaft\u00a0fur\u00a0Pneumologie\u00a0und\u00a0Beat mungsmedizin\u00a0(DGP)\u00a0Pneumologie,\u00a066(3):\u00a0133\u2013171.\u00a0\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2013).\u00a0Use\u00a0of\u00a0bedaquiline\u00a0in\u00a0t he\u00a0treatment\u00a0of\u00a0multidrug\u2010resistant\u00a0tuberculosis.\u00a0Geneva,\u00a0\nSwitzerland:\u00a0World\u00a0Health\u00a0Organization. \u00a0\nWHO\u00a0\u2010\u00a0World\u00a0Health\u00a0Organization\u00a0 (2015).\u00a0WHO\u00a0Mode l\u00a0List\u00a0of\u00a0Essen tial\u00a0Medicines:\u00a019th\u00a0List.\u00a0(April\u00a02015)\u00a0Amended\u00a0November\u00a0\n2015.\u00a0www.who.int/entity/medicines/publications/essentialmedici nes/EML_2015_FINAL_amended_NOV2015.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\u00a0\nWHO\u00a0\u2010\u00a0World\u00a0Health\u00a0Organization\u00a0 (2016).\u00a0WHO\u00a0treatment\u00a0guideline s\u00a0for\u00a0drug\u2010resistant\u00a0tuberculosis:\u00a02016\u00a0update.\u00a0Geneva,\u00a0\nSwitzerland:\u00a0World\u00a0Health\u00a0Organization.\u00a0 \u00a095\u00a04.4 Cabozantinib\u00a0\nHandelsname:\u00a0Cometriq\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0medull\u00e4res\u00a0\u00a0 \u00a0 \u00a0 S wedish\u00a0Orphan\u00a0Biovitrum/\u00a0\u00a0\nSchilddr\u00fcsenkarzinom\u00a0 \u00a0\u00a0 \u00a0 Ip sen\u00a0(seit\u00a0November\u00a02016)\u00a0\u00a0\u00a0\nATC\u2010Code:\u00a0L01XE26\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0August\u00a02014\u00a0\nDarreichungsform:\u00a0Kapsel\u00a0\u00a0 \u00a0 DDD:\u00a00,14\u00a0g\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0C ,\u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nCabozantinib\u00a0ist\u00a0ein\u00a0oral\u00a0zu\u00a0verabreichender\u00a0Multikinase\u2010Inhibi tor,\u00a0der\u00a0neben\u00a0den\u00a0\nRezeptortyrosinkinasen\u00a0 MET\u00a0 (Hepa tozyten\u2010Wachstumsfaktor\u2010Rezepto rprotein)\u00a0\nund\u00a0VEGF\u00a0(vaskul\u00e4rer\u00a0endothelialer\u00a0Wachtumsfaktor)\u00a0auch\u00a0die\u00a0RET \u00a0(Rearranged\u00a0\nDuring\u00a0Transfection )\u2010Kinase\u00a0hemmt,\u00a0deren\u00a0Aktivit\u00e4t\u00a0 eine\u00a0entscheidende\u00a0Rolle\u00a0bei\u00a0\nder\u00a0Pathogenese\u00a0des\u00a0medull\u00e4ren\u00a0Schilddr\u00fcsenkarzinoms\u00a0spielt\u00a0(Fa chinformation\u00a0\nCometriq\u00ae,\u00a02017).\u00a0\nDer\u00a0Wirkstoff\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02014\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0\nKommission\u00a0zugelassen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0medull\u00e4ren\u00a0Schildd r\u00fcsenkarzinoms\u00a0\nbei\u00a0 Erwachsenen\u00a0 mit\u00a0 progredienter,\u00a0 inoperabler,\u00a0 lokal\u00a0 fortgesch rittener\u00a0 oder\u00a0\nmetastasierter\u00a0Erkrankung.\u00a0In\u00a0diesem\u00a0Indikationsgebiet\u00a0steht\u00a0zu r\u00a0medikament\u00f6sen\u00a0\nTherapie\u00a0bisher\u00a0nur\u00a0das\u00a0Anfang\u00a02012\u00a0zugelassene\u00a0Vandetinib\u00a0(Cap relsa\u00ae)\u00a0mit\u00a0sehr\u00a0\n\u00e4hnlichem\u00a0Wirkmechanismus\u00a0zur\u00a0Verf\u00fcgung.\u00a0Die\u00a0Zulassung\u00a0erfolgte \u00a0unter\u00a0Aufla\u2010\ngen,\u00a0d.h.\u00a0der\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0muss\u00a0j\u00e4hrlich\u00a0we itere\u00a0Informati\u2010\nonen\u00a0zur\u00a0Sicherheit\u00a0und\u00a0Wirksamkeit\u00a0bereitstellen\u00a0sowie\u00a0bis\u00a0zum \u00a031.03.2019\u00a0Er\u2010\ngebnisse\u00a0einer\u00a0Dosisvergleichsst udie\u00a0(140\u00a0mg\u00a0vs.\u00a060\u00a0mg)\u00a0vorlege n\u00a0(EMA,\u00a02015).\u00a0\u00a0\nBei\u00a0der\u00a0Entscheidung\u00a0zur\u00a0Behandlung\u00a0mit\u00a0Cabozantinib\u00a0sollte\u00a0ber \u00fccksichtigt\u00a0wer\u2010\nden,\u00a0dass\u00a0der\u00a0Nutzen\u00a0bei\u00a0Patienten\u00a0mit\u00a0unbekanntem\u00a0oder\u00a0negativ em\u00a0RET\u2010Muta\u2010\ntionsstatus\u00a0 m\u00f6glicherweise\u00a0 geringer\u00a0 sein\u00a0 kann.\u00a0 Die\u00a0 empfohlene\u00a0 A nfangsdosis\u00a0\nbetr\u00e4gt\u00a0einmal\u00a0t\u00e4glich\u00a0140\u00a0mg\u00a0Cab ozantinib,\u00a0eingenommen\u00a0als\u00a0ein e\u00a0Kapsel\u00a0\u00e0\u00a080\u00a0mg\u00a0\nund\u00a0drei\u00a0Kapseln\u00a0\u00e0\u00a020\u00a0mg.\u00a0Da\u00a0bei\u00a0der\u00a0Mehrzahl\u00a0der\u00a0Patienten\u00a0dam it\u00a0zu\u00a0rechnen\u00a0ist,\u00a0\ndass\u00a0aufgrund\u00a0von\u00a0Nebenwirkungen\u00a0die\u00a0Dosis\u00a0gesenkt\u00a0oder\u00a0vor\u00fcber gehend\u00a0unter\u2010\nbrochen\u00a0werden\u00a0muss,\u00a0sollte\u00a0vor\u00a0allem\u00a0in\u00a0den\u00a0ersten\u00a0acht\u00a0Wochen \u00a0die\u00a0Therapie\u00a0\nengmaschig\u00a0\u00fcberwacht\u00a0werden.\u00a0\nC a b o z a n t i n i b \u00a0i s t \u00a0e i n \u00a0S u b s t r a t \u00a0d e s \u00a0C y t o c h r o m \u2010 P 4 5 0 \u2010 I s o e n z y m s \u00a0C Y P 3 A4\u00a0 und\u00a0 ein\u00a0\nInhibitor\u00a0des\u00a0P\u2010Glykoproteins\u00a0(P \u2010GP),\u00a0so\u00a0dass\u00a0vielf\u00e4ltige\u00a0pharm akokinetische\u00a0Inter\u2010\naktionen\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0m\u00f6glich\u00a0sind.\u00a0\nIm\u00a0September\u00a02016\u00a0wurde\u00a0Cabozantinib\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommi ssion\u00a0zuge\u2010\nlassen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0fo rtgeschrittenen\u00a0Nierenzellkarzi noms\u00a0bei\u00a0Erwach\u201096\u00a0senen\u00a0nach\u00a0vorangegangener\u00a0zielgerichteter\u00a0Therapie\u00a0gegen\u00a0VEGF\u00a0 (EMA,\u00a02016).\u00a0\nSeit\u00a0dem\u00a001.11.2016\u00a0ist\u00a0der\u00a0Wirkstoff\u00a0in\u00a0diesem\u00a0Anwendungsgebie t\u00a0als\u00a0Cabo\u2010\nmetyx\u00ae\u00a0von\u00a0IPSEN\u00a0Pharma\u00a0auf\u00a0dem\u00a0 deutschen\u00a0Markt.\u00a0Ab\u00a0dem\u00a0gleiche n\u00a0Datum\u00a0\nwird\u00a0IPSEN\u00a0Pharma\u00a0und\u00a0nicht\u00a0mehr\u00a0Swedish\u00a0Orphan\u00a0Biovitrum\u00a0als\u00a0A nbieter\u00a0f\u00fcr\u00a0\nCometriq\u00ae\u00a0 ausgewiesen\u00a0 (Lauer\u2010Fischer,\u00a0 2016).\u00a0 Die\u00a0 empfohlene\u00a0 Dos is\u00a0 betr\u00e4gt\u00a0\n60\u00a0mg\u00a0einmal\u00a0t\u00e4glich,\u00a0bei\u00a0notwe ndiger\u00a0Reduktion\u00a0aufgrund\u00a0von\u00a0Ne benwirkungen\u00a0\nsoll\u00a0sie\u00a0zun\u00e4chst\u00a0auf\u00a040\u00a0mg\u00a0t\u00e4g lich\u00a0und\u00a0danach\u00a0auf\u00a020\u00a0mg\u00a0t\u00e4glic h\u00a0gesenkt\u00a0werden.\u00a0\nDie\u00a0Zulassungsstudie\u00a0EXAM\u2010III\u00a0(Sponsor:\u00a0Exelixis,\u00a0Partner\u00a0von\u00a0I psen)\u00a0im\u00a0Anwen\u2010\ndungsgebiet\u00a0 Schilddr\u00fcsenkarzinom\u00a0 ist\u00a0 eine\u00a0 multizentrische,\u00a0 dopp elblinde,\u00a0 2:1\u2010\nrandomisierte,\u00a0placebokontrolli erte\u00a0Phase\u2010III\u2010Studie\u00a0an\u00a0330\u00a0Pat ienten\u00a0mit\u00a0progre\u2010\ndientem,\u00a0inoperablem,\u00a0lokal\u00a0fortgeschrittenem\u00a0oder\u00a0metastasiert em\u00a0MTC\u00a0(Elisai\u00a0et\u00a0\nal.,\u00a02013).\u00a068\u00a0Patienten\u00a0waren\u00a0mit\u00a0einem\u00a0Tyrosinkinaseinhibitor \u00a0(TKI)\u00a0vorbehan\u2010\ndelt,\u00a0davon\u00a034\u00a0mit\u00a0Vandetinib.\u00a0P rim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0das\u00a0progre ssionsfreie\u00a0\u00dcber\u2010\nleben\u00a0(Progression\u2010free\u00a0Survival ,\u00a0PFS),\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0das\u00a0Gesamt\u2010\n\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0die\u00a0Gesamtansprechrate\u00a0( Overall\u00a0Response\u00a0\nRate,\u00a0ORR).\u00a0Die\u00a0Initialdosis\u00a0von\u00a0Cabozantinib\u00a0in\u00a0der\u00a0Interventionsg ruppe\u00a0betrug\u00a0\neinmal\u00a0t\u00e4glich\u00a0140\u00a0mg,\u00a0jedoch\u00a0waren\u00a0in\u00a0Folge\u00a0von\u00a0schweren\u00a0unerw \u00fcnschten\u00a0Arz\u2010\nneimittelereignissen\u00a0(UAE)\u00a0bei\u00a0de r\u00a0Mehrzahl\u00a0der\u00a0Patienten\u00a0Dosis reduktionen\u00a0oder\u00a0\nTherapieunterbrechungen\u00a0 erforderlich,\u00a0 teilweise\u00a0 auch\u00a0 Therapieab br\u00fcche.\u00a0 Nach\u00a0\n13,9\u00a0Monaten\u00a0Therapiedauer\u00a0lag\u00a0das\u00a0mediane\u00a0PFS\u00a0in\u00a0der\u00a0Cabozanti nib\u2010Gruppe\u00a0bei\u00a0\n11,2\u00a0 Monaten\u00a0 gegen\u00fcber\u00a0 vier\u00a0 Monat en\u00a0 im\u00a0 Placebo\u2010Arm.\u00a0 Die\u00a0 Beurtei lung\u00a0 der\u00a0\nKrankheitsprogression\u00a0 erfolgte\u00a0 mittels\u00a0 bildgebender\u00a0 Verfahren.\u00a0 Die\u00a0 ORR\u00a0 nach\u00a0\nRECIST\u00a0(Response\u00a0Evaluation\u00a0Criteria\u00a0In\u00a0Solid\u00a0Tumors )\u2010Kriterien\u00a0war\u00a0unter\u00a0Cabozan\u2010\ntinib\u00a0wesentlich\u00a0h\u00f6her\u00a0als\u00a0unter\u00a0Placebo\u00a0(27,9\u00a0%\u00a0vs.\u00a00\u00a0%).\u00a0F\u00fcr\u00a0 das\u00a0OS\u00a0zeigte\u00a0sich\u00a0in\u00a0\nder\u00a0Gesamtpopulation\u00a0weder\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0geplanten\u00a0Interims analyse\u00a0noch\u00a0\nzum\u00a0Zeitpunkt\u00a0der\u00a0finalen\u00a0Analyse\u00a0ein\u00a0statistisch\u00a0signifikanter \u00a0Unterschied\u00a0zwi\u2010\nschen\u00a0 Interventions\u2010\u00a0 und\u00a0 Kontrollgruppe\u00a0 (G\u2010BA,\u00a0 2015).\u00a0 Statistis ch\u00a0 signifikante\u00a0\nVorteile\u00a0im\u00a0OS\u00a0gegen\u00fcber\u00a0dem\u00a0Placebo\u2010Arm\u00a0traten\u00a0lediglich\u00a0in\u00a0de r\u00a0Subgruppe\u00a0der\u00a0\nPatienten\u00a0mit\u00a0ECOG\u2010Performance\u00a0S tatus\u00a01\u00a0oder\u00a02\u00a0sowie\u00a0in\u00a0der\u00a0Sub gruppe\u00a0der\u00a0\nPatienten\u00a0mit\u00a0positivem\u00a0RET\u2010\u00a0Mut ationsstatus\u00a0auf.\u00a0Die\u00a0h\u00e4ufigste n\u00a0UAE\u00a0unter\u00a0Cabo\u2010\nzantinib\u00a0 waren\u00a0 Diarrhoe,\u00a0 Hand\u2010Fu\u00df\u2010Syndrom,\u00a0 Gewichtsabnahme,\u00a0 ver minderter\u00a0\nAppetit,\u00a0\u00dcbelkeit\u00a0und\u00a0Fatigue.\u00a0\nDie\u00a0 Zulassungsstudie\u00a0 METEOR\u00a0 f\u00fcr\u00a0 die\u00a0 Indikation\u00a0 Nierenzellkarzin om\u00a0 (Sponsor\u00a0\nExelixis,\u00a0Partner\u00a0von\u00a0Ipsen)\u00a0ist\u00a0eine\u00a0noch\u00a0nicht\u00a0abgeschlossene \u00a0multizentrische,\u00a0\nrandomisierte,\u00a0offene\u00a0Phase\u2010III\u2010 Studie\u00a0an\u00a0658\u00a0Patienten\u00a0mit\u00a0for tgeschrittenem,\u00a0\nmetastasiertem\u00a0Nierenzellkarzinom,\u00a0die\u00a0mit\u00a0mindestens\u00a0einem\u00a0VEG FR\u2010TKI\u00a0vorbe\u2010\nhandelt\u00a0 waren\u00a0 und\u00a0 innerhalb\u00a0 von\u00a0 se chs\u00a0 Monaten\u00a0 eine\u00a0 Krankheitspr ogression\u00a0\nerlitten\u00a0hatten\u00a0(Choueiri\u00a0et\u00a0al.,\u00a02016).\u00a0Die\u00a0Patienten,\u00a0die\u00a0sic h\u00a0in\u00a0einem\u00a0guten\u00a0All\u2010\ngemeinzustand\u00a0befanden\u00a0(Karnofsky\u2010Index\u00a0\u2265\u00a070\u00a0%\u00a0bzw.\u00a0ECOG\u2010Perfor mance\u00a0Status\u00a097\u00a00\u00a0oder\u00a01)\u00a0und\u00a0im\u00a0Mittel\u00a062\u00a0Jahre\u00a0a lt\u00a0waren,\u00a0erhielten\u00a0entweder\u00a0 einmal\u00a0t\u00e4glich\u00a0\n60\u00a0mg\u00a0Cabozantinib\u00a0oder\u00a010\u00a0mg\u00a0Everolimus.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war \u00a0das\u00a0PFS,\u00a0se\u2010\nkund\u00e4re\u00a0Endpunkte\u00a0das\u00a0OS,\u00a0Morbidit\u00e4t\u00a0und\u00a0Nebenwirkungen.\u00a0Bisher \u00a0liegen\u00a0die\u00a0\nAnalysen\u00a0dreier\u00a0Datenschnitte\u00a0vor.\u00a0Zum\u00a0ersten\u00a0Datenschnitt\u00a0betr ug\u00a0das\u00a0mediane\u00a0\nPFS\u00a0f\u00fcr\u00a0Cabozantinib\u00a07,4\u00a0Monate\u00a0im\u00a0Vergleich\u00a0zu\u00a03,9\u00a0Monaten\u00a0f\u00fcr \u00a0Everolimus.\u00a0\nHinsichtlich\u00a0des\u00a0OS\u00a0zeigte\u00a0sich\u00a0zu\u00a0allen\u00a0drei\u00a0Datenschnitten\u00a0ei n\u00a0statistisch\u00a0signifi\u2010\nkanter\u00a0Vorteil\u00a0f\u00fcr\u00a0Cabozantinib ;\u00a0beim\u00a0dritten\u00a0Datenschnitt\u00a0war\u00a0 die\u00a0mediane\u00a0\u00dcber\u2010\nlebenszeit\u00a0durch\u00a0die\u00a0Behandlung\u00a0 mit\u00a0Cabozantinib\u00a021,4\u00a0Monate\u00a0ge gen\u00fcber\u00a017,1\u00a0\nMonaten\u00a0mit\u00a0Everolimus.\u00a0Die\u00a0mitte ls\u00a0Patientenfrageb\u00f6gen\u00a0erhoben en\u00a0Daten\u00a0zum\u00a0\nEndpunkt\u00a0Lebensqualit\u00e4t\u00a0zeigten\u00a0keine\u00a0signifikanten\u00a0Unterschied e\u00a0zwischen\u00a0den\u00a0\nBehandlungsarmen.\u00a0Die\u00a0Endpunkte\u00a0zu\u00a0den\u00a0Nebenwirkungen\u00a0weisen\u00a0au f\u00a0relevante\u00a0\nNachteile\u00a0f\u00fcr\u00a0Cabozantinib\u00a0im\u00a0Vergleich\u00a0zu\u00a0Everolimus\u00a0hin,\u00a0insb esondere\u00a0bei\u00a0den\u00a0\nschweren\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03)\u00a0und\u00a0bei\u00a0Hypertonie,\u00a0Fatigue,\u00a0Diarrhoe\u00a0u nd\u00a0palmoplanta\u2010\nrer\u00a0Erythrodys\u00e4sthesie.\u00a0Auch\u00a0Dosisreduktionen\u00a0waren\u00a0unter\u00a0Caboz antinib\u00a0deutlich\u00a0\nh\u00e4ufiger\u00a0als\u00a0unter\u00a0Everolimus.\u00a0\nF\u00fcr\u00a0Patienten\u00a0mit\u00a0progredientem, \u00a0nicht\u2010resektablem,\u00a0lokal\u00a0fortg eschrittenem\u00a0oder\u00a0\nmetastasiertem\u00a0 medull\u00e4ren \u00a0Schilddr\u00fcsenkarzinom \u00a0stellt\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 geringen\u00a0\nZusatznutzen \u00a0von\u00a0Cabozantinib\u00a0fest\u00a0(G\u2010BA,\u00a02015).\u00a0Obwohl\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0sekund \u00e4ren\u00a0\nEndpunkt\u00a0OS\u00a0in\u00a0der\u00a0Gesamtpopulatio n\u00a0kein\u00a0statistisch\u00a0signifikan ter\u00a0Vorteil\u00a0ergibt,\u00a0\nbeurteilt\u00a0der\u00a0G\u2010BA\u00a0die\u00a0statistisch\u00a0signifikanten\u00a0Studienergebni sse\u00a0in\u00a0der\u00a0Subgruppe\u00a0\nder\u00a0Patienten\u00a0mit\u00a0bereits\u00a0einges chr\u00e4nktem\u00a0Allgemeinzustand\u00a0(ECO G\u00a01\u00a0bis\u00a02)\u00a0und\u00a0in\u00a0\nder\u00a0Subgruppe\u00a0der\u00a0Patienten\u00a0mit\u00a0positivem\u00a0RET\u2010M918T\u00a0Mutationsst atus\u00a0positiv.\u00a0\nNicht\u00a0der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0PFS,\u00a0sondern\u00a0Morbidit\u00e4t\u00a0bzw.\u00a0Symptom atik\u00a0und\u00a0Le\u2010\nbensqualit\u00e4t\u00a0werden\u00a0vom\u00a0G\u2010BA\u00a0zur\u00a0Bewertung\u00a0herangezogen,\u00a0wobei\u00a0 der\u00a0G\u2010BA\u00a0hier\u00a0\naufgrund\u00a0des\u00a0hohen\u00a0Verzerrungspotentials\u00a0und\u00a0heterogener,\u00a0in\u00a0de n\u00a0Einzelfragen\u00a0\nsowohl\u00a0g\u00fcnstiger\u00a0als\u00a0auch\u00a0ung\u00fcnstiger\u00a0oder\u00a0statistisch\u00a0nicht\u00a0si gnifikanter\u00a0Ergebnis\u2010\nse\u00a0f\u00fcr\u00a0Cabozantinib\u00a0die\u00a0Daten\u00a0als\u00a0nicht\u00a0valide\u00a0auswertbar\u00a0ansie ht.\u00a0Trotz\u00a0der\u00a0rele\u2010\nvanten\u00a0Nachteile\u00a0bei\u00a0den\u00a0schweren\u00a0UAE\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0 vor\u00a0dem\u00a0Hinter\u2010\ngrund\u00a0des\u00a0Schweregrades\u00a0der\u00a0Erkrankung\u00a0in\u00a0der\u00a0Gesamtbetrachtung \u00a0eine\u00a0bisher\u00a0\nnicht\u00a0erreichte,\u00a0moderate\u00a0Verbe sserung\u00a0des\u00a0therapierelevanten\u00a0N utzens.\u00a0\nF\u00fcr\u00a0 das\u00a0 Anwendungsgebiet\u00a0 Nierenzellkarzinom \u00a0s t u f t \u00a0d e r \u00a0G \u2010 B A \u00a0d a s \u00a0A u s m a \u00df \u00a0d e s \u00a0\nZusatznutzens\u00a0von\u00a0Cabozantinib\u00a0als\u00a0 nicht\u00a0quantifizierbar \u00a0ein\u00a0(G\u2010BA,\u00a02017).\u00a0Den\u00a0posi\u2010\ntiven\u00a0Ergebnissen\u00a0zum\u00a0Endpunkt\u00a0Gesamt\u00fcberleben\u00a0stehen\u00a0relevante \u00a0Nachteile\u00a0bei\u00a0\nden\u00a0Endpunkten\u00a0zu\u00a0Nebenwirkungen\u00a0gegen\u00fcber.\u00a0Die\u00a0Ergebnisse\u00a0zur\u00a0 Morbidit\u00e4t\u00a0und\u00a0\nzur\u00a0Lebensqualit\u00e4t\u00a0erachtet\u00a0der\u00a0G\u2010BA\u00a0als\u00a0unzureichend,\u00a0zudem\u00a0ge ht\u00a0er\u00a0aufgrund\u00a0der\u00a0\nfehlenden\u00a0Verblindung\u00a0von\u00a0einem\u00a0hohen\u00a0Verzerrungspotential\u00a0bei\u00a0 den\u00a0patientenbe\u2010\nrichteten\u00a0Endpunkten\u00a0zur\u00a0Morbidit\u00e4t\u00a0und\u00a0bei\u00a0den\u00a0Nebenwirkungen\u00a0 aus.\u00a0\n\u00a098\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 \u00a0Kosten\u00a0\n\u00a0\nzweiter\u00a0Multikinase\u2010\ninhibitor\u00a0in\u00a0dieser\u00a0\nIndikation\u00a0unsichere\u00a0Datenlage\u00a0f\u00fcr\u00a0\nden\u00a0Nutzen,\u00a0Risiko\u00a0f\u00fcr\u00a0\nschwere\u00a0UAE\u00a0 \u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel \u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus \u00a0a\u2010t\u2010Bewertung \u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 Not\u00a0acceptable\u00a0 Analogpr\u00e4parat\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nCabozantinib\u00a0\nIndikation\u00a0\nSchilddr\u00fcsenkarzinom \u00a0\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0140\u00a0mg \u00a0\u00a0\n\u00a0\n365\u00a0\u00a0\n\u00a0\n74.245,43\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nVandetanib\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\nCabozantinib \u00a0\nIndikation\u00a0Nierenzellkarzinom \u00a0\nVergleichstherapie\u00a0\u00a0\nEverolimus\u00a0\nNivolumumab \u00a01x\u00a0tgl.\u00a0300\u00a0mg\u00a0\n\u00a0\n\u00a0\n1x\u00a0tgl.\u00a060\u00a0mg\u00a0\n\u00a0\n1x\u00a0tgl.\u00a010\u00a0mg\u00a0\n3\u00a0mg/kg\u00a0KG\u00a0alle\u00a014\u00a0\nTage\u00a0365\u00a0\n\u00a0\n\u00a0\n365\u00a0\n\u00a0\n365\u00a0\n26\u00a057.896,67\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n109.559,98\u00a0\u20ac \u00a0\n\u00a0\n56.987,21\u00a0\u20ac\u00a0\n82.584,84\u00a0\u20ac \u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0wurde\u00a0keine\u00a0Versorgun gsanalyse\u00a0von\u00a0\nCabozantinib\u00a0erstellt.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nCabozantinib\u00a0ist\u00a0ein\u00a0oral\u00a0zu\u00a0verabreichender\u00a0Multikinase\u2010Inhibi tor,\u00a0der\u00a0die\u00a0Aktivit\u00e4\u2010\nten\u00a0mehrerer\u00a0Rezeptortyrosinkinasen\u00a0hemmt,\u00a0die\u00a0in\u00a0normale\u00a0Zellf unktionen\u00a0wie\u00a0\nauch\u00a0pathologische\u00a0Prozesse\u00a0bei\u00a0der\u00a0Zellproliferation,\u00a0Metastas ierung\u00a0und\u00a0Angio\u2010\ngenese\u00a0involviert\u00a0sind.\u00a0Der\u00a0Wirkstoff\u00a0bindet\u00a0an\u00a0die\u00a0katalytisch e\u00a0Dom\u00e4ne\u00a0von\u00a0MET\u00a0\n(Hepatozyten\u2010Wachstumsfaktor\u2010Rez eptorprotein)\u00a0 und\u00a0 VEGFR\u20102\u00a0 (vask ul\u00e4rer\u00a0 en\u2010\ndothelialer\u00a0Wachtumsfaktor\u2010Rezeptor\u00a02).\u00a0Dar\u00fcber\u00a0hinaus\u00a0wird\u00a0die \u00a0RET\u00a0(Rearran\u2010\nged\u00a0 during\u00a0 Transfection )\u2010Kinase\u00a0 inhibiert,\u00a0 deren\u00a0 Aktivit\u00e4t\u00a0 eine\u00a0 entscheidende\u00a0\nRolle\u00a0bei\u00a0der\u00a0Pathogenese\u00a0des\u00a0me dull\u00e4ren\u00a0Schilddr\u00fcsenkarzinoms\u00a0 spielt\u00a0(Fachin\u2010\n99\u00a0formation\u00a0Cometriq\u00ae,\u00a02017).\u00a0Weitere\u00a0durch\u00a0Cabozantinib\u00a0gehemmte \u00a0Tyrosinkina\u2010\nsen\u00a0 sind\u00a0 der\u00a0 GAS6\u2010Rezeptor\u00a0 (AXL), \u00a0 ROS1,\u00a0 TYRO3,\u00a0 MER,\u00a0 der\u00a0 Stammze llfaktor\u2010\nRezeptor\u00a0(KIT),\u00a0TRKB,\u00a0Fms\u2010artige\u00a0Tyrosinkinase\u20103\u00a0(FLT3)\u00a0und\u00a0TIE \u20102\u00a0(EMA,\u00a02016).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nCabozantinib\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02014\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission \u00a0zugelassen\u00a0\nf\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0medull\u00e4ren\u00a0Schilddr\u00fcsenkarzinoms\u00a0(MTC,\u00a0 Medullary\u00a0Thy\u2010\nreoid\u00a0Cancer)\u00a0bei\u00a0Erwachsenen\u00a0mit\u00a0prog redienter,\u00a0inoperabler,\u00a0lokal\u00a0f ortgeschrit\u2010\ntener\u00a0oder\u00a0metastasierter\u00a0Erkrankung\u00a0und\u00a0ist\u00a0seit\u00a0August\u00a02014\u00a0i n\u00a0Deutschland\u00a0auf\u00a0\ndem\u00a0Markt.\u00a0In\u00a0diesem\u00a0Indikationsgebiet\u00a0steht\u00a0zur\u00a0medikament\u00f6sen \u00a0Therapie\u00a0bis\u2010\nher\u00a0nur\u00a0das\u00a0Anfang\u00a02012\u00a0zugelassene\u00a0Vandetinib\u00a0(Caprelsa\u00ae)\u00a0mit\u00a0 sehr\u00a0\u00e4hnlichem\u00a0\nWirkungsmechanismus\u00a0zur\u00a0Verf\u00fcgung.\u00a0Da\u00a0es\u00a0nur\u00a0wenige\u00a0Patienten\u00a0m it\u00a0MTC\u00a0gibt,\u00a0\nhat\u00a0der\u00a0Wirkstoff\u00a0den\u00a0Status\u00a0eines\u00a0 Orphan\u2010Arzneimittels.\u00a0Die\u00a0Zulassung\u00a0erfolgte\u00a0\nunter\u00a0Auflagen,\u00a0d.h.\u00a0der\u00a0pU\u00a0muss\u00a0j\u00e4hrlich\u00a0weitere\u00a0Informationen \u00a0zur\u00a0Sicherheit\u00a0und\u00a0\nWirksamkeit\u00a0bereitstellen,\u00a0au\u00dferdem\u00a0bis\u00a0zum\u00a031.03.2019\u00a0eine\u00a0Dos isvergleichsstu\u2010\ndie\u00a0(140\u00a0mg\u00a0vs.\u00a060\u00a0mg)\u00a0abschlie\u00dfen\u00a0(EMA,\u00a02015).\u00a0\nBei\u00a0der\u00a0Entscheidung\u00a0\u00fcber\u00a0die\u00a0Aufnahme\u00a0der\u00a0Behandlung\u00a0mit\u00a0Caboz antinib\u00a0sollte\u00a0\nber\u00fccksichtigt\u00a0 werden,\u00a0 dass\u00a0 der\u00a0 Nutzen\u00a0 bei\u00a0 Patienten\u00a0 mit\u00a0 unbeka nntem\u00a0 oder\u00a0\nnegativem\u00a0RET\u2010Mutationsstatus\u00a0p otentiell\u00a0geringer\u00a0sein\u00a0kann.\u00a0\nDie\u00a0empfohlene\u00a0Anfangsdosis\u00a0betr\u00e4gt\u00a0einmal\u00a0t\u00e4glich\u00a0140\u00a0mg\u00a0Caboz antinib,\u00a0einge\u2010\nnommen\u00a0als\u00a0eine\u00a080\u00a0mg\u00a0Kapsel\u00a0und\u00a0drei\u00a020\u00a0mg\u00a0Kapseln.\u00a0Da\u00a0bei\u00a0der \u00a0Mehrzahl\u00a0der\u00a0\nPatienten\u00a0damit\u00a0zu\u00a0rechnen\u00a0ist,\u00a0dass\u00a0aufgrund\u00a0von\u00a0toxischen\u00a0Neb enwirkungen\u00a0die\u00a0\nDosis\u00a0gesenkt\u00a0oder\u00a0vor\u00fcbergehend\u00a0unterbrochen\u00a0werden\u00a0muss,\u00a0soll te\u00a0die\u00a0Therapie\u00a0\nvor\u00a0allem\u00a0in\u00a0den\u00a0ersten\u00a0acht\u00a0Woc hen\u00a0engmaschig\u00a0\u00fcberwacht\u00a0werden .\u00a0\nC a b o z a n t i n i b \u00a0i s t \u00a0e i n \u00a0S u b s t r a t \u00a0d e s \u00a0C y t o c h r o m \u2010 P 4 5 0 \u2010 I s o e n z y m s \u00a0C Y P 3 A4\u00a0 und\u00a0 ein\u00a0\nInhibitor\u00a0des\u00a0P\u2010Glykoproteins\u00a0(P \u2010GP),\u00a0sodass\u00a0vielf\u00e4ltige\u00a0pharma kokinetische\u00a0Inter\u2010\naktionen\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0m\u00f6glich\u00a0sind.\u00a0\nIm\u00a0September\u00a02016\u00a0wurde\u00a0Cabozantinib\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommi ssion\u00a0zuge\u2010\nlassen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0fo rtgeschrittenen\u00a0Nierenzellkarzi noms\u00a0bei\u00a0Erwach\u2010\nsenen\u00a0nach\u00a0vorangegangener\u00a0zielgerichteter\u00a0Therapie\u00a0gegen\u00a0VEGF\u00a0 (EMA,\u00a02016).\u00a0\nSeit\u00a0dem\u00a001.11.2016\u00a0ist\u00a0der\u00a0Wirkstoff\u00a0in\u00a0diesem\u00a0Anwendungsgebie t\u00a0als\u00a0Cabo\u2010\nmetyx\u00ae\u00a0von\u00a0IPSEN\u00a0Pharma\u00a0auf\u00a0dem\u00a0 deutschen\u00a0Markt.\u00a0Ab\u00a0dem\u00a0gleiche n\u00a0Datum\u00a0\nwird\u00a0IPSEN\u00a0Pharma\u00a0und\u00a0nicht\u00a0mehr\u00a0Swedish\u00a0Orphan\u00a0Biovitrum\u00a0als\u00a0A nbieter\u00a0f\u00fcr\u00a0\nCometriq\u00ae\u00a0 ausgewiesen\u00a0 (Lauer\u2010Fischer,\u00a0 2016).\u00a0 Die\u00a0 empfohlene\u00a0 Dos is\u00a0 betr\u00e4gt\u00a0\n60\u00a0mg\u00a0einmal\u00a0t\u00e4glich,\u00a0bei\u00a0notwe ndiger\u00a0Reduktion\u00a0aufgrund\u00a0von\u00a0Ne benwirkungen\u00a0\nsoll\u00a0sie\u00a0zun\u00e4chst\u00a0auf\u00a040\u00a0mg\u00a0t\u00e4g lich\u00a0und\u00a0danach\u00a0auf\u00a020\u00a0mg\u00a0t\u00e4glic h\u00a0gesenkt\u00a0werden.\u00a0100\u00a0Informationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nPro\u00a0Jahr\u00a0erkranken\u00a0in\u00a0Deutschland\u00a0rund\u00a07.000\u00a0Menschen\u00a0an\u00a0Schild dr\u00fcsenkrebs,\u00a0\ndem\u00a0h\u00e4ufigsten\u00a0malignen\u00a0endokrinen\u00a0Tumor.\u00a0Das\u00a0mittlere\u00a0Erkranku ngsalter\u00a0ist\u00a0bei\u00a0\nFrauen\u00a051\u00a0und\u00a0bei\u00a0M\u00e4nnern\u00a056\u00a0Jahre.\u00a0Frauen\u00a0sind\u00a0deutlich\u00a0h\u00e4ufig er\u00a0betroffen\u00a0(RKI\u00a0\n&\u00a0GEKID,\u00a02015).\u00a0Histologisch\u00a0unt erscheidet\u00a0man\u00a0verschiedene\u00a0Typ en.\u00a0Die\u00a0von\u00a0den\u00a0\nThyreozyten\u00a0 ausgehenden\u00a0 papill\u00e4ren\u00a0 und\u00a0 follikul\u00e4ren\u00a0 Karzinome,\u00a0 die\u00a0 auch\u00a0 als\u00a0\ndifferenzierte\u00a0Karzinome\u00a0bezeichnet\u00a0werden,\u00a0machen\u00a080\u00a0bis\u00a090\u00a0%\u00a0 aller\u00a0malignen\u00a0\nSchilddr\u00fcsentumore\u00a0aus\u00a0(Berger\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0medull\u00e4ren\u00a0Ka rzinome\u00a0mit\u00a0einer\u00a0\nH\u00e4ufigkeit\u00a0von\u00a0etwa\u00a05\u00a0%\u00a0gehen\u00a0vo n\u00a0den\u00a0parafollikul\u00e4ren\u00a0C\u2010Zellen \u00a0aus,\u00a0die\u00a0nicht\u00a0an\u00a0\nder\u00a0Schilddr\u00fcsenhormonsynthese\u00a0beteiligt\u00a0sind,\u00a0sondern\u00a0Calciton in\u00a0produzieren.\u00a0\nEtwa\u00a0ein\u00a0Viertel\u00a0der\u00a0medull\u00e4ren\u00a0Karzinome\u00a0werden\u00a0autosomal\u2010domi nant\u00a0vererbt\u00a0\nund\u00a0treten\u00a0famili\u00e4r\u00a0geh\u00e4uft\u00a0auf\u00a0im\u00a0Rahmen\u00a0der\u00a0sogenannten\u00a0Multi plen\u00a0endokrinen\u00a0\nNeoplasie\u00a0Typ\u00a02A/2B\u00a0(MEN\u20102\u2010Syndr om)\u00a0bzw.\u00a0des\u00a0famili\u00e4ren\u00a0medull\u00e4 ren\u00a0Schilddr\u00fc\u2010\nsenkarzinoms\u00a0( Familial\u00a0Medullary\u00a0Thyroid\u00a0Cancer ,\u00a0FMTC).\u00a0Molekulargenetisch\u00a0fin\u2010\nden\u00a0sich\u00a0hier\u00a0zu\u00a095\u00a0%\u00a0Keimbahnmutationen\u00a0des\u00a0RET\u2010Protoonkogens, \u00a0die\u00a0zu\u00a0einer\u00a0\n\u00dcberexpression\u00a0 des\u00a0 RET\u2010Rezeptors \u00a0f \u00fc h r e n . \u00a0D i e \u00a0n i c h t \u2010 h e r e d i t \u00e4 r e n \u00a0 medull\u00e4ren\u00a0\nSchilddr\u00fcsenkarzinome\u00a0bezeichnet\u00a0man\u00a0auch\u00a0als\u00a0sporadische\u00a0MTC.\u00a0 Hier\u00a0lassen\u00a0sich\u00a0\nin\u00a0ungef\u00e4hr\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0F\u00e4lle\u00a0somatische\u00a0RET\u2010Mutationen\u00a0nach weisen,\u00a0au\u00dfer\u2010\ndem\u00a0sind\u00a0beim\u00a0MTC\u00a0h\u00e4ufig\u00a0VEGF \u2010Rezeptoren\u00a0\u00fcberexprimiert.\u00a0\nDie\u00a0Prognose\u00a0der\u00a0differenzierten \u00a0Schilddr\u00fcsenkarzinome\u00a0ist\u00a0gut\u00a0 und\u00a0insgesamt\u00a0\ng\u00fcnstiger\u00a0als\u00a0die\u00a0der\u00a0medull\u00e4ren\u00a0 Schilddr\u00fcsenkarzinome.\u00a0Das\u00a0med ull\u00e4re\u00a0Karzinom\u00a0\nw\u00e4chst\u00a0meist\u00a0langsam,\u00a0metastasiert\u00a0aber\u00a0fr\u00fch\u00a0in\u00a0die\u00a0regionalen\u00a0 Lymphknoten\u00a0und\u00a0\nsp\u00e4ter\u00a0auch\u00a0h\u00e4matogen\u00a0mit\u00a0Fernmetastasen\u00a0vor\u00a0allem\u00a0in\u00a0Leber,\u00a0Lu nge\u00a0und\u00a0Kno\u2010\nchen\u00a0(Schmoll\u00a0&\u00a0H\u00f6ffken,\u00a02006).\u00a0Bei\u00a0Diagnose\u00a0im\u00a0fr\u00fchen\u00a0Stadium\u00a0 liegen\u00a0die\u00a0Zehn\u2010\njahres\u00fcberlebensraten\u00a0bei\u00a075\u00a0bis\u00a085\u00a0%,\u00a0jedoch\u00a0haben\u00a0zum\u00a0Zeitpun kt\u00a0der\u00a0Diagnose\u00a0\nbis\u00a0zu\u00a070\u00a0%\u00a0der\u00a0Betroffenen\u00a0Lym phknoten\u2010\u00a0oder\u00a0Fernmetastasen,\u00a0w as\u00a0die\u00a0\u00dcberle\u2010\nbensraten\u00a0nach\u00a010\u00a0Jahren\u00a0auf\u00a040\u00a0%\u00a0und\u00a0weniger\u00a0sinken\u00a0l\u00e4sst\u00a0(Roy \u00a0et\u00a0al.,\u00a02013).\u00a0Der\u00a0\nVerlauf\u00a0der\u00a0Krankheit\u00a0ist\u00a0indivi duell\u00a0sehr\u00a0unterschiedlich,\u00a0jed och\u00a0meistens\u00a0langj\u00e4h\u2010\nrig,\u00a0mit\u00a0langsamem\u00a0Fortschreiten \u00a0bei\u00a0nicht\u00a0selten\u00a0guter\u00a0Lebensq ualit\u00e4t.\u00a0\nMaligne\u00a0Neoplasien\u00a0der\u00a0Niere,\u00a0die \u00a0etwa\u00a02\u00a0%\u00a0aller\u00a0malignen\u00a0Tumor e\u00a0ausmachen,\u00a0\nk\u00f6nnen\u00a0von\u00a0verschiedenen\u00a0Geweben\u00a0ausgehen.\u00a0Im\u00a0Erwachsenenalter\u00a0 treten\u00a0die\u00a0\nvom\u00a0Epithel\u00a0der\u00a0Nierentubuli\u00a0ausg ehenden\u00a0Nierenzellkarzinome\u00a0(H ypernephrome)\u00a0\nmit\u00a0einem\u00a0Anteil\u00a0von\u00a0\u00fcber\u00a090\u00a0%\u00a0am\u00a0h\u00e4ufigsten\u00a0auf.\u00a0In\u00a0Deutschlan d\u00a0wird\u00a0die\u00a0Zahl\u00a0\nder\u00a0Neuerkrankungen\u00a0an\u00a0b\u00f6sartigen\u00a0Nierentumoren\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a020 16\u00a0auf\u00a016.500\u00a0\ngesch\u00e4tzt\u00a0(RKI\u00a0&\u00a0GEKID,\u00a02015).\u00a0M\u00e4nner\u00a0sind\u00a0etwa\u00a01,5\u00a0bis\u00a02mal\u00a0h\u00e4 ufiger\u00a0als\u00a0Frauen\u00a0\nbetroffen.\u00a0Das\u00a0mittlere\u00a0Erkrankungsalter\u00a0liegt\u00a0f\u00fcr\u00a0M\u00e4nner\u00a0bei\u00a06 8\u00a0Jahren\u00a0und\u00a0f\u00fcr\u00a0\nFrauen\u00a0bei\u00a072\u00a0Jahren.\u00a0101\u00a0Die\u00a0 Prognose\u00a0 beim\u00a0 Nierenzellkreb s\u00a0 ist\u00a0 vergleichsweise\u00a0 g\u00fcnstig,\u00a0 die\u00a0 relative\u00a0 5\u2010\nJahres\u2010\u00dcberlebensrate\u00a0betr\u00e4gt\u00a075\u00a0%\u00a0bei\u00a0M\u00e4nnern\u00a0und\u00a077\u00a0%\u00a0bei\u00a0Fra uen\u00a0(AWMF\u00a0\nLeitlinie,\u00a0 2017).\u00a0 Sie\u00a0 ist\u00a0 allerdings\u00a0 stark\u00a0 abh\u00e4ngig\u00a0 vom\u00a0 zugrund e\u00a0 liegenden\u00a0 Tu\u2010\nmorstadium.\u00a0So\u00a0sinkt\u00a0die\u00a0relativ e\u00a05\u2010Jahres\u2010\u00dcberlebensrate\u00a0von\u00a09 7\u00a0%\u00a0im\u00a0Stadium\u00a0I\u00a0\n\u00fcber\u00a087\u00a0%\u00a0im\u00a0Stadium\u00a0II\u00a0und\u00a069\u00a0%\u00a0im\u00a0Stadium\u00a0III\u00a0auf\u00a0nur\u00a0noch\u00a014 \u00a0%\u00a0im\u00a0Stadium\u00a0IV\u00a0\nab\u00a0(Tumorregister\u00a0M\u00fcnchen,\u00a02017).\u00a0Etwa\u00a0drei\u00a0Viertel\u00a0aller\u00a0Tumor e\u00a0werden\u00a0in\u00a0den\u00a0\nrelativ\u00a0fr\u00fchen\u00a0Stadien\u00a0T1\u00a0und\u00a0T2\u00a0d iagnostiziert,\u00a0oft\u00a0als\u00a0Zufall sbefund\u00a0im\u00a0Rahmen\u00a0\nsonografischer\u00a0abdomineller\u00a0Untersuchungen.\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassungsstudie\u00a0EXAM\u2010III\u00a0(Sponsor:\u00a0Exelixis,\u00a0Partner\u00a0von\u00a0I psen)\u00a0in\u00a0der\u00a0Indika\u2010\ntion\u00a0 Schilddr\u00fcsenkarzinom\u00a0 ist\u00a0 eine\u00a0 multizentrische,\u00a0 doppelblind e,\u00a0 2:1\u2010randomi\u2010\nsierte,\u00a0placebokontrollierte\u00a0Phase\u2010III\u2010Studie\u00a0an\u00a0330\u00a0Patienten\u00a0 mit\u00a0progredientem,\u00a0\ninoperablem,\u00a0 lokal\u00a0 fortgeschrittenem\u00a0 oder\u00a0 metastasiertem\u00a0 MTC\u00a0 (E lisei\u00a0 et\u00a0 al.,\u00a0\n2013).\u00a0 68\u00a0 Patienten\u00a0 waren\u00a0 mit\u00a0 einem\u00a0 Tyrosinkinasehemmstoff\u00a0 vorb ehandelt,\u00a0\ndavon\u00a034\u00a0mit\u00a0Vandetinib.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0das\u00a0progressions freie\u00a0\u00dcberleben\u00a0\n(Progression\u2010free\u00a0Survival ,\u00a0PFS),\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0das\u00a0Gesamt\u00fcberle\u2010\nben\u00a0(Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0die\u00a0Gesamtansprechrate\u00a0( Overall\u00a0Response\u00a0Rate ,\u00a0\nORR).\u00a0Die\u00a0Initialdosis\u00a0von\u00a0Cabozantinib\u00a0in\u00a0der\u00a0Interventionsgru ppe\u00a0(n=219)\u00a0betrug\u00a0\neinmal\u00a0t\u00e4glich\u00a0140\u00a0mg,\u00a0jedoch\u00a0waren\u00a0in\u00a0Folge\u00a0von\u00a0schweren\u00a0Neben wirkungen\u00a0bei\u00a0\nder\u00a0Mehrzahl\u00a0der\u00a0Patienten\u00a0Dosis reduktionen\u00a0(67\u00a0%)\u00a0oder\u00a0Therapi eunterbrechun\u2010\ngen\u00a0(65\u00a0%)\u00a0erforderlich,\u00a0bei\u00a016\u00a0%\u00a0wurde\u00a0die\u00a0Therapie\u00a0abgebroche n.\u00a0Nach\u00a013,9\u00a0\nMonaten\u00a0Therapiedauer\u00a0(Datenschnitt\u00a016.04.2011,\u00a0finale\u00a0Analyse\u00a0 des\u00a0PFS)\u00a0lag\u00a0das\u00a0\nmediane\u00a0PFS\u00a0in\u00a0der\u00a0Cabozantinib\u2010 Gruppe\u00a0bei\u00a011,2\u00a0Monaten\u00a0gegen\u00fcb er\u00a04\u00a0Monaten\u00a0\nim\u00a0Placebo\u2010Arm.\u00a0Die\u00a0Beurteilung\u00a0d er\u00a0Krankheitsprogression\u00a0erfol gte\u00a0mittels\u00a0bild\u2010\ngebender\u00a0Verfahren.\u00a0Die\u00a0ORR\u00a0nach\u00a0RECIST\u00a0( Response\u00a0Evaluation\u00a0Criteria\u00a0In\u00a0Solid\u00a0\nTumors)\u2010Kriterien\u00a0 war\u00a0 unter\u00a0 Cabozantinib\u00a0 wesentlich\u00a0 h\u00f6her\u00a0 als\u00a0 unter\u00a0 P lacebo\u00a0\n(27,9\u00a0%\u00a0vs.\u00a00\u00a0%).\u00a0F\u00fcr\u00a0das\u00a0OS\u00a0zeigte\u00a0sich\u00a0in\u00a0der\u00a0Gesamtpopulatio n\u00a0weder\u00a0zum\u00a0Zeit\u2010\npunkt\u00a0der\u00a0geplanten\u00a0Interimsanalyse\u00a0(Datenschnitt\u00a015.06.2011)\u00a0n och\u00a0bei\u00a0der\u00a0zwei\u2010\nten\u00a0Interimsanalyse\u00a0(Datenschnitt\u00a015.06.2012)\u00a0noch\u00a0zum\u00a0Zeitpunk t\u00a0der\u00a0finalen\u00a0\nAnalyse\u00a0ein\u00a0statistisch\u00a0signifikanter\u00a0Unterschied\u00a0zwischen\u00a0Inte rventions\u2010\u00a0und\u00a0Kon\u2010\ntrollgruppe\u00a0(G\u2010BA,\u00a02015).\u00a0Statistisch\u00a0signifikante\u00a0Vorteile\u00a0im\u00a0 OS\u00a0gegen\u00fcber\u00a0dem\u00a0\nPlacebo\u2010Arm\u00a0 zeigten\u00a0 sich\u00a0 ledigli ch\u00a0 in\u00a0 der\u00a0 Subgruppe\u00a0 der\u00a0 Patient e n \u00a0m i t \u00a0E C O G \u2010\nPerformance\u00a0Status\u00a01\u00a0oder\u00a02\u00a0sowie\u00a0in\u00a0der\u00a0Subgruppe\u00a0der\u00a0Patiente n\u00a0mit\u00a0positivem\u00a0\nRET\u2010M918T\u00a0Mutationsstatus.\u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0unter\u00a0Cabozantini b\u00a0waren\u00a0Diar\u2010\nrhoe,\u00a0Hand\u2010Fu\u00df\u2010Syndrom,\u00a0Gewichts abnahme,\u00a0verminderter\u00a0Appetit,\u00a0 \u00dcbelkeit\u00a0und\u00a0\nFatigue.\u00a0\nDie\u00a0 Zulassungsstudie\u00a0 METEOR\u00a0 f\u00fcr\u00a0 die\u00a0 Indikation\u00a0 Nierenzellkarzin om\u00a0 (Sponsor\u00a0\nExelixis,\u00a0Partner\u00a0von\u00a0Ipsen)\u00a0ist\u00a0eine\u00a0noch\u00a0nicht\u00a0abgeschlossene \u00a0multizentrische,\u00a0\nrandomisierte,\u00a0offene\u00a0Phase\u2010III\u2010 Studie\u00a0an\u00a0658\u00a0Patienten\u00a0mit\u00a0for tgeschrittenem,\u00a0102\u00a0metastasiertem\u00a0Nierenzellkarzinom,\u00a0die\u00a0mit\u00a0mindestens\u00a0einem\u00a0VEG FR\u2010TKI\u00a0vorbe\u2010\nhandelt\u00a0 waren\u00a0 und\u00a0 innerhalb\u00a0 von\u00a0 se chs\u00a0 Monaten\u00a0 eine\u00a0 Krankheitspr ogression\u00a0\nerlitten\u00a0hatten\u00a0(Choueiri\u00a0et\u00a0al.,\u00a02016).\u00a0Die\u00a0Patienten,\u00a0die\u00a0sic h\u00a0in\u00a0einem\u00a0guten\u00a0All\u2010\ngemeinzustand\u00a0befanden\u00a0(Karnofsky\u2010Index\u00a0\u2265\u00a070\u00a0%\u00a0bzw.\u00a0ECOG\u2010Perfor mance\u00a0Status\u00a0\n0\u00a0oder\u00a01)\u00a0und\u00a0im\u00a0Mittel\u00a062\u00a0Jahre\u00a0a lt\u00a0waren,\u00a0erhielten\u00a0entweder\u00a0 einmal\u00a0t\u00e4glich\u00a0\n60\u00a0mg\u00a0Cabozantinib\u00a0oder\u00a010\u00a0mg\u00a0Everolimus.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war \u00a0das\u00a0PFS,\u00a0se\u2010\nkund\u00e4re\u00a0Endpunkte\u00a0das\u00a0OS,\u00a0Morbidit\u00e4t\u00a0und\u00a0Nebenwirkungen.\u00a0Bisher \u00a0liegen\u00a0die\u00a0\nAnalysen\u00a0dreier\u00a0Datenschnitte\u00a0vor.\u00a0Zum\u00a0ersten\u00a0Datenschnitt\u00a0betr ug\u00a0das\u00a0mediane\u00a0\nPFS\u00a0f\u00fcr\u00a0Cabozantinib\u00a07,4\u00a0Monate\u00a0im\u00a0Vergleich\u00a0zu\u00a03,9\u00a0Monaten\u00a0f\u00fcr \u00a0Everolimus.\u00a0\nHinsichtlich\u00a0des\u00a0OS\u00a0zeigte\u00a0sich\u00a0zu\u00a0allen\u00a0drei\u00a0Datenschnitten\u00a0ei n\u00a0statistisch\u00a0signifi\u2010\nkanter\u00a0Vorteil\u00a0f\u00fcr\u00a0Cabozantinib ;\u00a0beim\u00a0dritten\u00a0Datenschnitt\u00a0war\u00a0 die\u00a0mediane\u00a0\u00dcber\u2010\nlebenszeit\u00a0durch\u00a0die\u00a0Behandlung\u00a0 mit\u00a0Cabozantinib\u00a021,4\u00a0Monate\u00a0ge gen\u00fcber\u00a017,1\u00a0\nMonaten\u00a0mit\u00a0Everolimus.\u00a0Die\u00a0mitte ls\u00a0Patientenfrageb\u00f6gen\u00a0erhoben en\u00a0Daten\u00a0zum\u00a0\nEndpunkt\u00a0Lebensqualit\u00e4t\u00a0zeigten\u00a0keine\u00a0signifikanten\u00a0Unterschied e\u00a0zwischen\u00a0den\u00a0\nBehandlungsarmen.\u00a0Die\u00a0Endpunkte\u00a0zu\u00a0den\u00a0Nebenwirkungen\u00a0weisen\u00a0au f\u00a0relevante\u00a0\nNachteile\u00a0f\u00fcr\u00a0Cabozantinib\u00a0im\u00a0Vergleich\u00a0zu\u00a0Everolimus\u00a0hin,\u00a0insb esondere\u00a0bei\u00a0den\u00a0\nschweren\u00a0UAE\u00a0(Grad\u00a0\u22653)\u00a0und\u00a0bei\u00a0Hypertonie,\u00a0Fatigue,\u00a0Diarrhoe\u00a0un d\u00a0palmoplanta\u2010\nrer\u00a0Erythrodys\u00e4sthesie.\u00a0Auch\u00a0Dosisreduktionen\u00a0waren\u00a0unter\u00a0Caboz antinib\u00a0deutlich\u00a0\nh\u00e4ufiger\u00a0als\u00a0unter\u00a0Everolimus.\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0Behandlung\u00a0der\u00a0medull\u00e4ren\u00a0Schilddr\u00fcsenkarzinome\u00a0ist\u00a0symptom orientiert\u00a0und\u00a0\nbesteht\u00a0vorrangig\u00a0in\u00a0der\u00a0chirurgischen\u00a0Resektion\u00a0des\u00a0Prim\u00e4rtumo rs\u00a0und\u00a0der\u00a0Meta\u2010\nstasen.\u00a0W\u00e4hrend\u00a0bei\u00a0der\u00a0multimodalen\u00a0Therapie\u00a0der\u00a0differenziert en\u00a0Schilddr\u00fcsen\u2010\nkarzinome\u00a0die\u00a0Radiojodtherapie\u00a0e ine\u00a0wichtige\u00a0Rolle\u00a0spielt,\u00a0ist\u00a0 sie\u00a0beim\u00a0MTC\u00a0nicht\u00a0\nsinnvoll,\u00a0da\u00a0die\u00a0C\u2010Zellen\u00a0keinen\u00a0Jodmetabolismus\u00a0besitzen.\u00a0Bei\u00a0 Patienten\u00a0mit\u00a0MTC\u00a0\nohne\u00a0 nachweisbare\u00a0 Lymphknotenmetastasen\u00a0 erfolgt\u00a0 standardm\u00e4\u00dfig\u00a0 d ie\u00a0 totale\u00a0\nThyreoidektomie\u00a0mit\u00a0prophylaktis cher\u00a0beidseitiger\u00a0zentraler\u00a0Lym phknotendissek\u2010\ntion\u00a0(Schlumberger\u00a0et\u00a0al.,\u00a02012).\u00a0Auch\u00a0wenn\u00a0neben\u00a0dem\u00a0Schilddr\u00fc sengewebe\u00a0das\u00a0\numliegende\u00a0Gewebe\u00a0oder\u00a0die\u00a0Lymphknoten\u00a0betroffen\u00a0sind\u00a0(Stadium\u00a0 III\u00a0oder\u00a0IV\u00a0a)\u00a0\noder\u00a0 Fernmetastasen\u00a0 vorliegen\u00a0 (Stadium\u00a0 IV\u00a0 b),\u00a0 ist\u00a0 die\u00a0 chirurgis che\u00a0 Resektion\u00a0\nHauptbehandlungsma\u00dfnahme.\u00a0Au\u00dferdem\u00a0wird\u00a0h\u00e4ufig\u00a0eine\u00a0externe\u00a0Str ahlenthera\u2010\npie\u00a0zur\u00a0Reduzierung\u00a0des\u00a0Risikos\u00a0f \u00fcr\u00a0Lokalrezidive\u00a0durchgef\u00fchrt. \u00a0Die\u00a0systemische\u00a0\nmedikament\u00f6se\u00a0Therapie\u00a0ist\u00a0dem\u00a0fortgeschrittenen\u00a0Krankheitsstad ium\u00a0mit\u00a0hoher\u00a0\nTumorlast,\u00a0ausgepr\u00e4gter\u00a0Symptomatik\u00a0und/oder\u00a0drohenden\u00a0Komplika tionen\u00a0vor\u2010\nbehalten.\u00a0Da\u00a0mit\u00a0zytotoxischer\u00a0Chemotherapie\u00a0nur\u00a0eine\u00a0relativ\u00a0g eringe\u00a0und\u00a0zeitlich\u00a0\nbegrenzte\u00a0 Ansprechrate\u00a0 erzielt\u00a0 wird,\u00a0 gelten\u00a0 RET\u2010\u00a0 und\u00a0 VEGFR\u2010Tyro sinkinase\u2010\nInhibitoren\u00a0als\u00a0vielversprechende,\u00a0die\u00a0Behandlungsaussichten\u00a0ve rbessernde\u00a0The\u2010\nrapieoption.\u00a0Die\u00a02015\u00a0\u00fcberarbeitete\u00a0Fassung\u00a0der\u00a0 American \u00a0Thyreoid\u00a0Association \u00a0\n(ATA)\u00a0Guidelines\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0MTC\u00a0empfiehlt\u00a0Vandetini b\u00a0und\u00a0Cabozan\u2010103\u00a0tinib\u00a0f\u00fcr\u00a0die\u00a0Erstlinientherapie\u00a0von\u00a0Patienten\u00a0mit\u00a0symptomatisc her\u00a0und\u00a0progressi\u2010\nver\u00a0Erkrankung\u00a0(Wells\u00a0et\u00a0al.,\u00a02015).\u00a0Hingewiesen\u00a0wird\u00a0hier\u00a0alle rdings\u00a0auf\u00a0noch\u00a0viele\u00a0\noffene\u00a0Fragen,\u00a0z.B.\u00a0hinsichtlich\u00a0 des\u00a0Auftretens\u00a0von\u00a0Resistenzen ,\u00a0der\u00a0Dosierung\u00a0und\u00a0\nTherapiedauer\u00a0und\u00a0des\u00a0unklaren\u00a0Benefits\u00a0f\u00fcr\u00a0das\u00a0OS.\u00a0\nDie\u00a0Therapie\u00a0des\u00a0Nierenzellkarzi noms\u00a0erfolgt\u00a0prim\u00e4r\u00a0operativ\u00a0mi t\u00a0kurativer\u00a0Inten\u2010\ntion\u00a0(AWMF,\u00a02017).\u00a0Bei\u00a0inoperablen\u00a0Patienten\u00a0oder\u00a0metastasierte r\u00a0Situation\u00a0(Sta\u2010\ndium\u00a0IV)\u00a0ist\u00a0die\u00a0Behandlung\u00a0in\u00a0der\u00a0Regel\u00a0palliativ.\u00a0Die\u00a0klassis che\u00a0Zytostatikathera\u2010\npie\u00a0spielt\u00a0in\u00a0der\u00a0Behandlung\u00a0des\u00a0 metastasierten\u00a0Nierenzellkarzi noms\u00a0keine\u00a0Rolle\u00a0\nmehr,\u00a0da\u00a0das\u00a0 Nierenzellkarzino m\u00a0 gegen\u00fcber\u00a0den\u00a0gebr\u00e4uchlichen\u00a0zy totoxischen\u00a0\nSubstanzen\u00a0h\u00e4ufig\u00a0resistent\u00a0ist\u00a0und\u00a0nur\u00a0niedrige\u00a0Ansprechraten\u00a0 erzielt\u00a0werden.\u00a0\nNachdem\u00a0bis\u00a02006\u00a0die\u00a0unspezifische\u00a0Immuntherapie\u00a0mit\u00a0subkutanem \u00a0Interferon\u00a0\nalpha\u00a0und/oder\u00a0Interleukin\u20102\u00a0Standard\u00a0in\u00a0der\u00a0palliativen\u00a0Therap ie\u00a0war,\u00a0werden\u00a0seit\u00a0\nEntwicklung\u00a0 der\u00a0 zielgerichteten\u00a0 Therapien\u00a0 Medikamente\u00a0 wie\u00a0 Multi kinase\u2010\nInhibitoren,\u00a0Angiogenese\u2010Inhibito ren\u00a0und\u00a0m\u2010TOR\u2010Inhibitoren\u00a0eing esetzt.\u00a0Die\u00a0Wahl\u00a0\ndes\u00a0geeigneten\u00a0Therapieplans\u00a0erf olgt\u00a0abh\u00e4ngig\u00a0von\u00a0Risikoprofil, \u00a0Zustand,\u00a0Komor\u2010\nbidit\u00e4t\u00a0und\u00a0Vorbehandlung\u00a0des\u00a0Patienten\u00a0sowie\u00a0vom\u00a0Toxizit\u00e4tsspe ktrum\u00a0und\u00a0der\u00a0\nzu\u00a0erwartenden\u00a0Effektivit\u00e4t\u00a0der\u00a0Wirkstoffe.\u00a0In\u00a0der\u00a0Erstlinie\u00a0we rden\u00a0bei\u00a0niedrigem\u00a0\noder\u00a0intermedi\u00e4rem\u00a0Risikoprofil\u00a0 (nach\u00a0dem\u00a0Prognose\u2010Score\u00a0MSKCC) \u00a0die\u00a0Tyrosin\u2010\nkinase\u2010Inhibitoren\u00a0 Sunitinib\u00a0 oder \u00a0 Pazopanib\u00a0 oder\u00a0 alternativ\u00a0 Bev acizumab\u00a0 plus\u00a0\nInterferon\u00a0alpha\u00a0verwendet,\u00a0bei\u00a0hohem\u00a0Risiko\u00a0der\u00a0mTOR\u2010Inhibitor \u00a0Temsirolimus.\u00a0\nIn\u00a0der\u00a0Zweitlinie\u00a0wird\u00a0nach\u00a0einer\u00a0Vortherapie\u00a0mit\u00a0Zytokinen\u00a0als \u00a0Standard\u00a0der\u00a0Tyro\u2010\nsinkinasehemmer\u00a0Axitinib\u00a0empfohl en.\u00a0Nach\u00a0Progress\u00a0unter\u00a0einer\u00a0V EGF\u2010basierten\u00a0\nVorbehandlung\u00a0sollen\u00a0bevorzugt\u00a0der\u00a0Checkpoint\u2010Inhibitor\u00a0Nivolum ab\u00a0oder\u00a0Cabo\u2010\nzantinib\u00a0eingesetzt\u00a0werden;\u00a0im\u00a0Falle\u00a0des\u00a0Versagens\u00a0soll\u00a0auf\u00a0die \u00a0jeweils\u00a0andere\u00a0\nSubstanz\u00a0gewechselt\u00a0werden.\u00a0Nach\u00a0Vortherapie\u00a0mit\u00a0Temsirolimus\u00a0w erden\u00a0gleich\u2010\nberechtigt\u00a0nebeneinander\u00a0die\u00a0VEGF\u2010TKIs\u00a0Axitinib,\u00a0Sorafenib,\u00a0Sun itinib,\u00a0Pazopanib\u00a0\nund\u00a0Cabozantinib\u00a0empfohlen.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDa\u00a0der\u00a0medizinische\u00a0Zusatznutzen\u00a0von\u00a0Cabozantinib\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0durch\u00a0\ndie\u00a0Zulassung\u00a0als\u00a0belegt\u00a0gilt,\u00a0bewertete\u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0de s\u00a0Zusatznutzens\u00a0\nausschlie\u00dflich\u00a0auf\u00a0der\u00a0Grundlage\u00a0der\u00a0Zulassungsstudien.\u00a0F\u00fcr\u00a0Pat ienten\u00a0mit\u00a0progre\u2010\ndientem,\u00a0 nicht\u2010resektablem,\u00a0 lokal\u00a0 fortgeschrittenem\u00a0 oder\u00a0 metast asiertem\u00a0\nmedull\u00e4ren\u00a0Schilddr\u00fcsenkarzinom\u00a0stellt\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 geringen\u00a0Zusatznutzen \u00a0\nvon\u00a0Cabozantinib\u00a0fest\u00a0(G\u2010BA,\u00a02015).\u00a0Obwohl\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0sekund\u00e4 ren\u00a0Endpunkt\u00a0OS\u00a0\nin\u00a0der\u00a0Gesamtpopulation\u00a0kein\u00a0statistisch\u00a0signifikanter\u00a0Vorteil\u00a0 ergibt,\u00a0wertet\u00a0der\u00a0G\u2010\nBA\u00a0die\u00a0statistisch\u00a0signifikanten\u00a0Studienergebnisse\u00a0in\u00a0der\u00a0Subgr uppe\u00a0der\u00a0Patienten\u00a0\nmit\u00a0bereits\u00a0eingeschr\u00e4nktem\u00a0Allg emeinzustand\u00a0(ECOG\u2010Performance\u00a0 Status\u00a01\u00a0und\u00a0\n2)\u00a0und\u00a0in\u00a0der\u00a0Subgruppe\u00a0der\u00a0Patienten\u00a0mit\u00a0positivem\u00a0RET\u2010M918T\u00a0M utationsstatus\u00a0\npositiv.\u00a0Nicht\u00a0der\u00a0prim\u00e4re\u00a0Endpunk t\u00a0PFS,\u00a0sondern\u00a0seine\u00a0Komponen ten\u00a0Morbidit\u00e4t\u00a0104\u00a0bzw.\u00a0Symptomatik\u00a0und\u00a0Lebensqualit\u00e4t\u00a0werden\u00a0vom\u00a0G\u2010BA\u00a0zur\u00a0Bewertu ng\u00a0herange\u2010\nzogen,\u00a0wobei\u00a0der\u00a0Ausschuss\u00a0hier\u00a0aufgrund\u00a0des\u00a0hohen\u00a0Verzerrungsp otentials\u00a0und\u00a0\nheterogener,\u00a0in\u00a0den\u00a0Einzelfragen \u00a0sowohl\u00a0g\u00fcnstiger\u00a0als\u00a0auch\u00a0ung\u00fc nstiger\u00a0oder\u00a0sta\u2010\ntistisch\u00a0nicht\u00a0signifikanter\u00a0Ergebnisse\u00a0f\u00fcr\u00a0Cabozantinib\u00a0die\u00a0Da ten\u00a0als\u00a0nicht\u00a0valide\u00a0\nauswertbar\u00a0ansieht.\u00a0Trotz\u00a0der\u00a0relevanten\u00a0Nachteile\u00a0bei\u00a0den\u00a0Nebe nwirkungen\u00a0und\u00a0\nhier\u00a0vor\u00a0allem\u00a0bei\u00a0den\u00a0schweren\u00a0UAE\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0vo r\u00a0dem\u00a0Hintergrund\u00a0\ndes\u00a0Schweregrades\u00a0der\u00a0Erkrankung\u00a0in\u00a0der\u00a0Gesamtbetrachtung\u00a0eine\u00a0 bisher\u00a0nicht\u00a0\nerreichte\u00a0moderate\u00a0Verbesserung\u00a0d es\u00a0therapierelevanten\u00a0Nutzens. \u00a0\nF\u00fcr\u00a0das\u00a0Anwendungsgebiet\u00a0Nierenze llkarzinom\u00a0stuft\u00a0der\u00a0G\u2010BA\u00a0das\u00a0 Ausma\u00df\u00a0des\u00a0\nZusatznutzens\u00a0von\u00a0Cabozantinib\u00a0als\u00a0nicht\u00a0quantifizierbar\u00a0ein\u00a0(G \u2010BA,\u00a02017).\u00a0Den\u00a0\npositiven\u00a0Ergebnissen\u00a0zum\u00a0Endpunk t\u00a0OS\u00a0stehen\u00a0relevante\u00a0Nachteil e\u00a0bei\u00a0den\u00a0End\u2010\npunkten\u00a0zu\u00a0Nebenwirkungen\u00a0gegen\u00fcber.\u00a0Die\u00a0Ergebnisse\u00a0zur\u00a0Morbidi t\u00e4t\u00a0und\u00a0zur\u00a0\nLebensqualit\u00e4t\u00a0erachtet\u00a0der\u00a0G\u2010BA\u00a0als\u00a0unzureichend,\u00a0zudem\u00a0geht\u00a0e r\u00a0aufgrund\u00a0der\u00a0\nfehlenden\u00a0Verblindung\u00a0von\u00a0einem\u00a0ho hen\u00a0Verzerrungspotential\u00a0bei\u00a0 den\u00a0patienten\u2010\nberichteten\u00a0Endpunkten\u00a0zur\u00a0Morbid it\u00e4t\u00a0und\u00a0bei\u00a0den\u00a0Nebenwirkunge n\u00a0aus.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0105\u00a0Quellen\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften\u00a0online\u00a0 (2017).\u00a0AWMF\u00a0\u2010\u00a0Leitlinie\u00a0\nNierenzellkarzinom,\u00a0Diagnostik,\u00a0Therapie\u00a0und\u00a0Nachsorge\u00a0.\u00a0www.aw mf.org/leitlinien/detail/ll/043\u2010017OL.html,\u00a0\nletzter\u00a0Zugriff:\u00a011.05.2017.\u00a0\nBerger\u00a0DP,\u00a0Engelhardt\u00a0R,\u00a0Mertels mann\u00a0R\u00a0(2014).\u00a0Das\u00a0Rote\u00a0Buch.\u00a0B erger\u00a0DP,\u00a0Duyster\u00a0J,\u00a0Engelhardt\u00a0M,\u00a0Engelhardt\u00a0R,\u00a0Hen\u00df\u00a0H,\u00a0\nMertelsmann\u00a0(Hrsg).\u00a0ecomed\u00a0MEDIZIN.\u00a0\nChoueiri\u00a0TK,\u00a0Escudier\u00a0B,\u00a0Powles\u00a0T,\u00a0Tannir\u00a0NM,\u00a0Mainwaring\u00a0PN,\u00a0Ri ni\u00a0BI\u00a0et\u00a0al.\u00a0(2016).\u00a0Cabozantinib \u00a0versus\u00a0everolimus\u00a0in\u00a0advanced \u00a0\nrenal\u00a0cell\u00a0carcinoma\u00a0(METEOR):\u00a0final\u00a0results\u00a0from\u00a0a\u00a0randomised, \u00a0open\u2010label,\u00a0phase\u00a03\u00a0trial.\u00a0The\u00a0Lancet\u00a0Oncology\u00a0\n17(7):\u00a0917\u2010927.\u00a0\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0Onkologie\u00a0onko pedia\u00a0(2017).\u00a0Cabozantinib\u00a0(Cabometyx\u00ae)\u00a0bei\u00a0\nNierenzellkarzinom\u00a0\u2014\u00a0Drug\u2010assessm ent.\u00a0https://www.onkopedia.com /de/drug\u2010\nassessment/guidelines/cabozantinib\u2010cabometyx\u2010r\u2010bei\u2010nierenzellka rzinom/@@view/html/index.html,\u00a0letzter\u00a0Zugriff:\u00a0\n11.05.2017.\u00a0\nElisei\u00a0R,\u00a0Schlumberger\u00a0MJ,\u00a0M\u00fclle r\u00a0SP,\u00a0Sch\u00f6ffski\u00a0P,\u00a0Brose\u00a0MS,\u00a0Sh ah\u00a0MH\u00a0et\u00a0al.\u00a0(2013).\u00a0Cabozantinib\u00a0in\u00a0progressive\u00a0medullary\u00a0thyr oid\u00a0\ncancer.\u00a0Journal\u00a0of\u00a0Clinical\u00a0Oncology\u00a031(29):\u00a03639\u20103646.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0Cometriq\u00ae\u00a0EPAR\u00a0Product\u00a0 Information.\u00a0www.ema.europa.eu/ema/index.jsp?curl=/pages\u00a0\n/medicines/human/medicines/002640/human_med_001726.jsp,\u00a0letzter \u00a0Zugriff:\u00a031.01.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0EPAR\u00a0summary\u00a0for\u00a0the\u00a0pu blic.\u00a0Cabometyx\u00ae.\u00a0Stand\u00a0der\u00a0Information:\u00a0Oktober\u00a02016.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Summary_fo r_the_public/human/004163\u00a0\n/WC500214073.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.05.2017.\u00a0\nFachinformation\u00a0Cometriq\u00ae\u00a0(2017) .\u00a0Fachinformation\u00a0Cometriq\u00ae.\u00a0ww w.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010\n_Summary_for_the_public/human/002640/WC500163707.pdf,\u00a0letzter\u00a0Z ugriff:\u00a005.05.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Cabozantinib.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/127/#tab/beschluesse,\u00a0letzt er\u00a0Zugriff:\u00a001.01.2016.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Cabozantinib\u00a0(neues\u00a0\nAnwendungsgebiet:\u00a0fortgeschrittenes\u00a0Nierenzellkarzinom)\u00a0\u2010\u00a0Gemei nsamer\u00a0Bundesausschuss.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/267/,\u00a0letzter\u00a0Zugriff:\u00a028.0 6.2017.\u00a0\nKaatsch\u00a0P,\u00a0Spix\u00a0C,\u00a0Katalinic\u00a0A,\u00a0 Hentschel\u00a0S,\u00a0Luttmann\u00a0S,\u00a0Stegma ier\u00a0C\u00a0et\u00a0al.\u00a0(2015).\u00a0Krebs\u00a0in\u00a0Deutschland\u00a02011/2012.\u00a010.\u00a0Ausgab e.\u00a0\nRobert\u00a0Koch\u2010Institut\u00a0(Hrsg)\u00a0und\u00a0die\u00a0Gesellschaft\u00a0der\u00a0epidemiolo gischen\u00a0Krebsregister\u00a0in\u00a0Deutschland\u00a0e.V.\u00a0(Hrsg).\u00a0\nBerlin.\u00a0\nLauer\u2010Fischer\u00a0(2016).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online.\u00a0St and\u00a0der\u00a0Information:\u00a0D ezember\u00a02016.\u00a0 www2.lauer\u2010\nfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosystem/,\u00a0letzter\u00a0Zugr iff:\u00a002.05.2017.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0Cabozantinib\u00a0(Cometriq\u00ae).\u00a0In\u00a0me dullary\u00a0thyroid\u00a0cancer:\u00a0more\u00a0ha rmful\u00a0than\u00a0beneficial,\u00a0as\u00a0is\u00a0\nvandetanib.\u00a0Prescrire\u00a0Int\u00a025(167):\u00a011\u201013.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0Online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Cabozantinib|Cometriq\u00ae.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=54052,\u00a0letzter\u00a0Zugriff:\u00a005.05.2017.\u00a0106\u00a0Roy\u00a0M,\u00a0Chen\u00a0H,\u00a0Sippel\u00a0RS\u00a0(2013).\u00a0Current\u00a0understanding\u00a0and\u00a0mana gement\u00a0of\u00a0medullary\u00a0thyroid\u00a0cancer.\u00a0Oncologist\u00a018(10):\u00a01093\u2010\n1100.\u00a0\u00a0\nSchlumberger\u00a0M,\u00a0Bastholt\u00a0L,\u00a0Dra lle\u00a0H,\u00a0Jarzab\u00a0B,\u00a0Pacini\u00a0F,\u00a0Smit\u00a0 JWA\u00a0(2012).\u00a0European\u00a0thyroid\u00a0association\u00a0guidelines\u00a0for\u00a0metasta tic\u00a0\nmedullary\u00a0thyroid\u00a0cancer.\u00a0Eur\u00a0Thyroid\u00a0J\u00a01(1):\u00a05\u201014.\u00a0\u00a0\nSchmoll\u00a0HJ,\u00a0H\u00f6ffken\u00a0KPK\u00a0(2006).\u00a0Kompendium\u00a0Internistische\u00a0Onkol ogie\u00a0Standards\u00a0in\u00a0Diagnostik\u00a0und\u00a0Therapie.\u00a0Berlin,\u00a0Heidelberg:\u00a0\nSpringer\u00a0Berlin\u00a0Heidelberg.\u00a0\u00a0\nTumorregister\u00a0M\u00fcnchen\u00a0(2015).\u00a0Tumorstatistik:\u00a0\u00dcberleben.\u00a0C64:\u00a0N ierenkarzinom.\u00a0Verf\u00fcgbar\u00a0unter:\u00a0https://www.tumorregister\u2010\nmuenchen.de/facts/surv\u201020150519/surv_C64__G.pdf,\u00a0letzter\u00a0Zugrif f:\u00a005.09.2017.\u00a0\nWells\u00a0SA,\u00a0Asa\u00a0SL,\u00a0Dralle\u00a0H,\u00a0Elisei \u00a0R,\u00a0Evans\u00a0DB,\u00a0Gagel\u00a0RF\u00a0et\u00a0al. \u00a0(2015).\u00a0Revised\u00a0American\u00a0Thyroid\u00a0Association\u00a0Guidelines\u00a0for\u00a0th e\u00a0\nManagement\u00a0of\u00a0Medullary\u00a0Thyroid\u00a0Carcinoma.\u00a0Thyroid\u00a025(6):\u00a0567\u20106 10.\u00a0\u00a0\n\u00a0\u00a0107\u00a04.5 Chols\u00e4ure\u00a0\nHandelsname:\u00a0Orphacol\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Angeborene\u00a0St\u00f6rung en\u00a0\u00a0\u00a0 Laboratoires\u00a0C.T.R.S.\u00a0\nder\u00a0prim\u00e4ren\u00a0Gallens\u00e4uresynthese\u00a0 \u00a0\nATC\u2010Code:\u00a0A05AA03\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Mai\u00a02014\u00a0\nDarreichungsform:\u00a0Hartkaps el\u00a0 \u00a0 DDD:\u00a00,25\u00a0g\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0O,\u00a0E,\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nChols\u00e4ure\u00a0(Orphacol\u00ae)\u00a0ist\u00a0zugelassen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0ang eborenen\u00a0St\u00f6run\u2010\ngen\u00a0der\u00a0prim\u00e4ren\u00a0Gallens\u00e4uresynt hese\u00a0mit\u00a0Mangel\u00a0der\u00a0Enzyme\u00a03\u03b2\u2010H ydroxy\u2010\u03945\u2010C27\u2010\nsteroid\u2010Oxidoreduktase\u00a0 (kurz\u00a0 3\u03b2\u2010HSD)\u00a0 oder\u00a0 \u03944\u20103\u2010Oxosteroid\u20105\u03b2\u2010Reduktase\u00a0 (kurz\u00a0\n\u03944\u20103\u2010oxoR)\u00a0bei\u00a0S\u00e4uglingen,\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0im\u00a0Alter\u00a0von\u00a0 einem\u00a0Monat\u00a0\nbis\u00a018\u00a0Jahren\u00a0sowie\u00a0bei\u00a0Erwachsenen.\u00a0Der\u00a0Wirkstoff,\u00a0der\u00a0aus\u00a0Rin der\u2010\u00a0und\u00a0Schafs\u2010\ngalle\u00a0durch\u00a0Aufreinigung\u00a0isoliert\u00a0wird,\u00a0hemmt\u00a0die\u00a0Aktivit\u00e4t\u00a0des \u00a0Enzyms\u00a0Cholesterol\u2010\n7\u03b1\u2010Hydroxylase\u00a0und\u00a0damit\u00a0die\u00a0Pro duktion\u00a0hepatotoxischer\u00a0Gallens \u00e4ure\u2010Vorstufen.\u00a0\nDas\u00a0Arzneimittel\u00a0wird\u00a0individuell\u00a0anhand\u00a0des\u00a0K\u00f6rpergewichts\u00a0und \u00a0Urin\u2010Analysen\u00a0\ndosiert\u00a0 und\u00a0 morgens\u00a0 oder\u00a0 abends\u00a0 zu\u00a0 den\u00a0 Mahlzeiten\u00a0 peroral\u00a0 einge nommen\u00a0\n(Fachinformation\u00a0Orphacol\u00ae,\u00a02015).\u00a0\nDas\u00a0Pr\u00e4parat\u00a0wurde\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0( European \u00a0Commission ,\u00a0EC)\u00a0\nals\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0( Orphan\u2010Arzneimittel)\u00a0und\u00a0unter\u00a0au\u00dfergew\u00f6hn\u2010\nlichen\u00a0Umst\u00e4nden\u00a0( Exceptional\u00a0Circumstances )\u00a0zugelassen\u00a0(EMA,\u00a02013),\u00a0unter\u00a0den\u00a0\nBedingungen\u00a0des\u00a0 Well\u2010established\u2010use \u00a0(d.h.\u00a0es\u00a0gibt\u00a0bereits\u00a0Erfahrungen\u00a0mit\u00a0dem\u00a0\nArzneistoff).\u00a0Der\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0legte\u00a0f\u00fcr\u00a0di e\u00a0Zulassung\u00a0keine\u00a0\neigenen\u00a0Studien\u00a0vor,\u00a0sondern\u00a0lediglich\u00a0bibliografisches\u00a0Materia l\u00a0mit\u00a0kleinen\u00a0Patien\u2010\ntenkohorten\u00a0und\u00a0Fallberichten.\u00a0F\u00fcr\u00a0beide\u00a0Enzymmangel\u2010Erkrankung en\u00a0zeigten\u00a0die\u00a0\nDaten,\u00a0dass\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0anderen\u00a0Behandlungsoptionen\u00a0dur ch\u00a0die\u00a0Therapie\u00a0\nmit\u00a0Chols\u00e4ure\u00a0eine\u00a0Lebertransplantation\u00a0vermieden\u00a0oder\u00a0zumindes t\u00a0hinausgez\u00f6\u2010\ngert\u00a0 werden\u00a0 kann.\u00a0 Ebenfalls\u00a0 verbesserten\u00a0 sich\u00a0 Laborparameter,\u00a0 h istologische\u00a0\nLeberl\u00e4sionen\u00a0sowie\u00a0die\u00a0Symptome \u00a0der\u00a0Patienten.\u00a0Therapieversage n\u00a0wurde\u00a0nur\u00a0\nbei\u00a0Patienten\u00a0mit\u00a0fortgeschritte ner\u00a0Lebersch\u00e4digung\u00a0beobachtet. \u00a0Zu\u00a0den\u00a0wichtigs\u2010\nten\u00a0 unerw\u00fcnschten\u00a0 Arzneimittelereignissen\u00a0 (UAE)\u00a0 geh\u00f6ren\u00a0 Durchfa ll,\u00a0 Juckreiz\u00a0\nsowie\u00a0eine\u00a0Erh\u00f6hung\u00a0der\u00a0Transaminasen,\u00a0die\u00a0nach\u00a0Dosisreduktion\u00a0 wieder\u00a0abklin\u2010\ngen\u00a0(EMA,\u00a02013).\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zusatz\u2010\nnutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt.\u00a0Das\u00a0Ausma\u00df\u00a0des\u00a0 Zusatznutzens \u00a0bewertete\u00a0der\u00a0\nG\u2010BA\u00a0als\u00a0 nicht\u00a0quantifizierbar ,\u00a0da\u00a0nur\u00a0limitierte\u00a0Evidenz\u00a0und\u00a0eine\u00a0unzureichenden\u00a0\nDatengrundlage\u00a0zu\u00a0patientenrelevanten\u00a0Endpunkten\u00a0vorliegen\u00a0(G\u2010B A,\u00a02014).\u00a0\u00a0108\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0Mittel\u00a0der\u00a0Wahl\u00a0\n\u00a0Aufgrund\u00a0begrenzter\u00a0\nDatenlage\u00a0Zusatznutzen\u00a0\nnicht\u00a0quantifizierbar\u00a0\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA/D\u00a0\u00a0 \u2013\u00a0 \u2013\u00a0Bravo\u00a0(major\u00a0\ntherapeutic\u00a0\nadvance)\u00a0Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nChols\u00e4ure\u00a0\n\u00a01\u20102x\u00a0tgl.\u00a0\n50\u00a0mg\u00a0\n250\u00a0mg\u00a0365\u00a0\n\u00a0\n\u00a0\u00a0\n33.323,71\u00a0\u2013\u00a066.647,42\u00a0\u20ac\u00a0\n166.433,55\u00a0\u2013\u00a0332.867,10\u00a0\u20ac\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0 Chols\u00e4ure\u00a0erstellt\u00a0werden.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nChols\u00e4ure\u00a0ist\u00a0eine\u00a0prim\u00e4re\u00a0Gallens\u00e4ure,\u00a0die\u00a0beim\u00a0Menschen\u00a0in\u00a0de r\u00a0Leber\u00a0syntheti\u2010\nsiert\u00a0wird\u00a0und\u00a0etwa\u00a0zwei\u00a0Drittel\u00a0der\u00a0prim\u00e4ren\u00a0Gallens\u00e4ure\u00a0in\u00a0de r\u00a0menschlichen\u00a0\nGallenfl\u00fcssigkeit\u00a0ausmacht.\u00a0Der\u00a0Wirkstoff\u00a0im\u00a0Fertigarzneimittel \u00a0entspricht\u00a0in\u00a0seiner\u00a0\nStruktur\u00a0humaner\u00a0Chols\u00e4ure,\u00a0wird\u00a0allerdings\u00a0aus\u00a0Rinder\u2010\u00a0und\u00a0Sch afsgalle\u00a0durch\u00a0\nAufreinigung\u00a0isoliert.\u00a0\u00a0\nChols\u00e4ure\u00a0hemmt\u00a0die\u00a0Aktivit\u00e4t\u00a0de s\u00a0Enzyms\u00a0Cholesterol\u20107\u03b1\u2010Hydroxy lase\u00a0und\u00a0damit\u00a0\ndie\u00a0Produktion\u00a0hepatotoxischer\u00a0Gallens\u00e4ure\u2010Vorstufen.\u00a0Zus\u00e4tzlic h\u00a0beschleunigt\u00a0der\u00a0\nWirkstoff\u00a0den\u00a0Gallenfluss\u00a0und\u00a0damit\u00a0die\u00a0hepatische\u00a0Clearance\u00a0de r\u00a0toxischen\u00a0Sub\u2010\nstanzen.\u00a0Au\u00dferdem\u00a0erleichtert\u00a0er\u00a0die\u00a0Resorption\u00a0von\u00a0Fett\u00a0und\u00a0fe ttl\u00f6slichen\u00a0Vitami\u2010\nnen\u00a0(EMA,\u00a02013).\u00a0\n109\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nChols\u00e4ure\u00a0ist\u00a0zugelassen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0angeborenen\u00a0St\u00f6 rungen\u00a0der\u00a0pri\u2010\nm\u00e4ren\u00a0Gallens\u00e4uresynthese\u00a0mit\u00a0M angel\u00a0der\u00a0Enzyme\u00a03\u03b2\u2010Hydroxy\u2010\u03945\u2010C27\u2010steroid\u2010\nO x i d o r e d u c t a s e \u00a0( k u r z \u00a03 \u03b2 \u2010 H S D ) \u00a0o d e r \u00a0\u03944\u20103\u2010Oxosteroid\u20105\u03b2\u2010Reductase\u00a0 (kurz\u00a0 \u03944\u20103\u2010\noxoR)\u00a0bei\u00a0S\u00e4uglingen,\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0im\u00a0Alter\u00a0von\u00a0ein em\u00a0Monat\u00a0bis\u00a018\u00a0\nJahren\u00a0sowie\u00a0bei\u00a0Erwachsenen.\u00a0\u00a0\nIn\u00a0Deutschland\u00a0ist\u00a0Chols\u00e4ure\u00a0in\u00a0Form\u00a0von\u00a0Hartkapseln\u00a0f\u00fcr\u00a0die\u00a0pe rorale\u00a0Gabe\u00a0in\u00a0den\u00a0\nDosierungen\u00a050\u00a0mg\u00a0und\u00a0250\u00a0mg\u00a0verf\u00fcgbar.\u00a0Die\u00a0Dosis\u00a0wird\u00a0individu ell\u00a0f\u00fcr\u00a0jeden\u00a0\nPatienten\u00a0festgelegt.\u00a0Daf\u00fcr\u00a0werd en\u00a0regelm\u00e4\u00dfig\u00a0toxische\u00a0Gallens\u00e4 uremetabolite\u00a0im\u00a0\nBlut\u00a0und/oder\u00a0Urin\u00a0chromatographisch\u00a0bestimmt,\u00a0die\u00a0bei\u00a0einer\u00a0un zureichenden\u00a0\nDosierung\u00a0von\u00a0Chols\u00e4ure\u00a0entstehen.\u00a0In\u00a0der\u00a0Regel\u00a0betr\u00e4gt\u00a0die\u00a0t\u00e4g liche\u00a0Dosis\u00a0f\u00fcr\u00a0\nbeide\u00a0Indikationen\u00a05\u00a0bis\u00a015\u00a0mg/k g\u00a0K\u00f6rpergewicht.\u00a0Die\u00a0Mindestdos is\u00a0liegt\u00a0bei\u00a050\u00a0mg\u00a0\npro\u00a0Tag,\u00a0die\u00a0Dosisanpassung\u00a0erfolgt\u00a0in\u00a0Schritten\u00a0von\u00a050\u00a0mg.\u00a0Die \u00a0Maximaldosis\u00a0f\u00fcr\u00a0\nErwachsene\u00a0betr\u00e4gt\u00a0500\u00a0mg\u00a0t\u00e4glich.\u00a0\nF\u00fcr\u00a0Patienten\u00a0\u00fcber\u00a065\u00a0Jahre\u00a0oder \u00a0mit\u00a0eingeschr\u00e4nkter\u00a0Nierenfunk tion\u00a0liegen\u00a0keine\u00a0\nDaten\u00a0zur\u00a0Behandlung\u00a0vor.\u00a0Der\u00a0Erf ahrungsumfang\u00a0bei\u00a0Patienten\u00a0mi t\u00a0eingeschr\u00e4nk\u2010\nter\u00a0Leberfunktion\u00a0ist\u00a0begrenzt.\u00a0\nDie\u00a0Hartkapseln\u00a0werden\u00a0morgens\u00a0und/oder\u00a0abends\u00a0t\u00e4glich\u00a0etwa\u00a0zur \u00a0gleichen\u00a0Zeit\u00a0\nzu\u00a0den\u00a0Mahlzeiten\u00a0unzerkaut\u00a0mit\u00a0Wasser\u00a0eingenommen.\u00a0Bei\u00a0Bedarf\u00a0 kann\u00a0die\u00a0t\u00e4gli\u2010\nche\u00a0Dosis\u00a0auf\u00a0mehrere\u00a0Einzelgabe n\u00a0aufgeteilt\u00a0werden.\u00a0Bei\u00a0S\u00e4ugli ngen\u00a0und\u00a0Kindern,\u00a0\ndie\u00a0nicht\u00a0in\u00a0der\u00a0Lage\u00a0sind\u00a0die\u00a0Kapseln\u00a0zu\u00a0schlucken,\u00a0k\u00f6nnen\u00a0die \u00a0Kapseln\u00a0auch\u00a0ge\u2010\n\u00f6ffnet\u00a0 und\u00a0 der\u00a0 Inhalt\u00a0 in\u00a0 S\u00e4uglingsnahrung\u00a0 oder\u00a0 Saft\u00a0 gegeben\u00a0 wer den\u00a0\n(Fachinformation\u00a0Orphacol\u00ae,\u00a02015).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nAngeborene\u00a0Defekte\u00a0der\u00a0Gallens\u00e4u resynthesen\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0extr em\u00a0seltenen\u00a0\ngenetisch\u00a0 bedingten\u00a0 Erkrankungen .\u00a0 Das\u00a0 kongenitale\u00a0 Gallens\u00e4uresy nthesedefekt\u00a0\nTyp\u00a01\u00a0entsteht\u00a0durch\u00a0einen\u00a0Defekt\u00a0in\u00a0dem\u00a0Gen,\u00a0das\u00a0f\u00fcr\u00a0das\u00a0Enzym \u00a03\u03b2\u2010Hydroxy\u2010\u03945\u2010\nC27\u2010steroid\u2010Oxidoreduktase\u00a0(3\u03b2\u2010HSD)\u00a0 kodiert,\u00a0so\u00a0dass\u00a0die\u00a0betroffen en\u00a0Patienten\u00a0an\u00a0\neinem\u00a03\u03b2\u2010HSD\u2010Mangel\u00a0leiden.\u00a0Bei\u00a0dem\u00a0kongenitalen\u00a0Gallens\u00e4uresyn thesedefekt\u00a0\nTyp\u00a02\u00a0liegt\u00a0ein\u00a0Mangel\u00a0der\u00a0\u03944\u20103\u2010Oxosteroid\u20105\u03b2\u2010Reduktase\u00a0(\u03944\u20103\u2010oxoR)\u00a0vor.\u00a0Beide\u00a0\nErkrankungen\u00a0werden\u00a0autosomal\u2010 rezessiv\u00a0vererbt\u00a0(Orphanet,\u00a02011a ,\u00a02011b).\u00a0\u00a0\nDurch\u00a0 den\u00a0 Enzymmangel\u00a0 wird\u00a0 bei\u00a0 beiden\u00a0 Erkrankungen\u00a0 zu\u00a0 wenig\u00a0 Gal lens\u00e4ure\u00a0\nsynthetisiert,\u00a0wodurch\u00a0sich\u00a0hepatotoxische\u00a0und\u00a0cholestatische\u00a0M etabolite\u00a0anrei\u2010\nchern.\u00a0 Die\u00a0 klinischen\u00a0 Symptome\u00a0 und\u00a0 das\u00a0 Manifestationsalter\u00a0 vari ieren,\u00a0 in\u00a0 der\u00a0\nRegel\u00a0finden\u00a0sich\u00a0jedoch\u00a0bereits\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Geburt\u00a0Anzei chen\u00a0einer\u00a0Cho\u2010\nlestase.\u00a0Unbehandelt\u00a0f\u00fchren\u00a0die\u00a0Erkrankungen\u00a0zum\u00a0Tod\u00a0durch\u00a0Zirr hose\u00a0und\u00a0Leber\u2010110\u00a0versagen.\u00a0Als\u00a0Behandlungsoptionen\u00a0stehen\u00a0lediglich\u00a0die\u00a0Zufuhr\u00a0v on\u00a0Gallens\u00e4uren\u00a0\nsowie\u00a0in\u00a0schweren\u00a0F\u00e4llen\u00a0eine\u00a0Lebertransplantation\u00a0zur\u00a0Verf\u00fcgun g\u00a0(EMA,\u00a02013).\u00a0\nDie\u00a0Pr\u00e4valenz\u00a0in\u00a0Europa\u00a0liegt\u00a0bei\u00a0etwa\u00a0drei\u00a0bis\u00a0f\u00fcnf\u00a0Patienten\u00a0 mit\u00a0einem\u00a03\u03b2\u2010HSD\u2010\nMangel\u00a0pro\u00a010\u00a0Mio.\u00a0Einwohner,\u00a0ein\u00a0\u03944\u20103\u2010oxoR\u2010Mangel\u00a0ist\u00a0etwa\u00a0zehnmal\u00a0seltener.\u00a0\nSch\u00e4tzungsweise\u00a0sollen\u00a0etwa\u00a075\u00a0Patienten\u00a0mit\u00a03\u03b2\u2010HSD\u2010Mangel\u00a0und\u00a0 15\u00a0Patienten\u00a0\nmit\u00a0\u03944\u20103\u2010oxoR\u2010Mangel\u00a0in\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0leben\u00a0(EMA,\u00a02013).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDas\u00a0Pr\u00e4parat\u00a0wurde\u00a0von\u00a0der\u00a0EMA\u00a0als\u00a0 Orphan\u2010Arzneimittel \u00a0und\u00a0unter\u00a0 Exceptional\u00a0\nCircumstances \u00a0unter\u00a0den\u00a0Bedingungen\u00a0des\u00a0 Well\u2010established\u2010use \u00a0zugelassen,\u00a0da\u00a0\nbereits\u00a0Erfahrungen\u00a0mit\u00a0dem\u00a0Arzn eistoff\u00a0vorliegen.\u00a0Chols\u00e4ure\u00a0wa r\u00a0in\u00a0der\u00a0Vergan\u2010\ngenheit\u00a0bereits\u00a0als\u00a0Rezepturarzne imittel\u00a0aus\u00a0Krankenhausapothek en\u00a0f\u00fcr\u00a0die\u00a0Indika\u2010\ntion\u00a0verwendet\u00a0worden,\u00a0aber\u00a0nicht\u00a0als\u00a0Fertigarzneimittel\u00a0zugela ssen.\u00a0Der\u00a0pU\u00a0legte\u00a0\nf\u00fcr\u00a0die\u00a0Zulassung\u00a0keine\u00a0eigenen\u00a0Studien\u00a0vor,\u00a0sondern\u00a0lediglich\u00a0 bibliografisches\u00a0\nMaterial\u00a0mit\u00a0kleinen\u00a0Patientenkohorten\u00a0und\u00a0Fallberichten.\u00a0Die\u00a0E MA\u00a0stufte\u00a0dieses\u00a0\nVorgehen\u00a0als\u00a0angemessen\u00a0ein,\u00a0da\u00a0nach\u00a0Ansicht\u00a0der\u00a0Beh\u00f6rde\u00a0kontro llierte\u00a0klinische\u00a0\nStudien\u00a0aufgrund\u00a0der\u00a0kleinen\u00a0Zahl\u00a0betroffener\u00a0Patienten\u00a0nicht\u00a0d urchf\u00fchrbar\u00a0und\u00a0\nauch\u00a0unethisch\u00a0seien.\u00a0Als\u00a0Begr\u00fcndung\u00a0f\u00fchrt\u00a0der\u00a0europ\u00e4ische\u00a0Beur teilungsbericht\u00a0\nan,\u00a0dass\u00a0es\u00a0derzeit\u00a0keine\u00a0andere\u00a0wirksame\u00a0Therapie\u00a0f\u00fcr\u00a0die\u00a0unbe handelt\u00a0rasch\u00a0\nfortschreitende\u00a0und\u00a0lebensbedrohliche\u00a0Erkrankung\u00a0gibt.\u00a0Daten\u00a0au s\u00a0der\u00a0Literatur\u00a0\ndeuten\u00a0darauf\u00a0hin,\u00a0dass\u00a0sich\u00a0der\u00a0Gesundheitszustand\u00a0der\u00a0Patient en\u00a0nach\u00a0Absetzen\u00a0\nvon\u00a0Pr\u00e4paraten\u00a0mit\u00a0Gallens\u00e4uren\u00a0schnell\u00a0verschlechtert.\u00a0\u00a0\nIn\u00a0den\u00a0europ\u00e4ischen\u00a0Beurteilungsbericht\u00a0gingen\u00a0Daten\u00a0von\u00a038\u00a0Pat ienten\u00a0mit\u00a03\u03b2\u2010\nHSD\u2010Mangel\u00a0ein,\u00a0die\u00a0bei\u00a0Beginn\u00a0der\u00a0Behandlung\u00a0zwischen\u00a0einem\u00a0Mo nat\u00a0und\u00a013,5\u00a0\nJahren\u00a0alt\u00a0waren.\u00a0Davon\u00a0erhielten\u00a021\u00a0Chols\u00e4ure,\u00a0acht\u00a0andere\u00a0Gal lens\u00e4uren\u00a0und\u00a0\nneun\u00a0keine\u00a0Gallens\u00e4uren.\u00a0Histori sche\u00a0Kontrollen\u00a0zeigen,\u00a0dass\u00a0di e\u00a0Erkrankung\u00a0un\u2010\nbehandelt\u00a0nach\u00a0mehreren\u00a0Jahren\u00a0zum\u00a0Tod\u00a0f\u00fchrt.\u00a0Langzeitdaten\u00a0f\u00fcr \u00a0die\u00a0Monothe\u2010\nrapie\u00a0mit\u00a0Chols\u00e4ure\u00a0liegen\u00a0f\u00fcr\u00a014\u00a0Patienten\u00a0\u00fcber\u00a0einen\u00a0Zeitraum \u00a0von\u00a0knapp\u00a013\u00a0\nJahren\u00a0vor.\u00a0\u00a0\nEbenfalls\u00a0wurden\u00a0Berichte\u00a0\u00fcber\u00a0elf\u00a0Patienten\u00a0mit\u00a0\u03944\u20103\u2010oxoR\u2010Mangel\u00a0vorgelegt,\u00a0die\u00a0\nzu\u00a0Beginn\u00a0der\u00a0Therapie\u00a0zwischen\u00a0null\u00a0und\u00a0zwei\u00a0Monate\u00a0alt\u00a0waren. \u00a0Sieben\u00a0wurden\u00a0\nmit\u00a0Chols\u00e4ure\u00a0behandelt\u00a0und\u00a0drei\u00a0 mit\u00a0anderen\u00a0Gallens\u00e4uren.\u00a0Ein\u00a0 Patient\u00a0erhielt\u00a0\nkeine\u00a0Behandlung.\u00a0Langzeitdaten\u00a0zur\u00a0Behandlung\u00a0mit\u00a0Chols\u00e4ure\u00a0li egen\u00a0f\u00fcr\u00a0sieben\u00a0\nPatienten\u00a0\u00fcber\u00a0einen\u00a0Zeit raum\u00a0von\u00a014\u00a0Jahren\u00a0vor.\u00a0\nF\u00fcr\u00a0beide\u00a0Enzymmangel\u2010Erkrankungen\u00a0zeigten\u00a0die\u00a0Daten,\u00a0dass\u00a0im\u00a0V ergleich\u00a0zu\u00a0den\u00a0\nanderen\u00a0Behandlungen\u00a0durch\u00a0die\u00a0Therapie\u00a0mit\u00a0Chols\u00e4ure\u00a0eine\u00a0Lebe rtransplantati\u2010\non\u00a0vermieden\u00a0oder\u00a0zumindest\u00a0hinausgez\u00f6gert\u00a0werden\u00a0kann.\u00a0Ebenfal ls\u00a0verbesser\u2010111\u00a0ten\u00a0sich\u00a0Laborparameter,\u00a0histolo gische\u00a0Leberl\u00e4sionen\u00a0sowie\u00a0die\u00a0 Symptome\u00a0der\u00a0\nPatienten.\u00a0Therapieversagen\u00a0wurd e\u00a0nur\u00a0bei\u00a0Patienten\u00a0mit\u00a0fortges chrittener\u00a0Leber\u2010\nsch\u00e4digung\u00a0beobachtet.\u00a0\u00a0\nZu\u00a0den\u00a0wichtigsten\u00a0UAE\u00a0wurden\u00a0in\u00a0den\u00a0Fallberichten\u00a0der\u00a028\u00a0mit\u00a0C hols\u00e4ure\u00a0behan\u2010\ndelten\u00a0Patienten\u00a0Durchfall,\u00a0Juckreiz\u00a0sowie\u00a0eine\u00a0Erh\u00f6hung\u00a0der\u00a0Tr ansaminasen\u00a0ge\u2010\nnannt.\u00a0Auf\u00a0Grundlage\u00a0der\u00a0verf\u00fcgbaren\u00a0Daten\u00a0l\u00e4sst\u00a0sich\u00a0die\u00a0H\u00e4ufi gkeit\u00a0nicht\u00a0valide\u00a0\nabsch\u00e4tzen.\u00a0 Da\u00a0 die\u00a0 beschriebenen\u00a0 Nebenwirkungen\u00a0 nach\u00a0 einer\u00a0 Dosi sreduktion\u00a0\nwieder\u00a0abklangen,\u00a0lag\u00a0in\u00a0diesen\u00a0F\u00e4llen\u00a0vermutlich\u00a0eine\u00a0\u00dcberdosi erung\u00a0vor.\u00a0Bei\u00a0\neinem\u00a0Patienten\u00a0wurde\u00a0nach\u00a0einer\u00a0Behandlungsdauer\u00a0von\u00a0mehr\u00a0als\u00a0 f\u00fcnf\u00a0Jahren\u00a0die\u00a0\nBildung\u00a0von\u00a0Gallensteinen\u00a0beschri eben.\u00a0Die\u00a0Zuverl\u00e4ssigkeit\u00a0der\u00a0 Daten\u00a0zu\u00a0UAE\u00a0ist\u00a0\ndadurch\u00a0 eingeschr\u00e4nkt,\u00a0 dass\u00a0 sie\u00a0 nicht\u00a0 systematisch\u00a0 erfasst\u00a0 wurd en\u00a0 und\u00a0 damit\u00a0\nSpontanmeldungen\u00a0entsprechen.\u00a0\nDer\u00a0pU\u00a0erhielt\u00a0bei\u00a0der\u00a0Zulassung\u00a0die\u00a0Auflage,\u00a0eine\u00a0Datenbank\u00a0al ler\u00a0Patienten\u00a0einzu\u2010\nrichten,\u00a0die\u00a0mit\u00a0Chols\u00e4ure\u00a0beha ndelt\u00a0werden,\u00a0und\u00a0in\u00a0regelm\u00e4\u00dfige n\u00a0Abst\u00e4nden\u00a0die\u00a0\nErgebnisse\u00a0an\u00a0die\u00a0zust\u00e4ndige\u00a0Beh\u00f6rde\u00a0zu\u00a0\u00fcbermitteln.\u00a0Die\u00a0Auswer tung\u00a0hat\u00a0bis\u00a0\nM\u00e4rz\u00a02017\u00a0zu\u00a0keiner\u00a0Ver\u00e4nderung\u00a0beim\u00a0Zulassungsstatus\u00a0gef\u00fchrt.\u00a0\nLeitlinienempfehlungen\u00a0\nEine\u00a0Literaturrecherche\u00a0konnte\u00a0weder\u00a0nationale\u00a0noch\u00a0internation ale\u00a0Leitlinien\u00a0f\u00fcr\u00a0\ndie\u00a0Behandlung\u00a0angeborener\u00a0Defekt e\u00a0der\u00a0Gallens\u00e4uresynthese\u00a0mit\u00a0 3\u03b2\u2010HSD\u2010\u00a0oder\u00a0\n\u03944\u20103\u2010oxoR\u2010Mangel\u00a0identifizieren.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0\u00a0\nDa\u00a0keine\u00a0kontrollierten\u00a0Studien\u00a0mit\u00a0Chols\u00e4ure\u00a0durchgef\u00fchrt\u00a0wurd en,\u00a0kam\u00a0der\u00a0G\u2010BA\u00a0\nim\u00a0November\u00a02014\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0nur\u00a0limitierte\u00a0Evidenz\u00a0u nd\u00a0eine\u00a0unzu\u2010\nreichenden\u00a0Datengrundlage\u00a0zu\u00a0pa tientenrelevanten\u00a0Endpunkten\u00a0vor liegen.\u00a0Wegen\u00a0\ndes\u00a0hohen\u00a0Verzerrungspotenzials\u00a0 l\u00e4sst\u00a0sich\u00a0ein\u00a0Zusatznutzen\u00a0dah er\u00a0nicht\u00a0quantifi\u2010\nzieren\u00a0(G\u2010BA,\u00a02014).\u00a0\n\u00a0 \u00a0112\u00a0Quellen\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2013).\u00a0European\u00a0Assessment\u00a0Rep ort:\u00a0Orphacol.\u00a0www.ema.europa.eu/docs/en_GB/d\u00a0\nocument_library/EPAR_\u2010_Public_assessment_report/human/001250/WC 500131542.pdf,\u00a0letzter\u00a0Zugriff:\u00a024.03.2017.\u00a0\nFachinformation\u00a0Orphacol\u00ae\u00a0(2015) .\u00a0Fachinformation\u00a0Orphacol\u00ae.\u00a0St and\u00a0der\u00a0Information:\u00a0April\u00a02015.\u00a0\nwww.fachinfo.de/api/search/fi/020216sobi,\u00a0letzter\u00a0Zugriff:\u00a024.0 3.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Chols\u00e4ure.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/113/,\u00a0letzter\u00a0Zugriff:\u00a024.0 3.2017.\u00a0\u00a0\nOrphanet\u00a0(2011a).\u00a0Gallens\u00e4uresynthesedefekt,\u00a0kongenitaler,\u00a0Typ\u00a0 1.\u00a0www.orpha.net/consor/cgi\u2010bin/Disease_Search.php?lng\u00a0\n=DE&data_id=11327&Disease_Disease_Search_diseaseGroup=gallensau re&Disease_Disease_Search_diseaseType=P\nat&Krankheite(n)/Krankheitsgruppe=Gallensauresynthesedefekt\u2010\u2010ko ngenitaler\u2010\u2010Typ\u20101&title=Gallensa,\u00a0letzter\u00a0Zugriff\u00a0\n24.03.2017.\u00a0\nOrphanet\u00a0(2011b).\u00a0Gallens\u00e4uresynthesedefekt,\u00a0kongenitaler,\u00a0Typ\u00a0 2.\u00a0www.orpha.net/consor/cgi\u2010bin/Disease_Search.php\u00a0\n?lng=DE&data_id=11329&Disease_Disease_Search_diseaseGroup=galle nsaure&Disease_Disease_Search_diseaseTy\npe=Pat&Krankheite(n)/Krankheitsgruppe=Gallensauresynthesedefekt \u2010\u2010kongenitaler\u2010\u2010Typ\u20102&title=Gallensa,\u00a0letzter\u00a0\nZugriff\u00a024.03.2017.\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0 Cholic\u00a0acid\u00a0(Orphacol\u00ae).\u00a0Decisi ve\u00a0in\u00a0some\u00a0hereditary\u00a0bile\u00a0acid\u00a0deficiencies.\u00a0Prescrire\u00a0Int\u00a025( 157):\u00a036\u201037.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0Online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Chols\u00e4ure|Orphacol\u00ae.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=52573,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\n\u00a0 \u00a0113\u00a04.6 Cobicistat\u00a0\nHandelsname:\u00a0Tybost\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HIV\u2010Infektion\u00a0 \u00a0 \u00a0 Gilead\u00a0Sciences\u00a0\nATC\u2010Code:\u00a0V03AX03\u00a0 \u00a0 \u00a0 Mar kteinf\u00fchrung:\u00a0April\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtablette\u00a0 \u00a0 DDD:\u00a0150\u00a0mg\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nCobicistat\u00a0(Tybost\u00ae)\u00a0ist\u00a0ein\u00a0Wirkstoffverst\u00e4rker\u00a0der\u00a0antiretrov iral\u00a0wirksamen\u00a0Pro\u2010\nteasehemmstoffe\u00a0Atazanavir\u00a0und\u00a0Darunavir\u00a0und\u00a0bei\u00a0gleichzeitiger \u00a0Gabe\u00a0mit\u00a0einer\u00a0\nder\u00a0genannten\u00a0Substanzen\u00a0zugelassen\u00a0zur\u00a0Behandlung\u00a0von\u00a0HIV\u20101\u2010Er krankungen.\u00a0\nOhne\u00a0Wirkstoffverst\u00e4rker\u00a0( Booster)\u00a0werden\u00a0HIV\u2010Proteasehemmer\u00a0rasch\u00a0von\u00a0Enzy\u2010\nmen\u00a0aus\u00a0der\u00a0Familie\u00a0CYP3A\u00a0in\u00a0der\u00a0Leber\u00a0abgebaut\u00a0und\u00a0es\u00a0resultie rt\u00a0kein\u00a0therapeu\u2010\ntisch\u00a0ausreichender\u00a0Wirkstoffspi egel.\u00a0Dieser\u00a0wird\u00a0durch\u00a0selekti ve\u00a0Hemmung\u00a0der\u00a0\nCYP3A\u2010Enzyme\u00a0mit\u00a0Cobicistat\u00a0erreicht.\u00a0Da\u00a0Cobicistat\u00a0selbst\u00a0nich t\u00a0antiretroviral\u00a0wirk\u2010\nsam\u00a0ist,\u00a0ist\u00a0seine\u00a0Kombination\u00a0mit\u00a0weiteren\u00a0Virustatika\u00a0obligat orisch.\u00a0Die\u00a0Filmtablette\u00a0\nmuss\u00a0einmal\u00a0t\u00e4glich\u00a0zusammen\u00a0mit\u00a0einer\u00a0Mahlzeit\u00a0und\u00a0gleichzeiti g\u00a0mit\u00a0Atazanavir\u00a0\noder\u00a0Darunavir\u00a0eingenommen\u00a0werden\u00a0(Fachinformation\u00a0Tybost\u00ae,\u00a0201 6).\u00a0\u00a0\nIn\u00a0der\u00a0Hauptzulassungsstudie\u00a0GS\u2010US\u2010216\u20100114\u00a0(Gallant\u00a0et\u00a0al.,\u00a020 13)\u00a0sowie\u00a0in\u00a0den\u00a0\nweiteren,\u00a0vom\u00a0pharmazeutischen\u00a0Un ternehmer\u00a0(pU)\u00a0finanzierten\u00a0St udien\u00a0wie\u00a0GS\u2010\nUS\u2010216\u20100105\u00a0(Elion\u00a0et\u00a0al.,\u00a02011)\u00a0oder\u00a0GS\u2010US\u2010216\u20100130\u00a0(Tashima\u00a0e t\u00a0al.,\u00a02014),\u00a0konn\u2010\nte\u00a0keine\u00a0\u00dcberlegenheit\u00a0der\u00a0Therapie\u00a0in\u00a0Bezug\u00a0auf\u00a0das\u00a0virologisc he\u00a0Ansprechen\u00a0\ngezeigt\u00a0 werden,\u00a0 wenn\u00a0 Cobicistat\u00a0 anstelle\u00a0 von\u00a0 Ritonavir\u00a0 zur\u00a0 Boos terung\u00a0 von\u00a0\nAtazanavir\u00a0oder\u00a0Darunavir\u00a0verwendet\u00a0wurde.\u00a0Cobicistat\u00a0war\u00a0Riton avir\u00a0jedoch\u00a0in\u00a0\nkeiner\u00a0der\u00a0Studien\u00a0unterlegen.\u00a0Auch\u00a0unerw\u00fcnschte\u00a0Arzneimitteler eignisse\u00a0(UAE),\u00a0\ndie\u00a0sich\u00a0haupts\u00e4chlich\u00a0in\u00a0Form\u00a0von\u00a0Gelbsucht,\u00a0\u00dcbelkeit\u00a0oder\u00a0Dia rrhoe\u00a0zeigten,\u00a0\ntraten\u00a0in\u00a0keiner\u00a0Vergleichsgrupp e\u00a0signifikant\u00a0h\u00e4ufiger\u00a0auf\u00a0(Eli on\u00a0et\u00a0al.,\u00a02013;\u00a0Gall\u2010\nant\u00a0et\u00a0al.,\u00a02013;\u00a0Tashima\u00a0et\u00a0al.,\u00a02014).\u00a0Mehr\u00a0als\u00a0700\u00a0therapien aive\u00a0Probanden\u00a0\nbeteiligten\u00a0sich\u00a0an\u00a0der\u00a0Hauptzulassungsstudie\u00a0und\u00a0erhielten\u00a0ein \u00a0Therapieregime\u00a0\nbestehend\u00a0aus\u00a0Emtricitabin,\u00a0Teno fovirdisoproxilfumarat\u00a0und\u00a0Ataz anavir,\u00a0das\u00a0durch\u00a0\nCobicistat\u00a0oder\u00a0in\u00a0der\u00a0Vergleichsgruppe\u00a0durch\u00a0Ritonavir\u00a0verst\u00e4r kt\u00a0wurde.\u00a0In\u00a0Bezug\u00a0\nauf\u00a0 das\u00a0 virologische\u00a0 Ansprechen\u00a0 zeigten\u00a0 sich\u00a0 keine\u00a0 signifikante n\u00a0 Unterschiede\u00a0\n(85,2\u00a0%\u00a0vs.\u00a087,4\u00a0%\u00a0in\u00a0der\u00a0Vergleichsgruppe)\u00a0und\u00a0UAE\u00a0traten\u00a0in\u00a0e twa\u00a0gleich\u00a0h\u00e4ufig\u00a0\nauf\u00a0(Gallant\u00a0et\u00a0al.,\u00a02013).\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0sieht\u00a0den\u00a0 Zusatznutzen \u00a0f\u00fcr\u00a0Cobicistat\u00a0\ngegen\u00fcber\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0(zVT)\u00a0mit\u00a0dem\u00a0e benfalls\u00a0als\u00a0\npharmakokinetischer\u00a0Verst\u00e4rkersubstanz\u00a0genutzten\u00a0Ritonavir\u00a0als\u00a0 nicht\u00a0belegt \u00a0an.\u00a0\nEine\u00a0Einsch\u00e4tzung,\u00a0inwieweit\u00a0sic h\u00a0Cobicistat\u00a0im\u00a0Vergleich\u00a0zu\u00a0Ri tonavir\u00a0auf\u00a0die\u00a0Le\u2010\nbensqualit\u00e4t\u00a0der\u00a0Patienten\u00a0auswirkt,\u00a0liegt\u00a0nicht\u00a0vor\u00a0(G\u2010BA,\u00a0201 4).\u00a0\u00a0114\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0\nzweiter\u00a0Wirkstoffverst\u00e4rker\u00a0\nzur\u00a0Kombination\u00a0mit\u00a0\nantiretroviral\u00a0wirksamen\u00a0\nProteasehemmstoffen\u00a0\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0\nder\u00a0zVT\u00a0ist\u00a0nicht\u00a0belegt\u00a0\n\u00a0g\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0\nKosten\u00a0Kombinationstherapien \u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nCobicistat\u00a0 \u00a0 1x\u00a0tgl.\u00a0150\u00a0mg \u00a0 365\u00a0 610,12\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nRitonavir\u00a0 1x\u00a0tgl.\u00a0100\u00a0mg\u00a0 365\u00a0 689,20\u00a0\u20ac\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nCobicistat\u00a0+\u00a0\u00a0\nAtazanavir\u00a0\nVergleichstherapie \u00a0\nRitonavir\u00a0+\u00a0\u00a0\nAtazanavir\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel\u00a0\nCobicistat\u00a0+\u00a0\u00a0\nDarunavir\u00a0\nVergleichstherapie \u00a0\nRitonavir\u00a0+\u00a0\u00a0\nDarunavir \u00a01x\u00a0tgl.\u00a0150\u00a0mg\u00a0+ \u00a0\n1x\u00a0tgl.\u00a0300\u00a0mg\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0100\u00a0mg\u00a0+\u00a0\n1x\u00a0tgl.\u00a0300\u00a0mg\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0150\u00a0mg\u00a0+ \u00a0\n1x\u00a0tgl.\u00a0800\u00a0mg\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0100\u00a0mg\u00a0+\u00a0\u00a0\n1x\u00a0tgl.\u00a0800\u00a0mg \u00a0365\u00a0\n\u00a0\n\u00a0\n365\u00a0\n\u00a0\n\u00a0\n365\u00a0\n\u00a0\n\u00a0\n365\u00a0\u00a0\n10.792,00\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n10.871,08\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n9.061,04\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n9.140,13\u00a0\u20ac \u00a0\nZus\u00e4tzlich\u00a0zu\u00a0den\u00a0oben\u00a0aufgef\u00fchrten\u00a0Mitteln\u00a0muss\u00a0die\u00a0Therapie\u00a0u m\u00a0ein\u00a0Backbone \u00a0(eine\u00a0Sockeltherapie)\u00a0erg\u00e4nzt\u00a0werden.\u00a0Hieraus\u00a0\nresultierende\u00a0Kosten\u00a0wurden\u00a0aus\u00a0Gr\u00fcnden\u00a0der\u00a0\u00dcbersichtlichkeit\u00a0n icht\u00a0aufgef\u00fchrt .\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnungszahlen\u00a0f\u00fcr\u00a0Cobicistat\u00a0steigen\u00a0seit\u00a0seiner\u00a0Markte inf\u00fchrung\u00a0Anfang\u00a0\n2014\u00a0zun\u00e4chst\u00a0nur\u00a0langsam\u00a0an.\u00a0Das\u00a0Maximum\u00a0liegt\u00a0bei\u00a0knapp\u00a0900\u00a0D DD\u00a0f\u00fcr\u00a0den\u00a0\nMonat\u00a0Oktober\u00a02015\u00a0bei\u00a0Kosten\u00a0von\u00a0rund\u00a01.500\u00a0Euro.\u00a0Im\u00a0Vergleich \u00a0zum\u00a0Vorjah\u2010\nresmonat\u00a0(ca.\u00a0300\u00a0DDD/500\u00a0Euro)\u00a0haben\u00a0sich\u00a0die\u00a0Zahlen\u00a0innerhalb \u00a0eines\u00a0Jahres\u00a0in\u00a0\netwa\u00a0verdreifacht.\u00a0\n115\u00a0Abbildung\u00a04.1:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nCobicistat\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nC o b i c i s t a t \u00a0( T y b o s t \u00ae ) \u00a0i s t \u00a0e i n \u00a0p h a r m a k o k i n e t i s c h e r \u00a0V e r s t \u00e4 r k e r \u00a0( B o oster)\u00a0 der\u00a0 HIV\u2010\nProteasehemmstoffe\u00a0Atazanavir\u00a0und\u00a0Darunavir\u00a0und\u00a0mit\u00a0diesen\u00a0geme insam\u00a0zur\u00a0Be\u2010\nhandlung\u00a0einer\u00a0HIV\u20101\u2010Erkrankung\u00a0zugelassen.\u00a0Die\u00a0Substanz\u00a0muss\u00a0m it\u00a0weiteren\u00a0anti\u2010\nretroviralen\u00a0Wirkstoffen\u00a0kombiniert\u00a0werden,\u00a0da\u00a0sie\u00a0selbst\u00a0keine \u00a0Wirksamkeit\u00a0gegen\u00a0\nHIV\u00a0zeigt\u00a0(Fachinforma tion\u00a0Tybost\u00ae,\u00a02016).\u00a0\nHIV\u2010Proteasehemmstoffe\u00a0wie\u00a0Darunavir,\u00a0Atazanavir\u00a0oder\u00a0Lopinavir \u00a0stellen\u00a0Substrate\u00a0\nder\u00a0Enzymsuperfamilie\u00a0Cytochrom\u00a0P450\u00a0dar.\u00a0Insbesondere\u00a0deren\u00a0Su bfamilie\u00a0CYP3A\u00a0\nist\u00a0bei\u00a0der\u00a0Metabolisierung\u00a0vieler\u00a0pharmazeutischer\u00a0Wirkstoffe\u00a0 beteiligt,\u00a0unter\u00a0ande\u2010\nrem\u00a0auch\u00a0der\u00a0meisten\u00a0HIV\u2010Proteasehemmstoffe,\u00a0die\u00a0durch\u00a0die\u00a0CYP\u2010 Enzyme\u00a0oxidiert\u00a0\nwerden.\u00a0Ohne\u00a0Blockade\u00a0der\u00a0CYP3A\u2010Enzymfamilie\u00a0ist\u00a0die\u00a0Anwendung\u00a0 entsprechender\u00a0\nProteasehemmstoffe\u00a0nur\u00a0eingeschr\u00e4nkt\u00a0m\u00f6glich,\u00a0da\u00a0sowohl\u00a0die\u00a0Pla smahalbwertszei\u2010\nten\u00a0als\u00a0auch\u00a0die\u00a0Wirkstoffspiegel\u00a0generell\u00a0stark\u00a0erniedrigt\u00a0wer den.\u00a0Der\u00a0Patient\u00a0m\u00fcss\u2010\nte\u00a0daher\u00a0sehr\u00a0h\u00e4ufig\u00a0hohe\u00a0Dosen\u00a0an\u00a0Wirkstoff\u00a0zu\u00a0sich\u00a0nehmen,\u00a0um \u00a0dennoch\u00a0einen\u00a0\ntherapeutischen\u00a0Effekt\u00a0erwarten\u00a0zu\u00a0k\u00f6nnen\u00a0(Gerber,\u00a02000).\u00a0\nCobicistat\u00a0blockiert\u00a0selektiv\u00a0di e\u00a0CYP3A\u2010Subfamilie\u00a0und\u00a0verlangs amt\u00a0somit\u00a0die\u00a0Abbau\u2010\nrate\u00a0von\u00a0CYP\u2010Substraten\u00a0wie\u00a0Atazanavir\u00a0und\u00a0Darunavir.\u00a0Der\u00a0Wirks toff\u00a0wird\u00a0einmal\u00a0\nt\u00e4glich\u00a0mit\u00a0einem\u00a0der\u00a0genannten\u00a0 Proteasehemmstoffe\u00a0zu\u00a0einer\u00a0Mah lzeit\u00a0eingenom\u2010\n116\u00a0men.\u00a0Die\u00a0Substanz\u00a0zeigt,\u00a0anders\u00a0als\u00a0andere\u00a0CYP\u2010Hemmstoffe,\u00a0wie\u00a0 z.\u00a0B.\u00a0Ritonavir,\u00a0\nselbst\u00a0keinerlei\u00a0antiretrovirale\u00a0Aktivit\u00e4t,\u00a0(Fachinformation\u00a0Ty bost\u00ae,\u00a02016).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nCobicistat\u00a0ist,\u00a0nach\u00a0Ritonavir,\u00a0der\u00a0zweite\u00a0zugelassene\u00a0pharmako kinetische\u00a0Hemm\u2010\nstoff\u00a0zur\u00a0Behandlung\u00a0von\u00a0Erwachsenen\u00a0mit\u00a0einer\u00a0HIV\u20101\u2010Infektion\u00a0 in\u00a0Kombination\u00a0\nmit\u00a0weiteren\u00a0antiretroviral\u00a0akti ven\u00a0Substanzen.\u00a0Da\u00a0aktuell\u00a0kein e\u00a0Daten\u00a0zur\u00a0Anwen\u2010\ndung\u00a0an\u00a0Kindern\u00a0oder\u00a0Jugendlichen\u00a0vorliegen,\u00a0ist\u00a0das\u00a0Pr\u00e4parat\u00a0f \u00fcr\u00a0diese\u00a0Patienten\u2010\ngruppen\u00a0nicht\u00a0zugelassen.\u00a0Der\u00a0Wirkstoff\u00a0wird\u00a0mit\u00a0einem\u00a0der\u00a0HIV\u2010 Proteasehemmer\u00a0\nAtazanavir\u00a0oder\u00a0Darunavir\u00a0komb iniert;\u00a0zur\u00a0Anwendung\u00a0in\u00a0Kombinat ion\u00a0mit\u00a0ande\u2010\nren\u00a0Proteasehemmstoffen,\u00a0z.B.\u00a0Lopi navir,\u00a0besteht\u00a0keine\u00a0Zulassun g.\u00a0Um\u00a0ausrei\u2010\nchende\u00a0Wirkstoffspiegel\u00a0zu\u00a0erreichen,\u00a0muss\u00a0t\u00e4glich\u00a0eine\u00a0Filmtab lette\u00a0zusammen\u00a0\nmit\u00a0dem\u00a0entsprechenden\u00a0Proteasehemmstoff\u00a0zum\u00a0Essen\u00a0eingenommen\u00a0 werden\u00a0\n(Fachinformation\u00a0Tybost\u00ae,\u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nRund\u00a084.700\u00a0Menschen\u00a0waren\u00a0Ende\u00a02015\u00a0in\u00a0Deutschland\u00a0mit\u00a0HIV\u20101\u00a0o der\u00a0HIV\u20102\u00a0\ninfiziert.\u00a0Die\u00a0Anzahl\u00a0der\u00a0ermitt elten\u00a0Neuinfektionen\u00a0lag\u00a0bei\u00a0ci rca\u00a03.000.\u00a0Mehr\u00a0als\u00a0\nzwei\u00a0Drittel\u00a0der\u00a0Betroffenen\u00a0sind\u00a0m\u00e4nnlich,\u00a0und\u00a0wie\u00a0in\u00a0den\u00a0Jahr en\u00a0zuvor\u00a0war\u00a0\ngleichgeschlechtlicher\u00a0Sexualverkehr\u00a0die\u00a0Hauptursache\u00a0f\u00fcr\u00a0die\u00a0\u00dc bertragung\u00a0des\u00a0HI\u2010\nVirus.\u00a0Seit\u00a0Beginn\u00a0der\u00a0Pandemie\u00a0Anfang\u00a0der\u00a01980er\u00a0Jahre\u00a0sind\u00a0al lein\u00a0in\u00a0Deutsch\u2010\nland\u00a0mehr\u00a0als\u00a025.000\u00a0mit\u00a0HIV\u2010infizierte\u00a0Patienten\u00a0gestorben.\u00a0Un behandelt\u00a0f\u00fchrt\u00a0\neine\u00a0HIV\u2010Erkrankung\u00a0zum\u00a0Endstadium \u00a0AIDS\u00a0(Acquired\u00a0Immuno\u2010Defici ency\u00a0Syndro\u2010\nme),\u00a0das\u00a0durch\u00a0eine\u00a0erh\u00f6hte\u00a0Anf\u00e4lligkeit\u00a0gegen\u00a0opportunistische \u00a0Infektionen\u00a0wie\u00a0\nzum\u00a0 Beispiel\u00a0 Cryptococcose,\u00a0 Toxo plasmose\u00a0 oder\u00a0 die\u00a0 Pneumocystisp neumonie\u00a0\ngekennzeichnet\u00a0 ist.\u00a0 Dar\u00fcber\u00a0 hinaus \u00a0 treten\u00a0 vermehrt\u00a0 maligne\u00a0 Tumo r e \u00a0w i e \u00a0d a s \u00a0\nKaposi\u2010Sarkom\u00a0und\u00a0St\u00f6rungen\u00a0des\u00a0 Nervensystems\u00a0auf\u00a0(RKI,\u00a02016a). \u00a0\nNach\u00a0einer\u00a0Sch\u00e4tzung\u00a0des\u00a0Robert\u00a0Koch\u2010Instituts\u00a0(RKI)\u00a0wissen\u00a0cir ca\u00a012.600\u00a0infizierte\u00a0\nPersonen\u00a0in\u00a0Deutschland\u00a0nichts\u00a0von\u00a0ihrer\u00a0HIV\u2010Erkrankung.\u00a0Durch\u00a0 eine\u00a0sp\u00e4te\u00a0Diag\u2010\nnose\u00a0erh\u00f6hen\u00a0sich\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0und\u00a0die\u00a0Sterbli chkeit.\u00a0Au\u00dferdem\u00a0\nk\u00f6nnen\u00a0HIV\u2010positive,\u00a0unbehandelte\u00a0Patienten\u00a0das\u00a0Virus\u00a0deutlich\u00a0 leichter\u00a0\u00fcbertra\u2010\ngen\u00a0als\u00a0solche,\u00a0die\u00a0erfolgreic h\u00a0therapiert\u00a0werden\u00a0(RKI,\u00a02016b). \u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0bereits\u00a0erh\u00e4ltliche\u00a0Substanz\u00a0Ritonavir\u00a0hebt\u00a0einerseits\u00a0als\u00a0 pharmakokinetischer\u00a0\nVerst\u00e4rker\u00a0durch\u00a0Hemmung\u00a0 der\u00a0CYP 3A\u2010Enzyme\u00a0die\u00a0Wirkstoffspiegel\u00a0 v o n\u00a0\u00a0H IV\u2010\nProteasehemmstoffen\u00a0an,\u00a0anderers eits\u00a0ist\u00a0sie\u00a0selbst\u00a0als\u00a0Proteas ehemmstoff\u00a0antivi\u2010\nral\u00a0wirksam.\u00a0Da\u00a0Ritonavir\u00a0als\u00a0Verst\u00e4rker\u00a0jedoch\u00a0in\u00a0subtherapeut ischen\u00a0Dosen\u00a0appli\u2010117\u00a0ziert\u00a0wird,\u00a0kann\u00a0eine\u00a0Resistenzbildung\u00a0gegen\u00a0die\u00a0Klasse\u00a0der\u00a0Pro teasehemmstoffe\u00a0\nnicht\u00a0ausgeschlossen\u00a0werden.\u00a0Das\u00a0 sich\u00a0strukturell\u00a0von\u00a0Ritonavir \u00a0ableitende\u00a0Cobicis\u2010\ntat\u00a0hingegen\u00a0besitzt\u00a0keine\u00a0nenne nswerte\u00a0Aktivit\u00e4t\u00a0gegen\u00a0HI\u2010Vire n\u00a0und\u00a0soll\u00a0diese\u00a0\nResistenzbildung\u00a0verhindern\u00a0(Xu\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nIn\u00a0verschiedenen\u00a0Studien\u00a0wurden\u00a0haupts\u00e4chlich\u00a0die\u00a0Unterschiede\u00a0 gegen\u00fcber\u00a0Ri\u2010\ntonavir\u00a0hinsichtlich\u00a0der\u00a0Arznei mittelnebenwirkungen\u00a0und\u00a0der\u00a0Bee influssung\u00a0der\u00a0\nPlasmaspiegel\u00a0der\u00a0Kombinationspa rtner\u00a0Atazanavir\u00a0und\u00a0Darunavir\u00a0 untersucht.\u00a0In\u00a0\neiner\u00a0Bio\u00e4quvialenzstudie\u00a0zeigte n\u00a0sich\u00a0beispielsweise\u00a0vergleich bare\u00a0Plasmaspiegel\u2010\nkonzentrationen\u00a0 von\u00a0 Atazanavir,\u00a0 unabh\u00e4ngig\u00a0 davon,\u00a0 ob\u00a0 dieses\u00a0 zus ammen\u00a0 mit\u00a0\nRitonavir\u00a0oder\u00a0Cobicistat\u00a0eingenommen\u00a0wurde\u00a0(Ramanathan\u00a0et\u00a0al., \u00a02009).\u00a0In\u00a0der\u00a0\nPhase\u00a0II\u2010Studie\u00a0GS\u2010US\u2010216\u20100105\u00a0zeigten\u00a0sich\u00a0keine\u00a0signifikanten \u00a0Abweichungen\u00a0in\u00a0\nBezug\u00a0auf\u00a0das\u00a0therapeutische\u00a0Ansprechen\u00a0auf\u00a0die\u00a0Therapie,\u00a0wenn\u00a0 Cobicistat\u00a0statt\u00a0\nRitonavir\u00a0in\u00a0Kombination\u00a0mit\u00a0Atazanavir\u00a0und\u00a0einer\u00a0Backbone\u2010Ther apie\u00a0mit\u00a0Emtrici\u2010\ntabin\u00a0und\u00a0Tenofovirdisoproxilfum arat\u00a0eingenommen\u00a0wurde\u00a0(Elion\u00a0e t\u00a0al.,\u00a02011).\u00a0\nIn\u00a0der\u00a0Studie\u00a0GS\u2010US\u2010216\u20100114\u00a0wurde\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0Cobicist at\u00a0in\u00a0Kombinati\u2010\non\u00a0mit\u00a0Atazanavir\u00a0sowie\u00a0Emtricitabin\u00a0und\u00a0Tenofovirdisoproxilfum arat\u00a0an\u00a0therapie\u2010\nnaiven\u00a0Erwachsenen\u00a0untersucht.\u00a0In\u00a0der\u00a0Vergleichsgruppe\u00a0wurde\u00a0an stelle\u00a0von\u00a0Cobi\u2010\ncistat\u00a0Ritonavir\u00a0verabreicht.\u00a0In\u00a0Bezug\u00a0auf\u00a0das\u00a0virologische\u00a0Ans prechen\u00a0zeigten\u00a0sich\u00a0\nkeine\u00a0signifikanten\u00a0Unterschiede\u00a0(85,2\u00a0%\u00a0vs.\u00a087,4\u00a0%\u00a0in\u00a0der\u00a0Verg leichsgruppe)\u00a0und\u00a0\nauch\u00a0das\u00a0Spektrum\u00a0der\u00a0UAW\u00a0war\u00a0ve rgleichbar\u00a0(Gallant\u00a0et\u00a0al.,\u00a0201 3).\u00a0\nIn\u00a0s\u00e4mtlichen\u00a0klinischen\u00a0Studien\u00a0zeigen\u00a0sich\u00a0keine\u00a0signifikante n\u00a0Unterschiede\u00a0hin\u2010\nsichtlich\u00a0des\u00a0Endpunktes\u00a0des\u00a0virologischen\u00a0Ansprechens,\u00a0wenn\u00a0Co bicistat\u00a0anstelle\u00a0\nvon\u00a0Ritonavir\u00a0zur\u00a0Verst\u00e4rkung\u00a0von \u00a0Atazanavir\u00a0oder\u00a0Darunavir\u00a0gen utzt\u00a0wurde.\u00a0Auch\u00a0\ndie\u00a0Vertr\u00e4glichkeit,\u00a0gemessen\u00a0an\u00a0der\u00a0Anzahl\u00a0und\u00a0am\u00a0Grad\u00a0der\u00a0UE, \u00a0war\u00a0vergleich\u2010\nbar.\u00a0Ein\u00a0Vorteil\u00a0ergibt\u00a0sich\u00a0durch\u00a0die\u00a0bessere\u00a0L\u00f6slichkeit\u00a0von\u00a0 Cobicistat,\u00a0wodurch\u00a0\nder\u00a0Wirkstoff\u00a0leichter\u00a0zu\u00a0einem\u00a0Kombinationspr\u00e4parat\u00a0verarbeite t\u00a0werden\u00a0kann\u00a0\nund,\u00a0anders\u00a0als\u00a0Ritonavir,\u00a0nicht\u00a0als\u00a0separates\u00a0Arzneimittel\u00a0ein genommen\u00a0werden\u00a0\nmuss.\u00a0Dies\u00a0kann\u00a0zu\u00a0einer\u00a0Verbesserung\u00a0der\u00a0Adh\u00e4renz\u00a0f\u00fchren\u00a0(Crut chley\u00a0et\u00a0al.,\u00a0\n2016).\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nGenerelles\u00a0Ziel\u00a0einer\u00a0erfolgreich en\u00a0antiretroviralen\u00a0Therapie\u00a0i st\u00a0die\u00a0Hemmung\u00a0der\u00a0\nVirusreplikation\u00a0und\u00a0damit\u00a0einhergehend\u00a0eine\u00a0Senkung\u00a0der\u00a0Virusl ast\u00a0bis\u00a0unter\u00a0die\u00a0\nNachweisgrenze,\u00a0die\u00a0Verhinderung \u00a0der\u00a0Krankheitsprogression\u00a0und\u00a0 der\u00a0Ausbildung\u00a0\ndes\u00a0Krankheitsvollbildes\u00a0AIDS\u00a0sow ie\u00a0die\u00a0Rekonstitution\u00a0der\u00a0zell ul\u00e4ren\u00a0Immunab\u2010\nwehr\u00a0(DAIG,\u00a02015).\u00a0\u00a0118\u00a0Geboostertes\u00a0 Atazanavir\u00a0 oder\u00a0 Darunavir\u00a0 werden\u00a0 in\u00a0 der\u00a0 aktuellen\u00a0 Leitlinie\u00a0 der\u00a0\nDeutschen\u00a0AIDS\u2010Gesellschaft\u00a0(DAIG)\u00a0zur\u00a0Behandlung\u00a0einer\u00a0HIV\u2010Erk rankung\u00a0in\u00a0Kom\u2010\nbination\u00a0mit\u00a0zwei\u00a0nucleosidischen \u00a0Reverse\u2010Transkriptase\u2010Inhibit oren\u00a0(NRTI)\u00a0emp\u2010\nfohlen.\u00a0Alternativ\u00a0kann\u00a0anstelle \u00a0des\u00a0Proteasehemmstoffes\u00a0ein\u00a0In tegrasehemmstoff\u00a0\noder\u00a0ein\u00a0nicht\u2010nucleosidischer\u00a0Reverse\u2010Transkriptase\u2010Hemmer\u00a0(NN RTI)\u00a0eingesetzt\u00a0\nwerden.\u00a0Cobicistat\u00a0wird\u00a0neben\u00a0Ri tonavir\u00a0als\u00a0gleichwertige\u00a0Boost ersubstanz\u00a0ge\u2010\nnannt;\u00a0die\u00a0Leitlinie\u00a0gibt\u00a0keine\u00a0Empfehlung\u00a0zur\u00a0Auswahl\u00a0des\u00a0phar makokinetischen\u00a0\nVerst\u00e4rkers.\u00a0Sie\u00a0weist\u00a0allerdings\u00a0darauf\u00a0hin,\u00a0dass\u00a0einige\u00a0der\u00a0m \u00f6glichen\u00a0Kombinatio\u2010\nnen\u00a0bereits\u00a0als\u00a0Fixkombinationen\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen,\u00a0welche\u00a0b evorzugt\u00a0werden\u00a0\nsollten,\u00a0da\u00a0sie\u00a0nachweislich\u00a0di e\u00a0Adh\u00e4renz\u00a0f\u00f6rdern\u00a0(DAIG,\u00a02015). \u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0sieht\u00a0in\u00a0seinem\u00a0Beschluss\u00a0vom\u00a018.\u00a0September\u00a02014\u00a0f\u00fcr\u00a0C obicistat\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0zVT\u00a0Ritonavir\u00a0zur\u00a0Behandlung\u00a0einer\u00a0HIV\u2010Infektion\u00a0in\u00a0Ko mbination\u00a0mit\u00a0\nAtazanavir\u00a0oder\u00a0Darunavir\u00a0 keinen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen .\u00a0Der\u00a0pU\u00a0hatte\u00a0\ndiesen\u00a0Zusatznutzen\u00a0von\u00a0Beginn\u00a0an \u00a0nicht\u00a0f\u00fcr\u00a0Cobicistat\u00a0reklamie rt\u00a0und\u00a0das\u00a0einzu\u2010\nreichende\u00a0Dossier\u00a0unvollst\u00e4ndig\u00a0vo rgelegt,\u00a0dementsprechend\u00a0konn te\u00a0kein\u00a0IQWiG\u2010\nGutachten\u00a0erstellt\u00a0werden.\u00a0Von\u00a0Seiten\u00a0des\u00a0pU\u00a0erfolgte\u00a0weder\u00a0ein e\u00a0Darstellung\u00a0des\u00a0\nmedizinischen\u00a0Nutzens\u00a0noch\u00a0eines\u00a0Zusatznutzens.\u00a0Der\u00a0G\u2010BA\u00a0stellt e\u00a0\u201eerhebliche\u00a0\nstrukturelle\u00a0M\u00e4ngel\u201d\u00a0bei\u00a0der\u00a0Vollst\u00e4ndigkeitspr\u00fcfung\u00a0fest\u00a0und\u00a0b eurteilte\u00a0Cobicistat\u00a0\nnicht,\u00a0weder\u00a0hinsichtlich\u00a0eines\u00a0Zusatznutzens\u00a0noch\u00a0hinsichtlich \u00a0eines\u00a0geringeren\u00a0\nNutzens\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0(G\u2010BA,\u00a02014).\u00a0\nVersorgungsanalysen\u00a0\nCobicistat\u00a0ist\u00a0in\u00a0Packungen\u00a0zu\u00a030\u00a0und\u00a090\u00a0Filmtabletten\u00a0erh\u00e4ltli ch.\u00a0Die\u00a0Packungen\u00a0\nsind\u00a0nicht\u00a0normiert.\u00a0Das\u00a0Pr\u00e4parat\u00a0wird\u00a0monatlich\u00a0vorwiegend\u00a0im\u00a0 einstelligen\u00a0Be\u2010\nreich\u00a0verordnet.\u00a0\n\u00a0\n\u00a0\n\u00a0 \u00a0119\u00a0Abbildung\u00a04.2:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Cobicistat\u00a0je\u00a0Monat \u00a0nach\u00a0\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.3:\u00a0Versicherte\u00a0mit\u00a0 mind.\u00a0einer\u00a0Verordnung\u00a0Cobicista t\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n120\u00a0Cobicistat\u00a0wird\u00a0\u00fcberwiegend\u00a0in\u00a0der\u00a0Altersgruppe\u00a0der\u00a050\u00a0bis\u00a059\u2010J \u00e4hrigen\u00a0verordnet.\u00a0\nDie\u00a0meisten\u00a0Patienten\u00a0sind\u00a0M\u00e4nner,\u00a0die\u00a0auch\u00a0die\u00a0deutliche\u00a0Mehrh eit\u00a0der\u00a0HIV\u2010\nInfizierten\u00a0ausmachen.\u00a0\nQuellen\u00a0\nCrutchley\u00a0RD,\u00a0Cheng\u00a0A,\u00a0Guduru\u00a0R\u00a0(2016).\u00a0Evaluating\u00a0the\u00a0role\u00a0of\u00a0 atazanavir/cobicistat\u00a0and\u00a0darunavir/cobicistat\u00a0fixed\u2010dose\u00a0\ncombinations\u00a0for\u00a0the\u00a0treatment\u00a0o f\u00a0HIV\u20101\u00a0infection.\u00a0HIV/AIDS\u00a0Res \u00a0Palliat\u00a0Care\u00a0(8):\u00a047.\u00a0\u00a0\nDAIG\u00a0\u2013\u00a0Deutsche\u00a0AIDS\u2010Gesellschaft\u00a0\u00a0(2015).\u00a0Deutsch\u2010\u00d6sterreichis che\u00a0Leitlinien\u00a0zur\u00a0antiretroviralen\u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion. \u00a0\nwww.daignet.de/site\u2010content/hiv\u2010therapie/leitlinien\u20101/Deutsch_O sterreichische\u00a0Leitlinien\u00a0zur\u00a0antiretroviralen\u00a0\nTherapie\u00a0der\u00a0HIV_Infektion.pdf,\u00a0letzter\u00a0Zugriff:\u00a031.03.2017.\u00a0\nElion\u00a0R,\u00a0Cohen\u00a0C,\u00a0Gathe\u00a0J,\u00a0Shalit \u00a0P,\u00a0Hawkins\u00a0T,\u00a0Liu\u00a0HC\u00a0et\u00a0al.\u00a0( 2011).\u00a0Phase\u00a02\u00a0study\u00a0of\u00a0cobicistat\u00a0versus\u00a0ritonavir\u00a0each\u00a0with\u00a0o nce\u2010daily\u00a0\natazanavir\u00a0and\u00a0fixed\u2010dose\u00a0emtricitabine/tenofovir\u00a0df\u00a0in\u00a0the\u00a0ini tial\u00a0treatment\u00a0of\u00a0HIV\u00a0infection.\u00a0AIDS,\u00a025(15):\u00a01881\u20101886.\u00a0\u00a0\nFachinformation\u00a0Tybost\u00ae\u00a0(2016).\u00a0Fachinformation\u00a0Tybost\u00ae.\u00a0Stand\u00a0 der\u00a0Information:\u00a0M\u00e4rz\u00a02017.\u00a0\nFricke\u00a0U\u00a0(2014).\u00a0Pharmakologische\u00a0Bewertung\u00a0neuer\u00a0Arzneimittel\u00a0 2014\u00a0durch\u00a0Prof.\u00a0Fricke,\u00a0Mitglied\u00a0der\u00a0Arzneimittelkommission\u00a0de r\u00a0\ndeutschen\u00a0\u00c4rzteschaft.\u00a0docplayer.org/23661339\u2010Pharmakologische\u2010 bewertung\u2010neuer\u2010arzneimittel\u20102014\u2010durch\u2010prof\u2010\nfricke\u2010mitglied\u2010der\u2010arzneimittelkommission\u2010der\u2010deutschen\u2010aerzte schaft.html,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nGallant\u00a0JE,\u00a0Koenig\u00a0E,\u00a0Andrade\u2010Villanueva\u00a0J,\u00a0Chetchotisakd\u00a0P,\u00a0De Jesus\u00a0E,\u00a0Antunes\u00a0F\u00a0et\u00a0al.\u00a0(2013).\u00a0Cobicistat\u00a0Versus\u00a0Ritonavir\u00a0a s\u00a0a\u00a0Pharma\u2010\ncoenhancer\u00a0of\u00a0Atazanavir\u00a0Plus\u00a0Emtricitabine/Tenofovir\u00a0Disoproxi l\u00a0Fumarate\u00a0in\u00a0Treatment\u2010Naive\u00a0HIV\u00a0Type\u00a01\u2013Infected\u00a0\nPatients:\u00a0Week\u00a048\u00a0Results.\u00a0Journal\u00a0Infect\u00a0Dis\u00a0208\u00a0(1):\u00a032\u201039.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesaussc huss\u00a0(2014).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bu ndesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nde\u2010\nrung\u00a0der\u00a0Arzneimittel\u2010Richtlinie \u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcs se\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Cobicistat.\u00a0Stand\u00a0der\u00a0Informatio n:\u00a018.\u00a0September\u00a02014.\u00a0 https://www.g\u2010ba.de/down\u00a0\nloads/40\u2010268\u20102949/2014\u201009\u201018_AM\u2010RL\u2010XII_Cobicistat_2014\u201004\u201001\u2010D\u2010 104_TrG.pdf ,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017.\u00a0\nGerber\u00a0JG\u00a0(2000).\u00a0Using\u00a0Pharmaco kinetics\u00a0to\u00a0Optimize\u00a0Antiretrov iral\u00a0Drug\u2010Drug\u00a0Interactions\u00a0in\u00a0the\u00a0Treatment\u00a0of\u00a0Human\u00a0\nImmunodeficiency\u00a0Virus\u00a0Infection.\u00a0Clin\u00a0Infect\u00a0Dis\u00a030\u00a0(Supplemen t\u00a02):\u00a0123\u2010129.\u00a0\u00a0\nGilead\u00a0(2016).\u00a0Fachinformation\u00a0Tybost\u00ae\u00a0150mg\u00a0Filmtabletten.\u00a0htt ps://www.gelbe\u2010 liste.de/produkte/tybost\u2010150mg\u2010\nfilmtabletten_841543/fachinformation,\u00a0letzter\u00a0Zugriff:\u00a031.03.20 17.\u00a0\nRamanathan\u00a0S,\u00a0Warren\u00a0D,\u00a0Wei\u00a0L,\u00a0Kearney\u00a0B\u00a0(2009).\u00a0Pharmacokineti c\u00a0Boosting\u00a0of\u00a0Atazanavir\u00a0with\u00a0 the\u00a0Pharmacoenhancer\u00a0GS\u20109350\u00a0\nversus\u00a0Ritonavir\u00a049th\u00a0Intersci.\u00a0Conf.\u00a0Antimicrob.\u00a0Agents\u00a0Chemot her.\u00a0\nwww.hivandhepatitis.com/2009icr/icaac/pdfs/2_Ramanathan.pdf,\u00a0le tzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016a).\u00a0Sch\u00e4tzung\u00a0der\u00a0Zahl\u00a0der\u00a0HIV\u2010 Neuinfektionen\u00a0und\u00a0der\u00a0Gesamtzahl\u00a0von\u00a0Menschen\u00a0mit\u00a0HIV\u00a0in\u00a0\nDeutschland\u00a0EpiBulletin\u00a02016;\u00a045(2014):\u00a0497\u2010512.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016b).\u00a0HIV\u2010Infektion/AIDS\u00a0RKI\u2010Ratg eber\u00a0f\u00fcr\u00a0\u00c4rzte.\u00a0 http://www.rki.de/DE/Content/Infekt/\u00a0\nEpidBull/Merkblaetter/Ratgeber_HIV_AIDS.html?nn=2374210 ,\u00a0letzter\u00a0Zugriff:\u00a031.03.2017.\u00a0\nTashima\u00a0K,\u00a0Crofoot\u00a0G,\u00a0Tomaka\u00a0FL,\u00a0Kakuda\u00a0TN,\u00a0Brochot\u00a0A,\u00a0Van\u00a0de\u00a0C asteele\u00a0T\u00a0et\u00a0al.\u00a0(2014).\u00a0Cobicistat\u2010boosted\u00a0darunavir\u00a0in\u00a0HIV\u20101\u2010\ninfected\u00a0adults:\u00a0week\u00a048\u00a0results\u00a0 of\u00a0a\u00a0Phase\u00a0IIIb,\u00a0open\u2010label\u00a0si ngle\u2010arm\u00a0trial.\u00a0AIDS\u00a0Research\u00a0and\u00a0Therapy\u00a011:\u00a039\u201051.\u00a0\u00a0\nXu\u00a0L,\u00a0Liu\u00a0H,\u00a0Murray\u00a0BP,\u00a0Callebaut \u00a0C,\u00a0Lee\u00a0MS,\u00a0Hong\u00a0A\u00a0et\u00a0al.\u00a0(201 0).\u00a0Cobicistat\u00a0(GS\u20109350):\u00a0A\u00a0Potent\u00a0and\u00a0Selective\u00a0Inhibitor\u00a0of\u00a0H uman\u00a0\nCYP3A\u00a0as\u00a0a\u00a0Novel\u00a0Pharmacoenhancer.\u00a0ACS\u00a0Med\u00a0Chem\u00a0Lett\u00a01(5):\u00a0209\u2010 213.\u00a0\u00a0 \u00a0121\u00a04.7 Daclatasvir\u00a0\nHandelsname:\u00a0Daklinza\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0\u00a0\u00a0 Bristol\u2010Myers\u00a0Squibb\u00a0 \u00a0\nATC\u2010Code:\u00a0J05AX14\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0\u00a0September\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a060 \u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nBei\u00a0seiner\u00a0Zulassung\u00a0im\u00a0September\u00a02014\u00a0war\u00a0Daclatasvir\u00a0(Daklinz a\u00ae)\u00a0der\u00a0erste\u00a0\nHemmstoff\u00a0des\u00a0viralen\u00a0Nicht\u2010Strukturproteins\u00a0NS5A.\u00a0Das\u00a0Phosphop rotein\u00a0besitzt\u00a0\neine\u00a0zentrale\u00a0Rolle\u00a0bei\u00a0der\u00a0RNA\u2010R eplikation\u00a0und\u00a0der\u00a0Virus\u2010Morph ogenese.\u00a0Bei\u00a0den\u00a0\nHepatitis\u2010C(HC)\u2010Mitteln\u00a0 wurde\u00a0 damit\u00a0 nach\u00a0 dem\u00a0 Polymeraseinhibito r\u00a0 Sofosbuvir\u00a0\ninnerhalb\u00a0eines\u00a0Jahres\u00a0ein\u00a0weiterer\u00a0Wirkstoff\u00a0als\u00a0erster\u00a0Vertre ter\u00a0einer\u00a0neuen\u00a0\nWirkstoffklasse\u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt.\u00a0\u00a0\nIn\u2010vitro\u2010Untersuchungen\u00a0zeigen,\u00a0dass\u00a0die\u00a0Resistenzschwelle\u00a0bei\u00a0 einer\u00a0Daclatasvir\u2010\nMonotherapie\u00a0aufgrund\u00a0sich\u00a0rasch\u00a0ausbildender\u00a0Punktmutationen\u00a0n iedrig\u00a0ange\u2010\nsiedelt\u00a0ist.\u00a0Das\u00a0Mittel\u00a0darf\u00a0daher\u00a0nur\u00a0in\u00a0Kombination\u00a0mit\u00a0ander en\u00a0Arzneimitteln\u00a0zur\u00a0\nBehandlung\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C\u00a0(cHC)\u00a0eingesetzt\u00a0werden\u00a0 (Fachinformation\u00a0\nDaklinza\u00ae,\u00a02016).\u00a0Gem\u00e4\u00df\u00a0Zulassung\u00a0sind\u00a0als\u00a0Kombinationspartner\u00a0 vor\u00a0allem\u00a0Sofos\u2010\nbuvir\u00a0und\u00a0je\u00a0nach\u00a0Krankheits\u2010\u00a0und\u00a0Behandlungsstadium\u00a0auch\u00a0Ribav irin\u00a0vorgesehen.\u00a0\nEine\u00a0Peginterferon\u2010basierte\u00a0Tripeltherapie\u00a0\u00fcber\u00a024\u00a0Wochen\u00a0wird\u00a0 lediglich\u00a0noch\u00a0bei\u00a0\nGenotyp\u20104\u2010Infektionen\u00a0ohne\u00a0Zirrh ose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirr hose\u00a0als\u00a0alterna\u2010\ntives\u00a0Behandlungsregime\u00a0beschrie ben\u00a0(Fachinformation\u00a0Daklinza\u00ae, \u00a02016).\u00a0Dacla\u2010\ntasvir\u00a0wird\u00a0bei\u00a0Erwachsenen\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a060\u00a0mg\u00a0nur\u00a0ei nmal\u00a0t\u00e4glich\u00a0ein\u2010\ngesetzt.\u00a0\nDie\u00a0klinischen\u00a0Erfahrungen\u00a0zu\u00a0Da clatasvir\u00a0basieren\u00a0auf\u00a0mehreren \u00a0zwischen\u00a02014\u00a0\nund\u00a02016\u00a0publizierten\u00a0randomisiert\u00a0kontrollierten\u00a0Untersuchunge n,\u00a0in\u00a0denen\u00a0die\u00a0\nWirksamkeit\u00a0von\u00a0Daclatasvir\u00a0bei\u00a0 chronischen\u00a0Hepatitiden\u2010Genotyp \u00a01\u00a0bis\u00a04\u00a0unter\u2010\nsucht\u00a0wurde.\u00a0S\u00e4mtliche\u00a0Studien\u00a0sind\u00a0herstellergesponsert.\u00a0In\u00a0de r\u00a0zulassungsrele\u2010\nvanten\u00a0AI444040\u2010Studie\u00a0wurde\u00a0das\u00a0Interferon\u2010freie\u00a0Therapieregim e\u00a0Daclatasvir\u00a0+\u00a0\nSofosbuvir\u00a0mit\u00a0und\u00a0ohne\u00a0Ribavirinzusatz\u00a0bei\u00a0therapieerfahrenen\u00a0 wie\u00a0auch\u00a0thera\u2010\npienaiven\u00a0Patienten\u00a0mit\u00a0cHC\u00a0erpr obt.\u00a0Auf\u00a0Basis\u00a0geringer\u00a0Patient enzahlen\u00a0pro\u00a0Sub\u2010\ngruppe\u00a0ergeben\u00a0sich\u00a0bei\u00a0Patienten\u00a0 mit\u00a0cHC\u2010Genotyp\u00a01,\u00a03\u00a0oder\u00a03\u00a0m it\u00a0und\u00a0ohne\u00a0\nVorbehandlung\u00a0unter\u00a0Daclatasvir\u00a0+\u00a0Sofosbuvir\u00a0\u00fcber\u00a012\u00a0bzw.\u00a024\u00a0Be handlungswo\u2010\nchen\u00a0hohe\u00a0Heilungsraten\u00a0von\u00a0100 \u00a0%\u00a0(AI444040\u2010Studie,\u00a0Sulkowski\u00a0et\u00a0al.,\u00a02014).\u00a0Ein\u00a0\nRibavirin\u2010Zusatz\u00a0kann\u00a0die\u00a0Heilungsrate\u00a0nicht\u00a0steigern.\u00a0Dieses\u00a0p ositive\u00a0Therapiean\u2010\nsprechen\u00a0l\u00e4sst\u00a0sich\u00a0auch\u00a0bei\u00a0HIV\u2010coinfizierten\u00a0Patienten\u00a0erreic hen\u00a0(ALLY\u20102,\u00a0Wyles\u00a0\net\u00a0al.,\u00a02015).\u00a0F\u00fcr\u00a0die\u00a0Behandlung\u00a0therapienaiver\u00a0Patienten\u00a0mit\u00a0 cHC\u2010Genotyp\u00a01\u00a0\nfindet\u00a0sich\u00a0eine\u00a0Untersuchung,\u00a0in\u00a0 der\u00a0eine\u00a0Daclatasvir\u2010Tripelth erapie\u00a0direkt\u00a0mit\u00a0\n122\u00a0einer\u00a0Telaprevir\u2010Tripeltherapie\u00a0 verglichen\u00a0wurde.\u00a0Darin\u00a0erweist \u00a0sich\u00a0Daclatasvir\u00a0\ngegen\u00fcber\u00a0der\u00a0Standardtherapie\u00a0i m\u00a0Hinblick\u00a0auf\u00a0das\u00a0virologische \u00a0Ansprechen\u00a0des\u00a0\nVirustyps\u00a0Genotyp\u00a0(GT)\u00a01b\u00a0als\u00a0ni cht\u2010unterlegen\u00a0(Jacobson\u00a0et\u00a0al. ,\u00a02016).\u00a0Direkte\u00a0\nVergleichsstudien\u00a0 zu\u00a0 anderen,\u00a0 dir ekt\u00a0 antiviral\u00a0 wirkenden\u00a0 Mittel n\u00a0 (Boceprevir,\u00a0\nSofosbuvir,\u00a0Simeprevir)\u00a0fehlen.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0cHC\u00a0GT\u00a02\u00a0und\u00a0 3\u00a0liegt\u00a0das\u00a0virologi\u2010\nsche\u00a0Ansprechen\u00a0einer\u00a0Daclatasvir\u00a0Tripeltherapie\u00a0\u00fcber\u00a012\u00a0bzw.\u00a01 6\u00a0Wochen\u00a0ver\u2010\ngleichbar\u00a0hoch\u00a0wie\u00a0bei\u00a0einer\u00a0dualen\u00a0Standardtherapie\u00a0\u00fcber\u00a024\u00a0Wo chen\u00a0(Dore\u00a0et\u00a0\nal.,\u00a02015).\u00a0Mit\u00a0Daclatasvir\u00a0l\u00e4sst\u00a0sich\u00a0die\u00a0Dauer\u00a0einer\u00a0Interfer on\u2010basierten\u00a0Behand\u2010\nlung\u00a0verk\u00fcrzen.\u00a0Ein\u00a0In terferon\u2010freies\u00a0Therapieregime\u00a0bestehend\u00a0 aus\u00a0Daclatasvir\u00a0+\u00a0\nSofosbuvir\u00a0+\u00a0Ribavirin\u00a0zeigt\u00a0bei\u00a0Patienten\u00a0mit\u00a0cHC\u00a0GT\u00a03\u00a0und\u00a0for tgeschrittener\u00a0Le\u2010\nbererkrankung\u00a0nach\u00a012\u00a0bzw.\u00a016\u00a0Be handlungwochen\u00a0virologische\u00a0Ans prechraten\u00a0\nvon\u00a088\u00a0%\u00a0bzw.\u00a092 \u00a0%.\u00a0(ALLY\u20103+;\u00a0Leroy\u00a0et\u00a0al.,\u00a02016).\u00a0Eine\u00a024\u2010w\u00f6chige\u00a0Daclatasvir\u2010\nTripeltherapie\u00a0bei\u00a0nicht\u00a0vorbehandelten\u00a0Patienten\u00a0mit\u00a0cHC\u00a0GT\u00a04\u00a0 steigert\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0dualen\u00a0Standardtherapie\u00a0\u00fcber\u00a048\u00a0Wochen\u00a0das\u00a0virologisch e\u00a0Ansprechen\u00a0\nvon\u00a050\u00a0%\u00a0auf\u00a0100 \u00a0%\u00a0(H\u00e9zode\u00a0et\u00a0al.,\u00a02015).\u00a0Valide\u00a0Untersuchungen,\u00a0die\u00a0die\u00a0Auswir\u2010\nkungen\u00a0Daclatasvir\u2010haltiger\u00a0Therapieregime\u00a0auf\u00a0die\u00a0Lebensqualit \u00e4t\u00a0von\u00a0Patienten\u00a0\nmit\u00a0cHC\u00a0im\u00a0Vergleich\u00a0zu\u00a0Standardtherapien\u00a0untersuchen,\u00a0wurden\u00a0n icht\u00a0durchge\u2010\nf\u00fchrt.\u00a0\nDas\u00a0dauerhafte\u00a0virologische\u00a0Ansprechen\u00a0insbesondere\u00a0der\u00a0Interfe ron\u2010freien\u00a0Re\u2010\ngime\u00a0ist\u00a0damit\u00a0sowohl\u00a0bei\u00a0therapienaiven\u00a0wie\u00a0auch\u00a0bei\u00a0therapiee rfahrenen\u00a0Patien\u2010\nten\u00a0hoch.\u00a0Allerdings\u00a0wurden\u00a0die\u00a0 Ergebnisse\u00a0\u00fcberwiegend\u00a0an\u00a0relat iv\u00a0kleinen\u00a0Patien\u2010\ntenkollektiven\u00a0erhoben\u00a0oder\u00a0es\u00a0f ehlen\u00a0hochwertige\u00a0direkte\u00a0Vergl eichsstudien\u00a0zu\u00a0\nanderen\u00a0 Peginterferon\u2010freien\u00a0 Therapieregimen\u00a0 (Suwanthawornkul\u00a0 e t\u00a0 al.,\u00a0 2016;\u00a0\nPeng\u00a0et\u00a0al.,\u00a02016).\u00a0Dass\u00a0die\u00a0Interferon\u2010freie\u00a0Tripeltherapie\u00a0be stehend\u00a0aus\u00a0Dacla\u2010\ntasvir,\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0 Vorteile\u00a0gegen\u00fcber\u00a0anderen\u00a0The rapiealternativen\u00a0\nbei\u00a0chronischen\u00a0Hepatitiden\u00a0GT\u00a03 \u00a0besitzt,\u00a0wird\u00a0in\u00a0aktuellen\u00a0sys tematischen\u00a0Analy\u2010\nsen\u00a0best\u00e4tigt\u00a0(Berden\u00a0et\u00a0al.,\u00a02017;\u00a0Gimeno\u2010Ballester\u00a0et\u00a0al.,\u00a020 16;\u00a0Nelson\u00a0et\u00a0al.,\u00a0\n2015).\u00a0F\u00fcr\u00a0die\u00a0restlichen\u00a0Genotypen\u00a0stehen\u00a0besser\u00a0evaluierte\u00a0Th erapieregime\u00a0zur\u00a0\nVerf\u00fcgung.\u00a0 Die\u00a0 h\u00e4ufigsten\u00a0 unerw\u00fcnschten\u00a0 Arzneimittelereignisse\u00a0 (UAE)\u00a0 unter\u00a0\nDaclatasvir\u00a0sind\u00a0Ersch\u00f6pfung,\u00a0Kopfschmerzen,\u00a0\u00dcbelkeit\u00a0und\u00a0An\u00e4mi e.\u00a0\u00a0\nWeil\u00a0direkte\u00a0Vergleichsstudien\u00a0 gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergl eichstherapie\u00a0\nfehlen,\u00a0wird\u00a02014\u00a0vom\u00a0Gemeinsamen\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0auf\u00a0Ba sis\u00a0indirekter\u00a0\nVergleiche\u00a0der\u00a0Zusatznutzen\u00a0von\u00a0 Daclatasvir\u00a0wie\u00a0folgt\u00a0eingesch\u00e4 tzt:\u00a0F\u00fcr\u00a0therapie\u2010\nnaive\u00a0Patienten\u00a0mit\u00a0cHC\u00a0vom\u00a0GT\u00a01,\u00a0aber\u00a0ohne\u00a0Zirrhose ,\u00a0wird\u00a0dem\u00a0Therapieregime\u00a0\nDaclatasvir\u00a0+\u00a0Sofosbuvir\u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0dualen\u00a0oder \u00a0dreifachen\u00a0\nInterferon\u2010basierten\u00a0 V ergleichstherapie\u00a0 ein\u00a0 Anhaltspunkt\u00a0 f\u00fcr\u00a0 einen \u00a0geringen\u00a0\nZusatznutzen \u00a0attestiert.\u00a0Das\u00a0neue\u00a0Daclatasvir \u2010Therapieregime\u00a0er\u00f6ffnet\u00a0die\u00a0M \u00f6g\u2010\nlichkeit\u00a0einer\u00a0Therapieverk\u00fcrzung\u00a0und\u00a0aufgrund\u00a0der\u00a0Interferon\u2010F reiheit\u00a0eine\u00a0besse\u2010\nre\u00a0Vertr\u00e4glichkeit\u00a0gegen\u00fcber\u00a0den\u00a0bisherigen\u00a0Therapiestandards.\u00a0 Kein\u00a0Zusatznut\u2010123\u00a0zen\u00a0wird\u00a0hingegen\u00a0f\u00fcr\u00a0 therapienaive\u00a0Patienten\u00a0mit\u00a0HC\u00a0GT\u00a01\u00a0und\u00a0kompensierter\u00a0\nZirrhose\u00a0 sowie\u00a0f\u00fcr \u00a0therapieerfahrene\u00a0Patienten\u00a0mit\u00a0diesem\u00a0Genotyp \u00a0gesehen.\u00a0\nAuch\u00a0bei\u00a0 therapienaiven\u00a0Patienten\u00a0mit\u00a0kompensierter\u00a0Zirrhose\u00a0sowie\u00a0f\u00fcr\u00a0t hera\u2010\npieerfahrene\u00a0Patienten\u00a0mit\u00a0HC\u00a0GT\u00a03 \u00a0ist\u00a0ein\u00a0Zusatznutzen\u00a0nicht\u00a0nachgewiesen .\u00a0Bei\u00a0\ntherapienaiven\u00a0wie\u00a0auch\u00a0therapieerfahrenen\u00a0Patienten\u00a0mit\u00a0HC\u00a0GT\u00a0 4\u00a0fehlt\u00a0ebenso\u00a0\nf\u00fcr\u00a0die\u00a0Interferon\u2010freie\u00a0Therapie\u00a0mit\u00a0Daclatasvir\u00a0ein\u00a0 Nachweis\u00a0f\u00fcr\u00a0einen\u00a0Zusatznut\u2010\nzen\u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergl eichstherapie.\u00a0Lediglich\u00a0f\u00fcr\u00a0d ie\u00a0Tripelthe\u2010\nrapie\u00a0von\u00a0Daclatasvir\u00a0mit\u00a0Peginterferon\u00a0und\u00a0Ribavirin\u00a0wird\u00a0bei\u00a0 therapienaiven\u00a0\nPatienten\u00a0mit\u00a0HC\u00a0GT\u00a04 \u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0dualen\u00a0Vergleichstherapie\u00a0\nohne\u00a0 Daclatasvir\u00a0 ein\u00a0 Anhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 betr\u00e4chtlichen\u00a0 Zusatznutzen \u00a0i m \u00a0\nHinblick\u00a0auf\u00a0das\u00a0dauerhafte\u00a0virologische\u00a0Ansprechen\u00a0reklamiert. \u00a0Die\u00a0vorliegenden\u00a0\nStudienergebnisse\u00a0sind\u00a0allerdings\u00a0mit\u00a0hoher\u00a0Unsicherheit\u00a0belast et\u00a0(G\u2010BA,\u00a02014).\u00a0\nBei\u00a0therapieerfahrenen\u00a0 Patienten\u00a0 mit\u00a0 diesem\u00a0 Genotyp \u00a0 kann\u00a0 die\u00a0 Interferon\u2010\nbasierte\u00a0Tripeltherapie\u00a0hingegen\u00a0 keinen\u00a0Zusatznutzen \u00a0verzeichnen.\u00a0\u00a0\nUntersuchungen\u00a0legen\u00a0nahe,\u00a0dass\u00a0durch\u00a0die\u00a0Behandlung\u00a0mit\u00a0direkt \u00a0antiviral\u00a0wir\u2010\nkenden\u00a0Mitteln\u00a0eine\u00a0bereits\u00a0vor liegende\u00a0Hepatitis\u2010B\u2010Erkrankung\u00a0 reaktiviert\u00a0wer\u2010\nden\u00a0kann.\u00a0Bei\u00a0Koinfektion\u00a0hemmt\u00a0das\u00a0Hepatitis\u2010C\u2010Virus\u00a0(HCV)\u00a0die \u00a0Replikation\u00a0von\u00a0\nHepatitis\u2010B\u2010Viren.\u00a0 Unter\u00a0 spezifi scher\u00a0 antiviraler\u00a0 Hepatitis\u2010C\u2010B ehandlung\u00a0 entf\u00e4llt\u00a0\ndiese\u00a0 Hemmfunktion.\u00a0 Seit\u00a0 Ende\u00a0 2016\u00a0 fordert\u00a0 daher\u00a0 die\u00a0 Europ\u00e4isch e\u00a0 Medizin\u2010\nAgentur\u00a0( European\u00a0Medicines\u00a0Agency ,\u00a0EMA)\u00a0vor\u00a0einer\u00a0HCV \u2010Behandlung\u00a0ein\u00a0Scree\u2010\nning\u00a0auf\u00a0Hepatitis\u2010B\u2010Koinfektion\u00a0(EMA,\u00a02016).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\nNeues\u00a0Wirkprinzip\u00a0zum\u00a0\nZeitpunkt\u00a0der\u00a0Zulassung,\u00a0\nallerdings\u00a0mit\u00a0niedriger\u00a0\nResistenzschwelle\u00a0\nbehaftet\u00a0Als\u00a0Peginterferonfreies\u00a0\nBehandlungsregime\u00a0\nZusatznutzen\u00a0beim\u00a0\nvirologischen\u00a0Anspre\u2010\nchen\u00a0bei\u00a0Genotyp\u00a03\u00a0teurer\u00a0im\u00a0Vergleich\u00a0zum\u00a0bis\u00a0\ndahin\u00a0\u00fcblichen\u00a0PEG\u2010\nbasierten\u00a0Regime\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung \u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 Mittel\u00a0der\u00a0Reserve\u00a0In\u00a0Kombination\u00a0mit\u00a0\nAsunaprevir\u00a0und\u00a0der\u00a0\nStandardtherapie\u00a0\nwerden\u00a0Wirkst\u00e4rke\u00a0\nerh\u00f6ht\u00a0und\u00a0Resis\u2010\ntenzen\u00a0verhindert\u00a0Offers\u00a0an\u00a0\nadvantage\u00a0\u00a0\n(bei\u00a0HCV\u2010Infek\u2010\ntionen\u00a0\u00a0\nGT\u20103\u00a0oder\u00a0\u20104)\u00a0Schrittinno\u2010\nvation\u00a0\n124\u00a0Kosten\u00a0Kombinationstherapie\u00a0\nWirkstoff \u00a0 Behandlungsmodus \u00a0Behandlungstage* \u00a0 Tagestherapiekosten \u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDaclatasvir\u00a0\nIn\u00a0Kombination\u00a0mit: \u00a01x\u00a0tgl.\u00a0 84\u00a0\u2013\u00a0168\u00a0Tage\u00a0320,15\u00a0\u20ac\u00a0\nSofosbuvir \u00a0 1x\u00a0tgl.\u00a0 84\u00a0\u2013\u00a0168\u00a0Tage \u00a0 600,31\u00a0\u20ac\u00a0\nBoceprevir \u00a0 3x\u00a0tgl.\u00a0800\u00a0mg \u00a0 196\u00a0\u2013\u00a0336\u00a0Tage \u00a0 112,36\u00a0\u20ac\u00a0\nTelaprevir\u00a0 3x\u00a0tgl.\u00a0750\u00a0mg \u00a0 84\u00a0\u2013\u00a0336\u00a0Tage \u00a0334,27\u00a0\u20ac\u00a0\nRibavirin\u00a01x\u00a0400\u00a0mg\u00a0+\u00a0\u00a0\n1x\u00a0600\u00a0mg \u00a0168\u00a0\u2013\u00a0336\u00a0Tage \u00a0 29,89\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB11)\u00a0 1x\u00a0w\u00f6chentlich \u00a024\u00a0\u2013\u00a048\u00a0Tage\u00a0oder\u00a0\nWochen\u00a0280,19\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB10)\u00a0 1x\u00a0w\u00f6chentlich \u00a024\u00a0\u2013\u00a048\u00a0Tage\u00a0oder\u00a0\nWochen\u00a0254,31\u00a0\u20ac\u00a0\n*Je\u00a0nach\u00a0Virenbelastung\u00a0ist\u00a0die\u00a0Therapiedauer\u00a012\u00a0Wochen\u00a0(84\u00a0Tag e),\u00a024\u00a0Wochen\u00a0(168\u00a0Tage)\u00a0oder\u00a048\u00a0Wochen\u00a0(336\u00a0Tage).\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nBereits\u00a0zwei\u00a0Monate\u00a0nach\u00a0seiner\u00a0Marktzulassung\u00a0erreicht\u00a0Daclata svir\u00a0seinen\u00a0Ver\u2010\nordnungs\u2010\u00a0und\u00a0Umsatzgipfel\u00a0im\u00a0Be obachtungszeitraum\u00a0bis\u00a0Ende\u00a0201 5.\u00a0Beide\u00a0fallen\u00a0\nim\u00a0Laufe\u00a0der\u00a0nachfolgenden\u00a012\u00a0Monate\u00a0deutlich\u00a0ab.\u00a0Dies\u00a0ist\u00a0weni ger\u00a0mit\u00a0dem\u00a0\nErgebnis\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0zu\u00a0erkl\u00e4ren\u00a0 als\u00a0vielmehr\u00a0\nmit\u00a0den\u00a0zahlreichen\u00a0Marktbewegungen\u00a0im\u00a0Segment\u00a0der\u00a0Hepatitismit tel\u00a0im\u00a0Zulas\u2010\nsungsjahr\u00a02014.\u00a0Mit\u00a0der\u00a0Zulassung\u00a0der\u00a0ersten\u00a0Fixkombinationen\u00a0( Harvoni\u00ae)\u00a0stand\u00a0\nbereits\u00a0wenige\u00a0Monate\u00a0sp\u00e4ter\u00a0eine\u00a0umfassend\u00a0evaluierte\u00a0Alternat ive\u00a0mit\u00a0verein\u2010\nfachtem\u00a0Einnahmeregime\u00a0zur\u00a0Verf\u00fcgung.\u00a0 \u00a0\n\u00a0 \u00a0125\u00a0Abbildung\u00a04.4:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nDaclatasvir\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nDaclatasvir\u00a0ist\u00a0 ein\u00a0selektiver\u00a0 Hemmstoff\u00a0des\u00a0Nicht\u2010Strukturprot eins\u00a05A\u00a0(NS5A).\u00a0\nNachdem\u00a0Virus\u2010RNA\u00a0in\u00a0das\u00a0Plasma\u00a0der\u00a0Wirtszelle\u00a0gelangt\u00a0ist,\u00a0vol lzieht\u00a0sich\u00a0die\u00a0\nvirale\u00a0Proteinbiosynthese\u00a0an\u00a0den \u00a0Ribosomen\u00a0des\u00a0Endoplasmatische n\u00a0Retikulums.\u00a0\nDas\u00a0w\u00e4hrend\u00a0der\u00a0Translation\u00a0ents tehende\u00a0Polyprotein\u00a0wird\u00a0mittel s\u00a0zellul\u00e4rer\u00a0sowie\u00a0\nviraler\u00a0Proteasen\u00a0in\u00a0mehrere\u00a0Strukturproteine\u00a0und\u00a0Nicht\u2010Struktu rproteine,\u00a0u.\u00a0a.\u00a0\nauch\u00a0das\u00a0Nicht\u2010Strukturprotein\u00a05A,\u00a0abgebaut.\u00a0W\u00e4hrend\u00a0Strukturpr oteine\u00a0des\u00a0HCV\u00a0\nentscheidend\u00a0f\u00fcr\u00a0die\u00a0Bildung\u00a0und\u00a0Freisetzung\u00a0infekti\u00f6ser\u00a0Viren\u00a0 sowie\u00a0den\u00a0Eintritt\u00a0\ndes\u00a0Virus\u00a0in\u00a0die\u00a0Wirtszelle\u00a0sind,\u00a0beteiligen\u00a0sich\u00a0Nicht\u2010Struktu rproteine\u00a0wesentlich\u00a0\nan\u00a0der\u00a0RNA\u2010Replikation\u00a0und\u00a0der\u00a0Virus\u2010Morphogenese\u00a0\u00a0(EMA,\u00a02014). \u00a0\u00a0\nResistenzen\u00a0gegen\u00fcber\u00a0Daclatasvir\u00a0konnten\u00a0in\u00a0Zellkulturen\u00a0insbe sondere\u00a0gegen\u2010\n\u00fcber\u00a0HCV\u00a0GT\u00a01\u00a0bis\u00a04\u00a0festgestellt\u00a0werden.\u00a0Die\u00a0Unempfindlichkeit\u00a0 entwickelte\u00a0sich\u00a0\ndurch\u00a0Substitutionen\u00a0an\u00a0der\u00a0terminalen\u00a0Aminos\u00e4ureregion\u00a0des\u00a0NS5 A\u2010Phospho\u2010\nproteins.\u00a0Diese\u00a0Ver\u00e4nderungen\u00a0f\u00fchrten\u00a0insbesondere\u00a0bei\u00a0HCV\u2010GT\u00a01 a,\u00a02\u00a0und\u00a03\u00a0zu\u00a0\neiner\u00a0h\u00f6hergradigen\u00a0Resistenz.\u00a0Hepatitis\u2010Viren\u00a0mit\u00a0entsprechend en\u00a0Resistenzen\u00a0\nwaren\u00a0aber\u00a0nach\u00a0wie\u00a0vor\u00a0empfindlich\u00a0gegen\u00fcber\u00a0antiviral\u00a0wirkend en\u00a0Protease\u2010\u00a0\noder\u00a0Polymeraseinhibitoren\u00a0(EMA,\u00a02014,\u00a0Wang\u00a0et\u00a0al.,\u00a02014)\u00a0\n\u00a0\n126\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDaclatasvir\u00a0ist\u00a0in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0zur\u00a0Be handlung\u00a0von\u00a0Er\u2010\nwachsenen\u00a0mit\u00a0cHC\u00a0zugelassen.\u00a0Es\u00a0 muss\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a060 \u00a0mg\u00a0nur\u00a0einmal\u00a0\nt\u00e4glich\u00a0eingenommen\u00a0werden.\u00a0Nach \u00a0derzeitigem\u00a0Zulassungsstatus\u00a0w erden\u00a0andere\u00a0\ndirekt\u00a0antiviral\u00a0wirkende\u00a0Mittel\u00a0(in\u00a0erster\u00a0Linie\u00a0Sofosbuvir,\u00a0R ibavirin)\u00a0als\u00a0Kombina\u2010\ntionspartner\u00a0f\u00fcr\u00a0Daclatasvir\u00a0genannt\u00a0(BMS,\u00a02016).\u00a0Bei\u00a0Patienten \u00a0mit\u00a0HCV\u2010Infek\u2010\ntionen\u00a0GT\u00a01,\u00a03\u00a0und\u00a04\u00a0ohne\u00a0Zirrhose\u00a0werden\u00a0duale\u00a0Therapien\u00a0zusam men\u00a0mit\u00a0Sofos\u2010\nbuvir\u00a0\u00fcber\u00a012\u00a0Wochen\u00a0empfohlen.\u00a0Interferon\u2010freie\u00a0Tripel\u2010Therapi en\u00a0zusammen\u00a0\nmit\u00a0Sofosbuvir\u00a0+\u00a0Ribavirin\u00a0kommen\u00a0bei\u00a0HCV\u2010Infektionen\u00a0mit\u00a0diese n\u00a0Genotypen\u00a0und\u00a0\nzus\u00e4tzlicher\u00a0Zirrhose\u00a0oder\u00a0bei\u00a0rezidivierenden\u00a0Krankheitsf\u00e4llen \u00a0nach\u00a0Lebertrans\u2010\nplantation\u00a0in\u00a0Frage.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a04\u2010Infektion\u00a0ohne\u00a0 Zirrhose\u00a0oder\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose\u00a0kann\u00a0alternativ\u00a0eine\u00a0Duotherapie\u00a0aus\u00a0Dac latasvir\u00a0und\u00a0So\u2010\nfosbuvir\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0oder\u00a0auch\u00a0ein\u00a0Interferon\u2010basiertes\u00a0T ripelregime,\u00a0be\u2010\nstehend\u00a0aus\u00a0Daclatasvir,\u00a0Peginte rferon\u00a0und\u00a0Ribavirin,\u00a0\u00fcber\u00a024\u00a0W ochen\u00a0eingesetzt\u00a0\nwerden.\u00a0Daclatasvir\u00a0darf\u00a0wegen\u00a0d er\u00a0Gefahr\u00a0sich\u00a0leicht\u00a0ausbilden der\u00a0Resistenzen\u00a0\nnicht\u00a0als\u00a0Monotherapeutikum\u00a0angewendet\u00a0werden\u00a0(EMA,\u00a02014;\u00a0BMS,\u00a0 2016).\u00a0\nBeim\u00a0Einsatz\u00a0von\u00a0Daclatasvir\u00a0sind\u00a0Interaktionen\u00a0mit\u00a0der\u00a0Begleit medikation\u00a0zu\u00a0be\u2010\nachten.\u00a0Starke\u00a0Induktoren\u00a0von\u00a0Isoenzym\u00a0Cytochrom\u00a0P450\u00a03A4\u00a0(CYP3 A4)\u00a0und\u00a0P\u2010Gly\u2010\nkoprotein \u00a0(P\u2010GP)\u00a0 wie\u00a0 Phenytoin,\u00a0 Carbamazepi n,\u00a0 Oxcarbazepin,\u00a0 Phenobarbital, \u00a0\nRifampicin,\u00a0Rifabutin,\u00a0Rifapent in\u00a0und\u00a0Johanniskraut\u00a0k\u00f6nnen\u00a0zu\u00a0e inem\u00a0Wirksam\u2010\nkeitsverlust\u00a0des\u00a0Virusstatikums\u00a0f\u00fchren.\u00a0Die\u00a0gemeinsame\u00a0Verabrei chung\u00a0ist\u00a0daher\u00a0\nkontraindiziert\u00a0(BMS,\u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0HC\u00a0ist\u00a0eine\u00a0weltweit\u00a0vorkommende\u00a0virale\u00a0Infektion,\u00a0die\u00a0als\u00a0 akute\u00a0wie\u00a0auch\u00a0\nchronische\u00a0Form\u00a0in\u00a0Erscheinung\u00a0tritt.\u00a0Verursacht\u00a0wird\u00a0die\u00a0Erkra nkung\u00a0durch\u00a0das\u00a0zu\u00a0\nder\u00a0Gruppe\u00a0der\u00a0RNA\u2010Viren\u00a0geh\u00f6rende\u00a0HCV,\u00a0von\u00a0dem\u00a0derzeit\u00a07\u00a0Genot ypen\u00a0mit\u00a067\u00a0\nSubtypen\u00a0bekannt\u00a0sind.\u00a0Weltweit\u00a0ist\u00a0GT\u00a01\u00a0der\u00a0h\u00e4ufigste\u00a0Genotyp\u00a0 (46\u00a0%),\u00a0gefolgt\u00a0\nvon\u00a0GT\u00a03\u00a0(30\u00a0%).\u00a0Die\u00a0GT\u00a02,\u00a04\u00a0und\u00a06\u00a0sind\u00a0verantwortlich\u00a0f\u00fcr\u00a0insg esamt\u00a023\u00a0%\u00a0der\u00a0\nErkrankungsf\u00e4lle.\u00a0Genotyp\u00a05\u00a0spielt\u00a0nur\u00a0eine\u00a0sehr\u00a0untergeordnete \u00a0Rolle\u00a0(<\u00a01\u00a0%).\u00a0In\u00a0\nden\u00a0meisten\u00a0europ\u00e4ischen\u00a0L\u00e4ndern\u00a0ist\u00a0beim\u00a0GT\u00a01\u00a0der\u00a0am\u00a0h\u00e4ufigste n\u00a0vorkommende\u00a0\nSubtyp\u00a01b,\u00a0wohingegen\u00a0in\u00a0Nordame rika,\u00a0Gro\u00dfbritannien,\u00a0Skandinav ien\u00a0und\u00a0Austra\u2010\nlien\u00a0der\u00a0GT\u00a01a\u00a0am\u00a0weitesten\u00a0verbreitet\u00a0ist\u00a0(RKI,\u00a02016).\u00a0\nIn\u00a0Europa\u00a0leben\u00a0ca.\u00a02\u00a0bis\u00a05\u00a0Mio.\u00a0HCV\u2010positive\u00a0Menschen.\u00a0Als\u00a0Ris ikogruppen\u00a0mit\u00a0\nbesonders\u00a0hoher\u00a0Krankheitspr\u00e4valenz\u00a0gelten\u00a0intraven\u00f6se\u00a0Drogenan wender,\u00a0M\u00e4n\u2010\nner,\u00a0die\u00a0mit\u00a0M\u00e4nnern\u00a0Sex\u00a0haben\u00a0(MSM),\u00a0Dialysepatienten,\u00a0Persone n,\u00a0die\u00a0vor\u00a0den\u00a0\n1990er\u00a0Jahren\u00a0h\u00e4ufig\u00a0Transfusionen\u00a0oder\u00a0vor\u00a0Ende\u00a0der\u00a01980er\u00a0Jah re\u00a0Plasmaderi\u2010\nvate\u00a0erhielten\u00a0(RKI,\u00a02014a).\u00a0In\u00a0Deutschland\u00a0liegt\u00a0die\u00a0Pr\u00e4valenz \u00a0mit\u00a00,3\u00a0%\u00a0im\u00a0inter\u2010127\u00a0nationalen\u00a0Vergleich\u00a0sehr\u00a0niedri g.\u00a0Pro\u00a0Jahr\u00a0muss\u00a0aber\u00a0auch\u00a0hier zulande\u00a0mit\u00a0ca.\u00a0\n5.000\u00a0Neuinfektionen\u00a0gerechnet\u00a0werden\u00a0(RKI,\u00a02016).\u00a0\u00a0\nDie\u00a0\u00dcbertragung\u00a0geschieht\u00a0fast\u00a0ausschlie\u00dflich\u00a0\u00fcber\u00a0Blut.\u00a0In\u00a075\u00a0 %\u00a0der\u00a0F\u00e4lle\u00a0verl\u00e4uft\u00a0\ndie\u00a0Infektion\u00a0unbemerkt.\u00a025\u00a0%\u00a0der\u00a0Infizierten\u00a0entwickeln\u00a0eine\u00a0a kute\u00a0Hepatitis\u00a0mit\u00a0\nunspezifischen\u00a0Beschwerden\u00a0und\u00a0Ei nschr\u00e4nkungen\u00a0der\u00a0Leberfunktio n.\u00a0Fulminante\u00a0\nVerl\u00e4ufe\u00a0sind\u00a0selten\u00a0(Thimme\u00a0et\u00a0al.,\u00a02014).\u00a0Symptomatisch\u00a0verla ufende\u00a0akute\u00a0He\u2010\npatitiden\u00a0zeigen\u00a0eine\u00a0Immunreaktion\u00a0der\u00a0Betroffenen\u00a0an,\u00a0was\u00a0die \u00a0Rate\u00a0an\u00a0Spon\u2010\ntanheilung\u00a0erh\u00f6ht:\u00a0Etwa\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0akut\u00a0verlaufenden\u00a0HCV\u2010In fektionen\u00a0heilt\u00a0\nspontan\u00a0aus,\u00a0w\u00e4hrend\u00a0es\u00a0bei\u00a0den\u00a0asymptomatischen\u00a0Verl\u00e4ufen\u00a0ledi glich\u00a0ca.\u00a030\u00a0%\u00a0\nsind.\u00a0Zwischen\u00a050\u00a0und\u00a085\u00a0%\u00a0aller\u00a0Ak utinfektionen\u00a0gehen\u00a0in\u00a0eine\u00a0 chronische\u00a0HC\u00a0\n\u00fcber,\u00a0die\u00a0durch\u00a0eine\u00a0st\u00e4ndige\u00a0Ver mehrung\u00a0von\u00a0HCV\u00a0gekennzeichnet \u00a0ist.\u00a0Innerhalb\u00a0\nvon\u00a020\u00a0bis\u00a030\u00a0Jahren\u00a0kommt\u00a0es\u00a0bei\u00a02\u00a0bis\u00a035\u00a0%\u00a0der\u00a0Betroffenen\u00a0zu \u00a0einer\u00a0Leberzir\u2010\nrhose.\u00a0Bei\u00a0diesen\u00a0Patienten\u00a0k\u00f6nnen\u00a0Lebertransplantationen\u00a0leben srettend\u00a0sein.\u00a0\nPro\u00a0Jahr\u00a0entwickeln\u00a0etwa\u00a02\u00a0bis\u00a04\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0Leberzirrh ose\u00a0ein\u00a0Leberzell\u2010\nkarzinom\u00a0(RKI,\u00a02014b).\u00a0\nIn\u00a0zahlreichen\u00a0F\u00e4llen\u00a0ist\u00a0der\u00a0genaue\u00a0\u00dcbertragungsweg\u00a0nicht\u00a0fest stellbar.\u00a0Aktuelle\u00a0\nAnalysen\u00a0geben\u00a0an,\u00a0dass\u00a0bei\u00a0den\u00a0F\u00e4llen,\u00a0denen\u00a0ein\u00a0\u00dcbertragungsw eg\u00a0h\u00f6chstwahr\u2010\nscheinlich\u00a0zugeordnet\u00a0werden\u00a0konnte,\u00a076\u00a0%\u00a0auf\u00a0intraven\u00f6sen\u00a0Drog enkonsum\u00a0zu\u2010\nr\u00fcckzuf\u00fchren\u00a0sind,\u00a08\u00a0%\u00a0auf\u00a0MSM,\u00a08\u00a0%\u00a0auf\u00a0den\u00a0Erhalt\u00a0von\u00a0Blutprod ukten,\u00a06\u00a0%\u00a0auf\u00a0\nheterosexuellen\u00a0Kontakt\u00a0mit\u00a0HCV\u2010Infizierten,\u00a01,5\u00a0%\u00a0auf\u00a0Dialyse\u00a0 und\u00a00,5\u00a0%\u00a0auf\u00a0eine\u00a0\nperinatale\u00a0\u00dcbertragung\u00a0(RKI,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIn\u00a0systematischen\u00a0\u00dcbersichtsarbeiten\u00a0werden\u00a0Vorteile\u00a0von\u00a0Interf eron\u2010basierten\u00a0\nTripeltherapien\u00a0mit\u00a0Daclatasvir\u00a0 gegen\u00fcber\u00a0Peginte rferon\u00a0+\u00a0Ribav irin\u00a0bei\u00a0HCV\u2010Infek\u2010\ntionen\u00a0GT\u00a01\u00a0aufgezeigt\u00a0(Suwantha wornkul\u00a0et\u00a0al.,\u00a02016;\u00a0Peng\u00a0et\u00a0a l.\u00a02016).\u00a0F\u00fcr\u00a0GT\u00a03\u00a0\ngeh\u00f6rt\u00a0die\u00a0Interferon\u2010freie\u00a0Tripeltherapie\u00a0bestehend\u00a0aus\u00a0Daclat asvir,\u00a0Sofosbuvir\u00a0\nund\u00a0Ribavirin\u00a0\u00fcber\u00a012\u00a0Wochen\u00a0(ohne\u00a0Zirrhose)\u00a0bzw.\u00a0\u00fcber\u00a024\u00a0Woche n\u00a0(mit\u00a0Zirrhose)\u00a0\naktuellen\u00a0systematischen\u00a0Analysen\u00a0zufolge\u00a0zu\u00a0den\u00a0Regimen\u00a0mit\u00a0de m\u00a0h\u00f6chsten\u00a0\ndauerhaften\u00a0virologischen\u00a0Ansprechen\u00a0(Berden\u00a0et\u00a0al.,\u00a02017;\u00a0Gime no\u2010Ballester\u00a0et\u00a0\nal.,\u00a02016,\u00a0Nelson\u00a0et\u00a0al.,\u00a02015).\u00a0Die\u00a0Interferon\u2010basierte\u00a0Tripel therapie\u00a0mit\u00a0hochdo\u2010\nsiertem\u00a0Daclatasvir\u00a0(60\u00a0mg)\u00a0zeigt\u00a0gegen\u00fcber\u00a0Peginterferon\u00a0+\u00a0Rib avirin\u00a0allein\u00a0bei\u00a0\nPatienten\u00a0mit\u00a0HCV\u00a0GT\u00a04\u00a0hohe\u00a0virologische\u00a0Ansprechraten\u00a0(100\u00a0%\u00a0v ersus\u00a050\u00a0%;\u00a0\nH\u00e9zode\u00a0et\u00a0al.,\u00a02014).\u00a0F\u00fcr\u00a0dar\u00fcbe r\u00a0hinausgehende\u00a0Empfehlungen\u00a0vo n\u00a0Daclatasvir\u2010\nTherapieregimen\u00a0fehlen\u00a0ausreiche nde\u00a0Daten\u00a0aus\u00a0klinischen\u00a0Studie n.\u00a0\u00a0\nAufgrund\u00a0von\u00a0Hinweisen\u00a0auf\u00a0eine\u00a0schwerwiegende\u00a0Interaktion\u00a0wird \u00a02015\u00a0von\u00a0der\u00a0\nEMA\u00a0ein\u00a0Warnhinweis\u00a0f\u00fcr\u00a0die\u00a0geme insame\u00a0Anwendung\u00a0von\u00a0Daclatasvi r\u00a0+\u00a0Sofosbu\u2010\nvir\u00a0mit\u00a0Amiodaron\u00a0ver\u00f6ffentlicht:\u00a0Mehrere\u00a0Fallberichte\u00a0weisen\u00a0d arauf\u00a0hin,\u00a0dass\u00a0das\u00a0128\u00a0Risiko\u00a0einer\u00a0schweren\u00a0Bradykardi e\u00a0oder\u00a0eines\u00a0Herzblocks\u00a0ansteig t,\u00a0wenn\u00a0diese\u00a0\nMittel\u00a0 gemeinsam\u00a0 verabreicht\u00a0 werden.\u00a0 Auf\u00a0 Amiodaron\u00a0 als\u00a0 Antiarrt hythmikum\u00a0\nsollte\u00a0daher\u00a0weitestgehend\u00a0verzichtet\u00a0werden.\u00a0Wenn\u00a0dies\u00a0nicht\u00a0m \u00f6glich\u00a0ist,\u00a0muss\u00a0\ndie\u00a0Herzfunktion\u00a0der\u00a0Betroffenen\u00a0w\u00e4hrend\u00a0der\u00a0Behandlung\u00a0engmasc hig\u00a0\u00fcberwacht\u00a0\nwerden\u00a0(EMA,\u00a02015).\u00a0\nVor\u00a0dem\u00a0Einsatz\u00a0direkt\u00a0antiviral\u00a0wirkender\u00a0Mittel\u00a0bei\u00a0HC\u2010Patien ten\u00a0ist\u00a0zudem\u00a0zu\u00a0\nbedenken,\u00a0 dass\u00a0 die\u00a0 Gabe\u00a0 von\u00a0 NS5A\u2010Inhibitoren\u00a0 wie\u00a0 Daclatasvir,\u00a0 L edipasvir\u00a0 oder\u00a0\nVelpatasvir\u00a0in\u00a0Kombination\u00a0mit\u00a0Sofosbuvir\u00a0und\u00a0ggf.\u00a0Ribavirin,\u00a0d ie\u00a0einen\u00a0prim\u00e4ren\u00a0\nrenalen\u00a0Metabolisierungsweg\u00a0aufweisen,\u00a0bei\u00a0Patienten\u00a0mit\u00a0dekomp ensierter\u00a0Zirrho\u2010\nse\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Infektionen\u00a0und\u00a0Laktatazidosen\u00a0ansteigen\u00a0lass en\u00a0kann\u00a0(DGVS,\u00a02016).\u00a0\u00a0\n2016\u00a0empfiehlt\u00a0die\u00a0EMA\u00a0vor\u00a0Beginn\u00a0einer\u00a0antiviralen\u00a0Behandlung\u00a0 der\u00a0chronischen\u00a0\nHepatitis\u00a0 B\u00a0 mit\u00a0 Sofosbuvir,\u00a0 Daclatasvir,\u00a0 Simeprevir,\u00a0 Ledipasvir ,\u00a0 Dasabuvir\u00a0 oder\u00a0\nOmbitasvir\u00a0grunds\u00e4tzlich\u00a0ein\u00a0Scr eening\u00a0auf\u00a0eine\u00a0Koinfektion\u00a0mit \u00a0Hepatitis\u00a0B.\u00a0Bei\u00a0\nHepatitis\u00a0B/Hepatitis\u00a0C\u2010Coinfekt ionen\u00a0hemmen\u00a0HCV\u00a0die\u00a0Aktivit\u00e4t\u00a0 und\u00a0Vermehrung\u00a0\nvon\u00a0 Hepatitis\u2010B\u2010Viren.\u00a0 Die\u00a0 spezi fisch\u00a0 wirkende\u00a0 antivirale\u00a0 Behan dlung\u00a0 sorgt\u00a0 f\u00fcr\u00a0\neinen\u00a0raschen\u00a0Abfall\u00a0von\u00a0HCV\u00a0und\u00a0f\u00fchrt\u00a0damit\u00a0zu\u00a0einer\u00a0Reaktivie rung\u00a0von\u00a0Hepati\u2010\ntis\u2010B\u2010Viren\u00a0(EMA,\u00a02016).\u00a0Coinfizierte\u00a0Patienten\u00a0m\u00fcssen\u00a0f\u00fcr\u00a0die\u00a0 Zeit\u00a0der\u00a0Behandlung\u00a0\neng\u00a0monitoriert\u00a0werden,\u00a0gegebenfalls\u00a0ist\u00a0eine\u00a0zus\u00e4tzliche\u00a0antiv irale\u00a0Behandlung\u00a0\nder\u00a0Hepatitis\u00a0B\u00a0erforderlich.\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0aktuelle\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroent erologie,\u00a0Verdau\u2010\nungs\u2010\u00a0und\u00a0Stoffwechselkrankheiten\u00a0 (DGVS,\u00a02016)\u00a0empfiehlt\u00a0f\u00fcr\u00a0di e\u00a0Ersttherapie\u00a0bei\u00a0\nHC\u00a0 ein\u00a0 Interferon\u2010freies\u00a0 Therapieregime.\u00a0 Da\u00a0 bei\u00a0 Kombinationsbeh andlung\u00a0 mit\u00a0\nRibavirin\u00a0mit\u00a0mehr\u00a0Nebenwirkungen\u00a0und\u00a0Intoleranzen\u00a0zu\u00a0rechnen\u00a0i st,\u00a0soll\u00a0bei\u00a0glei\u2010\ncher\u00a0Wirksamkeit\u00a0zudem\u00a0stets\u00a0eine\u00a0Therapieoption\u00a0ohne\u00a0Ribavirin \u00a0gew\u00e4hlt\u00a0wer\u2010\nden.\u00a0Es\u00a0wird\u00a0darauf\u00a0hingewiesen,\u00a0dass\u00a0die\u00a0Therapieauswahl\u00a0unter \u00a0Ber\u00fccksichtigung\u00a0\ndes\u00a0Zirrhosestatus,\u00a0des\u00a0Vortherapiestatus,\u00a0der\u00a0Komedikation\u00a0und \u00a0gegebenfalls\u00a0der\u00a0\nKomorbidit\u00e4ten\u00a0z u\u00a0erfolgen\u00a0hat.\u00a0\nDer\u00a0NS5A\u2010Inhibitor\u00a0Daclatasvir\u00a0ka nn\u00a0zur\u00a0Erst\u2010\u00a0und\u00a0Re\u2010Therapie\u00a0e iner\u00a0cHC\u00a0mit\u00a0Geno\u2010\ntyp\u00a01\u00a0bis\u00a06\u00a0eingesetzt\u00a0werden.\u00a0In\u00a0der\u00a0Leitlinie\u00a0wird \u00a0\u2013\u00a0allerdings\u00a0auf\u00a0einem\u00a0im\u00a0Ver\u2010\ngleich\u00a0zu\u00a0anderen\u00a0Therapieempfeh lungen\u00a0geringerem\u00a0Evidenzniveau \u00a0\u2013\u00a0das\u00a0direkt\u00a0\nantiviral\u00a0wirkende\u00a0Mittel\u00a0in\u00a0Kombination\u00a0mit\u00a0Sofosbuvir\u00a0+/\u2010\u00a0Rib avirin\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0\nWochen\u00a0als\u00a0Therapeoption\u00a0bei\u00a0Infektionen\u00a0mit\u00a0HCV\u00a0GT\u00a01\u00a0ohne\u00a0Zirr hose\u00a0genannt.\u00a0\nDie\u00a0zugrunde\u00a0liegende\u00a0Evidenz\u00a0umfasst\u00a0mehrere\u00a0kleine\u00a0Phase\u00a0II\u2010\u00a0 sowie\u00a0zwei\u00a0eben\u2010\nfalls\u00a0kleine\u00a0Phase\u00a0III\u2010Studien.\u00a0F\u00fcr\u00a0Infektionen\u00a0mit\u00a0HCV\u00a0GT\u00a03\u00a0wi rd\u00a0bei\u00a0Patienten\u00a0ohne\u00a0\nLeberzirrhose\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0regionaler\u00a0Resistenzen\u00a0ein e\u00a0duale\u00a0Therapie\u00a0\nmit\u00a0Daclatasvir\u00a0plus\u00a0Sofosbuvir\u00a0f\u00fcr\u00a0zw\u00f6lf\u00a0Wochen\u00a0empfohlen.\u00a0Hie rf\u00fcr\u00a0liegt\u00a0hoch\u2010129\u00a0wertige\u00a0Evidenz\u00a0vor.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a03\u00a0und\u00a0Leberzirrho se\u00a0kann\u00a0eine\u00a0\nTripeltherapie\u00a0mit\u00a0Ribavirin\u00a0sowie\u00a0eine\u00a0Verl\u00e4ngerung\u00a0der\u00a0Therap iedauer\u00a0das\u00a0viro\u2010\nlogische\u00a0Ansprechen\u00a0verbessern.\u00a0 Als\u00a0Therapieoption\u00a0wird\u00a0eine\u00a0Be handlung\u00a0mit\u00a0\nDaclatasvir\u00a0+\u00a0Sofosbuvir\u00a0gegebenenfalls\u00a0zusammen\u00a0mit\u00a0Ribavirin\u00a0 auch\u00a0f\u00fcr\u00a0Patien\u2010\nten\u00a0mit\u00a0HCV\u00a0GT\u00a04\u00a0genannt.\u00a0Allerdings\u00a0bezieht\u00a0sich\u00a0diese\u00a0Darstel lung\u00a0auf\u00a0geringe\u00a0\nPatientenzahlen,\u00a0 andere\u00a0 Therapi eregime\u00a0 sind\u00a0 besser\u00a0 evaluiert.\u00a0 D as\u00a0 dauerhafte\u00a0\nvirologische\u00a0Ansprechen\u00a0auf\u00a0Dacl atasvir\u00a0wird\u00a0ma\u00dfgeblich\u00a0durch\u00a0e ine\u00a0pr\u00e4existie\u2010\nrende\u00a0NS5A\u2010Variante\u00a0Y93H\u00a0beschr \u00e4nkt.\u00a0Dass\u00a0in\u00a0diesem\u00a0Fall\u00a0eine\u00a0T ripeltherapie\u00a0mit\u00a0\nRibavirin\u00a0das\u00a0Therapieergebnis\u00a0verbessert,\u00a0wird\u00a0vermutet,\u00a0ist\u00a0a ber\u00a0bisher\u00a0nicht\u00a0\nbelegt.\u00a0Die\u00a0kombinierte\u00a0Anwendung\u00a0von\u00a0Daclatasvir\u00a0plus\u00a0Sofosbuv ir\u00a0+/\u2010\u00a0Ribavirin\u00a0\nwird\u00a0aufgrund\u00a0besser\u00a0untersuchter\u00a0Therapiem\u00f6glichkeiten\u00a0nur\u00a0noc h\u00a0in\u00a0Ausnahme\u2010\nf\u00e4llen\u00a0bei\u00a0Patienten\u00a0mit\u00a0Leberzirrhose\u00a0empfohlen.\u00a0F\u00fcr\u00a0Patienten \u00a0mit\u00a0HCV\u00a0GT\u00a02,\u00a05\u00a0\nund\u00a06\u00a0wird\u00a0aufgrund\u00a0der\u00a0insgesamt\u00a0unzureichenden\u00a0Evidenz\u00a0keine\u00a0 Therapieemp\u2010\nfehlung\u00a0f\u00fcr\u00a0Daclatasvir\u00a0ausgesprochen.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDaclatasvir\u00a0wurde\u00a0Ende\u00a02014\u00a0durch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und \u00a0Wirtschaftlichkeit\u00a0im\u00a0\nGesundheitswesen\u00a0(IQWiG)\u00a0begutachtet.\u00a0Als\u00a0zVT\u00a0war\u00a0beispielsweis e\u00a0bei\u00a0HCV\u00a0GT\u00a01\u00a0\ndie\u00a0 duale\u00a0 Therapie\u00a0 (Kombination\u00a0 aus\u00a0 Peginterferon\u00a0 alfa\u00a0 und\u00a0 Riba virin)\u00a0 oder\u00a0 die\u00a0\u00a0\nTriple\u2010Therapie\u00a0(Kombination\u00a0aus\u00a0einem\u00a0Proteaseinhibitor\u00a0(Bocep revir\u00a0oder\u00a0Tela\u2010\nprevir),\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin)\u00a0\u00fcber\u00a024\u00a0bis\u00a048\u00a0Woche n\u00a0vorgesehen.\u00a0Die\u00a0\nKombination\u00a0von\u00a0Daclatasvir\u00a0und\u00a0 Sofosbuvir\u00a0sollte\u00a0dagegen\u00a0ledig lich\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0\nvon\u00a0Krankheitsdauer\u00a0und\u00a0\u2010fortschritt\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0bis\u00a024\u00a0Wochen\u00a0a ngewendet\u00a0werden.\u00a0\nAufgrund\u00a0mangelnder\u00a0Daten\u00a0und\u00a0methodischer\u00a0M\u00e4ngel\u00a0konnte\u00a0das\u00a0IQ WiG\u00a0in\u00a0seinem\u00a0\nersten\u00a0Zusatznutzendossier\u00a0f\u00fcr\u00a0Daclatasvir\u00a0in\u00a0 keinem\u00a0seiner\u00a0zugelassenen\u00a0Indikati\u2010\nonsgebiete\u00a0einen\u00a0Zusatznutzen\u00a0feststellen \u00a0(IQWiG,\u00a02014).\u00a0Zu\u00a0einem\u00a0sp\u00e4teren\u00a0Zeit\u2010\npunkt\u00a0 wird\u00a0 allerdings\u00a0 nach\u00a0 der\u00a0 Vorlage\u00a0 neuerer\u00a0 Studiendaten\u00a0 f\u00fcr \u00a0 therapienaive\u00a0\nPatienten\u00a0mit\u00a0GT\u00a04\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0 nicht\u00a0quantifizierbaren\u00a0Zusatznutzen \u00a0\nvon\u00a0Daclatasvir\u00a0in\u00a0Kombination\u00a0mit\u00a0Peginterferon\u00a0und\u00a0Ribavirin\u00a0 im\u00a0Vergleich\u00a0zur\u00a0zVT\u00a0\nattestiert\u00a0(IQWiG,\u00a02015).\u00a0\u00a0\nDemgegen\u00fcber\u00a0wird\u00a0vom\u00a0G\u2010BA\u00a0auf\u00a0Ba sis\u00a0eines\u00a0indirekten\u00a0Vergleich es\u00a0die\u00a0M\u00f6glich\u2010\nkeit\u00a0einer\u00a0Interferon\u2010freien\u00a0Therapie\u00a0mit\u00a0Daclatasvir\u00a0gegen\u00fcber \u00a0der\u00a0Interferon\u2010hal\u2010\ntigen\u00a0zVT\u00a0als\u00a0relevant\u00a0hinsichtlich\u00a0der\u00a0Vermeidung\u00a0von\u00a0UAE\u00a0bewe rtet.\u00a0In\u00a0der\u00a0Ge\u2010\nsamtbewertung\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0daher\u00a0einen\u00a0 Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0 geringen\u00a0Zu\u2010\nsatznutzen \u00a0durch\u00a0Daclatasvir\u00a0bei\u00a0therapienaiven\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01\u00a0oh ne\u00a0\nZirrhose.\u00a0Der\u00a0Verzicht\u00a0auf\u00a0einen\u00a0qualitativ\u00a0hochwertigen\u00a0Studie nbeleg\u00a0f\u00fcr\u00a0ein\u00a0pati\u2010\nentenrelevantes\u00a0Ergebnis\u00a0bei\u00a0diesem\u00a0Patientenkollektiv\u00a0wird\u00a0mit \u00a0der\u00a0Schwere\u00a0der\u00a0\nErkrankung\u00a0und\u00a0ihrer\u00a0Progredienz\u00a0sowie\u00a0dem\u00a0Nebenwirkungsrisiko\u00a0 bereits\u00a0beste\u2010\nhender\u00a0Therapieoptionen\u00a0erkl\u00e4rt.\u00a0 Kein\u00a0Zusatznutzen \u00a0wird\u00a0hingegen\u00a0f\u00fcr\u00a0therapie\u2010\nnaive\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01\u00a0und\u00a0 kompensierter\u00a0Zirrhose\u00a0sowie\u00a0f \u00fcr\u00a0therapieerfah\u2010130\u00a0rene\u00a0Patienten\u00a0mit\u00a0diesem\u00a0Genotyp\u00a0gesehen.\u00a0 Ein\u00a0Zusatznutzen\u00a0ist\u00a0ebenfalls\u00a0nicht\u00a0\nbelegt\u00a0f\u00fcr\u00a0therapienaive\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a03\u00a0und\u00a0kompensierter\u00a0Zir rhose\u00a0so\u2010\nwie\u00a0f\u00fcr\u00a0therapieerfahrene\u00a0Patien ten\u00a0mit\u00a0HCV\u00a0GT\u00a03.\u00a0Sowohl\u00a0f\u00fcr\u00a0th erapienaive\u00a0als\u00a0\nauch\u00a0f\u00fcr\u00a0therapieerfahrene\u00a0Patienten\u00a0mit\u00a0HCV\u00a0Genotyp\u00a04\u00a0wird\u00a0auf \u00a0Basis\u00a0der\u00a0vorlie\u2010\ngenden\u00a0Studienbelege\u00a0f\u00fcr\u00a0die\u00a0Interferon\u2010freie\u00a0Therapie\u00a0mit\u00a0Dacl atasvir\u00a0kein\u00a0Zu\u2010\nsatznutzen\u00a0 gesehen.\u00a0 Lediglich\u00a0 f\u00fcr\u00a0 die\u00a0 Tripeltherapie\u00a0 mit\u00a0 Pegint erferon\u00a0 und\u00a0\nRibavirin\u00a0wird\u00a0bei\u00a0therapienaiven\u00a0Patienten\u00a0mit\u00a0HCV\u00a0Genotyp\u00a04\u00a0g egen\u00fcber\u00a0der\u00a0\nzweckm\u00e4\u00dfigen\u00a0dualen\u00a0Vergleichstherapie\u00a0ohne\u00a0Daclatasvir\u00a0 ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\neinen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0im\u00a0Hinblick\u00a0auf\u00a0das\u00a0dauerhafte\u00a0virologische\u00a0\nAnsprechen\u00a0reklamiert.\u00a0Die\u00a0vorliegenden\u00a0Studienergebnisse\u00a0sind\u00a0 allerdings\u00a0mit\u00a0\nhoher\u00a0Unsicherheit\u00a0belastet\u00a0(G\u2010BA,\u00a02014).\u00a0Bei\u00a0therapieerfahrene n\u00a0Patienten\u00a0mit\u00a0\ndiesem\u00a0 Genotyp\u00a0 kann\u00a0 die\u00a0 Interfer on\u2010basierte\u00a0 Tripeltherapie\u00a0 hing egen\u00a0 keinen\u00a0\nZusatznutzen\u00a0verzeichnen.\u00a0\u00a0\nVersorgungsanalysen\u00a0\nEs\u00a0ist\u00a0nur\u00a0eine\u00a0Packungsgr\u00f6\u00dfe\u00a0von\u00a0Daklinza\u00ae\u00a0im\u00a0Handel.\u00a0Wie\u00a0bei\u00a0 den\u00a0anderen\u00a0di\u2010\nrekt\u00a0antiviral\u00a0wirkenden\u00a0Neuzug\u00e4ngen\u00a0aus\u00a0dem\u00a0Jahr\u00a02014\u00a0ist\u00a0auch \u00a0bei\u00a0Daclatasvir\u00a0\ndirekt\u00a0nach\u00a0dem\u00a0Marktzugang\u00a0ein\u00a0deutlicher\u00a0Verordnungsgipfel\u00a0zu \u00a0erkennen,\u00a0der\u00a0\nallerdings\u00a0bereits\u00a0nach\u00a02\u00a0Monaten\u00a0wieder\u00a0abflacht.\u00a0Bei\u00a0der\u00a0Gesc hlechterbetrach\u2010\ntung\u00a0ist\u00a0zu\u00a0erkennen,\u00a0dass\u00a0das\u00a0Mittel\u00a0gleicherma\u00dfen\u00a0an\u00a0Frauen\u00a0u nd\u00a0M\u00e4nner\u00a0verab\u2010\nreicht\u00a0wird,\u00a0mit\u00a0den\u00a0meisten\u00a0Verordnungen\u00a0in\u00a0der\u00a0Altersgruppe\u00a0d er\u00a050\u00a0bis\u00a060\u00a0J\u00e4h\u2010\nrigen.\u00a0Dabei\u00a0erhalten\u00a0M\u00e4nner\u00a0Dacl atasvir\u00a0deutlich\u00a0h\u00e4ufiger\u00a0als\u00a0 Frauen.\u00a0\u00a0\n\u00a0 \u00a0131\u00a0Abbildung\u00a04.5:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Daclatasvir\u00a0je\u00a0Mona t\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.6:\u00a0Versicherte\u00a0mit\u00a0 mind.\u00a0einer\u00a0Verordnung\u00a0Daclatasv ir\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n132\u00a0Quellen\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2012).\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0Geno typ\u00a01\u00a0\u2013\u00a0neue,\u00a0direkt\u00a0auf\u00a0die\u00a0Viren\u00a0wirkende\u00a0Arzneimittel.\u00a0AMB\u00a04 6,\u00a011a.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2016).\u00a0Bewertung: \u00a0Daclatasvir.\u00a0https://www.arznei\u2010\ntelegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Daclatasvir &ord=uaw,\u00a0letzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nBerden\u00a0FA,\u00a0Aaldering\u00a0BR,\u00a0Groenewoud\u00a0H,\u00a0IntHout\u00a0J,\u00a0Kievit\u00a0W,\u00a0Dre nth\u00a0JP\u00a0(2017).\u00a0Identification\u00a0of\u00a0the\u00a0Best\u00a0Direct\u2010Acting\u00a0Antivir al\u00a0\nRegimen\u00a0for\u00a0Patients\u00a0with\u00a0Hepatitis\u00a0C\u00a0Virus\u00a0Genotype\u00a03\u00a0Infectio n:\u00a0A\u00a0Systematic\u00a0Review\u00a0and\u00a0Network\u00a0Meta\u2010analysis.\u00a0\nClin\u00a0Gastroenterol\u00a0Hepatol.\u00a015(3):\u00a0349\u2010359.\u00a0\u00a0\nBMS\u00a0\u2013\u00a0Bristol\u2010Myers\u00a0Squibb\u00a0GmbH\u00a0&\u00a0Co.\u00a0KGaA\u00a0(2016).\u00a0Fachinformat ion\u00a0Daklinza\u00a0Filmtabletten.\u00a0Stand\u00a0September\u00a02016.\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten\u00a0u.a\u00a0(2016).\u00a0Aktuelle\u00a0Empfehlung\u00a0\nzur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C.\u00a0Stand\u00a0der\u00a0Information :\u00a0Dezember\u00a02016.\u00a0https://www.dgvs.de/wissen\u2010\nkompakt/leitlinien/leitlinien\u2010der\u2010dgvs/hepatitis\u2010c/,\u00a0letzter\u00a0Zu griff:\u00a008.03.2017.\u00a0\nDore\u00a0GJ,\u00a0Lawitz\u00a0E,\u00a0H\u00e9zode\u00a0C,\u00a0Shafran\u00a0SD,\u00a0Ramji\u00a0A,\u00a0Tatum\u00a0HA\u00a0et\u00a0a l.\u00a0(2015).\u00a0Daclatasvir\u00a0plus\u00a0pegin terferon\u00a0and\u00a0ribavirin\u00a0is\u00a0noni nferior\u00a0\nto\u00a0peginterferon\u00a0and\u00a0ribavirin\u00a0alone,\u00a0and\u00a0reduces\u00a0the\u00a0duration\u00a0 of\u00a0treatment\u00a0for\u00a0HCV\u00a0genotype\u00a02\u00a0or\u00a03\u00a0infection.\u00a0\nGastroenterology\u00a0148(2):\u00a0355\u2010366.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2014).\u00a0Committee\u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP )\u00a0Assessment\u00a0re port\u00a0Daklinza\u00a0\nInternational\u00a0non\u2010proprietary\u00a0name:\u00a0Daclatasvir.\u00a0Procedure\u00a0No.\u00a0 EMEA/H/C/003768/0000.\u00a026\u00a0June\u00a02014\u00a0\nEMA/419836/2014. \u00a0www.ema.europa.eu/docs/en_GB/document_library/ EPAR_\u2010\n_Public_assessment_report/human/003768/WC500172849.pdf,\u00a0letzter \u00a0Zugriff:\u00a020.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2015).\u00a0EMA\u00a0recommends\u00a0avoidanc e\u00a0of\u00a0certain\u00a0hepatitis\u00a0C\u00a0medicines\u00a0and\u00a0amiodarone\u00a0\ntogether.\u00a0Concomitant\u00a0use\u00a0may\u00a0increase\u00a0risk\u00a0of\u00a0slow\u00a0heart\u00a0rate\u00a0 and\u00a0related\u00a0problems.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news /2015/04/news_detail_002313.jsp&mid=\nWC0b01ac058004d5c1,\u00a0letzter\u00a0Zugriff:\u00a021.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Direct\u2010acting\u00a0antiviral s\u00a0for\u00a0hepatitis\u00a0C:\u00a0EMA\u00a0confirms\u00a0recommendation\u00a0to\u00a0screen\u00a0for\u00a0\nhepatitis\u00a0B.\u00a0Further\u00a0studies\u00a0needed\u00a0to\u00a0assess\u00a0risk\u00a0of\u00a0liver\u00a0can cer\u00a0with\u00a0these\u00a0medicines.\u00a0Press\u00a0release.\u00a0www.ema.eu\u00a0\nropa.eu/docs/en_GB/document_library/Press_release/2016/12/WC500 218204.pdf,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Daclatasvir.\u00a0 https://www.g\u2010ba.de/ \u00a0\ninformationen/nutzenbewertung/138/,\u00a0letzter\u00a0Zugriff\u00a020.03.2017. \u00a0\nGimeno\u2010Ballester\u00a0V,\u00a0Buti\u00a0M,\u00a0San\u00a0 Miguel\u00a0R,\u00a0Riveiro\u00a0M,\u00a0Esteban\u00a0R\u00a0 (2016).\u00a0Interferon\u2010free\u00a0therapies\u00a0for\u00a0patients\u00a0with\u00a0chronic\u00a0hep atitis\u00a0\nC\u00a0genotype\u00a03\u00a0infection:\u00a0A\u00a0systematic\u00a0review.\u00a0J\u00a0Viral\u00a0Hepat.\u00a0doi :\u00a010.1111/jvh.12660.\u00a0\nH\u00e9zode\u00a0C,\u00a0Hirschfield\u00a0GM,\u00a0Ghesquiere\u00a0W,\u00a0Sievert\u00a0W,\u00a0Rodriguez\u2010To rres\u00a0M,\u00a0Shafran\u00a0SD\u00a0et\u00a0al.\u00a0(2015).\u00a0 Daclatasvir\u00a0plus\u00a0peginterfero n\u00a0alfa\u00a0\nand\u00a0ribavirin\u00a0for\u00a0treatment\u2010naiv e\u00a0chronic\u00a0hepatitis\u00a0C\u00a0genotype\u00a0 1\u00a0or\u00a04\u00a0infection:\u00a0a\u00a0randomised\u00a0study.\u00a0Gut\u00a064(6):\u00a0948\u2010956.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2014).\u00a0Bericht\u00a0Nr.\u00a0261\u00a0Daclatasvir\u00a0\u2013\u00a0Nutzenbewertung \u00a0\ngem\u00e4\u00df\u00a0\u00a735a\u00a0SGB\u00a0V.\u00a0Auftrag:\u00a0A14\u201031\u00a0Version:\u00a01.0.\u00a0Stand:\u00a027.11.20 14.\u00a0\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2015).\u00a0Bericht\u00a0Nr.\u00a0276\u00a0Daclatasvir\u00a0(Addendum\u00a0zum\u00a0\nAuftrag\u00a0A14\u201031).\u00a0Auftrag:\u00a0A15\u201002,\u00a0Version\u00a01.0,\u00a0Stand\u00a029.01.2015 .\u00a0\nJacobson\u00a0I,\u00a0Zeuzem\u00a0S,\u00a0Flisiak\u00a0R,\u00a0 Knysz\u00a0B,\u00a0Lueth\u00a0S,\u00a0Zarebska\u2010Mic haluk\u00a0D\u00a0et\u00a0al.\u00a0(2016).\u00a0Daclatasvir\u00a0vs\u00a0telaprevir\u00a0plus\u00a0peginterf eron\u00a0\nalfa/ribavirin\u00a0for\u00a0hepatitis\u00a0C\u00a0v irus\u00a0genotype\u00a01.\u00a0World\u00a0J\u00a0Gastro enterol\u00a022(12):\u00a03418\u20103431.\u00a0\u00a0133\u00a0Leroy\u00a0V,\u00a0Angus\u00a0P,\u00a0Bronowicki\u00a0JP,\u00a0Dore\u00a0GJ,\u00a0Hezode\u00a0C,\u00a0Pianko\u00a0S\u00a0et \u00a0al.\u00a0(2016).\u00a0Daclatasvir,\u00a0sofosbuvir,\u00a0and\u00a0ribavirin\u00a0for\u00a0hepatit is\u00a0C\u00a0virus\u00a0\ngenotype\u00a03\u00a0and\u00a0advanced\u00a0liver\u00a0disease:\u00a0A\u00a0randomized\u00a0phase\u00a0III\u00a0s tudy\u00a0(ALLY\u20103+).\u00a0Hepatology\u00a063(5):\u00a01430\u20101441.\u00a0\u00a0\nNelson\u00a0DR,\u00a0Cooper\u00a0JN,\u00a0Lalezari\u00a0JP ,\u00a0Lawitz\u00a0E,\u00a0Pockros\u00a0PJ,\u00a0Gitlin \u00a0N\u00a0et\u00a0al.\u00a0(2015).\u00a0All\u2010oral\u00a012\u2010week \u00a0treatment\u00a0with\u00a0daclatasvir\u00a0p lus\u00a0sofosbuvir\u00a0\nin\u00a0patients\u00a0with\u00a0hepatitis\u00a0C\u00a0vir us\u00a0genotype\u00a03\u00a0infection:\u00a0ALLY\u20103 \u00a0phase\u00a0III\u00a0study.\u00a0Hepatology.61\u00a0(4):\u00a01127\u20101135.\u00a0\u00a0\nPeng\u00a0Q,\u00a0Li\u00a0K,\u00a0Cao\u00a0MR,\u00a0Bie\u00a0CQ,\u00a0Tang\u00a0HJ,\u00a0Tang\u00a0SH\u00a0(2016).\u00a0Daclatas vir\u00a0combined\u00a0with\u00a0peginterferon\u2010\u03b1\u00a0and\u00a0ribavirin\u00a0for\u00a0the\u00a0treatme nt\u00a0\nof\u00a0chronic\u00a0hepatitis\u00a0C:\u00a0a\u00a0meta\u2010a nalysis.\u00a0Springerplus\u00a05(1):\u00a0156 9.\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0Daclatasvir.\u00a0In\u00a0chronic\u00a0HCV\u00a0gen otype\u00a03\u00a0or\u00a04\u00a0infection.\u00a0Prescrire\u00a0Int\u00a024\u00a0(166):\u00a0290.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Daclatasvir.\u00a0www.ph armazeutische\u2010zeitung.de/index.php?id=54670,\u00a0letzter\u00a0Zugriff:\u00a0\n10.05.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014a).\u00a0Hepatitis\u00a0C\u00a0RKI\u2010Ratgeber\u00a0f\u00fc r\u00a0\u00c4rzte.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02014.\u00a0\nwww.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Hep atitisC.html,\u00a0letzter\u00a0Zugriff:\u00a009.02.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014b).\u00a0Virus\u2010Hepatitis\u00a0C:\u00a0Situatio nsbericht\u00a0Deutschland\u00a02013.\u00a0EpiBulletin\u00a02014;\u00a031(2014):275\u2010288. \u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016) .\u00a0Zur\u00a0Situation\u00a0bei\u00a0wichtigen\u00a0 Infektionskrankheiten\u00a0in\u00a0Deutschland\u00a0Hepatitis\u00a0C\u00a0im\u00a0Jahr\u00a02015.\u00a0\nEpiBulletin\u00a02016\u00a029(2016):255\u2010268.\u00a0\nSulkowski\u00a0MS,\u00a0Gardiner\u00a0DF,\u00a0Rodrig uez\u2010Torres\u00a0M,\u00a0Reddy\u00a0KR,\u00a0Hassan ein\u00a0T,\u00a0Jacobson\u00a0I\u00a0(2014).\u00a0Dacl atasvir\u00a0plus\u00a0sofosbuvir\u00a0for\u00a0\npreviously\u00a0treated\u00a0or\u00a0untreated\u00a0chronic\u00a0HCV\u00a0infection.\u00a0N\u00a0Engl\u00a0J \u00a0Med\u00a0370(3):\u00a0211\u2010221.\u00a0\u00a0\nSuwanthawornkul\u00a0T,\u00a0Anothaisintawee\u00a0T,\u00a0Sobhonslidsuk\u00a0A,\u00a0Thakkins tian\u00a0A,\u00a0Teerawattananon\u00a0Y\u00a0(2015).\u00a0Efficacy\u00a0of\u00a0Second\u00a0\nGeneration\u00a0Direct\u2010Acting\u00a0Antiviral\u00a0Agents\u00a0for\u00a0Treatment\u00a0Na\u00efve\u00a0H epatitis\u00a0C\u00a0Genotype\u00a01:\u00a0A\u00a0Systematic\u00a0Review\u00a0and\u00a0\nNetwork\u00a0Meta\u2010Analysis.\u00a0PLoS\u00a0One\u00a010\u00a0(12):\u00a0e0145953.\u00a0\u00a0\nThimme\u00a0R,\u00a0Heim\u00a0M,\u00a0Baumert\u00a0TF,\u00a0Nassal\u00a0M,\u00a0Moradpour\u00a0D\u00a0(2014).\u00a0Hep atitis\u00a0B\u00a0and\u00a0C:\u00a0from\u00a0molecular\u00a0virology\u00a0to\u00a0new\u00a0antiviral\u00a0\ntherapies\u00a0(part\u00a02).\u00a0Dtsch\u00a0Med\u00a0Wochenschr\u00a0139(15):\u00a0778\u2010782.\u00a0\nWang\u00a0C,\u00a0Jia\u00a0L,\u00a0O'Boyle\u00a0DR\u00a02nd,\u00a0Sun\u00a0JH,\u00a0Rigat\u00a0K,\u00a0Valera\u00a0L\u00a0et\u00a0al. \u00a0(2014).\u00a0Comparison\u00a0of\u00a0daclatasvi r\u00a0resistance\u00a0barriers\u00a0on\u00a0NS5A\u00a0 from\u00a0\nhepatitis\u00a0C\u00a0virus\u00a0genotypes\u00a01\u00a0to\u00a06:\u00a0implications\u00a0for\u00a0cross\u2010geno type\u00a0activity.\u00a0Antimicrob\u00a0Agents\u00a0Chemother.\u00a058(9):\u00a0\n5155\u20105163.\u00a0\nWyles\u00a0DL,\u00a0Ruane\u00a0PJ,\u00a0Sulkowski\u00a0MS,\u00a0Dieterich\u00a0D,\u00a0Luetkemeyer\u00a0A,\u00a0M organ\u00a0TR\u00a0et\u00a0al.\u00a0(2015).\u00a0Investigators.\u00a0Daclatasvir\u00a0plus\u00a0Sofosbu vir\u00a0\nfor\u00a0HCV\u00a0in\u00a0Patients\u00a0Coinfected\u00a0with\u00a0HIV\u20101.\u00a0NEJM\u00a0373(8):\u00a0714\u2010725 .\u00a0\u00a0\n\u00a0 \u00a0134\u00a04.8 Delamanid\u00a0\nHandelsname:\u00a0Deltyba\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Multiresistente\u00a0\u00a0 \u00a0 Otsuka\u00a0\nLungentuberkulose\u00a0\nATC\u2010Code:\u00a0J04AK06\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0April\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a00,2\u00a0g\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0O,\u00a0C,\u00a0 \u25bc \u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDelamanid\u00a0(Deltyba\u00ae)\u00a0hemmt\u00a0die\u00a0Synthese\u00a0der\u00a0Zellwandbestandteil e\u00a0Methoxy\u2010\u00a0und\u00a0\nKeto\u2010Mykols\u00e4ure\u00a0von\u00a0Mycobacterium\u00a0tuberculosis\u00a0(MTB).\u00a0Das\u00a0Nitro dihydroimida\u2010\nzooxazol\u00a0stellt\u00a0eine\u00a0neue\u00a0Therap ieoption\u00a0f\u00fcr\u00a0erwachsene\u00a0Patient en\u00a0mit\u00a0multiresis\u2010\ntenter\u00a0Lungentuberkulose\u00a0( Multi\u2010Drug\u00a0Resistant\u00a0Tuberculosis ,\u00a0MDR\u2010TB)\u00a0im\u00a0Rahmen\u00a0\neiner\u00a0geeigneten\u00a0Kombinationsbeh andlung\u00a0dar,\u00a0wenn\u00a0eine\u00a0andere\u00a0w irksame\u00a0Be\u2010\nhandlung\u00a0 aufgrund\u00a0 von\u00a0 Resistenzen\u00a0 oder\u00a0 aus\u00a0 Gr\u00fcnden\u00a0 der\u00a0 Vertr\u00e4gl ichkeit\u00a0 nicht\u00a0\nzusammengestellt\u00a0werden\u00a0kann\u00a0(CHMP,\u00a02014a).\u00a0\nNach\u00a0einem\u00a0ersten,\u00a0erfolglosen\u00a0Versuch\u00a0(CHMP,\u00a02013)\u00a0wurde\u00a0Delam anid\u00a0von\u00a0der\u00a0\nEurop\u00e4ischen\u00a0Kommission\u00a0(EC)\u00a0auf\u00a0Empfehlung\u00a0der\u00a0Europ\u00e4ischen\u00a0Zu lassungbeh\u00f6r\u2010\nde\u00a0(European\u00a0Medicines\u00a0Agency ,\u00a0EMA)\u00a0im\u00a0Kontext\u00a0eines\u00a0Mehrheitsbeschlusses\u00a0als\u00a0\nArzneimittel\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Leiden\u00a0( Orphan\u2010Arzneimittel)\u00a0(COMP,\u00a02014a;\u00a0\n2014b)\u00a0unter\u00a0besonderen\u00a0Bedingungen\u00a0sowie\u00a0zus\u00e4tzlicher,\u00a0engmasc higer\u00a0\u00dcberwa\u2010\nchung,\u00a0basierend\u00a0auf\u00a0Studiendaten\u00a0der\u00a0Phase\u00a0II,\u00a0am\u00a028.04.2014\u00a0z ugelassen\u00a0(EMA,\u00a0\n2014).\u00a0Im\u00a0Anhang\u00a0des\u00a0\u201eEurop\u00e4ischen\u00a0\u00f6ffentlichen\u00a0Beurteilungsber ichtes\u201c\u00a0(Euro\u2010\npean\u00a0Public\u00a0Assessment\u00a0Report ,\u00a0EPAR)\u00a0werden\u00a0aber\u00a0die\u00a0Bedenken\u00a0von\u00a0zw\u00f6lf\u00a0Mit\u2010\ngliedern\u00a0des\u00a0Ausschusses\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0Medicinal\u00a0Pro\u2010\nducts\u00a0for\u00a0Human\u00a0Use, \u00a0CHMP)\u00a0dokumentiert.\u00a0Obgleich\u00a0eine\u00a0Versorgungsl\u00fccke\u00a0( un\u2010\nmet\u00a0medical\u00a0need )\u00a0bei\u00a0Patienten\u00a0mit\u00a0MDR\u2010TB\u00a0bzw.\u00a0extensiv\u00a0resistenter\u00a0( Extensive\u00a0\nResistant, \u00a0XDR)\u00a0Lungentuberkulose\u00a0besteht,\u00a0konnten\u00a0diese\u00a0Mitglieder\u00a0des\u00a0C HMP\u00a0\neiner\u00a0Zulassung\u00a0von\u00a0Delamanid\u00a0nicht\u00a0 zustimmen.\u00a0Sie\u00a0f\u00fcrchten,\u00a0da ss\u00a0einerseits\u00a0\nkeine\u00a0angemessene\u00a0Tagesdosierung\u00a0v on\u00a0Delamanid\u00a0definiert\u00a0wurde\u00a0 und\u00a0somit\u00a0\nBehandlungserfolge\u00a0ausbleiben\u00a0sowie\u00a0die\u00a0Entwicklung\u00a0von\u00a0Resiste nzen.\u00a0Anderer\u2010\nseits\u00a0konnte\u00a0durch\u00a0die\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulassung\u00a0eingereichten\u00a0St udiendaten\u00a0nur\u00a0\nein\u00a0Therapieerfolg\u00a0\u00fcber\u00a0zwei\u00a0Monate,\u00a0nicht\u00a0jedoch\u00a0\u00fcber\u00a0die\u00a0bean tragte\u00a0Dauer\u00a0der\u00a0\nTherapie\u00a0von\u00a0sechs\u00a0Monaten\u00a0belegt\u00a0werden\u00a0(EMA,\u00a02014).\u00a0\nDer\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0musste\u00a0zudem\u00a0sowohl\u00a0f\u00fcr\u00a0\u00c4r zte\u00a0als\u00a0auch\u00a0\nf\u00fcr\u00a0 Patienten\u00a0 beh\u00f6rdlich\u00a0 beauftr agtes\u00a0 und\u00a0 genehmigtes\u00a0 Informati onsmaterial\u00a0\nerstellen\u00a0(Logo:\u00a0Blaue \u00a0Hand)\u00a0(BfArM,\u00a02017).\u00a0\n135\u00a0Delamanid\u00a0befindet\u00a0sich\u00a0als\u00a0Filmt ablette\u00a0mit\u00a050\u00a0mg\u00a0im\u00a0Handel,\u00a0d ie\u00a0empfohlene\u00a0\nDosierung\u00a0betr\u00e4gt\u00a0zweimal\u00a0t\u00e4g lich\u00a0100\u00a0mg\u00a0\u00fcber\u00a024\u00a0Wochen\u00a0(CHMP,\u00a0 2014a).\u00a0\nZulassungsbegr\u00fcndend\u00a0wurden\u00a0drei\u00a0vom\u00a0pU\u00a0gesponserte\u00a0Phase\u2010II\u2010St udien\u00a0vorge\u2010\nlegt.\u00a0Basierend\u00a0auf\u00a0einer\u00a0randomisierten,\u00a0placebokontrollierten \u00a0Studie\u00a0Trial\u00a0204\u00a0\nmit\u00a0Dauer\u00a0von\u00a0zwei\u00a0Monaten\u00a0und\u00a0einmonatiger\u00a0Nachbeobachtung,\u00a0ko nnten\u00a0die\u00a0\nProbanden\u00a0optional\u00a0an\u00a0einem\u00a0 open\u2010label\u00a0follow\u2010up \u00a0\u00fcber\u00a0sechs\u00a0Monate,\u00a0der\u00a0Studie\u00a0\nTrial\u00a0208,\u00a0teilnehmen.\u00a0Unabh\u00e4ngig\u00a0von\u00a0der\u00a0Teilnahme\u00a0an\u00a0 Trial\u00a0208, \u00a0erfolgte\u00a0eine\u00a0\nNachbeobachtung\u00a0\u00fcber\u00a024\u00a0Monate\u00a0nach\u00a0Einschluss\u00a0in\u00a0 Trial\u00a0204\u00a0in\u00a0Form\u00a0des\u00a0 Trial\u00a0\n116\u00a0(EMA,\u00a02014d).\u00a0\nDie\u00a0Zulassungsstudie\u00a0 Trial\u00a0204\u00a0(NCT00685360,\u00a0Sponsor:\u00a0Otsuka)\u00a0untersuchte\u00a0mul\u2010\ntizentrisch,\u00a0doppelblind,\u00a01:1:1\u00a0randomisiert\u00a0und\u00a0placebokontrol liert\u00a0in\u00a0Form\u00a0einer\u00a0\nPhase\u2010II\u2010Studie,\u00a0wie\u00a0hoch\u00a0der\u00a0Anteil\u00a0einer\u00a0Konversion\u00a0der\u00a0Sputu mkultur\u00a0( Sputum\u00a0\nCulture\u00a0Conversion ,\u00a0SCC)\u00a0im\u00a0Fl\u00fcssigkulturmedium\u00a0nach\u00a0zwei\u00a0Monaten\u00a0unter\u00a0der\u00a0\nGabe\u00a0von\u00a0Delamanid\u00a0zweimal\u00a0t\u00e4glich\u00a0in\u00a0der\u00a0Dosierung\u00a0100\u00a0mg\u00a0oder \u00a0200\u00a0mg\u00a0oder\u00a0\nPlacebo\u00a0 zus\u00e4tzlich\u00a0 zu\u00a0 einem\u00a0 optimierten\u00a0 Basistherapieregime\u00a0 ( Optimal\u00a0 Back\u2010\nground\u00a0Regimen ,\u00a0OBR)\u00a0nach\u00a0Empfehlungen\u00a0der\u00a0W HO\u00a0war.\u00a0Eingeschlossen\u00a0wurden\u00a0\nerwachsene\u00a0 Patienten\u00a0 zwischen\u00a0 18\u00a0 und\u00a0 64\u00a0 Lebensjahren\u00a0 mit\u00a0 MDR\u2010TB .\u00a0 Ausge\u2010\nschlossen\u00a0waren\u00a0Patienten\u00a0mit\u00a0Karnofsky\u00a0Score\u00a0unter\u00a050\u00a0%,\u00a0mit\u00a0H IV\u00a0(CD4+\u00a0Zellzahl\u00a0\nunter\u00a0350/ml\u00a0oder\u00a0unter\u00a0antiretroviraler\u00a0Therapie),\u00a0Patienten\u00a0u nter\u00a0Therapie\u00a0mit\u00a0\nAntiarrhythmika\u00a0 oder\u00a0 kardiovasku l\u00e4rer\u00a0 Erkrankung\u00a0 bzw.\u00a0 EKG\u2010Befun d\u00a0 QT\u2010\nZeitverl\u00e4ngerung\u00a0(Frauen\u00a0\u00fcber\u00a0470\u00a0msek\u00a0bzw.\u00a0M\u00e4nner\u00a0\u00fcber\u00a0450\u00a0mse k),\u00a0Arzneithe\u2010\nr a p i e \u00a0m i t \u00a0M o x i f l o x a c i n \u00a0s o w i e \u00a0d e n \u00a0 Standardausschlusskriterien\u00a0 Su bstanzmiss\u2010\nbrauch,\u00a0eingeschr\u00e4nkter\u00a0Leber\u2010\u00a0b zw.\u00a0Nierenfunktion,\u00a0Schwangersc haft\u00a0oder\u00a0Still\u2010\nzeit.\u00a0Von\u00a0den\u00a0481\u00a0randomisierten\u00a0MDR\u2010TB\u00a0Patienten\u00a0wurden\u00a0402\u00a0im \u00a0Rahmen\u00a0einer\u00a0\nmodifizierten\u00a0 Intention\u2010to\u2010Treat \u00a0Population\u00a0hinsichtlich\u00a0des\u00a0prim\u00e4ren\u00a0Endpunktes\u00a0\nSCC\u00a0am\u00a0Tag\u00a057\u00a0analysiert.\u00a0Unter\u00a0OBR\u00a0plus\u00a0Placebo\u00a0konnte\u00a0eine\u00a0SC C\u00a0in\u00a0Fl\u00fcssigkul\u2010\nturmedium\u00a0bei\u00a029,6\u00a0%\u00a0(37\u00a0von\u00a0125)\u00a0MDR\u2010TB\u00a0Patienten\u00a0beobachtet\u00a0w erden,\u00a0unter\u00a0\nGabe\u00a0von\u00a0OBR\u00a0plus\u00a0zweimal\u00a0t\u00e4glich\u00a0100\u00a0mg\u00a0Delamanid\u00a0waren\u00a0es\u00a045, 4\u00a0%\u00a0(64\u00a0von\u00a0\n141)\u00a0und\u00a0im\u00a0Studienarm\u00a0mit\u00a0200\u00a0mg\u00a0Delamanid\u00a0zweimal\u00a0t\u00e4glich\u00a041, 9\u00a0%\u00a0(57\u00a0von\u00a0\n136).\u00a0W\u00e4hrend\u00a0der\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0traten\u00a0als\u00a0UAE\u00a0\u00dcbelkei t,\u00a0Kopfschmerz,\u00a0\nPar\u00e4sthesien,\u00a0Tremor\u00a0oder\u00a0Tinnitus\u00a0im\u00a0Vergleich\u00a0zu\u00a0Placebo\u00a0h\u00e4uf iger\u00a0auf.\u00a0Palpitati\u2010\nonen\u00a0und\u00a0QT\u2010Zeitverl\u00e4ngerungen\u00a0sind\u00a0im\u00a0Kontext\u00a0unerw\u00fcnschter\u00a0Ar zneimitteler\u2010\neignisse\u00a0(UAE)\u00a0besonders\u00a0z u\u00a0nennen\u00a0(Gler\u00a0et\u00a0al.,\u00a02012).\u00a0\nDas\u00a0CHMP\u00a0weist\u00a0im\u00a0EPAR\u00a0darauf\u00a0hin,\u00a0dass\u00a0ein\u00a0Pr\u00fcfzentrum\u00a0auf\u00a0den \u00a0Philippinen\u00a0150\u00a0\nder\u00a0481\u00a0Patienten\u00a0betreute\u00a0und\u00a0f\u00fc r\u00a066\u00a0Patienten\u00a0mikrobiologisch \u00a0falschpositive\u00a0\nMTB\u00a0Befunde\u00a0\u00fcbermittelte.\u00a0Zudem\u00a0waren\u00a0in\u00a0der\u00a0Placebogruppe\u00a0mit\u00a0 einem\u00a0Anteil\u00a0\nvon\u00a022\u00a0%\u00a0mehr\u00a0Patienten\u00a0mit\u00a0XDR\u2010TB\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0Studiena rmen\u00a0mit\u00a0Dela\u2010136\u00a0manid\u00a0mit\u00a017\u00a0bzw.\u00a013\u00a0%.\u00a0Hierdurch\u00a0wird\u00a0die\u00a0Interpretation\u00a0der\u00a0E rgebnisse\u00a0der\u00a0\nStudie\u00a0Trial\u00a0204\u00a0erschwert\u00a0(EMA,\u00a02014d).\u00a0\nBei\u00a0der\u00a0Zulassungsstudie\u00a0 Trial\u00a0208\u00a0(NCT02573350,\u00a0Sponsor:\u00a0Otsuka)\u00a0handelt\u00a0es\u00a0sich\u00a0\num\u00a0eine\u00a0multizentrische,\u00a0nicht\u2010verblindete,\u00a0nicht\u2010kontrollierte \u00a0Verl\u00e4ngerung\u00a0der\u00a0\nPhase\u2010II\u2010Studie\u00a0 Trial\u00a0204\u00a0\u00fcber\u00a0eine\u00a0Dauer\u00a0von\u00a0sechs\u00a0Monaten,\u00a0d.h.\u00a0analog\u00a0zu\u00a0der\u00a0\nvon\u00a0der\u00a0WHO\u00a0empfohlenen\u00a0Dauer\u00a0ei ner\u00a0Initialphase\u00a0der\u00a0Pharmakoth erapie\u00a0der\u00a0\nMDR\u2010TB.\u00a0Es\u00a0nahmen\u00a0213\u00a0(44,2\u00a0%)\u00a0der\u00a0urspr\u00fcnglich\u00a0418\u00a0Teilnehmer\u00a0 aus\u00a0Studie\u00a0 Trial\u00a0\n204\u00a0teil\u00a0und\u00a0erhielten\u00a0erstmalig\u00a0(v orherige\u00a0Placebo\u2010Gruppe)\u00a0bzw.\u00a0w eiterhin\u00a0Dela\u2010\nmanid.\u00a0In\u00a0den\u00a0ersten\u00a0zwei\u00a0Wochen\u00a0waren\u00a0es\u00a0zweimal\u00a0t\u00e4glich\u00a0100\u00a0m g\u00a0mit\u00a0nachfol\u2010\ngender\u00a0M\u00f6glichkeit\u00a0einer\u00a0Auftit ration\u00a0auf\u00a0zweimal\u00a0t\u00e4glich\u00a0200\u00a0m g\u00a0f\u00fcr\u00a0die\u00a0verblei\u2010\nbenden\u00a0Wochen,\u00a0zus\u00e4tzlich\u00a0zu\u00a0OBR\u00a0nach\u00a0WHO.\u00a0Zu\u00a0beachten\u00a0ist\u00a0die\u00a0 Unterbrechung\u00a0\nder\u00a0Gabe\u00a0von\u00a0Delamanid,\u00a0welche\u00a0e inerseits\u00a0im\u00a0Studienprotokoll\u00a0v on\u00a0Trial\u00a0204\u00a0in\u00a0\nForm\u00a0einer\u00a0vierw\u00f6chigen\u00a0Nachbeob achtung\u00a0unter\u00a0OBR\u00a0begr\u00fcndet\u00a0wir d,\u00a0anderer\u2010\nseits\u00a0gab\u00a0es\u00a0Verz\u00f6gerungen\u00a0bei\u00a0d er\u00a0Aufnahme\u00a0von\u00a0Patienten\u00a0in\u00a0 Trial\u00a0208.\u00a0Dies\u00a0\nf\u00fchrte\u00a0bei\u00a0rund\u00a0einem\u00a0Drittel\u00a0der\u00a0Teilnehmer\u00a0zu\u00a0einer\u00a0Unterbrec hung\u00a0der\u00a0Gabe\u00a0\nvon\u00a0Delamanid\u00a0f\u00fcr\u00a0l\u00e4nger\u00a0als\u00a0vie r\u00a0Monate\u00a0(EMA,\u00a02014d;\u00a0Skripcono ka\u00a0et\u00a0al.,\u00a02013).\u00a0\nIn\u00a0der\u00a0zusammenfassenden\u00a0Auswertung\u00a0 Trial\u00a0116\u00a0der\u00a0Studien\u00a0 Trial\u00a0204\u00a0und\u00a0Trial\u00a0\n208\u00a0wurden\u00a0die\u00a0Langzeiteffekte\u00a0eine r\u00a0Therapie\u00a0der\u00a0MDR\u2010TB\u00a0mit\u00a0Delam anid\u00a0nach\u00a0\n24\u00a0Monaten\u00a0untersucht.\u00a0Basierend\u00a0auf\u00a0den\u00a0WHO\u2010Empfehlungen\u00a0wurde \u00a0nach\u00a0g\u00fcns\u2010\ntigem,\u00a0d.h.\u00a0Heilung,\u00a0oder\u00a0ung\u00fcnstigem\u00a0(Tod,\u00a0Fortschreiten\u00a0der\u00a0T B)\u00a0Ausgang\u00a0unter\u2010\nschieden.\u00a0Die\u00a0in\u00a0 Trial\u00a0116\u00a0zu\u00a0ber\u00fccksichtigenden\u00a0ne un\u00a0Subgruppen\u00a0(drei\u00a0Arme\u00a0in\u00a0\nTrial\u00a0204,\u00a0d.h.\u00a0Placebo,\u00a0100\u00a0mg\u00a0bzw.\u00a0200\u00a0mg\u00a0Delamanid\u00a0zweimal\u00a0t\u00e4glich\u00a0so wie\u00a0die\u00a0\njeweils\u00a0weiteren\u00a0drei\u00a0Variablen\u00a0in\u00a0 Trial\u00a0208\u00a0keine\u00a0Teilnahme,\u00a0Studienarme\u00a0Dela\u2010\nmanid\u00a0zweimal\u00a0t\u00e4glich\u00a0100\u00a0mg\u00a0oder\u00a0200\u00a0mg)\u00a0wurden\u00a0von\u00a0den\u00a0Autore n/dem\u00a0pU\u00a0\nzusammengef\u00fchrt\u00a0in\u00a0nur\u00a0zwei\u00a0neue\u00a0Subgruppen\u00a0\u201eDauer\u00a0der\u00a0Therapie \u00a0mit\u00a0Delama\u2010\nnid\u00a0bis\u00a0zu\u00a0zwei\u00a0Monate\u201c\u00a0oder\u00a0\u201eDauer\u00a0der\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0 l\u00e4nger\u00a0als\u00a0sechs\u00a0\nMonate\u201c,\u00a0wobei\u00a0die\u00a0Dosierung\u00a0au\u00dfer\u00a0Acht\u00a0gelassen\u00a0wurde.\u00a0So\u00a0erga b\u00a0diese\u00a0Analyse\u00a0\nunter\u00a0Ber\u00fccksichtigung\u00a0von\u00a0421\u00a0(87,5\u00a0%)\u00a0der\u00a0481\u00a0in\u00a0Studie\u00a0 Trial\u00a0204\u00a0randomisier\u2010\nten\u00a0MDR\u2010TB\u00a0Patienten\u00a0bei\u00a0einer\u00a0Therapiedauer\u00a0ab\u00a0sechs\u00a0Monaten\u00a0b ei\u00a0143\u00a0(74,5\u00a0%)\u00a0\nvon\u00a0192\u00a0dieser\u00a0neudefinierten\u00a0S ubgruppe\u00a0einen\u00a0Therapieerfolg\u00a0im \u00a0Vergleich\u00a0zu\u00a0\n126\u00a0(55\u00a0%)\u00a0von\u00a0229\u00a0MDR\u2010TB\u00a0Patienten\u00a0mit\u00a0einer\u00a0Gabe\u00a0von\u00a0Delamani d\u00a0\u2264\u00a0zwei\u00a0Mo\u2010\nnaten.\u00a0Es\u00a0zeigte\u00a0sich\u00a0eine\u00a0geringere\u00a0Mortalit\u00e4t\u00a0in\u00a0der\u00a0Subgrupp e\u00a0der\u00a0Langzeitgabe\u00a0\nvon\u00a0Delamanid\u00a0(1\u00a0%)\u00a0gegen\u00fcber\u00a08,3 \u00a0%\u00a0in\u00a0der\u00a0Subgruppe\u00a0\u201eDauer\u00a0der \u00a0Therapie\u00a0mit\u00a0\nDelamanid\u00a0bis\u00a0zu\u00a0zwei\u00a0Monate\u201c.\u00a0Selbstkritisch\u00a0f\u00fchren\u00a0die\u00a0Autore n\u00a0nachfolgende\u00a0\nPunkte\u00a0an:\u00a0Aussagen\u00a0zur\u00a0Therapie\u00a0der\u00a0XDR\u2010TB\u00a0k\u00f6nnen\u00a0nur\u00a0vorsicht ig\u00a0abgeleitet\u00a0\nwerden,\u00a0unterschiedliche\u00a0nationale\u00a0Behandlungsprogramme\u00a0der\u00a0MDR \u2010TB,\u00a0in\u00a0deren\u00a0\nKontext\u00a0die\u00a0Nachbeobachtung\u00a0stattfand,\u00a0f\u00fchrten\u00a0zu\u00a0Herausforderu ngen\u00a0bei\u00a0Samm\u2010\nlung\u00a0und\u00a0Abgleich\u00a0der\u00a0mikrobiologischen\u00a0Daten,\u00a0der\u00a0Informations \u2010Bias\u00a0im\u00a0Rahmen\u00a0\nder\u00a0zeitlichen\u00a0Abfolge\u00a0ist\u00a0zu\u00a0beachten,\u00a0eine\u00a0variable\u00a0Unterbrec hung\u00a0der\u00a0Gabe\u00a0von\u00a0137\u00a0Delamanid\u00a0zwischen\u00a0den\u00a0Studien\u00a0 Trial\u00a0204\u00a0und\u00a0Trial\u00a0208\u00a0sowie\u00a0m\u00f6glicherweise\u00a0\nunterschiedliche\u00a0Dosierung\u00a0von\u00a0Del amanid\u00a0bei\u00a0MDR\u2010TB\u2010Patienten\u00a0m it\u00a0Teilnahme\u00a0\nan\u00a0beiden\u00a0Studien\u00a0k\u00f6nnen\u00a0verzerre nd\u00a0wirken\u00a0(Skripconoka\u00a0et\u00a0al., \u00a02013).\u00a0\nErgebnisse\u00a0zu\u00a0p\u00e4diatrischen\u00a0Studien\u00a0werden\u00a0ab\u00a0November\u00a02019\u00a0erw artet\u00a0(EMA,\u00a0\n2016).\u00a0Seitens\u00a0der\u00a0WHO\u00a0wurden\u00a0zur\u00a0Therapie\u00a0von\u00a0MDR\u2010TB\u00a0bei\u00a0Erwac hsenen\u00a0sowie\u00a0\nKindern\u00a0und\u00a0Jugendlichen\u00a0mit\u00a0dem\u00a0 Wirkstoff\u00a0Delamanid\u00a0intermedi\u00e4 re\u00a0Handlungs\u2010\nanweisungen\u00a0herausgegeben.\u00a0In\u00a0der en\u00a0Kontext\u00a0wurde\u00a0die\u00a0Evidenz\u00a0e rneut\u00a0bewer\u2010\ntet\u00a0mit\u00a0dem\u00a0Fazit,\u00a0dass\u00a0zwar\u00a0sehr\u00a0limitierte\u00a0Studienergebnisse\u00a0 vorl\u00e4gen,\u00a0der\u00a0Wirk\u2010\nstoff\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0jedoch\u00a0o ftmals\u00a0die\u00a0letzte\u00a0verf\u00fcgbare\u00a0Th erapiem\u00f6glichkeit\u00a0\ndarstelle\u00a0und\u00a0unter\u00a0diversen\u00a0Bedingungen\u00a0eingesetzt\u00a0werden\u00a0k\u00f6nn e\u00a0(WHO,\u00a02014;\u00a0\n2016).\u00a0Folglich\u00a0wird\u00a0Delamanid\u00a0auf\u00a0der\u00a0Liste\u00a0der\u00a0essentiellen\u00a0A rzneimittel\u00a0der\u00a0WHO\u00a0\ngef\u00fchrt\u00a0(WHO,\u00a02015).\u00a0\nDaten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0wurden\u00a0im\u00a0Kontext \u00a0der\u00a0Phase\u2010II\u2010\nStudien\u00a0nicht\u00a0erhoben\u00a0(EMA,\u00a02014).\u00a0\nAuf\u00a0Antrag\u00a0wurde\u00a0der\u00a0pU\u00a0von\u00a0der\u00a0Verpflichtung\u00a0zur\u00a0 Nutzenbewertung \u00a0seitens\u00a0des\u00a0\nGemeinsamen\u00a0Bundesaussc husses\u00a0(G\u2010BA)\u00a0aufgrund\u00a0 Geringf\u00fcgigkeit \u00a0der\u00a0zu\u00a0erwarten\u2010\nden\u00a0Therapiekosten\u00a0zu\u00a0Lasten\u00a0der\u00a0gesetzlichen\u00a0Krankenversicheru ng\u00a0(GKV)\u00a0mit\u00a0Be\u2010\nschluss\u00a0des\u00a0G\u2010BA\u00a0vom\u00a017.\u00a0April\u00a02014\u00a0 freigestellt \u00a0(G\u2010BA,\u00a02014a,\u00a02014b).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0\u00a0Kosten\u00a0\n\u00a0Neuer\u00a0Wirkstoff\u00a0bei\u00a0\nMDR\u2010TB\u00a0Hemmstoff\u00a0der\u00a0\nZellwandsynthese\u00a0von\u00a0\nMTB\u00a0Reserve\u2010\nAntituberkulotikum\u00a0\nOrphan\u2010Arzneimittel;\u00a0\nG\u2010BA\u00a0Verfahren\u00a0\neingestellt \u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel \u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0erweitert\u00a0die\u00a0\nBehandlungs\u2010\nm\u00f6glichkeiten\u00a0der\u00a0\nMDR\u2010TB\u00a0possibly\u00a0helpful\u00a0 Schrittinnovation\u00a0\n\u00a0\n\u00a0\n138\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDelamanid\u00a0 2x\u00a0100\u00a0mg\u00a0tgl.\u00a0\u00fcber\u00a024\u00a0\nWochen\u00a0168,\u00a0da\u00a04\u00a0FTA\u00a0tgl.\u00a0\n\u00fcber\u00a024\u00a0Wochen\u00a025.200,14\u00a0\u20ac\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0 Delamanid\u00a0erstellt\u00a0werden.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nDelamanid,\u00a0ein\u00a0Nitrodihydroimida zooxazol,\u00a0hemmt\u00a0die\u00a0Synthese\u00a0de r\u00a0Zellwandbe\u2010\nstandteilen\u00a0Methoxy\u2010\u00a0und\u00a0Keto\u2010Mykols\u00e4ure\u00a0von\u00a0MTB.\u00a0\nW\u00e4hrend\u00a0der\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0ist\u00a0es\u00a0zu\u00a0Resistenzen\u00a0gekomm en.\u00a0Als\u00a0Ursa\u2010\nche\u00a0hierf\u00fcr\u00a0werden\u00a0Mutationen\u00a0in\u00a0einem\u00a0der\u00a0f\u00fcnf\u00a0Gene,\u00a0welche\u00a0Co enzym\u00a0F420\u00a0\nkodieren,\u00a0vermutet.\u00a0Kreuzresistenzen\u00a0mit\u00a0anderen\u00a0Antituberkulot ika\u00a0sind\u00a0nicht\u00a0\nbekannt.\u00a0Zu\u00a0beachten\u00a0ist\u00a0der\u00a0Einnahmezeitpunkt\u00a0von\u00a0Delamanid\u00a0na ch\u00a0der\u00a0Mahl\u2010\nzeit,\u00a0da\u00a0hierdurch\u00a0die\u00a0orale\u00a0Bioverf\u00fcgbarkeit\u00a0( Area\u00a0Under\u00a0the\u00a0Curve ,\u00a0AUC)\u00a0um\u00a0den\u00a0\nFaktor\u00a02,7\u00a0erh\u00f6ht\u00a0wird.\u00a0Delamanid\u00a0wird\u00a0zu\u00a0\u00fcber\u00a099,5\u00a0%\u00a0an\u00a0Plasma proteine\u00a0gebun\u2010\nden.\u00a0Die\u00a0Biotransformation\u00a0wird\u00a0\u00fcber\u00a0Albumin\u00a0und\u00a0Cytochromperox idasen\u00a0P450\u00a0\n3A4\u00a0(CYP3A4)\u00a0beschrieben,\u00a0was\u00a0im\u00a0Kontext\u00a0von\u00a0Interaktionen\u00a0zu\u00a0b er\u00fccksichtigen\u00a0\nist.\u00a0Aufgrund\u00a0der\u00a0Eliminationshalbwertzeit\u00a0von\u00a030\u00a0bis\u00a038\u00a0Stunde n\u00a0bzw.\u00a0der\u00a0Meta\u2010\nboliten\u00a0von\u00a0122\u00a0bis\u00a0322\u00a0Stunden\u00a0ist\u00a0theoretisch\u00a0noch\u00a0bis\u00a0ca.\u00a067 \u00a0Tage\u00a0nach\u00a0Absetzen\u00a0\nvon\u00a0Delamanid\u00a0mit\u00a0Interaktionen\u00a0 zu\u00a0rechnen.\u00a0Sowohl\u00a0pr\u00e4klinische \u00a0als\u00a0auch\u00a0klini\u2010\nsche\u00a0 Daten\u00a0 deuten\u00a0 auf\u00a0 QT\u2010Zeitverl\u00e4ngerung\u00a0 in\u00a0 Folge\u00a0 der\u00a0 Blockade \u00a0v o n \u00a0h E R G \u2010\nKaliumkan\u00e4len\u00a0hin.\u00a0Im\u00a0Tierversuch\u00a0(Kaninchen)\u00a0konnte\u00a0eine\u00a0blutg erinnungshem\u2010\nmende\u00a0Wirkung\u00a0gezeigt\u00a0werden.\u00a0Auf\u00a0eine\u00a0zuverl\u00e4ssige\u00a0Empf\u00e4ngnisv erh\u00fctung\u00a0ist\u00a0\nbei\u00a0der\u00a0Therapie\u00a0von\u00a0Frauen\u00a0im\u00a0geb\u00e4rf\u00e4higen\u00a0Alter\u00a0zu\u00a0achten,\u00a0da \u00a0pr\u00e4klinische\u00a0Da\u2010\nten\u00a0von\u00a0Delamanid\u00a0einerseits\u00a0Reproduktionstoxizit\u00e4t\u00a0als\u00a0auch\u00a0ei ne\u00a0Akkumulation\u00a0\ndes\u00a0Wirkstoffes\u00a0in\u00a0der\u00a0Muttermilch\u00a0zeigten.\u00a0Besonders\u00a0ist\u00a0die\u00a0K ontraindikation\u00a0\nHypoalbumin\u00e4mie\u00a0zu\u00a0beachten,\u00a0d.h.\u00a0unter\u00a02,8\u00a0g/dl\u00a0Serumalbumin\u00a0s ollte\u00a0Delamanid\u00a0\nnicht\u00a0angewendet\u00a0werden\u00a0(CHMP,\u00a02014b;\u00a0EMA,\u00a02014).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDelamanid\u00a0wurde\u00a0nach\u00a0einem\u00a0ersten,\u00a0abgelehnten\u00a0Zulassungsantrag \u00a0im\u00a0Jahr\u00a02013,\u00a0\nwelcher\u00a0 nur\u00a0 Phase\u2010II\u2010Daten\u00a0 \u00fcber\u00a0 eine\u00a0 zweimonatige\u00a0 Anwendung\u00a0 bei nhaltete,\u00a0\nobgleich\u00a0die\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0\u00fcber\u00a0sechs\u00a0Monate\u00a0beantragt \u00a0wurde\u00a0(CHMP,\u00a0\n2013)\u00a0von\u00a0der\u00a0EC\u00a0nach\u00a0Empfehlung\u00a0des\u00a0CHMP\u00a0der\u00a0EMA\u00a0im\u00a0Rahmen\u00a0ein es\u00a0zweiten\u00a0139\u00a0Verfahrens\u00a0am\u00a028.\u00a0April\u00a02014\u00a0zugelassen.\u00a0Im\u00a0Anhang\u00a0des\u00a0Bewertun gsberichts\u00a0der\u00a0\nEMA\u00a0werden\u00a0die\u00a0vom\u00a0Mehrheitsvotum\u00a0abweichenden\u00a0kritischen\u00a0Stand punkte\u00a0von\u00a0\nzw\u00f6lf\u00a0Mitgliedern\u00a0des\u00a0CHMP\u00a0dokumentiert,\u00a0insbesondere\u00a0ihre\u00a0offe nen\u00a0Fragen\u00a0zur\u00a0\nzielf\u00fchrenden\u00a0Dosierung\u00a0(m\u00f6gliche\u00a0Unterdosierung\u00a0bei\u00a0Gabe\u00a0von\u00a0z weimal\u00a0t\u00e4glich\u00a0\n100\u00a0mg\u00a0mit\u00a0potenziell\u00a0geringeren\u00a0Heilungsraten\u00a0sowie\u00a0Resistenzb ildung)\u00a0und\u00a0der\u00a0\nDifferenz\u00a0an\u00a0gepr\u00fcfter\u00a0vs.\u00a0zuge lassener\u00a0Therapiedauer\u00a0(EMA,\u00a0201 4).\u00a0Delamanid\u00a0ist\u00a0\nzugelassen:\u00a0\u201ezur\u00a0Anwendung\u00a0im\u00a0Ra hmen\u00a0einer\u00a0geeigneten\u00a0Kombinati onsbehand\u2010\nlung\u00a0f\u00fcr\u00a0multiresistente\u00a0Lungentuberkulose\u00a0(MDR\u2010TB)\u00a0bei\u00a0erwachs enen\u00a0Patienten,\u00a0\nwenn\u00a0 eine\u00a0 andere\u00a0 wirksame\u00a0 Behandlung\u00a0 aufgrund\u00a0 von\u00a0 Resistenzen\u00a0 o der\u00a0 aus\u00a0\nGr\u00fcnden\u00a0der\u00a0Vertr\u00e4glichkeit\u00a0nicht\u00a0zusammengestellt\u00a0werden\u00a0kann. \u201c\u00a0Besonders\u00a0zu\u00a0\nbeachten\u00a0ist,\u00a0dass\u00a0bereits\u00a0Resistenzen\u00a0gegen\u00a0den\u00a0Wirkstoff\u00a0Dela manid\u00a0gemeldet\u00a0\nwurden.\u00a0Es\u00a0sollte\u00a0eine\u00a0Kombinationstherapie\u00a0nach\u00a0WHO\u2010Empfehlung en\u00a0gew\u00e4hlt\u00a0\nwerden,\u00a0um\u00a0weitere\u00a0Resistenzen \u00a0zu\u00a0vermeiden\u00a0(CHMP,\u00a02014b).\u00a0\nDa\u00a0TB,\u00a0speziell\u00a0multiresistente\u00a0TB,\u00a0in\u00a0Westeuropa\u00a0nicht\u00a0h\u00e4ufig\u00a0 vorkommt,\u00a0wurde\u00a0\nDelamanid\u00a0bereits\u00a0im\u00a0Jahr\u00a02008\u00a0der\u00a0Status\u00a0als\u00a0Arzneimittel\u00a0zur\u00a0 Therapie\u00a0eines\u00a0\nseltenen\u00a0Leidens\u00a0vom\u00a0COMP\u00a0der\u00a0EMA\u00a0zuerkannt\u00a0und\u00a0auch\u00a0im\u00a0Rahmen\u00a0 der\u00a0Zulas\u2010\nsung\u00a0in\u00a02014\u00a0seitens\u00a0des\u00a0CHMP\u00a0ber\u00fccksichtigt\u00a0(COMP,\u00a02008,\u00a02014; \u00a0EMA,\u00a02014).\u00a0Bei\u00a0\nMDR\u2010TB\u00a0und\u00a0insbesondere\u00a0XDR\u2010TB\u00a0besteht\u00a0ein\u00a0sehr\u00a0gro\u00dfer\u00a0Bedarf\u00a0a n\u00a0antituberku\u2010\nl\u00f6sen\u00a0Therapiem\u00f6glichkeiten\u00a0( unmet\u00a0medical\u00a0need ),\u00a0sodass\u00a0Delamanid\u00a0bereits\u00a0in\u00a0\neinem\u00a0fr\u00fchen\u00a0Entwicklungsstadium\u00a0unter\u00a0besonderen\u00a0Bedingungen\u00a0( Conditional\u00a0\nApproval)\u00a0zugelassen\u00a0wurde.\u00a0Die\u00a0EMA\u00a0hat\u00a0den\u00a0pU\u00a0zur\u00a0Durchf\u00fchrung\u00a0weitere r\u00a0Stu\u2010\ndien,\u00a0 bspw.\u00a0 zur\u00a0 optimalen\u00a0 Dosier ung\u00a0 und\u00a0 Langzeitsicherheit,\u00a0 ver pflichtet\u00a0 und\u00a0\n\u00fcberpr\u00fcft\u00a0 j\u00e4hrlich\u00a0 anhand\u00a0 aktuelle r\u00a0 Erkenntnisse\u00a0 das\u00a0 Nutzen\u2010Ris iko\u2010Profil\u00a0 des\u00a0\nArzneimittels\u00a0(CHMP,\u00a02014b).\u00a0\nDelamanid\u00a0wird\u00a0\u00fcber\u00a024\u00a0Wochen,\u00a0d.h.\u00a0\u00fcber\u00a0sechs\u00a0Monate,\u00a0mit\u00a0zwei mal\u00a0t\u00e4glich\u00a0100\u00a0\nmg\u00a0zusammen\u00a0mit\u00a0einer\u00a0Mahlzeit \u00a0eingenommen\u00a0(CHMP,\u00a02014a).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0(vgl.\u00a0Bedaquilin)\u00a0\nTB\u00a0ist\u00a0eine\u00a0bakterielle\u00a0Infektionskrankheit,\u00a0mit\u00a0der\u00a0rund\u00a0ein\u00a0D rittel\u00a0der\u00a0Weltbev\u00f6l\u2010\nkerung\u00a0infiziert\u00a0sein\u00a0soll.\u00a0Circa\u00a05\u00a0bis\u00a010\u00a0%\u00a0der\u00a0Erwachsenen\u00a0da von\u00a0entwickeln\u00a0eine\u00a0\nbehandlungsbed\u00fcrftige\u00a0TB.\u00a0Global\u00a0sind\u00a0dies\u00a0j\u00e4hrlich\u00a0ca.\u00a09\u00a0Mio.\u00a0 Menschen\u00a0sowie\u00a0ca.\u00a0\n1,8\u00a0Mio.\u00a0Todesf\u00e4lle\u00a0durch\u00a0die\u00a0F olgen\u00a0der\u00a0TB\u00a0(Bruhn,\u00a02016a).\u00a0TB\u00a0 ist\u00a0somit\u00a0die\u00a0welt\u2010\nweit\u00a0h\u00e4ufigste\u00a0Todesursache.\u00a0Prinzipiell\u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0TB \u00a0um\u00a0eine\u00a0behandel\u2010\nbare\u00a0Erkrankung,\u00a0Resistenzen\u00a0geg en\u00a0etablierte\u00a0Pharmakotherapien \u00a0nehmen\u00a0je\u2010\ndoch\u00a0zu\u00a0und\u00a0die\u00a0Komorbidit\u00e4ten\u00a0sind\u00a0zu\u00a0beachten,\u00a0hier\u00a0speziell\u00a0 eine\u00a0Koinfektion\u00a0\nmit\u00a0HIV.\u00a0In\u00a0Europa\u00a0nimmt\u00a0die\u00a0Inzidenz\u00a0in\u00a0Richtung\u00a0der\u00a0Neuen\u00a0Una bh\u00e4ngigen\u00a0Staa\u2010\nten\u00a0(NUS;\u00a0Nachfolgestaaten\u00a0der\u00a0Sowjetunion)\u00a0zu,\u00a0bei\u00a0letzteren\u00a0i n\u00a0Folge\u00a0des\u00a0Zu\u2010\nsammenbruchs\u00a0der\u00a0\u00f6ffentlichen\u00a0Gesundheitswesens\u00a0entstandene\u00a0res istente\u00a0Erre\u2010\nger\u00a0stellen\u00a0ein\u00a0gro\u00dfes\u00a0Gesundheitsrisiko\u00a0dar\u00a0(RKI,\u00a02013).\u00a0140\u00a0Das\u00a0Robert\u00a0Koch\u2010Institut\u00a0z\u00e4hlte\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02015\u00a05.865\u00a0Erkrank te,\u00a0hierunter\u00a0502\u00a0\nF\u00e4lle\u00a0mit\u00a0\u201ejeglicher\u201c\u00a0Resistenz,\u00a0inkl.\u00a0125\u00a0F\u00e4lle\u00a0mit\u00a0Resistenz\u00a0 gegen\u00a0Isoniazid\u00a0und\u00a0\nRifampizin\u00a0( Multi\u2010Drug \u2010Resistence ,\u00a0MDR)\u00a0sowie\u00a013\u00a0F\u00e4lle\u00a0mit\u00a0extremer\u00a0Resistenz\u00a0\n(Extensive\u2010Drug\u2010Resistence,\u00a0XDR )\u00a0(Haas,\u00a02017;\u00a0RKI,\u00a02016).\u00a0\u00a0\nDer\u00a0haupts\u00e4chliche\u00a0Infektionsweg\u00a0von\u00a0TB\u00a0ist\u00a0die\u00a0Tr\u00f6pfcheninfekt ion,\u00a0die\u00a0Lunge\u00a0ist\u00a0\nvor\u00a0allem\u00a0betroffen.\u00a0Die\u00a0Keime,\u00a0 die\u00a0\u00fcber\u00a0Blutgef\u00e4\u00df\u2010\u00a0und\u00a0Lymphsy stem\u00a0verteilt\u00a0\nwerden,\u00a0k\u00f6nnen\u00a0auch\u00a0andere\u00a0Organe\u00a0befallen.\u00a0Nach\u00a0einer\u00a0Inkubati onszeit\u00a0von\u00a0\nsechs\u00a0bis\u00a0acht\u00a0Wochen\u00a0kann\u00a0eine\u00a0Immunantwort\u00a0gemessen\u00a0werden.\u00a0V on\u00a0den\u00a0\nInfizierten\u00a0erkrankt\u00a0nur\u00a0ein\u00a0Anteil\u00a0von\u00a05\u00a0bis\u00a010\u00a0%,\u00a0zumeist\u00a0kap selt\u00a0der\u00a0Organismus\u00a0\ndie\u00a0Mykobakterien\u00a0erfolgreich\u00a0ein,\u00a0dann\u00a0liegt\u00a0eine\u00a0latent\u00a0tuber kul\u00f6se\u00a0Infektion\u00a0\n(\u201eLTBI\u201c)\u00a0vor.\u00a0Bei\u00a0Schw\u00e4chung\u00a0der\u00a0k\u00f6rpereigenen\u00a0Abwehrkr\u00e4fte\u00a0kan n\u00a0es\u00a0zu\u00a0einer\u00a0\nReaktivierung\u00a0kommen.\u00a0Bei\u00a0akuter\u00a0 Lungen\u2010TB\u00a0k\u00f6nnen\u00a0die\u00a0Patienten \u00a0\u00fcber\u00a0Husten\u00a0\nmit\u00a0und\u00a0ohne\u00a0ggf.\u00a0blutigen\u00a0Auswurf,\u00a0Brustschmerz,\u00a0Atemnot,\u00a0Gewi chtsabnahme,\u00a0\nNachtschwei\u00df\u00a0sowie\u00a0reduziertes \u00a0Allgemeinbefinden\u00a0klagen.\u00a0\u00dcber\u00a0d as\u00a0Blut\u00a0k\u00f6nnen\u00a0\nauch\u00a0andere\u00a0Organe\u00a0befallen\u00a0werden\u00a0wie\u00a0Knochen,\u00a0Gelenke\u00a0oder\u00a0de r\u00a0Urogenital\u2010\nbereich.\u00a0Gef\u00fcrchtet\u00a0wird\u00a0die\u00a0tube rkul\u00f6se\u00a0Meningitis\u00a0als\u00a0seltene \u00a0aber\u00a0scherwiegen\u2010\nde\u00a0Komplikation.\u00a0Beg\u00fcnstigt\u00a0wird\u00a0die\u00a0Streuung\u00a0der\u00a0Mykobakterien \u00a0durch\u00a0ein\u00a0ge\u2010\nschw\u00e4chtes\u00a0Immunsystem,\u00a0beispielsweise\u00a0durch\u00a0Arzneimittel\u00a0(Immu nsuppressiva,\u00a0\nTNFalpha\u2010Blocker),\u00a0HIV\u2010Infektion,\u00a0Diabetes\u00a0mellitus,\u00a0Leberzirrh ose,\u00a0Alkohol\u2010\u00a0und\u00a0\nDrogenabusus\u00a0oder\u00a0Silikose.\u00a0\nTB\u00a0wird\u00a0mittels\u00a0Bildgebung\u00a0(R\u00f6ntgenuntersuchung)\u00a0und\u00a0mikrobiolo gischer\u00a0Diag\u2010\nnostik\u00a0 nachgewiesen.\u00a0 Weiterhin\u00a0 s tehen\u00a0 der\u00a0 Tuberkulin\u2010Hauttest\u00a0 n ach\u00a0 Mendel\u2010\nMantoux\u2010Methode\u00a0sowie\u00a0seit\u00a02005\u00a0der\u00a0 Interferon\u2010Gamma\u00a0Release\u00a0Assay ,\u00a0kurz:\u00a0\nIGRA\u00a0zur\u00a0Verf\u00fcgung.\u00a0\u00a0\nTB\u00a0wird\u00a0zur\u00a0Resistenzvermeidung\u00a0a usschlie\u00dflich\u00a0mit\u00a0Arzneimittel \u2010Kombinationen\u00a0\nbehandelt.\u00a0Diese\u00a0Therapie\u00a0t\u00f6tet\u00a0die\u00a0Erreger\u00a0ab\u00a0oder\u00a0stoppt\u00a0dere n\u00a0Vermehrung.\u00a0\nInfektionen\u00a0mit\u00a0empfindlichen\u00a0Erregern\u00a0( drug\u2010sensitive ,\u00a0DS\u2010TB)\u00a0werden\u00a0mit\u00a0\u201eErst\u2010\nrang\u00a0Antituberkulotika\u00a0der\u00a0WHO\u2010Gruppe\u00a01\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von \u00a0sechs\u00a0Mona\u2010\nten\u00a0behandelt.\u00a0Initial\u00a0wird\u00a0Isoni azid,\u00a0Rifampicin,\u00a0Pyrazinamid\u00a0 und\u00a0Ethambutol\u00a0\u00fcber\u00a0\nzwei\u00a0Monate\u00a0eingesetzt,\u00a0danach\u00a0 \u00fcber\u00a0vier\u00a0Monate\u00a0Isoniazid\u00a0und\u00a0R ifampicin.\u00a0Er\u2010\nscheint\u00a0der\u00a0Patient\u00a0unzuverl\u00e4ssig,\u00a0so\u00a0erfolgt\u00a0eine\u00a0Medikamenten einnahme\u00a0unter\u00a0\n\u00dcberwachung\u00a0( Directly\u00a0Observed\u00a0Therapy ,\u00a0DOT)\u00a0(RKI,\u00a02013).\u00a0Liegen\u00a0Resistenzen\u00a0\nvor,\u00a0verl\u00e4ngert\u00a0sich\u00a0die\u00a0Therapiedauer\u00a0\u00fcber\u00a0mindestens\u00a020\u00a0Monat e,\u00a0hierbei\u00a0wer\u2010\nden\u00a0Injektabilia\u00a0\u00fcber\u00a0acht\u00a0Mon ate\u00a0gegeben\u00a0(Bruhn,\u00a02016b).\u00a0\n\u00a0\n\u00a0141\u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDer\u00a0pU\u00a0hat\u00a0zur\u00a0Begr\u00fcndung\u00a0der\u00a0Zul assung\u00a0Phase\u2010II\u2010Studien\u00a0bei\u00a0de r\u00a0EMA\u00a0einge\u2010\nreicht,\u00a0wobei\u00a0seitens\u00a0der\u00a0EMA\u00a0aufgrund\u00a0nicht\u2010ausreichender\u00a0Date n\u00a0die\u00a0Zulassung\u00a0\nin\u00a02013\u00a0zun\u00e4chst\u00a0nicht\u00a0erteilt\u00a0wurde\u00a0(CHMP,\u00a02013).\u00a0\nZulassungsbegr\u00fcndend\u00a0wurden\u00a0Phase\u2010II\u2010Studien\u00a0seitens\u00a0des\u00a0pU\u00a0ein gereicht,\u00a0wobei\u00a0\nes\u00a0sich\u00a0um\u00a0einen\u00a0RCT\u00a0\u201e Trial\u00a0204\u201c \u00a0\u00fcber\u00a0zwei\u00a0Monate\u00a0mit\u00a0einmonatiger\u00a0Nachbe\u2010\nobachtung\u00a0handelt\u00a0und\u00a0nachfolgender\u00a0optionaler\u00a0Teilnahme\u00a0an\u00a0ein em\u00a0open\u2010label \u00a0\nfollow\u2010up \u00a0\u201eTrial\u00a0208\u201c\u00a0sowie\u00a0einer\u00a0weiterer\u00a0Nachbeobachtung\u00a0der\u00a0Teilnehmer\u00a0von\u00a0\n\u201eTrial\u00a0204\u201c\u00a0\u00fcber\u00a024\u00a0Monate\u00a0\u201e Trial\u00a0116\u201c\u00a0(EMA,\u00a02014).\u00a0\nBei\u00a0der\u00a0Zulassungsstudie\u00a0\u201e Trial\u00a0204\u201c\u00a0(NCT00685360,\u00a0Sponsor:\u00a0Otsuka)\u00a0handelt\u00a0es\u00a0\nsich\u00a0um\u00a0eine\u00a0multizentrische,\u00a0do ppelblinde,\u00a01:1:1\u00a0randomisierte ,\u00a0placebokontrol\u2010\nlierte\u00a0Phase\u2010II\u2010Studie.\u00a0481\u00a0an\u00a0MDR\u2010TB\u00a0erkrankte\u00a0Patienten,\u00a0erhi elten\u00a0f\u00fcr\u00a0zwei\u00a0Mo\u2010\nnate\u00a0entweder\u00a0Delamanid\u00a0zweimal\u00a0 t\u00e4glich\u00a0in\u00a0den\u00a0Dosierungen\u00a0100\u00a0 mg\u00a0oder\u00a0200\u00a0\nmg\u00a0 oder\u00a0 Placebo.\u00a0 Alle\u00a0 Patienten\u00a0 bekamen\u00a0 ein\u00a0 OBR\u00a0 nach\u00a0 WHO\u2010Leitli nie.\u00a0 Nach\u00a0\nachtw\u00f6chiger\u00a0Therapie\u00a0erfolgte\u00a0e ine\u00a0Nachbeobachtung\u00a0f\u00fcr\u00a0vier\u00a0Wo chen.\u00a0Prim\u00e4rer\u00a0\nEndpunkt\u00a0war\u00a0der\u00a0\u201eAnteil\u00a0Patienten\u00a0mit\u00a0negativem\u00a0Nachweis\u00a0von\u00a0T B\u2010Bakterien\u00a0im\u00a0\nSputum\u00a0( Sputum\u2010Culture\u00a0Conversion, \u00a0SCC)\u00a0in\u00a0Fl\u00fcssigmediumkultur\u00a0am\u00a0Tag\u00a057\u00a0in\u00a0\neiner\u00a0modifizierten\u00a0 Intention\u2010to\u2010Treat \u2010Population\u201c.\u00a0Patienten\u00a0mit\u00a0OBR\u00a0plus\u00a0100\u00a0mg\u00a0\nDelamanid\u00a0zweimal\u00a0t\u00e4glich\u00a0erzi elten\u00a0zu\u00a045,4\u00a0%\u00a0SCC\u00a0gegen\u00fcber\u00a029, 6\u00a0%\u00a0unter\u00a0Place\u2010\nbo\u00a0bzw.\u00a041,9\u00a0%\u00a0unter\u00a0OBR\u00a0plus\u00a0200\u00a0mg\u00a0Delamanid\u00a0zweimal\u00a0t\u00e4glich. \u00a0Sekund\u00e4re\u00a0\nEndpunkte\u00a0waren\u00a0\u201eSCC\u00a0mittels\u00a0Festkulturmedien\u201c\u00a0sowie\u00a0\u201edie\u00a0Zeit\u00a0 bis\u00a0zur\u00a0SCC\u00a0an\u2010\nhand\u00a0der\u00a0Nutzung\u00a0von\u00a0sowohl\u00a0Fl\u00fcssig\u2010\u00a0als\u00a0auch\u00a0Festkulturmedien\u201c .\u00a0Unter\u00a0Therapie\u00a0\nmit\u00a0 Delamanid\u00a0 traten\u00a0 \u00dcbelkeit,\u00a0 E rbrechen,\u00a0 Kopfschmerz,\u00a0 Par\u00e4sthe sien,\u00a0 Tremor\u00a0\noder\u00a0 Tinnitus\u00a0 im\u00a0 Vergleich\u00a0 zu\u00a0 Pl acebo\u00a0 h\u00e4ufiger\u00a0 auf.\u00a0 Palpitation en\u00a0 und\u00a0 QT\u2010\nZeitverl\u00e4ngerungen\u00a0sind\u00a0im\u00a0Rahmen\u00a0der\u00a0unerw\u00fcnschten\u00a0Effekte\u00a0( adverse\u00a0effects, \u00a0\nAE)\u00a0besonders\u00a0zu\u00a0nennen\u00a0(Gler\u00a0et \u00a0al.,\u00a02012).\u00a0Zu\u00a0beachten\u00a0ist,\u00a0d ass\u00a0ein\u00a0Pr\u00fcfzentrum\u00a0\n(Site\u00a0001)\u00a0auf\u00a0den\u00a0Philippinen\u00a0150\u00a0der\u00a0481\u00a0Patienten\u00a0betreute\u00a0und\u00a0f\u00fcr\u00a066 \u00a0Patienten\u00a0\nmikrobiologisch\u00a0falschpositive\u00a0M TB\u2010Befunde\u00a0\u00fcbermittelte,\u00a0welche \u00a0im\u00a0Rahmen\u00a0der\u00a0\nStudie\u00a0nur\u00a0bei\u00a0tats\u00e4chlich\u00a0identifizierter\u00a0MTB\u00a0Eingang\u00a0fanden.\u00a0 Weiterhin\u00a0befanden\u00a0\nsich\u00a0in\u00a0der\u00a0Placebogruppe\u00a0mit\u00a022\u00a0%\u00a0gegen\u00fcber\u00a017\u00a0%\u00a0bzw.\u00a013\u00a0%\u00a0in\u00a0 den\u00a0Delamanid\u2010\nGruppen\u00a0mehr\u00a0Patienten\u00a0mit\u00a0XDR\u2010TB,\u00a0sodass\u00a0die\u00a0Interpretation\u00a0so wie\u00a0die\u00a0Ergeb\u2010\nnisse\u00a0von\u00a0\u201e Trial\u00a0204\u201c \u00a0hierdurch\u00a0relativiert\u00a0werden\u00a0(EMA,\u00a02014).\u00a0T.\u00a0Hughes\u2010Davies\u00a0\nwirft\u00a0in\u00a0einem\u00a0Kommentar\u00a0zur\u00a0Publikation\u00a0von\u00a0Gler\u00a0und\u00a0Kollegen\u00a0 die\u00a0Frage\u00a0auf,\u00a0\ninwiefern\u00a0sich\u00a0Unterschiede\u00a0der\u00a0Verd\u00fcnnung\u00a0von\u00a0Mycobakterien\u00a0un d\u00a0Antituberku\u2010\nlostatika\u00a0aus\u00a0Sputum\u00a0bei\u00a0der\u00a0Kultivierung\u00a0auf\u00a0Fest\u2010\u00a0bzw.\u00a0in\u00a0Fl\u00fc ssigmedien\u00a0auswir\u2010\nken\u00a0(Hughes\u2010Davies\u00a0et\u00a0al.,\u00a02012).\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0Zulassungsstudie\u00a0\u00a0\u201e Trial\u00a0208\u201c \u00a0(NCT02573350,\u00a0Sponsor:\u00a0Otsuka)\u00a0\nkonnten\u00a0MDR\u2010TB\u2010Patienten,\u00a0welche\u00a0die\u00a0Studie\u00a0\u201e Trial\u00a0204\u201c \u00a0abgeschlossen\u00a0hatten,\u00a0142\u00a0eine\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0erst malig\u00a0aufnehmen\u00a0(Placebogruppe) \u00a0bzw.\u00a0fortf\u00fch\u2010\nren\u00a0(Delamanidgruppen).\u00a0Es\u00a0nahmen\u00a0213\u00a0(44,2\u00a0%)\u00a0der\u00a0418\u00a0Teilnehm er\u00a0aus\u00a0Studie\u00a0\n\u201eTrial\u00a0204\u201c \u00a0teil.\u00a0Diese\u00a0erhielten\u00a0zus\u00e4tzlich\u00a0zu\u00a0durchgehend\u00a0appliziertem\u00a0O BR\u00a0nach\u00a0\nWHO\u2010Leitlinie\u00a0nach\u00a0mindestens\u00a0vierw\u00f6chiger\u00a0Unterbrechung\u00a0der\u00a0Th erapie\u00a0(Nach\u2010\nbeobachtung\u00a0in\u00a0\u201e Trial\u00a0204\u201c :\u00a0Woche\u00a0neun\u00a0bis\u00a0zw\u00f6lf)\u00a0zweimal\u00a0t\u00e4glich\u00a0100\u00a0mg\u00a0Dela\u2010\nmanid\u00a0in\u00a0einer\u00a0vom\u00a0Pr\u00fcfarzt\u00a0nach\u00a0zwei\u00a0Wochen\u00a0auftitrierbaren\u00a0Do sierung\u00a0(zweimal\u00a0\nt\u00e4glich\u00a0100\u00a0mg\u00a0oder\u00a0200\u00a0mg)\u00a0f\u00fcr\u00a0weitere\u00a0sechs\u00a0Monate.\u00a0Verfahren sbedingt\u00a0erhielt\u00a0\nrund\u00a0ein\u00a0Drittel\u00a0der\u00a0Teilnehmer\u00a0zwischen\u00a0den\u00a0Studien\u00a0\u201e Trial\u00a0204\u201c \u00a0und\u00a0\u201eTrial\u00a0208\u201c\u00a0\nl\u00e4nger\u00a0als\u00a0vier\u00a0Monate\u00a0kein\u00a0Delamanid,\u00a0bei\u00a050%\u00a0der\u00a0Teilnehmer\u00a0b etrug\u00a0das\u00a0Inter\u2010\nvall\u00a0ohne\u00a0Delamanidgabe\u00a0weniger\u00a0als\u00a0zwei\u00a0Monate.\u00a0Die\u00a0Daten\u00a0von\u00a0 \u201eTrial\u00a0208\u201c \u00a0\nwurden\u00a0von\u00a0Skripconoka\u00a0und\u00a0Kollegen\u00a0gemeinsam\u00a0mit\u00a0\u201e Trial\u00a0116\u201c \u00a0publiziert\u00a0bzw.\u00a0\nk\u00f6nnen\u00a0im\u00a0EPAR\u00a0der\u00a0EMA\u00a0nachvollzog en\u00a0werden\u00a0(CHMP,\u00a02014b;\u00a0Skrip conoka\u00a0et\u00a0\nal.,\u00a02013).\u00a0\nIn\u00a0der\u00a0Zulassungsstudie\u00a0\u201e Trial\u00a0116\u201c\u00a0 (Sponsor:\u00a0Otsuka),\u00a0einer\u00a0\u00a0Beobachtungsstudie,\u00a0\nwerden\u00a0die\u00a0Langzeitergebnisse\u00a0der\u00a0in\u00a0\u201e Trial\u00a0204\u201c \u00a0behandelten\u00a0Patienten\u00a0mit\u00a0MDR\u2010\nTB\u00a0nach\u00a0bis\u00a0zu\u00a024\u00a0Monaten\u00a0ausgewertet,\u00a0ob\u00a0diese\u00a0an\u00a0Studie\u00a0\u201e Trial\u00a0208\u201c \u00a0teilge\u2010\nnommen\u00a0hatten\u00a0oder\u00a0nicht.\u00a0 Behandlungserfolge\u00a0wurden\u00a0von\u00a0Klinike rn\u00a0anhand\u00a0\nWHO\u2010Kriterien\u00a0beurteilt\u00a0und\u00a0zusammengefasst\u00a0als\u00a0erfolgreiche\u00a0( cured\u00a0bzw.\u00a0com\u2010\npleted)\u00a0Therapie\u00a0der\u00a0MDR\u2010TB\u00a0oder\u00a0nicht\u2010erfolgreich\u00a0( died,\u00a0failed,\u00a0defaulted ).\u00a0Von\u00a0\n421\u00a0an\u00a0\u201eTrial\u00a0204\u201c\u00a0teilnehmenden\u00a0MDR\u2010TB\u2010Patienten\u00a0konnten\u00a0die\u00a0Daten\u00a0von\u00a0390\u00a0\nim\u00a0Kontext\u00a0von\u00a0\u201e Trial\u00a0116\u201c\u00a0ausgewertet\u00a0werden\u00a0(Skripconoka\u00a0et\u00a0al.,\u00a02013).\u00a0\nAufgrund\u00a0 der\u00a0 limitierten\u00a0 Datenlage\u00a0 im\u00a0 Rahmen\u00a0 der\u00a0 Zulassung\u00a0 von\u00a0 Delamanid\u00a0\nseitens\u00a0der\u00a0EMA,\u00a0basierend\u00a0auf\u00a0Phase\u00a0II\u00a0Studienergebnissen,\u00a0hat \u00a0die\u00a0WHO\u00a0f\u00fcr\u00a0den\u00a0\nklinischen\u00a0Einsatz\u00a0von\u00a0Delamanid\u00a0intermedi\u00e4re\u00a0Handlungsempfehlu ngen\u00a0heraus\u2010\ng e g e b e n . \u00a0D i e \u00a0W H O \u00a0h a t \u00a0h i e r f\u00fc r \u00a0e i n e \u00a0 Guideline\u00a0 Development\u00a0 Group \u00a0 beauftragt,\u00a0\nbasierend\u00a0auf\u00a0den\u00a0Ergebnissen\u00a0der\u00a0Studien\u00a0\u201e Trial\u00a0204,\u00a0208\u201c \u00a0und\u00a0\u201e116\u201c\u00a0ein\u00a0Review\u00a0\nzu\u00a0erstellen\u00a0und\u00a0Behandlungsempfehlungen\u00a0mittels\u00a0GRADE\u2010Verfahre n\u00a0abzuleiten.\u00a0\nAls\u00a0 PICO\u2010Fragestellung\u00a0 ( Population,\u00a0 Intervention,\u00a0 Comparator,\u00a0 Outcome )\u00a0 wurde\u00a0\nformuliert:\u00a0 \u201cF\u00fchrt\u00a0 die\u00a0 zus\u00e4tzliche\u00a0 Gabe\u00a0 von\u00a0 Delamanid\u00a0 zu\u00a0 einem\u00a0 WHO\u2010\nBasistherapieregime\u00a0bei\u00a0Patiente n\u00a0mit\u00a0MDR\u2010TB\u00a0zu\u00a0einer\u00a0sicheren\u00a0 Verbesserung\u00a0des\u00a0\nTherapieergebnisses?\u201c\u00a0Vom\u00a0pU\u00a0erhielt\u00a0die\u00a0WHO\u00a0zus\u00e4tzliche\u00a0Daten. \u00a0Die\u00a0Kurzzeit\u2010\nwirksamkeit\u00a0von\u00a0Delamanid\u00a0wurde\u00a0anhand\u00a0der\u00a0in\u00a0\u201e Trial\u00a0204\u201c \u00a0erhobenen\u00a0Daten\u00a0\nmittels\u00a0des\u00a0prim\u00e4ren\u00a0Endpunktes\u00a0\u201eSCC\u00a0in\u00a0Fl\u00fcssigkulturmedium\u00a0nac h\u00a0zwei\u00a0Mona\u2010\nten\u201c\u00a0sowie\u00a0der\u00a0sekund\u00e4ren\u00a0Endpunkte\u00a0\u201eZeit\u00a0bis\u00a0zur\u00a0SCC\u201c\u00a0sowie\u00a0\u201eZ eit\u00a0bis\u00a0zum\u00a0posi\u2010\ntiven\u00a0Nachweis\u00a0mittels\u00a0MGIT\u2010Kultursystem\u201c\u00a0erfa\u00dft.\u00a0Zur\u00a0Ermittlun g\u00a0der\u00a0Langzeit\u2010\nWirksamkeit\u00a0wurden\u00a0die\u00a0Daten\u00a0der\u00a0Studienteilnehmer\u00a0von\u00a0\u201e Trial\u00a0204\u201c,\u00a0\u201e208\u201c\u00a0und\u00a0\n\u201e116\u201c\u00a0in\u00a0Gruppen\u00a0mit\u00a0einer\u00a0Anwendung\u00a0von\u00a0Delamanid\u00a0\u00fcber\u00a0kurze\u00a0Zeit,\u00a0 d.h.\u00a0bis\u00a0zu\u00a0\nzwei\u00a0Monaten,\u00a0oder\u00a0\u00fcber\u00a0l\u00e4ngere\u00a0Zeit,\u00a0d.h.\u00a0zwei\u00a0bis\u00a0sechs\u00a0Monat e,\u00a0zusammenge\u2010\nfasst.\u00a0Zum\u00a0Nachweis\u00a0der\u00a0Langzeit\u2010Wirksamkeit\u00a0von\u00a0Delamanid\u00a0wurd en\u00a0nunmehr\u00a0143\u00a0Festkulturmedien\u00a0genutzt,\u00a0es\u00a0wurde\u00a0nicht\u00a0nach\u00a0der\u00a0Dosierung\u00a0(10 0\u00a0mg\u00a0oder\u00a0200\u00a0\nmg\u00a0zweimal\u00a0t\u00e4glich)\u00a0unterschieden.\u00a0Als\u00a0Endpunkte\u00a0wurden\u00a0\u201eanhalt ende\u00a0SCC\u201c,\u00a0d.h.\u00a0\nSCC\u00a0nach\u00a0erwiesener\u00a0SCC\u00a0zum\u00a0Absc hluss\u00a0der\u00a0Initialphase\u00a0w\u00e4hrend\u00a0 der\u00a0nachfolgen\u2010\nden\u00a0Therapie\u00a0mit\u00a0OBR,\u00a0\u201eals\u00a0erfol greich\u00a0beurteilte\u00a0Therapie\u00a0seit ens\u00a0des\u00a0behandeln\u2010\nden\u00a0Arztes\u00a0nach\u00a024\u00a0Monaten\u201c\u00a0(WHO\u00a0Kategorien:\u00a0Heilung,\u00a0Behandlun gsabschluss,\u00a0\nScheitern\u00a0der\u00a0Behandlung\u00a0oder\u00a0Tod) \u00a0sowie\u00a0\u201eMortalit\u00e4t\u201c\u00a0(Beurteil ung\u00a0nach\u00a0WHO\u2010\nKriterien).\u00a0Resultate\u00a0zum\u00a0prim\u00e4ren\u00a0Wirksamkeitsendpunkt\u00a0SCC\u00a0nac h\u00a0zwei\u00a0Monaten\u00a0\nergeben\u00a0sich\u00a0aus\u00a0\u201e Trial\u00a0204\u201c .\u00a0Am\u00a0Tag\u00a057\u00a0konnte\u00a0unter\u00a0Therapie\u00a0von\u00a0OBR\u00a0plus\u00a0\nDelamanid\u00a0bei\u00a045,4\u00a0%\u00a0(100\u00a0mg\u00a0zw eimal\u00a0t\u00e4glich)\u00a0bzw.\u00a041,9\u00a0%\u00a0(200\u00a0 mg\u00a0zweimal\u00a0\nt\u00e4glich)\u00a0gegen\u00fcber\u00a029,6\u00a0%\u00a0unter\u00a0OBR\u00a0plus\u00a0Placebo\u00a0beobachtet\u00a0wer den.\u00a0Bei\u00a0der\u00a0\nAuswertung\u00a0des\u00a0sekund\u00e4ren\u00a0Endpunktes\u00a0\u201eZeit\u00a0bis\u00a0zur\u00a0SCC\u201c\u00a0ist\u00a0zu\u00a0 beachten,\u00a0dass\u00a0\nweniger\u00a0als\u00a050\u00a0%\u00a0bis\u00a0zum\u00a0Tag\u00a057\u00a0e ine\u00a0SCC\u00a0erreichten\u00a0und\u00a0somit\u00a0d ie\u00a0Berechnung\u00a0der\u00a0\nmedianen\u00a0Zeit\u00a0bis\u00a0zur\u00a0SCC\u00a0nicht\u00a0m\u00f6glich\u00a0ist.\u00a0Eine\u00a0Darstellung\u00a0d er\u00a0\u201eZeit\u00a0bis\u00a0zur\u00a0SCC\u201c\u00a0\nmittels\u00a0Kaplan\u2010Meier\u2010Kurve\u00a0zeigt\u00a0die\u00a0Unterschiede\u00a0der\u00a0Delamanid \u2010Gruppen\u00a0ge\u2010\ngen\u00fcber\u00a0Placebo\u00a0plus\u00a0OBR\u00a0zwische n\u00a0Tag\u00a036\u00a0und\u00a057\u00a0auf\u00a0(Gler\u00a0et\u00a0al .,\u00a02012;\u00a0Skripco\u2010\nnoka\u00a0et\u00a0al.,\u00a02013;\u00a0WHO,\u00a02014).\u00a0\nUm\u00a0die\u00a0Langzeit\u2010Wirksamkeit\u00a0der\u00a0 Therapie\u00a0von\u00a0MDR\u2010TB\u2010Patienten\u00a0m it\u00a0Delamanid\u00a0\nzu\u00a0bewerten,\u00a0fasste\u00a0der\u00a0pU\u00a0die\u00a0Daten\u00a0der\u00a0Studien\u00a0\u201e Trial\u00a0204,\u00a0208\u201c\u00a0 und\u00a0\u201e116\u201c\u00a0zu\u2010\nsammen.\u00a0Insgesamt\u00a0wurden\u00a0die\u00a0Da ten\u00a0von\u00a0421\u00a0der\u00a0481\u00a0Patienten\u00a0zu m\u00a0Ende\u00a0der\u00a024\u00a0\nMonate\u00a0ausgewertet,\u00a0d.h.\u00a0von\u00a087,5\u00a0%.\u00a0Aufgrund\u00a0\u00e4hnlicher\u00a0Ergebni sse\u00a0wurden\u00a0die\u00a0\nStudienarme\u00a0mit\u00a0OBR\u00a0plus\u00a0Delamanid\u00a0zweimal\u00a0t\u00e4glich\u00a0100\u00a0mg\u00a0und\u00a02 00\u00a0mg\u00a0zusam\u2010\nmengefasst\u00a0sowie\u00a0nur\u00a0nach\u00a0einer\u00a0Gabe\u00a0von\u00a0Delamanid\u00a0k\u00fcrzer\u00a0als\u00a0z wei\u00a0Monate\u00a0\noder\u00a0ab\u00a0sechs\u00a0Monaten\u00a0(sechs\u00a0bis\u00a0acht\u00a0Monate)\u00a0unterschieden.\u00a0De n\u00a0prim\u00e4ren\u00a0\nEndpunkt\u00a0der\u00a0Langzeitbetrachtung\u00a0\u201e zum\u00a0Monat\u00a024\u00a0anhaltende\u00a0SCC\u201c\u00a0 erreichten\u00a0\nunter\u00a0OBR\u00a0plus\u00a0Delamanid,\u00a0 welches\u00a0l\u00e4nger\u00a0als\u00a0sechs\u00a0Monate\u00a0gegeb en\u00a0wurde,\u00a0\n90,9\u00a0%\u00a0(130\u00a0von\u00a0143)\u00a0MDR\u2010TB\u2010Patienten\u00a0gegen\u00fcber\u00a070,9\u00a0%\u00a0der\u00a0Grup pe\u00a0einer\u00a0Gabe\u00a0\nvon\u00a0Delamanid\u00a0\u00fcber\u00a0eine\u00a0Dauer\u00a0von\u00a0bis\u00a0zu\u00a0zwei\u00a0Monaten.\u00a0Der\u00a0Endp unkt\u00a0erfolgrei\u2010\nches\u00a0Ergebnis\u00a0der\u00a0Therapie\u00a0von\u00a0MDR\u2010TB,\u00a0welches\u00a0mittels\u00a0Festmedi umkultur\u00a0nach\u2010\ngewiesen\u00a0wurde,\u00a0lag\u00a0in\u00a0der\u00a0Gruppe\u00a0mit\u00a0OBR\u00a0plus\u00a0Delamanid\u2010Gabe\u00a0\u00fc ber\u00a0sechs\u00a0\nMonate\u00a0bei\u00a074,5\u00a0%\u00a0gegen\u00fcber\u00a055\u00a0%\u00a0in\u00a0der\u00a0Gruppe\u00a0mit\u00a0OBR\u00a0plus\u00a0Del amanid\u00a0\u00fcber\u00a0\nweniger\u00a0als\u00a0zwei\u00a0Monate.\u00a0Im\u00a0Endpunkt\u00a0Mortalit\u00e4t\u00a0wies\u00a0die\u00a0Gruppe \u00a0mit\u00a0der\u00a0Gabe\u00a0\nvon\u00a0OBR\u00a0plus\u00a0Delamanid\u00a0\u00fcber\u00a0mehr\u00a0als\u00a0sechs\u00a0Monate\u00a0mit\u00a0zwei\u00a0Vers torbenen,\u00a0d.h.\u00a0\n1\u00a0%,\u00a0gegen\u00fcber\u00a019\u00a0Todesf\u00e4llen\u00a0(8,3\u00a0%)\u00a0in\u00a0der\u00a0Gruppe\u00a0mit\u00a0Gabe\u00a0vo n\u00a0OBR\u00a0plus\u00a0\nDelamanid\u00a0bis\u00a0zu\u00a0zwei\u00a0Monaten\u00a0ei ne\u00a0geringere\u00a0Sterblichkeit\u00a0auf. \u00a0Obschon\u00a0eine\u00a0\nVielzahl\u00a0methodischer\u00a0M\u00e4ngel\u00a0in\u00a0den\u00a0Studien\u00a0\u201e Trial\u00a0204,\u00a0208\u201c\u00a0 und\u00a0\u201e116\u201c\u00a0von\u00a0der\u00a0\nGDG\u00a0der\u00a0WHO\u00a0aufgezeigt\u00a0wurden,\u00a0s ch\u00e4tzen\u00a0die\u00a0Experten\u00a0einen\u00a0m\u00f6gl ichen\u00a0Nutzen\u00a0\nder\u00a0Therapie\u00a0mit\u00a0Delamanid\u00a0h\u00f6her\u00a0als\u00a0die\u00a0Risiken\u00a0der\u00a0Behandlung \u00a0ein\u00a0und\u00a0empfeh\u2010\nlen\u00a0den\u00a0therapeutischen\u00a0Einsatz\u00a0unter\u00a0gewissen\u00a0Voraussetzungen\u00a0 (Skripconoka\u00a0et\u00a0\nal.,\u00a02013;\u00a0WHO,\u00a02014).\u00a0Ergebnisse\u00a0zu\u00a0p\u00e4diatrischen\u00a0Studien\u00a0werd en\u00a0ab\u00a0November\u00a0144\u00a02019\u00a0 erwartet\u00a0 (EMA,\u00a0 2016).\u00a0 Daten\u00a0 zur\u00a0 gesundheitsbezogenen\u00a0 Leben squalit\u00e4t\u00a0\nwurden\u00a0im\u00a0Kontext\u00a0der\u00a0Phase\u00a0 II\u00a0Studien\u00a0nicht\u00a0erhoben.\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0Weltgesundheitsorganisation\u00a0WHO\u00a0f\u00fchrt\u00a0Delamanid\u00a0seit\u00a0April\u00a0 2015\u00a0auf\u00a0der\u00a0\nListe\u00a0essentieller\u00a0Arzneimittel\u00a0(WHO,\u00a02015).\u00a0\nU m \u00a0d e r \u00a0l i m i t i e r t e n \u00a0D a t e n l a g e \u00a0z u r \u00a0E v i d e n z \u00a0d e s \u00a0A n t i t u b e r k u l o t i k u m s\u00a0 Delamanid\u00a0\nmangels\u00a0abgeschlossener\u00a0Phase\u2010III\u2010Studien\u00a0gerecht\u00a0zu\u00a0werden,\u00a0ha t\u00a0die\u00a0WHO\u00a0Daten\u00a0\nder\u00a0Zulassungsbeh\u00f6rde\u00a0EMA,\u00a0des\u00a0pU\u00a0sowie\u00a0mittels\u00a0Literaturrecher che\u00a0verf\u00fcgbare\u00a0\nPublikationen\u00a0ausgewertet\u00a0und\u00a0mittels\u00a0GRADE\u2010Verfahren\u00a0intermedi \u00e4re\u00a0Handlungs\u2010\nleitf\u00e4den\u00a0zum\u00a0therapeutischen\u00a0Einsatz\u00a0von\u00a0Delamanid\u00a0sowohl\u00a0f\u00fcr\u00a0 Kinder\u00a0und\u00a0Ju\u2010\ngendliche\u00a0als\u00a0auch\u00a0Erwachsene\u00a0herausgegeben.\u00a0In\u00a0diesem\u00a0Kontext\u00a0 werden\u00a0f\u00fcnf\u00a0\nBereiche\u00a0besonders\u00a0hervorg ehoben\u00a0(WHO,\u00a02014,\u00a02016):\u00a0\n\uf0b7 Sorgf\u00e4ltige\u00a0 Ber\u00fccksichtigung\u00a0 der \u00a0 Patienten\u00a0 (HIV\u2010Status,\u00a0 Lebensa lter,\u00a0\nSchwangerschaft\u00a0bzw.\u00a0Stillzeit,\u00a0 Lokalisation\u00a0der\u00a0TB\u2010Infektion)\u00a0\n\uf0b7 Einhaltung\u00a0der\u00a0WHO\u2010Therapieregime\u00a0\n\uf0b7 Engmaschige\u00a0\u00dcberwachung\u00a0der\u00a0Therapie\u00a0\n\uf0b7 Aktive\u00a0 Pharmakovigilanz\u00a0 und\u00a0 geeign etes\u00a0 Management\u00a0 unerw\u00fcnschter \u00a0\nArzneimittelwirkungen\u00a0\n\uf0b7 Einverst\u00e4ndniserkl\u00e4rung\u00a0 der\u00a0 Patienten\u00a0 nach\u00a0 Aufkl\u00e4rung\u00a0 zur\u00a0 Daten lage\u00a0\nvon\u00a0Delamanid\u00a0\nBei\u00a0AWMF\u2010online\u00a0sind\u00a0Vorhaben\u00a0zur\u00a0Erstellung\u00a0zweier\u00a0neuer\u00a0S2k\u2010L eitlinien\u00a0einer\u2010\nseits\u00a0f\u00fcr\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0andererseits\u00a0f\u00fcr\u00a0Erwachsene\u00a0na chzulesen\u00a0f\u00fcr:\u00a0\n\u201eTuberkulose\u00a0im\u00a0Kindes\u2010\u00a0und\u00a0Jugendalter:\u00a0Diagnostik,\u00a0Pr\u00e4vention \u00a0und\u00a0Therapie\u201c\u00a0\nmit\u00a0Registernummer\u00a0048\u2010016,\u00a0geplante\u00a0Fertigstellung\u00a0zum\u00a031.\u00a0Mai \u00a02017\u00a0(Feiterna\u2010\nSperling\u00a0&\u00a0et\u00a0al.,\u00a02014)\u00a0und\u00a0f\u00fcr\u00a0\u201eTuberkulose\u00a0im\u00a0Erwachsenenalt er,\u00a0Empfehlungen\u00a0\nzur\u00a0 Diagnostik\u00a0 und\u00a0 Therapie,\u00a0 Chemopr\u00e4vention\u00a0 und\u00a0 Chemoprophylax e\u201c\u00a0 unter\u00a0\nRegisternummer\u00a0020\u2010019,\u00a0geplante\u00a0Fertigstellung\u00a0zum\u00a030.\u00a0Juni\u00a020 17\u00a0(Bauer,\u00a0Otto\u2010\nKnapp,\u00a0&\u00a0Schenkel,\u00a02014).\u00a0Eine\u00a0s ystematische\u00a0Evidenzbewertung\u00a0i st\u00a0im\u00a0Kontext\u00a0\nder\u00a0S2k\u2010Leitlinienvorhaben\u00a0nicht\u00a0vorgesehen\u00a0(Bauer\u00a0et\u00a0al.,\u00a02014 ).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nMit\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0vom\u00a017.\u00a0April\u00a02014\u00a0wurde\u00a0der\u00a0pU\u00a0von\u00a0der\u00a0 Verpflichtung\u00a0\nzur\u00a0Nutzenbewertung\u00a0des\u00a0Fertigarz neimittels\u00a0Deltyba\u00ae\u00a0mit\u00a0dem\u00a0Wi rkstoff\u00a0Dela\u2010145\u00a0manid\u00a0wegen\u00a0Geringf\u00fcgigkeit\u00a0frei gestellt.\u00a0Begr\u00fcndet\u00a0wird\u00a0dies\u00a0m it\u00a0Kapitel\u00a05\u00a0\u00a715\u00a0\nder\u00a0Verfahrensordnung\u00a0des\u00a0G\u2010BA\u00a0(G\u2010BA,\u00a02016),\u00a0welche\u00a0eine\u00a0Freist ellung\u00a0von\u00a0der\u00a0\nNutzenbewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0vorsieht,\u00a0wenn\u00a0die\u00a0zu\u00a0Lasten\u00a0der \u00a0GKV\u00a0anfallen\u2010\nden\u00a0Kosten\u00a0eine\u00a0Mio.\u00a0Euro\u00a0auf\u00a0Basis\u00a0des\u00a0Apothekenverkaufspreise s\u00a0binnen\u00a012\u00a0\nMonaten\u00a0nicht\u00a0\u00fcbersteigen\u00a0(G\u2010B A,\u00a02014a,\u00a02014b).\u00a0Bei\u00a0Therapiekos ten\u00a0f\u00fcr\u00a0eine\u00a024\u2010\nw\u00f6chige\u00a0Behandlung\u00a0in\u00a0H\u00f6he\u00a0von\u00a025.200,14\u00a0Euro\u00a0m\u00fcssten\u00a0in\u00a0Deutsc hland\u00a039\u00a0Pati\u2010\nenten\u00a0j\u00e4hrlich\u00a0behandelt\u00a0werden.\u00a0Beachtet\u00a0man\u00a0die\u00a0Daten\u00a0des\u00a0RKI ,\u00a0welches\u00a0im\u00a0\nRahmen\u00a0des\u00a0Infektionsschutzgesetzes\u00a0im\u00a0Jahr\u00a02015\u00a0125\u00a0MDR\u2010TB\u2010F\u00e4l le\u00a0gez\u00e4hlt\u00a0hat,\u00a0\nso\u00a0k\u00f6nnte\u00a0durchaus\u00a0auch\u00a0eine\u00a0regul\u00e4re\u00a0Nutzenbewertung\u00a0von\u00a0Delam anid\u00a0erfolgen\u00a0\n(Haas,\u00a02017).\u00a0\nQuellen\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2012).\u00a0Delamanid\u00a0gegen\u00a0Tbc\u00a0mit\u00a0mul tiresistenten\u00a0Mykobakterien.\u00a046,\u00a053.\u00a0\nBauer\u00a0T,\u00a0Otto\u2010Knapp\u00a0R,\u00a0Schenkel\u00a0K\u00a0(2014).\u00a0Tuberkulose\u00a0im\u00a0Erwach senenalter,\u00a0Empfehlungen\u00a0zur\u00a0Diagnostik\u00a0und\u00a0Therapie,\u00a0\nChemopr\u00e4vention\u00a0und\u00a0Chemoprophylaxe:\u00a0AWMF\u00a0angemeldetes\u00a0Leitlini envorhaben.\u00a0S2k\u00a0Registernummer\u00a0020\u2010019.\u00a0\nhttp://www.awmf.org/leitlinien/detail/anmeldung/1/ll/020\u2010019.ht ml,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 17).\u00a0\u00dcbersicht\u00a0Schulungsmaterial:\u00a0educational\u00a0material.\u00a0\nwww.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformation en/EducationalMaterial/Wirkstoff/_functions/\nD_node.html,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nBruhn\u00a0C\u00a0(2016).\u00a0Die\u00a0Sc hwindsucht\u00a0will\u00a0nicht\u00a0schwinden:\u00a0Warum\u00a0ei ne\u00a0Tuberkulose\u2010Eradikation\u00a0so\u00a0schwierig\u00a0ist.\u00a0Dtsch\u00a0\nApothekerzeitg\u00a0(45):\u00a042.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2013).\u00a0D elamanid_13\u20107_Q\u2010and\u2010A\u00a0on\u00a0refusal:\u00a0Refusal\u00a0of\u00a0the\u00a0marketing\u00a0\nauthorisation\u00a0for\u00a0Delamanid.\u00a0www.ema.europa.eu/docs/en_GB/docum ent_library/Summary_of_opinion_\u2010\n_Initial_authorisation/human/002552/WC500146651.pdf,\u00a0letzter\u00a0Zu griff:\u00a021.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 Deltyba,\u00a0INN\u2010Delamanid:\u00a0EPAR\u00a0Anhang\u00a01.\u00a0Summary\u00a0of\u00a0product\u00a0\ncharacteristics\u00a0SMPC\u00a0\u2010\u00a0Fachinformation.\u00a0www.ema.europa.eu/ema/i ndex.jsp?curl=pages/medicines/human\u00a0\n/medicines/002552/human_med_001699.jsp&mid=WC0b01ac058001d124,\u00a0 letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 EPAR\u00a0Delamanid:\u00a0SMPC\u00a0summary\u00a0of\u00a0product\u00a0characteristics.\u00a0\nwww.ema.europa.eu/\u00a0docs/en_GB/document_library/EPAR_\u2010\n_Product_Information/human/002552/WC500166232.pdf,\u00a0letzter\u00a0Zugr iff:\u00a021.06.2017.\u00a0\nChoueiri\u00a0TK,\u00a0Escudier\u00a0B,\u00a0Powles\u00a0T ,\u00a0Tannir\u00a0NM,\u00a0Mainwaring\u00a0PN,\u00a0Ri ni\u00a0BI,\u00a0Al\u00a0E\u00a0et\u00a0al.\u00a0(2016).\u00a0Cabozantinib\u00a0versus\u00a0everolimus\u00a0in\u00a0ad vanced\u00a0\nrenal\u00a0cell\u00a0carcinoma\u00a0(METEOR):\u00a0final\u00a0results\u00a0from\u00a0a\u00a0randomised, \u00a0open\u2010label,\u00a0phase\u00a03\u00a0trial.\u00a0Lancet\u00a0Oncol\u00a017\u00a0(7):\u00a0917\u2010927.\u00a0\nCOMP\u00a0(2008).\u00a0Public\u00a0summary\u00a0of\u00a0opinion\u00a0on\u00a0orphan\u00a0designation\u00a0De lamanid:\u00a0(R)\u20102\u2010Methyl\u20106\u2010nitro\u20102\u2010{4\u2010[4\u2010(4\u2010trifluoromethoxyphen\u2010\noxy)piperidin\u20101\u2010yl]phenoxymethyl}\u20102,3\u2010dihydroimidazo[2,1\u2010b]oxaz ole\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0tuberculosis.\u00a0EMA/COMP\u00a0\n/578275/2007\u00a0Rev.3.\u00a0 www.ema.europa.eu/docs/en_GB/doc\u00a0ument_library/Orphan_designati on/2009/10/ \u00a0\nWC500006083.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nCOMP\u00a0(2014).\u00a0Recommendation\u00a0for\u00a0maintenance\u00a0of\u00a0orphan\u00a0designati on\u00a0at\u00a0the\u00a0time\u00a0of\u00a0marketing\u00a0authorisation\u00a0Deltyba\u00a0\n(delamanid)\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0tu\u2010berculosis:\u00a0EMA/COMP/2642/2 014.\u00a0www.ema.europa.eu/ \u00a0\ndocs/en_GB/document_library/Orphan_review/2014/05/WC500166449.p df,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0146\u00a0EMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2013).\u00a0Refusal\u00a0of\u00a0the\u00a0marketin g\u00a0authorisation\u00a0for\u00a0Delamanid\u00a0(delamanid).\u00a0 www.ema.europa .\u00a0\neu/docs/en_GB/document_library/Summary_of_opinion_\u2010_Initial_aut horisation/human/002552/\u00a0\nWC500146651.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014).\u00a0EPAR\u00a0Delamanid.\u00a0SMPC\u00a0su mmary\u00a0of\u00a0product\u00a0characteristics.\u00a0www.ema.\u00a0europa.eu/docs\u00a0\n/en_GB/document_library/EPAR_\u2010_Product_Information/human/002552 /WC500166232.pdf,\u00a0letzter\u00a0Zugriff:\u00a012.07.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014a).\u00a0Deltyba:\u00a0EPAR\u00a0\u2010\u00a0Summar y\u00a0for\u00a0the\u00a0public.\u00a0 www.ema.europa.eu/docs/en_GB/doc \u00a0\nument_library/EPAR_\u2010_Summary_for_the_public/human/002552/WC5001 66235.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014b).\u00a0Public\u00a0summary\u00a0of\u00a0opin ion\u00a0on\u00a0orphan\u00a0designation\u00a0Delamanid.\u00a0(R)\u20102\u2010Methyl\u20106\u2010nitro\u20102\u2010\n{4\u2010[4\u2010(4\u2010trifluoromethoxyphenoxy)piperidin\u20101\u2010yl]phenoxymethyl}\u2010 2,3\u2010dihydroimidazo[2,1\u2010b]oxazole\u00a0for\u00a0the\u00a0\ntreatment\u00a0of\u00a0tu\u2010berculosis.\u00a0 www.ema.europa.eu/docs/en_GB/document_library/Orphan_designatio n/\u00a0\n2009/10/WC500006083.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014c).\u00a0Recommendation\u00a0for\u00a0mai ntenance\u00a0of\u00a0orphan\u00a0designation\u00a0at\u00a0the\u00a0time\u00a0of\u00a0marketing\u00a0\nauthorisation.\u00a0Deltyba\u00a0(delamanid)\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0tubercu losis.\u00a0www.ema.europa.eu/docs/en_GB/ \u00a0\ndocument_library/Orphan_review/2014/05/WC500166449.pdf,\u00a0letzter \u00a0Zugriff:\u00a012.07.2017.\u00a0\nEMA\u00a0\u2010\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2014d).\u00a0Assessment\u00a0report\u00a0Dela manid.\u00a0www.ema.europa.eu/docs/en_GB/document_library/ \u00a0\nEPAR_\u2010_Public_assessment_report/human/002552/WC500166234.pdf,\u00a0l etzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nEMA\u00a0\u2010\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0European\u00a0Medicines\u00a0Agen cy\u00a0decision\u00a0P/0269/2016\u00a0of\u00a07\u00a0October\u00a02016\u00a0on\u00a0the\u00a0\nacceptance\u00a0of\u00a0a\u00a0modification\u00a0of\u00a0an\u00a0agreed\u00a0paediatric\u00a0investigat ion\u00a0plan\u00a0for\u00a0delamanid\u00a0(Deltyba).\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC50 0216830.pdf,\u00a0letzter\u00a0Zugriff:\u00a012.07.2017.\u00a0\nFeiterna\u2010Sperling\u00a0C\u00a0et\u00a0al.\u00a0(2014).\u00a0Tuberkulose\u00a0im\u00a0Kindes\u2010\u00a0und\u00a0J ugendalter:\u00a0Diagnostik,\u00a0Pr\u00e4vention\u00a0und\u00a0Therapie:\u00a0AWMF\u00a0\nangemeldetes\u00a0Leitlinien\u00a0vor\u2010haben\u00a0S2k.\u00a0Registernummer\u00a0048\u2010016.\u00a0http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/048\u2010016.ht ml,\u00a0letzter\u00a0Zugriff:\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014a).\u00a0Beschl\u00fcsse\u00a0des\u00a0Geme insamen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0einen\u00a0Antrag\u00a0auf\u00a0Freistel\u2010\nlung\u00a0von\u00a0der\u00a0Nutzenbewertung\u00a0weg en\u00a0Geringf\u00fcgigkeit\u00a0nach\u00a0\u00a7\u00a035a\u00a0A bs.\u00a01aSGBV\u00a0\u201eInfektionen\u201c.\u00a0https://www.g\u2010\nba.de/downloads/39\u2010261\u20102042/2014\u201004\u201017_35a_Freistellung\u20102014\u2010F\u2010 00.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0des\u00a0Gemeinsame n\u00a0Bundesausschusses\u00a0\u00fcber\u00a0\neinen\u00a0Antrag\u00a0auf\u00a0Freistellung\u00a0von \u00a0der\u00a0Nutzenbewertung\u00a0wegen\u00a0Ger ingf\u00fcgigkeit\u00a0nach\u00a0\u00a7\u00a035a\u00a0Abs.1a\u00a0SGB\u00a0V\u00a0\n\u201eInfektionen\u201c.\u00a0https://www.g\u2010ba.de/downloads/40\u2010268\u20102909/2014\u20100 4\u201017_35a_Freistellung\u20102014\u2010F\u201000_TrG.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Verfahrensordnung\u00a0de s\u00a0Gemeinsamen\u00a0Bundesauschusses.\u00a0https://www.g\u2010\nba.de/downloads/62\u2010492\u20101331/VerfO_2016\u201010\u201020_iK\u20102017\u201001\u201020.pdf, \u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nGler\u00a0MT,\u00a0Skripconoka\u00a0V,\u00a0Sanchez\u2010Garavito\u00a0E,\u00a0Xiao\u00a0H,\u00a0Cabrera\u2010Riv ero\u00a0JL,\u00a0Vargas\u2010Vasquez\u00a0DE\u00a0et\u00a0al.(2012).\u00a0Delamanid\u00a0for\u00a0Multidrug \u2010\nResistant\u00a0Pulmonary\u00a0Tuberculosis.\u00a0NEJM\u00a0366(23):\u00a02151\u20102160.\u00a0\u00a0\nHaas\u00a0W\u00a0(2017).\u00a0Epidemiologische\u00a0Situation\u00a0in\u00a0Deutschland.\u00a0RKI\u00a0W elttuberkulosetag\u00a02017.\u00a0Vortrag\u00a01.\u00a0 www.rki.de/DE/Content/ \u00a0\nInfAZ/T/Tuberkulose/WTBTag2017/Vortrag_1.pdf?__blob=publication File,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0147\u00a0Hughes\u2010Davies\u00a0T,\u00a0Gler\u00a0MT,\u00a0Skripc onoka\u00a0V,\u00a0Sanchez\u2010Garavito\u00a0E,\u00a0Xi ao\u00a0H,\u00a0Cabrera\u2010Rivero\u00a0J\u00a0L,\u00a0Wells\u00a0CD\u00a0et\u00a0al.\u00a0(2012).\u00a0Comment\u00a0on:\u00a0\n\"Delamanid\u00a0for\u00a0Multidrug\u2010Resistant\u00a0Pulmonary\u00a0Tuberculosis\u00a0//\u00a0De lamanid\u00a0for\u00a0multidrug\u2010resistant\u00a0pulmonary\u00a0\ntuberculosis.\u00a0http://www.nejm.o rg/doi/full/10.1056/NEJMoa111243 3#t=comments,\u00a0letzter\u00a0Zugriff:\u00a0\u00a0\nPrescrire\u00a0International\u00a0(2017).\u00a0Delamanid\u00a0(deltyba \u00ae)and\u00a0multidrug\u2010resistant\u00a0pulmonary\u00a0tuberculosis.\u00a0Prescrire\u00a0Int\u00a0 26(181):\u00a089\u201092.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Delamanid|Deltyba\u00ae| 80|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=53125,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2013).\u00a0Tuberkulose:\u00a0RKI\u2010Ratgeber\u00a0f\u00fc r\u00a0\u00c4rzte.\u00a0\nwww.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tub erkulose.html,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016).\u00a0Berichte\u00a0zur\u00a0Epidemiologie\u00a0d er\u00a0Tuberkulose\u00a0in\u00a0Deutschland.\u00a0\nwww.rki.de/DE/Content/InfAZ/T/Tuberkulose/Archiv_Berichte_TB_in _Dtl_tab.html,\u00a0letzter\u00a0Zugriff:\u00a009.05.2017.\u00a0\nSchaberg\u00a0T,\u00a0Bauer\u00a0T,\u00a0Castell\u00a0S,\u00a0Dalhoff\u00a0K,\u00a0Detjen\u00a0A,\u00a0Diel\u00a0R,\u00a0Lo ddenkemper\u00a0R\u00a0et\u00a0al.\u00a0(2012).\u00a0Empfehlungen\u00a0zur\u00a0Therapie,\u00a0Chemopr\u00e4 \u2010\nvention\u00a0und\u00a0Chemoprophylaxe\u00a0der\u00a0Tuberkulose\u00a0im\u00a0Erwachsenen\u2010\u00a0und \u00a0Kindesalter.\u00a0Pneumologie\u00a066(3),\u00a0133\u2010171.\u00a0\u00a0\nSkripconoka\u00a0V,\u00a0Danilovits\u00a0M,\u00a0Pehme\u00a0L,\u00a0Tomson\u00a0T,\u00a0Skenders\u00a0G,\u00a0Kum mik\u00a0Tet\u00a0al.(2013).\u00a0Delamanid\u00a0improves\u00a0outcomes\u00a0and\u00a0reduces\u00a0\nmortality\u00a0in\u00a0multidrug\u2010resistant\u00a0tuberculosis.\u00a0Eur\u00a0Respir\u00a0J\u00a041( 6):\u00a01393\u20101400.\u00a0\u00a0\nWells\u00a0SA,\u00a0Asa\u00a0SL,\u00a0Dralle\u00a0H,\u00a0Elisei \u00a0R,\u00a0Evans\u00a0DB,\u00a0Gagel\u00a0RF\u00a0et\u00a0al. \u00a0(2015).\u00a0Revised\u00a0American\u00a0Thyroid\u00a0Association\u00a0Guidelines\u00a0for\u00a0th e\u00a0\nManagement\u00a0of\u00a0Medullary\u00a0Thyroid\u00a0Carcinoma.\u00a0Thyroid\u00a025\u00a0(6):\u00a0567\u2010 610.\u00a0\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2014).\u00a0The\u00a0use\u00a0of\u00a0delamanid\u00a0in \u00a0the\u00a0treatment\u00a0of\u00a0multidrug\u2010resi stant\u00a0tuber\u2010culosis.\u00a0Interim\u00a0\npolicy\u00a0guidance.\u00a0Geneva:\u00a0World\u00a0Health\u00a0Organization.\u00a0\napps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_e ng.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2015).\u00a0WHO\u00a0Model\u00a0List\u00a0of\u00a0Essen tial\u00a0Medicines.\u00a0 www.who.int/entity/medicines/ \u00a0\npublications/essentialmedicines/EML_2015_FINAL_amended_NOV2015. pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2016).\u00a0The\u00a0use\u00a0of\u00a0delamanid\u00a0in \u00a0the\u00a0treatment\u00a0of\u00a0multidrug\u2010resistant\u00a0tuberculosis\u00a0in\u00a0children\u00a0\nand\u00a0adolescents.\u00a02016\u00a0Update.\u00a0Interim\u00a0policy\u00a0guidance.\u00a0Geneva:\u00a0 World\u00a0Health\u00a0Organization.\u00a0\n\u00a0 \u00a0148\u00a04.9 Dexlansoprazol\u00a0\nHandelsname:\u00a0Dexilant\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0erosive\u00a0Refluxkrankheit\u00a0\u00a0 Takeda\u00a0 \u00a0\nATC\u2010Code:\u00a0A02BC06\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0April\u00a02014\u00a0\nDarreichungsform:\u00a0Hartkapseln\u00a0 \u00a0 DDD:\u00a030\u00a0mg\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDexlansoprazol\u00a0ist\u00a0ein\u00a0Protonenpumpen\u2010Inhibitor\u00a0(PPI),\u00a0der\u00a0wie\u00a0 alle\u00a0Arzneistoffe\u00a0\ndieser\u00a0Wirkstoffgruppe\u00a0die\u00a0Sekre tion\u00a0von\u00a0Magens\u00e4ure\u00a0verringert, \u00a0indem\u00a0er\u00a0die\u00a0\nH+/K+\u2010ATPase\u00a0in\u00a0den\u00a0Parietalzelle n\u00a0des\u00a0Magens\u00a0hemmt\u00a0(Fachinform ation\u00a0Dexi\u2010\nlant\u00ae,\u00a02017).\u00a0\u00a0\nDexlansoprazol\u00a0ist\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0Dexilant\u00ae\u00a0in\u00a0zwei\u00a0St\u00e4 rken\u00a0(30\u00a0mg\u00a0und\u00a0\n60\u00a0mg)\u00a0bei\u00a0Erwachsenen\u00a0und\u00a0Jugendl ichen\u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0f\u00fcr\u00a0meh rere\u00a0Indikatio\u2010\nnen\u00a0zugelassen.\u00a0Die\u00a0Dosierung\u00a0betr\u00e4gt\u00a0zur\u00a0Behandlung\u00a0der\u00a0erosiv en\u00a0Reflux\u00f6sopha\u2010\ngitis\u00a0(Erosive\u00a0Reflux\u00a0Disease ,\u00a0ERD)\u00a060\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0\u00fcber\u00a0vier\u00a0Wochen,\u00a0zur\u00a0\nErhaltungstherapie\u00a0bei\u00a0abgeheilter\u00a0ERD\u00a0einmal\u00a0t\u00e4glich\u00a030\u00a0mg\u00a0(bi s\u00a0zu\u00a0sechs\u00a0Monate\u00a0\nbei\u00a0Erwachsenen,\u00a0individuell\u00a0bei\u00a0Jugendlichen).\u00a0Zur\u00a0Linderung\u00a0v on\u00a0Sodbrennen\u00a0sowie\u00a0\nzur\u00a0kurzzeitigen\u00a0Behandlung\u00a0von\u00a0Sodbrennen\u00a0und\u00a0saurem\u00a0Aufsto\u00dfen \u00a0bei\u00a0symptoma\u2010\ntischer\u00a0nicht\u2010erosiver\u00a0gastro\u00f6sophagealer\u00a0Refluxkrankheit\u00a0( Non\u2010Erosive\u00a0Reflux\u00a0Dise\u2010\nase,\u00a0NERD)\u00a0wird\u00a0Dexlansoprazol\u00a0einmal\u00a0t\u00e4glich\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a0vier\u00a0Wo chen\u00a0verabreicht.\u00a0\nDie\u00a0Patienten\u00a0sollten\u00a0die\u00a0Hartkap seln\u00a0als\u00a0Ganzes\u00a0einnehmen\u00a0oder \u00a0bei\u00a0Schluckbe\u2010\nschwerden\u00a0das\u00a0enthaltene\u00a0Granulat\u00a0mit\u00a0einem\u00a0L\u00f6ffel\u00a0Apfelmus\u00a0ver mischen.\u00a0Das\u00a0\nGranulat\u00a0sollte\u00a0nicht\u00a0zerkaut\u00a0werden\u00a0(Fachinformation\u00a0Dexilant\u00ae ,\u00a02017).\u00a0\nF\u00fcr\u00a0die\u00a0verschiedenen\u00a0Indikation en\u00a0liegen\u00a0mehrere\u00a0herstellerges ponserte\u00a0rando\u2010\nmisierte\u00a0 kontrollierte\u00a0 Studien\u00a0 vor.\u00a0 Bei\u00a0 der\u00a0 achtw\u00f6chigen\u00a0 Behand l u n g \u00a0d e r \u00a0E R D \u00a0\nerwies\u00a0sich\u00a060\u00a0mg\u00a0Dexlansoprazol\u00a0t\u00e4glich\u00a0als\u00a0ebenso\u00a0wirksam\u00a0wie \u00a030\u00a0mg\u00a0Lansop\u2010\nrazol\u00a0pro\u00a0Tag,\u00a0die\u00a0Heilungsraten \u00a0lagen\u00a0jeweils\u00a0bei\u00a0rund\u00a090\u00a0%\u00a0(S harma\u00a0et\u00a0al.,\u00a02009).\u00a0\nDer\u00a0Score\u00a0f\u00fcr\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0\nHRQoL),\u00a0gemessen\u00a0mit\u00a0dem\u00a0PAGI\u2010QoL \u2010Instrument,\u00a0lag\u00a0mit\u00a0beiden\u00a0De xlansoprazol\u2010\nDosierungen\u00a0signifikant\u00a0h\u00f6her\u00a0al s\u00a0mit\u00a0dem\u00a0Placebo\u00a0(Fass\u00a0et\u00a0al., \u00a02009).\u00a0Die\u00a0klinische\u00a0\nRelevanz\u00a0der\u00a0Ver\u00e4nderungen\u00a0ist\u00a0jedoch\u00a0unklar.\u00a0Durch\u00a0Gabe\u00a0von\u00a030 \u00a0mg\u00a0Dexlanso\u2010\nprazol\u00a0pro\u00a0Tag\u00a0\u00fcber\u00a0sechs\u00a0Monate\u00a0lie\u00df\u00a0sich\u00a0der\u00a0Heilungserfolg\u00a0b ei\u00a0etwa\u00a075\u00a0%\u00a0der\u00a0\nTeilnehmer\u00a0und\u00a0deutlich\u00a0besser\u00a0als\u00a0mit\u00a0Placebo\u00a0aufrechterhalten .\u00a0Die\u00a0HRQoL\u00a0ver\u2010\nbesserte\u00a0sich\u00a0signifikant\u00a0gegen\u00fcber\u00a0der\u00a0Placebogruppe.\u00a0Genauere \u00a0Angaben\u00a0fehlen\u00a0\njedoch\u00a0(Metz\u00a0et\u00a0al.,\u00a02009).\u00a0Bei\u00a0der\u00a0Behandlung\u00a0der\u00a0NERD\u00a0mit\u00a0ein er\u00a0t\u00e4glichen\u00a0Dosis\u00a0\nvon\u00a030\u00a0mg\u00a0Dexlansoprazol\u00a0\u00fcber\u00a0vier\u00a0Wochen\u00a0konnte\u00a0der\u00a0PPI\u00a0im\u00a0Ver gleich\u00a0zum\u00a0\nPlacebo\u00a0Sodbrennen\u00a0deutlich\u00a0reduzieren.\u00a0Im\u00a0Median\u00a0lag\u00a0der\u00a0Antei l\u00a0beschwerde\u2010\nfreier\u00a0Tage\u00a0(bezogen\u00a0auf\u00a024\u00a0Stunden)\u00a0bei\u00a055\u00a0%\u00a0mit\u00a0Dexlansoprazo l\u00a0und\u00a0bei\u00a019\u00a0%\u00a0149\u00a0mit\u00a0Placebo,\u00a0beschwerdefreie\u00a0N\u00e4chte\u00a0gab\u00a0es\u00a0unter\u00a0Dexlansoprazol \u00a0bei\u00a073\u00a0%\u00a0im\u00a0\nVergleich\u00a0zu\u00a036\u00a0%\u00a0unter\u00a0Placebo\u00a0(Fass\u00a0et\u00a0al.,\u00a02009;\u00a02011).\u00a0Dies e\u00a0Studien\u00a0wurden\u00a0\nalle\u00a0mit\u00a0Teilnehmern\u00a0ab\u00a018\u00a0Jahren\u00a0durchgef\u00fchrt.\u00a0F\u00fcr\u00a0Jugendliche \u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0\nliegen\u00a0f\u00fcr\u00a0die\u00a0Abheilung\u00a0einer\u00a0ERD\u00a0mit\u00a060\u00a0mg\u00a0Dexlansoprazol\u00a0t\u00e4g lich\u00a0\u00fcber\u00a0acht\u00a0\nWochen\u00a0(NCT01642615,\u00a02015)\u00a0und\u00a0die\u00a0symptomatische\u00a0Behandlung\u00a0ei ner\u00a0NERD\u00a0\nmit\u00a030\u00a0mg\u00a0Dexlansoprazol\u00a0t\u00e4glich\u00a0\u00fcber\u00a0vier\u00a0Wochen\u00a0(NCT01642602, \u00a02014)\u00a0lediglich\u00a0\nDaten\u00a0aus\u00a0unkontrollierten\u00a0Studi en\u00a0bzw.\u00a0Studienphasen\u00a0vor.\u00a0In\u00a0e iner\u00a0randomisier\u2010\nten\u00a0kontrollierten\u00a0Studienphase\u00a0zur\u00a0Erhaltungstherapie\u00a0nach\u00a0der \u00a0Abheilung\u00a0einer\u00a0\nERD\u00a0mit\u00a030\u00a0mg\u00a0Dexlansoprazol\u00a0pro \u00a0Tag\u00a0\u00fcber\u00a016\u00a0Wochen\u00a0zeigten\u00a0sic h\u00a0bei\u00a082\u00a0%\u00a0der\u00a0\nTeilnehmer\u00a0der\u00a0Behandlungsgruppe\u00a0k eine\u00a0endoskopisch\u00a0erkennbaren \u00a0L\u00e4sionen,\u00a0in\u00a0\nder\u00a0Placebogruppe\u00a0bei\u00a058\u00a0%\u00a0(NCT01642615,\u00a02015).\u00a0\u00a0\nDas\u00a0Sicherheitsprofil\u00a0von\u00a0Dexlansoprazol\u00a0entspricht\u00a0dem\u00a0anderer \u00a0PPI.\u00a0Zu\u00a0den\u00a0h\u00e4u\u2010\nfigsten\u00a0 unerw\u00fcnschten\u00a0 Arzneimitte lereignissen\u00a0 (UAE)\u00a0 geh\u00f6ren\u00a0 Dur chfall,\u00a0 Bauch\u2010\nschmerzen,\u00a0 Kopfschmerzen,\u00a0 \u00dcbelke it,\u00a0 abdominale\u00a0 Beschwerden,\u00a0 Bl\u00e4 hungen\u00a0 und\u00a0\nVerstopfung.\u00a0Diese\u00a0Beschwerden\u00a0wurden\u00a0in\u00a0klinischen\u00a0Studien\u00a0\u00fcbe r\u00a0eine\u00a0maximale\u00a0\nBehandlungsdauer\u00a0von\u00a0einem\u00a0Jahr\u00a0erfasst.\u00a0Nach\u00a0der\u00a0Zulassung\u00a0gab \u00a0es\u00a0Berichte\u00a0\u00fcber\u00a0\nschwerwiegende\u00a0\u00dcberempfindlichkeitsreaktionen,\u00a0deren\u00a0H\u00e4ufigkeit \u00a0sich\u00a0jedoch\u00a0nicht\u00a0\nquantifizieren\u00a0l\u00e4sst.\u00a0Durch\u00a0die\u00a0 verringerte\u00a0Azidit\u00e4t\u00a0des\u00a0Magens \u00a0steigt\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0\ngastrointestinale\u00a0Infektionen\u00a0leicht\u00a0an.\u00a0Bei\u00a0langfristiger\u00a0Beha ndlung\u00a0kann\u00a0eine\u00a0Hy\u2010\npomagnesi\u00e4mie\u00a0auftreten.\u00a0Besonde rs\u00a0bei\u00a0h\u00f6heren\u00a0Dosierung\u00a0und\u00a0se hr\u00a0langer\u00a0An\u2010\nwendung\u00a0\u00fcber\u00a0ein\u00a0Jahr\u00a0wurde\u00a0ein\u00a0erh\u00f6htes\u00a0Frakturrisiko\u00a0beobacht et,\u00a0\u00fcberwiegend\u00a0\nbei\u00a0\u00e4lteren\u00a0Patienten\u00a0oder\u00a0bei\u00a0bestehenden\u00a0anderen\u00a0Risikofaktor en\u00a0(Fachinformati\u2010\non\u00a0Dexilant\u00ae,\u00a02017).\u00a0\nPPI\u00a0gelten\u00a0in\u00a0der\u00a0aktuellen\u00a0Leitlinie\u00a0zur\u00a0Behandlung\u00a0der\u00a0genann ten\u00a0Indikationen\u00a0als\u00a0\nMittel\u00a0der\u00a0ersten\u00a0Wahl.\u00a0Empfehlungen\u00a0f\u00fcr\u00a0einen\u00a0bestimmten\u00a0PPI\u00a0s pricht\u00a0die\u00a0Leitli\u2010\nnie\u00a0nicht\u00a0aus.\u00a0Als\u00a0\u00e4quivalente\u00a0Standarddosierungen\u00a0gelten\u00a0Omepr azol\u00a020\u00a0mg,\u00a0Pan\u2010\ntoprazol\u00a040\u00a0mg,\u00a0Lansoprazol\u00a030\u00a0mg,\u00a0Esomeprazol\u00a040\u00a0mg\u00a0und\u00a0Rabepr azol\u00a020\u00a0mg.\u00a0\nDexlansoprazol\u00a0wird\u00a0in\u00a0der\u00a02014\u00a0erstellten\u00a0Leitlinie\u00a0noch\u00a0nicht \u00a0erw\u00e4hnt\u00a0(DGVS,\u00a0\n2014).\u00a0\nDexlansoprazol\u00a0wurde\u00a0 keiner\u00a0fr\u00fchen\u00a0Nutzenbewertung \u00a0unterzogen ,\u00a0da\u00a0der\u00a0Her\u2010\nsteller\u00a0 f\u00fcr\u00a0 die\u00a0 Zulassung\u00a0 zum\u00a0 Te il\u00a0 Bezug\u00a0 auf\u00a0 die\u00a0 bestehenden\u00a0 Un terlagen\u00a0 zu\u00a0\nLansoprazol\u00a0genommen\u00a0hatte\u00a0(a\u2010t,\u00a02014).\u00a0\u00a0\nDexlansoprazol\u00a0ist\u00a0der\u00a0Festbetragsgruppe\u00a0PPI,\u00a0Gruppe\u00a01,\u00a0Stufe\u00a02 \u00a0zugeordnet\u00a0(G\u2010BA,\u00a0\n2015).\u00a0Als\u00a0einziger\u00a0PPI\u00a0ist\u00a0Dexlansoprazol\u00a0von\u00a0einer\u00a0Aufzahlung \u00a0in\u00a0H\u00f6he\u00a0von\u00a0zwei\u2010\nstelligen\u00a0Eurobetr\u00e4gen\u00a0betroffen.\u00a0\n\u00a0150\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0Weitere\u00a0Therapieoption\u00a0\nin\u00a0der\u00a0Gruppe\u00a0der\u00a0PPI\u00a0Kein\u00a0therapeutischer\u00a0\nZusatznutzen\u00a0gegen\u00fcber\u00a0\nanderen\u00a0PPI\u00a0belegt \u00a0Festbetragsgruppe:\u00a0GKV\u2010\nWirtschaftlichkeit\u00a0gew\u00e4hr\u2010\nleistet,\u00a0\u00a0\nmit\u00a0hohen\u00a0 Mehrkosten\u00a0f\u00fcr\u00a0\nPatienten \u00a0verbunden \u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Variante\u00a0ohne\u00a0\nbesonderen\u00a0\nStellenwert\u00a0\u2013\u00a0 \u2013\u00a0 Analogpr\u00e4parat\u00a0\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDexlansoprazol\u00a0\nTherapie\u00a0ERD\u00a0\n\u00a0\nErhaltungstherapie\u00a0ERD\u00a0\n\u00a0\nSymptomatische\u00a0Behandlung\u00a0\nNERD\u00a0\u00a0\n1x\u00a0tgl.\u00a060\u00a0mg\u00a0\u00fcber\u00a04\u00a0\nWochen\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a06\u00a0\nMonaten\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a04\u00a0\nWochen\u00a0\u00a0\n28\u00a0\n\u00a0\n183\u00a0\n\u00a0\n28\u00a0\u00a0\n90,63\u00a0\u20ac\u00a0\n\u00a0\n534,49\u00a0\u20ac\u00a0\n\u00a0\n81,78\u00a0\u20ac\u00a0\nMehrkosten\u00a0f\u00fcr\u00a0Patienten \u00a0 \u00a0 \u00a0 \u00a0\nTherapie\u00a0ERD\u00a0\n\u00a0\nErhaltungstherapie\u00a0ERD\u00a0\n\u00a0\nSymptomatische\u00a0Behandlung\u00a0\nNERD\u00a01x\u00a0tgl.\u00a060\u00a0mg\u00a0\u00fcber\u00a04\u00a0\nWochen\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a06\u00a0\nMonaten\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a04\u00a0\nWochen\u00a028\u00a0\n\u00a0\n183\u00a0\n\u00a0\n28\u00a075,17\u00a0\u20ac\u00a0\n\u00a0\n442,66\u00a0\u20ac\u00a0\n\u00a0\n67,73\u00a0\u20ac\u00a0\nFestbetrag\u00a0PPI\u00a0Gruppe\u00a01,\u00a0Stufe\u00a02\nTherapie\u00a0ERD\u00a0\n\u00a0\nErhaltungstherapie\u00a0ERD\u00a0\n\u00a0\nSymptomatische\u00a0Behandlung\u00a0\nNERD\u00a0\u00a0\n1x\u00a0tgl.\u00a0Standarddosis\u00a0\n\u00fcber\u00a04\u00a0Wochen\u00a0\n1x\u00a0tgl.\u00a0halbe\u00a0Standard\u2010\ndosis\u00a0bis\u00a0zu\u00a06\u00a0Monaten\u00a0\n1x\u00a0tgl.\u00a0halbe\u00a0Standard\u2010\ndosis\u00a0bis\u00a0zu\u00a04\u00a0Wochen\u00a0\u00a0\n28\u00a0\n\u00a0\n183\u00a0\n\u00a0\n28\u00a0\u00a0\n15,46\u00a0\u20ac\u00a0\n\u00a0\n101,04\u00a0\u20ac\u00a0\n\u00a0\n14,05\u00a0\u20ac\u00a0\nMehrkosten\u00a0f\u00fcr\u00a0Patienten \u00a0 \u00a0 \u00a0 \u00a0\nTherapie\u00a0ERD\u00a0\n\u00a0\nErhaltungstherapie\u00a0ERD\u00a0\n\u00a0\nSymptomatische\u00a0Behandlung\u00a0\nNERD\u00a01x\u00a0tgl.\u00a060\u00a0mg\u00a0\u00fcber\u00a04\u00a0\nWochen\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a06\u00a0\nMonaten\u00a0\n1x\u00a0tgl.\u00a030\u00a0mg\u00a0bis\u00a0zu\u00a04\u00a0\nWochen\u00a028\u00a0\n\u00a0\n183\u00a0\n\u00a0\n28\u00a075,17\u00a0\u20ac\u00a0\n\u00a0\n442,66\u00a0\u20ac\u00a0\n\u00a0\n67,73\u00a0\u20ac\u00a0\n151\u00a0Ausgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDurch\u00a0 die\u00a0 geringf\u00fcgigen\u00a0 Verordnun gszahlen\u00a0 k\u00f6nnen\u00a0 aus\u00a0 Datenschut zgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0erstellt\u00a0werden. \u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nWie\u00a0alle\u00a0PPI\u00a0hemmt\u00a0Dexlansoprazol\u00a0im\u00a0Magen\u00a0die\u00a0Aktivit\u00e4t\u00a0der\u00a0H+ /K+\u2010ATPase\u00a0in\u00a0\nden\u00a0Parietalzellen\u00a0des\u00a0Magens\u00a0und\u00a0verringert\u00a0auf\u00a0diesem\u00a0Weg\u00a0die \u00a0Sekretion\u00a0von\u00a0\nMagens\u00e4ure.\u00a0Dexlansoprazol\u00a0ist\u00a0wie\u00a0die\u00a0weiteren\u00a0Arzneistoffe\u00a0di eser\u00a0Wirkstoff\u2010\nklasse\u00a0ein\u00a0 Prodrug\u00a0und\u00a0wird\u00a0erst\u00a0im\u00a0sauren\u00a0Milieu\u00a0der\u00a0Parietalzellen\u00a0aktiviert\u00a0\n(Takeda,\u00a02017).\u00a0\u00a0\nDexlansoprazol\u00a0ist\u00a0das\u00a0R\u2010Enantiomer\u00a0von\u00a0Lansoprazol,\u00a0das\u00a0als\u00a0Ra zemat\u00a0von\u00a0R\u2010\u00a0und\u00a0\nS\u2010Enantiomer\u00a0vorliegt.\u00a0Beide\u00a0Enan tiomere\u00a0hemmen\u00a0die\u00a0Protonenpum pen\u00a0gleich\u00a0\nstark.\u00a0Da\u00a0die\u00a0Clearance\u00a0des\u00a0R\u2010En antiomers\u00a0aber\u00a0geringer\u00a0ausf\u00e4ll t\u00a0als\u00a0die\u00a0des\u00a0S\u2010\nEnantiomers,\u00a0bildet\u00a0Dexlansopraz ol\u00a0nach\u00a0der\u00a0Einnahme\u00a0von\u00a0Lansop razol\u00a0etwa\u00a080\u00a0%\u00a0\ndes\u00a0aktiven\u00a0Wirkstoffs\u00a0(a\u2010t,\u00a02014).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDexlansoprazol\u00a0ist\u00a0bei\u00a0Erwachsenen\u00a0und\u00a0Jugendlichen\u00a0ab\u00a012\u00a0Jahre n\u00a0zur\u00a0Behand\u2010\nlung\u00a0der\u00a0ERD,\u00a0zur\u00a0Erhaltungsther apie\u00a0bei\u00a0abgeheilter\u00a0ERD,\u00a0zur\u00a0L inderung\u00a0von\u00a0Sod\u2010\nbrennen\u00a0sowie\u00a0zur\u00a0kurzzeitigen\u00a0Behandlung\u00a0von\u00a0Sodbrennen\u00a0und\u00a0sa urem\u00a0Aufsto\u2010\n\u00dfen\u00a0bei\u00a0symptomatischer\u00a0NERD\u00a0(Ta keda,\u00a02017).\u00a0Im\u00a0Vergleich\u00a0zu\u00a0an deren\u00a0PPI\u00a0feh\u2010\nlen\u00a0in\u00a0der\u00a0Zulassung\u00a0von\u00a0Dexlansoprazol\u00a0weitere\u00a0Indikationen\u00a0wi e\u00a0etwa\u00a0die\u00a0Eradi\u2010\nkationstherapie\u00a0von\u00a0Helicobacter \u00a0pylori\u00a0und\u00a0die\u00a0Ulkustherapie\u00a0u nd\u00a0\u2010prophylaxe\u00a0\u00a0\n(a\u2010t,\u00a02014).\u00a0\nDas\u00a0Fertigarzneimittel\u00a0liegt\u00a0als\u00a0Hartkapseln\u00a0mit\u00a0ver\u00e4nderter\u00a0Wi rkstofffreisetzung\u00a0in\u00a0\nzwei\u00a0St\u00e4rken\u00a0(30\u00a0mg\u00a0und\u00a060\u00a0mg)\u00a0vor.\u00a0Dosierung\u00a0und\u00a0Behandlungsda uer\u00a0h\u00e4ngen\u00a0\nvon\u00a0der\u00a0Indikation\u00a0ab:\u00a0F\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0ERD\u00a0wird\u00a0eine\u00a0The rapie\u00a0mit\u00a060\u00a0mg\u00a0\neinmal\u00a0t\u00e4glich\u00a0\u00fcber\u00a0vier\u00a0Wochen\u00a0empfohlen,\u00a0bei\u00a0NERD\u00a030\u00a0mg\u00a0einma l\u00a0t\u00e4glich\u00a0\u00fcber\u00a0\nden\u00a0gleichen\u00a0Zeitraum.\u00a0Bei\u00a0Jugendlichen\u00a0und\u00a0Erwachsenen\u00a0werden\u00a0 zur\u00a0Erhaltungs\u2010\ntherapie\u00a030\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0verordnet.\u00a0Die\u00a0Therapiedauer\u00a0in\u00a0d ieser\u00a0Indikation\u00a0\nbetr\u00e4gt\u00a0bei\u00a0Erwachsenen\u00a0bis\u00a0zu\u00a0sechs\u00a0Monate,\u00a0f\u00fcr\u00a0Jugendliche\u00a0so llte\u00a0sie\u00a0aufgrund\u00a0\nfehlender\u00a0Daten\u00a0individuell\u00a0fest gelegt\u00a0werden.\u00a0Bei\u00a0eingeschr\u00e4nk ter\u00a0Nierenfunktion\u00a0\nund\u00a0leichter\u00a0Leberfunktionsst\u00f6rung \u00a0ist\u00a0keine\u00a0Dosisanpassung\u00a0not wendig,\u00a0bei\u00a0m\u00e4\u00dfig\u00a0\neingeschr\u00e4nkter\u00a0 Leberfunktion\u00a0 sollte\u00a0 der\u00a0 Arzt\u00a0 eine\u00a0 Anpassung\u00a0 de r\u00a0 maximalen\u00a0\nTagesdosis\u00a0auf\u00a030\u00a0mg\u00a0in\u00a0Erw\u00e4 gung\u00a0ziehen\u00a0(Takeda,\u00a02017).\u00a0\u00a0\nDie\u00a0Patienten\u00a0sollten\u00a0die\u00a0Hartkapseln\u00a0als\u00a0Ganzes\u00a0zusammen\u00a0mit\u00a0e iner\u00a0Mahlzeit\u00a0\noder\u00a0unabh\u00e4ngig\u00a0davon\u00a0einnehmen.\u00a0Bei\u00a0Schluckbeschwerden\u00a0ist\u00a0es\u00a0 auch\u00a0m\u00f6glich,\u00a0152\u00a0die\u00a0Kapseln\u00a0zu\u00a0\u00f6ffnen\u00a0und\u00a0das\u00a0enthaltene\u00a0Granulat\u00a0f\u00fcr\u00a0die\u00a0Einna hme\u00a0mit\u00a0einem\u00a0\nL\u00f6ffel\u00a0Apfelmus\u00a0zu\u00a0vermischen.\u00a0Das\u00a0Granulat\u00a0sollte\u00a0nicht\u00a0zerkau t\u00a0werden\u00a0(Takeda,\u00a0\n2017).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0 Definition\u00a0 der\u00a0 gastro\u00f6sophage alen\u00a0 Refluxkrankheit\u00a0 (GERD)\u00a0 fa sst\u00a0 mehrere\u00a0\nKrankheitsbilder\u00a0mit\u00a0st\u00f6renden\u00a0Symptomen\u00a0oder\u00a0Komplikationen\u00a0zu sammen,\u00a0die\u00a0\ndurch\u00a0R\u00fcckfluss\u00a0von\u00a0Mageninhalt\u00a0in\u00a0die\u00a0Speiser\u00f6hre\u00a0entstehen.\u00a0Z u\u00a0diesen\u00a0Krank\u2010\nheitsbildern\u00a0geh\u00f6ren\u00a0etwa\u00a0die\u00a0ERD\u00a0in\u00a0verschiedenen\u00a0Schweregrade n,\u00a0die\u00a0NERD\u00a0\noder\u00a0funktionelle\u00a0Refluxbeschwerden\u00a0wie\u00a0Sodbrennen.\u00a0Komplikatio nen\u00a0k\u00f6nnen\u00a0\nsich\u00a0in\u00a0der\u00a0Speiser\u00f6hre\u00a0selbst,\u00a0aber\u00a0auch\u00a0au\u00dferhalb\u00a0manifestier en.\u00a0Innerhalb\u00a0der\u00a0\nSpeiser\u00f6hre\u00a0k\u00f6nnen\u00a0sich\u00a0durch\u00a0den \u00a0Reflux\u00a0Stenosen\u00a0entwickeln,\u00a0a ber\u00a0auch\u00a0ein\u00a0\nBarrett\u2010\u00d6sophagus,\u00a0der\u00a0als\u00a0Pr\u00e4kanz erose\u00a0f\u00fcr\u00a0ein\u00a0Adenokarzinom\u00a0i m\u00a0distalen\u00a0Be\u2010\nreich\u00a0der\u00a0Speiser\u00f6hre\u00a0angesehen\u00a0wird.\u00a0Au\u00dferhalb\u00a0des\u00a0\u00d6sophagus\u00a0k ann\u00a0GERD\u00a0zu\u00a0\nSymptomen\u00a0 wie\u00a0 Laryngitis,\u00a0 chroni schem\u00a0 Husten\u00a0 oder\u00a0 Zahnerosionen \u00a0 f\u00fchren\u00a0\n(DGVS,\u00a02014).\u00a0\nGERD\u00a0gilt\u00a0als\u00a0h\u00e4ufige\u00a0Erkrankung\u00a0in\u00a0den\u00a0industrialisierten\u00a0L\u00e4nd ern,\u00a0die\u00a0Pr\u00e4valenz\u00a0\nwird\u00a0auf\u00a0etwa\u00a015\u00a0%\u00a0gesch\u00e4tzt\u00a0(DGVS,\u00a02014).\u00a0In\u00a0einer\u00a0Erhebung\u00a0de s\u00a0Robert\u00a0Koch\u2010\nInstituts\u00a0gaben\u00a0im\u00a0Jahr\u00a02009\u00a0rund\u00a0ein\u00a0Viertel\u00a0der\u00a0befragten\u00a0Erw achsenen\u00a0an,\u00a0unter\u00a0\nSodbrennen\u00a0oder\u00a0saurem\u00a0Aufsto\u00dfen\u00a0zu\u00a0leiden.\u00a0Rund\u00a014\u00a0%\u00a0berichtet en\u00a0\u00fcber\u00a0m\u00e4\u00dfi\u2010\nge\u00a0oder\u00a0starke\u00a0Beschwerden\u00a0(RKI,\u00a02013).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung\u00a0von\u00a0Dexlansoprazol\u00a0reichte\u00a0der\u00a0pharmazeutisch e\u00a0Unternehmer\u00a0\n(pU)\u00a0mehrere\u00a0randomisierte\u00a0kontrollierte\u00a0Studien\u00a0zu\u00a0verschieden en\u00a0Indikationen\u00a0ein.\u00a0\nZur\u00a0Behandlung\u00a0der\u00a0ERD\u00a0wurden\u00a0in\u00a0zwei\u00a0Studien\u00a0insgesamt\u00a04.092\u00a0P atienten\u00a0zwi\u2010\nschen\u00a018\u00a0und\u00a090\u00a0Jahren\u00a0eingeschlossen.\u00a071\u00a0%\u00a0der\u00a0Teilnehmer\u00a0litt en\u00a0unter\u00a0milden\u00a0\nBeschwerden,\u00a0bei\u00a029\u00a0%\u00a0war\u00a0eine\u00a0mittelschwere\u00a0bis\u00a0schwere\u00a0erosiv er\u00a0Reflux\u00f6so\u2010\nphagitis\u00a0diagnostiziert\u00a0worden.\u00a0Die\u00a0Teilnehmer\u00a0wurden\u00a0\u00fcber\u00a0acht \u00a0Wochen\u00a0behan\u2010\ndelt\u00a0und\u00a0erhielten\u00a0t\u00e4glich\u00a060\u00a0mg\u00a0Dexlansoprazol,\u00a090\u00a0mg\u00a0Dexlanso prazol\u00a0oder\u00a030\u00a0mg\u00a0\nLansoprazol.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0der\u00a0Anteil\u00a0der\u00a0Teilnehmer\u00a0mi t\u00a0endoskopisch\u00a0\nbest\u00e4tigter\u00a0Heilung,\u00a0Daten\u00a0zur\u00a0 Lebensqualit\u00e4t\u00a0wurden\u00a0nicht\u00a0erfa sst.\u00a0Beide\u00a0Studien\u00a0\nwaren\u00a0als\u00a0Nicht\u2010Unterlegenheitsstudien\u00a0konzipiert.\u00a0In\u00a0den\u00a0Studi en\u00a0lag\u00a0die\u00a0Heilungs\u2010\nrate\u00a0mit\u00a0Dexlansoprazol\u00a0bei\u00a092\u00a0bis\u00a095\u00a0%\u00a0der\u00a0Patienten,\u00a0mit\u00a0Lans oprazol\u00a0bei\u00a086\u00a0bis\u00a0\n92\u00a0%.\u00a0In\u00a0der\u00a0statistischen\u00a0Analyse\u00a0lie\u00df\u00a0sich\u00a0eine\u00a0Nicht\u2010\u00dcberleg enheit,\u00a0jedoch\u00a0keine\u00a0\n\u00dcberlegenheit\u00a0von\u00a0Dexlansoprazol\u00a0nachweisen.\u00a0Die\u00a0Dosierung\u00a0mit\u00a0 90\u00a0mg\u00a0zeigte\u00a0\nkeinen\u00a0eindeutig\u00a0h\u00f6heren\u00a0klinisc hen\u00a0Nutzen\u00a0als\u00a060\u00a0mg\u00a0(Sharma\u00a0et \u00a0al.,\u00a02009).\u00a0\u00a0153\u00a0In\u00a0zwei\u00a0weiteren\u00a0Studien\u00a0wurde\u00a0gepr\u00fcft,\u00a0wie\u00a0sich\u00a0die\u00a0Gabe\u00a0von\u00a0D exlansoprazol\u00a0in\u00a0\nverschiedenen\u00a0 Dosierungen\u00a0 \u00fcber\u00a0 einen\u00a0 Zeitraum\u00a0 von\u00a0 sechs\u00a0 Monaten \u00a0a u f \u00a0d e n \u00a0\nErhalt\u00a0des\u00a0Therapieerfolges\u00a0auswirkt.\u00a0445\u00a0Patienten\u00a0ab\u00a018\u00a0Jahre \u00a0mit\u00a0abgeheilter\u00a0\nERD,\u00a0die\u00a0bereits\u00a0an\u00a0einer\u00a0der\u00a0vorhergehenden\u00a0Studien\u00a0teilgenomm en\u00a0hatten,\u00a0er\u2010\nhielten\u00a0t\u00e4glich\u00a0entweder\u00a030\u00a0mg\u00a0o der\u00a060\u00a0mg\u00a0Dexlansoprazol\u00a0oder\u00a0P lacebo.\u00a0Am\u00a0Ende\u00a0\nder\u00a0Studie\u00a0lagen\u00a0bei\u00a075\u00a0%,\u00a083\u00a0%\u00a0 beziehungsweise\u00a027\u00a0%\u00a0der\u00a0Patien ten\u00a0keine\u00a0endo\u2010\nskopisch\u00a0feststellbaren\u00a0Erosionen\u00a0des\u00a0\u00d6sophagus\u00a0vor.\u00a0Dexlansopr azol\u00a0war\u00a0damit\u00a0\nPlacebo\u00a0\u00fcberlegen,\u00a0allerdings\u00a0lie\u00df\u00a0sich\u00a0kein\u00a0statistisch\u00a0signif ikanter\u00a0Unterschied\u00a0\nzwischen\u00a0den\u00a0beiden\u00a0Dosierungen\u00a0nachweisen.\u00a0Die\u00a0HRQoL\u00a0von\u00a0mit\u00a0D exlansoprazol\u00a0\nbehandelten\u00a0Patienten,\u00a0die\u00a0mit\u00a0dem\u00a0 Patient\u00a0Assessment\u00a0of\u00a0Upper\u00a0Gastrointestinal\u00a0\nDisorders\u00a0Quality\u00a0of\u00a0Life\u00a0 (PAGI\u2010QOL)\u2010Instrument\u00a0erfasst\u00a0wurde,\u00a0verbesserte\u00a0sich\u00a0\nsignifikant\u00a0gegen\u00fcber\u00a0der\u00a0Placebogruppe.\u00a0Genauere\u00a0Angaben\u00a0zur\u00a0G r\u00f6\u00dfenordnung\u00a0\nder\u00a0Verbesserung\u00a0und\u00a0der\u00a0klinischen\u00a0Relevanz \u00a0fehlen\u00a0jedoch\u00a0(Metz\u00a0et\u00a0al.,\u00a02009).\u00a0\nDie\u00a0zweite\u00a0Studie\u00a0umfasste\u00a0451\u00a0Pa tienten\u00a0ab\u00a018\u00a0Jahren,\u00a0die\u00a0pro\u00a0 Tag\u00a0entweder\u00a0\n60\u00a0mg\u00a0oder\u00a090\u00a0mg\u00a0Dexlansoprazol\u00a0oder\u00a0Placebo\u00a0erhielten.\u00a0Bei\u00a087\u00a0 %,\u00a082\u00a0%\u00a0bezie\u2010\nhungsweise\u00a0 26\u00a0%\u00a0 lie\u00dfen\u00a0 sich\u00a0 am\u00a0 Studienende\u00a0 endoskopisch\u00a0 keine\u00a0 \u00d6 sophagus\u2010\nL\u00e4sionen\u00a0feststellen.\u00a0Der\u00a0Unterschied\u00a0zu\u00a0Placebo\u00a0war\u00a0statistisc h\u00a0signifikant,\u00a0nicht\u00a0\njedoch\u00a0der\u00a0zwischen\u00a0den\u00a0beiden\u00a0Dosierungen\u00a0von\u00a0Dexlansoprazol.\u00a0 Die\u00a0Lebensqua\u2010\nlit\u00e4t,\u00a0gemessen\u00a0mit\u00a0dem\u00a0PAGI\u2010QOL\u2010Instrument,\u00a0verschlechterte\u00a0si ch\u00a0in\u00a0der\u00a0Place\u2010\nbogruppe\u00a0zum\u00a0Ende\u00a0der\u00a0Studie\u00a0in\u00a0klinisch\u00a0relevantem\u00a0Ausma\u00df,\u00a0w\u00e4h rend\u00a0sie\u00a0in\u00a0den\u00a0\nbeiden\u00a0Behandlungsgruppen\u00a0nahezu\u00a0konstant\u00a0blieb.\u00a0Die\u00a0Unterschie de\u00a0zwischen\u00a0\nden\u00a0Behandlungsgruppen\u00a0und\u00a0Placebo \u00a0waren\u00a0statistisch\u00a0signifikan t\u00a0(Howden\u00a0et\u00a0al.,\u00a0\n2009).\u00a0\nF\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0NERD\u00a0f\u00fchrte\u00a0der\u00a0pU\u00a0ebenfalls\u00a0mehrere\u00a0ran domisierte\u00a0\nkontrollierte\u00a0Studien\u00a0mit\u00a0verschiedenen\u00a0Dosierungen\u00a0durch.\u00a0305\u00a0 Patienten\u00a0ab\u00a018\u00a0\nJahren\u00a0erhielten\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0vier\u00a0Wochen\u00a0t\u00e4glich\u00a0en tweder\u00a030\u00a0mg\u00a0\nDexlansoprazol\u00a0oder\u00a0Placebo.\u00a0In\u00a0 der\u00a0Behandlungsgruppe\u00a0lag\u00a0der\u00a0m ediane\u00a0Anteil\u00a0\nvon\u00a0N\u00e4chten\u00a0ohne\u00a0Sodbrennen\u00a0bei\u00a073\u00a0%\u00a0im\u00a0Vergleich\u00a0zu\u00a036\u00a0%\u00a0unter \u00a0Placebo.\u00a0Die\u00a0\nHRQoL\u00a0wurde\u00a0nicht\u00a0explizit\u00a0erfasst\u00a0(Fass\u00a0et\u00a0al.,\u00a02011).\u00a0Im\u00a0Verg leich\u00a0von\u00a0t\u00e4glich\u00a0\n30\u00a0mg\u00a0beziehungsweise\u00a060\u00a0mg\u00a0Dexlansoprazol\u00a0mit\u00a0Placebo\u00a0bei\u00a0947\u00a0 Patienten\u00a0ab\u00a018\u00a0\nJahren\u00a0\u00fcber\u00a0vier\u00a0Wochen\u00a0f\u00fchrte\u00a0die\u00a0Einnahme\u00a0des\u00a0PPI\u00a0zu\u00a0signifik ant\u00a0mehr\u00a0Tagen\u00a0\n(bezogen\u00a0auf\u00a024\u00a0Stunden)\u00a0ohne\u00a0Sodbrennen.\u00a0Der\u00a0mediane\u00a0Anteil\u00a0la g\u00a0bei\u00a055\u00a0%\u00a0mit\u00a0\n30\u00a0mg\u00a0 Dexlansoprazol,\u00a0 50\u00a0%\u00a0 mit\u00a0 60\u00a0mg\u00a0 Dexlansoprazol\u00a0 und\u00a0 19\u00a0%\u00a0 mi t\u00a0 Placebo.\u00a0\nAllerdings\u00a0lie\u00df\u00a0sich\u00a0kein\u00a0signifikanter\u00a0Unterschied\u00a0zwischen\u00a0de n\u00a0beiden\u00a0Dosierun\u2010\ngen\u00a0feststellen.\u00a0Der\u00a0Score\u00a0f\u00fcr\u00a0H RQoL,\u00a0gemessen\u00a0mit\u00a0dem\u00a0PAGI\u2010QOL \u2010Instrument,\u00a0\nlag\u00a0 mit\u00a0 beiden\u00a0 Dexlansoprazol\u2010Dosierungen\u00a0 signifikant\u00a0 h\u00f6her\u00a0 als \u00a0m i t \u00a0P l a c e b o , \u00a0\njedoch\u00a0fehlen\u00a0Daten\u00a0zu\u00a0den\u00a0Ver\u00e4nderungen\u00a0des\u00a0Scores\u00a0im\u00a0Verlauf\u00a0 der\u00a0Behandlung\u00a0\nund\u00a0eine\u00a0Einordnung\u00a0der\u00a0klinische n\u00a0Relevanz\u00a0(Fass\u00a0et\u00a0al.,\u00a02009) .\u00a0Die\u00a0Ergebnisse\u00a0\neiner\u00a0Studie\u00a0zum\u00a0Vergleich\u00a0von\u00a0t\u00e4glich\u00a060\u00a0mg\u00a0beziehungsweise\u00a090 \u00a0mg\u00a0Dexlansop\u2010\nrazol\u00a0versus\u00a0Placebo\u00a0ist\u00a0lediglic h\u00a0in\u00a0Form\u00a0eines\u00a0Studienbericht s\u00a0publiziert.\u00a0Die\u00a0908\u00a0154\u00a0Teilnehmer\u00a0nahmen\u00a0die\u00a0Studienmedi kation\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von \u00a0vier\u00a0Wochen\u00a0\nein.\u00a0Der\u00a0Anteil\u00a0der\u00a0Tage\u00a0(bezoge n\u00a0auf\u00a024\u00a0Stunden)\u00a0ohne\u00a0Sodbrenn en\u00a0lag\u00a0mit\u00a060\u00a0mg\u00a0\nDexlansoprazol\u00a0bei\u00a046\u00a0%,\u00a0mit\u00a090\u00a0mg\u00a0bei\u00a053\u00a0%\u00a0und\u00a0mit\u00a0Placebo\u00a0bei \u00a017\u00a0%.\u00a0Die\u00a0Unter\u2010\nschiede\u00a0der\u00a0beiden\u00a0Dosierungen\u00a0waren\u00a0statistisch\u00a0signifikant\u00a0ge gen\u00fcber\u00a0Placebo,\u00a0\nallerdings\u00a0nicht\u00a0untereinander.\u00a0Die\u00a0HRQoL\u00a0wurde\u00a0in\u00a0dieser\u00a0Studi e\u00a0nicht\u00a0erfasst\u00a0\n(NCT00251745,\u00a02011).\u00a0\nDie\u00a0Wirksamkeit\u00a0bei\u00a0Jugendlichen\u00a0ab\u00a012\u00a0Jahren\u00a0mit\u00a0ERD\u00a0wurde\u00a0in\u00a0 einer\u00a0Studie\u00a0mit\u00a0\n63\u00a0Teilnehmern\u00a0untersucht.\u00a0In\u00a0der\u00a0ersten\u00a0Studienphase\u00a0erhielten \u00a0alle\u00a0Teilnehmer\u00a0\n60\u00a0mg\u00a0Dexlansoprazol\u00a0t\u00e4glich\u00a0\u00fcber\u00a0 einen\u00a0Zeitraum\u00a0von\u00a0acht\u00a0Woche n.\u00a0Am\u00a0Ende\u00a0\ndieser\u00a0Phase\u00a0waren\u00a0die\u00a0L\u00e4sionen\u00a0bei\u00a088\u00a0%\u00a0abgeheilt.\u00a0In\u00a0der\u00a0zwei ten\u00a0Studienphase\u00a0\nwurden\u00a051\u00a0dieser\u00a0Probanden\u00a0auf\u00a0einen\u00a0der\u00a0Studienarme\u00a0f\u00fcr\u00a0die\u00a0Er haltungsthera\u2010\npie\u00a0\u00fcber\u00a016\u00a0Wochen\u00a0randomisiert.\u00a0Die\u00a0Studienmedikation\u00a0in\u00a0diese r\u00a0Phase\u00a0war\u00a0\nDexlansoprazol\u00a030\u00a0mg\u00a0t\u00e4glich\u00a0oder\u00a0Placebo.\u00a0Am\u00a0Ende\u00a0der\u00a0Studie\u00a0l agen\u00a0bei\u00a082\u00a0%\u00a0der\u00a0\nTeilnehmer\u00a0in\u00a0der\u00a0Behandlungsgruppe\u00a0keine\u00a0endoskopisch\u00a0erkennba ren\u00a0L\u00e4sionen\u00a0\nvor,\u00a0in\u00a0der\u00a0Placebogruppe\u00a0waren\u00a0es\u00a058\u00a0%.\u00a0Statistische\u00a0Tests\u00a0wur den\u00a0mit\u00a0diesen\u00a0\nErgebnissen\u00a0 nicht\u00a0 durchgef\u00fchrt,\u00a0 auch\u00a0 fehlen\u00a0 Daten\u00a0 zur\u00a0 HRQoL\u00a0 (NC T01642615,\u00a0\n2015).\u00a0Die\u00a0Wirksamkeit\u00a0von\u00a030\u00a0mg\u00a0Dexlansoprazol\u00a0t\u00e4glich\u00a0bei\u00a0104 \u00a0Jugendlichen\u00a0mit\u00a0\nNERD\u00a0wurde\u00a0lediglich\u00a0in\u00a0einer\u00a0nicht\u2010kontrollierten\u00a0Studie\u00a0\u00fcber\u00a0 einen\u00a0Zeitraum\u00a0von\u00a0\nvier\u00a0Wochen\u00a0untersucht\u00a0(NCT01642602,\u00a02014).\u00a0\nDas\u00a0Sicherheitsprofil\u00a0von\u00a0Dexlansoprazol\u00a0entspricht\u00a0dem\u00a0anderer \u00a0PPI:\u00a0Zu\u00a0den\u00a0h\u00e4u\u2010\nfigsten\u00a0UAW\u00a0geh\u00f6ren\u00a0Durchfall,\u00a0Bauchschmerzen,\u00a0Kopfschmerzen,\u00a0\u00dc belkeit,\u00a0ab\u2010\ndominale\u00a0Beschwerden,\u00a0Bl\u00e4hungen\u00a0und\u00a0Verstopfung.\u00a0Diese\u00a0Beschwer den\u00a0wurden\u00a0\nin\u00a0klinischen\u00a0Studien\u00a0\u00fcber\u00a0eine\u00a0m aximale\u00a0Behandlungsdauer\u00a0von\u00a0e inem\u00a0Jahr\u00a0er\u2010\nfasst.\u00a0Nach\u00a0der\u00a0Zulassung\u00a0gab\u00a0es\u00a0Berichte\u00a0\u00fcber\u00a0schwerwiegende\u00a0\u00dc berempfindlich\u2010\nkeitsreaktionen,\u00a0deren\u00a0H\u00e4ufigkeit\u00a0sich\u00a0jedoch\u00a0nicht\u00a0quantifizie ren\u00a0l\u00e4sst.\u00a0Durch\u00a0die\u00a0\nverringerte\u00a0Azidit\u00e4t\u00a0des\u00a0Magens\u00a0nimmt\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0gastrointe stinale\u00a0Infektionen\u00a0\nleicht\u00a0 zu.\u00a0 Bei\u00a0 langfristiger\u00a0 Behandlung\u00a0 kann\u00a0 eine\u00a0 Hypomagnesi\u00e4m ie\u00a0 auftreten.\u00a0\nBesonders\u00a0bei\u00a0h\u00f6herer\u00a0Dosierung\u00a0und\u00a0sehr\u00a0langer\u00a0Anwendung\u00a0von\u00a0\u00fc ber\u00a0einem\u00a0\nJahr\u00a0wurde\u00a0ein\u00a0erh\u00f6htes\u00a0Frakturri siko\u00a0beobachtet,\u00a0\u00fcberwiegend\u00a0b ei\u00a0\u00e4lteren\u00a0Patien\u2010\nten\u00a0 oder\u00a0 bei\u00a0 bestehenden\u00a0 anderen\u00a0 Risikofaktoren\u00a0 (Fachinformatio n\u00a0 Dexilant\u00ae,\u00a0\n2017)\u00a0\nLeitlinienempfehlungen\u00a0\nZur\u00a0Behandlung\u00a0von\u00a0Refluxsymptome n\u00a0empfiehlt\u00a0die\u00a0aktuelle\u00a0deuts che\u00a0Leitlinie\u00a0\ndie\u00a0Behandlung\u00a0mit\u00a0einem\u00a0PPI\u00a0in\u00a0Standarddosis\u00a0\u00fcber\u00a0vier\u00a0Wochen, \u00a0wenn\u00a0Endosko\u2010\npie\u2010Befunde\u00a0 fehlen.\u00a0 Finden\u00a0 sich\u00a0 endoskopisch\u00a0 bei\u00a0 einem\u00a0 Patiente n\u00a0 mit\u00a0 Re\u2010\nfluxsymptomen\u00a0keine\u00a0L\u00e4sionen,\u00a0wi rd\u00a0die\u00a0halbe\u00a0Standarddosis\u00a0\u00fcber \u00a0den\u00a0gleichen\u00a0\nZeitraum\u00a0empfohlen.\u00a0Bei\u00a0leichter\u00a0Reflux\u00f6sophagitis\u00a0betr\u00e4gt\u00a0die\u00a0 Therapiedauer\u00a0vier\u00a0\nWochen,\u00a0bei\u00a0schwerer\u00a0Reflux\u00f6sopha gitis\u00a0acht\u00a0Wochen,\u00a0jeweils\u00a0in\u00a0 Standarddosie\u2010155\u00a0rung.\u00a0Bei\u00a0schwerer\u00a0Reflux\u00f6sophagi tis\u00a0empfiehlt\u00a0die\u00a0Leitlinie\u00a0ei ne\u00a0anschlie\u00dfende\u00a0\nLangzeittherapie,\u00a0Daten\u00a0liegen\u00a0allerdings\u00a0nur\u00a0f\u00fcr\u00a0eine\u00a0Therapie dauer\u00a0von\u00a0sechs\u00a0bis\u00a0\nzw\u00f6lf\u00a0Monaten\u00a0vor\u00a0(DGVS,\u00a02014).Empfehlungen\u00a0f\u00fcr\u00a0einen\u00a0bestimmte n\u00a0PPI\u00a0spricht\u00a0\ndie\u00a0 Leitlinie\u00a0 nicht\u00a0 aus.\u00a0 Als\u00a0 \u00e4quivalente\u00a0 Standarddosierungen\u00a0 ge lten\u00a0 Omeprazol\u00a0\n20\u00a0mg,\u00a0Pantoprazol\u00a040\u00a0mg,\u00a0Lansoprazol\u00a030\u00a0mg,\u00a0Esomeprazol\u00a040\u00a0mg\u00a0 und\u00a0Rabeprazol\u00a0\n20\u00a0mg.\u00a0Dexlansoprazol\u00a0wird\u00a0in\u00a0der\u00a02014\u00a0erstellten\u00a0Leitlinie\u00a0noc h\u00a0nicht\u00a0erw\u00e4hnt\u00a0\n(DGVS,\u00a02014).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung\u00a0hat\u00a0der\u00a0Herste ller\u00a0zum\u00a0Teil\u00a0Bezug\u00a0auf\u00a0die\u00a0Unt erlagen\u00a0zu\u00a0Lansop\u2010\nrazol\u00a0genommen.\u00a0Aus\u00a0diesem\u00a0Grund\u00a0besteht\u00a0f\u00fcr\u00a0Dexlansoprazol\u00a0kei n\u00a0Unterlagen\u2010\nschutz\u00a0und\u00a0es\u00a0entfiel\u00a0die\u00a0fr\u00fche\u00a0N utzenbewertung\u00a0(a\u2010t,\u00a02014).\u00a0Im \u00a0M\u00e4rz\u00a02015\u00a0hat\u00a0der\u00a0\nGemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0beschlossen,\u00a0Dexlansoprazol\u00a0e iner\u00a0Festbe\u2010\ntragsgruppe\u00a0zuzuordnen\u00a0(Protonenpumpenhemmer,\u00a0Gruppe\u00a01,\u00a0Stufe\u00a02 ).\u00a0Der\u00a0Be\u2010\nschluss\u00a0ist\u00a0im\u00a0Mai\u00a02015\u00a0in\u00a0Kraft\u00a0getreten\u00a0(G\u2010BA,\u00a02015).\u00a0\nQuellen\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014).\u00a0Protonenpumpenhemmer\u00a0Nr.\u00a06:\u00a0Dexl ansoprazol\u00a0(Dexilant).\u00a0a\u2010t\u00a045(8):\u00a075\u201076.\u00a0\u00a0\na\u2010t\u00a0d\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0datenbank\u00a0(2017).\u00a0Bewertung:\u00a0Dexlansop razol.\u00a0https://www.arznei\u2010telegramm.de/db/01wkstxt.\u00a0\nphp3?&knr=&art=mono&nummer=Dexlansoprazol&ord=uaw,\u00a0letzter\u00a0Zugr iff:\u00a020.04.2017.\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten\u00a0(2014).\u00a0S2k\u2010Leitlinie\u00a0\nGastro\u00f6sophageale\u00a0Refluxkrankheit.\u00a0www.awmf.org/leitlinien/deta il/ll/021\u2010013.html,\u00a0letzter\u00a0Zugriff:\u00a020.04.2017.\u00a0\nFachinformation\u00a0Dexilant\u00ae\u00a0(2017).\u00a0Fachinformation\u00a0Dexilant\u00ae.\u00a0St and\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0\u00a0\nFass\u00a0R,\u00a0Chey\u00a0WD,\u00a0Zakko\u00a0SF,\u00a0Andhivarothai\u00a0N,\u00a0Palmer\u00a0RN,\u00a0Perez\u00a0MC ,\u00a0Atkinson\u00a0SN\u00a0(2009).\u00a0Clinical\u00a0t rial:\u00a0the\u00a0effects\u00a0of\u00a0the\u00a0proton \u00a0\npump\u00a0inhibitor\u00a0dexlansoprazole\u00a0MR\u00a0on\u00a0daytime\u00a0and\u00a0nighttime\u00a0hear tburn\u00a0in\u00a0patients\u00a0with\u00a0non\u2010erosive\u00a0reflux\u00a0disease.\u00a0\nAliment\u00a0Pharmacol\u00a0&\u00a0Therap\u00a029(12):\u00a01261\u20101272.\u00a0\u00a0\nFass\u00a0R,\u00a0Johnson\u00a0DA,\u00a0Orr\u00a0WC,\u00a0Han\u00a0C,\u00a0Mody\u00a0R,\u00a0Stern\u00a0KN\u00a0et\u00a0al.\u00a0(201 1).\u00a0The\u00a0Effect\u00a0of\u00a0Dexlansoprazole\u00a0MR\u00a0on\u00a0Nocturnal\u00a0Heartburn\u00a0and \u00a0\nGERD\u2010Related\u00a0Sleep\u00a0Disturbances\u00a0in\u00a0Patients\u00a0With\u00a0Symptomatic\u00a0GE RD.\u00a0Amer\u00a0J\u00a0Gastroenterol\u00a0106(3):\u00a0421\u2010431.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Arzneimittel\u2010Richtli nie/Anlage\u00a0IX:\u00a0Festbetragsgruppenbildung\u00a0\nProtonenpumpenhemmer,\u00a0Gruppe\u00a01,\u00a0in\u00a0Stufe\u00a02.\u00a0https://www.g\u2010ba.de /informationen/beschluesse/2213/,\u00a0letzter\u00a0\nZugriff:\u00a020.04.2017.\u00a0\nHowden\u00a0CW,\u00a0Larsen\u00a0LM,\u00a0Perez\u00a0MC,\u00a0Palmer\u00a0R,\u00a0Atkinson\u00a0SN\u00a0(2009).\u00a0C linical\u00a0trial:\u00a0efficacy\u00a0and\u00a0safet y\u00a0of\u00a0dexlansoprazole\u00a0MR\u00a060\u00a0and \u00a0\n90\u00a0mg\u00a0in\u00a0healed\u00a0erosive\u00a0oesophagitis\u00a0\u2010\u00a0maintenance\u00a0of\u00a0healing\u00a0a nd\u00a0symptom\u00a0relief.\u00a0Aliment\u00a0Pharmacol\u00a0&\u00a0Therap\u00a0\n30(9):\u00a0895\u2010907.\u00a0\u00a0\nMetz\u00a0DC,\u00a0Howden\u00a0CW,\u00a0Perez\u00a0MC,\u00a0Larsen\u00a0L,\u00a0O\u2019NeilL\u00a0J,\u00a0Atkinson\u00a0SN\u00a0 (2009).\u00a0Clinical\u00a0trial:\u00a0dexlansoprazole\u00a0MR,\u00a0a\u00a0proton\u00a0pump\u00a0\ninhibitor\u00a0with\u00a0dual\u00a0delayed\u2010release\u00a0technology,\u00a0effectively\u00a0con trols\u00a0symptoms\u00a0and\u00a0prevents\u00a0 relapse\u00a0in\u00a0patients\u00a0with\u00a0\nhealed\u00a0erosive\u00a0oesophagitis.\u00a0Alimentary\u00a0Pharmacology\u00a0&\u00a0Therapeu tics\u00a029(7):\u00a0742\u2010754.\u00a0\u00a0156\u00a0NCT00251745\u00a0(2011).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Dexlansoprazole\u00a0Modi fied\u00a0Release\u00a0Formulation\u00a0to\u00a0Treat\u00a0Heartburn.\u00a0\nhttps://www.clinicaltrials.gov/ct2/show/results/NCT00251745,\u00a0le tzter\u00a0Zugriff\u00a020.04.2017.\u00a0\nNCT01642602\u00a0(2014).\u00a0Safety\u00a0and\u00a0Efficacy\u00a0of\u00a0Dexlansoprazole\u00a0Dela yed\u2010Release\u00a0Capsules\u00a0in\u00a0Treating\u00a0Symptomatic\u00a0Non\u2010Erosive\u00a0\nGastroesophageal\u00a0Reflux\u00a0Disease\u00a0in\u00a0Adolescents.\u00a0https://www.cli nicaltrials.gov/ct2/show/results/NCT01642602,\u00a0\nletzter\u00a0Zugriff:\u00a020.04.2017.\u00a0\nNCT01642615\u00a0(2015).\u00a0Safety\u00a0and\u00a0Efficacy\u00a0of\u00a0Dexlansoprazole\u00a0Dela yed\u2010Release\u00a0Capsules\u00a0for\u00a0Healing\u00a0of\u00a0Erosive\u00a0Esophagitis\u00a0and\u00a0\nMaintenance\u00a0of\u00a0Healed\u00a0Erosive\u00a0Esophagitis\u00a0and\u00a0Relief\u00a0of\u00a0Heartbu rn\u00a0in\u00a0Adolescents.\u00a0\nhttps://www.clinicaltrials.gov/ct2/show/results/NCT01642615,\u00a0le tzter\u00a0Zugriff:\u00a020.04.2017.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Dexlansoprazol.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=52025,\u00a0letzter\u00a0Zugriff:\u00a020.04.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut(2013).\u00a0Gesundheitsberichterstattung\u00a0 des\u00a0Bundes,\u00a0Heft\u00a055:\u00a0\u2010\u00a0Gastritis,\u00a0Magen\u2010\u00a0und\u00a0\nZw\u00f6lffingerdarmgeschw\u00fcre.\u00a0www.rki.de/DE/Content/Gesundheitsmoni toring/Gesundheitsberichterstattung\u00a0\n/Themenhefte/gastritis_inhalt.html?nn=2370692,\u00a0letzter\u00a0Zugriff\u00a0 20.04.2017\u00a0\nSharma\u00a0P,\u00a0Shaheen\u00a0NJ,\u00a0Perez\u00a0MC,\u00a0Pilmer\u00a0BL,\u00a0Lee\u00a0M,\u00a0Atkinson\u00a0SN\u00a0e t\u00a0al.\u00a0(2009).\u00a0Clinical\u00a0trials:\u00a0h ealing\u00a0of\u00a0erosive\u00a0oesophagitis\u00a0 with\u00a0\ndexlansoprazole\u00a0MR,\u00a0a\u00a0proton\u00a0pump\u00a0inhibitor\u00a0with\u00a0a\u00a0novel\u00a0dual\u00a0d elayed\u2010release\u00a0formulation\u00a0\u2010\u00a0results\u00a0from\u00a0two\u00a0\nrandomized\u00a0controlled\u00a0studies.\u00a0Alimentary\u00a0Pharmacology\u00a0&\u00a0Therap eutics\u00a029(7):\u00a0731\u2010741.\u00a0\n\u00a0\u00a0157\u00a04.10 Dimethylfumarat\u00a0\nHandelsname:\u00a0Tecfidera\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0schubf\u00f6rmig\u00a0remittierende\u00a0 Biogen\u00a0Idec\u00a0\nMultiple\u00a0Sklerose\u00a0\nATC\u2010Code:\u00a0N07XX09\u00a0 \u00a0 \u00a0 Mar kteinf\u00fchrung:\u00a0M\u00e4rz\u00a02014\u00a0\nDarreichungsform:\u00a0Kapsel\u00a0\u00a0 \u00a0 DDD:\u00a00,48\u00a0g\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a02\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDie\u00a0immunmodulierenden\u00a0Effekte\u00a0vo n\u00a0Fumars\u00e4ureestern\u00a0bei\u00a0Psorias is\u2010Patienten\u00a0\nsind\u00a0seit\u00a01959\u00a0bekannt.\u00a0Bei\u00a0einem\u00a0gleichzeitig\u00a0an\u00a0Psoriasis\u00a0und \u00a0Multipler\u00a0Sklerose\u00a0\n(MS)\u00a0erkrankten\u00a0Patienten\u00a0ergaben\u00a0sich\u00a0in\u00a0einem\u00a0Krankenhaus\u00a0in\u00a0 Bochum\u00a0Hinwei\u2010\nse,\u00a0dass\u00a0durch\u00a0Fumars\u00e4ureester\u00a0die\u00a0H\u00e4ufigkeit\u00a0von\u00a0MS\u2010Sch\u00fcben\u00a0re duziert\u00a0werden\u00a0\nk\u00f6nnten\u00a0(Stahl,\u00a02014).\u00a0Aus\u00a0dem\u00a0seit\u00a01994\u00a0vom\u00a0Bundesinstitut\u00a0f\u00fcr \u00a0Arzneimittel\u00a0und\u00a0\nMedizinprodukte\u00a0(BfArM)\u00a0zur\u00a0Therapie\u00a0der\u00a0schweren\u00a0Psoriasis\u00a0zug elassenen\u00a0Arz\u2010\nneimittel\u00a0Fumaderm\u00ae,\u00a0das\u00a0neben\u00a0120\u00a0mg\u00a0Dimethylfumarat\u00a0(=56 \u00a0%)\u00a0(DMF)\u00a0weitere\u00a0\nFumars\u00e4ureethylester\u00a0enth\u00e4lt\u00a0(AMIS,\u00a02017),\u00a0wurde\u00a0nunmehr\u00a0magens aftresitent\u00a0\nverkapseltes\u00a0reines\u00a0DMF\u00a0zur\u00a0\u201eBehandlung\u00a0von\u00a0erwachsenen\u00a0Patient en\u00a0mit\u00a0Re\u2010\nlapsing\u2010Remitting \u00a0MS\u201c\u00a0(RRMS)\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0(EC)\u00a0auf\u00a0Empfeh\u2010\nlung\u00a0der\u00a0 European\u00a0Medicines\u00a0Agency \u00a0(EMA)\u00a0als\u00a0\u201eneuer\u00a0Wirkstoff\u201c\u00a0mit\u00a0hieraus\u00a0\nresultierendem\u00a0Unterlagenschutz \u00a0am\u00a030.01.2014\u00a0zugelassen\u00a0sowie\u00a0 ab\u00a0M\u00e4rz\u00a02014\u00a0\nin\u00a0der\u00a0Lauer\u2010Taxe\u00a0gef\u00fchrt\u00a0(a\u2010t,\u00a02014a;\u00a0CHMP,\u00a02014c;\u00a0Lauer\u2010Fisch er,\u00a02017).\u00a0Die\u00a0ma\u2010\ng e n s a f t r e s i s t e n t e n \u00a0H a r t k a p s e l n \u00a0s o l l e n \u00a02 x \u00a0t \u00e4 g l i c h \u00a0( t g l . ) \u00a0w \u00e4 h r e n d \u00a0e i n e r \u00a0M a h l z e i t \u00a0\neingenommen\u00a0 werden,\u00a0 initial\u00a0 120\u00a0mg \u00a0 2x\u00a0tgl.\u00a0 f\u00fcr\u00a0 sieben\u00a0 Tage,\u00a0 sof ern\u00a0 toleriert\u00a0\n240\u00a0mg\u00a02x\u00a0tgl.\u00a0ab\u00a0der\u00a0zweiten\u00a0Woche\u00a0(CHMP,\u00a02017).\u00a0Die\u00a0immunmodu lierende\u00a0bzw.\u00a0\nentz\u00fcndungshemmende\u00a0Wirkung\u00a0wird\u00a0sowohl\u00a0durch\u00a0Agonismus\u00a0am\u00a0 Hydroxy\u00a0Car\u2010\nboxylic\u00a0Acid\u00a0Receptor\u00a02 \u00a0(HCAR2)\u00a0als\u00a0auch\u00a0\u00fcber\u00a0die\u00a0Aktivierung\u00a0des\u00a0 Nuclear\u00a0factor\u00a0\n(erythroid\u2010derived\u00a02)\u2010like\u00a02 \u00a0(Nrf2)\u2010Transkriptionswegs\u00a0postuliert,\u00a0ist\u00a0aber\u00a0final\u00a0nicht\u00a0\nerkl\u00e4rt\u00a0(Chen,\u00a02014;\u00a0Viegener,\u00a02014).\u00a0\nZur\u00a0Therapie\u00a0der\u00a0MS\u00a0besteht\u00a0Beda rf\u00a0an\u00a0risikoarmen\u00a0immunmodulier enden\u00a0Arz\u2010\nneimitteln,\u00a0um\u00a0vor\u00a0allem\u00a0die\u00a0Krankheitsprogression\u00a0durch\u00a0eine\u00a0D auertherapie\u00a0zu\u00a0\nverlangsamen.\u00a0In\u00a0diesem\u00a0Kontext\u00a0sogenannten\u00a0 unmet\u00a0medical\u00a0needs \u00a0erfolgte\u00a0die\u00a0\nZulassung\u00a0 von\u00a0 DMF\u00a0 basierend\u00a0 auf\u00a0 den\u00a0 beiden\u00a0 Phase\u2010III\u2010Studien\u00a0 DE FINE\u00a0 und\u00a0\nCONFIRM\u00a0(a\u2010t,\u00a02014a).\u00a0\nIn\u00a0 der\u00a0 zulassungsrelevanten\u00a0 Ph ase\u2010III\u2010Studie\u00a0 DEFINE\u00a0 bzw.\u00a0 109MS3 01\u00a0 (Sponsor:\u00a0\nBiogen,\u00a0NCT00420212)\u00a0wurden\u00a0multizentrisch,\u00a0doppelblind,\u00a01:1:1\u00a0 randomisiert,\u00a0\nplacebokontrolliert\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0von\u00a0240\u00a0mg\u00a0D MF\u00a0(Studienna\u2010\nme:\u00a0BG\u201012)\u00a02x\u00a0oder\u00a03x\u00a0tgl.\u00a0gege n\u00fcber\u00a0Placebo\u00a0an\u00a01.234\u00a0Patienten \u00a0mit\u00a0RRMS\u00a0\u00fcber\u00a0\n96\u00a0Wochen\u00a0gepr\u00fcft.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0Schubrate\u00a0binnen\u00a0z wei\u00a0Jahren,\u00a0\n158\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0die\u00a0Anzahl\u00a0Ga dolinium(GD)\u2010aufnehmender,\u00a0T1\u2010 \u00a0sowie\u00a0T2\u2010\nL\u00e4sionen\u00a0in\u00a0der\u00a0Magnetresonanzto mographie\u00a0(MRT),\u00a0j\u00e4hrliche\u00a0Schu brate\u00a0sowie\u00a0\nMorbidit\u00e4t\u00a0anhand\u00a0der\u00a0 Expanded\u00a0Disability\u00a0Status\u00a0Scale \u00a0(EDSS).\u00a0Eingeschlossen\u00a0\nwerden\u00a0konnten\u00a0RRMS\u00a0Patienten\u00a0zwischen\u00a018\u00a0und\u00a055\u00a0Lebensjahren\u00a0g em\u00e4\u00df\u00a0McDo\u2010\nnald\u2010Kriterien\u00a01\u20104,\u00a0EDSS\u00a00,0\u00a0bis\u00a05,0\u00a0und\u00a0einem\u00a0Schub\u00a0im\u00a0Vorjahr .\u00a0Ausgeschlossen\u00a0\nwaren\u00a0 RRMS\u2010Patienten\u00a0 mit\u00a0 chronischen\u00a0 Immun\u2010,\u00a0 Krebs\u2010,\u00a0 akuten\u00a0 uro logischen,\u00a0\npulmonalen\u00a0bzw.\u00a0gastrointestinalen\u00a0Erkrankungen\u00a0bzw.\u00a0Frauen\u00a0in\u00a0 Schwangerschaft\u00a0\noder\u00a0Stillzeit\u00a0(ClinicalTrials.gov,\u00a02007b).\u00a0Gold\u00a0und\u00a0Kollegen\u00a0b erichten\u00a0zum\u00a0prim\u00e4ren\u00a0\nEndpunkt\u00a0\u201eAnteil\u00a0Patienten\u00a0mit\u00a0Schub\u201c,\u00a0dass\u00a0unter\u00a0DMF\u00a02x\u00a0tgl.\u00a02 7%,\u00a0bei\u00a03x\u00a0tgl.\u00a0\nDMF\u00a026\u00a0%\u00a0gegen\u00fcber\u00a046\u00a0%\u00a0unter\u00a0Placebo\u00a0betroffen\u00a0waren\u00a0(p<0,0001 )\u00a0(Gold\u00a0et\u00a0al.,\u00a0\n2012).\u00a0Hieraus\u00a0ergibt\u00a0sich\u00a0eine\u00a0Risikoreduktion\u00a0von\u00a049\u00a0%\u00a0bzw.\u00a05 0\u00a0%\u00a0von\u00a02x\u00a0bzw.\u00a0\n3x\u00a0tgl.\u00a0DMF\u00a0gegen\u00fcber\u00a0Placebo.\u00a0Ling\u00a0vom\u00a0CDER\u00a0der\u00a0FDA\u00a0stellte\u00a0im \u00a0summary\u00a0review \u00a0\nfest,\u00a0dass\u00a0im\u00a0patientenrelevanten\u00a0sekund\u00e4ren\u00a0Endpunkt\u00a0\u201eReduktio n\u00a0der\u00a0\u00fcber\u00a024\u00a0\nWochen\u00a0anhaltenden\u00a0Behinderungsprogression\u201c\u00a0gegen\u00fcber\u00a0Placebo\u00a00 ,169,\u00a0DMF\u00a02x\u00a0\n0,128\u00a0bzw.\u00a03x\u00a0t\u00e4glich\u00a00,119\u00a0eine\u00a0Risikoreduktion\u00a0durch\u00a0DMF\u00a0in\u00a0H \u00f6he\u00a0von\u00a023\u00a0%\u00a0bzw.\u00a0\n31\u00a0%\u00a0gegen\u00fcber\u00a0Placebo\u00a0(p=0,1893\u00a0bzw.\u00a0p=0,0760)\u00a0eine\u00a0zwar\u00a0numer ische\u00a0aber\u00a0nicht\u00a0\nstatistische\u00a0Signifikanz\u00a0gezeigt\u00a0werden\u00a0konnte,\u00a0obwohl\u00a0die\u00a0Erge bnisse\u00a0des\u00a0Endpunk\u2010\ntes\u00a0\u201eReduktion\u00a0von\u00a0\u00fcber\u00a012\u00a0Wochen\u00a0anhaltender\u00a0Behinderungsprogr ession\u201c\u00a0statis\u2010\ntisch\u00a0signifikant\u00a0f\u00fcr\u00a0DMF\u00a0ausfielen\u00a0(CDER,\u00a02013b).\u00a0\nIn\u00a0der\u00a0zweiten\u00a0zulassungsbegr\u00fcndenden\u00a0Phase\u2010III\u2010Studie\u00a0CONFIRM\u00a0 bzw.\u00a0109MS3\u00a0\n02\u00a0(Sponsor:\u00a0Biogen,\u00a0NCT00451451)\u00a0wurde,\u00a0\u00e4hnlich\u00a0der\u00a0Studie\u00a0DEF INE,\u00a0multizent\u2010\nrisch,\u00a0doppelblind,\u00a01:1:1:1\u00a0randomisiert,\u00a0placebokontrolliert\u00a0d ie\u00a0Wirksamkeit\u00a0und\u00a0\nSicherheit\u00a0von\u00a0DMF\u00a02x\u00a0bzw.\u00a03x\u00a0tgl.\u00a0240\u00a0mg\u00a0gegen\u00fcber\u00a0Placebo\u00a0sow ie\u00a0nunmehr\u00a0in\u00a0\neinem\u00a0zus\u00e4tzlichen\u00a0Arm\u00a0mit\u00a0aktivem\u00a0Komparator\u00a0Glatirameracetat\u00a0 20\u00a0mg\u00a0tgl.\u00a0an\u00a0\n1.417\u00a0RRMS\u2010Patienten\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0gepr\u00fcft.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0j\u00e4hrli\u2010\nche\u00a0Schubrate\u00a0binnen\u00a0zwei\u00a0Jahren,\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0Ver\u00e4nderu ng\u00a0von\u00a0T1\u2010\u00a0\nbzw.\u00a0T2\u2010L\u00e4sionen\u00a0im\u00a0MRT,\u00a0Anteil\u00a0Patienten\u00a0mit\u00a0Sch\u00fcben\u00a0sowie\u00a0Ver \u00e4nderung\u00a0des\u00a0\nEDSS.\u00a0Ein\u2010\u00a0und\u00a0Ausschlusskriterien\u00a0\u00e4hnelten\u00a0der\u00a0Studie\u00a0DEFINE\u00a0( ClinicalTrials.gov,\u00a0\n2007a).\u00a0Zum\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0berichten\u00a0Fox\u00a0et\u00a0al.\u00a0eine\u00a0j\u00e4hrlic he\u00a0Schubrate\u00a0von\u00a0\n0,224\u00a0unter\u00a0DMF\u00a02x\u00a0tgl.,\u00a00,198\u00a0b ei\u00a0DMF\u00a03x\u00a0tgl.\u00a0gegen\u00fcber\u00a00,401\u00a0 unter\u00a0Placebo,\u00a0was\u00a0\neiner\u00a0Risikoreduktion\u00a0von\u00a044\u00a0%\u00a0bzw.\u00a051\u00a0%\u00a0entspricht\u00a0(<0,0001)\u00a0( Fox\u00a0et\u00a0al.,\u00a02012).\u00a0In\u00a0\nCONFIRM\u00a0konnte\u00a0die\u00a0Wirkung\u00a0von\u00a0DMF\u00a0zur\u00a0Reduktion\u00a0der\u00a0\u201eBehinderu ngsprogres\u2010\nsion\u201c\u00a0weder\u00a0\u00fcber\u00a0\u201ezw\u00f6lf\u201c\u00a0noch\u00a0\u201e\u00fcber\u00a024\u00a0Wochen\u201c\u00a0statistisch\u00a0sign ifikant\u00a0(p\u2010Werte\u00a0>\u00a0\n0,05)\u00a0nachgewiesen\u00a0werden,\u00a0d.h.\u00a0e s\u00a0sind\u00a0weitere\u00a0Langzeitstudien \u00a0zur\u00a0Pr\u00fcfung\u00a0eines\u00a0\nE f f e k t e s \u00a0v o n \u00a0D M F \u00a0a u f \u00a0d i e \u00a0B e h i n d e r u n g s p r o g r e s s i o n \u00a0n o t w e n d i g \u00a0( C D E R,\u00a0 2013a,\u00a0\n2013b).\u00a0\nAufgrund\u00a0des\u00a0Studiendesigns\u00a0von\u00a0CONFIRM\u00a0ist\u00a0ein\u00a0Vergleich\u00a0mit\u00a0G latirameracetat\u00a0\nauf\u00a0Unter\u2010\u00a0oder\u00a0\u00dcberlegenheit\u00a0nicht\u00a0m\u00f6glich\u00a0und\u00a0dieser\u00a0Studiena rm\u00a0wurde\u00a0weder\u00a0\nvom\u00a0CDER\u00a0noch\u00a0dem\u00a0CHMP\u00a0der\u00a0EMA\u00a0ber\u00fccksichtigt\u00a0(CDER,\u00a02013b;\u00a0CHM P,\u00a02014b).\u00a0159\u00a0Weiterhin\u00a0ist\u00a0zu\u00a0beachten,\u00a0dass\u00a0\u00fcber\u00a020\u00a0%\u00a0der\u00a0randomiserten\u00a0RRM S\u2010Patienten\u00a0die\u00a0\nTeilnahme\u00a0an\u00a0den\u00a0Studien\u00a0abbrachen\u00a0( Drop\u2010outs ).\u00a0Es\u00a0stellt\u00a0sich\u00a0generell\u00a0die\u00a0Frage,\u00a0\nwie\u00a0 eine\u00a0 sinnvolle\u00a0 Verblindung\u00a0 von\u00a0 Arzneimitteln\u00a0 mit\u00a0 unerw\u00fcnsch ter\u00a0 Wirkung\u00a0\n(Adverse\u00a0 Effect) \u00a0 Hautr\u00f6tung\u00a0 bzw.\u00a0 Hitzewallung\u00a0 ( Flush)\u00a0 oder\u00a0 gastrointestinaler\u00a0\nBeschwerden\u00a0(Durchfall,\u00a0Oberbauchschmerz,\u00a0\u00dcbelkeit)\u00a0m\u00f6glich\u00a0ist .\u00a0Xu\u00a0et\u00a0al.\u00a0gehen\u00a0\nin\u00a0einem\u00a0Cochrane\u2010Review\u00a0der\u00a0b eiden\u00a0Zulassungsstudien\u00a0daher\u00a0von \u00a0Verzerrungs\u2010\npotenzial\u00a0infolge\u00a0der\u00a0 Drop\u00a0Outs \u00a0(Attrition\u00a0Bias) \u00a0aus\u00a0und\u00a0erstellten\u00a0 Likely\u2010case\u00a0Sce\u2010\nnarios,\u00a0welche\u00a0diese\u00a0 Drop\u2010outs \u00a0ber\u00fccksichtigen\u00a0(Xu\u00a0et\u00a0al.,\u00a02015).\u00a0\nNach\u00a0 Abschluss\u00a0 der\u00a0 beiden\u00a0 zulassungsbegr\u00fcndenden\u00a0 Studien\u00a0 DEFINE \u00a0 und\u00a0\nCONFIRM\u00a0konnten\u00a0die\u00a0RRMS\u2010Patienten\u00a0am\u00a0 Open\u2010Label \u00a0Verl\u00e4ngerungsarm\u00a0ENDO\u00a0\nRSE\u00a0bzw.\u00a0109MS303\u00a0(Sponsor:\u00a0Biogen,\u00a0NCT00835770)\u00a0teilnehmen,\u00a0we lcher\u00a0die\u00a0\nLangzeitsicherheit\u00a0von\u00a0DMF\u00a0anhand\u00a0des\u00a0prim\u00e4ren\u00a0Endpunktes\u00a0\u201eAnza hl\u00a0Patienten\u00a0\nmit\u00a0unerw\u00fcnschten\u00a0Effekten\u201c\u00a0sowie\u00a0einer\u00a0Vielzahl\u00a0sekund\u00e4rer\u00a0End punkte\u00a0pr\u00fcfen\u00a0\nsoll.\u00a0 Abschlie\u00dfende\u00a0 Ergebnisse\u00a0 werden\u00a0 ab\u00a0 Februar\u00a0 2023\u00a0 erwartet\u00a0 (ClinicalTri\u2010\nals.gov,\u00a02009).\u00a0Bei\u00a0den\u00a0in\u00a02016\u00a0publizierten\u00a0\u201esechs\u00a0Jahres\u00a0Zwis chenergebnissen\u00a0\neiner\u00a0Subgruppe\u00a0der\u00a0Studie\u00a0ENDORSE\u201c\u00a0ist\u00a0zu\u00a0beachten,\u00a0dass\u00a0es\u00a0si ch\u00a0um\u00a0eine\u00a0post\u2010\nhoc\u2010Analyse\u00a0von\u00a0Patienten\u00a0neu\u00a0di agnostizierter\u00a0 RRMS\u00a0handelt,\u00a0be i\u00a0denen\u00a0nach\u00a0\nZulassungsbericht\u00a0( European\u00a0Public\u00a0Assessment\u00a0Report ,\u00a0EPAR)\u00a0tendenziell\u00a0st\u00e4rkere\u00a0\nEffekte\u00a0der\u00a0Substanz\u00a0zu\u00a0erwarten \u00a0sind\u00a0(CHMP,\u00a02014b;\u00a0Gold\u00a0et\u00a0al. ,\u00a02016).\u00a0\nIm\u00a0gesamten\u00a0klinischen\u00a0Studienprogramm\u00a0traten\u00a0unter\u00a0Placebo\u00a0zwe i\u00a0und\u00a0unter\u00a0\nDMF\u00a0f\u00fcnf\u00a0Todesf\u00e4lle\u00a0auf,\u00a0welche\u00a0sich\u00a0wie\u00a0folgt\u00a0erkl\u00e4ren:\u00a0zwei\u00a0V erkehrsunf\u00e4lle,\u00a0ein\u00a0\nvollendeter\u00a0Suizid,\u00a0aber\u00a0auch\u00a0zwei\u00a0Todesf\u00e4lle\u00a0in\u00a0Folge\u00a0MS\u2010Progr ession\u00a0im\u00a0DMF\u2010\nStudienarm\u00a0(CHMP,\u00a02014b).\u00a0Nach\u00a0im\u00a0Januar\u00a02014\u00a0erfolgter\u00a0Zulassu ng\u00a0traten\u00a0im\u00a0\nklinischen\u00a0Alltag\u00a0bereits\u00a0ab\u00a0April\u00a02014\u00a0mehrere\u00a0F\u00e4lle\u00a0von\u00a0progr essiver\u00a0multifokaler\u00a0\nLeukencephalopathie\u00a0(PML)\u00a0in\u00a0Folge\u00a0von\u00a0Infektionen\u00a0mit\u00a0dem\u00a0John \u00a0Cunningham\u00a0\n(JC)\u00a0Virus\u00a0auf,\u00a0mit\u00a0dessen\u00a0Wildtyp\u00a050\u00a0%\u00a0bis\u00a060\u00a0%\u00a0der\u00a0Bev\u00f6lkerun g\u00a0infiziert\u00a0sind.\u00a0Die\u00a0\nPML\u00a0kann\u00a0t\u00f6dlich\u00a0verlaufen\u00a0und\u00a0is t\u00a0differenzialdiagnostisch\u00a0(mi ttels\u00a0Serologie\u00a0und\u00a0\nMRT)\u00a0von\u00a0einem\u00a0MS\u2010Schub\u00a0zu\u00a0unterscheiden,\u00a0wobei\u00a0im\u00a0Vorfeld\u00a0nich t\u00a0immer\u00a0eine\u00a0\nLeukopenie\u00a0auftritt\u00a0(Balak\u00a0&\u00a0Hajdarbegovic,\u00a02016;\u00a0Nieuwkamp\u00a0et\u00a0 al.,\u00a02015;\u00a0Rosen\u2010\nkranz\u00a0et\u00a0al.,\u00a02015;\u00a0Sweetser\u00a0et\u00a0al.,\u00a02013;\u00a0van\u00a0Oosten\u00a0et\u00a0al.,\u00a02 013).\u00a0Da\u00a0ein\u00a0Gruppen\u2010\neffekt\u00a0fumars\u00e4urehaltiger\u00a0Arzneimittel\u00a0vermutet\u00a0wird,\u00a0wurde\u00a0sei tens\u00a0des\u00a0BfArM\u00a0\nein\u00a0Stufenplanverfahren\u00a0der\u00a0Stufe\u00a0II\u00a0f\u00fcr\u00a0die\u00a0in\u00a0Deutschland\u00a0zug elassenen\u00a0DMF\u2010\nhaltigen\u00a0Fertigarzneimittel\u00a0Fumaderm\u00ae/Fumaderm\u00a0initial\u00ae\u00a0und\u00a0ein \u00a0Worksharing\u2010\nVariation\u2010 Verfahren\u00a0des\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use, \u00a0CHMP\u00a0\nauf\u00a0europ\u00e4ischer\u00a0Ebene\u00a0mit\u00a0dem\u00a0BfArM\u00a0als\u00a0Rapporteur\u00a0der\u00a0EMA\u00a0f\u00fcr \u00a0Tecfidera\u00ae\u00a0\ndurchgef\u00fchrt.\u00a0Die\u00a0mittels\u00a0mehrere r\u00a0Roter\u2010Hand\u2010Briefe\u00a0kommunizie rten\u00a0\u00c4nderun\u2010\ngen\u00a0 der\u00a0 Gebrauchs\u2010\u00a0 und\u00a0 Fachinform ationen\u00a0 stellen\u00a0 einen\u00a0 Minimalk onsens\u00a0 des\u00a0\nCHMP\u00a0dar.\u00a0Beachtlicherweise\u00a0sehen\u00a0G\u2010BA\u00a0und\u00a0\u201eKrankheitsbezogenes \u00a0Kompetenz\u2010\nnetz\u00a0MS\u201c\u00a0(KKNMS)\u00a0in\u00a0Ihren\u00a0Empfehlungen\u00a0zur\u00a0qualit\u00e4tsgesicherten \u00a0Anwendung\u00a0160\u00a0abweichend\u00a0von\u00a0der\u00a0Fachinformatio n\u00a0noch\u00a0engmaschigere\u00a0Labor\u2010\u00a0(a lle\u00a06\u00a0anstatt\u00a0\nalle\u00a012\u00a0Wochen,\u00a0bzw.\u00a0bei\u00a0entsprechenden\u00a0Laborwerten\u00a0noch\u00a0k\u00fcrzer e\u00a0Intervalle)\u00a0\nund\u00a0MRT\u2010Kontrollen\u00a0zum\u00a0Schutz\u00a0der\u00a0Patienten\u00a0vor\u00a0(AKd\u00c4,\u00a02014b,\u00a02 015a,\u00a02015b;\u00a0\u00a0\na\u2010t,\u00a0 2013a,\u00a0 2013b,\u00a0 2014a,\u00a0 2014c,\u00a0 2015a,\u00a0 2015b,\u00a0 2015c,\u00a0 2016a,\u00a0 20 16b,\u00a0 2016c,\u00a0\n2016d;\u00a0BfArM,\u00a02014,\u00a02015a,\u00a0 2015b,\u00a02015c;\u00a0EMA,\u00a02015;\u00a0G\u2010BA,\u00a02016c ;\u00a0KKNMS,\u00a0\n2015;\u00a0Lauktien,\u00a02015).\u00a0\nBetrachtet\u00a0man\u00a0die\u00a0Effekte\u00a0von\u00a0DMF\u00a0auf\u00a0die\u00a0Morbidit\u00e4t,\u00a0so\u00a0ergeb en\u00a0sich\u00a0unter\u2010\nschiedliche\u00a0Ergebnisse.\u00a0\u00a0So\u00a0wird\u00a0die\u00a0Schubrate\u00a0in\u00a0beiden\u00a0Studie n\u00a0bis\u00a0zu\u00a0zwei\u00a0Jahren\u00a0\nDauer\u00a0in\u00a0der\u00a0zugelassenen\u00a0Dosierung\u00a0statistisch\u00a0signifikant\u00a0um\u00a0 44\u00a0%\u00a0bis\u00a047\u00a0%\u00a0ge\u2010\nsenkt\u00a0(Fox\u00a0et\u00a0al.,\u00a02012;\u00a0Gold\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0St\u00e4rke\u00a0dieses\u00a0 Effektes,\u00a0d.h.\u00a0der\u00a0Re\u2010\nduktion\u00a0der\u00a0j\u00e4hrlichen\u00a0MS\u2010Schubrate,\u00a0wird\u00a0in\u00a0Meta\u2010Analysen,\u00a0bei spielsweise\u00a0vom\u00a0\nInstitute\u00a0for\u00a0Clinical\u00a0and\u00a0Economic\u00a0Review \u00a0(ICER)\u00a0in\u00a0den\u00a0drei\u00a0Gruppen\u00a0 most\u00a0effecti\u2010\nve,\u00a0second\u00a0most\u00a0effective\u00a0 und\u00a0least\u00a0effective \u00a0gegen\u00fcber\u00a0 Supportive\u2010Care \u00a0abgestuft\u00a0\ndargestellt,\u00a0wobei\u00a0DMF\u00a0in\u00a0die\u00a0z weite\u00a0Gruppe\u00a0f\u00e4llt\u00a0(ICER\u2010Review. org,\u00a02017;\u00a0Seidner,\u00a0\n2016).\u00a0Andererseits\u00a0\u00a0zeigte\u00a0sich\u00a0\u00a0nur\u00a0in\u00a0der\u00a0Studie\u00a0DEFINE\u00a0eine \u00a0statistisch\u00a0signifikante\u00a0\nReduktion\u00a0des\u00a0Patientenanteils\u00a0mit\u00a0Behinderungsprogression\u00a0EDSS \u00a0nach\u00a0zwei\u00a0Jahren\u00a0\n(Placebo\u00a027,1\u00a0%,\u00a0DMF\u00a02x\u00a0tgl.\u00a016,4\u00a0%\u00a0p=0,0050)\u00a0(Gold\u00a0et\u00a0al.,\u00a0201 2),\u00a0nicht\u00a0hingegen\u00a0in\u00a0\nder\u00a0Studie\u00a0 CONFIRM\u00a0(Placebo\u00a0 16,9\u00a0%,\u00a0 DMF\u00a02x\u00a0tgl.\u00a0 12,8\u00a0%\u00a0 p=0,2536 )\u00a0(Fox\u00a0et\u00a0al.,\u00a0\n2012).\u00a0Ein\u00a0differenziertes\u00a0Bild\u00a0ergibt\u00a0sich\u00a0in\u00a0den\u00a0 likely\u2010case \u00a0scenario\u00a0Analysen\u00a0des\u00a0\nCochrane\u2010Reviews,\u00a0welche\u00a0die\u00a0 drop\u2010out\u2010Rate\u00a0von\u00a0\u00fcber\u00a020\u00a0%\u00a0ber\u00fccksichtigt\u00a0(Xu\u00a0et\u00a0al.,\u00a0\n2015).\u00a0Vom\u00a0CHMP\u00a0wurde\u00a0der\u00a0Effekt\u00a0von\u00a0DMF\u00a0auf\u00a0die\u00a0Morbidit\u00e4t,\u00a0d. h.\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0\nBehinderungsprogression,\u00a0als\u00a0nicht\u00a0ausreichend\u00a0nachgewiesen\u00a0ein gesch\u00e4tzt,\u00a0sodass\u00a0\neine\u00a0Indikation\u00a0zur\u00a0Krankheitsmodifikation\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulass ung\u00a0nicht\u00a0gegeben\u00a0\nist.\u00a0Begr\u00fcndet\u00a0wird\u00a0dies\u00a0mit\u00a0methodischen\u00a0Schw\u00e4chen\u00a0gepoolter\u00a0D aten\u00a0sowie\u00a0vorge\u2010\nlegten\u00a0Post\u2010Hoc\u2010Analysen.\u00a0Weiterhin\u00a0sei\u00a0laut\u00a0CHMP\u00a0die\u00a0Extrapolation\u00a0der\u00a0pivota len\u00a0\nStudiendaten\u00a0der\u00a0RRMS\u2010Patienten\u00a0auf\u00a0SPMS\u2010Populationen\u00a0zwecks\u00a0In dikationserwei\u2010\nterung\u00a0nicht\u00a0m\u00f6glich\u00a0(CHMP,\u00a02014b).\u00a0\nDaten\u00a0zu\u00a0 Adverse\u00a0Events \u00a0(AE)\u00a0liegen\u00a0einerseits\u00a0aus\u00a0den\u00a0Studien\u00a0zur\u00a0Zulassung\u00a0von\u00a0\nDMF\u00a0bei\u00a0RRMS,\u00a0andererseits\u00a0zu\u00a0den\u00a0in\u00a0Deutschland\u00a0seit\u00a01994\u00a0zuge lassenen\u00a0Fer\u2010\ntigarzneimitteln\u00a0Fumaderm\u00ae/Fumaderm\u00a0initial\u00ae\u00a0mit\u00a060\u00a0%\u00a0wirkungsb estimmendem\u00a0\nBestandteil\u00a0DMF\u00a0vor,\u00a0welches\u00a0 Off\u2010Label\u00a0bei\u00a0MS\u00a0eingesetzt\u00a0wurde.\u00a0Bei\u00a0H\u00f6chstdosie\u2010\nrung\u00a0von\u00a0Fumaderm\u00ae\u00a0werden\u00a0t\u00e4glich\u00a0720\u00a0mg\u00a0DMF\u00a0zugef\u00fchrt.\u00a0Es\u00a0zeig te\u00a0sich\u00a0in\u00a0den\u00a0\nStudien\u00a0aufgrund\u00a0der\u00a0Ausschlusskriterien\u00a0ein\u00a0mildes\u00a0AE\u2010Profil\u00a0m it\u00a0ca.\u00a0einem\u00a0Drittel\u00a0\nFlush\u00a0 und\u00a0 rund\u00a0 einem\u00a0 Viertel\u00a0 gastrointestinalen\u00a0 Beschwerden\u00a0 (Oberbau chbe\u2010\nschwerden,\u00a0\u00dcbelkeit,\u00a0Durchfall),\u00a0welche\u00a0durch\u00a0Einnahme\u00a0von\u00a0DMF\u00a0 nach\u00a0der\u00a0Mahl\u2010\nzeit\u00a0reduziert\u00a0werden\u00a0k\u00f6nnen.\u00a0Bei\u00a0Persistenz\u00a0ist\u00a0die\u00a0Adh\u00e4renz\u00a0e iner\u00a0Dauertherapie\u00a0\nbeeintr\u00e4chtigt.\u00a0Im\u00a0klinischen\u00a0Alltag\u00a0werden\u00a0diese\u00a0AE\u00a0wohl\u00a0h\u00e4ufi ger\u00a0berichtet\u00a0(Be\u2010\nreau\u00a0et\u00a0al.,\u00a02016,\u00a02017;\u00a0Pugliatti\u00a0et\u00a0al.,\u00a02016).\u00a0Andererseits\u00a0 traten\u00a0unter\u00a0DMF\u00a0auch\u00a0\nLeuko\u2010\u00a0und\u00a0Lymphopenien\u00a0unterschiedlichen\u00a0Ausma\u00dfes\u00a0auf,\u00a0wobei\u00a0d ie\u00a0Lymphozy\u2010161\u00a0ten\u00a0im\u00a0Mittel\u00a030\u00a0%\u00a0unter\u00a0den\u00a0Basiswert\u00a0mit\u00a0einem\u00a0Nadir\u00a0ab\u00a0Woche \u00a048\u00a0absinken.\u00a0\nHierdurch\u00a0k\u00f6nnen\u00a0in\u00a0seltenen\u00a0F\u00e4llen\u00a0opportunistische\u00a0Infektione n\u00a0sowie\u00a0die\u00a0PML\u00a0\nauftreten\u00a0(BfArM,\u00a02015c).\u00a0In\u00a0Studien\u00a0waren\u00a0geringf\u00fcgige\u00a0Erh\u00f6hun g\u00a0der\u00a0Leberwerte\u00a0\nsowie\u00a0als\u00a0renale\u00a0AE\u00a0Proteinurie,\u00a0H\u00e4maturie\u00a0bzw.\u00a0Mikroalbuminuri e\u00a0zu\u00a0beobachten\u00a0\n(CHMP,\u00a02014a).\u00a0Von\u00a0der\u00a0AKd\u00c4\u00a0liegen\u00a0zwischenzeitlich\u00a0aus\u00a0dem\u00a0kli nischen\u00a0Alltag\u00a0\nEinzelfallberichte\u00a0 ( Case\u2010Reports )\u00a0 zu\u00a0 akutem\u00a0 Nierenversagen\u00a0 unter\u00a0 DMF\u00a0 sowie\u00a0\nreversiblem\u00a0 Kaposi\u2010Sarkom\u00a0 und\u00a0 Nokardiose\u00a0 unter\u00a0 Fumaderm\u00ae\u00a0 vor,\u00a0 s odass\u00a0 im\u00a0\nklinischen\u00a0 Alltag\u00a0 verst\u00e4rkt\u00a0 hierauf\u00a0 geachtet\u00a0 werden\u00a0 sollte\u00a0 (AKd \u00c4,\u00a0 2009,\u00a0 2013,\u00a0\n2014a).\u00a0Vom\u00a0 Pharmacovigilance\u00a0Risk \u00a0Assessment\u00a0Committee, \u00a0PRAC\u00a0der\u00a0EMA\u00a0wur\u2010\nden\u00a0im\u00a0Rahmen\u00a0des\u00a0Pharmakovigila nz\u2010Planes\u00a0die\u00a0Durchf\u00fchrung\u00a0zahl reicher\u00a0zus\u00e4tz\u2010\nlicher\u00a0Studien\u00a0angeordnet,\u00a0neben\u00a0dem\u00a0 Open\u2010Label \u00a0Verl\u00e4ngerungsarm\u00a0der\u00a0pivota\u2010\nlen\u00a0Studien\u00a0ENDORSE\u00a0(Sponsor:\u00a0Biogen,\u00a0NCT00835770\u00a0109MS303)\u00a0des sen\u00a0Ergeb\u2010\nnisse\u00a0ab\u00a02023\u00a0erwartet\u00a0werden\u00a0sowie\u00a0die\u00a0Sicherheitsstudie\u00a0ESTEE M\u00a0(Sponsor:\u00a0\nBiogen,\u00a0 NCT02047097\u00a0 109MS401)\u00a0 deren\u00a0 Ergebnisse\u00a0 ab\u00a0 2024\u00a0 vorliege n\u00a0 sollen\u00a0\n(CHMP,\u00a02014b).\u00a0Auch\u00a0das\u00a0CDER\u00a0der\u00a0FDA\u00a0fordert\u00a0weitere\u00a0Studien\u00a0zu r\u00a0Abkl\u00e4rung\u00a0des\u00a0\nRisikoprofils,\u00a0insbesondere\u00a0zum\u00a0Ausschluss\u00a0eines\u00a0Mi\u00dfbrauchspote nzials\u00a0der\u00a0Sub\u2010\nstanz,\u00a0pr\u00e4klinisch\u00a0erwiesener\u00a0Nephrotoxozit\u00e4t\u00a0oder\u00a0Malignit\u00e4t\u00a0( CDER,\u00a02013c).\u00a0\nDaten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0 Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life \u00a0\n(HRQoL)\u00a0wurden\u00a0als\u00a0terti\u00e4re\u00a0Endpunkte\u00a0mittels\u00a0der\u00a0Erhebungsinst rumente\u00a0 36\u2010Item\u00a0\nShort\u2010Form\u00a0Health\u00a0Survey \u00a0(SF\u201036)\u00a0gesammelt.\u00a0Im\u00a0Rahmen\u00a0eines\u00a0Cochrane\u00a0Reviews,\u00a0\nder\u00a0 publizierte\u00a0 Daten\u00a0 f\u00fcr\u00a0 1.461\u00a0 Studienteilnehmer\u00a0 ber\u00fccksichtig en\u00a0 konnte,\u00a0 er\u2010\nbrachten\u00a0in\u00a0der\u00a0physischen\u00a0Komponente\u00a0( Physical\u00a0Component\u00a0Summary ,\u00a0PCS)\u00a0nach\u00a0\nzwei\u00a0Jahren\u00a0DMF\u00a0gegen\u00fcber\u00a0Placeb o\u00a0eine\u00a0geringf\u00fcgige\u00a0Verbesserun g,\u00a0jedoch\u00a0nicht\u00a0\nin\u00a0der\u00a0mentalen\u00a0Komponente\u00a0( Mental\u00a0Component\u00a0Summary,\u00a0 MCS)\u00a0des\u00a0SF\u201036\u00a0(Xu\u00a0\net\u00a0al.,\u00a02015).\u00a0\nDer\u00a0G\u2010BA\u00a0ging\u00a0bei\u00a0DMF\u00a0zun\u00e4chst\u00a0nicht\u00a0von\u00a0einem\u00a0neuen\u00a0Wirkstoff\u00a0 aus,\u00a0leitete\u00a0\njedoch\u00a0nach\u00a0Vorliegen\u00a0der\u00a0Einsch \u00e4tzung\u00a0des\u00a0CHMP\u00a0ein\u00a0Nutzenbewer tungsverfah\u2010\nren\u00a0ein\u00a0(a\u2010t,\u00a02014b).\u00a0Zur\u00a0Nutze nbewertung\u00a0von\u00a0DMF\u00a0gegen\u00fcber\u00a0zwe ckm\u00e4\u00dfiger\u00a0\nVergleichstherapie\u00a0(zVT),\u00a0besteh end\u00a0aus\u00a0Interferon\u00a0(IFN)\u00a0\u00df\u20101a\u00a0b zw.\u00a0IFN\u00a0\u00df\u20101b\u00a0oder\u00a0\nGlatirameracetat,\u00a0legte\u00a0der\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0ei ne\u00a0Netzwerk\u2010\nMetanalyse\u00a0(NMA)\u00a0zum\u00a0indirekten\u00a0Vergleich\u00a0von\u00a0vierzehn\u00a0Studien\u00a0 zur\u00a0Therapie\u00a0der\u00a0\nRRMS\u00a0vor.\u00a0Der\u00a0G\u2010BA\u00a0bem\u00e4ngelt\u00a0methodische\u00a0Schw\u00e4chen,\u00a0indem\u00a0bei\u00a0N MA\u00a0oftmals\u00a0\nnicht\u00a0alle\u00a0Daten\u00a0zu\u00a0Endpunkten\u00a0und\u00a0 AE\u00a0publiziert\u00a0werden\u00a0( Publication\u00a0Bias ),\u00a0nicht\u00a0\nalle\u00a0Arzneimittel\u00a0mit\u00a0Wirkstoff\u00a0IFN\u00a0\u00df\u20101a\u00a0in\u00a0der\u00a0NMA\u00a0ber\u00fccksicht igt\u00a0wurden,\u00a0ob\u2010\ngleich\u00a0der\u00a0pU\u00a0selbst\u00a0IFN\u00a0\u00df\u20101a\u00a0(Handelsname:\u00a0Avonex\u00ae)\u00a0vertreibt. \u00a0Laut\u00a0G\u2010BA\u00a0hat\u00a0der\u00a0\npU\u00a0die\u00a0grundlegenden\u00a0Annahmen\u00a0einer\u00a0NMA\u00a0von\u00a0\u00c4hnlichkeit\u00a0(Effekt modifikato\u2010\nren),\u00a0Homogenit\u00e4t\u00a0und\u00a0Konsistenz\u00a0 nicht\u00a0ad\u00e4quat\u00a0gepr\u00fcft.\u00a0Konkret \u00a0f\u00fchrt\u00a0der\u00a0G\u2010BA\u00a0\naus,\u00a0dass\u00a0die\u00a0an\u00a0den\u00a0unterschied lichen\u00a0Studien\u00a0teilnehmenden\u00a0MS \u2010Patienten\u00a0einen\u00a0\nVergleich\u00a0bzw.\u00a0eine\u00a0Aussage\u00a0zum\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0zVT\u00a0unm\u00f6 glich\u00a0gestalten\u00a0162\u00a0(Vortherapie\u00a0 mit\u00a0 unterschiedlichen\u00a0 Arzneimitteln\u00a0 oder\u00a0 therapien aive\u00a0 Patienten,\u00a0\nSchubh\u00e4ufigkeit,\u00a0Zeit\u00a0zwischen\u00a0Erstdiagnose\u00a0und\u00a0Studienbeginn,\u00a0 Schwere\u00a0und\u00a0Ver\u2010\nlauf\u00a0der\u00a0MS,\u00a0gemessen\u00a0mittels\u00a0EDSS).\u00a0Bemerkenswert\u00a0ist,\u00a0dass\u00a0St udien\u00a0zu\u00a0DMF\u00a0die\u00a0\nneueren\u00a0MS\u2010Kriterien\u00a0nach\u00a0McDonald\u00a0und\u00a0in\u00a0\u00fcbrigen\u00a0Studien\u00a0die\u00a0\u00e4 lteren,\u00a0weniger\u00a0\nsensitiven\u00a0 Poser\u2010Kriterien\u00a0 nutzt e n , \u00a0w a s \u00a0d a z u \u00a0f \u00fc h r t e , \u00a0d a s s \u00a0P a t i e nten\u00a0 unter\u00a0 DMF\u2010\nTherapie\u00a0in\u00a0der\u00a0Synopse\u00a0eine\u00a0geringere\u00a0Krankheitsschwere\u00a0zeigte n.\u00a0Der\u00a0pU\u00a0doku\u2010\nmentierte\u00a0diesen\u00a0Sachverhalt,\u00a0folgerte\u00a0aber\u00a0nichts\u00a0daraus.\u00a0Folg lich\u00a0konnte\u00a0basierend\u00a0\nauf\u00a0den\u00a0vom\u00a0pU\u00a0ein\u2010\u00a0und\u00a0auch\u00a0nachgereichten\u00a0Unterlagen\u00a0seitens\u00a0 des\u00a0G\u2010BA\u00a0 kein\u00a0\nZusatznutzen\u00a0gegen\u00fcber\u00a0zVT\u00a0im\u00a0ersten\u00a0Beschluss \u00a0vom\u00a016.\u00a0Oktober\u00a02014\u00a0festgestellt\u00a0\nwerden\u00a0(G\u2010BA,\u00a02014a,\u00a02014b,\u00a02014c,\u00a02014d,\u00a02016c).\u00a0\nIm\u00a0Kontext\u00a0von\u00a0Stufenplan\u00a0bzw.\u00a0 Worksharing\u2010Variation \u2010Verfahren\u00a0des\u00a0CHMP\u00a0mit\u00a0\nBfArM\u00a0als\u00a0Rapporteur\u00a0erfolgten\u00a0d rei\u00a0weitere\u00a0G\u2010BA\u00a0Beschl\u00fcsse\u00a0im\u00a0 Kontext\u00a0neuer\u00a0\nSachverhalte\u00a0zur\u00a0qualit\u00e4tsgesicherten\u00a0Anwendung\u00a0von\u00a0DMF.\u00a0Hierbe i\u00a0folgte\u00a0der\u00a0G\u2010\nBA\u00a0interessanterweise\u00a0der\u00a0Empfeh lung\u00a0des\u00a0KKNMS\u00a0und\u00a0geht\u00a0mit\u00a0sei nen\u00a0Vorgaben\u00a0\nbetreffs\u00a0Blutbildkontrollen\u00a0sowi e\u00a0MRT\u00a0\u00fcber\u00a0die\u00a0beh\u00f6rdlichen\u00a0Ano rdnungen\u00a0(Fach\u2010\u00a0\nund\u00a0Gebrauchsinformation)\u00a0der\u00a0EMA\u00a0in\u00a0Form\u00a0von\u00a0k\u00fcrzeren\u00a0Untersuc hungsinterval\u2010\nlen\u00a0zum\u00a0Schutz\u00a0der\u00a0MS\u2010Patienten\u00a0hinaus.\u00a0Inwiefern\u00a0sich\u00a0die\u00a0Kost en\u00a0dieser\u00a0zus\u00e4tzli\u2010\nchen\u00a0Ma\u00dfnahmen,\u00a0d.h.\u00a0Laboruntersuchungen\u00a0und\u00a0zus\u00e4tzliche\u00a0MRTs,\u00a0 auswirken,\u00a0\nbleibt\u00a0noch\u00a0zu\u00a0pr\u00fcfen\u00a0(BfArM,\u00a02015c;\u00a0G\u2010BA,\u00a02015a,\u00a02015c,\u00a02015b, \u00a02015e,\u00a02015d,\u00a0\n2016a,\u00a02016b,\u00a02016c).\u00a0\nUm\u00a0den\u00a0therapeutischen\u00a0Stellenwert\u00a0von\u00a0DMF\u00a0einzusch\u00e4tzen,\u00a0bedar f\u00a0es\u00a0weiterer\u00a0\nStudien,\u00a0welche\u00a0 Head\u2010to\u2010Head \u00a0DMF\u00a0direkt\u00a0mit\u00a0aktivem\u00a0Komparator\u00a0\u00fcber\u00a0einen\u00a0\nl\u00e4ngeren\u00a0Zeitraum\u00a0unter\u00a0klinischen\u00a0Alltagsbedingungen\u00a0an\u00a0allen\u00a0 relevanten\u00a0Patien\u2010\ntengruppen\u00a0vergleichen.\u00a0Die\u00a0AKd \u00c4\u00a0sowie\u00a0die\u00a0Kassen\u00e4rztliche\u00a0Bund esvereinigung\u00a0\n(KBV)\u00a0empfehlen\u00a0derzeit\u00a0einen\u00a0Beginn\u00a0der\u00a0Therapie\u00a0von\u00a0RRMS\u00a0mit\u00a0 IFN\u00a0bzw.\u00a0Glati\u2010\nrameracetat\u00a0(KBV,\u00a02016).\u00a0\n\u00a0\u00a0163\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nDrittes\u00a0orales\u00a0MS\u2010\nArzneimittel;\u00a0\nZulassung\u00a0f\u00fcr\u00a0RRMS\u00a0Daten\u00a0pU\u00a0kein\u00a0Nachweis\u00a0\nZN,\u00a0Schubrate\u00a0reduziert,\u00a0\nlangfristige\u00a0Behinde\u2010\nrungsprogression\u00a0nicht\u00a0in\u00a0\nallen\u00a0Studien\u00a0statistisch\u00a0\nsignifikant;\u00a0langfristiges\u00a0\nNutzen\u2010Risiko\u2010Profil\u00a0unklar\u00a0nach\u00a0\nErstattungsbetrags\u2010\nverhandlung\u00a0teils\u00a0\ng\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\n\u2013\u00a0Mittel\u00a0der\u00a0Reserve\u00a0\nbei\u00a0Unvertr\u00e4glich\u2010\nkeit\u00a0von\u00a0IFN\u00a0\u00df\u00a0oder\u00a0\nGlatirameracetat\u00a0\u00a0 Nothing\u00a0new\u00a0\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDimethylfumarat\u00a0 2x\u00a0tgl.\u00a0 365\u00a0 15.938,03\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nInterferon\u00a0Beta\u20101a \u00a0 1\u00a0bzw.\u00a03x\u00a0w\u00f6chentlich \u00a0 52\u00a0bzw.\u00a0156\u00a0\n\u00a022.154,60\u00a0\u2013\u00a025.102,22\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\nInterferon\u00a0Beta\u20101b\u00a0\n\u00a0\nGlatirameracetat\u00a0\n\u00a0\u00a0\n1x\u00a0alle\u00a02\u00a0Tage\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0\n\u00a0\u00a0\n183\u00a0\n\u00a0\n365\u00a0\n\u00a0\u00a0\n16.411,32\u00a0\u2013\u00a019.483,79\u00a0\u20ac\u00a0\n\u00a0\n13.791,69\u00a0\u2013\u00a018.549,50\u00a0\u20ac \u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nBereits\u00a0vor\u00a0Listung\u00a0in\u00a0der\u00a0Lauer\u2010Taxe\u00a0zum\u00a001.03.2014\u00a0wurde\u00a0Dime thylfumarat\u00a0abge\u2010\nrechnet\u00a0und\u00a0zeigte\u00a0mit\u00a0offizielle r\u00a0Listung\u00a0einen\u00a0Verbrauch\u00a0von\u00a0 35.000\u00a0DDD\u00a0monat\u2010\nlich,\u00a0welcher\u00a0in\u00a0den\u00a0folgenden\u00a0Monaten\u00a0weiter\u00a0anstieg\u00a0bis\u00a0zu\u00a0ei nem\u00a0Gipfel\u00a0im\u00a0Januar\u00a0\n2015\u00a0mit\u00a090.000\u00a0DDD\u00a0monatlich.\u00a0Der\u00a0Erstattungsbetrag,\u00a0der\u00a0zu\u00a0ei ner\u00a0deutlichen\u00a0\nPreisreduktion\u00a0in\u00a0H\u00f6he\u00a0von\u00a042,3\u00a0%\u00a0f\u00fchrte\u00a0(Lauer\u2010Fischer,\u00a02017), \u00a0ist\u00a0ab\u00a0Mai\u00a02015\u00a0\ndeutlich\u00a0sichtbar.\u00a0Zudem\u00a0f\u00e4llt\u00a0ein\u00a0s\u00e4gezahnf\u00f6rmiger\u00a0Quartalsver brauch\u00a0auf,\u00a0was\u00a0auf\u00a0\neine\u00a0Verordnung\u00a0durch\u00a0Fach\u00e4rzte\u00a0schlie\u00dfen\u00a0l\u00e4sst.\u00a0\n\u00a0\n164\u00a0Abbildung\u00a04.7:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nDimethylfumarat\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nSeit\u00a01959\u00a0ist\u00a0bekannt,\u00a0dass\u00a0Fumars\u00e4ureester\u00a0bei\u00a0Patienten\u00a0mit\u00a0P soriasis\u00a0eine\u00a0Wir\u2010\nkung\u00a0zeigen.\u00a0Im\u00a0August\u00a01994\u00a0wurde\u00a0ein\u00a0Gemisch\u00a0von\u00a0Fumars\u00e4ureest ern\u00a0(Handels\u2010\nname:\u00a0Fumaderm\u00ae;\u00a055,81\u00a0%\u00a0DMF)\u00a0seitens\u00a0des\u00a0BfArM\u00a0zur\u00a0Therapie\u00a0de r\u00a0Psoriasis\u00a0\nzugelassen.\u00a0Bei\u00a0einem\u00a0Patienten,\u00a0der\u00a0neben\u00a0Psoriasis\u00a0auch\u00a0noch\u00a0 an\u00a0MS\u00a0litt\u00a0und\u00a0mit\u00a0\nFumars\u00e4ureestern\u00a0behandelt\u00a0wurde,\u00a0ergaben\u00a0sich\u00a0Hinweise,\u00a0dass\u00a0a uch\u00a0eine\u00a0Re\u2010\nduktion\u00a0der\u00a0Sch\u00fcbe\u00a0bei\u00a0MS\u00a0ggf.\u00a0hierdurch\u00a0bedingt\u00a0sein\u00a0k\u00f6nnte\u00a0(S tahl,\u00a02014).\u00a0Es\u00a0\nzeigten\u00a0sich\u00a0entz\u00fcndungshemmende\u00a0und\u00a0zytoprotektive\u00a0Effekte\u00a0von \u00a0DMF\u00a0auch\u00a0bei\u00a0\nMS,\u00a0wobei\u00a0der\u00a0Wirkungsmechanismus\u00a0nicht\u00a0vollst\u00e4ndig\u00a0aufgekl\u00e4rt\u00a0 ist\u00a0(Viegener,\u00a0\n2014).\u00a0 Pr\u00e4klinisch\u00a0 konnte\u00a0 ein\u00a0 Agonismus\u00a0 am\u00a0 hydroxycarboxylic\u00a0acid\u00a0receptor\u00a02 \u00a0\n(HCAR 2)\u00a0nachgewiesen\u00a0werden\u00a0(Chen,\u00a02014).\u00a0Weiterhin\u00a0wird\u00a0aufgrund\u00a0pr\u00e4 klini\u2010\nscher\u00a0 Daten\u00a0 eine\u00a0 Wirkung\u00a0 mittels\u00a0 Aktivierung\u00a0 des\u00a0 Nuclear\u00a0factor\u00a0 (erythroid\u2010\nderived\u00a02)\u2010like\u00a02\u00a0(Nrf2)\u2010Transskriptionswegs\u00a0 postuliert,\u00a0 hierdurch\u00a0 ergeben\u00a0 sich\u00a0\nimmunmodulatorische\u00a0und\u00a0antiinflammatorische\u00a0Eigenschaften,\u00a0die \u00a0sich\u00a0bei\u00a0Pso\u2010\nriasis\u2010Patienten\u00a0unter\u00a0DMF\u00a0in\u00a0ei nem\u00a0ver\u00e4nderten\u00a0Profil\u00a0der\u00a0Lymp hozoytenph\u00e4no\u2010\ntypen\u00a0zeigt,\u00a0wobei\u00a0sich\u00a0die\u00a0Effekte\u00a0mittels\u00a0Herunterregulation\u00a0 proinflammatori\u2010\nscher\u00a0 Zytokine\u00a0 (T H1,\u00a0 TH17)\u00a0 sowie\u00a0 Hochregulation\u00a0 entz\u00fcndungshemmenden\u00a0 T H2\u00a0\nerkl\u00e4ren\u00a0lassen.\u00a0Zudem\u00a0wird\u00a0w\u00e4hrend\u00a0der\u00a0Therapie\u00a0mit\u00a0DMF\u00a0ein\u00a0Ab fall\u00a0der\u00a0Lym\u2010\nphozyten\u00a0um\u00a0durchschnittlich\u00a030\u00a0%\u00a0 des\u00a0Ausgangswertes\u00a0beobachtet ,\u00a0was\u00a0zu\u00a0be\u2010\nachten\u00a0ist\u00a0(CHMP,\u00a02017).\u00a0\n165\u00a0DMF\u00a0wird\u00a0als\u00a0magensaftresistente\u00a0Mikrotablette\u00a0in\u00a0magensaftresi stenter\u00a0Kapsel\u00a0\nverabreicht,\u00a0es\u00a0wird\u00a0durch\u00a0Esterasen\u00a0in\u00a0den\u00a0aktiven\u00a0Prim\u00e4rmetab oliten\u00a0Monome\u2010\nthylfumarat\u00a0(MMF)\u00a0verstoffwechselt,\u00a0der\u00a0wiederum\u00a0zu\u00a027\u00a0%\u00a0bis\u00a040 \u00a0%\u00a0an\u00a0Plasmaei\u2010\nwei\u00dfe\u00a0gebunden\u00a0wird.\u00a0Der\u00a0weitere\u00a0Abbau\u00a0verl\u00e4uft\u00a0\u00fcber\u00a0den\u00a0Zitrat zyklus,\u00a0prim\u00e4res\u00a0\nEndprodukt\u00a0ist\u00a0Kohlenstoffdioxid,\u00a0das\u00a0ausgeatmet\u00a0wird,\u00a015,5\u00a0%\u00a0w erden\u00a0renal\u00a0und\u00a0\n0,9\u00a0%\u00a0\u00fcber\u00a0den\u00a0Stuhl\u00a0ausgeschieden\u00a0(CHMP,\u00a02017).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nFumars\u00e4ureester\u00a0 werden\u00a0 seit\u00a0 mehreren\u00a0 Jahrzehnten\u00a0 in\u00a0 der\u00a0 symptom atischen\u00a0\nTherapie\u00a0 der\u00a0 Psoriasis\u00a0 vorwiegend\u00a0 als\u00a0 Rezepturzubereitungen\u00a0 ein gesetzt\u00a0 (DAC\u00a0\nNRF,\u00a02017).\u00a0Seit\u00a01994\u00a0steht\u00a0auch\u00a0ein\u00a0vom\u00a0BfArM\u00a0in\u00a0Deutschland\u00a0z ugelassenes\u00a0\nFertigarzneimittel\u00a0mit\u00a0neben\u00a0DMF \u00a0(55,81\u00a0%\u00a0je\u00a0Dosis)\u00a0drei\u00a0Ethylh ydrogenfumaraten\u00a0\n(Calcium\u2010,\u00a0Magnesium\u2010\u00a0und\u00a0Zinksa lz)\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0\u201eFum aderm\u00ae\u201c\u00a0zur\u00a0\nVerf\u00fcgung\u00a0(AMIS,\u00a02017).\u00a0In\u00a0diesem\u00a0Kontext\u00a0erstaunt\u00a0es,\u00a0dass\u00a0DMF \u00a0von\u00a0der\u00a0Europ\u00e4\u2010\nischen\u00a0Kommission\u00a0( European\u00a0commission ,\u00a0EC)\u00a0am\u00a030.01.2014\u00a0die\u00a0Zulassung\u00a0in\u00a0der\u00a0\nIndikation:\u00a0\u201eBehandlung\u00a0von\u00a0erwa chsenen\u00a0Patienten\u00a0mit\u00a0RRMS\u201c\u00a0als \u00a0\u201eneuer\u201c\u00a0Wirk\u2010\nstoff\u00a0und\u00a0hieraus\u00a0resultierendem\u00a0Unterlagenschutz\u00a0in\u00a0der\u00a0EU\u00a0erh ielt\u00a0(at,\u00a02014a;\u00a0\nCHMP,\u00a02014c).\u00a0Ab\u00a001.03.2014\u00a0erfolgte\u00a0die\u00a0Aufnahme\u00a0in\u00a0die\u00a0Lauer\u2010 Taxe\u00a0(Lauer\u2010\nFischer,\u00a02017).\u00a0Die\u00a0magensaftressitenten\u00a0Hartkapseln\u00a0sollen\u00a02x \u00a0tgl.\u00a0w\u00e4hrend\u00a0einer\u00a0\nMahlzeit\u00a0eingenommen\u00a0werden,\u00a0inital\u00a0f\u00fcr\u00a0eine\u00a0Woche\u00a02x \u00a0tgl.\u00a0120\u00a0mg,\u00a0hiernach\u00a0\ndauerhaft\u00a02x \u00a0tgl.\u00a0240\u00a0mg\u00a0(CHMP,\u00a02017).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nBei\u00a0MS\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0die\u00a0h\u00e4ufigste\u00a0chronisch\u2010entz\u00fcndliche\u00a0 Erkrankung\u00a0des\u00a0\nzentralen\u00a0Nervensystems\u00a0bei\u00a0jungen\u00a0Menschen,\u00a0welche\u00a0zur\u00a0atrauma tischen\u00a0Be\u2010\nhinderung\u00a0f\u00fchrt.\u00a0Die\u00a0Pr\u00e4valenz\u00a0von\u00a0MS\u00a0in\u00a0Europa\u00a0betr\u00e4gt\u00a083\u00a0je\u00a01 00.000\u00a0Einwohner,\u00a0\ndie\u00a0Inzidenz\u00a04,3\u00a0(Kamm\u00a0et\u00a0al.,\u00a02014).\u00a0Abweichend\u00a0hiervon\u00a0geht\u00a0d as\u00a0Wei\u00dfbuch\u00a0MS\u00a0\nvon\u00a0einer\u00a0Inzidenz\u00a0von\u00a08\u00a0und\u00a0einer\u00a0Pr\u00e4valenz\u00a0von\u00a0175\u00a0bis\u00a0289\u00a0je \u00a0100.000\u00a0Einwoh\u2010\nner\u00a0in\u00a0Deutschland\u00a0aus,\u00a0also\u00a0insgesamt\u00a0143.000\u00a0bis\u00a0199.500\u00a0Pati enten\u00a0(Ble\u00df\u00a0et\u00a0al.,\u00a0\n2016).\u00a0Die\u00a0Erstdiagnose\u00a0wird\u00a0h\u00e4ufig\u00a0zwischen\u00a0dem\u00a020.\u00a0und\u00a040.\u00a0Le bensjahr\u00a0gestellt,\u00a0\nbei\u00a0Frauen\u00a0tendenziell\u00a0zwei\u00a0bis\u00a0f\u00fcnf\u00a0Jahre\u00a0fr\u00fcher\u00a0und\u00a02,3\u2010mal\u00a0h \u00e4ufiger\u00a0als\u00a0bei\u00a0M\u00e4n\u2010\nnern,\u00a0die\u00a0Lebenserwartung\u00a0ist\u00a0in\u00a0Folge\u00a0von\u00a0MS\u00a0um\u00a0sieben\u00a0bis\u00a0zeh n\u00a0Jahre\u00a0verk\u00fcrzt.\u00a0\nDie\u00a0\u00c4tiologie\u00a0der\u00a0MS\u00a0ist\u00a0unbekannt,\u00a0sowohl\u00a0Umwelt\u2010\u00a0(Breitengrad ,\u00a0Sonnenlichtex\u2010\nposition,\u00a0Vitamin\u2010D\u2010Blutspiegel, \u00a0Rauchen,\u00a0Infektion\u00a0mit\u00a0dem\u00a0Eps tein\u2010Barr\u2010Virus)\u00a0als\u00a0\nauch\u00a0genetische\u00a0Faktoren\u00a0werden\u00a0aus\u00a0epidemiologischen\u00a0Daten\u00a0abg eleitet.\u00a0Patho\u2010\nphysiologisch\u00a0ist\u00a0von\u00a0einer\u00a0fehlgeleiteten\u00a0Reaktion\u00a0des\u00a0Immunsy stems\u00a0auszuge\u2010\nhen,\u00a0wodurch\u00a0das\u00a0Nervenzellen\u00a0 umh\u00fcllende\u00a0Myelin\u00a0in\u00a0Folge\u00a0entz\u00fcn dlicher\u00a0Ver\u00e4n\u2010\nderungen\u00a0abgebaut\u00a0wird,\u00a0und\u00a0die\u00a0Nervenzellen\u00a0langfristig\u00a0Ihre\u00a0F unktion\u00a0einb\u00fc\u00dfen.\u00a0\nBei\u00a020\u00a0%\u00a0der\u00a0MS\u2010Patienten\u00a0tritt\u00a0an fangs\u00a0eine\u00a0Opticusneuritis\u00a0au f,\u00a0d.h.\u00a0Sehst\u00f6run\u2010\ngen,\u00a0 weiterhin\u00a0 werden\u00a0 Sensibilit\u00e4tsst\u00f6rungen\u00a0 oder\u00a0 Gangunsicherh eit\u00a0 berichtet,\u00a0166\u00a0welche\u00a0auch\u00a0fehlgedeutet\u00a0werden\u00a0k\u00f6nnen\u00a0und\u00a0somit\u00a0die\u00a0Diagnose\u00a0M S\u00a0verz\u00f6gern\u00a0\n(Kamm\u00a0et\u00a0al.,\u00a02014).\u00a0Binnen\u00a0sechs\u00a0bis\u00a0acht\u00a0Wochen\u00a0k\u00f6nnen\u00a0sich\u00a0d iese\u00a0Symptome\u00a0\nauch\u00a0zur\u00fcckbilden.\u00a0Unbehandelt\u00a0geht\u00a0man\u00a0von\u00a0einer\u00a0Rate\u00a0von\u00a01,8\u00a0 Sch\u00fcben\u00a0pro\u00a0\nJahr\u00a0aus.\u00a0Nach\u00a0differenzialdiagn ostischer\u00a0Abkl\u00e4rung\u00a0k\u00f6nnen\u00a0mitt els\u00a0MRT\u00a0unter\u00a0\nGabe\u00a0von\u00a0Gadolinium\u00a0als\u00a0Kontra stmittel\u00a0die\u00a0entz\u00fcndlichen\u00a0L\u00e4sion en\u00a0nachgewiesen\u00a0\nund\u00a0MS\u00a0diagnostiziert\u00a0werden\u00a0(Gold,\u00a02012).\u00a0\nBei\u00a080\u00a0%\u00a0verl\u00e4uft\u00a0die\u00a0MS\u00a0schubf\u00f6rmig\u00a0( relapsing\u2010remitting \u00a0MS,\u00a0RRMS)\u00a0und\u00a0geht\u00a0\nnach\u00a0ca.\u00a0neunzehn\u00a0Jahren,\u00a0im\u00a0Mittel\u00a0um\u00a0das\u00a040.\u00a0Lebensjahr,\u00a0in\u00a0e ine\u00a0sekund\u00e4r\u00a0pro\u2010\ngrediente\u00a0MS\u00a0(SPMS)\u00a0\u00fcber.\u00a0Bei\u00a015\u00a0%,\u00a0zumeist\u00a0bei\u00a0Erstdiagnose\u00a0um \u00a0das\u00a040.\u00a0Lebens\u2010\njahr,\u00a0verl\u00e4uft\u00a0die\u00a0MS\u00a0prim\u00e4r\u00a0progressiv\u00a0(PPMS),\u00a0wobei\u00a0bei\u00a040\u00a0%\u00a0 dieser\u00a0Patienten\u00a0\nauch\u00a0zus\u00e4tzlich\u00a0Sch\u00fcbe\u00a0auftreten\u00a0k\u00f6nnen,\u00a0was\u00a0als\u00a0progressive\u2010re lapsing\u00a0MS\u00a0(PRMS)\u00a0\nbezeichnet\u00a0wird.\u00a0Weiterhin\u00a0werden\u00a0in\u00a0der\u00a0Fr\u00fchphase\u00a0radiologisch \u00a0sowie\u00a0klinisch\u00a0\nisoliertes\u00a0Syndrom\u00a0( radiologically\u00a0or \u00a0clinically\u00a0isolated\u00a0syndrom ,\u00a0RIS\u00a0bzw.\u00a0CIS)\u00a0un\u2010\nterschieden\u00a0(Kamm\u00a0et\u00a0al.,\u00a02014).\u00a0Vom\u00a0RIS\u00a0wird\u00a0bei\u00a0typischen\u00a0MRT \u2010Befunden\u00a0ohne\u00a0\nklinische\u00a0Symptome\u00a0gesprochen.\u00a0Beim\u00a0CIS\u00a0liegt\u00a0bei\u00a0typischen\u00a0MRT \u2010Befunden\u00a0ein\u00a0\neinzelnes\u00a0Symptom\u00a0vor.\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nZur\u00a0Therapie\u00a0der\u00a0MS\u00a0besteht\u00a0Beda rf\u00a0an\u00a0risikoarmen\u00a0immunmodulier enden\u00a0Arz\u2010\nneimitteln,\u00a0um\u00a0vor\u00a0allem\u00a0die\u00a0Krankheitsprogression\u00a0durch\u00a0eine\u00a0D auertherapie\u00a0zu\u00a0\nverlangsamen.\u00a0In\u00a0diesem\u00a0Kontext\u00a0sogenannten\u00a0 Unmet\u00a0Medical\u00a0Needs \u00a0erfolgte\u00a0die\u00a0\nZulassung\u00a0 von\u00a0 DMF\u00a0 basierend\u00a0 auf\u00a0 den\u00a0 beiden\u00a0 Phase\u2010III\u2010Studien\u00a0 DE FINE\u00a0 und\u00a0\nCONFIRM\u00a0(at,\u00a02014a).\u00a0\nIn\u00a0 der\u00a0 zulassungsrelevanten\u00a0 Ph ase\u2010III\u2010Studie\u00a0 DEFINE\u00a0 bzw.\u00a0 109MS3 01\u00a0 (Sponsor:\u00a0\nBiogen,\u00a0NCT00420212)\u00a0wurden\u00a0multizentrisch,\u00a0doppelblind,\u00a01:1:1\u00a0 randomisiert,\u00a0\nplacebokontrolliert\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0von\u00a0240\u00a0mg\u00a0D MF\u00a0(Studienna\u2010\nme:\u00a0BG\u201012)\u00a02x\u00a0oder\u00a03x\u00a0tgl.\u00a0gege n\u00fcber\u00a0Placebo\u00a0an\u00a01.234\u00a0Patienten \u00a0mit\u00a0RRMS\u00a0\u00fcber\u00a0\n96\u00a0Wochen\u00a0gepr\u00fcft.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0Schubrate\u00a0binnen\u00a0z wei\u00a0Jahren,\u00a0\nsekund\u00e4re\u00a0Endpunkte\u00a0die\u00a0Anzahl\u00a0GD \u2010aufnehmender,\u00a0T1\u2010\u00a0sowie\u00a0T2\u2010L\u00e4 sionen\u00a0im\u00a0\nMRT,\u00a0j\u00e4hrliche\u00a0Schubrate\u00a0sowie\u00a0Morbidit\u00e4t\u00a0anhand\u00a0der\u00a0EDSS.\u00a0Eing eschlossen\u00a0wer\u2010\nden\u00a0konnten\u00a0RRMS\u00a0Patienten\u00a0zwischen\u00a018\u00a0und\u00a055\u00a0Lebensjahren\u00a0gem\u00e4 \u00df\u00a0McDonald\u2010\nKriterien\u00a01\u20104,\u00a0EDSS\u00a00,0\u00a0bis\u00a05,0\u00a0und\u00a0einem\u00a0Schub\u00a0im\u00a0Vorjahr,\u00a0aus geschlossen\u00a0waren\u00a0\nRRMS\u2010Patienten\u00a0mit\u00a0chronischen\u00a0I mmun\u2010,\u00a0Krebs\u2010,\u00a0akuten\u00a0urologisc hen,\u00a0pulmona\u2010\nlen\u00a0bzw.\u00a0gastrointestinalen\u00a0Erkrankungen\u00a0bzw.\u00a0Frauen\u00a0in\u00a0Schwang erschaft\u00a0oder\u00a0\nStillzeit\u00a0(ClinicalTrials.gov,\u00a02007b).\u00a0Gold\u00a0et\u00a0al.\u00a0berichten\u00a0zu m\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0\n\u201eAnteil\u00a0Patienten\u00a0mit\u00a0Schub\u201c,\u00a0dass\u00a0unter\u00a0DMF\u00a02x\u00a0tgl.\u00a027\u00a0%,\u00a0bei\u00a0 3x\u00a0tgl.\u00a0DMF\u00a026\u00a0%\u00a0\ngegen\u00fcber\u00a046\u00a0%\u00a0unter\u00a0Placebo\u00a0betro ffen\u00a0waren\u00a0(p<0,0001)\u00a0(Gold\u00a0e t\u00a0al.,\u00a02012).\u00a0\nHieraus\u00a0ergibt\u00a0sich\u00a0eine\u00a0Risikoreduktion\u00a0von\u00a049\u00a0%\u00a0bzw.\u00a050\u00a0%\u00a0von \u00a02x\u00a0bzw.\u00a03x\u00a0tgl.\u00a0\nDMF\u00a0gegen\u00fcber\u00a0Placebo.\u00a0Dr.\u00a0Ling\u00a0vom\u00a0CDER\u00a0der\u00a0FDA\u00a0stellte\u00a0im\u00a0 summary\u00a0review \u00a0167\u00a0fest,\u00a0da\u00df\u00a0im\u00a0patientenrelevant en\u00a0sekund\u00e4ren\u00a0Endpunkt\u00a0Reduktion\u00a0 der\u00a0\u201e\u00fcber\u00a024\u00a0\nWochen\u00a0anhaltenden\u00a0Behinderungsp rogression\u201c\u00a0gegen\u00fcber\u00a0Placebo\u00a00 ,169,\u00a0DMF\u00a0\n2x\u00a00,128\u00a0bzw.\u00a03x\u00a0t\u00e4glich\u00a00,119\u00a0eine\u00a0Risikoreduktion\u00a0durch\u00a0DMF\u00a0i n\u00a0H\u00f6he\u00a0von\u00a023\u00a0%\u00a0\nbzw.\u00a031\u00a0%\u00a0gegen\u00fcber\u00a0Placebo\u00a0(p=0,1893\u00a0bzw.\u00a0p=0,0760)\u00a0zwar\u00a0numer ische\u00a0aber\u00a0\nnicht\u00a0statistische\u00a0Signifikanz\u00a0g ezeigt\u00a0werden\u00a0konnte,\u00a0obwohl\u00a0di e\u00a0Ergebnisse\u00a0des\u00a0\nEndpunktes\u00a0Reduktion\u00a0von\u00a0\u201e\u00fcber\u00a012\u00a0Wochen\u00a0anhaltender\u00a0Behinderun gsprogressi\u2010\non\u201c\u00a0statistisch\u00a0signifikant\u00a0f\u00fcr\u00a0DMF\u00a0ausfielen\u00a0(CDER,\u00a02013b).\u00a0\nIn\u00a0 der\u00a0 zweiten\u00a0 zulassungsbegr\u00fcndenden\u00a0 Phase\u2010III\u2010Studie\u00a0 CONFIRM\u00a0 bzw.\u00a0 109M\u00a0\nS302\u00a0(Sponsor:\u00a0Biogen,\u00a0NCT00451451)\u00a0wurde,\u00a0\u00e4hnlich\u00a0der\u00a0Studie\u00a0D EFINE,\u00a0multi\u2010\nzentrisch,\u00a0doppelblind,\u00a01:1:1:1\u00a0randomisiert,\u00a0placebokontrollie rt\u00a0die\u00a0Wirksamkeit\u00a0\nund\u00a0Sicherheit\u00a0von\u00a0DMF\u00a02x\u00a0bzw.\u00a03x\u00a0tgl.\u00a0240\u00a0mg\u00a0gegen\u00fcber\u00a0Placebo \u00a0sowie\u00a0nunmehr\u00a0\nin\u00a0einem\u00a0zus\u00e4tzlichen\u00a0Arm\u00a0mit\u00a0aktivem\u00a0Komparator\u00a0Glatirameracet at\u00a020\u00a0mg\u00a0tgl.\u00a0an\u00a0\n1.417\u00a0RRMS\u2010Patienten\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0gepr\u00fcft.\u00a0Prim\u00e4rer\u00a0Endpunkt \u00a0war\u00a0die\u00a0j\u00e4hrli\u2010\nche\u00a0Schubrate\u00a0binnen\u00a0zwei\u00a0Jahren,\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0Ver\u00e4nderu ng\u00a0von\u00a0T1\u2010\u00a0\nbzw.\u00a0T2\u2010L\u00e4sionen\u00a0im\u00a0MRT,\u00a0Anteil\u00a0Patienten\u00a0mit\u00a0Sch\u00fcben\u00a0sowie\u00a0Ver \u00e4nderung\u00a0des\u00a0\nEDSS.\u00a0Ein\u2010\u00a0und\u00a0Ausschlu\u00dfkriterien\u00a0\u00e4hnelten\u00a0der\u00a0Studie\u00a0DEFINE\u00a0(C linicalTrials.gov,\u00a0\n2007a).\u00a0Zum\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0berichten\u00a0Fox\u00a0et\u00a0al.\u00a0eine\u00a0j\u00e4hrlic he\u00a0Schubrate\u00a0von\u00a0\n0,224\u00a0unter\u00a0DMF\u00a02x\u00a0tgl.,\u00a00,198\u00a0b ei\u00a0DMF\u00a03x\u00a0tgl.\u00a0gegen\u00fcber\u00a00,401\u00a0 unter\u00a0Placebo,\u00a0was\u00a0\neiner\u00a0Risikoreduktion\u00a0von\u00a044\u00a0%\u00a0bzw.\u00a051\u00a0%\u00a0entspricht\u00a0(<0,0001)\u00a0( Fox\u00a0et\u00a0al.,\u00a02012).\u00a0In\u00a0\nCONFIRM\u00a0konnte\u00a0die\u00a0Wirkung\u00a0von\u00a0DMF\u00a0zur\u00a0Reduktion\u00a0der\u00a0\u201eBehinderu ngsprogres\u2010\nsion\u201c\u00a0weder\u00a0\u00fcber\u00a0\u201ezw\u00f6lf\u201c\u00a0noch\u00a0\u201e\u00fcber\u00a024\u00a0Wochen\u201c\u00a0statistisch\u00a0sign ifikant\u00a0(p\u2010Werte\u00a0\n>0,05)\u00a0nachgewiesen\u00a0werden,\u00a0d.h.\u00a0es\u00a0sind\u00a0weitere\u00a0Langzeitstudie n\u00a0zur\u00a0Pr\u00fcfung\u00a0\neines\u00a0Effektes\u00a0von\u00a0DMF\u00a0zur\u00a0Behinderungsprogression\u00a0notwendig\u00a0(C DER,\u00a02013a,\u00a0\n2013b).\u00a0\nAufgrund\u00a0des\u00a0Studiendesigns\u00a0von\u00a0CONFIRM\u00a0ist\u00a0ein\u00a0Vergleich\u00a0mit\u00a0G latirameracetat\u00a0\nauf\u00a0Unter\u2010\u00a0oder\u00a0\u00dcberlegenheit\u00a0nicht\u00a0m\u00f6glich\u00a0und\u00a0dieser\u00a0Studiena rm\u00a0wurde\u00a0weder\u00a0\nvom\u00a0CDER\u00a0noch\u00a0dem\u00a0CHMP\u00a0der\u00a0EMA\u00a0ber\u00fccksichtigt\u00a0(CDER,\u00a02013b;\u00a0CHM P,\u00a02014b).\u00a0\nWeiterhin\u00a0 ist\u00a0 zu\u00a0 ber\u00fccksichtigen,\u00a0 dass\u00a0 \u00fcber\u00a0 20\u00a0%\u00a0 der\u00a0 randomiser ten\u00a0 RRMS\u2010\nPatienten\u00a0die\u00a0Teilnahme\u00a0an\u00a0den\u00a0Studien\u00a0nicht\u00a0beendeten\u00a0( Drop\u2010outs ).\u00a0Es\u00a0stellt\u00a0sich\u00a0\ngenerell\u00a0die\u00a0Frage,\u00a0wie\u00a0eine\u00a0si nnvolle\u00a0Verblindung\u00a0von\u00a0Arzneimi tteln\u00a0mit\u00a0 Adverse\u00a0\nEffect\u00a0( A E ) \u00a0H a u t r \u00f6 t u n g \u00a0b z w . \u00a0H i t z e w a l l u n g \u00a0( Flush)\u00a0 oder\u00a0 gastrointestinaler\u00a0 Be\u2010\nschwerden\u00a0(Durchfall,\u00a0Oberbauchs chmerz,\u00a0\u00dcbelkeit)\u00a0m\u00f6glich\u00a0ist.\u00a0 Xu\u00a0und\u00a0Kollegen\u00a0\ngehen\u00a0in\u00a0einem\u00a0Cochrane\u2010Review\u00a0der\u00a0beiden\u00a0Zulassungsstudien\u00a0dah er\u00a0von\u00a0attriti\u2010\non\u00a0bias\u00a0aus\u00a0und\u00a0erstellten\u00a0 Likely\u2010case\u00a0Scenarios ,\u00a0welches\u00a0diese\u00a0 Drop\u2010outs \u00a0ber\u00fcck\u2010\nsichtigen\u00a0(Xu\u00a0et\u00a0al.,\u00a02015).\u00a0\nNach\u00a0 Abschluss\u00a0 der\u00a0 beiden\u00a0 zulassungsbegr\u00fcndenden\u00a0 Studien\u00a0 DEFINE \u00a0 und\u00a0\nCONFIRM\u00a0konnten\u00a0die\u00a0RRMS\u2010Patienten\u00a0am\u00a0 Open\u2010label \u00a0Verl\u00e4ngerungsarm\u00a0ENDOR\u2010\nSE\u00a0 bzw.\u00a0 109MS303\u00a0 (Sponsor:\u00a0 Biogen,\u00a0 NCT00835770)\u00a0 teilnehmen,\u00a0 wel cher\u00a0 die\u00a0168\u00a0Langzeitsicherheit\u00a0von\u00a0DMF\u00a0anhand\u00a0des\u00a0prim\u00e4ren\u00a0Endpunktes\u00a0\u201eAnza hl\u00a0Patienten\u00a0\nmit\u00a0unerw\u00fcnschten\u00a0Effekten\u201c\u00a0sowie\u00a0einer\u00a0Vielzahl\u00a0sekund\u00e4rer\u00a0End punkte\u00a0pr\u00fcfen\u00a0\nsoll.\u00a0 Abschlie\u00dfende\u00a0 Ergebnisse\u00a0 werden\u00a0 ab\u00a0 Februar\u00a0 2023\u00a0 erwartet\u00a0 (ClinicalTri\u2010\nals.gov,\u00a02009).\u00a0Bei\u00a0den\u00a0in\u00a02016\u00a0publizierten\u00a0\u201esechs\u00a0Jahres\u00a0Zwis chenergebnissen\u00a0\neiner\u00a0Subgruppe\u201c\u00a0der\u00a0Studie\u00a0ENDORSE\u00a0ist\u00a0zu\u00a0beachten,\u00a0dass\u00a0es\u00a0si ch\u00a0um\u00a0eine\u00a0post\u2010\nhoc\u2010Analyse\u00a0von\u00a0Patienten\u00a0neu\u00a0di agnostizierter\u00a0 RRMS\u00a0handelt,\u00a0be i\u00a0denen\u00a0nach\u00a0\nZulassungsbericht\u00a0( European\u00a0Public\u00a0Assessment\u00a0Report ,\u00a0EPAR)\u00a0tendenziell\u00a0st\u00e4rkere\u00a0\nEffekte\u00a0der\u00a0Substanz\u00a0zu\u00a0erwarten \u00a0sind\u00a0(CHMP,\u00a02014b;\u00a0Gold\u00a0et\u00a0al. ,\u00a02016).\u00a0\nIm\u00a0gesamten\u00a0klinischen\u00a0Studienprogramm\u00a0traten\u00a0unter\u00a0Placebo\u00a0zwe i\u00a0und\u00a0unter\u00a0\nDMF\u00a0f\u00fcnf\u00a0Todesf\u00e4lle\u00a0auf,\u00a0welche\u00a0sich\u00a0wie\u00a0folgt\u00a0erkl\u00e4ren,\u00a0zwei\u00a0V erkehrsunf\u00e4lle,\u00a0ein\u00a0\nvollendeter\u00a0Suizid,\u00a0aber\u00a0auch\u00a0zwei\u00a0Todesf\u00e4lle\u00a0in\u00a0Folge\u00a0MS\u2010Progr ession\u00a0im\u00a0DMF\u2010\nStudienarm\u00a0(CHMP,\u00a02014b).\u00a0Nach\u00a0im\u00a0Januar\u00a02014\u00a0erfolgter\u00a0Zulassu ng\u00a0traten\u00a0im\u00a0\nklinischen\u00a0Alltag\u00a0bereits\u00a0ab\u00a0April\u00a02014\u00a0mehrere\u00a0F\u00e4lle\u00a0von\u00a0progr essiver\u00a0multifokaler\u00a0\nLeukencephalopathie\u00a0(PML)\u00a0in\u00a0Folge\u00a0von\u00a0Infektionen\u00a0mit\u00a0dem\u00a0John \u00a0Cunningham\u00a0\n(JC)\u00a0Virus\u00a0auf,\u00a0mit\u00a0dessen\u00a0Wildtyp\u00a050\u00a0%\u00a0bis\u00a060\u00a0%\u00a0der\u00a0Bev\u00f6lkerun g\u00a0infiziert\u00a0sind.\u00a0Die\u00a0\nPML\u00a0kann\u00a0t\u00f6dlich\u00a0verlaufen\u00a0und\u00a0is t\u00a0nur\u00a0differenzialdiagnostisch \u00a0(Blutbild\u00a0und\u00a0MRT)\u00a0\nvon\u00a0einem\u00a0MS\u2010Schub\u00a0zu\u00a0unterscheid en,\u00a0wobei\u00a0im\u00a0Vorfeld\u00a0nicht\u00a0imm er\u00a0eine\u00a0Leuko\u2010\npenie\u00a0auftritt\u00a0(Balak\u00a0&\u00a0Hajdarbeg ovic,\u00a02016;\u00a0Nieuwkamp\u00a0et\u00a0al.,\u00a0 2015;\u00a0Rosenkranz\u00a0\net\u00a0al.,\u00a02015;\u00a0Sweetser\u00a0et\u00a0al.,\u00a02013;\u00a0van\u00a0Oosten\u00a0et\u00a0al.,\u00a02013).\u00a0 Da\u00a0ein\u00a0Gruppeneffekt\u00a0\nfumars\u00e4urehaltiger\u00a0 Arzneimittel\u00a0 vermutet\u00a0 wird,\u00a0 wurde\u00a0 seitens\u00a0 de s\u00a0 BfArM\u00a0 ein\u00a0\nStufenplanverfahren\u00a0der\u00a0Stufe\u00a0II\u00a0f\u00fcr\u00a0die\u00a0in\u00a0Deutschland\u00a0zugelas senen\u00a0DMF\u2010haltigen\u00a0\nFertigarzneimittel\u00a0Fumaderm\u00ae/Fumaderm\u00a0initial\u00ae\u00a0und\u00a0ein\u00a0 Worksharing\u2010Variation\u2010\nVerfahren\u00a0des\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use, \u00a0CHMP\u00a0auf\u00a0euro\u2010\np\u00e4ischer\u00a0Ebene\u00a0mit\u00a0dem\u00a0BfArM\u00a0als\u00a0Rapporteur\u00a0der\u00a0EMA\u00a0f\u00fcr\u00a0Tecfide ra\u00ae\u00a0durchge\u2010\nf\u00fchrt.\u00a0Die\u00a0mittels\u00a0mehrerer\u00a0Rote r\u2010Hand\u2010Briefe\u00a0kommunizierten\u00a0\u00c4n derungen\u00a0der\u00a0\nGebrauchs\u2010\u00a0und\u00a0Fachinformationen\u00a0stellen\u00a0einen\u00a0Minimalkonsens\u00a0d es\u00a0CHMP\u00a0dar.\u00a0\nBeachtlicherweise\u00a0 sehen\u00a0 G\u2010BA\u00a0 und\u00a0 \u201eKrankheitsbezogenes\u00a0 Kompetenz netz\u00a0 MS\u201c\u00a0\n(KKNMS)\u00a0in\u00a0Ihren\u00a0Empfehlungen\u00a0zur\u00a0qualit\u00e4tsgesicherten\u00a0Anwendun g\u00a0abweichend\u00a0\nvon\u00a0der\u00a0Fachinformation\u00a0noch\u00a0engmaschigere\u00a0Labor\u2010\u00a0und\u00a0MRT\u2010Kontr ollen\u00a0zum\u00a0\nSchutz\u00a0der\u00a0Patienten\u00a0vor\u00a0(AKdAE,\u00a02014b,\u00a02015a,\u00a02015b;\u00a0at,\u00a02013a ,\u00a02013b,\u00a02014a,\u00a0\n2014c,\u00a02015a,\u00a02015b,\u00a02015c,\u00a02016a,\u00a02016b,\u00a02016c,\u00a02016d;\u00a0BfArM,\u00a0 2014,\u00a02015a,\u00a0\n2015b,\u00a02015c;\u00a0EMA,\u00a02015;\u00a0G\u2010BA,\u00a02016c ;\u00a0KKNMS,\u00a02015;\u00a0Lauktien,\u00a020 15).\u00a0\nBetrachtet\u00a0man\u00a0die\u00a0Effekte\u00a0von\u00a0DMF\u00a0auf\u00a0die\u00a0Morbidit\u00e4t,\u00a0so\u00a0ergib t\u00a0sich\u00a0ein\u00a0differen\u2010\nziertes\u00a0Bild.\u00a0Einerseits\u00a0wird\u00a0die\u00a0Schubrate\u00a0in\u00a0beiden\u00a0Studien\u00a0b is\u00a0zu\u00a0zwei\u00a0Jahren\u00a0\nDauer\u00a0in\u00a0der\u00a0zugelassenen\u00a0Dosierung\u00a0statistisch\u00a0signifikant\u00a0um\u00a0 44\u00a0%\u00a0bis\u00a047\u00a0%\u00a0ge\u2010\nsenkt\u00a0(Fox\u00a0et\u00a0al.,\u00a02012;\u00a0Gold\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0St\u00e4rke\u00a0dieses\u00a0 Effektes,\u00a0d.h.\u00a0der\u00a0Re\u2010\nduktion\u00a0der\u00a0j\u00e4hrlichen\u00a0MS\u2010Schubrate,\u00a0wird\u00a0in\u00a0Meta\u2010Analysen,\u00a0bei spielsweise\u00a0vom\u00a0\nInstitute\u00a0for\u00a0Clinical\u00a0and\u00a0Economic\u00a0Review \u00a0(ICER)\u00a0in\u00a0den\u00a0drei\u00a0Gruppen\u00a0 most\u00a0effecti\u2010\nve,\u00a0second\u00a0most\u00a0effective \u00a0und\u00a0least\u00a0effective \u00a0gegen\u00fcber\u00a0 Supportive\u00a0Care \u00a0abgestuft\u00a0169\u00a0dargestellt,\u00a0wobei\u00a0DMF\u00a0in\u00a0die\u00a0zweite\u00a0Gruppe\u00a0f\u00e4llt\u00a0(ICER\u2010Review. org,\u00a02017;\u00a0Seidner,\u00a0\n2016).\u00a0Andererseits\u00a0kommt\u00a0es\u00a0bei\u00a0 MS\u00a0vielmehr\u00a0auf\u00a0die\u00a0Verz\u00f6gerun g\u00a0der\u00a0Behinde\u2010\nrungsprogression\u00a0an,\u00a0wobei\u00a0in\u00a0der\u00a0Studie\u00a0DEFINE\u00a0eine\u00a0statistisc h\u00a0signifikante\u00a0Re\u2010\nduktion\u00a0des\u00a0Patientenanteils\u00a0mit\u00a0Behinderungsprogression\u00a0EDSS\u00a0n ach\u00a0zwei\u00a0Jahren\u00a0\ngezeigt\u00a0werden\u00a0konnte\u00a0(Placebo\u00a02 7,1\u00a0%,\u00a0DMF\u00a02x\u00a0tgl.\u00a016,4\u00a0%\u00a0p=0,0 050)\u00a0(Gold\u00a0et\u00a0al.,\u00a0\n2012),\u00a0in\u00a0der\u00a0Studie\u00a0CONFIRM\u00a0hingegen\u00a0nicht\u00a0(Placebo\u00a016,9\u00a0%,\u00a0DM F\u00a02x\u00a0tgl.\u00a012,8\u00a0%\u00a0\np=0,2536)\u00a0(Fox\u00a0et\u00a0al.,\u00a02012).\u00a0Ein\u00a0differenziertes\u00a0Bild\u00a0ergibt\u00a0s ich\u00a0in\u00a0den\u00a0 Likely\u2010case \u00a0\nScenario\u00a0Analysen\u00a0des\u00a0Cochrane\u2010Reviews,\u00a0welche\u00a0die\u00a0 Drop\u2010out\u2010Rate\u00a0von\u00a0\u00fcber\u00a020\u00a0%\u00a0\nber\u00fccksichtigt\u00a0(Xu\u00a0et\u00a0al.,\u00a02015).\u00a0Vom\u00a0CHMP\u00a0wurde\u00a0der\u00a0Effekt\u00a0von \u00a0DMF\u00a0auf\u00a0die\u00a0\nMorbidit\u00e4t,\u00a0d.h.\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0Behinderungsprogression,\u00a0als\u00a0 nicht\u00a0ausreichend\u00a0\nnachgewiesen\u00a0eingesch\u00e4tzt,\u00a0sodass\u00a0eine\u00a0Indikation\u00a0zur\u00a0Krankheit smodifikation\u00a0im\u00a0\nRahmen\u00a0der\u00a0Zulassung\u00a0nicht\u00a0gegeben\u00a0ist.\u00a0Begr\u00fcndet\u00a0wird\u00a0dies\u00a0mit \u00a0methodischen\u00a0\nSchw\u00e4chen\u00a0gepoolter\u00a0Daten\u00a0sowie\u00a0vorgelegten\u00a0 Post\u2010Hoc\u2010Analysen.\u00a0Weiterhin\u00a0sei\u00a0\nlaut\u00a0CHMP\u00a0die\u00a0Extrapolation\u00a0der\u00a0pivotalen\u00a0Studiendaten\u00a0der\u00a0RRMS \u2010Patienten\u00a0auf\u00a0\nSPMS\u2010Populationen\u00a0zwecks\u00a0Indikationserweiterung\u00a0nicht\u00a0m\u00f6glich\u00a0( CHMP,\u00a02014b).\u00a0\nDaten\u00a0zu\u00a0AE\u00a0liegen\u00a0einerseits\u00a0aus\u00a0den\u00a0Studien\u00a0zur\u00a0Zulassung\u00a0von \u00a0DMF\u00a0bei\u00a0RRMS\u00a0\nandererseits\u00a0zu\u00a0den\u00a0in\u00a0Deutschla nd\u00a0seit\u00a01994\u00a0zugelassenen\u00a0Ferti garzneimitteln\u00a0Fu\u2010\nmaderm\u00ae/Fumaderm\u00a0initial\u00ae\u00a0mit\u00a060\u00a0%\u00a0wirkungsbestimmendem\u00a0Bestand teil\u00a0DMF\u00a0\nvor,\u00a0welches\u00a0 off\u2010Label\u00a0bei\u00a0MS\u00a0eingesetzt\u00a0wurde.\u00a0Bei\u00a0H\u00f6chstdosierung\u00a0von\u00a0Fuma\u2010\nderm\u00ae\u00a0werden\u00a0t\u00e4glich\u00a0720\u00a0mg\u00a0DMF\u00a0zugef\u00fchrt.\u00a0Es\u00a0zeigte\u00a0sich\u00a0in\u00a0de n\u00a0Studien\u00a0auf\u2010\ngrund\u00a0der\u00a0Ausschlusskriterien\u00a0ein\u00a0mildes\u00a0AE\u2010Profil\u00a0mit\u00a0ca.\u00a0eine m\u00a0Drittel\u00a0 Flush\u00a0und\u00a0\nrund\u00a0 einem\u00a0 Viertel\u00a0 gastrointestinalen\u00a0 Beschwerden\u00a0 (Oberbauchbes chwerden,\u00a0\n\u00dcbelkeit,\u00a0Durchfall),\u00a0welche\u00a0durch\u00a0Einnahme\u00a0von\u00a0DMF\u00a0nach\u00a0der\u00a0Ma hlzeit\u00a0reduziert\u00a0\nwerden\u00a0k\u00f6nnen,\u00a0bei\u00a0Persistenz\u00a0ist\u00a0die\u00a0Adh\u00e4renz\u00a0einer\u00a0Dauerthera pie\u00a0beeintr\u00e4ch\u2010\ntigt.\u00a0Im\u00a0klinischen\u00a0Alltag\u00a0werden\u00a0diese\u00a0AE\u00a0wohl\u00a0h\u00e4ufiger\u00a0berich tet\u00a0(Bereau\u00a0et\u00a0al.,\u00a0\n2016,\u00a02017;\u00a0Pugliatti\u00a0et\u00a0al.,\u00a02016).\u00a0Andererseits\u00a0traten\u00a0unter\u00a0 DMF\u00a0auch\u00a0Leuko\u2010\u00a0und\u00a0\nLymphopenie\u00a0unterschiedlichen\u00a0Au sma\u00dfes\u00a0auf,\u00a0wobei\u00a0die\u00a0Lymphozyt en\u00a0im\u00a0Mittel\u00a0\n30\u00a0%\u00a0unter\u00a0den\u00a0Basiswert\u00a0mit\u00a0einem\u00a0Nadir\u00a0ab\u00a0Woche\u00a048\u00a0absinken.\u00a0 Hierdurch\u00a0tre\u2010\nten\u00a0in\u00a0seltenen\u00a0F\u00e4llen\u00a0opportunis tische\u00a0Infektionen\u00a0sowie\u00a0PML\u00a0a uf\u00a0(BfArM,\u00a02015c).\u00a0\nIn\u00a0Studien\u00a0waren\u00a0geringf\u00fcgige\u00a0Erh\u00f6hung\u00a0der\u00a0Leberwerte\u00a0sowie\u00a0als \u00a0renale\u00a0AE\u00a0Pro\u2010\nteinurie,\u00a0H\u00e4maturie\u00a0bzw.\u00a0Mikroalbuminurie\u00a0zu\u00a0beobachten\u00a0(CHMP,\u00a0 2014a).\u00a0Von\u00a0\nder\u00a0 AKdAE\u00a0 liegen\u00a0 zwischenzeitlich\u00a0 aus\u00a0 dem\u00a0 klinischen\u00a0 Alltag\u00a0 Ein zelfallberichte\u00a0\n(Case\u2010Reports )\u00a0zu\u00a0akutem\u00a0Nierenversagen\u00a0unter\u00a0DMF\u00a0sowie\u00a0reversiblem\u00a0Kaposi\u2010\nSarkom\u00a0und\u00a0Nokardiose\u00a0unter\u00a0Fumaderm\u00ae\u00a0vor,\u00a0sodass\u00a0im\u00a0klinischen \u00a0Alltag\u00a0ver\u2010\nst\u00e4rkt\u00a0hierauf\u00a0geachtet\u00a0werden\u00a0sollte\u00a0(AKdAE,\u00a02009,\u00a02013,\u00a02014a ).\u00a0Vom\u00a0Pharmaco\u2010\nvigilance\u00a0Risk\u00a0Assessment\u00a0Committee, \u00a0PRAC,\u00a0der\u00a0EMA\u00a0wurden\u00a0im\u00a0Rahmen\u00a0des\u00a0\nPharmakovigilanz\u2010Planes\u00a0die\u00a0Durchf\u00fchrung\u00a0zahlreicher\u00a0zus\u00e4tzlich er\u00a0Studien\u00a0ange\u2010\nordnet,\u00a0neben\u00a0dem\u00a0 Open\u2010label \u00a0Verl\u00e4ngerungsarm\u00a0der\u00a0pivotalen\u00a0Studien\u00a0ENDORSE\u00a0\n(Sponsor:\u00a0Biogen,\u00a0NCT00835770\u00a0 109MS303)\u00a0dessen\u00a0Ergebnisse\u00a0ab\u00a020 23\u00a0erwartet\u00a0\nw e r d e n \u00a0s o w i e \u00a0d i e \u00a0S i c h e r h e i t s s t u d i e \u00a0E S T E E M \u00a0( S p o n s o r : \u00a0B i o g e n , \u00a0N C T 02047097\u00a0170\u00a0109MS401)\u00a0deren\u00a0Ergebnisse\u00a0ab\u00a02024\u00a0vorliegen\u00a0sollen\u00a0(CHMP,\u00a02014 b).\u00a0Auch\u00a0das\u00a0\nCDER\u00a0der\u00a0FDA\u00a0fordert\u00a0weitere\u00a0Studien\u00a0zur\u00a0Abkl\u00e4rung\u00a0des\u00a0Risikopr ofils,\u00a0insbesonde\u2010\nre\u00a0zum\u00a0Ausschluss\u00a0eines\u00a0Missbrauchspotenzials\u00a0der\u00a0Substanz,\u00a0pr\u00e4 klinisch\u00a0erwiese\u2010\nner\u00a0Nephrotoxozit\u00e4t\u00a0oder\u00a0Ma lignit\u00e4t\u00a0(CDER,\u00a02013c).\u00a0\nDaten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0 Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life \u00a0\n(HRQoL)\u00a0wurden\u00a0als\u00a0terti\u00e4re\u00a0Endpunkte\u00a0mittels\u00a0der\u00a0Erhebungsinst rumente\u00a0 36\u2010Item\u00a0\nShort\u2010Form\u00a0Health\u00a0Survey \u00a0(SF\u201036)\u00a0gesammelt.\u00a0Im\u00a0Rahmen\u00a0eines\u00a0Cochrane\u00a0Reviews,\u00a0\nder\u00a0publizierte\u00a0Daten\u00a0f\u00fcr\u00a01.461\u00a0Studienteilnehmern\u00a0ber\u00fccksichti gen\u00a0konnte,\u00a0er\u2010\nbrachten\u00a0in\u00a0der\u00a0physischen\u00a0Komponente\u00a0(PCS)\u00a0nach\u00a0zwei\u00a0Jahren\u00a0DM F\u00a0gegen\u00fcber\u00a0\nPlacebo\u00a0eine\u00a0geringf\u00fcgige\u00a0Verbesserung,\u00a0jedoch\u00a0nicht\u00a0in\u00a0der\u00a0men talen\u00a0Komponen\u2010\nte\u00a0(MCS)\u00a0des\u00a0SF\u201036\u00a0(Xu\u00a0et\u00a0al.,\u00a02015).\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0von\u00a0der\u00a0Deutschen\u00a0Gesellschaf t\u00a0f\u00fcr\u00a0Neurologie\u00a0(DGN)\u00a0im\u00a0Janu ar\u00a02012\u00a0heraus\u2010\ngegebene\u00a0S2e\u2010Leitlinie\u00a0\u201eDiagnose\u00a0und\u00a0Therapie\u00a0der\u00a0Multiplen\u00a0Skl erose\u201c\u00a0wurde\u00a0im\u00a0\nAugust\u00a02014\u00a0erg\u00e4nzt\u00a0und\u00a0nach\u00a0\u00dcberpr\u00fcfung\u00a0im\u00a0August\u00a02015\u00a0mit\u00a0ein er\u00a0G\u00fcltigkeit\u00a0\nf\u00fcr\u00a0weitere\u00a0zwei\u00a0Jahre\u00a0versehen,\u00a0d.h.\u00a0bis\u00a0September\u00a02017\u00a0verl\u00e4n gert.\u00a0Vorweg\u00a0zu\u00a0\nbemerken\u00a0ist,\u00a0dass\u00a0eine\u00a0kausale\u00a0Therapie\u00a0der\u00a0MS\u00a0derzeit\u00a0nicht\u00a0m \u00f6glich\u00a0ist,\u00a0d.h.\u00a0alle\u00a0\naktuell\u00a0verf\u00fcgbaren\u00a0Therapien\u00a0so llen\u00a0den\u00a0Krankheitsverlauf\u00a0posi tiv\u00a0beeinflussen.\u00a0\nBei\u00a0der\u00a0Pharmakotherapie\u00a0der\u00a0MS\u00a0unterschiedet\u00a0man\u00a0die\u00a0Therapie\u00a0 des\u00a0akuten\u00a0\nKrankheitsschubes,\u00a0wobei\u00a0hochdosi ertes\u00a0Methylprednisolon\u00a0als\u00a0er ste\u00a0Wahl\u00a0und\u00a0\n(nicht\u00a0medikament\u00f6s)\u00a0die\u00a0Plasmaseparation\u00a0als\u00a0zweite\u00a0Wahl\u00a0gelte n,\u00a0sowie\u00a0die\u00a0\n\u201everlaufsmodifizierenden\u00a0Therapien\u201c.\u00a0Die\u00a0Auswahl\u00a0der\u00a0Substanzen \u00a0erfolgt\u00a0anhand\u00a0\nder\u00a0Verlaufsform.\u00a0Unterschieden\u00a0werden\u00a0die\u00a0milde/moderate\u00a0(Basi stherapie)\u00a0und\u00a0\ndie\u00a0hochaktive\u00a0Verlaufsform\u00a0(Eskalationstherapie).\u00a0Die\u00a0Zulassun g\u00a0und\u00a0Empfehlung\u00a0\neinzelner\u00a0Substanzen\u00a0orientiert\u00a0sich\u00a0am\u00a0Krankheitsstadium\u00a0und\u00a0K rankheitsverlauf:\u00a0\nCIS,\u00a0RRMS,\u00a0SPMS\u00a0oder\u00a0PPMS.\u00a0Bei\u00a0CIS\u00a0oder\u00a0milder\u00a0Verlaufsform\u00a0wer den\u00a0Glatira\u2010\nmeracetat\u00a0oder\u00a0IFN\u00a0\u00df\u20101a\u00a0bzw.\u00a01b\u00a0gegeben,\u00a0bei\u00a0RRMS\u00a0k\u00f6nnen\u00a0altern ativ\u00a0pegylier\u2010\ntes(PEG)\u00a0IFN\u00a0\u00df\u20101a\u00a0und\u00a0als\u00a0orale\u00a0Darreichungsformen\u00a0DMF\u00a0und\u00a0Teri flumonid\u00a0einge\u2010\nsetzt\u00a0werden.\u00a0F\u00fcr\u00a0die\u00a0Eskalation\u00a0bei\u00a0hochaktiver\u00a0RRMS\u00a0stehen\u00a0Al emtuzumab,\u00a0Fin\u2010\ngolimod\u00a0 oder\u00a0 Natalizumab\u00a0 zur\u00a0 Verf\u00fcgung;\u00a0 Mitoxantron\u00a0 oder\u00a0 bei\u00a0 fu lminantem\u00a0\nVerlauf\u00a0auch\u00a0Cyclophosphamid\u00a0gelten\u00a0als\u00a0Mittel\u00a0zweiter\u00a0Wahl,\u00a0vo r\u00a0allem\u00a0bei\u00a0SPMS\u00a0\n(GOLD,\u00a02012).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nZu\u00a0DMF\u00a0liegen\u00a0vier\u00a0Beschl\u00fcsse\u00a0des \u00a0G\u2010BA\u00a0vor,\u00a0wobei\u00a0neben\u00a0dem\u00a0reg ul\u00e4ren\u00a0Verfah\u2010\nren\u00a0neue\u00a0Erkenntnisse\u00a0zum\u00a0Nutzen\u2010 Risiko\u2010Profil\u00a0von\u00a0DMF\u00a0dreimal\u00a0 \u00c4nderungen\u00a0der\u00a0\nqualit\u00e4tsgesicherten\u00a0Anwendung\u00a0zu\u00a0neuen\u00a0Beschl\u00fcssen\u00a0f\u00fchrten\u00a0(G\u2010 BA,\u00a02014d).\u00a0171\u00a0Das\u00a0erste\u00a0Nutzenbewertungsverfahren\u00a0verz\u00f6gerte\u00a0sich,\u00a0da\u00a0der\u00a0G\u2010B A\u00a0bei\u00a0DMF\u00a0zu\u2010\nn\u00e4chst\u00a0nicht\u00a0von\u00a0einem\u00a0neuen\u00a0Wirkstoff\u00a0ausging\u00a0(at,\u00a02014a;\u00a0G\u2010BA ,\u00a02014e).\u00a0Im\u00a0\nersten\u00a0Beschluss\u00a0vom\u00a016.\u00a0Oktober\u00a02014\u00a0konnte\u00a0der\u00a0G\u2010BA\u00a0keinen\u00a0Zu satznutzen\u00a0von\u00a0\nDMF\u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0(zVT)\u00a0IFN\u00a0\u00df\u20101 a\u00a0bzw.\u00a01b\u00a0oder\u00a0\nGlatirameracetat\u00a0feststellen,\u00a0da\u00a0der\u00a0pU\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0 vorlegte.\u00a0Anzu\u2010\nmerken\u00a0 ist,\u00a0 dass\u00a0 der\u00a0 pU,\u00a0 obwohl\u00a0 in\u00a0 der\u00a0 zulassungsrelevanten\u00a0 Pha se\u2010III\u2010Studie\u00a0\n109MS302/CONFIRM\u00a0(NCT00451451)\u00a0ein\u00a0Vergleich\u00a0von\u00a0DMF,\u00a0Placebo\u00a0u nd\u00a0Glati\u2010\nrameracetat\u00a0gegeben\u00a0ist,\u00a0mittels\u00a0eines\u00a0indirekten\u00a0Vergleiches\u00a0i n\u00a0Form\u00a0einer\u00a0Netz\u2010\nwerk\u2010Metaanalyse\u00a0(NMA)\u00a0\u00fcber\u00a0vierzehn\u00a0Studien\u00a0einen\u00a0Nachweis\u00a0erb ringen\u00a0wollte.\u00a0\nMethodisch\u00a0k\u00f6nnen\u00a0NMA\u00a0Studienerg ebnisse\u00a0verzerrt\u00a0wiedergeben,\u00a0d a\u00a0Daten\u00a0zu\u00a0\nEndpunkten\u00a0und\u00a0unerw\u00fcnschten\u00a0Effe kten\u00a0unvollst\u00e4ndig\u00a0dargestellt \u00a0werden\u00a0k\u00f6n\u2010\nnen\u00a0(publication\u00a0bias ).\u00a0Konkret\u00a0kritisiert\u00a0der\u00a0G\u2010BA\u00a0die\u00a0fehlende\u00a0Ber\u00fccksichtigung\u00a0\naller\u00a0Arzneimittel\u00a0mit\u00a0Wirkstoff\u00a0IFN\u00a0\u00df\u20101a,\u00a0wobei\u00a0der\u00a0pU\u00a0nur\u00a0Reb if\u00ae\u00a044\u00a0\u00b5g\u00a0subkutan\u00a0\n(sc)\u00a0einschloss,\u00a0nicht\u00a0jedoch\u00a0Avonex\u00ae\u00a030\u00a0\u00b5g\u00a0intramuskul\u00e4r\u00a0(i.m. ),\u00a0welches\u00a0der\u00a0pU\u00a0\nzudem\u00a0selbst\u00a0vertreibt.\u00a0Weiterhin\u00a0fehlt\u00a0dieser\u00a0NMA\u00a0laut\u00a0G\u2010BA\u00a0ei ne\u00a0ad\u00e4quate\u00a0Pr\u00fc\u2010\nfung\u00a0grundlegender\u00a0Annahmen\u00a0von\u00a0\u00c4hnlichkeit\u00a0(Effektmodifikatore n),\u00a0Homogeni\u2010\nt\u00e4t\u00a0sowie\u00a0Konsistenz,\u00a0d.h.\u00a0es\u00a0be stehen\u00a0relevante\u00a0Unterschiede\u00a0b ei\u00a0den\u00a0jeweils\u00a0in\u00a0\nStudien\u00a0eingeschlossenen\u00a0Patientenpopulationen\u00a0die\u00a0einen\u00a0Vergle ich\u00a0bzw.\u00a0eine\u00a0\nAussage\u00a0zum\u00a0Zusatznutzen\u00a0gegen\u00fcbe r\u00a0zVT\u00a0unm\u00f6glich\u00a0machen\u00a0(vorher iger\u00a0Phar\u2010\nmakotherapie,\u00a0 d.h.\u00a0 Vortherapie\u00a0 oder\u00a0 therapienaive\u00a0 Patienten,\u00a0 Sc hubh\u00e4ufigkeit,\u00a0\nKrankheitsdauer\u00a0zu\u00a0Studienbeginn,\u00a0Krankheitsschwere\u00a0(EDSS)\u00a0und\u00a0 \u2010verlauf).\u00a0Be\u2010\nsonders\u00a0zu\u00a0beachten\u00a0ist,\u00a0dass\u00a0Studien\u00a0mit\u00a0DMF\u00a0die\u00a0Krankheitssch were\u00a0nach\u00a0den\u00a0\nneuen,\u00a0revidierten\u00a0McDonald\u2010Kriterien\u00a0werteten,\u00a0die\u00a0anderen\u00a0Stu dien\u00a0jedoch\u00a0die\u00a0\n\u00e4lteren,\u00a0weniger\u00a0sensitiven\u00a0Pose r\u2010Kriterien\u00a0nutzten,\u00a0wodurch\u00a0in \u00a0der\u00a0Synopse\u00a0die\u00a0\nPatienten\u00a0in\u00a0Studien\u00a0mit\u00a0DMF\u00a0ein e\u00a0geringere\u00a0Krankheitsschwere\u00a0z eigten.\u00a0Obgleich\u00a0\nder\u00a0pU\u00a0dies\u00a0im\u00a0Dossier\u00a0dokumentierte,\u00a0folgerte\u00a0er\u00a0nichts\u00a0zur\u00a0Be wertung\u00a0der\u00a0\u00c4hn\u2010\nlichkeit\u00a0der\u00a0Studien\u00a0in\u00a0der\u00a0NMA.\u00a0Nachgereichte\u00a0Auswertungen\u00a0kon nten\u00a0den\u00a0G\u2010BA\u00a0\nnicht\u00a0\u00fcberzeugen,\u00a0da\u00a0auch\u00a0diese\u00a0m ethodische\u00a0M\u00e4ngel\u00a0innehatten\u00a0( G\u2010BA,\u00a02014e).\u00a0\nIm\u00a0zweiten\u00a0Beschluss\u00a0vom\u00a08.\u00a0Januar\u00a02015\u00a0wird\u00a0ein\u00a0Hinweis\u00a0auf\u00a0de n\u00a0Rote\u2010Hand\u2010\nBrief\u00a0(RHB)\u00a0vom\u00a03.\u00a0Dezember\u00a02014\u00a0erg\u00e4nzt\u00a0und\u00a0auf\u00a0die\u00a0Aufkl\u00e4rung \u00a0der\u00a0Patienten\u00a0\n\u00fcber\u00a0das\u00a0Risiko\u00a0einer\u00a0letalen\u00a0PML \u00a0in\u00a0Folge\u00a0JC\u2010Virus\u2010Infektion\u00a0s owie\u00a0n\u00f6tige\u00a0Kontroll\u2010\u00a0\nund\u00a0Sicherheitsma\u00dfnahmen\u00a0beim\u00a0therapeutischen\u00a0Gebrauch\u00a0von\u00a0DMF\u00a0 hingewie\u2010\nsen\u00a0(AKdAE,\u00a02014b;\u00a0G\u2010BA,\u00a02015b,\u00a02015d).\u00a0\nDer\u00a0dritte\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0vom\u00a023.\u00a0Juni\u00a02016\u00a0erfolgte\u00a0im\u00a0Kon text\u00a0eines\u00a0andau\u2010\nernden\u00a0Worksharing\u2010Variation\u2010Verfahrens \u00a0 (WVV)\u00a0 der\u00a0 Zulassungsbeh\u00f6rden\u00a0 EMA\u00a0\nund\u00a0BfArM\u00a0zu\u00a0DMF\u2010haltigen\u00a0Arzneimitteln\u00a0aufgrund\u00a0des\u00a0Auftretens \u00a0von\u00a0schwer\u2010\nwiegenden,\u00a0letalen\u00a0Nebenwirkungen \u00a0und\u00a0f\u00fchrt\u00a0noch\u00a0vor\u00a0Ma\u00dfnahmen\u00a0 der\u00a0Zulas\u2010\nsungsbeh\u00f6rden\u00a0und\u00a0offizieller\u00a0\u00c4nderung\u00a0der\u00a0Fachinformation\u00a0eine \u00a0Vielzahl\u00a0von\u00a0\nMa\u00dfnahmen\u00a0zum\u00a0Schutz\u00a0von\u00a0Patien ten\u00a0an\u00a0(G\u2010BA,\u00a02015c,\u00a02015e).\u00a0172\u00a0Im\u00a0vierten\u00a0Beschluss\u00a0vom\u00a07.\u00a0Januar\u00a02016\u00a0geht\u00a0der\u00a0G\u2010BA\u00a0auf\u00a0die\u00a0E rgebnisse\u00a0des\u00a0\nWVV\u00a0und\u00a0den\u00a0zweiten\u00a0RHB\u00a0\u201eNeue\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Senkung\u00a0des\u00a0Risikos \u00a0einer\u00a0PML\u00a0\n\u2013\u00a0vermehrte\u00a0\u00dcberwachung\u00a0und\u00a0Absetzen\u00a0der\u00a0Therapie\u201c\u00a0vom\u00a023.\u00a0Nove mber\u00a02015\u00a0\nein\u00a0(G\u2010BA,\u00a02016a,\u00a02016b).\u00a0Bemerkenswert\u00a0ist,\u00a0dass\u00a0der\u00a0G\u2010BA\u00a0der\u00a0 Expertise\u00a0des\u00a0\nKrankheitsbezogenen\u00a0Kompetenznetz es\u00a0Multiple\u00a0Sklerose\u00a0(KKNMS)\u00a0f olgt\u00a0und\u00a0eng\u2010\nmaschigere\u00a0Kontrollen\u00a0zur\u00a0qualit \u00e4tsgesicherten\u00a0Anwendung\u00a0von\u00a0DM F\u00a0in\u00a0der\u00a0GKV\u00a0\nvorgibt\u00a0als\u00a0im\u00a0RHB\u00a0bzw.\u00a0der\u00a0ge\u00e4nderten\u00a0Fachinformation\u00a0empfohle n,\u00a0der\u00a0zwischen\u00a0\nZulassungsbeh\u00f6rden\u00a0 EMA,\u00a0 BfArM\u00a0 und\u00a0 pU\u00a0 abgestimmt\u00a0 wurde\u00a0 (AKdAE,\u00a0 2 015b;\u00a0\nKKNMS,\u00a02015).\u00a0In\u00a0diesem\u00a0Kontext\u00a0fand\u00a0auch\u00a0eine\u00a0zweite\u00a0m\u00fcndliche \u00a0Anh\u00f6rung\u00a0statt\u00a0\n(G\u2010BA,\u00a02016c).\u00a0Zu\u00a0den\u00a0zus\u00e4tzlichen\u00a0Kosten\u00a0der\u00a0nunmehr\u00a0intensivi erten\u00a0Diagnostik\u00a0\n(h\u00e4ufigere\u00a0MRTs,\u00a0Blutbilder,\u00a0Arzt kontakte)\u00a0werden\u00a0seitens\u00a0des\u00a0G \u2010BA\u00a0keine\u00a0Anga\u2010\nben\u00a0gemacht.\u00a0\nVersorgungsanalysen\u00a0\nAbbildung\u00a04.8:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Dimethylfumarat\u00a0je\u00a0 Monat\u00a0\nnach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n\u00a0\u00a0\n173\u00a0Abbildung\u00a04.9:\u00a0Versicherte\u00a0mit\u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Dimethylf umarat\u00a0\nnach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nEs\u00a0zeigt\u00a0sich,\u00a0dass\u00a0MS\u00a0h\u00e4ufig\u00a0im \u00a0fr\u00fchen\u00a0Erwachsenen\u00a0Alter\u00a0auftr itt,\u00a0d.h.\u00a020.\u00a0bis\u00a0\n59.\u00a0Lebensjahr,\u00a0Frauen\u00a0h\u00e4ufiger\u00a0a ls\u00a0M\u00e4nner\u00a0betroffen\u00a0sind.\u00a0Zu\u00a0b eachten\u00a0ist\u00a0die\u00a0\nverk\u00fcrzte\u00a0Lebenserwartung\u00a0um\u00a0sieben\u00a0bis\u00a0zehn\u00a0Jahre.\u00a0\nQuellen\u00a0\nAKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2015b) .\u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Tecfidera\u00ae\u00a0(Dimethylfumarat).\u00a0\nwww.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2015/20151123.pd f,\u00a0letzter\u00a0Zugriff:\u00a014.06.2017.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2009).\u00a0 Reversibles\u00a0Kaposi\u2010Sarkom\u00a0un ter\u00a0Fumaderm\u2010assoziierter\u00a0\nLymphozytopenie.\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0106(47):\u00a02380.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2013).\u00a0 Nokardiose\u00a0bei\u00a0Lymphopenie\u00a0durch\u00a0Fumaderm\u00ae:\u00a0(Aus\u00a0der\u00a0UAW\u2010\nDatenbank).\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0110(23\u201024):\u00a01220\u20101221.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2014a). \u00a0Akutes\u00a0Nierenversagen\u00a0unter\u00a0der\u00a0Behandlung\u00a0mit\u00a0Fumars\u00e4ure\u00a0\nbei\u00a0Multipler\u00a0Sklerose:\u00a0(Aus\u00a0der\u00a0UAW\u2010Datenbank).\u00a0Deutsches\u00a0\u00c4rzt eblatt\u00a0111(25):\u00a01177\u20101178.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2014b). \u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Tecfidera\u00ae\u00a0(Dimethylfumarat).\u00a0\nwww.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2014/20141204.pd f,\u00a0letzter\u00a0Zugriff:\u00a014.06.2017.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2015a). \u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Fumaderm\u00ae\u00a0initial/Fumaderm\u00ae\u00a0\n(Fumars\u00e4ureester).\u00a0 www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2015/20151124.pd f,\u00a0letzter\u00a0Zugriff:\u00a0\n14.06.2017.\u00a0\n174\u00a0AKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2015b). \u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Tecfidera\u00ae\u00a0(Dimethylfumarat):\u00a0zweiter\u00a0RHB\u00a0\n23.11.2015.\u00a0 www.akdae.de/Arzneimittelsicherh eit/RHB/Archiv/2015/20151123.pd f,\u00a0letzter\u00a0Zugriff:\u00a014.06.2017.\u00a0\nAMIS\u00a0(2017).\u00a0Fumaderm\u00a0\u2010\u00a0biogen\u00a0Zul.\u2010Nr.\u00a027561.01.00.\u00a0 https://portal.dimdi.de/websearch/servlet/FlowController/Docume nts\u2010\ndisplay#__DEFANCHOR__ ,\u00a0letzter\u00a0Zugriff:\u00a014.06.2017.\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2013a).\u00a0Fumars\u00e4ureester\u00a0(FUMADERM)\u00a0\u2026pro gressive\u00a0multifokale\u00a0Leukenzephalopathie:\u00a0Nebenwirkungen.\u00a0\na\u2010t\u00a044(5):\u00a047.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2013b).\u00a0Fumars\u00e4ureester\u00a0(FUMADERM)\u00a0bei\u00a0 Psoriasis:\u00a0Korrespondenz.\u00a0a\u2010t\u00a044(4):\u00a035\u201336.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014a).\u00a0Dimethylfumarat\u00a0(Tecfidera)\u00a0geg en\u00a0multiple\u00a0Sklerose:\u00a0Neu\u00a0auf\u00a0dem\u00a0Markt.\u00a0a\u2010t\u00a045(3):\u00a028\u201029.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014b).\u00a0Jetzt\u00a0doch\u00a0\u2010\u00a0fr\u00fche\u00a0Nutzenbewert ung\u00a0von\u00a0Dimethylfumarat\u00a0(TECFIDERA):\u00a0Kurz\u00a0und\u00a0b\u00fcndig.\u00a0a\u2010t\u00a045(6) :\u00a0\n63.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014c).\u00a0PML\u00a0jetzt\u00a0auch\u00a0unter\u00a0MS\u2010Mittel\u00a0 Dimethylfumarat\u00a0(TECFIDERA):\u00a0Warnhinweis.\u00a0a\u2010t\u00a045(11),\u00a0112.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2015a).\u00a0DIMETHYLFUMARAT\u00a0(TECFIDERA)\u00a0\u2026\u00a0h \u00e4ufigere\u00a0Blutbildkontrollen\u00a0angeordnet:\u00a0Nebenwirkungen.\u00a0a\u2010\nt\u00a046(11):\u00a0114.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2015b).\u00a0PML\u00a0UNTER\u00a0FUMARS\u00c4UREESTERN\u00a0(FUM ADERM,TECFIDERA)\u2026\u00a0auch\u00a0bei\u00a0nur\u00a0m\u00e4\u00dfiger\u00a0Lymphopenie:\u00a0\nNebenwirkungen.\u00a0a\u2010t\u00a046(4):\u00a040.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2015c).\u00a0PML\u00a0UNTER\u00a0FUMARS\u00c4UREESTERN\u00a0(FUM ADERM,TECFIDERA)\u2026\u00a0auch\u00a0bei\u00a0nur\u00a0m\u00e4\u00dfiger\u00a0Lymphopenie:\u00a0\nNebenwirkungen.\u00a0a\u2010t\u00a046(10):\u00a0101\u2013102.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016a).\u00a0A kteneinsicht\u00a0best\u00e4tigt\u00a0PML\u00a0unt er\u00a0Dimethylfumarat\u00a0(TECFIDERA)\u00a0bei\u00a0m\u00e4\u00dfiger\u00a0Lymphopenie:\u00a0Kurz\u00a0\nund\u00a0b\u00fcndig.\u00a0a\u2010t\u00a047(5):\u00a049.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016b).\u00a0DIMETHYLFUMARAT\u00a0(TECFIDERA):\u00a0ER STE\u00a0PML\u00a0BEI\u00a0NUR\u00a0M\u00c4\u00dfIGER\u00a0LYMPHOPENIE:\u00a0Nebenwirkungen.\u00a0\na\u2010t\u00a047(2):\u00a024.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016c).\u00a0PML\u00a0unter\u00a0Dimethylfumarat\u00a0(TECF IDERA)\u00a0\u2010\u00a0Beh\u00f6rden\u00a0mauern:\u00a0Kurz\u00a0und\u00a0b\u00fcndig.\u00a0a\u2010t\u00a047(4),\u00a039\u201340.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016d).\u00a0PML\u00a0UNTER\u00a0DIMETHYLFUMARAT\u00a0BEI\u00a0M S\u00a0\u2026TECFIDERA:\u00a0Risikomanagement\u00a0der\u00a0Beh\u00f6rden\u00a0weiterhin\u00a0\nunzureichend.\u00a0a\u2010t\u00a047(10):\u00a098\u201399.\u00a0\u00a0\nBalak\u00a0D,\u00a0Hajdarbegovic\u00a0E\u00a0(2016).\u00a0More\u00a0on\u00a0PML\u00a0in\u00a0Patients\u00a0Treate d\u00a0with\u00a0Dimethyl\u00a0Fumarate.\u00a0NEJM\u00a0374(3):\u00a0294\u2010296.\u00a0\nB\u00e9reau\u00a0M,\u00a0Clerc\u00a0C,\u00a0Jary\u00a0A,\u00a0Lavier\u00a0A,\u00a0Chamard\u00a0L,\u00a0Magnin\u00a0E\u00a0et\u00a0al. \u00a0(2016).\u00a0Safety\u00a0of\u00a0Dimethylfumarate\u00a0in\u00a0clinical\u00a0practice:\u00a0a\u00a0reg ional\u00a0\nstudy.\u00a0Fundamental\u00a0&\u00a0Clinical\u00a0Pharmacology\u00a030(4):\u00a081.\u00a0\nBereau\u00a0M,\u00a0Sandoz\u00a0O,\u00a0Clerc\u00a0C,\u00a0Jary \u00a0A,\u00a0Ziegler\u00a0F,\u00a0Berger\u00a0E\u00a0et\u00a0al. \u00a0(2017).\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0Dimethylfumarate\u00a0in\u00a0relapsing\u00a0r emitting\u00a0\nmultiple\u00a0sclerosis:\u00a0a\u00a0real\u00a0life\u00a0regional\u00a0study.\u00a0 http://onlinelibrary.wiley.com/o/ cochrane/clcentral/articles/42 1/CN\u2010\n01364421/frame.html ,\u00a0letzter\u00a0Zugriff:\u00a018.07.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 14).\u00a0Tecfidera\u00a0(Dimethylfumarat) :\u00a0Erster\u00a0Fall\u00a0einer\u00a0progressive n\u00a0\nmultifokalen\u00a0Leukenzephalopathie\u00a0(PML).\u00a0\nhttp://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigi lanz/DE/RI/2014/RI\u2010tecfidera.html ,\u00a0letzter\u00a0\nZugriff:\u00a023.06.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 15a).\u00a0Dimethylfumarathaltige\u00a0Arzneimittel\u00a0(Tecfidera,\u00a0\nFumaderm)\u00a0und\u00a0progressive\u00a0multifokale\u00a0Leukencephalopathie\u00a0(PML) :\u00a0Abschluss\u00a0des\u00a0Worksharing\u2010Variation\u2010175\u00a0Verfahrens.\u00a0 http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigi lanz/DE/RI/2015/RI\u2010\ndimethylfumarat2.html ,\u00a0letzter\u00a0Zugriff:\u00a023.06.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 15b).\u00a0Dimethylfumarathaltige\u00a0Arzneimittel\u00a0(Tecfidera,\u00a0\nFumaderm):\u00a0Progressive\u00a0multifokale\u00a0Leukencephalopathie\u00a0(PML)\u00a0in \u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Anwendung\u00a0\ndimethylfumarathaltiger\u00a0Arzneimittel.\u00a0http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigi lanz/DE/RI/2015/RI\u2010dimethylfumarat.html,\u00a0\nletzter\u00a0Zugriff:\u00a023.06.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 15c).\u00a0Worksharing\u2010Variation\u00a0Verfahren\u00a0des\u00a0CHMP\u00a0zu\u00a0\nFumarathaltigen\u00a0Arzneimitteln\u00a0(Tecfidera/\u00a0Fumaderm)\u00a0und\u00a0PML.\u00a0http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharma kovigilanz/Gremien/RoutinesitzungPar63A\nMG/77Sitzung/pkt\u20103\u20102\u20101.pdf?__blob=publicationFile&v=2,\u00a0letzter\u00a0 Zugriff:\u00a023.06.2017.\u00a0\nBle\u00df\u00a0HH\u00a0et\u00a0al.\u00a0(2016).\u00a0Wei\u00dfbuch\u00a0Multiple\u00a0Sklerose:\u00a0Versorgungss ituation\u00a0in\u00a0Deutschland.\u00a0Spr inger\u00a0Berlin\u00a0Heidelberg.\u00a0\nCDER\u00a0(2013a).\u00a0Medical\u00a0review\u00a0\u2010\u00a0Tecfidera\u00a0\u2010\u00a0dimethylfumarate.\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063O rig1s000MedR.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.06.2017.\u00a0\nCDER\u00a0(2013b).\u00a0Summary\u00a0review\u00a0Tecfidera\u00a0\u2010\u00a0dimethylfumarate.\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063O rig1s000SumR.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.06.2017.\u00a0\nCDER\u00a0(2013c).\u00a0Tecfidera\u00a0(dimethyl\u00a0fumarate)\u00a0delayed\u2010release\u00a0cap sules,\u00a0120\u00a0mg\u00a0and\u00a0240\u00a0mg.\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/2 04063Orig1s000ltr.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.06.2017.\u00a0\nChen\u00a0H,\u00a0Assmann\u00a0J,\u00a0Krenz\u00a0A,\u00a0Rahman\u00a0M,\u00a0Grimm\u00a0M\u00a0et\u00a0al.\u00a0(2014).\u00a0Hy droxycarboxylic\u00a0acid\u00a0receptor\u00a02\u00a0mediates\u00a0dimethyl\u00a0fumarate's\u00a0\nprotective\u00a0effect\u00a0in\u00a0EAE.\u00a0The\u00a0Journal\u00a0of\u00a0clinical\u00a0investigation \u00a0124\u00a0(5):\u00a02188\u20102192.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 EPAR:\u00a0Public\u00a0assessment\u00a0report\u00a0\u2010\u00a0Tecfidera,\u00a0common\u00a0name\u2010\ndimethyl\u00a0fumarate.\u00a0www.ema.europa.eu/docs/en_GB/document_librar y/EPAR_\u2010\n_Public_assessment_report/human/002601/WC500162070.pdf,\u00a0letzter \u00a0Zugriff:\u00a009.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014c).\u00a0 EPAR\u00a0SMOP.\u00a0Tecfidera,\u00a0INN\u2010dimethyl\u00a0fumarate.\u00a0European\u00a0\npublic\u00a0assessment\u00a0report\u00a0\u2010\u00a0summary\u00a0of\u00a0opinion.\u00a0www.ema.europa.e u/docs/en_GB/document_library/EPAR_\u2010\n_Summary_for_the_public/human/002601/WC500162072.pdf,\u00a0letzter\u00a0Z ugriff:\u00a009.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2017).\u00a0T ecfidera;\u00a0EPAR\u2010Product\u00a0Information.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010\n_Product_Information/human/002601/WC500162069.pdf,\u00a0letzter\u00a0Zugr iff:\u00a001.05.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 All\u00a0authorised\u00a0presentations.\u00a0Dimethylfumarat.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_All_Authorised_presentations/human/002601/WC500162071.pdf,\u00a0let zter\u00a0Zugriff:\u00a030.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2017).\u00a0T ecfidera;\u00a0EPAR\u2010Product\u00a0Information:\u00a0EPAR\u00a0Dimethylfumarat\u00a0\nAnnex\u00a0I.\u00a0Retrieved\u00a0from\u00a0www.ema.europa.eu/docs/en_GB/document_l ibrary/EPAR_\u2010\n_Product_Information/human/002601/WC500162069.pdf,\u00a0letzter\u00a0Zugr iff:\u00a030.06.2017.\u00a0\nClinicalTrials.gov\u00a0(200 7a).\u00a0CONFIRM.\u00a0Efficacy\u00a0and\u00a0Safety\u00a0Study\u00a0 of\u00a0Oral\u00a0BG00012\u00a0With\u00a0Active\u00a0Reference\u00a0in\u00a0Relapsing\u2010Remitting\u00a0\nMultiple\u00a0Sclerosis.\u00a0https://www.clinicaltrials.gov/ct2/show/results/NCT00451451?ter m=%22Dimethylfumarate%22+AND+%22CONFIR\nM%22&rank=1&show_locs=Y&sect=X0123456#all,\u00a0letzter\u00a0Zugriff:\u00a001. 05.2017.\u00a0176\u00a0ClinicalTrials.gov\u00a0(2007b).\u00a0Effi cacy\u00a0and\u00a0Safety\u00a0of\u00a0Oral\u00a0BG00012 \u00a0in\u00a0Relapsing\u2010Remitting\u00a0Mult iple\u00a0Sclerosis\u00a0(DEFINE).\u00a0\nhttps://www.clinicaltrials.gov/c t2/show/NCT00420212?term=%22Dim ethylfumarate%22AND%22DEFINE%22&rank\n=1,\u00a0letzter\u00a0Zugriff:\u00a030.06.2017.\u00a0\nClinicalTrials.gov\u00a0(2009).\u00a0BG00012\u00a0Monotherapy\u00a0Safety\u00a0and\u00a0Effic acy\u00a0Extension\u00a0Study\u00a0in\u00a0Multiple\u00a0Sclerosis\u00a0(MS)\u00a0\n(ENDORSE).https://www.clinicaltria ls.gov/ct2/show/results/NCT00 835770?term=%22Dimethylfumarate%22+AND+\n%22ENDORSE%22&rank=1&show_locs=Y,\u00a0letzter\u00a0Zugriff:\u00a030.06.2017.\u00a0\nDAC\u00a0NRF\u00a0(2017).\u00a0Dimethylfumarat\u00a0und\u00a0Ethylhydrogenfumarat\u2010Salze: \u00a0DAC/NRF\u2010Rezepturhinweis.\u00a0id=1112.\u00a0Retrieved\u00a0from\u00a0\nhttp://dacnrf.pharmazeutische\u2010zeitung.de/index.php?id=rh\u2010ausgab e&nrf_id=1112\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0Updated\u00a0recommendations \u00a0to\u00a0minimise\u00a0the\u00a0risk\u00a0of\u00a0the\u00a0rare\u00a0brain\u00a0infection\u00a0PML\u00a0with\u00a0\nTecfidera.\u00a0EMA/627077/2015\u00a0corr.\u00a0www.ema.europa.eu/docs/en_GB/do cument_library/Press_release/201 5/10/WC500196017.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n23.06.2017.\u00a0\nFox\u00a0RJ,\u00a0Miller\u00a0DH,\u00a0Ph illips\u00a0JT,\u00a0Hutchinson\u00a0M,\u00a0Havrdova\u00a0E,\u00a0Kita\u00a0 M\u00a0et\u00a0al.\u00a0(2012).\u00a0Placebo\u2010Controlled\u00a0Phase\u00a03\u00a0Study\u00a0of\u00a0Oral\u00a0BG\u201012 \u00a0or\u00a0\nGlatiramer\u00a0in\u00a0Multiple\u00a0Sclerosis\u00a0NEJM,\u00a0367(12):\u00a01087\u20131097.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014a).\u00a0Beschluss:\u00a0\u00fcber\u00a0ein e\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Ri chtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0\nBeschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen \u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0\nDimethylfumarat.\u00a0Retrieved\u00a0from\u00a0https://www.g\u2010ba.de/downloads/3 9\u2010261\u20102075/2014\u201010\u201016_AM\u2010RL\u2010\nXII_Dimethylfumarat_2014\u201005\u201001\u2010D\u2010100_BAnz.pdf,\u00a0letzter\u00a0Zugriff: \u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014b).\u00a0Informationen\u00a0zur\u00a0z weckm\u00e4\u00dfigen\u00a0Vergleichstherapie:\u00a0Dimethylfumarat\u00a0\n(Tecfidera).\u00a0\u00a0https://www.g\u2010ba.de/downloads/92\u2010975\u20101046/Informa tionen\u00a0%20zur\u00a0%20zVT\u00a0\n%20Dimethylfumarat.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014c).\u00a0M\u00fcndliche\u00a0Anh\u00f6rung: \u00a0Dimethylfumarat.\u00a0gem\u00e4\u00df\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a019\u00a0Abs.\u00a02\u00a0\nVerfahrensordnung.\u00a0https://www.g\u2010ba.de/downloads/91\u20101031\u2010111/20 14\u201009\u2010\n08_Wortprotokoll_end_Dimethylfumarat.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.0 6.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014d).\u00a0Nutzenbewertungsver fahren\u00a0zum\u00a0Wirkstoff\u00a0Dimethylfumarat.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/111/,\u00a0letzter\u00a0Zugriff:\u00a008.0 6.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014e).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0Di methylfumarat.\u00a0zum\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0\nder\u00a0AM\u2010RL:\u00a0Anlage\u00a0XII.\u00a0https://www.g\u2010ba.de/downloads/40\u2010268\u2010297 7/2014\u201010\u201016_AM\u2010RL\u2010\nXII_Dimethylfumarat_2014\u201005\u201001\u2010D\u2010100_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a0 08.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015a).\u00a0Bekanntmachung\u00a0des\u00a0 Stellungnahmeverfahrens\u00a0im\u00a0Bundesanzeiger:\u00a0\u00c4nderung\u00a0\nqualit\u00e4tsgesicherter\u00a0Anwendung.\u00a0https://www.g\u2010ba.de/downloads/4 0\u2010268\u20103268/2015\u201006\u201023_AM\u2010RL\u2010XII\u2010\nSN_Dimethylfumarat_2014\u201005\u201001\u2010D\u2010100_Aenderung_BAnz.pdf,\u00a0letzter \u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015b).\u00a0Beschluss\u00a02:\u00a0Dimeth ylfumarat.\u00a0BAnz\u00a0AT\u00a021.01.2015\u00a0B2.\u00a0https://www.g\u2010\nba.de/downloads/39\u2010261\u20102145/2015\u201001\u201008_AM\u2010RL\u2010XII_Dimethylfumara t\u2010\u00a0%C3\u00a0%84nderung\u2010qgA_2014\u201005\u201001\u2010D\u2010\n100_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015c).\u00a0Beschluss:\u00a0Dimethyl fumarat.\u00a0\u00c4nderung\u00a0qualit\u00e4tsgesicherte\u00a0Anwendung.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 39\u2010261\u20102286/2015\u201006\u201023_AM\u2010RL\u2010XII\u2010 SN_Dimethylfumarat_2014\u201005\u201001\u2010D\u2010\n100_Aenderung.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015d).\u00a0Tragende\u00a0Gr\u00fcnde\u00a02:\u00a0 Dimethylfumarat.\u00a0https://www.g\u2010ba.de/downloads/40\u2010268\u2010\n3076/2015\u201001\u201008_AM\u2010RL\u2010XII_Dimethylfumarat\u2010\u00a0%C3\u00a0%84nderung\u2010qgA_2 014\u201005\u201001\u2010D\u2010100_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n08.06.2017.\u00a0177\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015e).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0\u00c4n derung\u00a0qualit\u00e4tsgesicherte\u00a0Anwendung.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20103267/2015\u201006\u201023_AM\u2010RL\u2010XII\u2010SN_Dimethylfum arat_2014\u201005\u201001\u2010D\u2010\n100_Aenderung_TrG.pdf\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016a).\u00a0Beschluss:\u00a0\u00c4nderung \u00a0\u2010\u00a0Anforderung\u00a0der\u00a0qualit\u00e4tsgesicherten\u00a0Anwendung.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 39\u2010261\u20102445/2016\u201001\u201007_AM\u2010RL\u2010XII_ Dimethylfumarat\u2010Aenderung_2014\u201005\u201001\u2010D\u2010\n100_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016b).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0\u00c4n derung\u00a0Anforderung\u00a0an\u00a0qualit\u00e4tsgesicherte\u00a0Anwendung.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 40\u2010268\u20103527/2016\u201001\u201007_AM\u2010RL\u2010XII_ Dimethylfumarat\u2010Aenderung_2014\u201005\u201001\u2010D\u2010\n100_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016c).\u00a0Zusammenfassende\u00a0Do kumentation:\u00a0Dimethylfumarat.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20103603/2016\u201001\u201007_AM\u2010RL\u2010XII_Dimethylfumara t\u2010Aenderung_2014\u201005\u201001\u2010D\u2010100_ZD.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nGold\u00a0R,\u00a0Giovannoni\u00a0G,\u00a0Phillips\u00a0JT ,\u00a0Fox\u00a0RJ,\u00a0Zhang\u00a0A,\u00a0\u00a0Marantz\u00a0JL \u00a0(2016).\u00a0Sustained\u00a0Effect\u00a0of\u00a0Delayed\u2010Release\u00a0Dimethyl\u00a0Fumarate\u00a0 in\u00a0\nNewly\u00a0Diagnosed\u00a0Patients\u00a0with\u00a0Relapsing\u2010Remitting\u00a0Multiple\u00a0Scle rosis:\u00a06\u2010Year\u00a0Interim\u00a0Results\u00a0From\u00a0an\u00a0Extension\u00a0of\u00a0\nthe\u00a0DEFINE\u00a0and\u00a0CONFIRM\u00a0Studies.\u00a0Neurol\u00a0Ther\u00a05(1):\u00a045\u201057.\u00a0\u00a0\nGold\u00a0R,\u00a0Kappos\u00a0L,\u00a0Arnold\u00a0DL,\u00a0Bar \u2010Or\u00a0A,\u00a0Giovannoni\u00a0G,\u00a0Selmaj\u00a0K\u00a0e t\u00a0al.\u00a0(2012).\u00a0Placebo\u2010Controlled\u00a0Phase\u00a03\u00a0Study\u00a0of\u00a0Oral\u00a0BG\u201012\u00a0fo r\u00a0\nRelapsing\u00a0Multiple\u00a0Sclerosis.\u00a0NEJM\u00a0367(12):\u00a01098\u20131107.\u00a0\u00a0\nGold\u00a0R\u00a0(2012).\u00a0Diagnose\u00a0und\u00a0Therapie\u00a0der\u00a0Multiplen\u00a0Sklerose:\u00a0S2 e\u2010Leitlinie\u00a0DGN.\u00a0AWMF\u2010Registernummer\u00a0030/050.\u00a0\nhttps://www.dgn.org/images/red _leitlinien/LL_2012/pdf/030\u2010\n050l_S2e_Multiple_Sklerose_Diagnostik_Therapie_2014\u201008_verlaeng ert.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nICER\u2010Review.org\u00a0(2017).\u00a0A\u00a0look\u00a0at\u00a0disease\u2010modifying\u00a0Therapies.\u00a0 https://icer\u2010review.org/wp\u2010\ncontent/uploads/2017/03/CTAF_MS_RAAG_030617.pdf,\u00a0letzter\u00a0Zugrif f:\u00a023.06.2017.\u00a0\nKamm\u00a0CP\u00a0et\u00a0al.\u00a0(2014).\u00a0Multiple\u00a0s clerosis:\u00a0Current\u00a0knowledge\u00a0an d\u00a0future\u00a0outlook.\u00a0European\u00a0Neurology\u00a072(3\u20104):\u00a0132\u2010141.\u00a0\u00a0\nKBV\u00a0\u2013\u00a0Kassen\u00e4rztliche\u00a0Bundesvereinigung\u00a0(2016).\u00a0Wirkstoff\u00a0AKTUE LL\u00a0\u2010\u00a0Ausgabe\u00a001/2016.\u00a0\nwww.akdae.de/Arzneimitteltherapie/WA/Archiv\u2010Fertigarzneimittel/ Immuntherapeutika\u2010MS.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n24.06.2017.\u00a0\nKKNMS\u00a0(2015).\u00a0PML\u00a0unter\u00a0Dimethylfumarat.\u00a0www.kompetenznetz\u2010mult iplesklerose.de/wp\u2010content/uploads/2010/05/kknms\u00a0\n\u2010dmsg_ptx_stellungnahme%20dmfpml_20151214_frei.pdf,\u00a0letzter\u00a0Zug riff:\u00a014.06.2017.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0WEBAPO\u00a0Inf oSystem.\u00a0https://www.lauer\u2010fisc her.de/LF/Seiten/Verwaltung/Kundencenter/1.aspx,\u00a0letzter\u00a0\nZugriff:\u00a013.06.2017.\u00a0\nLauktien,\u00a0G\u00a0(2015).\u00a0Abwehr\u00a0von\u00a0Gefahren\u00a0durch\u00a0Arzneimittel,\u00a0Stu fe\u00a0II:\u00a0Anh\u00f6rung\u00a0zu\u00a0Fumaderm\u00a0im\u00a0Rahmen\u00a0des\u00a0\nStufenplanverfahrens.\u00a0\nhttp://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharma kovigilanz/Risikoinfor mationen/RisikoBewV\nerf/a\u2010f/fumaderm_anhoerung.pdf?__blob=publicationFile&v=1,\u00a0letz ter\u00a0Zugriff:\u00a022.06.2017.\u00a0\nNieuwkamp\u00a0DJ\u00a0(2015).\u00a0PML\u00a0in\u00a0Patients\u00a0Treated\u00a0with\u00a0Dimethyl\u00a0Fuma rate\u00a0NEJM\u00a0373(6):\u00a0582\u2010584.\u00a0\u00a0\nPugliatti\u00a0M,\u00a0Vettorazzi\u00a0C,\u00a0Della\u00a0Coletta\u00a0E,\u00a0Caniatti\u00a0LM,\u00a0Baldi\u00a0 E,\u00a0Rossi\u00a0S\u00a0et\u00a0al.\u00a0(2016).\u00a0Diet\u00a0composition\u00a0and\u00a0dimethylfumarate \u00a0(DMF)\u00a0\nside\u00a0effects\u00a0in\u00a0relapsing\u2010remitting\u00a0multiple\u00a0sclerosis\u00a0(RRMS)\u00a0p atients:\u00a0A\u00a0pilot\u00a0study\u00a0In\u00a0Mult iple\u00a0Sclerosis.\u00a0Conference:\u00a0\n32nd\u00a0Congress\u00a0of\u00a0the\u00a0European\u00a0Committee\u00a0for\u00a0Treatment\u00a0and\u00a0Resea rch\u00a0in\u00a0Multiple\u00a0Sclerosis,\u00a0ECTRIMS\u00a02016.\u00a0\nMultiple\u00a0Sclerosis\u00a0J\u00a022(3\u00a0Suppl):\u00a088\u2010399.\u00a0\nRosenkranz\u00a0T,\u00a0Novas\u00a0M,\u00a0Terborg\u00a0C\u00a0(2015).\u00a0PML\u00a0in\u00a0a\u00a0Patient\u00a0with\u00a0 Lymphocytopenia\u00a0Treated\u00a0with\u00a0Dimethyl\u00a0Fumarate:\u00a0Corrections.\u00a0\nNEJM\u00a0372(15):\u00a01476\u20101478.\u00a0\u00a0178\u00a0Seidner\u00a0M\u00a0(2016).\u00a0Disease\u2010Modify ing\u00a0Therapies\u00a0for\u00a0Relapsing\u2010Rem itting\u00a0and\u00a0Primary\u2010Progressive\u00a0Multiple\u00a0Sclerosis:\u00a0Effectivenes s\u00a0\nand\u00a0Value.\u00a0https://icer\u2010review.org/wp\u2010content/uploads/2016/08/I CER_Draft_MS_Report_112216.pdf,\u00a0letzter\u00a0\nZugriff:\u00a023.06.2017.\u00a0\nStahl\u00a0J\u00a0(2014).\u00a0Klinikum\u00a0leistet\u00a0per\u00a0Zufall\u00a0Pionierarbeit\u00a0f\u00fcr\u00a0M S\u2010Medikament.\u00a0Der\u00a0Westen.\u00a0\nhttps://www.derwesten.de/staedte/bochum/klinikum\u2010leistet\u2010per\u2010zu fall\u2010pionierarbeit\u2010fuer\u2010ms\u2010medikament\u2010\nid9747301.html,\u00a0letzter\u00a0Zugriff:\u00a018.07.2017.\u00a0\nSweetser\u00a0MT,\u00a0Dawson\u00a0KT,\u00a0\u00a0Bozic\u00a0C\u00a0(2013).\u00a0Manufacturer\u2019s\u00a0Respons e\u00a0to\u00a0Case\u00a0Reports\u00a0of\u00a0PML.NEJM\u00a0368(17):\u00a01659\u20101661.\u00a0\u00a0\nvan\u00a0Oosten\u00a0BW,\u00a0Killestein\u00a0J,\u00a0Bar khof\u00a0F,\u00a0Polman\u00a0CH,\u00a0\u00a0Wattjes\u00a0MP\u00a0 (2013).\u00a0PML\u00a0in\u00a0a\u00a0Patient\u00a0Treated\u00a0with\u00a0Dimethyl\u00a0Fumarate\u00a0from\u00a0a\u00a0\nCompounding\u00a0Pharmacy.\u00a0NEJM\u00a0368(17):\u00a01658\u20101659.\u00a0\u00a0\nViegener\u00a0U\u00a0(2014).\u00a0Fumars\u00e4ure\u00a0\u2010\u00a0P soriasismittel\u00a0senkt\u00a0MS\u2010Schubr ate.\u00a0http://www.pharmazeutische\u2010\nzeitung.de/index.php?id=43648,\u00a0letzter\u00a0Zugriff:\u00a013.06.2017.\u00a0\nXu\u00a0Z,\u00a0Zhang\u00a0F,\u00a0Sun\u00a0F,\u00a0Gu\u00a0K,\u00a0Dong\u00a0S,\u00a0He\u00a0D\u00a0(2015).\u00a0Dimethyl\u00a0fumar ate\u00a0for\u00a0multiple\u00a0sclerosis.\u00a0\nhttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011076.pu b2/pdf,\u00a0letzter\u00a0Zugriff:\u00a015.06.2017.\u00a0\n\u00a0 \u00a0179\u00a04.11 Dolutegravir\u00a0\nHandelsnamen:\u00a0Tivicay\u00ae/in\u00a0Triumeq\u00ae\u00a0\u00a0 Pharmazeutischer\u00a0Unternehme r:\u00a0\nmit\u00a0Abacavir\u00a0und\u00a0Lamivudin\u00a0 \u00a0 ViiV\u00a0Healthcare\u00a0GmbH\u00a0\nIndikation:\u00a0HIV\u2010Infektion\u00a0\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0\nATC\u2010Code:\u00a0J05AX12/J05AR13\u00a0 \u00a0 Februar/September\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtablette\u00a0 \u00a0 DDD:\u00a050\u00a0mg/1\u00a0D\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDolutegravir\u00a0(Tivicay \u00ae)\u00a0und\u00a0seit\u00a0September\u00a02014\u00a0in\u00a0der\u00a0fixen\u00a0Kombination\u00a0mit\u00a0\nAbacavir\u00a0und\u00a0Lamivudin\u00a0(Triumeq\u00ae)\u00a0ist\u00a0nach\u00a0Raltegravir\u00a0und\u00a0Elvi tegravir\u00a0der\u00a0dritte\u00a0\nin\u00a0 Deutschland\u00a0 verf\u00fcgb are\u00a0 Integrase\u2010Hemmstoff,\u00a0 der\u00a0 in\u00a0 Kombinati on\u00a0 mit\u00a0 zwei\u00a0\nweiteren\u00a0Substanzen\u00a0als\u00a0 Backbone \u00a0(Sockeltherapie)\u00a0zur\u00a0Behandlung\u00a0einer\u00a0HIV\u2010\nInfektion\u00a0zun\u00e4chst\u00a0bei\u00a0therapien aiven\u00a0oder\u00a0vorbehandelten\u00a0Patie nten\u00a0ab\u00a0zw\u00f6lf\u00a0\nJahren\u00a0zugelassen\u00a0worden\u00a0ist.\u00a0Do lutegravir\u00a0hemmt\u00a0die\u00a0virale\u00a0Int egrase.\u00a0Dieses\u00a0\nEnzym\u00a0ist\u00a0f\u00fcr\u00a0den\u00a0Einbau\u00a0des\u00a0vira len\u00a0Erbguts\u00a0in\u00a0die\u00a0Wirtszelle\u00a0 verantwortlich.\u00a0Wird\u00a0\ndieser\u00a0f\u00fcr\u00a0die\u00a0Virusreplikation\u00a0essentielle\u00a0Schritt\u00a0unterbunden ,\u00a0kann\u00a0das\u00a0Virus\u00a0in\u00a0\nder\u00a0Zielzelle\u00a0nicht\u00a0mehr\u00a0repliziert\u00a0werden.\u00a0Die\u00a0Gabe\u00a0von\u00a0Dolute gravir\u00a0erfolgt\u00a0ein\u2010\nmal\u00a0t\u00e4glich\u00a0unabh\u00e4ngig\u00a0von\u00a0den\u00a0Mahlzeiten.\u00a0Tivicay\u00ae\u00a0ist\u00a0auch\u00a0be i\u00a0vorhandener\u00a0\noder\u00a0vermuteter\u00a0Resistenz\u00a0gegen\u00a0 Integrasehemmstoffe\u00a0wirksam\u00a0und \u00a0zugelassen.\u00a0\nBei\u00a0dieser\u00a0Indikation\u00a0m\u00fcssen\u00a0zwei\u00a0Filmtabletten\u00a0pro\u00a0Tag\u00a0eingeno mmen\u00a0werden,\u00a0\nentsprechend\u00a0 100\u00a0mg\u00a0 Dolutegravir.\u00a0 Seit\u00a0 April\u00a0 2017\u00a0 stehen\u00a0 auch\u00a0 T abletten\u00a0 zur\u00a0\nVerf\u00fcgung,\u00a0die\u00a010\u00a0bzw.\u00a025\u00a0mg\u00a0Dolutegravir\u00a0enthalten\u00a0(Fachinform ation\u00a0Tivicay\u00ae,\u00a0\n2017).\u00a0Dolutegravir\u00a0ist\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0K\u00f6rpergewich ts\u00a0nachtr\u00e4glich\u00a0\nauch\u00a0f\u00fcr\u00a0Kinder\u00a0ab\u00a0einem\u00a0Alter\u00a0v on\u00a0sechs\u00a0Jahren\u00a0zugelassen\u00a0word en\u00a0(EMA,\u00a02017).\u00a0\u00a0\nDie\u00a0weiteren\u00a0wirksamen\u00a0Bestandteile\u00a0in\u00a0Triumeq\u00ae\u00a0sind\u00a0die\u00a0beiden \u00a0schon\u00a0l\u00e4nger\u00a0\nerh\u00e4ltlichen\u00a0 kompetitiven\u00a0 Inhibito ren\u00a0 der\u00a0 reversen\u00a0 Transkriptas e\u00a0 Abacavir\u00a0 und\u00a0\nLamivudin.\u00a0Die\u00a0fixe\u00a0Kombination\u00a0 ist\u00a0zur\u00a0Anwendung\u00a0an\u00a0Erwachsene n\u00a0und\u00a0Jugendli\u2010\nchen\u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a0zw\u00f6lf\u00a0Ja hren\u00a0zugelassen,\u00a0die\u00a0mindestens \u00a040\u00a0kg\u00a0wiegen\u00a0\n(Fachinformation\u00a0Triumeq\u00ae,\u00a02017).\u00a0\u00a0\nDolutegravir\u00a0wurde\u00a0in\u00a0mehreren\u00a0Zulassungsstudien\u00a0(u.a.\u00a0SINGLE,\u00a0 Walmsley\u00a0et\u00a0al.,\u00a0\n2013\u00a0und\u00a0SAILING,\u00a0Cahn\u00a0et\u00a0al.,\u00a02013)\u00a0mit\u00a0anderen\u00a0 First\u2010Line\u00a0 (Erstlinien)\u2010Regimen\u00a0\nverglichen,\u00a0die\u00a0Substanzen\u00a0unterschiedlicher\u00a0Wirkstoffklassen\u00a0e nthielten,\u00a0darunter\u00a0\nder\u00a0 nicht\u2010nucleosidische\u00a0 Reverse\u2010 Transkriptase\u2010Hemmstoff\u00a0 Efavir enz\u00a0 und\u00a0 der\u00a0\nIntegrasehemmstoff\u00a0Raltegravir.\u00a0Die\u00a0Studien\u00a0wurden\u00a0vom\u00a0pharmaze utischen\u00a0Un\u2010\nternehmer\u00a0(pU)\u00a0gesponsert.\u00a0Dolut egravir\u00a0zeigte\u00a0in\u00a0Bezug\u00a0auf\u00a0das \u00a0virologische\u00a0An\u2010\nsprechen\u00a0keine\u00a0Unterlegenheit\u00a0ge gen\u00fcber\u00a0den\u00a0Vergleichssubstanze n.\u00a0Ma\u00dfgeblich\u00a0\nf\u00fcr\u00a0die\u00a0Ermittlung\u00a0dieses\u00a0Parameters\u00a0war\u00a0das\u00a0Erreichen\u00a0einer\u00a0Vi ruslast\u00a0unter\u00a0die\u00a0\nNachweisgrenze\u00a0von\u00a050\u00a0Kopien/ml.\u00a0Hautausschl\u00e4ge,\u00a0psychiatrische \u00a0Erkrankungen\u00a0und\u00a0180\u00a0Erkrankungen\u00a0des\u00a0Nervensystems\u00a0bei\u00a0M\u00e4nnern\u00a0traten\u00a0bei\u00a0therapien aiven\u00a0Patienten\u00a0\njedoch\u00a0deutlich\u00a0weniger\u00a0h\u00e4ufig\u00a0auf\u00a0als\u00a0bei\u00a0der\u00a0Gabe\u00a0der\u00a0zweckm\u00e4 \u00dfigen\u00a0Vergleichsthe\u2010\nrapie\u00a0(zVT)\u00a0mit\u00a0Efavirenz.\u00a0Bei\u00a0bereits\u00a0vorbehandelten\u00a0Patienten \u00a0kam\u00a0es\u00a0im\u00a0Vergleich\u00a0\nzur\u00a0Therapie\u00a0mit\u00a0Raltegravir\u00a0seltener\u00a0zu\u00a0schweren\u00a0Nebenwirkunge n\u00a0wie\u00a0Infektionen.\u00a0\nZudem\u00a0profitierten\u00a0Patienten\u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a050\u00a0Jahren,\u00a0da\u00a0u nter\u00a0Anwendung\u00a0von\u00a0\nDolutegravir\u00a0in\u00a0dieser\u00a0Gruppe\u00a0seltener\u00a0Erkrankungen\u00a0des\u00a0Nervens ystems\u00a0auftraten\u00a0als\u00a0\nim\u00a0Kontrollarm\u00a0(Cahn\u00a0et\u00a0al.,\u00a02013;\u00a0IQWiG,\u00a02014;\u00a0Walmsley\u00a0et\u00a0al. ,\u00a02013).\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0beurteilte\u00a0den\u00a0 Zusatznutzen \u00a0f\u00fcr\u00a0den\u00a0\nneuen\u00a0Integrasehemmstoff\u00a0f\u00fcr\u00a0therapienaive\u00a0Erwachsene\u00a0als\u00a0 betr\u00e4chtlich .\u00a0Dar\u2010\n\u00fcber\u00a0hinaus\u00a0konnte\u00a0ein\u00a0 geringer\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0antiretroviral\u00a0vorbehandelte\u00a0\nErwachsene\u00a0festgestellt\u00a0werden,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Behandlung\u00a0mit\u00a0ein em\u00a0Integrase\u2010\nInhibitor\u00a0die\u00a0erste\u00a0Therapieoption\u00a0darstellt\u00a0(G\u2010BA,\u00a02014).\u00a0\u00a0\nDa\u00a0bei\u00a0der\u00a0Therapie\u00a0mit\u00a0Triumeq\u00ae\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0Standardth erapien\u00a0(z.B.\u00a0\nEfavirenz\u00a0plus\u00a0Tenofovir\u00a0und\u00a0Emtricitabin)\u00a0weniger\u00a0Nebenwirkung en\u00a0wie\u00a0Erkran\u2010\nkungen\u00a0des\u00a0Nervensystems\u00a0und\u00a0Hautausschl\u00e4ge\u00a0auftraten,\u00a0wurde\u00a0di esem\u00a0Mittel\u00a0\nbei\u00a0 bislang\u00a0 unvorbehandelten\u00a0 Patienten\u00a0 ein\u00a0 betr\u00e4chtlicher \u00a0Zusatznutzen \u00a0z u e r \u2010\nkannt.\u00a0F\u00fcr\u00a0andere\u00a0Patientengruppen\u00a0konnte\u00a0wegen\u00a0der\u00a0aktuellen\u00a0D atenlage\u00a0 kein\u00a0\nZusatznutzen \u00a0festgestellt\u00a0werden\u00a0(G\u2010BA,\u00a02015).\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\nweiterer\u00a0Vertreter\u00a0aus\u00a0\nder\u00a0Klasse\u00a0der\u00a0Integrase\u2010\nHemmstoffe\u00a0mit\u00a0\nsubgruppenspezifischem\u00a0\nVorteil\u00a0Wirksamkeit\u00a0der\u00a0zVT\u00a0\nnicht\u00a0unterlegen,\u00a0\nWirkstoff\u00a0besser\u00a0\nvertr\u00e4glich,\u00a0\nResistenzbarriere\u00a0relativ\u00a0\nhoch\u00a0teurer\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0 \u2013\u00a0 Possibly\u00a0helpful\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0\n\u00a0\n181\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDolutegravir\u00a0in\u00a0Tivicay\u00ae\u00a0(ohne\u00a0\nBackbone )\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a050\u00a0mg\u00a0\n\u00a0365\u00a0 8.658,12\u00a0\u2013\u00a017.316,25\u00a0\u20ac\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0\ntherapienaive\u00a0Erwachsene\u00a0und\u00a0\nJugendliche\u00a0ab\u00a012\u00a0Jahre \u00a0\u00a0 \u00a0\u00a0\nEfavirenz\u00a0(ohne\u00a0 Backbone )\u00a0 1x\u00a0tgl.\u00a0600\u00a0mg\u00a0 365\u00a0 2.226,46\u00a0\u20ac\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0\u00a0\nantiretroviral\u00a0vorbehandelte\u00a0\nErwachsene,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Be\u2010\nhandlung\u00a0mit\u00a0einem\u00a0INI\u00a0die\u00a0\nerste\u00a0Therapieoption\u00a0darstellt\u00a0\u00a0\nRaltegravir\u00a0(ohne\u00a0 Backbone )\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0anti\u2010\nretroviral\u00a0vorbehandelte\u00a0Er\u2010\nwachsene,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Behand\u2010\nlung\u00a0mit\u00a0einem\u00a0Integrase\u2010\nInhibitor\u00a0eine\u00a0nachrangige\u00a0\nTherapieoption\u00a0darstellt\u00a0\u00a0\nRaltegravir\u00a0(ohne\u00a0 Backbone )\u00a0\nMaraviroc\u00a0(ohne\u00a0 Backbone )\u00a0\nNevirapin\u00a0(ohne\u00a0 Backbone )\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0antire\u2010\ntroviral\u00a0vorbehandelte\u00a0Jugendli\u2010\nche\u00a0ab\u00a012\u00a0Jahre\u00a0\nRaltegravir\u00a0(ohne\u00a0 Backbone )\u00a0\nNevirapin\u00a0(ohne\u00a0 Backbone )\u00a0\nDolutegravir\u00a0(in\u00a0Triumeq\u00ae)\u00a0\n\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0\ntherapienaive\u00a0Erwachsene\u00a0\nEfavirenz\u00a0plus\u00a0Abacavir\u00a0und\u00a0\nLamivudin\u00a0\nEfavirenz\u00a0plus\u00a0Emtricitabin\u00a0und\u00a0\nTenofovirdisoproxil \u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n2x\u00a0tgl.\u00a0400\u00a0mg\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n2x\u00a0tgl.\u00a0400\u00a0mg\u00a0\n2x\u00a0tgl.\u00a0300\u00a0mg\u00a0\n2x\u00a0tgl.\u00a0200\u00a0mg\u00a0\n\u00a0\n\u00a0\n\u00a0\n2x\u00a0tgl.\u00a0400\u00a0mg\u00a0\n2x\u00a0tgl.\u00a0200\u00a0mg\u00a0\n1x\u00a0tgl.\u00a050\u00a0mg/600\u00a0\nmg/300\u00a0mg\u00a0\n\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0\u00a0\n600\u00a0mg/600\u00a0mg/300\u00a0mg\u00a0\n1x\u00a0tgl.\u00a0\u00a0\n600\u00a0mg/200\u00a0mg/245\u00a0mg\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0\n365\u00a0\n365\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0\n365\u00a0\n365\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0\n\u00a0\n365\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n10.522,22\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n10.522,22\u00a0\u20ac\u00a0\n13.054,83\u00a0\u20ac\u00a0\n1.697,37\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n10.522,22\u00a0\u20ac\u00a0\n1.697,37\u00a0\u20ac\u00a0\n14.324,95\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n9.282,98\u00a0\u20ac\u00a0\n\u00a0\n12.182,24\u00a0\u20ac\u00a0\n\u00a0\nZus\u00e4tzlich\u00a0zu\u00a0den\u00a0oben\u00a0aufgef\u00fchrten\u00a0Mitteln\u00a0muss\u00a0die\u00a0Therapie\u00a0u m\u00a0eine\u00a0Sockeltherapie\u00a0(Backbone)\u00a0erg\u00e4nzt\u00a0werden.\u00a0Hieraus\u00a0result ie\u2010\nrende\u00a0Kosten\u00a0wurden\u00a0aus\u00a0Gr\u00fcnden\u00a0der\u00a0\u00dcbersichtlichkeit\u00a0nicht\u00a0auf gef\u00fchrt.\u00a0In\u00a0den\u00a0Kostenberechnungen\u00a0f\u00fcr\u00a0Triumeq\u00ae\u00a0und\u00a0die\u00a0dazugeh \u00f6\u2010\nrige\u00a0Vergleichstherapie\u00a0sind\u00a0diese\u00a0Kosten\u00a0bereits\u00a0enthalten.\u00a0F\u00fc r\u00a0die\u00a0Teilpopulation\u00a0der\u00a0Kinder\u00a0ab\u00a0sechs\u00a0Jahren,\u00a0f\u00fcr\u00a0die\u00a0Dolute gravir\u00a0\nnachtr\u00e4glich\u00a0zugelassen\u00a0worden\u00a0ist,\u00a0wurden\u00a0die\u00a0Kosten\u00a0nicht\u00a0ber echnet.\u00a0\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnungszahlen\u00a0f\u00fcr\u00a0den\u00a0Integrasehemmstoff\u00a0Dolutegravir\u00a0i m\u00a0Pr\u00e4parat\u00a0Tivi\u2010\ncay\u00ae\u00a0sind\u00a0seit\u00a0seiner\u00a0Markteinf\u00fchrung\u00a0kontinuierlich\u00a0angestiegen.\u00a0Be reits\u00a0nach\u00a0einem\u00a0\nhalben\u00a0Jahr\u00a0nach\u00a0Markteinf\u00fchrung\u00a0lag\u00a0der\u00a0Verbrauch\u00a0bei\u00a0mehr\u00a0als \u00a025.000\u00a0DDD\u00a0pro\u00a0\nMonat.\u00a0Im\u00a0Juli\u00a02014\u00a0wurden\u00a0bereits\u00a0fast\u00a027.500\u00a0DDD\u00a0verordnet,\u00a0d ie\u00a0zusammen\u00a0mehr\u00a0\nals\u00a0800.000\u00a0Euro\u00a0kosteten\u00a0(Abbildung\u00a04.10),\u00a0die\u00a0Verordnungen\u00a0vo n\u00a0\u00fcber\u00a030.000\u00a0DDD\u00a0\nim\u00a0Oktober\u00a02015\u00a0entsprachen\u00a0nur\u00a0noch\u00a0einem\u00a0Umsatz\u00a0von\u00a0rund\u00a0730. 000\u00a0Euro.\u00a0\u00a0182\u00a0Abbildung\u00a04.10:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nTivicay\u00ae\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.11:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nTriumeq\u00ae\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n183\u00a0Triumeq\u00ae\u00a0(Abbildung\u00a04.11)\u00a0wurde\u00a0im\u00a0September\u00a02014\u00a0eingef\u00fchrt,\u00a0e rreichte\u00a0aber\u00a0\nerst\u00a0im\u00a0Januar\u00a02015\u00a0sprunghaft\u00a0ein\u00a0hohes\u00a0Verordnungsniveau\u00a0von\u00a0 20.000\u00a0DDD.\u00a0Die\u00a0\nmeisten\u00a0Verordnungen\u00a0hatte\u00a0Triumeq\u00ae\u00a0im\u00a0Oktober\u00a02015\u00a0mit\u00a0rund\u00a035 .500\u00a0DDD.\u00a0\nDiese\u00a0f\u00fchrten\u00a0zu\u00a0Bruttoums\u00e4tzen\u00a0von\u00a0knapp\u00a01,5\u00a0Mio.\u00a0Euro.\u00a0 \u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nZu\u00a0den\u00a0Humanen\u00a0Immundefizienz\u2010Vir en\u00a0(HIV)\u00a0werden\u00a0die\u00a0beiden\u00a0Ret roviren\u00a0HIV\u20101\u00a0\nund\u00a0HIV\u20102\u00a0gez\u00e4hlt,\u00a0die\u00a0beide\u00a0in\u00a0der\u00a0Lage\u00a0sind,\u00a0das\u00a0 Acquired\u00a0Immuno\u2010Deficiency\u00a0\nSyndrome \u00a0(AIDS)\u00a0auszul\u00f6sen.\u00a0Die\u00a0Viren\u00a0ve rf\u00fcgen\u00a0\u00fcber\u00a0Enzyme,\u00a0die\u00a0eine\u00a0Sc hl\u00fcssel\u2010\nrolle\u00a0bei\u00a0der\u00a0Behandlung\u00a0infizier ter\u00a0Personen\u00a0spielen.\u00a0Dies\u00a0sin d\u00a0die\u00a0Reverse\u00a0Tran\u2010\nskriptase,\u00a0welche\u00a0die\u00a0virale\u00a0RNA \u00a0in\u00a0einen\u00a0proviralen\u00a0DNA\u2010Strang \u00a0umschreibt,\u00a0die\u00a0\nI n t e g r a s e , \u00a0d i e \u00a0d e n \u00a0D N A \u2010 S t r a n g \u00a0i n \u00a0 den\u00a0 Zellkern\u00a0 transportiert\u00a0 und \u00a0 diesen\u00a0 ins\u00a0\nmenschliche\u00a0Erbgut\u00a0einbaut,\u00a0sowie\u00a0die\u00a0HIV\u2010Protease,\u00a0die\u00a0neu\u00a0syn thetisierte\u00a0Virus\u2010\nproteine\u00a0spaltet,\u00a0wodurch\u00a0das\u00a0Vir us\u00a0reift\u00a0und\u00a0neue\u00a0Zellen\u00a0befal len\u00a0kann\u00a0(Kirchhoff,\u00a0\n2010).\u00a0\nDolutegravir\u00a0ist\u00a0ein\u00a0HIV\u20101\u2010Integraseinhibitor\u00a0(INI),\u00a0der\u00a0durch\u00a0 die\u00a0Hemmung\u00a0des\u00a0f\u00fcr\u00a0\ndie\u00a0Virusreplikation\u00a0essentiellen\u00a0Einbaus\u00a0der\u00a0proviralen\u00a0DNA\u00a0in \u00a0die\u00a0genomische\u00a0\nWirts\u2010DNA\u00a0die\u00a0Ausbreitung\u00a0einer\u00a0Virusinfektion\u00a0blockiert\u00a0(ViiV, \u00a02015).\u00a0\nMit\u00a0Dolutegravir\u00a0steht\u00a0erstmals\u00a0ein\u00a0Wirkstoff\u00a0aus\u00a0der\u00a0Klasse\u00a0de r\u00a0INI\u00a0zur\u00a0Verf\u00fcgung,\u00a0\nder\u00a0unabh\u00e4ngig\u00a0von\u00a0einer\u00a0Mahlzeit\u00a0nur\u00a0einmal\u00a0t\u00e4glich\u00a0eingenomme n\u00a0wird.\u00a0Da\u00a0er\u00a0\neinen\u00a0Chelatkomplex\u00a0mit\u00a0mehrwertigen\u00a0Kationen\u00a0wie\u00a0Aluminium,\u00a0Ca lcium,\u00a0Eisen\u00a0\nund\u00a0Magnesium\u00a0bildet,\u00a0ist\u00a0ein\u00a0zeitlicher\u00a0Abstand\u00a0einzuhalten,\u00a0w enn\u00a0parallel\u00a0ent\u2010\nsprechende\u00a0Inhaltsstoffe\u00a0enthaltende\u00a0Antazida\u00a0oder\u00a0Mineralstoff pr\u00e4parate\u00a0ange\u2010\nwandt\u00a0werden\u00a0(ViiV,\u00a02015).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDolutegravir\u00a0ist\u00a0nach\u00a0Raltegravir\u00a0und\u00a0Elvitegravir\u00a0der\u00a0dritte\u00a0z ugelassene\u00a0Integrase\u2010\nHemmstoff\u00a0zur\u00a0Behandlung\u00a0einer\u00a0In fektion\u00a0mit\u00a0HIV\u20101\u00a0bei\u00a0Erwachse nen\u00a0und\u00a0Ju\u2010\ngendlichen\u00a0im\u00a0Alter\u00a0von\u00a0\u00fcber\u00a012\u00a0Jahren.\u00a0Die\u00a0empfohlene\u00a0Dosierun g\u00a0liegt\u00a0bei\u00a0einer\u00a0\nFilmtablette\u00a0entsprechend\u00a050\u00a0mg\u00a0D olutegravir,\u00a0einmal\u00a0t\u00e4glich\u00a0mi t\u00a0oder\u00a0unabh\u00e4ngig\u00a0\nvon\u00a0einer\u00a0Mahlzeit. \u00a0Dolutegravir \u00a0darf\u00a0auch\u00a0bei\u00a0Patienten,\u00a0die\u00a0\u00fcber\u00a0eine\u00a0klinisch\u00a0\nnachgewiesene\u00a0oder\u00a0vermutete\u00a0Resistenz\u00a0gegen\u00fcber\u00a0Integrasehemms toffen\u00a0ver\u2010\nf\u00fcgen,\u00a0eingesetzt\u00a0werden.\u00a0In\u00a0diesem\u00a0Fall\u00a0betr\u00e4gt\u00a0die\u00a0Dosierung\u00a0 zweimal\u00a0t\u00e4glich\u00a050\u00a0\nmg\u00a0(ViiV,\u00a02015).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Virus\u2010\u00dcbertragung\u00a0erfolgt\u00a0im\u00a0Falle\u00a0von\u00a0HIV\u00a0durch\u00a0direkten\u00a0K ontakt\u00a0mit\u00a0einer\u00a0\ninfekti\u00f6sen\u00a0K\u00f6rperfl\u00fcssigkeit\u00a0(Blut,\u00a0Sperma,\u00a0Vaginalsekret,\u00a0Dar mfl\u00fcssigkeit,\u00a0Mutter\u2010184\u00a0milch).\u00a0Zu\u00a0den\u00a0h\u00e4ufigsten\u00a0Infektionswegen\u00a0z\u00e4hlen\u00a0ungesch\u00fctzte\u00a0S exualkontakte,\u00a0\nintraven\u00f6se\u00a0Drogenapplikation\u00a0und\u00a0die\u00a0\u00dcbertragung\u00a0\u00a0auf\u00a0Neugebor ene\u00a0durch\u00a0die\u00a0\nGeburt\u00a0oder\u00a0anschlie\u00dfendes\u00a0Stillen.\u00a0W\u00e4hrend\u00a0der\u00a0Akutphase\u00a0der\u00a0I nfektion\u00a0kommt\u00a0\nes\u00a0bei\u00a0einem\u00a0Teil\u00a0der\u00a0Betroffene n\u00a0zu\u00a0unspezifischen\u00a0Symptomen\u00a0w ie\u00a0Fieber,\u00a0Abge\u2010\nschlagenheit,\u00a0Durchfall,\u00a0oralen\u00a0 Ulcera\u00a0oder\u00a0Hautausschl\u00e4gen;\u00a0h\u00e4 ufig\u00a0wird\u00a0diese\u00a0\nSymptomatik\u00a0von\u00a0Betroffenen\u00a0und\u00a0Behandelnden\u00a0aber\u00a0als\u00a0gew\u00f6hnlic he\u00a0Erk\u00e4ltung\u00a0\nmissdeutet.\u00a0Danach\u00a0geht\u00a0die\u00a0Krankheit\u00a0in\u00a0ein\u00a0symptomarmes\u00a0oder\u00a0 g\u00e4nzlich\u00a0symp\u2010\ntomfreies\u00a0Stadium\u00a0\u00fcber,\u00a0in\u00a0dem.\u00a0gelegentlich\u00a0Haut\u2010\u00a0oder\u00a0Schleim hautver\u00e4nderun\u2010\ngen\u00a0oder\u00a0gastrointestinale\u00a0Beschwerden\u00a0auftreten.\u00a0Unbehandelt\u00a0i st\u00a0der\u00a0Patient\u00a0\nsowohl\u00a0nach,\u00a0jedoch\u00a0insbesondere\u00a0\u00a0w\u00e4hrend\u00a0der\u00a0Akutphase\u00a0in\u00a0der\u00a0 Lage,\u00a0weitere\u00a0\nPersonen\u00a0zu\u00a0infizieren\u00a0(RKI,\u00a02016a).\u00a0\nDas\u00a0Endstadium\u00a0einer\u00a0HIV\u2010Erkrank ung,\u00a0AIDS,\u00a0ist\u00a0gekennzeichnet\u00a0d urch\u00a0eine\u00a0erh\u00f6h\u2010\nte\u00a0Anf\u00e4lligkeit\u00a0gegen\u00fcber\u00a0opportunistischen\u00a0Infektionen\u00a0wie\u00a0zum \u00a0Beispiel\u00a0Cryp\u2010\ntococcose,\u00a0Toxoplasmose\u00a0oder\u00a0die\u00a0Pneumocystispneumonie.\u00a0Dar\u00fcber \u00a0hinaus\u00a0tre\u2010\nten\u00a0vermehrt\u00a0maligne\u00a0Tumore\u00a0wie\u00a0das\u00a0Kaposi\u2010Sarkom\u00a0und\u00a0St\u00f6rungen \u00a0des\u00a0Nerven\u2010\nsystems\u00a0auf\u00a0(RKI,\u00a02016a).\u00a0\nNach\u00a0Angaben\u00a0des\u00a0Robert\u00a0Koch\u2010Instituts\u00a0(RKI)\u00a0waren\u00a0Ende\u00a02015\u00a0ru nd\u00a084.700\u00a0Men\u2010\nschen\u00a0in\u00a0Deutschland\u00a0mit\u00a0HIV\u20101\u00a0od er\u00a0HIV\u20102\u00a0infiziert.\u00a0Die\u00a0Zahl\u00a0d er\u00a0ermittelten\u00a0Neu\u2010\ninfektionen\u00a0lag\u00a0bei\u00a0circa\u00a03.000.\u00a0 Mehr\u00a0als\u00a0zwei\u00a0Drittel\u00a0der\u00a0Betr offenen\u00a0sind\u00a0m\u00e4nn\u2010\nlich,\u00a0und\u00a0wie\u00a0in\u00a0den\u00a0Jahren\u00a0zuvor\u00a0war\u00a0gleichgeschlechtlicher\u00a0Se xualverkehr\u00a0die\u00a0\nHauptursache\u00a0f\u00fcr\u00a0die\u00a0\u00dcbertragung\u00a0des\u00a0HI\u2010Virus.\u00a0Seit\u00a0Beginn\u00a0der\u00a0 Pandemie\u00a0Anfang\u00a0\nder\u00a01980er\u00a0Jahre\u00a0sind\u00a0allein\u00a0in\u00a0Deutschland\u00a0mehr\u00a0als\u00a025.000\u00a0mit \u00a0HIV\u00a0infizierte\u00a0Pa\u2010\ntienten\u00a0gestorben\u00a0(RKI,\u00a02016b).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Dolutegravir\u00a0f\u00fc r\u00a0nicht\u00a0vorbehandelte\u00a0Patiente n\u00a0basiert\u00a0auf\u00a0meh\u2010\nreren\u00a0klinischen\u00a0Studien,\u00a0darunter\u00a0die\u00a0zwei\u00a0doppelblinden,\u00a0rand omisiert\u2010kontrol\u2010\nlierten\u00a0Studien\u00a0SINGLE\u00a0und\u00a0SPRING\u20101.\u00a0In\u00a0diese\u00a0beiden\u00a0vom\u00a0Herste ller\u00a0gesponsorten\u00a0\nStudien\u00a0wurden\u00a0rund\u00a01.000\u00a0Teilnehmer\u00a0eingeschlossen.\u00a0Die\u00a0zVT\u00a0be stand\u00a0aus\u00a0Kom\u2010\nbinationen\u00a0 von\u00a0 Efavirenz\u00a0 mit\u00a0 zwei\u00a0 nucleosidischen\u00a0 Reverse\u2010Trans kriptase\u2010\nInhibitoren\u00a0(NRTI).\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0der\u00a0Wirksamkeitsstudie n\u00a0war\u00a0jeweils\u00a0die\u00a0\nSenkung\u00a0der\u00a0Plasmavir\u00e4mie\u00a0auf\u00a0weniger\u00a0als\u00a050\u00a0RNA\u2010Kopien/ml\u00a0nach \u00a048\u00a0bzw.\u00a096\u00a0\nWochen.\u00a0Unterschiede\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Mortalit\u00e4t\u00a0waren\u00a0nicht\u00a0fe ststellbar,\u00a0jedoch\u00a0\nzeigten\u00a0sich\u00a0bei\u00a0therapienaiven\u00a0erwachsenen\u00a0Patienten\u00a0signifika nt\u00a0weniger\u00a0Ne\u2010\nbenwirkungen,\u00a0wenn\u00a0sie\u00a0mit\u00a0Dolutegravir\u00a0behandelt\u00a0worden\u00a0sind.\u00a0 Insbesondere\u00a0\nHauterkrankungen\u00a0(4,7\u00a0%\u00a0vs.\u00a014,1\u00a0%),\u00a0psychiatrische\u00a0Erkrankunge n\u00a0(33,1\u00a0%\u00a0vs.\u00a0\n42,0\u00a0%)\u00a0 sowie\u00a0 Erkrankungen\u00a0 des\u00a0 Nervensystems\u00a0 bei\u00a0 m\u00e4nnlichen\u00a0 Pro banden\u00a0\n(26,8\u00a0%\u00a0vs.\u00a055,0\u00a0%)\u00a0traten\u00a0im\u00a0Vergleich\u00a0zur\u00a0Behandlung\u00a0mit\u00a0der\u00a0 zVT\u00a0signifikant\u00a0\nseltener\u00a0auf.\u00a0Au\u00dferdem\u00a0kam\u00a0es\u00a0zu\u00a0bedeutend\u00a0weniger\u00a0Therapieabbr \u00fcchen\u00a0auf\u2010185\u00a0grund\u00a0 von\u00a0 unerw\u00fcnschten\u00a0 Arzneimittelereignissen\u00a0 (UAE)\u00a0 (3,4\u00a0 %\u00a0 vs .\u00a0 12,2\u00a0 %)\u00a0\n(IQWiG,\u00a02014;\u00a0van\u00a0Lunzen\u00a0et\u00a0al.,\u00a02012;\u00a0Walmley\u00a0et\u00a0al.,\u00a02013).\u00a0I n\u00a0der\u00a0SAILING\u2010\nStudie,\u00a0 die\u00a0 nicht\u00a0 therapienaive ,\u00a0 sondern\u00a0 bereits\u00a0 vorbehandelte\u00a0 Patienten\u00a0 ein\u2010\nschloss,\u00a0die\u00a0aufgrund\u00a0bestehender\u00a0Resistenzen\u00a0zwingend\u00a0einer\u00a0Be handlung\u00a0mit\u00a0\neinem\u00a0 Integrasehemmstoff\u00a0 bedurften,\u00a0 zeigten\u00a0 sich\u00a0 ebenfalls\u00a0 weni ger\u00a0 UAE\u00a0 bei\u00a0\nAnwendung\u00a0von\u00a0Dolutegravir\u00a0bei\u00a0ges teigertem\u00a0virologischen\u00a0Anspr echen.\u00a0Da\u00a0die\u00a0\nGabe\u00a0eines\u00a0Integrasehemmers\u00a0in\u00a0a llen\u00a0F\u00e4llen\u00a0obligatorisch\u00a0war,\u00a0 wurde\u00a0Raltegravir\u00a0\nund\u00a0nicht\u00a0Efavirenz\u00a0als\u00a0Vergleichssubstanz\u00a0verwendet.\u00a0Schwere\u00a0B egleiterscheinun\u2010\ngen,\u00a0insbesondere\u00a0Infektionen,\u00a0traten\u00a0signifikant\u00a0seltener\u00a0auf\u00a0 als\u00a0in\u00a0der\u00a0Kontroll\u2010\ngruppe\u00a0(9,8\u00a0%\u00a0vs.\u00a014,6\u00a0%).\u00a0Bei\u00a0Studienteilnehmern\u00a0\u00fcber\u00a050\u00a0Jahre n\u00a0traten\u00a0au\u00dfer\u2010\ndem\u00a0seltener\u00a0Erkrankungen\u00a0des\u00a0Nervensystems\u00a0auf\u00a0(11,8\u00a0%\u00a0vs.\u00a026, 2\u00a0%).\u00a0Bei\u00a0Patien\u2010\nten\u00a0unter\u00a050\u00a0Jahren\u00a0waren\u00a0keine\u00a0signifikanten\u00a0Unterschiede\u00a0nach weisbar\u00a0(Cahn\u00a0et\u00a0\nal.,\u00a02013;\u00a0IQWiG\u00a02014).\u00a0Die\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0von\u00a0Dolu tegravir\u00a0sind\u00a0\na u \u00df e r d e m \u00a0i n \u00a0d e n \u00a0S t u d i e n \u00a0S P R I N G \u2010 2 , \u00a0d i e \u00a0i n h a l t l i c h \u00a0a u f \u00a0S P R I N G \u2010 1 \u00a0a ufbaut,\u00a0 und\u00a0\nVIKING\u20103\u00a0untersucht\u00a0worden.\u00a0Dolutegravir\u00a0zeigte\u00a0sich\u00a0gegen\u00fcber\u00a0 der\u00a0zVT\u00a0nicht\u00a0\nunterlegen\u00a0(Raffi\u00a0et\u00a0al.,\u00a02013) \u00a0und\u00a0war\u00a0in\u00a0vielen\u00a0F\u00e4llen\u00a0sogar\u00a0 wirksam,\u00a0wenn\u00a0andere\u00a0\nTherapieregime\u00a0zuvor\u00a0versagt\u00a0ha tten\u00a0(Castagna\u00a0et\u00a0al.,\u00a02014).\u00a0Al s\u00a0Grundlage\u00a0f\u00fcr\u00a0die\u00a0\nZulassungserweiterung\u00a0um\u00a0die\u00a0Altersgruppe\u00a0der\u00a0Kinder\u00a0und\u00a0Jugend lichen\u00a0ab\u00a0einem\u00a0\nAlter\u00a0von\u00a0sechs\u00a0Jahren\u00a0dient\u00a0die\u00a0Studie\u00a0IMPAACT\u00a01093.\u00a0Wiznia\u00a0un d\u00a0Kollegen\u00a0konn\u2010\nten\u00a0in\u00a0dieser\u00a0offenen\u00a0Studie,\u00a0an\u00a0der\u00a0insgesamt\u00a023\u00a0therapienaive \u00a0Testpersonen\u00a0im\u00a0\nAlter\u00a0von\u00a0sechs\u00a0bis\u00a0zw\u00f6lf\u00a0Jahren \u00a0teilnahmen,\u00a0die\u00a0Sicherheit\u00a0und \u00a0auch\u00a0die\u00a0Wirksam\u2010\nkeit\u00a0von\u00a0Dolutegravir\u00a0best\u00e4tigen\u00a0(Wiznia\u00a0et\u00a0al.,\u00a02016).\u00a0In\u00a0der\u00a0 Gesamtbetrachtung\u00a0\nkonnte\u00a0eine\u00a0verbesserte\u00a0Vertr\u00e4glichkeit\u00a0von\u00a0Dolutegravir\u00a0im\u00a0Ver gleich\u00a0zu\u00a0Therapien\u00a0\nmit\u00a0Efavirenz\u00a0oder\u00a0Raltegravir\u00a0gezeigt\u00a0werden.\u00a0Die\u00a0Wirksamkeit\u00a0 hingegen\u00a0scheint\u00a0\nvergleichbar\u00a0mit\u00a0anderen\u00a0Therapieregimen\u00a0zu\u00a0sein.\u00a0\nLeitlinienempfehlungen\u00a0\nSinn\u00a0und\u00a0Zweck\u00a0der\u00a0antiretroviralen\u00a0Therapie\u00a0(ART)\u00a0ist\u00a0die\u00a0m\u00f6gl ichst\u00a0vollst\u00e4ndige\u00a0\nHemmung\u00a0der\u00a0HIV\u2010Replikation,\u00a0die\u00a0Unterdr\u00fcckung\u00a0infektionsbeding ter\u00a0Symptome\u00a0\nund\u00a0damit\u00a0einhergehend\u00a0die\u00a0Verminderung\u00a0der\u00a0Krankheitsprogressi on.\u00a0Durch\u00a0eine\u00a0\nerfolgreiche\u00a0 ART\u00a0hat\u00a0sich\u00a0die\u00a0langfristige\u00a0 Prognose\u00a0f\u00fcr\u00a0 HIV\u2010inf izierte\u00a0Patienten\u00a0\ndeutlich\u00a0gebessert\u00a0und\u00a0die\u00a0Kontagiosit\u00e4t\u00a0ist\u00a0stark\u00a0abgesenkt.\u00a0P atienten\u00a0werden\u00a0in\u00a0\nder\u00a0Regel\u00a0ein\u00a0Leben\u00a0lang\u00a0behandelt.\u00a0Bei\u00a0der\u00a0Auswahl\u00a0einer\u00a0optim alen\u00a0ART\u00a0m\u00fcssen\u00a0\ndaher\u00a0die\u00a0individuelle\u00a0Lebenssituation,\u00a0vorhandene\u00a0Koinfektione n\u00a0und\u00a0Komorbidi\u2010\nt\u00e4ten,\u00a0auftretende\u00a0Resistenzen\u00a0s owie\u00a0die\u00a0spezifischen\u00a0Nebenwirk ungen\u00a0der\u00a0ein\u2010\nzelnen\u00a0 Medikamente\u00a0 ber\u00fccksichtigt\u00a0 werden\u00a0 (DAIG,\u00a0 2015).\u00a0 Resisten zen\u00a0 gegen\u00a0\neinzelne\u00a0Wirkstoffe\u00a0oder\u00a0ganze\u00a0Wirkstoffgruppen\u00a0schr\u00e4nken\u00a0die\u00a0A uswahl\u00a0m\u00f6gli\u2010\ncher\u00a0HIV\u2010Therapieoptionen\u00a0mehr\u00a0und\u00a0mehr\u00a0ein.\u00a0F\u00fcr\u00a0die\u00a0Behandlung \u00a0einer\u00a0HIV\u2010\nInfektion\u00a0steht\u00a0mittlerweile\u00a0eine \u00a0gro\u00dfe\u00a0Anzahl\u00a0von\u00a0Wirkstoffen\u00a0 zur\u00a0Verf\u00fcgung,\u00a0die\u00a0\ndas\u00a0Virus\u00a0in\u00a0seiner\u00a0Replikation\u00a0an\u00a0unterschiedlicher\u00a0Stelle\u00a0hem men.\u00a0Sie\u00a0lassen\u00a0sich\u00a0186\u00a0in\u00a0 die\u00a0 Klassen\u00a0 der\u00a0 NRTI,\u00a0 nicht\u2010nuc leosidische\u00a0 Reverse\u2010Transkrip tase\u2010Inhibitoren\u00a0\n(NNRTI),\u00a0Proteaseinhibitoren\u00a0(PI),\u00a0Integraseinhibitoren\u00a0(INI)\u00a0u nd\u00a0Entry\u2010Inhibitoren\u00a0\neinteilen.\u00a0F\u00fcr\u00a0die\u00a0Anwendung\u00a0eines\u00a0Proteaseinhibitors\u00a0wird\u00a0oftm als\u00a0ein\u00a0pharmako\u2010\nkinetischer\u00a0 Booster\u00a0(Verst\u00e4rker)\u00a0wie\u00a0Ritonavir\u00a0od er\u00a0Cobicistat\u00a0 hinzugegeben.\u00a0\nDie\u00a0aktuelle\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0AIDS\u2010Gesellschaft\u00a0empfiehl t\u00a0zur\u00a0Behandlung\u00a0\neiner\u00a0HIV\u2010Erkrankung\u00a0den\u00a0Einsatz\u00a0von\u00a0zwei\u00a0NRTI\u00a0zusammen\u00a0mit\u00a0ein er\u00a0dritten\u00a0Sub\u2010\nstanz\u00a0aus\u00a0den\u00a0Gruppen\u00a0der\u00a0NNRTI,\u00a0der\u00a0INI\u00a0oder\u00a0einem\u00a0geboosterte n\u00a0PI.\u00a0Dolutegra\u2010\nvir\u00a0wird\u00a0neben\u00a0Elvitegravir\u00a0und\u00a0Raltegravir\u00a0als\u00a0Therapieoption\u00a0 explizit\u00a0genannt\u00a0\n(DAIG,\u00a02015).\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIm\u00a0G\u2010BA\u2010Beschluss\u00a0vom\u00a07.\u00a0August\u00a02014\u00a0sah\u00a0der\u00a0Ausschuss\u00a0in\u00a0der\u00a0A nwendung\u00a0von\u00a0\nDolutegravir\u00a0in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0antiretroviral\u00a0wirksame n\u00a0Substanzen\u00a0bei\u00a0\ntherapienaiven\u00a0Patienten\u00a0einen\u00a0 betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0\n(Efavirenz\u00a0in\u00a0Kombination\u00a0mit\u00a0Te nofovirdisoproxil\u00a0plus\u00a0Emtricit abin\u00a0oder\u00a0Abacavir\u00a0\nplus\u00a0Lamivudin)\u00a0als\u00a0belegt\u00a0an.\u00a0Diese\u00a0Einsch\u00e4tzung\u00a0beruht\u00a0auf\u00a0ei nem\u00a0deutlich\u00a0ver\u2010\nbesserten\u00a0Nebenwirkungsprofil\u00a0der\u00a0 innovativen\u00a0Substanz,\u00a0da\u00a0insb esondere\u00a0schwe\u2010\nre\u00a0Nebenwirkungen\u00a0unter\u00a0Therapie\u00a0mit\u00a0Dolutegravir\u00a0seltener\u00a0auft reten\u00a0als\u00a0unter\u00a0\nder\u00a0Vergleichstherapie.\u00a0Die\u00a0Date n,\u00a0die\u00a0der\u00a0pU\u00a0f\u00fcr\u00a0die\u00a0gesundhei tsbezogene\u00a0Le\u2010\nbensqualit\u00e4t\u00a0vorgelegt\u00a0hat,\u00a0sind\u00a0nach\u00a0Angaben\u00a0des\u00a0G\u2010BA\u00a0nicht\u00a0au sreichend\u00a0f\u00fcr\u00a0die\u00a0\nAbleitung\u00a0eines\u00a0Zusatznutzens\u00a0f\u00fcr \u00a0die\u00a0Patienten.\u00a0F\u00fcr\u00a0antiretrov iral\u00a0vorbehandelte\u00a0\nErwachsene,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Behandlung\u00a0mit\u00a0einem\u00a0Integrase\u2010Inhibit or\u00a0die\u00a0erste\u00a0The\u2010\nrapieoption\u00a0darstellt,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0lediglich\u00a0einen\u00a0Hinweis\u00a0a uf\u00a0einen\u00a0 geringen\u00a0\nZusatznutzen \u00a0bei\u00a0der\u00a0Anwendung\u00a0von\u00a0Dolutegra vir\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0mit\u00a0Ral\u2010\ntegravir.\u00a0Beide\u00a0Integrasehemmer\u00a0 wurden\u00a0in\u00a0dieser\u00a0Untersuchung\u00a0m it\u00a0zwei\u00a0NNRTI\u00a0\nkombiniert.\u00a0F\u00fcr\u00a0die\u00a0anderen\u00a0Patientengruppen\u00a0der\u00a0therapienaiven \u00a0oder\u00a0vorbehan\u2010\ndelten\u00a0Jugendlichen\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Jahren\u00a0sowie\u00a0der\u00a0antiretroviral\u00a0 vorbehandelten\u00a0Er\u2010\nwachsenen,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Behandlung\u00a0mit\u00a0einem\u00a0Integrase\u2010Inhibito r\u00a0eine\u00a0nachrangige\u00a0\nTherapieoption\u00a0darstellt,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0 keinen\u00a0Zusatznutzen\u00a0 (G\u2010BA,\u00a02014).\u00a0\nNach\u00a0Auffassung\u00a0des\u00a0IQWiG\u00a0liegt\u00a0in\u00a0der\u00a0Anwendung\u00a0von\u00a0Dolutegrav ir\u00a0bei\u00a0therapie\u2010\nnaiven\u00a0Erwachsenen\u00a0ein\u00a0betr\u00e4chtlicher\u00a0Zusatznutzen\u00a0vor.\u00a0Da\u00a0f\u00fcr\u00a0 die\u00a0Anwendung\u00a0\nan\u00a0vor\u2010\u00a0oder\u00a0unvorbehandelten\u00a0Jugendlichen\u00a0keine\u00a0Daten\u00a0vorgeleg t\u00a0worden\u00a0sind,\u00a0\nergibt\u00a0sich\u00a0hier\u00a0laut\u00a0IQWiG\u00a0auch\u00a0kein\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznut zen.\u00a0F\u00fcr\u00a0vorbehan\u2010\ndelte\u00a0Erwachsene\u00a0ergebe\u00a0sich\u00a0nur\u00a0ein\u00a0geringer\u00a0Zusatznutzen,\u00a0wob ei\u00a0zu\u00a0beachten\u00a0\nsei,\u00a0dass\u00a0dieser\u00a0sich\u00a0nur\u00a0im\u00a0Bereich\u00a0der\u00a0UAE\u00a0zeige,\u00a0nicht\u00a0jedoc h\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0\nMortalit\u00e4t\u00a0(IQWiG,\u00a02014).\u00a0\u00a0\n\u00a0 \u00a0187\u00a0Versorgungsanalysen\u00a0\nAbbildung\u00a04.12:\u00a0Anzahl\u00a0verordnete r\u00a0Packungen\u00a0Tivicay\u00ae\u00a0je\u00a0Monat\u00a0 nach\u00a0Pa\u2010\nckungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nW\u00e4hrend\u00a0zun\u00e4chst\u00a0N2\u2010Packungen\u00a0zu\u00a0 je\u00a030\u00a0Filmtabletten\u00a0verordnet\u00a0 wurden,\u00a0\nliegt\u00a0die\u00a0nicht\u2010normierte\u00a090er\u2010Pa ckungsgr\u00f6\u00dfe\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0V erordnungs\u2010\nzahlen\u00a0seit\u00a0Anfang\u00a02015\u00a0vorn.\u00a0 Zwischen\u00a0knapp\u00a0300\u00a0und\u00a0500\u00a0Packun gen\u00a0Tivicay\u00ae\u00a0\nwerden\u00a0monatlich\u00a0insgesamt\u00a0an\u00a0d ie\u00a0Versicherten\u00a0ausgegeben.\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0\n188\u00a0Abbildung\u00a04.13:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Triumeq\u00ae\u00a0je\u00a0Monat\u00a0 nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u20102015)\u00a0\n\u00a0\nTriumeq\u00aewurde\u00a0ab\u00a0Januar\u00a02015\u00a0in\u00a0unterschiedlichem\u00a0Ausma\u00df\u00a0ohne\u00a0A ngabe\u00a0der\u00a0\nPackungsgr\u00f6\u00dfe\u00a0abgegeben,\u00a0die\u00a0Zahlen\u00a0bewegen\u00a0sich\u00a0zwischen\u00a0156\u00a0u nd\u00a0338\u00a0Pa\u2010\nckungen\u00a0 pro\u00a0 Monat.\u00a0 Von\u00a0 den\u00a0 N1\u2010Packungen\u00a0 wurden\u00a0 gleichbleibend\u00a0 r und\u00a0 150\u00a0\nPackungen\u00a0monatlich\u00a0verordnet.\u00a0\n\u00a0 \u00a0\n189\u00a0Abbildung\u00a04.14:\u00a0Versicherte\u00a0mit\u00a0mindestens\u00a0einer\u00a0Verordnung\u00a0Tiv icay\u00ae\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nInsbesondere\u00a0m\u00e4nnliche\u00a0Personen\u00a0 im\u00a0Alter\u00a0von\u00a030\u00a0bis\u00a059\u00a0Jahren\u00a0e rhalten\u00a0Tivi\u2010\ncay\u00ae,\u00a0es\u00a0handelt\u00a0sich\u00a0h\u00f6chstens\u00a0um\u00a0knapp\u00a0300\u00a0Patienten.\u00a0\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Verordnungszahlen\u00a0an\u00a0wenige\u00a0Personen\u00a0wurd en\u00a0f\u00fcr\u00a0\nTriumeq\u00ae\u00a0keine\u00a0weiteren\u00a0Vers orgungsanalysen\u00a0erstellt.\u00a0\nQuellen\u00a0\nCahn\u00a0P,\u00a0Pozniak\u00a0AL,\u00a0Mingrone\u00a0H,\u00a0Shuldyakov\u00a0A,\u00a0Brites\u00a0C,\u00a0Andrade \u2010Villanueva\u00a0JF\u00a0et\u00a0al.\u00a0(2013).\u00a0Dolutegravir\u00a0versus\u00a0raltegravir\u00a0i n\u00a0\nantiretroviral\u2010experienced,\u00a0inte grase\u2010inhibitor\u2010naive\u00a0adults\u00a0wi th\u00a0HIV.\u00a0Week\u00a048\u00a0results\u00a0fr om\u00a0the\u00a0randomised,\u00a0double\u2010\nblind,\u00a0non\u2010inferiority\u00a0SAILING\u00a0study.\u00a0Lancet\u00a0382(9893):\u00a0700\u2010708 .\u00a0\u00a0\nCastagna\u00a0A,\u00a0Maggiolo\u00a0F,\u00a0Penco\u00a0G,\u00a0 Wright\u00a0D,\u00a0Mills\u00a0A,\u00a0Grossberg\u00a0R \u00a0et\u00a0al.\u00a0(2014).\u00a0Dolutegravir\u00a0in\u00a0Antiretroviral\u2010Experienced\u00a0Pati ents\u00a0\nWith\u00a0Raltegravir\u2010\u00a0and/or\u00a0Elviteg ravir\u2010Resistant\u00a0HIV\u20101:\u00a024\u2010Week\u00a0 Results\u00a0of\u00a0the\u00a0Phase\u00a0III\u00a0VIKING\u20103\u00a0Study.\u00a0J.\u00a0Infect.\u00a0Dis.,\u00a0\n210(3),\u00a0354\u2013362.\u00a0\u00a0\nDAIG\u00a0\u2013\u00a0Deutsche\u00a0AIDS\u2010Gesellschaft\u00a0e.V.\u00a0und\u00a0\u00d6sterreichische\u00a0AIDS \u00a0Gesellschaft\u00a0(2015):\u00a0Deutsch\u2010 \u00d6sterreichische\u00a0Leitlinie\u00a0zur\u00a0\nantiretroviralen\u00a0Therapie\u00a0der\u00a0HIV\u2010Infektion.\u00a0AWMF\u2010Registernumme r:\u00a0055\u2010001\u00a0Version\u00a06..\u00a0\nhttp://www.daignet.de/site\u2010content/hiv\u2010therapie/leitlinien\u20101/Deutsch_Osterreichische%20Leitlinien%20zur%20antiretroviralen %20Therapie%20der%20HIV_Infektion.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2017).\u00a0Tivicay.\u00a0Procedural\u00a0ste ps\u00a0taken\u00a0and\u00a0scientific\u00a0information\u00a0after\u00a0the\u00a0authorisation.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Procedural _steps_taken_and_scientific_inf\u00a0\normation_after_authorisation/human/002753/WC500171906.pdf,\u00a0letz ter\u00a0Zugriff:\u00a030.05.2017.\u00a0\nFachinformation\u00a0Tivicay\u00ae\u00a0(2017).\u00a0Fachinformation\u00a0Tivicay\u00ae\u00a010/25 /50mg\u00a0Filmtabletten.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0\n190\u00a0Fachinformation\u00a0Triumeq\u00ae\u00a0(2017).\u00a0 Fachinformation\u00a0Triumeq\u00ae\u00a050/60 0/300mg\u00a0Filmtabletten.\u00a0Stand\u00a0der \u00a0Information:\u00a0Januar\u00a02017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0\nArzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0 Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0d ie\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimittel\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Dolutegravir.\u00a0https://www.g\u2010ba.d e/downloads/39\u2010261\u20102044/2014\u201008\u201007_AM\u2010RL\u2010\nXII_Dolutegravir_2014\u201002\u201015\u2010D\u2010099_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a007 .02.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0\nArzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0 Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0d ie\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Dolutegravir/Abacavir/Lamivudin. \u00a0https://www.g\u2010ba.de/downloads/39\u2010261\u2010\n2209/2015\u201003\u201019_AM\u2010RL\u2010XII_Dolutegravir\u2010Kombi_2014\u201010\u201001\u2010D\u2010131_B Anz.pdf,\u00a0letzter\u00a0Zugriff:\u00a007.02.2017.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundheits wesen\u00a0(2014).\u00a0IQWiG\u2010Berichte\u00a0Nr.\u00a0221\u00a0Dolutegravir\u00a0\u2010\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0Dossierbewertung\u00a0A14\u201008.\u00a0Ver sion\u00a01.0.\u00a0https://www.g\u2010ba.de/downloads/92\u2010\n975\u2010455/2014\u201005\u201013_Nutzenbewertung%20IQWIG_Dolutegravir.pdf,\u00a0le tzter\u00a0Zugriff:\u00a007.02.2017.\u00a0\nKirchhoff\u00a0F\u00a0(2010).\u00a0Humanes\u00a0Immundefizienz\u2010Virus\u00a0(HIV).\u00a0In:\u00a0Doe rr\u00a0HW,\u00a0\u00a0Gerlich\u00a0WH\u00a0(Hrsg.),\u00a0Medi zinische\u00a0Virologie.\u00a0\u00a0Stuttgart: \u00a0\nGeorg\u00a0Thieme\u00a0Verlag:\u00a0315\u2013331.\u00a0\nPrescrire\u00a0International\u00a0(2014).\u00a0Dolutegravir.\u00a0The\u00a0third\u00a0integra se\u00a0inhibitor:\u00a0one\u00a0more\u00a0option.\u00a0Prescrire\u00a0Int\u00a023(154):\u00a0262\u2010263.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Dolutegravir|Tivicay\u00ae|83|2014\u00a0.\u00a0http://www.pharmazeutische\u2010\nzeitung.de/?id=51230,\u00a0letzter\u00a0Zugriff:\u00a002.06.\u00a02017.\u00a0\nRaffi\u00a0F,\u00a0Jaeger\u00a0H,\u00a0Quiros\u2010Roldan\u00a0 E,\u00a0Albrecht\u00a0H,\u00a0Belonosova\u00a0E,\u00a0G atell\u00a0JM,\u00a0et\u00a0al.\u00a0(2013).\u00a0Once\u2010daily\u00a0dolutegravir\u00a0versus\u00a0twice\u2010d aily\u00a0\nraltegravir\u00a0in\u00a0antiretroviral\u2010naive\u00a0adults\u00a0with\u00a0HIV\u20101\u00a0infection \u00a0(SPRING\u20102\u00a0study):\u00a096\u00a0week\u00a0results\u00a0from\u00a0a\u00a0randomised,\u00a0\ndouble\u2010blind,\u00a0non\u2010inferiority\u00a0trial.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a013(11):\u00a0 927\u2010935.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016).\u00a0Epidemiologisches\u00a0Bulletin.\u00a0 Sch\u00e4tzung\u00a0der\u00a0Zahl\u00a0der\u00a0HIV\u2010Neuinfektionen\u00a0und\u00a0der\u00a0Gesamtzahl\u00a0vo n\u00a0\nMenschen\u00a0mit\u00a0HIV\u00a0in\u00a0Deutschland.\u00a0Stand\u00a0der\u00a0Information:\u00a0Ende\u00a020 15.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016b).\u00a0HIV/AIDS.\u00a0RKI\u2010Ratgeber\u00a0f\u00fcr\u00a0 \u00c4rzte.\u00a0Stand\u00a0der\u00a0Information:\u00a008.03.2016.\u00a0\nwww.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_HIV _AIDS.html?nn=2374210.\u00a0letzter\u00a0Zugriff:\u00a0\n18.09.2017.\u00a0\nvan\u00a0Lunzen\u00a0J,\u00a0Maggiolo\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Rakhmanova\u00a0A,\u00a0Yeni\u00a0P,\u00a0You ng\u00a0B\u00a0et\u00a0al.\u00a0(2012).\u00a0Once\u00a0daily\u00a0dolutegravir\u00a0(S/GSK1349572)\u00a0in\u00a0\ncombination\u00a0therapy\u00a0in\u00a0antiretroviral\u2010naive\u00a0adults\u00a0with\u00a0HIV:\u00a0pl anned\u00a0interim\u00a048\u00a0week\u00a0results\u00a0from\u00a0SPRING\u20101,\u00a0a\u00a0dose\u2010\nranging,\u00a0randomised,\u00a0phase\u00a02b\u00a0trial.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a012(2):\u00a01 11\u2010118.\u00a0\u00a0\nWalmsley\u00a0SL,\u00a0Antela\u00a0A,\u00a0Clumeck\u00a0N ,\u00a0Duiculescu\u00a0D,\u00a0Eberhard\u00a0A,Guti \u00e9rrez\u00a0F\u00a0et\u00a0al.\u00a0(2013).\u00a0Dolutegravir\u00a0plus\u00a0Abacavir\u2013Lamivudine\u00a0fo r\u00a0\nthe\u00a0Treatment\u00a0of\u00a0HIV\u20101\u00a0Infection.\u00a0NEJM\u00a0369(19):\u00a01807\u20101818.\u00a0\u00a0\nWiznia\u00a0AA,\u00a0Alvero\u00a0C,\u00a0Fenton\u00a0T,\u00a0George\u00a0K,\u00a0Townley\u00a0E,\u00a0Hazra\u00a0R\u00a0et\u00a0 al.\u00a0(2016).\u00a0IMPAACT\u00a01093:\u00a0Dolutegravir\u00a0in\u00a06\u201012\u00a0Year\u00a0Old\u00a0HIV\u00a0\nInfected\u00a0Children:\u00a048\u2010Week\u00a0Results.\u00a0www.croiconference.org/site s/default/files/posters\u20102016/816.pdf,\u00a0letzter\u00a0\nZugriff:\u00a002.06.2017.\u00a0\n\u00a0\u00a0191\u00a04.12 Elosulfase\u00a0alfa\u00a0\nHandelsname:\u00a0Vimizim\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Mucopolysaccharidose\u00a0Typ\u00a0IVA\u00a0 BioMarin\u00a0\nATC\u2010Code:\u00a0A16AB12\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02014\u00a0\nDarreichungsform:\u00a0Konzentrat\u00a0zur\u00a0\u00a0\nHerstellung\u00a0einer\u00a0Injektionsl\u00f6sung\u00a0 \u00a0 DDD:\u00a020\u00a0mg\u00a0Erwachsene,\u00a0\u00a0\n\u00a0 \u00a0\u00a0\u00a0\u00a07 \u00a0 m g \u00a0 K i n d e r \u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O, \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nElosulfase\u00a0alfa\u00a0(Vimizim\u00ae)\u00a0ist\u00a0die\u00a0rekombinante\u00a0Form\u00a0des\u00a0humane n\u00a0Enzyms\u00a0N\u2010Acetyl\u2010\ngalactosamin\u20106\u2010Sulfatase.\u00a0Der\u00a0Wirkstoff\u00a0ersetzt\u00a0das\u00a0fehlende\u00a0En zym\u00a0bei\u00a0Patienten\u00a0\nmit\u00a0der\u00a0genetisch\u00a0bedingten\u00a0lysosomalen\u00a0Speicherkrankheit\u00a0Mucop olysaccharidose\u00a0\n(MPS)\u00a0Typ\u00a0IVA,\u00a0bei\u00a0der\u00a0die\u00a0Patienten\u00a0unter\u00a0schwerwiegenden\u00a0Defo rmit\u00e4ten\u00a0des\u00a0\nSkeletts,\u00a0Einschr\u00e4nkungen\u00a0der\u00a0Mobilit\u00e4t,\u00a0Ausdauer\u00a0und\u00a0der\u00a0Atmun g\u00a0leiden\u00a0(EMA,\u00a0\n2014a).\u00a0\u00a0\nElosulfase\u00a0alfa\u00a0ist\u00a0als\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Erkrankungen\u00a0( Orphan\u2010Arzneimittel)\u00a0\nund\u00a0f\u00fcr\u00a0Patienten\u00a0aller\u00a0Alterskl assen\u00a0zugelassen.\u00a0Die\u00a0Behandlun g\u00a0sollte\u00a0so\u00a0bald\u00a0wie\u00a0\nm\u00f6glich\u00a0nach\u00a0der\u00a0Diagnosestellung \u00a0beginnen.\u00a0In\u00a0Deutschland\u00a0ist\u00a0 das\u00a0Arzneimittel\u00a0\nals\u00a0Konzentrat\u00a0zur\u00a0Herstellung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0im\u00a0Handel. \u00a0Elosulfase\u00a0alfa\u00a0\nwird\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a02\u00a0mg/kg\u00a0K\u00f6rpergewicht\u00a0(KG)\u00a0einmal\u00a0w\u00f6che ntlich\u00a0verab\u2010\nreicht\u00a0(Fachinformation\u00a0Vimizim\u00ae,\u00a02016).\u00a0\nDie\u00a0Wirksamkeit\u00a0belegte\u00a0der\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0be i\u00a0der\u00a0Zulassung\u00a0\nvor\u00a0allem\u00a0mit\u00a0den\u00a0Ergebnissen\u00a0einer\u00a0durch\u00a0ihn\u00a0finanzierten,\u00a0ran domisierten\u00a0kontrol\u2010\nlierten\u00a0Studie\u00a0(MOR\u2010004)\u00a0mit\u00a0176\u00a0Patienten\u00a0zwischen\u00a05\u00a0und\u00a057\u00a0Ja hren,\u00a0die\u00a0innerhalb\u00a0\nvon\u00a0sechs\u00a0Minuten\u00a0zwischen\u00a030\u00a0und\u00a0325\u00a0Meter\u00a0gehen\u00a0konnten.\u00a0Nach \u00a024\u00a0Wochen\u00a0\nhatte\u00a0sich\u00a0die\u00a0gesch\u00e4tzte\u00a0Gehstr ecke\u00a0bei\u00a0w\u00f6chentlicher\u00a0Behandlu ng\u00a0im\u00a0Vergleich\u00a0zu\u00a0\nPlacebo\u00a0im\u00a0Mittel\u00a0um\u00a022,5\u00a0Meter\u00a0verbessert\u00a0(Hendriksz\u00a0et\u00a0al.,\u00a02 014).\u00a0Im\u00a0Hinblick\u00a0auf\u00a0\ndie\u00a0Lebensqualit\u00e4t,\u00a0gemessen\u00a0mit\u00a0dem\u00a0MPS\u00a0 Health\u00a0Assessment\u00a0Questionnaire ,\u00a0zeig\u2010\nten\u00a0sich\u00a0im\u00a0Vergleich\u00a0zu\u00a0Placebo\u00a0keine\u00a0statistisch\u00a0signifikante n\u00a0Auswirkungen\u00a0der\u00a0\nBehandlung\u00a0(EMA,\u00a02014a).\u00a0Die\u00a0pos itiven\u00a0Effekte\u00a0auf\u00a0die\u00a0Ausdauer \u00a0hielten\u00a0in\u00a0 Follow\u2010\nup\u2010Studien\u00a0bis\u00a0156\u00a0Wochen\u00a0an.\u00a0Daten\u00a0zur\u00a0Lebensqualit\u00e4t\u00a0wurden\u00a0nic ht\u00a0erhoben\u00a0\n(EMA,\u00a02014a;\u00a0Hendriksz\u00a0et\u00a0al.,\u00a02016).\u00a0Weitere\u00a0unkontrollierte\u00a0S tudien\u00a0untersuchten\u00a0\nPatienten\u00a0unter\u00a0f\u00fcnf\u00a0Jahre\u00a0(MOR\u2010007)\u00a0(Jones\u00a0et\u00a0al.,\u00a02015)\u00a0oder\u00a0 mit\u00a0schweren\u00a0Mobili\u2010\nt\u00e4tseinschr\u00e4nkungen\u00a0(MOR\u2010006)\u00a0(Harmatz\u00a0et\u00a0al.,\u00a02017).\u00a0Da\u00a0keine\u00a0 Vergleichsgruppen\u00a0\neingeschlossen\u00a0wurden,\u00a0ist\u00a0die\u00a0Au ssagekraft\u00a0dieser\u00a0Studien\u00a0star k\u00a0eingeschr\u00e4nkt.\u00a0\u00a0\nZu\u00a0den\u00a0wichtigsten\u00a0unerw\u00fcnschte n\u00a0Arzneimittelereignissen\u00a0(UAE)\u00a0 geh\u00f6ren\u00a0Ana\u2010\nphylaxie\u00a0 und\u00a0 schwere\u00a0 allergische\u00a0 Reaktionen.\u00a0 Au\u00dferdem\u00a0 k\u00f6nnen\u00a0 vo r\u00a0 allem\u00a0 zu\u00a0192\u00a0Beginn\u00a0 der\u00a0 Behandlung\u00a0 weitere\u00a0 Infusionsreaktionen\u00a0 auftreten,\u00a0 so \u00a0z . B . \u00a0K o p f \u2010\nschmerzen,\u00a0\u00dcbelkeit,\u00a0Erbrechen,\u00a0 Fieber,\u00a0Sch\u00fcttelfrost\u00a0und\u00a0Bauch schmerzen.\u00a0In\u00a0den\u00a0\nklinischen\u00a0Studien\u00a0waren\u00a0diese\u00a0Reaktionen\u00a0leicht\u00a0oder\u00a0mittelsch wer.\u00a0Antik\u00f6rper\u00a0\ngegen\u00a0den\u00a0Wirkstoff\u00a0wurden\u00a0bei\u00a0allen\u00a0Patienten\u00a0beobachtet,\u00a0jedo ch\u00a0war\u00a0die\u00a0klini\u2010\nsche\u00a0 Wirksamkeit\u00a0 selbst\u00a0 bei\u00a0 Vorhandensein\u00a0 von\u00a0 neutralisierenden \u00a0 Antik\u00f6rpern\u00a0\nnicht\u00a0beeintr\u00e4chtigt.\u00a0Bei\u00a0der\u00a0Zulassung\u00a0von\u00a0Elosulfase\u00a0alfa\u00a0erh ielt\u00a0der\u00a0pU\u00a0die\u00a0Aufla\u2010\nge,\u00a0ein\u00a0Register\u00a0zu\u00a0erstellen,\u00a0in\u00a0das\u00a0alle\u00a0behandelten\u00a0Patiente n\u00a0eingeschlossen\u00a0und\u00a0\n\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0bis\u00a0zu\u00a010\u00a0Jahren\u00a0beobachtet\u00a0werden\u00a0(EMA ,\u00a02014a).\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt.\u00a0Das\u00a0 Ausma\u00df\u00a0des \u00a0Zusatznutzens \u00a0bewer\u2010\ntete\u00a0der\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0als\u00a0 gering,\u00a0da\u00a0nicht\u2010schwerwie\u2010\ngende\u00a0 Symptome\u00a0 der\u00a0 Erkrankung\u00a0 nur\u00a0 moderat\u00a0 verbessert\u00a0 werden.\u00a0 Be i\u00a0 dieser\u00a0\nBewertung\u00a0wurde\u00a0auch\u00a0ber\u00fccksichti gt,\u00a0dass\u00a0die\u00a0Verbesserung\u00a0mit\u00a0 den\u00a0vorherigen\u00a0\nTherapieoptionen\u00a0nicht\u00a0erreic ht\u00a0werden\u00a0konnte\u00a0(G\u2010BA,\u00a02014).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0Mittel\u00a0der\u00a0Wahl\u00a0 Beleg\u00a0f\u00fcr\u00a0geringen\u00a0\nZusatznutzen\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0 Judgement\u00a0reserved\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nElosulfase\u00a0alfa \u00a0 Infusion\u00a02\u00a0mg/kg\u00a0KG\u00a0\nw\u00f6chentlich \u00a052\u00a0 494.804,04\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\u00a0\n193\u00a0Ausgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0konnten\u00a0aus\u00a0Datenschu tzgr\u00fcnden\u00a0kei\u2010\nne\u00a0Versorgungsanalysen\u00a0von\u00a0Elo sulfase\u00a0alfa\u00a0erstellt\u00a0werden.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nElosulfase\u00a0alfa\u00a0ist\u00a0eine\u00a0rekombinante\u00a0Form\u00a0des\u00a0Enzyms\u00a0N\u2010Acetylg alactosamin\u20106\u2010\nSulfatase,\u00a0das\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Aminos\u00e4uresequenz\u00a0und\u00a0die\u00a0Gl ykosylierungsstel\u2010\nlen\u00a0dem\u00a0nat\u00fcrlich\u00a0vorkommenden\u00a0Protein\u00a0im\u00a0Menschen\u00a0entspricht.\u00a0 Der\u00a0Wirkstoff\u00a0\nwird\u00a0in\u00a0Ovarialzellen\u00a0des\u00a0chinesischen\u00a0Zwerghamsters\u00a0hergestell t.\u00a0\u00a0\nDer\u00a0Wirkstoff\u00a0ersetzt\u00a0das\u00a0Enzym,\u00a0das\u00a0bei\u00a0Patienten\u00a0mit\u00a0Mucopoly saccharidose\u00a0Typ\u00a0\nIVA\u00a0fehlt.\u00a0Im\u00a0K\u00f6rper\u00a0wird\u00a0die\u00a0Aufnahme\u00a0von\u00a0Elosulfase\u00a0alfa\u00a0in\u00a0d ie\u00a0Lysosomen\u00a0\u00fcber\u00a0\nMannose\u20106\u2010Phosphat\u2010Rezeptoren\u00a0vermittelt.\u00a0Dadurch\u00a0wird\u00a0die\u00a0intr azellul\u00e4re\u00a0En\u2010\nzymaktivit\u00e4t\u00a0wieder\u00a0hergestellt\u00a0 und\u00a0damit\u00a0auch\u00a0der\u00a0bei\u00a0der\u00a0Erkr ankung\u00a0gehemmte\u00a0\nAbbau\u00a0der\u00a0Glucosaminglykane\u00a0Keratansulfat\u00a0und\u00a0Chondroitin\u20106\u2010Sul fat\u00a0(Fachinfor\u2010\nmation\u00a0Vimizim\u00ae,\u00a02016).\u00a0\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nElosulfase\u00a0alfa\u00a0ist\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0Vimizim\u00ae\u00a0zur\u00a0Behandl ung\u00a0der\u00a0Muco\u2010\npolysaccharidose\u00a0vom\u00a0Typ\u00a0IVA\u00a0bei\u00a0 Patienten\u00a0aller\u00a0Altersklassen\u00a0 zugelassen.\u00a0Die\u00a0\nBehandlung\u00a0sollte\u00a0so\u00a0bald\u00a0wie\u00a0m \u00f6glich\u00a0nach\u00a0der\u00a0Diagnosestellung \u00a0beginnen.\u00a0\nIn\u00a0Deutschland\u00a0ist\u00a0das\u00a0Arzneimittel\u00a0als\u00a0Konzentrat\u00a0zur\u00a0Herstell ung\u00a0einer\u00a0Infusions\u2010\nl\u00f6sung\u00a0im\u00a0Handel.\u00a0Die\u00a0L\u00f6sung\u00a0enth\u00e4lt\u00a0Elosulfase\u00a0alfa\u00a0in\u00a0einer\u00a0K onzentration\u00a0von\u00a01\u00a0\nmg/ml\u00a0und\u00a0muss\u00a0vor\u00a0der\u00a0Infusion\u00a0mit\u00a0isotoner\u00a0Kochsalzl\u00f6sung\u00a0in\u00a0 aseptischer\u00a0Tech\u2010\nnik\u00a0verd\u00fcnnt\u00a0werden.\u00a0Das\u00a0Infusionsvolumen\u00a0richtet\u00a0sich\u00a0nach\u00a0dem \u00a0K\u00f6rpergewicht\u00a0\ndes\u00a0Patienten\u00a0und\u00a0liegt\u00a0entweder\u00a0bei\u00a0100\u00a0ml\u00a0(unter\u00a025\u00a0kg\u00a0KG)\u00a0od er\u00a0bei\u00a0250\u00a0ml\u00a0(ab\u00a0\n25\u00a0kg\u00a0KG).\u00a0Elosulfase\u00a0alfa\u00a0wird\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a02\u00a0mg/kg\u00a0KG\u00a0e inmal\u00a0w\u00f6chentlich\u00a0\nverabreicht,\u00a0dabei\u00a0sollte\u00a0die\u00a0Infusion\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0 etwa\u00a0vier\u00a0Stunden\u00a0\nerfolgen.\u00a0Wegen\u00a0der\u00a0Gefahr\u00a0von\u00a0\u00dc berempfindlichkeitsreaktionen\u00a0s ollten\u00a0die\u00a0Pati\u2010\nenten\u00a030\u00a0bis\u00a060\u00a0Minuten\u00a0vor\u00a0Beginn\u00a0der\u00a0Infusion\u00a0Antihistaminika \u00a0mit\u00a0oder\u00a0ohne\u00a0\nAntipyretika\u00a0erhalten.\u00a0\u00a0\nDas\u00a0Konzentrat\u00a0muss\u00a0im\u00a0K\u00fchlschrank\u00a0gelagert\u00a0werden.\u00a0Nach\u00a0der\u00a0Ve rd\u00fcnnung\u00a0ist\u00a0\nder\u00a0Arzneistoff\u00a024\u00a0Stunden\u00a0im\u00a0K\u00fchlschrank\u00a0stabil,\u00a0anschlie\u00dfend\u00a0 weitere\u00a024\u00a0Stun\u2010\nden\u00a0bei\u00a0Raumtemperatur.\u00a0Allerdings\u00a0wird\u00a0aus\u00a0mikrobiologischer\u00a0S icht\u00a0die\u00a0sofortige\u00a0\nVerwendung\u00a0nach\u00a0Verd\u00fcnnung\u00a0empfohlen \u00a0(Fachinformation\u00a0Vimizim\u00ae, \u00a02016).\u00a0\n\u00a0194\u00a0Informationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Mucopolysaccharidose\u00a0Typ\u00a0IVA\u00a0(Synonym:\u00a0Morquio\u2010A\u2010Syndrom,\u00a0M PS\u00a0IVA)\u00a0ist\u00a0\neine\u00a0seltene\u00a0genetische\u00a0Erkrank ung,\u00a0die\u00a0autosomal\u2010rezessiv\u00a0vere rbt\u00a0wird\u00a0und\u00a0zu\u00a0\nden\u00a0lysosomalen\u00a0Speicherkrankheiten\u00a0z\u00e4hlt.\u00a0Sie\u00a0entsteht\u00a0durch\u00a0M utationen\u00a0in\u00a0dem\u00a0\nGen,\u00a0das\u00a0f\u00fcr\u00a0das\u00a0lysosomale\u00a0Enzym\u00a0N\u2010Acetylgalactosamin\u20106\u2010Sulfat ase\u00a0kodiert.\u00a0Die\u2010\nses\u00a0Enzym\u00a0baut\u00a0die\u00a0Glucosaminogl ykane\u00a0Keratansulfat\u00a0und\u00a0Chondro itin\u20106\u2010Sulfat\u00a0\nab.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0MPS\u00a0IVA\u00a0fehlt\u00a0dieses\u00a0Enzym,\u00a0so\u00a0dass\u00a0Gluco saminoglykane\u00a0im\u00a0\nK\u00f6rper\u00a0kumulieren.\u00a0Klinisch\u00a0macht\u00a0sich\u00a0die\u00a0Erkrankung\u00a0mit\u00a0einer \u00a0fortschreitenden\u00a0\nDeformierung\u00a0des\u00a0Skeletts\u00a0bemerkb ar.\u00a0Die\u00a0Gelenke\u00a0sind\u00a0\u00fcberstrec kbar,\u00a0was\u00a0zu\u00a0\nh\u00e4ufigen\u00a0Luxationen,\u00a0besonders\u00a0an\u00a0H\u00fcfte\u00a0und\u00a0Knie\u00a0f\u00fchrt.\u00a0Die\u00a0max imale\u00a0K\u00f6rpergr\u00f6\u2010\n\u00dfe,\u00a0die\u00a0je\u00a0nach\u00a0Schweregrad\u00a0zwischen\u00a01,00\u00a0und\u00a01,50\u00a0Meter\u00a0liegt, \u00a0erreichen\u00a0viele\u00a0\nPatienten\u00a0bereits\u00a0im\u00a0Alter\u00a0von\u00a0etwa\u00a0acht\u00a0Jahren.\u00a0Die\u00a0Verformung en\u00a0des\u00a0Skeletts\u00a0\nk\u00f6nnen\u00a0auch\u00a0zu\u00a0neurologischen\u00a0A usf\u00e4llen\u00a0und\u00a0einer\u00a0Kompression\u00a0d es\u00a0R\u00fccken\u2010\nmarks\u00a0im\u00a0Bereich\u00a0der\u00a0Halswirbels\u00e4ule\u00a0f\u00fchren.\u00a0\u00a0\nDie\u00a0Patienten\u00a0m\u00fcssen\u00a0sich\u00a0h\u00e4ufig\u00a0orthop\u00e4dischen\u00a0Operationen\u00a0unt erziehen\u00a0und\u00a0\nleiden\u00a0unter\u00a0bedeutsamen\u00a0Einschr \u00e4nkungen\u00a0der\u00a0Mobilit\u00e4t,\u00a0Ausdaue r\u00a0und\u00a0Atmung.\u00a0\nBereits\u00a0im\u00a0jugendlichen\u00a0Alter\u00a0sind\u00a0viele\u00a0Patienten\u00a0deshalb\u00a0auf\u00a0 Gehhilfen\u00a0oder\u00a0auf\u00a0\neinen\u00a0Rollstuhl\u00a0angewiesen.\u00a0 Zu\u00a0de n\u00a0wichtigsten\u00a0Symptomen\u00a0des\u00a0At emsystems\u00a0\ngeh\u00f6ren\u00a0h\u00e4ufige\u00a0Atemwegsinfektio nen,\u00a0obstruktive\u00a0Erkrankungen\u00a0d er\u00a0Atemwege\u00a0\nund\u00a0Atemnot\u00a0bis\u00a0hin\u00a0zum\u00a0Lungenversagen.\u00a0Au\u00dferdem\u00a0k\u00f6nnen\u00a0Geh\u00f6rve rlust,\u00a0Tr\u00fc\u2010\nbungen\u00a0von\u00a0Linse\u00a0und\u00a0Hornhaut\u00a0sowie\u00a0Herzklappenerkrankungen\u00a0auf treten.\u00a0Die\u00a0\nPrognose\u00a0und\u00a0die\u00a0Lebenserwartung\u00a0h\u00e4ngt\u00a0neben\u00a0der\u00a0Qualit\u00e4t\u00a0der\u00a0B ehandlung\u00a0vor\u00a0\nallem\u00a0 vom\u00a0 Schweregrad\u00a0 der\u00a0 Erkrankung\u00a0 ab,\u00a0 der\u00a0 sehr\u00a0 stark\u00a0 variier en\u00a0 kann\u00a0\n(Orphanet,\u00a02007).\u00a0\nDie\u00a0Inzidenz\u00a0von\u00a0MPS\u00a0IVA\u00a0wird\u00a0europaweit\u00a0auf\u00a0etwa\u00a00,06\u00a0pro\u00a010.0 00\u00a0Lebendgebur\u2010\nten\u00a0gesch\u00e4tzt.\u00a0Damit\u00a0leben\u00a0etwa\u00a01.300\u00a0Patienten\u00a0mit\u00a0dieser\u00a0Erkr ankung\u00a0in\u00a0der\u00a0EU\u00a0\n(EMA,\u00a02014a).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDas\u00a0Pr\u00e4parat\u00a0wurde\u00a0von\u00a0der\u00a0European\u00a0Medicines\u00a0Agency\u00a0(EMA)\u00a0als\u00a0 Arzneimittel\u00a0\nf\u00fcr\u00a0seltene\u00a0Leiden\u00a0( Orphan\u2010Arzneimittel)\u00a0zugelassen.\u00a0\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0den\u00a0Daten\u00a0von\u00a0zwei\u00a0abgeschlossenen\u00a0Stu dien.\u00a0Zwischen\u2010\nergebnisse\u00a0von\u00a0vier\u00a0weiteren\u00a0laufenden\u00a0Studien\u00a0wurden\u00a0im\u00a0europ\u00e4 ischen\u00a0\u00f6ffentli\u2010\nchen\u00a0Beurteilungsbericht\u00a0ebenfalls\u00a0ber\u00fccksichtigt.\u00a0In\u00a0die\u00a0Dosis findungsstudie\u00a0MO\u00a0\nR\u2010002\u00a0waren\u00a020\u00a0Patienten\u00a0zwischen\u00a05\u00a0und\u00a018\u00a0Jahren\u00a0\u00fcber\u00a0einen\u00a0Ze itraum\u00a0von\u00a072\u00a0\nWochen\u00a0eingeschlossen.\u00a0Die\u00a0Hauptstudie\u00a0MOR\u2010004\u00a0umfasste\u00a0176\u00a0Pat ienten,\u00a0die\u00a0\nrandomisiert\u00a0einer\u00a0Placebo\u2010Behandlung\u00a0oder\u00a0einem\u00a0der\u00a0Behandlung sarme\u00a0(2\u00a0mg/\u00a0195\u00a0kg\u00a0KG\u00a0Elosulfase\u00a0alfa\u00a0einmal\u00a0w\u00f6chentlich\u00a0oder\u00a0alle\u00a0zwei\u00a0Wochen) \u00a0zugeteilt\u00a0wurden.\u00a0\nDie\u00a0Teilnehmer\u00a0waren\u00a0zwischen\u00a05\u00a0und\u00a057\u00a0Jahre\u00a0alt\u00a0und\u00a0in\u00a0der\u00a0Lag e,\u00a0innerhalb\u00a0von\u00a0\nsechs\u00a0Minuten\u00a0zwischen\u00a030\u00a0und\u00a0325\u00a0(durchschnittlich\u00a0200)\u00a0Metern \u00a0zu\u00a0gehen.\u00a0Nach\u00a0\n24\u00a0Wochen\u00a0hatte\u00a0sich\u00a0die\u00a0gesch\u00e4tz te\u00a0Gehstrecke\u00a0in\u00a0der\u00a0Gruppe\u00a0mi t\u00a0der\u00a0w\u00f6chentli\u2010\nchen\u00a0Behandlung\u00a0im\u00a0Vergleich\u00a0zu\u00a0 Placebo\u00a0(14\u00a0Meter)\u00a0im\u00a0Mittel\u00a0um \u00a022,5\u00a0auf\u00a037\u00a0\nMeter\u00a0verbessert.\u00a0Bei\u00a0der\u00a014\u2010t\u00e4gigen\u00a0Behandlung\u00a0war\u00a0der\u00a0Untersc hied\u00a0nicht\u00a0signi\u2010\nfikant.\u00a0Im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t,\u00a0gemessen\u00a0mit\u00a0dem\u00a0MP S\u00a0Health\u00a0Assess\u2010\nment\u00a0Questionnaire ,\u00a0zeigten\u00a0sich\u00a0im\u00a0Vergleich\u00a0zu\u00a0P lacebo\u00a0keine\u00a0statistisch\u00a0signif i\u2010\nkanten\u00a0Auswirkungen\u00a0der\u00a0Behandlung\u00a0(EMA,\u00a02014a;\u00a0Hendriksz\u00a0et\u00a0al .,\u00a02014).\u00a0Die\u00a0\npositiven\u00a0 Effekte\u00a0 auf\u00a0 die\u00a0 Ausdauer\u00a0 hielten\u00a0 in\u00a0 den\u00a0 ber\u00fccksichtig ten\u00a0Follow\u2010up \u2010\nStudien\u00a0bei\u00a0Patienten\u00a0mit\u00a0w\u00f6chentlicher\u00a0Behandlung\u00a0bis\u00a0156\u00a0Woch en\u00a0an.\u00a0Daten\u00a0\nzur\u00a0Lebensqualit\u00e4t\u00a0wurden\u00a0nicht \u00a0erhoben\u00a0(EMA,\u00a02014a;\u00a0Hendriksz\u00a0 et\u00a0al.,\u00a02016).\u00a0\nNach\u00a0der\u00a0Zulassung\u00a0wurden\u00a0weitere\u00a0klinische\u00a0Studien\u00a0abgeschloss en.\u00a0Die\u00a0unkon\u2010\ntrollierte\u00a0Studie\u00a0MOR\u2010007\u00a0untersuchte\u00a015\u00a0Patienten,\u00a0die\u00a0j\u00fcnger\u00a0 als\u00a0f\u00fcnf\u00a0Jahre\u00a0wa\u2010\nren,\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a052\u00a0Wochen.\u00a0Dabei\u00a0nahm\u00a0die\u00a0Ausschei dung\u00a0von\u00a0\nKeratansulfat\u00a0im\u00a0Urin\u00a0deutlich\u00a0ab,\u00a0was\u00a0als\u00a0Zeichen\u00a0f\u00fcr\u00a0einen\u00a0ve rbesserten\u00a0Abbau\u00a0\nvon\u00a0Glucosaminoglykanen\u00a0zu\u00a0deute n\u00a0ist.\u00a0Bei\u00a0den\u00a0Auswirkungen\u00a0auf \u00a0das\u00a0Wachs\u2010\ntumsverhalten\u00a0war\u00a0zwar\u00a0ein\u00a0positiver\u00a0Trend\u00a0im\u00a0Vergleich\u00a0zu\u00a0Date n\u00a0aus\u00a0Studien\u00a0mit\u00a0\nunbehandelten\u00a0Patienten\u00a0erkennbar.\u00a0Wegen\u00a0der\u00a0starken\u00a0intraindiv iduellen\u00a0Varia\u2010\nbilit\u00e4t\u00a0ist\u00a0die\u00a0klinische\u00a0Relevanz\u00a0jedoch\u00a0nicht\u00a0klar.\u00a0Die\u00a0Vertr \u00e4glichkeit\u00a0war\u00a0ver\u2010\ngleichbar\u00a0mit\u00a0den\u00a0Ergebnissen\u00a0aus\u00a0Studien\u00a0mit\u00a0\u00e4lteren\u00a0Patienten \u00a0(EMA,\u00a02014b;\u00a0\nJones\u00a0et\u00a0al.,\u00a02015).\u00a0Ergebnisse\u00a0der\u00a0Erweiterungsphase\u00a0der\u00a0Studi e\u00a0\u00fcber\u00a0einen\u00a0Zeit\u2010\nraum\u00a0von\u00a0insgesamt\u00a0bis\u00a0zu\u00a0208\u00a0Wo chen\u00a0sind\u00a0noch\u00a0nicht\u00a0publiziert .\u00a0\nWeitere\u00a0unkontrollierte\u00a0Studien\u00a0waren\u00a0 Follow\u2010up \u2010Untersuchungen\u00a0zur\u00a0Dosisfin\u2010\ndungsstudie\u00a0 (MOR\u2010100)\u00a0 beziehungsweise\u00a0 der\u00a0 randomisierten\u00a0 Zulass ungsstudie\u00a0\n(MOR\u2010005)\u00a0(Hendriksz\u00a0et\u00a0al.,\u00a02016)\u00a0oder\u00a0umfassten\u00a0einige\u00a0wenige \u00a0Patienten\u00a0mit\u00a0\nschwerer\u00a0Mobilit\u00e4tseinschr\u00e4nkung\u00a0(MOR\u2010006)\u00a0(EMA,\u00a02015b;\u00a0Harmatz \u00a0et\u00a0al.,\u00a02017).\u00a0\nDie\u00a0Ergebnisse\u00a0waren\u00a0teilweise\u00a0sehr\u00a0heterogen\u00a0und\u00a0in\u00a0ihrer\u00a0klin ischen\u00a0Relevanz\u00a0\nnicht\u00a0immer\u00a0\u00fcberzeugend.\u00a0Einige\u00a0der\u00a0Studien\u00a0wurden\u00a0durch\u00a0den\u00a0Sp onsor\u00a0vorzeitig\u00a0\nbeendet,\u00a0da\u00a0in\u00a0den\u00a0USA\u00a0Elosulfase\u00a0alfa\u00a0im\u00a0Rahmen\u00a0eines\u00a0 Compassionate\u00a0Use \u2010\nProgramms\u00a0vor\u00a0der\u00a0Zulassung\u00a0verf\u00fcgbar\u00a0wurde\u00a0und\u00a0Patienten\u00a0darau fhin\u00a0auf\u00a0eige\u2010\nnen\u00a0Wunsch\u00a0aus\u00a0den\u00a0Studien\u00a0ausschieden.\u00a0Da\u00a0keine\u00a0Vergleichsgrup pen\u00a0untersucht\u00a0\nwurden,\u00a0ist\u00a0die\u00a0Aussagekraft\u00a0dies er\u00a0Studien\u00a0stark\u00a0eingeschr\u00e4nkt .\u00a0\u00a0\nEine\u00a0randomierte\u00a0Studie\u00a0(MOR\u2010008)\u00a0\u00fcber\u00a052\u00a0Wochen\u00a0zum\u00a0Vergleich\u00a0 zweier\u00a0Dosie\u2010\nrungen\u00a0von\u00a0Elosulfase\u00a0alfa\u00a0(2\u00a0versus\u00a04\u00a0mg/kg\u00a0KG)\u00a0bei\u00a025\u00a0Patient en\u00a0ab\u00a0sieben\u00a0Jahren\u00a0\nmit\u00a0weniger\u00a0starken\u00a0Mobilit\u00e4tseinschr\u00e4nkungen\u00a0zeigte\u00a0in\u00a0beiden\u00a0 Gruppen\u00a0keine\u00a0\nstatistisch\u00a0signifikante\u00a0Ver\u00e4nde rung\u00a0der\u00a0Gehstrecke.\u00a0Ob\u00a0dieses\u00a0 Ergebnis\u00a0durch\u00a0die\u00a0\nkleine\u00a0Fallzahl\u00a0bei\u00a0starken\u00a0interindividuellen\u00a0Schwankungen\u00a0ode r\u00a0durch\u00a0den\u00a0besse\u2010196\u00a0ren\u00a0Gesundheitszustand\u00a0der\u00a0Patienten\u00a0im\u00a0Vergleich\u00a0zu\u00a0vorherigen \u00a0Studien\u00a0zustan\u2010\nde\u00a0gekommen\u00a0ist,\u00a0bleibt\u00a0unklar\u00a0 (Burton\u00a0et\u00a0al.,\u00a02015;\u00a0EMA,\u00a02015a ).\u00a0\nZu\u00a0den\u00a0UAE\u00a0geh\u00f6ren\u00a0Anaphylaxie\u00a0und\u00a0schwere\u00a0allergische\u00a0Reaktion en.\u00a0Au\u00dferdem\u00a0\nk\u00f6nnen\u00a0weitere\u00a0Infusionsreaktionen\u00a0auftreten\u00a0wie\u00a0Kopfschmerzen, \u00a0\u00dcbelkeit,\u00a0Er\u2010\nbrechen,\u00a0 Fieber,\u00a0 Sch\u00fcttelfrost\u00a0 und\u00a0 Bauchschmerzen.\u00a0 In\u00a0 den\u00a0 klini schen\u00a0 Studien\u00a0\nwaren\u00a0diese\u00a0Reaktionen\u00a0leicht\u00a0oder\u00a0mittelschwer.\u00a0Sie\u00a0traten\u00a0am\u00a0 h\u00e4ufigsten\u00a0in\u00a0den\u00a0\nersten\u00a0zw\u00f6lf\u00a0Behandlungswochen\u00a0auf,\u00a0danach\u00a0waren\u00a0sie\u00a0seltener\u00a0( Fachinformation\u00a0\nVimizim\u00ae,\u00a02016).\u00a0\u00a0\nIn\u00a0den\u00a0klinischen\u00a0Studien\u00a0traten\u00a0bei\u00a0allen\u00a0Patienten\u00a0Antik\u00f6rper \u00a0gegen\u00a0Elosulfase\u00a0\nalfa\u00a0auf,\u00a0bei\u00a0etwa\u00a080\u00a0%\u00a0der\u00a0Te ilnehmer\u00a0neutralisierende\u00a0Antik\u00f6r per,\u00a0die\u00a0die\u00a0Bin\u2010\ndung\u00a0von\u00a0Elosulfase\u00a0alfa\u00a0an\u00a0den\u00a0Rezeptor\u00a0verhindern\u00a0k\u00f6nnen.\u00a0All erdings\u00a0war\u00a0die\u00a0\nklinische\u00a0 Wirksamkeit\u00a0 (Verbesserung\u00a0 der\u00a0 Symptome,\u00a0 verringerte\u00a0 A usscheidung\u00a0\nvon\u00a0Keratansulfat\u00a0im\u00a0Urin)\u00a0dadurch\u00a0nicht\u00a0beeintr\u00e4chtigt\u00a0(EMA,\u00a02 014a).\u00a0\u00a0\nIn\u00a0keiner\u00a0der\u00a0Studien,\u00a0die\u00a0nach\u00a0der\u00a0Zulassung\u00a0abgeschlossen\u00a0wur den,\u00a0zeigten\u00a0sich\u00a0\nneue\u00a0Sicherheitssignale.\u00a0Aktualisierungen\u00a0des\u00a0europ\u00e4ischen\u00a0\u00f6ffe ntlichen\u00a0Beurtei\u2010\nlungsberichtes\u00a0konstatieren\u00a0keine\u00a0Ver\u00e4nderungen\u00a0in\u00a0der\u00a0Nutzen\u2010R isiko\u2010Absch\u00e4t\u2010\nzung\u00a0(EMA,\u00a02014b,\u00a02015a,\u00a02015b).\u00a0\u00a0\nInformationen\u00a0zur\u00a0Sicherheit\u00a0von\u00a0Patienten\u00a0\u00fcber\u00a065\u00a0Jahren\u00a0liege n\u00a0derzeit\u00a0noch\u00a0\nnicht\u00a0vor.\u00a0Ebenso\u00a0fehlen\u00a0Daten\u00a0zur\u00a0Anwendung\u00a0von\u00a0Elosulfase\u00a0alf a\u00a0bei\u00a0Schwange\u2010\nren\u00a0(Fachinformation\u00a0Vimizim\u00ae,\u00a02016)\u00a0\nBei\u00a0der\u00a0Zulassung\u00a0von\u00a0Elosulfase\u00a0alfa\u00a0erhielt\u00a0der\u00a0pU\u00a0die\u00a0Auflag e,\u00a0ein\u00a0Register\u00a0zu\u00a0\nerstellen,\u00a0in\u00a0das\u00a0alle\u00a0behandelten\u00a0Patienten\u00a0eingeschlossen\u00a0und \u00a0\u00fcber\u00a0einen\u00a0Zeit\u2010\nraum\u00a0von\u00a0bis\u00a0zu\u00a0zehn\u00a0Jahren\u00a0beo bachtet\u00a0werden\u00a0(EMA,\u00a02014a).\u00a0\nLeitlinienempfehlungen\u00a0\nF\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0MPS\u00a0IVA\u00a0existieren\u00a0ein\u00a0franz\u00f6sisches\u00a0Beh andlungsprotokoll\u00a0\nsowie\u00a0ein\u00a0internationaler\u00a0Expertenkonsensus.\u00a0Beide\u00a0Leitlinien\u00a0w eisen\u00a0darauf\u00a0hin,\u00a0\ndass\u00a0die\u00a0spezifischen\u00a0therapeutischen\u00a0Optionen\u00a0sehr\u00a0begrenzt\u00a0si nd.\u00a0Dazu\u00a0geh\u00f6rt\u00a0\ndie\u00a0Enzymersatztherapie\u00a0 mit\u00a0Elosulfase\u00a0alfa.\u00a0\nIn\u00a0der\u00a0franz\u00f6sischen\u00a0Leitlinie\u00a0wird\u00a0die\u00a0Behandlung\u00a0mit\u00a0Elosulfa se\u00a0alfa\u00a0f\u00fcr\u00a0Patienten\u00a0\nempfohlen,\u00a0die\u00a0noch\u00a0laufen\u00a0k\u00f6nnen.\u00a0Bei\u00a0leichteren\u00a0Erkrankungsfo rmen\u00a0kann\u00a0eine\u00a0\nEnzymersatztherapie\u00a0im\u00a0Einzelfa ll\u00a0erwogen\u00a0werden\u00a0(HAS,\u00a02016).\u00a0\nDer\u00a0internationale\u00a0Expertenkonse ns\u00a0r\u00e4t\u00a0zu\u00a0einem\u00a0fr\u00fchen\u00a0Beginn\u00a0d er\u00a0Enzymersatz\u2010\ntherapie,\u00a0sobald\u00a0die\u00a0Diagnose\u00a0best\u00e4tigt\u00a0ist.\u00a0Eine\u00a0Einschr\u00e4nkung \u00a0auf\u00a0bestimmte\u00a0Pati\u2010\nentengruppen\u00a0wird\u00a0nicht\u00a0vorgenommen\u00a0(Hendriksz\u00a0et\u00a0al.,\u00a02015).\u00a0197\u00a0Eine\u00a0weitere\u00a0spezifische\u00a0Therapi eoption,\u00a0die\u00a0allogene\u00a0Stammzell transplantation\u00a0\nmit\u00a0Zellen\u00a0aus\u00a0Knochenmark\u00a0oder\u00a0Nabelschnurblut,\u00a0wird\u00a0in\u00a0beiden \u00a0Leitlinien\u00a0kri\u2010\ntisch\u00a0gesehen.\u00a0Der\u00a0internationale\u00a0Expertenkonsens\u00a0weist\u00a0auf\u00a0die \u00a0limitierte\u00a0Daten\u2010\nbasis\u00a0und\u00a0wenig\u00a0ermutigende\u00a0Ergebnisse\u00a0in\u00a0klinischen\u00a0Studien\u00a0hi n\u00a0(Hendriksz\u00a0et\u00a0al.,\u00a0\n2015).\u00a0Die\u00a0franz\u00f6sische\u00a0Leitlinie\u00a0sieht\u00a0einen\u00a0Stellenwert\u00a0f\u00fcr\u00a0d ieses\u00a0Verfahrens\u00a0nur\u00a0\nin\u00a0Einzelf\u00e4llen,\u00a0etwa\u00a0bei\u00a0sehr\u00a0fr\u00fcher\u00a0Diagnosestellung\u00a0im\u00a0Neuge borenenalter\u00a0(HAS,\u00a0\n2016).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Verbesserung\u00a0der\u00a0Symptome\u00a0und\u00a0der\u00a0Lebensqualit\u00e4t\u00a0der\u00a0Pa tienten\u00a0haben\u00a0\nau\u00dferdem\u00a0unterst\u00fctzende\u00a0Therapien\u00a0mit\u00a0Arzneimitteln\u00a0oder\u00a0operat iven\u00a0Verfahren\u00a0\neinen\u00a0wichtigen\u00a0Stellenwert\u00a0(HAS ,\u00a02016;\u00a0Hendriksz \u00a0et\u00a0al.,\u00a02015) .\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0zog\u00a0der\u00a0Gemeinsame\u00a0Bundesaussschuss\u00a0(G\u2010BA)\u00a0di e\u00a0Zulassungs\u2010\nstudie\u00a0sowie\u00a0weitere\u00a0laufende\u00a0Studien\u00a0heran.\u00a0Auf\u00a0dieser\u00a0Basis\u00a0k am\u00a0der\u00a0G\u2010BA\u00a0im\u00a0\nNovember\u00a02014\u00a0zu\u00a0dem\u00a0Schluss,\u00a0d ass\u00a0f\u00fcr\u00a0Elosulfase\u00a0alfa\u00a0ein\u00a0 geringer\u00a0Zusatznutzen \u00a0\nbelegt\u00a0ist,\u00a0da\u00a0nicht\u2010schwerwiegende\u00a0Symptome\u00a0der\u00a0Erkrankung\u00a0nur \u00a0moderat\u00a0ver\u2010\nbessert\u00a0werden.\u00a0Bei\u00a0dieser\u00a0Bewertung\u00a0wurde\u00a0auch\u00a0ber\u00fccksichtigt, \u00a0dass\u00a0die\u00a0Verbes\u2010\nserung\u00a0mit\u00a0den\u00a0vorherigen\u00a0Therapieoptionen\u00a0nicht\u00a0erreicht\u00a0werde n\u00a0konnte\u00a0(G\u2010BA,\u00a0\n2014).\u00a0\nQuellen\u00a0\nBurton\u00a0BK,\u00a0Berger\u00a0KI,\u00a0Lewis\u00a0GD,\u00a0T arnopolsky\u00a0M,\u00a0Treadwell\u00a0M,\u00a0Mit chell\u00a0JJ\u00a0et\u00a0al.\u00a0(2015).\u00a0Safety\u00a0and\u00a0physiological\u00a0effects\u00a0of\u00a0two \u00a0\ndifferent\u00a0doses\u00a0of\u00a0elosulfase\u00a0alfa\u00a0in\u00a0patients\u00a0with\u00a0morquio\u00a0a\u00a0s yndrome:\u00a0A\u00a0randomized,\u00a0double\u2010blind,\u00a0pilot\u00a0study.\u00a0\nAmerican\u00a0Journal\u00a0of\u00a0Medical\u00a0Genetics\u00a0Part\u00a0A,\u00a0167(10):\u00a02272\u20132281 .\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014a).\u00a0European\u00a0Public\u00a0Assess ment\u00a0Report\u00a0Vimizim.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Public_assessment_report/human/002779/WC500169242.pdf,\u00a0letzter \u00a0Zugriff:\u00a030.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014b).\u00a0European\u00a0Public\u00a0Assess ment\u00a0Report\u00a0Vimizim.\u00a0Erg\u00e4nzung\u00a003.12.2014.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Assessment _Report_\u2010\n_Variation/human/002779/WC500177987.pdf,\u00a0letzter\u00a0Zugriff:\u00a030.03 .2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015a).\u00a0European\u00a0Public\u00a0Assess ment\u00a0Report\u00a0Vimizim.\u00a0Erg\u00e4nzung\u00a007.08.2015.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Assessment _Report_\u2010\n_Variation/human/002779/WC500191744.pdf,\u00a0letzter\u00a0Zugriff:\u00a030.03 .2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015b).\u00a0European\u00a0Public\u00a0Assess ment\u00a0Report\u00a0Vimizim.\u00a0Erg\u00e4nzung\u00a017.09.2015.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Assessment _Report_\u2010\n_Variation/human/002779/WC500193818.pdf,\u00a0letzter\u00a0Zugriff:\u00a030.03 .2017.\u00a0198\u00a0EMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Package\u00a0leaflet:\u00a0Inform ation\u00a0for\u00a0the\u00a0user.\u00a0Vimizim\u00a01\u00a0mg/ml\u00a0concentrate\u00a0for\u00a0solution\u00a0fo r\u00a0\ninfusion\u00a0elosulfase\u00a0alfa.\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02016.\u00a0in: \u00a0Summary\u00a0of\u00a0the\u00a0risk\u00a0management\u00a0plan\u00a0(RMP)\u00a0for\u00a0\nVimizim\u00a0(elosulfase\u00a0alfa).\u00a0www.ema.europa.eu/docs/en_GB/documen t_library/EPAR_\u2010\n_Product_Information/human/002779/WC500169239.pdf,\u00a0letzter\u00a0Zugr iff\u00a030.03.2017.\u00a0\nFachinformation\u00a0Vimizim\u00ae\u00a0(2016).\u00a0Fachinformation\u00a0Vimizim\u00a0\u00ae.\u00a0Sta nd\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02016.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Product_Information/human/002779/WC500169239.pdf,\u00a0letzter\u00a0Zugr iff:\u00a030.03.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Elosulfase\u00a0alfa.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/120/,\u00a0letzter\u00a0Zugriff:\u00a030.0 3.2017.\u00a0\nHarmatz\u00a0PR,\u00a0Mengel\u00a0E,\u00a0Geberhiwot\u00a0T,\u00a0Muschol\u00a0N,\u00a0Hendriksz\u00a0CJ,\u00a0Bu rton\u00a0BK\u00a0et\u00a0al.\u00a0(2017).\u00a0Impact\u00a0of\u00a0elosulfase\u00a0alfa\u00a0in\u00a0patients\u00a0wi th\u00a0\nmorquio\u00a0A\u00a0syndrome\u00a0who\u00a0have\u00a0limited\u00a0ambulation:\u00a0An\u00a0open\u2010label,\u00a0 phase\u00a02\u00a0study.\u00a0American\u00a0Journal\u00a0of\u00a0Medical\u00a0\nGenetics\u00a0Part\u00a0A\u00a0173(2):\u00a0375\u2010383.\u00a0\u00a0\nHAS\u00a0\u2013\u00a0Haute\u00a0Authorit\u00e9\u00a0de\u00a0Sant\u00e9\u00a0(2016).\u00a0Protocole\u00a0national\u00a0de\u00a0di agnostic\u00a0et\u00a0de\u00a0soins:\u00a0Mucopolysaccharidoses.\u00a0www.has\u2010\nsante.fr/por+tail/jcms/c_2659923/fr/pnds\u2010mucopolysaccharidoses, \u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nHendriksz\u00a0CJ,\u00a0Berger\u00a0KI,\u00a0Giugliani\u00a0R,\u00a0Harmatz\u00a0P,\u00a0Kampmann\u00a0C,\u00a0Ma ckenzie\u00a0WG\u00a0et\u00a0al.\u00a0(2015).\u00a0International\u00a0guidelines\u00a0for\u00a0the\u00a0\nmanagement\u00a0and\u00a0treatment\u00a0of\u00a0Morquio\u00a0A\u00a0syndrome.\u00a0Am\u00a0J\u00a0Med\u00a0Geneti cs.\u00a0Part\u00a0A,\u00a0167A(1):\u00a011\u201025.\u00a0\u00a0\nHendriksz\u00a0CJ,\u00a0Burton\u00a0B,\u00a0Fleming\u00a0TR,\u00a0Harmatz\u00a0P,\u00a0Hughes\u00a0D,\u00a0Jones\u00a0 SA\u00a0et\u00a0al.\u00a0(2014).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0enzyme\u00a0replacement\u00a0\ntherapy\u00a0with\u00a0BMN\u00a0110\u00a0(elosulfase\u00a0alfa)\u00a0for\u00a0Morquio\u00a0A\u00a0syndrome\u00a0( mucopolysaccharidosis\u00a0IVA):\u00a0a\u00a0phase\u00a03\u00a0randomised\u00a0\nplacebo\u2010controlled\u00a0study.\u00a0Journal\u00a0of\u00a0Inherited\u00a0Metabolic\u00a0Diseas e\u00a037(6):\u00a0979\u201090.\u00a0\u00a0\nHendriksz\u00a0CJ,\u00a0Parini\u00a0R,\u00a0AlSayed\u00a0M D,\u00a0Raiman\u00a0J,\u00a0Giugliani\u00a0R,\u00a0Sola no\u00a0Villarreal\u00a0ML\u00a0et\u00a0al.\u00a0(2016).\u00a0 Long\u2010term\u00a0endurance\u00a0and\u00a0safety\u00a0 of\u00a0\nelosulfase\u00a0alfa\u00a0enzyme\u00a0replaceme nt\u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0Mor quio\u00a0A\u00a0syndrome.\u00a0Molecular\u00a0Genetics\u00a0and\u00a0\nMetabolism,\u00a0119(1\u20132):\u00a0131\u2010143.\u00a0\u00a0\nJones,\u00a0SA,\u00a0Bialer\u00a0M,\u00a0Parini\u00a0R,\u00a0Martin\u00a0K,\u00a0Wang\u00a0H,\u00a0Yang\u00a0K\u00a0et\u00a0al.\u00a0 (2015).\u00a0Safety\u00a0and\u00a0clin ical\u00a0activity\u00a0of\u00a0elosulfase\u00a0alfa\u00a0in\u00a0pedi atric\u00a0\npatients\u00a0with\u00a0Morquio\u00a0A\u00a0syndrome\u00a0(mucopolysaccharidosis\u00a0IVA)\u00a0le ss\u00a0than\u00a05\u00a0y.\u00a0Pediatric\u00a0Research\u00a078(6):\u00a0717\u2010722.\u00a0\nOrphanet\u00a0(2007).\u00a0Mukopolysaccharidose\u00a0Typ\u00a04.\u00a0www.orpha.net/cons or/cgi\u2010bin/OC_Exp.php?lng=DE&Expert=582,\u00a0letzter\u00a0Zugriff:\u00a0\n27.03.2017.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0New\u00a0drugs,\u00a0new\u00a0indications\u00a0in\u00a02 015:\u00a0little\u00a0progress,\u00a0and\u00a0threats\u00a0to\u00a0access\u00a0to\u00a0quality\u00a0healthca re\u00a0for\u00a0\nall.\u00a0Prescrire\u00a0Int\u00a025:\u00a0136\u2010139.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Elosu lfase\u00a0alfa|Vimizim\u00ae|40|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=53126,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017.\u00a0\n\u00a0\u00a0199\u00a04.13 Empagliflozin\u00a0\nHandelsname:\u00a0Jardiance\u00ae\u00a0\u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0 \u00a0 Boehringer\u00a0Ingelheim\u00a0\nATC\u2010Code: \u00a0A10BX12\u00a0(neu:\u00a0A10BK03)\u00a0 Mar kteinf\u00fchrung:\u00a0August\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a017,5\u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0Empagliflozin\u00a0(Jardiance\u00ae)\u00a0stand\u00a0neben\u00a0Dapagliflozin\u00a0und\u00a0Ca nagliflozin\u00a0(nach\u00a0\nMarktr\u00fccknahme\u00a0in\u00a0Deutschland\u00a0aktuell\u00a0nicht\u00a0verf\u00fcgbar)\u00a0der\u00a0drit te\u00a0selektive\u00a0Inhi\u2010\nbitor\u00a0 des\u00a0 natriumabh\u00e4ngigen\u00a0 Glukosetransporters\u00a0 Typ\u00a0 2\u00a0 ( Sodium\u2010Glucose\u00a0 Co\u2010\nTransporter\u00a02 ,\u00a0SGLT\u20102)\u00a0zur\u00a0Verf\u00fcgung.\u00a0Die\u00a0kompetitive,\u00a0reversible\u00a0Hemmung\u00a0de s\u00a0\nTransporters\u00a0bewirkt\u00a0eine\u00a0Verminderung\u00a0der\u00a0Wiederaufnahme\u00a0von\u00a0G lucose\u00a0aus\u00a0\ndem\u00a0Prim\u00e4rharn\u00a0und\u00a0bewirkt\u00a0somit\u00a0eine\u00a0Reduktion\u00a0des\u00a0Blutzuckers piegels.\u00a0Ferner\u00a0\nwird\u00a0auch\u00a0eine\u00a0weitere\u00a0Isoform\u00a0des\u00a0Rezeptors,\u00a0SGLT\u20101,\u00a0im\u00a0Nieren tubulus\u00a0expri\u2010\nmiert,\u00a0der\u00a0im\u00a0Gegensatz\u00a0zu\u00a0SGLT\u20102\u00a0durch\u00a0eine\u00a0hohe\u00a0Substrataffin it\u00e4t\u00a0und\u00a0Trans\u2010\nportkapazit\u00e4t\u00a0charakterisiert,\u00a0a ber\u00a0nur\u00a0zu\u00a0einem\u00a0Zehntel\u00a0an\u00a0der \u00a0R\u00fcckresorption\u00a0\nbeteiligt\u00a0ist.\u00a0Aufgrund\u00a0der\u00a0selektiven\u00a0Wirkungsweise\u00a0ist\u00a0die\u00a0An wendung\u00a0der\u00a0Sub\u2010\nstanzklasse\u00a0mit\u00a0einem\u00a0geringen\u00a0Risiko\u00a0f\u00fcr\u00a0Hypoglyk\u00e4mien\u00a0verbund en\u00a0(Idris\u00a0et\u00a0al.,\u00a0\n2009).\u00a0Die\u00a0mechanistisch\u00a0assoziierte\u00a0osmotische\u00a0Diurese\u00a0f\u00fchrt\u00a0z u\u00a0Gewichtsverlust\u00a0\nund\u00a0Blutdrucksenkung\u00a0(Bailey,\u00a02011).\u00a0Die\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0K ommission\u00a0( Eu\u2010\nropean\u00a0Commission ,\u00a0EC)\u00a02014\u00a0erteilte\u00a0Zulassung\u00a0f\u00fcr\u00a0Empagliflozin\u00a0zur\u00a0Behandlung\u00a0\ndes\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0umfasst\u00a0sowohl\u00a0die\u00a0Monotherapie\u00a0bei \u00a0bestehender\u00a0\nUnvertr\u00e4glichkeit\u00a0oder\u00a0Kontraindikation\u00a0gegen\u00fcber\u00a0Metformin\u00a0als \u00a0auch\u00a0die\u00a0Kom\u2010\nbinationstherapie\u00a0mit\u00a0anderen\u00a0blutzuckersenkenden\u00a0Arzneimitteln \u00a0einschlie\u00dflich\u00a0\nInsulin\u00a0 (EMA,\u00a0 2015).\u00a0 Chemisch\u00a0 handelt\u00a0 es\u00a0 sich\u00a0 klassentypisch\u00a0 um \u00a0 ein\u00a0 C\u2010Aryl\u2010\nGlycosid,\u00a0dessen\u00a0Struktur\u00a0seine\u00a0metabolische\u00a0Stabilit\u00e4t\u00a0gegen\u00fcb er\u00a0intestinalen\u00a0\u00df\u2010\nGlucosidasen\u00a0gew\u00e4hrleistet\u00a0(Bojunga\u00a0&\u00a0Sch\u00f6lmerich,\u00a02015).\u00a0Die\u00a0e mpfohlene\u00a0Ta\u2010\ngesdosierung\u00a0betr\u00e4gt\u00a0sowohl\u00a0f\u00fcr\u00a0die\u00a0Mono\u2010\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Komb inationstherapie\u00a0\n10\u00a0mg\u00a0Empagliflozin,\u00a0die\u00a0jedoch\u00a0bei\u00a0guter\u00a0Vertr\u00e4glichkeit\u00a0und\u00a0u nter\u00a0Ber\u00fccksichti\u2010\ngung\u00a0der\u00a0Nierenfunktion\u00a0(eGFR\u00a0\u2265\u00a060\u00a0ml/min/1,73\u00a0m2)\u00a0auf\u00a025\u00a0mg\u00a0erh\u00f6ht\u00a0werden\u00a0\nkann,\u00a0falls\u00a0eine\u00a0engere\u00a0Blutzuckerkontrolle\u00a0 indiziert\u00a0 ist\u00a0(Fach information\u00a0Jardi\u2010\nance\u00ae,\u00a02017).\u00a0\nDie\u00a0 SGLT\u20102\u2010Inhibitoren\u00a0 reduzierten\u00a0 in\u00a0 den\u00a0 zulassungsbegr\u00fcndende n\u00a0 Studien\u00a0\ndurchschnittlich\u00a0den\u00a0HbA1c\u2010Wert\u00a0gegen\u00fcber\u00a0Placebo\u00a0in\u00a0\u00e4hnlichem\u00a0 Ausma\u00df.\u00a0Unter\u00a0\nEmpagliflozin\u00a0betrug\u00a0die\u00a0absolut e\u00a0Reduktion\u00a0des\u00a0HbA1c\u2010Wertes\u00a0zw ischen\u00a0\u20100,66\u00a0\n(10\u00a0mg)\u00a0und\u00a0\u20100,77\u00a0Prozentpunkte\u00a0(25\u00a0mg)\u00a0(EMPA\u2010REG\u00a0MONO,\u00a0Roden\u00a0e t\u00a0al.,\u00a02013)\u00a0\nf\u00fcr\u00a0Canagliflozin\u00a0betrug\u00a0sie\u00a0von \u00a00,91\u00a0bis\u00a01,16\u00a0%\u00a0(Stenl\u00f6f\u00a0et\u00a0al .,\u00a02014)\u00a0und\u00a0f\u00fcr\u00a0Dapa\u2010\ngliflozin\u00a00,66\u00a0%\u00a0(Ferrannini\u00a0et\u00a0al .,\u00a02010).\u00a0In\u00a0weiteren,\u00a0vom\u00a0ph armazeutischen\u00a0Un\u2010200\u00a0ternehmer\u00a0(pU)\u00a0zum\u00a0Zweck\u00a0der\u00a0Zulassung\u00a0initiierten\u00a0und\u00a0finanzie rten\u00a0Vergleichs\u2010\nstudien\u00a0mit\u00a0Glimepirid\u00a0(EMPA\u2010REG\u00a0H2H\u2010SU,\u00a0Ridderstr\u00e5le\u00a0et\u00a0al.,\u00a02 014)\u00a0und\u00a0Sitaglip\u2010\ntin\u00a0(EMPA\u2010REG\u00a0MONO,\u00a0Roden\u00a0et\u00a0al.,\u00a02013),\u00a0war\u00a0Empagliflozin\u00a0bez\u00fc glich\u00a0der\u00a0Sen\u2010\nkung\u00a0des\u00a0HbA1c\u2010Wertes\u00a0nicht\u00a0unterlegen.\u00a0Die\u00a0Ergebnisse\u00a0der\u00a0EMPA \u2010REG\u00a0Outcome\u2010\nStudie\u00a0(Zinman\u00a0et\u00a0al.,\u00a02015)\u00a0zeigt en\u00a0f\u00fcr\u00a0Empagliflozin\u00a0im\u00a0Vergl eich\u00a0zu\u00a0Placebo\u00a0\nzus\u00e4tzlich\u00a0zur\u00a0Standard\u2010Medikation\u00a0ein\u00a0signifikant\u00a0geringeres\u00a0R isiko\u00a0f\u00fcr\u00a0kardiovas\u2010\nkul\u00e4re\u00a0Ereignisse.\u00a0Dies\u00a0trug\u00a0ma\u00dfgeblich\u00a0zu\u00a0einer\u00a0neuen\u00a0Bewertun g\u00a0der\u00a0Substanz\u00a0\nbei,\u00a0obgleich\u00a0die\u00a0Validit\u00e4t\u00a0der\u00a0Resultate\u00a0nach\u00a0wie\u00a0vor\u00a0diskutie rt\u00a0wird.\u00a0Im\u00a0Januar\u00a0\n2017\u00a0wurde\u00a0die\u00a0Zulassung\u00a0auf\u00a0den\u00a0Studiendaten\u00a0basierend\u00a0erweite rt\u00a0und\u00a0um\u00a0die\u00a0\nReduktion\u00a0der\u00a0kardiovaskul\u00e4ren\u00a0Morbidit\u00e4t\u00a0und\u00a0Mortalit\u00e4t\u00a0erg\u00e4nz t\u00a0(Fachinforma\u2010\ntion\u00a0Jardiance \u00ae,\u00a02017).\u00a0Daten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0( Health\u2010\nRelated\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurden\u00a0nicht\u00a0erhoben.\u00a0Die\u00a0im\u00a0Rahmen\u00a0seltener\u00a0\nunerw\u00fcnschter\u00a0Wirkungen\u00a0festgeste llte\u00a0diabetische\u00a0Ketoazidose\u00a0w ar\u00a0bereits\u00a0The\u2010\nma\u00a0 eines\u00a0 Risikobewertungverfahrens\u00a0 des\u00a0 Ausschusses\u00a0 f\u00fcr\u00a0 Risikobe wertung\u00a0 im\u00a0\nBereich\u00a0 der\u00a0 Pharmakovigilanz\u00a0 ( Pharmakovigilance\u00a0 Risk\u00a0 Assessment\u00a0 Committee ,\u00a0\nPRAC)\u00a0der\u00a0EMA,\u00a0das\u00a0entsprechende\u00a0Empfehlungen\u00a0zur\u00a0Minimierung\u00a0d es\u00a0Risikos\u00a0\nherausgab\u00a0(BfArM,\u00a02016).\u00a0Der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0\nMedicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use ,\u00a0CHMP)\u00a0besch\u00e4ftigte\u00a0sich\u00a0k\u00fcrzlich\u00a0mit\u00a0der\u00a0Be\u2010\nwertung\u00a0 des\u00a0 Risikos\u00a0 f\u00fcr\u00a0 Amputationen\u00a0 unter\u00a0 Therapie\u00a0 mit\u00a0 SGLT\u20102\u2010 Inhibitoren,\u00a0\nnachdem\u00a0in\u00a0zwei\u00a0Studien\u00a0mit\u00a0dem\u00a0Wirkstoff\u00a0Canagliflozin\u00a0ein\u00a0erh \u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0\nvorwiegend\u00a0 die\u00a0 Zehen\u00a0 betreffende\u00a0 A mputationen\u00a0 detektiert\u00a0 wurde. \u00a0 In\u00a0 der\u00a0\nCANVAS\u2010Studie\u00a0betrug\u00a0die\u00a0Inziden z\u00a0unter\u00a0Therapie\u00a0mit\u00a0t\u00e4glich\u00a010 0\u00a0mg\u00a0Canagliflozin\u00a0\n7,\u00a0bei\u00a0300\u00a0mg\u00a05\u00a0und\u00a0unter\u00a0Placebo\u00a03\u00a0je\u00a01.000\u00a0Patientenjahre.\u00a0Di e\u00a0Analyse\u00a0von\u00a0\nCANVAS\u2010R\u00a0ergab\u00a0die\u00a0Inzidenz\u00a0inne rhalb\u00a0des\u00a0Canagliflozin\u2010Arms\u00a08, \u00a0innerhalb\u00a0der\u00a0\nPlacebo\u2010Gruppe\u00a04\u00a0je\u00a01.000\u00a0Patientenjahre.\u00a0Das\u00a0Gremium\u00a0folgte\u00a0de n\u00a0Empfehlungen\u00a0\ndes\u00a0PRAC,\u00a0das\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Produktinformationen\u00a0f\u00fcr\u00a0s\u00e4mtli che\u00a0Gliflozine\u00a0\nund\u00a0die\u00a0Aufnahme\u00a0von\u00a0Warnhinweisen\u00a0sowie\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Risikore duktion\u00a0\nforderte\u00a0(EMA,\u00a02017).\u00a0\nSeit\u00a0Markteintritt\u00a0wurde\u00a0der\u00a0Nutz en\u00a0von\u00a0Empagliflozin\u00a0bereits\u00a0z weimal\u00a0bewertet.\u00a0\nIm\u00a0ersten\u00a0Verfahren\u00a0bezweifelt e\u00a0der\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0 (G\u2010BA)\u00a0die\u00a0\nEignung\u00a0der\u00a0vom\u00a0pU\u00a0vorgelegten\u00a0Daten\u00a0zur\u00a0Bewertung\u00a0und\u00a0stellte\u00a0 keinen\u00a0Beleg\u00a0f\u00fcr\u00a0\neinen\u00a0Zusatznutzen\u00a0fest\u00a0(G\u2010BA,\u00a02015).\u00a0Erst\u00a0bei\u00a0erneuter\u00a0Nutzenb ewertung,\u00a0die\u00a0auf\u00a0\nAntrag\u00a0des\u00a0pU\u00a0eingeleitet\u00a0wurde,\u00a0konnte\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen \u00a0\nfestgestellt\u00a0 werden\u00a0 (G\u2010BA,\u00a0 2016),\u00a0 dessen\u00a0 Ausma\u00df\u00a0 aufgrund\u00a0 der\u00a0 Re sultate\u00a0 der\u00a0\nEMPA\u2010REG\u00a0 Outcome\u2010Studie\u00a0als\u00a0 betr\u00e4chtlich \u00a0eingesch\u00e4tzt\u00a0wurde.\u00a0Damit\u00a0ist\u00a0Em\u2010\npagliflozin\u00a0erst\u00a0das\u00a0zweite\u00a0oral e\u00a0Antidiabetikum\u00a0nach\u00a0Metformin ,\u00a0f\u00fcr\u00a0das\u00a0eine\u00a0\nMortalit\u00e4tssenkung\u00a0 f\u00fcr\u00a0 Diabetespatienten\u00a0 mit\u00a0 kardiovaskul\u00e4rer\u00a0 K omorbidit\u00e4t\u00a0\nnachgewiesen\u00a0werden\u00a0konnte.\u00a0Der\u00a0G \u2010BA\u00a0folgte\u00a0in\u00a0seiner\u00a0Entscheid ung\u00a0nicht\u00a0der\u00a0\nEinsch\u00e4tzung\u00a0des\u00a0Instituts\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0 im\u00a0Gesundheitswe\u2010\nsen\u00a0(IQWiG).\u00a0Das\u00a0IQWiG\u00a0hielt\u00a0die\u00a0genannte\u00a0Studie\u00a0aufgrund\u00a0mange lnder\u00a0\u00dcbertrag\u2010201\u00a0barkeit\u00a0auf\u00a0die\u00a0deutsche\u00a0Behandlungspraxis\u00a0sowie\u00a0der\u00a0regional\u00a0s tark\u00a0unterschiedli\u2010\nchen\u00a0Auspr\u00e4gung\u00a0der\u00a0Effekte\u00a0auf\u00a0 multinationaler\u00a0Ebene\u00a0f\u00fcr\u00a0ungee ignet\u00a0zur\u00a0Bewer\u2010\ntung\u00a0(IQWiG,\u00a02016).\u00a0So\u00a0zeigte\u00a0die\u00a0Subgruppenanalyse\u00a0f\u00fcr\u00a0den\u00a0pri m\u00e4ren\u00a0Endpunkt\u00a0\nund\u00a0den\u00a0kardiovaskul\u00e4r\u00a0bedingten\u00a0Tod\u00a0positive\u00a0Effekte\u00a0ausschlie \u00dflich\u00a0f\u00fcr\u00a0Studien\u2010\nzentren\u00a0in\u00a0Lateinamerika\u00a0(HR\u00a00,58\u00a0\u2013\u00a00,89),\u00a0Afrika\u00a0(HR\u00a00,86)\u00a0und \u00a0Asien\u00a0(HR\u00a00,70),\u00a0\nw\u00e4hrend\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0europ\u00e4ische n\u00a0Raum\u00a0Nachteile\u00a0im\u00a0Verh\u00e4ltnis\u00a0 st\u00e4rker\u00a0zeigten\u00a0\n(HR\u00a01,02)\u00a0(Zinman\u00a0et\u00a0al.,\u00a02015).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0 Weitere\u00a0blutzuckersenkende\u00a0\nTherapieoption\u00a0mit\u00a0\nsubgruppenspezifischem\u00a0\nVorteil\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0\nkardiovaskul\u00e4rer\u00a0\nKomorbidit\u00e4t\u00a0Hinweis\u00a0auf\u00a0\nZusatznutzen\u00a0nur\u00a0in\u00a0\nEMPA\u2010Reg\u00a0gegen\u00fcber\u00a0\nPlacebo,\u00a0\u00a0\nSenkung\u00a0der\u00a0Mortalit\u00e4t\u00a0\nbei\u00a0Hochrisikogruppe\u00a0teils\u00a0teurer\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere? \u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Umstrittenes\u00a0\nTherapieprinzip\u00a0Daten\u00a0zur\u00a0\nLangzeitsicherheit\u00a0\nfehlen,\u00a0Zweifel\u00a0an\u00a0\nErgebnissen\u00a0von\u00a0\nEMPA\u2010REG\u00a0\nangebracht\u00a0Judgment\u00a0reserved\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0\nKosten\u00a0der\u00a0Monotherapien\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nZu\u00a0bewertendes\u00a0\nArzneimittel \u00a0\u00a0 \u00a0 \u00a0\nEmpagliflozin\u00a0 \u00a0 1x\u00a0tgl.\u00a0 365\u00a0 401,83\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 13,03\u00a0\u2013\u00a078,17\u00a0\u20ac\u00a0\nGlimepirid\u00a0\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 29,67\u00a0\u2013\u00a0152,29\u00a0\u20ac\u00a0\n\u00a0\n\u00a0 \u00a0\n202\u00a0Kosten\u00a0der\u00a0Kombinationstherapien\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nZu\u00a0bewertendes\u00a0\nArzneimittel\u00a0(AM) \u00a0\u00a0 \u00a0 \u00a0\nEmpagliflozin\u00a0\u00b1\u00a0\u00a0\nMetformin\u00a0(MET)\u00a01x\u00a0tgl.\u00a0\n2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0365\u00a0\n365\u00a0\u00a0\n735,11\u00a0\u2013\u00a0801,26\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 47,79\u00a0\u2013\u00a0187,55\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0 1x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 66,04\u00a0\u2013\u00a0233,32\u00a0\u20ac\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nEmpagliflozin\u00a0+ \u00a0 1x\u00a0tgl.\u00a0 365\u00a0 \u00a0\nGlibenclamid\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 716,76\u00a0\u2010790,37\u00a0\u00a0\u20ac\u00a0\nGlimepirid\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 735,01\u00a0\u2013\u00a0836,14\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 47,79\u00a0\u2013\u00a0187,55\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0 1x\u00a0tgl.\u00a0+\u00a0MET\u00a0s.o.\u00a0 365\u00a0 66,04\u00a0\u2013\u00a0233,32\u00a0\u20ac\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nEmpagliflozin\u00a0+ \u00a0 1x\u00a0tgl.\u00a0 365\u00a0 \u00a0\nGlibenclamid\u00a0+\u00a0MET\u00a0oder\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 749,84\u00a0\u2013\u00a0889,59\u00a0\u20ac\u00a0\nGlimepirid\u00a0+\u00a0MET\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 768,09\u00a0\u2013\u00a0935,36\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)*\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00b1\u00a0MET\u00a0oder\u00a0 2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0 365\u00a0 425,70\u00a0\u2013\u00a0884,47\u00a0\u20ac*\u00a0\nKonventionelle\u00a0\nInsulintherapie\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 392,62\u00a0\u2013\u00a0785,25\u00a0\u20ac*\u00a0\nZu\u00a0bewertendes\u00a0AM \u00a0 \u00a0 \u00a0 \u00a0\nEmpagliflozin\u00a0+\u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)*\u00a0\n\u00b1\u00a0MET\u00a0\nVergleichstherapie \u00a01x\u00a0tgl.\u00a0\n1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0\n2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0365\u00a0\n365\u00a0\n365\u00a0\u00a0\n1.094,66\u00a0\u2013\u00a01.487,29\u00a0\u20ac\u00a0\n1.127,74\u00a0\u2013\u00a01.586,51\u00a0\u20ac \u00a0\nHumaninsulin\u00a0(NPH\u2010Ins.)*\u00a0 1\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00b1\u00a0Metformin\u00a0 2\u00a0\u2013\u00a03x\u00a0tgl.\u00a0 365\u00a0 425,70\u00a0\u2013\u00a0884,47\u00a0\u20ac\u00a0\nKonventionelle\u00a0\nInsulintherapie\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 392,62\u00a0\u2013\u00a0785,25\u00a0\u20ac\u00a0\n*Angaben\u00a0exkl.\u00a0zus\u00e4tzliche\u00a0GKV\u2010Leistungen\u00a0f\u00fcr\u00a0Blutzuckerteststr eifen,\u00a0Lanzetten,\u00a0Einmalnadeln\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nSeit\u00a0 Markteinf\u00fchrung\u00a0 im\u00a0 August\u00a0 2014\u00a0 stiegen\u00a0 die\u00a0 Bruttoums\u00e4tze\u00a0 d es\u00a0 SGLT\u20102\u2010\nInhibitors\u00a0Empagliflozin\u00a0stetig\u00a0 an\u00a0und\u00a0verf\u00fcnffachten\u00a0sich\u00a0nahe zu\u00a0von\u00a0Dezember\u00a0\n2014\u00a0bis\u00a0Dezember\u00a02015\u00a0(Abb.\u00a04.15).\u00a0Mit\u00a0der\u00a0Ver\u00f6ffentlichung\u00a0de s\u00a0G\u2010BA\u2010Beschlusses\u00a0\nvom\u00a0 Februar\u00a0 2015,\u00a0 der\u00a0 keinen\u00a0 Zusatznutzen\u00a0 gegen\u00fcber\u00a0 der\u00a0 zweckm\u00e4 \u00dfigen\u00a0 Ver\u2010\ngleichstherapie\u00a0(zVT)\u00a0feststellte,\u00a0geht\u00a0zun\u00e4chst\u00a0eine\u00a0Stagnatio n\u00a0der\u00a0Ums\u00e4tze\u00a0einher.\u00a0\nIm\u00a0 M\u00e4rz\u00a0 2015\u00a0 erfolgte\u00a0 nach\u00a0 Aufnahme\u00a0 des\u00a0 Wirkstoffs\u00a0 in\u00a0 die\u00a0 Packu ngs\u2010\ngr\u00f6\u00dfenverordnung\u00a0 (DIMDI,\u00a0 2015)\u00a0 eine\u00a0 Aktualisierung\u00a0 der\u00a0 im\u00a0 Markt \u00a0 befindlichen\u00a0\nPackungsgr\u00f6\u00dfen,\u00a0sodass\u00a0nun\u00a0auch\u00a0eine\u00a0den\u00a0Erfordernissen\u00a0der\u00a0Dau ertherapie\u00a0ent\u2010\nsprechende\u00a0normierte\u00a0Packungsgr\u00f6\u00dfe\u00a0N3\u00a0verf\u00fcgbar\u00a0war.\u00a0Daraus\u00a0erg ibt\u00a0sich\u00a0ein\u00a0Ein\u2010\nfluss\u00a0 auf\u00a0 das\u00a0 Verordnungsverhalten,\u00a0 sodass\u00a0 DDD\u00a0 und\u00a0 Bruttoums\u00e4tz e\u00a0 tendenziell\u00a0\nsteigen.\u00a0Ab\u00a0Juli\u00a02015\u00a0sinken\u00a0beide\u00a0Parameter\u00a0und\u00a0erreichen\u00a0jewe ils\u00a0im\u00a0August\u00a0das\u00a0203\u00a0jeweilige\u00a0Minimum.\u00a0Im\u00a0August\u00a0zeigt\u00a0sich\u00a0auch\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0 Verh\u00e4ltnisses\u00a0von\u00a0\nDDD\u00a0zu\u00a0Bruttoums\u00e4tzen\u00a0aufgrund\u00a0der\u00a0aktualisierten\u00a0DDD\u00a0von\u00a010\u00a0mg \u00a0auf\u00a017,5\u00a0mg.\u00a0\nVom\u00a0August,\u00a0in\u00a0dem\u00a0der\u00a0pU\u00a0die\u00a0po sitiven\u00a0Ergebnisse\u00a0der\u00a0EMPA\u2010REG \u00a0Outcome\u2010Studie\u00a0\nerstmals\u00a0 ver\u00f6ffentlichte,\u00a0 bis\u00a0 zum\u00a0 Jahresende\u00a0 2015\u00a0 erreichen\u00a0 bei de\u00a0 Gr\u00f6\u00dfen\u00a0 ihre\u00a0\nMaximalwerte\u00a0innerhalb\u00a0des\u00a0Beobachtungszeitraums.\u00a0\nAbbildung\u00a04.15:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nEmpagliflozin\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie \u00a0\nEmpagliflozin\u00a0ist\u00a0ein\u00a0selektiver \u00a0Inhibitor\u00a0des\u00a0im\u00a0Nierengewebe\u00a0 exprimierten,\u00a0natri\u2010\numabh\u00e4ngigen\u00a0Glukosetransporters\u00a0Typ\u00a02.\u00a0Die\u00a0Funktion\u00a0der\u00a0in\u00a0der \u00a0Membran\u00a0des\u00a0\ndistalen\u00a0Abschnitts\u00a0des\u00a0Nierentubulus\u00a0lokalisierten\u00a0SGLT\u20101\u00a0und\u00a0 des\u00a0proximal\u00a0vor\u2010\nkommenden\u00a0SGLT\u20102\u00a0besteht\u00a0in\u00a0der\u00a0R\u00fcckresorption\u00a0von\u00a0Glucose\u00a0aus\u00a0 dem\u00a0Prim\u00e4r\u2010\nharn.\u00a0Dabei\u00a0besitzt\u00a0SGLT\u20102\u00a0die \u00a0geringere\u00a0Substrataffinit\u00e4t\u00a0(K 0,5\u00a0=\u00a02\u00a0mM\u00a0vs.\u00a0K 0,5\u00a0=\u00a00,4\u00a0\nmM)\u00a0(Bailey,\u00a02011)\u00a0aber\u00a0h\u00f6here\u00a0Transportkapazit\u00e4t\u00a0( Low\u00a0affinity,\u00a0High\u00a0capacity )\u00a0\nund\u00a0ist\u00a0zu\u00a090\u00a0%\u00a0am\u00a0Wiederaufnahmem echanismus\u00a0beteiligt\u00a0(Bojunga \u00a0et\u00a0al.,\u00a02015).\u00a0\nDie\u00a0kompetitive,\u00a0reversible\u00a0Hemmu ng\u00a0des\u00a0Transporters\u00a0bewirkt\u00a0ei ne\u00a0Verminde\u2010\nrung\u00a0der\u00a0Wiederaufnahme\u00a0und\u00a0tr\u00e4gt\u00a0somit\u00a0zu\u00a0einer\u00a0Reduktion\u00a0des\u00a0 Blutzuckerspie\u2010\ngels\u00a0bei\u00a0Mit\u00a0der\u00a0vermehrten\u00a0Ausscheidung\u00a0von\u00a0Glucose\u00a0geht\u00a0langf ristig\u00a0ein\u00a0kalori\u2010\nsches\u00a0Defizit\u00a0einher,\u00a0das\u00a0zu\u00a0Gewi chtsverlust\u00a0f\u00fchrt.\u00a0Dieser\u00a0Effe kt\u00a0f\u00fchrt\u00a0erg\u00e4nzt\u00a0um\u00a0\ndie\u00a0natriuretische\u00a0Wirkung\u00a0zu\u00a0einer\u00a0Blutdrucksenkung\u00a0(Abdul\u2010Gha ni\u00a0et\u00a0al.,\u00a02016).\u00a0\nDas\u00a0niedrige\u00a0Hypoglyk\u00e4mierisiko\u00a0der\u00a0Gliflozine\u00a0resultiert\u00a0aus\u00a0d er\u00a0hohen\u00a0Selektivit\u00e4t\u00a0\n204\u00a0f\u00fcr\u00a0den\u00a0SGLT\u20102\u2010Inhibitor,\u00a0die\u00a0bei\u00a0Empagliflozin\u00a0(IC 50\u00a03,1\u00a0nM)\u00a0in\u00a0der\u00a0Gegen\u00fcberstel\u2010\nlung\u00a0mit\u00a0Dapagliflozin\u00a0(IC 50\u00a01,2\u00a0nM)\u00a0und\u00a0Canagliflozin\u00a0(IC 50\u00a02,7\u00a0nM)\u00a0die\u00a0die\u00a0h\u00f6chste\u00a0\nAuspr\u00e4gung\u00a0aufweist\u00a0(Neumiller,\u00a02014).\u00a0Strukturell\u00a0leiten\u00a0sich\u00a0 die\u00a0Vertreter\u00a0vom\u00a0\nGlykosid\u00a0Phlorizin\u00a0ab,\u00a0das\u00a0in\u00a0der\u00a0Rinde\u00a0einiger\u00a0Obstb\u00e4ume\u00a0wie\u00a0K irsche\u00a0und\u00a0Apfel\u00a0\nvorkommt\u00a0und\u00a0ebenfalls\u00a0eine\u00a0inhibierende\u00a0Wirkung\u00a0auf\u00a0SGLT\u00a0besit zt.\u00a0Bei\u00a0Em\u2010\npagliflozin\u00a0handelt\u00a0es\u00a0sich\u00a0kla ssentypisch\u00a0um\u00a0ein\u00a0C\u2010Aryl\u2010Glycos id,\u00a0dessen\u00a0Struktur\u00a0\nseine\u00a0metabolische\u00a0Stabilit\u00e4t\u00a0geg en\u00fcber\u00a0der\u00a0f\u00fcr\u00a0den\u00a0Abbau\u00a0veran twortlichen\u00a0intes\u2010\ntinalen\u00a0\u00df\u2010Glucosidasen\u00a0gew\u00e4hrleistet\u00a0(Bojunga\u00a0et\u00a0al.,\u00a02015).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat \u00a0\nDie\u00a0von\u00a0der\u00a0EMA\u00a02014\u00a0erteilte\u00a0Zul assung\u00a0f\u00fcr\u00a0Empagliflozin\u00a0zur\u00a0B ehandlung\u00a0des\u00a0\nTyp\u20102\u2010Diabetes\u00a0sieht\u00a0die\u00a0Monothe rapie\u00a0bei\u00a0einer\u00a0bestehenden\u00a0Unv ertr\u00e4glichkeit\u00a0\noder\u00a0bei\u00a0einer\u00a0Kontraindikation\u00a0g egen\u00fcber\u00a0Metformin\u00a0vor.\u00a0Eine\u00a0K ombinationsthe\u2010\nrapie\u00a0 mit\u00a0 anderen\u00a0 blutzuckersenk enden\u00a0 Arzneimitteln\u00a0 einschlie\u00dfl ich\u00a0 Insulin\u00a0 ist\u00a0\nebenfalls\u00a0zugelassen.\u00a0Bei\u00a0Mono\u2010\u00a0und\u00a0Kombinationstherapie\u00a0wird\u00a0v orausgesetzt,\u00a0\ndass\u00a0im\u00a0Vorfeld\u00a0durchgef\u00fchrte\u00a0Ma\u00dfnahmen\u00a0zur\u00a0\u00c4nderung\u00a0der\u00a0Lebens \u2010\u00a0und\u00a0Ern\u00e4h\u2010\nrungsgewohnheiten\u00a0den\u00a0Blutzucker\u00a0nicht\u00a0zufriedenstellend\u00a0senken \u00a0konnten.\u00a0Die\u00a0\nempfohlene\u00a0Tagesdosierung\u00a0(DDD)\u00a0betr\u00e4gt\u00a0sowohl\u00a0f\u00fcr\u00a0die\u00a0Mono\u2010\u00a0al s\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0\nKombinationstherapie\u00a0 10\u00a0mg,\u00a0 die\u00a0 jedoch\u00a0 bei\u00a0 guter\u00a0 Vertr\u00e4glichkei t\u00a0 und\u00a0 solider\u00a0\nNierenfunktion\u00a0(eGFR\u00a0\u2265\u00a060\u00a0ml/min/1,73\u00a0m2)\u00a0auf\u00a025\u00a0mg\u00a0erh\u00f6ht\u00a0werden\u00a0kann,\u00a0wenn\u00a0\neine\u00a0engere\u00a0Blutzuckerkontrolle\u00a0i ndiziert\u00a0ist\u00a0(Boehringer\u00a0Ingel heim,\u00a02017).\u00a0\nWeiterhin\u00a0 stand\u00a0 mit\u00a0 Synjardy\u00ae\u00a0 seit\u00a0 Mai\u00a0 2015\u00a0 eine\u00a0 Fixkombination \u00a0a u s \u00a0E m p a \u2010\ngliflozin\u00a0und\u00a0Metformin\u00a0f\u00fcr\u00a0die\u00a0antidiabetische\u00a0Therapie\u00a0zur\u00a0Ve rf\u00fcgung.\u00a0Die\u00a0Zulas\u2010\nsung\u00a0sah\u00a0eine\u00a0Behandlung\u00a0von\u00a0Patienten,\u00a0die\u00a0unter\u00a0der\u00a0maximal\u00a0v ertr\u00e4glichen\u00a0\nDosis\u00a0von\u00a0Metformin\u00a0allein\u00a0oder\u00a0 in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0blut zuckersenkenden\u00a0\nArzneimitteln,\u00a0 einschlie\u00dflich\u00a0 Insulin,\u00a0 unzureichend\u00a0 eingestellt \u00a0 werden\u00a0 konnten\u00a0\nbzw.\u00a0die\u00a0bereits\u00a0eine\u00a0Kombination\u00a0aus\u00a0Empagliflozin\u00a0und\u00a0Metform in\u00a0in\u00a0Form\u00a0ge\u2010\ntrennter\u00a0Tabletten\u00a0erhalten\u00a0hatten\u00a0(EMA\u00a02015b).\u00a0Nachdem\u00a0der\u00a0G\u2010B A\u00a0im\u00a0Septem\u2010\nber\u00a02016\u00a0keinen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0(G\u2010BA\u00a02016a)\u00a0fests tellte,\u00a0reagierte\u00a0\nder\u00a0pU\u00a0mit\u00a0der\u00a0Einstellung\u00a0des\u00a0Vertriebs\u00a0in\u00a0Deutschland\u00a0zum\u00a001. 11.2016.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet \u00a0\nUngef\u00e4hr\u00a0422\u00a0Mio.\u00a0Menschen\u00a0weltweit\u00a0haben\u00a0Diabetes\u00a0(WHO,\u00a02016). \u00a0In\u00a0Deutsch\u2010\nland\u00a0haben\u00a07,4\u00a0%\u00a0bei\u00a0einer\u00a0Gesamt bev\u00f6lkerung\u00a0von\u00a0ca.\u00a080,7\u00a0Mio.\u00a0 Menschen\u00a0Dia\u2010\nbetes\u00a0(WHO,\u00a02017),\u00a0von\u00a0diesen\u00a0wie derum\u00a0\u2013\u00a0unter\u00a0Ber\u00fccksichtigung \u00a0einer\u00a0Dunkel\u2010\nziffer\u00a0von\u00a0zwei\u00a0Mio.\u00a0Menschen\u00a0\u2013\u00a0betr\u00e4gt\u00a0der\u00a0Anteil\u00a0an\u00a0Typ\u20102\u2010Dia betes\u2010Erkrankten\u00a0\nsch\u00e4tzungsweise\u00a095\u00a0%\u00a0(Tamayo\u00a0&\u00a0Rathmann,\u00a02016).\u00a0Nicht\u00a0zuletzt\u00a0a ufgrund\u00a0der\u00a0\nInstallation\u00a0 eines\u00a0 Disease\u2010Management\u2010Programmes \u00a0( D M P ) \u00a0f \u00fc r \u00a0T y p \u2010 1 \u00a0u n d \u00a0\u2010 2 \u2010\nDiabetes\u00a0ist\u00a0die\u00a0Generierung\u00a0epidemiologischer\u00a0Daten\u00a0f\u00fcr\u00a0das\u00a0Bu ndesgebiet\u00a0be\u2010205\u00a0g\u00fcnstigt.\u00a0Anhand\u00a0der\u00a0Ergebnisse\u00a0ist\u00a0eine\u00a0Tendenz\u00a0zur\u00a0\u00dcberdiagno stik\u00a0zu\u00a0vermuten,\u00a0\ndie\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0hohe\u00a0Erkrankungspr\u00e4valenz\u00a0ber\u00fccksichtig t\u00a0werden\u00a0sollte.\u00a0\nBereits\u00a0seit\u00a02012\u00a0sehen\u00a0die\u00a0amerikanischen\u00a0und\u00a0europ\u00e4ischen\u00a0Gui delines\u00a0f\u00fcr\u00a0Typ\u2010\n2\u2010Diabetes\u00a0keine\u00a0Titration\u00a0auf\u00a0e inen\u00a0HbA1c\u00a0von\u00a0<\u00a06,5\u00a0vor,\u00a0sonde rn\u00a0definieren\u00a0einen\u00a0\npatientenindividuellen\u00a0Zielkorrid or\u00a0von\u00a07,5\u00a0\u2013\u00a08,0\u00a0%\u00a0oder\u00a0h\u00f6her\u00a0 (Inzucchi\u00a0et\u00a0al.,\u00a0\n2012).\u00a0 Auch\u00a0 die\u00a0 Nationale\u00a0 Versorgungsleitlinie\u00a0 Typ\u20102\u2010Diabetes\u00a0 b eschreibt\u00a0 eine\u00a0\nSpanne\u00a0von\u00a06,5\u00a0\u2013\u00a07,5\u00a0%\u00a0(NVL,\u00a02013).\u00a0Die\u00a0im\u00a0DMP\u2010Qualit\u00e4tsbericht \u00a02015\u00a0der\u00a0Kas\u2010\nsen\u00e4rztlichen\u00a0Vereinigung\u00a0Nordrh ein\u00a0(KVNo)\u00a0vorgenommene\u00a0Analyse \u00a0der\u00a0Daten\u00a0\nzeigt,\u00a0dass\u00a0eine\u00a0erheblicher\u00a0Anteil,\u00a0im\u00a0Mittel\u00a041,5\u00a0%,\u00a0der\u00a0Pati enten,\u00a0die\u00a0mindestens\u00a0\nein\u00a0halbes\u00a0Jahr\u00a0am\u00a0DMP\u00a0teilnahmen,\u00a0einen\u00a0HbA1c\u00a0<\u00a06,5\u00a0aufwiesen. \u00a0So\u00a0k\u00f6nnten\u00a0\nMenschen\u00a0mit\u00a0Vorstadien\u00a0des\u00a0Diabetes,\u00a0mit\u00a0HbA1c\u2010Werten\u00a0im\u00a0Graub ereich\u00a0oder\u00a0\n\u201enicht\u00a0 wirklich\u00a0 n\u00fcchternen\u201c\u00a0 N\u00fcchternblutglukosewerten\u00a0 f\u00e4lschlic herweise\u00a0 die\u00a0\nDiagnose\u00a0Diabetes\u00a0erhalten\u00a0haben.\u00a0Im\u00a0Rahmen\u00a0des\u00a0Gesundheitsmoni torings\u00a0des\u00a0\nRobert\u00a0 Koch\u2010Institutes\u00a0 (RKI)\u00a0 durchgef\u00fchrte\u00a0 Befragungen,\u00a0 Untersu chungen\u00a0 und\u00a0\nTests\u00a0von\u00a0ca.\u00a08.000\u00a0Teilnehmern\u00a0im\u00a0Alter\u00a0zwischen\u00a018\u00a0und\u00a079\u00a0Jah ren\u00a0ergab,\u00a0dass\u00a0\nf\u00fcr\u00a07,2\u00a0%\u00a0der\u00a0deutschen\u00a0Bev\u00f6lker ung\u00a0ein\u00a0diagnostizierter\u00a0Diabet es\u00a0vorliegt\u00a0(Hei\u2010\ndemann\u00a0et\u00a0al.,\u00a02013),\u00a01998\u00a0zeigte\u00a0der\u00a0Bundessurvey\u00a0des\u00a0RKI\u00a0noch \u00a0eine\u00a0Pr\u00e4valenz\u00a0\nvon\u00a05,2\u00a0%.\u00a0Bezogen\u00a0auf\u00a0die\u00a0Anzah l\u00a0der\u00a0Betroffenen\u00a0entspricht\u00a0da s\u00a0einer\u00a0Erh\u00f6hung\u00a0\ndes\u00a0Anteils\u00a0um\u00a0etwa\u00a038\u00a0%.\u00a0Etwa\u00a0ein\u00a0Drittel\u00a0des\u00a0beobachteten\u00a0Ans tiegs\u00a0wird\u00a0auf\u00a0\nden\u00a0demografischen\u00a0Wandel\u00a0zur\u00fcck gef\u00fchrt,\u00a0w\u00e4hrend\u00a0f\u00fcr\u00a0den\u00a0Hauptt eil\u00a0urs\u00e4chlich\u00a0\nein\u00a0Zusammenspiel\u00a0verschiedener\u00a0 Faktoren\u00a0wie\u00a0Ver\u00e4nderung\u00a0des\u00a0Le bensstils\u00a0so\u2010\nwie\u00a0der\u00a0Lebensbedingungen\u00a0wie\u00a0z.B.\u00a0vermehrte\u00a0Schadstoffexpositi on\u00a0vermutet\u00a0\nwird\u00a0(Tamayo\u00a0&\u00a0Rathmann,\u00a02016).\u00a0Die\u00a0Erkrankungsh\u00e4ufigkeit\u00a0nimmt \u00a0mit\u00a0dem\u00a0Alter\u00a0\nzu.\u00a0W\u00e4hrend\u00a0die\u00a0Pr\u00e4valenz\u00a0des\u00a0Ty p\u20102\u2010Diabetes\u00a0bei\u00a0den\u00a0Befragten\u00a0 zwischen\u00a040\u00a0und\u00a0\n59\u00a0Jahren\u00a0zwischen\u00a04\u00a0und\u00a010\u00a0%\u00a0lag,\u00a0stieg\u00a0der\u00a0Wert\u00a0in\u00a0der\u00a0Alters gruppe\u00a0zwischen\u00a070\u00a0\nund\u00a079\u00a0Jahren\u00a0auf\u00a0\u00fcber\u00a020\u00a0%\u00a0an\u00a0(Heidemann\u00a0et\u00a0al.,\u00a02013).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0klinische\u00a0Wirksamkeit\u00a0und\u00a0Si cherheit\u00a0wurde\u00a0in\u00a0elf\u00a0vom\u00a0pU\u00a0fi nanzierten\u00a0doppel\u2010\nblinden,\u00a0 placebo\u2010\u00a0 und\u00a0 aktivkontrollierten\u00a0 klinischen\u00a0 Studien\u00a0 un tersucht\u00a0 (EMA,\u00a0\n2016a).\u00a0 Gegen\u00fcber\u00a0 Placebo\u00a0 senkte\u00a0 E mpagliflozin\u00a0 den\u00a0 HbA1c\u2010Wert\u00a0 u m\u00a0\n0,74\u00a0%(10\u00a0mg)\u00a0bis\u00a00,85\u00a0%\u00a0(25\u00a0mg)\u00a0(EMPA\u2010REG\u00a0MONO,\u00a0Roden\u00a0et\u00a0al.,\u00a0 2013)\u00a0und\u00a0\nzeigte\u00a0damit\u00a0\u00e4hnlich\u00a0starke\u00a0Effekte\u00a0wie\u00a0Dapagliflozin\u00a0mit\u00a00,66\u00a0 %\u00a0(Ferrannini\u00a0et\u00a0al.,\u00a0\n2010)\u00a0und\u00a0Canagliflozin\u00a0um\u00a00,91\u00a0bis\u00a01,16\u00a0%\u00a0(Stenl\u00f6f\u00a0et\u00a0al.,\u00a0201 4).\u00a0Im\u00a0Vergleich\u00a0der\u00a0\nKombinationstherapie\u00a0mit\u00a0Metformin\u00a0erzielte\u00a0mit\u00a0Glimepirid\u00a0(Rid derstr\u00e5le\u00a0et\u00a0al.,\u00a0\n2014)\u00a0 zeigte\u00a0 innerhalb\u00a0 des\u00a0 Beobachtungszeitraums\u00a0 von\u00a0 zwei\u00a0 Jahre n\u00a0 f\u00fcr\u00a0 Em\u2010\npagliflozin\u00a0eine\u00a0um\u00a00,11\u00a0%\u00a0st\u00e4rkere\u00a0Senkung\u00a0des\u00a0HbA1c,\u00a0eine\u00a0h\u00f6h ere\u00a0Reduktion\u00a0\ndes\u00a0K\u00f6rpergewichts\u00a0(\u2010\u00a04,5\u00a0kg)\u00a0so wie\u00a0geringere\u00a0Inzidenz\u00a0von\u00a0Hypo glyk\u00e4mien\u00a0(1,24\u00a0%\u00a0\nvs.\u00a012,11\u00a0%),\u00a0wohingegen\u00a0schwerwiegende\u00a0unerw\u00fcnschte\u00a0Ereignisse \u00a0h\u00e4ufiger\u00a0auf\u2010\ntraten\u00a0(16\u00a0%\u00a0vs.\u00a011\u00a0%).\u00a0Die\u00a0Arzneimittelkommission\u00a0der\u00a0deutsche n\u00a0\u00c4rzteschaft\u00a0206\u00a0(Akd\u00c4)\u00a0leitet\u00a0eine\u00a0vergleichbare\u00a0Wirksamkeit\u00a0ab,\u00a0schlie\u00dft\u00a0jedoc h\u00a0eine\u00a0Verzerrung\u00a0\nder\u00a0Ergebnisse\u00a0hin\u00a0zur\u00a0Untersch\u00e4tzung\u00a0der\u00a0Behandlungseffekte\u00a0vo n\u00a0Glimepirid\u00a0\naufgrund\u00a0methodischer\u00a0Unstimmigkeiten\u00a0nicht\u00a0aus\u00a0(Akd\u00c4,\u00a02014).\u00a0F \u00fcr\u00a0den\u00a0Vergleich\u00a0\nmit\u00a0Sitagliptin\u00a0ergab\u00a0eine\u00a0explorative\u00a0Analyse\u00a0eine\u00a0\u00e4hnliche\u00a0Wi rksamkeit\u00a0(EMPA\u2010\nREG\u00a0MONO,\u00a0Roden\u00a0et\u00a0al.,\u00a02013).\u00a0Der\u00a0Aspekt\u00a0der\u00a0gesundheitsbezoge nen\u00a0Lebens\u2010\nqualit\u00e4t\u00a0wurde\u00a0in\u00a0den\u00a0zulassungsbegr\u00fcndenden\u00a0Studien\u00a0nicht\u00a0gezi elt\u00a0untersucht,\u00a0\nsodass\u00a0eine\u00a0Einsch\u00e4tzung\u00a0nicht\u00a0m\u00f6glich\u00a0ist.\u00a0Der\u00a0Beurteilung\u00a0der \u00a0klinischen\u00a0Sicher\u2010\nheit\u00a0wurde\u00a0im\u00a0Europ\u00e4ischen\u00a0 \u00d6ffentlichen\u00a0Beurteilungsbericht\u00a0( European\u00a0 Public\u00a0\nAssessment\u00a0Report ,\u00a0EPAR)\u00a0eine\u00a0Analyse\u00a0der\u00a0gepoolten\u00a0Daten\u00a0s\u00e4mtlicher\u00a0zulas\u2010\nsungsbegr\u00fcndender\u00a0Phase\u00a0III\u00a0Studien\u00a0mit\u00a0einem\u00a0Patientenkollekti v\u00a0von\u00a0 12.873\u00a0\nzugrunde\u00a0gelegt.\u00a0Dabei\u00a0traten\u00a0 Adverse\u00a0Events \u00a0(AE)\u00a0wie\u00a0Genitalinfektionen,\u00a0(4,7\u00a0%\u00a0\u2010\u00a0\n4,4\u00a0%\u00a0vs.\u00a0Placebo\u00a01,0\u00a0%),\u00a0bedingt\u00a0durch\u00a0osmotische\u00a0Diurese\u00a0bzw. \u00a0Glucosurie,\u00a0und\u00a0\nHypoglyk\u00e4mien\u00a0(10,9\u00a0\u2013\u00a012,6\u00a0%\u00a0vs .\u00a0Placebo\u00a012,6\u00a0%)\u00a0unter\u00a0Empaglif lozin\u00a0h\u00e4ufiger\u00a0\nauf.\u00a0Dabei\u00a0zeigte\u00a0sich\u00a0in\u00a0der\u00a0Monotherapie\u00a0(<\u00a01\u00a0%)\u00a0(Roden\u00a0et\u00a0al .,\u00a02013)\u00a0ein\u00a0geringe\u2010\nres\u00a0Risiko\u00a0f\u00fcr\u00a0Unterzuckerungen\u00a0als\u00a0in\u00a0der\u00a0Kombination\u00a0mit\u00a0Metf ormin\u00a0und\u00a0einem\u00a0\nSulfonylharnstoff\u00a0(11,5\u00a0\u2013\u00a016,1\u00a0%)\u00a0(H\u00e4ring\u00a0et\u00a0al.,\u00a02013)\u00a0oder\u00a0In sulin\u00a0(19,5%\u00a0\u2010\u00a028,4\u00a0%)\u00a0\n(NCT01011868).\u00a0Mit\u00a0der\u00a0wirkmechanistisch\u00a0bedingten\u00a0osmotischen\u00a0 Diurese\u00a0bzw.\u00a0\nGlucosurie\u00a0sind\u00a0auch\u00a0h\u00e4ufig\u00a0urogenitale\u00a0Infektionen\u00a0( urinary\u00a0tract\u00a0infections ,\u00a0UTI)\u00a0\nassoziiert\u00a0 (Boehringer\u00a0 Ingelheim,\u00a0 2017).\u00a0 Eine\u00a0 seltene,\u00a0 jedoch\u00a0 s chwerwiegende\u00a0\nKomplikation\u00a0stellen\u00a0Ketoazidosen\u00a0auch\u00a0atypischer\u00a0Auspr\u00e4gung\u00a0da r,\u00a0die\u00a0aufgrund\u00a0\nnormaler\u00a0oder\u00a0nur\u00a0gering\u00a0erh\u00f6hter\u00a0Blutzuckerspiegel\u00a0schwer\u00a0zu\u00a0d iagnostizieren\u00a0\nsind.\u00a0Mit\u00a0dieser\u00a0Problematik\u00a0besch\u00e4ftigte\u00a0sich\u00a0der\u00a0Ausschuss\u00a0f\u00fc r\u00a0Risikobewertung\u00a0\n(Pharmakovigilance\u00a0Risk\u00a0Assessment\u00a0Committee ,\u00a0PRAC)\u00a0der\u00a0EMA),\u00a0der\u00a0Empfehlun\u2010\ngen\u00a0zur\u00a0Minimierung\u00a0des\u00a0Risikos\u00a0herausgab\u00a0(BfArM,\u00a02016).\u00a0In\u00a0ein em\u00a0aktuellen\u00a0\nVerfahren\u00a0zur\u00a0Beurteilung\u00a0des\u00a0Risikos\u00a0von\u00a0Zeh\u2010Amputationen\u00a0w\u00e4hr end\u00a0der\u00a0Thera\u2010\npie\u00a0mit\u00a0SGLT\u20102\u2010Inhibitoren\u00a0steht\u00a0der\u00a0Beschluss\u00a0der\u00a0Europ\u00e4ischen \u00a0Kommission\u00a0noch\u00a0\naus.\u00a0Der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0\nHuman\u00a0Use ,\u00a0CHMP)\u00a0hatte\u00a0die\u00a0in\u00a0den\u00a0Studien\u00a0CANVAS\u00a0und\u00a0CANVAS\u2010R\u00a0erstmals\u00a0\nfestgestellte\u00a0unerw\u00fcnschte\u00a0Wirkung\u00a0urspr\u00fcnglich\u00a0nur\u00a0f\u00fcr\u00a0Canagli flozin\u00a0diskutiert\u00a0\nund\u00a0nachfolgend\u00a0auf\u00a0die\u00a0gesamte\u00a0 Wirkstoffklasse\u00a0ausgeweitet.\u00a0Da mit\u00a0folgte\u00a0das\u00a0\nGremium\u00a0den\u00a0Empfehlungen\u00a0des\u00a0PRA C,\u00a0das\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Produk tinformati\u2010\nonen\u00a0sowie\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Risikoreduktion\u00a0gefordert\u00a0hatte\u00a0(EMA,\u00a0 2017).\u00a0Die\u00a0\nEMPA\u2010REG\u00a0 Outcome\u2010Studie\u00a0(Zinman\u00a0et\u00a0al.,\u00a02015)\u00a0zeigte\u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0von\u00a0Em\u2010\npagliflozin\u00a0im\u00a0Vergleich\u00a0zu\u00a0Plac ebo\u00a0zus\u00e4tzlich\u00a0zur\u00a0Standard\u2010Med ikation\u00a0ein\u00a0signifi\u2010\nkant\u00a0geringeres\u00a0Risiko\u00a0f\u00fcr\u00a0kardiovaskul\u00e4re\u00a0Ereignisse.\u00a0Die\u00a0im\u00a0R ahmen\u00a0von\u00a0Auflagen\u00a0\nder\u00a0 amerikanischen\u00a0 Zulassungsbeh\u00f6rde\u00a0 ( Food\u00a0 and\u00a0 Drug\u00a0 Administration ,\u00a0 FDA)\u00a0\ndurch\u00a0den\u00a0pU\u00a0finanzierte\u00a0Sicherheitsstudie\u00a0detektierte\u00a0bei\u00a0Pati enten\u00a0mit\u00a0bereits\u00a0\nerh\u00f6htem\u00a0kardiovaskul\u00e4rem\u00a0Risiko\u00a0ein\u00a0um\u00a014\u00a0%\u00a0geringeres\u00a0relativ es\u00a0Risiko\u00a0hin\u2010\nsichtlich\u00a0der\u00a0Endpunkte\u00a0kardiovas kul\u00e4r\u00a0bedingter\u00a0Tod,\u00a0nicht\u2010t\u00f6d licher\u00a0Myokardin\u2010\nfarkt\u00a0(ausgenommen\u00a0stummer\u00a0Myok ardinfarkt)\u00a0und\u00a0nicht\u2010t\u00f6dlicher\u00a0 Schlaganfall.\u00a0\nDie\u00a0langfristige\u00a0Senkung\u00a0des\u00a0HbA1c\u2010Werts\u00a0fiel\u00a0dabei\u00a0eher\u00a0gering \u00a0aus.\u00a0Die\u00a0Studien\u2010207\u00a0ergebnisse\u00a0waren\u00a0essentieller\u00a0Bestandteil\u00a0des\u00a0Antrages\u00a0auf\u00a0Zula ssungserweiterung\u00a0\nan\u00a0FDA\u00a0und\u00a0EMA,\u00a0der\u00a0von\u00a0beiden\u00a0Gremien\u00a0umgesetzt\u00a0wurde.\u00a0Die\u00a0Aus sagekraft\u00a0\nbzw.\u00a0Qualit\u00e4t\u00a0der\u00a0Studie\u00a0wurde\u00a0dabei\u00a0heterogen\u00a0bewertet.\u00a0Die\u00a0FD A\u00a0nennt\u00a0in\u00a0ihrem\u00a0\nDossier\u00a0(FDA,\u00a02016)\u00a0die\u00a0Problematik,\u00a0dass\u00a0nicht\u00a0nachvollziehbar \u00a0sei,\u00a0ob\u00a0stumme\u00a0\nHerzinfarkte\u00a0 von\u00a0 Anfang\u00a0 an\u00a0 vom\u00a0 prim\u00e4ren\u00a0 Endpunkt\u00a0 ausgeschlossen \u00a0 gewesen\u00a0\nw\u00e4ren\u00a0oder\u00a0ob\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0na chtr\u00e4gliche\u00a0\u00c4nderung\u00a0im\u00a0Studien protokoll\u00a0hande\u2010\nle.\u00a0So\u00a0lie\u00dfe\u00a0sich\u00a0nach\u00a0Inklusion\u00a0dieses\u00a0Faktors\u00a0keine\u00a0signifika nte\u00a0\u00dcberlegenheit\u00a0\ngegen\u00fcber\u00a0Placebo\u00a0mehr\u00a0feststellen.\u00a0Auch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Quali t\u00e4t\u00a0und\u00a0Wirtschaft\u2010\nlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0(IQWiG)\u00a0\u00e4u\u00dferte\u00a0sich\u00a0bezugnehmend\u00a0 auf\u00a0regionale\u00a0\nUnterschiede\u00a0der\u00a0multinational\u00a0erhobenen\u00a0Daten\u00a0skeptisch\u00a0und\u00a0be zweifelte\u00a0die\u00a0\n\u00dcbertragbarkeit\u00a0der\u00a0Ergebnisse\u00a0a uf\u00a0die\u00a0deutsche\u00a0Behandlungsprax is.\u00a0So\u00a0zeigte\u00a0die\u00a0\nSubgruppenanalyse\u00a0f\u00fcr\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0kardiovaskul\u00e4r\u00a0bedi ngter\u00a0Tod\u00a0aus\u2010\nschlie\u00dflich\u00a0positive\u00a0Effekte\u00a0f\u00fcr\u00a0 Studienzentren\u00a0in\u00a0Lateinamerik a\u00a0(HR\u00a00,58\u00a0\u2013\u00a00,89),\u00a0\nAfrika\u00a0(HR\u00a00,86)\u00a0und\u00a0Asien\u00a0(HR\u00a00,70),\u00a0w\u00e4hrend\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0euro p\u00e4ischen\u00a0Raum\u00a0\nNachteile\u00a0im\u00a0Verh\u00e4ltnis\u00a0st\u00e4rker\u00a0zeigten\u00a0(HR\u00a01,02)\u00a0(Zinman\u00a0et\u00a0al .,\u00a02015).\u00a0Weiterhin\u00a0\nbeschr\u00e4nkt\u00a0sich\u00a0der\u00a0nachgewiesene\u00a0Nutzen\u00a0nur\u00a0auf\u00a0Teilnehmer\u00a0\u2265\u00a06 5\u00a0Jahre\u00a0(HR\u00a01,04\u00a0\nvs.\u00a00,71)\u00a0mit\u00a0einem\u00a0HbA1c\u00a0<\u00a08,5\u00a0%\u00a0(0,76\u00a0vs.\u00a01,14)\u00a0(Zinman\u00a0et\u00a0al .,\u00a02015).\u00a0In\u00a0diesem\u00a0\nZusammenhang\u00a0bleiben\u00a0die\u00a0Ergebnisse\u00a0der\u00a0Langzeitstudien\u00a0zu\u00a0Dapa gliflozin\u00a0NCT01\u00a0\n730534\u00a0und\u00a0Canagliflozin\u00a0NCT0103\u00a02629\u00a0abzuwarten,\u00a0die\u00a0insbesond ere\u00a0im\u00a0Hinblick\u00a0\nauf\u00a0einen\u00a0m\u00f6glichen\u00a0Klasseneffek t\u00a0in\u00a0die\u00a0Beurteilung\u00a0zu\u00a0integri eren\u00a0sind.\u00a0\u00a0\nLeitlinienempfehlungen \u00a0\nDie\u00a0 aktuelle\u00a0 Nationale\u00a0 Versorgungsleitlinie\u00a0 (NVL)\u00a0 wurde\u00a0 unter\u00a0 B eteiligung\u00a0 ver\u2010\nschiedener\u00a0Institutionen\u00a0erarbeitet.\u00a0Erstmalig\u00a0enth\u00e4lt\u00a0diese\u00a0ei nen\u00a0Therapiealgo\u2010\nrithmus,\u00a0der\u00a0zwei\u00a0unterschiedlich e\u00a0Stufenschemata\u00a0beschreibt\u00a0un d\u00a0gleicherma\u00dfen\u00a0\nempfiehlt\u00a0(B\u00c4K,\u00a0KBV,\u00a0AWMF,\u00a02013).\u00a0Diese\u00a0Entscheidung\u00a0beruht\u00a0auf \u00a0dem\u00a0Dissens\u00a0\nzwischen\u00a0Akd\u00c4\u00a0und\u00a0Deutscher\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Allgemeinmedizin\u00a0u nd\u00a0Familienme\u2010\ndizin\u00a0(DEGAM)\u00a0auf\u00a0der\u00a0einen\u00a0Seite\u00a0und\u00a0der\u00a0Deutschen\u00a0Diabetes\u00a0Ge sellschaft\u00a0(DDG)\u00a0\nund\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Innere\u00a0Medizin\u00a0(DGIM)\u00a0auf\u00a0de r\u00a0anderen\u00a0Seite.\u00a0\nIn\u00a0einem\u00a0Informationsschreiben\u00a0gehen\u00a0die\u00a0Herausgeber\u00a0auf\u00a0die\u00a0be stehende\u00a0Prob\u2010\nlematik\u00a0ein\u00a0und\u00a0benennen\u00a0ihre\u00a0jeweiligen\u00a0Beweggr\u00fcnde\u00a0(B\u00c4K,\u00a0KBV, \u00a0AWMF,\u00a02015).\u00a0\nAkd\u00c4\u00a0und\u00a0DEGAM\u00a0empfehlen\u00a0vorrang ig\u00a0Wirkstoffe,\u00a0die\u00a0in\u00a0Studien\u00a0g ezeigt\u00a0haben,\u00a0\ndass\u00a0sie\u00a0klinische\u00a0Endpunkte\u00a0wirksam\u00a0beeinflussen\u00a0k\u00f6nnen,\u00a0sodas s\u00a0ein\u00a0signifikanter\u00a0\nEinfluss\u00a0auf\u00a0mikro\u2010\u00a0und/oder\u00a0makrovaskul\u00e4re\u00a0Ereignisse\u00a0belegt\u00a0i st.\u00a0Liegt\u00a0allein\u00a0der\u00a0\nNachweis\u00a0f\u00fcr\u00a0eine\u00a0Senkung\u00a0des\u00a0HbA1c\u2010Wertes\u00a0eines\u00a0Wirkstoffes\u00a0vo r,\u00a0wird\u00a0dieser\u00a0\nnachrangig\u00a0empfohlen,\u00a0da\u00a0f\u00fcr\u00a0die\u00a0Organisationen\u00a0nicht\u00a0ersichtli ch\u00a0sei,\u00a0ob\u00a0Folge\u2010\nsch\u00e4den\u00a0des\u00a0Diabetes\u00a0positiv\u00a0beeinflusst\u00a0w\u00fcrden.\u00a0F\u00fcr\u00a0DGIM\u00a0und\u00a0D DG\u00a0hingegen\u00a0ist\u00a0\nma\u00dfgeblich,\u00a0dass\u00a0einige\u00a0neue\u00a0oral e\u00a0Antidiabetika\u00a0ein\u00a0geringeres \u00a0Risiko\u00a0f\u00fcr\u00a0Hy\u2010\npoglyk\u00e4mien\u00a0und\u00a0damit\u00a0ein\u00a0g\u00fcnstigeres\u00a0Nebenwirkungsprofil\u00a0aufwi esen\u00a0als\u00a0Sul\u2010\nfonylharnstoffe,\u00a0deren\u00a0Wirksamkeitsnachweise\u00a0sie\u00a0dar\u00fcber\u00a0hinaus \u00a0kritisch\u00a0bewer\u2010208\u00a0ten.\u00a0Einigkeit\u00a0besteht\u00a0unter\u00a0den \u00a0Experten,\u00a0dass\u00a0f\u00fcr\u00a0Patienten,\u00a0 die\u00a0das\u00a0individuell\u00a0\nvereinbarte\u00a0 HbA1c\u2010Ziel\u00a0 durch\u00a0 Lebensstil\u00e4nderungen\u00a0 nicht\u00a0 erreich en\u00a0 konnten,\u00a0\nMetformin\u00a0das\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl\u00a0ist.\u00a0Bei\u00a0ungen\u00fcgendem\u00a0Ansp rechen\u00a0auf\u00a0die\u00a0\nMonotherapie\u00a0nennen\u00a0Akd\u00c4\u00a0und\u00a0DEGA M\u00a0drei\u00a0gleichwertige\u00a0m\u00f6gliche\u00a0 Therapieop\u2010\ntionen,\u00a0die\u00a0eine\u00a0Kombination\u00a0von\u00a0Metformin\u00a0mit\u00a0Insulin,\u00a0Glibenc lamid\u00a0oder\u00a0einem\u00a0\nDipeptidypeptidase\u2010Inhibitor\u00a0vorsehen.\u00a0Die\u00a0jeweilige\u00a0Kombinatio n\u00a0kann\u00a0bei\u00a0einer\u00a0\nnicht\u00a0ausreichenden\u00a0Blutzuckersenkung\u00a0auf\u00a0eine\u00a0Monotherapie\u00a0mit \u00a0Insulin\u00a0umge\u2010\nstellt\u00a0 werden.\u00a0 Demgegen\u00fcber\u00a0 ford ern\u00a0 die\u00a0 diabetischen\u00a0 Fachgesell schaften\u00a0 bei\u00a0\nerfolgloser\u00a0Metformin\u2010Behandlung\u00a0e ine\u00a0nach\u00a0Patientenpr\u00e4ferenz\u00a0u nd\u00a0Therapiezie\u2010\nlen\u00a0ausgew\u00e4hlte\u00a0Kombination\u00a0zweier\u00a0oraler\u00a0Antidiabetika.\u00a0Prinzi piell\u00a0k\u00f6nnten\u00a0nach\u00a0\nAnsicht\u00a0der\u00a0diabetischen\u00a0Fachgesellschaften\u00a0alle\u00a0verf\u00fcgbaren\u00a0Su bstanzen\u00a0kombi\u2010\nniert\u00a0werden,\u00a0wobei\u00a0der\u00a0Einsatz\u00a0von\u00a0Sulfonylharnstoffen\u00a0aufgrun d\u00a0bestehender\u00a0\nHinweise\u00a0 auf\u00a0 eine\u00a0 m\u00f6glicherweise\u00a0 erh\u00f6hte\u00a0 kardiovaskul\u00e4re\u00a0 Mortal it\u00e4t\u00a0 kritisch\u00a0\nbewertet\u00a0wird.\u00a0Die\u00a0NVL\u00a0wurde\u00a0im\u00a0August\u00a02013\u00a0ver\u00f6ffentlicht\u00a0und\u00a0 zuletzt\u00a0im\u00a0No\u2010\nvember\u00a0 2014\u00a0 aktualisiert.\u00a0 Folglich\u00a0 reflektieren\u00a0 die\u00a0 formulierte n\u00a0 Empfehlungen\u00a0\nnicht\u00a0in\u00a0allen\u00a0Punkten\u00a0die\u00a0derzeitige\u00a0Evidenz.\u00a0Bereits\u00a02013\u00a0ver \u00f6ffentlichten\u00a0Hem\u2010\nmingsen\u00a0et\u00a0al.\u00a0einen\u00a0Cochrane\u2010\u00a0R eview,\u00a0in\u00a0dem\u00a0die\u00a0Autoren\u00a0Sulfo nylharnstoffen\u00a0\ngegen\u00fcber\u00a0Metformin\u00a0weniger\u00a0nicht\u00a0 t\u00f6dliche\u00a0makrovaskul\u00e4re\u00a0Kompl ikationen\u00a0(RR\u00a0\n0,67,\u00a095%\u00a0CI\u00a00,48\u00a0bis\u00a00,93;\u00a0P=0.02;\u00a0n=3018;\u00a03\u00a0Studien)\u00a0sowie\u00a0ke ine\u00a0signifikanten\u00a0\nUnterschiede\u00a0bez\u00fcglich\u00a0der\u00a0kardiovaskul\u00e4ren\u00a0Tode\u00a0(RR\u00a01,47;\u00a095%\u00a0 CI\u00a00,54\u00a0bis\u00a04,01;\u00a0\nP=0,45;\u00a0n=3528;\u00a06\u00a0Studien)\u00a0postulierten.\u00a0Auch\u00a0eine\u00a0weitere\u00a0\u00dcber sichtsarbeit\u00a0(Pal\u2010\nmer\u00a0et\u00a0al.,\u00a02016)\u00a0formulierte\u00a0keinen\u00a0Nachteil\u00a0im\u00a0Vergleich\u00a0zu\u00a0a nderen\u00a0Antidiabeti\u2010\nka.\u00a0Bei\u00a0unzureichendem\u00a0Erfolg\u00a0sie ht\u00a0die\u00a0Empfehlung\u00a0der\u00a0beiden\u00a0F achgesellschaften\u00a0\neine\u00a0Dreierkombination\u00a0verschiedener\u00a0Antidiabetika\u00a0einschlie\u00dfli ch\u00a0der\u00a0GLP\u20101\u00a0Ago\u2010\nnisten\u00a0oder\u00a0die\u00a0Umstellung\u00a0auf\u00a0e ine\u00a0Monotherapie\u00a0mit\u00a0Insulin\u00a0vo r.\u00a0\u00a0\nSGLT\u20102\u2010Inhibitoren\u00a0listet\u00a0die\u00a0NVL\u00a0unter\u00a0den\u00a0Medikamenten\u00a0ohne\u00a0g esicherte\u00a0g\u00fcns\u2010\ntige\u00a0Beeinflussung\u00a0klinischer\u00a0Endpunkte.\u00a0Diese\u00a0Einsch\u00e4tzung\u00a0ber \u00fccksichtigt\u00a0nicht\u00a0\nden\u00a0aktuellen\u00a0Kenntnisstand.\u00a0Die\u00a0Ergebnisse\u00a0der\u00a0EMPA\u2010REG\u00a0 Outcome\u2010Studie\u00a0(Zin\u2010\nman\u00a0et\u00a0al.,\u00a02015)\u00a0bewirkten\u00a0auf\u00a0internationaler\u00a0Ebene\u00a0eine\u00a0Neub ewertung\u00a0des\u00a0\nWirkstoffs\u00a0Empagliflozin.\u00a0So\u00a0erfolgte\u00a0im\u00a0Mai\u00a02016\u00a0die\u00a0Integrati on\u00a0der\u00a0Substanz\u00a0in\u00a0\ndie\u00a0\u00fcberarbeitete\u00a0Leitlinie\u00a0zur\u00a0B ehandlung\u00a0der\u00a0Herzinsuffizienz \u00a0durch\u00a0die\u00a0 European\u00a0\nSociety\u00a0of\u00a0Cardiology \u00a0(ESC)\u00a0(Ponikowski\u00a0et\u00a0al.,\u00a02016).\u00a0Die\u00a0Handlungsempfehlung\u00a0\nsieht\u00a0den\u00a0Einsatz\u00a0des\u00a0SGLT\u20102\u2010Inhibitors\u00a0bei\u00a0Patienten\u00a0mit\u00a0Typ\u20102 \u2010Diabetes\u00a0vor,\u00a0und\u00a0\nverweist\u00a0auf\u00a0protektive\u00a0bzw.\u00a0l ebensverl\u00e4ngernde\u00a0Effekte.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIm\u00a0Mai\u00a02015\u00a0wurde\u00a0der\u00a0Zusatznutzen\u00a0von\u00a0Empagliflozin\u00a0durch\u00a0den\u00a0 G\u2010BA\u00a0f\u00fcr\u00a0f\u00fcnf\u00a0\nPatientengruppen\u00a0bewertet.\u00a0Als\u00a0z weckm\u00e4\u00dfige\u00a0Vergleichstherapien\u00a0 (zVT)\u00a0wurden\u00a0\nf\u00fcr\u00a0die\u00a0Monotherapie\u00a0mit\u00a0Empagliflozin\u00a0die\u00a0Behandlung\u00a0mit\u00a0Sulfo nylharnstoffen,\u00a0\nf\u00fcr\u00a0die\u00a0Kombination\u00a0mit\u00a0einem\u00a0a nderen\u00a0Antidiabetikum\u00a0Metformin\u00a0 oder\u00a0Sulfonyl\u2010209\u00a0harnstoffe\u00a0und\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0mit\u00a0mindestens\u00a0zwei\u00a0weiteren \u00a0blutzuckersen\u2010\nkenden\u00a0Arzneimitteln\u00a0Metformin\u00a0und\u00a0Insulin\u00a0festgelegt\u00a0(G\u2010BA,\u00a020 15).\u00a0Lediglich\u00a0f\u00fcr\u00a0\ndie\u00a0Kombination\u00a0Empagliflozin/Metformin\u00a0legte\u00a0der\u00a0pU\u00a0Daten\u00a0vor. \u00a0Die\u00a0vorgelegte\u00a0\nInterimsanalyse\u00a0 der\u00a0 multizentrischen,\u00a0 doppelblinden,\u00a0 randomisie rten\u00a0 Studie\u00a0\n1245.28\u00a0(EMPA\u2010REG\u00a0H2H\u2010SU,\u00a0Ridderstr\u00e5le\u00a0et\u00a0al.,\u00a02014)\u00a0untersucht \u00a0im\u00a0direkten\u00a0\nVergleich\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0von\u00a0Empagliflozin\u00a0in\u00a0K ombination\u00a0mit\u00a0\nMetformin\u00a0 gegen\u00fcber\u00a0 der\u00a0 Zweiertherapie\u00a0 mit\u00a0 Metformin\u00a0 und\u00a0 Glimep irid\u00a0 \u00fcber\u00a0\neinen\u00a0Zeitraum\u00a0von\u00a052\u00a0Wochen.\u00a0De r\u00a0G\u2010BA\u00a0stellte\u00a0methodische\u00a0M\u00e4ng el\u00a0fest,\u00a0die\u00a0\nkeine\u00a0Interpretation\u00a0der\u00a0Ergebnisse\u00a0hinsichtlich\u00a0der\u00a0Hypoglyk\u00e4m ierate\u00a0sowie\u00a0hin\u2010\nsichtlich\u00a0des\u00a0Auftretens\u00a0nicht\u2010s chwerwiegender\u00a0(u.a.\u00a0Erkrankung en\u00a0der\u00a0Nieren\u00a0und\u00a0\nder\u00a0 Harnwege\u00a0 sowie\u00a0 Genitalinfekt ionen)\u00a0 und\u00a0 schwerwiegender\u00a0 uner w\u00fcnschter\u00a0\nArzneimittelereignisse\u00a0(UAE)\u00a0zulie\u00dfen.\u00a0Weiterhin\u00a0fehlten\u00a0die\u00a0in \u00a0Anbetracht\u00a0des\u00a0\nchronischen\u00a0Krankheitsverlaufes\u00a0 notwendigen\u00a0Langzeitdaten\u00a0sowoh l\u00a0zu\u00a0patienten\u2010\nrelevanten\u00a0Endpunkten\u00a0wie\u00a0Gesamt mortalit\u00e4t\u00a0und\u00a0Lebensqualit\u00e4t\u00a0a ls\u00a0auch\u00a0zum\u00a0\ngenerellen\u00a0 Sicherheitsprofil.\u00a0 Folglich\u00a0 sah\u00a0 das\u00a0 Gremium\u00a0 keinen\u00a0 B eleg\u00a0 f\u00fcr\u00a0 einen\u00a0\nZusatznutzen.\u00a0Auf\u00a0Antrag\u00a0des\u00a0pU\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02016\u00a0ein\u00a0erneutes \u00a0Bewertungs\u2010\nverfahren\u00a0eingeleitet,\u00a0wof\u00fcr\u00a0unter\u00a0anderem\u00a0die\u00a0Ergebnisse\u00a0der\u00a0E MPA\u2010REG\u00a0 Outco\u2010\nme\u2010Studie\u00a0vorgelegt\u00a0wurden.\u00a0Dabei\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0randomi sierte,\u00a0drei\u2010\narmige,\u00a0placebokontrollierte,\u00a0mul tizentrische\u00a0Studie,\u00a0die\u00a07.028 \u00a0Patienten\u00a0mit\u00a0einer\u00a0\nmanifesten\u00a0kardiovaskul\u00e4ren\u00a0Erkrankung\u00a0und\u00a0bisher\u00a0unzureichende r\u00a0Blutzucker\u2010\nkontrolle\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0242\u00a0Wochen\u00a0beobachtete.\u00a0Die\u00a0E inteilung\u00a0der\u00a0\nPatientengruppen\u00a0sowie\u00a0die\u00a0zVT\u00a0wurden\u00a0aus\u00a0dem\u00a0vorausgegangenen\u00a0 Verfahren\u00a0\n\u00fcbernommen\u00a0und\u00a0um\u00a0eine\u00a0weitere\u00a0Partizipation\u00a0der\u00a0jeweiligen\u00a0Kol lektive\u00a0in\u00a01)\u00a0\nohne\u00a0und\u00a02)\u00a0mit\u00a0kardiovaskul\u00e4re/r\u00a0Erkrankung\u00a0erg\u00e4nzt.\u00a0F\u00fcr\u00a0erste re\u00a0wurden\u00a0keine\u00a0\nDaten\u00a0vorgelegt,\u00a0sodass\u00a0ein\u00a0Zusatznutzen\u00a0nicht\u00a0belegt\u00a0werden\u00a0ko nnte.\u00a0F\u00fcr\u00a0Patien\u2010\nten\u00a0mit\u00a0manifester\u00a0kardiovaskul\u00e4rer\u00a0Erkrankung\u00a0stellte\u00a0der\u00a0G\u2010BA \u00a0f\u00fcr\u00a0die\u00a0Behand\u2010\nlung\u00a0mit\u00a0Empagliflozin\u00a0mit\u00a0einem\u00a0oder\u00a0mehreren\u00a0oralen\u00a0Antidiabe tika\u00a0und/oder\u00a0\nInsulin\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutze n\u00a0fest,\u00a0der\u00a0aus\u00a0den\u00a0\nstatistisch\u00a0signifikanten\u00a0Vorteilen\u00a0f\u00fcr\u00a0die\u00a0Endpunkte\u00a0Gesamtmor talit\u00e4t,\u00a0Herzinsuffi\u2010\nzienz,\u00a0Nierenversagen\u00a0sowie\u00a0Beginn\u00a0einer\u00a0dauerhaften\u00a0Nierenersa tztherapie\u00a0abge\u2010\nleitet\u00a0wurde.\u00a0Nachteile\u00a0hinsichtlich\u00a0\u00a0des\u00a0Auftretens\u00a0von\u00a0Genita linfektionen\u00a0recht\u2010\nfertigten\u00a0nach\u00a0Ansicht\u00a0des\u00a0Gremiums\u00a0keine\u00a0Herabstufung\u00a0des\u00a0Ausm a\u00dfes\u00a0des\u00a0Zu\u2010\nsatznutzens\u00a0(G\u2010BA,\u00a02016b).\u00a0Einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringe n\u00a0Zusatznutzen\u00a0\nstellte\u00a0der\u00a0G\u2010BA\u00a0f\u00fcr\u00a0Patienten\u00a0ohne\u00a0kardiovaskul\u00e4re\u00a0Erkrankung\u00a0 f\u00fcr\u00a0die\u00a0Behand\u2010\nlung\u00a0in\u00a0Kombination\u00a0mit\u00a0Metformin\u00a0fest.\u00a0Damit\u00a0folgte\u00a0die\u00a0Instit ution\u00a0nicht\u00a0der\u00a0\nEinsch\u00e4tzung\u00a0des\u00a0IQWiG,\u00a0das\u00a0die\u00a0Studie\u00a0aufgrund\u00a0mangelnder\u00a0\u00dcber tragbarkeit\u00a0auf\u00a0\ndie\u00a0deutsche\u00a0Behandlungspraxis\u00a0so wie\u00a0regional\u00a0unterschiedlich\u00a0s tark\u00a0ausgepr\u00e4gter\u00a0\nEffekte\u00a0als\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0ungeeignet\u00a0ablehnte\u00a0(IQWiG,\u00a02016) .\u00a0\n\u00a0210\u00a0Versorgungsanalysen\u00a0\nAbbildung\u00a04.16:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Empagliflozin\u00a0je\u00a0M onat\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nMit\u00a0der\u00a0Aufnahme\u00a0des\u00a0Mittels\u00a0in\u00a0die\u00a0Packungsgr\u00f6\u00dfenverordnung\u00a0im \u00a0M\u00e4rz\u00a02015\u00a0\n(DIMDI,\u00a02016),\u00a0stehen\u00a0normierte\u00a0Packungseinheiten\u00a0f\u00fcr\u00a0die\u00a0Dauer therapie\u00a0(N3)\u00a0zur\u00a0\nVerf\u00fcgung\u00a0und\u00a0erm\u00f6glichen\u00a0auch\u00a0e ine\u00a0Versorgung\u00a0\u00fcber\u00a0den\u00a0Zeitrau m\u00a0eines\u00a0voll\u2010\nst\u00e4ndigen\u00a0Quartals.\u00a0Insbesondere\u00a0in\u00a0den\u00a0Abschnitten\u00a0M\u00e4rz\u00a0bis\u00a0Ma i\u00a0und\u00a0Juni\u00a0bis\u00a0\nAugust\u00a02015\u00a0zeigen\u00a0sich\u00a0die\u00a0Auswirkungen\u00a0deutlich\u00a0in\u00a0der\u00a0jeweil s\u00a0r\u00fcckl\u00e4ufigen\u00a0\nAnzahl\u00a0der\u00a0verordneten\u00a0Packungen.\u00a0Ab\u00a0September\u00a02015\u00a0steigen\u00a0die \u00a0Verordnungen\u00a0\u00a0\nstark\u00a0an,\u00a0bis\u00a0sie\u00a0im\u00a0Dezember\u00a02015\u00a0den\u00a0Maximalwert\u00a0erreichen.\u00a0Z eitlich\u00a0l\u00e4sst\u00a0sich\u00a0\nhier\u00a0ein\u00a0Zusammenhang\u00a0zur\u00a0Ver\u00f6ffentlichung\u00a0der\u00a0positiven\u00a0Ergebn isse\u00a0der\u00a0EMPA\u2010\nREG\u2010Outcome\u00a0Studie\u00a0im\u00a0August\u00a02015\u00a0durch\u00a0den\u00a0pU\u00a0herstellen,\u00a0die\u00a0letztendlic h\u00a0zu\u00a0\neiner\u00a0Neubewertung\u00a0von\u00a0Empagliflozin\u00a0f\u00fchrten.\u00a0\u00a0\n\u00a0\u00a0\n211\u00a0Abbildung\u00a04.17:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Empaglif lozin\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\nObgleich\u00a0 das\u00a0 herangezogene\u00a0 Versi chertenkollektiv\u00a0 keinen\u00a0 repr\u00e4se ntativen\u00a0 Aus\u2010\nschnitt\u00a0f\u00fcr\u00a0die\u00a0gesamte\u00a0deutsche\u00a0Bev\u00f6lkerung\u00a0bildet,\u00a0zeigt\u00a0sich \u00a0ein\u00a0dem\u00a0aktuellen\u00a0\nKenntnisstand\u00a0entsprechendes\u00a0Profil\u00a0(Abb.\u00a04.17):\u00a0Die\u00a0Erkrankung sh\u00e4ufigkeit\u00a0nimmt\u00a0\nmit\u00a0dem\u00a0Alter\u00a0zu\u00a0(Heidemann\u00a0et\u00a0al.,\u00a02013).\u00a0In\u00a0Abb.\u00a04.17\u00a0sind\u00a0di e\u00a0meisten\u00a0Versicher\u2010\nten\u00a0mit\u00a0Empagliflozin\u2010Verordnung\u00a0zwischen\u00a050\u00a0und\u00a069\u00a0Jahre\u00a0alt,\u00a0 in\u00a0den\u00a0Altersgrup\u2010\npen\u00a0ab\u00a040\u00a0Jahren\u00a0wird\u00a0Empagliflozin\u00a0ann\u00e4hernd\u00a0doppelt\u00a0so\u00a0oft\u00a0be i\u00a0M\u00e4nnern\u00a0ver\u2010\nordnet.\u00a0\u00a0\nQuellen\u00a0\nAbdul\u2010Ghani\u00a0M,\u00a0Del\u00a0Prato\u00a0S,\u00a0Chilton\u00a0R,\u00a0DeFronzo\u00a0RA\u00a0(2016).\u00a0SGLT 2\u00a0inhibitors\u00a0and\u00a0cardiovascular\u00a0risk:\u00a0lessons\u00a0learned\u00a0from\u00a0the\u00a0\nEMPA\u2010REG\u00a0OUTCOME\u00a0study.\u00a0Diabetes\u00a0Care\u00a039(5):\u00a0717\u2010725.\u00a0\nAkd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0\u00c4rzte\u00a0(2014).\u00a0Neue\u00a0Arzneimitt el,\u00a0Jardiance\u00ae\u00a0(Empagliflozin).\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2015).\u00a0Empagliflozin:\u00a0Erstes\u00a0neues \u00a0orales\u00a0Antidiabetikum\u00a0mit\u00a0Verbesserung\u00a0der\u00a0kardiovaskul\u00e4ren\u00a0\nPrognose\u00a0bei\u00a0Typ\u20102\u2010Diabetikern?\u00a0AMB\u00a049:\u00a082.\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014).\u00a0Neu\u00a0auf\u00a0dem\u00a0Markt.\u00a0SGLT\u20102\u2010Hemmer \u00a0Empagliflozin\u00a0(Jardiance)\u00a0bei\u00a0Typ\u20102\u2010Diabetes.\u00a0a\u2010t\u00a045:\u00a075.\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016).\u00a0Therapiekritik\u00a0Empagliflozin.\u00a0a\u2010 t\u00a047:\u00a065\u201066.\u00a0\nBailey\u00a0CJ\u00a0(2011).\u00a0Renal\u00a0glucose\u00a0reabsorption\u00a0inhibitors\u00a0to\u00a0trea t\u00a0diabetes.\u00a0Trends\u00a0in\u00a0Pharmacological\u00a0Sciences\u00a032(2):\u00a063\u201071.\u00a0\n212\u00a0B\u00c4K\u00a0\u2010\u00a0Bundes\u00e4rztekammer,\u00a0Kassen\u00e4rztliche\u00a0Bundesvereinigung\u00a0(KBV ),\u00a0Arbeitsgemeinschaft\u00a0der\u00a0Wissenschaftlichen\u00a0Medizinischen\u00a0\nFachgesellschaften\u00a0(AWMF)\u00a0(2015).\u00a0NVL\u2010INFO\u00a02015/1.\u00a0Therapie\u00a0des \u00a0Typ\u20102\u2010Diabetes\u00a0\u2013\u00a0Uneinigkeit\u00a0bei\u00a0den\u00a0\nMedikamenten?\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 16).\u00a0Informationsbrief\u00a0zu\u00a0SGLT2\u2010Inhibitoren:\u00a0Aktualisierte\u00a0\nHinweise\u00a0zum\u00a0Risiko\u00a0einer\u00a0diabetischen\u00a0Ketoazidose.\u00a0Stand\u00a0der\u00a0I nformation:\u00a0M\u00e4rz\u00a02016.\u00a0\nhttps://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/\u00a0Phar mako\u00a0\nvigilanz/Risikoinformationen/RI_rhb/2016/info\u2010sglt2.pdf?__blob= publicationFile&v=2,\u00a0letzte r\u00a0Zugriff:\u00a026.04.2017.\u00a0\nBoehringer\u00a0Ingelheim\u00a0(2017).\u00a0Fachinformation\u00a0Jardiance\u00ae,\u00a0Stand\u00a0 der\u00a0Information:\u00a0Januar\u00a02017\u00a0\nhttp://www.fachinfo.de/suche/fi/021054\u00a0\nBojunga\u00a0J,\u00a0Sch\u00f6merich\u00a0J\u00a0(2015).\u00a0SGLT2\u2010Inhibitoren.\u00a0Arzneimittel therapie\u00a033:\u00a0137\u2010145.\u00a0\nDIMDI\u00a0(2016).\u00a0Regeln\u00a0f\u00fcr\u00a0Messzahlen.\u00a0Anlage\u00a01\u00a0Stand\u00a0Mai\u00a02015.\u00a0\nhttps://www.dimdi.de/dynamic/de/amg/packungsgroessen/historie/a nlage1/packungsgroessen\u2010anlage\u20101\u2010\n20150520.pdf,\u00a0letzter\u00a0Zugriff\u00a026.04.2017.\u00a0\u00a0\nH\u00e4ring\u00a0HU,\u00a0Merker\u00a0L,\u00a0Seewaldt\u2010Becker\u00a0E,\u00a0Weimer\u00a0M,\u00a0Meinicke\u00a0T,\u00a0W oerle\u00a0HJ,\u00a0Broedl\u00a0UC;\u00a0EMPA\u2010REG\u00a0METSU\u00a0Trial\u00a0Investigators..\u00a0\nEmpagliflozin\u00a0as\u00a0add\u2010on\u00a0to\u00a0metformin\u00a0plus\u00a0sulfonylurea\u00a0in\u00a0patie nts\u00a0with\u00a0type\u00a02\u00a0diabetes:\u00a0a\u00a024\u2010week,\u00a0randomized,\u00a0\ndouble\u2010blind,\u00a0placebo\u2010controlled\u00a0trial.\u00a0Diabetes\u00a0Care.\u00a02013\u00a0Nov ;36(11):3396\u2010404.\u00a0doi:\u00a010.2337/dc12\u20102673\u00a0.\u00a0Epub\u00a0\n2013\u00a0Aug\u00a020.\u00a0\nKVNo\u00a0(2015).\u00a0DMP\u2010Qualit\u00e4tssicherungsbericht\u00a02015\u00a0\u2013\u00a0KVNo,\u00a0https: //www.kvno.de/downloads/quali/qualbe_dmp15.pdf,\u00a0letzter\u00a0\nZugriff:\u00a008.06.2017.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2015a)\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Ag ency,\u00a0Committee\u00a0for\u00a0Medical\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0\n(CHMP):\u00a0International\u00a0Nonproprietari\u00a0Use\u00a0(INN)\u2010empagliflozin/me tformin.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Summary_for_the_public/human/003770/WC500188002.pdf,\u00a0letzter\u00a0Z ugriff:\u00a022.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2015b)\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Ag ency,\u00a0Committee\u00a0for\u00a0Medical\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0\n(CHMP):\u00a0Inernational\u00a0Nonpropriet ari\u00a0Use\u00a0(INN)\u2010empagliflozin,\u00a0Zu letzt\u00a0aktuaslisiert:\u00a01.\u00a0Februar\u00a02017,\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Summary_for_the_public/human/002677/WC500168595.pdf,\u00a0Letzter\u00a0Z ugriff:\u00a022.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2017).\u00a0European\u00a0Medicines\u00a0Agen cy,\u00a0Committee\u00a0for\u00a0Medical\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP):\u00a0\nSGLT2\u00a0inhibitors\u00a0(previously\u00a0can agliflozin)\u00a0Article\u201020\u00a0procedur e\u00a0\u2010\u00a0SGLT2\u00a0inhibitors:\u00a0information\u00a0on\u00a0potential\u00a0risk\u00a0of\u00a0\ntoe\u00a0amputation\u00a0to\u00a0be\u00a0included\u00a0in\u00a0prescribing\u00a0information.\u00a0Stand \u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/Referrals_documen t/SGLT2_inhibitors_Canagl\u00a0\niflozin_20/Opinion_provided_by_Committee_for_Medicinal_Products _for_Human_Use/WC500222187.pdf,\u00a0letzter\u00a0\nZugriff:\u00a002.05.2017.\u00a0\nFachinformation\u00a0Jardiance\u00ae(2017).\u00a0Fachinformation\u00a0Jardiance\u00ae.\u00a0S tand\u00a0der\u00a0Information:\u00a0Januar\u00a02017.\u00a0\nwww.fachinfo.de/suche/fi/021054,\u00a0letzter\u00a0Zugriff:\u00a020.07.2017.\u00a0\nFerrannini\u00a0E,\u00a0Ramos\u00a0SJ,\u00a0Salsali\u00a0A,\u00a0Tang\u00a0W,\u00a0List\u00a0JF\u00a0(2010).\u00a0Dapa gliflozin\u00a0Monotherapy\u00a0in\u00a0Type\u00a02\u00a0Diabetic\u00a0Patients\u00a0With\u00a0Inadequa te\u00a0\nGlycemic\u00a0Control\u00a0by\u00a0Diet\u00a0and\u00a0Exercise:\u00a0A\u00a0randomized,\u00a0double\u2010bli nd,\u00a0placebo\u2010controlled,\u00a0phase\u00a03\u00a0trial.\u00a0Diabetes\u00a0Care\u00a0\n33(10):\u00a02217\u20102224.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0Arzneimit\u2010\ntelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbe wertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0\nnach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Empagliflozin.\u00a0Stand\u00a0der\u00a0Informationen:\u00a05.\u00a0F ebruar\u00a02015,\u00a0https://www.g\u2010ba.de/downloads/40\u2010\n268\u20103100/2015\u201002\u201005_AM\u2010RL\u2010XII_Empagliflozin_2014\u201008\u201015\u2010D\u2010123_Tr G.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.07.2017.\u00a0213\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016a).\u00a0Beschluss\u00a0des\u00a0Gemei nsamen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0\nArzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die \u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Empagliflozin/Metformin.\u00a0Stand\u00a0d er\u00a0Informationen:\u00a0September\u00a02016,\u00a0\nhttps://www.g\u2010ba.de/downloads/ 40\u2010268\u20103956/2016\u201009\u201001_AM\u2010RL\u2010XII_ Empagliflozin_Metformin_D\u2010215_TrG.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016b).\u00a0Beschluss\u00a0des\u00a0Gemei nsamen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0\nArzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die \u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Empagliflozin.\u00a0(Erneute\u00a0Bewertun g).\u00a0Stand\u00a0der\u00a0Informationen:\u00a0September\u00a02016,\u00a0\nhttps://www.g\u2010ba.de/downloads/ 40\u2010268\u20103955/2016\u201009\u201001_AM\u2010RL\u2010XII_ Empagliflozin_D\u2010214_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n21.06.2017.\u00a0\nHeidemann\u00a0C,\u00a0Du\u00a0Y,\u00a0Schubert\u00a0I,\u00a0Rathmann\u00a0W,\u00a0Scheidt\u2010Nave\u00a0C\u00a0(2013 ).\u00a0Pravalenz\u00a0und\u00a0zeitliche\u00a0Entwicklung\u00a0des\u00a0bekannten\u00a0Diabetes\u00a0\nmellitus:\u00a0Ergebnisse\u00a0der\u00a0Studie\u00a0zur\u00a0Gesundheit\u00a0Erwachsener\u00a0in\u00a0D eutschland\u00a0(DEGS1).\u00a0In:\u00a0Bundesgesundheitsblatt,\u00a0\nGesundheitsforschung,\u00a0Gesundheitsschutz\u00a056\u00a0(5\u20106):\u00a0668\u2013677.\u00a0\u00a0\nIDF\u00a0\u2010\u00a0International\u00a0Diabetes\u00a0Fed eration\u00a0(2015).\u00a0IDF\u00a0Diabetes\u00a0At las\u00a0(7th\u00a0ed.).\u00a0http://www.diabetesatlas.org/resources/2015\u2010\natlas.html,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nIdris\u00a0I,\u00a0Donnelly\u00a0R\u00a0(2009).\u00a0Sodium\u2013glucose\u00a0co\u2010transporter\u20102\u00a0inh ibitors:\u00a0an\u00a0emerging\u00a0new\u00a0class\u00a0of\u00a0oral\u00a0antidiabetic\u00a0drug.\u00a0Diabe tes,\u00a0\nObesity\u00a0and\u00a0Metabolism\u00a011:\u00a079\u201088.\u00a0\nInzucchi\u00a0SE,\u00a0Bergenstal\u00a0RM,\u00a0Buse\u00a0JB,\u00a0Diamant\u00a0M,\u00a0Ferrannini\u00a0E,\u00a0N auck\u00a0M\u00a0et\u00a0al.\u00a0(2012).\u00a0Management\u00a0of\u00a0hyperglycaemia\u00a0in\u00a0type\u00a02\u00a0\ndiabetes:\u00a0a\u00a0patient\u2010centered\u00a0approach.\u00a0Position\u00a0statement\u00a0of\u00a0th e\u00a0American\u00a0Diabetes\u00a0Association\u00a0(ADA)\u00a0and\u00a0the\u00a0\nEuropean\u00a0Association\u00a0for\u00a0the\u00a0Study\u00a0of\u00a0Diabetes\u00a0(EASD).\u00a0Diabetol ogia,\u00a055(6):\u00a01577\u20101596.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2016).\u00a0Empagliflozin\u00a0\u2010\u00a0Dossierbewertung\u00a0A16\u201012,\u00a0\nhttps://www.g\u2010ba.de/downloads/ 92\u2010975\u20101377/2016\u201005\u201030_Nutzenbewe rtung\u2010IQWiG_Empagliflozin.pdf,\u00a0letzter\u00a0\nZugriff:\u00a021.06.2017.\u00a0\nNationale\u00a0Versorgungsleitlinie\u00a0\u201e Therapie\u00a0des\u00a0Typ\u20102\u2010Diabetes\u201c\u00a0(2 013).\u00a0In:\u00a0Zeitschrift\u00a0f\u00fcr\u00a0Evidenz,\u00a0Fortbildung\u00a0und\u00a0Qualit\u00e4t\u00a0im\u00a0\nGesundheitswesen\u00a0107\u00a0(8),\u00a0S.\u00a0515.\u00a0\nNCT01011868\u00a0(2014).\u00a0Results.\u00a0https://clinicaltrials.gov/ct2/sho w/NCT01011868?term=1245.33&rank=1,\u00a0letzter\u00a0Zugriff:\u00a0\n08.06.2017.\u00a0\nNeumiller\u00a0JJ\u00a0(2014).\u00a0Empagliflozi n:\u00a0a\u00a0new\u00a0sodium\u2010glucose\u00a0co\u2010tra nsporter\u00a02\u00a0(SGLT2)\u00a0inhibitor\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0type\u00a02\u00a0diabet es.\u00a0\nDrugs\u00a0in\u00a0context\u00a03\u00a0(21):\u00a02262.\u00a0\u00a0\nPonikowski\u00a0P,\u00a0Voors\u00a0AA,\u00a0Anker\u00a0SD,\u00a0Bueno\u00a0H,\u00a0Cleland\u00a0JGF,\u00a0Coats\u00a0A ndrew\u00a0JS\u00a0et\u00a0al.\u00a0(2016).\u00a02016\u00a0ESC\u00a0Guidelines\u00a0for\u00a0the\u00a0diagnosis\u00a0a nd\u00a0\ntreatment\u00a0of\u00a0acute\u00a0and\u00a0chronic\u00a0heart\u00a0failure:\u00a0The\u00a0Task\u00a0Force\u00a0fo r\u00a0the\u00a0diagnosis\u00a0and\u00a0treatment\u00a0of\u00a0acute\u00a0and\u00a0chronic\u00a0\nheart\u00a0failure\u00a0of\u00a0the\u00a0European\u00a0Society\u00a0of\u00a0Cardiology\u00a0(ESC).\u00a0Deve loped\u00a0with\u00a0the\u00a0special\u00a0contribution\u00a0of\u00a0the\u00a0Heart\u00a0\nFailure\u00a0Association\u00a0(HFA)\u00a0of\u00a0the \u00a0ESC.\u00a0Eur\u00a0Heart\u00a0J\u00a037\u00a0(27):\u00a02129 \u20102200.\u00a0\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0New\u00a0Products\u00a0Empagliflozin\u00a0(Jar diance\u00ae).\u00a0Prescrire\u00a0Int\u00a025\u00a0(172):\u00a0145.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0ArzneistoffeEmpagli flozin|Jardiance\u00ae.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=54053,\u00a0letzter\u00a0Zugriff:20.07.2017.\u00a0\nRidderstr\u00e5le\u00a0M,\u00a0Andersen\u00a0KR,\u00a0Zelle r\u00a0C,\u00a0Kim\u00a0G,\u00a0Woerle\u00a0HJ,\u00a0Broedl \u00a0UC\u00a0(2014).\u00a0Comparison\u00a0of\u00a0empagliflozin\u00a0and\u00a0glimepiride\u00a0as\u00a0add\u2010 on\u00a0\nto\u00a0metformin\u00a0in\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes.\u00a0A\u00a0104\u2010week\u00a0rando mised,\u00a0active\u2010controlled,\u00a0double\u2010blind,\u00a0phase\u00a03\u00a0\ntrial.\u00a0The\u00a0Lancet\u00a0Diabetes\u00a0&\u00a0Endocrinology\u00a02\u00a0(9):\u00a0691\u2010700.\u00a0\u00a0\nRoden\u00a0M,\u00a0Weng\u00a0J,\u00a0Eilbracht\u00a0J,\u00a0Delafont\u00a0B,\u00a0Kim\u00a0G,\u00a0Woerle,\u00a0Hans\u00a0J ,\u00a0Broedl\u00a0UC\u00a0(2013).\u00a0Empagliflozin\u00a0monotherapy\u00a0with\u00a0sitagliptin\u00a0 as\u00a0\nan\u00a0active\u00a0comparator\u00a0in\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes.\u00a0A\u00a0random ised,\u00a0double\u2010blind,\u00a0placebo\u2010controlled,\u00a0phase\u00a03\u00a0trial.\u00a0\nThe\u00a0Lancet\u00a0Diabetes\u00a0&\u00a0Endocrinology\u00a01\u00a0(3):\u00a0208\u2010219.\u00a0214\u00a0Stenl\u00f6f\u00a0K,\u00a0Cefalu\u00a0WT,\u00a0Kim\u00a0K\u2010A,\u00a0Joda,\u00a0E,\u00a0Alba\u00a0M,\u00a0Edwards\u00a0R\u00a0et\u00a0al .\u00a0(2014).\u00a0Long\u2010term\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0canagliflozin\u00a0monoth erapy\u00a0\nin\u00a0patients\u00a0with\u00a0type\u00a02\u00a0diabetes\u00a0inadequately\u00a0controlled\u00a0with\u00a0d iet\u00a0and\u00a0exercise:\u00a0findings\u00a0from\u00a0the\u00a052\u2010week\u00a0\nCANTATA\u2010M\u00a0study.\u00a0Current\u00a0Medical\u00a0Research\u00a0and\u00a0Opinion\u00a030(2):\u00a016 3\u2010175.\u00a0\u00a0\nTamayo\u00a0T,\u00a0Rathmann\u00a0W\u00a0(2016).\u00a0Epidemiologie\u00a0des\u00a0Diabetes\u00a0in\u00a0Deut schland.\u00a0Deutscher\u00a0Gesundheitsbericht\u00a02016.\u00a0\nhttps://www.diabetesde.org/system/files/documents/fileadmin/use rs/Patientenseite/PDFs_und_TEXTE/Infomateri\nal/Gesundheitsbericht_2016.pdf, \u00a0letzter\u00a0Zugriff:\u00a008.06.2017.\u00a0\nZinman\u00a0B,\u00a0Wanner\u00a0C,\u00a0Lachin\u00a0JM,\u00a0Fitchett\u00a0D,\u00a0Bluhmki\u00a0E,\u00a0Hantel\u00a0S\u00a0 et\u00a0al.\u00a0(2015).\u00a0Empagliflozin,\u00a0cardiovascular\u00a0outcomes,\u00a0and\u00a0mort ality\u00a0\nin\u00a0type\u00a02\u00a0diabetes.\u00a0NEJM\u00a0373\u00a0(22):\u00a02117\u20102128.\u00a0\n\u00a0 \u00a0215\u00a04.14 Ibrutinib\u00a0\nHandelsname:\u00a0Imbruvica\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0lymphatische\u00a0\u00a0 Janssen\u2010Cilag\u00a0\nLeuk\u00e4mie,\u00a0Mantelzell\u2010Lymphom,\u00a0\u00a0\nMorbus\u00a0Waldenstr\u00f6m\u00a0 \u00a0 \u00a0 \u00a0\nATC\u2010Code:\u00a0L01XE27\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0November\u00a02014\u00a0\nDarreichungsform:\u00a0Kapsel\u00a0\u00a0 \u00a0 DDD:\u00a00,49\u00a0g\u00a0 \u00a0 \u00a0\u00a0O, \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDer\u00a0Wirkstoff\u00a0Ibrutinib\u00a0(Imbruvica\u00ae)\u00a0ist\u00a0der\u00a0erste\u00a0Tyrosinkinas e\u2010Inhibitor,\u00a0der\u00a0ge\u2010\nzielt\u00a0die\u00a0Signal\u00fcbertragung\u00a0\u00fc ber\u00a0den\u00a0B\u2010Zell\u2010Rezeptor\u00a0( B\u2010cell\u00a0Receptor ,\u00a0BCR)\u00a0beein\u2010\nflusst.\u00a0Durch\u00a0kovalente\u00a0Bindung\u00a0im\u00a0aktiven\u00a0Zentrum\u00a0wird\u00a0das\u00a0Enz ym\u00a0Bruton\u00a0Tyro\u2010\nsinkinase\u00a0(BTK),\u00a0das\u00a0essentiell\u00a0an\u00a0der\u00a0durch\u00a0Antigen\u2010Stimulatio n\u00a0des\u00a0BCR\u00a0initiali\u2010\nsierten\u00a0Signalkaskade\u00a0beteiligt\u00a0ist,\u00a0selektiv\u00a0und\u00a0irreversibel\u00a0 blockiert.\u00a0Die\u00a0Hem\u2010\nmung\u00a0der\u00a0BTK\u00a0sowie\u00a0der\u00a0beteiligten\u00a0sekund\u00e4ren\u00a0Botenstoffe\u00a0( Second\u00a0Messenger )\u00a0\nwirkt\u00a0sich\u00a0auf\u00a0Proliferation\u00a0und\u00a0\u00dcberleben\u00a0der\u00a0pathologisch\u00a0ver \u00e4nderten\u00a0B\u2010Zellen\u00a0\naus\u00a0(Lee\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nBereits\u00a02012\u00a0best\u00e4tigte\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Commission ,\u00a0EC)\u00a0die\u00a0\nOrphan\u00a0Designation\u00a0f\u00fcr\u00a0Ibrutinib\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0lymph atischen\u00a0\nLeuk\u00e4mie\u00a0( Chronic\u00a0Lymphocytic\u00a0Leukemia ,\u00a0CLL)\u00a0(EU/3/12/984).\u00a0In\u00a0weiteren\u00a0Verfah\u2010\nren\u00a0 wurde\u00a0 die\u00a0 Ausweisung\u00a0 als\u00a0 \u201eArzneimittel\u00a0 f\u00fcr\u00a0 seltene\u00a0 Leiden\u201c\u00a0 f\u00fcr\u00a0 Mantelzell\u2010\nLymphom\u00a0( Mantle\u00a0Cell\u00a0Lymphoma ,\u00a0MCL)\u00a0(EU/3/13/1115)\u00a0und\u00a0Morbus\u00a0Waldenstr\u00f6m\u00a0\n(MW)\u00a0(EU/3/14/1264)\u00a0genehmigt,\u00a0die\u00a0Zulassung\u00a0gew\u00e4hrte\u00a0die\u00a0EC\u00a0am \u00a015.\u00a0November\u00a0\n2014\u00a0(EMA,\u00a02014).\u00a0Die\u00a0Einzelsubstanz\u00a0ist\u00a0indiziert\u00a0f\u00fcr\u00a0die\u00a0Beha ndlung\u00a0von\u00a0Patienten\u00a0\nmit\u00a0nicht\u00a0vorbehandelter\u00a0CLL,\u00a0bei\u00a0rezidiviertem\u00a0oder\u00a0refrakt\u00e4re m\u00a0MCL\u00a0sowie\u00a0seit\u00a0Juli\u00a0\n2015\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0bei\u00a0MW\u00a0bei\u00a0Patienten,\u00a0die\u00a0mindestens\u00a0ein e\u00a0vorangehende\u00a0\nTherapie\u00a0 erhalten\u00a0 haben\u00a0 bzw.\u00a0 zur\u00a0 Erstlinien\u2010Therapie,\u00a0 wenn\u00a0 eine \u00a0C h e m o \u2010\nImmuntherapie\u00a0nicht\u00a0geeignet\u00a0ist\u00a0(EMA,\u00a02015).\u00a0Eine\u00a0weitere\u00a0Zula ssungserweiterung\u00a0\nbetrifft\u00a0den\u00a0Einsatz\u00a0bei\u00a0CLL\u00a0sowohl\u00a0einzeln\u00a0als\u00a0auch\u00a0in\u00a0Kombina tion\u00a0mit\u00a0Bendamustin\u00a0\nund\u00a0Rituximab\u00a0nach\u00a0mindestens\u00a0ei ner\u00a0Vortherapie\u00a0(EMA,\u00a02016).\u00a0\u00a0\nDie\u00a0Dosierung\u00a0ist\u00a0f\u00fcr\u00a0das\u00a0jewei lige\u00a0Indikationsg ebiet\u00a0standardi siert.\u00a0Patienten\u00a0mit\u00a0\nMCL\u00a0erhalten\u00a0t\u00e4glich\u00a0560\u00a0mg\u00a0(vie r\u00a0Kapseln),\u00a0bei\u00a0der\u00a0Behandlung\u00a0 von\u00a0CLL\u00a0sowohl\u00a0als\u00a0\nEinzelsubstanz\u00a0als\u00a0auch\u00a0bei\u00a0einer\u00a0Kombination\u00a0420\u00a0mg\u00a0(drei\u00a0Kaps eln)\u00a0sowie\u00a0bei\u00a0MW\u00a0\n420\u00a0mg.\u00a0Die\u00a0Metabolisierung\u00a0von\u00a0Ibrutinib\u00a0erfolgt\u00a0in\u00a0der\u00a0Leber\u00a0 haupts\u00e4chlich\u00a0durch\u00a0\ndas\u00a0Cytochrom\u2010P450\u2010Isoenzym\u00a03A4  (CYP3A4),\u00a0sodass\u00a0sich\u00a0bei\u00a0gleichzeitiger\u00a0Einnah\u2010\nme\u00a0Wechselwirkungen\u00a0mit\u00a0mittelst arken\u00a0bis\u00a0starken\u00a0CYP\u2010Inhibitor en\u00a0ergeben,\u00a0die\u00a0\neine\u00a0Anpassung\u00a0des\u00a0Dosierregimes\u00a0erfordern\u00a0(Fachinformation\u00a0Imb ruvica\u00ae,\u00a02016).\u00a0\u00a0216\u00a0In\u00a0der\u00a0vom\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0gesponserten\u00a0zulas sungsrelevan\u2010\nten\u00a0Phase\u2010Ib\u20102\u2010Studie\u00a0PCYC\u20101102\u2010CA\u00a0(NCT01105247,\u00a0Byrd\u00a0et\u00a0al.,\u00a02 013)\u00a0an\u00a085\u00a0Patien\u2010\nten\u00a0mit\u00a0rezidivierten\u00a0bzw.\u00a0refra kt\u00e4ren\u00a0Non\u2010Hodgkin\u2010Lymphomen\u00a0la g\u00a0die\u00a0Gesamtan\u2010\nsprechrate\u00a0( Overall\u00a0Response\u00a0Rate ,\u00a0ORR)\u00a0bei\u00a0der\u00a0Ibrutinib\u2010Gruppe\u00a0bei\u00a071\u00a0%.\u00a0Zu\u00a0den\u00a0\nam\u00a0h\u00e4ufigsten\u00a0beobachteten\u00a0unerw\u00fcnschten\u00a0Arzneimittelereignisse n\u00a0(UAE)\u00a0geh\u00f6r\u2010\nten\u00a0 Diarrhoe,\u00a0 Fatigue\u00a0 sowie\u00a0 Infektionen\u00a0 der\u00a0 oberen\u00a0 Atemwege.\u00a0 H\u00e4 matologische\u00a0\nKomplikationen\u00a0 wie\u00a0 An\u00e4mie,\u00a0 Thrombozyto\u2010\u00a0 oder\u00a0 Neutropenie\u00a0 traten \u00a0s e l t e n \u00a0a u f . \u00a0\nSchwere\u00a0UAE\u00a0(Grad\u00a0\u22653)\u00a0waren\u00a0Pneumonie\u00a0(12\u00a0%)\u00a0und\u00a0Dehydration\u00a0(6 \u00a0%).\u00a0\u00a0\nAuch\u00a0 in\u00a0 der\u00a0 vom\u00a0 pU\u00a0 gesponserten\u00a0 zulassungsrelevanten\u00a0 Phase\u2010II\u2010S tudie\u00a0 (NCT\u00a0\n01236391,\u00a0Wang\u00a0et\u00a0al.,\u00a02013)\u00a0bei\u00a0Patienten\u00a0mit\u00a0rezidiviertem\u00a0od er\u00a0refrakt\u00e4rem\u00a0MCL\u00a0\nergab\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0mit\u00a0Ibrutinib\u00a0eine\u00a0hohe\u00a0Ansprechr ate\u00a0(68\u00a0%).\u00a0Das\u00a0\nmediane,\u00a0progressionsfreien\u00a0\u00dcberleben\u00a0( Progression\u2010free\u00a0Survival ,\u00a0PFS)\u00a0betrug\u00a013,8\u00a0\nMonate.\u00a0Nach\u00a018\u00a0Monaten\u00a0wurde\u00a0ein\u00a0Gesamt\u00fcberleben\u00a0(Overall\u00a0Surv ival,\u00a0OS)\u00a0von\u00a0\n58\u00a0%\u00a0detektiert.\u00a0Die\u00a0Auswertung\u00a0der\u00a0Studie\u00a0zeigte\u00a0ein\u00a0\u00e4hnliches \u00a0Nebenwirkungsprofil\u00a0\nwie\u00a0bereits\u00a0bei\u00a0Byrd\u00a0und\u00a0Kollegen\u00a0(2013).\u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0wa ren\u00a0Diarrhoe,\u00a0Fati\u2010\ngue,\u00a0An\u00e4mie\u00a0und\u00a0Infektionen\u00a0der\u00a0oberen\u00a0Luftwege.\u00a0Schwere\u00a0UAE\u00a0(G rad\u00a0\u22653),\u00a0die\u00a0bei\u00a0\u2265\u00a0\n5\u00a0%\u00a0der\u00a0Patienten\u00a0auftraten,\u00a0waren\u00a0Neutropenie\u00a0(16\u00a0%),\u00a0Thromboz ytopenie\u00a0(11\u00a0%),\u00a0\nDiarrhoe\u00a0(50\u00a0%),\u00a0abdominale\u00a0Schmerzen\u00a0(5\u00a0%)\u00a0und\u00a0Fatigue\u00a0(5\u00a0%).\u00a0\nWeiterhin\u00a0liegen\u00a0die\u00a0Ergebnisse\u00a0von\u00a0zwei\u00a0vom\u00a0pU\u00a0durchgef\u00fchrten\u00a0 Phase\u2010III\u2010Stu\u2010\ndien\u00a0mit\u00a0Patienten\u00a0mit\u00a0rezidivierter\u00a0oder\u00a0refrakt\u00e4rer\u00a0CLL\u00a0bzw.\u00a0 kleinzelligem\u00a0B\u2010Zell\u2010\nLymphom\u00a0( Small\u00a0Lymphocytic\u00a0Lymphoma ,\u00a0SLL)\u00a0zur\u00a0Verf\u00fcgung.\u00a0Die\u00a0offene\u00a0Studie\u00a0\nRESONATE\u00a0(NCT01578707,\u00a0Byrd\u00a0et\u00a0al.,\u00a02014)\u00a0mit\u00a0391\u00a0Probanden\u00a0ver glich\u00a0das\u00a0PFS\u00a0\nunter\u00a0Ibrutinib\u00a0mit\u00a0Ofatumumab,\u00a0wobei\u00a0sich\u00a0der\u00a0BTK\u2010Inhibitor\u00a0si gnifikant\u00a0\u00fcberle\u2010\ngen\u00a0zeigte\u00a0(9,4\u00a0Monate\u00a0vs.\u00a08,1\u00a0Monate).\u00a0Insbesondere\u00a0zu\u00a0Beginn\u00a0 der\u00a0Therapie\u00a0mit\u00a0\nIbrutinib\u00a0wurde\u00a0das\u00a0Auftreten\u00a0eines\u00a0Lymphozytose\u00a0beobachtet,\u00a0di e\u00a0\u00fcber\u00a0mehrere\u00a0\nMonate\u00a0 persistieren\u00a0 kann.\u00a0 Diese\u00a0 Komplikation\u00a0 deuteten\u00a0 die\u00a0 Autor e n \u00a0n i c h t \u00a0a l s \u00a0\nProgression,\u00a0sondern\u00a0f\u00fchrten\u00a0dies\u00a0auf\u00a0ein\u00a0vermindertes\u00a0 Homing\u00a0der\u00a0CLL\u2010Zellen\u00a0in\u00a0\nLymphknoten,\u00a0Knochenmark\u00a0und\u00a0der\u00a0Milz\u00a0infolge\u00a0ver\u00e4nderter\u00a0Expre ssion\u00a0von\u00a0Che\u2010\nmokinen\u00a0durch\u00a0Ibrutinib\u00a0zur\u00fcck.\u00a0Die\u00a0HELIOS\u2010Studie\u00a0(Chanan\u2010Khan\u00a0 et\u00a0al.,\u00a02016)\u00a0\nzeigte\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0von\u00a0Ibrutinib\u00a0mit\u00a0Bendamustin\u00a0und\u00a0Ri tuximab\u00a0(BR)\u00a0eine\u00a0\nSteigerung\u00a0der\u00a0Rate\u00a0h\u00e4matologisc her\u00a0Remissionen\u00a0bei\u00a0den\u00a0Patient en.\u00a0Das\u00a0unter\u00a0\nEinbeziehung\u00a0unabh\u00e4ngiger\u00a0Experten\u00a0( Independent\u00a0Review\u00a0Committee ,\u00a0IRC)\u00a0be\u2010\nwertete\u00a0PFS\u00a0nach\u00a018\u00a0Monaten\u00a0betrug\u00a079\u00a0%\u00a0unter\u00a0Ibrutinib\u00a0im\u00a0Verg leich\u00a0zu\u00a024\u00a0%\u00a0in\u00a0\nder\u00a0BR\u2010Gruppe\u00a0(Chanan\u2010Khan\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Indikation\u00a0MW\u00a0liegt\u00a0eine\u00a0 einarmige\u00a0vom\u00a0pU\u00a0gesponserte\u00a0S tudie\u00a012\u2010015\u00a0\n(NCT01614821,\u00a0Treon\u00a0et\u00a0al.,\u00a02015)\u00a0vor,\u00a0die\u00a0an\u00a0drei\u00a0Zentren\u00a0in\u00a0d en\u00a0USA\u00a0mit\u00a0einem\u00a0\nTeilnehmerkollektiv\u00a0von\u00a063\u00a0vorbeh andelten\u00a0(mindestens\u00a0eine\u00a0Vort herapie)\u00a0Patien\u2010\nten\u00a0mit\u00a0symptomatischem\u00a0MW\u00a0durch gef\u00fchrt\u00a0wurde.\u00a0Die\u00a0Probanden\u00a0er hielten\u00a0bis\u00a0217\u00a0zum\u00a0Progress\u00a0des\u00a0MW\u00a0oder\u00a0Auftrete n\u00a0schwerer\u00a0Nebenwirkungen\u00a0t\u00e4gl ich\u00a0420\u00a0mg\u00a0\nIbrutinib.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt,\u00a0die\u00a0ORR,\u00a0betrug\u00a090,5\u00a0%.\u00a0Dabei\u00a0 sprachen\u00a0Patien\u2010\nten\u00a0mit\u00a0einer\u00a0MYD88L265P\u2010Mutation\u00a0sowie\u00a0dem\u00a0CXR4\u2010Wildtyp\u00a0besond ers\u00a0gut\u00a0an.\u00a0\nDas\u00a0gesch\u00e4tzte\u00a0PFS\u00a0bzw.\u00a0OS\u00a0f\u00fcr\u00a0alle\u00a0Teilnehmer\u00a0lag\u00a0nach\u00a0zwei\u00a0Ja hren\u00a0bei\u00a069,1\u00a0%\u00a0\nbzw.\u00a095,2\u00a0%.\u00a0UAE\u00a0der\u00a0Ibrutinib\u2010Monotherapie\u00a0in\u00a0der\u00a0Zulassungsst udie\u00a0vom\u00a0Schwe\u2010\nregrad\u00a0\u2265\u00a03\u00a0waren\u00a0Neutropenie\u00a0(15\u00a0%),\u00a0Thrombozytopenie\u00a0(13\u00a0%),\u00a0f ebrile\u00a0Neutro\u2010\npenie\u00a0 (2\u00a0%),\u00a0 Infektionen\u00a0 wie\u00a0 Pneumonie,\u00a0 Herpes\u00a0 Zoster,\u00a0 Harnwegs infekte\u00a0 und\u00a0\nVorhofflimmern\u00a0(jeweils\u00a02\u00a0%)\u00a0(Kapoor\u00a0et\u00a0al.,\u00a02017).\u00a0\nDie\u00a0Nutzenbewertung\u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0diente\u00a0vor\u00a0dem\u00a0Hintergrund\u00a0 der\u00a0Orphan\u2010\nDesignation\u00a0der\u00a0Feststellung\u00a0des\u00a0Ausma\u00dfes\u00a0des\u00a0Zusatznutzens\u00a0von \u00a0Ibrutinib.\u00a0Der\u00a0\nGemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0konstatierte\u00a0f\u00fcr\u00a0die\u00a0vom\u00a0pU\u00a0f \u00fcr\u00a0die\u00a0Indikati\u2010\non\u00a0CLL\u00a0vorgelegte\u00a0offene,\u00a0multizentrische\u00a0Phase\u2010III\u2010Studie\u00a0PCYC\u20101112\u2010 CA\u00a0(RESO\u2010\nNATE,\u00a0Byrd\u00a0et\u00a0al.,\u00a02014)\u00a0ein\u00a0hohes\u00a0Verzerrungsrisiko\u00a0aufgrund\u00a0d er\u00a0fehlenden\u00a0Ver\u2010\nblindung\u00a0und\u00a0stufte\u00a0den\u00a0Umfang\u00a0des\u00a0 Zusatznutzens \u00a0als\u00a0nicht\u00a0quantifizierbar \u00a0ein.\u00a0\nF\u00fcr\u00a0das\u00a0Anwendungsgebiet\u00a0 MCL\u00a0kam\u00a0das\u00a0Gremium\u00a0zu\u00a0einer\u00a0\u00e4hnlichen\u00a0Einsch\u00e4t\u2010\nzung,\u00a0da\u00a0die\u00a0herangezogene\u00a0Phase \u2010II\u2010Studie\u00a0(Wang\u00a0et\u00a0al.,\u00a02013)\u00a0 keine\u00a0Vergleichs\u2010\ntherapie\u00a0untersuchte.\u00a0Der\u00a0 Zusatznutzen \u00a0wurde\u00a0ebenfalls\u00a0als\u00a0 nicht\u00a0quantifizierbar \u00a0\nbeurteilt\u00a0(G\u2010BA,\u00a02015).\u00a0F\u00fcr\u00a0das\u00a0Anwendungsgebiet\u00a0MW\u00a0f\u00fchrte\u00a0der\u00a0 G\u2010BA\u00a0aufgrund\u00a0\nder\u00a0geringen\u00a0Fallzahlen\u00a0keine\u00a0Bewertung\u00a0durch.\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0\u00a0Kosten\u00a0\nWeiterer\u00a0Tyrosinkinase\u2010\nInhibitor,\u00a0erster\u00a0\nHemmstoff\u00a0der\u00a0BTK\u00a0Fehlen\u00a0von\u00a0Studien\u00a0mit\u00a0\nzVT\u00a0bei\u00a0MW\u00a0und\u00a0MCL,\u00a0\nsowie\u00a0von\u00a0Verblindung\u00a0\nbei\u00a0CLL\u00a0erschweren\u00a0\nVergleich\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus \u00a0a\u2010t\u2010Bewertung \u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0MCL,\u00a0CLL:\u00a0\nJudgement\u00a0\nreserved\u00a0\nMorbus\u00a0\nWaldenstr\u00f6m:\u00a0\nNothing\u00a0New\u00a0Analogpr\u00e4parat\u00a0\n\u00a0\n218\u00a0Kosten\u00a0\nWirkstoff \u00a0 Behandlungsmodus \u00a0 Behandlungstage \u00a0Jahrestherapiekosten \u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nIbrutinib\u00a0\nCLL\u00a0\u00a0\n1x\u00a0tgl.\u00a0420\u00a0mg\u00a0\u00a0\n365\u00a0\u00a0\n81.695,67\u00a0\u20ac\u00a0\nMCL\u00a0\nMW\u00a01x\u00a0tgl.\u00a0560\u00a0mg\u00a0\n1x\u00a0tgl.\u00a0420\u00a0mg\u00a0365\u00a0\n365\u00a0108.927,56\u00a0\u20ac\u00a0\n81.695,67\u00a0\u20ac \u00a0\nPreise\u00a0excl.\u00a0Kosten\u00a0f\u00fcr\u00a0zu s\u00e4tzliche\u00a0GKV\u2010Leistungen\u00a0\nVersorgungsanalysen\u00a0\nInnerhalb\u00a0von\u00a0drei\u00a0Monaten\u00a0steigt\u00a0die\u00a0Anzahl\u00a0der\u00a0verordneten\u00a0DD D\u00a0sprunghaft\u00a0auf\u00a0\n2.271\u00a0an.\u00a0Diese\u00a0Entwicklung\u00a0reflektiert\u00a0den\u00a0Stellenwert\u00a0des\u00a0 Orphan\u2010Arzneimittels\u00a0\nf\u00fcr\u00a0Patienten,\u00a0denen\u00a0nun\u00a0eine\u00a0spezifische\u00a0Therapie\u00a0zur\u00a0Verf\u00fcgun g\u00a0steht.\u00a0F\u00fcr\u00a0den\u00a0\nVerlauf\u00a0der\u00a0zweiten\u00a0Jahresh\u00e4lfte\u00a02015\u00a0zeigt\u00a0Abb.\u00a04.18\u00a0einen\u00a0ste tigen\u00a0Anstieg\u00a0der\u00a0\nDDD\u00a0der\u00a0zum\u00a0Jahresende\u00a0mit\u00a04.371\u00a0den\u00a0Maximalwert\u00a0erreicht.\u00a0In\u00a0d iesen\u00a0Zeitraum\u00a0\nf\u00e4llt\u00a0auch\u00a0die\u00a0im\u00a0Juli\u00a0best\u00e4tigte\u00a0Indikationserweiterung,\u00a0die\u00a0n un\u00a0mit\u00a0der\u00a0Behand\u2010\nlung\u00a0von\u00a0Morbus\u00a0Waldenstr\u00f6m\u00a0ein\u00a0 weiteres\u00a0Patientenkollektiv\u00a0erf asst.\u00a0Die\u00a0Abga\u2010\nbepreise\u00a0des\u00a0pU\u00a0blieben\u00a0w\u00e4hrend\u00a0 des\u00a0dargestellten\u00a0Beobachtungsz eitraums\u00a0kon\u2010\nstant.\u00a0Seit\u00a0November\u00a02015\u00a0sind\u00a0Importpr\u00e4parate\u00a0mit\u00a0ca.\u00a017\u00a0%\u00a0g\u00fcn stigerem\u00a0Abga\u2010\nbepreis\u00a0verf\u00fcgbar\u00a0(Lauer\u2010Fischer,\u00a02015).\u00a0In\u00a0der\u00a0Folge\u00a0sinken\u00a0di e\u00a0Bruttoums\u00e4tze\u00a0von\u00a0\n1,38\u00a0Mio.\u00a0im\u00a0Oktober\u00a02015\u00a0auf\u00a01,12\u00a0Mio.\u00a0im\u00a0Folgemonat.\u00a0\n\u00a0 \u00a0219\u00a0Abbildung\u00a04.18:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nIbrutinib\u00a0je\u00a0Monat\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nIbrutinib\u00a0 (Imbruvica\u00ae)\u00a0 ist\u00a0 ein\u00a0 niedermolekularer\u00a0 (small\u2010molecul e)\u00a0 Inhibitor\u00a0 der\u00a0\nBruton\u2010Tyrosin\u2010Kinase\u00a0(BTK),\u00a0die\u00a0eine\u00a0zentrale\u00a0Rolle\u00a0im\u00a0B\u2010Zell\u2010 Rezeptor\u00a0(BCR)\u00a0\u2010\u00a0\nSignalweg\u00a0spielt.\u00a0Ibrutinib\u00a0bind et\u00a0kovalent\u00a0an\u00a0das\u00a0Cystein\u00a0481\u00a0 (C481)\u00a0der\u00a0BTK\u00a0und\u00a0\ninhibiert\u00a0dadurch\u00a0irreversibel\u00a0die\u00a0Phosphorylierung\u00a0des\u00a0Enzyms\u00a0 sowie\u00a0die\u00a0nachfol\u2010\ngenden\u00a0 Schritte\u00a0 in\u00a0 der\u00a0 Signaltran sduktionskette.\u00a0 Der\u00a0 membranst\u00e4 ndige\u00a0 B\u2010\nZellrezeptor\u00a0wird\u00a0auf\u00a0normalen\u00a0B\u2010 Zellen,\u00a0aber\u00a0auch\u00a0vielen\u00a0B\u2010Zel l\u2010Lymphomen\u00a0ex\u2010\nprimiert\u00a0und\u00a0ist\u00a0Ausgangspunkt\u00a0einer\u00a0vielstufigen\u00a0Signalkaskade ,\u00a0die\u00a0beteiligt\u00a0ist\u00a0an\u00a0\nder\u00a0 Steuerung\u00a0 zellul\u00e4rer\u00a0 Schl\u00fcsselfunktionen\u00a0 wie\u00a0 Wachstum,\u00a0 Diff erenzierung,\u00a0\nProliferation\u00a0und\u00a0\u00dcberleben.\u00a0Pr\u00e4klinische\u00a0Studien\u00a0zeigten,\u00a0dass \u00a0Ibrutinib\u00a0in\u00a0vivo\u00a0die\u00a0\nProliferation\u00a0und\u00a0das\u00a0\u00dcberleben\u00a0maligner\u00a0B\u2010Zellen\u00a0sowie\u00a0in\u00a0vitr o\u00a0die\u00a0Migration\u00a0und\u00a0\nSubstratadh\u00e4sion\u00a0der\u00a0Zellen\u00a0effektiv\u00a0hemmt\u00a0(Lee\u00a0et\u00a0al.,\u00a02016).\u00a0 \u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nAm\u00a015.\u00a0November\u00a02014\u00a0gew\u00e4hrte\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Com\u2010\nmission,\u00a0EC)\u00a0die\u00a0Zulassung\u00a0von\u00a0Ibrutinib\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0erwach senen\u00a0\nPatienten\u00a0mit\u00a0chronischer\u00a0lymphatischer\u00a0Leuk\u00e4mie\u00a0( Chronic\u00a0Lymphocytic\u00a0Leuke\u2010\nmia,\u00a0CLL)\u00a0f\u00fcr\u00a0 Patienten,\u00a0die\u00a0 mindestens\u00a0eine\u00a0vorangehende\u00a0Therapie \u00a0erhal ten\u00a0\nhaben,\u00a0oder\u00a0zur\u00a0Erstlinien\u2010Therapie\u00a0bei\u00a0Patienten\u00a0mit\u00a0einer\u00a017p \u2010Deletion\u00a0oder\u00a0\n220\u00a0einer\u00a0TP53\u2010Mutation,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Chemo\u2010Immuntherapie\u00a0nicht\u00a0gee ignet\u00a0sind.\u00a0Die\u00a0\nZulassung\u00a0umfasste\u00a0\u00fcberdies\u00a0die\u00a0Behandlung\u00a0des\u00a0rezidivierten\u00a0od er\u00a0refrakt\u00e4ren\u00a0\nMantelzell\u2010Lymphom\u00a0( Mantle\u00a0Cell\u00a0Lymphoma ,\u00a0MCL)\u00a0(EMA,\u00a02014).\u00a0Diese\u00a0wurde\u00a0im\u00a0\nJuli\u00a02015\u00a0erweitert\u00a0und\u00a0auf\u00a0 Patienten\u00a0mit\u00a0Morbus\u00a0Waldenstr\u00f6m\u00a0(M W)\u00a0in\u00a0der\u00a0\nZweitlinie\u00a0 oder\u00a0 in\u00a0 der\u00a0 Erstlinie \u00a0 bei\u00a0 bestehender\u00a0 Kontraindikati o n \u00a0g e g e n \u00a0e i n e \u00a0\nChemo\u2010Immuntherapie\u00a0ausgedehnt\u00a0(EMA,\u00a02015).\u00a0Seit\u00a0Mai\u00a02016\u00a0liegt \u00a0auch\u00a0eine\u00a0\nZulassung\u00a0zur\u00a0Monotherapie\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0erwachsener\u00a0Patie nten\u00a0mit\u00a0nicht\u00a0\nvorbehandelter\u00a0CLL,\u00a0sowie\u00a0seit\u00a0August\u00a02016\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0 mit\u00a0Bendamustin\u00a0\nund\u00a0Rituximab\u00a0bei\u00a0vorbehandelten\u00a0Patienten\u00a0vor\u00a0(EMA,\u00a02016).\u00a0F\u00fcr \u00a0s\u00e4mtliche\u00a0Indi\u2010\nkationsgebiete\u00a0stimmte\u00a0die\u00a0EC\u00a0der \u00a0Ausweisung\u00a0als\u00a0\u201eArzneimittel\u00a0 f\u00fcr\u00a0seltene\u00a0Lei\u2010\nden\u201c\u00a0(Orphan\u00a0Designation )\u00a0zu.\u00a0Bei\u00a0Ibrutinib\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0oral\u00a0verf\u00fcg\u2010\nbaren\u00a0BTK\u2010Inhibitor,\u00a0der\u00a0in\u00a0Form\u00a0von\u00a0Kapseln\u00a0mit\u00a0je\u00a0140\u00a0mg\u00a0des\u00a0 Wirkstoffs\u00a0einge\u2010\nnommen\u00a0wird.\u00a0Die\u00a0t\u00e4gliche\u00a0Dosis\u00a0ist\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Indikatio nsgebiet\u00a0fixiert\u00a0und\u00a0\nbetr\u00e4gt\u00a0bei\u00a0MCL\u00a0560\u00a0mg,\u00a0bei\u00a0CLL\u00a0 und\u00a0MW\u00a0420\u00a0mg.\u00a0Bei\u00a0Toxizit\u00e4tsre aktionen\u00a0sowie\u00a0\ngleichzeitiger\u00a0Einnahme\u00a0mittelstarker\u00a0CYP3A4\u2010Inhibitoren\u00a0ist\u00a0ei ne\u00a0Dosisanpassung\u00a0\nvorgesehen\u00a0(Fachinformat ion\u00a0Imbruvica\u00ae,\u00a02016).\u00a0\u00a0\nIbrutinib\u00a0unterliegt\u00a0einer\u00a0 zus\u00e4tzlichen\u00a0\u00dcberwachung.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0chronische\u00a0lymphatische\u00a0Leuk\u00e4mie\u00a0ist\u00a0die\u00a0h\u00e4ufigste\u00a0leuk\u00e4mis che\u00a0Erkrankung\u00a0in\u00a0\nden\u00a0westlichen\u00a0Industriel\u00e4ndern\u00a0und\u00a0tritt\u00a0\u00fcberwiegend\u00a0im\u00a0h\u00f6here n\u00a0Lebensalter\u00a0\nauf.\u00a0In\u00a0Deutschland\u00a0erkranken\u00a0j\u00e4hrlich\u00a0etwa\u00a03.000\u00a0M\u00e4nner\u00a0und\u00a02. 000\u00a0Frauen.\u00a0Bei\u00a0\nden\u00a0M\u00e4nnern\u00a0entspricht\u00a0dies\u00a0einem\u00a0Anteil\u00a0von\u00a0ca.\u00a01,1%\u00a0an\u00a0allen\u00a0 Krebserkrankun\u2010\ngen\u00a0und\u00a0etwa\u00a041,8\u00a0%\u00a0aller\u00a0Leuk\u00e4mien,\u00a0bei\u00a0den\u00a0Frauen\u00a0liegen\u00a0beid e\u00a0Anteile\u00a0gering\u2010\nf\u00fcgig\u00a0niedriger.\u00a0Das\u00a0mittlere\u00a0Er krankungsalter\u00a0lag\u00a02011\u00a0bei\u00a072\u00a0 Jahren\u00a0f\u00fcr\u00a0M\u00e4nner\u00a0\nund\u00a075\u00a0Jahren\u00a0bei\u00a0Frauen,\u00a0das\u00a0mediane\u00a0Sterbealter\u00a0bei\u00a077\u00a0Jahren \u00a0f\u00fcr\u00a0M\u00e4nner\u00a0und\u00a0\n82\u00a0Jahren\u00a0f\u00fcr\u00a0Frauen(GEKID,\u00a02017;\u00a0DGHO,\u00a02014).\u00a0\nDas\u00a0wesentlich\u00a0seltenere\u00a0Mantelzell\u2010Lymphom\u00a0macht\u00a07\u00a0bis\u00a09\u00a0%\u00a0all er\u00a0in\u00a0Europa\u00a0\nauftretenden\u00a0malignen\u00a0Lymphome\u00a0au s\u00a0und\u00a0bef\u00e4llt\u00a0generell\u00a0\u00e4ltere\u00a0 Menschen\u00a0im\u00a0\nmittleren\u00a0Erkrankungsalter\u00a0von\u00a065\u00a0Jahren.\u00a0Obwohl\u00a0als\u00a0indolentes \u00a0Lymphom\u00a0kate\u2010\ngorisiert,\u00a0zeigt\u00a0sich\u00a0klinisch\u00a0ein\u00a0h\u00e4ufig\u00a0aggressiver\u00a0Verlauf.\u00a0 Die\u00a0mediane\u00a0\u00dcberle\u2010\nbenszeit\u00a0liegt\u00a0bei\u00a0etwa\u00a0f\u00fcnf\u00a0Jahren\u00a0und\u00a0weist\u00a0somit\u00a0die\u00a0schlech teste\u00a0Prognose\u00a0aller\u00a0\nB\u2010Zell\u2010Lymphome\u00a0auf\u00a0(Dreyling\u00a0M\u00a0et\u00a0al.\u00a02014).\u00a0\nMorbus\u00a0Waldenstr\u00f6m\u00a0ist\u00a0mit\u00a0240\u00a0Neuerkrankungen\u00a0j\u00e4hrlich\u00a0in\u00a0Deut schland\u00a0und\u00a0\neinem\u00a0Anteil\u00a0von\u00a01\u00a0bis\u00a02\u00a0%\u00a0das\u00a0seltenste\u00a0maligne\u00a0Lymphom\u00a0(Kompe tenznetz\u00a0Ma\u2010\nligne\u00a0Lymphome\u00a0e.V.\u00a02015).\u00a0Wie\u00a0bei\u00a0MCL\u00a0erfolgt\u00a0eine\u00a0palliative\u00a0 Versorgung.\u00a0F\u00fcr\u00a0die\u00a0\nPrognose\u00a0wird\u00a0der\u00a0sog.\u00a0\u201aInternat ional\u00a0scoring\u00a0system\u00a0for\u00a0Walden str\u00f6m\u2019s\u00a0macroglo\u2010\nbulinemia\u201c\u00a0(ISSWM)\u00a0herangezogen,\u00a0wonach\u00a0in\u00a0drei\u00a0Risikogruppen\u00a0k ategorisiert\u00a0221\u00a0wird.\u00a0So\u00a0liegt\u00a0das\u00a05\u2010Jahres\u00fcberleben\u00a0bei\u00a0Hochrisikopatienten\u00a0be i\u00a036\u00a0%\u00a0im\u00a0Vergleich\u00a0\nzu\u00a087\u00a0%\u00a0in\u00a0der\u00a0Niedrigrisikogruppe\u00a0(DGHO,\u00a02017).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nI n \u00a0d e r \u00a0v o m \u00a0p U \u00a0g e s p o n s e r t e n \u00a0z u l a ssungsrelevanten\u00a0 multizentrische n,\u00a0 offenen,\u00a0\nrandomisierten\u00a0 Phase\u00a0 Ib/II\u2010Studie\u00a0 PCYC\u20101102\u2010CA\u00a0 (NCT01105247,\u00a0 By rd\u00a0 JC\u00a0 at\u00a0 al.\u00a0\n2013)\u00a0 mit\u00a0 85\u00a0 Patienten\u00a0 mit\u00a0 rezidivierten\u00a0 oder\u00a0 refrakt\u00e4ren\u00a0 Non\u2010H odgkin\u2010Lym\u2010\nphomen\u00a0betrug\u00a0die\u00a0ORR\u00a0der\u00a0Ibrutinib\u2010Gruppe\u00a071\u00a0%,\u00a0das\u00a0PFS\u00a0nach\u00a02 6\u00a0Monaten\u00a0von\u00a0\n75\u00a0%\u00a0.\u00a0Dabei\u00a0z\u00e4hlten\u00a0Diarrhoe,\u00a0 Fatigue,\u00a0An\u00e4mie\u00a0und\u00a0Infektionen\u00a0 der\u00a0oberen\u00a0Atem\u2010\nwege\u00a0zu\u00a0den\u00a0h\u00e4ufigsten\u00a0UAE.\u00a0Ferner\u00a0wurden\u00a0schwere\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03 )\u00a0wie\u00a0Pneumo\u2010\nnie\u00a0(12\u00a0%),\u00a0Neuropenie\u00a0(15\u00a0%)\u00a0und\u00a0Dehydration\u00a0(6\u00a0%).\u00a0In\u00a0einer\u00a0r andomisierten\u00a0\nStudie\u00a0bei\u00a0vorbehandelten\u00a0Patienten\u00a0war\u00a0Ibrutinib\u00a0dem\u00a0Ofatumuma b\u00a0signifikant\u00a0\n\u00fcberlegen\u00a0(Byrd\u00a0JC,\u00a0Brown\u00a0JR,\u00a0O\u2019Brien\u00a0S,\u00a0et\u00a0al.\u00a02014).\u00a0Eine\u00a0wei tere\u00a0Studie\u00a0zeigte\u00a0f\u00fcr\u00a0\ndie\u00a0Kombination\u00a0Ibrutinib\u00a0+\u00a0Bendamustin\u00a0+\u00a0Rituximab\u00a0gegen\u00fcber\u00a0B endamustin\u00a0+\u00a0\nRituximab\u00a0eine\u00a0Steigerung\u00a0der\u00a0Rat e\u00a0h\u00e4matologischer\u00a0Remissionen\u00a0 (Chanan\u2010Khan\u00a0\net\u00a0al.,\u00a02016).\u00a0\u00a0\nWeiterhin\u00a0 liegen\u00a0 die\u00a0 Ergebnisse\u00a0 von\u00a0 zwei\u00a0 vom\u00a0 pU\u00a0 durchgef\u00fchrten\u00a0 Phase\u2010III\u2010\nStudien\u00a0mit\u00a0Patienten\u00a0mit\u00a0rezidivierter\u00a0oder\u00a0refrakt\u00e4rer\u00a0CLL\u00a0bz w.\u00a0kleinzelligem\u00a0B\u2010\nZell\u2010Lymphom\u00a0 ( Small\u00a0 Lymphocytic\u00a0 Lymphoma ,\u00a0 SLL)\u00a0 zur\u00a0 Verf\u00fcgung.\u00a0 Die\u00a0 offene\u00a0\nStudie\u00a0RESONATE\u00a0(NCT01578707,\u00a0Byrd\u00a0et\u00a0al.,\u00a02014)\u00a0mit\u00a0391\u00a0Proban den\u00a0verglich\u00a0\ndas\u00a0PFS\u00a0unter\u00a0Ibrutinib\u00a0mit\u00a0Ofatumumab,\u00a0wobei\u00a0sich\u00a0der\u00a0BTK\u2010Inhi bitor\u00a0signifikant\u00a0\n\u00fcberlegen\u00a0zeigte\u00a0(9,4\u00a0Monate\u00a0vs.\u00a08,1\u00a0Monate).\u00a0Insbesondre\u00a0zu\u00a0Be ginn\u00a0der\u00a0Therapie\u00a0\nmit\u00a0Ibrutinib\u00a0wurde\u00a0das\u00a0Auftreten\u00a0eines\u00a0Lymphozytose\u00a0beobachtet ,\u00a0die\u00a0\u00fcber\u00a0meh\u2010\nrere\u00a0Monate\u00a0persistieren\u00a0kann.\u00a0Diese\u00a0Komplikation\u00a0deuteten\u00a0die\u00a0 Autoren\u00a0nicht\u00a0als\u00a0\nProgression,\u00a0sondern\u00a0f\u00fchrten\u00a0dies\u00a0auf\u00a0ein\u00a0vermindertes\u00a0 Homing\u00a0der\u00a0CLL\u2010Zellen\u00a0in\u00a0\nLymphknoten,\u00a0 Knochenmark\u00a0 und\u00a0 der\u00a0 Milz\u00a0 infolge\u00a0 ver\u00e4nderter\u00a0 Expre ssion\u00a0 von\u00a0\nChemokinen\u00a0durch\u00a0Ibrutinib\u00a0zur\u00fcck.\u00a0Die\u00a0HELIOS\u2010Studie\u00a0(Chanan\u2010Kh an\u00a0et\u00a0al.,\u00a02016)\u00a0\nzeigte\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0von\u00a0Ibrutinib\u00a0mit\u00a0Bendamustin\u00a0und\u00a0Ri tuximab\u00a0(BR)\u00a0eine\u00a0\nSteigerung\u00a0der\u00a0Rate\u00a0h\u00e4matologisc her\u00a0Remissionen\u00a0bei\u00a0den\u00a0Patient en.\u00a0Das\u00a0unter\u00a0\nEinbeziehung\u00a0unabh\u00e4ngiger\u00a0Experten\u00a0( Independent\u00a0Review\u00a0Committee ,\u00a0IRC)\u00a0be\u2010\nwertete\u00a0PFS\u00a0nach\u00a018\u00a0Monaten\u00a0betrug\u00a079\u00a0%\u00a0unter\u00a0Ibrutinib\u00a0im\u00a0Verg leich\u00a0zu\u00a024\u00a0%\u00a0in\u00a0\nder\u00a0BR\u2010Gruppe\u00a0(Chanan\u2010Khan\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nDie\u00a0Phase\u2010II\u2010Studie\u00a0(Sponsor:\u00a0pU,\u00a0NCT01236391,\u00a0Wang\u00a0et\u00a0al.,\u00a0201 3)\u00a0mit\u00a0111\u00a0Pati\u2010\nenten\u00a0mit\u00a0rezidiviertem\u00a0oder\u00a0ref rakt\u00e4rem\u00a0MCL\u00a0durchgef\u00fchrte\u00a0erga b\u00a0eine\u00a0ORR\u00a0von\u00a0\n68\u00a0%\u00a0und\u00a0ein\u00a0medianes\u00a0PFS\u00a0von\u00a013,8\u00a0Monaten.\u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0 waren\u00a0Diarrho\u2010\ne,\u00a0Fatigue,\u00a0An\u00e4mie\u00a0und\u00a0Infektionen\u00a0der\u00a0oberen\u00a0Atemwege.\u00a0Schwere \u00a0UAE\u00a0(Grad\u00a0\u2265\u00a0\n3),\u00a0die\u00a0bei\u00a0\u2265\u00a05\u00a0%\u00a0der\u00a0Patienten\u00a0auftraten,\u00a0waren\u00a0Neutropenie\u00a0(1 6\u00a0%),\u00a0Thrombozy\u2010\ntopenie\u00a0(11\u00a0%),\u00a0Diarrhoe\u00a0(6\u00a0%),\u00a0 abdominale\u00a0Schmerzen\u00a0(5\u00a0%)\u00a0und\u00a0 Fatigue\u00a0(5\u00a0%).\u00a0222\u00a0Die\u00a0der\u00a0Zulassung\u00a0zugrunde\u00a0liege nde\u00a0Evidenz\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0 MW\u00a0gr\u00fcndet\u00a0auf\u00a0\nder\u00a0vom\u00a0pU\u00a0unterst\u00fctzten\u00a0einarmige\u00a0Phase\u2010II\u2010Studie\u00a012\u2010015\u00a0(NCT0 1614821,\u00a0Treon\u00a0\net\u00a0al.,\u00a02015)\u00a0des\u00a0US\u2010amerikanischen\u00a0 Dana\u2010Farber\u00a0Cancer\u00a0Institute \u00a0mit\u00a063\u00a0vorthera\u2010\npierten\u00a0Patienten\u00a0mit\u00a0symptomatischem\u00a0MW.\u00a0Das\u00a0PFS\u00a0bzw.\u00a0OS\u00a0betru g\u00a0nach\u00a024\u00a0\nMonaten\u00a069,1\u00a0%\u00a0bzw.\u00a095,2\u00a0%,\u00a0die\u00a0ORR\u00a090,5\u00a0%.\u00a0Damit\u00a0erreichte\u00a0die \u00a0Anwendung\u00a0von\u00a0\nIbrutinib\u00a0die\u00a0bisher\u00a0h\u00f6chste\u00a0Remission\u00a0unter\u00a0den\u00a0monotherapeuti schen\u00a0Interven\u2010\nti o nen\u00a0bei\u00a0vo rtherapi ertem \u00a0MW.\u00a0Zu\u00a0den\u00a0h\u00e4uf i g sten\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03) \u00a0g e h \u00f6 r t e n \u00a0\nNeutropenie\u00a0 (15\u00a0 %),\u00a0 Thrombozytopenie\u00a0 (13\u00a0 %),\u00a0 febrile\u00a0 Neutropeni e,\u00a0 An\u00e4mie,\u00a0\nInfektionen\u00a0wie\u00a0Pneumonie,\u00a0Herpes\u00a0Zoster,\u00a0Harnwegsinfekte\u00a0und\u00a0V orhofflimmern\u00a0\n(jeweils\u00a0ca.\u00a02\u00a0%).\u00a0\nDer\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Hu\u2010\nman\u00a0Use,\u00a0CHMP)\u00a0bef\u00fcrwortete\u00a0angesichts\u00a0der\u00a0positiven\u00a0Effekte\u00a0von\u00a0Ibrut inib\u00a0des\u2010\nsen\u00a0Zulassung,\u00a0beanstandete\u00a0jedoch\u00a0das\u00a0Fehlen\u00a0von\u00a0Langzeitdaten \u00a0zur\u00a0Wirksam\u2010\nkeit\u00a0wie\u00a0auch\u00a0zu\u00a0unerw\u00fcnschten\u00a0Wirkungen.\u00a0Daher\u00a0wurde\u00a0die\u00a0Zulas sungserteilung\u00a0\nan\u00a0Bedingungen\u00a0gekn\u00fcpft.\u00a0Diese\u00a0sehen\u00a0die\u00a0regelm\u00e4\u00dfige\u00a0Vorlage\u00a0vo n\u00a0aktualisierten\u00a0\nBerichten\u00a0\u00fcber\u00a0die\u00a0Unbedenklichkeit\u00a0des\u00a0Arzneimittels\u00a0( Periodic\u00a0Safety\u00a0Update\u00a0\nReport,\u00a0PSUR)\u00a0sowie\u00a0die\u00a0Implementierung \u00a0eines\u00a0Risiko\u2010Management\u2010Plans \u00a0(RMP)\u00a0\nvor.\u00a0Weiterhin\u00a0sollte\u00a0die\u00a0finale\u00a0Auswertung\u00a0der\u00a0Studie\u00a0MCL3001\u00a0 vorgelegt\u00a0und\u00a0\nDaten\u00a0der\u00a0Nachbeobachtung\u00a0der\u00a0Studie\u00a01112\u00a0zu\u00a0Krankheitsprogress ion\u00a0und\u00a0Todes\u2010\nf\u00e4llen\u00a0sowie\u00a0zum\u00a0PFS\u00a02\u00a0( Progression\u00a0Free\u00a0Survival\u00a02 )\u00a0erfasst\u00a0und\u00a0an\u00a0die\u00a0Beh\u00f6rde\u00a0\n\u00fcbermittelt\u00a0werden\u00a0(EMA,\u00a02014).\u00a0\nIm\u00a0Jahr\u00a02015\u00a0publizierten\u00a0Byrd\u00a0und\u00a0Kollegen\u00a0erste\u00a0Ergebnisse\u00a0zu \u00a0unerw\u00fcnschten\u00a0\nEreignissen\u00a0nach\u00a0dreij\u00e4hriger\u00a0Ei nnahme\u00a0von\u00a0Ibrutinib.\u00a0Die\u00a0Auswe rtung\u00a0umfasste\u00a0\nDaten\u00a0der\u00a0Phase\u00a0Ib/II\u2010Studie\u00a0PCYC\u20101102\u2010CA\u00a0sowie\u00a0der\u00a0Phase\u00a0II\u2010St udie\u00a0PCYC\u20101103\u2010\nCA\u00a0(Sponsor:\u00a0Pharmacyclics)\u00a0von\u00a0132\u00a0Patienten\u00a0mit\u00a0therapienaive r\u00a0und\u00a0rezidivier\u2010\nter\u00a0bzw.\u00a0refrakt\u00e4rer\u00a0CLL.\u00a0Zu\u00a0den\u00a0beobachteten\u00a0UAE\u00a0mit\u00a0Schweregr ad\u00a0\u2265\u00a03\u00a0geh\u00f6rten\u00a0\narterielle\u00a0Hypertonie,\u00a0Pneumonie,\u00a0Neutropenie\u00a0und\u00a0Thrombozytope nie.\u00a0Die\u00a0Er\u2010\ngebnisse\u00a0best\u00e4tigten\u00a0die\u00a0Beobachtungen\u00a0aus\u00a0vorangegangenen\u00a0Stud ien.\u00a0In\u00a0der\u00a0\nGesamtschau\u00a0fehlen\u00a0jedoch\u00a0insbesondere\u00a0Langzeitdaten\u00a0zu\u00a0kardiov askul\u00e4ren\u00a0Ne\u2010\nbenwirkungen.\u00a0Dabei\u00a0geh\u00f6ren\u00a0Herz \u2010Kreislauf\u2010Erkrankungen\u00a0zu\u00a0den\u00a0 h\u00e4ufigen\u00a0Kom\u2010\nplikationen\u00a0 einer\u00a0 medikament\u00f6sen\u00a0 und\u00a0 radiologischen\u00a0 Tumortherap ie,\u00a0 die\u00a0 mit\u00a0\neinem\u00a0erh\u00f6hten\u00a0kardialen\u00a0Sterberisiko\u00a0assoziiert\u00a0sind\u00a0(Henson\u00a0e t\u00a0al.,\u00a02016).\u00a0Die\u00a0\nEurop\u00e4ische\u00a0 Gesellschaft\u00a0 f\u00fcr\u00a0 Kardiologie\u00a0 ( European\u00a0 Society\u00a0 of\u00a0 Cardiology,\u00a0 ESC )\u00a0\nver\u00f6ffentlichte\u00a0k\u00fcrzlich\u00a0ein\u00a0Positionspapier,\u00a0in\u00a0dem\u00a0die\u00a0Expert en\u00a0auf\u00a0die\u00a0Bedeutung\u00a0\ndieser\u00a0Problematik\u00a0aufmerksam\u00a0ma chen\u00a0und\u00a0Strategien\u00a0zur\u00a0Risikor eduktion\u00a0kardi\u2010\novaskul\u00e4rer\u00a0Komplikationen\u00a0vors tellen\u00a0(Zamorano\u00a0et\u00a0al.,\u00a02016).\u00a0\nDar\u00fcber\u00a0 hinaus\u00a0 fehlen\u00a0 Erhebungen\u00a0 zur\u00a0 gesundheitsbezogenen\u00a0 Leben squalit\u00e4t\u00a0\n(Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL).\u00a0In\u00a0einer\u00a0noch\u00a0bis\u00a0voraussichtlich\u00a02020\u00a0223\u00a0laufenden\u00a0 Phase\u2010III\u2010Studie\u00a0 (NCT\u00a0 02048813)\u00a0 soll\u00a0 insbesondere\u00a0 die ses\u00a0Outcome\u00a0\nerhoben\u00a0werden. \u00a0\nLeitlinienempfehlungen\u00a0\nIm\u00a0Anwendungsgebiet\u00a0CLL\u00a0ist\u00a0die\u00a0e inzige\u00a0kurative\u00a0Therapiem\u00f6glic hkeit\u00a0die\u00a0allogene\u00a0\nKnochenmark\u2010\u00a0 bzw.\u00a0 Blutstammzelltransplantation,\u00a0 die\u00a0 jedoch\u00a0 eine s\u00a0 geeigneten\u00a0\nSpenders\u00a0bedarf\u00a0und\u00a0mit\u00a0hoher\u00a0Morbidit\u00e4t\u00a0und\u00a0Mortalit\u00e4t\u00a0verbund en\u00a0ist.\u00a0W\u00e4hrend\u00a0\nPatienten\u00a0im\u00a0Binet\u2010Stadium\u00a0A\u00a0und\u00a0B\u00a0und\u00a0Patienten\u00a0mit\u00a0einer\u00a0stab ilen\u00a0Erkrankung\u00a0\nh\u00e4ufig\u00a0keiner\u00a0Therapie\u00a0bed\u00fcrfe n\u00a0und\u00a0nur\u00a0engmaschig\u00a0beobachtet\u00a0w erden\u00a0(Watch\u2010\nand\u2010Wait \u2010Strategie),\u00a0besteht\u00a0im\u00a0Binet\u2010Stadium\u00a0C\u00a0und\u00a0bei\u00a0einer\u00a0rasch\u00a0vor anschrei\u2010\ntenden\u00a0oder\u00a0symptomatischen\u00a0Erkrankung\u00a0immer\u00a0eine\u00a0Therapieindik ation.\u00a0Gene\u2010\nrell\u00a0haben\u00a0Patienten\u00a0mit\u00a0del(17p 13)\u00a0oder\u00a0TP53\u2010\u00a0Mutation\u00a0eine\u00a0un g\u00fcnstige\u00a0Progno\u2010\nse,\u00a0zusammen\u00a0mit\u00a0den\u00a0nicht\u00a0oder\u00a0nur\u00a0unzureichend\u00a0auf\u00a0die\u00a0Erstli nientherapie\u00a0\nansprechenden\u00a0Patienten\u00a0gelten\u00a0s ie\u00a0als\u00a0Hochrisiko\u2010CLL\u2010Patienten .\u00a0Ein\u00a0allgemein\u00a0\ng\u00fcltiges\u00a0Behandlungsregime\u00a0gibt\u00a0e s\u00a0nicht,\u00a0die\u00a0Therapiewahl\u00a0orie ntiert\u00a0sich\u00a0am\u00a0\nAllgemeinzustand\u00a0und\u00a0der\u00a0Komorbidit\u00e4t,\u00a0ermittelt\u00a0z.B.\u00a0durch\u00a0den \u00a0CIRS\u00a0(Cumulative\u00a0\nIllness\u00a0 Rating\u00a0 Scale )\u2010Score,\u00a0 am\u00a0 genetischen\u00a0 Status,\u00a0 an\u00a0 der\u00a0 Nierenfunktion\u00a0 und\u00a0\nweniger\u00a0am\u00a0kalendarischen\u00a0Alter. \u00a0Wenn\u00a0immer\u00a0m\u00f6glich,\u00a0soll\u00a0die\u00a0T herapie\u00a0im\u00a0Rah\u2010\nmen\u00a0klinischer\u00a0Studien\u00a0erfolgen.\u00a0F\u00fcr\u00a0die\u00a0Patienten\u00a0mit\u00a0Nachweis \u00a0einer\u00a0del(17p13)\u00a0\nbzw.\u00a0TP53\u2010Mutation,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemo\u2010Immuntherapie\u00a0nicht\u00a0infr age\u00a0kommt,\u00a0\nwird\u00a0Ibrutinib\u00a0neben\u00a0Idelalisib\u00a0b ereits\u00a0in\u00a0der\u00a0Erstlinie\u00a0empfoh len.\u00a0Weiterhin\u00a0stellt\u00a0\ndie\u00a0 Behandlung\u00a0 mit\u00a0 Ibrutinib\u00a0 als\u00a0 Monotherapie\u00a0 oder\u00a0 in\u00a0 Kombinati on\u00a0 mit\u00a0\nBendamustin\u00a0und\u00a0Rituximab\u00a0eine\u00a0Option\u00a0f\u00fcr\u00a0jene\u00a0Hochrisikopatien ten\u00a0dar,\u00a0die\u00a0\nnicht\u00a0auf\u00a0die\u00a0Standardtherapien\u00a0ansprechen,\u00a0nur\u00a0eine\u00a0kurze\u00a0Remi ssion\u00a0(unter\u00a0zwei\u00a0\nJahren)\u00a0erzielen\u00a0oder\u00a0bei\u00a0Vorlie gen\u00a0einer\u00a0del\u00a0(17p13)\u00a0bzw.\u00a0TP53 \u2010Mutation\u00a0ein\u00a0\nRezidiv\u00a0erleiden.\u00a0Aktuell\u00a0wird\u00a0unter\u00a0Beteiligung\u00a0diverser\u00a0Fachg esellschaften\u00a0eine\u00a0\nS3\u2010Leitlinie\u00a0zum\u00a0Thema\u00a0CLL\u00a0erarb eitet,\u00a0deren\u00a0Fertigstellung\u00a0zum \u00a030.06.2017\u00a0ge\u2010\nplant\u00a0ist\u00a0(DGHO,\u00a02014;\u00a0AWMF,\u00a02017).\u00a0\nIn\u00a0der\u00a0Therapie\u00a0des\u00a0rezidivierten\u00a0oder\u00a0refrakt\u00e4ren\u00a0MCL\u00a0steht\u00a0mi t\u00a0Ibrutinib\u00a0ein\u00a0\nweiterer\u00a0Wirkstoff\u00a0zur\u00a0Verf\u00fcgung.\u00a0Die\u00a0Leitlinie\u00a0der\u00a0DGHO\u00a0nennt\u00a0 diese\u00a0Option\u00a0als\u00a0\nTherapieansatz\u00a0und\u00a0verweist\u00a0auf\u00a0das\u00a0Fehlen\u00a0randomisierter\u00a0Studi en\u00a0(DGHO,\u00a02016).\u00a0\nDer\u00a0Einsatz\u00a0von\u00a0Ibrutinib\u00a0zur\u00a0Be handlung\u00a0des\u00a0MW\u00a0Zweitlinie\u00a0oder \u00a0in\u00a0Erstlinie\u00a0bei\u00a0\nbestehender\u00a0Kontraindikation\u00a0gegen\u00a0eine\u00a0Chemo\u2010Immuntherapie\u00a0wir d\u00a0aktuell\u00a0in\u00a0\nkeiner\u00a0Leitlinie\u00a0erfasst.\u00a0Die\u00a0Leitlinie\u00a0der\u00a0DGHO,\u00a0Stand\u00a002/2010 ,\u00a0legt\u00a0keine\u00a0Stan\u2010\ndardtherapien\u00a0fest\u00a0und\u00a0ber\u00fccksichtigt\u00a0damit\u00a0die\u00a0ungen\u00fcgende\u00a0Dat enlage\u00a0(DGHO,\u00a0\n2010).\u00a0\n\u00a0224\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDie\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0von\u00a0Ibrutinib\u00a0mit\u00a0Beschluss\u00a0vom\u00a016.04 .2015\u00a0wurde\u00a0\nentsprechend\u00a0seiner\u00a0Zulassung\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0durchgef\u00fchrt.\u00a0Hier\u00a0gilt\u00a0der\u00a0\nmedizinische\u00a0Zusatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt\u00a0und\u00a0da s\u00a0Ausma\u00df\u00a0wird\u00a0\nausschlie\u00dflich\u00a0auf\u00a0der\u00a0Basis\u00a0de r\u00a0Zulassungsstudien\u00a0bewertet.\u00a0\nF\u00fcr\u00a0die\u00a0Indikation\u00a0 MCL\u00a0hat\u00a0der\u00a0G\u2010BA\u00a0den\u00a0 Zusatznutzen \u00a0aufgrund\u00a0der\u00a0lediglich\u00a0ein\u2010\narmigen,\u00a0 Open\u2010label \u00a0 durchgef\u00fchrten\u00a0 Zulassungsstudie\u00a0 als\u00a0 nicht\u00a0 quantifizierbar \u00a0\nbewertet.\u00a0Zum\u00a0gleichen\u00a0Ergebnis\u00a0kam\u00a0der\u00a0Ausschuss\u00a0bei\u00a0der\u00a0Bewer tung\u00a0f\u00fcr\u00a0die\u00a0\nIndikation\u00a0 CLL.\u00a0 Er\u00a0 attestiert\u00a0 der\u00a0 aktiv\u00a0 kontrollierten,\u00a0 offenen\u00a0 Phase\u2010III\u2010Stu die\u00a0\nRESONATE\u00a0ein\u00a0hohes\u00a0Verzerrungsris iko\u00a0aufgrund\u00a0der\u00a0fehlenden\u00a0Ver blindung.\u00a0\u00a0\nEin\u00a0am\u00a001.08.2015\u00a0begonnenes\u00a0Verfahren\u00a0zur\u00a0Nutzenbewertung\u00a0des\u00a0 neuen\u00a0An\u2010\nwendungsgebietes\u00a0MW\u00a0wurde\u00a0aufgrund\u00a0der\u00a0Einstufung\u00a0als\u00a0\u201eArzneimi ttel\u00a0zur\u00a0\u00a0Be\u2010\nhandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u201c\u00a0eingestellt.\u00a0Weiterhin\u00a0\u00fcbersch ritt\u00a0der\u00a0Umsatz\u00a0\nvon\u00a0Ibrutinib\u00a0im\u00a0Oktober\u00a02015\u00a0die\u00a0Grenze\u00a0von\u00a050\u00a0Mio.\u00a0Euro,\u00a0was\u00a0 eine\u00a0erneute\u00a0\nNutzenbewertung\u00a0erforderlich\u00a0machte.\u00a0F\u00fcr\u00a0das\u00a0Anwendungsgebiet\u00a0\u00a0 CLL\u00a0konnte\u00a0f\u00fcr\u00a0\nPatienten,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemotherapie\u00a0angezeigt\u00a0war,\u00a0kein\u00a0Zusat znutzen\u00a0belegt\u00a0\nwerden.\u00a0F\u00fcr\u00a0Patienten,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemotherapie\u00a0nicht\u00a0angezei gt\u00a0ist,\u00a0wurde\u00a0ein\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0nicht\u2010quantifizierbaren\u00a0Zusatznutzen\u00a0im\u00a0 Vergleich\u00a0zu\u00a0Ofa\u2010\ntumumab\u00a0plus\u00a0 Best\u2010Supportive\u2010Care \u00a0(BSC)\u00a0festgestellt.\u00a0Gleiches\u00a0ergab\u00a0sich\u00a0auch\u00a0f\u00fcr\u00a0\nPatienten\u00a0 mit\u00a0 17p\u2010Delet ion\u00a0 oder\u00a0 einer\u00a0 TP53\u2010 Mutation,\u00a0 die\u00a0 f\u00fcr\u00a0 ei ne\u00a0 Chemo\u2010\nImmuntherapie\u00a0ungeeignet\u00a0sind.\u00a0F\u00fcr\u00a0die\u00a0Indikation\u00a0 MCL\u00a0konnte\u00a0f\u00fcr\u00a0die\u00a0Teilpopula\u2010\ntion\u00a0von\u00a0Patienten,\u00a0f\u00fcr\u00a0die\u00a0Temsirolismus\u00a0eine\u00a0Behandlungsoptio n\u00a0darstellt,\u00a0ein\u00a0\nHinweis\u00a0 auf\u00a0 einen\u00a0 betr\u00e4chtlichen\u00a0 Zusatznutzen \u00a0 im\u00a0 Vergleich\u00a0 zu\u00a0 Temsirolimus\u00a0\ngefunden\u00a0werden.\u00a0 F\u00fcr\u00a0die\u00a0\u00fcbrigen\u00a0Patienten\u00a0konnte\u00a0kein\u00a0Zusatznutzen \u00a0belegt\u00a0\nwerden.\u00a0F\u00fcr\u00a0Anwendungsgebiet\u00a0 MW\u00a0konnte\u00a0kein\u00a0belegbarer\u00a0Zusatznutzen \u00a0festge\u2010\nstellt\u00a0werden.\u00a0\nNach\u00a0Erweiterung\u00a0der\u00a0Zulassung,\u00a0die\u00a0das\u00a0neue\u00a0Anwendungsgebiet\u00a0a ls\u00a0Einzelsub\u2010\nstanz\u00a0zur\u00a0Behandlung\u00a0erwachsener\u00a0Patienten\u00a0mit\u00a0nicht\u00a0vorbehande lter\u00a0CLL\u00a0vor\u2010\nsieht\u00a0und\u00a0\u00dcberschreitung\u00a0der\u00a0Umsatzgrenze\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0wurd e\u00a0ein\u00a0erneutes\u00a0\nBewertungsverfahren\u00a0eigeleitet\u00a0und\u00a0der\u00a0Beschluss\u00a0am\u00a015.12.2016\u00a0 ver\u00f6ffentlicht.\u00a0\nDer\u00a0G\u2010BA\u00a0kam\u00a0zu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0f\u00fcr\u00a0Patienten,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0C hemo\u2010Immun\u2010\ntherapie\u00a0infrage\u00a0kommt,\u00a0ein\u00a0 Zusatznutzen \u00a0gegen\u00fcber\u00a0einer\u00a0Kombination\u00a0aus\u00a0FCR\u00a0\nnicht\u00a0belegt \u00a0ist.\u00a0Zur\u00a0geleichen\u00a0Einsch\u00e4tzung\u00a0kam\u00a0er\u00a0bei\u00a0Patienten,\u00a0bei\u00a0dene n\u00a0eine\u00a0\nBehandlung\u00a0mit\u00a0FCR\u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0gilt\u00a0gegen\u00fcber\u00a0einer\u00a0Chem o\u2010Immuntherapie\u00a0\nnach\u00a0Ma\u00dfgabe\u00a0des\u00a0Arztes\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0Zulassungsst atus.\u00a0Auch\u00a0f\u00fcr\u00a0\nPatienten,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemo\u2010Im muntherapie\u00a0nicht\u00a0infrage\u00a0kommt \u00a0und\u00a0die\u00a0keine\u00a0\n17p\u2010Deletion\u00a0oder\u00a0TP53\u2010Mutation\u00a0aufweisen,\u00a0gilt\u00a0ein\u00a0 Zusatznutzen \u00a0im\u00a0Vergleich\u00a0zu\u00a0\neiner\u00a0BSC\u00a0 nicht\u00a0belegt .\u00a0225\u00a0Dar\u00fcber\u00a0hinaus\u00a0wurde\u00a0am\u00a001.10.2016\u00a0ein\u00a0weiteres\u00a0Verfahren\u00a0einge leitet,\u00a0um\u00a0den\u00a0\nZusatznutzen\u00a0innerhalb\u00a0des\u00a0neuen\u00a0 Anwendungsgebietes,\u00a0dass\u00a0die\u00a0K ombination\u00a0\nvon\u00a0Ibrutinib\u00a0mit\u00a0BR\u00a0zur\u00a0Behandlung\u00a0erwachsener\u00a0Patienten\u00a0mit\u00a0C LL,\u00a0die\u00a0mindes\u2010\ntens\u00a0eine\u00a0vorangehende\u00a0Therapie\u00a0erhalten\u00a0haben\u00a0umfasst.\u00a0Auch\u00a0in \u00a0diesem\u00a0Fall\u00a0\nwurde\u00a0die\u00a0Umsatzgrenze\u00a0von\u00a05 0\u00a0Mio.\u00a0Euro\u00a0\u00fcberschritten.\u00a0\nVersorgungsanalysen\u00a0\nIm\u00a0dritten\u00a0Monat\u00a0nach\u00a0Markteintritt\u00a0zeigt\u00a0sich\u00a0ein\u00a0sprunghafter \u00a0Anstieg\u00a0der\u00a0Anzahl\u00a0\nder\u00a0verordneten\u00a0Packungen\u00a0auf\u00a080\u00a0Einheiten.\u00a0Dieser\u00a0Effekt\u00a0ist\u00a0d urchaus\u00a0charakte\u2010\nristisch\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0 Orphan\u00a0Designation \u00a0und\u00a0spiegelt\u00a0den\u00a0therapeutischen\u00a0\nBedarf\u00a0wieder.\u00a0Erst\u00a0im\u00a0M\u00e4rz\u00a0und\u00a0April\u00a02015\u00a0wird\u00a0dieser\u00a0Trend\u00a0un terbrochen.\u00a0Asso\u2010\nziiert\u00a0ist\u00a0dieser\u00a0Trendwechsel\u00a0mit\u00a0dem\u00a0Abschluss\u00a0des\u00a0ersten\u00a0Ver fahrens\u00a0zur\u00a0Nut\u2010\nzenbewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0am\u00a016.\u00a0April\u00a02015,\u00a0in\u00a0dem\u00a0das\u00a0Gremi um\u00a0lediglich\u00a0\neinen\u00a0nicht\u2010quantifizierbaren\u00a0Zusatznutzen\u00a0feststellte.\u00a0Trotzde m\u00a0nehmen\u00a0die\u00a0Ver\u2010\nordnungsvolumina\u00a0mit\u00a0leichter\u00a0Fluktuation\u00a0bis\u00a0zum\u00a0Jahresende\u00a0zu \u00a0und\u00a0erreichen\u00a0\nim\u00a0Dezember\u00a0einen\u00a0Maximalwert\u00a0von\u00a0147\u00a0Packungen.\u00a0Bereits\u00a0seit\u00a0M arkteintritt\u00a0\nsind\u00a0zwei\u00a0verschiedenen\u00a0Packungsgr\u00f6\u00dfen\u00a0verf\u00fcgbar:\u00a0Zum\u00a0einen\u00a0ein e\u00a0Einheit\u00a0ohne\u00a0\nNormierung\u00a0mit\u00a090\u00a0Kapseln\u00a0und\u00a0zum\u00a0anderen\u00a0eine\u00a0N3\u2010Gr\u00f6\u00dfe\u00a0mit\u00a0120 \u00a0Kapseln.\u00a0Im\u00a0\nHinblick\u00a0auf\u00a0die\u00a0Verordnungsh\u00e4ufi gkeit\u00a0\u00fcberwiegt\u00a0der\u00a0Anteil\u00a0der \u00a0Einheiten\u00a0ohne\u00a0\nNormierung,\u00a0obgleich\u00a0mit\u00a0r\u00fcckl\u00e4ufiger\u00a0Tendenz.\u00a0Lag\u00a0ihr\u00a0Anteil\u00a0a m\u00a0Gesamtvolumen\u00a0\nim\u00a0M\u00e4rz\u00a02015\u00a0noch\u00a0bei\u00a069\u00a0%\u00a0sind\u00a0es\u00a0zu\u00a0Jahresende\u00a053\u00a0%.\u00a0\u00a0\nIm\u00a0in\u00a0Abb.\u00a04.19\u00a0dargestellten\u00a0Versichertenkollektiv\u00a0wurden\u00a095\u00a0% \u00a0der\u00a0Packungen\u00a0\naus\u00a02015\u00a0f\u00fcr\u00a0Erkrankte\u00a0zwischen\u00a050\u00a0und\u00a089\u00a0verordnet.\u00a0Dabei\u00a0betr \u00e4gt\u00a0der\u00a0Anteil\u00a0\nallein\u00a0f\u00fcr\u00a0die\u00a0Altersgruppe\u00a0der\u00a070\u2010\u00a0bis\u00a079\u2010J\u00e4hrigen\u00a043\u00a0%.\u00a0Diese \u00a0Verteilung\u00a0reflektiert\u00a0\ndurchaus\u00a0die\u00a0epidemiologische\u00a0Rea lit\u00e4t.\u00a0So\u00a0liegt\u00a0das\u00a0mittlere\u00a0E rkrankungsalter\u00a0von\u00a0\nCLL\u00a0in\u00a0der\u00a0siebten\u00a0Lebensdekade,\u00a0f\u00fcr\u00a0MCL\u00a0in\u00a0der\u00a0sechsten.\u00a0Dageg en\u00a0entspricht\u00a0die\u00a0\nbeobachtete\u00a0 Geschlechterverteilung\u00a0 nicht\u00a0 dem\u00a0 aktuellen\u00a0 wissensc haftlichen\u00a0\nStand,\u00a0die\u00a0Erkrankungen\u00a0haben\u00a0bei \u00a0beiden\u00a0Geschlechtern\u00a0eine\u00a0\u00e4hn liche\u00a0Pr\u00e4valenz.\u00a0226\u00a0Abbildung\u00a0 4.19:\u00a0 Anzahl\u00a0 verordneter\u00a0 Packungen\u00a0 Ibrutinib\u00a0 je\u00a0 Monat \u00a0 nach\u00a0 Pa\u2010\nckungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015) \u00a0\n\u00a0\nAbbildung\u00a04.20:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Ibrutini b\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n227\u00a0Quellen\u00a0\nAMB\u00a0\u2013\u00a0Arzneimittelbrief\u00a0(2015).\u00a0Ibrutinib:\u00a0Erste\u00a0Ergebnisse\u00a0zu\u00a0 unerw\u00fcnschten\u00a0Ereignissen\u00a0nach\u00a0dreij\u00e4hriger\u00a0Einnahme\u00a0und\u00a0zum\u00a0\nKrankheitsverlauf\u00a0nach\u00a0Absetzen\u00a0des\u00a0Wirkstoffs.AMB\u00a049:\u00a068b.\u00a0\nAMB\u00a0\u2013\u00a0Arzneimittelbrief\u00a0(2016).\u00a0Kardiovaskul\u00e4re\u00a0Nebenwirkungen\u00a0 und\u00a0Komplikationen\u00a0bei\u00a0onkologischen\u00a0Therapien.\u00a0AMB\u00a050:\u00a089.\u00a0\nAWMF\u00a0online\u00a0(2017).\u00a0Angemeldetes\u00a0Leitlinienvorhaben.\u00a0Registernu mmer\u00a0018\u00a0\u2010\u00a0032OL.\u00a0Klassifikation\u00a0S3.\u00a0Diagnostik,\u00a0Therapie\u00a0und\u00a0\nNachsorge\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0einer\u00a0chronisch\u00a0lymphatischen\u00a0Leuk\u00e4 mie.\u00a0\nhttp://www.awmf.org/leitlinien/detail/anmeldung/1/ll/018\u2010032OL. html,\u00a0letzter\u00a0Zugriff\u00a030.04.2017.\u00a0\nByrd\u00a0JC,\u00a0Brown\u00a0JR,\u00a0O\u2019Brien\u00a0S,\u00a0Barrientos\u00a0JC,\u00a0Kay\u00a0NE,\u00a0Reddy\u00a0NM\u00a0e t\u00a0al.\u00a0(2014).\u00a0Ibrutinib\u00a0versus\u00a0Ofatumumab\u00a0in\u00a0Previously\u00a0Treated \u00a0\nChronic\u00a0Lymphoid\u00a0Leukemia.\u00a0NEJM\u00a0371(3):\u00a0213\u2010223.\u00a0\u00a0\nByrd\u00a0JC,\u00a0Furman\u00a0RR,\u00a0Coutre\u00a0SE,\u00a0Burger\u00a0JA,\u00a0Blum\u00a0KA,\u00a0Coleman\u00a0M\u00a0et \u00a0al.\u00a0(2015).\u00a0Three\u2010year\u00a0follow\u2010up\u00a0of\u00a0treatment\u2010na\u00efve\u00a0and\u00a0\npreviously\u00a0treated\u00a0patients\u00a0with \u00a0CLL\u00a0and\u00a0SLL\u00a0receiving\u00a0single\u2010a gent\u00a0ibrutinib.\u00a0Blood\u00a0125\u00a0(16):\u00a02497\u20102506.\u00a0\u00a0\nByrd\u00a0JC,\u00a0Furman\u00a0RR,\u00a0Coutre\u00a0SE,\u00a0Flinn\u00a0IW,\u00a0Burger\u00a0JA,\u00a0Blum\u00a0KA\u00a0et\u00a0 al.(2013).\u00a0Targeting\u00a0BTK\u00a0with\u00a0Ibrutinib\u00a0in\u00a0Relapsed\u00a0Chronic\u00a0\nLymphocytic\u00a0Leukemia.\u00a0NEJM\u00a0369(1):\u00a032\u201042.\u00a0\u00a0\nChanan\u2010Khan\u00a0A,\u00a0Cramer\u00a0P.,\u00a0Demirk an,\u00a0F,\u00a0Fraser\u00a0G,\u00a0Silva\u00a0RS,\u00a0Gros icki\u00a0S,\u00a0Hallek\u00a0M\u00a0et\u00a0al.\u00a0(2016).\u00a0Ibrutinib\u00a0combined\u00a0with\u00a0\nbendamustine\u00a0and\u00a0rituximab\u00a0compared\u00a0with\u00a0placebo,\u00a0bendamustine, \u00a0and\u00a0rituximab\u00a0for\u00a0previously\u00a0treated\u00a0chronic\u00a0\nlymphocytic\u00a0leukaemia\u00a0or\u00a0small\u00a0lymphocytic\u00a0lymphoma\u00a0(HELIOS):\u00a0a \u00a0randomised,\u00a0double\u2010blind,\u00a0phase\u00a03\u00a0study.\u00a0The\u00a0\nLancet\u00a0Oncology\u00a017(2):\u00a0200\u2010211.\u00a0\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0Medizinische\u00a0O nkologie\u00a0e.V.\u00a0(2016).\u00a0Mantelzell\u2010Lymphom.\u00a0Stand\u00a0der\u00a0\nInformation:\u00a0Februar\u00a02016.\u00a0ICD\u00a0C83.1.\u00a0https://www.onkopedia.com /de/onkopedia/archive/guidelines/mantelzell\u2010\nlymphom/version\u201014032017T145051/@@view/html/index.html,\u00a0letzter \u00a0Zugrifff:\u00a015.09.17.\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0Medizinische\u00a0O nkologie\u00a0e.V.\u00a0(2014).\u00a0Chronische\u00a0Lymphatische\u00a0Leuk\u00e4mie\u00a0(CLL).\u00a0\nStand\u00a0der\u00a0Information:\u00a0November\u00a02014.\u00a0https://www.onkopedia.com /de/onkopedia/archive/guidelines/\u00a0\nchronische\u2010lymphatische\u2010leukaemie\u2010cll/version\u201011012017T142015/@ @view/html/index.html,\u00a0letzter\u00a0Zugrifff:\u00a0\n12.01.17.\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0Medizinische\u00a0O nkologie\u00a0e.V.\u00a0(2010).\u00a0Morbus\u00a0Waldenstr\u00f6m\u00a0(Stand\u00a0der\u00a0\nInformation:\u00a0Februar\u00a02010).\u00a0https://www.onkopedia.com/de/onkope dia/archive/guidelines/morbus\u2010\nwaldenstroem/version\u201017052017T143636/@@view/html/index.html,,\u00a0l etzter\u00a0Zugrifff:\u00a015.12.16.\u00a0\nDreyling\u00a0M,\u00a0Geisler\u00a0C,\u00a0Hermine\u00a0 O,\u00a0Kluin\u2010Nelemans\u00a0HC,\u00a0Le\u00a0Gouill\u00a0 S,\u00a0Rule\u00a0S\u00a0et\u00a0al.\u00a0(2014).\u00a0Newly\u00a0diagnosed\u00a0and\u00a0relapsed\u00a0mantle\u00a0ce ll\u00a0\nlymphoma:\u00a0ESMO\u00a0Clinical \u00a0Practice\u00a0Guidelines\u00a0for\u00a0diagnosis,\u00a0trea tment\u00a0and\u00a0follow\u2010up.\u00a0Ann\u00a0O ncol,\u00a025\u00a0(Suppl\u00a03),\u00a0iii83\u2010\n92.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014).\u00a0Summary\u00a0of\u00a0product\u00a0char acteristics.\u00a0Stand\u00a0der\u00a0Information:\u00a0Oktober\u00a02016.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Product_Information/human/003791/WC500177775.pdf,\u00a0letzter\u00a0Zugr iff:\u00a028.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Assessment\u00a0report.\u00a0Imbr uvica.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Assessment _Report_\u2010\n_Variation/human/003791/WC500191947.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06 .2017.\u00a0\nFachinformation\u00a0Imbruvica\u00ae\u00a0(2016).\u00a0Fachinformation\u00a0Imbruvica\u00ae.\u00a0 Stand\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0\u00a0\nFricke\u00a0U,\u00a0G\u00fcnther\u00a0J,\u00a0Niepraschk\u2010 von\u00a0Dollen\u00a0K,\u00a0Zawinell\u00a0A\u00a0(2017) .\u00a0Anatomisch\u2010therapeutische\u2010chemische\u00a0Klassifikation\u00a0mit\u00a0\nTagesdosen\u00a0\u2010\u00a0Amtliche\u00a0Fassung\u00a0des \u00a0ATC\u2010Index\u00a0mit\u00a0DDD\u2010Angaben\u00a0f\u00fcr \u00a0Deutschland\u00a0im\u00a0Jahre\u00a02017.\u00a0\nhttp://www.dimdi.de/dynamic/de/klassi/downloadcenter/atcddd/ver sion2017/atc\u2010ddd\u2010amtlich\u20102017.pdf,\u00a0letzter\u00a0\nZugriff:\u00a013.01.2017.\u00a0228\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013Ibrutinib.\u00a0Stand\u00a0der\u00a0In formation:\u00a0April\u00a02015.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104102/2016\u201012\u201015_AM\u2010RL\u2010XII_Ibrutinib_nAWG _D\u2010249_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2017.\u00a0\nGEKID\u00a0\u2013\u00a0Gesellschaft\u00a0der\u00a0epidemio logischen\u00a0Krebsregister\u00a0in\u00a0Deu tschland\u00a0(2017).\u00a0GEKID\u2010Atlas.\u00a0\nhttp://www.gekid.de/Atlas/CurrentVersion/atlas.html,\u00a0letzter\u00a0Zu grifff:\u00a015.09.17.\u00a0\nKapoor\u00a0P,\u00a0Ansell\u00a0SM,\u00a0Fonseca\u00a0R,\u00a0 Chanan\u2010Khan\u00a0A,\u00a0Kyle\u00a0RA,\u00a0Kumar\u00a0S K\u00a0et\u00a0al.\u00a0(2017).\u00a0Diagnosis\u00a0and\u00a0management\u00a0of\u00a0Waldenstr\u00f6m\u00a0\nmacroglobulinemia:\u00a0Mayo\u00a0stratification\u00a0of\u00a0macroglobulinemia\u00a0and \u00a0risk\u2010adapted\u00a0therapy\u00a0(mSMART)\u00a0guidelines\u00a02016.\u00a0\nJAMA\u00a0oncology.\u00a0\nLauer\u2010Fischer\u00a0(2015).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a0November\u00a02015.\u00a0http://www2.lauer\u2010\nfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosystem/,\u00a0letzter\u00a0Zugr iff:\u00a031.03.2017.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a0Mai\u00a02017.\u00a0http://www2.lauer\u2010\nfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosystem/,\u00a0letzter\u00a0Zugr iff:\u00a031.03.2017.\u00a0\nLee\u00a0CS,\u00a0Rattu\u00a0MA,\u00a0Kim\u00a0SS\u00a0(2016).\u00a0A\u00a0review\u00a0of\u00a0a\u00a0novel,\u00a0Bruton\u2019s\u00a0 tyrosine\u00a0kinase\u00a0inhibitor,\u00a0ibrutinib.\u00a0Journal\u00a0of\u00a0Oncology\u00a0Pharm acy\u00a0\nPractice\u00a022(1):\u00a092\u2010104.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0Ibrutinib\u00a0\u2010\u00a0Relapsed\u00a0chronic\u00a0ly mphocytic\u00a0leukaemia\u00a0and\u00a0mantle\u00a0cell\u00a0lymphoma:\u00a0uncertain\u00a0impact\u00a0 on\u00a0\nsurvival.\u00a0Prescrire\u00a0Int\u00a025(170):\u00a089\u201092.\u00a0\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutischen\u00a0Zeitung\u00a0online\u00a0(2017).\u00a0Neue\u00a0Arzneimittel, \u00a0Ibrutinib.\u00a0\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=55374,\u00a0letzter\u00a0Zugriff:\u00a001.08.2017.\u00a0\nTreon\u00a0SP,\u00a0Tripsas\u00a0CK,\u00a0Meid\u00a0K,\u00a0Warren\u00a0D,\u00a0Varma\u00a0G,\u00a0Green\u00a0R\u00a0et\u00a0al. \u00a0(2015).\u00a0Ibrutinib\u00a0in\u00a0previously\u00a0treated\u00a0Waldenstr\u00f6m\u2019s\u00a0\nmacroglobulinemia.\u00a0NEJM\u00a0372(15):\u00a01430\u20101440.\u00a0\nWang\u00a0ML,\u00a0Rule\u00a0S,\u00a0Martin\u00a0P,\u00a0Goy\u00a0A,\u00a0Auer\u00a0R,\u00a0Kahl\u00a0BS\u00a0et\u00a0al.\u00a0(2013) .\u00a0Targeting\u00a0BTK\u00a0with\u00a0Ibrutinib\u00a0in\u00a0Relapsed\u00a0or\u00a0Refractory\u00a0Mantle \u2010Cell\u00a0\nLymphoma.\u00a0NEJM\u00a0369(6):\u00a0507\u2010516.\u00a0\n\u00a0 \u00a0229\u00a04.15 Idelalisib\u00a0\nHandelsname:\u00a0Zydelig\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0lymphatische\u00a0\u00a0 Gilead\u00a0Sciences\u00a0\nLeuk\u00e4mie,\u00a0Follikul\u00e4res\u00a0Lymphom\u00a0 \u00a0\nATC\u2010Code:\u00a0L01XX47\u00a0 \u00a0 \u00a0 Mar kteinf\u00fchrung:\u00a0Oktober\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtablette\u00a0 \u00a0 DDD:\u00a00,3\u00a0g\u00a0 \u00a0         \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nIdelalisib\u00a0ist\u00a0ein\u00a0oral\u00a0einzunehm ender\u00a0Hemmstoff\u00a0der\u00a0Phosphoino sitol\u20103\u2010Kinase\u00a0\n(PI3\u2010Kinase)\u00a0 und\u00a0 hemmt\u00a0 selektiv\u00a0 die\u00a0 Isoform\u00a0 Phosphatidylinosito l\u20103\u2010Kinase\u2010\u03b4\u00a0\n(PI3K\u03b4)\u00a0(Fachinformation\u00a0Zydelig\u00ae,\u00a02016).\u00a0Diese\u00a0ist\u00a0bei\u00a0reifen\u00a0 B\u2010Zell\u2010Neoplasien\u00a0wie\u00a0\nder\u00a0chronischen\u00a0lymphatischen\u00a0Leuk\u00e4mie\u00a0(CLL)\u00a0und\u00a0follikul\u00e4ren\u00a0L ymphomen\u00a0(FL)\u00a0\nhyperaktiv\u00a0und\u00a0verantwortlich\u00a0f\u00fc r\u00a0die\u00a0Bildung\u00a0einer\u00a0Reihe\u00a0von\u00a0 second\u00a0messengers ,\u00a0\ndie\u00a0eine\u00a0wichtige\u00a0Rolle\u00a0in\u00a0verschiedenen\u00a0Signaltransduktionsweg en\u00a0spielen,\u00a0welche\u00a0\ndie\u00a0Proliferation,\u00a0das\u00a0\u00dcberleben,\u00a0das\u00a0 Homing\u00a0und\u00a0die\u00a0Retention\u00a0maligner\u00a0Zellen\u00a0in\u00a0\nLymphgewebe\u00a0und\u00a0Knochenmark\u00a0vermitteln.\u00a0\nDer\u00a0Wirkstoff\u00a0wurde\u00a0im\u00a0September\u00a02014\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Komm ission\u00a0zuge\u2010\nlassen\u00a0zur\u00a0Behandlung\u00a0von\u00a0Erwachse nen\u00a0mit\u00a0CLL\u00a0in\u00a0Kombination\u00a0mi t\u00a0Rituximab\u00a0in\u00a0\nder\u00a0Zweitlinie\u00a0oder\u00a0als\u00a0Erstlinientherapie\u00a0bei\u00a0Vorliegen\u00a0einer\u00a0 17p\u2010Deletion\u00a0oder\u00a0\nTP53\u2010Mutation,\u00a0wenn\u00a0eine\u00a0Chemoimm untherapie\u00a0nicht\u00a0infrage\u00a0kommt .\u00a0Eine\u00a0wei\u2010\ntere\u00a0Indikation\u00a0ist\u00a0die\u00a0Monotherapie\u00a0von\u00a0Patienten\u00a0mit\u00a0FL\u00a0nach\u00a0 Versagen\u00a0von\u00a0zwei\u00a0\nvorausgegangenen\u00a0Therapielinien\u00a0 (EMA,\u00a02016).\u00a0Die\u00a0empfohlene\u00a0Dos is\u00a0von\u00a0Idelali\u2010\nsib\u00a0betr\u00e4gt\u00a0zweimal\u00a0t\u00e4glich\u00a0150\u00a0mg\u00a0oral.\u00a0\u00a0\nAufgrund\u00a0einer\u00a0erh\u00f6hten\u00a0Anzahl\u00a0infektionsbedingter\u00a0Todesf\u00e4lle\u00a0u nter\u00a0Idelalisib\u00a0in\u00a0\ndrei\u00a0laufenden\u00a0klinischen\u00a0Studien\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02016\u00a0ein\u00a0europ\u00e4 isches\u00a0Risikobe\u2010\nwertungsverfahren\u00a0eingeleitet\u00a0(EMA,\u00a02016).\u00a0Der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Ri sikobewertung\u00a0im\u00a0\nBereich\u00a0der\u00a0Pharmakovigilanz\u00a0( Pharmacovigilance\u00a0Risk\u00a0Assessment\u00a0Committee \u00a0\u2013\u00a0\nPRAC)\u00a0empfahl\u00a0die\u00a0Aufnahme\u00a0beso nderer\u00a0Warnhinweise\u00a0und\u00a0Vorsicht sma\u00dfnah\u2010\nmen\u00a0bez\u00fcglich\u00a0des\u00a0Risikos\u00a0f\u00fcr\u00a0schwerwiegende\u00a0Infektionen\u00a0in\u00a0die \u00a0Fachinformation\u00a0\nund\u00a0eine\u00a0Einschr\u00e4nkung\u00a0der\u00a0Zulassung\u00a0f\u00fcr\u00a0die\u00a0Teilpopulation\u00a0der \u00a0Patienten\u00a0mit\u00a0CLL\u00a0\nbei\u00a0Vorliegen\u00a0einer\u00a017p\u2010Deletion\u00a0oder\u00a0einer\u00a0TP53\u2010Mutation,\u00a0die\u00a0 f\u00fcr\u00a0eine\u00a0Chemo\u2010\nimmuntherapie\u00a0ungeeignet\u00a0sind.\u00a0F\u00fcr\u00a0diese\u00a0Teilpopulation\u00a0sollte\u00a0 Idelalisib\u00a0nicht\u00a0\nmehr\u00a0als\u00a0Erstlinientherapie\u00a0ange wendet\u00a0werden,\u00a0sondern\u00a0nur\u00a0noch \u00a0zur\u00a0Fortset\u2010\nzung\u00a0der\u00a0Therapie\u00a0bei\u00a0Patienten,\u00a0bei\u00a0denen\u00a0bereits\u00a0eine\u00a0Erstlin ientherapie\u00a0mit\u00a0\nIdelalisib\u00a0begonnen\u00a0wurde.\u00a0Nach\u00a0 Abschluss\u00a0des\u00a0Risikobewertungsv erfahrens\u00a0wur\u2010\nde\u00a0diese\u00a0Anwendungsbeschr\u00e4nkung\u00a0im\u00a0September\u00a02016\u00a0wieder\u00a0gelock ert,\u00a0so\u00a0dass\u00a0\nIdelalisib\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0einer\u00a017p\u2010Deletion\u00a0oder\u00a0einer\u00a0TP53 \u2010Mutation,\u00a0bei\u00a0de\u2010\nnen\u00a0keine\u00a0anderen\u00a0Therapien\u00a0geeignet\u00a0sind,\u00a0auch\u00a0in\u00a0der\u00a0Erstlini e\u00a0angewendet\u00a0\n230\u00a0werden\u00a0kann.\u00a0Ebenfalls\u00a0noch\u00a0im\u00a0September\u00a02016\u00a0erfolgte\u00a0eine\u00a0Ind ikationserweite\u2010\nrung\u00a0f\u00fcr\u00a0Idelalisib\u00a0dahingehend,\u00a0dass\u00a0es\u00a0nicht\u00a0nur\u00a0in\u00a0Kombinati on\u00a0mit\u00a0Rituximab,\u00a0\nsondern\u00a0 auch\u00a0 mit\u00a0 Ofatumumab\u00a0 (weit erer\u00a0 monoklonaler\u00a0 anti\u2010CD20\u2010An tik\u00f6rper)\u00a0\nangewendet\u00a0werden\u00a0kann\u00a0(EMA,\u00a02016).\u00a0\u00a0\nIn\u00a0einem\u00a0Rote\u2010Hand\u2010Brief\u00a0(RHB)\u00a0vom\u00a023.\u00a0M\u00e4rz\u00a02016\u00a0informiert\u00a0der \u00a0pharmazeuti\u2010\nsche\u00a0Unternehmer\u00a0(pU)\u00a0\u00fcber\u00a0die\u00a0Anwendungsbeschr\u00e4nkungen\u00a0und\u00a0Ma\u00df nahmen\u00a0\nzur\u00a0 Risikominimierung\u00a0 im\u00a0 Rahmen\u00a0 der\u00a0 Sicherheits\u00fcberpr\u00fcfung\u00a0 durc h\u00a0 die\u00a0 EMA\u00a0\n(Akd\u00c4,\u00a02016).\u00a0In\u00a0einem\u00a0weiteren\u00a0Rote\u2010Hand\u2010Brief\u00a0vom\u00a023.\u00a0August\u00a0 2016\u00a0werden\u00a0die\u00a0\nErgebnisse\u00a0des\u00a0Risikobewertungsverfahrens\u00a0und\u00a0die\u00a0aktualisierte n\u00a0risikominimie\u2010\nrenden\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Vorbeugung\u00a0von\u00a0Infektionen\u00a0dargestellt,\u00a0in sbesondere\u00a0\nbez\u00fcglich\u00a0einer\u00a0Pneumocystis\u2010jir ovecii\u2010Pneumonie\u00a0(PJP)\u00a0und\u00a0eine r\u00a0Infektion\u00a0mit\u00a0\ndem\u00a0Cytomegalievirus\u00a0(CMV).\u00a0\nBasis\u00a0der\u00a0Zulassung\u00a0von\u00a0Idelalisib\u00a0sind\u00a0die\u00a0Zwischenergebnisse\u00a0 einer\u00a0vorzeitig\u00a0be\u2010\nendeten\u00a0Phase\u2010III\u2010Studie\u00a0an\u00a0Patie nten\u00a0mit\u00a0CLL\u00a0sowie\u00a0eine\u00a0Phase\u2010 II\u2010Studie\u00a0an\u00a0Pati\u2010\nenten\u00a0mit\u00a0FL.\u00a0In\u00a0der\u00a0multizentri schen,\u00a0doppelblinden,\u00a0randomisi erten,\u00a0placebokon\u2010\ntrollierten\u00a0Phase\u2010III\u2010Studie\u00a0(GS \u2010US\u2010312\u201002\u20100116,\u00a0gesponsert\u00a0von \u00a0Gilead\u00a0Sciences)\u00a0\nwurde\u00a0Idelalisib\u00a0in\u00a0Kombination\u00a0mit\u00a0Rituximab\u00a0verglichen\u00a0mit\u00a0Ri tuximab\u00a0plus\u00a0Pla\u2010\ncebo.\u00a0In\u00a0Europa\u00a0ist\u00a0Rituximab\u00a0als\u00a0Monotherapie\u00a0der\u00a0CLL\u00a0allerdin gs\u00a0nicht\u00a0zugelassen\u00a0\nund\u00a0wird\u00a0auch\u00a0nicht\u00a0von\u00a0Leitlinien\u00a0empfohlen\u00a0(AMB,\u00a02015).\u00a0Einge schlossen\u00a0wurden\u00a0\ninsgesamt\u00a0220\u00a0vorbehandelte\u00a0Pati enten\u00a0mit\u00a0CLL,\u00a0die\u00a0innerhalb\u00a0vo n\u00a024\u00a0Monaten\u00a0\nnach\u00a0letzter\u00a0Behandlung\u00a0einen\u00a0Progress\u00a0zeigten\u00a0und\u00a0aus\u00a0verschie denen\u00a0Gr\u00fcnden\u00a0\nf\u00fcr\u00a0 eine\u00a0 zytotoxische\u00a0 Chemotherapie\u00a0 ungeeignet\u00a0 erschienen\u00a0 (Furm ann\u00a0 et\u00a0 al.,\u00a0\n2014).\u00a0 Nach\u00a0 einer\u00a0 1:1\u2010Randomisierung\u00a0 erhielten\u00a0 die\u00a0 Patienten\u00a0 in sgesamt\u00a0 acht\u00a0\nInfusionen\u00a0Rituximab,\u00a0initial\u00a0alle\u00a0zwei\u00a0Wochen\u00a0375\u00a0mg/m2,\u00a0die\u00a0letzten\u00a0drei\u00a0Infusio\u2010\nnen\u00a0alle\u00a0vier\u00a0Wochen\u00a0500\u00a0mg/m2,\u00a0im\u00a0Verum\u2010Arm\u00a0plus\u00a0zweimal\u00a0t\u00e4glich\u00a0150\u00a0mg\u00a0\nIdelalisib\u00a0per\u00a0os,\u00a0im\u00a0Kontroll\u2010Arm\u00a0plus\u00a0zweimal\u00a0t\u00e4glich\u00a0Placebo .\u00a0Als\u00a0genetische\u00a0\nRisikofaktoren\u00a0f\u00fcr\u00a0eine\u00a0ung\u00fcnstige\u00a0Prognose\u00a0hatten\u00a0knapp\u00a045\u00a0%\u00a0d er\u00a0Patienten\u00a0eine\u00a0\n17p\u2010Deletion\u00a0oder\u00a0eine\u00a0TP53\u2010Mutation.\u00a0Nahezu\u00a0alle\u00a0Patienten\u00a0war en\u00a0bereits\u00a0mit\u00a0\nanti\u2010CD20\u2010Antik\u00f6rpern\u00a0 vorbehandelt.\u00a0 Prim\u00e4rer\u00a0 Endpunkt\u00a0 war\u00a0 das\u00a0 p rogressions\u2010\nfreie\u00a0\u00dcberleben\u00a0( Progression\u2010free\u00a0Survival ,\u00a0PFS),\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0u.a.\u00a0\ndas\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0die\u00a0Ansprechrate.\u00a0Die\u00a0Studie\u00a0wur\u2010\nde\u00a0nach\u00a0der\u00a0ersten\u00a0geplanten\u00a0Zwischenanalyse\u00a0vorzeitig\u00a0abgebroc hen,\u00a0da\u00a0Idelalisib\u00a0\nplus\u00a0Rituximab\u00a0das\u00a0PFS\u00a0nach\u00a024\u00a0Wochen\u00a0im\u00a0Vergleich\u00a0zu\u00a0Rituximab \u00a0allein\u00a0eindeutig\u00a0\nverl\u00e4ngert\u00a0hatte\u00a0(93\u00a0%\u00a0versus\u00a046\u00a0%).\u00a0Auch\u00a0die\u00a0Ansprechrate\u00a0(81\u00a0 %\u00a0versus\u00a013\u00a0%)\u00a0und\u00a0\ndas\u00a0OS\u00a0nach\u00a012\u00a0Monaten\u00a0(92\u00a0%\u00a0versus\u00a080\u00a0%)\u00a0wurden\u00a0verbessert,\u00a0wo bei\u00a0besonders\u00a0\ndie\u00a0 Patienten\u00a0 mit\u00a0 prognostisch\u00a0 ung\u00fcnstigen\u00a0 genetischen\u00a0 Faktoren \u00a0g u t \u00a0a u f \u00a0d i e \u00a0\nBehandlung\u00a0mit\u00a0Idelalisib\u00a0ansprachen.\u00a0F\u00fcr\u00a0die\u00a0gesundheitsbezoge ne\u00a0Lebensquali\u2010\nt\u00e4t\u00a0(Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0fand\u00a0sich\u00a0im\u00a0Vergleich\u00a0zur\u00a0Kontrollgrup\u2010\npe\u00a0eine\u00a0statistisch\u00a0signifikante\u00a0und\u00a0klinisch\u00a0relevante\u00a0Verbess erung\u00a0des\u00a0k\u00f6rperli\u2010231\u00a0chen,\u00a0funktionellen\u00a0und\u00a0sozialen\u00a0Wohlbefindens.\u00a0Schwere\u00a0unerw\u00fcn schte\u00a0Arznei\u2010\nmittelereignisse\u00a0 (UAE)\u00a0 (Grad\u00a0 \u2265\u00a0 3) ,\u00a0 vor\u00a0 allem\u00a0 Pneumonien,\u00a0 Fieber \u00a0 und\u00a0 febrile\u00a0\nNeutropenien,\u00a0traten\u00a0bei\u00a040\u00a0%\u00a0der\u00a0mit\u00a0Idelalisib\u00a0und\u00a0Rituximab\u00a0 bzw.\u00a0bei\u00a035\u00a0%\u00a0der\u00a0\nPatienten\u00a0im\u00a0Kontroll\u2010Arm\u00a0auf.\u00a0N ach\u00a0der\u00a0vorzeitigen\u00a0Beendigung\u00a0 der\u00a0Studie\u00a0GS\u2010US\u2010\n312\u20100116\u00a0konnten\u00a0auf\u00a0Wunsch\u00a0alle\u00a0Patienten,\u00a0die\u00a0die\u00a0Studienmedi kation\u00a0vertragen\u00a0\nhatten\u00a0und\u00a0eine\u00a0Krankheitsprogre ssion\u00a0erlitten,\u00a0in\u00a0die\u00a0noch\u00a0lau fende\u00a0unverblindete\u00a0\nExtensionsstudie\u00a0GS\u2010US\u2010312\u20100117\u00a0aufgenommen\u00a0werden.\u00a0Hier\u00a0erhalt en\u00a0alle\u00a0Pati\u2010\nenten\u00a0Idelalisib,\u00a0diejenigen\u00a0des \u00a0vorherigen\u00a0Verum\u2010Arms\u00a0zweimal\u00a0 t\u00e4glich\u00a0300\u00a0mg\u00a0\nund\u00a0die\u00a0des\u00a0vorherigen\u00a0Kontroll\u2010Arms\u00a0zweimal\u00a0t\u00e4glich\u00a0150\u00a0mg.\u00a0Zu r\u00a0Ermittlung\u00a0des\u00a0\nOS\u00a0der\u00a0Patienten\u00a0aus\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0wurden\u00a0Daten\u00a0der\u00a0Ext ensionsstudie\u00a0\nGS\u2010US\u2010312\u20100117\u00a0in\u00a0die\u00a0Ana lyse\u00a0des\u00a0OS\u00a0einbezogen.\u00a0\nIn\u00a0der\u00a0noch\u00a0laufenden\u00a0multizentrischen\u00a0unverblindeten\u00a0Phase\u2010III \u2010Studie\u00a0GS\u2010US\u2010\n312\u20100119\u00a0(Sponsor:\u00a0Gilead)\u00a0wurden\u00a0261\u00a0Patienten\u00a0mit\u00a0vorbehandel ter\u00a0CLL\u00a0und\u00a0\neiner\u00a0Progression\u00a0von\u00a0unter\u00a024\u00a0Monaten\u00a0seit\u00a0Abschluss\u00a0der\u00a0letzt en\u00a0vorangehenden\u00a0\nTherapie\u00a0per\u00a0Randomisierung\u00a0im\u00a0Verh\u00e4ltnis\u00a02\u00a0:\u00a01\u00a0\u00fcber\u00a0jeweils\u00a024 \u00a0Wochen\u00a0mit\u00a0Idela\u2010\nlisib\u00a0150\u00a0mg\u00a0zweimal\u00a0t\u00e4glich\u00a0plus\u00a0zw\u00f6lf\u00a0Infusionen\u00a0Ofatumumab\u00a0( acht\u00a0Dosen\u00a0im\u00a0\nw\u00f6chentlichen\u00a0Abstand\u00a0und\u00a0anschlie\u00dfend\u00a0vier\u00a0Dosen\u00a0im\u00a0vierw\u00f6chen tlichen\u00a0Ab\u2010\nstand)\u00a0oder\u00a0ausschlie\u00dflich\u00a0mit\u00a0zw \u00f6lf\u00a0Infusionen\u00a0Ofatumumab\u00a0beha ndelt\u00a0(Jones\u00a0et\u00a0\nal.,\u00a02015).\u00a0Auch\u00a0in\u00a0dieser\u00a0Studie\u00a0wurde\u00a0also\u00a0im\u00a0Kontroll\u2010Arm\u00a0de r\u00a0monoklonale\u00a0\nAntik\u00f6rper\u00a0 als\u00a0 Monotherapie\u00a0 nach\u00a0 Vorbehandlung\u00a0 mit\u00a0 anti\u2010CD20\u2010An tik\u00f6rpern\u00a0\neingesetzt.\u00a0Die\u00a0meisten\u00a0Patiente n\u00a0zeigten\u00a0ung\u00fcnstige\u00a0zytogeneti sche\u00a0Prognosefak\u2010\ntoren,\u00a039,5\u00a0%\u00a0hatten\u00a0eine\u00a017p\u2010Del etion\u00a0und/oder\u00a0eine\u00a0TP53\u2010Mutat ion.\u00a0Prim\u00e4rer\u00a0\nEndpunkt\u00a0war\u00a0das\u00a0PFS,\u00a0zu\u00a0den\u00a0sekund\u00e4ren\u00a0Endpunkten\u00a0geh\u00f6rten\u00a0das \u00a0OS\u00a0und\u00a0die\u00a0\nGesamtansprechrate\u00a0( Overall\u00a0Response\u00a0Rate ,\u00a0ORR).\u00a0W\u00e4hrend\u00a0das\u00a0mediane\u00a0PFS\u00a0mit\u00a0\n16,3\u00a0Monaten\u00a0im\u00a0Idelalisib\u2010Arm\u00a0s ignifikant\u00a0gegen\u00fcber\u00a0acht\u00a0Monat en\u00a0im\u00a0Kontroll\u2010\nArm\u00a0verl\u00e4ngert\u00a0war,\u00a0konnte\u00a0f\u00fcr\u00a0das\u00a0mediane\u00a0OS\u00a0bisher\u00a0kein\u00a0signi fikanter\u00a0Unter\u2010\nschied\u00a0gezeigt\u00a0werden.\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Idelalisib\u00a0bei\u00a0Patienten\u00a0mit\u00a0vorbehandeltem\u00a0F L\u00a0basiert\u00a0auf\u00a0der\u00a0\nvom\u00a0pU\u00a0gesponserten\u00a0einarmigen\u00a0P hase\u2010II\u2010Studie\u00a0101\u201009\u00a0an\u00a0insges amt\u00a0125\u00a0Patien\u2010\nten\u00a0mit\u00a0indolentem\u00a0B\u2010Zell\u2010Non\u2010Hodgkin\u2010Lymphom,\u00a0darunter\u00a072\u00a0Pati enten\u00a0mit\u00a0FL\u00a0\n(Gopal\u00a0et\u00a0al.,\u00a0 2014).\u00a0Alle\u00a0Patienten\u00a0waren\u00a0refrakt\u00e4r\u00a0gegen\u00fcber\u00a0 Rituximab\u00a0und\u00a0\nmindestens\u00a0einem\u00a0alkylierendem\u00a0Zytostatikum\u00a0der\u00a0Vortherapie\u00a0und \u00a0befanden\u00a0sich\u00a0\nzu\u00a0etwa\u00a090\u00a0%\u00a0in\u00a0einem\u00a0fortgeschrittenem\u00a0Stadium\u00a0(III\u00a0oder\u00a0IV)\u00a0i hrer\u00a0Erkrankung.\u00a0\nSie\u00a0erhielten\u00a0zweimal\u00a0t\u00e4glich\u00a0 150\u00a0mg\u00a0Idelalisib\u00a0oral\u00a0als\u00a0Monoth erapie\u00a0bis\u00a0zum\u00a0Auf\u2010\ntreten\u00a0von\u00a0Anzeichen\u00a0einer\u00a0Krankheitsprogression\u00a0oder\u00a0nicht\u2010akz eptabler\u00a0Neben\u2010\nwirkungen\u00a0bzw.\u00a0bis\u00a0zum\u00a0Tod.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0von\u00a0einem \u00a0unabh\u00e4ngigen\u00a0\nKomitee\u00a0beurteilte\u00a0ORR.\u00a0Ein\u00a0volls t\u00e4ndiges\u00a0oder\u00a0partielles\u00a0Anspr echen\u00a0zeigten\u00a054\u00a0%\u00a0\nder\u00a0Patienten\u00a0mit\u00a0FL.\u00a0Die\u00a0Lebensqualit\u00e4t\u00a0nach\u00a0dem\u00a0FACT\u2010Lym\u2010Frag ebogen\u00a0zeigte\u00a0\nkeine\u00a0signifikanten\u00a0Ver\u00e4nderungen.\u00a0Als\u00a0UAE\u00a0Grad\u00a0\u2265\u00a03\u00a0traten\u00a0Diar rh\u00f6,\u00a0Neutropenie,\u00a0232\u00a0Pneumonie\u00a0und\u00a0Dyspnoe\u00a0auf.\u00a0Von\u00a0insgesamt\u00a028\u00a0Todesf\u00e4llen\u00a0traten\u00a0 11\u00a0w\u00e4hrend\u00a0oder\u00a0\ninnerhalb\u00a0von\u00a030\u00a0Tagen\u00a0nach\u00a0der\u00a0letzten\u00a0Einnahme\u00a0von\u00a0Idelalisb\u00a0 auf\u00a0(AMB,\u00a02015).\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G \u2010BA)\u00a0unterteilt\u00a0in\u00a0der\u00a0fr\u00fchen\u00a0 Nutzenbewer\u2010\ntung\u00a0im\u00a0Anwendungsgebiet\u00a01\u00a0die\u00a0vorbehandelten\u00a0Patienten\u00a0mit\u00a0CLL \u00a0in\u00a0vier\u00a0Teilpo\u2010\npulationen\u00a0 mit\u00a0 unterschiedlichen\u00a0 zweckm\u00e4\u00dfigen\u00a0 Vergleichstherapi en\u00a0 (zVT),\u00a0 die\u00a0\nvon\u00a0der\u00a0vom\u00a0pU\u00a0festgelegten\u00a0einhe itlichen\u00a0zVT\u00a0Rituximab\u00a0mono\u00a0in \u00a0der\u00a0die\u00a0Zulas\u2010\nsung\u00a0begr\u00fcndenden\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0abweichen\u00a0(G\u2010BA,\u00a02015). \u00a0Die\u00a0Anwen\u2010\ndung\u00a0von\u00a0Rituximab\u00a0bei\u00a0der\u00a0CLL\u00a0ist\u00a0jedoch\u00a0nur\u00a0in\u00a0Kombination\u00a0mi t\u00a0einer\u00a0Chemothe\u2010\nrapie\u00a0zulassungskonform\u00a0und\u00a0zudem\u00a0 bei\u00a0Patienten,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0C hemotherapie\u00a0\nungeeignet\u00a0sind,\u00a0kein\u00a0Therapiest andard.\u00a0Weil\u00a0der\u00a0G\u2010BA\u00a0au\u00dferdem\u00a0 die\u00a0in\u00a0der\u00a0Studie\u00a0\ngetroffenen\u00a0 Ausschlusskriterien\u00a0 f\u00fcr\u00a0 eine\u00a0 Chemotherapie\u00a0 bem\u00e4ngel t,\u00a0 macht\u00a0 er\u00a0\nkeine\u00a0Aussage\u00a0zum\u00a0quantitativen\u00a0Zusatznutzen\u00a0von\u00a0Idelalisib.\u00a0Vo r\u00a0dem\u00a0Hinter\u2010\ngrund\u00a0der\u00a0Schwere\u00a0der\u00a0Erkrankung\u00a0und\u00a0der\u00a0besonderen\u00a0Versorgungs situation\u00a0von\u00a0\nCLL\u2010Patienten,\u00a0die\u00a0f\u00fcr\u00a0weitere\u00a0z ugelassene\u00a0medikament\u00f6se\u00a0Therap ien\u00a0nicht\u00a0infrage\u00a0\nkommen,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0dennoch\u00a0be i\u00a0Patienten\u00a0der\u00a0Teilpopulation \u00a01b\u00a0mit\u00a0rezidi\u2010\nvierender\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemo therapie\u00a0nicht\u00a0indiziert\u00a0ist,\u00a0 einen\u00a0Anhaltspunkt\u00a0\nf\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0 von\u00a0Idelalisib\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0( Best\u2010Supportive\u2010Care ).\u00a0\nIm\u00a0Anwendungsgebiet\u00a02,\u00a0der\u00a0Erstlinienbehandlung\u00a0von\u00a0CLL\u2010Patient en\u00a0mit\u00a017p\u2010\nDeletion\u00a0oder\u00a0TP53\u2010Mutation,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Chemotherapie\u00a0ungeeig net\u00a0sind,\u00a0liefert\u00a0\ndie\u00a0Zulassungsstudie\u00a0GS\u2010US\u2010312\u2010011 6\u00a0genauso\u00a0wenig\u00a0relevante\u00a0Dat en\u00a0f\u00fcr\u00a0einen\u00a0\nVergleich\u00a0von\u00a0Idelalisib\u00a0mit\u00a0der\u00a0zVT\u00a0 Best\u2010Supportive\u2010Care ,\u00a0weil\u00a0ausschlie\u00dflich\u00a0vor\u2010\nbehandelte\u00a0Patienten\u00a0eingeschlo ssen\u00a0waren\u00a0und\u00a0der\u00a0Vergleich\u00a0mit \u00a0Rituximab\u00a0die\u00a0\nzVT\u00a0nicht\u00a0abbildet.\u00a0Doch\u00a0auch\u00a0hier\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0vor\u00a0dem\u00a0Hinte rgrund\u00a0der\u00a0beson\u2010\nderen\u00a0Versorgungssituation\u00a0dieser\u00a0Patientengruppe\u00a0einen\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0\nnicht\u00a0 quantifizierbaren \u00a0Zusatznutzen ,\u00a0 weil\u00a0 Subgruppenanalysen\u00a0 deutliche\u00a0 Be\u2010\nhandlungseffekte\u00a0insbesondere\u00a0f\u00fcr\u00a0diese\u00a0Patienten\u00a0zeigen.\u00a0Da\u00a0au fgrund\u00a0der\u00a0kurzen\u00a0\nLaufzeit\u00a0der\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0die\u00a0Daten\u00a0unzureichend\u00a0sind, \u00a0das\u00a0Ausma\u00df\u00a0des\u00a0\nZusatznutzens\u00a0auf\u00a0Basis\u00a0einer\u00a0Ext rapolation\u00a0von\u00a0Ergebnissen\u00a0bew ertet\u00a0wurde\u00a0und\u00a0\nder\u00a0pU\u00a0der\u00a0EMA\u00a0weitere\u00a0Daten\u00a0vorzulegen\u00a0hat,\u00a0wurde\u00a0dieser\u00a0G\u2010BA\u2010 Beschluss\u00a0auf\u00a0\nein\u00a0Jahr\u00a0befristet.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Drittlinientherapie\u00a0von\u00a0Patienten\u00a0mit\u00a0FL\u00a0sieht\u00a0der\u00a0G\u2010BA \u00a0einen\u00a0Zusatznutzen \u00a0\nals\u00a0nicht\u00a0belegt\u00a0an ,\u00a0da\u00a0die\u00a0zulassungsbegr\u00fcndende \u00a0einarmige,\u00a0offene\u00a0Phase\u2010II\u2010\nStudie\u00a0101\u201009\u00a0keine\u00a0aussagekr\u00e4ftigen\u00a0Daten\u00a0liefert.\u00a0\nF\u00fcr\u00a0die\u00a0erneute\u00a0Nutzenbewertung\u00a0von\u00a0Idelalisib\u00a0in\u00a0der\u00a0Behandlun g\u00a0der\u00a0CLL\u00a0nach\u00a0\nFristablauf\u00a0bezieht\u00a0der\u00a0G\u2010BA\u00a0Ana lysen\u00a0zum\u00a0finalen\u00a0Datenschnitt\u00a0 der\u00a0Studie\u00a0GS\u2010US\u2010\n312\u20100116\u00a0und\u00a0unterst\u00fctzende\u00a0Daten\u00a0aus\u00a0der\u00a0Extensionsstudie\u00a0GS\u2010U S\u2010312\u20100117\u00a0mit\u00a0\nein,\u00a0deren\u00a0Ergebnisse\u00a0zum\u00a0OS\u00a0und\u00a0zum\u00a0PFS\u00a0das\u00a0Resultat\u00a0der\u00a0Erstb ewertung\u00a0best\u00e4\u2010\ntigen\u00a0(G\u2010BA,\u00a02016).\u00a0Im\u00a0Anwendungsgebiet\u00a01\u00a0hebt\u00a0der\u00a0G\u2010BA\u00a0die\u00a0bei \u00a0der\u00a0Erstbewer\u2010233\u00a0tung\u00a0durchgef\u00fchrte\u00a0Differenzierung\u00a0von\u00a0vier\u00a0Teilpopulationen\u00a0in \u00a0Abh\u00e4ngigkeit\u00a0des\u00a0\nErfolgs\u00a0der\u00a0Vortherapie\u00a0auf\u00a0und\u00a0 fasst\u00a0diese\u00a0in\u00a0zwei\u00a0Teilpopulat ionen\u00a01a\u00a0und\u00a01b\u00a0\nzusammen.\u00a0F\u00fcr\u00a0die\u00a0Teilpopulation\u00a01a\u00a0der\u00a0Patienten\u00a0mit\u00a0rezidivie render\u00a0oder\u00a0re\u2010\nfrakt\u00e4rer\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemotherapie\u00a0indiziert\u00a0ist,\u00a0gilt\u00a0d er\u00a0Zusatznutzen \u00a0auf\u2010\ngrund\u00a0fehlender\u00a0Daten\u00a0als\u00a0 nicht\u00a0belegt .\u00a0In\u00a0der\u00a0Teilpopulation\u00a01b\u00a0der\u00a0Patienten\u00a0mit\u00a0\nrezidivierter\u00a0oder\u00a0refrakt\u00e4rer\u00a0C LL,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemotherapie\u00a0 nicht\u00a0geeignet\u00a0ist,\u00a0\nsieht\u00a0der\u00a0G\u2010BA\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0Schweregrades\u00a0der\u00a0Erk rankung\u00a0einen\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0 von\u00a0Idelalisib\u00a0gegen\u00fcber\u00a0der\u00a0neben\u00a0Ibrutinib\u00a0\nals\u00a0zVT\u00a0bestimmten\u00a0 Best\u2010Supportive\u2010Care ,\u00a0der\u00a0aber\u00a0aufgrund\u00a0der\u00a0fehlenden\u00a0Um\u2010\nsetzung\u00a0der\u00a0Vergleichstherapie\u00a0und\u00a0der\u00a0kritisierten\u00a0Studienmeth odik\u00a0nicht\u00a0quanti\u2010\nfizierbar\u00a0ist.\u00a0Im\u00a0Anwendungsgebiet\u00a02,\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Neubewertung\u00a0die \u00a0Fort\u2010\nsetzung\u00a0einer\u00a0bereits\u00a0initiierten\u00a0Therapie\u00a0mit\u00a0Idelalisib\u00a0bei\u00a0f \u00fcr\u00a0eine\u00a0Chemoimmun\u2010\ntherapie\u00a0ungeeigneten\u00a0Patienten\u00a0m it\u00a017p\u2010Deletion\u00a0 oder\u00a0TP53\u2010Muta tion,\u00a0gilt\u00a0der\u00a0\nZusatznutzen \u00a0 gegen\u00fcber\u00a0 der\u00a0 zVT\u00a0 Ibrutinib\u00a0 oder\u00a0 Best\u2010Supportive\u2010Care \u00a0 aufgrund\u00a0\nfehlender\u00a0Daten\u00a0als\u00a0 nicht\u00a0belegt .\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 \u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen\u00a0 \u00a0\u00a0Kosten\u00a0\nweitere\u00a0Therapie\u2010\noption,\u00a0oraler\u00a0Kinase\u2010\nHemmstoff\u00a0mit\u00a0\nneuartigem\u00a0\nWirkprinzip\u00a0in\u00a0Teilindikationen\u00a0nicht\u00a0\nquantifizierbarer\u00a0\nZusatznutzen;\u00a0noch\u00a0\nungen\u00fcgende\u00a0Daten\u2010\nbasis;\u00a0schwere\u00a0infekti\u00f6se\u00a0\nNebenwirkungen\u00a0\u00a0\u00a0teurer\u00a0als\u00a0zVT\u00a0Chemo\u2010\nimmuntherapie,\u00a0unge\u2010\nf\u00e4hr\u00a0gleich\u00a0teuer\u00a0in\u00a0\nKombination\u00a0mit\u00a0\nRituximab\u00a0wie\u00a0zVT\u00a0\nIbrutinib\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0Prescir\ne\u00a0PZ\u00a0\nA\u00a0Umstrittenes\u00a0\nTherapieprpinzip\u00a0Aussagekraft\u00a0der\u00a0\nZulassungsstudie\nn\u00a0begrenzt;\u00a0Daten\u00a0\naus\u00a0weiteren\u00a0\n(lau\u2010fenden)\u00a0\nStudien\u00a0\nerforderlich\u00a0Use\u00a0\nshould\u00a0\nbe\u00a0\nlimited\u00a0\nto\u00a0\nclinical\u00a0\ntrials\u00a0Schrittinnovatio\nn\u00a0\n\u00a0 \u00a0\n234\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertende\u00a0Arzneimittel \u00a0\u00a0 \u00a0\u00a0\nIdelalisib\u00a0\nRituximab\u00a02x\u00a0tgl.\u00a0150\u00a0mg\u00a0\u00a0\nWoche\u00a01:\u00a0375\u00a0mg/m2\u00a0\u00a0\nWoche\u00a02,\u00a04,\u00a06,\u00a08,\u00a012,\u00a0\n16\u00a0und\u00a020:\u00a0500\u00a0mg/m2\u00a0365\u00a0\n8\u00a055.874,32\u00a0\u20ac\u00a0\n28.958,77\u00a0\u20ac\u00a0\n\u00a084.833,09\u00a0\u20ac\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0Patienten\u00a0\nmit\u00a0rez.\u00a0oder\u00a0refr.\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0\neine\u00a0Chemotherapie\u00a0angezeigt\u00a0ist \u00a0\u00a0 \u00a0 \u00a0\nFludarabin \u00a0 alle\u00a028\u00a0Tage\u00a0Tag\u00a01,\u00a02\u00a0\nund\u00a03:\u00a025\u00a0mg/m2\u00a018 \u00a01967,47\u00a0\u20ac \u00a0\n\u00a0\nCyclophosphamid \u00a0\n\u00a0\n\u00a0\nRituximab \u00a0\n\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0Patienten\u00a0\nmit\u00a0rez.\u00a0oder\u00a0refr.\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0\neine\u00a0Chemotherapie\u00a0nicht\u00a0\nangezeigt\u00a0ist\u00a0und\u00a0zur\u00a0\nFortsetzung\u00a0der\u00a0Therapie\u00a0bei\u00a0\nPatienten\u00a0mit\u00a017p\u2010Deletion\u00a0oder\u00a0\nTP53\u2010Mutation,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0\nChemoimmuntherapie\u00a0unge\u2010\neignet\u00a0waren\u00a0und\u00a0bei\u00a0denen\u00a0\nbereits\u00a0eine\u00a0Erstlinientherapie\u00a0\nmit\u00a0Idelalisib\u00a0initiiert\u00a0wurde\u00a0\nIbrutinib\u00a0\nBest\u2010Supportive\u2010Care\u00a0\n\u00a0\n\u00a0\nVergleichstherapie\u00a0f\u00fcr\u00a0Patienten\u00a0\nmit\u00a0FL,\u00a0refrakt\u00e4r\u00a0gegen\u00fcber\u00a0zwei\u00a0\nvorausgegangenen\u00a0\nTherapielinien\u00a0\u00a0\nBest\u2010Supportive\u2010Care \u00a0alle\u00a028\u00a0Tage;\u00a0Tag\u00a01,\u00a02\u00a0\nund\u00a03:\u00a0250\u00a0mg/m2\u00a0\nalle\u00a028\u00a0Tage;\u00a0\nZyklus\u00a01:\u00a0375\u00a0mg/m2\u00a0\u00a0\nZyklus\u00a02\u00a0\u2013\u00a06:\u00a0500\u00a0mg/m2\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n1x\u00a0tgl.\u00a0420\u00a0mg\u00a0\nPatientenindividuell\u00a0\nunterschiedlich\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nPatientenindividuell\u00a0\nunterschiedlich \u00a018\u00a0\n\u00a0\n\u00a0\n6\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0\n365\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n365\u00a0410,40\u00a0\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n21.509,03\u00a0\u20ac\u00a0\n\u00a023886,90 \u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a081.695,67\u00a0\u20ac\u00a0\n\u00a0\nVersorgungsanalysen\u00a0\nKurz\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Oktober\u00a02014\u00a0stiegen\u00a0die\u00a0Veror dnungen\u00a0des\u00a0\noralen\u00a0Tyrosinkinase\u2010Inhibitors\u00a0Idelalisib\u00a0schnell\u00a0an\u00a0und\u00a0pende lten\u00a0sich\u00a0im\u00a0vier\u2010\nten\u00a0Quartal\u00a02015\u00a0bei\u00a0monatlich\u00a0ca.\u00a01.100\u00a0DDDs\u00a0mit\u00a0einem\u00a0Umsatz\u00a0 von\u00a0\u00fcber\u00a0\n200.000\u00a0Euro\u00a0(Abbildung\u00a04.21)\u00a0ein.\u00a0\u00a0\n\u00a0235\u00a0Abbildung\u00a04.21:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Idelalisib\u00a0\nnach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015) \u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nIdelalisib\u00a0ist\u00a0der\u00a0erste\u00a0therapeutisch\u00a0verf\u00fcgbare\u00a0Hemmstoff\u00a0der \u00a0Phosphoinositol\u20103\u2010\nKinase\u00a0(PI3\u2010Kinase),\u00a0einer\u00a0Lipidkinase\u00a0mit\u00a0vier\u00a0verschiedenen\u00a0k atalytischen\u00a0Isofor\u2010\nmen,\u00a0 die\u00a0 nach\u00a0 rezeptorvermittelt er\u00a0 Aktivierung\u00a0 Inositolphosphat e\u00a0 als\u00a0Lipid\u2010\nSecond\u2010Messenger \u00a0f\u00fcr\u00a0zahlreiche\u00a0Enzyme\u00a0bilden,\u00a0wodurch\u00a0Zellproliferation,\u00a0Diffe \u2010\nrenzierung\u00a0 und\u00a0 \u00dcberleben\u00a0 reguliert\u00a0 werden\u00a0 (Fachinformation\u00a0 Zyde lig\u00ae,\u00a0 2016).\u00a0\nW\u00e4hrend\u00a0die\u00a0\u03b1\u2010\u00a0und\u00a0\u03b2\u2010Isoformen\u00a0der\u00a0Phosphoinositol\u20103\u2010Kinase\u00a0in\u00a0 vielen\u00a0Geweben\u00a0\nvorkommen,\u00a0wird\u00a0die\u00a0\u03b4\u2010Isoform\u00a0vor\u00a0allem\u00a0in\u00a0zirkulierenden\u00a0Leuko zyten,\u00a0aber\u00a0auch\u00a0\nin\u00a0Lymphknoten,\u00a0Milz\u00a0und\u00a0Thymus\u00a0exprimiert.\u00a0Der\u00a0oral\u00a0einzunehme nde\u00a0Wirkstoff\u00a0\nIdelalisib\u00a0hemmt\u00a0selektiv\u00a0die\u00a0Ph osphatidylinositol\u20103\u2010Kinase\u2010\u03b4\u00a0( PI3K\u03b4),\u00a0die\u00a0bei\u00a0reifen\u00a0\nB\u2010Zell\u2010Neoplasien\u00a0wie\u00a0der\u00a0chroni schen\u00a0lymphatischen\u00a0Leuk\u00e4mie\u00a0un d\u00a0follikul\u00e4ren\u00a0\nLymphomen\u00a0hyperaktiv\u00a0ist\u00a0und\u00a0eine\u00a0wichtige\u00a0Rolle\u00a0f\u00fcr\u00a0verschiede ne\u00a0Signaltrans\u2010\nduktionswege\u00a0spielt,\u00a0welche\u00a0die\u00a0P roliferation,\u00a0das\u00a0\u00dcberleben,\u00a0d as\u00a0Homing\u00a0und\u00a0die\u00a0\nRetention\u00a0maligner\u00a0Zellen\u00a0in\u00a0Lym phgewebe\u00a0und\u00a0Knochenmark\u00a0vermit teln.\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nIdelalisib\u00a0wurde\u00a0im\u00a0September\u00a02014\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommiss ion\u00a0zugelassen\u00a0\nzur\u00a0Behandlung\u00a0von\u00a0Erwachsenen\u00a0mit\u00a0chronischer\u00a0lymphatischer\u00a0Le uk\u00e4mie\u00a0(CLL)\u00a0in\u00a0\nKombination\u00a0mit\u00a0Rituximab\u00a0in\u00a0der\u00a0Zweitlinie\u00a0oder\u00a0als\u00a0Erstlinien therapie\u00a0bei\u00a0Vorlie\u2010\n236\u00a0gen\u00a0einer\u00a017p\u2010Deletion\u00a0oder\u00a0TP53\u2010 Mutation,\u00a0wenn\u00a0eine\u00a0Chemo\u2010/Imm untherapie\u00a0\nnicht\u00a0infrage\u00a0kommt.\u00a0Eine\u00a0weitere\u00a0Indikation\u00a0ist\u00a0die\u00a0Monotherap ie\u00a0von\u00a0Patienten\u00a0\nmit\u00a0follikul\u00e4rem\u00a0Lymphom\u00a0(FL)\u00a0na ch\u00a0Versagen\u00a0von\u00a0zwei\u00a0vorausgega ngenen\u00a0Thera\u2010\npielinien.\u00a0Die\u00a0empfohlene\u00a0Dosis\u00a0von\u00a0Idelalisib\u00a0betr\u00e4gt\u00a0zweimal\u00a0 t\u00e4glich\u00a0150\u00a0mg\u00a0oral.\u00a0\nAlle\u00a0mit\u00a0Idelalisib\u00a0behandelten\u00a0Patienten\u00a0sollten\u00a0\u00fcber\u00a0die\u00a0gesa mte\u00a0Behandlungs\u2010\ndauer\u00a0und\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von \u00a0zwei\u00a0bis\u00a0sechs\u00a0Monaten\u00a0nach\u00a0B ehandlungsen\u2010\nde\u00a0prophylaktisch\u00a0gegen\u00a0eine\u00a0Pne umocystis\u2010jirovecii\u2010Pneumonie\u00a0( PJP)\u00a0behandelt\u00a0\nwerden\u00a0(Fachinformation\u00a0Zydelig\u00ae,\u00a02016).\u00a0F\u00fcr\u00a0Patienten\u00a0mit\u00a0Anze ichen\u00a0f\u00fcr\u00a0eine\u00a0\nfr\u00fchere\u00a0Infektion\u00a0mit\u00a0dem\u00a0Zytomegalievirus\u00a0wird\u00a0eine\u00a0regelm\u00e4\u00dfig e\u00a0klinische\u00a0und\u00a0\nLabor\u00fcberwachung\u00a0 hinsichtlich\u00a0 des\u00a0 erneuten\u00a0 Auftretens\u00a0 empfohlen .\u00a0 Dar\u00fcber\u00a0\nhinaus\u00a0 sollte\u00a0 die\u00a0 Neutrophilenzahl\u00a0 \u00fcberwacht\u00a0 und\u00a0 im\u00a0 Falle\u00a0 einer \u00a0s c h w e r e n \u00a0\nNeutropenie\u00a0die\u00a0Behandlung\u00a0unterbrochen\u00a0werden.\u00a0Bei\u00a0Patienten\u00a0m it\u00a0Anzeichen\u00a0\nf\u00fcr\u00a0systemische\u00a0Infektionen\u00a0sollte\u00a0Idelalisib\u00a0nicht\u00a0angewendet\u00a0 werden.\u00a0Aufgrund\u00a0\nseiner\u00a0Metabolisierung\u00a0zeigt\u00a0Ide lalisib\u00a0eine\u00a0Vielzahl\u00a0von\u00a0Inter aktionen\u00a0mit\u00a0anderen\u00a0\nArzneimitteln\u00a0(CYP3A\u2010Induktoren\u00a0bzw.\u00a0\u2010Substraten),\u00a0die\u00a0vor\u00a0alle m\u00a0bei\u00a0\u00e4lteren\u00a0Pati\u2010\nenten\u00a0mit\u00a0CLL\u00a0und\u00a0mehreren\u00a0Komorbidit\u00e4ten\u00a0beachtet\u00a0werden\u00a0m\u00fcsse n.\u00a0\nAufgrund\u00a0einer\u00a0erh\u00f6hten\u00a0Anzahl\u00a0infektionsbedingter\u00a0Todesf\u00e4lle\u00a0u nter\u00a0Idelalisib\u00a0in\u00a0\ndrei\u00a0laufenden\u00a0klinischen\u00a0Studien\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02016\u00a0ein\u00a0europ\u00e4 isches\u00a0Risikobe\u2010\nwertungsverfahren\u00a0eingeleitet\u00a0(EMA,\u00a02016).\u00a0Der\u00a0Ausschuss\u00a0f\u00fcr\u00a0Ri sikobewertung\u00a0im\u00a0\nBereich\u00a0 der\u00a0 Pharmakovigilanz\u00a0 ( Pharmacovigilance\u00a0 Risk\u00a0 Assessment\u00a0 Committee ,\u00a0\nPRAC)\u00a0empfahl,\u00a0besondere\u00a0Warnhinweise\u00a0und\u00a0Vorsichtsma\u00dfnahmen\u00a0be z\u00fcglich\u00a0des\u00a0\nRisikos\u00a0f\u00fcr\u00a0schwerwiegende\u00a0Infek tionen\u00a0in\u00a0die\u00a0Fachinformation\u00a0a ufzunehmen\u00a0und\u00a0\ndie\u00a0Zulassung\u00a0f\u00fcr\u00a0die\u00a0Teilpopulat ion\u00a0der\u00a0Patienten\u00a0mit\u00a0CLL\u00a0bei\u00a0 Vorliegen\u00a0einer\u00a017p\u2010\nDeletion\u00a0oder\u00a0einer\u00a0TP53\u2010Mutation ,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Chemoimmunthera pie\u00a0ungeeignet\u00a0\nsind,\u00a0einzuschr\u00e4nken.\u00a0F\u00fcr\u00a0diese\u00a0Teilpopulation\u00a0sollte\u00a0Idelalisi b\u00a0nicht\u00a0mehr\u00a0als\u00a0Erst\u2010\nlinientherapie\u00a0angewendet\u00a0werden,\u00a0sondern\u00a0nur\u00a0noch\u00a0zur\u00a0Fortsetz ung\u00a0der\u00a0Thera\u2010\npie\u00a0bei\u00a0Patienten,\u00a0bei\u00a0denen\u00a0bereits\u00a0eine\u00a0Erstlinientherapie\u00a0mi t\u00a0Idelalisib\u00a0begonnen\u00a0\nwurde.\u00a0 Nach\u00a0 Abschluss\u00a0 des\u00a0 Risiko bewertungsverfahrens\u00a0 wurde\u00a0 dies e\u00a0 Anwen\u2010\ndungsbeschr\u00e4nkung\u00a0im\u00a0September\u00a02016\u00a0wieder\u00a0gelockert,\u00a0so\u00a0dass\u00a0I delalisib\u00a0f\u00fcr\u00a0\nPatienten\u00a0mit\u00a0einer\u00a017p\u2010Deletion\u00a0 oder\u00a0einer\u00a0TP53\u2010Mutation,\u00a0bei\u00a0 denen\u00a0keine\u00a0an\u2010\nderen\u00a0Therapien\u00a0geeignet\u00a0sind,\u00a0auch\u00a0in\u00a0der\u00a0Erstlinie\u00a0angewendet \u00a0werden\u00a0kann.\u00a0\nEbenfalls\u00a0noch\u00a0im\u00a0September\u00a0erfol gte\u00a0eine\u00a0Indikationserweiterun g\u00a0f\u00fcr\u00a0Idelalisib\u00a0\ndahingehend,\u00a0dass\u00a0es\u00a0nicht\u00a0nur\u00a0in\u00a0Kombination\u00a0mit\u00a0Rituximab,\u00a0so ndern\u00a0auch\u00a0mit\u00a0\ndem\u00a0monoklonalen\u00a0anti\u2010CD20\u2010Antik\u00f6rper\u00a0Ofatumumab\u00a0angewendet\u00a0wer den\u00a0kann\u00a0\n(EMA,\u00a02016).\u00a0\u00a0\nIn\u00a0einem\u00a0Rote\u2010Hand\u2010Brief\u00a0vom\u00a023.\u00a0M\u00e4rz\u00a02016\u00a0informierte\u00a0der\u00a0pU\u00a0\u00fc ber\u00a0die\u00a0Anwen\u2010\ndungsbeschr\u00e4nkungen\u00a0und\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Risikominimierung\u00a0im\u00a0Rahm en\u00a0der\u00a0\nSicherheits\u00fcberpr\u00fcfung\u00a0durch\u00a0die\u00a0EMA\u00a0(Gilead,\u00a02016).\u00a0In\u00a0einem\u00a0w eiteren\u00a0Rote\u2010\nHand\u2010Brief\u00a0vom\u00a023.08.2016\u00a0werden\u00a0d ie\u00a0Ergebnisse\u00a0des\u00a0Risikobewer tungsverfah\u2010\nrens\u00a0und\u00a0die\u00a0aktualisierten\u00a0risikominimierenden\u00a0Ma\u00dfnahmen\u00a0zur\u00a0V orbeugung\u00a0von\u00a0237\u00a0Infektionen\u00a0dargestellt,\u00a0insbeso ndere\u00a0auch\u00a0die\u00a0weiteren\u00a0Empfehl ungen\u00a0bez\u00fcglich\u00a0\neiner\u00a0Pneumocystis\u2010jirovecii\u2010Pne umonie\u00a0(PJP)\u00a0und\u00a0einer\u00a0Infektio n\u00a0mit\u00a0dem\u00a0Cy\u2010\ntomegalievirus\u00a0(CMV)\u00a0(Gilead,\u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0CLL\u00a0ist\u00a0mit\u00a0\u00fcber\u00a0einem\u00a0Drittel\u00a0aller\u00a0diagnostizierten\u00a0Leuk\u00e4 mie\u2010F\u00e4lle\u00a0die\u00a0h\u00e4ufigs\u2010\nte\u00a0leuk\u00e4mische\u00a0Erkrankung\u00a0in\u00a0den\u00a0westlichen\u00a0Industriel\u00e4ndern\u00a0un d\u00a0in\u00a0ihrem\u00a0nat\u00fcr\u2010\nlichen\u00a0Verlauf\u00a0sehr\u00a0heterogen\u00a0(GE KID,\u00a02015).\u00a0Sie\u00a0bef\u00e4llt\u00a0vorwie gend\u00a0\u00e4ltere\u00a0Men\u2010\nschen,\u00a0das\u00a0mediane\u00a0Alter\u00a0bei\u00a0Ers tdiagnose\u00a0liegt\u00a0zwischen\u00a072\u00a0und \u00a075\u00a0Jahren.\u00a0In\u00a0\nDeutschland\u00a0erkranken\u00a0j\u00e4hrlich\u00a0etwa\u00a03.000\u00a0M\u00e4nner\u00a0und\u00a02.000\u00a0Frau en,\u00a0es\u00a0sterben\u00a0\nj\u00e4hrlich\u00a0etwa\u00a01.000\u00a0M\u00e4nner\u00a0und\u00a0850\u00a0Frauen\u00a0an\u00a0CLL\u00a0(Wendtner\u00a0et\u00a0a l.,\u00a02017).\u00a0Bei\u00a0\ndiesem\u00a0indolent\u00a0fortschreitenden \u00a0B\u2010Zell\u2010Non\u2010Hodgkin\u2010Lymphom\u00a0ver mehren\u00a0sich\u00a0\nungebremst\u00a0 immun\u2010inkompetente\u00a0 B\u2010Lymphozyten\u00a0 und\u00a0 \u00fcberschwemmen\u00a0 u nd\u00a0\nbeeintr\u00e4chtigen\u00a0Knochenmark,\u00a0Lymphknoten,\u00a0Milz,\u00a0Leber\u00a0und\u00a0Blut. \u00a0H\u00e4ufig\u00a0sind\u00a0die\u00a0\nBetroffenen\u00a0 beschwerdefrei\u00a0 und\u00a0 di e\u00a0 Diagnose\u00a0 der\u00a0 Blut\u2010Lymphozyto se\u00a0 erfolgt\u00a0\nzuf\u00e4llig\u00a0im\u00a0Rahmen\u00a0einer\u00a0Routinekontrolle\u00a0des\u00a0Blutbildes.\u00a0Mit\u00a0F ortschreiten\u00a0der\u00a0\nErkrankung\u00a0treten\u00a0Lymphknotenvergr\u00f6\u00dferung,\u00a0Spleno\u2010\u00a0und\u00a0Hepatome galie\u00a0und\u00a0\nZeichen\u00a0der\u00a0Knochenmarkinfiltrat ion\u00a0mit\u00a0An\u00e4mie,\u00a0Thrombopenie\u00a0un d\u00a0Neutropenie\u00a0\nauf.\u00a0Klinische\u00a0Beschwerden\u00a0k\u00f6nnen\u00a0sich\u00a0au\u00dferdem\u00a0in\u00a0Fatigue,\u00a0B\u2010S ymptomen\u00a0(Fie\u2010\nber,\u00a0 Nachtschwei\u00df,\u00a0 Gewichtsverlu st),\u00a0 Hautver\u00e4nderungen\u00a0 sowie\u00a0 er h\u00f6hter\u00a0 In\u2010\nfektneigung\u00a0\u00e4u\u00dfern.\u00a0Damit\u00a0die\u00a0Di agnose\u00a0einer\u00a0CLL\u00a0gestellt\u00a0werde n\u00a0kann,\u00a0m\u00fcssen\u00a0\nmehr\u00a0als\u00a05.000\u00a0B\u2010Lymphozyten/\u00b5l\u00a0B lut\u00a0nachweisbar\u00a0sein.\u00a0Die\u00a0in\u00a0D eutschland\u00a0\u00fcbli\u2010\nche\u00a0Stadieneinteilung\u00a0nach\u00a0Binet\u00a0prognostiziert\u00a0den\u00a0Verlauf\u00a0der \u00a0Erkrankung\u00a0an\u2010\nhand\u00a0des\u00a0Ausma\u00dfes\u00a0von\u00a0Lymphadeno pathie,\u00a0Splenomegalie\u00a0und\u00a0Hepat omegalie\u00a0\nsowie\u00a0An\u00e4mie\u00a0und\u00a0Thrombozytopenie\u00a0(Maurer\u00a0&\u00a0Hallek,\u00a02013).\u00a0Pati enten\u00a0im\u00a0Sta\u2010\ndium\u00a0C\u00a0befinden\u00a0sich\u00a0in\u00a0einer\u00a0fortgeschrittenen\u00a0Phase\u00a0der\u00a0Erkra nkung\u00a0und\u00a0weisen\u00a0\neinen\u00a0H\u00e4moglobinwert\u00a0unter\u00a010\u00a0g/dl\u00a0und/oder\u00a0einen\u00a0Thrombozytenw ert\u00a0unter\u00a0\n100.000/\u00b5l\u00a0auf.\u00a0Die\u00a0Ursachen\u00a0chro nischer\u00a0Leuk\u00e4mien\u00a0gelten\u00a0als\u00a0w eitgehend\u00a0unge\u2010\nkl\u00e4rt,\u00a0heredit\u00e4re\u00a0Faktoren\u00a0und\u00a0zytogenetische\u00a0Aberrationen\u00a0erh\u00f6 hen\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0\ndie\u00a0Entstehung\u00a0einer\u00a0CLL.\u00a0F\u00fcr\u00a0die\u00a0Proliferation\u00a0und\u00a0das\u00a0\u00dcberleb en\u00a0von\u00a0malignen\u00a0\nCLL\u2010Lymphozyten\u00a0 ist\u00a0 der\u00a0 B\u2010Zell\u2010Re zeptor\u00a0 (BCR)\u2010Signalweg\u00a0 essenti ell:\u00a0 Nach\u00a0 dem\u00a0\nheutigen\u00a0Verst\u00e4ndnis\u00a0expandiert\u00a0d ie\u00a0CLL\u2010Erkrankung\u00a0aus\u00a0sogenann ten\u00a0Proliferati\u2010\nonszentren\u00a0in\u00a0Lymphknoten,\u00a0Knochenmark\u00a0und\u00a0Milz,\u00a0in\u00a0denen\u00a0der\u00a0B CR\u2010Signalweg\u00a0\n\u00fcberaktiviert\u00a0ist.\u00a0Dieser\u00a0Signalw eg\u00a0nimmt\u00a0seinen\u00a0Ausgang\u00a0vom\u00a0me mbrangebunde\u2010\nnen\u00a0Rezeptor\u2010BCR\u2010Komplex\u00a0und\u00a0bes teht\u00a0aus\u00a0einer\u00a0vielstufigen\u00a0Sig nalkaskade\u00a0mit\u00a0\nzahlreichen\u00a0weiteren\u00a0Kinasen,\u00a0z.B.\u00a0der\u00a0Phosphatidylinositol\u00a03\u2010K inase\u00a0(PI3\u2010Kinase),\u00a0\nund\u00a0Adapterproteinen.\u00a0\nDas\u00a0FL\u00a0ist\u00a0das\u00a0h\u00e4ufigste\u00a0indolente\u00a0Non\u2010Hodgkin\u2010Lymphom\u00a0(NHL)\u00a0un d\u00a0macht\u00a0in\u00a0\nunseren\u00a0Breiten\u00a020\u00a0bis\u00a035\u00a0Prozent\u00a0aller\u00a0neu\u00a0diagnostizierten\u00a0NH L\u2010Patienten\u00a0aus\u00a0\n(Buske\u00a0et\u00a0al.,\u00a02017).\u00a0Das\u00a0mittlere\u00a0Erkrankungsalter\u00a0liegt\u00a0bei\u00a06 0\u00a0bis\u00a065\u00a0Jahren,\u00a0Frau\u2010238\u00a0en\u00a0sind\u00a0etwas\u00a0h\u00e4ufiger\u00a0betroffen\u00a0als\u00a0M\u00e4nner.\u00a0Bei\u00a0\u00fcber\u00a080\u00a0%\u00a0der\u00a0 Betroffenen\u00a0wird\u00a0\ndas\u00a0typischerweise\u00a0sehr\u00a0langsam\u00a0fortschreitende\u00a0Lymphom\u00a0erst\u00a0im \u00a0fortgeschritte\u2010\nnen\u00a0Stadium\u00a0diagnostiziert.\u00a0Die\u00a0 Stadieneinteilung\u00a0erfolgt\u00a0nach\u00a0 Ann\u00a0Arbor\u00a0in\u00a0die\u00a0\nStadien\u00a0I\u00a0bis\u00a0IV.\u00a0Die\u00a0Symptomatik\u00a0ist\u00a0gepr\u00e4gt\u00a0von\u00a0meist\u00a0schmerz losen\u00a0Lymphkno\u2010\ntenvergr\u00f6\u00dferungen,\u00a0 au\u00dferdem\u00a0 k\u00f6nne n\u00a0 unspezifische\u00a0 Allgemeinsympt ome\u00a0 wie\u00a0\nM\u00fcdigkeit,\u00a0Schw\u00e4che\u00a0und\u00a0Bl\u00e4sse,\u00a0B\u2010 Symptome\u00a0(Fieber,\u00a0Nachtschwei \u00df,\u00a0Gewichts\u2010\nverlust),\u00a0Spleno\u2010\u00a0und\u00a0Hepatomega lie\u00a0sowie\u00a0St\u00f6rungen\u00a0der\u00a0H\u00e4matop oese\u00a0mit\u00a0An\u00e4\u2010\nmie,\u00a0Thrombozytopenie\u00a0und\u00a0Leukozytopenie\u00a0auftreten.\u00a0Der\u00a0klinisc he\u00a0Verlauf\u00a0folli\u2010\nkul\u00e4rer\u00a0Lymphome\u00a0ist\u00a0sehr\u00a0variab el,\u00a0\u00dcberlebenszeiten\u00a0reichen\u00a0vo n\u00a0einigen\u00a0Jahren\u00a0\nbis\u00a0\u00fcber\u00a0zwei\u00a0Jahrzehnte.\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nBasis\u00a0der\u00a0Zulassung\u00a0von\u00a0Idelalisib\u00a0sind\u00a0die\u00a0Zwischenergebnisse\u00a0 einer\u00a0vorzeitig\u00a0be\u2010\nendeten\u00a0Phase\u2010III\u2010Studie\u00a0an\u00a0Patie nten\u00a0mit\u00a0CLL\u00a0sowie\u00a0eine\u00a0Phase\u2010 II\u2010Studie\u00a0an\u00a0Pati\u2010\nenten\u00a0mit\u00a0FL.\u00a0In\u00a0der\u00a0multizentri schen,\u00a0doppelblinden,\u00a0randomisi erten,\u00a0placebokon\u2010\ntrollierten\u00a0Phase\u2010III\u2010Studie\u00a0(GS \u2010US\u2010312\u201002\u20100116,\u00a0gesponsert\u00a0von \u00a0Gilead\u00a0Sciences)\u00a0\nwurde\u00a0Idelalisib\u00a0in\u00a0Kombination\u00a0mit\u00a0Rituximab\u00a0verglichen\u00a0mit\u00a0Ri tuximab\u00a0plus\u00a0Pla\u2010\ncebo.\u00a0In\u00a0Europa\u00a0ist\u00a0allerdings\u00a0Rituximab\u00a0als\u00a0Monotherapie\u00a0der\u00a0C LL\u00a0nicht\u00a0zugelassen\u00a0\nund\u00a0wird\u00a0auch\u00a0nicht\u00a0von\u00a0Leitlinien\u00a0empfohlen\u00a0(AMB,\u00a02015).\u00a0Einge schlossen\u00a0wurden\u00a0\ninsgesamt\u00a0220\u00a0vorbehandelte\u00a0Pati enten\u00a0mit\u00a0CLL,\u00a0die\u00a0innerhalb\u00a0vo n\u00a024\u00a0Monaten\u00a0\nnach\u00a0letzter\u00a0Behandlung\u00a0einen\u00a0Progress\u00a0zeigten\u00a0und\u00a0aus\u00a0verschie denen\u00a0Gr\u00fcnden\u00a0\nf\u00fcr\u00a0 eine\u00a0 zytotoxische\u00a0 Chemotherapie\u00a0 ungeeignet\u00a0 erschienen\u00a0 (Furm ann\u00a0 et\u00a0 al.,\u00a0\n2014).\u00a0Nach\u00a01:1\u2010Randomisierung\u00a0erhielten\u00a0die\u00a0Patienten\u00a0insgesam t\u00a0acht\u00a0Infusio\u2010\nnen\u00a0Rituximab,\u00a0initial\u00a0alle\u00a0zwei\u00a0Wochen\u00a0375\u00a0mg/m2,\u00a0die\u00a0letzten\u00a0drei\u00a0Infusionen\u00a0alle\u00a0\nvier\u00a0Wochen\u00a0500\u00a0mg/m2,\u00a0im\u00a0Verum\u2010Arm\u00a0plus\u00a0zweimal\u00a0t\u00e4glich\u00a0150\u00a0mg\u00a0Idelalisib\u00a0per\u00a0\nos,\u00a0im\u00a0Kontroll\u2010Arm\u00a0plus\u00a0zweimal\u00a0t\u00e4glich\u00a0Placebo.\u00a0Als\u00a0genetisch e\u00a0Risikofaktoren\u00a0f\u00fcr\u00a0\neine\u00a0 ung\u00fcnstige\u00a0 Prognose\u00a0 hatten\u00a0 knapp\u00a0 45\u00a0 Prozent\u00a0 der\u00a0 Patienten\u00a0 eine\u00a0 17p\u2010\nDeletion\u00a0oder\u00a0eine\u00a0TP53\u2010Mutation.\u00a0Nahezu\u00a0alle\u00a0Patienten\u00a0waren\u00a0b ereits\u00a0mit\u00a0anti\u2010\nCD20\u2010Antik\u00f6rpern\u00a0 vorbehandelt.\u00a0 Prim\u00e4rer\u00a0 Endpunkt\u00a0 war\u00a0 das\u00a0 progre ssionsfreie\u00a0\n\u00dcberleben\u00a0( Progression\u2010free\u00a0Survival ,\u00a0PFS),\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0u.a.\u00a0das\u00a0\nGesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0die\u00a0Ansprechrate.\u00a0Die\u00a0Studie\u00a0wurde\u00a0\nnach\u00a0der\u00a0ersten\u00a0geplanten\u00a0Zwischenanalyse\u00a0vorzeitig\u00a0abgebrochen ,\u00a0da\u00a0Idelalisib\u00a0\nplus\u00a0Rituximab\u00a0das\u00a0PFS\u00a0nach\u00a024\u00a0Wochen\u00a0im\u00a0Vergleich\u00a0zu\u00a0Rituximab \u00a0allein\u00a0eindeutig\u00a0\nverl\u00e4ngert\u00a0hatte\u00a0(93\u00a0%\u00a0versus\u00a046\u00a0%).\u00a0Auch\u00a0die\u00a0Ansprechrate\u00a0(81\u00a0 %\u00a0versus\u00a013\u00a0%)\u00a0und\u00a0\ndas\u00a0Gesamt\u00fcberleben\u00a0nach\u00a012\u00a0Monaten\u00a0(92\u00a0%\u00a0versus\u00a080\u00a0%)\u00a0wurden\u00a0v erbessert,\u00a0\nwobei\u00a0besonders\u00a0die\u00a0Patienten\u00a0m it\u00a0prognostisch\u00a0ung\u00fcnstigen\u00a0gene tischen\u00a0Fakto\u2010\nren\u00a0gut\u00a0auf\u00a0die\u00a0Behandlung\u00a0mit\u00a0Id elalisib\u00a0ansprachen.\u00a0F\u00fcr\u00a0die\u00a0g esundheitsbezoge\u2010\nne\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0fand\u00a0sich\u00a0im\u00a0Vergleich\u00a0\nzur\u00a0Kontrollgruppe\u00a0eine\u00a0statistisch\u00a0signifikante\u00a0und\u00a0klinisch\u00a0r elevante\u00a0Verbesse\u2010\nrung\u00a0des\u00a0k\u00f6rperlichen,\u00a0funktione llen\u00a0und\u00a0sozialen\u00a0Wohlbefindens \u00a0(EMA,\u00a02016).\u00a0239\u00a0Schwere\u00a0unerw\u00fcnschte\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0(Grad\u00a0\u2265\u00a03),\u00a0v or\u00a0allem\u00a0Pneu\u2010\nmonien,\u00a0Fieber\u00a0und\u00a0febrile\u00a0Neutropenien,\u00a0traten\u00a0bei\u00a040\u00a0%\u00a0der\u00a0mi t\u00a0Idelalisib\u00a0und\u00a0\nRituximab\u00a0Behandelten\u00a0bzw.\u00a0bei\u00a035\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontroll\u2010A rm\u00a0auf.\u00a0Nach\u00a0der\u00a0\nvorzeitigen\u00a0Beendigung\u00a0der\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0konnten\u00a0auf\u00a0Wu nsch\u00a0alle\u00a0Pati\u2010\nenten,\u00a0die\u00a0die\u00a0Studienmedikation\u00a0vertragen\u00a0hatten\u00a0und\u00a0eine\u00a0Kran kheitsprogression\u00a0\nerlitten,\u00a0 in\u00a0 die\u00a0 noch\u00a0 laufende\u00a0 unverblindete\u00a0 Extensionsstudie\u00a0 G S\u2010US\u2010312\u20100117\u00a0\naufgenommen\u00a0werden.\u00a0Hier\u00a0erhalten\u00a0alle\u00a0Patienten\u00a0Idelalisib,\u00a0di e\u00a0des\u00a0vorherigen\u00a0\nVerum\u2010Arms\u00a0zweimal\u00a0t\u00e4glich\u00a0300\u00a0mg\u00a0und\u00a0die\u00a0des\u00a0vorherigen\u00a0Kontro llArms\u00a0zweimal\u00a0\nt\u00e4glich\u00a0150\u00a0mg.\u00a0Zur\u00a0Ermittlung\u00a0des\u00a0OS\u00a0der\u00a0Patienten\u00a0aus\u00a0Studie\u00a0 GS\u2010US\u2010312\u20100116\u00a0\nwurden\u00a0Daten\u00a0der\u00a0Extensionsst udie\u00a0GS\u2010US\u2010312\u20100117\u00a0in\u00a0die\u00a0Analyse \u00a0des\u00a0Gesamt\u2010\n\u00fcberlebens\u00a0einbezogen.\u00a0\nIn\u00a0drei\u00a0weiteren\u00a0doppelblinden,\u00a0r andomisierten,\u00a0placebokontroll ierten\u00a0Phase\u2010III\u2010\nStudien\u00a0GS\u2010US\u2010312\u20100123\u00a0(Idelalisib\u00a0plus\u00a0Bendamustin\u00a0plus\u00a0Rituxi mab\u00a0bei\u00a0zuvor\u00a0\nunbehandelter\u00a0CLL),\u00a0GS\u2010US\u2010313\u20100124\u00a0(Idelalisib\u00a0plus\u00a0Rituximab\u00a0b ei\u00a0vorbehandel\u2010\ntem\u00a0NHL)\u00a0und\u00a0GS\u2010US\u2010313\u20100125\u00a0(Ide lalisib\u00a0plus\u00a0Bendamustin\u00a0plus\u00a0R ituximab\u00a0bei\u00a0\nvorbehandeltem\u00a0 NHL)\u00a0 wurde\u00a0 Idelalisib\u00a0 bei\u00a0 Patientengruppen,\u00a0 f\u00fcr\u00a0 die\u00a0 es\u00a0 keine\u00a0\nZulassung\u00a0besitzt,\u00a0oder\u00a0in\u00a0nicht\u00a0zugelassener\u00a0Kombination\u00a0mit\u00a0a nderen\u00a0Arzneimit\u2010\nteln\u00a0angewendet.\u00a0Hier\u00a0kam\u00a0es\u00a0im\u00a0Behandlungsarm\u00a0zu\u00a0Todesf\u00e4llen,\u00a0 die\u00a0zur\u00a0\u00dcberpr\u00fc\u2010\nfung\u00a0der\u00a0Risiken\u00a0von\u00a0Idelalisib\u00a0 durch\u00a0den\u00a0PRAC\u00a0f\u00fchrten\u00a0(EMA,\u00a020 16).\u00a0\nIn\u00a0der\u00a0noch\u00a0laufenden\u00a0multizentr ischen,\u00a0unverblindeten\u00a0Phase\u2010II I\u2010Studie\u00a0GS\u2010US\u2010\n312\u20100119,\u00a0ebenfalls\u00a0gesponsert\u00a0von\u00a0Gilead\u00a0Sciences,\u00a0wurden\u00a0261\u00a0 Patienten\u00a0mit\u00a0\nvorbehandelter\u00a0CLL\u00a0und\u00a0einer\u00a0Progression\u00a0von\u00a0unter\u00a024\u00a0Monaten\u00a0s eit\u00a0Abschluss\u00a0\nder\u00a0letzten\u00a0vorangehenden\u00a0Therapie\u00a0per\u00a0Randomisierung\u00a0im\u00a0Verh\u00e4l tnis\u00a02:1\u00a0\u00fcber\u00a0\njeweils\u00a024\u00a0Wochen\u00a0mit\u00a0Idelalisib\u00a0150\u00a0mg\u00a0zweimal\u00a0t\u00e4glich\u00a0und\u00a012\u00a0 Infusionen\u00a0Ofatu\u2010\nmumab\u00a0(acht\u00a0Dosen\u00a0im\u00a0w\u00f6chentlichen\u00a0Abstand\u00a0und\u00a0anschlie\u00dfend\u00a0vie r\u00a0Dosen\u00a0im\u00a0\nvierw\u00f6chentlichen\u00a0Abstand)\u00a0oder\u00a0ausschlie\u00dflich\u00a0mit\u00a0zw\u00f6lf\u00a0Infusi onen\u00a0Ofatumumab\u00a0\nbehandelt\u00a0(Jones\u00a0et\u00a0al.,\u00a02015).\u00a0Auch\u00a0in\u00a0dieser\u00a0Studie\u00a0wurde\u00a0als o\u00a0im\u00a0Kontroll\u2010Arm\u00a0\nder\u00a0 monoklonale\u00a0 Antik\u00f6rper\u00a0 als\u00a0 Monotherapie\u00a0 nach\u00a0 Vorbehandlung\u00a0 mit\u00a0 anti\u2010\nCD20\u2010Antik\u00f6rpern\u00a0eingesetzt.\u00a0Die\u00a0meisten\u00a0Patienten\u00a0zeigten\u00a0ung\u00fc nstige\u00a0zytogene\u2010\ntische\u00a0Prognosefaktoren,\u00a039,5\u00a0Pr ozent\u00a0hatten\u00a0eine\u00a017p\u2010Deletion\u00a0 und/oder\u00a0eine\u00a0\nTP53\u2010Mutation.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0progressionsfreie\u00a0\u00dcber lebenszeit,\u00a0zu\u00a0\nden\u00a0sekund\u00e4ren\u00a0Endpunkten\u00a0geh\u00f6rten\u00a0das\u00a0OS\u00a0und\u00a0die\u00a0Gesamtansprec hrate\u00a0(Over\u2010\nall\u00a0Response\u00a0Rate ,\u00a0ORR).\u00a0W\u00e4hrend\u00a0das\u00a0mediane\u00a0PFS\u00a0mit\u00a016,3\u00a0Monaten\u00a0im\u00a0Idelali\u2010\nsib\u2010Arm\u00a0gegen\u00fcber\u00a08\u00a0Monaten\u00a0im\u00a0Kontroll\u2010Arm\u00a0signifikant\u00a0verl\u00e4ng ert\u00a0war,\u00a0konnte\u00a0\nf\u00fcr\u00a0das\u00a0mediane\u00a0OS\u00a0bisher\u00a0kein\u00a0s ignifikanter\u00a0Unterschied\u00a0gezeig t\u00a0werden.\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Idelalisib\u00a0bei\u00a0Patienten\u00a0mit\u00a0vorbehandeltem\u00a0F L\u00a0basiert\u00a0auf\u00a0der\u00a0\nvom\u00a0pU\u00a0gesponserten\u00a0einarmigen\u00a0P hase\u2010II\u2010Studie\u00a0101\u201009\u00a0an\u00a0insges amt\u00a0125\u00a0Patien\u2010\nten\u00a0mit\u00a0indolentem\u00a0B\u2010Zell\u2010Non\u2010Hodgkin\u2010Lymphom,\u00a0darunter\u00a072\u00a0Pati enten\u00a0mit\u00a0FL\u00a0240\u00a0(Gopal\u00a0et\u00a0al.,\u00a0 2014).\u00a0Alle\u00a0Patienten\u00a0waren\u00a0refrakt\u00e4r\u00a0gegen\u00fcber\u00a0 Rituximab\u00a0und\u00a0\nmindestens\u00a0einem\u00a0alkylierendem\u00a0Zytostatikum\u00a0der\u00a0Vortherapie\u00a0und \u00a0befanden\u00a0sich\u00a0\nzu\u00a0etwa\u00a090\u00a0%\u00a0in\u00a0einem\u00a0fortgeschrittenem\u00a0Stadium\u00a0III\u00a0oder\u00a0IV\u00a0ihr er\u00a0Erkrankung.\u00a0Sie\u00a0\nerhielten\u00a0zweimal\u00a0t\u00e4glich\u00a0150\u00a0mg\u00a0Idelalisib\u00a0oral\u00a0als\u00a0Monotherap ie\u00a0bis\u00a0zum\u00a0Auftre\u2010\nten\u00a0von\u00a0Anzeichen\u00a0einer\u00a0Krankheit sprogression\u00a0oder\u00a0nicht\u00a0akzept abler\u00a0Nebenwir\u2010\nkungen\u00a0bzw.\u00a0bis\u00a0zum\u00a0Tod.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0von\u00a0einem\u00a0un abh\u00e4ngigen\u00a0\nKomitee\u00a0beurteilte\u00a0ORR.\u00a054\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0FL\u00a0zeigten\u00a0ein\u00a0v ollst\u00e4ndiges\u00a0oder\u00a0\npartielles\u00a0Ansprechen.\u00a0Die\u00a0Lebensqualit\u00e4t\u00a0nach\u00a0dem\u00a0FACT\u2010Lym\u2010Fra gebogen\u00a0zeigte\u00a0\nkeine\u00a0signifikanten\u00a0Ver\u00e4nderungen.\u00a0Als\u00a0UAE\u00a0Grad\u00a0\u2265\u00a03\u00a0traten\u00a0Diar rh\u00f6,\u00a0Neutropenie,\u00a0\nPneumonie\u00a0und\u00a0Dyspnoe\u00a0auf.\u00a0Von\u00a0insgesamt\u00a028\u00a0Todesf\u00e4llen\u00a0traten\u00a0 11\u00a0w\u00e4hrend\u00a0\noder\u00a0innerhalb\u00a0von\u00a030\u00a0Tagen\u00a0nach \u00a0der\u00a0letzten\u00a0Einnahme\u00a0von\u00a0Idela lisb\u00a0auf\u00a0(AMB,\u00a0\n2015).\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0CLL\u00a0ist\u00a0nach\u00a0derzeitigem\u00a0Kenntnisstand\u00a0nicht\u00a0heilbar.\u00a0Die\u00a0e inzige\u00a0kurative\u00a0Opti\u2010\non\u00a0 besteht\u00a0 in\u00a0 der\u00a0 allogenen\u00a0 Sta mmzelltransplantation,\u00a0 die\u00a0 aufgr und\u00a0 schwerer\u00a0\ntherapieassoziierter\u00a0 Komplikationen\u00a0 nur\u00a0 f\u00fcr\u00a0 eine\u00a0 begrenzte\u00a0 Zahl \u00a0 an\u00a0 Patienten\u00a0\ninfrage\u00a0kommt\u00a0(Maurer\u00a0&\u00a0Hallek,\u00a02013).\u00a0W\u00e4hrend\u00a0Patienten\u00a0im\u00a0Bin et\u2010Stadium\u00a0A\u00a0\nund\u00a0B\u00a0und\u00a0Patienten\u00a0mit\u00a0einer\u00a0stabilen\u00a0Erkrankung\u00a0h\u00e4ufig\u00a0keiner \u00a0Therapie\u00a0bed\u00fcr\u2010\nfen\u00a0und\u00a0nur\u00a0engmaschig\u00a0beobachtet\u00a0werden\u00a0( Watch\u2010and\u2010Wait \u2010Strategie),\u00a0besteht\u00a0\nim\u00a0Binet\u2010Stadium\u00a0C\u00a0und\u00a0bei\u00a0einer\u00a0 rasch\u00a0voranschreitenden\u00a0oder\u00a0s ymptomatischen\u00a0\nErkrankung\u00a0 immer\u00a0 eine\u00a0 Therapieindikation.\u00a0 Generell\u00a0 haben\u00a0 Patien ten\u00a0 mit\u00a0\ndel(17p13)\u00a0oder\u00a0TP53\u2010Mutation\u00a0eine\u00a0ung\u00fcnstige\u00a0Prognose.\u00a0Zusamme n\u00a0mit\u00a0den\u00a0\nnicht\u00a0oder\u00a0nur\u00a0unzureichend\u00a0auf\u00a0die\u00a0Erstlinientherapie\u00a0ansprech enden\u00a0Patienten\u00a0\ngelten\u00a0sie\u00a0als\u00a0Hochrisiko\u2010CLL\u2010Pa tienten.\u00a0Ein\u00a0allgemein\u00a0g\u00fcltiges \u00a0Behandlungsregime\u00a0\ngibt\u00a0es\u00a0nicht,\u00a0die\u00a0Therapiewahl\u00a0orientiert\u00a0sich\u00a0vor\u00a0allem\u00a0am\u00a0Al lgemeinzustand,\u00a0an\u00a0\nrelevanten\u00a0Komorbidit\u00e4ten\u00a0und\u00a0am\u00a0genetischen\u00a0Status\u00a0(Wendtner\u00a0e t\u00a0al.,\u00a02017).\u00a0Da\u00a0\netwa\u00a070\u00a0%\u00a0der\u00a0neu\u00a0diagnostizierten\u00a0Patienten\u00a0\u00e4lter\u00a0als\u00a065\u00a0Jahre \u00a0sind\u00a0und\u00a0zu\u00a0einem\u00a0\nGro\u00dfteil\u00a0mehrere\u00a0Begleiterkrankungen\u00a0mit\u00a0Medikation\u00a0sowie\u00a0eine\u00a0 eingeschr\u00e4nkte\u00a0\nNierenfunktion\u00a0 aufweisen,\u00a0 was\u00a0 entscheidenden\u00a0 Einfluss\u00a0 auf\u00a0 die\u00a0 V ertr\u00e4glichkeit\u00a0\naggressiver\u00a0Chemotherapien\u00a0hat,\u00a0 werden\u00a0sie\u00a0mit\u00a0Hilfe\u00a0des\u00a0Cumula tive\u00a0Illness\u00a0Ra\u2010\nting\u00a0Scale\u00a0(CIRS)\u2010Score\u00a0in\u00a0die\u00a0drei\u00a0Gruppen\u00a0fit,\u00a0unfit\u00a0und\u00a0gebr echlich\u00a0eingeteilt,\u00a0um\u00a0\nihre\u00a0Eignung\u00a0f\u00fcr\u00a0bestimmte\u00a0Therapien\u00a0abzusch\u00e4tzen.\u00a0F\u00fcr\u00a0die\u00a0\u201efit ten\u201c\u00a0Patienten\u00a0in\u00a0\ngutem\u00a0Allgemeinzustand\u00a0ist\u00a0in\u00a0 der\u00a0Erstlinienbehandlung\u00a0die\u00a0aggr essive\u00a0Chemoim\u2010\nmuntherapie,\u00a0basierend\u00a0auf\u00a0der\u00a0Kombination\u00a0eines\u00a0Purinnukleosid \u2010Analogons\u00a0mit\u00a0\neinem\u00a0Anti\u2010CD20\u2010Antik\u00f6rper\u00a0(Ritu ximab,\u00a0Ofatumumab\u00a0oder\u00a0Obinutuz umab)\u00a0Stan\u2010\ndard,\u00a0wobei\u00a0das\u00a0Regime\u00a0FCR\u00a0(Fluda rabin\u00a0+\u00a0Cyclophosphamid\u00a0+\u00a0Ritu ximab)\u00a0prim\u00e4r\u00a0\nempfohlen\u00a0wird.\u00a0Mittlerweile\u00a0bevorzugt\u00a0man\u00a0allerdings\u00a0f\u00fcr\u00a0die\u00a0\u201e fitten\u201c\u00a0Patienten\u00a0\njenseits\u00a0des\u00a065.\u00a0Lebensjahres\u00a0wegen\u00a0seines\u00a0g\u00fcnstigeren\u00a0Toxizit\u00e4 tsprofils\u00a0das\u00a0Re\u2010\ngime\u00a0Bendamustin\u00a0plus\u00a0Rituximab.\u00a0Komorbide\u00a0Patienten\u00a0mit\u00a0klinis ch\u00a0relevanten\u00a0241\u00a0Begleiterkrankungen\u00a0erhalten\u00a0in\u00a0der\u00a0Erstlinie\u00a0anstelle\u00a0von\u00a0Flud arabin\u00a0und\u00a0Cyclo\u2010\nphosphamid\u00a0 die\u00a0 f\u00fcr\u00a0 sie\u00a0 besser\u00a0 vertr\u00e4glichen\u00a0 Zytostatika\u00a0 Chloram bucil\u00a0 oder\u00a0\nBendamustin\u00a0in\u00a0Kombination\u00a0mit\u00a0einem\u00a0CD20\u2010Antik\u00f6rper.\u00a0F\u00fcr\u00a0Patie nten\u00a0\u226565\u00a0Jahre\u00a0\nist\u00a0auch\u00a0die\u00a0Therapie\u00a0mit\u00a0dem\u00a0oralen\u00a0Tyrosinkinase\u2010Inhibitor\u00a0Ib rutinib\u00a0eine\u00a0Option.\u00a0\nDie\u00a0palliativen\u00a0supportiven\u00a0Ma\u00dfnahmen\u00a0f\u00fcr\u00a0die\u00a0k\u00f6rperlich\u00a0stark\u00a0 beeintr\u00e4chtigten\u00a0\nbzw.\u00a0gebrechlichen\u00a0Patienten\u00a0k\u00f6nnen\u00a0ebenfalls\u00a0antineoplastisch\u00a0 wirksame\u00a0Sub\u2010\nstanzen\u00a0wie\u00a0Steroide,\u00a0Chlorambuc il,\u00a0Bendamustin\u00a0oder\u00a0Rituximab\u00a0 in\u00a0angepasster\u00a0\nDosierung\u00a0beinhalten.\u00a0Bei\u00a0Hochri sikopatienten\u00a0mit\u00a0einer\u00a017p\u2010Del etion\u00a0und/oder\u00a0\nTP53\u2010Mutation\u00a0 wird\u00a0 bereits\u00a0 in\u00a0 d er\u00a0 Erstlinie\u00a0 eine\u00a0 Behandlung\u00a0 mit \u00a0 dem\u00a0 Kinase\u2010\nInhibitor\u00a0 Ibrutinib\u00a0 oder,\u00a0 bei\u00a0 Kontraindikation\u00a0 gegen\u00a0 Ibrutinib, \u00a0di e \u00a0K o m b i n a t i o n\u00a0\nIdelalisib\u00a0plus\u00a0Rituximab\u00a0empfoh len.In\u00a0der\u00a0Zweitlinie\u00a0und\u00a0allen \u00a0folgenden\u00a0Linien\u00a0\nm\u00fcssen\u00a0bei\u00a0der\u00a0Auswahl\u00a0der\u00a0Rezidi vtherapie\u00a0neben\u00a0dem\u00a0k\u00f6rperlich en\u00a0Zustand\u00a0und\u00a0\ndem\u00a0Risikoprofil\u00a0die\u00a0Art\u00a0der\u00a0Vortherapie\u00a0und\u00a0die\u00a0damit\u00a0erreicht e\u00a0Remissionsdauer\u00a0\nber\u00fccksichtigt\u00a0werden.\u00a0Wenn\u00a0das\u00a0Ansprechen\u00a0auf\u00a0die\u00a0Vorlinienthe rapie\u00a0gut\u00a0ist\u00a0und\u00a0\nmindestens\u00a0zwei\u00a0Jahre\u00a0dauert,\u00a0kann\u00a0diese\u00a0wiederholt\u00a0werden,\u00a0bei \u00a0fr\u00fcher\u00a0eintre\u2010\ntenden\u00a0Rezidiven\u00a0sollte\u00a0die\u00a0vorang egangene\u00a0Therapie\u00a0nicht\u00a0mehr\u00a0 eingesetzt\u00a0wer\u2010\nden.\u00a0 Neben\u00a0 Ibrutinib,\u00a0 Idelalisib/Rituximab\u00a0 und\u00a0 dem\u00a0 BCL2\u2010Hemmer\u00a0 Venetoclax\u00a0\nkommen\u00a0also\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Rezidivtherapie\u00a0intensive\u00a0Chemoimmunth erapien\u00a0infra\u2010\nge,\u00a0allerdings\u00a0sind\u00a0mehrfach\u00a0vor behandelte\u00a0Patienten\u00a0durch\u00a0eine \u00a0eingeschr\u00e4nkte\u00a0\nNieren\u2010\u00a0 und\u00a0 Knochenmarkfunktion\u00a0 h\u00e4ufig\u00a0 zunehmend\u00a0 ungeeignet\u00a0 f\u00fcr \u00a0w e i t e r e \u00a0\naggressive\u00a0 Behandlungen.\u00a0 Hochris iko\u2010CLL\u2010Patienten\u00a0 sowie\u00a0 therapi ebed\u00fcrftige\u00a0\nPatienten\u00a0mit\u00a0Nachweis\u00a0einer\u00a017p \u2010Deletion\u00a0bzw.\u00a0TP53\u2010Mutation\u00a0im \u00a0Rezidiv\u00a0sollten\u00a0\neiner\u00a0allogenen\u00a0Stammzelltranspl antation\u00a0zugef\u00fchrt\u00a0werden,\u00a0sofe rn\u00a0ihr\u00a0k\u00f6rperli\u2010\ncher\u00a0Zustand\u00a0und\u00a0die\u00a0Spendersituation\u00a0dies\u00a0erlauben.\u00a0Da\u00a0CLL\u2010Pat ienten\u00a0krankheits\u2010\u00a0\nund\u00a0therapiebedingt\u00a0h\u00e4ufig\u00a0Infekti onskomplikationen\u00a0zeigen,\u00a0hab en\u00a0eine\u00a0konse\u2010\nquente\u00a0antibiotische,\u00a0antimykotische\u00a0und\u00a0virustatische\u00a0Therapie \u00a0bei\u00a0Infektzeichen\u00a0\nund\u00a0 die\u00a0 Substitution\u00a0 von\u00a0 Immunglobulinen\u00a0 bei\u00a0 Hypogammaglobulin\u00e4 mie\u00a0 und\u00a0\ngleichzeitig\u00a0erh\u00f6hter\u00a0Infektfrequenz\u00a0zentrale\u00a0Bedeutung\u00a0f\u00fcr\u00a0das \u00a0Langzeit\u00fcberle\u2010\nben.\u00a0\nDie\u00a0Therapie\u00a0des\u00a0FL\u00a0erfolgt\u00a0stadienadaptiert\u00a0und\u00a0nur\u00a0bei\u00a0besteh ender\u00a0Symptoma\u2010\ntik\u00a0oder\u00a0drohenden\u00a0Komplikationen.\u00a0W\u00e4hrend\u00a0in\u00a0den\u00a0Stadien\u00a0I\u00a0und \u00a0II\u00a0in\u00a0erster\u00a0Linie\u00a0\nmit\u00a0 lokaler\u00a0 Bestrahlung\u00a0 der\u00a0 bet roffenen\u00a0 Lymphknotenregionen\u00a0 und \u00a0k u r a t i v e m \u00a0\nAnspruch\u00a0behandelt\u00a0wird,\u00a0erfolgt\u00a0im\u00a0Stadium\u00a0III\u00a0und\u00a0IV\u00a0beim\u00a0Auf treten\u00a0krankheits\u2010\nassoziierter\u00a0Symptome\u00a0eine\u00a0syste mische\u00a0medikament\u00f6se\u00a0Behandlung \u00a0mit\u00a0palliati\u2010\nvem\u00a0Therapieanspruch\u00a0(Buske\u00a0et\u00a0al.,\u00a02017).\u00a0Standard\u00a0f\u00fcr\u00a0die\u00a0Ind uktionstherapie\u00a0in\u00a0\nder\u00a0Erstlinie\u00a0ist\u00a0bei\u00a0\u201emedizinisch\u00a0fitten\u201c\u00a0Patienten\u00a0in\u00a0gutem\u00a0A llgemeinzustand\u00a0eine\u00a0\nImmunchemotherapie,\u00a0in\u00a0der\u00a0Rituximab\u00a0kombiniert\u00a0wird\u00a0mit\u00a0Anthra zyklin\u2010haltiger\u00a0\nChemotherapie\u00a0(z.B.\u00a0R\u2010CHOP)\u00a0oder,\u00a0speziell\u00a0bei\u00a0\u00e4lteren\u00a0Patiente n\u00a0wegen\u00a0besserer\u00a0\nVertr\u00e4glichkeit,\u00a0mit\u00a0Bendamustin.\u00a0Auf\u00a0die\u00a0prim\u00e4re\u00a0Immunchemothe rapie\u00a0folgt\u00a0eine\u00a0\nErhaltungstherapie\u00a0mit\u00a0Rituximab\u00a0in\u00a0zweimonatigem\u00a0Abstand\u00a0\u00fcber\u00a0 zwei\u00a0Jahre.\u00a0242\u00a0Auch\u00a0im\u00a0Rezidiv\u00a0ist\u00a0f\u00fcr\u00a0die\u00a0Indu ktionstherapie\u00a0die\u00a0Kombination\u00a0 von\u00a0Rituximab\u00a0mit\u00a0\nChemotherapie\u00a0Standard,\u00a0wobei\u00a0a ndere\u00a0zytotoxische\u00a0Wirkstoffe\u00a0al s\u00a0in\u00a0der\u00a0Pri\u2010\nm\u00e4rtherapie\u00a0zum\u00a0Einsatz\u00a0kommen\u00a0s ollten.\u00a0Als\u00a0Erhaltungstherapie\u00a0 im\u00a0Rezidiv\u00a0wird\u00a0\nRituximab\u00a0in\u00a0dreimonatigem\u00a0Abstand\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0gegeben.\u00a0Erf olgt\u00a0das\u00a0Rezidiv\u00a0\nnach\u00a0initialer\u00a0Immunchemotherapie \u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten,\u00a0 wird\u00a0von\u00a0einer\u00a0\nRefrakt\u00e4rit\u00e4t\u00a0gegen\u00fcber\u00a0Rituximab\u00a0ausgegangen.\u00a0F\u00fcr\u00a0diese\u00a0Patien ten,\u00a0die\u00a0bislang\u00a0\nmit\u00a0einer\u00a0alleinigen\u00a0patienteni ndividuellen\u00a0Chemotherapie\u00a0bzw.\u00a0 Best\u00a0Supportive\u00a0\nCare\u00a0behandelt\u00a0wurden,\u00a0ist\u00a0f\u00fcr\u00a0d ie\u00a0Induktion\u00a0die\u00a0Kombination\u00a0de s\u00a0Anti\u2010CD20\u2010\nAntik\u00f6rpers\u00a0Obinutuzumab\u00a0mit\u00a0Bendamustin\u00a0eine\u00a0Option.\u00a0F\u00fcr\u00a0Patie nten,\u00a0die\u00a0auf\u00a0\nzwei\u00a0vorausgegangene\u00a0Therapielin ien\u00a0nicht\u00a0angesprochen\u00a0haben,\u00a0w ird\u00a0Idelalisib\u00a0als\u00a0\nMonotherapie\u00a0empfohlen.\u00a0Als\u00a0Konsolidierung\u00a0kann,\u00a0alternativ\u00a0zur \u00a0Erhaltungsthe\u2010\nrapie\u00a0mit\u00a0Rituximab,\u00a0eine\u00a0Radioimmuntherapie\u00a0mit\u00a090Y\u2010markiertem \u00a0Ibritumomab\u2010\nTiuxetan\u00a0oder,\u00a0insbesondere\u00a0f\u00fcr\u00a0Patienten\u00a0\u2264\u00a060\u00a0Jahre\u00a0mit\u00a0fr\u00fchen \u00a0Rezidiven,\u00a0eine\u00a0\nmyeloablative\u00a0Hochdosischemother apie\u00a0gefolgt\u00a0von\u00a0einer\u00a0autologe n\u00a0Stammzell\u2010\ntransplantation\u00a0erwogen\u00a0werden.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G \u2010BA)\u00a0unterteilt\u00a0in\u00a0der\u00a0fr\u00fchen\u00a0 Nutzenbewer\u2010\ntung\u00a0im\u00a0Anwendungsgebiet\u00a01\u00a0die\u00a0vorbehandelten\u00a0Patienten\u00a0mit\u00a0CLL \u00a0in\u00a0vier\u00a0Teilpo\u2010\npulationen\u00a0 mit\u00a0 unterschiedlichen\u00a0 zweckm\u00e4\u00dfigen\u00a0 Vergleichstherapi en\u00a0 (zVT),\u00a0 die\u00a0\nvon\u00a0der\u00a0vom\u00a0pU\u00a0festgelegten\u00a0einhe itlichen\u00a0zVT\u00a0Rituximab\u00a0mono\u00a0in \u00a0der\u00a0die\u00a0Zulas\u2010\nsung\u00a0begr\u00fcndenden\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0abweichen\u00a0(G\u2010BA,\u00a02015). \u00a0Die\u00a0Anwen\u2010\ndung\u00a0von\u00a0Rituximab\u00a0bei\u00a0der\u00a0CLL\u00a0ist\u00a0jedoch\u00a0nur\u00a0in\u00a0Kombination\u00a0mi t\u00a0einer\u00a0Chemothe\u2010\nrapie\u00a0zulassungskonform\u00a0und\u00a0zudem\u00a0 bei\u00a0Patienten,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0C hemotherapie\u00a0\nungeeignet\u00a0sind,\u00a0kein\u00a0Therapiest andard.\u00a0Weil\u00a0der\u00a0G\u2010BA\u00a0au\u00dferdem\u00a0 die\u00a0in\u00a0der\u00a0Studie\u00a0\ngetroffenen\u00a0 Ausschlusskriterien\u00a0 f\u00fcr\u00a0 eine\u00a0 Chemotherapie\u00a0 bem\u00e4ngel t,\u00a0 macht\u00a0 er\u00a0\nkeine\u00a0Aussage\u00a0zum\u00a0quantitativen\u00a0Zusatznutzen\u00a0von\u00a0Idelalisib.\u00a0Vo r\u00a0dem\u00a0Hinter\u2010\ngrund\u00a0der\u00a0Schwere\u00a0der\u00a0Erkrankung\u00a0und\u00a0der\u00a0besonderen\u00a0Versorgungs situation\u00a0von\u00a0\nCLL\u2010Patienten,\u00a0die\u00a0f\u00fcr\u00a0weitere\u00a0z ugelassene\u00a0medikament\u00f6se\u00a0Therap ien\u00a0nicht\u00a0infrage\u00a0\nkommen,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0dennoch\u00a0be i\u00a0Patienten\u00a0der\u00a0Teilpopulation \u00a01b\u00a0mit\u00a0rezidi\u2010\nvierender\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemo therapie\u00a0nicht\u00a0indiziert\u00a0ist,\u00a0 einen\u00a0Anhaltspunkt\u00a0\nf\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0 von\u00a0Idelalisib\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0 Best\u2010Supportive\u2010Care .\u00a0Im\u00a0\nAnwendungsgebiet\u00a0 2,\u00a0 der\u00a0 Erstlinienbehandlung\u00a0 von\u00a0 CLL\u2010Patienten\u00a0 mit\u00a0 17p\u2010\nDeletion\u00a0oder\u00a0TP53\u2010Mutation,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Chemotherapie\u00a0ungeeig net\u00a0sind,\u00a0liefert\u00a0\ndie\u00a0Zulassungsstudie\u00a0GS\u2010US\u2010312\u20100116\u00a0ebenfalls\u00a0keine\u00a0relevanten\u00a0 Daten\u00a0f\u00fcr\u00a0einen\u00a0\nVergleich\u00a0von\u00a0Idelalisib\u00a0mit\u00a0der\u00a0zVT\u00a0 Best\u2010Supportive\u2010Care ,\u00a0weil\u00a0ausschlie\u00dflich\u00a0vor\u2010\nbehandelte\u00a0Patienten\u00a0eingeschlo ssen\u00a0waren\u00a0und\u00a0der\u00a0Vergleich\u00a0mit \u00a0Rituximab\u00a0die\u00a0\nzVT\u00a0nicht\u00a0abbildet.\u00a0Doch\u00a0auch\u00a0hier\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0vor\u00a0dem\u00a0Hinte rgrund\u00a0der\u00a0beson\u2010\nderen\u00a0Versorgungssituation\u00a0dieser\u00a0Patientengruppe\u00a0einen\u00a0 Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0\nnicht\u00a0 quantifizierbaren\u00a0 Zusatznutzen ,\u00a0 weil\u00a0 Subgruppenanalysen\u00a0 deutliche\u00a0 Be\u2010243\u00a0handlungseffekte\u00a0 insbesondere\u00a0 f\u00fcr\u00a0 diese\u00a0 Patienten\u00a0 zeigen\u00a0 und\u00a0 la ut\u00a0European\u00a0\nPublic\u00a0Assesment\u00a0Report \u00a0(EPAR)\u00a0der\u00a0EMA\u00a0die\u00a0Daten\u00a0ei ne\u00a0Extrapolation\u00a0der\u00a0Ergeb\u2010\nnisse\u00a0 von\u00a0 vorbehandelten\u00a0 auf\u00a0 nicht\u2010vorbehandelte\u00a0 Patienten\u00a0 erm\u00f6 glichen.\u00a0 Da\u00a0\naufgrund\u00a0der\u00a0kurzen\u00a0Laufzeit\u00a0der\u00a0Studie\u00a0GS\u2010US\u2010312\u20100116\u00a0die\u00a0Date n\u00a0unzureichend\u00a0\nsind,\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzen s\u00a0auf\u00a0Basis\u00a0einer\u00a0Extrapolatio n\u00a0von\u00a0Ergebnissen\u00a0\nbewertet\u00a0wurde\u00a0und\u00a0der\u00a0pU\u00a0der\u00a0EMA\u00a0weitere\u00a0Daten\u00a0vorzulegen\u00a0hat, \u00a0wurde\u00a0die\u00a0\nG\u00fcltigkeit\u00a0dieses\u00a0G\u2010BA\u2010Beschlu sses\u00a0auf\u00a0ein\u00a0Jahr\u00a0befristet.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Drittlinientherapie\u00a0von\u00a0 Patienten\u00a0mit\u00a0Follikul\u00e4rem\u00a0Lymp hom\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0\neinen\u00a0Zusatznutzen\u00a0als\u00a0nicht\u00a0belegt\u00a0an,\u00a0da\u00a0die\u00a0zulassungsbegr\u00fcn dende\u00a0einarmige,\u00a0\noffene\u00a0Phase\u2010II\u2010Studie\u00a0101\u201009\u00a0kein e\u00a0aussagekr\u00e4ftigen\u00a0Daten\u00a0lief ert.\u00a0\nF\u00fcr\u00a0die\u00a0erneute\u00a0Nutzenbewertung\u00a0von\u00a0Idelalisib\u00a0in\u00a0der\u00a0Behandlun g\u00a0der\u00a0CLL\u00a0nach\u00a0\nFristablauf\u00a0bezieht\u00a0der\u00a0G\u2010BA\u00a0Ana lysen\u00a0zum\u00a0finalen\u00a0Datenschnitt\u00a0 der\u00a0Studie\u00a0GS\u2010US\u2010\n312\u20100116\u00a0und\u00a0 unterst\u00fctzende\u00a0Daten\u00a0aus\u00a0der\u00a0Extensionsstudie\u00a0GS\u2010U S\u2010312\u20100117\u00a0\nein,\u00a0deren\u00a0Ergebnisse\u00a0zum\u00a0OS\u00a0und\u00a0PFS\u00a0das\u00a0Ergebnis\u00a0der\u00a0Erstbewer tung\u00a0best\u00e4tigen\u00a0\n(G\u2010BA,\u00a02016).\u00a0Im\u00a0Anwendungsgebiet\u00a01\u00a0hebt\u00a0das\u00a0Gremium\u00a0die\u00a0bei\u00a0de r\u00a0Erstbewer\u2010\ntung\u00a0durchgef\u00fchrte\u00a0Differenzierung\u00a0von\u00a0vier\u00a0Teilpopulationen\u00a0in \u00a0Abh\u00e4ngigkeit\u00a0des\u00a0\nErfolgs\u00a0der\u00a0Vortherapie\u00a0auf\u00a0und\u00a0f asst\u00a0diese\u00a0in\u00a0den\u00a0zwei\u00a0Teilpop ulationen\u00a01a\u00a0und\u00a01b\u00a0\nzusammen.\u00a0F\u00fcr\u00a0die\u00a0Teilpopulation\u00a01a\u00a0der\u00a0Patienten\u00a0mit\u00a0rezidivie render\u00a0oder\u00a0re\u2010\nfrakt\u00e4rer\u00a0CLL,\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0Chemotherapie\u00a0indiziert\u00a0ist,\u00a0gilt\u00a0d er\u00a0Zusatznutzen \u00a0auf\u2010\ngrund\u00a0fehlender\u00a0Daten\u00a0als\u00a0 nicht\u00a0belegt .\u00a0In\u00a0der\u00a0Teilpopulation\u00a01\u00a0b\u00a0der\u00a0Patienten\u00a0mit\u00a0\nrezidivierender\u00a0oder\u00a0refrakt\u00e4rer \u00a0CLL,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Chemotherapi e\u00a0nicht\u00a0geeignet\u00a0\nsind,\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0Schweregrades\u00a0d er\u00a0Erkrankung\u00a0\neinen\u00a0Anhaltspunkt \u00a0f\u00fcr\u00a0einen\u00a0 Zusatznutzen \u00a0von\u00a0Idelalisib\u00a0gegen\u00fcber\u00a0der\u00a0neben\u00a0\nIbrutinib\u00a0als\u00a0zVT\u00a0bestimmten\u00a0 Best\u2010Supportive\u2010Care ,\u00a0der\u00a0aber\u00a0weiterhin\u00a0aufgrund\u00a0\nder\u00a0fehlenden\u00a0Umsetzung\u00a0der\u00a0Vergleichstherapie\u00a0und\u00a0der\u00a0kritisie rten\u00a0Studienme\u2010\nthodik\u00a0nicht\u00a0quantifizierbar \u00a0ist.\u00a0Im\u00a0Anwendungsgebiet\u00a02,\u00a0das\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0\nNeubewertung\u00a0vor\u00fcbergehend\u00a0nicht\u00a0mehr\u00a0die\u00a0\u00a0Erstlinienbehandlung \u00a0sondern\u00a0nur\u00a0\ndie\u00a0Fortsetzung\u00a0einer\u00a0bereits\u00a0initiierten\u00a0Therapie\u00a0mit\u00a0Idelalis ib\u00a0bei\u00a0f\u00fcr\u00a0eine\u00a0Chemo\u2010\nimmuntherapie\u00a0 ungeeigneten\u00a0 Patient en\u00a0 mit\u00a0 17p\u2010Deletion\u00a0 oder\u00a0 TP53 \u2010Mutation\u00a0\u00a0\nbeinhaltete,\u00a0 gilt\u00a0 der\u00a0 Zusatznutz en\u00a0 gegen\u00fcber\u00a0 der\u00a0 zVT\u00a0 Ibrutinib\u00a0 oder\u00a0Best\u2010\nSupportive\u2010Care \u00a0aufgrund\u00a0fehlender\u00a0Date n\u00a0als\u00a0nicht\u00a0belegt.\u00a0\nIm\u00a0neuen\u00a0Anwendungsgebiet\u00a0der\u00a0Kombination\u00a0von\u00a0Idelalisib\u00a0mit\u00a0Of atumumab\u00a0\nsieht\u00a0der\u00a0G\u2010BA\u00a0keinen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0(G\u2010BA,\u00a02017) .\u00a0Weder\u00a0f\u00fcr\u00a0Pati\u2010\nenten,\u00a0die\u00a0mindestens\u00a0eine\u00a0vorangehende\u00a0Therapie\u00a0erhalten\u00a0haben ,\u00a0noch\u00a0f\u00fcr\u00a0die\u00a0\nErstlinientherapie\u00a0bei\u00a0Vorliegen\u00a0einer\u00a017p\u2010Deletion\u00a0oder\u00a0einer\u00a0 TP53\u2010Mutation\u00a0legt\u00a0\nder\u00a0pU\u00a0relevante\u00a0Daten \u00a0vor,\u00a0die\u00a0eine\u00a0Bewert ung\u00a0des\u00a0Zusatznutzen s\u00a0erm\u00f6glichen.\u00a0\n\u00a0244\u00a0Versorgungsanalysen\u00a0\nKurz\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Oktober\u00a02014\u00a0stiegen\u00a0die\u00a0Veror dnungen\u00a0des\u00a0\noralen\u00a0Tyrosinkinase\u2010Inhibitors\u00a0Idelalisib\u00a0schnell\u00a0an\u00a0und\u00a0pende lten\u00a0sich\u00a0im\u00a0vierten\u00a0\nQuartal\u00a02015\u00a0bei\u00a0monatlich\u00a0ca.\u00a040\u00a0N2\u2010Packungen\u00a0bzw.\u00a01200\u00a0DDDs\u00a0m it\u00a0einem\u00a0Um\u2010\nsatz\u00a0von\u00a0\u00fcber\u00a0200.000\u00a0Euro\u00a0ein.\u00a0\u00a0\nAbbildung\u00a04.22:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Idealisib\u00a0je\u00a0Monat \u00a0nach\u00a0Pa\u2010\nckungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\u00a0\n\u00a0 \u00a0\n245\u00a0Abbildung\u00a04.23:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Idealisi b\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nDie\u00a0etwa\u00a070\u00a0Versicherten\u00a0im\u00a0Be obachtungszeitraum\u00a02015\u00a0waren\u00a0zu\u00a0 75\u00a0%\u00a0m\u00e4nnlich\u00a0und\u00a0\ngeh\u00f6rten\u00a0vor\u00a0allem\u00a0der\u00a0Altersgr uppe\u00a0der\u00a060\u2010\u00a0bis\u00a080\u2010J\u00e4hrigen\u00a0an. \u00a0\nQuellen\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2015).\u00a0Neues\u00a0onkologisches\u00a0Arzneim ittel:\u00a0Idelalisib\u00a0(Zydelig\u00ae).\u00a0 https://www.der\u2010\narzneimittelbrief.de/de/Artikel.aspx?J=2015&S=02 ,\u00a0letzter\u00a0Zugriff:\u00a006.04.2017.\u00a0\natd\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2017).\u00a0Idealisib.\u00a0 \u00a0\nhttps://www.arznei\u2010telegramm.de/db/01wkstxt.php3?&knr=&art=mono &nummer=Idelalisib&ord=uaw ,\u00a0letzter\u00a0\nZugriff:\u00a001.05.2017\u00a0\nBuske\u00a0C,\u00a0Dreyling\u00a0M,\u00a0Herold\u00a0M,\u00a0Lohri\u00a0A,\u00a0Neumeister\u00a0P,\u00a0Willenbac her\u00a0W\u00a0(2017).\u00a0Follikul\u00e4res\u00a0Lymphom.\u00a0 https://www.dgho\u2010\nonkopedia.de/de/onkopedia/leitlinien/follikulaeres\u2010lymphom ,\u00a0letzter\u00a0Zugriff:\u00a012.09.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0European\u00a0Medicines\u00a0Agen cy\u00a0\u2010\u00a0Find\u00a0medicine\u00a0\u2010\u00a0Zydelig.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/003843/human_med_001803.jsp&m\nid=WC0b01ac058001d124 ,\u00a0letzter\u00a0Zugriff:\u00a022.12.2016\u00a0\nFachinformation\u00a0Zydelig\u00a0\u00ae\u00a0(201 6).\u00a0Fachinformation\u00a0Zydelig\u00a0 \u00ae.\u00a0http://www.fachinfo.de/suche/fi/020354 ,\u00a0letzter\u00a0Zugriff:\u00a022.12.2016\u00a0\nFurman\u00a0RR,\u00a0Sharman\u00a0JP,\u00a0Coutre\u00a0SE ,\u00a0Cheson\u00a0BD,\u00a0Pagel\u00a0JM,\u00a0Hillmen\u00a0 P\u00a0et\u00a0al.\u00a0(2014).\u00a0Idelalisib\u00a0and\u00a0Rituximab\u00a0in\u00a0Relapsed\u00a0Chronic\u00a0\nLymphocytic\u00a0Leukemia.\u00a0NEJM,\u00a0370(11):\u00a0997\u20101007.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Idelalisib\u00a0\u2010\u00a0Gemeinsamer\u00a0\nBundesausschuss.\u00a0 https://www.g\u2010ba.de/informationen/nutzenbewertung/142/#tab/besc hluesse,\u00a0letzter\u00a0Zugriff:\u00a0\n19.01.2017.\u00a0\n246\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Idelalisib\u00a0(Neubewertung\u00a0nach\u00a0\nFristablauf)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss. \u00a0https://www.g\u2010ba.de/informationen/nutzenbewertung/226/ ,\u00a0letzter\u00a0\nZugriff:\u00a022.12.2016\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Obinutuzumab\u00a0(neues\u00a0\nAnwendungsgebiet)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss.\u00a0 https://www.g\u2010ba.de/informationen/nutzenbewertung/249/ ,\u00a0\nletzter\u00a0Zugriff:\u00a016.02.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Idelalisib\u00a0(Neubewertung\u00a0nach\u00a0\nFristablauf)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss.https://www.g\u2010ba.de/informationen/nutzenbewertung/226/#tab/beschluesse,\u00a0letzt er\u00a0Zugriff:\u00a026.01.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Idelalisib\u00a0(neues\u00a0Anwendungsgebiet\u00a0\u2010\u00a0\nneuer\u00a0Kombinationspartner)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss.\u00a0 https://www.g\u2010\nba.de/informationen/nutzenbewertung/263/ ,\u00a0letzter\u00a0Zugriff:\u00a006.07.2017.\u00a0\nGEKID\u00a0\u2013\u00a0Gesellschaft\u00a0der\u00a0epidemio logischen\u00a0Krebsregister\u00a0e.V.(2 015).\u00a0Krebs\u00a0in\u00a0Deutschland.\u00a0\nwww.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deuts chland/krebs_in_deutschland_node.html ,\u00a0\nletzter\u00a0Zugriff:\u00a023.12.2016.\u00a0\nGilead\u00a0Sciences\u00a0GmbH\u00a0(2016).\u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Zydelig\u00ae.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2016/201 60323.pdf ,\u00a0letzter\u00a0Zugriff:\u00a022.12.2016.\u00a0\nGilead\u00a0Sciences\u00a0GmbH\u00a0(2016).\u00a0Rote\u2010Hand\u2010Brief\u00a0zu\u00a0Zydelig\u00ae.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2016/201 60823.pdf,\u00a0letzter\u00a0Zugriff:\u00a022.12.2016.\u00a0\nGopal\u00a0AK,\u00a0Kahl\u00a0BS,\u00a0de\u00a0Vos\u00a0S,\u00a0Wagner\u2010Johnston\u00a0ND,\u00a0Schuster\u00a0SJ,\u00a0J urczak\u00a0WJ\u00a0et\u00a0al.\u00a0(2014).\u00a0PI3K\u03b4\u00a0Inhibition\u00a0by\u00a0Idelalisib\u00a0in\u00a0Pati ents\u00a0\nwith\u00a0Relapsed\u00a0Indolent\u00a0Lymphoma.\u00a0New\u00a0England\u00a0Journal\u00a0of\u00a0Medicin e,\u00a0370(11):\u00a01008\u20101018.\u00a0\u00a0\nJones\u00a0JA,\u00a0Wach\u00a0M,\u00a0Robak\u00a0T,\u00a0Brown\u00a0JR,\u00a0Menter\u00a0AR,\u00a0Vandenberghe\u00a0E\u00a0 et\u00a0al.\u00a0(2015).\u00a0Results\u00a0of\u00a0a\u00a0phase \u00a0III\u00a0randomized,\u00a0controlled\u00a0st udy\u00a0\nevaluating\u00a0the\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0idelalisib\u00a0(IDELA)\u00a0in\u00a0com bination\u00a0with\u00a0ofatumumab\u00a0(OFA)\u00a0for\u00a0previously\u00a0treated\u00a0\nchronic\u00a0lymphocytic\u00a0leukemia\u00a0(CLL).\u00a0J\u00a0Clin\u00a0Oncol\u00a0(ASCO\u00a0Annual\u00a0M eeting)\u00a02015;33\u00a0(Suppl):abstr\u00a07023.\u00a0\nMaurer\u00a0C,\u00a0Hallek\u00a0M\u00a0(2013).\u00a0Chronis che\u00a0lymphatische\u00a0Leuk\u00e4mie.\u00a0DM W\u00a0\u2010\u00a0Deutsche\u00a0Medizinische\u00a0Wochenschrift,\u00a0138(42):\u00a02153\u20102166.\u00a0\u00a0\nPrescrire\u00a0(2016).\u00a0Idelasib:\u00a0death\u00a0from\u00a0Infections.\u00a0Prescrire\u00a0In t\u00a025\u00a0(175):\u00a0243.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe.\u00a0Idela lisib|Zydelig\u00ae.\u00a0 www.pharmazeutische\u2010zeitung.de/?id=54982 ,\u00a0letzter\u00a0\nZugriff:\u00a020.07.2017.\u00a0\nWendtner\u00a0CM,\u00a0Dreger\u00a0P,\u00a0Gregor\u00a0M, \u00a0Greil\u00a0R,\u00a0Knauf\u00a0WU,\u00a0Pritzkuleit \u00a0R\u00a0et\u00a0al.\u00a0(2017).\u00a0Chronische\u00a0lymphatische\u00a0Leuk\u00e4mie.\u00a0\nhttps://www.onkopedia.com/de/onkopedia/guidelines/chronische\u2010ly mphatische\u2010leukaemie\u2010\ncll/@@view/pdf/index.pdf?filename=chronische\u2010lymphatische\u2010leuka emie\u2010cll.pdf ,\u00a0letzter\u00a0Zugriff:\u00a011.09.2017.\u00a0\n\u00a0\n\u00a0 \u00a0247\u00a04.16 Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0\nHandelsname:\u00a0Harvoni\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0 GILEAD\u00a0Sciences\u00a0GmbH\u00a0\nATC\u2010Code:\u00a0J05AX65\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0Dezember\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0Standarddosis\u00a0\u00a0          \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nDas\u00a0 direkt\u00a0 antiviral\u00a0 wirkende\u00a0 Ledipasvir\u00a0 steht\u00a0 nur\u00a0 mit\u00a0 Sofosbuv ir\u00a0 als\u00a0 Fixkom\u2010\nbination\u00a0zweier\u00a0Wirkprinzipien\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0chronisch en\u00a0Hepatitis\u00a0C\u00a0\n(HC)\u00a0zur\u00a0Verf\u00fcgung\u00a0(Handelsname:\u00a0 Harvoni\u00ae).\u00a0Es\u00a0vereinigt\u00a0den\u00a0pa ngenotypischen\u00a0\nNS5B\u2010Polymeraseinhibitor\u00a0Sofos buvir\u00a0mit\u00a0dem\u00a0NS5A\u2010Hemmstoff\u00a0Ledi pasvir.\u00a0Beide\u00a0\nWirkstoffe\u00a0sind\u00a0potent\u00a0antiviral\u00a0wirksam\u00a0und\u00a0gut\u00a0vertr\u00e4glich.\u00a0W \u00e4hrend\u00a0sich\u00a0aber\u00a0\ngegen\u00a0 Sofosbuvir\u00a0 vergleichsweise \u00a0 selten\u00a0 Resistenzen\u00a0 ausbilden,\u00a0 liegt\u00a0 die\u00a0\nResistenzschwelle\u00a0bei\u00a0NS5A\u2010Inhibi toren\u00a0wie\u00a0Ledipasvir\u00a0oder\u00a0dem\u00a0 wenige\u00a0Monate\u00a0\nzuvor\u00a0als\u00a0erster\u00a0Vertreter\u00a0diese r\u00a0Wirkstoffgruppe\u00a0zugelassenen\u00a0 Daclatasvir\u00a0niedrig.\u00a0\nDiese\u00a0 Wirkstoffe\u00a0 d\u00fcrfen\u00a0 daher\u00a0 auch\u00a0 nicht\u00a0 als\u00a0 Monotherapeutika\u00a0 z um\u00a0 Einsatz\u00a0\nkommen.\u00a0Die\u00a0feste\u00a0Kombination\u00a0ka nn\u00a0laut\u00a0Zulassung\u00a0angewendet\u00a0we rden\u00a0bei\u00a0HC\u2010\nVirus\u00a0(HCV)\u2010Infektionen\u00a0Genotyp\u00a0 (GT)\u00a01,\u00a03,\u00a04,\u00a05\u00a0und\u00a06.\u00a0Die\u00a0fest e\u00a0Kombination,\u00a0\nbestehend\u00a0aus\u00a090\u00a0mg\u00a0Ledipasvir\u00a0und\u00a0400\u00a0mg\u00a0Sofosbuvir,\u00a0wird\u00a0nur\u00a0 einmal\u00a0t\u00e4glich\u00a0\nverabreicht,\u00a0 was\u00a0 sich\u00a0 positiv\u00a0 auf\u00a0 die\u00a0 Therapietreue\u00a0 auswirken\u00a0 k ann\u00a0 (Fach\u2010\ninformation\u00a0Harvoni\u00ae,\u00a02016).\u00a0\u00a0\nDie\u00a0verf\u00fcgbare\u00a0Evidenz\u00a0aus\u00a0kontrollierten\u00a0klinischen\u00a0Studien\u00a0l\u00e4 sst\u00a0einen\u00a0deutlichen\u00a0\nZusatznutzen\u00a0 der\u00a0 kombinierten\u00a0 Anwendung\u00a0 zweier\u00a0 direkt\u00a0 antiviral \u00a0 wirkender\u00a0\nMittel\u00a0im\u00a0Vergleich\u00a0zu\u00a0einer\u00a0Pegin terferon\u2010basierten\u00a0Therapie\u00a0e rkennen,\u00a0wenn\u00a0\nPatienten\u00a0mit\u00a0chronischer\u00a0HC\u2010GT\u00a0 1\u00a0behandelt\u00a0werden\u00a0(Prescrire,\u00a0 2016;\u00a0Ahmed\u00a0et\u00a0\nal.,\u00a0 2016).\u00a0 Unabh\u00e4ngig\u00a0 von\u00a0 der\u00a0 Auspr\u00e4gung\u00a0 der\u00a0 Lebererkrankung\u00a0 ( mit/ohne\u00a0\nZirrhose),\u00a0 den\u00a0 Polymorphismen\u00a0 bei m\u00a0 Patientenkollektiv\u00a0 (IL28b\u2010Ge notyp)\u00a0 sowie\u00a0\neinem\u00a0 vorangehenden\u00a0 Therapievers agen\u00a0 f\u00fchrte\u00a0 die\u00a0 Zweierkombinati on\u00a0 in\u00a0 den\u00a0\nzulassungsrelevanten\u00a0 und\u00a0 allesamt \u00a0 herstellergesponserten\u00a0 Studie n\u00a0 zu\u00a0 hohen\u00a0\nErfolgsraten\u00a0 (ION\u20101,\u00a0 Afdahl\u00a0 et\u00a0 al.,\u00a0 2014a;\u00a0 ION\u20102,\u00a0 Afdahl\u00a0 et\u00a0 al. ,\u00a0 2014b;\u00a0 ION\u20103,\u00a0\nKowdley\u00a0et\u00a0al.,\u00a02014c;\u00a0LONESTAR,\u00a0Lawitz\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0als\u00a0 prim\u00e4rer\u00a0Endpunkt\u00a0\ndefinierte\u00a0dauerhafte\u00a0virologisc he\u00a0Ansprechrate\u00a0lag\u00a0jeweils\u00a0zwi schen\u00a094\u00a0und\u00a099\u00a0%.\u00a0\nDaten\u00a0 zur\u00a0 gesundheitsbezogenen\u00a0 Lebensqualit\u00e4t\u00a0 wurden\u00a0 nicht\u00a0 erho ben.\u00a0 Hohe\u00a0\nvirologische\u00a0Ansprechraten\u00a0scheinen\u00a0\u00f6ffentlich\u00a0gef\u00f6rderten\u00a0Stud ien\u00a0zufolge\u00a0auch\u00a0\nbei\u00a0Patienten\u00a0mit\u00a0HIV\u2010Coinfektio n\u00a0gegeben\u00a0(ERADICATE,\u00a0Osinusi\u00a0e t\u00a0al.,\u00a02015;\u00a0ION\u2010\n4,\u00a0Naggie\u00a0et\u00a0al.,\u00a02015).\u00a0Bei\u00a0HCV\u2010GT\u20104\u2010Infizierten\u00a0wird\u00a0das\u00a0daue rhaft\u00a0virologische\u00a0\nAnsprechen\u00a0von\u00a0Ledipasvir\u00a0+\u00a0Sofo sbuvir\u00a0und\u00a0von\u00a0Peginterferon\u00a0+\u00a0 Ribavirin\u00a0als\u00a0\n\u00e4quivalent\u00a0angesehen.\u00a0Lediglich\u00a0die\u00a0k\u00fcrzere\u00a0Behandlungszeit\u00a0unt er\u00a0Ledipasvir\u00a0und\u00a0\n248\u00a0Sofosbuvir\u00a0 lassen\u00a0 geringere\u00a0 Ra ten\u00a0 unerw\u00fcnschter\u00a0 Arzneimittelere ignisse\u00a0 (UAE)\u00a0\nerwarten\u00a0(SYNERGY,\u00a0Kohli\u00a0et\u00a0al.,\u00a02015).\u00a0Der\u00a0therapeutische\u00a0Stel lenwert\u00a0von\u00a0Ledi\u2010\npasvir\u00a0+\u00a0Sofosbuvir\u00a0bei\u00a0der\u00a0Behandlung\u00a0von\u00a0GT\u00a03,\u00a05\u00a0und\u00a06\u00a0ist\u00a0zu m\u00a0derzeitigen\u00a0\nZeitpunkt\u00a0 aufgrund\u00a0 unzureichender\u00a0 bzw.\u00a0 methodisch\u00a0 zweifelhafter \u00a0U n t e r s u \u2010\nchungsergebnisse\u00a0nicht\u00a0abschlie\u00dfend\u00a0zu\u00a0bestimmen.\u00a0F\u00fcr\u00a0die\u00a0Behan dlung\u00a0von\u00a0HCV\u2010\nGT\u00a02\u00a0ist\u00a0die\u00a0Fixkombination\u00a0nicht\u00a0vorgesehen.\u00a0\nUntersuchungen\u00a0legen\u00a0nahe,\u00a0dass\u00a0durch\u00a0die\u00a0Behandlung\u00a0mit\u00a0direkt \u00a0antiviral\u00a0wir\u2010\nkenden\u00a0Mitteln\u00a0eine\u00a0bereits\u00a0vor liegende\u00a0Hepatitis\u2010B\u2010Erkrankung\u00a0 re\u2010aktiviert\u00a0wer\u2010\nden\u00a0kann.\u00a0Bei\u00a0Koinfektion\u00a0hemmt\u00a0das\u00a0Hepatitis\u2010C\u2010Virus\u00a0(HCV)\u00a0die \u00a0Replikation\u00a0von\u00a0\nHepatitis\u2010B\u2010Viren.\u00a0 Unter\u00a0 spezifi scher\u00a0 antiviraler\u00a0 Hepatitis\u2010C\u2010B ehandlung\u00a0 entf\u00e4llt\u00a0\ndiese\u00a0Hemmfunktion.\u00a0Seit\u00a0Ende\u00a02016\u00a0fordert\u00a0daher\u00a0die\u00a0europ\u00e4isch e\u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0 vor\u00a0 einer\u00a0 HCV\u2010Behandlung\u00a0 ein\u00a0 Screening\u00a0 auf\u00a0 Hepatitis\u2010B\u2010Ko infektion\u00a0\n(BfArM,\u00a02015;\u00a0FDA,\u00a02015).\u00a0\nDa\u00a0 in\u00a0 keiner\u00a0 der\u00a0 im\u00a0 Bewertungsverfahren\u00a0 vorgelegten\u00a0 Studien\u00a0 die \u00a0g e f o r d e r t e \u00a0\nzweckm\u00e4\u00dfige\u00a0Vergleichstherapie\u00a0untersucht\u00a0wurde,\u00a0musste\u00a0der\u00a0G\u2010B A\u00a0bei\u00a0der\u00a0fr\u00fc\u2010\nhen\u00a0Nutzenbewertung\u00a0auf\u00a0historische\u00a0Vergleiche\u00a0der\u00a0kombinierten \u00a0Anwendung\u00a0\nvon\u00a0Ledipasvir\u00a0und\u00a0Sofosbuvir\u00a0geg en\u00fcber\u00a0der\u00a0Duotherapie,\u00a0besteh end\u00a0aus\u00a0Pegin\u2010\nterferon\u00a0 +\u00a0 Ribavirin,\u00a0 bzw.\u00a0 der\u00a0 Tripeltherapie,\u00a0 bestehend\u00a0 aus\u00a0 Pe ginterferon\u00a0 +\u00a0\nRibavirin\u00a0+\u00a0(Boceprevir\u00a0oder\u00a0Telaprevir)\u00a0zur\u00fcckgreifen\u00a0(G\u2010BA,\u00a02 015).\u00a0Aus\u00a0diesen\u00a0\nleitet\u00a0der\u00a0G\u2010BA\u00a0f\u00fcr\u00a0therapienaiv e\u00a0wie\u00a0auch\u00a0f\u00fcr\u00a0therapieerfahren e\u00a0HC\u2010Patienten\u00a0mit\u00a0\nGT\u00a01\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrhose\u00a0im\u00a0Hinblick\u00a0 auf\u00a0das\u00a0virologi\u2010\nsche\u00a0Ansprechen\u00a0einen\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0ab.\u00a0\nDa\u00a0die\u00a0Behandlungsdauer\u00a0deutlich\u00a0k\u00fcrzer\u00a0ist\u00a0als\u00a0bei\u00a0der\u00a0Tripelt herapie,\u00a0wird\u00a0f\u00fcr\u00a0die\u00a0\nFixkombination\u00a0auch\u00a0im\u00a0Hinblick\u00a0auf\u00a0therapiebedingte\u00a0Nebenwirku ngen\u00a0ein\u00a0Vorteil\u00a0\ngesehen.\u00a0F\u00fcr\u00a0HC\u2010Patienten\u00a0mit\u00a0GT\u00a01 \u00a0sowie\u00a0HIV\u2010Coinfektion\u00a0 wird\u00a0gegen\u00fcber\u00a0der\u00a0\nPeginterferon\u2010gest\u00fctzten\u00a0Vergleichstherapie\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatz\u2010\nnutzen\u00a0erkannt,\u00a0der \u00a0allerdings \u00a0nicht\u00a0quantifizierbar\u00a0ist .\u00a0Dieses\u00a0Urteil\u00a0wird\u00a0auch\u00a0f\u00fcr\u00a0\ndie\u00a0Gabe\u00a0von\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0in\u00a0Kombination\u00a0mit\u00a0Ribavir in\u00a0im\u00a0Vergleich\u00a0zur\u00a0\nBest\u2010Supportive\u2010Care \u00a0(BSC)\u00a0bei\u00a0HC\u2010Patienten\u00a0mit\u00a0GT\u00a01\u00a0und\u00a0dekompensierter\u00a0Zir\u2010\nrhose\u00a0gef\u00e4llt.\u00a0Bei\u00a0HCV\u2010GT\u20104\u2010Infektionen\u00a0wird\u00a0f\u00fcr\u00a0Ledipasvir\u00a0+\u00a0S ofosbuvir\u00a0ein\u00a0 An\u2010\nhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 geringen\u00a0 Zusatznutzen \u00a0 gegen\u00fcber\u00a0 einer\u00a0 Peginterferon\u2010\nbasierten\u00a0Vergleichstherapie\u00a0anerkannt,\u00a0da\u00a0mit\u00a0der\u00a0verk\u00fcrzten\u00a0A nwendungsdauer\u00a0\nauch\u00a0geringere\u00a0Nebenwirkungsraten\u00a0erwartet\u00a0werden.\u00a0\u00a0\nSo\u00a0ergibt\u00a0sich\u00a0in\u00a0der\u00a0Gesamtschau\u00a0der\u00a0(Zusatz\u2010)Nutzenbewertung\u00a0 eine\u00a0\"gelbe\u00a0Am\u2010\npel\".\u00a0W\u00fcrde\u00a0Harvoni\u00ae\u00a0ausschlie\u00dflich\u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0bei\u00a0Patient en\u00a0mit\u00a0Genotyp\u00a01\u00a0\nohne\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrh ose\u00a0bewertet,\u00a0w\u00e4re\u00a0eine\u00a0\"gr\u00fcne \u00a0Ampel\"\u00a0in\u00a0der\u00a0\nKategorie\u00a0(Zusatz\u2010)Nutzen\u00a0zu\u00a0vergeben.\u00a0\n\u00a0 \u00a0249\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0Erste\u00a0Fixkombination\u00a0\nzweier\u00a0direkt\u00a0antiviral\u00a0\nwirkender\u00a0Mittel \u00a0Zusatznutzen\u00a0in\u00a0Bezug\u00a0\nauf\u00a0dauerhaftes\u00a0\nvirologisches\u00a0Ansprechen\u00a0\nund\u00a0Vertr\u00e4glichkeit\u00a0bei\u00a0\nHCV\u00a0Genotyp\u00a01 \u00a0teurer\u00a0im\u00a0Vergleich\u00a0zum\u00a0bis\u00a0\ndahin\u00a0\u00fcblichen\u00a0PEG\u2010\nbasierten\u00a0Regime \u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0Mittel\u00a0der\u00a0Wahl\u00a0\nbei\u00a0chronischer\u00a0HC\u2010\nGenotyp\u00a01\u00a0ohne\u00a0\noder\u00a0mit\u00a0\nkompensierter\u00a0\nLeberzirrhose\u00a0einfache,\u00a0wirksame\u00a0\nund\u00a0offensichtlich\u00a0\ngut\u00a0vertr\u00e4gliche\u00a0\nTherapie,\u00a0extrem\u00a0\nteuer\u00a0Offers\u00a0an\u00a0advantage\u00a0\nin\u00a0HCV\u20101\u2010infection\u00a0\nJudgement\u00a0reserved\u00a0\nHCV\u00a03/4\u00a0Schrittinnovation\u00a0\n\u00a0\nKosten\u00a0Kombinationstherapie \u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage*\u00a0 Tagestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nLedipasvir/Sofosbuvir \u00a0 1x\u00a0tgl.\u00a0 56\u00a0\u2013\u00a0168\u00a0Tage\u00a0 630,94\u00a0\u20ac\u00a0\nIn\u00a0Kombination\u00a0mit: \u00a0 \u00a0 \u00a0 \u00a0\nSofosbuvir\u00a0 1x\u00a0tgl.\u00a0 84\u00a0\u2013\u00a0168\u00a0Tage\u00a0 600,31\u00a0\u20ac\u00a0\nBoceprevir\u00a0 3x\u00a0tgl.\u00a0800\u00a0mg\u00a0 196\u00a0\u2013\u00a0336\u00a0Tage\u00a0 112,36\u00a0\u20ac\u00a0\nTelaprevir\u00a0 3x\u00a0tgl.\u00a0750\u00a0mg\u00a0 84\u00a0\u2013\u00a0336\u00a0Tage\u00a0 334,27\u00a0\u20ac\u00a0\nRibavirin\u00a01x\u00a0400\u00a0mg\u00a0+\u00a0\u00a0\n1x\u00a0600\u00a0mg\u00a0168\u00a0\u2013\u00a0336\u00a0Tage\u00a0 29,89\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB11)\u00a0 1x\u00a0w\u00f6chentlich\u00a024\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0280,19\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB10)\u00a0 1x\u00a0w\u00f6chentlich\u00a024\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0254,31\u00a0\u20ac\u00a0\n*Je\u00a0nach\u00a0Virenbelastung\u00a0ist\u00a0die\u00a0Therapiedauer\u00a012\u00a0Wochen\u00a0(84\u00a0Tag e),\u00a024\u00a0Wochen\u00a0(168\u00a0Tage)\u00a0oder\u00a048\u00a0Wochen\u00a0(336\u00a0Tage).\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nH a r v o n i \u00ae \u00a0i s t \u00a0e i n \u00a0h o c h p r e i s i g e s \u00a0A r z n e i m i t t e l . \u00a0D i r e k t \u00a0n a c h \u00a0d e r \u00a0M a rkteinf\u00fchrung\u00a0\nlagen\u00a0die\u00a0monatlichen\u00a0Kosten\u00a0bei\u00a0einem\u00a0Spitzenwert\u00a0von\u00a010\u00a0Mio.\u00a0 Euro.\u00a0In\u00a0der\u00a0\nzweiten\u00a0Jahresh\u00e4lfte\u00a0sanken\u00a0die\u00a0Ums\u00e4tze\u00a0parallel\u00a0zu\u00a0den\u00a0Verordn ungen\u00a0um\u00a0knapp\u00a0\n50\u00a0%.\u00a0\u00a0\n250\u00a0Abbildung\u00a04.24:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Ledi\u2010\npasvir\u00a0+\u00a0Sofosbuvir\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nWie\u00a0bei\u00a0Daclatasvir\u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0Ledipasvir\u00a0um\u00a0einen\u00a0sel ektiven\u00a0Hemmstoff\u00a0\ndes\u00a0viralen\u00a0Nicht\u2010Strukturproteins\u00a05A\u00a0(NS5A).\u00a0Nicht\u2010Strukturpro teine\u00a0entstehen\u00a0\nw\u00e4hrend\u00a0der\u00a0viralen\u00a0Proteinbiosyn these,\u00a0indem\u00a0virale\u00a0Proteasen\u00a0 das\u00a0bei\u00a0der\u00a0ribo\u2010\nsomalen\u00a0 Translation\u00a0 entstehende\u00a0 Polyprotein\u00a0 in\u00a0 Struktur\u2010\u00a0 und\u00a0 Ni cht\u2010Struktur\u2010\nproteine\u00a0abbauen.\u00a0Nicht\u2010Strukturproteine\u00a0sind\u00a0wesentlich\u00a0an\u00a0der \u00a0RNA\u2010Replikation\u00a0\nund\u00a0der\u00a0Virus\u2010Morphogenese\u00a0beteiligt.\u00a0In\u00a0Harvoni\u00ae\u00a0ist\u00a0Ledipasvi r\u00a0mit\u00a0Sofosbuvir,\u00a0\neinem\u00a0Hemmstoff\u00a0der\u00a0RNA\u2010abh\u00e4ngigen \u00a0RNA\u2010Polymerase\u2010NS5B\u00a0des\u00a0HCV\u00a0 kombi\u2010\nniert.\u00a0Sofosbuvir\u00a0ist\u00a0ein\u00a0Nukleo tid\u2010Prodrug,\u00a0das\u00a0in\u00a0den\u00a0Hepatoz yten\u00a0nach\u00a0intrazellu\u2010\nl\u00e4rer\u00a0Metabolisierung\u00a0in\u00a0das\u00a0pharm akologisch\u00a0aktive\u00a0Uridin\u2010Anal ogon\u2010Triphosphat\u00a0\numgewandelt\u00a0 wird.\u00a0 Das\u00a0 Nukleotid\u2010A nalogon\u00a0 konkurriert\u00a0 intrazellu l\u00e4r\u00a0 mit\u00a0 dem\u00a0\nnat\u00fcrlichen\u00a0Nukleotid\u00a0um\u00a0den\u00a0Einbau\u00a0in\u00a0die\u00a0wachsende\u00a0HCV\u2010RNA\u2010Ke tte\u00a0und\u00a0wird\u00a0\nnach\u00a0Anbindung\u00a0an\u00a0das\u00a0aktive\u00a0Zentrum\u00a0der\u00a0NS5B\u2010Polymerase\u00a0von\u00a0di eser\u00a0als\u00a0fal\u2010\nscher\u00a0Baustein\u00a0in\u00a0die\u00a0HCV\u2010RNA\u00a0in tegriert,\u00a0was\u00a0zum\u00a0Kettenabbruch \u00a0f\u00fchrt\u00a0(Gilead,\u00a0\n2016).\u00a0\u00a0\nIn\u00a0Zellkulturen\u00a0konnten\u00a0HCV\u00a0der\u00a0GT\u00a01a\u00a0und\u00a01b\u00a0mit\u00a0reduzierter\u00a0Em pfindlichkeit\u00a0\ngegen\u00fcber\u00a0Ledipasvir\u00a0beobachtet\u00a0werden.\u00a0F\u00fcr\u00a0GT\u00a01a\u00a0wurden\u00a0Q30H/R \u2010,\u00a0L31I/\u00a0M/V\u2010,\u00a0\nP32L\u2010\u00a0und\u00a0Y93T\u2010Varianten,\u00a0f\u00fcr\u00a0GT\u00a01b\u00a0A92K\u2010\u00a0und\u00a0Y93H\u2010Varianten\u00a0mi t\u00a0verminderter\u00a0\nEmpfindlichkeit\u00a0gefunden.\u00a0Ebenfa lls\u00a0in\u2010vitro\u00a0konnten\u00a0f\u00fcr\u00a0die\u00a0GT \u00a01b,\u00a02a,\u00a02b,\u00a03a,\u00a04a,\u00a0\n251\u00a05a\u00a0und\u00a06a\u00a0Mutanten\u00a0selektiert\u00a0werden,\u00a0die\u00a0weniger\u00a0auf\u00a0Sofosbuvi r\u00a0reagieren.\u00a0Hier\u00a0\nergeben\u00a0sich\u00a0in\u00a0erster\u00a0Linie\u00a0S282T\u2010Varianten\u00a0mit\u00a0verminderter\u00a0E mpfindlichkeit.\u00a0Bei\u00a0\nKombination\u00a0der\u00a0beiden\u00a0Wirkprinzipien\u00a0sind\u00a0Sofosbuvir\u2010resistent e\u00a0Varianten\u00a0noch\u00a0\nuneingeschr\u00e4nkt\u00a0empfindlich\u00a0gege n\u00fcber\u00a0Ledipasvir\u00a0und\u00a0umgekehrt. \u00a0Auch\u00a0gegen\u2010\n\u00fcber\u00a0anderen\u00a0direkt\u00a0antiviral\u00a0wir kenden\u00a0Mitteln\u00a0resistente\u00a0Vari anten\u00a0zeigten\u00a0so\u2010\nwohl\u00a0Sofosbuvir\u00a0und\u00a0Ledipasvir\u00a0in\u2010 vitro\u00a0ihre\u00a0volle\u00a0Wirksamkeit\u00a0 (Gilead,\u00a02016).\u00a0\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nLedipasvir\u00a0+\u00a0Sofosbuvir\u00a0besitzt\u00a0 bei\u00a0Erwachsenen\u00a0alleine\u00a0oder\u00a0in \u00a0Kombination\u00a0mit\u00a0\nanderen\u00a0antiviral\u00a0wirkenden\u00a0Arzneimitteln\u00a0eine\u00a0Zulassung\u00a0zur\u00a0Be handlung\u00a0der\u00a0HC\u00a0\nder\u00a0GT\u00a01,\u00a03,\u00a04,\u00a05\u00a0und\u00a06.\u00a0Solange\u00a0keine\u00a0Leberzirrhose\u00a0vorliegt,\u00a0 sind\u00a012\u00a0Behandlungs\u2010\nwochen\u00a0mit\u00a0der\u00a0dualen\u00a0Therapie\u00a0ausreichend.\u00a0Bei\u00a0Infektionen\u00a0mit \u00a0GT\u00a01\u00a0und\u00a0niedri\u2010\nger\u00a0Viruslast\u00a0gen\u00fcgen\u00a0f\u00fcr\u00a0eine\u00a0Ersttherapie\u00a0sogar\u00a0acht\u00a0Behandlu ngswochen,\u00a0um\u00a0\ndauerhaftes\u00a0virologisches\u00a0Anspre chen\u00a0zu\u00a0erreichen.\u00a0Bei\u00a0Retherap ie\u00a0soll\u00a0die\u00a0feste\u00a0\nKombination\u00a0zusammen\u00a0mit\u00a0Ribavirin\u00a0angewendet\u00a0oder\u00a0die\u00a0Behandlu ngsdauer\u00a0auf\u00a0\n24\u00a0Wochen\u00a0erh\u00f6ht\u00a0werden.\u00a0Das\u00a0gilt \u00a0auch,\u00a0wenn\u00a0eine\u00a0Leberzirrhose \u00a0vorliegt.\u00a0Bei\u00a0\nPatienten\u00a0nach\u00a0Lebertransplantation\u00a0wird\u00a0eine\u00a0Tripeltherapie\u00a0mi t\u00a0Ribavirin\u00a0\u00fcber\u00a0\nzw\u00f6lf\u00a0Wochen\u00a0empfohlen.\u00a0Falls\u00a0Ri bavirin\u00a0nicht\u00a0eingesetzt\u00a0werden \u00a0kann,\u00a0wird\u00a0die\u00a0\nalleinige\u00a0Behandlung\u00a0mit\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Woc hen\u00a0empfohlen,\u00a0\nwenn\u00a0keine\u00a0Leberzirrhose\u00a0vorliegt ,\u00a0oder\u00a0\u00fcber\u00a024\u00a0Wochen,\u00a0sofern\u00a0 bereits\u00a0eine\u00a0Le\u2010\nberzirrhose\u00a0vorliegt\u00a0(Gilead,\u00a02016).\u00a0\u00a0\nPatienten\u00a0mit\u00a0HCV\u2010GT\u00a03\u00a0und\u00a0kompensierter\u00a0Zirrhose\u00a0oder\u00a0nach\u00a0Ver sagen\u00a0einer\u00a0\nvorangegangenen\u00a0 antiviralen\u00a0 Beha ndlung\u00a0 sollen\u00a0 die\u00a0 Fixkombinatio n\u00a0 zusammen\u00a0\nmit\u00a0Ribavirin\u00a0\u00fcber\u00a024\u00a0Wochen\u00a0erhalten.\u00a0\u00a0\nDie\u00a0Fixkombination\u00a0aus\u00a090\u00a0mg\u00a0Ledipasvir\u00a0und\u00a0400\u00a0mg\u00a0Sofosbuvir\u00a0w ird\u00a0einmal\u00a0t\u00e4g\u2010\nlich\u00a0verabreicht.\u00a0Beim\u00a0Einsatz\u00a0vo n\u00a0Ledipasvir\u00a0sind\u00a0Interaktione n\u00a0mit\u00a0der\u00a0Begleit\u2010\nmedikation\u00a0zu\u00a0beachten.\u00a0Starke\u00a0Induktoren\u00a0von\u00a0CYP3A4\u00a0und\u00a0P\u2010GP\u00a0w ie\u00a0Phenytoin,\u00a0\nCarbamazepin,\u00a0Oxcarbazepin,\u00a0Phen obarbital,\u00a0Rifampicin,\u00a0Rifabuti n,\u00a0Rifapentin\u00a0und\u00a0\nJohanniskraut\u00a0k\u00f6nnen\u00a0zu\u00a0einem\u00a0Wirksamkeitsverlust\u00a0des\u00a0Virusstat ikums\u00a0f\u00fchren.\u00a0\nDie\u00a0gemeinsame\u00a0Verabreichung\u00a0ist\u00a0daher\u00a0kontraindiziert\u00a0(Gilead, \u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Hepatitis\u00a0C\u00a0ist\u00a0eine\u00a0weltwei t\u00a0vorkommende\u00a0virale\u00a0Infektion, \u00a0die\u00a0als\u00a0akute\u00a0wie\u00a0\nauch\u00a0chronische\u00a0Form\u00a0in\u00a0Erscheinung\u00a0tritt.\u00a0Verursacht\u00a0wird\u00a0die\u00a0 Erkrankung\u00a0durch\u00a0\ndas\u00a0zu\u00a0der\u00a0Gruppe\u00a0der\u00a0RNA\u2010Viren\u00a0geh\u00f6rende\u00a0HCV,\u00a0von\u00a0dem\u00a0derzeit\u00a0 7\u00a0GT\u00a0mit\u00a067\u00a0\nSubtypen\u00a0bekannt\u00a0sind.\u00a0Weltweit\u00a0ist\u00a0GT\u00a01\u00a0der\u00a0h\u00e4ufigste\u00a0GT\u00a0(46\u00a0% ),\u00a0gefolgt\u00a0von\u00a0GT\u00a03\u00a0\n(30\u00a0%).\u00a0Die\u00a0GT\u00a02,\u00a04\u00a0und\u00a06\u00a0sind\u00a0verantwortlich\u00a0f\u00fcr\u00a0insgesamt\u00a023\u00a0 %\u00a0der\u00a0Erkrankungs\u2010\nf\u00e4lle.\u00a0GT\u00a05\u00a0spielt\u00a0nur\u00a0eine\u00a0sehr\u00a0untergeordnete\u00a0Rolle\u00a0(<\u00a01\u00a0%).\u00a0 In\u00a0den\u00a0meisten\u00a0euro\u2010252\u00a0p\u00e4ischen\u00a0L\u00e4ndern\u00a0ist\u00a0beim\u00a0GT\u00a01\u00a0der\u00a0am\u00a0h\u00e4ufigsten\u00a0vorkommende\u00a0Su btyp\u00a01b,\u00a0wo\u2010\nhingegen\u00a0in\u00a0Nordamerika,\u00a0Gro\u00dfbritannien,\u00a0Skandinavien\u00a0und\u00a0Austr alien\u00a0der\u00a0GT\u00a01a\u00a0\nam\u00a0weitesten\u00a0verbreitet\u00a0ist\u00a0(RKI,\u00a02016).\u00a0\nIn\u00a0Europa\u00a0leben\u00a0ca.\u00a0zwei\u00a0bis\u00a0f\u00fcnf\u00a0Mio.\u00a0HCV\u2010positive\u00a0Menschen.\u00a0A ls\u00a0Risikogruppen\u00a0\nmit\u00a0besonders\u00a0hoher\u00a0Krankheitspr\u00e4valenz\u00a0gelten\u00a0intraven\u00f6se\u00a0Drog enanwender,\u00a0\nM\u00e4nner,\u00a0die\u00a0mit\u00a0M\u00e4nnern\u00a0Sex\u00a0haben\u00a0(MSM),\u00a0Dialysepatienten,\u00a0Pers onen,\u00a0die\u00a0vor\u00a0\nden\u00a01990er\u00a0Jahren\u00a0h\u00e4ufig\u00a0Transfusionen\u00a0oder\u00a0vor\u00a0Ende\u00a0der\u00a01980er \u00a0Jahre\u00a0Plas\u2010\nmaderivate\u00a0erhielten\u00a0(RKI,\u00a02014a).\u00a0In\u00a0Deutschland\u00a0liegt\u00a0die\u00a0Pr\u00e4 valenz\u00a0mit\u00a00,3\u00a0%\u00a0im\u00a0\ninternationalen\u00a0Vergleich\u00a0sehr\u00a0niedrig.\u00a0Pro\u00a0Jahr\u00a0muss\u00a0aber\u00a0auch \u00a0hierzulande\u00a0mit\u00a0ca.\u00a0\n5.000\u00a0Neuinfektionen\u00a0gerechnet\u00a0werden\u00a0(RKI,\u00a02016).\u00a0\u00a0\nDie\u00a0\u00dcbertragung\u00a0geschieht\u00a0fast\u00a0ausschlie\u00dflich\u00a0\u00fcber\u00a0das\u00a0Blut.\u00a0In \u00a075\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0ver\u2010\nl\u00e4uft\u00a0die\u00a0Infektion\u00a0unbemerkt.\u00a0E in\u00a0Viertel\u00a0der\u00a0Infizierten\u00a0entw ickelt\u00a0eine\u00a0akute\u00a0\nHepatitis\u00a0mit\u00a0unspezifischen\u00a0Beschwerden\u00a0und\u00a0Einschr\u00e4nkungen\u00a0de r\u00a0Leberfunkti\u2010\non.\u00a0Fulminante\u00a0Verl\u00e4ufe\u00a0sind\u00a0selten\u00a0(Thimme\u00a0et\u00a0al.,\u00a02014).\u00a0Symp tomatisch\u00a0verlau\u2010\nfende\u00a0akute\u00a0Hepatitiden\u00a0zeigen\u00a0eine\u00a0Immunreaktion\u00a0der\u00a0Betroffen en\u00a0an,\u00a0was\u00a0die\u00a0\nRate\u00a0 an\u00a0 Spontanheilung\u00a0 erh\u00f6ht:\u00a0 Etwa\u00a0 die\u00a0 H\u00e4lfte\u00a0 der\u00a0 akut\u00a0 verlauf enden\u00a0 HCV\u2010\nInfektionen\u00a0heilt\u00a0spontan\u00a0aus,\u00a0w\u00e4hrend\u00a0es\u00a0bei\u00a0den\u00a0asymptomatisc hen\u00a0Verl\u00e4ufen\u00a0\nlediglich\u00a0ca.\u00a030\u00a0%\u00a0sind.\u00a0Zwischen\u00a050\u00a0und\u00a085\u00a0%\u00a0aller\u00a0Akutinfekti onen\u00a0gehen\u00a0in\u00a0eine\u00a0\nHC\u00a0\u00fcber,\u00a0die\u00a0durch\u00a0eine\u00a0st\u00e4ndige\u00a0Vermehrung\u00a0von\u00a0HCV\u00a0gekennzeich net\u00a0ist.\u00a0Inner\u2010\nhalb\u00a0von\u00a020\u00a0bis\u00a030\u00a0Jahren\u00a0kommt\u00a0es\u00a0bei\u00a02\u00a0bis\u00a035\u00a0%\u00a0der\u00a0Betroffen en\u00a0zu\u00a0einer\u00a0Leber\u2010\nzirrhose.\u00a0Bei\u00a0diesen\u00a0Patienten\u00a0k\u00f6nnen\u00a0Lebertransplantationen\u00a0le bensrettend\u00a0sein.\u00a0\nEtwa\u00a02\u00a0bis\u00a04\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0Leberzirrhose\u00a0entwickeln\u00a0pro\u00a0J ahr\u00a0ein\u00a0Leberzell\u2010\nkarzinom\u00a0(RKI,\u00a02014b).\u00a0\nIn\u00a0zahlreichen\u00a0F\u00e4llen\u00a0ist\u00a0der\u00a0genaue\u00a0\u00dcbertragungsweg\u00a0nicht\u00a0fest stellbar.\u00a0Aktuelle\u00a0\nAnalysen\u00a0geben\u00a0an,\u00a0dass\u00a0bei\u00a0den\u00a0F\u00e4llen,\u00a0denen\u00a0ein\u00a0\u00dcbertragunswe g\u00a0hochwahr\u2010\nscheinlich\u00a0 zugeordnet\u00a0 werden\u00a0 konnte,\u00a0 76\u00a0%\u00a0 auf\u00a0 intraven\u00f6sen\u00a0 Drog enkonsum\u00a0\nzur\u00fcckzuf\u00fchren\u00a0sind,\u00a08\u00a0%\u00a0auf\u00a0MSM,\u00a08\u00a0%\u00a0auf\u00a0den\u00a0Erhalt\u00a0von\u00a0Blutpr odukten,\u00a06\u00a0%\u00a0auf\u00a0\nheterosexuellen\u00a0Kontakt\u00a0mit\u00a0HCV\u2010 Infizierten,\u00a01,5\u00a0%\u00a0auf\u00a0Dialyse\u00a0 und\u00a00,5\u00a0%\u00a0auf\u00a0eine\u00a0\nperinatale\u00a0\u00dcbertragung\u00a0(RKI,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0therapeutische\u00a0Wirksamkeit\u00a0v on\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0bei\u00a0 HCV\u2010GT\u00a01\u00a0ist\u00a0in\u00a0\nexperimentellen,\u00a0kontrollierten\u00a0Einzelstudien\u00a0und\u00a0deren\u00a0systema tischen\u00a0Zusam\u2010\nmenfassungen\u00a0nachgewiesen\u00a0(Ahmed\u00a0et\u00a0al.,\u00a02016;\u00a0Suwanthawornkul\u00a0 et\u00a0al.,\u00a02016).\u00a0\nUnabh\u00e4ngig\u00a0von\u00a0der\u00a0Auspr\u00e4gung\u00a0der\u00a0Lebererkrankung\u00a0(mit/ohne\u00a0Zir rhose),\u00a0den\u00a0\nPolymorphismen\u00a0beim\u00a0Patientenko llektiv\u00a0(IL28b\u2010GT)\u00a0sowie\u00a0einem\u00a0v orangehenden\u00a0\nTherapieversagen\u00a0 f\u00fchrte\u00a0 die\u00a0 Zweierkombination\u00a0 in\u00a0 den\u00a0 zulassungs relevanten\u00a0\nStudien\u00a0zu\u00a0hohen\u00a0Erfolgsraten\u00a0(ION\u20101,\u00a0Afdahl\u00a0et\u00a0al.,\u00a02014a;\u00a0ION \u20102,\u00a0Afdahl\u00a0et\u00a0al.,\u00a0253\u00a02014b;\u00a0 ION\u20103,\u00a0 Kowdley\u00a0 et\u00a0 al.,\u00a0 20 14c;\u00a0 LONESTAR,\u00a0 Lawitz\u00a0 et\u00a0 al.,\u00a0 2 014).\u00a0 Die\u00a0 als\u00a0\nprim\u00e4rer\u00a0 Endpunkt\u00a0 definierte\u00a0 dauerhafte\u00a0 virologische\u00a0 Ansprechra t e \u00a0l a g \u00a0j e w e i l s \u00a0\nzwischen\u00a094\u00a0und\u00a099\u00a0%.\u00a0In\u00a0einer\u00a0aktuellen\u00a0Kohortenstudie\u00a0mit\u00a01.7 58\u00a0Patienten\u00a0\nwurden\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0HCV\u2010Infektionen\u00a0des\u00a0GT\u00a01\u00a0nun\u00a0die\u00a0 in\u00a0kontrollierten\u00a0\nklinischen\u00a0Studien\u00a0gefundenen\u00a0Erfolgsraten\u00a0auch\u00a0f\u00fcr\u00a0Normalbedin gungen\u00a0best\u00e4\u2010\ntigt.\u00a0Nach\u00a0zw\u00f6lf\u00a0Behandlungswochen\u00a0mit\u00a0Sofosbuvir\u00a0+\u00a0Ledipasvir\u00a0 lagen\u00a0die\u00a0Raten\u00a0\neines\u00a0dauerhaften\u00a0virologischen\u00a0Ansprechens\u00a0bei\u00a0ca.\u00a096\u00a0%,\u00a0schwe re\u00a0unerw\u00fcnschte\u00a0\nArzneimittelereignisse\u00a0(UAE)\u00a0lag en\u00a0bei\u00a05,5\u00a0%\u00a0der\u00a0Teilnehmer\u00a0vor \u00a0und\u00a0f\u00fchrten\u00a0bei\u00a0\n1,5\u00a0%\u00a0zu\u00a0einem\u00a0Behandlungsabbruch\u00a0(Calleja\u00a0et\u00a0al.,\u00a02017).\u00a0Die\u00a0k ombinierte\u00a0An\u2010\nwendung\u00a0mit\u00a0Ribavirin\u00a0erh\u00f6ht\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0UAE,\u00a0ohne\u00a0den\u00a0Thera pieerfolg\u00a0gegen\u00a0\nHCV\u2010GT\u00a01\u00a0ma\u00dfgeblich\u00a0zu\u00a0beeinflussen.\u00a0Dies\u00a0gilt\u00a0f\u00fcr\u00a0die\u00a0Erstbeha ndlung\u00a0von\u00a0Patien\u2010\nten\u00a0mit\u00a0und\u00a0ohne\u00a0Zirrhose\u00a0sowie\u00a0f\u00fcr\u00a0die\u00a0Re\u2010Therapie\u00a0von\u00a0Patient en\u00a0ohne\u00a0Zirrhose.\u00a0\nOb\u00a0therapieerfahrenen\u00a0Patienten\u00a0m it\u00a0Zirrhose\u00a0von\u00a0einem\u00a0Ribaviri n\u2010Zusatz\u00a0profitie\u2010\nren,\u00a0ist\u00a0derzeit\u00a0nicht\u00a0sicher\u00a0zu\u00a0beantworten\u00a0(Ferreira\u00a0et\u00a0al.,\u00a0 2016;\u00a0Ahmed\u00a0et\u00a0al.,\u00a0\n2016).\u00a0Hohes\u00a0virologisches\u00a0Ansprechen\u00a0scheint\u00a0auch\u00a0bei\u00a0Patiente n\u00a0mit\u00a0deutlich\u00a0\nfortgeschrittener\u00a0Lebererkrankung\u00a0oder\u00a0mit\u00a0HIV\u2010Coinfektion\u00a0gege ben\u00a0(ERADICATE,\u00a0\nOsinusi\u00a0et\u00a0al.,\u00a02015;\u00a0ION\u20104,\u00a0Naggie\u00a0et\u00a0al.,\u00a02015).\u00a0Bei\u00a0HCV\u00a0GT\u20104 \u2010Infizierten\u00a0wird\u00a0das\u00a0\ndauerhaft\u00a0virologische\u00a0Anspreche n\u00a0von\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0u nd\u00a0von\u00a0Peginterfe\u2010\nron\u00a0+\u00a0Ribavirin\u00a0als\u00a0\u00e4quivalent\u00a0angesehen.\u00a0Die\u00a0k\u00fcrzere\u00a0Behandlun gszeit\u00a0unter\u00a0Ledi\u2010\npasvir\u00a0+\u00a0Sofosbuvir\u00a0lassen\u00a0aber\u00a0geringere\u00a0Raten\u00a0UAE\u00a0erwarten\u00a0(S YNERGY,\u00a0Kohli\u00a0et\u00a0al.,\u00a0\n2015).\u00a0\nDie\u00a0Fixkombination\u00a0wird\u00a0allgemein\u00a0als\u00a0gut\u00a0vertr\u00e4glich\u00a0beschrieb en.\u00a0Zwar\u00a0werden\u00a0\ndiverse\u00a0Nebenwirkungen\u00a0berichtet,\u00a0diese\u00a0sind\u00a0aber\u00a0\u00fcberwiegend\u00a0m ild\u00a0bis\u00a0moderat\u00a0\nausgepr\u00e4gt.\u00a0Die\u00a0am\u00a0h\u00e4ufigsten\u00a0berichteten\u00a0Nebenwirkungen\u00a0im\u00a0Zus ammenhang\u00a0\nmit\u00a0der\u00a0Anwendung\u00a0der\u00a0Fixkombination\u00a0sind\u00a0Ersch\u00f6pfung,\u00a0Kopfschm erzen,\u00a0\u00dcbel\u2010\nkeit\u00a0und\u00a0Schlaflosigkeit.\u00a0\u00a0\nSowohl\u00a0die\u00a0deutsche\u00a0Zulassungsbeh\u00f6rde\u00a0BfArM\u00a0wie\u00a0auch\u00a0die\u00a0amerik anische\u00a0Zulas\u2010\nsungsbeh\u00f6rde\u00a0FDA\u00a0informieren\u00a0im\u00a0M\u00e4rz\u00a02015\u00a0\u00fcber\u00a0schwerwiegende\u00a0H erzrhyth\u2010\nmusst\u00f6rungen\u00a0im\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Einnahme\u00a0von\u00a0Sofosbuvir\u2010ha ltigen\u00a0Mit\u2010\nteln.\u00a0Bei\u00a0Einnahme\u00a0von\u00a0Sovaldi\u00ae\u00a0bzw.\u00a0von\u00a0Harvoni\u00ae\u00a0kam\u00a0es\u00a0in\u00a0Ein zelf\u00e4llen\u00a0zu\u00a0\nschwerwiegenden\u00a0 Bradykardien,\u00a0 die\u00a0 bei\u00a0 einigen\u00a0 Betroffenen\u00a0 zum\u00a0 E insatz\u00a0 von\u00a0\nHerzschrittmachern\u00a0f\u00fchrte\u00a0und\u00a0in\u00a0einem\u00a0Fall\u00a0sogar\u00a0t\u00f6dlich\u00a0endet e\u00a0(BfArM,\u00a02015;\u00a0\nFDA,\u00a02015).\u00a0Alle\u00a0Patienten\u00a0erhielten\u00a0neben\u00a0anderen\u00a0Hepatitismit teln\u00a0(Simeprevir,\u00a0\nDaclatasvir)\u00a0mit\u00a0Amiodaron\u00a0und\u00a0Betablockern\u00a0noch\u00a0weitere\u00a0Arznei mittel,\u00a0die\u00a0selbst\u00a0\nEinfluss\u00a0auf\u00a0den\u00a0Herzrhythmus\u00a0haben\u00a0k\u00f6nnen.\u00a0Wie\u00a0es\u00a0zu\u00a0dieser\u00a0We chselwirkung\u00a0\nkommt,\u00a0ist\u00a0derzeit\u00a0noch\u00a0nicht\u00a0bekannt.\u00a0Bis\u00a0weitere\u00a0Untersuchung sergebnisse\u00a0vor\u2010\nliegen,\u00a0wird\u00a0eine\u00a0engmaschige\u00a0EKG \u2010Kontrolle\u00a0bei\u00a0entsprechend\u00a0be handelten\u00a0Pati\u2010\nenten\u00a0empfohlen.\u00a0Ferner\u00a0sollten\u00a0 Patienten,\u00a0die\u00a0gleichzeitig\u00a0mit \u00a0den\u00a0genannten\u00a0\nantiviralen\u00a0 Arzneimitteln\u00a0 und\u00a0 Arzneimitteln\u00a0 behandelt\u00a0 werden,\u00a0 d ie\u00a0 selbst\u00a0 eine\u00a0254\u00a0Bradykardie\u00a0verursachen\u00a0k\u00f6nnen\u00a0(z.B.\u00a0Amiodaron),\u00a0\u00fcber\u00a0Beschwerd en\u00a0informiert\u00a0\nwerden,\u00a0die\u00a0auf\u00a0das\u00a0Vorliegen\u00a0von\u00a0Herzrhythmusst\u00f6rungen\u00a0hinweis en\u00a0k\u00f6nnen.\u00a0\nDazu\u00a0z\u00e4hlen\u00a0etwa\u00a0Schwindel,\u00a0starke\u00a0M\u00fcdigkeit,\u00a0Kurzatmigkeit,\u00a0Br ustschmerz\u00a0(An\u2010\ngina\u00a0pectoris),\u00a0Verwirrtheit\u00a0oder\u00a0Ged\u00e4chtnisst\u00f6rungen\u00a0(BfArM,\u00a02 015).\u00a0M\u00f6glicher\u2010\nweise\u00a0ist\u00a0das\u00a0Risiko\u00a0dieser\u00a0Interaktion\u00a0bei\u00a0Patienten\u00a0mit\u00a0vorbe stehenden\u00a0kardialen\u00a0\nKomorbidit\u00e4ten\u00a0oder\u00a0bei\u00a0fortschr eitender\u00a0Lebererkrankung\u00a0erh\u00f6ht .\u00a0\u00a0\nSofosbuvir\u00a0 ist\u00a0 Substrat\u00a0 des\u00a0 intestinalen\u00a0 Glucoproptein\u2010P\u2010Wirkst offtransporters.\u00a0\nUm\u00a0eine\u00a0Verminderung\u00a0der\u00a0Plasmakonzentrationen\u00a0von\u00a0Sofosbuvir\u00a0z u\u00a0vermeiden,\u00a0\nist\u00a0 die\u00a0 gemeinsame\u00a0 Anwendung\u00a0 mit\u00a0 potenten\u00a0 Enzyminduktoren\u00a0 wie\u00a0 R ifampin,\u00a0\nRifabutin,\u00a0Carbamazepin,\u00a0Phenytoin,\u00a0Phenobarbital,\u00a0Oxcarbazepin ,\u00a0Ritonavir\u00a0oder\u00a0\nJohanniskraut\u00a0kontraindiziert\u00a0(Pockros,\u00a02017;\u00a0Fachinformation\u00a0H arvoni\u00ae,\u00a02016).\u00a0\u00a0\nDar\u00fcber\u00a0hinaus\u00a0legen\u00a0Untersuchungen\u00a0nahe,\u00a0dass\u00a0durch\u00a0die\u00a0Behand lung\u00a0mit\u00a0direkt\u00a0\nantiviral\u00a0wirkenden\u00a0Mitteln\u00a0wie\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0die\u00a0Gef ahr\u00a0besteht,\u00a0dass\u00a0\neine\u00a0Hepatitis\u2010B\u2010Erkrankung\u00a0reaktiviert\u00a0wird.\u00a0Ein\u00a0Screening\u00a0vor \u00a0der\u00a0Behandlung\u00a0ist\u00a0\ndaher\u00a0seit\u00a0Ende\u00a02016\u00a0gefordert\u00a0(E MA,\u00a02016).\u00a0Schlie\u00dflich\u00a0ist\u00a0vor \u00a0dem\u00a0Einsatz\u00a0direkt\u00a0\nantiviral\u00a0wirkender\u00a0Mittel\u00a0bei\u00a0HC \u2010Patienten\u00a0zu\u00a0bedenken,\u00a0dass\u00a0d ie\u00a0Gabe\u00a0von\u00a0Sofos\u2010\nbuvir\u00a0und\u00a0ggf.\u00a0Ribavirin\u00a0zusamme n\u00a0mit\u00a0NS5A\u2010Inhibitoren\u00a0wie\u00a0Dacl atasvir,\u00a0Ledipas\u2010\nvir\u00a0oder\u00a0Velpatasvir,\u00a0die\u00a0einen\u00a0 prim\u00e4ren\u00a0renalen\u00a0Metabolisierun gsweg\u00a0aufweisen,\u00a0\nbei\u00a0 Patienten\u00a0 mit\u00a0 dekompensierter\u00a0 Zirrhose\u00a0 das\u00a0 Risiko\u00a0 f\u00fcr\u00a0 Infek tionen\u00a0 und\u00a0\nLaktatazidosen\u00a0ansteigen\u00a0lassen\u00a0kann\u00a0(DGVS,\u00a02016).\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0aktuelle\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroent erologie,\u00a0Verdau\u2010\nu n g s \u2010 \u00a0u n d \u00a0S t o f f w e c h s e l k r a n k h e i t e n \u00a0( D G V S ) \u00a0e m p f i e h l t \u00a0f \u00fc r \u00a0d i e \u00a0E r s t therapie\u00a0 bei\u00a0\nchronischer\u00a0HC\u00a0ein\u00a0Interferon\u2010freies\u00a0Therapieregime\u00a0(DGVS,\u00a02016 ).\u00a0Da\u00a0bei\u00a0Kombi\u2010\nnationsbehandlung\u00a0mit\u00a0Ribavirin\u00a0mit\u00a0mehr\u00a0Nebenwirkungen\u00a0und\u00a0Int oleranzen\u00a0zu\u00a0\nrechnen\u00a0 sind,\u00a0 soll\u00a0 bei\u00a0 gleicher\u00a0 Wirksamkeit\u00a0 stets\u00a0 eine\u00a0 Therapie option\u00a0 ohne\u00a0\nRibavirin\u00a0gew\u00e4hlt\u00a0werden.\u00a0Es\u00a0wird\u00a0darauf\u00a0hingewiesen,\u00a0dass\u00a0die\u00a0 Therapieauswahl\u00a0\nunter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0Zirrhosestatus,\u00a0des\u00a0Vortherapiestatu s,\u00a0der\u00a0Komedikati\u2010\non\u00a0und\u00a0gegebenfalls\u00a0der\u00a0Komor bidit\u00e4ten\u00a0zu\u00a0erfolgen\u00a0hat.\u00a0\u00a0\nLedipasvir\u00a0ist\u00a0in\u00a0Kombination\u00a0mit\u00a0dem\u00a0nukleosidischen\u00a0NS5B\u2010Poly merase\u2010Inhibitor\u00a0\nSofosbuvir\u00a0zur\u00a0Erst\u2010\u00a0und\u00a0Re\u2010Therapie\u00a0HC\u2010Infektionen\u00a0der\u00a0GT\u00a01,\u00a04 ,\u00a05\u00a0und\u00a06\u00a0einsetz\u2010\nbar.\u00a0Bei\u00a0HCV\u2010GT\u00a01\u2010Infektionen\u00a0liegen\u00a0hochwertige\u00a0klinische\u00a0Stud ien\u00a0zum\u00a0dauerhaf\u2010\nten\u00a0virologischen\u00a0Ansprechen\u00a0(SVR)\u00a0vor.\u00a0Die\u00a0SVR\u2010Raten\u00a0liegen\u00a0je \u00a0nach\u00a0Vorgeschich\u2010\nte\u00a0zwischen\u00a094\u00a0und\u00a0100\u00a0%.\u00a0Bei\u00a0therapienaiven\u00a0Patienten\u00a0ohne\u00a0Zir rhose\u00a0und\u00a0niedri\u2010\nger\u00a0Ausgangsviruslast\u00a0(<\u00a06\u00a0Mio.\u00a0IU/ml)\u00a0gen\u00fcgen\u00a0acht\u00a0Behandlungs wochen.\u00a0Thera\u2010\npienaive\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0mit\u00a0hoher\u00a0Viruslast,\u00a0therapiee rfahrene\u00a0Patienten\u00a0\nund\u00a0solche\u00a0mit\u00a0Zirrhose\u00a0werden\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0behandelt.\u00a0Bei \u00a0Patienten\u00a0mit\u00a0255\u00a0Zirrhose\u00a0und\u00a0negativen\u00a0Pr\u00e4diktore n\u00a0f\u00fcr\u00a0den\u00a0weiteren\u00a0Krankheitsv erlauf,\u00a0wie\u00a0etwa\u00a0\ndem\u00a0Versagen\u00a0einer\u00a0Vorbehandlung\u00a0oder\u00a0einer\u00a0niedrigen\u00a0Thrombozy tenzahl,\u00a0kann\u00a0\nzus\u00e4tzlich\u00a0Ribavirin\u00a0erforderlich\u00a0werden.\u00a0Der\u00a0Umfang\u00a0klinischer \u00a0Daten\u00a0bei\u00a0GT\u20104\u2010\nInfektionen\u00a0ist\u00a0geringer\u00a0als\u00a0bei\u00a0GT\u20101\u2010Infektionen.\u00a0Es\u00a0liegen\u00a0ei nige\u00a0kleinere\u00a0Phase\u2010II\u2010\nStudien\u00a0vor.\u00a0Die\u00a0SVR\u2010Raten\u00a0werden\u00a0auf\u00a0Basis\u00a0geringer\u00a0Fallzahlen \u00a0mit\u00a093\u00a0%\u00a0angege\u2010\nben.\u00a0Eine\u00a0bereits\u00a0bestehende\u00a0NS5A\u2010Resistenz\u00a0oder\u00a0der\u00a0Nachweis\u00a0d es\u00a0HCV\u2010GT\u00a04\u00a0\nging\u00a0 mit\u00a0 einem\u00a0 Therapieversagen\u00a0 einher.\u00a0 Die\u00a0 Leitlinienautoren\u00a0 e mpfehlen\u00a0 die\u00a0\nFixkombination\u00a0bei\u00a0HCV\u2010Infektionen\u00a0GT\u20104\u00a0unabh\u00e4ngig\u00a0von\u00a0Vorthera pie\u00a0und\u00a0Zirrho\u2010\nse\u00a0 \u00fcber\u00a0 zw\u00f6lf\u00a0 Wochen.\u00a0 Soweit\u00a0 eine\u00a0 Leberzirrhose\u00a0 vorliegt,\u00a0 kann\u00a0 zus\u00e4tzlich\u00a0\nRibavirin\u00a0erforderlich\u00a0werden.\u00a0Auch\u00a0f\u00fcr\u00a0Infektionen\u00a0mit\u00a0HCV\u2010GT\u00a0 5\u00a0und\u00a06\u00a0sind\u00a0nur\u00a0\nbegrenzte\u00a0Untersuchungsdaten\u00a0vorhanden.\u00a0Die\u00a0SVR\u2010Raten\u00a0liegen\u00a0\u2013\u00a0 unabh\u00e4ngig\u00a0\nvon\u00a0Vortherapie\u00a0und\u00a0Zirrhosestatu s\u00a0\u2013\u00a0bei\u00a0einer\u00a0Behandlungsdauer \u00a0von\u00a0zw\u00f6lf\u00a0Wo\u2010\nchen\u00a0zwischen\u00a089\u00a0%\u00a0und\u00a096\u00a0%.\u00a0Wenn\u00a0negative\u00a0Pr\u00e4diktoren\u00a0vorhande n\u00a0sind,\u00a0wird\u00a0\nauch\u00a0bei\u00a0diesen\u00a0GT\u00a0die\u00a0zus\u00e4tzlic he\u00a0Gabe\u00a0von\u00a0Ribavirin\u00a0empfohlen .\u00a0\nIm\u00a0Fall\u00a0einer\u00a0Kontraindikation\u00a0f \u00fcr\u00a0die\u00a0Anwendung\u00a0von\u00a0Ribavirin\u00a0 kann\u00a0eine\u00a0Therapie\u00a0\nmit\u00a0der\u00a0Fixkombination\u00a0Ledipasvir\u00a0und\u00a0Sofosbuvir\u00a0auf\u00a024\u00a0Wochen\u00a0 ausgedehnt\u00a0\nwerden.\u00a0Versagt\u00a0die\u00a0Behandlung\u00a0mi t\u00a0Ledipasvir\u2010haltigen\u00a0Kombinat ionen\u00a0aus\u00a0direkt\u00a0\nwirkenden\u00a0antiviralen\u00a0Mitteln\u00a0m\u00fc ssen\u00a0bei\u00a0der\u00a0weiteren\u00a0Therapiep lanung\u00a0Resisten\u2010\nzentwicklungen,\u00a0etwa\u00a0Patienten\u00a0m it\u00a0NS5A\u2010RAV\u00a0oder\u00a0Y93H/N,\u00a0ber\u00fcck sichtigt\u00a0wer\u2010\nden.\u00a0\u00a0\nInfektionen\u00a0mit\u00a0GT\u00a03\u00a0sollen\u00a0laut \u00a0Leitlinie\u00a0wegen\u00a0unzureichender \u00a0Wirkeffekte\u00a0von\u00a0\nLedipasvir\u00a0auf\u00a0diesen\u00a0GT\u00a0nicht\u00a0m it\u00a0Ledipasvir\u2010haltigen\u00a0Kombinat ionen\u00a0behandelt\u00a0\nwerden.\u00a0Auch\u00a0f\u00fcr\u00a0GT\u20102\u2010Infektionen\u00a0ist\u00a0die\u00a0Fixkombination\u00a0aus\u00a0Le dipasvir\u00a0und\u00a0So\u2010\nfosbuvir\u00a0+/\u2010\u00a0Ribavirin\u00a0nicht\u00a0vorgesehen.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0fasst\u00a0in\u00a0seiner\u00a0Beschluss fassung\u00a0vom\u00a0\nMai\u00a02015\u00a0den\u00a0Zusatznutzen\u00a0von\u00a0Ledipasvir/Sofosbuvir\u00a0im\u00a0Vergleic h\u00a0zur\u00a0bis\u00a0dato\u00a0\n\u00fcblichen\u00a0Vergleichtherapie\u00a0wie\u00a0 folgt\u00a0zusammen\u00a0(G\u2010BA,\u00a02015):\u00a0\u00a0\nIn\u00a0der\u00a0klinischen\u00a0Erprobung\u00a0der\u00a0Fixkombination\u00a0wurde\u00a0in\u00a0keiner\u00a0 der\u00a0Untersuchun\u2010\ngen\u00a0eine\u00a0der\u00a0vom\u00a0G\u2010BA\u00a0definierte n\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichstherap ien\u00a0als\u00a0Kon\u2010\ntrollbehandlung\u00a0gew\u00e4hlt.\u00a0In\u00a0Ermangelung\u00a0der\u00a0geforderten\u00a0Daten\u00a0w urden\u00a0in\u00a0der\u00a0\nfr\u00fchen\u00a0Nutzenbewertung\u00a0historische\u00a0Vergleiche\u00a0der\u00a0kombinierten\u00a0 Anwendung\u00a0von\u00a0\nLedipasvir\u00a0und\u00a0Sofosbuvir\u00a0gegen\u00a0die\u00a0Duotherapie\u00a0bestehend\u00a0aus\u00a0P eginterferon\u00a0+\u00a0\nRibavirin\u00a0oder\u00a0die\u00a0Tripeltherapie\u00a0bestehend\u00a0aus\u00a0Peginterferon+\u00a0 Ribavirin\u00a0+\u00a0(Boce\u2010\nprevir\u00a0or\u00a0Telaprevir)\u00a0 vorgelegt.\u00a0Derartige \u00a0indirekte\u00a0Vergleiche \u00a0sind\u00a0grunds\u00e4tzlich\u00a0\nmit\u00a0einer\u00a0erh\u00f6hten\u00a0Ergebnisunsicherheit\u00a0belastet.\u00a0In\u00a0Bezug\u00a0auf\u00a0 ein\u00a0dauerhaftes\u00a0\nvirologisches\u00a0Ansprechen\u00a0ergibt\u00a0sich\u00a0bei\u00a0dieser\u00a0Betrachtung\u00a0ein \u00a0dramatischer\u00a0Ef\u2010256\u00a0fekt\u00a0f\u00fcr\u00a0die\u00a0Fixkombination\u00a0bei\u00a0HCV\u2010GT\u00a01\u2010Infektionen\u00a0ohne\u00a0Leber zirrhose.\u00a0Daraus\u00a0\nwird\u00a0vom\u00a0G\u2010BA\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatzn utzen\u00a0abgeleitet.\u00a0\nDa\u00a0die\u00a0Behandlungsdauer\u00a0deutlich\u00a0k\u00fcrzer\u00a0ist\u00a0als\u00a0bei\u00a0der\u00a0Tripelt herapie,\u00a0wird\u00a0f\u00fcr\u00a0die\u00a0\nFixkombination\u00a0auch\u00a0im\u00a0Hinblick\u00a0auf\u00a0therapiebedingte\u00a0Nebenwirku ngen\u00a0ein\u00a0Vorteil\u00a0\ngesehen.\u00a0Ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0ei nen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0wird\u00a0auch\u00a0f\u00fcr\u00a0\nHCV\u2010GT\u00a0 1\u2010Infektionen\u00a0 mit\u00a0 Leberzirrhose\u00a0 gesehen.\u00a0 Das\u00a0 dauerhafte\u00a0 virologische\u00a0\nAnsprechen\u00a0liegt\u00a0unter\u00a0der\u00a0Fixkombination\u00a0bei\u00a0100\u00a0%.\u00a0Auch\u00a0hier\u00a0 ist\u00a0die\u00a0Behand\u2010\nlungsdauer\u00a0k\u00fcrzer\u00a0als\u00a0bei\u00a0der\u00a0zVT,\u00a0so\u00a0dass\u00a0weniger\u00a0Nebenwirkung en\u00a0zu\u00a0erwarten\u00a0\nsind.\u00a0 F\u00fcr\u00a0 Patienten\u00a0 mit\u00a0 HIV\u2010Coinfektionen\u00a0 wird\u00a0 gegen\u00fcber\u00a0 der\u00a0 Pe ginterferon\u2010\ngest\u00fctzten\u00a0Vergleichtherapie\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatzn utzen\u00a0erkannt,\u00a0der\u00a0\nallerdings\u00a0nicht\u00a0quantifizierbar\u00a0ist.\u00a0Dies\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Ga be\u00a0von\u00a0Ledipasvir\u00a0+\u00a0\nSofosbuvir\u00a0in\u00a0Kombination\u00a0mit\u00a0Ribavirin\u00a0im\u00a0Vergleich\u00a0zur\u00a0BSC\u00a0be i\u00a0HC\u2010Patienten\u00a0mit\u00a0\nGT\u00a01\u00a0und\u00a0dekompensierter\u00a0Zirrhose.\u00a0\nBei\u00a0GT\u20104\u2010Infektionen\u00a0werden\u00a0Ledipasvir\u00a0+\u00a0Sofosbuvir\u00a0und\u00a0die\u00a0zwe ckm\u00e4\u00dfige\u00a0Thera\u2010\npie\u00a0mit\u00a0Peginterferon\u00a0+\u00a0Ribavirin\u00a0im\u00a0Hinblick\u00a0auf\u00a0das\u00a0virologis che\u00a0Ansprechen\u00a0als\u00a0\n\u00e4quivalent\u00a0beschrieben.\u00a0Da\u00a0Ledipasvir\u00a0und\u00a0Sofosbuvir\u00a0f\u00fcr\u00a0diese\u00a0 Ergebnisse\u00a0aber\u00a0\ndeutlich\u00a0k\u00fcrzer\u00a0angewendet\u00a0werden\u00a0m\u00fcssen,\u00a0werden\u00a0geringere\u00a0Nebe nwirkungsra\u2010\nten\u00a0 erwartet.\u00a0 Daraus\u00a0 wird\u00a0 ein\u00a0 Anhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 geringen\u00a0 Zusatznutzen \u00a0\nabgeleitet.\u00a0\u00a0\nF\u00fcr\u00a0Infektionen\u00a0mit\u00a0HCV\u2010GT\u00a03\u00a0wird\u00a0unabh\u00e4ngig\u00a0vom\u00a0Zirrhosestatus \u00a0weder\u00a0f\u00fcr\u00a0die\u00a0\nErst\u2010\u00a0noch\u00a0f\u00fcr\u00a0die\u00a0Re\u2010Therapie\u00a0ein\u00a0Zusatznutzen \u00a0festgestellt.\u00a0\u00a0\nVersorgungsanalysen\u00a0\nF\u00fcr\u00a0Harvoni\u00ae\u00a0ist\u00a0nur\u00a0eine\u00a0Packung sgr\u00f6\u00dfe\u00a0im\u00a0Handel.\u00a0Breits\u00a0kurz\u00a0 nach\u00a0seiner\u00a0Zulas\u2010\nsung\u00a0Ende\u00a02014\u00a0wird\u00a0das\u00a0Kombinationspr\u00e4parat\u00a0im\u00a0Vergleich\u00a0zu\u00a0an deren\u00a0Neuein\u2010\nf\u00fchrungen\u00a0in\u00a0diesem\u00a0Therapiegebiet\u00a0sehr\u00a0h\u00e4ufig\u00a0verordnet\u00a0mit\u00a0ei nem\u00a0kurzzeitigen\u00a0\nGipfel\u00a0drei\u00a0Monate\u00a0nach\u00a0der\u00a0Mark tzugeh\u00f6rigkeit.\u00a0Seither\u00a0ebbt\u00a0di e\u00a0Verordnung\u00a0um\u00a0\netwa\u00a050\u00a0%\u00a0ab.\u00a0Es\u00a0werden\u00a0eher\u00a0M\u00e4 nner\u00a0als\u00a0Frauen\u00a0mit\u00a0Ledipasvir\u00a0+ \u00a0Sofosbuvir\u00a0be\u2010\nhandelt.\u00a0Der\u00a0Verordnungsgipfel\u00a0 liegt\u00a0wie\u00a0bei\u00a0den\u00a0anderen\u00a0direkt \u00a0antiviral\u00a0wirken\u2010\nden\u00a0Mitteln\u00a0zwischen\u00a050\u00a0und\u00a060\u00a0Jahren.\u00a0\u00a0\n\u00a0 \u00a0257\u00a0Abbildung\u00a04.25:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Ledipasvir\u00a0+\u00a0Sofos buvir\u00a0je\u2010\nMonat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.26:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Ledipasv ir\u00a0+\u00a0Sofos\u2010\nbuvir\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\n258\u00a0Quellen\u00a0\nAfdhal\u00a0N,\u00a0Reddy\u00a0KR,\u00a0Nelson\u00a0DR,\u00a0L awitz\u00a0E,\u00a0Gordon\u00a0SC,\u00a0Schiff\u00a0E\u00a0et \u00a0al.\u00a0(2014b).\u00a0Ledipasvir\u00a0and\u00a0sofosbuvir\u00a0for\u00a0previously\u00a0treated\u00a0 HCV\u00a0\ngenotype\u00a01\u00a0infection.\u00a0N\u00a0Engl\u00a0J\u00a0Med.;\u00a0370(16):\u00a01483\u20101493.\u00a0\nAfdhal\u00a0N,\u00a0Zeuzem\u00a0S,\u00a0Kwo\u00a0P,\u00a0Chojkier\u00a0M,\u00a0Gitlin\u00a0N,\u00a0Puoti\u00a0M\u00a0et\u00a0al. \u00a0(2014a).\u00a0Ledipasvir\u00a0and\u00a0sofosbuvir\u00a0for\u00a0untreated\u00a0HCV\u00a0genotype\u00a0 1\u00a0\ninfection.\u00a0N\u00a0Engl\u00a0J\u00a0Med.;\u00a0370(20):\u00a01889\u20101898.\u00a0\nAhmed\u00a0H,\u00a0Elgebaly\u00a0A,\u00a0Abushouk\u00a0AI,\u00a0Hammad\u00a0AM,\u00a0Attia\u00a0A,\u00a0Negida\u00a0A\u00a0 (2016).\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0sofosbuvir\u00a0plus\u00a0ledipasvir\u00a0with\u00a0\nand\u00a0without\u00a0ribavirin\u00a0for\u00a0chronic\u00a0HCV\u00a0genotype\u20101\u00a0infection:\u00a0a\u00a0s ystematic\u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0Antivir\u00a0Ther.\u00a0doi:\u00a0\n10.3851/IMP3083.\u00a0[Epub\u00a0ahead\u00a0of\u00a0print].\u00a0\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2014).\u00a0Hepatitis\u00a0C:\u00a0Ledipasvir\u00a0plu s\u00a0Sofosbuvir\u00a0in\u00a0einer\u00a0Tablette\u00a0t\u00e4glich\u00a0\u2010\u00a0eine\u00a0Phase\u2010III\u2010Studie. \u00a0AMB\u00a048,\u00a0\n61a.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2017).\u00a0Bewertung: \u00a0Sofosbuvir\u00a0+\u00a0Ledipasvir.\u00a0https://www.arznei\u2010\ntelegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Sofosbuvir% 20XXXXX%20Ledipasvir&ord=uaw\u00a0\nletzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 15).\u00a0Sofosbuvir:\u00a0Herzrhythmusst\u00f6rungen\u00a0als\u00a0m\u00f6gliche\u00a0\nWechselwirkung\u00a0mit\u00a0anderen\u00a0direkt\u00a0wirksamen\u00a0antiviralen\u00a0Arzneim itteln\u00a0(DAA)\u00a0in\u00a0der\u00a0Behandlung\u00a0der\u00a0Hepatitis\u00a0C\u00a0in\u00a0\nKombination\u00a0mit\u00a0Arzneimitteln,\u00a0die\u00a0eine\u00a0Bradykardie\u00a0verursachen \u00a0k\u00f6nnen\u00a0(z.B.\u00a0Amiodaron).\u00a0Stand\u00a0der\u00a0Information:\u00a0\nM\u00e4rz\u00a02015.\u00a0https://www.bfarm.de/SharedDocs/Risikoinformationen/ Pharmakovigilanz/DE/RI/2015/RI\u2010\nsofosbuvir.html,\u00a0letzter\u00a0Zugriff\u00a010.02.2017.\u00a0\nCalleja\u00a0JL,\u00a0Crespo\u00a0J,\u00a0Rinc\u00f3n\u00a0D,\u00a0Ruiz\u2010Antor\u00e1n\u00a0B,\u00a0Fernandez\u00a0I,\u00a0Pe rell\u00f3\u00a0C\u00a0et\u00a0al.\u00a0(2017).\u00a0Effectiveness,\u00a0safety\u00a0and\u00a0clinical\u00a0outco mes\u00a0of\u00a0\ndirect\u2010acting\u00a0antiviral\u00a0therapy\u00a0 in\u00a0HCV\u00a0genotype\u00a01\u00a0infection:\u00a0Re sults\u00a0from\u00a0a\u00a0Spanish\u00a0real\u2010world\u00a0cohort.\u00a0J\u00a0Hepatol\u00a0\nS0168\u20108278(17):\u00a030063\u201030066.\u00a0doi:\u00a010.1016/j.jhep.2017.01.028.\u00a0[ Epub\u00a0ahead\u00a0of\u00a0print].\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten\u00a0u.a.\u00a0(2016).\u00a0Aktuelle\u00a0Empfehlung\u00a0\nzur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C.\u00a0Stand\u00a0der\u00a0Information :\u00a0Dezember\u00a02016.\u00a0https://www.dgvs.de/wissen\u2010\nkompakt/leitlinien/leitlinien\u2010der\u2010dgvs/hepatitis\u2010c/,\u00a0letzter\u00a0Zu griff:\u00a008.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Press\u00a0release.\u00a0Direct\u2010a cting\u00a0antivirals\u00a0for\u00a0hepatitis\u00a0C :\u00a0EMA\u00a0confirms\u00a0recommendation\u00a0t o\u00a0\nscreen\u00a0for\u00a0hepatitis\u00a0B\u00a0Further\u00a0studies\u00a0needed\u00a0to\u00a0assess\u00a0risk\u00a0of \u00a0liver\u00a0cancer\u00a0with\u00a0these\u00a0medicines.\u00a0EMA/824717/2016.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news /2016/12/news_detail_002669.jsp&mid=\nWC0b01ac058004d5c1,\u00a0letzter\u00a0Zugriff\u00a010.02.2017.\u00a0\nFachinformation\u00a0Harvoni\u00ae\u00a0(2016).\u00a0 Fachinformation\u00a0Harvoni\u00ae\u00a090\u00a0mg /400\u00a0mg\u00a0Filmtabletten.\u00a0Stand\u00a0d er\u00a0Information:\u00a0Juli\u00a02016.\u00a0\u00a0\nFDA\u00a0\u2013\u00a0FDA\u00a0Drug\u00a0Safety\u00a0Communicati on\u00a0(2015).\u00a0FDA\u00a0warns\u00a0of\u00a0seriou s\u00a0slowing\u00a0of\u00a0the\u00a0heart\u00a0rate\u00a0when\u00a0antiarrhythmic\u00a0drug\u00a0\namiodarone\u00a0is\u00a0used\u00a0with\u00a0hepatitis\u00a0C\u00a0treatments\u00a0containing\u00a0sofos buvir\u00a0(Harvoni)\u00a0or\u00a0Sovald i\u00a0in\u00a0combination\u00a0with\u00a0\nanother\u00a0Direct\u00a0Acting\u00a0Antiviral\u00a0drug.\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4 rz\u00a02015.\u00a0\nhttps://www.fda.gov/Drugs/DrugSafety/ucm439484.htm,\u00a0letzter\u00a0Zug riff\u00a023.03.2017.\u00a0\u00a0\u00a0\nFerreira\u00a0VL,\u00a0Assis\u00a0Jarek\u00a0NA,\u00a0Tonin\u00a0FS,\u00a0Borba\u00a0HH,\u00a0Wiens\u00a0A,\u00a0Muzzi llo\u00a0DA\u00a0et\u00a0al.\u00a0(2017).\u00a0Ledipasvir/sofosbuvir\u00a0with\u00a0or\u00a0without\u00a0rib avirin\u00a0\nfor\u00a0the\u00a0treatment\u00a0of\u00a0chronic\u00a0hepatitis\u00a0C\u00a0genotype\u00a01:\u00a0A\u00a0pairwise \u00a0meta\u2010analysis.\u00a0J\u00a0Gastroenterol\u00a0Hepatol\u00a032(4):\u00a0749\u2010\n755.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(n.d.).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Ledipasvir/Sofosbuvir\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/150/,\u00a0letzter\u00a0Zugriff\u00a009.02 .2017.\u00a0259\u00a0Kohli\u00a0A,\u00a0Osinusi\u00a0A,\u00a0Sims\u00a0Z,\u00a0Nelson\u00a0A,\u00a0Meissner\u00a0EG,\u00a0Barrett\u00a0LL\u00a0e t\u00a0al.\u00a0(2015).\u00a0Virological\u00a0response\u00a0after\u00a06\u00a0week\u00a0triple\u2010drug\u00a0reg imens\u00a0for\u00a0\nhepatitis\u00a0C:\u00a0a\u00a0proof\u2010of\u2010concept\u00a0phase\u00a02A\u00a0cohort\u00a0study.\u00a0Lancet\u00a03 85(9973):\u00a01107\u20101113.\u00a0\nKowdley\u00a0KV,\u00a0Gordon\u00a0SC,\u00a0Reddy\u00a0KR, \u00a0Rossaro\u00a0L,\u00a0Bernstein\u00a0DE,\u00a0Lawit z\u00a0E\u00a0et\u00a0al.\u00a0(2014).\u00a0Ledipasvir\u00a0and\u00a0sofosbuvir\u00a0for\u00a08\u00a0or\u00a012\u00a0weeks\u00a0 for\u00a0\nchronic\u00a0HCV\u00a0without\u00a0cirrhosis.\u00a0NEJM\u00a0370(20):\u00a01879\u20101888.\u00a0\nLawitz\u00a0E,\u00a0Poordad\u00a0FF,\u00a0Pang\u00a0PS,\u00a0Hyland\u00a0RH,\u00a0Ding\u00a0X,\u00a0Mo\u00a0H\u00a0et\u00a0al.\u00a0( 2014).\u00a0Sofosbuvir\u00a0and\u00a0ledipasvir\u00a0fixed\u2010dose\u00a0combination\u00a0with\u00a0an d\u00a0\nwithout\u00a0ribavirin\u00a0in\u00a0treatment\u2010naive\u00a0and\u00a0previously\u00a0treated\u00a0pat ients\u00a0with\u00a0genotype\u00a01\u00a0hepatitis\u00a0C\u00a0virus\u00a0infection\u00a0\n(LONESTAR):\u00a0an\u00a0open\u2010label,\u00a0randomised,\u00a0phase\u00a02\u00a0trial.\u00a0Lancet\u00a038 3(9916):\u00a0515\u2010523.\u00a0\u00a0\nNaggie\u00a0S,\u00a0Cooper\u00a0C,\u00a0Saag\u00a0M,\u00a0Work owski\u00a0K,\u00a0Ruane\u00a0P,\u00a0Towner\u00a0WJ\u00a0et\u00a0 al.\u00a0(2015).\u00a0Ledipasvir\u00a0and\u00a0Sofosbuvir\u00a0for\u00a0HCV\u00a0in\u00a0Patients\u00a0\nCoinfected\u00a0with\u00a0HIV\u20101.\u00a0NEJM\u00a0373(8):\u00a0705\u2010713.\u00a0\nOsinusi\u00a0A,\u00a0Meissner\u00a0EG,\u00a0Lee\u00a0YJ,\u00a0Bon\u00a0D,\u00a0Heytens\u00a0L,\u00a0Nelson\u00a0A\u00a0et\u00a0a l.\u00a0(2015).\u00a0Virologic\u00a0response\u00a0fo llowing\u00a0combined\u00a0ledipasvir\u00a0and \u00a0\nsofosbuvir\u00a0administration\u00a0in\u00a0pat ients\u00a0with\u00a0HCV\u00a0genotype\u00a01\u00a0and\u00a0H IV\u00a0co\u2010infection.\u00a0JAMA\u00a0313(12):\u00a01232\u20101239.\u00a0\u00a0\nPockros\u00a0PJ\u00a0(2017).\u00a0Direct\u2010acting\u00a0antivirals\u00a0for\u00a0the\u00a0treatment\u00a0o f\u00a0hepatitis\u00a0C\u00a0virus\u00a0infection.\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a020 17.\u00a0\nhttps://www.uptodate.com/contents/direct\u2010acting\u2010antivirals\u2010for\u2010 the\u2010treatment\u2010of\u2010hepatitis\u2010c\u2010virus\u2010infection,\u00a0letzter\u00a0\nZugriff:\u00a023.03.2017.\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0Ledipasvir\u00a0+\u00a0sofosbuvir\u00a0(Harvon i).\u00a0A\u00a0therapeutic\u00a0advance\u00a0in\u00a0genotype\u00a01\u00a0hepatitis\u00a0C\u00a0virus\u00a0infec tion,\u00a0\ndespite\u00a0uncertainties.\u00a0Prescrire\u00a0Int\u00a024(166):\u00a0285\u2010289.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2015).\u00a0Pharmazeutische\u00a0Zeitung\u00a0on line.\u00a0Ledipasvir.\u00a0http://www.pharmazeutische\u2010\nzeitung.de/index.php?id=55827,\u00a0letzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014a).\u00a0Hepatitis\u00a0C\u00a0RKI\u2010Ratgeber\u00a0f\u00fc r\u00a0\u00c4rzte.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02014.\u00a0\nwww.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Hep atitisC.html,\u00a0letzter\u00a0Zugriff:\u00a009.02.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014b).\u00a0Robert\u00a0Koch\u2010Institut:\u00a0Virus \u2010Hepatitis\u00a0C:\u00a0Situationsbericht\u00a0Deutschland\u00a02013.\u00a0\nhttp://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/31/Art _01.html,\u00a0letzter\u00a0Zugriff:\u00a014.01.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016) .\u00a0Zur\u00a0Situation\u00a0bei\u00a0wichtigen\u00a0 Infektionskrankheiten\u00a0in\u00a0Deutschland\u00a0Hepatitis\u00a0C\u00a0im\u00a0Jahr\u00a02015.\u00a0\nEpiBulletin\u00a029:\u00a0255\u2010268.\u00a0\nSuwanthawornkul\u00a0T,\u00a0Anothaisintawee\u00a0T,\u00a0Sobhonslidsuk\u00a0A,\u00a0Thakkins tian\u00a0A,\u00a0Teerawattananon\u00a0Y\u00a0(2015).\u00a0Efficacy\u00a0of\u00a0Second\u00a0\nGeneration\u00a0Direct\u2010Acting\u00a0Antiviral\u00a0Agents\u00a0for\u00a0Treatment\u00a0Na\u00efve\u00a0H epatitis\u00a0C\u00a0Genotype\u00a01:\u00a0A\u00a0Systematic\u00a0Review\u00a0and\u00a0\nNetwork\u00a0Meta\u2010Analysis.\u00a0PLoS\u00a0One\u00a010(12):\u00a0e0145953.\u00a0\nThimme\u00a0R,\u00a0Heim\u00a0M,\u00a0Baumert\u00a0TF,\u00a0Nassal\u00a0M,\u00a0Moradpour\u00a0D\u00a0(2014).\u00a0Hep atitis\u00a0B\u00a0and\u00a0C:\u00a0from\u00a0molecular\u00a0virology\u00a0to\u00a0new\u00a0antiviral\u00a0\ntherapies\u00a0(part\u00a02).\u00a0Dtsch\u00a0Med\u00a0Wochenschr\u00a0139(15):\u00a0778\u2010782.\u00a0\n\u00a0 \u00a0260\u00a04.17 Macitentan\u00a0\nHandelsname:\u00a0Opsumit\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Pulmonal\u00a0arter ielle\u00a0Hypertonie\u00a0 Actelion\u00a0\nWHO\u2010Funktionsklasse\u00a0II\u00a0bis\u00a0III\u00a0\nATC\u2010Code:\u00a0C02KX04\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Februar\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a010\u00a0mg\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0 \u25bc \u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nEs\u00a0handelt\u00a0sich\u00a0bei\u00a0Macitentan\u00a0(Handelsname:\u00a0Opsumit\u00ae)\u00a0um\u00a0den\u00a0n unmehr\u00a0vierten\u00a0\nEndothelinrezeptorantagonisten\u00a0(ERA),\u00a0welcher\u00a0aus\u00a0dem\u00a0Wirkstoff \u00a0Bosentan\u00a0ent\u2010\nwickelt\u00a0wurde.\u00a0Ambrisentan\u00a0ist\u00a0e ine\u00a0weitere\u00a0Therapiealternative ,\u00a0Sitaxentan\u00a0hin\u2010\ngegen\u00a0wurde\u00a0im\u00a0Dezember\u00a02010\u00a0in\u00a0Folge\u00a0letaler\u00a0Hepatotoxizit\u00e4t\u00a0a u\u00dfer\u00a0Handel\u00a0ge\u2010\nnommen\u00a0(Luria,\u00a02011;\u00a0Schwabe\u00a0&\u00a0P affrath,\u00a02015).\u00a0Macitentan\u00a0bloc kiert\u00a0als\u00a0dualer\u00a0ERA\u00a0\ndie\u00a0beiden\u00a0Endothelinrezeptoren\u00a0(ER),\u00a0dies\u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Vasod ilatation\u00a0der\u00a0pulmona\u2010\nlen\u00a0Arterien\u00a0(CHMP,\u00a02013a;\u00a0Fachinformation\u00a0Opsumit\u00ae,\u00a02017).\u00a0Mac itentan\u00a0wurde\u00a0im\u00a0\nDezember\u00a02013\u00a0von\u00a0der\u00a0europ\u00e4ischen\u00a0Kommission\u00a0( European\u00a0Commission ,\u00a0EC)\u00a0zur\u00a0\nLangzeitbehandlung\u00a0der\u00a0pulmonal\u00a0 arteriellen\u00a0Hypertonie\u00a0(PAH)\u00a0be i\u00a0erwachsenen\u00a0\nPatienten\u00a0mit\u00a0Funktionsklassen\u00a0( Functional\u00a0Classes ,\u00a0WHO\u2010FC)\u00a0II\u00a0und\u00a0III\u00a0als\u00a0Mono\u2010\u00a0\noder\u00a0 in\u00a0 Kombinationstherapie\u00a0 zugelassen\u00a0 (CHMP,\u00a0 2013a;\u00a0 Fachinfor mation\u00a0 Op\u2010\nsumit\u00ae,\u00a02017).\u00a0Das\u00a0Anwendungsgebiet\u00a0beinhaltet\u00a0Patienten\u00a0mit\u00a0so wohl\u00a0idiopathi\u2010\nscher\u00a0und\u00a0heredit\u00e4rer\u00a0PAH\u00a0als\u00a0auch\u00a0PAH\u00a0in\u00a0Assoziation\u00a0mit\u00a0Binde gewebserkran\u2010\nkungen\u00a0oder\u00a0korrigierten,\u00a0einfach en\u00a0angeborenen\u00a0Herzfehlern\u00a0(Fa chinformation\u00a0\nOpsumit\u00ae,\u00a02017).\u00a0Da\u00a0es\u00a0sich\u00a0bei\u00a0der\u00a0PAH\u00a0um\u00a0eine\u00a0seltene\u00a0Erkanku ng\u00a0handelt,\u00a0er\u2010\nfolgte\u00a0 bereits\u00a0 im\u00a0 Jahr\u00a0 2011\u00a0 di e\u00a0 Zuerkennung\u00a0 der\u00a0 sogenannten\u00a0 Orphan\u2010Arz\u2010\nneimittel\u2010Status,\u00a0obgl eich\u00a0weitere\u00a0ERA\u00a0verf\u00fc gbar\u00a0sind\u00a0(COMP,\u00a020 11).\u00a0\nMacitentan\u00a0wird\u00a0als\u00a0Filmtabletten\u00a0mit\u00a010\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0zur\u00a0 gleichen\u00a0Uhrzeit\u00a0mit\u00a0\noder\u00a0ohne\u00a0Mahlzeit\u00a0eingenommen.\u00a0Im\u00a0klinischen\u00a0Alltag\u00a0sind\u00a0die\u00a0v orwiegende\u00a0Meta\u2010\nbolisierung\u00a0\u00fcber\u00a0Cytochrom\u2010P450\u2010Isoenzym\u00a03A4\u00a0(CYP3A4),\u00a0die\u00a0hohe \u00a0Plasmaeiwei\u00df\u2010\nbindung\u00a0 sowie\u00a0 die\u00a0 Teratogenit\u00e4t\u00a0 im\u00a0 Tierversuch\u00a0 von\u00a0 Macitentan\u00a0 z u\u00a0 beachten\u00a0\n(Fachinformation\u00a0Opsumit\u00ae,\u00a02017).\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Macitentan\u00a0basiert\u00a0auf\u00a0der\u00a0Phase\u2010III\u2010Studie\u00a0S ERAPHIN\u00a0(Sponsor:\u00a0\nActelion,\u00a0 NCT00660179;\u00a0 AC\u2010055\u2010302),\u00a0 welche\u00a0 doppelblind,\u00a0 1:1:1\u00a0 r andomisiert,\u00a0\nplacebokontrolliert\u00a0die\u00a0Effekte\u00a0 von\u00a03\u00a0oder\u00a010\u00a0mg\u00a0Macitentan\u00a0ein mal\u00a0t\u00e4glich\u00a0ge\u2010\ngen\u00fcber\u00a0Placebo\u00a0auf\u00a0die\u00a0Mortalit\u00e4t\u00a0und\u00a0Morbidit\u00e4t\u00a0von\u00a0PAH\u2010Patie nten\u00a0pr\u00fcfte.\u00a0Es\u00a0\nist\u00a0der\u00a0erste\u00a0RCT\u00a0mit\u00a0\u201eharten\u00a0Endpunkten\u201d\u00a0zu\u00a0einem\u00a0ERA.\u00a0Eingesc hlossen\u00a0werden\u00a0\nkonnten\u00a0PAH\u2010Patienten\u00a0mit\u00a0unter\u00a0anderem\u00a0WHO\u2010FC\u00a0II,\u00a0III\u00a0oder\u00a0IV\u00a0 ab\u00a0dem\u00a0zw\u00f6lften\u00a0\nLebensjahr\u00a0und\u00a0einer\u00a0Sechsminutengehstrecke\u00a0( Six\u2010Minute\u2010Walk\u2010Distance ,\u00a06MWD)\u00a0\u2265\u00a0\n50\u00a0m\u00a0sowie\u00a0durch\u00a0Katheteruntersuchung\u00a0des\u00a0rechten\u00a0Herzens\u00a0gesic herter\u00a0Diagnose\u00a0\n261\u00a0PAH.\u00a0Es\u00a0handelte\u00a0sich\u00a0um\u00a0therapienaive\u00a0und\u00a0bereits\u00a0in\u00a0Therapie\u00a0 befindliche\u00a0PAH\u2010\nPatienten\u00a0mit\u00a0stabiler\u00a0Einstellung\u00a0einer\u00a0Pharmakotherapie.\u00a0Erla ubt\u00a0waren\u00a0Phospho\u2010\ndiesterase\u20105\u2010Inhibitoren\u00a0 (PDE\u20105\u2010I,\u00a0 vorwiegend\u00a0 Sildenafil\u00a0 >60\u00a0%\u00a0 i n \u00a0a l l e n \u00a0S t u d i e n \u2010\nArmen),\u00a0orale\u00a0oder\u00a0inhalierbare\u00a0Prostanoide,\u00a0Kalziumkanalblocke r\u00a0oder\u00a0L\u2010Arginin.\u00a0\nEine\u00a0Antikoagulantientherapie\u00a0er hielten\u00a0mehr\u00a0als\u00a050\u00a0%\u00a0der\u00a0Patie nten.\u00a0Nicht\u00a0zul\u00e4s\u2010\nsig\u00a0war\u00a0eine\u00a0Pharmakotherapie\u00a0mit\u00a0anderen\u00a0ERA\u00a0oder\u00a0die\u00a0Gabe\u00a0von \u00a0anderen\u00a0\nProstanoiden,\u00a0spezifischen\u00a0Immunsuppressiva\u00a0oder\u00a0Gabe\u00a0von\u00a0CYP3A \u2010Induktoren\u00a0\n(CHMP,\u00a02013a;\u00a0ClinicalTrials.\u00a0gov,\u00a02008a).\u00a028\u00a0Tage\u00a0nach\u00a0eingehe ndem\u00a0Screening\u00a0\nwurden\u00a0742\u00a0Patienten\u00a0mit\u00a0PAH\u00a0in\u00a0weltweit\u00a0158\u00a0Zentren\u00a0in\u00a039\u00a0L\u00e4nd ern\u00a0randomi\u2010\nsiert\u00a0und\u00a0bis\u00a0zu\u00a021\u00a0(Placebo\u2010Arm)\u00a0bzw.\u00a0bis\u00a0zu\u00a025\u00a0Monate\u00a0(Macite ntan\u00a010\u00a0mg)\u00a0be\u2010\nhandelt\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013).\u00a0Als\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0wurde\u00a0die\u00a0 Zeit\u00a0bis\u00a0zum\u00a0Eintre\u2010\nten\u00a0eines\u00a0kombinierten\u00a0Morbidit\u00e4ts\u2010\u00a0und\u00a0Mortalit\u00e4tsendpunktes\u00a0d efiniert:\u00a0Tod,\u00a0\natriale\u00a0Septotomie,\u00a0Lungentransp lantation,\u00a0Beginn\u00a0einer\u00a0intrave n\u00f6sen\u00a0oder\u00a0subku\u2010\ntanen\u00a0Prostanoidbehandlung\u00a0oder\u00a0Verschlechterung\u00a0der\u00a0PAH.\u00a0Als\u00a0s ekund\u00e4re\u00a0End\u2010\npunkte\u00a0 wurde\u00a0 die\u00a0 \u00c4nderung\u00a0 diverser\u00a0 Parameter\u00a0 erhoben\u00a0 wie\u00a0 6MWD,\u00a0 WHO\u2010FC,\u00a0\nHospitalisierung,\u00a0Borg\u2010Dyspnoe\u2010Index\u00a0(BDI)\u00a0oder\u00a0Lebensqualit\u00e4t\u00a0 mittels\u00a0Fragenbogen\u00a0\n(Medical\u2010Outcome\u2010Study\u201036\u2010Item\u2010Short\u2010Form\u2010Questionnaire ,\u00a0 SF36)\u00a0 (ClinicalTri\u2010\nals.gov,\u00a02008a).\u00a0Patienten\u00a0konnten\u00a0bei\u00a0Verschlechterung\u00a0der\u00a0PAH \u00a0nach\u00a0Entblindung\u00a0\nder\u00a0Studienmedikation\u00a0an\u00a0der\u00a0offe nen\u00a0Langzeitstudie\u00a0SERAPHIN\u2010OL \u00a0(NCT006678\u00a0\n23)\u00a0mit\u00a010\u00a0mg\u00a0Macitentan\u00a0einmal\u00a0t\u00e4glich\u00a0teilnehmen,\u00a0deren\u00a0Ergeb nisse\u00a0ab\u00a0Dezem\u2010\nber\u00a02018\u00a0erwartet\u00a0werden\u00a0(ClinicalTrials.gov,\u00a02008b).\u00a0Der\u00a0prim\u00e4 re,\u00a0kombinierte\u00a0\nMortalit\u00e4ts\u2010/\u00a0Morbidit\u00e4tsendpunkt\u00a0trat\u00a0bei\u00a046,4\u00a0%\u00a0der\u00a0Placebogr uppe,\u00a0bei\u00a038,0\u00a0%\u00a0\nim\u00a0Arm\u00a0mit\u00a03\u00a0mg\u00a0sowie\u00a0bei\u00a031,4\u00a0% \u00a0im\u00a0Arm\u00a0mit\u00a010\u00a0mg\u00a0Macitentan\u00a0ei n.\u00a0\u00a0\nAnalysiert\u00a0man\u00a0die\u00a0Einzelkomponenten,\u00a0so\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0die\u00a0Ve rschlechterung\u00a0der\u00a0\nPAH\u00a0diesen\u00a0Endpunkt\u00a0ma\u00dfgeblich\u00a0pr\u00e4gt,\u00a0wobei\u00a0dies\u00a0bei\u00a037,2\u00a0%\u00a0(93 \u00a0Patienten)\u00a0\nunter\u00a0Placebo,\u00a028,8\u00a0%\u00a0(72\u00a0Patienten)\u00a0mit\u00a03\u00a0mg\u00a0bzw.\u00a024,4\u00a0%\u00a0(59\u00a0P atienten)\u00a0mit\u00a0\n10\u00a0mg\u00a0Macitentan\u00a0der\u00a0Fall\u00a0war\u00a0(CDER,\u00a02013;\u00a0Pulido\u00a0et\u00a0al.,\u00a02013) .\u00a0In\u00a0diesem\u00a0Kontext\u00a0\nist\u00a0weiterhin\u00a0zu\u00a0beachten,\u00a0dass\u00a0aufgrund\u00a0des\u00a0Studiendesigns\u00a095\u00a0 PAH\u2010Patienten,\u00a0die\u00a0\nan\u00a0einer\u00a0progredient\u00a0letalen\u00a0Erkrankung\u00a0leiden,\u00a0in\u00a0der\u00a0Placebog ruppe\u00a0keine\u00a0Basis\u2010\ntherapie\u00a0der\u00a0PAH\u00a0erhielten.\u00a0Dies\u00a0wurde\u00a0in\u00a0der\u00a0Anh\u00f6rung\u00a0des\u00a0Geme insamen\u00a0Bun\u2010\ndesausschusses\u00a0(G\u2010BA)\u00a0mehrfach\u00a0adressiert\u00a0und\u00a0Macchia\u00a0und\u00a0Kolle gen\u00a0weisen\u00a0in\u00a0\neinem\u00a0Leserbrief\u00a0der\u00a0Originalpub likation\u00a0darauf\u00a0hin\u00a0(Macchia\u00a0et \u00a0al.,\u00a02014).\u00a0Die\u00a0\nErgebnisse\u00a0des\u00a0prim\u00e4ren\u00a0Endpunkte s\u00a0fallen\u00a0in\u00a0regionalen\u00a0Subgrup pen\u00a0tendenziell\u00a0\naber\u00a0nicht\u00a0signifikant\u00a0unterschiedlich\u00a0aus\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013 ).\u00a0Yussuf\u00a0und\u00a0Wittes\u00a0\nnennen\u00a0in\u00a0ihrem\u00a0Reviewartikel\u00a0exemplarisch\u00a0die\u00a0SERAPHIN\u2010Studie, \u00a0um\u00a0die\u00a0Fach\u00f6f\u2010\nfentlichkeit\u00a0f\u00fcr\u00a0regionale\u00a0unterschiedliche\u00a0Ergebnisse\u00a0im\u00a0Konte xt\u00a0klinischer\u00a0Studien\u00a0\nzu\u00a0sensibilisieren\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013;\u00a0Yusuf\u00a0&\u00a0Wittes,\u00a02016). \u00a0Desgleichen\u00a0spiegelt\u00a0\ndas\u00a0Statistic\u00a0Review \u00a0f\u00fcr\u00a0Macitentan\u00a0der\u00a0amerikanischen\u00a0Zulassungsbeh\u00f6rde\u00a0 Food\u00a0\nand\u00a0Drug\u00a0Administrations \u00a0(FDA)\u00a0diesen\u00a0Sachverhalt\u00a0wider,\u00a0indem\u00a0explizit\u00a0auf\u00a0ge\u2010\ngenl\u00e4ufige\u00a0Trends\u00a0der\u00a0Ergebniss e\u00a0der\u00a0amerikanischen\u00a0Subgruppen\u00a0 der\u00a0SERAPHIN\u2010262\u00a0Studie\u00a0hingewiesen\u00a0wird\u00a0(CDER,\u00a02012).\u00a0Das\u00a0Endpunktrisiko\u00a0in\u00a0der \u00a0relativ\u00a0kleinen\u00a0\nnordamerikanischen\u00a0Patientengruppe\u00a0war\u00a0unter\u00a0Placebo\u00a0deutlich\u00a0g eringer\u00a0als\u00a0in\u00a0\nden\u00a0\u00fcbrigen\u00a0Teilen\u00a0der\u00a0Welt.\u00a0Offe nbar\u00a0zeigt\u00a0sich\u00a0hier\u00a0ein\u00a0weltw eit\u00a0sehr\u00a0unter\u2010\nschiedlicher\u00a0Standard\u00a0der\u00a0Basistherapie\u00a0bzw.\u00a0medizinischen\u00a0Beha ndlungsm\u00f6glich\u2010\nkeiten\u00a0der\u00a0PAH.\u00a0Tonelli\u00a0und\u00a0Dwei k\u00a0verweisen\u00a0im\u00a0Kontext\u00a0eigener\u00a0 Studien\u00a0zur\u00a0PAH\u00a0\nauf\u00a0die\u00a0Schwierigkeit,\u00a0die\u00a0besonders\u00a0zu\u00a0Dissens\u00a0unter\u00a0mehreren\u00a0 Experten\u00a0f\u00fchrt,\u00a0bei\u00a0\nder\u00a0Zuordnung\u00a0der\u00a0Todesursache\u00a0PAH\u00a0bei\u00a0nicht\u00a0hospitalisierten\u00a0P atienten\u00a0mit\u00a0ggf.\u00a0\nKomorbidit\u00e4ten\u00a0in\u00a0einer\u00a0Gr\u00f6\u00dfenordnung\u00a0von\u00a0rund\u00a0einem\u00a0Viertel\u00a0de r\u00a0F\u00e4lle\u00a0hin\u00a0\n(Tonelli\u00a0&\u00a0Dweik,\u00a02014).\u00a0\nAnalysiert\u00a0man\u00a0die\u00a0Endpunkte\u00a0der\u00a0SERAPHIN\u2010Studie\u00a0\u201eTod\u00a0jeglicher \u00a0Ursache\u00a0bis\u00a0\nBehandlungsende\u00a0 ( End\u00a0 Of\u00a0 Treatment ,\u00a0 EOT)\u201c,\u00a0 \u201eTod\u00a0 jeglicher\u00a0 Ursache\u00a0 bis\u00a0 Stu\u2010\ndienende\u00a0( End\u00a0Of\u00a0Study ,\u00a0EOS)\u201c\u00a0und\u00a0\u201eTod\u00a0wegen\u00a0PAH\u00a0bis\u00a0EOS\u201c,\u00a0so\u00a0zeigt\u00a0sich\u00a0kein\u00a0\nstatistisch\u00a0 signifikanter\u00a0 Unterschied\u00a0 zwischen\u00a0 Placebo\u00a0 und\u00a0 10\u00a0m g\u00a0 Macitentan\u00a0\u00a0\n(G\u2010BA,\u00a02014a).\u00a0Somit\u00a0erkl\u00e4rt\u00a0sich,\u00a0dass\u00a0basierend\u00a0auf\u00a0der\u00a0SERAP HIN\u2010Studie\u00a0weder\u00a0\nFDA\u00a0noch\u00a0EMA\u00a0dem\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0einen\u00a0 Mortality\u00a0Claim \u00a0\ngew\u00e4hrten\u00a0(CDER,\u00a02013;\u00a0CHMP,\u00a02013a).\u00a0In\u00a0vorherigen\u00a0Studien\u00a0zur\u00a0 PAH,\u00a0welche\u00a0\noftmals\u00a0zw\u00f6lf\u00a0bis\u00a016\u00a0Wochen\u00a0dauerten,\u00a0hat\u00a0sich\u00a0die\u00a06MWD\u00a0als\u00a0Sur rogatparameter\u00a0\nzur\u00a0Absch\u00e4tzung\u00a0der\u00a0Morbidit\u00e4t\u00a0etabliert.\u00a0Unter\u00a0Placebo\u00a0nahm\u00a0di e\u00a06MWD\u00a0vom\u00a0\nBasiswert\u00a0bis\u00a0Monat\u00a0sechs\u00a0um\u00a09,4 \u00a0m\u00a0ab,\u00a0unter\u00a010\u00a0mg\u00a0Macitentan\u00a0u m\u00a012,5\u00a0m\u00a0zu,\u00a0\nwas\u00a0einer\u00a0mittleren\u00a0Verbesserung\u00a0von\u00a0ca.\u00a022\u00a0m\u00a0unter\u00a0Macitentan\u00a0 entspricht.\u00a0Als\u00a0\npatienten\u2010\u00a0und\u00a0klinischrelevant\u00a0werden\u00a0laut\u00a0Literatur\u00a0und\u00a0G\u2010BA\u00a0 Verbesserungen\u00a0\n\u226541\u00a0m\u00a0angesehen\u00a0(G\u2010BA,\u00a02014a).\u00a0Die\u00a0Einstufung\u00a0in\u00a0WHO\u2010FC\u00a0erfolgt \u00a0\u00e4rztlich\u00a0oftmals\u00a0\nsubjektiv\u00a0(G\u2010BA,\u00a02014b,\u00a02017b).\u00a0In\u00a0der\u00a0SERAPHIN\u2010Studie\u00a0wurde\u00a0ei ne\u00a0Verbesserung\u00a0\nder\u00a0WHO\u2010FC\u00a0unter\u00a010\u00a0mg\u00a0Macitenta n\u00a0bei\u00a022,3\u00a0%\u00a0der\u00a0PAH\u2010Patienten\u00a0 gegen\u00fcber\u00a0\n12,9\u00a0%\u00a0der\u00a0Placebogruppe\u00a0dokumentiert\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013).\u00a0Mi ttels\u00a0einer\u00a0Post\u2010\nhoc\u2010Auswertung\u00a0konnte\u00a0f\u00fcr\u00a0eine\u00a0T herapie\u00a0mit\u00a010\u00a0mg\u00a0Macitentan\u00a0ei ne\u00a0statistisch\u00a0\nsignifikante\u00a0relative\u00a0Reduktion\u00a0d er\u00a0Hospitalisierungsrate\u00a0wegen \u00a0PAH\u00a0bis\u00a0EOT\u00a0um\u00a0\n50\u00a0%\u00a0nachgewiesen\u00a0werden,\u00a0welche\u00a0der\u00a0G\u2010BA\u00a0in\u00a0seiner\u00a0ersten\u00a0Bewe rtung\u00a0jedoch\u00a0in\u00a0\nabsoluter\u00a0 Betrachtung\u00a0 (11\u00a0 pro\u00a0 100\u00a0 Patientenjahre)\u00a0 als\u00a0 gering\u00a0 ei nstufte\u00a0 (G\u2010BA,\u00a0\n2014a).\u00a0\nAls\u00a0 unerw\u00fcnschte\u00a0 Arzneimittelere ignisse\u00a0 im\u00a0 Kontext\u00a0 der\u00a0 SERAPHIN \u2010Studie\u00a0 von\u00a0\nbesonderem\u00a0 Interesse\u00a0 werden\u00a0 \u201eVerri ngerung\u00a0 des\u00a0 H\u00e4moglobinwertes\u201c ,\u00a0 \u201eKopf\u2010\nschmerzen\u201c\u00a0 sowie\u00a0 \u201eNasopharyngitis\u201c\u00a0 berichtet.\u00a0 ERA\u2010gruppenspezif ische\u00a0 Leber\u2010\nfunktionsst\u00f6rungen\u00a0traten\u00a0nicht\u00a0auf\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013).\u00a0Date n\u00a0zur\u00a0gesundheitsbe\u2010\nzogenen\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurden\u00a0in\u00a0der\u00a0\nSERAPHIN\u2010Studie\u00a0mittels\u00a0BDI\u00a0und\u00a0SF36\u00a0in\u00a0Form\u00a0einer\u00a0Ver\u00e4nderung\u00a0 vom\u00a0Basiswert\u00a0\nbis\u00a0Monat\u00a0sechs\u00a0erfasst.\u00a0Die\u00a0Be wertung\u00a0der\u00a0Ergebnisse\u00a0im\u00a0ersten \u00a0Nutzenbewer\u2010\ntungsverfahren\u00a0des\u00a0G\u2010BA\u00a0zeigte\u00a0in\u00a0beiden\u00a0F\u00e4llen\u00a0keine\u00a0klinische \u00a0Relevanz\u00a0(G\u2010BA,\u00a0\n2014a).\u00a0263\u00a0Macitentan\u00a0 wurde\u00a0 vom\u00a0 G\u2010BA\u00a0 zweima l\u00a0 bewertet.\u00a0 Bei\u00a0 Zulassung\u00a0 als\u00a0 Orphan\u2010\nArzneimittel \u00a0wird\u00a0ein\u00a0Zusatznutzen\u00a0automatisch\u00a0zuerkannt\u00a0und\u00a0nur\u00a0dessen\u00a0Aus ma\u00df\u00a0\nbewertet.\u00a0In\u00a0einem\u00a0ersten\u00a0Beschluss\u00a0vom\u00a017.\u00a0Juli\u00a02014\u00a0wird\u00a0ein\u00a0 geringer\u00a0Zusatz\u2010\nnutzen\u00a0anerkannt.\u00a0Einschr\u00e4nkend\u00a0wird\u00a0f estgestellt:\u00a0\u201eDie\u00a0Aussagekraft\u00a0 zur\u00a0Gr\u00f6\u00dfen\u2010\nordnung\u00a0der\u00a0Effekte\u00a0ist\u00a0beeintr\u00e4chtigt,\u00a0da\u00a0lediglich\u00a0ein\u00a0Vergle ich\u00a0gegen\u00fcber\u00a0Place\u2010\nbo\u00a0vorliegt.\u00a0Eine\u00a0direkt\u00a0vergle ichende\u00a0Studie\u00a0gegen\u00fcber\u00a0bereits \u00a0zahlreichen\u00a0auf\u00a0\ndem\u00a0Markt\u00a0zugelassenen\u00a0Wirkstoffe n\u00a0w\u00e4re\u00a0ebenfalls\u00a0m\u00f6glich\u00a0gewes en.\u201c\u00a0(G\u2010BA,\u00a0\n2014a,\u00a0S.\u00a04).\u00a0Nach\u00a0\u00dcberschreiten\u00a0eines\u00a0Umsatzes\u00a0von\u00a050\u00a0Mio.\u00a0Eur o\u00a0binnen\u00a0zw\u00f6lf\u00a0\nMonaten\u00a0 zu\u00a0 Lasten\u00a0 der\u00a0 gesetzliche n\u00a0 Krankenversicherung\u00a0 (GKV)\u00a0 m\u00fc ssen\u00a0 auch\u00a0\nArzneimittel\u00a0zur\u00a0Therapie\u00a0selten er\u00a0Leiden\u00a0ein\u00a0regul\u00e4res\u00a0Nutzenb ewertungsverfah\u2010\nren\u00a0durchlaufen.\u00a0Der\u00a0pU\u00a0legte\u00a0im\u00a0regul\u00e4ren\u00a0Nutzenbewertungsverf ahren\u00a0wiede\u2010\nrum\u00a0die\u00a0Daten\u00a0der\u00a0Studie\u00a0SERAPHIN\u00a0vor,\u00a0welche\u00a0Macitentan\u00a0mit\u00a0Pl acebo\u00a0verglich\u00a0\nund\u00a0keine\u00a0R\u00fcckschl\u00fcsse\u00a0auf\u00a0einen\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0verf\u00fcgb arer\u00a0zweckm\u00e4\u2010\n\u00dfiger\u00a0Vergleichstherapie\u00a0(zVT)\u00a0zul\u00e4sst.\u00a0Folglich\u00a0wurde\u00a0vom\u00a0G\u2010BA \u00a0im\u00a0zweiten\u00a0Be\u2010\nschluss\u00a0vom\u00a06.\u00a0April\u00a02017\u00a0basierend\u00a0auf\u00a0den\u00a0vom\u00a0pU\u00a0eingereichte n\u00a0Unterlagen\u00a0\nkein\u00a0Zusatznutzen \u00a0gegen\u00fcber\u00a0zVT\u00a0festgeste llt\u00a0(G\u2010BA,\u00a02017a,\u00a02017b).\u00a0\nIm\u00a0Sinne\u00a0einer\u00a0qualit\u00e4tsgesicherten\u00a0Anwendung\u00a0von\u00a0Macitentan\u00a0si nd\u00a0die\u00a0beh\u00f6rd\u2010\nlich\u00a0beauftragten\u00a0und\u00a0freigegebenen\u00a0Schulungsmaterialen\u00a0(\u201eBlaue \u00a0Hand\u201c)\u00a0des\u00a0pU\u00a0\nf\u00fcr\u00a0\u00c4rzte\u00a0(Checkliste\u00a0und\u00a0FAQ)\u00a0und\u00a0Patienten\u00a0(Brosch\u00fcre\u00a0und\u00a0Not fallkarte)\u00a0zu\u00a0be\u2010\nr\u00fccksichtigen\u00a0(Actelion,\u00a02015a,\u00a02015b,\u00a02015c,\u00a02015d).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\nVierter\u00a0Endothelinrezeptor\u2010\nAntagonist \u00a0G\u2010BA\u00a0zweiter\u00a0Beschluss,\u00a0\nim\u00a0regul\u00e4ren\u00a0\nNutzenbewertungs\u2010\nverfahren\u00a0kein\u00a0ZN\u00a0\u00a0g\u00fcnstiger\u00a0als\u00a0zVT,\u00a0da\u00a0\nbereits\u00a0Erstattungs\u2010\nbetrag\u00a0verhandelt\u00a0\nwurde\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0\n\u00a0\n264\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nMacitentan\u00a0 1x\u00a0tgl.\u00a010\u00a0mg\u00a0 365\u00a0 33.736,34\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nBosentan\u00a0 2x\u00a0tgl.\u00a0125\u00a0mg\u00a0 365\u00a0 42.892,32\u00a0\u20ac\u00a0\nAmbrisentan\u00a0 1x\u00a0tgl.\u00a05\u00a0\u2013\u00a010\u00a0mg\u00a0 365\u00a0 45.030,42\u00a0\u20ac\u00a0\nSildenafil*\u00a0 3x\u00a0tgl.\u00a020\u00a0mg\u00a0 365\u00a0 8.038,40\u00a0\u2013\u00a010.206,60\u00a0\u20ac\u00a0\nTadalafil\u00a0 1x\u00a0tgl.\u00a040\u00a0mg\u00a0 365\u00a0 10.964,73\u00a0\u20ac\u00a0\nRiociguat\u00a0 3x\u00a0tgl.\u00a02,5\u00a0mg\u00a0 365\u00a0 31.825,50\u00a0\u20ac\u00a0\nIloprost\u00a0 6\u00a0\u2013\u00a09x\u00a0tgl.\u00a05\u00a0\u00b5g\u00a0 365\u00a073.967,83\u00a0\u2013\u00a0110.951,75\u00a0\u20ac\u00a0\n*\u00a0generisch\u00a0verf\u00fcgbar\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnung\u00a0von\u00a0Macitentan\u00a0nimmt\u00a0ab\u00a0Listung\u00a0in\u00a0der\u00a0Lauer\u2010Tax e\u00a0im\u00a0Februar\u00a0\n2014\u00a0zu\u00a0bis\u00a0Juni\u00a02014\u00a0ein\u00a0erstes\u00a0Plateau\u00a0mit\u00a0ca.\u00a01.500\u00a0DDD\u00a0mona tlich\u00a0erreicht\u00a0wird,\u00a0\nwas\u00a0im\u00a0Kontext\u00a0des\u00a0Nutzenbewertungsverfahrens\u00a0des\u00a0G\u2010BA\u00a0erkl\u00e4rt\u00a0 werden\u00a0kann,\u00a0\nda\u00a0sich\u00a0mit\u00a0Ver\u00f6ffentlichung\u00a0des\u00a0IQWiG\u2010Dossiers\u00a0im\u00a0Mai\u00a02014\u00a0zun \u00e4chst\u00a0ein\u00a0Hin\u2010\nweis\u00a0und\u00a0mit\u00a0Beschlussfassung\u00a0des\u00a0G\u2010BA\u00a0im\u00a0Juli\u00a02014\u00a0die\u00a0Zuerken nung\u00a0eines\u00a0gerin\u2010\ngen\u00a0Zusatznutzens\u00a0des\u00a0 Orphan\u2010Arzneimittels\u00a0ergibt\u00a0(G\u2010BA,\u00a02014c).\u00a0Danach\u00a0steigen\u00a0\ndie\u00a0Verordnungen\u00a0weiter\u00a0auf\u00a0ca.\u00a02.000\u00a0DDD\u00a0monatlich\u00a0an\u00a0und\u00a0bild en\u00a0von\u00a0Septem\u2010\nber\u00a02014\u00a0bis\u00a0Februar\u00a02015\u00a0ein\u00a0zweites\u00a0Plateau,\u00a0welches\u00a0die\u00a0Zeit \u00a0der\u00a0Erstattungsbe\u2010\ntragsverhandlungen\u00a0zwischen\u00a0GKV\u2010Spitzenverband\u00a0und\u00a0pU\u00a0umfasst,\u00a0 obgleich\u00a0die\u00a0\nVerordnung\u00a0von\u00a0Arzneimitteln\u00a0ohne\u00a0Erstattungsbetrag\u00a0nach\u00a0\u00a7\u00a0130b \u00a0SGB\u00a0V\u00a0als\u00a0\nunwirtschaftlich\u00a0eingesch\u00e4tzt\u00a0wird\u00a0(KV\u00a0NO,\u00a02017).\u00a0Ab\u00a0Februar\u00a020 15\u00a0steigen\u00a0die\u00a0\nVerordnungen\u00a0in\u00a0Folge\u00a0des\u00a0nunmehr \u00a0vorliegenden\u00a0Erstattungsbetra ges,\u00a0welcher\u00a0zu\u00a0\neiner\u00a025%igen\u00a0Preisreduktion\u00a0f\u00fchr te\u00a0(Lauer\u2010Fischer,\u00a02017),\u00a0weit er\u00a0an\u00a0und\u00a0errei\u2010\nchen\u00a0im\u00a0November\u00a02015\u00a0das\u00a0Maximu m\u00a0von\u00a0fast\u00a04.000\u00a0DDD\u00a0monatlich. \u00a0\n\u00a0\u00a0265\u00a0Abbildung\u00a04.27:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nMacitentan\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nBeim\u00a0Wirkstoff\u00a0Macitentan\u00a0handelt\u00a0es\u00a0sich\u00a0neben\u00a0Ambrisentan,\u00a0Bo sentan\u00a0und\u00a0\nSitaxentan,\u00a0welches\u00a0seit\u00a0Dezember\u00a02010\u00a0in\u00a0Folge\u00a0letaler\u00a0Hepatot oxizit\u00e4t\u00a0au\u00dfer\u00a0\nHandel\u00a0genommen\u00a0wurde\u00a0(Luria,\u00a02011),\u00a0um\u00a0den\u00a0vierten\u00a0Vertreter\u00a0a us\u00a0der\u00a0Gruppe\u00a0\nder\u00a0ERA.\u00a0Der\u00a0Wirkstoff\u00a0wurde\u00a0durch\u00a0Molek\u00fclvariation\u00a0von\u00a0Bosenta n\u00a0abgeleitet\u00a0\n(Schwabe\u00a0&\u00a0Paffrath,\u00a02015).\u00a0\nEndothelin\u00a0(ET)\u00a0ist\u00a0ein\u00a0aus\u00a0einundzwanzig\u00a0Aminos\u00e4uren\u00a0bestehend es\u00a0Polypeptid\u00a0\nmit\u00a0drei\u00a0Isoformen\u00a0(ET 1,\u00a0ET2\u00a0und\u00a0ET 3),\u00a0welches\u00a0\u00fcber\u00a0zwei\u00a0Rezeptoren\u00a0ET A\u00a0und\u00a0ET B\u00a0\nphysiologisch\u00a0wirkt.\u00a0Der\u00a0im\u00a0Kontext\u00a0der\u00a0PAH\u00a0relevante\u00a0vasokonst riktorische\u00a0Effekt\u00a0\nvon\u00a0ET 1\u00a0wird\u00a0\u00fcber\u00a0Kontraktion\u00a0der\u00a0glatten\u00a0Gef\u00e4\u00dfmuskulatur\u00a0vorwiegend\u00a0\u00fc ber\u00a0den\u00a0\nETA\u2010Rezeptor\u00a0vermittelt.\u00a0\u00dcber\u00a0ET B\u2010Rezeptoren\u00a0wird\u00a0indirekt\u00a0eine\u00a0Gef\u00e4\u00dfrelaxation\u00a0\n\u00fcber\u00a0die\u00a0Freisetzung\u00a0von\u00a0Stickstoffmonoxid\u00a0(NO)\u00a0und\u00a0Prostacycli n\u00a0(PGI 2)\u00a0bewirkt.\u00a0\nBei\u00a0PAH\u00a0liegen\u00a0vermehrt\u00a0ET A\u2010Rezeptoren\u00a0vor.\u00a0Akut\u00a0werden\u00a0durch\u00a0ET 1\u00a0Vasokonstrik\u2010\ntion,\u00a0Thrombozytenaggregation,\u00a0E rh\u00f6hung\u00a0der\u00a0vaskul\u00e4ren\u00a0Permeabi lit\u00e4t,\u00a0Entz\u00fcn\u2010\ndung\u00a0und\u00a0Volumenretention\u00a0bewirkt.\u00a0Chronisch\u00a0kommt\u00a0es\u00a0zu\u00a0Zellpr oliferation,\u00a0\nFibrose\u00a0und\u00a0Aktivierung\u00a0weiterer\u00a0Mediatoren\u00a0(Monaco\u00a0&\u00a0Davila,\u00a02 016;\u00a0Nieber\u00a0&\u00a0\nW e r t h e r , \u00a02 0 0 7 ) . \u00a0I n \u00a0v i t r o \u00a0k o n n t e \u00a0f \u00fc r \u00a0M a c i t e n t a n \u00a0d i e \u00a0P r \u00e4 f e r e n z \u00a0e i ner\u00a0 st\u00e4rkeren\u00a0\nHemmung\u00a0des\u00a0ET A\u2010\u00a0gegen\u00fcber\u00a0dem\u00a0ET B\u2010Rezeptor\u00a0gezeigt\u00a0werden,\u00a0die\u00a0sich\u00a0in\u00a0vitro\u00a0\nfast\u00a0 100\u2010fach\u00a0 auswirkt.\u00a0 F\u00fcr\u00a0 das\u00a0 inzwischen\u00a0 aufgrund\u00a0 der\u00a0 Hepatot oxizit\u00e4t\u00a0 nicht\u00a0\n266\u00a0m e h r \u00a0v e r f \u00fc g b a r e \u00a0S i t a x e n t a n \u00a0w a r \u00a0d i e \u00a0P r \u00e4 v a l e n z \u00a0f \u00fc r \u00a0d e n \u00a0E T A\u2010\u00a0 gegen\u00fcber\u00a0 ET B\u2010\nRezeptor\u00a06.500\u2010fach\u00a0(Nieber\u00a0&\u00a0Werther,\u00a02007;\u00a0CHMP,\u00a02013a).\u00a0Maci tentan\u00a0wirkt\u00a0\nsomit\u00a0in\u00a0Folge\u00a0der\u00a0Blockade\u00a0der\u00a0ER\u00a0im\u00a0Rahmen\u00a0der\u00a0PAH\u00a0einer\u00a0Vaso konstriktion\u00a0der\u00a0\npulmonalen\u00a0Arterien\u00a0sowie\u00a0Proliferation\u00a0der\u00a0entsprechenden\u00a0glat ten\u00a0Gef\u00e4\u00dfmus\u2010\nkelzellen,\u00a0Fibrose,\u00a0Hypertrophie \u00a0und\u00a0Inflammation\u00a0entgegen\u00a0(fac hinfo.de,\u00a02017).\u00a0\nDie\u00a0 Bioverf\u00fcgbarkeit\u00a0 von\u00a0 Macitentan\u00a0 konnte\u00a0 mangels\u00a0 verf\u00fcgbarer\u00a0 intraven\u00f6ser\u00a0\nDarreichungsform\u00a0nicht\u00a0bestimmt\u00a0werden\u00a0(CHMP,\u00a02013a),\u00a0maximale\u00a0 Plasmaspiegel\u00a0\nwerden\u00a0nach\u00a0acht\u00a0Stunden\u00a0erreicht.\u00a0Als\u00a0Eliminationshalbwertzeit \u00a0werden\u00a0f\u00fcr\u00a0Maci\u2010\ntentan\u00a0sechzehn\u00a0Stunden\u00a0bzw.\u00a0f\u00fcr\u00a0den\u00a0aktiven\u00a0Metaboliten\u00a048\u00a0Stu nden\u00a0dokumen\u2010\ntiert.\u00a0Beide\u00a0Substanzen\u00a0werden\u00a0zu\u00a0\u00fcber\u00a099\u00a0%\u00a0an\u00a0Plasmaeiwei\u00dfe\u00a0ge bunden.\u00a0Der\u00a0\nAbbau\u00a0von\u00a0Macitentan\u00a0verl\u00e4uft\u00a0\u00fcbe rwiegend\u00a0(>99\u00a0%)\u00a0\u00fcber\u00a0CYP3A4,\u00a0 was\u00a0im\u00a0Kon\u2010\ntext\u00a0von\u00a0Interaktionen\u00a0zu\u00a0beachten\u00a0ist.\u00a0Haupts\u00e4chlich\u00a0wird\u00a0Maci tentan\u00a0bzw.\u00a0die\u00a0\nAbbauprodukte\u00a0\u00fcber\u00a0die\u00a0Niere\u00a0ausgeschieden.\u00a0Im\u00a0Tierversuch\u00a0erwi es\u00a0sich\u00a0Maci\u2010\ntentan\u00a0als\u00a0teratogen,\u00a0d.h.\u00a0vor\u00a0Therapiebeginn\u00a0ist\u00a0eine\u00a0Schwange rschaft\u00a0auszu\u2010\nschlie\u00dfen\u00a0und\u00a0w\u00e4hrend\u00a0der\u00a0Therapie\u00a0ist\u00a0eine\u00a0sichere\u00a0Empf\u00e4ngnisv erh\u00fctung\u00a0zu\u00a0\ngew\u00e4hrleisten,\u00a0welche\u00a0mittels\u00a0monatlicher\u00a0Schwangerschaftstests \u00a0zu\u00a0belegen\u00a0ist\u00a0\n(Actelion,\u00a02015d;\u00a0fachinfo.de,\u00a02017).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nBereits\u00a0 im\u00a0 September\u00a0 2011\u00a0 wurde\u00a0 Macitentan\u00a0 der\u00a0 Status\u00a0 als\u00a0 Arzne imittel\u00a0 zur\u00a0\nTherapie\u00a0seltener\u00a0Leiden\u00a0seitens\u00a0des\u00a0 Committee\u00a0on\u00a0orphan\u00a0medicinal\u00a0products \u00a0\n(COMP)\u00a0 der\u00a0 EMA\u00a0 zuerkannt,\u00a0 obglei ch\u00a0 bereits\u00a0 drei\u00a0 weitere\u00a0 Arzneim ittel\u00a0 der\u00a0\ngleichen\u00a0 Wirkstoffklasse\u00a0 zur\u00a0 Verf\u00fcgung\u00a0 standen\u00a0 (COMP,\u00a0 2011).\u00a0 Di e\u00a0 Zulassung\u00a0\ndurch\u00a0den\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0 for\u00a0Human\u00a0Medicinal\u00a0\nProducts,\u00a0CHMP)\u00a0der\u00a0EMA\u00a0erfolgte\u00a0am\u00a020.\u00a0Dez\u00a02013\u00a0(CHMP,\u00a02013b).\u00a0\nMacitentan\u00a0ist\u00a0zur\u00a0Langzeitbehandlung\u00a0erwachsener\u00a0Patienten\u00a0mit \u00a0pulmonal\u00a0arte\u2010\nrieller\u00a0Hypertonie\u00a0(PAH)\u00a0der\u00a0WHO \u2010Funktionsklassen\u00a0(WHO\u2010FC)\u00a0II\u00a0u nd\u00a0III\u00a0in\u00a0Mono\u2010\u00a0\noder\u00a0Kombinationstherapie\u00a0zugela ssen\u00a0worden.\u00a0Dies\u00a0beinhaltet\u00a0PA H\u00a0in\u00a0Assoziation\u00a0\nmit\u00a0korrigierten\u00a0einfachen\u00a0angebo renen\u00a0Herzfehlern,\u00a0mit\u00a0Bindege webserkrankun\u2010\ngen,\u00a0erbliche\u00a0und\u00a0idiopathische\u00a0PAH\u00a0(fachinfo.de,\u00a02017).\u00a0\nAufnahme\u00a0in\u00a0die\u00a0Lauer\u2010Taxe\u00a0erfolgte\u00a0erstmalig\u00a0zum\u00a01.\u00a0Februar\u00a020 14,\u00a0Macitentan\u00a0\nwird\u00a0in\u00a0der\u00a0Dosierung\u00a0von\u00a010\u00a0mg\u00a0t\u00e4glich\u00a0zur\u00a0gleichen\u00a0Uhrzeit\u00a0zu \u00a0oder\u00a0unabh\u00e4ngig\u00a0\nvon\u00a0einer\u00a0Mahlzeit\u00a0eingenommen\u00a0(fachinfo.de,\u00a02017).\u00a0\nIm\u00a0klinischen\u00a0Alltag\u00a0ist\u00a0zu\u00a0beachten,\u00a0dass\u00a0Daten\u00a0zu\u00a0Patienten\u00a0m it\u00a0einem\u00a0Lebensal\u2010\nter\u00a0von\u00a0>75\u00a0Jahren\u00a0nur\u00a0begrenzt\u00a0vorliegen,\u00a0f\u00fcr\u00a0Kinder\u00a0und\u00a0Jugen dliche\u00a0die\u00a0Sicher\u2010\nheit\u00a0und\u00a0Wirksamkeit\u00a0von\u00a0Macitentan\u00a0bisher\u00a0noch\u00a0nicht\u00a0erwiesen\u00a0 ist\u00a0sowie\u00a0bei\u00a0\nNieren\u2010\u00a0bzw.\u00a0Leberfunktionsst\u00f6rungen\u00a0limitierte\u00a0Erfahrungswerte \u00a0vorliegen,\u00a0was\u00a0267\u00a0zu\u00a0 den\u00a0 Kontraindikationen\u00a0 dialysepflichtige\u00a0 Niereninsuffizienz\u00a0 sowie\u00a0 schwere\u00a0\nLeberinsuffizienz\u00a0f\u00fchrte\u00a0(fachinfo.de,\u00a02017).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0WHO\u00a0unterscheidet\u00a0bei\u00a0erh\u00f6htem\u00a0Blutdruck\u00a0im\u00a0Lungenkreislauf \u00a0(pulmonale\u00a0\nHypertonie,\u00a0PH)\u00a0f\u00fcnf\u00a0Gruppen:\u00a01,\u00a0die\u00a0pulmonal\u00a0arterielle\u00a0Hypert onie\u00a0(PAH);\u00a02,\u00a0\nFolgen\u00a0von\u00a0Linksherzerkrankungen ;\u00a03,\u00a0Folgen\u00a0von\u00a0Lungenerkrankun gen\u00a0und/\u00a0oder\u00a0\nHypoxie;\u00a04,\u00a0chronisch\u00a0thromboemb olische\u00a0pulmonale\u00a0Hypertonie\u00a0(C TEPH)\u00a0sowie\u00a05,\u00a0\npulmonale\u00a0Hypertonie\u00a0mit\u00a0unklarem\u00a0multifaktoriellem\u00a0Mechanismus .\u00a0\nIn\u00a0der\u00a0WHO\u00a0Gruppe\u00a01\u00a0PAH,\u00a0wird\u00a0ferner\u00a0nach\u00a0idiopathischer\u00a0(IPAH) ,\u00a0heredit\u00e4rer\u00a0\n(HPAH),\u00a0medikamenten\u2010(bspw.\u00a0durch \u00a0Appetitz\u00fcgler\u00a0induzierte,\u00a0DPA H)/toxin\u2010\u00a0oder\u00a0\nstrahlen\u2010assoziierter\u00a0oder\u00a0mit\u00a0diversen\u00a0Erkrankungen\u00a0(Bindegewe bserkrankungen,\u00a0\nportale\u00a0Hypertension,\u00a0angeborene \u00a0Herzfehler\u00a0oder\u00a0HIV\u2010Infektione n)\u00a0assoziierter\u00a0\nPAH\u00a0unterschieden.\u00a0Im\u00a0Jahr\u00a02014\u00a0betrug\u00a0die\u00a0Pr\u00e4valenz\u00a0der\u00a0PAH\u00a025 ,9\u00a0je\u00a0Mio.\u00a0Er\u2010\nwachsener,\u00a0die\u00a0Inzidenz\u00a03,9\u00a0je\u00a0Mio.\u00a0Erwachsener\u00a0in\u00a0Deutschland. \u00a0Definiert\u00a0ist\u00a0die\u00a0\nPAH\u00a0als\u00a0pulmonal\u2010arterieller\u00a0Mitteldruck\u00a0\u226525\u00a0mm\u00a0Hg\u00a0bei\u00a0normalem \u00a0pulmonal\u2010\narteriellen\u00a0Verschlussdruck\u00a0von\u00a0\u226415\u00a0mm\u00a0Hg\u00a0sowie\u00a0pulmonal\u2010vaskul \u00e4rem\u00a0Wider\u2010\nstand\u00a0>\u00a0240\u00a0dyn*s*cm\u20105.\u00a0\nEs\u00a0handelt\u00a0sich\u00a0bei\u00a0der\u00a0PAH\u00a0um\u00a0eine\u00a0unheilbare,\u00a0chronisch\u00a0progr ediente\u00a0Erkran\u2010\nkung,\u00a0wobei\u00a0als\u00a0ultima\u00a0ratio\u00a0Lung en\u2010\u00a0bzw.\u00a0kombinierte\u00a0Herz\u2010Lung en\u2010Transplan\u2010\ntationen\u00a0erfolgen\u00a0k\u00f6nnen\u00a0(Hoeper\u00a0et\u00a0al.,\u00a02017).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIn\u00a0der\u00a0zulassungsrelevanten\u00a0Ph ase\u2010III\u2010Studie\u00a0SERA PHIN\u00a0(Sponsor: \u00a0Actelion,\u00a0NCT006\u00a0\n60179;\u00a0AC\u2010055\u2010302)\u00a0wurden\u00a0multizentrisch,\u00a0doppelblind,\u00a01:1:1\u00a0ra ndomisiert,\u00a0pla\u2010\ncebokontrolliert\u00a0und\u00a0ereignisorientiert\u00a0die\u00a0Effekte\u00a0von\u00a03\u00a0bzw.\u00a0 10\u00a0mg\u00a0Macitentan\u00a0\noder\u00a0Placebo\u00a0auf\u00a0Mortalit\u00e4t\u00a0und\u00a0Morbidit\u00e4t\u00a0von\u00a0Patienten\u00a0mit\u00a0PA H\u00a0gepr\u00fcft\u00a0(Pulido\u00a0\net\u00a0al.,\u00a02013a).\u00a0Es\u00a0ist\u00a0der\u00a0erste\u00a0RCT\u00a0mit\u00a0\u201eharten\u00a0Endpunkten\u201c\u00a0zu \u00a0einem\u00a0ERA.\u00a0Zudem\u00a0\nwurden\u00a0unterst\u00fctzend\u00a0Zwischenergebnisse\u00a0des\u00a0 Open\u2010label \u2010Armes\u00a0\u201eSERAPHIN\u00a0OL\u201c\u00a0\n(NCT00667823;\u00a0AC\u2010055\u2010303)\u00a0zum\u00a0Nachweis\u00a0der\u00a0Wirksamkeit\u00a0und\u00a0Sich erheit\u00a0vorge\u2010\nlegt\u00a0(CHMP,\u00a02013a).\u00a0\nIn\u00a0SERAPHIN\u00a0wurden\u00a028\u00a0Tage\u00a0nach\u00a0Screening\u00a0742\u00a0Patienten\u00a0mit\u00a0PAH \u00a0in\u00a0weltweit\u00a0\n158\u00a0Zentren\u00a0in\u00a039\u00a0L\u00e4ndern\u00a0randomisiert\u00a0und\u00a0\u00fcber\u00a0einundzwanzig\u00a0( Plazebo)\u00a0bis\u00a0zu\u00a0\n25\u00a0Monate\u00a0(Macitentan\u00a010\u00a0mg)\u00a0behandelt.\u00a0In\u00a0die\u00a0Studie\u00a0konnten\u00a0P AH\u00a0Patienten\u00a0\nder\u00a0WHO\u2010FC\u00a0II,\u00a0III\u00a0und\u00a0IV\u00a0aufgenommen\u00a0werden,\u00a0die\u00a0idiopathische \u00a0PAH,\u00a0heredit\u00e4re\u00a0\nPAH,\u00a0 PAH\u00a0 im\u00a0 Kontext\u00a0 von\u00a0 Bindegewe bserkrankungen,\u00a0 HIV,\u00a0 arzneimit tel\u2010\u00a0 oder\u00a0\ntoxininduzierte\u00a0PAH\u00a0 oder\u00a0PAH\u00a0auf grund\u00a0einfacher,\u00a0mittels\u00a0Operat ion\u00a0vor\u00a0\u00fcber\u00a0268\u00a0zw\u00f6lf\u00a0Monaten\u00a0korrigierter\u00a0angeborener\u00a0 systemisch\u2010pulmonaler\u00a0Shunts \u00a0aufwiesen.\u00a0\nWeiterhin\u00a0 musste\u00a0 die\u00a0 PAH\u2010Diagnose\u00a0 durch\u00a0 Katheteruntersuchung\u00a0 de s\u00a0 rechten\u00a0\nHerzens\u00a0gesichert\u00a0sein.\u00a0Die\u00a06MWD\u00a0sollte\u00a0\u226550\u00a0m\u00a0betragen\u00a0und\u00a0das\u00a0 zw\u00f6lfte\u00a0Lebens\u2010\njahr\u00a0vollendet\u00a0sein.\u00a0Patientinnen\u00a0m\u00fcssen\u00a0vor\u00a0Behandlungsbeginn\u00a0 einen\u00a0negativen\u00a0\nGravidit\u00e4tstest\u00a0vorweisen\u00a0und\u00a0zuverl\u00e4ssige\u00a0Kontrazeption\u00a0sicher stellen\u00a0(ClinicalTri\u2010\nals.gov,\u00a0 2008a).\u00a0 Teilnehmen\u00a0 konnt en\u00a0 therapienaive\u00a0 PAH\u2010Patienten \u00a0b z w . \u00a0P A H \u2010\nPatienten\u00a0mit\u00a0stabiler\u00a0Einstellung\u00a0einer\u00a0Pharmakotherapie\u00a0der\u00a0P AH\u00a0mit\u00a0PDE\u20105\u2010I,\u00a0\noralen\u00a0oder\u00a0inhalierbaren\u00a0Prostan oiden,\u00a0Kalziumkanalblockern\u00a0od er\u00a0L\u2010Arginin.\u00a0Eine\u00a0\nAntikoagulanzien\u2010Therapie\u00a0erhielten\u00a0mehr\u00a0als\u00a050\u00a0%\u00a0der\u00a0Patienten .\u00a0Nicht\u00a0zul\u00e4ssig\u00a0\nwar\u00a0eine\u00a0Pharmakotherapie\u00a0mit\u00a0ERA\u00a0(Bosentan\u00a0oder\u00a0Ambrisentan),\u00a0 intraven\u00f6se\u00a0\noder\u00a0subkutane\u00a0Gabe\u00a0von\u00a0Prostanoiden\u00a0(bspw.\u00a0Epoprostenol\u00a0oder\u00a0T reprostinil),\u00a0\nspezifische\u00a0Immunsuppressiva\u00a0(Calc ineurin\u00a0oder\u00a0mTOR\u2010Inhibitoren \u00a0wie\u00a0Cyclosporin\u00a0\nA\u00a0oder\u00a0Tacrolimus,\u00a0Everolimus\u00a0bzw.\u00a0Sirolimus),\u00a0CYP3A\u2010Induktoren \u00a0oder\u00a0jegliche\u00a0\nStudienmedikation\u00a0mit\u00a0Ausnahme\u00a0von\u00a0Macitentan\u00a0(CHMP,\u00a02013a).\u00a0\nAls\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0zum\u00a0Nachweis\u00a0der\u00a0Wirksamkeit\u00a0von\u00a0Macitent an\u00a0zur\u00a0Therapie\u00a0\nder\u00a0PAH\u00a0wurde\u00a0die\u00a0Zeit\u00a0bis\u00a0zum\u00a0Eintreten\u00a0eines\u00a0kombinierten\u00a0Mor talit\u00e4ts\u2010/Morbidi\u2010\nt\u00e4tsereignisses\u00a0definiert,\u00a0welches\u00a0sich\u00a0ergibt\u00a0aus:\u00a0\u201eTod\u201c\u00a0oder\u00a0 \u201eunerw\u00fcnschtes\u00a0Ereig\u2010\nnis\u201c\u00a0(Adverse\u00a0Event ,\u00a0AE)\u00a0oder\u00a0\u201eatriale\u00a0Septostomie\u00a0 bzw.\u00a0Hospitalisation\u00a0hierf\u00fcr\u201c\u00a0o der\u00a0\n\u201eLungentransplantation\u00a0bzw.\u00a0Hospitalisation\u00a0hierzu\u201c\u00a0oder\u00a0\u201eEskal ation\u00a0der\u00a0Pharmako\u2010\ntherapie\u00a0mittels\u00a0iv\u00a0oder\u00a0sc\u00a0Prostanoidgabe\u00a0(bspw.\u00a0Epoprostenol\u00a0 oder\u00a0Treprostinil)\u00a0\nbzw.\u00a0Hospitalisation\u00a0hierf\u00fcr\u201c\u00a0oder\u00a0\u201eanderweitige\u00a0Verschlechteru ng\u00a0der\u00a0PAH\u201c,\u00a0defi\u2010\nniert\u00a0 als\u00a0 kombiniertes\u00a0 Auftreten \u00a0d e r \u00a0p a t i e n t e n i n dividuellen\u00a0 Par ameter\u00a0 dreier\u00a0\u00a0\nKriterien:\u00a0\u00a0\n1.\u00a0zweifach\u00a0best\u00e4tigte\u00a0Abnahme\u00a0der\u00a06MWD\u00a0um\u00a015\u00a0%\u00a0im\u00a0Vergleich\u00a0zu m\u00a0Zeitpunkt\u00a0\nder\u00a0Randomisierung\u00a0in\u00a0Kombination\u00a0mit\u00a0\u00a0\n2.\u00a0Verschlechterung\u00a0der\u00a0PAH\u2010Sympt ome\u00a0(h\u00f6here\u00a0WHO\u2010FC,\u00a0bei\u00a0WHO\u2010FC \u00a0IV\u00a0seit\u00a0\nRandomisierung\u00a0keine\u00a0Besserung,\u00a0Rechtsherzinsuffizienz,\u00a0welche\u00a0 nicht\u00a0auf\u00a0Diure\u2010\ntikagabe\u00a0anspricht)\u00a0sowie\u00a0\u00a0\n3.\u00a0Bedarf\u00a0einer\u00a0Eskalation\u00a0der\u00a0P harmakotherapie\u00a0mit\u00a0Prostanoid\u00a0 (bspw.\u00a0Iloprost),\u00a0\nPDE\u20105\u2010I\u00a0 (Sildenafil,\u00a0 Tadalafil),\u00a0 nach\u00a0 Unterbrechung\u00a0 der\u00a0 Studien medikation\u00a0 ERA\u00a0\n(Bosentan,\u00a0Ambrisentan)\u00a0\u00a0\u00a0bzw.\u00a0in traven\u00f6ser\u00a0Gabe\u00a0von\u00a0Diuretika. \u00a0\u00a0\nAls\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0wurden\u00a0defi niert:\u201eVer\u00e4nderung\u00a0der\u00a06MWD\u00a0 von\u00a0Ran\u2010\ndomisierung\u00a0bis\u00a0zum\u00a0Zeitpunkt\u00a0sechs\u00a0Monate\u201c;\u00a0\u201eAnteil\u00a0der\u00a0Patien ten\u00a0mit\u00a0Verbes\u2010\nserung\u00a0der\u00a0WHO\u2010FC\u00a0im\u00a0Zeitraum\u00a0Randomisierung\u00a0bis\u00a0sechster\u00a0Monat \u201c,\u00a0\u201eZeit\u00a0bis\u00a0\nzum\u00a0PAH\u00a0bedingten\u00a0Tod\u201c\u00a0bzw.\u00a0\u201ebis \u00a0zur\u00a0Hospitalisierung\u00a0in\u00a0Folge\u00a0 von\u00a0PAH\u201c\u00a0bzw.\u00a0\n\u201eTod\u00a0jeglicher\u00a0Ursache\u201c\u00a0(EOT\u00a0bzw .\u00a0EOS),\u00a0sowie\u00a0weitere\u00a0\u00c4nderung\u00a0 des\u00a0BDI,\u00a0HRQoL\u00a0\n(SF36)\u00a0und\u00a0Laborparameter\u00a0NTproBNP.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0trat\u00a0b ei\u00a046,4\u00a0%\u00a0der\u00a0\nPatienten\u00a0unter\u00a0Scheinmedikament\u00a0(Plazebo),\u00a038,0\u00a0%\u00a0unter\u00a0Macite ntan\u00a0mit\u00a03\u00a0mg\u00a0\nsowie\u00a031,4\u00a0%\u00a0unter\u00a0Gabe\u00a0von\u00a010\u00a0mg\u00a0Macitentan\u00a0auf\u00a0(Pulido\u00a0et\u00a0al. ,\u00a02013a).\u00a0Zu\u00a0be\u2010269\u00a0achten\u00a0ist,\u00a0dass\u00a0Patienten\u00a0nach\u00a0Erreichen\u00a0des\u00a0Behandlungsendes\u00a0 oder\u00a0Erreichen\u00a0\ndes\u00a0 kombinierten\u00a0 prim\u00e4ren\u00a0 Studienendpunktes\u00a0 in\u00a0 die\u00a0 offene\u00a0 Exten sionsstudie\u00a0\nSERAPHIN\u2010OL\u00a0aufgenommen\u00a0und\u00a0eine \u00a0Pharmakotherapie\u00a0mit\u00a010\u00a0mg\u00a0Mac itentan\u00a0\nerhalten\u00a0konnten.\u00a0Weiterhin\u00a0erhielten\u00a0>60\u00a0%\u00a0der\u00a0Studienteilnehm er\u00a0eine\u00a0Basisthe\u2010\nrapie\u00a0der\u00a0PAH,\u00a0zumeist\u00a0PDE\u20105\u2010I\u00a0(Sildenafil)\u00a0(im\u00a0Placebo\u2010Arm\u00a060, 2\u00a0%,\u00a03\u00a0mg\u00a0Maci\u2010\ntentan\u00a062,1\u00a0%\u00a0und\u00a010\u00a0mg\u00a0Macitentan\u00a061,4\u00a0%).\u00a0Allerdings\u00a0erhielte n\u00a0in\u00a0der\u00a0Place\u2010\nbogruppe\u00a0 95\u00a0 Patienten,\u00a0 welche\u00a0 zuvo r\u00a0 keine\u00a0 PAH\u2010Therapie\u00a0 bekommen \u00a0 hatten,\u00a0\nw\u00e4hrend\u00a0der\u00a0SERAPHIN\u2010Studie\u00a0bis\u00a0zum\u00a0Eintreten\u00a0des\u00a0prim\u00e4ren\u00a0Endp unktes\u00a0keine\u00a0\nPharmakotherapie\u00a0der\u00a0PAH\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013a).\u00a0Dies\u00a0wird\u00a0sowo hl\u00a0in\u00a0Leserbriefen\u00a0\nzur\u00a0Originalpublikation\u00a0als\u00a0\u201eunethisch\u201c\u00a0bezeichnet\u00a0(Macchia\u00a0et\u00a0 al.,\u00a02014)\u00a0als\u00a0auch\u00a0\nin\u00a0den\u00a0Anh\u00f6rungen\u00a0des\u00a0G\u2010BA\u00a0kritisch\u00a0hinterfragt\u00a0(G\u2010BA,\u00a02014b,\u00a02 017b).\u00a0Als\u00a0Erkl\u00e4\u2010\nrung\u00a0werden\u00a0die\u00a0zum\u00a0Teil\u00a0unzurei chenden\u00a0Versorgungssysteme\u00a0in\u00a0d en\u00a0Studienl\u00e4n\u2010\ndern\u00a0angef\u00fchrt\u00a0(Pulido\u00a0et\u00a0al.,\u00a02014).\u00a0Betrachtet\u00a0man\u00a0die\u00a0Ergebn isse\u00a0des\u00a0kombinier\u2010\nten\u00a0prim\u00e4ren\u00a0Endpunktes\u00a0(Placebo\u00a046,4\u00a0%\u00a0gegen\u00fcber\u00a038,0\u00a0%\u00a0unter\u00a0 3\u00a0mg\u00a0Maci\u2010\ntentan\u00a0sowie\u00a031,4\u00a0%\u00a0unter\u00a010\u00a0mg\u00a0Macitentan)\u00a0detailliert,\u00a0so\u00a0f\u00e4l lt\u00a0auf,\u00a0dass\u00a0die\u00a0\nVerschlechterung\u00a0der\u00a0PAH\u00a0\u00fcberwiegend\u00a0zu\u00a0diesem\u00a0Ergebnis\u00a0beitr\u00e4g t,\u00a0d.h.\u00a0Plazebo\u00a0\n37,2\u00a0%,\u00a028,8\u00a0%\u00a0unter\u00a03\u00a0mg\u00a0Macitentan\u00a0und\u00a024,4\u00a0%\u00a0unter\u00a0Therapie\u00a0 mit\u00a010\u00a0mg\u00a0(Pu\u2010\nlido\u00a0et\u00a0al.,\u00a02013a).\u00a0Im\u00a0Zulassungsbericht\u00a0des\u00a0 Center\u00a0for\u00a0Drug\u00a0evaluation\u00a0and\u00a0Rese\u2010\narch\u00a0(CDER)\u00a0der\u00a0FDA\u00a0wird\u00a0angemerkt,\u00a0dass\u00a0bei\u00a069\u00a0der\u00a0341\u00a0Patienten\u00a0( 20,23\u00a0%)\u00a0mit\u00a0\nkombiniertem\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0Uneinigkeit\u00a0bei\u00a0der\u00a0Best\u00e4tigung\u00a0 des\u00a0Vorliegens\u00a0\ndieses\u00a0Endpunktes\u00a0herrschte\u00a0(CDER,\u00a02013).\u00a0Auf\u00a0den\u00a0fachlichen\u00a0Di ssens\u00a0bei\u00a0einem\u00a0\nViertel\u00a0der\u00a0Einstufungen\u00a0von\u00a0Todesf\u00e4llen\u00a0in\u00a0Studien\u00a0zur\u00a0PAH\u00a0au\u00df erhalb\u00a0einer\u00a0Hos\u2010\npitalisierung\u00a0oder\u00a0in\u00a0Folge\u00a0von\u00a0K omorbidit\u00e4ten\u00a0wird\u00a0in\u00a0einem\u00a0Ko mmentar\u00a0zu\u00a0Pulido\u00a0\nund\u00a0Kollegen\u00a0hingewiesen\u00a0(Tonelli\u00a0&\u00a0Dweik,\u00a02014).\u00a0\nDer\u00a0G\u2010BA\u00a0f\u00fchrte\u00a0im\u00a0ersten\u00a0Nutzenbewertungsverfahren\u00a0aus,\u00a0welche s\u00a0nur\u00a0die\u00a0zuge\u2010\nlassene\u00a0Dosierung\u00a010\u00a0mg\u00a0Macitentan\u00a0t\u00e4glich\u00a0und\u00a0Plazebo\u00a0ber\u00fccksi chtigte,\u00a0dass\u00a0die\u00a0\nAnalyse\u00a0der\u00a0Endpunkte\u00a0\u201eTod\u00a0jeglicher\u00a0Ursache\u00a0bis\u00a0EOT\u201c,\u00a0\u201eTod\u00a0jeg licher\u00a0Ursache\u00a0bis\u00a0\nEOS\u201c\u00a0und\u00a0\u201eTod\u00a0wegen\u00a0PAH\u00a0bis\u00a0EOS\u201c,\u00a0also\u00a0die\u00a0Mortalit\u00e4t\u00a0betreffen de\u00a0Endpunkte,\u00a0\nkeinen\u00a0statistisch\u00a0signifikanten\u00a0Unterschied\u00a0zeigte\u00a0(G\u2010BA,\u00a02014 c).\u00a0Die\u00a0Morbidit\u00e4t\u00a0\nbetreffend\u00a0akzeptierte\u00a0der\u00a0G\u2010BA\u00a0i n\u00a0Folge\u00a0fehlender\u00a0Validierung\u00a0 den\u00a0kombinierten\u00a0\nEndpunkt\u00a0 Mortalit\u00e4t/Morbidit\u00e4t\u00a0 nicht\u00a0 (G\u2010BA,\u00a0 2014c).\u00a0 Als\u00a0 patient enrelevanten\u00a0\nSurrogatparameter\u00a0akzeptiert\u00a0der\u00a0G\u2010BA\u00a0die\u00a0Ver\u00e4nderung\u00a0der\u00a06MWD. \u00a0Unter\u00a0Pla\u2010\nzebo\u00a0nahm\u00a0die\u00a06MWD\u00a0vom\u00a0Basiswert\u00a0bis\u00a0Monat\u00a0sechs\u00a0um\u00a09,4\u00a0m\u00a0ab,\u00a0w ohingegen\u00a0\nunter\u00a010\u00a0mg\u00a0Macitentan\u00a0diese\u00a0um\u00a012,5\u00a0m\u00a0zunahm,\u00a0d.h.\u00a0dies\u00a0entspr icht\u00a0einer\u00a0mitt\u2010\nleren\u00a0Verbesserung\u00a0von\u00a0ca.\u00a022\u00a0m\u00a0unter\u00a0Macitentan.\u00a0Laut\u00a0Literatu r\u00a0geht\u00a0der\u00a0G\u2010BA\u00a0\njedoch\u00a0erst\u00a0ab\u00a0einer\u00a0Verbesserung\u00a0der\u00a06MWD\u00a0von\u00a0\u00fcber\u00a041\u00a0m\u00a0als\u00a0kl inisch\u2010\u00a0und\u00a0\npatientenrelevant\u00a0aus,\u00a0d.h.\u00a0der\u00a0G\u2010BA\u00a0sch\u00e4tzt\u00a0die\u00a0Ergebnisse\u00a0der \u00a0SERAPHIN\u2010Studie\u00a0\nzur\u00a0Verbesserung\u00a0der\u00a06MWD\u00a0f\u00fcr\u00a0de n\u00a0Beleg\u00a0eines\u00a0Zusatznutzens\u00a0als \u00a0zu\u00a0gering\u00a0ein\u00a0\n(G\u2010BA,\u00a02014c).\u00a0Die\u00a0WHO\u2010FC\u00a0dienen\u00a0als\u00a0Anhaltspunkt\u00a0der\u00a0Schwere\u00a0d er\u00a0Erkrankung,\u00a0\nobgleich\u00a0die\u00a0\u00e4rztliche\u00a0Einstufung\u00a0der\u00a0Subjektivit\u00e4t\u00a0unterliegt\u00a0 und\u00a0indivuell\u00a0unter\u2010270\u00a0schiedlich\u00a0ausfallen\u00a0kann,\u00a0was\u00a0auch\u00a0Professor\u00a0Hoeper\u00a0in\u00a0der\u00a0ers ten\u00a0Anh\u00f6rung\u00a0des\u00a0\nG\u2010BA\u00a0best\u00e4tigte\u00a0(G\u2010BA,\u00a02014b).\u00a0In\u00a0der\u00a0SERAPHIN\u2010Studie\u00a0wird\u00a0eine \u00a0Verbesserung\u00a0\nder\u00a0 WHO\u2010FC\u00a0 bis\u00a0 Monat\u00a0 sechs\u00a0 gegen\u00fcber\u00a0 Basiswert\u00a0 in\u00a0 der\u00a0 Macitenta n\u00a0 10\u00a0mg\u2010\nGruppe\u00a0bei\u00a022,3\u00a0%\u00a0der\u00a0Patienten\u00a0 gegen\u00fcber\u00a012,9\u00a0%\u00a0in\u00a0der\u00a0Plazebo \u2010Gruppe\u00a0be\u2010\nschrieben\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013a).\u00a0\nDas\u00a0im\u00a0Rahmen\u00a0der\u00a0SERAPHIN\u2010Studie\u00a0bis\u00a0zum\u00a0Zeitpunkt\u00a0EOT\u00a0und\u00a028\u00a0 Tage\u00a0hin\u2010\nausgehend\u00a0erfa\u00dfte\u00a0Nebenwirkungsprofil\u00a0stellt\u00a0sich\u00a0wie\u00a0folgt\u00a0dar :\u00a0Schwerwiegende\u00a0\nunerw\u00fcnschte\u00a0Ereignisse\u00a0( Severe\u00a0Unexpected\u00a0Events, \u00a0SUE)\u00a0traten\u00a0im\u00a0Macitentan\u2010\n10\u00a0mg\u2010Arm\u00a0statistisch\u00a0signifika nt\u00a0seltener\u00a0gegen\u00fcber\u00a0Plazeboauf \u00a0(45\u00a0gegen\u00fcber\u00a0\n55\u00a0%),\u00a0desgleichen\u00a0schwere\u00a0UE\u00a0(34,7\u00a0%\u00a0gegen\u00fcber\u00a045\u00a0%).\u00a0Bei\u00a0dies er\u00a0summarischen\u00a0\nBetrachtung\u00a0wurden\u00a0allerdings\u00a0Ereignisse\u00a0eingeschlossen\u00a0deren\u00a0A uftreten\u00a0durch\u00a0\ndie\u00a0Therapie\u00a0verringert\u00a0wurde.\u00a0D ie\u00a0h\u00e4ufigsten\u00a0Ereignisse\u00a0waren\u00a0 Verschlechterung\u00a0\nder\u00a0PAH\u00a0und\u00a0Rechtsherzinsuffizienz,\u00a0welche\u00a0auch\u00a0im\u00a0Kontext\u00a0der\u00a0 Morbidit\u00e4tsend\u2010\npunkte\u00a0genannt\u00a0werden\u00a0(G\u2010BA,\u00a02014c).\u00a0Die\u00a0Therapieabbr\u00fcche\u00a0in\u00a0Fo lge\u00a0UE\u00a0fanden\u00a0\nsich\u00a0im\u00a0Plazebo\u2010Arm\u00a0in\u00a0etwa\u00a0gleich\u00a0h\u00e4ufig\u00a0wie\u00a0im\u00a0Macitentan\u201010\u00a0 mg\u2010Arm\u00a0(12,4\u00a0\ngegen\u00fcber\u00a010,7\u00a0%)\u00a0ohne\u00a0statistisch \u00a0signifikanten\u00a0Unterschied,\u00a0w obei\u00a0hierf\u00fcr\u00a0wie\u2010\nderum\u00a0Rechtsherzinsuffizienz\u00a0als \u00a0auch\u00a0Verschlechterung\u00a0der\u00a0PAH\u00a0 urs\u00e4chlich\u00a0wa\u2010\nren.\u00a0Hervorzuheben\u00a0ist\u00a0die\u00a0stati stisch\u00a0signifikante\u00a0\u201eVerringeru ng\u00a0des\u00a0H\u00e4moglobins\u201c\u00a0\nals\u00a0UE\u00a0bei\u00a0Macitentan\u00a010\u00a0mg\u00a0zu\u00a015,7\u00a0%\u00a0gegen\u00fcber\u00a0bei\u00a04,8\u00a0%\u00a0der\u00a0P atienten\u00a0mit\u00a0\nPlazebo,\u00a0H\u00e4moglobinwerte\u00a0unter\u00a08 \u00a0g/dl\u00a0wurden\u00a0bei\u00a04,3\u00a0bzw.\u00a00,4\u00a0% \u00a0der\u00a0Patienten\u00a0\ngemessen.\u00a0Bei\u00a0UE\u00a0im\u00a0Kontext\u00a0mit\u00a0abnormer\u00a0Leberfunktion\u00a0bzw.\u00a0Leb erst\u00f6rungen\u00a0\nzeigte\u00a0sich\u00a0in\u00a0der\u00a0Analyse\u00a0des\u00a0G\u2010BA/IQWiG\u00a0eine\u00a0geringere\u00a0Auspr\u00e4 gung\u00a0unter\u00a0The\u2010\nrapie\u00a0mit\u00a010\u00a0mg\u00a0Macitentan\u00a0als\u00a0unter\u00a0Gabe\u00a0von\u00a0Placebo\u00a0(8,7\u00a0%\u00a0ge gen\u00fcber\u00a014,5\u00a0%),\u00a0\ndies\u00a0ergibt\u00a0einen\u00a0statistisch\u00a0signifikanten\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0The rapie\u00a0mit\u00a0Macitentan\u00a0\n(G\u2010BA,\u00a02014c).\u00a0In\u00a0der\u00a0Originalp ublikation\u00a0wurden\u00a0relevante\u00a0Lebe rfunktionsst\u00f6run\u2010\ngen\u00a0(Erh\u00f6hungen\u00a0von\u00a0SGOT\u00a0oder\u00a0S GPT\u00a0\u00fcber\u00a0das\u00a0Dreifache\u00a0und\u00a0Bilir ubinerh\u00f6hun\u2010\ngen\u00a0\u00fcber\u00a0das\u00a0Zweifache\u00a0der\u00a0oberen\u00a0Norm)\u00a0mit\u00a0jeweils\u00a01,7%\u00a0der\u00a0Pa tienten\u00a0in\u00a0bei\u2010\nden\u00a0Gruppen\u00a0gleich\u00a0h\u00e4ufig\u00a0beobachtet.\u00a0Numerisch\u00a0h\u00e4ufiger\u00a0traten \u00a0unter\u00a010\u00a0mg\u00a0\nMacitentan\u00a0Kopfschmerz,\u00a0Nasophary ngitis\u00a0sowie\u00a0Infekte\u00a0der\u00a0obere n\u00a0Atemwege\u00a0\nauf\u00a0(Pulido\u00a0et\u00a0al.,\u00a02013a).\u00a0Prinzipiell\u00a0wertet\u00a0der\u00a0G\u2010BA\u00a0eine\u00a0Re duktion\u00a0von\u00a0Kranken\u2010\nhausaufenthalten\u00a0als\u00a0patientenrelevant.\u00a0Die\u00a0in\u00a0einer\u00a0post\u2010hoc\u2010A uswertung\u00a0gezeig\u2010\nte\u00a0Reduktion\u00a0der\u00a0Hospitalisierung srate\u00a0(Hospitalisierung\u00a0wegen\u00a0 PAH\u00a0bis\u00a0EOT)\u00a0war\u00a0\nstatistisch\u00a0signifikant\u00a050\u00a0%,\u00a0wenn\u00a0Plazebo\u00a0gegen\u00fcber\u00a010\u00a0mg\u00a0Maci tentan\u2010Arm\u00a0ver\u2010\nglichen\u00a0werden.\u00a0Der\u00a0G\u2010BA\u00a0wertet\u00a0dies\u00a0jedoch\u00a0in\u00a0absoluter\u00a0Betrac htung\u00a0(11/100\u00a0\nPatientenjahre)\u00a0als\u00a0gering\u00a0(G\u2010BA,\u00a02014c).\u00a0Im\u00a0Endpunkt\u00a0\u201eVer\u00e4nder ung\u00a0des\u00a0BDI\u00a0vom\u00a0\nBasiswert\u00a0bis\u00a0Monat\u00a06\u201c\u00a0konnte\u00a0eine\u00a0Mittelwertsdifferenz\u00a0zwische n\u00a0Macitentan\u2010\n10\u00a0mg\u2010\u00a0und\u00a0Plazebogruppe\u00a0von\u00a0\u20100, 5\u00a0gezeigt\u00a0werden,\u00a0was\u00a0unterhalb \u00a0des\u00a0in\u00a0der\u00a0\nLiteratur\u00a0genannten\u00a0Wertes\u00a0von \u00a0einem\u00a0Skalenpunkt\u00a0liegt,\u00a0weshalb \u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010\nBA\u00a0eine\u00a0Aussage\u00a0zum\u00a0Zusatznutzen\u00a0 von\u00a0Macitentan\u00a0hierdurch\u00a0nicht \u00a0m\u00f6glich\u00a0ist.\u00a0271\u00a0Die\u00a0HRQoL\u00a0wurde\u00a0mittels\u00a0Version\u00a02 \u00a0des\u00a0SF\u201036\u00a0erhoben,\u00a0welcher\u00a0ac ht\u00a0einzelne\u00a0\nDimensionen\u00a0sowie\u00a0k\u00f6rperliche\u00a0( Physical\u00a0Component\u00a0Summary ,\u00a0PCS)\u00a0und\u00a0psychi\u2010\nsche\u00a0(Mental\u00a0Component\u00a0Summary ,\u00a0MCS)\u00a0Summenskalen\u00a0beinhaltet.\u00a0Mit\u00a0Ausnah\u2010\nme\u00a0der\u00a0Dimension\u00a0\u201eAllgemeine\u00a0Gesundheitswahrnehmung\u201c\u00a0ist\u00a0der\u00a0Be handlungsef\u2010\nfekt\u00a0statistisch\u00a0signifikant,\u00a0der\u00a0Vergleich\u00a010\u00a0mg\u00a0Macitentan\u00a0ge gen\u00fcber\u00a0Plazebo\u00a0der\u00a0\nSummenskalen\u00a0mit\u00a03,4\u00a0Punkten\u00a0MCS\u00a0und\u00a03,0\u00a0Punkten\u00a0PCS\u00a0ist\u00a0auch\u00a0s tatistisch\u00a0signi\u2010\nfikant.\u00a0Der\u00a0G\u2010BA\u00a0wertet\u00a0die\u00a0Ergebnisse\u00a0jedoch\u00a0aufgrund\u00a0der\u00a0Gr\u00f6\u00df e\u00a0der\u00a0Effekte\u00a0\nsowie\u00a095\u2010%\u2010Konfidenzintervall\u00a0dieser\u00a0Skalen\u00a0unterhalb\u00a0der\u00a0Irrel evanzschwelle\u00a0und\u00a0\nFehlen\u00a0 einer\u00a0 individuellen\u00a0 Responderanalyse\u00a0 als\u00a0 klinisch\u00a0 nicht\u00a0 relevant\u00a0 (G\u2010BA,\u00a0\n2014c).\u00a0\nAnderson,\u00a0Good\u00a0und\u00a0Gellad\u00a0fragen\u00a0in\u00a0Form\u00a0eines\u00a0kritischen\u00a0Leser briefes\u00a0zur\u00a0Origi\u2010\nnalpublikation\u00a0der\u00a0Studie\u00a0SERAPHIN\u00a0nach\u00a0dem\u00a0Umfang\u00a0externer\u00a0Unt erst\u00fctzung\u00a0der\u00a0\nAutoren\u00a0mittels\u00a0Datenauswertung\u00a0durch\u00a0den\u00a0pU\u00a0sowie\u00a0 Medical\u00a0Writing \u00a0(Anderson\u00a0\net\u00a0al.,\u00a02014).\u00a0Desgleichen\u00a0richten\u00a0Macchia,\u00a0Mariani\u00a0und\u00a0Tognoni \u00a0in\u00a0einem\u00a0weiteren\u00a0\nLeserbrief\u00a0den\u00a0Focus\u00a0auf\u00a0drei\u00a0offene\u00a0Fragen\u00a0zur\u00a0SERAPHIN\u2010Studie ,\u00a0indem\u00a0der\u00a0Be\u2010\nhandlungseffekt\u00a0auf\u00a0die\u00a0Mortalit \u00e4t\u00a0ihnen\u00a0inkonsistent\u00a0erscheint ,\u00a0der\u00a0Effekt\u00a0der\u00a0\nTherapie\u00a0auf\u00a0die\u00a06MWD\u00a0als\u00a0Surrogatparameter\u00a0der\u00a0Morbidit\u00e4t\u00a0nich t\u00a0signifikant\u00a0\nwahrgenommen\u00a0wird\u00a0und\u00a0der\u00a0ethische\u00a0Aspekt,\u00a095\u00a0Patienten\u00a0(>\u00a012\u00a0% )\u00a0mit\u00a0PAH\u00a0(die\u00a0\nprogredient\u00a0letal\u00a0verl\u00e4uft)\u00a0in\u00a0der\u00a0Placebogruppe\u00a0keine\u00a0Basisthe rapie\u00a0zu\u00a0offerieren\u00a0\n(Macchia\u00a0et\u00a0al.,\u00a02014).\u00a0Yussuf\u00a0und\u00a0Wittes\u00a0f\u00fchren\u00a0in\u00a0ihrem\u00a0Komme ntar\u00a0die\u00a0SERA\u2010\nPHIN\u2010Studie\u00a0als\u00a0Beispiel\u00a0an,\u00a0wel ches\u00a0zwar\u00a0nicht\u00a0statistisch\u00a0sig nifikant,\u00a0jedoch\u00a0ten\u2010\ndenziell\u00a0weltweit\u00a0gro\u00dfe\u00a0Unterschiede\u00a0in\u00a0der\u00a0Behandlung\u00a0der\u00a0PAH\u00a0 in\u00a0unterschiedli\u2010\nchen\u00a0L\u00e4nder\u00a0aufzeigt\u00a0(Yusuf\u00a0&\u00a0Wittes,\u00a02016).\u00a0Betrachtet\u00a0man\u00a0unt er\u00a0diesem\u00a0Aspekt\u00a0\ndie\u00a0 Subgruppenanalysen\u00a0 des\u00a0 Appendi x\u00a0 der\u00a0 Originalpublikation\u00a0 der \u00a0S E R A P H I N \u2010\nStudie,\u00a0so\u00a0fallen\u00a0die\u00a0Unterschied e\u00a0der\u00a0geographischen\u00a0Regionen\u00a0 betreffs\u00a0des\u00a0pri\u2010\nm\u00e4ren\u00a0Endpunktes\u00a0auf\u00a0(Abb.\u00a08\u00a0A\u00a0 und\u00a0B\u00a0in\u00a0Pulido\u00a0et\u00a0al.,\u00a02013a,\u00a01 0).\u00a0\nLeitlinienempfehlungen\u00a0\nBei\u00a0neudiagnostizierter\u00a0PAH\u00a0(EKG, \u00a0Szintigraphie)\u00a0geh\u00f6rt\u00a0auch\u00a0di e\u00a0Durchf\u00fchrung\u00a0\neines\u00a0Vasoreagibilit\u00e4tstests\u00a0im\u00a0Kontext\u00a0einer\u00a0Rechtsherzkathete runtersuchung\u00a0zur\u00a0\nleitliniengerechten\u00a0Versorgung.\u00a0Responder\u00a0sollen\u00a0initial\u00a0Kalziu mantagonisten\u00a0wie\u00a0\nbspw.\u00a0 Amlodipin\u00a0 mit\u00a0 bis\u00a0 zu\u00a0 20\u00a0 mg\u00a0 t\u00e4glich\u00a0 erhalten.\u00a0 Anhand\u00a0 einer \u00a0R i s i \u2010\nkostratifizierung\u00a0der\u00a0\u201egesch\u00e4tzt en\u00a0Einjahresmortalit\u00e4t\u201c\u00a0wird\u00a0di e\u00a0weitere\u00a0Therapie\u00a0\ndefiniert,\u00a0wobei\u00a0man\u00a0in\u00a0geringes\u00a0(<5\u00a0%),\u00a0intermedi\u00e4res\u00a0(5\u00a0bis\u00a01 0\u00a0%)\u00a0und\u00a0hohes\u00a0\nRisiko\u00a0(>10\u00a0%)\u00a0unterteilt.\u00a0Hierzu \u00a0werden\u00a0folgende\u00a0Parameter\u00a0ber \u00fccksichtigt:\u00a0Klini\u2010\nsche\u00a0Manifestation\u00a0einer\u00a0Rechtsherzinsuffizienz\u00a0(ja/nein),\u00a0Prog ression\u00a0(nein/lang\u2010\nsam/schnell),\u00a0Synkopen\u00a0(keine/gele gentlich,\u00a0orthostatisch\u00a0oder\u00a0 bei\u00a0ungew\u00f6hnli\u2010\ncher\u00a0k\u00f6rperlicher\u00a0Belastung/geh\u00e4u ft,\u00a0schon\u00a0bei\u00a0geringer\u00a0k\u00f6rperl icher\u00a0Belastung),\u00a0\nWHO\u2010FC\u00a0(I\u00a0oder\u00a0II/III/IV),\u00a06MWD\u00a0(>\u00a0440\u00a0m/165\u2010440\u00a0m/\u00a0<165\u00a0m),\u00a0Sp iroergometrie,\u00a0\nLaborwerte\u00a0BNP\u2010\u00a0bzw.\u00a0NT\u2010pro\u2010BNP\u2010 Serumspiegel,\u00a0kardiale\u00a0Bildgebu ng\u00a0(Echokardi\u2010272\u00a0ographie\u00a0bzw.\u00a0Kardio\u2010Magnetresonanztomographie)\u00a0sowie\u00a0Beurteilu ng\u00a0der\u00a0H\u00e4mo\u2010\ndynamik.\u00a0\nF\u00fcr\u00a0 \u201etypische\u201c\u00a0 PAH\u2010Patienten\u00a0 mit \u00a0 geringem\u00a0 bzw.\u00a0 intermedi\u00e4rem\u00a0 Ri siko\u00a0 erfolgt\u00a0\ninitial\u00a0 eine\u00a0 \u201efr\u00fche\u00a0 orale\u00a0 duale\u00a0 Kombinationstherapie\u201c\u00a0 mit\u00a0 ERA\u00a0 ( Ambrisentan,\u00a0\nBosentan\u00a0oder\u00a0Macitentan)\u00a0plus\u00a0PDE\u20105\u2010Inhibitor\u00a0(Sildenafil\u00a0oder \u00a0Tadalafil)\u00a0bzw.\u00a0\nStimulator\u00a0der\u00a0l\u00f6slichen\u00a0Guanylatcyclase\u00a0( soluble\u00a0Guanylate\u00a0Cyclase ,\u00a0sGCS)\u00a0(Rioci\u2010\nguat).\u00a0Bei\u00a0Hochrisikopatienten\u00a0kommt\u00a0eine\u00a0Dreifachkombination\u00a0u nter\u00a0Nutzung\u00a0\nder\u00a0Therapieoptionen\u00a0ERA\u00a0plus\u00a0PDE\u20105\u2010I\u00a0bzw.\u00a0sGCS\u00a0und\u00a0iv\u2010Prostazy klin\u2010Analogon\u00a0\nzur\u00a0 Anwendung.\u00a0 Bei\u00a0 Rechtsherzdekompensation\u00a0 ist\u00a0 die\u00a0 Pr\u00fcfung\u00a0 ein er\u00a0 Lungen\u2010\ntransplantation\u00a0indiziert.\u00a0Patienten\u00a0mit\u00a0atypischer\u00a0PAH\u00a0erhalte n\u00a0initial\u00a0eine\u00a0Mono\u2010\ntherapie\u00a0mit\u00a0PDE\u20105\u2010I\u00a0(Hoeper\u00a0et\u00a0al.,\u00a02017).\u00a0Supportiv\u00a0werden\u00a0Di uretika,\u00a0Sauerstoff\u2010\nlangzeittherapie,\u00a0 Antikoagulatio n,\u00a0 Ausgleichen\u00a0 von\u00a0 An\u00e4mie\u00a0 bzw.\u00a0 Eisenmangel,\u00a0\nImpfungen\u00a0 (j\u00e4hrlich:\u00a0 Influenza,\u00a0 einmalig:\u00a0 Pneumokokkenpneumonie )\u00a0 sowie\u00a0 be\u2010\ntreutes\u00a0k\u00f6rperliches\u00a0Training\u00a0in\u00a0der\u00a0ESC\u2010Leitlinie\u00a0(Gali\u00e8\u00a0et\u00a0al .,\u00a02016)\u00a0bzw.\u00a0im\u00a0Kom\u2010\nmentar\u00a0der\u00a0DGK\u00a0empfohlen\u00a0(Rosenkranz\u00a0et\u00a0al.,\u00a02016).\u00a0\nIm\u00a0Kommentar\u00a0der\u00a0DGK\u00a0zu\u00a0den\u00a0\u201eESC/ERS\u2010Leitlinien\u00a0zur\u00a0Diagnostik\u00a0 und\u00a0Therapie\u00a0\nder\u00a0pulmonale\u00a0Hypertonie\u201c\u00a0merke n\u00a0Prof.\u00a0Rosenkranz\u00a0und\u00a0Kollegen\u00a0 an,\u00a0dass\u00a0einer\u2010\nseits\u00a0im\u00a0klinischen\u00a0Alltag\u00a0\u201eder\u00a0nicht\u00a0immer\u00a0indikationsgerechte \u00a0Einsatz\u00a0von\u00a0teuren\u00a0\nund\u00a0mit\u00a0Nebenwirkungen\u00a0behafteten\u00a0PAH\u2010Therapien\u00a0bei\u00a0Patienten,\u00a0 die\u00a0zwar\u00a0eine\u00a0\npulmonale\u00a0Hypertonie,\u00a0jedoch\u00a0kein e\u00a0pulmonal\u00a0arterielle\u00a0Hyperton ie\u00a0haben\u201c\u00a0erfol\u2010\nge,\u00a0andereseits\u00a0aber\u00a0auch\u00a0\u201edie\u00a0nicht\u00a0immer\u00a0konsequente\u00a0Behandlu ng\u00a0von\u00a0Patien\u2010\nten\u00a0mit\u00a0PAH\u00a0(heutzutage\u00a0viele\u00a0M\u00f6 glichkeiten,\u00a0komplexe\u00a0Therapiee ntscheidungen,\u00a0\nsiehe\u00a0Therapiealgorithmus)\u201c,\u00a0es\u00a0 sich\u00a0also\u00a0um\u00a0das\u00a0Vorliegen\u00a0von\u00a0 \u00dcber\u2010\u00a0bzw.\u00a0Unter\u2010\nversorgung\u00a0handelt\u00a0(Rosenkranz\u00a0et\u00a0al.,\u00a02016b,\u00a0218).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDurch\u00a0den\u00a0Zulassungsstatus\u00a0 Orphan\u00a0Drug ,\u00a0d.h.\u00a0als\u00a0Arzneimittel\u00a0zur\u00a0Therapie\u00a0in\u00a0\nEuropa\u00a0seltener\u00a0Leiden,\u00a0wird\u00a0Macitentan\u00a0per\u00a0Verfahrensordnung\u00a0d es\u00a0G\u2010BA\u00a0auto\u2010\nmatisch\u00a0ein\u00a0Zusatznutzen\u00a0attestiert.\u00a0In\u00a0einer\u00a0ersten\u00a0Bewertung\u00a0 stellte\u00a0der\u00a0G\u2010BA\u00a0\nlediglich\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0f\u00fcr\u00a0die\u00a0Anzahl\u00a0der\u00a0Patie nten\u00a0und\u00a0Patien\u2010\ntengruppen\u00a0im\u00a0Beschluss\u00a0vom\u00a017.\u00a0Juli\u00a02014\u00a0unter\u00a0Ber\u00fccksichtigun g\u00a0des\u00a0Kompara\u2010\ntors\u00a0Plazebo\u00a0als\u00a0gering\u00a0fest\u00a0(G\u2010BA,\u00a02014a).\u00a0In\u00a0den\u00a0tragenden\u00a0Gr \u00fcnden\u00a0zum\u00a0Be\u2010\nschluss\u00a0werden\u00a0die\u00a0Ergebnisse\u00a0der\u00a0vom\u00a0pU\u00a0vorgelegten,\u00a0zulassung sbegr\u00fcndenden\u00a0\nSERAPHIN\u2010Studie\u00a0detailliert\u00a0aufgearbeitet\u00a0(G\u2010BA,\u00a02014c).\u00a0\n\u00dcberschreitet\u00a0der\u00a0zu\u00a0Lasten\u00a0der\u00a0 GKV\u00a0get\u00e4tigte\u00a0Umsatz\u00a0auf\u00a0Basis\u00a0 des\u00a0Apotheken\u2010\nverkaufspreises\u00a0die\u00a0Grenze\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0binnen\u00a0zw\u00f6lf\u00a0Monate n,\u00a0so\u00a0erfolgt\u00a0\neine\u00a0regul\u00e4re\u00a0Nutzenbewertung.\u00a0B asierend\u00a0auf\u00a0den\u00a0vom\u00a0pU\u00a0vorgele gten\u00a0Unterla\u2010\ngen,\u00a0d.h.\u00a0Daten\u00a0der\u00a0zulassungsrel evanten\u00a0Studie\u00a0SERAPHIN,\u00a0welch e\u00a0Macitentan\u00a0in\u00a0273\u00a0der\u00a0zugelassenen\u00a0Dosierung\u00a010\u00a0mg\u00a0gegen\u00fcber\u00a0Plazebo\u00a0verglich,\u00a0ko nnte\u00a0kein\u00a0Zu\u2010\nsatznutzen\u00a0gegen\u00fcber\u00a0verf\u00fcgbarer\u00a0 zVT,\u00a0die\u00a0im\u00a0nunmehr\u00a0regul\u00e4ren\u00a0 Verfahren\u00a0ge\u2010\nfordert\u00a0wurde,\u00a0dargelegt\u00a0werden\u00a0(G\u2010BA,\u00a02017a).\u00a0Somit\u00a0erkl\u00e4ren\u00a0s ich\u00a0auch\u00a0die\u00a0un\u2010\nterschiedlichen\u00a0G\u2010BA\u00a0Beschl\u00fcsse\u00a0f\u00fcr\u00a0das\u00a0gleiche\u00a0Arzneimittel\u00a0zu \u00a0unterschiedlichen\u00a0\nZeitpunkten. \u00a0\nVersorgungsanalysen\u00a0\nAbbildung\u00a04.28:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Macitentan\u00a0je\u00a0Mona t\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nDie\u00a0Abbildung\u00a04.28\u00a0zeigt\u00a0die\u00a0Anzahl\u00a0monatlich\u00a0verordneter\u00a0Menge n\u00a0Macitentan\u00a0\nnach\u00a0Packungsgr\u00f6\u00dfen.\u00a0Es\u00a0ist\u00a0ein\u00a0 wellenf\u00f6rmiger\u00a0Anstieg\u00a0der\u00a0Vero rdnungen\u00a0er\u2010\nkennbar;\u00a0es\u00a0handelt\u00a0sich\u00a0lediglich\u00a0um \u00a0die\u00a0Packungsgr\u00f6\u00dfe\u00a0N1.\u00a0\n\u00a0 \u00a0\n274\u00a0Abbildung\u00a04.29:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Macitent an\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\nDie\u00a0Abbildung\u00a04.29\u00a0bildet\u00a0die\u00a0Ver sicherten\u00a0mit\u00a0mindestens\u00a0einer \u00a0Verordnung\u00a0Maci\u2010\ntentan,\u00a0differenziert\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht,\u00a0ab.\u00a0Es\u00a0zeigt\u00a0s ich,\u00a0dass\u00a0weibliche\u00a0\nVersicherte\u00a0 deutlich\u00a0 h\u00e4ufiger\u00a0 Mac itentan\u00a0 verordnet\u00a0 bekommen\u00a0 als \u00a0 m\u00e4nnliche,\u00a0\ninsbesondere\u00a0in\u00a0den\u00a0Altersklasse n\u00a00\u00a0bis\u00a059\u00a0Versicherte.\u00a0In\u00a0h\u00f6he rem\u00a0Alter\u00a0gibt\u00a0es\u00a0\nzwischen\u00a0den\u00a0Geschlechtern\u00a0keine\u00a0Verordnungsunterschiede\u00a0mehr.\u00a0 Auff\u00e4llig\u00a0ist\u00a0\nau\u00dferdem,\u00a0dass\u00a0Macitentan\u00a0offensichtlich\u00a0bei\u00a0weiblichen\u00a0Versich erten\u00a0in\u00a0der\u00a0Al\u2010\ntersklasse\u00a050\u00a0bis\u00a059\u00a0am\u00a0h\u00e4u figsten\u00a0verordnet\u00a0wird.\u00a0\nQuellen\u00a0\nActelion\u00a0(2015a).\u00a0Macitentan:\u00a0H\u00e4ufig\u00a0gestellte\u00a0Fragen\u00a0im\u00a0Umgang \u00a0mit\u00a0Opsumit\u00ae.\u00a0Blaue\u00a0Handinformation\u00a0f\u00fcr\u00a0\u00c4rzte.\u00a0\nwww.bfarm.de/SharedDocs/Downloads /DE/Arzneimittel/Pharmakovigil anz/Risikoinformationen/EducationMaterial\n/Anlagen/macitentan\u2010opsumit\u2010aerz te2.pdf?__blob=publicationFile& v=2,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nActelion\u00a0(2015b).\u00a0Notfallkarte\u00a0f\u00fc r\u00a0Patienten:\u00a0Blaue\u00a0Handinforma tion\u00a0f\u00fcr\u00a0Patienten.\u00a0www.bfarm.de/SharedDocs/Downloads/DE/\u00a0\nArzneimittel/Pharmakovigilanz/Ris ikoinformationen/EducationMate rial/Anlagen/macitentan\u2010opsumit\u2010\npatienten2.pdf?__blob=publicatio nFile&v=2,\u00a0letzter\u00a0Zugriff:\u00a020. 06.2017.\u00a0\nActelion\u00a0(2015c).\u00a0Opsumit\u00ae\u00a010\u00a0mg\u00a0Macitentan:\u00a0Eine\u00a0Behandlung\u00a0mi t\u00a0Opsumit\u00ae\u00a0\u2013\u00a0Was\u00a0Patienten\u00a0und\u00a0ihre\u00a0Angeh\u00f6rigen\u00a0dar\u00fcber\u00a0\nwissen\u00a0sollten.\u00a0Blaue\u00a0Handinformation\u00a0f\u00fcr\u00a0Patienten.\u00a0www.bfarm. de/SharedDocs/Downloads/DE/\u00a0\nArzneimittel/Pharmakovigilanz/Ris ikoinformationen/EducationMate rial/Anlagen/macitentan\u2010opsumit\u2010\npatienten1.pdf?__blob=publicatio nFile&v=2,\u00a0letzter\u00a0Zugriff:\u00a020. 06.2017.\u00a0\n275\u00a0Actelion\u00a0(2015d).\u00a0Opsumit\u00ae\u00a0\u2013\u00a0Checkliste\u00a0f\u00fcr\u00a0den\u00a0Verordner:\u00a0Chec kliste\u00a0f\u00fcr\u00a0den\u00a0Verordner.\u00a0Blaue\u00a0Handinformation.\u00a0\nwww.bfarm.de/SharedDocs/Downloads /DE/Arzneimittel/Pharmakovigil anz/Risikoinformationen/EducationMaterial\n/Anlagen/macitentan\u2010opsumit\u2010aerz te1.pdf?__blob=publicationFile& v=2,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nAnderson\u00a0TS,\u00a0Good\u00a0CB,\u00a0Gellad\u00a0WF\u00a0(2014).\u00a0Macitentan\u00a0and\u00a0pulmonar y\u00a0arterial\u00a0hypertension.\u00a0Correspondence.\u00a0NEJM\u00a0370(1):81.\u00a0\nCDER\u00a0\u2013\u00a0Center\u00a0for\u00a0Drug\u00a0Evaluation\u00a0and\u00a0Research\u00a0(2012).\u00a0Macitent an:\u00a0Statistical\u00a0Review.\u00a0https://www.accessdata.fda.gov/\u00a0\ndrugsatfda_docs/nda/2013/204410Orig1s000StatR.pdf,\u00a0letzter\u00a0Zugr iff:\u00a020.06.2017.\u00a0\nCDER\u00a0\u2013\u00a0Center\u00a0for\u00a0Drug\u00a0Evaluation\u00a0and\u00a0Research\u00a0(2013).\u00a0Macitent an:\u00a0summary\u00a0review.\u00a0https://www.acc\u00a0essdata.fda.gov/\u00a0\ndrugsatfda_docs/nda/2013/204410Orig1s000SumR.pdf,\u00a0letzter\u00a0Zugri ff:\u00a020.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2013a).\u00a0 Opsumit\u00a0\u2013\u00a0CHMP\u00a0AR:\u00a0assessment\u00a0report.\u00a0EMA/457699/2013.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_\u2010_Public_ass essment_report/human/002697/\u00a0\nWC500160900.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2013b).\u00a0 Opsumit\u00a0\u2013\u00a0Summary\u00a0of\u00a0opinion\u00a0(initial\u00a0authorisation):\u00a0\nEMA/CHMP/590387/2013.\u00a0www.ema.europa.eu/docs/en_GB/document_lib rary/Summary_of_opinion_\u2010\n_Initial_authorisation/human/002697/WC500153142.pdf,\u00a0letzter\u00a0Zu griff:\u00a020.06.2017.\u00a0\nClinicalTrials.gov\u00a0(2008a).\u00a0ACT\u2010064992\u00a0NCT00660179:\u00a0SERAPHIN.\u00a0S tudy\u00a0of\u00a0Macitentan\u00a0(ACT\u2010064992)\u00a0on\u00a0Morbidity\u00a0and\u00a0Mortality\u00a0in\u00a0\nPatients\u00a0with\u00a0Symp\u2010tomatic\u00a0Pulmonary\u00a0Arterial\u00a0Hypertension\u00a0(SER APHIN).\u00a0https://www.clinicaltrials.gov\u00a0\n/ct2/show/study/NCT00660179?term=NCT00660179&rank=1&sect=X01234 56,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nClinicalTrials.gov\u00a0(2008b).\u00a0NCT00667823:\u00a0Clinical\u00a0Study\u00a0to\u00a0Asse ss\u00a0the\u00a0Long\u2010term\u00a0Safety\u00a0and\u00a0Tolerability\u00a0of\u00a0ACT\u00a0064992\u00a0in\u00a0Patie nts\u00a0\nWith\u00a0Symptomatic\u00a0Pulmonary\u00a0Arterial\u00a0Hypertension\u00a0(SERAPHIN\u00a0OL). \u00a0https://www.clinicaltrials.gov/ct2/show/\u00a0\nstudy/NCT00667823?term=AC\u2010055\u2010303&rank=1,\u00a0letzter\u00a0Zugriff:\u00a001.0 8.2017.\u00a0\nCOMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Orphan\u00a0Medicinal\u00a0Products\u00a0(2011).\u00a0Public\u00a0s ummary\u00a0of\u00a0opinion\u00a0on\u00a0orphan\u00a0designation:\u00a0Macitentan\u00a0for\u00a0the\u00a0\ntreatment\u00a0of\u00a0pulmonary\u00a0arterial\u00a0hypertension.\u00a0www.ema.europa.eu /docs/en_GB/document_library/Orphan_\u00a0\ndesignation/2011/10/WC500116527.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.06.201 7.\u00a0\nFachinformation\u00a0Opsumit\u00ae\u00a0(2017).\u00a0Fachinformation\u00a0Opsumit\u00ae\u00a010\u00a0mg \u00a0Filmtabletten.\u00a0www.fachinfo.de/full/pdf/020039#view=FitH&\u00a0\npagemode=none&toolbar=1&statusbar=0&messages=0&navpanes=0,\u00a0letz ter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nFDA/CDER.\u00a0(2012).\u00a0Macitentan:\u00a0Statistical\u00a0Review.\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410O rig1s000StatR.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nGalie\u00a0N,\u00a0Humbert\u00a0M,\u00a0Vachiery\u00a0JL,\u00a0Gibbs\u00a0S,\u00a0Lang\u00a0I,\u00a0Torbicki\u00a0A\u00a0et \u00a0al.\u00a0(2016).\u00a02015\u00a0ESC/ERS\u00a0Guidelines\u00a0for\u00a0the\u00a0diagnosis\u00a0and\u00a0trea tment\u00a0\nof\u00a0pulmonary\u00a0hypertension:\u00a0The\u00a0Joint\u00a0Task\u00a0Force\u00a0for\u00a0the\u00a0Diagnos is\u00a0and\u00a0Treatment\u00a0of\u00a0Pulmonary\u00a0Hypertension\u00a0of\u00a0the\u00a0\nEuropean\u00a0Society\u00a0of\u00a0Cardiology\u00a0(ESC)\u00a0and\u00a0the\u00a0European\u00a0Respirato ry\u00a0Society\u00a0(ERS):\u00a0Endorsed\u00a0by:\u00a0Association\u00a0for\u00a0\nEuropean\u00a0Paediatric\u00a0and\u00a0Congenital\u00a0Cardiology\u00a0(AEPC),\u00a0Internati onal\u00a0Society\u00a0for\u00a0Heart\u00a0and\u00a0Lung\u00a0Transplantation\u00a0\n(ISHLT).\u00a0European\u00a0Heart\u00a0J\u00a037(1):\u00a067\u2010119.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014a).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0Wi rkstoff:\u00a0Macitentan.\u00a0https://www.g\u2010ba.de/downloads/40\u2010\n268\u20102888/2014\u201007\u201017_AM\u2010RL\u2010XII_Macitentan_2014\u201002\u201001\u2010D\u2010096_TrG.p df,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014b).\u00a0M\u00fcndliche\u00a0Anh\u00f6rung\u00a0 \u2010\u00a0Wortprotokoll.\u00a0Wirkstoff:\u00a0Ma citentan.\u00a0Hg.\u00a0v.\u00a0Gemeinsamer\u00a0\nBundesausschuss\u00a0.\u00a0http s://www.g\u2010 ba.de/downloads/91\u20101031\u2010101/201 4\u201006\u201010_Wortprotokoll_end_Macitentan.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a015.05.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014c).\u00a0Nutzenbewertungsver fahren\u00a0zum\u00a0Wirkstoff\u00a0Macitentan.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/101/,\u00a0letzter\u00a0Zugriff:\u00a025.0 7.2017.\u00a0276\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017a).\u00a0Beschluss\u00a0\u00fcber\u00a0eine \u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII:\u00a0\nMacitentan.\u00a0Neubewertung\u00a0eines\u00a0Orphan\u2010Drugs\u00a0nach\u00a0\u00dcberschreitung \u00a0der\u00a050\u00a0Mio.\u00a0Euro\u00a0Grenze.\u00a0https://www.g\u2010\nba.de/downloads/39\u2010261\u20102910/2017\u201004\u201006_AM\u2010RL\u2010XII_Macitentan_D\u20102 60_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017b).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0Ma citentan.\u00a0Neubewertung\u00a0eines\u00a0Orphan\u2010Drugs\u00a0nach\u00a0\n\u00dcberschreitung\u00a0der\u00a050\u00a0Mio.\u00a0Euro\u00a0Grenze.\u00a0https://www.g\u2010ba.de/dow nloads/40\u2010268\u20104310/2017\u201004\u201006_AM\u2010RL\u2010\nXII_Macitentan_D\u2010260_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017c).\u00a0Tragende\u00a0Gr\u00fcnde:\u00a0Ma citentan.\u00a0Neubewertung\u00a0eines\u00a0Orphan\u2010Drugs\u00a0nach\u00a0\n\u00dcberschreitung\u00a0der\u00a050\u00a0Mio.\u00a0Euro\u00a0Grenze.\u00a0https://www.g\u2010ba.de/dow nloads/40\u2010268\u20104310/2017\u201004\u201006_AM\u2010RL\u2010\nXII_Macitentan_D\u2010260_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nHoeper\u00a0MM,\u00a0Ghofrani\u00a0HA,\u00a0Grunig\u00a0E,\u00a0Klose\u00a0H,\u00a0Olschewski\u00a0H,\u00a0Rosenk ranz\u00a0S\u00a0(2017).\u00a0Pulmonary\u00a0Hypertension.\u00a0\nhttps://www.aerzteblatt.de/archiv/186048/Pulmonale\u2010Hypertonie,\u00a0 letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nKV\u00a0NO\u00a0\u2013\u00a0Kassen\u00e4rztliche\u00a0Vereinigung\u00a0Nordrhein(2017).\u00a0\u00dcbersicht\u00a0 zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a735a\u00a0SGB\u00a0V.\u00a0\nhttps://www.kvno.de/downloads/verordnungen/uebersicht_fnb.pdf,\u00a0 letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0WebApo.\u00a0Macitentan.\u00a0Opsumit\u00ae.\u00a0Preise\u00a0und\u00a0 Packungsgr\u00f6\u00dfen,\u00a0letzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nLuria\u00a0X\u00a0(2011).\u00a0Public\u00a0statement \u00a0on\u00a0Thelin:\u00a0Withdrawal\u00a0of\u00a0the\u00a0m arketing\u00a0authorisation\u00a0in\u00a0the\u00a0European\u00a0Union:\u00a0THELIN,\u00a0INN\u2010sita\u2010\nxentan\u00a0sodium.\u00a0www.ema.europa.eu/docs/en_GB/document_library/Pu blic_statement/2011/03/WC500102\u00a0\n595.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.06.2017.\u00a0\nMacchia\u00a0A,\u00a0Mariani\u00a0J,\u00a0Tognoni\u00a0G\u00a0(2014).\u00a0Macitentan\u00a0and\u00a0pulmonar y\u00a0arterial\u00a0hypertension.\u00a0Correspondence.\u00a0NEJM\u00a0370(1):82.\u00a0\nMonaco\u00a0TJ,\u00a0Davila\u00a0CD\u00a0(2016).\u00a0Safety,\u00a0efficacy,\u00a0and\u00a0clinical\u00a0uti lity\u00a0of\u00a0macitentan\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0pulmonary\u00a0arterial\u00a0hyper tension.\u00a0\nDrug\u00a0design,\u00a0development\u00a0and\u00a0therapy\u00a010:\u00a01675\u20101682.\u00a0\u00a0\nNieber\u00a0K,\u00a0Werther\u00a0J\u00a0(2007).\u00a0Endothelin\u2010Antagonisten:\u00a0Mehr\u00a0Leben squalit\u00e4t\u00a0f\u00fcr\u00a0PAH\u2010Patienten.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=3998,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nPulido\u00a0T,\u00a0Adzerikho\u00a0I,\u00a0Channick,\u00a0 RN,\u00a0Delcroix\u00a0M,\u00a0Galie\u00a0N,\u00a0Ghofr ani\u00a0HA,\u00a0Simonneau\u00a0G\u00a0et\u00a0al.\u00a0(2013a).\u00a0Macitentan\u00a0and\u00a0morbidity\u00a0an d\u00a0\nmortality\u00a0in\u00a0pulmonary\u00a0arterial\u00a0 hypertension.\u00a0NEJM\u00a0369(9):\u00a0809\u2010 818.\u00a0\u00a0\nPulido\u00a0T,\u00a0Adzerikho\u00a0I,\u00a0Channick,\u00a0 RN,\u00a0Delcroix\u00a0M,\u00a0Galie\u00a0N,\u00a0Ghofr ani\u00a0HA,\u00a0Simonneau\u00a0G\u00a0et\u00a0al.\u00a0(2013b).\u00a0Macitentan\u00a0and\u00a0morbidity\u00a0an d\u00a0\nmortality\u00a0in\u00a0pulmonary\u00a0arterial\u00a0 hypertension:\u00a0Protocol.\u00a0NEJM\u00a036 9(9):\u00a0809.\u00a0\u00a0\nPulido\u00a0T,\u00a0Rubin\u00a0LJ,\u00a0Simonneau\u00a0G\u00a0(2014).\u00a0Macitentan\u00a0and\u00a0pulmonar y\u00a0arterial\u00a0hypertension.\u00a0NEJM\u00a0370(1):\u00a082\u201083.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0ArzneistoffeMaciten tan|Opsumit\u00ae|17|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=51228#,\u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\nRosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Hoeper\u00a0MM,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C\u00a0( 2015).\u00a0Pocket\u2010Leitlinie:\u00a0Diagnostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonalen \u00a0\nHypertonie\u00a0(Version\u00a02015).\u00a0Diagn ostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonal en\u00a0Hypertonie:\u00a0Kurzfassung\u00a0der\u00a0\"ESC/ERS\u00a0\nGuidelines\u00a0f\u00fcr\u00a0the\u00a0diagnosis\u00a0and\u00a0treatment\u00a0of\u00a0pulmonary\u00a0hyperte nsion\"\u00a0(2.\u00a0Auflage).\u00a0Pocket\u2010Leitlinien.\u00a0Gr\u00fcndwald:\u00a0\nB\u00f6rm\u00a0Bruckmeier\u00a0www.leitlinien.dgk.org/files/2016_K_PLL_Pulmona le_Hypertonie.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nRosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Hoeper\u00a0MM,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C\u00a0( 2016a).\u00a0Pocket\u2010Leitlinie:\u00a0Diagnostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonale n\u00a0\nHypertonie\u00a0(Version\u00a02015).\u00a0Diagn ostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonal en\u00a0Hypertonie:\u00a0Kurzfassung\u00a0der\u00a0\"ESC/ERS\u00a0\nGuidelines\u00a0f\u00fcr\u00a0the\u00a0diagnosis\u00a0and\u00a0treatment\u00a0of\u00a0pulmonary\u00a0hyperte nsion\"\u00a0(3.\u00a0Auflage).\u00a0Pocket\u2010Leitlinien.\u00a0Gr\u00fcndwald:\u00a0\nB\u00f6rm\u00a0Bruckmeier\u00a0www.leitlinien.dgk.org/files/2016_K_PLL_Pulmona le_Hypertonie.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0277\u00a0Rosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C,\u00a0Hoeper\u00a0MM\u00a0( 2016b).\u00a0Kommentar\u00a0zu\u00a0den\u00a02015\u00a0ESC/ERS\u2010Leitlinien\u00a0zur\u00a0Diagnostik \u00a0\nund\u00a0Therapie\u00a0der\u00a0pulmonalen\u00a0Hypertonie.\u00a0www.leitlinien.dgk.org/files/2016_Kommentar_zur_ESC_LL_Pulmonal e_Hypertonie.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(2015).\u00a0Arzneiverordnungs\u2010Report\u00a02015:\u00a0Ak tuelle\u00a0Daten,\u00a0Kosten,\u00a0Trends\u00a0und\u00a0Kommentare.\u00a0Springer:\u00a0Berlin\u00a0\nHeidelberg.\u00a0\nTonelli\u00a0AR,\u00a0Dweik\u00a0RA\u00a0(2014).\u00a0Macitentan\u00a0and\u00a0pulmonary\u00a0arterial\u00a0 hypertension.\u00a0Correspondence.\u00a0NEJM\u00a0370(1):81.\u00a0\nYusuf\u00a0S,\u00a0Wittes\u00a0J\u00a0(2016).\u00a0Interpreting\u00a0Geographic\u00a0Variations\u00a0in \u00a0Results\u00a0of\u00a0Randomized,\u00a0Controlled\u00a0Trials.\u00a0NEJM\u00a0375(23):\u00a02263\u20102 271.\u00a0\n\u00a0 \u00a0278\u00a04.18 Nalmefen\u00a0\nHandelsname:\u00a0Selincro\u00ae\u00a0 \u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums\u00a0 Lundbeck\u00a0GmbH\u00a0\nbei\u00a0alkoholabh\u00e4ngigen\u00a0Erwachsenen\u00a0\nATC\u2010Code:\u00a0N07BB05\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0September\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtablette\u00a0 \u00a0 DDD:\u00a018\u00a0mg\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nNalmefen\u00a0(Selincro\u00ae)\u00a0ist\u00a0ein\u00a0Opioidsystem\u2010Modulator\u00a0zur\u00a0Minderu ng\u00a0des\u00a0Verlan\u2010\ngens\u00a0nach\u00a0Alkohol\u00a0bei\u00a0Erwachsene n\u00a0mit\u00a0einer\u00a0Alkoholabh\u00e4ngigkeit .\u00a0Die\u00a0Zulassung\u00a0\nbetrifft\u00a0die\u00a0Anwendung\u00a0zur\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums,\u00a0wenn\u00a0s ich\u00a0dieser\u00a0auf\u00a0\neinem\u00a0 hohen\u00a0 Risikoniveau\u00a0 befindet:\u00a0 Gem\u00e4\u00df\u00a0 WHO\u00a0 Risikoniveaus\u00a0 ( Drinking\u00a0 Risk\u00a0\nLevels)\u00a0gilt\u00a0dies\u00a0f\u00fcr\u00a0M\u00e4nner\u00a0mit\u00a0einem\u00a0Alkoholkonsum\u00a0>\u00a060\u00a0g\u00a0pro\u00a0Tag\u00a0u nd\u00a0f\u00fcr\u00a0Frau\u2010\nen\u00a0mit\u00a0>\u00a040\u00a0g\u00a0pro\u00a0Tag.\u00a0Es\u00a0sollten\u00a0zudem\u00a0keine\u00a0k\u00f6rperlichen\u00a0Entz ugserscheinungen\u00a0\nvorliegen\u00a0oder\u00a0keine\u00a0sofortige\u00a0E ntgiftung\u00a0erforderlich\u00a0sein.\u00a0Di e\u00a0Anwendung\u00a0des\u00a0\nFertigarzneimittels\u00a0findet\u00a0bei\u00a0Bedarf\u00a0mit\u00a018\u00a0mg\u00a0pro\u00a0Tag\u00a0statt,\u00a0 wenn\u00a0sich\u00a0der\u00a0Alko\u2010\nholkonsum\u00a0zwei\u00a0Wochen\u00a0nach\u00a0einer\u00a0initialen\u00a0Untersuchung\u00a0weiterh in\u00a0auf\u00a0einem\u00a0\nhohen\u00a0Risikoniveau\u00a0befindet.\u00a0Ein e\u00a0Verschreibung\u00a0sollte\u00a0grunds\u00e4t zlich\u00a0nur\u00a0in\u00a0Ver\u2010\nbindung\u00a0mit\u00a0einer\u00a0kontinuierlichen\u00a0psychosozialen\u00a0Begleitung\u00a0er folgen,\u00a0um\u00a0die\u00a0\nTherapieadh\u00e4renz\u00a0und\u00a0die\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums\u00a0zu\u00a0unters t\u00fctzen.\u00a0Laut\u00a0\nZulassungsbeh\u00f6rde\u00a0stellt\u00a0Nalmefen\u00a0eine\u00a0Therapieoption\u00a0zur\u00a0Trink mengenredukti\u2010\non\u00a0als\u00a0intermedi\u00e4res\u00a0Ziel\u00a0auf\u00a0dem\u00a0Weg\u00a0zur\u00a0Abstinenz\u00a0dar\u00a0(EMA,\u00a02 016),\u00a0w\u00e4hrend\u00a0\nder\u00a0Opioid\u2010Antagonist\u00a0Naltrexon\u00a0oder\u00a0der\u00a0Glutamat\u2010Antagonist\u00a0Ac amprosat\u00a0die\u00a0\nReduktion\u00a0des\u00a0R\u00fcckfallrisikos\u00a0nach\u00a0einem\u00a0Entzug\u00a0sowie\u00a0die\u00a0Erhal tung\u00a0der\u00a0Absti\u2010\nnenz\u00a0unterst\u00fctzen\u00a0(AWMF,\u00a02016).\u00a0Vor\u00a0dem\u00a0Hintergrund\u00a0der\u00a0interna tionalen\u00a0Kritik,\u00a0\nwie\u00a0etwa\u00a0hinsichtlich\u00a0der\u00a0fehlenden\u00a0direkten\u00a0Vergleichsstudien\u00a0 (Head\u00a0to\u00a0Head )\u00a0\n(Spence,\u00a02014;\u00a0Wise,\u00a02014),\u00a0sollte\u00a0Nalmefen\u00a0bei\u00a0vorliegender\u00a0In dikation\u00a0allenfalls\u00a0als\u00a0\nTherapieversuch\u00a0im\u00a0Rahmen\u00a0von\u00a0weiteren\u00a0unterst\u00fctzenden\u00a0psychoso zialen\u00a0Ma\u00df\u2010\nnahmen\u00a0Anwendung\u00a0finden.\u00a0Die\u00a0Trinkmengenreduktion\u00a0ist\u00a0im\u00a0Rahmen \u00a0abstinenzge\u2010\nst\u00fctzter\u00a0Behandlungskonzepte\u00a0allerdings\u00a0von\u00a0besonderer\u00a0Bedeutun g\u00a0(Kurz,\u00a02012).\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0zwei\u00a0sechsmonatigen\u00a0und\u00a0einer\u00a0einj\u00e4hri gen\u00a0doppelblin\u2010\nden\u00a0randomisierten\u00a0placebokontrollierten\u00a0Studie:\u00a0ESENSE\u00a01\u00a0(Mann \u00a0et\u00a0al.,\u00a02013),\u00a0\nESENSE\u00a02\u00a0(Gual\u00a0et\u00a0al.,\u00a02013)\u00a0und\u00a0SENSE\u00a0(van\u00a0den\u00a0Brink,\u00a02014),\u00a0d ie\u00a0zum\u00a0Teil\u00a0zum\u00a0\nZeitpunkt\u00a0der\u00a0Zulassung\u00a0noch\u00a0nicht\u00a0ver\u00f6ffentlicht\u00a0waren.\u00a0Die\u00a0Pa tienten\u00a0der\u00a0drei\u00a0\nvom\u00a0Hersteller\u00a0gesponserten\u00a0Studien\u00a0nahmen\u00a0zus\u00e4tzlich\u00a0an\u00a0einer\u00a0 psychosozialen\u00a0\nIntervention\u00a0(BRENDA,\u00a0Starosta\u00a0et\u00a0al.,\u00a02006)\u00a0zur\u00a0F\u00f6rderung\u00a0der\u00a0 Therapieadh\u00e4renz\u00a0\nund\u00a0der\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums\u00a0teil.\u00a0In\u00a0der\u00a0Studie\u00a0ESENSE \u00a01\u00a0zeigte\u00a0sich\u00a0in\u00a0\nder\u00a0 Nalmefengruppe\u00a0 nach\u00a0 24\u00a0 Wochen\u00a0 eine\u00a0 signifikant\u00a0 gr\u00f6\u00dfere\u00a0 Redu ktion\u00a0 der\u00a0\nschweren\u00a0Trinktage\u00a0gegen\u00fcber\u00a0der\u00a0Placebogruppe\u00a0von\u00a0im\u00a0Mittel\u00a02, 3\u00a0Tagen\u00a0pro\u00a0279\u00a0Monat.\u00a0Zus\u00e4tzlich\u00a0lag\u00a0in\u00a0der\u00a0Nalmefengruppe\u00a0eine\u00a0gegen\u00fcber\u00a0der\u00a0 Placebogruppe\u00a0\nsignifikant\u00a0gr\u00f6\u00dfere\u00a0Trinkmengenreduktion\u00a0um\u00a0im\u00a0Mittel\u00a011\u00a0g\u00a0pro\u00a0 Tag\u00a0vor\u00a0(Mann\u00a0et\u00a0\nal.,\u00a02013).\u00a0Traten\u00a0nach\u00a0Ergebnissen\u00a0der\u00a0zweiten\u00a0Studie\u00a0(ESENSE\u00a0 2)\u00a0unter\u00a0Nalmefen\u00a0\n1,7\u00a0schwere\u00a0Trinktage\u00a0pro\u00a0Monat\u00a0weniger\u00a0auf\u00a0(Gual\u00a0et\u00a0al.,\u00a02013) ,\u00a0fehlten\u00a0in\u00a0der\u00a0\ndritten\u00a0einj\u00e4hrigen\u00a0Studie\u00a0(SENSE)\u00a0nach\u00a0einem\u00a0Zeitraum\u00a0von\u00a0sech s\u00a0Monaten\u00a0signi\u2010\nfikante\u00a0Unterschiede\u00a0zwischen\u00a0de n\u00a0Behandlungsgruppen.\u00a0Nach\u00a0eine m\u00a0Jahr\u00a0kam\u00a0es\u00a0\nunter\u00a0Nalmefen\u00a0gegen\u00fcber\u00a0der\u00a0Placebobehandlung\u00a0jedoch\u00a0zu\u00a01,6\u00a0sc hweren\u00a0Trink\u2010\ntagen\u00a0pro\u00a0Monat\u00a0weniger\u00a0und\u00a0es\u00a0verringerte\u00a0sich\u00a0die\u00a0Alkoholmeng e\u00a0um\u00a06,5\u00a0g\u00a0pro\u00a0\nTag\u00a0(van\u00a0den\u00a0Brink\u00a0et\u00a0al.,\u00a02014).\u00a0Studien,\u00a0in\u00a0denen\u00a0Nalmefen\u00a0mi t\u00a0einem\u00a0anderen\u00a0\nWirkstoff\u00a0verglichen\u00a0wurde,\u00a0gibt\u00a0es\u00a0bisher\u00a0nicht.\u00a0Ein\u00a0 Zusatznutzen \u00a0gegen\u00fcber\u00a0der\u00a0\nzweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0mit\u00a0Naltrexon\u00a0konnte\u00a0aufgrund\u00a0f ehlender\u00a0ge\u2010\neigneter\u00a0Daten\u00a0daher\u00a0 nicht\u00a0belegt \u00a0werden\u00a0(IQWiG,\u00a02014;\u00a0G\u2010BA,\u00a02015).\u00a0\u00a0\nHinsichtlich\u00a0der\u00a0Gr\u00f6\u00dfe\u00a0des\u00a0Effektes\u00a0von\u00a0Nalmefen\u00a0bestehen\u00a0insge samt\u00a0Unsicher\u2010\nheiten:\u00a0Zum\u00a0einen\u00a0kam\u00a0es\u00a0zu\u00a0hohen\u00a0Abbruchraten\u00a0und\u00a0unterschiedl ichen\u00a0Ergebnis\u2010\nsen\u00a0der\u00a0Sensitivit\u00e4tsanalysen.\u00a0Da\u00a0einige\u00a0Patienten\u00a0ihre\u00a0Trinkme nge\u00a0in\u00a0Erwartung\u00a0\nder\u00a0Studienteilnahme\u00a0verringerten,\u00a0entsprach\u00a0die\u00a0Gesamtpopulati on\u00a0schlie\u00dflich\u00a0\nnicht\u00a0mehr\u00a0vollst\u00e4ndig\u00a0den\u00a0Bedingungen\u00a0der\u00a0Zulassung.\u00a0Demnach\u00a0e rgaben\u00a0post\u00a0\nhoc\u00a0Analysen\u00a0der\u00a0(Ziel\u2010)\u00a0Populat ion\u00a0mit\u00a0einem\u00a0Trinkverhalten\u00a0au f\u00a0einem\u00a0hohen\u00a0\nRisikolevel\u00a0Therapieeffekte,\u00a0die\u00a0deutlich\u00a0gr\u00f6\u00dfer\u00a0ausfielen\u00a0als\u00a0 in\u00a0der\u00a0Gesamtpopula\u2010\ntion.\u00a0Zum\u00a0anderen\u00a0nahmen\u00a0die\u00a0unspezifischen\u00a0Therapieeffekte\u00a0dur ch\u00a0die\u00a0psycho\u2010\nsoziale\u00a0Unterst\u00fctzung\u00a0offenbar\u00a0ke inen\u00a0geringen\u00a0Stellenwert\u00a0ein. \u00a0Die\u00a0Wirksamkeit\u00a0\nvon\u00a0Nalmefen\u00a0allein\u00a0war\u00a0daneben \u00a0eher\u00a0moderat\u00a0ausgepr\u00e4gt.\u00a0\u00a0\nZu\u00a0den\u00a0h\u00e4ufigsten\u00a0unerw\u00fcnschten\u00a0Arzneimittelereignissen\u00a0(UAE)\u00a0n ach\u00a0der\u00a0Ein\u2010\nnahme\u00a0von\u00a0Nalmefen\u00a0geh\u00f6ren\u00a0Schwi ndel,\u00a0Kopfschmerzen,\u00a0\u00dcbelkeit\u00a0u nd\u00a0Schlaflo\u2010\nsigkeit,\u00a0die\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0in\u00a0der\u00a0Mehrzahl\u00a0leicht\u00a0b is\u00a0mittelschwer\u00a0aus\u2010\ngepr\u00e4gt\u00a0waren\u00a0und\u00a0im\u00a0Laufe\u00a0der\u00a0Behandlung\u00a0abnahmen.\u00a0Unter\u00a0Nalme fen\u00a0traten\u00a0\nzudem\u00a0psychiatrische\u00a0St\u00f6rungen\u00a0wie\u00a0Verwirrtheit\u00a0auf,\u00a0die\u00a0ebenfa lls\u00a0im\u00a0Verlauf\u00a0der\u00a0\nBehandlung\u00a0 abklangen.\u00a0 Wenn\u00a0 das\u00a0 Arzneimittel\u00a0 zusammen\u00a0 mit\u00a0 opioid haltigen\u00a0\nArzneimitteln\u00a0 eingenommen\u00a0 wird,\u00a0 aktuelle\u00a0 psychiatrische\u00a0 Begleit erkrankungen\u00a0\noder\u00a0leichte\u00a0bis\u00a0mittelschwere\u00a0L eber\u2010\u00a0oder\u00a0Nierenfunktionsst\u00f6ru ngen\u00a0vorliegen\u00a0\noder\u00a0Krampfanf\u00e4lle\u00a0in\u00a0der\u00a0Krankengeschichte\u00a0auftraten,\u00a0sollte\u00a0d er\u00a0Therapie\u00a0mit\u00a0\nNalmefen\u00a0besondere\u00a0Aufmerksamkei t\u00a0geschenkt\u00a0werden.\u00a0Zudem\u00a0ist\u00a0V orsicht\u00a0bei\u00a0\nder\u00a0Anwendung\u00a0bei\u00a0Patienten\u00a0 \u00fcber\u00a065\u00a0Jahren\u00a0geboten.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0280\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0\nWeitere\u00a0Therapieoption\u00a0\nzur\u00a0Minderung\u00a0des\u00a0\nVerlangens\u00a0nach\u00a0Alkohol\u00a0Fehlen\u00a0geeigneter\u00a0Daten\u00a0\nf\u00fcr\u00a0die\u00a0Bewertung\u00a0ungef\u00e4hr\u00a0gleich\u00a0zur\u00a0zVt\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung \u00a0 AMB\u00a0Prescrire\u00a0 PZ\u00a0\nC\u00a0 Umstrittenes\u00a0Therapieprinzip\u00a0 \u2013\u00a0 Nothing\u00a0new\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff \u00a0 Behandlungsmodus \u00a0Behandlungstage \u00a0 Jahrestherapiekosten \u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nNalmefen\u00a0 bei\u00a0Bedarf\u00a0\u00a0\n\u00a0bei\u00a0Bedarf\u00a0\n1\u00a0Tag,\u00a0max.\u00a090\u2010183\u00a0*\u00a0890,72\u00a0\u20ac/6\u00a0Monate\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nNaltrexon \u00a0 kontinuierlich\u00a01x\u00a0tgl. \u00a0max.\u00a090\u2010183\u00a0* \u00a0 889,98\u00a0\u20ac/6\u00a0Monate \u00a0\n*gem\u00e4\u00df\u00a0AM\u2010RL\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0von\u00a0Nalmefen\u00a0im\u00a0September\u00a02014\u00a0startet en\u00a0die\u00a0Verord\u2010\nnungszahlen\u00a0im\u00a0Oktober\u00a0auf\u00a0einem\u00a0vergleichsweise\u00a0hohen\u00a0Niveau\u00a0g egen\u00fcber\u00a0der\u00a0\nweiteren\u00a0Entwicklung\u00a0bis\u00a0Dezember\u00a02015.\u00a0Der\u00a0Bruttoumsatz\u00a0fand\u00a0i m\u00a0Oktober\u00a02014\u00a0\nmit\u00a016.828,29\u00a0Euro\u00a0sein\u00a0Maximum.\u00a0Das\u00a0im\u00a0November\u00a02014\u00a0ver\u00f6ffent lichte\u00a0Gutach\u2010\nten\u00a0des\u00a0IQWiG\u00a0zur\u00a0Nutzenbewertung\u00a0von\u00a0Nalmefen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V ,\u00a0in\u00a0dem\u00a0ein\u00a0\nZusatznutzen\u00a0von\u00a0Nalmefen\u00a0als\u00a0nicht\u00a0belegt\u00a0konstatiert\u00a0wurde,\u00a0s piegelt\u00a0sich\u00a0in\u00a0einem\u00a0\nersten\u00a0R\u00fcckgang\u00a0der\u00a0Verordnungsza hlen\u00a0wider.\u00a0Nach\u00a0Beschlussfass ung\u00a0des\u00a0Gemein\u2010\nsamen\u00a0Bundesausschusses\u00a0(G\u2010BA)\u00a0im\u00a0Februar\u00a02015\u00a0und\u00a0seinem\u00a0Inkra fttreten\u00a0im\u00a0\nM\u00e4rz\u00a0erreichte\u00a0der\u00a0Bruttoumsatz\u00a0nur\u00a0noch\u00a011.748,50\u00a0Euro.\u00a0Die\u00a0Di fferenz\u00a0zwischen\u00a0\nDDD\u2010Menge\u00a0und\u00a0Bruttoumsatz\u00a0ab\u00a0September\u00a02015\u00a0geht\u00a0vermutlich\u00a0au f\u00a0die\u00a0Verein\u2010\nbarung\u00a0eines\u00a0Erstattungsbetrags\u00a0nach\u00a0\u00a7\u00a0130b\u00a0SGB\u00a0V\u00a0zur\u00fcck.\u00a0\u00a0\n\u00a0\n281\u00a0Abbildung\u00a04.30:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\nNalmefen\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nAls\u00a0Opioidsystem\u2010Modulator\u00a0besitzt\u00a0Nalmefen\u00a0ein\u00a0eigenes\u00a0\u03bc\u2010,\u00a0\u03b4\u2010\u00a0 und\u00a0\u03ba\u2010Rezep\u2010\ntorprofil.\u00a0In\u2010vitro\u2010Studien\u00a0zeigt en\u00a0die\u00a0selektiven\u00a0Opioid\u2010Rezep toreigenschaften\u00a0mit\u00a0\nantagonistischer\u00a0Aktivit\u00e4t\u00a0am\u00a0\u03bc\u2010\u00a0und\u00a0\u03b4\u2010Rezeptor\u00a0und\u00a0mit\u00a0partiel ler\u00a0agonistischer\u00a0\nAktivit\u00e4t\u00a0am\u00a0\u03ba\u2010Rezeptor.\u00a0In\u2010vivo \u2010Studien\u00a0best\u00e4tigten\u00a0die\u00a0Verrin gerung\u00a0des\u00a0Alkohol\u2010\nkonsums.\u00a0Es\u00a0wird\u00a0angenommen,\u00a0dass\u00a0dieser\u00a0Effekt\u00a0auf\u00a0die\u00a0Modulie rung\u00a0kortiko\u2010\nmesolimbischer\u00a0 Funktionen\u00a0 zur\u00fcckgeht.\u00a0 Bisher\u00a0 gibt\u00a0 es\u00a0 keine\u00a0 Hinw e i s e \u00a0a u f \u00a0e i n \u00a0\nAbh\u00e4ngigkeits\u2010\u00a0oder\u00a0Missbrauchspo tenzial\u00a0bei\u00a0diesem\u00a0Wirkstoff\u00a0( EMA,\u00a02016). \u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nNalmefen\u00a0ist\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0Selincro\u00ae\u00a0f\u00fcr\u00a0die\u00a0Behandlun g\u00a0Erwachsener\u00a0\nmit\u00a0einer\u00a0Alkoholabh\u00e4ngigkeit\u00a0zug elassen.\u00a0Ziel\u00a0ist\u00a0die\u00a0Reduktio n\u00a0des\u00a0Alkoholkon\u2010\nsums,\u00a0wenn\u00a0sich\u00a0dieser\u00a0auf\u00a0einem\u00a0hohen\u00a0Risikoniveau\u00a0befindet:\u00a0G em\u00e4\u00df\u00a0WHO\u00a0\nDrinking\u00a0Risk\u00a0Level \u00a0gilt\u00a0dies\u00a0f\u00fcr\u00a0M\u00e4nner\u00a0mit\u00a0einem\u00a0Alkoholkonsum\u00a0>\u00a060\u00a0g\u00a0pro\u00a0Tag\u00a0\nund\u00a0>\u00a040\u00a0g\u00a0pro\u00a0Tag\u00a0f\u00fcr\u00a0Frauen.\u00a0Es\u00a0sollten\u00a0zudem\u00a0keine\u00a0k\u00f6rperlic hen\u00a0Entzugser\u2010\nscheinungen\u00a0vorliegen\u00a0und\u00a0keine\u00a0sofortige\u00a0Entgiftung\u00a0erforderli ch\u00a0sein.\u00a0Die\u00a0An\u2010\nwendung\u00a0des\u00a0Fertigarzneimittels\u00a0f indet\u00a0ausschlie\u00dflich\u00a0bei\u00a0Patie nten\u00a0statt,\u00a0deren\u00a0\nAlkoholkonsum\u00a0sich\u00a0zwei\u00a0Wochen\u00a0nach\u00a0der\u00a0initialen\u00a0Untersuchung\u00a0 weiterhin\u00a0auf\u00a0\neinem\u00a0hohen\u00a0Risikoniveau\u00a0befinde t.\u00a0Eine\u00a0Verschreibung\u00a0erfolgt\u00a0g runds\u00e4tzlich\u00a0nur\u00a0\n282\u00a0in\u00a0Verbindung\u00a0mit\u00a0kontinuierlicher\u00a0psychosozialer\u00a0Begleitung,\u00a0u m\u00a0die\u00a0Therapiead\u2010\nh\u00e4renz\u00a0und\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums\u00a0zu\u00a0unterst\u00fctzen.\u00a0Nalmef en\u00a0stellt\u00a0eine\u00a0\nTherapieoption\u00a0zur\u00a0Trinkmengenre duktion\u00a0als\u00a0intermedi\u00e4res\u00a0Ziel\u00a0 auf\u00a0dem\u00a0Weg\u00a0zur\u00a0\nAbstinenz\u00a0dar\u00a0(EMA,\u00a02016).\u00a0\nNalmefen\u00a0unterliegt\u00a0Verordnungseinschr\u00e4nkungen\u00a0gem\u00e4\u00df\u00a0Arzneimitt el\u2010Richtlinie\u00a0\n(AM\u2010RL),\u00a0Nr.\u00a02\u00a0der\u00a0Anlage\u00a0III,\u00a0und\u00a0ist\u00a0nur\u00a0dann\u00a0verordnungsf\u00e4hi g,\u00a0wenn\u00a0Patienten\u00a0\neine\u00a0Abstinenztherapie\u00a0beginnen\u00a0sollen,\u00a0eine\u00a0entsprechende\u00a0Ther apie\u00a0jedoch\u00a0nicht\u00a0\nzeitnah\u00a0zur\u00a0Verf\u00fcgung\u00a0steht.\u00a0Zur\u00a0Unterst\u00fctzung\u00a0der\u00a0Aufrechterha ltung\u00a0der\u00a0Absti\u2010\nnenz\u00a0ist\u00a0das\u00a0Arzneimittel\u00a0im\u00a0Rahmen\u00a0eines\u00a0therapeutischen\u00a0Gesam tkonzepts\u00a0mit\u00a0\nbegleitenden\u00a0psychosozialen\u00a0Ma\u00dfna hmen\u00a0f\u00fcr\u00a0drei\u00a0Monate\u00a0verordnun gsf\u00e4hig.\u00a0In\u00a0\nbegr\u00fcndeten\u00a0Ausnahmef\u00e4llen\u00a0kann\u00a0di e\u00a0Verordnung\u00a0\u00fcber\u00a0maximal\u00a0dre i\u00a0weitere\u00a0\nMonate\u00a0erfolgen\u00a0(G\u2010BA,\u00a02014;\u00a02015).\u00a0\nDas\u00a0Arzneimittel\u00a0liegt\u00a0als\u00a0Filmtablette\u00a0\u00e0\u00a018\u00a0mg\u00a0vor,\u00a0die\u00a0nach\u00a0B edarf\u00a0eingenommen\u00a0\nwird:\u00a0Sp\u00fcrt\u00a0der\u00a0Patient\u00a0das\u00a0Verlangen,\u00a0Alkohol\u00a0zu\u00a0trinken,\u00a0soll te\u00a0ein\u00a0bis\u00a0zwei\u00a0Stun\u2010\nden\u00a0vor\u00a0dem\u00a0Konsum\u00a0eine\u00a0Tablette\u00a0eingenommen\u00a0werden.\u00a0Hat\u00a0er\u00a0ber eits\u00a0Alkohol\u00a0\ngetrunken,\u00a0sollte\u00a0die\u00a0Einnahme\u00a0so\u00a0schnell\u00a0wie\u00a0m\u00f6glich\u00a0stattfind en.\u00a0Die\u00a0maximale\u00a0\nTagesdosis\u00a0liegt\u00a0bei\u00a0einer\u00a0Tablette.\u00a0Aufgrund\u00a0fehlender\u00a0Studien ergebnisse\u00a0ist\u00a0f\u00fcr\u00a0\neine\u00a0Behandlung,\u00a0die\u00a0\u00fcber\u00a0einen\u00a0 Zeitraum\u00a0von\u00a0einem\u00a0Jahr\u00a0hinausg eht,\u00a0Vorsicht\u00a0\ngeboten\u00a0(EMA,\u00a02016).\u00a0\u00a0\nEs\u00a0liegen\u00a0keine\u00a0besonderen\u00a0Lager ungsbedingungen\u00a0f\u00fcr\u00a0das\u00a0Arzneim ittel\u00a0vor.\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nAlkoholabh\u00e4ngigkeit\u00a0und\u00a0Alkoholmi ssbrauch\u00a0geh\u00f6ren\u00a0weltweit\u00a0zu\u00a0d en\u00a0h\u00e4ufigsten\u00a0\npsychischen\u00a0St\u00f6rungen.\u00a0In\u00a0der\u00a0EU \u00a0liegt\u00a0die\u00a0Pr\u00e4valenz\u00a0der\u00a0Alkhoh olabh\u00e4ngigkeit\u00a0bei\u00a0\n3,5\u00a0%\u00a0der\u00a0Bev\u00f6lkerung\u00a0zwischen\u00a015\u00a0und\u00a064\u00a0Jahren.\u00a0Bei\u00a0M\u00e4nnern\u00a0be tr\u00e4gt\u00a0die\u00a0Er\u2010\nkrankungsrate\u00a05,4\u00a0%\u00a0und\u00a0bei\u00a0Frauen\u00a01,0\u00a0%.\u00a0S\u00fcdeurop\u00e4ische\u00a0L\u00e4nder \u00a0weisen\u00a0dabei\u00a0\nniedrigere\u00a0Pr\u00e4valenzraten\u00a0auf\u00a0als\u00a0n\u00f6rdlichere\u00a0Staaten.\u00a0Einer\u00a0vo n\u00a0sieben\u00a0Todesf\u00e4l\u2010\nlen\u00a0geht\u00a0bei\u00a0M\u00e4nnern\u00a0auf\u00a0Alkoholkonsum\u00a0zur\u00fcck,\u00a0bei\u00a0Frauen\u00a0ist\u00a0e s\u00a0einer\u00a0von\u00a0drei\u2010\nzehn.\u00a0Dem\u00a0Gro\u00dfteil\u00a0der\u00a0alkoholbedingten\u00a0Todesf\u00e4lle\u00a0ging\u00a0ein\u00a0Abh \u00e4ngigkeitssyn\u2010\ndrom\u00a0voraus\u00a0(Rehm\u00a0et\u00a0al.,\u00a02013).\u00a0Jeder\u00a0schwere\u00a0Trinktag\u00a0ist\u00a0mit \u00a0einem\u00a0erh\u00f6hten\u00a0\nMorbidit\u00e4ts\u2010\u00a0und\u00a0Unfallrisiko\u00a0 verbunden\u00a0(Rehm\u00a0et\u00a0al.,\u00a02010).\u00a0\u00a0\nZu\u00a0den\u00a0diagnostischen\u00a0Kriterien\u00a0f\u00fcr\u00a0ein\u00a0Abh\u00e4ngigkeitssyndrom\u00a0na ch\u00a0ICD\u201010\u00a0geh\u00f6\u2010\nren\u00a0der\u00a0starke\u00a0Wunsch\u00a0oder\u00a0Zwang, \u00a0Alkohol\u00a0zu\u00a0konsumieren,\u00a0und\u00a0d ie\u00a0verminderte\u00a0\nKontrollf\u00e4higkeit.\u00a0Es\u00a0k\u00f6nnen\u00a0k\u00f6 rperliche\u00a0Entzugssyndrome\u00a0auftre ten,\u00a0die\u00a0Betroffe\u2010\nne\u00a0durch\u00a0einen\u00a0vermehrten\u00a0Konsum\u00a0zu\u00a0lindern\u00a0versuchen.\u00a0Auff\u00e4lli g\u00a0sind\u00a0bei\u00a0Alko\u2010\nholabh\u00e4ngigkeit\u00a0 zudem\u00a0 die\u00a0 Toleranzsteigerung\u00a0 und\u00a0 das\u00a0 au\u00dfer\u00a0 Acht \u00a0 lassen\u00a0 der\u00a0\nRegeln\u00a0eines\u00a0gesellschaftlich\u00a0\u00fcblichen\u00a0Trinkverhaltens.\u00a0Dar\u00fcber \u00a0hinaus\u00a0vernachl\u00e4s\u2010283\u00a0sigen\u00a0Betroffene\u00a0andere\u00a0Aktivit\u00e4ten\u00a0oder\u00a0Interessen\u00a0zugunsten\u00a0d es\u00a0Alkoholkon\u2010\nsums\u00a0und\u00a0setzen\u00a0ihren\u00a0Konsum\u00a0trotz\u00a0k\u00f6rperlicher,\u00a0sozialer\u00a0oder\u00a0 psychischer\u00a0Folgen\u00a0\nweiter\u00a0fort.\u00a0Ein\u00a0Abh\u00e4ngigkeitssyndrom\u00a0 wird\u00a0diagnostiziert,\u00a0wenn \u00a0im\u00a0 Laufe\u00a0des\u00a0\nletzten\u00a0Jahres\u00a0drei\u00a0oder\u00a0mehr\u00a0di eser\u00a0Kriterien\u00a0vorhanden\u00a0waren\u00a0 (Kurz,\u00a02012).\u00a0\u00a0\nNeben\u00a0den\u00a0typischen\u00a0Kontrollverl usten\u00a0liegt\u00a0bei\u00a0einem\u00a0mindesten s\u00a0ebenso\u00a0gro\u00dfen\u00a0\nAnteil\u00a0Betroffener\u00a0das\u00a0sogenannte\u00a0 \u201eSpiegeltrinken\u201c\u00a0vor.\u00a0Patient en\u00a0nehmen\u00a0dabei\u00a0\n\u00fcber\u00a0den\u00a0Tag\u00a0verteilt\u00a0gro\u00dfe\u00a0Menge n\u00a0Alkohol\u00a0zu\u00a0sich,\u00a0um\u00a0den\u00a0Blut spiegel\u00a0von\u00a0Alko\u2010\nhol\u00a0aufrecht\u00a0zu\u00a0erhalten\u00a0(Kurz,\u00a02012).\u00a0\u00a0\nR\u00fcckf\u00e4lle\u00a0werden\u00a0trotz\u00a0verschiedener\u00a0therapeutischer\u00a0Interventi onen\u00a0und\u00a0hoher\u00a0\nEigenmotivation\u00a0als\u00a0Teil\u00a0der\u00a0Erkrankung\u00a0und\u00a0auch\u00a0der\u00a0Entwicklun g\u00a0auf\u00a0dem\u00a0oft\u00a0\nlangen\u00a0Weg\u00a0aus\u00a0der\u00a0Sucht\u00a0betrachtet.\u00a0Dabei\u00a0unterscheidet\u00a0man\u00a0zw ischen\u00a0R\u00fcckf\u00e4l\u2010\nlen\u00a0(Relapses)\u00a0mit\u00a0einem\u00a0massiven\u00a0Kontrollverlust\u00a0und\u00a0Ausrutschern\u00a0( Slips),\u00a0der\u00a0\netwas\u00a0milderen\u00a0Form\u00a0des\u00a0R\u00fcckfalls\u00a0(Seitz\u00a0et\u00a0al.,\u00a02013).\u00a0Geh\u00f6rte n\u00a0fr\u00fcher\u00a0strenge\u00a0\nR\u00fcckfallregelungen\u00a0zu\u00a0einer\u00a0abstinenzorientierten\u00a0Therapie,\u00a0ent wickeln\u00a0sich\u00a0zu\u2010\nnehmend\u00a0flexiblere\u00a0Modelle\u00a0unter \u00a0dem\u00a0Begriff\u00a0der\u00a0abstinenzgest\u00fc tzten\u00a0Therapie.\u00a0\nDarunter\u00a0werden\u00a0weitestgehend\u00a0abstinente\u00a0Bedingungen\u00a0verstanden ,\u00a0die\u00a0mehr\u00a0\nMenschen\u00a0den\u00a0Eintritt\u00a0in\u00a0eine\u00a0therapeutische\u00a0Situation\u00a0erm\u00f6glic hen\u00a0sollen.\u00a0Die\u00a0\nTatsache,\u00a0dass\u00a0die\u00a0Entw\u00f6hnungstherapie\u00a0mit\u00a0dem\u00a0Ziel\u00a0der\u00a0Abstine nz\u00a0in\u00a0diesem\u00a0\nZusammenhang\u00a0 nur\u00a0 eine\u00a0 von\u00a0 verschiedenen\u00a0 Therapieoptionen\u00a0 darste llt,\u00a0 wird\u00a0\ninnerhalb\u00a0der\u00a0Suchtmedizin\u00a0aktuell\u00a0kontrovers\u00a0diskutiert.\u00a0Moder ne\u00a0Motivations\u2010\nmodelle\u00a0 und\u00a0 subjektive\u00a0 sowie\u00a0 phase nspezifische\u00a0 Ressourcen\u00a0 indiv idueller\u00a0 Be\u2010\ntroffener\u00a0stellen\u00a0dabei\u00a0die\u00a0Abstinenz\u00a0als\u00a0bestes\u00a0Mittel\u00a0und\u00a0obe rstes\u00a0Therapieziel\u00a0in\u00a0\nFrage\u00a0(Kurz,\u00a02012).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Wirksamkeit\u00a0von\u00a0Nalmefen\u00a0hinsichtlich\u00a0der\u00a0Verringerung\u00a0des\u00a0 Alkoholkonsums\u00a0\nbei\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0Alkoholabh\u00e4ngigkeit\u00a0wurde\u00a0in\u00a0drei \u00a0doppelblinden\u00a0\nrandomisierten\u00a0placebokontrollierten\u00a0Wirksamkeitsstudien\u00a0unters ucht:\u00a0ESENSE\u00a01\u00a0\n(Mann\u00a0et\u00a0al.,\u00a02013)\u00a0und\u00a0ESENSE\u00a02\u00a0(Gual\u00a0et\u00a0al.,\u00a02013)\u00a0\u00fcber\u00a0einen \u00a0Beobachtungszeit\u2010\nraum\u00a0von\u00a0sechs\u00a0Monaten\u00a0sowie\u00a0eine\u00a0weitere\u00a0Studie\u00a0\u00fcber\u00a0einen\u00a0Zei traum\u00a0von\u00a0\neinem\u00a0Jahr\u00a0(SENSE,\u00a0van\u00a0den\u00a0Brink\u00a0et\u00a0al.,\u00a02014).\u00a0In\u00a0den\u00a0sechsmon atigen\u00a0Studien\u00a0\nwurden\u00a0insgesamt\u00a0598\u00a0Patienten\u00a0(ESENSE\u00a01)\u00a0bzw.\u00a0678\u00a0Patienten\u00a0(E SENSE\u00a02)\u00a0ent\u2010\nweder\u00a0mit\u00a0Nalmefen\u00a0oder\u00a0mit\u00a0Placebo\u00a0behandelt\u00a0(Mann\u00a0et\u00a0al.,\u00a0201 3;\u00a0Gual\u00a0et\u00a0al.,\u00a0\n2013).\u00a0Die\u00a0einj\u00e4hrige\u00a0Studie\u00a0(SENSE)\u00a0umfasste\u00a0insgesamt\u00a0665\u00a0Pat ienten\u00a0(van\u00a0den\u00a0\nBrink\u00a0et\u00a0al.,\u00a02014).\u00a0Alle\u00a0Patienten\u00a0der\u00a0drei\u00a0Studien\u00a0nahmen\u00a0zus \u00e4tzlich\u00a0an\u00a0einer\u00a0\npsychosozialen\u00a0Intervention\u00a0(BRENDA)\u00a0zur\u00a0F\u00f6rderung\u00a0der\u00a0Therapie adh\u00e4renz\u00a0und\u00a0\nder\u00a0Reduktion\u00a0des\u00a0Alkoholkonsums\u00a0 teil.\u00a0Insgesamt\u00a0wurden\u00a0von\u00a0die sen\u00a01.941\u00a0Pati\u2010\nenten\u00a01.144\u00a0bei\u00a0Bedarf\u00a0mit\u00a0Nalmefen\u00a0(18\u00a0mg\u00a0pro\u00a0Tag)\u00a0behandelt\u00a0( Mann\u00a0et\u00a0al.,\u00a0\n2013;\u00a0Gual\u00a0et\u00a0al.,\u00a02013;\u00a0van\u00a0de n\u00a0Brink\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0284\u00a0Zu\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkten\u00a0der\u00a0Studien\u00a0geh\u00f6rten\u00a0die\u00a0Reduzierung \u00a0der\u00a0Tage\u00a0mit\u00a0\nstarkem\u00a0Alkoholkonsum\u00a0im\u00a0Monat\u00a0und\u00a0die\u00a0pro\u00a0Trinktag\u00a0konsumierte \u00a0Alkoholmen\u2010\nge.\u00a0Ein\u00a0schwerer\u00a0Trinktag\u00a0entsprach\u00a0in\u00a0diesen\u00a0Studien\u00a0bei\u00a0M\u00e4nne rn\u00a0einem\u00a0Konsum\u00a0\nvon\u00a0\u2265\u00a060\u00a0g\u00a0reinem\u00a0Alkohol\u00a0pro\u00a0Tag\u00a0und\u00a0bei\u00a0Frauen\u00a0\u2265\u00a040\u00a0g.\u00a0Zu\u00a0den \u00a0Ergebnissen\u00a0von\u00a0\nESENSE\u00a01\u00a0geh\u00f6rte\u00a0nach\u00a024\u00a0Wochen\u00a0ein\u00a0signifikant\u00a0h\u00f6herer\u00a0Therapi eeffekt\u00a0in\u00a0der\u00a0\nNalmefengruppe\u00a0von\u00a0im\u00a0Mittel\u00a02,3\u00a0schweren\u00a0Trinktagen\u00a0pro\u00a0Monat\u00a0 weniger\u00a0als\u00a0in\u00a0\nder\u00a0 Placebogruppe.\u00a0 Zus\u00e4tzlich\u00a0 lag\u00a0 in\u00a0 der\u00a0 Nalmefengruppe\u00a0 eine\u00a0 ge gen\u00fcber\u00a0 der\u00a0\nPlacebogruppe\u00a0signifikant\u00a0gr\u00f6\u00dfer e\u00a0Trinkmengenreduktion\u00a0um\u00a0im\u00a0Mi ttel\u00a011\u00a0g\u00a0pro\u00a0\nTag\u00a0vor\u00a0(Mann\u00a0et\u00a0al.,\u00a02013).\u00a0Nach\u00a0Ergebnissen\u00a0der\u00a0Studie\u00a0ESENSE \u00a02\u00a0traten\u00a0unter\u00a0\nNalmefen\u00a01,7\u00a0schwere\u00a0Trinktage\u00a0p ro\u00a0Monat\u00a0weniger\u00a0auf\u00a0(Gual\u00a0et\u00a0a l.,\u00a02013).\u00a0\u00a0\nDiesen\u00a0Studien\u00a0lag\u00a0zum\u00a0Teil\u00a0ein\u00a0unspezifischer\u00a0Effekt\u00a0zugrunde, \u00a0da\u00a0einige\u00a0Patienten\u00a0\nmit\u00a0einem\u00a0hohen\u00a0Risikolevel\u00a0ihren\u00a0Alkoholkonsum\u00a0bereits\u00a0zwische n\u00a0Screening\u00a0und\u00a0\nRandomisierung,\u00a0also\u00a0in\u00a0Erwartung\u00a0der\u00a0Studienteilnahme,\u00a0reduzie rten.\u00a0 Bei\u00a0der\u00a0\nRandomisierung\u00a0war\u00a0ihr\u00a0Alkoholkonsum\u00a0bereits\u00a0so\u00a0niedrig,\u00a0dass\u00a0w enig\u00a0Spielraum\u00a0\nf\u00fcr\u00a0eine\u00a0m\u00f6gliche\u00a0Verbesserung\u00a0bestand.\u00a0Deshalb\u00a0wurden\u00a0post\u00a0hoc \u00a0solche\u00a0Patien\u2010\nten\u00a0als\u00a0Zielgruppe\u00a0definiert,\u00a0die\u00a0bei\u00a0Randomisierung\u00a0weiterhin\u00a0 einen\u00a0hohen\u00a0oder\u00a0\nsehr\u00a0Alkoholkonsum\u00a0aufwiesen.\u00a0Aufgrunddessen\u00a0fiel\u00a0der\u00a0Behandlun gseffekt\u00a0in\u00a0der\u00a0\npost\u00a0hoc\u00a0Population\u00a0gegen\u00fcber\u00a0den\u00a0oben\u00a0angegebenen\u00a0Ergebnissen\u00a0 der\u00a0Gesamt\u2010\npopulation\u00a0gr\u00f6\u00dfer\u00a0aus.\u00a0In\u00a0beiden\u00a0Studien\u00a0waren\u00a0die\u00a0Abbruchraten \u00a0hoch,\u00a0sie\u00a0lagen\u00a0\nzum\u00a0Teil\u00a0bei\u00a050\u00a0%\u00a0(Mann\u00a0et\u00a0al. ,\u00a02013;\u00a0Gual\u00a0et\u00a0al.,\u00a02013;\u00a0EMA,\u00a02 016).\u00a0\nIn\u00a0der\u00a0einj\u00e4hrigen\u00a0Studie\u00a0(SENSE)\u00a0fehlten\u00a0nach\u00a0einem\u00a0Zeitraum\u00a0v on\u00a0sechs\u00a0Monaten\u00a0\nsignifikante\u00a0Unterschiede\u00a0zwisch en\u00a0den\u00a0Behandlungsgruppen.\u00a0Nach \u00a0einem\u00a0Jahr\u00a0\ntraten\u00a0unter\u00a0Nalmefen\u00a0gegen\u00fcber\u00a0 der\u00a0Placebobehandlung\u00a0jedoch\u00a0pr o\u00a0Monat\u00a01,6\u00a0\nschwere\u00a0Trinktage\u00a0weniger\u00a0auf\u00a0und\u00a0 es\u00a0verringerte\u00a0sich\u00a0die\u00a0Alkoh olmenge\u00a0um\u00a06,5\u00a0g\u00a0\npro\u00a0Tag\u00a0(van\u00a0den\u00a0Brink\u00a0et\u00a0al.,\u00a02014).\u00a0Allerdings\u00a0reduzierte\u00a0sic h\u00a0auch\u00a0in\u00a0dieser\u00a0Studie\u00a0\ndie\u00a0Anzahl\u00a0der\u00a0Patienten\u00a0mit\u00a0einem\u00a0Trinkverhalten\u00a0auf\u00a0hohem\u00a0Ris ikolevel\u00a0in\u00a0Erwar\u2010\ntung\u00a0der\u00a0Studienteilnahme,\u00a0zudem\u00a0 lagen\u00a0hohe\u00a0Abbruchraten\u00a0vor.\u00a0E rgebnisse\u00a0der\u00a0\nAnalysen\u00a0der\u00a0post\u00a0hoc\u00a0Zielpopulation\u00a0erreichten\u00a0auch\u00a0hier\u00a0h\u00f6her e\u00a0Werte\u00a0von\u00a0bei\u2010\nspielsweise\u00a03,6\u00a0schweren\u00a0Trinktagen\u00a0weniger\u00a0unter\u00a0Nalmefen\u00a0als\u00a0 in\u00a0der\u00a0undiffe\u2010\nrenzierten\u00a0Zielgruppe\u00a0(van\u00a0den\u00a0 Brink\u00a0et\u00a0al.,\u00a02014;\u00a0EMA,\u00a02016).\u00a0 \u00a0\nDie\u00a0Verordnungsf\u00e4higkeit\u00a0laut\u00a0AM\u2010RL\u00a0bezieht\u00a0sich\u00a0auf\u00a0drei\u00a0bis\u00a0s echs\u00a0Monate\u00a0und\u00a0\ngem\u00e4\u00df\u00a0Indikation\u00a0lediglich\u00a0auf\u00a0die\u00a0Trinkmengenreduktion\u00a0auf\u00a0dem \u00a0Weg\u00a0zur\u00a0Absti\u2010\nnenz.\u00a0 Von\u00a0 der\u00a0 Arzneimittelkommission\u00a0 der\u00a0 deutschen\u00a0 \u00c4rzteschaft\u00a0 (Akd\u00c4)\u00a0wird\u00a0\nbezweifelt,\u00a0ob\u00a0eine\u00a0drei\u2010\u00a0bis\u00a0se chsmonatige\u00a0Verringerung\u00a0der\u00a0Tr inkmenge\u00a0und\u00a0\u2010\nh\u00e4ufigkeit\u00a0die\u00a0Wahrscheinlichkeit\u00a0erh\u00f6ht,\u00a0eine\u00a0Abstinenz\u00a0zu\u00a0err eichen.\u00a0Aufgrund\u00a0\nder\u00a0 breiten\u00a0 Ausschlusskriterien\u00a0 der\u00a0 Studien\u00a0 best\u00fcnde\u00a0 au\u00dferdem\u00a0 e ine\u00a0 einge\u2010\nschr\u00e4nkte\u00a0\u00dcbertragbarkeit\u00a0auf\u00a0di e\u00a0reale\u00a0Versorgungssituation\u00a0(A Kd\u00c4,\u00a02014).\u00a0285\u00a0Zu\u00a0den\u00a0h\u00e4ufigsten\u00a0UAE\u00a0geh\u00f6ren\u00a0Schwindel,\u00a0Kopfschmerzen,\u00a0\u00dcbelkei t\u00a0und\u00a0Schlaflo\u2010\nsigkeit,\u00a0die\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0in\u00a0der\u00a0Mehrzahl\u00a0leicht\u00a0b is\u00a0mittelschwer\u00a0aus\u2010\ngepr\u00e4gt\u00a0waren\u00a0und\u00a0im\u00a0Laufe\u00a0der\u00a0Behandlung\u00a0abnahmen.\u00a0Unter\u00a0Nalme fen\u00a0traten\u00a0\nzudem\u00a0psychiatrische\u00a0St\u00f6rungen\u00a0wie\u00a0Verwirrtheit\u00a0auf,\u00a0die\u00a0ebenfa lls\u00a0im\u00a0Verlauf\u00a0der\u00a0\nBehandlung\u00a0abklangen.\u00a0Es\u00a0ist\u00a0Vorsicht\u00a0geboten,\u00a0wenn\u00a0das\u00a0Arzneim ittel\u00a0zusammen\u00a0\nmit\u00a0opioidhaltigen\u00a0Arzneimitteln\u00a0eingenommen\u00a0wird,\u00a0aktuelle\u00a0psy chiatrische\u00a0Be\u2010\ngleiterkrankungen,\u00a0leichte\u00a0bis\u00a0m ittelschwere\u00a0Leber\u2010\u00a0oder\u00a0Nieren funktionsst\u00f6run\u2010\ngen\u00a0vorliegen\u00a0oder\u00a0Krampfanf\u00e4lle \u00a0in\u00a0der\u00a0Krankengeschichte\u00a0auftr aten.\u00a0Zu\u00a0dem\u00a0ist\u00a0\nVorsicht\u00a0bei\u00a0der\u00a0Anwendung\u00a0bei\u00a0Patienten\u00a0\u00fcber\u00a065\u00a0Jahren\u00a0geboten .\u00a0\u00a0\nStudien\u00a0in\u00a0denen\u00a0Nalmefen\u00a0mit\u00a0einem\u00a0anderen\u00a0Wirkstoff\u00a0vergliche n\u00a0wurde,\u00a0liegen\u00a0\nbisher\u00a0nicht\u00a0vor\u00a0(IQWiG,\u00a02014).\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nIn\u00a0der\u00a0Behandlung\u00a0alkoholbezogener\u00a0St\u00f6rungen\u00a0soll\u00a0sich\u00a0gem\u00e4\u00df\u00a0de m\u00a0Versorgungs\u2010\nalgorithmus\u00a0der\u00a0Arbeitsgemeinschaft\u00a0der\u00a0Wissenschaftlichen\u00a0Medi zinischen\u00a0Fach\u2010\ngesellschaften\u00a0 (AWMF)\u2010Leitlinie \u00a0 nach\u00a0 einem\u00a0 qualifzierten\u00a0 Entzug \u00a0n a h t l o s \u00a0e i n e \u00a0\nPostakutbehandlung\u00a0anschlie\u00dfen.\u00a0Als\u00a0prim\u00e4res\u00a0Therapieziel\u00a0gilt\u00a0 dabei\u00a0die\u00a0dauer\u2010\nhafte\u00a0Abstinenz,\u00a0als\u00a0sekund\u00e4res\u00a0 Ziel\u00a0die\u00a0Alkoholreduktion\u00a0(AWMF ,\u00a02016).\u00a0\u00a0\nIn\u00a0der\u00a0Postakutbehandlung\u00a0sollten\u00a0gem\u00e4\u00df\u00a0AWMF\u2010Leitlinie\u00a0eine\u00a0Ent w\u00f6hnungsbe\u2010\nhandlung,\u00a0die\u00a0medikament\u00f6se\u00a0R\u00fcckfallprophylaxe\u00a0oder\u00a0andere\u00a0Form en\u00a0der\u00a0Posta\u2010\nkutbehandlung\u00a0angeboten\u00a0werden.\u00a0Zu\u00a0anderen\u00a0Formen\u00a0der\u00a0Postakutb ehandlung\u00a0\ngeh\u00f6ren\u00a0 die\u00a0 \u00fcbliche\u00a0 vertrags\u00e4rztliche\u00a0 Versorgung\u00a0 beziehungsweis e\u00a0 ambulante\u00a0\nPsychotherapie\u00a0und\u00a0die\u00a0ambulante\u00a0oder\u00a0station\u00e4re\u00a0psychiatrische \u00a0Weiterbehand\u2010\nlung.\u00a0Die\u00a0Wahl\u00a0des\u00a0geeigneten\u00a0Se ttings\u00a0f\u00fcr\u00a0die\u00a0Entw\u00f6hnungsbehan dlung\u00a0\u2013\u00a0ambu\u2010\nlant,\u00a0ganzt\u00e4gig\u00a0ambulant,\u00a0teilst ation\u00e4r\u00a0oder\u00a0station\u00e4r\u00a0\u2013\u00a0sowie\u00a0 die\u00a0angemessene\u00a0\nBehandlungsdauer\u00a0und\u00a0\u2010intensit\u00e4t\u00a0 f\u00e4llt\u00a0dabei\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0ve rschiedener\u00a0Fakto\u2010\nren\u00a0wie\u00a0dem\u00a0Schweregrad,\u00a0Alter\u00a0o der\u00a0der\u00a0Anwesenheit\u00a0komorbider\u00a0 St\u00f6rungen\u00a0aus.\u00a0\nVerhaltenstherapie,\u00a0 Kontingenzma nagement\u00a0 oder\u00a0 angeleitete\u00a0 Grupp en\u00a0 stellen\u00a0\neinige\u00a0der\u00a0verschiedenen\u00a0Interve ntionsformen\u00a0der\u00a0Entw\u00f6hnungsbeh andlung\u00a0dar.\u00a0\nIn\u00a0 der\u00a0 medikament\u00f6sen\u00a0 R\u00fcckfallprophylaxe\u00a0 kann\u00a0 zus\u00e4tzlich\u00a0 zur\u00a0 ps ychosozialen\u00a0\nBeratung\u00a0 eine\u00a0 Pharmakotherapie\u00a0 mit\u00a0 Acomprosat,\u00a0 Naltrexon,\u00a0 Nalme fen\u00a0 oder\u00a0\nDisulfiram\u00a0stattfinden.\u00a0Dabei\u00a0soll\u00a0\u00fcber\u00a0die\u00a0m\u00f6glichen\u00a0Risiken\u00a0d er\u00a0pharmakologi\u2010\nschen\u00a0Behandlung\u00a0aufgekl\u00e4rt\u00a0werden .\u00a0Erg\u00e4nzend\u00a0zu\u00a0den\u00a0Empfehlung en\u00a0einzelner\u00a0\nInterventionen\u00a0wird\u00a0die\u00a0Kombination\u00a0verschiedener\u00a0Interventions formen\u00a0als\u00a0Kom\u2010\nplexbehandlung\u00a0im\u00a0multiprofession ellen\u00a0Setting\u00a0empfohlen\u00a0(AWMF, \u00a02016).\u00a0Gem\u00e4\u00df\u00a0\nder\u00a0Leitlinie\u00a0des\u00a0 National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence \u00a0(NICE)\u00a0kann\u00a0\nNalmefen\u00a0bei\u00a0Alkhoholabh\u00e4ngigkeit\u00a0zur\u00a0Trinkmengenreduktion\u00a0eing esetzt\u00a0werden,\u00a0\nsofern\u00a0eine\u00a0Indikation\u00a0entsprech end\u00a0der\u00a0Zulassung\u00a0vorliegt\u00a0(NIC E,\u00a02014).\u00a0286\u00a0W\u00e4hrend\u00a0Naltrexon\u00a0oder\u00a0auch\u00a0Acamprosat\u00a0eingesetzt\u00a0werden,\u00a0um\u00a0da s\u00a0R\u00fcckfallrisi\u2010\nko\u00a0nach\u00a0einem\u00a0Entzug\u00a0zu\u00a0senken\u00a0und\u00a0die\u00a0Erhaltung\u00a0der\u00a0Abstinenz\u00a0 zu\u00a0unterst\u00fctzen,\u00a0\ngilt\u00a0Nalmefen\u00a0als\u00a0Therapieoption,\u00a0wenn\u00a0das\u00a0Ziel\u00a0die\u00a0Trinkmengen reduktion\u00a0ist.\u00a0Es\u00a0\nfindet\u00a0demnach\u00a0in\u00a0einem\u00a0anderen\u00a0Behandlungskonzept\u00a0Anwendung\u00a0al s\u00a0die\u00a0bislang\u00a0\nverf\u00fcgbaren\u00a0Arzneimittel\u00a0Naltrexon\u00a0oder\u00a0Acamprosat.\u00a0F\u00fcr\u00a0Nalmefe n\u00a0spricht\u00a0die\u00a0\naktuelle\u00a0Fassung\u00a0der\u00a0AWMF\u2010Leitlinie\u00a0zurzeit\u00a0eine\u00a0\u201eKann\u201c\u2010Empfehl ung\u00a0f\u00fcr\u00a0die\u00a0Be\u2010\nhandlung\u00a0der\u00a0Alkoholabh\u00e4ngigkeit\u00a0m it\u00a0dem\u00a0Ziel\u00a0einer\u00a0Trinkmengen reduktion\u00a0aus,\u00a0\nau\u00dferhalb\u00a0der\u00a0 station\u00e4ren\u00a0 Entw\u00f6hnung,\u00a0die\u00a0im\u00a0Rahmen\u00a0eines\u00a0Gesam tbehand\u2010\nlungsplans\u00a0stattfinden\u00a0sollte\u00a0(AWMF,\u00a02016).\u00a0\nLaut\u00a0Deutscher\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Psychiatrie\u00a0und\u00a0Psychotherapie, \u00a0Psychosomatik\u00a0\nund\u00a0Nervenheilkunde\u00a0(DGPPN)\u00a0zielt\u00a0die\u00a0Trinkmengenreduktion\u00a0bei\u00a0 Alkoholabh\u00e4n\u2010\ngigkeit\u00a0 darauf\u00a0 ab,\u00a0 Patienten\u00a0 in\u00a0 fr\u00fcheren\u00a0 Stadien\u00a0 der\u00a0 Abh\u00e4ngigke i t \u00a0d e n \u00a0e r s t e n \u00a0\nSchritt\u00a0in\u00a0einen\u00a0therapeutischen\u00a0Prozess\u00a0zu\u00a0erm\u00f6glichen\u00a0(G\u2010BA,\u00a0 2015).\u00a0Ein\u00a0wesent\u2010\nlicher\u00a0Grund\u00a0f\u00fcr\u00a0eine\u00a0Nicht\u2010Inanspruchnahme\u00a0einer\u00a0Therapie\u00a0war\u00a0 nach\u00a0Angaben\u00a0\nBetroffener,\u00a0dass\u00a0sie\u00a0noch\u00a0nicht\u00a0bereit\u00a0f\u00fcr\u00a0eine\u00a0abstinenzorien tierte\u00a0Therapie\u00a0wa\u2010\nren\u00a0(Samsha,\u00a02013).\u00a0Aus\u00a0Sicht\u00a0der\u00a0Akd\u00c4\u00a0besteht\u00a0der\u00a0h\u00e4ufigste\u00a0Be darf\u00a0f\u00fcr\u00a0eine\u00a0Be\u2010\nhandlung\u00a0mit\u00a0Nalmefen\u00a0gerade\u00a0bei\u00a0den\u00a0Patienten,\u00a0die\u00a0trotz\u00a0mehrf acher\u00a0Therapie\u2010\nversuche\u00a0keine\u00a0Abstinenz\u00a0erreicht\u00a0haben\u00a0(Akd\u00c4,\u00a02014). \u00a0Vor\u00a0dem\u00a0Hintergrund\u00a0der\u00a0\ninternationalen\u00a0Kritik,\u00a0wie\u00a0etwa\u00a0 hinsichtlich\u00a0der\u00a0fehlenden\u00a0dir ekten\u00a0Vergleichsstu\u2010\ndien\u00a0(Head\u00a0to\u00a0Head )\u00a0(Spence,\u00a02014;\u00a0Wise,\u00a02014),\u00a0sollte\u00a0Nalmefen\u00a0bei\u00a0vorliegender\u00a0\nIndikation\u00a0als\u00a0Therapieversuch\u00a0im\u00a0Rahmen\u00a0von\u00a0weiteren\u00a0unterst\u00fct zenden\u00a0psycho\u2010\nsozialen\u00a0Ma\u00dfnahmen\u00a0Anwendung\u00a0finden.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V \u00a0\nIm\u00a0November\u00a02014\u00a0ver\u00f6ffentlichte\u00a0das\u00a0IQWiG\u00a0ein\u00a0Gutachten\u00a0zur\u00a0Nu tzenbewertung\u00a0\nvon\u00a0Nalmefen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0Als\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichstherap ie\u00a0(zVT)\u00a0hat\u00a0der\u00a0\nG\u2010BA\u00a0Naltrexon\u00a0zur\u00a0Unterst\u00fctzung\u00a0der\u00a0Reduktion\u00a0des\u00a0Alkoholismus \u00a0(gem\u00e4\u00df\u00a0Zulas\u2010\nsung\u00a0in\u00a0Verbindung\u00a0mit\u00a0psychosozialer\u00a0Unterst\u00fctzung)\u00a0festgelegt .\u00a0Nach\u00a0Ma\u00dfgaben\u00a0\nder\u00a0Verordungseinschr\u00e4nkung\u00a0in\u00a0An lage\u00a0III\u00a0Nr.\u00a02\u00a0der\u00a0AM\u2010RL\u00a0ist\u00a0N altrexon\u00a0erstat\u2010\ntungsf\u00e4hig,\u00a0 wenn\u00a0 andere\u00a0 Ma\u00dfnahmen\u00a0 im\u00a0 Sinne\u00a0 einer\u00a0 Abstinenzthera pie\u00a0 nicht\u00a0\nrechtzeitig\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen .\u00a0Dies\u00a0gilt\u00a0allerdings\u00a0nur\u00a0f\u00fcr\u00a0 drei\u00a0Monate\u00a0und\u00a0in\u00a0\nAusnahmef\u00e4llen\u00a0f\u00fcr\u00a0maximal\u00a0drei\u00a0w eitere\u00a0Monate\u00a0(IQWiG,\u00a02014).\u00a0\u00a0\nNalmefen\u00a0ist\u00a0aufgrund\u00a0der\u00a0Indika tion\u00a0(s.o.)\u00a0ebenfalls\u00a0lediglich \u00a0zur\u00a0Unterst\u00fctzung\u00a0\nder\u00a0Aufrechterhaltung\u00a0der\u00a0Abstinenz\u00a0bei\u00a0alkoholkranken\u00a0Patiente n\u00a0im\u00a0Rahmen\u00a0\neines\u00a0 therapeutischen\u00a0 Gesamtkonz epts\u00a0 mit\u00a0 begleitenden\u00a0 psychosoz ialen\u00a0 Ma\u00df\u2010\nnahmen\u00a0\u00fcber\u00a0drei\u00a0Monate\u00a0verordnungsf\u00e4hig\u00a0(Nr.\u00a02\u00a0der\u00a0Anlage\u00a0III\u00a0 AM\u2010RL).\u00a0Dem\u2010\nnach\u00a0erfolgte\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Nalmefen\u00a0gegen\u00fcber\u00a0Naltre xon\u00a0jeweils\u00a0in\u00a0\nVerbindung\u00a0mit\u00a0psychosozialer\u00a0Unterst\u00fctzung.\u00a0Als\u00a0Bewertungsgrun dlage\u00a0dienten\u00a0\npatientenrelevante\u00a0Endpunkte\u00a0randomisierter\u00a0kontrollierter\u00a0Stud ien\u00a0(RCTs),\u00a0die\u00a0287\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mindestens\u00a0zw\u00f6lf\u00a0Wochen\u00a0umfassten.\u00a0Hinsichtl ich\u00a0der\u00a0Rele\u2010\nvanz\u00a0f\u00fcr\u00a0Versicherte\u00a0der\u00a0Gesetzlichen\u00a0Krankenversicherung\u00a0(GKV) ,\u00a0waren\u00a0dabei\u00a0vor\u00a0\nallem\u00a0 die\u00a0 Zeitpunkte\u00a0 zwischen\u00a0 zw\u00f6lf\u00a0 und\u00a0 24\u00a0 Wochen\u00a0 von\u00a0 Bedeutung \u00a0(I Q W i G , \u00a0\n2014).\u00a0\nAufgrund\u00a0fehlender\u00a0Studien,\u00a0die\u00a0einen\u00a0direkten\u00a0Vergleich\u00a0von\u00a0Na lmefen\u00a0gegen\u00fcber\u00a0\nNaltrexon\u00a0zulassen,\u00a0legte\u00a0der\u00a0Hersteller\u00a0einen\u00a0adjustierten\u00a0ind irekten\u00a0Vergleich\u00a0\nvor.\u00a0Dazu\u00a0wurden\u00a0insgesamt\u00a0elf\u00a0Studien\u00a0eingeschlossen\u00a0und\u00a0Place bo\u00a0als\u00a0Br\u00fccken\u2010\nkomparator\u00a0verwendet.\u00a0Das\u00a0IQWiG\u00a0s tufte\u00a0diesen\u00a0Vergleich\u00a0aber\u00a0al s\u00a0nicht\u00a0geeignet\u00a0\nein,\u00a0um\u00a0einen\u00a0Zusatznutzen\u00a0von\u00a0Nalmefen\u00a0gegen\u00fcber\u00a0Naltrexon\u00a0abz uleiten.\u00a0Insge\u2010\nsamt\u00a0lagen\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0f\u00fcr\u00a0diese\u00a0Bewertung\u00a0vor.\u00a0Sech s\u00a0von\u00a0sieben\u00a0\nStudien\u00a0zu\u00a0Naltrexon\u00a0waren\u00a0au\u00dferdem\u00a0nicht\u00a0geeignet,\u00a0um\u00a0die\u00a0Frag estellung\u00a0zu\u00a0\nbeantworten,\u00a0da\u00a0die\u00a0eingeschlossenen\u00a0Patienten\u00a0bereits\u00a0abstinen t\u00a0waren\u00a0(IQWiG,\u00a0\n2014).\u00a0\u00a0\nDer\u00a0Einsch\u00e4tzung\u00a0des\u00a0IQWiG,\u00a0dass\u00a0ein\u00a0 Zusatznutzen \u00a0von\u00a0Nalmefen\u00a0gegen\u00fcber\u00a0der\u00a0\nzVT\u00a0Naltrexon\u00a0 nicht\u00a0belegt \u00a0ist,\u00a0schloss\u00a0sich\u00a0der\u00a0G\u2010BA\u00a0im\u00a0Februar\u00a02015\u00a0an\u00a0(G\u2010BA,\u00a0\n2015).\u00a0\nVersorgungsanalysen\u00a0\nMit\u00a0der\u00a0Markteinf\u00fchrung\u00a0von\u00a0Nalmefen\u00a0im\u00a0September\u00a02014\u00a0startete n\u00a0die\u00a0Verord\u2010\nnungszahlen\u00a0im\u00a0Oktober\u00a0bereits\u00a0auf\u00a0einem\u00a0vergleichsweise\u00a0hohen\u00a0 Niveau\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0weiteren\u00a0Entwicklung\u00a0bis\u00a0zum\u00a0Dezember\u00a02015.\u00a0Das\u00a0im\u00a0Nov ember\u00a02014\u00a0\nver\u00f6ffentlichte\u00a0Gutachten\u00a0des\u00a0IQWiG\u00a0zur\u00a0Nutzenbewertung\u00a0von\u00a0Nal mefen\u00a0nach\u00a0\u00a7\u00a0\n35a\u00a0SGB\u00a0V,\u00a0in\u00a0dem\u00a0ein\u00a0Zusatznutzen\u00a0von\u00a0Nalmefen\u00a0als\u00a0nicht\u00a0beleg t\u00a0angesehen\u00a0\nwurde,\u00a0spiegelte\u00a0sich\u00a0auch\u00a0in\u00a0einem\u00a0ersten\u00a0R\u00fcckgang\u00a0der\u00a0Verordn ungszahlen\u00a0wi\u2010\nder.\u00a0Dieser\u00a0Trend\u00a0setzte\u00a0sich\u00a0nach\u00a0der\u00a0Beschlussfassung\u00a0des\u00a0G\u2010B A\u00a0im\u00a0Februar\u00a02015\u00a0\nund\u00a0seinem\u00a0Inkrafttreten\u00a0im\u00a0M\u00e4rz\u00a0\u2013\u00a0wenn\u00a0auch\u00a0mit\u00a0gewissen\u00a0Schwa nkungen\u00a0\u2010\u00a0fort.\u00a0\nZumeist\u00a0bekamen\u00a0M\u00e4nner\u00a0zwischen\u00a050\u00a0und\u00a059\u00a0Jahren\u00a0das\u00a0Nalmefen\u2010h altige\u00a0Mittel\u00a0\nverordnet,\u00a0was\u00a0mit\u00a0der\u00a0h\u00f6heren\u00a0Pr\u00e4valenz\u00a0der\u00a0Alkoholabh\u00e4ngigkei t\u00a0bei\u00a0M\u00e4nnern\u00a0\nerkl\u00e4rt\u00a0werden\u00a0kann.\u00a0\n\u00a0 \u00a0288\u00a0Abbildung\u00a04.31:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Nalmefen\u00a0je\u00a0Monat\u00a0 nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.32:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Nalmefen \u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\n289\u00a0Quellen\u00a0\nAkd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2014). \u00a0Stellungnahme\u00a0zu\u00a0Namelfen,\u00a0Nr.\u00a025,\u00a0A14\u201030,\u00a0Version\u00a01.0,\u00a0Stand\u00a0\nder\u00a0Information:\u00a0\u00a0November\u00a02014.\u00a0www.akdae.de/Stellungnahmen/AM NOG/A\u2010Z/Nalmefen/Nalmefen.pdf\u00a0,\u00a0letzter\u00a0\nZugriff:\u00a029.03.2016.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014).\u00a0Nalmefen\u00a0(Selincro)\u00a0bei\u00a0Alkohola bh\u00e4ngigkeit.\u00a0a\u2010t\u00a045:\u00a081\u20103\u00a0\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften,\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Psychiatrie\u00a0und\u00a0\nPsychotherapie,\u00a0Psychosomatik\u00a0und\u00a0Nervenheilkunde\u00a0(DGPPN),\u00a0Deut sche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Suchtforschung\u00a0und\u00a0\nSuchttherapie\u00a0e.V.\u00a0(DG\u2010Sucht)\u00a0(Hrsg.)\u00a0(2016).\u00a0S3\u2010Leitlinie\u00a0\u201eScr eening,\u00a0Diagnose\u00a0und\u00a0Behandlung\u00a0alkoholbezogener\u00a0\nSt\u00f6rungen\u201c.\u00a0AWMF\u2010Register\u00a0Nr.\u00a0076\u2010001,\u00a0Stand\u00a0der\u00a0Information:\u00a0F ebruar\u00a02016.\u00a0\nwww.awmf.org/uploads/tx_szleitlinien/076\u2010001l_S3\u2010Leitlinie_Alko hol_2016\u201002.pdf,\u00a0letzter\u00a0Zugriff:\u00a029.03.2016.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Zusammenfassung\u00a0der\u00a0Mer kmale\u00a0des\u00a0Arzneimittels\u00a0Selincro.\u00a0Stand\u00a0der\u00a0Information:\u00a0\nM\u00e4rz\u00a02016.\u00a0www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/002583/human_med_001620.jsp&m\nid=WC0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a022.03.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Pfaffrath\u00a0D\u00a0(Hrsg.).\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a0Berlin\u00a0\nHeidelberg:\u00a0Springer.\u00a0S.\u00a037\u2010198.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie:\u00a0Anlage\u00a0III\u00a0Nr.\u00a02\u00a0\u2013\u00a0Alkoho lentw\u00f6hnungsmittel,\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a0\n2014.\u00a0https://www.g\u2010ba.de/downlo ads/40\u2010268\u20102702/2014\u201002\u201020_AM\u2010R L\u2010III_Nr2\u2010\nAlkoholentwoehnungsmittel_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a022.03.2017. \u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Zusammenfassende\u00a0Dok umentation\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0\n(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0A rzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0\nSGB\u00a0V\u00a0\u2013\u00a0Nalmefen\u00a0vom\u00a019.\u00a0Februar\u00a02015,\u00a0Stand\u00a0der\u00a0Information:\u00a0M \u00e4rz\u00a02015.\u00a0https://www.g\u2010ba.de/downloads/40\u2010\n268\u20103178/2015\u201002\u201019_AM\u2010RL\u2010XII_Nalmefen_2014\u201009\u201001\u2010D\u2010127_ZD.pdf\u00a0 ,\u00a0letzter\u00a0Zugriff:\u00a006.04.2017.\u00a0\nGual\u00a0A,\u00a0He\u00a0Y,\u00a0Torup\u00a0L,\u00a0van\u00a0den\u00a0Brink\u00a0W,\u00a0Mann\u00a0K,\u00a0(ESENSE\u00a02\u00a0study \u00a0group)\u00a0(2013).\u00a0A\u00a0randomized,\u00a0double\u00a0blind,\u00a0placebo\u2010controlled. \u00a0\nEfficacy\u00a0study\u00a0of\u00a0nalmefene,\u00a0as\u2010needed\u2010use,\u00a0in\u00a0patients\u00a0with\u00a0al cohol\u00a0dependence.\u00a0European\u00a0\nNeuropsychopharmacology\u00a023:\u00a01432\u20101442.\u00a0\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2014).\u00a0IQWiG\u2010Berichte\u00a0Nr.\u00a0257.\u00a0Nalmefen\u00a0\u2013\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V,\u00a0Dossierbewertung\u00a0A14\u201030,\u00a0Ver sion\u00a01.0.\u00a0Stand\u00a0der\u00a0Information:\u00a0November\u00a0\n2014.\u00a0https://www.g\u2010ba.de/download s/92\u2010975\u2010616/2014\u201012\u201001_Nalme fen_Nutzenbewertung_IQWiG.pdf\u00a0,\u00a0letzter\u00a0\nZugriff:\u00a022.03.2017.\u00a0\nKurz\u00a0M\u00a0(2012).\u00a0St\u00f6rungen\u00a0durch\u00a0psychotrope\u00a0Substanzen.\u00a0In:\u00a0Flei schhacker\u00a0WW,\u00a0Hinterhuber\u00a0H\u00a0(Hrsg.).\u00a0Lehrbuch\u00a0Psychiatrie.\u00a0Wien \u00a0\nNew\u00a0York:\u00a0Springer,\u00a051\u2010110.\u00a0\nMann\u00a0K,\u00a0Bladstr\u00f6m\u00a0A,\u00a0Torup\u00a0L,\u00a0Gual\u00a0A,\u00a0van\u00a0den\u00a0Brink\u00a0W\u00a0(2013).\u00a0E xtending\u00a0the\u00a0treatment\u00a0options\u00a0in\u00a0alcohol\u00a0dependence:\u00a0A\u00a0\nrandomized\u00a0controlled\u00a0study\u00a0of\u00a0as\u2010needed\u00a0Nalmefene.\u00a0Biol\u00a0Psychi atry\u00a073:\u00a0706\u2010713.\u00a0\nNaudet\u00a0F,\u00a0Palpacuer\u00a0C,\u00a0Boussageon\u00a0R,\u00a0Laviolle\u00a0B\u00a0(2016).\u00a0Evaluat ion\u00a0in\u00a0alcolohl\u00a0use\u00a0disorders\u00a0\u2013\u00a0insights\u00a0from\u00a0the\u00a0nalmefene\u00a0\nexperience.\u00a0BMC\u00a0Medicine\u00a014:119.\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2014) .\u00a0Nalmefene\u00a0for\u00a0reducing\u00a0alcohol\u00a0consumption\u00a0in\u00a0people\u00a0with\u00a0\nalcohol\u00a0dependence,\u00a0Technology\u00a0appraisal\u00a0guidance\u00a0[TA325],\u00a0Stan d\u00a0der\u00a0Information:\u00a0November\u00a02014.\u00a0\nhttps://www.nice.org.uk/guidance/TA325/chapter/1\u2010Guidance\u00a0,\u00a0let zter\u00a0Zugriff:\u00a002.04.2017\u00a0\u00a0\nPrescrire\u00a0International\u00a0(2014).\u00a0Namelfene.\u00a023\u00a0(150):\u00a0151\u2010152.\u00a0290\u00a0PZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Nalemfen.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0\nwww.pharmazeutische\u2010zeitung.de/?id=54683\u00a0,\u00a0letzter\u00a0Zugriff:\u00a010. 04.2017.\u00a0\u00a0\u00a0\nRehm\u00a0J,\u00a0Baliunas\u00a0D,\u00a0Borges\u00a0GLG,\u00a0Graham\u00a0K,\u00a0Irving\u00a0H,\u00a0Kehoe\u00a0T,\u00a0et \u00a0al.\u00a0(2010).\u00a0The\u00a0relation\u00a0between\u00a0different\u00a0dimensions\u00a0of\u00a0alcoh ol\u00a0\ncomsumption\u00a0and\u00a0burden\u00a0of\u00a0disea se\u00a0\u2013\u00a0an\u00a0overview.\u00a0Addiction\u00a0105( 5):\u00a0817\u2010843.\u00a0\nRehm\u00a0J,\u00a0Shield\u00a0KD,\u00a0Gme\u00a0G,\u00a0Rehm\u00a0MX,\u00a0Frick\u00a0U\u00a0(2013).\u00a0Modeling\u00a0the \u00a0impact\u00a0of\u00a0alcohol\u00a0dependance\u00a0on\u00a0mortality\u00a0burden\u00a0and\u00a0the\u00a0\neffect\u00a0of\u00a0available\u00a0treatment\u00a0interventions\u00a0in\u00a0the\u00a0European\u00a0Uni on.\u00a0European\u00a0Neuropsychopharmacology\u00a023:\u00a089\u201097.\u00a0\nSAMSHA\u00a0\u2013\u00a0Substance\u00a0Abuse\u00a0and\u00a0Mental\u00a0Health\u00a0Services\u00a0Administrat ion\u00a0(2013).\u00a0Results\u00a0from\u00a0the\u00a02012\u00a0National\u00a0Survey\u00a0on\u00a0Drug\u00a0Use\u00a0\nand\u00a0Health:\u00a0Summary\u00a0of\u00a0National\u00a0Findings.\u00a0NSDUH\u00a0Series\u00a0H\u201046.\u00a0HH S\u00a0Publication\u00a0No.\u00a0(SMA)\u00a013\u00a0\u2010\u00a04795.\u00a0Rockville:\u00a0\nSubstance\u00a0Abuse\u00a0and\u00a0Mental\u00a0Health\u00a0Services\u00a0Administration.\u00a0\nSeitz\u00a0HK,\u00a0Lesch\u00a0OM,\u00a0Spanagel\u00a0R,\u00a0 Beutel\u00a0M,\u00a0Redecker\u00a0T\u00a0\u00a0(Hrsg.)\u00a0( 2013).\u00a0Alkoholabh\u00e4ngigkeit,In:\u00a0Deutsche\u00a0Hauptstelle\u00a0f\u00fcr\u00a0Suchtfr agen\u00a0\ne.V.\u00a0(2013).\u00a0Suchtmedizinische\u00a0Reihe\u00a0Band\u00a01.\u00a0Hamm:\u00a0Deutschen\u00a0Ha uptstelle\u00a0f\u00fcr\u00a0Suchtfragen\u00a0e.V..\u00a0\u00a0\nSpence\u00a0D\u00a0(2014).\u00a0Bad\u00a0medicine:\u00a0nalmefene\u00a0in\u00a0alcohol\u00a0misuse.\u00a0BMJ \u00a0348:g1531.\u00a0\nStarosta\u00a0AN,\u00a0Leeman\u00a0RF,\u00a0Volpice lli\u00a0JR\u00a0(2006).\u00a0The\u00a0BRENDA\u00a0model: \u00a0integrating\u00a0psychosocial\u00a0treatment\u00a0and\u00a0pharmacotherapy\u00a0for\u00a0the \u00a0\ntreatment\u00a0of\u00a0alcohol\u00a0use\u00a0disorders.\u00a0J\u00a0psychiatr\u00a0pract\u00a012(2):\u00a080 .\u00a0\nWise\u00a0J\u00a0(2014).\u00a0Decision\u00a0to\u00a0recommend\u00a0drug\u00a0to\u00a0cut\u00a0drink\u00a0dependen ce\u00a0proves\u00a0controversial.\u00a0BMJ\u00a0348:g6054.\u00a0\n\u00a0 \u00a0291\u00a04.19 Obinutuzumab\u00a0\nHandelsname:\u00a0Gazyvaro\u00ae\u00a0\u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikationen:\u00a0chronische\u00a0lymphatische\u00a0\u00a0 Hoffmann\u2010La\u00a0Roche\u00a0\u00a0\nLeuk\u00e4mie,\u00a0Follikul\u00e4res\u00a0Lymphom\u00a0\nATC\u2010Code:\u00a0L01XC15\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0August\u00a02014\u00a0\nDarreichungsform:\u00a0Konzentrat\u00a0zur\u00a0Her\u2010\u00a0 \u00a0\nstellung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0 \u00a0 DDD:\u00a048\u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nObinutuzumab\u00a0 ist\u00a0 ein\u00a0 monoklonaler\u00a0 humanisierter\u00a0 Typ\u2010II\u2010Anti\u2010CD2 0\u2010Antik\u00f6rper\u00a0\nder\u00a0IgG1\u2010Subklasse,\u00a0der\u00a0normale\u00a0 und\u00a0von\u00a0der\u00a0chronischen\u00a0lymphat ischen\u00a0Leuk\u00e4\u2010\nmie\u00a0 (CLL)\u00a0 transformierte\u00a0 CD20\u2010po sitive\u00a0 B\u2010Lymphozyten\u00a0 sowohl\u00a0 dir ekt\u00a0 als\u00a0 auch\u00a0\nindirekt\u00a0\u00fcber\u00a0Stimulation\u00a0von\u00a0E ffektorzellen\u00a0des\u00a0Immunsystems\u00a0u nd\u00a0Aktivierung\u00a0\ndes\u00a0Komplementsystems\u00a0zerst\u00f6rt\u00a0(Fachinformation\u00a0Gazyvaro\u00ae,\u00a02016 ).\u00a0Im\u00a0Gegen\u2010\nsatz\u00a0zu\u00a0den\u00a0Typ\u2010I\u2010anti\u2010CD20\u2010Anti k\u00f6rpern\u00a0Rituximab\u00a0und\u00a0Ofatumuma b\u00a0ist\u00a0Obinutu\u2010\nzumab\u00a0ein\u00a0Typ\u2010II\u2010CD20\u2010Antik\u00f6rper,\u00a0dessen\u00a0Zuckerrest\u00a0im\u00a0Bereich\u00a0 der\u00a0Fc\u2010Region\u00a0\ndurch\u00a0\u201eGlycogen \u2010Engineering \u201c\u00a0modifiziert\u00a0wurde.\u00a0Daraus\u00a0 soll\u00a0eine\u00a0erh\u00f6hte\u00a0Affinit\u00e4t\u00a0\nzum\u00a0Fc\u03b3\u2010Rezeptor\u00a0IIIa\u00a0auf\u00a0der\u00a0Oberfl\u00e4che\u00a0von\u00a0Immuneffektorzelle n\u00a0resultieren\u00a0mit\u00a0\nbspw.\u00a0verst\u00e4rkter\u00a0Antik\u00f6rper\u2010abh\u00e4 ngiger,\u00a0zellvermittelter\u00a0Zytot oxizit\u00e4t\u00a0(Antibody\u00a0\nDependent\u00a0Cellula r\u00a0Cytotoxicity ,\u00a0ADCC).\u00a0Die\u00a0Typ\u2010II\u2010Bindung\u00a0von\u00a0Obinutuzumab\u00a0an\u00a0\ndas\u00a0CD20\u2010Antigen\u00a0aktiviert\u00a0dar\u00fcbe r\u00a0hinaus\u00a0Lysosomen,\u00a0die\u00a0eine\u00a0n icht\u2010apoptotische\u00a0\nSelbstzerst\u00f6rung\u00a0der\u00a0B\u2010Lymphozyten\u00a0und\u00a0damit\u00a0ihren\u00a0direkten\u00a0Zel ltod\u00a0(Direct\u00a0Cell\u00a0\nDeath,\u00a0DCD)\u00a0herbeif\u00fchren\u00a0sollen.\u00a0\nHoffmann\u2010La\u00a0Roche\u00a0hat\u00a0auch\u00a0Rituximab\u00a0(Mabthera\u00ae)\u00a0entwickelt,\u00a0da s\u00a0zwar\u00a0bereits\u00a0\n2013\u00a0aus\u00a0dem\u00a0Patent\u00a0gelaufen\u00a0ist,\u00a0wof\u00fcr\u00a0aber\u00a0erst\u00a0k\u00fcrzlich\u00a0zum\u00a0 15.04.2017\u00a0das\u00a0\nerste\u00a0Biosimilar\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0Truxima\u00ae\u00a0vom\u00a0pharmazeut ischen\u00a0Un\u2010\nternehmer\u00a0(pU)\u00a0Mundipharma\u00a0auf\u00a0dem\u00a0deutschen\u00a0Markt\u00a0ausgeboten\u00a0w urde\u00a0(Lau\u2010\ner\u2010Fischer,\u00a02017).\u00a0Obinutuzumab\u00a0wurde\u00a0im\u00a0Juli\u00a02014\u00a0von\u00a0der\u00a0Euro p\u00e4ischen\u00a0Kom\u2010\nmission\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0zugelassen\u00a0zur\u00a0Erstlinientherapie\u00a0von\u00a0CLL\u00a0in\u00a0Kom\u2010\nbination\u00a0mit\u00a0Chlorambucil\u00a0bei\u00a0Patienten,\u00a0die\u00a0aufgrund\u00a0von\u00a0Begle iterkrankungen\u00a0f\u00fcr\u00a0\neine\u00a0Therapie\u00a0mit\u00a0einer\u00a0vollst\u00e4 ndigen\u00a0Dosis\u00a0Fludarabin\u00a0nicht\u00a0ge eignet\u00a0sind\u00a0(EMA,\u00a0\n2016).\u00a0Im\u00a0Juni\u00a02016\u00a0erfolgte\u00a0eine\u00a0Zulassungserweiterung\u00a0auf\u00a0das \u00a0Anwendungsge\u2010\nbiet\u00a0Follikul\u00e4res\u00a0Lymphom\u00a0(FL).\u00a0Seitdem\u00a0ist\u00a0Obinutuzumab\u00a0in\u00a0Kom bination\u00a0mit\u00a0\nBendamustin,\u00a0gefolgt\u00a0von\u00a0einer\u00a0Erhaltungstherapie\u00a0nur\u00a0mit\u00a0Obinu tuzumab,\u00a0indi\u2010\nziert\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0FL,\u00a0die\u00a0 auf\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Rituxim ab\u00a0oder\u00a0einem\u00a0Ritu\u2010\nximab\u2010haltigen\u00a0Regime\u00a0nicht\u00a0ange sprochen\u00a0haben\u00a0oder\u00a0w\u00e4hrend\u00a0bzw .\u00a0bis\u00a0zu\u00a0sechs\u00a0\nMonate\u00a0nach\u00a0der\u00a0Behandlung\u00a0progredient\u00a0wurden.\u00a0\u00a0292\u00a0Obinutuzumab\u00a0wird\u00a0nicht\u00a0nach\u00a0K\u00f6rperoberfl\u00e4che\u00a0dosiert,\u00a0sondern\u00a0 in\u00a0beiden\u00a0Indi\u2010\nkationen\u00a0in\u00a0der\u00a0Standarddosierung\u00a01.000\u00a0mg\u00a0verabreicht.\u00a0Es\u00a0soll \u00a0in\u00a0sechs\u00a0Behand\u2010\nlungszyklen\u00a0von\u00a0jeweils\u00a028\u00a0Tagen\u00a0 gegeben\u00a0werden,\u00a0im\u00a0Zyklus\u00a01\u00a0an \u00a0den\u00a0Tagen\u00a01,\u00a08\u00a0\nund\u00a015,\u00a0in\u00a0den\u00a0Zyklen\u00a02\u00a0bis\u00a06\u00a0nur\u00a0an\u00a0Tag\u00a01.\u00a0Die\u00a0Erhaltungsthera pie\u00a0beim\u00a0FL\u00a0erfolgt\u00a0\nebenfalls\u00a0mit\u00a01.000\u00a0mg\u00a0alle\u00a0zwei\u00a0Monate\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0oder\u00a0bi s\u00a0zu\u00a0einer\u00a0Krank\u2010\nheitsprogression.\u00a0 Wegen\u00a0 des\u00a0 Risi kos\u00a0 infusionsbedingter\u00a0 Reaktion en\u00a0 (Infusion\u2010\nRelated\u00a0Reaction ,\u00a0IRR)\u00a0erfolgt\u00a0in\u00a0der\u00a0Indikation \u00a0CLL\u00a0bei\u00a0der\u00a0ersten\u00a0Infusion\u00a0am \u00a0Tag\u00a01\u00a0\nim\u00a0Zyklus\u00a01\u00a0eine\u00a0Aufteilung\u00a0der\u00a0Dosis\u00a0in\u00a0100\u00a0mg\u00a0und\u00a0900\u00a0mg.\u00a0Wen n\u00a0die\u00a0erste\u00a0Infu\u2010\nsion\u00a0mit\u00a0100\u00a0mg\u00a0ohne\u00a0\u00c4nderung\u00a0der\u00a0Infusionsgeschwindigkeit\u00a0und\u00a0 ohne\u00a0Unterbre\u2010\nchung\u00a0vertragen\u00a0wird,\u00a0kann\u00a0die\u00a0zweite\u00a0Infusion\u00a0mit\u00a0900\u00a0mg\u00a0noch\u00a0 am\u00a0selben\u00a0Tag\u00a0\nverabreicht\u00a0werden.\u00a0Wenn\u00a0w\u00e4hrend\u00a0der\u00a0Verabreichung\u00a0der\u00a0ersten\u00a01 00\u00a0mg\u00a0\u00c4nde\u2010\nrungen\u00a0der\u00a0Infusionsgeschwindigkeit\u00a0oder\u00a0Unterbrechungen\u00a0vorgen ommen\u00a0wer\u2010\nden\u00a0m\u00fcssen,\u00a0darf\u00a0die\u00a0zweite\u00a0Dosis\u00a0erst\u00a0am\u00a0folgenden\u00a0Tag\u00a0infundi ert\u00a0werden.\u00a0Da\u00a0\nInzidenz\u00a0und\u00a0Schweregrad\u00a0von\u00a0IRR\u00a0in\u00a0Studien\u00a0bei\u00a0den\u00a0Folgebehand lungen\u00a0sehr\u00a0\nstark\u00a0zur\u00fcckgingen,\u00a0k\u00f6nnen\u00a0sowohl\u00a0die\u00a01.000\u00a0mg\u2010Dosen\u00a0an\u00a0den\u00a0Tag en\u00a08\u00a0und\u00a015\u00a0\ndes\u00a0ersten\u00a0Behandlungszyklus\u00a0als\u00a0auch\u00a0an\u00a0den\u00a0Tagen\u00a01\u00a0der\u00a0folgen den\u00a0Zyklen\u00a0ohne\u00a0\nAufteilung\u00a0verabreicht\u00a0werden.\u00a0Vor\u00a0jeder\u00a0Infusion\u00a0von\u00a0Obinutuzu mab\u00a0sollte\u00a0aber\u00a0\neine\u00a0risikoadaptierte\u00a0Pr\u00e4medikation\u00a0mit\u00a0Glucocorticoiden,\u00a0antip yretisch\u00a0wirksa\u2010\nmen\u00a0Analgetika\u00a0und\u00a0Antihistaminika\u00a0erfolgen.\u00a0Dabei\u00a0muss\u00a0die\u00a0eng maschige\u00a0\u00dcber\u2010\nwachung\u00a0 durch\u00a0 einen\u00a0 erfahrenen\u00a0 Arzt\u00a0 gew\u00e4hrleistet\u00a0 und\u00a0 eine\u00a0 Ausr \u00fcstung\u00a0 zur\u00a0\nWiederbelebung\u00a0sofort\u00a0verf\u00fcgbar\u00a0sein.\u00a0F\u00fcr\u00a0Patienten\u00a0mit\u00a0hoher\u00a0T umorlast,\u00a0hoher\u00a0\nzirkulierender\u00a0Lymphozytenzahl\u00a0und/oder\u00a0einer\u00a0Nierenfunktionsst \u00f6rung\u00a0wird\u00a0wegen\u00a0\ndes\u00a0erh\u00f6hten\u00a0Risikos\u00a0f\u00fcr\u00a0das\u00a0Auftreten\u00a0eines\u00a0Tumorlysesyndroms\u00a0 eine\u00a0Prophylaxe\u00a0\nbestehend\u00a0aus\u00a0ad\u00e4quater\u00a0Hydratation\u00a0sowie\u00a0der\u00a0Gabe\u00a0von\u00a0Urikosta tika\u00a0(z.B.\u00a0Allopu\u2010\nrinol)\u00a0oder\u00a0Rasburicase\u00a0zw\u00f6lf\u00a0bis\u00a024\u00a0Stunden\u00a0vor\u00a0Beginn\u00a0der\u00a0Inf usion\u00a0von\u00a0Obinutu\u2010\nzumab\u00a0empfohlen.\u00a0\nDie\u00a0zulassungsrelevante\u00a0Studie\u00a0CL L11\u00a0(gesponsert\u00a0vom\u00a0Hoffmann\u2010L a\u00a0Roche)\u00a0f\u00fcr\u00a0die\u00a0\nIndikation\u00a0CLL\u00a0ist\u00a0eine\u00a0in\u00a0Deutsc hland\u00a0von\u00a0der\u00a0CLL\u2010Studiengrupp e\u00a0initiierte\u00a0multi\u2010\nzentrische,\u00a0offene,\u00a0randomisier te,\u00a0dreiarmige\u00a0Phase\u2010III\u2010Studie\u00a0 an\u00a0Patienten\u00a0mit\u00a0\nnicht\u00a0vorbehandelter\u00a0CLL\u00a0und\u00a0klin isch\u00a0relevanten\u00a0Komorbidit\u00e4ten \u00a0(Goede\u00a0et.\u00a0al.,\u00a0\n2014).\u00a0Insgesamt\u00a0wurden\u00a0781\u00a0Patienten\u00a0mit\u00a0reduziertem\u00a0Allgemein zustand\u00a0(CIRS\u2010\u00a0\n(Cumulative\u00a0Illness\u00a0Rating\u00a0Scale )\u00a0Score\u00a0>\u00a06\u00a0und/oder\u00a0eingeschr\u00e4nkte\u00a0Nierenfunkti\u2010\non\u00a0mit\u00a0CrCl\u00a030\u00a0\u2013\u00a069\u00a0ml/min)\u00a0in\u00a0einem\u00a0medianen\u00a0Alter\u00a0von\u00a073\u00a0Jahr en\u00a02:2:1\u00a0in\u00a0die\u00a0\nBehandlungsarme\u00a0Obinutuzumab\u00a0plus\u00a0 Chlorambucil,\u00a0Rituximab\u00a0plus\u00a0 Chlorambucil\u00a0\nund\u00a0Chlorambucil\u2010Monotherapie\u00a0randomisiert.\u00a0In\u00a0Stufe\u00a01a\u00a0wurde\u00a0O binutuzumab\u00a0\nplus\u00a0Chlorambucil\u00a0an\u00a0356\u00a0Patienten\u00a0verglichen\u00a0mit\u00a0Chlorambucil\u2010 Mono,\u00a0in\u00a0Stufe\u00a02\u00a0\nwurde\u00a0der\u00a0Vergleich\u00a0mit\u00a0Rituximab\u00a0plus\u00a0Chlorambucil\u00a0an\u00a0663\u00a0Pati enten\u00a0durchge\u2010\nf\u00fchrt.\u00a0Die\u00a0Behandlung\u00a0erfolgte\u00a0\u00fcber\u00a0sechs\u00a0Zyklen\u00a0\u00e0\u00a028\u00a0Tage.\u00a0Obi nutuzumab\u00a0wurde\u00a0\nim\u00a0ersten\u00a0Behandlungszyklus\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a01.000\u00a0mg\u00a0absolut \u00a0an\u00a0Tag\u00a01,\u00a08\u00a0und\u00a0\n15\u00a0infundiert,\u00a0in\u00a0den\u00a0folgenden\u00a0Zyklen\u00a0nur\u00a0an\u00a0Tag\u00a01.\u00a0Chlorambuc il\u00a0wurde\u00a0in\u00a0allen\u00a0293\u00a0sechs\u00a0Behandlungszyklen\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a00,5\u00a0mg/kg\u00a0K\u00f6rpergewi cht\u00a0(KG)\u00a0oral\u00a0\nverabreicht.\u00a0Rituximab\u00a0im\u00a0Kontrollarm\u00a0wurde\u00a0in\u00a0einer\u00a0Dosierung\u00a0 von\u00a0375\u00a0mg/m2\u00a0\nan\u00a0Tag\u00a01\u00a0des\u00a0ersten\u00a0Zyklus\u00a0und\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a0500\u00a0mg/m2\u00a0an\u00a0Tag\u00a01\u00a0der\u00a0\nfolgenden\u00a0Zyklen\u00a0appliziert.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0das\u00a0vom\u00a0Pr\u00fcf arzt\u00a0beurteilte\u00a0\nprogressionsfreie\u00a0\u00dcberleben\u00a0( Progession\u2010free\u00a0Surivival ,\u00a0PFS).\u00a0Das\u00a0Gesamt\u00fcberle\u2010\nben\u00a0(Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0die\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0geh\u00f6rten\u00a0zu\u00a0den\u00a0sekund\u00e4ren\u00a0Endpunkten.\u00a0In\u00a0der\u00a0\nAnalyse\u00a0der\u00a0Stufe\u00a01a\u00a0betrug\u00a0das\u00a0mediane\u00a0PFS\u00a026,7\u00a0Monate\u00a0unter\u00a0O binutuzumab\u00a0\nplus\u00a0Chlorambucil\u00a0vs.\u00a011,1\u00a0Monate\u00a0unter\u00a0Monotherapie\u00a0mit\u00a0Chlora mbucil.\u00a0Hin\u2010\nsichtlich\u00a0des\u00a0OS\u00a0konnte\u00a0ein\u00a0signifikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0Kombi nationstherapie\u00a0ge\u2010\nzeigt\u00a0werden.\u00a0Zum\u00a0Zeitpunkt\u00a0der\u00a0Stufe\u20102\u2010Analyse\u00a0war\u00a0unter\u00a0Obinu tuzumab\u00a0plus\u00a0\nChloambucil\u00a0gegen\u00fcber\u00a0Rituximab\u00a0plus\u00a0Chlorambucil\u00a0das\u00a0PFS\u00a0um\u00a011 ,5\u00a0Monate\u00a0\nverl\u00e4ngert\u00a0(26,7\u00a0vs.\u00a015,2\u00a0Monate ),\u00a0das\u00a0OS\u00a0unterschied\u00a0sich\u00a0in\u00a0b eiden\u00a0Gruppen\u00a0nicht\u00a0\nsignifikant.\u00a0Ein\u00a0im\u00a0Juli\u00a02015\u00a0publiziertes\u00a0Update\u00a0der\u00a0Studie\u00a0ze igte\u00a0in\u00a0der\u00a0Stufe\u00a01a\u00a0\nein\u00a0PFS\u00a0von\u00a029,9\u00a0Monaten\u00a0im\u00a0Interventionsarm\u00a0vs.\u00a011,1\u00a0Monaten\u00a0i n\u00a0der\u00a0Kontroll\u2010\ngruppe,\u00a0in\u00a0der\u00a0Stufe\u00a02\u00a0ein\u00a0PFS\u00a0von\u00a029,2\u00a0Monaten\u00a0vs.15,4\u00a0Monaten \u00a0(Goede\u00a0et\u00a0al.,\u00a0\n2015).\u00a0Die\u00a0Daten\u00a0zur\u00a0HRQoL\u00a0und\u00a0Symptomatik\u00a0wurden\u00a0im\u00a0Wesentlich en\u00a0mit\u00a0dem\u00a0\nEORTC\u2010QLQ\u2010C30\u2010Fragebogen\u00a0erhoben.\u00a0In\u00a0Bezug\u00a0auf\u00a0den\u00a0Endpunkt\u00a0HRQ oL\u00a0konnten\u00a0\nzwischen\u00a0 den\u00a0 Behandlungsgruppen\u00a0 keine\u00a0 statistisch\u00a0 signifikanten \u00a0 Unterschiede\u00a0\ngezeigt\u00a0werden\u00a0(EMA,\u00a02016).\u00a0Die\u00a0Inzidenz\u00a0an\u00a0unerw\u00fcnschten\u00a0Arzne imittelereignis\u2010\nsen\u00a0(UAE)\u00a0Grad\u00a0\u2265\u00a03\u00a0war\u00a0insgesamt\u00a0unter\u00a0Obinutuzumab\u00a0plus\u00a0Chlora mbucil\u00a0im\u00a0Ver\u2010\ngleich\u00a0zu\u00a0Rituximab\u00a0plus\u00a0Chloram bucil\u00a0signifikant\u00a0h\u00f6her,\u00a0vor\u00a0al lem\u00a0infusionsbeding\u2010\nte\u00a0Reaktionen,\u00a0Neutropenien\u00a0und\u00a0 Thrombozytopenien\u00a0traten\u00a0h\u00e4ufig er\u00a0auf.\u00a0\nBasis\u00a0der\u00a0Zulassung\u00a0in\u00a0der\u00a0Indikation\u00a0FL\u00a0ist\u00a0die\u00a0derzeit\u00a0noch\u00a0l aufende\u00a0multizen\u2010\ntrische,\u00a0offene,\u00a01:1\u2010randomise rte\u00a0Phase\u2010III\u2010Studie\u00a0GADOLIN\u00a0(Spo nsor:\u00a0Hoffmann\u2010La\u00a0\nRoche)\u00a0an\u00a0insgesamt\u00a0413\u00a0Patienten\u00a0mit\u00a0indolentem\u00a0Non\u2010Hodgkin\u2010Ly mphom\u00a0(NHL),\u00a0\ndie\u00a0auf\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Rituximab\u00a0oder\u00a0einem\u00a0Rituximab\u2010halt igem\u00a0Regime\u00a0\nnicht\u00a0angesprochen\u00a0haben\u00a0oder\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten\u00a0nach\u00a0 der\u00a0letzten\u00a0\nDosis\u00a0von\u00a0Rituximab\u00a0progredient\u00a0wurden\u00a0(Sehn\u00a0et\u00a0al.,\u00a02016).\u00a081\u00a0 %\u00a0(n=335)\u00a0der\u00a0\nPatienten\u00a0hatten\u00a0ein\u00a0FL,\u00a0diese\u00a0gr\u00f6\u00dfte\u00a0Teilpopulation\u00a0wurde\u00a0als\u00a0 zulassungsrelevante\u00a0\nSubgruppe\u00a0 definiert.\u00a0 Die\u00a0 Interventionsgruppe\u00a0 erhielt\u00a0 als\u00a0 Indukt ionstherapie\u00a0\nObinutuzumab\u00a0in\u00a0Kombination\u00a0mi t\u00a0Bendamustin,\u00a0die\u00a0Kontrollgruppe \u00a0Bendamustin\u2010\nMono\u00a0\u00fcber\u00a0sechs\u00a0Zyklen\u00a0mit\u00a0einer\u00a0Dauer\u00a0von\u00a0jeweils\u00a028\u00a0Tagen.\u00a0Pa tienten\u00a0in\u00a0der\u00a0\nInterventionsgruppe,\u00a0 bei\u00a0 denen\u00a0 es\u00a0 am\u00a0 Ende\u00a0 der\u00a0 Induktionstherapi e\u00a0 zu\u00a0 keiner\u00a0\nKrankheitsprogression\u00a0gekommen\u00a0war,\u00a0bekamen\u00a0anschlie\u00dfend\u00a0eine\u00a0E rhaltungs\u2010\ntherapie\u00a0mit\u00a0Obinutuzumab\u00a0einmal\u00a0alle\u00a0zwei\u00a0Monate\u00a0\u00fcber\u00a0zwei\u00a0Jah re\u00a0oder\u00a0bis\u00a0zu\u00a0\neiner\u00a0Krankheitsprogression.\u00a0Obinutuzumab\u00a0wurde\u00a0als\u00a0Infusion\u00a0mi t\u00a0einer\u00a0Gesamt\u2010\ndosis\u00a0von\u00a01.000\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a08\u00a0und\u00a015\u00a0im\u00a0ersten\u00a0Zyklus\u00a0und\u00a0in\u00a0d en\u00a0folgenden\u00a0f\u00fcnf\u00a0\nZyklen\u00a0nur\u00a0an\u00a0Tag\u00a01\u00a0verabreicht,\u00a0in\u00a0der\u00a0Erhaltungstherapie\u00a0wurd en\u00a0ebenfalls\u00a0je\u2010\nweils\u00a01.000\u00a0mg\u00a0gegeben.\u00a0Bendamustin\u00a0wurde\u00a0in\u00a0allen\u00a0sechs\u00a0Zyklen \u00a0an\u00a0Tag\u00a01\u00a0und\u00a02\u00a0294\u00a0infundiert,\u00a0in\u00a0Kombination\u00a0mit\u00a0O binutuzumab\u00a0in\u00a0einer\u00a0Dosierung\u00a0 von\u00a090\u00a0mg\u00a0pro\u00a0m2\u00a0\nK\u00f6rperoberfl\u00e4che\u00a0pro\u00a0Tag,\u00a0bei\u00a0alleiniger\u00a0Gabe\u00a0in\u00a0einer\u00a0Dosierun g\u00a0von\u00a0120\u00a0mg/\u00a0\nm2/Tag.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0war\u00a0das\u00a0IRC\u00a0( Independent\u00a0Review\u00a0Commit\u2010\ntee)\u00a0bewertete\u00a0PFS,\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0unter\u00a0anderem\u00a0das\u00a0OS ,\u00a0das\u00a0An\u2010\nsprechen,\u00a0die\u00a0Dauer\u00a0des\u00a0Ansprechens,\u00a0die\u00a0\u00c4nderung\u00a0der\u00a0HRQoL\u00a0und \u00a0die\u00a0Vertr\u00e4g\u2010\nlichkeit.\u00a0F\u00fcr\u00a0die\u00a0Teilpopulation\u00a0der\u00a0Patienten\u00a0mit\u00a0FL\u00a0wurde\u00a0zum \u00a0zweiten\u00a0Daten\u2010\nschnitt\u00a0vom\u00a001.05.2015\u00a0ein\u00a0medianes\u00a0PFS\u00a0von\u00a029,2\u00a0Monaten\u00a0im\u00a0Int erventionsarm\u00a0\ngegen\u00fcber\u00a013,8\u00a0Monaten\u00a0im\u00a0Kontro llarm\u00a0erreicht.\u00a0Bez\u00fcglich\u00a0des\u00a0O S\u00a0zeigte\u00a0sich\u00a0zu\u00a0\ndiesem\u00a0Zeitpunkt\u00a0ein\u00a0statistisch\u00a0signifikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0Obin utuzumab,\u00a0der\u00a0Medi\u2010\nan\u00a0 wurde\u00a0 in\u00a0 beiden\u00a0 Behandlungsgr uppen\u00a0 jedoch\u00a0 noch\u00a0 nicht\u00a0 erreich t . \u00a0F \u00fc r \u00a0d i e \u00a0\nHRQoL,\u00a0gemessen\u00a0an\u00a0den\u00a0Skalen\u00a0de s\u00a0krebsspezifischen\u00a0Fragebogens \u00a0FACT\u2010G\u00a0und\u00a0\ndes\u00a0lymphomspezifischen\u00a0Fragebog ens\u00a0FACT\u2010Lym,\u00a0zeigt\u00a0sich\u00a0kein\u00a0s tatistisch\u00a0signifi\u2010\nkanter\u00a0Unterschied\u00a0in\u00a0den\u00a0Behandlungsarmen.\u00a0Auch\u00a0bei\u00a0den\u00a0schwer wiegenden\u00a0\nUAE\u00a0Grad\u00a0\u2265\u00a03\u00a0in\u00a0der\u00a0Induktionsphase\u00a0unterschieden\u00a0sich\u00a0beide\u00a0St udienarme\u00a0insge\u2010\nsamt\u00a0 nicht.\u00a0 W\u00e4hrend\u00a0 in\u00a0 der\u00a0 Interventionsgruppe\u00a0 h\u00e4ufiger\u00a0 schwerw iegende\u00a0\nNeutropenien\u00a0 und\u00a0 IRR\u00a0 als\u00a0 in\u00a0 der\u00a0 Kontrollgruppe\u00a0 auftraten,\u00a0 kam\u00a0 e s\u00a0 unter\u00a0 der\u00a0\nBendamustin\u2010Monotherapie\u00a0h\u00e4ufiger\u00a0zu\u00a0Thrombozytopenien.\u00a0\u00a0\nIn\u00a0der\u00a0multizentrischen,\u00a0offenen ,\u00a0randomisierten\u00a0Phase\u2010III\u2010Stud ie\u00a0GOYA\u00a0verglich\u00a0\nder\u00a0pU\u00a0Obinutuzumab\u00a0in\u00a0der\u00a0Kombination\u00a0mit\u00a0dem\u00a0Chemotherapie\u2010Re gime\u00a0CHOP\u00a0\n(Cyclophosphamid,\u00a0Doxorubicin,\u00a0Vincristin,\u00a0Prednison)\u00a0mit\u00a0Ritux imab\u00a0plus\u00a0CHOP\u00a0an\u00a0\nPatienten\u00a0mit\u00a0nicht\u2010vorbehandeltem\u00a0diffusen\u00a0gro\u00dfzelligen\u00a0B\u2010Zell \u2010Lymphom,\u00a0dem\u00a0\nh\u00e4ufigsten\u00a0Subtyp\u00a0des\u00a0hochmalignen\u00a0NHL\u00a0(DAZ\u00a0online,\u00a02016a).\u00a0Im\u00a0 Juli\u00a02016\u00a0gab\u00a0\nRoche\u00a0bekannt,\u00a0dass\u00a0der\u00a0prim\u00e4re\u00a0Endpunkt,\u00a0das\u00a0vom\u00a0Pr\u00fcfarzt\u00a0beur teilte\u00a0PFS,\u00a0nicht\u00a0\nerreicht\u00a0wurde\u00a0(ASH,\u00a02016).\u00a0\u00a0\nDie\u00a0globale\u00a01:1\u2010randomisierte\u00a0 Phase\u2010III\u2010Studie\u00a0GALLIUM\u00a0(Sponsor :\u00a0Hoffmann\u2010La\u00a0\nRoche)\u00a0untersucht\u00a0an\u00a01.202\u00a0Patienten\u00a0mit\u00a0nicht\u00a0vorbehandeltem\u00a0F L\u00a0Obinutuzumab\u00a0\nplus\u00a0Chemotherapie\u00a0(CHOP,\u00a0CVP\u00a0oder\u00a0Bendamustin)\u00a0vs.\u00a0Rituximab\u00a0p lus\u00a0Chemothe\u2010\nrapie\u00a0in\u00a0einer\u00a0sechs\u00a0bis\u00a0acht\u00a0Zyklen\u00a0umfassenden\u00a0Induktionsther apie,\u00a0gefolgt\u00a0von\u00a0\neiner\u00a0 zweij\u00e4hrigen\u00a0 Erhaltungstherapie\u00a0 mit\u00a0 dem\u00a0 jeweiligen\u00a0 monokl onalen\u00a0 Anti\u2010\nCD20\u2010Antik\u00f6rper\u00a0allein\u00a0alle\u00a0zwei\u00a0 Monate\u00a0(DGHO,\u00a02016a).\u00a0Bislang\u00a0 sind\u00a0noch\u00a0keine\u00a0\nErgebnisse\u00a0publiziert\u00a0worden.\u00a0\u00a0\nF\u00fcr\u00a0das\u00a0Orphan\u2010Arzneimittel\u00a0Obinutuzumab\u00a0gilt\u00a0 gem\u00e4\u00df\u00a0(fr\u00fcher)\u00a0Nutzenbewertung\u00a0\nder\u00a0medizinische\u00a0Zusatznutzen\u00a0dur ch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt.\u00a0D er\u00a0Gemeinsame\u00a0\nBundesausschuss\u00a0(G\u2010BA)\u00a0bewertet\u00a0lediglich\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatz nutzens\u00a0auf\u00a0der\u00a0\nGrundlage\u00a0der\u00a0Zulassungsstudien.\u00a0Im\u00a0Anwendungsgebiet\u00a0 CLL\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0\nnicht\u00a0quantifizierbaren\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0Obinutuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Chlo\u2010\nrambucil\u00a0bei\u00a0 Patienten\u00a0mit\u00a0nicht\u00a0vorbehandelter\u00a0CLL,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Therapie\u00a0m it\u00a0\nFludarabin\u00a0nicht\u00a0geeignet\u00a0sind \u00a0(G\u2010BA,\u00a02014).\u00a0Zwar\u00a0war\u00a0das\u00a0mediane\u00a0PFS\u00a0in\u00a0der\u00a0295\u00a0Zulassungsstudie\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Stufe\u20102\u2010Analyse\u00a0im\u00a0Intervent ionsarm\u00a0gegen\u2010\n\u00fcber\u00a0dem\u00a0Kontrollarm\u00a0um\u00a011,8\u00a0Monate\u00a0verl\u00e4ngert,\u00a0jedoch\u00a0ist\u00a0umst ritten,\u00a0ob\u00a0dieses\u00a0\nE r g e b n i s \u00a0f \u00fc r \u00a0P a t i e n t e n \u00a0r e l e v a n t \u00a0i s t . \u00a0D i e \u00a0D a t e n \u00a0z u m \u00a0s e k u n d \u00e4 r e n \u00a0E ndpunkt\u00a0 OS\u00a0\nsch\u00e4tzt\u00a0der\u00a0G\u2010BA\u00a0aufgrund\u00a0der\u00a0relativ\u00a0kurzen\u00a0Studienlaufzeit\u00a0al s\u00a0unreif\u00a0ein,\u00a0zudem\u00a0\nist\u00a0 eine\u00a0 Signifikanz\u00a0 dieses\u00a0 Endpunktes\u00a0 in\u00a0 der\u00a0 Studienpopulation \u00a0w e g e n \u00a0h o h e n \u00a0\nDurchschnittsalters\u00a0 und\u00a0 nicht\u00a0 krankheitsbedingter,\u00a0 konkurrieren der\u00a0 Todesursa\u2010\nchen\u00a0auch\u00a0bei\u00a0l\u00e4ngerer\u00a0Studiendauer\u00a0schwer\u00a0zu\u00a0erreichen.\u00a0Dass\u00a0d ie\u00a0Gesamtrate\u00a0an\u00a0\nUAE\u00a0Grad\u00a0\u2265\u00a03\u00a0unter\u00a0Obinutuzumab\u00a0plus\u00a0Chlorambucil\u00a0im\u00a0Vergleich\u00a0 zu\u00a0Rituximab\u00a0\nplus\u00a0Chlorambucil\u00a0h\u00f6her\u00a0war,\u00a0beurteilt\u00a0der\u00a0G\u2010BA\u00a0aufgrund\u00a0der\u00a0za hlreichen\u00a0Studi\u2010\nenprotokoll\u00e4nderungen,\u00a0die\u00a0vor\u00a0allem\u00a0die\u00a0Intensivierung\u00a0der\u00a0Pr\u00e4 medikation\u00a0zur\u00a0\nVerringerung\u00a0der\u00a0infusionsbedingt en\u00a0Nebenwirkungen\u00a0betrafen,\u00a0al s\u00a0nicht\u00a0interpre\u2010\ntierbar.\u00a0\nBeim\u00a02016\u00a0neu\u00a0zugelassenen\u00a0Anwendungsgebiet\u00a0 FL,\u00a0das\u00a0in\u00a0vorausgegangener\u00a0The\u2010\nrapie\u00a0auf\u00a0Rituximab\u00a0oder\u00a0Rituximab\u2010haltiger\u00a0Therapie\u00a0kein\u00a0Anspr echen\u00a0zeigte\u00a0oder\u00a0\neine\u00a0Progression\u00a0w\u00e4hrend\u00a0oder\u00a0bis\u00a0zu\u00a0sechs\u00a0Monate\u00a0nach\u00a0der\u00a0Beha ndlung\u00a0aufwies,\u00a0\nsieht\u00a0der\u00a0G\u2010BA\u00a0ebenfalls\u00a0einen\u00a0 nicht\u00a0quantifizierbaren\u00a0Zusatznutzen\u00a0 (G\u2010BA,\u00a02016).\u00a0\nSeine\u00a0 Bewertung\u00a0 beruht\u00a0 auf\u00a0 den\u00a0 Ergebnissen\u00a0 des\u00a0 vierten\u00a0 Datensch nittes\u00a0 vom\u00a0\n01.05.2015\u00a0der\u00a0GADOLIN\u2010Studie\u00a0f\u00fcr\u00a0die\u00a0Teilpopulation\u00a0der\u00a0Patien ten\u00a0mit\u00a0follikul\u00e4rem\u00a0\nNHL.\u00a0Zu\u00a0diesem\u00a0Zeitpunkt\u00a0war\u00a0bez\u00fcglich\u00a0des\u00a0OS\u00a0die\u00a0Zahl\u00a0der\u00a0Erei gnisse\u00a0in\u00a0beiden\u00a0\nBehandlungsarmen\u00a0gering\u00a0und\u00a0der\u00a0Median\u00a0noch\u00a0nicht\u00a0erreicht.\u00a0Die \u00a0Daten\u00a0zum\u00a0all\u2010\ngemeinen\u00a0Gesundheitszustand\u00a0als\u00a0Endpunkt\u00a0in\u00a0der\u00a0Kategorie\u00a0Morbi dit\u00e4t\u00a0und\u00a0zur\u00a0\nHRQoL\u00a0beurteilt\u00a0der\u00a0G\u2010BA\u00a0als\u00a0wenig\u00a0aussagekr\u00e4ftig\u00a0aufgrund\u00a0des\u00a0 hohen\u00a0Verzerrungs\u2010\npotentials\u00a0infolge\u00a0der\u00a0offen\u00a0(unverblindet)\u00a0durchgef\u00fchrten\u00a0Stud ie.\u00a0Hinsichtlich\u00a0der\u00a0\nU A E \u00a0si nd \u00a0d ur ch \u00a0d i e \u00a0un t er s chi e d l i ch e n \u00a0B eh and l u ng sp ha s e n \u00a0(I n du k ti onstherapie\u00a0in\u00a0\nbeiden\u00a0Studienarmen,\u00a0gegen\u00a0FL\u00a0gerichtete\u00a0Erhaltungstherapie\u00a0nur \u00a0im\u00a0Interventions\u2010\narm)\u00a0Verzerrungen\u00a0zugunsten\u00a0von\u00a0Obinutuzumab\u00a0nicht\u00a0auszuschlie\u00df en;\u00a0im\u00a0Vergleich\u00a0\nder\u00a0Ergebnisse\u00a0f\u00fcr\u00a0die\u00a0Zeit\u00a0der\u00a0Induktionstherapie\u00a0sieht\u00a0der\u00a0G\u2010 BA\u00a0in\u00a0der\u00a0Gesamtschau\u00a0\nkeinen\u00a0Unterschied\u00a0b ez\u00fcglich\u00a0der\u00a0UAE.\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 (Zusatz\u2010)Nutzen\u00a0 Kosten\u00a0\n\u00a0dritter\u00a0Anti\u2010CD20\u2010\nAntik\u00f6rper\u00a0in\u00a0der\u00a0Indikation\u00a0\nCLL,\u00a0zweiter\u00a0Anti\u2010CD20\u2010\nAntik\u00f6rper\u00a0in\u00a0der\u00a0Indikation\u00a0\nFL\u00a0bislang\u00a0kein\u00a0ausrei\u2010\nchender\u00a0Beleg\u00a0f\u00fcr\u00a0\n\u00dcberlegenheit\u00a0gegen\u00fcber\u00a0\nbestehenden\u00a0\nTherapieoptionen\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\n296\u00a0Kosten\u00a0Kombinationstherapien\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertende\u00a0Arzneimittel \u00a0\nin\u00a0der\u00a0Indikation\u00a0CLL:\u00a0\nObinutuzumab\u00a0+ \u00a0\u00a0\n\u00a0\n6\u00a0Zyklen\u00a0\u00e0\u00a028\u00a0Tage\u00a0\nZyklus\u00a01:\u00a0je\u00a01.000\u00a0mg\u00a0\nan\u00a0Tag\u00a01,\u00a08\u00a0und\u00a015\u00a0\nZyklus\u00a02\u00a0\u2013\u00a06:\u00a01.000\u00a0mg\u00a0\nan\u00a0Tag\u00a01\u00a0\u00a0\u00a0\n\u00a0\n8\u00a0\u00a0\n\u00a0\n31.925,36\u00a0\u20ac\u00a0\nChlorambucil\u00a0 6\u00a0Zyklen\u00a0\u00e1\u00a028\u00a0Tage\u00a0\njeweils\u00a00,5\u00a0mg/kg\u00a0an\u00a0\nTag\u00a01\u00a0und\u00a015\u00a012\u00a0 344,52\u00a0\u20ac\u00a0\n\u00a0\nin\u00a0der\u00a0Indikation\u00a0FL:\u00a0\n1.\u00a0Jahr\u00a0\nObinutuzumab\u00a0+\u00a0\u00a0\n\u00a0\n\u00a0\nInduktionstherapie:\u00a0\n6\u00a0Zyklen\u00a0\u00e0\u00a028\u00a0Tage\u00a0\nZyklus\u00a01:\u00a0je\u00a01.000\u00a0mg\u00a0\nan\u00a0Tag\u00a01,\u00a08\u00a0und\u00a015\u00a0\nZyklus\u00a02\u00a0\u2013\u00a06:\u00a01.000\u00a0mg\u00a0\nan\u00a0Tag\u00a01\u00a0\nErhaltungstherapie:\u00a0\n1.000\u00a0mg\u00a0alle\u00a02\u00a0\nMonate\u00a0\u00a0\n\u00a0\n\u00a0\n8\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n3\u00a032.269,88\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n31.925,36\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n11.972,01\u00a0\u20ac \u00a0\nBendamustin\u00a0\n\u00a0\n\u00a0\n\u00a0\n2.\u00a0und\u00a03.\u00a0Jahr\u00a0\nObinutuzumab\u00a0\n\u00a0\n\u00a0Induktionstherapie:\u00a0\n6\u00a0Zyklen\u00a0\u00e0\u00a028\u00a0Tage\u00a0\n90\u00a0mg/m2\u00a0an\u00a0Tag\u00a01\u00a0\nund\u00a02\u00a0\n\u00a0\nErhaltungstherapie\u00a0\n1.000\u00a0mg\u00a0alle\u00a02\u00a0\nMonate\u00a012\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n9\u00a0\n\u00a0\n\u00a06617,87\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n35.916,03\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n86.431,27\u00a0\u20ac\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2010\u2013\u00a0 \u2010\u2013\u00a0 \u2010\u2013\u00a0 Analogpr\u00e4parat\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDer\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0wurde \u00a0fast\u00a0ausschlie\u00dflich\u00a0als\u00a0Rezept ur\u00a0abgerechnet,\u00a0\nwobei\u00a0im\u00a0Januar\u00a0und\u00a0Februar\u00a0sowie\u00a0im\u00a0November\u00a0und\u00a0Dezember\u00a02015 \u00a0ein\u00a0Um\u2010\nsatzmaximum\u00a0von\u00a0etwa\u00a070.000\u00a0Euro\u00a0erreicht\u00a0wurde\u00a0(s.u.).\u00a0Die\u00a0daz wischen\u00a0liegen\u2010\nden\u00a0Umsatzr\u00fcckg\u00e4nge\u00a0k\u00f6nnen\u00a0dara uf\u00a0zur\u00fcckgef\u00fchrt\u00a0werden,\u00a0dass\u00a0ge m\u00e4\u00df\u00a0Behand\u2010\nlungsprotokoll\u00a0die\u00a0Gabe\u00a0im\u00a0erste n\u00a0Monat\u00a0dreifach\u00a0so\u00a0hoch\u00a0dosier t\u00a0erfolgt\u00a0wie\u00a0in\u00a0\nden\u00a0nachfolgenden\u00a0f\u00fcnf\u00a0Monaten.\u00a0297\u00a0Abbildung\u00a04.33:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\nObinutuzumab\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nObinutuzumab\u00a0 ist\u00a0 ein\u00a0 rekombinanter\u00a0 monoklonaler\u00a0 humanisierter\u00a0 T yp\u2010II\u2010Anti\u2010\nCD20\u2010Antik\u00f6rper\u00a0der\u00a0IgG1\u2010Subkla sse\u00a0und\u00a0wird\u00a0eingesetzt\u00a0bei\u00a0CLL\u00a0 (Fachinformation\u00a0\nGazyvaro\u00ae,\u00a02016).\u00a0Die\u00a0bei\u00a0der\u00a0CL L\u00a0abnormal\u00a0vermehrten\u00a0B\u2010Lymphoz yten\u00a0vom\u00a0B\u2010\nZell\u2010Typ\u00a0tragen\u00a0auf\u00a0ihrer\u00a0Oberfl\u00e4 che\u00a0das\u00a0Phosphoprotein\u00a0CD20,\u00a0d as\u00a0nur\u00a0auf\u00a0malig\u2010\nnen\u00a0und\u00a0nicht\u00a0malignen\u00a0Pr\u00e4\u2010B\u2010Ze llen\u00a0und\u00a0reifen\u00a0B\u2010Zellen\u00a0und\u00a0wed er\u00a0von\u00a0h\u00e4mato\u2010\npetischen\u00a0Stammzellen\u00a0noch\u00a0von\u00a0n ormalen\u00a0Plasmazellen\u00a0exprimiert \u00a0wird.\u00a0Mono\u2010\nklonale\u00a0Anti\u2010CD20\u2010Antik\u00f6rper\u00a0zer st\u00f6ren\u00a0die\u00a0CD20\u2010positiven\u00a0B\u2010Lym phozyten\u00a0sowohl\u00a0\ndirekt\u00a0als\u00a0auch\u00a0indirekt\u00a0\u00fcber\u00a0St imulation\u00a0von\u00a0Effektorzellen\u00a0de s\u00a0Immunsystems\u00a0und\u00a0\nAktivierung\u00a0 des\u00a0 Komplementsystem s.\u00a0 Im\u00a0 Gegensatz\u00a0 zu\u00a0 den\u00a0 Typ\u2010I\u2010an ti\u2010CD20\u2010\nAntik\u00f6rpern\u00a0Rituximab\u00a0und\u00a0Ofatumumab\u00a0ist\u00a0Obinutuzumab\u00a0ein\u00a0Typ\u2010I I\u2010CD20\u2010Anti\u2010\nk\u00f6rper,\u00a0dessen\u00a0Zuckerrest\u00a0im\u00a0Bere ich\u00a0der\u00a0Fc\u2010Region\u00a0durch\u00a0Glycog en\u2010Engineering \u00a0\nmodifiziert\u00a0wurde.\u00a0Daraus\u00a0soll\u00a0e ine\u00a0erh\u00f6hte\u00a0Affinit\u00e4t\u00a0zum\u00a0Fc\u03b3\u2010R ezeptor\u00a0IIIa\u00a0auf\u00a0der\u00a0\nOberfl\u00e4che\u00a0von\u00a0Immuneffektorzellen\u00a0(z.B.\u00a0nat\u00fcrliche\u00a0Killerzelle n,\u00a0Makrophagen,\u00a0\nMonozyten)\u00a0mit\u00a0beispielsweise\u00a0ve rst\u00e4rkter\u00a0ADCC\u00a0resultieren.\u00a0Die \u00a0Typ\u2010II\u2010Bindung\u00a0\nvon\u00a0Obinutuzumab\u00a0an\u00a0das\u00a0CD20\u2010Anti gen\u00a0aktiviert\u00a0dar\u00fcber\u00a0hinaus\u00a0L ysosomen,\u00a0die\u00a0\neine\u00a0nicht\u2010apoptotische\u00a0Selbstzerst\u00f6rung\u00a0der\u00a0B\u2010Lymphozyten\u00a0und\u00a0 damit\u00a0ihren\u00a0DCD\u00a0\nherbeif\u00fchren\u00a0soll.\u00a0\nHoffmann\u2010La\u00a0Roche\u00a0hat\u00a0auch\u00a0Rituximab\u00a0(Mabthera\u00ae)\u00a0entwickelt,\u00a0da s\u00a0zwar\u00a0bereits\u00a0\n2013\u00a0aus\u00a0dem\u00a0Patent\u00a0gelaufen\u00a0ist,\u00a0wof\u00fcr\u00a0aber\u00a0erst\u00a0k\u00fcrzlich\u00a0zum\u00a0 15.04.2017\u00a0das\u00a0\nerste\u00a0Biosimilar\u00a0unter\u00a0dem\u00a0Hande lsnamen\u00a0Truxima\u00ae\u00a0vom\u00a0pU\u00a0Mundiph arma\u00a0auf\u00a0\n298\u00a0dem\u00a0 deutschen\u00a0 Markt\u00a0 ausgeboten\u00a0 wurde\u00a0 (WEBAPO\u00ae\u00a0 InfoSystem).\u00a0 Seit \u00a0d e m \u00a0\n15.07.2017\u00a0ist\u00a0Rituximab\u00a0auch\u00a0von\u00a0der\u00a0Hexal\u00a0AG\u00a0unter\u00a0dem\u00a0Handel snamen\u00a0Rixa\u2010\nthon\u00ae\u00a0im\u00a0Handel.\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nObinutuzumab\u00a0wurde\u00a0im\u00a0Juli\u00a02014\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission \u00a0als\u00a0Orphan\u2010\nArzneimittel\u00a0zugelassen\u00a0zur\u00a0Erstlinientherapie\u00a0von\u00a0CLL\u00a0in\u00a0Kombi nation\u00a0mit\u00a0Chlora\u2010\nmbucil\u00a0bei\u00a0Patienten,\u00a0die\u00a0aufgr und\u00a0von\u00a0Begleiterkrankungen\u00a0f\u00fcr\u00a0 eine\u00a0Therapie\u00a0mit\u00a0\neiner\u00a0vollst\u00e4ndigen\u00a0Dosis\u00a0Fludara bin\u00a0nicht\u00a0geeignet\u00a0sind\u00a0(EMA,\u00a0 2016).\u00a0Die\u00a0FDA\u00a0\nhatte\u00a0bereits\u00a0Mitte\u00a02013\u00a0ein\u00a0beschleunigtes\u00a0Zulassungsverfahren \u00a0durchgef\u00fchrt,\u00a0\nnachdem\u00a0sie\u00a0dem\u00a0Wirkstoff\u00a0im\u00a0Mai\u00a0den\u00a0Status\u00a0 Breakthrough\u00a0Therapy\u00a0Designation \u00a0\nzuerkannt\u00a0hatte\u00a0(DAZ\u00a0online,\u00a02013).\u00a0Im\u00a0Juni\u00a02016\u00a0erfolgte\u00a0eine\u00a0 Zulassungserweite\u2010\nrung\u00a0auf\u00a0das\u00a0Anwendungsgebiet\u00a0FL\u00a0(EMA,\u00a02016).\u00a0Seitdem\u00a0ist\u00a0Obinu tuzumab\u00a0in\u00a0\nKombination\u00a0mit\u00a0Bendamustin,\u00a0gefo lgt\u00a0von\u00a0einer\u00a0Erhaltungstherap ie\u00a0nur\u00a0mit\u00a0Obi\u2010\nnutuzumab,\u00a0indiziert\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0FL,\u00a0die\u00a0auf\u00a0eine\u00a0Behandl ung\u00a0mit\u00a0Rituximab\u00a0\noder\u00a0einem\u00a0Rituximab\u2010haltigen\u00a0Regime\u00a0nicht\u00a0angesprochen\u00a0haben\u00a0o der\u00a0w\u00e4hrend\u00a0\nbzw.\u00a0bis\u00a0zu\u00a0sechs\u00a0Monate\u00a0nach\u00a0de r\u00a0Behandlung\u00a0progredient\u00a0wurden .\u00a0\u00a0\nObinutuzumab\u00a0wird\u00a0in\u00a0der\u00a0Standarddosierung\u00a01.000\u00a0mg\u00a0verabreicht .\u00a0Es\u00a0soll\u00a0in\u00a0\nsechs\u00a0Behandlungszyklen\u00a0von\u00a0jewe ils\u00a028\u00a0Tagen\u00a0gegeben\u00a0werden,\u00a0im \u00a0Zyklus\u00a01\u00a0an\u00a0\nden\u00a0Tagen\u00a01,\u00a08\u00a0und\u00a015,\u00a0in\u00a0den\u00a0Zyklen\u00a02\u00a0bis\u00a06\u00a0nur\u00a0an\u00a0Tag\u00a01.\u00a0Die\u00a0 Erhaltungstherapie\u00a0\nbeim\u00a0FL\u00a0erfolgt\u00a0ebenfalls\u00a0mit\u00a01.000\u00a0mg\u00a0alle\u00a0zwei\u00a0Monate\u00a0\u00fcber\u00a0zw ei\u00a0Jahre\u00a0oder\u00a0bis\u00a0\nzu\u00a0einer\u00a0Krankheitsprogression.\u00a0 Wegen\u00a0des\u00a0Risikos\u00a0IRR\u00a0erfolgt\u00a0i n\u00a0der\u00a0Indikation\u00a0CLL\u00a0\nbei\u00a0der\u00a0ersten\u00a0Infusion\u00a0am\u00a0Tag\u00a01 \u00a0im\u00a0Zyklus\u00a01\u00a0eine\u00a0Aufteilung\u00a0de r\u00a0Dosis\u00a0in\u00a0100\u00a0mg\u00a0\nund\u00a0900\u00a0mg.\u00a0Wenn\u00a0die\u00a0erste\u00a0Infusion\u00a0mit\u00a0100\u00a0mg\u00a0ohne\u00a0\u00c4nderung\u00a0de r\u00a0Infusionsge\u2010\nschwindigkeit\u00a0und\u00a0ohne\u00a0Unterbrechung\u00a0vertragen\u00a0wird,\u00a0kann\u00a0die\u00a0z weite\u00a0Infusion\u00a0\nmit\u00a0900\u00a0mg\u00a0noch\u00a0am\u00a0selben\u00a0Tag\u00a0verabreicht\u00a0werden;\u00a0wenn\u00a0w\u00e4hrend\u00a0 der\u00a0Verabrei\u2010\nchung\u00a0der\u00a0ersten\u00a0100\u00a0mg\u00a0\u00c4nderungen\u00a0der\u00a0Infusionsgeschwindigkeit \u00a0oder\u00a0Unter\u2010\nbrechungen\u00a0vorgenommen\u00a0werden\u00a0m\u00fcssen,\u00a0darf\u00a0die\u00a0zweite\u00a0Dosis\u00a0ers t\u00a0am\u00a0folgen\u2010\nden\u00a0Tag\u00a0infundiert\u00a0werden.\u00a0Da\u00a0Inzidenz\u00a0und\u00a0Schweregrad\u00a0von\u00a0IRR\u00a0 in\u00a0Studien\u00a0bei\u00a0\nden\u00a0Folgebehandlungen\u00a0sehr\u00a0stark\u00a0zur\u00fcckgingen,\u00a0k\u00f6nnen\u00a0sowohl\u00a0di e\u00a01.000\u2010mg\u2010\nDosen\u00a0an\u00a0den\u00a0Tagen\u00a08\u00a0und\u00a015\u00a0des\u00a0ersten\u00a0Behandlungszyklus\u00a0als\u00a0au ch\u00a0an\u00a0den\u00a0Tagen\u00a0\n1\u00a0der\u00a0folgenden\u00a0Zyklen\u00a0ohne\u00a0Aufteilung\u00a0verabreicht\u00a0werden.\u00a0Vor\u00a0 jeder\u00a0Infusion\u00a0\nvon\u00a0Obinutuzumab\u00a0sollte\u00a0aber\u00a0ein e\u00a0risikoadaptierte\u00a0Pr\u00e4medikatio n\u00a0mit\u00a0Glukokor\u2010\ntikoiden,\u00a0antipyretisch\u00a0wirksamen\u00a0Analgetika\u00a0und\u00a0Antihistaminik a\u00a0erfolgen,\u00a0au\u00dfer\u2010\ndem\u00a0muss\u00a0die\u00a0engmaschige\u00a0\u00dcberwachung\u00a0durch\u00a0einen\u00a0erfahrenen\u00a0Arz t\u00a0gew\u00e4hr\u2010\nleistet\u00a0und\u00a0eine\u00a0Ausr\u00fcstung\u00a0zur\u00a0Wiederbelebung\u00a0sofort\u00a0verf\u00fcgbar \u00a0sein.\u00a0F\u00fcr\u00a0Patien\u2010\nten\u00a0 mit\u00a0 hoher\u00a0 Tumorlast\u00a0 und/oder\u00a0 hoher\u00a0 zirkulierender\u00a0 Lymphozyt enzahl\u00a0\nund/oder\u00a0einer\u00a0Nierenfunktionsst\u00f6rung\u00a0wird\u00a0wegen\u00a0des\u00a0erh\u00f6hten\u00a0R isikos\u00a0f\u00fcr\u00a0das\u00a0\nAuftreten\u00a0eines\u00a0Tumorlysesyndroms\u00a0eine\u00a0Prophylaxe\u00a0bestehend\u00a0aus \u00a0ad\u00e4quater\u00a0299\u00a0Hydratation\u00a0sowie\u00a0der\u00a0Gabe\u00a0von\u00a0Urikostatika\u00a0(z.B.\u00a0Allopurinol)\u00a0 oder\u00a0Rasburicase\u00a012\u00a0\nbis\u00a024\u00a0Stunden\u00a0vor\u00a0Beginn\u00a0der\u00a0Infu sion\u00a0von\u00a0Obinutuzumab\u00a0empfohl en.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0CLL\u00a0ist\u00a0mit\u00a0\u00fcber\u00a0einem\u00a0Drittel\u00a0aller\u00a0diagnostizierten\u00a0Leuk\u00e4 mie\u2010F\u00e4lle\u00a0die\u00a0h\u00e4ufigs\u2010\nte\u00a0leuk\u00e4mische\u00a0Erkrankung\u00a0in\u00a0den\u00a0westlichen\u00a0Industriel\u00e4ndern\u00a0(G EKID,\u00a02015).\u00a0Der\u00a0\nVerlauf\u00a0und\u00a0die\u00a0Symptome\u00a0sind\u00a0insgesamt\u00a0heterogen.\u00a0Sehr\u00a0h\u00e4ufig\u00a0 ist\u00a0die\u00a0CLL\u00a0indo\u2010\nlent\u00a0und\u00a0schreitet\u00a0\u00fcber\u00a0Jahre\u00a0oder\u00a0gar\u00a0Jahrzehnte\u00a0nur\u00a0langsam\u00a0v oran,\u00a0aber\u00a0es\u00a0\nkommen\u00a0auch\u00a0rasch\u00a0fortschreitende\u00a0Erkrankungen\u00a0vor.\u00a0Betroffen\u00a0s ind\u00a0vorwiegend\u00a0\n\u00e4ltere\u00a0Menschen,\u00a0das\u00a0mediane\u00a0Alter\u00a0bei\u00a0Erstdiagnose\u00a0liegt\u00a0zwisc hen\u00a072\u00a0und\u00a075\u00a0\nJahren.\u00a0In\u00a0Deutschland\u00a0erkranken\u00a0j\u00e4hrlich\u00a0etwa\u00a03.000\u00a0M\u00e4nner\u00a0und \u00a02.000\u00a0Frauen\u00a0\nund\u00a0sterben\u00a0j\u00e4hrlich\u00a0etwa\u00a01.000\u00a0M\u00e4nner\u00a0und\u00a0850\u00a0Frauen\u00a0an\u00a0CLL\u00a0(W endtner\u00a0et\u00a0al.,\u00a0\n2017).\u00a0Bei\u00a0dem\u00a0niedrig\u00a0malignen\u00a0B\u2010Zell\u2010NHL\u00a0vermehren\u00a0sich\u00a0ungeb remst\u00a0immunin\u2010\nkompetente\u00a0B\u2010Lymphozyten\u00a0und\u00a0\u00fcberschwemmen\u00a0und\u00a0beeintr\u00e4chtigen\u00a0 Knochen\u2010\nmark,\u00a0Lymphknoten,\u00a0Milz,\u00a0Leber\u00a0und\u00a0Blut.\u00a0H\u00e4ufig\u00a0sind\u00a0die\u00a0Betrof fenen\u00a0beschwer\u2010\ndefrei\u00a0und\u00a0die\u00a0Diagnose\u00a0der\u00a0Blut\u2010 Lymphozytose\u00a0erfolgt\u00a0zuf\u00e4llig\u00a0 im\u00a0Rahmen\u00a0einer\u00a0\nRoutinekontrolle\u00a0des\u00a0Blutbildes.\u00a0F\u00fchrendes\u00a0Symptom\u00a0ist\u00a0eine\u00a0Ver gr\u00f6\u00dferung\u00a0der\u00a0\nperipheren\u00a0Lymphknoten\u00a0(Lymphadeno pathie).\u00a0Durch\u00a0Infiltration\u00a0d er\u00a0Organe\u00a0mit\u00a0\nLymphozyten\u00a0treten\u00a0au\u00dferdem\u00a0Spleno\u2010\u00a0und\u00a0Hepatomegalie\u00a0sowie\u00a0Zei chen\u00a0der\u00a0\nKnochenmarkinfiltration\u00a0mit\u00a0An\u00e4mie,\u00a0Thrombopenie\u00a0und\u00a0Neutropeni e\u00a0und\u00a0damit\u00a0\nverbundenen\u00a0h\u00e4matologischen\u00a0und\u00a0im munologischen\u00a0Fehlfunktionen\u00a0 auf.\u00a0Klini\u2010\nsche\u00a0Beschwerden\u00a0k\u00f6nnen\u00a0sich\u00a0zude m\u00a0in\u00a0Fatigue,\u00a0Bl\u00e4sse,\u00a0B\u2010Sympto men\u00a0(Nacht\u2010\nschwei\u00df,\u00a0Fieber,\u00a0Gewichtsverlust ),\u00a0Hautver\u00e4nderungen\u00a0sowie\u00a0erh\u00f6 hter\u00a0Infektnei\u2010\ngung\u00a0\u00e4u\u00dfern.\u00a0Damit\u00a0die\u00a0Diagnose\u00a0einer\u00a0CLL\u00a0gestellt\u00a0werden\u00a0kann, \u00a0m\u00fcssen\u00a0mehr\u00a0als\u00a0\n5.000\u00a0klonale\u00a0B\u2010Lymphozyten/\u00b5l\u00a0Blut\u00a0nachweisbar\u00a0sein.\u00a0Die\u00a0in\u00a0De utschland\u00a0und\u00a0\nEuropa\u00a0\u00fcbliche\u00a0Stadieneinteilung\u00a0nach\u00a0Binet\u00a0prognostiziert\u00a0den\u00a0 Verlauf\u00a0der\u00a0Er\u2010\nkrankung\u00a0anhand\u00a0des\u00a0Ausma\u00dfes\u00a0von\u00a0Lymphadenopathie,\u00a0Splenomegali e\u00a0und\u00a0He\u2010\npatomegalie\u00a0sowie\u00a0An\u00e4mie\u00a0und\u00a0Thrombozytopenie\u00a0(Maurer\u00a0&\u00a0Hallek, \u00a02013).\u00a0Pati\u2010\nenten\u00a0im\u00a0Stadium\u00a0C\u00a0befinden\u00a0sich\u00a0in\u00a0einem\u00a0fortgeschrittenem\u00a0Sta dium\u00a0der\u00a0Erkran\u2010\nkung\u00a0und\u00a0weisen\u00a0einen\u00a0H\u00e4moglobinwert\u00a0unter\u00a010\u00a0g/dl\u00a0und/oder\u00a0ein en\u00a0Thrombozy\u2010\ntenwert\u00a0unter\u00a0100.000/\u00b5l\u00a0auf.\u00a0Die\u00a0Ursachen\u00a0chronischer\u00a0Leuk\u00e4mie n\u00a0gelten\u00a0als\u00a0\nweitgehend\u00a0 ungekl\u00e4rt,\u00a0 heredit\u00e4re\u00a0 Faktoren\u00a0 und\u00a0 zytogenetische\u00a0 Ab errationen\u00a0\nerh\u00f6hen\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0die \u00a0Entstehung\u00a0einer\u00a0CLL.\u00a0\u00a0\nDas\u00a0FL\u00a0ist\u00a0das\u00a0h\u00e4ufigste\u00a0indolente\u00a0NHL\u00a0und\u00a0macht\u00a0in\u00a0unseren\u00a0Bre iten\u00a020\u00a0bis\u00a035\u00a0%\u00a0\naller\u00a0neu\u00a0diagnostizierten\u00a0NHL\u2010P atienten\u00a0aus\u00a0(GEKID,\u00a02015).\u00a0Das \u00a0mittlere\u00a0Erkran\u2010\nkungsalter\u00a0liegt\u00a0bei\u00a060\u00a0bis\u00a065\u00a0Jahren,\u00a0Frauen\u00a0sind\u00a0etwas\u00a0h\u00e4ufig er\u00a0betroffen\u00a0als\u00a0\nM\u00e4nner.\u00a0Bei\u00a0\u00fcber\u00a080\u00a0%\u00a0der\u00a0Betroffenen\u00a0wird\u00a0das\u00a0typischerweise\u00a0s ehr\u00a0langsam\u00a0\nfortschreitende\u00a0Lymphom\u00a0erst\u00a0im\u00a0fortgeschrittenen\u00a0Stadium\u00a0diagn ostiziert\u00a0(Buske\u00a0\net\u00a0al.,\u00a02017).\u00a0Die\u00a0Stadieneinteilung\u00a0erfolgt\u00a0nach\u00a0Ann\u00a0Arbor\u00a0in\u00a0 die\u00a0Stadien\u00a0I\u00a0bis\u00a0IV.\u00a0FL\u00a0\nGrad\u00a01\u20103A\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0indolenten,\u00a0Grad\u00a03B\u00a0zu\u00a0den\u00a0aggressiven \u00a0Lymphomen.\u00a0300\u00a0Die\u00a0Symptomatik\u00a0ist\u00a0gepr\u00e4gt\u00a0von\u00a0 meist\u00a0schmerzlosen\u00a0Lymphknotenv ergr\u00f6\u00dferun\u2010\ngen,\u00a0au\u00dferdem\u00a0k\u00f6nnen\u00a0unspezifisc he\u00a0Allgemeinsymptome\u00a0wie\u00a0M\u00fcdigk eit,\u00a0Abge\u2010\nschlagenheit\u00a0und\u00a0Bl\u00e4sse,\u00a0B\u2010Sympto me\u00a0(Nachtschwei\u00df,\u00a0Fieber,\u00a0Gewi chtsverlust),\u00a0\nSpleno\u2010\u00a0 und\u00a0 Hepatomegalie\u00a0 sowie\u00a0 St\u00f6rungen\u00a0 der\u00a0 H\u00e4matopoese\u00a0 mit\u00a0 A n\u00e4mie,\u00a0\nThrombozytopenie\u00a0und\u00a0Leukozytopenie\u00a0auftreten.\u00a0Der\u00a0klinische\u00a0Ve rlauf\u00a0der\u00a0FL\u00a0ist\u00a0\nsehr\u00a0variabel,\u00a0\u00dcberlebenszeiten\u00a0reichen\u00a0von\u00a0einigen\u00a0Jahren\u00a0bis\u00a0 \u00fcber\u00a0zwei\u00a0Jahr\u2010\nzehnte.\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0zulassungsrelevante\u00a0Studie\u00a0C LL11\u00a0(gesponsert\u00a0von\u00a0Hoffmann\u2010L a\u00a0Roche)\u00a0f\u00fcr\u00a0die\u00a0\nIndikation\u00a0CLL\u00a0ist\u00a0eine\u00a0in\u00a0Deutschland\u00a0von\u00a0der\u00a0CLL\u00a0Studiengrupp e\u00a0initiierte\u00a0multi\u2010\nzentrische,\u00a0offene,\u00a0randomisier te,\u00a0dreiarmige\u00a0Phase\u2010III\u2010Studie\u00a0 an\u00a0Patienten\u00a0mit\u00a0\nnicht\u00a0vorbehandelter\u00a0CLL\u00a0und\u00a0klinisch\u00a0relevanten\u00a0Komorbidit\u00e4ten \u00a0(Goede\u00a0et.\u00a0al,\u00a0\n2014).\u00a0Insgesamt\u00a0wurden\u00a0781\u00a0Patienten\u00a0mit\u00a0reduziertem\u00a0Allgemein zustand\u00a0CIRS\u2010\nScore\u00a0>\u00a06\u00a0und/oder\u00a0eingeschr\u00e4nkte\u00a0Nierenfunktion\u00a0mit\u00a0CrCl\u00a030\u00a0\u2013\u00a069\u00a0ml /min)\u00a0in\u00a0\neinem\u00a0medianen\u00a0Alter\u00a0von\u00a073\u00a0Jahren\u00a02:2:1\u00a0randomisiert\u00a0in\u00a0die\u00a0Be handlungsarme\u00a0\nObinutuzumab\u00a0plus\u00a0Chlorambucil,\u00a0Rituximab\u00a0plus\u00a0Chlorambucil\u00a0und \u00a0Chlorambucil\u2010\nMonotherapie.\u00a0In\u00a0Stufe\u00a01a\u00a0an\u00a0356\u00a0Patienten\u00a0wurde\u00a0Obinutuzumab\u00a0p lus\u00a0Chloram\u2010\nbucil\u00a0verglichen\u00a0mit\u00a0Chlorambucil\u2010Mono,\u00a0in\u00a0Stufe\u00a02\u00a0an\u00a0663\u00a0Patie nten\u00a0wurde\u00a0der\u00a0\nVergleich\u00a0mit\u00a0Rituximab\u00a0plus\u00a0Chlorambucil\u00a0durchgef\u00fchrt.\u00a0Die\u00a0Beh andlung\u00a0erfolgte\u00a0\n\u00fcber\u00a0sechs\u00a0Zyklen\u00a0\u00e0\u00a028\u00a0Tage.\u00a0Obinutuzumab\u00a0wurde\u00a0im\u00a0ersten\u00a0Behan dlungszyklus\u00a0in\u00a0\neiner\u00a0Dosis\u00a0von\u00a01.000\u00a0mg\u00a0absolut\u00a0an\u00a0Tag\u00a01,\u00a08\u00a0und\u00a015\u00a0infundiert, \u00a0in\u00a0den\u00a0folgenden\u00a0\nZyklen\u00a0nur\u00a0an\u00a0Tag\u00a01,\u00a0Chlorambucil\u00a0wurde\u00a0in\u00a0allen\u00a0sechs\u00a0Behandlu ngszyklen\u00a0in\u00a0einer\u00a0\nDosis\u00a0von\u00a00,5\u00a0mg/kg\u00a0K\u00f6rpergewicht\u00a0oral\u00a0verabreicht.\u00a0Rituximab\u00a0i m\u00a0Kontrollarm\u00a0\nwurde\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a0375\u00a0mg/m2\u00a0an\u00a0Tag\u00a01\u00a0des\u00a0ersten\u00a0Zyklus\u00a0und\u00a0in\u00a0einer\u00a0\nDosierung\u00a0von\u00a0500\u00a0mg/m2\u00a0an\u00a0Tag\u00a01\u00a0der\u00a0folgenden\u00a0Zyklen\u00a0appliziert.\u00a0Prim\u00e4rer\u00a0End\u2010\npunkt\u00a0war\u00a0das\u00a0vom\u00a0Pr\u00fcfarzt\u00a0beurteilte\u00a0PFS.\u00a0Das\u00a0OS\u00a0und\u00a0die\u00a0HRQoL \u00a0geh\u00f6rten\u00a0zu\u00a0den\u00a0\nsekund\u00e4ren\u00a0Endpunkten.\u00a0In\u00a0der\u00a0Analyse\u00a0der\u00a0Stufe\u00a01a\u00a0betrug\u00a0das\u00a0m ediane\u00a0PFS\u00a026,7\u00a0\nMonate\u00a0unter\u00a0Obinutuzumab\u00a0plus\u00a0Chlorambucil\u00a0versus\u00a011,1\u00a0Monate\u00a0 unter\u00a0Mono\u2010\ntherapie\u00a0mit\u00a0Chlorambucil.\u00a0Hinsichtlich\u00a0des\u00a0OS\u00a0konnte\u00a0ein\u00a0signi fikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0\ndie\u00a0Kombinationstherapie\u00a0gezeigt\u00a0werden.\u00a0Zum\u00a0Zeitpunkt\u00a0der\u00a0Stuf e\u20102\u2010Analyse\u00a0war\u00a0\nunter\u00a0Obinutuzumab\u00a0plus\u00a0Chloambucil\u00a0gegen\u00fcber\u00a0Rituximab\u00a0plus\u00a0Ch lorambucil\u00a0das\u00a0\nPFS\u00a0um\u00a011,5\u00a0Monate\u00a0verl\u00e4ngert\u00a0(26,7\u00a0vs.\u00a015,2\u00a0Monate),\u00a0das\u00a0OS\u00a0un terschied\u00a0sich\u00a0in\u00a0\nbeiden\u00a0Gruppen\u00a0nicht\u00a0signifikant.\u00a0Ein\u00a0im\u00a0Juli\u00a02015\u00a0publiziertes \u00a0Update\u00a0der\u00a0Studie\u00a0\nzeigte\u00a0in\u00a0der\u00a0Stufe\u00a01a\u00a0ein\u00a0PFS\u00a0von\u00a029,9\u00a0Monaten\u00a0im\u00a0Intervention sarm\u00a0versus\u00a011,1\u00a0\nMonaten\u00a0in\u00a0der\u00a0Kontrollgruppe,\u00a0i n\u00a0der\u00a0Stufe\u00a02\u00a0ein\u00a0PFS\u00a0von\u00a029,2\u00a0 Monaten\u00a0versus\u00a0\n15,4\u00a0Monaten\u00a0(Goede\u00a0et\u00a0al.,\u00a02015).\u00a0Die\u00a0Daten\u00a0zur\u00a0HRQoL\u00a0und\u00a0Symp tomatik\u00a0wur\u2010\nden\u00a0im\u00a0Wesentlichen\u00a0mit\u00a0dem\u00a0EORT C\u2010QLQ\u2010C30\u2010Fragebogen\u00a0erhoben.\u00a0I n\u00a0Bezug\u00a0auf\u00a0\nden\u00a0Endpunkt\u00a0HRQoL\u00a0konnten\u00a0zwisc hen\u00a0den\u00a0Behandlungsgruppen\u00a0kein e\u00a0statistisch\u00a0\nsignifikanten\u00a0Unterschiede\u00a0gezeigt\u00a0werden\u00a0(EMA,\u00a02016).\u00a0Die\u00a0Inzi denz\u00a0an\u00a0UAE\u00a0Grad\u00a0301\u00a0\u2265\u00a03\u00a0war\u00a0insgesamt\u00a0unter\u00a0Obinutuzumab\u00a0plus\u00a0Chlorambucil\u00a0im\u00a0Vergl eich\u00a0zu\u00a0Rituxi\u2010\nmab\u00a0plus\u00a0Chlorambucil\u00a0signifikant\u00a0h\u00f6her,\u00a0vor\u00a0allem\u00a0infusionsbed ingte\u00a0Reaktionen,\u00a0\nNeutropenien\u00a0und\u00a0Thrombozytopenien\u00a0traten\u00a0h\u00e4ufiger\u00a0auf.\u00a0\nBasis\u00a0der\u00a0Zulassung\u00a0in\u00a0der\u00a0Indikation\u00a0FL\u00a0ist\u00a0die\u00a0derzeit\u00a0noch\u00a0l aufende\u00a0multizentri\u2010\nsche,\u00a0offene,\u00a01:1\u2010randomiserte\u00a0P hase\u2010III\u2010Studie\u00a0GADOLIN\u00a0(Sponso r:\u00a0Hoffmann\u2010La\u00a0\nRoche)\u00a0an\u00a0insgesamt\u00a0413\u00a0Patienten\u00a0mit\u00a0indolentem\u00a0NHL,\u00a0die\u00a0auf\u00a0e ine\u00a0Behandlung\u00a0\nmit\u00a0Rituximab\u00a0oder\u00a0einem\u00a0Rituximab\u2010haltigen\u00a0Regime\u00a0nicht\u00a0angesp rochen\u00a0haben\u00a0\noder\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten\u00a0nach\u00a0der\u00a0letzten\u00a0Dosis\u00a0von\u00a0Rit uximab\u00a0progre\u2010\ndient\u00a0wurden\u00a0(Sehn\u00a0et\u00a0al.,\u00a02016).\u00a081\u00a0%\u00a0(n=335)\u00a0der\u00a0Patienten\u00a0ha tten\u00a0ein\u00a0FL,\u00a0diese\u00a0\ngr\u00f6\u00dfte\u00a0 Teilpopulation\u00a0 wurde\u00a0 als\u00a0 zulassungsrelevante\u00a0 Subgruppe\u00a0 d efiniert.\u00a0 Die\u00a0\nInterventionsgruppe\u00a0erhielt\u00a0als\u00a0Induktionstherapie\u00a0Obinutuzumab \u00a0in\u00a0Kombination\u00a0\nmit\u00a0Bendamustin,\u00a0die\u00a0Kontrollgruppe\u00a0Bendamustin\u2010Mono\u00a0\u00fcber\u00a0sechs \u00a0Zyklen\u00a0mit\u00a0\neiner\u00a0Dauer\u00a0von\u00a0jeweils\u00a028\u00a0Tagen. \u00a0Patienten\u00a0in\u00a0der\u00a0Intervention sgruppe,\u00a0bei\u00a0denen\u00a0\nes\u00a0am\u00a0Ende\u00a0der\u00a0Induktionstherapie\u00a0zu\u00a0keiner\u00a0Krankheitsprogressi on\u00a0gekommen\u00a0\nwar,\u00a0bekamen\u00a0anschlie\u00dfend\u00a0eine\u00a0Erhaltungstherapie\u00a0mit\u00a0Obinutuzu mab\u00a0einmal\u00a0\nalle\u00a0zwei\u00a0Monate\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0oder\u00a0bis\u00a0zu\u00a0einer\u00a0Krankheitspr ogression.\u00a0Obinu\u2010\ntuzumab\u00a0wurde\u00a0als\u00a0Infusion\u00a0mit\u00a0einer\u00a0Gesamtdosis\u00a0von\u00a01.000\u00a0mg\u00a0a n\u00a0Tag\u00a01,\u00a08\u00a0und\u00a0\n15\u00a0im\u00a0ersten\u00a0Zyklus\u00a0und\u00a0in\u00a0den\u00a0f olgenden\u00a0f\u00fcnf\u00a0Zyklen\u00a0nur\u00a0an\u00a0Tag \u00a01\u00a0verabreicht,\u00a0in\u00a0\nder\u00a0 Erhaltungstherapie\u00a0 wurden\u00a0 ebenfalls\u00a0 jeweils\u00a0 1.000\u00a0 mg\u00a0 absolu t\u00a0 gegeben.\u00a0\nBendamustin\u00a0wurde\u00a0in\u00a0allen\u00a0sechs\u00a0Zyklen\u00a0an\u00a0Tag\u00a01\u00a0und\u00a02\u00a0infundie rt,\u00a0in\u00a0Kombinati\u2010\non\u00a0mit\u00a0Obinutuzumab\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a090\u00a0mg\u00a0pro\u00a0m2\u00a0K\u00f6rperoberfl\u00e4che\u00a0pro\u00a0\nTag,\u00a0bei\u00a0alleiniger\u00a0Gabe\u00a0in\u00a0einer\u00a0Dosierung\u00a0von\u00a0120\u00a0mg/m2/Tag.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0\nder\u00a0Studie\u00a0war\u00a0das\u00a0durch\u00a0ein\u00a0unabh\u00e4ngiges\u00a0Gremium\u00a0bewertete\u00a0PFS ,\u00a0sekund\u00e4re\u00a0\nEndpunkte\u00a0waren\u00a0unter\u00a0anderem\u00a0das\u00a0OS,\u00a0das\u00a0Ansprechen,\u00a0die\u00a0Dauer \u00a0des\u00a0Anspre\u2010\nchens,\u00a0die\u00a0\u00c4nderung\u00a0der\u00a0HRQoL\u00a0und\u00a0die\u00a0Vertr\u00e4glichkeit.\u00a0F\u00fcr\u00a0die\u00a0 Teilpopulation\u00a0der\u00a0\nPatienten\u00a0mit\u00a0FL\u00a0wurde\u00a0zum\u00a0zweiten\u00a0Datenschnitt\u00a0vom\u00a001.05.2015\u00a0 ein\u00a0medianes\u00a0\nPFS\u00a0von\u00a029,2\u00a0Monaten\u00a0im\u00a0Interve ntionsarm\u00a0gegen\u00fcber\u00a013,8\u00a0Monaten \u00a0im\u00a0Kontroll\u2010\narm\u00a0erreicht.\u00a0Bez\u00fcglich\u00a0des\u00a0OS\u00a0zeigte\u00a0sich\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a0 ein\u00a0statistisch\u00a0signi\u2010\nfikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0Obinutuzumab,\u00a0der\u00a0Median\u00a0wurde\u00a0in\u00a0beiden\u00a0B ehandlungsgrup\u2010\npen\u00a0jedoch\u00a0noch\u00a0nicht\u00a0erreicht.\u00a0F\u00fcr\u00a0die\u00a0HRQoL,\u00a0gemessen\u00a0an\u00a0den\u00a0 Skalen\u00a0des\u00a0Krebs\u2010\nspezifischen\u00a0 Fragebogens\u00a0 FACT\u2010G\u00a0 und\u00a0 des\u00a0 Lymphom\u2010spezifischen\u00a0 Fr agebogens\u00a0\nFACT\u2010Lym,\u00a0zeigte\u00a0sich\u00a0kein\u00a0statistisch\u00a0signifikanter\u00a0Unterschie d\u00a0in\u00a0den\u00a0Behand\u2010\nlungsarmen.\u00a0Auch\u00a0bei\u00a0den\u00a0schwerwiegenden\u00a0unerw\u00fcnschten\u00a0Ereignis sen\u00a0Grad\u00a0\u2265\u00a03\u00a0\nin\u00a0der\u00a0Induktionsphase\u00a0unterschieden\u00a0sich\u00a0beide\u00a0Studienarme\u00a0ins gesamt\u00a0nicht.\u00a0\nW\u00e4hrend\u00a0in\u00a0der\u00a0Interventionsgruppe\u00a0h\u00e4ufiger\u00a0schwerwiegende\u00a0Neut ropenien\u00a0und\u00a0\nI R R \u00a0a l s \u00a0i n \u00a0d e r \u00a0K o n t r o l l g r u p p e \u00a0a u f t r a t e n , \u00a0k a m \u00a0e s \u00a0u n t e r \u00a0d e r \u00a0B e n d a mustin\u2010\nMonotherapie\u00a0h\u00e4ufiger\u00a0zu\u00a0Thrombozytopenien.\u00a0\u00a0\nIn\u00a0der\u00a0multizentrischen,\u00a0offenen ,\u00a0randomisierten\u00a0Phase\u2010III\u2010Stud ie\u00a0GOYA\u00a0verglich\u00a0\nHoffmann\u2010La\u00a0Roche\u00a0Obinutuzumab\u00a0in\u00a0der\u00a0Kombination\u00a0mit\u00a0CHOP\u00a0mit\u00a0 Rituximab\u00a0302\u00a0plus\u00a0CHOP\u00a0an\u00a0Patienten\u00a0mit\u00a0nicht \u00a0vorbehandeltem\u00a0diffusen\u00a0gro\u00dfze lligen\u00a0B\u2010Zell\u2010\nLymphom,\u00a0dem\u00a0h\u00e4ufigsten\u00a0Subtyp\u00a0des\u00a0hochmalignen\u00a0NHL\u00a0(DAZ\u00a0online ,\u00a02016b).\u00a0Im\u00a0\nJuli\u00a02016\u00a0gab\u00a0Roche\u00a0bekannt,\u00a0dass\u00a0der\u00a0prim\u00e4re\u00a0Endpunkt,\u00a0das\u00a0vom \u00a0Pr\u00fcfarzt\u00a0beur\u2010\nteilte\u00a0PFS,\u00a0nicht\u00a0erreicht\u00a0wurde\u00a0(ASH,\u00a02016).\u00a0\nDie\u00a0globale\u00a01:1\u2010randomisierte\u00a0 Phase\u2010III\u2010Studie\u00a0GALLIUM\u00a0(Sponsor :\u00a0Hoffmann\u2010La\u00a0\nRoche)\u00a0untersucht\u00a0an\u00a01.202\u00a0Patienten\u00a0mit\u00a0nicht\u00a0vorbehandeltem\u00a0F L\u00a0Obinutuzumab\u00a0\nplus\u00a0Chemotherapie\u00a0(CHOP,\u00a0CVP\u00a0oder\u00a0Bendamustin)\u00a0versus\u00a0Rituxima b\u00a0plus\u00a0Chemo\u2010\ntherapie\u00a0in\u00a0einer\u00a0sechs\u00a0bis\u00a0acht\u00a0Zyklen\u00a0umfassenden\u00a0Induktionst herapie\u00a0gefolgt\u00a0\nvon\u00a0einer\u00a0zweij\u00e4hrigen\u00a0Erhaltungstherapie\u00a0mit\u00a0dem\u00a0jeweiligen\u00a0mo noklonalen\u00a0Anti\u2010\nCD20\u2010Antik\u00f6rper\u00a0allein\u00a0alle\u00a0zwei\u00a0 Monate\u00a0(DGHO,\u00a02016b).\u00a0Die\u00a0bisl ang\u00a0noch\u00a0nicht\u00a0\npublizierten\u00a0Ergebnisse\u00a0der\u00a0ersten\u00a0Zwischenanalyse\u00a0zeigen\u00a0ein\u00a0l \u00e4ngeres\u00a0PFS\u00a0unter\u00a0\nder\u00a0Behandlung\u00a0auf\u00a0Basis\u00a0von\u00a0Obinutuzumab\u00a0als\u00a0unter\u00a0der\u00a0Rituxim ab\u2010basierten\u00a0\nVergleichstherapie.\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0CLL\u00a0ist\u00a0nach\u00a0derzeitigem\u00a0Kenntnisstand\u00a0nicht\u00a0heilbar.\u00a0Die\u00a0e inzige\u00a0kurative\u00a0Opti\u2010\non\u00a0 besteht\u00a0 in\u00a0 der\u00a0 allogenen\u00a0 Sta mmzelltransplantation,\u00a0 die\u00a0 aufgr und\u00a0 schwerer\u00a0\ntherapieassoziierter\u00a0 Komplikationen\u00a0 nur\u00a0 f\u00fcr\u00a0 eine\u00a0 begrenzte\u00a0 Zahl \u00a0 an\u00a0 Patienten\u00a0\ninfrage\u00a0kommt\u00a0(Maurer\u00a0&\u00a0Hallek,\u00a02013).\u00a0W\u00e4hrend\u00a0Patienten\u00a0im\u00a0Bin et\u2010Stadium\u00a0A\u00a0\nund\u00a0B\u00a0und\u00a0Patienten\u00a0mit\u00a0einer\u00a0stabilen\u00a0Erkrankung\u00a0h\u00e4ufig\u00a0keiner \u00a0Therapie\u00a0bed\u00fcr\u2010\nfen\u00a0und\u00a0nur\u00a0engmaschig\u00a0beobachtet\u00a0werden\u00a0( Watch\u2010and\u2010Wait \u2010Strategie),\u00a0besteht\u00a0\nim\u00a0Binet\u2010Stadium\u00a0C\u00a0und\u00a0bei\u00a0einer\u00a0 rasch\u00a0voranschreitenden\u00a0oder\u00a0s ymptomatischen\u00a0\nErkrankung\u00a0immer\u00a0eine\u00a0Therapieindikation.\u00a0Ein\u00a0allgemein\u00a0g\u00fcltige s\u00a0Behandlungsre\u2010\ngime\u00a0gibt\u00a0es\u00a0nicht,\u00a0die\u00a0Therapiewahl\u00a0orientiert\u00a0sich\u00a0vor\u00a0allem\u00a0 am\u00a0Allgemeinzu\u2010\nstand,\u00a0an\u00a0relevanten\u00a0Komorbidit\u00e4ten\u00a0und\u00a0am\u00a0genetischen\u00a0Status\u00a0( Wendtner\u00a0et\u00a0al.,\u00a0\n2017).\u00a0Da\u00a0etwa\u00a070\u00a0%\u00a0der\u00a0neu\u00a0diagnostizierten\u00a0Patienten\u00a0\u00e4lter\u00a0al s\u00a065\u00a0Jahre\u00a0sind\u00a0und\u00a0\nzu\u00a0einem\u00a0Gro\u00dfteil\u00a0mehrere\u00a0Beglei terkrankungen\u00a0mit\u00a0Medikation\u00a0so wie\u00a0eine\u00a0einge\u2010\nschr\u00e4nkte\u00a0Nierenfunktion\u00a0aufweisen,\u00a0was\u00a0entscheidenden\u00a0Einfluss \u00a0auf\u00a0die\u00a0Vertr\u00e4g\u2010\nlichkeit\u00a0aggressiver\u00a0Chemotherapien\u00a0hat,\u00a0werden\u00a0sie\u00a0mit\u00a0Hilfe\u00a0d es\u00a0CIRS\u2010Score\u00a0in\u00a0die\u00a0\ndrei\u00a0Gruppen\u00a0fit,\u00a0unfit\u00a0und\u00a0gebrechlich\u00a0eingeteilt,\u00a0um\u00a0ihre\u00a0Eig nung\u00a0f\u00fcr\u00a0bestimmte\u00a0\nTherapien\u00a0abzusch\u00e4tzen.\u00a0F\u00fcr\u00a0die\u00a0 \u201efitten\u201c\u00a0Patienten\u00a0in\u00a0gutem\u00a0All gemeinzustand\u00a0ist\u00a0\nin\u00a0der\u00a0Erstlinienbehandlung\u00a0die\u00a0a ggressive\u00a0Chemoimmuntherapie,\u00a0 basierend\u00a0auf\u00a0\nder\u00a0Kombination\u00a0eines\u00a0Purinnukleo sid\u2010Analogons\u00a0mit\u00a0einem\u00a0Anti\u2010C D20\u2010Antik\u00f6rper\u00a0\n(Rituximab,\u00a0Ofatumumab\u00a0oder\u00a0Obinutuzumab)\u00a0Standard,\u00a0wobei\u00a0das\u00a0R egime\u00a0FCR\u00a0\n(Fludarabin\u00a0+\u00a0Cyclophosphamid\u00a0+\u00a0 Rituximab)\u00a0prim\u00e4r\u00a0empfohlen\u00a0wir d.\u00a0Mittlerweile\u00a0\nbevorzugt\u00a0man\u00a0allerdings\u00a0f\u00fcr\u00a0die\u00a0\u201efitten\u201c\u00a0Patienten\u00a0jenseits\u00a0de s\u00a065.\u00a0Lebensjahres\u00a0\nwegen\u00a0seines\u00a0g\u00fcnstigeren\u00a0Toxizit\u00e4 tsprofils\u00a0das\u00a0Regime\u00a0Bendamust in\u00a0plus\u00a0Rituxi\u2010\nmab.\u00a0Komorbide\u00a0Patienten\u00a0mit\u00a0klinisch\u00a0relevanten\u00a0Begleiterkrank ungen\u00a0erhalten\u00a0in\u00a0\nder\u00a0Erstlinie\u00a0anstelle\u00a0von\u00a0Fluda rabin\u00a0und\u00a0Cyclophosphamid\u00a0die\u00a0f \u00fcr\u00a0sie\u00a0besser\u00a0ver\u2010\ntr\u00e4glichen\u00a0Zytostatika\u00a0Chlorambucil\u00a0oder\u00a0Bendamustin\u00a0in\u00a0Kombina tion\u00a0mit\u00a0einem\u00a0303\u00a0CD20\u2010Antik\u00f6rper.\u00a0F\u00fcr\u00a0Patienten\u00a0\u226565\u00a0Jahre\u00a0ist\u00a0auch\u00a0die\u00a0Therapie\u00a0 mit\u00a0dem\u00a0oralen\u00a0\nTyrosinkinase\u2010Inhibitor\u00a0 Ibrutini b\u00a0 eine\u00a0 Option.\u00a0 Die\u00a0 palliativen\u00a0 supportiven\u00a0 Ma\u00df\u2010\nnahmen\u00a0f\u00fcr\u00a0die\u00a0k\u00f6rperlich\u00a0stark\u00a0beeintr\u00e4chtigten\u00a0bzw.\u00a0gebrechli chen\u00a0Patienten\u00a0\nk\u00f6nnen\u00a0ebenfalls\u00a0antineoplastisch\u00a0wirksame\u00a0Substanzen\u00a0wie\u00a0Stero ide,\u00a0Chlorambu\u2010\ncil,\u00a0Bendamustin\u00a0oder\u00a0Rituximab\u00a0in\u00a0angepasster\u00a0Dosierung\u00a0beinha lten.\u00a0Bei\u00a0Hochri\u2010\nsikopatienten\u00a0mit\u00a0einer\u00a017p\u2010Deletion\u00a0und/oder\u00a0TP53\u2010Mutation\u00a0wir d\u00a0bereits\u00a0in\u00a0der\u00a0\nErstlinie\u00a0eine\u00a0Behandlung\u00a0mit\u00a0dem\u00a0Kinase\u2010Inhibitor\u00a0Ibrutinib\u00a0od er,\u00a0bei\u00a0Kontraindi\u2010\nkation\u00a0gegen\u00a0Ibrutinib,\u00a0die\u00a0Kombination\u00a0Idelalisib\u00a0plus\u00a0Rituxim ab\u00a0empfohlen.\u00a0In\u00a0der\u00a0\nZweitlinie\u00a0und\u00a0allen\u00a0folgenden\u00a0Linien\u00a0m\u00fcssen\u00a0bei\u00a0der\u00a0Auswahl\u00a0de r\u00a0Rezidivtherapie\u00a0\nneben\u00a0dem\u00a0k\u00f6rperlichen\u00a0Zustand\u00a0und\u00a0dem\u00a0Risikoprofil\u00a0die\u00a0Art\u00a0der \u00a0Vortherapie\u00a0und\u00a0\ndie\u00a0damit\u00a0erreichte\u00a0Remissionsdauer\u00a0ber\u00fccksichtigt\u00a0werden.\u00a0Wenn \u00a0das\u00a0Anspre\u2010\nchen\u00a0auf\u00a0die\u00a0Vorlinientherapie\u00a0gut\u00a0ist\u00a0und\u00a0mindestens\u00a0zwei\u00a0Jahr e\u00a0betr\u00e4gt,\u00a0kann\u00a0\ndiese\u00a0wiederholt\u00a0werden,\u00a0bei\u00a0fr \u00fcheren\u00a0Rezidiven\u00a0sollte\u00a0die\u00a0vora ngegangene\u00a0The\u2010\nrapie\u00a0nicht\u00a0mehr\u00a0eingesetzt\u00a0 werden.\u00a0Neben\u00a0Ibrutinib,\u00a0Idelalisib /Rituximab\u00a0und\u00a0\ndem\u00a0BCL2\u2010Hemmer\u00a0Venetoclax\u00a0komme n\u00a0also\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Rezidivther apie\u00a0intensi\u2010\nve\u00a0Chemoimmuntherapien\u00a0infrage,\u00a0 allerdings\u00a0sind\u00a0mehrfach\u00a0vorbeh andelte\u00a0Pati\u2010\nenten\u00a0durch\u00a0eine\u00a0eingeschr\u00e4nkte\u00a0N ieren\u2010\u00a0und\u00a0Knochenmarkfunktion \u00a0h\u00e4ufig\u00a0zu\u2010\nnehmend\u00a0ungeeignet\u00a0f\u00fcr\u00a0weitere\u00a0aggressive\u00a0Behandlungen.\u00a0Hochris iko\u2010CLL\u2010Patien\u2010\nten\u00a0sowie\u00a0therapiebed\u00fcrftige\u00a0Pati enten\u00a0mit\u00a0Nachweis\u00a0einer\u00a017p\u2010D eletion\u00a0bzw.\u00a0\nTP53\u2010Mutation\u00a0im\u00a0Rezidiv\u00a0sollten\u00a0einer\u00a0allogenen\u00a0Stammzelltrans plantation\u00a0zuge\u2010\nf\u00fchrt\u00a0werden,\u00a0sofern\u00a0ihr\u00a0k\u00f6rperlicher\u00a0Zustand\u00a0und\u00a0die\u00a0Spendersi tuation\u00a0dies\u00a0erlau\u2010\nben.\u00a0Da\u00a0CLL\u2010Patienten\u00a0krankheits \u2010\u00a0und\u00a0therapiebedingt\u00a0h\u00e4ufig\u00a0In fektionskomplika\u2010\ntionen\u00a0zeigen,\u00a0haben\u00a0eine\u00a0konsequente\u00a0antibiotische,\u00a0antimykoti sche\u00a0und\u00a0virusta\u2010\ntische\u00a0Therapie\u00a0bei\u00a0Infektzeichen\u00a0und\u00a0die\u00a0Substitution\u00a0von\u00a0Immu nglobulinen\u00a0bei\u00a0\nHypogammaglobulin\u00e4mie\u00a0und\u00a0gleichze itig\u00a0erh\u00f6hter\u00a0Infektfrequenz\u00a0 zentrale\u00a0Bedeu\u2010\ntung\u00a0f\u00fcr\u00a0das\u00a0Langzeit\u00fcberleben.\u00a0\nDie\u00a0Therapie\u00a0des\u00a0FL\u00a0erfolgt\u00a0stadienadaptiert\u00a0und\u00a0nur\u00a0bei\u00a0besteh ender\u00a0Symptoma\u2010\ntik\u00a0oder\u00a0drohenden\u00a0Komplikationen.\u00a0W\u00e4hrend\u00a0in\u00a0den\u00a0Stadien\u00a0I\u00a0und \u00a0II\u00a0in\u00a0erster\u00a0Linie\u00a0\nmit\u00a0 lokaler\u00a0 Bestrahlung\u00a0 der\u00a0 bet roffenen\u00a0 Lymphknotenregionen\u00a0 und \u00a0k u r a t i v e m \u00a0\nAnspruch\u00a0behandelt\u00a0wird,\u00a0erfolgt\u00a0im\u00a0Stadium\u00a0III\u00a0und\u00a0IV\u00a0beim\u00a0Auf treten\u00a0krankheits\u2010\nassoziierter\u00a0Symptome\u00a0eine\u00a0syste mische\u00a0medikament\u00f6se\u00a0Behandlung \u00a0mit\u00a0palliati\u2010\nvem\u00a0Therapieanspruch\u00a0(Buske\u00a0et\u00a0al.,\u00a02017).\u00a0Standard\u00a0f\u00fcr\u00a0die\u00a0Ind uktionstherapie\u00a0in\u00a0\nder\u00a0Erstlinie\u00a0ist\u00a0bei\u00a0\u201emedizinisch\u00a0fitten\u201c\u00a0Patienten\u00a0eine\u00a0Immun chemotherapie,\u00a0in\u00a0\nder\u00a0 Rituximab\u00a0 kombiniert\u00a0 wird\u00a0 mit\u00a0 Anthrazyklin\u2010haltiger\u00a0 Chemoth erapie\u00a0 (z.B.\u00a0\u00a0\nR\u2010CHOP)\u00a0oder,\u00a0speziell\u00a0bei\u00a0\u00e4ltere n\u00a0Patienten\u00a0wegen\u00a0besserer\u00a0Ver tr\u00e4glichkeit,\u00a0mit\u00a0\nBendamustin.\u00a0Auf\u00a0die\u00a0prim\u00e4re\u00a0Immunchemotherapie\u00a0folgt\u00a0eine\u00a0Erha ltungstherapie\u00a0\nmit\u00a0Rituximab\u00a0in\u00a0zweimonatigem\u00a0Abstand\u00a0\u00fcber\u00a0zwei\u00a0Jahre.\u00a0Auch\u00a0im \u00a0Rezidiv\u00a0ist\u00a0f\u00fcr\u00a0\ndie\u00a0Induktion\u00a0die\u00a0Kombination\u00a0von\u00a0Rituximab\u00a0mit\u00a0Chemotherapie\u00a0S tandard,\u00a0wobei\u00a0\nals\u00a0zytotoxische\u00a0Wirkstoffe\u00a0andere\u00a0als\u00a0in\u00a0der\u00a0Prim\u00e4rtherapie\u00a0zu m\u00a0Einsatz\u00a0kommen\u00a0\nsollten.\u00a0Als\u00a0Erhaltungstherapie\u00a0im\u00a0Rezidiv\u00a0wird\u00a0Rituximab\u00a0in\u00a0dr eimonatigem\u00a0Ab\u2010304\u00a0stand\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0gegeben.\u00a0Erfolgt\u00a0das\u00a0Rezidiv\u00a0nach\u00a0initial er\u00a0Immunchemothe\u2010\nrapie\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monate n,\u00a0wird\u00a0von\u00a0einer\u00a0Refrakt\u00e4rit\u00e4t \u00a0gegen\u00fcber\u00a0Ritu\u2010\nximab\u00a0ausgegangen.\u00a0F\u00fcr\u00a0diese\u00a0Pat ienten,\u00a0die\u00a0bislang\u00a0mit\u00a0einer\u00a0a lleinigen\u00a0patienten\u2010\nindividuellen\u00a0Chemotherapie\u00a0bzw.\u00a0BSC\u00a0behandelt\u00a0wurden,\u00a0ist\u00a0f\u00fcr\u00a0 die\u00a0Induktion\u00a0die\u00a0\nKombination\u00a0von\u00a0Obinutuzumab/Bendamustin\u00a0eine\u00a0Option.\u00a0F\u00fcr\u00a0Patie nten,\u00a0die\u00a0auf\u00a0\nzwei\u00a0 vorausgegangene\u00a0 Therapielinien\u00a0 nicht\u00a0 angesprochen\u00a0 haben,\u00a0 i s t \u00a0d e r \u00a0P I 3 K \u2010\nInhibitor\u00a0Idelalisib\u00a0als\u00a0Monotherapie\u00a0zugelassen.\u00a0Als\u00a0Konsolidi erung\u00a0kann,\u00a0alterna\u2010\ntiv\u00a0 zur\u00a0 Erhaltungstherapie\u00a0 mit\u00a0 Rituximab,\u00a0 eine\u00a0 Radioimmuntherap ie\u00a0 mit\u00a0 90Y\u2010\nmarkiertem\u00a0Ibritumomab\u2010Tiuxetan\u00a0oder,\u00a0insbesondere\u00a0f\u00fcr\u00a0Patiente n\u00a0\u2264\u00a060\u00a0Jahre\u00a0\nmit\u00a0fr\u00fchen\u00a0Rezidiven,\u00a0eine\u00a0myeloablative\u00a0Hochdosischemotherapie \u00a0g ef ol g t\u00a0v o n\u00a0\neiner\u00a0autologen\u00a0Stammzelltrans plantation\u00a0erwogen\u00a0werden.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nF\u00fcr\u00a0das\u00a0Orphan\u2010Arzneimittel\u00a0Obinutuzumab\u00a0gilt\u00a0 gem\u00e4\u00df\u00a0(fr\u00fcher)\u00a0Nutzenbewertung\u00a0\nder\u00a0medizinische\u00a0Zusatznutzen\u00a0dur ch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0d er\u00a0G\u2010BA\u00a0bewertet\u00a0\nlediglich\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0auf\u00a0der\u00a0Grundlage\u00a0der\u00a0Zu lassungsstudien.\u00a0\nIm\u00a0Anwendungsgebiet\u00a0CLL\u00a0sieht\u00a0der\u00a0 G\u2010BA\u00a0einen\u00a0nicht\u00a0quantifizierbaren\u00a0Zusatz\u2010\nnutzen\u00a0f\u00fcr\u00a0Obinutuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Chlorambucil\u00a0bei\u00a0Patienten \u00a0mit\u00a0nicht\u00a0\nvorbehandelter\u00a0 CLL,\u00a0 die\u00a0 f\u00fcr\u00a0 eine\u00a0 Therapie\u00a0 mit\u00a0 Fludarabin\u00a0 nicht\u00a0 geeignet\u00a0 sind\u00a0\u00a0\n(G\u2010BA,\u00a02014).\u00a0Zwar\u00a0war\u00a0das\u00a0mediane\u00a0progressionsfreie\u00a0\u00dcberleben\u00a0 in\u00a0der\u00a0Zulas\u2010\nsungsstudie\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Stufe\u20102\u2010Analyse\u00a0im\u00a0Interventionsa rm\u00a0gegen\u00fcber\u00a0\ndem\u00a0Kontrollarm\u00a0um\u00a011,8\u00a0Monate\u00a0v erl\u00e4ngert,\u00a0jedoch\u00a0ist\u00a0umstritte n,\u00a0ob\u00a0dieses\u00a0\nE r g e b n i s \u00a0f \u00fc r \u00a0P a t i e n t e n \u00a0r e l e v a n t \u00a0i s t . \u00a0D i e \u00a0D a t e n \u00a0z u m \u00a0s e k u n d \u00e4 r e n \u00a0E ndpunkt\u00a0 OS\u00a0\nsch\u00e4tzt\u00a0der\u00a0G\u2010BA\u00a0aufgrund\u00a0der\u00a0relativ\u00a0kurzen\u00a0Studienlaufzeit\u00a0al s\u00a0unreif\u00a0ein,\u00a0zudem\u00a0\nist\u00a0 eine\u00a0 Signifikanz\u00a0 dieses\u00a0 Endpunktes\u00a0 in\u00a0 der\u00a0 Studienpopulation \u00a0w e g e n \u00a0h o h e n \u00a0\nDurchschnittsalters\u00a0 und\u00a0 nicht\u00a0 krankheitsbedingter,\u00a0 konkurrieren der\u00a0 Todesursa\u2010\nchen\u00a0auch\u00a0bei\u00a0l\u00e4ngerer\u00a0Studiendauer\u00a0schwer\u00a0zu\u00a0erreichen.\u00a0Dass\u00a0d ie\u00a0Gesamtrate\u00a0an\u00a0\nunerw\u00fcnschten\u00a0Ereignissen\u00a0Grad\u00a0\u2265\u00a03\u00a0unter\u00a0Obinutuzumab\u00a0plus\u00a0Chlo rambucil\u00a0im\u00a0\nVergleich\u00a0zu\u00a0Rituximab\u00a0plus\u00a0Chlorambucil\u00a0h\u00f6her\u00a0war,\u00a0beurteilt\u00a0d er\u00a0G\u2010BA\u00a0aufgrund\u00a0\nder\u00a0zahlreichen\u00a0Studienprotokoll\u00e4 nderungen,\u00a0die\u00a0vor\u00a0allem\u00a0die\u00a0I ntensivierung\u00a0der\u00a0\nPr\u00e4medikation\u00a0zur\u00a0Verringerung\u00a0der\u00a0infusionsbedingten\u00a0Nebenwirk ungen\u00a0betra\u2010\nfen,\u00a0als\u00a0nicht\u00a0interpretierbar.\u00a0\nIm\u00a02016\u00a0neu\u00a0zugelassenen\u00a0Anwendung sgebiet\u00a0FL,\u00a0das\u00a0in\u00a0vorausgega ngener\u00a0Thera\u2010\npie\u00a0auf\u00a0Rituximab\u00a0oder\u00a0Rituximab \u2010haltiger\u00a0Therapie\u00a0kein\u00a0Ansprec hen\u00a0zeigte\u00a0oder\u00a0\neine\u00a0Progression\u00a0w\u00e4hrend\u00a0oder\u00a0bis\u00a0zu\u00a0sechs\u00a0Monate\u00a0nach\u00a0der\u00a0Beha ndlung\u00a0aufwies,\u00a0\nsieht\u00a0der\u00a0G\u2010BA\u00a0ebenfalls\u00a0einen\u00a0nicht\u00a0quantifizierbaren\u00a0Zusatznu tzen\u00a0(G\u2010BA,\u00a02016).\u00a0\nSeine\u00a0 Bewertung\u00a0 beruht\u00a0 auf\u00a0 den\u00a0 Ergebnissen\u00a0 des\u00a0 vierten\u00a0 Datensch nittes\u00a0 vom\u00a0\n01.05.2015\u00a0der\u00a0GADOLIN\u2010Studie\u00a0f\u00fcr\u00a0die\u00a0Teilpopulation\u00a0der\u00a0Patien ten\u00a0mit\u00a0follikul\u00e4\u2010\nrem\u00a0NHL.\u00a0Zu\u00a0diesem\u00a0Zeitpunkt\u00a0war\u00a0 bez\u00fcglich\u00a0des\u00a0OS\u00a0die\u00a0Zahl\u00a0der\u00a0 Ereignisse\u00a0in\u00a0\nbeiden\u00a0Behandlungsarmen\u00a0gering\u00a0und\u00a0der\u00a0Median\u00a0noch\u00a0nicht\u00a0erreic ht.\u00a0Die\u00a0Daten\u00a0305\u00a0zum\u00a0allgemeinen\u00a0Gesundheitszustand\u00a0als\u00a0Endpunkt\u00a0in\u00a0der\u00a0Kategori e\u00a0Morbidit\u00e4t\u00a0\nund\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0beurteilt\u00a0der\u00a0G\u2010BA\u00a0 als\u00a0wenig\u00a0aussa\u2010\ngekr\u00e4ftig\u00a0aufgrund\u00a0des\u00a0hohen\u00a0Verz errungspotentials\u00a0infolge\u00a0der\u00a0 offen\u00a0(unverblin\u2010\ndet)\u00a0durchgef\u00fchrten\u00a0Studie.\u00a0Hinsichtlich\u00a0der\u00a0UAE\u00a0sind\u00a0durch\u00a0die \u00a0unterschiedlichen\u00a0\nBehandlungsphasen\u00a0(Induktionstherapie\u00a0in\u00a0beiden\u00a0Studienarmen,\u00a0g egen\u00a0FL\u00a0gerich\u2010\ntete\u00a0Erhaltungstherapie\u00a0nur\u00a0im\u00a0In terventionsarm)\u00a0Verzerrungen\u00a0z ugunsten\u00a0von\u00a0\nObinutuzumab\u00a0nicht\u00a0auszuschlie\u00dfe n;\u00a0im\u00a0Vergleich\u00a0der\u00a0Ergebnisse\u00a0 f\u00fcr\u00a0die\u00a0Zeit\u00a0der\u00a0\nInduktionstherapie\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0in\u00a0der\u00a0Gesamtschau\u00a0keinen\u00a0Unt erschied\u00a0bez\u00fcg\u2010\nlich\u00a0der\u00a0UAE.\u00a0\nVersorgungsanalysen\u00a0\nIm\u00a0 untersuchten\u00a0 Zeitraum\u00a0 bekamen\u00a0 29\u00a0 Versicherte\u00a0 das\u00a0 Orphan\u2010Arzneimittel\u00a0\nObinutuzumab\u00a0verordnet.\u00a0Sie\u00a0waren,\u00a0passend\u00a0zur\u00a0Indikation\u00a0und\u00a0I nzidenz\u00a0der\u00a0CLL,\u00a0\ninsbesondere\u00a0aus\u00a0der\u00a0Altersgruppe\u00a0der\u00a070\u00a0bis\u00a079\u00a0J\u00e4hrigen\u00a0und\u00a0\u00fcb erwiegend\u00a0m\u00e4nn\u2010\nlich.\u00a0Der\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0wurde\u00a0fast\u00a0ausschlie\u00dflich\u00a0als\u00a0 Rezeptur\u00a0abgerech\u2010\nnet,\u00a0wobei\u00a0im\u00a0Januar\u00a0und\u00a0Februar\u00a0sowie\u00a0im\u00a0November\u00a0und\u00a0Dezember \u00a02015\u00a0ein\u00a0\nUmsatzmaximum\u00a0von\u00a0etwa\u00a070.000\u00a0Euro\u00a0erreicht\u00a0wurde\u00a0(s.u.).\u00a0Die\u00a0d azwischen\u00a0\nliegenden\u00a0Umsatzr\u00fcckg\u00e4nge\u00a0k\u00f6nnen\u00a0darauf\u00a0zur\u00fcckgef\u00fchrt\u00a0werden,\u00a0d ass\u00a0gem\u00e4\u00df\u00a0\nBehandlungsprotokoll\u00a0die\u00a0Gabe\u00a0im\u00a0ersten\u00a0Monat\u00a0dreifach\u00a0so\u00a0hoch\u00a0 dosiert\u00a0erfolgt\u00a0\nwie\u00a0in\u00a0den\u00a0nachfolgenden\u00a0f\u00fcnf\u00a0Monaten.\u00a0\nAbbildung\u00a04.34:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Obinutuzumab\u00a0je\u00a0Mo nat\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n306\u00a0Abbildung\u00a04.35:\u00a0Versicherte\u00a0m it\u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Obinutuz umab\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nIm\u00a0 untersuchten\u00a0 Zeitraum\u00a0 bekamen\u00a0 29\u00a0 Versicherte\u00a0 das\u00a0 Orphan\u2010Arzneimittel\u00a0\nObinutuzumab\u00a0verordnet.\u00a0Sie\u00a0waren,\u00a0passend\u00a0zur\u00a0Indikation\u00a0und\u00a0I nzidenz\u00a0der\u00a0CLL,\u00a0\ninsbesondere\u00a0aus\u00a0der\u00a0Altersgruppe\u00a0der\u00a070\u00a0bis\u00a079\u00a0J\u00e4hrigen\u00a0und\u00a0\u00fcb erwiegend\u00a0m\u00e4nn\u2010\nlich.\u00a0\nQuellen\u00a0\nASH\u00a0\u2013\u00a0American\u00a0Society\u00a0of\u00a0Hematology\u00a0(2016).\u00a0Obinutuzumab\u00a0or\u00a0Ri tuximab\u00a0Plus\u00a0CHOP\u00a0in\u00a0Patients\u00a0with\u00a0Previously\u00a0Untreated\u00a0\nDiffuse\u00a0Large\u00a0B\u2010Cell\u00a0Lymphoma:\u00a0Final\u00a0Results\u00a0from\u00a0an\u00a0Open\u2010Label ,\u00a0Randomized\u00a0Phase\u00a03\u00a0Study\u00a0(GOYA).\u00a0\nhttps://ash.confex.com/ash/2016/webprogram/Paper96159.html,\u00a0let zter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nBuske\u00a0C,\u00a0Dreyling\u00a0M,\u00a0Herold\u00a0M,\u00a0Lohri\u00a0A,\u00a0Neumeister\u00a0P,\u00a0Willenbac her\u00a0W\u00a0(2017).\u00a0Follikul\u00e4res\u00a0Lymphom.\u00a0https://www.dgho\u2010\nonkopedia.de/de/onkopedia/leitlinien/follikulaeres\u2010lymphom,\u00a0let zter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nDAZ\u00a0\u2013\u00a0Deutsche\u00a0Apotheker\u00a0Zeitung\u00a0online\u00a0(2013).\u00a0Leuk\u00e4mie:\u00a0Obinu tuzumab\u00a0in\u00a0den\u00a0USA\u00a0zugelassen.\u00a0https://www.deutsche\u2010\napotheker\u2010zeitung.de/news/artikel/2013/11/04/obinutuzumab\u2010in\u2010de n\u2010usa\u2010zugelassen,\u00a0letzter\u00a0Zugriff:\u00a002.02.2017.\u00a0\nDAZ\u00a0\u2013\u00a0Deutsche\u00a0Apotheker\u00a0Zeitung\u00a0online\u00a0(2016b).\u00a0Positives\u00a0Votu m\u00a0f\u00fcr\u00a0Truxima:\u00a0Rituximab\u2010Bio similar\u00a0vor\u00a0der\u00a0Zulassung.\u00a0\nhttps://www.deutsche\u2010apotheker\u2010zeitung.de/news/artikel/2016/12/ 19/rituximab\u2010biosimilar\u2010vor\u2010der\u2010zulassung,\u00a0\nletzter\u00a0Zugriff:\u00a002.03.2017.\u00a0\nDAZ\u00a0\u2013\u00a0Deutsche\u00a0Apotheker\u00a0Zeitung\u00a0online\u00a0(2016a).\u00a0R\u00fcckschlag\u00a0f\u00fcr \u00a0Roche:\u00a0Neuer\u00a0CD\u201020\u2010Antik\u00f6rper\u00a0nicht\u00a0besser\u00a0als\u00a0MabThera.\u00a0\nhttps://www.deutsche\u2010apotheker\u2010zeitung.de/news/artikel/2016/07/ 18/neuer\u2010cd\u201020\u2010antikorper\u2010nicht\u2010besser\u2010als\u2010\nmabthera,\u00a0letzter\u00a0Zugriff:\u00a023.02.2017.\u00a0\n307\u00a0DGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0medizinische\u00a0O nkologie\u00a0(2014).\u00a0Leuk\u00e4mie\u00a0(\u00a0CLL\u00a0).\u00a0\nhttps://www.onkopedia.com/de/onkopedia/guidelines/chronische\u2010ly mphatische\u2010leukaemie\u2010\ncll/@@view/pdf/20160216\u2010144758.pdf?filename=chronische\u2010lymphati sche\u2010leukaemie\u2010cll.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n23.12.2016.\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0medizinische\u00a0O nkologie\u00a0(2016b).\u00a0ASH\u00a0Konferenz\u00a0Dez.\u00a02016\u00a0GALLIUM\u2010Studie.\u00a0\nhttps://www.dgho.de/.../ASH\u00a02016\u00a0FL\u00a0\u2010\u00a0Obinutuzumab.pdf,\u00a0letzter \u00a0Zugriff:\u00a023.02.2017.\u00a0\nDGHO\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0medizinische\u00a0O nkologie\u00a0(2016a).\u00a0Follikul\u00e4res\u00a0Lymphom.\u00a0\nhttps://www.dgho.de/informationen/nachrichten/ASH%202016%20FL%2 0\u2010%20Obinutuzumab.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n08.06.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Gazyvaro.\u00a0obinutuzumab. \u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/002799/human_med_001780.jsp&m\nid=WC0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a002.02.2017.\u00a0\nFachinformation\u00a0Gazyvaro\u00ae\u00a0(2016) .\u00a0Fachinformation\u00a0Gazyvaro\u00ae.\u00a0ht tp://www.fachinfo.de/suche/gazyvaro\u00a0,\u00a0letzter\u00a0Zugriff:\u00a0\u00a0\n02.02.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Obinutuzumab\u00a0\u2010\u00a0Gemeinsamer\u00a0\nBundesausschuss.\u00a0https ://www.g\u2010 ba.de/informationen/nutzenbewert ung/131/,\u00a0letzter\u00a0Zugriff:\u00a002.03.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Obinutuzumab\u00a0(neues\u00a0\nAnwendungsgebiet)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss.\u00a0https://www.g\u2010 ba.de/informationen/nutzenbewertung/249/,\u00a0\nletzter\u00a0Zugriff:\u00a016.02.2017.\u00a0\nGEKID\u00a0\u2013\u00a0Gesellschaft\u00a0der\u00a0epidemio logischen\u00a0Krebsregister\u00a0in\u00a0Deu tschland\u00a0e.V.\u00a0(2015).\u00a0Krebs\u00a0in\u00a0Deutschland.\u00a0\nwww.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deuts chland/krebs_in_deutschland_node.html,\u00a0\nletzter\u00a0Zugriff:\u00a023.12.2016.\u00a0\nGoede\u00a0V,\u00a0Fischer\u00a0K,\u00a0Busch\u00a0R,\u00a0Engelke\u00a0A,\u00a0Eichhorst\u00a0B,\u00a0Wendtner\u00a0C M\u00a0et\u00a0al.\u00a0(2014).\u00a0Obinutuzumab\u00a0plus\u00a0Chlorambucil\u00a0in\u00a0Patients\u00a0wit h\u00a0\nCLL\u00a0and\u00a0Coexisting\u00a0Conditions.\u00a0NEJM\u00a0370(12):\u00a01101\u20101110.\u00a0\u00a0\nGoede\u00a0V,\u00a0Fischer\u00a0K,\u00a0Engelke\u00a0A,\u00a0Schlag\u00a0R,\u00a0Lepretre\u00a0S,\u00a0Montero\u00a0LF C\u00a0et\u00a0al.\u00a0(2015).\u00a0Obinutuzumab\u00a0as\u00a0frontline\u00a0treatment\u00a0of\u00a0chronic \u00a0\nlymphocytic\u00a0leukemia:\u00a0updated\u00a0results\u00a0of\u00a0the\u00a0CLL11\u00a0study.\u00a0Leuke mia,\u00a029(7):\u00a01602.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0WebApo.\u00a0Obinutuzumab.\u00a0Gazyvaro\u00ae.\u00a0Preise\u00a0u nd\u00a0Packungsgr\u00f6\u00dfen,\u00a0letzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nMaurer\u00a0C,\u00a0Hallek\u00a0M\u00a0(2013).\u00a0Chronis che\u00a0lymphatische\u00a0Leuk\u00e4mie.\u00a0DM W\u00a0\u2010\u00a0Deutsche\u00a0Medizinische\u00a0Wochenschrift,\u00a0138(42):\u00a02153\u20102166.\u00a0\u00a0\nonkopedia\u00a0(2017).\u00a0Leitlinie\u00a0CLL\u00a0aktualisiert\u00a0\u2014\u00a0Onkopedia\u00a0Deutsc h.\u00a0Retrieved\u00a0June\u00a01,\u00a02017,\u00a0from\u00a0\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Obinu tuzumab|Gazyvaro\u00ae|86|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=54054,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017.\u00a0\nSehn\u00a0LH,\u00a0Chua\u00a0N,\u00a0Mayer\u00a0J,\u00a0Dueck\u00a0G,\u00a0Trn\u011bn\u00fd\u00a0M,\u00a0Bouabdallah\u00a0K\u00a0et\u00a0a l.\u00a0(2016).\u00a0Obinutuzumab\u00a0plus\u00a0bendamustine\u00a0versus\u00a0\nbendamustine\u00a0monotherapy\u00a0in\u00a0patients\u00a0with\u00a0rituximab\u2010refractory\u00a0 indolent\u00a0non\u2010Hodgkin\u00a0lymphoma\u00a0(GADOLIN):\u00a0a\u00a0\nrandomised,\u00a0controlled,\u00a0open\u2010labe l,\u00a0multicentre,\u00a0phase\u00a03\u00a0trial. \u00a0The\u00a0Lancet\u00a0Oncology\u00a017(8):\u00a01081\u20101093.\u00a0\nWendtner\u00a0CM,\u00a0Dreger\u00a0P,\u00a0Gregor\u00a0M, \u00a0Greil\u00a0R,\u00a0Knauf\u00a0WU,\u00a0Pritzkuleit \u00a0R\u00a0et\u00a0al.(2017).\u00a0Chronische\u00a0lymphatische\u00a0Leuk\u00e4mie.\u00a0\nhttps://www.onkopedia.com/de/onkopedia/guidelines/chronische\u2010ly mphatische\u2010leukaemie\u2010\ncll/@@view/html/index.html,\u00a0letzter\u00a0Zugriff:\u00a008.09.2017.\u00a0308\u00a04.20 Olodaterol\u00a0\nHandelsname:\u00a0Striverdi\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\nIndikation:\u00a0Chronische\u00a0obstruktive\u00a0\u00a0\u00a0 Boehringer\u00a0Ingelheim\u00a0\nLungenkrankheit\u00a0\u00a0 \u00a0\nATC\u2010Code:\u00a0R03AC19\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Mai\u00a02014\u00a0\nDarreichungsform:\u00a0L\u00f6sung\u00a0zur \u00a0Inhalation\u00a0 DDD:\u00a05\u00a0\u00b5g\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nNach\u00a0 Abschluss\u00a0 des\u00a0 dezentralen\u00a0 Z ulassungsverfahrens\u00a0 unter\u00a0 niede rl\u00e4ndischer\u00a0\nF\u00fchrung\u00a0(MEB,\u00a02014)\u00a0best\u00e4tigte\u00a0das\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimit tel\u00a0und\u00a0Medizin\u2010\nprodukte\u00a0(BfArM)\u00a0die\u00a0Zulassung\u00a0des\u00a0neuen\u00a0Wirkstoffes\u00a0Olodaterol \u00a0(Striverdi\u00ae),\u00a0der\u00a0\nseit\u00a0dem\u00a015.\u00a0Mai\u00a02014\u00a0in\u00a0Deutschland\u00a0verf\u00fcgbar\u00a0ist.\u00a0Damit\u00a0stand en\u00a0f\u00fcnf\u00a0lang\u00a0wir\u2010\nkende\u00a0Beta 2\u2010Rezeptoragonisten\u00a0( Long\u00a0Acting\u00a0Beta\u20102\u00a0Agonists ,\u00a0LABA),\u00a0auch\u00a0Beta 2\u2010\nSympatomimetika\u00a0genannt,\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0obstruk tiven\u00a0Lungen\u2010\nkrankheit\u00a0( Chronic\u00a0Obstructive\u00a0Pulmonary\u00a0Disease ,\u00a0COPD)\u00a0in\u00a0Deutschland\u00a0zur\u00a0Ver\u2010\nf\u00fcgung.\u00a0Der\u00a0Wirkmechanismus\u00a0zielt\u00a0auf\u00a0die\u00a0Erweiterung\u00a0der\u00a0Bronc hien\u00a0und\u00a0der\u00a0\nVerminderung\u00a0der\u00a0Lungen\u00fcberbl\u00e4hun g,\u00a0um\u00a0die\u00a0Symptomatik\u00a0der\u00a0Erkr ankung\u00a0zu\u00a0\nlindern.\u00a0Die\u00a0Substanz\u00a0stimuliert\u00a0den\u00a0Beta 2\u2010Adrenorezeptor\u00a0in\u00a0der\u00a0glatten\u00a0Muskula\u2010\ntur\u00a0der\u00a0Atemwege\u00a0und\u00a0bewirkt\u00a0dadurch\u00a0die\u00a0Relaxation\u00a0des\u00a0Gewebes \u00a0(Fachinforma\u2010\ntion\u00a0Striverdi\u00a0Respimat\u00ae,\u00a02016).\u00a0In\u00a0Folge\u00a0chemischer\u00a0Modifikati onen\u00a0besitzt\u00a0die\u00a0\nstrukturell\u00a0von\u00a0Adrenalin\u00a0und\u00a0Noradrenalin\u00a0abgeleitete\u00a0Substanz \u00a0eine\u00a0terminale\u00a0\nHalbwertszeit\u00a0von\u00a045\u00a0Stunden\u00a0und\u00a0z\u00e4hlt\u00a0daher\u00a0zur\u00a0Gruppe\u00a0der\u00a0lan g\u00a0wirkenden\u00a0\nBeta2\u2010Rezeptoragonisten.\u00a0 Die\u00a0empfohle ne\u00a0Tagesdosis\u00a0betr\u00e4gt\u00a05\u00a0\u00b5g\u00a0(zwe i\u00a0H\u00fcbe)\u00a0\nund\u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0mithilfe\u00a0e ines\u00a0speziellen\u00a0Inhalators\u00a0(R espimat\u00ae)\u00a0appliziert.\u00a0\nDabei\u00a0sollte\u00a0die\u00a0Einnahme\u00a0stets\u00a0 zur\u00a0gleichen\u00a0Tageszeit\u00a0erfolgen ,\u00a0um\u00a0durch\u00a0die\u00a0\nErhaltung\u00a0eines\u00a0 Steady\u2010States \u00a0(Wirkspiegels)\u00a0eine\u00a0therapeutisch\u00a0optimale\u00a0Wirk\u2010\nstoffkonzentration\u00a0zu\u00a0erzielen\u00a0( Fachinformation\u00a0Striverdi\u00a0Respi mat\u00ae,\u00a02016).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Fixkombination\u00a0von\u00a0Olodaterol\u00a0und\u00a0Tiotropium\u00a0(Spiolto\u00ae) \u00a0liegt\u00a0seit\u00a01.\u00a0Juli\u00a0\n2015\u00a0die\u00a0Zulassung\u00a0vom\u00a0BfArM\u00a0vor\u00a0(G\u2010BA,\u00a02015).\u00a0\u00a0\nIm\u00a0 Rahmen\u00a0 regulatorischer\u00a0 Anforderungen\u00a0 f\u00fchrte\u00a0 der\u00a0 pharmazeutis che\u00a0 Unter\u2010\nnehmer\u00a0(pU)\u00a0f\u00fcr\u00a0Olodaterol\u00a0allein\u00a0neben\u00a0Studien\u00a0zur\u00a0Dosisfindun g\u00a0auch\u00a0Phase\u2010III\u2010\nStudien\u00a0Head\u2010to\u2010Head\u00a0 mit\u00a0indikationsgleichen\u00a0Substa nzen\u00a0durch\u00a0(MEB,\u00a02014)\u00a0und\u00a0\nfinanzierte\u00a0sie.\u00a0In\u00a0den\u00a0zwei\u00a0identischen\u00a0kontrollierten\u00a0Studien \u00a0NCT00793624\u00a0und\u00a0\nNCT00796653\u00a0(Koch\u00a0et\u00a0al.,\u00a02014)\u00a0wurde\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0Oloda terol\u00a0(einmal\u00a0\nt\u00e4glich\u00a05\u00a0\u00b5g\u00a0oder\u00a010\u00a0\u00b5g)\u00a0und\u00a0dem\u00a0LABA\u00a0Formoterol\u00a0(zweimal\u00a0t\u00e4gli ch\u00a012\u00a0\u00b5g)\u00a0gegen\u2010\n\u00fcber\u00a0Placebo\u00a0bei\u00a0einem\u00a0multinatio nalen\u00a0Patientenkollektiv\u00a0mit\u00a09 04\u00a0bzw.\u00a0934\u00a0Pro\u2010\nbanden\u00a0getestet.\u00a0F\u00fcr\u00a0den\u00a0Endpunkt\u00a0Einsekundenkapazit\u00e4t\u00a0(FEV 1)\u00a0nach\u00a024\u00a0Wochen\u00a0\nzeigten\u00a0beide\u00a0Substanzen\u00a0eine\u00a0signifikante\u00a0Verbesserung\u00a0der\u00a0Lun genfunktion\u00a0in\u00a0309\u00a0\u00e4hnlicher\u00a0Gr\u00f6\u00dfenordnung\u00a0(Olodate rol\u00a0vs.\u00a0Formoterol:\u00a00,075\u00a0l\u00a0vs. \u00a00,054\u00a0l).\u00a0Die\u00a0Vali\u2010\ndit\u00e4t\u00a0 der\u00a0 Ergebnisse\u00a0 wird\u00a0 aufgrund\u00a0 methodischer\u00a0 Unstimmigkeiten \u00a0 heterogen\u00a0\nbewertet\u00a0 (NICE,\u00a0 2015).\u00a0 Die\u00a0 Teilnehmer\u00a0 wurden\u00a0 nach\u00a0 einer\u00a0 Co\u2010Medi kation\u00a0 mit\u00a0\nTiotropium\u00a0stratifiziert.\u00a0Folglich\u00a0ist\u00a0unklar,\u00a0ob\u00a0die\u00a0beobachte ten\u00a0Effekte\u00a0auf\u00a0Olo\u2010\ndaterol\u00a0allein\u00a0oder\u00a0die\u00a0auf\u00a0die\u00a0Kombination\u00a0mit\u00a0Tiotropium\u00a0zur\u00fc ckzuf\u00fchren\u00a0sind.\u00a0\nDie\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0\nwurde\u00a0mittels\u00a0Frageb\u00f6gen\u00a0erfasst\u00a0( St.\u00a0George's\u00a0Respiratory\u00a0Questionnaire, \u00a0SGRQ;\u00a0\nMahler\u00a0Transitional\u00a0Dyspnea\u00a0Index ,\u00a0TDI).\u00a0Die\u00a0Auswertung\u00a0der\u00a0Daten\u00a0des\u00a0TDI\u00a0zeigte\u00a0\nerst\u00a0nach\u00a0Durchf\u00fchrung\u00a0einer\u00a0 Post\u2010hoc\u2010Analyse\u00a0einen\u00a0signifikanten\u00a0Vorteil\u00a0von\u00a0\nOlodaterol\u00a0gegen\u00fcber\u00a0Placebo.\u00a0Auch\u00a0die\u00a0Ergebnisse\u00a0des\u00a0SGRQ\u00a0zeig ten\u00a0eine\u00a0\u00e4hnli\u2010\nche\u00a0Tendenz,\u00a0wobei\u00a0sich\u00a0im\u00a0Mittel\u00a0keine\u00a0klinisch\u00a0relevante\u00a0Verb esserung\u00a0ergab\u00a0\n(die\u00a0Differenz\u00a0betr\u00e4gt\u00a0weniger\u00a0als\u00a0vier\u00a0Punkte)\u00a0(NICE,\u00a02015).\u00a0V ergleiche\u00a0mit\u00a0weite\u2010\nren\u00a0 LABA\u00a0 beschr\u00e4nken\u00a0 sich\u00a0 auf\u00a0 systematische\u00a0 \u00dcbersichtsarbeiten. \u00a0R o s k e l l \u00a0u n d \u00a0\nKollegen\u00a0konstatierten\u00a0im\u00a0Jahr\u00a0201 4\u00a0nach\u00a0Einbeziehung\u00a0von\u00a018\u00a0St udien\u00a0bez\u00fcglich\u00a0\nder\u00a0Wirksamkeit\u00a0die\u00a0\u00dcberlegenhei t\u00a0von\u00a0Indacaterol\u00a0gegen\u00fcber\u00a0Olo daterol,\u00a0die\u00a0sich\u00a0\nnach\u00a0Reduktion\u00a0auf\u00a0design\u00e4hnliche\u00a0Studien\u00a0relativiere.\u00a0Das\u00a0Erge bnis\u00a0einer\u00a0Meta\u2010\nAnalyse\u00a0von\u00a033\u00a0randomisierten\u00a0kontrollierten\u00a0Studien\u00a0konnte\u00a0geg en\u00fcber\u00a0der\u00a0Mono\u2010\ntherapie\u00a0mit\u00a0anderen\u00a0LABA\u00a0keinen\u00a0 signifikanten\u00a0Vorteil\u00a0f\u00fcr\u00a0Olod aterol\u00a0feststellen\u00a0\n(Donohue\u00a0et\u00a0al.,\u00a02017).\u00a0In\u00a0einer\u00a0weiteren\u00a0zulassungsbegr\u00fcndende n\u00a0kontrollierten\u00a0\nCross\u2010Over\u2010 Studie\u00a0 NCT01040689\u00a0 sowie\u00a0 der\u00a0 Replikationsstudie\u00a0 (NCT01040728)\u00a0\n(Lange\u00a0et\u00a0al.,\u00a02014)\u00a0wurden\u00a0je\u00a0108\u00a0bzw.\u00a0122\u00a0Probanden\u00a0sechs\u00a0Woc hen\u00a0mit\u00a0Olo\u2010\ndaterol\u00a0(5\u00a0\u00b5\u00a0oder\u00a010\u00a0\u00b5g)\u00a0und\u00a0Tiotropium\u00a0(18\u00a0\u00b5g)\u00a0in\u00a0der\u00a0Vergleic hsgruppe\u00a0behan\u2010\ndelt.\u00a0Dabei\u00a0zeigten\u00a0beide\u00a0Substa nzen\u00a0einen\u00a0\u00e4hnlichen\u00a0Effekt\u00a0auf \u00a0die\u00a0Lungenfunkti\u2010\non.\u00a0Die\u00a0niederl\u00e4ndische\u00a0Zulass ungsbeh\u00f6rde\u00a0forderte\u00a0die\u00a0Erhebung \u00a0weiterer\u00a0Daten,\u00a0\ndie\u00a0Auflagen\u00a0zur\u00a0Durchf\u00fchrung\u00a0von\u00a0 Post\u00a0Authorization\u00a0Safety\u00a0Studies \u00a0formulierte,\u00a0\num\u00a0insbesondere\u00a0kardiovaskul\u00e4re \u00a0Risiken\u00a0bei\u00a0Langzeitanwendung\u00a0( \u00fcber\u00a0ein\u00a0Jahr)\u00a0\nzu\u00a0erfassen.\u00a0Auch\u00a0die\u00a0Initiierung\u00a0einer\u00a0 Drug\u00a0Utilization\u00a0Study \u00a0zur\u00a0Untersuchung\u00a0des\u00a0\nOff\u2010label\u00a0Use \u00a0bei\u00a0Asthma\u00a0war\u00a0Gegenstand\u00a0des\u00a0 Forderungs\u2010Kataloges\u00a0(MEB,\u00a02014) .\u00a0\nDer\u00a0 pU\u00a0 reichte\u00a0 kein\u00a0 Dossier\u00a0 zum\u00a0 Nutzenbewertungsverfahren\u00a0 ein,\u00a0 sodass\u00a0 der\u00a0\nGemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0am\u00a017.\u00a0Juli\u00a02014\u00a0ohne\u00a0Beleg\u00a0 keinen\u00a0Zusatz\u2010\nnutzen\u00a0feststellen \u00a0konnte.\u00a0Es\u00a0erfolgte\u00a0die\u00a0Eingruppierung\u00a0in\u00a0die\u00a0bestehende\u00a0Fest\u2010\nbetragsgruppe\u00a0\u201eBeta 2\u2010Sympatomimetika,\u00a0inhalativ\u00a0or al,\u00a0Gruppe\u00a01\u201c\u00a0(G\u2010BA,\u00a02014).\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0310\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0\u00a0Kosten\u00a0\n\u00a0Weitere\u00a0\nTherapieoption\u00a0zur\u00a0\nBehandlung\u00a0der\u00a0\nCOPD\u00a0\u00a0\n\u00a0Kein\u00a0Dossier\u00a0durch\u00a0pU\u00a0\nvorgelegt,\u00a0kein\u00a0\nZusatznutzen\u00a0belegt,\u00a0\nEingruppierung\u00a0in\u00a0\nFestbetragsgruppe\u00a0\u00a0Festbetragsgruppe:\u00a0GKV\u2010\nWirtschaftlichkeit\u00a0\ngew\u00e4hrleistet,\u00a0\u00a0\nhohe\u00a0Mehrkosten \u00a0f\u00fcr\u00a0\nPatienten\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Variante\u00a0ohne\u00a0\nbesonderen\u00a0\nStellenwert\u00a0\u2013\u00a0 Nothing\u00a0new\u00a0 Analogpr\u00e4parat\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nOlodaterol\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 608,33\u00a0\u20ac\u00a0\nFestbetragsgruppe*\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 438,61\u00a0\u20ac\u00a0\nMehrkosten\u00a0f\u00fcr\u00a0Patienten\u00a0 \u00a0 \u00a0 169,72\u00a0\u20ac\u00a0\n*Festbetragsgruppe :\u00a0Beta2\u2010Sympatomimetika,\u00a0inhalativ\u00a0oral,\u00a0Gruppe\u00a01,\u00a0Stufe\u00a02\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDas\u00a0Verh\u00e4ltnis\u00a0der\u00a0Bruttoums\u00e4tze\u00a0zu\u00a0den\u00a0verordneten\u00a0Tagesdosen\u00a0 des\u00a0langwir\u2010\nkenden\u00a0Beta 2\u2010Rezeptoragonisten\u00a0Olodaterol\u00a0ist\u00a0\u00fcber\u00a0den\u00a0gesamten\u00a0Beobachtung s\u2010\nzeitraum\u00a0konstant.\u00a0Diese\u00a0Entwicklung\u00a0kann\u00a0auf\u00a0die\u00a0durch\u00a0den\u00a0G\u2010B A\u00a0vorgenomme\u2010\nne\u00a0Eingruppierung\u00a0in\u00a0eine\u00a0Festbetragsgruppe\u00a0(G\u2010BA,\u00a02015)\u00a0zur\u00fcck gef\u00fchrt\u00a0werden,\u00a0\ndie\u00a0 Preisverhandlungen\u00a0 zwischen\u00a0 pU\u00a0 und\u00a0 GKV\u00a0 (Gesetzlicher\u00a0 Kranke nkassen)\u2010\nSpitzenverband\u00a0entgegenwirkte.\u00a0Tr otz\u00a0fehlender\u00a0Belege\u00a0f\u00fcr\u00a0einen \u00a0Zusatznutzen\u00a0\ngegen\u00fcber\u00a0den\u00a0Vergleichstherapien\u00a0 stiegen\u00a0die\u00a0Verordnungs\u2010Volum ina\u00a0innerhalb\u00a0\nvon\u00a014\u00a0Monaten\u00a0nach\u00a0Markteinf\u00fchrung\u00a0auf\u00a0den\u00a0Maximalwert\u00a0von\u00a0ca. \u00a040.000\u00a0Euro\u00a0\nbzw.\u00a030.000\u00a0DDD\u00a0an.\u00a0Erst\u00a0nach\u00a0August\u00a02015\u00a0sinken\u00a0sowohl\u00a0Bruttou ms\u00e4tze\u00a0als\u00a0auch\u00a0\ndie\u00a0DDD.\u00a0Ein\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Markteinf\u00fchrung\u00a0der\u00a0Wirkstoff kombination\u00a0\nOlodaterol\u00a0und\u00a0Tiotropium\u00a0(Spiolto\u00ae),\u00a0die\u00a0am\u00a01.\u00a0Juli\u00a02015\u00a0mit\u00a0i dentischer\u00a0Indika\u2010\ntion\u00a0durch\u00a0das\u00a0BfArM\u00a0zugelassen\u00a0wurde,\u00a0ist\u00a0naheliegend.\u00a0So\u00a0sieh t\u00a0die\u00a0Leitlinie\u00a0in\u00a0\nfortgeschrittenen\u00a0Krankheitsstadien\u00a0die\u00a0Kombination\u00a0von\u00a0LABA\u00a0un d\u00a0lang\u00a0wirk\u2010\nsamen\u00a0 Anticholinergika\u00a0 ( Long\u00a0 Acting\u00a0 Muscarinic\u00a0 Antagonist ,\u00a0 LAMA)\u00a0 (GOLD,\u00a0\n311\u00a02017)\u00a0vor.\u00a0Die\u00a0Anwendung\u00a0des\u00a0Kombinationspr\u00e4parates\u00a0bietet\u00a0nebe n\u00a0der\u00a0Ver\u2010\neinfachung\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0auc h\u00a0wirtschaftliche\u00a0Vorteile.\u00a0\u00a0\nAbbildung\u00a04.36:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nOlodaterol\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nMit\u00a0 Olodaterol\u00a0 standen\u00a0 2014\u00a0 f\u00fcnf\u00a0 lang\u00a0 wirkende\u00a0 Beta 2\u2010Rezeptoragonisten\u00a0 zur\u00a0\nVerf\u00fcgung.\u00a0Die\u00a0Gruppe\u00a0der\u00a0Betarezeptoren\u00a0wird\u00a0in\u00a0drei\u00a0Subtypen\u00a0 kategorisiert:\u00a0\nTyp\u00a01\u00a0ist\u00a0in\u00a0der\u00a0Herzmuskulatur,\u00a0Typ\u00a02\u00a0vorwiegend\u00a0in\u00a0der\u00a0glatte n\u00a0Muskulatur\u00a0der\u00a0\nAtemwege\u00a0und\u00a0Typ\u00a03\u00a0haupts\u00e4chlich\u00a0im\u00a0Fettgewebe\u00a0lokalisiert.\u00a0Dur ch\u00a0Bindung\u00a0von\u00a0\nOlodaterol\u00a0an\u00a0den\u00a0Beta 2\u2010Rezeptor\u00a0wird\u00a0intrazellul\u00e4r\u00a0das\u00a0Enzym\u00a0Adenylylcyclase\u00a0\naktiviert,\u00a0welches\u00a0die\u00a0Bildung\u00a0von\u00a0zyklischem\u00a0Adenosin\u20103\u00b4,5\u00b4\u2010Mo nophosphat\u00a0( cyclic\u00a0\nAdenosine\u00a0Monophosphate ,\u00a0cAMP)\u00a0vermittelt.\u00a0Die\u00a0er h\u00f6hte\u00a0cAMP\u2010Konzentration\u00a0\nbewirkt\u00a0eine\u00a0Relaxation\u00a0der\u00a0glatten\u00a0Muskulatur\u00a0und\u00a0somit\u00a0eine\u00a0B ronchodilatation\u00a0\n(Boehringer\u00a0Ingelheim,\u00a02016).\u00a0Strukturell\u00a0von\u00a0den\u00a0physiologisch en\u00a0Liganden\u00a0No\u2010\nradrenalin\u00a0und\u00a0Adrenalin\u00a0abgeleitet,\u00a0weisen\u00a0alle\u00a0Beta 2\u2010Sympatomimetika\u00a0eine\u00a01\u2010\nPhenyl\u20102\u2010Aminoethanol\u2010 Struktur\u00a0 auf,\u00a0 die\u00a0 infolge\u00a0 unterschiedlich er\u00a0 Modifikation\u00a0\neine\u00a0h\u00f6here\u00a0Stabilit\u00e4t\u00a0gegen\u00fcber\u00a0abbauenden\u00a0Enzymen\u00a0gew\u00e4hrleist et.\u00a0So\u00a0ergibt\u00a0\nsich\u00a0f\u00fcr\u00a0Olodaterol\u00a0eine\u00a0terminale\u00a0Halbwertszeit\u00a0von\u00a045\u00a0Stunden \u00a0nach\u00a0Inhalation.\u00a0\nAufgrund\u00a0der\u00a0langen\u00a0Verweildauer\u00a0z\u00e4hlt\u00a0der\u00a0Wirkstoff\u00a0innerhalb\u00a0 seiner\u00a0Substanz\u2010\nklasse\u00a0 zu\u00a0 den\u00a0 ultra\u2010lang\u00a0 wirkenden\u00a0 Beta 2\u2010Rezeptoragonisten \u00a0(Ultra\u2010long\u2010acting\u00a0\nBeta\u20102\u00a0Agonists ),\u00a0die\u00a0im\u00a0Gegensatz\u00a0zu\u00a0den\u00a0kurz \u2010\u00a0(z.B.\u00a0Salbutamol) \u00a0oder\u00a0lang\u2010 \u00a0(z.B.\u00a0\n312\u00a0Formoterol,\u00a0 Salmeterol) \u00a0wirkenden\u2010Beta 2\u2010Rezeptoragonisten\u00a0 nur\u00a0 einmal\u00a0 t\u00e4glich\u00a0\nangewendet\u00a0werden\u00a0m\u00fcssen\u00a0 (Donohue\u00a0et\u00a0al.,\u00a02017).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDas\u00a0Pr\u00e4parat\u00a0durchlief\u00a0ein\u00a0dezentrales\u00a0Zulassungsverfahren\u00a0unte r\u00a0niederl\u00e4ndischer\u00a0\nVerfahrensf\u00fchrung\u00a0(MEB,\u00a02014)\u00a0und\u00a0wurde\u00a0am\u00a022.\u00a0November\u00a02013\u00a0(B oehringer\u00a0\nIngelheim,\u00a02016)\u00a0durch\u00a0das\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0 Medizinprodukte\u00a0\n(BfArM)\u00a0best\u00e4tigt.\u00a0Die\u00a0Indikation\u00a0betrifft\u00a0die\u00a0Dauerbehandlung\u00a0 erwachsener\u00a0Pati\u2010\nenten\u00a0mit\u00a0COPD.\u00a0Mit\u00a0Hilfe\u00a0eines\u00a0 speziellen\u00a0Inhalators\u00a0wird\u00a0die\u00a0 in\u00a0Patronen\u00a0zu\u00a0je\u00a060\u00a0\nH\u00fcben\u00a0abgef\u00fcllte\u00a0Inhalationsl\u00f6sung \u00a0einmal\u00a0t\u00e4glich\u00a0appliziert,\u00a0w obei\u00a0die\u00a0empfohle\u2010\nne\u00a0Tagesdosis\u00a05\u00a0\u00b5g\u00a0(zwei\u00a0H\u00fcbe)\u00a0betr\u00e4gt.\u00a0Dabei\u00a0gilt\u00a0zu\u00a0beachten, \u00a0dass\u00a0die\u00a0Einnahme\u00a0\nstets\u00a0zur\u00a0gleichen\u00a0Tageszeit\u00a0erf olgen\u00a0sollte,\u00a0um\u00a0den\u00a0optimalen\u00a0 Wirkspiegel\u00a0zu\u00a0ge\u2010\nw\u00e4hrleisten.\u00a0Eine\u00a0Dosisanpassung\u00a0f\u00fcr\u00a0besondere\u00a0Patientengruppen \u00a0ist\u00a0nicht\u00a0vorge\u2010\nsehen,\u00a0auch\u00a0nicht\u00a0bei\u00a0schweren\u00a0Nieren\u2010\u00a0und\u00a0Leberfunktionsst\u00f6run gen,\u00a0die\u00a0Daten\u2010\nlage\u00a0ist\u00a0hier\u00a0unzureichend.\u00a0F\u00fcr\u00a0K inder\u00a0und\u00a0Jugendliche\u00a0unter\u00a018 \u00a0Jahren\u00a0liegt\u00a0kein\u00a0\nrelevanter\u00a0Nutzen\u00a0f\u00fcr\u00a0eine\u00a0Therapie\u00a0mit\u00a0Olodaterol\u00a0vor\u00a0(Boehrin ger\u00a0Ingelheim,\u00a0\n2016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Bezeichnung\u00a0COPD\u00a0fasst\u00a0die\u00a0verschiedenen\u00a0Krankheitsbilder\u00a0c hronische\u00a0ob\u2010\nstruktive\u00a0Bronchitis\u00a0und\u00a0Lungenemphysem\u00a0zusammen.\u00a0Entsprechend\u00a0 der\u00a0Definiti\u2010\non\u00a0der\u00a0Global\u00a0Initiative\u00a0for\u00a0Chronic\u00a0Obstructive\u00a0Lung\u00a0Disease \u00a0(GOLD)\u00a0ist\u00a0die\u00a0Erkran\u2010\nkung\u00a0durch\u00a0dauerhafte\u00a0Atemwegsbeschwerden\u00a0(Husten,\u00a0Auswurf,\u00a0Ate mnot),\u00a0ver\u2010\nminderte\u00a0Lungenbel\u00fcftung\u00a0sowie\u00a0Ve r\u00e4nderungen\u00a0in\u00a0den\u00a0Atemwegen\u00a0( obstruktive\u00a0\nBronchitis)\u00a0und\u00a0des\u00a0Lungengewebes\u00a0(Emphysem)\u00a0charakterisiert.\u00a0F \u00fcr\u00a0die\u00a0Betroffe\u2010\nnen\u00a0ergeben\u00a0sich\u00a0mit\u00a0Krankheitsprogression\u00a0h\u00e4ufig\u00a0gravierende\u00a0k \u00f6rperliche\u00a0Ein\u2010\nschr\u00e4nkungen,\u00a0die\u00a0sich\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0auswirken\u00a0k\u00f6nnen. \u00a0Dar\u00fcber\u00a0hinaus\u00a0\nbesteht\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0COPD\u00a0ein\u00a0h\u00f6heres\u00a0Risiko\u00a0f\u00fcr\u00a0die\u00a0Entwi cklung\u00a0von\u00a0Komor\u2010\nbidit\u00e4ten\u00a0wie\u00a0pulmonaler\u00a0Herzkrankheit\u00a0und\u00a0Malnutrition\u00a0(Cavail l\u00e8s\u00a0et\u00a0al.,\u00a02013).\u00a0\nWie\u00a0bei\u00a0Asthma\u00a0spielen\u00a0Entz\u00fcndungsprozesse\u00a0eine\u00a0wichtige\u00a0Rolle, \u00a0die\u00a0sich\u00a0jedoch\u00a0\nlaborchemisch\u00a0 unterscheiden\u00a0 (GOLD,\u00a0 2017).\u00a0 Im\u00a0 weiteren\u00a0 Verlauf\u00a0 n ehmen\u00a0 die\u00a0\nentz\u00fcndlichen\u00a0Prozesse\u00a0und\u00a0strukturellen\u00a0Ver\u00e4nderungen\u00a0zu\u00a0und\u00a0k ommen\u00a0auch\u00a0\nbei\u00a0Beendigung\u00a0des\u00a0Tabakkonsums\u00a0\u2013\u00a0einer\u00a0der\u00a0wichtigsten\u00a0Gegenma \u00dfnahmen\u00a0\u2013\u00a0\nnicht\u00a0zum\u00a0Stillstand\u00a0(Hogg\u00a0et\u00a0al.,\u00a02004).\u00a0\u00a0\nDie\u00a0genauen\u00a0Ursachen\u00a0der\u00a0COPD\u00a0sind\u00a0bisher\u00a0nicht\u00a0eindeutig\u00a0ident ifiziert,\u00a0was\u00a0die\u00a0\nEntwicklung\u00a0besserer\u00a0Therapieoptionen\u00a0erschwert\u00a0(Ngkelo\u00a0&\u00a0Adcoc k,\u00a02013).\u00a0Es\u00a0\nwird\u00a0vermutet,\u00a0dass\u00a0ein\u00a0Zusammenha ng\u00a0verschiedener\u00a0Faktoren\u00a0wie \u00a0Exposition\u00a0\ngegen\u00fcber\u00a0sch\u00e4dlichen\u00a0Gasen\u00a0und\u00a0Pa rtikeln\u00a0in\u00a0Kombination\u00a0mit\u00a0ge netischer\u00a0Dispo\u2010\nsition,\u00a0\u00dcberempfindlichkeit\u00a0der\u00a0 Atemwege\u00a0sowie\u00a0vermindertem\u00a0Lun genwachstum\u00a0313\u00a0w\u00e4hrend\u00a0der\u00a0Kindheit\u00a0besteht\u00a0(GO LD,\u00a02017).\u00a0Weltweit\u00a0waren\u00a02010\u00a0 gesch\u00e4tzte\u00a0384\u00a0\nMio.\u00a0Menschen\u00a0an\u00a0COPD\u00a0erkrankt,\u00a0was\u00a0einer\u00a0Pr\u00e4valenz\u00a0von\u00a011,7\u00a0%\u00a0 bzw.\u00a0drei\u00a0Mio.\u00a0\nToten\u00a0j\u00e4hrlich\u00a0entspricht.\u00a0Unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0aktuellen \u00a0Tendenzen\u00a0hin\u2010\nsichtlich\u00a0des\u00a0steigendem\u00a0Tabakkonsums\u00a0und\u00a0der\u00a0Ver\u00e4nderung\u00a0der\u00a0A ltersstruktur\u00a0in\u00a0\nden\u00a0Industriestaaten,\u00a0ergaben\u00a0Kalkulationen\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02030\u00a0e inen\u00a0weiteren\u00a0\nAnstieg\u00a0der\u00a0Erkrankungen\u00a0mit\u00a0berechneten\u00a0viereinhalb\u00a0Mio.\u00a0COPD\u2010 Toten\u00a0pro\u00a0Jahr\u00a0\n(Adeloye\u00a0et\u00a0al.,\u00a02015,\u00a0Mathers\u00a0&\u00a0Loncar,\u00a02006).\u00a0Genaue\u00a0Angaben\u00a0 zur\u00a0Pr\u00e4valenz\u00a0in\u00a0\nDeutschland\u00a0liegen\u00a0nicht\u00a0vor,\u00a0da\u00a0die\u00a0Misch\u2010Diagnose\u00a0COPD\u00a0sowohl \u00a0bei\u00a0Vorliegen\u00a0\neiner\u00a0chronischen\u00a0Bronchitis\u00a0als\u00a0auch\u00a0bei\u00a0einer\u00a0dauerhaften\u00a0Ver engung\u00a0der\u00a0unte\u2010\nren\u00a0Atemwege\u00a0(ggf.\u00a0in\u00a0Kombination\u00a0mit\u00a0Lungenemphysem)\u00a0gestellt\u00a0 wird.\u00a0Die\u00a0pr\u00e4zi\u2010\nse\u00a0Datenerfassung\u00a0gestaltet\u00a0sic h\u00a0daher\u00a0schwierig\u00a0(RKI,\u00a02017).\u00a0 \u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDer\u00a0pU\u00a0f\u00fchrte\u00a0den\u00a0regulatorischen\u00a0Anforderungen\u00a0der\u00a0Europ\u00e4ische n\u00a0Union\u00a0(EU)\u00a0\nentsprechende\u00a0Phase\u2010III\u2010Studien\u00a0 durch,\u00a0die\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0 Olodaterol\u00a0 Head\u2010\nto\u2010Head\u00a0 zu\u00a0 Formoterol\u00a0 untersuchten.\u00a0 F\u00fcr\u00a0 die\u00a0 zwei\u00a0 identischen\u00a0 Studien\u00a0\n(NCT00793624,\u00a0NCT00796653,\u00a0Koch\u00a0et\u00a0al.,\u00a02014)\u00a0wurden\u00a0904\u00a0bzw.\u00a09 34\u00a0Probanden\u00a0\naus\u00a020\u00a0L\u00e4ndern\u00a0mit\u00a0mehrheitlich\u00a0mittelschwerer\u00a0COPD\u00a0rekrutiert\u00a0 und\u00a024\u00a0Wochen\u00a0\nmit\u00a0t\u00e4glich\u00a05\u00a0oder\u00a010\u00a0\u00b5g\u00a0Olodaterol\u00a0oder\u00a0zweimal\u00a0t\u00e4glich\u00a012\u00a0\u00b5g\u00a0 Formoterol\u00a0behan\u2010\ndelt.\u00a0Die\u00a0Gesamtschau\u00a0der\u00a0Ergebnisse\u00a0zeigt\u00a0f\u00fcr\u00a0beide\u00a0Substanzen \u00a0eine\u00a0im\u00a0Vergleich\u00a0\nzu\u00a0Placebo\u00a0signifikante\u00a0Verbesserung\u00a0der\u00a0Lungenfunktion\u00a0in\u00a0\u00e4hnl ichem\u00a0Ausma\u00df\u00a0\n(NCT00793624:\u00a0Olodaterol\u00a0vs.\u00a0Formoterol;\u00a0FEV 1\u00a0nach\u00a024\u00a0Wochen :\u00a00,075\u00a0l:\u00a00,054\u00a0l;\u00a0FEV 1\u00a0\nAUC0\u20103h:\u00a00,151\u00a0l:\u00a00,177\u00a0l).\u00a0Die\u00a0Validit\u00e4t\u00a0der\u00a0Studienergebnisse\u00a0wird\u00a0d abei\u00a0durch\u00a0\nmethodische\u00a0M\u00e4ngel\u00a0gemindert.\u00a0So \u00a0erfolgte\u00a0eine\u00a0Stratifizierung\u00a0 der\u00a0Probanden\u00a0\nanhand\u00a0der\u00a0Einnahme\u00a0von\u00a0Tiotropium.\u00a0Studienbegleitend\u00a0f\u00fchrten\u00a0d iese\u00a0ihre\u00a0Medi\u2010\nkation\u00a0weiter,\u00a0einschlie\u00dflich\u00a0inhalativer\u00a0Kortikosteroide.\u00a0In\u00a0d er\u00a0Folge\u00a0kann\u00a0nicht\u00a0\ngekl\u00e4rt\u00a0werden,\u00a0ob\u00a0innerhalb\u00a0einer\u00a0Teilpopulation\u00a0die\u00a0positiven \u00a0Effekte\u00a0auf\u00a0Olo\u2010\ndaterol\u00a0allein\u00a0zur\u00fcckzuf\u00fchren\u00a0sind\u00a0oder\u00a0zus\u00e4tzlich\u00a0durch\u00a0die\u00a0Ko mbination\u00a0mit\u00a0Ti\u2010\notropium\u00a0verst\u00e4rkt\u00a0wurden\u00a0(NICE,\u00a02015).\u00a0Effekte\u00a0auf\u00a0die\u00a0Gesundh eitsbezogene\u00a0\nLebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurden\u00a0kontinuierlich\u00a0mit\u2010\ntels\u00a0validierter\u00a0Frageb\u00f6gen\u00a0( St.\u00a0George's\u00a0Respiratory\u00a0Questionnaire, \u00a0SGRQ;\u00a0Mahler\u00a0\nTransitional\u00a0Dyspnea\u00a0Index ,\u00a0TDI)\u00a0erfasst.\u00a0Erst\u00a0nach\u00a0Durchf\u00fchrung\u00a0einer\u00a0 Post\u2010hoc\u2010\nAnalyse\u00a0aufgrund\u00a0der\u00a0im\u00a0Vergleich\u00a0hohen\u00a0Rate\u00a0an\u00a0Therapieabbr\u00fcch en\u00a0innerhalb\u00a0\nder\u00a0Placebo\u2010Gruppe\u00a0einer\u00a0Studie\u00a0(25,3\u00a0%\u00a0vs.\u00a015,9\u00a0bis\u00a018,9\u00a0%\u00a0im\u00a0 Verum\u2010Arm)\u00a0ergab\u00a0\nsich\u00a0im\u00a0TDI\u00a0nach\u00a024\u00a0Wochen\u00a0f\u00fcr\u00a0Olodaterol\u00a0ein\u00a0statistisch\u00a0signi fikanter\u00a0Vorteil\u00a0\ngegen\u00fcber\u00a0Placebo.\u00a0Eine\u00a0\u00e4hnliche\u00a0Tendenz\u00a0zeigte\u00a0sich\u00a0auch\u00a0f\u00fcr\u00a0S GRQ.\u00a0In\u00a0der\u00a0Ge\u2010\nsamtschau\u00a0zeigten\u00a0die\u00a0Ergebnisse \u00a0beider\u00a0Studien\u00a0keine\u00a0klinische \u00a0Signifikanz\u00a0(Diffe\u2010\nrenz\u00a0weniger\u00a0als\u00a0vier\u00a0Punkte)\u00a0(Koch\u00a0et\u00a0al.,\u00a02014;\u00a0NICE,\u00a02015).\u00a0 Keine\u00a0der\u00a0beiden\u00a0\nSubstanzen\u00a0senkte\u00a0signifikant\u00a0di e\u00a0Exazerbationsrate,\u00a0das\u00a0Studie ndesign\u00a0war\u00a0aber\u00a0\nnicht\u00a0explizit\u00a0auf\u00a0die\u00a0Erfassung \u00a0dieses\u00a0Endpunktes\u00a0angelegt.\u00a0Zu \u00a0den\u00a0h\u00e4ufigsten\u00a0314\u00a0unerw\u00fcnschten\u00a0Effekten\u00a0(UE)\u00a0(Inzidenz\u00a0unter\u00a05\u00a0%)\u00a0in\u00a0der\u00a0mit\u00a0Olo daterol\u00a0behandel\u2010\nten\u00a0Teilpopulationen\u00a0geh\u00f6rten\u00a0neb en\u00a0Nasopharyngitis,\u00a0dem\u00a0einzig en\u00a0Outcome,\u00a0das\u00a0\nin\u00a0beiden\u00a0Olodaterol\u2010Gruppen\u00a0(5 \u00a0\u00b5g,\u00a010\u00a0\u00b5g)\u00a0gegen\u00fcber\u00a0Placebo\u00a0si gnifikant\u00a0st\u00e4rker\u00a0\nauftrat,\u00a0Infektionen\u00a0der\u00a0oberen\u00a0Atemwege\u00a0und\u00a0Exazerbationen.\u00a0We itere\u00a0Verglei\u2010\nche\u00a0zur\u00a0Wirksamkeit\u00a0anderer\u00a0LABA\u00a0beschr\u00e4nkten\u00a0sich\u00a0auf\u00a0Ergebnis se\u00a0systemati\u2010\nscher\u00a0\u00dcbersichtsarbeiten,\u00a0die\u00a0unterschiedliche\u00a0Resultate\u00a0formul ierten.\u00a0Nach\u00a0Aus\u2010\nwertung\u00a0von\u00a018\u00a0Studien\u00a0im\u00a0Jahr\u00a02014\u00a0beurteilten\u00a0Roskell\u00a0und\u00a0Kol legen\u00a0Indacaterol\u00a0\nbezogen\u00a0auf\u00a0FEV 1\u00a0als\u00a0wirksamste\u00a0Substanz\u00a0in\u00a0der\u00a0Gesamtschau.\u00a0Bei\u00a0ausschlie\u00dfli\u2010\ncher\u00a0 Betrachtung\u00a0 design\u00e4hnlicher\u00a0 Studien\u00a0 zeigten\u00a0 beide\u00a0 Substanz en\u00a0 eine\u00a0 ver\u2010\ngleichbare\u00a0Wirksamkeit.\u00a0Eine\u00a0wei tere\u00a0Meta\u2010Analyse\u00a0von\u00a033\u00a0random isierten\u00a0kon\u2010\ntrollierten\u00a0Studien\u00a0fand\u00a0keinen\u00a0signifikanten\u00a0Vorteil\u00a0der\u00a0Monot herapie\u00a0mit\u00a0Olo\u2010\ndaterol\u00a0gegen\u00fcber\u00a0anderen\u00a0LABA \u00a0(Donohue\u00a0et\u00a0al.,\u00a02017).\u00a0Aufgrund \u00a0seiner\u00a0langen\u00a0\nHalbwertszeit\u00a0muss\u00a0die\u00a0Substanz\u00a0nur\u00a0einmal\u00a0statt\u00a0zweimal\u00a0t\u00e4glic h\u00a0(wie\u00a0bei\u00a0Salme\u2010\nt e r o l , \u00a0F o r m o t e r o l ) \u00a0v e r a b r e i c h t \u00a0w e r d e n , \u00a0w a s \u00a0e i n e n \u00a0A d h \u00e4 r e n z \u2010 V o r t e il\u00a0 bedeuten\u00a0\nkann.\u00a0Es\u00a0existieren\u00a0jedoch\u00a0keine\u00a0 Belege\u00a0f\u00fcr\u00a0einen\u00a0positiven\u00a0Eff ekt\u00a0der\u00a0Vereinfa\u2010\nchung\u00a0des\u00a0Therapieregimes\u00a0(einmal\u00a0t\u00e4glich\u00a0vs.\u00a0zweimal\u00a0t\u00e4glich)\u00a0 auf\u00a0die\u00a0klinische\u00a0\nWirksamkeit\u00a0(Haynes\u00a0et\u00a0al.\u00a02008,\u00a0Gorenoi\u00a0et\u00a0al.,\u00a02007)\u00a0von\u00a0Olod aterol.\u00a0Weiterhin\u00a0\nfinanzierte\u00a0 der\u00a0 pU\u00a0 eine\u00a0 placebokontrollierte\u00a0 Cross\u2010Over \u00a0 Studie\u00a0 (NCT01040689)\u00a0\nsowie\u00a0eine\u00a0Replikationsstudie\u00a0(NCT\u00a001040728)\u00a0(Lange\u00a0et\u00a0al.,\u00a0201 4)\u00a0mit\u00a0je\u00a0108\u00a0bzw.\u00a0\n122\u00a0Teilnehmern,\u00a0die\u00a0jeweils\u00a0sechs\u00a0Wochen\u00a0mit\u00a0Olodaterol\u00a0(5\u00a0und \u00a010\u00a0\u00b5g),\u00a0Ti\u2010\notropium\u00a0(18\u00a0\u00b5g)\u00a0oder\u00a0Placebo\u00a0behandelt\u00a0wurden.\u00a0F\u00fcr\u00a0beide\u00a0Subst anzen\u00a0wurde\u00a0\neine\u00a0\u00e4hnliche\u00a0Wirksamkeit\u00a0auf\u00a0die\u00a0Lungenfunktion\u00a0(FEV 1\u2010Profil\u00a0\u00fcber\u00a024\u00a0Stunden)\u00a0\npostuliert.\u00a0Die\u00a0geringe\u00a0Probande nzahl\u00a0sowie\u00a0die\u00a0kurzen\u00a0Beobacht ungszeitr\u00e4ume\u00a0\nrelativieren\u00a0 die\u00a0 Aussagekraft\u00a0 der\u00a0 Ergebnisse,\u00a0 sodass\u00a0 weitere\u00a0 Un tersuchungen\u00a0\nnotwendig\u00a0sind,\u00a0falls\u00a0beabsichti gt\u00a0ist,\u00a0den\u00a0Stellenwert\u00a0der\u00a0The rapie\u00a0mit\u00a0Olodaterol\u00a0\ngegen\u00fcber\u00a0der\u00a0Vergleichstherapie\u00a0festzulegen.\u00a0Die\u00a0Auflagen\u00a0der\u00a0 niederl\u00e4ndischen\u00a0\nZulassungsbeh\u00f6rde\u00a0sehen\u00a0die\u00a0Durchf\u00fchrung\u00a0von\u00a0 Post\u00a0Authorization\u00a0Safety\u00a0Studies \u00a0\n(PASS)\u00a0 zur\u00a0 Einsch\u00e4tzung\u00a0 kardiovas kul\u00e4rer\u00a0 Risiken\u00a0 insbesondere\u00a0 b ei\u00a0 Langzeitan\u2010\nwendung\u00a0(\u00fcber\u00a0ein\u00a0Jahr)\u00a0vor.\u00a0Auch\u00a0eine\u00a0 Drug\u00a0Utilisa tion\u00a0Study \u00a0(DUS)\u00a0zur\u00a0Untersu\u2010\nchung\u00a0des\u00a0 Off\u2010label\u00a0 use \u00a0bei\u00a0 Asthma\u00a0ist\u00a0Gegenstand\u00a0der\u00a0Anforderungen\u00a0(MEB,\u00a0\n2014).\u00a0 Aufgrund\u00a0 fehlender\u00a0 Untersuchungen\u00a0 zur\u00a0 Wirksamkeit\u00a0 und\u00a0 Si cherheit\u00a0\nschlie\u00dft\u00a0der\u00a0pU\u00a0die\u00a0Anwendung\u00a0von \u00a0Olodaterol\u00a0bei\u00a0Asthmapatiente n\u00a0aus.\u00a0Die\u00a0 Food\u00a0\nand\u00a0Drug\u00a0Administration \u00a0(FDA)\u00a0formulierte\u00a0bereits\u00a02010\u00a0Anforderungen\u00a0f\u00fcr\u00a0die\u00a0\nTherapie\u00a0mit\u00a0LABA\u00a0und\u00a0reagierte\u00a0damit\u00a0auf\u00a0Ergebnisse\u00a0zweier\u00a0Stu dien\u00a0zum\u00a0Wirk\u2010\nstoff\u00a0Salmeterol\u00a0( Salmeterol\u00a0Multi\u2010center\u00a0Asthma\u00a0Research\u00a0Trial ,\u00a0SMART;\u00a0 Salme\u2010\nterol\u00a0Nationwide\u00a0Surveillance\u00a0Study ,\u00a0SNS)\u00a0sowie\u00a0einer\u00a0durch\u00a0die\u00a0FDA\u00a0durchgef\u00fchr\u2010\nten\u00a0Meta\u2010Analyse.\u00a0F\u00fcr\u00a0die\u00a0untersuchten\u00a0LABA\u00a0wurde\u00a0ein\u00a0im\u00a0Vergle ich\u00a0zu\u00a0Placebo\u00a0\nh\u00f6heres\u00a0Risiko\u00a0f\u00fcr\u00a0asthmabedingte\u00a0Hospitalisierungen\u00a0sowie\u00a0Tode sf\u00e4lle\u00a0festgestellt\u00a0\n(FDA,\u00a02010).\u00a0\u00a0\n\u00a0315\u00a0Leitlinienempfehlungen\u00a0\nBis\u00a0heute\u00a0ist\u00a0COPD\u00a0nicht\u00a0heilbar,\u00a0sodass\u00a0sich\u00a0die\u00a0Pharmakothera pie\u00a0auf\u00a0die\u00a0Reduk\u2010\ntion\u00a0der\u00a0Symptome,\u00a0H\u00e4ufigkeit\u00a0und\u00a0Schwere\u00a0der\u00a0Exazerbationen\u00a0so wie\u00a0die\u00a0Verbes\u2010\nserung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0beschr\u00e4nkt.\u00a0In\u00a0Deutschland\u00a0liegt\u00a0derz eit\u00a0keine\u00a0g\u00fcltige\u00a0\nLeitlinie\u00a0vor.\u00a0Unter\u00a0Leitung\u00a0der \u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Pne umologie\u00a0und\u00a0Be\u2010\natmungsmedizin\u00a0(DGP)\u00a0sowie\u00a0der\u00a0Deutschen\u00a0Atemwegsliga\u00a0wird\u00a0aktu ell\u00a0eine\u00a0neue\u00a0\nLeitlinie:\u00a0 \u201eDiagnostik,\u00a0 Pr\u00e4vention\u00a0 und\u00a0 Therapie\u00a0 der\u00a0 COPD\u201c\u00a0 erarb eitet\u00a0 (AWMF\u00a0\n2017).\u00a0F\u00fcr\u00a02018\u00a0ist\u00a0die\u00a0Ver\u00f6ffentlichung\u00a0der\u00a0\u00fcberarbeiteten\u00a0Nat ionalen\u00a0Versor\u2010\ngungsleitlinie\u00a0(NV L)\u00a0COPD\u00a0geplant.\u00a0\u00a0\nAuf\u00a0internationaler\u00a0Ebene\u00a0sehen\u00a0 die\u00a0Empfehlungen\u00a0der\u00a0GOLD\u00a0nach\u00a0 Kategorisie\u2010\nrung\u00a0der\u00a0Patienten\u00a0in\u00a0Abh\u00e4ngigke it\u00a0der\u00a0Schwere\u00a0der\u00a0Symptomatik\u00a0 und\u00a0H\u00e4ufigkeit\u00a0\nder\u00a0Exazerbationen\u00a0(ABCD\u2010Einteil ung)\u00a0eine\u00a0gruppenspezifische\u00a0Ph armakotherapie\u00a0\nvor.\u00a0Dabei\u00a0bilden\u00a0Bronchodilatatoren\u00a0die\u00a0Basismedikation.\u00a0Durch \u00a0Reduktion\u00a0der\u00a0\nbronchialen\u00a0Muskelspannung\u00a0f\u00fchren \u00a0sie\u00a0zu\u00a0einer\u00a0Erweiterung\u00a0der\u00a0 Atemwege\u00a0und\u00a0\nReduktion\u00a0der\u00a0Lungen\u00fcberbl\u00e4hung\u00a0und\u00a0lindern\u00a0somit\u00a0die\u00a0Beschwerd en.\u00a0Die\u00a0jewei\u2010\nligen\u00a0Substanzen\u00a0rekrutieren\u00a0sich\u00a0aus\u00a0drei\u00a0Wirkstoffklassen:\u00a0Be ta2\u2010Agonisten\u00a0wer\u2010\nden\u00a0je\u00a0nach\u00a0Wirkeintritts\u2010\u00a0und\u00a0Halbwertszeit\u00a0in\u00a0langwirksame\u00a0(L ABA)\u00a0und\u00a0kurzwirk\u2010\nsame\u00a0(Short\u2010acting \u00a0Beta\u20102\u00a0Agonists ,\u00a0SABA)\u00a0eingeteilt.\u00a0Letztere\u00a0sind\u00a0nicht\u00a0Bestand\u2010\nteil\u00a0der\u00a0Basistherapie\u00a0sondern\u00a0wer den\u00a0zumeist\u00a0im\u00a0Rahmen\u00a0einer\u00a0N otfallversorgung\u00a0\nbzw.\u00a0nur\u00a0zu\u00a0Behandlung\u00a0leichter\u00a0Erkrankungsstufen\u00a0eingesetzt.\u00a0W eiterhin\u00a0stehen\u00a0\nAnticholinergika\u00a0zur\u00a0Verf\u00fcgung,\u00a0welche\u00a0die\u00a0bronchokonstriktoris che\u00a0Wirkung\u00a0von\u00a0\nAcetylcholin\u00a0antagonisieren.\u00a0\u00c4hnlich\u00a0wie\u00a0die\u00a0Beta 2\u2010Agonisten\u00a0k\u00f6nnen\u00a0sie\u00a0in\u00a0kurz\u2010\u00a0\n(Short\u2010acting\u00a0 Muscarinic\u00a0 Antagonist ,\u00a0 SAMA)\u00a0 und\u00a0 langwirkende\u00a0 ( Long\u2010acting\u00a0\nMuscarinic\u00a0Antagonist ,\u00a0LAMA)\u00a0gruppiert\u00a0werden.\u00a0Im\u00a0Krankheitsstadium\u00a0B\u00a0werden\u00a0\nbeide\u00a0Klassen\u00a0in\u00a0der\u00a0Regel\u00a0im\u00a0Rahmen\u00a0einer\u00a0jeweiligen\u00a0Monothera pie\u00a0eingesetzt.\u00a0\nErst\u00a0bei\u00a0einer\u00a0Einstufung\u00a0in\u00a0Stufe\u00a0C\u00a0zeigen\u00a0LAMA\u00a0die\u00a0beste\u00a0Evid enz\u00a0und\u00a0k\u00f6nnen\u00a0ggf.\u00a0\nmit\u00a0LABA\u00a0kombiniert\u00a0werden.\u00a0Im\u00a0h\u00f6chsten\u00a0Schweregrad\u00a0D\u00a0werden\u00a0gr unds\u00e4tzlich\u00a0\nKombinationen\u00a0empfohlen.\u00a0Das\u00a0Methylxanthin\u00a0Theophyllin\u00a0wird\u00a0auf grund\u00a0seines\u00a0\nung\u00fcnstigen\u00a0Nebenwirkungsprofils\u00a0und\u00a0Interaktionspotentials\u00a0bei \u00a0geringer\u00a0bron\u2010\nchodilatorischer\u00a0 Wirkung\u00a0 nicht\u00a0 empfohlen.\u00a0 Inhalierbare\u00a0 Glucokor ticoide\u00a0 sollten\u00a0\neher\u00a0zur\u00fcckhaltend,\u00a0und\u00a0dann\u00a0auch\u00a0nur\u00a0bei\u00a0h\u00e4ufigen\u00a0Exazerbation en,\u00a0die\u00a0trotz\u00a0\neiner\u00a0dualen\u00a0Bronchodilatation\u00a0auftreten\u00a0bzw.\u00a0beim\u00a0Asthma\u2010COPD\u2010 Overlap\u00a0(ACO),\u00a0\neingesetzt\u00a0werden\u00a0(GOLD,\u00a02017).\u00a0\nDie\u00a0Leitlinie\u00a0nennt\u00a0Olodaterol\u00a0als\u00a0Vertreter\u00a0der\u00a0LABA,\u00a0gibt\u00a0jed och\u00a0keine\u00a0Pr\u00e4ferenz\u00a0\ngegen\u00fcber\u00a0anderen\u00a0Substanzen \u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0vor.\u00a0\n\u00a0\u00a0316\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0 pU\u00a0 reichte\u00a0 kein\u00a0 Dossier\u00a0 zum\u00a0 Nutzenbewertungsverfahren\u00a0 ein,\u00a0 sodass\u00a0 der\u00a0\nGemeinsame\u00a0Bundesauschuss\u00a0(G\u2010BA)\u00a0in\u00a0seinem\u00a0Beschluss\u00a0vom\u00a017.\u00a0Ju li\u00a02014\u00a0keinen\u00a0\nBeleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0feststellen\u00a0konnte.\u00a0Es\u00a0erfolgte\u00a0di e\u00a0Eingruppierung\u00a0in\u00a0\ndie\u00a0bestehende\u00a0Festbetragsgruppe\u00a0\u201eBeta 2\u2010Sympatomimetika,\u00a0i nhalativ\u00a0oral,\u00a0Grup\u2010\npe\u00a01\u201c)\u00a0(G\u2010BA,\u00a02014).\u00a0 \u00a0\nVersorgungsanalysen\u00a0\nDas\u00a0Volumen\u00a0der\u00a0verordneten\u00a0Packungen\u00a0(Abb.\u00a04.37)\u00a0des\u00a0langwirke nden\u00a0Beta 2\u2010\nRezeptoragonisten\u00a0Olodaterol\u00a0steigt\u00a0im\u00a0Verlauf\u00a0von\u00a014\u00a0Monaten\u00a0n ach\u00a0Marktein\u2010\nf\u00fchrung\u00a0und\u00a0erreicht\u00a0im\u00a0Juli\u00a02015\u00a0 den\u00a0Maximalwert\u00a0von\u00a0427.\u00a0Zu\u00a0d ieser\u00a0Entwicklung\u00a0\ntrug\u00a0auch\u00a0die\u00a0Eingruppierung\u00a0des\u00a0Wirkstoffs\u00a0in\u00a0eine\u00a0Festbetrags gruppe\u00a0ein,\u00a0die\u00a0\neine\u00a0wirtschaftliche\u00a0Verordnung\u00a0zu\u00a0Lasten\u00a0der\u00a0GKV\u00a0bedingte,\u00a0obg leich\u00a0der\u00a0G\u2010BA\u00a0\nkeinen\u00a0Zusatznutzen\u00a0feststellen\u00a0konnte\u00a0(G\u2010BA,\u00a02014).\u00a0Dar\u00fcber\u00a0hi naus\u00a0lag\u00a0der\u00a0Ab\u2010\ngabepreis\u00a0des\u00a0pU\u00a0unter\u00a0dem\u00a0Niveau\u00a0des\u00a0Festbetrages\u00a0(Lauer\u2010Fisch er,\u00a02017),\u00a0sodass\u00a0\nsich\u00a0innerhalb\u00a0des\u00a0Beobachtungszeitraums\u00a0keine\u00a0Mehrkosten\u00a0ergab en,\u00a0ebenfalls\u00a0\nein\u00a0wichtiger\u00a0Aspekt\u00a0f\u00fcr\u00a0die\u00a0Akzeptanz\u00a0durch\u00a0Patienten.\u00a0Erst\u00a0se it\u00a0August\u00a02015\u00a0ist\u00a0\ndie\u00a0Tendenz\u00a0r\u00fcckl\u00e4ufig.\u00a0Zeitlich\u00a0kann\u00a0hier\u00a0ein\u00a0Zusammenhang\u00a0zur \u00a0Markteinf\u00fchrung\u00a0\ndes\u00a0Kombinationspr\u00e4parates\u00a0von\u00a0Olodaterol\u00a0und\u00a0Tiotropium\u00a0\u00a0herge stellt\u00a0werden,\u00a0\ndass\u00a0seit\u00a0dem\u00a01.\u00a0Juli\u00a02015\u00a0mit\u00a0identischer\u00a0Indikation\u00a0verf\u00fcgbar \u00a0ist.\u00a0Weiterhin\u00a0f\u00e4llt\u00a0\nder\u00a0hohe\u00a0Anteil\u00a0von\u00a0Packungen\u00a0ohne \u00a0Normgr\u00f6\u00dfe\u00a0auf,\u00a0der\u00a0bis\u00a0zu\u00a067 \u00a0%\u00a0(Juli\u00a02015)\u00a0\ndes\u00a0Gesamtvolumens\u00a0ausmacht.\u00a0Urs\u00e4chlich\u00a0daf\u00fcr\u00a0ist\u00a0die\u00a0Aufnahme\u00a0 der\u00a0Substanz\u00a0in\u00a0\ndie\u00a0Packungsgr\u00f6\u00dfenverordnung,\u00a0die\u00a0eine\u00a0Einteilung\u00a0der\u00a0Normgr\u00f6\u00dfe n\u00a0in\u00a020,\u00a060\u00a0und\u00a0\n200\u00a0Einzeldosen\u00a0vorsieht\u00a0(DIMDI,\u00a02014).\u00a0Diese\u00a0Einstufung\u00a0entspr ach\u00a0nicht\u00a0den\u00a0vom\u00a0\npU\u00a0vertriebenen\u00a0Einheiten,\u00a0sodass\u00a0eine\u00a0Aktualisierung\u00a0der\u00a0im\u00a0Ma rkt\u00a0befindlichen\u00a0\nPackungen\u00a0stattfand.\u00a0Die\u00a0Normgr\u00f6\u00dfe\u00a01\u00a0(N1,\u00a060\u00a0Hub)\u00a0wurde\u00a0zu\u00a0N2,\u00a0 die\u00a0N3\u00a0(3mal\u00a060\u00a0\nHub)\u00a0lag\u00a0nun\u00a0au\u00dferhalb\u00a0des\u00a0definierten\u00a0Bereiches\u00a0und\u00a0besitzt\u00a0da her\u00a0keine\u00a0Normie\u2010\nrung\u00a0mehr.\u00a0\nIn\u00a0der\u00a0dargestellten\u00a0Population\u00a0(Abb.\u00a04.38)\u00a0nimmt\u00a0die\u00a0Anzahl\u00a0de r\u00a0Versicherten,\u00a0die\u00a0\nOlodaterol\u00a0einnehmen,\u00a0mit\u00a0dem\u00a0Alter\u00a0zu.\u00a0So\u00a0sind\u00a098\u00a0%\u00a0der\u00a0Proban den\u00a0mindestens\u00a0\n40\u00a0Jahre\u00a0alt.\u00a0Diese\u00a0Beobachtung\u00a0reflektiert\u00a0den\u00a0aktuellen\u00a0Kennt nisstand,\u00a0wonach\u00a0\ndas\u00a0Risiko\u00a0f\u00fcr\u00a0COPD\u00a0ab\u00a0der\u00a0dritten\u00a0und\u00a0vierten\u00a0Lebensdekade\u00a0zun immt\u00a0(Mannino\u00a0\n&\u00a0Buist,\u00a02007).\u00a0Insgesamt\u00a0\u00fcberwiegt\u00a0der\u00a0Anteil\u00a0der\u00a0m\u00e4nnlichen\u00a0V ersicherten\u00a0(58\u00a0\n%).\u00a0Die\u00a0Frage\u00a0nach\u00a0dem\u00a0Einfluss\u00a0 des\u00a0Geschlechts\u00a0auf\u00a0die\u00a0Erkrank ungswahrschein\u2010\nlichkeit\u00a0wird\u00a0bisher\u00a0kontrovers\u00a0diskutiert\u00a0(Mannino\u00a0&\u00a0Buist,\u00a020 07).\u00a0\n\u00a0 \u00a0317\u00a0Abbildung\u00a04.37:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Olodaterol\u00a0je\u00a0Mona t\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.38:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Olodater ol\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n318\u00a0Quellen\u00a0\nKoch\u00a0A,\u00a0PizzichiniE,\u00a0Hamilton\u00a0A, \u00a0Hart\u00a0L,\u00a0Korducki\u00a0L,\u00a0De\u00a0Salvo\u00a0M \u00a0(2014).\u00a0Lung\u00a0function\u00a0effcacy\u00a0and\u00a0symptomatic\u00a0benefit\u00a0of\u00a0oloda terol\u00a0\nonce\u00a0daily\u00a0delivered\u00a0via\u00a0Respima t\u00ae\u00a0versus\u00a0placebo\u00a0and\u00a0formotero l\u00a0twice\u00a0daily\u00a0in\u00a0patients \u00a0with\u00a0gOlD\u00a02\u20134\u00a0COPD:\u00a0\nresults\u00a0from\u00a0two\u00a0replicate\u00a048\u2010week\u00a0studies.\u00a09(1):\u00a0697\u2010714.\u00a0\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2014).Neu\u00a0auf\u00a0dem\u00a0Markt.\u00a0ME\u00a0TOO:\u00a0OLODAT EROL\u2010INHALAT(STRIVERDI \u00a0RESPIMAT)\u00a0BEI\u00a0COPD.\u00a0\nhttps://www.arznei\u2010telegramm.de/html/2014_07/1407070_01.html,\u00a0l etzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nCavaill\u00e8s\u00a0A,\u00a0Brinchault\u2010Rabin\u00a0G,\u00a0D ixmier\u00a0A,\u00a0Goupil\u00a0F,\u00a0Gut\u2010Gober t\u00a0C,\u00a0Marchand\u2010Adam\u00a0S,\u00a0Meurice\u00a0JC,\u00a0Morel\u00a0H,\u00a0Person\u2010Tacnet\u00a0C,\u00a0\nLeroyer\u00a0C,\u00a0Diot\u00a0P(2013).\u00a0Europ\u00a0Resp\u00a0Rev\u00a022\u00a0(130):\u00a0454\u2010475.\u00a0\nMannino\u00a0DM,\u00a0Buist\u00a0AS\u00a0(2007).Global\u00a0burden\u00a0of\u00a0COPD:\u00a0risk\u00a0factors ,\u00a0prevalence,\u00a0and\u00a0future\u00a0trends.\u00a0Lancet\u00a0370\u00a0(9589):\u00a0765\u2010773.\u00a0\nDIMDI\u00a0(2014)\u00a0Deutsches\u00a0Institut\u00a0f\u00fc r\u00a0Medizinische\u00a0Dokumentation\u00a0 und\u00a0Information,\u00a0Packungsgr\u00f6\u00dfenverordnung\u00a0Anlage\u00a01,\u00a0\nhttps://www.dimdi.de/dynamic/de/amg/packungsgroessen/historie/a nlage1/packungsgroessen\u2010anlage\u20101\u2010\n201412.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nDonohue\u00a0JF,\u00a0Betts\u00a0KA,\u00a0Du\u00a0EX,\u00a0Altman\u00a0P,\u00a0Goyal\u00a0P,\u00a0Keininger\u00a0DL\u00a0et \u00a0al.\u00a0(2017).\u00a0Comparative\u00a0efficacy\u00a0of\u00a0long\u2010acting\u00a0\u03b22\u2010agonists\u00a0as \u00a0\nmonotherapy\u00a0for\u00a0chronic\u00a0obstruct ive\u00a0pulmonary\u00a0disease:\u00a0a\u00a0networ k\u00a0meta\u2010analysis.\u00a0Int\u00a0J\u00a0Chron\u00a0Obstruct\u00a0Pulmon\u00a0Dis\u00a0\n12:\u00a0367.\u00a0\nFachinformation\u00a0Striverdi\u00a0Respimat\u00ae\u00a0(2016).\u00a0Fachinformation\u00a0Str iverdi\u00a0Respimat\u00ae.\u00a0www.fachinfo.de/suche/striverdirespimat,\u00a0\nletzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2010),\u00a0FDA\u00a0Drug\u00a0Safety\u00a0Comm unication:\u00a0New\u00a0safety\u00a0requirements\u00a0for\u00a0long\u2010acting\u00a0inhaled\u00a0\nasthma\u00a0medications\u00a0called\u00a0Long\u2010Acting\u00a0Beta\u2010Agonists\u00a0(LABAs),\u00a0https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinform ationforpatientsandproviders/ucm200776.htm,\u00a0\nStand\u00a0der\u00a0Information:03.08.2016,\u00a0letzter\u00a0Zugriff:\u00a030.04.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0\nArzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die \u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0und\u00a0Anlage\u00a0IX\u00a0\u2013\u00a0Festbetragsgruppen bildung\u00a0Beta2\u2010Sympathomimetika,\u00a0inhalativ\u00a0oral,\u00a0\nGruppe\u00a01,\u00a0in\u00a0Stufe\u00a02\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a03\u00a0in\u00a0Verbindung\u00a0mit\u00a0Absa tz\u00a04\u00a0Satz\u00a01\u00a0SGB\u00a0V\u00a0\u2013\u00a0Olodaterol.\u00a0https://www.g\u2010\nba.de/downloads/39\u2010261\u20102031/2014\u201007\u201017_AM\u2010RL\u2010IX\u2010XII_Beta2\u2010\nSympathomimetika_inhalativ_Eingr_Olodaterol_Gr1_BAnz.pdf,\u00a0letzt er\u00a0Zugriff:\u00a020.03.2017.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0\nArzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die \u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0Tiotropium/\u00a0Olodaterol.\u00a0https://ww w.g\u2010ba.de/downloads/39\u2010261\u20102487/2016\u201002\u2010\n04_AM\u2010RL\u2010XII_Tiotropium_Olodaterol_2015\u201008\u201015\u2010D\u2010175_BAnz.pdf,\u00a0l etzter\u00a0Zugriff:\u00a020.03.2017\u00a0\nGOLD\u00a0\u2013\u00a0Global\u00a0Initiative\u00a0For\u00a0Chr onic\u00a0Obstructive\u00a0Lung\u00a0Disease\u00a0( 2017).\u00a0Global\u00a0Strategy\u00a0for\u00a0the\u00a0Diagnosis,\u00a0Management\u00a0and\u00a0\nPrevention\u00a0of\u00a0COPD.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0http:/ /goldcopd.org/download/326/,\u00a0letzter\u00a0Zugriff:\u00a0\n04.07.2017.\u00a0\nGorenoi\u00a0V,\u00a0Sch\u00f6nermark\u00a0MP,\u00a0Hagen\u00a0A,\u00a0Deutsches\u00a0Institut\u00a0f\u00fcrMediz inische\u00a0Dokumentation\u00a0und\u00a0Information\u00a0(DIMDI)\u00a0(Hrsg.)\u00a0(2007).\u00a0\nMa\u00dfnahmen\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Compliance\u00a0bzw.\u00a0Adherence\u00a0in\u00a0der \u00a0Arzneimitteltherapie\u00a0mit\u00a0Hinblick\u00a0auf\u00a0den\u00a0\nTherapieerfolg.\u00a0Schriftenreihe\u00a0Health\u00a0Technologie\u00a0Assessment,\u00a0B d.\u00a065.\u00a0K\u00f6ln:\u00a0DIMDI.\u00a0\nHaynes\u00a0RB,\u00a0Ackloo\u00a0E,\u00a0Sahota\u00a0N\u00a0et\u00a0al.:\u00a0Interventions\u00a0for\u00a0enhanci ng\u00a0medication\u00a0adherence.\u00a0Cochrane\u00a0Database\u00a0Systematic\u00a0Review\u00a0\n2008;\u00a0Issue\u00a02:\u00a0CD000011\u00a0319\u00a0Koch\u00a0A,\u00a0Pizzichini\u00a0E,\u00a0Hamilton\u00a0A,\u00a0Hart\u00a0L,\u00a0Korducki\u00a0L,\u00a0De\u00a0Salvo\u00a0 M\u00a0(2014).\u00a0Lung\u00a0function\u00a0efficacy\u00a0and\u00a0symptomatic\u00a0benefit\u00a0of\u00a0\nolodaterol\u00a0once\u00a0daily\u00a0delivered\u00a0via\u00a0Respimat\u00ae\u00a0versus\u00a0placebo\u00a0an d\u00a0formoterol\u00a0twice\u00a0daily\u00a0in\u00a0patients\u00a0with\u00a0gOlD\u00a02\u20134\u00a0\nCOPD:\u00a0results\u00a0from\u00a0two\u00a0replicate\u00a048\u2010week\u00a0studies.\u00a0Int\u00a0J\u00a0Chron\u00a0O bstruct\u00a0Pulmon\u00a0Dis\u00a02014\u00a09:\u00a0697\u2010714.\u00a0\nLange\u00a0P,\u00a0Aumann\u00a0JL,\u00a0Hamilton\u00a0A,\u00a0Tetzlaff\u00a0K,\u00a0Ting\u00a0N,\u00a0Derom\u00a0E\u00a0et\u00a0 al.\u00a0(2014).\u00a0The\u00a024\u2010Hour\u00a0Lung\u00a0Function\u00a0Time\u00a0Profile\u00a0of\u00a0Olodatero l\u00a0\nOnce\u00a0Daily\u00a0Versus\u00a0Placebo\u00a0and\u00a0Tiotropium\u00a0in\u00a0Patients\u00a0with\u00a0Moder ate\u00a0to\u00a0Very\u00a0Severe\u00a0Chronic\u00a0Obstructive\u00a0Pulmonary\u00a0\nDisease.\u00a0J\u00a0Pulm\u00a0Respir\u00a0Med\u00a04:196.\u00a0\nLAUER\u2010FISCHER\u00a0(2017).\u00a0Archiv\u00a01.5.2014\u00a0\u2013\u00a015.12.2015,\u00a0letzter\u00a0Zug riff:\u00a018.06.2017.\u00a0\nMathers\u00a0CD,\u00a0Loncar\u00a0D\u00a0(2006).\u00a0Projections\u00a0of\u00a0Global\u00a0Mortality\u00a0an d\u00a0Burden\u00a0of\u00a0Disease\u00a0from\u00a02002\u00a0to\u00a02030.\u00a0PLoS\u00a0Medicine\u00a03(11):\u00a0e44 2.\u00a0\u00a0\nMEB\u00a0\u2013\u00a0Medicines\u00a0Evaluation\u00a0Board \u00a0in\u00a0the\u00a0Netherlands\u00a0(2014).\u00a0PUB LIC\u00a0ASSESSMENT\u00a0REPORT\u00a0of\u00a0the\u00a0Medicines\u00a0Evaluation\u00a0Board\u00a0in\u00a0\nthe\u00a0Netherlands.\u00a0Striverdi\u00a0Respimat\u00a02.5\u00a0micrograms,\u00a0solution\u00a0fo r\u00a0inhalation\u00a0Boehringer\u00a0Ingelheim\u00a0International\u00a0\nGmbH,\u00a0Germany.\u00a0https://db.cbg\u2010meb.nl/Pars/h112058.pdf,\u00a0letzter\u00a0 Zugriff:\u00a004.07.2017.\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2015) .\u00a0Chronic\u00a0obstructive\u00a0pulmonary\u00a0disease:\u00a0olodaterol.\u00a0Evidence\u00a0\nsummary.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02015.\u00a0Nice.org.uk/guida nce/esnm54,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0Olodaterol\u00a0(Striverdi\u00a0Respimat\u00ae ).\u00a0Just\u00a0another\u00a0beta\u00a02\u2010agonist.\u00a0Prescrire\u00a0Int\u00a025\u00a0(170):\u00a095.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe,\u00a0 Olodaterol.\u00a0Stand\u00a0der\u00a0Informationen:\u00a0August\u00a02016.\u00a0\nwww.pharmazeutische\u2010zeitung.de/in dex.php?id=52575,\u00a0letzter\u00a0Zugr iff:\u00a003.05.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u00a0Institut,\u00a0Chronische\u00a0Lungenkrankheiten,\u00a0\nhttp://www.rki.de/DE/Content/Gesundheitsmonitoring/Themen/Chron ische_Erkrankungen/lungenerkrankungen/lu\nngenerkrankungen_node.html\u00a0Letzter\u00a0Zugriff:\u00a030.04.2017\u00a0\u00a0\nRoskell\u00a0NS,\u00a0Anzueto\u00a0A,\u00a0Hamilton\u00a0A,\u00a0Disse\u00a0B,\u00a0Becker\u00a0K\u00a0(2014).\u00a0On ce\u2010daily\u00a0long\u2010acting\u00a0beta\u2010agonis ts\u00a0for\u00a0chronic\u00a0obstructive\u00a0pulm o\u2010\nnary\u00a0disease:\u00a0an\u00a0indirect\u00a0comparison\u00a0of\u00a0olodaterol\u00a0and\u00a0indacate rol.\u00a0Int\u00a0J\u00a0Chron\u00a0Obstruct\u00a0Pulmon\u00a0Dis\u00a09(1):\u00a0813\u2010824.\u00a0\n\u00a0 \u00a0320\u00a04.21 Riociguat\u00a0\nHandelsname:\u00a0Adempas\u00ae\u00a0\u00a0 \u00a0 Pharmazeutische\u00a0Unternehmer:\u00a0\nIndikationen:\u00a0Chronisch\u00a0thrombo\u2010\u00a0 \u00a0 Bayer/MSD\u00a0\nembolische\u00a0pulmonale\u00a0Hyperto nie\u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Mai\u00a02014\u00a0\nPulmonal\u00a0arterielle\u00a0Hypertonie\u00a0\nATC\u2010Code:\u00a0C02KX05\u00a0 \u00a0 \u00a0 \u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a04,5\u00a0mg\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O, \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nRiociguat\u00a0(Handelsname:\u00a0Adempas\u00ae )\u00a0greift\u00a0in\u00a0den\u00a0Signalweg\u00a0NO\u2010sG C\u2010cGMP\u00a0ein,\u00a0\nindem\u00a0es\u00a0die\u00a0Bindung\u00a0vonendogenem\u00a0Stickstoffmonoxid\u00a0(NO)\u00a0an\u00a0das \u00a0Enzym\u00a0l\u00f6sli\u2010\nche\u00a0Guanylatcyclase\u00a0( soluble\u00a0Guanylatcyclase \u00a0sGC)\u00a0stabilisiert\u00a0sowie\u00a0unabh\u00e4ngig\u00a0\nvon\u00a0NO\u00a0die\u00a0sGC\u00a0direkt\u00a0stimuliert.\u00a0Cyclisches\u00a0Guanosinmonophosph at\u00a0(cGMP)\u00a0wie\u2010\nderum\u00a0beeinflusst\u00a0intrazellul\u00e4r\u00a0den\u00a0Gef\u00e4\u00dftonus,\u00a0die\u00a0Proliferati on\u00a0glatter\u00a0Gef\u00e4\u00df\u2010\nmuskelzellen,\u00a0Fibrose\u00a0und\u00a0Inflammation.\u00a0Bei\u00a0Hochdruck\u00a0im\u00a0Lungen kreislauf\u00a0(pul\u2010\nmonaler\u00a0Hypertonie,\u00a0PH)\u00a0und\u00a0desse n\u00a0Subtyp\u00a0pulmonal\u00a0arterieller\u00a0 Hypertonie\u00a0(PAH)\u00a0\nstellt\u00a0der\u00a0NO\u2010sGC\u2010cGMP\u2010Signalweg \u00a0eine\u00a0Zielstruktur\u00a0einer\u00a0Pharma kotherapie\u00a0dar\u00a0\n(CHMP,\u00a02017;\u00a0Mutschler\u00a0et\u00a0al.,\u00a02016).\u00a0\nDie\u00a0Zulassung\u00a0erfolgte\u00a0seitens\u00a0der\u00a0amerikanischen\u00a0Beh\u00f6rde\u00a0( Food\u00a0and\u00a0Drug\u00a0Admi\u2010\nnistration ,\u00a0FDA)\u00a0in\u00a02013\u00a0sowie\u00a0seitens\u00a0der\u00a0europ\u00e4ischen\u00a0Kommission\u00a0( European \u00a0\nCommission ,\u00a0 EC)\u00a0 im\u00a0 M\u00e4rz\u00a0 2014\u00a0 f\u00fcr\u00a0 zwei\u00a0 Subtypen\u00a0 der\u00a0 insgesamt\u00a0 f\u00fcnf\u00a0 WHO\u2010\nGruppen\u00a0der\u00a0PH:\u00a0f\u00fcr\u00a0die\u00a0PAH\u00a0und\u00a0die\u00a0chronisch\u00a0thromboembolische \u00a0pulmonale\u00a0\nHypertonie\u00a0(CTEPH),\u00a0wobei\u00a0 die\u00a0Anwendung\u00a0 auf\u00a0 die\u00a0Funktionsklasse n\u00a0(Functional\u00a0\nClasses,\u00a0WHO\u2010FC)\u00a0II\u00a0und\u00a0III\u00a0von\u00a0vier\u00a0der\u00a0WHO\u00a0beschr\u00e4nkt\u00a0wurde\u00a0(CDER,\u00a02 013;\u00a0CHMP,\u00a0\n2014,\u00a02017).\u00a0Es\u00a0handelt\u00a0sich\u00a0um\u00a0seltene\u00a0Leiden,\u00a0sodass\u00a0bereits\u00a0 im\u00a0Jahr\u00a02007\u00a0die\u00a0\nAnerkennung\u00a0 als\u00a0 Orphan\u2010A r z n e i m i t t e l \u00a0e r f o l g t e \u00a0( C O M P , \u00a02 0 0 7 ) . \u00a0R i o c i g u a t \u00a0w i r d \u00a0a l s \u00a0\nFilmtablette\u00a0dreimal\u00a0t\u00e4glich\u00a0gegeben,\u00a0wobei\u00a0individuell\u00a0alle\u00a0zw ei\u00a0Wochen\u00a0bis\u00a0zur\u00a0\nmaximal\u00a0tolerierten\u00a0Dosierung\u00a0von\u00a03x\u00a02,5\u00a0mg\u00a0auftitriert\u00a0wird.\u00a0\nZur\u00a0Begr\u00fcndung\u00a0der\u00a0Zulassung\u00a0von\u00a0Riociguat\u00a0legte\u00a0der\u00a0pharmazeut ische\u00a0Unter\u2010\nnehmer\u00a0 (pU)\u00a0 der\u00a0 EMA\u00a0 die\u00a0 von\u00a0 ihm\u00a0 gesponserten\u00a0 Phase\u2010III\u2010Studien\u00a0 CHEST\u20101\u00a0\n(CTEPH,\u00a0NCT00855465)\u00a0und\u00a0PATENT\u20101\u00a0(PAH,\u00a0NCT00810693)\u00a0vor\u00a0sowie\u00a0 Zwischener\u2010\ngebnisse\u00a0 derer\u00a0 unverblindeter\u00a0 Langzeitarme\u00a0 CHEST\u20102\u00a0 (NCT00910429 )\u00a0 bzw.\u00a0\nPATENT\u20102\u00a0(NCT00863681)\u00a0(CHMP,\u00a02014).\u00a0\nDie\u00a0Zulassungsstudie\u00a0CHEST\u20101\u00a0untersuchte\u00a0multizentrisch,\u00a0doppel blind,\u00a02:1\u00a0rand\u2010\nomisiert,\u00a0placebokontrolliert\u00a0in\u00a0Form\u00a0einer\u00a0Phase\u2010III\u2010Studie\u00a0di e\u00a0Effekte\u00a0von\u00a0indivi\u2010\nduell\u00a0dosistitriertem\u00a0Riociguat\u00a0 auf\u00a0261\u00a0randomiserte,\u00a0inoperabl e\u00a0bzw.\u00a0nach\u00a0pul\u2010\nmonaler\u00a0Endarteriektomie\u00a0(PEA)\u00a0t herapierefrakt\u00e4re\u00a0Patienten\u00a0mit \u00a0CTEPH\u00a0\u00fcber\u00a016\u00a0\n321\u00a0Wochen.\u00a0Als\u00a0Startdosis\u00a0wurde\u00a0Riociguat\u00a0mit\u00a0dreimal\u00a0t\u00e4glich\u00a01,0\u00a0 mg\u00a0definiert,\u00a0alle\u00a0\nzwei\u00a0Wochen\u00a0um\u00a00,5\u00a0mg\u00a0auftitriert\u00a0bis\u00a0Zeichen\u00a0von\u00a0Hypotonie\u00a0bzw .\u00a0systolischer\u00a0\nBlutdruck\u00a0<95\u00a0mm\u00a0Hg\u00a0auftraten\u00a0bzw.\u00a02,5\u00a0mg\u00a0dreimal\u00a0t\u00e4glich\u00a0errei cht\u00a0wurden.\u00a0Bei\u00a0\nAnzeichen\u00a0einer\u00a0Hypotonie\u00a0war\u00a0ge m\u00e4\u00df\u00a0Studienprotokoll\u00a0eine\u00a024\u2010st \u00fcndige\u00a0Thera\u2010\npiepause\u00a0 mit\u00a0 nachfolgender\u00a0 Dosisr eduktion\u00a0 um\u00a00,5\u00a0mg\u00a0 vorgegeben. \u00a0 Prim\u00e4rer\u00a0\nEndpunkt\u00a0 war\u00a0 die\u00a0 Verbesserung\u00a0 der\u00a0 Sechsminutengehstrecke\u00a0 ( Six\u00a0 Minute\u00a0 Walk\u00a0\nDistance,\u00a06MWD),\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0die\u00a0\u00c4nderung\u00a0h\u00e4modynamischer\u00a0Param eter,\u00a0\nWHO\u2010FC\u00a0sowie\u00a0Morbidit\u00e4ts\u2010\u00a0bzw.\u00a0Lebensqualit\u00e4tsindices\u00a0(Borg\u2010Dys pnoe\u2010Skala,\u00a0BDS;\u00a0\nf\u00fcnfdimensionaler\u00a0Fragebogen\u00a0zur \u00a0Erfassung\u00a0der\u00a0gesundheitsbezog enen\u00a0Lebensquali\u2010\nt\u00e4t\u00a0der\u00a0EuroQol\u00a0Group:\u00a0EQ\u20105D;\u00a0 Living\u00a0with\u00a0Pulmonary\u00a0Hypertension ,\u00a0LPH)\u00a0zwischen\u00a0\nRandomisierung\u00a0und\u00a0Woche\u00a016\u00a0(Ghofrani\u00a0et\u00a0al.,\u00a02013a).\u00a0Statistis ch\u00a0signifikant\u00a0konnte\u00a0\nim\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0eine\u00a0Verbesserung\u00a0der\u00a06MWD\u00a0\u00fcber\u00a039\u00a0m\u00a0unter \u00a0Verum\u00a0und\u00a0\nunter\u00a0Placebo\u00a0eine\u00a0Abnahme\u00a0um\u00a06\u00a0m\u00a0dokumentiert\u00a0werden,\u00a0sodass\u00a0v on\u00a0einem\u00a0Ge\u2010\nsamteffekt\u00a0von\u00a045\u00a0m\u00a0berichtet\u00a0wird\u00a0(ClinicalTrials.gov,\u00a02008a;\u00a0 Ghofrani\u00a0et\u00a0al.,\u00a02013a).\u00a0\nDie\u00a0multizentrische,\u00a0offene\u00a0Verl\u00e4ngerungsstudie\u00a0CHEST\u20102\u00a0(CHMP,\u00a0 2014)\u00a0l\u00e4uft\u00a0bis\u00a0Ende\u00a0\nDezember\u00a02018,\u00a0Sicherheit\u00a0und\u00a0Vertr\u00e4glichkeit\u00a0bilden\u00a0nunmehr\u00a0de n\u00a0prim\u00e4ren\u00a0End\u2010\npunkt,\u00a0die\u00a0\u00c4nderung\u00a0der\u00a06MWD\u00a0den\u00a0sekund\u00e4ren\u00a0(ClinicalTrials.gov ,\u00a02009a).\u00a0Vorab\u00a0\nwurden\u00a0Zweijahresdaten\u00a0zu\u00a0237\u00a0Patienten\u00a0publiziert,\u00a0welche\u00a093\u00a0% \u00a0\u201eGesamt\u00fcberle\u2010\nben\u201c\u00a0und\u00a082\u00a0%\u00a0\u201e\u00dcberleben\u00a0ohne\u00a0klinische\u00a0Verschlechterung\u201c\u00a0( Clinical\u00a0Worsening\u2010Free\u00a0\nSurvival,\u00a0CWFS)\u00a0zeigten,\u00a0obschon\u00a0bei\u00a0129\u00a0(54\u00a0%)\u00a0der\u00a0Patienten\u00a0schwerwieg ende\u00a0un\u2010\nerw\u00fcnschte\u00a0Ereignisse\u00a0( Serious\u00a0Adverse\u00a0Events, \u00a0SAE)\u00a0auftraten\u00a0und\u00a014\u00a0(6\u00a0%)\u00a0die\u00a0The\u2010\nrapie\u00a0aufgrund\u00a0unerw\u00fcnschter\u00a0Arzneimittelereignisse\u00a0( Adverse\u00a0Events )\u00a0nicht\u00a0fortf\u00fchr\u2010\nten\u00a0(Simonneau\u00a0et\u00a0al.,\u00a02016).\u00a0\nBei\u00a0der\u00a0Interpretation\u00a0der\u00a0Studi en,\u00a0vor\u00a0allem\u00a0bei\u00a0CHEST\u20101,\u00a0ist\u00a0 die\u00a0kurze\u00a0Studien\u2010\ndauer\u00a0von\u00a016\u00a0Wochen\u00a0zu\u00a0ber\u00fccksichtigen,\u00a0bei\u00a0CHEST\u20102\u00a0die\u00a0Tatsach e,\u00a0dass\u00a0es\u00a0sich\u00a0\num\u00a0einen\u00a0 open\u2010label \u00a0Verl\u00e4ngerungsarm\u00a0vorselektierter\u00a0Patienten\u00a0handelt,\u00a0dessen\u00a0\nErgebnisse\u00a0erst\u00a0ab\u00a02019\u00a0ver\u00f6ffen tlicht\u00a0werden.\u00a0In\u00a0CHEST\u20101\u00a0konnt e\u00a0keine\u00a0statistisch\u00a0\nsignifikante\u00a0Reduktion\u00a0der\u00a0Mortalit\u00e4t\u00a0gezeigt\u00a0werden.\u00a0Als\u00a0Surro gatparameter\u00a0der\u00a0\nMorbidit\u00e4t\u00a0hat\u00a0sich\u00a0die\u00a06MWD\u00a0etabliert,\u00a0im\u00a0Kontext\u00a0der\u00a0PAH\u00a0bzw. \u00a0chronischer\u00a0\nLungenerkrankungen\u00a0geht\u00a0man\u00a0von\u00a0einer\u00a0minimal\u00a0klinisch\u00a0relevant en\u00a0Differenz\u00a0\n(MID)\u00a0vom\u00a0>41\u00a0m\u00a0aus,\u00a0um\u00a0auf\u00a0eine\u00a0Verbesserung\u00a0zu\u00a0schlie\u00dfen.\u00a0F\u00fcr \u00a0CTEPH\u00a0wurde\u00a0\neine\u00a0MID\u00a0nicht\u00a0definiert.\u00a0Obglei ch\u00a0in\u00a0CHEST\u20101\u00a0eine\u00a0statistisch\u00a0 signifikante\u00a0Mittel\u2010\nwertsdifferenz\u00a0der\u00a06MWD\u00a0von\u00a045,7\u00a0 m\u00a0gegen\u00fcber\u00a0Placebo\u00a0gezeigt\u00a0we rden\u00a0konnte,\u00a0\nist\u00a0der\u00a0absolute\u00a0Effekt\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0als\u00a0gering\u00a0zu\u00a0bewerte n,\u00a0da\u00a0die\u00a0Werte\u00a0wei\u2010\nterhin\u00a0im\u00a0pathologischen\u00a0Bereich \u00a0liegen\u00a0(AMB,\u00a02014).\u00a0Eine\u00a0\u00c4nder ung\u00a0der\u00a0WHO\u2010FC\u00a0\nkann\u00a0laut\u00a0EMA\u00a0als\u00a0sekund\u00e4rer\u00a0Endpunkt\u00a0in\u00a0Studien\u00a0dienen,\u00a0obwohl \u00a0die\u00a0Einstufung\u00a0\nsubjektiv\u00a0von\u00a0Arzt\u00a0und\u00a0Patienten\u00a0abh\u00e4ngig\u00a0ist.\u00a0In\u00a0CHEST\u20101\u00a0konnt e\u00a0statistisch\u00a0signifi\u2010\nkant\u00a0eine\u00a0Verbesserung\u00a0der\u00a0WHO\u2010F C\u00a0unter\u00a0Riociguat\u00a02,5\u00a0mg\u00a0gegen\u00fc ber\u00a0Placebo\u00a0\nnachgewiesen\u00a0werden\u00a0(32,9\u00a0%\u00a0zu\u00a014,9\u00a0%).\u00a0Der\u00a0sekund\u00e4re\u00a0Endpunkt\u00a0 \u201eZeit\u00a0bis\u00a0zur\u00a0322\u00a0klinischen\u00a0Verschlechterung\u201c\u00a0( Time\u00a0To\u00a0Clinical\u00a0Worsening, \u00a0TTCW)\u00a0ist\u00a0nach\u00a0Ein\u2010\nsch\u00e4tzung\u00a0des\u00a0Gemeinsamen\u00a0Bundesausschusses\u00a0(G\u2010BA)\u00a0nicht\u00a0ration al\u00a0zusammen\u2010\ngesetzt\u00a0und\u00a0zudem\u00a0nicht\u00a0validiert,\u00a0sodass\u00a0eine\u00a0Ableitung\u00a0der\u00a0Pa tientenrelevanz\u00a0\nnicht\u00a0eindeutig\u00a0m\u00f6glich\u00a0ist\u00a0(G\u2010BA,\u00a02014a).\u00a0Mittels\u00a0psychophysis chem\u00a0Messsystem\u00a0\nBDS\u00a0konnten\u00a0 Patienten\u00a0Erm\u00fcdungsempfinden\u00a0und\u00a0 Dyspnoe\u00a0dokumentie ren,\u00a0in\u00a0\nCHEST\u20101\u00a0konnte\u00a0statistisch\u00a0signifikant\u00a0eine\u00a0Verbesserung\u00a0um\u00a0ein e\u00a0dadurch\u00a0festge\u2010\nlegte\u00a0Einheit\u00a0nachgewiesen\u00a0werden,\u00a0obschon\u00a0f\u00fcr\u00a0CTEPH\u00a0oder\u00a0PAH\u00a0k eine\u00a0Validie\u2010\nrung\u00a0vorlag.\u00a0F\u00fcr\u00a0Effekte\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0wurden\u00a0nach\u00a0EQ\u2010 5D\u00a0eine\u00a0statistisch\u00a0\nsignifikante\u00a0Verbesserung\u00a0unter\u00a0R iociguat\u00a02,5\u00a0mg\u00a0gemessen,\u00a0mitt els\u00a0LPH\u2010Fragebogen\u00a0\nkonnte\u00a0 dieser\u00a0 Effekt\u00a0 nicht\u00a0 gezeigt\u00a0 werden.\u00a0 Unerw\u00fcnschte\u00a0 Arzneim ittelereignisse\u00a0\nwurden\u00a0nur\u00a0bis\u00a0zwei\u00a0Tage\u00a0nach\u00a0Ende\u00a0der\u00a0Studienmedikation\u00a0erhobe n,\u00a0viele\u00a0uner\u2010\nw\u00fcnschte\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0leiten\u00a0sich\u00a0aus\u00a0dem\u00a0Wirkm echanismus\u00a0von\u00a0\nRiociguat\u00a0ab,\u00a0jedoch\u00a0wird\u00a0besonde res\u00a0Augenmerk\u00a0auf\u00a0H\u00e4moptysis\u00a0g elenkt.\u00a0Im\u00a0Ergeb\u2010\nnis\u00a0leitete\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 geringen\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0CTEPH \u00a0ab,\u00a0wobei\u00a0\nder\u00a0 Zulassungsstatus\u00a0 als\u00a0 Orphan\u2010A r z n e i m i t t e l \u00a0s o w i e \u00a0d i e \u00a0p r i m \u00e4 r e \u00a0P r \u00fc f u n g \u00a0e i n e r \u00a0\nDurchf\u00fchrung\u00a0einer\u00a0PEA\u00a0an\u00a0einem\u00a0 der\u00a0drei\u00a0deutschen\u00a0Zentren\u00a0ber\u00fc cksichtigt\u00a0werden\u00a0\nmuss\u00a0(G\u2010BA,\u00a02014a),\u00a0da\u00a0diese\u00a0eine\u00a0Heilung\u00a0statt\u00a0einer\u00a0symptomat ischen\u00a0Pharmako\u2010\ntherapie\u00a0erm\u00f6glicht.\u00a0\nIn\u00a0der\u00a0Zulassungsstudie\u00a0PATENT\u20101,\u00a0die\u00a0der\u00a0Studie\u00a0CHEST\u20101\u00a0sehr\u00a0\u00e4 hnelt,\u00a0wurden\u00a0\nmultizentrisch,\u00a0doppelblind,\u00a0nunmehr\u00a04:2:1\u00a0randomisiert\u00a0und\u00a0pla cebokontrolliert\u00a0\nin\u00a0Form\u00a0einer\u00a0Phase\u2010III\u2010Studie\u00a0di e\u00a0Effekte\u00a0von\u00a0Riociguat\u00a0in\u00a0ind ividueller\u00a0Dosistitra\u2010\ntion\u00a0bis\u00a0zu\u00a0einer\u00a0Tagesh\u00f6chstdosis\u00a0von\u00a0dreimal\u00a02,5\u00a0mg,\u00a0Placebo\u00a0 oder\u00a01,5\u00a0mg\u00a0(ex\u2010\nplorativ,\u00a0vom\u00a0G\u2010BA\u00a0nicht\u00a0ber\u00fccksichtigt)\u00a0an\u00a0445\u00a0therapienaiven\u00a0 oder\u00a0vortherapier\u2010\nten\u00a0(Endothelinrezeptorantagonisten\u00a0ERA\u00a0bzw.\u00a0Prostanoide)\u00a0Patie nten\u00a0mit\u00a0PAH\u00a0\n\u00fcber\u00a012\u00a0Wochen\u00a0untersucht.\u00a0Im\u00a0Anschluss\u00a0konnten\u00a0die\u00a0Probanden\u00a0i n\u00a0den\u00a0open\u2010\nlabel\u00a0Langzeitarm\u00a0PATENT\u20102\u00a0wechseln,\u00a0der\u00a0noch\u00a0bis\u00a0Dezember\u00a02018\u00a0anda uern\u00a0\nwird\u00a0(ClinicalTrials.gov,\u00a02009b).\u00a0In\u00a0PATENT\u20101\u00a0eingeschlossen\u00a0wa ren\u00a0Patienten\u00a0mit\u00a0\nsymptomatischer\u00a0PAH\u00a0nach\u00a0WHO\u2010Gruppe\u00a0I,\u00a0ausgeschlossen\u00a0waren\u00a0Pat ienten\u00a0mit\u00a0\npulmonalem\u00a0 Hochdruck\u00a0 (PH),\u00a0 chronisch\u00a0 obstruktiver\u00a0 Lungenerkrank ung\u00a0 (Chronic\u00a0\nObstructive\u00a0Pulmonary\u00a0Disease ,\u00a0COPD),\u00a0unkontrolliertem\u00a0arteriellem\u00a0Hochdruck\u00a0oder\u00a0\nLinksherzfehler\u00a0(ClinicalTrials.\u00a0gov,\u00a02008b).\u00a0\nBei\u00a0der\u00a0Interpretation\u00a0von\u00a0PATENT\u20101\u00a0sind\u00a0die\u00a0kurze\u00a0Studiendauer \u00a0und\u00a0ein\u00a0Vergleich\u00a0\nmit\u00a0Placebo\u00a0zu\u00a0ber\u00fccksichtigen,\u00a0 obgleich\u00a0mehrere\u00a0zweckm\u00e4\u00dfige\u00a0Ve rgleichsthera\u2010\npien\u00a0(zVT)\u00a0zur\u00a0Verf\u00fcgung\u00a0standen.\u00a0Es\u00a0traten\u00a0zwei\u00a0(0,8\u00a0%)\u00a0Todesf \u00e4lle\u00a0unter\u00a02,5\u00a0mg\u00a0\nRiociguat\u00a0und\u00a0drei\u00a0(2,4\u00a0%)\u00a0unter\u00a0Placebo\u00a0in\u00a0PATENT\u20101\u00a0auf,\u00a0worau s\u00a0sich\u00a0kein\u00a0statis\u2010\ntisch\u00a0signifikanter\u00a0Unterschied\u00a0in\u00a0der\u00a0Mortalit\u00e4t\u00a0ergab\u00a0(Ghofra ni\u00a0et\u00a0al.,\u00a02013b).\u00a0Im\u00a0\nprim\u00e4ren\u00a0Endpunkt\u00a0konnte\u00a0eine\u00a0Verbesserung\u00a0der\u00a06MWD\u00a0zwischen\u00a0Ra ndomisie\u2010\nrung\u00a0und\u00a0Woche\u00a012\u00a0um\u00a029,6\u00a0m\u00a0unter\u00a02,5\u00a0mg\u00a0Riociguat\u00a0und\u00a0eine\u00a0Ver schlechterung\u00a0\nvom\u00a05,6\u00a0m\u00a0im\u00a0Placebo\u2010Arm,\u00a0d.h.\u00a0e ine\u00a0Mittelwertsdifferenz\u00a0von\u00a035 ,78\u00a0m\u00a0statistisch\u00a0323\u00a0signifikant\u00a0gezeigt\u00a0werden\u00a0(Ghofrani\u00a0et\u00a0al.,\u00a02013b).\u00a0Der\u00a0G\u2010BA\u00a0w ertete\u00a0das\u00a0Ergebnis,\u00a0\nwelches\u00a0unterhalb\u00a0der\u00a0MID\u00a0von\u00a041\u00a0m\u00a0liegt,\u00a0als\u00a0klinisch\u00a0gering\u00a0( G\u2010BA,\u00a02014a).\u00a0Als\u00a0\nsekund\u00e4rer\u00a0Endpunkt\u00a0zur\u00a0Morbidit\u00e4t\u00a0wurde\u00a0die\u00a0\u00c4nderung\u00a0der\u00a0WHO\u2010F C\u00a0zwischen\u00a0\nRandomisierung\u00a0und\u00a0Woche\u00a012\u00a0erhoben:\u00a0Unter\u00a02,5\u00a0mg\u00a0Riociguat\u00a0(20 ,9\u00a0%)\u00a0konnte\u00a0\nstatistisch\u00a0signifikant\u00a0eine\u00a0Verbesserung\u00a0gegen\u00fcber\u00a0Placebo\u00a0(14 ,4\u00a0%)\u00a0nachgewie\u2010\nsen\u00a0werden,\u00a0wobei\u00a0eine\u00a0patientenrelevante\u00a0Validierung\u00a0des\u00a0Surro gatparameters\u00a0\nnach\u00a0Auffassung\u00a0des\u00a0G\u2010BA\u00a0nicht\u00a0gegeben\u00a0ist\u00a0(G\u2010BA,\u00a02014a).\u00a0Auch\u00a0 der\u00a0Endpunkt\u00a0\nTTCW\u00a0fiel\u00a0statistisch\u00a0signifikant \u00a0zu\u00a0Gunsten\u00a0von\u00a0Riociguat\u00a0aus, \u00a0wobei\u00a0Validierungs\u2010\nstudien\u00a0zum\u00a0kombinierten\u00a0Endpunkt\u00a0fehlen\u00a0und\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0die\u00a0R ationale\u00a0der\u00a0\nAuswahl\u00a0der\u00a0einzelnen\u00a0Parameter\u00a0nicht\u00a0zu\u00a0ersehen\u00a0war\u00a0(G\u2010BA,\u00a0201 4a).\u00a0Mittels\u00a0BDS\u00a0\nkonnten\u00a0statistisch\u00a0signifikante\u00a0Effekte\u00a0von\u00a0Riociguat\u00a0auf\u00a0Ver\u00e4 nderung\u00a0von\u00a0Dysp\u2010\nnoe\u00a0und\u00a0Erm\u00fcdungsempfinden\u00a0gezeigt\u00a0werden,\u00a0obgleich\u00a0der\u00a0G\u2010BA\u00a0di e\u00a0absoluten\u00a0\nklinischen\u00a0Effekte\u00a0f\u00fcr\u00a0PAH\u2010Patienten\u00a0als\u00a0gering\u00a0bewertete\u00a0(G\u2010BA ,\u00a02014a).\u00a0Aspekte\u00a0\nder\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0\nwurden\u00a0 mittels\u00a0 EQ\u20105D\u2010\u00a0 und\u00a0 LPH\u2010Fragebogen\u00a0 erfasst,\u00a0 wobei\u00a0 der\u00a0 EQ\u2010 5D\u00a0 keinen\u00a0\nstatistisch\u00a0signifikanten\u00a0Unters chied\u00a0zeigte,\u00a0der\u00a0LPH\u00a0jedoch\u00a0f\u00fc r\u00a0die\u00a0physische\u00a0und\u00a0\ndie\u00a0 emotionale\u00a0 Dom\u00e4ne\u00a0 einen\u00a0 statistisch\u00a0 signifikanten\u00a0 Unterschi ed\u00a0 ergab.\u00a0 Die\u00a0\nErfassung\u00a0UAE\u00a0im\u00a0Rahmen\u00a0von\u00a0PATENT\u20101\u00a0dauerte\u00a0nur\u00a0bis\u00a0zwei\u00a0Tage\u00a0 nach\u00a0Behand\u2010\nlungsende,\u00a0unter\u00a02,5\u00a0mg\u00a0Riociguat\u00a0traten\u00a0diese\u00a0bei\u00a089,4\u00a0%,\u00a0unte r\u00a0Placebo\u00a0bei\u00a0er\u2010\nstaunlichen\u00a085,7\u00a0%\u00a0auf.\u00a0Im\u00a0Ergebnis\u00a0kommt\u00a0der\u00a0G\u2010BA\u00a0f\u00fcr\u00a0die\u00a0 Indikation\u00a0PAH \u00a0zur\u00a0\nBewertung\u00a0\u201e geringer\u00a0Zusatznutzen \u201c\u00a0(G\u2010BA,\u00a02014a).\u00a0Oh,\u00a0Youn\u00a0und\u00a0Kang\u00a0merken\u00a0im\u00a0\nJahr\u00a02013\u00a0in\u00a0einem\u00a0Leserbrief\u00a0zur\u00a0Originalpublikation\u00a0von\u00a0PATEN T\u20101\u00a0an,\u00a0dass\u00a0die\u00a0\nPr\u00e4medikation\u00a0(ERA\u00a0und\u00a0Prostanoi de)\u00a0in\u00a0den\u00a0Efficacy\u2010Analysen\u00a0un d\u00a0die\u00a0Gabe\u00a0oraler\u00a0\nAntikoagulantien\u00a0zu\u00a0ber\u00fccksichtigen\u00a0sind.\u00a0Archer\u00a0f\u00fchrt\u00a0im\u00a0Edito rial\u00a0der\u00a0Original\u2010\npublikationen\u00a0von\u00a0CHEST\u20101\u00a0und\u00a0PATENT\u20101\u00a0aus,\u00a0dass\u00a0bei\u00a0CTEPH\u00a0eine \u00a0PEA\u00a0die\u00a06MWD\u00a0\num\u00a0100\u00a0m\u00a0(unter\u00a0Riociguat\u00a045,7\u00a0m)\u00a0erh\u00f6ht,\u00a0die\u00a0morbidit\u00e4tstrigge rnden\u00a0Effekte\u00a0von\u00a0\nRiociguat\u00a0auf\u00a0die\u00a0rechtsventrikul\u00e4re\u00a0Leistung\u00a0im\u00a0Kontext\u00a0der\u00a0pi votalen\u00a0Studien\u00a0\nnicht\u00a0erfasst\u00a0wurden,\u00a0in\u00a0den\u00a0Subgruppen\u00a0in\u00a0PATENT\u20101\u00a0mit\u00a0zus\u00e4tzl icher\u00a0Gabe\u00a0von\u00a0\nProstanoiden\u00a0sich\u00a0ein\u00a0gr\u00f6\u00dferer\u00a0Be nefit\u00a0zeigte,\u00a052\u00a0%\u00a0im\u00a0Placebo\u2010 Arm\u00a0von\u00a0PATENT\u20101\u00a0\nkeine\u00a0Therapie\u00a0der\u00a0PAH\u00a0erhielten\u00a0und\u00a0hinterfragt\u00a0die\u00a0Verbindung en\u00a0der\u00a0Autoren\u00a0\nmit\u00a0dem\u00a0Sponsor\u00a0kritisch\u00a0(Archer,\u00a02013).\u00a0\nDie\u00a0vorzeitig\u00a0abgebrochene\u00a0Phase \u2010II\u2010Studie\u00a0\u201eRISE\u2010IIP\u201c\u00a0(Sponsor: \u00a0Bayer,\u00a0NCT021\u00a0\n38825),\u00a0welche\u00a0Riociguat\u00a0bei\u00a0Patienten\u00a0mit\u00a0pulmonaler\u00a0Hypertoni e\u00a0aufgrund\u00a0idio\u2010\npathischer\u00a0interstitieller\u00a0Pneumonie\u00a0(PH\u2010IIP)\u00a0\u00fcber\u00a026\u00a0Wochen\u00a0pr \u00fcfte,\u00a0zeigte\u00a0\u00dcber\u2010\nsterblichkeit\u00a0und\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0das\u00a0Auftreten\u00a0unerw\u00fcn schter\u00a0Effekte\u00a0in\u00a0\nder\u00a0Riociguat\u2010Gruppe\u00a0(ClinicalTri als.gov,\u00a02014).\u00a0Es\u00a0folgte\u00a0die\u00a0 Anpassung\u00a0der\u00a0Zulas\u2010\nsung\u00a0unter\u00a0Aufnahme\u00a0der\u00a0PH\u2010IIP\u00a0als\u00a0Kontraindikation\u00a0und\u00a0Kommuni kation\u00a0mittels\u00a0\nRote\u2010Hand\u2010Brief\u00a0(BfArM,\u00a02016;\u00a0EMA,\u00a02016).\u00a0324\u00a0In\u00a0der\u00a0Phase\u2010II\u2010Studie\u00a0PATENT\u2010P LUS\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT01179334 )\u00a0wurde\u00a0multi\u2010\nzentrisch,\u00a0doppelblind,\u00a02:1\u00a0randomisiert,\u00a0placebokontrolliert\u00a0d ie\u00a0Gabe\u00a0von\u00a0dosisti\u2010\ntriertem\u00a0 Riociguat\u00a0 zus\u00e4tzlich\u00a0 zu\u00a0 dreimal\u00a0 t\u00e4glich\u00a0 20\u00a0mg\u00a0 Sildenaf il\u00a0 mit\u00a0 prim\u00e4rem\u00a0\nEndpunkt\u00a0\u201e\u00c4nderung\u00a0des\u00a0liegend\u00a0gemessenen\u00a0Blutdrucks\u00a0vier\u00a0Stund en\u00a0nach\u00a0Arznei\u2010\nmittelgabe\u201c\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0und\u00a0anschlie\u00dfender\u00a0 Open\u2010Label \u00a0Verl\u00e4ngerung\u00a0an\u00a017\u00a0\nPAH\u2010Patienten\u00a0untersucht.\u00a0Aufgrund\u00a0dreier\u00a0Todesf\u00e4lle\u00a0und\u00a0UAE\u00a0in \u00a0der\u00a0Verl\u00e4nge\u2010\nrungsphase\u00a0wurde\u00a0die\u00a0Studie\u00a0abgebrochen\u00a0(Gali\u00e8\u00a0et\u00a0al.,\u00a02015).\u00a0D ie\u00a0Fachinformation\u00a0\nf\u00fchrt\u00a0 unter\u00a0 \u201eGegenanzeigen\u201c\u00a0 die\u00a0 Kombination\u00a0 mit\u00a0 NO\u2010Donatoren\u00a0 bz w.\u00a0 PDE\u20105\u2010\nInhibitoren\u00a0(PDE\u20105\u2010I)\u00a0als\u00a0absolute\u00a0Kontraindikation\u00a0auf\u00a0(CHMP,\u00a0 2017).\u00a0\nBestrebungen\u00a0zur\u00a0Erweiterung\u00a0der\u00a0zugelassenen\u00a0Anwendungsgebiete \u00a0f\u00fcr\u00a0Patienten\u00a0\nmit\u00a0angeborenen\u00a0Herzerkrankungen\u00a0( Congenital\u00a0Heart\u00a0Diseases ,\u00a0PH\u2010CHD),\u00a0welche\u00a0\nd e r \u00a0p U \u00a0m i t t e l s \u00a0e i n e r \u00a0S u b g r u p p e n a n a l y s e \u00a0d e r \u00a0p i v o t a l e n \u00a0S t u d i e n \u00a0P A TENT\u20101\u00a0 und\u00a0\nPATENT\u20102\u00a0erwirken\u00a0wollte,\u00a0wurden \u00a0seitens\u00a0des\u00a0pU\u00a0nach\u00a0\u00dcbermittlu ng\u00a0eines\u00a0Fragen\u2010\nkataloges\u00a0der\u00a0EMA\u00a0eingestellt.\u00a0Zu\u00a0beachten\u00a0ist,\u00a0dass\u00a0in\u00a0diesen\u00a0 Studien\u00a0nur\u00a08\u00a0%\u00a0der\u00a0\nTeilnehmer\u00a0eine\u00a0PH\u2010CHD\u00a0aufwiesen\u00a0(Bayer\u00a0Vital\u00a0GmbH,\u00a02016;\u00a0CHMP\u00a0 EMA,\u00a02016;\u00a0\nRosenkranz\u00a0et\u00a0al.,\u00a02015).\u00a0Aktuell\u00a0sind\u00a0in\u00a0der\u00a0Datenbank\u00a0 Clinicaltrials.gov \u00a044\u00a0Studien\u00a0\nmit\u00a0Riociguat\u00a0registriert,\u00a0d.h.\u00a0die\u00a0Anwendungsm\u00f6glichkeiten\u00a0des \u00a0urspr\u00fcnglich\u00a0als\u00a0\nArzneimittel\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Leiden\u00a0zugelassenen\u00a0Riocigua t\u00a0wird\u00a0intensiv\u00a0un\u2010\ntersucht\u00a0(ClinicalTrials.gov,\u00a02017).\u00a0\nDas\u00a0BfArM\u00a0weist\u00a0im\u00a0Rahmen\u00a0der\u00a0Anwendung\u00a0von\u00a0Riociguat\u00a0auf\u00a0die\u00a0N otwendigkeit\u00a0\neiner\u00a0fundierten\u00a0Diagnostik\u00a0hin,\u00a0um\u00a0die\u00a0Anwendung\u00a0des\u00a0Arzneimit tels\u00a0im\u00a0Rahmen\u00a0\nder\u00a0gesetzlich\u00a0zugelassenen\u00a0Indikationen\u00a0zu\u00a0gew\u00e4hrleisten,\u00a0d.h. \u00a0ausschlie\u00dflich\u00a0in\u00a0den\u00a0\nWHO\u2010Gruppen\u00a0 pulmonaler\u00a0 Hypertonie\u00a0 1\u00a0 (PAH),\u00a0 1.1,\u00a0 1.2,\u00a0 1.4.1\u00a0 sowi e\u00a0 4\u00a0 (CTEPH)\u00a0\n(Mittmann,\u00a02016).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\nNeues\u00a0Wirkprinzip,\u00a0\nCTEPH:\u00a0Erstes\u00a0zugelas\u2010\nsenes\u00a0Arzneimittel;\u00a0\nChirurgische\u00a0PEA\u00a0\nweiterhin\u00a0Therapie\u00a0der\u00a0\nWahl;\u00a0\u00a0\nPAH:\u00a0Weitere\u00a0\nTherapieoption\u00a0Mit\u00a0Orphan\u2010\nArzneimittel\u2010Zulassung\u00a0\nautomatisch\u00a0\nZusatznutzen\u00a0zuerkannt,\u00a0\nlaut\u00a0G\u2010BA\u00a0geringes\u00a0\nAusma\u00df\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\n\u00a0\n325\u00a0Wie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0Schwach\u00a0statistisch\u00a0\nsignifikant\u00a0CTEPH:\u00a0Possibly\u00a0\nhelpful\u00a0\nPAH:\u00a0Nothing\u00a0new\u00a0Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nRiociguat\u00a0 3x\u00a0tgl.\u00a01\u00a0FTA\u00a0 365\u00a0 31.825,50\u00a0\u20ac\u00a0\nF\u00fcr\u00a0PAH\u00a0Kosten\u00a0der\u00a0zVT:\u00a0s.\u00a0Kap.\u00a04.17\u00a0Macitentan\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnungen\u00a0 von\u00a0Riociguat\u00a0nehmen\u00a0ab\u00a0Markteinf\u00fchrung\u00a0zu\u00a0und \u00a0e rr e i c h en\u00a0\nzeitgleich\u00a0mit\u00a0Publikation\u00a0des\u00a0IQWiG\u2010Dossiers\u00a0der\u00a0Nutzenbewertu ng\u00a0mit\u00a0ca.\u00a01.800\u00a0\nDDD\u00a0pro\u00a0Monat\u00a0ein\u00a0erstes\u00a0Plateau,\u00a0welches\u00a0von\u00a0August\u00a02014\u00a0bis\u00a0D ezember\u00a02014\u00a0\nandauert.\u00a0Im\u00a0Januar\u00a02015\u00a0steigen\u00a0die\u00a0Verordnungen\u00a0auf\u00a0ca.\u00a03.400 \u00a0DDD\u00a0monatlich\u00a0\nund\u00a0schwanken\u00a0fortan\u00a0zwischen\u00a02.800\u00a0und\u00a03.500\u00a0DDD\u00a0je\u00a0Monat.\u00a0Zei tgleich\u00a0mit\u00a0der\u00a0\nPublikation\u00a0des\u00a0Erstattungsbetrages\u00a0nach\u00a0\u00a7\u00a0130b\u00a0SGB\u00a0V\u00a0erreichen \u00a0die\u00a0Verordnungen\u00a0\nmit\u00a0\u00fcber\u00a04.500\u00a0DDD\u00a0im\u00a0Juli\u00a02015\u00a0den\u00a0maximalen\u00a0Wert\u00a0des\u00a024\u2010monat igen\u00a0Betrach\u2010\ntungszeitraumes.\u00a0 Abschlie\u00dfend\u00a0 pendelt\u00a0 die\u00a0 Anzahl\u00a0 der\u00a0 Verordnung en\u00a0 zwischen\u00a0\n3.200\u00a0und\u00a03.800\u00a0DDD\u00a0monatlich.\u00a0Di e\u00a0Kosten\u00a0der\u00a0Verordnungen\u00a0entw ickeln\u00a0sich\u00a0paral\u2010\nlel,\u00a0wobei\u00a0sich\u00a0die\u00a020\u00a0%ige\u00a0Senkung\u00a0des\u00a0Apothekenverkaufspreise s\u00a0in\u00a0Folge\u00a0des\u00a0Er\u2010\nstattungsbetrages\u00a0mit\u00a0Listung\u00a0in\u00a0der\u00a0Lauer\u2010Taxe\u00a0ab\u00a0August\u00a02015\u00a0 deutlich\u00a0abzeichnet.\u00a0\n\u00a0 \u00a0326\u00a0Abbildung\u00a04.39:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nRiociguat\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nD e r \u00a0W i r k s t o f f \u00a0R i o c i g u a t \u00a0g r e i f t \u00a0a l s \u00a0S t i m u l a t o r \u00a0d e r \u00a0s G C \u00a0i n \u00a0d e n \u00a0N O \u2010sGC\u2010cGMP\u2010\nSignalweg\u00a0ein,\u00a0der\u00a0am\u00a0Pathomecha nismus\u00a0der\u00a0PAH\u00a0ma\u00dfgeblich\u00a0betei ligt\u00a0sein\u00a0soll\u00a0\n(Mutschler\u00a0et\u00a0al.,\u00a02016).\u00a0Einerseits\u00a0wird\u00a0durch\u00a0Riociguat\u00a0die\u00a0B indung\u00a0endogenen\u00a0\nStickstoffmonoxids\u00a0(NO)\u00a0an\u00a0sGC\u00a0stabilisiert,\u00a0andererseits\u00a0die\u00a0s GC\u00a0unabh\u00e4ngig\u00a0von\u00a0\nNO\u00a0direkt\u00a0stimuliert.\u00a0cGMP\u00a0beeinflusst\u00a0als\u00a0intrazellul\u00e4rer\u00a0Bote nstoff\u00a0Gef\u00e4\u00dftonus,\u00a0\nProliferation\u00a0glatter\u00a0Gef\u00e4\u00dfmuske lzellen,\u00a0Fibrose\u00a0und\u00a0Inflammati on.\u00a0Dies\u00a0verbessert\u00a0\ndie\u00a0 pulmovaskul\u00e4re\u00a0 H\u00e4modynamik\u00a0 un d\u00a0 die\u00a0 k\u00f6rperliche\u00a0 Leistungsf\u00e4h igkeit\u00a0 der\u00a0\nCTEPH\u2010\u00a0bzw.\u00a0PAH\u2010Patienten.\u00a0Rioci guat\u00a0weist\u00a0mit\u00a094\u00a0%\u00a0eine\u00a0hohe\u00a0B ioverf\u00fcgbarkeit\u00a0\nsowie\u00a0eine\u00a0rasche\u00a0Resorption\u00a0auf.\u00a0Es\u00a0erreicht\u00a0binnen\u00a0einer\u00a0bis\u00a0 anderthalb\u00a0Stunden\u00a0\nmaximale\u00a0Plasmaspiegel,\u00a0wobei\u00a0 mit\u00a095\u00a0%\u00a0eine\u00a0hohe\u00a0Bindungsrate\u00a0a n\u00a0Plasmaeiwei\u2010\n\u00dfe\u00a0zu\u00a0beachten\u00a0ist.\u00a0Zur\u00a0Vermeidung\u00a0klinisch\u00a0relevanter\u00a0Interakt ionen\u00a0ist\u00a0die\u00a0Meta\u2010\nbolisierung\u00a0 \u00fcber\u00a0 diverse\u00a0 Cytochrom\u00a0 P450\u2010Isoenzyme\u00a0 (CYP1A1,\u00a0 3A4, \u00a0 3A5,\u00a0 2J2)\u00a0\nsowie\u00a0der\u00a0Transport\u00a0\u00fcber\u00a0P\u2010Glykoprotein\u00a0(P\u2010GP)\u00a0bzw.\u00a0 Breast\u00a0Cancer\u00a0Resistance\u2010\nProtein\u00a0(BCRP)\u00a0zu\u00a0ber\u00fccksichtigen.\u00a0Raucher\u00a0sollten\u00a0vor\u00a0Therapiebeginn\u00a0 in\u00a0Folge\u00a0der\u00a0\nMetabolisierung\u00a0\u00fcber\u00a0CYP1A1\u00a0eine\u00a0Entw\u00f6hnung\u00a0erfolgreich\u00a0abgesch lossen\u00a0haben.\u00a0\nAus\u00a0pr\u00e4klinischen\u00a0Daten\u00a0geht\u00a0eine\u00a0Teratogenit\u00e4t\u00a0durch\u00a0Knochensc h\u00e4digung\u00a0hervor,\u00a0\nsodass\u00a0vor\u00a0und\u00a0w\u00e4hrend\u00a0der\u00a0Therapie\u00a0mit\u00a0Riociguat\u00a0eine\u00a0Schwange rschaft\u00a0mittels\u00a0\ngeigneter\u00a0Verh\u00fctungsmittel\u00a0und\u00a0mo natlicher\u00a0Tests\u00a0mit\u00a0Sicherheit \u00a0ausgeschlossen\u00a0\nwerden\u00a0muss\u00a0(CDER,\u00a02013;\u00a0CHMP,\u00a02017).\u00a0\n327\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nRiociguat\u00a0wurde\u00a0im\u00a0Oktober\u00a02013\u00a0von\u00a0der\u00a0FDA\u00a0zugelassen\u00a0(CDER,\u00a02 013).\u00a0Seitens\u00a0\nder\u00a0EC\u00a0erfolgte\u00a0basierend\u00a0auf\u00a0der\u00a0positiven\u00a0Empfehlung\u00a0der\u00a0EMA\u00a0 die\u00a0Zulassung\u00a0im\u00a0\nM\u00e4rz\u00a02014.\u00a0Bereits\u00a0im\u00a0Jahr\u00a02007\u00a0wurde\u00a0der\u00a0Status\u00a0als\u00a0Arzneimitt el\u00a0zur\u00a0Therapie\u00a0\nseltener\u00a0Leiden\u00a0 Orphan\u2010Arzneimittel\u00a0anerkannt\u00a0(CHMP,\u00a02014;\u00a0COMP,\u00a02007).\u00a0Die\u00a0\nAufnahme\u00a0in\u00a0die\u00a0Lauer\u2010Taxe\u00a0fand\u00a0erst\u00a0ab\u00a0Mai\u00a02014\u00a0statt\u00a0(Lauer\u00a0F ischer\u00a0GmbH,\u00a0\n2017).\u00a0\nRiociguat\u00a0wurde\u00a0f\u00fcr\u00a0zwei\u00a0Gruppen\u00a0des\u00a0erh\u00f6hten\u00a0Blutdrucks\u00a0im\u00a0Lun genkreislauf\u00a0\n(pulmonale\u00a0 Hypertonie,\u00a0 PH)\u00a0 zugelassen.\u00a0 Laut\u00a0 aktueller\u00a0 Fachinfor mation\u00a0 (Stand\u00a0\nJanuar\u00a02017)\u00a0beschr\u00e4nkt\u00a0sich\u00a0die\u00a0gesetzlich\u00a0zugelassene\u00a0Anwendu ng\u00a0wiederum\u00a0auf\u00a0\nzwei\u00a0der\u00a0vier\u00a0WHO\u2010FC,\u00a0d.h.\u00a0Rioci guat\u00a0wird\u00a0bei\u00a0Erwachsenen\u00a0Patie nten\u00a0der\u00a0WHO\u2010FC\u00a0\nII\u00a0bis\u00a0III\u00a0mit\u00a0inoperabler\u00a0CTEPH,\u00a0persistierender\u00a0oder\u00a0rezidivi erender\u00a0CTEPH\u00a0nach\u00a0\nchirurgischer\u00a0Intervention\u00a0zur\u00a0V erbesserung\u00a0der\u00a0k\u00f6rperlichen\u00a0Le istungsf\u00e4higkeit\u00a0\nangewendet.\u00a0Erwachsene\u00a0Patienten\u00a0mit\u00a0PAH\u00a0der\u00a0WHO\u2010FC\u00a0II\u00a0bis\u00a0III\u00a0 k\u00f6nnen\u00a0Rioci\u2010\nguat\u00a0zur\u00a0Verbesserung\u00a0der\u00a0k\u00f6rperlichen\u00a0Leistungsf\u00e4higkeit\u00a0als\u00a0M ono\u2010\u00a0oder\u00a0Kombi\u2010\nnationstherapie\u00a0 mit\u00a0 Endothelin\u2010Rezeptorantagonist\u00a0 (ERA)\u00a0 erhalte n , \u00a0w o b e i \u00a0e i n \u00a0\nWirksamkeitsnachweis\u00a0f\u00fcr\u00a0heredit\u00e4re\u00a0bzw.\u00a0idiopathische\u00a0PAH\u00a0oder \u00a0PAH\u00a0in\u00a0Assozia\u2010\ntion\u00a0mit\u00a0Bindegewebserkrankungen\u00a0vorliegt\u00a0(CHMP,\u00a02017).\u00a0\nRiociguat\u00a0wird\u00a0zu\u00a0Beginn\u00a0der\u00a0Therapie\u00a0dreimal\u00a0t\u00e4glich\u00a0in\u00a0einer\u00a0 Dosis\u00a0von\u00a01\u00a0mg\u00a0in\u00a0\neinem\u00a0Dosierungsintervall\u00a0von\u00a0se chs\u00a0bis\u00a0acht\u00a0Stunden\u00a0gegeben.\u00a0E inmal\u00a0zu\u00a0Thera\u2010\npiebeginn\u00a0sollte\u00a0entschieden\u00a0wer den,\u00a0ob\u00a0die\u00a0Filmtabletten\u00a0vor,\u00a0 zu\u00a0oder\u00a0nach\u00a0dem\u00a0\nEssen\u00a0 eingenommen\u00a0 werden\u00a0 und\u00a0 dies\u00a0 sollte\u00a0 \u00fcber\u00a0 die\u00a0 gesamte\u00a0 Thera piedauer\u00a0\nfortgef\u00fchrt\u00a0werden.\u00a0Eine\u00a0Einnahme\u00a0unabh\u00e4ngig\u00a0von\u00a0den\u00a0Mahlzeiten \u00a0sollten\u00a0Pati\u2010\nenten\u00a0mit\u00a0Hypotonieneigung\u00a0in\u00a0Folge\u00a0von\u00a0Plasmaspitzenkonzentrat ionen\u00a0vermei\u2010\nden.\u00a0In\u00a0Schritten\u00a0von\u00a00,5\u00a0mg\u00a0alle\u00a0zwei\u00a0Wochen\u00a0wird\u00a0die\u00a0Dosis\u00a0au f\u00a0die\u00a0angestrebte\u00a0\nErhaltungsdosis\u00a0von\u00a0dreimal\u00a0t\u00e4glich\u00a02,5\u00a0mg\u00a0erh\u00f6ht,\u00a0sofern\u00a0der\u00a0s ystolische\u00a0Blut\u2010\ndruck\u00a0\u00fcber\u00a095\u00a0mm\u00a0Hg\u00a0gemessen\u00a0wird\u00a0und\u00a0Anzeichen\u00a0einer\u00a0Hypotonie \u00a0ausbleiben.\u00a0\nBei\u00a0Therapieunterbrechungen\u00a0l\u00e4nger\u00a0als\u00a0drei\u00a0Tage\u00a0muss\u00a0eine\u00a0erne ute\u00a0Auftitration\u00a0\nerfolgen.\u00a0Erfahrungen\u00a0zur\u00a0Anwendung\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendliche n\u00a0liegen\u00a0nicht\u00a0\nvor,\u00a0bei\u00a0\u00e4lteren\u00a0Patienten\u00a0muss\u00a0 auf\u00a0ein\u00a0erh\u00f6htes\u00a0Hypotonierisik o\u00a0geachtet\u00a0werden.\u00a0\nZur\u00a0Anwendung\u00a0bei\u00a0Leber\u2010\u00a0(Child\u2010Pugh\u00a0B,\u00a0C\u00a0kontraindiziert)\u00a0und\u00a0 Niereninsuffizienz\u00a0\n(glomerul\u00e4re\u00a0Filtrationsrate\u00a0<50\u00a0bis\u00a030\u00a0ml/min,\u00a0darunter\u00a0nicht\u00a0 empfohlen)\u00a0wird\u00a0auf\u00a0\neine\u00a0erh\u00f6hte\u00a0Arzneistoffexposition\u00a0hingewiesen.\u00a0Patienten\u00a0mit\u00a0S chluckst\u00f6rungen\u00a0\nk\u00f6nnen\u00a0 zerm\u00f6rserte\u00a0 Filmtabletten\u00a0 mit\u00a0 Wasser\u00a0 oder\u00a0 Apfelmus\u00a0 einne hmen\u00a0\n(MSD/Bayer\u00a0Vital\u00a0GmbH,\u00a02017).\u00a0\n\u00a0\u00a0328\u00a0Informationen\u00a0zum\u00a0Indikationsgebiet\u00a0(vgl.\u00a0erg\u00e4nzend\u00a0Kap.\u00a04.17\u00a0M acitentan)\u00a0\nDie\u00a0WHO\u00a0unterscheidet\u00a0bei\u00a0erh\u00f6htem\u00a0Blutdruck\u00a0im\u00a0Lungenkreislauf \u00a0f\u00fcnf\u00a0Gruppen\u00a0\n(WHO\u2010Gruppen):\u00a0(1)\u00a0die\u00a0PAH,\u00a0(2)\u00a0Folgen\u00a0von\u00a0Linksherzerkrankunge n,\u00a0(3)\u00a0Folgen\u00a0\nvon\u00a0Lungenerkrankungen\u00a0und/oder\u00a0Hypoxie,\u00a0(4)\u00a0CTEPH\u00a0sowie\u00a0(5)\u00a0pu lmonale\u00a0Hy\u2010\npertonie\u00a0mit\u00a0unklarem\u00a0multifaktoriellen\u00a0Mechanismus.\u00a0\nIn\u00a0der\u00a0WHO\u00a0Gruppe\u00a01,\u00a0der\u00a0PAH,\u00a0wird\u00a0ferner\u00a0nach\u00a0idiopathischer\u00a0( IPAH),\u00a0heredit\u00e4rer\u00a0\n(HPAH),\u00a0medikamenten\u2010(bspw.\u00a0durch\u00a0Appetitz\u00fcgler\u00a0induzierte,\u00a0DPA H)/toxin\u2010\u00a0oder\u00a0\nstrahlenassoziierter\u00a0oder\u00a0mit\u00a0diversen\u00a0Erkrankungen\u00a0(Bindegeweb serkrankungen,\u00a0\nportale\u00a0Hypertension,\u00a0angeborene \u00a0Herzfehler\u00a0oder\u00a0HIV\u2010Infektione n)\u00a0assoziierter\u00a0\nPAH\u00a0unterschieden.\u00a0Im\u00a0Jahr\u00a02014\u00a0betrug\u00a0die\u00a0Pr\u00e4valenz\u00a0der\u00a0PAH\u00a025 ,9\u00a0je\u00a0Mio.\u00a0Er\u2010\nwachsener,\u00a0die\u00a0Inzidenz\u00a03,9\u00a0je\u00a0Mio.\u00a0Erwachsener\u00a0in\u00a0Deutschland. \u00a0Definiert\u00a0ist\u00a0die\u00a0\nPAH\u00a0als\u00a0pulmonal\u2010arterieller\u00a0Mitteldruck\u00a0\u226525\u00a0mm\u00a0Hg\u00a0(mPAP)\u00a0bei\u00a0n ormalem\u00a0pul\u2010\nmonal\u2010arteriellen\u00a0 Verschlussdruck \u00a0v o n \u00a0\u2264 1 5 \u00a0 m m \u00a0H g \u00a0s o w i e \u00a0p u l m o n a l \u2010 vaskul\u00e4rem\u00a0\nWiderstand\u00a0( Pulmonary\u00a0Vascular\u00a0Resistance ,\u00a0PVR)\u00a0>\u00a0240\u00a0dyn*s*cm\u20105.\u00a0\nEs\u00a0handelt\u00a0sich\u00a0bei\u00a0der\u00a0PAH\u00a0um\u00a0eine\u00a0unheilbare,\u00a0chronisch\u00a0progr ediente\u00a0Erkran\u2010\nkung,\u00a0wobei\u00a0als\u00a0ultima\u00a0ratio\u00a0Lung en\u2010\u00a0bzw.\u00a0kombini erte\u00a0Herz\u2010Lung en\u2010Transplanta\u2010\ntionen\u00a0erfolgen\u00a0k\u00f6nnen\u00a0 (Hoeper\u00a0et\u00a0al.,\u00a02017).\u00a0\nBis\u00a0zur\u00a0Markteinf\u00fchrung\u00a0von\u00a0Riociguat\u00a0war\u00a0kein\u00a0weiteres\u00a0Arzneim ittel\u00a0zur\u00a0Behand\u2010\nlung\u00a0 der\u00a0 chronisch\u00a0 thromboemboli sch\u2010pulmonalen\u00a0 Hypertonie\u00a0 zugel assen.\u00a0 Die\u00a0\nInzidenz\u00a0der\u00a0CTEPH\u00a0betr\u00e4gt\u00a03\u00a0je\u00a0Mio.\u00a0Einwohner\u00a0in\u00a0Deutschland\u00a0( AMB,\u00a02014).\u00a0Nach\u00a0\naktueller\u00a0DGK\u2010Leitlinie\u00a0stellt\u00a0die\u00a0chirurgische\u00a0PAE\u00a0weiterhin\u00a0d ie\u00a0Erstlinientherapie\u00a0\ndar\u00a0(Rosenkranz\u00a0et\u00a0al.,\u00a02016a;\u00a0Rosenkranz\u00a0et\u00a0al.,\u00a02016b,\u00a0Galie\u00a0 et\u00a0al.,\u00a02015\u00a0und\u00a0\n2016).\u00a0Je\u00a0nach\u00a0OP\u2010Erfahrung\u00a0des\u00a0jeweiligen\u00a0Zentrums\u00a0werden\u00a063\u00a0b is\u00a090\u00a0%\u00a0der\u00a0\nanfragenden\u00a0Patienten\u00a0mit\u00a0CTEPH\u00a0in\u00a0Deutschland\u00a0als\u00a0operabel\u00a0ein gestuft\u00a0(Kerck\u2010\nhoff\u00a0Klinik,\u00a02015).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nZur\u00a0Begr\u00fcndung\u00a0der\u00a0Zulassung\u00a0von\u00a0Riociguat\u00a0legte\u00a0der\u00a0pU\u00a0der\u00a0EMA \u00a0die\u00a0von\u00a0ihm\u00a0\ngesponserten\u00a0Phase\u2010III\u2010Studien\u00a0CHEST\u20101\u00a0(CTEPH)\u00a0und\u00a0PATENT\u20101\u00a0(PA H)\u00a0sowie\u00a0Zwi\u2010\nschenergebnisse\u00a0 derer\u00a0 unverblindeter\u00a0 Langzeitarme\u00a0 CHEST\u20102\u00a0 bzw.\u00a0 PATENT\u20102\u00a0 vor\u00a0\n(CHMP,\u00a02014).\u00a0\nDie\u00a0Zulassungsstudie\u00a0CHEST\u20101\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT00855465)\u00a0unte rsuchte\u00a0multi\u2010\nzentrisch,\u00a0doppelblind,\u00a02:1\u00a0randomisiert,\u00a0placebokontrolliert\u00a0i n\u00a0Form\u00a0einer\u00a0Phase\u2010\nIII\u2010Studie\u00a0die\u00a0Effekte\u00a0von\u00a0indivi duell\u00a0dosistitriertem\u00a0Riocigua t\u00a0bei\u00a0261\u00a0randomiser\u2010\nten,\u00a0inoperablen\u00a0bzw.\u00a0nach\u00a0PEA\u00a0therapierefrakt\u00e4ren\u00a0Patienten\u00a0mi t\u00a0CTEPH\u00a0\u00fcber\u00a016\u00a0\nWochen.\u00a0Als\u00a0Startdosis\u00a0wurde\u00a0Riociguat\u00a0mit\u00a0dreimal\u00a0t\u00e4glich\u00a01,0\u00a0 mg\u00a0definiert,\u00a0alle\u00a0\nzwei\u00a0Wochen\u00a0um\u00a00,5\u00a0mg\u00a0auftitriert\u00a0bis\u00a0Zeichen\u00a0von\u00a0Hypotonie\u00a0bzw .\u00a0systolischer\u00a0329\u00a0Blutdruck\u00a0<95\u00a0mm\u00a0Hg\u00a0auftraten\u00a0bzw .\u00a02,5\u00a0mg\u00a0dreimal\u00a0t\u00e4glich\u00a0errei cht\u00a0wurden.\u00a0Bei\u00a0\nAnzeichen\u00a0einer\u00a0Hypotonie\u00a0war\u00a0ge m\u00e4\u00df\u00a0Studienprotokoll\u00a0eine\u00a024\u2010st \u00fcndige\u00a0Thera\u2010\npiepause\u00a0 mit\u00a0 nachfolgender\u00a0 Dosisr eduktion\u00a0 um\u00a0 0,5\u00a0mg\u00a0 vorgegeben. \u00a0 Prim\u00e4rer\u00a0\nEndpunkt\u00a0war\u00a0die\u00a0Verbesserung\u00a0der\u00a06MWD,\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0die \u00a0\u00c4nderung\u00a0\nh\u00e4modynamischer\u00a0Parameter,\u00a0WHO\u2010F C\u00a0sowie\u00a0Morbidit\u00e4ts\u2010\u00a0bzw.\u00a0Leben squalit\u00e4ts\u2010\nindices\u00a0(BDS,\u00a0EQ\u20105D,\u00a0LPH)\u00a0zwischen\u00a0Randomisierung\u00a0und\u00a0Woche\u00a016\u00a0 (Ghofrani\u00a0et\u00a0\nal.,\u00a02013).\u00a0Statistisch\u00a0signifikant\u00a0konnte\u00a0im\u00a0prim\u00e4ren\u00a0Endpunkt \u00a0eine\u00a0Verbesserung\u00a0\nder\u00a06MWD\u00a0\u00fcber\u00a039\u00a0m\u00a0unter\u00a0Verum\u00a0erzielt\u00a0werden,\u00a0wobei\u00a0die\u00a06MWD\u00a0u nter\u00a0Pla\u2010\nzebo\u00a0um\u00a06\u00a0m\u00a0abnahm,\u00a0sodass\u00a0von\u00a0einem\u00a0Gesamteffekt\u00a0von\u00a045\u00a0m\u00a0beri chtet\u00a0wird\u00a0\n(ClinicalTrials.gov,\u00a02008a;\u00a0Ghofrani\u00a0et\u00a0al.,\u00a02013a).\u00a0\nDie\u00a0multizentrische,\u00a0offene\u00a0Verl\u00e4 ngerungsstudie\u00a0CHEST\u20102\u00a0(Sponso r:\u00a0Bayer,\u00a0NCT009\u00a0\n10429)\u00a0l\u00e4uft\u00a0bis\u00a0Ende\u00a0Dezember\u00a02018,\u00a0Sicherheit\u00a0und\u00a0Vertr\u00e4glich keit\u00a0bilden\u00a0nun\u2010\nmehr\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt,\u00a0die\u00a0\u00c4nderung\u00a0der\u00a06MWD\u00a0den\u00a0sekund\u00e4re n\u00a0(Clini\u2010\ncalTrials.gov,\u00a02009a).\u00a0Vorab\u00a0wurden\u00a0Zweijahresdaten\u00a0zu\u00a0237\u00a0Pati enten\u00a0publiziert,\u00a0\nwelche\u00a093\u00a0%\u00a0\u201eGesamt\u00fcberleben\u201c\u00a0und\u00a082\u00a0%\u00a0CWFS\u00a0zeigten,\u00a0obschon\u00a0be i\u00a0129\u00a0(54\u00a0%)\u00a0\nder\u00a0Patienten\u00a0SAE\u00a0auftraten\u00a0und\u00a014\u00a0(6%)\u00a0die\u00a0Therapie\u00a0aufgrund\u00a0A E\u00a0nicht\u00a0fortf\u00fchr\u2010\nten\u00a0(Simonneau\u00a0et\u00a0al.,\u00a02016).\u00a0\nBei\u00a0der\u00a0Interpretation\u00a0der\u00a0Studi en,\u00a0vor\u00a0allem\u00a0bei\u00a0CHEST\u20101,\u00a0ist\u00a0 die\u00a0kurze\u00a0Studien\u2010\ndauer\u00a0von\u00a016\u00a0Wochen\u00a0zu\u00a0ber\u00fccksichtigen,\u00a0bei\u00a0CHEST\u20102\u00a0die\u00a0Tatsach e,\u00a0dass\u00a0es\u00a0sich\u00a0\num\u00a0 einen\u00a0 Open\u2010Label \u00a0 Verl\u00e4ngerungsarm\u00a0 vorselektierter\u00a0 Patienten\u00a0 handelt\u00a0 und\u00a0\neine\u00a0endg\u00fcltige\u00a0Publikation\u00a0erst\u00a0ab\u00a02019\u00a0zu\u00a0erwarten\u00a0ist.\u00a0In\u00a0CH EST\u20101\u00a0konnte\u00a0keine\u00a0\nstatistisch\u00a0 signifikante\u00a0 Redukti on\u00a0 der\u00a0 Mortalit\u00e4t\u00a0 gezeigt\u00a0 werde n . \u00a0A l s \u00a0S u r r o g a t \u2010\nparameter\u00a0der\u00a0Morbidit\u00e4t\u00a0hat\u00a0sich\u00a0die\u00a06MWD\u00a0etabliert,\u00a0im\u00a0Kontex t\u00a0der\u00a0PAH\u00a0bzw.\u00a0\nchronischen\u00a0Lungenerkrankungen\u00a0geht\u00a0man\u00a0von\u00a0einer\u00a0MID\u00a0vom\u00a0>41\u00a0m \u00a0aus,\u00a0um\u00a0auf\u00a0\neine\u00a0Verbesserung\u00a0zu\u00a0schlie\u00dfen,\u00a0f\u00fcr\u00a0CTEPH\u00a0wurde\u00a0eine\u00a0MID\u00a0nicht\u00a0 definiert.\u00a0Ob\u2010\ngleich\u00a0in\u00a0CHEST\u20101\u00a0eine\u00a0statistisch\u00a0signifikante\u00a0Mittelwertsdiff erenz\u00a0der\u00a06MWD\u00a0von\u00a0\n45,7\u00a0m\u00a0gegen\u00fcber\u00a0Placebo\u00a0gezeigt\u00a0werden\u00a0konnte,\u00a0ist\u00a0der\u00a0absolut e\u00a0Effekt\u00a0f\u00fcr\u00a0die\u00a0\nPatienten\u00a0als\u00a0gering\u00a0zu\u00a0bewerten,\u00a0da\u00a0die\u00a0Werte\u00a0weiterhin\u00a0im\u00a0pat hologischen\u00a0Be\u2010\nreich\u00a0liegen\u00a0(AMB,\u00a02014).\u00a0Die\u00a0WHO\u2010FC\u00a0kann\u00a0laut\u00a0EMA\u00a0als\u00a0sekund\u00e4r er\u00a0Endpunkt\u00a0in\u00a0\nStudien\u00a0dienen,\u00a0obwohl\u00a0die\u00a0Einstufung\u00a0subjektiv\u00a0von\u00a0Arzt\u00a0und\u00a0Pa tienten\u00a0abh\u00e4ngig\u00a0\nist.\u00a0In\u00a0CHEST\u20101\u00a0konnte\u00a0statistisc h\u00a0signifikant\u00a0eine\u00a0Verbesserun g\u00a0der\u00a0WHO\u2010FC\u00a0unter\u00a0\nRiociguat\u00a02,5\u00a0mg\u00a0gegen\u00fcber\u00a0Placebo\u00a0nachgewiesen\u00a0werden\u00a0(32,9\u00a0%\u00a0 zu\u00a014,9\u00a0%).\u00a0Der\u00a0\nsekund\u00e4re\u00a0Endpunkt\u00a0TTCW\u00a0ist\u00a0nach\u00a0Einsch\u00e4tzung\u00a0des\u00a0G\u2010BA\u00a0nicht\u00a0ra tional\u00a0zusam\u2010\nmengesetzt\u00a0und\u00a0zudem\u00a0nicht\u00a0validiert,\u00a0sodass\u00a0eine\u00a0Ableitung\u00a0der \u00a0Patientenrele\u2010\nvanz\u00a0nicht\u00a0eindeutig\u00a0m\u00f6glich\u00a0is t\u00a0(G\u2010BA,\u00a02014b).\u00a0Mittels\u00a0BDS\u00a0k\u00f6n nen\u00a0Patienten\u00a0\nErm\u00fcdungsempfinden\u00a0und\u00a0Dyspnoe\u00a0dokumentieren,\u00a0in\u00a0CHEST\u20101\u00a0konnte \u00a0statistisch\u00a0\nsignifikant\u00a0eine\u00a0Verbesserung\u00a0um\u00a0eine\u00a0Einheit\u00a0nachgewiesen\u00a0werd en,\u00a0obschon\u00a0f\u00fcr\u00a0\nCTEPH\u00a0oder\u00a0PAH\u00a0keine\u00a0Validierung\u00a0vorliegt.\u00a0Effekte\u00a0auf\u00a0die\u00a0HRQo L\u00a0wurden\u00a0in\u00a0CHEST\u2010330\u00a01\u00a0nach\u00a0EQ\u20105D\u00a0als\u00a0statistisch\u00a0signifikante\u00a0Verbesserung\u00a0unter\u00a0Ri ociguat\u00a02,5\u00a0mg\u00a0erho\u2010\nben,\u00a0mittels\u00a0LPH\u2010Fragebogen\u00a0konnte\u00a0dieser\u00a0Effekt\u00a0nicht\u00a0gezeigt\u00a0 werden.\u00a0\nViele\u00a0AE\u00a0leiten\u00a0sich\u00a0aus\u00a0dem\u00a0Wirkmechanismus\u00a0von\u00a0Riociguat\u00a0ab,\u00a0 jedoch\u00a0wird\u00a0\nbesonderes\u00a0Augenmerk\u00a0auf\u00a0H\u00e4moptysis\u00a0gelenkt.\u00a0UAE\u00a0wurden\u00a0l\u00e4ngste ns\u00a0zwei\u00a0Tage\u00a0\nnach\u00a0Ende\u00a0der\u00a0Studienmedikation\u00a0erhoben.\u00a0Im\u00a0Ergebnis\u00a0leitet\u00a0der \u00a0G\u2010BA\u00a0einen\u00a0\ngeringen\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0CTEPH\u00a0ab,\u00a0wobei\u00a0der\u00a0Zul assungsstatus\u00a0\nOrphan\u2010Arzneimittel \u00a0sowie\u00a0die\u00a0prim\u00e4re\u00a0Pr\u00fcfung\u00a0einer \u00a0chirurgischen\u00a0Intervention,\u00a0\nd.h.\u00a0Durchf\u00fchrung\u00a0einer\u00a0PEA,\u00a0an\u00a0einem\u00a0der\u00a0drei\u00a0deutschen\u00a0Zentre n\u00a0ber\u00fccksichtigt\u00a0\nwerden\u00a0muss\u00a0(G\u2010BA,\u00a02014b).\u00a0\nIn\u00a0der\u00a0Korrespondenz\u00a0zu\u00a0Ghofrani\u00a0und\u00a0Kollegen\u00a0(2013a)\u00a0im\u00a0New\u00a0En gland\u00a0Journal\u00a0of\u00a0\nMedicine\u00a0wird\u00a0zu\u00a0Bedenken\u00a0gegeben,\u00a0dass\u00a0in\u00a0erster\u00a0Linie\u00a0die\u00a0PEA \u00a0als\u00a0chirurgische\u00a0\nIntervention\u00a0des\u00a0CTEPH\u00a0an\u00a0spezia lisierten\u00a0Zentren\u00a0Patienten\u00a0dau erhafte\u00a0Heilung\u00a0\ne r m \u00f6 g l i c h t \u00a0u n d \u00a0d i e s \u00a0n i c h t \u00a0d u r c h \u00a0e ine\u00a0 Pharmakotherapie\u00a0 zu\u00a0 ersetz en\u00a0 oder\u00a0 die\u00a0\nDurchf\u00fchrung\u00a0der\u00a0PEA\u00a0unn\u00f6tig\u00a0zu\u00a0verz\u00f6gern\u00a0ist\u00a0(Auger\u00a0&\u00a0Jamieson ,\u00a02013).\u00a0Ein\u00a0\nKommentar\u00a0zu\u00a0CHEST\u20101\u00a0(Archer\u00a02013)\u00a0weist\u00a0darauf\u00a0hin,\u00a0dass\u00a0der\u00a0N utzen\u00a0einer\u00a0PEA\u00a0\nmit\u00a0100\u00a0m\u00a06MWD\u2010Zunahme\u00a0den\u00a0von\u00a0Ri ociguat\u00a0deutlich\u00a0\u00fcbersteigt.\u00a0\nIn\u00a0der\u00a0Zulassungsstudie\u00a0PATENT\u20101\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT00810693), \u00a0welche\u00a0der\u00a0Stu\u2010\ndie\u00a0CHEST\u20101\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT00855465)\u00a0sehr\u00a0\u00e4hnelt,\u00a0wurden\u00a0m ultizentrisch,\u00a0\ndoppelblind,\u00a0nunmehr\u00a04:2:1\u00a0randomisiert,\u00a0placebokontrolliert\u00a0in \u00a0Form\u00a0einer\u00a0Phase\u2010\nIII\u2010Studie\u00a0die\u00a0Effekte\u00a0von\u00a0Riocig uat\u00a0in\u00a0individueller\u00a0Dosistitr ation\u00a0bis\u00a0zu\u00a0einer\u00a0Tages\u2010\nh\u00f6chstdosis\u00a0von\u00a0dreimal\u00a02,5\u00a0mg,\u00a0Plazebo\u00a0oder\u00a01,5\u00a0mg\u00a0(explorativ )\u00a0an\u00a0445\u00a0therapiena\u2010\niven\u00a0oder\u00a0vortherapierten\u00a0(Endothelinrezeptorantagonisten\u00a0ERA\u00a0b zw.\u00a0Prostanoide)\u00a0\nPatienten\u00a0mit\u00a0PAH\u00a0\u00fcber\u00a012\u00a0Wochen\u00a0untersucht.\u00a0Im\u00a0Anschluss\u00a0konnt en\u00a0die\u00a0Proban\u2010\nden\u00a0in\u00a0den\u00a0 Open\u2010Label \u00a0Langzeitarm\u00a0PATENT\u20102\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT00863681)\u00a0wech\u2010\nseln,\u00a0der\u00a0noch\u00a0bis\u00a0Dezember\u00a02018\u00a0andauern\u00a0wird\u00a0(ClinicalTrials. gov,\u00a02009b).\u00a0\nEingeschlossen\u00a0waren\u00a0Patienten\u00a0mi t\u00a0symptomatischer\u00a0PAH\u00a0nach\u00a0WHO \u2010Gruppe\u00a0I,\u00a0\nausgeschlossen\u00a0 waren\u00a0 Patienten\u00a0 mit\u00a0 PH,\u00a0 COPD,\u00a0 unkontrolliertem\u00a0 a rteriellem\u00a0\nHochdruck\u00a0oder\u00a0Linksherzfehler\u00a0(ClinicalTrials.gov,\u00a02008b).\u00a0Bei \u00a0der\u00a0Interpretation\u00a0\nvon\u00a0PATENT\u20101\u00a0sind\u00a0die\u00a0kurze\u00a0Studiendauer\u00a0und\u00a0ein\u00a0Vergleich\u00a0mit\u00a0 Placebo\u00a0zu\u00a0be\u2010\nr\u00fccksichtigen,\u00a0obgleich\u00a0mehrere\u00a0 zVT\u00a0zur\u00a0Verf\u00fcgung\u00a0standen.\u00a0Es\u00a0t raten\u00a0in\u00a0PATENT\u20101\u00a0\nzwei\u00a0(0,8\u00a0%)\u00a0Todesf\u00e4lle\u00a0unter\u00a02,5\u00a0mg\u00a0Riociguat\u00a0und\u00a0drei\u00a0(2,4\u00a0%) \u00a0unter\u00a0Plazebo\u00a0auf,\u00a0\nworaus\u00a0 sich\u00a0 kein\u00a0 statistisch\u00a0 signifikanter\u00a0 Unterschied\u00a0 in\u00a0 der\u00a0 M ortalit\u00e4t\u00a0 ergibt\u00a0\n(Ghofrani\u00a0et\u00a0al.,\u00a02013b?).\u00a0Im\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0konnte\u00a0eine\u00a0Ver besserung\u00a0der\u00a0\n6MWD\u00a0zwischen\u00a0Randomisierung\u00a0und\u00a0Woche\u00a012\u00a0um\u00a030\u00a0m\u00a0unter\u00a02,5\u00a0mg\u00a0 Riociguat\u00a0\nund\u00a0eine\u00a0Verschlechterung\u00a0vom\u00a06\u00a0m\u00a0im\u00a0Placebo\u2010Arm,\u00a0d.h.\u00a0eine\u00a0Mit telwertsdiffe\u2010\nrenz\u00a0von\u00a036\u00a0m\u00a0statistisch\u00a0signifikant\u00a0gezeigt\u00a0werden\u00a0(Ghofrani\u00a0 et\u00a0al.,\u00a02013b).\u00a0Der\u00a0\u00a0\nG\u2010BA\u00a0wertet\u00a0das\u00a0Ergebnis,\u00a0welches\u00a0unterhalb\u00a0der\u00a0MID\u00a0von\u00a041\u00a0m\u00a0li egt,\u00a0als\u00a0klinisch\u00a0\ngering\u00a0(G\u2010BA,\u00a02014b).\u00a0Als\u00a0sekund\u00e4rer\u00a0Endpunkt\u00a0zur\u00a0Morbidit\u00e4t\u00a0wu rde\u00a0die\u00a0\u00c4nde\u2010331\u00a0rung\u00a0der\u00a0WHO\u2010FC\u00a0zwischen\u00a0Randomisierung\u00a0und\u00a0Woche\u00a012\u00a0erhoben,\u00a0u nter\u00a02,5\u00a0mg\u00a0\nRiociguat\u00a0 (20,9\u00a0%)\u00a0 konnte\u00a0 statistisch\u00a0 signifikant\u00a0 eine\u00a0 Verbesse rung\u00a0 gegen\u00fcber\u00a0\nPlacebo\u00a0(14,4\u00a0%)\u00a0nachgewiesen\u00a0we rden,\u00a0wobei\u00a0der\u00a0Surrogatparamet er\u00a0nach\u00a0Auf\u2010\nfassung\u00a0des\u00a0G\u2010BA\u00a0nicht\u00a0patientenrelevant\u00a0ist\u00a0(G\u2010BA,\u00a02014b).\u00a0Auc h\u00a0der\u00a0Endpunkt\u00a0\nTTCW\u00a0fiel\u00a0statistisch\u00a0signifikant \u00a0zu\u00a0Gunsten\u00a0von\u00a0Riociguat\u00a0aus, \u00a0wobei\u00a0Validierungs\u2010\nstudien\u00a0zum\u00a0kombinierten\u00a0Endpunkt\u00a0fehlen\u00a0und\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0eine\u00a0 Begr\u00fcndung\u00a0f\u00fcr\u00a0\nAuswahl\u00a0der\u00a0einzelnen\u00a0Parameter\u00a0fehlt\u00a0(G\u2010BA,\u00a02014b).\u00a0Mittels\u00a0BD S\u00a0konnten\u00a0statis\u2010\ntisch\u00a0signifikante\u00a0Effekte\u00a0von\u00a0Riociguat\u00a0auf\u00a0Ver\u00e4nderung\u00a0von\u00a0Dy spnoe\u00a0und\u00a0Erm\u00fc\u2010\ndungsempfinden\u00a0 gezeigt\u00a0 werden,\u00a0 der\u00a0 G\u2010BA\u00a0 bewertet\u00a0 die\u00a0 absoluten\u00a0 klinischen\u00a0\nEffekte\u00a0f\u00fcr\u00a0PAH\u2010Patienten\u00a0jedoch\u00a0als\u00a0gering\u00a0(G\u2010BA,\u00a02014b).\u00a0Aspe kte\u00a0der\u00a0HRQoL\u00a0\nwurden\u00a0mittels\u00a0EQ\u20105D\u2010\u00a0und\u00a0LPH\u2010Fragebogen\u00a0erfasst,\u00a0wobei\u00a0der\u00a0EQ\u2010 5D\u00a0keinen\u00a0statis\u2010\ntisch\u00a0signifikanten\u00a0Unterscheid\u00a0zeigte,\u00a0der\u00a0LPH\u00a0jedoch\u00a0f\u00fcr\u00a0die\u00a0 physische\u00a0und\u00a0die\u00a0emo\u2010\ntionale\u00a0Dom\u00e4ne\u00a0einen\u00a0statistisch\u00a0signifikanten\u00a0Unterschied\u00a0erga b.\u00a0Die\u00a0Erfassung\u00a0von\u00a0\nAE\u00a0im\u00a0Rahmen\u00a0von\u00a0PATENT\u20101\u00a0dauerte\u00a0nur\u00a0bis\u00a0zwei\u00a0Tage\u00a0nach\u00a0Behand lungsende,\u00a0\nunter\u00a02,5\u00a0mg\u00a0Riociguat\u00a0traten\u00a0diese\u00a0bei\u00a089,4\u00a0%,\u00a0unter\u00a0Plazebo\u00a0b ei\u00a085,7\u00a0%\u00a0auf\u00a0(G\u2010BA,\u00a0\n2014b).\u00a0Signifikant\u00a0h\u00e4ufiger\u00a0waren\u00a0unter\u00a0Riociguat\u00a0Hypotonien\u00a0b ei\u00a010%\u00a0der\u00a0Patien\u2010\nten\u00a0im\u00a0Vergleich\u00a02%\u00a0unter\u00a0Placebo,\u00a0Synkopen\u00a0jedoch\u00a0seltener:\u00a01% \u00a0versus\u00a04\u00a0%\u00a0(Ghof\u2010\nrani\u00a0et\u00a0al.,\u00a02013b).\u00a0\nOh,\u00a0Youn\u00a0und\u00a0Kang\u00a0merken\u00a0in\u00a0einem\u00a0Leserbrief\u00a0zur\u00a0Originalpublik ation\u00a0von\u00a0PATENT\u2010\n1\u00a0an,\u00a0dass\u00a0die\u00a0Basistherapie\u00a0(ERA\u00a0oder\u00a0Prostanoide)\u00a0in\u00a0den\u00a0Effi cacy\u2010Analysen\u00a0und\u00a0die\u00a0\nGabe\u00a0oraler\u00a0Antikoagulantien\u00a0zu\u00a0ber\u00fccksichtigen\u00a0sind\u00a0(Oh\u00a0et\u00a0al. ,\u00a02013).\u00a0Die\u00a0kleine\u00a0\nGruppe\u00a0von\u00a0Patienten,\u00a0die\u00a0zus\u00e4tzlich\u00a0Prostanoide\u00a0erhielten,\u00a0hat te\u00a0mit\u00a0106\u00a0m\u00a06MWD\u00a0\neinen\u00a0deutlichen\u00a0gr\u00f6\u00dferen\u00a0Nutzen\u00a0von\u00a0Riociguat\u00a0als\u00a0die\u00a0\u00fcbrigen. \u00a0Die\u00a0Interaktion\u00a0\nzwischen\u00a0den\u00a0Basistherapiegruppen\u00a0war\u00a0jedoch\u00a0nicht\u00a0signifikant. \u00a0\u00a0\nArcher\u00a0f\u00fchrt\u00a0im\u00a0Editorial\u00a0der\u00a0Originalpublikationen\u00a0von\u00a0CHEST\u20101 \u00a0und\u00a0PATENT\u20101\u00a0\nunter\u00a0anderem\u00a0aus,\u00a0dass\u00a0bei\u00a0CTEPH\u00a0eine\u00a0PEA\u00a0die\u00a0morbidit\u00e4tstrigg ernden\u00a0Effekte\u00a0\nvon\u00a0Riociguat\u00a0auf\u00a0die\u00a0rechtsventrikul\u00e4re\u00a0Leistung\u00a0im\u00a0Kontext\u00a0de r\u00a0pivotalen\u00a0Studien\u00a0\nnicht\u00a0erfasst\u00a0wurden,\u00a052\u00a0%\u00a0im\u00a0Placebo\u2010Arm\u00a0von\u00a0PATENT\u20101\u00a0keine\u00a0Th erapie\u00a0der\u00a0PAH\u00a0\nerhielten\u00a0und\u00a0hinterfragt\u00a0die\u00a0Verbindungen\u00a0der\u00a0Autoren\u00a0mit\u00a0dem\u00a0 Sponsor\u00a0kritisch\u00a0\n(Archer,\u00a02013).\u00a0\nDie\u00a0 vorzeitig\u00a0 abgebrochene\u00a0 Phase\u2010II\u2010Studie\u00a0 \u201eRISE\u2010IIP\u201c\u00a0 (Sponsor: \u00a0B a y e r , \u00a0N C T 0 2 1 \u00a0\n38825),\u00a0welche\u00a0die\u00a0Gabe\u00a0von\u00a0individuell\u00a0dosistitriertem\u00a0Riocigu at\u00a0bei\u00a0Patienten\u00a0mit\u00a0\npulmonaler\u00a0 Hypertonie\u00a0aufgrund\u00a0 id iopathischer\u00a0 interstitieller\u00a0P neumonie\u00a0(PH\u2010IIP)\u00a0\n\u00fcber\u00a026\u00a0Wochen\u00a0pr\u00fcfte,\u00a0zeigte\u00a0\u00dcbersterblichkeit\u00a0und\u00a0ein\u00a0erh\u00f6hte s\u00a0Risiko\u00a0f\u00fcr\u00a0das\u00a0\nAuftreten\u00a0unerw\u00fcnschter\u00a0Effekte\u00a0 in\u00a0der\u00a0Riociguat\u2010Gruppe\u00a0(Clinic alTrials.gov,\u00a02014).\u00a0\nEs\u00a0folgte\u00a0die\u00a0Anpassung\u00a0der\u00a0Zulassung\u00a0unter\u00a0Aufnahme\u00a0der\u00a0PH\u2010IIP \u00a0als\u00a0Kontraindikati\u2010\non\u00a0und\u00a0Kommunikation\u00a0mittels\u00a0Rote\u2010Hand\u2010Brief\u00a0(BfArM,\u00a02016;\u00a0EMA, \u00a02016).\u00a0332\u00a0In\u00a0der\u00a0Phase\u2010II\u2010Studie\u00a0PATENT\u2010P LUS\u00a0(Sponsor:\u00a0Bayer,\u00a0NCT01179334 )\u00a0wurde\u00a0multi\u2010\nzentrisch,\u00a0doppelblind,\u00a02:1\u00a0randomisiert,\u00a0placebokontrolliert\u00a0d ie\u00a0Gabe\u00a0von\u00a0dosisti\u2010\ntriertem\u00a0 Riociguat\u00a0 zus\u00e4tzlich\u00a0 zu\u00a0 dreimal\u00a0 t\u00e4glich\u00a0 20\u00a0mg\u00a0 Sildenaf il\u00a0 mit\u00a0 prim\u00e4rem\u00a0\nEndpunkt\u00a0\u201e\u00c4nderung\u00a0des\u00a0liegend\u00a0gemessenen\u00a0Blutdrucks\u00a04\u00a0Stunden\u00a0 nach\u00a0Arznei\u2010\nmittelgabe\u201c\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0und\u00a0anschlie\u00dfender\u00a0 Open\u2010Label \u00a0Verl\u00e4ngerung\u00a0an\u00a0\n17\u00a0PAH\u2010Patienten\u00a0untersucht.\u00a0Aufgrund\u00a0dreier\u00a0Todesf\u00e4lle\u00a0und\u00a0une rw\u00fcnschter\u00a0Arz\u2010\nneimitteleffekte\u00a0in\u00a0der\u00a0Verl\u00e4ngerungsphase\u00a0wurde\u00a0die\u00a0Studie\u00a0abg ebrochen\u00a0(Gali\u00e8\u00a0et\u00a0\nal.,\u00a02015).\u00a0Die\u00a0Fachinformation\u00a0f\u00fchrt\u00a0unter\u00a0\u201eGegenanzeigen\u201c\u00a0die \u00a0Kombination\u00a0mit\u00a0\nNO\u2010Donatoren\u00a0bzw.\u00a0PDE\u20105\u2010I\u00a0als\u00a0ab solute\u00a0Kontraindikation\u00a0(CHMP,\u00a0 2017).\u00a0\nBestrebungen\u00a0zur\u00a0Erweiterung\u00a0der\u00a0zugelassenen\u00a0Anwendungsgebiete \u00a0f\u00fcr\u00a0Patien\u2010\nten\u00a0mit\u00a0PH\u2010CHD,\u00a0welche\u00a0der\u00a0pU\u00a0mittels\u00a0einer\u00a0Subgruppenanalyse\u00a0d er\u00a0pivotalen\u00a0\nStudien\u00a0PATENT\u20101\u00a0und\u00a0PATENT\u20102\u00a0erwirken\u00a0wollte,\u00a0wurden\u00a0seitens\u00a0d es\u00a0pU\u00a0nach\u00a0\n\u00dcbermittlung\u00a0eines\u00a0Fragenkataloge s\u00a0der\u00a0EMA\u00a0eingestellt.\u00a0Zu\u00a0beac hten\u00a0ist,\u00a0dass\u00a0in\u00a0\ndiesen\u00a0Studien\u00a0nur\u00a08\u00a0%\u00a0der\u00a0Teilnehmer\u00a0eine\u00a0PH\u2010CHD\u00a0aufwiesen\u00a0(Ba yer\u00a0Vital\u00a0GmbH,\u00a0\n2016;\u00a0CHMP\u00a0EMA,\u00a02016;\u00a0Rosenkranz,\u00a0Ghofrani\u00a0et\u00a0al.,\u00a02015).\u00a0Aktue ll\u00a0sind\u00a0in\u00a0der\u00a0\nDatenbank\u00a0 Clinicaltrial.gov \u00a044\u00a0Studien\u00a0mit\u00a0Riociguat\u00a0registriert,\u00a0d.h.\u00a0die\u00a0Anwen\u2010\ndungsm\u00f6glichkeiten\u00a0des\u00a0urspr\u00fcnglich\u00a0als\u00a0Arzneimittel\u00a0zur\u00a0Therap ie\u00a0seltener\u00a0Leiden\u00a0\nzugelassenen\u00a0Riociguats\u00a0werden\u00a0in tensiv\u00a0untersucht\u00a0(ClinicalTri als.gov,\u00a02017).\u00a0\nDas\u00a0BfArM\u00a0auf\u00a0die\u00a0Notwendigkeit\u00a0 einer\u00a0fundierten\u00a0Diagnostik\u00a0hin ,\u00a0um\u00a0die\u00a0Anwen\u2010\ndung\u00a0von\u00a0Riociguat\u00a0im\u00a0Rahmen\u00a0der\u00a0gesetzlich\u00a0zugelassenen\u00a0Indika tionen\u00a0zu\u00a0ge\u2010\nw\u00e4hrleisten,\u00a0d.h.\u00a0ausschlie\u00dflich\u00a0 in\u00a0den\u00a0WHO\u2010Gruppen\u00a01,\u00a01.1,\u00a01.2 ,\u00a01.4.1\u00a0sowie\u00a04\u00a0\n(Mittmann,\u00a02016).\u00a0\nLeitlinienempfehlungen\u00a0(vgl.\u00a0erg\u00e4nzend\u00a0Kap.\u00a04.17\u00a0Macitentan)\u00a0\nDie\u00a0von\u00a0der\u00a0deutschen\u00a0Gesellschaf t\u00a0f\u00fcr\u00a0Kardiologie\u00a0DGK\u00a0\u00fcbernomm enen\u00a0Leitlinien\u00a0\n(Rosenkranz\u00a0et\u00a0al.,\u00a02015) \u00a0der\u00a0europ\u00e4ischen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Kardiologie\u00a0( European\u00a0\nSociety\u00a0of\u00a0Cardiology,\u00a0 ESC)\u00a0zur\u00a0Diagnose\u00a0und\u00a0Therapie\u00a0pulmonaler\u00a0Hypertonie,\u00a0\nf\u00fchren\u00a0insbesondere\u00a0zu\u00a0PAH\u00a0und\u00a0CT EPH\u00a0nachfolgendes\u00a0aus\u00a0(Galie\u00a0e t\u00a0al.,\u00a02015\u00a0und\u00a0\n2016):\u00a0\n\u201eBei\u00a0neudiagnostizierter\u00a0PAH\u00a0(EK G,\u00a0Szintigraphie)\u00a0geh\u00f6rt\u00a0auch\u00a0d ie\u00a0Durchf\u00fchrung\u00a0\neines\u00a0 Vasoreagibilit\u00e4tstests\u00a0 im\u00a0 Kontext\u00a0 einer\u00a0 Rechtsherzkathete r\u2010Untersuchung\u00a0\nzur\u00a0leitliniengerechten\u00a0Versorgung.\u00a0Responder\u00a0sollen\u00a0initial\u00a0Ka lziumantangonisten\u00a0\nwie\u00a0bspw.\u00a0Amlodipin\u00a0mit\u00a0bis\u00a0zu\u00a020\u00a0mg\u00a0t\u00e4glich\u00a0erhalten.\u00a0Anhand\u00a0e iner\u00a0Risikostratifi\u2010\nzierung\u00a0der\u00a0\u201egesch\u00e4tzten\u00a0Einjahr esmortalit\u00e4t\u201c\u00a0wird\u00a0die\u00a0weitere\u00a0 Therapie\u00a0definiert,\u00a0\nwobei\u00a0man\u00a0in\u00a0geringes\u00a0(<\u00a05\u00a0%),\u00a0intermedi\u00e4res\u00a0(5\u00a0bis\u00a010\u00a0%)\u00a0und\u00a0h ohes\u00a0Risiko\u00a0\n(>\u00a010\u00a0%)\u00a0unterteilt.\u00a0Hierzu\u00a0werden\u00a0folgende\u00a0Parameter\u00a0ber\u00fccksichti gt:\u00a0Klinische\u00a0\nManifestation\u00a0einer\u00a0Rechtsherzin suffizienz\u00a0(ja/nein),\u00a0Progressi on\u00a0(nein/langsam/\u00a0\nschnell),\u00a0 Synkopen\u00a0 (keine/gelege ntlich,\u00a0 orthostatisch\u00a0 oder\u00a0 bei\u00a0 ungew\u00f6hnlicher\u00a0333\u00a0k\u00f6rperlicher\u00a0Belastung/geh\u00e4uft,\u00a0schon\u00a0bei\u00a0geringer\u00a0k\u00f6rperlicher \u00a0Belastung),\u00a0WHO\u2010\nFC\u00a0(I\u00a0oder\u00a0II/III/IV),\u00a06MWD\u00a0(>\u00a0440\u00a0m/165\u2010440\u00a0m/<165\u00a0m),\u00a0Spiroer gometrie,\u00a0BNP\u00a0\nbzw.\u00a0 NT\u2010pro\u2010BNP\u2010Serumspiegel,\u00a0 ka rdiale\u00a0 Bildgebung\u00a0 (Echokardiogr aphie\u00a0 cMRT)\u00a0\nsowie\u00a0Beurteilung\u00a0der\u00a0H\u00e4modynamik.\u00a0\nF\u00fcr\u00a0\u201etypische\u201c\u00a0PAH\u2010Patienten\u00a0mit\u00a0geringem\u00a0bzw.\u00a0intermedi\u00e4rem\u00a0Ri siko\u00a0erfolgt\u00a0\ninitial\u00a0eine\u00a0\u201efr\u00fche\u00a0orale\u00a0duale\u00a0K ombinationstherapie\u201c\u00a0mit\u00a0ERA\u00a0( Ambrisentan,\u00a0\nBosentan\u00a0oder\u00a0Macitentan)\u00a0plus\u00a0PDE\u20105\u2010Inhibitor\u00a0(Sildenafil\u00a0oder \u00a0Tadalafil)\u00a0bzw.\u00a0\nStimulator\u00a0der\u00a0l\u00f6slichen\u00a0Guanylat cyclase,\u00a0sGCS\u00a0(Riociguat).\u00a0Bei \u00a0Hochrisikopatien\u2010\nten\u00a0kommt\u00a0eine\u00a0Dreifachkombination\u00a0unter\u00a0Nutzung\u00a0der\u00a0Therapieop tionen\u00a0ERA\u00a0\nplus\u00a0 PDE\u20105\u2010I\u00a0 bzw.\u00a0 sGCS\u00a0 und\u00a0 i.v.\u00a0 Prostazyklin\u2010Analogon\u00a0 zur\u00a0 Anwen dung.\u00a0 Bei\u00a0\nRechtsherzdekompensation\u00a0ist\u00a0die\u00a0Evaluation\u00a0einer\u00a0Lungentranspl antation\u00a0indi\u2010\nziert.\u00a0Patienten\u00a0mit\u00a0atypischer\u00a0PAH\u00a0erhalten\u00a0initial\u00a0eine\u00a0Monot herapie\u00a0mit\u00a0PDE\u2010\n5\u2010I\u00a0(Hoeper\u00a0et\u00a0al.,\u00a02017).\u00a0Suppo rtiv\u00a0werden\u00a0Diuretika,\u00a0Sauersto fflangzeittherapie,\u00a0\nAntikoagulation,\u00a0Ausgleichen\u00a0von\u00a0An\u00e4mie\u00a0bzw.\u00a0Eisenmangel,\u00a0Impfu ngen\u00a0(j\u00e4hrli\u2010\nche\u00a0Influenza,\u00a0einmalig\u00a0Pneumokokkenpneumonie)\u00a0sowie\u00a0betreutes\u00a0 k\u00f6rperliches\u00a0\nTraining\u00a0in\u00a0der\u00a0ESC\u2010Leitlinie\u00a0bzw.\u00a0dem\u00a0Kommentar\u00a0der\u00a0DGK\u00a0empfoh len.\u201c\u00a0(Rosen\u2010\nkranz\u00a0et\u00a0al.,\u00a02016b,\u00a0220).\u00a0\nIm\u00a0Kommentar\u00a0dieser\u00a0Leitlinien\u00a0merken\u00a0Prof.\u00a0Rosenkranz\u00a0und\u00a0Koll egen\u00a0an,\u00a0dass\u00a0\neinerseits\u00a0 im\u00a0 klinischen\u00a0 Alltag\u00a0 \u201eder\u00a0 nicht\u00a0 immer\u00a0 indikationsger echte\u00a0 Einsatz\u00a0 von\u00a0\nteuren\u00a0und\u00a0mit\u00a0Nebenwirkungen\u00a0behafteten\u00a0PAH\u2010Therapien\u00a0bei\u00a0Pati enten,\u00a0die\u00a0zwar\u00a0\neine\u00a0pulmonale\u00a0Hypertonie,\u00a0jedoch\u00a0keine\u00a0pulmonal\u00a0arterielle\u00a0Hyp ertonie\u00a0haben\u201c\u00a0\nerfolge,\u00a0 andererseits\u00a0 aber\u00a0 auch\u00a0 \u201e d i e \u00a0n i c h t \u00a0i m m e r \u00a0k o n s e q u e n t e \u00a0B e handlung\u00a0 von\u00a0\nPatienten\u00a0mit\u00a0PAH\u00a0(heutzutage\u00a0viele\u00a0M\u00f6glichkeiten,\u00a0komplexe\u00a0The rapieentscheidun\u2010\ngen,\u00a0siehe\u00a0Therapiealgorithmus)\u201c,\u00a0es\u00a0sich\u00a0also\u00a0um\u00a0das\u00a0Vorliegen \u00a0von\u00a0\u00dcber\u2010\u00a0und\u00a0Un\u2010\nterversorgung\u00a0handelt\u00a0(Rosenkranz\u00a0et\u00a0al.,\u00a02016b,\u00a0218).\u00a0\nZur\u00a0Therapie\u00a0der\u00a0CTEPH\u00a0wird\u00a0auf\u00a0spezialisierte\u00a0Zentren\u00a0hingewie sen.\u00a0Die\u00a0chirurgi\u2010\nsche\u00a0Endarterieektomie\u00a0stellt\u00a0i mmer\u00a0noch\u00a0die\u00a0erste\u00a0Wahl\u00a0dar.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nMit\u00a0Zulassung\u00a0von\u00a0Riociguat\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Leiden\u00a0( Orphan\u2010Arzneimittel)\u00a0\nwird\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V\u00a0automatisch\u00a0ein\u00a0Zusatzn utzen\u00a0aner\u2010\nkannt,\u00a0der\u00a0G\u2010BA\u00a0bewertet\u00a0die\u00a0vom\u00a0pU\u00a0vorgelegten\u00a0Unterlagen\u00a0ledi glich\u00a0nach\u00a0Aus\u2010\nma\u00df\u00a0des\u00a0Zusatznutzens\u00a0f\u00fcr\u00a0die\u00a0betreffende\u00a0Anzahl\u00a0von\u00a0Patienten\u00a0 bzw.\u00a0\u2010gruppen.\u00a0\nMit\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0vom\u00a016.\u00a0Oktober\u00a02014\u00a0wird\u00a0Riociguat\u00a0zur\u00a0 Anwendung\u00a0bei\u00a0\nerwachsenen\u00a0Patienten\u00a0mit\u00a0CTEPH\u00a0 und\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0P AH\u00a0jeweils\u00a0ein\u00a0\ngeringer\u00a0Zusatznutzen\u00a0attestiert\u00a0(G\u2010BA,\u00a02014a).\u00a0In\u00a0den\u00a0tragende n\u00a0Gr\u00fcnden\u00a0zum\u00a0\nBeschluss\u00a0wird\u00a0ausgef\u00fchrt,\u00a0dass\u00a0der\u00a0G\u2010BA\u00a0von\u00a0der\u00a0seitens\u00a0des\u00a0IQ WiG\u00a0empfohlenen\u00a0\nMethodik\u00a0abgewichen\u00a0ist.\u00a0Die\u00a0Bewertung\u00a0basiert\u00a0auf\u00a0den\u00a0zulassun gsbegr\u00fcndenden\u00a0334\u00a0Studien\u00a0CHEST\u20101\u00a0und\u00a0PATENT\u20101,\u00a0welche\u00a016\u00a0bzw.\u00a012\u00a0Wochen\u00a0andauert en\u00a0und\u00a0somit\u00a0\nnur\u00a0eine\u00a0limitierte\u00a0Datengrundlag e\u00a0zur\u00a0Nutzenbewertung\u00a0lieferte n.\u00a0Es\u00a0zeigten\u00a0sich\u00a0\nbinnen\u00a016\u00a0Wochen\u00a0plus\u00a0zwei\u00a0Tagen\u00a0 Nachbeobachtung\u00a0hinsichtlich\u00a0d er\u00a0Mortali\u00e4t\u00a0\nkeine\u00a0statistisch\u00a0signifikanten\u00a0Unterschiede.\u00a0Die\u00a0Morbidit\u00e4t\u00a0wu rde\u00a0anhand\u00a0Surro\u2010\ngatparameter\u00a0\u201e\u00c4nderung\u00a0der\u00a06MWD\u201c\u00a0und\u00a0\u201e\u00c4nderung\u00a0der\u00a0WHO\u2010/NYHA\u2010Kl asse\u201c\u00a0\nerfasst\u00a0und\u00a0konnte\u00a0unter\u00a0Therapie\u00a0mit\u00a0Riociguat\u00a0statistisch\u00a0sig nifikant\u00a0verbessert\u00a0\nwerden.\u00a0Der\u00a0kombinierte\u00a0Endpunkt\u00a0TTCW\u00a0war\u00a0nicht\u00a0validiert,\u00a0eine \u00a0rationale\u00a0Aus\u2010\nwahl\u00a0seiner\u00a0Endpunktkomponenten\u00a0kann\u00a0seitens\u00a0IQWiG\u00a0und\u00a0G\u2010BA\u00a0nic ht\u00a0nachvoll\u2010\nzogen\u00a0werden;\u00a0f\u00fcr\u00a0diesen\u00a0kombinierten\u00a0Endpunkt\u00a0TTCW\u00a0war\u00a0der\u00a0Nac hweis\u00a0eines\u00a0\nstatistisch\u00a0signifikanten\u00a0Behandlungseffektes\u00a0nicht\u00a0m\u00f6glich.\u00a0Mi ttels\u00a0BDS\u00a0wurde\u00a0die\u00a0\nMorbidit\u00e4t\u00a0ermittelt,\u00a0eine\u00a0statistisch\u00a0signifikante\u00a0Verbesserun g\u00a0konnte\u00a0unter\u00a0Rioci\u2010\nguat\u00a0gezeigt\u00a0werden,\u00a0deren\u00a0absoluter,\u00a0klinischer\u00a0Effekt\u00a0jedoch\u00a0 seitens\u00a0des\u00a0G\u2010BA\u00a0als\u00a0\ngering\u00a0eingesch\u00e4tzt\u00a0wurde.\u00a0Insgesamt\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Effekte\u00a0der\u00a0 Endpunkte\u00a0unter\u00a0\nTherapie\u00a0mit\u00a0Riociguat\u00a0ein\u00a0gerin ger\u00a0Zusatznutzen\u00a0erkannt\u00a0(G\u2010BA, \u00a02014a).\u00a0\nVersorgungsanalysen\u00a0\nRiociguat\u00a0wurde\u00a0in\u00a0den\u00a0Jahren\u00a02014\u00a0und\u00a02015\u00a0haupts\u00e4chlich\u00a0in\u00a0de r\u00a0Packungsgr\u00f6\u00dfe\u00a0\nN2\u00a0verordnet.\u00a0In\u00a0den\u00a0ersten\u00a0drei\u00a0Monaten\u00a0nach\u00a0Zulassung\u00a0wurde\u00a0k eine\u00a0Angabe\u00a0zur\u00a0\nPackungsgr\u00f6\u00dfe\u00a0gemacht,\u00a0nach\u00a0neun\u00a0Monaten\u00a0wurde\u00a0die\u00a0Packungsgr\u00f6\u00df e\u00a0N3\u00a0ver\u2010\nordnet,\u00a0deren\u00a0Anteil\u00a0an\u00a0allen\u00a0ve rordneten\u00a0Packungen\u00a0im\u00a0Dezember \u00a02015\u00a0rund\u00a0ein\u00a0\nF\u00fcnftel\u00a0betr\u00e4gt.\u00a0\n\u00a0\u00a0335\u00a0Abbildung\u00a04.40:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Riociguat\u00a0je\u00a0Monat \u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.41:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Riocigua t\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\n336\u00a0Betrachtet\u00a0man\u00a0die\u00a0Anzahl\u00a0Kranke nversicherter,\u00a0welche\u00a0Riociguat \u00a0im\u00a0Jahr\u00a02015\u00a0\nerhielten,\u00a0nach\u00a0Lebensalterdekaden,\u00a0so\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0vor\u00a0alle n\u00a0Patienten\u00a0\u00fcber\u00a060\u00a0\nLebensjahren\u00a0betroffen\u00a0waren\u00a0und\u00a0bei\u00a0j\u00fcngeren\u00a0Patienten\u00a0vorwieg end\u00a0Frauen\u00a0mit\u00a0\ndem\u00a0Arzneimittel\u00a0behandelt\u00a0wurden.\u00a0\nQuellen\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2014).\u00a0Riociguat\u00a0zur\u00a0Behandlung\u00a0de r\u00a0pulmonalen\u00a0arteriellen\u00a0Hypertonie.\u00a0AMB\u00a048:\u00a028\u201032.\u00a0\nArcher\u00a0SL\u00a0(2013).\u00a0Riociguat\u00a0for\u00a0 pulmonary\u00a0hypertension\u00a0\u2010\u00a0a\u00a0glas s\u00a0half\u00a0full.\u00a0NEJM\u00a0369(4):\u00a0386\u2010388.\u00a0\nAuger\u00a0WR,\u00a0Jamieson\u00a0SW\u00a0(2013).\u00a0Correspondence:\u00a0Riociguat\u00a0for\u00a0pul monary\u00a0hypertension.\u00a0NEJM\u00a0369(23):\u00a02268.\u00a0\nBayer\u00a0Vital\u00a0GmbH\u00a0(2016).\u00a0Adempas,\u00a0INN\u00a0\u2010\u00a0riociguat:\u00a0Withdrawal\u00a0o f\u00a0EMEA/H/C/002737/0011.\u00a0R\u00fccknahme\u00a0des\u00a0Antrages\u00a0auf\u00a0\nIndikationserweiterung\u00a0Riociguat\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0angeborenen\u00a0 Herzerkrankungen.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/Withdraw\u00a0al_lette r/2016/09/WC500212924.pdf,\u00a0letzter\u00a0\nZugriff:\u00a029.05.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 16).\u00a0Rote\u00a0Hand\u00a0Brief\u00a0zu\u00a0Adempas\u00a0(Riociguat):\u00a0Neue\u00a0\nKontraindikation\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0pulmonaler\u00a0Hypertonie\u00a0in\u00a0Ver bindung\u00a0mit\u00a0idiopathischer\u00a0interstitieller\u00a0\nPneumonie\u00a0(PH\u2010IIP).\u00a0https://www.bfarm.de/SharedDocs/Risikoinfor mationen/Pharmakovigilanz/DE/RHB/2016/rhb\u2010\nadempas.html,\u00a0letzter\u00a0Zugriff:\u00a024.05.2017.\u00a0\nCDER\u00a0\u2013\u00a0Center\u00a0for\u00a0Drug\u00a0Evaluation\u00a0and\u00a0Research\u00a0(2013).\u00a0Approval \u00a0Letter\u00a0Application\u00a0Number:\u00a0204819Orig1s000.\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204819O rig1s000TOC.cfm,\u00a0letzter\u00a0Zugriff:\u00a024.05.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 Adempas\u00a0\u2010\u00a0SMOP:\u00a0EMA/CHMP/807324/2013.\u00a0Summary\u00a0of\u00a0\nopinion.\u00a0http://www.ema.europa.eu/docs/en_GB/document_library/S ummary_of_opinion_\u2010\n_Initial_authorisation/human/002737/WC500160094.pdf,\u00a0letzter\u00a0Zu griff:\u00a026.05.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 Assessment\u00a0report:\u00a0Adempas,\u00a0INN\u2010\u00a0riociguat.\u00a0\nEMA/CHMP/734750/2013.\u00a0http://www.ema.europa.eu/docs/en_GB/docum ent_library/EPAR_\u2010\n_Public_assessment_report/human/002737/WC500165036.pdf,\u00a0letzter \u00a0Zugriff:\u00a026.05.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2016).\u00a0E MA\u00a0CHMP\u00a0Withdrawal\u00a0of\u00a0the\u00a0application\u00a0for\u00a0a\u00a0change\u00a0to\u00a0the\u00a0\nmarketing\u00a0authoristion\u00a0for\u00a0Adempas,\u00a0INN\u00a0\u2010\u00a0riociguat.\u00a0EMA/560099 /2016\u00a0EMEA/H/C/002737/II/011.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/Medicine_QA/2016/ 09/WC500212922.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n26.05.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2017).\u00a0E MA\u00a0SMPC\u00a0Adempas,\u00a0INN\u2010\u00a0riociguat:\u00a0EPAR\u00a0Annex\u00a0I\u00a0Summary\u00a0of\u00a0\nproduct\u00a0characteristics.\u00a0www.ema.europa.eu/docs/en_GB/document_ library/EPAR_\u2010\n_Product_Information/human/002737/WC500165034.pdf,\u00a0letzter\u00a0Zugr iff:\u00a026.05.2017.\u00a0\nClinicalTrials.gov\u00a0(2008a).\u00a0CHE ST\u20101\u00a0NCT00855465:\u00a0A\u00a0Study\u00a0to\u00a0Eva luate\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Oral\u00a0BAY63\u20102521\u00a0in\u00a0Patients\u00a0With\u00a0\nCTEPH.\u00a0(CHEST\u20101).\u00a0https://www.clinicaltrials.gov/ct2/show/NCT00 855465?term=nct00855465&rank=1,\u00a0letzter\u00a0\nZugriff:\u00a026.05.2017.\u00a0\nClinicalTrials.gov\u00a0(2008b).\u00a0PATENT\u20101\u00a0NCT00810693:\u00a0A\u00a0Study\u00a0to\u00a0Ev aluate\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Oral\u00a0BAY63\u20102521\u00a0in\u00a0Patients\u00a0With\u00a0\nPulmonary\u00a0Arterial\u00a0Hyperte nsion\u00a0(PAH)\u00a0(PATENT\u20101).\u00a0\nhttps://www.clinicaltrials.gov/ct2/show/NCT00810693?term=nct008 10693&rank=1,\u00a0letzter\u00a0Zugriff:\u00a026.05.2017.\u00a0\u00a0\nClinicalTrials.gov\u00a0(2009a).\u00a0CHEST\u20102\u00a0NCT00910429:\u00a0BAY63\u20102521\u00a0\u2010\u00a0L ong\u2010term\u00a0Extension\u00a0Study\u00a0in\u00a0Patients\u00a0With\u00a0Chronic\u00a0Throm\u2010\nboembolic\u00a0Pulmonary\u00a0Hypertension\u00a0(CHEST\u20102).\u00a0https://www.clinicaltrials.gov/ct2/show/NCT00910429?term=nct009 10429&rank=1,\u00a0letzter\u00a0Zugriff:\u00a026.05.2017.\u00a0337\u00a0ClinicalTrials.gov\u00a0(2009b).\u00a0PATENT\u20102\u00a0NCT00863681.\u00a0\nhttps://www.clinicaltrials.gov/ct2/show/NCT00863681?term=nct008 63681&rank=1,\u00a0letzter\u00a0Zugriff:\u00a026.05.2017.\u00a0\nClinicalTrials.gov\u00a0(2014).\u00a0RISE\u2010IIP\u00a0NCT02138825:\u00a0Efficacy\u00a0and\u00a0S afety\u00a0of\u00a0Riociguat\u00a0in\u00a0Patients\u00a0With\u00a0Symptomatic\u00a0Pulmonary\u00a0\nHypertension\u00a0(PH)\u00a0Associated\u00a0With\u00a0Idiopathic\u00a0pneumonias\u00a0(IIP)\u00a0( RISE\u2010IIP).\u00a0\nhttps://clinicaltrials.gov/ct2/show/results/NCT02138825?show_lo cs=Y&sect=X0123456#all,\u00a0letzter\u00a0Zugriff:\u00a0\n26.05.2017.\u00a0\nClinicalTrials.gov\u00a0(2017).\u00a0Suche:\u00a0\"Riociguat\".\u00a0https://www.clin icaltrials.gov/ct2/res ults?term=riociguat&pg=1,\u00a0letzter\u00a0Zugriff :\u00a0\n26.05.2017.\u00a0\nCOMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Orphan\u00a0Medicinal\u00a0Products\u00a0(2007).\u00a0Public\u00a0s ummary\u00a0of\u00a0opinion\u00a0on\u00a0orphan\u00a0designation\u00a0[Riociguat].\u00a0\nEMA/COMP/35953/2008\u00a0Rev.\u00a03.\u00a0\u00a0www.ema.europa.eu/docs/en_GB/document_library/Orphan_designatio n/2009/10/WC500006390.pdf,\u00a0letzter\u00a0\nZugriff:\u00a029.05.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0RISE\u2010IIP:\u00a0Adempas\u00a0not\u00a0f or\u00a0use\u00a0in\u00a0patients\u00a0with\u00a0pulmonary\u00a0hypertension\u00a0caused\u00a0by\u00a0\nidiopathic\u00a0interstitial\u00a0pneumonia.\u00a0Press\u00a0release.\u00a0www.ema.europa.eu/docs/en_GB/do cument_library/Press_release/201 6/06/WC500209316.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n06.06.2017.\u00a0\nGali\u00e8\u00a0N,\u00a0M\u00fcller\u00a0K,\u00a0Scalise\u00a0AV,\u00a0Gr \u00fcnig\u00a0E\u00a0(2015).\u00a0PATENT\u00a0PLUS:\u00a0a\u00a0 blinded,\u00a0randomised\u00a0and\u00a0extension\u00a0study\u00a0of\u00a0riociguat\u00a0plus\u00a0silde nafil\u00a0\nin\u00a0pulmonary\u00a0arterial\u00a0hypertension.\u00a0Eur\u00a0Respir\u00a0J\u00a045(5):1314\u2010132 2.\u00a0\nGalie\u00a0N,\u00a0Humbert\u00a0M,\u00a0Vachiery\u00a0JL,\u00a0Gibbs\u00a0S,\u00a0Lang\u00a0I,\u00a0Torbicki\u00a0A\u00a0et \u00a0al.\u00a0(2016).\u00a02015\u00a0ESC/ERS\u00a0Guidelines\u00a0for\u00a0the\u00a0diagnosis\u00a0and\u00a0trea tment\u00a0\nof\u00a0pulmonary\u00a0hypertension:\u00a0The\u00a0Joint\u00a0Task\u00a0Force\u00a0for\u00a0the\u00a0Diagnos is\u00a0and\u00a0Treatment\u00a0of\u00a0Pulmonary\u00a0Hypertension\u00a0of\u00a0the\u00a0\nEuropean\u00a0Society\u00a0of\u00a0Cardiology\u00a0(ESC)\u00a0and\u00a0the\u00a0European\u00a0Respirato ry\u00a0Society\u00a0(ERS):\u00a0Endorsed\u00a0by:\u00a0Association\u00a0for\u00a0\nEuropean\u00a0Paediatric\u00a0and\u00a0Congenital\u00a0Cardiology\u00a0(AEPC),\u00a0Internati onal\u00a0Society\u00a0for\u00a0Heart\u00a0and\u00a0Lung\u00a0Transplantation\u00a0\n(ISHLT).\u00a0Europ\u00a0Heart\u00a0J\u00a037(1):\u00a067\u2010119.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014a).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bundesausschus\u2010ses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Riociguat.\u00a0https://www .g\u2010ba.de/downloads/40\u2010268\u20102978/2014\u201010\u2010\n16_AM\u2010RL\u2010XII_Riociguat_2014\u201005\u201001\u2010D\u2010103_TrG.pdf,\u00a0letzter\u00a0Zugrif f:\u00a024.05.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Riociguat.\u00a0https://www .g\u2010ba.de/downloads/40\u2010268\u20102978/2014\u201010\u2010\n16_AM\u2010RL\u2010XII_Riociguat_2014\u201005\u201001\u2010D\u2010103_TrG.pdf,\u00a0letzter\u00a0Zugrif f:\u00a018.06.2017.\u00a0\nGhofrani\u00a0HA,\u00a0D'Armini\u00a0AM,\u00a0Grimminger\u00a0F,\u00a0Hoeper\u00a0MM,\u00a0Jansa\u00a0P,\u00a0Kim \u00a0NH\u00a0et\u00a0al.\u00a0(2013a).\u00a0Riociguat\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0chronic\u00a0\nthromboembolic\u00a0pulmonary\u00a0hypertension.\u00a0NEJM\u00a0369:319\u2010329.\u00a0\nGhofrani\u00a0HA,\u00a0Galie\u00a0N,\u00a0Grimminger\u00a0F,\u00a0Grunig\u00a0E,\u00a0Humbert\u00a0M,\u00a0Jing\u00a0Z C\u00a0et\u00a0al.\u00a0(2013b).\u00a0Riociguat\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0pulmonary\u00a0arte rial\u00a0\nhypertension.\u00a0NEJM\u00a0369(4):\u00a0330\u2013340.\u00a0\nGhofrani\u00a0HA,\u00a0Simonneau\u00a0G,\u00a0Rubin\u00a0LJ\u00a0(2013).\u00a0Riociguat\u00a0for\u00a0pulmon ary\u00a0hypertension.\u00a0NEJM\u00a0369(23):2268.\u00a0\nHoeper\u00a0MM,\u00a0Ghofrani\u00a0HA,\u00a0Grunig\u00a0E,\u00a0Klose\u00a0H,\u00a0Olschewski\u00a0H,\u00a0Rosenk ranz\u00a0S\u00a0(2017).\u00a0Pulmonary\u00a0Hypertension.\u00a0\nhttps://www.aerzteblatt.de/archiv/186048/Pulmonale\u2010Hypertonie,\u00a0 letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nKerckhoff\u00a0Klinik.\u00a0(2015) .\u00a0Operative\u00a0Therapie\u00a0\u2010\u00a0pulmonale\u00a0Endart eriektomie\u00a0(PEA=Aussch\u00e4lung\u00a0der\u00a0Lungenarterien).\u00a0www.kerckhoff\u2010\nklinik.de/abteilungen/thoraxchiru rgie/pulmonale_hypertonie_ctep h/behandlungtherapie/\u00a0\u00a0\nLauer\u00a0Fischer\u00a0GmbH\u00a0(2017).\u00a0WEBAPO\u00a0InfoSystem.letzter\u00a0Zugriffhtt ps://www.cgm.com/lauer\u2010fischer/index.de.jsp\u00a0\u00a0338\u00a0Mittmann\u00a0C\u00a0(2016).\u00a0Riociguat\u00a0(Adempas)\u00a0bei\u00a0pulmonaler\u00a0Hypertoni e\u2010\u00a0genaue\u00a0Diagnostik\u00a0entscheidend.\u00a0Bulletin\u00a0zur\u00a0Arznei\u2010\nmittelsicherheit\u00a07\u00a0(03\u20102016).\u00a0 www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigil anz/\u00a0\nBulletin/2016/3\u20102016.pdf?__blob=publicationFile&v=4,\u00a0letzter\u00a0Zu griff:\u00a018.06.2017.\u00a0\nMSD/Bayer\u00a0Vital\u00a0GmbH\u00a0(2017).\u00a0Fachinformation\u00a0Adempas\u00a0\u2010\u00a0Riocigua t.\u00a0\nwww.msd.de/fileadmin/files/fach informationen/adempas.pdf\u00a0\u00a0\nMutschler\u00a0E,\u00a0Geisslinger\u00a0G,\u00a0Menzel\u00a0S,\u00a0Ruth\u00a0P,\u00a0Schmidtko\u00a0A\u00a0(2016 ).\u00a0Pharmakologie\u00a0kompakt.\u00a0St uttgart.\u00a0Wissenschaftliche\u00a0\nVerlagsgesellschaft.\u00a0\nOh\u00a0J,\u00a0Youn\u00a0JC,\u00a0Kang\u00a0SM\u00a0(2013).\u00a0Correspondence:\u00a0Riociguat\u00a0for\u00a0Pu lmonary\u00a0Hypertension.\u00a0NEJM\u00a02013\u00a0369:2266\u20102268.\u00a0\nRosenkranz\u00a0S,\u00a0Ghofrani\u00a0HA,\u00a0Beghetti\u00a0M,\u00a0Ivy\u00a0D,Frey\u00a0R,\u00a0Fritsch\u00a0A\u00a0 et\u00a0al.\u00a0(2015a).\u00a0Riociguat\u00a0for\u00a0pulmonary\u00a0arterial\u00a0hypertension\u00a0\nassociated\u00a0with\u00a0congenital\u00a0heart\u00a0disease.\u00a0Heart\u00a0101(22):1792\u201017 99.\u00a0\nRosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Hoeper\u00a0MM,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C\u00a0( 2016).\u00a0Diagnostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonalen\u00a0Hypertonie:\u00a0ESC\u00a0\nPocket\u00a0Guidelines\u00a0(2.\u00a0Auflage).\u00a0Pocket\u2010Leitlinien.\u00a0Gr\u00fcnwald:\u00a0B\u00f6 rm\u00a0Bruckmeier.letzter\u00a0\nZugriffleitlinien.dgk.org/files/2016_K_PLL_Pulmonale_Hypertonie .pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nRosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Hoeper\u00a0MM,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C\u00a0( 2015b).\u00a0Pocket\u2010Leitlinie:\u00a0Diagnostik\u00a0und\u00a0Therapie\u00a0der\u00a0pulmonale n\u00a0\nHypertonie\u00a0(Version\u00a02015):\u00a0Kurzf assung\u00a0der\u00a0\"ESC/ERS\u00a0Guidelines\u00a0 f\u00fcr\u00a0the\u00a0diagnosis\u00a0and\u00a0treatment\u00a0of\u00a0pulmonary\u00a0\nhypertension\".www.leitlinien.dgk.org/files/2016_K_PLL_Pulmonale _Hypertonie.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2017.\u00a0\nRosenkranz\u00a0S,\u00a0Baldus\u00a0S,\u00a0Gr\u00fcnig\u00a0E,\u00a0Klose\u00a0H,\u00a0Opitz\u00a0C,\u00a0Hoeper\u00a0MM\u00a0( 2016).\u00a0Kommentar\u00a0zu\u00a0den\u00a02015\u00a0ESC/ERS\u2010Leitlinien\u00a0zur\u00a0Diagnostik\u00a0\nund\u00a0Therapie\u00a0der\u00a0pulmonalen\u00a0Hypertonie.\u00a0http://leitlinien.dgk.o rg/2016/kommentar\u2010zu\u2010den\u20102015\u2010escers\u2010leitlinien\u2010\nzur\u2010diagnostik\u2010und\u2010therapie\u2010der\u2010pulmonalen\u2010hypertonie/,\u00a0letzter \u00a0Zugriff:\u00a018.06.2017.\u00a0\nSimonneau\u00a0G,\u00a0D'Armini\u00a0AM,\u00a0Ghofrani \u00a0HA,\u00a0Grimminger\u00a0F,\u00a0Jansa\u00a0P,\u00a0K im\u00a0NH\u00a0et\u00a0al.\u00a0(2016).\u00a0Predictors\u00a0of\u00a0long\u2010term\u00a0outcomes\u00a0in\u00a0patien ts\u00a0\ntreated\u00a0with\u00a0riociguat\u00a0for\u00a0chronic\u00a0thromboembolic\u00a0pulmonary\u00a0hyp er\u2010tension.\u00a0The\u00a0Lancet\u00a0Respiratory\u00a0Medicine\u00a0\n4(5):372\u2010380.\u00a0\n\u00a0\u00a0339\u00a04.22 Siltuximab\u00a0\nHandelsname:\u00a0Sylvant\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Castleman\u2010Krankheit\u00a0 \u00a0 Janssen\u2010Cilag\u00a0\nATC\u2010Code:\u00a0L04AC11\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02014\u00a0\u00a0\nDarreichungsform:\u00a0Pulver\u00a0zur\u00a0Herstellung\u00a0 \u00a0\neiner\u00a0Infusionsl\u00f6sung\u00a0 \u00a0 \u00a0 DDD:\u00a037\u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nSiltuximab\u00a0(Sylvant \u00ae)\u00a0ist\u00a0ein\u00a0chim\u00e4rer\u00a0(human\u2010murin)\u00a0monoklonaler\u00a0Antik\u00f6rper,\u00a0\nder\u00a0l\u00f6sliches\u00a0humanes\u00a0Interleukin\u20106\u00a0(IL\u20106)\u00a0spezifisch\u00a0und\u00a0mit\u00a0h oher\u00a0Affinit\u00e4t\u00a0bindet\u00a0\nund\u00a0dadurch\u00a0dessen\u00a0Interaktion\u00a0sowohl\u00a0mit\u00a0l\u00f6slichen\u00a0als\u00a0auch\u00a0mi t\u00a0membrange\u2010\nbundenen\u00a0humanen\u00a0IL\u20106\u2010Rezeptoren\u00a0verhindert\u00a0(Fachinformation\u00a0Sy lvant\u00ae,\u00a02016).\u00a0\nDas\u00a0entz\u00fcndungsf\u00f6rdernde\u00a0Zytokin\u00a0Interleukin\u20106\u00a0wird\u00a0von\u00a0verschi edenen\u00a0Zellty\u2010\npen,\u00a0vor\u00a0allem\u00a0des\u00a0Immunsystems,\u00a0produziert\u00a0und\u00a0ist\u00a0beteiligt\u00a0a n\u00a0einer\u00a0Vielzahl\u00a0\nphysiologischer\u00a0Prozesse,\u00a0wie\u00a0beis pielsweise\u00a0der\u00a0Teilung\u00a0und\u00a0Di fferenzierung\u00a0h\u00e4\u2010\nmatopoetischer\u00a0Vorl\u00e4uferzellen\u00a0sowie\u00a0von\u00a0B\u2010Zellen\u00a0(einschlie\u00dfli ch\u00a0ihrer\u00a0terminalen\u00a0\nDifferenzierung\u00a0und\u00a0Stimulation\u00a0vo n\u00a0IgM\u2010\u00a0und\u00a0IgG\u2010Synthese),\u00a0der \u00a0Differenzierung\u00a0\nvon\u00a0Nervenzellen,\u00a0der\u00a0Angiogenes e\u00a0und\u00a0der\u00a0Bildung\u00a0von\u00a0Akute\u2010Pha se\u2010Proteinen\u00a0in\u00a0\nder\u00a0Leber\u00a0(Chen\u00a0&\u00a0Chen,\u00a02015).\u00a0Erh\u00f6hte\u00a0IL\u20106\u00a0Spiegel\u00a0sind\u00a0nachwe isbar\u00a0sowohl\u00a0im\u00a0\nZusammenhang\u00a0mit\u00a0Infekten\u00a0und\u00a0Traumata\u00a0als\u00a0auch\u00a0bei\u00a0Autoimmun\u2010\u00a0 und\u00a0Tumor\u2010\nerkrankungen.\u00a0\nDas\u00a0Orphan\u2010Arzneimittel\u00a0ist\u00a0indiziert\u00a0zur\u00a0 Behandlung\u00a0von\u00a0erwachsenen\u00a0Pati enten\u00a0mit\u00a0\nmultizentrischer\u00a0Castleman\u2010Krankheit\u00a0( Multicentric\u00a0Castleman\u2018s\u00a0Disease ,\u00a0MCD),\u00a0die\u00a0\nHIV\u2010\u00a0und\u00a0HHV\u20108\u00a0(Humanes\u00a0Herpesvirus\u20108)\u2010negativ\u00a0sind.\u00a0\nDie\u00a0empfohlene\u00a0Dosis\u00a0betr\u00e4gt\u00a011\u00a0mg/kg\u00a0K\u00f6rpergewicht\u00a0(KG)\u00a0und\u00a0wi rd\u00a0als\u00a0intrave\u2010\nn\u00f6se\u00a0Infusion\u00a0in\u00a0dreiw\u00f6chigem\u00a0 Behandlungzyklus\u00a0verabreicht.\u00a0\u00a0\nIn\u00a0Deutschland\u00a0und\u00a0Europa\u00a0gab\u00a0es\u00a0bislang\u00a0keine\u00a0f\u00fcr\u00a0die\u00a0Indikati on\u00a0MCD\u00a0zugelasse\u2010\nnen\u00a0Arzneimittel.\u00a0Der\u00a0nicht\u00a0gege n\u00a0Interleukin\u20106\u00a0selbst,\u00a0sondern \u00a0gegen\u00a0den\u00a0IL\u20106\u2010\nRezeptor\u00a0gerichtete\u00a0monoklonale\u00a0 Antik\u00f6rper\u00a0Tocilizumab\u00a0(RoActem ra\u00ae)\u00a0wird\u00a0in\u00a0\nEuropa\u00a0seit\u00a02009\u00a0zur\u00a0Behandlung\u00a0der\u00a0Rheumatoiden\u00a0Arthritis\u00a0eing esetzt.\u00a0In\u00a0Japan\u00a0\nhat\u00a0der\u00a0Wirkstoff\u00a0schon\u00a0seit\u00a02005\u00a0eine\u00a0Zulassung\u00a0f\u00fcr\u00a0die\u00a0multiz entrische\u00a0Cast\u2010\nleman\u2010Krankheit;\u00a0in\u00a0Frankreich\u00a0wurde\u00a02014\u00a0der\u00a0 Off\u2010Label\u2010Gebrauch\u00a0bei\u00a0bestimm\u2010\nten\u00a0Formen\u00a0dieser\u00a0Erkrankung\u00a0genehmigt\u00a0(Prescrire,\u00a02016).\u00a0\nDie\u00a0 vom\u00a0 Hersteller\u00a0 gesponserte\u00a0 Zulassungsstudie\u00a0 (MCD2001)\u00a0 bei\u00a0 7 9\u00a0 MCD\u2010\nPatienten\u00a0ist\u00a0eine\u00a0multizentrisc he,\u00a0doppelblinde,\u00a02:1\u2010randomisi erte,\u00a0placebokon\u2010\ntrollierte\u00a0Phase\u2010II\u2010Studie,\u00a0die \u00a0zuvor\u00a0negativ\u00a0auf\u00a0HIV\u2010\u00a0und\u00a0HHV\u2010 8\u00a0getestet\u00a0wurden\u00a0340\u00a0(van\u00a0Rhee\u00a0et\u00a0al.,\u00a02014).\u00a0Alle\u00a0Pa tienten\u00a0erhielten\u00a0als\u00a0Basis\u00a0ein e\u00a0symptomatische\u00a0 Best\u2010\nSupportive\u2010Care \u00a0(BSC)\u2010Behandlung,\u00a0der\u00a0Verum\u2010Arm\u00a0 (n=53)\u00a0zus\u00e4tzlich\u00a0Siltuximab,\u00a0\nder\u00a0 Vergleichsarm\u00a0 (n=26)\u00a0 eine\u00a0 Placebo\u2010Infusion.\u00a0 Bei\u00a0 Therapiever sagen\u00a0 wurde\u00a0\nentblindet,\u00a0danach\u00a0war\u00a0ein\u00a0 Crossover \u00a0vom\u00a0Placebo\u2010\u00a0in\u00a0den\u00a0Verum\u2010Arm\u00a0m\u00f6glich.\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0das\u00a0dauerha fte\u00a0Ansprechen\u00a0der\u00a0Tumore\u00a0der\u00a0 Lymphknoten\u00a0\nund\u00a0der\u00a0Symptome\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mindestens\u00a018\u00a0Wochen\u00a0o hne\u00a0ein\u00a0\nTherapieversagen.\u00a0Sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0unter\u00a0anderem\u00a0die\u00a0Z eit\u00a0bis\u00a0zum\u00a0\nTherapieversagen,\u00a0das\u00a0Gesamt\u00fcberl eben\u00a0nach\u00a0einem\u00a0Jahr,\u00a0die\u00a0Verb esserung\u00a0der\u00a0\nSymptome\u00a0sowie\u00a0die\u00a0Vertr\u00e4glichkeit.\u00a0Die\u00a0Ver\u00e4nderung\u00a0der\u00a0gesundh eitsbezogenen\u00a0\nLebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurde\u00a0mittels\u00a0der\u00a0k\u00f6rperli\u2010\nchen\u00a0und\u00a0der\u00a0psychischen\u00a0Summens kala\u00a0des\u00a0Gesundheitsfragebogens \u00a0SF\u201036\u00a0er\u2010\nfasst.\u00a0W\u00e4hrend\u00a0in\u00a0der\u00a0Placebogruppe\u00a0kein\u00a0Ansprechen\u00a0festgestell t\u00a0werden\u00a0konnte,\u00a0\nsprachen\u00a018\u00a0der\u00a053\u00a0Patienten\u00a0bzw.\u00a034\u00a0%\u00a0im\u00a0Siltuximab\u2010Arm\u00a0dauerh aft\u00a0auf\u00a0die\u00a0\nBehandlung\u00a0 an.\u00a0 Die\u00a0 mittlere\u00a0 Zeit\u00a0 bis\u00a0 zum\u00a0 Therapieversagen\u00a0 lag\u00a0 i n\u00a0 der\u00a0 Place\u2010\nbogruppe\u00a0bei\u00a0134\u00a0Tagen;\u00a0in\u00a0der\u00a0Verumgruppe\u00a0wurde\u00a0dieser\u00a0sekund\u00e4 re\u00a0Endpunkt\u00a0\nim\u00a0Beobachtungszeitraum\u00a0nicht\u00a0erreicht.\u00a0Der\u00a0Median\u00a0des\u00a0Gesamt\u00fcb erlebens\u00a0wur\u2010\nde\u00a0in\u00a0beiden\u00a0Gruppen\u00a0nicht\u00a0erreicht.\u00a0Die\u00a0H\u00e4lfte\u00a0der\u00a0Patienten\u00a0d er\u00a0Placebo\u2010Gruppe\u00a0\nwechselte\u00a0nach\u00a0Therapieversagen\u00a0in\u00a0den\u00a0Siltuximab\u2010Arm.\u00a0H\u00e4ufig\u00a0a uftretende,\u00a0aber\u00a0\nnicht\u00a0schwerwiegende\u00a0unerw\u00fcnscht e\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0 von\u00a0Siltuximab\u00a0\nwaren\u00a0Hautjucken,\u00a0Exanthem,\u00a0Infektionen\u00a0der\u00a0oberen\u00a0Atemwege\u00a0und \u00a0lokale\u00a0\u00d6de\u2010\nme.\u00a0 Die\u00a0 Rate\u00a0 der\u00a0 schwerwiegenden\u00a0 UAE\u00a0 (Grad\u00a0 \u2265\u00a0 3),\u00a0 z.B.\u00a0 Fatigue\u00a0 u nd\u00a0 Nacht\u2010\nschwei\u00df,\u00a0lag\u00a0im\u00a0Siltuximab\u2010Arm\u00a0nicht\u00a0h\u00f6her\u00a0als\u00a0im\u00a0Kontrollarm.\u00a0 Auch\u00a0bez\u00fcglich\u00a0der\u00a0\nFatigue\u00a0als\u00a0Symptom\u00a0mit\u00a0starkem\u00a0Einfluss\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t \u00a0gab\u00a0es\u00a0keinen\u00a0\nUnterschied\u00a0zwischen\u00a0beiden\u00a0Studienarmen.\u00a0Nach\u00a0dem\u00a0 Cut\u2010off\u00a0f\u00fcr\u00a0die\u00a0prim\u00e4re\u00a0\nAnalyse\u00a0konnten\u00a0Patienten\u00a0des\u00a0Siltuximab\u2010Arms\u00a0die\u00a0Therapie\u00a0in\u00a0d er\u00a0noch\u00a0laufen\u2010\nden\u00a0unkontrollierten\u00a0Extensionsst udie\u00a0MCD2002\u00a0zur\u00a0Langzeitbeoba chtung\u00a0fortset\u2010\nzen.\u00a0Zum\u00a0Zeitpunkt\u00a0der\u00a0Interimsan alyse\u00a0nach\u00a0einer\u00a0mittleren\u00a0Beh andlungsdauer\u00a0\nvon\u00a05\u00a0Jahren\u00a0erhielten\u00a0alle\u00a019\u00a0Patienten\u00a0weiterhin\u00a0ohne\u00a0Therapi eunterbrechung\u00a0\nSiltuximab\u00a0und\u00a0waren\u00a0rezidivfrei;\u00a0Hinweise\u00a0auf\u00a0eine\u00a0kumulative\u00a0 Toxizit\u00e4t\u00a0von\u00a0Siltu\u2010\nximab\u00a0gab\u00a0es\u00a0nicht\u00a0(van\u00a0Rhee\u00a0et\u00a0al.,\u00a02015).\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0konstatiert\u00a0einen\u00a0aufgrun d\u00a0der\u00a0unzu\u2010\nreichenden\u00a0 wissenschaftlichen\u00a0 Datenlage\u00a0 nicht\u00a0 quantifizierbaren\u00a0 Zusatznutzen \u00a0\n(G\u2010BA,\u00a02014).\u00a0Obwohl\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0\u201edauerhafte s\u00a0Ansprechen\u00a0\nvon\u00a0Tumor\u00a0und\u00a0Symptomen\u201c\u00a0ein\u00a0Vort eil\u00a0von\u00a0Siltuximab\u00a0zeigt,\u00a0bewe rtet\u00a0der\u00a0G\u2010BA\u00a0\nwegen\u00a0des\u00a0Fehlens\u00a0standardisierter\u00a0Remissionskriterien\u00a0f\u00fcr\u00a0MCD\u2010 Patienten\u00a0nicht\u00a0\ndas\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens.\u00a0Bei\u00a0den\u00a0von\u00a0Patienten\u00a0berichteten \u00a0Endpunkten\u00a0zur\u00a0\nVerbesserung\u00a0der\u00a0Symptome\u00a0zeigt\u00a0sich\u00a0kein\u00a0Unterschied\u00a0zwischen\u00a0 Verum\u2010\u00a0und\u00a0\nKontroll\u2010Arm,\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Verbesserung\u00a0der\u00a0HRQoL\u00a0ergibt\u00a0si ch\u00a0ein\u00a0geringer\u00a0\nVorteil\u00a0von\u00a0Siltuximab\u00a0nur\u00a0hinsichtlich\u00a0der\u00a0psychischen,\u00a0nicht\u00a0 aber\u00a0der\u00a0k\u00f6rperlichen\u00a0\nSymptomatik.\u00a0Eine\u00a0Aussage\u00a0zum\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0ist\u00a0nich t\u00a0m\u00f6glich,\u00a0da\u00a0341\u00a0zum\u00a0einen\u00a0bei\u00a0den\u00a0Ergebnissen\u00a0hinsichtlich\u00a0der\u00a0UAE\u00a0nicht\u00a0sicher \u00a0unterschieden\u00a0\nwerden\u00a0kann\u00a0zwischen\u00a0Krankheitssymptomen\u00a0und\u00a0unerw\u00fcnschten\u00a0Arzn eimitteler\u2010\neignissen.\u00a0Zum\u00a0anderen\u00a0ist\u00a0nicht\u00a0auszuschlie\u00dfen,\u00a0dass\u00a0aus\u00a0dem\u00a0D esign\u00a0der\u00a0Phase\u2010\nII\u2010Studie\u00a0\u2013\u00a0mit\u00a0der\u00a0M\u00f6glichkeit\u00a0eines\u00a0fr\u00fchen\u00a0 Crossover \u00a0in\u00a0den\u00a0Verum\u2010Arm\u00a0\u2013\u00a0eine\u00a0\nVerzerrung\u00a0der\u00a0Ergeb nisse\u00a0resultiert.\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0erster\u00a0zugelassener\u00a0\nWirkstoff\u00a0zur\u00a0\nBehandlung\u00a0der\u00a0\nmultizentrischen\u00a0\nCastleman\u2010Krankheit\u00a0unklare\u00a0Datenlage;\u00a0\nVergleich\u00a0nur\u00a0gegen\u00fcber\u00a0\nPlacebo\u00a0und\u00a0nicht\u00a0\ngegen\u00fcber\u00a0anderen\u00a0\nremissionsinduzierenden\u00a0\nTherapieformen\u00a0kein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0 possibly\u00a0helpful\u00a0 \u2013\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel\u00a0 \u00a0\u00a0 \u00a0 \u00a0\nSiltuximab\u00a0 11\u00a0mg/kg\u00a0KG\u00a0alle\u00a0drei\u00a0\nWochen\u00a017,38\u00a0 87.695,25\u00a0\u20ac\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0wurden\u00a0keine\u00a0Versorgu ngsanalysen\u00a0\nvon\u00a0Siltuximab\u00a0erstellt.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nSiltuximab\u00a0ist\u00a0ein\u00a0rekombinanter\u00a0chim\u00e4rer\u00a0(human\u2010muriner)\u00a0monok lonaler\u00a0Anti\u2010\nk\u00f6rper,\u00a0der\u00a0l\u00f6sliches\u00a0humanes\u00a0IL\u2010 6\u00a0spezifisch\u00a0und\u00a0mit\u00a0hoher\u00a0Aff init\u00e4t\u00a0bindet\u00a0und\u00a0\ndadurch\u00a0dessen\u00a0Interaktion\u00a0sowohl\u00a0mit\u00a0l\u00f6slichen\u00a0als\u00a0auch\u00a0mit\u00a0me mbrangebunde\u2010\nnen\u00a0humanen\u00a0IL\u20106\u2010Rezeptoren\u00a0verhindert\u00a0(Fachinformation\u00a0Sylvant \u00ae,\u00a02016).\u00a0IL\u20106\u00a0\nist\u00a0ein\u00a0pleiotrop\u00a0wirksames\u00a0entz\u00fcndungsf\u00f6rderndes\u00a0Zytokin,\u00a0das\u00a0 von\u00a0verschiede\u2010\nnen\u00a0Zelltypen\u00a0produziert\u00a0wird,\u00a0darunter\u00a0T\u2010Zellen,\u00a0B\u2010Zellen,\u00a0Lym phozyten,\u00a0Monozy\u2010\nten,\u00a0Fibroblasten\u00a0sowie\u00a0entartete\u00a0Zellen.\u00a0Es\u00a0ist\u00a0beteiligt\u00a0an\u00a0e iner\u00a0Vielzahl\u00a0physiolo\u2010\n342\u00a0gischer\u00a0Prozesse\u00a0wie\u00a0beispielswe ise\u00a0der\u00a0Teilung\u00a0und\u00a0Differenzie rung\u00a0h\u00e4matopoeti\u2010\nscher\u00a0Vorl\u00e4uferzellen\u00a0sowie\u00a0von\u00a0 B\u2010Zellen\u00a0(einschlie\u00dflich\u00a0ihrer\u00a0 terminalen\u00a0Differen\u2010\nzierung\u00a0und\u00a0Stimulation\u00a0der\u00a0Sekretion\u00a0von\u00a0Antik\u00f6rpern),\u00a0der\u00a0Dif ferenzierung\u00a0von\u00a0\nNervenzellen,\u00a0der\u00a0Angiogenese\u00a0und\u00a0der\u00a0Bildung\u00a0hepatischer\u00a0Akute \u2010Phase\u2010Proteine\u00a0\n(Chen\u00a0&\u00a0Chen,\u00a02015).\u00a0Erh\u00f6hte\u00a0IL\u20106\u00a0Spiegel\u00a0sind\u00a0nachweisbar\u00a0sowo hl\u00a0im\u00a0Zusam\u2010\nmenhang\u00a0mit\u00a0Infekten\u00a0und\u00a0Traumata \u00a0als\u00a0auch\u00a0bei\u00a0Autoimmun\u2010\u00a0und\u00a0T umorerkran\u2010\nkungen.\u00a0 Weil\u00a0 IL\u20106\u00a0 die\u00a0 Akute\u2010Phasen\u2010Expression\u00a0 des\u00a0 C\u2010reaktiven\u00a0 P roteins\u00a0 (CRP)\u00a0\nstimuliert,\u00a0f\u00fchrt\u00a0die\u00a0Behandlung\u00a0mit\u00a0Siltuximab\u00a0zu\u00a0einer\u00a0messba ren\u00a0Suppression\u00a0\nder\u00a0CRP\u2010Serumkonzentration.\u00a0\nDer\u00a0nicht\u00a0gegen\u00a0IL\u20106\u00a0selbst,\u00a0so ndern\u00a0gegen\u00a0den\u00a0IL\u20106\u2010Rezeptor\u00a0ge richtete\u00a0monoklo\u2010\nnale\u00a0Antik\u00f6rper\u00a0Tocilizumab\u00a0des\u00a0 japanischen\u00a0Pharmaunternehmens\u00a0 CHUGAI\u00a0wird\u00a0\nin\u00a0Europa\u00a0unter\u00a0dem\u00a0Namen\u00a0RoActemra\u00ae\u00a0seit\u00a02009\u00a0zur\u00a0Behandlung\u00a0d er\u00a0Rheumato\u2010\niden\u00a0Arthritis\u00a0eingesetzt.\u00a0In\u00a0Japan\u00a0hat\u00a0der\u00a0Wirkstoff\u00a0schon\u00a0sei t\u00a02005\u00a0eine\u00a0Zulassung\u00a0\nf\u00fcr\u00a0die\u00a0MCD,\u00a0in\u00a0Frankreich\u00a0wurde\u00a02014\u00a0der\u00a0 Off\u2010Label\u2010Gebrauch\u00a0bei\u00a0bestimmten\u00a0\nFormen\u00a0dieser\u00a0Erkrankung\u00a0genehmigt\u00a0(Prescrire,\u00a02016).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nSiltuximab\u00a0ist\u00a0indiziert\u00a0zur\u00a0Behandlung\u00a0von\u00a0erwachsenen\u00a0Patient en,\u00a0die\u00a0sowohl\u00a0\nHIV\u2010\u00a0als\u00a0auch\u00a0HHV\u20108\u2010negativ\u00a0sind.\u00a0Da\u00a0es\u00a0nur\u00a0wenige\u00a0Patienten\u00a0mi t\u00a0dieser\u00a0Erkran\u2010\nkung\u00a0gibt,\u00a0wurde\u00a0der\u00a0Wirkstoff\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0ausgewiesen.\u00a0\nDie\u00a0empfohlene\u00a0Dosis\u00a0betr\u00e4gt\u00a011\u00a0mg/kg\u00a0KG\u00a0und\u00a0wird\u00a0als\u00a0intraven\u00f6 se\u00a0Infusion\u00a0\u00fcber\u00a0\neinen\u00a0Zeitraum\u00a0von\u00a0etwa\u00a0einer\u00a0Stunde\u00a0verabreicht.\u00a0Der\u00a0dreiw\u00f6chi ge\u00a0Behandlungs\u2010\nzyklus\u00a0wird\u00a0wiederholt,\u00a0bis\u00a0der\u00a0Patient\u00a0keinen\u00a0Nutzen\u00a0mehr\u00a0aus\u00a0 der\u00a0Behandlung\u00a0\nzieht.\u00a0\u00a0\nW\u00e4hrend\u00a0der\u00a0ersten\u00a0zw\u00f6lf\u00a0Monate\u00a0der\u00a0Behandlung\u00a0und\u00a0danach\u00a0bei\u00a0j edem\u00a0dritten\u00a0\nBehandlungszyklus\u00a0sollten\u00a0als\u00a0Therapievoraussetzung\u00a0vor\u00a0jeder\u00a0G abe\u00a0die\u00a0Neutro\u2010\nphilen\u2010\u00a0und\u00a0die\u00a0Thrombozytenzahl\u00a0 sowie\u00a0der\u00a0H\u00e4moglobinwert\u00a0besti mmt\u00a0werden,\u00a0\ndie\u00a0in\u00a0der\u00a0Fachinformation\u00a0vorge gebene\u00a0Werte\u00a0nicht\u00a0unter\u2010\u00a0bzw.\u00a0 \u00fcberschreiten\u00a0\nd\u00fcrfen.\u00a0Vor\u00a0einer\u00a0Behandlung\u00a0mit\u00a0Siltuximab\u00a0sollten\u00a0Infektionen ,\u00a0auch\u00a0lokale,\u00a0be\u2010\nhandelt\u00a0werden,\u00a0da\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0schwerwiegende\u00a0Inf ektionen,\u00a0ein\u2010\nschlie\u00dflich\u00a0Pneumonie\u00a0und\u00a0Seps is,\u00a0auftraten\u00a0(EMA,\u00a02017).\u00a0\nSiltuximab\u00a0unterliegt\u00a0einer\u00a0zus\u00e4tzlichen\u00a0\u00dcberwachung.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Castleman\u2010Krankheit\u00a0( Castleman\u2010Disease ,\u00a0CD)\u00a0ist\u00a0eine\u00a0seltene\u00a0lymphoprolifera\u2010\ntive\u00a0Erkrankung,\u00a0deren\u00a0Symptome\u00a0recht\u00a0unspezifisch\u00a0sind\u00a0und\u00a0den en\u00a0des\u00a0multiplen\u00a0\nMyeloms\u00a0 und\u00a0 anderer\u00a0 lymphatischer\u00a0 Systemerkrankungen\u00a0 \u00e4hneln.\u00a0 Si e\u00a0 kann\u00a0 in\u00a0343\u00a0jedem\u00a0Alter\u00a0auftreten.\u00a0Da\u00a0die\u00a0Erkrankung\u00a0keine\u00a0Kodierung\u00a0nach\u00a0d er\u00a0ICD\u201010\u2010Klassi\u2010\nfikation\u00a0aufweist\u00a0und\u00a0in\u00a0keinem\u00a0Krebsregister\u00a0aufgef\u00fchrt\u00a0wird,\u00a0 ist\u00a0die\u00a0Datenlage\u00a0\nzur\u00a0Inzidenz\u00a0sehr\u00a0d\u00fcnn;\u00a0die\u00a0Pr\u00e4va lenz\u00a0f\u00fcr\u00a0die\u00a0multizentrische\u00a0F orm\u00a0wird\u00a0auf\u00a0weni\u2010\nger\u00a0als\u00a01:100.000\u00a0gesch\u00e4tzt\u00a0(Pre scrire,\u00a02016).\u00a0Bei\u00a0der\u00a0erstmals \u00a01954\u00a0von\u00a0dem\u00a0Pa\u2010\nthologen\u00a0Dr.\u00a0Benjamin\u00a0Castleman\u00a0 beschriebenen\u00a0angiofollikul\u00e4ren \u00a0Lymphknoten\u2010\nhyperplasie\u00a0sind\u00a0zwei\u00a0Formen\u00a0zu\u00a0unterscheiden.\u00a0Die\u00a0lokalisierte \u00a0bzw.\u00a0unizentrische\u00a0\nForm\u00a0(UCD)\u00a0tritt\u00a0\u00fcberwiegend\u00a0bei\u00a0jungen\u00a0Erwachsenen\u00a0auf\u00a0und\u00a0bet rifft\u00a0nur\u00a0einen\u00a0\neinzelnen\u00a0Bereich\u00a0oder\u00a0eine\u00a0einzelne\u00a0Gruppe\u00a0von\u00a0Lymphknoten,\u00a0h\u00e4 ufig\u00a0im\u00a0Medias\u2010\ntinum\u00a0oder\u00a0im\u00a0Mesenteriem.\u00a0Bei\u00a0de r\u00a0disseminierten\u00a0bzw.\u00a0multizen trischen\u00a0Form,\u00a0\ndie\u00a0etwa\u00a030\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0ausmacht\u00a0und\u00a0sich\u00a0in\u00a0einem\u00a0mittleren\u00a0Al ter\u00a0von\u00a050\u00a0bis\u00a065\u00a0\nJahren\u00a0manifestiert,\u00a0sind\u00a0zahlreiche\u00a0Lymphknoten\u00a0in\u00a0verschieden en\u00a0anatomischen\u00a0\nBereichen\u00a0sowie\u00a0meistens\u00a0Milz\u00a0und\u00a0 Leber\u00a0vergr\u00f6\u00dfert\u00a0(Dispenzieri \u00a0et\u00a0al.,\u00a02012).\u00a0Das\u00a0\nklinische\u00a0Bild\u00a0ist\u00a0vielf\u00e4ltig,\u00a0neben\u00a0Fatigue\u00a0und\u00a0den\u00a0sogenannte n\u00a0B\u2010Symptomen\u00a0\nFieber,\u00a0Nachtschwei\u00df\u00a0und\u00a0Gewichtsverlust\u00a0k\u00f6nnen\u00a0\u00dcbelkeit\u00a0und\u00a0Er brechen,\u00a0\u00d6de\u2010\nme,\u00a0Hautausschl\u00e4ge,\u00a0Husten,\u00a0peri phere\u00a0Neuropathien,\u00a0Nierenfunkt ionsst\u00f6rungen,\u00a0\nAn\u00e4mie,\u00a0Leukozytopenie,\u00a0Thrombozytopenie\u00a0und\u00a0erh\u00f6hte\u00a0Entz\u00fcndung sparameter\u00a0\n(z.B.\u00a0CRP\u2010Wert)\u00a0auftreten.\u00a0Patho physiologisch\u00a0spielt\u00a0die\u00a0\u00dcberpr oduktion\u00a0von\u00a0Zyto\u2010\nkinen\u00a0(u.a.\u00a0IL\u20106)\u00a0in\u00a0den\u00a0hyperplastischen\u00a0Lymphknoten\u00a0eine\u00a0gro\u00df e\u00a0Rolle.\u00a0Virusinfek\u2010\ntionen,\u00a0insbesondere\u00a0mit\u00a0HIV,\u00a0si nd\u00a0ein\u00a0wichtiger\u00a0Risikofaktor\u00a0f \u00fcr\u00a0die\u00a0multizentri\u2010\nsche\u00a0Verlaufsform.\u00a0Bei\u00a0nahezu\u00a0a llen\u00a0HIV\u2010positiven\u00a0Patienten\u00a0mit \u00a0MCD\u00a0findet\u00a0man\u00a0\nden\u00a0HHV\u20108,\u00a0dem\u00a0eine\u00a0Schl\u00fcsselfunktion\u00a0als\u00a0Trigger\u00a0der\u00a0Krankheit \u00a0zugeschrieben\u00a0\nwird\u00a0und\u00a0der\u00a0auch\u00a0bei\u00a0etwa\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0Erkrankungen\u00a0bei\u00a0HIV\u2010 negativen\u00a0Erkran\u2010\nkungen\u00a0beteiligt\u00a0ist.\u00a0Allerdings \u00a0sind\u00a0die\u00a0meisten\u00a0MCD\u2010Patienten \u00a0sowohl\u00a0HIV\u2010\u00a0als\u00a0\nauch\u00a0HHV\u20108\u2010negativ;\u00a0bei\u00a0ihnen\u00a0is t\u00a0die\u00a0\u00c4tiologie\u00a0der\u00a0Krankheit\u00a0u nbekannt,\u00a0weshalb\u00a0\nman\u00a0hier\u00a0von\u00a0der\u00a0idiopathischen\u00a0MCD\u00a0spricht.\u00a0\nDer\u00a0Verlauf\u00a0ist\u00a0sehr\u00a0unterschi edlich\u00a0und\u00a0kann\u00a0\u00fcber\u00a0Jahre\u00a0indole nt,\u00a0schubweise\u00a0\noder\u00a0schnell\u00a0und\u00a0aggressiv\u00a0sein.\u00a0Etwa\u00a0ein\u00a0Viertel\u00a0der\u00a0Patienten \u00a0stirbt\u00a0innerhalb\u00a0\neines\u00a0Jahres\u00a0nach\u00a0Diagnosestell ung,\u00a0die\u00a0mittlere\u00a0\u00dcberlebenszeit \u00a0betr\u00e4gt\u00a02,5\u00a0Jahre\u00a0\n(Prescrire,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0vom\u00a0Hersteller\u00a0gesponserte\u00a0 Zulassungsstudie\u00a0MCD2001\u00a0ist\u00a0ein e\u00a0multizentri\u2010\nsche,\u00a0doppelblinde,\u00a02:1\u2010randomis ierte,\u00a0placebokontrollierte\u00a0Pha se\u2010II\u2010Studie\u00a0mit\u00a079\u00a0\nMCD\u2010Patienten,\u00a0die\u00a0zuvor\u00a0negativ\u00a0auf\u00a0HIV\u2010\u00a0und\u00a0HHV\u20108\u00a0getestet\u00a0wu rden\u00a0(van\u00a0Rhee\u00a0\net\u00a0 al.,\u00a0 2014).\u00a0 Alle\u00a0 Patienten\u00a0 erhielten\u00a0 als\u00a0 Basis\u00a0 eine\u00a0 symptoma tische\u00a0 BSC\u2010\nBehandlung,\u00a0 der\u00a0 Verum\u2010Arm\u00a0 (n=53)\u00a0 zus\u00e4tzlich\u00a0 Siltuximab,\u00a0 der\u00a0 Ver gleichsarm\u00a0\n(n=26)\u00a0eine\u00a0Placebo\u2010Infusion.\u00a0Bei\u00a0Therapieversagen\u00a0wurde\u00a0entbli ndet,\u00a0danach\u00a0war\u00a0\nein\u00a0Crossover \u00a0vom\u00a0Placebo\u2010\u00a0in\u00a0den\u00a0Verum\u2010Arm\u00a0m \u00f6glich.\u00a0Als\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0w ar\u00a0\ndas\u00a0dauerhafte\u00a0Ansprechen\u00a0der\u00a0Tumore\u00a0der\u00a0Lymphknoten\u00a0und\u00a0der\u00a0Sy mptome\u00a0\n\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mindestens\u00a018\u00a0Wochen\u00a0ohne\u00a0ein\u00a0Therapiev ersagen\u00a0defi\u2010344\u00a0niert,\u00a0sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0unter\u00a0anderem\u00a0die\u00a0Zeit\u00a0bis\u00a0zum \u00a0Therapieversa\u2010\ngen,\u00a0das\u00a0OS\u00a0nach\u00a0einem\u00a0Jahr,\u00a0die\u00a0Verbesserung\u00a0der\u00a0Symptome\u00a0sowi e\u00a0die\u00a0Vertr\u00e4g\u2010\nlichkeit.\u00a0Die\u00a0Ver\u00e4nderung\u00a0der\u00a0HRQoL\u00a0wurde\u00a0mittels\u00a0der\u00a0k\u00f6rperlic hen\u00a0und\u00a0der\u00a0psy\u2010\nchischen\u00a0Summenskala\u00a0des\u00a0Gesundheitsfragebogens\u00a0SF\u201036\u00a0erfasst.\u00a0 W\u00e4hrend\u00a0in\u00a0der\u00a0\nPlacebogruppe\u00a0kein\u00a0Ansprechen\u00a0festgestellt\u00a0werden\u00a0konnte,\u00a0sprac hen\u00a018\u00a0der\u00a053\u00a0\nPatienten\u00a0bzw.\u00a034\u00a0%\u00a0im\u00a0Siltuximab\u2010Arm\u00a0dauerhaft\u00a0auf\u00a0die\u00a0Behandl ung\u00a0an.\u00a0Die\u00a0\nmittlere\u00a0Zeit\u00a0bis\u00a0zum\u00a0Therapieversagen\u00a0lag\u00a0in\u00a0der\u00a0Placebogruppe \u00a0bei\u00a0134\u00a0Tagen;\u00a0in\u00a0\nder\u00a0Verumgruppe\u00a0wurde\u00a0dieser\u00a0sekund\u00e4re\u00a0Endpunkt\u00a0im\u00a0Beobachtungs zeitraum\u00a0\nnicht\u00a0erreicht.\u00a0Der\u00a0Median\u00a0des\u00a0Gesamt\u00fcberlebens\u00a0wurde\u00a0in\u00a0beiden \u00a0Gruppen\u00a0nicht\u00a0\nerreicht.\u00a0Die\u00a0H\u00e4lfte\u00a0der\u00a0Patient en\u00a0der\u00a0Placebo\u2010Gruppe\u00a0wechselte \u00a0nach\u00a0Therapie\u2010\nversagen\u00a0in\u00a0den\u00a0Siltuximab\u2010Arm.\u00a0H\u00e4ufig\u00a0auftretende,\u00a0aber\u00a0nicht\u00a0 schwerwiegende\u00a0\nUAE\u00a0von\u00a0Siltuximab\u00a0waren\u00a0Hautjuc ken,\u00a0Exanthem,\u00a0Infektionen\u00a0der\u00a0 oberen\u00a0Atem\u2010\nwege\u00a0und\u00a0lokale\u00a0\u00d6deme.\u00a0Die\u00a0Rate\u00a0d er\u00a0schwerwiegenden\u00a0UAE\u00a0(Grad\u00a0\u2265 \u00a03),\u00a0z.B.\u00a0Fati\u2010\ngue\u00a0und\u00a0Nachtschwei\u00df,\u00a0lag\u00a0im\u00a0Siltuximab\u2010Arm\u00a0nicht\u00a0h\u00f6her\u00a0als\u00a0im\u00a0 Kontrollarm.\u00a0\nAuch\u00a0bez\u00fcglich\u00a0der\u00a0Fatigue\u00a0als\u00a0do minierendem\u00a0MCD\u2010Symptom\u00a0mit\u00a0st arkem\u00a0Ein\u2010\nfluss\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0gab\u00a0es\u00a0keinen\u00a0Unterschied\u00a0zwischen \u00a0beiden\u00a0Studien\u2010\narmen.\u00a0Nach\u00a0dem\u00a0 Cut\u2010off\u00a0f\u00fcr\u00a0die\u00a0prim\u00e4re\u00a0Analyse\u00a0konnten\u00a0Patienten\u00a0des\u00a0Siltuxi\u2010\nmab\u2010Arms\u00a0die\u00a0Therapie\u00a0in\u00a0der\u00a0noch\u00a0laufenden\u00a0unkontrollierten\u00a0Ex tensionsstudie\u00a0\nMCD2002\u00a0zur\u00a0Langzeitbeobachtung\u00a0fortsetzen.\u00a0Zum\u00a0Zeitpunkt\u00a0der\u00a0I nterimsanalyse\u00a0\nnach\u00a0einer\u00a0mittleren\u00a0Behandlungsd auer\u00a0von\u00a0f\u00fcnf\u00a0Jahren\u00a0erhielten \u00a0alle\u00a019\u00a0Patienten\u00a0\nweiterhin\u00a0ohne\u00a0Therapieunterbrechung\u00a0Siltuximab\u00a0und\u00a0waren\u00a0rezid ivfrei,\u00a0Hinweise\u00a0\nauf\u00a0eine\u00a0kumulative\u00a0Toxizit\u00e4t\u00a0vo n\u00a0Siltuximab\u00a0gab\u00a0es\u00a0nicht\u00a0(van\u00a0 Rhee\u00a0et\u00a0al.,\u00a02015).\u00a0\nKlinische,\u00a0zum\u00a0Teil\u00a0noch\u00a0laufende\u00a0Phase\u00a0II\u2010Studien\u00a0gibt\u00a0es\u00a0auch \u00a0in\u00a0anderen\u00a0Anwen\u2010\ndungsgebieten\u00a0 wie\u00a0 Multiples\u00a0 Myelom,\u00a0 Prostatakarzinom\u00a0 und\u00a0 Nieren karzinom,\u00a0\njedoch\u00a0ist\u00a0die\u00a0Datenlage\u00a0zur\u00a0Einsch\u00e4tzung\u00a0des\u00a0Nutzens\u00a0und\u00a0Schad ens\u00a0von\u00a0Siltuxi\u2010\nmab\u00a0hier\u00a0widerspr\u00fcchlich\u00a0und\u00a0unzureichend\u00a0(Chen\u00a0&\u00a0Chen,\u00a02015).\u00a0\nLeitlinienempfehlungen\u00a0\nBei\u00a0der\u00a0unizentrischen\u00a0Form\u00a0kann\u00a0 der\u00a0erkrankte\u00a0Lymphknoten\u00a0bzw. \u00a0die\u00a0Raumfor\u2010\nderung\u00a0in\u00a0der\u00a0Regel\u00a0vollst\u00e4ndig\u00a0und\u00a0kurativ\u00a0chirurgisch\u00a0entfern t\u00a0werden.\u00a0F\u00fcr\u00a0die\u00a0\nmultizentrische\u00a0Form\u00a0ist\u00a0ein\u00a0allgemein\u00a0anerkannter\u00a0Therapiestan dard\u00a0bisher\u00a0nicht\u00a0\netabliert,\u00a0klinische\u00a0Behandlungsleitlinien\u00a0fehlen\u00a0(van\u00a0Rhee\u00a0et\u00a0 al,\u00a02014).\u00a0Mit\u00a0einer\u00a0\nKombination\u00a0aus\u00a0antientz\u00fcndlichen\u00a0und\u00a0immunsuppressiven\u00a0Medikam enten\u00a0(z.B.\u00a0\nKortikosteroide),\u00a0Lymphom\u2010wirksa mer\u00a0Chemo\u2010\u00a0bzw.\u00a0Chemoimmunthera pie\u00a0(z.B.\u00a0\nCHOP\u00a0 (Cyclophosphamid,\u00a0 Doxorubici n , \u00a0V i n c r i s t i n , \u00a0P r e d n i s o n ) , \u00a0R i t uximab)\u00a0 und\u00a0\nmonoklonalen\u00a0 Antik\u00f6rpern\u00a0 zur\u00a0 Blockade\u00a0 des\u00a0 IL\u20106\u2010Signalwegs\u00a0 (z.B. \u00a0 Tocilizumab)\u00a0\nwird\u00a0versucht,\u00a0die\u00a0Masse\u00a0der\u00a0Lymphknoten\u00a0zu\u00a0reduzieren\u00a0und\u00a0sowo hl\u00a0eine\u00a0Symp\u2010\ntomlinderung\u00a0als\u00a0auch\u00a0eine\u00a0Remission\u00a0zu\u00a0erzielen.\u00a0In\u00a0Deutschlan d\u00a0und\u00a0Europa\u00a0gibt\u00a0\nes\u00a0bislang\u00a0keine\u00a0f\u00fcr\u00a0die\u00a0Indikati on\u00a0MCD\u00a0zugelassenen\u00a0Arzneimitt el.\u00a0345\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0hat\u00a0bei\u00a0Siltuximab\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznut\u2010\nzens\u00a0auf\u00a0der\u00a0Basis\u00a0der\u00a0Zulassungsstudie\u00a0MCD2001\u00a0bewertet\u00a0und\u00a0ko nstatiert\u00a0einen\u00a0\naufgrund\u00a0der\u00a0unzureichenden\u00a0wissenschaftlichen\u00a0Datenlage\u00a0nicht\u00a0 quantifizierba\u2010\nren\u00a0Zusatznutzen\u00a0(G\u2010BA,\u00a02014).\u00a0Obwohl\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0prim\u00e4ren\u00a0End punkt\u00a0\u201edauer\u2010\nhaftes\u00a0Ansprechen\u00a0von\u00a0Tumor\u00a0und\u00a0Symptomen\u201c\u00a0ein\u00a0Vorteil\u00a0von\u00a0Silt uximab\u00a0zeigt,\u00a0\nbewertet\u00a0der\u00a0G\u2010BA\u00a0wegen\u00a0des\u00a0Fehlens\u00a0standardisierter\u00a0Remissions kriterien\u00a0f\u00fcr\u00a0\nMCD\u2010Patienten\u00a0nicht\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens.\u00a0Bei\u00a0den\u00a0von\u00a0P atienten\u00a0be\u2010\nrichteten\u00a0Endpunkten\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Symptome\u00a0zeigt\u00a0sich\u00a0k ein\u00a0Unterschied\u00a0\nzwischen\u00a0Verum\u2010\u00a0und\u00a0Kontroll\u2010Arm ,\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Verbesserung \u00a0der\u00a0Lebensqua\u2010\nlit\u00e4t\u00a0ergibt\u00a0sich\u00a0ein\u00a0geringer\u00a0Vorteil\u00a0von\u00a0Siltuximab\u00a0nur\u00a0hinsi chtlich\u00a0der\u00a0psychi\u2010\nschen,\u00a0nicht\u00a0aber\u00a0der\u00a0k\u00f6rperlichen\u00a0Symptomatik.\u00a0Eine\u00a0Aussage\u00a0zu m\u00a0Ausma\u00df\u00a0des\u00a0\nZusatznutzens\u00a0ist\u00a0nicht\u00a0m\u00f6glich,\u00a0da\u00a0zum\u00a0einen\u00a0bei\u00a0den\u00a0Ergebniss en\u00a0hinsichtlich\u00a0der\u00a0\nUAE\u00a0nicht\u00a0sicher\u00a0unterschieden\u00a0werden\u00a0kann\u00a0zwischen\u00a0Krankheitss ymptomen\u00a0und\u00a0\nunerw\u00fcnschten\u00a0Nebenwirkungen.\u00a0Zum\u00a0anderen\u00a0ist\u00a0nicht\u00a0auszuschlie \u00dfen,\u00a0dass\u00a0aus\u00a0\ndem\u00a0Design\u00a0der\u00a0Phase\u2010II\u2010Studie\u00a0mi t\u00a0der\u00a0M\u00f6glichkeit\u00a0eines\u00a0fr\u00fchen \u00a0Crossover \u00a0in\u00a0den\u00a0\nVerum\u2010Arm\u00a0eine\u00a0Verzerrung\u00a0resultiert.\u00a0\nQuellen\u00a0\nChen\u00a0R,\u00a0Chen\u00a0B\u00a0(2015).\u00a0 Siltuximab\u00a0(CNTO\u00a0328):\u00a0a\u00a0promising\u00a0optio n\u00a0for\u00a0human\u00a0malignancies.\u00a0Drug\u00a0Des\u00a0Devel\u00a0Ther\u00a09:\u00a03455\u20103458.\u00a0\nDispenzieri\u00a0A,\u00a0Armitage\u00a0JO,\u00a0Loe\u00a0 MJ,\u00a0Geyer\u00a0SM,\u00a0Allred\u00a0J,\u00a0Camoria no\u00a0JK\u00a0et\u00a0al.\u00a0(2012).\u00a0The\u00a0clinical\u00a0spectrum\u00a0of\u00a0Castleman\u2019s\u00a0disea se.\u00a0Am\u00a0\nJ\u00a0Hematol\u00a087(11):\u00a0997\u20101002.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2017).\u00a0Find\u00a0medicine\u00a0\u2010\u00a0Sylvant \u00a0\u2010\u00a0siltuximab.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/003708/human_med_001769.jsp&m\nid=WC0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a023.03.2017.\u00a0\nFachinformation\u00a0Sylvant\u00ae(2016).\u00a0 FachInfo\u2010Service.\u00a0www.fachinfo. de/suche/sylvant,\u00a0letzter\u00a0Zugriff:\u00a016.03.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Siltuximab.\u00a0www.g\u2010\nba.de/informationen/nutzenbewertung/122/#tab/nutzenbewertung,\u00a0l etzter\u00a0Zugriff:\u00a030.03.2017.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0New\u00a0Products.\u00a0Siltuximab\u00a0(Sylva nt\u00ae)\u00a0Prescrire\u00a0Int.\u00a025\u00a0(169):\u00a061\u201064.\u00a0\u00a0\nvan\u00a0Rhee\u00a0F,\u00a0Casper\u00a0C,\u00a0Voorhees\u00a0PM,\u00a0Fayad\u00a0LE,\u00a0van\u00a0de\u00a0Velde\u00a0H,\u00a0Ve rmeulen\u00a0J\u00a0et\u00a0al.\u00a0(2015).\u00a0A\u00a0phase\u00a02,\u00a0open\u2010label,\u00a0multicenter\u00a0stu dy\u00a0\nof\u00a0the\u00a0long\u2010term\u00a0safety\u00a0of\u00a0siltuximab\u00a0(an\u00a0anti\u2010interleukin\u20106\u00a0mo noclonal\u00a0antibody)\u00a0in\u00a0pati ents\u00a0with\u00a0multicentric\u00a0\nCastleman\u00a0disease.\u00a0Oncotarget\u00a06(30):\u00a0408\u2010419.\u00a0\u00a0\nvan\u00a0Rhee\u00a0F,\u00a0Wong\u00a0RS,\u00a0Munshi\u00a0N,\u00a0Rossi\u00a0JF,\u00a0Ke\u00a0XY,\u00a0Foss\u00e5\u00a0A\u00a0et\u00a0al.\u00a0 (2014).\u00a0Siltuximab\u00a0for\u00a0multicentric\u00a0Castleman\u2019s\u00a0disease:\u00a0a\u00a0\nrandomised,\u00a0double\u2010blind,\u00a0placebo\u2010controlled\u00a0trial.\u00a0Lancet\u00a0Onco l\u00a015(9):\u00a0966\u2010974.\u00a0\u00a0\n\u00a0 \u00a0346\u00a04.23 Simeprevir\u00a0\nHandelsname \u00a0Olysio\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0 Janssen\u00a0Cilag\u00a0\nATC\u2010Code:\u00a0J05AE14\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a001.06.2014\u00a0\nDarreichungsform:\u00a0Hartkaps eln\u00a0 \u00a0 DDD:\u00a00,15\u00a0g\u00a0oral\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0Simeprevir\u00a0(Olysio\u00ae)\u00a0wurde\u00a02014\u00a0nach\u00a0Telaprevir\u00a0und\u00a0Bocepre vir\u00a0ein\u00a0weiterer\u00a0\nProteaseinhibitor\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C\u00a0(c HC)\u00a0zugelassen.\u00a0\nSimeprevir\u00a0kann\u00a0laut\u00a0Zulassung\u00a0h ierzulande\u00a0bei\u00a0HC\u2010Virus\u00a0(HCV)\u2010I nfektionen\u00a0der\u00a0\nGenotypen\u00a0(GT)\u00a01\u00a0und\u00a04\u00a0eingesetzt\u00a0werden.\u00a0\u00a0\nSchon\u00a0vor\u00a0Behandlungsbeginn\u00a0wurd e\u00a0bei\u00a06\u00a0von\u00a08\u00a0Studienpatienten\u00a0 das\u00a0Auftreten\u00a0\nresistenter\u00a0Virusvarianten\u00a0(Q80K)\u00a0gegen\u00fcber\u00a0Simeprevir\u00a0beobacht et.\u00a0Dieser\u00a0virale\u00a0\nPolymorphismus\u00a0l\u00e4sst\u00a0die\u00a0Ansprechraten\u00a0auf\u00a0Simeprevir\u00a0bei\u00a0besti mmten\u00a0Patien\u2010\ntenkollektiven\u00a0deutlich\u00a0absinken.\u00a0Aus\u00a0diesem\u00a0Grund\u00a0wird\u00a0vor\u00a0Beh andlungsbeginn\u00a0\nein\u00a0Test\u00a0auf\u00a0NS3\u2010Q80K\u2010Polymorphismus\u00a0empfohlen,\u00a0wenn\u00a0Simeprevir \u00a0zusammen\u00a0\nmit\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei\u00a0HCV\u2010GT\u00a01a\u2010Patient\u00a0eing esetzt\u00a0werden\u00a0soll\u00a0\noder\u00a0wenn\u00a0bereits\u00a0eine\u00a0Leberzirrhose\u00a0vorliegt\u00a0(Fachinformation\u00a0 Olysio\u00ae,\u00a0 2016,\u00a0\nManns\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nZulassungsrelevant\u00a0 waren\u00a0 drei\u00a0 ra ndomisierte\u00a0 herstellergesponser te\u00a0 Studien\u00a0\n(PROMISE,\u00a0Forns\u00a0et\u00a0al.,\u00a02014;\u00a0QUEST\u00a01,\u00a0Jacobson\u00a0et\u00a0al.,\u00a02014;\u00a0Q UEST\u00a02,\u00a0Manns\u00a0et\u00a0\nal.,\u00a02014).\u00a0In\u00a0diesen\u00a0Studien\u00a0wurden\u00a0die\u00a0Effekte\u00a0der\u00a0Tripelther apie\u00a0bestehend\u00a0aus\u00a0\nSimeprevir,\u00a0Peginterferon\u00a0und\u00a0Ribavirin\u00a0auf\u00a0chronische\u00a0Infektio nen\u00a0mit\u00a0dem\u00a0HCV\u2010\nGT\u00a0 1\u00a0 untersucht.\u00a0 Als\u00a0 Vergleichsgruppe\u00a0 diente\u00a0 die\u00a0 duale\u00a0 Standard therapie\u00a0 aus\u00a0\nPeginterferon\u00a0und\u00a0Ribavirin.\u00a0Bei\u00a0therapienaiven\u00a0und\u00a0therapieerf ahrenen\u00a0Patienten\u00a0\nlag\u00a0 die\u00a0 virologische\u00a0 Ansprechrate\u00a0 zw\u00f6lf\u00a0 Wochen\u00a0 nach\u00a0 Behandlungs ende\u00a0 unter\u00a0\nSimeprevir\u2010basierter\u00a0Behandlung\u00a0bei\u00a080\u00a0%\u00a0versus\u00a050\u00a0bzw.\u00a035\u00a0%\u00a0un ter\u00a0Standardbe\u2010\nhandlung.\u00a0Des\u00a0Weiteren\u00a0liegt\u00a0eine\u00a0 offene\u00a0randomisierte\u00a0Studie\u00a0d er\u00a0Phase\u00a0IIa\u00a0vor,\u00a0in\u00a0\nder\u00a0ein\u00a0Interferon\u2010freies\u00a0Behandl ungsregime\u00a0bestehend\u00a0aus\u00a0Simep revir\u00a0in\u00a0Kombi\u2010\nnation\u00a0mit\u00a0Sofosbuvir\u00a0getestet\u00a0wurde\u00a0(COSMOS,\u00a0Lawitz\u00a0et\u00a0al.,\u00a020 14)\u00a0sowie\u00a0eine\u00a0un\u2010\nkontrollierte,\u00a0offene\u00a0Studie\u00a0Phase\u2010III\u00a0an\u00a0einem\u00a0HIV\u2010koinfiziert en\u00a0Patientenkollektiv\u00a0\n(Dieterich\u00a0et\u00a0al.,\u00a02014).\u00a0Auch\u00a0in\u00a0diesen\u00a0Untersuchungen\u00a0werden\u00a0 bei\u00a0therapienaiven\u00a0\nwie\u00a0 auch\u00a0 bei\u00a0 therapieerfahrenen\u00a0 G T\u00a0 1\u2010Tr\u00e4gern\u00a0 hohe\u00a0 virologische\u00a0 Ansprechraten\u00a0\nerreicht.\u00a0Allerdings\u00a0enthielten\u00a0die\u00a0Untersuchungen\u00a0keine\u00a0geeign eten\u00a0Daten,\u00a0um\u00a0den\u00a0\nEinfluss\u00a0von\u00a0Simeprevir\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0absch\u00e4tzen\u00a0zu\u00a0k\u00f6 nnen.\u00a0\nAnhand\u00a0der\u00a0vorliegenden\u00a0Untersuc hungsdaten\u00a0beschreibt\u00a0der\u00a0Gemei nsame\u00a0Bun\u2010\ndesausschuss\u00a0(G\u2010BA)\u00a0im\u00a0Jahr\u00a02014\u00a0den\u00a0Zusatznutzen\u00a0von\u00a0Simeprevi r\u00a0f\u00fcr\u00a0die\u00a0unter\u2010347\u00a0schiedlichen\u00a0Patientengruppen\u00a0wie\u00a0folgt:\u00a0F\u00fcr\u00a0 therapienaive\u00a0wie\u00a0auch\u00a0therapieer\u2010\nfahrene\u00a0Patienten\u00a0mit\u00a0GT\u00a01 \u00a0wird\u00a0aufgrund\u00a0der\u00a0deutlichen\u00a0Verbesserung\u00a0des\u00a0dau\u2010\nerhaften\u00a0 virologischen\u00a0 Ansprechens\u00a0 f\u00fcr\u00a0 die\u00a0 Simeprevir\u2010basierte\u00a0 Tripeltherapie\u00a0\ngegen\u00fcber\u00a0 der\u00a0 dualen\u00a0 Standardtherapie\u00a0 ein\u00a0 Hinweis\u00a0 auf\u00a0 einen\u00a0 betr\u00e4chtlichen\u00a0\nZusatznutzen \u00a0festgestellt.\u00a0F\u00fcr\u00a0vorherige\u00a0 Non\u2010Responder \u00a0trifft\u00a0dies\u00a0ebenfalls\u00a0zu,\u00a0\nwenn\u00a0eine\u00a0Simeprevir\u2010basierte\u00a0Tri peltherapie\u00a0mit\u00a0einer\u00a0Tripelth erapie\u00a0auf\u00a0Basis\u00a0\nvon\u00a0Boceprevir\u00a0oder\u00a0Telaprevir\u00a0verglichen\u00a0wird.\u00a0Als\u00a0Begr\u00fcndung\u00a0 wird\u00a0hier\u00a0eine\u00a0\ndeutliche\u00a0Reduktion\u00a0therapiebedingter\u00a0schwerwiegender\u00a0unerw\u00fcnsc hter\u00a0Arznei\u2010\nmittelereignisse\u00a0(UAE)\u00a0durch\u00a0Sime previr\u00a0angegeben .\u00a0Sowohl\u00a0bei\u00a0 therapienaiven\u00a0\nund\u00a0therapieerfahrenen\u00a0Patienten\u00a0mit\u00a0GT\u00a04 \u00a0wie\u00a0auch\u00a0bei\u00a0solchen\u00a0mit\u00a0 Hepatitis\u00a0C\u00a0\nGT\u00a01\u2010\u00a0oder\u00a04\u2010HIV\u2010Koinfektionen \u00a0wird\u00a0der\u00a0Simeprevir\u2010basierten\u00a0Tripeltherapie\u00a0ein\u00a0\nAnhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 geringen\u00a0 Zusatznutzen \u00a0 attestiert,\u00a0 da\u00a0 im\u00a0 Vergleich\u00a0 zur\u00a0\ndualen\u00a0Standardtherapie\u00a0die\u00a0Beha ndlungsdauer\u00a0relevant\u00a0verk\u00fcrzt\u00a0 und\u00a0damit\u00a0die\u00a0\nInterferon\u2010basierte\u00a0Nebenwirkung srate\u00a0verringert\u00a0werden\u00a0kann\u00a0(G \u2010BA,\u00a02014).\u00a0\u00a0\nAktuelle\u00a0Metaanalysen\u00a0best\u00e4tigen\u00a0 die\u00a0Wirksamkeit\u00a0von\u00a0Simeprevir \u00a0bei\u00a0cHC.\u00a0So\u00a0\nliegt\u00a0das\u00a0dauerhafte\u00a0virologische \u00a0Ansprechen\u00a0unter\u00a0Tripeltherap ie\u00a0mit\u00a0Simeprevir,\u00a0\nPeginferteron\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei\u00a0HCV\u2010GT\u00a01\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach \u00a0Behandlungs\u2010\nende\u00a0h\u00f6her\u00a0als\u00a0unter\u00a0der\u00a0Standardbehandlung\u00a0mit\u00a0Peginterferon\u00a0+ \u00a0Ribavirin\u00a0ohne\u00a0\ndass\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0abnimmt.\u00a0 Allerdings\u00a0liegen\u00a0f\u00fcr\u00a0eine\u00a0ab schlie\u00dfende\u00a0Ein\u2010\nsch\u00e4tzung\u00a0des\u00a0Nebenwirkungsprofils\u00a0von\u00a0Simeprevir\u00a0insbesondere\u00a0 im\u00a0Hinblick\u00a0auf\u00a0\nseltene\u00a0unerw\u00fcnschte\u00a0Ereignisse\u00a0od er\u00a0seine\u00a0Langzeitvertr\u00e4glichk eit\u00a0immer\u00a0noch\u00a0zu\u00a0\nwenige\u00a0Studiendaten\u00a0vor\u00a0(Qu\u00a0et\u00a0al.,\u00a02016).\u00a0Eine\u00a0\u00dcberlegenheit\u00a0g egen\u00fcber\u00a0Pegin\u2010\nterferon\u00a0alfa\u00a0+\u00a0Ribavirin\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Tripeltherapie\u00a0mi t\u00a0Simeprevir\u00a0auch\u00a0bei\u00a0\nPatienten\u00a0mit\u00a0HCV/HIV\u2010Coinfektionen\u00a0(Andersohn\u00a0et\u00a0al.,\u00a02016).\u00a0A llerdings\u00a0st\u00fctzen\u00a0\ns i c h \u00a0d i e s e \u00a0E r g e b n i s s e \u00a0a u f \u00a0h i s t o r i s c h e \u00a0V e r g l e i c h e . \u00a0E i n \u00a0d a u e r h a f t es\u00a0 virologisches\u00a0\nAnsprechen\u00a0ist\u00a0bei\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0zu\u00a0Therapiebeginn\u00a0im \u00a0historischen\u00a0\nVergleich\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach\u00a0Beha ndlungsende\u00a0auch\u00a0mit\u00a0der\u00a0gemein samen\u00a0Ver\u2010\nabreichung\u00a0von\u00a0Simeprevir\u00a0mit\u00a0Sofosbuvir\u00a0zu\u00a0erreichen\u00a0\u2013\u00a0unabh\u00e4n gig\u00a0vom\u00a0Nach\u2010\nweis\u00a0von\u00a0Q80K\u2010Varianten\u00a0(Kwo\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nNach\u00a0den\u00a0Ergebnissen\u00a0eines\u00a0indirekten\u00a0Vergleiches\u00a0steigt\u00a0bei\u00a0de r\u00a0Behandlung\u00a0von\u00a0\nHCV\u2010GT\u00a04\u00a0das\u00a0virologische\u00a0Ansprechen\u00a0mit\u00a0dem\u00a0Zusatz\u00a0von\u00a0Simepre vir\u00a0zur\u00a0Basis\u2010\ntherapie\u00a0mit\u00a0Peginterferon\u00a0+\u00a0Ribavirin\u00a0an\u00a0(Van\u00a0Sanden\u00a0et\u00a0al.,\u00a02 016).\u00a0Eine\u00a0aktuelle\u00a0\nEinzelstudie\u00a0zeigt\u00a0f\u00fcr\u00a0die\u00a0duale \u00a0Virustatikabehandlung\u00a0mit\u00a0Sime previr\u00a0+\u00a0Sofosbuvir\u00a0\nbei\u00a0HCV\u2010Infektion\u2010GT\u00a04\u00a0nach\u00a0zw\u00f6lf\u00a0Behandlungswochen\u00a0ein\u00a0hohes\u00a0v irologisches\u00a0\nAnsprechen\u00a0von\u00a0100\u00a0%\u00a0bei\u00a0Patienten\u00a0mit\u00a0fortgeschrittener\u00a0Lebere rkrankung\u00a0oder\u00a0\nZirrhose\u00a0(El\u00a0Raziky\u00a0et\u00a0al.,\u00a02017).\u00a0\u00a0\nUntersuchungen\u00a0 legen\u00a0 nahe,\u00a0 dass\u00a0 durch\u00a0 die\u00a0 Behandlung\u00a0 mit\u00a0 direkt \u00a0 antiviral\u2010\nwirkenden\u00a0 Mitteln\u00a0 eine\u00a0 bereits\u00a0 vorliegende\u00a0 Hepatitis\u2010B\u2010Erkranku ng\u00a0 reaktiviert\u00a0348\u00a0werden\u00a0kann.\u00a0Bei\u00a0Koinfektion\u00a0hemmt\u00a0das\u00a0HCV\u00a0die\u00a0Replikation\u00a0von\u00a0 Hepatitis\u2010B\u2010\nViren.\u00a0Unter\u00a0spezifischer\u00a0antivi raler\u00a0Hepatitis\u2010C\u2010Behandlung\u00a0en tf\u00e4llt\u00a0diese\u00a0Hemm\u2010\nfunktion.\u00a0Seit\u00a0Ende\u00a02016\u00a0fordert\u00a0daher\u00a0die\u00a0Europ\u00e4ische\u00a0Medizin\u2010 Agentur\u00a0( Euro\u2010\npean\u00a0Medicines\u00a0Agency, \u00a0EMA)\u00a0vor\u00a0einer\u00a0HCV\u2010Behandlung\u00a0ein\u00a0Screening\u00a0auf\u00a0Hepati\u2010\ntis\u2010B\u2010Koinfektion\u00a0(EMA,\u00a02016).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0\nWeiterer\u00a0\nProteaseinhibitor\u00a0Gegen\u00fcber\u00a0anderen\u00a0\nVirustatika\u00a0keinen\u00a0klaren\u00a0\nZusatznutzen\u00a0\u00a0teurer\u00a0im\u00a0Vergleich\u00a0zum\u00a0bis\u00a0\ndahin\u00a0\u00fcblichen\u00a0PEG\u2010\nbasierten\u00a0Regime\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus \u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0\u00a0 Mittel\u00a0der\u00a0Reserve\u00a0 \u2013\u00a0 Possibly\u00a0helpful\u00a0 Analogpr\u00e4parat\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage*\u00a0 Tagestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSimeprevir\u00a0\nIn\u00a0Kombination\u00a0mit: \u00a01x\u00a0tgl.\u00a0\n\u00a084\u00a0Tage\u00a0\n\u00a0334,27\u00a0\u20ac\u00a0\n\u00a0\nSofosbuvir\u00a0 1x\u00a0tgl.\u00a0 84\u00a0\u2013\u00a0168\u00a0Tage\u00a0 600,31\u00a0\u20ac\u00a0\nBoceprevir\u00a0 3x\u00a0tgl.\u00a0800\u00a0mg\u00a0 196\u00a0\u2013\u00a0336\u00a0Tage\u00a0 112,36\u00a0\u20ac\u00a0\nTelaprevir\u00a0 3x\u00a0tgl.\u00a0750\u00a0mg\u00a084\u00a0\u2013\u00a0336\u00a0Tage\u00a0334,27\u00a0\u20ac\u00a0\nRibavirin\u00a0 1x\u00a0400\u00a0mg\u00a0+\u00a0\u00a0\n1x\u00a0600\u00a0mg\u00a0168\u00a0\u2013\u00a0336\u00a0Tage\u00a0 29,89\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB11)\u00a0 1x\u00a0w\u00f6chentlich\u00a0 24\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0280,19\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB10)\u00a0 1x\u00a0w\u00f6chentlich\u00a0 24\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0254,31\u00a0\u20ac\u00a0\n*Je\u00a0nach\u00a0Virenbelastung\u00a0ist\u00a0die\u00a0Therapiedauer\u00a012\u00a0Wochen\u00a0(84\u00a0Tag e),\u00a024\u00a0Wochen\u00a0(168\u00a0Tage)\u00a0oder\u00a048\u00a0Wochen\u00a0(336\u00a0Tage). \u00a0\n\u00a0\u00a0\n349\u00a0Ausgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Mai\u00a02014\u00a0stiegen\u00a0die\u00a0Verordnungzahl en\u00a0von\u00a0Sime\u2010\nprevir\u00a0rasch\u00a0an\u00a0und\u00a0erreichten\u00a0bereits\u00a0zwei\u00a0Monate\u00a0sp\u00e4ter\u00a0ihren \u00a0H\u00f6hepunkt\u00a0(Ab\u2010\nbildung\u00a04.42).\u00a0Der\u00a0nachfolgende\u00a0deutliche\u00a0R\u00fcckgang\u00a0der\u00a0Verordnu ngen\u00a0im\u00a0Jahr\u00a0\n2015\u00a0ist\u00a0weniger\u00a0mit\u00a0dem\u00a0substanzspezifischen\u00a0Ergebnis\u00a0der\u00a0fr\u00fch en\u00a0Nutzenbewer\u2010\ntung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0als\u00a0vielmehr\u00a0durch\u00a0die\u00a0zahlreichen\u00a0Marktbew egungen\u00a0im\u00a0\nArzneimittelsegment\u00a0\u201echronische\u00a0 Hepatitis\u00a0C\u201c\u00a0im\u00a0Zulassungsjahr\u00a0 2014\u00a0zu\u00a0erkl\u00e4ren.\u00a0\nDurch\u00a0die\u00a0Zulassung\u00a0diverser\u00a0Fixkombinationen\u00a0stehen\u00a0mittlerwei le\u00a0therapeutisch\u00a0\n\u00fcberlegene\u00a0Alternativen\u00a0mit\u00a0verei nfachtem\u00a0Einnahmeregime\u00a0zur\u00a0Ve rf\u00fcgung\u00a0(vgl.\u00a0\nKapitel\u00a04.16\u00a0und\u00a04.25).\u00a0\u00a0\nAbbildung\u00a04.42:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nSimeprevir\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nSimeprevir\u00a0ist\u00a0ein\u00a0spezifischer\u00a0Hemmstoff\u00a0der\u00a0NS3/4A\u2010Serinprote ase\u00a0von\u00a0HCV,\u00a0die\u00a0\nf\u00fcr\u00a0die\u00a0virale\u00a0Replikation\u00a0erforderlich\u00a0ist.\u00a0Aufgrund\u00a0der\u00a0hohen \u00a0genetischen\u00a0Variabi\u2010\nlit\u00e4t\u00a0des\u00a0HCV\u00a0k\u00f6nnen\u00a0sich\u00a0beim\u00a0Einsatz\u00a0direkt\u00a0antiviral\u00a0wirkend er\u00a0Mittel\u00a0h\u00e4ufig\u00a0\nResistenzen\u00a0entwickeln.\u00a0Zudem\u00a0wurde\u00a0schon\u00a0vor\u00a0Behandlungsbeginn \u00a0bei\u00a06\u00a0von\u00a08\u00a0\nStudienpatienten\u00a0das\u00a0Auftreten\u00a0von\u00a0resistenten\u00a0Virusvarianten\u00a0( Q80K)\u00a0gegen\u00fcber\u00a0\nSimeprevir\u00a0beobachtet.\u00a0Deshalb\u00a0wird\u00a0wie\u00a0bei\u00a0den\u00a0Proteaseinhibit oren\u00a0Boceprevir\u00a0\nund\u00a0Telaprevir\u00a0auch\u00a0bei\u00a0Simeprevir\u00a0von\u00a0einer\u00a0Monotherapie\u00a0abger aten.\u00a0In\u00a0Kombi\u2010\n350\u00a0nation\u00a0mit\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0wurden\u00a0bei\u00a0therapienaiven\u00a0P atienten\u00a0unab\u2010\nh\u00e4ngig\u00a0vom\u00a0Vorliegen\u00a0der\u00a0Q80K\u2010Variante\u00a0hohe\u00a0Ansprechraten\u00a0errei cht\u00a0(Kwo\u00a0et\u00a0al.,\u00a0\n2016).\u00a0Bei\u00a0Patienten\u00a0mit\u00a0Leberzirrhose\u00a0und\u00a0HCV\u2010GT\u00a01a\u2010Infektione n\u00a0hatte\u00a0das\u00a0Vor\u2010\nliegen\u00a0der\u00a0Q80K\u2010Variante\u00a0allerdings\u00a0einen\u00a0negativen\u00a0Effekt\u00a0auf\u00a0 den\u00a0Therapieerfolg\u00a0\n(SVR\u2010Rate\u00a074 \u00a0%\u00a0mit\u00a0Q80K\u2010Polymorphismus\u00a0versus\u00a092 \u00a0%\u00a0ohne\u00a0Q80K\u2010Polymorphis\u2010\nmus)\u00a0(Lawitz\u00a0et\u00a0al.,\u00a02016).\u00a0Dies\u00a0war\u00a0auch\u00a0der\u00a0Fall,\u00a0wenn\u00a0PEG\u2010In terferon\u2010basierte\u00a0\nTherapieregime\u00a0an\u00a0GT\u00a01a\u2010Tr\u00e4ger\u00a0v erabreicht\u00a0wurden.\u00a0Studiendaten \u00a0zufolge\u00a0l\u00e4sst\u00a0\nein\u00a0viraler\u00a0NS3\u2010Q80K\u2010Polymorphismus\u00a0in\u00a0diesem\u00a0Fall\u00a0die\u00a0Ansprech raten\u00a0auf\u00a0Sime\u2010\nprevir\u00a0mit\u00a0einer\u00a0absoluten\u00a0Differenz\u00a0von\u00a031 \u00a0%\u00a0deutlich\u00a0absinken\u00a0(Jacobson\u00a0et\u00a0al.,\u00a0\n2014;\u00a0Manns\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nSimeprevir\u00a0 (Olysio\u00ae;\u00a0 Janssen\u2010Cilag,\u00a0 2016)\u00a0 ist\u00a0 ausschlie\u00dflich\u00a0 in \u00a0 Kombination\u00a0 mit\u00a0\nweiteren\u00a0antiviralen\u00a0Mitteln\u00a0bei\u00a0erwachsenen\u00a0Patienten\u00a0zur\u00a0Beha ndlung\u00a0der\u00a0cHC\u00a0\nzugelassen.\u00a0Das\u00a0Mittel\u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a01 50\u00a0mg\u00a0verabreicht. \u00a0\nF\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0HCV\u2010GT\u00a01\u2010\u00a0und\u00a0HCV\u2010GT\u00a04\u2010Infektionen\u00a0wird\u00a0di e\u00a0kombinierte\u00a0\nAnwendung\u00a0von\u00a0Simeprevir\u00a0mit\u00a0Sof osbuvir\u00a0angegeben.\u00a0Liegt\u00a0bereit s\u00a0eine\u00a0Leberzir\u2010\nrhose\u00a0vor,\u00a0wird\u00a0die\u00a0Behandlungsdauer\u00a0von\u00a0zw\u00f6lf\u00a0auf\u00a024\u00a0Wochen\u00a0ve rdoppelt\u00a0oder\u00a0\nzus\u00e4tzlich\u00a0 noch\u00a0 Ribavirin\u00a0 verabreicht.\u00a0 F\u00fcr\u00a0 beide\u00a0 GT\u00a0 k\u00f6nnen\u00a0 auch \u00a0I n t e r f e r o n \u2010\nbasierte\u00a0Therapieregime\u00a0zusammen\u00a0 mit\u00a0Peginterferon\u00a0und\u00a0Ribaviri n\u00a0eingesetzt\u00a0\nwerden.\u00a0Die\u00a0Behandlungsdauer\u00a0ist\u00a0dabei\u00a0\u2013\u00a0mit\u00a024\u00a0bis\u00a048\u00a0Wochen\u00a0j e\u00a0nach\u00a0individu\u2010\nellem\u00a0Risikoprofil\u00a0\u2013\u00a0deutlich\u00a0h\u00f6her\u00a0als\u00a0bei\u00a0Kombinationen\u00a0versc hiedener\u00a0Virustati\u2010\nka.\u00a0Die\u00a0Behandlung\u00a0von\u00a0HCV\u2010Infek tionen\u00a0GT\u00a02,3,5\u00a0und\u00a06\u00a0ist\u00a0nicht \u00a0untersucht.\u00a0\u00a0\nWenn\u00a0 Simeprevir\u00a0 zusammen\u00a0 mit\u00a0 Peginterferon\u00a0 und\u00a0 Ribavirin\u00a0 bei\u00a0 HC V\u2010GT\u00a0 1a\u2010\nPatient\u00a0eingesetzt\u00a0werden\u00a0soll\u00a0oder\u00a0wenn\u00a0bereits\u00a0eine\u00a0Leberzirr hose\u00a0vorliegt,\u00a0wird\u00a0\nvor\u00a0Behandlungsbeginn\u00a0ein\u00a0Test\u00a0auf\u00a0NS3\u2010Q80K\u2010Polymorphismus\u00a0empf ohlen.\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Hepatitis\u00a0C\u00a0ist\u00a0eine\u00a0weltwei t\u00a0vorkommende\u00a0virale\u00a0Infektion, \u00a0die\u00a0als\u00a0akute\u00a0wie\u00a0\nauch\u00a0chronische\u00a0Form\u00a0in\u00a0Erscheinung\u00a0tritt.\u00a0Verursacht\u00a0wird\u00a0die\u00a0 Erkrankung\u00a0durch\u00a0\ndas\u00a0zu\u00a0der\u00a0Gruppe\u00a0der\u00a0RNA\u2010Viren\u00a0geh\u00f6rende\u00a0HCV,\u00a0von\u00a0dem\u00a0derzeit\u00a0 7\u00a0GT\u00a0mit\u00a067\u00a0\nSubtypen\u00a0bekannt\u00a0sind.\u00a0Weltweit\u00a0ist\u00a0GT\u00a01\u00a0der\u00a0h\u00e4ufigste\u00a0GT\u00a0(46\u00a0% ),\u00a0gefolgt\u00a0von\u00a0GT\u00a03\u00a0\n(30\u00a0%).\u00a0Die\u00a0GT\u00a02,\u00a04\u00a0und\u00a06\u00a0sind\u00a0verantwortlich\u00a0f\u00fcr\u00a0insgesamt\u00a023\u00a0 %\u00a0der\u00a0Erkrankungs\u2010\nf\u00e4lle.\u00a0GT\u00a05\u00a0spielt\u00a0nur\u00a0eine\u00a0sehr\u00a0untergeordnete\u00a0Rolle\u00a0(<\u00a01\u00a0%).\u00a0 In\u00a0den\u00a0meisten\u00a0euro\u2010\np\u00e4ischen\u00a0L\u00e4ndern\u00a0ist\u00a0beim\u00a0GT\u00a01\u00a0der\u00a0am\u00a0h\u00e4ufigsten\u00a0vorkommende\u00a0Su btyp\u00a01b,\u00a0wo\u2010\nhingegen\u00a0in\u00a0Nordamerika,\u00a0Gro\u00dfbritannien,\u00a0Skandinavien\u00a0und\u00a0Austr alien\u00a0der\u00a0GT\u00a01a\u00a0\nam\u00a0weitesten\u00a0verbreitet\u00a0ist\u00a0(RKI,\u00a02016).\u00a0351\u00a0In\u00a0Europa\u00a0leben\u00a0ca.\u00a0zwei\u00a0bis\u00a0f\u00fcnf\u00a0Mio.\u00a0HCV\u2010positive\u00a0Menschen.\u00a0A ls\u00a0Risikogruppen\u00a0\nmit\u00a0besonders\u00a0hoher\u00a0Krankheitspr\u00e4valenz\u00a0gelten\u00a0intraven\u00f6se\u00a0Drog enanwender,\u00a0\nM\u00e4nner,\u00a0die\u00a0mit\u00a0M\u00e4nnern\u00a0Sex\u00a0haben\u00a0(MSM),\u00a0Dialysepatienten,\u00a0Pers onen,\u00a0die\u00a0vor\u00a0\nden\u00a01990er\u00a0Jahren\u00a0h\u00e4ufig\u00a0Transfusionen\u00a0oder\u00a0vor\u00a0Ende\u00a0der\u00a01980er \u2010Jahre\u00a0Plas\u2010\nmaderivate\u00a0erhielten\u00a0(RKI,\u00a02014a).\u00a0In\u00a0Deutschland\u00a0liegt\u00a0die\u00a0Pr\u00e4 valenz\u00a0mit\u00a00,3\u00a0%\u00a0im\u00a0\ninternationalen\u00a0Vergleich\u00a0sehr\u00a0niedrig.\u00a0Pro\u00a0Jahr\u00a0muss\u00a0aber\u00a0auch \u00a0hierzulande\u00a0mit\u00a0ca.\u00a0\n5.000\u00a0Neuinfektionen\u00a0gerechnet\u00a0werden\u00a0(RKI,\u00a02016).\u00a0\u00a0\nDie\u00a0\u00dcbertragung\u00a0geschieht\u00a0fast\u00a0ausschlie\u00dflich\u00a0\u00fcber\u00a0Blut.\u00a0In\u00a075\u00a0 %\u00a0der\u00a0F\u00e4lle\u00a0verl\u00e4uft\u00a0\ndie\u00a0Infektion\u00a0unbemerkt.\u00a025\u00a0%\u00a0der\u00a0Infizierten\u00a0entwickeln\u00a0eine\u00a0a kute\u00a0Hepatitis\u00a0mit\u00a0\nunspezifischen\u00a0Beschwerden\u00a0und\u00a0Ei nschr\u00e4nkungen\u00a0der\u00a0Leberfunktio n.\u00a0Fulminante\u00a0\nVerl\u00e4ufe\u00a0 sind\u00a0 selten\u00a0 (Thimme\u00a0 et\u00a0 al.,\u00a0 2014).\u00a0 Symptomatisch\u00a0 verla ufende\u00a0 akute\u00a0\nHepatitiden\u00a0zeigen\u00a0eine\u00a0Immunrea ktion\u00a0der\u00a0Betroffenen\u00a0an,\u00a0was\u00a0d ie\u00a0Rate\u00a0an\u00a0Spon\u2010\ntanheilung\u00a0erh\u00f6ht:\u00a0Etwa\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0akut\u00a0verlaufenden\u00a0HCV\u2010In fektionen\u00a0heilt\u00a0\nspontan\u00a0aus,\u00a0w\u00e4hrend\u00a0es\u00a0bei\u00a0den\u00a0asymptomatischen\u00a0Verl\u00e4ufen\u00a0ledi glich\u00a0ca.\u00a030\u00a0%\u00a0\nsind.\u00a0Zwischen\u00a050\u00a0und\u00a085\u00a0%\u00a0aller\u00a0Akutinfektionen\u00a0gehen\u00a0in\u00a0eine\u00a0 cHC\u00a0\u00fcber,\u00a0die\u00a0\ndurch\u00a0eine\u00a0st\u00e4ndige\u00a0Vermehrung\u00a0von\u00a0HCV\u00a0gekennzeichnet\u00a0ist.\u00a0Inne rhalb\u00a0von\u00a020\u00a0bis\u00a0\n30\u00a0Jahren\u00a0kommt\u00a0es\u00a0bei\u00a02\u00a0bis\u00a035\u00a0%\u00a0der\u00a0Betroffenen\u00a0zu\u00a0einer\u00a0Lebe rzirrhose.\u00a0Bei\u00a0\ndiesen\u00a0Patienten\u00a0k\u00f6nnen\u00a0Lebertransplantationen\u00a0lebensrettend\u00a0se in.\u00a0Etwa\u00a02\u00a0bis\u00a0\n4\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0Leberzirrh ose\u00a0entwickeln\u00a0pro\u00a0Jahr\u00a0ein\u00a0Leb erzellkarzinom\u00a0\n(RKI,\u00a02014b).\u00a0\nIn\u00a0zahlreichen\u00a0F\u00e4llen\u00a0ist\u00a0der\u00a0genaue\u00a0\u00dcbertragungsweg\u00a0nicht\u00a0fest stellbar.\u00a0Aktuelle\u00a0\nAnalysen\u00a0geben\u00a0an,\u00a0dass\u00a0bei\u00a0den\u00a0F\u00e4llen,\u00a0denen\u00a0ein\u00a0\u00dcbertragunswe g\u00a0hochwahr\u2010\nscheinlich\u00a0 zugeordnet\u00a0 werden\u00a0 konnte,\u00a0 76 \u00a0%\u00a0 auf\u00a0 intraven\u00f6sen\u00a0 Drogenkonsum\u00a0\nzur\u00fcckzuf\u00fchren\u00a0sind,\u00a08 \u00a0%\u00a0auf\u00a0MSM,\u00a08 \u00a0%\u00a0auf\u00a0den\u00a0Erhalt\u00a0von\u00a0Blutprodukten,\u00a06 \u00a0%\u00a0auf\u00a0\nheterosexuellen\u00a0Kontakt\u00a0 mit\u00a0HCV\u2013Infizierten,\u00a01,5 \u00a0%\u00a0auf\u00a0Dialyse\u00a0und\u00a00,5 \u00a0%\u00a0auf\u00a0eine\u00a0\nperinatale\u00a0\u00dcbertragung\u00a0(RKI,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nF\u00fcr\u00a0Simeprevir\u00a0liegen\u00a0Studien\u00a0zur\u00a0Behandlung\u00a0der\u00a0cHC\u00a0vom\u00a0GT\u00a01\u00a0u nd\u00a04\u00a0vor.\u00a0Im\u00a0Jahr\u00a0\n2014\u00a0waren\u00a0drei\u00a0Phase\u2010III\u2010\u00a0Studien\u00a0zulassungsrelevant\u00a0(Forns\u00a0et \u00a0al.,\u00a02014;\u00a0Jacobson\u00a0\net\u00a0al.,\u00a02014;\u00a0Manns\u00a0et\u00a0al.,\u00a02014).\u00a0In\u00a0mehreren\u00a0Phase\u2010II\u2010Studien \u00a0wurde\u00a0Simeprevir\u00a0\ngegen\u00a0Plazebo\u00a0und\u00a0im\u00a0Direktverglei ch\u00a0gegen\u00a0Telaprevir\u00a0oder\u00a0gege n\u00a0ein\u00a0Interferon\u2010\nfreies\u00a0 Behandlungsregime\u00a0 getestet\u00a0 (Lawitz\u00a0 et\u00a0 al.,\u00a0 2014).\u00a0 Deswei teren\u00a0 lag\u00a0 eine\u00a0\neinarmige\u00a0Studie\u00a0an\u00a0einem\u00a0HIV\u2010koi nfizierten\u00a0Patientenkollektiv\u00a0 vor\u00a0(Dieterich\u00a0et\u00a0al,\u00a0\n2014).\u00a0All\u00a0diese\u00a0Studien\u00a0untersuchten\u00a0die\u00a0Effekte\u00a0von\u00a0Simeprevi r\u00a0auf\u00a0chronische\u00a0\nInfektionen\u00a0mit\u00a0Hepatitis\u00a0C\u00a0GT\u00a01.\u00a0Klinische\u00a0Erfahrungen\u00a0zur\u00a0Beh andlung\u00a0einer\u00a0cHC\u00a0\nGT\u00a04\u00a0stammten\u00a0von\u00a0einer\u00a0begrenzten\u00a0Anzahl\u00a0von\u00a0Patienten\u00a0aus\u00a0ein er\u00a0einarmigen,\u00a0\nnicht\u00a0verblindeten\u00a0Studie\u00a0(EMA,\u00a02014).\u00a0Untersuchungen\u00a0an\u00a0Patien ten\u00a0mit\u00a0HCV\u00a0GT\u00a0\n2,\u00a03\u00a0sowie\u00a05\u00a0und\u00a06\u00a0wurden\u00a0gar\u00a0nicht\u00a0durchgef\u00fchrt.\u00a0\u00a0352\u00a0Mittlerweile\u00a0liegen\u00a0Metaanalysen\u00a0der\u00a0bislang\u00a0durchgef\u00fchrten\u00a0Stu dien\u00a0mit\u00a0Sime\u2010\nprevir\u00a0vor,\u00a0die\u00a0dessen\u00a0Wirksamkeit\u00a0best\u00e4tigen.\u00a0So\u00a0liegt\u00a0das\u00a0dau erhafte\u00a0virologische\u00a0\nAnsprechen\u00a0unter\u00a0Tripeltherapie\u00a0 mit\u00a0Simeprevir,\u00a0Peginferteron\u00a0u nd\u00a0Ribavirin\u00a0bei\u00a0\nHCV\u00a0GT\u00a01\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach\u00a0Behandlungsende\u00a0h\u00f6her\u00a0als\u00a0unter\u00a0der\u00a0 Standardbe\u2010\nhandlung\u00a0mit\u00a0Peginterferon\u00a0+\u00a0Ribavirin\u00a0(RR\u00a01,69,\u00a095\u00a0%\u00a0CI:\u00a01,37\u00a0 bis\u00a02,08,\u00a0P<0.001).\u00a0\nDabei\u00a0steigt\u00a0die\u00a0Rate\u00a0an\u00a0schwerwiegenden\u00a0unerw\u00fcnschten\u00a0Arzneimi ttelereignisse\u00a0\n(UAE)\u00a0durch\u00a0den\u00a0Zusatz\u00a0von\u00a0Simeprevir\u00a0nicht\u00a0an,\u00a0vielmehr\u00a0gibt\u00a0e s\u00a0Hinweise\u00a0auf\u00a0\neine\u00a0bessere\u00a0Vertr\u00e4glichkeit\u00a0(RR\u00a00,67,\u00a095\u00a0%\u00a0CI:\u00a00,47\u00a0bis\u00a00,94,\u00a0 P=0,023).\u00a0Die\u00a0Anzahl\u00a0\nvon\u00a0Therapieabbrechern\u00a0aufgrund\u00a0von\u00a0UAE\u00a0liegt\u00a0lediglich\u00a0numeris ch\u00a0aber\u00a0nicht\u00a0\nstatistisch\u00a0signifikant\u00a0h\u00f6her\u00a0(Qu\u00a0et\u00a0al.,\u00a02016).\u00a0F\u00fcr\u00a0eine\u00a0absch lie\u00dfende\u00a0Einsch\u00e4tzung\u00a0\ndes\u00a0Nebenwirkungsprofils\u00a0von\u00a0Sim eprevir\u00a0insbesondere\u00a0im\u00a0Hinblic k\u00a0auf\u00a0seltene\u00a0\nunerw\u00fcnschte\u00a0 Ereignisse\u00a0 oder\u00a0 sein e\u00a0 Langzeitvertr\u00e4glichkeit\u00a0 werd en\u00a0 aber\u00a0 noch\u00a0\nweitere\u00a0Studien\u00a0erforderlich\u00a0sein.\u00a0Nach\u00a0einem\u00a0historischen\u00a0Verg leich\u00a0ist\u00a0ein\u00a0dauer\u2010\nhaftes\u00a0virologisches\u00a0Ansprechen\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach\u00a0Behandlungsen de\u00a0mit\u00a0der\u00a0\ngemeinsamen\u00a0Verabreichung\u00a0von\u00a0Sim eprevir\u00a0mit\u00a0Sofosbuvir\u00a0zu\u00a0erre ichen\u00a0(97\u00a0%\u00a0vs.\u00a0\n87\u00a0%)\u00a0\u2013\u00a0unabh\u00e4ngig\u00a0vom\u00a0Zirrhosestatus\u00a0der\u00a0Patienten\u00a0und\u00a0dem\u00a0Nac hweis\u00a0von\u00a0\nQ80K\u2010Varianten\u00a0(Kwo\u00a0et\u00a0al.,\u00a02016).\u00a0Eine\u00a0\u00dcberlegenheit\u00a0gegen\u00fcber \u00a0Peginterferon\u00a0+\u00a0\nRibavirin\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Tripeltherapie\u00a0mit\u00a0Simeprevir\u00a0auc h\u00a0bei\u00a0Patienten\u00a0mit\u00a0\nHCV/HIV\u2010Coinfektionen.\u00a0Das\u00a0virologische\u00a0Ansprechen\u00a024\u00a0Wochen\u00a0na ch\u00a0Behand\u2010\nlungsende\u00a0lag\u00a0unter\u00a0der\u00a0Tripeltherapie\u00a0absolut\u00a0um\u00a045\u00a0%\u00a0h\u00f6her\u00a0al s\u00a0unter\u00a0Peginter\u2010\nferon\u00a0+\u00a0Ribavirin\u00a0allein.\u00a0Allerdings\u00a0waren\u00a0auch\u00a0hier\u00a0aufgrund\u00a0d er\u00a0unkontrollierten\u00a0\nBasisstudie\u00a0nur\u00a0historische\u00a0Vergleiche\u00a0m\u00f6glich\u00a0(Andersohn\u00a0et\u00a0al .,\u00a02016).\u00a0F\u00fcr\u00a0die\u00a0\nBehandlung\u00a0von\u00a0HCV\u00a0GT\u00a04\u00a0liegen\u00a0mittlerweile\u00a0weitere\u00a0klinische\u00a0D aten\u00a0aus\u00a0einarmi\u2010\ngen,\u00a0unverblindeten,\u00a0aber\u00a0auch\u00a0randomisierten\u00a0Studien\u00a0vor.\u00a0Nach \u00a0indirekter\u00a0Ver\u2010\ngleichsanalyse\u00a0von\u00a0Basisdaten\u00a0au s\u00a0einer\u00a0einarmigen\u00a0Simeprevir\u2010S tudie\u00a0steigt\u00a0das\u00a0\nvirologische\u00a0 Ansprechen\u00a0 mit\u00a0 dem\u00a0 Zusatz\u00a0 von\u00a0 Simeprevir\u00a0 zum\u00a0 Stand ardregime\u00a0\nPeginterferon\u00a0alfa\u00a0+\u00a0Ribavirin\u00a0ab solut\u00a0um\u00a022\u00a0bis\u00a033\u00a0%\u00a0(Van\u00a0Sand en\u00a0et\u00a0al.,\u00a02016).\u00a0\nEine\u00a0aktuelle\u00a0randomisiert\u2010kontrollierte\u00a0Einzelstudie\u00a0zeigt\u00a0f\u00fcr \u00a0eine\u00a0duale\u00a0Behand\u2010\nlung\u00a0bestehend\u00a0aus\u00a0Simeprevir\u00a0und\u00a0Sofosbuvir\u00a0bei\u00a0HCV\u2010Infektion\u00a0 vom\u00a0GT\u00a04\u00a0nach\u00a0\nzw\u00f6lf\u00a0Behandlungswochen\u00a0hohes\u00a0vi rologisches\u00a0Ansprechen\u00a0von\u00a0100\u00a0 %\u00a0unabh\u00e4ngig\u00a0\nvom\u00a0Zirrhosestatus\u00a0(El\u00a0Raziky\u00a0et\u00a0al.,\u00a02017).\u00a0\nDie\u00a0wichtigsten\u00a0UAE\u00a0unter\u00a0der\u00a0Behandlung\u00a0mit\u00a0Simeprevir\u00a0sind\u00a0Ha utreaktionen\u00a0\neinschlie\u00dflich\u00a0R\u00f6tungen\u00a0und\u00a0Juckreiz\u00a0sowie\u00a0deutliche\u00a0Photosensi bilisierungsreakti\u2010\nonen.\u00a0Dar\u00fcber\u00a0hinaus\u00a0kommt\u00a0es\u00a0h\u00e4ufig\u00a0zu\u00a0\u00dcbelkeit,\u00a0Verstopfung\u00a0u nd\u00a0Atemnot\u00a0\n(letzteres\u00a0vor\u00a0allem\u00a0in\u00a0Kombination\u00a0mit\u00a0Ribavirin).\u00a0Au\u00dferdem\u00a0k\u00f6 nnen\u00a0die\u00a0Biliru\u2010\nbinwerte\u00a0 ansteigen,\u00a0 weswegen\u00a0 ein e\u00a0 regelm\u00e4\u00dfige\u00a0 Kontrolle\u00a0 dieses\u00a0 Parameters\u00a0\nempfohlen\u00a0wird\u00a0(Fachinformation\u00a0Olysio\u00ae,\u00a02016).\u00a0\u00a0\nAufgrund\u00a0von\u00a0Hinweisen\u00a0auf\u00a0eine\u00a0schwerwiegende\u00a0Interaktion\u00a0wird \u00a02015\u00a0von\u00a0der\u00a0\nEurop\u00e4ischen\u00a0Zulassungsbeh\u00f6rde\u00a0ein\u00a0Warnhinwies\u00a0f\u00fcr\u00a0die\u00a0gemeinsa me\u00a0Anwen\u2010353\u00a0dung\u00a0von\u00a0Simeprevir\u00a0+\u00a0Sofosbuvir\u00a0mit\u00a0Amiodaron\u00a0ver\u00f6ffentlicht:\u00a0 Mehrere\u00a0Fallbe\u2010\nrichte\u00a0weisen\u00a0darauf\u00a0hin,\u00a0dass\u00a0das\u00a0Risiko\u00a0einer\u00a0schweren\u00a0Bradyk ardie\u00a0oder\u00a0eines\u00a0\nHerzblocks\u00a0ansteigt,\u00a0wenn\u00a0diese\u00a0Mittel\u00a0gemeinsam\u00a0verabreicht\u00a0we rden.\u00a0Auf\u00a0Amio\u2010\ndaron\u00a0als\u00a0Antiarrthythmikum\u00a0sollt e\u00a0daher\u00a0weitestgehend\u00a0verzicht et\u00a0werden.\u00a0Wenn\u00a0\ndies\u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0muss\u00a0die\u00a0Herzfunktion\u00a0der\u00a0Betroffenen\u00a0w \u00e4hrend\u00a0der\u00a0Be\u2010\nhandlung\u00a0engmaschig\u00a0\u00fcberwacht\u00a0werden\u00a0(EMA,\u00a02015).\u00a0\n2016\u00a0empfiehlt\u00a0die\u00a0europ\u00e4ische\u00a0Zulassungsbeh\u00f6rde\u00a0vor\u00a0Beginn\u00a0ein er\u00a0antiviralen\u00a0\nBehandlung\u00a0der\u00a0cHC\u00a0B\u00a0mit\u00a0Sofosbuv ir,\u00a0Daclatasvir,\u00a0Simeprevir,\u00a0L edipasvir,\u00a0Dasabu\u2010\nvir\u00a0oder\u00a0Ombitasvir\u00a0grunds\u00e4tzlich\u00a0ein\u00a0Screening\u00a0auf\u00a0eine\u00a0Koinfe ktion\u00a0mit\u00a0Hepatitis\u00a0\nB.\u00a0Bei\u00a0Hepatitis\u00a0B/Hepatitis\u00a0C\u2010Coinfektionen\u00a0hemmen\u00a0HCV\u00a0die\u00a0Akt ivit\u00e4t\u00a0und\u00a0Ver\u2010\nmehrung\u00a0 von\u00a0 Hepatitis\u2010B\u2010Viren.\u00a0 D ie\u00a0 spezifisch\u00a0 wirkende\u00a0 antivira le\u00a0 Behandlung\u00a0\nsorgt\u00a0f\u00fcr\u00a0einen\u00a0raschen\u00a0Abfall\u00a0von\u00a0HCV\u00a0und\u00a0f\u00fchrt\u00a0damit\u00a0zu\u00a0einer \u00a0Reaktivierung\u00a0von\u00a0\nHepatitis\u2010B\u2010Viren\u00a0(EMA,\u00a02016).\u00a0Coinfizierte\u00a0Patienten\u00a0m\u00fcssen\u00a0f\u00fc r\u00a0die\u00a0Zeit\u00a0der\u00a0Be\u2010\nhandlung\u00a0eng\u00a0monitoriert\u00a0werden,\u00a0gegebenfalls\u00a0ist\u00a0eine\u00a0zus\u00e4tzli che\u00a0antivirale\u00a0Be\u2010\nhandlung\u00a0der\u00a0Hepatitis\u00a0B\u00a0erforderlich. \u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0aktuelle\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroent erologie,\u00a0Verdau\u2010\nungs\u2010\u00a0und\u00a0Stoffwechselkrankheiten\u00a0(DGSV)\u00a0empfiehlt\u00a0f\u00fcr\u00a0die\u00a0Erst therapie\u00a0bei\u00a0cHC\u00a0\nein\u00a0Interferon\u2010freies\u00a0Therapieregime\u00a0(DGVS,\u00a02016).\u00a0Da\u00a0bei\u00a0Kombi nationsbehand\u2010\nlung\u00a0mit\u00a0Ribavirin\u00a0mit\u00a0mehr\u00a0Nebenwirkungen\u00a0und\u00a0Intoleranzen\u00a0zu\u00a0 rechnen\u00a0sind,\u00a0\nsoll\u00a0bei\u00a0gleicher\u00a0Wirksamkeit\u00a0stets\u00a0eine\u00a0Therapieoption\u00a0ohne\u00a0Ri bavirin\u00a0gew\u00e4hlt\u00a0\nwerden.\u00a0Es\u00a0wird\u00a0darauf\u00a0hingewiesen,\u00a0dass\u00a0die\u00a0Therapieauswahl\u00a0un ter\u00a0Ber\u00fccksichti\u2010\ngung\u00a0des\u00a0Zirrhosestatus,\u00a0des\u00a0Vor therapiestatus,\u00a0der\u00a0Komedikatio n\u00a0und\u00a0gegeben\u2010\nfalls\u00a0der\u00a0Komorbidit\u00e4ten\u00a0zu\u00a0erfolgen\u00a0hat.\u00a0\u00a0\nDie\u00a0Leitlinienautoren\u00a0geben\u00a0an,\u00a0dass\u00a0Simeprevir\u00a0in\u00a0Kombination\u00a0 mit\u00a0anderen\u00a0Sub\u2010\nstanzen\u00a0in\u00a0der\u00a0Erst\u2010\u00a0und\u00a0Re\u2010Therapie\u00a0f\u00fcr\u00a0die\u00a0HCV\u2010GT\u00a01\u00a0und\u00a04\u00a0ein gesetzt\u00a0werden\u00a0\nkann.\u00a0In\u00a0Deutschland\u00a0ist\u00a0der\u00a0Wirkstoff\u00a0noch\u00a0im\u00a0Handel,\u00a0in\u00a0\u00d6ster reich\u00a0nicht\u00a0mehr.\u00a0\nSimeprevir\u00a0wird\u00a0in\u00a0der\u00a0Leitlinie\u00a0lediglich\u00a0in\u00a0Kombination\u00a0mit\u00a0S ofosbuvir\u00a0bei\u00a0Patien\u2010\nten\u00a0mit\u00a0cHC\u00a0vom\u00a0GT\u00a01\u00a0mit\u00a0und\u00a0ohne\u00a0Zirrhose\u00a0als\u00a0Therapieoption,\u00a0 allerdings\u00a0auf\u00a0\nabgestuften\u00a0Empfehlungsgrad,\u00a0genannt.\u00a0Eine\u00a0ebenfalls\u00a0m\u00f6gliche\u00a0K ombination\u00a0von\u00a0\nSimeprevir\u00a0mit\u00a0Daclatasvir\u00a0wird\u00a0wegen\u00a0unzureichender\u00a0Therapieer gebnisse\u00a0und\u00a0\ninsgesamt\u00a0mangelnder\u00a0Daten\u00a0nicht\u00a0empfohlen.\u00a0Eine\u00a0duale\u00a0Therapie \u00a0bestehend\u00a0aus\u00a0\nSimeprevir\u00a0und\u00a0Sofosbuvir\u00a0wird\u00a0bei\u00a0Patienten\u00a0mit\u00a0cHC\u00a0vom\u00a0GT\u00a04\u00a0a llerdings\u00a0mit\u00a0\nabgestuftem\u00a0Empfehlungsgrad\u00a0als\u00a0Therapieoption\u00a0genannt,\u00a0aber\u00a0we gen\u00a0besser\u00a0\nevaluierter\u00a0Therapiealternativen \u00a0nicht\u00a0generell\u00a0empfohlen.\u00a0Da\u00a0N S3\u2010Protease\u2010Inhi\u2010\nbitoren,\u00a0 zu\u00a0 denen\u00a0 auch\u00a0 Simeprevir\u00a0 z\u00e4hlt,\u00a0 hepatisch\u00a0 metabolisier t\u00a0 werden\u00a0 und\u00a0\ndamit\u00a0 bei\u00a0 unzureichender\u00a0 Elimination\u00a0 toxische\u00a0 Effekte\u00a0 in\u00a0 Zusamm enhang\u00a0 mit\u00a0354\u00a0diesen\u00a0Mitteln\u00a0auftreten\u00a0k\u00f6nnten ,\u00a0werden\u00a0die\u00a0Vertreter\u00a0dieser\u00a0W irkstoffgruppe\u00a0\nauch\u00a0nicht\u00a0bei\u00a0Patienten\u00a0mit\u00a0dekompensierter\u00a0Leberzirrhose\u00a0empf ohlen.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0fasst\u00a0in\u00a0seiner\u00a0Beschlussfassung\u00a0im\u00a0November\u00a02014\u00a0den\u00a0 Zusatznutzen\u00a0\nvon\u00a0Simeprevir\u00a0im\u00a0Vergleich\u00a0zur\u00a0bis\u00a0dato\u00a0\u00fcblichen\u00a0Vergleichsthe rapie\u00a0wie\u00a0folgt\u00a0\nzusammen\u00a0(G\u2010BA,\u00a02014):\u00a0\u00a0\nF\u00fcr\u00a0bisher\u00a0 unbehandelte\u00a0Patienten\u00a0mit\u00a0und\u00a0ohne\u00a0Leberzirrhose\u00a0mit\u00a0HCV\u2010GT\u00a01\u2010\nInfektionen \u00a0liegt\u00a0ein\u00a0 Hinweis\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0von\u00a0Simepre\u2010\nvir\u00a0in\u00a0Kombination\u00a0mit\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0gegen\u00fcb er\u00a0der\u00a0zweckm\u00e4\u00dfi\u2010\ngen\u00a0 Vergleichstherapie\u00a0 Peginterferon\u00a0 alfa\u00a0 +\u00a0 Ribavirin\u00a0 vor.\u00a0 Dies er\u00a0 Zusatznutzen\u00a0\nzeigt\u00a0sich\u00a0in\u00a0einer\u00a0deutlichen\u00a0Ve rbesserung\u00a0des\u00a0therapierelevan ten\u00a0Nutzens,\u00a0ge\u2010\nmessen\u00a0 als\u00a0 statistisch\u00a0 signifikante\u00a0 Verbesserung\u00a0 des\u00a0 dauerhafte n\u00a0 virologischen\u00a0\nAnsprechens.\u00a0Der\u00a0G\u2010BA\u00a0weist\u00a0darauf\u00a0hin,\u00a0dass\u00a0die\u00a0bisherigen\u00a0Stu dienergebnisse\u00a0\ndarauf\u00a0hindeuten,\u00a0dass\u00a0das\u00a0virolo gische\u00a0Ansprechen\u00a0zudem\u00a0durch\u00a0 das\u00a0Merkmal\u00a0\nQ80K\u2010Polymorphismus\u00a0sowie\u00a0das\u00a0Merkmal\u00a0IL28B\u2010GT\u00a0(CC/CT/TT)\u00a0modif iziert\u00a0wird.\u00a0\nPatienten\u00a0mit\u00a0einem\u00a0IL28B\u2010GT\u00a0CC\u00a0sowie\u00a0Patienten\u00a0mit\u00a0einem\u00a0Q80K\u2010 Polymorphis\u2010\nmus\u00a0erreichten\u00a0danach\u00a0kein\u00a0signifikantes\u00a0virologisches\u00a0Therapie ansprechen\u00a0auf\u00a0\nSimeprevir.\u00a0\nF\u00fcr\u00a0bereits\u00a0vorbehandelte\u00a0Patienten\u00a0mit\u00a0HCV\u2010GT \u00a01\u2010Infektion \u00a0liegt\u00a0ein\u00a0 Hinweis\u00a0f\u00fcr\u00a0\neinen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0von\u00a0Simeprevir\u00a0in\u00a0Kombination\u00a0mit\u00a0Peginterfe\u2010\nron\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0gegen\u00fcber \u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichsthe rapie\u00a0Peginter\u2010\nferon\u00a0alfa\u00a0+\u00a0Ribavirin\u00a0vor.\u00a0Dieser\u00a0\u00e4u\u00dfert\u00a0sich\u00a0in\u00a0einer\u00a0statist isch\u00a0signifikanten\u00a0Ver\u2010\nbesserung\u00a0des\u00a0dauerhaften\u00a0virologischen\u00a0Ansprechens,\u00a0in\u00a0einer\u00a0k linisch\u00a0bedeut\u2010\nsamen\u00a0Verbesserung\u00a0der\u00a0Fatigue \u00a0und\u00a0des\u00a0Gesundheitszustandes\u00a0sow ie\u00a0durch\u00a0die\u00a0\nrelevante\u00a0Vermeidung\u00a0von\u00a0unerw\u00fcns chten\u00a0Arzneimittelereignissen\u00a0 (UAE).\u00a0\nF\u00fcr\u00a0Non\u2010Responder \u00a0auf\u00a0eine\u00a0vorhergehende\u00a0Behandlung\u00a0wird\u00a0ebenfalls\u00a0ein\u00a0 Hin\u2010\nweis\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0von\u00a0Simeprevir\u00a0in\u00a0Kombination\u00a0mit\u00a0\nPeginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Ver gleichstherapie\u00a0\n(zVT)\u00a0Telaprevir\u00a0+\u00a0Peginterferon \u00a0alfa\u00a0+\u00a0Ribavirin\u00a0gesehen,\u00a0der\u00a0 sich\u00a0durch\u00a0eine\u00a0rele\u2010\nvante\u00a0Vermeidung\u00a0schwerwiegender\u00a0UAE\u00a0ergibt.\u00a0\nF\u00fcr\u00a0therapienaive\u00a0sowie\u00a0therapieerfahrene\u00a0Patienten\u00a0mit\u00a0HCV\u2010GT \u00a04\u2010Infektion \u00a0\nwird\u00a0f\u00fcr\u00a0Simeprevir\u00a0in\u00a0Kombination\u00a0mit\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0R ibavirin\u00a0gegen\u00fcber\u00a0\nder\u00a0zVT\u00a0Peginterferon\u00a0alfa\u00a0+\u00a0Ribavirin\u00a0aufgrund\u00a0der\u00a0Verk\u00fcrzung\u00a0 der\u00a0Therapiedauer\u00a0\nund\u00a0der\u00a0damit\u00a0einhergehenden\u00a0rele vanten\u00a0Vermeidung\u00a0von\u00a0UAE\u00a0ein\u00a0 Anhaltspunkt\u00a0\nf\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0gesehen.\u00a0F\u00fcr\u00a0 Non\u2010Responder \u00a0dieser\u00a0Patienten\u2010\ngruppe\u00a0ist\u00a0dagegen\u00a0ein\u00a0 Zusatznutzen\u00a0nicht\u00a0belegt .\u00a0355\u00a0F\u00fcr\u00a0therapienaive\u00a0 sowie\u00a0 therapieerfahrene\u00a0 Patienten\u00a0 mit\u00a0 HCV\u2010GT \u00a01\u00a0 oder\u00a0 4\u2010\nInfektion\u00a0sowie\u00a0HIV\u2010Coinfektion \u00a0wird\u00a0f\u00fcr\u00a0Simeprevir\u00a0in\u00a0Kombination\u00a0mit\u00a0Peginter\u2010\nferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0Peginterferon\u00a0alfa\u00a0+ \u00a0Ribavirin\u00a0aufgrund\u00a0\neiner\u00a0relevanten\u00a0Vermeidung\u00a0von\u00a0UAE\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zu\u2010\nsatznutzen \u00a0gesehen.\u00a0F\u00fcr\u00a0 Non\u2010Responder \u00a0dieser\u00a0Patientengruppe\u00a0ist\u00a0dagegen\u00a0ein\u00a0\nZusatznutzen\u00a0nicht\u00a0belegt \u00a0(G\u2010BA,\u00a02014).\u00a0\nZum\u00a0 Zusatznutzen\u00a0 von\u00a0 Simeprevir\u00a0 innerhalb\u00a0 eines\u00a0 Interferon\u2010frei en\u00a0 Behand\u2010\nlungsregimes\u00a0 lie\u00df\u00a0 sich\u00a0 damals\u00a0 ke ine\u00a0 sichere\u00a0 Aussage\u00a0 treffen.\u00a0 Ph ase\u2010II\u2010Studien\u00a0\nlie\u00dfen\u00a0f\u00fcr\u00a0bislang\u00a0als\u00a0schwer\u00a0therapierbar\u00a0geltende\u00a0Patientenko llektive\u00a0wie\u00a0Non\u2010\nResponder\u00a0mit\u00a0m\u00e4\u00dfiger\u00a0und\u00a0schwerer\u00a0Lebersch\u00e4digung\u00a0wie\u00a0auch\u00a0f\u00fcr \u00a0therapienaive\u00a0\nPersonen\u00a0mit\u00a0schwerer\u00a0Lebersch\u00e4di gung\u00a0hohe\u00a0Erfolgsraten\u00a0von\u00a0\u00fcbe r\u00a090\u00a0%\u00a0erken\u2010\nnen,\u00a0wenn\u00a0Simeprevir\u00a0gemeinsam\u00a0m it\u00a0Sofosbuvir\u00a0eingesetzt\u00a0wurde. \u00a0Eine\u00a0Drei\u2010\nfachtherapie\u00a0 zusammen\u00a0 mit\u00a0 Ribavirin\u00a0 konnte\u00a0 die\u00a0 Heilungsraten\u00a0 ni cht\u00a0 steigern\u00a0\n(Lawitz,\u00a02014;\u00a0Degr\u00e9\u00a0et\u00a0al.,\u00a02017).\u00a0\u00a0\nF\u00fcr\u00a0eine\u00a0tragf\u00e4hige\u00a0Einsch\u00e4tzung \u00a0des\u00a0Nebenwirkungsprofils\u00a0von\u00a0S imeprevir\u00a0insbe\u2010\nsondere\u00a0im\u00a0Hinblick\u00a0auf\u00a0seltene\u00a0UAE\u00a0oder\u00a0seine\u00a0Langzeitvertr\u00e4gl ichkeit\u00a0fehlten\u00a0\ndamals\u00a0ebenfalls\u00a0Studiendaten.\u00a0D ie\u00a0vorliegenden\u00a0Untersuchungser gebnisse\u00a0liefer\u2010\nten\u00a0allerdings\u00a0keine\u00a0Hinweise\u00a0da rauf,\u00a0dass\u00a0die\u00a0Therapie\u00a0von\u00a0zuv or\u00a0unbehandelten\u00a0\nPatienten\u00a0schlechter\u00a0vertragen\u00a0w ird,\u00a0wenn\u00a0Simeprevir\u00a0zus\u00e4tzlich \u00a0zu\u00a0einer\u00a0Interfe\u2010\nron\u2010basierten\u00a0 Therapie\u00a0 gegeben\u00a0 wird\u00a0 (IQWiG,\u00a0 2014).\u00a0 Im\u00a0 Vergleich \u00a0 zu\u00a0 anderen\u00a0\nTripeltherapien\u00a0(Telaprevir,\u00a0PEG\u2010Interferon\u00a0\u03b1\u00a0und\u00a0Ribavirin)\u00a0ga b\u00a0es\u00a0vielmehr\u00a0den\u00a0\nHinweis\u00a0auf\u00a0eine\u00a0bessere\u00a0Vertr \u00e4glichkeit\u00a0(IQWiG,\u00a02014;\u00a0G\u2010BA,\u00a020 14).\u00a0\nVersorgungsanalysen\u00a0\nVon\u00a0Olysio\u00ae\u00a0sind\u00a0zwei\u00a0Packungsgr\u00f6 \u00dfen\u00a0im\u00a0Handel,\u00a0eine\u00a0davon\u00a0ohne \u00a0Zuordnung\u00a0\neiner\u00a0Normgr\u00f6\u00dfe.\u00a0Simeprevir\u00a0wu rde\u00a02015\u00a0nur\u00a0an\u00a0einzelne\u00a0Personen \u00a0verordnet.\u00a0\nEs\u00a0wurden\u00a0sowohl\u00a0Frauen\u00a0wie\u00a0auch \u00a0M\u00e4nner\u00a0damit\u00a0behandelt,\u00a0in\u00a0ers ter\u00a0Linie\u00a0\naber\u00a0M\u00e4nner\u00a0zwischen\u00a050\u00a0und\u00a070\u00a0Jahren.\u00a0\u00a0\n\u00a0\n\u00a0\u00a0356\u00a0Abbildung\u00a04.43:\u00a0Anzahl\u00a0verordnete r\u00a0Packungen\u00a0Simeprevir\u00a0je\u00a0Mona t\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.44:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Simeprev ir\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n357\u00a0Quellen\u00a0\nAndersohn\u00a0F,\u00a0Claes\u00a0AK,\u00a0Kulp\u00a0W,\u00a0Ma hlich\u00a0J,\u00a0Rockstroh\u00a0JK\u00a0(2016).\u00a0 Simeprevir\u00a0with\u00a0pegylated\u00a0interferon\u00a0alfa\u00a02a\u00a0plus\u00a0ribavirin\u00a0for \u00a0\ntreatment\u00a0of\u00a0hepatitis\u00a0C\u00a0virus\u00a0genotype\u00a01\u00a0in\u00a0patients\u00a0with\u00a0HIV: \u00a0a\u00a0meta\u2010analysis\u00a0and\u00a0historical\u00a0comparison.\u00a0BMC\u00a0\nInfect\u00a0Dis\u00a016:\u00a010.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2017).\u00a0Bewertung: \u00a0Simeprevir.\u00a0https://www.arznei\u2010telegramm.de/\u00a0\ndb/01wkstxt.php3?&knr=&art=mono&nummer=Simeprevir&ord=uaw,\u00a0letz ter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nDegr\u00e9\u00a0D,\u00a0Serst\u00e9\u00a0T,\u00a0Lasser\u00a0L,\u00a0Delwaide\u00a0J,\u00a0Starkel\u00a0P,\u00a0Laleman\u00a0W,\u00a0 et\u00a0al.\u00a0(2017).\u00a0Sofosbuvir\u00a0in\u00a0Combination\u00a0with\u00a0Simeprevir\u00a0+/\u2010\u00a0Ri bavirin\u00a0\nin\u00a0Genotype\u00a04\u00a0Hepatitis\u00a0C\u00a0Patients\u00a0with\u00a0Advanced\u00a0Fibrosis\u00a0or\u00a0Ci rrhosis:\u00a0A\u00a0Real\u2010World\u00a0Experience\u00a0from\u00a0Belgium.\u00a0PLoS\u00a0\nOne\u00a012(1):e0170933.\u00a0doi:\u00a010.1371/journal.pone.0170933.\u00a0\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten\u00a0u.a.\u00a0(2016).\u00a0Aktuelle\u00a0Empfehlung\u00a0\nzur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Hepatitis\u00a0C.\u00a0Stand\u00a0Dezember\u00a02016.\u00a0 Verf\u00fcgbar\u00a0unter:\u00a0https://www.dgvs.de/wissen\u2010\nkompakt/leitlinien/leitlinien\u2010der\u2010dgvs/hepatitis\u2010c/\u00a0,\u00a0letzter\u00a0Z ugriff:\u00a008.03.2017.\u00a0\nDieterich\u00a0D,\u00a0Rockstroh\u00a0JK,\u00a0Orkin \u00a0C,\u00a0Guti\u00e9rrez\u00a0F,\u00a0Klein\u00a0MB,\u00a0Reyn es\u00a0J,\u00a0et\u00a0al.\u00a0(2014).\u00a0Simeprevir\u00a0(TMC435)\u00a0With\u00a0Pegylated\u00a0\nInterferon/Ribavirin\u00a0in\u00a0Patients\u00a0Coinfected\u00a0With\u00a0HCV\u00a0Genotype\u00a01 \u00a0and\u00a0HIV\u20101:\u00a0A\u00a0Phase\u00a03\u00a0Study.\u00a0Clin\u00a0Infect\u00a0Dis\u00a09\u00a0(11):\u00a0\n1579\u20101587.\u00a0\u00a0\nEl\u00a0Raziky\u00a0M,\u00a0Gamil\u00a0M,\u00a0Ashour\u00a0MK,\u00a0Sameea\u00a0EA,\u00a0Doss\u00a0W,\u00a0Hamada\u00a0Y\u00a0et \u00a0al.\u00a0(2017).\u00a0Simeprevir\u00a0plus\u00a0sofosbuvir\u00a0for\u00a0eight\u00a0or\u00a012\u00a0weeks\u00a0i n\u00a0\ntreatment\u2010na\u00efve\u00a0and\u00a0treatment\u2010experienced\u00a0hepatitis\u00a0C\u00a0virus\u00a0gen otype\u00a04\u00a0patients\u00a0with\u00a0or\u00a0without\u00a0cirrhosis.\u00a0J\u00a0Viral\u00a0\nHepat\u00a02017.\u00a024\u00a0(2):102\u2010110.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicine\u00a0Agency\u00a0( 2014).\u00a0Committee\u00a0for\u00a0Medicinal\u00a0 Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP)\u00a0Assessment\u00a0report\u00a0OLYSIO\u00a0\nInternational\u00a0non\u2010proprietary\u00a0name:\u00a0SIMEPREVIR\u00a0Procedure\u00a0No.\u00a0EM EA/H/C/002777/000020\u00a0March\u00a02014\u00a0\nEMA/CHMP/285947/2014\u00a0,\u00a0letzter\u00a0Zugriff:\u00a021.01.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0Pharmacovigilance\u00a0Risk\u00a0 Assessment\u00a0Committee.\u00a0PRAC\u00a0recommendations\u00a0on\u00a0signals\u00a0for\u00a0\nupdate\u00a0of\u00a0the\u00a0product\u00a0information\u00a0Adopted\u00a0at\u00a0the\u00a07\u201010\u00a0April\u00a0201 5\u00a0PRAC\u00a01.\u00a0Daclatasvir;\u00a0sofosbuvir;\u00a0sofosbuvir,\u00a0\nledipasvir\u00a0\u2013\u00a0Arrhythmia\u00a0(EPITT\u00a0no\u00a018177).\u00a023\u00a0April\u00a02015\u00a0EMA/PRA C/239532/2015.\u00a0\nwww.ema.europa.eu/docs/en_GB/do cument_library/PRAC_recommendati on_on_signal/2015/05/WC500186846.p\ndf\u00a0,\u00a0letzter\u00a0Zugriff:\u00a011.04.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016a).\u00a0Direct\u2010acting\u00a0antivira ls\u00a0for\u00a0hepatitis\u00a0C:\u00a0EMA\u00a0confirms\u00a0recommendation\u00a0to\u00a0screen\u00a0for\u00a0\nhepatitis\u00a0B\u00a0Further\u00a0studies\u00a0needed\u00a0to\u00a0assess\u00a0risk\u00a0of\u00a0liver\u00a0canc er\u00a0with\u00a0these\u00a0medicines.\u00a0EMA/824717/2016.\u00a0\nwww.ema.europa.eu/docs/en_GB/do cument_library/Press_release/201 6/12/WC500218204.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n10.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016b).\u00a0Direct\u2010acting\u00a0antivira ls\u00a0for\u00a0hepatitis\u00a0C:\u00a0EMA\u00a0confirms\u00a0recommendation\u00a0to\u00a0screen\u00a0for\u00a0\nhepatitis\u00a0B\u00a0Further\u00a0studies\u00a0needed\u00a0to\u00a0assess\u00a0risk\u00a0of\u00a0liver\u00a0canc er\u00a0with\u00a0these\u00a0medicines.\u00a0EMA/824717/2016.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/Referrals_documen t/Direct\u2010\nacting_antivirals_for_hepatitis_C_20/Opinion_provided_by_Commit tee_for_Medicinal_Products_for_Human_Use/\nWC500218179.pdf\u00a0,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nFachinformation\u00a0OLYSIO\u00ae\u00a0(2016).\u00a0 Fachinformation\u00a0OLYSIO\u00ae\u00a0150\u00a0mg\u00a0 Hartkapseln.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0\nForns\u00a0X,\u00a0Lawitz\u00a0E,\u00a0Zeuzem\u00a0S,\u00a0Gane\u00a0E,\u00a0Bronowicki\u00a0JP,\u00a0Andreone\u00a0P, \u00a0et\u00a0al.\u00a0(2014).\u00a0Simeprevir\u00a0with\u00a0peginterferon\u00a0and\u00a0ribavirin\u00a0lea ds\u00a0to\u00a0\nhigh\u00a0rates\u00a0of\u00a0SVR\u00a0in\u00a0patients\u00a0with\u00a0HCV\u00a0genotype\u00a01\u00a0who\u00a0relapsed\u00a0 after\u00a0previous\u00a0therapy:\u00a0a\u00a0phase\u00a03\u00a0trial.\u00a0\nGastroenterology\u00a0146:\u00a01669\u20101679.e3.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0358\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Simeprevir.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/118/\u00a0,\u00a0letzter\u00a0Zugriff:\u00a009. 02.2017.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2014).\u00a0Simeprevir\u00a0\u2010\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0\nV.\u00a0Auftrag\u00a0A14\u201018.\u00a0Version\u00a01.0.\u00a0Stand:\u00a028.08.2014.\u00a0\nJacobson\u00a0IM,\u00a0Dore\u00a0GJ,\u00a0Foster\u00a0GR,\u00a0Fried\u00a0MW,\u00a0Radu\u00a0M,\u00a0Rafalsky\u00a0VV, \u00a0et\u00a0al.\u00a0(2014).\u00a0Simeprevir\u00a0with\u00a0pegylated\u00a0interferon\u00a0\u03b1\u00a0\u00a02a\u00a0+\u00a0\nribavirin\u00a0in\u00a0treatment\u2010naive\u00a0pat ients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C\u00a0 virus\u00a0genotype\u00a01\u00a0infection\u00a0(QUEST\u20101):\u00a0A\u00a0Phase\u00a0III,\u00a0\nrandomised,\u00a0double\u2010blind,\u00a0placebo\u2010controlled\u00a0trial.\u00a0Lancet\u00a0384: \u00a0(9941):\u00a0403\u2010413.\u00a0\u00a0\nJanssen\u2010Cilag\u00a0International\u00a0NV\u00a0( 2016)\u00a0Fachinformation\u00a0OLYSIO\u00ae\u00a01 50\u00a0mg\u00a0Hartkapseln.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0\nKwo\u00a0P,\u00a0Gitlin\u00a0N,\u00a0Nahass\u00a0R,\u00a0Bernstein\u00a0D,\u00a0Etzkorn\u00a0K,\u00a0Rojter\u00a0S\u00a0et\u00a0 al.\u00a0(2016).\u00a0Simeprevir\u00a0plus\u00a0sofosbuvir\u00a0(12\u00a0and\u00a08\u00a0weeks)\u00a0in\u00a0hepa titis\u00a0C\u00a0\nvirus\u00a0genotype\u00a01\u2010infected\u00a0patients\u00a0without\u00a0cirrhosis:\u00a0OPTIMIST\u2010 1,\u00a0a\u00a0phase\u00a03,\u00a0randomized\u00a0study.\u00a0Hepatology\u00a064:\u00a0\u00a0\n370\u2010380.\u00a0\u00a0\nLawitz\u00a0E,\u00a0Matusow\u00a0G,\u00a0DeJesus\u00a0E,\u00a0Yoshida\u00a0EM,\u00a0Felizarta\u00a0F,\u00a0Ghalib \u00a0R,\u00a0et\u00a0al.\u00a0(2016).\u00a0Simeprevir\u00a0pl us\u00a0sofosbuvir\u00a0in\u00a0 patients\u00a0with\u00a0 chronic\u00a0\nhepatitis\u00a0C\u00a0virus\u00a0genotype\u00a01\u00a0infection\u00a0and\u00a0cirrhosis:\u00a0A\u00a0phase\u00a03 \u00a0study\u00a0(OPTIMIST\u20102).\u00a0Hepatology\u00a064:\u00a0360\u2010369.\u00a0\u00a0\nLawitz\u00a0E,\u00a0Sulkowski\u00a0MS,\u00a0Ghalib\u00a0R,\u00a0Rodriguez\u2010Torres\u00a0M,\u00a0Younossi\u00a0 ZM,\u00a0Corregidor\u00a0A\u00a0et\u00a0al.\u00a0(2014).\u00a0Simeprevir\u00a0+\u00a0sofosbuvir,\u00a0with\u00a0o r\u00a0\nwithout\u00a0ribavirin,\u00a0to\u00a0treat\u00a0chronic\u00a0infection\u00a0with\u00a0hepatitis\u00a0C\u00a0 virus\u00a0genotype\u00a01\u00a0in\u00a0non\u2010responders\u00a0to\u00a0pegylated\u00a0\ninterferon\u00a0and\u00a0ribavirin\u00a0and\u00a0treatment\u2010na\u00efve\u00a0patients:\u00a0the\u00a0COSM OS\u00a0randomised\u00a0study.\u00a0Lancet\u00a0384\u00a0(9956):\u00a01756\u2010\n1765.\u00a0\nManns\u00a0M,\u00a0Marcellin\u00a0P,\u00a0Poordad\u00a0F,\u00a0de\u00a0Araujo\u00a0ES,\u00a0Buti\u00a0M,\u00a0Horsmans \u00a0Y\u00a0et\u00a0al.\u00a0(2014).\u00a0Simeprevir\u00a0with\u00a0pegylated\u00a0interferon\u00a0\u03b1\u00a0\u00a02a\u00a0or \u00a02b\u00a0\n+\u00a0ribavirin\u00a0in\u00a0treatment\u2010naive\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0 C\u00a0virus\u00a0genotype\u00a01\u00a0infection\u00a0(QUEST\u20102)\u00a0\u2010\u00a0a\u00a0randomised,\u00a0\ndouble\u2010blind,\u00a0placebo\u2010controlle d\u00a0Phase\u00a0III\u00a0trial.\u00a0Lancet\u00a0384\u00a0(9 941):\u00a0414\u2010426.\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0Simeprevir.\u00a0Chronic\u00a0hepatitis\u00a0C :\u00a0an\u00a0option\u00a0for\u00a0some\u00a0patients.\u00a0Prescrire\u00a0Int\u00a024\u00a0(160):\u00a0120.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Simeprevir|Olysio\u00ae| 83|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=53129,\u00a0letzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nQu\u00a0Y,\u00a0Li\u00a0T,\u00a0Wang\u00a0L,\u00a0Liu\u00a0F,\u00a0Ye\u00a0Q\u00a0(2016).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0 simeprevir\u00a0for\u00a0chronic\u00a0hepatitis \u00a0virus\u00a0C\u00a0genotype\u00a01\u00a0infection:\u00a0 A\u00a0meta\u2010\nanalysis.\u00a0Clin\u00a0Res\u00a0Hepatol\u00a0Gastroenterol\u00a040(2):\u00a0203\u2010212.\u00a0\u00a0\nRKI\u00a0\u2013\u2010\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014a).\u00a0Hepatitis\u00a0C\u00a0RKI\u2010Ratgeber\u00a0f \u00fcr\u00a0\u00c4rzte.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02014.\u00a0\nhttp://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratge ber_HepatitisC.html,\u00a0letzter\u00a0Zugriff:\u00a009.02.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014b).\u00a0Virus\u2010Hepatitis\u00a0C:\u00a0Situatio nsbericht\u00a0Deutschland\u00a02013.\u00a0EpiBulletin\u00a02014;\u00a031(2014):275\u2010288. \u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016) .\u00a0Zur\u00a0Situation\u00a0bei\u00a0wichtigen\u00a0 Infektionskrankheiten\u00a0in\u00a0Deutschland\u00a0Hepatitis\u00a0C\u00a0im\u00a0Jahr\u00a02015.\u00a0\nEpiBulletin\u00a02016;\u00a029(2016):255\u2010268.\u00a0\nThimme\u00a0R,\u00a0Heim\u00a0M,\u00a0Baumert\u00a0TF,\u00a0Nassal\u00a0M,\u00a0Moradpour\u00a0D\u00a0(2014).\u00a0Hep atitis\u00a0B\u00a0and\u00a0C:\u00a0from\u00a0molecular\u00a0virology\u00a0to\u00a0new\u00a0antiviral\u00a0\ntherapies\u00a0(part\u00a02).\u00a0Dtsch\u00a0Med\u00a0Wochenschr\u00a0139(15):\u00a0778\u2010782.\u00a0\nVan\u00a0Sanden\u00a0S,\u00a0Pisini\u00a0M,\u00a0Duchesne\u00a0I,\u00a0Mehnert\u00a0A,\u00a0Belsey\u00a0J\u00a0(2016). \u00a0Indirect\u00a0comparison\u00a0of\u00a0the\u00a0antiviral\u00a0efficacy\u00a0of\u00a0peginterferon \u00a0alpha\u00a0\n2a\u00a0plus\u00a0ribavirin\u00a0used\u00a0with\u00a0or\u00a0without\u00a0simeprevir\u00a0in\u00a0genotype\u00a04 \u00a0hepatitis\u00a0C\u00a0virus\u00a0infection,\u00a0where\u00a0common\u00a0\ncomparator\u00a0study\u00a0arms\u00a0are\u00a0lacking:\u00a0a\u00a0special\u00a0application\u00a0of\u00a0the \u00a0matching\u00a0adjusted\u00a0indirect\u00a0comparison\u00a0\nmethodology.\u00a0Curr\u00a0Med\u00a0Res\u00a0Opin\u00a032(1):\u00a0147\u2010154.\u00a0\u00a0\n\u00a0 \u00a0359\u00a04.24 Simoctocog\u00a0alfa\u00a0\nHandelsname:\u00a0Nuwiq\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0H\u00e4mophilie\u00a0A\u00a0 \u00a0 \u00a0 Octapharma\u00a0AB\u00a0\nATC\u2010Code:\u00a0B02BD17\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0November\u00a02014\u00a0\nDarreichungsform:\u00a0Pulver\u00a0zur\u00a0\u00a0\nHerstellung\u00a0einer\u00a0Injektionsl\u00f6sung\u00a0 DDD:\u00a0500\u00a0I.E.\u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nSimoctocog\u00a0alfa\u00a0(Nuwiq\u00ae)\u00a0ist\u00a0ein\u00a0rekombinanter\u00a0humaner\u00a0Blutgeri nnungsfaktor\u00a0\nVIII,\u00a0der\u00a0in\u00a0genetisch\u00a0ver\u00e4nderten\u00a0menschlichen\u00a0embryonalen\u00a0Nie renzellen\u00a0herge\u2010\nstellt\u00a0wird.\u00a0Im\u00a0Hinblick\u00a0auf\u00a0den\u00a0Wirkungsmechanismus\u00a0gibt\u00a0es\u00a0ke ine\u00a0Unterschiede\u00a0\nzu\u00a0aus\u00a0Plasma\u00a0isoliertem\u00a0humanen\u00a0Faktor\u00a0VIII\u00a0(EMA,\u00a02014).\u00a0Das\u00a0F ertigarzneimittel,\u00a0\ndas\u00a0nach\u00a0Rekonstitution\u00a0intraven\u00f6s\u00a0verabreicht\u00a0wird,\u00a0steht\u00a0in\u00a0v ier\u00a0verschiedenen\u00a0\nKonzentrationen\u00a0zur\u00a0Verf\u00fcgung.\u00a0Simoctocog\u00a0alfa\u00a0ist\u00a0zur\u00a0Behandlu ng\u00a0und\u00a0Prophyla\u2010\nxe\u00a0von\u00a0Blutungen\u00a0bei\u00a0Patienten\u00a0mit\u00a0H\u00e4mophilie\u00a0A\u00a0bei\u00a0allen\u00a0Alter sgruppen\u00a0zugelas\u2010\nsen.\u00a0Die\u00a0zu\u00a0verabreichende\u00a0Dosis\u00a0h\u00e4ngt\u00a0vom\u00a0Schweregrad\u00a0des\u00a0Fakt or\u2010VIII\u2010Mangels,\u00a0\nArt\u00a0der\u00a0Behandlung\u00a0(Bedarfstherapie\u00a0oder\u00a0Prophylaxe),\u00a0Ort\u00a0und\u00a0A usma\u00df\u00a0der\u00a0Blu\u2010\ntung\u00a0und\u00a0dem\u00a0klinischen\u00a0Zustand\u00a0des\u00a0Patienten\u00a0ab.\u00a0\u00a0\nBisher\u00a0liegen\u00a0zur\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0von\u00a0Simoctocog\u00a0alf a\u00a0nur\u00a0Daten\u00a0aus\u00a0\nherstellergesponserten\u00a0Studien\u00a0mit\u00a0Patienten\u00a0vor,\u00a0die\u00a0bereits\u00a0z uvor\u00a0mit\u00a0Faktor\u2010VIII\u2010\nPr\u00e4paraten\u00a0 behandelt\u00a0 wurden.\u00a0 Die\u00a0 Wirksamkeit\u00a0 belegte\u00a0 der\u00a0 Pharma zeutische\u00a0\nUnternehmer\u00a0(pU)\u00a0mit\u00a0drei\u00a0unkontrollierten\u00a0Studien\u00a0(GENA\u201001,\u00a0GE NA\u201003,\u00a0GENA\u2010\n08)\u00a0an\u00a0insgesamt\u00a0135\u00a0Patienten\u00a0(Erwachsene,\u00a0Kinder\u00a0und\u00a0Jugendli che),\u00a0die\u00a0die\u00a0\nAkutbehandlung\u00a0 von\u00a0 Blutungsepisoden\u00a0 beziehungsweise\u00a0 eine\u00a0 prophy laktische\u00a0\nGabe\u00a0untersuchten\u00a0(Klukowska\u00a0et\u00a0al.,\u00a02016;\u00a0Lissitchkov\u00a0et\u00a0al.,\u00a0 2016;\u00a0Tiede\u00a0et\u00a0al.,\u00a0\n2016).\u00a0Bei\u00a0der\u00a0Mehrzahl\u00a0(je\u00a0nach\u00a0Studie\u00a0zwischen\u00a082\u00a0und\u00a0100\u00a0%)\u00a0 der\u00a0insgesamt\u00a0\nrund\u00a01.100\u00a0Blutungsepisoden\u00a0wurde\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0Simoctoco g\u00a0alfa\u00a0nach\u00a0\nvorgegebenen\u00a0Kriterien\u00a0als\u00a0ausge zeichnet\u00a0oder\u00a0gut\u00a0bewertet.\u00a0W\u00e4h rend\u00a0der\u00a0pro\u2010\nphylaktischen\u00a0Behandlung\u00a0traten\u00a0 bei\u00a0Jugendlichen\u00a0und\u00a0Erwachsene n\u00a0im\u00a0Mittel\u00a00,2\u00a0\nBlutungsepisoden\u00a0pro\u00a0Monat\u00a0auf,\u00a0bei\u00a0Kindern\u00a00,3\u00a0Blutungsepisode n\u00a0pro\u00a0Monat.\u00a0\nVergleiche\u00a0 mit\u00a0 anderen\u00a0 Faktor\u2010VIII\u2010Pr\u00e4paraten\u00a0 sowie\u00a0 Daten\u00a0 zur\u00a0 L ebensqualit\u00e4t\u00a0\nfehlen\u00a0bisher.\u00a0Ebenso\u00a0gibt\u00a0es\u00a0keine\u00a0Erfahrungen\u00a0mit\u00a0der\u00a0Behandl ung\u00a0von\u00a0Patien\u2010\nten,\u00a0die\u00a0bisher\u00a0keine\u00a0Faktor\u2010VIII\u2010 Pr\u00e4parate\u00a0erhalten\u00a0hatten,\u00a0so wie\u00a0von\u00a0Jugendli\u2010\nchen,\u00a0die\u00a0\u00e4lter\u00a0als\u00a014,\u00a0aber\u00a0j\u00fcng er\u00a0als\u00a018\u00a0Jahre\u00a0sind\u00a0(EMA,\u00a0201 4).\u00a0\nDaten\u00a0zur\u00a0Sicherheit\u00a0liegen\u00a0f\u00fcr\u00a0rund\u00a016.000\u00a0verabreichte\u00a0Einzel dosen\u00a0vor,\u00a0der\u00a0\nl\u00e4ngste\u00a0Erfahrungsumfang\u00a0betr\u00e4gt\u00a0rund\u00a065\u00a0Wochen.\u00a0Als\u00a0unerw\u00fcnsch te\u00a0Arzneimit\u2010\ntelereignisse\u00a0(UAE)\u00a0traten\u00a0in\u00a0den\u00a0Zulassungsstudien\u00a0gelegentlic h\u00a0Kopfschmerzen,\u00a0\nSchwindel,\u00a0Par\u00e4sthesien,\u00a0Mundtrockenheit,\u00a0R\u00fcckenschmerzen\u00a0und\u00a0E ntz\u00fcndungen\u00a0360\u00a0oder\u00a0Schmerzen\u00a0an\u00a0der\u00a0Injektionsstelle\u00a0auf\u00a0(EMA,\u00a02014).\u00a0Als\u00a0neu er\u00a0Wirkstoff\u00a0steht\u00a0\nSimoctocog\u00a0alfa\u00a0unter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung\u00a0(schwarzes\u00a0Dreie ck).\u00a0Im\u00a0Juli\u00a02016\u00a0\nstartete\u00a0die\u00a0EMA\u00a0ein\u00a0Risikobewertungsverfahren\u00a0f\u00fcr\u00a0alle\u00a0Faktor\u2010 VIII\u2010Produkte\u00a0im\u00a0\nHinblick\u00a0auf\u00a0die\u00a0Entwicklung\u00a0neutralisierender\u00a0Antik\u00f6rper,\u00a0die\u00a0 die\u00a0Wirksamkeit\u00a0der\u00a0\nGerinnungsfaktoren\u00a0verringern\u00a0(EMA,\u00a02016).\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0war\u00a0 kein\u00a0Zusatznutzen \u00a0feststellbar,\u00a0da\u00a0\nder\u00a0pU\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0vorlegte\u00a0(G\u2010BA,\u00a02015).\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0\u00a0Kosten\u00a0\n\u00a0Weitere\u00a0Therapieoption\u00a0\nf\u00fcr\u00a0Patienten\u00a0mit\u00a0\nH\u00e4mophilie\u00a0A\u00a0\n(Prophylaxe\u00a0und\u00a0\nBehandlung\u00a0von\u00a0\nBlutungsepisoden)\u00a0Keine\u00a0therapeutisch\u00a0\nrelevanten\u00a0Vorteile,\u00a0es\u00a0\nfehlen\u00a0Vergleichs\u2010\nstudien\u00a0mit\u00a0anderen\u00a0\nFaktor\u2010VIII\u2010Pr\u00e4paraten\u00a0teils\u00a0g\u00fcnstiger,\u00a0teils\u00a0teurer\u00a0\nals\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSimoctocog\u00a0alfa\u00a0 20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0160.125,00\u00a0\u20ac\u00b2\u00a0\n240.187,50\u00a0\u20ac\u00b2\u00a0\n320.250,00\u00a0\u20ac\u00b2\u00a0\n480.375,00\u00a0\u20ac\u00b2\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nTuroctocog\u00a0alfa\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFortsetzung\u00a0auf\u00a0\nn\u00e4chster\u00a0Seite\u00a020\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01\u00a0440\u00a0i.E1\u00a0\n50\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n50\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0156\u00a0\n183\u00a0\n156\u00a0\n183\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0194.220,00\u00a0\u20ac\u00b2\u00a0\n227.835,00\u00a0\u20ac\u00b2\u00a0\n388.440,00\u00a0\u20ac\u00b2\u00a0\n455.670,00\u00a0\u20ac\u00b2\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n361\u00a0Wirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nOctocog\u00a0alfa\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nMoroctocog\u00a0alfa\u00a020\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0\n\u00a0\n122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0151.890,00\u00a0\u20ac\u00b2\u00a0\n227.835,00\u00a0\u20ac\u00b2\u00a0\n303.780,00\u00a0\u20ac\u00b2\u00a0\n455.670,00\u00a0\u20ac\u00b2\u00a0\n\u00a0\n177.510,00\u00a0\u20ac\u00b2\u00a0\n266.265,00\u00a0\u20ac\u00b2\u00a0\n355.020,00\u00a0\u20ac\u00b2\u00a0\n532.530,00\u00a0\u20ac\u00b2 \u00a0\n1Dosierung\u00a0pro\u00a0Behandlung\u00a0f\u00fcr\u00a0Erwachsene:\u00a020.i.E\u00a0bis\u00a040\u00a0i.E\u00a0/kg\u00a0 =\u00a01\u00a0440\u00a0i.E\u00a0\u2010\u00a02880\u00a0i.E\u00a0bei\u00a072\u00a0kg\u00a0\n2Preisberechnungen\u00a0beruhen\u00a0lediglich\u00a0auf\u00a0dem\u00a0Herstellerabgabepre is:\u00a0Gro\u00dfhandelszuschl\u00e4ge\u00a0unber\u00fccksichtigt\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nSimoctocog\u00a0alfa\u00a0ist\u00a0ein\u00a0rekombinanter\u00a0humaner\u00a0Blutgerinnungsfak tor\u00a0VIII,\u00a0der\u00a0in\u00a0\ngenetisch\u00a0ver\u00e4nderten\u00a0menschlichen\u00a0embryonalen\u00a0Nierenzellen\u00a0her gestellt\u00a0wird.\u00a0\nDadurch\u00a0weist\u00a0der\u00a0Wirkstoff\u00a0die\u00a0f\u00fcr\u00a0humane\u00a0Proteine\u00a0typischen\u00a0G lykosylierungs\u2010\nmuster\u00a0auf\u00a0und\u00a0vermeidet\u00a0m\u00f6glicherweise\u00a0antigen\u00a0wirkende\u00a0Epitop e.\u00a0Im\u00a0Vergleich\u00a0\nzu\u00a0nativem\u00a0humanen\u00a0Faktor\u00a0VIII\u00a0wurde\u00a0bei\u00a0Simoctocog\u00a0alfa\u00a0die\u00a0B\u2010 Dom\u00e4ne\u00a0entfernt\u00a0\nund\u00a0im\u00a0Gegenzug\u00a0f\u00fcr\u00a0eine\u00a0verbesserte\u00a0Stabilit\u00e4t\u00a0und\u00a0Wirksamkeit \u00a0eine\u00a0Peptidkette\u00a0\nmit\u00a021\u00a0Aminos\u00e4uren\u00a0eingef\u00fcgt.\u00a0Dadurch\u00a0besteht\u00a0Simoctocog\u00a0alfa\u00a0a us\u00a01440\u00a0Amino\u2010\ns\u00e4uren\u00a0und\u00a0weist\u00a0ein\u00a0Molekulargewicht\u00a0von\u00a0170\u00a0kDa\u00a0auf.\u00a0\u00a0\nSimoctocog\u00a0alfa\u00a0wirkt\u00a0im\u00a0K\u00f6rper\u00a0 wie\u00a0ein\u00a0aus\u00a0Plasma\u00a0isolierter\u00a0h umaner\u00a0Faktor\u00a0VIII:\u00a0\nFaktor\u00a0VIII\u00a0ist\u00a0ein\u00a0Cofaktor\u00a0des\u00a0Blutgerinnungsfaktors\u00a0IXa,\u00a0der \u00a0im\u00a0Gerinnungssys\u2010\ntem\u00a0Faktor\u00a0X\u00a0zu\u00a0Faktor\u00a0Xa\u00a0aktiviert.\u00a0Faktor\u00a0Xa\u00a0katalysiert\u00a0die\u00a0 Umwandlung\u00a0von\u00a0\nProthrombin\u00a0zu\u00a0Thrombin,\u00a0das\u00a0wiederum\u00a0die\u00a0Bildung\u00a0von\u00a0Fibrin\u00a0au s\u00a0Fibrinogen\u00a0\nund\u00a0somit\u00a0die\u00a0Blutstillung\u00a0beg\u00fcnstigt\u00a0(EMA,\u00a02014).\u00a0\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nSimoctocog\u00a0alfa\u00a0ist\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0Nuwiq\u00ae\u00a0zur\u00a0Behandlun g\u00a0und\u00a0Prophy\u2010\nlaxe\u00a0von\u00a0Blutungen\u00a0bei\u00a0Patienten\u00a0mit\u00a0H\u00e4mophilie\u00a0A\u00a0bei\u00a0allen\u00a0Alt ersgruppen\u00a0zuge\u2010\nlassen.\u00a0Das\u00a0Fertigarzneimittel\u00a0liegt\u00a0als\u00a0Pulver\u00a0in\u00a0einer\u00a0Durchs techflasche\u00a0vor,\u00a0das\u00a0\nvor\u00a0der\u00a0intraven\u00f6sen\u00a0Injektion\u00a0mit\u00a0Wasser\u00a0f\u00fcr\u00a0Injektionszwecke\u00a0 in\u00a0eine\u00a0klare\u00a0Injek\u2010\ntionsl\u00f6sung\u00a0\u00fcberf\u00fchrt\u00a0werden\u00a0muss.\u00a0Der\u00a0Wirkstoff\u00a0ist\u00a0in\u00a0vier\u00a0ve rschiedenen\u00a0Dosie\u2010\nrungen\u00a0im\u00a0Handel,\u00a0die\u00a0nach\u00a0dem\u00a0A ufl\u00f6sen\u00a0einer\u00a0Konzentration\u00a0von \u00a0100,\u00a0200,\u00a0400\u00a0\nbzw.\u00a0800\u00a0I.E.\u00a0pro\u00a0Milliliter\u00a0entsprechen.\u00a0\u00a0\nDie\u00a0zu\u00a0verabreichende\u00a0Dosis\u00a0h\u00e4ngt\u00a0vom\u00a0Schweregrad\u00a0des\u00a0Faktor\u2010VI II\u2010Mangels,\u00a0der\u00a0\nArt\u00a0der\u00a0Behandlung\u00a0(Bedarfstherapie\u00a0oder\u00a0Prophylaxe),\u00a0Ort\u00a0und\u00a0A usma\u00df\u00a0der\u00a0Blu\u2010\ntung\u00a0und\u00a0dem\u00a0klinischen\u00a0Zustand\u00a0des\u00a0Patienten\u00a0ab.\u00a0F\u00fcr\u00a0die\u00a0proph ylaktische\u00a0Be\u2010\nhandlung\u00a0werden\u00a0\u00fcblicherweise\u00a020\u00a0bis\u00a040\u00a0I.E.\u00a0pro\u00a0Kilogramm\u00a0K\u00f6rp ergewicht\u00a0(KG)\u00a0362\u00a0alle\u00a0zwei\u00a0bis\u00a0drei\u00a0Tage\u00a0verwendet.\u00a0Individuelle\u00a0Abweichungen\u00a0si nd\u00a0m\u00f6glich.\u00a0Im\u00a0\nLaufe\u00a0der\u00a0Behandlung\u00a0werden\u00a0Kon trollen\u00a0des\u00a0Faktor\u2010VIII\u2010Spiegels \u00a0empfohlen.\u00a0\u00a0\nDer\u00a0Wirkstoff\u00a0ist\u00a0w\u00e4rmeempfindlich\u00a0und\u00a0muss\u00a0im\u00a0K\u00fchlschrank\u00a0gela gert\u00a0werden.\u00a0\nNach\u00a0der\u00a0Rekonstitution\u00a0sollte\u00a0die\u00a0Injektionsl\u00f6sung\u00a0aus\u00a0Gr\u00fcnden \u00a0der\u00a0mikrobiellen\u00a0\nStabilit\u00e4t\u00a0sofort\u00a0verwendet\u00a0werden.\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nBei\u00a0einer\u00a0H\u00e4mophilie\u00a0A\u00a0besteht\u00a0ein \u00a0Defekt\u00a0in\u00a0dem\u00a0Gen,\u00a0das\u00a0f\u00fcr\u00a0d en\u00a0Blutgerinnungs\u2010\nfaktor\u00a0VIII\u00a0codiert.\u00a0Die\u00a0Erkrankung\u00a0wird\u00a0X\u2010chromosomal\u2010rezessiv \u00a0\u00fcber\u00a0die\u00a0m\u00fctterli\u2010\nche\u00a0 Linie\u00a0 vererbt.\u00a0 Allerdings\u00a0 manifestiert\u00a0 sich\u00a0 das\u00a0 Krankheitsb ild\u00a0 nahezu\u00a0 ohne\u00a0\nAusnahme\u00a0 nur\u00a0 bei\u00a0 M\u00e4nnern.\u00a0 Die\u00a0 Pr\u00e4valenz\u00a0 wird\u00a0 mit\u00a0 1:5.000\u00a0 Knaben geburten\u00a0\nangegeben.\u00a0Wie\u00a0stark\u00a0die\u00a0Erkrankung\u00a0ausgepr\u00e4gt\u00a0ist,\u00a0h\u00e4ngt\u00a0von\u00a0d avon\u00a0ab,\u00a0wie\u00a0\nhoch\u00a0die\u00a0Restgerinnungsaktivit\u00e4t\u00a0ausf\u00e4llt.\u00a0Diese\u00a0ist\u00a0proportion al\u00a0zur\u00a0Blutungsnei\u2010\ngung.\u00a0Eine\u00a0schwere\u00a0H\u00e4mophilie\u00a0liegt\u00a0vor,\u00a0wenn\u00a0die\u00a0Restgerinnung saktivit\u00e4t\u00a0weni\u2010\nger\u00a0als\u00a0ein\u00a0Prozent\u00a0des\u00a0Normwerts\u00a0betr\u00e4gt.\u00a0Zwischen\u00a0ein\u00a0und\u00a0f\u00fcn f\u00a0Prozent\u00a0spricht\u00a0\nman\u00a0von\u00a0einer\u00a0mittelschweren\u00a0H\u00e4mo philie.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0leic hter\u00a0H\u00e4mophilie\u00a0\nfindet\u00a0sich\u00a0eine\u00a0Restgerinnungsaktivit\u00e4t\u00a0von\u00a05\u00a0bis\u00a015\u00a0Prozent,\u00a0 w\u00e4hrend\u00a0bei\u00a0Subh\u00e4\u2010\nmophilie\u00a0die\u00a0Restgerinnungsaktivit\u00e4t\u00a0bei\u00a015\u00a0bis\u00a050\u00a0%\u00a0liegt\u00a0(Bun des\u00e4rztekammer,\u00a0\n2014;\u00a0IQWiG,\u00a02015).\u00a0\nVor\u00a0allem\u00a0bei\u00a0einer\u00a0schweren\u00a0H \u00e4mophilie\u00a0k\u00f6nnen\u00a0spontan\u00a0und\u00a0ohne \u00a0\u00e4u\u00dferen\u00a0\nAnlass\u00a0 ausgedehnte\u00a0 Blutungen\u00a0 vor\u00a0 allem\u00a0 in\u00a0 Gelenken\u00a0 und\u00a0 Muskeln\u00a0 auftreten.\u00a0\nBlutungen\u00a0in\u00a0den\u00a0Gelenken\u00a0verursachen\u00a0nicht\u00a0nur\u00a0Schmerzen,\u00a0sond ern\u00a0k\u00f6nnen\u00a0zu\u00a0\nbleibenden\u00a0Gelenksch\u00e4den\u00a0f\u00fchren.\u00a0 Oft\u00a0sind\u00a0die\u00a0gro\u00dfen\u00a0Gelenke\u00a0wi e\u00a0Ellenbogen,\u00a0\nKnie\u00a0und\u00a0Sprunggelenke\u00a0betroffen. \u00a0Blutungen\u00a0in\u00a0der\u00a0Muskulatur\u00a0k \u00f6nnen\u00a0zu\u00a0einer\u00a0\nMuskelschrumpfung\u00a0f\u00fchren,\u00a0die\u00a0sich\u00a0auch\u00a0auf\u00a0Gelenke\u00a0und\u00a0benachb arte\u00a0Nerven\u00a0\nauswirken.\u00a0Lebensgef\u00e4hrlich\u00a0sind\u00a0innere\u00a0Blutungen,\u00a0vor\u00a0allem\u00a0im \u00a0Bereich\u00a0von\u00a0Kopf\u00a0\nund\u00a0Gehirn\u00a0(IQWiG,\u00a02015).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0f\u00fcnf\u00a0offe nen\u00a0einarmigen\u00a0klinischen\u00a0Stu dien\u00a0mit\u00a0insge\u2010\nsamt\u00a0135\u00a0Patienten,\u00a0die\u00a0bereits\u00a0vorher\u00a0Faktor\u00a0VIII\u2010Produkte\u00a0erh alten\u00a0hatten,\u00a0aber\u00a0\nbei\u00a0denen\u00a0keine\u00a0relevante\u00a0Aktivit\u00e4t\u00a0eines\u00a0Inhibitors\u00a0gegen\u00a0Fakt or\u00a0VIII\u00a0nachweisbar\u00a0\nwar.\u00a0Zwei\u00a0der\u00a0Studien\u00a0(GENA\u201001,\u00a0GENA\u201009)\u00a0waren\u00a0prim\u00e4r\u00a0als\u00a0pharm akokinetische\u00a0\nUntersuchungen\u00a0ausgelegt,\u00a0eine\u00a0zur\u00a0Untersuchung\u00a0von\u00a0langfristig er\u00a0Immunogeni\u2010\nt\u00e4t\u00a0und\u00a0Vertr\u00e4glichkeit\u00a0(GENA\u201004)\u00a0und\u00a0zwei\u00a0f\u00fcr\u00a0den\u00a0Wirksamkeits nachweis\u00a0(GENA\u2010\n08,\u00a0GENA\u201003).\u00a0Von\u00a0den\u00a0Studienteilnehmern\u00a0waren\u00a059\u00a0zwischen\u00a0zwei \u00a0und\u00a0zw\u00f6lf\u00a0\nJahre\u00a0alt,\u00a0drei\u00a0Patienten\u00a0sind\u00a0Jugendliche\u00a0zwischen\u00a012\u00a0und\u00a014\u00a0J ahren.\u00a0Es\u00a0fehlen\u00a0\nbisher\u00a0Daten\u00a0f\u00fcr\u00a0Patienten,\u00a0die\u00a0 \u00e4lter\u00a0als\u00a014,\u00a0aber\u00a0j\u00fcnger\u00a0als\u00a01 8\u00a0Jahre\u00a0sind.\u00a0Einge\u2010363\u00a0schlossen\u00a0wurden\u00a0in\u00a0die\u00a0Studien\u00a0Patienten\u00a0mit\u00a0schwerer\u00a0H\u00e4mophil ie\u00a0A,\u00a0definiert\u00a0\nals\u00a0Faktor\u2010VIII\u2010Aktivit\u00e4t\u00a0unter\u00a0einem\u00a0Prozent\u00a0(Kinder)\u00a0beziehun gsweise\u00a0h\u00f6chstens\u00a0\nein\u00a0Prozent\u00a0(Jugendliche\u00a0und\u00a0Erwachsene).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0der\u00a0Wirksamkeit\u00a0zieht\u00a0die\u00a0EMA\u00a0drei\u00a0der\u00a0Studie n\u00a0heran.\u00a0Simoc\u2010\ntocog\u00a0alfa\u00a0wurde\u00a0in\u00a0den\u00a0Studien\u00a0in\u00a0verschiedenen\u00a0Behandlungssit uationen\u00a0unter\u2010\nsucht:\u00a0Eine\u00a0Studie\u00a0testete\u00a0den\u00a0Wirkstoff\u00a0als\u00a0Mittel\u00a0zur\u00a0Akutbeh andlung\u00a0von\u00a0Blu\u2010\ntungsepisoden\u00a0(GENA\u201001),\u00a0die\u00a0be iden\u00a0anderen\u00a0(GENA\u201008,\u00a0GENA\u201003)\u00a0 zur\u00a0Prophyla\u2010\nxe\u00a0und\u00a0Behandlung\u00a0von\u00a0Durchbruchblutungen.\u00a0Gem\u00e4\u00df\u00a0der\u00a0EMA\u2010Richtl inie\u00a0zu\u00a0Stu\u2010\ndien\u00a0mit\u00a0Faktor\u2010VIII\u2010Produkten\u00a0wu rde\u00a0der\u00a0Erfolg\u00a0der\u00a0Akutbehandl ung\u00a0nach\u00a0vorge\u2010\ngebenen\u00a0Kriterien\u00a0auf\u00a0einer\u00a0viers tufigen\u00a0Skala\u00a0durch\u00a0Patient\u00a0un d\u00a0Arzt\u00a0bewertet\u00a0\n(ausgezeichnet,\u00a0gut,\u00a0moderat,\u00a0kei ne\u00a0Wirkung).\u00a0In\u00a0der\u00a0GENA\u201001\u2010St udie\u00a0mit\u00a022\u00a0Ju\u2010\ngendlichen\u00a0und\u00a0Erwachsenen\u00a0wurd e\u00a0der\u00a0Erfolg\u00a0in\u00a0rund\u00a060\u00a0%\u00a0der\u00a0in sgesamt\u00a0986\u00a0\nBlutungsepisoden\u00a0mit\u00a0ausgezeichnet,\u00a0bei\u00a0weiteren\u00a034\u00a0%\u00a0mit\u00a0gut\u00a0b ewertet\u00a0(Tiede\u00a0et\u00a0\nal.,\u00a02016).\u00a0In\u00a0der\u00a0GENA\u201008\u2010Studie\u00a0mit\u00a032\u00a0Jugendlichen\u00a0und\u00a0Erwac hsenen\u00a0traten\u00a0bei\u00a0\nprophylaktischer\u00a0Behandlung\u00a0(30\u00a0bis\u00a040\u00a0I.\u00a0E.\u00a0Simoctocog\u00a0alfa\u00a0pr o\u00a0kg\u00a0KG\u00a0alle\u00a0zwei\u00a0\nTage\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0sechs\u00a0Monaten)\u00a0insgesamt\u00a044\u00a0Blutun gsepisoden\u00a0\nauf,\u00a0pro\u00a0Teilnehmer\u00a0im\u00a0Mittel\u00a0rund\u00a00,2\u00a0Blutungsepisoden\u00a0pro\u00a0Mon at.\u00a0Davon\u00a0wur\u2010\nden\u00a0insgesamt\u00a030\u00a0mit\u00a0Simoctocog\u00a0alfa\u00a0behandelt.\u00a0Die\u00a0Wirksamkeit \u00a0bei\u00a0den\u00a0aus\u2010\nwertbaren\u00a028\u00a0Blutungsepisoden\u00a0wurde\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0als\u00a0ausgeze ichnet\u00a0oder\u00a0gut\u00a0\nbewertet\u00a0(Lissitchkov\u00a0et\u00a0al.,\u00a02016).\u00a0In\u00a0der\u00a0Studie\u00a0an\u00a059\u00a0Kinder n\u00a0(GENA\u201003)\u00a0lag\u00a0die\u00a0\nmittlere\u00a0Anzahl\u00a0von\u00a0Blutungsepisoden\u00a0bei\u00a0rund\u00a00,3\u00a0pro\u00a0Monat.\u00a0In sgesamt\u00a0wurden\u00a0108\u00a0\nBlutungsepisoden\u00a0beobachtet,\u00a0die\u00a0alle\u00a0mit\u00a0Simoctocog\u00a0alfa\u00a0behan delt\u00a0wurden.\u00a0Dabei\u00a0\nwurde\u00a0die\u00a0Wirksamkeit\u00a0des\u00a0Pr\u00e4parats\u00a0in\u00a071\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0als\u00a0ausge zeichnet,\u00a0in\u00a011\u00a0%\u00a0der\u00a0\nF\u00e4lle\u00a0als\u00a0gut\u00a0bewertet\u00a0(Klukowska\u00a0et\u00a0al.,\u00a02016).\u00a0In\u00a0den\u00a0drei\u00a0St udien\u00a0wurde\u00a0die\u00a0prophy\u2010\nlaktische\u00a0Wirksamkeit\u00a0von\u00a0Simoctocog\u00a0bei\u00a0chirurgischen\u00a0Eingriff en\u00a0an\u00a0insgesamt\u00a013\u00a0\nPatienten\u00a0beobachtet\u00a0und\u00a0bei\u00a085\u00a0%\u00a0als\u00a0ausgezeichnet\u00a0bewertet\u00a0(E MA,\u00a02014).\u00a0\u00a0\nEine\u00a0Literaturrecherche\u00a0in\u00a0PubMed\u00a0und\u00a0der\u00a0Cochrane\u00a0Library\u00a0fand \u00a0keine\u00a0weiteren\u00a0\nabgeschlossenen\u00a0publizierten\u00a0Studien.\u00a0Eine\u00a0Recherche\u00a0in\u00a0Studien registern\u00a0(clini\u2010\ncaltrials.gov,\u00a0EudraCT)\u00a0ermittelt e\u00a0zwei\u00a0abgeschlossene\u00a0Studien, \u00a0deren\u00a0Ergebnisse\u00a0\nnur\u00a0in\u00a0Registern\u00a0publiziert\u00a0sind. \u00a0GENA\u201011\u00a0ist\u00a0eine\u00a0offene,\u00a0eina rmige\u00a0Erweiterungs\u2010\nstudie\u00a0zu\u00a0GENA\u201001\u00a0mit\u00a0lediglich\u00a0drei\u00a0Teilnehmern\u00a0(GENA\u201011,\u00a02010 ).\u00a0GENA\u201021\u00a0un\u2010\ntersuchte\u00a0an\u00a066\u00a0Teilnehmern\u00a0in\u00a0einer\u00a0offenen\u00a0einarmigen\u00a0Studie\u00a0 die\u00a0Wirksamkeit\u00a0\neiner\u00a0prophylaktischen\u00a0Behandlung\u00a0mit\u00a0Simoctocog\u00a0alfa\u00a0\u00fcber\u00a0eine n\u00a0Zeitraum\u00a0von\u00a0\nsechs\u00a0Monaten.\u00a0Im\u00a0Mittel\u00a0traten\u00a0bei\u00a0den\u00a0so\u00a0behandelten\u00a0Probande n\u00a0hochgerech\u2010\nnet\u00a0auf\u00a0ein\u00a0Jahr\u00a0im\u00a0Mittel\u00a0rund\u00a0drei\u00a0Blutungsepisoden\u00a0auf\u00a0(Eudr aCT\u00a02013\u2010001556\u2010\n35).\u00a0Weitere\u00a0derzeit\u00a0noch\u00a0laufende\u00a0Studien\u00a0setzen\u00a0Untersuchunge n\u00a0mit\u00a0einarmi\u2010\ngem\u00a0Design\u00a0(GENA\u201013,\u00a0GENA\u201015,\u00a0GENA\u201021b)\u00a0oder\u00a0als\u00a0nicht\u2010interven tionelle\u00a0Studie\u00a0\n(GENA\u201099)\u00a0fort,\u00a0bzw.\u00a0testen\u00a0Sim octocog\u00a0an\u00a0bisher\u00a0unbehandelten\u00a0 Patienten\u00a0mit\u00a0\nH\u00e4mophilie\u00a0A\u00a0(GENA\u201005).\u00a0\u00a0364\u00a0Daten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0liegen\u00a0f\u00fcr\u00a0Simoct ocog\u00a0alfa\u00a0nicht\u00a0vor.\u00a0\nIn\u00a0die\u00a0Bewertung\u00a0der\u00a0Sicherheit\u00a0im\u00a0europ\u00e4ischen\u00a0Beurteilungsber icht\u00a0flie\u00dfen\u00a0alle\u00a0\nf\u00fcnf\u00a0Zulassungsstudien\u00a0ein.\u00a0Der\u00a0Erfahrungsumfang\u00a0liegt\u00a0damit\u00a0in sgesamt\u00a0bei\u00a0rund\u00a0\n16.000\u00a0verabreichten\u00a0Einzeldosen,\u00a0die\u00a0l\u00e4ngste\u00a0Studie\u00a0umfasste\u00a0i m\u00a0Mittel\u00a0einen\u00a0\nAnwendungszeitraum\u00a0von\u00a0rund\u00a065\u00a0Wochen.\u00a0Gelegentlich\u00a0traten\u00a0Kopf schmerzen,\u00a0\nSchwindel,\u00a0Par\u00e4sthesien,\u00a0Mundtrockenheit,\u00a0R\u00fcckenschmerzen\u00a0und\u00a0E ntz\u00fcndungen\u00a0\noder\u00a0Schmerzen\u00a0an\u00a0der\u00a0Injektionsstelle\u00a0auf.\u00a0Nur\u00a0in\u00a0einem\u00a0Fall\u00a0f anden\u00a0sich\u00a0nicht\u2010\nneutralisierende\u00a0Antik\u00f6rper\u00a0gegen\u00a0Faktor\u00a0VIII.\u00a0Selten\u00a0kam\u00a0es\u00a0zu \u00a0\u00dcberempfindlich\u2010\nkeits\u2010\u00a0oder\u00a0allergischen\u00a0Reaktionen\u00a0(EMA,\u00a02014).\u00a0\nIm\u00a0Juli\u00a02016\u00a0startete\u00a0die\u00a0EMA\u00a0auf\u00a0Antrag\u00a0des\u00a0Paul\u2010Ehrlich\u2010Insti tuts\u00a0ein\u00a0Risikobewer\u2010\ntungsverfahren\u00a0f\u00fcr\u00a0alle\u00a0Faktor\u2010V III\u2010Produkte\u00a0im\u00a0Hinblick\u00a0auf\u00a0di e\u00a0Entwicklung\u00a0neutrali\u2010\nsierender\u00a0Antik\u00f6rper,\u00a0die\u00a0die\u00a0Wirksamkeit\u00a0der\u00a0Gerinnungsfaktore n\u00a0verringern\u00a0k\u00f6n\u2010\nnen.\u00a0Ausl\u00f6ser\u00a0war\u00a0die\u00a0Publikation\u00a0einer\u00a0Studie\u00a0mit\u00a0Hinweisen\u00a0da rauf,\u00a0dass\u00a0das\u00a0Risiko\u00a0\nm\u00f6glicherweise\u00a0bei\u00a0rekombinanten\u00a0Faktor\u2010VIII\u2010Produkten\u00a0h\u00f6her\u00a0se in\u00a0k\u00f6nnte\u00a0als\u00a0bei\u00a0\nden\u00a0Pr\u00e4paraten,\u00a0die\u00a0aus\u00a0humanem\u00a0Plasma\u00a0isoliert\u00a0werden\u00a0(Peyvand i\u00a0et\u00a0al.,\u00a02016).\u00a0\nLeitlinienempfehlungen\u00a0\nDer\u00a0Wirkstoff\u00a0Simoctocog\u00a0alfa\u00a0wird\u00a0derzeit\u00a0in\u00a0keiner\u00a0der\u00a0betrac hteten\u00a0Leitlinie\u00a0\nexplizit\u00a0erw\u00e4hnt.\u00a0Die\u00a0Querschnittsleitlinie\u00a0zur\u00a0Therapie\u00a0mit\u00a0Bl utkomponenten\u00a0und\u00a0\nPlasmaderivaten\u00a0der\u00a0Bundes\u00e4rztekammer\u00a0bezieht\u00a0sich\u00a0bei\u00a0den\u00a0Empf ehlungen\u00a0zur\u00a0\nBehandlung\u00a0der\u00a0H\u00e4mophilie\u00a0A\u00a0allge mein\u00a0auf\u00a0Faktor\u2010VIII\u2010Pr\u00e4parate \u00a0und\u00a0gibt\u00a0an,\u00a0\ndass\u00a0sich\u00a0die\u00a0Pharmakokinetik\u00a0und\u00a0klinische\u00a0Wirksamkeit\u00a0rekombi nanter\u00a0Pr\u00e4parate\u00a0\nim\u00a0wesentlichen\u00a0nicht\u00a0von\u00a0denen\u00a0der\u00a0Plasmapr\u00e4parate\u00a0unterscheid et.\u00a0Indikationen\u00a0\nf\u00fcr\u00a0den\u00a0Einsatz\u00a0von\u00a0Faktor\u2010VIII\u2010Pr \u00e4paraten\u00a0sieht\u00a0die\u00a0Leitlinie\u00a0 im\u00a0Bedarfsfall\u00a0bei\u00a0allen\u00a0\nspontanen\u00a0oder\u00a0traumatischen\u00a0Blutungen,\u00a0sobald\u00a0sie\u00a0ein\u00a0minimale s\u00a0Ausma\u00df\u00a0\u00fcber\u2010\nsteigen.\u00a0Eine\u00a0prophylaktische\u00a0Dauerbehandlung\u00a0empfiehlt\u00a0die\u00a0Lei tlinie\u00a0vorwiegend\u00a0\nbei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0mit\u00a0 schwerer\u00a0H\u00e4mophilie,\u00a0um\u00a0Gelenk sch\u00e4den\u00a0zu\u00a0\nvermeiden.\u00a0 Bei\u00a0 Erwachsenen\u00a0 sollt e\u00a0 die\u00a0 Notwendigkeit\u00a0 einer\u00a0 proph ylaktischen\u00a0\nDauerbehandlung\u00a0im\u00a0Einzelfall\u00a0be dacht\u00a0werden.\u00a0Zeitlich\u00a0befriste te\u00a0prophylaktische\u00a0\nGaben\u00a0sollten\u00a0bei\u00a0operativen\u00a0Eingriffen\u00a0sowie\u00a0bei\u00a0besonderen\u00a0k\u00f6 rperlichen\u00a0oder\u00a0\npsychischen\u00a0Belastungen\u00a0erfolge n\u00a0(Bundes\u00e4rztekammer,\u00a02014).\u00a0\u00a0\nDiese\u00a0Empfehlungen\u00a0zur\u00a0Dauerbehandlung\u00a0werden\u00a0auch\u00a0von\u00a0einem\u00a0eu rop\u00e4ischen\u00a0\nKonsensus\u00a0mitgetragen,\u00a0der\u00a0keine\u00a0Angaben\u00a0zur\u00a0Auswahl\u00a0von\u00a0Faktor \u2010VIII\u2010Pr\u00e4paraten\u00a0\nmacht\u00a0(Giangrande\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0Leitlinie\u00a0der\u00a0 World\u00a0Federation\u00a0of\u00a0Hemophilia \u00a0\ngibt\u00a0explizit\u00a0an,\u00a0dass\u00a0sie\u00a0rekombinante\u00a0Pr\u00e4parate\u00a0nicht\u00a0grunds\u00e4 tzlich\u00a0gegen\u00fcber\u00a0\naus\u00a0Plasma\u00a0isolierten\u00a0Pr\u00e4paraten \u00a0vorzieht.\u00a0Allerdings\u00a0sollten\u00a0z ur\u00a0Vermeidung\u00a0von\u00a0\nInfektionen\u00a0bei\u00a0den\u00a0aus\u00a0Plasma\u00a0i solierten\u00a0Pr\u00e4paraten\u00a0bevorzugt\u00a0 virusinaktivierte\u00a0365\u00a0Produkte,\u00a0nicht\u00a0aber\u00a0Kryopr\u00e4zipitate\u00a0oder\u00a0frisches\u00a0gefrorenes\u00a0P lasma\u00a0eingesetzt\u00a0\nwerden\u00a0(Makris\u00a0&\u00a0Kasper,\u00a02013).\u00a0\u00a0\nEine\u00a0Evidenzkartierung\u00a0des\u00a0IQWiG\u00a0zum\u00a0Vergleich\u00a0einer\u00a0prophylakt ischen\u00a0mit\u00a0einer\u00a0\nanlassbezogenen\u00a0Behandlung\u00a0mit\u00a0 Faktor\u00a0VIII\u2010Produkten\u00a0bei\u00a0Patien ten\u00a0mit\u00a0schwe\u2010\nrer\u00a0H\u00e4mophilie\u00a0A\u00a0konnte\u00a0f\u00fcr\u00a0Juge ndliche\u00a0und\u00a0Erwachsene\u00a0einen\u00a0Hi nweis\u00a0auf\u00a0einen\u00a0\nZusatznutzen\u00a0der\u00a0prophylaktischen\u00a0Behandlung\u00a0im\u00a0Hinblick\u00a0auf\u00a0sc hwere\u00a0Blutungen\u00a0\nzeigen.\u00a0Im\u00a0Hinblick\u00a0auf\u00a0Schmerzen\u00a0und\u00a0den\u00a0allgemeinen\u00a0Gesundhei tszustand\u00a0war\u00a0\nlediglich\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0zu\u00a0verzeichne n.\u00a0F\u00fcr\u00a0Kinder\u00a0war\u00a0\nin\u00a0der\u00a0prophylaktischen\u00a0Behandlung\u00a0nur\u00a0im\u00a0Hinblick\u00a0auf\u00a0schwere\u00a0 Blutungen\u00a0ein\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0festzustellen.\u00a0Zu\u00a0den\u00a0wicht igsten\u00a0Komplikati\u2010\nonen\u00a0bei\u00a0der\u00a0Behandlung\u00a0der\u00a0H\u00e4mo philie\u00a0A\u00a0geh\u00f6rt\u00a0das\u00a0Auftreten\u00a0v on\u00a0Antik\u00f6rpern\u00a0\n(Inhibitoren)\u00a0gegen\u00a0Faktor\u00a0VIII,\u00a0die\u00a0den\u00a0Blutgerinnungsfaktor\u00a0i naktivieren\u00a0und\u00a0so\u00a0\ndas\u00a0Risiko\u00a0f\u00fcr\u00a0Blutungen\u00a0erh\u00f6hen.\u00a0Die\u00a0Bildung\u00a0von\u00a0Inhibitoren\u00a0w ird\u00a0bei\u00a0bis\u00a0zu\u00a030\u00a0\nProzent\u00a0der\u00a0vorher\u00a0unbehandelten\u00a0Patienten\u00a0mit\u00a0schwerer\u00a0H\u00e4mophi lie\u00a0A\u00a0innerhalb\u00a0\nder\u00a0ersten\u00a0100\u00a0Tage\u00a0nach\u00a0Exposition\u00a0beobachtet.\u00a0Als\u00a0wesentliche \u00a0Faktoren,\u00a0die\u00a0die\u00a0\nBildung\u00a0von\u00a0Inhibitoren\u00a0f\u00f6rdern,\u00a0gelten\u00a0Dosis\u00a0und\u00a0Applikationsh \u00e4ufigkeit\u00a0der\u00a0ein\u2010\ngesetzten\u00a0Pr\u00e4parate.\u00a0M\u00f6glicherweise\u00a0spielen\u00a0auch\u00a0der\u00a0Schweregra d\u00a0der\u00a0Erkran\u2010\nkung,\u00a0bestimmte\u00a0genetische\u00a0Mutationsformen\u00a0und\u00a0die\u00a0Ethnizit\u00e4t\u00a0d es\u00a0Patienten\u00a0\neine\u00a0Rolle\u00a0(IQWiG,\u00a02015).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIm\u00a0Februar\u00a02015\u00a0ver\u00f6ffentlichte\u00a0das\u00a0IQWiG\u00a0ein\u00a0Gutachten\u00a0zur\u00a0fr\u00fc hen\u00a0Nutzenbe\u2010\nwertung\u00a0von\u00a0Simoctocog\u00a0alfa.\u00a0Als\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichstherapie \u00a0wurden\u00a0re\u2010\nkombinante\u00a0 oder\u00a0 aus\u00a0 humanem\u00a0 Plasm a\u00a0 gewonnene\u00a0 Blutgerinnungsfakt or\u2010VIII\u2010\nPr\u00e4parate\u00a0herangezogen.\u00a0Der\u00a0Hersteller\u00a0legte\u00a0f\u00fcr\u00a0einen\u00a0direkten \u00a0Vergleich\u00a0lediglich\u00a0\nDaten\u00a0aus\u00a0einer\u00a0Bio\u00e4quivalenzuntersuchung\u00a0gegen\u00fcber\u00a0Octocog\u00a0alf a\u00a0nach\u00a0einer\u00a0\nEinmaldosis\u00a0vor.\u00a0Die\u00a0vorgelegten \u00a0indirekten\u00a0Vergleiche\u00a0beruhten \u00a0nicht\u00a0auf\u00a0einer\u00a0\nsystematischen\u00a0Literaturrecherche\u00a0und\u00a0umfassten\u00a0nicht\u00a0alle\u00a0rele vanten\u00a0Studien.\u00a0\nDas\u00a0IQWiG\u00a0kam\u00a0daher\u00a0zu\u00a0dem\u00a0Sch luss,\u00a0dass\u00a0das\u00a0Dossier\u00a0keine\u00a0geei gneten\u00a0Daten\u00a0f\u00fcr\u00a0\ndie\u00a0Bewertung\u00a0enth\u00e4lt\u00a0und\u00a0ein\u00a0 Zusatznutzen \u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0folglich\u00a0 nicht\u00a0\nbelegt\u00a0ist.\u00a0Dieser\u00a0Einsch\u00e4tzung\u00a0schlo ss\u00a0sich\u00a0der\u00a0G\u2010BA\u00a0im\u00a0Mai\u00a02015\u00a0an\u00a0 (G\u2010BA,\u00a02015).\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0Si moctocog\u00a0alfa\u00a0erstellt\u00a0werden.\u00a0\n\u00a0\n\u00a0366\u00a0Quellen\u00a0\nBundes\u00e4rztekammer\u00a0(2014).\u00a0Querschnitts\u2010Leitlinien\u00a0(B\u00c4K)\u00a0zur\u00a0The rapie\u00a0mit\u00a0Blutkomponenten\u00a0und\u00a0Plasmaderivaten\u00a0\u2013\u00a04.\u00a0\naktualisierte\u00a0und\u00a0\u00fcberarbeitete\u00a0Auflage.\u00a0http://www.bundesaerzt ekammer.de/aerzte/medizin\u2010\nethik/wissenschaftlicher\u2010beirat/veroeffentlichungen/haemotherap ie\u2010transfusionsmedizin/querschnitt\u2010leitlinie/,\u00a0\nletzter\u00a0Zugriff:\u00a020.02.2017\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2014).\u00a0European\u00a0Assessment\u00a0Rep ort:\u00a0Nuwiq.\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi cines/002813/human_med_001781.jsp&m\nid=WC0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a004.07.2017.\u00a0\nEMA\u00a0\u2010\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Review\u00a0of\u00a0factor\u00a0VIII\u00a0m edicines\u00a0and\u00a0risk\u00a0of\u00a0developing\u00a0 inhibitors\u00a0in\u00a0patients\u00a0starting \u00a0\ntreatment\u00a0for\u00a0haemophilia\u00a0A.\u00a0http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hum an/referrals/Factor_VIII/human_referral_pra\nc_000060.jsp&mid=WC0b01ac05805c516f,\u00a0letzter\u00a0Zugriff:\u00a015.02.201 7\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Simoctocog\u00a0alfa.\u00a0\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/148/,\u00a0letzter\u00a0Zugriff:\u00a015.0 2.2017\u00a0\nGENA\u201011\u00a0(2010).\u00a0GENA\u201011\u00a0.https://www.clinicaltrialsregister.eu/ ctr\u2010search/search?query=2010\u2010023242\u201069,\u00a0letzter\u00a0Zugriff:\u00a0\n23.02.2017.\u00a0\nGiangrande\u00a0P,\u00a0Seitz\u00a0R,\u00a0Behr\u2010Gro ss,\u00a0ME,\u00a0Berger\u00a0K,\u00a0Hilger\u00a0A,\u00a0Klei n\u00a0H,\u00a0Mannucci\u00a0PM\u00a0(2014).\u00a0Kreuth\u00a0III:\u00a0European\u00a0consensus\u00a0proposa ls\u00a0\nfor\u00a0treatment\u00a0of\u00a0haemophilia\u00a0with\u00a0coagulation\u00a0factor\u00a0concentrat es.\u00a0Haemophilia\u00a020(3):\u00a0322\u2010325.\u00a0\u00a0\nIQWiG\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundhe itswesen\u00a0(2015).\u00a0[A13\u201007]\u00a0Therapie\u00a0von\u00a0H\u00e4mophilie\u2010Patienten\u00a0\u2010\u00a0\nRapid\u00a0Report.\u00a0https://www.iqwig.de/de/projekte\u2010ergebnisse/proje kte/arzneimittelbewertung/a13\u201007\u2010therapie\u2010von\u2010\nhamophilie\u2010patienten\u2010rapid\u2010report.3253.html#overview,\u00a0letzter\u00a0Z ugriff:\u00a020.02.2017.\u00a0\nKlukowska\u00a0A,\u00a0Szczepa\u0144ski\u00a0T,\u00a0Vdovi n\u00a0V,\u00a0Knaub\u00a0S,\u00a0Jansen\u00a0M,\u00a0Liesne r\u00a0R\u00a0(2016).\u00a0Novel,\u00a0human\u00a0cell\u00a0line\u2010derived\u00a0recombinant\u00a0factor\u00a0V III\u00a0\n(Human\u2010cl\u00a0rhFVIII,\u00a0Nuwiq\u00a0\u00ae\u00a0)\u00a0in\u00a0children\u00a0with\u00a0severe\u00a0haemophili a\u00a0A:\u00a0efficacy,\u00a0safety\u00a0and\u00a0pharmacokinetics.\u00a0\nHaemophilia\u00a022(2):\u00a0232\u2010239.\u00a0\nLissitchkov\u00a0T,\u00a0Hampton\u00a0K,\u00a0von\u00a0Depka\u00a0M,\u00a0Hay\u00a0C,\u00a0Rangarajan\u00a0S,\u00a0Tud denham\u00a0E\u00a0et\u00a0al.\u00a0(2016).\u00a0Novel,\u00a0human\u00a0cell\u00a0line\u2010derived\u00a0\nrecombinant\u00a0factor\u00a0VIII\u00a0(human\u2010cl\u00a0rhFVIII;\u00a0Nuwiq\u00ae\u00a0)\u00a0in\u00a0adults\u00a0w ith\u00a0severe\u00a0haemophilia\u00a0A:\u00a0efficacy\u00a0and\u00a0safety.\u00a0\nHaemophilia\u00a022(2):\u00a0225\u2013231.\u00a0\u00a0\nMakris\u00a0M,\u00a0Kasper\u00a0C\u00a0(2013).\u00a0The\u00a0W orld\u00a0Federation\u00a0of\u00a0Hemophilia\u00a0g uideline\u00a0on\u00a0management\u00a0of\u00a0haemo philia.\u00a0Haemophilia\u00a019(1):\u00a01.\u00a0\nPeyvandi\u00a0F,\u00a0Mannucci\u00a0PM,\u00a0Garagio la\u00a0I,\u00a0El\u2010Beshlawy\u00a0A.,\u00a0Elalfy,\u00a0M ,\u00a0Ramanan\u00a0V,\u00a0Rosendaal\u00a0FR\u00a0(2016).\u00a0A\u00a0Randomized\u00a0Trial\u00a0of\u00a0Factor\u00a0 VIII\u00a0\nand\u00a0Neutralizing\u00a0Antibodies\u00a0in\u00a0Hemophilia\u00a0A.\u00a0New\u00a0England\u00a0Journa l\u00a0of\u00a0Medicine,\u00a0374(21),\u00a02054\u20132064.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Arzneistoffe:\u00a0Simoctocog\u00a0a lfa|Nuwiq\u00ae|16|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=55377,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017.\u00a0\nTiede\u00a0A,\u00a0Oldenburg\u00a0J,\u00a0Lissitchkov\u00a0T,\u00a0Knaub\u00a0S,\u00a0Bichler\u00a0J,\u00a0Manco\u2010 Johnson\u00a0MJ\u00a0(2016).\u00a0Prophylaxis\u00a0vs.\u00a0on\u2010demand\u00a0treatment\u00a0with\u00a0\nNuwiq\u00ae\u00a0(Human\u2010cl\u00a0rhFVIII)\u00a0in\u00a0ad ults\u00a0with\u00a0severe\u00a0haemophilia\u00a0A.\u00a0 Haemophilia\u00a022(3):\u00a0374\u2010380.\u00a0\n\u00a0\u00a0367\u00a04.25 Sofosbuvir\u00a0\nHandelsname:\u00a0Sovaldi\u00a0\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0 GILEAD\u00a0Sciences\u00a0GmbH\u00a0\nATC\u2010Code:\u00a0J05AX15\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0Februar\u00a02014\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a00,4\u00a0g\u00a0oral\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc \u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nSofosbuvir\u00a0(Sovaldi\u00ae)\u00a0bot\u00a0bei\u00a0der\u00a0Marktzulassung\u00a02014\u00a0als\u00a0RNA\u2010a bh\u00e4ngiger\u00a0RNA\u2010\nNS5B\u2010Polymerasehemmstoff\u00a0ein\u00a0neu artiges\u00a0Wirkprinzip\u00a0f\u00fcr\u00a0die\u00a0Beh andlung\u00a0einer\u00a0\nchronischen\u00a0Hepatitis\u00a0C\u00a0(cHC).\u00a0Als\u00a0Kombinationspartner\u00a0standen\u00a0 zum\u00a0damaligen\u00a0\nZeitpunkt\u00a0in\u00a0erster\u00a0Linie\u00a0(Peg)Interferone\u00a0und\u00a0Ribavirin\u00a0zur\u00a0Ve rf\u00fcgung.\u00a0Mittlerweile\u00a0\nhat\u00a0sich\u00a0der\u00a0Markt\u00a0direkt\u00a0antiviral\u00a0wirkender\u00a0Mittel\u00a0weiter\u00a0ent wickelt\u00a0und\u00a0es\u00a0wur\u2010\nden\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0vom\u00a0zugrunde liegenden\u00a0Genotyp\u00a0(GT)\u00a0neue,\u00a0be sser\u00a0wirksame\u00a0\nund\u00a0vertr\u00e4glichere\u00a0Therapier egime\u00a0bei\u00a0cHC\u00a0etabliert.\u00a0\u00a0\nSofosbuvir\u00a0ist\u00a0in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0Arzneimitteln\u00a0zur\u00a0Beh andlung\u00a0der\u00a0cHC\u00a0\nbei\u00a0Erwachsenen\u00a0zugelassen.\u00a0Gem\u00e4\u00df\u00a0der\u00a0Zulassung\u00a0werden\u00a0bei\u00a0HC\u00a0V irus\u00a0(HCV)\u2010\nInfektionen\u00a0vom\u00a0GT\u00a01,\u00a03,\u00a04,\u00a05\u00a0und\u00a06\u00a0als\u00a0regelhafte\u00a0Kombinations partner\u00a0Ribavirin\u00a0\nund\u00a0Peginterferon\u00a0alfa\u00a0angegeben.\u00a0Ein\u00a0Verzicht\u00a0auf\u00a0Peginterfero n\u00a0alfa\u00a0ist\u00a0dann\u00a0\nm\u00f6glich,\u00a0wenn\u00a0eine\u00a0Behandlung\u00a0 mit\u00a0diesem\u00a0im\u00a0individuellen\u00a0Fall\u00a0 nicht\u00a0angemessen\u00a0\nist\u00a0oder\u00a0nicht\u00a0vertragen\u00a0wird.\u00a0Handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0HCV\u2010Infe ktion\u00a0vom\u00a0GT\u00a02,\u00a0ist\u00a0\ndie\u00a0Anwendung\u00a0von\u00a0Sofosbuvir\u00a0allein\u00a0mit\u00a0Ribavirin\u00a0ausreichend.\u00a0 Die\u00a0Dauer\u00a0der\u00a0\nBehandlung\u00a0liegt\u00a0in\u00a0der\u00a0Regel\u00a0be i\u00a0zw\u00f6lf\u00a0Wochen;\u00a0wenn\u00a0bereits\u00a0ei ne\u00a0hohe\u00a0Aus\u2010\ngangsviruslast\u00a0oder\u00a0fortgeschri ttene\u00a0Krankheitsstadien\u00a0vorliege n,\u00a0sind\u00a0es\u00a024\u00a0Wo\u2010\nchen\u00a0(Fachinformation\u00a0Sovaldi\u00ae,\u00a02016;\u00a0EMA,\u00a02013).\u00a0\nDas\u00a0Mittel\u00a0ist\u00a0zur\u00a0Erstbehandlung\u00a0wie\u00a0auch\u00a0zur\u00a0Re\u2010Therapie\u00a0eins etzbar\u00a0(DGVS,\u00a0\n2016).\u00a0Seine\u00a0therapeutische\u00a0Wirksamkeit\u00a0f\u00fcr\u00a0HCV\u2010Infektionen\u00a0GT\u00a0 1,\u00a02\u00a0und\u00a03\u00a0ist\u00a0in\u00a0\nden\u00a0zugelassenen\u00a0Therapieregimen\u00a0in\u00a0verschiedenen\u00a0klinischen\u00a0St udien\u00a0nachge\u2010\nwiesen.\u00a0Von\u00a0allen\u00a0neu\u00a0zugelassen en\u00a0Wirkstoffen\u00a0gegen\u00a0cHC\u00a0bietet \u00a0Sofosbuvir\u00a0die\u00a0\nbreiteste\u00a0Beleglage\u00a0bez\u00fcglich\u00a0de r\u00a0verschiedenen\u00a0Virusgenotypen. \u00a0Allerdings\u00a0liegen\u00a0\nf\u00fcr\u00a0das\u00a0Mittel\u00a0nur\u00a0wenige\u00a0Studien\u00a0im\u00a0direkten\u00a0Vergleich\u00a0mit\u00a0den \u00a0vom\u00a0Gemeinsa\u2010\nmen\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0f\u00fcr\u00a0d ie\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0festge legten\u00a0zweck\u2010\nm\u00e4\u00dfigen\u00a0Vergleichstherapien\u00a0(zVT)\u00a0vor.\u00a0In\u00a0den\u00a0f\u00fcr\u00a0die\u00a0Zulassung \u00a0relevanten,\u00a0her\u2010\nstellergesponserten\u00a0Studien\u00a0wurde \u00a0Sofosbuvir\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0vo m\u00a0zugrundelie\u2010\ngenden\u00a0GT\u00a0als\u00a0Kombination\u00a0zusammen\u00a0mit\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0R ibavirin\u00a0oder\u00a0\nals\u00a0Interferon\u2010freies\u00a0Therapiere gime\u00a0nur\u00a0in\u00a0Kombination\u00a0mit\u00a0Rib avirin\u00a0gegen\u00a0die\u00a0\nduale\u00a0Standardtherapie\u00a0bestehend\u00a0aus\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Rib avirin\u00a0gepr\u00fcft.\u00a0\nNicht\u00a0alle\u00a0Studien\u00a0waren\u00a0verbli ndet\u00a0oder\u00a0mehrarmig\u00a0(NEUTRINO,\u00a0L awitz\u00a0et\u00a0al.,\u00a0\n2013;\u00a0FISSION,\u00a0Lawitz\u00a0et\u00a0al.,\u00a02013;\u00a0POSITRON,\u00a0Jacobson\u00a0et\u00a0al.,\u00a0 2013;\u00a0FUSION,\u00a0Ja\u2010\n368\u00a0cobson\u00a0et\u00a0al.,\u00a02013).\u00a0Bei\u00a0den\u00a0GT\u00a01,\u00a02\u00a0und\u00a04\u00a0bis\u00a06\u00a0lag\u00a0das\u00a0anhal tende\u00a0virologische\u00a0\nAnsprechen\u00a0nach\u00a0zw\u00f6lf\u00a0Behandlungswochen\u00a0unter\u00a0den\u00a0Sofosbuvir\u2010Th erapieregi\u2010\nmen\u00a0\u00fcber\u00a090\u00a0%.\u00a0Bei\u00a0therapienaiven\u00a0Patienten\u00a0mit\u00a0Hepatitis\u00a0C\u00a0GT\u00a0 3\u00a0lagen\u00a0die\u00a0An\u2010\nsprechraten\u00a0nach\u00a024\u00a0Behandlungswochen\u00a0ebenfalls\u00a0bei\u00a0\u00fcber\u00a090\u00a0%.\u00a0 Demgegen\u00fcber\u00a0\nzeigten\u00a0therapieerfahrene\u00a0Patienten\u00a0mit\u00a0Hepatitis\u00a0C\u00a0GT\u00a03\u00a0nach\u00a0d ieser\u00a0Behand\u2010\nlungsdauer\u00a0etwas\u00a0niedrigere\u00a0Ansp rechraten\u00a0(VALENCE,\u00a0Zeusem\u00a0et\u00a0a l.,\u00a02014).\u00a0Auf\u2010\ngrund\u00a0unzureichender\u00a0Untersuchungsdaten\u00a0lassen\u00a0sich\u00a0in\u00a0Bezug\u00a0au f\u00a0die\u00a0GT\u00a04,\u00a05\u00a0\nund\u00a06\u00a0f\u00fcr\u00a0Sofosbuvir\u00a0im\u00a0Rahmen\u00a0seiner\u00a0Zulassung\u00a0keine\u00a0validen\u00a0A ussagen\u00a0bzgl.\u00a0\nseines\u00a0therapeutischen\u00a0Stellenwer ts\u00a0treffen\u00a0(Prescrire,\u00a02015).\u00a0 Wie\u00a0sich\u00a0Sofosbuvir\u00a0\nin\u00a0den\u00a0Zulassungsstudien\u00a0auf\u00a0die \u00a0Lebensqualit\u00e4t\u00a0der\u00a0Behandelten \u00a0auswirkte,\u00a0wurde\u00a0\nmittlerweile\u00a0auch\u00a0\u2013\u00a0finanziell\u00a0durch\u00a0den\u00a0Hersteller\u00a0unterst\u00fctzt \u00a0\u2013\u00a0metaanalytisch\u00a0\nausgewertet.\u00a0Danach\u00a0gibt\u00a0es\u00a0Hinw eise\u00a0darauf,\u00a0dass\u00a0die\u00a0Behandlun g\u00a0mit\u00a0Interferon\u2010\nfreien,\u00a0Sofosbuvir\u2010basierten\u00a0Reg imen\u00a0nur\u00a0einen\u00a0schwach\u00a0positive n\u00a0Einfluss\u00a0auf\u00a0die\u00a0\nLebensqualit\u00e4t\u00a0der\u00a0betroffenen\u00a0Patienten\u00a0hat.\u00a0Interferon\u2010basier te\u00a0Regime\u00a0wirken\u00a0\nsich\u00a0dagegen\u00a0tendenziell\u00a0negativ\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0der\u00a0Anw ender\u00a0aus\u00a0(Stepa\u2010\nnova\u00a0et\u00a0al.,\u00a02014).\u00a0\nSofosbuvir\u00a0durchlief\u00a0Ende\u00a02014\u00a0nach\u00a0den\u00a0Proteaseinhibitoren\u00a0Boc eprevir\u00a0und\u00a0Tela\u2010\nprevir\u00a0als\u00a0drittes\u00a0der\u00a0neuen\u00a0Hepatitis\u2010C\u2010Mittel\u00a0die\u00a0fr\u00fche\u00a0Nutze nbewertung.\u00a0Bei\u00a0\nfolgenden\u00a0Patientengruppen\u00a0konnte\u00a0 der\u00a0G\u2010BA\u00a0auf\u00a0Basis\u00a0der\u00a0Eviden zbegutachtung\u00a0\ndurch\u00a0das\u00a0IQWiG\u00a0f\u00fcr\u00a0Sofosbuvir\u00a0ei nen\u00a0Zusatznutzen\u00a0feststellen\u00a0( G\u2010BA,\u00a02014):\u00a0\nGegen\u00fcber\u00a0der\u00a0zVT\u00a0wird\u00a0f\u00fcr\u00a0eine\u00a0Sofosbuvir\u2010basierte\u00a0Tripelthera pie\u00a0aufgrund\u00a0der\u00a0\nVerk\u00fcrzung\u00a0der\u00a0Therapiedauer\u00a0und\u00a0der\u00a0damit\u00a0einhergehenden\u00a0besse ren\u00a0Vertr\u00e4g\u2010\nlichkeit\u00a0bei\u00a0 therapienaiven\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01 \u00a0ohne\u00a0bzw.\u00a0mit\u00a0Zirrhose\u00a0ein\u00a0\nAnhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 geringen\u00a0 Zusatznutzen \u00a0 attestiert.\u00a0 Bei\u00a0 therapienaiven\u00a0\nPatienten\u00a0mit\u00a0HCV\u00a0GT\u00a02 \u00a0wird\u00a0f\u00fcr\u00a0die\u00a0duale\u00a0Therapie\u00a0 mit\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0\nim\u00a0Vergleich\u00a0zur\u00a0Peginterferon\u2010basierten\u00a0zVT\u00a0ein\u00a0 Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen\u00a0\nZusatznutzen \u00a0gesehen.\u00a0Bei\u00a0 therapieerfahrenen\u00a0Patienten \u00a0ergibt\u00a0sich\u00a0aufgrund\u00a0der\u00a0\nzugrundeliegenden\u00a0Datenqualit\u00e4t\u00a0lediglich\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0\nZusatznutzen .\u00a0Dies\u00a0wird\u00a0mit\u00a0der\u00a0Verbesserung \u00a0des\u00a0dauerhaften\u00a0virologischen\u00a0 An\u2010\nsprechens\u00a0(SVR),\u00a0der\u00a0M\u00f6glichkeit\u00a0 eines\u00a0Interferon\u2010freien\u00a0Therap ieregimes\u00a0und\u00a0der\u00a0\ndamit\u00a0verbundenen\u00a0relevanten\u00a0Vermeidung\u00a0unerw\u00fcnschter\u00a0Arzneimit telereignisse\u00a0\n(UAE)\u00a0begr\u00fcndet.\u00a0F\u00fcr\u00a0die\u00a0duale\u00a0Therapie\u00a0Sofosbuvir\u00a0und\u00a0Ribaviri n\u00a0besteht\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0Peginterferon\u2010basierten\u00a0zVT\u00a0bei\u00a0 therapienaiven\u00a0wie\u00a0auch\u00a0bei\u00a0therapieer\u2010\nfahrenen\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a03 \u00a0aufgrund\u00a0der\u00a0M\u00f6glichkeit\u00a0 einer\u00a0Interferon\u2010freien\u00a0\nTherapie\u00a0und\u00a0der\u00a0damit\u00a0einhergehenden\u00a0Vermeidung\u00a0Interferon\u2010bed ingter\u00a0UAE\u00a0\nein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen .\u00a0F\u00fcr\u00a0eine\u00a0Sofosbuvir\u2010basierte\u00a0\nTripeltherapie\u00a0sowie\u00a0f\u00fcr\u00a0die\u00a0duale\u00a0Therapie\u00a0mit\u00a0Sofosbuvir\u00a0und\u00a0 Ribavirin\u00a0wird\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0zVT\u00a0mit\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei\u00a0 Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01\u00a0bis\u00a06\u2010\nHIV\u2010Koinfektion\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutze n\u00a0gesehen.\u00a0\u00a0369\u00a0Die\u00a0Bewertung\u00a0in\u00a0der\u00a0Kategorie\u00a0(Z usatz\u2010)Nutzen\u00a0zeigt\u00a0aufgrund\u00a0d es\u00a0unterschiedli\u2010\nchen\u00a0Nutzenprofils\u00a0in\u00a0den\u00a0einzelnen\u00a0Subgruppen\u00a0\"gelb\".\u00a0F\u00fcr\u00a0ausg ew\u00e4hlte\u00a0Patien\u2010\ntengruppen\u00a0w\u00e4re\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Markteinf\u00fchrung\u00a0jedoch\u00a0eine\u00a0\" gr\u00fcne\u00a0Ampel\"\u00a0\ngerechtfertigt\u00a0gewesen,\u00a0da\u00a0mit\u00a0Sofosbuvir\u00a0erstmals\u00a0eine\u00a0hoch\u00a0wi rksame,\u00a0Interfe\u2010\nron\u2010freie\u00a0Therapieoption\u00a0(f\u00fcr\u00a0ei nzelne\u00a0HCV\u2010Genotypen)\u00a0zur\u00a0Verf\u00fc gung\u00a0stand.\u00a0\nMittlerweile\u00a0liegen\u00a0z ahlreiche\u00a0Studienergebnisse\u00a0zur\u00a0therapeuti schen\u00a0Wirksamkeit\u00a0\nalternativer\u00a0Therapieregime\u00a0vor, \u00a0bei\u00a0denen\u00a0Sofosbuvir\u00a0in\u00a0Kombin ation\u00a0mit\u00a0anderen\u00a0\ndirekt\u00a0 wirkenden\u00a0 Virustatika\u00a0 ein gesetzt\u00a0 wird.\u00a0 Gegen\u00fcber\u00a0 einer\u00a0 P eginterferon\u2010\nbasierten\u00a0Behandlung\u00a0lassen\u00a0sich\u00a0f\u00fcr\u00a0diese\u00a0Therapieregime\u00a0Vorte ile\u00a0im\u00a0Hinblick\u00a0auf\u00a0\ndas\u00a0dauerhafte\u00a0virologische\u00a0Ansprechen\u00a0und\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0 ableiten.\u00a0Die\u00a0Er\u2010\ngebnisse\u00a0dieser\u00a0Untersuchungen\u00a0sind\u00a0im\u00a0vorliegenden\u00a0Report\u00a0bei\u00a0 den\u00a0entsprechen\u2010\nden\u00a0Kombinationspartnern\u00a0(Simeprevir,\u00a0Ledipasvir\u00a0und\u00a0Daclatasvi r)\u00a0dargestellt.\u00a0\u00a0\nUntersuchungen\u00a0legen\u00a0nahe,\u00a0dass\u00a0durch\u00a0die\u00a0Behandlung\u00a0mit\u00a0direkt \u00a0antiviral\u00a0wir\u2010\nkenden\u00a0Mitteln\u00a0eine\u00a0bereits\u00a0vor liegende\u00a0Hepatitis\u2010B\u2010Erkrankung\u00a0 reaktiviert\u00a0wer\u2010\nden\u00a0kann.\u00a0Bei\u00a0Koinfektion\u00a0hemmt\u00a0das\u00a0HCV\u00a0die\u00a0Replikation\u00a0von\u00a0Hep atitis\u2010B\u2010Viren.\u00a0\nUnter\u00a0spezifischer\u00a0antiviraler\u00a0Hepatitis\u2010C\u2010Behandlung\u00a0entf\u00e4llt\u00a0 diese\u00a0Hemmfunkti\u2010\non.\u00a0Seit\u00a0Ende\u00a02016\u00a0fordert\u00a0daher\u00a0die\u00a0 European\u00a0Medicines\u00a0Agency \u00a0(EMA)\u00a0vor\u00a0einer\u00a0\nHCV\u2010Behandlung\u00a0ein\u00a0Screening\u00a0auf\u00a0 Hepatitis\u2010B\u2010Koinfektion\u00a0(EMA,\u00a0 2016).\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 (Zusatz\u2010)Nutzen\u00a0 Kosten\u00a0\n\u00a0Neues\u00a0Wirkprinzip\u00a0zum\u00a0\nZeitpunkt\u00a0der\u00a0Zulassung\u00a0\u00a0In\u00a0Kombination\u00a0mit\u00a0\nRibavirin\u00a0Zusatznutzen\u00a0\nbei\u00a0HCV\u00a0Genotyp\u00a02.\u00a0In\u00a0\nKombination\u00a0mit\u00a0PEG\u2010\nInterferon\u00a0mittlerweile\u00a0\nnicht\u00a0mehr\u00a0Mittel\u00a0der\u00a01.\u00a0\nWahl\u00a0teurer\u00a0im\u00a0Vergleich\u00a0zum\u00a0bis\u00a0\ndahin\u00a0\u00fcblichen\u00a0PEG\u2010\nbasierten\u00a0Regime\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke/Klaus\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0\u00a0 Mittel\u00a0der\u00a0Reserve*\u00a0K\u00fcrzere\u00a0\nTherapiedauer\u00a0\nm\u00f6glich\u00a0Offers\u00a0an\u00a0\nadvantage,\u00a0seems\u00a0\nless\u00a0toxic\u00a0Schrittinnovation\u00a0\n*\u00a0\u2013\u00a0allerdings\u00a0mit\u00a0Unsicherheiten\u00a0hinsichtlich\u00a0Nutzen\u00a0und\u00a0Risik en\u00a0\n\u00a0\n\u00a0\n370\u00a0Kosten\u00a0Kombinationstherapie\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage*\u00a0 Tagestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSofosbuvir\u00a0\nIn\u00a0Kombination\u00a0mit: \u00a01x\u00a0tgl.\u00a0\n\u00a084\u00a0\u2013\u00a0168\u00a0Tage\u00a0\n\u00a0600,31\u00a0\u20ac\u00a0\n\u00a0\nBoceprevir\u00a0 3x\u00a0tgl.\u00a0800\u00a0mg\u00a0 196\u00a0\u2013\u00a0336\u00a0Tage\u00a0 112,36\u00a0\u20ac\u00a0\nTelaprevir\u00a0 3x\u00a0tgl.\u00a0750\u00a0mg\u00a0 84\u00a0\u2013\u00a0336\u00a0Tage\u00a0 334,27\u00a0\u20ac\u00a0\nRibavirin\u00a01x\u00a0400\u00a0mg\u00a0+\u00a0\u00a0\n1x\u00a0600\u00a0mg\u00a0168\u00a0\u2013\u00a0336\u00a0Tage\u00a0 29,89\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB11)\u00a0 1x\u00a0w\u00f6chentlich\u00a024\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0280,19\u00a0\u20ac\u00a0\nPeginterferon\u00a0(L03AB10)\u00a0 1x\u00a0w\u00f6chentlich\u00a024\u00a0\u2013\u00a048\u00a0Tage\noder\u00a0Wochen\u00a0254,31\u00a0\u20ac\u00a0\n*Je\u00a0nach\u00a0Virenbelastung\u00a0ist\u00a0die\u00a0Therapiedauer\u00a012\u00a0Wochen\u00a0(84\u00a0Tag e),\u00a024\u00a0Wochen\u00a0(168\u00a0Tage)\u00a0oder\u00a048\u00a0Wochen\u00a0(336\u00a0Tage). \u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0Anfang\u00a02014\u00a0stiegen\u00a0die\u00a0Verordnungszah len\u00a0\u2013\u00a0und\u00a0damit\u00a0\nauch\u00a0der\u00a0Bruttoumsatz\u00a0\u2013\u00a0von\u00a0Sofosbuvir\u00a0rasch\u00a0an.\u00a0W\u00e4hrend\u00a0des\u00a0Be obachtungszeit\u2010\nraums\u00a0von\u00a0Anfang\u00a02014\u00a0bis\u00a0Ende\u00a02015\u00a0lag\u00a0der\u00a0H\u00f6hepunkt\u00a0des\u00a0Brutt oumsatzes\u00a0mit\u00a0\nsechs\u00a0Mio.\u00a0Euro\u00a0im\u00a0Oktober\u00a02014\u00a0(Abbildung\u00a04.45).\u00a0Der\u00a0deutliche \u00a0R\u00fcckgang\u00a0der\u00a0\nVerordnungen\u00a0im\u00a0Jahr\u00a02015\u00a0steht\u00a0vermutlich\u00a0weniger\u00a0mit\u00a0dem\u00a0diff erenzierten\u00a0Er\u2010\ngebnis\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0in\u00a0Zusammenhan g,\u00a0als\u00a0vielmehr\u00a0\nmit\u00a0den\u00a0zahlreichen\u00a0Marktbewegungen\u00a0im\u00a0Segment\u00a0der\u00a0Hepatitismit tel\u00a0im\u00a0Zulas\u2010\nsungsjahr\u00a0von\u00a0Sofosbuvir.\u00a0Durch\u00a0die\u00a0Zulassung\u00a0diverser\u00a0Fixkombi nationen\u00a0(z.T.\u00a0auch\u00a0\nmit\u00a0Sofosbuvir\u00a0als\u00a0Kombinationspartner)\u00a0stehen\u00a0mittlerweile\u00a0the rapeutisch\u00a0\u00fcberle\u2010\ngene\u00a0Alternativen\u00a0mit\u00a0vereinfach tem\u00a0Einnahmeregime\u00a0zur\u00a0Verf\u00fcgun g.\u00a0\u00a0\n\u00a0 \u00a0371\u00a0Abbildung\u00a04.45:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nSofosbuvir\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nSofosbuvir\u00a0hemmt\u00a0die\u00a0RNA\u2010abh\u00e4ngi ge\u00a0RNA\u2010Polymerase\u2010NS5B\u00a0des\u00a0HCV\u00a0 unabh\u00e4ngig\u00a0\nvom\u00a0GT.\u00a0Die\u00a0RNA\u2010Polymerase\u2010NS5B\u00a0 besitzt\u00a0eine\u00a0Schl\u00fcsselfunktion\u00a0 bei\u00a0der\u00a0Poly\u2010\nmerisation\u00a0von\u00a0Ribonukleotidtri phosphaten\u00a0im\u00a0Rahmen\u00a0der\u00a0Virusre plikation.\u00a0So\u2010\nfosbuvir\u00a0ist\u00a0ein\u00a0Nukleotid\u2010Prodrug,\u00a0das\u00a0in\u00a0den\u00a0Hepatozyten\u00a0nach \u00a0intrazellul\u00e4rer\u00a0\nMetabolisierung\u00a0in\u00a0das\u00a0pharmakolog isch\u00a0aktive\u00a0Uridin\u2010Analogon\u2010T riphosphat\u00a0um\u2010\ngewandelt\u00a0wird.\u00a0Das\u00a0Nukleotid\u2010Analogon\u00a0konkurriert\u00a0intrazellul\u00e4 r\u00a0mit\u00a0dem\u00a0nat\u00fcrli\u2010\nchen\u00a0Nukleotid\u00a0um\u00a0den\u00a0Einbau\u00a0in\u00a0d ie\u00a0wachsende\u00a0HCV\u2010RNA\u2010Kette\u00a0und \u00a0wird\u00a0nach\u00a0\nAnbindung\u00a0an\u00a0das\u00a0aktive\u00a0Zentrum\u00a0der\u00a0NS5B\u2010Polymerase\u00a0von\u00a0dieser\u00a0 als\u00a0falscher\u00a0\nBaustein\u00a0in\u00a0die\u00a0HCV\u2010RNA\u00a0integrie rt.\u00a0Dies\u00a0f\u00fchrt\u00a0zum\u00a0Kettenabbruc h\u00a0(Gilead,\u00a02016;\u00a0\nEMA,\u00a02013).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDas\u00a0Virusstatikum\u00a0Sovaldi\u00ae\u00a0ist\u00a0i n\u00a0Kombination\u00a0mit\u00a0anderen\u00a0Arzne imitteln\u00a0zur\u00a0Be\u2010\nhandlung\u00a0der\u00a0cHC\u00a0bei\u00a0Erwachsenen\u00a0zugelassen.\u00a0Welche\u00a0Mittel\u00a0als\u00a0 Kombinations\u2010\npartner\u00a0in\u00a0Frage\u00a0kommen\u00a0und\u00a0wie\u00a0lange\u00a0diese\u00a0Behandlung\u00a0durchgef \u00fchrt\u00a0werden\u00a0soll,\u00a0\nentscheidet\u00a0sich\u00a0mit\u00a0dem\u00a0verursachenden\u00a0GT,\u00a0dem\u00a0Krankheitsstadi um\u00a0und\u00a0ob\u00a0eine\u00a0\nVorbehandlung\u00a0bereits\u00a0stattgefunden\u00a0hat.\u00a0\u00a0\n372\u00a0Bei\u00a0cHC\u00a0vom\u00a0GT\u00a01,\u00a03,\u00a04,\u00a05\u00a0und\u00a06\u00a0wird\u00a0eine\u00a0Kombinationsbehandlun g\u00a0mit\u00a0Ribavirin\u00a0\nund\u00a0Peginterferon\u00a0alfa\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0empfohlen.\u00a0Ein\u00a0Verzich t\u00a0auf\u00a0Peginterfe\u2010\nrone\u00a0ist\u00a0dann\u00a0m\u00f6glich,\u00a0wenn\u00a0eine \u00a0Behandlung\u00a0mit\u00a0diesen\u00a0im\u00a0indiv iduellen\u00a0Fall\u00a0nicht\u00a0\nangemessen\u00a0ist\u00a0oder\u00a0nicht\u00a0vertragen\u00a0wird.\u00a0Bei\u00a0cHC\u00a0vom\u00a0GT\u00a02\u00a0ist\u00a0 \u00fcber\u00a0die\u00a0Behand\u2010\nlungsdauer\u00a0von\u00a0zw\u00f6lf\u00a0Wochen\u00a0lediglich\u00a0Ribavirin\u00a0als\u00a0Kombination spartner\u00a0erfor\u2010\nderlich.\u00a0Wenn\u00a0bei\u00a0den\u00a0Betroffene n\u00a0eine\u00a0niedrige\u00a0Ansprechrate\u00a0zu \u00a0bef\u00fcrchten\u00a0ist,\u00a0\nsollte\u00a0die\u00a0Therapiedauer\u00a0von\u00a0zw\u00f6lf\u00a0Wochen\u00a0auf\u00a024\u00a0Wochen\u00a0erh\u00f6ht\u00a0 werden.\u00a0Dies\u00a0\nist\u00a0etwa\u00a0bei\u00a0hoher\u00a0Ausgangsviruslast\u00a0der\u00a0Fall\u00a0oder\u00a0wenn\u00a0bereits \u00a0eine\u00a0fortgeschrit\u2010\ntene\u00a0Fibrose\u00a0vorliegt\u00a0(Gilead,\u00a02016;\u00a0EMA,\u00a02013).\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Hepatitis\u00a0C\u00a0ist\u00a0eine\u00a0weltwei t\u00a0vorkommende\u00a0virale\u00a0Infektion, \u00a0die\u00a0als\u00a0akute\u00a0wie\u00a0\nauch\u00a0chronische\u00a0Form\u00a0in\u00a0Erscheinung\u00a0tritt.\u00a0Verursacht\u00a0wird\u00a0die\u00a0 Erkrankung\u00a0durch\u00a0\ndas\u00a0zu\u00a0der\u00a0Gruppe\u00a0der\u00a0RNA\u2010Viren\u00a0geh\u00f6rende\u00a0HCV,\u00a0von\u00a0dem\u00a0derzeit\u00a0 sieben\u00a0GT\u00a0mit\u00a0\n67\u00a0Subtypen\u00a0bekannt\u00a0sind.\u00a0Weltweit\u00a0ist\u00a0GT\u00a01\u00a0der\u00a0h\u00e4ufigste\u00a0GT\u00a0(4 6\u00a0%),\u00a0gefolgt\u00a0von\u00a0\nGT\u00a03\u00a0(30\u00a0%).\u00a0Die\u00a0GT\u00a02,\u00a04\u00a0und\u00a06\u00a0sind\u00a0verantwortlich\u00a0f\u00fcr\u00a0insgesam t\u00a023\u00a0%\u00a0der\u00a0Erkran\u2010\nkungsf\u00e4lle.\u00a0GT\u00a05\u00a0spielt\u00a0nur\u00a0eine\u00a0sehr\u00a0untergeordnete\u00a0Rolle\u00a0(<\u00a01 \u00a0%).\u00a0In\u00a0den\u00a0meisten\u00a0\neurop\u00e4ischen\u00a0L\u00e4ndern\u00a0ist\u00a0beim\u00a0GT\u00a01\u00a0der\u00a0am\u00a0h\u00e4ufigsten\u00a0vorkommend e\u00a0Subtyp\u00a01b,\u00a0\nwohingegen\u00a0in\u00a0Nordamerika,\u00a0Gro\u00dfbritannien,\u00a0Skandinavien\u00a0und\u00a0Aus tralien\u00a0der\u00a0GT\u00a0\n1a\u00a0am\u00a0weitesten\u00a0verbreitet\u00a0ist\u00a0(RKI,\u00a02016).\u00a0\nIn\u00a0Europa\u00a0leben\u00a0ca.\u00a0zwei\u00a0bis\u00a0f\u00fcnf\u00a0Mio.\u00a0HCV\u2010positive\u00a0Menschen.\u00a0A ls\u00a0Risikogruppen\u00a0\nmit\u00a0besonders\u00a0hoher\u00a0Krankheitspr\u00e4valenz\u00a0gelten\u00a0intraven\u00f6se\u00a0Drog enanwender,\u00a0\nM\u00e4nner,\u00a0die\u00a0mit\u00a0M\u00e4nnern\u00a0Sex\u00a0haben\u00a0(MSM),\u00a0Dialysepatienten,\u00a0Pers onen,\u00a0die\u00a0vor\u00a0\nden\u00a01990er\u00a0Jahren\u00a0h\u00e4ufig\u00a0Transfusionen\u00a0oder\u00a0vor\u00a0Ende\u00a0der\u00a01980er \u2010Jahre\u00a0Plas\u2010\nmaderivate\u00a0erhielten\u00a0(RKI,\u00a02014a).\u00a0In\u00a0Deutschland\u00a0liegt\u00a0die\u00a0Pr\u00e4 valenz\u00a0mit\u00a00,3\u00a0%\u00a0im\u00a0\ninternationalen\u00a0Vergleich\u00a0sehr\u00a0niedrig.\u00a0Pro\u00a0Jahr\u00a0muss\u00a0aber\u00a0auch \u00a0hierzulande\u00a0mit\u00a0ca.\u00a0\n5.000\u00a0Neuinfektionen\u00a0gerechnet\u00a0werden\u00a0(RKI,\u00a02016).\u00a0\u00a0\nDie\u00a0\u00dcbertragung\u00a0geschieht\u00a0fast\u00a0ausschlie\u00dflich\u00a0\u00fcber\u00a0Blut.\u00a0In\u00a075\u00a0 %\u00a0der\u00a0F\u00e4lle\u00a0verl\u00e4uft\u00a0\ndie\u00a0Infektion\u00a0unbemerkt.\u00a025\u00a0%\u00a0der\u00a0Infizierten\u00a0entwickeln\u00a0eine\u00a0a kute\u00a0Hepatitis\u00a0mit\u00a0\nunspezifischen\u00a0Beschwerden\u00a0und\u00a0Ei nschr\u00e4nkungen\u00a0der\u00a0Leberfunktio n.\u00a0Fulminante\u00a0\nVerl\u00e4ufe\u00a0 sind\u00a0 selten\u00a0 (Thimme\u00a0 et\u00a0 al.,\u00a0 2014).\u00a0 Symptomatisch\u00a0 verla ufende\u00a0 akute\u00a0\nHepatitiden\u00a0zeigen\u00a0eine\u00a0Immunrea ktion\u00a0der\u00a0Betroffenen\u00a0an,\u00a0was\u00a0d ie\u00a0Rate\u00a0an\u00a0Spon\u2010\ntanheilung\u00a0erh\u00f6ht:\u00a0Etwa\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0akut\u00a0verlaufenden\u00a0HCV\u2010In fektionen\u00a0heilt\u00a0\nspontan\u00a0aus,\u00a0w\u00e4hrend\u00a0es\u00a0bei\u00a0den\u00a0asymptomatischen\u00a0Verl\u00e4ufen\u00a0ledi glich\u00a0ca.\u00a030\u00a0%\u00a0\nsind.\u00a0Zwischen\u00a050\u00a0und\u00a085\u00a0%\u00a0aller\u00a0Akutinfektionen\u00a0gehen\u00a0in\u00a0eine\u00a0 cHC\u00a0\u00fcber,\u00a0die\u00a0\ndurch\u00a0eine\u00a0st\u00e4ndige\u00a0Vermehrung\u00a0von\u00a0HCV\u00a0gekennzeichnet\u00a0ist.\u00a0Inne rhalb\u00a0von\u00a020\u00a0bis\u00a0\n30\u00a0Jahren\u00a0kommt\u00a0es\u00a0bei\u00a02\u00a0bis\u00a035\u00a0%\u00a0der\u00a0Betroffenen\u00a0zu\u00a0einer\u00a0Lebe rzirrhose.\u00a0Bei\u00a0\ndiesen\u00a0Patienten\u00a0k\u00f6nnen\u00a0Lebertransplantationen\u00a0lebensrettend\u00a0se in.\u00a0Etwa\u00a02\u00a0bis\u00a0373\u00a04\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0Leberzirrh ose\u00a0entwickeln\u00a0pro\u00a0Jahr\u00a0ein\u00a0Leb erzellkarzinom\u00a0\n(RKI,\u00a02014b).\u00a0\nIn\u00a0zahlreichen\u00a0F\u00e4llen\u00a0ist\u00a0der\u00a0genaue\u00a0\u00dcbertragungsweg\u00a0nicht\u00a0fest stellbar.\u00a0Aktuelle\u00a0\nAnalysen\u00a0geben\u00a0an,\u00a0dass\u00a0bei\u00a0den\u00a0F\u00e4llen,\u00a0denen\u00a0ein\u00a0\u00dcbertragunswe g\u00a0hochwahr\u2010\nscheinlich\u00a0 zugeordnet\u00a0 werden\u00a0 konnte,\u00a0 76 \u00a0%\u00a0 auf\u00a0 intraven\u00f6sen\u00a0 Drogenkonsum\u00a0\nzur\u00fcckzuf\u00fchren\u00a0sind,\u00a08 \u00a0%\u00a0auf\u00a0MSM,\u00a08 \u00a0%\u00a0auf\u00a0den\u00a0Erhalt\u00a0von\u00a0Blutprodukten,\u00a06\u00a0%\u00a0auf\u00a0\nheterosexuellen\u00a0Kontakt\u00a0 mit\u00a0HCV\u2013Infizierten,\u00a01,5 \u00a0%\u00a0auf\u00a0Dialyse\u00a0und\u00a00,5 \u00a0%\u00a0auf\u00a0eine\u00a0\nperinatale\u00a0\u00dcbertragung\u00a0(RKI,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nSofosbuvir\u00a0ist\u00a0zur\u00a0Erstbehandlung\u00a0wie\u00a0auch\u00a0zur\u00a0Re\u2010Therapie\u00a0eins etzbar\u00a0(DGVS,\u00a0\n2016).\u00a0Seine\u00a0therapeutische\u00a0Wirks amkeit\u00a0in\u00a0den\u00a0zugelassenen\u00a0The rapieregimen\u00a0f\u00fcr\u00a0\nHCV\u2010Infektionen\u00a0GT\u00a01,\u00a02\u00a0und\u00a03\u00a0ist\u00a0in\u00a0verschiedenen\u00a0klinischen\u00a0S tudien\u00a0nachgewie\u2010\nsen.\u00a0F\u00fcr\u00a0die\u00a0GT\u00a04,\u00a05\u00a0und\u00a06\u00a0sind\u00a0aufgrund\u00a0unzureichender\u00a0Untersu chungsdaten\u00a0\nkeine\u00a0validen\u00a0Aussagen\u00a0zum\u00a0therapeutischen\u00a0Stellenwert\u00a0von\u00a0Sofo sbuvir\u00a0m\u00f6glich\u00a0\n(Prescrire,\u00a02015).\u00a0\u00a0\nNach\u00a0einer\u00a0systematischen\u00a0Literatur\u00fcbersicht\u00a0zeigt\u00a0Sofosbuvir\u00a0i n\u00a0Kombination\u00a0mit\u00a0\nPeginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0 bei\u00a0der\u00a0Behandlung\u00a0von\u00a0HCV\u00a0GT\u00a0 1\u00a0im\u00a0Vergleich\u00a0zur\u00a0\nStandardtherapie\u00a0bestehend\u00a0aus\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin \u00a0nach\u00a024\u00a0Wochen\u00a0\nin\u00a0 Bezug\u00a0 auf\u00a0 das\u00a0 anhaltende\u00a0 virologische\u00a0 Ansprechen\u00a0 (Sustained\u00a0 Virological\u00a0\nResponse,\u00a0SVR)\u00a0eine\u00a0signifikante\u00a0\u00dcberlegenheit\u00a0(RR\u00a01,98\u00a0(95 \u00a0%CI\u00a01,24\u20103,14).\u00a0Wird\u00a0\nSofosbuvir\u00a0mit\u00a0einem\u00a0anderen\u00a0direkt\u00a0wirkenden\u00a0antiviralen\u00a0Mitte l\u00a0kombiniert,\u00a0liegt\u00a0\ndie\u00a0 SVR\u00a0 gegen\u00fcber\u00a0 der\u00a0 Standardtherapie\u00a0 bereits\u00a0 nach\u00a0 zw\u00f6lf\u00a0 Woche n\u00a0 deutlich\u00a0\nh\u00f6her\u00a0(93\u00a0\u2010100 \u00a0%\u00a0versus\u00a051 \u00a0%)\u00a0(Suwanthawornkul\u00a0et\u00a0al.,\u00a02015).\u00a0Untersuchungen,\u00a0\ndie\u00a0die\u00a0Sofosbuvir\u2010basierte\u00a0Trip eltherapie\u00a0direkt\u00a0mit\u00a0einer\u00a0Boc eprevir\u2010\u00a0bzw.\u00a0Telap\u2010\nrevir\u2010basierten\u00a0Tripeltherapie\u00a0v ergleichen,\u00a0fehlen.\u00a0In\u00a0einer\u00a0of fenen,\u00a0randomisiert\u00a0\nkontrollierten\u00a0Nicht\u2010Unterlegenheitsstudie\u00a0an\u00a0Patienten\u00a0mit\u00a0HCV \u00a0GT\u00a02\u00a0oder\u00a03\u00a0er\u2010\ngeben\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0duale\u00a0Therapi e\u00a0mit\u00a0Ribavirin\u00a0nach\u00a0zw\u00f6lf\u00a0Woch en\u00a0\u00e4hnliche\u00a0viro\u2010\nlogische\u00a0Wirkeffekte\u00a0wie\u00a0unter\u00a0einer\u00a0Standardtherapie\u00a0mit\u00a0Pegin ferferon\u00a0alfa\u00a0und\u00a0\nRibavirin\u00a0nach\u00a024\u00a0Wochen\u00a0(Lawitz\u00a0et\u00a0al.,\u00a02013;\u00a0Prescrire,\u00a02015) .\u00a0In\u00a0einer\u00a0Subgrup\u2010\npenanalyse\u00a0finden\u00a0sich\u00a0aber\u00a0Hinweise\u00a0darauf,\u00a0dass\u00a0Sofosbuvir\u2010ba sierte\u00a0Therapiere\u2010\ngime\u00a0auf\u00a0HCV\u00a0GT\u00a03\u00a0geringere\u00a0Ansprechraten\u00a0besitzen.\u00a0\u00a0\nBez\u00fcglich\u00a0unerw\u00fcnschter\u00a0Arzneimittelereignissen\u00a0(UAE)\u00a0ergeben\u00a0s ich\u00a0in\u00a0klinischen\u00a0\nStudien\u00a0 regelm\u00e4\u00dfig\u00a0 Vorteile\u00a0 f\u00fcr\u00a0 d ie\u00a0 Peginterferon\u2010freien\u00a0 Therap ieregime.\u00a0 Die\u00a0\nbisherigen\u00a0Erfahrungen\u00a0lassen\u00a0Sofosbuvir\u00a0als\u00a0gut\u00a0vertr\u00e4glich\u00a0er scheinen.\u00a0Die\u00a0am\u00a0\nh\u00e4ufigsten\u00a0berichteten\u00a0UAE\u00a0sind\u00a0Ersch\u00f6pfung,\u00a0Kopfschmerzen,\u00a0\u00dcbe lkeit,\u00a0Schlaflo\u2010\nsigkeit\u00a0und\u00a0An\u00e4mie\u00a0(Pockros,\u00a02017).\u00a0Insgesamt\u00a0scheint\u00a0aber\u00a0die\u00a0 Vertr\u00e4glichkeit\u00a0von\u00a0374\u00a0Sofosbuvir\u00a0aufgrund\u00a0der\u00a0h\u00e4ufig\u00a0unverblindeten\u00a0Datenerhebung\u00a0in\u00a0 den\u00a0klinischen\u00a0\nUntersuchungen\u00a0nicht\u00a0abschlie\u00dfend\u00a0beurteilbar.\u00a0\nSowohl\u00a0das\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0 (BfArM),\u00a0wie\u00a0\nauch\u00a0die\u00a0amerikanische\u00a0Zulassungsbeh\u00f6rde\u00a0FDA\u00a0informieren\u00a0im\u00a0M\u00e4r z\u00a02015\u00a0\u00fcber\u00a0\nschwerwiegende\u00a0Herzrhythmusst\u00f6r ungen\u00a0im\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Ei nnahme\u00a0\nvon\u00a0Sofosbuvir\u2010haltigen\u00a0Mitteln.\u00a0Bei\u00a0Einnahme\u00a0von\u00a0Sovaldi\u00ae\u00a0bzw. \u00a0von\u00a0Harvoni\u00ae\u00a0\nkam\u00a0es\u00a0in\u00a0Einzelf\u00e4llen\u00a0zu\u00a0schwerwiegenden\u00a0Bradykardien,\u00a0die\u00a0bei \u00a0einigen\u00a0Betroffe\u2010\nnen\u00a0zum\u00a0Einsatz\u00a0von\u00a0Herzschrittmachern\u00a0f\u00fchrte\u00a0und\u00a0in\u00a0einem\u00a0Fall \u00a0sogar\u00a0t\u00f6dlich\u00a0\nendete\u00a0(BfArM,\u00a02015;\u00a0FDA,\u00a02015).\u00a0Alle\u00a0Patienten\u00a0erhielten\u00a0neben \u00a0anderen\u00a0Hepati\u2010\ntismitteln\u00a0(Simeprevir,\u00a0Daclatas vir)\u00a0mit\u00a0Amiodaron\u00a0und\u00a0Betabloc kern\u00a0noch\u00a0weitere\u00a0\nArzneimittel,\u00a0die\u00a0selbst\u00a0Einfluss\u00a0auf\u00a0den\u00a0Herzrhythmus\u00a0haben\u00a0k\u00f6 nnen.\u00a0Wie\u00a0es\u00a0zu\u00a0\ndieser\u00a0Wechselwirkung\u00a0kommt,\u00a0ist\u00a0derzeit\u00a0noch\u00a0nicht\u00a0bekannt.\u00a0Bi s\u00a0weitere\u00a0Unter\u2010\nsuchungsergebnisse\u00a0vorliegen,\u00a0wir d\u00a0eine\u00a0engmaschige\u00a0EKG\u2010Kontrol le\u00a0bei\u00a0entspre\u2010\nchend\u00a0behandelten\u00a0Patienten\u00a0empfohlen.\u00a0Ferner\u00a0sollten\u00a0Patienten ,\u00a0die\u00a0gleichzeitig\u00a0\nmit\u00a0den\u00a0genannten\u00a0antiviralen\u00a0Arzneimitteln\u00a0und\u00a0Arzneimitteln\u00a0b ehandelt\u00a0werden,\u00a0\ndie\u00a0selbst\u00a0eine\u00a0Bradykardie\u00a0verursachen\u00a0k\u00f6nnen\u00a0(z.B.\u00a0Amiodaron) ,\u00a0\u00fcber\u00a0Beschwer\u2010\nden\u00a0informiert\u00a0werden,\u00a0die\u00a0auf\u00a0d as\u00a0Vorliegen\u00a0von\u00a0Herzrhythmusst \u00f6rungen\u00a0hinwei\u2010\nsen\u00a0k\u00f6nnen.\u00a0Dazu\u00a0z\u00e4hlen\u00a0etwa\u00a0Schwindel,\u00a0starke\u00a0M\u00fcdigkeit,\u00a0Kurza tmigkeit,\u00a0Brust\u2010\nschmerz\u00a0(Angina\u00a0pectoris),\u00a0Verwirrtheit\u00a0oder\u00a0Ged\u00e4chtnisst\u00f6runge n\u00a0(BfArM,\u00a02015).\u00a0\nM\u00f6glicherweise\u00a0ist\u00a0das\u00a0Risiko\u00a0dieser\u00a0Interaktion\u00a0bei\u00a0Patienten\u00a0 mit\u00a0vorbestehenden\u00a0\nkardialen\u00a0Komorbidit\u00e4ten\u00a0oder\u00a0be i\u00a0fortschreitender\u00a0Lebererkrank ung\u00a0erh\u00f6ht.\u00a0\u00a0\nSofosbuvir\u00a0 ist\u00a0 Substrat\u00a0 des\u00a0 intestinalen\u00a0 Glucoproptein\u2010P\u2010Wirkst offtransporters.\u00a0\nUm\u00a0eine\u00a0Verminderung\u00a0der\u00a0Plasmakonzentrationen\u00a0von\u00a0Sofosbuvir\u00a0z u\u00a0vermeiden,\u00a0\nist\u00a0 die\u00a0 gemeinsame\u00a0 Anwendung\u00a0 mit\u00a0 potenten\u00a0 Enzyminduktoren\u00a0 wie\u00a0 R ifampin,\u00a0\nRifabutin,\u00a0Carbamazepin,\u00a0Phenytoin,\u00a0Phenobarbital,\u00a0Oxcarbazepin ,\u00a0Ritonavir\u00a0oder\u00a0\nJohanniskraut\u00a0kontraindiziert\u00a0 (Pockros,\u00a02017;\u00a0Gilead,\u00a02016).\u00a0\u00a0\nDar\u00fcber\u00a0hinaus\u00a0legen\u00a0Untersuchungen\u00a0nahe,\u00a0dass\u00a0durch\u00a0die\u00a0Behand lung\u00a0mit\u00a0So\u2010\nfosbuvir\u00a0die\u00a0Gefahr\u00a0besteht,\u00a0dass\u00a0eine\u00a0Hepatitis\u2010B\u2010Erkrankung\u00a0r e\u2010aktiviert\u00a0wird.\u00a0Ein\u00a0\nScreening\u00a0vor\u00a0der\u00a0Behandlung\u00a0is t\u00a0daher\u00a0seit\u00a0Ende\u00a02016\u00a0gefordert \u00a0(EMA,\u00a02016).\u00a0\nSchlie\u00dflich\u00a0ist\u00a0vor\u00a0dem\u00a0Einsatz\u00a0direkt\u00a0antiviral\u00a0wirkender\u00a0Mitt el\u00a0bei\u00a0Hepatitis\u2010C\u2010\nPatienten\u00a0zu\u00a0bedenken,\u00a0dass\u00a0die\u00a0Gabe\u00a0von\u00a0Sofosbuvir\u00a0und\u00a0ggf.\u00a0Ri bavirin\u00a0zusammen\u00a0\nmit\u00a0NS5A\u2010Inhibitoren\u00a0wie\u00a0Daclata svir,\u00a0Ledipasvir\u00a0oder\u00a0Velpatasv ir,\u00a0die\u00a0einen\u00a0pri\u2010\nm\u00e4ren\u00a0renalen\u00a0Metabolisierungsweg \u00a0aufweisen,\u00a0bei\u00a0Patienten\u00a0mit\u00a0 dekompensier\u2010\nter\u00a0Zirrhose\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Infektionen\u00a0und\u00a0Laktatazidosen\u00a0anst eigen\u00a0lassen\u00a0kann\u00a0\n(DGVS,\u00a02016).\u00a0\u00a0\n\u00a0\n\u00a0375\u00a0Leitlinienempfehlungen\u00a0\nDie\u00a0aktuelle\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroent erologie,\u00a0Verdau\u2010\nungs\u2010\u00a0und\u00a0Stoffwechselkrankheiten\u00a0(DGVS)\u00a0empfiehlt\u00a0f\u00fcr\u00a0die\u00a0Erst therapie\u00a0bei\u00a0cHC\u00a0\nein\u00a0Interferon\u2010freies\u00a0Therapieregime\u00a0(DGVS,\u00a02016).\u00a0Da\u00a0bei\u00a0Kombi nationsbehand\u2010\nlung\u00a0mit\u00a0Ribavirin\u00a0mit\u00a0mehr\u00a0UAE\u00a0und\u00a0Intoleranzen\u00a0zu\u00a0rechnen\u00a0ist ,\u00a0soll\u00a0bei\u00a0gleicher\u00a0\nWirksamkeit\u00a0stets\u00a0eine\u00a0Therapieoption\u00a0ohne\u00a0Ribavirin\u00a0gew\u00e4hlt\u00a0we rden.\u00a0Es\u00a0wird\u00a0\ndarauf\u00a0hingewiesen,\u00a0dass\u00a0die\u00a0Therapieauswahl\u00a0unter\u00a0Ber\u00fccksichti gung\u00a0des\u00a0Zirrho\u2010\nsestatus,\u00a0des\u00a0Vortherapiestatus, \u00a0der\u00a0Komedikation\u00a0und\u00a0gegebenfa lls\u00a0der\u00a0Komorbi\u2010\ndit\u00e4ten\u00a0zu\u00a0erfolgen\u00a0hat.\u00a0\u00a0\nSofosbuvir\u00a0wird\u00a0von\u00a0der\u00a0Leitlinie\u00a0nahezu\u00a0ausschlie\u00dflich\u00a0in\u00a0Komb ination\u00a0mit\u00a0ande\u2010\nren\u00a0direkt\u00a0antiviral\u00a0wirkenden\u00a0Mitteln\u00a0(z.B.\u00a0gemeinsam\u00a0mit\u00a0Ledi pasvir\u00a0oder\u00a0Velpa\u2010\ntasvir)\u00a0empfohlen.\u00a0Dies\u00a0gilt\u00a0\u2013\u00a0allerdings\u00a0auf\u00a0der\u00a0Basis\u00a0untersc hiedlicher\u00a0Evidenzgra\u2010\nde\u00a0\u2013\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01,\u00a03,\u00a04,\u00a05\u00a0und\u00a06.\u00a0Lediglich\u00a0bei\u00a0G T\u00a02\u00a0wird\u00a0auf\u00a0Basis\u00a0eines\u00a0\nEvidenzgrads\u00a01b\u00a0eine\u00a0duale\u00a0Therapie,\u00a0bestehend\u00a0aus\u00a0Sofosbuvir\u00a0m it\u00a0Ribavirin,\u00a0\u00fcber\u00a0\nzw\u00f6lf\u00a0Wochen\u00a0als\u00a0Ersttherapie\u00a0bei\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0empfo hlen.\u00a0\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0fasst\u00a0in\u00a0seiner\u00a0Beschlussfassung\u00a0im\u00a0September\u00a02014\u00a0den \u00a0Zusatznutzen\u00a0\nvon\u00a0Sofosbuvir\u00a0im\u00a0Vergleich\u00a0zur\u00a0 bis\u00a0dato\u00a0\u00fcblichen\u00a0Vergleichther apie\u00a0wie\u00a0folgt\u00a0zu\u2010\nsammen\u00a0(G\u2010BA,\u00a02014):\u00a0\u00a0\nF\u00fcr\u00a0eine\u00a0Sofosbuvir\u2010basierte\u00a0Tripeltherapie\u00a0besteht\u00a0im\u00a0Vergleic h\u00a0zur\u00a0Boceprevir\u2010\u00a0\noder\u00a0Telaprevir\u2010basierten\u00a0Tripel therapie\u00a0bzw.\u00a0im\u00a0Vergleich\u00a0zur\u00a0 dualen\u00a0Therapie\u00a0\nbestehend\u00a0aus\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei\u00a0 therapienaiven\u00a0Patienten\u00a0mit\u00a0\nHCV\u00a0GT\u00a01\u00a0ohne\u00a0bzw.\u00a0mit\u00a0Zirrhose \u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznut\u2010\nzen.\u00a0Als\u00a0Begr\u00fcndung\u00a0wird\u00a0eine\u00a0bessere\u00a0Vertr\u00e4glichkeit\u00a0aufgrund\u00a0der \u00a0Verk\u00fcrzung\u00a0\nder\u00a0Therapiedauer\u00a0beim\u00a0Sofosbuvir \u2010basierten\u00a0Therapieregime\u00a0ange geben.\u00a0\nF\u00fcr\u00a0die\u00a0duale\u00a0Therapie\u00a0mit\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0wird\u00a0gegen\u00fc ber\u00a0der\u00a0zVT\u00a0Pegin\u2010\nferteron\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei \u00a0therapienaiven\u00a0Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a02\u00a0ein\u00a0Hin\u2010\nweis\u00a0 auf\u00a0 einen\u00a0 betr\u00e4chtlichen\u00a0 Zusatznutzen \u00a0 gesehen.\u00a0 Bei\u00a0 therapieerfahrenen\u00a0\nPatienten \u00a0ergibt\u00a0sich\u00a0lediglich\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen .\u00a0\nDer\u00a0Zusatznutzen\u00a0wird\u00a0mit\u00a0der\u00a0signifikanten\u00a0Verbesserung\u00a0des\u00a0SV R,\u00a0der\u00a0M\u00f6glich\u2010\nkeit\u00a0eines\u00a0Interferon\u2010freien\u00a0Therapieregimes\u00a0und\u00a0der\u00a0damit\u00a0verb undenen\u00a0relevan\u2010\nten\u00a0Vermeidung\u00a0von\u00a0UAE\u00a0begr\u00fcndet.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0duale\u00a0Therapie\u00a0mit\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0besteht\u00a0geg en\u00fcber\u00a0der\u00a0zVT\u00a0\nPeginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0bei\u00a0 therapienaiven\u00a0und\u00a0therapieerfahrenen\u00a0Pati\u2010\nenten\u00a0mit\u00a0HCV\u00a0GT\u00a03 \u00a0aufgrund\u00a0der\u00a0M\u00f6glichkeit\u00a0einer\u00a0In terferon\u2010freien\u00a0Therapie\u00a0und\u00a0376\u00a0der\u00a0 damit\u00a0 einhergehenden\u00a0 Vermei dung\u00a0 Interferon\u2010bedingter\u00a0 UAE\u00a0 ei n\u00a0Anhalts\u2010\npunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen. \u00a0\u00a0\nF\u00fcr\u00a0eine\u00a0Sofosbuvir\u2010basierte\u00a0Tripeltherapie\u00a0sowie\u00a0f\u00fcr\u00a0die\u00a0duale \u00a0Therapie\u00a0beste\u2010\nhend\u00a0aus\u00a0Sofosbuvir\u00a0und\u00a0Ribavirin\u00a0wird\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0Pegint erferon\u00a0alfa\u00a0und\u00a0\nRibavirin\u00a0bei\u00a0 Patienten\u00a0mit\u00a0HCV\u00a0GT\u00a01\u00a0bis\u00a06/HIV\u2010Koinfektion \u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\neinen\u00a0geringen\u00a0Zusatznutzen \u00a0gesehen.\u00a0\u00a0\nKein\u00a0Zusatznutzen \u00a0wird\u00a0dagegen\u00a0f\u00fcr\u00a0die\u00a0Sofosbuvir\u2010basierte\u00a0Tripeltherapie\u00a0gegen\u2010\n\u00fcber\u00a0der\u00a0zVT\u00a0bestehend\u00a0aus\u00a0Boceprevir\u00a0oder\u00a0Telaprevir\u00a0+\u00a0Peginte rferon\u00a0alfa\u00a0+\u00a0Riba\u2010\nvirin\u00a0f\u00fcr\u00a0therapieerfahrene\u00a0Patienten\u00a0mit\u00a0GT\u00a01\u00a0attestiert.\u00a0Dies \u00a0gilt\u00a0auch\u00a0bei\u00a0therapie\u2010\nnaiven\u00a0und\u00a0\u2010erfahrenen\u00a0Patienten\u00a0von\u00a0GT\u00a03\u00a0bis\u00a06\u00a0f\u00fcr\u00a0die\u00a0Sofosbu vir\u2010basierte\u00a0Tripel\u2010\ntherapie\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0bestehend\u00a0aus\u00a0Peginterferon\u00a0alfa\u00a0und \u00a0Ribavirin.\u00a0\nVersorgungsanalysen\u00a0\nBei\u00a0Sovaldi\u00ae\u00a0ist\u00a0nur\u00a0eine\u00a0Packungsgr\u00f6\u00dfe\u00a0im\u00a0Handel.\u00a0Im\u00a0ersten\u00a0Un tersuchungsjahr\u00a0\nliegen\u00a0die\u00a0Verordnungsdaten\u00a0in\u00a0etwa\u00a0doppelt\u00a0so\u00a0hoch\u00a0wie\u00a0im\u00a0zwei ten\u00a0Jahr\u00a0des\u00a0\nUntersuchungszeitraumes.\u00a0 Bei\u00a0 der\u00a0 Geschlechterbetrachtung\u00a0 f\u00e4llt\u00a0 auf,\u00a0 dass\u00a0 das\u00a0\nMittel\u00a0gleicherma\u00dfen\u00a0an\u00a0Frauen\u00a0und\u00a0M\u00e4nner\u00a0mit\u00a0einem\u00a0Verordnungs gipfel\u00a0zwi\u2010\nschen\u00a050\u00a0und\u00a060\u00a0Jahren\u00a0verabreicht\u00a0wird,\u00a0dass\u00a0aber\u00a0M\u00e4nner\u00a0insge samt\u00a0h\u00e4ufiger\u00a0\nein\u00a0Rezept\u00a0mit\u00a0Sofosbuvir\u00a0erhalten\u00a0als\u00a0Frauen.\u00a0\u00a0\n\u00a0 \u00a0377\u00a0Abbildung\u00a04.46:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Sofosbuvir\u00a0je\u00a0Mona t\u00a0nach\u00a0\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.47:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Sofosbuv ir\u00a0nach\u00a0\nAlter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\n378\u00a0Quellen\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2013).\u00a0Sofosbuvir\u00a0kombiniert\u00a0mit\u00a0p egyliertem\u00a0Interferon\u20102a\u00a0und\u00a0Ribavirin\u00a0zur\u00a0Behandlung\u00a0der\u00a0\nchronischen\u00a0Hepatitis\u00a0C.\u00a0AMB\u00a047,\u00a059a.\u00a0\nAnonymous\u00a0(2015).\u00a0Sofosbuvir\u00a0(Sova ldi\u00b0).\u00a0Active\u00a0against\u00a0hepatit is\u00a0C\u00a0virus,\u00a0but\u00a0evaluation\u00a0is\u00a0incomplete.\u00a0Prescrire\u00a0Int\u00a024\u00a0(156 ):\u00a05\u201010.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016).\u00a0Bewertung:\u00a0Sofosbuvir.\u00a0https://w ww.arznei\u2010\ntelegramm.de/db/01wkstxt.php3?&knr=&art=mono&nummer=Sofosbuvir& ord=uaw,\u00a0letzter\u00a0Zugriff:\u00a010.05.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 15).\u00a0Sofosbuvir:\u00a0Herzrhythmusst\u00f6rungen\u00a0als\u00a0m\u00f6gliche\u00a0\nWechselwirkung\u00a0mit\u00a0anderen\u00a0direkt\u00a0wirksamen\u00a0antiviralen\u00a0Arzneim itteln\u00a0(DAA)\u00a0in\u00a0der\u00a0Behandlung\u00a0der\u00a0Hepatitis\u00a0C\u00a0in\u00a0\nKombination\u00a0mit\u00a0Arzneimitteln,\u00a0die\u00a0eine\u00a0Bradykardie\u00a0verursachen \u00a0k\u00f6nnen\u00a0(z.B.\u00a0Amiodaron).\u00a0Stand\u00a0der\u00a0Information:\u00a0\nM\u00e4rz\u00a02015. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovig ilanz/DE/RI/2015/RI\u2010\nsofosbuvir.html \u00a0,\u00a0letzter\u00a0Zugriff\u00a010.02.2017.\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten\u00a0u.a.\u00a0(2016).\u00a0Aktuelle\u00a0Empfehlung\u00a0\nzur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Hep atitis\u00a0C\u00a0\u00a0Stand\u00a0der\u00a0Information :\u00a0Dezember\u00a02016.\u00a0 https://www.dgvs.de/wissen\u2010\nkompakt/leitlinien/leitlinien\u2010der\u2010dgvs/hepatitis\u2010c/ \u00a0,\u00a0letzter\u00a0Zugriff:\u00a008.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2013).\u00a0Committee\u00a0for\u00a0Medicinal \u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP )\u00a0Assessment\u00a0report\u00a0Sovaldi\u00a0\nInternational\u00a0non\u2010proprietary\u00a0name:\u00a0Sofosbuvir\u00a0Procedure\u00a0No.\u00a0EM EA/H/C/002798/0000.\u00a021\u00a0November\u00a02013\u00a0\nEMA/CHMP/688774/2013.\u00a0www.ema.europa.eu/docs/en_GB/document_lib rary/EPAR_\u2010\n_Public_assessment_report/human/002798/WC500160600.pdf,\u00a0letzter \u00a0Zugriff:\u00a007.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Direct\u2010acting\u00a0antiviral s\u00a0for\u00a0hepatitis\u00a0C:\u00a0EMA\u00a0confirms\u00a0recommendation\u00a0to\u00a0screen\u00a0for\u00a0\nhepatitis\u00a0B\u00a0Further\u00a0studies\u00a0needed\u00a0to\u00a0assess\u00a0risk\u00a0of\u00a0liver\u00a0canc er\u00a0with\u00a0these\u00a0medicines.\u00a0EMA/824717/2016.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Referrals_ document/Direct\u2010\nacting_antivirals_for_hepatitis_C_20/Opinion_provided_by_Commit tee_for_Medicinal_Products_for_Human_Use/\nWC500218179.pdf \u00a0,\u00a0letzter\u00a0Zugriff:\u00a010.02.2017.\u00a0\nFachinformation\u00a0Sovaldi\u00a0(2016).\u00a0Fachinformation\u00a0Sovaldi.\u00a0Stand\u00a0 der\u00a0Information:\u00a0September\u00a02016.\u00a0\nFDA\u00a0\u2013\u00a0FDA\u00a0Drug\u00a0Safety\u00a0Communicati on\u00a0(2015).\u00a0FDA\u00a0warns\u00a0of\u00a0seriou s\u00a0slowing\u00a0of\u00a0the\u00a0heart\u00a0rate\u00a0when\u00a0antiarrhythmic\u00a0drug\u00a0\namiodarone\u00a0is\u00a0used\u00a0with\u00a0hepatitis\u00a0C\u00a0treatments\u00a0containing\u00a0sofos buvir\u00a0(Harvoni)\u00a0or\u00a0Sovald i\u00a0in\u00a0combination\u00a0with\u00a0\nanother\u00a0Direct\u00a0Acting\u00a0Antiviral\u00a0drug.Stand\u00a0der\u00a0Information:\u00a0M\u00e4r z\u00a02015.\u00a0\nhttps://www.fda.gov/Drugs/ DrugSafety/ucm439484.htm ,\u00a0letzter\u00a0Zugriff:\u00a023.03.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Sofosbuvir.\u00a0 https://www.g\u2010\nba.de/informationen/nutzenbewertung/102/#tab/beschluesse\u00a0, \u00a0letzter\u00a0Zugriff:\u00a009.02.2017.\u00a0\nJacobson\u00a0IM,\u00a0Gordon\u00a0SC,\u00a0Kowdley\u00a0KV,\u00a0Yoshida\u00a0EM,\u00a0Rodriguez\u2010Torre s\u00a0M,\u00a0Sulkowski\u00a0MS\u00a0et\u00a0al.\u00a0(2013).\u00a0Sofosbuvir\u00a0for\u00a0hepatitis\u00a0C\u00a0\ngenotype\u00a02\u00a0or\u00a03\u00a0in\u00a0patients\u00a0without\u00a0treatment\u00a0options.\u00a0NEJM\u00a0368 (20):\u00a01867\u201077.\u00a0\nLawitz\u00a0E,\u00a0Mangia\u00a0A,\u00a0Wyles\u00a0D,\u00a0Rodriguez\u2010Torres\u00a0M,\u00a0Hassanein\u00a0T,\u00a0G ordon\u00a0SC\u00a0et\u00a0al.\u00a0(2013).\u00a0Sofosbuvir\u00a0for\u00a0previously\u00a0untreated\u00a0chr onic\u00a0\nhepatitis\u00a0C\u00a0infection.\u00a0NEJM\u00a013(5):\u00a01878\u201087.\u00a0\nPockros\u00a0PJ\u00a0(2017).\u00a0Direct\u2010acting\u00a0antivirals\u00a0for\u00a0the\u00a0treatment\u00a0o f\u00a0hepatitis\u00a0C\u00a0virus\u00a0infection.\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a020 17.\u00a0\nhttps://www.uptodate.com/contents/direct\u2010acting\u2010antivirals\u2010for\u2010 the\u2010treatment\u2010of\u2010hepatitis\u2010c\u2010virus\u2010infection\u00a0,\u00a0\nletzter\u00a0Zugriff:\u00a023.03.2017.\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0Sofosbuvir\u00a0(Sovaldi\u00b0).\u00a0Active\u00a0a gainst\u00a0hepatitis\u00a0C\u00a0virus,\u00a0but\u00a0ev aluation\u00a0is\u00a0incomplete.\u00a0Prescri re\u00a0Int\u00a024\u00a0\n(156):\u00a05\u201010.\u00a0379\u00a0PZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Sofosbuvir.\u00a0www.pha rmazeutische\u2010zeitung.de/index.php?id=51231,\u00a0letzter\u00a0Zugriff:\u00a0\n10.05.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014a).\u00a0Hepatitis\u00a0C\u00a0RKI\u2010Ratgeber\u00a0f\u00fc r\u00a0\u00c4rzte.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02014.\u00a0\nwww.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Hep atitisC.html\u00a0 ,\u00a0letzter\u00a0Zugriff:\u00a009.02.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2014b).\u00a0Virus\u2010Hepatitis\u00a0C:\u00a0Situatio nsbericht\u00a0Deutschland\u00a02013.\u00a0EpiBulletin\u00a02014;\u00a031(2014):275\u2010288. \u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016) .\u00a0Zur\u00a0Situation\u00a0bei\u00a0wichtigen\u00a0 Infektionskrankheiten\u00a0in\u00a0Deutschland\u00a0Hepatitis\u00a0C\u00a0im\u00a0Jahr\u00a02015.\u00a0\nEpiBulletin\u00a029(2016):255\u2010268.\u00a0\nStepanova\u00a0M,\u00a0Nader\u00a0F,\u00a0Cure\u00a0S,\u00a0Bourhis\u00a0F,\u00a0Hunt\u00a0S,\u00a0Younossi\u00a0ZM\u00a0(2 014).\u00a0Patients'\u00a0preferences\u00a0and\u00a0health\u00a0utility\u00a0assessment\u00a0with\u00a0 SF\u2010\n6D\u00a0and\u00a0EQ\u20105D\u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C\u00a0treated\u00a0with\u00a0 sofosbuvir\u00a0regimens.\u00a0Aliment\u00a0Pharmacol\u00a0Ther\u00a040(6):\u00a0\n676\u201085.\u00a0\nSuwanthawornkul\u00a0T,\u00a0Anothaisintawee\u00a0T,\u00a0Sobhonslidsuk\u00a0A,\u00a0Thakkins tian\u00a0A,\u00a0Teerawattananon\u00a0Y\u00a0(2015).\u00a0Efficacy\u00a0of\u00a0Second\u00a0\nGeneration\u00a0Direct\u2010Acting\u00a0Antiviral\u00a0Agents\u00a0for\u00a0Treatment\u00a0Na\u00efve\u00a0H epatitis\u00a0C\u00a0Genotype\u00a01:\u00a0A\u00a0Systematic\u00a0Review\u00a0and\u00a0\nNetwork\u00a0Meta\u2010Analysis.\u00a0PLoS\u00a0One\u00a010\u00a0(12):\u00a0e0145953.\u00a0\nThimme\u00a0R,\u00a0Heim\u00a0M,\u00a0Baumert\u00a0TF,\u00a0Nassal\u00a0M,\u00a0Moradpour\u00a0D\u00a0(2014).\u00a0Hep atitis\u00a0B\u00a0and\u00a0C:\u00a0from\u00a0molecular\u00a0virology\u00a0to\u00a0new\u00a0antiviral\u00a0\ntherapies\u00a0(part\u00a02).\u00a0Dtsch\u00a0Med\u00a0Wochenschr\u00a0139(15):\u00a0778\u2010782.\u00a0\nZeuzem\u00a0S,\u00a0Dusheiko\u00a0GM,\u00a0Salupere\u00a0R,\u00a0Mangia\u00a0A,\u00a0Flisiak\u00a0R,\u00a0Hyland\u00a0 RH\u00a0et\u00a0al.\u00a0(2014).\u00a0Sofosbuvir\u00a0and\u00a0ribavirin\u00a0in\u00a0HCV\u00a0genotypes\u00a02\u00a0a nd\u00a0\n3.\u00a0NEJM\u00a0370(21):\u00a01993\u20102001.\u00a0\n\u00a0\u00a0380\u00a04.26 Sucroferric\u00a0Oxyhydroxid\u00a0\nHandelsname:\u00a0Velphoro\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Phosphatbinder\u00a0bei\u00a0H\u00e4mo\u2010\u00a0\u00a0 Vifor\u00a0Fresenius\u00a0Medical\u00a0C are\u00a0\noder\u00a0Peritonealdialyse\u00a0\nATC\u2010Code:\u00a0V03AE05\u00a0 \u00a0 \u00a0 Mar kteinf\u00fchrung:\u00a0Oktober\u00a02014\u00a0\nDarreichungsform:\u00a0Kautabletten\u00a0 \u00a0 DDD:\u00a01,5\u00a0g\u00a0oral\u00a0(bezogen\u00a0auf\u00a0Ei sen)\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nBei\u00a0Sucroferric\u00a0 Oxyhydroxid\u00a0 (Handelsname:\u00a0 Velphoro\u00ae)\u00a0 handelt\u00a0es \u00a0si ch \u00a0um \u00a0e i n en \u00a0\nvielkernigen\u00a0Eisen(III )\u2010hydroxid\u2010oxid\u2010Saccharose\u2010St\u00e4rke\u2010Komplex ,\u00a0welcher\u00a0im\u00a0Gastro\u2010\nintestinaltrakt\u00a0Phosphationen\u00a0aufnimmt,\u00a0hierdurch\u00a0die\u00a0Phosphata ufnahme\u00a0aus\u00a0der\u00a0\nNahrung\u00a0und\u00a0somit\u00a0auch\u00a0den\u00a0Phosphatspiegel\u00a0im\u00a0Serum\u00a0reduziert.\u00a0 Seitens\u00a0der\u00a0Euro\u2010\np\u00e4ischen\u00a0Kommission\u00a0( European\u00a0Commission ,\u00a0EC)\u00a0erfolgte\u00a0die\u00a0Zulassung\u00a0als\u00a0Arznei\u2010\nmittel\u00a0 unter\u00a0 besonderer\u00a0 \u00dcberwachung\u00a0 auf\u00a0 Empfehlung\u00a0 der\u00a0 European\u00a0 Medicines\u00a0\nAgency\u00a0(EMA)\u00a0am\u00a026.\u00a0August\u00a02014\u00a0im\u00a0Anwendungsgebiet\u00a0\u201eKontrolle\u00a0des\u00a0Se rumphos\u2010\nphatspiegels\u00a0bei\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0chronischen\u00a0Nierener krankungen\u00a0( Chro\u2010\nnic\u00a0Kidney\u00a0Disease ,\u00a0CKD)\u00a0und\u00a0H\u00e4mo\u2010\u00a0(HD)\u00a0oder\u00a0Peritonealdialyse\u00a0(PD)\u00a0im\u00a0Kontext\u00a0\neines\u00a0 multiplen\u00a0 Therapieansatzes\u201c\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 Calciumpr\u00e4 paraten,\u00a0 1,25\u2010\nDihydroxyvitamin\u00a0D3\u00a0oder\u00a0Analoga \u00a0bzw.\u00a0Calcimimetika\u00a0zur\u00a0Vermeid ung\u00a0der\u00a0Entste\u2010\nhung\u00a0einer\u00a0renalen\u00a0Osteodystrophie\u00a0(CHMP,\u00a02014b;\u00a0CHMP,\u00a02014a).\u00a0 Die\u00a0Aufnahme\u00a0in\u00a0\ndie\u00a0Lauer\u2010Taxe\u00a0erfolgte\u00a0zum\u00a001.10.2014.\u00a0Die\u00a0Initialdosis\u00a0betr\u00e4g t\u00a03x1\u00a0Kautablette\u00a0(KTA)\u00a0\nt\u00e4glich\u00a0(tgl.)\u00a0entsprechend\u00a01.500\u00a0mg\u00a0Eisen,\u00a0wobei\u00a0zu\u00a0beachten\u00a0i st,\u00a0dass\u00a0jede\u00a0KTA\u00a0einen\u00a0\nZuckeranteil\u00a0von\u00a0750\u00a0mg\u00a0Saccharose\u00a0plus\u00a0700\u00a0mg\u00a0St\u00e4rke\u00a0entsprech end\u00a00,116\u00a0Brotein\u2010\nheiten\u00a0(BE)\u00a0enth\u00e4lt,\u00a0was\u00a0bei\u00a0einer\u00a0tgl.\u00a0H\u00f6chstdosis\u00a0von\u00a0sechs\u00a0K TA\u00a0zur\u00a0Aufnahme\u00a0von\u00a0\n0,696\u00a0BE\u00a0bzw.\u00a04.500\u00a0mg\u00a0Saccharose\u00a0f\u00fchrt\u00a0(Lauer\u2010Fischer,\u00a02017).\u00a0\nDie\u00a0 Zulassung\u00a0 von\u00a0 Sucroferric\u00a0 Oxyh ydroxid\u00a0 basiert\u00a0 auf\u00a0 einer\u00a0 mul tizentrischen,\u00a0\noffenen,\u00a0randomisierten,\u00a0aktiv\u2010k ontrollierten,\u00a0zweiphasigen\u00a0Stu die\u00a0PA\u2010CL\u201005A\u00a0bzw.\u00a0\nPA\u2010CL\u201005B\u00a0(Sponsor:\u00a0Vifor\u00a0Fresenius\u00a0Medical\u00a0Care,\u00a0NCT01324128\u00a0b zw.\u00a0NCT01464\u00a0\n190).\u00a0Eingeschlossen\u00a0werden\u00a0konnten\u00a0erwachsene\u00a0CKD\u2010Patienten\u00a0un ter\u00a0HD\u00a0bzw.\u00a0\nPD,\u00a0welche\u00a0einen\u00a0Serumphosphatspiegel\u00a0von\u00a0mindestens\u00a01,94\u00a0mmol/ l\u00a0aufwiesen.\u00a0\nIn\u00a0Behandlungsphase\u00a0(BP)\u00a01\u00a0wurden\u00a0710\u00a0Patienten\u00a0zu\u00a0Sucroferric\u00a0 Oxyhydroxid\u00a0und\u00a0\n349\u00a0zu\u00a0Sevelamercarbonat\u00a0im\u00a0Verh\u00e4ltnis\u00a02:1\u00a0randomisiert,\u00a0wobei\u00a0 zwischen\u00a0Woche\u00a0\n24\u00a0und\u00a027\u00a0die\u00a0BP\u00a02\u00a0stattfand.\u00a0Als\u00a0Teilnehmer\u00a0f\u00fcr\u00a0BP\u00a02\u00a0wurden\u00a0sy stematisch\u00a0die\u00a0\nersten\u00a0100\u00a0Patienten\u00a0mit\u00a0Sucroferric\u00a0Oxyhydroxid\u2010Medikation,\u00a0we lche\u00a0unter\u00a0Dialy\u2010\nse\u00a0in\u00a0Woche\u00a020\u00a0einen\u00a0Serumphospha tspiegel\u00a0<1,78\u00a0mmol/l\u00a0aufwiese n,\u00a0selektiert.\u00a0\nWiederum\u00a099\u00a0CKD\u2010Patienten\u00a0re\u2010ra ndomisierte\u00a0man\u00a01:1\u00a0in\u00a0eine\u00a0Grup pe\u00a0mit\u00a0Su\u2010\ncroferric\u00a0 Oxyhydroxid\u00a0 in\u00a0 bisheri ger\u00a0 Erhaltungsdosis\u00a0 sowie\u00a0 eine\u00a0 zweite\u00a0 Gruppe\u00a0\n(n=49)\u00a0mit\u00a0 Low\u00a0Dose \u00a0fix\u00a01,25\u00a0g\u00a0Sucroferric\u00a0Oxyhydro xid\u00a0pro\u00a0Tag,\u00a0d.h.\u00a0diese\u00a0erhiel\u2010381\u00a0ten\u00a0als\u00a0Placeboersatz\u00a0bewusst\u00a0unt erdosiertes\u00a0Sucroferric\u00a0Oxyhyd roxid.\u00a0Die\u00a0\u00fcbrigen\u00a0\nCKD\u2010HD\u2010/PD\u2010Patienten\u00a0 erhielten\u00a0 g em\u00e4\u00df\u00a0 Randomisierung\u00a0 Verum\u2010\u00a0 bzw. \u00a0Ko n t r o l l \u2010\nmedikation\u00a0in\u00a0den\u00a0Wochen\u00a024\u00a0bis\u00a027\u00a0kontinuierlich.\u00a0An\u00a0der\u00a0nachf olgenden,\u00a0von\u00a0\nWoche\u00a027\u00a0bis\u00a0Woche\u00a052\u00a0andauernden\u00a0Extensionstudie\u00a0PA\u2010CL\u201005B\u00a0kon nten\u00a0au\u00dfer\u00a0\nden\u00a049\u00a0Patienten\u00a0der\u00a0 low\u2010dose\u2010Sucroferric\u00a0Oxyhydroxid\u2010Gruppe\u00a0alle\u00a0mit\u00a0einem\u00a0\nSerumcalciumspiegel\u00a0\u22642,75\u00a0mmol/l\u00a0teilnehmen,\u00a0d.h.\u00a0dass\u00a0nunmehr\u00a0 n=268\u00a0CKD\u2010\nPatienten\u00a0des\u00a0Sevelamercarbonat\u2010 Armes\u00a0sowie\u00a0n=391\u00a0des\u00a0Sucroferr ic\u2010Oxyhydro\u2010\nxid\u2010Armes\u00a0eingeschlossen\u00a0wurden.\u00a0Weiterhin\u00a0wurde\u00a0die\u00a0Dosierung\u00a0 im\u00a0Sevelamer\u2010\ncarbonat\u2010Arm\u00a0nunmehr\u00a0auf\u00a02,4\u00a0bis\u00a014,4\u00a0g\u00a0tgl.\u00a0erweitert.\u00a0Vor\u00a0BP\u00a0 1\u00a0erfolgte\u00a0eine\u00a0zwei\u2010\u00a0\nbis\u00a0vierw\u00f6chige\u00a0 Washout\u2010Phase,\u00a0um\u00a0zuvor\u00a0eingesetzte\u00a0Phosphatbinder\u00a0zu\u00a0eliminie\u2010\nren,\u00a0wobei\u00a0zu\u00a0beachten\u00a0ist,\u00a0dass\u00a0rund\u00a0ein\u00a0Drittel\u00a0der\u00a0Patienten \u00a0zuvor\u00a0Sevelamercar\u2010\nbonat\u00a0 erhielten,\u00a0 was\u00a0 ein\u00a0 zus\u00e4tzliches\u00a0 Verzerrungspotenzial\u00a0 der\u00a0 Zulassungsstudie\u00a0\ndarstellt\u00a0(ClinicalTrials.gov,\u00a02011;\u00a0Floege\u00a0et\u00a0al.,\u00a02014;\u00a0Floeg e\u00a0et\u00a0al.,\u00a02015).\u00a0\nAls\u00a0Ergebnisse\u00a0wurden\u00a0von\u00a0Floege\u00a0und\u00a0Kollegen\u00a0(2015)\u00a0berichtet, \u00a0dass\u00a0die\u00a0Serum\u2010\nphosphatspiegel\u00a0in\u00a0Woche\u00a012\u00a0unter\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0um\u00a00, 71\u00a0mmol/l\u00a0redu\u2010\nziert\u00a0 werden\u00a0 konnten,\u00a0 gegen\u00fcber\u00a0 einer\u00a0 Senkung\u00a0 von\u00a0 0,79\u00a0mmol/l\u00a0 d urch\u00a0 Se\u2010\nvelamercarbonat,\u00a0was\u00a0Nicht\u2010Unterlegenheit\u00a0nachweist.\u00a0Die\u00a0Nicht\u2010 Adh\u00e4renz\u00a0betrug\u00a0\nunter\u00a0Sucroferric\u00a0Oxyhydroxid\u00a015, 1\u00a0%\u00a0gegen\u00fcber\u00a021,3\u00a0%\u00a0unter\u00a0Sev elamercarbonat.\u00a0\nUnerw\u00fcnschte\u00a0Arzneimittelereignisse\u00a0( Adverse\u00a0events, \u00a0AE)\u00a0traten\u00a0zu\u00a083,2\u00a0%\u00a0unter\u00a0\nSucroferric\u00a0 Oxyhydroxid\u00a0 auf,\u00a0 wohingegen\u00a0 76,1\u00a0%\u00a0 AE\u00a0 unter\u00a0 Sevelam ercarbonat\u00a0\nberichtet\u00a0wurden\u00a0(Floege\u00a0et\u00a0al.,\u00a02014).\u00a0\nIn\u00a0BP\u00a01\u00a0des\u00a0Sucroferric\u00a0Oxyhydro xid\u2010Armes\u00a0wurde\u00a0als\u00a0Startdosier ung\u00a05\u00a0g\u00a0tgl.\u00a0Sucro\u2010\nferric\u00a0Oxyhydroxid\u00a0gegeben\u00a0(=2\u00a0KTA\u00a0\u00e0\u00a0500\u00a0mg\u00a0Eisen,\u00a0d.h.\u00a01.000\u00a0m g\u00a0Eisen),\u00a0laut\u00a0\nFachinformation\u00a0 (FI)\u00a0 werden\u00a0 aber\u00a0 1.500\u00a0mg\u00a0 als\u00a0 Initialdosis\u00a0 empf ohlen\u00a0 (CHMP,\u00a0\n2014b).\u00a0Die\u00a0Startdosierung\u00a0des\u00a0aktiven\u00a0Komparators\u00a0Sevelamercar bonat\u00a0betrug\u00a0\n4,8\u00a0g\u00a0tgl.\u00a0(laut\u00a0FI\u00a0werden,\u00a0abh\u00e4ngig\u00a0vom\u00a0Serumphosphatspiegel,\u00a0 zwei\u00a0Initialdosie\u2010\nrungen\u00a0unterschieden,\u00a02,4\u00a0g\u00a0tgl.\u00a0[1,78\u20102,42\u00a0mmol/l]\u00a0bzw.\u00a04,8\u00a0g\u00a0 tgl.\u00a0[>2,42\u00a0mmol/\u00a0\nl])\u00a0(CHMP,\u00a02009).\u00a0In\u00a0den\u00a0ersten\u00a0acht\u00a0Wochen\u00a0von\u00a0PA\u2010CL\u201005A\u00a0erfol gte\u00a0eine\u00a0Dosistit\u2010\nration\u00a0in\u00a0beiden\u00a0Studienarmen,\u00a0hiernach\u00a0sollte\u00a0die\u00a0Erhaltungsdo sierung\u00a0konstant\u00a0\ngehalten\u00a0werden,\u00a0wobei\u00a0aus\u00a0Gr\u00fcnden\u00a0von\u00a0Sicherheit\u00a0und\u00a0Wirksamke it\u00a0eine\u00a0Anpas\u2010\nsung\u00a0laut\u00a0Protokoll\u00a0m\u00f6glich\u00a0war. \u00a0Desgleichen\u00a0so llte\u00a0die\u00a0Co\u2010Medi kation,\u00a0bestehend\u00a0\naus\u00a0ggf.\u00a0Vitamin\u00a0D,\u00a0\u2010Analoga\u00a0oder\u00a0Calcimimetika,\u00a0w\u00e4hrend\u00a0der\u00a0St udie\u00a0in\u00a0konstanter\u00a0\nDosierung\u00a0erfolgen,\u00a0obgleich\u00a0auch\u00a0hierbei\u00a0eine\u00a0Anpassung\u00a0aus\u00a0gl eichen\u00a0Gr\u00fcnden\u00a0\nm\u00f6glich\u00a0war.\u00a0Der\u00a0G\u2010BA\u00a0bem\u00e4ngelt\u00a0 das\u00a0Studiendesign,\u00a0welches\u00a0zu\u00a0e iner\u00a0Verzerrung\u00a0\nf\u00fchrt,\u00a0 indem\u00a0 die\u00a0 Initialdosierungen\u00a0 gem\u00e4\u00df\u00a0 Studienprotokoll\u00a0 von\u00a0 denen\u00a0 in\u00a0 den\u00a0\nFachinformationen\u00a0abweichen,\u00a0was\u00a0f\u00fcr\u00a0Verum\u00a0Sucroferric\u00a0Oxyhydro xid\u00a0zur\u00a0Unter\u2010\ndosierung\u00a0und\u00a0f\u00fcr\u00a0den\u00a0aktiven\u00a0Komparator\u00a0bei\u00a051\u00a0%\u00a0der\u00a0CKD\u2010Patie nten\u00a0im\u00a0Se\u2010\nvelamercarbonat\u2010Arm\u00a0zu\u00a0\u00dcberdosie rung\u00a0f\u00fchrte.\u00a0Zudem\u00a0sah\u00a0der\u00a0G\u2010BA \u00a0in\u00a0der\u00a0in\u00a0den\u00a0\nWochen\u00a024\u00a0bis\u00a027\u00a0durchgef\u00fchrte\u00a0BP\u00a02\u00a0ein\u00a0hohes\u00a0Verzerrungspotenz ial,\u00a0da\u00a0bei\u00a0382\u00a0Auswertung\u00a0der\u00a0Extensionsstudie\u00a0PA\u2010CL\u201005B\u00a0zum\u00a0Zeitpunkt\u00a0Woche\u00a05 2\u00a0nur\u00a0noch\u00a0\n45,4\u00a0%\u00a0der\u00a0urspr\u00fcnglich\u00a0in\u00a0den\u00a0Suc roferric\u00a0Oxyhydroxid\u2010Studiena rm\u00a0randomisier\u2010\nten\u00a0CKD\u2010Patienten\u00a0gegen\u00fcber\u00a065,0\u00a0 %\u00a0der\u00a0dem\u00a0Sevelamercarbonat\u2010Ar m\u00a0zugeteilten\u00a0\nverglichen\u00a0wurden.\u00a0Laut\u00a0G\u2010BA\u00a0w\u00e4re\u00a0ein\u00a0Vergleich\u00a0zu\u00a0Woche\u00a024,\u00a0d. h.\u00a0vor\u00a0Beginn\u00a0der\u00a0\nBP\u00a02,\u00a0mit\u00a0einem\u00a0geringeren\u00a0Verzerrungspotenzial\u00a0behaftet,\u00a0jedoc h\u00a0w\u00e4re\u00a0die\u00a0Dauer\u00a0\nder\u00a0Studie\u00a0nunmehr\u00a0zu\u00a0kurz\u00a0(Floege \u00a0et\u00a0al.,\u00a02014;\u00a0G\u2010BA,\u00a02015b).\u00a0\nEs\u00a0wurden\u00a0keine\u00a0patientenorientierten\u00a0Endpunkte\u00a0wie\u00a0Reduktion\u00a0v on\u00a0kardiovasku\u2010\nl\u00e4rer\u00a0 oder\u00a0 Gesamtmortalit\u00e4t\u00a0 oder\u00a0 Surrogatendpunkte\u00a0 wie\u00a0 Knochend ichte\u00a0 oder\u00a0\nGef\u00e4\u00dfcalcifizierung\u00a0gezeigt.\u00a0Aus\u00a0dem\u00a0 Safety\u00a0Set \u00a0(n=1055)\u00a0ergibt\u00a0sich,\u00a0dass\u00a0behand\u2010\nlungsbedingte\u00a0Therapieabbr\u00fcche\u00a0zu\u00a015,7\u00a0%\u00a0unter\u00a0Sucroferric\u00a0Oxyh ydroxid\u00a0gegen\u2010\n\u00fcber\u00a06,6\u00a0%\u00a0unter\u00a0Sevelarcarbonat\u00a0auftraten.\u00a0Weiterhin\u00a0kam\u00a0es\u00a0un ter\u00a0Sucroferric\u00a0\nOxyhydroxid\u00a0bei\u00a045,1\u00a0%\u00a0der\u00a0CKD\u2010Pa tienten\u00a0zu\u00a0gastrointestinalen\u00a0 AE\u00a0gegen\u00fcber\u00a0\n33,6\u00a0%\u00a0unter\u00a0Sevelamercarbonat,\u00a0d. h.\u00a0unter\u00a0Verum\u00a0vermehrt\u00a0zu\u00a0Du rchfall\u00a0und\u00a0\nverf\u00e4rbtem\u00a0Stuhlgang,\u00a0wohingegen\u00a0unter\u00a0aktivem\u00a0Komparator\u00a0h\u00e4ufi ger\u00a0Verstop\u2010\nfung,\u00a0\u00dcbelkeit\u00a0 oder\u00a0Schwindel\u00a0auftraten.\u00a0Daten\u00a0zur\u00a0 gesundheitsb ezogenen\u00a0Le\u2010\nbensqualit\u00e4t\u00a0wurden\u00a0nicht\u00a0erhoben,\u00a0jedoch\u00a0wird\u00a0von\u00a0Floege\u00a0et\u00a0al .\u00a0die\u00a0Darrei\u2010\nchungsform\u00a0Kautablette\u00a0sowie\u00a0die\u00a0in\u00a0den\u00a0Studienphasen\u00a0beobachte te\u00a0geringere\u00a0\nAnzahl\u00a0tgl.\u00a0einzunehmender\u00a0Table tten\u00a0als\u00a0der\u00a0Adh\u00e4renz\u00a0f\u00f6rderlic h\u00a0berichtet,\u00a0wobei\u00a0\nbei\u00a0zulassungskonformer\u00a0Initialdosierung\u00a0sowohl\u00a0f\u00fcr\u00a0Sucroferric \u00a0Oxyhydroxid\u00a0als\u00a0\nauch\u00a0f\u00fcr\u00a0Sevelamercarbonat\u00a0tgl.\u00a0drei\u00a0Tabletten\u00a0mit\u00a0nachfolgend\u00a0 individueller\u00a0Titra\u2010\ntion\u00a0vorgesehen\u00a0sind\u00a0(G\u2010BA,\u00a02015c ;\u00a0HAS,\u00a02015;\u00a0NICE,\u00a02015;\u00a0Floeg e\u00a0et\u00a0al.,\u00a02014).\u00a0\nDer\u00a0G\u2010BA\u00a0kommt\u00a0in\u00a0seinem\u00a0Beschluss\u00a0vom\u00a019.\u00a0M\u00e4rz\u00a02015\u00a0im\u00a0Rahmen\u00a0 der\u00a0Nutzen\u2010\nbewertung\u00a0von\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0zum\u00a0Ergebnis,\u00a0dass\u00a0aufgru nd\u00a0der\u00a0vom\u00a0phar\u2010\nmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0durchgef\u00fchrten\u00a0zulassungsbegr\u00fcnde nden\u00a0Studie\u00a0\nkein\u00a0Zusatznutzen \u00a0gegen\u00fcber\u00a0zweckm\u00e4\u00dfiger\u00a0Vergleich stherapie\u00a0(zVT)\u00a0gegeben\u00a0ist,\u00a0\nweder\u00a0bei\u00a0CKD\u2010Patienten,\u00a0welche\u00a0 mit\u00a0calciumhaltigen\u00a0Phosphatbin dern\u00a0behandelt\u00a0\nwerden\u00a0k\u00f6nnen\u00a0(zVT\u00a0calciumhaltige\u00a0Phosphatbinder\u00a0in\u00a0Mono\u2010\u00a0oder\u00a0 Kombinations\u2010\ntherapie,\u00a0Sevelamerhydrochlorid,\u00a0Sevelamer\u2010\u00a0oder\u00a0Lanthancarbona t)\u00a0noch\u00a0bei\u00a0CKD\u2010\nPatienten,\u00a0bei\u00a0denen\u00a0aufgrund\u00a0von\u00a0Kontraindikationen,\u00a0bspw.\u00a0Hyp erkalz\u00e4mie,\u00a0nur\u00a0\ncalciumfreie\u00a0Phosphatbinder\u00a0eingesetzt\u00a0werden\u00a0k\u00f6nnen\u00a0(zVT\u00a0Sevel amerhydrochlo\u2010\nrid,\u00a0Sevelamer\u2010\u00a0oder\u00a0Lanthancarbonat)\u00a0(G\u2010BA,\u00a02015a;\u00a0G\u2010BA,\u00a02015b ;\u00a0G\u2010BA,\u00a02015c).\u00a0\nHutchinson\u00a0stellt\u00a0in\u00a0seinem\u00a0Kommentar\u00a0zur\u00a0Publikation\u00a0der\u00a0Studi e\u00a0mehrere\u00a0kritische\u00a0\nFragen:\u00a0einerseits,\u00a0ob\u00a0die\u00a0Reduktion\u00a0der\u00a0Anzahl\u00a0Tabletten\u00a0gleic hzeitig\u00a0die\u00a0Adh\u00e4renz\u00a0\nerh\u00f6ht,\u00a0obschon\u00a0gastrointestinale\u00a0AE\u00a0bei\u00a0einem\u00a0Arzneimittel\u00a0zur \u00a0Dauertherapie\u00a0diese\u00a0\nmindern,\u00a0 weiterhin\u00a0 die\u00a0 Forderung\u00a0 nach\u00a0 Langzeitstudien\u00a0 mit\u00a0 harte n\u00a0 Endpunkten\u00a0\nsowie\u00a0die\u00a0generelle\u00a0Frage\u00a0zur\u00a0Du rchf\u00fchrung\u00a0von\u00a0Studien\u00a0mit\u00a0Labo rwert\u00a0assoziierter\u00a0\nDosistitration\u00a0und\u00a0schlie\u00dflich\u00a0die\u00a0Frage\u00a0nach\u00a0dem\u00a0Beginn\u00a0der\u00a0me dikament\u00f6sen\u00a0The\u2010383\u00a0rapie\u00a0 einer\u00a0 Hyperphosphat\u00e4mie\u00a0 bei\u00a0 Niereninsuffizienz\u00a0 vor\u00a0 dem\u00a0 Hi ntergrund\u00a0 der\u00a0\nunterschiedlichen\u00a0Empfehlungen\u00a0in\u00a0den\u00a0Leitlinien\u00a0(Hutchison,\u00a020 14).\u00a0\nSomit\u00a0handelt\u00a0es\u00a0sich\u00a0bei\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0neben\u00a0Sevelam erhydrochlorid,\u00a0\nSevelamercarbonat\u2010\u00a0und\u00a0Lanthancar bonat\u00a0um\u00a0einen\u00a0weiteren\u00a0calciu mfreien\u00a0Phos\u2010\nphatbinder,\u00a0welcher\u00a0vom\u00a0G\u2010BA\u00a0ohne \u00a0Zusatznutzen\u00a0bewertet\u00a0wurde\u00a0u nd\u00a0der\u00a0im\u00a0\naktuellen\u00a0 Clinical\u00a0Pathway\u00a0 des\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence \u00a0\n(NICE)\u00a0nicht\u00a0empfohlen\u00a0wird\u00a0mit\u00a0Hinweis\u00a0auf\u00a0den\u00a0 Evidence\u00a0Summary \u00a0zu\u00a0Sucroferric\u00a0\nOxyhydroxid\u00a0(G\u2010BA,\u00a02015c;\u00a0NICE,\u00a02015).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiterer\u00a0calciumfreier\u00a0\nPhosphatbinder\u00a0zur\u00a0\nTherapie\u00a0der\u00a0Hyper\u2010\nphosphat\u00e4mie\u00a0bei\u00a0H\u00e4mo\u2010\u00a0\nbzw.\u00a0Peritonealdialyse\u00a0unter\u00a0Therapie\u00a0mit\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0\nkommt\u00a0es\u00a0h\u00e4ufiger\u00a0zu\u00a0\nUAW,\u00a0die\u00a0zum\u00a0Therapie\u2010\nabbruch\u00a0f\u00fchren;\u00a0laut\u00a0\u00a0\nG\u2010BA\u00a0kein\u00a0Zusatznutzen\u00a0je\u00a0nach\u00a0vom\u00a0G\u2010BA\u00a0\ndefinierter\u00a0Patientengruppe\u00a0\nvergleichbar\u00a0bzw.\u00a0teurer\u00a0als\u00a0\nzVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0 1\u00a0\u2013\u00a03x\u00a0tgl.\u00a01\u20132\u00a0KTA\u00a0 365\u00a0781,38\u00a0\u2013\u00a04.688,30\u00a0\u20ac\u00a0\n2.344,79\u00a0\u20ac\u00a0[1,5\u00a0g\u00a0DDD]\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nCalciumcarbonat \u00a0 3x\u00a0tgl.\u00a02\u00a0\u2013\u00a06\u00a0FTA \u00a0 365\u00a0268,60\u00a0\u2013895,35\u00a0\u20ac \u00a0\n358,14\u00a0\u20ac\u00a0[4,0\u00a0g\u00a0DDD] \u00a0\nCalciumacetat\u00a0 6\u00a0\u2013\u00a014\u00a0FTA\u00a0tgl.\u00a0 365\u00a0151,60\u00a0\u2013404,27\u00a0\u20ac \u00a0\n405,22\u00a0\u20ac\u00a0[6,0\u00a0g\u00a0DDD]\u00a0\nCalciumacetat\u00a0+\u00a0 \u00a0\nMagnesiumcarbonat\u00a03\u00a0\u2013\u00a010\u00a0FTA\u00a0tgl.\u00a0 365\u00a0 294,88\u00a0\u2013\u00a01.179,53\u00a0\u20ac \u00a0\nSevelamercarbonat\u00a0 3\u00a0\u2013\u00a08\u00a0FTA\u00a0tgl.\u00a0\u00a0 365\u00a01.236,68\u00a0\u20137.997,15\u00a0\u20ac\u00a0\n4.265,16\u00a0\u20ac\u00a0[6,4\u00a0g\u00a0DDD]\u00a0\nSevelamerhydrochlorid\u00a0 3\u00a0\u2013\u00a015\u00a0FTA\u00a0tgl.\u00a0\u00a0 365\u00a01.599,43\u00a0\u20137.997,15\u00a0\u20ac \u00a0\n4.265,15\u00a0\u20ac\u00a0[6,4\u00a0g\u00a0DDD]\u00a0\nLanthancarbonat \u00a0 3x\u00a0tgl.\u00a0750\u00a0mg \u00a0 365\u00a01.186,70\u00a0\u20135.933,48\u00a0\u20ac \u00a0\n3.560,09\u00a0\u20ac\u00a0[2,3\u00a0g\u00a0DDD] \u00a0\n384\u00a0Nach\u00a0 Markteinf\u00fchrung\u00a0 zum\u00a0 1.10.2014\u00a0 zu\u00a0 einem\u00a0 Apothekenverkaufspr eis\u00a0 von\u00a0\n366,01\u00a0Euro\u00a0erfolgten\u00a0zum\u00a01.10.2015\u00a0(200,63\u00a0Euro)\u00a0sowie\u00a01.10.20 16\u00a0Preissenkun\u2010\ngen,\u00a0sodass\u00a0aktuell\u00a0eine\u00a0Packung \u00a0mit\u00a090\u00a0KTA\u00a0Velphoro\u00ae\u00a0zu\u00a0192,67 \u00a0Euro\u00a047\u00a0%\u00a0g\u00fcns\u2010\ntiger\u00a0im\u00a0Vergleich\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Markteinf\u00fchrung\u00a0ist.\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nNach\u00a0Listung\u00a0in\u00a0der\u00a0Lauer\u2010Taxe\u00a0ab\u00a01.10.2014\u00a0steigen\u00a0die\u00a0Verordn ungen\u00a0von\u00a0Su\u2010\ncroferric\u00a0Oxyhydroxid\u00a0bis\u00a0zu\u00a01.480\u00a0DDD\u00a0je\u00a0Monat\u00a0an.\u00a0Ab\u00a0Vorliege n\u00a0des\u00a0mit\u00a0dem\u00a0\nGKV\u2010Spitzenverband\u00a0verhandelten\u00a0Erstattungsbetrages\u00a0mit\u00a0Listung \u00a0in\u00a0der\u00a0Lauer\u2010\nTaxe\u00a0ab\u00a001.10.2015\u00a0wird\u00a0die\u00a0Preissenkung\u00a0\u00a0deutlich\u00a0sichtbar\u00a0(La uer\u2010Fischer,\u00a02017).\u00a0\nAbbildung\u00a04.48:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nBei\u00a0 Sucroferric\u00a0 Oxyhydroxid\u00a0 handelt\u00a0 es\u00a0 sich\u00a0 um\u00a0 einen\u00a0 vielkernig en\u00a0 Eisen(III)\u2010\nhydroxid\u2010oxid(pn\u2010FeOOH)\u2010Saccharos e\u2010St\u00e4rke\u2010Komplex\u00a0(Handelsname: \u00a0Velphoro\u00ae),\u00a0\nder\u00a0im\u00a0Magen\u2010Darm\u2010Trakt\u00a0Phosphationen\u00a0aufnimmt,\u00a0wodurch\u00a0die\u00a0Pho sphatauf\u2010\nnahme\u00a0aus\u00a0der\u00a0Nahrung\u00a0und\u00a0somit\u00a0auch\u00a0der\u00a0Phosphatspiegel\u00a0im\u00a0Ser um\u00a0reduziert\u00a0\nwird.\u00a0Da\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0praktisch\u00a0unl\u00f6slichen\u00a0Komplex\u00a0handelt ,\u00a0wird\u00a0sehr\u00a0wenig\u00a0\nEisen\u00a0(nur\u00a0\u00fcber\u00a0die\u00a0Abbauprodukte)\u00a0in\u00a0den\u00a0Blutkreislauf\u00a0aufgeno mmen.\u00a0Zu\u00a0beach\u2010\nten\u00a0ist\u00a0der\u00a0Zuckeranteil\u00a0von\u00a0750\u00a0mg\u00a0Saccharose\u00a0entsprechend\u00a00,1 16\u00a0BE\u00a0je\u00a0KTA,\u00a0\n385\u00a0insbesondere\u00a0bei\u00a0Diabetikern\u00a0und\u00a0 hoher\u00a0Dosierung\u00a0von\u00a0bis\u00a0zu\u00a0max imal\u00a0sechs\u00a0KTA\u00a0\nt\u00e4glich\u00a0entsprechend\u00a00,696\u00a0BE\u00a0bzw.\u00a04.500\u00a0mg\u00a0Saccharose\u00a0(WebAPO, \u00a02017).\u00a0In\u00a0vitro\u00a0\nkonnte\u00a0 gezeigt\u00a0 werden,\u00a0 dass\u00a0 die\u00a0 Abbauprodukte\u00a0 des\u00a0 Saccharose\u2010St \u00e4rke\u2010Kom\u2010\nplexes,\u00a0wie\u00a0Glucose\u00a0oder\u00a0Fructose,\u00a0bzw.\u00a0Maltose,\u00a0in\u00a0den\u00a0Blutkre islauf\u00a0aufgenom\u2010\nmen\u00a0werden\u00a0k\u00f6nnen\u00a0(CHMP,\u00a02014a;\u00a0CHMP,\u00a02014b).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nAuf\u00a0Empfehlung\u00a0des\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use, \u00a0CHMP\u00a0der\u00a0\nEMA\u00a0erteilte\u00a0die\u00a0EC\u00a0am\u00a026.\u00a0August\u00a02014\u00a0die\u00a0europaweite\u00a0Zulassun g\u00a0von\u00a0Sucroferric\u00a0\nOxyhydroxid\u00a0zur\u00a0Kontrolle\u00a0des\u00a0Ser umphosphatspiegels\u00a0erwachsener \u00a0Patienten\u00a0mit\u00a0\nchronischen\u00a0Nierenerkrankungen \u00a0CKD,\u00a0welche\u00a0HD\u00a0oder\u00a0PD\u00a0ben\u00f6tigen.\u00a0Die\u00a0Auf\u2010\nnahme\u00a0in\u00a0die\u00a0Lauer\u2010Taxe\u00a0erfolgte\u00a0zum\u00a001.10.2014\u00a0(CHMP,\u00a02014b;\u00a0C HMP,\u00a02014a;\u00a0\nWebAPO,\u00a02017).\u00a0Sucroferric\u00a0Oxyhyd roxid\u00a0wird\u00a0im\u00a0Kontext\u00a0eines\u00a0mu ltiplen\u00a0Thera\u2010\npieansatzes\u00a0in\u00a0Kombination\u00a0mit\u00a0C alciumpr\u00e4paraten,\u00a01,25\u2010Dihydrox vitamin\u00a0D3\u00a0oder\u00a0\nAnaloga\u00a0bzw.\u00a0Calcimimetika\u00a0zur\u00a0V ermeidung\u00a0der\u00a0Entstehung\u00a0einer\u00a0 renalen\u00a0Osteo\u2010\ndystrophie\u00a0eingesetzt\u00a0(CHMP,\u00a02014b ).\u00a0Initial\u00a0werden\u00a01.500\u00a0mg,\u00a0e ntsprechend\u00a0drei\u00a0\nKTA,\u00a0mit\u00a0den\u00a0Mahlzeiten\u00a0eingenommen\u00a0und\u00a0alle\u00a0zwei\u00a0bis\u00a0vier\u00a0Woch en\u00a0dem\u00a0Se\u2010\nrumphosphatspiegel\u00a0entsprechend\u00a0die\u00a0Dosierung\u00a0angepasst\u00a0bis\u00a0zu\u00a0 einer\u00a0maxima\u2010\nlen\u00a0Dosierung\u00a0von\u00a03.000\u00a0mg\u00a0(=6\u00a0KTA)\u00a0t\u00e4glich.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nAls\u00a0CKD\u00a0wird\u00a0eine\u00a0Sch\u00e4digung\u00a0der\u00a0Nieren,\u00a0nachweisbar\u00a0durch\u00a0Albu minurie,\u00a0oder\u00a0\neine\u00a0reduzierte\u00a0Funktion\u00a0der\u00a0Nieren,\u00a0messbar\u00a0durch\u00a0eine\u00a0geminde rte\u00a0glomerul\u00e4re\u00a0\nFiltrationsrate\u00a0(GFR)\u00a0<\u00a060\u00a0ml/min \u00a0bezogen\u00a0auf\u00a01,73m\u00b2\u00a0K\u00f6rperober fl\u00e4che\u00a0(KOF),\u00a0von\u00a0\ndrei\u00a0Monaten\u00a0oder\u00a0l\u00e4ngerer\u00a0Dauer \u00a0definiert.\u00a0Eine\u00a0abstufende\u00a0Kla ssifikation\u00a0der\u00a0\nEinschr\u00e4nkung\u00a0der\u00a0Nierenfunktion\u00a0ist\u00a0mittels\u00a0GFR\u00a0m\u00f6glich,\u00a0wobei \u00a0f\u00fcnf\u00a0Stufen\u00a0un\u2010\nterteilt\u00a0werden:\u00a0>90\u00a0(1),\u00a060\u00a0bis\u00a089\u00a0(2),\u00a030\u00a0bis\u00a059\u00a0(3),\u00a015\u00a0bis\u00a0 29\u00a0(4)\u00a0und\u00a0<15\u00a0ml\u00a0je\u00a0min\u00a0\npro\u00a01,73m\u00b2\u00a0KOF\u00a0(5)\u00a0(Levey;\u00a0Coresh,\u00a02012).\u00a0Laut\u00a0\u201eStudie\u00a0zur\u00a0Gesu ndheit\u00a0Erwachse\u2010\nner\u00a0in\u00a0Deutschland\u00a02008\u20102011\u201c\u00a0DEGS1\u00a0liegt\u00a0bei\u00a0Patienten\u00a0mit\u00a0Dia betes\u00a0mellitus\u00a0\neine\u00a0 2,25fach\u00a0 h\u00f6here\u00a0 und\u00a0 bei\u00a0 arte riellen\u00a0 Hypertonikern\u00a0 eine\u00a0 3,4 6fach\u00a0 h\u00f6here\u00a0\nPr\u00e4valenz\u00a0einer\u00a0eingeschr\u00e4nkten\u00a0 Nierenfunktion\u00a0vor\u00a0(Girndt,\u00a0201 6).\u00a0Diese\u00a0Deter\u2010\nminanten\u00a0der\u00a0CKD\u00a0sollten\u00a0daher\u00a0f r\u00fchzeitig\u00a0therapiert\u00a0werden,\u00a0wo bei\u00a0zur\u00a0Senkung\u00a0\nerh\u00f6hten\u00a0 Bluthochdruckes\u00a0 Angiotensinkonversionsenzym\u00a0 (ACE)\u2010Hemm er\u00a0 bzw.\u00a0\nAngiotensinrezeptorblocker\u00a0 (ARB) \u00a0 oder\u00a0 Diuretika\u00a0 empfohlen\u00a0 werde n\u00a0 (Levey;\u00a0\nCoresh,\u00a02012).\u00a0Im\u00a0Jahr\u00a02015\u00a0erhielten\u00a0in\u00a0Deutschland\u00a083.325\u00a0Pat ienten\u00a0mit\u00a0termi\u2010\nnaler\u00a0Niereninsuffizienz\u00a0in\u00a0721\u00a0Z entren\u00a0HD\u00a0oder\u00a0PD\u00a0(MNC,\u00a02016), \u00a0somit\u00a0ergibt\u00a0sich\u00a0\nbei\u00a0einer\u00a0Einwohnerzahl\u00a0von\u00a081,9\u00a0Mio.\u00a0im\u00a0Jahr\u00a02015\u00a0(DESTATIS)\u00a0e ine\u00a0Pr\u00e4valenz\u00a0von\u00a0\n1,0\u00a0 je\u00a0 1.000\u00a0 Einwohnern.\u00a0 Als\u00a0 Folge\u00a0 der\u00a0 Dialyse\u00a0 kommt\u00a0 es\u00a0 bei\u00a0 HD\u2010 \u00a0b z w . \u00a0P D \u2010\nPatienten\u00a0zu\u00a0einem\u00a0erh\u00f6hten\u00a0Phosphatspiegel\u00a0im\u00a0Serum,\u00a0welcher\u00a0m it\u00a0einer\u00a0erh\u00f6h\u2010\nten\u00a0Mortalit\u00e4t\u00a0korreliert\u00a0(Block;\u00a0et\u00a0al.,\u00a01998).\u00a0386\u00a0Evidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0 Zulassung\u00a0 von\u00a0 Sucroferric\u00a0 Oxyh ydroxid\u00a0 basiert\u00a0 auf\u00a0 einer\u00a0 mul tizentrischen,\u00a0\noffenen,\u00a0randomisierten,\u00a0aktiv\u2010k ontrollierten\u00a0zweiphasigen\u00a0Stud ie\u00a0PA\u2010CL\u201005A\u00a0bzw.\u00a0\nPA\u2010CL\u201005B\u00a0(Sponsor:\u00a0Vifor/Fresenius\u00a0Medical\u00a0Care,\u00a0NCT01324128\u00a0b zw.\u00a0NCT0146\u00a0\n4190).\u00a0Eingeschlossen\u00a0werden\u00a0konnten\u00a0erwachsene\u00a0CKD\u2010Patienten\u00a0u nter\u00a0HD\u00a0bzw.\u00a0\nPD,\u00a0welche\u00a0einen\u00a0Serumphosphatspiegel\u00a0von\u00a0mindestens\u00a01,94\u00a0mmol/ l\u00a0aufwiesen.\u00a0\nIn\u00a0der\u00a0wiederum\u00a0zweiphasigen\u00a0Studie\u00a0PA\u2010CL\u201005A\u00a0wurden\u00a0710\u00a0Patien ten\u00a0in\u00a0BP\u00a01\u00a0zu\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0und\u00a0349\u00a0zu\u00a0Sevelamercarbonat\u00a0im\u00a0Verh\u00e4lt nis\u00a02:1\u00a0rando\u2010\nmisiert,\u00a0wobei\u00a0zwischen\u00a0Woche\u00a024\u00a0und\u00a027\u00a0die\u00a0BP\u00a02\u00a0eingebettet\u00a0wu rde.\u00a0F\u00fcr\u00a0BP\u00a02\u00a0\nwurden\u00a0 systematisch\u00a0 die\u00a0 ersten\u00a0 100\u00a0 Patienten\u00a0 mit\u00a0 Sucroferric\u00a0 Ox yhydroxid\u2010\nMedikation,\u00a0welche\u00a0dialysiert\u00a0wurden\u00a0und\u00a0in\u00a0Woche\u00a020\u00a0eine\u00a0Serum phosphatspie\u2010\ngel\u00a0<1,78\u00a0mmol/l\u00a0aufwiesen,\u00a0selektiert\u00a0und\u00a0wiederum\u00a099\u00a0CKD\u2010Pati enten\u00a01:1\u00a0re\u2010\nrandomisiert\u00a0in\u00a0eine\u00a0Gruppe\u00a0mit\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0in\u00a0bish eriger\u00a0Erhaltungs\u2010\ndosis\u00a0sowie\u00a0eine\u00a0zweite\u00a0Gruppe\u00a0(n=49)\u00a0mit\u00a0 Low\u00a0Dose \u00a0fix\u00a01,25\u00a0g\u00a0Sucroferric\u00a0Oxyhyd\u2010\nrocid\u00a0pro\u00a0Tag,\u00a0d.h.\u00a0diese\u00a0erhielten\u00a0als\u00a0Placeboersatz\u00a0bewusst\u00a0u nterdosiertes\u00a0Sucro\u2010\nferric\u00a0Oxyhydroxid.\u00a0Die\u00a0\u00fcbrigen\u00a0CKD\u2010HD\u2010/PD\u2010Patienten\u00a0erhielten\u00a0 gem\u00e4\u00df\u00a0Randomi\u2010\nsierung\u00a0Verum\u2010\u00a0bzw.\u00a0Kontrollmedikation\u00a0in\u00a0den\u00a0Wochen\u00a024\u00a0bis\u00a027\u00a0 kontinuierlich.\u00a0\nAn\u00a0der\u00a0nachfolgenden,\u00a0von\u00a0Woche\u00a02 7\u00a0bis\u00a0Woche\u00a052\u00a0andauernden\u00a0Ext ensionstudie\u00a0\nPA\u2010CL\u201005B\u00a0konnten\u00a0au\u00dfer\u00a0den\u00a049\u00a0Patienten\u00a0der\u00a0 Low\u2010Dose \u2010Sucroferric\u00a0Oxyhydro\u2010\nxid\u2010Gruppe\u00a0alle\u00a0anderen\u00a0mit\u00a0einem\u00a0Serumcalciumspiegel\u00a0\u22642,75\u00a0mmo l/l\u00a0teilneh\u2010\nmen,\u00a0d.h.\u00a0dass\u00a0nunmehr\u00a0n=268\u00a0CKD\u2010Patienten\u00a0des\u00a0Sevelamercarbona tarmes\u00a0sowie\u00a0\nn=391\u00a0des\u00a0Sucroferric\u00a0Oxyhydroxid\u2010Armes\u00a0eingeschlossen\u00a0wurden.\u00a0 Die\u00a0Dosierung\u00a0\nim\u00a0Sevelamercarbonat\u2010Arm\u00a0wurde\u00a0nunmehr\u00a0auf\u00a02,4\u00a0bis\u00a014,4\u00a0g\u00a0tgl.\u00a0 erweitert.\u00a0Vor\u00a0\nBP\u00a01\u00a0erfolgte\u00a0eine\u00a0zwei\u2010\u00a0bis\u00a0vierw\u00f6chige\u00a0 Washout\u2010Phase,\u00a0um\u00a0zuvor\u00a0eingesetzte\u00a0\nPhosphatbinder\u00a0zu\u00a0eliminieren,\u00a0wobei\u00a0zu\u00a0beachten\u00a0ist,\u00a0dass\u00a0rund \u00a0ein\u00a0Drittel\u00a0der\u00a0\nPatienten\u00a0zuvor\u00a0Sevelamercarbona t\u00a0erhielten,\u00a0was\u00a0ein\u00a0zus\u00e4tzlich es\u00a0Verzerrungspo\u2010\ntenzial\u00a0der\u00a0Zulassungsstudie\u00a0darstellt\u00a0(ClinicalTrials.gov,\u00a0201 1;\u00a0ClinicalTrials.gov,\u00a0\n2011;\u00a0Floege;\u00a0et\u00a0al.,\u00a02014;\u00a0Floege;\u00a0et\u00a0al.,\u00a02015).\u00a0\nAls\u00a0Ergebnisse\u00a0wurden\u00a0von\u00a0Floege\u00a0et\u00a0al.\u00a0berichtet,\u00a0dass\u00a0die\u00a0Ser umphosphatspiegel\u00a0\nin\u00a0Woche\u00a012\u00a0unter\u00a0Sucroferric\u00a0O xyhydroxid\u00a0um\u00a00,71\u00a0mmol/l\u00a0reduzi ert\u00a0werden\u00a0\nkonnten,\u00a0gegen\u00fcber\u00a0einer\u00a0Senkung\u00a0von\u00a00,79\u00a0mmol/l\u00a0durch\u00a0Sevelame rcarbonat,\u00a0\nwas\u00a0eine\u00a0Nicht\u2010Unterlegenheit\u00a0nachweist.\u00a0Die\u00a0Nicht\u2010Adh\u00e4renz\u00a0bet rug\u00a0unter\u00a0Sucro\u2010\nferric\u00a0Oxyhydroxid\u00a015,1\u00a0%\u00a0gegen\u00fcber\u00a021,3\u00a0%\u00a0unter\u00a0Sevelamercarbo nat.\u00a0AE\u00a0traten\u00a0\nzu\u00a083,2\u00a0%\u00a0unter\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0auf,\u00a0wohingegen\u00a076,1\u00a0%\u00a0 AE\u00a0unter\u00a0Se\u2010\nvelamercarbonat\u00a0berichtet\u00a0wu rden\u00a0(Floege;\u00a0et\u00a0al.,\u00a02014).\u00a0\nIn\u00a0BP\u00a01\u00a0des\u00a0Sucroferric\u00a0Oxyhydro xid\u2010Armes\u00a0wurde\u00a0als\u00a0Startdosier ung\u00a05\u00a0g\u00a0tgl.\u00a0Sucro\u2010\nferric\u00a0Oxyhydroxid\u00a0gegeben\u00a0(=2\u00a0KTA\u00a0\u00e0\u00a0500\u00a0mg\u00a0Eisen,\u00a0d.h.\u00a01.000\u00a0m g\u00a0Eisen),\u00a0laut\u00a0\nFachinformation\u00a0werden\u00a0aber\u00a01.500\u00a0mg\u00a0als\u00a0Initialdosis\u00a0empfohlen \u00a0(CHMP,\u00a02014b).\u00a0\nDie\u00a0Startdosierung\u00a0des\u00a0aktiven\u00a0K omparators\u00a0Sevelamercarbonat\u00a0be trug\u00a04,8\u00a0g\u00a0tgl.\u00a0387\u00a0(laut\u00a0Fachinformation\u00a0werden,\u00a0abh\u00e4ngig\u00a0vom\u00a0Serumphosphatspiegel ,\u00a0zwei\u00a0Initial\u2010\ndosierungen\u00a0unterschieden,\u00a02,4\u00a0g\u00a0tgl.\u00a0[1,78\u00a0bis\u00a02,42mmol/l]\u00a0bzw .\u00a04,8\u00a0g\u00a0tgl.\u00a0[>2,42\u00a0\nmmol/l])\u00a0(CHMP,\u00a02009).\u00a0In\u00a0den\u00a0ersten\u00a0acht\u00a0Wochen\u00a0von\u00a0PA\u2010CL\u201005A\u00a0 erfolgte\u00a0eine\u00a0\nDosistitration\u00a0in\u00a0beiden\u00a0Studienarmen,\u00a0hiernach\u00a0sollte\u00a0die\u00a0Erha ltungsdosierung\u00a0\nkonstant\u00a0gehalten\u00a0werden,\u00a0wobei\u00a0aus\u00a0Gr\u00fcnden\u00a0von\u00a0Sicherheit\u00a0und\u00a0 Wirksamkeit\u00a0\neine\u00a0Anpassung\u00a0laut\u00a0Protokoll\u00a0m\u00f6g lich\u00a0war.\u00a0Desgleichen\u00a0sollte\u00a0d ie\u00a0Komedikation,\u00a0\nbestehend\u00a0aus\u00a0ggf.\u00a0Vitamin\u00a0D,\u00a0\u2010Analoga\u00a0oder\u00a0Calcimimetika,\u00a0w\u00e4hr end\u00a0der\u00a0Studie\u00a0in\u00a0\nkonstanter\u00a0Dosierung\u00a0erfolgen,\u00a0obgleich\u00a0auch\u00a0hierbei\u00a0eine\u00a0Anpas sung\u00a0aus\u00a0gleichen\u00a0\nGr\u00fcnden\u00a0m\u00f6glich\u00a0war.\u00a0Der\u00a0G\u2010BA\u00a0be m\u00e4ngelt\u00a0das\u00a0Studiendesign,\u00a0welc hes\u00a0zu\u00a0einer\u00a0\nVerzerrung\u00a0f\u00fchrt,\u00a0indem\u00a0die\u00a0Init ialdosierungen\u00a0gem\u00e4\u00df\u00a0Studienpro tokoll\u00a0von\u00a0denen\u00a0\nin\u00a0den\u00a0Fachinformationen\u00a0abweich en.\u00a0Dies\u00a0f\u00fchrte\u00a0f\u00fcr\u00a0Verum\u00a0Sucro ferric\u00a0Oxyhyd\u2010\nroxid\u00a0zur\u00a0Unterdosierung\u00a0und\u00a0f\u00fcr\u00a0den\u00a0aktiven\u00a0Komparator\u00a0bei\u00a051\u00a0 %\u00a0der\u00a0CKD\u2010Pati\u2010\nenten\u00a0im\u00a0Sevelamercarbonat\u2010Arm\u00a0zu\u00a0\u00dcberdosierung.\u00a0Zudem\u00a0sah\u00a0der\u00a0 G\u2010BA\u00a0in\u00a0der\u00a0in\u00a0\nden\u00a0Wochen\u00a024\u00a0bis\u00a027\u00a0durchgef\u00fchrte\u00a0BP\u00a02\u00a0ein\u00a0hohes\u00a0Verzerrungspo tenzial,\u00a0da\u00a0bei\u00a0\nAuswertung\u00a0der\u00a0Extensionsstudie\u00a0PA\u2010CL\u201005B\u00a0zum\u00a0Zeitpunkt\u00a0Woche\u00a05 2\u00a0nur\u00a0noch\u00a0\n45,4\u00a0%\u00a0der\u00a0urspr\u00fcnglich\u00a0in\u00a0den\u00a0Suc roferric\u00a0Oxyhydroxid\u2010Studiena rm\u00a0randomisier\u2010\nten\u00a0CKD\u2010Patienten\u00a0mit\u00a065,0\u00a0%\u00a0der \u00a0dem\u00a0Sevelamercarbonat\u2010Arm\u00a0zuge teilten\u00a0vergli\u2010\nchen\u00a0wurden.\u00a0Laut\u00a0G\u2010BA\u00a0w\u00e4re\u00a0ein\u00a0Vergleich\u00a0zu\u00a0Woche\u00a024,\u00a0d.h.\u00a0vor \u00a0Beginn\u00a0der\u00a0BP\u00a02,\u00a0\nmit\u00a0einem\u00a0geringeren\u00a0Verzerrungsp otenzial\u00a0behaftet,\u00a0jedoch\u00a0w\u00e4re \u00a0die\u00a0Dauer\u00a0der\u00a0\nStudie\u00a0dann\u00a0zu\u00a0kurz\u00a0(Floege; \u00a0et\u00a0al.,\u00a02014;\u00a0G\u2010BA,\u00a02015c).\u00a0\nEs\u00a0wurden\u00a0keine\u00a0patientenorientierte\u00a0Endpunkte\u00a0wie\u00a0Reduktion\u00a0vo n\u00a0kardiovasku\u2010\nl\u00e4rer\u00a0 oder\u00a0 Gesamtmortalit\u00e4t\u00a0 oder\u00a0 Surrogatendpunkte\u00a0 wie\u00a0 Knochend ichte\u00a0 oder\u00a0\nGef\u00e4\u00dfcalcifizierung\u00a0gezeigt.\u00a0Aus\u00a0dem\u00a0 Safety\u00a0Set \u00a0(n=1055)\u00a0ergibt\u00a0sich,\u00a0dass\u00a0behand\u2010\nlungsbedingte\u00a0Therapieabbr\u00fcche\u00a0zu\u00a015,7\u00a0%\u00a0unter\u00a0Sucroferric\u00a0Oxyh ydroxid\u00a0gegen\u2010\n\u00fcber\u00a06,6\u00a0%\u00a0unter\u00a0Sevelamercarbonat\u00a0auftraten.\u00a0Weiterhin\u00a0kam\u00a0es\u00a0 unter\u00a0Sucrofer\u2010\nric\u00a0Oxyhydroxid\u00a0bei\u00a045,1\u00a0%\u00a0der\u00a0CKD\u2010Patienten\u00a0zu\u00a0gastrointestina len\u00a0AE\u00a0gegen\u00fcber\u00a0\n33,6\u00a0%\u00a0unter\u00a0Sevelamercarbonat,\u00a0d. h.\u00a0unter\u00a0Verum\u00a0vermehrt\u00a0zu\u00a0Du rchfall\u00a0und\u00a0\nverf\u00e4rbtem\u00a0Stuhlgang,\u00a0wohingegen \u00a0unter\u00a0dem\u00a0aktiven\u00a0Komparator\u00a0h \u00e4ufiger\u00a0Ver\u2010\nstopfung,\u00a0\u00dcbelkeit\u00a0oder\u00a0Schwindel\u00a0auftraten.\u00a0Daten\u00a0zur\u00a0gesundhe itsbezogenen\u00a0\nLebensqualit\u00e4t\u00a0wurden\u00a0nicht\u00a0erhoben,\u00a0jedoch\u00a0wird\u00a0von\u00a0Floege\u00a0und \u00a0Kollegen\u00a0die\u00a0\nDarreichungsform\u00a0KTA\u00a0sowie\u00a0die\u00a0in\u00a0den\u00a0Studienphasen\u00a0beobachtete \u00a0geringere\u00a0\nAnzahl\u00a0t\u00e4glich\u00a0einzunehmender\u00a0Tabl etten\u00a0als\u00a0der\u00a0Adh\u00e4renz\u00a0f\u00f6rder lich\u00a0berichtet,\u00a0\nwobei\u00a0bei\u00a0zulassungskonformer\u00a0Initialdosierung\u00a0sowohl\u00a0f\u00fcr\u00a0Sucro ferric\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0\nSevelamercarbonat\u00a0t\u00e4glich\u00a0drei\u00a0T abletten\u00a0mit\u00a0nachfolgend\u00a0indivi dueller\u00a0Titration\u00a0\nvorgesehen\u00a0sind\u00a0(HAS,\u00a02015;\u00a0NICE,\u00a02015;\u00a0G\u2010BA,\u00a02015d).\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0von\u00a0\u201e Kidney\u00a0Disease:\u00a0Improving\u00a0Global\u00a0Outcomes \u201c\u00a0KDIGO\u00a0in\u00a02009\u00a0herausgege\u2010\nbene\u00a0\u201cClinical\u00a0Practice\u00a0Guideline\u00a0for\u00a0the\u00a0Diagnosis,\u00a0Evaluation,\u00a0Prev ention,\u00a0and\u00a0\nTreatment\u00a0of\u00a0Chronic\u00a0Kidney\u00a0Disease\u2010Mineral\u00a0and\u00a0Bone\u00a0Disorder \u201d\u00a0(CKD\u2010MBD)\u00a0und\u00a0388\u00a0in\u00a02013\u00a0angepasste\u00a0Praxisleitlinie\u00a0wurde\u00a0im\u00a0Jahr\u00a02017\u00a0aktualisi ert.\u00a0Bei\u00a0CKD\u2010Patienten\u00a0\nohne\u00a0Dialyse\u00a0ist\u00a0hiernach\u00a0der\u00a0Einsatz\u00a0von\u00a0Phosphatbindern\u00a0nur\u00a0a uf\u00a0progressive\u00a0und\u00a0\npersistierende\u00a0 Hyperphosphat\u00e4mie\u00a0 beschr\u00e4nkt.\u00a0 Bei\u00a0 Dialysepatient en\u00a0 wurde\u00a0 auf\u2010\ngrund\u00a0des\u00a0globalen\u00a0Charakters\u00a0der\u00a0Leitlinie\u00a0auf\u00a0eine\u00a0Stellungna hme\u00a0zur\u00a0Pr\u00e4ferenz\u00a0\ncalciumhaltiger\u00a0oder\u00a0calciumfreier\u00a0Phosphatbinder\u00a0verzichtet\u00a0(K etteler,\u00a02017).\u00a0\nDas\u00a0NICE\u00a0empfiehlt\u00a0im\u00a0aktuell\u00a0geltenden\u00a0C linical\u00a0Pathway \u00a0als\u00a0erste\u00a0Ma\u00dfnahme\u00a0zur\u00a0\nReduktion\u00a0von\u00a0Hyperphosphat\u00e4mie\u00a0eine\u00a0patientenindividuelle\u00a0Di\u00e4t .\u00a0Der\u00a0NICE\u00a0 path\u2010\nway\u00a0f\u00fchrt\u00a0weiter\u00a0aus,\u00a0dass\u00a0als\u00a0Erstlinienmedikation\u00a0Calciumacetat\u00a0 und\u00a0bei\u00a0dessen\u00a0\nUnvertr\u00e4glichkeit\u00a0Calciumcarbona t\u00a0eingesetzt\u00a0werden\u00a0sollen.\u00a0Fal ls\u00a0diese\u00a0Therapie\u00a0\ninsbesondere\u00a0bei\u00a0Dialysepatienten\u00a0nicht\u00a0ausreicht\u00a0und\u00a0der\u00a0Serum calciumspiegel\u00a0\nansteigt\u00a0oder\u00a0der\u00a0Serumparathormonspiegel\u00a0abf\u00e4llt,\u00a0kann\u00a0eine\u00a0Ko mbinationsthe\u2010\nrapie\u00a0mit\u00a0calciumfreiem\u00a0Phosphatbinder\u00a0oder\u00a0die\u00a0Monotherapie\u00a0mi t\u00a0Sevelamer\u2010\nhydrochlorid\u00a0 bzw.\u00a0 Lanthancarbona t\u00a0 erwogen\u00a0 werden\u00a0 (NICE,\u00a0 2017).\u00a0 Sucroferric\u00a0\nOxyhydroxid\u00a0wird\u00a0im\u00a0 Clinical\u00a0Pathway \u00a0des\u00a0NICE\u00a0nicht\u00a0ber\u00fccksichtigt,\u00a0hier\u00a0wird\u00a0\nlediglich\u00a0auf\u00a0das\u00a0 Evidence\u00a0Summary \u00a0zur\u00a0Substanz\u00a0hingewiesen\u00a0(NICE,\u00a02015).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0pr\u00fcfte,\u00a0ob\u00a0die\u00a0phosphatbindende\u00a0Therapie\u00a0mit\u00a0Sucroferr ic\u00a0Oxyhydroxid\u00a0\nbei\u00a0Patienten\u00a0mit\u00a0CKD\u00a0unter\u00a0HD\u00a0oder\u00a0PD\u00a0gegen\u00fcber\u00a0zVT\u00a0einen\u00a0zus\u00e4 tzlichen\u00a0Nutzen\u00a0\naufweist.\u00a0Der\u00a0Einsatz\u00a0des\u00a0Phosphatbinders\u00a0sollte\u00a0im\u00a0Kontext\u00a0ein es\u00a0multiplen\u00a0The\u2010\nrapieansatzes\u00a0 mit\u00a0 Calcium\u2010Pr\u00e4par aten,\u00a0 1,25\u2010Dihydroxyvitamin\u00a0D3\u00a0 bzw.\u00a0 \u2010Analoga\u00a0\noder\u00a0Calcimimetika\u00a0zur\u00a0Vermeidung \u00a0einer\u00a0renalen\u00a0Osteodystrophie \u00a0erfolgen,\u00a0was\u00a0\nin\u00a0den\u00a0Studien\u00a0und\u00a0im\u00a0Dossier\u00a0des\u00a0pU\u00a0nur\u00a0bedingt\u00a0umgesetzt\u00a0wurd e.\u00a0Der\u00a0G\u2010BA\u00a0\nunterscheidet\u00a0im\u00a0Anwendungsgebiet\u00a0von\u00a0Sucroferric\u00a0Oxyhydroxid\u00a0z wei\u00a0Gruppen\u00a0\nvon\u00a0Patienten:\u00a0einerseits\u00a0Dialysepatienten,\u00a0bei\u00a0denen\u00a0calciumha ltige\u00a0Phosphatbin\u2010\nder\u00a0eingesetzt\u00a0werden\u00a0k\u00f6nnen,\u00a0wobei\u00a0als\u00a0zVT\u00a0vom\u00a0G\u2010BA\u00a0calciumhal tige\u00a0Phosphat\u2010\nbinder\u00a0in\u00a0Mono\u2010\u00a0oder\u00a0Kombinationstherapie\u00a0oder\u00a0Sevelamer\u00a0oder\u00a0L anthancarbo\u2010\nnat\u00a0vorgegeben\u00a0werden,\u00a0andererse its\u00a0Patienten,\u00a0bei\u00a0denen\u00a0dies\u00a0a ufgrund\u00a0von\u00a0\nKontraindikationen\u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0wobei\u00a0als\u00a0zVT\u00a0Sevelamer\u00a0o der\u00a0Lanthancarbo\u2010\nnat\u00a0genannt\u00a0werden.\u00a0F\u00fcr\u00a0beide\u00a0Gruppen\u00a0konnte\u00a0der\u00a0pU\u00a0mittels\u00a0Vor lage\u00a0der\u00a0zulas\u2010\nsungsbegr\u00fcndenden\u00a0Studien\u00a0PA\u2010CL\u201003A\u00a0(Phase\u00a0II)\u00a0sowie\u00a0PA\u2010CL\u201005A/ B\u00a0(Phase\u2010III)\u00a0\nkeinen\u00a0Zusatznutzen \u00a0belegen,\u00a0da\u00a0diese\u00a0Subgruppen\u00a0nicht\u00a0getrennt\u00a0ausgewertet\u00a0\nwurden.\u00a0\nIm\u00a0Einzelnen\u00a0begr\u00fcndete\u00a0der\u00a0G\u2010BA\u00a0seinen\u00a0Beschluss\u00a0vom\u00a019.03.201 5\u00a0damit,\u00a0dass\u00a0\nf\u00fcr\u00a0die\u00a0beiden\u00a0definierten\u00a0Patientengruppen,\u00a0d.h.\u00a0CKD\u2010Patienten \u00a0mit\u00a0HD\u00a0bzw.\u00a0PD\u00a0\nund\u00a0Eignung\u00a0zur\u00a0Therapie\u00a0mit\u00a0calciumhaltigen\u00a0Phosphatbindern\u00a0bz w.\u00a0Kontraindika\u2010\ntion\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0mit\u00a0calciumhaltigen\u00a0 Phosphatbindern,\u00a0 insg esamt\u00a0 nur\u00a0die\u00a0\nDaten\u00a0der\u00a0Phase\u2010II\u2010\u00a0und\u00a0Phase\u2010III\u2010Studien\u00a0vorgelegt\u00a0wurden,\u00a0aus \u00a0denen\u00a0diese\u00a0Diffe\u2010\nrenzierung\u00a0nicht\u00a0m\u00f6glich\u00a0ist.\u00a0In\u00a0 der\u00a0sechsarmigen\u00a0Dosisfindungs studie\u00a0PA\u2010CL\u201003A\u00a0389\u00a0erhielten\u00a064\u00a0%\u00a0der\u00a0Patienten\u00a0den\u00a0 aktiven\u00a0Komparator\u00a0Sevelamerhy drochlorid\u00a0in\u00a0\neiner\u00a0\u00dcberdosierung\u00a0von\u00a0fix\u00a04,8\u00a0g\u00a0tgl.;\u00a0laut\u00a0Protokoll\u00a0war,\u00a0im\u00a0 Gegensatz\u00a0zur\u00a0zuge\u2010\nlassenen\u00a0Anwendung,\u00a0weder\u00a0in\u00a0der\u00a0I nterventions\u2010\u00a0noch\u00a0in\u00a0der\u00a0Kon trollgruppe\u00a0eine\u00a0\npatientenindividuelle\u00a0T itration\u00a0der\u00a0Dosierung\u00a0von\u00a0Verum\u00a0bzw.\u00a0Ko mparator\u00a0vorge\u2010\nsehen.\u00a0Zudem\u00a0wurde\u00a0hier\u00a0der\u00a0multi ple\u00a0Therapieansatz\u00a0gem\u00e4\u00df\u00a0der\u00a0Z ulassung\u00a0von\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0nicht\u00a0bzw.\u00a0nur\u00a0bedingt\u00a0umgesetzt,\u00a0sodas s\u00a0die\u00a0Phase\u2010II\u2010\nDosisfindungsstudie\u00a0zur\u00a0Ableitung\u00a0eines\u00a0Zusatznutzens\u00a0gegen\u00fcber \u00a0zVT\u00a0laut\u00a0G\u2010BA\u00a0\nnicht\u00a0geeignet\u00a0ist\u00a0(G\u2010BA,\u00a02015a ;\u00a0G\u2010BA,\u00a02015b;\u00a0G\u2010BA,\u00a02015c;\u00a0G\u2010BA ,\u00a02015d).\u00a0\nVersorgungsanalysen\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0ist\u00a0bei\u00a0der\u00a0TK\u00a0haupts\u00e4chlich\u00a0als\u00a0N2\u00a0Pac kung\u00a0abgerechnet\u00a0\nworden.\u00a0\nAbbildung\u00a04.49:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Sucroferric\u00a0Oxyhyd roxid\u00a0je\u00a0\u00a0\nMonat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n390\u00a0Abbildung\u00a04.50:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Sucrofer ric\u00a0Oxyhyd\u2010\nroxid\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nSucroferric\u00a0Oxyhydroxid\u00a0wurde\u00a0vor\u00a0allem\u00a0M\u00e4nnern\u00a0verordnet.\u00a0Ledi glich\u00a0in\u00a0der\u00a0\nAltersgruppe\u00a0der\u00a040\u00a0bis\u00a049\u2010J\u00e4hrigen\u00a0gibt\u00a0es\u00a0eine\u00a0Patientin\u00a0mehr \u00a0als\u00a0Patienten\u00a0mit\u00a0\nVerordnungen.\u00a0Bei\u00a0Patienten\u00a0unter\u00a017\u00a0und\u00a0\u00fcber\u00a089\u00a0Jahren\u00a0wurde\u00a0d er\u00a0Wirkstoff\u00a0\nnicht\u00a0verordnet.\u00a0\nQuellen\u00a0\nBlock\u00a0GA,\u00a0Hulbert\u2010Shearon\u00a0TE,\u00a0Levin\u00a0NW,\u00a0Port\u00a0FK\u00a0(1998).\u00a0Associa tion\u00a0of\u00a0serum\u00a0phosphorus\u00a0and\u00a0calcium\u00a0x\u00a0phosphate\u00a0product\u00a0with\u00a0\nmortality\u00a0risk\u00a0in\u00a0chronic\u00a0hemodialysis\u00a0patients.\u00a0Am\u00a0J\u00a0Kidney\u00a0Di s\u00a031(4):607\u2010617.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2009).\u00a0S evelamercarbonat\u00a0\u2010Renvela.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Product_Information/human/000993/WC500052610.pdf,\u00a0letzter\u00a0Zugr iff:\u00a030.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 SMOP\u00a0initial\u00a0authorisation.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/Summary_of_opinio n_\u2010\n_Initial_authorisation/human/002705/WC500169354.pdf,\u00a0letzter\u00a0Zu griff:\u00a026.06.2017.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 SMPC.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Product_Information/human/002705/WC500175254.pdf,\u00a0letzter\u00a0Zugr iff:\u00a026.06.2017.\u00a0\nClinicalTrials.gov\u00a0(2011).\u00a0A\u00a0Phase\u00a03\u00a0Study\u00a0to\u00a0Investigate\u00a0the\u00a0S afety\u00a0and\u00a0Efficacy\u00a0of\u00a0PA21,\u00a0a\u00a0Pho sphate\u00a0Binder,\u00a0in\u00a0Dialysis\u00a0Pat ients.\u00a0\nhttps://www.clinicaltrials.gov /ct2/show/study/NCT01324128?term= PA\u2010CL05A&rank=2&sect=X056,\u00a0letzter\u00a0Zugriff:\u00a0\n30.06.2017.\u00a0\n391\u00a0DESTATIS\u00a0\u2013\u00a0Statistisches\u00a0Bundesamt\u00a0(2016).\u00a0Deutlicher\u00a0Bev\u00f6lkeru ngsanstieg\u00a0im\u00a0Jahr\u00a02015\u00a0auf\u00a0mindestens\u00a081,9\u00a0Millionen.\u00a0Presse\u2010\nmitteilung.\u00a0https://www.destatis.de/DE/PresseService/Presse/Pre ssemitteilungen/2016/01/PD16_032_12411.html,\u00a0\nletzter\u00a0Zugriff:\u00a006.09.2017.\u00a0\nFloege\u00a0J,\u00a0Covic\u00a0AC,\u00a0Ketteler\u00a0M,\u00a0M ann\u00a0JFE,\u00a0Rastogi\u00a0A,\u00a0Spinowitz\u00a0 B\u00a0(2015).\u00a0Long\u2010term\u00a0effects\u00a0of\u00a0the\u00a0iron\u2010based\u00a0phosphate\u00a0binder, \u00a0\nsucroferric\u00a0oxyhydroxi de,\u00a0in\u00a0dialysis\u00a0patients.\u00a0Nephrol\u00a0Dial\u00a0Tr ansplan\u00a030(6):\u00a01037\u20101046.\u00a0\nFloege\u00a0J,\u00a0Covic\u00a0AC,\u00a0Ketteler\u00a0M, \u00a0Rastogi\u00a0A,\u00a0Chong\u00a0EM,\u00a0Gaillard\u00a0S ,\u00a0Lisk\u00a0LJ,\u00a0Sprague\u00a0SM\u00a0et\u00a0al.\u00a0(2014).\u00a0A\u00a0phase\u00a0III\u00a0study\u00a0of\u00a0the\u00a0e fficacy\u00a0\nand\u00a0safety\u00a0of\u00a0a\u00a0novel\u00a0iron\u2010based\u00a0phosphate\u00a0binder\u00a0in\u00a0dialysis\u00a0p atients.\u00a0Kidney\u00a0Int\u00a086(3):638\u201047.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015a).\u00a0Beschluss.\u00a0https:// www.g\u2010ba.de/downloads/39\u2010261\u20102211/2015\u201003\u201019_AM\u2010RL\u2010\nXII_Sucroferric_2014\u201010\u201001\u2010D\u2010136_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a026. 06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015b).\u00a0M\u00fcndliche\u00a0Anh\u00f6rung. \u00a0https://www.g\u2010ba.de/downloads/91\u20101031\u2010144/2015\u201002\u2010\n09_Wortprotokoll_end_ \u00a0Sucroferric_Oxyhydroxide.pdf,\u00a0letzter\u00a0Zugriff:\u00a026.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015c).\u00a0Tragende\u00a0Gr\u00fcnde.\u00a0 https://www.g\u2010ba.de/downloads/40\u2010268\u20103158/2015\u201003\u2010\n19_AM\u2010RL\u2010XII_Sucroferric_2014\u201010\u201001\u2010D\u2010136_TrG.pdf ,\u00a0letzter\u00a0Zugriff:\u00a026.06.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015d).\u00a0Zusammenfassende\u00a0Do kumentation.\u00a0 https://www.g\u2010ba.de/downloads/40\u2010268\u2010\n3289/2015\u201003\u201019_AM\u2010RL\u2010XII_Sucroferric_2014\u201010\u201001\u2010D\u2010136_ZD.pdf ,\u00a0letzter\u00a0Zugriff:\u00a026.06.2017.\u00a0\nGirndt\u00a0(2016).\u00a0The\u00a0Prevalence\u00a0of\u00a0Renal\u00a0Failure.\u00a0Results\u00a0from\u00a0th e\u00a0German\u00a0Health\u00a0Interview\u00a0and\u00a0Ex amination\u00a0Survey\u00a0for\u00a0Adults,\u00a0\n2008\u20102011\u00a0(DEGS1).\u00a0Deutsches\u00a0Arzteblatt\u00a0international\u00a0113\u00a06.\u00a0\nHAS\u00a0(2015).\u00a0VELPHORO_SUMMARY_CT13935.\u00a0 https://www.has\u2010sante.fr/portail/plugins/ModuleXitiKLEE/types/F ileDocument/ \u00a0\ndoXiti.jsp?id=c_2571405,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nHutchison\u00a0AJ\u00a0(2014).\u00a0Novel\u00a0phosphate\u00a0binders:\u00a0plus\u00a0\u00e7a\u00a0change,\u00a0p lus\u00a0c'est\u00a0la\u00a0m\u00eame\u00a0chose.\u00a0Kidney\u00a0Int\u00a086(3):471\u20104.\u00a0\nKetteler\u00a0M,\u00a0Block\u00a0GA,\u00a0Evenepoel\u00a0P,\u00a0Fukagawa\u00a0M,\u00a0Herzog\u00a0CA,\u00a0McCan n\u00a0L\u00a0et\u00a0al.\u00a0(2017).\u00a0Executive\u00a0summary\u00a0of\u00a0the\u00a02017\u00a0KDIGO\u00a0Chronic\u00a0\nKidney\u00a0Disease\u2010Mineral\u00a0and\u00a0Bone\u00a0Disorder\u00a0(CKD\u2010MBD)\u00a0Guideline\u00a0Up date.\u00a0Kidney\u00a0int\u00a092(1):26\u201036.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0Lauer\u2010Taxe.\u00a0 https://www.cgm.com/lauer\u2010fischer/impressum_lf/impressum~1.de.j sp,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017\u00a0\nLevey\u00a0AS,\u00a0Coresh\u00a0J\u00a0(2012).\u00a0Chronic\u00a0kidney\u00a0disease.\u00a0Lancet\u00a0379(9 811):165\u201080.\u00a0\nMNC\u00a0(2016).\u00a0Zusammenfassender\u00a0Jahresbericht\u00a0der\u00a0Berichterstelle r\u00a0zur\u00a0Dialysebehandlung\u00a0f\u00fcr\u00a0das \u00a0Berichtsjahr\u00a02015.\u00a0https://www. g\u2010\nba.de/downloads/17\u201098\u20104261/2016\u201010\u201020_QSD\u2010RL_MNC\u2010Jahresbericht\u2010 2015_Bericht\u2010MNC.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n27.06.2017.\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2015) .\u00a0Hyperphosphataemia\u00a0in\u00a0adults\u00a0with\u00a0chronic\u00a0kidney\u00a0disease\u00a0on\u00a0\ndialysis:\u00a0sucroferric\u00a0oxyhydroxide.\u00a0 https://www.nice.org.uk/advice/esnm51/chapter/Key\u2010points\u2010from\u2010t he\u2010\nevidence# ,\u00a0letzter\u00a0Zugriff:\u00a028.06.2017.\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2017) .\u00a0Hyperphosphataemia\u00a0in\u00a0chronic\u00a0kidney\u00a0disease\u00a0overview.\u00a0\nhttps://pathways.nice.org.uk/pathways/hyperphosph \u00a0ataemia\u2010in\u2010chronic\u2010kidney\u2010disease#content=view\u2010\nnode%3Anodes\u2010second\u2010line\u2010phosphate\u2010binder\u2010treatment\u2010for\u2010adults, \u00a0letzter\u00a0Zugriff:\u00a028.06.2017.\u00a0\nWIdO\u00a0(2017)\u00a0ATC\u2010Klassifikation\u00a0mit\u00a0Tagesdosen\u00a0f\u00fcr\u00a0den\u00a0deutschen \u00a0Arzneimittelmarkt\u00a0des\u00a0GKV\u2010Arzneimittelindex\u00a0 www.wido.de/ \u00a0\nfileadmin/wido/downloads/zip\u2010Arzneimittel/wido_arz_atc\u2010methodik _0517.zip,\u00a0letzter\u00a0Zugriff:\u00a016.07.2017392\u00a04.27 Teduglutid\u00a0\nHandelsname:\u00a0Revestive\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Kurzdarmsyndrom\u00a0 \u00a0 Shire\u00a0Deutschland\u00a0GmbH\u00a0\nATC\u2010Code:\u00a0A16AX08\u00a0 \u00a0 \u00a0 Marktein f\u00fchrung:\u00a0September\u00a02014\u00a0\u00a0\nDarreichungsform:\u00a0Pulver\u00a0und\u00a0\u00a0 \u00a0\nL\u00f6sungsmittel\u00a0zum\u00a0Herstellen\u00a0\u00a0\neiner\u00a0Injektionsl\u00f6sung\u00a0 \u00a0 \u00a0 DDD:\u00a05\u00a0mg\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O, \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nSeit\u00a0September\u00a02014\u00a0ist\u00a0Teduglutid\u00a0(Revestive\u00ae)\u00a0in\u00a0Deutschland\u00a0 als\u00a0erster\u00a0Vertre\u2010\nter\u00a0der\u00a0neuen\u00a0Substanzklasse\u00a0der\u00a0GLP\u20102\u00a0( Glucagon\u2010Like\u00a0Peptide\u20102 )\u2010Analoga\u00a0verf\u00fcg\u2010\nbar,\u00a0nachdem\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Commission ,\u00a0EC)\u00a0 bereits\u00a0\n2012\u00a0die\u00a0Zulassung\u00a0des\u00a0Pr\u00e4parates\u00a0als\u00a0 Orphan\u00a0Designation \u00a0(EMA,\u00a02009)\u00a0f\u00fcr\u00a0das\u00a0\nIndikationsgebiet\u00a0 Kurzdarmsyndrom\u00a0 (KDS)\u00a0 bei\u00a0 Erwachsenen\u00a0 erteilt \u00a0h a t t e . \u00a0D e r \u00a0\nEinsatz\u00a0der\u00a0Substanz\u00a0erfolgt\u00a0im\u00a0Anschluss\u00a0an\u00a0die\u00a0intestinale\u00a0Ad aptionsphase\u00a0nach\u00a0\neinem\u00a0chirurgischen\u00a0Eingriff\u00a0bei\u00a0Patienten\u00a0im\u00a0stabilen\u00a0Zustand. \u00a0Seit\u00a0dem\u00a029.\u00a0Juni\u00a0\n2016\u00a0liegt\u00a0eine\u00a0erweiterte\u00a0Zulassung\u00a0vor,\u00a0die\u00a0die\u00a0Anwendung\u00a0bei \u00a0Kindern\u00a0ab\u00a0einem\u00a0\nJahr\u00a0und\u00a0Jugendlichen\u00a0erlaubt\u00a0und\u00a0keinen\u00a0vorangegangenen\u00a0chirur gischen\u00a0Eingriff\u00a0\nvoraussetzt\u00a0(EMA,\u00a02012a).\u00a0Das\u00a0aus\u00a033\u00a0Aminos\u00e4uren\u00a0bestehende\u00a0Pol ypeptid\u00a0GLP\u20102\u00a0\nwird\u00a0von\u00a0den\u00a0L\u2010Zellen\u00a0des\u00a0Ileums\u00a0und\u00a0Colons\u00a0sezerniert\u00a0und\u00a0verm ittelt\u00a0zahlreiche\u00a0\nProzesse\u00a0wie\u00a0Steigerung\u00a0des\u00a0intestinalen\u00a0und\u00a0portalen\u00a0Blutfluss es,\u00a0Beeinflussung\u00a0\ndes\u00a0Wachstums\u00a0der\u00a0Darmmucosa\u00a0sowie\u00a0Verbesserung\u00a0der\u00a0Aufnahme\u00a0vo n\u00a0Nah\u2010\nrungsbestandteilen\u00a0in\u00a0die\u00a0Blutbahn\u00a0(Tee\u00a0et\u00a0al.,\u00a02011;\u00a0Drucker\u00a0& \u00a0Yusta\u00a02014).\u00a0Von\u00a0\ndiesen\u00a0Effekten\u00a0leitet\u00a0sich\u00a0das\u00a0Wirkprinzip\u00a0von\u00a0Teduglutid\u00a0ab,\u00a0 das\u00a0nach\u00a0gentechno\u2010\nlogischer\u00a0Modifikation\u00a0gegen\u00fcber\u00a0 dem\u00a0physiologischen\u00a0Vorbild\u00a0ei ne\u00a0verl\u00e4ngerte\u00a0\nHalbwertszeit\u00a0aufweist\u00a0(GLP\u20102:\u00a07\u00a0Min.\u00a0vs.\u00a0Teduglutid:\u00a02\u00a0bis\u00a03\u00a0S tunden).\u00a0Teduglutid\u00a0\nbewirkt\u00a0sowohl\u00a0eine\u00a0Zunahme\u00a0der\u00a0Darmzottenh\u00f6he\u00a0als\u00a0auch\u00a0der\u00a0Dar mkryptentiefe\u00a0\nder\u00a0Darmschleimhaut.\u00a0In\u00a0der\u00a0Kons equenz\u00a0soll\u00a0der\u00a0Bedarf\u00a0an\u00a0der\u00a0b en\u00f6tigten\u00a0paren\u2010\nteralen\u00a0Ern\u00e4hrung\u00a0(pE)\u00a0reduziert\u00a0und\u00a0somit\u00a0die\u00a0Lebensqualit\u00e4t\u00a0d er\u00a0Patienten\u00a0ver\u2010\nbessert\u00a0werden.\u00a0Die\u00a0empfohlene\u00a0t\u00e4gliche\u00a0Dosierung\u00a0betr\u00e4gt\u00a0f\u00fcr\u00a0a lle\u00a0Altersgruppen\u00a0\n0,05\u00a0mg\u00a0pro\u00a0kg\u00a0K\u00f6rpergewicht\u00a0(KG)\u00a0und\u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0subcu tan\u00a0in\u00a0den\u00a0Bauch\u00a0\noder\u00a0den\u00a0Oberschenkel\u00a0appliziert.\u00a0Dabei\u00a0sollte\u00a0f\u00fcr\u00a0jede\u00a0Injekti on\u00a0der\u00a0rekonstituier\u2010\nten\u00a0L\u00f6sung\u00a0ein\u00a0anderer\u00a0der\u00a0vier\u00a0abdominalen\u00a0Quadranten\u00a0gew\u00e4hlt\u00a0 werden\u00a0(EMA,\u00a0\n2012b).\u00a0\u00a0\nDer\u00a0Wirksamkeitsnachweis\u00a0innerhal b\u00a0des\u00a0Zulassungsverfahrens\u00a0gr\u00fc ndet\u00a0sich\u00a0auf\u00a0\nzwei\u00a0 sechsmonatige,\u00a0 multizentris che,\u00a0 doppelblinde,\u00a0 randomisiert e\u00a0 Phase\u2010III\u2010\nStudien,\u00a0die\u00a0durch\u00a0den\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0gespon sert\u00a0wurden.\u00a0\nIn\u00a0Untersuchung\u00a0CL0600\u2010004\u00a0(Jeppesen\u00a0et\u00a0al.,\u00a02011)\u00a0wurde\u00a0ein\u00a0Pa tientenkollektiv\u00a0\nvon\u00a084\u00a0KDS\u2010Patienten\u00a0in\u00a0drei\u00a0Gruppen\u00a0kategorisiert,\u00a0die\u00a0Teduglu tid\u00a00,1\u00a0mg/kgKG/\u00a0393\u00a0Tag,\u00a0 0,05\u00a0mg/kgKG/Tag\u00a0 oder\u00a0 Placebo\u00a0 erhielten.\u00a0 Prim\u00e4rer\u00a0 Endpunkt \u00a0w a r \u00a0d i e \u00a0A n \u2010\nsprechrate,\u00a0die\u00a0mittels\u00a0eines\u00a0graduierten\u00a0Scores,\u00a0der\u00a0die\u00a0Inten sit\u00e4t\u00a0und\u00a0Dauer\u00a0der\u00a0\nerforderlichen\u00a0Infusionen\u00a0an\u00a0pE\u00a0ber\u00fccksichtigt,\u00a0ermittelt\u00a0worde n\u00a0war.\u00a0\u00a0\nIn\u00a0der\u00a0Behandlungspraxis\u00a0besitzt\u00a0die\u00a0pE\u00a0einen\u00a0zentralen\u00a0Stellen wert.\u00a0Die\u00a0Therapie\u00a0\nwird\u00a0patientenindividuell\u00a0gestal tet\u00a0und\u00a0variiert\u00a0bez\u00fcglich\u00a0Umfa ng\u00a0und\u00a0Intensit\u00e4t\u00a0\n(AWMF,\u00a02014).\u00a0Die\u00a0umf\u00e4ngliche\u00a0\u00c4nderung\u00a0der\u00a0pE\u00a0fungiert\u00a0hier\u00a0als \u00a0Surrogatpara\u2010\nmeter\u00a0f\u00fcr\u00a0die\u00a0Beurteilung\u00a0des\u00a0Effekts\u00a0der\u00a0Therapie\u00a0mit\u00a0dem\u00a0GLP\u2010 2\u2010Analogon.\u00a0F\u00fcr\u00a0\ndie\u00a0Dosis\u00a00,1\u00a0mg/kg\u00a0wurde\u00a0kein\u00a0s ignifikantes\u00a0Erg ebnis\u00a0erzielt\u00a0( 6,3\u00a0%\u00a0(Placebo)\u00a0vs.\u00a0\n25\u00a0%,\u00a0p=0,161).\u00a0Dem\u00a0statistischen\u00a0Analyseplan\u00a0entsprechend,\u00a0der \u00a0ein\u00a0hierarchi\u2010\nsches\u00a0Modell\u00a0verfolgte,\u00a0sind\u00a0di e\u00a0Studienergebnisse\u00a0lediglich\u00a0al s\u00a0deskriptiv\u00a0zu\u00a0be\u2010\ntrachten\u00a0(EMA,\u00a02012b).\u00a0Die\u00a0Resultate\u00a0der\u00a0Gruppe\u00a0mit\u00a00,05\u00a0mg/kg, \u00a0di e\u00a0so wo hl\u00a0\ngegen\u00fcber\u00a0Placebo\u00a0als\u00a0auch\u00a0gegen\u00fcber\u00a0der\u00a0h\u00f6heren\u00a0Dosis\u00a0signifik ant\u00a0besser\u00a0ab\u2010\nschnitt\u00a0(45,7\u00a0%,\u00a0p=0,007),\u00a0k\u00f6nnen\u00a0daher\u00a0innerhalb\u00a0der\u00a0vorgelegt en\u00a0Evidenz\u00a0ledig\u2010\nlich\u00a0supportiv\u00a0sein.\u00a0Innerhalb\u00a0des\u00a0Patientenkollektivs\u00a0mussten\u00a0 18\u00a0Teilnehmer\u00a0die\u00a0\nw\u00f6chentliche\u00a0Zeit\u00a0der\u00a0pE\u00a0um\u00a0mindestens\u00a0einen\u00a0Tag\u00a0erh\u00f6hen.\u00a0Aufgr und\u00a0einer\u00a0ver\u2010\ngleichsweise\u00a0hohen\u00a0Anzahl\u00a0innerhalb\u00a0der\u00a0Placebo\u2010Gruppe\u00a0konnte\u00a0a uch\u00a0hier\u00a0kein\u00a0\nsignifikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0mit\u00a0Teduglutid\u00a0belegt\u00a0we rden\u00a0(Placebo,\u00a025\u00a0%\u00a0\nvs.\u00a00,05\u00a0mg,\u00a031,4\u00a0%\u00a0vs.\u00a00,1\u00a0mg,\u00a09,4\u00a0%).\u00a0Ein\u00a0komplettes\u00a0Absetzen \u00a0wurde\u00a0nur\u00a0im\u00a0\nInterventionsarm\u00a0mit\u00a00,05\u00a0mg\u00a0(n=3)\u00a0erreicht.\u00a0\nDie\u00a0Studie\u00a0STEPS,\u00a0CL0600\u2010020\u00a0(Jeppesen\u00a0et\u00a0al.,\u00a02005)\u00a0beobachtet e\u00a086\u00a0Patienten,\u00a0\ndie\u00a0in\u00a0zwei\u00a0Behandlungsgruppen\u00a0eingeteilt\u00a0und\u00a0\u00fcber\u00a024\u00a0Wochen\u00a0mi t\u00a00,05\u00a0mg/\u00a0\nkgKG/Tag\u00a0oder\u00a0Placebo\u00a0behandelt\u00a0wurden.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0wa r\u00a0definiert\u00a0als\u00a0\n\u201ein\u00a0Woche\u00a020\u00a0erzielte\u00a0und\u00a0bis\u00a0Woche\u00a024\u00a0aufrechterhaltene\u00a0Anspre chrate,\u00a0die\u00a0eine\u00a0\nmindestens\u00a020\u00a0%\u00a0umfassende\u00a0Reduktion\u00a0der\u00a0w\u00f6chentlich\u00a0ben\u00f6tigten \u00a0pE\u00a0bedeute\u2010\nte,\u00a0gegen\u00fcber\u00a0Beobachtungsbeginn\u201c.\u00a0Der\u00a0Anteil\u00a0der\u00a0 Responder \u00a0betrug\u00a063\u00a0%\u00a0in\u00a0der\u00a0\nTeduglutid\u2010\u00a0und\u00a030\u00a0%\u00a0in\u00a0der\u00a0Placebogruppe\u00a0(p=0,002).\u00a0Die\u00a0Anzahl \u00a0der\u00a0Patienten,\u00a0\nbei\u00a0denen\u00a0nach\u00a024\u00a0Wochen\u00a0eine\u00a0Reduktion\u00a0der\u00a0pE\u00a0um\u00a0mindestens\u00a0ei nen\u00a0Tag\u00a0pro\u00a0\nWoche\u00a0erzielt\u00a0werden\u00a0konnte,\u00a0\u00fcbe rwog\u00a0im\u00a0Interventionsarm\u00a0mit\u00a048 ,8\u00a0%\u00a0vs.\u00a0Place\u2010\nbo\u00a020,9\u00a0%.\u00a0Aus\u00a0der\u00a0Analyse\u00a0der\u00a0kombinierten\u00a0Daten\u00a0von\u00a0STEPS\u00a0und \u00a0deren\u00a0zweij\u00e4h\u2010\nriger\u00a0unverblindeter\u00a0Verl\u00e4nger ungsstudie\u00a0STEPS\u20102,\u00a0CL0600\u2010021\u00a0(S chwartz\u00a0et\u00a0al.,\u00a0\n2016)\u00a0ging\u00a0eine\u00a0weitere\u00a0Verbesserung\u00a0der\u00a0Ansprechrate\u00a0hervor,\u00a0d ie\u00a092\u00a0%\u00a0im\u00a0Inter\u2010\nventionsarm\u00a0und\u00a050\u00a0%\u00a0innerhalb\u00a0der\u00a0Placebo\u2010Gruppe\u00a0erreichte.\u00a0Di e\u00a0gesundheitsbe\u2010\nzogene\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurde\u00a0mittels\u00a0der\u00a0\nFrageb\u00f6gen\u00a0 Short\u00a0Form\u00a036 \u00a0(SF36),\u00a0EuroQol\u00a0Five\u00a0Dimensions\u00a0Questionnaire \u00a0(EQ5D)\u00a0\nin\u00a0STEPS\u00a0und\u00a0 Inflammatory\u00a0Bowel\u00a0Disease\u00a0Questionnaire \u00a0(IBDQ)\u00a0in\u00a0CL0600\u2010004\u00a0\nerfasst.\u00a0In\u00a0der\u00a0Auswertung\u00a0wurden \u00a0keine\u00a0signifikanten\u00a0Unterschi ede\u00a0zwischen\u00a0den\u00a0\nBehandlungsgruppen\u00a0detektiert.\u00a0\u00a0394\u00a0F\u00fcr\u00a0beide\u00a0Studien\u00a0ergeben\u00a0sich\u00a0methodisch\u00a0begr\u00fcndete\u00a0Limitation en.\u00a0Der\u00a0Bedarf\u00a0\nan\u00a0pE\u00a0zeigte\u00a0eine\u00a0hohe\u00a0Spannweite\u00a0in\u00a0STEPS\u00a0zwischen\u00a03,6\u00a0und\u00a034\u00a0 l/Woche\u00a0zu\u00a0Be\u2010\nobachtungsbeginn.\u00a0Auch\u00a0variierte\u00a0die\u00a0klinische\u00a0Ausgangssituatio n\u00a0der\u00a0Teilnehmer\u00a0\nbez\u00fcglich\u00a0der\u00a0L\u00e4nge\u00a0des\u00a0verblieb enen\u00a0Darms\u00a0oder\u00a0dem\u00a0Vorhandense in\u00a0von\u00a0Colon\u2010\nAbschnitten.\u00a0Die\u00a0Inklusionskriterien\u00a0der\u00a0Studie\u00a0CL0600\u2010004\u00a0schl ossen\u00a0Patienten\u00a0\nein,\u00a0die\u00a0bereits\u00a0mindestens\u00a0zw\u00f6lf\u00a0Monate\u00a0eine\u00a0pE\u00a0erhielten.\u00a0Im\u00a0 Hinblick\u00a0auf\u00a0den\u00a0\nzeitlichen\u00a0Umfang\u00a0der\u00a0Adaptionspha se,\u00a0der\u00a0bis\u00a0zu\u00a0zwei\u00a0Jahre\u00a0bet r\u00e4gt,\u00a0und\u00a0dem\u00a0\nErgebnis\u00a0der\u00a0Placebo\u2010Gruppe,\u00a0ist\u00a0 ein\u00a0m\u00f6glicher\u00a0positiver\u00a0Einflu ss\u00a0auf\u00a0die\u00a0Ansprech\u2010\nrate\u00a0vorstellbar.\u00a0\nUnter\u00a0 Therapie\u00a0 mit\u00a0 Teduglutid\u00a0 und\u00a0 Placebo\u00a0 wurden\u00a0 h\u00e4ufig\u00a0 moderat e\u00a0Adverse\u00a0\nEvents\u00a0(AE,\u00a0unerw\u00fcnschte\u00a0Arzneimittelereignisse)\u00a0wie\u00a0Bauchschmerzen,\u00a0 \u00dcbelkeit,\u00a0\nErbrechen,\u00a0Bl\u00e4hungen\u00a0und\u00a0Obstipation\u00a0beobachtet.\u00a0In\u00a0den\u00a0Interve ntionsgruppen\u00a0\nwurden\u00a0Leber\u00a0und\u00a0Bauchspeicheldr\u00fcse\u00a0betreffende\u00a0AE\u00a0sowie\u00a0drei\u00a0K rebsf\u00e4lle\u00a0do\u2010\nkumentiert.\u00a0Die\u00a0Analyse\u00a0der\u00a0kombinierten\u00a0Daten\u00a0aus\u00a0CL0600\u2010004\u00a0u nd\u00a0STEPS\u00a0zeigte\u00a0\neine\u00a0Erh\u00f6hung\u00a0des\u00a0C\u2010reaktiven\u00a0Proteins\u00a0(CRP),\u00a0das\u00a0zum\u00a0Beobachtu ngsende\u00a0im\u00a0\nMittel\u00a0um\u00a01,43\u00a0mg/l\u00a0im\u00a0Vergleich\u00a0zur\u00a0Ausgangssituation\u00a0anstieg\u00a0 \u2013\u00a0ein\u00a0wichtiger\u00a0\nAspekt,\u00a0da\u00a0ein\u00a0erh\u00f6hter\u00a0CRP\u2010Serumspiegel\u00a0als\u00a0Indiz\u00a0bei\u00a0der\u00a0Beur teilung\u00a0der\u00a0Risiken\u00a0\nf\u00fcr\u00a0Arteriosklerose,\u00a0Insulinresistenz\u00a0und\u00a0des\u00a0Metabolischen\u00a0Syn droms\u00a0herangezo\u2010\ngen\u00a0wird.\u00a0Weiterhin\u00a0wurde,\u00a0insbesondere\u00a0in\u00a0der\u00a0weiterf\u00fchrenden\u00a0 Studie\u00a0STEPS\u00a02,\u00a0\ndie\u00a0Bildung\u00a0von\u00a0Antik\u00f6rpern\u00a0gege n\u00a0Teduglutid\u00a0beobachtet.\u00a0Die\u00a0Be deutung\u00a0des\u00a0\nimmunogenen\u00a0Potentials\u00a0der\u00a0Thera pie\u00a0mit\u00a0dem\u00a0GLP\u20102\u00a0Analogon\u00a0ist\u00a0 bisher\u00a0nicht\u00a0\ngekl\u00e4rt.\u00a0\u00a0\nUm\u00a0weitere\u00a0Daten\u00a0auch\u00a0zur\u00a0Einsch\u00e4tzung\u00a0der\u00a0Risiken\u00a0zu\u00a0generiere n,\u00a0wurde\u00a0der\u00a0pU\u00a0\nmit\u00a0der\u00a0Einrichtung\u00a0eines\u00a0internationalen\u00a0Registers\u00a0(EUPAS7973) \u00a0sowie\u00a0der\u00a0Vorlage\u00a0\nregelm\u00e4\u00dfig\u00a0aktualisierter\u00a0Berichte\u00a0zur\u00a0Unbedenklichkeit\u00a0des\u00a0Arz neimittels\u00a0( Periodic\u00a0\nSafety\u00a0Update\u00a0Report ,\u00a0PSUR)\u00a0beauflagt.\u00a0\nIm\u00a0Verfahren\u00a0der\u00a0Zulassungserweiterung\u00a0zur\u00a0Anwendung\u00a0bei\u00a0Kinder n\u00a0ab\u00a0einem\u00a0Jahr\u00a0\nlegte\u00a0der\u00a0pU\u00a0die\u00a0prospektive,\u00a0offene,\u00a0vergleichende\u00a0Studie\u00a0TED\u2010 C13\u2010003\u00a0(Carter\u00a0et\u00a0\nal.,\u00a02017)\u00a0vor.\u00a0Die\u00a0Interventionsgruppe\u00a0kategorisierte\u00a0drei\u00a0Gru ppen:\u00a00,0125\u00a0mg/kg/d\u00a0\n(n\u2009=\u20098),\u00a00,025\u00a0mg/kg/d\u00a0(n\u2009=\u200914),\u00a00,05\u00a0mg/kg/d\u00a0(n\u2009=\u200915),\u00a0die\u00a0ohn e\u00a0Randomisierung\u00a0mit\u00a0\neinem\u00a0Patientenkollektiv\u00a0(n=5)\u00a0verglichen\u00a0wurde,\u00a0das\u00a0die\u00a0jeweil ige\u00a0Standardtherapie\u00a0\n(Best\u2010Supportive\u2010Care ,\u00a0BSC)\u00a0erhielt.\u00a0Im\u00a0Median\u00a0betrug\u00a0die\u00a0Reduktion\u00a0des\u00a0pE\u2010Volu\u2010\nmens\u00a0sowie\u00a0der\u00a0Kalorien\u00a0bei\u00a0BSC\u00a00\u00a0bis\u00a01\u00a0%,\u00a00,0125\u00a0mg/kg/d\u00a00\u00a0bis \u00a06\u00a0%,\u00a00,025\u2009mg/kg/d\u00a0\n41\u00a0bis\u00a045\u00a0%\u00a0und\u00a00,05\u00a0mg/kg/d\u00a025\u00a0bis\u00a050\u00a0%.\u00a0Ein\u00a0vollst\u00e4ndiges\u00a0Abs etzen\u00a0der\u00a0pE\u00a0erreich\u2010\nten\u00a0drei\u00a0Patienten\u00a0der\u00a0Interventionsgruppe\u00a00,05\u00a0mg/kg/d\u00a0und\u00a0ein \u00a0Teilnehmer\u00a0der\u00a0\nZielpopulation\u00a0mit\u00a00,025\u00a0mg/kg/d.\u00a0Den\u00a0Ergebnissen\u00a0wurde\u00a0sowohl\u00a0 von\u00a0den\u00a0Autoren\u00a0\nals\u00a0auch\u00a0vom\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use \u00a0(CHMP)\u00a0ein\u00a0deskrip\u2010\ntiver\u00a0Stellenwert\u00a0beigemessen\u00a0(EMA,\u00a02012b).\u00a0\u00a0395\u00a0Die\u00a0Bewertung\u00a0des\u00a0Gemeinsamen\u00a0B undesausschusses\u00a0(G\u2010BA)\u00a0erfolgte \u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0\nAbsatz\u00a01\u00a0Satz\u00a010\u00a0SGB\u00a0V\u00a0unter\u00a0Annahme\u00a0eines\u00a0Zusatznutzens\u00a0f\u00fcr\u00a0Te duglutid\u00a0anhand\u00a0\nzulassungsrelevanter\u00a0Studien.\u00a0Der\u00a0 pU\u00a0legte\u00a0in\u00a0seinen\u00a0Dossiers\u00a0d ie\u00a0Daten\u00a0der\u00a0Stu\u2010\ndien\u00a0STEPS,\u00a0CL0600\u2010004\u00a0und\u00a0der\u00a0offenen,\u00a0nicht\u2010placebokontrollie rten\u00a0Follow\u2010up \u2010\nUntersuchungen\u00a0STEPS\u20102\u00a0und\u00a0CL0600\u2010005\u00a0vor.\u00a0Dabei\u00a0betrachtete\u00a0da s\u00a0Gremium\u00a0\nstets\u00a0die\u00a0Ergebnisse\u00a0der\u00a0Teilpopulation,\u00a0die\u00a0die\u00a0zugelassene\u00a0Do sis\u00a0von\u00a00,05\u00a0mg/kg\u00a0\nK\u00f6rpergewicht\u00a0pro\u00a0Tag\u00a0erhalten\u00a0hatte.\u00a0Die\u00a0supportive\u00a0Studie\u00a0CL0 600\u2010004\u00a0wurde\u00a0\naufgrund\u00a0der\u00a0fehlenden\u00a0statistischen\u00a0Signifikanz\u00a0nicht\u00a0ber\u00fccksi chtigt.\u00a0Der\u00a0G\u2010BA\u00a0\nnahm\u00a0an,\u00a0dass\u00a0bereits\u00a0mit\u00a0einer\u00a0Reduktion\u00a0des\u00a0Volumens\u00a0der\u00a0pE\u00a0e in\u00a0Gewinn\u00a0an\u00a0\nLebensqualit\u00e4t\u00a0 einhergehe.\u00a0 Eine\u00a0 Verbesserung\u00a0 der\u00a0 Ansprechrate\u00a0 w urde\u00a0 nur\u00a0 in\u00a0\nSTEPS\u00a0realisiert,\u00a0wohingegen\u00a0in\u00a0keiner\u00a0der\u00a0beiden\u00a0Studien\u00a0ein\u00a0E ffekt\u00a0auf\u00a0die\u00a0HRQoL\u00a0\nbelegt\u00a0werden\u00a0konnte.\u00a0Im\u00a0Hinblic k\u00a0auf\u00a0die\u00a0Ergebnisse\u00a0bez\u00fcglich\u00a0 Morbidit\u00e4t\u00a0und\u00a0\nLebensqualit\u00e4t\u00a0sowie\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0AE,\u00a0die\u00a0in\u00a0s\u00e4mt lichen\u00a0Gruppen\u00a0\nh\u00e4ufig\u00a0auftraten,\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 geringen\u00a0Zusatznutzen \u00a0fest\u00a0(G\u2010BA,\u00a02015).\u00a0\nIn\u00a0einem\u00a0weiteren\u00a0Verfahren\u00a0zur\u00a0Bewertung\u00a0des\u00a0neuen\u00a0Anwendungsg ebietes\u00a0f\u00fcr\u00a0\nKinder\u00a0ab\u00a0einem\u00a0Jahr \u00a0legte\u00a0der\u00a0pU\u00a0die\u00a0Studie\u00a0TED\u2010C13\u2010003\u00a0(Carter\u00a0et\u00a0al.,\u00a02017)\u00a0vor. \u00a0\nInnerhalb\u00a0der\u00a0Teilpopulation,\u00a0die\u00a0die\u00a0zulassungskonforme\u00a0Dosier ung\u00a00,05\u00a0mg/kg\u00a0\nt\u00e4glich\u00a0 erhielt,\u00a0 senkte\u00a0 Teduglutid\u00a0 das\u00a0 erforderliche\u00a0 Infusionsv olumen\u00a0 um\u00a0 25\u00a0%\u00a0\nw\u00e4hrend\u00a0in\u00a0der\u00a0BSC\u2010Gruppe\u00a0keine\u00a0Ver\u00e4nderung\u00a0beobachtet\u00a0wurde.\u00a0E in\u00a0komplettes\u00a0\nAbsetzen\u00a0der\u00a0pE\u00a0wurde\u00a0nur\u00a0in\u00a0der\u00a0Interventionsgruppe\u00a0dokumentie rt.\u00a0Parameter\u00a0\nzur\u00a0Erfassung\u00a0der\u00a0HRQoL\u00a0waren\u00a0nicht\u00a0definiert.\u00a0Methodische\u00a0Limi tationen\u00a0wie\u00a0die\u00a0\nkurze\u00a0Studiendauer,\u00a0die\u00a0geringe\u00a0Fallzahl\u00a0und\u00a0die\u00a0ungleiche\u00a0Vert eilung\u00a0der\u00a0Alters\u2010\nstruktur\u00a0in\u00a0beiden\u00a0Patientengruppen\u00a0mindern\u00a0die\u00a0Validit\u00e4t\u00a0der\u00a0E rgebnisse,\u00a0sodass\u00a0\nder\u00a0G\u2010BA\u00a0den\u00a0Zusatznutzen\u00a0als\u00a0 nicht\u00a0quantifizierbar \u00a0einstufte\u00a0(G\u2010BA,\u00a02017).\u00a0\n\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 \u00a0\u00a0\u00a0\u00a0(Zusatz\u2010)Nutzen \u00a0 \u00a0\u00a0\u00a0Kosten\u00a0\n\u00a0Erster\u00a0Vertreter\u00a0der\u00a0\nWirkstoffgruppe\u00a0GLP\u2010\n2\u2010Analoga\u00a0mit\u00a0neuem\u00a0\nTherapieansatz\u00a0\n\u00a0Signifikante\u00a0\nVerbesserung\u00a0\npatientenrelevanter\u00a0\nEndpunkte,\u00a0keine\u00a0\nVerbesserung\u00a0der\u00a0\nHRQoL\u00a0belegt\u00a0\u00a0kein\u00a0Vergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\n\u00a0\n396\u00a0Kosten\u00a0\nWirkstoff \u00a0 Behandlungsmodus \u00a0 Behandlungstage \u00a0Jahrestherapiekosten \u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nTeduglutid\u00a0 1x\u00a0tgl.\u00a05\u00a0mg\u00a0s.c.\u00a0\nInjektion\u00a0365\u00a0 274.231,54\u00a0\u20ac\u00a0\nLaut\u00a0Fachinformation\u00a0betr\u00e4gt\u00a0die\u00a0empfohlene\u00a0Dosierung\u00a0einmal\u00a0t\u00e4 glich\u00a00,05\u00a0mg/kg\u00a0K\u00f6rpergewicht.\u00a0Die\u00a0Dosierung\u00a0betr\u00e4gt\u00a0bei\u00a0\neinem\u00a0durchschnittlichen\u00a0K\u00f6rpergewicht\u00a0von\u00a072\u00a0kg\u00a03,6\u00a0mg\u00a0t\u00e4glich \u00a0\nDie\u00a0Preisverhandlungen\u00a0zwischen\u00a0GKV\u2010Spitzenverband\u00a0und\u00a0pU\u00a0f\u00fchrt en\u00a0zur\u00a0Einf\u00fch\u2010\nrung\u00a0eines\u00a0Erstattungsbetrags\u00a0zum\u00a015.\u00a0September\u00a02015\u00a0(GKV\u2010SV,\u00a02 015).\u00a0Zusam\u2010\nmen\u00a0mit\u00a0dem\u00a0Pflichtrabatt\u00a0des\u00a0pU\u00a0ergibt\u00a0sich\u00a0beispielhaft\u00a0f\u00fcr\u00a0d ie\u00a0Packungseinheit\u00a0\nN2\u00a0(25x\u00a05\u00a0mg)\u00a0eine\u00a0Preisreduktion\u00a0von\u00a030\u00a0%\u00a0vom\u00a0urspr\u00fcnglichen\u00a0V erkaufspreis\u00a0\n(Lauer\u2010Fischer,\u00a02017).\u00a0Die\u00a0t\u00e4glichen\u00a0Therapiekosten\u00a0betragen\u00a0f\u00fc r\u00a0Dosierungen\u00a0bis\u00a0\nzu\u00a05\u00a0mg\u00a0Teduglutid\u00a0751,40\u00a0Euro.\u00a0 Der\u00a0Berechnung\u00a0liegen\u00a0hier\u00a0kein e\u00a0Teilpackungen\u00a0\nzugrunde,\u00a0da\u00a0nach\u00a0Rekonstitution\u00a0der\u00a0Gesamtpulvermenge\u00a0das\u00a0ben\u00f6 tigte\u00a0Volumen\u00a0\nentnommen\u00a0 und\u00a0 die\u00a0 restliche\u00a0 L\u00f6sung\u00a0 aus\u00a0 Gr\u00fcnden\u00a0 der\u00a0 mangelnden\u00a0 S tabilit\u00e4t\u00a0\nverworfen\u00a0wird.\u00a0F\u00fcr\u00a0die\u00a0GKV\u00a0entstehen\u00a0ohne\u00a0Teduglutid\u00a0t\u00e4glich\u00a0K osten\u00a0durch\u00a0die\u00a0\npE\u00a0zwischen\u00a0100\u00a0und\u00a0500\u00a0Euro\u00a0(KVN,\u00a02008).\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung \u00a0 AMB\u00a0Prescrire\u00a0 PZ\u00a0\nA\u00a0 Umstrittenes\u00a0Therapieprinzip\u00a0 \u2013\u00a0Possibly\u00a0\nhelpful\u00a0Sprunginnovation\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0wurden\u00a0keine\u00a0Versorgu ngsanalysen\u00a0\nvon\u00a0Teduglutid\u00a0erstellt.\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nMit\u00a0Teduglutid\u00a0(Revestive\u00ae)\u00a0steht\u00a0seit\u00a02014\u00a0die\u00a0erste\u00a0medikamen t\u00f6se\u00a0Therapieop\u2010\ntion\u00a0f\u00fcr\u00a0Patientien\u00a0mit\u00a0KDS\u00a0zur\u00a0Verf\u00fcgung.\u00a0Strukturell\u00a0handelt\u00a0 es\u00a0sich\u00a0um\u00a0ein\u00a0Ana\u2010\nlogon\u00a0des\u00a0Polypeptids\u00a0GLP\u20102,\u00a0das \u00a0vorwiegend\u00a0von\u00a0L\u2010Zellen\u00a0des\u00a0te rminalen\u00a0Ileums\u00a0\nund\u00a0Colons\u00a0gebildet\u00a0wird.\u00a0Wie\u00a0GLP\u20101\u00a0wird\u00a0das\u00a0Molek\u00fcl\u00a0nur\u00a0wenige \u00a0Minuten\u00a0nach\u00a0\nNahrungsaufnahme\u00a0freigesetzt\u00a0und\u00a0rasch\u00a0durch\u00a0Dipeptidylpeptidas en\u00a0Typ\u00a04\u00a0(DPP\u2010\n4)\u00a0inaktiviert\u00a0(Plasmahalbwertzeit\u00a07\u00a0Minuten).\u00a0Physiologisch\u00a0st eigert\u00a0GLP\u20102\u00a0den\u00a0\nintestinalen\u00a0und\u00a0portalen\u00a0Blutfl uss,\u00a0beeinflusst\u00a0das\u00a0Wachstum\u00a0d er\u00a0Darmmucosa\u00a0\nund\u00a0f\u00f6rdert\u00a0die\u00a0Aufnahmef\u00e4higkeit\u00a0der\u00a0Nahrungsbestandteile\u00a0in\u00a0d ie\u00a0Blutbahn\u00a0(Tee\u00a0\net\u00a0al.,\u00a02011;\u00a0Drucker\u00a0&\u00a0Yusta\u00a02014).\u00a0Das\u00a0rekombinant\u00a0hergestell te\u00a0Teduglutid\u00a0setzt\u00a0\nsich\u00a0wie\u00a0sein\u00a0physiologisches\u00a0Vorbild\u00a0aus\u00a033\u00a0Aminos\u00e4uren\u00a0zusamm en.\u00a0Um\u00a0die\u00a0397\u00a0Stabilit\u00e4t\u00a0gegen\u00fcber\u00a0den\u00a0abbauenden\u00a0DPP\u20104\u2010Enzymen\u00a0zu\u00a0erh\u00f6hen,\u00a0w urde\u00a0an\u00a0zwei\u2010\nter\u00a0Position\u00a0der\u00a0Aminos\u00e4uresequenz\u00a0Alanin\u00a0durch\u00a0Glycin\u00a0ausgetau scht\u00a0und\u00a0so\u00a0eine\u00a0\nverl\u00e4ngerte\u00a0Halbwertszeit\u00a0von\u00a02\u00a0bis\u00a0drei\u00a0Stunden\u00a0generiert\u00a0(Tee \u00a0et\u00a0al.,\u00a02011).\u00a0Im\u00a0\nRahmen\u00a0der\u00a0Therapie\u00a0mit\u00a0dem\u00a0GLP\u2010 2\u2010Analogon\u00a0sollen\u00a0das\u00a0normale\u00a0W achstum\u00a0der\u00a0\nDarmschleimhaut\u00a0und\u00a0damit\u00a0einhe rgehend\u00a0Darmzottenh\u00f6he\u00a0und\u00a0Darmk ryptentie\u2010\nfe\u00a0g\u00fcnstig\u00a0beeinflusst\u00a0werden,\u00a0sodass\u00a0die\u00a0intestinale\u00a0Resorptio n\u00a0von\u00a0K\u00f6rperfl\u00fcssig\u2010\nkeiten\u00a0und\u00a0N\u00e4hrstoffen\u00a0zunimmt.\u00a0(EMA,\u00a02012b).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nObwohl\u00a0die\u00a0EC\u00a0bereits\u00a02012\u00a0die\u00a0Zulassung\u00a0f\u00fcr\u00a0Teduglutid\u00a0erteilt e,\u00a0ist\u00a0das\u00a0Pr\u00e4parat\u00a0\nerst\u00a0seit\u00a0September\u00a02014\u00a0in\u00a0Deutschland\u00a0verf\u00fcgbar.\u00a0Das\u00a0best\u00e4tig te\u00a0Indikationsge\u2010\nbiet\u00a0sah\u00a0zun\u00e4chst\u00a0die\u00a0Anwendung\u00a0bei\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0K DS\u00a0vor.\u00a0Dabei\u00a0\nsollte\u00a0erst\u00a0nach\u00a0einer\u00a0dem\u00a0chirurgischen\u00a0Eingriff\u00a0folgenden\u00a0int estinalen\u00a0Adaptions\u2010\nphase\u00a0bei\u00a0stabilem\u00a0Zustand\u00a0des\u00a0Patienten\u00a0die\u00a0Therapie\u00a0begonnen\u00a0 werden.\u00a0Mit\u00a0\nZulassungserweiterung\u00a02016\u00a0ist\u00a0auch\u00a0der\u00a0Einsatz\u00a0bei\u00a0Kindern\u00a0und \u00a0Jugendlichen\u00a0ab\u00a0\neinem\u00a0Jahr\u00a0vorgesehen.\u00a0Die\u00a0Dosie rung\u00a0erfolgt\u00a0in\u00a0allen\u00a0Altersgru ppen\u00a0in\u00a0Abh\u00e4ngig\u2010\nkeit\u00a0vom\u00a0KG\u00a00,05mg/kg\u00a0und\u00a0wird\u00a0einmal\u00a0t\u00e4glich\u00a0subcutan\u00a0injizier t.\u00a0Dabei\u00a0ist\u00a0zu\u00a0\nbeachten,\u00a0dass\u00a0bei\u00a0jeder\u00a0Applikation\u00a0ein\u00a0anderer\u00a0der\u00a0vier\u00a0Quadr anten\u00a0des\u00a0Abdo\u2010\nmens\u00a0ausgew\u00e4hlt\u00a0werden\u00a0sollte.\u00a0Alternativ\u00a0kann\u00a0auch\u00a0eine\u00a0Injekt ion\u00a0in\u00a0den\u00a0Ober\u2010\nschenkel\u00a0erfolgen.\u00a0Bei\u00a0Vorliegen\u00a0 m\u00e4\u00dfiger\u00a0bis\u00a0schwerer\u00a0Nierenfun ktionsst\u00f6rungen\u00a0\n(Creatinin\u2010Clearance\u00a0<50\u00a0ml/min)\u00a0sowie\u00a0terminaler\u00a0Niereninsuffi zienz\u00a0sollte\u00a0die\u00a0\nt\u00e4gliche\u00a0Dosis\u00a0um\u00a050\u00a0%\u00a0reduziert\u00a0w erden.\u00a0F\u00fcr\u00a0den\u00a0Einsatz\u00a0bei\u00a0sc hwerer\u00a0St\u00f6rung\u00a0der\u00a0\nLeberfunktion\u00a0liegen\u00a0keine\u00a0Daten\u00a0vor\u00a0(EMA,\u00a02012b).\u00a0Bereits\u00a0am\u00a01 1.\u00a0Dezember\u00a0\n2001\u00a0best\u00e4tigte\u00a0die\u00a0EC\u00a0die\u00a0Einstufung\u00a0der\u00a0Substanz\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0(EMA,\u00a0\n2009a).\u00a0\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nGem\u00e4\u00df\u00a0der\u00a0aktuell\u00a0g\u00fcltigen\u00a0 S3\u00a0Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellsch aft\u00a0f\u00fcr\u00a0 Ern\u00e4h\u2010\nrungsmedizin\u00a0zur\u00a0Klinischen\u00a0Ern\u00e4 hrung\u00a0in\u00a0der\u00a0Gastroenterologie\u00a0 \u2013\u00a0Chronisches\u00a0\nDarmversagen\u00a0wird\u00a0das\u00a0KDS\u00a0wie\u00a0fo lgt\u00a0definiert:\u00a0\u201eDer\u00a0Begriff\u00a0[\u2026] \u00a0bezeichnet\u00a0ein\u00a0\nDarmversagen\u00a0nach\u00a0ausgedehnter\u00a0R esektion\u00a0mit\u00a0der\u00a0Unf\u00e4higkeit,\u00a0w egen\u00a0einer\u00a0\neingeschr\u00e4nkten\u00a0resorptiven\u00a0Kapa zit\u00e4t\u00a0des\u00a0Darms\u00a0(Obstruktion,\u00a0D ysmotilit\u00e4t,\u00a0kon\u2010\ngenitale\u00a0Erkrankung,\u00a0krankheitsassoziierte\u00a0verminderte\u00a0Absorpti on),\u00a0die\u00a0Protein\u2010,\u00a0\nEnergie\u2010,\u00a0 Fl\u00fcssigkeits\u2010\u00a0 und\u00a0 Mikr on\u00e4hrstoffbilanz\u00a0 mit\u00a0 einer\u00a0 konv entionellen\u00a0 Di\u00e4t\u00a0\naufrechtzuerhalten.\u201c\u00a0Dabei\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0neue\u00a0Definit ion,\u00a0die\u00a0nicht\u00a0\nmehr\u00a0den\u00a0Bezug\u00a0zur\u00a0verbliebenen\u00a0D\u00fcnndarml\u00e4nge\u00a0(100\u00a0bis\u00a0150\u00a0cm)\u00a0 herstellt.\u00a0Art\u00a0\nund\u00a0Umfang\u00a0der\u00a0Supplementation\u00a0variieren\u00a0je\u00a0nach\u00a0Zustand\u00a0und\u00a0an atomischen\u00a0\nGegebenheiten.\u00a0Die\u00a0Wahrscheinlichk eit\u00a0der\u00a0Notwendigkeit\u00a0der\u00a0pE\u00a0 korreliert\u00a0mit\u00a0\nder\u00a0L\u00e4nge\u00a0des\u00a0verbliebenen\u00a0Darms\u00a0 sowie\u00a0dem\u00a0Vorhandensein\u00a0eines\u00a0 kontinuierli\u2010\nchen\u00a0Colons\u00a0(Messing\u00a0et\u00a0al.,\u00a01999).\u00a0Sind\u00a0gr\u00f6\u00dfere\u00a0Darmabschnitte \u00a0vorhanden,\u00a0ist\u00a0398\u00a0auch\u00a0das\u00a0Ausschleichen\u00a0der\u00a0pE\u00a0\u00fcbe r\u00a0einen\u00a0l\u00e4ngeren\u00a0Zeitraum\u00a0m\u00f6gl ich\u00a0(Wilmore\u00a0et\u00a0\nal.,\u00a01997).\u00a0So\u00a0zeigte\u00a0eine\u00a0prosp ektive\u00a0Studie,\u00a0dass\u00a055\u00a0%\u00a0der\u00a012 4\u00a0beobachteten\u00a0\nPatienten\u00a0mit\u00a0KDS\u00a0nach\u00a0f\u00fcnf\u00a0Jahren\u00a0nicht\u00a0mehr\u00a0auf\u00a0eine\u00a0pE\u00a0angew iesen\u00a0waren\u00a0\n(Messing\u00a0et\u00a0al.,\u00a01997).\u00a0Die\u00a0Notwendigkeit\u00a0einer\u00a0Darmresektion\u00a0k ann\u00a0durch\u00a0ange\u2010\nborene\u00a0Anomalien\u00a0bedingt\u00a0oder\u00a0in\u00a0der\u00a0Folge\u00a0vaskul\u00e4rer\u00a0Sch\u00e4digun gen,\u00a0entz\u00fcndli\u2010\ncher\u00a0Prozesse\u00a0bzw.\u00a0Traumata\u00a0oder\u00a0von\u00a0Tumorerkrankungen\u00a0erworben \u00a0sein\u00a0(Buch\u2010\nmann\u00a0et\u00a0al.,\u00a02006).\u00a0Nach\u00a0dem\u00a0Eingriff\u00a0durchl\u00e4uft\u00a0der\u00a0verblieben e\u00a0Darm\u00a0einen\u00a0An\u2010\npassungsprozess\u00a0an\u00a0die\u00a0neuen\u00a0Ge gebenheiten,\u00a0der\u00a0in\u00a0drei\u00a0Abschni tte\u00a0gegliedert\u00a0\nwird.\u00a0Die\u00a0sich\u00a0unmittelbar\u00a0anschlie\u00dfende\u00a0Hypersekretionsphase,\u00a0 die\u00a0bis\u00a0zu\u00a0einem\u00a0\nMonat\u00a0andauert,\u00a0ist\u00a0durch\u00a0einen\u00a0hohen\u00a0Elektrolyt\u2010\u00a0und\u00a0Fl\u00fcssigke itsverlust\u00a0(bis\u00a0zu\u00a0\n10\u00a0l\u00a0tgl.)\u00a0und\u00a0hohes\u00a0Stuhlvolume n\u00a0(>2,5\u00a0l\u00a0tgl.)\u00a0gekennzeichnet. \u00a0Innerhalb\u00a0einer\u00a0\nZeitspanne\u00a0von\u00a048\u00a0Stunden\u00a0bis\u00a0zu\u00a0zwei\u00a0Jahren\u00a0findet\u00a0die\u00a0Adaptio nsphase\u00a0statt,\u00a0die\u00a0\ninsbesondere\u00a0innerhalb\u00a0der\u00a0ersten\u00a0sechs\u00a0Monate\u00a0zu\u00a0verbesserten\u00a0 Resorptionsra\u2010\nten\u00a0f\u00fchrt.\u00a0Ist\u00a0die\u00a0maximale\u00a0Anpassung\u00a0erreicht,\u00a0spricht\u00a0man\u00a0von \u00a0der\u00a0Stabilisie\u2010\nrungs\u2010\u00a0oder\u00a0Erhaltungsphase.\u00a0Mit\u00a0 der\u00a0langfristigen\u00a0Versorgung\u00a0d er\u00a0Patienten\u00a0mit\u00a0\npE\u00a0geht\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0Komplikationen\u00a0wie\u00a0Katheter\u2010Inf ektionen,\u00a0Gef\u00e4\u00df\u2010\u00a0\nund\u00a0 Lebererkrankungen\u00a0 sowie\u00a0 Galle nfunktionsst\u00f6rungen\u00a0 einher\u00a0 (Pi roni\u00a0 et\u00a0 al.,\u00a0\n2011).\u00a0Dar\u00fcber\u00a0hinaus\u00a0wirkt\u00a0sich\u00a0die\u00a0Erkrankung\u00a0massiv\u00a0auf\u00a0die\u00a0 Lebensqualit\u00e4t\u00a0der\u00a0\nBetroffenen\u00a0aus.\u00a0Neben\u00a0krankheitsspezifischen\u00a0Symptomen\u00a0wie\u00a0Bau chschmerzen\u00a0\nund\u00a0\u00dcbelkeit\u00a0stellt\u00a0die\u00a0Integration\u00a0der\u00a0\u201ek\u00fcnstlichen\u00a0Ern\u00e4hrung\u201c \u00a0in\u00a0den\u00a0Alltag\u00a0eine\u00a0\nHerausforderung\u00a0dar.\u00a0In\u00a0der\u00a0Folg e\u00a0ergeben\u00a0sich\u00a0h\u00e4ufig\u00a0starke\u00a0ps ychische\u00a0Belastun\u2010\ngen\u00a0(Winkler\u00a0et.\u00a0al,\u00a02010).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0multizentrische,\u00a0doppelblinde ,\u00a0(1:2:2)\u00a0randomisierte\u00a0Phase\u00a0 III\u00a0Studie\u00a0CL0600\u2010\n004\u00a0(Jeppesen\u00a0et\u00a0al.,\u00a02011)\u00a0definierte\u00a0zwei\u00a0Interventionsgruppe n\u00a0mit\u00a0t\u00e4glich\u00a00,1\u00a0\nmg/kg\u00a0(n=33)\u00a0und\u00a00,05\u00a0mg/kg\u00a0(n=35)\u00a0sowie\u00a0einen\u00a0Placebo\u2010Arm\u00a0(n=1 6).\u00a0Prim\u00e4rer\u00a0\nEndpunkt\u00a0war\u00a0die\u00a0Ansprechrate\u00a0gegen\u00fcber\u00a0Beobachtungsbeginn\u00a0( Graded\u00a0Respon\u2010\nse\u00a0Score),\u00a0die\u00a0mittels\u00a0eines\u00a0abgestuften \u00a0Punktesystems\u00a0erfasst\u00a0wurde,\u00a0w elches\u00a0die\u00a0\nIntensit\u00e4t\u00a0(20\u00a0bis\u00a0100\u00a0%\u00a0umfassende\u00a0Reduktion\u00a0der\u00a0w\u00f6chentlich\u00a0b en\u00f6tigten\u00a0pE)\u00a0\nund\u00a0die\u00a0Dauer\u00a0der\u00a0Infusionen\u00a0in\u00a0der\u00a016.\u00a0und\u00a024.\u00a0Beobachtungswoc he\u00a0ber\u00fccksich\u2010\ntigt.\u00a0Gem\u00e4\u00df\u00a0einer\u00a0\u00c4nderung\u00a0des\u00a0P rotokolls\u00a0wurde\u00a0eine\u00a0Kategorisi erung\u00a0der\u00a0Be\u2010\nobachtungsdauer\u00a0(16\u00a0und\u00a020\u00a0sowie\u00a020\u00a0und\u00a024\u00a0Wochen)\u00a0und\u00a0eine\u00a0Gra duierung\u00a0der\u00a0\nAnsprechrate\u00a020\u00a0bis\u00a0100\u00a0%\u00a0vorgenommen.\u00a0Die\u00a0Datenauswertung\u00a0folg te\u00a0einem\u00a0\nstatistischen\u00a0Analysenplan,\u00a0der\u00a0ein\u00a0hierarchisches\u00a0Testverfahre n\u00a0vorsah.\u00a0F\u00fcr\u00a0die\u00a0\nDosis\u00a00,1\u00a0mg/kg\u00a0konnte\u00a0kein\u00a0signifikantes\u00a0Ergebnis\u00a0erzielt\u00a0werd en\u00a0(6,3\u00a0%\u00a0(Placebo)\u00a0\nvs.\u00a025\u00a0%,\u00a0p=0,161),\u00a0so\u00a0dass\u00a0der\u00a0Studie\u00a0lediglich\u00a0ein\u00a0supportive r\u00a0Charakter\u00a0zugespro\u2010\nchen\u00a0werden\u00a0kann\u00a0(EMA,\u00a02012c).\u00a0Die\u00a0Ergebnisse\u00a0der\u00a0Gruppe\u00a0mit\u00a00, 05mg/kg,\u00a0die\u00a0\nsowohl\u00a0gegen\u00fcber\u00a0Placebo\u00a0als\u00a0auch\u00a0gegen\u00fcber\u00a0der\u00a0h\u00f6heren\u00a0Dosis\u00a0s ignifikant\u00a0bes\u2010\nser\u00a0abschnitt\u00a0(45,7%,\u00a0p=0,007),\u00a0k\u00f6nnen\u00a0daher\u00a0nur\u00a0deskriptiv\u00a0zur \u00a0Ableitung\u00a0einer\u00a0399\u00a0Hypothese\u00a0dienen.\u00a0Innerhalb\u00a0des\u00a0Patientenkollektivs\u00a0konnten\u00a018\u00a0 Teilnehmer\u00a0die\u00a0\nw\u00f6chentliche\u00a0Zeit\u00a0der\u00a0pE\u00a0um\u00a0mindestens\u00a0einen\u00a0Tag\u00a0verringern.\u00a0Au fgrund\u00a0einer\u00a0\nvergleichsweise\u00a0hohen\u00a0Anzahl\u00a0i nnerhalb\u00a0der\u00a0Placebo\u2010Gruppe\u00a0konnt e\u00a0auch\u00a0hier\u00a0kein\u00a0\nsignifikanter\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0mit\u00a0Teduglutid\u00a0belegt\u00a0we rden\u00a0(Placebo,\u00a025\u00a0%\u00a0\nvs.\u00a00,05mg,\u00a031,4\u00a0%\u00a0vs.\u00a00,1\u00a0mg,\u00a09,4\u00a0%).\u00a0Ein\u00a0komplettes\u00a0Absetzen\u00a0 der\u00a0pE\u00a0wurde\u00a0nur\u00a0\nim\u00a0Interventionsarm\u00a0mit\u00a00,05\u00a0mg\u00a0(n=3)\u00a0erreicht.\u00a0Der\u00a0Rekrutierun gsalgorhythmus\u00a0\nschloss\u00a0Patienten\u00a0ein,\u00a0die\u00a0berei ts\u00a0mindestens\u00a0zw\u00f6lf\u00a0Monate\u00a0eine \u00a0pE\u00a0erhielten.\u00a0Im\u00a0\nHinblick\u00a0auf\u00a0den\u00a0zeitlichen\u00a0Umfang \u00a0der\u00a0Adaptionsphase,\u00a0der\u00a0bis\u00a0 zu\u00a0zwei\u00a0Jahre\u00a0\nbetr\u00e4gt,\u00a0und\u00a0dem\u00a0Ergebnis\u00a0der\u00a0Placebo\u2010Gruppe\u00a0ist\u00a0ein\u00a0m\u00f6glicher\u00a0 positiver\u00a0Einfluss\u00a0\nauf\u00a0die\u00a0Ansprechrate\u00a0vorstellbar.\u00a0Bez\u00fcglich\u00a0der\u00a0gesundheitsbezo genen\u00a0Lebensqua\u2010\nlit\u00e4t\u00a0(Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL),\u00a0die\u00a0mittels\u00a0der\u00a0Frageb\u00f6gen\u00a0 Short\u00a0Form\u00a0\n36\u00a0(SF36),\u00a0EuroQol\u00a0Five\u00a0Dimensions\u00a0Questionnaire \u00a0(EQ5D)\u00a0und\u00a0 Inflammatory\u00a0Bowel\u00a0\nDisease\u00a0Questionnaire \u00a0(IBDQ)\u00a0erfasst\u00a0wurde,\u00a0konnten\u00a0keine\u00a0signifikanten\u00a0Unter\u2010\nschiede\u00a0zwischen\u00a0den\u00a0Behandlungsg ruppen\u00a0detektiert\u00a0werden.\u00a0Die\u00a0 Eignung\u00a0der\u00a0\nScores\u00a0ist\u00a0fraglich,\u00a0da\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0KDS\u00a0keine\u00a0klinisch\u00a0re levante\u00a0minimale\u00a0\nDifferenz\u00a0evaluiert\u00a0wurde\u00a0(EMA,\u00a02012c).\u00a0\u00a0\nInnerhalb\u00a0des\u00a0Zulassungsverfahrens\u00a0bildet\u00a0die\u00a0multizentrische,\u00a0 doppelblinde,\u00a01:1\u2010\nrandomisierte\u00a0Phase\u00a0III\u00a0Studie\u00a0CL0600\u2010020\u00a0(STEPS)\u00a0(Jeppesen\u00a0et\u00a0 al.,\u00a02005)\u00a0die\u00a0\nKernevidenz\u00a0zur\u00a0Wirksamkeit\u00a0von\u00a0Teduglutid\u00a0beim\u00a0KDS\u00a0bei\u00a0Erwachs enen.\u00a0Die\u00a086\u00a0\nPatienten\u00a0wurden\u00a0in\u00a0zwei\u00a0Behandlungsgruppen\u00a0eingeteilt\u00a0und\u00a0\u00fcber \u00a024\u00a0Wochen\u00a0mit\u00a0\n0,05mg/kg/Tag\u00a0oder\u00a0Placebo\u00a0behandelt.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die \u00a0in\u00a0Woche\u00a020\u00a0\nerzielte\u00a0und\u00a0bis\u00a0Woche\u00a024\u00a0aufrechterhaltene\u00a0Ansprechrate\u00a0gegen\u00fc ber\u00a0Beobach\u2010\ntungsbeginn,\u00a0definiert\u00a0als\u00a0mindestens\u00a020\u00a0%\u00a0umfassende\u00a0Reduktion \u00a0der\u00a0w\u00f6chent\u2010\nlich\u00a0ben\u00f6tigten\u00a0pE.\u00a0Der\u00a0Anteil\u00a0der\u00a0 Responder \u00a0betrug\u00a063\u00a0%\u00a0in\u00a0der\u00a0Teduglutid\u00a0\u2013\u00a0und\u00a0\n30\u00a0%\u00a0in\u00a0der\u00a0Placebogruppe\u00a0(p=0,002).\u00a0F\u00fcr\u00a0den\u00a0Endpunkt\u00a0der\u00a0Anzah l\u00a0der\u00a0Patienten,\u00a0\nbei\u00a0denen\u00a0nach\u00a024\u00a0Wochen\u00a0eine\u00a0Reduktion\u00a0der\u00a0pE\u00a0um\u00a0mindestens\u00a0ei nen\u00a0Tag\u00a0pro\u00a0\nWoche\u00a0erzielt\u00a0werden\u00a0konnte,\u00a0fa nden\u00a0sich\u00a0im\u00a0Interventionsarm\u00a048 ,8\u00a0%\u00a0vs.\u00a020,9\u00a0%\u00a0\nin\u00a0der\u00a0Placebogruppe.\u00a0F\u00fcr\u00a0die\u00a0mit\u00a0 Hilfe\u00a0eines\u00a0KDS\u2010spezifischen\u00a0 Fragebogens\u00a0(SDS\u2010\nQoL)\u00a0gemessene\u00a0HRQoL\u00a0ergaben\u00a0sich\u00a0keine\u00a0signifikanten\u00a0Unterschi ede,\u00a0sodass\u00a0in\u00a0\nder\u00a0Gesamtschau\u00a0der\u00a0verf\u00fcgbaren\u00a0 Untersuchungen\u00a0kein\u00a0Beleg\u00a0f\u00fcr\u00a0e inen\u00a0positiven\u00a0\nEffekt\u00a0von\u00a0Teduglutid\u00a0f\u00fcr\u00a0diesen\u00a0Endpunkt\u00a0vorliegt.\u00a0Dar\u00fcber\u00a0hin aus\u00a0zeigen\u00a0sich\u00a0\nmethodisch\u00a0begr\u00fcndete\u00a0Limitationen,\u00a0die\u00a0auf\u00a0die\u00a0Inklusionskrite rien\u00a0zur\u00fcckzuf\u00fch\u2010\nren\u00a0sind.\u00a0Das\u00a0Studienprotokoll\u00a0legitimierte\u00a0eine\u00a0hohe\u00a0Spannweit e\u00a0f\u00fcr\u00a0den\u00a0Bedarf\u00a0\nan\u00a0pE\u00a0zu\u00a0Beobachtungsbeginn,\u00a0der\u00a0zwischen\u00a03,6\u00a0und\u00a034\u00a0l/Woche\u00a0la g.\u00a0Auch\u00a0die\u00a0\nklinische\u00a0Ausgangssituation\u00a0der\u00a0Teilnehmer,\u00a0ein\u00a0wichtiger\u00a0progn ostischer\u00a0Faktor,\u00a0\nvariierte\u00a0bez\u00fcglich\u00a0der\u00a0L\u00e4nge\u00a0de s\u00a0verbliebenen\u00a0Darms\u00a0oder\u00a0des\u00a0V orhandenseins\u00a0\nvon\u00a0 Colon\u2010Abschnitten.\u00a0 Die\u00a0 Empfehlung\u00a0 des\u00a0 CHMP\u00a0 sah\u00a0 eine\u00a0 \u00dcberpr\u00fc fung\u00a0 des\u00a0\nTherapieerfolges\u00a0 nach\u00a0 sechsmonat i g e r \u00a0B e h a n d l u n g \u00a0s o w i e \u00a0d i e \u00a0B e e n d igung\u00a0 bei\u00a0\nAusbleiben\u00a0vor.\u00a0Diese\u00a0Entscheidung\u00a0orientierte\u00a0sich\u00a0nicht\u00a0zulet zt\u00a0an\u00a0den\u00a0kurzen\u00a0\nBeobachtungsspannen\u00a0der\u00a0vom\u00a0pU\u00a0vor gelegten\u00a0Studien.\u00a0Aus\u00a0den\u00a0gep oolten\u00a0Daten\u00a0400\u00a0von\u00a0STEPS\u00a0und\u00a0dessen\u00a0zweij\u00e4hriger\u00a0unverblindeter\u00a0Verl\u00e4ngerungss tudie\u00a0CL0600\u2010\n021\u00a0(STEPS\u20102)\u00a0(Schwartz\u00a0et\u00a0al.,\u00a02016)\u00a0ging\u00a0eine\u00a0weitere\u00a0Verbess erung\u00a0der\u00a0An\u2010\nsprechrate\u00a0hervor,\u00a0die\u00a092\u00a0%\u00a0im\u00a0Interventionsarm\u00a0und\u00a050\u00a0%\u00a0innerh alb\u00a0der\u00a0Placebo\u2010\nGruppe\u00a0erreichte.\u00a0\u00a0\nInsgesamt\u00a0gestaltet\u00a0sich\u00a0die\u00a0Dat enlage\u00a0heterogen.\u00a0So\u00a0konnte\u00a0nur \u00a0die\u00a0STEPS\u2010\u00a0Studie\u00a0\ndie\u00a0\u00dcberlegenheit\u00a0der\u00a0Substanz\u00a0g egen\u00fcber\u00a0Placebo\u00a0bez\u00fcglich\u00a0der\u00a0 Reduktion\u00a0des\u00a0\nben\u00f6tigten\u00a0Volumens\u00a0an\u00a0pE\u00a0belegen,\u00a0jedoch\u00a0ohne\u00a0Einfluss\u00a0auf\u00a0die \u00a0Lebensqualit\u00e4t.\u00a0\nDer\u00a0CHMP\u00a0konsultierte\u00a0daher\u00a0eine\u00a0gesondert\u00a0einberufene\u00a0Experten gruppe,\u00a0um\u00a0\neine\u00a0Einsch\u00e4tzung\u00a0zur\u00a0klinisch en\u00a0Relevanz\u00a0der\u00a0Studienergebnisse \u00a0zu\u00a0erhalten.\u00a0Diese\u00a0\nsprach\u00a0insbesondere\u00a0der\u00a0Studie\u00a0CL0600\u2010020\u00a0einen\u00a0hohen\u00a0Stellenwe rt\u00a0zu.\u00a0Es\u00a0w\u00fcr\u2010\nden\u00a0 Patienten\u00a0 profitieren,\u00a0 deren\u00a0 Ausgangssituation\u00a0 durch\u00a0 die\u00a0 Ve rsorgung\u00a0 mit\u00a0\ngeringen\u00a0pE\u2010Volumina\u00a0charakterisiert\u00a0ist,\u00a0da\u00a0die\u00a0Spanne\u00a0bis\u00a0zum \u00a0Absetzen\u00a0der\u00a0\nTherapie\u00a0weniger\u00a0ausgepr\u00e4gt\u00a0sei.\u00a0F\u00fcr\u00a0Betroffene\u00a0mit\u00a0h\u00f6herem\u00a0Ver sorgungsauf\u2010\nwand\u00a0bestehe\u00a0der\u00a0Vorteil\u00a0in\u00a0der\u00a0R eduktion\u00a0der\u00a0pE\u00a0(EMA,\u00a02012c).\u00a0\nDie\u00a0unter\u00a0Therapie\u00a0mit\u00a0Teduglutid\u00a0und\u00a0Placebo\u00a0am\u00a0h\u00e4ufigsten\u00a0beo bachteten\u00a0 Unfa\u2010\nvourable\u00a0Adverse\u00a0Events \u00a0(UAE)\u00a0betreffen\u00a0erwartungsgem\u00e4\u00df\u00a0den\u00a0Verdauungstrakt\u00a0\nund\u00a0\u00e4u\u00dferten\u00a0sich\u00a0in\u00a0Bauchschmerzen,\u00a0\u00dcbelkeit,\u00a0Erbrechen,\u00a0Bl\u00e4hu ngen\u00a0und\u00a0Obsti\u2010\npation.\u00a0In\u00a0den\u00a0Interventionsgruppen\u00a0wurden\u00a0die\u00a0Leber\u00a0und\u00a0die\u00a0Ba uchspeicheldr\u00fcse\u00a0\nbetreffende\u00a0AE\u00a0sowie\u00a0drei\u00a0Krebsf\u00e4 lle\u00a0dokumentiert.\u00a0Die\u00a0Analyse\u00a0 der\u00a0kombinierten\u00a0\nDaten\u00a0aus\u00a0CL0600\u2010004\u00a0und\u00a0CL0600\u20100 20\u00a0zeigte\u00a0eine\u00a0moderate\u00a0Erh\u00f6hu ng\u00a0des\u00a0CRP,\u00a0\ndas\u00a0zum\u00a0Beobachtungsende\u00a0im\u00a0Mitte l\u00a0um\u00a01,43\u00a0mg/l\u00a0im\u00a0Vergleich\u00a0zu r\u00a0Ausgangssi\u2010\ntuation\u00a0anstieg.\u00a0Der\u00a0Surrogatpar ameter\u00a0gilt\u00a0als\u00a0Pr\u00e4diktor\u00a0f\u00fcr\u00a0d ie\u00a0Beurteilung\u00a0des\u00a0\nkardiovaskul\u00e4ren\u00a0Risikos.\u00a0Weiter hin\u00a0wurde,\u00a0insbesondere\u00a0in\u00a0der\u00a0 weiterf\u00fchrenden\u00a0\nStudie\u00a0 CL0600\u2010021,\u00a0 die\u00a0 Bildung\u00a0 von\u00a0 Antik\u00f6rpern\u00a0 gegen\u00a0 Teduglutid \u00a0( A n t i \u2010 D r u g \u2010\nAntibodies,\u00a0ADA)\u00a0beobachtet.\u00a0Die \u00a0Inzidenz\u00a0stieg\u00a0mit\u00a0der\u00a0Behandl ungsdauer\u00a0auf\u00a0\n18\u00a0%\u00a0nach\u00a0sechs,\u00a027\u00a0%\u00a0nach\u00a0zw\u00f6lf\u00a0und\u00a038\u00a0%\u00a0nach\u00a018\u00a0Monaten\u00a0an.\u00a0D ie\u00a0Bedeutung\u00a0\ndes\u00a0immunogenen\u00a0Potentials\u00a0f\u00fcr\u00a0d ie\u00a0Therapie\u00a0mit\u00a0dem\u00a0GLP\u20102\u2010Analo gon\u00a0ist\u00a0bisher\u00a0\nnicht\u00a0gekl\u00e4rt.\u00a0Zwar\u00a0zeigten\u00a0Studien\u00a0keinen\u00a0negativen\u00a0Einfluss,\u00a0 jedoch\u00a0spiegeln\u00a0die\u00a0\nUntersuchungszeitr\u00e4ume\u00a0in\u00a0der\u00a0Gesamtschau\u00a0nicht\u00a0die\u00a0Gegebenheit en\u00a0einer\u00a0Lang\u2010\nzeittherapie\u00a0wieder.\u00a0\nDie\u00a0im\u00a0Rahmen\u00a0des\u00a0Bewertungsverfa hrens\u00a0konsultierte\u00a0Expertengru ppe\u00a0stufte\u00a0die\u00a0\nRisiken\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0im\u00a0Rahmen\u00a0der\u00a0Auflagen\u00a0an\u00a0den\u00a0pU\u00a0ge forderte\u00a0Initiali\u2010\nsierung\u00a0eines\u00a0internationalen\u00a0Registers\u00a0(EUPAS7973)\u00a0als\u00a0handhab bar\u00a0ein.\u00a0Auch\u00a0die\u00a0\nVorlage\u00a0von\u00a0PSUR\u00a0ist\u00a0Bes tandteil\u00a0der\u00a0Auflagen.\u00a0\nBereits\u00a02009\u00a0hatte\u00a0die\u00a0EMA\u00a0der\u00a0Durchf\u00fchrung\u00a0eines\u00a0 Paediatric\u00a0Investigation\u00a0Plan \u00a0\nzugestimmt\u00a0(EMA,\u00a02009d).\u00a0Auf\u00a0Grundlage\u00a0der\u00a0Ergebnisse\u00a0der\u00a0prosp ektiven,\u00a0offe\u2010\nnen,\u00a0vergleichenden\u00a0Studie\u00a0TED\u2010C13\u2010003\u00a0(Carter\u00a0et\u00a0al.,\u00a02016)\u00a0st ellte\u00a0der\u00a0pU\u00a0den\u00a0\nAntrag\u00a0auf\u00a0Erweiterung\u00a0der\u00a0Zulassung\u00a0zur\u00a0Anwendung\u00a0bei\u00a0Kindern\u00a0 ab\u00a0einem\u00a0Jahr.\u00a0401\u00a0Das\u00a0Patientenkollektiv\u00a0umfasste\u00a0aus\u00a017\u00a0Behandlungszentren\u00a0in\u00a0de n\u00a0USA\u00a0und\u00a0Gro\u00df\u2010\nbritannien\u00a0rekrutierte\u00a042\u00a0Probanden\u00a0zwischen\u00a0einem\u00a0und\u00a018\u00a0Jahre n,\u00a0bei\u00a0denen\u00a0\nmindestens\u00a0zw\u00f6lf\u00a0Monate\u00a0vor\u00a0dem\u00a0Screening\u00a0ein\u00a0KDS\u00a0aufgrund\u00a0eine r\u00a0Resektion\u00a0\nvorlag\u00a0und\u00a0die\u00a0bereits\u00a0drei\u00a0Monate\u00a0stabil\u00a0auf\u00a0eine\u00a0pE\u00a0eingestel lt\u00a0waren.\u00a0Dabei\u00a0er\u2010\nhielten\u00a037\u00a0Patienten\u00a0Teduglutid\u00a0und\u00a0f\u00fcnf\u00a0die\u00a0BSC.\u00a0Eine\u00a0Randomis ierung\u00a0wurde\u00a0nicht\u00a0\ndurchgef\u00fchrt.\u00a0 Die\u00a0 Interventionsgruppe\u00a0 kategorisierte\u00a0 drei\u00a0 Kohor ten:\u00a0 0,0125\u2009mg/\u00a0\nkg/d\u00a0(n\u2009=\u20098),\u00a00,025\u2009mg/kg/d\u00a0(n\u2009=\u200914)\u00a0und\u00a00,05\u2009mg/kg/d\u00a0(n\u2009=\u200915). \u00a0Der\u00a0Beobachtungs\u2010\nzeitraum\u00a0betrug\u00a0zw\u00f6lf\u00a0Wochen\u00a0zuz \u00fcglich\u00a0einem\u00a0zweiw\u00f6chigen\u00a0Scree ning\u00a0und\u00a0einer\u00a0\nvierw\u00f6chigen\u00a0Follow\u2010up\u2010Phase.\u00a0Die\u00a0 Endpunkte\u00a0umfassten\u00a0die\u00a0Ver\u00e4n derung\u00a0der\u00a0\nben\u00f6tigten\u00a0pE\u00a0inkl.\u00a0der\u00a0Anzahl\u00a0der\u00a0Patienten,\u00a0die\u00a0ein\u00a0Absetzen\u00a0 der\u00a0Therapie\u00a0reali\u2010\nsierten.\u00a0Die\u00a0\u00c4nderung\u00a0der\u00a0erforderlichen\u00a0enteralen\u00a0Ern\u00e4hrung\u00a0(E E)\u00a0sowie\u00a0Volumen\u00a0\nund\u00a0Kalorien\u00a0der\u00a0pE\u00a0wurden\u00a0anhand\u00a0der\u00a0Verordnungsdaten\u00a0ermittel t.\u00a0Dar\u00fcber\u00a0\nhinaus\u00a0wurden\u00a0anhand\u00a0von\u00a0Patiente n\u2010Tageb\u00fcchern\u00a0die\u00a0t\u00e4gliche\u00a0Dau er\u00a0der\u00a0pE\u2010Infu\u2010\nsionen\u00a0und\u00a0der\u00a0Umfang\u00a0der\u00a0ben\u00f6tigten\u00a0EE\u00a0erfasst.\u00a0Insgesamt\u00a0redu zieren\u00a0methodi\u2010\nsche\u00a0Limitationen\u00a0die\u00a0Validit\u00e4t\u00a0der\u00a0Resultate.\u00a0Neben\u00a0der\u00a0gering en\u00a0Fallzahl\u00a0ist\u00a0die\u00a0\nAltersstruktur\u00a0 in\u00a0 beiden\u00a0 Gruppen\u00a0 ungleich\u00a0 verteilt.\u00a0 In\u00a0 der\u00a0 Inte rventionsgruppe\u00a0\nwaren\u00a0acht\u00a0von\u00a015\u00a0Patienten\u00a0\u00fcber ,\u00a0in\u00a0der\u00a0Kontrollgruppe\u00a0keiner\u00a0 unter\u00a0drei\u00a0Jahren.\u00a0\nIm\u00a0Median\u00a0betrug\u00a0die\u00a0Reduktion\u00a0des\u00a0pE\u2010Volumens\u00a0sowie\u00a0der\u00a0Kalori en\u00a0bei\u00a0BSC\u00a00\u00a0\u2013\u00a0\n1\u00a0%,\u00a0bei\u00a00,0125\u2009mg/kg/d\u00a00\u00a0\u2013\u00a06\u00a0%,\u00a0bei\u00a00,025\u2009mg/kg/d\u00a041\u00a0\u2013\u00a045\u00a0%\u00a0un d\u00a0bei\u00a00,05\u2009mg/kg/\u00a0\nd\u00a025\u00a0bis\u00a050\u00a0%.\u00a0Ein\u00a0vollst\u00e4ndiges\u00a0Absetzen\u00a0der\u00a0pE\u00a0erreichten\u00a0dre i\u00a0Patienten\u00a0der\u00a0\nInterventionsgruppe\u00a0 0,05\u2009mg/kg/d\u00a0 und\u00a0 ein\u00a0 Teilnehmer\u00a0 der\u00a0 Zielpop ulation\u00a0 mit\u00a0\n0,025\u2009mg/kg/d.\u00a0Bemerkenswert\u00a0sind\u00a0die\u00a0Wirksamkeitsunterschiede, \u00a0die\u00a0sich\u00a0in\u00a0der\u00a0\nGegen\u00fcberstellung\u00a0der\u00a0Ergebnisse\u00a0d er\u00a0Tagebucheintr\u00e4ge\u00a0und\u00a0Veror dnungsdaten\u00a0\nabzeichnen.\u00a0Der\u00a0Stellenwert\u00a0der\u00a0Reduktion\u00a0f\u00fcr\u00a0den\u00a0Patienten\u00a0kan n\u00a0aus\u00a0den\u00a0Daten\u00a0\nnicht\u00a0abgeleitet\u00a0werden,\u00a0da\u00a0keine\u00a0Parameter\u00a0zur\u00a0Erfassung\u00a0der\u00a0H RQoL\u00a0definiert\u00a0\nwaren.\u00a0Weiterhin\u00a0repr\u00e4sentiert\u00a0der\u00a0Untersuchungszeitraum\u00a0von\u00a0zw \u00f6lf\u00a0Monaten\u00a0\nnicht\u00a0die\u00a0Umst\u00e4nde\u00a0der\u00a0Langzeittherapie.\u00a0\u00a0\nLeitlinienempfehlungen\u00a0\nDie\u00a0S3\u2010Leitlinie\u00a0zur\u00a0Klinischen\u00a0Ern\u00e4hrung\u00a0in\u00a0der\u00a0Gastroenterolo gie\u00a0\u2013\u00a0Chronisches\u00a0\nDarmversagen\u00a0unter\u00a0Federf\u00fchrung\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0 Ern\u00e4hrungsme\u2010\ndizin\u00a0bildet\u00a0die\u00a0derzeitige\u00a0Evid enz\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0Kurz darmsyndroms\u00a0ab\u00a0\n(AWMF,\u00a02014). \u00a0Basis\u00a0der\u00a0Therapie\u00a0ist\u00a0die\u00a0enterale\u00a0und\u00a0parenterale\u00a0Ern\u00e4hrung.\u00a0\nWeitere\u00a0 Optionen\u00a0 bestehen\u00a0 in\u00a0 der \u00a0 Durchf\u00fchrung\u00a0 rekonstruktiver\u00a0 E ingriffe\u00a0 zur\u00a0\nVerbesserung\u00a0der\u00a0anatomischen\u00a0Situation\u00a0und\u00a0der\u00a0Darmtransplanta tion\u00a0bei\u00a0Schei\u2010\ntern\u00a0der\u00a0pE.\u00a0Pharmakotherapeutische\u00a0Ma\u00dfnahmen\u00a0dienen\u00a0der\u00a0Verbes serung\u00a0der\u00a0\nSymptomatik\u00a0und\u00a0orientieren\u00a0sich\u00a0an\u00a0patientenindividuellen\u00a0Erfo rdernissen.\u00a0Die\u00a0\nAnwendung\u00a0von\u00a0Teduglutid\u00a0wird\u00a0mit\u00a0Bezug\u00a0auf\u00a0die\u00a0Zulassungsstudi en\u00a0bei\u00a0Patien\u2010\nten\u00a0 mit\u00a0 einem\u00a0 stabilen\u00a0 infusionspflichtigen\u00a0 Darmversagen\u00a0 empfoh len,\u00a0 um\u00a0 die\u00a0\nInfusionsmenge\u00a0 zu\u00a0 verringern\u00a0 und\u00a0 damit\u00a0 infusionsfreie\u00a0 Tage\u00a0 zu\u00a0 g ewinnen.\u00a0 Im\u00a0402\u00a0Hinblick\u00a0auf\u00a0die\u00a0Nichtverf\u00fcgbarkeit\u00a0des\u00a0Pr\u00e4parates\u00a0in\u00a0Deutschla nd\u00a0zum\u00a0Zeitpunkt\u00a0\nder\u00a0Erarbeitung\u00a0der\u00a0Leitlinie\u00a0und\u00a0dem\u00a0Fehlen\u00a0von\u00a0Langzeitdaten\u00a0 postulierten\u00a0die\u00a0\nAutoren\u00a0im\u00a0Konsens\u00a0den\u00a0Empfehlungsgrad\u00a0B\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0mit\u00a0d em\u00a0GLP\u20102\u2010\nAnalogon.\u00a0Weitere\u00a0medikament\u00f6se\u00a0 Interventionen\u00a0zielen\u00a0auf\u00a0die\u00a0R eduktion\u00a0des\u00a0\nStuhlvolumens,\u00a0um\u00a0Fl\u00fcssigkeits\u2010\u00a0 und\u00a0Elektrolytverluste\u00a0zu\u00a0reduz ieren.\u00a0Daf\u00fcr\u00a0wer\u2010\nden\u00a0 intraven\u00f6s\u00a0 applizierte\u00a0 Protonenpumpenhemmer\u00a0 (Empfehlungsgra d\u00a0 C)\u00a0 und\u00a0\nsubcutan\u00a0 verabreichtes\u00a0 Somatostatin\u00a0 oder\u00a0 Somatostatinanaloga\u00a0 (E mpfehlungs\u2010\ngrad\u00a0C)\u00a0eingesetzt.\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nGem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0Absatz\u00a01\u00a0Satz\u00a010\u00a0Halbs.\u00a01\u00a0SGBV\u00a0gilt\u00a0der\u00a0Zusatznutze n\u00a0f\u00fcr\u00a0Teduglutid\u00a0\nals\u00a0belegt,\u00a0sodass\u00a0die\u00a0Bewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0auf\u00a0Grundlage\u00a0d er\u00a0zulassungsre\u2010\nlevanten\u00a0Studien\u00a0erfolgt.\u00a0Der\u00a0pU \u00a0legt\u00a0in\u00a0seinen\u00a0Dossiers\u00a0die\u00a0Da ten\u00a0der\u00a0Studien\u00a0\nCL0600\u2010020\u00a0 STEPS,\u00a0 CL0600\u2010004\u00a0 und\u00a0 de r\u00a0 offenen,\u00a0 nicht\u00a0 placebokont rollierten\u00a0\nfollow\u2010up\u2010Untersuchungen\u00a0CL0600\u2010 021\u00a0(STEPS\u20102)\u00a0und\u00a0CL0600\u2010005\u00a0vo r.\u00a0Das\u00a0Gremi\u2010\num\u00a0bezog\u00a0sich\u00a0bei\u00a0der\u00a0Beurteilung\u00a0auf\u00a0die\u00a0Ergebnisse\u00a0der\u00a0Teilpo pulation,\u00a0die\u00a0die\u00a0\nzugelassene\u00a0Dosis\u00a0von\u00a00,05\u00a0mg/kg\u00a0K\u00f6rpergewicht\u00a0erhalten\u00a0hatten. \u00a0Die\u00a0Untersu\u2010\nchung\u00a0CL0600\u2010004\u00a0zeigte\u00a0keine\u00a0signifikanten\u00a0Ergebnisse\u00a0und\u00a0wurd e\u00a0daher\u00a0nicht\u00a0\nber\u00fccksichtigt.\u00a0In\u00a0der\u00a0multizent rischen,\u00a0doppelblinden,\u00a0randomi sierten\u00a0Phase\u00a0III\u00a0\nStudie\u00a0CL0600\u2010020\u00a0(STEPS)\u00a0betrug\u00a0der\u00a0Anteil\u00a0der\u00a0 Responder \u00a063\u00a0%\u00a0in\u00a0der\u00a0Teduglu\u2010\ntid\u2010\u00a0und\u00a030\u00a0%\u00a0in\u00a0der\u00a0Placebogruppe\u00a0(p=0,002).\u00a0Die\u00a0Anzahl\u00a0der\u00a0Pa tienten,\u00a0bei\u00a0denen\u00a0\nnach\u00a024\u00a0Wochen\u00a0eine\u00a0Reduktion\u00a0der\u00a0pE\u00a0um\u00a0mindestens\u00a0einen\u00a0Tag\u00a0pr o\u00a0Woche\u00a0\nerzielt\u00a0 werden\u00a0 konnte,\u00a0 \u00fcberwog\u00a0 im\u00a0 Interventionsarm\u00a0 mit\u00a0 48,8\u00a0 %\u00a0 v s.\u00a0 Placebo\u00a0\n20,9\u00a0%\u00a0p=\u00a00,008.\u00a0Grunds\u00e4tzlich\u00a0nimmt\u00a0der\u00a0G\u2010BA\u00a0an,\u00a0dass\u00a0bereits\u00a0 mit\u00a0einer\u00a0Redukti\u2010\non\u00a0des\u00a0Volumens\u00a0der\u00a0pE\u00a0ein\u00a0Gewinn\u00a0an\u00a0Lebensqualit\u00e4t\u00a0einhergeht. \u00a0Sowohl\u00a0unter\u00a0\nTherapie\u00a0mit\u00a0Teduglutid\u00a0als\u00a0auch\u00a0unter\u00a0Placebo\u00a0traten\u00a0h\u00e4ufig\u00a0AE \u00a0auf\u00a0(UAE\u00a083\u00a0%\u00a0vs.\u00a0\n79\u00a0%,\u00a0SUAE\u00a036\u00a0%\u00a0vs.\u00a028\u00a0%).\u00a0Im\u00a0H inblick\u00a0auf\u00a0die\u00a0Ergebnisse\u00a0bez\u00fcg lich\u00a0Morbidit\u00e4t\u00a0und\u00a0\nLebensqualit\u00e4t\u00a0 unter\u00a0 Ber\u00fccksicht igung\u00a0 der\u00a0 AE\u00a0 stellte\u00a0 der\u00a0 G\u2010BA\u00a0 e inen\u00a0 geringen\u00a0\nZusatznutzen\u00a0fest\u00a0(G\u2010BA,\u00a02015).\u00a0\u00a0\nEin\u00a0weiteres\u00a0Bewertungsverfahren\u00a0wurde\u00a02016\u00a0eingeleitet,\u00a0um\u00a0das \u00a0neue\u00a0Anwen\u2010\ndungsgebiet\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0ab\u00a0einem\u00a0Jahr\u00a0zu\u00a0beurt eilen.\u00a0Der\u00a0pU\u00a0\nreichte\u00a0die\u00a0prospektive,\u00a0offene, \u00a0vergleichende\u00a0Studie\u00a0TED\u2010C13\u20100 03\u00a0(Carter\u00a0et\u00a0al.,\u00a0\n2016)\u00a0ein.\u00a0Dabei\u00a0erhielten\u00a037\u00a0Patienten\u00a0Teduglutid\u00a0und\u00a0f\u00fcnf\u00a0die \u00a0Standardtherapie\u00a0\nBSC.\u00a0Eine\u00a0Randomisierung\u00a0wurde\u00a0nicht\u00a0durchgef\u00fchrt.\u00a0Der\u00a0G\u2010BA\u00a0bez ieht\u00a0sich\u00a0in\u00a0\nseinem\u00a0Beschluss\u00a0auf\u00a0die\u00a0Teilpopulation\u00a0(n=15),\u00a0die\u00a0eine\u00a0der\u00a0Zu lassung\u00a0entspre\u2010\nchende\u00a0Dosierung\u00a0von\u00a00,05mg/kg\u00a0t\u00e4glich\u00a0erhalten\u00a0hat.\u00a0Der\u00a0Beobac htungszeitraum\u00a0\nbetrug\u00a0zw\u00f6lf\u00a0Wochen\u00a0zuz\u00fcglich\u00a0einer\u00a0zweiw\u00f6chigen\u00a0Screening\u2010\u00a0und \u00a0einer\u00a0vierw\u00f6\u2010\nchigen\u00a0Follow\u2010up\u2010Phase.\u00a0Endpunkt \u00a0der\u00a0Studie\u00a0war\u00a0die\u00a0erreichte\u00a0V olumenreduktion\u00a0\nder\u00a0pE\u00a0auf\u00a0Grundlage\u00a0der\u00a0vom\u00a0Pr\u00fcf arzt\u00a0verschriebenen\u00a0Volumina\u00a0s owie\u00a0der\u00a0von\u00a0403\u00a0Patienten\u00a0oder\u00a0Angeh\u00f6rigen\u00a0gef\u00fchr ten\u00a0Tageb\u00fccher.\u00a0Im\u00a0Median\u00a0senk te\u00a0Teduglutid\u00a0\ndas\u00a0erforderliche\u00a0Infusionsvolumen\u00a0um\u00a025\u00a0%\u00a0bzw.\u00a01,3\u00a0l,\u00a0w\u00e4hrend\u00a0 in\u00a0der\u00a0Placebo\u2010\ngruppe\u00a0keine\u00a0Ver\u00e4nderung\u00a0beobachtet\u00a0wurde.\u00a0Das\u00a0komplette\u00a0Absetz en\u00a0der\u00a0pE\u00a0\ngelang\u00a0nur\u00a0in\u00a0der\u00a0Interventionsg ruppe.\u00a0Parameter\u00a0zur\u00a0Erfassung\u00a0 der\u00a0Lebensqualit\u00e4t\u00a0\nwurden\u00a0nicht\u00a0definiert.\u00a0UAE\u00a0traten\u00a0in\u00a0beiden\u00a0Teilpopulationen\u00a0\u00e4 hnlich\u00a0h\u00e4ufig\u00a0auf,\u00a0\nwobei\u00a053\u00a0%\u00a0unter\u00a0Teduglutid\u00a0und\u00a060\u00a0%\u00a0unter\u00a0BSC \u00a0mindestens\u00a0ein\u00a0SAE\u00a0entwickel\u2010\nten.\u00a0Da\u00a0methodische\u00a0Limitationen\u00a0wie\u00a0die\u00a0kurze\u00a0Studiendauer,\u00a0di e\u00a0geringe\u00a0Fallzahl\u00a0\nund\u00a0die\u00a0ungleiche\u00a0Verteilung\u00a0der\u00a0Altersstruktur\u00a0in\u00a0beiden\u00a0Patie ntengruppen\u00a0die\u00a0\nAussagekraft\u00a0der\u00a0Untersuchung\u00a0schw\u00e4chen,\u00a0sch\u00e4tzte\u00a0der\u00a0G\u2010BA\u00a0den\u00a0 Zusatznutzen\u00a0\nauf\u00a0der\u00a0Grundlage\u00a0der\u00a0limitierten \u00a0Daten\u00a0und\u00a0heterogenen\u00a0Ergebni sse\u00a0als\u00a0nicht\u00a0\nquantifizierbar\u00a0ein\u00a0(G\u2010BA,\u00a02017).\u00a0\u00a0\nQuellen\u00a0\nat\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016).\u00a0Arzneimitteldatenbank\u00a0Bewertung\u00a0T eduglutid\u00a0Stand\u00a0der\u00a0Information:\u00a0Mai\u00a02016.\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften\u00a0 e.V.\u00a0(2014).\u00a0Klinisch e\u00a0Ern\u00e4hrung\u00a0in\u00a0der\u00a0\nGastroenterologie\u00a0(Teil\u00a03)\u00a0\u2013\u00a0Chr onisches\u00a0Darmversagen,\u00a0Register nummer\u00a0073\u00a0\u2013\u00a0026.\u00a0\nwww.awmf.org/leitlinien/detail/ll/073\u2010026.html,\u00a0letzter\u00a0Zugriff :\u00a022.06.2017.\u00a0\nBuchman\u00a0AL\u00a0(2006).\u00a0Etiology\u00a0and\u00a0initial\u00a0management\u00a0of\u00a0short\u00a0bow el\u00a0syndrome.\u00a0Gastroenterology\u00a0130(2):\u00a0S5\u2010S15.\u00a0\nCarter\u00a0BA,\u00a0Cohran\u00a0VC,\u00a0Cole\u00a0CR,\u00a0Corkins\u00a0MR,\u00a0Dimmitt\u00a0RA,\u00a0Duggan\u00a0C \u00a0et\u00a0al.\u00a0(2017).\u00a0Outcomes\u00a0from\u00a0a\u00a012\u2010Week,\u00a0Open\u2010Label,\u00a0\nMulticenter\u00a0Clinical\u00a0Trial\u00a0of\u00a0Te duglutide\u00a0in\u00a0Pediatric\u00a0Short\u00a0Bo wel\u00a0Syndrome.\u00a0J\u00a0Pediatr\u00a0181:102\u2010111.e5.\u00a0\nDrucker\u00a0DJ,\u00a0Yusta\u00a0B\u00a0(2014).\u00a0Physiology\u00a0and\u00a0Pharmacology\u00a0of\u00a0the\u00a0 Enteroendocrine\u00a0Hormone\u00a0Glucagon\u2010Like\u00a0Peptide\u20102\u00a0Annu\u00a0Rev\u00a0\nPhysiol\u00a076:\u00a0561\u2010583.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2009a).\u00a0Orphan\u00a0Designation\u00a0Ted uglutide.\u00a0(EU/3/01/077)\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/Orphan_designatio n/2009/10/WC500006275.pdf ,\u00a0letzter\u00a0\nZugriff:\u00a009.06.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2009b).\u00a0European\u00a0Medicines\u00a0Age ncy\u00a0decision\u00a0P/238/2010.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/PIP_decisi on/WC500199386.pdf ,\u00a0letzter\u00a0Zugriff:\u00a0\n13.06.2017.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2012a).\u00a0Annex\u00a0I.\u00a0Summary\u00a0of\u00a0pr oduct\u00a0characteristics.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02017.\u00a0\nwww.ema.europa.eu/docs/en_GB/docu ment_library/EPAR__Product_Inf ormation/human/002345/WC500132926.\npdf,\u00a0letzter\u00a0Zugriff:\u00a024.04.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2012b).\u00a0Revestive\u00ae\u00a0EPAR\u00a0\u2010\u00a0All\u00a0 Authorised\u00a0presentations,\u00a0Stand\u00a0der\u00a0Information:\u00a0Dezember\u00a0\n2016.\u00a0www.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010\n_All_Authorised_presentations/human/002345/WC500132927.pdf ,\u00a0letzter\u00a0Zugriff:\u00a017.04.2017.\u00a0\nFachinformation\u00a0Revestive\u00ae\u00a0\u2010\u00a0Fac hinfo\u2010Service\u00ae,\u00a0Stand\u00a0der\u00a0Infor mation:\u00a0M\u00e4rz\u00a02017.\u00a0 https://www.fachinfo.de/suche/fi/021206 ,\u00a0\nletzter\u00a0Zugriff,\u00a0letzter\u00a0Zugriff:\u00a009.06.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0404\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Teduglutid.\u00a0 https://www.g\u2010\nba.de/informationen/nutzenbewertung/133/#tab/beschluesse ,\u00a0letzter\u00a0Zugriff:\u00a017.04.2017.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Teduglutid\u00a0(neues\u00a0Anwendungsgebiet\u00a0\u2010\u00a0\nf\u00fcr\u00a0Patienten\u00a0ab\u00a0dem\u00a0Alter\u00a0von\u00a01\u00a0Jahr).\u00a0 https://www.g\u2010\nba.de/informationen/nutzenbewertung/133/#tab/beschluesse ,\u00a0letzter\u00a0Zugriff:\u00a017.01.2017.\u00a0\nGKV\u2010SV\u00a0\u2013\u00a0Gesetzliche\u00a0Krankenversicherung\u00a0\u2010\u00a0Spitzenverband\u00a0(2015 ).\u00a0Erstattungsbetragsverhandlungen\u00a0nach\u00a0\u00a7\u00a0130b\u00a0SGB\u00a0V.\u00a0Details\u00a0\nzum\u00a0Wirkstoff\u00a0Teduglutid.\u00a0Stand\u00a0der\u00a0Information:\u00a0September\u00a02015 .\u00a0\u00a0https://www.gkv\u2010spitzenverband.de/kranken\u00a0\nversicherung/ arzneimittel/verhandlungen_nach_amnog/ebv_130b/wirkstoff_298180 .jsp,\u00a0letzter\u00a0Zugriff:\u00a0\n25.04.2017.\u00a0\nJeppesen\u00a0PB,\u00a0Gilroy\u00a0R,\u00a0Pertkiewicz\u00a0M,\u00a0Allard\u00a0JP,\u00a0Messing\u00a0B,\u00a0O'K eefe\u00a0SJ\u00a0(2011).\u00a0Randomised\u00a0placebo\u2010controlled\u00a0trial\u00a0of\u00a0teduglut ide\u00a0in\u00a0\nreducing\u00a0parenteral\u00a0nutrition\u00a0and/or\u00a0intravenous\u00a0fluid\u00a0requirem ents\u00a0in\u00a0patients\u00a0with\u00a0short\u00a0bowel\u00a0syndrome.\u00a0Gut\u00a0\n60(7):902\u2010914.\u00a0\nJeppesen\u00a0PB,\u00a0Sanguinetti\u00a0EL,\u00a0Buchman\u00a0A,\u00a0Howard\u00a0L,\u00a0Scolapio\u00a0J\u00a0S, \u00a0Ziegler\u00a0TR\u00a0et\u00a0al.\u00a0(2005).\u00a0Teduglutide\u00a0(ALX\u20100600),\u00a0a\u00a0dipeptidyl \u00a0\npeptidase\u00a0IV\u00a0resistant\u00a0glucagon\u2010like\u00a0peptide\u00a02\u00a0analogue,\u00a0improv es\u00a0intestinal\u00a0function\u00a0in\u00a0short\u00a0bowel\u00a0syndrome\u00a0\npatients.\u00a0Gut\u00a054(9):\u00a01224\u20101231.\u00a0\nKVN\u00a0\u2013\u00a0Kassen\u00e4rztliche\u00a0Vereinigung\u00a0Nordrhein\u00a0(2008).\u00a0Parenterale \u00a0Ern\u00e4hrung\u00a0\u2013\u00a0was\u00a0tun?,\u00a0Stand\u00a0der\u00a0Information\u00a0August\u00a02008,\u00a0\nhttps://www.kvno.de/10praxis/40verordnungen/10arzneimittel/a_z/ parenteral/index.html ,\u00a0letzter\u00a0Zugriff:\u00a0\n05.05.2017.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0WebApo.\u00a0Teduglutid.\u00a0Revestive\u00ae.\u00a0Preise\u00a0un d\u00a0Packungsgr\u00f6\u00dfen,\u00a0letzter\u00a0Zugriff:\u00a002.06.2017.\u00a0\nMessing\u00a0B,\u00a0Crenn\u00a0P,\u00a0Beau\u00a0P,\u00a0Boutron\u2010Ruault\u00a0MC,\u00a0Rambaud\u00a0JC,\u00a0\u00a0Mat uchansky\u00a0C\u00a0(1999).\u00a0Long\u2010term\u00a0survival\u00a0and\u00a0parenteral\u00a0nutrition\u00a0\ndependence\u00a0in\u00a0adult\u00a0patients\u00a0with\u00a0the\u00a0short\u00a0bowel\u00a0syndrome.\u00a0Gas troenterology\u00a0117(5):\u00a01043\u201350.\u00a0  \nPironi\u00a0L,\u00a0Joly\u00a0F,\u00a0Forbes\u00a0A,\u00a0Colo mb\u00a0V,\u00a0Lyszkowska\u00a0M,\u00a0Baxter\u00a0J\u00a0et \u00a0al.\u00a0(2011).\u00a0Long\u2010term\u00a0follow\u2010up\u00a0of\u00a0patients\u00a0on\u00a0home\u00a0parenteral \u00a0\nnutrition\u00a0in\u00a0Europe:\u00a0implications\u00a0for\u00a0intestinal\u00a0transplantatio n.\u00a0Gut\u00a060(1):\u00a017\u201325.\u00a0  \nPrescrire\u00a0International\u00a0(2016).\u00a0Teduglutide.\u00a0For\u00a0patients\u00a0requi ring\u00a0permanent\u00a0parenteral\u00a0nutrition\u00a0for\u00a0short\u00a0bowel\u00a0syndrome.\u00a0\nPrescrire\u00a0Int\u00a025\u00a0(168):\u00a034\u201035.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2014).\u00a0Neue\u00a0Arzneistoffe\u00a0Teduglut id.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0 www.pharmazeutische\u2010\nzeitung.de/index.php?id=54685 ,\u00a0letzter\u00a0Zugriff:\u00a022.06.2017.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(2011).\u00a0Arzneiverordnungs\u2010Report\u00a02011.\u00a0Be rlin,\u00a0Heidelberg:\u00a0Springer\u2010Verlag.\u00a0\nSchwartz\u00a0LK,\u00a0O\u2019Keefe\u00a0SJ,\u00a0Fujioka\u00a0 K,\u00a0Gabe\u00a0SM,\u00a0Lamprecht\u00a0G,\u00a0Pape\u00a0 UF,\u00a0Jeppesen\u00a0PB\u00a0et\u00a0al.\u00a0(2016).\u00a0Long\u2010term\u00a0teduglutide\u00a0for\u00a0the\u00a0tr eatment\u00a0\nof\u00a0patients\u00a0with\u00a0intestinal\u00a0failu re\u00a0associated\u00a0with\u00a0short\u00a0bowel \u00a0syndrome.\u00a0Clin\u00a0Transl\u00a0Gastroenterol\u00a07(2):\u00a0e142.\u00a0\nTee\u00a0CT,\u00a0Wallis\u00a0K,\u00a0Gabe\u00a0SM\u00a0(2011).\u00a0Emerging\u00a0treatment\u00a0options\u00a0fo r\u00a0short\u00a0bowel\u00a0syndrome:\u00a0potentia l\u00a0role\u00a0of\u00a0teduglutide.\u00a0Clin\u00a0Exp \u00a0\nGastroenterol\u00a04:\u00a0189\u201096.\u00a0\u00a0\nWilmore\u00a0DW,\u00a0Lacey\u00a0JM,\u00a0Soultanaki s\u00a0RP,\u00a0Bosch\u00a0RL,\u00a0Byrne\u00a0TA\u00a0(1997) .\u00a0Factors\u00a0predicting\u00a0a\u00a0successful\u00a0outcome\u00a0after\u00a0pharmacologic\u00a0\nbowel\u00a0compensation.\u00a0Annals\u00a0of\u00a0Surgery\u00a0226(3):\u00a0288\u201092;\u00a0discussio n\u00a0292\u20103.\u00a0\u00a0\nWinkler\u00a0MF,\u00a0Wetle\u00a0T,\u00a0Smith\u00a0C,\u00a0 Hagan\u00a0E,\u00a0O\u2019Sullivan,\u00a0Maillet\u00a0J,\u00a0T ouger\u2010Decker\u00a0R\u00a0(2010).\u00a0The\u00a0Meaning\u00a0of\u00a0Food\u00a0and\u00a0Eating\u00a0among\u00a0\nHome\u00a0Parenteral\u00a0Nutrition\u2010Dependent\u00a0Adults\u00a0with\u00a0Intestinal\u00a0Fail ure:\u00a0A\u00a0Qualitative\u00a0Inquiry.\u00a0J\u00a0Am\u00a0Diet\u00a0Assoc\u00a0110(11):\u00a0\n1676\u20131683.\u00a0\u00a0\n\u00a0 \u00a0405\u00a04.28 Trastuzumab\u00a0Emtansin\u00a0\nHandelsname:\u00a0Kadcyla\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HER2\u2010positives\u00a0\u00a0 \u00a0 Roche\u00a0\nMammakarzinom\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02014\u00a0\nATC\u2010Code:\u00a0L01XC14\u00a0\nDarreichungsform:\u00a0Pulver\u00a0zur\u00a0Herstellung\u00a0\u00a0\neines\u00a0Infusionsl\u00f6sungskonzentrats\u00a0 \u00a0 DDD:\u00a00,14\u00a0g\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nTrastuzumab\u00a0Emtansin\u00a0ist\u00a0ein\u00a0Ant ik\u00f6rper\u2010Wirkstoff\u2010Konjugat,\u00a0bei \u00a0dem\u00a0der\u00a0gegen\u00a0\nHER2\u00a0gerichtete\u00a0monoklonale\u00a0Anti k\u00f6rper\u00a0Trastuzumab\u00a0kovalent\u00a0\u00fcbe r\u00a0einen\u00a0Thio\u2010\nether\u2010Linker\u00a0(4\u2010[N\u2010Maleimidometh yl]cyclohexan\u20101\u2010carboxylat,\u00a0MCC )\u00a0an\u00a0den\u00a0zyto\u2010\ntoxischen\u00a0Mitosehemmstoff\u00a0DM1,\u00a0e in\u00a0Maytansinderivat,\u00a0gebunden\u00a0i st\u00a0(Fachinfor\u2010\nmation\u00a0Kadcyla\u00ae,\u00a02016).\u00a0Der\u00a0Begriff\u00a0Emtansin\u00a0bezeichnet\u00a0den\u00a0MCC \u2010DM1\u2010Komplex.\u00a0\nAn\u00a0jedes\u00a0Molek\u00fcl\u00a0Trastuzumab\u00a0sind\u00a0durchschnittlich\u00a03,5\u00a0DM1\u2010Mole k\u00fcle\u00a0kovalent\u00a0\ngebunden.\u00a0Die\u00a0Wirkung\u00a0des\u00a0Konjugats\u00a0beruht\u00a0auf\u00a0beiden\u00a0Komponent en:\u00a0Nach\u00a0\nselektiver\u00a0Bindung\u00a0an\u00a0den\u00a0extrazellul\u00e4ren\u00a0HER2\u2010Rezeptor\u00a0entfalt et\u00a0Trastuzumab\u00a0\nseine\u00a0Antitumorwirkung\u00a0\u00fcber\u00a0die\u00a0Induktion\u00a0einer\u00a0Antik\u00f6rper\u2010abh\u00e4 ngigen\u00a0zellver\u2010\nmittelten\u00a0 Zytotoxizit\u00e4t\u00a0 ( Antibody\u00a0 Dependent\u00a0 Cellular\u00a0 Cytotoxicity ,\u00a0 ADCC)\u00a0 sowie\u00a0\n\u00fcber\u00a0die\u00a0Hemmung\u00a0nachgeschalteter\u00a0intrazellul\u00e4rer\u00a0Signal\u00fcbertra gungsketten.\u00a0Der\u00a0\nHER2\u2010Rezeptor\u2010Trastuzumab\u2010Emtans in\u2010Komplex\u00a0 wird\u00a0 mittels\u00a0 Endozyt ose\u00a0 in\u00a0 die\u00a0\nT u m o r z e l l e \u00a0a u f g e n o m m e n \u00a0u n d \u00a0i n \u00a0d e n\u00a0 Lysosomen\u00a0 proteolytisch\u00a0 abgeb aut.\u00a0 Das\u00a0\ndadurch\u00a0erst\u00a0in\u00a0der\u00a0Zielzelle\u00a0fre igesetzte\u00a0Lysin\u2010gebundene\u00a0Emta nsin\u00a0bindet\u00a0an\u00a0Tu\u2010\nbulin\u00a0und\u00a0verhindert\u00a0die\u00a0Polymer isation\u00a0von\u00a0Mikrotubuli,\u00a0wodurc h\u00a0der\u00a0Aufbau\u00a0der\u00a0\nMitosespindel\u00a0und\u00a0die\u00a0nachfolgende \u00a0Zellteilung\u00a0gehemmt\u00a0werden.\u00a0 Die\u00a0kovalente\u00a0\nBindung\u00a0zwischen\u00a0Trastuzumab\u00a0und\u00a0DM1\u00a0\u00fcber\u00a0die\u00a0MCC\u2010Br\u00fccke\u00a0soll\u00a0d ie\u00a0systemi\u2010\nsche\u00a0 Freisetzung\u00a0 von\u00a0 DM1\u00a0 begrenz en\u00a0 und\u00a0 dessen\u00a0 zielgerichtete\u00a0 Ab gabe\u00a0 ver\u2010\nst\u00e4rken.\u00a0Trastuzumab\u00a0Emtansin\u00a0is t\u00a0als\u00a0Monotherapie\u00a0zugelassen\u00a0z ur\u00a0Behandlung\u00a0\nvon\u00a0 erwachsenen\u00a0 Patientinnen\u00a0 mit\u00a0 HER2\u2010positivem,\u00a0 inoperablem,\u00a0 l okal\u00a0 fortge\u2010\nschrittenem\u00a0oder\u00a0metastasiertem\u00a0 Brustkrebs,\u00a0die\u00a0zuvor\u00a0\u2013\u00a0einzeln \u00a0oder\u00a0kombiniert\u00a0\n\u2013\u00a0Trastuzumab\u00a0und\u00a0ein\u00a0Taxan\u00a0erhalten\u00a0haben.\u00a0Die\u00a0Patientinnen\u00a0so llten\u00a0entweder\u00a0\neine\u00a0vorherige\u00a0Behandlung\u00a0gegen\u00a0die\u00a0lokal\u00a0fortgeschrittene\u00a0oder \u00a0metastasierte\u00a0\nErkrankung\u00a0erhalten\u00a0oder\u00a0ein\u00a0Rezidiv\u00a0w\u00e4hrend\u00a0oder\u00a0innerhalb\u00a0von \u00a0sechs\u00a0Monaten\u00a0\nnach\u00a0Beendigung\u00a0der\u00a0adjuvanten\u00a0Behandlung\u00a0entwickelt\u00a0haben.\u00a0\nDie\u00a0empfohlene\u00a0Dosis\u00a0betr\u00e4gt\u00a03,6\u00a0mg/kg\u00a0K\u00f6rpergewicht\u00a0(KG)\u00a0und\u00a0w ird\u00a0im\u00a021\u2010Tage\u2010\nZyklus\u00a0als\u00a0intraven\u00f6se\u00a0Infusion\u00a0verabreicht.\u00a0\u00a0\nDas\u00a0Pr\u00e4parat\u00a0ist\u00a0im\u00a0K\u00fchlschran k\u00a0bei\u00a02\u00a0bis\u00a08\u00b0C\u00a0zu\u00a0lagern.\u00a0406\u00a0In\u00a0die\u00a0multizentrische,\u00a0unverbli ndet\u00a0durchgef\u00fchrte,\u00a0randomisier te,\u00a0kontrollierte\u00a0\nZulassungsstudie\u00a0EMILIA\u00a0(Sponsor:\u00a0Hoffmann\u2010La\u00a0Roche,\u00a0vormals\u00a0Ge nentech)\u00a0wur\u2010\nden\u00a0991\u00a0Patienten\u00a0(986\u00a0Frauen\u00a0und\u00a05\u00a0M\u00e4nner)\u00a0mit\u00a0HER2\u2010postivem,\u00a0 lokal\u00a0fortge\u2010\nschrittenem\u00a0 oder\u00a0 metastasiertem\u00a0 Mammakarzinom\u00a0 eingeschlossen,\u00a0 d ie\u00a0 mit\u00a0\nTrastuzumab\u00a0und\u00a0einem\u00a0Taxan\u00a0vorbehandelt\u00a0waren.\u00a0Die\u00a0Vorbehandlu ng\u00a0konnte\u00a0im\u00a0\nadjuvanten\u00a0oder\u00a0im\u00a0inoperablen\u00a0Setting\u00a0erfolgt\u00a0sein.\u00a0F\u00fcr\u00a0den\u00a0Ei nschluss\u00a0in\u00a0die\u00a0\nStudie\u00a0sollte\u00a0die\u00a0Krankheitsprogression\u00a0der\u00a0Patienten\u00a0w\u00e4hrend\u00a0o der\u00a0unmittelbar\u00a0\nnach\u00a0der\u00a0Behandlung\u00a0der\u00a0lokal\u00a0fortgeschrittenen\u00a0oder\u00a0metastasie rten\u00a0Erkrankung\u00a0\noder\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten\u00a0nach\u00a0Abschluss\u00a0einer\u00a0adjuvante n\u00a0Therapie\u00a0\naufgetreten\u00a0sein\u00a0(Verma\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0Patienten\u00a0wurden\u00a0nac h\u00a01:1\u00a0Randomisie\u2010\nrung\u00a0behandelt\u00a0mit\u00a0Trastuzumab\u00a0Emtansin\u00a0(3,6\u00a0mg/kg\u00a0alle\u00a021\u00a0Tage )\u00a0oder\u00a0mit\u00a0Lapa\u2010\ntinib\u00a0(1.250\u00a0mg\u00a0oral\u00a0einmal\u00a0t\u00e4glich)\u00a0plus\u00a0Capecitabin\u00a0(1.000\u00a0mg /m2\u00a0oral\u00a0zweimal\u00a0\nt\u00e4glich\u00a0an\u00a0Tag\u00a01\u00a0bis\u00a014\u00a0im\u00a021\u2010t\u00e4gigen\u00a0Zyklus).\u00a0Voraussetzung\u00a0f\u00fc r\u00a0die\u00a0Teilnahme\u00a0an\u00a0\nder\u00a0Studie\u00a0war\u00a0ein\u00a0guter\u00a0Allgemeinzustand\u00a0(ECOG\u00a00\u00a0und\u00a01),  das\u00a0mediane\u00a0Alter\u00a0der\u00a0\nPatienten\u00a0betrug\u00a053\u00a0Jahre.\u00a0Als\u00a0prim\u00e4re\u00a0Endpunkte\u00a0wurden\u00a0das\u00a0pro gressionsfreie\u00a0\n\u00dcberleben\u00a0 ( Progression\u2010free\u00a0 Survival ,\u00a0 PFS)\u00a0 und\u00a0 das\u00a0 Gesamt\u00fcberleben\u00a0 ( Overall\u00a0\nSurvival,\u00a0 OS)\u00a0 gew\u00e4hlt,\u00a0 wichtige\u00a0 sekund\u00e4re\u00a0 Endpunkte\u00a0 waren\u00a0 die\u00a0 objektive \u00a0A n \u2010\nsprechrate\u00a0und\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0Progression\u00a0der\u00a0Symptome.\u00a0Zus\u00e4t zlich\u00a0wurden\u00a0als\u00a0\npatientenrelevante\u00a0 Endpunkte\u00a0 die\u00a0 unerw\u00fcnschten\u00a0 Arzneimittelerei gnisse\u00a0 (UAE)\u00a0\nund\u00a0 die\u00a0 gesundheitsbezogene\u00a0 Lebensqualit\u00e4t\u00a0 ( H e a l t h \u00a0R e l a t e d \u00a0Q u a l i t y \u00a0o f \u00a0L i f e ,\u00a0\nHRQoL)\u00a0untersucht.\u00a0Die\u00a0mediane\u00a0Behandlungsdauer\u00a0war\u00a0im\u00a0Trastuzu mab\u00a0Emtan\u2010\nsin\u2010Arm\u00a0l\u00e4nger\u00a0als\u00a0im\u00a0Lapatinib\u2010 Capecitabin\u2010Arm\u00a0(7,6\u00a0Monate\u00a0vs. \u00a05,5\u00a0bzw.\u00a05,3\u00a0\nMonate\u00a0beim\u00a0zweiten\u00a0Datenschnitt).\u00a0Zum\u00a0Zeitpunkt\u00a0des\u00a0ersten\u00a0Dat enschnittes\u00a0\nergab\u00a0die\u00a0final\u2010konfirmatorische\u00a0Analyse\u00a0des\u00a0Endpunktes\u00a0PFS,\u00a0da ss\u00a0Trastuzumab\u00a0\nEmtansin\u00a0das\u00a0PFS\u00a0um\u00a03,2\u00a0Monate\u00a0gegen\u00fcber\u00a0der\u00a0Vergleichsgruppe\u00a0v erl\u00e4ngerte\u00a0\n(9,6\u00a0versus\u00a06,4\u00a0Monate).\u00a0Beim\u00a0nicht\u00a0geplanten\u00a0zweiten\u00a0Datenschn itt\u00a0sechs\u00a0Monate\u00a0\nsp\u00e4ter\u00a0verl\u00e4ngerte\u00a0Trastuzumab\u00a0Emtansin\u00a0auch\u00a0das\u00a0mediane\u00a0Gesamt \u00fcberleben\u00a0\n(30,9\u00a0vs.\u00a025,1\u00a0Monate).\u00a0Der\u00a0Vorteil\u00a0der\u00a0Behandlung\u00a0mit\u00a0Trastuzu mab\u00a0Emtansin\u00a0im\u00a0\nGesamtergebnis\u00a0zeigte\u00a0sich\u00a0auch\u00a0i n\u00a0der\u00a0Mehrzahl\u00a0der\u00a0zuvor\u00a0spezi fizierten\u00a0Sub\u2010\ngruppen.\u00a0Allerdings\u00a0war\u00a0bei\u00a0den\u00a0Patienten\u00a0zwischen\u00a065\u00a0und\u00a074\u00a0Ja hren\u00a0(n=113)\u00a0der\u00a0\nVorteil\u00a0bez\u00fcglich\u00a0PFS\u00a0und\u00a0OS\u00a0nicht\u00a0mehr\u00a0statistisch\u00a0signifikant ,\u00a0und\u00a0bei\u00a0den\u00a0Patien\u2010\ntinnen\u00a0\u2265\u00a075\u00a0Jahre\u00a0(n=23)\u00a0zeigte\u00a0sich\u00a0ein\u00a0Vorteil\u00a0eher\u00a0f\u00fcr\u00a0eine\u00a0 Behandlung\u00a0mit\u00a0Lapa\u2010\ntinib\u00a0plus\u00a0Capecitabin\u00a0(AMB,\u00a02014).\u00a0Schwere\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03)\u00a0kame n\u00a0unter\u00a0Lapatinib\u00a0\nplus\u00a0Capecitabin\u00a0h\u00e4ufiger\u00a0vor\u00a0als\u00a0unter\u00a0Trastuzumab\u00a0Emtansin.\u00a0I m\u00a0Einzelnen\u00a0traten\u00a0\nunter\u00a0 der\u00a0 Vergleichstherapie\u00a0 h\u00e4uf iger\u00a0 Durchfall,\u00a0 \u00dcbelkeit,\u00a0 Erbr echen\u00a0 und\u00a0 das\u00a0\nHand\u2010Fu\u00df\u2010Syndrom\u00a0auf,\u00a0dagegen\u00a0kam\u00a0es\u00a0unter\u00a0Trastuzumab\u00a0Emtansin \u00a0h\u00e4ufiger\u00a0zu\u00a0\nThrombozytopenien\u00a0 und\u00a0 erh\u00f6hten\u00a0 Transaminase\u2010Werten.\u00a0 Unter\u00a0 Trast uzumab\u00a0\nEmtansin\u00a0ergab\u00a0sich\u00a0eine\u00a0Verl\u00e4ngerung\u00a0der\u00a0medianen\u00a0Zeit\u00a0bis\u00a0zur \u00a0Verschlechterung\u00a0\nder\u00a0HRQoL\u00a0(physisch/funktionale\u00a0 Komponente,\u00a0ermittelt\u00a0mit\u00a0der\u00a0T OI\u2010FFB\u00a0Subskala\u00a0\ndes\u00a0FACT\u2010B).\u00a0Dieser\u00a0Vorteil\u00a0war\u00a0 allerdings\u00a0nur\u00a0in\u00a0der\u00a0zahlenm\u00e4\u00df ig\u00a0\u00fcberwiegenden\u00a0407\u00a0Subgruppe\u00a0der\u00a0kaukasischen\u00a0Patienten\u00a0statistisch\u00a0signifikant\u00a0un d\u00a0aufgrund\u00a0des\u00a0\noffenen\u00a0Studiendesigns\u00a0kaum\u00a0aussagekr\u00e4ftig\u00a0(G\u2010BA,\u00a02014).\u00a0\u00a0\nIn\u00a0 eine\u00a0 weitere\u00a0 offene,\u00a0 randomis ierte,\u00a0 kontrollierte\u00a0 Phase\u2010III\u2010 Studie\u00a0 (TH3RESA,\u00a0\nKrop\u00a0et\u00a0al.,\u00a02014)\u00a0wurden\u00a0602\u00a0Patientinnen\u00a0mit\u00a0metastasiertem\u00a0H ER2\u2010positiven\u00a0\nMam m akarz i nom \u00a0ei ng eschl o ssen, \u00a0di e\u00a0z uv o r\u00a0scho n\u00a0m i ndestens\u00a0z wei \u00a0A nti\u2010HER2\u2010\ngerichtete\u00a0Therapien\u00a0mit\u00a0Trastuzumab\u00a0oder\u00a0Lapatinib\u00a0sowie\u00a0Taxan e\u00a0erhalten\u00a0hat\u2010\nten.\u00a0Nach\u00a0einer\u00a02:1\u2010Randomisierung\u00a0wurden\u00a0404\u00a0Patientinnen\u00a0mit\u00a0 Trastuzumab\u00a0\nEmtansin\u00a0(3,6\u00a0mg/kg\u00a0KG\u00a0alle\u00a021\u00a0Tage)\u00a0und\u00a0198\u00a0Patientinnen\u00a0mit\u00a0e iner\u00a0Therapie\u00a0\nnach\u00a0Wahl\u00a0des\u00a0Pr\u00fcfarztes,\u00a0\u00fcberwiegend\u00a0Trastuzumab\u00a0plus\u00a0Chemothe rapie,\u00a0\u00fcber\u00a0\neinen\u00a0Zeitraum\u00a0von\u00a018\u00a0Monaten\u00a0behandelt.\u00a0Ein\u00a0 Cross\u2010Over \u00a0(Wechsel)\u00a0war\u00a0m\u00f6glich;\u00a0\n44\u00a0Patientinnen\u00a0wechselten\u00a0aus\u00a0dem\u00a0Vergleichs\u2010\u00a0in\u00a0den\u00a0Therapiea rm\u00a0mit\u00a0Trastuzu\u2010\nmab\u00a0Emtansin.\u00a0Prim\u00e4re\u00a0Endpunkte\u00a0waren\u00a0das\u00a0PFS\u00a0und\u00a0das\u00a0OS.\u00a0Die\u00a0T herapie\u00a0mit\u00a0\nTrastuzumab\u00a0Emtansin\u00a0verl\u00e4ngerte\u00a0das\u00a0PFS\u00a0gegen\u00fcber\u00a0der\u00a0Therapie \u00a0nach\u00a0Wahl\u00a0des\u00a0\nArztes\u00a0statistisch\u00a0signifikant\u00a0u m\u00a02,9\u00a0Monate\u00a0(6,2\u00a0Monate\u00a0vs.\u00a03, 3\u00a0Monate).\u00a0Das\u00a0\nmediane\u00a0OS\u00a0war\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Interimsanalyse\u00a0im\u00a0Trastuzumab \u00a0Emtansin\u2010\nArm\u00a0noch\u00a0nicht\u00a0erreicht.\u00a0Unter\u00a0Trastuzumab\u00a0Emtansin\u00a0traten\u00a0als\u00a0 schwerwiegende\u00a0\nUAE\u00a0(Grad\u00a0\u2265\u00a03)\u00a0h\u00e4ufiger\u00a0Thrombozytopenien\u00a0als\u00a0im\u00a0Vergleichsarm\u00a0 auf,\u00a0unter\u00a0der\u00a0\nVergleichstherapie\u00a0kam\u00a0es\u00a0h\u00e4ufiger\u00a0zu\u00a0schwerwiegenden\u00a0Neutropen ien,\u00a0febrilen\u00a0\nNeutropenien\u00a0und\u00a0Diarrhoen.\u00a0Insge samt\u00a0waren\u00a0die\u00a0schwerwiegenden \u00a0UAE\u00a0(Grad\u00a0\n\u2265\u00a03)\u00a0unter\u00a0Trastuzumab\u00a0Emtansin\u00a0seltener.\u00a0\nIn\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0le gte\u00a0der\u00a0Gemeinsame\u00a0Bundesaussch uss\u00a0(G\u2010BA)\u00a0\nim\u00a0Gegensatz\u00a0zum\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU),\u00a0der\u00a0die\u00a0Ver gleichsthera\u2010\npie\u00a0Lapatinib\u00a0plus\u00a0Capecitabin\u00a0f\u00fcr\u00a0die\u00a0gesamte\u00a0Zielpopulation\u00a0h eranzieht\u00a0und\u00a0die\u00a0\nEMILIA\u2010Studie\u00a0auf\u00a0Basis\u00a0der\u00a0Gesamtpopulation\u00a0in\u00a0sein\u00a0Dossier\u00a0f\u00fc r\u00a0die\u00a0fr\u00fche\u00a0Nut\u2010\nzenbewertung\u00a0 einschlie\u00dft,\u00a0 unterschiedliche\u00a0 zweckm\u00e4\u00dfige\u00a0 Vergleic hstherapien\u00a0\n(zVT)\u00a0f\u00fcr\u00a0vier\u00a0Teilpopulationen\u00a0fest\u00a0(G\u2010BA,\u00a02014).\u00a0Der\u00a0G\u2010BA\u00a0sie ht\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0\ndes\u00a0Zusatznutzens\u00a0nur\u00a0die\u00a0Patientengruppe\u00a0b\u00a0(n=605\u00a0bzw.\u00a061\u00a0%\u00a0de r\u00a0eingeschlosse\u2010\nnen\u00a0 Patientinnen)\u00a0 als\u00a0 relevant\u00a0 a n,\u00a0 die\u00a0 wegen\u00a0 HER2\u2010positivem,\u00a0 me tastasiertem\u00a0\nBrustkrebs\u00a0in\u00a0einer\u00a0vorangegange nen\u00a0Therapie\u00a0Trastuzumab,\u00a0Taxan e\u00a0und\u00a0Anth\u2010\nrazykline\u00a0erhalten\u00a0hatte,\u00a0da\u00a0nur \u00a0f\u00fcr\u00a0diese\u00a0Teilpopulation\u00a0die\u00a0V ergleichstherapie\u00a0\nLapatinib\u00a0plus\u00a0Capecitabin\u00a0zulassungskonform\u00a0eingesetzt\u00a0wurde.\u00a0 F\u00fcr\u00a0diese\u00a0Patien\u2010\ntengruppe\u00a0stuft\u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0Trast uzumab\u00a0Emtan\u2010\nsin\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0aufgrund\u00a0de r\u00a0moderaten\u00a0Verl\u00e4ngerung\u00a0des\u00a0O S,\u00a0der\u00a0f\u00fcr\u00a0die\u00a0\nPatientinnen\u00a0bedeutsamen\u00a0Vermeidung\u00a0relevanter\u00a0UAE\u00a0und\u00a0des\u00a0posi tiven\u00a0Einflus\u2010\nses\u00a0auf\u00a0die\u00a0HRQoL\u00a0als\u00a0betr\u00e4chtlich\u00a0ein.\u00a0Da\u00a0lediglich\u00a0eine\u00a0unver blindete\u00a0Studie\u00a0mit\u00a0\nhohem\u00a0Verzerrungspotential\u00a0zu\u00a0den\u00a0Endpunkten\u00a0UAE\u00a0und\u00a0HRQoL\u00a0im\u00a0R ahmen\u00a0der\u00a0\nfr\u00fchen\u00a0Nutzenbewertung\u00a0vorliegt,\u00a0kann\u00a0er\u00a0nur\u00a0einen\u00a0 Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtli\u2010\nchen\u00a0Zusatznutzen \u00a0konstatieren.\u00a0F\u00fcr\u00a0die\u00a0anderen\u00a0drei\u00a0Teilpopulationen\u00a0gilt\u00a0der\u00a0408\u00a0Zusatznutzen \u00a0aufgrund\u00a0 fehlender\u00a0 Daten\u00a0 zum\u00a0 Ve rgleich\u00a0 mit\u00a0 der\u00a0 zweckm\u00e4\u00dfigen\u00a0\nVergleichstherapie\u00a0als\u00a0 nicht\u00a0belegt .\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0 (Zusatz\u2010)Nutzen\u00a0 Kosten\u00a0\n\u00a0\nWeitere\u00a0Therapie\u2010\noption,\u00a0allerd ings\u00a0erstes\u00a0\nAntik\u00f6rper\u2010Wirkstoff\u2010\nKonjugat\u00a0in\u00a0diesem\u00a0\nIndikationsgebiet\u00a0Therapieoption\u00a0f\u00fcr\u00a0\nvorbehandelte\u00a0Patienten\u00a0\nmit\u00a0HER2\u2010positivem\u00a0\nmetastasierten\u00a0\nMammakarzinom;\u00a0noch\u00a0\nungen\u00fcgende\u00a0Datenlage\u00a0teurer\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nTrastuzumab\u00a0Emtansin\u00a0 3,6\u00a0mg/kg\u00a0alle\u00a021\u00a0Tage\u00a0 17\u00a0 89.496,33\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nLapatinib\u00a0 1.250\u00a0mg\u00a0tgl. \u00a0 365\u00a0 44.906,21\u00a0\u20ac\u00a0\nCapecitabin \u00a0 1.000\u00a0mg/m2\u00a02x\u00a0tgl.\u00a0\u00a0\nan\u00a0Tag\u00a01\u00a0\u2013\u00a014,\u00a0alle\u00a021\u00a0Tage\u00a0238\u00a0 2009,75\u00a0\u20ac\u00a0\nzVT\u00a0gesamt\u00a0 \u00a0 \u00a0 46.915,96\u00a0\u20ac\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus\u00a0 a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0Vielversprechende\u00a0\nDaten;\u00a0Ergebnisse\u00a0\nm\u00fcssen\u00a0aber\u00a0\ndurch\u00a0weitere\u00a0\nStudien\u00a0best\u00e4tigt\u00a0\nwerden\u00a0Judgement\u00a0\nreserved\u00a0Sprunginnovation\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nDas\u00a0Antik\u00f6rper\u2010Wirkstoff\u2010Konjugat\u00a0Trastuzumab\u00a0Emtansin\u00a0wurde\u00a0fa st\u00a0ausschlie\u00df\u2010\nlich\u00a0als\u00a0Rezeptur\u00a0abgerechnet\u00a0und\u00a0erreichte\u00a0unmittelbar\u00a0nach\u00a0se iner\u00a0Markteinf\u00fch\u2010\nrung\u00a0im\u00a0Januar\u00a02014\u00a0ein\u00a0relativ\u00a0konstantes\u00a0Verordnungsplateau\u00a0\u00fc ber\u00a0den\u00a0gesam\u2010\nten\u00a0 Beobachtungszeitraum\u00a0 mit\u00a0 einem\u00a0 monatlichen\u00a0 Bruttoumsatz\u00a0 von \u00a0e t w a \u00a0\n650.000\u00a0Euro.\u00a0\u00a0\n\u00a0\n\u00a0\n409\u00a0Abbildung\u00a04.51:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\nTrastuzumab\u00a0Emtansin\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nTrastuzumab\u00a0Emtansin\u00a0ist\u00a0ein\u00a0Ant ik\u00f6rper\u2010Wirkstoff\u2010Konjugat,\u00a0bei \u00a0dem\u00a0der\u00a0gegen\u00a0\nHER2\u00a0gerichtete\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0Trastuzumab\u00a0kovalent\u00a0\u00fcbe r\u00a0einen\u00a0MCC\u00a0\nan\u00a0den\u00a0zytotoxischen\u00a0Mitosehemms toff\u00a0DM1,\u00a0ein\u00a0Maytansinderivat, \u00a0gebunden\u00a0ist\u00a0\n(Fachinformation\u00a0 Kadcyla\u00ae,\u00a0 2016).\u00a0 Der\u00a0 Begriff\u00a0 Emtansin\u00a0 bezeichn et\u00a0 den\u00a0 MCC\u2010\nDM1\u2010Komplex.\u00a0 An\u00a0 jedes\u00a0 Molek\u00fcl\u00a0 Trastuzumab\u00a0 sind\u00a0 durchschnittlich \u00a03 , 5 \u00a0D M 1 \u2010\nMolek\u00fcle\u00a0kovalent\u00a0gebunden.\u00a0Die\u00a0Wirkung\u00a0des\u00a0Konjugats\u00a0beruht\u00a0au f\u00a0beiden\u00a0Kom\u2010\nponenten:\u00a0Nach\u00a0selektiver\u00a0Bindung \u00a0an\u00a0den\u00a0extrazellul\u00e4ren\u00a0HER2\u2010R ezeptor\u00a0entfaltet\u00a0\nTrastuzumab\u00a0 seine\u00a0 Antitumorwirkung\u00a0 \u00fcber\u00a0 die\u00a0 Induktion\u00a0 einer\u00a0 Ant ik\u00f6rper\u2010\nabh\u00e4ngigen\u00a0zellvermittelten\u00a0Zyto toxizit\u00e4t\u00a0ADCC\u00a0sowie\u00a0\u00fcber\u00a0die\u00a0H emmung\u00a0nachge\u2010\nschalteter\u00a0 intrazellul\u00e4rer\u00a0 Signal\u00fcbertragungsketten.\u00a0 Der\u00a0 HER2\u2010R ezeptor\u2010Trastuzu\u2010\nmab\u2010Emtansin\u2010Komplex\u00a0wird\u00a0mittels\u00a0Endozytose\u00a0in\u00a0die\u00a0Tumorzelle\u00a0 aufgenommen\u00a0\nund\u00a0in\u00a0den\u00a0Lysosomen\u00a0proteolytisch\u00a0abgebaut.\u00a0Das\u00a0dadurch\u00a0erst\u00a0i n\u00a0der\u00a0Zielzelle\u00a0\nfreigesetzte\u00a0Lysin\u2010gebundene\u00a0Emtansin\u00a0bindet\u00a0an\u00a0Tubulin\u00a0und\u00a0ver hindert\u00a0die\u00a0Poly\u2010\nmerisation\u00a0von\u00a0Mikrotubuli,\u00a0wodurch\u00a0der\u00a0Aufbau\u00a0der\u00a0Mitosespinde l\u00a0und\u00a0die\u00a0nachfol\u2010\ngende\u00a0Zellteilung\u00a0gehemmt\u00a0werden.\u00a0Die\u00a0kovalente\u00a0Bindung\u00a0zwische n\u00a0Trastuzumab\u00a0\nund\u00a0DM1\u00a0\u00fcber\u00a0die\u00a0MCC\u2010Br\u00fccke\u00a0soll\u00a0die\u00a0systemische\u00a0Freisetzung\u00a0vo n\u00a0DM1\u00a0begrenzen\u00a0\nund\u00a0dessen\u00a0zielgerichtete\u00a0Abgabe\u00a0verst\u00e4rken\u00a0(EMA,\u00a02017).\u00a0\n\u00a0\n410\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nTrastuzumab\u00a0Emtansin\u00a0ist\u00a0als\u00a0Mon otherapie\u00a0zugelassen\u00a0zur\u00a0Behand lung\u00a0von\u00a0er\u2010\nwachsenen\u00a0Patienten\u00a0mit\u00a0HER2\u2010pos itivem,\u00a0inoperablem,\u00a0lokal\u00a0fort geschrittenem\u00a0\noder\u00a0metastasiertem\u00a0Brustkrebs,\u00a0 die\u00a0zuvor\u00a0\u2013\u00a0einzeln\u00a0oder\u00a0kombin iert\u00a0\u2013\u00a0Trastuzu\u2010\nmab\u00a0und\u00a0ein\u00a0Taxan\u00a0erhalten\u00a0haben.\u00a0Die\u00a0Patienten\u00a0sollten\u00a0entwede r\u00a0eine\u00a0vorherige\u00a0\nBehandlung\u00a0gegen\u00a0die\u00a0lokal\u00a0fortge schrittene\u00a0oder\u00a0metastasierte\u00a0 Erkrankung\u00a0erhal\u2010\nten\u00a0oder\u00a0ein\u00a0Rezidiv\u00a0w\u00e4hrend\u00a0oder\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten\u00a0n ach\u00a0Beendigung\u00a0\nder\u00a0adjuvanten\u00a0Behandlung\u00a0entwickelt\u00a0haben.\u00a0\nDie\u00a0empfohlene\u00a0Dosis\u00a0von\u00a0Trastuzumab\u00a0Emtansin\u00a0betr\u00e4gt\u00a03,6\u00a0mg/kg \u00a0KG\u00a0und\u00a0wird\u00a0im\u00a0\n21\u2010Tage\u2010Zyklus\u00a0als\u00a0intraven\u00f6se\u00a0Infusion\u00a0verabreicht.\u00a0Die\u00a0erste\u00a0 Gabe\u00a0sollte\u00a0\u00fcber\u00a0einen\u00a0\nZeitraum\u00a0von\u00a090\u00a0Minuten\u00a0infundiert\u00a0werden,\u00a0bei\u00a0guter\u00a0Vertr\u00e4glic hkeit\u00a0ist\u00a0bei\u00a0den\u00a0\nFolgeinfusionen\u00a0die\u00a0Verk\u00fcrzung\u00a0d er\u00a0Applikationsdauer\u00a0auf\u00a030\u00a0Min uten\u00a0m\u00f6glich.   \nWeil\u00a0Trastuzumab\u00a0Emtansin\u00a0vermutlich\u00a0haupts\u00e4chlich\u00a0\u00fcber\u00a0CYP3A4\u00a0 und\u00a0in\u00a0geringe\u2010\nrem\u00a0Ma\u00dfe\u00a0\u00fcber\u00a0CYP3A5\u00a0verstoffwechselt\u00a0wird,\u00a0sollten\u00a0starke\u00a0CYP3 A4\u2010Hemmer\u00a0wie\u00a0\nbeispielsweise\u00a0Ketoconazol,\u00a0Vori conazol,\u00a0Clarithromycin\u00a0und\u00a0Rit onavir\u00a0w\u00e4hrend\u00a0\nder\u00a0Behandlung\u00a0vermieden\u00a0werden.\u00a0\nDas\u00a0Pr\u00e4parat\u00a0ist\u00a0im\u00a0K\u00fchlschrank\u00a0bei\u00a02\u00a0bis\u00a08\u00a0\u00b0C\u00a0zu\u00a0lagern.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nBrustkrebs\u00a0betrifft\u00a0fast\u00a0ausschlie\u00dflich\u00a0Frauen,\u00a0der\u00a0Anteil\u00a0der\u00a0 M\u00e4nner\u00a0an\u00a0den\u00a0re\u2010\ngistrierten\u00a0Neuerkrankungsf\u00e4llen\u00a0liegt\u00a0bei\u00a0etwa\u00a01\u00a0%\u00a0(KiD,\u00a02015) .\u00a0Bei\u00a0Frauen\u00a0ist\u00a0das\u00a0\nMammakarzinom\u00a0der\u00a0mit\u00a0Abstand\u00a0h\u00e4ufigste\u00a0maligne\u00a0Tumor.\u00a0In\u00a0Deuts chland\u00a0wird\u00a0\ndie\u00a0Zahl\u00a0der\u00a0Neuerkrankungen\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02016\u00a0auf\u00a065.500\u00a0gesch \u00e4tzt,\u00a0etwa\u00a0eine\u00a0\nvon\u00a0acht\u00a0Frauen\u00a0erkrankt\u00a0im\u00a0Laufe\u00a0ihres\u00a0Lebens\u00a0an\u00a0Brustkrebs.\u00a0I m\u00a0Jahr\u00a02012\u00a0star\u2010\nben\u00a0rund\u00a017.750\u00a0Frauen\u00a0an\u00a0der\u00a0Erkrankung.\u00a0Das\u00a0mittlere\u00a0Erkranku ngsalter\u00a0liegt\u00a0bei\u00a0\n64\u00a0Jahren,\u00a0\u00fcber\u00a0ein\u00a0Viertel\u00a0der\u00a0betroffenen\u00a0Frauen\u00a0sind\u00a0bei\u00a0Dia gnosestellung\u00a0j\u00fcn\u2010\nger\u00a0als\u00a055\u00a0Jahre.\u00a0Durch\u00a0Fortschritte\u00a0in\u00a0der\u00a0Fr\u00fcherkennung\u00a0und\u00a0i n\u00a0der\u00a0Therapie\u00a0\nversterben\u00a0heute\u00a0weniger\u00a0Frauen\u00a0an\u00a0Brustkrebs\u00a0als\u00a0noch\u00a0vor\u00a010\u00a0J ahren.\u00a0Die\u00a0relati\u2010\nve\u00a05\u2010Jahres\u2010\u00dcberlebensrate\u00a0aller\u00a0Frauen\u00a0liegt\u00a0bei\u00a087\u00a0%,\u00a0bei\u00a0Bet roffenen\u00a0mit\u00a0lokal\u00a0\nbegrenzten\u00a0Stadien\u00a0ist\u00a0sie\u00a0deutlich\u00a0h\u00f6her.\u00a0\nMaligne\u00a0Tumore\u00a0des\u00a0Brustdr\u00fcsengew ebes\u00a0k\u00f6nnen\u00a0von\u00a0den\u00a0Epithelien \u00a0der\u00a0Milch\u2010\ng\u00e4nge\u00a0(duktales\u00a0Karzinom)\u00a0oder\u00a0der\u00a0Brustdr\u00fcsenl\u00e4ppchen\u00a0(lobul\u00e4r e\u00a0Karzinome)\u00a0\nausgehen.\u00a0Im\u00a0Gegensatz\u00a0zu\u00a0den\u00a0In\u2010situ\u2010Karzinomen,\u00a0bei\u00a0denen\u00a0die \u00a0malignen\u00a0Zellen\u00a0\nnoch\u00a0nicht\u00a0\u00fcber\u00a0die\u00a0Basalmembran\u00a0hinaus\u00a0gewachsen\u00a0sind,\u00a0haben\u00a0d ie\u00a0Tumorzellen\u00a0\nbeim\u00a0invasiven\u00a0Mammakarzinom\u00a0die\u00a0Basalmembran\u00a0zerst\u00f6rt\u00a0und\u00a0sind \u00a0in\u00a0das\u00a0angren\u2010\nzende\u00a0Gewebe\u00a0eingedrungen.\u00a0Histopathologisch\u00a0sind\u00a080\u00a0bis\u00a085\u00a0%\u00a0d er\u00a0Mammakarzi\u2010\nnome\u00a0invasiv,\u00a0mit\u00a0eine r\u00a0H\u00e4ufigkeit\u00a0von\u00a0\u00fcber\u00a070\u00a0%\u00a0dominiert\u00a0das\u00a0 invasiv\u00a0duktale\u00a0411\u00a0Karzinom\u00a0(Berger\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0Einteilung\u00a0der\u00a0Mammakarzino me\u00a0in\u00a0vier\u00a0Stadi\u2010\nen\u00a0erfolgt\u00a0je\u00a0nach\u00a0Gr\u00f6\u00dfe\u00a0des\u00a0Prim\u00e4rtumors,\u00a0Anzahl\u00a0und\u00a0Ausma\u00df\u00a0de r\u00a0befallenen\u00a0\nLymphknoten\u00a0und\u00a0dem\u00a0Vorliegen\u00a0vo n\u00a0Metastasen.\u00a0Auf\u00a0der\u00a0Basis\u00a0von \u00a0Genexpressi\u2010\nonsmustern\u00a0werden\u00a0mit\u00a0immunhistochemischen\u00a0Markern\u00a0f\u00fcr\u00a0\u00d6strogen \u2010\u00a0und\u00a0Pro\u2010\ngesteronrezeptor\u00a0(HR),\u00a0HER2\u00a0und\u00a0Proliferationsfraktion\u00a0(Marker\u00a0 Ki67)\u00a0vier\u00a0moleku\u2010\nlare\u00a0 Subtypen\u00a0 unterschieden.\u00a0 Neben\u00a0 Tumorgr\u00f6\u00dfe\u00a0 und\u00a0 \u2010ausbreitung\u00a0 sind\u00a0 diese\u00a0\nSubtypen\u00a0entscheidend\u00a0f\u00fcr\u00a0Prognose\u00a0und\u00a0Therapie.\u00a0Bei\u00a0etwa\u00a015\u00a0bi s\u00a020\u00a0%\u00a0der\u00a0Frau\u2010\nen\u00a0mit\u00a0neu\u00a0diagnostiziertem\u00a0Brustkrebs\u00a0und\u00a0etwa\u00a025\u00a0%\u00a0mit\u00a0metast asierter\u00a0Erkran\u2010\nkung\u00a0wird\u00a0eine\u00a0HER2\u2010\u00dcberexpression\u00a0festgestellt.\u00a0Diese\u00a0geht\u00a0mit \u00a0einem\u00a0aggressi\u2010\nveren\u00a0Verlauf,\u00a0einem\u00a0erh\u00f6hten\u00a0Risiko\u00a0f\u00fcr\u00a0fr\u00fche\u00a0Metastasierung,\u00a0 h\u00f6heren\u00a0Rezidiv\u2010\nraten\u00a0und\u00a0erh\u00f6hter\u00a0Sterblichkeit\u00a0 einher\u00a0(W\u00f6rmann\u00a0et\u00a0al.,\u00a02016). \u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIn\u00a0die\u00a0multizentrische,\u00a0unverbli ndet\u00a0durchgef\u00fchrte,\u00a0randomisier te,\u00a0kontrollierte\u00a0\nZulassungsstudie\u00a0EMILIA\u00a0(Sponsor:\u00a0Hoffmann\u2010La\u00a0Roche,\u00a0vormals\u00a0Ge nentech)\u00a0wur\u2010\nden\u00a0991\u00a0Patientinnen\u00a0(986\u00a0Frauen\u00a0und\u00a05\u00a0M\u00e4nner)\u00a0mit\u00a0HER2\u2010postive m,\u00a0lokal\u00a0fortge\u2010\nschrittenem\u00a0 oder\u00a0 metastasiertem\u00a0 Mammakarzinom\u00a0 eingeschlossen,\u00a0 d ie\u00a0 mit\u00a0\nTrastuzumab\u00a0und\u00a0einem\u00a0Taxan\u00a0vorbehandelt\u00a0waren.\u00a0Die\u00a0Vorbehandlu ng\u00a0konnte\u00a0im\u00a0\nadjuvanten\u00a0oder\u00a0im\u00a0inoperablen\u00a0Setting\u00a0erfolgt\u00a0sein.\u00a0F\u00fcr\u00a0den\u00a0Ei nschluss\u00a0in\u00a0die\u00a0\nStudie\u00a0sollte\u00a0die\u00a0Krankheitsprogression\u00a0der\u00a0Patientinnen\u00a0w\u00e4hren d\u00a0oder\u00a0unmittel\u2010\nbar\u00a0nach\u00a0der\u00a0Behandlung\u00a0der\u00a0lokal\u00a0fortgeschrittenen\u00a0oder\u00a0metast asierten\u00a0Erkran\u2010\nkung\u00a0oder\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Mo naten\u00a0nach\u00a0Abschluss\u00a0einer\u00a0adju vanten\u00a0Therapie\u00a0\naufgetreten\u00a0sein\u00a0(Verma\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0Patientinnen\u00a0wurden\u00a0 nach\u00a01:1\u00a0Randomi\u2010\nsierung\u00a0behandelt\u00a0mit\u00a0Trastuzumab\u00a0Emtansin\u00a0(3,6\u00a0mg/kg\u00a0alle\u00a021\u00a0T age)\u00a0oder\u00a0mit\u00a0\nLapatinib\u00a0(1.250\u00a0mg\u00a0oral\u00a0einmal\u00a0t\u00e4glich)\u00a0plus\u00a0Capecitabin\u00a0(1.00 0\u00a0mg/m2\u00a0oral\u00a0zwei\u2010\nmal\u00a0t\u00e4glich\u00a0an\u00a0Tag\u00a01\u00a0bis\u00a014\u00a0im\u00a021\u2010t\u00e4gigen\u00a0Zyklus).\u00a0Voraussetzun g\u00a0f\u00fcr\u00a0die\u00a0Teilnahme\u00a0\nan\u00a0der\u00a0Studie\u00a0war\u00a0ein\u00a0guter\u00a0Allgemeinzustand\u00a0(ECOG\u00a00\u00a0und\u00a01),\u00a0da s\u00a0mediane\u00a0Alter\u00a0\nder\u00a0Patienten\u00a0betrug\u00a053\u00a0Jahre.\u00a0Als\u00a0prim\u00e4re\u00a0Endpunkte\u00a0wurden\u00a0das \u00a0PFS\u00a0und\u00a0das\u00a0OS\u00a0\ngew\u00e4hlt,\u00a0wichtige\u00a0sekund\u00e4re\u00a0Endpunk te\u00a0waren\u00a0die\u00a0objektive\u00a0Anspr echrate\u00a0(Objec\u2010\ntive\u00a0Response\u00a0Rate ,\u00a0ORR)\u00a0und\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0Progression\u00a0der\u00a0Symptome.\u00a0Zus\u00e4tz\u2010\nlich\u00a0wurden\u00a0als\u00a0patientenrelevante\u00a0Endpunkte\u00a0die\u00a0UAE\u00a0und\u00a0die\u00a0HR QoL\u00a0untersucht.\u00a0\nDie\u00a0mediane\u00a0Behandlungsdauer\u00a0war\u00a0im\u00a0Trastuzumab\u00a0Emtansin\u2010Arm\u00a0l\u00e4 nger\u00a0als\u00a0im\u00a0\nLapatinib\u2010Capecitabin\u2010Arm\u00a0(7,6\u00a0Monate\u00a0vs.\u00a05,5\u00a0bzw.\u00a05,3\u00a0Monate\u00a0b eim\u00a0zweiten\u00a0\nDatenschnitt).\u00a0W\u00e4hrend\u00a0der\u00a0Studi e\u00a0wurden\u00a0zwei\u00a0Datenschnitte\u00a0dur chgef\u00fchrt.\u00a0Zum\u00a0\nZeitpunkt\u00a0des\u00a0ersten\u00a0Datenschnittes\u00a0ergab\u00a0die\u00a0final\u2010konfirmator ische\u00a0Analyse\u00a0des\u00a0\nEndpunktes\u00a0PFS,\u00a0dass\u00a0Trastuzumab\u00a0Emtansin\u00a0das\u00a0PFS\u00a0um\u00a03,2\u00a0Monate \u00a0gegen\u00fcber\u00a0\nder\u00a0Vergleichsgruppe\u00a0verl\u00e4ngerte\u00a0( 9,6\u00a0vs.\u00a06,4\u00a0Monate).\u00a0Beim\u00a0nic ht\u00a0geplanten\u00a0zwei\u2010\nten\u00a0Datenschnitt\u00a0sechs\u00a0Monate\u00a0sp\u00e4 ter\u00a0verl\u00e4ngerte\u00a0Trastuzumab\u00a0Em tansin\u00a0auch\u00a0\ndas\u00a0mediane\u00a0Gesamt\u00fcberleben\u00a0(30,9\u00a0vs.\u00a025,1\u00a0Monate).\u00a0Der\u00a0Vorteil \u00a0der\u00a0Behandlung\u00a0\nmit\u00a0Trastuzumab\u00a0Emtansin\u00a0im\u00a0Gesamtergebnis\u00a0zeigte\u00a0sich\u00a0auch\u00a0in\u00a0 der\u00a0Mehrzahl\u00a0412\u00a0der\u00a0zuvor\u00a0spezifizierten\u00a0Subgruppen.\u00a0Allerdings\u00a0war\u00a0bei\u00a0den\u00a0Pat ientinnen\u00a0zwischen\u00a0\n65\u00a0und\u00a074\u00a0Jahren\u00a0(n=113)\u00a0der\u00a0Vorteil\u00a0bez\u00fcglich\u00a0PFS\u00a0und\u00a0OS\u00a0nicht \u00a0mehr\u00a0statistisch\u00a0\nsignifikant,\u00a0und\u00a0bei\u00a0den\u00a0Patientinnen\u00a0\u2265\u00a075\u00a0Jahre\u00a0(n=23)\u00a0zeigte\u00a0 sich\u00a0ein\u00a0Vorteil\u00a0eher\u00a0\nf\u00fcr\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Lapatinib\u00a0plus\u00a0Capecitabin\u00a0(AMB,\u00a02014). \u00a0Schwere\u00a0UAE\u00a0\n(Grad\u00a0\u2265\u00a03)\u00a0kamen\u00a0unter\u00a0Lapatinib\u00a0plus\u00a0Capecitabin\u00a0h\u00e4ufiger\u00a0vor\u00a0 als\u00a0unter\u00a0Trastu\u2010\nzumab\u00a0Emtansin.Im\u00a0Einzelnen\u00a0traten\u00a0unter\u00a0Trastuzumab\u00a0Emtansin\u00a0h \u00e4ufiger\u00a0Throm\u2010\nbozytopenien\u00a0 und\u00a0 erh\u00f6hte\u00a0 Transami nase\u2010Werte\u00a0 auf,\u00a0 dagegen\u00a0 waren\u00a0 Diarrhoe,\u00a0\n\u00dcbelkeit,\u00a0 Erbrechen\u00a0 und\u00a0 Hand\u2010Fu\u00df\u2010Syndrom\u00a0 unter\u00a0 Lapatinib\u00a0 plus\u00a0 C apecitabin\u00a0\nh\u00e4ufiger.\u00a0Unter\u00a0Trastuzumab\u00a0Emtansin\u00a0ergab\u00a0sich\u00a0eine\u00a0Verl\u00e4ngeru ng\u00a0der\u00a0medianen\u00a0\nZeit\u00a0bis\u00a0zur\u00a0Verschlechterung\u00a0der\u00a0HRQoL\u00a0(physisch/funktionale\u00a0K omponente,\u00a0er\u2010\nmittelt\u00a0mit\u00a0der\u00a0TOI\u2010FFB\u00a0Subskala\u00a0des\u00a0FACT\u2010B).\u00a0Dieser\u00a0Vorteil\u00a0wa r\u00a0allerdings\u00a0nur\u00a0in\u00a0\nder\u00a0zahlenm\u00e4\u00dfig\u00a0\u00fcberwiegenden\u00a0S ubgruppe\u00a0der\u00a0kaukasischen\u00a0Patien tinnen\u00a0statis\u2010\ntisch\u00a0signifikant\u00a0und\u00a0aufgrund\u00a0des\u00a0offenen\u00a0Studiendesigns\u00a0kaum\u00a0 aussagekr\u00e4ftig\u00a0\u00a0\n(G\u2010BA,\u00a02014).\u00a0Die\u00a0Ergebnisse\u00a0des\u00a0f\u00fcr\u00a0November\u00a02014\u00a0erwarteten\u00a0A bschlusses\u00a0der\u00a0\ndritten\u00a0Studienphase\u00a0wurden\u00a0noch\u00a0nicht\u00a0ver\u00f6ffentlicht.\u00a0\nIn\u00a0 eine\u00a0 weitere\u00a0 offene,\u00a0 randomisierte,\u00a0 kontrollierte\u00a0 Phase\u2010III\u2010 Studie\u00a0 (TH3RESA)\u00a0\nwurden\u00a0602\u00a0Patientinnen\u00a0mit\u00a0metastasiertem\u00a0HER2\u2010positiven\u00a0Mamma karzinom\u00a0\neingeschlossen,\u00a0die\u00a0zuvor\u00a0schon\u00a0mindestens\u00a0zwei\u00a0anti\u2010HER2\u2010geric htete\u00a0Therapien\u00a0\nmit\u00a0Trastuzumab\u00a0oder\u00a0Lapatinib\u00a0sowie\u00a0Taxane\u00a0erhalten\u00a0hatten\u00a0(Kr op\u00a0et\u00a0al.,\u00a02014).\u00a0\nNach\u00a0 einer\u00a0 2:1\u2010Randomisierung\u00a0 wurden\u00a0 404\u00a0 Patientinnen\u00a0 mit\u00a0 Trast uzumab\u00a0\nEmtansin\u00a0(3,6\u00a0mg/kg\u00a0alle\u00a021\u00a0Tage)\u00a0und\u00a0198\u00a0Patientinnen\u00a0mit\u00a0eine r\u00a0Therapie\u00a0nach\u00a0\nWahl\u00a0des\u00a0Pr\u00fcfarztes,\u00a0\u00fcberwiegend\u00a0Trastuzumab\u00a0plus\u00a0Chemotherapie ,\u00a0\u00fcber\u00a0einen\u00a0\nZeitraum\u00a0von\u00a018\u00a0Monaten\u00a0behandelt.\u00a0Ein\u00a0 Cross\u2010Over \u00a0war\u00a0m\u00f6glich,\u00a044\u00a0Patientinnen\u00a0\nwechselten\u00a0aus\u00a0dem\u00a0Vergleichs\u2010\u00a0in\u00a0den\u00a0Therapiearm\u00a0mit\u00a0Trastuzum ab\u00a0Emtansin.\u00a0\nPrim\u00e4re\u00a0Endpunkte\u00a0waren\u00a0das\u00a0PFS\u00a0und\u00a0das\u00a0OS.\u00a0Die\u00a0Therapie\u00a0mit\u00a0Tr astuzumab\u00a0\nEmtansin\u00a0verl\u00e4ngerte\u00a0das\u00a0PFS\u00a0gegen\u00fcber\u00a0der\u00a0Therapie\u00a0nach\u00a0Wahl\u00a0d es\u00a0Arztes\u00a0statis\u2010\ntisch\u00a0signifikant\u00a0um\u00a02,9\u00a0Monate\u00a0(6,2\u00a0Monate\u00a0vs.\u00a03,3\u00a0Monate).\u00a0Da s\u00a0mediane\u00a0OS\u00a0war\u00a0\nzum\u00a0 Zeitpunkt\u00a0 der\u00a0 Interimsanalyse\u00a0 im\u00a0 Trastuzumab\u00a0 Emtansin\u2010Arm\u00a0 n och\u00a0 nicht\u00a0\nerreicht.\u00a0Unter\u00a0Trastuzumab\u00a0Emta nsin\u00a0traten\u00a0als\u00a0schwerwiegende\u00a0 UAE\u00a0(Grad\u00a0\u2265\u00a03)\u00a0\nh\u00e4ufiger\u00a0Thrombozytopenien\u00a0als\u00a0im\u00a0Vergleichsarm\u00a0auf,\u00a0unter\u00a0der\u00a0 Vergleichsthera\u2010\npie\u00a0kam\u00a0es\u00a0h\u00e4ufiger\u00a0zu\u00a0schwerwiegenden\u00a0Neutropenien,\u00a0febrilen\u00a0N eutropenien\u00a0\nund\u00a0Diarrhoen.\u00a0Insgesamt\u00a0waren\u00a0die\u00a0schwerwiegende\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03 )\u00a0unterTrastu\u2010\nzumab\u00a0Emtansin\u00a0seltener.\u00a0\nLeitlinienempfehlungen\u00a0\nDas\u00a0 Behandlungskonzept\u00a0 f\u00fcr\u00a0 das\u00a0 Mammakarzinom\u00a0 richtet\u00a0 sich\u00a0 nach\u00a0 dem\u00a0 Tu\u2010\nmorstadium\u00a0und\u00a0der\u00a0Histopatholog ie\u00a0einschlie\u00dflich\u00a0der\u00a0Immunhist ologie\u00a0und\u00a0be\u2010\ninhaltet\u00a0sowohl\u00a0die\u00a0lokalen\u00a0Verfahren\u00a0Operation\u00a0und\u00a0Bestrahlung \u00a0als\u00a0auch\u00a0die\u00a0\nsystemische\u00a0Therapie\u00a0mit\u00a0konventionellen\u00a0Zytostatika,\u00a0zielgeric hteten\u00a0Arzneimit\u2010\nteln\u00a0(Monoklonale\u00a0Antik\u00f6rper,\u00a0Ty rosinkinasehemmstoffe)\u00a0und\u00a0Anti hormonen.\u00a0F\u00fcr\u00a0413\u00a0Deutschland\u00a0werden\u00a0von\u00a0der\u00a0Arbeitsgemeinschaft\u00a0Gyn\u00e4kologische\u00a0O nkologie\u00a0e.V.\u00a0\n(AGO)\u00a0j\u00e4hrlich\u00a0evidenzbasierte\u00a0Leitlinien\u00a0erstellt\u00a0(AGO,\u00a0n.d.). \u00a0W\u00e4hrend\u00a0im\u00a0lokal\u00a0\nbegrenzten,\u00a0im\u00a0lokal\u00a0fortgeschrittenen\u00a0und\u00a0im\u00a0lokal\u00a0rezidiviert em\u00a0Stadium\u00a0I\u00a0bis\u00a0III\u00a0\ndie\u00a0Therapieintention\u00a0kurativ\u00a0ist,\u00a0wird\u00a0das\u00a0Stadium\u00a0IV\u00a0mit\u00a0Auft reten\u00a0von\u00a0Fernmeta\u2010\nstasen\u00a0palliativ\u00a0behandelt\u00a0mit\u00a0dem \u00a0Ziel\u00a0der\u00a0Symptomlinderung\u00a0un d\u00a0Verl\u00e4ngerung\u00a0\nder\u00a0progressionsfreien\u00a0\u00dcberlebenszeit.\u00a0Die\u00a0Intensit\u00e4t\u00a0der\u00a0multi modalen\u00a0Therapie\u00a0\u2013\u00a0\nund\u00a0hier\u00a0vor\u00a0allem\u00a0die\u00a0Auswahl\u00a0der\u00a0verwendeten\u00a0Medikamente\u00a0\u2013\u00a0h\u00e4 ngt\u00a0von\u00a0der\u00a0\nAggressivit\u00e4t\u00a0der\u00a0Erkrankung,\u00a0dem\u00a0Hormon\u2010\u00a0und\u00a0HER2\u2010Rezeptorstat us,\u00a0vorherigen\u00a0\nBehandlungen,\u00a0 von\u00a0 Begleiterkrankungen,\u00a0 vom\u00a0 Allgemeinzustand\u00a0 und \u00a0v o n \u00a0d e n \u00a0\nW\u00fcnschen\u00a0der\u00a0Patientinnen\u00a0ab.\u00a0\nBei\u00a0Patientinnen\u00a0mit\u00a0lokal\u00a0fortgeschrittenen\u00a0Karzinomen\u00a0(Stadiu m\u00a0IIB\u00a0und\u00a0III)\u00a0gibt\u00a0\nes\u00a0in\u00a0der\u00a0Regel\u00a0eine\u00a0Indikation\u00a0z ur\u00a0konventionellen\u00a0Chemotherap ie,\u00a0bei\u00a0HER2\u2010\npositiven\u00a0Karzinomen\u00a0wird\u00a0diese\u00a0 mit\u00a0gezielter\u00a0Anti\u2010HER2\u2010Therapi e\u00a0kombiniert.\u00a0Wie\u00a0\nzur\u00a0adjuvanten\u00a0Therapie\u00a0werden\u00a0auch\u00a0bei\u00a0inoperablen\u00a0Karzinomen\u00a0 Anthrazykline\u00a0\nund\u00a0Taxane\u00a0\u00fcber\u00a0eine\u00a0Behandlungsdauer\u00a0von\u00a0mindestens\u00a018\u00a0Wochen\u00a0 eingesetzt.\u00a0\nBei\u00a0 Nicht\u2010Ansprechen\u00a0 w\u00e4hrend\u00a0 zweier\u00a0 Zyklen\u00a0 einer\u00a0 solchen\u00a0 Anthra zyklin\u2010\u00a0 und\u00a0\nTaxan\u2010haltigen\u00a0Chemotherapie\u00a0ka nn\u00a0auf\u00a0ein\u00a0weniger\u00a0toxisches\u00a0Sch ema\u00a0mit\u00a0Vino\u2010\nrelbin\u00a0und\u00a0Capecitabin\u00a0gewechselt\u00a0werden\u00a0(W\u00f6rmann\u00a0et\u00a0al.,\u00a02016) .\u00a0Zus\u00e4tzlich\u00a0wird\u00a0\nTrastuzumab\u00a0\u00fcber\u00a0ein\u00a0Jahr\u00a0gegeben,\u00a0in\u00a0der\u00a0Regel\u00a0simultan\u00a0zu\u00a0Tax anen\u00a0und,\u00a0wegen\u00a0\ndes\u00a0erh\u00f6hten\u00a0Kardiomyopathie\u2010Risikos,\u00a0sequentiell\u00a0zu\u00a0Anthrazykl inen.\u00a0\nBeim\u00a0metastasierten\u00a0HER2\u2010positiven\u00a0Mammakarzinom\u00a0kommen\u00a0neben\u00a0l okalthe\u2010\nrapeutischen\u00a0Ma\u00dfnahmen\u00a0(Operation,\u00a0Bestrahlung)\u00a0ebenfalls\u00a0Anthr azykline\u00a0und\u00a0\nTaxane\u00a0als\u00a0Zytostatika\u00a0der\u00a0ersten\u00a0Wahl\u00a0zum\u00a0Einsatz,\u00a0auch\u00a0beim\u00a0R ezidiv\u00a0nach\u00a0Anth\u2010\nrazyklin\u2010\u00a0 und/oder\u00a0 Taxan\u2010haltiger\u00a0 Chemotherapie.\u00a0 Neben\u00a0 Trastuzu mab\u00a0 finden\u00a0\nauch\u00a0Pertuzumab\u00a0und\u00a0Lapatinib\u00a0als\u00a0gezielt\u00a0gegen\u00a0HER2\u00a0gerichtete \u00a0Wirkstoffe\u00a0An\u2010\nwendung.\u00a0Bei\u00a0Chemotherapie\u2010geeigneten\u00a0Patientinnen\u00a0ist\u00a0mittlerw eile,\u00a0unabh\u00e4n\u2010\ngig\u00a0vom\u00a0Hormonrezeptor\u2010Status,\u00a0die\u00a0Kombination\u00a0aus\u00a0Docetaxel\u00a0un d\u00a0einer\u00a0dualen\u00a0\nzielgerichteten\u00a0Therapie\u00a0aus\u00a0Per tuzumab\u00a0und\u00a0Trastuzumab\u00a0klinisc her\u00a0Standard.\u00a0Bei\u00a0\nnicht\u00a0f\u00fcr\u00a0Chemotherapie\u00a0geeigneten\u00a0Patientinnen\u00a0mit\u00a0positivem\u00a0H R\u2010Status\u00a0wird\u00a0\nTrastuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0einem\u00a0Aromatase\u2010Hemmstoff\u00a0angewe ndet,\u00a0HR\u2010\nnegative\u00a0Patientinnen\u00a0erhalten\u00a0Trastuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0L apatinib\u00a0oder\u00a0\nnur\u00a0Lapatinib.\u00a0Bei\u00a0Refraktarit\u00e4t,\u00a0Progress\u00a0oder\u00a0Unvertr\u00e4glichke it\u00a0kommt\u00a0leitlinien\u2010\ngerecht\u00a0Trastuzumab\u00a0Emtansin\u00a0zum \u00a0Einsatz,\u00a0bei\u00a0Chemotherapie\u2010gee igneten\u00a0Pati\u2010\nentinnen\u00a0alternativ\u00a0zur\u00a0Kombination\u00a0von\u00a0Capecitabin\u00a0mit\u00a0Lapatin ib.\u00a0Sowohl\u00a0die\u00a0\nChemotherapie\u00a0als\u00a0auch\u00a0die\u00a0Anti\u2010HER2\u2010Therapie\u00a0sollte\u00a0bis\u00a0zum\u00a0Pr ogress\u00a0oder\u00a0bis\u00a0\nzum\u00a0Auftreten\u00a0intolerabler\u00a0Neben wirkungen\u00a0fortgef\u00fchrt\u00a0werden.\u00a0\n\u00a0414\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nW\u00e4hrend\u00a0der\u00a0pU\u00a0die\u00a0Vergleichstherapie\u00a0Lapatinib\u00a0plus\u00a0Capecitabi n\u00a0f\u00fcr\u00a0die\u00a0gesamte\u00a0\nZielpopulation\u00a0heranzieht\u00a0und\u00a0di e\u00a0EMILIA\u2010Studie\u00a0auf\u00a0Basis\u00a0der\u00a0G esamtpopulation\u00a0\nin\u00a0sein\u00a0Dossier\u00a0f\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0einschlie\u00dft,\u00a0legt \u00a0der\u00a0G\u2010BA\u00a0unter\u2010\nschiedliche\u00a0zVT\u00a0f\u00fcr\u00a0vier\u00a0Teilpopulationen\u00a0fest\u00a0(G\u2010BA,\u00a02014).\u00a0De r\u00a0G\u2010BA\u00a0sieht\u00a0f\u00fcr\u00a0\nseine\u00a0Nutzenbewertung\u00a0nur\u00a0die\u00a0Patientengruppe\u00a0b\u00a0(n=605\u00a0bzw.\u00a061\u00a0 %\u00a0der\u00a0einge\u2010\nschlossenen\u00a0Patienten)\u00a0als\u00a0relevant\u00a0an,\u00a0die\u00a0wegen\u00a0HER2\u2010positive m\u00a0metastasiertem\u00a0\nBrustkrebs\u00a0in\u00a0einer\u00a0vorangegange nen\u00a0Therapie\u00a0Trastuzumab,\u00a0Taxan e\u00a0und\u00a0Anth\u2010\nrazykline\u00a0erhalten\u00a0hatte,\u00a0da\u00a0nur \u00a0f\u00fcr\u00a0diese\u00a0Teilpopulation\u00a0die\u00a0V ergleichstherapie\u00a0\nLapatinib\u00a0plus\u00a0Capecitabin\u00a0zulassungskonform\u00a0eingesetzt\u00a0wurde.\u00a0 F\u00fcr\u00a0diese\u00a0Patien\u2010\nten\u00a0stuft\u00a0der\u00a0G\u2010BA\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0Trastuzumab \u00a0Emtansin\u00a0\ngegen\u00fcber\u00a0der\u00a0zVT\u00a0aufgrund\u00a0der\u00a0mo deraten\u00a0Verl\u00e4ngerung\u00a0des\u00a0OS,\u00a0d er\u00a0bedeutsa\u2010\nmen\u00a0Vermeidung\u00a0relevanter\u00a0UAE\u00a0und\u00a0 des\u00a0positiven\u00a0Einflusses\u00a0auf\u00a0 die\u00a0HRQoL\u00a0als\u00a0\nbetr\u00e4chtlich\u00a0ein.\u00a0Er\u00a0sieht\u00a0allerdings\u00a0nur\u00a0einen\u00a0 Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen\u00a0\nZusatznutzen ,\u00a0da\u00a0lediglich\u00a0eine\u00a0unverblindete\u00a0Studie\u00a0mit\u00a0hohem\u00a0Verzerrungsp o\u2010\ntential\u00a0zu\u00a0den\u00a0Endpunkten\u00a0UAE\u00a0und\u00a0HRQoL\u00a0im\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nu tzenbewer\u2010\ntung\u00a0vorliegt.\u00a0F\u00fcr\u00a0die\u00a0anderen\u00a0drei\u00a0Teilpopulationen\u00a0gilt\u00a0der\u00a0 Zusatznutzen \u00a0auf\u2010\ngrund\u00a0fehlender\u00a0Daten\u00a0zum\u00a0Ve rgleich\u00a0mit\u00a0der\u00a0zVT\u00a0als\u00a0 nicht\u00a0belegt .\u00a0\nVersorgungsanalysen\u00a0\nDas\u00a0Antik\u00f6rper\u2010Wirkstoff\u2010Konjugat\u00a0Trastuzumab\u00a0Emtansin\u00a0wurde\u00a0fa st\u00a0ausschlie\u00df\u2010\nlich\u00a0als\u00a0Rezeptur\u00a0abgerechnet\u00a0und\u00a0erreichte\u00a0unmittelbar\u00a0nach\u00a0se iner\u00a0Markteinf\u00fch\u2010\nrung\u00a0im\u00a0Januar\u00a02014\u00a0ein\u00a0relativ\u00a0konstantes\u00a0Verordnungsplateau\u00a0\u00fc ber\u00a0den\u00a0gesam\u2010\nten\u00a0 Beobachtungszeitraum\u00a0 mit\u00a0 einem\u00a0 monatlichen\u00a0 Bruttoumsatz\u00a0 von \u00a0e t w a \u00a0\n650.000\u00a0Euro.\u00a0\u00dcber\u00a0200\u00a0Versicherte\u00a0der\u00a0TK\u00a0wurden\u00a0mit\u00a0dem\u00a0neuen\u00a0 Wirkstoff\u00a0be\u2010\nhandelt.\u00a0Aufgrund\u00a0des\u00a0Indikationsgebietes\u00a0handelt\u00a0es\u00a0sich\u00a0aussc hlie\u00dflich\u00a0um\u00a0Frau\u2010\nen\u00a0\u00fcberwiegend\u00a0mittleren\u00a0und\u00a0h\u00f6heren\u00a0Alters\u00a0mit\u00a0einem\u00a0Maximum\u00a0i n\u00a0der\u00a0Gruppe\u00a0\nder\u00a050\u00a0bis\u00a059\u2010J\u00e4hrigen.\u00a0\n\u00a0\n\u00a0 \u00a0415\u00a0Abbildung\u00a04.52:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Trastuzu mab\u00a0\nEmtansin\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nAbbildung\u00a04.53:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Trastuzumab\u00a0Emtans in\u00a0je\u00a0\nMonat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n416\u00a0Quellen\u00a0\nAGO\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0Gyn\u00e4kologische\u00a0Onkologie\u00a0e.V.\u00a0Online\u00a0 (n.d.).Empfehlungen\u00a0gyn\u00e4kologische\u00a0Onkologie\u00a0Kommission\u00a0\nMamma.\u00a0 www.ago\u2010online.de/de/infothek\u2010fuer\u2010aerzte/leitlinienempfehlunge n/mamma/, \u00a0letzter\u00a0Zugriff:\u00a011.09.2017.\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2014).\u00a0Neues\u00a0onkologisches\u00a0Arzneim ittel:\u00a0Trastuzumab\u00a0Emtansin.\u00a0 https://www.der\u2010\narzneimittelbrief.de/de/Artikel.aspx?J=2014&S=18 ,\u00a0letzter\u00a0Zugriff:\u00a022.06.2017.\u00a0\nBerger\u00a0DP,\u00a0Engelhardt\u00a0R,\u00a0Mertelsmann\u00a0R\u00a0(2014).\u00a0Das\u00a0rote\u00a0Buch.\u00a0e comed\u00a0MEDIZIN.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2017).\u00a0Kadcyla.\u00a0trastuzumab\u00a0em tansine.\u00a0www.ema.europa.eu/ema/inde x.jsp?curl=pages/medic\u00a0\nines/human/medicines/002389/human _med_001712.jsp&mid=WC0b01ac05 8001d124 ,\u00a0letzter\u00a0Zugriff:\u00a009.06.2017.\u00a0\nFachinformation\u00a0Kadcyla\u00ae\u00a0(2016).\u00a0 Fachinformation\u00a0Kadcyla\u00ae\u00a0Stand \u00a0der\u00a0Information:\u00a0Oktober\u00a02016.\u00a0\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0\nArzneimittel\u2010Richtlinie\u00a0(AM\u2010RL) :\u00a0Anlage\u00a0XII\u00a0\u2010Beschl\u00fcsse\u00a0\u00fcber\u00a0di e\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Trastuzumab\u00a0Emtansin.\u00a0 https://www.g\u2010ba.de/downloads/39\u2010261\u201020\u00a008/2014\u201006\u2010\n19_AM\u2010RL\u2010XII_Trastuzumab\u2010Emtansin_2014\u201001\u201001\u2010D\u2010084_BAnz.pdf ,\u00a0letzter\u00a0Zugriff:\u00a022.06.2017.\u00a0\u00a0\nKrop\u00a0IE,\u00a0Kim,\u00a0SB,\u00a0Gonz\u00e1lez\u2010Mart\u00ed n\u00a0A,\u00a0LoRusso\u00a0PM,\u00a0Ferrero\u00a0JM,\u00a0Sm itt\u00a0M\u00a0et\u00a0al.\u00a0(2014).\u00a0Trastuzumab\u00a0emtansine\u00a0versus\u00a0treatment\u00a0of\u00a0\nphysician\u2019s\u00a0choice\u00a0for\u00a0pretreated\u00a0HER2\u2010positive\u00a0advanced\u00a0breast \u00a0cancer\u00a0(TH3RESA):\u00a0a\u00a0randomised,\u00a0open\u2010label,\u00a0phase\u00a0\n3\u00a0trial.\u00a0Lancet\u00a0Oncol\u00a015(7):\u00a0689\u2010699.\u00a0\u00a0\nPrescrire\u00a0International\u00a0(2014).\u00a0An\u00a0inadequately\u00a0assessed\u00a0combin ation\u00a0of\u00a0two\u00a0cytotoxic\u00a0drugs.\u00a0Prescrire\u00a0Int\u00a023(155):\u00a0289.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Arzneistoffe:\u00a0Trast uzumab\u00a0Emtansin|Kadcyla\u00ae|86|2014.\u00a0 www.pharmazeutische\u2010\nzeitung.de/?id=50894 ,\u00a0letzter\u00a0Zugriff:\u00a015.06.2017.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2015) .\u00a0Krebs\u00a0in\u00a0Deutschland\u00a02011/20 12.\u00a010.\u00a0Ausgabe.\u00a0Robert\u00a0Koch\u2010Institut\u00a0(Hrsg)\u00a0und\u00a0die\u00a0Gesellscha ft\u00a0\nder\u00a0epidemiologischen\u00a0Krebsregister\u00a0in\u00a0Deutschland\u00a0e.V.\u00a0(Hrsg). \u00a0Berlin,\u00a02015.\u00a0\nVerma\u00a0S,\u00a0Miles\u00a0D,\u00a0Gianni\u00a0L,\u00a0Krop \u00a0IE,\u00a0Welslau\u00a0M,\u00a0Baselga\u00a0J\u00a0et\u00a0al .\u00a0(2012).\u00a0Trastuzumab\u00a0Emtansine\u00a0for\u00a0HER2\u2010Positive\u00a0Advanced\u00a0Brea st\u00a0\nCancer.\u00a0NEJM\u00a0367(19):\u00a01783\u20101791.\u00a0\u00a0\nW\u00f6rmann\u00a0B,\u00a0Aebi\u00a0S,\u00a0Decker\u00a0T,\u00a0Fehm\u00a0T,\u00a0Greil\u00a0R,\u00a0Harbeck\u00a0N\u00a0et\u00a0al.\u00a0 (2016).\u00a0Mammakarzinom\u00a0der\u00a0Frau.\u00a0Onkopedia\u00a0Leitlinien.\u00a0DGHO\u00a0\nDeutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0H\u00e4matologie\u00a0und\u00a0Medizinische\u00a0Onkologi e\u00a0e.V.\u00a0\nhttps://www.onkopedia.com/de/onkopedia/guidelines/mammakarzinom \u2010der\u2010\nfrau/@@view/pdf/index.pdf?filename=mammakarzinom\u2010der\u2010frau.pdf ,\u00a0letzter\u00a0Zugriff:\u00a011.09.2017.\u00a0\n\u00a0 \u00a0417\u00a04.29 Turoctocog\u00a0alfa\u00a0\nHandelsname:\u00a0NovoEight\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0H\u00e4mophilie\u00a0A\u00a0 \u00a0 \u00a0 Novo\u00a0Nordisk\u00a0 \u00a0\nATC\u2010Code:\u00a0B02BD16\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02014\u00a0\nDarreichungsform:\u00a0Pulver\u00a0zur\u00a0Herstellung\u00a0\neiner\u00a0Injektionsl\u00f6sung\u00a0 \u00a0 \u00a0 DDD:\u00a0100\u00a0I.E.\u00a0parenteral\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nTuroctocog\u00a0alfa\u00a0(NovoEight \u00ae)\u00a0ist\u00a0ein\u00a0rekombinanter\u00a0humaner\u00a0Blutgerinnungsfaktor\u00a0\nVIII,\u00a0der\u00a0in\u00a0genetisch\u00a0ver\u00e4ndert en\u00a0Ovarialzelllinien\u00a0des\u00a0chines ischen\u00a0Hamsters\u00a0herge\u2010\nstellt\u00a0wird.\u00a0Im\u00a0Hinblick\u00a0auf\u00a0den\u00a0Wirkungsmechanismus\u00a0gibt\u00a0es\u00a0ke ine\u00a0Unterschiede\u00a0zu\u00a0\naus\u00a0Plasma\u00a0isoliertem\u00a0humanen\u00a0Faktor\u00a0VIII\u00a0(EMA,\u00a02013).\u00a0\u00a0\nDas\u00a0Fertigarzneimittel,\u00a0das\u00a0nach\u00a0Rekonstitution\u00a0intraven\u00f6s\u00a0vera breicht\u00a0wird,\u00a0steht\u00a0\nin\u00a0sechs\u00a0verschiedenen\u00a0Konzentra tionen\u00a0zur\u00a0Verf\u00fcgung.\u00a0Turoctoco g\u00a0alfa\u00a0ist\u00a0zur\u00a0\nBehandlung\u00a0und\u00a0Prophylaxe\u00a0von\u00a0Blutungen\u00a0bei\u00a0Patienten\u00a0mit\u00a0H\u00e4mop hilie\u00a0A\u00a0bei\u00a0\nallen\u00a0Altersgruppen\u00a0zugelassen.\u00a0D ie\u00a0zu\u00a0verabreichende\u00a0Dosis\u00a0h\u00e4n gt\u00a0vom\u00a0Schwere\u2010\ngrad\u00a0des\u00a0Faktor\u2010VIII\u2010Mangels,\u00a0Art \u00a0der\u00a0Behandlung\u00a0(Bedarfstherap ie\u00a0oder\u00a0Prophyla\u2010\nxe),\u00a0Ort\u00a0und\u00a0Ausma\u00df\u00a0der\u00a0Blutung\u00a0und\u00a0dem\u00a0klinischen\u00a0Zustand\u00a0des\u00a0 Patienten\u00a0ab.\u00a0\nBisher\u00a0liegen\u00a0zur\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0nur\u00a0Daten\u00a0aus\u00a0hers teller\u2010gespon\u2010\nserten\u00a0 Studien\u00a0 mit\u00a0 Patienten\u00a0 vor,\u00a0 die\u00a0 bereits\u00a0 zuvor\u00a0 mit\u00a0 Faktor\u2010 VIII\u2010Pr\u00e4paraten\u00a0\nbehandelt\u00a0wurden.\u00a0Die\u00a0Wirksamkeit\u00a0belegte\u00a0der\u00a0pharmazeutische\u00a0U nternehmer\u00a0\n(pU)\u00a0mit\u00a0zwei\u00a0unkontrollierten\u00a0Studien\u00a0an\u00a0150\u00a0Jugendlichen\u00a0und\u00a0 Erwachsenen\u00a0\n(Guardian\u2122\u00a01)\u00a0(Lentz\u00a0et\u00a0al.,\u00a02013)\u00a0sowie\u00a063\u00a0Kindern\u00a0(Guardian\u2122\u00a0 3)\u00a0(Kulkarni\u00a0et\u00a0al.,\u00a0\n2013).\u00a0In\u00a0beiden\u00a0Studien\u00a0wurde\u00a0nur\u00a0die\u00a0prophylaktische\u00a0Behandlu ng\u00a0sowie\u00a0die\u00a0\nTherapie\u00a0von\u00a0Durchbruchblutungen\u00a0untersucht,\u00a0nicht\u00a0jedoch\u00a0die\u00a0a nlassbezogene\u00a0\nBehandlung\u00a0( on\u00a0demand ).\u00a0Die\u00a0mittlere\u00a0j\u00e4hrliche\u00a0Blutung srate\u00a0pro\u00a0Patient\u00a0lag\u00a0in\u00a0Gua\u2010\nrdian\u2122\u00a01\u00a0bei\u00a06,5,\u00a0in\u00a0Guardian\u2122\u00a03\u00a0bei\u00a05,33.\u00a0Die\u00a0insgesamt\u00a0499\u00a0Bl utungsepisoden\u00a0in\u00a0\nGuardian\u2122\u00a01\u00a0lie\u00dfen\u00a0sich\u00a0in\u00a081\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0ausgezeichnet\u00a0oder\u00a0gu t\u00a0mit\u00a0Turoctocog\u00a0alfa\u00a0\nbehandeln,\u00a0von\u00a0den\u00a0126\u00a0Blutungsepisoden\u00a0in\u00a0Guardian\u2122\u00a03\u00a0traf\u00a0das \u00a0auf\u00a092\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0\nzu.\u00a0 In\u00a0 beiden\u00a0 Studien\u00a0 wurden\u00a0 Daten\u00a0 zur\u00a0 gesundheitsbezogenen\u00a0 Leb ensqualit\u00e4t\u00a0\n(Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0erhoben,\u00a0es\u00a0ergab\u00a0sich\u00a0allerdings\u00a0kein\u00a0Unter\u2010\nschied\u00a0zwischen\u00a0Beginn\u00a0und\u00a0Ende\u00a0der\u00a0Studie.\u00a0Vergleiche\u00a0mit\u00a0ande ren\u00a0Faktor\u2010VIII\u2010\nPr\u00e4paraten\u00a0fehlen\u00a0(EMA,\u00a02013).\u00a0\nDie\u00a0Guardian\u2122\u00a02\u2010Studie,\u00a0eine\u00a0Er weiterungsstudie\u00a0aller\u00a0bisherige n\u00a0Studien\u00a0mit\u00a0213\u00a0\nPatienten\u00a0(Kinder,\u00a0Jugendliche\u00a0und\u00a0Erwachsene),\u00a0war\u00a0zum\u00a0Zeitpun kt\u00a0der\u00a0Zulassung\u00a0\nnoch\u00a0nicht\u00a0abgeschlossen\u00a0(Lentz\u00a0et\u00a0al.,\u00a02016).\u00a0Inzwischen\u00a0liege n\u00a0im\u00a0europ\u00e4ischen\u00a0\nStudienregister\u00a0aber\u00a0einige\u00a0Ergebnisse\u00a0vor:\u00a0Der\u00a0gr\u00f6\u00dfte\u00a0Teil\u00a0der \u00a0Probanden\u00a0erhielt\u00a0418\u00a0eine\u00a0prophylaktische\u00a0Behandlung.\u00a0Die\u00a0j\u00e4hrliche\u00a0Blutungsrate\u00a0pro \u00a0Patient\u00a0lag\u00a0im\u00a0\nMedian\u00a0je\u00a0nach\u00a0Altersgruppe\u00a0zwischen\u00a01,08\u00a0und\u00a01,57.\u00a0Die\u00a0insgesa mt\u00a01.782\u00a0Blu\u2010\ntungsepisoden\u00a0lie\u00dfen\u00a0sich\u00a0je\u00a0nach\u00a0Altersgruppe\u00a0in\u00a088\u00a0bis\u00a091\u00a0%\u00a0d er\u00a0F\u00e4lle\u00a0erfolgreich\u00a0\n(Bewertung\u00a0ausgezeichnet\u00a0oder\u00a0gut)\u00a0behandeln.\u00a022\u00a0Patienten\u00a0erhi elten\u00a0eine\u00a0an\u2010\nlassbezogene\u00a0Behandlung.\u00a0Bei\u00a097\u00a0%\u00a0der\u00a0391\u00a0Blutungsepisoden\u00a0wurd e\u00a0ein\u00a0ausge\u2010\nzeichneter\u00a0oder\u00a0guter\u00a0Behandlung seffekt\u00a0erzielt\u00a0(EMA,\u00a02013).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0der\u00a0Sicherheit\u00a0lagen\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Zulass ung\u00a0Daten\u00a0zu\u00a0214\u00a0\nPatienten\u00a0mit\u00a0insgesamt\u00a0rund\u00a033.000\u00a0Expositionstagen\u00a0vor.\u00a0H\u00e4ufi ge\u00a0unerw\u00fcnschte\u00a0\nArzneimittelwirkungen\u00a0waren\u00a0Reakt ionen\u00a0an\u00a0der\u00a0Injektionsstelle\u00a0 und\u00a0ein\u00a0Anstieg\u00a0\nder\u00a0Leberenzyme.\u00a0In\u00a0keiner\u00a0der\u00a0b isher\u00a0abgeschlossenen\u00a0Studien\u00a0w urde\u00a0die\u00a0Bildung\u00a0\nneutralisierender\u00a0Antik\u00f6rper\u00a0beobachtet\u00a0(EMA,\u00a02013).\u00a0 Als\u00a0neuer\u00a0Wirkstoff\u00a0steht\u00a0\nTuroctocog\u00a0alfa\u00a0unter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung.\u00a0 Im\u00a0Juli\u00a02016\u00a0startete\u00a0die\u00a0 Euro\u2010\npean\u00a0Medicines\u00a0Agency \u00a0(EMA)\u00a0ein\u00a0Risikobewertungsverfahren\u00a0f\u00fcr\u00a0alle\u00a0Faktor\u2010VIII\u2010\nProdukte\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Entwicklung\u00a0neutralisierender\u00a0Anti k\u00f6rper,\u00a0die\u00a0die\u00a0\nWirksamkeit\u00a0der\u00a0Gerinnungsfaktore n\u00a0verringern\u00a0k\u00f6nnen\u00a0(EMA,\u00a02016 ).\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0war\u00a0 kein\u00a0Zusatznutzen \u00a0feststellbar,\u00a0da\u00a0\nder\u00a0pU\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0vorlegte\u00a0(G\u2010BA,\u00a02014).\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\nWeitere\u00a0Therapieoption\u00a0\nf\u00fcr\u00a0Patienten\u00a0mit\u00a0\nH\u00e4mophilie\u00a0A\u00a0\n(Prophylaxe\u00a0und\u00a0\nBehandlung\u00a0von\u00a0\nBlutungsepisoden)\u00a0Keine\u00a0therapeutisch\u00a0\nrelevanten\u00a0Vorteile,\u00a0es\u00a0\nfehlen\u00a0Vergleichs\u2010\nstudien\u00a0mit\u00a0anderen\u00a0\nFaktor\u2010VIII\u2010Pr\u00e4paraten\u00a0\u00fcberwiegend\u00a0teurer\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0 \u00a0\n419\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nTuroctocoq\u00a0alfa1\u00a0 20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n50\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E3\u00a0\n50\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E3\u00a0\n\u00a0156\u00a0\n183\u00a0\n156\u00a0\n183\u00a0\n\u00a0194.220,00\u00a0\u20ac\u00a0\n227.835,00\u00a0\u20ac\u00a0\n485.550,00\u00a0\u20ac\u00a0\n569.587,50\u00a0\u20ac\u00a0\nVergleichstherapie\u00b2 \u00a0 \u00a0 \u00a0 \u00a0\nOctocog\u00a0alfa\u00a0\u00a0 20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E3\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E3\u00a0\n\u00a0122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0197.640,00\u00a0\u20ac\u00a0\n296.460,00\u00a0\u20ac\u00a0\n395.280,00\u00a0\u20ac\u00a0\n592.920,00\u00a0\u20ac\u00a0\nMoroctocog\u00a0alfa\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nSimoctocog\u00a0alfa\u00a020\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E1\u00a0\n\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n20\u00a0i.E\u00a0/kg\u00a0/\u00a01.440\u00a0i.E3\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02.880\u00a0i.E3\u00a0\n40\u00a0i.E\u00a0/kg\u00a0/\u00a02\u00a0880\u00a0i.E3\u00a0122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0\n\u00a0\n122\u00a0\n183\u00a0\n122\u00a0\n183\u00a0177.510,00\u00a0\u20ac4\u00a0\n266.265,00\u00a0\u20ac4\u00a0\n355.020,00\u00a0\u20ac4\u00a0\n532.530,00\u00a0\u20ac4\u00a0\n\u00a0\n160.125,00\u00a0\u20ac4\u00a0\n240.187,50\u00a0\u20ac4\u00a0\n320.250,00\u00a0\u20ac4\u00a0\n480.375,00\u00a0\u20ac4\u00a0\n1\u00a0Dosierung\u00a0f\u00fcr\u00a0Erwachsene\u00a020\u201040\u00a0I.E./kg\u00a0alle\u00a02\u00a0Tage\u00a0oder\u00a020\u201050\u00a0 I.E./kg\u00a03x/Woche\u00a0\n\u00b2\u00a0I.d.R.\u00a0ist\u00a0die\u00a0Dosierung\u00a0f\u00fcr\u00a0alle\u00a0Pr\u00e4parate\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0 Vergleichstherapie\u00a0alters\u00fcbergreifend\u00a0gem\u00e4\u00df\u00a0Fachinformation\u00a020\u00a0 \u2013\u00a0\u00a0\u00a0\n40\u00a0I.\u00a0E.\u00a0pro\u00a0kg\u00a0K\u00f6rpergewicht\u00a0alle\u00a02\u00a0\u2013\u00a03\u00a0Tage;\u00a0Abweichungen\u00a0wer den\u00a0separat\u00a0vermerkt\u00a0\u00a0\n3\u00a0Dosierung\u00a0pro\u00a0Behandlung\u00a0f\u00fcr\u00a0Erwachsene:\u00a020.i.E\u00a0bis\u00a040\u00a0i.E\u00a0/\u00a0Ki logramm\u00a0=\u00a01\u00a0440\u00a0i.E\u00a0\u00a0\u2010\u00a02880\u00a0i.E\u00a0bei\u00a072\u00a0Kilogramm\u00a0\n4\u00a0Preisberechnungen\u00a0beruhen\u00a0lediglich\u00a0auf\u00a0dem\u00a0Herstellerabgabepr eis;\u00a0Gro\u00dfhandelszuschl\u00e4ge\u00a0unber\u00fccksichtigt.\u00a0\u00a0\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nTuroctocog\u00a0alfa\u00a0ist\u00a0ein\u00a0rekombin anter\u00a0humaner\u00a0Blutgerinnungsfak tor\u00a0VIII,\u00a0der\u00a0in\u00a0\ngenetisch\u00a0 ver\u00e4nderten\u00a0 Ovarialzelll inien\u00a0 des\u00a0 chinesischen\u00a0 Hamste rs\u00a0 hergestellt\u00a0\nwird.\u00a0Bei\u00a0der\u00a0Aufreinigung\u00a0aus\u00a0dem\u00a0Kulturmedium\u00a0kommen\u00a0keine\u00a0me nschlichen\u00a0\noder\u00a0tierischen\u00a0Proteine\u00a0zum\u00a0Ein satz.\u00a0Im\u00a0Vergleich\u00a0zu\u00a0nativem\u00a0h umanen\u00a0Faktor\u00a0VIII\u00a0\nwurde\u00a0bei\u00a0Turoctocog\u00a0alfa\u00a0die\u00a0B\u2010Dom\u00e4ne\u00a0auf\u00a021\u00a0Aminos\u00e4uren\u00a0verk\u00fc rzt\u00a0und\u00a0f\u00fcr\u00a0\neine\u00a0verbesserte\u00a0Stabilit\u00e4t\u00a0und\u00a0Wirksamkeit\u00a0die\u00a0Tyrosinreste\u00a0su lfatiert.\u00a0Dadurch\u00a0\nbesteht\u00a0Turoctocog\u00a0alfa\u00a0aus\u00a01.445\u00a0Aminos\u00e4uren\u00a0und\u00a0weist\u00a0ein\u00a0Mol ekulargewicht\u00a0\nvon\u00a0166\u00a0kDa\u00a0auf.\u00a0\u00a0\nTuroctocog\u00a0alfa\u00a0wirkt\u00a0im\u00a0K\u00f6rper\u00a0wie\u00a0aus\u00a0Plasma\u00a0isolierter\u00a0human er\u00a0Faktor\u00a0VIII:\u00a0\nFaktor\u00a0VIII\u00a0ist\u00a0ein\u00a0Cofaktor\u00a0des\u00a0Blutgerinnungsfaktors\u00a0IXa,\u00a0der \u00a0im\u00a0Gerinnungssys\u2010\ntem\u00a0Faktor\u00a0X\u00a0zu\u00a0Faktor\u00a0Xa\u00a0aktiviert.\u00a0Faktor\u00a0Xa\u00a0katalysiert\u00a0die\u00a0 Umwandlung\u00a0von\u00a0\nProthrombin\u00a0zu\u00a0Thrombin,\u00a0das\u00a0wiederum\u00a0die\u00a0Bildung\u00a0von\u00a0Fibrin\u00a0au s\u00a0Fibrinogen\u00a0\nund\u00a0somit\u00a0die\u00a0Blutstillung\u00a0beg\u00fcnstigt\u00a0(EMA,\u00a02013).\u00a0\u00a0\n\u00a0420\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nTuroctocog\u00a0alfa\u00a0ist\u00a0unter\u00a0dem\u00a0Handelsnamen\u00a0NovoEight\u00ae\u00a0zur\u00a0Behan dlung\u00a0und\u00a0\nProphylaxe\u00a0von\u00a0Blutungen\u00a0bei\u00a0Patienten\u00a0mit\u00a0H\u00e4mophilie\u00a0A\u00a0bei\u00a0all en\u00a0Altersgruppen\u00a0\nzugelassen.\u00a0Das\u00a0Fertigarzneimitte l\u00a0liegt\u00a0als\u00a0Pulver\u00a0in\u00a0einer\u00a0Du rchstechflasche\u00a0vor,\u00a0\ndas\u00a0vor\u00a0der\u00a0intraven\u00f6sen\u00a0Injektion\u00a0mit\u00a0Wasser\u00a0f\u00fcr\u00a0Injektionszwe cke\u00a0in\u00a0eine\u00a0klare\u00a0\nInjektionsl\u00f6sung\u00a0\u00fcberf\u00fchrt\u00a0werden\u00a0muss.\u00a0Der\u00a0Wirkstoff\u00a0ist\u00a0in\u00a0se chs\u00a0verschiedenen\u00a0\nDosierungen\u00a0im\u00a0Handel,\u00a0die\u00a0nach\u00a0dem\u00a0Aufl\u00f6sen\u00a0einer\u00a0Konzentratio n\u00a0zwischen\u00a062,5\u00a0\nund\u00a0750\u00a0I.E.\u00a0pro\u00a0Milliliter\u00a0entsprechen.\u00a0\u00a0\nDie\u00a0zu\u00a0verabreichende\u00a0Dosis\u00a0h\u00e4ngt\u00a0vom\u00a0Schweregrad\u00a0des\u00a0Faktor\u2010VI II\u2010Mangels,\u00a0Art\u00a0\nder\u00a0Behandlung\u00a0(Bedarfstherapie\u00a0oder\u00a0Prophylaxe),\u00a0Ort\u00a0und\u00a0Ausma \u00df\u00a0der\u00a0Blutung\u00a0\nund\u00a0dem\u00a0klinischen\u00a0Zustand\u00a0des\u00a0Patienten\u00a0ab.\u00a0Anhaltspunkte\u00a0f\u00fcr\u00a0 Dosis\u00a0und\u00a0Dosie\u2010\nrungsintervalle\u00a0in\u00a0verschiedenen\u00a0Situationen\u00a0sind\u00a0in\u00a0den\u00a0Fachin formationen\u00a0aufge\u2010\nf\u00fchrt.\u00a0F\u00fcr\u00a0die\u00a0prophylaktische\u00a0Be handlung\u00a0werden\u00a0\u00fcblicherweise\u00a0 20\u00a0bis\u00a040\u00a0I.E.\u00a0pro\u00a0\nKilogramm\u00a0K\u00f6rpergewicht\u00a0(kg\u00a0KG)\u00a0 alle\u00a0zwei\u00a0Tage\u00a0oder\u00a020\u00a0bis\u00a050\u00a0I .E.\u00a0pro\u00a0kg\u00a0KG\u00a0alle\u00a0\ndrei\u00a0Tage\u00a0verwendet.\u00a0Individuelle\u00a0Abweichungen\u00a0sind\u00a0m\u00f6glich.\u00a0Im \u00a0Laufe\u00a0der\u00a0Be\u2010\nhandlung\u00a0werden\u00a0Kontrollen\u00a0des\u00a0 Faktor\u2010VIII\u2010Spiegels\u00a0empfohlen.\u00a0 \u00a0\nDer\u00a0Wirkstoff\u00a0ist\u00a0w\u00e4rmeempfindlich\u00a0und\u00a0muss\u00a0im\u00a0K\u00fchlschrank\u00a0gela gert\u00a0werden.\u00a0\nW\u00e4hrend\u00a0der\u00a0Haltbarkeitsdauer\u00a0ka nn\u00a0das\u00a0Pr\u00e4parat\u00a0einmal\u00a0f\u00fcr\u00a0maxi mal\u00a0einen\u00a0Mo\u2010\nnat\u00a0bei\u00a0Raumtemperatur\u00a0bis\u00a0zu\u00a025\u00a0\u00b0C\u00a0aufbewahrt\u00a0werden.\u00a0Nach\u00a0der \u00a0Rekonstitution\u00a0\nsollte\u00a0die\u00a0Injektionsl\u00f6sung\u00a0aus\u00a0Gr\u00fcnden\u00a0der\u00a0mikrobiellen\u00a0Stabil it\u00e4t\u00a0sofort\u00a0verwen\u2010\ndet\u00a0werden.\u00a0\u00a0\nAls\u00a0 neuer\u00a0 Wirkstoff\u00a0 steht\u00a0 Turoctocog\u00a0 alfa\u00a0 unter\u00a0 zus\u00e4tzlicher\u00a0 \u00dcb erwachung\u00a0\n(schwarzes\u00a0Dreieck).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nBei\u00a0einer\u00a0H\u00e4mophilie\u00a0A\u00a0besteht\u00a0ein \u00a0Defekt\u00a0in\u00a0dem\u00a0Gen,\u00a0das\u00a0f\u00fcr\u00a0d en\u00a0Blutgerinnungs\u2010\nfaktor\u00a0VIII\u00a0codiert.\u00a0Die\u00a0Erkrankung\u00a0wird\u00a0X\u2010chromosomal\u2010rezessiv \u00a0\u00fcber\u00a0die\u00a0m\u00fctterli\u2010\nche\u00a0 Linie\u00a0 vererbt.\u00a0 Allerdings\u00a0 manifestiert\u00a0 sich\u00a0 das\u00a0 Krankheitsb ild\u00a0 nahezu\u00a0 ohne\u00a0\nAusnahme\u00a0nur\u00a0bei\u00a0M\u00e4nnern.\u00a0Die\u00a0Pr \u00e4valenz\u00a0wird\u00a0mit\u00a01:5000\u00a0Knabeng eburten\u00a0an\u2010\ngegeben.\u00a0Wie\u00a0stark\u00a0die\u00a0Erkrankung\u00a0ausgepr\u00e4gt\u00a0ist,\u00a0h\u00e4ngt\u00a0von\u00a0dav on\u00a0ab,\u00a0wie\u00a0hoch\u00a0\ndie\u00a0Restgerinnungsaktivit\u00e4t\u00a0ausf\u00e4llt.\u00a0Diese\u00a0ist\u00a0proportional\u00a0zu r\u00a0Blutungsneigung.\u00a0\nEine\u00a0schwere\u00a0H\u00e4mophilie\u00a0liegt\u00a0v or,\u00a0wenn\u00a0die\u00a0Restgerinnungsaktiv it\u00e4t\u00a0weniger\u00a0als\u00a0\nein\u00a0Prozent\u00a0des\u00a0Normwerts\u00a0betr\u00e4gt.\u00a0Zwischen\u00a01\u00a0und\u00a05\u00a0%\u00a0spricht\u00a0m an\u00a0von\u00a0einer\u00a0\nmittelschweren\u00a0H\u00e4mophilie.\u00a0Bei\u00a0Patienten\u00a0mit\u00a0leichter\u00a0H\u00e4mophili e\u00a0findet\u00a0sich\u00a0eine\u00a0\nRestgerinnungsaktivit\u00e4t\u00a0von\u00a05\u00a0bis\u00a015\u00a0%,\u00a0w\u00e4hrend\u00a0bei\u00a0Subh\u00e4mophil ie\u00a0die\u00a0Restgerin\u2010\nnungsaktivit\u00e4t\u00a0bei\u00a015\u00a0bis\u00a050\u00a0%\u00a0lie gt\u00a0(B\u00c4Kr,\u00a02014;\u00a0IQWiG,\u00a02015). \u00a0421\u00a0Vor\u00a0allem\u00a0bei\u00a0einer\u00a0schweren\u00a0H\u00e4mophilie\u00a0k\u00f6nnen\u00a0spontan\u00a0und\u00a0ohne \u00a0\u00e4u\u00dferen\u00a0An\u2010\nlass\u00a0ausgedehnte\u00a0Blutungen\u00a0vor\u00a0allem\u00a0in\u00a0Gelenken\u00a0und\u00a0Muskeln\u00a0au ftreten.\u00a0Blutun\u2010\ngen\u00a0in\u00a0den\u00a0Gelenken\u00a0verursachen\u00a0nicht\u00a0nur\u00a0Schmerzen,\u00a0sondern\u00a0k\u00f6 nnen\u00a0zu\u00a0blei\u2010\nbenden\u00a0Gelenksch\u00e4den\u00a0f\u00fchren.\u00a0Oft\u00a0sind\u00a0die\u00a0gro\u00dfen\u00a0Gelenke\u00a0wie\u00a0El lenbogen,\u00a0Knie\u00a0\nund\u00a0Sprunggelenke\u00a0betroffen.\u00a0Blutungen\u00a0in\u00a0der\u00a0Muskulatur\u00a0k\u00f6nnen \u00a0zu\u00a0einer\u00a0Mus\u2010\nkelschrumpfung\u00a0f\u00fchren,\u00a0die\u00a0sich\u00a0auch\u00a0auf\u00a0Gelenke\u00a0und\u00a0benachbart e\u00a0Nerven\u00a0aus\u2010\nwirken.\u00a0Lebensgef\u00e4hrlich\u00a0sind\u00a0i nnere\u00a0Blutungen,\u00a0vor\u00a0allem\u00a0im\u00a0Be reich\u00a0von\u00a0Kopf\u00a0\nund\u00a0Gehirn\u00a0(IQWiG,\u00a02015).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassung\u00a0 beruht\u00a0im\u00a0Wesentlichen\u00a0auf\u00a0 drei\u00a0offenen\u00a0einarmige n\u00a0klinischen\u00a0\nStudien\u00a0an\u00a0Patienten\u00a0mit\u00a0schwerer\u00a0H\u00e4mophilie\u00a0A\u00a0(Faktor\u2010VIII\u2010Akt ivit\u00e4t\u00a0h\u00f6chstens\u00a0\nein\u00a0Prozent),\u00a0die\u00a0bereits\u00a0vorher\u00a0Faktor\u00a0VIII\u2010Produkte\u00a0erhalten\u00a0 hatten,\u00a0aber\u00a0bei\u00a0\ndenen\u00a0keine\u00a0relevante\u00a0Aktivit\u00e4t\u00a0 eines\u00a0Inhibitors\u00a0gegen\u00a0Faktor\u00a0V III\u00a0nachweisbar\u00a0war.\u00a0\nPatienten,\u00a0die\u00a0bisher\u00a0keine\u00a0Faktor\u2010VIII\u2010Produkte\u00a0erhalten\u00a0hatte n,\u00a0waren\u00a0ausge\u2010\nschlossen.\u00a0In\u00a0den\u00a0Studien,\u00a0die\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0abge schlossen\u00a0waren,\u00a0\nwurde\u00a0 ausschlie\u00dflich\u00a0 die\u00a0 prophylaktische\u00a0 Behandlung\u00a0 sowie\u00a0 die\u00a0 T herapie\u00a0 von\u00a0\nDurchbruchblutungen\u00a0untersucht.\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0 On\u00a0demand \u2010Behandlung\u00a0fehlen.\u00a0\nIn\u00a0die\u00a0Studie\u00a0Guardian\u2122\u00a01\u00a0wurden\u00a0150\u00a0m\u00e4nnliche\u00a0Jugendliche\u00a0und\u00a0 Erwachsene\u00a0\nzwischen\u00a0zw\u00f6lf\u00a0und\u00a056\u00a0Jahren\u00a0eingeschlossen\u00a0(Lentz\u00a0et\u00a0al.,\u00a02013 ).\u00a0Sie\u00a0erhielten\u00a0zur\u00a0\nBlutungsprophylaxe\u00a020\u00a0I. E.\u00a0Turoctocog\u00a0alfa\u00a0pro\u00a0 kg\u00a0KG\u00a0je\u00a0nach\u00a0Faktor\u2010VIII\u2010Spiegel\u00a0\nentweder\u00a0alle\u00a0zwei\u00a0Tage\u00a0oder\u00a0dreimal\u00a0w\u00f6chentlich\u00a0\u00fcber\u00a0einen\u00a0Zei traum\u00a0von\u00a0rund\u00a0\nsechs\u00a0Monaten\u00a0mit\u00a0durchschnittlich\u00a085\u00a0Expositionstagen.\u00a0Im\u00a0Mitt el\u00a0traten\u00a06,50\u00a0\nBlutungsepisoden\u00a0pro\u00a0Patient\u00a0und\u00a0Jahr\u00a0auf,\u00a0im\u00a0Median\u00a03,66\u00a0Blutu ngsepisoden\u00a0pro\u00a0\nPatient\u00a0und\u00a0Jahr.\u00a0499\u00a0Blutungsepisoden\u00a0wurden\u00a0mit\u00a0Turoctocog\u00a0al fa\u00a0behandelt,\u00a0\ndabei\u00a0wurde\u00a0das\u00a0Ansprechen\u00a0in\u00a081 \u00a0%\u00a0der\u00a0F\u00e4lle\u00a0mit\u00a0ausgezeichnet\u00a0oder\u00a0gut\u00a0bewer\u2010\ntet.\u00a0In\u00a0einer\u00a0Substudie\u00a0mit\u00a0neun\u00a0Patienten,\u00a0die\u00a0sich\u00a0einer\u00a0gepl anten\u00a0Operation\u00a0\nunterziehen\u00a0mussten,\u00a0erhielten\u00a0di e\u00a0Teilnehmer\u00a0vor\u00a0dem\u00a0Eingriff\u00a0 eine\u00a0Initialdosis,\u00a0\nw\u00e4hrend\u00a0und\u00a0nach\u00a0der\u00a0Operation\u00a0wurde\u00a0das\u00a0Pr\u00e4parat\u00a0je\u00a0nach\u00a0Bluts piegel\u00a0dosiert.\u00a0\nDie\u00a0Behandlung\u00a0wurde\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0als\u00a0erfolgreich\u00a0bewertet\u00a0( ausgezeichnet\u00a0oder\u00a0\ngut).\u00a0Daten\u00a0zur\u00a0HRQoL\u00a0wurden\u00a0mit\u00a0krankheitsbezogenen\u00a0und\u00a0alters spezifischen\u00a0\nFrageb\u00f6gen\u00a0zur\u00a0Lebensqualit\u00e4t\u00a0und\u00a0Behandlungszufriedenheit\u00a0erho ben\u00a0(HAEMO\u2010\nQOL,\u00a0HEMO\u2010SAT,\u00a0EQ\u20105D),\u00a0allerdings \u00a0ergaben\u00a0sich\u00a0keine\u00a0wesentlich en\u00a0Ver\u00e4nderun\u2010\ngen\u00a0zwischen\u00a0Beginn\u00a0und\u00a0Ende\u00a0der\u00a0Studie\u00a0(EMA,\u00a02013;\u00a0Lentz\u00a0et\u00a0al .,\u00a02013).\u00a0\nIn\u00a0die\u00a0Guardian\u2122\u00a03\u2010Studie\u00a0wurden\u00a063\u00a0Jungen\u00a0unter\u00a0zw\u00f6lf\u00a0Jahren\u00a0e ingeschlossen\u00a0\n(Kulkarni\u00a0et\u00a0al.,\u00a02013).\u00a0Sie\u00a0erhielten\u00a025\u00a0bis\u00a050\u00a0I.E.\u00a0Turoctoco g\u00a0alfa\u00a0pro\u00a0 kg\u00a0KG\u00a0jeden\u00a0\nzweiten\u00a0Tag\u00a0oder\u00a025\u00a0bis\u00a060\u00a0I.E.\u00a0pro\u00a0 kg\u00a0KG\u00a0dreimal\u00a0pro\u00a0Woche.\u00a0Die\u00a0Expositionszeit\u00a0\nlag\u00a0bei\u00a0rund\u00a04,5\u00a0Monaten,\u00a0im\u00a0Durc hschnitt\u00a050\u00a0Expositionstagen\u00a0e ntsprechend.\u00a0\nW\u00e4hrend\u00a0der\u00a0Studie\u00a0traten\u00a0im\u00a0Du rchschnitt\u00a05,33\u00a0Blutungsepisoden \u00a0pro\u00a0Patient\u00a0und\u00a0422\u00a0Jahr\u00a0auf,\u00a0im\u00a0Median\u00a03,0\u00a0Blutungsepisoden\u00a0pro\u00a0Patient\u00a0und\u00a0Jahr.\u00a0 Die\u00a0Behandlung\u00a0\nvon\u00a0insgesamt\u00a0126\u00a0Blutungsepisoden\u00a0wurde\u00a0in\u00a092 \u00a0%\u00a0der\u00a0F\u00e4lle\u00a0als\u00a0erfolgreich\u00a0(aus\u2010\ngezeichnet\u00a0oder\u00a0gut)\u00a0bewertet.\u00a0Bei\u00a0zwei\u00a0Teilnehmern\u00a0war\u00a0ein\u00a0kle iner\u00a0operativer\u00a0\nEingriff\u00a0w\u00e4hrend\u00a0der\u00a0Studienlauf zeit\u00a0notwendig,\u00a0in\u00a0beiden\u00a0F\u00e4lle n\u00a0wurde\u00a0der\u00a0Be\u2010\nhandlungseffekt\u00a0als\u00a0ausgezeichnet\u00a0eingestuft.\u00a0Die\u00a0krankheitsspe zifische\u00a0Lebens\u2010\nqualit\u00e4t\u00a0wurde\u00a0mit\u00a0dem\u00a0HAEMO\u2010QOL\u2010Instrument\u00a0erhoben,\u00a0dabei\u00a0zeig te\u00a0sich\u00a0kein\u00a0\nUnterschied\u00a0zwischen\u00a0Beginn\u00a0und\u00a0Ende\u00a0der\u00a0Studie\u00a0(EMA,\u00a02013).\u00a0\nDie\u00a0Guardian\u2122\u00a02\u2010Studie\u00a0ist\u00a0eine \u00a0Erweiterungsstudie,\u00a0in\u00a0die\u00a0Pati enten\u00a0aus\u00a0allen\u00a0\nvorherigen\u00a0Untersuchungen\u00a0einge hen\u00a0(Lentz\u00a0et\u00a0al.,\u00a02016).\u00a055\u00a0der \u00a0insgesamt\u00a0213\u00a0\nPatienten\u00a0waren\u00a0Kinder\u00a0unter\u00a0zw\u00f6 lf\u00a0Jahre,\u00a023\u00a0Jugendliche\u00a0und\u00a013 5\u00a0Erwachsene.\u00a022\u00a0\nder\u00a0erwachsenen\u00a0Probanden\u00a0erhiel ten\u00a0eine\u00a0anlassbezogene\u00a0Behandl ung\u00a0von\u00a0Blu\u2010\ntungsepisoden,\u00a0die\u00a0anderen\u00a0Teilnehmer\u00a0nahmen\u00a0am\u00a0Pr\u00e4ventionsarm\u00a0 der\u00a0Studie\u00a0\nteil.\u00a0Sie\u00a0erhielten\u00a0als\u00a0Blutungsprophylaxe\u00a025\u00a0bis\u00a050\u00a0I.E.\u00a0Turoc tocog\u00a0alfa\u00a0alle\u00a0zwei\u00a0\nTage\u00a0oder\u00a020\u00a0bis\u00a060\u00a0I.E.\u00a0pro\u00a0kg\u00a0KG\u00a0dreimal\u00a0w\u00f6chentlich.\u00a0Der\u00a0eur op\u00e4ische\u00a0Beurtei\u2010\nlungsbericht\u00a0enth\u00e4lt\u00a0die\u00a0Studienergebnisse\u00a0nur\u00a0bis\u00a0zum\u00a021.\u00a0Nove mber\u00a02011.\u00a0Die\u00a0\nvollst\u00e4ndigen\u00a0Daten\u00a0bis\u00a0Ende\u00a0Juni\u00a02016\u00a0sind\u00a0noch\u00a0nicht\u00a0wissensc haftlich\u00a0publiziert,\u00a0\nfinden\u00a0sich\u00a0teilweise\u00a0aber\u00a0im\u00a0europ\u00e4ischen\u00a0Studienregister.\u00a0All erdings\u00a0ist\u00a0jeweils\u00a0\nnur\u00a0der\u00a0Median\u00a0angegeben.\u00a0Dabei\u00a0lag\u00a0die\u00a0mediane\u00a0Blutungsrate\u00a0pr o\u00a0Jahr\u00a0und\u00a0\nPatient\u00a0bei\u00a0Kindern\u00a0unter\u00a0sechs\u00a0Jahren\u00a0bei\u00a01,08\u00a0(Spanne\u00a00\u00a0bis\u00a01 2,12),\u00a0bei\u00a0Kindern\u00a0\nzwischen\u00a0sechs\u00a0und\u00a0zw\u00f6lf\u00a0Jahren\u00a0bei\u00a01,57\u00a0(Spanne\u00a00\u00a0bis\u00a010,8),\u00a0b ei\u00a0Jugendlichen\u00a0bei\u00a0\n1,57\u00a0(Spanne\u00a00\u00a0bis\u00a06,1)\u00a0und\u00a0bei\u00a0Erwachsenen\u00a0bei\u00a01,37\u00a0(Spanne\u00a00\u00a0 bis\u00a017,92).\u00a0W\u00e4hrend\u00a0\nder\u00a0prophylaktischen\u00a0Behandlung\u00a0traten\u00a0insgesamt\u00a01.782\u00a0Blutungs episoden\u00a0auf,\u00a0die\u00a0\nje\u00a0nach\u00a0Altersgruppe\u00a0in\u00a088\u00a0bis\u00a091\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0erfolgreich\u00a0(Bewe rtung\u00a0ausgezeichnet\u00a0\noder\u00a0gut)\u00a0behandelt\u00a0wurden.\u00a0Bei\u00a0der\u00a0 On\u00a0demand \u2010Behandlung\u00a0kam\u00a0es\u00a0zu\u00a0391\u00a0Blu\u2010\ntungsepisoden,\u00a0bei\u00a0denen\u00a0in\u00a097\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0ein\u00a0ausgezeichneter\u00a0 oder\u00a0guter\u00a0Behand\u2010\nlungseffekt\u00a0erzielt\u00a0wurde.\u00a017\u00a0Patienten\u00a0unterzogen\u00a0sich\u00a0w\u00e4hrend \u00a0der\u00a0Studie\u00a0einer\u00a0\nkleinen\u00a0oder\u00a0gro\u00dfen\u00a0Operation,\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0war\u00a0die\u00a0Behandlu ng\u00a0mit\u00a0Turoctocog\u00a0\nalfa\u00a0erfolgreich\u00a0(Behandlungseffekt\u00a0ausgezeichnet\u00a0oder\u00a0gut)\u00a0(Gu ardian\u2122\u00a02,\u00a02008).\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0der\u00a0Sicherheit\u00a0lagen\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Zulass ung\u00a0Daten\u00a0zu\u00a0214\u00a0\nPatienten\u00a0mit\u00a0insgesamt\u00a0rund\u00a033.000\u00a0Expositionstagen\u00a0vor.\u00a0H\u00e4ufi ge\u00a0unerw\u00fcnschte\u00a0\nArzneimittelwirkungen\u00a0waren\u00a0Reakt ionen\u00a0an\u00a0der\u00a0Injektionsstelle\u00a0 und\u00a0ein\u00a0Anstieg\u00a0\nder\u00a0Leberenzyme.\u00a0In\u00a0keiner\u00a0der\u00a0b isher\u00a0abgeschlossenen\u00a0Studien\u00a0w urde\u00a0die\u00a0Bildung\u00a0\nneutralisierender\u00a0Antik\u00f6rper\u00a0be obachtet\u00a0(EMA,\u00a02013;\u00a0Guardian\u2122\u00a02 ,\u00a02008).\u00a0\nEine\u00a0Recherche\u00a0in\u00a0Studienregistern\u00a0(clinicaltrials.gov,\u00a0EudraCT )\u00a0ermittelte\u00a0weitere\u00a0\nStudien,\u00a0unter\u00a0anderem\u00a0zu\u00a0bisher\u00a0nicht\u00a0behandelten\u00a0p\u00e4diatrische n\u00a0Patienten,\u00a0die\u00a0\njedoch\u00a0noch\u00a0nicht\u00a0abgeschlossen\u00a0sind.\u00a0\u00a0\nIm\u00a0Juli\u00a02016\u00a0startete\u00a0die\u00a0EMA\u00a0auf\u00a0Antrag\u00a0des\u00a0Paul\u2010Ehrlich\u2010Insti tuts\u00a0ein\u00a0Risikobe\u2010\nwertungsverfahren\u00a0f\u00fcr\u00a0alle\u00a0Faktor\u2010VIII\u2010Produkte\u00a0im\u00a0Hinblick\u00a0auf \u00a0die\u00a0Entwicklung\u00a0423\u00a0neutralisierender\u00a0Antik\u00f6rper,\u00a0d ie\u00a0die\u00a0Wirksamkeit\u00a0der\u00a0Gerinnung sfaktoren\u00a0verrin\u2010\ngern\u00a0k\u00f6nnen.\u00a0Ausl\u00f6ser\u00a0war\u00a0die\u00a0Publikation\u00a0einer\u00a0Studie\u00a0mit\u00a0Hinw eisen\u00a0darauf,\u00a0dass\u00a0\ndas\u00a0Risiko\u00a0m\u00f6glicherweise\u00a0bei\u00a0rek ombinanten\u00a0Faktor\u2010VIII\u2010Produkt en\u00a0h\u00f6her\u00a0sein\u00a0\nk\u00f6nnte\u00a0als\u00a0bei\u00a0den\u00a0Pr\u00e4paraten,\u00a0di e\u00a0aus\u00a0humanem\u00a0Plasma\u00a0isoliert\u00a0 werden\u00a0(Peyvandi\u00a0\net\u00a0al.,\u00a02016).\u00a0\nLeitlinienempfehlungen\u00a0\nDer\u00a0Wirkstoff\u00a0Turoctocog\u00a0alfa\u00a0wird\u00a0derzeit\u00a0in\u00a0keiner\u00a0der\u00a0betrac hteten\u00a0Leitlinie\u00a0\nexplizit\u00a0erw\u00e4hnt.\u00a0Die\u00a0Querschnittsleitlinie\u00a0zur\u00a0Therapie\u00a0mit\u00a0Bl utkomponenten\u00a0und\u00a0\nPlasmaderivaten\u00a0der\u00a0Bundes\u00e4rztekammer\u00a0bezieht\u00a0sich\u00a0bei\u00a0den\u00a0Empf ehlungen\u00a0zur\u00a0\nBehandlung\u00a0der\u00a0H\u00e4mophilie\u00a0A\u00a0allge mein\u00a0auf\u00a0Faktor\u2010VIII\u2010Pr\u00e4parate \u00a0und\u00a0gibt\u00a0an,\u00a0\ndass\u00a0sich\u00a0die\u00a0Pharmakokinetik\u00a0und\u00a0klinische\u00a0Wirksamkeit\u00a0rekombi nanter\u00a0Pr\u00e4parate\u00a0\nim\u00a0Wesentlichen\u00a0nicht\u00a0von\u00a0denen\u00a0der\u00a0Plasmapr\u00e4parate\u00a0unterscheid et.\u00a0Indikatio\u2010\nnen\u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0von\u00a0Faktor\u2010V III\u2010Pr\u00e4paraten\u00a0sieht\u00a0die\u00a0Leitli nie\u00a0im\u00a0Bedarfsfall\u00a0bei\u00a0\nallen\u00a0spontanen\u00a0oder\u00a0traumatischen\u00a0Blutungen,\u00a0sobald\u00a0sie\u00a0ein\u00a0mi nimales\u00a0Ausma\u00df\u00a0\n\u00fcbersteigen.\u00a0Eine\u00a0prophylaktisch e\u00a0Dauerbehandlung\u00a0empfiehlt\u00a0die \u00a0Leitlinie\u00a0vor\u2010\nwiegend\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0mit\u00a0schwerer\u00a0H\u00e4mophilie,\u00a0u m\u00a0Gelenksch\u00e4\u2010\nden\u00a0zu\u00a0vermeiden.\u00a0Bei\u00a0Erwachsenen\u00a0sollte\u00a0die\u00a0Notwendigkeit\u00a0eine r\u00a0prophylakti\u2010\nschen\u00a0Dauerbehandlung\u00a0im\u00a0Einzelf all\u00a0bedacht\u00a0werden.\u00a0Zeitlich\u00a0be fristete\u00a0prophy\u2010\nlaktische\u00a0Gaben\u00a0sollten\u00a0bei\u00a0operativen\u00a0Eingriffen\u00a0sowie\u00a0bei\u00a0bes onderen\u00a0k\u00f6rperli\u2010\nchen\u00a0oder\u00a0psychischen\u00a0Belastungen\u00a0erfolgen\u00a0(B\u00c4K,\u00a02014).\u00a0\u00a0\nDiese\u00a0Empfehlungen\u00a0zur\u00a0Dauerbehandlung\u00a0werden\u00a0auch\u00a0von\u00a0einem\u00a0eu rop\u00e4ischen\u00a0\nKonsensus\u00a0mitgetragen,\u00a0der\u00a0keine\u00a0Angaben\u00a0zur\u00a0Auswahl\u00a0von\u00a0Faktor \u2010VIII\u2010Pr\u00e4pa\u2010\nraten\u00a0macht\u00a0(Giangrande\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0Leitlinie\u00a0der\u00a0 World\u00a0Federation\u00a0of\u00a0Hemo\u2010\nphilia\u00a0gibt\u00a0explizit\u00a0an,\u00a0dass\u00a0sie\u00a0rekombinante\u00a0Pr\u00e4parate\u00a0nicht\u00a0grunds \u00e4tzlich\u00a0gegen\u2010\n\u00fcber\u00a0aus\u00a0Plasma\u00a0isolierten\u00a0Pr\u00e4paraten\u00a0vorzieht.\u00a0Allerdings\u00a0soll ten\u00a0zur\u00a0Vermeidung\u00a0\nvon\u00a0Infektionen\u00a0bei\u00a0den\u00a0aus\u00a0Plasma\u00a0isolierten\u00a0Pr\u00e4paraten\u00a0bevorz ugt\u00a0virusinakti\u2010\nvierte\u00a0Produkte,\u00a0nicht\u00a0aber\u00a0Kryopr\u00e4zipitate\u00a0oder\u00a0frisches\u00a0gefro renes\u00a0Plasma\u00a0einge\u2010\nsetzt\u00a0werden\u00a0(Makris\u00a0&\u00a0Kasper,\u00a02013).\u00a0\u00a0\nEine\u00a0Evidenzkartierung\u00a0des\u00a0IQWiG\u00a0zum\u00a0Vergleich\u00a0einer\u00a0prophylakt ischen\u00a0versus\u00a0\neiner\u00a0anlassbezogenen\u00a0Behandlung\u00a0mit\u00a0Faktor\u00a0VIII\u2010Produkten\u00a0bei\u00a0 Patienten\u00a0mit\u00a0\nschwerer\u00a0H\u00e4mophilie\u00a0A\u00a0konnte\u00a0f\u00fcr\u00a0Jugendliche\u00a0und\u00a0Erwachsene\u00a0ein en\u00a0Hinweis\u00a0auf\u00a0\neinen\u00a0 Zusatznutzen\u00a0 der\u00a0 prophyla ktischen\u00a0 Behandlung\u00a0 im\u00a0 Hinblick\u00a0 auf\u00a0 schwere\u00a0\nBlutungen\u00a0zeigen.\u00a0Im\u00a0Zusammenhang\u00a0mit\u00a0Schmerzen\u00a0und\u00a0dem\u00a0allgeme inen\u00a0Ge\u2010\nsundheitszustand\u00a0war\u00a0nur\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutze n\u00a0zu\u00a0verzeich\u2010\nnen.\u00a0F\u00fcr\u00a0Kinder\u00a0war\u00a0f\u00fcr\u00a0die\u00a0prophylaktische\u00a0Behandlung\u00a0nur\u00a0bezo gen\u00a0auf\u00a0schwere\u00a0\nBlutungen\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0festzustellen .\u00a0Zu\u00a0den\u00a0wichtigs\u2010\nten\u00a0Komplikationen\u00a0bei\u00a0der\u00a0Beha ndlung\u00a0der\u00a0H\u00e4mophilie\u00a0A\u00a0geh\u00f6rt\u00a0d as\u00a0Auftreten\u00a0\nvon\u00a0 Antik\u00f6rpern\u00a0 (Inhibitoren)\u00a0 geg en\u00a0 Faktor\u00a0 VIII,\u00a0 die\u00a0 den\u00a0 Blutge rinnungsfaktor\u00a0424\u00a0inaktivieren\u00a0und\u00a0so\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Blutungen\u00a0erh\u00f6hen.\u00a0Die\u00a0Bildu ng\u00a0von\u00a0Inhibitoren\u00a0\nwird\u00a0bei\u00a0bis\u00a0zu\u00a030\u00a0%\u00a0der\u00a0vorher\u00a0unbehandelten\u00a0Patienten\u00a0mit\u00a0sch werer\u00a0H\u00e4mophilie\u00a0\nA\u00a0innerhalb\u00a0der\u00a0ersten\u00a0100\u00a0Tage\u00a0nach\u00a0Exposition\u00a0beobachtet.\u00a0Als \u00a0wesentliche\u00a0\nFaktoren,\u00a0die\u00a0die\u00a0Bildung\u00a0von\u00a0Inhibitoren\u00a0f\u00f6rdern,\u00a0gelten\u00a0Dosis \u00a0und\u00a0Applikations\u2010\nh\u00e4ufigkeit\u00a0der\u00a0eingesetzten\u00a0Pr\u00e4p arate.\u00a0M\u00f6glicherweise\u00a0spielen\u00a0a uch\u00a0der\u00a0Schwere\u2010\ngrad\u00a0der\u00a0Erkrankung,\u00a0bestimmte\u00a0ge netische\u00a0Mutationsformen\u00a0und\u00a0d ie\u00a0Ethnizit\u00e4t\u00a0\ndes\u00a0Patienten\u00a0eine\u00a0Rolle\u00a0(IQWiG,\u00a02015).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIm\u00a0April\u00a02014\u00a0ver\u00f6ffentlichte\u00a0das\u00a0IQWiG\u00a0ein\u00a0Gutachten\u00a0zur\u00a0fr\u00fche n\u00a0Nutzenbewer\u2010\ntung\u00a0von\u00a0Turoctocog\u00a0alfa.\u00a0Als\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichstherapie\u00a0wu rden\u00a0rekombi\u2010\nnante\u00a0oder\u00a0aus\u00a0humanem\u00a0Plasma\u00a0gewonnene\u00a0Blutgerinnungsfaktor\u2010VI II\u2010Pr\u00e4parate\u00a0\nherangezogen.\u00a0Der\u00a0pU\u00a0legte\u00a0keine \u00a0relevante\u00a0Studie\u00a0f\u00fcr\u00a0die\u00a0Bewer tung\u00a0des\u00a0Zusatz\u2010\nnutzens\u00a0vor.\u00a0Weiteren\u00a0\u00dcberlegungen,\u00a0nach\u00a0denen\u00a0der\u00a0PU\u00a0durch\u00a0Tur ocotocog\u00a0alfa\u00a0\neine\u00a0Verbesserung\u00a0der\u00a0Versorgun gssicherheit\u00a0und\u00a0eine\u00a0verbessert e\u00a0Integration\u00a0\nvon\u00a0H\u00e4mophilie\u2010Patienten\u00a0in\u00a0ein\u00a0n ormales\u00a0soziales\u00a0Leben\u00a0postuli erte,\u00a0folgte\u00a0das\u00a0\nIQWiG\u00a0nicht,\u00a0da\u00a0keine\u00a0entsprechenden\u00a0vergleichenden\u00a0Daten\u00a0zu\u00a0pa tientenrelevan\u2010\nten\u00a0Endpunkten\u00a0vorgelegt\u00a0wurden.\u00a0Das\u00a0IQWiG\u00a0kam\u00a0daher\u00a0zu\u00a0dem\u00a0Sch luss,\u00a0dass\u00a0das\u00a0\nDossier\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0enth\u00e4lt\u00a0und\u00a0ei n\u00a0Zusatznutzen \u00a0\ngegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0folglich\u00a0 nicht\u00a0belegt \u00a0ist.\u00a0Dieser\u00a0\nEinsch\u00e4tzung\u00a0schloss\u00a0sich\u00a0der\u00a0G\u2010B A\u00a0im\u00a0Juli\u00a02014\u00a0an\u00a0(G\u2010BA,\u00a02014) .\u00a0\nQuellen\u00a0\nB\u00c4K\u00a0\u2013\u00a0Bundes\u00e4rztekammer\u00a0(2014).\u00a0Querschnitts\u2010Leitlinien\u00a0(B\u00c4K)\u00a0z ur\u00a0Therapie\u00a0mit\u00a0Blutkomponenten\u00a0und\u00a0Plasmaderivaten\u00a0\u2013\u00a04.\u00a0\naktualisierte\u00a0und\u00a0\u00fcberarbeitete\u00a0Auflage.\u00a0http://www.bundesaerzt ekammer.de/aerzte/medizin\u2010\nethik/wissenschaftlicher\u2010beirat/veroeffentlichungen/haemotherap ie\u2010transfusionsmedizin/querschnitt\u2010leitlinie/\u00a0,\u00a0\nletzter\u00a0Zugriff:\u00a012.05.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2013).\u00a0European\u00a0Assessment\u00a0Rep ort:\u00a0NovoEight.\u00a0www.ema.europa.eu/ema/index.jsp?curl=pa\u00a0\nges/medicines/human/medicines/002719/human_med_001701.jsp&mid=W C0b01ac058001d124,\u00a0letzter\u00a0Zugriff:\u00a0\n21.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Review\u00a0of\u00a0factor\u00a0VIII\u00a0m edicines\u00a0and\u00a0risk\u00a0of\u00a0developing\u00a0 inhibitors\u00a0in\u00a0patients\u00a0starting \u00a0\ntreatment\u00a0for\u00a0haemophilia\u00a0A.\u00a0www.ema.europa.eu/ema/index.jsp?cu rl=pages/medicines/human/\u00a0\nreferrals/Factor_VIII/human_refe rral_prac_000060.jsp&mid=WC0b01 ac05805c516f,\u00a0letzter\u00a0Zugriff:\u00a015.02.2017.\u00a0\nEU\u00a0Clinical\u00a0Trials\u00a0Register\u00a0(2009).\u00a0Clinical\u00a0trial\u00a0results:\u00a0Saf ety\u00a0and\u00a0Efficacy\u00a0of\u00a0Turoctocog\u00a0Alfa\u00a0in\u00a0Prevention\u00a0and\u00a0Ondemand\u00a0\nTreatment\u00a0of\u00a0Bleeding\u00a0Episodes\u00a0i n\u00a0Subjects\u00a0with\u00a0Haemophilia\u00a0A\u00a0S ub\u2010trial:\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Turoctocog\u00a0Alfa\u00a0in\u00a0\nPrevention\u00a0and\u00a0Treatment\u00a0of\u00a0Bleed ing\u00a0During\u00a0Surgic.\u00a0.\u00a0https://w ww.clinicaltrialsregister.eu/ctr\u2010search/trial/2008\u2010\n005945\u201046/results\u00a0,\u00a0letzter\u00a0Zugriff:\u00a012.05.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundessausschuss\u00a0(2014).\u00a0Nutzenbewertungsver fahren\u00a0zum\u00a0Wirkstoff\u00a0Turoctocog\u00a0alfa.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/99/,\u00a0letzter\u00a0Zugriff:\u00a021.02 .2017.\u00a0425\u00a0Giangrande\u00a0P,\u00a0Seitz\u00a0R,\u00a0Behr\u2010Gross\u00a0M,\u00a0Berger\u00a0K,\u00a0Hilger\u00a0A,\u00a0Klein\u00a0 H\u00a0et\u00a0al.\u00a0(2014).\u00a0Kreuth\u00a0III:\u00a0European\u00a0consensus\u00a0proposals\u00a0for\u00a0\ntreatment\u00a0of\u00a0haemophilia\u00a0with\u00a0coagulation\u00a0factor\u00a0concentrates.\u00a0 Haemophilia\u00a020(3):\u00a0322\u2010325.\u00a0\u00a0\nGuardian\u00a02\u00a0(2008).\u00a0Guardian\u00a02.\u00a0https://www.clinicaltrialsregist er.eu/ctr\u2010search/trial/2008\u2010005945\u201046/results,\u00a0letzter\u00a0Zugriff: \u00a0\n08.08.2017.\u00a0\nIGWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2015).\u00a0[A13\u201007]\u00a0Therapie\u00a0von\u00a0H\u00e4mophilie\u2010Patienten\u00a0\u2010\u00a0\nRapid\u00a0Report.\u00a0https://www.iqwig.de/de/projekte\u2010ergebnisse/proje kte/arzneimittelbewertung/a13\u201007\u2010therapie\u2010von\u2010\nhamophilie\u2010patienten\u2010rapid\u2010report.3253.html#overview,\u00a0letzter\u00a0Z ugriff:\u00a012.05.2017.\u00a0\nKulkarni\u00a0R,\u00a0Karim\u00a0FA,\u00a0Glamocanin \u00a0S,\u00a0Janic\u00a0D,\u00a0Vdovin\u00a0V,\u00a0Ozelo\u00a0M\u00a0 et\u00a0al.\u00a0(2013).\u00a0Results\u00a0from\u00a0a\u00a0la rge\u00a0multinational\u00a0clinical\u00a0tria l\u00a0\n(guardianTM3)\u00a0using\u00a0prophylactic\u00a0treatment\u00a0with\u00a0turoctocog\u00a0alfa \u00a0in\u00a0paediatric\u00a0patients\u00a0with\u00a0severe\u00a0haemophilia\u00a0A:\u00a0\nsafety,\u00a0efficacy\u00a0and\u00a0pharmacokinetics.\u00a0Haemophilia\u00a019(5):\u00a0698\u20107 05.\u00a0\u00a0\nLentz\u00a0SR,\u00a0Cerqueira\u00a0M,\u00a0Janic\u00a0D,\u00a0 Kempton\u00a0C,\u00a0Matytsina\u00a0I,\u00a0Misgav\u00a0 M\u00a0et\u00a0al.\u00a0(2016).\u00a0Interim\u00a0results\u00a0from\u00a0a\u00a0large\u00a0multinational\u00a0ext ension\u00a0\ntrial\u00a0(guardian\u00a0TM\u00a02)\u00a0using\u00a0turoctocog\u00a0alfa\u00a0for\u00a0prophylaxis\u00a0and \u00a0treatment\u00a0of\u00a0bleeding\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0\nhaemophilia\u00a0A.\u00a0Haemophilia\u00a022(5):\u00a0e445\u2013e449.\u00a0\nLentz\u00a0SR,\u00a0Misgav\u00a0M,\u00a0Ozelo\u00a0M,\u00a0\u0160al ek\u00a0SZ,\u00a0Veljkovic\u00a0D,\u00a0Recht\u00a0M\u00a0et\u00a0 al.\u00a0(2013).\u00a0Results\u00a0from\u00a0a\u00a0large\u00a0multinational\u00a0clinical\u00a0trial\u00a0\n(guardianTM1)\u00a0using\u00a0prophylactic\u00a0treatment\u00a0with\u00a0turoctocog\u00a0alfa \u00a0in\u00a0adolescent\u00a0and\u00a0adult\u00a0patients\u00a0with\u00a0severe\u00a0\nhaemophilia\u00a0A:\u00a0safety\u00a0and\u00a0effica cy.\u00a0Haemophilia\u00a019(5):\u00a0691\u2010697. \u00a0\u00a0\nMakris\u00a0M,\u00a0Kasper\u00a0C\u00a0(2013).\u00a0The\u00a0W orld\u00a0Federation\u00a0of\u00a0Hemophilia\u00a0g uideline\u00a0on\u00a0management\u00a0of\u00a0haemo philia.\u00a0Haemoph ilia\u00a019(1):\u00a01.\u00a0\u00a0\nPeyvandi\u00a0F,\u00a0Mannucci\u00a0PM,\u00a0Garagio la\u00a0I,\u00a0El\u2010Beshlawy\u00a0A,\u00a0Elalfy\u00a0M,\u00a0 Ramanan\u00a0V\u00a0et\u00a0al.\u00a0(2016).\u00a0A\u00a0Randomized\u00a0Trial\u00a0of\u00a0Factor\u00a0VIII\u00a0and\u00a0\nNeutralizing\u00a0Antibodies\u00a0in\u00a0Hem ophilia\u00a0A.\u00a0NEJM\u00a0374(21):\u00a02054\u2010206 4.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Turoc tocog\u00a0alfa|NovoEight\u00ae|16|2014.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=50893,\u00a0letzter\u00a0Zugriff:\u00a018.04.2017. \u00a0\nPZ.\u00a0(2016).\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0\u2010\u00a0Arzneistoffe:\u00a0Turo ctocog\u00a0alfa|NovoEight\u00ae|16|2014.\u00a0Retrieved\u00a0April\u00a018,\u00a02017,\u00a0from\u00a0\nhttp://www.pharmazeutische\u2010zeitung.de/index.php?id=50893\u00a0\n\u00a0 \u00a0426\u00a04.1 Umeclidinium\u00a0+\u00a0Vilanterol\u00a0\nHandelsname:\u00a0Anoro\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0obstruktive\u00a0 \u00a0 GlaxoSmithKline\u00a0\nLungenerkrankung\u00a0\nATC\u2010Code:\u00a0R03AL03\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juli\u00a02014\u00a0\nDarreichungsform:\u00a0Pulver\u00a0zur\u00a0Inhalation\u00a0 DDD:\u00a01\u00a0DE\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0 Markteinf\u00fchrung\u00a0 der\u00a0 Wirkstoffkombination\u00a0 Umeclidinium\u00a0 und\u00a0 V ilanterol\u00a0\n(Anoro\u00ae)\u00a0im\u00a0Juli\u00a02014\u00a0stand\u00a0neben\u00a0 Glykopyrronium\u00a0und\u00a0Indacatero l\u00a0(Ultibro\u00ae,\u00a0\nXoterna\u00ae)\u00a0 die\u00a0 zweite\u00a0 Fixkombination\u00a0 eines\u00a0 langwirkenden\u00a0 Anticho linergikums\u00a0\n(Long\u2010acting\u00a0 Muscarinic\u00a0 Antagonist ,\u00a0 LAMA)\u00a0 mit\u00a0 einem\u00a0 lang\u00a0 wirkenden\u00a0 Beta 2\u2010\nAgonisten\u00a0( Long\u2010acting\u00a0Beta\u00a0Agonist ,\u00a0LABA)\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0ob\u2010\nstruktiven\u00a0Lungenkrankheit\u00a0( Chronic\u00a0Obstructive\u00a0Disease ,\u00a0COPD)\u00a0zur\u00a0Verf\u00fcgung.\u00a0\nUmeclidinium\u00a0ist\u00a0eine\u00a0Substanz\u00a0m it\u00a0antagonistischer\u00a0Wirkung\u00a0am\u00a0 Muscarinrezep\u2010\ntor\u00a0Typ\u00a03\u00a0(M 3),\u00a0dessen\u00a0Blockade\u00a0in\u00a0den\u00a0Bronchien\u00a0zu\u00a0einer\u00a0Dilatation\u00a0des\u00a0Gew ebes\u00a0\nf\u00fchrt\u00a0und\u00a0somit\u00a0die\u00a0Bel\u00fcftung\u00a0der\u00a0Lunge\u00a0erleichtert.\u00a0Bei\u00a0Vilant erol\u00a0handelt\u00a0es\u00a0sich\u00a0\num\u00a0einen\u00a0Agonisten\u00a0am\u00a0Beta 2\u2010Rezeptor,\u00a0dessen\u00a0Bindung\u00a0eine\u00a0Bronchodilatation\u00a0\nbewirkt.\u00a0Beide\u00a0Substanzen\u00a0flute n\u00a0schnell\u00a0an\u00a0(maximale\u00a0Plasmakon zentration\u00a0nach\u00a0\n5\u00a0bis\u00a015\u00a0Minuten)\u00a0und\u00a0weisen\u00a0lange\u00a0Halbwertszeiten\u00a0auf\u00a0(Umeclid inium\u00a019\u00a0Stun\u2010\nden,\u00a0Vilanterol\u00a011\u00a0Stunden)\u00a0(Burghuber\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0empfo hlene\u00a0Tagesdosis\u00a0\nf\u00fcr\u00a0das\u00a0Inhalationspulver\u00a0betr\u00e4gt\u00a055\u00a0\u00b5g\u00a0Umeclidinium\u00a0und\u00a022\u00a0\u00b5g\u00a0 Vilanterol.\u00a0Bei\u00a0\nbestehenden\u00a0Komorbidit\u00e4ten\u00a0wie\u00a0N ieren\u2010\u00a0sowie\u00a0leichten\u00a0bis\u00a0mitte lschweren\u00a0Le\u2010\nberfunktionsst\u00f6rungen\u00a0ist\u00a0keine\u00a0Anpassung\u00a0des\u00a0Dosierungsregimes \u00a0notwendig.\u00a0Zur\u00a0\nAnwendung\u00a0 bei\u00a0 schweren\u00a0 Lebererkrankungen\u00a0 wurden\u00a0 keine\u00a0 Untersuch ungen\u00a0\ndurchgef\u00fchrt\u00a0(Fachinformation\u00a0Anoro\u00ae,\u00a02016).\u00a0\nDas\u00a0vom\u00a0pharmazeutischen\u00a0Unterneh mer\u00a0(pU)\u00a0durchgef\u00fchrte\u00a0Studien programm\u00a0\nzur\u00a0Zulassung\u00a0umfasst\u00a0acht\u00a0Phase\u2010III\u2010Studien\u00a0an\u00a0insgesamt\u00a06.835 \u00a0Patienten.\u00a0In\u00a0den\u00a0\ndrei\u00a0randomisierten,\u00a0kontrollierten\u00a0Studien\u00a0(DB2113360,\u00a0DB21133 74,\u00a0ZEP117115)\u00a0\n(DeCramer\u00a0et\u00a0al.,\u00a02014;\u00a0Maleki\u2010Yazdi\u00a0et\u00a0al.,\u00a02014)\u00a0wurde\u00a0an\u00a0ins gesamt\u00a01.747\u00a0Pati\u2010\nenten\u00a0mit\u00a0einer\u00a0COPD\u00a0(Einsekundenkapazit\u00e4t\u00a0(FEV 1)\u00a0mindestens\u00a0<\u00a080\u00a0%\u00a0des\u00a0Soll\u2010\nwerts)\u00a0die\u00a0Wirksamkeit\u00a0der\u00a0fixen\u00a0Kombination\u00a0Umeclidinium\u2010Vilan terol\u00a0(55\u00a0\u00b5g\u00a0zu\u00a0\n22\u00a0\u00b5g)\u00a0 gegen\u00fcber\u00a0 dem\u00a0 aktiven\u00a0 Komparator\u00a0 Tiotropium\u00a0 (18\u00a0\u00b5g)\u00a0 unte rsucht\u00a0\n(Burghuber\u00a0et\u00a0al.,\u00a02014).\u00a0Es\u00a0konnte\u00a0kein\u00a0statistisch\u00a0signifikan ter\u00a0Unterschied\u00a0f\u00fcr\u00a0die\u00a0\nEndpunkte\u00a0 Mortalit\u00e4t,\u00a0 Morbidit\u00e4t,\u00a0 gesundheitsbezogene\u00a0 Lebensqua lit\u00e4t\u00a0 (Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0und\u00a0Symptomatik\u00a0be legt\u00a0werden\u00a0(IQWiG,\u00a02014).\u00a0\nAufgrund\u00a0des\u00a0Fehlens\u00a0valider\u00a0Daten\u00a0kann\u00a0f\u00fcr\u00a0das\u00a0Auftreten\u00a0schwe rer\u00a0unerw\u00fcnsch\u2010\nter\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0bei\u00a0Langzeitanwendung\u00a0insbeson dere\u00a0hinsichtlich\u00a0427\u00a0kardio\u2010\u00a0 und\u00a0 zerebrovaskul\u00e4rer\u00a0 Komplikationen\u00a0 keine\u00a0 Bewertung\u00a0 zu r\u00a0 Sicherheit\u00a0\nvorgenommen\u00a0werden.\u00a0Diese\u00a0Aspekte\u00a0untersucht\u00a0aktuell\u00a0eine\u00a0durch \u00a0den\u00a0pU\u00a0finan\u2010\nzierte\u00a0Post\u2010Authorization\u00a0Safety\u00a0Study \u00a0(PASS)\u00a0(201038\u00a0GSK,\u00a02016),\u00a0deren\u00a0Ergebnis\u2010\nse\u00a0voraussichtlich\u00a02021\u00a0vorliegen.\u00a0\nDer\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0sah\u00a0 keinen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznut\u2010\nzen\u00a0gegen\u00fcber\u00a0den\u00a0genannten\u00a0zweckm\u00e4\u00dfi gen\u00a0Vergleichstherapien\u00a0(zVT) .\u00a0Die\u00a0vor\u2010\ngelegten\u00a0Studien\u00a0zeigten\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0mittleren\u00a0Schwereger aden\u00a0der\u00a0COPD\u00a0\n(50\u00a0%\u00a0\u2264\u00a0FEV1\u00a0<\u00a080\u00a0%\u00a0Soll)\u00a0keine\u00a0statistisch\u00a0signifikanten\u00a0Unter schiede\u00a0f\u00fcr\u00a0die\u00a0End\u2010\npunkte\u00a0Mortalit\u00e4t,\u00a0Morbidit\u00e4t,\u00a0HRQoL\u00a0und\u00a0Symptomatik.\u00a0F\u00fcr\u00a0Erkra nkte\u00a0mit\u00a0schwe\u2010\nreren\u00a0COPD\u2010Stadien\u00a0(30\u00a0%\u00a0\u2264\u00a0FEV1\u00a0<\u00a050\u00a0%\u00a0Soll\u00a0bzw.\u00a0FEV1\u00a0<\u00a050\u00a0%\u00a0od er\u00a0respiratori\u2010\nscher\u00a0 Insuffizienz)\u00a0 mit\u00a0 mindestens\u00a0 zwei\u00a0 Exazerbationen\u00a0 j\u00e4hrlich \u00a0 wurden\u00a0 keine\u00a0\nverwertbaren\u00a0Daten\u00a0vom\u00a0pU\u00a0vorgelegt\u00a0(G\u2010BA,\u00a02015).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nWeitere\u00a0Therapieoption\u00a0 kein\u00a0Vorteil\u00a0gegen\u00fcber\u00a0\nzVT\u00a0teils\u00a0g\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen\u00a0Stellenwert\u00a0 \u2013\u00a0 \u2013\u00a0Analogpr\u00e4parat\u00a0\nKosten*\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nUmeclidinium\u00a0plus\u00a0Vilanterol\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 718,08\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nTiotropium\u00a0\u00a0 1x\u00a0tgl.\u00a0 365\u00a0 580,88\u00a0\u20ac\u00a0\nund/oder\u00a0 \u00a0 \u00a0 \u00a0\nFormoterol\u00a0 2x\u00a0tgl.\u00a0 365\u00a0 296,42\u00a0\u20ac\u00a0\nSalmeterol\u00a0 2x\u00a0tgl.\u00a0 365\u00a0 209,94\u00a0\u20ac\u00a0\n*\u00a0excl.\u00a0inhalativer\u00a0Corticosteroide\u00a0bei\u00a0Patienten\u00a0mit\u00a0COPD\u2010Stuf en\u00a0\u2265\u00a0III\u00a0mit\u00a0\u2265\u00a02\u00a0Exazerbationen\u00a0pro\u00a0Jahr\u00a0\n428\u00a0Ausgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nObwohl\u00a0Studien\u00a0keinen\u00a0Vorteil\u00a0gegen\u00fcber\u00a0anderen\u00a0Vergleichsthera pien\u00a0belegten,\u00a0\nstiegen\u00a0sowohl\u00a0die\u00a0Bruttoums\u00e4tze\u00a0als\u00a0auch\u00a0die\u00a0verordneten\u00a0Tages dosen\u00a0im\u00a0Verlauf\u00a0\nder\u00a0 Markteinf\u00fchrung\u00a0an\u00a0 und\u00a0 erreichten\u00a0 ihr\u00a0 Maximum\u00a0 im\u00a0 Oktober\u00a0 20 15\u00a0 mit\u00a0ca.\u00a0\n70.000\u00a0Euro\u00a0bzw.\u00a040.000\u00a0DDD.\u00a0In\u00a0den\u00a0beiden\u00a0darauffolgenden\u00a0Mona ten\u00a0zeigen\u00a0beide\u00a0\nParameter\u00a0einen\u00a0Einbruch.\u00a0Nachdem\u00a0der\u00a0G\u2010BA\u00a0bereits\u00a0im\u00a0Januar\u00a020 15\u00a0die\u00a0Eingrup\u2010\npierung\u00a0der\u00a0Wirkstoffkombination\u00a0in\u00a0die\u00a0entsprechende\u00a0Festbetra gsgruppe\u00a0vorge\u2010\nnommen\u00a0hatte,\u00a0f\u00fchrten\u00a0die\u00a0Preisverhandlungen\u00a0zwischen\u00a0dem\u00a0Spitz enverband\u00a0der\u00a0\ngesetzlichen\u00a0Krankenkassen\u00a0und\u00a0d em\u00a0pU\u00a0zu\u00a0einem\u00a0Erstattungsbetra g,\u00a0der\u00a0unter\u00a0den\u00a0\nbisherigen\u00a0Abgabepreisen\u00a0lag\u00a0(GSK\u00a0&\u00a0GKV,\u00a02015).\u00a0In\u00a0Abb.\u00a04.54\u00a0ze igt\u00a0sich\u00a0resultierend\u00a0\nim\u00a0August\u00a02015\u00a0eine\u00a0vor\u00fcbergehende\u00a0Reduktion\u00a0der\u00a0Bruttoums\u00e4tze. \u00a0\nAbbildung\u00a04.54:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nUmeclidinium\u00a0+\u00a0Vilanterol\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nMit\u00a0Markteinf\u00fchrung\u00a0der\u00a0Wirksto ffkombination\u00a0Umeclidinium\u00a0und\u00a0V ilanterol\u00a0im\u00a0\nJuli\u00a02014\u00a0steht\u00a0neben\u00a0Glykopyrronium\u00a0und\u00a0Indacaterol\u00a0(Ultibro\u00ae, \u00a0Xoterna\u00ae)\u00a0die\u00a0\nzweite\u00a0Fixkombination\u00a0eines\u00a0LAMA\u00a0mit\u00a0einem\u00a0LABA\u00a0zur\u00a0Behandlung\u00a0 der\u00a0COPD\u00a0zur\u00a0\nVerf\u00fcgung.\u00a0Das\u00a0als\u00a0Bromidsalz\u00a0vorliegende\u00a0Umeclidinium\u00a0ist\u00a0eine \u00a0strukturell\u00a0von\u00a0\nAtropin\u00a0abgeleitete\u00a0Substanz\u00a0mit \u00a0antagonistischer\u00a0Wirkung\u00a0am\u00a0M 3\u2010Rezeptor,\u00a0der\u00a0in\u00a0\nder\u00a0Membran\u00a0glatter\u00a0Muskelzellen\u00a0 lokalisiert\u00a0ist.\u00a0Der\u00a0endogene\u00a0 Ligand\u00a0f\u00fcr\u00a0die\u00a0\n429\u00a0Gruppe\u00a0der\u00a0Muscarinrezeptoren\u00a0ist\u00a0Acetylcholin,\u00a0dessen\u00a0Bindung\u00a0 eine\u00a0intrazellul\u00e4re\u00a0\nenzymatisch\u00a0gesteuerte\u00a0Kaskade\u00a0initiiert\u00a0(G\u2010Protein\u00a0gekoppelter \u00a0Rezeptor),\u00a0die\u00a0final\u00a0\neine\u00a0 Kontraktion\u00a0 der\u00a0 betreffenden\u00a0 Muskulatur\u00a0 ausl\u00f6st.\u00a0 Eine\u00a0 Bloc k a d e \u00a0d e s \u00a0M 3\u2010\nRezeptors\u00a0in\u00a0den\u00a0Bronchien\u00a0f\u00fchrt\u00a0daher\u00a0zu\u00a0einer\u00a0Dilatation\u00a0des\u00a0 Gewebes\u00a0und\u00a0erleich\u2010\ntert\u00a0so\u00a0die\u00a0Bel\u00fcftung\u00a0der\u00a0Lunge.\u00a0Bei\u00a0Vilanterol\u00a0handelt\u00a0es\u00a0sich \u00a0um\u00a0einen\u00a0Agonisten\u00a0\nam\u00a0Beta 2\u2010Adrenorezeptor,\u00a0der\u00a0sich\u00a0von\u00a0dessen\u00a0endogenem\u00a0Ligand\u00a0Adrenalin \u00a0bzw.\u00a0\nNoradrenalin\u00a0ableitet\u00a0und\u00a0zur\u00a0besseren\u00a0Bioverf\u00fcgbarkeit\u00a0als\u00a0Tri fenat\u2010Salz\u00a0vorliegt.\u00a0\nNach\u00a0 Bindung\u00a0 an\u00a0 den\u00a0 Rezeptor,\u00a0 der\u00a0 vorwiegend\u00a0 in\u00a0 der\u00a0 glatten\u00a0 Mus kulatur\u00a0 der\u00a0\nAtemwege\u00a0vorkommt,\u00a0wird\u00a0intrazellul\u00e4r\u00a0das\u00a0Enzym\u00a0Adenylylcyclase \u00a0aktiviert,\u00a0welche\u00a0\ndie\u00a0Bildung\u00a0von\u00a0zyklischem\u00a0Ad enosin\u20103\u00b4,5\u00b4\u2010Monophosphat\u00a0( cyclic\u00a0AMP,\u00a0cAMP)\u00a0ver\u2010\nmittelt.\u00a0Die\u00a0erh\u00f6hte\u00a0cAMP\u2010Konzent ration\u00a0bewirkt\u00a0eine\u00a0Relaxation \u00a0der\u00a0glatten\u00a0Musku\u2010\nlatur\u00a0 und\u00a0 somit\u00a0 eine\u00a0 Bronchodilatation\u00a0 (Fachinformation\u00a0 Anoro\u00ae, \u00a02 0 1 6 ; \u00a0B l a i r \u00a0& \u00a0\nDeeks,\u00a02015).\u00a0Beide\u00a0Substanzen\u00a0fluten\u00a0schnell\u00a0an\u00a0(die\u00a0maximale\u00a0 Plasmakonzentrati\u2010\non\u00a0wird\u00a0nach\u00a05\u00a0bis\u00a015\u00a0Minuten\u00a0erreicht)\u00a0und\u00a0weisen\u00a0lange\u00a0Halbwe rtszeiten\u00a0auf\u00a0(Ume\u2010\nclidinium\u00a019\u00a0Stunden,\u00a0Vilanterol\u00a0elf\u00a0Stunden)\u00a0(Burghuber\u00a0et\u00a0al. ,\u00a02014).\u00a0\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDie\u00a0mit\u00a0Erteilung\u00a0der\u00a0Zulassung\u00a0f \u00fcr\u00a0Umeclidinium\u2010Vilanterol\u2010Inh alat\u00a0(Anoro\u00ae)\u00a0am\u00a08.\u00a0\nMai\u00a02014\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Commission ,\u00a0EC)\u00a0best\u00e4tig\u2010\nte\u00a0Indikation\u00a0beinhaltet\u00a0die\u00a0bronchialerweiternde\u00a0Erhaltungsthe rapie\u00a0zur\u00a0Symp\u2010\ntomlinderung\u00a0bei\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0COPD.\u00a0Die\u00a0Applikatio n\u00a0erfolgt\u00a0mithil\u2010\nfe\u00a0eines\u00a0Trockenpulver\u2010Inhalators ,\u00a0der,\u00a0entsprechend\u00a0der\u00a0jeweil igen\u00a0Packungsgr\u00f6\u2010\n\u00dfe,\u00a0sieben\u00a0bzw.\u00a030\u00a0Dosen\u00a0enth\u00e4lt.\u00a0Das\u00a0Arzneimittel\u00a0wird\u00a0einmal\u00a0 t\u00e4glich\u00a0immer\u00a0zur\u00a0\ngleichen\u00a0Zeit\u00a0angewendet.\u00a0Die\u00a0empfohlene\u00a0Tagesdosis\u00a0betr\u00e4gt\u00a055\u00a0 \u00b5g\u00a0Umeclidinium\u00a0\nund\u00a0 22\u00a0\u00b5g\u00a0 Vilanterol\u00a0 und\u00a0 bedarf\u00a0 bei\u00a0 bestehenden\u00a0 Komorbidit\u00e4ten\u00a0 bei\u00a0 Nieren\u2010\u00a0\nsowie\u00a0leichten\u00a0bis\u00a0mittelschweren\u00a0Leberfunktionsst\u00f6rungen\u00a0keine r\u00a0Anpassung.\u00a0Zur\u00a0\nAnwendung\u00a0 bei\u00a0 schweren\u00a0 Lebererkrankungen\u00a0 wurden\u00a0 keine\u00a0 Untersuch ungen\u00a0\ndurchgef\u00fchrt\u00a0(Fachinformation\u00a0Anoro\u00ae,\u00a02016).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Bezeichnung\u00a0COPD\u00a0fasst\u00a0verschiedene\u00a0Krankheitsbilder\u00a0wie\u00a0ch ronische\u00a0ob\u2010\nstruktive\u00a0Bronchitis\u00a0und\u00a0Lungenemphysem\u00a0zusammen.\u00a0Entsprechend\u00a0 der\u00a0Definiti\u2010\non\u00a0der\u00a0Global\u00a0Initiative\u00a0for\u00a0Chronic\u00a0Obstructive\u00a0Lung\u00a0Disease \u00a0(GOLD)\u00a0ist\u00a0die\u00a0Erkran\u2010\nkung\u00a0durch\u00a0dauerhafte\u00a0Atemwegsbeschwerden\u00a0(Husten,\u00a0Auswurf,\u00a0Ate mnot),\u00a0ver\u2010\nminderte\u00a0 Lungenbel\u00fcftung\u00a0 sowie\u00a0 Ver\u00e4nderungen\u00a0 der\u00a0 Atemwege\u00a0 (obst ruktive\u00a0\nBronchitis)\u00a0und\u00a0des\u00a0Lungengewebes\u00a0(Emphysem)\u00a0charakterisiert.\u00a0W ie\u00a0bei\u00a0Asthma\u00a0\nspielen\u00a0Entz\u00fcndungsprozesse\u00a0eine\u00a0 wichtige\u00a0Rolle,\u00a0die\u00a0sich\u00a0labor chemisch\u00a0vonei\u2010\nnander\u00a0unterscheiden\u00a0(GOLD,\u00a02017).\u00a0Im\u00a0weiteren\u00a0Verlauf\u00a0nehmen\u00a0d ie\u00a0entz\u00fcndli\u2010\nchen\u00a0Prozesse\u00a0und\u00a0strukturellen\u00a0Ver\u00e4nderungen\u00a0zu\u00a0und\u00a0kommen\u00a0auc h\u00a0bei\u00a0Rauch\u2010\nverzicht,\u00a0einer\u00a0der\u00a0wichtigsten\u00a0Ma\u00dfnahmen,\u00a0nicht\u00a0zum\u00a0Stillstand \u00a0(H og g\u00a0et\u00a0al ., \u00a0430\u00a02004).\u00a0Die\u00a0genauen\u00a0Ursachen\u00a0der\u00a0COPD\u00a0sind\u00a0bisher\u00a0aber\u00a0nicht\u00a0ein deutig\u00a0identifi\u2010\nziert\u00a0(Ngkelo\u00a0&\u00a0Adcock,\u00a02013).\u00a0Es\u00a0wird\u00a0jedoch\u00a0vermutet,\u00a0dass\u00a0ei ne\u00a0Exposition\u00a0von\u00a0\nsch\u00e4dlichen\u00a0 Gasen\u00a0 und\u00a0 Partikeln\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 genetischer\u00a0 Disposition,\u00a0\n\u00dcberempfindlichkeit\u00a0der\u00a0Atemwege\u00a0sowie\u00a0vermindertem\u00a0Lungenwachs tum\u00a0w\u00e4h\u2010\nrend\u00a0der\u00a0Kindheit\u00a0zu\u00a0COPD\u00a0f\u00fchren\u00a0kann\u00a0(GOLD,\u00a02017).\u00a0Weltweit\u00a0wa ren\u00a02010\u00a0ge\u2010\nsch\u00e4tzte\u00a0384\u00a0Mio.\u00a0Menschen\u00a0an\u00a0COPD\u00a0erkrankt,\u00a0was\u00a0einer\u00a0Pr\u00e4valen z\u00a0von\u00a011,7\u00a0%\u00a0\nbzw.\u00a0drei\u00a0Mio.\u00a0Toten\u00a0j\u00e4hrlich\u00a0entspricht.\u00a0Unter\u00a0Ber\u00fccksichtigun g\u00a0der\u00a0aktuellen\u00a0Ten\u2010\ndenzen,\u00a0wie\u00a0steigendem\u00a0Tabakkonsum\u00a0und\u00a0Ver\u00e4nderung\u00a0der\u00a0Altersst ruktur\u00a0in\u00a0den\u00a0\nIndustriestaaten,\u00a0ergaben\u00a0Kalkulationen\u00a0f\u00fcr\u00a02030\u00a0einen\u00a0weiteren \u00a0Anstieg\u00a0der\u00a0Erkran\u2010\nkungen\u00a0mit\u00a0errechneten\u00a0viereinhalb\u00a0Mio.\u00a0COPD\u2010Toten\u00a0pro\u00a0Jahr\u00a0(Ma thers\u00a0&\u00a0Loncar,\u00a0\n2006;\u00a0Adeloye\u00a0et\u00a0al.,\u00a02015).\u00a0Genaue\u00a0Angaben\u00a0zur\u00a0Pr\u00e4valenz\u00a0in\u00a0De utschland\u00a0liegen\u00a0\nnicht\u00a0vor,\u00a0da\u00a0COPD\u00a0eine\u00a0Krankheit\u00a0mit\u00a0pathophysiologischen\u00a0Misc hbildern\u00a0ist.\u00a0Die\u00a0\nDiagnose\u00a0COPD\u00a0wird\u00a0bei\u00a0Vorliegen\u00a0einer\u00a0chronischen\u00a0Bronchitis\u00a0m it\u00a0einer\u00a0zus\u00e4tzli\u2010\nchen\u00a0dauerhaften\u00a0Verengung\u00a0der\u00a0u nteren\u00a0Atemwege\u00a0mit\u00a0oder\u00a0ohne\u00a0L ungenemphy\u2010\nsem\u00a0gestellt\u00a0(RKI,\u00a02016).\u00a0Die\u00a0Datenerfassung\u00a0gestaltet\u00a0sich\u00a0dah er\u00a0schwierig.\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIm\u00a0Auftrag\u00a0des\u00a0sponsernden\u00a0pU\u00a0wurden\u00a0drei\u00a0zulassungsbegr\u00fcndende ,\u00a0randomi\u2010\nsierte,\u00a0kontrollierte\u00a0Studien\u00a0(DB2113360,\u00a0DB2113374,\u00a0ZEP117115) \u00a0(DeCramer\u00a0et\u00a0\nal.,2014;\u00a0Maleki\u2010Yazdi\u00a0et\u00a0al.,\u00a02014)\u00a0an\u00a0insgesamt\u00a01.747\u00a0Patient en\u00a0mit\u00a0einer\u00a0COPD\u00a0\nvon\u00a0einer\u00a0FEV 1\u00a0von\u00a0mindestens\u00a0<80\u00a0%\u00a0des\u00a0Sollwerts)\u00a0durchgef\u00fchrt,\u00a0um\u00a0die\u00a0Wirk\u2010\nsamkeit\u00a0der\u00a0fixen\u00a0Kombination\u00a0Umeclidinium\u00a0plus\u00a0Vilanterol\u00a0(55\u00a0 \u00b5g/22\u00a0\u00b5g)\u00a0mit\u00a0\nTiotropium\u00a0(18\u00a0\u00b5g)\u00a0als\u00a0aktivem\u00a0Komparator\u00a0zu\u00a0vergleichen\u00a0(EMA,\u00a0 2014).\u00a0Dabei\u00a0\ndiente\u00a0der\u00a0FEV 1\u2010Talwert\u00a0nach\u00a0einer\u00a0Therapiedauer\u00a0von\u00a024\u00a0Wochen\u00a0als\u00a0prim\u00e4rer\u00a0\nEndpunkt,\u00a0 der\u00a0 zum\u00a0 Beleg\u00a0 der\u00a0 klinisch\u00a0 relevanten\u00a0 \u00dcberlegenheit\u00a0 b ez\u00fcglich\u00a0 der\u00a0\nReduktion\u00a0 der\u00a0 Kurzatmigkeit\u00a0 um\u00a0 im\u00a0 Mittel\u00a0 100\u00a0ml\u00a0 betragen\u00a0 sollte \u00a0 (Donohue,\u00a0\n2005).\u00a0Ein\u00a0entsprechendes\u00a0Ergebnis\u00a0wurde\u00a0nur\u00a0in\u00a0einer\u00a0der\u00a0Studi en\u00a0erreicht\u00a0(Blair\u00a0\n&\u00a0Deeks,\u00a02015).\u00a0Kein\u00a0statistisch \u00a0signifikanter\u00a0Unterschied\u00a0zeig te\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Endpunk\u2010\nte\u00a0Mortalit\u00e4t,\u00a0Morbidit\u00e4t,\u00a0HRQoL\u00a0(gemessen\u00a0mittels\u00a0 St.\u00a0George\u00b4s\u00a0Respiratory\u00a0Questi\u2010\nonnaire,\u00a0SGRQ)\u00a0und\u00a0Symptomatik\u00a0(nach\u00a0 Transition\u2010Dyspnea\u2010Index ,\u00a0TDI)\u00a0(Burghuber\u00a0\net\u00a0al.,\u00a02014;\u00a0EMA,\u00a02015).\u00a0Der\u00a0Einfluss\u00a0auf\u00a0die\u00a0Exazerbationsrat e\u00a0im\u00a0Vergleich\u00a0zu\u00a0Pla\u2010\ncebo\u00a0ist\u00a0nicht\u00a0belegt\u00a0und\u00a0zeigt\u00a0 in\u00a0den\u00a0Studien\u00a0heterogene\u00a0Ergeb nisse\u00a0(Burghuber\u00a0et\u00a0\nal.,\u00a02014).\u00a0Beobachtet\u00a0wurde\u00a0sowohl\u00a0eine\u00a0Reduktion\u00a0um\u00a050\u00a0%\u00a0als\u00a0 auch\u00a0eine\u00a0Erh\u00f6\u2010\nhung\u00a0um\u00a020\u00a0bzw.\u00a090\u00a0%\u00a0(Fachinformation\u00a0Anoro\u00ae,\u00a02016;\u00a0EMA,\u00a02014)\u00a0 gegen\u00fcber\u00a0\nTiotropium.\u00a0Der\u00a0pU\u00a0weist\u00a0darauf\u00a0hin,\u00a0dass\u00a0das\u00a0Design\u00a0der\u00a0Studie n\u00a0nicht\u00a0gezielt\u00a0auf\u00a0\ndie\u00a0Wirkung\u00a0der\u00a0Behandlungen\u00a0auf\u00a0COPD\u2010Exazerbationen\u00a0abgestimmt \u00a0war\u00a0(Fachin\u2010\nformationAnoro\u00ae,\u00a02016).\u00a0In\u00a0der\u00a0Gegen\u00fcberstellung\u00a0von\u00a0Untersuchu ngen\u00a0zur\u00a0Ver\u2010\ntr\u00e4glichkeit\u00a0zeigte\u00a0die\u00a0Wirkstoffkombination\u00a0Umeclidinium/Vilan terol\u00a0ein\u00a0\u00e4hnliches\u00a0\nProfil\u00a0wie\u00a0die\u00a0Einzelsubstanzen,\u00a0die\u00a0Therapie\u00a0mit\u00a0Tiotropiumbro mid\u00a0oder\u00a0der\u00a0Kom\u2010\nbination\u00a0Salmeterol\u00a0und\u00a0Fluticason\u00a0(Blair\u00a0&\u00a0Deeks,\u00a02015).\u00a0Die\u00a0i n\u00a0Studien\u00a0am\u00a0h\u00e4u\u2010431\u00a0figsten\u00a0beobachteten\u00a0UAE\u00a0waren\u00a0Kopfschmerzen\u00a0(7\u00a0bis\u00a010\u00a0%\u00a0Umecli dinium/Vilan\u2010\nterol\u00a0vs.\u00a04\u00a0bis\u00a07\u00a0%\u00a0Komparatoren)\u00a0und\u00a0Nasopharyngitits\u00a0(3\u00a0bis\u00a01 0\u00a0%\u00a0vs.\u00a02\u00a0bis\u00a08\u00a0%)\u00a0\n(Blair\u00a0&\u00a0Deeks,\u00a02015).\u00a0Weiterhin\u00a0zeigt\u00a0das\u00a0UE\u2010Spektrum\u00a0der\u00a0Komb ination\u00a0Umeclidi\u2010\nnium/Vilanterol\u00a0das\u00a0f\u00fcr\u00a0LAMA\u00a0und\u00a0LABA\u00a0klassentypische\u00a0Profil.\u00a0E s\u00a0wurden\u00a0sowohl\u00a0\nanticholinerge\u00a0Wirkungen\u00a0wie\u00a0Mundtrockenheit\u00a0und\u00a0Obstipation\u00a0al s\u00a0auch\u00a0gelegent\u2010\nlich\u00a0muscarinerge\u00a0wie\u00a0Herzrhythmusst\u00f6rungen\u00a0und\u00a0Tachykardien\u00a0de tektiert.\u00a0Daten\u00a0\nf\u00fcr\u00a0eine\u00a0valide\u00a0Bewertung\u00a0der\u00a0La ngzeitsicherheit,\u00a0insbesondere\u00a0 hinsichtlich\u00a0kardio\u2010\u00a0\nund\u00a0zerebrovaskul\u00e4rer\u00a0Komplikationen\u00a0fehlen.\u00a0Zur\u00a0Kl\u00e4rung\u00a0dieser \u00a0Risiken\u00a0wurde\u00a0eine\u00a0\nPASS\u00a0(GSK,\u00a02016)\u00a0initiiert,\u00a0die\u00a0fr\u00fchestens\u00a02021\u00a0abgeschlossen\u00a0w ird.\u00a0Offen\u00a0bleibt\u00a0die\u00a0\nFrage,\u00a0wie\u00a0sich\u00a0der\u00a0Einfluss\u00a0der\u00a0nur\u00a0einmal\u00a0t\u00e4glichen\u00a0Anwendung ,\u00a0die\u00a0grunds\u00e4tzlich\u00a0\neine\u00a0Vereinfachung\u00a0darstellt,\u00a0au f\u00a0die\u00a0Adh\u00e4renz\u00a0gestaltet.\u00a0Ob\u00a0si ch\u00a0die\u00a0Krankheitsbelas\u2010\ntung\u00a0durch\u00a0eine\u00a0potentiell\u00a0gr\u00f6\u00dfere\u00a0Adh\u00e4renz\u00a0verringert,\u00a0wurde\u00a0i m\u00a0klinischen\u00a0Setting\u00a0\nnicht\u00a0untersucht.\u00a0\nLeitlinienempfehlungen\u00a0\nBis\u00a0heute\u00a0ist\u00a0COPD\u00a0nicht\u00a0heilbar,\u00a0sodass\u00a0sich\u00a0die\u00a0Pharmakothera pie\u00a0auf\u00a0die\u00a0Reduktion\u00a0\nder\u00a0Symptome,\u00a0H\u00e4ufigkeit\u00a0und\u00a0Schwere\u00a0der\u00a0Exazerbationen\u00a0sowie\u00a0a uf\u00a0die\u00a0Verbesse\u2010\nrung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0beschr\u00e4nkt.\u00a0In\u00a0Deutschland\u00a0liegt\u00a0derzei t\u00a0keine\u00a0g\u00fcltige\u00a0Leitli\u2010\nnie\u00a0vor.\u00a0Unter\u00a0L eitung\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Pneumolog ie\u00a0und\u00a0Beatmungs\u2010\nmedizin\u00a0(DGP)\u00a0sowie\u00a0der\u00a0Deutschen\u00a0Atemwegsliga\u00a0wird\u00a0aktuell\u00a0ein e\u00a0neue\u00a0Leitlinie:\u00a0\n\u201eDiagnostik,\u00a0Pr\u00e4vention\u00a0und\u00a0Therapie\u00a0der\u00a0COPD\u201c\u00a0erarbeitet\u00a0(AWMF ,\u00a02017).\u00a0F\u00fcr\u00a02018\u00a0\nist\u00a0die\u00a0Ver\u00f6ffentlichung\u00a0der\u00a0\u00fcberarbeiteten\u00a0Nationalen\u00a0Versorgu ngsleitlinie\u00a0(NVL)\u00a0\nCOPD\u00a0geplant.\u00a0\u00a0\nAuf\u00a0internationaler\u00a0Ebene\u00a0sehen\u00a0 die\u00a0Empfehlungen\u00a0der\u00a0GOLD\u00a0nach\u00a0 Kategorisie\u2010\nrung\u00a0der\u00a0Patienten\u00a0in\u00a0Abh\u00e4ngigke it\u00a0der\u00a0Schwere\u00a0der\u00a0Symptomatik\u00a0 und\u00a0H\u00e4ufigkeit\u00a0\nder\u00a0Exazerbationen\u00a0(ABCD\u2010Einteil ung)\u00a0eine\u00a0gruppenspezifische\u00a0Ph armakotherapie\u00a0\nvor.\u00a0Dabei\u00a0bilden\u00a0Bronchodilatatoren\u00a0die\u00a0Basismedikation.\u00a0Durch \u00a0Reduktion\u00a0der\u00a0\nbronchialen\u00a0Muskelspannung\u00a0f\u00fchren \u00a0sie\u00a0zu\u00a0einer\u00a0Erweiterung\u00a0der\u00a0 Atemwege\u00a0und\u00a0\nlindern\u00a0somit\u00a0die\u00a0Beschwerden.\u00a0Di e\u00a0jeweiligen\u00a0Substanzen\u00a0rekrut ieren\u00a0sich\u00a0aus\u00a0\ndrei\u00a0 Wirkstoffklassen:\u00a0 Beta 2\u2010Agonisten\u00a0 werden\u00a0 je\u00a0 nach\u00a0 Wirkeintritt\u2010\u00a0 und\u00a0 Halb\u2010\nwertszeit\u00a0in\u00a0langwirksame\u00a0und\u00a0kurzwirksame\u00a0( Short\u2010acting\u00a0Beta\u2010 2\u00a0Agonists ,\u00a0SABA)\u00a0\neingeteilt.\u00a0Letztere\u00a0sind\u00a0nicht\u00a0 Bestandteil\u00a0der\u00a0Basistherapie,\u00a0 sondern\u00a0werden\u00a0zu\u2010\nmeist\u00a0im\u00a0Rahmen\u00a0einer\u00a0Notfallversorgung\u00a0bzw.\u00a0nur\u00a0zur\u00a0Behandlung \u00a0leichter\u00a0Er\u2010\nkrankungsstufen\u00a0eingesetzt.\u00a0Weiterhin\u00a0stehen\u00a0Anticholinergika\u00a0z ur\u00a0Verf\u00fcgung,\u00a0die\u00a0\ndie\u00a0bronchokonstriktorische\u00a0Wirkung\u00a0von\u00a0Acetylcholin\u00a0antagonisi eren.\u00a0\u00c4hnlich\u00a0wie\u00a0\ndie\u00a0Beta 2\u2010Agonisten\u00a0k\u00f6nnen\u00a0sie\u00a0in\u00a0kurz\u2010\u00a0( Short\u2010acting\u00a0Muscarinergic\u00a0Antagonist ,\u00a0\nSAMA)\u00a0und\u00a0langwirkende\u00a0(LAMA)\u00a0gruppiert\u00a0werden.\u00a0Im\u00a0Krankheitsst adium\u00a0B\u00a0wer\u2010\nden\u00a0beide\u00a0Klassen\u00a0im\u00a0Rahmen\u00a0eine r\u00a0Monotherapie\u00a0eingesetzt.\u00a0Erst \u00a0mit\u00a0Progression\u00a0\nzu\u00a0Stufe\u00a0C\u00a0besitzen\u00a0LAMA\u00a0die\u00a0beste\u00a0Evidenz\u00a0und\u00a0k\u00f6nnen\u00a0ggf.\u00a0mit\u00a0 LABA\u00a0kombiniert\u00a0\nwerden.\u00a0Im\u00a0h\u00f6chsten\u00a0Schweregrad\u00a0D\u00a0werden\u00a0grunds\u00e4tzlich\u00a0Kombinat ionen\u00a0emp\u2010432\u00a0fohlen.\u00a0Das\u00a0Methylxanthin\u00a0Theophyllin\u00a0wird\u00a0aufgrund\u00a0seines\u00a0ung\u00fc nstigen\u00a0Neben\u2010\nwirkungsprofils\u00a0 und\u00a0 Interaktionspotentials\u00a0 bei\u00a0 moderater\u00a0 bronch odilatorischer\u00a0\nWirkung\u00a0nicht\u00a0empfohlen.\u00a0Inhalierbare\u00a0Glucocorticoide\u00a0sollten\u00a0e her\u00a0zur\u00fcckhaltend\u00a0\nnur\u00a0bei\u00a0h\u00e4ufigen\u00a0Exazerbationen,\u00a0die\u00a0trotz\u00a0einer\u00a0dualen\u00a0Broncho dilatation\u00a0auftre\u2010\nten\u00a0bzw.\u00a0beim\u00a0Asthma\u2010COPD\u2010 Overlap\u2010Syndrom,\u00a0eingesetzt\u00a0werden.\u00a0\nDie\u00a0Leitlinie\u00a0nennt\u00a0die\u00a0Kombination\u00a0Umeclidinium\u2010Vilanterol\u2010Inh alat\u00a0neben\u00a0ande\u2010\nren,\u00a0jedoch\u00a0ohne\u00a0eine\u00a0Pr\u00e4ferenz\u00a0zu\u00a0\u00e4u\u00dfern.\u00a0Insgesamt\u00a0zeige\u00a0eine \u00a0Kombination\u00a0aus\u00a0\nLABA\u00a0und\u00a0LAMA\u00a0zwar\u00a0keine\u00a0zus\u00e4tzlichen\u00a0vorteilhaften\u00a0Effekte,\u00a0ei n\u00a0Synergismus\u00a0\nbezogen\u00a0auf\u00a0patientenrelevante\u00a0Endpunkte\u00a0sei\u00a0dennoch\u00a0belegt.\u00a0St udien\u00a0zeigten\u00a0\neine\u00a0 \u00dcberlegenheit\u00a0 gegen\u00fcber\u00a0 der \u00a0 Monotherapie\u00a0 bez\u00fcglich\u00a0 Verbess erung\u00a0 der\u00a0\nFEV1,\u00a0Reduktion\u00a0der\u00a0Symptome\u00a0sowie\u00a0Ve rminderung\u00a0der\u00a0Exazerbationen. \u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nIm\u00a0 Januar\u00a0 2015\u00a0 wurde\u00a0 der\u00a0 Zusatznutzen\u00a0 von\u00a0 Umeclidinium\u2010Vilanter ol\u2010Inhalat\u00a0\n(Anoro\u00ae)\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0f\u00fcr\u00a0zwei\u00a0definierte\u00a0Patientengruppen\u00a0ge pr\u00fcft.\u00a0Die\u00a0Eintei\u2010\nlung\u00a0sowie\u00a0die\u00a0Festlegung\u00a0der\u00a0zVT\u00a0erfolgte\u00a0unter\u00a0Ber\u00fccksichtigu ng\u00a0der\u00a0aktuellen\u00a0\nGOLD\u2010Empfehlungen\u00a02014.\u00a0Ab\u00a0Vorliegen\u00a0eines\u00a0mittleren\u00a0Schwereger ades\u00a0(50\u00a0%\u00a0\n\u2264FEV1\u00a0<80\u00a0%\u00a0Soll)\u00a0stellen\u00a0LABA\u00a0(Formoterol\u00a0oder\u00a0Salmeterol)\u00a0oder\u00a0LAM A\u00a0(Tiotropi\u2010\num)\u00a0oder\u00a0eine\u00a0Kombination\u00a0die\u00a0zVT\u00a0dar.\u00a0Bei\u00a0dar\u00fcberhinausgehende n\u00a0Stufen\u00a0(30\u00a0%\u00a0\n\u2264FEV1\u00a0<50\u00a0%\u00a0Soll\u00a0bzw.\u00a0FEV 1\u00a0<50\u00a0%\u00a0oder\u00a0respiratorischer\u00a0Insuffizienz)\u00a0mit\u00a0mindes\u2010\ntens\u00a0zwei\u00a0Exazerbationen\u00a0j\u00e4hrlich\u00a0wird\u00a0die\u00a0genannte\u00a0Behandlung\u00a0 um\u00a0inhalative\u00a0\nCorticoteroide\u00a0erg\u00e4nzt.\u00a0\u00a0\nDer\u00a0 pU\u00a0 legte\u00a0 die\u00a0 drei\u00a0 vergleic henden,\u00a0 randomisiert\u00a0 kontrolliert en\u00a0 Studien\u00a0 vor\u00a0\n(DB211\u00a03360,\u00a0DB2113374,\u00a0ZEP117115)\u00a0(DeCramer\u00a0et\u00a0al.\u00a0,2014;\u00a0Male ki\u2010Yazdi\u00a0et\u00a0al.,\u00a0\n2014),\u00a0die\u00a0den\u00a0Vergleich\u00a0von\u00a0Umeclidinium\u2010Vilanterol\u00a0mit\u00a0Tiotro pium\u00a0untersuch\u2010\nten.\u00a0F\u00fcr\u00a0die\u00a0erste\u00a0Patientengruppe\u00a0zeigte\u00a0sich\u00a0kein\u00a0statistisch \u00a0signifikanter\u00a0Unter\u2010\nschied\u00a0f\u00fcr\u00a0die\u00a0Endpunkte\u00a0Mortalit\u00e4t,\u00a0Morbidit\u00e4t,\u00a0HRQoL\u00a0SGRQ\u00a0und \u00a0Symptomatik\u00a0\n(nach\u00a0TDI).\u00a0Sowohl\u00a0f\u00fcr\u00a0die\u00a0vom\u00a0pU\u00a0nicht\u00a0differenziert\u00a0untersuch ten\u00a0moderaten\u00a0und\u00a0\nschweren\u00a0Exazerbationen\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Therapieabbr\u00fcche\u00a0wegen \u00a0UAE\u00a0lagen\u00a0\nheterogene\u00a0Studienergebnisse\u00a0vor ,\u00a0die\u00a0keine\u00a0sichere\u00a0Bewertung\u00a0e rlaubten\u00a0(G\u2010BA,\u00a0\n2015).\u00a0Daher\u00a0konnte\u00a0der\u00a0G\u2010BA\u00a0 keinen\u00a0Zusatznutzen \u00a0feststellen.\u00a0Weiterhin\u00a0eigne\u2010\nten\u00a0sich\u00a0die\u00a0vorgelegten\u00a0Daten\u00a0n icht\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0der\u00a0zwei ten\u00a0Patientenpo\u2010\npulation,\u00a0sodass\u00a0der\u00a0G\u2010BA\u00a0auch\u00a0hi er\u00a0keinen\u00a0Zusatznutzen\u00a0konstat ierte.\u00a0In\u00a0den\u00a0drei\u00a0\ndirekt\u00a0 vergleichenden\u00a0 Studien\u00a0 waren\u00a0 zu\u00a0 wenige\u00a0 Patienten\u00a0 eingesc hlossen,\u00a0 bei\u00a0\ndenen\u00a0die\u00a0Krankheitskriterien\u00a0und\u00a0\u2010charakteristika\u00a0den\u00a0Vorgaben \u00a0entsprachen.\u00a0Das\u00a0\nGremium\u00a0folgte\u00a0damit\u00a0der\u00a0Einsch\u00e4tzung\u00a0des\u00a0Instituts\u00a0f\u00fcr\u00a0Qualit\u00e4 t\u00a0und\u00a0Wirtschaft\u2010\nlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0(IQWiG,\u00a02014).\u00a0433\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Anzahl\u00a0der\u00a0verordneten\u00a0Packungen\u00a0(Abb.\u00a04.55)\u00a0des\u00a0Kombinatio nspr\u00e4parates\u00a0\nUmeclidinium\u2010Vilanterol\u2010Inhalat\u00a0(A noro\u00ae)\u00a0steigen\u00a0ab\u00a0Markteinf\u00fch rung\u00a0im\u00a0Juli\u00a02014\u00a0\nstetig\u00a0auf\u00a0einen\u00a0Maximalwert\u00a0von\u00a0ca.\u00a0675\u00a0im\u00a0Oktober\u00a02015\u00a0an.\u00a0Au ch\u00a0der\u00a0Beschluss\u00a0\ndes\u00a0G\u2010BA\u00a0vom\u00a0Januar\u00a02015,\u00a0in\u00a0dem\u00a0kein\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznut zen\u00a0festgestellt\u00a0\nwerden\u00a0konnte,\u00a0bewirkte\u00a0keine\u00a0St agnation.\u00a0Erst\u00a0seit\u00a0November\u00a020 15\u00a0ist\u00a0die\u00a0Ten\u2010\ndenz\u00a0r\u00fcckl\u00e4ufig.\u00a0Es\u00a0ist\u00a0anzumerk en,\u00a0dass\u00a0bei\u00a0Markteinf\u00fchrung\u00a0le diglich\u00a0die\u00a0Norm\u2010\ngr\u00f6\u00dfe\u00a0N1\u00a0verf\u00fcgbar\u00a0war.\u00a0Aktuell\u00a0befindet\u00a0sich\u00a0neben\u00a0der\u00a0nicht\u2010n ormierten\u00a0Pa\u2010\nckungseinheit\u00a0nur\u00a0noch\u00a0die\u00a0Gr\u00f6\u00dfe\u00a0 N2\u00a0in\u00a0Handel\u00a0(Lauer\u2010Taxe\u00a0Stand \u00a028.02.2017).\u00a0\nAbbildung\u00a04.55:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Umeclidinium\u00a0+\u00a0Vil anterol\u00a0je\u00a0\nMonat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\n\u00a0\nDie\u00a0dargestellte\u00a0Population\u00a0(Abb. \u00a04.56)\u00a0zeigt\u00a0einen\u00a0Anstieg\u00a0der \u00a0Erkrankungen\u00a0mit\u00a0\nzunehmendem\u00a0Alter.\u00a0Dies\u00a0reflekti ert\u00a0den\u00a0allgemeinen\u00a0Stand\u00a0der\u00a0E rkenntnis,\u00a0wo\u2010\nnach\u00a0 die\u00a0 Erkrankungswahrscheinlichkeit\u00a0 mit\u00a0 fortschreitendem\u00a0 Leb ensalter\u00a0 zu\u2010\nnimmt.\u00a0Die\u00a0Versicherten,\u00a0die\u00a0das \u00a0Medikament\u00a0erhielten,\u00a0waren\u00a0zw ischen\u00a040\u00a0und\u00a0\n89\u00a0Jahre\u00a0alt\u00a0und\u00a0\u00fcberwiegend\u00a0m\u00e4nnlich.\u00a0\n\u00a0 \u00a0\n434\u00a0Abbildung\u00a04.56:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Umeclidi nium\u00a0+\u00a0\nVilanterol\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\nQuellen\u00a0\nAdeloye\u00a0D,\u00a0Chua\u00a0S,\u00a0Lee\u00a0C,\u00a0Basquill\u00a0C,\u00a0Papana\u00a0A,\u00a0Theodoratou\u00a0E\u00a0e t\u00a0al.\u00a0(2015).\u00a0Global\u00a0and\u00a0regional\u00a0estimates\u00a0of\u00a0COPD\u00a0prevalence: \u00a0\nSystematic\u00a0review\u00a0and\u00a0meta\u2010analy sis.\u00a0J\u00a0Global\u00a0Health\u00a05(2):\u00a02041 5.\u00a0\u00a0\nBlair\u00a0HA,\u00a0Deeks\u00a0ED\u00a0(2015).\u00a0Umec lidinium/Vilanterol:\u00a0A\u00a0Review\u00a0of \u00a0Its\u00a0Use\u00a0as\u00a0Maintenance\u00a0Therapy\u00a0in\u00a0Adults\u00a0with\u00a0Chronic\u00a0\nObstructive\u00a0Pulmonary\u00a0Disease.\u00a0Drugs\u00a075(1):\u00a061\u201074.\u00a0\u00a0\nBurghuber\u00a0C,\u00a0Oleschewski\u00a0H,\u00a0Studnicka\u00a0M\u00a0(2014):\u00a0Umeclidinium/Vi lanterol\u00a0bei\u00a0der\u00a0Behandlung\u00a0der\u00a0chronisch\u00a0obstruktiven\u00a0\nLungenerkrankung\u00a0(COPD).\u00a0Journal\u00a0of\u00a0Medical\u00a0Drug\u00a0Reviews\u00a0(4):\u00a01 09\u2010120.\u00a0\nDeCramer\u00a0M,\u00a0Anzueto\u00a0A,\u00a0Kerwin\u00a0E,\u00a0Kaelin\u00a0T,\u00a0Richard\u00a0N,\u00a0Crater\u00a0G\u00a0 et\u00a0al.\u00a0(2014).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0umeclidinium\u00a0plus\u00a0vilante rol\u00a0\nversus\u00a0tiotropium,\u00a0vilanterol,\u00a0or\u00a0umeclidinium\u00a0monotherapies\u00a0ov er\u00a024\u00a0weeks\u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0obstructive\u00a0\npulmonary\u00a0disease.\u00a0Results\u00a0from\u00a0two\u00a0multicentre,\u00a0blinded,\u00a0rando mised\u00a0controlled\u00a0trials.\u00a0Lancet\u00a0Resp\u00a0Med\u00a02\u00a0(6):\u00a0472\u2010\n486.\u00a0\nDonohue\u00a0JF\u00a0(2005).\u00a0Minimal\u00a0Clinic ally\u00a0Important\u00a0Differences\u00a0in\u00a0 COPD\u00a0Lung\u00a0Function.\u00a0COPD:\u00a0Journal\u00a0of\u00a0Chronic\u00a0Obstructive\u00a0\nPulmonary\u00a0Disease\u00a02(1):\u00a0111\u2010124.\u00a0\u00a0\nDonohue\u00a0JF,\u00a0Maleki\u2010Yazdi\u00a0MR,\u00a0Kilbride\u00a0S,\u00a0Mehta\u00a0R,\u00a0Kalberg\u00a0C,\u00a0Ch urch\u00a0A\u00a0(2013).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0once\u2010daily\u00a0\numeclidinium/vilanterol\u00a062.5/25\u00a0m cg\u00a0in\u00a0COPD.\u00a0Respiratory\u00a0Medici ne.\u00a0107(10):\u00a01538\u20101546.\u00a0\nEMA\u00a0\u00a0European\u00a0Medicines\u00a0Agency,\u00a0Committee\u00a0for\u00a0Medical\u00a0Products\u00a0 for\u00a0Human\u00a0Use\u00a0(CHMP)\u00a0(2014).\u00a0International\u00a0Nonproprietary\u00a0\nUse\u00a0(INN)\u2010umeclidinium\u00a0bromide\u00a0/v ilanterol.\u00a0Stand\u00a0der\u00a0Informati on:\u00a0September\u00a02016.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Summary_for_the_public/human/002751/WC500168426.pdf,\u00a0letzter\u00a0Z ugriff:\u00a028.\u00a0Februar\u00a02017.\u00a0\n435\u00a0EMA\u2010European\u00a0Medicines\u00a0Agency\u00a0(2 014).\u00a0Anoro,\u00a0INN\u2010umeclidinium\u00a0b romide/vilanterol.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Summary_for_the_public/human/002751/WC500168426.pdf,\u00a0letzter\u00a0Z ugriff:\u00a028.\u00a0Februar\u00a02017.\u00a0\nFachinformation\u00a0Anoro\u00ae\u00a0(2016).\u00a0Fachinformation\u00a0Anoro\u00ae.\u00a0Stand\u00a0de r\u00a0Information:\u00a0September\u00a02016.\u00a0www.fachinfo.de/api/search/fi,\u00a0\nletzter\u00a0Zugriff:\u00a028.02.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015a).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Umeclidinium/Vilantero l.\u00a0https://www.g\u2010ba.de/downloads/40\u2010268\u2010\n3075/2015\u201001\u201008_AM\u2010RL\u2010XII_Umeclidinium\u2010Vilanterol_2014\u201007\u201015\u2010D\u2010 117_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a015.03.2017.\u00a0\nG\u2010BA\u00a0\u00ac\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015b).\u00a0Beschluss\u00a0des\u00a0Gemei nsamen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0des\u00a0\nArzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die \u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Umeclidinium/Vilanterol.\u00a0Stand\u00a0d er\u00a0Informationen\u00a08.\u00a0Januar\u00a02015.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20103075/2015\u201001\u201008_AM\u2010RL\u2010XII_Umeclidinium\u2010V ilanterol_2014\u201007\u201015\u2010D\u2010117_TrG.pdf,\u00a0letzter\u00a0\nZugriff\u00a015.03.2017.\u00a0\nGKV\u00a0Spitzenverband\u00a0(2015).\u00a0GEErstattungsbetrag\u00a0f\u00fcr\u00a0fixe\u00a0Wirksto ffkombination\u00a0f\u00fcr\u00a0COPD\u2010Patienten\u00a0vereinbart\u00a0\u2010\u00a0Gemeinsame\u00a0\nPressemitteilung.\u00a0\u00a0https://www.gkv\u2010\nspitzenverband.de/media/dokumente/presse/pressemitteilungen/201 5_1/Gm_PM_2015\u201007\u201027_AMNOG_\u2010\n_GlaxoSmithKline_Stackelber g.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\nGOLD\u00a0\u2013\u00a0Global\u00a0Initiative\u00a0For\u00a0Chr onic\u00a0Obstructive\u00a0Lung\u00a0Disease\u00a0( 2017).\u00a0Global\u00a0Strategy\u00a0for\u00a0the\u00a0Diagnosis,\u00a0Management\u00a0and\u00a0\nPrevention\u00a0of\u00a0COPD.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0http:/ /goldcopd.org/download/326/,\u00a0letzter\u00a0Zugriff:\u00a0\n04.07.2017.\u00a0\nGSK\u00a0\u2013\u00a0GlaxoSmithKline\u00a0(2016).\u00a0Find\u00a0Studies.\u00a0Study\u00a0ID\u00a0201038.\u00a0St and\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02017.\u00a0https://www.gsk\u2010clinicalstudyre \u00a0\ngister.com/study/201038#ps,\u00a0letzter\u00a0Zugriff:\u00a020.03.2017.\u00a0\nGSK\u00a0\u2013\u00a0GlaxoSmithKline,\u00a0GKV\u2010Spitze nverband\u00a0(2015).\u00a0Gemeinsame\u00a0Pr essemitteilung:\u00a0Erstattungsbetrag\u00a0f\u00fcr\u00a0fixe\u00a0Wirkstoffkombina\u2010\ntion\u00a0f\u00fcr\u00a0COPD\u2010Patienten\u00a0vereinbart.\u00a0https://www.gkv\u2010spitzenverb and.de/media/dokumente/presse/pressemitteilu\u00a0\nngen/2015_1/Gm_PM_2015\u201007\u201027_AMNOG_\u2010_GlaxoSmithKline_Stackelber g.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.03.2017.\u00a0\nGSK\u2010GlaxoSmithKline\u00a0(n.d.)Post\u2010aut horisation\u00a0Safety\u00a0(PAS)\u00a0Obser vational\u00a0Cohort\u00a0Study\u00a0to\u00a0Quantify\u00a0the\u00a0Incidence\u00a0and\u00a0Comparative \u00a0\nSafety\u00a0of\u00a0Selected\u00a0Cardiovascula r\u00a0and\u00a0Cerebrovascular\u00a0Events\u00a0in \u00a0COPD\u00a0Patients\u00a0Using\u00a0Inhaled\u00a0UMEC/VI\u00a0Combination\u00a0\nor\u00a0Inhaled\u00a0UMEC\u00a0versus\u00a0Tiotropium\u00a0(Study\u00a0201038).\u00a0.\u00a0https://www .gsk\u2010clinicalstudyregister.com/study/201038#ps,\u00a0\nletzter\u00a0Zugriff:\u00a021.04.2017.\u00a0\nHogg\u00a0JC,\u00a0Chu\u00a0F,\u00a0Utokap arch\u00a0S,\u00a0Woods\u00a0R,\u00a0Elliott\u00a0WM,\u00a0Buzatu\u00a0L\u00a0et\u00a0 al.\u00a0(2004):.The\u00a0Nature\u00a0of\u00a0Small\u2010Airway\u00a0Obstruction\u00a0in\u00a0Chronic\u00a0\nObstructive\u00a0Pulmonary\u00a0Disease.\u00a0NEJM\u00a0351\u00a0(13):\u00a01367.\u00a0\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2014).\u00a0IQWiG\u2010Bericht\u2010Nr.\u00a0248.\u00a0Dossierbewertung\u00a0\nUmeclidinium/Vilanterol.\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Au ftrag\u00a0A14\u201022.\u00a0Stand\u00a0der\u00a0Information\u00a0Oktober\u00a0\n2014.\u00a0https://www.g\u2010ba.de/download s/92\u2010975\u2010560/A14\u201022_Umeclidin ium\u2010Vilanterol_Nutzenbewertung\u201035a\u2010SGB\u2010\nV.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.03.2017.\u00a0\nJames\u00a0F,\u00a0Donohue\u00a0MD\u00a0(2005).\u00a0Minimal\u00a0Clinically\u00a0Important\u00a0Differ ences\u00a0in\u00a0COPD\u00a0Lung\u00a0Function,\u00a0COPD:\u00a0J\u00a0Chron\u00a0Obstr\u00a0Pulm\u00a0Dis\u00a0\n2(1):111\u2010124.\u00a0\nMaleki\u2010Yazdi\u00a0MR,\u00a0Kaelin\u00a0T,\u00a0Richard\u00a0N,\u00a0Zvarich\u00a0M,\u00a0Church\u00a0A\u00a0(2014 ).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0umeclidinium/vilanterol\u00a062.5/25\u00a0mcg\u00a0a nd\u00a0\ntiotropium\u00a018\u00a0mcg\u00a0in\u00a0chronic\u00a0obstructive\u00a0pulmonary\u00a0disease:\u00a0Res ults\u00a0of\u00a0a\u00a024\u2010week,\u00a0randomized,\u00a0controlled\u00a0trial.\u00a0\nRespir\u00a0Med\u00a0108(12):\u00a01752\u20101760.\u00a0\u00a0436\u00a0Mathers\u00a0CD,\u00a0Loncar\u00a0D,\u00a0Boreham\u00a0J,\u00a0Thun\u00a0M,\u00a0Heath\u00a0J,\u00a0Doll\u00a0R\u00a0(2006) .\u00a0Projections\u00a0of\u00a0Global\u00a0Mortality\u00a0and\u00a0Burden\u00a0of\u00a0Disease\u00a0from\u00a020 02\u00a0\nto\u00a02030.\u00a0PLoS\u00a0Medicine\u00a03(11):\u00a0e442.\u00a0\u00a0\nNgkelo\u00a0A,\u00a0Adcock\u00a0IM\u00a0(2013).\u00a0New\u00a0treatments\u00a0for\u00a0COPD.\u00a0Curr\u00a0Op\u00a0Ph armacol\u00a013(3):\u00a0362\u2010369.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2016).\u00a0Chronische\u00a0Lungenerkrankunge n\u00a02016.\u00a0\nhttp://www.rki.de/DE/Content/Gesundheitsmonitoring/Themen/Chron ische_Erkrankungen/lungenerkrankungen/lu\nngenerkrankungen_tab.html,\u00a0letzter\u00a0Zugriff:\u00a015.03.2017.\u00a0\n\u00a0 \u00a0437\u00a04.2 Vedolizumab \u00a0\nHandelsname:\u00a0Entyvio\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikationen:\u00a0Morbus\u00a0Crohn/Colitis\u00a0ulcerosa\u00a0Millennium\u00a0Pharmace uticals,\u00a0\u00a0\nATC\u2010Code:\u00a0L04AA33\u00a0 \u00a0 \u00a0 jetzt\u00a0Takeda\u00a0\nDarreichungsform:\u00a0Pulver\u00a0f.\u00a0e.\u00a0Konzentrat\u00a0 Markteinf\u00fchrung:\u00a0Juli \u00a02014\u00a0\nz.\u00a0Herstellung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0\u00a0 DDD:\u00a05,4\u00a0mg\u00a0parenteral\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0Vedolizumab\u00a0(Handelsname:\u00a0En tyvio\u00ae)\u00a0steht\u00a0ein\u00a0humanisierter ,\u00a0monoklonaler\u00a0\nAntik\u00f6rper\u00a0zur\u00a0Verf\u00fcgung,\u00a0welcher\u00a0spezifisch\u00a0an\u00a0\u03b14\u03b27\u2010Integrin\u00a0b indet\u00a0und\u00a0hier\u2010\ndurch\u00a0 das\u00a0 Eindringen\u00a0 von\u00a0 T\u2010Helfer\u2010Lymphozyten\u00a0 in\u00a0 die\u00a0 Darmwand\u00a0 v erhindert.\u00a0\nAndere\u00a0Integrine,\u00a0wie\u00a0\u03b14\u03b21\u2010,\u00a0wel ches\u00a0von\u00a0Natalizumab\u00a0inhibiert\u00a0 wird,\u00a0oder\u00a0\u03b1E\u03b27\u2010\nIntegrin\u00a0werden\u00a0nicht\u00a0gehemmt\u00a0(CHMP,\u00a02014a).\u00a0Seitens\u00a0der\u00a0europ\u00e4 ischen\u00a0Kom\u2010\nmission\u00a0(EC)\u00a0erhielt\u00a0Vedolizumab\u00a0am\u00a022.\u00a0Mai\u00a02014\u00a0die\u00a0Zulassung\u00a0 zur\u00a0Behandlung\u00a0\nvon\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0mittelschwerem\u00a0bis\u00a0schwerem\u00a0aktiv en\u00a0Morbus\u00a0\nCrohn\u00a0(MC)\u00a0bzw.\u00a0Colitis\u00a0ulcerosa\u00a0(CU),\u00a0die\u00a0entweder\u00a0auf\u00a0konvent ionelle\u00a0Therapie\u00a0\noder\u00a0 einen\u00a0 der\u00a0 Tumornekrosefaktor\u2010alpha\u2010(TNF\u03b1)\u2010Antagonisten\u00a0 unz ureichend\u00a0\nangesprochen\u00a0haben,\u00a0nicht\u00a0mehr\u00a0d arauf\u00a0ansprechen\u00a0oder\u00a0eine\u00a0Unve rtr\u00e4glichkeit\u00a0\ngegen\u00a0eine\u00a0entsprechende\u00a0Behandlung\u00a0aufweisen\u00a0(CHMP,\u00a02014b).\u00a0Ve dolizumab\u00a0\nwird\u00a0als\u00a0Infusion\u00a0mit\u00a0300\u00a0mg\u00a0Wirkstoff\u00a0\u00fcber\u00a030\u00a0Minuten\u00a0verabrei cht,\u00a0zu\u00a0Beginn\u00a0der\u00a0\nTherapie\u00a0in\u00a0den\u00a0Wochen\u00a00,\u00a02\u00a0und\u00a06,\u00a0sodann\u00a0im\u00a0Abstand\u00a0von\u00a0acht\u00a0W ochen.\u00a0Bei\u00a0\nung\u00fcnstigem\u00a0Ansprechen\u00a0kann\u00a0die\u00a0Dosierungsfrequenz\u00a0auf\u00a0alle\u00a0vie r\u00a0Wochen\u00a0redu\u2010\nziert\u00a0werden.\u00a0Bei\u00a0Unterbrechung\u00a0 der\u00a0Therapie\u00a0mit\u00a0Vedolizumab\u00a0ka nn\u00a0diese\u00a0auch\u00a0\nnach\u00a0bis\u00a0zu\u00a0einem\u00a0Jahr\u00a0sowohl\u00a0bei\u00a0MC\u00a0als\u00a0auch\u00a0bei\u00a0CU\u00a0wiederaufg enommen\u00a0werden,\u00a0\nhierbei\u00a0kann\u00a0auch\u00a0ein\u00a0vierw\u00f6chiges\u00a0Dosierungsintervall\u00a0erfolgen \u00a0(CHMP,\u00a02014a).\u00a0\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Vedolizumab\u00a0zur \u00a0Therapie\u00a0bei\u00a0CED\u00a0beruht\u00a0auf\u00a0d en\u00a0Phase\u2010III\u2010\nStudien\u00a0GEMINI\u00a0I\u00a0(CU)\u00a0sowie\u00a0GEMINI\u00a0II\u00a0und\u00a0III\u00a0(MC).\u00a0\nF\u00fcr\u00a0die\u00a0Indikation\u00a0CU\u00a0wurden\u00a0zwei\u00a0integrierte,\u00a0multizentrische, \u00a0doppelblinde,\u00a0ran\u2010\ndomisierte,\u00a0placebokontrollierte \u00a0Phase\u2010III\u2010Studien\u00a0GEMINI\u00a0I\u00a0bzw .\u00a0C13006\u00a0(Sponsor:\u00a0\nMillennium\u00a0Pharmaceuticals;\u00a0NCT00783718)\u00a0mit\u00a0Vedolizumab\u00a0in\u00a0fix er\u00a0Dosis\u00a0von\u00a0\n300\u00a0mg\u00a0durchgef\u00fchrt,\u00a0wobei\u00a0eine\u00a0sechsw\u00f6chige\u00a0Initialphase\u00a0von\u00a0e iner\u00a0Erhaltungs\u2010\nphase\u00a0von\u00a0Woche\u00a07\u00a0bis\u00a052\u00a0unterschieden\u00a0wird.\u00a0Eingeschlossen\u00a0wur den\u00a0895\u00a0CU\u2010\nPatienten\u00a0mit\u00a0einem\u00a0 Mayo\u2010Clinic\u00a0Score \u00a0von\u00a06\u00a0bis\u00a012\u00a0sowie\u00a0unzureichendem\u00a0An\u2010\nsprechen\u00a0der\u00a0Therapie\u00a0mit\u00a0Immunmodulatoren\u00a0oder\u00a0TNF \u03b1\u2010Antagonisten.\u00a0In\u00a0der\u00a0\nsechsw\u00f6chigen\u00a0Initialphase\u00a0mit\u00a0Infusionen\u00a0an\u00a0Tag\u00a01\u00a0und\u00a015\u00a0erfol gte\u00a0in\u00a0der\u00a0Kohorte\u00a0\n1\u00a0mit\u00a0n=374\u00a0CU\u2010Patienten\u00a0eine\u00a03:2\u00a0 Randomisierung\u00a0zu\u00a0Vedolizumab \u00a0oder\u00a0Placebo,\u00a0\nin\u00a0Kohorte\u00a02\u00a0wurden\u00a0n=521\u00a0CU\u2010Patienten\u00a0 Open\u2010Label \u00a0therapiert.\u00a0Die\u00a0CU\u2010Patienten,\u00a0\nwelche\u00a0in\u00a0Woche\u00a06\u00a0ein\u00a0therapeutisches\u00a0Ansprechen\u00a0zeigten\u00a0( Responder ),\u00a0wurden\u00a0438\u00a0f\u00fcr\u00a0die\u00a0Erhaltungsphase\u00a0nunmehr\u00a01:1:1\u00a0randomisiert\u00a0zu\u00a0Vedolizum ab\u00a0alle\u00a0acht\u00a0\nWochen,\u00a0alle\u00a0vier\u00a0Wochen\u00a0oder\u00a0Pl acebo.\u00a0Nach\u00a0Woche\u00a052\u00a0konnten\u00a0di e\u00a0Patienten\u00a0an\u00a0\nder\u00a0Langzeitstudie\u00a0C13008\u00a0(Sponsor:\u00a0Millennium\u00a0Pharmaceuticals, \u00a0NCT00790933)\u00a0\nteilnehmen,\u00a0welche\u00a0im\u00a0Juli\u00a02017\u00a0beendet\u00a0wird.\u00a0Den\u00a0prim\u00e4ren\u00a0Endp unkt\u00a0der\u00a0Initial\u2010\nphase,\u00a0das\u00a0klinische\u00a0Ansprechen\u00a0a uf\u00a0zweimalige\u00a0Gabe\u00a0von\u00a0300\u00a0mg\u00a0 Vedolizumab,\u00a0\ndefiniert\u00a0als\u00a0\u226530\u00a0%\u00a0des\u00a0Baselinewertes\u00a0oder\u00a0\u22653\u00a0Punkte\u00a0des\u00a0 Mayo\u2010Scores,\u00a0 erreich\u2010\nten\u00a025,5\u00a0%\u00a0unter\u00a0Placebo\u00a0sowie\u00a0 47,1\u00a0%\u00a0unter\u00a0Vedolizumab,\u00a0eine\u00a0k linische\u00a0Remissi\u2010\non\u00a0(Mayo\u2010score \u00a0<\u00a02)\u00a0erzielten\u00a05\u00a0%\u00a0unter\u00a0Placebo\u00a0und\u00a017\u00a0%\u00a0unter\u00a0Vedolizumab\u00a0\n(p<0,0001).\u00a0Zu\u00a0Woche\u00a052\u00a0zeigten\u00a024\u00a0%\u00a0unter\u00a0Placebo,\u00a057\u00a0%\u00a0bei\u00a0ac htw\u00f6chiger\u00a0Gabe\u00a0\nvon\u00a0Vedolizumab\u00a0(V8)\u00a0sowie\u00a052\u00a0%\u00a0 bei\u00a0vierw\u00f6chiger\u00a0Gabe\u00a0von\u00a0Vedol izumab\u00a0(V4)\u00a0\nklinisches\u00a0Ansprechen\u00a0(n=126/122/125)\u00a0und\u00a0klinische\u00a0Remission\u00a0b ei\u00a016\u00a0%\u00a0unter\u00a0\nPlacebo,\u00a042\u00a0%\u00a0unter\u00a0V8\u00a0sowie\u00a045\u00a0%\u00a0unter\u00a0V4.\u00a0Somit\u00a0konnte\u00a0statis tisch\u00a0signifikant\u00a0\ngegen\u00fcber\u00a0Placebo\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0Vedolizumab\u00a0nachgewiesen\u00a0 werden.\u00a0Unter\u2010\nschiede\u00a0hinsichtlich\u00a0Mortaltit\u00e4t\u00a0zeigten\u00a0sich\u00a0nicht,\u00a0Daten\u00a0zur\u00a0 gesundheitsbezogenen\u00a0\nLebensqualit\u00e4t\u00a0( Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life ,\u00a0HRQoL)\u00a0wurden\u00a0mittels\u00a0den\u00a0Erhe\u2010\nbungsinstrumenten\u00a0 Inflammatory\u00a0Bowel\u00a0Disease\u00a0Questionnaire, \u00a0IBDQ,\u00a0Short\u00a0Form\u2010\n36,\u00a0SF\u201036\u00a0sowie\u00a0 EuroQoL,\u00a0EQ\u20105D\u00a0untersucht,\u00a0laut\u00a0Fachinformation\u00a0waren\u00a0die\u00a0Verbes\u2010\nserungen\u00a0in\u00a0den\u00a0Wochen\u00a06\u00a0und\u00a052\u00a0\u201esignifikant\u00a0gr\u00f6\u00dfer\u201c\u00a0(Feagan,\u00a02 013;\u00a0ClinicalTri\u2010\nals.gov,\u00a02008a;\u00a0CHMP,\u00a02014c;\u00a02014a).\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung\u00a0in\u00a0der\u00a0Indikation\u00a0mittelschwere\u00a0bis\u00a0schwere\u00a0M C\u00a0wurden\u00a0die\u00a0\nbeiden\u00a0Phase\u2010III\u2010Studien\u00a0GEMINI\u00a0II\u00a0und\u00a0III\u00a0durchgef\u00fchrt.\u00a0Die\u00a0zw eiphasige,\u00a0multi\u2010\nzentrische,\u00a0 doppelblinde,\u00a0 randomi sierte,\u00a0 placebokontrollierte\u00a0 P hase\u2010III\u2010Studie\u00a0\nGEMINI\u00a0II\u00a0bzw.\u00a0C13007\u00a0(Sponsor:\u00a0Millennium\u00a0Pharmaceuticals;\u00a0NCT 00783692)\u00a0war\u00a0\n\u00e4hnlich\u00a0GEMINI\u00a0I\u00a0konzipiert.\u00a0W\u00e4hrend\u00a0der\u00a0sechsw\u00f6chigen\u00a0Initialp hase\u00a0erhielt\u00a0die\u00a0\nKohorte\u00a01,\u00a0welche\u00a03:2\u00a0randomisiert\u00a0war,\u00a0entweder\u00a0300\u00a0mg\u00a0Vedoliz umab\u00a0(n=220)\u00a0\nan\u00a0den\u00a0Tagen\u00a01\u00a0und\u00a015\u00a0oder\u00a0Placebo\u00a0(n=148),\u00a0in\u00a0Kohorte\u00a02\u00a0wurde\u00a0 Open\u2010Label \u00a0\nVedolizumab\u00a0analog\u00a0verabreicht\u00a0(n=747).\u00a0Hiernach\u00a0wurden\u00a0die\u00a0 Responder \u00a0(n=461)\u00a0\nf\u00fcr\u00a0die\u00a0Erhaltungsphase\u00a0von\u00a0Woche\u00a07\u00a0bis\u00a052\u00a0im\u00a0Verh\u00e4ltnis\u00a01:1:1\u00a0 randomisiert\u00a0und\u00a0\nerhielten\u00a0entweder\u00a0300\u00a0mg\u00a0Vedolizumab\u00a0alle\u00a0vier\u00a0(V4)\u00a0(n=154)\u00a0bz w.\u00a0acht\u00a0Wochen\u00a0\n(V8)\u00a0(n=154)\u00a0oder\u00a0Placebo\u00a0(n=153).\u00a0Im\u00a0Anschluss\u00a0war\u00a0eine\u00a0Teilna hme\u00a0an\u00a0der\u00a0Lang\u2010\nzeitsicherheitsstudie\u00a0 C13008\u00a0 (Sponsor:\u00a0 Millennium\u00a0 Pharmaceutica ls,\u00a0 NCT0079\u00a0\n0933)\u00a0 mit\u00a0 Open\u2010Label \u00a0 Therapie\u00a0 Vedolizumab\u00a0 m\u00f6glich.\u00a0 Eingeschlossen\u00a0 werden\u00a0\nkonnten\u00a0Patienten\u00a0mit\u00a0mittelsch werem\u00a0bzw.\u00a0schwerem\u00a0MC,\u00a0einem\u00a0 Crohn\u2019s\u00a0Dise\u2010\nase\u00a0Activity\u00a0Index, \u00a0CDAI\u00a0von\u00a0220\u00a0bis\u00a0450\u00a0sowie\u00a0Wirkungsverlust\u00a0unter\u00a0Glucocorti\u2010\ncoid,\u00a0Immunmodulator\u00a0oder\u00a0TNF \u03b1\u2010Antagonist.\u00a0In\u00a0der\u00a0Initialphase\u00a0waren\u00a0als\u00a0prim\u00e4\u2010\nre\u00a0Endpunkte\u00a0in\u00a0Woche\u00a06\u00a0der\u00a0Anteil\u00a0Patienten\u00a0in\u00a0klinischer\u00a0Remi ssion\u00a0(CDAI\u2010Score\u00a0\n\u2264150\u00a0Punkte)\u00a0sowie\u00a0mit\u00a0verbessertem\u00a0klinischen\u00a0Ansprechen\u00a0(Abna hme\u00a0des\u00a0CDAI\u2010\nScores\u00a0\u2265100\u00a0Punkte\u00a0Woche\u00a00\u00a0bis\u00a0Woche\u00a06)\u00a0definiert,\u00a0wobei\u00a0nur\u00a0f\u00fc r\u00a0\u201eklinische\u00a0Re\u2010\nmission\u201c\u00a0(Placebo\u00a07\u00a0%,\u00a0Vedolizumab\u00a015\u00a0%)\u00a0statistische\u00a0Signifika nz\u00a0(p<0,05)\u00a0gezeigt\u00a0\nwerden\u00a0konnte,\u00a0bei\u00a0verbessertem\u00a0klinischen\u00a0Ansprechen\u00a0jedoch\u00a0ni cht\u00a0(Placebo\u00a0439\u00a026\u00a0%\u00a0gegen\u00fcber\u00a0Vedolizumab\u00a031\u00a0%).\u00a0In\u00a0Woche\u00a052\u00a0wurde\u00a0bei\u00a022\u00a0%\u00a0un ter\u00a0Placebo\u00a0\ngegen\u00fcber\u00a039\u00a0%\u00a0V4\u00a0(p<0,001)\u00a0bzw.\u00a036\u00a0%\u00a0V8\u00a0(p<0,05)\u00a0\u201eklinische\u00a0Re mission\u201c\u00a0nach\u2010\ngewiesen,\u00a0ein\u00a0\u201everbessertes\u00a0klinisches\u00a0Ansprechen\u201c\u00a0bei\u00a030\u00a0%\u00a0unt er\u00a0Placebo,\u00a0bei\u00a0\n44\u00a0%\u00a0unter\u00a0V4\u00a0sowie\u00a045\u00a0%\u00a0unter\u00a0V8\u00a0(p<0,001)\u00a0(ClinicalTrials.gov ,\u00a02008b;\u00a0Sandborn,\u00a0\n2013).\u00a0In\u00a0GEMINI\u00a0II\u00a0traten\u00a0unter\u00a0Vedolizumab\u00a0vermehrt\u00a0schwere\u00a0N ebenwirkungen\u00a0\n(24,4\u00a0%\u00a0versus\u00a015,3\u00a0%),\u00a0schwere\u00a0Infektionen\u00a0(5,5\u00a0%\u00a0versus\u00a03,0\u00a0% )\u00a0und\u00a0mehr\u00a0Infekti\u2010\nonen\u00a0(44,1\u00a0%\u00a0gegen\u00fcber\u00a040,2\u00a0%)\u00a0auf.\u00a0Im\u00a0Rahmen\u00a0exploratorischer\u00a0 Analysen\u00a0zur\u00a0\nHRQoL\u00a0konnte\u00a0laut\u00a0Fachinformation\u00a0sowohl\u00a0f\u00fcr\u00a0V4\u00a0als\u00a0auch\u00a0V8\u00a0ein e\u00a0signifikante\u00a0\nVerbesserung\u00a0der\u00a0EQ\u20105D\u2010\u00a0und\u00a0VAS\u2010 Werte,\u00a0von\u00a0IBDQ\u2010Gesamt\u2010Score\u00a0al s\u00a0auch\u00a0IBDQ\u2010\nSubskalen\u00a0 f\u00fcr\u00a0 Darmsymptome\u00a0 und\u00a0 K\u00f6rperfunktion\u00a0 gezeigt\u00a0 werden\u00a0 (S andborn,\u00a0\n2013;\u00a0CHMP,\u00a02014a).\u00a0In\u00a0der\u00a0erg\u00e4nzenden\u00a0Studie\u00a0GEMINI\u00a0III\u00a0mit\u00a0ku rzer,\u00a0zehnw\u00f6chi\u2010\nger\u00a0Dauer\u00a0mit\u00a0Patienten,\u00a0welche\u00a0zuvor\u00a0unter\u00a0TNF\u03b1\u2010Antagonisten\u00a0W irkungsverlust\u00a0\nzeigten,\u00a0konnte\u00a0zwischen\u00a0Vedolizumab\u00a0und\u00a0Scheinmedikament\u00a0im\u00a0pr im\u00e4ren\u00a0End\u2010\npunkt\u00a0\u201eklinische\u00a0Remission\u00a0in\u00a0Woche\u00a06\u201c\u00a0kein\u00a0Unterschied\u00a0gezeigt \u00a0werden\u00a0(CHMP,\u00a0\n2014a).\u00a0\nIm\u00a0klinischen\u00a0Alltag\u00a0zu\u00a0beachten\u00a0ist,\u00a0dass\u00a0sich\u00a0unter\u00a0der\u00a0Thera pie\u00a0mit\u00a0Vedolizumab\u00a0\nbei\u00a04\u00a0%\u00a0der\u00a0Patienten\u00a0Antik\u00f6rper \u00a0gegen\u00a0Vedolizumab\u00a0(Anti\u2010Drug\u2010A ntik\u00f6rper,\u00a0ADA)\u00a0\nb i l d e n \u00a0u n d \u00a0b e i \u00a04 \u00a0 % \u00a0i n f u s i o n s a s s o z i i e r t e \u00a0R e a k t i o n e n \u00a0( I A R ) \u00a0a u f t r e ten\u00a0 (Hafner\u2010\nBlumenstiel\u00a0et\u00a0al.,\u00a02015).\u00a0\nDer\u00a0G\u2010BA\u00a0identifizierte\u00a0gem\u00e4\u00df\u00a0de r\u00a0Zulassung\u00a0von\u00a0Vedolizumab\u00a0vie r\u00a0Subgruppen\u00a0im\u00a0\nKontext\u00a0 der\u00a0 Nutzenbewertung,\u00a0 einerseits\u00a0 die\u00a0 beiden\u00a0 chronisch\u2010en tz\u00fcndlichen\u00a0\nDarmerkrankungen\u00a0(CED)\u00a0CU\u00a0und\u00a0MC,\u00a0andererseits\u00a0jeweils\u00a0\u201ePatient en,\u00a0die\u00a0auf\u00a0\nkonventionelle\u00a0 Therapie\u00a0 oder\u00a0 TNF \u03b1\u2010Antagonisten\u00a0 unzureichend\u00a0 ang esprochen\u00a0\nhaben,\u00a0 nicht\u00a0 mehr\u00a0 darauf\u00a0 ansprechen\u00a0 oder\u00a0 eine\u00a0 Unvertr\u00e4glichkeit \u00a0g e g e n \u00a0e i n e \u00a0\nentsprechende\u00a0Behandlung\u00a0aufweisen\u201c.\u00a0Im\u00a0Beschluss\u00a0vom\u00a08.\u00a0Januar \u00a02015\u00a0konnte\u00a0\nder\u00a0G\u2010BA\u00a0aufgrund\u00a0des\u00a0vom\u00a0pU\u00a0vorgelegten\u00a0indirekten\u00a0Vergleiches \u00a0nach\u00a0Bucher\u00a0\nkeinen\u00a0Zusatznutzen \u00a0gegen\u00fcber\u00a0zweckm\u00e4\u00dfiger\u00a0Vergleichstherapie\u00a0zVT\u00a0feststellen\u00a0\n(G\u2010BA,\u00a02015a).\u00a0\nDer\u00a0G\u2010BA\u00a0f\u00fchrt\u00a0als\u00a0Begr\u00fcndung\u00a0hierzu\u00a0aus,\u00a0dass\u00a0die\u00a0Studien\u00a0GEMI NI\u00a0I\u00a0und\u00a0ULTRA\u00a01\u00a0\nbzw.\u00a02\u00a0(Adalimumab)\u00a0zu\u00a0unterschiedliche\u00a0Studiendesigns\u00a0und\u00a0\u2010pop ulationen\u00a0auf\u2010\nweisen,\u00a0um\u00a0basierend\u00a0auf\u00a0einem\u00a0adjustierten\u00a0Vergleich\u00a0nach\u00a0Buch er\u00a0Aussagen\u00a0zum\u00a0\nZusatznutzen\u00a0gegen\u00fcber\u00a0zVT\u00a0ableiten\u00a0zu\u00a0k\u00f6nnen,\u00a0insbesondere\u00a0die \u00a0unterschiedli\u2010\nche\u00a0Randomisierung\u00a0von\u00a0 Respondern \u00a0und\u00a0Non\u2010Respondern \u00a0in\u00a0den\u00a0Initial\u2010\u00a0und\u00a0Er\u2010\nhaltungsphasen\u00a0der\u00a0Studien.\u00a0Auch\u00a0die\u00a0Vergleiche\u00a0mit\u00a0den\u00a0Studien \u00a0GEMINI\u00a0II\u00a0und\u00a0III\u00a0\nerkannte\u00a0der\u00a0G\u2010BA\u00a0mit\u00a0Hinweis\u00a0auf\u00a0die\u00a0geringen\u00a0Effektst\u00e4rken\u00a0be i\u00a0MC\u00a0nicht\u00a0an\u00a0\u00a0\n(G\u2010BA,\u00a02015b).\u00a0\n\u00a0440\u00a0Der\u00a0Stellenwert\u00a0der\u00a0Therapie\u00a0mit\u00a0Vedolizumab\u00a0ist\u00a0in\u00a0Ermangelung \u00a0von\u00a0direkt\u00a0ver\u2010\ngleichenden\u00a0 Studien\u00a0 Vedolizum ab/TNF\u03b1\u2010Antagonisten\u00a0 bei\u00a0 TNF \u03b1\u2010Antagonisten\u2010\nnaiven\u00a0 CED\u2010Patienten\u00a0 unklar.\u00a0 Zudem\u00a0 fehlen\u00a0 Langzeitdaten\u00a0 zur\u00a0 Sic herheit.\u00a0 Falls\u00a0\njedoch\u00a0Basis\u2010\u00a0(Azathioprin,\u00a06\u2010Me rcaptopurin\u2010)\u00a0und\u00a0Eskalationsth erapie\u00a0erfolglos\u00a0\nverlaufen,\u00a0stellt\u00a0Vedolizumab\u00a0ggf.\u00a0eine\u00a0zus\u00e4tzliche\u00a0Option\u00a0dar\u00a0 (AKd\u00c4\u00a0&\u00a0KBV,\u00a02016;\u00a0\nHAS,\u00a02015;\u00a0AKd\u00c4,\u00a02014).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nErster\u00a0selektiver\u00a0\u03b1 4\u03b27\u2010\nIntegrinantagonist\u00a0bei\u00a0\nCED\u00a0Keine\u00a0Studien\u00a0gegen\u2010\n\u00fcber\u00a0zVT,\u00a0daher\u00a0kein\u00a0\nNachweis\u00a0eines\u00a0\nZusatznutzens\u00a0seitens\u00a0\ndes\u00a0G\u2010BA\u00a0\u00a0Nach\u00a0erfolgter\u00a0Verhandlung\u00a0\neines\u00a0Erstattungsbetrages\u00a0\nnur\u00a0teils\u00a0g\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA/C\u00a0 \u2013\u00a0 \u2013\u00a0 Nothing\u00a0new\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nVedolizumab*\u00a0 1\u00a0Infusion\u00a0alle\u00a08\u00a0oder\u00a0\n4\u00a0Wochen\u00a06,5\u00a0\u2013\u00a013\u00a0 21.017,96\u00a0\u2013\u00a039.114,14\u00a0\u20ac\u00a0\nVergleichstherapie \u00a0 \u00a0 \u00a0 \u00a0\nAdalimumab\u00a0 1x\u00a0s.c.\u00a0alle\u00a02\u00a0Wochen\u00a0\nbzw.\u00a01x\u00a0w\u00f6chentlich\u00a026\u00a0\u2013\u00a052\u00a0 22.669,23\u00a0\u2013\u00a045.338,45\u00a0\u20ac\u00a0\n\u00a0\nInfliximab\u00a0*\u00a0\nInfliximab\u00a0Biosimilars\u00a0(Flixabi,\u00a0\nInflectra,\u00a0Remsima)*\u00a0\u00a0\n1x\u00a0alle\u00a08\u00a0Wochen\u00a0i.v.\u00a0\n1x\u00a0alle\u00a08\u00a0Wochen\u00a0i.v.\u00a0\u00a0\n6,5\u00a0\n6,5\u00a0\u00a0\n26.825,51\u00a0\u20ac\u00a0\n20.260,30\u00a0\u2013\u00a023.926,60\u00a0\u20ac\u00a0\n*\u00a0Applikation\u00a0als\u00a0Infusionsl\u00f6sung,\u00a0d.h.\u00a0inkl.\u00a0Herstellung\u00a0bezog en\u00a0auf\u00a072\u00a0kg\u00a0KG\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nBei\u00a0Vedolizumab\u00a0handelt\u00a0es\u00a0sich\u00a0u m\u00a0einen\u00a0humanisierten\u00a0monoklon alen\u00a0Antik\u00f6r\u2010\nper,\u00a0welcher\u00a0spezifisch\u00a0an\u00a0\u03b1 4\u03b27\u2010Integrin\u00a0bindet,\u00a0das\u00a0bevorzugt\u00a0auf\u00a0in\u00a0die\u00a0Darmwand\u00a0\neindringenden\u00a0T\u2010Helfer\u2010Lymphozyt en\u00a0exprimiert\u00a0wird.\u00a0Diese\u00a0k\u00f6nne n\u00a0sich\u00a0hierdurch\u00a0\nnicht\u00a0mehr\u00a0an\u00a0 Mucosal\u00a0Addression\u00a0Cellular\u00a0Adhesion \u00a0Molecule\u20101 \u00a0(MAdCAM\u20101)\u00a0auf\u00a0\n441\u00a0den\u00a0 Darm\u2010Endothelzellen\u00a0 anheften,\u00a0 so\u00a0 dass\u00a0 ihre\u00a0 Einwanderung\u00a0 in\u00a0 Gewebe\u00a0 im\u00a0\nMagen\u2010Darm\u2010Trakt\u00a0und\u00a0damit\u00a0ver bundene\u00a0gastrointestinale\u00a0Entz\u00fcnd ungsreaktio\u2010\nnen\u00a0 gehemmt\u00a0 werden.\u00a0 Andere\u00a0 Integrine,\u00a0 wie\u00a0 \u03b1 4\u03b21\u2010,\u00a0 welches\u00a0 von\u00a0 Natalizumab\u00a0\ninhibiert\u00a0wird,\u00a0oder\u00a0\u03b1 E\u03b27\u2010Integrin \u00a0werden\u00a0nicht\u00a0gehemmt.\u00a0(CHMP,\u00a02014c).\u00a0\nZulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nSeitens\u00a0der\u00a0EC\u00a0erhielt\u00a0Vedolizumab\u00a0auf\u00a0Empfehlung\u00a0des\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0\nProducts\u00a0for\u00a0Human\u00a0Use \u00a0CHMP\u00a0am\u00a022.\u00a0Mai\u00a02014\u00a0die\u00a0Zulassung\u00a0zur\u00a0Behandlung\u00a0von\u00a0\nerwachsenen\u00a0Patienten\u00a0mit\u00a0mittelschwerem\u00a0bis\u00a0schwerem\u00a0aktiven\u00a0M C\u00a0bzw.\u00a0CU,\u00a0\ndie\u00a0entweder\u00a0auf\u00a0konventionelle\u00a0Therapie\u00a0oder\u00a0einen\u00a0der\u00a0Tumorne krosefaktor\u2010\nalpha\u2010(TNF \u03b1)\u2010Antagonisten\u00a0unzureichend\u00a0ange sprochen\u00a0haben,\u00a0nicht\u00a0mehr\u00a0dara uf\u00a0\nansprechen\u00a0oder\u00a0eine\u00a0Unvertr\u00e4glichkeit\u00a0gegen\u00a0eine\u00a0entsprechende \u00a0Behandlung\u00a0\naufweisen\u00a0(CHMP,\u00a02014b).\u00a0Die\u00a0Aufnahme\u00a0in\u00a0die\u00a0Lauer\u2010Taxe\u00a0erfolgt e\u00a0zum\u00a015.\u00a0Juli\u00a0\n2014\u00a0 (WebAPO,\u00a0 2017).\u00a0 Vedolizumab\u00a0 wird\u00a0 nach\u00a0 aseptischer\u00a0 Rekonsti tution\u00a0 als\u00a0\nInfusion\u00a0mit\u00a0300 \u00a0mg\u00a0Wirkstoff\u00a0\u00fcber\u00a030\u00a0Minuten\u00a0 unter\u00a0\u00e4rztlicher\u00a0\u00dcberwachung\u00a0\nverabreicht,\u00a0zu\u00a0Beginn\u00a0der\u00a0Therapie\u00a0in\u00a0den\u00a0Wochen\u00a00,\u00a02\u00a0und\u00a06,\u00a0s odann\u00a0im\u00a0Abstand\u00a0\nvon\u00a0acht\u00a0Wochen.\u00a0Bei\u00a0ung\u00fcnstigem\u00a0Ansprechen\u00a0kann\u00a0die\u00a0Dosierungs frequenz\u00a0auf\u00a0\nalle\u00a0vier\u00a0Wochen\u00a0reduziert\u00a0werden.\u00a0Bei\u00a0Colitis\u00a0ulcerosa\u00a0sollte\u00a0 in\u00a0Woche\u00a010\u00a0ent\u2010\nschieden\u00a0werden,\u00a0ob\u00a0bei\u00a0fehlendem\u00a0Ansprechen\u00a0auf\u00a0die\u00a0Therapie\u00a0m it\u00a0Vedolizumab\u00a0\ndiese\u00a0fortgef\u00fchrt\u00a0wird.\u00a0Bei\u00a0MC\u00a0sollte\u00a0in\u00a0Woche\u00a010\u00a0bei\u00a0bisher\u00a0ni cht\u00a0erfolgtem\u00a0An\u2010\nsprechen\u00a0\u00fcber\u00a0eine\u00a0zus\u00e4tzliche\u00a0Gabe\u00a0entschieden\u00a0werden,\u00a0ab\u00a0Woch e\u00a014\u00a0ist\u00a0die\u00a0\nTherapie\u00a0bei\u00a0Ausbleiben\u00a0des\u00a0Erfolges\u00a0zu\u00a0beenden.\u00a0Patienten\u00a0mit\u00a0 MC,\u00a0welche\u00a0auf\u00a0\ndie\u00a0Therapie\u00a0ansprechen,\u00a0erhalte n\u00a0Vedolizumab\u00a0ab\u00a0Woche\u00a014\u00a0alle\u00a0 acht\u00a0Wochen,\u00a0\nggf.\u00a0kann\u00a0das\u00a0Dosierungsintervall\u00a0auch\u00a0auf\u00a0eine\u00a0vierw\u00f6chige\u00a0App likation\u00a0verk\u00fcrzt\u00a0\nwerden.\u00a0Bei\u00a0Unterbrechung\u00a0der\u00a0The rapie\u00a0mit\u00a0Vedolizumab\u00a0kann\u00a0die se\u00a0auch\u00a0nach\u00a0\nbis\u00a0zu\u00a0einem\u00a0Jahr\u00a0sowohl\u00a0bei\u00a0MC\u00a0 als\u00a0auch\u00a0bei\u00a0CU\u00a0wiederaufgenomm en\u00a0werden,\u00a0\nhierbei\u00a0kann\u00a0auch\u00a0ein\u00a0vierw\u00f6chige s\u00a0Dosierungsintervall\u00a0erfolgen \u00a0(CHMP,\u00a02014c).\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nMorbus\u00a0Crohn\u00a0und\u00a0die\u00a0nur\u00a0die\u00a0Mucosa\u00a0des\u00a0Dickdarms\u00a0betreffende\u00a0C olitis\u00a0ulcerosa\u00a0\nz\u00e4hlen\u00a0zu\u00a0den\u00a0schubf\u00f6rmig\u00a0verlau fenden,\u00a0immunologisch\u00a0bedingten \u00a0chroni sch\u2010\nentz\u00fcndlichen\u00a0Darmerkrankungen.\u00a0Al s\u00a0Leitsymptome\u00a0werden\u00a0Bauchsc hmerz,\u00a0teils\u00a0\nblutige\u00a0Diarrhoe\u00a0und\u00a0bei\u00a0CU\u00a0auch\u00a0peranale\u00a0Blutung\u00a0genannt,\u00a0zude m\u00a0k\u00f6nnen\u00a0extra\u2010\nintestinale\u00a0Manifestationen\u00a0an\u00a0Augen,\u00a0Haut\u00a0oder\u00a0Gelenken\u00a0auftre ten.\u00a0Die\u00a0H\u00e4ufig\u2010\nkeit\u00a0von\u00a0CU\u00a0betr\u00e4gt\u00a01/198\u00a0und\u00a0von\u00a0MC\u00a01/310\u00a0in\u00a0Europa\u00a0(Wehkamp\u00a0e t\u00a0al.,\u00a02016).\u00a0\nDas\u00a0Weissbuch\u00a0Gastroenterologie\u00a0nennt\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02014\u00a026.368\u00a0 F\u00e4lle\u00a0mit\u00a0MC\u00a0und\u00a0\n19.922\u00a0F\u00e4lle\u00a0mit\u00a0CU\u00a0als\u00a0Diagnose\u00a0einer\u00a0station\u00e4ren\u00a0Behandlung\u00a0( DGVS\u00a0et\u00a0al.\u00a0,\u00a0\n2017).\u00a0Als\u00a0Ursachen\u00a0der\u00a0CED\u00a0wurden\u00a0einerseits\u00a0\u00fcber\u00a0160\u00a0Risikoge ne\u00a0gefunden,\u00a0\nandererseits\u00a0aber\u00a0auch\u00a0Umweltfak toren\u00a0wie\u00a0Antibiotikagabe\u00a0in\u00a0de r\u00a0Jugend\u00a0oder\u00a0\nRauchen\u00a0bei\u00a0MC.\u00a0Als\u00a0Paradigmenwe chsel\u00a0ist\u00a0die\u00a0Interpretation\u00a0de r\u00a0CED\u00a0als\u00a0\u201eDysbi\u2010442\u00a0ose\u201c\u00a0bzw.\u00a0komplexe\u00a0\u201eBarriere\u2010Erkrankung\u201c\u00a0der\u00a0Darmschleimhaut\u00a0zu \u00a0verstehen,\u00a0\nwobei\u00a0die\u00a0bisherige\u00a0Definition\u00a0von\u00a0CU\u00a0und\u00a0MC\u00a0als\u00a0Autoimmunerkra nkungen\u00a0hier\u2010\nvon\u00a0abgel\u00f6st\u00a0wird.\u00a0Die\u00a0Diagnostik\u00a0gestaltet\u00a0sich\u00a0komplex,\u00a0da\u00a0ch ronische\u00a0Diarrhoe,\u00a0\nbei\u00a0CU\u00a0auch\u00a0blutig,\u00a0Gewichtsverl ust\u00a0und\u00a0Bauchschmerzen\u00a0vielerle i\u00a0Ursachen\u00a0auf\u2010\nweisen\u00a0k\u00f6nnen.\u00a040 \u00a0%\u00a0der\u00a0Patienten\u00a0remittieren\u00a0nach\u00a0einem\u00a0ersten\u00a0CED\u2010Schub,\u00a0\n20\u00a0%\u00a0entwickeln\u00a0einen\u00a0steroidrefrakt\u00e4ren\u00a0Verlauf\u00a0und\u00a040 \u00a0%\u00a0entwickeln\u00a0w\u00e4hrend\u00a0\ndes\u00a0Ausschleichens\u00a0der\u00a0Steroide\u00a0einen\u00a0neuen\u00a0Schub\u00a0(Wehkamp\u00a0et\u00a0a l.,\u00a02016).\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Vedolizumab\u00a0zur \u00a0Therapie\u00a0bei\u00a0CED\u00a0beruht\u00a0auf\u00a0d en\u00a0Phase\u2010III\u2010\nStudien\u00a0GEMINI\u00a0I\u00a0(CU)\u00a0sowie\u00a0GEMINI\u00a0II\u00a0und\u00a0III\u00a0(MC).\u00a0\nF\u00fcr\u00a0die\u00a0Indikation\u00a0CU\u00a0wurden\u00a0zwei\u00a0integrierte,\u00a0multizentrische, \u00a0doppelblinde,\u00a0ran\u2010\ndomisierte,\u00a0 placebokontrollierte \u00a0 Phase\u2010III\u2010Studien\u00a0 GEMINI\u00a0 I\u00a0 (C1 3006;\u00a0 NCT\u00a0 007\u00a0\n83718)\u00a0mit\u00a0Vedolizumab\u00a0in\u00a0fixer\u00a0Dosis\u00a0von\u00a0300\u00a0mg\u00a0durchgef\u00fchrt,\u00a0 es\u00a0gab\u00a0eine\u00a0\nsechsw\u00f6chige\u00a0Initialphase\u00a0und\u00a0eine\u00a0Erhaltungsphase\u00a0von\u00a0Woche\u00a07\u00a0 bis\u00a052\u00a0wird.\u00a0\nEingeschlossen\u00a0wurden\u00a0895\u00a0CU\u2010Patienten\u00a0mit\u00a0einem\u00a0 Mayo\u2010Clinic\u00a0Score \u00a0von\u00a06\u00a0bis\u00a0\n12\u00a0sowie\u00a0unzureichendem\u00a0Ansprechen\u00a0der\u00a0Therapie\u00a0mit\u00a0Immunmodula toren\u00a0oder\u00a0\nTNF\u03b1\u2010Antagonisten.\u00a0In\u00a0der\u00a0sechsw\u00f6chi gen\u00a0Initialphase\u00a0mit\u00a0Infusionen \u00a0an\u00a0Tag\u00a01\u00a0und\u00a0\n15\u00a0erfolgte\u00a0in\u00a0der\u00a0Kohorte\u00a01\u00a0mit\u00a0n=374\u00a0CU\u2010Patienten\u00a0eine\u00a03:2\u00a0Ra ndomisierung\u00a0zu\u00a0\nVedolizumab\u00a0oder\u00a0Placebo,\u00a0in\u00a0Kohorte\u00a02\u00a0wurden\u00a0n=521\u00a0CU\u2010Patiente n\u00a0open\u2010Label\u00a0\ntherapiert.\u00a0Die\u00a0CU\u2010Patienten,\u00a0we lche\u00a0in\u00a0Woche\u00a06\u00a0ein\u00a0therapeutis ches\u00a0Ansprechen\u00a0\nzeigten\u00a0(Responder ),\u00a0wurden\u00a0f\u00fcr\u00a0die\u00a0Erhaltungsphase\u00a0nunmehr\u00a0im\u00a0Verh\u00e4ltnis\u00a01:1:1\u00a0\nrandomisiert\u00a0zu\u00a0300 \u00a0mg\u00a0Vedolizumab\u00a0alle\u00a0acht\u00a0Wochen,\u00a0alle\u00a0vier\u00a0Wochen\u00a0oder\u00a0\nPlazebo.\u00a0Nach\u00a0Woche\u00a052\u00a0konnten\u00a0di e\u00a0Patienten\u00a0an\u00a0der\u00a0Langzeitstu die\u00a0C13008\u00a0\n(Sponsor:\u00a0Millenium\u00a0Pharmaceuticals,\u00a0NCT00790933)\u00a0teilnehmen,\u00a0w elche\u00a0im\u00a0Juli\u00a0\n2017\u00a0beendet\u00a0wird.\u00a0Den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0der\u00a0Initialphase,\u00a0das\u00a0 klinische\u00a0Anspre\u2010\nchen\u00a0auf\u00a0zweimalige\u00a0Gabe\u00a0von\u00a0300\u00a0mg\u00a0Vedolizumab,\u00a0definiert\u00a0als\u00a0 \u226530\u00a0%\u00a0des\u00a0Base\u2010\nlinewertes\u00a0 oder\u00a0 \u22653\u00a0 Punkte\u00a0 des\u00a0 Mayo\u2010Scores,\u00a0 erreichten\u00a0 25,5 \u00a0%\u00a0 unter\u00a0 Placebo\u00a0\nsowie\u00a047,1 \u00a0%\u00a0unter\u00a0Vedolizumab,\u00a0eine\u00a0klinische\u00a0Remission\u00a0( Mayo\u2010Score \u00a0<2)\u00a0erziel\u2010\nten\u00a05\u00a0%\u00a0unter\u00a0Placebo\u00a0und\u00a017 \u00a0%\u00a0unter\u00a0Vedolizumab\u00a0(p<0,0001).\u00a0Zu\u00a0Woche\u00a052\u00a0\nzeigten\u00a024 \u00a0%\u00a0unter\u00a0Placebo,\u00a057 \u00a0%\u00a0bei\u00a0achtw\u00f6chiger\u00a0Gabe\u00a0von\u00a0Vedolizumab\u00a0(V8)\u00a0\nsowie\u00a052 \u00a0%\u00a0bei\u00a0vierw\u00f6chiger\u00a0Gabe\u00a0von\u00a0Vedo lizumab\u00a0(V4)\u00a0klinisches\u00a0Ansprec hen\u00a0\n(n=126/122/125)\u00a0und\u00a0klinische\u00a0Remission\u00a0bei\u00a016 \u00a0%\u00a0unter\u00a0Placebo,\u00a042 \u00a0%\u00a0unter\u00a0V8\u00a0\nsowie\u00a045 \u00a0%\u00a0unter\u00a0V4.\u00a0Somit\u00a0konnte\u00a0statistisch\u00a0signifikant\u00a0gegen\u00fcber\u00a0Plac ebo\u00a0die\u00a0\nWirksamkeit\u00a0von\u00a0Vedolizumab\u00a0nachgewiesen\u00a0werden.\u00a0Unterschiede\u00a0h insichtlich\u00a0\nder\u00a0Mortaltit\u00e4t\u00a0zeigten\u00a0sich\u00a0nic ht.\u00a0Daten\u00a0zur\u00a0gesundheitsbezoge nen\u00a0Lebensqualit\u00e4t\u00a0\n(Health\u00a0Related\u00a0Quality\u00a0of\u00a0Life, \u00a0HRQoL)\u00a0wurden\u00a0mittels\u00a0den\u00a0Erhebungsinstrumen\u2010\nten\u00a0Inflammatory\u00a0Bowel\u00a0Disease\u00a0Questionnaire \u00a0IBDQ,\u00a0Short\u00a0Form\u201036 \u00a0SF\u201036\u00a0sowie\u00a0\nEuroQoL\u00a0EQ\u20105D\u00a0untersucht,\u00a0laut\u00a0Fachinformation\u00a0waren\u00a0die\u00a0Verbesserunge n\u00a0in\u00a0443\u00a0den\u00a0Wochen\u00a06\u00a0und\u00a052\u00a0\u201esignifikant\u00a0gr\u00f6\u00dfer\u201c.\u00a0(CHMP,\u00a02014a,\u00a0CHMP,\u00a02 014c;\u00a0Clinical\u00a0\nTrials.gov,\u00a02008a;\u00a0Feagan,\u00a02013).\u00a0\nF\u00fcr\u00a0die\u00a0Zulassung\u00a0in\u00a0der\u00a0Indikation\u00a0mittelschwere\u00a0bis\u00a0schwere\u00a0M C\u00a0wurden\u00a0die\u00a0\nbeiden\u00a0Phase\u2010III\u2010Studien\u00a0GEMINI\u00a0II\u00a0und\u00a0III\u00a0durchgef\u00fchrt.Die\u00a0zwe iphasige,\u00a0multi\u2010\nzentrische,\u00a0 doppelblinde,\u00a0 randomi sierte,\u00a0 placebokontrollierte\u00a0 P hase\u2010III\u2010Studie\u00a0\nGEMINI\u00a0II\u00a0bzw.\u00a0C13007\u00a0(Sponsor:\u00a0Millennium\u00a0Pharmaceuticals;\u00a0NCT 00783692)\u00a0war\u00a0\n\u00e4hnlich\u00a0GEMINI\u00a0I\u00a0konzipiert.\u00a0W\u00e4hrend\u00a0der\u00a0sechsw\u00f6chigen\u00a0Initialp hase\u00a0erhielt\u00a0die\u00a0\nKohorte\u00a01,\u00a0welche\u00a03:2\u00a0randomisiert\u00a0war,\u00a0entweder\u00a0300\u00a0mg\u00a0Vedoliz umab\u00a0(n=220)\u00a0\nan\u00a0den\u00a0Tagen\u00a01\u00a0und\u00a015\u00a0oder\u00a0Placebo\u00a0(n=148),\u00a0in\u00a0Kohorte\u00a02\u00a0wurde\u00a0 open\u2010label \u00a0Vedo\u2010\nlizumab\u00a0analog\u00a0verabreicht\u00a0(n=747).\u00a0Hiernach\u00a0wurden\u00a0die\u00a0 Responder \u00a0(n=461)\u00a0f\u00fcr\u00a0\ndie\u00a0Erhaltungsphase\u00a0von\u00a0Woche\u00a07\u00a0bis\u00a052\u00a0im\u00a0Verh\u00e4ltnis\u00a01:1:1\u00a0rand omisiert\u00a0und\u00a0\nerhielten\u00a0entweder\u00a0300mg\u00a0Vedolizumab\u00a0alle\u00a0vier\u00a0(V4)\u00a0(n=154)\u00a0bzw .\u00a0acht\u00a0Wochen\u00a0\n(V8)\u00a0(n=154)\u00a0oder\u00a0Placebo\u00a0(n=153).\u00a0Im\u00a0Anschluss\u00a0war\u00a0eine\u00a0Teilna hme\u00a0an\u00a0der\u00a0Lang\u2010\nzeitsicherheitsstudie\u00a0 C13008\u00a0 (Sponsor:\u00a0 Millennium\u00a0 Pharmaceutica ls,\u00a0 NCT00790\u00a0\n933)\u00a0mit\u00a0Open\u2010Label \u00a0Therapie\u00a0Vedolizumab\u00a0m\u00f6glich.\u00a0Eingeschlossen\u00a0werden\u00a0konn\u2010\nten\u00a0Patienten\u00a0mit\u00a0mittelschwe rem\u00a0bzw.\u00a0schwerem\u00a0MC,\u00a0einem\u00a0 Crohn\u2019s\u00a0Disease\u00a0\nActivity\u00a0Index \u00a0(CDAI)\u00a0von\u00a0220\u00a0bis\u00a0450\u00a0sowie\u00a0Wirkungsverlust\u00a0unter\u00a0Glucocortic oid,\u00a0\nImmunmodulator\u00a0oder\u00a0TNF\u03b1\u2010Antagonist.\u00a0In\u00a0der\u00a0Initialphase\u00a0waren\u00a0 als\u00a0prim\u00e4re\u00a0\nEndpunkte\u00a0in\u00a0Woche\u00a06\u00a0der\u00a0Anteil\u00a0Patienten\u00a0in\u00a0klinischer\u00a0Remissi on\u00a0(CDAI\u2010Score\u00a0\n\u2264150\u00a0Punkte)\u00a0sowie\u00a0mit\u00a0verbessertem\u00a0klinischen\u00a0Ansprechen\u00a0(Abna hme\u00a0des\u00a0CDAI\u2010\nScores\u00a0\u2265100\u00a0Punkte\u00a0Woche\u00a00\u00a0bis\u00a0Woche\u00a06)\u00a0definiert,\u00a0wobei\u00a0nur\u00a0f\u00fc r\u00a0\u201eklinische\u00a0Re\u2010\nmission\u201c\u00a0(Placebo\u00a07 \u00a0%,\u00a0Vedolizumab\u00a015 \u00a0%)\u00a0statistische\u00a0Signifikanz\u00a0(p<0,05)\u00a0gezeigt\u00a0\nwerden\u00a0konnte,\u00a0bei\u00a0verbessertem\u00a0klinischen\u00a0Ansprechen\u00a0jedoch\u00a0ni cht\u00a0(Placebo\u00a0\n26\u00a0%\u00a0gegen\u00fcber\u00a0Vedolizumab\u00a031%).\u00a0In\u00a0Woche\u00a052\u00a0wurde\u00a0bei\u00a022 \u00a0%\u00a0unter\u00a0Placebo\u00a0\ngegen\u00fcber\u00a039 \u00a0%\u00a0V4\u00a0(p<0,001)\u00a0bzw.\u00a036 \u00a0%\u00a0V8\u00a0(p<0,05)\u00a0\u201eklinische\u00a0Remission\u201c\u00a0nach\u2010\ngewiesen,\u00a0ein\u00a0\u201everbessertes\u00a0klinisches\u00a0Ansprechen\u201c\u00a0bei\u00a030 \u00a0%\u00a0unter\u00a0Placebo,\u00a0bei\u00a0\n44\u00a0%\u00a0unter\u00a0V4\u00a0sowie\u00a045 \u00a0%\u00a0unter\u00a0V8\u00a0(p<0,001)\u00a0(ClinicalTrials.gov,\u00a02008b;\u00a0Sandborn,\u00a0\n2013).\u00a0In\u00a0GEMINI\u00a0II\u00a0traten\u00a0unter\u00a0Vedolizumab\u00a0vermehrt\u00a0schwere\u00a0N ebenwirkungen\u00a0\n(24,4\u00a0%\u00a0versus\u00a015,3 \u00a0%),\u00a0schwere\u00a0Infektionen\u00a0(5,5 \u00a0%\u00a0versus\u00a03,0 \u00a0%)\u00a0und\u00a0mehr\u00a0Infekti\u2010\nonen\u00a0(44,1 \u00a0%\u00a0gegen\u00fcber\u00a040,2 \u00a0%)\u00a0auf.\u00a0Im\u00a0Rahmen\u00a0exploratorischer\u00a0Analysen\u00a0zur\u00a0\nHRQoL\u00a0konnte\u00a0laut\u00a0Fachinformation\u00a0sowohl\u00a0f\u00fcr\u00a0V4\u00a0als\u00a0auch\u00a0V8\u00a0ein e\u00a0signifikante\u00a0\nVerbesserung\u00a0 von\u00a0 EQ\u20105D,\u00a0 VAS\u2010Wert en,\u00a0 IBDQ\u2010Gesamt\u2010Score\u00a0 als\u00a0 auch\u00a0 IBDQ\u2010\nSubskalen\u00a0f\u00fcr\u00a0Darmsymptome\u00a0und\u00a0K\u00f6rperfunktion\u00a0gezeigt\u00a0werden\u00a0(C HMP,\u00a02014c;\u00a0\nSandborn,\u00a02013).\u00a0\nIn\u00a0der\u00a0erg\u00e4nzenden\u00a0Studie\u00a0GEMINI\u00a0III\u00a0mit\u00a0kurzer,\u00a0zehnw\u00f6chiger\u00a0D auer\u00a0mit\u00a0Patien\u2010\nten,\u00a0welche\u00a0zuvor\u00a0unter\u00a0TNF\u03b1\u2010Antagonisten\u00a0Wirkungsverlust\u00a0zeigt en,\u00a0konnte\u00a0zwi\u2010\nschen\u00a0Vedolizumab\u00a0und\u00a0Scheinmedikament\u00a0im\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0\u201ekl inische\u00a0Re\u2010\nmission\u00a0in\u00a0Woche\u00a06\u201c\u00a0kein\u00a0Unters chied\u00a0gezeigt\u00a0werden\u00a0(CHMP,\u00a02014 c).\u00a0444\u00a0Unter\u00a0Therapie\u00a0mit\u00a0Vedolizumab\u00a0entwickeln\u00a04 \u00a0%\u00a0der\u00a0Patienten\u00a0ADA\u00a0gegen\u00a0Vedoli\u2010\nzumab\u00a0und/oder\u00a0IAR\u00a0(Hafner\u2010Blume nstiel,\u00a0Mentzer,\u00a0&\u00a0Weisser,\u00a0201 5).\u00a0\nDer\u00a0Stellenwert\u00a0der\u00a0Therapie\u00a0mit\u00a0Vedolizumab\u00a0ist\u00a0in\u00a0Ermangelung \u00a0von\u00a0direkt\u00a0ver\u2010\ngleichenden\u00a0Studien\u00a0Vedolizumab/TNF \u03b1\u2010Antagonisten\u00a0bei\u00a0TNF \u03b1\u2010Antagonisten\u00a0nai\u2010\nven\u00a0CED\u2010Patienten\u00a0unklar.\u00a0Zudem\u00a0fehlen\u00a0Daten\u00a0zur\u00a0Sicherheit\u00a0sow ie\u00a0Deeskalation\u00a0\nnach\u00a0Langzeitanwendung.\u00a0Falls\u00a0jedo ch\u00a0Basis\u2010\u00a0(Azathioprin,\u00a06\u2010Mer captopurin)\u00a0und\u00a0\nEskalationstherapie\u00a0erfolglos\u00a0ve rlaufen,\u00a0stellt\u00a0Vedolizumab\u00a0ein e\u00a0zus\u00e4tzliche\u00a0Option\u00a0\ndar\u00a0(AKdAE,\u00a02014;\u00a0AKdAE\u00a0&\u00a0KBV,\u00a02016;\u00a0has,\u00a02015).\u00a0\nLeitlinienempfehlungen\u00a0\nUm\u00a0eine\u00a0\u00dcbertherapie\u00a0mit\u00a0starken\u00a0Nebenwirkungen\u00a0zu\u00a0vermeiden,\u00a0e rfolgt\u00a0die\u00a0\nBehandlung\u00a0der\u00a0CED\u00a0MC\u00a0und\u00a0CU\u00a0in\u00a0 Eskalationsstufen,\u00a0angepasst\u00a0an \u00a0die\u00a0patienten\u2010\nindividuelle\u00a0Lokalisation\u00a0sowie\u00a0den\u00a0klinischen\u00a0Verlauf\u00a0der\u00a0CED\u00a0 und\u00a0das\u00a0therapeuti\u2010\nsche\u00a0Ansprechen.\u00a0In\u00a0Leitlinien\u00a0zu\u00a0CU\u00a0(aus\u00a02011)\u00a0und\u00a0MC\u00a0(aus\u00a0201 4)\u00a0der\u00a0Deutschen\u00a0\nGesellschaft\u00a0 f\u00fcr\u00a0 Gastroenterologi e,\u00a0 Verdauungs\u2010\u00a0 und\u00a0 Stoffwechse lkrankheiten\u00a0\n(DGVS)\u00a0wird\u00a0Vedolizumab\u00a0derzeit\u00a0historisch\u00a0bedingt\u00a0nicht\u00a0genann t\u00a0(Dignass\u00a0&\u00a0et\u00a0\nal.,\u00a02011;\u00a0Prei\u00df\u00a0&\u00a0et\u00a0al.,\u00a02014).\u00a0Die\u00a0dritten\u00a0europ\u00e4ischen\u00a0Kons ensusleitlinien\u00a0der\u00a0\nEuropean\u00a0Crohn\u2019s\u00a0and\u00a0Colitis\u00a0Organisation, \u00a0ECCO\u00a0zur\u00a0Therapie\u00a0der\u00a0CU\u00a0bzw.\u00a0MC\u00a0\nhingegen\u00a0ber\u00fccksichtigen\u00a0bereits \u00a0Vedolizumab,\u00a0es\u00a0ist\u00a0jedoch\u00a0auf \u00a0den\u00a0zulassungs\u2010\nkonformen\u00a0 Einsatz\u00a0als\u00a0Reservemi ttel\u00a0nach\u00a0Versagen\u00a0von\u00a0Steroiden \u00a0 bzw.\u00a0 TNF \u03b1\u2010\nAntagonisten\u00a0zu\u00a0achten\u00a0(Gomoll\u00f3n \u00a0et\u00a0al.,\u00a02017;\u00a0Harbord\u00a0et\u00a0al.,\u00a0 2017).\u00a0\nAls\u00a0 Therapieziel\u00a0 der\u00a0 CU\u00a0 wird\u00a0 eine\u00a0 glucocorticosteroidfreie\u00a0 klin ische\u00a0 Remission\u00a0\nangestrebt,\u00a0welche\u00a0als\u00a0endoskopisch\u00a0best\u00e4tigte\u00a0mucosale\u00a0Heilung \u00a0zu\u00a0verstehen\u00a0ist.\u00a0\nZur\u00a0Therapie\u00a0des\u00a0akuten\u00a0Schubes\u00a0 kommen\u00a0als\u00a0Arzneimittel\u00a0lokal\u00a0b zw.\u00a0systemisch\u00a0\n5\u2010Aminosalicylate\u00a0oder\u00a0Prednisolo n\u00a0zum\u00a0Einsatz.\u00a0Zum\u00a0Remissionse rhalt\u00a0werden\u00a0bei\u00a0\nmilden\u00a0Verlaufsformen\u00a0E.\u00a0coli\u00a0Ni ssle\u00a0Bakterienkulturen\u00a0eingeset zt,\u00a0bei\u00a0m\u00e4\u00dfigem\u00a0bis\u00a0\nschwerem\u00a0 Krankheitsverlauf\u00a0 Azath ioprin.\u00a0 Zur\u00a0 Eskalation\u00a0 k\u00f6nnen\u00a0 T NF\u03b1\u2010Anta\u2010\ngonisten\u00a0(Adalimumab\u00a0subcutan\u00a0(sc),\u00a0Infliximab\u00a0intraven\u00f6s\u00a0(iv)\u00a0 oder\u00a0Golimumab\u00a0\nsc)\u00a0angewendet\u00a0werden.\u00a0Wird\u00a0hierdurch\u00a0keine\u00a0Remission\u00a0erreicht\u00a0 oder\u00a0kommt\u00a0es\u00a0\nw\u00e4hrend\u00a0einer\u00a0bestehenden\u00a0Therapie\u00a0zum\u00a0Wirkungsverlust,\u00a0so\u00a0kann \u00a0auf\u00a0Vedoli\u2010\nzumab\u00a0zur\u00fcckgegriffen\u00a0werden.\u00a0Die\u00a0chirurgische\u00a0Intervention\u00a0ist \u00a0die\u00a0Ultima\u00a0ratio\u00a0\n(Danese\u00a0&\u00a0Fiocchi,\u00a02011;\u00a0Digna ss\u00a0et\u00a0al.,\u00a02011;\u00a0Harbord\u00a0et\u00a0al.,\u00a0 2017).\u00a0\nAuch\u00a0bei\u00a0MC\u00a0ist\u00a0das\u00a0Behandlungsziel\u00a0der\u00a0Erhalt\u00a0einer\u00a0klinischen \u00a0Remission.\u00a0Man\u00a0\nbeginnt\u00a0die\u00a0Pharmakotherapie\u00a0bei\u00a0 ileoz\u00f6kalem\u00a0MC\u00a0mit\u00a0Budenosid\u00a0s owie\u00a0alternativ\u00a0\nmit\u00a0Mesalazin,\u00a0bei\u00a0MC\u00a0im\u00a0Kolon\u00a0wird\u00a0Mesalazin\u00a0sowie\u00a0bei\u00a0schwere r\u00a0Aktivit\u00e4t\u00a0Pred\u2010\nnisolon\u00a0eingesetzt.\u00a0Zum\u00a0Erhalt\u00a0der\u00a0Remission\u00a0wird\u00a0Nikotinabstin enz\u00a0und\u00a0als\u00a0Arz\u2010\nneimittel\u00a0gem\u00e4\u00df\u00a0Leitlinie\u00a0Azathioprin\u00a0empfohlen.\u00a0Zur\u00a0Eskalation \u00a0steht\u00a0Methotrexat\u00a0\nzur\u00a0Verf\u00fcgung,\u00a0weiterhin\u00a0die\u00a0TNF \u03b1\u2010Antagonisten\u00a0(Adalimumab\u00a0oder\u00a0Infliximab),\u00a0bei\u00a0445\u00a0fehlender\u00a0Remission\u00a0oder\u00a0Wirkungsv erlust\u00a0kann\u00a0auf\u00a0Vedolizumab\u00a0z ur\u00fcckgegriffen\u00a0\nwerden\u00a0(Baumgart\u00a0&\u00a0Sandborn,\u00a0 2012;\u00a0Gomoll\u00f3n\u00a0et\u00a0al.,\u00a02017;\u00a0Prei\u00df \u00a0et\u00a0al.,\u00a02014).\u00a0\nBei\u00a0Wirkungsverlust\u00a0von\u00a0TNF \u03b1\u2010Antagonisten\u00a0bestehen\u00a0im\u00a0klinischen\u00a0Alltag\u00a0mehrere\u00a0\nBehandlungsoptionen,\u00a0einerseits\u00a0d ie\u00a0Erh\u00f6hung\u00a0der\u00a0Dosis\u00a0bzw.\u00a0die \u00a0Verk\u00fcrzung\u00a0des\u00a0\nDosierungsintervalls,\u00a0andererseits\u00a0eine\u00a0Kombination\u00a0mit\u00a0Immunmo dulatoren,\u00a0die\u00a0\nRotation\u00a0der\u00a0TNF \u03b1\u2010Antagonisten\u00a0(unterschiedliche\u00a0Zulassungen\u00a0f\u00fcr\u00a0MC\u00a0bzw.\u00a0CU)\u00a0\nsowie\u00a0 ein\u00a0 erneuter\u00a0 Therapieversuch\u00a0 mit\u00a0 erstem\u00a0 TNF \u03b1\u2010Antagonisten\u00a0 (Prescrire\u00a0\nInternational,\u00a02015).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0G\u2010BA\u00a0identifizierte\u00a0gem\u00e4\u00df\u00a0de r\u00a0Zulassung\u00a0von\u00a0Vedolizumab\u00a0vie r\u00a0Subgruppen\u00a0im\u00a0\nKontext\u00a0der\u00a0Nutzenbewertung:\u00a0einerseits\u00a0die\u00a0beiden\u00a0CED\u00a0CU\u00a0und\u00a0M C,\u00a0andererseits\u00a0\njeweils\u00a0\u201ePatienten,\u00a0die\u00a0auf\u00a0konventionelle\u00a0Therapie\u00a0unzureichen d\u00a0angesprochen\u00a0\nhaben,\u00a0 nicht\u00a0 mehr\u00a0 darauf\u00a0 ansprechen\u00a0 oder\u00a0 eine\u00a0 Unvertr\u00e4glichkeit \u00a0g e g e n \u00a0e i n e \u00a0\nentsprechende\u00a0Behandlung\u00a0aufweisen\u201c\u00a0sowie\u00a0\u201ePatienten,\u00a0welche\u00a0au f\u00a0einen\u00a0TNF \u03b1\u2010\nAntagonisten\u00a0unzureichend\u00a0angesprochen\u00a0haben,\u00a0nicht\u00a0mehr\u00a0darauf \u00a0ansprechen\u00a0\noder\u00a0eine\u00a0Unvertr\u00e4glichkeit\u00a0gegen\u00a0eine\u00a0entsprechende\u00a0Behandlung \u00a0aufweisen\u201c.\u00a0Im\u00a0\nBeschluss\u00a0vom\u00a08.\u00a0Januar\u00a02015\u00a0ko nnte\u00a0der\u00a0G\u2010BA\u00a0aufgrund\u00a0des\u00a0vom\u00a0p U\u00a0vorgelegten\u00a0\nindirekten\u00a0Vergleiches\u00a0nach\u00a0Bucher\u00a0keinen\u00a0Zusatznutzen\u00a0gegen\u00fcbe r\u00a0zVT\u00a0feststellen\u00a0\n(G\u2010BA,\u00a02015a).\u00a0\nDer\u00a0G\u2010BA\u00a0f\u00fchrt\u00a0als\u00a0Begr\u00fcndung\u00a0hierzu\u00a0aus,\u00a0dass\u00a0die\u00a0Studien\u00a0GEMI NI\u00a0I\u00a0und\u00a0ULTRA\u00a01\u00a0\nbzw.\u00a02\u00a0(Adalimumab)\u00a0zu\u00a0unterschiedliche\u00a0Studiendesigns\u00a0und\u00a0\u2010pop ulationen\u00a0auf\u2010\nweisen,\u00a0um,\u00a0basierend\u00a0auf\u00a0einem\u00a0adjustierten\u00a0Vergleich\u00a0nach\u00a0Buc her,\u00a0Aussagen\u00a0\nzum\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0zVT\u00a0 ableiten\u00a0zu\u00a0k\u00f6nnen,\u00a0insbesondere \u00a0die\u00a0unter\u2010\nschiedliche\u00a0Randomisierung\u00a0von\u00a0Re spondern\u00a0und\u00a0Non\u2010Respondern\u00a0in \u00a0Initial\u2010\u00a0und\u00a0\nErhaltungsphasen\u00a0der\u00a0Studien.\u00a0Auch\u00a0die\u00a0Vergleiche\u00a0mit\u00a0den\u00a0Studi en\u00a0GEMINI\u00a0II\u00a0und\u00a0\nIII\u00a0erkannte\u00a0der\u00a0G\u2010BA\u00a0mit\u00a0Hinweis\u00a0auf\u00a0die\u00a0geringen\u00a0Effektst\u00e4rke n\u00a0bei\u00a0MC\u00a0nicht\u00a0an\u00a0\u00a0\n(G\u2010BA,\u00a02015b).\u00a0\nVersorgungsanalysen\u00a0\nVedolizumab\u00a0wird\u00a0entweder\u00a0als\u00a0Rez eptur\u00a0oder\u00a0als\u00a0N1\u00a0Packung\u00a0abge rechnet.\u00a0Der\u00a0\nAnteil\u00a0der\u00a0Rezepturen\u00a0an\u00a0allen\u00a0abgerechneten\u00a0Packungsarten\u00a0betr \u00e4gt\u00a0nach\u00a0der\u00a0\nEinf\u00fchrung\u00a0im\u00a0Juli\u00a02014\u00a0ungef\u00e4hr\u00a0ein\u00a0Viertel.\u00a0\n\u00a0\u00a0446\u00a0Abbildung\u00a04.57:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Vedolizumab\u00a0je\u00a0Mon at\u00a0nach\u00a0\nPackungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nAbbildung\u00a04.58:\u00a0Versicherte\u00a0mit\u00a0mind.\u00a0einer\u00a0Vedolizumab\u00a0nach\u00a0Al ter\u00a0und\u00a0\nGeschlecht\u00a0(2015)\u00a0\u00a0\n\u00a0\n447\u00a0Vedolizumab\u00a0wird\u00a0vor\u00a0allem\u00a0j\u00fcngeren\u00a0Patienten\u00a0verordnet,\u00a0es\u00a0sin d\u00a0vor\u00a0allem\u00a0Frau\u2010\nen\u00a0zwischen\u00a018\u00a0und\u00a039,\u00a0die\u00a0das\u00a0Pr\u00e4parat\u00a0bekommen.\u00a0In\u00a0den\u00a0Alters klassen\u00a0zwischen\u00a0\n40\u00a0und\u00a059\u00a0Jahren\u00a0ist\u00a0das\u00a0Geschlechterverh\u00e4ltnis\u00a0ausgewogen,\u00a0um\u00a0 sich\u00a0im\u00a0Alter\u00a0\nzwischen\u00a060\u00a0und\u00a079\u00a0wieder\u00a0umzukehren.\u00a0\nQuellen\u00a0\nAKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0&\u00a0KBV\u00a0\u2013 \u00a0Kassen\u00e4rztliche\u00a0Bundesvereinigung\u00a0(2016).\u00a0Wirkstoff\u00a0AKTUELL\u00a0\u2010\u00a0\nAusgabe\u00a005/2016:\u00a0Vedolizumab.\u00a0Information\u00a0nach\u00a0\u00a7\u00a073(8)\u00a0SGB\u00a0V.\u00a0www.akdae.de/Arzneimitteltherapie/WA/Archiv/Vedolizumab.pdf,\u00a0le tzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\nAKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2014). \u00a0Neue\u00a0Arzneimittel\u00a0Entyvio\u00a0(Vedolizumab).\u00a0\nwww.akdae.de/Arzneimitteltherapie/NA/Archiv/201412\u2010Entyvio.pdf, \u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\nBaumgart\u00a0DC,\u00a0Sandborn\u00a0WJ\u00a0(2012).\u00a0Crohn's\u00a0disease.\u00a0Lancet\u00a0380(98 53):\u00a01590\u20101605.\u00a0\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014a).\u00a0 SPC\u00a0Vedolizumab\u00a0Entyvio:\u00a0EPAR\u00a0Annex\u00a0I\u00a0\u2010\u00a0Summary\u00a0of\u00a0product\u00a0\ncharacteristics.\u00a0www.ema.europa.eu/docs/en\u00a0_GB/document_library /EPAR_\u2010\n_Product_Information/human/002782/WC500168528.pdf,\u00a0letzter\u00a0Zugr iff:\u00a025.07.2017.\u00a0\u00a0\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014b).\u00a0 Entyvio,\u00a0INN\u2010vedolizumab:\u00a0Summary\u00a0for\u00a0the\u00a0public.\u00a0\nEMA/337860/2014. \u00a0www.ema.europa.eu/docs/en\u00a0_GB/document_library /EPAR_\u2010\n_Summary_for_the_public/human/002782/WC500168532.pdf,\u00a0letzter\u00a0Z ugriff:\u00a025.07.2017.\u00a0\u00a0\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014c).\u00a0 Assessment\u00a0report\u00a0EPAR:\u00a0E ntyvio,\u00a0INN\u2010vedolizumab.\u00a0\nwww.ema.europa.eu/docs/en\u00a0_ GB/document_library/EPAR_\u2010\n_Public_assessment_report/human/002782/WC500168530,.pdf,\u00a0letzte r\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\u00a0\nClinicalTrials.gov\u00a0(200 8a).\u00a0Study\u00a0of\u00a0Vedolizumab\u00a0(MLN00002)\u00a0in\u00a0 Patients\u00a0with\u00a0moderate\u00a0to\u00a0severe\u00a0Ulcerative\u00a0Colitis:\u00a0GEMINI\u00a0I.\u00a0\nNCT00783718.\u00a0https://www.clinicaltrials.gov/ct2/show/NCT0078371 8?term=NCT00783718&rank=1,\u00a0letzter\u00a0Zugriff:\u00a0\n25.07.2017.\u00a0\u00a0\u00a0\nClinicalTrials.gov\u00a0(2008b).\u00a0Study\u00a0of\u00a0Vedolizumab\u00a0(MLN0002)\u00a0in\u00a0P atients\u00a0with\u00a0moderate\u00a0to\u00a0sever e\u00a0Crohn's\u00a0Disease\u00a0(GEMINI\u00a0II):\u00a0\nNCT00783692.\u00a0https://www.clinicaltrials.gov/ct2/show/NCT0078369 2?term=NCT00783692&rank=1,\u00a0letzter\u00a0Zugriff:\u00a0\n25.07.2017.\u00a0\u00a0\u00a0\nDanese\u00a0S,\u00a0Fiocchi\u00a0C\u00a0(2 011).\u00a0Ulcerative\u00a0colitis:\u00a0review\u00a0article. \u00a0NEJM\u00a0365(18):\u00a01713\u20101725.\u00a0\u00a0\nDGVS\u00a0\u2013\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Gastroenterologie,\u00a0Verdauungs\u2010 \u00a0und\u00a0Stoffwechselkrankheiten,\u00a0L erch\u00a0MM,\u00a0Lammert\u00a0F\u00a0(Hrsg.)\u00a0\n(2017).\u00a0Weissbuch\u00a0Gastroenterologische\u00a0Erkrankungen\u00a02017:\u00a0Gegen wart\u00a0und\u00a0Zukunft\u00a0der\u00a0Versorgung\u00a0von\u00a0Erkran\u2010\nkungen\u00a0des\u00a0Magen\u2010Darm\u2010Traktes,\u00a0der\u00a0Leber\u00a0und\u00a0der\u00a0Bauchspeicheld r\u00fcse\u00a0in\u00a0Deutschland.\u00a0Berlin:\u00a0Frischtexte\u00a0Verlag.\u00a0\nDignass\u00a0A,\u00a0Preiss\u00a0JC,\u00a0Aust\u00a0DE,\u00a0A utschbach\u00a0F,\u00a0Ballauff\u00a0A,\u00a0Barret ton\u00a0G\u00a0et\u00a0al.\u00a0(2011).\u00a0Aktualisierte\u00a0Leitlinie\u00a0zur\u00a0Diagnostik\u00a0und \u00a0Therapie\u00a0\nder\u00a0Colitis\u00a0ulcerosa\u00a02011\u00a0\u2010\u00a0Ergebnisse\u00a0einer\u00a0Evidenzbasierten\u00a0K onsensuskonferenz.\u00a0Z\u00a0Gastroenterol\u00a049(9):\u00a01276\u2010\n1341.\u00a0\u00a0\nFeagan\u00a0BG\u00a0(2013).\u00a0Vedolizumab\u00a0as\u00a0induction\u00a0and\u00a0maintenance\u00a0ther apy\u00a0for\u00a0ulcerative\u00a0colitis.\u00a0NEJM\u00a0369(8):\u00a0699\u2010710.\u00a0\u00a0\nFricke\u00a0U\u00a0(2015).\u00a0Pharmakologische\u00a0Bewertungen\u00a0(Prof.\u00a0Fricke)\u00a0\u2010\u00a0 2014:\u00a0InVo.\u00a0Informationen\u00a0zu\u00a0Verordnungen\u00a0in\u00a0der\u00a0GKV.\u00a0\nhttps://www.kvwl.de/arzt/verordnung/arzneimittel/info/invo/phar m_bewert_am_2014_invo.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n25.07.2017.\u00a0\u00a0448\u00a0Fricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015a).\u00a0Beschluss\u00a0Vedolizum ab:\u00a0\u00c4nderung\u00a0der\u00a0AM\u2010RL:\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0\nNutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a0 35a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Vedolizumab.\u00a0Retrieved\u00a0from\u00a0\nhttps://www.g\u2010ba.de/downloads/ 39\u2010261\u20102143/2015\u201001\u201008_AM\u2010RL\u2010XII_ Vedolizumab_2014\u201007\u201015\u2010D\u2010122_BAnz.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2015b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0\u2010\u00a0V edolizumab.\u00a0https://www.g\u2010ba.de/downloads/40\u2010268\u2010\n3074/2015\u201001\u201008_AM\u2010RL\u2010XII_Vedolizumab_2014\u201007\u201015\u2010D\u2010122_TrG.pdf, \u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\nGomoll\u00f3n\u00a0F,\u00a0Dignass\u00a0A,\u00a0Annese\u00a0V,\u00a0Tilg\u00a0H,\u00a0Van\u00a0Assche\u00a0G,\u00a0Lindsay\u00a0 JO\u00a0et\u00a0al.\u00a0(2017).\u00a03rd\u00a0European\u00a0Evidence\u2010based\u00a0Consensus\u00a0on\u00a0the\u00a0\nDiagnosis\u00a0and\u00a0Management\u00a0of\u00a0Crohn's\u00a0Disease\u00a02016:\u00a0Part\u00a01:\u00a0Diagn osis\u00a0and\u00a0Medical\u00a0Managem ent.\u00a0J\u00a0Crohn's\u00a0Colitis\u00a0\n11\u00a0(1):\u00a03\u201025.\u00a0\u00a0\nHafner\u2010Blumenstiel\u00a0V,\u00a0Mentzer\u00a0D,\u00a0Weisser\u00a0K\u00a0(2015).\u00a0\u00dcberempfindl ichkeits\u2010\u00a0und\u00a0Infusionsreaktionen\u00a0unter\u00a0intraven\u00f6ser\u00a0Therapie\u00a0\nmit\u00a0monoklonalen\u00a0Antik\u00f6rpern.\u00a0www.bfarm.de/SharedDocs/Downloads /DE/Arzneimittel\u00a0\n/Pharmakovigilanz/Bulletin/2015/ 2\u20102015.pdf?__blob=publicationFi le&v=3,\u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\u00a0\nHarbord\u00a0M,\u00a0Eliakim\u00a0R,\u00a0Bettenworth\u00a0D,\u00a0Karmiris\u00a0K,\u00a0Katsanos\u00a0K,\u00a0Ko pylov\u00a0U\u00a0et\u00a0al.\u00a0(2017).\u00a0Third\u00a0European\u00a0Evidence\u2010based\u00a0Consensus\u00a0 on\u00a0\nDiagnosis\u00a0and\u00a0Management\u00a0of\u00a0Ulcerative\u00a0Colitis.\u00a0Part\u00a02:\u00a0Current \u00a0Management.\u00a0J\u00a0Crohn's\u00a0Colitis\u00a011(7):769\u2010784.\u00a0\nhas\u00a0\u2013\u00a0Haute\u00a0Autorit\u00e9\u00a0de\u00a0Sant\u00e9\u00a0(2015).\u00a0Entyvio\u00a0\u2010\u00a0Vedolizumab:\u00a0Br ief\u00a0summary\u00a0of\u00a0the\u00a0transparency\u00a0committee\u00a0opinion.\u00a0\nENTYVIO_SApub_CT13507_EN_\u00a0val.\u00a0https://www.has\u2010sante.fr/portail /upload/docs/application/pdf/2015\u2010\n10/entyvio_summary_ct13507.pdf,\u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\nPrei\u00df\u00a0JC,\u00a0Bokemeyer\u00a0B,\u00a0Buhr\u00a0HJ,\u00a0Digna\u00df\u00a0A,\u00a0H\u00e4user\u00a0W,\u00a0Hartmann\u00a0F\u00a0 et\u00a0al.\u00a0(2014).\u00a0Aktualisierte\u00a0S3\u2010L eitlinie\u2010\u2010\"Diagnostik\u00a0und\u00a0Ther apie\u00a0\ndes\u00a0Morbus\u00a0Crohn\"\u00a02014:\u00a0AWMF\u2010Reg\u2010Nr.\u00a0021\u2010004.\u00a0Z\u00a0Gastroenterol\u00a05 2(12):\u00a01431\u20101484.\u00a0\u00a0\nPrescrire\u00a0International\u00a0(2015).\u00a0Vedolizumab\u00a0(Entyvio):\u00a0No\u00a0prove n\u00a0advantage\u00a0in\u00a0Crohn's\u00a0disease\u00a0or \u00a0ulcerative\u00a0colitis.\u00a0Prescrire \u00a0Int.\u00a0\n24(162):\u00a0178\u2010179.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Vedolizumab\u00a0\u2010\u00a0Entyv io:\u00a0Neue\u00a0Arzneistoffe.www.pharmazeutische\u2010zeitung.de/ind\u00a0\nex.php?id=53474#,\u00a0letzter\u00a0Zugriff:\u00a012.05.2017.\u00a0\nSandborn\u00a0WJ\u00a0(2013).\u00a0Vedolizumab\u00a0as\u00a0induction\u00a0and\u00a0maintenance\u00a0th erapy\u00a0for\u00a0Crohn's\u00a0disease.NEJM\u00a0369(8):\u00a0711\u2010721.\u00a0\u00a0\nLauer\u2010Taxe\u00a0(2017).\u00a0Lauer\u2010Taxe\u00a0WebApo\u00a0online.\u00a0https://www.cgm.co m/lauer\u2010fischer/index.de.jsp\u00a0\u00a0\nWehkamp\u00a0J,\u00a0G\u00f6tz\u00a0M,\u00a0Herrlinger\u00a0K,\u00a0Steurer\u00a0W,\u00a0Stange\u00a0EF\u00a0(2016).\u00a0I nflammatory\u00a0Bowel\u00a0Disease.\u00a0Dtsch\u00a0\u00c4rztebl\u00a0int\u00a0113(5):\u00a072\u201082.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Vedolizumab\u00a0\u2010\u00a0Entyv io:\u00a0Neue\u00a0Arzneistoffe.\u00a0www.pharmazeutische\u2010\nzeitung.de/index.php?id=53474#,\u00a0letzter\u00a0Zugriff:\u00a025.07.2017.\u00a0\u00a0\nSandborn\u00a0WJ\u00a0(2013).\u00a0Vedolizumab\u00a0as\u00a0induction\u00a0and\u00a0maintenance\u00a0th erapy\u00a0for\u00a0Crohn's\u00a0disease.\u00a0NEJM\u00a0369(8):\u00a0711\u2010721.\u00a0\u00a0\n\u00a0 \u00a0449\u00a04.3 Vilanterol\u00a0+\u00a0Fluticasonfuroat\u00a0\nHandelsname:\u00a0Relvar \u00ae\u00a0Ellipta\u00ae\u00a0 \u00a0 Pharmazeut ischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Asthma\u00a0bronchiale,\u00a0\u00a0 \u00a0 GlaxoSmithKline\u00a0\nchronisch\u00a0obstruktive\u00a0Lungenerkrankung\u00a0\nATC\u2010Code:\u00a0R03AK10\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02014\u00a0\nDarreichungsform:\u00a0Inhalationspulver\u00a0 DDD:\u00a025\u00a0\u00b5g\u00a0(Vilanterol)\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nZusammenfassung\u00a0und\u00a0Bewertung\u00a0\nMit\u00a0der\u00a0Zulassung\u00a0des\u00a0Vilanterol\u00a0(als\u00a0Trifenatat)\u2010\u00a0und\u00a0Fluticas onfuroat\u2010haltigen\u00a0\nInhalates\u00a0(Relvar\u00ae\u00a0Ellipta\u00ae) \u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0( European\u00a0Commis\u2010\nsion,\u00a0EC)\u00a0stand\u00a02014\u00a0die\u00a0f\u00fcnfte\u00a0Kombination\u00a0aus\u00a0inhalativem\u00a0Glucoco rticoid\u00a0(ICS)\u00a0\nund\u00a0langwirkendem\u00a0Beta 2\u2010Sympatomimetikum\u00a0 (Long\u2010acting\u00a0Beta\u00a0 Agonists,\u00a0LABA)\u00a0\nzur\u00a0Verf\u00fcgung.\u00a0Die\u00a0Indikation\u00a0umfasst\u00a0sowohl\u00a0die\u00a0Therapie\u00a0von\u00a0A sthma\u00a0ab\u00a0dem\u00a013.\u00a0\nLebensjahr\u00a0als\u00a0auch\u00a0die\u00a0Anwendung\u00a0zur\u00a0Symptomlinderung\u00a0bei\u00a0chro nisch\u00a0obstruk\u2010\ntiver\u00a0Lungenkrankheit\u00a0( Chronic\u00a0Obstructive\u00a0Pulmonary\u00a0Disease ,\u00a0COPD)\u00a0bei\u00a0erwach\u2010\nsenen\u00a0Patienten\u00a0(EMA,\u00a02013a).\u00a0V ilanterol,\u00a0ein\u00a0Agonist\u00a0am\u00a0Beta 2\u2010Rezeptor,\u00a0bewirkt\u00a0\ndie\u00a0Relaxation\u00a0glatter\u00a0Muskelze llen\u00a0der\u00a0Atemwege\u00a0und\u00a0erzeugt\u00a0da mit\u00a0eine\u00a0Bron\u2010\nchodilatation.\u00a0In\u00a0Folge\u00a0f\u00fchrt\u00a0di es\u00a0zu\u00a0einer\u00a0besseren\u00a0Bel\u00fcftung\u00a0 der\u00a0Lunge\u00a0und\u00a0somit\u00a0\nzur\u00a0Symptomlinderung.\u00a0Bei\u00a0Asthma \u00a0sowie\u00a0COPD\u00a0liegt\u00a0ein\u00a0Entz\u00fcndun gsprozess\u00a0im\u00a0\nBronchialgewebe\u00a0vor,\u00a0der\u00a0mit\u00a0Flu ticasonfuroat,\u00a0einem\u00a0immunmodul ierenden\u00a0Korti\u2010\nkosteroid,\u00a0abgeschw\u00e4cht\u00a0werden\u00a0soll\u00a0(EMA,\u00a02013b).\u00a0Die\u00a0Anwendung \u00a0erfolgt\u00a0einmal\u00a0\nt\u00e4glich\u00a0zur\u00a0gleichen\u00a0Zeit,\u00a0um\u00a0durch\u00a0die\u00a0Erhaltung\u00a0eines\u00a0Wirkspi egels\u00a0(Steady\u2010States) \u00a0\ntherapeutisch\u00a0optimale\u00a0Wirkstoffkonzentrationen\u00a0zu\u00a0erzielen.\u00a0Di e\u00a0empfohlene\u00a0Do\u2010\nsierung\u00a0 betr\u00e4gt\u00a0 bei\u00a0 Asthma\u00a0 Dosis\u00a0 92/22\u00a0\u00b5g\u00a0 (Fluticasonfuroat/Vil anterol),\u00a0 die\u00a0 bei\u00a0\nungen\u00fcgender\u00a0Symptomkontrolle\u00a0auf\u00a0184/22\u00a0\u00b5g\u00a0angepasst\u00a0werden\u00a0ka nn.\u00a0Bei\u00a0COPD\u00a0\nPatienten\u00a0sieht\u00a0die\u00a0Empfehlung\u00a0des\u00a0pharmazeutischen\u00a0Unternehmer s\u00a0(pU)\u00a0nur\u00a0die\u00a0\nDosierung\u00a092/22\u00a0\u00b5g\u00a0vor.\u00a0Bei\u00a0Vorli egen\u00a0mittelschwerer\u00a0bis\u00a0schwer er\u00a0Leberfunktions\u2010\nst\u00f6rungen\u00a0betr\u00e4gt\u00a0die\u00a0H\u00f6chstdosis\u00a092/22\u00a0\u00b5g\u00a0(EMA,\u00a02013a).\u00a0\nDie\u00a0 Kernevidenz\u00a0 innerhalb\u00a0 des\u00a0 Zulassungsverfahrens\u00a0 f\u00fcr\u00a0 das\u00a0 Indi kationsgebiet\u00a0\nAsthma\u00a0besteht\u00a0im\u00a0Wesentlichen\u00a0au s\u00a0den\u00a0vom\u00a0pU\u00a0gesponserten\u00a0Stud ien\u00a0HZA106\u00a0\n827,\u00a0HZA106829\u00a0und\u00a0HZA106837\u00a0(EMA,\u00a02013b).\u00a0In\u00a0der\u00a0Gesamtschau\u00a0v erbesserte\u00a0\ndie\u00a0Kombination\u00a0Fluticasonfuroat/Vilanterol\u00a0(FF/Vl)\u00a092/22\u00a0\u00b5g\u00a0nu r\u00a0gegen\u00fcber\u00a0Pla\u2010\ncebo\u00a0 signifikant\u00a0 die\u00a0 Lungenfunktion,\u00a0 die\u00a0 mit\u00a0 Hilfe\u00a0 der\u00a0 co\u2010prim\u00e4 ren\u00a0 Endpunkte\u00a0\n\u00c4nderung\u00a0des\u00a0FEV 1\u2010Talwertes\u00a0(vor\u00a0Bronchiodilatato r\u2010Gabe\u00a0und\u00a0vor\u00a0Medikation)\u00a0ge\u2010\ngen\u00fcber\u00a0dem\u00a0Ausgangswert\u00a0bei\u00a0Fortschreiben\u00a0des\u00a0zuletzt\u00a0beobacht eten\u00a0Wertes\u00a0\n(Last\u00a0Observation\u00a0Carried\u00a0Forward ,\u00a0LOCF)\u00a0zum\u00a0Ende\u00a0des\u00a0Beobachtungszeitraumes\u00a0\nFEV1\u00a0(LCOF)\u00a0sowie\u00a0das\u00a0gewichte te\u00a0mittlere\u00a0serielle\u00a0FEV 1\u00a0\u00fcber\u00a00\u00a0bis\u00a024\u00a0Stunden\u00a0nach\u00a0\nMedikation\u00a0FEV 1\u00a0(0\u201024h)\u00a0beschrieben\u00a0wurde,\u00a0um\u00a0172\u00a0ml\u00a0FEV 1\u00a0(LCOF)\u00a0bzw.\u00a0302\u00a0ml\u00a0450\u00a0FEV1\u00a0(0\u00a0bis\u00a024h)\u00a0zu\u00a0erreichen.\u00a0F\u00fcr\u00a0den\u00a0Vergleich\u00a0mit\u00a0der\u00a0Monotherap ie\u00a0mit\u00a0Fluti\u2010\ncasonfuroat\u00a092\u00a0\u00b5g\u00a0konnte\u00a0aufgrund\u00a0fehlender\u00a0Signifikanz\u00a0keine\u00a0E insch\u00e4tzung\u00a0vor\u2010\ngenommen\u00a0werden\u00a0(Bleecker\u00a0et\u00a0al.,\u00a02013).\u00a0In\u00a0einer\u00a0weiteren\u00a0dopp elblinden,\u00a0ran\u2010\ndomisierten,\u00a0kontrollierten\u00a0Studie\u00a0( Randomised\u00a0Controlled\u00a0Trial ,\u00a0RCT)\u00a0(O\u00b4Byrne\u00a0et\u00a0\nal.,\u00a02013)\u00a0mit\u00a0FF/VI\u00a0184/22\u00a0\u00b5g\u00a0konnte\u00a0ein\u00a0signifikanter\u00a0Vorteil \u00a0gegen\u00fcber\u00a0der\u00a0Mo\u2010\nnotherapie\u00a0mit\u00a0ICS\u00a0184\u00a0\u00b5g\u00a0FF\u00a0und\u00a0500\u00a0\u00b5g\u00a0Fluticasonpropionat\u00a0(FP )\u00a0belegt\u00a0werden.\u00a0\nBez\u00fcglich\u00a0 der\u00a0 \u00c4nderung\u00a0 des\u00a0 FEV 1\u2010Talwertes\u00a0 zeigte\u00a0 sich\u00a0 ein\u00a0 Behandlungsunter\u2010\nschied\u00a0zu\u00a0den\u00a0Einzelsubstanzen\u00a0von\u00a0193\u00a0ml\u00a0zu\u00a0FF\u00a0(p\u00a0<\u00a00,001)\u00a0und \u00a0210\u00a0ml\u00a0zu\u00a0FP\u00a0(p\u00a0<\u00a0\n0,001).\u00a0F\u00fcr\u00a0den\u00a0sowohl\u00a0klinisch\u00a0als\u00a0auch\u00a0patientenrelevanten\u00a0En dpunkt\u00a0der\u00a0pro\u2010\nzentualen\u00a0\u00c4nderung\u00a0der\u00a024\u2010Stunden\u2010Phasen\u00a0im\u00a0Vergleich\u00a0ohne\u00a0Begl eitmedikation\u00a0\ngegen\u00fcber\u00a0dem\u00a0Ausgangswert\u00a0senkte\u00a0FF/VI\u00a0184/22\u00a0\u00b5g\u00a0die\u00a0Rate\u00a0um\u00a01 1,7\u00a0%\u00a0st\u00e4rker\u00a0\nals\u00a0FF\u00a0allein\u00a0(p\u00a0<\u00a00,001).\u00a0Der\u00a0Vergleich\u00a0mit\u00a0FP\u00a0ist\u00a0statistisch \u00a0nicht\u00a0aussagekr\u00e4ftig\u00a0\n(6,3\u00a0%;\u00a0p=0,067).\u00a0Weitere\u00a0Verglei che\u00a0zur\u00a0Wirksamkeit\u00a0auf\u00a0die\u00a0Lu ngenfunktion\u00a0mit\u00a0\nanderen\u00a0ICS/LABA\u00a0Kombinationen\u00a0sind\u00a0begrenzt.\u00a0Der\u00a0pU\u00a0legte\u00a0ledi glich\u00a0die\u00a0verglei\u2010\nchende\u00a0Studie\u00a0HZA\u00a0113091\u00a0(Woodcock\u00a0et\u00a0al.\u00a02013)\u00a0vor.\u00a0In\u00a0der\u00a0Geg en\u00fcberstellung\u00a0\nvon\u00a0FF/Vl\u00a092/\u00a022\u00a0\u00b5g\u00a0mit\u00a0FP/Salmeterol\u00a0250/50\u00a0\u00b5g\u00a0wurden\u00a0hinsicht lich\u00a0der\u00a0Wirk\u2010\nsamkeit\u00a0auf\u00a0die\u00a0Lungenfunktion \u00a0sowie\u00a0patientenbezogener\u00a0Endpunk te\u00a0keine\u00a0signi\u2010\nfikanten\u00a0 Ergebnisse\u00a0 detektiert.\u00a0 Auch\u00a0 die\u00a0 Eignung\u00a0 des\u00a0 gew\u00e4hlten\u00a0 Komparators\u00a0\nFluticasonfuroat\u00a0 ist\u00a0 fraglich,\u00a0 da\u00a0 die\u00a0 Substanz\u00a0 zum\u00a0 Untersuchung szeitpunkt\u00a0 im\u00a0\nGegensatz\u00a0zu\u00a0Fluticasonpropionat\u00a0nicht\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0zugel assen\u00a0war.\u00a0Eine\u00a0\neingeschr\u00e4nkte\u00a0Datenlage\u00a0liegt\u00a0a uch\u00a0f\u00fcr\u00a0Asthma\u2010Exazerbationen\u00a0v or.\u00a0So\u00a0registrier\u2010\nte\u00a0die\u00a0RCT\u00a0(Bateman\u00a0et\u00a0al,\u00a02013)\u00a0eine\u00a0Reduktion\u00a0des\u00a0Risikos\u00a0dur ch\u00a0FF/Vl\u00a092/22\u00a0\u00b5g\u00a0\ngegen\u00fcber\u00a0FF\u00a092\u00a0\u00b5g\u00a0um\u00a020\u00a0%.\u00a0Bei\u00a0der\u00a0Bewertung\u00a0dieser\u00a0Beobachtun g\u00a0ist\u00a0ein\u00a0m\u00f6gli\u2010\nches\u00a0Verzerrungspotential\u00a0angesichts\u00a0methodischer\u00a0Limitationen\u00a0 zu\u00a0ber\u00fccksichti\u2010\ngen.\u00a0Auch\u00a0die\u00a0Beurteilung\u00a0durch\u00a0den\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimi ttel\u00a0(Committee\u00a0\nfor\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use, \u00a0CHMP)\u00a0der\u00a0 European\u00a0Medicines\u00a0Agency \u00a0\n(EMA)\u00a0fiel\u00a0heterogen\u00a0aus.\u00a0Einige\u00a0Mitglieder\u00a0des\u00a0CHMP\u00a0waren\u00a0gege n\u00a0die\u00a0Empfeh\u2010\nlung\u00a0zur\u00a0Marktzulassung\u00a0und\u00a0kritisierten\u00a0insbesondere\u00a0das\u00a0Fehle n\u00a0von\u00a0Belegen,\u00a0die\u00a0\ndie\u00a0\u00dcberlegenheit\u00a0bzw.\u00a0Nicht\u2010Unterlegenheit\u00a0von\u00a0FF/Vl\u00a0gegen\u00fcber \u00a0anderen\u00a0ICS\u00a0\nund\u00a0LABA\u00a0sowohl\u00a0in\u00a0der\u00a0Kombination\u00a0als\u00a0auch\u00a0in\u00a0der\u00a0Monotherapie \u00a0zeigten\u00a0(EMA,\u00a0\n2013).\u00a0\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0regulatorischen\u00a0Anforderungen\u00a0der\u00a0EMA\u00a0legte\u00a0der\u00a0p U\u00a0f\u00fcr\u00a0die\u00a0Indi\u2010\nkation\u00a0COPD\u00a0die\u00a0gepoolten\u00a0Daten\u00a0der\u00a0Studien\u00a0HZC102970\u00a0und\u00a0HZC10 2871\u00a0(Drans\u2010\nfield\u00a0et\u00a0al.,\u00a02013)\u00a0vor.\u00a0Die\u00a0Ziel stellung\u00a0bestand\u00a0in\u00a0der\u00a0Unters uchung\u00a0des\u00a0Risikos\u00a0f\u00fcr\u00a0\ndas\u00a0Auftreten\u00a0mittelschwerer\u00a0bis\u00a0schwerer\u00a0Exazerbationen\u00a0unter\u00a0 FF/Vl\u00a044/22\u00a0\u00b5g,\u00a0\n92/22\u00a0\u00b5g,\u00a0 184/22\u00a0\u00b5g\u00a0 und\u00a0 VI\u00a0 allein.\u00a0 Erst\u00a0 nach\u00a0 Analyse\u00a0 der\u00a0 zusamm engef\u00fchrten\u00a0\nDaten\u00a0wurde\u00a0ein\u00a0signifikantes\u00a0Ergebnis\u00a0generiert,\u00a0das\u00a0f\u00fcr\u00a0alle\u00a0 Dosierungen\u00a0eine\u00a0\nRisikoreduktion\u00a0gegen\u00fcber\u00a0Vl\u00a0von\u00a021\u00a0bis\u00a034\u00a0%\u00a0aufwies.\u00a0Diese\u00a0\u00dcbe rlegenheit\u00a0be\u2010\nstand\u00a0auch\u00a0f\u00fcr\u00a0den\u00a0sekund\u00e4ren\u00a0Endpunkt\u00a0der\u00a0moderaten\u00a0Exazerbati onen.\u00a0Der\u00a0\nEndpunkt\u00a0\u201eschwere\u00a0Exazerbationen\u201c\u00a0wurde\u00a0nicht\u00a0separat\u00a0erfasst.\u00a0 F\u00fcr\u00a0den\u00a0patien\u2010451\u00a0tenrelevanten\u00a0Endpunkt\u00a0des\u00a0n\u00e4chtlichen\u00a0Erwachens\u00a0sowie\u00a0Dyspnoe\u00a0 schnitt\u00a0die\u00a0\nKombination\u00a0 FF/Vl\u00a0 92/22\u00a0\u00b5g\u00a0 gegen\u00fcber\u00a0 der\u00a0 Monotherapie\u00a0 besser\u00a0 ab \u00a0 (mittlere\u00a0\nDifferenz\u00a0\u20100,08\u00a0p\u00a0<\u00a00,0012;\u00a0\u20100,09\u00a0p\u00a0<\u00a00,0001).\u00a0Die\u00a0placebokontr ollierte\u00a0Studie\u00a0\nHZC112206\u00a0(Kerwin\u00a0et\u00a0al.,\u00a02013)\u00a0untersuchte\u00a0den\u00a0Einfluss\u00a0der\u00a0Ko mparatoren\u00a0FF/VI\u00a0\n44/22\u00a0\u00b5g,\u00a092/22\u00a0\u00b5g\u00a0auf\u00a0die\u00a0Lungenfunktion,\u00a0die\u00a0durch\u00a0die\u00a0co\u2010pri m\u00e4ren\u00a0Endpunkte\u00a0\n\u201emittleres\u00a0gewichtetes\u00a0FEV 1\u201c\u00a0(0\u00a0bis\u00a04\u00a0Stunden\u00a0nach\u00a0Bronchodilatatorgabe)\u00a0und\u00a0\n\u201e\u00c4nderung\u00a0des\u00a0FEV 1\u201c\u00a0(nach\u00a023\u00a0bis\u00a024\u00a0Stunden)\u00a0charakterisiert\u00a0wurde.\u00a0Dabei\u00a0ver\u2010\nbesserte\u00a0die\u00a0Kombination\u00a092/22\u00a0\u00b5g\u00a0gegen\u00fcber\u00a0Placebo\u00a0(FEV 1\u00a0\u00a00\u20104=173\u00a0ml;\u00a0Konfiden\u2010\nzintervall\u00a0( Confidence\u00a0Interval ,\u00a0CI)\u00a0123\u00a0bis\u00a0224\u00a0ml;\u00a0p\u00a0<\u00a00,001;\u00a0FEV 1\u00a0\u00a023\u201024=115\u00a0ml\u00a060\u00a0\nbis\u00a0169\u00a0ml\u00a0p\u00a0<\u00a00,001)\u00a0sowie\u00a0FF\u00a092\u00a0\u00b5g\u00a0(FEV 1\u00a0\u00a00\u20104=120\u00a0ml;\u00a0CI\u00a070\u00a0bis\u00a0170\u00a0ml;\u00a0p<0,001,\u00a0\nFEV1\u00a0\u00a023\u201024=82\u00a0ml;\u00a0CI\u00a028\u00a0bis\u00a0136\u00a0ml;\u00a0p\u00a0<\u00a00,03)\u00a0signifikant\u00a0die\u00a0Lungenfunkt ion,\u00a0w\u00e4h\u2010\nrend\u00a0der\u00a0Vergleich\u00a0mit\u00a0VI\u00a0keinen\u00a0 Beleg\u00a0f\u00fcr\u00a0einen\u00a0Vorteil\u00a0auswei st\u00a0(FEV 1=48\u00a0ml;\u00a0\np=0,082).\u00a0Im\u00a0Hinblick\u00a0auf\u00a0die\u00a0zur\u00a0Best\u00e4tigung\u00a0der\u00a0klinischen\u00a0Re levanz\u00a0(Minimal\u00a0\nClinically\u00a0Important\u00a0Difference ,\u00a0MCID)\u00a0mindestens\u00a0geforderte\u00a0\u00c4nderung\u00a0des\u00a0Volu\u2010\nmens\u00a0von\u00a0100\u00a0bis\u00a0150\u00a0ml\u00a0(Glissen\u00a0et\u00a0al.,\u00a02007)\u00a0ist\u00a0der\u00a0Stellenw ert\u00a0des\u00a0Behand\u2010\nlungsunterschieds\u00a0zwischen\u00a0der\u00a0Kombination\u00a0und\u00a0der\u00a0Monotherapie \u00a0mit\u00a0FF\u00a0frag\u2010\nlich.\u00a0So\u00a0unterschreitet\u00a0das\u00a0CI\u00a0das\u00a0geforderte\u00a0Niveau.\u00a0Wie\u00a0berei ts\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0\nAsthma\u00a0formulierten\u00a0einige\u00a0Exper ten\u00a0des\u00a0CHMP\u00a0eine\u00a0abweichende\u00a0S tellungnahme\u00a0\nund\u00a0konstatierten,\u00a0dass\u00a0keine\u00a0\u00dcber legenheit\u00a0der\u00a0Kombination\u00a0geg en\u00fcber\u00a0Placebo\u00a0\nbez\u00fcglich\u00a0des\u00a0Einflusses\u00a0auf\u00a0die\u00a0 Symptomatik\u00a0belegt\u00a0sei.\u00a0Auch\u00a0d ie\u00a0Eignung\u00a0des\u00a0\neingesetzten\u00a0Komparators\u00a0Vilante rol,\u00a0der\u00a0keine\u00a0Zulassung\u00a0f\u00fcr\u00a0di e\u00a0gepr\u00fcfte\u00a0Indika\u2010\ntion\u00a0aufwies,\u00a0wurde\u00a0im\u00a0Hinblick\u00a0 auf\u00a0m\u00f6gliche\u00a0Alternativen\u00a0bem\u00e4n gelt.\u00a0\u00a0\nDie\u00a0Experten\u00a0kritisierten\u00a0weiterhin\u00a0das\u00a0nicht\u00a0abschlie\u00dfend\u00a0absc h\u00e4tzbare\u00a0Risiko\u00a0f\u00fcr\u00a0\nPneumonien,\u00a0das\u00a0insbesondere\u00a0in\u00a0 der\u00a0COPD\u2010Studie\u00a0(Dransfield\u00a0et\u00a0 al.,\u00a02013)\u00a0in\u00a0\ns\u00e4mtlichen\u00a0Gruppen\u00a0mit\u00a0Intervention\u00a0erh\u00f6ht\u00a0war.\u00a0In\u00a0den\u00a0FF/Vl\u2010Ar men\u00a0lag\u00a0der\u00a0\nAnteil\u00a0im\u00a0Mittel\u00a0bei\u00a06\u00a0%,\u00a0w\u00e4hrend\u00a0er\u00a0bei\u00a0Vl\u00a0allein\u00a03,3\u00a0%\u00a0und\u00a0be i\u00a0Placebo\u00a0unter\u00a01\u00a0%\u00a0\nlag.\u00a0Daher\u00a0beauflagte\u00a0die\u00a0Europ\u00e4 ische\u00a0Kommission\u00a0den\u00a0pU\u00a0mit\u00a0der \u00a0Durchf\u00fchrung\u00a0von\u00a0\nPost\u2010Authorization\u2010Safety\u2010Studies \u00a0(PASS),\u00a0um\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Pneumonien\u00a0f\u00fcr\u00a0beide\u00a0\nIndikationen\u00a0zu\u00a0untersuchen.\u00a0Im\u00a0Rahmen\u00a0der\u00a0Erstellung\u00a0eines\u00a0Rev iews\u00a0zum\u00a0Einsatz\u00a0\nvon\u00a0ICS\u00a0bei\u00a0COPD\u00a0durch\u00a0das\u00a0 Pharmacovigilance\u00a0Risk \u00a0Assessment\u00a0Committee \u00a0(PRAC)\u00a0\nder\u00a0EMA\u00a0wurde\u00a0die\u00a0Problematik\u00a0als\u00a0Klasseneffekt\u00a0diskutiert\u00a0und\u00a0 die\u00a0Aufnahme\u00a0in\u00a0\nentsprechende\u00a0Patienten\u2010\u00a0und\u00a0Fachinformationen\u00a0empfohlen\u00a0(EMA,\u00a0 2016c).\u00a0\u00a0\nDer\u00a0 pU\u00a0 reichte\u00a0 kein\u00a0 Dossier\u00a0 zum\u00a0 Nutzenbewertungsverfahren\u00a0 ein,\u00a0 sodass\u00a0 der\u00a0\nGemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0 keine\u00a0Bewertung \u00a0nach\u00a0\u00a735a\u00a0SGBV\u00a0vorneh\u2010\nmen\u00a0konnte.\u00a0Es\u00a0erfolgte\u00a0die\u00a0Eingruppierung\u00a0in\u00a0die\u00a0bestehende\u00a0Fe stbetragsgruppe\u00a0\n\u201eKombinationen\u00a0von\u00a0Glucocorticoiden\u00a0mit\u00a0langwirksamen\u00a0Beta 2\u2010Sympathomime\u2010\ntika,\u00a0Gruppe\u00a01\u201c\u00a0(G\u2010BA,\u00a02014).\u00a0\n\u00a0452\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nWeitere\u00a0Kombination\u00a0\nICS/LABA\u00a0zur\u00a0Therapie\u00a0\nAsthma\u00a0und\u00a0COPD\u00a0Es\u00a0fehlen\u00a0Studien\u00a0zur\u00a0\nWirksamkeit\u00a0\u00a0\nmit\u00a0weiteren\u00a0\nzugelassenen\u00a0ICS/LABA\u2010\nKombinationen\u00a0\u00a0Festbetragsgruppe:\u00a0GKV\u2010\nWirtschaftlichkeit\u00a0\ngew\u00e4hrleistet,\u00a0\u00a0\nkeine\u00a0Mehrkosten\u00a0f\u00fcr\u00a0\nPatienten.\u00a0\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0Fricke/Klaus a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 Variante\u00a0ohne\u00a0besonderen\u00a0Stellenwert\u00a0 \u2013\u00a0Nothing\u00a0\nnew\u00a0Analogpr\u00e4parat\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nVilanterol\u00a0+\u00a0Fluticasonfuroat\u00a0 1\u00a0x\u00a0tgl.\u00a01\u00a0Hub\u00a0 365\u00a0 536,31\u00a0\u20ac\u00a0\nFestbetragsgruppe*\u00a0\u00a0 1\u00a0x\u00a0tgl.\u00a01\u00a0Hub\u00a0 365\u00a0 536,31\u00a0\u20ac\u00a0\nMehrkosten\u00a0f\u00fcr\u00a0Patienten\u00a0 \u00a0 \u00a0 keine\u00a0\n*Festbetragsgruppe :\u00a0Kombinationen\u00a0von\u00a0Glucocorticoi den\u00a0mit\u00a0langwirksamen\u00a0Beta2\u2010Sym pathomimetika,\u00a0Gruppe\u00a01,\u00a0Stufe\u00a03\u00a0\nAusgew\u00e4hlte\u00a0Versorgungsanalysen\u00a0\nSeit\u00a0 Markteintritt\u00a0 der\u00a0 Kombination\u00a0 Fluticasonfuroat/Vilanterol\u00a0 im\u00a0 Januar\u00a0 2014\u00a0\nsteigen\u00a0innerhalb\u00a0des\u00a0betrachteten\u00a0Zeitraums\u00a0die\u00a0Bruttoums\u00e4tze\u00a0 und\u00a0DDD\u00a0mit\u00a0\nFluktuationen\u00a0stetig\u00a0an.\u00a0Mit\u00a0Inkrafttreten\u00a0des\u00a0Festbetrages\u00a0zum \u00a01.\u00a0Juli\u00a02014\u00a0sanken\u00a0\ndie\u00a0Verkaufspreise\u00a0im\u00a0Mittel\u00a0um\u00a012\u00a0%\u00a0(Lauer\u2010Fischer,\u00a02017).\u00a0Im\u00a0 November\u00a02015\u00a0\nerreichten\u00a0sowohl\u00a0die\u00a0Bruttoums\u00e4tze\u00a0als\u00a0auch\u00a0die\u00a0DDD\u00a0jeweils\u00a0ih ren\u00a0Maximalwert\u00a0\nmit\u00a0302.039\u00a0Euro\u00a0bzw.\u00a0211.200\u00a0DDD.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n453\u00a0Abbildung\u00a04.59:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nVilanterol\u00a0+\u00a0Fluticasonfuroat\u00a0nach\u00a0Monaten\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nWirkstoff\u00a0und\u00a0Pharmakologie\u00a0\nNach\u00a0Zulassungserteilung\u00a0durch\u00a0die\u00a0EC\u00a0am\u00a013.\u00a0November\u00a02013\u00a0stan d\u00a0mit\u00a0dem\u00a0\nPr\u00e4parat\u00a0Vilanterol\u2010Fluticason\u2010Inhalat\u00a0(Relvar\u00a0Ellipta\u00ae)\u00a0die\u00a0f\u00fc nfte\u00a0Wirkstoffkombi\u2010\nnation\u00a0aus\u00a0ICS\u00a0und\u00a0langwirksamen\u00a0 Beta2\u2010Sympathomimetikum\u00a0zur\u00a0Ve rf\u00fcgung.\u00a0Bei\u00a0\nVilanterol\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0Agonisten\u00a0am\u00a0Beta2\u2010Rezeptor ,\u00a0der\u00a0in\u00a0der\u00a0glat\u2010\nten\u00a0Muskulatur\u00a0der\u00a0Atemwege\u00a0vorkommt.\u00a0Strukturell\u00a0leitet\u00a0sich\u00a0d ie\u00a0Substanz\u00a0von\u00a0\ndessen\u00a0endogenen\u00a0Liganden\u00a0Adrenalin\u00a0und\u00a0Noradrenalin\u00a0ab.\u00a0Nach\u00a0B indung\u00a0an\u00a0den\u00a0\nRezeptor\u00a0wird\u00a0intrazellul\u00e4r\u00a0das\u00a0Enzym\u00a0Adenylylcyclase\u00a0aktiviert ,\u00a0das\u00a0die\u00a0Bildung\u00a0\nvon\u00a0zyklischem\u00a0Adenosin\u20103\u00b4,5\u00b4\u2010Monophosphat\u00a0(cAMP,\u00a0 cyclic\u00a0AMP)\u00a0vermittelt.\u00a0In\u00a0\nseiner\u00a0 Funktion\u00a0 als\u00a0 sekund\u00e4rer\u00a0 Botenstoff\u00a0 ( Second\u00a0 Messenger ) \u00a0w i r d \u00a0du rc h \u00a0d i e \u00a0\ninduzierte\u00a0Konzentrationserh\u00f6hung\u00a0des\u00a0Molek\u00fcls\u00a0die\u00a0Relaxation\u00a0d er\u00a0glatten\u00a0Mus\u2010\nkulatur\u00a0bewirkt\u00a0und\u00a0somit\u00a0eine\u00a0Bronchodilatation\u00a0erzeugt.\u00a0Aufgr und\u00a0der\u00a0Halb\u2010\nwertszeit\u00a0von\u00a0elf\u00a0Stunden\u00a0z\u00e4hlt\u00a0Vilanterol\u00a0in\u00a0die\u00a0Gruppe\u00a0der\u00a0LA BA.\u00a0Die\u00a0Wirksamkeit\u00a0\nvon\u00a0Fluticasonfuroat\u00a0beruht\u00a0auf\u00a0einem\u00a0starken\u00a0antiimflammatoris chen\u00a0\u00a0Effekt\u00a0mit\u00a0\nReduktion\u00a0der\u00a0Asthma\u2010\u00a0und\u00a0COPD\u2010Symptomatik,\u00a0dessen\u00a0Mechanismus\u00a0 bisher\u00a0nicht\u00a0\ngenau\u00a0identifiziert\u00a0wurde.\u00a0Im\u00a0Rahmen\u00a0des\u00a0Klasseneffektes\u00a0ist\u00a0f\u00fc r\u00a0Kortikosteroide\u00a0\nein\u00a0vielgestaltiger\u00a0Einfluss\u00a0sowo hl\u00a0auf\u00a0zellul\u00e4re\u00a0(z.B.\u00a0Lymphoz yten,\u00a0Makrophagen,\u00a0\nEosinophile)\u00a0als\u00a0auch\u00a0mediatorische\u00a0(z.B.\u00a0Zytokine,\u00a0Chemokine)\u00a0 Bestandteile\u00a0des\u00a0\nImmunsystems\u00a0belegt\u00a0(EMA,\u00a02013b).\u00a0\n454\u00a0Zulassung\u00a0und\u00a0Pr\u00e4parat\u00a0\nDie\u00a0Zulassung\u00a0umfasst\u00a0zwei\u00a0Indikationen.\u00a0Zum\u00a0einen\u00a0wird\u00a0die\u00a0Kom bination\u00a0Vilan\u2010\nterol/Fluticasonfuroat\u00a0f\u00fcr\u00a0die\u00a0regelm\u00e4\u00dfige\u00a0Behandlung\u00a0von\u00a0Asthm a\u2010Patienten\u00a0im\u00a0\nerwachsenen\u00a0Alter\u00a0und\u00a0Jugendlichen\u00a0ab\u00a012\u00a0Jahren\u00a0eingesetzt,\u00a0bei \u00a0denen\u00a0die\u00a0Kom\u2010\nbination\u00a0aus\u00a0LABA\u00a0und\u00a0ICS\u00a0angezeigt\u00a0ist.\u00a0Die\u00a0Anwendung\u00a0der\u00a0empf ohlenen\u00a0Dosis\u00a0\n92/22\u00a0\u00b5g\u00a0(Fluticasonfuroat/Vilanterol)\u00a0erfolgt\u00a0einmal\u00a0t\u00e4glich\u00a0immer\u00a0z ur\u00a0gleichen\u00a0\nZeit\u00a0und\u00a0kann\u00a0bei\u00a0ungen\u00fcgendem\u00a0Ansprechen\u00a0auf\u00a0184/22 \u00a0\u00b5g\u00a0angepasst\u00a0werden.\u00a0\nBei\u00a0der\u00a0Zielpopulation\u00a0f\u00fcr\u00a0COPD\u00a0h andelt\u00a0es\u00a0sich\u00a0um\u00a0erwachsene\u00a0P atienten\u00a0mit\u00a0\neiner\u00a0Einsekundenkapazit\u00e4t\u00a0(FEV 1)\u00a0von\u00a0<70 \u00a0%\u00a0des\u00a0Normwertes\u00a0(nach\u00a0Anwendung\u00a0\neines\u00a0Bronchodilatators),\u00a0die\u00a0trotz\u00a0regelm\u00e4\u00dfiger\u00a0bronchienerwei ternder\u00a0Therapie\u00a0\nExazerbationen\u00a0 entwickelten.\u00a0 Die\u00a0 empfohlene\u00a0 t\u00e4gliche\u00a0 Dosis\u00a0 betr \u00e4gt\u00a0 ebenfalls\u00a0\n92/22\u00a0\u00b5g.\u00a0Die\u00a0Anwendung\u00a0des\u00a0h\u00f6her\u00a0dosierten\u00a0Pr\u00e4parates\u00a0184/22 \u00a0\u00b5g\u00a0ist\u00a0f\u00fcr\u00a0diese\u00a0\nIndikation\u00a0nicht\u00a0angezeigt,\u00a0da\u00a0f\u00fcr\u00a0h\u00f6here\u00a0ICS\u2010Konzentration\u00a0bei \u00a0COPD\u00a0kein\u00a0zus\u00e4tzli\u2010\ncher\u00a0Nutzen\u00a0belegt\u00a0ist\u00a0(EMA,\u00a02013a).\u00a0Sowohl\u00a0bei\u00a0\u00e4lteren\u00a0Patient en\u00a0\u00fcber\u00a065\u00a0Jahren\u00a0\nals\u00a0auch\u00a0bei\u00a0Nierenfunktionsst\u00f6rungen\u00a0sind\u00a0keine\u00a0Anpassungen\u00a0de r\u00a0Dosis\u00a0erforder\u2010\nlich.\u00a0Bei\u00a0eingeschr\u00e4nkter\u00a0Leberf unktion\u00a0kann\u00a0die\u00a0systemisch\u00a0ver f\u00fcgbare\u00a0Konzentra\u2010\ntion\u00a0von\u00a0Fluticasonfuroat\u00a0erh\u00f6ht\u00a0sein,\u00a0sodass\u00a0ab\u00a0mittelschweren \u00a0Funktionsst\u00f6run\u2010\ngen\u00a0der\u00a0Leber\u00a0die\u00a0H\u00f6chstdosis\u00a092/22 \u00a0\u00b5g\u00a0betr\u00e4gt.\u00a0\nInformationen\u00a0zum\u00a0Indikationsgebiet\u00a0\nDie\u00a0Bezeichnung\u00a0COPD\u00a0fasst\u00a0die\u00a0verschiedenen\u00a0Krankheitsbilder\u00a0c hronische\u00a0ob\u2010\nstruktive\u00a0Bronchitis\u00a0und\u00a0Lungenemphysem\u00a0zusammen.\u00a0Entsprechend\u00a0 der\u00a0Definiti\u2010\non\u00a0der\u00a0Global\u00a0Initiative\u00a0For\u00a0Chronic\u00a0Obstructive\u00a0Lung\u00a0Disease \u00a0(GOLD)\u00a0ist\u00a0die\u00a0Erkran\u2010\nkung\u00a0durch\u00a0dauerhafte\u00a0Atemwegsbeschwerden\u00a0(Husten,\u00a0Auswurf,\u00a0Ate mnot),\u00a0ver\u2010\nminderte\u00a0Lungenbel\u00fcftung\u00a0sowie\u00a0Ve r\u00e4nderungen\u00a0in\u00a0den\u00a0Atemwegen\u00a0( obstruktive\u00a0\nBronchitis)\u00a0und\u00a0des\u00a0Lungengewebes\u00a0(Emphysem)\u00a0charakterisiert.\u00a0F \u00fcr\u00a0die\u00a0Betroffe\u2010\nnen\u00a0ergeben\u00a0sich\u00a0mit\u00a0Krankheitsprogression\u00a0h\u00e4ufig\u00a0gravierende\u00a0k \u00f6rperliche\u00a0Ein\u2010\nschr\u00e4nkungen,\u00a0die\u00a0sich\u00a0auf\u00a0die\u00a0Lebensqualit\u00e4t\u00a0auswirken\u00a0k\u00f6nnen. \u00a0Dar\u00fcber\u00a0hinaus\u00a0\nbesteht\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0COPD\u00a0ein\u00a0h\u00f6heres\u00a0Risiko\u00a0f\u00fcr\u00a0die\u00a0Entwi cklung\u00a0von\u00a0Komor\u2010\nbidit\u00e4ten\u00a0wie\u00a0pulmonaler\u00a0Herzkrankheit\u00a0und\u00a0Malnutrition\u00a0(Cavail l\u00e8s\u00a0et\u00a0al.,\u00a02013).\u00a0\nWie\u00a0bei\u00a0Asthma\u00a0spielen\u00a0Entz\u00fcndungsprozesse\u00a0eine\u00a0wichtige\u00a0Rolle, \u00a0die\u00a0sich\u00a0jedoch\u00a0\nlaborchemisch\u00a0 unterscheiden\u00a0 (GOLD,\u00a0 2017).\u00a0 Im\u00a0 weiteren\u00a0 Verlauf\u00a0 n ehmen\u00a0 die\u00a0\nentz\u00fcndlichen\u00a0Prozesse\u00a0und\u00a0strukturellen\u00a0Ver\u00e4nderungen\u00a0zu\u00a0und\u00a0k ommen\u00a0auch\u00a0\nbei\u00a0Beendigung\u00a0des\u00a0Tabakkonsums\u00a0\u2013\u00a0einer\u00a0der\u00a0wichtigsten\u00a0Gegenma \u00dfnahmen\u00a0\u2013\u00a0\nnicht\u00a0zum\u00a0Stillstand\u00a0(Hogg\u00a0et\u00a0al.,\u00a02004).\u00a0\u00a0\nDie\u00a0genauen\u00a0Ursachen\u00a0der\u00a0COPD\u00a0sind\u00a0bisher\u00a0nicht\u00a0eindeutig\u00a0ident ifiziert,\u00a0was\u00a0die\u00a0\nEntwicklung\u00a0besserer\u00a0Therapieoptionen\u00a0erschwert\u00a0(Ngkelo\u00a0&\u00a0Adcoc k,\u00a02013).\u00a0Es\u00a0\nwird\u00a0vermutet,\u00a0dass\u00a0ein\u00a0Zusammenha ng\u00a0verschiedener\u00a0Faktoren\u00a0wie \u00a0Exposition\u00a0\ngegen\u00fcber\u00a0sch\u00e4dlichen\u00a0Gasen\u00a0und\u00a0Pa rtikeln\u00a0in\u00a0Kombination\u00a0mit\u00a0ge netischer\u00a0Dispo\u2010455\u00a0sition,\u00a0\u00dcberempfindlichkeit\u00a0der\u00a0 Atemwege\u00a0sowie\u00a0vermindertem\u00a0Lun genwachstum\u00a0\nw\u00e4hrend\u00a0der\u00a0Kindheit\u00a0besteht\u00a0(GO LD,\u00a02017).\u00a0Weltweit\u00a0waren\u00a02010\u00a0 gesch\u00e4tzte\u00a0384\u00a0\nMio.\u00a0Menschen\u00a0an\u00a0COPD\u00a0erkrankt,\u00a0was\u00a0einer\u00a0Pr\u00e4valenz\u00a0von\u00a011,7\u00a0%\u00a0 bzw.\u00a03\u00a0Mio.\u00a0\nToten\u00a0j\u00e4hrlich\u00a0entspricht.\u00a0Unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0aktuellen \u00a0Tendenzen\u00a0hin\u2010\nsichtlich\u00a0des\u00a0steigendem\u00a0Tabakkonsums\u00a0und\u00a0der\u00a0Ver\u00e4nderung\u00a0der\u00a0A ltersstruktur\u00a0in\u00a0\nden\u00a0Industriestaaten,\u00a0ergaben\u00a0Kalkulationen\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02030\u00a0e inen\u00a0weiteren\u00a0\nAnstieg\u00a0der\u00a0Erkrankungen\u00a0mit\u00a0ber echneten\u00a04,5\u00a0Mio.\u00a0COPD\u2010Toten\u00a0pr o\u00a0Jahr\u00a0(Adeloye\u00a0\net\u00a0al.,\u00a02015,\u00a0Mathers\u00a0&\u00a0Loncar,\u00a02006).\u00a0Genaue\u00a0Angaben\u00a0zur\u00a0Pr\u00e4va lenz\u00a0in\u00a0Deutsch\u2010\nland\u00a0liegen\u00a0nicht\u00a0vor,\u00a0da\u00a0die\u00a0Misch\u2010Diagnose\u00a0COPD\u00a0sowohl\u00a0bei\u00a0Vo rliegen\u00a0einer\u00a0\nchronischen\u00a0Bronchitis\u00a0als\u00a0auch\u00a0 bei\u00a0einer\u00a0dauerhaften\u00a0Verengung \u00a0der\u00a0unteren\u00a0\nAtemwege\u00a0(ggf.\u00a0in\u00a0Kombination\u00a0mit\u00a0Lungenemphysem)\u00a0gestellt\u00a0wird .\u00a0Die\u00a0pr\u00e4zise\u00a0\nDatenerfassung\u00a0gestaltet\u00a0sic h\u00a0daher\u00a0schwierig\u00a0(RKI,\u00a02017).\u00a0\nBei\u00a0Asthma\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0chronisch\u00a0entz\u00fcndliche\u00a0Erkra nkung\u00a0der\u00a0Atem\u2010\nwege,\u00a0die\u00a0durch\u00a0eine\u00a0bronchiale\u00a0Hyperreagibilit\u00e4t\u00a0und\u00a0eine\u00a0vari able\u00a0Atemwegsob\u2010\nstruktion\u00a0gekennzeichnet\u00a0ist\u00a0(Gillesen\u00a0&\u00a0Welte,\u00a02014).\u00a0Die\u00a0bron chiale\u00a0Entz\u00fcndung\u00a0\nver\u00e4ndert\u00a0das\u00a0Lungengewebe,\u00a0insb esondere\u00a0die\u00a0glatten\u00a0Muskelzell en,\u00a0und\u00a0f\u00fchrt\u00a0zu\u00a0\neiner\u00a0neuronalen\u00a0\u00dcberempfindlichk eit.\u00a0Die\u00a0resultierende\u00a0unspezi fische\u00a0bronchiale\u00a0\nHyperreagibilit\u00e4t\u00a0ist\u00a0charakteristisch\u00a0f\u00fcr\u00a0die\u00a0Erkrankung\u00a0(Lomm atzsch,\u00a02012),\u00a0die\u00a0\nanhand\u00a0der\u00a0klinischen\u00a0oder\u00a0laborc hemischen\u00a0Parameter\u00a0kategorisi ert\u00a0wird:\u00a0Das\u00a0oft\u00a0\nbereits\u00a0im\u00a0Kindes\u2010\u00a0und\u00a0Jugendal ter\u00a0auftretende\u00a0allergische\u00a0Asth ma\u00a0korreliert\u00a0mit\u00a0\ndem\u00a0Nachweis\u00a0einer\u00a0Allergie\u00a0sowie\u00a0spezifischer\u00a0Antik\u00f6rper\u00a0im\u00a0Se rum\u00a0und\u00a0ist\u00a0die\u00a0\nh\u00e4ufigste\u00a0Form.\u00a0Findet\u00a0sich\u00a0weder \u00a0anamnestisch\u00a0noch\u00a0klinisch\u00a0ei n\u00a0Hinweis\u00a0auf\u00a0eine\u00a0\nallergische\u00a0Sensibilisierung\u00a0spricht\u00a0man\u00a0vom\u00a0intrinsischen\u00a0Asth ma,\u00a0das\u00a0oft\u00a0erst\u00a0im\u00a0\nErwachsenenalter\u00a0beginnt\u00a0und\u00a0dessen\u00a0Ursachen\u00a0nach\u00a0wie\u00a0vor\u00a0Gegen stand\u00a0der\u00a0\nForschung\u00a0sind.\u00a0Weiterhin\u00a0kann\u00a0eine\u00a0Einteilung\u00a0anhand\u00a0des\u00a0Statu s\u00a0der\u00a0eosinophi\u2010\nlen\u00a0Granulozyten\u00a0vorgenommen\u00a0werden,\u00a0der\u00a0bei\u00a0ca.\u00a050\u00a0%\u00a0der\u00a0Asthm a\u2010Patienten\u00a0\nkeine\u00a0Ver\u00e4nderung\u00a0aufweist\u00a0(McGrath\u00a0et\u00a0al.,\u00a02012).\u00a0F\u00fcr\u00a0Patiente n\u00a0mit\u00a0eosinophi\u2010\nlem\u00a0Asthma\u00a0zeigten\u00a0Studien\u00a0ein\u00a0sehr\u00a0gutes\u00a0Ansprechen\u00a0auf\u00a0Glucoc orticoide\u00a0sowie\u00a0\neine\u00a0Antik\u00f6rpertherapie\u00a0(Wenzel\u00a0et\u00a0al.,\u00a02013).\u00a0Die\u00a0Einteilung\u00a0d er\u00a0f\u00fcr\u00a0die\u00a0Asthma\u2010\ntherapie\u00a0zur\u00a0Verf\u00fcgung\u00a0stehenden\u00a0Substanzgruppen\u00a0erfolgt\u00a0anhand \u00a0der\u00a0Wirkdauer\u00a0\nin\u00a0Langzeit\u2010\u00a0( Controler )\u00a0und\u00a0Bedarfstherapeutika\u00a0( Reliever).\u00a0F\u00fcr\u00a0die\u00a0Langzeitthera\u2010\npie\u00a0sind\u00a0ICS\u00a0Mittel\u00a0der\u00a0ersten\u00a0Wahl.\u00a0Alternativ\u00a0k\u00f6nnen\u00a0auch\u00a0ora le\u00a0ICS,\u00a0LABA,\u00a0Theo\u2010\nphyllin,\u00a0Antileukotriene\u00a0und\u00a0Omalizumab\u00a0(Anti\u2010IgE\u2010Antik\u00f6rper)\u00a0e ingesetzt\u00a0werden.\u00a0\nZu\u00a0den\u00a0Bedarfsmedikamenten\u00a0z\u00e4hlen\u00a0rasch\u00a0wirksame\u00a0Beta 2\u2010Sympathomimetika\u00a0\n(SABA)\u00a0und\u00a0Ipatropiumbromid.\u00a0\u00a0\nDie\u00a0Weltgesundheitsorganisation\u00a0(WHO)\u00a0stuft\u00a0die\u00a0Erkrankung\u00a0als\u00a0 eine\u00a0der\u00a0bedeu\u2010\ntendsten\u00a0Volkskrankheiten\u00a0ein\u00a0und\u00a0sch\u00e4tzt\u00a0die\u00a0Zahl\u00a0der\u00a0Betroffe nen\u00a0auf\u00a0334\u00a0Mio.\u00a0\nMenschen\u00a0weltweit\u00a0(WHO,\u00a02014).\u00a0Di e\u00a0Ergebnisse\u00a0der\u00a0Literaturrech erche\u00a0des\u00a0Deut\u2010\nschen\u00a0Wei\u00dfbuches\u00a0Lunge\u00a0ergaben\u00a0Lebenszeitpr\u00e4valenzen\u00a0von\u00a06,1\u00a0bi s\u00a08,8\u00a0%\u00a0f\u00fcr\u00a0456\u00a0Deutschland\u00a0(Gillesen\u00a0&\u00a0Welte,\u00a02014).\u00a0Dabei\u00a0zeigten\u00a0die\u00a0Daten\u00a0a us\u00a0der\u00a0auf\u00a0Selbst\u2010\neinsch\u00e4tzung\u00a0 von\u00a0 22.050\u00a0 Teilnehmern\u00a0 beruhenden\u00a0 Studie\u00a0 des\u00a0 Rober t\u2010Koch\u2010\nInstitutes\u00a0(RKI),\u00a0dass\u00a0im\u00a0Kindesalter\u00a0mehr\u00a0Jungen\u00a0betroffen\u00a0sin d.\u00a0Dieses\u00a0Verh\u00e4ltnis\u00a0\nkehrt\u00a0sich\u00a0ab\u00a0dem\u00a014.\u00a0Lebensjahr\u00a0um,\u00a0sodass\u00a0bei\u00a0Erwachsenen\u00a0die \u00a0Pr\u00e4valenz\u00a0bei\u00a0\nFrauen\u00a0in\u00a0allen\u00a0Lebensjahren \u00a0gr\u00f6\u00dfer\u00a0ist\u00a0(RKI,\u00a02012).\u00a0\u00a0\nEvidenz\u00a0zum\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0\nIm\u00a0Beurteilungsbericht\u00a0der\u00a0EMA\u00a0w ird\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0Asthma\u00a0d en\u00a0vom\u00a0pU\u00a0vorge\u2010\nlegten\u00a0Studien\u00a0HZA106827,\u00a0HZA106829\u00a0und\u00a0HZA106837\u00a0die\u00a0h\u00f6chste\u00a0E videnz\u00a0zuge\u2010\nsprochen\u00a0(EMA,\u00a02013a).\u00a0Ziel\u00a0der\u00a0doppelblinden\u00a0RCT\u00a0HZA106827\u00a0(Bl eecker\u00a0at\u00a0al.,\u00a0\n2014)\u00a0war\u00a0die\u00a0Untersuchung\u00a0der\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0der\u00a0K ombination\u00a0\nFluticasonfuroat/Vilanterol\u00a0(FF/VI)\u00a0(92\u00b5g/\u00a022\u00b5g)\u00a0gegen\u00fcber\u00a0der\u00a0 Monotherapie\u00a0mit\u00a0\nFluticasonfuroat\u00a0(FF)\u00a0(92\u00a0\u00b5g).\u00a0Daf\u00fcr\u00a0wurden\u00a0609\u00a0Patienten\u00a0mit\u00a0p ersistierendem\u00a0\nAsthma\u00a0ab\u00a0dem\u00a013.\u00a0Lebensjahr\u00a0rekrutiert\u00a0und\u00a0\u00fcber\u00a0einen\u00a0Zeitraum \u00a0von\u00a0zw\u00f6lf\u00a0Wo\u2010\nchen\u00a0beobachtet.\u00a0Der\u00a0Effekt\u00a0auf\u00a0die\u00a0Lungenfunktion\u00a0wurde\u00a0durch\u00a0 die\u00a0ko\u2010prim\u00e4ren\u00a0\nEndpunkte\u00a0\u00c4nderung\u00a0des\u00a0FEV 1\u2010Talwertes\u00a0(vor\u00a0Bronchiodilatatorgabe\u00a0und\u00a0vor\u00a0Me\u2010\ndikation)\u00a0gegen\u00fcber\u00a0dem\u00a0Ausgangs wert\u00a0bei\u00a0Fortschreiben\u00a0des\u00a0LOCF \u00a0zum\u00a0Ende\u00a0des\u00a0\nBeobachtungszeitraumes\u00a0(FEV1 LOCF)\u00a0sowie\u00a0das\u00a0gewichtete\u00a0mittlere\u00a0serielle\u00a0FEV 1\u00a0\n\u00fcber\u00a00\u00a0bis\u00a024\u00a0Stunden\u00a0nach\u00a0Medikation\u00a0(FEV 1\u00a0\u00a00\u201024h)\u00a0erfasst.\u00a0Im\u00a0Vergleich\u00a0zu\u00a0Placebo\u00a0\nzeigt\u00a0sich\u00a0die\u00a0Kombination\u00a0\u00fcberl egen\u00a0und\u00a0erzielte\u00a0signifikante\u00a0 Behandlungsunter\u2010\nschiede\u00a0von\u00a0172\u00a0ml\u00a0(FEV 1\u00a0\u00a0LOCF)\u00a0bzw.\u00a0302\u00a0ml\u00a0(FEV 1\u00a0\u00a00\u201024h).\u00a0Die\u00a0Interpretation\u00a0der\u00a0Da\u2010\nten\u00a0hinsichtlich\u00a0der\u00a0Gegen\u00fcberstellung\u00a0zur\u00a0Monotherapie\u00a0mit\u00a0FF\u00a0 92\u00a0\u00b5g\u00a0ist\u00a0aufgrund\u00a0\nfehlender\u00a0Signifikanz\u00a0(p=0,405)\u00a0nicht\u00a0m\u00f6glich.\u00a0Die\u00a0Studie\u00a0HZA10 6829\u00a0(O\u2018Byrne\u00a0et\u00a0\nal.,\u00a02013)\u00a0untersuchte\u00a0an\u00a0586\u00a0Patienten\u00a0mit\u00a0moderatem\u00a0bis\u00a0schwe rem\u00a0Asthma\u00a0\n\u00fcber\u00a024\u00a0Wochen\u00a0die\u00a0Wirksamkeit\u00a0der\u00a0Kombination\u00a0FF/VI\u00a0(184\u00a0\u00b5g/\u00a02 2\u00b5g\u00a0einmal\u00a0\nt\u00e4glich)\u00a0sowie\u00a0der\u00a0Monotherapie\u00a0mit\u00a0FF\u00a0(einmal\u00a0t\u00e4glich)\u00a0184\u00a0\u00b5g\u00a0 und\u00a0FP\u00a0500\u00a0\u00b5g\u00a0\n(zweimal\u00a0t\u00e4glich).\u00a0Bez\u00fcglich\u00a0des\u00a0FEV 1\u2010Talwertes\u00a0zeigt\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0ein\u00a0\ngr\u00f6\u00dferer\u00a0Behandlungsunterschied\u00a0zu\u00a0den\u00a0Einzelsubstanzen\u00a0mit\u00a0193 \u00a0ml\u00a0gegen\u00fcber\u00a0\nFF\u00a0(p<0,001)\u00a0und\u00a0210\u00a0ml\u00a0im\u00a0Vergleich\u00a0zu\u00a0FP\u00a0(p<0,001).\u00a0Diese\u00a0Ten denz\u00a0zeigt\u00a0sich\u00a0\nauch\u00a0f\u00fcr\u00a0den\u00a0sekund\u00e4ren\u00a0Endpunkt\u00a0der\u00a0prozentualen\u00a0\u00c4nderung\u00a0der\u00a0 24\u2010Stunden\u2010\nPhasen\u00a0 ohne\u00a0 Bedarfsmedikation\u00a0 geg en\u00fcber\u00a0 dem\u00a0 Ausgangswert.\u00a0 So\u00a0 se nkte\u00a0 die\u00a0\nZweiertherapie\u00a0die\u00a0Rate\u00a0signifikant\u00a0um\u00a011,7\u00a0%\u00a0(p<0,001)\u00a0st\u00e4rker \u00a0als\u00a0FF.\u00a0F\u00fcr\u00a0die\u00a0\nTherapie\u00a0 mit\u00a0 FP\u00a0 (6,3\u00a0 %;\u00a0 p=0,067)\u00a0 konnten\u00a0 keine\u00a0 interpretationsf \u00e4higen\u00a0 Daten\u00a0\nerhoben\u00a0werden.\u00a0Den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0HZA106837\u00a0(Bat eman\u00a0et\u00a0al.,\u00a0\n2013)\u00a0stellte\u00a0die\u00a0Zeit\u00a0bis\u00a0zum\u00a0Auftreten\u00a0der\u00a0ersten\u00a0Asthma\u2010Exaz erbation\u00a0unter\u00a0\nTherapie\u00a0mit\u00a0FF/VI\u00a0(92\u00a0\u00b5g/22\u00a0\u00b5g)\u00a0bzw.\u00a0FF\u00a092\u00a0\u00b5g\u00a0dar.\u00a0Der\u00a0Beobach tungszeitraum\u00a0\nwurde\u00a0auf\u00a0mindestens\u00a024\u00a0bis\u00a0maximal\u00a076\u00a0Wochen\u00a0fixiert\u00a0und\u00a0betru g\u00a0im\u00a0Mittel\u00a052\u00a0\n(FF/VI)\u00a0und\u00a052,7\u00a0(FF)\u00a0Wochen.\u00a0Im\u00a0Ergebnis\u00a0senkte\u00a0die\u00a0Kombinatio n\u00a0das\u00a0Risiko\u00a0um\u00a0\n20\u00a0%\u00a0st\u00e4rker\u00a0als\u00a0unter\u00a0Monotherapie\u00a0mit\u00a0FF\u00a0(p=0,036).\u00a0Das\u00a0Patie ntenkollektiv\u00a0\nz\u00e4hlte\u00a02.019\u00a0Asthmatiker\u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0(mittleres\u00a0Alter\u00a042\u00a0Ja hre),\u00a0die\u00a0innerhalb\u00a0457\u00a0eines\u00a0Jahres\u00a0mindestens\u00a0eine\u00a0Exazerbation\u00a0entwickelt\u00a0hatten\u00a0und \u00a0ein\u00a0ICS\u00a0oder\u00a0die\u00a0\nKombination\u00a0ICS\u00a0plus\u00a0LABA\u00a0anwendeten.\u00a0Zwar\u00a0gew\u00e4hrleistet\u00a0die\u00a0Ra ndomisierung\u00a0\neine\u00a0gleiche\u00a0Verteilung\u00a0der\u00a0Therapieschemata\u00a0in\u00a0den\u00a0zwei\u00a0Gruppe n\u00a0(ICS\u00a0vs.\u00a0ICS\u00a0\nplus\u00a0LABA),\u00a0f\u00fcr\u00a0die\u00a0mittlere\u00a0ICS \u2010Dosis\u00a0vor\u00a0Studienbeginn\u00a0liegen \u00a0aber\u00a0keine\u00a0Informa\u2010\ntionen\u00a0vor,\u00a0sodass\u00a0einige\u00a0Probanden\u00a0mit\u00a0Versuchsbeginn\u00a0eine\u00a0h\u00f6h ere\u00a0Dosierung\u00a0\nerhalten\u00a0haben\u00a0k\u00f6nnten.\u00a0In\u00a0der\u00a0F olge\u00a0kann\u00a0eine\u00a0Verzerrung\u00a0der\u00a0E rgebnisse\u00a0nicht\u00a0\nausgeschlossen\u00a0werden\u00a0(NICE,\u00a02014).\u00a0Weiterhin\u00a0war\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Beantra\u2010\ngung\u00a0der\u00a0Zulassung\u00a0Fluticasonfur oat\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0Asthma\u00a0n icht\u00a0zugelassen,\u00a0\nsodass\u00a0die\u00a0Eignung\u00a0als\u00a0Komparator\u00a0in\u00a0Anbetracht\u00a0m\u00f6glicher\u00a0Alter nativen\u00a0wie\u00a0Fluti\u2010\ncasonpropionat\u00a0 fraglich\u00a0 scheint.\u00a0 Weiterhin\u00a0 liegt\u00a0 mit\u00a0 der\u00a0 RCT\u00a0 HZ A113091\u00a0\n(Woodcock\u00a0et\u00a0al.,\u00a02013)\u00a0eine\u00a0vom\u00a0pU\u00a0gesponserte\u00a0Untersuchung\u00a0vo r,\u00a0die\u00a0den\u00a0\nVergleich\u00a0 FF/Vl\u00a0 92\u00a0 \u00b5g/22\u00a0 \u00b5g\u00a0 mit\u00a0 der\u00a0 ICS\u2010LABA\u00a0 Kombination\u00a0 Flutic asonpropio\u2010\nnat/Salmeterol\u00a0250/50\u00a0\u00b5g\u00a0(FP/S)\u00a0untersucht.\u00a0Vor\u00a0Randomisierung\u00a0 wurde\u00a0w\u00e4hrend\u00a0\nder\u00a0vierw\u00f6chigen\u00a0Vorlaufphase\u00a0die\u00a0Medikation\u00a0der\u00a0 Teilnehmer\u00a0auf \u00a0 250\u00a0\u00b5g\u00a0FP\u00a0\nzweimal\u00a0t\u00e4glich\u00a0und\u00a0Salbutamol\u00a0vereinheitlicht.\u00a0Die\u00a0Daten\u00a0zeigt en\u00a0keine\u00a0statistisch\u00a0\nsignifikanten\u00a0 Unterschiede\u00a0 bez\u00fcg lich\u00a0 der\u00a0 \u00c4nderung\u00a0 des\u00a0 mittleren \u00a0 gewichteten\u00a0\nFEV1\u00a0nach\u00a024\u00a0Wochen\u00a0sowie\u00a0sekund\u00e4rer\u00a0Endpunkte,\u00a0die\u00a0mittels\u00a0Frageb\u00f6 gen\u00a0wie\u00a0\nAsthma\u00a0Control\u00a0Test \u00a0und\u00a0Asthma\u00a0Quality\u00a0of\u00a0Life \u00a0erfasst\u00a0wurden.\u00a0Das\u00a0Design\u00a0der\u00a0\nStudie\u00a0zielte\u00a0nicht\u00a0auf\u00a0die\u00a0Untersuchung\u00a0des\u00a0Einflusses\u00a0auf\u00a0das \u00a0Auftreten\u00a0von\u00a0\nExazerbationen.\u00a0F\u00fcr\u00a0dieses\u00a0 Outcome\u00a0liegen\u00a0hinsichtlich\u00a0des\u00a0Vergleichs\u00a0mit\u00a0anderen\u00a0\nICS/LABA\u2010Kombinationen\u00a0keine\u00a0Daten\u00a0vor.\u00a0In\u00a0der\u00a0Gesamtschau\u00a0wurd e\u00a0der\u00a0Stellen\u2010\nwert\u00a0der\u00a0Kombination\u00a0FF/VI\u00a0auch\u00a0vom\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimi ttel\u00a0hetero\u2010\ngen\u00a0bewertet.\u00a0So\u00a0positionierten\u00a0sich\u00a0elf\u00a0Mitglieder\u00a0gegen\u00a0die\u00a0E mpfehlung\u00a0des\u00a0\nCHMP\u00a0zur\u00a0Marktzulassung\u00a0des\u00a0Pr\u00e4parates\u00a0und\u00a0bemerkten\u00a0insbesonde re\u00a0das\u00a0Feh\u2010\nlen\u00a0von\u00a0Belegen,\u00a0die\u00a0die\u00a0\u00dcberleg enheit\u00a0bzw.\u00a0Nicht\u2010Unterlegenhei t\u00a0von\u00a0FF/Vl\u00a0ge\u2010\ngen\u00fcber\u00a0anderen\u00a0ICS\u00a0und\u00a0LABA\u00a0sowohl\u00a0in\u00a0Kombination\u00a0als\u00a0auch\u00a0in\u00a0 der\u00a0Monothera\u2010\npie\u00a0zeigten\u00a0(EMA,\u00a02013b).\u00a0\nDie\u00a0Hauptevidenz\u00a0f\u00fcr\u00a0die\u00a0Indikation\u00a0COPD\u00a0sieht\u00a0die\u00a0EMA\u00a0in\u00a0vier\u00a0 vom\u00a0pU\u00a0vorgeleg\u2010\nten\u00a0Studien\u00a0formuliert.\u00a0F\u00fcr\u00a0die\u00a0zwei\u00a0parallel\u00a0durchgef\u00fchrten\u00a0re plizierten\u00a0Studien\u00a0\nHZC102970\u00a0und\u00a0HZC102871\u00a0(Dransfield\u00a0et\u00a0al,\u00a02013)\u00a0wurden\u00a01.622\u00a0u nd\u00a01.633\u00a0Teil\u2010\nnehmer\u00a0aus\u00a015\u00a0L\u00e4ndern\u00a0ab\u00a040\u00a0Jahren\u00a0mit\u00a0COPD\u00a0\u00fcber\u00a052\u00a0Wochen\u00a0beob achtet.\u00a0Die\u00a0\nEinschlusskriterien\u00a0sahen\u00a0eine\u00a0FEV 1\u00a0\u2264\u00a070\u00a0%\u00a0des\u00a0Normwertes\u00a0nach\u00a0Anwendung\u00a0\neines\u00a0Bronchodilatators,\u00a0das\u00a0Auftreten\u00a0mindestens\u00a0einer\u00a0Exazerb ation\u00a0im\u00a0Vorjahr\u00a0\nsowie\u00a0mindestens\u00a0zehn\u00a0Packungsj ahre\u00a0(20\u00a0Zigaretten\u00a0pro\u00a0Tag\u00a0und\u00a0 Jahr,\u00a0mindestens\u00a0\n10\u00a0Jahre\u00a0lang)\u00a0vor.\u00a0Nach\u00a0einer\u00a0vierw\u00f6chigen\u00a0Vorlauf\u2010Phase\u00a0mit\u00a0H armonisierung\u00a0der\u00a0\nMedikation\u00a0auf\u00a0FP/S\u00a0250/50\u00a0\u00b5g\u00a0zweimal\u00a0t\u00e4glich\u00a0erfolgte\u00a0mit\u00a0Beob achtungsbeginn\u00a0\ndie\u00a0Umstellung\u00a0auf\u00a0FF/Vl\u00a044/22\u00a0\u00b5g,\u00a0FF/Vl\u00a092/22\u00a0\u00b5g,\u00a0FF/Vl\u00a0188/22 \u00a0\u00b5g\u00a0und\u00a0VI\u00a022\u00a0\u00b5g.\u00a0\nPrim\u00e4re\u00a0Endpunkte\u00a0waren\u00a0die\u00a0Raten\u00a0von\u00a0moderaten\u00a0(Verschlechteru ng\u00a0der\u00a0Symp\u2010\ntomatik,\u00a0die\u00a0eine\u00a0Behandlung\u00a0mit\u00a0oralen\u00a0CS\u00a0und/oder\u00a0Antibiotika \u00a0erfordert)\u00a0bis\u00a0\nschweren\u00a0 (Hospitalisierung\u00a0 erfor derlich)\u00a0 Exazerbationen\u00a0 innerha lb\u00a0 des\u00a0 Beob\u2010458\u00a0achtungszeitraums.\u00a0In\u00a0HZC102970\u00a0konnte\u00a0f\u00fcr\u00a0alle\u00a0Dosierungen\u00a0und \u00a0in\u00a0HZC102871\u00a0\nf\u00fcr\u00a0die\u00a0Kombination\u00a0FF/VI\u00a092/22\u00a0\u00b5g\u00a0nur\u00a0gegen\u00fcber\u00a0VI\u00a022\u00a0\u00b5g\u00a0ein\u00a0s tatistisch\u00a0signifi\u2010\nkantes\u00a0Ergebnis\u00a0detektiert\u00a0werde n.\u00a0Erst\u00a0nach\u00a0Analyse\u00a0der\u00a0gepool ten\u00a0Daten\u00a0ergibt\u00a0\nsich\u00a0f\u00fcr\u00a0alle\u00a0Dosierungen\u00a0ein\u00a0signifikantes\u00a0Ergebnis,\u00a0wobei\u00a0die \u00a0Risikoreduktion\u00a0bei\u00a0\n21\u00a0bis\u00a034\u00a0%\u00a0lag.\u00a0F\u00fcr\u00a0die\u00a0sekund\u00e4ren\u00a0Endpunkte\u00a0Rate\u00a0und\u00a0Zeit\u00a0bis \u00a0zum\u00a0Auftreten\u00a0der\u00a0\nersten\u00a0moderaten\u00a0Exazerbation\u00a0zeigte\u00a0sich\u00a0ebenfalls\u00a0ein\u00a0signifi kanter\u00a0Vorteil\u00a0ge\u2010\ngen\u00fcber\u00a0VI\u00a025\u00a0\u00b5g.\u00a0Das\u00a0Outcome\u00a0schwere\u00a0Exazerbationen\u00a0wurde\u00a0nich t\u00a0separat\u00a0\nverglichen,\u00a0sodass\u00a0diesbez\u00fcglich\u00a0keine\u00a0Beurteilung\u00a0vorgenommen\u00a0 werden\u00a0konnte.\u00a0\nDie\u00a0Kombination\u00a0FF/VI\u00a092/22\u00a0\u00b5g\u00a0schnitt\u00a0gegen\u00fcber\u00a0VI\u00a025\u00b5g\u00a0bei\u00a0de n\u00a0patientenbe\u2010\nzogenen\u00a0Endpunkten\u00a0wie\u00a0n\u00e4chtliche m\u00a0Erwachen\u00a0sowie\u00a0Dyspnoe\u00a0signi fikant\u00a0besser\u00a0\nab\u00a0(mittlere\u00a0Differenz\u00a0\u20100,08\u00a0p<0,0012;\u00a0\u20100,09\u00a0p<\u00a00,0001).\u00a0Eine\u00a0w eitere\u00a024\u2010w\u00f6chige\u00a0\nRCT\u00a0HZC112206\u00a0(Kerwin\u00a0et\u00a0al.,\u00a02013)\u00a0untersuchte\u00a0die\u00a0Wirksamkeit \u00a0von\u00a0FF/VI\u00a044/22\u00a0\n\u00b5g,\u00a092/22\u00a0\u00b5g,\u00a0FF\u00a092\u00a0\u00b5g,\u00a0VI\u00a022\u00a0\u00b5g\u00a0und\u00a0Placebo.\u00a0Erfasst\u00a0wurden\u00a0di e\u00a0ko\u2010prim\u00e4ren\u00a0\nEndpunkte\u00a0mittleres\u00a0gewichtetes\u00a0FEV 1\u00a0(0\u00a0bis\u00a04h\u00a0nach\u00a0Bronchodilatatorgabe)\u00a0an\u00a0Tag\u00a0\n168\u00a0und\u00a0\u00c4nderung\u00a0des\u00a0FEV 1\u00a0(nach\u00a023\u00a0bis\u00a024\u00a0Stunden)\u00a0an\u00a0Tag\u00a0169.\u00a0Dabei\u00a0verbesser\u2010\nte\u00a0die\u00a0Kombination\u00a092/22\u00a0\u00b5g\u00a0gegen\u00fcber\u00a0Placebo\u00a0sowie\u00a0FF\u00a092\u00a0\u00b5g\u00a0si gnifikant\u00a0die\u00a0\nLungenfunktion\u00a0(FEV 1=173\u00a0ml,\u00a00.123\u00a0bis\u00a00.224\u00a0p<0,001;\u00a0FEV 1=115\u00a0ml\u00a00.060\u00a0bis\u00a0\n0.169\u00a0p<0,001)\u00a0(FEV 1=120ml\u00a0CI\u00a00.070\u00a0bis\u00a00.170\u00a0p<0,001,\u00a0FEV 1=82\u00a0ml\u00a00.028\u00a0bis\u00a0\n0.136\u00a0p<0,03)\u00a0w\u00e4hrend\u00a0der\u00a0Vergleic h\u00a0mit\u00a0VI\u00a0keinen\u00a0Beleg\u00a0f\u00fcr\u00a0ein en\u00a0Vorteil\u00a0aus\u2010\nweist\u00a0(FEV 1=48\u00a0ml,\u00a0p=0,082).\u00a0Dabei\u00a0unterschr eiten\u00a0einige\u00a0CI\u00a0 die\u00a0minimal\u00a0ge forderte\u00a0\n\u00c4nderung\u00a0zur\u00a0klinischen\u00a0Relevanz,\u00a0die\u00a0in\u00a0der\u00a0Literatur\u00a0mit\u00a0100\u00a0 ml\u00a0bis\u00a0150\u00a0ml\u00a0ange\u2010\ngeben\u00a0ist\u00a0(Gilissen\u00a0et\u00a0al.,\u00a02007).\u00a0Das\u00a0Studiendesign\u00a0sah\u00a0die\u00a0Au swertung\u00a0der\u00a0Daten\u00a0\nnach\u00a0einer\u00a0statistischen\u00a0Hierarchie\u00a0vor.\u00a0In\u00a0der\u00a0Folge\u00a0ergaben\u00a0s ich\u00a0f\u00fcr\u00a0die\u00a0sekund\u00e4\u2010\nren\u00a0Endpunkte\u00a0keine\u00a0statistisch\u00a0signifikanten\u00a0Ergebnisse.\u00a0Auch\u00a0 bez\u00fcglich\u00a0dieser\u00a0\nIndikation\u00a0vertraten\u00a0einige\u00a0Mitglieder\u00a0des\u00a0CHMP\u00a0eine\u00a0Divergent\u00a0 Position\u00a0und\u00a0sa\u2010\nhen\u00a0die\u00a0\u00dcberlegenheit\u00a0der\u00a0Kombination\u00a0bez\u00fcglich\u00a0des\u00a0Einflusses\u00a0 auf\u00a0die\u00a0Sympto\u2010\nmatik\u00a0gen\u00fcber\u00a0Placebo\u00a0nicht\u00a0ausreichend\u00a0belegt.\u00a0Weiterhin\u00a0bezwe ifelten\u00a0sie\u00a0die\u00a0\nEignung\u00a0von\u00a0Vilanterol\u00a0als\u00a0Kompar ator,\u00a0da\u00a0f\u00fcr\u00a0das\u00a0Indikationsge biet\u00a0auch\u00a0zugelas\u2010\nsene\u00a0LABA\u00a0zur\u00a0Verf\u00fcgung\u00a0gestande n\u00a0h\u00e4tten\u00a0(EMA,\u00a02013b).\u00a0Ein\u00a0weit ere\u00a0Kritikpunkt\u00a0\nbeinhaltet\u00a0das\u00a0aufgrund\u00a0methodischer\u00a0Limitationen\u00a0nicht\u00a0abschli e\u00dfend\u00a0einsch\u00e4tz\u2010\nbare\u00a0Risiko\u00a0des\u00a0Auftretens\u00a0schwe rer\u00a0Pneumonien,\u00a0die\u00a0insbesonder e\u00a0in\u00a0den\u00a0Studien\u00a0\nHZC102970\u00a0und\u00a0HZC102871\u00a0(Dransfield\u00a0et\u00a0al.,\u00a02013)\u00a0in\u00a0s\u00e4mtlichen \u00a0Verum\u2010Gruppen\u00a0\naufgetreten\u00a0waren.\u00a0Die\u00a0Inzidenz\u00a0 betrug\u00a0in\u00a0allen\u00a0Fl/VI\u2010Armen\u00a0ca. \u00a06\u00a0%\u00a0(FF/Vl\u00a044/22\u00a0\n\u00b5g\u00a05,9\u00a0%,\u00a0FF/Vl\u00a092/22\u00a0\u00b5g\u00a06,3\u00a0%,\u00a0FF/Vl\u00a0188/22\u00a0\u00b5g\u00a06,8\u00a0%)\u00a0und\u00a0lieg t\u00a0deutlich\u00a0\u00fcber\u00a0dem\u00a0\nAnteil\u00a0bei\u00a0VI\u00a0allein\u00a0(3,3\u00a0%)\u00a0bzw.\u00a0Plazebo\u00a0(<\u00a01\u00a0%).\u00a0Auch\u00a0der\u00a0CHM P\u00a0best\u00e4tigte\u00a0diesen\u00a0\nAspekt\u00a0und\u00a0stellte\u00a0die\u00a0Bedingung\u00a0zur\u00a0Zulassung,\u00a0eine\u00a0PASS\u00a0zur\u00a0U ntersuchung\u00a0des\u00a0\nRisikos\u00a0im\u00a0Vergleich\u00a0zu\u00a0anderen\u00a0 ICS/LABA\u00a0Kombinationen\u00a0bei\u00a0COPD \u00a0und\u00a0Asthma\u00a0\ndurchzuf\u00fchren\u00a0(EMA,\u00a02013b).\u00a0Das\u00a0diesbez\u00fcglich\u00a02016\u00a0vom\u00a0PRAC\u00a0ers tellte\u00a0Review\u00a0\nzum\u00a0Einsatz\u00a0von\u00a0ICS\u00a0bei\u00a0COPD\u00a0erkannte\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0des\u00a0A uftretens\u00a0von\u00a0\nPneumonien\u00a0als\u00a0Klasseneffekt\u00a0und\u00a0empfahl\u00a0die\u00a0Aufnahme\u00a0eines\u00a0ent sprechenden\u00a0\nHinweises\u00a0in\u00a0Fach\u2010\u00a0und\u00a0Patienteninformation\u00a0(EMA,\u00a02016).\u00a0459\u00a0Leitlinienempfehlungen\u00a0\nBis\u00a0heute\u00a0ist\u00a0COPD\u00a0nicht\u00a0heilbar,\u00a0sodass\u00a0sich\u00a0die\u00a0Pharmakothera pie\u00a0auf\u00a0die\u00a0Reduk\u2010\ntion\u00a0der\u00a0Symptome\u00a0wie\u00a0H\u00e4ufigkeit\u00a0und\u00a0Schwere\u00a0der\u00a0Exazerbationen \u00a0sowie\u00a0die\u00a0\nVerbesserung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0beschr\u00e4nkt.\u00a0In\u00a0Deutschland\u00a0lieg t\u00a0derzeit\u00a0keine\u00a0\ng\u00fcltige\u00a0Leitlinie\u00a0vor.\u00a0Unter\u00a0der\u00a0Federf\u00fchrung\u00a0der\u00a0Deutschen\u00a0Ges ellschaft\u00a0f\u00fcr\u00a0Pneu\u2010\nmologie\u00a0und\u00a0Beatmungsmedizin\u00a0(DGP) \u00a0sowie\u00a0der\u00a0Deutschen\u00a0Atemwegs liga\u00a0wird\u00a0\naktuell\u00a0eine\u00a0neue\u00a0Leitlinie:\u00a0\u201eDiagnostik,\u00a0Pr\u00e4vention\u00a0und\u00a0Therap ie\u00a0der\u00a0COPD\u201c\u00a0erar\u2010\nbeitet\u00a0(AWMF,\u00a02017).\u00a0F\u00fcr\u00a02018\u00a0ist\u00a0die\u00a0Ver\u00f6ffentlichung\u00a0der\u00a0\u00fcber arbeiteten\u00a0Natio\u2010\nnalen\u00a0Versorgungsleitlinie\u00a0(NVL)\u00a0COPD\u00a0geplant.\u00a0\u00a0\nAuf\u00a0internationaler\u00a0Ebene\u00a0sehen\u00a0 die\u00a0Empfehlungen\u00a0der\u00a0GOLD\u00a0nach\u00a0 Kategorisie\u2010\nrung\u00a0der\u00a0Patienten\u00a0nach\u00a0Schwere\u00a0der\u00a0Symptomatik\u00a0und\u00a0H\u00e4ufigkeit\u00a0 der\u00a0Exazerbati\u2010\nonen\u00a0 (ABCD\u2010Einteilung)\u00a0 eine\u00a0 gruppenspezifische\u00a0 Pharmakotherapie \u00a0v o r . \u00a0D a b e i \u00a0\nbilden\u00a0Bronchodilatatoren\u00a0die\u00a0Basismedikation.\u00a0Durch\u00a0Reduktion\u00a0 der\u00a0bronchialen\u00a0\nMuskelspannung\u00a0f\u00fchren\u00a0sie\u00a0zu\u00a0einer\u00a0Erweiterung\u00a0der\u00a0Atemwege\u00a0und \u00a0lindern\u00a0somit\u00a0\ndie\u00a0Beschwerden.\u00a0Die\u00a0jeweiligen\u00a0Substanzen\u00a0rekrutieren\u00a0sich\u00a0aus \u00a0drei\u00a0Wirkstoff\u2010\nklassen:\u00a0Beta2\u2010Agonisten\u00a0werden\u00a0je\u00a0nach\u00a0Wirkeintritt\u2010\u00a0und\u00a0Halbw ertszeit\u00a0in\u00a0lang\u2010\nwirksame\u00a0(LABA)\u00a0und\u00a0kurzwirksame\u00a0( Short\u2010acting\u00a0Beta\u20102\u00a0Agonists ,\u00a0SABA)\u00a0einge\u2010\nteilt.\u00a0Letztere\u00a0sind\u00a0nicht\u00a0Bestan dteil\u00a0der\u00a0Basistherapie\u00a0sonder n\u00a0werden\u00a0zumeist\u00a0im\u00a0\nRahmen\u00a0einer\u00a0Notfallversorgung\u00a0bzw.\u00a0nur\u00a0zu\u00a0Behandlung\u00a0leichter\u00a0 Erkrankungsstu\u2010\nfen\u00a0eingesetzt.\u00a0Weiterhin\u00a0stehen \u00a0Anticholinergika\u00a0zur\u00a0Verf\u00fcgung ,\u00a0welche\u00a0die\u00a0bron\u2010\nchokonstriktorische\u00a0 Wirkung\u00a0 von\u00a0 Acetylcholin\u00a0 antagonisieren.\u00a0 \u00c4h nlich\u00a0 wie\u00a0 die\u00a0\nBeta2\u2010Agonisten\u00a0k\u00f6nnen\u00a0sie\u00a0in\u00a0kurz\u00a0( Short\u2010acting\u00a0Muscarinic\u00a0Antagonist ,\u00a0SAMA)\u2010\u00a0\nund\u00a0langwirksame\u00a0( Long\u2010Acting\u00a0Muscarinic\u00a0Antagonist ,\u00a0LAMA)\u00a0gruppiert\u00a0werden.\u00a0\nIm\u00a0Krankheitsstadium\u00a0B\u00a0werden\u00a0beide\u00a0Klassen\u00a0im\u00a0Rahmen\u00a0einer\u00a0Mon otherapie\u00a0\neingesetzt.\u00a0Erst\u00a0mit\u00a0Progression \u00a0zu\u00a0Stufe\u00a0C\u00a0besitzen\u00a0LAMA\u00a0die\u00a0b este\u00a0Evidenz\u00a0und\u00a0\nk\u00f6nnen\u00a0ggf.\u00a0mit\u00a0LABA\u00a0kombiniert\u00a0werden.\u00a0Im\u00a0h\u00f6chsten\u00a0Schweregrad \u00a0D\u00a0werden\u00a0\ngrunds\u00e4tzlich\u00a0 Kombinationen\u00a0 empfohlen.\u00a0 Das\u00a0 Methylxanthin\u00a0 Theoph yllin\u00a0 wird\u00a0\naufgrund\u00a0seines\u00a0ung\u00fcnstigen\u00a0Nebenwirkungsprofils\u00a0und\u00a0Interaktio nspotentials\u00a0bei\u00a0\nmoderater\u00a0bronchodilatorischer\u00a0Wirkung\u00a0nicht\u00a0empfohlen.\u00a0Inhalie rbare\u00a0Glucocor\u2010\nticoide\u00a0sollten\u00a0eher\u00a0zur\u00fcckhaltend\u00a0nur\u00a0bei\u00a0h\u00e4ufigen\u00a0Exazerbatio nen,\u00a0die\u00a0trotz\u00a0einer\u00a0\ndualen\u00a0 Bronchodilatation\u00a0 auftreten\u00a0 bzw.\u00a0 beim\u00a0 Asthma\u2010COPD\u2010 Overlap\u2010Syndrom\u00a0\n(ACOS),\u00a0eingesetzt\u00a0werden\u00a0(GOLD,\u00a02017).\u00a0\nF\u00fcr\u00a0die\u00a0Therapie\u00a0von\u00a0Asthma\u00a0steht\u00a0derzeit\u00a0ebenfalls\u00a0keine\u00a0g\u00fclti ge\u00a0deutsche\u00a0Leitli\u2010\nnie\u00a0zu\u00a0Verf\u00fcgung.\u00a0Die\u00a0f\u00fcr\u00a0November\u00a02016\u00a0angek\u00fcndigte\u00a0neue\u00a0Natio nale\u00a0Versor\u2010\ngungsleitlinie\u00a0S3\u00a0Asthma\u00a0(AWMF,\u00a02017)\u00a0ist\u00a0nach\u00a0wie\u00a0vor\u00a0in\u00a0Bearb eitung.\u00a0Die\u00a0regel\u2010\nm\u00e4\u00dfig\u00a0aktualisierten\u00a0Empfehlunge n\u00a0der\u00a0Global\u00a0Initiative\u00a0on\u00a0Asth ma\u00a0(GINA)\u00a0bilden\u00a0\ndie\u00a0derzeitige\u00a0Evidenz\u00a0ab.\u00a0Diese\u00a0nimmt\u00a0eine\u00a0Einteilung\u00a0anhand\u00a0d er\u00a0H\u00e4ufigkeit\u00a0der\u00a0\nSymptome,\u00a0Rate\u00a0j\u00e4hrlicher\u00a0Exazerbationen\u00a0sowie\u00a0dem\u00a0FEV 1\u00a0in\u00a0f\u00fcnf\u00a0Stufen\u00a0vor.\u00a0Der\u00a0\nEinsatz\u00a0der\u00a0Kombination\u00a0ICS/LABA\u00a0wird\u00a0erst\u00a0ab\u00a0Stufe\u00a03\u00a0bei\u00a0Erwac hsenen\u00a0erwogen.\u00a0460\u00a0Der\u00a0Zusatz\u00a0des\u00a0LABA\u00a0trage\u00a0dabei\u00a0 evident\u00a0zu\u00a0einer\u00a0Verbesserung\u00a0d er\u00a0Lungenfunkti\u2010\non\u00a0sowie\u00a0einer\u00a0Reduktion\u00a0der\u00a0Rat e\u00a0j\u00e4hrlicher\u00a0Exazerbationen\u00a0bei \u00a0(Evidenzlevel\u00a0A).\u00a0\nF\u00fcr\u00a0Kinder\u00a0(6\u00a0bis\u00a011\u00a0Jahre)\u00a0wird\u00a0die\u00a0Erh\u00f6hung\u00a0der\u00a0t\u00e4glichen\u00a0ICS \u2010Dosis\u00a0auf\u00a0ein\u00a0mitt\u2010\nleres\u00a0Niveau\u00a0empfohlen,\u00a0da\u00a0ein\u00a0\u00e4hnlicher\u00a0oder\u00a0\u00fcberlegenerer\u00a0Eff ekt\u00a0gegen\u00fcber\u00a0\nLABA\u00a0zu\u00a0erwarten\u00a0sei\u00a0(GINA,\u00a02017).\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\nDer\u00a0pU\u00a0legte\u00a0kein\u00a0Dossier\u00a0zum\u00a0Nutzenbewertungsverfahren\u00a0vor,\u00a0so dass\u00a0der\u00a0G\u2010BA\u00a0\nkeine\u00a0Bewertung\u00a0nach\u00a0\u00a735a\u00a0SGBV\u00a0vornehmen\u00a0konnte.\u00a0Das\u00a0Gremium\u00a0f\u00fc hrte\u00a0die\u00a0Ein\u2010\ngruppierung\u00a0in\u00a0die\u00a0bestehende\u00a0Festbetragsgruppe\u00a0\u201eKombinationen\u00a0 von\u00a0Glucocorti\u2010\ncoiden\u00a0mit\u00a0langwirksamen\u00a0Beta 2\u2010Sympathomimetika,\u00a0Gruppe\u00a01\u201c\u00a0durch\u00a0(G\u2010BA,\u00a02014).\u00a0\nVersorgungsanalysen\u00a0\nAbbildung\u00a04.60:\u00a0Anzahl\u00a0verordneter\u00a0Packungen\u00a0Vilanterol\u00a0+\u00a0Fluti casonfuroat\u00a0\nje\u00a0Monat\u00a0nach\u00a0Packungsgr\u00f6\u00dfen\u00a0(2014\u00a0\u2013\u00a02015)\u00a0\n\u00a0\nSeit\u00a0Markteintritt\u00a0im\u00a0Januar\u00a02014\u00a0stiegen\u00a0die\u00a0Verordnungsvolumi na\u00a0mit\u00a0geringer\u00a0\nFluktuation\u00a0stetig\u00a0an\u00a0und\u00a0erreichen\u00a0im\u00a0November\u00a02015\u00a0ein\u00a0Maximu m\u00a0von\u00a03.140\u00a0\nPackungen.\u00a0Mit\u00a0der\u00a0vom\u00a0G\u2010BA\u00a0vorgenommenen\u00a0Eingruppierung\u00a0der\u00a0Ko mbination\u00a0\nin\u00a0eine\u00a0Festbetragsgruppe\u00a0(G\u2010BA,\u00a02014)\u00a0ging\u00a0eine\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0wi rtschaftliche\u00a0Ver\u2010\nordnungsweise\u00a0einher.\u00a0Ferner\u00a0entstanden\u00a0f\u00fcr\u00a0Patienten\u00a0keine\u00a0Meh rkosten,\u00a0sodass\u00a0\nein\u00a0positiver\u00a0Einfluss\u00a0auf\u00a0die\u00a0Ak zeptanz\u00a0der\u00a0Verordnenden\u00a0vorst ellbar\u00a0ist.\u00a0Auff\u00e4llig\u00a0\n461\u00a0ist,\u00a0dass\u00a0keine\u00a0normierten\u00a0Packungen\u00a0abgerechnet\u00a0wurden.\u00a0Der\u00a0pU \u00a0stellte\u00a0keine\u00a0\nPackungsgr\u00f6\u00dfe\u00a0zur\u00a0Verf\u00fcgung,\u00a0die\u00a0mit\u00a0den\u00a0Normgr\u00f6\u00dfen\u00a0des\u00a0Deutsch en\u00a0Institutes\u00a0\nf\u00fcr\u00a0Dokumentation\u00a0und\u00a0Information\u00a0in\u00a0Gesundheitswesen\u00a0(DIMDI)\u00a0\u00fc bereinstimm\u2010\nte.\u00a0\nAbbildung\u00a04.61:\u00a0Versicherte\u00a0mit \u00a0mind.\u00a0einer\u00a0Verordnung\u00a0Vilanter ol\u00a0+\u00a0Fluti\u2010\ncasonfuroat\u00a0nach\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0(2015)\u00a0\n\u00a0\nBis\u00a0zur\u00a0Altersgruppe\u00a0der\u00a0\u00dcber\u201060\u2010J\u00e4hrigen\u00a0nimmt\u00a0die\u00a0Anzahl\u00a0der\u00a0 Versicherten,\u00a0die\u00a0\ndie\u00a0Kombination\u00a0Vilanterol/Fluti casonfuroat\u00a0erhalten\u00a0tendenziel l\u00a0zu\u00a0und\u00a0geht\u00a0\u00fcber\u00a0\ndie\u00a0folgenden\u00a0drei\u00a0Dekaden\u00a0stark\u00a0zur\u00fcck.\u00a0Im\u00a0Vergleich\u00a0ist\u00a0die\u00a0A ltersgruppe\u00a050\u00a0bis\u00a0\n59\u00a0(23\u00a0%)\u00a0ab\u00a0st\u00e4rksten\u00a0vertreten.\u00a0Bei\u00a0Interpretation\u00a0der\u00a0Grafik \u00a0muss\u00a0ber\u00fccksichtigt\u00a0\nwerden,\u00a0dass\u00a0die\u00a0Kombination\u00a0Vilanterol\u00a0plus\u00a0Fluticasonfuroat\u00a0b ei\u00a0zwei\u00a0unter\u2010\nschiedlichen\u00a0Erkrankungen\u00a0eingesetzt\u00a0wird.\u00a0Das\u00a0abgebildete\u00a0Erge bnis\u00a0zeigt\u00a0also\u00a0\neine\u00a0\u00dcberlappung\u00a0der\u00a0Charakteris tika\u00a0beider\u00a0Zielpopulationen.\u00a0S o\u00a0tritt\u00a0Asthma\u00a0\nbereits\u00a0im\u00a0Kindesalter\u00a0auf\u00a0(Gillesen\u00a0&\u00a0Welte,\u00a02014),\u00a0COPD\u00a0erst\u00a0 ab\u00a0der\u00a0dritten\u00a0bis\u00a0\nvierten\u00a0Lebensdekade\u00a0auf\u00a0(Manni no\u00a0&\u00a0Buist,\u00a02007).\u00a0Hinsichtlich\u00a0 des\u00a0Geschlechts\u00a0\nzeigen\u00a0sich\u00a0unterschiedliche\u00a0Effekte.\u00a0Im\u00a0Kindesalter\u00a0sind\u00a0die\u00a0m eisten\u00a0Asthmapati\u2010\nenten\u00a0m\u00e4nnlich.\u00a0Dieses\u00a0Verh\u00e4ltnis\u00a0kehrt\u00a0sich\u00a0in\u00a0den\u00a0weiteren\u00a0Le bensjahren\u00a0um,\u00a0\nsodass\u00a0die\u00a0Pr\u00e4valenz\u00a0ab\u00a0dem\u00a014.\u00a0Lebensjahr\u00a0bei\u00a0M\u00e4dchen\u00a0h\u00f6her\u00a0is t\u00a0(RKI,\u00a02012).\u00a0\nDieser\u00a0Effekt\u00a0zeigt\u00a0sich\u00a0auch\u00a0f\u00fc r\u00a0die\u00a0in\u00a0Abb.\u00a04.61\u00a0gezeigte\u00a0Pop ulation\u00a0beim\u00a0Ver\u2010\ngleich\u00a0der\u00a0Altersgruppen\u00a00\u00a0bis\u00a017\u00a0und\u00a018\u00a0bis\u00a029\u00a0Jahre.\u00a0Obwohl\u00a0h \u00e4ufig\u00a0diskutiert,\u00a0\nzeigt\u00a0sich\u00a0bei\u00a0COPD\u00a0keine\u00a0gesch lechterspezifische\u00a0Tendenz.\u00a0\n462\u00a0Quellen\u00a0\nKoch\u00a0A,\u00a0Pizzichini\u00a0E,\u00a0Hamilton\u00a0A,\u00a0Hart\u00a0L,\u00a0Korducki\u00a0L,\u00a0De\u00a0Salvo\u00a0 M\u00a0(2014).\u00a0Lung\u00a0function\u00a0efficacy\u00a0and\u00a0symptomatic\u00a0benefit\u00a0of\u00a0\nolodaterol\u00a0once\u00a0daily\u00a0delivered\u00a0via\u00a0Respimat\u00ae\u00a0versus\u00a0placebo\u00a0an d\u00a0formoterol\u00a0twice\u00a0daily\u00a0in\u00a0patients\u00a0with\u00a0gOlD\u00a02\u20134\u00a0\nCOPD:\u00a0results\u00a0from\u00a0two\u00a0replicate\u00a048\u2010week\u00a0studies.\u00a0Int\u00a0J\u00a0Chron\u00a0O bstruct\u00a0Pulmon\u00a0Dis\u00a02014\u00a09:\u00a0697\u2010714.\u00a0\na\u2010t\u00a0\u2010\u00a0arznei\u2010telegramm\u00a0(2014).\u00a0Neu\u00a0auf\u00a0dem\u00a0Markt:\u00a0Asthma/COPD:\u00a0 Fluticasonfuroat\u2010Vilanterol\u2010Inhalat\u00a0(Relvar\u00a0Ellipta)\u00a0a\u2010t\u00a045:\u00a029 \u201030.\u00a0\nAWMF\u00a0online\u00a0(2017).\u00a0Nationale\u00a0VersorgungsLeitlinie\u00a0Asthma.\u00a0http ://www.awmf.org/leitlinien/detail/anmeldung/1/ll/nvl\u2010002.html,\u00a0\nletzter\u00a0Zugriff\u00a030.04.2017.\u00a0\nBateman\u00a0ED,\u00a0O'Byrne\u00a0PM,\u00a0Busse\u00a0WW, \u00a0L\u00f6tvall\u00a0J,\u00a0Bleecker\u00a0ER,\u00a0Ander sen\u00a0L\u00a0et\u00a0al.\u00a0(2014).\u00a0Once\u2010daily\u00a0fluticasone\u00a0furoate\u00a0(FF)/vilant erol\u00a0\nreduces\u00a0risk\u00a0of\u00a0severe\u00a0exacerbati ons\u00a0in\u00a0asthma\u00a0versus\u00a0FF\u00a0alone. \u00a0Thorax\u00a069(4):312\u2010319.\u00a0\nBleecker\u00a0ER,\u00a0L\u00f6tvall\u00a0J,\u00a0O'Byrne\u00a0PM,\u00a0Woodcock\u00a0A,\u00a0Busse\u00a0WW,\u00a0Kerwi n\u00a0EM\u00a0et\u00a0al.\u00a0(2014).\u00a0Fluticasone\u00a0Furoate\u2013Vilanterol\u00a0100\u201025\u00a0mcg\u00a0\nCompared\u00a0with\u00a0Fluticasone\u00a0Furoate\u00a0100\u00a0mcg\u00a0in\u00a0Asthma:\u00a0A\u00a0Randomiz ed\u00a0Trial.\u00a0The\u00a0Journal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0\nImmunology.\u00a0Practice\u00a02(5):\u00a0553\u2010561.\u00a0\nCavaill\u00e8s\u00a0A,\u00a0Brinchault\u2010Rabin\u00a0G,\u00a0D ixmier\u00a0A,\u00a0Goupil\u00a0F,\u00a0Gut\u2010Gober t\u00a0C,\u00a0Marchand\u2010Adam\u00a0S\u00a0et\u00a0al.\u00a0(2013).\u00a0Comorbidities\u00a0of\u00a0COPD.\u00a0Eur\u00a0\nrespir\u00a0Rev\u00a022(130):454\u201075.\u00a0\nMannino\u00a0DM,\u00a0Buist\u00a0AS\u00a0(2007).Global\u00a0burden\u00a0of\u00a0COPD:\u00a0risk\u00a0factors ,\u00a0prevalence,\u00a0and\u00a0future\u00a0trends.\u00a0Lancet\u00a0370\u00a0(9589):\u00a0765\u2010773.\u00a0\nDIMDI\u00a0(2014)\u00a0Deutsches\u00a0Institut\u00a0f\u00fc r\u00a0Medizinische\u00a0Dokumentation\u00a0 und\u00a0Information,\u00a0Packungsgr\u00f6\u00dfenverordnung\u00a0Anlage\u00a01,\u00a0\nhttps://www.dimdi.de/dynamic/de/amg/packungsgroessen/historie/a nlage1/packungsgroessen\u2010anlage\u20101\u2010\n201412.pdf,\u00a0letzter\u00a0Zugriff\u00a030.04.2017.\u00a0\nDransfield\u00a0MT,\u00a0Bourbeau\u00a0J,\u00a0Jones\u00a0PW,\u00a0Hanania\u00a0NA,\u00a0Mahler\u00a0DA,\u00a0Ves tbo\u00a0J\u00a0et\u00a0al.\u00a0(2013).Once\u2010daily\u00a0inhaled\u00a0fluticasone\u00a0furoate\u00a0and\u00a0\nvilanterol\u00a0versus\u00a0vilanterol\u00a0onl y\u00a0for\u00a0prevention\u00a0of\u00a0exacerbatio ns\u00a0of\u00a0COPD:\u00a0two\u00a0replicate\u00a0double\u2010blind,\u00a0parallel\u2010group,\u00a0\nrandomised\u00a0controlled\u00a0trials.\u00a0Lancet\u00a0Respir\u00a0Med\u00a01(3):210\u2010223.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2013a).\u00a0Annex\u00a0I.\u00a0Summary\u00a0of\u00a0pr oduct\u00a0characteristics.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02015.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Product_Information/human/001250/WC500150993.pdf,\u00a0letzter\u00a0Zugr iff:\u00a024.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0EPAR\u00a0Scientific\u00a0Conclus ions.\u00a0Stand\u00a0der\u00a0Information:\u00a0Juli\u00a02016.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Scientific_Conclusion/human/002673/WC500210328.pdf,\u00a0letzter\u00a0Zu griff:\u00a024.03.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2013b).\u00a0Assessment\u00a0report\u00a0Relv ar\u00a0Ellipta.\u00a0International\u00a0non\u2010proprietary\u00a0name:\u00a0fluticasone\u00a0\nfuroate\u00a0/\u00a0vilanterol.\u00a0Procedure\u00a0No.\u00a0EMEA/H/C/002673/0000,\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Public_assessment_report/human/002673/WC500157635.pdf,\u00a0letzter \u00a0Zugriff:\u00a024.03.2017.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2010).\u00a0FDA\u00a0Drug\u00a0Safety\u00a0Comm unication:\u00a0New\u00a0safety\u00a0requirements\u00a0for\u00a0long\u2010acting\u00a0inhaled\u00a0\nasthma\u00a0medications\u00a0called\u00a0Long\u2010Acting\u00a0Beta\u2010Agonists\u00a0(LABAs).\u00a0St and\u00a0der\u00a0Information:\u00a0August\u00a02016.\u00a0\nhttps://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinform ationforpatientsandproviders/ucm200776.htm,\u00a0\nletzter\u00a0Zugriff:\u00a030.04.2017.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2015).\u00a0Neue\u00a0Arzneimittel\u00a02014.\u00a0In:\u00a0Schwabe \u00a0U,\u00a0Paffrath\u00a0D\u00a0(Hrsg.)\u00a0Arzneiverordnungs\u2010Report\u00a02015.\u00a037\u2010198.\u00a0\nBerlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2014).\u00a0Beschluss\u00a0des\u00a0Gemein samen\u00a0Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimit\u2010\ntelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbe wertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0\nnach\u00a0\u00a7\u00a036a\u00a0SGB\u00a0V\u00a0und\u00a0Anlage\u00a0IX\u00a0\u2013\u00a0Festbetragsgruppenbildung\u00a0Beta 2\u2010Sympathomimetika,\u00a0inhalativ\u00a0oral,\u00a0Gruppe\u00a01,\u00a0in\u00a0\nStufe\u00a02\u00a0nach\u00a0\u00a7\u00a035a\u00a0Absatz\u00a03\u00a0in\u00a0Verbindung\u00a0mit\u00a0Absatz\u00a04\u00a0Satz\u00a01\u00a0S GB\u00a0V.\u00a0https://www.g\u2010ba.de/downloads/39\u2010261\u2010463\u00a02031/2014\u201007\u201017_AM\u2010RL\u2010IX\u2010XII_Beta2\u2010Sympathomimetika_inhalativ_E ingr_Olodaterol_Gr1_BAnz.pdf,\u00a0letzter\u00a0\nZugriff:\u00a020.03.2017.\u00a0\nGillissen\u00a0A,\u00a0Buhl\u00a0R,\u00a0Kardos\u00a0P,\u00a0P uhan\u00a0M,\u00a0Rabe\u00a0KF,\u00a0Rothe\u00a0T\u00a0et\u00a0al. \u00a0(2008).Trial\u00a0end\u2010point\u00a0in\u00a0chronic\u00a0obstructive\u00a0pulmonary\u00a0diseas e\u00a0\n(COPD):\u00a0minimal\u00a0clinically\u00a0importa nt\u00a0difference.\u00a0Pneumologie\u00a062 (3):149\u2010155.\u00a0\nGillissen\u00a0A,\u00a0Welte\u00a0T\u00a0(2014).\u00a0Wei\u00df buch\u00a0Lunge\u00a02014\u00a0\u2013\u00a0Herausforder ungen,\u00a0Zukunftsperspektiven,\u00a0Forschungsans\u00e4tze\u00a0\u2013\u00a0Zur\u00a0Lage\u00a0und\u00a0\nZukunft\u00a0der\u00a0Pneumologie\u00a0in\u00a0Deuts chland.\u00a0Bielefeld:\u00a0Frische\u00a0Text e\u00a0Verlag.\u00a0\nGINA\u00a0\u2013\u00a0Global\u00a0Initiative\u00a0For\u00a0Asthma\u00a0(2017).\u00a0Global\u00a0Strategy\u00a0for \u00a0Asthma\u00a0Management\u00a0and\u00a0Prevention.\u00a0Stand\u00a0der\u00a0Information\u00a02017\u00a0\nhttp://ginasthma.org/download/ 317/,\u00a0letzter\u00a0Zugriff:\u00a004.03.2017 .\u00a0\nWHO\u00a0(2014).\u00a0Global\u00a0Ast hma\u00a0Report.\u00a0http://www.globalasthmareport .org/resources/Global_Asth ma_Report_2014.pdf,\u00a0letzter\u00a0\nZugriff:\u00a015.08.17.\u00a0\nGOLD\u00a0\u2013\u00a0Global\u00a0Initiative\u00a0For\u00a0Chr onic\u00a0Obstructive\u00a0Lung\u00a0Disease\u00a0( 2017).\u00a0Global\u00a0Strategy\u00a0for\u00a0the\u00a0Diagnosis,\u00a0Management\u00a0and\u00a0\nPrevention\u00a0of\u00a0COPD.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0http:/ /goldcopd.org/download/326/,\u00a0letzter\u00a0Zugriff:\u00a0\n04.07.2017.\u00a0\nGorenoi\u00a0V,\u00a0Sch\u00f6nermark\u00a0MP,\u00a0Hagen\u00a0A,\u00a0Deutsches\u00a0Institut\u00a0f\u00fcrMediz inische\u00a0Dokumentation\u00a0und\u00a0Information\u00a0(DIMDI)\u00a0(Hrsg.)\u00a0(2007).\u00a0\nMa\u00dfnahmen\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Compliance\u00a0bzw.\u00a0Adherence\u00a0in\u00a0der \u00a0Arzneimitteltherapie\u00a0mit\u00a0Hinblick\u00a0auf\u00a0den\u00a0\nTherapieerfolg.\u00a0Schriftenreihe\u00a0Health\u00a0Technologie\u00a0Assessment,\u00a0B d.\u00a065.\u00a0K\u00f6ln:\u00a0DIMDI.\u00a0\nHaynes\u00a0RB,\u00a0Ackloo\u00a0E,\u00a0Sahota\u00a0N\u00a0et\u00a0al.:\u00a0Interventions\u00a0for\u00a0enhanci ng\u00a0medication\u00a0adherence.\u00a0Cochrane\u00a0Database\u00a0Systematic\u00a0Review\u00a0\n2008;\u00a0Issue\u00a02:\u00a0CD000011,\u00a0letzter\u00a0Zugriff:\u00a015.08.17.\u00a0\nKerwin\u00a0EM,\u00a0Scott\u2010Wilson\u00a0C,\u00a0Sanfor d\u00a0L,\u00a0Rennard\u00a0S,\u00a0Agusti\u00a0A,\u00a0Barn es\u00a0N\u00a0et\u00a0al.\u00a0(2013).\u00a0A\u00a0randomised\u00a0trial\u00a0of\u00a0fluticasone\u00a0\nfuroate/vilanterol\u00a0(50/25\u00a0\u03bcg;\u00a0100/25\u00a0\u03bcg)\u00a0on\u00a0lung\u00a0function\u00a0in\u00a0CO PD.\u00a0Respir\u00a0Med\u00a0107(4):560\u2010569..\u00a0\nLange\u00a0P,\u00a0Aumann\u00a0JL,\u00a0Hamilton\u00a0A,\u00a0Tetzlaff\u00a0K,\u00a0Ting\u00a0N\u00a0et\u00a0al.\u00a0(2014 ).\u00a0The\u00a024\u2010Hour\u00a0Lung\u00a0Function\u00a0Time\u00a0Profile\u00a0of\u00a0Olodaterol\u00a0Once\u00a0Da ily\u00a0\nVersus\u00a0Placebo\u00a0and\u00a0Tiotropium\u00a0in\u00a0Patients\u00a0with\u00a0Moderate\u00a0to\u00a0Very \u00a0Severe\u00a0Chronic\u00a0Obstructive\u00a0Pulmonary\u00a0Disease.\u00a0J\u00a0\nPulm\u00a0Respir\u00a0Med\u00a04:196.\u00a0\nLauer\u2010Fischer\u00a0(2017).\u00a0Archiv\u00a01.5. 2014\u00a0\u2013\u00a015.12.20 15.\u00a0www.webapo. de,\u00a0letzter\u00a0Zugrifff:\u00a015.08.17.\u00a0\nLommatzsch\u00a0M\u00a0(2012).\u00a0Airway\u00a0Hyperresponsiveness:\u00a0New\u00a0Insights\u00a0i nto\u00a0the\u00a0Pathogenesis.\u00a0Semin\u00a0Resp ir\u00a0Crit\u00a0Care\u00a0Med\u00a033(06):\u00a0579\u201058 7.\u00a0\u00a0\nMathers\u00a0CD,\u00a0Loncar\u00a0D,\u00a0Boreham\u00a0J,\u00a0Thun\u00a0M,\u00a0Heath\u00a0J,\u00a0Doll\u00a0R\u00a0(2006) .\u00a0Projections\u00a0of\u00a0Global\u00a0Mortality\u00a0and\u00a0Burden\u00a0of\u00a0Disease\u00a0from\u00a020 02\u00a0\nto\u00a02030.\u00a0PLoS\u00a0Medicine\u00a03(11):\u00a0e442.\u00a0\u00a0\nMcGrath\u00a0KW,\u00a0Icitovic\u00a0N,\u00a0Boushey\u00a0 HA,\u00a0Lazarus\u00a0SC,\u00a0Sutherland\u00a0ER,\u00a0 Chinchilli\u00a0VM\u00a0et\u00a0al.\u00a0(2012).\u00a0A\u00a0la rge\u00a0subgroup\u00a0of\u00a0mild\u2010to\u2010modera te\u00a0\nasthma\u00a0is\u00a0persistently\u00a0noneosino philic.\u00a0Am\u00a0J\u00a0Respir\u00a0Crit\u00a0Care\u00a0M ed\u00a0185(6):612\u2010619.\u00a0\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2015) .\u00a0Chronic\u00a0obstructive\u00a0pulmonary\u00a0disease:\u00a0olodaterol.\u00a0Evidence\u00a0\nsummary.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02015.\u00a0Nice.org.uk/guida nce/esnm54,\u00a0letzter\u00a0Zugrifff:\u00a015.08.17.\u00a0\nO\u2019Byrne\u00a0PM,\u00a0Bleecker\u00a0ER,\u00a0Bateman\u00a0ED,\u00a0Busse\u00a0WW,\u00a0Woodcock\u00a0A,\u00a0Fort h\u00a0R\u00a0et\u00a0al.\u00a0(2014).\u00a0Once\u2010daily\u00a0fluticasone\u00a0furoate\u00a0alone\u00a0or\u00a0\ncombined\u00a0with\u00a0vilanterol\u00a0in\u00a0persistent\u00a0asthma.\u00a0Eur\u00a0Respir\u00a0J\u00a043( 3):773\u2010782.\u00a0\nPrescrire\u00a0International\u00a0(2016).\u00a0Vilanterol\u00a0+\u00a0fluticasone.\u00a0Asthm a\u00a0and\u00a0COPD:\u00a0yet\u00a0another\u00a0beta\u20102\u00a0agonist\u00a0and\u00a0corticosteroid\u00a0\ncombination.\u00a0Prescrire\u00a0Int\u00a025\u00a0(170):\u00a094.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2014).\u00a0Neue\u00a0Arzneistoffe:\u00a0 Vilanterol,\u00a0Relvar\u00ae\u00a0Ellipta\u00ae:28.\u00a0www.pharmazeutische\u2010\nzeitung.de/indexphp?id=50892,\u00a0letzter\u00a0Zugrifff:\u00a015.08.17.\u00a0464\u00a0RKI\u00a0\u2013\u00a0Robert\u00a0Koch\u00a0Institut\u00a0(2017).\u00a0Chronische\u00a0Lungenkrankheiten .\u00a0http://www.rki.de/DE/Content/Gesundheitsmonitoring\u00a0\n/Themen/Chronische_Erkrankungen/lungenerkrankungen/lungenerkran kungen_node.html,\u00a0letzter\u00a0Zugriff:\u00a0\n30.04.2017.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2012)\u00a0Daten\u00a0und\u00a0Fakten:\u00a0Ergebnisse\u00a0 der\u00a0Studie\u00a0\u00bbGesundheit\u00a0in\u00a0Deutschland\u00a0aktuell\u00a02010\u00ab.\u00a0Beitr\u00e4ge\u00a0z ur\u00a0\nGesundheitsberichterstattung\u00a0des\u00a0Bundes.\u00a0RKI,\u00a0Berlin.\u00a0\nRoskell\u00a0NS,\u00a0Anzueto\u00a0A,\u00a0Hamilton\u00a0A,\u00a0Disse\u00a0B,\u00a0Becker\u00a0K\u00a0(2014).\u00a0On ce\u2010daily\u00a0long\u2010acting\u00a0beta\u2010agonis ts\u00a0for\u00a0chronic\u00a0obstructive\u00a0pulm o\u2010\nnary\u00a0disease:\u00a0an\u00a0indirect\u00a0comparison\u00a0of\u00a0olodaterol\u00a0and\u00a0indacate rol.\u00a0Int\u00a0J\u00a0Chron\u00a0Obstruct\u00a0Pulmon\u00a0Dis\u00a09(1):\u00a0813\u2010824.\u00a0\nWenzel\u00a0S,\u00a0Ford\u00a0L,\u00a0Pearlman\u00a0D,\u00a0Sp ector\u00a0S,\u00a0Sher\u00a0L,\u00a0Skobieranda\u00a0F\u00a0 et\u00a0al.\u00a0(2013).\u00a0Dupilumab\u00a0in\u00a0persistent\u00a0asthma\u00a0with\u00a0elevated\u00a0\neosinophil\u00a0levels.\u00a0NEJM\u00a0368(26):\u00a02455\u20102466.\u00a0\nWoodcock\u00a0A,\u00a0Bleecker\u00a0ER,\u00a0L\u00f6tvall\u00a0J,\u00a0O'Byrne\u00a0PM,\u00a0Bateman\u00a0ED,\u00a0Med ley\u00a0H\u00a0et\u00a0al.\u00a0(2013).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Fluticasone\u00a0\nFuroate/Vilanterol\u00a0Compared\u00a0With\u00a0Fluticasone\u00a0Propionate/Salmete rol\u00a0Combination\u00a0in\u00a0Adult\u00a0and\u00a0Adolescent\u00a0\nPatients\u00a0With\u00a0Persistent\u00a0Asthma:\u00a0A\u00a0Randomized\u00a0Trial.\u00a0Chest.\u00a0144 (4):1222\u20101229.\u00a0\u00a0\n\u00a0 \u00a0465\u00a0Tabelle\u00a05.1:\u00a0Zusammenfassung\u00a0der\u00a0Wirkstoffbewertungen\u00a0(neue\u00a0Wir kstoffe\u00a0des\u00a0\nJahres\u00a02014)\u00a0nach\u00a0dem\u00a0im\u00a0Report\u00a0genutzten\u00a0Ampelschema\u00a0\u00a0\n\u00a0\n1\u00a0nur\u00a0bei\u00a0mindestens\u00a0einer\u00a0positiven\u00a0Empfehlung\u00a0\n*\u00a0Mehrkosten\u00a0f\u00fcr\u00a0Patienten\u00a0 \u00a0\n466\u00a05 Diskussion\u00a0\nGerd\u00a0Glaeske\u00a0\nInsgesamt\u00a0wurden\u00a032\u00a0der\u00a0im\u00a0Jahre\u00a02014\u00a0neu\u00a0in\u00a0den\u00a0Arzneimittelma rkt\u00a0in\u00a0Deutsch\u2010\nland\u00a0eingef\u00fchrten\u00a0Wirkstoffe\u00a0im\u00a0 Innovationsreport\u00a02017\u00a0bewertet \u00a0(vgl.\u00a0zusam\u2010\nmenfassende\u00a0Tabelle\u00a05.1),\u00a0im\u00a0Inno vationsreport\u00a02016\u00a0waren\u00a0es\u00a0mi t\u00a023\u00a0Produkten\u00a0\ndeutlich\u00a0weniger.\u00a0Im\u00a0diesj\u00e4hrigen\u00a0Innovationsreport\u00a0wurden\u00a0am\u00a0h \u00e4ufigsten\u00a0antivi\u2010\nrale\u00a0Mittel\u00a0zur\u00a0systemischen\u00a0Anwendung\u00a0(J05)\u00a0sowie\u00a0antineoplast ische\u00a0Mittel\u00a0(L01)\u00a0\nmit\u00a0jeweils\u00a0f\u00fcnf\u00a0Wirkstoffen\u00a0untersucht.\u00a0Die\u00a0Mittel\u00a0bei\u00a0obstruk tiven\u00a0Atemwegser\u2010\nkrankungen\u00a0(R03)\u00a0sind\u00a0am\u00a0zweith\u00e4ufigsten\u00a0mit\u00a0drei\u00a0Wirkstoffen\u00a0v ertreten.\u00a0Zwei\u00a0\nbehandelte\u00a0Wirkstoffe\u00a0waren\u00a0es\u00a0bei\u00a0den\u00a0ATC\u20103\u2010Gruppen\u00a0A10,\u00a0A16,\u00a0 B02,\u00a0C02,\u00a0J04,\u00a0\nL04,\u00a0N07\u00a0und\u00a0V03.\u00a0Die\u00a0\u00fcbrigen\u00a0ATC\u2010Gruppen\u00a0(A02,\u00a0A05,\u00a0C10)\u00a0wurde n\u00a0von\u00a0jeweils\u00a0\neinem\u00a0Wirkstoff\u00a0repr\u00e4senti ert\u00a0(vgl.\u00a0Tabelle\u00a05.2).\u00a0\nTabelle\u00a05.2:\u00a0Untersuchte\u00a0ATC\u2010Gruppen\u00a0nach\u00a0H\u00e4ufigkeit\u00a0\nUntersuchte\u00a0ATC\u20103\u2010Gruppen\u00a0Anzahl\u00a0Wirkstoffe\u00a0\u00a0\nnach\u00a0H\u00e4ufigkeit\u00a0\nJ05\u00a0Antivirale\u00a0Mittel\u00a0zur\u00a0 systemischen\u00a0Anwendung\u00a0 5\u00a0\nL01\u00a0Antineoplastische\u00a0Mittel\u00a0 5\u00a0\nR03\u00a0Mittel\u00a0bei\u00a0obstruktiven\u00a0 Atemwegserkrankungen\u00a0 3\u00a0\nA10\u00a0 Antidiabetika\u00a0 2\u00a0A16\u00a0 Andere\u00a0Mittel\u00a0f\u00fcr\u00a0das\u00a0aliment\u00e4re\u00a0System\u00a0und\u00a0den\u00a0Stoffwechse l\u00a0 2\u00a0\nB02\u00a0 Antih\u00e4morrhagika\u00a0 2\u00a0C02\u00a0 Antihypertensiva\u00a0 2\u00a0J04\u00a0 Mittel\u00a0gegen\u00a0Mykobakterien\u00a0 2\u00a0L04\u00a0 Immunsuppressiva\u00a0 2\u00a0N07\u00a0 Andere\u00a0Mittel\u00a0f\u00fcr\u00a0das\u00a0Nervensystem\u00a0 2\u00a0V03\u00a0 Alle\u00a0\u00fcbrigen\u00a0therapeutischen\u00a0Mittel\u00a0 2\u00a0\nA02\u00a0Mittel\u00a0bei\u00a0s\u00e4urebedingten\u00a0Erkrankungen\u00a0 1\u00a0\nA05\u00a0Gallen\u2010\u00a0und\u00a0Lebertherapie\u00a0 1\u00a0\nC10\u00a0Mittel,\u00a0die\u00a0den\u00a0Lipidstoffwechsel\u00a0beeinflussen\u00a0 1\u00a0\n\u00a0\nDie\u00a0gr\u00f6\u00dfere\u00a0Anzahl\u00a0der\u00a0untersuchten\u00a0Wirkstoffe\u00a0ist\u00a0u.a.\u00a0auf\u00a0den \u00a0hohen\u00a0Anteil\u00a0an\u00a0\nZulassungen\u00a0f\u00fcr\u00a0Orphan\u2010Arzneimittel\u00a0zur\u00fcckzuf\u00fchren\u00a0\u2013\u00a0im\u00a0Report\u00a0 2016\u00a0geh\u00f6rten\u00a0\nlediglich\u00a0drei\u00a0(13\u00a0%)\u00a0Wirkstoffe\u00a0in\u00a0diese\u00a0Gruppe,\u00a02017\u00a0dagegen\u00a0 zw\u00f6lf\u00a0(38\u00a0%).\u00a0Dies\u00a0\nwaren\u00a0im\u00a0Einzelnen\u00a0drei\u00a0Krebsar zneimittel,\u00a0zwei\u00a0Mittel\u00a0gegen\u00a0Lu ngentuberkulose,\u00a0467\u00a0zwei\u00a0Mittel\u00a0gegen\u00a0Lungenhochdruck\u00a0und\u00a0jeweils\u00a0ein\u00a0Mittel\u00a0zur\u00a0Be handlung\u00a0bei\u00a0\nspeziellen\u00a0Erkrankungen.\u00a0\nTabelle\u00a05.3:\u00a0 Orphan\u2010Arzneimittel\u00a0mit\u00a0f\u00fchrender\u00a0Indikation\u00a0\nOrphan\u2010Arzneimittel\u00a0 \u00a0F\u00fchrende\u00a0Indikation\u00a0\nCabozantinib/Cometriq\u00ae/Ipsen\u00a0\u00a0 \u00a0 Medull\u00e4res\u00a0Schilddr\u00fcsenkarzinom\u00a0 (Kap.\u00a04.4)\u00a0\nIbrutinib/Imbruvica\u00ae/Janssen\u2010Cilag\u00a0u.a.\u00a0\u00a0 \u00a0Chronische\u00a0lymphathische\u00a0Leuk\u00e4mie\u00a0(Kap.\u00a04.14)\u00a0\nObinutuzumab/Gazyvaro\u00ae/Roche\u00a0\u00a0 \u00a0 Chronische\u00a0lymphatische\u00a0Leuk\u00e4mie \u00a0(Kap.\u00a04.19)\u00a0\nBedaquilin/Situro\u00ae/Janssen\u00a0\u00a0 \u00a0Multiresistente\u00a0Lungentuberkulose\u00a0(Kap.\u00a04.3)\u00a0\nDelamanid/Deltyba\u00ae/Otsuka\u00a0\u00a0 \u00a0 Multiresistente\u00a0Lungentuberkulose\u00a0( Kap.\u00a04.8)\u00a0\nMacitentan/Opsumit\u00ae/Actelion\u00a0\u00a0 \u00a0Pulmonal\u00a0arterielle\u00a0Hypertonie\u00a0(Kap.\u00a04.17)\u00a0\nRiociguat/Adempas\u00ae/Bayer,MSD\u00a0\u00a0 \u00a0 Pulmonal\u00a0arterielle\u00a0Hypertonie\u00a0( Kap.\u00a04.21)\u00a0\nAlipogentiparvovec/Glybera\u00ae/UniQuere\u00a0\u00a0 \u00a0Famili\u00e4re\u00a0Lipoproteinlipasedefizienz\u00a0(Kap.\u00a04.2)\u00a0\nChols\u00e4ure/Orphacol\u00ae/Laboratoire\u00a0C.T.R.S.\u00a0\u00a0 \u00a0 Angeborene\u00a0St\u00f6rung\u00a0d er\u00a0Gallens\u00e4uresynthese\u00a0(Kap.\u00a04.5)\u00a0\nElosulfase\u00a0alfa/Vimizim\u00ae/BioMarin\u00a0\u00a0 \u00a0Mucopolysaccharidose\u00a0Typ\u00a0IVA\u00a0(Kap.\u00a04.12)\u00a0\nSiltuximab/Sylvant\u00ae/Janssen\u2010Cilag\u00a0\u00a0 \u00a0 Castleman\u2010Krankheit\u00a0(Kap.\u00a04 .22)\u00a0\nTeduglutid/Revestive\u00ae/Shire\u00a0Deutschland\u00a0\u00a0 \u00a0Kurzdarmsyndrom\u00a0(Kap.\u00a04.27)\u00a0\n\u00a0\nBei\u00a0 strenger\u00a0 Auslegung\u00a0 des\u00a0 Begriffes\u00a0 \u201eSeltene\u00a0 Krankheiten\u201c\u00a0 ( Orphan\u00a0 Disease )\u00a0\nw\u00fcrde\u00a0man\u00a0nicht\u00a0alle\u00a0diese\u00a0Wirkstoffe\u00a0zur\u00a0Behandlung\u00a0dieser\u00a0Kra nkheiten\u00a0klassifi\u2010\nzieren,\u00a0die\u00a0pro\u00a0Jahr\u00a0nach\u00a0der\u00a0europ\u00e4ischen\u00a0Definition\u00a0bei\u00a0maxim al\u00a0f\u00fcnf\u00a0von\u00a010.000\u00a0\nBewohnern\u00a0eines\u00a0Landes\u00a0auftreten. \u00a0Immer\u00a0noch\u00a0werden\u00a0n\u00e4mlich\u00a0f\u00fcr \u00a0Arzneimittel,\u00a0\ndie\u00a0auch\u00a0bei\u00a0Krankheiten\u00a0mit\u00a0h\u00f6herer\u00a0Inzidenz\u00a0eine\u00a0Wirksamkeit\u00a0 zeigen,\u00a0Indikati\u2010\nonsanspr\u00fcche\u00a0gew\u00e4hlt,\u00a0die\u00a0mit\u00a0der\u00a0 Orphan\u00a0Disease \u2010Definition\u00a0schwer\u00a0in\u00a0Einklang\u00a0\nzu\u00a0bringen\u00a0sind,\u00a0maximal\u00a0d\u00fcrfen\u00a0ca.\u00a040.000\u00a0Personen\u00a0betroffen\u00a0s ein.\u00a0Die\u00a0Vorteile\u00a0\neines\u00a0solchen\u00a0Vorgehens\u00a0sind\u00a0un\u00fcbersehbar:\u00a0Bei\u00a0 Orphan\u2010Arzneimitteln\u00a0wird\u00a0in\u00a0der\u00a0\nfr\u00fchen\u00a0Nutzenbewertung\u00a0grunds\u00e4tzlich\u00a0ein\u00a0Zusatznutzen\u00a0angenomme n,\u00a0Nachwei\u2010\nse\u00a0 zum\u00a0 Zusatznutzen\u00a0 im\u00a0 Verh\u00e4ltni s \u00a0z u \u00a0e i n e r \u00a0z w e c k m \u00e4 \u00df i g e n \u00a0V e r g l e i chstherapie\u00a0\nm\u00fcssen\u00a0durch\u00a0den\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(pU)\u00a0nicht\u00a0vorgel egt\u00a0werden.\u00a0\nNachweispflicht\u00a0besteht\u00a0allerdings\u00a0f\u00fcr\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznut zens,\u00a0das\u00a0dann\u00a0\ndurch\u00a0den\u00a0Gemeinsamen\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0bewertet\u00a0werden\u00a0mu ss\u00a0und\u00a0\nauch\u00a0Auswirkungen\u00a0auf\u00a0die\u00a0Preisverhandlungen\u00a0und\u00a0auf\u00a0die\u00a0Preisf indung\u00a0hat.\u00a0Dies\u00a0\nschafft\u00a0f\u00fcr\u00a0die\u00a0pU\u00a0insgesamt\u00a0einen\u00a0maximalen\u00a0Spielraum\u00a0in\u00a0der\u00a0V ermarktung\u00a0und\u00a0\nf\u00fcr\u00a0ihre\u00a0Preisforderungen.\u00a0Eine\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0findet\u00a0er st\u00a0dann\u00a0statt,\u00a0\nwenn\u00a0der\u00a0GKV\u2010Umsatz\u00a0des\u00a0jeweiligen\u00a0 Orphan\u2010Arzneimittels\u00a0die\u00a0Grenze\u00a0von\u00a050\u00a0\nMio.\u00a0Euro\u00a0in\u00a0den\u00a0letzten\u00a0zw\u00f6lf\u00a0Monaten\u00a0\u00fcberschreitet,\u00a0bis\u00a0dahin \u00a0gilt\u00a0der\u00a0Zusatznut\u2010468\u00a0zen\u00a0als\u00a0belegt.\u00a0Dies\u00a0ist\u00a0im\u00a0bewe rteten\u00a0Jahrgang\u00a0inzwischen\u00a0f\u00fcr\u00a0 Ibrutinib\u00a0(Imbruvica\u00ae)\u00a0\nund\u00a0Macitentan\u00a0(Opsumit\u00ae)\u00a0der\u00a0Fall.\u00a0Die\u00a0Notwendigkeit,\u00a0therapeu tische\u00a0M\u00f6glichkei\u2010\nten\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0seltenen\u00a0Krankheiten\u00a0zu\u00a0verbessern,\u00a0 ist\u00a0zweifelsohne\u00a0\ngegeben.\u00a0Schlupfl\u00f6cher\u00a0f\u00fcr\u00a0artifiziell\u00a0konstruierte\u00a0kleine\u00a0Pati entengruppen\u00a0in\u00a0gr\u00f6\u00dfe\u2010\nr e n \u00a0K r a n k h e i t s e n t i t \u00e4 t e n \u00a0m i t \u00a0d e m \u00a0Z i e l , \u00a0d i e \u00a0V o r t e i l e \u00a0d e r \u00a0 Orphan\u2010Arzneimittel\u00a0 im\u00a0\nAMNOG\u2010Prozess\u00a0f\u00fcr\u00a0sich\u00a0zu\u00a0nutzen ,\u00a0sollten\u00a0aber\u00a0geschlossen\u00a0werd en.\u00a0\nDas\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0wird\u00a0aber\u00a0keineswegs\u00a0\nh\u00e4ufig\u00a0besonders\u00a0positiv\u00a0bewertet.\u00a0Im\u00a0Gegenteil:\u00a0Eine\u00a0Evaluatio n\u00a0des\u00a0Ausma\u00dfes\u00a0\ndes\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0bestimmte\u00a0Patientengruppen\u00a0bei\u00a053\u00a0 Orphan\u2010Arzneimitteln\u00a0\nund\u00a0bei\u00a0319\u00a0Nicht\u2010 Orphan\u2010Arzneimitteln\u00a0hat\u00a0gezeigt,\u00a0dass\u00a0die\u00a0 Orphan\u2010Arzneimittel\u00a0\nnur\u00a0 f\u00fcr\u00a0 9\u00a0%\u00a0 der\u00a0 Patientengruppen\u00a0 einen\u00a0 betr\u00e4chtlichen\u00a0 Zusatznut zen\u00a0 zeigten,\u00a0\nw\u00e4hrend\u00a0dies\u00a0bei\u00a013\u00a0%\u00a0der\u00a0Nicht\u2010 Orphan\u2010Arzneimittel\u00a0der\u00a0Fall\u00a0war.\u00a0Ein\u00a0umgekehr\u2010\ntes\u00a0Verh\u00e4ltnis\u00a0ergab\u00a0sich\u00a0bei\u00a0 der\u00a0Gegen\u00fcberstellung\u00a0des\u00a0nicht\u2010q uantifizierbaren\u00a0\nZusatznutzens\u00a0auf\u00a0der\u00a0Ebene\u00a0von\u00a0Patientengruppen:\u00a0Hier\u00a0lag\u00a0der\u00a0 Wert\u00a0f\u00fcr\u00a0 Orphan\u2010\nArzneimittel\u00a0bei\u00a051\u00a0%,\u00a0bei\u00a0den\u00a0Nicht\u2010 Orphan\u2010Arzneimitteln\u00a0bei\u00a04\u00a0%,\u00a0ein\u00a0geringer\u00a0\nZusatznutzen\u00a0f\u00fcr\u00a032\u00a0%\u00a0bei\u00a0den\u00a0 Orphan\u2010Arzneimitteln\u00a0und\u00a014\u00a0%\u00a0bei\u00a0den\u00a0Nicht\u2010\nOrphan\u2010Arzneimitteln\u00a0(Schwabe\u00a0&\u00a0Paffrath\u00a02016,\u00a0161).\u00a0All\u00a0das\u00a0sind\u00a0Hin weise\u00a0daf\u00fcr,\u00a0\ndie\u00a0Pr\u00fcfung\u00a0der\u00a0 Orphan\u2010Arzneimittel\u00a0im\u00a0AMNOG\u00a0Prozess\u00a0zu\u00a0differenzieren\u00a0und\u00a0\neine\u00a0bessere\u00a0Grundlage\u00a0f\u00fcr\u00a0die\u00a0 Preisverhandlungen\u00a0zu\u00a0suchen\u00a0und \u00a0zu\u00a0finden.\u00a0\nDie\u00a0 bisherige\u00a0 Sonderstellung\u00a0 der\u00a0 Orphan\u2010Arzneimittel\u00a0 ist\u00a0 bereits\u00a0 h\u00e4ufiger\u00a0 vom\u00a0\nInstitut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundheitswese n\u00a0(IQWiG)\u00a0oder\u00a0von\u00a0\nder\u00a0Arzneimittelkommission\u00a0der\u00a0d eutschen\u00a0\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0kri tisiert\u00a0worden.\u00a0\nEin\u00a0Beitrag\u00a0unter\u00a0der\u00a0\u00dcberschrift\u00a0\u201eZu\u00a0guter\u00a0Letzt\u00a0ist\u00a0alles\u00a0sel ten\u201c\u00a0hat\u00a0die\u00a0entspre\u2010\nchenden\u00a0Argumente\u00a0zusammengetragen\u00a0(Windeler\u00a0et\u00a0al.,\u00a02010).\u00a0Im\u00a0 Mittelpunkt\u00a0\nsteht\u00a0dabei\u00a0die\u00a0Kritik,\u00a0dass\u00a0die\u00a0pharmazeutischen\u00a0Unternehmer\u00a0\u201e relativ\u00a0h\u00e4ufige\u00a0\nKrankheiten,\u00a0wie\u00a0zum\u00a0Beispiel\u00a0Kre bserkrankungen,\u00a0in\u00a0kleine\u00a0Unte rgruppen\u00a0zerle\u2010\ngen\u201c\u00a0(Slicing)\u00a0(Dingermann,\u00a02013,\u00a035),\u00a0um\u00a0einen\u00a0 Orphan\u2010Disease\u2010Status\u00a0f\u00fcr\u00a0die\u00a0\nrelativ\u00a0wenigen\u00a0Patienten\u00a0erreic hen\u00a0zu\u00a0k\u00f6nnen.\u00a0Schlie\u00dflich\u00a0kam\u00a0 es\u00a0gerade\u00a0im\u00a0Be\u2010\nreich\u00a0der\u00a0Krebstherapie\u00a0nach\u00a0der\u00a0 Zulassung\u00a0eines\u00a0Mittels\u00a0h\u00e4ufig \u00a0genug\u00a0zu\u00a0einer\u00a0\ngewollten\u00a0oder\u00a0zumindest\u00a0zu\u00a0einer\u00a0tolerierten\u00a0Indikationsauswei tung,\u00a0weil\u00a0dann\u00a0\nauch\u00a0andere\u00a0Patientengruppen\u00a0im\u00a0Rahmen\u00a0eines\u00a0Therapieversuchs\u00a0m it\u00a0diesem\u00a0\nneuen\u00a0Wirkstoff\u00a0behandelt\u00a0wurden.\u00a0Man\u00a0spricht\u00a0in\u00a0diesem\u00a0Zusamme nhang\u00a0\u2013\u00a0wie\u00a0\nim\u00a0Software\u2010Umfeld\u00a0\u2013\u00a0auch\u00a0von\u00a0einem\u00a0\u201eTrojaner\u201c,\u00a0mit\u00a0dem\u00a0diese\u00a0I ndikationsaus\u2010\nweitung\u00a0m\u00f6glichst\u00a0unauff\u00e4llig\u00a0ger\u00e4uschlos\u00a0passiert\u00a0\u2013\u00a0zur\u00a0Steige rung\u00a0des\u00a0Umsatzes,\u00a0\nohne\u00a0in\u00a0eine\u00a0Zulassung\u00a0investieren\u00a0zu\u00a0m\u00fcssen\u00a0(Dingermann,\u00a02013) .\u00a0Der\u00a0Umsatz\u00a0f\u00fcr\u00a0\nalle\u00a0Orphan\u2010Arzneimittel\u00a0in\u00a0Deutschland\u00a0betrug\u00a0im\u00a0Jahre\u00a02010\u00a0immerhin\u00a0bere its\u00a0\num\u00a0die\u00a0zwei\u00a0Mrd.\u00a0Euro.\u00a0469\u00a0Es\u00a0gibt\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0einige\u00a0Beispiele\u00a0f\u00fcr\u00a0solche\u00a0Strateg ien:\u00a0Bei\u00a0vier\u00a0im\u00a0Innovati\u2010\nonsreport\u00a02017\u00a0bewerteten\u00a0 Orphan\u2010Arzneimitteln\u00a0(Cabozantinib,\u00a0Ibrutinib,\u00a0Obinutu\u2010\nzumab,\u00a0Riociguat)\u00a0finden\u00a0wir\u00a0zwe i\u00a0Indikationen.\u00a0Beim\u00a0Wirkstoff\u00a0 Imatinib\u00a0(Glivec\u00ae,\u00a0hier\u00a0\nnicht\u00a0bewertet)\u00a0sind\u00a0es\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0neun\u00a0Indikationen.\u00a0 \u00dcber\u00a0die\u00a0Abgrenzbar\u2010\nkeit\u00a0dieser\u00a0einzelnen\u00a0Krankheiten,\u00a0die\u00a0jeweils\u00a0zu\u00a0einem\u00a0 Orphan\u2010Arzneimittel\u2010Status\u00a0\ngef\u00fchrt\u00a0haben,\u00a0l\u00e4sst\u00a0sich\u00a0ohne\u00a0Frage\u00a0unterschiedlicher\u00a0Meinung\u00a0 sein.\u00a0Bei\u00a0Imatinib\u00a0\ngeht\u00a0 es\u00a0 dabei\u00a0 beispielsweise\u00a0 um\u00a0 eine\u00a0 Philadelphia\u2010Chromosom\u00a0 (bc r\u2010abl)\u2010positive\u00a0\nchronische\u00a0myeloische\u00a0Leuk\u00e4mie\u00a0( Ph+\u2010CML),\u00a0eine\u00a0Philadelphia\u2010Chr omosom\u2010positive\u00a0\nakute\u00a0lymphatische\u00a0Leuk\u00e4mie\u00a0(Ph+ \u2010ALL),\u00a0eine\u00a0myelodysplastische/ myeloproliferative\u00a0\nErkrankung\u00a0(MDS/MPD)\u00a0in\u00a0Verbindung\u00a0mit\u00a0Gen\u2010Umlagerungen\u00a0des\u00a0PDG F\u2010Rezeptors\u00a0\n(Platelet\u2010derived\u00a0Growth\u00a0Factor )\u00a0oder\u00a0einen\u00a0c\u2010Kit\u2010(CD\u00a0117)\u2010positiver\u00a0maligner\u00a0gastro\u2010\nintestinaler\u00a0Stromatumor\u00a0(GIST)\u00a0(Dingermann,\u00a02013).\u00a0Die\u00a0oben\u00a0er w\u00e4hnte\u00a0Rege\u2010\nlung,\u00a0nach\u00a0der\u00a0auch\u00a0f\u00fcr\u00a0einen\u00a0solchen\u00a0 Orphan\u2010Arzneimittel\u2010Wirkstoff\u00a0ab\u00a0einem\u00a0\nGKV\u2010Umsatz\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0der\u00a0Nachweis\u00a0eines\u00a0Zusatznutzens\u00a0er bracht\u00a0werden\u00a0\nmuss,\u00a0h\u00e4tte\u00a0daher\u00a0f\u00fcr\u00a0dieses\u00a0Produkt\u00a0l\u00e4ngst\u00a0angewendet\u00a0werden\u00a0m \u00fcssen.\u00a0In\u00a0der\u00a0\nZwischenzeit\u00a0ist\u00a0der\u00a0 Orphan\u2010Arzneimittel\u2010Status\u00a0f\u00fcr\u00a0dieses\u00a0Produkt\u00a0allerdings\u00a0erlo\u2010\nschen,\u00a0es\u00a0ist\u00a0mittlerweile\u00a0als\u00a0Generikum\u00a0erh\u00e4ltlich.\u00a0\u00a0\nEine\u00a0\u00e4hnliche\u00a0Entwicklung\u00a0wie\u00a0beim\u00a0Imatinib\u00a0k\u00f6nnte\u00a0sich\u00a0auch\u00a0f\u00fc r\u00a0das\u00a02014\u00a0zuge\u2010\nlassene\u00a0Ibrutinib\u00a0(Imbruvica\u00ae)\u00a0ergeben.\u00a0Dieses\u00a0Mittel\u00a0wurde\u00a0ebe nfalls\u00a0als\u00a0 Orphan\u2010\nA r z n e i m i t t e l \u00a0f \u00fc r \u00a0d i e \u00a0B e h a n d l u n g \u00a0v o n \u00a0P a t i e n t e n \u00a0m i t \u00a0c h r o n i s c h e r \u00a0l ymphatischer\u00a0\nLeuk\u00e4mie,\u00a0 Morbus\u00a0 Waldenstr\u00f6m\u00a0 und\u00a0 Mantelzell\u2010Lymphom\u00a0 zugelassen\u00a0 und\u00a0 er\u2010\nreichte\u00a02016\u00a0bereits\u00a0einen\u00a0Industrieumsatz\u00a0von\u00a0knapp\u00a0140\u00a0Mio.\u00a0E uro.\u00a0Damit\u00a0d\u00fcrfte\u00a0\ndas\u00a0GKV\u2010Limit\u00a0von\u00a050\u00a0Mio.\u00a0Euro\u00a0ohne\u00a0Zweifel\u00a0\u00fcberschritten\u00a0sein. \u00a0Auch\u00a0beim\u00a0als\u00a0\nOrphan\u2010Arzneimittel\u00a0im\u00a0Jahr\u00a02014\u00a0zugelassenen\u00a0Riociguat\u00a0(Adempas\u00ae)\u00a0f\u00e4 llt\u00a0auf,\u00a0\ndass\u00a0neben\u00a0den\u00a0zugelassenen\u00a0Anwendungsgebieten\u00a0CTEPH\u00a0und\u00a0PAH\u00a0WH O\u2010FC\u00a0II\u00a0\nund\u00a0 III\u00a0 weitere\u00a0 Studien\u00a0 mit\u00a0 dem\u00a0 Ziel\u00a0 der\u00a0 Indikationserweiterung \u00a0 durchgef\u00fchrt\u00a0\nwurden.\u00a0Die\u00a0Studien\u00a0\u201eRISE\u2010IIP\u201c\u00a0und\u00a0\u201ePATENT\u2010plus\u201c\u00a0wurden\u00a0jedoch\u00a0 abgebrochen\u00a0\nund\u00a0weitere\u00a0Kontraindikationen\u00a0in\u00a0der\u00a0Fachinformation\u00a0erg\u00e4nzt,\u00a0 teils\u00a0kommuni\u2010\nziert\u00a0mittels\u00a0Rote\u2010Hand\u2010Brief\u00a0(Bayer,\u00a02016).\u00a0\nNeben\u00a0den\u00a0zw\u00f6lf\u00a0 Orphan\u2010Arzneimitteln\u00a0wurden\u00a0im\u00a0Jahre\u00a02014\u00a0weitere\u00a020\u00a0in\u00a0den\u00a0\nMarkt\u00a0eingef\u00fchrte\u00a0Wirkstoffe\u00a0ana lysiert.\u00a0Die\u00a0Bewertungen\u00a0nach\u00a0z wei\u00a0Jahren\u00a0Erfah\u2010\nrungen\u00a0mit\u00a0diesen\u00a0neuen\u00a0Mitteln\u00a0fallen\u00a0deutlich\u00a0weniger\u00a0gut\u00a0aus \u00a0als\u00a0in\u00a0den\u00a0Jahren\u00a0\nzuvor:\u00a0\nKein\u00a0einziges\u00a0Mittel\u00a0erreicht\u00a0ein en\u00a0Gesamtscore,\u00a0der\u00a0eine\u00a0gr\u00fcne \u00a0Ampel\u00a0rechtfer\u2010\ntigt,\u00a0bei\u00a017\u00a0der\u00a0hier\u00a0bewerteten\u00a0Mittel\u00a0kam\u00a0es\u00a0beim\u00a0Gesamtscore \u00a0zu\u00a0einer\u00a0gelben,\u00a0\nbei\u00a015\u00a0zu\u00a0einer\u00a0roten\u00a0Ampel.\u00a0Acht\u00a0gelbe\u00a0und\u00a0vier\u00a0rote\u00a0Gesamtsco re\u2010Bewertungen\u00a0\nentfielen\u00a0auf\u00a0Orphan\u2010Arzneimittel.\u00a0F\u00fcr\u00a0 Orphan\u2010Arzneimittel\u00a0wurden\u00a0keine\u00a0Kosten\u2010470\u00a0vergleiche\u00a0vom\u00a0G\u2010BA\u00a0angegeben,\u00a0au\u00dfer\u00a0f\u00fcr\u00a0Ibrutinib\u00a0und\u00a0Macitent an.\u00a0Sie\u00a0\u00fcber\u2010\nschritten\u00a0die\u00a050\u00a0Mio.\u00a0Umsatzgrenze\u00a0und\u00a0wurden\u00a0vom\u00a0G\u2010BA\u00a0nachtr\u00e4g lich\u00a0verglichen.\u00a0\u00a0\nBei\u00a0der\u00a0Kostenbewertung\u00a0aller\u00a0Mittel\u00a0wurde\u00a0bei\u00a0acht\u00a0Wirkstoffen \u00a0die\u00a0gelbe\u00a0und\u00a0bei\u00a0\nvier\u00a0Wirkstoffen,\u00a0bzw.\u00a0Wirkstoffkombinationen\u00a0(Cobicistat,\u00a0Dexl ansoprazol,\u00a0Olo\u2010\ndaterol\u00a0und\u00a0Vilanterol\u00a0+\u00a0Fluticasonfuroat)\u00a0die\u00a0gr\u00fcne\u00a0Ampel\u00a0verg eben.\u00a0Dexlansop\u2010\nrazol\u00a0und\u00a0Olodaterol\u00a0sind\u00a0allerdings\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0mit\u00a0Mehr kosten\u00a0verbunden.\u00a0\nAnzumerken\u00a0ist\u00a0au\u00dferdem,\u00a0dass\u00a0die\u00a0Kombination\u00a0Vilanterol\u00a0und\u00a0Fl uticasonfuroat\u00a0\nin\u00a0 ihrer\u00a0 Festbetragsgruppe\u00a0 nicht\u00a0 das\u00a0 g\u00fcnstigste\u00a0 Pr\u00e4parat\u00a0 darste llt.\u00a0 Der\u00a0 gr\u00f6\u00dfte\u00a0\nAnteil\u00a0der\u00a02014\u00a0neu\u00a0in\u00a0den\u00a0Markt\u00a0gebrachten\u00a0Arzneimittel\u00a0war\u00a0al so\u00a0deutlich\u00a0kos\u2010\ntenintensiver\u00a0als\u00a0die\u00a0zweckm \u00e4\u00dfigen\u00a0Vergleichstherapien.\u00a0\nImmerhin\u00a0f\u00fcnf\u00a0Wirkstoffen\u00a0wurde\u00a0be im\u00a0Vergleich\u00a0mit\u00a0verf\u00fcgbaren\u00a0 Therapien\u00a0eine\u00a0\ngr\u00fcne\u00a0Ampel\u00a0gegeben,\u00a0bei\u00a013\u00a0eine\u00a0gelbe.\u00a0Dies\u00a0hei\u00dft,\u00a0dass\u00a0mehr\u00a0a ls\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0\nneu\u00a0in\u00a0den\u00a0Markt\u00a0gebrachten\u00a0Pr\u00e4parate\u00a0zumindest\u00a0eine\u00a0positiv\u00a0zu \u00a0bewertende\u00a0\nErg\u00e4nzung\u00a0des\u00a0vorhandenen\u00a0Arzneim ittelrepertoires\u00a0anbieten.\u00a0Bei \u00a014\u00a0Wirkstoffen\u00a0\nkonnte\u00a0eine\u00a0solche\u00a0positive\u00a0Erg\u00e4n zung\u00a0nicht\u00a0festgestellt\u00a0werden .\u00a0Dies\u00a0betraf\u00a0\u00fcbri\u2010\ngens\u00a0auch\u00a0die\u00a0drei\u00a0 Orphan\u2010Arzneimittel\u00a0Cabozantinib,\u00a0Macitentan\u00a0und\u00a0Obinutu\u2010\nzumab.\u00a0\nBeim\u00a0 wichtigsten\u00a0 Kriterium,\u00a0 dem\u00a0 nachgewiesenen\u00a0 Zusatznutzen,\u00a0 wu rde\u00a0 15mal\u00a0\neine\u00a0rote\u00a0Ampel\u00a0vergeben,\u00a0der\u00a0\u00fcbe rwiegende\u00a0Anteil\u00a0erhielt\u00a0eine\u00a0 gelbe\u00a0Ampel.\u00a0\nDamit\u00a0ist\u00a0der\u00a0gr\u00f6\u00dfere\u00a0Anteil\u00a0der\u00a0 neuen\u00a0Arzneimittel\u00a0f\u00fcr\u00a0Patient en\u00a0zumindest\u00a0mit\u00a0\neinem\u00a0Nutzenzugewinn\u00a0verbunden.\u00a0\n26\u00a0der\u00a032\u00a0bewerteten\u00a0Wirkstoffe\u00a0(zum\u00a0Teil\u00a0als\u00a0Wirkstoffgruppe)\u00a0 wurden\u00a0zwischen\u2010\nzeitlich\u00a0 in\u00a0 bestehende\u00a0 Leitlinien\u00a0 aufgenommen.\u00a0 Dies\u00a0 betrifft\u00a0 ir ritierenderweise\u00a0\nauch\u00a0solche,\u00a0bei\u00a0denen\u00a0keine\u00a0Erw eiterung\u00a0des\u00a0Therapierepertoire s\u00a0und\u00a0des\u00a0Zu\u2010\nsatznutzens\u00a0festgestellt\u00a0und\u00a0eine\u00a0rote\u00a0Gesamtscore\u2010Ampel\u00a0vergeb en\u00a0wurde\u00a0(expli\u2010\nzit\u00a0Cabozantinib,\u00a0Cobicistat,\u00a0Idelalisib,\u00a0Macitentan,\u00a0Nalmefen, \u00a0Obinutuzumab\u00a0und\u00a0\nSimeprevir).\u00a0\nWie\u00a0wichtig\u00a0die\u00a0sorgf\u00e4ltige\u00a0Beobachtung\u00a0in\u00a0der\u00a0\u201eAlltagsanwendun g\u201c\u00a0neuer\u00a0Mittel\u00a0\nist,\u00a0zeigt\u00a0die\u00a0Anzahl\u00a0der\u00a0Aussendungen\u00a0von\u00a0Rote\u2010Hand\u2010Briefen\u00a0zu \u00a0den\u00a0neu\u00a0angebo\u2010\ntenen\u00a0 Arzneimitteln:\u00a0 F\u00fcr\u00a0 sechs\u00a0 Mittel\u00a0 wurden\u00a0 solche\u00a0 Hinweise\u00a0 ve rschickt\u00a0\n(18,75\u00a0%),\u00a0f\u00fcr\u00a0zwei\u00a0(Dimethylfumarat\u00a0und\u00a0Idelalisib)\u00a0sogar\u00a0zwei mal\u00a0innerhalb\u00a0der\u00a0\nersten\u00a0 beiden\u00a0 Behandlungsjahre.\u00a0 D ies\u00a0 zeigt\u00a0 exemplarisch,\u00a0 wie\u00a0 no twendig\u00a0 eine\u00a0\nsystematische\u00a0Nebenwirkungsforschung\u00a0nach\u00a0der\u00a0Zulassung\u00a0als\u00a0Bas is\u00a0f\u00fcr\u00a0mehr\u00a0\nTherapiesicherheit\u00a0angesehen\u00a0werden\u00a0muss,\u00a0da\u00a0in\u00a0den\u00a0Zulassungss tudien\u00a0wegen\u00a0\nder\u00a0Ein\u2010\u00a0und\u00a0Ausschlusskriterien \u00a0zu\u00a0wenig\u00a0verallgemeinerbare\u00a0Hi nweise\u00a0auf\u00a0die\u00a0\nVertr\u00e4glichkeit\u00a0und\u00a0auf\u00a0die\u00a0H\u00e4ufigkeit\u00a0von\u00a0unerw\u00fcnschten\u00a0Arznei mittelereignissen\u00a0\nzusammengetragen\u00a0werden\u00a0k\u00f6nnen.\u00a0Hinzu\u00a0kommt,\u00a0dass\u00a0die\u00a0Zahl\u00a0der\u00a0 in\u00a0Zulas\u2010471\u00a0sungsstudien\u00a0eingeschlossenen\u00a0Patienten\u00a0zu\u00a0gering\u00a0ist,\u00a0um\u00a0selte ne\u00a0unerw\u00fcnschte\u00a0\nArzneimittelereignisse\u00a0(UAE)\u00a0zu\u00a0entdecken\u00a0und\u00a0zu\u00a0erfassen.\u00a0Um\u00a0m it\u00a0einer\u00a095%igen\u00a0\nWahrscheinlichkeit\u00a0eine\u00a0UAE\u00a0identifizieren\u00a0zu\u00a0k\u00f6nnen,\u00a0die\u00a0bei\u00a0e inem\u00a0von\u00a01.000\u00a0\nbehandelten\u00a0Patienten\u00a0auftreten,\u00a0ist\u00a0die\u00a0Anwendung\u00a0an\u00a03.000\u00a0Pat ienten\u00a0notwen\u2010\ndig,\u00a0bei\u00a0einer\u00a0Relation\u00a0von\u00a01\u00a0zu\u00a010.000\u00a0bereits\u00a0an\u00a030.000\u00a0(Port a\u00a0&\u00a0Hartzema,\u00a01987).\u00a0\nDies\u00a0stellt\u00a0erneut\u00a0unter\u00a0Beweis,\u00a0wie\u00a0notwendig\u00a0gezielt\u00a0und\u00a0syst ematisch\u00a0durchge\u2010\nf\u00fchrte\u00a0Studien\u00a0zu\u00a0unerw\u00fcnschten\u00a0Ereignissen\u00a0und\u00a0Nebenwirkungen\u00a0 nach\u00a0der\u00a0Zu\u2010\nlassung\u00a0eines\u00a0Arzneimittels\u00a0bei\u00a0 unselektierten\u00a0Patientengruppen \u00a0im\u00a0Rahmen\u00a0einer\u00a0\nmethodisch\u00a0guten\u00a0Versorgungsforschung\u00a0sind.\u00a0Ergebnisse\u00a0aus\u00a0neue ren\u00a0Studien\u00a0\nhaben\u00a0diesen\u00a0Aspekt\u00a0erneut\u00a0best\u00e4tigt\u00a0(Downing\u00a0et\u00a0al.,\u00a02017).\u00a0Be i\u00a0rund\u00a0einem\u00a0Drit\u2010\ntel\u00a0aller\u00a0zwischen\u00a02001\u00a0und\u00a02010\u00a0 neu\u00a0zugelassenen\u00a0Arzneimittel\u00a0 (bei\u00a071\u00a0von\u00a0222)\u00a0\nwurden\u00a0 erst\u00a0 nach\u00a0 der\u00a0 Marktzulassung\u00a0 ernsthafte\u00a0 Vertr\u00e4glichkeits probleme\u00a0 er\u2010\nkannt.\u00a0Oft\u00a0f\u00fchrt\u00a0dies\u00a0zu\u00a0neuen\u00a0Anwendungseinschr\u00e4nkungen\u00a0oder\u00a0w eitergehenden\u00a0\nAuflagen\u00a0bei\u00a0der\u00a0Anwendung,\u00a0beispielsweise\u00a0dass\u00a0bestimmte\u00a0Patie nten\u00a0das\u00a0Mittel\u00a0\nnicht\u00a0mehr\u00a0bekommen\u00a0d\u00fcrfen\u00a0oder\u00a0dass\u00a0bestimmte\u00a0Werte\u00a0w\u00e4hrend\u00a0de r\u00a0Behand\u2010\nlung\u00a0regelm\u00e4\u00dfig\u00a0\u00fcberpr\u00fcft\u00a0werden\u00a0 m\u00fcssen.\u00a0Drei\u00a0Wirkstoffe\u00a0musste n\u00a0wegen\u00a0Si\u2010\ncherheitsbedenken\u00a0ganz\u00a0vom\u00a0Markt\u00a0genommen\u00a0werden:\u00a0Valdecoxib\u00a0(B extra\u00ae,\u00a0zur\u00a0\nBehandlung\u00a0 von\u00a0 Schmerzen\u00a0 bei\u00a0 Arthrose\u00a0 und\u00a0 Arthritis)\u00a0 wegen\u00a0 Herz \u2010Kreislauf\u2010\nRisiken,\u00a0Tegaserod\u00a0(Zelnorm\u00ae,\u00a0zur\u00a0Behandlung\u00a0des\u00a0Reizdarmsyndro ms)\u00a0ebenfalls\u00a0\nwegen\u00a0 Herz\u2010Kreislauf\u2010Risiken\u00a0 und\u00a0 Efalizumab\u00a0 (Raptiva\u00ae,\u00a0 zur\u00a0 Beha ndlung\u00a0 der\u00a0\nSchuppenflechte)\u00a0aufgrund\u00a0eines\u00a0erh\u00f6hten\u00a0Risikos\u00a0einer\u00a0progress iven\u00a0multifokalen\u00a0\nLeukenzephalopathie,\u00a0 einer\u00a0 lebens bedrohlichen\u00a0 Virus\u2010Infektion\u00a0 d es\u00a0 Gehirns.\u00a0\n\u201eNeu\u201c\u00a0bedeutet\u00a0bei\u00a0Arzneimitteln\u00a0daher\u00a0nicht\u00a0automatisch\u00a0auch\u00a0\u201e besser\u201c\u00a0als\u00a0lange\u00a0\nerprobte,\u00a0 bew\u00e4hrte\u00a0 Mittel.\u00a0 Denn\u00a0 manche\u00a0 Nebenwirkungen\u00a0 von\u00a0 Arzne imitteln\u00a0\nk\u00f6nnen\u00a0erst\u00a0nach\u00a0l\u00e4ngerer\u00a0Anwendung\u00a0erkannt\u00a0werden,\u00a0etwa\u00a0solche ,\u00a0die\u00a0sehr\u00a0\nselten\u00a0vorkommen,\u00a0aber\u00a0schwerwiegend\u00a0sind,\u00a0oder\u00a0solche,\u00a0die\u00a0sic h\u00a0erst\u00a0\u00fcber\u00a0einen\u00a0\nl\u00e4ngeren\u00a0 Anwendungszeitraum\u00a0 entwickeln.\u00a0 Bei\u00a0 schon\u00a0 lange\u00a0 Zeit\u00a0 ei ngesetzten\u00a0\nWirkstoffen\u00a0ist\u00a0dagegen\u00a0das\u00a0Nebe nwirkungsspektrum\u00a0gut\u00a0charakter isiert,\u00a0die\u00a0Risi\u2010\nken\u00a0der\u00a0Anwendung\u00a0sind\u00a0daher\u00a0besser\u00a0absch\u00e4tzbar.\u00a0In\u00a0der\u00a0AMNOG\u2010F r\u00fchbewer\u2010\ntung\u00a0k\u00f6nnen\u00a0solche\u00a0unerw\u00fcnschten \u00a0Ereignisse\u00a0wegen\u00a0der\u00a0Einschr\u00e4n kungen\u00a0der\u00a0\nZulassungsstudien\u00a0(zu\u00a0wenige\u00a0Patie nten,\u00a0zu\u00a0kurze\u00a0Laufzeiten,\u00a0se lektierte\u00a0Patien\u2010\ntengruppen\u00a0usw.)\u00a0weder\u00a0erkannt\u00a0noch\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0ber\u00fccksic htigt\u00a0werden,\u00a0\ndie\u00a0G\u2010BA\u00a0Bewertungen\u00a0\u00fcbersch\u00e4tzen\u00a0daher\u00a0den\u00a0Nutzen\u00a0und\u00a0untersch \u00e4tzen\u00a0m\u00f6gli\u2010\nche\u00a0Risiken.\u00a0Neben\u00a0anderen\u00a0Gr\u00fcnden\u00a0sollte\u00a0schon\u00a0zur\u00a0Gew\u00e4hrleist ung\u00a0der\u00a0Patien\u2010\nten\u2010\u00a0und\u00a0Behandlungssicherheit\u00a0der\u00a0Fr\u00fchbewertung\u00a0eine\u00a0Sp\u00e4tbewer tung\u00a0folgen.\u00a0\nEine\u00a0bessere\u00a0Nutzen\u2010Schaden\u2010Relation\u00a0k\u00f6nnte\u00a0so\u00a0als\u00a0Basis\u00a0der\u00a0Be wertung\u00a0und\u00a0der\u00a0\nPreisfestsetzung\u00a0angewendet\u00a0werden.\u00a0\nDar\u00fcber\u00a0hinaus\u00a0wurden\u00a0vom\u00a0pU\u00a0in\u00a0Abstimmung\u00a0mit\u00a0dem\u00a0BfArM\u00a0vierma l\u00a0Blaue\u2010\nHand\u2010Schulungsmaterialien\u00a0 (Chols\u00e4u re,\u00a0 Delamanid,\u00a0 Elosulfase\u00a0 alf a\u00a0 und\u00a0 Maci\u2010\ntentan)\u00a0f\u00fcr\u00a0\u00c4rzte\u00a0und\u00a0Patienten\u00a0mit\u00a0wichtigen\u00a0Informationen\u00a0zu\u00a0 solchen\u00a0Arzneimit\u2010472\u00a0teln\u00a0erstellt,\u00a0bei\u00a0denen\u00a0die\u00a0Informationen\u00a0in\u00a0der\u00a0Packungsbeila ge\u00a0allein\u00a0nicht\u00a0aus\u2010\nreichen,\u00a0um\u00a0das\u00a0Risiko\u00a0bei\u00a0der\u00a0Anwendung\u00a0zu\u00a0minimieren.\u00a0Diese\u00a0A rt\u00a0von\u00a0Schu\u2010\nlungsmaterial\u00a0wurde\u00a0Ende\u00a02016\u00a0ei ngef\u00fchrt\u00a0\u2013\u00a0ein\u00a0im \u00a0Vergleich\u00a0zum \u00a0Rote\u2010Hand\u2010Brief\u00a0\nausf\u00fchrlicher\u00a0formuliertes\u00a0Infor mationsangebot\u00a0f\u00fcr\u00a0\u00c4rzte\u00a0und\u00a0Pa tienten.\u00a0\nTabelle\u00a05.1\u00a0fasst\u00a0diese\u00a0im\u00a0Innovationsreport\u00a02017\u00a0getroffenen\u00a0B ewertungen\u00a0nach\u00a0\ndem\u00a0im\u00a0Report\u00a0genutzten\u00a0Ampelsche ma\u00a0zusammen.\u00a0Die\u00a0folgenden\u00a0Tab ellen\u00a05.4\u00a0\n(ohne\u00a0Orphan\u2010Arzneimittel)\u00a0und\u00a05.5\u00a0(ausschlie\u00dflich\u00a0 Orphan\u2010Arzneimittel)\u00a0bilden\u00a0\ndie\u00a0Gesamtscores\u00a0aller\u00a0Innovationsbewertungen\u00a0ab.\u00a0\u00a0\nDie\u00a0Karte\u00a0in\u00a0Abbildung\u00a05.1\u00a0zeigt\u00a0die\u00a0Verordnungsanteile\u00a0der\u00a0TK\u2010 Versicherten\u00a0(je\u00a0\nTausend\u00a0Versicherte)\u00a0im\u00a0Vergleich\u00a0zu\u00a0allen\u00a0TK\u00a0Versicherten.\u00a0In\u00a0 den\u00a0Verordnungs\u2010\npr\u00e4valenzen\u00a0der\u00a0neuen,\u00a0im\u00a0Zusatznutzen\u00a0mit\u00a0\u201erot\u201c\u00a0bewerteten\u00a0Wir kstoffe\u00a0aus\u00a0dem\u00a0\nJahr\u00a02014\u00a0wird\u00a0sichtbar,\u00a0dass\u00a0No rdrhein\u2010Westfalen\u00a0(3,71\u00a0\u2030),\u00a0Ham burg\u00a0(3,54\u00a0\u2030)\u00a0\nund\u00a0das\u00a0Saarland\u00a0(2,86\u00a0\u2030)\u00a0bei\u00a0den\u00a0Verordnungen\u00a0dieser\u00a0Wirkstoff e\u00a0im\u00a0Jahr\u00a02015\u00a0\nf\u00fchrten.\u00a0 Bayern\u00a0 (1,12\u00a0\u2030),\u00a0 Bremen\u00a0 (1,27\u00a0\u2030)\u00a0 und\u00a0 Mecklenburg\u2010Vorpo mmern\u00a0\n(1,36\u00a0\u2030)\u00a0zeigen\u00a0die\u00a0geringsten\u00a0Verordnungspr\u00e4valenzen\u00a0dieser\u00a0Wi rkstoffe,\u00a0die\u00a0am\u00a0\nschlechtesten\u00a0in\u00a0unseren\u00a0Bewertungen\u00a0abgeschnitten\u00a0hatten.\u00a0\u00a0\nQuellen\u00a0\nBayer\u00a0AG\u00a0(2017).\u00a0Gesch\u00e4ftsbericht\u00a02016.\u00a0Erweiterte\u00a0Fassung.\u00a0\nwww.geschaeftsbericht2016.bayer.de/serviceseiten/downloads/file s/bayer_gb16_gesamt.pdf,\u00a0\u00a0\nletzter\u00a0Zugriff:\u00a003.08.2017.\u00a0\nBensing\u00a0C,\u00a0Kleinfeld\u00a0A\u00a0(2011).\u00a0Der\u00a0\u201eMilliarden\u2010Nischenmarkt\u201c\u00a0mi t\u00a0Sonderstatus:\u00a0Orphan\u00a0drugs.\u00a0Monitor\u00a0Versorgungsforschung\u00a0(1): \u00a012.\u00a0\nDingermann\u00a0T\u00a0(2013).\u00a0Orphan\u00a0Drugs: \u00a0Alles\u00a0andere\u00a0als\u00a0Waisenknabe n.\u00a0Pharmazeutische\u00a0Zeitung\u00a022:\u00a030\u201037\u00a0\nDowning\u00a0NS,\u00a0Shah\u00a0ND,\u00a0Aminawung\u00a0JA,\u00a0Pease\u00a0AM,\u00a0Zeitoun\u00a0JD,\u00a0Krumho lz\u00a0HM\u00a0et\u00a0al.\u00a0(2017).\u00a0Postmarket \u00a0Safety\u00a0Events\u00a0Among\u00a0Novel\u00a0\nTherapeutics\u00a0Approved\u00a0by\u00a0the\u00a0US\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0Be tween\u00a02001\u00a0and\u00a02010.\u00a0JAMA\u00a0317(18):\u00a01854\u20101863.\u00a0\nProta\u00a0MS,\u00a0Hartzema\u00a0AG\u00a0(1987).\u00a0The\u00a0contribution\u00a0of\u00a0epidemiology\u00a0 to\u00a0the\u00a0study\u00a0of\u00a0drugs.\u00a0Drug\u00a0Intell\u00a0Clin\u00a0Pharm\u00a021(9):\u00a0741\u2010747.\u00a0\nWindeler\u00a0J,\u00a0Koch\u00a0K,\u00a0Lange\u00a0S,\u00a0Ludwig\u00a0WD\u00a0(2010).\u00a0Zu\u00a0guter\u00a0Letzt\u00a0i st\u00a0alles\u00a0selten.\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0107(42):\u00a0A2032\u2010A2034.\u00a0\n\u00a0 \u00a0473\u00a0Tabelle\u00a05.4:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung\u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0 Kosten\u00a0 \u00a0 Gesamt\u2010Score\u00a0\n\u00a0\nCobicistat\u00a0\nDexlansoprazol\u00a0\nEmpagliflozin\u00a0\nNalmefen\u00a0\nOlodaterol\u00a0\nSimeprevir\u00a0\nSimoctocog\u00a0alfa\u00a0\nSucroferric\u2010\nOxyhydroxid\u00a0\nTuroctocog\u00a0alfa\u00a0\nUmeclidinium\u00a0\n+\u00a0Vilanterol\u00a0\nVilanterol\u00a0\u00a0\n+\u00a0Fluticasonfuroat\u00a0\u00a0Cobicistat\u00a0\nDexlansoprazol\u00a0\nIdelalisib\u00a0\nNalmefen\u00a0\nOlodaterol\u00a0\nSimeprevir\u00a0\nSimoctocog\u00a0alfa\u00a0\nSucroferric\u2010\nOxyhydroxid\u00a0\nTuroctocog\u00a0alfa\u00a0\nUmeclidinium\u00a0+\u00a0\nVilanterol\u00a0\nVilanterol\u00a0\u00a0\n+\u00a0Fluticasonfuroat\u00a0\u00a0\n\u00a0\u00a0Albiglutid\u00a0\nDaclatasvir\u00a0\nDolutegravir\u00a0\nLedipasvir\u00a0\u00a0\n+\u00a0Sofosbuvir\u00a0\nSimeprevir\u00a0\nSofosbuvir\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0\u00a0\nTuroctocog\u00a0alfa\u00a0\u00a0\u00a0Cobicistat\u00a0(2)\u00a0\nDexlansoprazol\u00a0(2)\u00a0\nIdelalisib\u00a0(2)\u00a0\nNalmefen\u00a0(1)\u00a0\nOlodaterol\u00a0(2)\u00a0\nSimeprevir\u00a0(0)\u00a0\nSimoctocog\u00a0alfa\u00a0(1)\u00a0\nSucroferric\u2010\u00a0\nOxyhydroxid\u00a0(1)\u00a0\nTuroctocog\u00a0alfa\u00a0(0)\u00a0\nUmeclidinium\u00a0\n+\u00a0Vilanterol\u00a0(1)\u00a0\nVilanterol\u00a0\u00a0\n+\u00a0Fluticasonfuroat\u00a0(2)\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAlbiglutid\u00a0\nDaclatasvir\u00a0\nDimethylfumarat\u00a0\nDolutegravir\u00a0\nIdelalisib\u00a0\nLedipasvir\u00a0\u00a0\n+\u00a0Sofosbuvir\u00a0\nSofosbuvir\u00a0\nTrastuzumab\u00a0Emtansin\u00a0\nVedolizumab\u00a0\u00a0Albiglutid\u00a0\nDaclatasvir\u00a0\nDimethylfumarat\u00a0\nDolutegravir\u00a0\nEmpagliflozin\u00a0\nLedipasvir\u00a0\u00a0\n+\u00a0Sofosbuvir\u00a0\nSofosbuvir\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0\nVedolizumab\u00a0\n\u00a0\u00a0Dimethylfumarat\u00a0\nEmpagliflozin\u00a0\nIdelalisib\u00a0\nNalmefen\u00a0\nSimoctocog\u00a0alfa\u00a0\nSucroferric\u2010\nOxyhydroxid\u00a0\nUmeclidinium\u00a0+\u00a0\nVilanterol\u00a0\nVedolizumab\u00a0\u00a0Albiglutid\u00a0(3)\u00a0\nDaclatasvir\u00a0(3)\u00a0\nDimethylfumarat\u00a0(4)\u00a0\nDolutegravir\u00a0(3)\u00a0\nEmpagliflozin\u00a0(3)\u00a0\nLedipasvir\u00a0\u00a0\n+\u00a0Sofosbuvir\u00a0(3)\u00a0\nSofosbuvir\u00a0(3)\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0(3)\u00a0\nVedolizumab\u00a0(4)\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0Cobicistat\u00a0\nDexlansoprazol*\u00a0\nOlodaterol*\u00a0\nVilanterol\u00a0+\u00a0\nFluticasonfuroat\u00a0\u00a0\n\u00a0\u00a0\u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts\u00a0wurden\u00a0die\u00a0einzelnen\u00a0Punkte\u00a0der\u00a0Inn ovationsbewertung\u00a0separat\u00a0betrachtet,\u00a0der\u00a0\npatientenrelevante\u00a0Zusatznutzen\u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die \u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0P unkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0\nAmpel\u00a0=\u00a02\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte; \u00a0Kosten:\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02 \u00a0Punkte;\u00a0\nGesamt:\u00a0rote\u00a0Ampel\u00a0=\u00a0h\u00f6chstens\u00a02\u00a0Punkt e,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkt e,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0mehr.\u00a0\n*\u00a0Mehrkosten\u00a0f\u00fcr\u00a0Patienten\u00a0\n\u00a0 \u00a0474\u00a0Tabelle\u00a05.5:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung\u00a0 Orphan\u2010Arzneimittel\u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0 Gesamt\u2010Score\u00a0\n\u00a0\nCabozantinib\u00a0\nMacitentan\u00a0\nObinutuzumab\u00a0\u00a0Alipogentiparvovec\u00a0\nCabozantinib\u00a0\u00a0\nMacitentan\u00a0\nObinutuzumab\u00a0\u00a0Alipogentiparvovec\u00a0(2)\u00a0\nCabozantinib\u00a0(0)\u00a0\nMacitentan\u00a0(0)\u00a0\nObinutuzumab\u00a0(0)\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\nBedaquilin\u00a0\nDelamanid\u00a0\nIbrutinib\u00a0\nRiociguat\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Bedaquilin\u00a0\nChols\u00e4ure\u00a0\nDelamanid\u00a0\nElosulfase\u00a0alfa\u00a0\nIbrutinib\u00a0\nRiociguat\u00a0\nSiltuximab\u00a0\nTeduglutid\u00a0\u00a0\n\u00a0\u00a0Bedaquilin\u00a0(3)\u00a0\nChols\u00e4ure\u00a0(4)\u00a0\nDelamanid\u00a0(3)\u00a0\nElosulfase\u00a0alfa\u00a0(4)\u00a0\nIbrutinib\u00a0(3)\u00a0\nRiociguat\u00a0(3)\u00a0\nSiltuximab\u00a0(4)\u00a0\nTeduglutid\u00a0(4)\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\nAlipogentiparvovec\u00a0\nChols\u00e4ure\u00a0\u00a0\nElosulfase\u00a0alfa\u00a0\nSiltuximab\u00a0\nTeduglutid\u00a0\n\u00a0\u00a0\u00a0\u00a0 \u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts\u00a0wurden\u00a0die\u00a0einzelnen\u00a0Punkte\u00a0der\u00a0Inn ovationsbewertung\u00a0separat\u00a0betrachtet,\u00a0der\u00a0\npatientenrelevante\u00a0Zusatznutzen\u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die \u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0P unkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0\nAmpel\u00a0=\u00a02\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte\u00a0 Gesamt:\u00a0rote\u00a0Ampel\u00a0=\u00a0h\u00f6chstens\u00a02\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkt e,\u00a0gr\u00fcne\u00a0\nAmpel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0mehr.\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0475\u00a0Abbildung\u00a05.1:\u00a0Verordnungspr\u00e4valenz\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0aus\u00a0de m\u00a0Jahr\u00a02014\u00a0\nohne\u00a0Zusatznutzen\u00a0(\u201erote\u00a0Ampel\u201c)\u00a0f\u00fcr\u00a0TK\u2010Versicherte\u00a0in\u00a0Promille \u00a0nach\u00a0Bundes\u2010\nl\u00e4ndern\u00a0(nur\u00a0Verordnungen\u00a0im\u00a0Jahr\u00a02015)\u00a0\n\u00a0\n\u00a0\n\u00a0 \u00a0\n476\u00a06 Biosimilars\u00a0in\u00a0der\u00a0Onkologie \u00a0\nDr.\u00a0Stanislava\u00a0Dicheva,\u00a0Prof.\u00a0Dr.\u00a0med.\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\nDefinition\u00a0\nBiologische\u00a0Arzneimittel\u00a0werden \u00a0in\u00a0lebenden\u00a0Zellen\u00a0oder\u00a0Organis men\u00a0mittels\u00a0bio\u2010\ntechnologischer\u00a0 Verfahren\u00a0 herges tellt.\u00a0 Ihre\u00a0 arzneilich\u00a0 wirksame n\u00a0 Bestandteile\u00a0\nweisen\u00a0sehr\u00a0komplexe\u00a0Molek\u00fclstrukturen\u00a0und\u00a0ein\u00a0gro\u00dfes\u00a0Molekular gewicht\u00a0auf.\u00a0\nTherapeutisch\u00a0werden\u00a0sie\u00a0als\u00a0Wachstumshormone,\u00a0Insuline,\u00a0Granul o\u2010\u00a0oder\u00a0Eryth\u2010\nropoese\u2010stimulierende\u00a0Wirkstoffe,\u00a0 Enzyme,\u00a0monoklonale\u00a0Antik\u00f6rpe r\u00a0(moAK)\u00a0sowie\u00a0\nBlutprodukte,\u00a0Sera\u00a0und\u00a0Impfstoffe \u00a0eingesetzt\u00a0(M\u00fcller\u2010Berghaus\u00a0e t\u00a0al.,\u00a02013).\u00a0\nBiotechnologisch\u00a0hergestellte\u00a0Ar zneimittel\u00a0werden\u00a0in\u00a0Europa\u00a0aus schlie\u00dflich\u00a0zentral\u00a0\nzugelassen.\u00a0Wenn\u00a0die\u00a0Patente\u00a0und\u00a0die\u00a0\u00fcbrigen\u00a0Schutzfristen\u00a0f\u00fcr\u00a0 die\u00a0pharmakolo\u2010\ngisch\u2010toxikologischen\u00a0und\u00a0klinischen\u00a0Daten\u00a0eines\u00a0biologischen\u00a0A rzneimittels\u00a0abge\u2010\nlaufen\u00a0sind,\u00a0k\u00f6nnen\u00a0andere\u00a0pharm azeutische\u00a0Unternehmer\u00a0(pU)\u00a0die \u00a0Zulassung\u00a0von\u00a0\nArzneimitteln\u00a0mit\u00a0einem\u00a0\u00e4hnlichen\u00a0arzneilich\u00a0wirksamen\u00a0Bestandt eil\u00a0beantragen.\u00a0\nAuf\u00a0Basis\u00a0des\u00a0Zulassungsantrags\u00a0wird\u00a0eine\u00a0wissenschaftliche\u00a0Bew ertung\u00a0des\u00a0Arz\u2010\nneimittels\u00a0durch\u00a0den\u00a0Ausschuss\u00a0f\u00fcr\u00a0Humanarzneimittel\u00a0( Committee\u00a0for\u00a0Medicinal\u00a0\nProducts\u00a0for\u00a0Human\u00a0Use ,\u00a0CHMP)\u00a0der\u00a0Europ\u00e4ischen\u00a0Arzneimittel\u2010Agentur\u00a0(EMA)\u00a0\nvorgenommen.\u00a0Im\u00a0Falle\u00a0eines\u00a0positiven\u00a0Votums\u00a0(sog.\u00a0 positive\u00a0opinion )\u00a0wird\u00a0die\u00a0\nZulassung\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0ausgesprochen.\u00a0Die\u00a0r elevanten\u00a0In\u2010\nformationen\u00a0zu\u00a0einer\u00a0Arzneimitte lzulassung\u00a0werden\u00a0anschlie\u00dfend\u00a0 in\u00a0einem\u00a0euro\u2010\np\u00e4ischen\u00a0 \u00f6ffentlichen\u00a0 Beurteilungsbericht\u00a0 ( Eu r o p e a n \u00a0P u b l i c\u00a0A s s e s s me n t \u00a0Re p or t ,\u00a0\nEPAR)\u00a0ver\u00f6ffentlicht\u00a0(BfArM,\u00a02013a).\u00a0\nDie\u00a0so\u00a0zugelassenen\u00a0Arzneimittel\u00a0sind\u00a0sog.\u00a0Biosimilars\u00a0(auch\u00a0bi osimilare\u00a0Arzneimit\u2010\ntel,\u00a0Follow\u2010on\u00a0Biologics ).\u00a0Sie\u00a0enthalten\u00a0nach\u00a0der\u00a0konsentierten\u00a0Definition\u00a0der\u00a0EMA\u00a0\neine\u00a0Version\u00a0des\u00a0Wirkstoffes\u00a0von\u00a0einem\u00a0bereits\u00a0in\u00a0der\u00a0EU\u00a0zugela ssenen\u00a0biologi\u2010\nschen\u00a0Arzneimittel\u00a0(sog .\u00a0Referenzarzneimittel),\u00a0bei\u00a0der\u00a0die\u00a0aus reichende\u00a0\u00c4hnlich\u2010\nkeit\u00a0(Biosimilarit\u00e4t)\u00a0mit\u00a0dem\u00a0Referenzarzneimittel\u00a0hinsichtlich \u00a0der\u00a0Qualit\u00e4t,\u00a0der\u00a0\nbiologischen\u00a0Aktivit\u00e4t,\u00a0der\u00a0Sich erheit\u00a0und\u00a0Wirksamkeit\u00a0anhand\u00a0e ines\u00a0umfassenden\u00a0\nZulassungsverfahrens\u00a0nachgewiesen\u00a0wurde\u00a0(EMA,\u00a02014).\u00a0\u00a0\nZugelassene\u00a0Biosimilars\u00a0\nBiosimilars\u00a0sind\u00a0seit\u00a0\u00fcber\u00a0zehn\u00a0Jahren\u00a0in\u00a0Europa\u00a0verf\u00fcgbar\u00a0und\u00a0 haben\u00a0in\u00a0diesem\u00a0\nZeitraum\u00a0zunehmend\u00a0an\u00a0Bedeutung\u00a0f\u00fcr\u00a0die\u00a0Arzneimitteltherapie\u00a0ge wonnen.\u00a0In\u00a0der\u00a0\nEU\u00a0wurden\u00a0bereits\u00a031\u00a0Biosimilars\u00a0zugelassen\u00a0(Stand:\u00a001.05.2017, \u00a0Quelle:\u00a0EMA,\u00a02017).\u00a0\u00a0\n\u00a0477\u00a0In\u00a0der\u00a0Onkologie\u00a0werden\u00a0zurzeit\u00a0insbesondere\u00a0Biosimilars\u00a0mit\u00a0de n\u00a0Wirkstoffen\u00a0Epoe\u2010\ntin\u00a0alfa/zeta\u00a0und\u00a0Filgrastim\u00a0angewendet\u00a0(Ludwig\u00a0&\u00a0Dicheva,\u00a02016 ).\u00a0Ende\u00a0Februar\u00a0\n2017\u00a0wurde\u00a0mit\u00a0Truxima\u00ae\u00a0(INN\u00a0Rituximab)\u00a0der\u00a0erste\u00a0monoklonale\u00a0A ntik\u00f6rper\u00a0in\u00a0einer\u00a0\nonkologischen\u00a0Indikation\u00a0als\u00a0Biosimilar\u00a0zugelassen\u00a0(Hudis\u00a02007; \u00a0EMA,\u00a02017).\u00a0In\u00a0Ta\u2010\nbelle\u00a06.1\u00a0sind\u00a0die\u00a0in\u00a0Europa\u00a0zugelassenen\u00a0Biosimilars\u00a0dargestel lt,\u00a0die\u00a0in\u00a0der\u00a0Onkologie\u00a0\nzur\u00a0Anwendung\u00a0kommen\u00a0(Stand:\u00a001.05.2017,\u00a0Quelle:\u00a0EMA,\u00a02017).\u00a0\u00a0\n\u00a0\nTabelle\u00a06.1:\u00a0Zugelassene\u00a0Biosimilars\u00a0mit\u00a0Anwendung\u00a0in\u00a0der\u00a0Onkol ogie\u00a0\nFertigarzneimittel\u00a0\n(pU\u00a0in\u00a0Deutschland)\u00a0INN\u00a0 Referenzarzneimittel\u00a0 Zulassung\u00a0\u00a0\nAbseamed\u00ae\u00a0\u00a0\n(Medice)\u00a0Epoetin\u00a0alfa\u00a0 Eprex\u00ae/Erypo\u00ae\u00a0 2007\u00a0\nBinocrit\u00ae\u00a0\u00a0\n(Sandoz)\u00a0Epoetin\u00a0alfa\u00a0 Eprex\u00ae/Erypo\u00ae\u00a0 2007\u00a0\nEpoetin\u00a0alfa\u00a0Hexal\u00ae\u00a0\u00a0\n(Hexal)\u00a0Epoetin\u00a0alfa\u00a0 Eprex\u00ae/Erypo\u00ae\u00a0 2007\u00a0\nRetacrit\u00ae\u00a0\u00a0\n(Pfizer\u00a0Pharma)\u00a0Epoetin\u00a0zeta\u00a0 Eprex\u00ae/Erypo\u00ae\u00a0 2007\u00a0\nSilapo\u00ae\u00a0\u00a0\n(Stada)\u00a0Epoetin\u00a0zeta\u00a0 Eprex\u00ae/Erypo\u00ae\u00a0 2007\u00a0\nTevagrastim\u00ae\u00a0\u00a0\n(Teva)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2008\u00a0\nRatiograstim\u00ae\u00a0\u00a0\n(Ratiopharm)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2008\u00a0\nFilgrastim\u00a0Hexal\u00ae\u00a0\u00a0\n(Hexal)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2009\u00a0\nZarzio\u00ae\u00a0\u00a0\n(Sandoz)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2009\u00a0\nNivestim\u00ae\u00a0\u00a0\n(Pfizer\u00a0Pharma)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2010\u00a0\nGrastofil\u00ae\u00a0\u00a0\n(Stada)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2013\u00a0\nAccofil\u00ae\u00a0\u00a0\n(Accord)\u00a0Filgrastim\u00a0 Neupogen\u00ae\u00a0 2014\u00a0\nTruxima\u00ae\u00a0\u00a0\n(Mundipharma)\u00a0Rituximab\u00a0 MabThera\u00ae\u00a0 2017\u00a0\n(Stand:\u00a001.05.2017,\u00a0Quelle:\u00a0EMA,\u00a02017,\u00a0pU\u00a0erg\u00e4nzt\u00a0durch\u00a0Lauer\u2010T axe)\u00a0\n\u00a0\u00a0478\u00a0Zulassung\u00a0\nDie\u00a0biotechnologische\u00a0Herstellung \u00a0bedingt\u00a0bei\u00a0allen\u00a0Biologika\u00a0e ine\u00a0gewisse\u00a0Variabi\u2010\nlit\u00e4t\u00a0(Mikroheterogenit\u00e4t)\u00a0zwischen\u00a0Produkten\u00a0aus\u00a0unterschiedli chen\u00a0Herstellungs\u2010\nverfahren,\u00a0aber\u00a0auch\u00a0zwischen\u00a0ve rschiedenen\u00a0Chargen\u00a0desselben\u00a0P roduktes\u00a0(Weise\u00a0\net\u00a0al.,\u00a02012).\u00a0Biosimilars\u00a0k\u00f6nne n\u00a0deswegen\u00a0mit\u00a0dem\u00a0Referenzarzn eimittel\u00a0strukturell\u00a0\nnicht\u00a0vollkommen\u00a0identisch\u00a0sein,\u00a0genauso\u00a0wie\u00a0auch\u00a0zwei\u00a0Chargen\u00a0 eines\u00a0Referenzarz\u2010\nneimittels\u00a0strukturell\u00a0nicht\u00a0vollkommen\u00a0identisch\u00a0sind.\u00a0Daher\u00a0m uss\u00a0bei\u00a0der\u00a0Zulassung\u00a0\nvon\u00a0Biosimilars\u00a0der\u00a0Nachweis\u00a0der\u00a0\u00c4hnlichkeit\u00a0des\u00a0Arzneimittels\u00a0 mit\u00a0einem\u00a0Refe\u2010\nrenzarzneimittel\u00a0erbracht\u00a0werden.\u00a0\u00a0\nDie\u00a0rechtliche\u00a0Basis\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0von\u00a0Biosimilars\u00a0sind\u00a0Art ikel\u00a010\u00a0Abs.\u00a04\u00a0der\u00a0\nRichtlinie\u00a02001/83/EC\u00a0und\u00a0die\u00a0Richtlinie\u00a02003/63/EC,\u00a0\u00a7\u00a04,\u00a0Teil\u00a0 II\u00a0des\u00a0Anhangs\u00a0I\u00a0\ndieser\u00a0Richtlinie.\u00a0F\u00fcr\u00a0die\u00a0Zulassung\u00a0sind\u00a0im\u00a0Gegensatz\u00a0zur\u00a0Zula ssung\u00a0von\u00a0Generika,\u00a0\nbei\u00a0der\u00a0der\u00a0Nachweis\u00a0der\u00a0Bio\u00e4qui valenz\u00a0ausreichend\u00a0ist,\u00a0ein\u00a0vol lst\u00e4ndiges\u00a0Dossier\u00a0\nzur\u00a0Qualit\u00e4t\u00a0des\u00a0Arzneimittels\u00a0e rforderlich,\u00a0ebenso\u00a0wie\u00a0pr\u00e4klin ische\u00a0(pharmakolo\u2010\ngisch\u2010toxikologische)\u00a0und\u00a0klinische\u00a0Studien\u00a0zur\u00a0klinischen\u00a0Wirk samkeit\u00a0und\u00a0Sicher\u2010\nheit\u00a0als\u00a0Beleg\u00a0der\u00a0Vergleichbark eit\u00a0mit\u00a0dem\u00a0Referenzarzneimitte l.\u00a0\u00a0\nF\u00fcr\u00a0Biosimilars\u00a0gelten\u00a0dieselben\u00a0strengen\u00a0Anforderungen\u00a0wie\u00a0f\u00fcr \u00a0jedes\u00a0neue\u00a0Biolo\u2010\ngikum.\u00a0F\u00fcr\u00a0ihre\u00a0Zulassung\u00a0durchla ufen\u00a0Biosimilars\u00a0ein\u00a0umfassend es,\u00a0ma\u00dfgeschnei\u2010\ndertes\u00a0(an\u00a0die\u00a0Komplexit\u00e4t\u00a0des\u00a0W irkstoffes\u00a0angepasstes)\u00a0Entwick lungs\u2010\u00a0und\u00a0Zulas\u2010\nsungsprogramm,\u00a0bei\u00a0dem\u00a0sie\u00a0hinsichtlich\u00a0der\u00a0Struktur,\u00a0der\u00a0biolo gischen\u00a0Funktiona\u2010\nlit\u00e4t,\u00a0der\u00a0Pharmakokinetik\u00a0und\u00a0\u2010dynamik\u00a0sowie\u00a0der\u00a0klinischen\u00a0Wi rksamkeit\u00a0und\u00a0\nSicherheit\u00a0einschlie\u00dflich\u00a0der\u00a0I mmunogenit\u00e4t\u00a0mit\u00a0dem\u00a0Referenzarz neimittel\u00a0vergli\u2010\nchen\u00a0werden.\u00a0Der\u00a0Vergleich\u00a0erfol gt\u00a0anhand\u00a0speziell\u00a0konzipierter \u00a0sensitiver\u00a0Test\u2010\u00a0\nund\u00a0Analysenverfahren,\u00a0um\u00a0insbesondere\u00a0die\u00a0krankheits\u2010\u00a0und\u00a0pati entenbedingte\u00a0\nVariabilit\u00e4t\u00a0zu\u00a0minimieren,\u00a0damit\u00a0arzneimittelbezogene\u00a0Untersch iede\u00a0zum\u00a0Refe\u2010\nrenzarzneimittel\u00a0erkannt\u00a0werden\u00a0k\u00f6nnen.\u00a0Die\u00a0Vergleichbarkeitsgr enzen\u00a0(\u00c4quiva\u2010\nlenzgrenzen)\u00a0werden\u00a0dabei\u00a0wirkstoffspezifisch\u00a0definiert,\u00a0so\u00a0das s\u00a0sie\u00a0den\u00a0gr\u00f6\u00dftm\u00f6g\u2010\nlichen\u00a0 Wirksamkeitsunterschied\u00a0 ohne\u00a0 klinische\u00a0 Relevanz\u00a0 ber\u00fccksi chtigen.\u00a0 Die\u00a0\nAminos\u00e4uresequenz\u00a0muss\u00a0beim\u00a0Biosi milar\u00a0die\u00a0gleiche\u00a0wie\u00a0beim\u00a0Ref erenzarzneimit\u2010\ntel\u00a0sein;\u00a0kleinere\u00a0(posttranslationale)\u00a0Modifikationen\u00a0werden\u00a0n ur\u00a0dann\u00a0akzeptiert,\u00a0\nwenn\u00a0sie\u00a0als\u00a0nicht\u2010klinisch\u2010relevant\u00a0bewertet\u00a0werden\u00a0k\u00f6nnen.\u00a0Da s\u00a0Ziel\u00a0der\u00a0zwin\u2010\ngend\u00a0erforderlichen\u00a0klinischen\u00a0Studien\u00a0ist\u00a0es\u00a0dabei\u00a0nicht\u00a0die\u00a0W irksamkeit\u00a0per\u00a0se\u00a0\noder\u00a0den\u00a0Nutzen\u00a0des\u00a0Biosimilars\u00a0f\u00fcr\u00a0 individuelle\u00a0Patienten\u00a0nach zuweisen.\u00a0Der\u00a0\nBeleg\u00a0daf\u00fcr\u00a0ist\u00a0bereits\u00a0mit\u00a0der\u00a0 Zulassung\u00a0des\u00a0Referenzarzneimit tels\u00a0erfolgt.\u00a0Statt\u2010\ndessen\u00a0dienen\u00a0diese\u00a0Studien\u00a0dazu,\u00a0klinisch\u00a0relevante\u00a0Unterschie de\u00a0hinsichtlich\u00a0der\u00a0\nSicherheit\u00a0und\u00a0Wirksamkeit\u00a0zwischen\u00a0dem\u00a0potentiellen\u00a0Biosimilar \u00a0und\u00a0dem\u00a0in\u00a0der\u00a0\nEU\u00a0zugelassenen\u00a0Referenzarzneimi ttel\u00a0erkennbar\u00a0zu\u00a0machen\u00a0bzw.\u00a0a uszuschlie\u00dfen.\u00a0\nDie\u00a0pharmazeutische\u00a0Darreichungsform,\u00a0die\u00a0Wirkst\u00e4rke\u00a0und\u00a0der\u00a0Da rreichungsweg\u00a0479\u00a0d\u00fcrfen\u00a0sich\u00a0nicht\u00a0unterscheiden\u00a0vom\u00a0Referenzarzneimittel\u00a0(Weise \u00a0et\u00a0al.,\u00a02012;\u00a0\nSchneider\u00a0&\u00a0Weise,\u00a02015;\u00a0McCamish\u00a0&\u00a0Woollett,\u00a02012).\u00a0\u00a0\nExtrapolation\u00a0\nWenn\u00a0bei\u00a0einem\u00a0potentiellen\u00a0Biosimilar\u00a0der\u00a0Nachweis\u00a0der\u00a0verglei chbaren\u00a0Wirk\u2010\nsamkeit\u00a0und\u00a0Sicherheit\u00a0mit\u00a0dem\u00a0Referenzarzneimittel\u00a0in\u00a0einer\u00a0de r\u00a0zugelassenen\u00a0\nIndikationen\u00a0erbracht\u00a0wurde,\u00a0verzichtet\u00a0die\u00a0EMA\u00a0auf\u00a0zus\u00e4tzliche \u00a0Studien\u00a0f\u00fcr\u00a0die\u00a0\nanderen\u00a0Indikationen\u00a0des\u00a0Referenzarzneimittels\u00a0(Weise\u00a0et\u00a0al.,\u00a02 014).\u00a0Dies\u00a0erfolgt\u00a0\nunter\u00a0der\u00a0Voraussetzung,\u00a0dass\u00a0kein e\u00a0klinisch\u00a0relevanten\u00a0Untersc hiede\u00a0bestehen,\u00a0\nweil\u00a0der\u00a0relevante\u00a0Wirkmechanismus\u00a0und/oder\u00a0die\u00a0in\u00a0den\u00a0extrapol ierten\u00a0Indikati\u2010\nonen\u00a0f\u00fcr\u00a0die\u00a0Wirksamkeit\u00a0verantwortlichen\u00a0Rezeptoren\u00a0die\u00a0gleich en\u00a0sind,\u00a0und\u00a0eine\u00a0\nwissenschaftliche\u00a0Begr\u00fcndung\u00a0vorgelegt\u00a0wird.\u00a0Wenn\u00a0der\u00a0Wirkmecha nismus\u00a0ein\u00a0\nanderer\u00a0oder\u00a0unbekannt\u00a0ist,\u00a0werden \u00a0weitere\u00a0Daten\u00a0verlangt,\u00a0beis pielweise\u00a0zu\u00a0den\u00a0\npharmakodynamischen\u00a0Parametern\u00a0und/oder\u00a0spezifische,\u00a0sensitive\u00a0 Funktionstests,\u00a0\ndie\u00a0die\u00a0jeweiligen\u00a0pharmakologischen\u00a0Wirkungen\u00a0widerspiegeln\u00a0(W eise\u00a0et\u00a0al.\u00a02014;\u00a0\nEbbers,\u00a02014).\u00a0\nDurch\u00a0eine\u00a0Extrapolation\u00a0der\u00a0Daten\u00a0von\u00a0einer\u00a0Indikation\u00a0auf\u00a0die \u00a0weiteren\u00a0Indikati\u2010\nonen\u00a0des\u00a0Referenzarzneimittels\u00a0k ann\u00a0die\u00a0Zulassung\u00a0des\u00a0Biosimila rs\u00a0f\u00fcr\u00a0alle\u00a0Indika\u2010\ntionen\u00a0erfolgen,\u00a0auch\u00a0wenn\u00a0f\u00fcr\u00a0di ese\u00a0keine\u00a0klinischen\u00a0Studien\u00a0m it\u00a0dem\u00a0Biosimilar\u00a0\ndurchgef\u00fchrt\u00a0wurden.\u00a0Bei\u00a0der\u00a0Extrapolation\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0e in\u00a0etabliertes\u00a0\nwissenschaftliches,\u00a0im\u00a0Rahmen\u00a0der \u00a0Arzneimittelzulassung\u00a0akzepti ertes\u00a0Konzept.\u00a0\nDieses\u00a0wird\u00a0seit\u00a0Jahren\u00a0auch\u00a0bei \u00a0patentgesch\u00fctzten\u00a0Biologika\u00a0na ch\u00a0einer\u00a0\u00c4nderung\u00a0\ndes\u00a0Herstellungsprozesses\u00a0oder\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulassung\u00a0einer\u00a0ne uen\u00a0Darreichungs\u2010\nform\u00a0angewendet.\u00a0Biologika,\u00a0so\u00a0auch\u00a0Biosimilars,\u00a0kommen\u00a0bereits \u00a0sehr\u00a0lange\u00a0zur\u00a0\nAnwendung\u00a0in\u00a0extrapolierten\u00a0Indikationen,\u00a0ohne\u00a0dass\u00a0sich\u00a0dadurc h\u00a0relevante\u00a0Nach\u2010\nteile\u00a0hinsichtlich\u00a0Wirksamkeit\u00a0oder\u00a0Sicherheit\u00a0in\u00a0diesen\u00a0Indika tionen\u00a0gezeigt\u00a0h\u00e4tten\u00a0\n(Weise\u00a0&\u00a0Wolff\u2010Holz,\u00a02016).\u00a0\u00a0\nSicherheit\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0Zulassung\u00a0wird\u00a0die\u00a0Sicherheit\u00a0potentieller\u00a0Biosim ilars\u00a0im\u00a0Vergleich\u00a0\nzum\u00a0 Referenzarzneimittel\u00a0 untersucht.\u00a0 Zu\u00a0 den\u00a0 wichtigsten\u00a0 Sicherh eitsaspekten\u00a0\ngeh\u00f6ren\u00a0die\u00a0H\u00e4ufigkeit\u00a0von\u00a0(schweren)\u00a0therapiebedingten\u00a0unerw\u00fcn schten\u00a0Ereig\u2010\nnissen\u00a0sowie\u00a0die\u00a0Immunogenit\u00e4t\u00a0der\u00a0Biosimilars.\u00a0Um\u00a0die\u00a0 Langzeit sicherheit\u00a0zu\u00a0\nbest\u00e4tigen,\u00a0sind\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0eines\u00a0Biosimilars\u00a0\u2013\u00a0wie\u00a0auch \u00a0bei\u00a0allen\u00a0neuen\u00a0\nArzneimitteln\u00a0\u2013\u00a0Studien\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung\u00a0( Post\u2010Authorisation\u00a0Safety\u00a0Study ,\u00a0\nPASS)\u00a0ebenso\u00a0wie\u00a0eine\u00a0weitere\u00a0 Risikobewertung\u00a0anhand\u00a0eines\u00a0 Risk\u00a0Management\u00a0\nPlan\u00a0(RMP)\u00a0vorgeschrieben.\u00a0Alle\u00a0Biosimilars,\u00a0die\u00a0seit\u00a02013\u00a0zugelass en\u00a0wurden,\u00a0stehen\u00a0\nunter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung\u00a0und\u00a0werden\u00a0in\u00a0den\u00a0EU\u2010Mitgliedsta aten\u00a0mit\u00a0einem\u00a0\nschwarzen,\u00a0auf\u00a0dem\u00a0Kopf\u00a0stehenden\u00a0Dreieck\u00a0gekennzeichnet\u00a0(BfArM ,\u00a02013b).\u00a0Gene\u2010480\u00a0rell\u00a0sch\u00e4tzen\u00a0Experten\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0neue,\u00a0unbekannte\u00a0(schwere )\u00a0Nebenwirkungen\u00a0\nbei\u00a0Biosimilars\u00a0nach\u00a0der\u00a0Zulassung\u00a0als\u00a0sehr\u00a0viel\u00a0geringer\u00a0ein\u00a0a ls\u00a0bei\u00a0neuen\u00a0Biologika\u00a0\n(Weise\u00a0et\u00a0al.,\u00a02012).\u00a0\nAlle\u00a0Biologika\u00a0bergen\u00a0aufgrund\u00a0ihrer\u00a0Gr\u00f6\u00dfe\u00a0und\u00a0molekularen\u00a0Komp lexit\u00e4t\u00a0generell\u00a0\nein\u00a0immunogenes\u00a0Potenzial.\u00a0Verschiedene\u00a0Faktoren\u00a0des\u00a0Patienten, \u00a0wie\u00a0u.a.\u00a0die\u00a0\nindividuelle\u00a0Immunantwort,\u00a0der\u00a0Allgemeinzustand,\u00a0Begleiterkrank ungen\u00a0und\u00a0Be\u2010\ngleittherapie\u00a0(z.B.\u00a0Immunsuppre ssiva),\u00a0beeinflussen\u00a0die\u00a0Immunog enit\u00e4t,\u00a0die\u00a0nat\u00fcr\u2010\nlich\u00a0auch\u00a0durch\u00a0die\u00a0Erkrankung\u00a0(z.B.\u00a0Krankheitsstadium)\u00a0und\u00a0das \u00a0Arzneimittel\u00a0(z.B.\u00a0\ngalenische\u00a0Formulierung,\u00a0Darrei chungsweg,\u00a0Dosis)\u00a0bestimmt\u00a0wird\u00a0 (Weise\u00a0et\u00a0al.,\u00a0\n2012;\u00a0Chamberlain,\u00a02013;\u00a0Schellekens,\u00a02004).\u00a0\u00a0\nZur\u00a0Evaluation\u00a0der\u00a0Immunogenit\u00e4t\u00a0von\u00a0Biologika\u00a0wird\u00a0das\u00a0Auftret en\u00a0von\u00a0Antik\u00f6rpern\u00a0\ngegen\u00a0den\u00a0Wirkstoff\u00a0( Anti\u2010Drug\u00a0Antibodies ,\u00a0ADA)\u00a0detektiert.\u00a0Diese\u00a0Antik\u00f6rper\u00a0k\u00f6n\u2010\nnen\u00a0schwache\u00a0Immunreaktionen\u00a0ohne\u00a0negative\u00a0Auswirkungen\u00a0auf\u00a0den \u00a0Patienten\u00a0\nausl\u00f6sen,\u00a0aber\u00a0auch\u00a0durch\u00a0Ver\u00e4nderungen\u00a0der\u00a0Pharmakokinetik\u00a0und \u00a0Toxizit\u00e4t\u00a0die\u00a0\nWirksamkeit\u00a0und\u00a0Sicherheit\u00a0der\u00a0Biologika\u00a0beeintr\u00e4chtigen.\u00a0Neutr alisierende\u00a0Antik\u00f6r\u2010\nper,\u00a0die\u00a0am\u00a0endogenen\u00a0Liganden\u00a0bzw.\u00a0den\u00a0endogenen\u00a0Konterpart\u00a0de s\u00a0therapeuti\u2010\nschen\u00a0Proteins\u00a0binden,\u00a0k\u00f6nnen\u00a0auch\u00a0schwere\u00a0Reaktionen\u00a0hervorruf en\u00a0(Kessler\u00a0et\u00a0al.,\u00a0\n2006;\u00a0Ebbers\u00a0et\u00a0al.,\u00a02012).\u00a0Ein\u00a0besonders\u00a0bekanntes\u00a0Beispiel\u00a0da f\u00fcr\u00a0ist\u00a0die\u00a0\u201ePure\u00a0Red\u2010\nCell\u00a0Aplasia\u201c\u00a0nach\u00a0subkutaner\u00a0Gabe\u00a0von\u00a0Epoetin\u00a0alfa\u00a0(Eprex\u00ae/Ery po\u00ae).\u00a0Bei\u00a0diesem\u00a0\nOriginatorarzneimittel\u00a0traten\u00a0nac h\u00a0einer\u00a0\u00c4nderung\u00a0der\u00a0Rezeptur\u00a0 und\u00a0der\u00a0Applikati\u2010\nonsvorrichtung\u00a0neutralisierende\u00a0 Antik\u00f6rper\u00a0gegen\u00a0Erythropoetin\u00a0 bei\u00a0Patienten\u00a0mit\u00a0\nchronischer\u00a0Niereninsuffizienz\u00a0a uf\u00a0(Bennett,\u00a02004).\u00a0Um\u00a0eine\u00a0Erh \u00f6hung\u00a0der\u00a0Immuno\u2010\ngenit\u00e4t\u00a0 bei\u00a0 einem\u00a0 potentiellen\u00a0 Biosimilar\u00a0 im\u00a0 Vergleich\u00a0 zum\u00a0 Refe renzarzneimittel\u00a0\nauszuschlie\u00dfen,\u00a0wird\u00a0im\u00a0Rahmen\u00a0d er\u00a0Zulassung\u00a0das\u00a0Auftreten\u00a0solc her\u00a0Antik\u00f6rper\u00a0\nuntersucht\u00a0(EMA,\u00a02014).\u00a0\u00a0\nBiosimilars\u00a0in\u00a0der\u00a0Onkologie\u00a0\nBiologika\u00a0werden\u00a0bereits\u00a0seit\u00a0de n\u00a01990er\u00a0Jahren\u00a0in\u00a0der\u00a0Onkologi e\u00a0eingesetzt.\u00a0Ins\u2010\nbesondere\u00a0die\u00a0monoklonalen\u00a0Anti k\u00f6rper\u00a0(moAk)\u00a0\u2013\u00a0eine\u00a0Untergruppe \u00a0von\u00a0Biologika\u00a0\n\u2013\u00a0haben\u00a0in\u00a0Kombination\u00a0mit\u00a0Zytos tatika\u00a0die\u00a0Therapieergebnisse\u00a0s owohl\u00a0bei\u00a0h\u00e4ma\u2010\ntologischen\u00a0Systemerkrankungen\u00a0( z.B.\u00a0Rituximab\u00a0bei\u00a0malignen\u00a0Lym phomen)\u00a0als\u00a0\na u c h \u00a0b e i \u00a0s o l i d e n \u00a0T u m o r e n \u00a0( z . B . \u00a0T r a s t u z u m a b \u00a0b e i m \u00a0M a m m a k a r z i n o m ) \u00a0 deutlich\u00a0\nverbessert\u00a0(Dobbelste in\u00a0&\u00a0Moll,\u00a02014).\u00a0\u00a0\nBiosimilars\u00a0mit\u00a0den\u00a0Wirkstoffen\u00a0Epoetin\u00a0und\u00a0Filgrastim\u00a0sind\u00a0in\u00a0 den\u00a0letzten\u00a0Jahren\u00a0\nimmer\u00a0wichtiger\u00a0f\u00fcr\u00a0die\u00a0Arzneimitteltherapie\u00a0in\u00a0der\u00a0Onkologie\u00a0g eworden.\u00a0Zwischen\u2010\nzeitlich\u00a0sind\u00a0die\u00a0Patente\u00a0f\u00fcr\u00a0za hlreiche\u00a0Biologika\u00a0mit\u00a0moAk\u00a0abg elaufen\u00a0und\u00a0weitere\u00a0\nwerden\u00a0folgen.\u00a0Dazu\u00a0geh\u00f6ren\u00a0unter\u00a0anderem\u00a0Rituximab\u00a0(MabThera\u00ae) ,\u00a0Cetuximab\u00a0\n(Erbitux\u00ae),\u00a0Trastuzumab\u00a0(Herceptin\u00ae),\u00a0Panitumumab\u00a0(Vectibix\u00ae),\u00a0 Ipilimumab\u00a0(Yer\u2010481\u00a0voy\u00ae),\u00a0Bevacizumab\u00a0(Avastin\u00ae),\u00a0Darbepoetin\u00a0alfa\u00a0(Aranesp\u00ae)\u00a0und\u00a0 Pegfilgrastim\u00a0(Neu\u2010\nlasta\u00ae)\u00a0(GaBI,\u00a02015).\u00a0\u00a0\nIm\u00a0Mai\u00a02017\u00a0befanden\u00a0sich\u00a0zahlreiche\u00a0potentielle\u00a0Biosimilars,\u00a0d ie\u00a0in\u00a0onkologischen\u00a0\nIndikationen\u00a0zugelassen\u00a0werden\u00a0sollen,\u00a0wie\u00a0u.\u00a0a.\u00a0Rituximab,\u00a0Bev acizumab,\u00a0Trastu\u2010\nzumab,\u00a0Darbepoetin\u00a0alfa\u00a0und\u00a0Pegfilgrastim,\u00a0bereits\u00a0in\u00a0der\u00a0Phase \u00a0III\u00a0der\u00a0klinischen\u00a0\nPr\u00fcfung,\u00a0so\u00a0dass\u00a0in\u00a0naher\u00a0Zukunft\u00a0mit\u00a0weiteren\u00a0Zulassungen\u00a0von\u00a0 Biosimilars\u00a0zu\u00a0\nrechnen\u00a0ist\u00a0(Tabelle\u00a06.2).\u00a0\u00a0\nRituximab\u00a0\nRituximab\u00a0ist\u00a0ein\u00a0gentechnisch\u00a0hergestellter,\u00a0chim\u00e4rer\u00a0(Maus/Me nsch)\u00a0moAk\u00a0der\u00a0\nIgG1\u2010\u03ba\u00a0Subklasse.\u00a0Er\u00a0richtet\u00a0sich\u00a0spezifisch\u00a0gegen\u00a0das\u00a0B\u2010Zell\u2010A ntigen\u00a0CD20.\u00a0Es\u00a0bin\u2010\ndet\u00a0 an\u00a0 CD20\u2010exprimierende\u00a0 B\u2010Zellen,\u00a0 einschlie\u00dflich\u00a0 maligner\u00a0 Zel len,\u00a0 und\u00a0 f\u00fchrt\u00a0\ndurch\u00a0die\u00a0Aktivierung\u00a0des\u00a0menschlichen\u00a0Immunsystems\u00a0zur\u00a0B\u2010Zell\u2010 Lyse,\u00a0die\u00a0durch\u00a0\nKomplement\u2010abh\u00e4ngige\u00a0Zytotoxizi t\u00e4t\u00a0und\u00a0Antik\u00f6rper\u2010abh\u00e4ngige\u00a0zel lul\u00e4re\u00a0Zytotoxi\u2010\nzit\u00e4t\u00a0vermittelt\u00a0wird.\u00a0Rituximab\u00a0weist\u00a0auch\u00a0eine\u00a0immunsuppressi ve\u00a0Wirkung\u00a0auf\u00a0\nund\u00a0wird\u00a0als\u00a0ein\u00a0sog.\u00a0antirheumatisches\u00a0Basistherapeutikum\u00a0( Disease\u00a0Modifying\u00a0\nAntirheumatic\u00a0Drugs ,\u00a0DMARD)\u00a0eingesetzt\u00a0(Fachinf ormation\u00a0MabThera\u00ae,\u00a02016).\u00a0\nRituximab\u00a0(MabThera\u00ae)\u00a0ist\u00a0in\u00a0Europa\u00a0seit\u00a01998\u00a0zur\u00a0Behandlung\u00a0vo n\u00a0Non\u2010Hodgkin\u2010\nLymphomen\u00a0 (NHL)H\u00a0 der\u00a0 B\u2010Zell\u00a0 Reihe,\u00a0 einschlie\u00dflich\u00a0 der\u00a0 chronisch en\u00a0 lymphati\u2010\nschen\u00a0Leuk\u00e4mie,\u00a0zugelassen.\u00a02006\u00a0erfolgte\u00a0die\u00a0Zulassungserweite rung\u00a0zur\u00a0Behand\u2010\nlung\u00a0von\u00a0schwerer,\u00a0aktiver\u00a0Rheumatoider\u00a0Arthritis\u00a0(RA),\u00a0die\u00a0ung en\u00fcgend\u00a0auf\u00a0andere\u00a0\nDMARD,\u00a0einschlie\u00dflich\u00a0einer\u00a0oder\u00a0mehrerer\u00a0Therapien\u00a0mit\u00a0Tumorne krosefaktor\u2010\u03b1\u2010\nHemmern,\u00a0angesprochen\u00a0oder\u00a0diese\u00a0nicht\u00a0vertragen\u00a0haben,\u00a0und\u00a0von \u00a0Granulomatose\u00a0\nmit\u00a0Polyangiitis\u00a0(Wegenersche\u00a0Gr anulomatose)\u00a0sowie\u00a0der\u00a0mikrosko pischen\u00a0Polyangii\u2010\ntis\u00a0(Fachinformation\u00a0MabThera\u00ae,\u00a02016).\u00a0\nErste\u00a0sog.\u00a0Biokopien\u00a0(auch\u00a0 Biogenerics ,\u00a0Similar\u00a0Biologics)\u00a0zu\u00a0Rituximab\u00a0(z.B.\u00a0Reditux\u00ae\u00a0\nvom\u00a0pU\u00a0Dr.\u00a0Reddy\u2018s\u00a0in\u00a0Indien)\u00a0werden\u00a0seit\u00a0Jahren,\u00a0u.a.\u00a0in\u00a0Indie n,\u00a0S\u00fcdamerika\u00a0und\u00a0\nRussland\u00a0vertrieben.\u00a0Solche\u00a0Arzneimittel\u00a0wurden\u00a0jedoch\u00a0nicht\u00a0na ch\u00a0den\u00a0in\u00a0der\u00a0EU\u00a0f\u00fcr\u00a0\nBiosimilars\u00a0geltenden\u00a0strengen\u00a0wissenschaftlichen\u00a0Standards\u00a0zug elassen\u00a0(EMA,\u00a02017;\u00a0\nQureshi\u00a0et\u00a0al.,\u00a02013).\u00a0\u00a0\nIm\u00a0Februar\u00a02017\u00a0wurde\u00a0das\u00a0erste\u00a0Biosimilar\u00a0mit\u00a0Rituximab\u00a0(Truxi ma\u00ae,\u00a0Celltrion;\u00a0\nReferenzarzneimittel:\u00a0MabThera\u00ae)\u00a0in\u00a0der\u00a0EU\u00a0zugelassen.\u00a0Die\u00a0Zula ssung\u00a0erfolgte\u00a0f\u00fcr\u00a0\nalle\u00a0Anwendungsgebiete\u00a0des\u00a0Refer enzarzneimittels\u00a0(EMA,\u00a02017).\u00a0Z u\u00a0f\u00fcnf\u00a0weiteren\u00a0\nBiosimilars\u00a0mit\u00a0Rituximab\u00a0(Blitzima\u00ae,\u00a0Ritemvia\u00ae,\u00a0Tuxella\u00ae,\u00a0Rixa thon\u00ae,\u00a0Riximyo\u00ae)\u00a0\nbesteht\u00a0eine\u00a0positive\u00a0Empfehlung \u00a0zur\u00a0Zulassung\u00a0des\u00a0CHMP,\u00a0so\u00a0das s\u00a0sie\u00a0demn\u00e4chst\u00a0\nzugelassen\u00a0werden\u00a0(EMA,\u00a0n.d.).\u00a0482\u00a0F\u00fcr\u00a0die\u00a0Zulassung\u00a0von\u00a0Truxima\u00ae\u00a0legte\u00a0der\u00a0pharmazeutische\u00a0Untern ehmer\u00a0eine\u00a0rand\u2010\nomisierte,\u00a0 kontrollierte,\u00a0 doppelblinde\u00a0 Phase\u2010I\u2010Studie\u00a0 vor\u00a0 im\u00a0 Ve rgleich\u00a0 zum\u00a0 Refe\u2010\nrenzarzneimittel\u00a0 MabThera\u00ae\u00a0 in\u00a0 der\u00a0 Kombinationstherapie\u00a0 mit\u00a0 Meth otrexat\u00a0 und\u00a0\nFols\u00e4ure\u00a0bei\u00a0154\u00a0Patienten\u00a0mit\u00a0RA.\u00a0In\u00a0dieser\u00a0wurden\u00a0die\u00a0Wirksam keitsendpunkte,\u00a0die\u00a0\ndefiniert\u00a0waren\u00a0als\u00a0die\u00a0die\u00a020%ige/50%ige\u00a0bzw.\u00a070%ige\u00a0Besserung \u00a0nach\u00a0den\u00a0Kriterien\u00a0\ndes\u00a0American\u00a0 College\u00a0 of\u00a0 Rheumatology \u00a0 (ACR20\u2010,\u00a0 ACR50\u2010\u00a0 und\u00a0 ARC70\u2010Response\u2010\nRaten)\u00a0sowie\u00a0die\u00a0Zeit\u00a0bis\u00a0zum\u00a0ACR20\u2010Ansprechen,\u00a0die\u00a0\u00c4nderung\u00a0de r\u00a0Krankheitsaktivi\u2010\nt\u00e4t\u00a0(gemessen\u00a0mit\u00a0dem\u00a0 Disease\u00a0Activity\u00a0Score \u00a0(DAS28)),\u00a0die\u00a0Rate\u00a0der\u00a0Patienten\u00a0mit\u00a0\ngutem\u00a0Ansprechen\u00a0nach\u00a0den\u00a0sog.\u00a0EULAR\u2010Kriterien,\u00a0der\u00a0 Simplified\u00a0Disease\u00a0Activity\u00a0\nIndex\u00a0(SDAI)\u00a0sowie\u00a0der\u00a0 Clinical\u00a0Disease\u00a0Activity\u00a0Index \u00a0(CDAI),\u00a0unter\u00a0dem\u00a0potentiellen\u00a0\nBiosimilar\u00a0und\u00a0dem\u00a0Referenzarzneimittel\u00a0gleich\u00a0h\u00e4ufig\u00a0erreicht. \u00a0Auch\u00a0die\u00a0Rate\u00a0der\u00a0\nunerw\u00fcnschten\u00a0Arzneimittelereignisse\u00a0(UAE)\u00a0war\u00a0\u00e4hnlich.\u00a0F\u00fcr\u00a0die \u00a0Beurteilung\u00a0der\u00a0\nklinischen\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0wurden\u00a0zwei\u00a0weitere\u00a0klini sche\u00a0Studien\u00a0be\u2010\nr\u00fccksichtigt:\u00a0eine\u00a0einarmige\u00a0offene\u00a0Studie\u00a0bei\u00a087\u00a0Patienten\u00a0mit \u00a0RA,\u00a0die\u00a0auch\u00a0eine\u00a0\nUmstellung\u00a0 vom\u00a0 Referenzarzneimittel\u00a0 auf\u00a0 das\u00a0 Biosimilar\u00a0 beinhalt ete,\u00a0 sowie\u00a0 eine\u00a0\nrandomisierte,\u00a0kontrollierte,\u00a0doppelblinde\u00a0Phase\u2010III\u2010Studie\u00a0im\u00a0 Vergleich\u00a0mit\u00a0Rituxan\u00ae\u00a0\nund\u00a0MabThera \u00ae\u00a0hinsichtlich\u00a0der\u00a0Pharmakokinetik,\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0b ei\u00a0\n372\u00a0Patienten\u00a0mit\u00a0RA.\u00a0Auch\u00a0in\u00a0di esen\u00a0Studien\u00a0zeigten\u00a0sich\u00a0keine \u00a0relevanten\u00a0Unter\u2010\nschiede\u00a0zwischen\u00a0den\u00a0einzelnen \u00a0Therapiearmen\u00a0(EMA,\u00a02017).\u00a0\nWeiterhin\u00a0wurde\u00a0eine\u00a0randomisi erte,\u00a0kontrollier te,\u00a0doppelblinde \u00a0Phase\u2010I/III\u2010Studie\u00a0\nmit\u00a0121\u00a0unbehandelten\u00a0Patienten\u00a0mit\u00a0CD20\u2010positivem\u00a0follikul\u00e4rem \u00a0Lymphom\u00a0(FL)\u00a0\nim\u00a0Stadium\u00a0III\u2010IV\u00a0im\u00a0Vergleich\u00a0zu\u00a0Rituxan\u00ae\u00a0in\u00a0Kombination\u00a0mit\u00a0C yclophosphamid,\u00a0\nVincristin\u00a0und\u00a0Prednison\u00a0durchgef\u00fchrt.\u00a0Der\u00a0prim\u00e4re\u00a0Wirksamkeits endpunkt\u00a0\u2013\u00a0das\u00a0\nGesamtansprechen\u00a0( Overall\u00a0Response\u00a0Rate ,\u00a0ORR)\u00a0\u2013\u00a0war\u00a0in\u00a0beiden\u00a0Armen\u00a0nach\u00a024\u00a0\nWochen\u00a0vergleichbar:\u00a097,0\u00a0%\u00a0im\u00a0Biosimilar\u2010Arm\u00a0vs.\u00a092,6\u00a0%\u00a0im\u00a0Rit uxan\u00ae\u2010Arm\u00a0( Per\u2010\nprotocol\u2010Auswertung).\u00a0Auch\u00a0unerw\u00fcnschte\u00a0Ereignisse,\u00a0wie\u00a0Infektionen\u00a0und \u00a0infusi\u2010\nonsbedingte\u00a0Reaktionen,\u00a0traten\u00a0\u00e4 hnlich\u00a0h\u00e4ufig\u00a0auf\u00a0(EMA,\u00a02017).\u00a0 \u00a0\nDerzeit\u00a0befinden\u00a0sich\u00a0sieben\u00a0potenzielle\u00a0Biosimilars\u00a0mit\u00a0Rituxi mab\u00a0bereits\u00a0in\u00a0der\u00a0\nPhase\u00a0 III\u00a0 der\u00a0 klinischen\u00a0 Pr\u00fcfung\u00a0 (ClinicalTrials,\u00a0 2016).\u00a0 RTXM83 \u00a0(M abx i en c e)\u00a0w i rd \u00a0\naktuell\u00a0in\u00a0den\u00a0Indikationen\u00a0diff us\u00a0gro\u00dfzelliges\u00a0B\u2010Zell\u2010Lymphom\u00a0 (DLBCL)\u00a0und\u00a0anderen\u00a0\nNon\u2010Hodgkin\u2010Lymphomen\u00a0 (NHL)\u00a0 in\u00a0 Phase\u2010III\u2010Studien\u00a0 untersucht.\u00a0 Mi t\u00a0 GP2013\u00a0\n(Sponsor:\u00a0Sandoz)\u00a0wurden\u00a0bereits\u00a0zwei\u00a0Studien\u00a0bei\u00a0RA\u00a0abgeschlos sen,\u00a0von\u00a0denen\u00a0\neine\u00a0als\u00a0Switch\u2010Studie\u00a0(Phase\u00a0III)\u00a0von\u00a0MabThera\u00ae\u00a0oder\u00a0Rituxan\u00ae\u00a0(ASSIST\u2010RT)\u00a0auf \u00a0das\u00a0\nBiosimilar\u00a0konzipiert\u00a0war.\u00a0Eine\u00a0 weitere\u00a0Studie\u00a0in\u00a0der\u00a0Indikatio n\u00a0FL\u00a0zeigte\u00a0bei\u00a0629\u00a0\nPatienten\u00a0vergleichbare\u00a0ORR\u00a0(87,1\u00a0%\u00a0vs.\u00a087,5\u00a0%)\u00a0(Kim\u00a0et\u00a0al.,\u00a020 17).\u00a0Pfizer\u00a0schloss\u00a0mit\u00a0\nPF\u201005280586\u00a0eine\u00a0Studie\u00a0bei\u00a0RA\u00a0bereits\u00a02016\u00a0ab,\u00a0die\u00a0einen\u00a0 Switch\u00a0von\u00a0den\u00a0Refe\u2010\nrenzarzneimitteln\u00a0auf\u00a0das\u00a0Biosimi lar\u00a0beinhaltete,\u00a0und\u00a0f\u00fchrt\u00a0mom entan\u00a0eine\u00a0Phase\u2010III\u2010\nStudie\u00a0in\u00a0der\u00a0Indikation\u00a0FL\u00a0durch.\u00a0Die\u00a0Phase\u2010III\u2010Studien\u00a0mit\u00a0BC D\u2010020\u00a0(Biocad)\u00a0und\u00a0\nBI695500\u00a0(Boehringer\u00a0Ingelheim)\u00a0bei\u00a0RA\u00a0wurden\u00a0auch\u00a0bereits\u00a0abge schlossen,\u00a0w\u00e4h\u2010483\u00a0rend\u00a0Amgen\u00a0mit\u00a0ABP\u00a0798\u00a0momentan\u00a0noch\u00a0Phase\u2010III\u2010Studien\u00a0bei\u00a0RA\u00a0u nd\u00a0FL\u00a0durch\u2010\nf\u00fchrt\u00a0(ClinicalTrials,\u00a020 16;\u00a0Kim\u00a0et\u00a0al.,\u00a02017).\u00a0\nTrastuzumab\u00a0\nTrastuzumab\u00a0ist\u00a0ein\u00a0rekombinanter,\u00a0humanisierter\u00a0IgG \u2081\u2010\u03ba\u00a0moAk.\u00a0Er\u00a0bindet\u00a0mit\u00a0hoher\u00a0\nAffinit\u00e4t\u00a0und\u00a0Spezifit\u00e4t\u00a0an\u00a0die\u00a0 extrazellul\u00e4re\u00a0Dom\u00e4ne\u00a0des\u00a0human en\u00a0epidermalen\u00a0\nWachstumsfaktor\u2010Rezeptors\u00a0vom\u00a0Typ\u00a02\u00a0(HER2),\u00a0der\u00a0ma\u00dfgeblich\u00a0am\u00a0T umorwachstum\u00a0\nbeteiligt\u00a0ist.\u00a0Dadurch\u00a0werden\u00a0das\u00a0Liganden\u2010unabh\u00e4ngige\u00a0HER2\u2010Sig nal\u00a0und\u00a0die\u00a0proteo\u2010\nlytische\u00a0 Spaltung\u00a0 dieser\u00a0 extrazellul\u00e4ren\u00a0 Dom\u00e4ne\u00a0 inhibiert\u00a0 und\u00a0 d ie\u00a0 Proliferation\u00a0\nmenschlicher\u00a0Tumorzellen,\u00a0die\u00a0HER2\u00a0verst\u00e4rkt\u00a0exprimieren,\u00a0gehem mt.\u00a0Trastuzumab\u00a0\nwirkt\u00a0zus\u00e4tzlich\u00a0\u00fcber\u00a0eine\u00a0Antik\u00f6rper\u2010abh\u00e4ngige\u00a0zellvermittelte \u00a0Zytotoxizit\u00e4t.\u00a0Eine\u00a0\n\u00dcberexpression\u00a0von\u00a0HER2\u00a0kommt\u00a0h\u00e4ufig\u00a0insbesondere\u00a0bei\u00a0Mammakarz inomen,\u00a0aber\u00a0\nauch\u00a0bei\u00a0Magenkarzinomen\u00a0vor\u00a0(Fachinformation\u00a0Herceptin\u00ae,\u00a02016) .\u00a0\nTrastuzumab\u00a0(Herceptin\u00ae)\u00a0wurde\u00a0in\u00a0Europa\u00a0im\u00a0Jahr\u00a02000\u00a0zur\u00a0Thera pie\u00a0von\u00a0Patientin\u2010\nnen\u00a0 mit\u00a0 HER2\u2010positivem\u00a0 metastasiertem\u00a0 Mammakarzinom\u00a0 und\u00a0 HER2\u2010po sitivem\u00a0\nMammakarzinom\u00a0im\u00a0Fr\u00fchstadium\u00a0sowie\u00a0mit\u00a0HER2\u2010positivem\u00a0metastasi ertem\u00a0Ma\u2010\ngenkarzinom\u00a0zugelassen\u00a0(Fachinformation\u00a0Herceptin\u00ae,\u00a02016).\u00a0Der\u00a0 Patentschutz\u00a0ist\u00a0in\u00a0\nEuropa\u00a0bereits\u00a02015\u00a0abgelaufen.\u00a0Momentan\u00a0befinden\u00a0sich\u00a0sieben\u00a0p otentielle\u00a0Biosi\u2010\nmilars\u00a0in\u00a0der\u00a0Phase\u00a0III\u00a0der\u00a0klinischen\u00a0Pr\u00fcfung\u00a0(Tabelle\u00a06.2)\u00a0(C linicalTrials,\u00a02016).\u00a0\n2014\u00a0wurde\u00a0in\u00a0S\u00fcdkorea\u00a0ein\u00a0Biosimilar\u00a0mit\u00a0Trastuzumab\u00a0zugelasse n,\u00a0nachdem\u00a0\nbereits\u00a02013\u00a0eine\u00a0Biokopie\u00a0in\u00a0Indien\u00a0auf\u00a0den\u00a0Markt\u00a0gebracht\u00a0wur de\u00a0(Cortes\u00a0et\u00a0al.,\u00a0\n2014).\u00a0F\u00fcr\u00a0SB3\u00a0(Samsung\u00a0Bioepis),\u00a0CT\u2010P6\u00a0und\u00a0Myl\u00a01401O\u00a0(Mylan)\u00a0w urde\u00a0Ende\u00a02016\u00a0\ndie\u00a0Zulassung\u00a0bei\u00a0der\u00a0EMA\u00a0beantragt\u00a0(Rugo\u00a0et\u00a0al.,\u00a02017).\u00a0Mit\u00a0My l\u00a01401O\u00a0wurde\u00a0\nbereits\u00a0eine\u00a0randomisierte,\u00a0kontrollierte,\u00a0doppelblinde\u00a0Phase\u2010I II\u2010Studie\u00a0bei\u00a0458\u00a0\nFrauen\u00a0mit\u00a0metastasiertem\u00a0Mammakarzinom\u00a0abgeschlossen\u00a0(Rugo\u00a0et\u00a0 al.,\u00a02017).\u00a0\nDer\u00a0 prim\u00e4re\u00a0 Wirksamkeitsendpunkt\u00a0 ORR\u00a0 war\u00a0 in\u00a0 beiden\u00a0 Armen\u00a0 vergle ichbar:\u00a0\n69,6\u00a0%\u00a0(95\u00a0%\u00a0KI,\u00a063,6\u00a0%\u00a0\u2013\u00a075,5\u00a0%)\u00a0im\u00a0Biosimilar\u2010Arm\u00a0vs.\u00a064,0\u00a0%\u00a0 (95\u00a0%\u00a0KI,\u00a057,8\u00a0%\u00a0\u2013\u00a0\n70,2\u00a0%)\u00a0im\u00a0Herceptin\u00ae\u2010Arm.\u00a0Die\u00a0Differenz\u00a0zwischen\u00a0beiden\u00a0Armen\u00a0 hinsichtlich\u00a0ORR\u00a0\nbetrug\u00a05,5\u00a0(95\u00a0%\u00a0KI,\u00a0\u20103,08\u00a0\u2013\u00a014,04)\u00a0und\u00a0lag\u00a0innerhalb\u00a0der\u00a0pr\u00e4de finierten\u00a0\u00c4quiva\u2010\nlenzgrenzen.\u00a0Das\u00a0progressionsfreie\u00a0\u00dcberleben\u00a0( Progression\u2010free\u00a0Survival ,\u00a0PFS)\u00a0und\u00a0\ndas\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0waren\u00a0auch\u00a0vergleichbar\u00a0und\u00a0ohne\u00a0\nsignifikante\u00a0Unterschiede\u00a0zwischen\u00a0beiden\u00a0Therapiearmen.\u00a0Mindes tens\u00a0ein\u00a0uner\u2010\nw\u00fcnschtes\u00a0Arzneimittelereignis\u00a0(UAE)\u00a0w\u00e4hrend\u00a0der\u00a0Therapie\u00a0erlit ten\u00a098,6\u00a0%\u00a0der\u00a0\nPatientinnen\u00a0im\u00a0Biosimilar\u2010Arm\u00a0und\u00a094,7\u00a0%\u00a0der\u00a0Patientinnen\u00a0im\u00a0H erceptin\u00ae\u2010Arm;\u00a0\nam\u00a0h\u00e4ufigsten\u00a0traten\u00a0Neutropenien\u00a0(57,5\u00a0%\u00a0vs.\u00a053,3\u00a0%),\u00a0peripher e\u00a0Neuropathien\u00a0\n(23,1\u00a0%\u00a0vs.\u00a024,8\u00a0%)\u00a0und\u00a0Diarrhoen\u00a0 (20,6\u00a0%\u00a0vs.\u00a020,7\u00a0%)\u00a0auf\u00a0(Rugo \u00a0et\u00a0al.,\u00a02017).\u00a0\nMit\u00a0CT\u2010P6\u00a0(Celltrion)\u00a0laufen\u00a0noch\u00a0Phase\u2010III\u2010Studien\u00a0zur\u00a0neoadju vanten\u00a0Therapie\u00a0des\u00a0\nMammakarzinoms\u00a0und\u00a0sowie\u00a0zur\u00a0Therapie\u00a0des\u00a0metastasierten\u00a0Mammak arzinoms.\u00a0484\u00a0Die\u00a0Studie\u00a0mit\u00a0SB3\u00a0(Samsung\u00a0Bioepis)\u00a0zur\u00a0neoadjuvanten\u00a0Therapie \u00a0des\u00a0Mamma\u2010\nkarzinoms\u00a0ist\u00a0abgeschlossen,\u00a0aber\u00a0noch\u00a0nicht\u00a0ver\u00f6ffentlicht.\u00a0Pf izer\u00a0hat\u00a0zwei\u00a0Phase\u2010\nIII\u2010Studien\u00a0mit\u00a0PF\u201005280014\u00a0zur\u00a0neoadjuvanten\u00a0Therapie\u00a0des\u00a0Mamm akarzinoms\u00a0in\u00a0\nKombination\u00a0mit\u00a0Docetaxel\u00a0und\u00a0Ca rboplatin\u00a0und\u00a0bei\u00a0metastasierte m\u00a0Mammakar\u2010\nzinom\u00a0in\u00a0Kombination\u00a0mit\u00a0Paclitaxel\u00a0bereits\u00a0abgeschlossen,\u00a0aber \u00a0noch\u00a0nicht\u00a0publi\u2010\nziert\u00a0(Kim\u00a0et\u00a0al.,\u00a02017).\u00a0Eine\u00a0w eitere\u00a0Phase\u2010III\u2010Studie\u00a0in\u00a0der\u00a0 Erstlinien\u2010Therapie\u00a0des\u00a0\nmetastasierten\u00a0Mammakarzinoms\u00a0in\u00a0Kombination\u00a0 mit\u00a0Paclitaxel\u00a0 l\u00e4u ft\u00a0 noch\u00a0bis\u00a0\n2019.\u00a0Auch\u00a0die\u00a0Phase\u2010III\u2010Studie\u00a0mit\u00a0ABP\u00a0980\u00a0(Amgen)\u00a0zur\u00a0neoadju vanten\u00a0Therapie\u00a0\ndes\u00a0 fr\u00fchen\u00a0 Mammakarzinoms\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 Paclitaxel\u00a0 ist\u00a0 abg eschlossen\u00a0\n(Amgen,\u00a02016).\u00a0\nBevacizumab\u00a0\nBevacizumab\u00a0ist\u00a0ein\u00a0rekombinanter,\u00a0humanisierter\u00a0IgG \u2081\u2010\u03ba\u00a0moAk\u00a0und\u00a0bindet\u00a0selek\u2010\ntiv\u00a0an\u00a0den\u00a0humanen\u00a0vaskul\u00e4ren\u00a0endothelialen\u00a0Wachstumsfaktor\u00a0(VE GF).\u00a0Durch\u00a0die\u00a0\nHemmung\u00a0der\u00a0biologischen\u00a0Aktivit\u00e4 t\u00a0von\u00a0VEGF\u00a0soll\u00a0die\u00a0Angiogenes e\u00a0von\u00a0Tumoren\u00a0\ngehemmt\u00a0und\u00a0das\u00a0Tumorwachstum\u00a0sowie\u00a0die\u00a0Metastasierung\u00a0gestoppt \u00a0werden\u00a0\n(Fachinformation\u00a0Avastin\u00ae,\u00a02017).\u00a0\nBevacizumab\u00a0(Avastin\u00ae)\u00a0wurde\u00a02005\u00a0in\u00a0Europa\u00a0zugelassen.\u00a0Er\u00a0wird \u00a0eingesetzt\u00a0zur\u00a0\nBehandlung\u00a0von\u00a0erwachsenen\u00a0Patien ten\u00a0mit\u00a0metastasiertem\u00a0Kolon\u2010\u00a0 oder\u00a0Rektum\u2010\nkarzinom,\u00a0mit\u00a0metastasiertem\u00a0Ma mmakarzinom,\u00a0mit\u00a0inoperablem\u00a0for tgeschritte\u2010\nnen,\u00a0metastasierten\u00a0oder\u00a0rezidiv ierenden\u00a0nicht\u2010kleinzelligen\u00a0Br onchialkarzinom,\u00a0\nmit\u00a0fortgeschrittenem\u00a0und/oder\u00a0metastasierten\u00a0Nierenzellkarzino m,\u00a0mit\u00a0epithelia\u2010\nlem\u00a0Ovarialkarzinom,\u00a0Eileiterkarzinom\u00a0oder\u00a0prim\u00e4ren\u00a0Peritonealk arzinom\u00a0und\u00a0mit\u00a0\npersistierendem,\u00a0rezidivierenden \u00a0oder\u00a0metastasierten\u00a0Zervixkarz inom\u00a0(Fachinfor\u2010\nmation\u00a0Avastin\u00ae,\u00a02017).\u00a0\n2013\u00a0erhielt\u00a0ein\u00a0Bevacizumab\u2010Pr\u00e4parat\u00a0eine\u00a0Zulassung\u00a0als\u00a0Biokop ie\u00a0in\u00a0Indien\u00a0und\u00a0\nwurde\u00a0im\u00a0Juni\u00a02016\u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt\u00a0(Bennett\u00a0et\u00a0al.,\u00a0201 4).\u00a0Ende\u00a02016\u00a0\nbeantragte\u00a0Amgen\u00a0die\u00a0Zulassung\u00a0von\u00a0ABP\u00a0215\u00a0als\u00a0Biosimilar\u00a0in\u00a0Eu ropa\u00a0und\u00a0den\u00a0\nUSA,\u00a0nachdem\u00a0die\u00a0Phase\u2010III\u2010Studie\u00a0 bei\u00a0NSCLC\u00a0im\u00a0Vergleich\u00a0zu\u00a0Ava stin\u00ae\u00a0in\u00a0Kombina\u2010\ntion\u00a0mit\u00a0Carboplatin\u00a0und\u00a0Paclitaxel\u00a0abgeschlossen\u00a0wurde\u00a0und\u00a0ver gleichbare\u00a0Ergeb\u2010\nnisse\u00a0hinsichtlich\u00a0der\u00a0Wirksamkeit\u00a0(prim\u00e4rer\u00a0Endpunkt:\u00a0ORR)\u00a0und \u00a0Sicherheit\u00a0ge\u2010\nzeigt\u00a0hatten\u00a0(Kim\u00a0et\u00a0al.,\u00a02017).\u00a0F\u00fcr\u00a0die\u00a0Pr\u00fcfung\u00a0von\u00a0BI695502\u00a0r ekrutiert\u00a0Boehringer\u00a0\nIngelheim\u00a0momentan\u00a0Patienten\u00a0in\u00a0den\u00a0Indikationen\u00a0CRC\u00a0und\u00a0NSCLC. \u00a0SB8\u00a0von\u00a0Sam\u2010\nsung\u00a0Bioepis\u00a0und\u00a0PF\u201006439535\u00a0von\u00a0Pfizer\u00a0werden\u00a0in\u00a0laufenden\u00a0Pha se\u2010III\u2010Studien\u00a0\nbeim\u00a0metastasierten\u00a0NSCLC\u00a0gepr \u00fcft\u00a0(ClinicalTrials,\u00a02016).\u00a0\n\u00a0\n\u00a0485\u00a0Weitere\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0\nCetuximab\u00a0(Erbitux\u00ae)\u00a0ist\u00a0ein\u00a0chim\u00e4rer\u00a0(Maus/Mensch)\u00a0IgG1\u2010moAk,\u00a0 der\u00a0spezifisch\u00a0\ngegen\u00a0den\u00a0humanen\u00a0epidermalen\u00a0Wachstumsfaktor\u2010Rezeptor\u00a0vom\u00a0Typ\u00a0 1\u00a0(EGFR\u00a0\noder\u00a0HER1)\u00a0gerichtet\u00a0ist.\u00a0Durch\u00a0die\u00a0Hemmung\u00a0der\u00a0EGFR\u2010Signalwege \u00a0werden\u00a0die\u00a0\nFunktionen\u00a0in\u00a0der\u00a0Steuerung\u00a0der\u00a0\u00dcberlebensf\u00e4higkeit\u00a0von\u00a0Zellen, \u00a0des\u00a0Ablaufs\u00a0des\u00a0\nZellzyklus,\u00a0der\u00a0Angiogenese,\u00a0der\u00a0Zellmigration\u00a0sowie\u00a0der\u00a0zellul \u00e4ren\u00a0Invasion\u00a0bzw.\u00a0\nMetastasierung\u00a0gehemmt\u00a0(Fachinformation\u00a0Erbitux\u00ae,\u00a02014).\u00a0\u00a0\nCetuximab\u00a0ist\u00a0zugelassen\u00a0zur\u00a0Be handlung\u00a0des\u00a0metastasierten,\u00a0EGF R\u00a0(epidermalen\u00a0\nWachstumsfaktor\u2010Rezeptor)\u00a0exprim ierenden\u00a0Kolorektalkarzinoms\u00a0mi t\u00a0Ras\u2010Wildtyp\u00a0\nund\u00a0von\u00a0Patienten\u00a0mit\u00a0Plattenepithelkarzinom\u00a0im\u00a0Kopf\u2010\u00a0und\u00a0Halsb ereich.\u00a0Die\u00a0Zu\u2010\nlassung\u00a0erfolgte\u00a0in\u00a0Europa\u00a0im\u00a0Jahr\u00a02004;\u00a0der\u00a0Patentschutz\u00a0soll\u00a0 bereits\u00a0im\u00a0Juni\u00a02014\u00a0\nabgelaufen\u00a0 sein\u00a0 (Fachinformation\u00a0 Erbitux\u00ae,\u00a0 2014).\u00a0 Es\u00a0 konnten\u00a0 al lerdings\u00a0 keine\u00a0\nDaten\u00a0zur\u00a0Entwicklung\u00a0und\u00a0Pr\u00fcfung\u00a0von\u00a0Biosimilars\u00a0mit\u00a0Cetuximab \u00a0gefunden\u00a0wer\u2010\nden\u00a0(Tabelle\u00a06.2).\u00a0Es\u00a0fand\u00a0sich\u00a0lediglich\u00a0ein\u00a0Hinweis\u00a0im\u00a0Biosim ilar\u2010Portfolio\u00a0des\u00a0pU\u00a0\nAMGEN,\u00a0dass\u00a0ABP\u00a0494\u00a0als\u00a0Biosimilar\u00a0mit\u00a0Cetuximab\u00a0entwickelt\u00a0wir d\u00a0(AMGEN,\u00a0\n2017).\u00a0\nPanitumumab\u00a0 (Vectibix\u00ae)\u00a0 ist\u00a0 ein\u00a0 humaner,\u00a0 monoklonaler\u00a0 IgG \u2082\u2010 m o A k , \u00a0d e r \u00a0w i e \u00a0\nCetuximab\u00a0spezifisch\u00a0gegen\u00a0den\u00a0humanen\u00a0epidermalen\u00a0Wachstumsfak tor\u2010Rezep\u2010\ntor\u00a0vom\u00a0Typ\u00a01\u00a0(EGFR\u00a0oder\u00a0HER1)\u00a0gerichtet\u00a0ist.\u00a0Panitumumab\u00a0ist\u00a0s eit\u00a02007\u00a0in\u00a0Europa\u00a0\nverf\u00fcgbar\u00a0und\u00a0zur\u00a0Behandlung\u00a0von\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0meta stasiertem\u00a0\nkolorektalem\u00a0 Karzinom\u00a0 (mCRC,\u00a0 metastatic\u00a0 Colorectal\u00a0 Cancer )\u00a0 mit\u00a0 RAS\u2010Wildtyp\u00a0\nindiziert\u00a0(Amgen,\u00a02016).\u00a0Der\u00a0Patentschutz\u00a0soll\u00a02018\u00a0ablaufen.\u00a0A uch\u00a0bei\u00a0diesem\u00a0\nWirkstoff\u00a0finden\u00a0sich\u00a0derzeit\u00a0noch\u00a0keine\u00a0Hinweise\u00a0auf\u00a0die\u00a0Entwi cklung\u00a0von\u00a0Biosimi\u2010\nlars\u00a0(Tabelle\u00a06.2)\u00a0(ClinicalTrials,\u00a02016).\u00a0\nIpilimumab\u00a0(Yervoy\u00ae)\u00a0ist\u00a0ein\u00a0human er,\u00a0IgG1\u2010moAk,\u00a0der\u00a0gegen\u00a0CTLA \u20104\u00a0(zytotoxisches\u00a0\nT\u2010Lymphozyten\u2010assoziiertes\u00a0Antig en\u20104)\u00a0auf\u00a0der\u00a0Oberfl\u00e4che\u00a0von\u00a0T\u2010 Lymphozyten\u00a0ge\u2010\nrichtet\u00a0ist.\u00a0Die\u00a0Hemmung\u00a0der\u00a0Aktivierung\u00a0der\u00a0T\u2010Zellen\u00a0durch\u00a0CTL A\u20104\u00a0wird\u00a0mit\u00a0der\u00a0\nBindung\u00a0von\u00a0Ipilimumab\u00a0an\u00a0dieses\u00a0Antigen\u00a0aufgehoben\u00a0und\u00a0die\u00a0geg en\u00a0die\u00a0Krebszel\u2010\nlen\u00a0gerichtete\u00a0Immunantwort\u00a0verst\u00e4rkt.\u00a0Ipilimumab\u00a0wurde\u00a02011\u00a0zu r\u00a0Behandlung\u00a0von\u00a0\nfortgeschrittenen\u00a0 (nicht\u2010resezierbaren\u00a0 oder\u00a0 metastasierten)\u00a0 Mel anomen\u00a0 bei\u00a0 Er\u2010\nwachsenen\u00a0zugelassen\u00a0(Fachinformation\u00a0Yervoy\u00ae,\u00a02016).\u00a0Der\u00a0Paten tschutz\u00a0soll\u00a02021\u00a0\nablaufen\u00a0(Tabelle\u00a06.2)\u00a0(ClinicalTrials,\u00a02016).\u00a0\nDarbepoetin\u00a0alfa\u00a0\nDarbepoetin\u00a0alfa\u00a0ist\u00a0ein\u00a0gentechnisch\u00a0hergestelltes\u00a0humanes\u00a0Ery thropoetin,\u00a0das\u00a0die\u00a0\nErythropoese\u00a0durch\u00a0denselben\u00a0Mechanismus\u00a0wie\u00a0das\u00a0endogene\u00a0Hormo n\u00a0stimuliert.\u00a0\nEs\u00a0tr\u00e4gt\u00a0aber\u00a0f\u00fcnf\u00a0Stickstoff\u2010gebundene\u00a0Kohlenhydratketten,\u00a0w\u00e4h rend\u00a0das\u00a0endogene\u00a0486\u00a0Hormon\u00a0und\u00a0die\u00a0rekombinanten\u00a0humanen\u00a0Erythropoetine\u00a0nur\u00a0drei\u00a0so lche\u00a0Ketten\u00a0\nhaben.\u00a0Dadurch\u00a0wird\u00a0der\u00a0enzymatische\u00a0Abbau\u00a0des\u00a0Molek\u00fcls\u00a0verlang samt\u00a0und\u00a0eine\u00a0\nl\u00e4ngere\u00a0terminale\u00a0Halbwertszeit\u00a0erzielt\u00a0(Fachinformation\u00a0Aranes p\u00ae,\u00a02015).\u00a0\nDarbepoetin\u00a0alfa\u00a0(Aranesp\u00ae)\u00a0wurde\u00a02001\u00a0zugelassen\u00a0zur\u00a0Behandlun g\u00a0der\u00a0sympto\u2010\nmatischen\u00a0An\u00e4mie\u00a0bei\u00a0chronischer \u00a0Niereninsuffizienz\u00a0bei\u00a0erwachs enen\u00a0und\u00a0p\u00e4diat\u2010\nrischen\u00a0Patienten\u00a0und\u00a0der\u00a0symptoma tischen\u00a0An\u00e4mie\u00a0bei\u00a0erwachsene n\u00a0Tumorpati\u2010\nenten\u00a0 mit\u00a0 nicht\u2010myeloischen\u00a0 malignen\u00a0 Erkrankungen,\u00a0 die\u00a0 eine\u00a0 Che motherapie\u00a0\nerhalten.\u00a0Der\u00a0Patentschutz\u00a0ist\u00a02016\u00a0abgelaufen.\u00a0Zwei\u00a0potentiell e\u00a0Biosimilars,\u00a0BCD\u2010\n066\u00a0von\u00a0Biocad\u00a0und\u00a0JR\u2010131\u00a0von\u00a0Kissei\u00a0Pharmaceutical\u00a0haben\u00a0berei ts\u00a0in\u00a0Phase\u2010I\u2010\nStudien\u00a0 ihre\u00a0 Vergleichbarkeit\u00a0 mit\u00a0 Aranesp\u00ae\u00a0 hinsichtlich\u00a0 der\u00a0 Pha rmakokinetik,\u00a0\nPharmakodynamik\u00a0und\u00a0Sicherheit\u00a0bei\u00a0gesunden\u00a0Probanden\u00a0nachgewie sen\u00a0und\u00a0bis\u00a0\nEnde\u00a02017\u00a0sollen\u00a0auch\u00a0die\u00a0Phase\u2010III\u2010Studien\u00a0bei\u00a0Patienten\u00a0mit\u00a0A n\u00e4mie\u00a0aufgrund\u00a0\nchronischer\u00a0Niereninsuffizienz\u00a0abgeschlossen\u00a0sein\u00a0(ClinicalTria ls,\u00a02016).\u00a0\nPegfilgrastim\u00a0\nPegfilgrastim\u00a0entspricht\u00a0in\u00a0seiner\u00a0Aminos\u00e4urensequenz\u00a0Filgrasti m.\u00a0Es\u00a0ist\u00a0ein\u00a0gen\u2010\ntechnisch\u00a0hergestelltes,\u00a0kovalentes\u00a0Konjugat\u00a0von\u00a0Filgrastim\u00a0mit \u00a0einem\u00a0Polyethyl\u2010\nenglycol\u2010Molek\u00fcl\u00a0und\u00a0weist\u00a0daher\u00a0aufgrund\u00a0der\u00a0verminderten\u00a0rena len\u00a0Clearance\u00a0\neine\u00a0verl\u00e4ngerte\u00a0Verweildauer\u00a0im\u00a0 menschlichen\u00a0K\u00f6rper\u00a0im\u00a0Verglei ch\u00a0zu\u00a0Filgrastim\u00a0\nauf.\u00a0Seine\u00a0Wirkung\u00a0entspricht\u00a0dem\u00a0humanen\u00a0Granulozyten\u2010Kolonie\u2010 stimulierenden\u00a0\nFaktor\u00a0(G\u2010CSF)\u00a0und\u00a0f\u00f6rdert\u00a0die\u00a0Reifung\u00a0sowie\u00a0Differenzierung\u00a0vo n\u00a0Vorl\u00e4uferzellen\u00a0\nder\u00a0Granulopoese\u00a0zu\u00a0neutrophilen \u00a0Granulozyten\u00a0bzw.\u00a0deren\u00a0erh\u00f6ht e\u00a0Freisetzungs\u2010\nrate\u00a0aus\u00a0dem\u00a0Knochenmark\u00a0(Fa chinformation\u00a0Neulasta\u00ae).\u00a0\nPegfilgrastim\u00a0(Neulasta\u00ae)\u00a0wurde\u00a02002\u00a0zugelassen\u00a0zur\u00a0Verk\u00fcrzung\u00a0 der\u00a0Dauer\u00a0von\u00a0\nNeutropenien\u00a0sowie\u00a0zur\u00a0Verminder ung\u00a0der\u00a0H\u00e4ufigkeit\u00a0neutropenisc hen\u00a0Fiebers\u00a0bei\u00a0\nerwachsenen\u00a0Patienten,\u00a0die\u00a0wegen \u00a0einer\u00a0malignen\u00a0Erkrankung\u00a0mit\u00a0 zytotoxischer\u00a0\nChemotherapie\u00a0 behandelt\u00a0 werden.\u00a0 Der\u00a0 Patentschutz\u00a0 soll\u00a0 2017\u00a0 abla ufen.\u00a0 Zwei\u00a0\npotentielle\u00a0Biosimilars,\u00a0LA\u2010EP2006\u00a0von\u00a0Sandoz\u00a0und\u00a0MYL\u20101401H\u00a0von \u00a0Mylan,\u00a0werden\u00a0\nbereits\u00a0entwickelt\u00a0(ClinicalTr ials,\u00a02016).\u00a0 LA\u2010EP2006\u00a0von\u00a0Sandoz \u00a0wurde\u00a0in\u00a0einer\u00a0\nrandomisierten,\u00a0doppelblinden\u00a0Ph ase\u2010III\u2010Studie\u00a0(PROTECT\u20101)\u00a0bei\u00a0 316\u00a0Patientinnen\u00a0\nmit\u00a0Brustkrebs\u00a0und\u00a0myelosuppressiver\u00a0Chemotherapie\u00a0mit\u00a0Docetaxe l,\u00a0Doxorubicin\u00a0\nund\u00a0Cyclophosphamid\u00a0im\u00a0Vergleich\u00a0zu\u00a0Neulasta\u00ae\u00a0untersucht\u00a0(Harbe ck\u00a0et\u00a0al.,\u00a02016).\u00a0\nDer\u00a0prim\u00e4re\u00a0Wirksamkeitsendpunkt,\u00a0die\u00a0Dauer\u00a0der\u00a0schweren\u00a0Neutro penien\u00a0(mit\u00a0\neiner\u00a0Neutrophilenzahl\u00a0\u2264\u00a0500\u00a0Zellen/\u00b5l),\u00a0war\u00a0in\u00a0beiden\u00a0Armen\u00a0ve rgleichbar:\u00a00,75\u00a0\nTage\u00a0(Standardabweichung:\u00a0\u00b1\u00a00,88\u00a0Tage)\u00a0unter\u00a0LA\u2010EP2006\u00a0und\u00a00,83 \u00a0Tage\u00a0(\u00b1\u00a00.90\u00a0\nTage)\u00a0unter\u00a0Neulasta\u00ae.\u00a0Die\u00a0Differenz\u00a0in\u00a0der\u00a0Wirksamkeit\u00a0betrug\u00a0 0,07\u00a0Tage\u00a0(90\u00a0%\u00a0KI\u00a0\n(\u20100,09\u20130,23);\u00a095\u00a0%\u00a0KI\u00a0(\u20100,12\u20130,26)\u00a0und\u00a0beide\u00a0Konfidenzintervall e\u00a0lagen\u00a0innerhalb\u00a0\nder\u00a0pr\u00e4definierten\u00a0\u00c4quivalenzgren zen\u00a0von\u00a0\u00b1\u00a01\u00a0Tag.\u00a0Mindestens\u00a0ei ne\u00a0UAE\u00a0erlitten\u00a0\n88,1\u00a0%\u00a0der\u00a0Patientinnen\u00a0im\u00a0Biosimilar\u2010Arm\u00a0und\u00a082,8\u00a0%\u00a0der\u00a0Patien tinnen\u00a0im\u00a0Neulas\u2010487\u00a0ta\u00ae\u2010Arm\u00a0w\u00e4hrend\u00a0der\u00a0Therapie;\u00a0Art\u00a0und\u00a0die\u00a0H\u00e4ufigkeit\u00a0der\u00a0UAE\u00a0wa ren\u00a0in\u00a0beiden\u00a0\nv e r g l e i c h b a r . \u00a0D i e \u00a0h \u00e4 u f i g s t e n \u00a0U A E \u00a0w a r e n \u00a0A l o p e z i e \u00a0( 5 1 , 6 \u00a0 % \u00a0v s . \u00a05 0 , 3\u00a0%),\u00a0 Nausea\u00a0\n(40,9\u00a0%\u00a0vs.\u00a037,6\u00a0%),\u00a0Asthenie\u00a0(39,6\u00a0%\u00a0vs.\u00a035,7\u00a0%),\u00a0Erbrechen\u00a0(2 1,4\u00a0%\u00a0vs.\u00a021,7\u00a0%)\u00a0und\u00a0\nNeutropenie\u00a0(17,0\u00a0%\u00a0vs.\u00a021,7\u00a0%).\u00a042\u00a0Patienten\u00a0hatten\u00a0insgesamt\u00a0 UE,\u00a0die\u00a0auf\u00a0Pegfil\u2010\ngrastim\u00a0zur\u00fcckzuf\u00fchren\u00a0waren:\u00a019\u00a0(11,9\u00a0%)\u00a0unter\u00a0dem\u00a0Biosimilar\u00a0 und\u00a023\u00a0(14,6\u00a0%)\u00a0\nunter\u00a0Neulasta\u00ae.\u00a0Schwere\u00a0UAE,\u00a0die\u00a0bei\u00a0mindestens\u00a02\u00a0%\u00a0der\u00a0Patien ten\u00a0auftraten,\u00a0\nwaren\u00a0febrile\u00a0Neutropenien\u00a0(5,7\u00a0%\u00a0im\u00a0Biosimilar\u2010Arm\u00a0vs.\u00a07,6\u00a0%\u00a0i m\u00a0Neulasta\u00ae\u2010Arm)\u00a0\nund\u00a0Neutropenien\u00a0(1,9\u00a0%\u00a0im\u00a0Biosimilar\u2010Arm\u00a0vs.\u00a03,8\u00a0%\u00a0im\u00a0Neulasta \u00ae\u2010Arm).\u00a0Diese\u00a0UE\u00a0\nwaren\u00a0bei\u00a0drei\u00a0Patienten\u00a0(1,9\u00a0%)\u00a0bzw.\u00a0bei\u00a0zwei\u00a0Patienten\u00a0(1,3\u00a0% )\u00a0im\u00a0Biosimilar\u2010Arm\u00a0\nund\u00a0bei\u00a0keinem\u00a0Patienten\u00a0im\u00a0Neulasta\u00ae\u2010Arm\u00a0mit\u00a0der\u00a0Gabe\u00a0von\u00a0Pegf ilgrastim\u00a0kausal\u00a0\nverbunden\u00a0(Harbeck\u00a0et\u00a0al.,\u00a02016).\u00a0MYL\u20101401H\u00a0hat\u00a0bereits\u00a0in\u00a0Phas e\u2010I\u2010Studie\u00a0die\u00a0\nVergleichbarkeit\u00a0mit\u00a0Neulasta\u00ae\u00a0hinsichtlich\u00a0der\u00a0Pharmakokinetik ,\u00a0Pharmakodyna\u2010\nmik\u00a0und\u00a0Sicherheit\u00a0bei\u00a0gesunden\u00a0Probanden\u00a0demonstriert.\u00a0Auch\u00a0ei ne\u00a0randomisier\u2010\nte,\u00a0kontrollierte,\u00a0doppelblinde\u00a0 Phase\u2010II/III\u2010Studie\u00a0bei\u00a0Patient innen\u00a0mit\u00a0Brustkrebs\u00a0\nund\u00a0neoadjuvanter\u00a0oder\u00a0adjuvanter\u00a0 Chemotherapie\u00a0zum\u00a0Vergleich\u00a0v on\u00a0MYL\u20101401H\u00a0\nmit\u00a0Neulasta\u00ae\u00a0ist\u00a02016\u00a0abgeschlossen\u00a0worden.\u00a0Die\u00a0Ergebnisse\u00a0die ser\u00a0Studie\u00a0wur\u2010\nden\u00a0aber\u00a0noch\u00a0nicht\u00a0publiziert\u00a0(Clinical\u00a0Trials,\u00a02016a).\u00a0\n\u00a0\u00a0488\u00a0Tabelle\u00a06.2:\u00a0Onkologische\u00a0Biosimilars\u00a0in\u00a0der\u00a0Pipeline  \nWirkstoff\u00a0 Referenz\u2010\narzneimittel\u00a0Patentablauf\u00a0\nEuropa\u00a0Potentielle\u00a0Biosimilars\u00a0(pU)*\u00a0\nMonoklonale  Antik\u00f6rper\u00a0zur\u00a0Anwendung\u00a0in\u00a0der\u00a0Onkologie\u00a0\nRituximab  MabThera\u00ae\u00a0 Nov\u00a02013\u00a0RTXM83\u00a0(Mabxience)\u00a0\nGP2013\u00a0(Sandoz)\u00a0\nHLX01\u00a0(Shanghai\u00a0Henlius\u00a0Biotech)\u00a0PF\u201005280586\u00a0(Pfizer)\u00a0\nBCD\u2010020\u00a0(Biocad)\u00a0\nBI695500\u00a0(Boehringer\u00a0Ingelheim)\u00a0\nABP\u00a0798\u00a0(Amgen)\u00a0\nTrastuzumab\u00a0 Herceptin\u00ae\u00a0Aug\u00a02015\u00a0\n(UK:\u00a0Jul\u00a02014)\u00a0SB3\u00a0(Samsung\u00a0Bioepis)\u00a0\nBCD\u2010022\u00a0(Biocad)\u00a0\nCT\u2010P6\u00a0(Celltrion)\u00a0 \u00a0\nPF\u201005280014\u00a0(Pfizer)\u00a0\nABP\u00a0980\u00a0(Amgen)\u00a0\nHercules/Myl\u00a01401O\u00a0(Mylan)\u00a0\nHLX02\u00a0(Shanghai\u00a0Henlius\u00a0Biotech)\u00a0\nBevacizumab\u00a0 Avastin\u00ae\u00a0 Jan\u00a02022\u00a0BI695502\u00a0(Boehringer\u00a0Ingelheim)\u00a0\u00a0\nSB8\u00a0(Samsung\u00a0Bioepis)\u00a0\nPF\u201006439535\u00a0(Pfizer)\u00a0\nBCD\u2010021\u00a0(Biocad)\u00a0\nABP\u00a0215\u00a0(Amgen)\u00a0\nFKB238\u00a0(Centus\u00a0Biotherapeutics\u00a0Ltd)\u00a0\nPanitumumab\u00a0 Vectibix\u00ae\u00a0 2018\u00a0 k.\u00a0D.\u00a0\nIpilimumab\u00a0 Yervoy\u00ae\u00a0 2021\u00a0 k.\u00a0D.\u00a0\nCetuximab\u00a0 Erbitux\u00ae\u00a0 Jun\u00a02014\u00a0 k.\u00a0D.\u00a0\nAndere\u00a0\nDarbepoetin\u00a0alfa\u00a0 Aranesp\u00ae\u00a0 Jul\u00a02016\u00a0BCD\u2010066\u00a0(Biocad)\u00a0\nJR\u2010131\u00a0(Kissei\u00a0Pharmaceutical)\u00a0\nPegfilgrastim\u00a0 Neulasta\u00ae\u00a0 Aug\u00a02017\u00a0LA\u2010EP2006\u00a0(Sandoz)\u00a0\nMYL\u20101401H\u00a0(Mylan)\u00a0\n*In\u00a0Phase\u00a0III\u00a0der\u00a0klinischen\u00a0Pr\u00fc fung;\u00a0Stand:\u00a001.05.2017;\u00a0k.D.:\u00a0 keine\u00a0Daten\u00a0(GaBI,\u00a02015;\u00a0ClinicalTrials.gov,\u00a02016)\u00a0\nBedenken\u00a0gegen\u00a0Biosimilars\u00a0\nGegen\u00a0den\u00a0Einsatz\u00a0von\u00a0Biosimilars\u00a0werden\u00a0auch\u00a0heute\u00a0noch\u00a0h\u00e4ufig \u00a0Bedenken\u00a0ge\u00e4u\u2010\n\u00dfert.\u00a0Diese\u00a0betreffen\u00a0insbesondere\u00a0die\u00a0pharmazeutische\u00a0Qualit\u00e4t ,\u00a0die\u00a0Wirksamkeit\u00a0\n(vor\u00a0allem\u00a0in\u00a0extrapolierten\u00a0Indikationen),\u00a0die\u00a0Sicherheit\u00a0(ins besondere\u00a0aufgrund\u00a0der\u00a0\npotenziellen\u00a0Immunogenit\u00e4t)\u00a0und\u00a0die\u00a0Austauschbarkeit\u00a0mit\u00a0dem\u00a0Re ferenzarzneimittel\u00a0\n(BfArM,\u00a0 2013a;\u00a0 McCamish\u00a0 &\u00a0 Woollett,\u00a0 2012).\u00a0 In\u00a0 den\u00a0 onkologischen \u00a0 Indikationen\u00a0\nbeziehen\u00a0sich\u00a0die\u00a0Bedenken\u00a0vor\u00a0allem\u00a0auf\u00a0die\u00a0Extrapolation\u00a0zwis chen\u00a0verschiedenen\u00a0\nStadien\u00a0einer\u00a0Krebserkrankung\u00a0(metastasiert\u00a0vs.\u00a0lokalisiert),\u00a0z wischen\u00a0verschiedenen\u00a0\nonkologischen\u00a0Indikationen\u00a0und\u00a0T herapieregimen\u00a0(neoadjuvant\u00a0vs. \u00a0adjuvant)\u00a0und\u00a0auf\u00a0\ndie\u00a0Extrapolation\u00a0zwischen\u00a0Krebs\u2010\u00a0und\u00a0Autoimmunerkrankungen\u00a0(z. \u00a0B.\u00a0bei\u00a0Rituximab).\u00a0489\u00a0Auch\u00a0wurden\u00a0h\u00e4ufig\u00a0von\u00a0Experten\u00a0und\u00a0Fachgesellschaften\u00a0die\u00a0Endp unkte\u00a0der\u00a0klini\u2010\nschen\u00a0Studien\u00a0zu\u00a0onkologischen\u00a0Bi osimilars\u00a0kritisch\u00a0hinterfragt \u00a0(Cortes\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nAufgrund\u00a0des\u00a0strengen,\u00a0wissenschaftlich\u00a0fundierten\u00a0Zulassungsve rfahrens\u00a0der\u00a0EMA\u00a0\n\u2013\u00a0mit\u00a0inzwischen\u00a0auch\u00a0jahrelang\u00a0gesammelten\u00a0Erfahrungen\u00a0zu\u00a0Bios imilars\u00a0\u2013\u00a0kann\u00a0\ndavon\u00a0ausgegangen\u00a0werden,\u00a0dass\u00a0die\u00a0\u00c4hnlichkeit\u00a0in\u00a0Qualit\u00e4t,\u00a0Wir ksamkeit\u00a0und\u00a0\nSicherheit\u00a0des\u00a0Biosimilars\u00a0mit\u00a0dem\u00a0Referenzarzneimittel\u00a0bei\u00a0in\u00a0 Europa\u00a0zugelasse\u2010\nnen\u00a0Arzneimitteln\u00a0gew\u00e4hrleistet\u00a0ist.\u00a0Bedenken\u00a0hinsichtlich\u00a0der\u00a0 Sicherheit\u00a0erschei\u2010\nnen\u00a0auch\u00a0unbegr\u00fcndet\u00a0angesichts\u00a0der\u00a0engmaschigen\u00a0Sicherheits\u00fcbe rwachung\u00a0der\u00a0\nBiosimilars\u00a0nach\u00a0ihrer\u00a0Markteinf\u00fchrung\u00a0sowie\u00a0der\u00a0langen\u00a0praktis chen\u00a0Erfahrung\u00a0\nmit\u00a0Biosimilars\u00a0in\u00a0Europa\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0mehr\u00a0als\u00a0zehn \u00a0Jahren,\u00a0in\u00a0dem\u00a0\nkeine\u00a0schweren,\u00a0unbekannten\u00a0Nebenwirkungen\u00a0oder\u00a0andere\u00a0Sicherhe itsprobleme\u00a0\naufgetreten\u00a0sind.\u00a0\nDer\u00a0Nachweis\u00a0der\u00a0Biosimilarit\u00e4t\u00a0bei\u00a0moAk\u00a0wird\u00a0durch\u00a0die\u00a0Heterog enit\u00e4t\u00a0mancher\u00a0\nh\u00e4matologischer\u00a0Neoplasien\u00a0und\u00a0s olider\u00a0Tumoren\u00a0erschwert,\u00a0ebens o\u00a0wie\u00a0durch\u00a0die\u00a0\nTatsache,\u00a0dass\u00a0in\u00a0onkologischen\u00a0Indikationen\u00a0mitunter\u00a0pharmakod ynamische\u00a0Marker\u00a0\nfehlen,\u00a0die\u00a0das\u00a0Ansprechen\u00a0der\u00a0Tumorerkrankungen\u00a0zuverl\u00e4ssig\u00a0ab bilden.\u00a0Dar\u00fcber\u00a0\nhinaus\u00a0erfolgt\u00a0die\u00a0Anwendung\u00a0von\u00a0Biosimilars\u00a0h\u00e4ufig\u00a0in\u00a0Kombinat ion\u00a0mit\u00a0anderen\u00a0\nonkologischen\u00a0Wirkstoffen.\u00a0Daher \u00a0m\u00fcssen\u00a0bei\u00a0Biosimilars\u00a0in\u00a0onko logischen\u00a0Indikati\u2010\nonen\u00a0neben\u00a0den\u00a0etablierten\u00a0Endpunkten\u00a0zur\u00a0Wirksamkeit,\u00a0wie\u00a0beis pielsweise\u00a0das\u00a0OS\u00a0\nund\u00a0das\u00a0krankheitsfreie\u00a0\u00dcberleben\u00a0( Disease\u00a0Free\u00a0Survival ,\u00a0DFS),\u00a0auch\u00a0Surrogatend\u2010\npunkte\u00a0wie\u00a0die\u00a0ORR,\u00a0das\u00a0PFS\u00a0sowie\u00a0die\u00a0prozentuale\u00a0Abnahme\u00a0der\u00a0T umormasse\u00a0und\u00a0\ndie\u00a0pathologisch\u00a0nachgewiesene\u00a0 komplette\u00a0Remission\u00a0( Complete\u00a0Remission ,\u00a0CR)\u00a0akzep\u2010\ntiert\u00a0werden.\u00a0Dies\u00a0ist\u00a0auch\u00a0dadurch\u00a0bedingt,\u00a0dass\u00a0die\u00a0Auswahl\u00a0d er\u00a0Endpunkte\u00a0sowie\u00a0\nder\u00a0Studienpopulation\u00a0in\u00a0der\u00a0klinischen\u00a0Pr\u00fcfung\u00a0von\u00a0Biosimilars \u00a0dem\u00a0Nachweis\u00a0rele\u2010\nvanter\u00a0Unterschiede\u00a0in\u00a0der\u00a0Wirksamkeit\u00a0im\u00a0Vergleich\u00a0zum\u00a0Referen zarzneimittel\u00a0dient\u00a0\n(Weise\u00a0et\u00a0al.,\u00a02012).\u00a0Daf\u00fcr\u00a0sind\u00a0die\u00a0etablierten\u00a0\u00dcberlebensendp unkte\u00a0bedingt\u00a0durch\u00a0\nSt\u00f6rfaktoren\u00a0( Confounder )\u00a0wie\u00a0die\u00a0Tumorlast,\u00a0das\u00a0Krankheitsstadium\u00a0und\u00a0die\u00a0vorhe\u2010\nrigen\u00a0Therapien\u00a0nicht\u00a0immer\u00a0ausreichend\u00a0sensitiv,\u00a0um\u00a0produktbed ingte\u00a0Unterschie\u2010\nde\u00a0zu\u00a0detektieren\u00a0(Socinski\u00a0et\u00a0al.,\u00a02015).\u00a0\u00a0\nAuch\u00a0Bedenken\u00a0gegen\u00a0die\u00a0Extrapolationen,\u00a0die\u00a0die\u00a0Onkologie\u00a0betr effen\u00a0\u00a0\n\uf0b7 zwischen\u00a0 verschiedenen\u00a0 Stadien\u00a0 der\u00a0 gleichen\u00a0 Krebsart\u00a0 (metastasi ert\u00a0 vs.\u00a0\nlokalisiert),\u00a0\u00a0\n\uf0b7 zwischen\u00a0verschiedenen\u00a0onkologischen\u00a0Indikationen\u00a0\u00a0\n\uf0b7 und\u00a0 insbesondere\u00a0 die\u00a0 Extrapolati on\u00a0 zwischen\u00a0 Krebs\u2010\u00a0 und\u00a0 Autoimmu ner\u2010\nkrankungen\u00a0(wie\u00a0z.B.\u00a0bei\u00a0Rituximab),\u00a0\u00a0490\u00a0k\u00f6nnen\u00a0nur\u00a0durch\u00a0mehr\u00a0Informationen\u00a0zur\u00a0genauen\u00a0Vorgehensweise\u00a0 im\u00a0jeweiligen\u00a0\nExtrapolationsverfahren\u00a0ausger\u00e4umt\u00a0werden.\u00a0Nach\u00a0der\u00a0Markteinf\u00fch rung\u00a0durchlau\u2010\nfen\u00a0alle\u00a0biologischen\u00a0Arzneimitt el\u00a0diverse\u00a0\u00c4nderungen\u00a0des\u00a0Herst ellungsverfahrens,\u00a0\nbei\u00a0denen\u00a0das\u00a0gleiche\u00a0wissenschaftliche\u00a0Prinzip\u00a0der\u00a0Extrapolati on\u00a0zur\u00a0Anwendung\u00a0\nkommt.\u00a0Dar\u00fcber\u00a0werden\u00a0jedoch\u00a0meist\u00a0weder\u00a0die\u00a0\u00c4rzteschaft\u00a0noch\u00a0d ie\u00a0Patienten\u00a0\ninformiert\u00a0(Vezer\u00a0et\u00a0al.,\u00a02016).\u00a0Dass\u00a0bei\u00a0diesen\u00a0zahlreichen\u00a0\u00c4n derungen\u00a0weder\u00a0\nSicherheits\u2010\u00a0noch\u00a0Wirksamkeitsprobleme\u00a0entstanden\u00a0sind,\u00a0kann\u00a0al s\u00a0Beleg\u00a0daf\u00fcr\u00a0\nangef\u00fchrt\u00a0werden,\u00a0dass\u00a0die\u00a0Extrapolation\u00a0als\u00a0wissenschaftliches \u00a0Instrument\u00a0auch\u00a0\nbei\u00a0der\u00a0\u00dcberpr\u00fcfung\u00a0der\u00a0Biosimilarit\u00e4t\u00a0geeignet\u00a0ist.\u00a0\nAustauschbarkeit\u00a0und\u00a0Substitution\u00a0\nOb\u00a0ein\u00a0Referenzarzneimittel\u00a0gegen\u00a0ein\u00a0Biosimilar\u00a0mit\u00a0einem\u00a0\u00e4hnl ichen\u00a0arzneilich\u00a0\nwirksamen\u00a0Bestandteil\u00a0(durch\u00a0den\u00a0Arzt)\u00a0austauschbar\u00a0bzw.\u00a0(durch \u00a0den\u00a0Apotheker)\u00a0\nsubstituierbar\u00a0ist,\u00a0wird\u00a0bei\u00a0der\u00a0Zulassung\u00a0eines\u00a0Biosimilars\u00a0ni cht\u00a0beschlossen.\u00a0Dazu\u00a0\ngibt\u00a0es\u00a0in\u00a0den\u00a0einzelnen\u00a0Mitgliedsstaaten\u00a0der\u00a0EU\u00a0unterschiedlic he\u00a0Regelungen.\u00a0In\u00a0\nDeutschland\u00a0ist\u00a0eine\u00a0automatische\u00a0Substitution\u00a0durch\u00a0den\u00a0Apothe ker\u00a0(ohne\u00a0Wis\u2010\nsen\u00a0des\u00a0Arztes)\u00a0momentan\u00a0nach\u00a0de m\u00a0Rahmenvertrag\u00a0\u00fcber\u00a0die\u00a0Arznei mittelversor\u2010\ngung\u00a0nach\u00a0\u00a7\u00a0129\u00a0Absatz\u00a02\u00a0SGB\u00a0V\u00a0zwischen\u00a0dem\u00a0GKV\u2010Spitzenverband\u00a0 und\u00a0dem\u00a0\nDeutschen\u00a0Apothekerverband\u00a0e.\u00a0V.\u00a0nur\u00a0zul\u00e4ssig\u00a0f\u00fcr\u00a0sogenannte\u00a0 Bioidenticals ,\u00a0die\u00a0in\u00a0\nder\u00a0gleichen\u00a0Produktionsst\u00e4tte\u00a0\u2013\u00a0also\u00a0im\u00a0gleichen\u00a0Herstellungsv erfahren\u00a0und\u00a0vom\u00a0\ngleichen\u00a0Hersteller\u00a0\u2013\u00a0produziert,\u00a0aber\u00a0von\u00a0unterschiedlichen\u00a0pU \u00a0vertrieben\u00a0wer\u2010\nden.\u00a0\u00a0\nGegen\u00a0die\u00a0Substitution\u00a0von\u00a0Refer enzarzneimitteln\u00a0durch\u00a0Biosimil ars\u00a0wird\u00a0beson\u2010\nders\u00a0h\u00e4ufig\u00a0das\u00a0Argument\u00a0vorgebracht,\u00a0dass\u00a0dadurch\u00a0die\u00a0Nachverf olgbarkeit\u00a0der\u00a0\nArzneimittel\u00a0gef\u00e4hrdet\u00a0ist\u00a0und\u00a0d ie\u00a0Beurteilung\u00a0von\u00a0aufgetretene n\u00a0Nebenwirkungen\u00a0\nnicht\u00a0m\u00f6glich\u00a0ist.\u00a0Das\u00a0Problem\u00a0der\u00a0schlechten\u00a0Nachverfolgbarkei t\u00a0betrifft\u00a0aller\u2010\ndings\u00a0nicht\u00a0nur\u00a0die\u00a0Biosimilars,\u00a0sondern\u00a0infolge\u00a0der\u00a0inh\u00e4renten \u00a0Chargenvariabilit\u00e4t\u00a0\njedes\u00a0Biologikum.\u00a0Zwar\u00a0sieht\u00a0die \u00a0aktuelle\u00a0europ\u00e4ische\u00a0Pharmakov igilanz\u2010Richtlinie\u00a0\ndie\u00a0Nachverfolgbarkeit\u00a0vor,\u00a0diese\u00a0Regelung\u00a0ist\u00a0aber\u00a0noch\u00a0nicht\u00a0 f\u00fcr\u00a0alle\u00a0biologischen\u00a0\nArzneimittel\u00a0national\u00a0implementi ert.\u00a0Dabei\u00a0ist\u00a0dies\u00a0bei\u00a0Arzneim itteln\u00a0besonders\u00a0\nproblematisch,\u00a0die\u00a0von\u00a0Patienten\u00a0selbst\u00a0\u2013\u00a0ohne\u00a0direkte\u00a0\u00e4rztlich e\u00a0Aufsicht\u00a0\u2013\u00a0appli\u2010\nziert\u00a0werden,\u00a0wie\u00a0beispielsweise \u00a0Etanercept\u00a0oder\u00a0Insulin\u00a0glargi n.\u00a0In\u00a0solchen\u00a0F\u00e4llen\u00a0\nerfolgt\u00a0meist\u00a0keine\u00a0Chargendokumentation\u00a0durch\u00a0den\u00a0Arzt.\u00a0Die\u00a0Ar zneimittelkom\u2010\nmission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0hat\u00a0bereits\u00a02014\u00a0in\u00a0ei ner\u00a0Bekanntgabe\u00a0\nim\u00a0Deutschen\u00a0\u00c4rzteblatt\u00a0auf\u00a0die\u00a0 Notwendigkeit\u00a0hingewiesen,\u00a0bei\u00a0 Meldungen\u00a0von\u00a0\nNebenwirkungen\u00a0neben\u00a0der\u00a0Wirkstoffbezeichnung\u00a0( International\u00a0Nonproprietary\u00a0\nName,\u00a0INN)\u00a0auch\u00a0die\u00a0Handelsbezeichnung\u00a0und\u00a0\u2013\u00a0wenn\u00a0m\u00f6glich\u00a0\u2013\u00a0die\u00a0Cha rgen\u2010\nnummer\u00a0anzugeben,\u00a0um\u00a0im\u00a0Rahmen\u00a0der\u00a0Pharmakovigilanz\u00a0eine\u00a0geziel te\u00a0Nachver\u2010\nfolgung\u00a0von\u00a0Meldungen\u00a0zu\u00a0Nebenwir kungen\u00a0zu\u00a0erm\u00f6glichen\u00a0(Akd\u00c4,\u00a02 014).\u00a0491\u00a0Empfehlungen\u00a0zum\u00a0Einsatz\u00a0von\u00a0Biosimilars\u00a0\nDas\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0(PEI),\u00a0das\u00a0in\u00a0Deutschland\u00a0unter\u00a0ander em\u00a0f\u00fcr\u00a0die\u00a0Pharmako\u2010\nvigilanz\u00a0bei\u00a0Biologika\u00a0(z.\u00a0B.\u00a0moAk)\u00a0zust\u00e4ndig\u00a0ist,\u00a0hat\u00a0sich\u00a0in\u00a0 einem\u00a0Positionspapier\u00a0zum\u00a0\nEinsatz\u00a0von\u00a0Biosimilars\u00a0daf\u00fcr\u00a0au sgesprochen,\u00a0dass\u00a0Biosimilars\u00a0n ach\u00a0erwiesener\u00a0\u00c4qui\u2010\nvalenz\u00a0und\u00a0erfolgter\u00a0Zulassung\u00a0grunds\u00e4tzlich\u00a0wie\u00a0Originalproduk te\u00a0eingesetzt\u00a0werden\u00a0\nk\u00f6nnen\u00a0(PEI,\u00a02015).\u00a0Nach\u00a0Auffassung\u00a0vom\u00a0PEI\u00a0umfasst\u00a0dies\u00a0sowohl \u00a0Patienten,\u00a0die\u00a0\nnoch\u00a0keine\u00a0Therapie\u00a0mit\u00a0Biologika\u00a0erhalten\u00a0haben,\u00a0als\u00a0auch\u00a0solc he\u00a0Patienten,\u00a0die\u00a0\nbereits\u00a0mit\u00a0dem\u00a0Referenzarzneimi ttel\u00a0behandelt\u00a0werden.\u00a0Am\u00a0Beisp iel\u00a0des\u00a0Wirkstoffs\u00a0\nInfliximab\u00a0vergleicht\u00a0das\u00a0PEI\u00a0da s\u00a0Referenzarzneimittel\u00a0Remicade\u00ae\u00a0mit\u00a0den\u00a0ersten\u00a0\nBiosimilars\u00a0Inflectra\u00ae\u00a0und\u00a0Remsima\u00ae,\u00a0zu\u00a0denen\u00a0dem\u00a0PEI\u00a0auch\u00a0ein\u00a0 Jahr\u00a0nach\u00a0Marktein\u2010\nf\u00fchrung\u00a0 keine\u00a0 Meldungen\u00a0 zu\u00a0 oder\u00a0 Hinweise\u00a0 auf\u00a0 umstellungsbedingt e\u00a0 Probleme\u00a0\nvorlagen.\u00a0Au\u00dferdem\u00a0verweist\u00a0das\u00a0PEI\u00a0auf\u00a0Patientendaten\u00a0aus\u00a0noch \u00a0weltweit\u00a0laufen\u2010\nden\u00a0klinischen\u00a0Studien\u00a0sowie\u00a0aus\u00a0Therapieregistern,\u00a0aus\u00a0denen\u00a0s ich\u00a0keine\u00a0Hinweise\u00a0\nauf\u00a0Sicherheitsprobleme\u00a0durch\u00a0eine\u00a0Umstellung\u00a0ergaben. \u00a0\nDie\u00a0European\u00a0Society\u00a0for\u00a0Medical\u00a0Oncology \u00a0(ESMO)\u00a0sprach\u00a0sich\u00a0Anfang\u00a02017\u00a0in\u00a0\neinem\u00a0aktuellen\u00a0Positionspapier\u00a0ebenfalls\u00a0f\u00fcr\u00a0den\u00a0Einsatz\u00a0von\u00a0B iosimilars\u00a0in\u00a0der\u00a0\nOnkologie\u00a0aus.\u00a0Insbesondere\u00a0wurde \u00a0dabei\u00a0die\u00a0Bedeutung\u00a0von\u00a0Biosi milars\u00a0f\u00fcr\u00a0die\u00a0\nBezahlbarkeit\u00a0onkologischer\u00a0Ther apien\u00a0und\u00a0die\u00a0finanzielle\u00a0Nachh altigkeit\u00a0der\u00a0Ge\u2010\nsundheitssysteme\u00a0in\u00a0Europa\u00a0betont\u00a0(Tabernero\u00a0et\u00a0al.,\u00a02017).\u00a0Dab ei\u00a0bef\u00fcrwortet\u00a0die\u00a0\nESMO\u00a0 ausdr\u00fccklich\u00a0 nicht\u00a0 die\u00a0 automatische\u00a0 Substitution\u00a0 durch\u00a0 den \u00a0 Apotheker\u00a0\naufgrund\u00a0der\u00a0Komplexit\u00e4t\u00a0biologischer\u00a0Arzneimittel,\u00a0aber\u00a0die\u00a0Um stellung\u00a0durch\u00a0\nden\u00a0behandelnden\u00a0Arzt.\u00a0Als\u00a0wichtigste\u00a0Voraussetzung\u00a0f\u00fcr\u00a0eine\u00a0Um stellung\u00a0der\u00a0\nPatienten\u00a0vom\u00a0Referenzarzneimittel\u00a0auf\u00a0ein\u00a0Biosimilar\u00a0oder\u00a0aber \u00a0auch\u00a0von\u00a0einem\u00a0\nBiosimilar\u00a0auf\u00a0ein\u00a0anderes\u00a0Biosimilar\u00a0wird\u00a0von\u00a0der\u00a0ESMO\u00a0die\u00a0aus f\u00fchrliche\u00a0Informa\u2010\ntion\u00a0und\u00a0Beratung\u00a0des\u00a0Patienten\u00a0empfohlen\u00a0(Tabernero\u00a0et\u00a0al.,\u00a020 17).\u00a0\nDie\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(Akd\u00c4)\u00a0bef \u00fcrwortete\u00a0bereits\u00a0\n2008\u00a0in\u00a0einer\u00a0Stellungnahme\u00a0zum\u00a0therapeutischen\u00a0Einsatz\u00a0von\u00a0Bio similars,\u00a0diese\u00a0bei\u00a0\nBeginn\u00a0 einer\u00a0 Behandlung\u00a0 ebenso\u00a0 einzusetzen\u00a0 wie\u00a0 ein\u00a0 Originalprod ukt.\u00a0 Auch\u00a0 die\u00a0\nUmstellung\u00a0von\u00a0bereits\u00a0mit\u00a0einem\u00a0Referenzarzneimittel\u00a0behandelt en\u00a0Patienten\u00a0auf\u00a0\nein\u00a0Biosimilar,\u00a0beispielsweise\u00a0aus\u00a0Kostengr\u00fcnden,\u00a0wurde\u00a0bei\u00a0Bea chtung\u00a0der\u00a0zugelas\u2010\nsenen\u00a0Anwendungsgebiete\u00a0und\u00a0unter\u00a0der\u00a0Voraussetzung\u00a0der\u00a0engmasc higen\u00a0\u00dcber\u2010\nwachung\u00a0(wie\u00a0bei\u00a0einer\u00a0Neueinstellung)\u00a0empfohlen\u00a0(Akd\u00c4,\u00a02008).\u00a0\nBedeutung\u00a0und\u00a0Einsparpotentiale\u00a0durch\u00a0Biosimilars\u00a0\nIn\u00a0Deutschland\u00a0sind\u00a0derzeit\u00a0221\u00a0Arzneimittel\u00a0mit\u00a0173\u00a0gentechnis ch\u00a0hergestellten\u00a0\nWirkstoffen\u00a0verf\u00fcgbar\u00a0(vfa,\u00a02017).\u00a0Biologika\u00a0geh\u00f6ren\u00a0seit\u00a0Jahre n\u00a0zu\u00a0den\u00a0umsatz\u2010\nst\u00e4rksten\u00a0Arzneimitteln\u00a0weltweit.\u00a0492\u00a0Ihre\u00a0Ausgaben\u00a0zu\u00a0Lasten\u00a0der\u00a0Gese tzlichen\u00a0Krankenversicherung\u00a0(G KV)\u00a0in\u00a0Deutsch\u2010\nland\u00a0hat\u00a0sich\u00a0im\u00a0Zeitraum\u00a02005\u00a0bis\u00a02015\u00a0verdreifacht\u00a0und\u00a0betrug \u00a0im\u00a0Jahr\u00a02015\u00a07,2\u00a0\nMrd.\u00a0Euro\u00a0und\u00a0beanspruchte\u00a0damit\u00a0rund\u00a020\u00a0%\u00a0des\u00a0gesamten\u00a0Umsatze s\u00a0f\u00fcr\u00a0Fer\u2010\ntigarzneimittel\u00a0(Schaufler\u00a0&\u00a0Telchow,\u00a02016).\u00a0Insbesondere\u00a0Onkol ogika\u00a0\u2013\u00a0und\u00a0davon\u00a0\nvor\u00a0allem\u00a0moAk\u00a0\u2013\u00a0erzielen\u00a0seit\u00a0J ahren\u00a0hohe\u00a0Ums\u00e4tze.\u00a02015\u00a0betrug \u00a0der\u00a0Umsatz\u00a0f\u00fcr\u00a0\nmoAk\u00a0in\u00a0onkologischen\u00a0Indikationen\u00a01,64\u00a0Mrd.\u00a0Euro\u00a0in\u00a0der\u00a0GKV,\u00a0o bwohl\u00a0auf\u00a0sie\u00a0mit\u00a0\n11,2\u00a0Mio.\u00a0verordneten\u00a0DDD\u00a0lediglich\u00a05,3\u00a0%\u00a0des\u00a0Verordnungsvolume ns\u00a0aller\u00a0Onko\u2010\nlogika\u00a0entfielen.\u00a02015\u00a0waren\u00a0die\u00a0monoklonalen\u00a0Antik\u00f6rper\u00a0erneut \u00a0mit\u00a0weitem\u00a0\nAbstand\u00a0die\u00a0umsatzst\u00e4rkste\u00a0Onkologikagruppe\u00a0in\u00a0der\u00a0GKV.\u00a0Zu\u00a0den\u00a0 umsatzst\u00e4rksten\u00a0\nWirkstoffen\u00a0in\u00a0individuell\u00a0hergestellten\u00a0parenteralen\u00a0L\u00f6sungen\u00a0 und\u00a0Zytostatika\u2010\nZubereitungen\u00a0 geh\u00f6rten\u00a0 2015\u00a0 Bevac izumab\u00a0 (Bruttoumsatz\u00a0 520,7\u00a0 Mio .\u00a0 Euro),\u00a0\nTrastuzumab\u00a0(Bruttoumsatz\u00a0405,9\u00a0Mio.\u00a0Euro)\u00a0und\u00a0Rituximab\u00a0(Brutt oumsatz\u00a0286,5\u00a0\nMio.\u00a0Euro)\u00a0(Schaufler\u00a0et\u00a0al.,\u00a02016).\u00a0\nDa\u00a0die\u00a0medikament\u00f6se\u00a0Behandlung\u00a0onkologischer\u00a0Erkrankungen\u00a0mit\u00a0 neuen\u00a0Wirk\u2010\nstoffen\u00a0eine\u00a0erhebliche\u00a0und\u00a0stetig\u00a0zunehmende\u00a0finanzielle\u00a0Belas tung\u00a0der\u00a0Gesund\u2010\nheitssysteme\u00a0darstellt,\u00a0k\u00f6nnen\u00a0Biosimilars\u00a0mit\u00a0Einsatz\u00a0in\u00a0onkol ogischen\u00a0Indikatio\u2010\nnen\u00a0dazu\u00a0beitragen,\u00a0die\u00a0krankheitsbezogenen\u00a0Ausgaben\u00a0zu\u00a0senken\u00a0 und\u00a0die\u00a0Nach\u2010\nhaltigkeit\u00a0der\u00a0Gesundheitssysteme\u00a0aufrechtzuerhalten.\u00a0Zwar\u00a0sind \u00a0Biosimilars\u00a0meist\u00a0\nnur\u00a0etwa\u00a020\u00a0bis\u00a030\u00a0%\u00a0g\u00fcnstiger\u00a0al s\u00a0die\u00a0jeweiligen\u00a0Referenzarzne imittel;\u00a0jedoch\u00a0\nkonnte\u00a0eine\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0veranlasste\u00a0Analys e\u00a0des\u00a0Biosimi\u2010\nlarmarktes\u00a0im\u00a0europ\u00e4ischen\u00a0Wirtschaftsraum\u00a0zeigen,\u00a0dass\u00a0die\u00a0Ver f\u00fcgbarkeit\u00a0von\u00a0\nBiosimilars\u00a0einen\u00a0Preiswettbewerb\u00a0mit\u00a0dem\u00a0Referenzarzneimittel\u00a0 und\u00a0mit\u00a0anderen\u00a0\nBiosimilars\u00a0erzeugt.\u00a0Je\u00a0h\u00f6her\u00a0die\u00a0Marktdurchdringung\u00a0des\u00a0Biosim ilars\u00a0ist,\u00a0desto\u00a0\nh\u00f6her\u00a0 wird\u00a0 die\u00a0 Wahrscheinlichkeit\u00a0 eingesch\u00e4tzt,\u00a0 dass\u00a0 der\u00a0 Anbiet er\u00a0 des\u00a0 Refe\u2010\nrenzarzneimittels\u00a0 mit\u00a0 Preissenkungen\u00a0 reagiert\u00a0 (Quintiles\u00a0 IMS,\u00a0 2 017).\u00a0 Dar\u00fcber\u00a0\nhinaus\u00a0erm\u00f6glichen\u00a0Biosimilars\u00a0Patienten\u00a0in\u00a0\u00e4rmeren\u00a0L\u00e4ndern\u00a0den \u00a0Zugang\u00a0zu\u00a0die\u2010\nsen\u00a0heute\u00a0zur\u00a0Behandlung\u00a0onkologi scher\u00a0Erkrankungen\u00a0unverzichtb aren\u00a0Arznei\u2010\nmitteln\u00a0(The\u00a0Lancet,\u00a02017).\u00a0\nMomentan\u00a0spielen\u00a0Biosimilars\u00a0eher\u00a0eine\u00a0untergeordnete\u00a0Rolle\u00a0in\u00a0 der\u00a0Arzneimittel\u2010\nversorgung\u00a0in\u00a0Deutschland.\u00a0Im\u00a0 Jahr\u00a02016\u00a0entfielen\u00a0auf\u00a0Biosimila rs\u00a0lediglich\u00a01,9\u00a0%\u00a0\n(19,19\u00a0Mio.\u00a0DDD)\u00a0des\u00a0Verordnungsvolumens\u00a0(in\u00a0DDD)\u00a0der\u00a0biologisc hen\u00a0Arzneimit\u2010\ntel.\u00a0Der\u00a0Umsatzanteil\u00a0betrug\u00a0mit\u00a00,18\u00a0Mrd.\u00a0Euro\u00a0nur\u00a03,2\u00a0%\u00a0vom\u00a0G esamtumsatz\u00a0der\u00a0\nBiologika\u00a0(5,89\u00a0Mrd.\u00a0Euro).\u00a0Im\u00a0Vergleich\u00a0dazu\u00a0setzten\u00a0die\u00a0nicht \u00a0mehr\u00a0patentge\u2010\nsch\u00fctzten\u00a0Biologika\u00a02,39\u00a0Mrd.\u00a0Euro\u00a0um\u00a0und\u00a0beanspruchten\u00a071,5\u00a0%\u00a0 des\u00a0Verord\u2010\nnungsvolumens\u00a0(in\u00a0DDD)\u00a0aller\u00a0Biologika.\u00a0Die\u00a0Verordnungsanteile\u00a0 der\u00a0Biosimilars\u00a0\nunterschieden\u00a0sich\u00a0sehr\u00a0stark\u00a0je\u00a0nach\u00a0Wirkstoff.\u00a0W\u00e4hrend\u00a0bei\u00a0Ep oetin\u00a040,1\u00a0%\u00a0und\u00a0\nbei\u00a0Filgrastim\u00a0sogar\u00a072,4\u00a0%\u00a0des\u00a0Verordnungsvolumens\u00a0(in\u00a0DDD)\u00a0au f\u00a0Biosimilars\u00a0\nentfielen,\u00a0waren\u00a0es\u00a0bei\u00a0Infliximab\u00a032,6\u00a0%,\u00a0bei\u00a0Etanercept\u00a08,3\u00a0% \u00a0und\u00a0bei\u00a0Insulin\u00a0493\u00a0glargin\u00a0nur\u00a03,5\u00a0%.\u00a0Auch\u00a0ein\u00a0Jahr\u00a0nach\u00a0ihrer\u00a0Markteinf\u00fchrung\u00a0mac hen\u00a0Infliximab\u2010\nBiosimilars\u00a0nur\u00a0etwa\u00a0ein\u00a0Drittel\u00a0 des\u00a0Marktes\u00a0aus\u00a0(AG\u00a0Pro\u00a0Biosim ilars,\u00a02016).\u00a0\u00a0\nFazit\u00a0\nBiosimilars\u00a0werden\u00a0in\u00a0Europa\u00a0nach\u00a0wissenschaftlich\u00a0fundierten\u00a0u nd\u00a0streng\u00a0kontrol\u2010\nlierten\u00a0Zulassungsverfahren\u00a0in\u00a0den\u00a0Markt\u00a0eingef\u00fchrt,\u00a0so\u00a0dass\u00a0ih re\u00a0ausreichende\u00a0\nVergleichbarkeit\u00a0mit\u00a0einem\u00a0seit\u00a0l \u00e4ngerer\u00a0Zeit\u00a0zugelassenen\u00a0Refe renzarzneimittel\u00a0\nhinsichtlich\u00a0der\u00a0Qualit\u00e4t,\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0gew\u00e4hrlei stet\u00a0ist.\u00a0F\u00fcr\u00a0Biosimi\u2010\nlars\u00a0gelten\u00a0die\u00a0gleichen\u00a0strenge n\u00a0Anforderungen,\u00a0die\u00a0auch\u00a0bei\u00a0R eferenzarzneimit\u2010\nteln\u00a0 nach\u00a0 einer\u00a0 \u00c4nderung\u00a0 des\u00a0 Her stellungsverfahrens\u00a0 zum\u00a0 Nachwei s\u00a0 der\u00a0 Ver\u2010\ngleichbarkeit\u00a0mit\u00a0dem\u00a0vorherigen\u00a0Produkt\u00a0zur\u00a0Anwendung\u00a0kommen.\u00a0 Biosimilars\u00a0\nf\u00f6rdern\u00a0den\u00a0Wettbewerb\u00a0im\u00a0Arzneimittelmarkt\u00a0und\u00a0k\u00f6nnen\u00a0den\u00a0Zuga ng\u00a0zu\u00a0medi\u2010\nkament\u00f6sen\u00a0Therapien\u00a0mit\u00a0Biologika\u00a0verbessern.\u00a0Dadurch\u00a0leisten\u00a0 sie\u00a0einen\u00a0wichti\u2010\ngen\u00a0Beitrag\u00a0zur\u00a0Kostensenkung\u00a0in\u00a0den\u00a0solidarisch\u00a0finanzierten\u00a0G esundheitssyste\u2010\nmen\u00a0in\u00a0Europa\u00a0und\u00a0verbessern\u00a0die\u00a0Therapiem\u00f6glichkeiten\u00a0in\u00a0\u00e4rmer en\u00a0L\u00e4ndern.\u00a0\u00a0\nBiosimilars\u00a0sind\u00a0aus\u00a0klinischer\u00a0Sicht\u00a0geeignete\u00a0Alternativen\u00a0zu \u00a0den\u00a0ni cht\u00a0m ehr\u00a0\npatentgesch\u00fctzten,\u00a0aber\u00a0weiterhin\u00a0kostspieligen\u00a0Referenzarzneim itteln.\u00a0Die\u00a0lang\u2010\nj\u00e4hrigen\u00a0Erfahrungen\u00a0mit\u00a0Biosimilars\u00a0st\u00fctzen\u00a0die\u00a0unproblematisc he\u00a0Austauschbar\u2010\nkeit\u00a0der\u00a0Referenzarzneimittel\u00a0durch\u00a0Biosimilars.\u00a0Keine\u00a0der\u00a0bish er\u00a0publizierten\u00a0Er\u2010\ngebnisse\u00a0aus\u00a0klinischen\u00a0Studien,\u00a0Registern\u00a0und\u00a0wissenschaftlich en\u00a0Arbeiten\u00a0spre\u2010\nchen\u00a0gegen\u00a0die\u00a0Anwendung\u00a0von\u00a0Biosimilars.\u00a0Auch\u00a0gab\u00a0es\u00a0in\u00a0Europa \u00a0keine\u00a0einzige\u00a0\nMarktr\u00fccknahme\u00a0von\u00a0Biosimilars\u00a0aufgrund\u00a0von\u00a0Sicherheitsbedenken \u00a0oder\u00a0unzu\u2010\nreichender\u00a0Wirksamkeit.\u00a0\nDie\u00a0h\u00e4ufig\u00a0im\u00a0Zusammenhang\u00a0mit\u00a0der\u00a0Anwendung\u00a0von\u00a0Biosimilars\u00a0ge \u00e4u\u00dferten\u00a0\nBedenken\u00a0und\u00a0\u00c4ngste\u00a0m\u00fcssen\u00a0durch \u00a0unabh\u00e4ngige,\u00a0verst\u00e4ndliche\u00a0Inf ormationen\u00a0\nf\u00fcr\u00a0\u00c4rzte,\u00a0Pflegekr\u00e4fte\u00a0und\u00a0Patienten\u00a0ausger\u00e4umt\u00a0werden.\u00a0Die\u00a0\u00c4r zteschaft\u00a0\u2013\u00a0insbe\u2010\nsondere\u00a0auch\u00a0die\u00a0H\u00e4matologen\u00a0und\u00a0Onkologen,\u00a0da\u00a0in\u00a0naher\u00a0Zukunft \u00a0eine\u00a0stetig\u00a0\nwachsende\u00a0Zahl\u00a0von\u00a0Biosimilars\u00a0in\u00a0onkologischen\u00a0Indikationen\u00a0ve rf\u00fcgbar\u00a0sein\u00a0wird\u00a0\n\u2013\u00a0muss\u00a0sich\u00a0mit\u00a0der\u00a0Zulassung\u00a0von\u00a0Biosimilars\u00a0vertraut\u00a0machen.\u00a0 Detaillierte\u00a0Kennt\u2010\nnisse\u00a0der\u00a0Merkmale\u00a0von\u00a0Biosimilars,\u00a0des\u00a0Konzeptes\u00a0der\u00a0Extrapola tion,\u00a0der\u00a0Aus\u2010\ntauschbarkeit\u00a0und\u00a0des\u00a0Sicherheit sprofils,\u00a0einschlie\u00dflich\u00a0der\u00a0Im munogenit\u00e4t,\u00a0sind\u00a0\nwesentliche\u00a0Voraussetzungen\u00a0f\u00fcr\u00a0evidenzbasierte,\u00a0zweckm\u00e4\u00dfige\u00a0un d\u00a0wirtschaftli\u2010\nche\u00a0Therapieentscheidungen.\u00a0\u00a0\n\u00a0\u00a0494\u00a0Quellen\u00a0\nAG\u00a0Pro\u00a0Biosimilars\u00a0(2016).\u00a0Biosi milars\u00a0in\u00a0Zahlen.\u00a0http://probio similars.de/img_upload/2017/02/Marktdaten\u2010Biosimilars_Dezember\u2010\n2016.pdf?ddl=1,\u00a0letzter\u00a0Zugriff:\u00a028.02.2017.\u00a0\nAkd\u00c4\u00a0\u2010\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2008). \u00a0Stellungnahme\u00a0der\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\n\u00c4rzteschaft\u00a0zu\u00a0Biosimilars.\u00a0www.akdae.de/Stellungnahmen/Weitere /20081209.pdf,\u00a0letzter\u00a0Zugriff:\u00a005.07.2017.\u00a0\nAMGEN\u00a0(2016).\u00a0Amgen\u00a0And\u00a0Allergan\u00a0Announce\u00a0Top\u2010Line\u00a0Results\u00a0From \u00a0Phase\u00a03\u00a0Study\u00a0Evaluating\u00a0ABP\u00a0980\u00a0Compared\u00a0With\u00a0\nTrastuzumab\u00a0In\u00a0Patients\u00a0With\u00a0Human\u00a0Epidermal\u00a0Growth\u00a0Factor\u00a0Rece ptor\u00a02\u2010Positive\u00a0Early\u00a0Breast\u00a0Cancer\u00a0.\u00a0\nwww.amgen.com/media/news\u2010releases/2016/07/amgen\u2010and\u2010allergan\u2010an nounce\u2010top\u2010line\u2010results\u2010from\u2010phase\u20103\u2010\nstudy\u2010evaluating\u2010abp\u2010980\u2010compared\u2010with\u2010trastuzumab\u2010in\u2010patients\u2010 with\u2010human\u2010epidermal\u2010growth\u2010factor\u2010receptor\u2010\n2\u2010positive\u2010early\u2010breast\u2010cancer/,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nAMGEN\u00a0(2017).\u00a0Our\u00a0Pipeline.\u00a0http://www.amgenbiosimilars.com/our \u2010products/our\u2010pipeline/,\u00a0letzter\u00a0Zugriff:\u00a027.06.\u00a02017.\u00a0\nBennett\u00a0CL,\u00a0Chen\u00a0B,\u00a0Hermanson\u00a0T,\u00a0Wyatt\u00a0MD,\u00a0Schulz\u00a0RM,\u00a0Georganto poulos\u00a0P\u00a0et\u00a0al.\u00a0(2014).\u00a0Regulatory\u00a0and\u00a0clinical\u00a0considerations\u00a0\nfor\u00a0biosimilar\u00a0oncology\u00a0drugs\u00a0Lan cet\u00a0Oncol.\u00a015(13):\u00a0e594\u2013e605.\u00a0\nBennett\u00a0CL,\u00a0Luminari\u00a0S,\u00a0Nissenson\u00a0AR,\u00a0Tallman\u00a0MS,\u00a0Klinge\u00a0SA,\u00a0Mc Williams\u00a0N\u00a0et\u00a0al.\u00a0(2004).\u00a0Pure\u00a0R ed\u2010Cell\u00a0Aplasia\u00a0and\u00a0Epoetin\u00a0\nTherapy\u00a0N.\u00a0Engl.\u00a0J.\u00a0Med.\u00a0351(14):\u00a01403\u20131408.\u00a0\u00a0\nBennett\u00a0CL,\u00a0Qureshi\u00a0Z,\u00a0Singh\u00a0S,\u00a0Magwood\u00a0J\u00a0(2013).\u00a0Rituximab\u00a0and \u00a0biosimilars\u00a0\u2010\u00a0equivalence\u00a0and\u00a0re ciprocity.\u00a0Biosimilars\u00a02013(3) :\u00a019.\u00a0\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 13a)Zentralisiertes\u00a0Verfahren\u00a0.\u00a0\nwww.bfarm.de/DE/Arzneimittel/zul/zulassungsverfahren/zVerf/_nod e.html,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nBfArM\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(20 13b)Arzneimittel\u00a0unter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung.\u00a0\nwww.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformation en/AM_zusUeb/_node.html,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nBristol\u2010Myers\u00a0Squibb\u00a0(n.d.)YERVOY\u00a05\u00a0mg/ml\u00a0Konzentrat\u00a0zur\u00a0Herste llung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0\u2010\u00a0PatientenInfo\u2010Service\u00a0.\u00a0https://w ww.patienten\u00a0\ninfo\u2010service.de/a\u2010z\u2010liste/xyz/yervoy\u20105\u2010mgml\u2010konzentrat\u2010zur\u2010hers tellung\u2010einer\u2010infusionsloesung/,\u00a0letzter\u00a0Zugriff:\u00a027.6.2017.\u00a0\nBundes\u00e4rztekammer\u00a0(2014).\u00a0Arzneimittelkommission\u00a0der\u00a0Deutschen\u00a0 \u00c4rzteschaft\u00a0\u2013\u00a0\u201eAus\u00a0der\u00a0UAW\u2010Datenbank\u201c:\u00a0Bei\u00a0\nNebenwirkungsmeldungen\u00a0zu\u00a0biologischen\u00a0Arzneimitteln\u00a0sollte\u00a0auc h\u00a0die\u00a0Handelsbezeichnung\u00a0und\u00a0die\u00a0\nChargennummer\u00a0angegeben\u00a0werden,\u00a0111(46):\u00a0A\u20102032\u20102033.\u00a0\u00a0\nChamberlain\u00a0P\u00a0(2013).\u00a0Assessing\u00a0immunogenicity\u00a0of\u00a0biosimilar\u00a0th erapeutic\u00a0monoclonal\u00a0antibodies:\u00a0regulatory\u00a0and\u00a0bioanalytical\u00a0\nconsiderations.\u00a0Bioanalysis\u00a05(5):\u00a0561\u2010574.\u00a0\u00a0\nCHMP\u00a0\u2010\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2014).\u00a0G uideline\u00a0on\u00a0similar\u00a0biological\u00a0medicinal\u00a0products.\u00a0\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific _guideline/2014/10/WC500176768.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a027.06.\u00a02017.\u00a0\nCHMP\u00a0\u2010\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2016).\u00a0A ssessment\u00a0report\u00a0Truxima\u00a0.\u00a0\nwww.ema.europa.eu/docs/en_GB/document_library/EPAR_\u2010_Public_assessment_report/human/004112/WC500222695.pdf,\u00a0letzter \u00a0Zugriff:\u00a027.06.\u00a02017.\u00a0\nClinicalTrials.gov\u00a0(2016).\u00a0Clinical\u00a0Study\u00a0to\u00a0Compare\u00a0the\u00a0Effica cy\u00a0and\u00a0Safety\u00a0of\u00a0Rituximab\u00a0Biosimilar\u00a0HLX01\u00a0and\u00a0Rituximab\u00a0in\u00a0Co mbination\u00a0With\u00a0\nCHOP,\u00a0in\u00a0Previously\u00a0Untreated\u00a0Subjects\u00a0With\u00a0CD20+\u00a0DLBCL\u00a0\u2010\u00a0Full\u00a0 Text\u00a0View\u00a0\u2010\u00a0ClinicalTrials.gov\u00a0.\u00a0https://clinicaltrials.gov/ct2 /show/\u00a0\nNCT02787239,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nClinicalTrials.gov\u00a0(2016a).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0Study\u00a0With\u00a0MYL\u2010 1401H\u00a0and\u00a0Neulasta.\u00a0\nhttps://clinicaltrials.gov/ct2/show/NCT02467868?term=MYL\u20101401H& rank=1,\u00a0letzter\u00a0Zugriff:\u00a027.06.2017.\u00a0495\u00a0Cort\u00e9s\u00a0J,\u00a0Curigliano\u00a0G,\u00a0Di\u00e9ras\u00a0V\u00a0(2014).\u00a0Expert\u00a0perspectives\u00a0on \u00a0biosimilar\u00a0monoclonal\u00a0antibodies\u00a0in\u00a0breast\u00a0cancer\u00a0Breast\u00a0Cance r\u00a0Res.\u00a0Treat.\u00a0\n144(2):\u00a0233\u2010239.\u00a0\u00a0\nDobbelstein\u00a0M,\u00a0Moll\u00a0U\u00a0(2014).\u00a0Targeting\u00a0tumour\u2010supportive\u00a0cellu lar\u00a0machineries\u00a0in\u00a0anticancer\u00a0drug\u00a0development.\u00a0Nat.\u00a0Rev.\u00a0Drug\u00a0\nDiscov.\u00a013(3):\u00a0179\u2010196.\u00a0\u00a0\nEbbers\u00a0HC\u00a0(2014).\u00a0Biosimilars:\u00a0In\u00a0support\u00a0of\u00a0extrapolation\u00a0of\u00a0i ndications\u00a0J.\u00a0Crohn\u2019s\u00a0Colitis\u00a08(5):\u00a0431\u2010435.\u00a0\u00a0\nEbbers\u00a0HC,\u00a0Crow\u00a0SA,\u00a0Vulto\u00a0AG,\u00a0Sc hellekens\u00a0H\u00a0(2012).\u00a0Interchange ability,\u00a0immunogenicity\u00a0and\u00a0biosi milars.\u00a0Nat.\u00a0Biotechnol.\u00a030(12 ):\u00a0\n1186\u20101190.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2014).\u00a0Commitee\u00a0for\u00a0Medicinal\u00a0 Products\u00a0for\u00a0Human\u00a0Use\u00a0(CHMP):\u00a0Guideline\u00a0on\u00a0similar\u00a0\nbiological\u00a0medicinal\u00a0products.\u00a0www.ema.europa.eu/docs/en_GB/doc ument_library/Scientific_guideline/2014/10/\u00a0\nWC500176768.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2017.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2017).\u00a0Truxima\u00ae:\u00a0European\u00a0Publ ic\u00a0Assessment\u00a0Report.\u00a0www.ema.europa.eu/docs/en_GB/\u00a0\ndocument_library/EPAR_\u2010_Public_assessment_report/human/004112/W C500222695.pdf,\u00a0letzter\u00a0Zugriff:\u00a020.03.2017.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(n.d.).\u00a0\nwww.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/sm op_search.jsp&mid=WC0b01ac058001d127\n&source=homeMedSearch&category=human&keyword=rituximab&isNewQue ry=true,\u00a0letzter\u00a0Zugriff:\u00a001.06.2017.\u00a0\nFachinformation\u00a0Aranesp\u00ae\u00a0(2015).\u00a0 Fachinformation\u00a0Aranesp\u00ae.\u00a0Stan d\u00a0der\u00a0Information:\u00a0September\u00a02015.\u00a0\nFachinformation\u00a0Erbitux\u00ae(n.d.)Fa chinformation\u00a0Erbitux\u00ae.https:// www.fachinfo.de/pdf/008483,\u00a0let zter\u00a0Zugriff:\u00a027.07.2017.\u00a0\nFachinformation\u00a0Herceptin\u00ae\u00a0(n.d.)Fachinformation\u00a0Herceptin\u00ae.\u00a0ht tps://www.roche.de/dok/Herceptin\u2010reg\u2010600\u2010mg\u2010fachinfo\u20100\u2010na\u2010\nattach.pdf,\u00a0letzter\u00a0Zugriff:\u00a0letzter\u00a0Zugriff:\u00a027.07.2017.\u00a0\nFachinformation\u00a0MabThera\u00a0\u00ae(n.d.)Fachinformation\u00a0MabThera\u00a0\u00ae\u00a0.\u00a0ht tps://www.roche.de/res/literatur_protected/845/MAB\u2010sc\u2010em\u2010\nhcp\u2010leitfaden\u2010original\u2010e9660733d84f593270aa7a7ee9d047c4.pdf,\u00a0le tzter\u00a0Zugriff:\u00a027.06.\u00a02017.\u00a0\nFachinformation\u00a0Neulasta\u00a0\u00ae\u00a0(2015).\u00a0Neulasta\u00a0\u00ae\u00a0Fachinformation\u00a0N eulasta\u00a0\u00ae\u00a0.\u00a0Stand:\u00a0Mai\u00a02015.\u00a0\nFachinformation\u00a0Vectib ix\u00ae\u00a0(n.d.)\u00a0Fachinformation\u00a0Vectibix\u00ae.\u00a0htt ps://fachkreise.amgen.de/x_download.php?t=f&n=1&id=239,\u00a0\nletzter\u00a0Zugriff:\u00a027.06.2017.\u00a0\nGaBI\u00a0Journal\u00a0Editor\u00a0(2015).\u00a0Patent\u00a0expiry\u00a0dates\u00a0for\u00a0best\u2010sellin g\u00a0biologicals.\u00a0Generics\u00a0Biosimila rs\u00a0Initiat.\u00a0J.\u00a04(4):\u00a0178\u2010179.\u00a0 \u00a0\nHarbeck\u00a0N,\u00a0Lipatov\u00a0O,\u00a0Frolova\u00a0M,\u00a0Udovitsa\u00a0D,\u00a0Topuzov\u00a0E,\u00a0Ganea\u2010M otan\u00a0DE\u00a0et\u00a0al.\u00a0(2016).\u00a0Randomized,\u00a0double\u2010blind\u00a0study\u00a0comparing \u00a0\nproposed\u00a0biosimilar\u00a0LA\u2010EP2006\u00a0with \u00a0reference\u00a0pegfilgrastim\u00a0in\u00a0b reast\u00a0cancer\u00a0Futur.\u00a0Oncol.\u00a012(11):\u00a01359\u20101367.\u00a0\nHudis\u00a0CA\u00a0(2007).\u00a0Trastuzumab\u00a0\u2010\u00a0Me chanism\u00a0of\u00a0Action\u00a0and\u00a0Use\u00a0in\u00a0C linical\u00a0Practice\u00a0N.\u00a0Engl.\u00a0J.\u00a0Med.\u00a0357(1):\u00a039\u201351.\u00a0\nKessler\u00a0M,\u00a0Goldsmith\u00a0D,\u00a0Schellekens\u00a0H\u00a0(2006).\u00a0Immunogenicity\u00a0of \u00a0biopharmaceuticals.\u00a0Nephrol.\u00a0Dial.\u00a0Transplant.\u00a021(Supplement\u00a05 ):\u00a0v9\u2010v12.\u00a0\u00a0\nKim\u00a0WS,\u00a0Coiffier\u00a0B,\u00a0Kwon\u00a0H\u2010C,\u00a0Kim \u00a0S\u00a0(2017).\u00a0Clinical\u00a0developmen t\u00a0of\u00a0CT\u2010P10\u00a0and\u00a0other\u00a0biosimilar\u00a0cancer\u00a0therapeutics.\u00a0Futur.\u00a0On col.\u00a0\n13(15s):\u00a031\u201044.\u00a0\u00a0\nLudwig\u00a0W,\u00a0Dicheva\u00a0S\u00a0(2016).\u00a0Bios imilars\u00a0in\u00a0der\u00a0Onkologie:\u00a0Eine\u00a0 therapeutische\u00a0Alternative\u00a0zu\u00a0Referenzarzneimitteln?\u00a0Z\u00a0\nGastroenterol\u00a054(11):\u00a01223\u20101229.\u00a0\u00a0\nMcCamish\u00a0M,\u00a0Woollett\u00a0G\u00a0(2012).\u00a0Th e\u00a0State\u00a0of\u00a0the\u00a0Art\u00a0in\u00a0the\u00a0Deve lopment\u00a0of\u00a0Biosimilars.\u00a0Clin.\u00a0Pharmacol.\u00a0Ther.\u00a091(3):\u00a0405\u2010417.\u00a0 \u00a0496\u00a0M\u00fcller\u2010Berghaus\u00a0J,\u00a0Volkers\u00a0P,\u00a0Scherer\u00a0J,\u00a0Cichutek\u00a0K\u00a0(2013).\u00a0Bes onderheiten\u00a0bei\u00a0der\u00a0Regulierung\u00a0biologischer\u00a0Arzneimittel\u00a0in\u00a0de r\u00a0\nindividualisierten\u00a0Medizin\u00a0Bundesgesundheitsbl,\u00a056,\u00a01538\u20131544.\u00a0\nPEI\u00a0\u2010\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0(2015).\u00a0Position\u00a0des\u00a0Paul\u2010Ehrlich\u2010I nstituts\u00a0zum\u00a0Einsatz\u00a0von\u00a0Biosimilars\u00a0.\u00a0\nwww.pei.de/DE/arzneimittel/immunglobuline\u2010monoklonale\u2010antikoerp er/monoklonale\u2010antikoerper/zusatz/position\u2010\npei\u2010interchangebility\u2010biosimilars \u2010inhalt.html,\u00a0letzter\u00a0Zugriff: \u00a027.07.2017.\u00a0\nQuintilesIMS\u00a0(2017).\u00a0The\u00a0Impact\u00a0of\u00a0Biosimilar\u00a0Competition\u00a0in\u00a0Eu rope\u00a0.\u00a0http://www.medicinesforeurope.com/wp\u2010\ncontent/uploads/2017/05/IMS\u2010Biosimilar\u20102017_V9.pdf,\u00a0letzter\u00a0Zug riff:\u00a027.07.2017.\u00a0\nRoche\u00a0Registration\u00a0Limited\u00a0(n.d.)Fachinformation\u00a0Avastin\u00ae\u00a0.\u00a0htt ps://www.roche.de/dok/Avastin\u2010reg\u2010Infusionsloesungskonzentrat\u2010\nfachinfo\u20100\u2010na\u2010attach.pdf,\u00a0letzter\u00a0Zugriff:\u00a027.07.2017.\u00a0\nRugo\u00a0HS,\u00a0Barve\u00a0A,\u00a0Waller\u00a0CF,\u00a0Hern andez\u2010Bronchud\u00a0M,\u00a0Herson\u00a0J,\u00a0Yu an\u00a0J\u00a0et\u00a0al.\u00a0(2017).\u00a0Effect\u00a0of\u00a0a\u00a0Proposed\u00a0Trastuzumab\u00a0Biosimilar \u00a0\nCompared\u00a0With\u00a0Trastuzumab\u00a0on\u00a0Overall\u00a0Response\u00a0Rate\u00a0in\u00a0Patients\u00a0 With\u00a0ERBB2\u00a0(HER2)\u2013Positive\u00a0Metastatic\u00a0Breast\u00a0\nCancer.\u00a0JAMA\u00a0317(1):\u00a037.\u00a0\u00a0\nSchaufler\u00a0J,\u00a0Telschow\u00a0C\u00a0(2016).\u00a0GKV\u2010Arzneimittelmarkt\u00a02015:\u00a0Tre nds\u00a0und\u00a0Marktsegmente\u00a0In\u00a0Arzneiverordnungs\u2010Report\u00a02016.\u00a0(pp.\u00a0\n135\u2013157).\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer\u00a0Berlin\u00a0Heidelberg.\u00a0\u00a0\nSchaufler\u00a0J,\u00a0Telschow\u00a0C,\u00a0Weiss\u00a0J\u00a0(2016).\u00a0Erg\u00e4nzende\u00a0statistisch e\u00a0\u00dcbersicht\u00a0In\u00a0Arzneiverordnungs\u2010Report\u00a02016.\u00a0(pp.\u00a0785\u2013821).\u00a0Be rlin,\u00a0\nHeidelberg:\u00a0Springer\u00a0Berlin\u00a0Heidelberg.\u00a0\u00a0\nSchellekens\u00a0H\u00a0(2004).\u00a0Biosimilar\u00a0therapeutic\u00a0agents:\u00a0issues\u00a0wit h\u00a0bioequivalence\u00a0and\u00a0immunogenicity.\u00a0Eur.\u00a0J.\u00a0Clin.\u00a0Invest.,\u00a034( 12),\u00a0797\u2013799.\u00a0\u00a0\nSchneider\u00a0CK,\u00a0Weise\u00a0M\u00a0(2015).\u00a0Regulatorische\u00a0Aspekte\u00a0zu\u00a0Biosimi lars.\u00a0Z.\u00a0Rheumatol.\u00a074(8):\u00a0695\u2010700.\u00a0\u00a0\nSocinski\u00a0MA,\u00a0Curigliano\u00a0G,\u00a0Jacobs \u00a0I,\u00a0Gumbiner\u00a0B,\u00a0MacDonald\u00a0J,\u00a0T homas\u00a0D\u00a0(2015).\u00a0Clinical\u00a0considerations\u00a0for\u00a0the\u00a0development\u00a0of\u00a0\nbiosimilars\u00a0in\u00a0oncology\u00a0MAbs,\u00a07(2),\u00a0286\u2010293.\u00a0\u00a0\nTabernero\u00a0J,\u00a0Vyas\u00a0M,\u00a0Giuliani\u00a0R,\u00a0Arnold\u00a0D,\u00a0Cardoso\u00a0F,\u00a0Casali\u00a0PG \u00a0et\u00a0al.\u00a0(2017).\u00a0Biosimilars:\u00a0a\u00a0position\u00a0paper\u00a0of\u00a0the\u00a0European\u00a0S ociety\u00a0\nfor\u00a0Medical\u00a0Oncology,\u00a0with\u00a0parti cular\u00a0reference\u00a0to\u00a0oncology\u00a0pre scribers\u00a0ESMO\u00a0Open,\u00a01(6).\u00a0\nhttp://esmoopen.bmj.com/content/1/6/e000142\u00a0\nThe\u00a0Lancet\u00a0(2017).\u00a0Improving\u00a0acce ss\u00a0to\u00a0biosimilars\u00a0in\u00a0low\u2010incom e\u00a0countries.\u00a0Lancet\u00a0389(10082):\u00a01860.\u00a0\nVezer\u00a0B,\u00a0Buzas\u00a0Z,\u00a0Sebeszta\u00a0M,\u00a0\u00a0Zrubka\u00a0Z\u00a0(2016).\u00a0Authorized\u00a0manu facturing\u00a0changes\u00a0for\u00a0therapeutic\u00a0monoclonal\u00a0antibodies\u00a0(mAbs)\u00a0\nin\u00a0European\u00a0Public\u00a0Assessment\u00a0Report\u00a0(EPAR)\u00a0documents\u00a0Curr.\u00a0Med .\u00a0Res.\u00a0Opin.,\u00a032(5),\u00a0829\u2010834.\u00a0\u00a0\nvfa.\u00a0Die\u00a0forschenden\u00a0Pharma\u2010Unternehmen\u00a0(2017).\u00a0Zugelassene\u00a0gen technische\u00a0Arzneimittel\u00a0in\u00a0Deutschland\u00a0.\u00a0\nhttps://www.vfa.de/de/arzneimittel\u2010forschung/datenbanken\u2010zu\u2010arz neimitteln/amzulassungen\u2010gentec.html,\u00a0letzter\u00a0\nZugriff:\u00a004.07.2017.\u00a0\nWeise\u00a0M,\u00a0Bielsky\u00a0M\u2010C,\u00a0De\u00a0Smet\u00a0K,\u00a0 Ehmann\u00a0F,\u00a0Ekman\u00a0N,\u00a0Giezen\u00a0TJ\u00a0e t\u00a0al.\u00a0(2012).\u00a0Biosimilars:\u00a0what\u00a0clinicians\u00a0should\u00a0know.\u00a0Blood\u00a0\n120(26):\u00a05111\u20105117.\u00a0\u00a0\nWeise\u00a0M,\u00a0Kurki\u00a0P,\u00a0Wolff\u2010Holz\u00a0E,\u00a0Bielsky\u00a0M\u2010C,\u00a0Schneider\u00a0CK\u00a0(2014 ).\u00a0Biosimilars:\u00a0the\u00a0science\u00a0of\u00a0extrapolation.\u00a0Blood\u00a0124(22):\u00a031 91\u20103196.\u00a0\u00a0\nWeise\u00a0M,\u00a0Wolff\u2010Holz\u00a0E\u00a0(2016).\u00a0O pportunities\u00a0and\u00a0challenges\u00a0of\u00a0e xtrapolation\u00a0for\u00a0biosimilars.\u00a0Z.\u00a0Gastroenterol.\u00a054(11):\u00a01211\u201012 16.\u00a0\u00a0\n\u00a0 \u00a0497\u00a07 Keypoints\u00a0und\u00a0Fazit\u00a0\n7.1 Keypoints\u00a0\n\uf0b7 Der\u00a0Innovationsreport\u00a02017\u00a0bewertet\u00a032\u00a0der\u00a0auf\u00a0dem\u00a0Arzneimittel markt\u00a0neu\u00a0\neingef\u00fchrten\u00a0Wirkstoffe\u00a0bzw.\u00a0Wirk stoffkombinationen\u00a0des\u00a0Jahres\u00a0 2014.\u00a0\u00a0\n\uf0b7 2014\u00a0war\u00a0ein\u00a0hoher\u00a0Anteil\u00a0an\u00a0 Orphan\u2010Arzneimitteln\u00a0unter\u00a0den\u00a0Zulassungen.\u00a0Im\u00a0\nReport\u00a02016\u00a0(neue\u00a0Arzneimittel\u00a0d es\u00a0Jahres\u00a02013)\u00a0geh\u00f6rten\u00a0ledigl ich\u00a0drei\u00a0(13\u00a0%)\u00a0\nWirkstoffe\u00a0in\u00a0diese\u00a0Gruppe,\u00a02017\u00a0dagegen\u00a0zw\u00f6lf\u00a0(38\u00a0%).\u00a0\n\uf0b7 Im\u00a0Jahr\u00a02014\u00a0wurden\u00a0am\u00a0h\u00e4ufigsten\u00a0antivirale\u00a0Mittel\u00a0zur\u00a0systemi schen\u00a0Anwen\u2010\ndung\u00a0(z.B.\u00a0bei\u00a0Hepatitis\u00a0C)\u00a0sowie\u00a0antineoplastische\u00a0Mittel\u00a0(z.B .\u00a0bei\u00a0Krebserkran\u2010\nkungen)\u00a0mit\u00a0jeweils\u00a0f\u00fcnf\u00a0Wirkstoffen\u00a0neu\u00a0in\u00a0den\u00a0Arzneimittelmar kt\u00a0eingef\u00fchrt\u00a0\nund\u00a0in\u00a0diesen\u00a0Innovationsreport\u00a0aufgenommen.\u00a0Mittel\u00a0bei\u00a0obstruk tiven\u00a0Atem\u2010\nwegserkrankungen\u00a0sind\u00a0am\u00a0zweith\u00e4ufigsten\u00a0mit\u00a0drei\u00a0Wirkstoffen\u00a0v ertreten.\u00a0Die\u00a0\nweiteren\u00a019\u00a0Wirkstoffe\u00a0verteilten\u00a0sich\u00a0auf\u00a0unterschiedliche\u00a0Ind ikationsbereiche.\u00a0\u00a0\n\uf0b7 Insgesamt\u00a0fallen\u00a0die\u00a0Bewertungen\u00a0nach\u00a0zwei\u00a0Jahren\u00a0Erfahrung\u00a0mit \u00a0diesen\u00a0neu\u2010\nen\u00a0Mitteln\u00a0weniger\u00a0positiv\u00a0aus\u00a0als\u00a0in\u00a0den\u00a0Vorjahren.\u00a0Keines\u00a0der \u00a0neuen\u00a0Mittel\u00a0\nerzielte\u00a0im\u00a0Gesamtscore\u00a0die\u00a0Best note\u00a0(\u201egr\u00fcne\u00a0Gesamtampel\u201c).\u00a017\u00a0 der\u00a0bewerte\u2010\nt e n \u00a0P r o d u k t e \u00a0e r h i e l t e n \u00a0d i e \u00a0G e s a m t a m p e l \u00a0\u201e g e l b \u201c , \u00a0d a v o n \u00a0a c h t \u00a0 Orphan\u2010\nArzneimittel.\u00a0Fast\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0bewerteten\u00a0Mittel,\u00a0n\u00e4mlich\u00a015 ,\u00a0erhielten\u00a0einen\u00a0\nroten\u00a0Gesamtscore,\u00a0davon\u00a0vier\u00a0 Orphan\u2010Arzneimittel.\u00a0Damit\u00a0\u00fcberzeugt\u00a0auch\u00a0\ndieser\u00a0Untersuchungszeitraum\u00a0nicht\u00a0mit\u00a0echten\u00a0therapeutischen\u00a0I nnovationen,\u00a0\ndie\u00a0sowohl\u00a0einen\u00a0zus\u00e4tzlichen\u00a0Nutzen\u00a0als\u00a0auch\u00a0einen\u00a0Effizienzge winn\u00a0in\u00a0der\u00a0\nVersorgung\u00a0erm\u00f6glichen.\u00a0\n\uf0b7 Die\u00a0Kostenbewertung\u00a0aller\u00a0Mittel \u00a0ergibt\u00a0einen\u00a0deutlich\u00a0negative n\u00a0Aspekt:\u00a0der\u00a0\ngr\u00f6\u00dfte\u00a0Anteil\u00a0der\u00a0in\u00a02014\u00a0eingef \u00fchrten\u00a0Mittel\u00a0war\u00a0teurer\u00a0als\u00a0di e\u00a0zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie.\u00a0Bei\u00a0acht\u00a0Wirkstoffen\u00a0(bzw.\u00a0Kombinationen\u00a0vo n\u00a0Wirkstof\u2010\nfen)\u00a0zeigte\u00a0die\u00a0Ampel\u00a0\u201egelb\u201c,\u00a0nu r\u00a0bei\u00a0vier\u00a0konnte\u00a0eine\u00a0\u201egr\u00fcne\u00a0A mpel\u201c\u00a0vergeben\u00a0\nwerden\u00a0 (Cobicistat,\u00a0 Vilanterol\u00a0 +\u00a0 Fluticasonfuroat,\u00a0 Dexlansopraz ol\u00a0 und\u00a0 Olo\u2010\ndaterol,\u00a0die\u00a0letzten\u00a0beiden\u00a0Wirkstoffe\u00a0sind\u00a0mit\u00a0Mehrkosten\u00a0f\u00fcr\u00a0 die\u00a0Patienten\u00a0\nverbunden).\u00a0\n\uf0b7 Die\u00a0Pr\u00e4parate\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a02014\u00a0wurden\u00a0im\u00a0Jahr\u00a02015\u00a0im\u00a0 Vergleich\u00a0zu\u00a0\nden\u00a0Wirkstoffen\u00a0aus\u00a0dem\u00a0Jahr\u00a02013\u00a0(im\u00a0Jahr\u00a02014)\u00a0sehr\u00a0viel\u00a0h\u00e4uf iger\u00a0verordnet:\u00a0\n98,3\u00a0Tsd.\u00a0Packungen\u00a0zu\u00a0Lasten\u00a0der\u00a0TK\u00a0vs.\u00a038,5\u00a0Tsd.\u00a0Packungen.\u00a0D er\u00a0Jahrgang\u00a0\n2014\u00a0umfasste\u00a0aber\u00a0auch\u00a0eine\u00a0deutl ich\u00a0gr\u00f6\u00dfere\u00a0Anzahl\u00a0neuer\u00a0Wirk stoffe.\u00a0\u00a0\n\uf0b7 Der\u00a0Umsatz\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02014\u00a0hat\u00a0sich\u00a0gege n\u00fcber\u00a0dem\u00a0\nJahrgang\u00a0 2013\u00a0 (jeweils\u00a0 im\u00a0 Jahr\u00a0 nach\u00a0 ihrer\u00a0 Markteinf\u00fchrung)\u00a0 nahe zu\u00a0 ver\u2010\nf\u00fcnffacht.\u00a0498\u00a0\uf0b7 Bez\u00fcglich\u00a0des\u00a0Vergleichs\u00a0mit\u00a0den \u00a0verf\u00fcgbaren\u00a0Therapien\u00a0zeigte\u00a0d ie\u00a0Ampel\u00a0bei\u00a0\nimmerhin\u00a0f\u00fcnf\u00a0Wirkstoffen\u00a0\u201egr\u00fcn\u201c,\u00a0bei\u00a013\u00a0\u201egelb\u201c.\u00a0Damit\u00a0bieten\u00a0r und\u00a060\u00a0%\u00a0der\u00a0\nneu\u00a0in\u00a0den\u00a0Markt\u00a0gebrachten\u00a0Arzneimittel\u00a0zumindest\u00a0eine\u00a0positiv \u00a0zu\u00a0bewertende\u00a0\nErg\u00e4nzung\u00a0des\u00a0vorhandenen\u00a0Arzneimittelrepertoires.\u00a0Bei\u00a014\u00a0der\u00a0M ittel,\u00a0davon\u00a0\ndrei\u00a0Orphan\u2010Arzneimittel,\u00a0konnte\u00a0eine\u00a0solch e\u00a0positive\u00a0Erg\u00e4nzung\u00a0nicht\u00a0fest ge\u2010\nstellt\u00a0werden.\u00a0\u00a0\n\uf0b7 Die\u00a0Analyse\u00a0des\u00a0nachgewiesenen\u00a0Zusatznutzens\u00a0als\u00a0wichtigstem\u00a0Kr iterium\u00a0ergab\u00a0\nf\u00fcr\u00a015\u00a0Arzneimittel\u00a0eine\u00a0\u201erote\u00a0Ampel\u201c.\u00a0Der\u00a0\u00fcberwiegende\u00a0Anteil\u00a0 erhielt\u00a0aller\u2010\ndings\u00a0(und\u00a0h\u00f6chstens)\u00a0eine\u00a0\u201egelbe\u00a0Ampel\u201c.\u00a0Damit\u00a0ist\u00a0der\u00a0gr\u00f6\u00dfere \u00a0Anteil\u00a0der\u00a0neu\u2010\nen\u00a0Arzneimittel\u00a0f\u00fcr\u00a0viele\u00a0Patienten\u00a0zumindest\u00a0mit\u00a0einem\u00a0Nutzenz ugewinn\u00a0ver\u2010\nbunden.\u00a0\n\uf0b7 Nach\u00a0wie\u00a0vor\u00a0erstaunlich\u00a0und\u00a0irritierend\u00a0ist,\u00a0dass\u00a0trotz\u00a0des\u00a0ge ringen\u00a0therapeuti\u2010\nschen\u00a0Fortschritts\u00a0und\u00a0negativer\u00a0Bewertungen\u00a0Arzneimittel\u00a0Einga ng\u00a0in\u00a0beste\u2010\nhende\u00a0Leitlinien\u00a0gefunden\u00a0haben.\u00a0Dies\u00a0betrifft\u00a0z.B.\u00a0Cabozantini b,\u00a0Cobicistat,\u00a0\nNalmefen\u00a0oder\u00a0Obinutuzumab,\u00a0bei\u00a0denen\u00a0keine\u00a0Erweiterung\u00a0des\u00a0The rapie\u2010\nrepertoires\u00a0und\u00a0des\u00a0Zusatznutzens\u00a0festgestellt\u00a0und\u00a0eine\u00a0rote\u00a0Ge samtscore\u2010\nampel\u00a0vergeben\u00a0wurde.\u00a0\u00a0\n\uf0b7 Hervorzuheben\u00a0ist\u00a0die\u00a0sorgf\u00e4ltig e\u00a0Beobachtung\u00a0in\u00a0der\u00a0\u201eAlltagsan wendung\u201c\u00a0\nneuer\u00a0Mittel\u00a0durch\u00a0die\u00a0Aussendungen\u00a0von\u00a0Rote\u2010Hand\u2010Briefen:\u00a0F\u00fcr\u00a0 sechs\u00a0Mit\u2010\ntel\u00a0wurden\u00a0solche\u00a0Hinweise\u00a0versc hickt\u00a0(20\u00a0%),\u00a0f\u00fcr\u00a0zwei\u00a0davon\u00a0so gar\u00a0zweimal\u00a0\ninnerhalb\u00a0der\u00a0ersten\u00a0beiden\u00a0Behandlungsjahre\u00a0(Dimethylfumarat\u00a0u nd\u00a0Idelali\u2010\nsib).\u00a0 Dies\u00a0 dokumentiert\u00a0 exemplar isch\u00a0 die\u00a0 Notwendigkeit\u00a0 einer\u00a0 sy stemati\u2010\nschen\u00a0Nebenwirkungsforschung\u00a0nach\u00a0der\u00a0Zulassung\u00a0als\u00a0Basis\u00a0f\u00fcr\u00a0m ehr\u00a0Thera\u2010\npiesicherheit,\u00a0die\u00a0in\u00a0den\u00a0Zulassungsstudien\u00a0weniger\u00a0Ber\u00fccksicht igung\u00a0finden.\u00a0\u00a0\n\uf0b7 Der\u00a0Ende\u00a02016\u00a0in\u00a0Abstimmung\u00a0mit\u00a0pU\u00a0und\u00a0BfArM\u00a0eingef\u00fchrte\u00a0Einsat z\u00a0von\u00a0\nBlaue\u00a0Hand\u2010Schulungsmaterialien\u00a0(C hols\u00e4ure,\u00a0Delamanid,\u00a0Elosulfa se\u00a0alfa\u00a0und\u00a0\nMacitentan)\u00a0sind\u00a0wichtige\u00a0und\u00a0not wendige\u00a0Ans\u00e4tze,\u00a0um\u00a0das\u00a0Risiko \u00a0bei\u00a0der\u00a0\nAnwendung\u00a0neuer\u00a0Arzneimittel\u00a0zu\u00a0minimieren.\u00a0\n\uf0b7 Biosimilars\u00a0nehmen\u00a0derzeit\u00a0eine\u00a0w esentliche\u00a0Rolle\u00a0in\u00a0der\u00a0Arznei mittelthera\u2010\npie\u00a0ein.\u00a0Durch\u00a0zahlreiche\u00a0Patentabl\u00e4ufe\u00a0und\u00a0den\u00a0Einsatz\u00a0von\u00a0Bio simliars\u00a0wird\u00a0\nsowohl\u00a0deren\u00a0Bedeutung\u00a0als\u00a0auch\u00a0die\u00a0Realisierungsm\u00f6glichkeit\u00a0vo n\u00a0Einspar\u2010\npotenzialen\u00a0weiter\u00a0wachsen.\u00a0Einsparungen\u00a0von\u00a0bis\u00a0zu\u00a0500\u00a0Mio.\u00a0Eu ro\u00a0f\u00fcr\u00a0die\u00a0\nGKV\u00a0werden\u00a0in\u00a0den\u00a0n\u00e4chsten\u00a0Jahren\u00a0 durchaus\u00a0erreichbar\u00a0sein.\u00a0 Auf grund\u00a0\u00a0\nder\u00a0Studienlage\u00a0ist\u00a0dabei\u00a0nicht\u00a0von\u00a0klinischen\u00a0Nachteilen\u00a0f\u00fcr\u00a0d ie\u00a0Patienten\u00a0\nauszugehen. \u00a0499\u00a07.2 Fazit\u00a0\nNeben\u00a0dieser\u00a0bewertungsorientier ten\u00a0\u00dcbersicht\u00a0sollen\u00a0drei\u00a0Aspek te\u00a0im\u00a0diesj\u00e4hri\u2010\ngen\u00a0Innovationsreport\u00a0besond ers\u00a0hervorgehoben\u00a0werden:\u00a0\nDie\u00a0steigende\u00a0Vermarktung\u00a0von\u00a0Orphan\u2010Arzneimitteln\u00a0ist\u00a0un\u00fcberse hbar.\u00a0So\u00a0sehr\u00a0es\u00a0\nauch\u00a0w\u00fcnschenswert\u00a0ist,\u00a0dass\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0seltenen\u00a0Erkrank ungen\u00a0neue\u00a0Be\u2010\nhandlungsoptionen\u00a0 erschlossen\u00a0 werden,\u00a0 so\u00a0 deutlich\u00a0 muss\u00a0 jedoch\u00a0 a uch\u00a0 betont\u00a0\nwerden,\u00a0dass\u00a0im\u00a0Rahmen\u00a0des\u00a0AMNOG\u2010Verfahrens\u00a0die\u00a0Vermarktung\u00a0von \u00a0Orphan\u2010\nArzneimitteln\u00a0nicht\u00a0ausreichend\u00a0geregelt\u00a0ist.\u00a0Es\u00a0wird\u00a0grunds\u00e4tz lich\u00a0davon\u00a0ausge\u2010\ngangen,\u00a0 dass\u00a0 Orphan\u2010Arzneimittel\u00a0 einen\u00a0 Zusatznutzen\u00a0 aufweisen.\u00a0 Daher\u00a0 wird\u00a0\nnicht,\u00a0wie\u00a0bei\u00a0anderen\u00a0neuen\u00a0Arzneimitteln,\u00a0gegen\u00a0eine\u00a0m\u00f6gliche \u00a0zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie\u00a0gepr\u00fcft,\u00a0um\u00a0eine\u00a0Bewertung\u00a0des\u00a0patientenorie ntierten\u00a0Zusatz\u2010\nnutzens\u00a0abgeben\u00a0zu\u00a0k\u00f6nnen.\u00a0Die\u00a0bis herigen\u00a0Ergebnisse\u00a0auch\u00a0in\u00a0di esem\u00a0Innovati\u2010\nonsreport\u00a0zeigen\u00a0allerdings,\u00a0dass\u00a0f\u00fcr\u00a0einen\u00a0Teil\u00a0der\u00a0 Orphan\u2010Arzneimittel\u00a0ein\u00a0solcher\u00a0\nZusatznutzen\u00a0nicht\u00a0erkennbar\u00a0ist\u00a0(bei\u00a0vier\u00a0von\u00a0zw\u00f6lf\u00a0Wirkstoffe n).\u00a0Wegen\u00a0solcher\u00a0\nErgebnisse\u00a0 muss\u00a0 das\u00a0 AMNOG\u00a0 dringend\u00a0 die\u00a0 Regelungen\u00a0 f\u00fcr\u00a0 die\u00a0 Orphan\u2010\nArzneimittel\u00a0um\u00a0die\u00a0Bewertung\u00a0des\u00a0Zusatznutzens\u00a0erg\u00e4nzen,\u00a0um\u00a0le tztlich\u00a0auch\u00a0in\u00a0\nregul\u00e4re\u00a0Preisverhandlungen\u00a0eint reten\u00a0zu\u00a0k\u00f6nnen,\u00a0die\u00a0derzeit\u00a0er st\u00a0dann\u00a0m\u00f6glich\u00a0\nsind,\u00a0wenn\u00a0ein\u00a0GKV\u2010Umsatz\u00a0von\u00a0\u00fcber\u00a050\u00a0Mio.\u00a0Euro\u00a0pro\u00a0Jahr\u00a0\u00fcbersc hritten\u00a0wird.\u00a0\nDiese\u00a0Grenze\u00a0sollte\u00a0gestrichen\u00a0werden\u00a0\u2013\u00a0auch\u00a0 Orphan\u2010Arzneimittel\u00a0m\u00fcssen\u00a0mit\u00a0\nMarkteintritt\u00a0 grunds\u00e4tzlich\u00a0 der\u00a0 \u00fcblichen\u00a0 Nutzenbewertung,\u00a0 einsc hlie\u00dflich\u00a0 der\u00a0\nPreisverhandlung\u00a0unterliegen,\u00a0bevo r\u00a0sie\u00a0im\u00a0Rahmen\u00a0der\u00a0GKV\u00a0veror dnet\u00a0werden\u00a0\nk\u00f6nnen.\u00a0Die\u00a0Preisentwicklungen\u00a0de r\u00a0letzten\u00a0Jahre\u00a0in\u00a0diesem\u00a0Bere ich\u00a0zeigen\u00a0deut\u2010\nlich,\u00a0wie\u00a0sehr\u00a0pU\u00a0diese\u00a0AMNOG\u2010R egelungen\u00a0nutzen,\u00a0um\u00a0unangemesse n\u00a0hohe\u00a0Prei\u2010\nse\u00a0im\u00a0Markt\u00a0zu\u00a0erzielen.\u00a0Die\u00a0Bewertung\u00a0des\u00a0Zusatznutzens\u00a0w\u00fcrde\u00a0 auch\u00a0eine\u00a0Nut\u2010\nzen\u2010Schaden\u2010Bewertung\u00a0einbeziehen.\u00a0Es\u00a0ist\u00a0nicht\u00a0nachvollziehbar ,\u00a0dass\u00a0bei\u00a0allen\u00a0\nneuen\u00a0Arzneimitteln\u00a0diese\u00a0Risikob ewertung\u00a0einflie\u00dft,\u00a0letztlich\u00a0 auch\u00a0zugunsten\u00a0der\u00a0\nPatienten,\u00a0die\u00a0vor\u00a0Nebenwirkungen\u00a0gesch\u00fctzt\u00a0werden\u00a0sollen,\u00a0dass \u00a0aber\u00a0ausgerechnet\u00a0\nPatienten\u00a0 mit\u00a0 seltenen\u00a0 Erkrankungen\u00a0 von\u00a0 dieser\u00a0 \u201eSchutzfunktion\u201c \u00a0a u s g e n o m m e n \u00a0\nwerden.\u00a0\nDringend\u00a0erforderlich\u00a0sind\u00a0systematische\u00a0Marktbeobachtungen\u00a0nac h\u00a0der\u00a0Zulas\u2010\nsung\u00a0eines\u00a0neuen\u00a0Arzneimittels.\u00a0 Nationale\u00a0und\u00a0internationale\u00a0Da ten\u00a0weisen\u00a0darauf\u00a0\nhin,\u00a0dass\u00a0bestimmte\u00a0Nebenwirkungen\u00a0erst\u00a0im\u00a0Rahmen\u00a0einer\u00a0unselek tierten\u00a0und\u00a0\nbreiten\u00a0Anwendung\u00a0an\u00a0Patienten\u00a0nach\u00a0der\u00a0Zulassung\u00a0erkannt\u00a0werde n.\u00a0Die\u00a0Anzahl\u00a0\nder\u00a0Rote\u2010Hand\u2010Briefe\u00a0bei\u00a0etwa\u00a020\u00a0%\u00a0der\u00a0hier\u00a0bewerteten\u00a0neuen\u00a0Ar zneimittel\u00a0schon\u00a0\ninnerhalb\u00a0der\u00a0ersten\u00a0beiden\u00a0Vermarktungsjahre\u00a0ist\u00a0hierf\u00fcr\u00a0ein\u00a0w ichtiges\u00a0Indiz.\u00a0In\u00a0\ndiesem\u00a0Zusammenhang\u00a0ist\u00a0daher\u00a0die\u00a0Forderung\u00a0nach\u00a0einer\u00a0\u201eSp\u00e4tbew ertung\u201c\u00a0neu\u2010\ner\u00a0Arzneimittel\u00a0erneut\u00a0zu\u00a0betonen,\u00a0die\u00a0etwa\u00a0drei\u00a0bis\u00a0f\u00fcnf\u00a0Jahre \u00a0nach\u00a0der\u00a0fr\u00fchen\u00a0\nNutzenbewertung\u00a0stattfinden\u00a0sollte.\u00a0In\u00a0diesem\u00a0Zeitraum\u00a0stehen\u00a0z us\u00e4tzliche\u00a0Daten\u00a0500\u00a0\u00fcber\u00a0den\u00a0Patientennutzen\u00a0und\u00a0auch\u00a0\u00fcber\u00a0neue\u00a0Risiken\u00a0zur\u00a0Verf\u00fcgu ng,\u00a0die\u00a0eine\u00a0\nbessere\u00a0Bewertungsbasis\u00a0als\u00a0unmittelbar\u00a0nach\u00a0der\u00a0Zulassung\u00a0erm\u00f6 glichen.\u00a0Dies\u00a0gilt\u00a0\ninsbesondere\u00a0mit\u00a0Blick\u00a0auf\u00a0die\u00a0Strategie\u00a0der\u00a0beschleunigten\u00a0Zul assung\u00a0unter\u00a0dem\u00a0\nAspekt\u00a0verk\u00fcrzter\u00a0Zulassungsregelungen,\u00a0f\u00fcr\u00a0Arzneimittel\u00a0( adaptive\u00a0licensing ),\u00a0die\u00a0\ninternational\u00a0diskutiert\u00a0und\u00a0in\u00a0E inzelf\u00e4llen\u00a0bereits\u00a0umgesetzt\u00a0 wird.\u00a0In\u00a0diesem\u00a0Zu\u2010\nsammenhang\u00a0besteht\u00a0die\u00a0Gefahr,\u00a0dass\u00a0die\u00a0Wirksamkeit\u00a0der\u00a0neuen\u00a0A rzneimittel\u00a0\n\u00fcber\u2010,\u00a0die\u00a0Risiken\u00a0aber\u00a0untersch\u00e4tzt\u00a0werden.\u00a0Das\u00a0AMNOG\u00a0sollte\u00a0d iese\u00a0Entwicklun\u2010\ngen\u00a0in\u00a0seinen\u00a0Abl\u00e4ufen\u00a0zur\u00a0Bewertung\u00a0neuer\u00a0Arzneimittel\u00a0und\u00a0die \u00a0Notwendigkeit\u00a0\neiner\u00a0\u201eSp\u00e4tbewertung\u201c\u00a0auf\u00a0europ\u00e4ischer\u00a0Ebene\u00a0ber\u00fccksichtigen.\u00a0\nDas\u00a0AMNOG\u2010Verfahren\u00a0ist\u00a0als\u00a0lernendes\u00a0System\u00a0eingef\u00fchrt\u00a0worden. \u00a0Im\u00a0Laufe\u00a0der\u00a0\nvergangenen\u00a0Jahre\u00a0sind\u00a0allerdings\u00a0nicht\u00a0nur\u00a0Erfolge\u00a0bez\u00fcglich\u00a0d er\u00a0strukturierten\u00a0\nMarkteinf\u00fchrung\u00a0neuer\u00a0Arzneimitte l\u00a0nach\u00a0Aspekten\u00a0der\u00a0Evidenz\u00a0un d\u00a0des\u00a0Patien\u2010\ntennutzens\u00a0zu\u00a0erkennen,\u00a0sondern\u00a0auch\u00a0Schw\u00e4chen,\u00a0so\u00a0z.B.\u00a0bez\u00fcgli ch\u00a0des\u00a0Markt\u2010\nsegmentes\u00a0 der\u00a0 Orphan\u2010Arzneimittel,\u00a0 die\u00a0 ohne\u00a0 re gul\u00e4re\u00a0 Nutzenbewertung\u00a0 und\u00a0\nPreisverhandlungen\u00a0auf\u00a0den\u00a0Arzneimittelmarkt\u00a0dr\u00e4ngen\u00a0oder\u00a0bez\u00fcg lich\u00a0einer\u00a0ad\u00e4\u2010\nquaten\u00a0 Schaden\u2010Nutzen\u2010Bewertung\u00a0 v on\u00a0 Arzneimitteln,\u00a0 die\u00a0 aufgrund \u00a0e i n e r \u00a0b e \u2010\nschleunigten\u00a0Zulassung\u00a0Eingang\u00a0in\u00a0den\u00a0Arzneimittelmarkt\u00a0finden. \u00a0Hier\u00a0muss\u00a0sich\u00a0\ndas\u00a0AMNOG\u00a0den\u00a0ver\u00e4nderten\u00a0Rahmenbedingungen\u00a0anpassen,\u00a0um\u00a0weiter hin\u00a0posi\u2010\ntiv\u00a0auf\u00a0die\u00a0Qualit\u00e4t\u00a0der\u00a0Arzneimittelversorgung\u00a0f\u00fcr\u00a0die\u00a0Versich erten\u00a0der\u00a0GKV\u00a0ein\u2010\nwirken\u00a0zu\u00a0k\u00f6nnen.\u00a0 \u00a0501\u00a08 Abk\u00fcrzungsverzeichnis\u00a0\n\u00b5g\u00a0\u00a0 Mikrogramm\u00a0\nAE\u00a0 Adverse\u00a0Events ,\u00a0unerw\u00fcnschtes\u00a0Ereignis\u00a0(s.\u00a0UE)\u00a0\nAkd\u00c4\u00a0 Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0\nALL\u00a0 Akute\u00a0Lymphoblastenleuk\u00e4mie\u00a0\u00a0AMNOG\u00a0 Arzneimittelmarktneuordnungsgesetz\u00a0AP\u00a0 akzelerierte\u00a0Phase\u00a0\nAUC\u00a0 Area\u00a0under\u00a0the\u00a0Curve,\u00a0 Fl\u00e4che\u00a0unter\u00a0der\u00a0Kurve \u00a0\na\u2010t\u00a0 arznei\u2010telegramm\u00ae\u00a0atd\u00a0 Arzneimitteldatenbank\u00a0des\u00a0arznei\u2010telegramm\u00ae\u00a0ATC\u2010Code\u00a0 Anatomisch\u2010Therap eutisch\u2010Chemischer\u00a0Code\u00a0\nAWMF\u00a0 Arbeitsgemeinschaft\u00a0der\u00a0Wis senschaftlichen\u00a0Medizinischen\u00a0\nFachgesellschaften\u00a0e.V.\u00a0\nBDI\u00a0 Borg\u2010Dyspnoe\u2010Index\u00a0\u00a0\nBfArM\u00a0 Bundesinstitut\u00a0f\u00fcr\u00a0Arzn eimittel\u00a0und\u00a0Medizinprodukte\u00a0\nBK\u00a0 Blastenkrise\u00a0BSC\u00a0 Best\u2010Supportive\u2010Care\u00a0\nbzgl.\u00a0 bez\u00fcglich\u00a0\nca.\u00a0 circa\u00a0\ncAMP\u00a0 cyclo\u2010AMP ,\u00a0zyklisches\u00a0Adenosin\u2010 3\u00b4,\u00a05\u00b4\u2010monophosphat\u00a0( cyclic\u00a0~)\u00a0\nCcyR\u00a0 Complete\u00a0Cytogenetic\u00a0Response,\u00a0 komplette\u00a0zytogenetische\u00a0\nRemission\u00a0\nCHMP\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use,\u00a0 Ausschuss\u00a0f\u00fcr\u00a0\nHumanarzneimittel\u00a0\nCML\u00a0 Chronische\u00a0Myeloische\u00a0Leuk\u00e4mie\u00a0\nCOPD\u00a0 Chronic\u00a0Obstructive\u00a0Pulmonary\u00a0Disease ,\u00a0Chronisch\u00a0obstruktive\u00a0\nLungenerkrankung\u00a0\u00a0\nCP\u00a0 chronische\u00a0Phase\u00a0CR\u00a0 Complete \u00a0Remission ,\u00a0komplette\u00a0Remission\u00a0\nCTCAE\u00a0 Common\u00a0Toxicity\u00a0Criteria\u00a0for\u00a0Adverse\u00a0Events,\u00a0 Allgemeine\u00a0\nTerminologiekriterien\u00a0von\u00a0 unerw\u00fcnschten\u00a0Ereignissen\u00a0\nDDD\u00a0 Defined\u00a0Daily\u00a0Dose, \u00a0definierte\u00a0Tagesdosis\u00a0\nDIMDI\u00a0 Deutsches\u00a0Institut\u00a0f\u00fcr\u00a0Medizinische\u00a0Dokumentation\u00a0und\u00a0\nInformation\u00a0\nDGN\u00a0 Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Neurologie\u00a0e.V.\u00a0DKG\u00a0 Deutsche\u00a0Krebsgesellschaft\u00a0e.V.\u00a0\nDPhG\u00a0 Deutsche\u00a0Pharmazeutische\u00a0Gesellschaft\u00a0e.V.\u00a0\nDSM\u00a0 Diagnostic\u00a0and\u00a0Statistical\u00a0Ma nual\u00a0of\u00a0Mental\u00a0Disorders,\u00a0\nDiagnostischer\u00a0und\u00a0statistischer\u00a0Leitfaden\u00a0psychischer\u00a0St\u00f6runge n\u00a0502\u00a0eGFR\u00a0 estimated\u00a0glomerular\u00a0filtration\u00a0rate ,\u00a0gesch\u00e4tzte\u00a0glomerul\u00e4re\u00a0\nFiltrationsrate\u00a0\u00a0\nEMA\u00a0 European\u00a0Medicines\u00a0Agency ,\u00a0Europ\u00e4ische\u00a0Arzneimittel\u2010Agentur\u00a0\nESC\u00a0 European\u00a0Society\u00a0of\u00a0Cardiology ,\u00a0Europ\u00e4ische\u00a0Gesellschaft\u00a0f\u00fcr\u00a0\nKardiologie,\u00a0Herz\u2010\u00a0und\u00a0 Kreislaufforschung\u00a0e.V.\u00a0\u00a0\nESMO\u00a0\u00a0 European\u00a0Society\u00a0of\u00a0Medical\u00a0Oncology, \u00a0Europ\u00e4ische\u00a0Gesellschaft\u00a0\u00a0\nf\u00fcr\u00a0Medizinische\u00a0Onkologie\u00a0\nFDA\u00a0 Food\u00a0and\u00a0Drug\u00a0Administration ,\u00a0US\u2010Amerikanische\u00a0\nZulassungsbeh\u00f6rde\u00a0\nFEV1\u00a0 Forced\u00a0Expiratory\u00a0Pressure\u00a0in\u00a01\u00a0Second ,\u00a0Einsekundenkapazit\u00e4t\u00a0\nFI\u00a0 Fachinformation\u00a0FTA\u00a0 Filmtablette\u00a0\nG\u2010BA\u00a0 Gemeinsamer\u00a0Bundesausschuss\u00a0\nGIST\u00a0 Gastrointestinale\u00a0Stromatumoren\u00a0\u00a0GKV\u00a0 Gesetzliche\u00a0Krankenversicherung\u00a0\nGOLD\u00a0 Global\u00a0Initiative\u00a0For\u00a0Chronic\u00a0Obstructive\u00a0Lung\u00a0Disease,\u00a0 Globale\u00a0\nInitiative\u00a0f\u00fcr\u00a0chronisch\u00a0obstruktive\u00a0Lungenerkrankungen\u00a0\nHbA1c\u00a0 Glykiertes\u00a0H\u00e4moglobin\u00a0HR\u00a0 Hazard\u00a0Ratio\u00a0\nIRR\u00a0 infusionsbedingte\u00a0Reaktionen\u00a0\nIDF\u00a0 International\u00a0Diabetes\u00a0Federation \u00a0\nIC50\u00a0 half\u00a0maximal\u00a0inhibitory\u00a0concentration ,\u00a0mittlere\u00a0inhibitorische\u00a0\nKonzentration\u00a0\u00a0\nI.E.\u00a0 Internationale\u00a0Einheiten\u00a0\ni.m.\u00a0 intramuskul\u00e4r\u00a0i.v.\u00a0 intraven\u00f6s\u00a0\nICD\u00a0 International\u00a0Statistical\u00a0Classification\u00a0of\u00a0Diseases\u00a0and\u00a0Re lated\u00a0\nHealth\u00a0Problems,\u00a0Internationale\u00a0 statistische\u00a0Klassifikation\u00a0der \u00a0\nKrankheiten\u00a0und\u00a0verwandter\u00a0Gesundheitsprobleme\u00a0\nImiD\u00a0 Immunomodulatory\u00a0Drugs, \u00a0immunmodulierende\u00a0Wirkstoffe\u00a0\u00a0\nIQWiG\u00a0 Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundhei tswesen\u00a0\nkg\u00a0 Kilogramm\u00a0KG\u00a0 K\u00f6rpergewicht\u00a0\nKOF\u00a0 K\u00f6rperoberfl\u00e4che\u00a0\nKRK\u00a0 metastasiertes\u00a0Kolorektalkarzinom\u00a0KTA\u00a0 Kautabletten\u00a0LABA\u00a0 Long\u2010acting\u00a0Beta\u20102\u00a0Agonist ,\u00a0lang\u00a0wirkender\u00a0Beta2\u2010Rezeptoragonist\u00a0\u00a0\nlaBCC\u00a0 lokal\u00a0fortgeschrittenes\u00a0Basalzellkarzinom\u00a0\u00a0\nLL\u00a0 Leitlinie\u00a0 \u00a0MaHR\u00a0 R\u00fcckgang\u00a0der\u00a0Leukozyten\u00a0a uf\u00a0Normalwerte\u00a0oder\u00a0fehlende\u00a0\nAnzeichen\u00a0einer\u00a0Leuk\u00e4mie\u00a0(gutes\u00a0 h\u00e4matologisches\u00a0Ansprechen)\u00a0\u00a0503\u00a0mBCC\u00a0 metastasiertem\u00a0Basalzellkarzinom\u00a0\nMcyR\u00a0 Major\u00a0Cytogenetic\u00a0Response,\u00a0g ute\u00a0zytogenetische\u00a0Remission\u00a0\nMio.\u00a0 Millionen\u00a0Ml\u00a0 Milliliter\u00a0MM\u00a0 multiples\u00a0Melanom\u00a0\u00a0\nMS\u00a0 Multiple\u00a0Sklerose\u00a0\nnM\u00a0 Nanomolar\u00a0NCCN\u00a0 National\u00a0Comprehensive\u00a0Cancer\u00a0Network,\u00a0 Allianz\u00a0von\u00a0Krebszentren\u00a0\nin\u00a0den\u00a0USA\u00a0\nNOAK\u00a0 Neue\u00a0Orale\u00a0An tikoagulanzien\u00a0\nNSCLC\u00a0 Non\u00a0Small\u00a0Cell\u00a0Lung\u00a0Cancer,\u00a0 nicht\u2010kleinzellige s\u00a0Lungenkarzinom\u00a0\nNVL\u00a0 Nationale\u00a0Versorgungsleitlinie\u00a0\nOS\u00a0 Overall\u00a0Survival ,\u00a0Gesamt\u00fcberleben\u00a0\u00a0\nO/W\u00a0\u00a0 Emulsion\u00a0 \u00d6l\u2010in\u2010Wasser\u00a0Emulsion\u00a0pCR\u00a0 pathologische\u00a0Komplettremission\u00a0\nPFS\u00a0 progressionsfreies \u00a0\u00dcberleben\u00a0\nPh\n+\u2010CML\u00a0 Philadelphia\u2010Chromosom\u2010posi tive\u00a0chronische\u00a0myeloische\u00a0Leuk \u00e4mie\u00a0\npU\u00a0 pharmazeutischer\u00a0Unternehmer\u00a0PZ\u00a0 Pharmazeutische\u00a0Zeitung\u00a0\nRECIST\u00a0 Response\u00a0Evaluation\u00a0Criteria\u00a0In\u00a0Solid\u00a0Tumors,\u00a0 Kriterien\u00a0f\u00fcr\u00a0die\u00a0\nBewertung\u00a0des\u00a0Ansprechens\u00a0der\u00a0B ehandlung\u00a0bei\u00a0soliden\u00a0Tumoren\u00a0\nRDS\u00a0\u00a0 Reizdarmsyndrom\u00a0( Irritable\u00a0Bowel\u00a0Syndrome, \u00a0IBS)\u00a0\nRDS\u2010O\u00a0 Reizdarmsyndrom,\u00a0das\u00a0mit\u00a0 einer\u00a0Obstipation\u00a0einhergeht\u00a0\nRKI\u00a0 Robert\u00a0Koch\u2010Institut\u00a0\nRMS\u00a0 Reference\u00a0Member\u00a0State \u00a0\nrPFS\u00a0 radiologisch\u00a0gesichertes\u00a0 progressionsfreies\u00a0\u00dcberleben\u00a0\nsc.\u00a0 subkutan\u00a0\nSF36\u00a0 Medical\u2010Outcome\u2010Study\u201036\u2010Item\u2010Short\u2010Form\u2010Questionnaire \u00a0\nSGB\u00a0V\u00a0 Sozialgesetzbuch\u00a05\u00a0SGLT\u00a0 Sodium\u2010Glucose\u00a0Co\u2010Transporter \u00a0\nTK\u00a0 Techniker\u00a0Krankenkasse\u00a0\nTKI\u00a0 Tyrosinkinase\u2010Inhibitor\u00a0Tsd.\u00a0 Tausend\u00a0\nU(A)E\u00a0 Unerw\u00fcnschtes\u00a0(Arzneimittel)ereignis\u00a0\nUAW\u00a0 Unerw\u00fcnschte\u00a0Arzneimittelwirkung(en)\u00a0vs.\u00a0 versus\u00a0\nWHO\u00a0 World\u00a0Health\u00a0Organization ,\u00a0Weltgesundheitsorganisation\u00a0\nWIdO\u00a0 Wissenschaftliches\u00a0Institut\u00a0der\u00a0Ortskrankenkassen\u00a0\nz.B.\u00a0\u00a0 zum\u00a0Beispiel\u00a0ZNS\u00a0 Zentrales\u00a0Nervensystem\u00a0zVT\u00a0 zentrale\u00a0Vergleichstherapie\u00a0504\u00a09 Anhang:\u00a0Nutzenbewertungs\u2010News\u00a0zu\u00a0neuen\u00a0Arzneimitteln\u00a0\nF\u00fcr\u00a0\u00c4rzte\u00a0 online\u00a0unter:\u00a0\u00a0\nhttp://www.socium.uni\u2010bremen.de/uploads/Mitarbeiter/GerdGlaeske /Inno\u00a0\nvationsreport/Nutzenbewertungs_News/TK_Arztenews_Innoreport_201 7_.pdf\u00a0\nF\u00fcr\u00a0Patienten\u00a0 online\u00a0unter:\u00a0\nwww.socium.uni\u2010bremen.de/uploads /Mitarbeiter/GerdGlaeske/Innova tions\u00a0\nreport/Nutzenbewertungs_News/TK_Patientennews_Innoreport_2017.p df\u00a0\n10 Lebensl\u00e4ufe\u00a0\nHerausgeber\u00a0und\u00a0Autoren\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0in\u00a0Aachen\u00a0 und\u00a0Hamburg,\u00a0dort\u00a0auch\u00a0Promotio n.\u00a0Ab\u00a01981\u00a0Wissenschaftli\u2010\ncher\u00a0Mitarbeiter\u00a0im\u00a0Bremer\u00a0Insti tut\u00a0f\u00fcr\u00a0Pr\u00e4ventionsforschung\u00a0un d\u00a0Sozialmedizin\u00a0(BIPS),\u00a0dort\u00a0ab\u00a0\n1985\u00a0 Leiter\u00a0 der\u00a0 Abteilung\u00a0 Arzneim ittelepidemiologie,\u00a0 Projektlei tung\u00a0 einer\u00a0 Arzneimittelbewer\u2010\ntungsstudie\u00a0(Bewertender\u00a0Arzneimi ttelindex,\u00a0hrsg.\u00a0von\u00a0E.\u00a0Greise r).\u00a0Ab\u00a01988\u00a0Leiter\u00a0von\u00a0Pharmako\u2010\nlogischen\u00a0Beratungsdiensten\u00a0in\u00a0K rankenkassen,\u00a0Leiter\u00a0der\u00a0Abteil ung\u00a0Verbandspolitik\u00a0beim\u00a0Ver\u2010\nband\u00a0 der\u00a0 Angestellten\u00a0 Krankenkassen\u00a0 (VdAK),\u00a0 sp\u00e4ter\u00a0 der\u00a0 Abteilun g\u00a0 f\u00fcr\u00a0 medizinisch\u2010wissen\u2010\nschaftliche\u00a0Grundsatzfragen,\u00a0zul etzt\u00a0bei\u00a0der\u00a0BARMER\u00a0Ersatzkasse .\u00a0\nSeit\u00a01999\u00a0Professor\u00a0f\u00fcr\u00a0Arznei mittelversorgungsforschung\u00a0am\u00a0Zen trum\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS),\u00a0ab\u00a0\n2015\u00a0im\u00a0SOCIUM\u00a0der\u00a0Universit\u00e4t\u00a0Br emen,\u00a0Forschungszentrum\u00a0Unglei chheit\u00a0und\u00a0Sozialpolitik.\u00a0Ab\u00a0\n2007\u00a0 Co\u2010Leiter\u00a0 der\u00a0 Abteilung\u00a0 G esundheits\u00f6konomie,\u00a0 Gesundheitspo litik\u00a0 und\u00a0 Versorgungsfor\u2010\nschung,\u00a0 ab\u00a0 2015\u00a0 umbenannt\u00a0 in\u00a0 Abte ilung\u00a0 soziale\u00a0 Ungleichheit\u00a0 und \u00a0 Sozialpolitik:\u00a0 Gesundheit,\u00a0\nPflege\u00a0und\u00a0Alterssicherung.\u00a0\nVon\u00a0 2003\u00a0 bis\u00a0 2009\u00a0 vom\u00a0 Gesundheits minister\u00a0 berufenes\u00a0 Mitglied\u00a0 im \u00a0 Sachverst\u00e4ndigenrat\u00a0 zur\u00a0\nBegutachtung\u00a0der\u00a0Entwicklung\u00a0i m\u00a0Gesundheitswesen\u00a0(www.svr\u2010gesun dheit.de),\u00a0seit\u00a02003\u00a0Mitglied\u00a0\nim\u00a0wissenschaftlichen\u00a0Beirat\u00a0der \u00a0Bundeszentrale\u00a0f\u00fcr\u00a0gesundheitl iche\u00a0Aufkl\u00e4rung\u00a0(BZgA),\u00a0Bis\u00a02013\u00a0\nMitglied\u00a0 in\u00a0 der\u00a0 BTM\u2010Kommission\u00a0 d es\u00a0 Bundesinstitutes\u00a0 f\u00fcr\u00a0 Arzneim ittel\u00a0 und\u00a0 Medizinprodukte\u00a0\n(BfArM).\u00a0Von\u00a02007\u00a0bis\u00a0zum\u00a0R\u00fccktritt\u00a0am\u00a025.\u00a0M\u00e4rz\u00a02008\u00a0von\u00a0der\u00a0Ge sundheitsministerin\u00a0berufenes\u00a0\nMitglied\u00a0und\u00a0gew\u00e4hlter\u00a0Vorsitzende r\u00a0im\u00a0wissenschaftlichen\u00a0Beira t\u00a0des\u00a0BVA\u00a0zur\u00a0Erstellung\u00a0eines\u00a0\nGutachtens\u00a0zum\u00a0morbidit\u00e4tsorient ierten\u00a0Risikostrukturausgleichs .\u00a0\nMitglied\u00a0der\u00a0Drug\u2010Utilization\u2010Research\u2010Group\u00a0der\u00a0WHO,\u00a0seit\u00a02005 \u00a0nach\u00a0vierj\u00e4hriger\u00a0T\u00e4tigkeit\u00a0als\u00a01.\u00a0\nVorsitzender\u00a0der\u00a0Gesellschaft\u00a0f\u00fc r\u00a0Arzneimittelanwendungsforschu ng\u00a0und\u00a0Arzneimittelepidemiolo\u2010\ngie\u00a0(GAA)\u00a0nun\u00a0Berater\u00a0des\u00a0Vorstands,\u00a02006\u00a0bis\u00a02014\u00a0Mitglied\u00a0im\u00a0 gesch\u00e4ftsf\u00fchrenden\u00a0Vorstand\u00a0des\u00a0\nDeutschen\u00a0Netzwerkes\u00a0Versorgung sforschung\u00a0(DNVF).\u00a0Mitglied\u00a0in\u00a0d iversen\u00a0medizinischen\u00a0und\u00a0\nepidemiologischen\u00a0 Fachgesellschaf ten.\u00a0 Ab\u00a0 2009\u00a0 vom\u00a0 \u00f6sterreichisc hen\u00a0 Bundesminister\u00a0 f\u00fcr\u00a0 Ge\u2010\nsundheit\u00a0berufenes\u00a0Mitglied\u00a0des\u00a0 Kommission\u00a0f\u00fcr\u00a0rationale\u00a0Arznei mitteltherapie.505\u00a0Prof.\u00a0Dr.\u00a0Wolf\u2010D ieter\u00a0Ludwig\u00a0\nStudium\u00a0der\u00a0Humanmedizin\u00a0in\u00a0Louvain\u00a0(Belgien),\u00a0Frankfurt\u00a0am\u00a0Mai n\u00a0und\u00a0Berlin\u00a0bis\u00a01979.\u00a0Von\u00a01979\u00a0\nbis\u00a01981\u00a0Wissenschaftlicher\u00a0Mitarbeiter\u00a0am\u00a0Pharmakologischen\u00a0In stitut\u00a0der\u00a0Freien\u00a0Universit\u00e4t\u00a0(FU)\u00a0\nBerlin.\u00a0Von\u00a01981\u00a0bis\u00a01993\u00a0Fort\u2010\u00a0und\u00a0Weiterbildung\u00a0zum\u00a0Facharzt\u00a0 f\u00fcr\u00a0Innere\u00a0Medizin\u00a0mit\u00a0Zusatzbe\u2010\nzeichnung\u00a0H\u00e4matologie/internistische\u00a0Onkologie\u00a0in\u00a0der\u00a0Abteilung \u00a0f\u00fcr\u00a0Innere\u00a0Medizin\u00a0mit\u00a0Schwer\u2010\npunkt\u00a0H\u00e4matologie\u00a0und\u00a0Onkologie\u00a0d es\u00a0Universit\u00e4tsklinikums\u00a0Stegl itz\u00a0der\u00a0FU\u00a0Berlin.\u00a01982\u00a0Promotion\u00a0\nund\u00a01991\u00a0Habilitation.\u00a0Im\u00a0Jahr\u00a01994\u00a0Berufung\u00a0auf\u00a0C3\u2010Professur\u00a0f \u00fcr\u00a0Innere\u00a0Medizin\u00a0f\u00fcr\u00a0H\u00e4matologie.\u00a0\nOnkologie\u00a0und\u00a0Angewandte\u00a0Molekularbiologie\u00a0im\u00a0Fachbereich\u00a0Unive rsit\u00e4tsklinikum\u00a0Rudolf\u2010Virchow\u00a0\n(Bereich\u00a0Berlin\u2010Buch).\u00a0Von\u00a02001\u00a0bis\u00a0August\u00a02017\u00a0Chefarzt\u00a0der\u00a0Kl inik\u00a0f\u00fcr\u00a0H\u00e4matologie,\u00a0Onkologie,\u00a0\nTumorimmunologie\u00a0und\u00a0 Palliativmedizin,\u00a0Robert\u2010R\u00f6ssle\u2010Klinik,\u00a0HE LIOS\u00a0Klinikum\u00a0Berlin\u2010Buch.\u00a0\nUnter\u00a0anderem\u00a0seit\u00a02006\u00a0Vorsit zender\u00a0der\u00a0Arzneimittelkommission \u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0und\u00a0\nMit\u2010Herausgeber\u00a0des\u00a0unabh\u00e4ngigen\u00a0I nformationsblatts\u00a0DER\u00a0ARZNEIM ITTELBRIEF.\u00a0Fachredakteur\u00a0\nf\u00fcr\u00a0das\u00a0Gebiet\u00a0\u201eArzneimittelthe rapie\u00a0und\u00a0H\u00e4matologie\u201c\u00a0der\u00a0mediz inisch\u2010wissenschaftlichen\u00a0Re\u2010\ndaktion\u00a0des\u00a0Deutschen\u00a0\u00c4rztebla ttes.\u00a0Seit\u00a0M\u00e4rz\u00a02013\u00a0Mitglied\u00a0des \u00a0Management\u00a0Board\u00a0der\u00a0Euro\u2010\npean\u00a0Medicines\u00a0Agency\u00a0(EMA)\u00a0als\u00a0Vertreter\u00a0der\u00a0europ\u00e4ischen\u00a0\u00c4rzt eschaft.\u00a0\nDr.\u00a0P.H.\u00a0Stanislava\u00a0Dicheva \u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0in\u00a0W\u00fcrzburg\u00a0von\u00a02002\u00a0bis\u00a02007.\u00a0Absolvieru ng\u00a0des\u00a0Praktischen\u00a0Jahres\u00a02008\u00a0\nbis\u00a02009\u00a0in\u00a0einer\u00a0\u00f6ffentlichen\u00a0Ap otheke\u00a0in\u00a0Karlstadt,\u00a02009\u00a0Appr obation\u00a0zur\u00a0Apothekerin.\u00a0Von\u00a02009\u00a0\nbis\u00a02016\u00a0wissenschaftliche\u00a0Mitar beiterin\u00a0und\u00a0Doktorandin\u00a0im\u00a0Zen trum\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS),\u00a0ab\u00a0\n2015\u00a0SOCIUM,\u00a0Forschungszentrum\u00a0U ngleichheit\u00a0und\u00a0 Sozialpolitik,\u00a0 Abteilung\u00a0Soziale\u00a0Ungleichheit\u00a0\nund\u00a0Sozialpolitik:\u00a0Gesundheit,\u00a0Pfle ge\u00a0und\u00a0Alter\u00a0an\u00a0der\u00a0Universi t\u00e4t\u00a0Bremen;\u00a0Nebent\u00e4tigkeit\u00a0als\u00a0\nApothekerin\u00a0in\u00a0einer\u00a0\u00f6ffentlichen\u00a0 Apotheke\u00a0in\u00a0Bremen.\u00a0Promotion \u00a0zum\u00a0Dr.\u00a0P.H.\u00a0im\u00a0Jahr\u00a02016.\u00a0Seit\u00a0\n2016\u00a0Referentin\u00a0in\u00a0der\u00a0Gesch\u00e4ft sstelle\u00a0der\u00a0Arzneimittelkommissi on\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0\n(Akd\u00c4)\u00a0in\u00a0Berlin.\u00a0\nD\u00f6rte\u00a0Fuchs,\u00a0Apothekerin\u00a0\nStudium\u00a0der\u00a0Pharmazie.\u00a0Seit\u00a01990\u00a0h auptberuflich\u00a0in\u00a0einer\u00a0Kranke nhausapotheke\u00a0t\u00e4tig.\u00a0Im\u00a0Jahr\u00a0\n1994\u00a0Abschluss\u00a0der\u00a0Weiterbildung\u00a0zur\u00a0Fachapothekerin\u00a0f\u00fcr\u00a0Klinis che\u00a0Pharmazie,\u00a0im\u00a0Jahr\u00a02008\u00a0\nAbschluss\u00a0der\u00a0Weiterbildung\u00a0im\u00a0Bereich\u00a0\u201eNaturheilkunde\u00a0und\u00a0Hom\u00f6 opathie\u201c.\u00a0Dozentin\u00a0f\u00fcr\u00a0Pflege\u2010\nkr\u00e4fte.\u00a0Seit\u00a0Juni\u00a02010\u00a0Wissenschaf tliche\u00a0Mitarbeiterin\u00a0am\u00a0Zentr um\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS),\u00a0ab\u00a02015\u00a0\nSOCIUM,\u00a0Forschungszentrum\u00a0Unglei chheit\u00a0und\u00a0Sozialpolitik,\u00a0Abtei lung:\u00a0Gesundheit,\u00a0Pflege\u00a0und\u00a0\nAlterssicherung\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Bremen.\u00a0\nDr.\u00a0Judith\u00a0G\u00fcnther,\u00a0Apothekerin\u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0an\u00a0der\u00a0Un iversit\u00e4t\u00a0des\u00a0Saarlandes,\u00a0Saarbr \u00fccken,\u00a0und\u00a0Approbation\u00a0zur\u00a0\nApothekerin.\u00a0Zwischen\u00a01989\u00a0und\u00a019 93\u00a0Anfertigung\u00a0einer\u00a0Promotion \u00a0zum\u00a0Dr.\u00a0rer.\u00a0nat.\u00a0am\u00a0Institut\u00a0\nf\u00fcr\u00a0Pharmakologie\u00a0der\u00a0Universit\u00e4 t\u00a0zu\u00a0K\u00f6ln\u00a0unter\u00a0der\u00a0Leitung\u00a0von \u00a0Prof.\u00a0Dr.\u00a0U.\u00a0Fricke.\u00a0Anschlie\u00dfend\u00a0\nbis\u00a01999\u00a0Leiterin\u00a0des\u00a0Pharmakolog ischen\u00a0Beratungsdienstes\u00a0der\u00a0A OK\u2010Regionaldirektion\u00a0Essen\u00a0und\u00a0\nElternzeit.\u00a0 Freie\u00a0 Mitarbeit\u00a0 in\u00a0 d iversen\u00a0 gesundheitspolitisch\u00a0 re levanten\u00a0 Projekten,\u00a0 u.a.\u00a0 GEK\u2010\nArzneimittelindex.\u00a0Zwischen\u00a01999 \u00a0und\u00a02002\u00a0wissenschaftliche\u00a0Mit arbeiterin\u00a0des\u00a0Wissenschaftli\u2010\nchen\u00a0Instituts\u00a0der\u00a0AOK\u00a0(WIdO).\u00a0Seit\u00a02002\u00a0wissenschaftliche\u00a0Mita rbeiterin\u00a0bei\u00a0Pharma Facts\u00a0GmbH,\u00a0\nB\u00fcroleitung\u00a0Freiburg.\u00a0Fachapothekerin\u00a0f\u00fcr\u00a0Arzneimittelinformati on.\u00a0Bis\u00a02015\u00a0Mitarbeiterin\u00a0am\u00a0\nZentrum\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS),\u00a0 jetzt\u00a0SOCIUM,\u00a0Forschungszentru m\u00a0Ungleichheit\u00a0und\u00a0Sozialpolitik,\u00a0\nAbteilung:\u00a0Gesundheit,\u00a0Pflege\u00a0und\u00a0 Alterssicherung\u00a0an\u00a0der\u00a0Univer sit\u00e4t\u00a0Bremen. \u00a0\nAutorin\u00a0und\u00a0Coautorin\u00a0bzw.\u00a0pharm azeutisch\u2010pharmakologische\u00a0Bera terin\u00a0diverser\u00a0Arzneimittel\u2010\nPublikationen\u00a0f\u00fcr\u00a0Fachpersonal\u00a0 und\u00a0Laien\u00a0(\u201eNeue\u00a0Arzneimittel\u201c;\u00a0 \u201eArzneistoff\u2010Profile\u201c;\u00a0\u201eArzneiver\u2010\nordnungsReport\u201c;\u00a0\u201eHandbuch\u00a0Medika mente\u201c;\u00a0\u201eHandbuch\u00a0Selbstmedika tion;\u00a0\u201eHandbuch\u00a0Rezept\u2010506\u00a0freie\u00a0Medikamente\u201c;\u00a0\u201eNebenwirkun g\u00a0Sucht\u201c).\u00a0Mitglied\u00a0des\u00a0Deutsch en\u00a0Netzwerk\u00a0f\u00fcr\u00a0Evidenzbasier\u2010\nte\u00a0Medizin\u00a0(DNEbM),\u00a0Sprecherin\u00a0des\u00a0Fachbereiches\u00a0Evidenzbasiert e\u00a0Pharmazie.\u00a0Mitglied\u00a0bei\u00a0der\u00a0\nDeutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Phar makologie\u00a0und\u00a0Toxikologie\u00a0(DGPT) \u00a0sowie\u00a0in\u00a0der\u00a0Gesellschaft\u00a0f\u00fcr\u00a0\nArzneimittelanwendungsforschung\u00a0 und\u00a0Arzneimittelepidemiologie\u00a0( GAA).\u00a0\u00a0\nDr.\u00a0Iris\u00a0Hinneburg,\u00a0Medizinjournalistin\u00a0und\u00a0wissenschaftliche\u00a0A utorin\u00a0\nIris\u00a0Hinneburg\u00a0studierte\u00a0Pharmaz ie\u00a0an\u00a0der\u00a0Philipps\u2010Universit\u00e4t\u00a0 Marburg\u00a0und\u00a0wurde\u00a0an\u00a0der\u00a0Martin\u2010\nLuther\u2010Universit\u00e4t\u00a0Halle\u2010Wittenberg\u00a0promoviert.\u00a0Nach\u00a0T\u00e4tigkeite n\u00a0in\u00a0Forschung\u00a0und\u00a0Lehre\u00a0in\u00a0Halle\u00a0\nund\u00a0Helsinki\u00a0arbeitet\u00a0sie\u00a0heute\u00a0fr eiberuflich\u00a0als\u00a0Medizinjourna listin\u00a0und\u00a0wissenschaftliche\u00a0Autorin.\u00a0\nAu\u00dferdem\u00a0produziert\u00a0sie\u00a0Podcasts\u00a0 mit\u00a0Themen\u00a0zur\u00a0evidenzbasierte n\u00a0Medizin\u00a0und\u00a0Pharmazie\u00a0und\u00a0\nengagiert\u00a0sich\u00a0im\u00a0Deutschen\u00a0Netz werk\u00a0Evidenzbasierte\u00a0Medizin.\u00a0\nSaskia\u00a0Ritter,\u00a0Apothekerin\u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0an\u00a0der\u00a0Martin\u2010Luther\u2010Universit\u00e4t\u00a0Halle\u2010Wi ttenberg,\u00a0Halle\u00a0(Saale)\u00a0und\u00a0Appro\u2010\nbation\u00a0zur\u00a0Apothekerin\u00a02014.\u00a0Anschlie\u00dfend\u00a0Arbeit\u00a0in\u00a0der\u00a0\u00f6ffentl ichen\u00a0Apotheke.\u00a0Seit\u00a02016\u00a0T\u00e4tigkeit\u00a0\nals\u00a0wissenschaftliche\u00a0Mitarbeiterin\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Bremen,\u00a0 SOCIUM\u00a0\u2013\u00a0Forschungszentrum\u00a0f\u00fcr\u00a0\nUngleichheit\u00a0und\u00a0Sozialpolitik\u00a0i n\u00a0der\u00a0Abteilung\u00a0f\u00fcr\u00a0Gesundheit, \u00a0Pflege\u00a0und\u00a0Alterssicherung.\u00a0\nDr.\u00a0P.H.\u00a0Kristin\u00a0Sauer,\u00a0MPH\u00a0\nStudium\u00a0der\u00a0Physiotherapie\u00a0an\u00a0der \u00a0Hanze\u00a0University\u00a0of\u00a0Applied\u00a0S cience\u00a0Groningen,\u00a0Niederlande\u00a0\n2001\u00a0bis\u00a02005.\u00a0Anschlie\u00dfend\u00a0Arbeit \u00a0in\u00a0verschiedenen\u00a0Physiothera piepraxen\u00a0und\u00a0als\u00a0Lehrkraft\u00a0f\u00fcr\u00a0\nPhysiotherapie.\u00a02007\u00a0bis\u00a02009\u00a0Studium\u00a0Master\u00a0Public\u00a0Health/Pfle gewissenschaften\u00a0an\u00a0der\u00a0Univer\u2010\nsit\u00e4t\u00a0Bremen\u00a0mit\u00a0dem\u00a0Schwerpunkt\u00a0Versorgungsforschung.\u00a02014\u00a0Pro motion\u00a0(Dr.\u00a0PH)\u00a0zur\u00a0Multimo\u2010\ndalen\u00a0Therapie\u00a0bei\u00a0Kindern\u00a0und\u00a0Ju gendlichen\u00a0mit\u00a0chronischen\u00a0Erk rankungen.\u00a02009\u00a0bis\u00a02017\u00a0wis\u2010\nsenschaftliche\u00a0Mitarbeiterin\u00a0im\u00a0SOCIUM\u00a0(ehemals\u00a0Zentrum\u00a0f\u00fcr\u00a0Soz ialpolitik)\u00a0Soziale\u00a0Ungleichheit\u00a0\nund\u00a0Sozialpolitik):\u00a0Gesundheit,\u00a0Pf lege\u00a0und\u00a0Alterssicherung\u00a0an\u00a0d er\u00a0Universit\u00e4t\u00a0Bremen.\u00a0Seit\u00a02016\u00a0\nMedical\u00a0Writing,\u00a0Beratung\u00a0und\u00a0Sc hulung\u00a0bei\u00a0Kristin\u00a0Sauer\u00a0Medica l\u00a0Writing\u00a0und\u00a0Consulting.\u00a0\u00a0\nLutz\u00a0Muth,\u00a0Apotheker\u00a0\u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0an\u00a0der\u00a0Jo hannes\u00a0Gutenberg\u2010Universit\u00e4t\u00a0in\u00a0 Mainz\u00a0und\u00a0Approbation\u00a0zum\u00a0\nApotheker\u00a0in\u00a02003.\u00a0Im\u00a0Anschluss\u00a0daran\u00a0mehrere\u00a0Jahre\u00a0t\u00e4tig\u00a0in\u00a0\u00f6f fentlichen\u00a0Apotheken,\u00a0pharma\u2010\nzeutischer\u00a0 Industrie\u00a0 sowie\u00a0 bei\u00a0 Kostentr\u00e4gern\u00a0 (Vertrags\u2010\u00a0 und\u00a0 Ver sorgungsmanagement\u00a0 sowie\u00a0\nVerordnungssteuerung).\u00a0Abschluss\u00a0 als\u00a0MBA\u00a0in\u00a0Health\u00a0Care\u00a0Managem ent\u00a0in\u00a02007,\u00a0Geriatrischer\u00a0\nPharmazie\u00a0in\u00a02013\u00a0sowie\u00a0Fachwe iterbildung\u00a0in\u00a0Arzneimittelinform ation\u00a0in\u00a02017.\u00a0Seit\u00a0Januar\u00a02017\u00a0\nWissenschaftlicher\u00a0Mitarbeiter\u00a0im \u00a0SOCIUM\u00a0in\u00a0der\u00a0Abteilung\u00a0Gesun dheit,\u00a0Pflege\u00a0und\u00a0Alterssiche\u2010\nrung\u00a0AG\u00a0Professor\u00a0Glaeske\u00a0 der\u00a0Universit\u00e4t\u00a0Bremen.\u00a0\nAndr\u00e9\u00a0Morawetz,\u00a0Apotheker\u00a0\nStudium\u00a0der\u00a0Pharmazie\u00a0an\u00a0der\u00a0TU\u00a0B raunschweig\u00a02008\u00a0bis\u00a02012,\u00a0dan ach\u00a0T\u00e4tigkeit\u00a0in\u00a0der\u00a0pharma\u2010\nzeutischen\u00a0Industrie,\u00a0in\u00a0\u00f6ffentlichen\u00a0Apotheken\u00a0sowie\u00a0bei\u00a0einer \u00a0gesetzlichen\u00a0Krankenversicherung\u00a0\nim\u00a0Bereich\u00a0der\u00a0Apothekenabrechnung\u00a0und\u00a0Rechnungspr\u00fcfung.\u00a0Seit\u00a02 016\u00a0wissenschaftlicher\u00a0Mit\u2010\narbeiter\u00a0 im\u00a0 SOCIUM\u00a0 in\u00a0 der\u00a0 Abte ilung\u00a0 Gesundheit,\u00a0 Pflege\u00a0 und\u00a0 Alte rssicherung.\u00a0 Aktueller\u00a0 For\u2010\nschungsschwerpunkt\u00a0sind\u00a0durch\u00a0Viren \u00a0ausgel\u00f6ste\u00a0Erkrankungen\u00a0wie \u00a0Hepatitis\u00a0C\u00a0sowie\u00a0Infektionen\u00a0\nmit\u00a0HIV.\u00a0\n\u00a0\n\u00a0507\u00a0Projektmitarbeiterinnen\u00a0\u00a0\nAnnika\u00a0Becker,\u00a0B.A.\u00a0\nStudium\u00a0Public\u00a0Health\u00a0\u2010\u00a0Gesundheitsversorgung,\u00a0\u2010\u00f6konomie\u00a0und\u00a0\u2010m anagement.\u00a0Von\u00a0Juli\u00a02015\u00a0bis\u00a0\nSeptember\u00a02017\u00a0studentische\u00a0Mita rbeiterin\u00a0am\u00a0SOCIUM\u00a0\u2013\u00a0Forschung szentrum\u00a0Ungleichheit\u00a0und\u00a0\nSozialpolitik,\u00a0Abteilung\u00a0f\u00fcr\u00a0Ges undheit,\u00a0Pflege\u00a0und\u00a0Alterssiche rung\u00a0der\u00a0Universit\u00e4t\u00a0Bremen.\u00a0\nAngela\u00a0Fritsch\u00a0\nStudium\u00a0 der\u00a0 Geographie\u00a0 an\u00a0 der\u00a0 Uni versit\u00e4t\u00a0 Bonn\u00a0 (Abschluss:\u00a0 Dipl .\u00a0 Geograph.).\u00a0 Anschlie\u00dfend\u00a0\nAusbildung\u00a0zur\u00a0Organisationsprog rammiererin\u00a0am\u00a0Control\u00a0Data\u00a0Ins titut\u00a0in\u00a0Dortmund\u00a0(Abschluss:\u00a0\nOrganisationsprogrammiererin).\u00a0D anach\u00a0Anstellung\u00a0in\u00a0verschieden en\u00a0Softwareh\u00e4usern.\u00a0Seit\u00a0M\u00e4rz\u00a0\n2005\u00a0 Mitarbeiterin\u00a0 im\u00a0 SOCIUM,\u00a0 Fo rschungszentrum\u00a0 Ungleichheit\u00a0 un d\u00a0 Sozialpolitik,\u00a0 Abteilung\u00a0\nGesundheit,\u00a0Pflege\u00a0und\u00a0Alterssich erung\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Breme n.\u00a0Seit\u00a0Februar\u00a02016\u00a0Mitarbeite\u2010\nrin\u00a0im\u00a0Competenzzentrum\u00a0f\u00fcr\u00a0Vers orgungsforschung\u00a0in\u00a0der\u00a0Dermato logie\u00a0(CVderm)\u00a0am\u00a0Universi\u2010\nt\u00e4tsklinikum\u00a0Hamburg\u2010Eppendorf.\u00a0\nDipl.\u00a0Soz.\u00a0Friederike\u00a0H\u00f6fel\u00a0\nStudium\u00a0der\u00a0Soziologie\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Bremen.\u00a0Bis\u00a02015\u00a0Wiss enschaftliche\u00a0Mitarbeiterin\u00a0am\u00a0\nZentrum\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS) ,\u00a0jetzt\u00a0im\u00a0SOCIUM,\u00a0Forschungszen trum\u00a0Ungleichheit \u00a0und\u00a0Sozialpoli\u2010\ntik,\u00a0Abteilung:\u00a0Gesundheit,\u00a0Pfle ge\u00a0und\u00a0Alterssicherung\u00a0an\u00a0der\u00a0U niversit\u00e4t\u00a0Bremen.\u00a0Herausgeberin\u00a0\ndes\u00a0Buches\u00a0\u201eVersorgungsforsc hung\u201c\u00a0im\u00a0Schattauer\u00a0Verlag.\u00a0\nLinda\u00a0Christin\u00a0Jespersen,\u00a0B.A.\u00a0\nAbsolventin\u00a0des\u00a0Bachelorstudiums\u00a0 Soziologie\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0 Bremen.\u00a0Masterstudium\u00a0Stadt\u2010\u00a0\nund\u00a0Regionalentwicklung\u00a0M.A.\u00a0ebenfalls\u00a0an\u00a0Universit\u00e4t\u00a0Bremen.\u00a0S eit\u00a0Januar\u00a02017\u00a0studentische\u00a0\nMitarbeiterin\u00a0beim\u00a0SOCIUM\u00a0\u2013\u00a0Fo rschungszentrum\u00a0Ungleichheit\u00a0und\u00a0 Sozialpolitik,\u00a0Abteilung\u00a0Ge\u2010\nsundheit,\u00a0Pflege\u00a0und\u00a0Alterssicherung.\u00a0\u00a0\nPia\u00a0K\u00e4mpfert,\u00a0B.A.\u00a0\u00a0\nAbsolventin\u00a0des\u00a0Bachelorstudiums\u00a0Public\u00a0Health\u00a0an\u00a0der\u00a0Universit \u00e4t\u00a0Bremen.\u00a0Seit\u00a0Januar\u00a02016\u00a0\nstudentische\u00a0 Mitarbeiterin\u00a0 am\u00a0 SOC IUM\u00a0 \u2013\u00a0 Forschungszentrum\u00a0 Unglei chheit\u00a0 und\u00a0 Sozialpolitik,\u00a0\nAbteilung\u00a0f\u00fcr\u00a0Gesundheit,\u00a0Pflege\u00a0 und\u00a0Alterssicherung\u00a0der\u00a0Univer sit\u00e4t\u00a0Bremen.\u00a0Praktika\u00a0im\u00a0Versor\u2010\ngungsmanagement\u00a0 der\u00a0 Techniker\u00a0 Kr ankenkasse\u00a0 und\u00a0 im\u00a0 Programm\u00a0 \u201eVer sorgung\u00a0 verbessern\u00a0 \u2013\u00a0\nPatienten\u00a0informieren\u201c\u00a0der\u00a0 Bertelsmann\u00a0Stiftung.\u00a0\u00a0\nLinda\u00a0Richter,\u00a0B.A.\u00a0\nMasterstudium\u00a0Public\u00a0Health/Gesun dheitswissenschaften\u00a0an\u00a0der\u00a0Un iversit\u00e4t\u00a0Bielefeld.\u00a0Seit\u00a02013\u00a0\nstudentische\u00a0 Mitarbeiterin\u00a0 am\u00a0 SOC IUM\u00a0 \u2013\u00a0 Forschungszentrum\u00a0 Unglei chheit\u00a0 und\u00a0 Sozialpolitik,\u00a0\nAbteilung\u00a0f\u00fcr\u00a0Gesundheit,\u00a0Pflege\u00a0 und\u00a0Alterssicherung\u00a0der\u00a0Univer sit\u00e4t\u00a0Bremen.\u00a0\nCornelia\u00a0Trittin,\u00a0M.A.\u00a0\nBuchh\u00e4ndlerin,\u00a0Studium\u00a0der\u00a0Germa nistik\u00a0und\u00a0Kunstgeschichte\u00a0an\u00a0d er\u00a0Universit\u00e4t\u00a0Hamburg.\u00a0T\u00e4tig\u2010\nkeiten\u00a0in\u00a0Wirtschaft\u00a0und\u00a0Industrie ,\u00a0u.a.\u00a0Mitarbeiterin\u00a0im\u00a0Proje kt\u00a0\"Bundeskoordination\u00a0Frauen\u2010\ngesundheit\"\u00a0des\u00a0Arbeitskreises\u00a0F rauengesundheit\u00a0in\u00a0Medizin,\u00a0Psy chotherapie\u00a0und\u00a0Gesellschaft\u00a0\n(AKF),\u00a0gef\u00f6rdert\u00a0vom\u00a0Bundesminis terium\u00a0f\u00fcr\u00a0Familie,\u00a0Senioren,\u00a0F rauen\u00a0und\u00a0Jugend.\u00a0Von\u00a02006\u00a0bis\u00a0\n2008\u00a0Mitarbeiterin\u00a0der\u00a0Gm\u00fcnder\u00a0Ersatzkasse\u00a0(GEK)\u00a0bei\u00a0Prof.\u00a0Dr.\u00a0 Gerd\u00a0Glaeske,\u00a0Universit\u00e4t\u00a0Bre\u2010\nmen,\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozia lpolitik\u00a0(ZeS)\u00a0\u2013\u00a0jetzt\u00a0SOCIUM\u00a0\u2013\u00a0Forschung szentrum\u00a0Ungleichheit\u00a0und\u00a0Sozi\u2010\nalpolitik,\u00a0Abteilung:\u00a0Gesundheit,\u00a0 Pflege\u00a0und\u00a0Alterssicherung\u00a0\u2013\u00a0 seit\u00a02008\u00a0Wissenschaftliche\u00a0Mitar\u2010\nbeiterin\u00a0der\u00a0Universit\u00e4t\u00a0Bremen,\u00a0ebenda.\u00a0\u00a0508\u00a0(Co\u2010)Herausgeberin\u00a0von\u00a0drei\u00a0Sammelb\u00e4nden\u00a0der\u00a0(BARMER)\u00a0GEK\u00a0Schri ftenreihe\u00a0zur\u00a0Gesundheits\u2010\nanalyse\u00a0(Die\u00a0GKV\u00a0der\u00a0Zukunft,\u00a0Alt ern\u00a0in\u00a0unserer\u00a0Gesellschaft,\u00a0V ersorgungsforschung\u00a0zwischen\u00a0\nRoutinedaten,\u00a0Qualit\u00e4tssicherung \u00a0und\u00a0Patientenorientierung).\u00a0\nSarah\u00a0Volz\u00a0\nStudium\u00a0des\u00a0Integrierten\u00a0Designs\u00a0an\u00a0der\u00a0Hochschule\u00a0f\u00fcr\u00a0K\u00fcnste\u00a0B remen\u00a0im\u00a0Master.\u00a0Bis\u00a02015\u00a0\nMitarbeiterin\u00a0am\u00a0Zentrum\u00a0f\u00fcr\u00a0Sozialpolitik\u00a0(ZeS),\u00a0jetzt\u00a0SOCIUM\u00a0 \u2013\u00a0Forschungszentrum\u00a0Ungleichheit\u00a0\nund\u00a0Sozialpolitik,\u00a0Abte ilung:\u00a0Gesundheit,\u00a0Pf lege\u00a0und\u00a0Alterssich erung\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Bremen.\u00a0\n \n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}